

0001662774-24-00001110-Q Quince Therapeutics, Inc. 2024111320241113170923170923170923 0 0001662774-24-000011 10-Q 95 20240930 20241113 20241113 Quince Therapeutics, Inc.
0001662774 2836 901024039 CA 1231 10-Q 34 001-38890 241455572 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080
Cortexymc, Inc. 201601104 10-Q 1 qncx-20240930.htm 10-Q qncx-2024093000016627742024Q3false-12-
31.0016,000xbrli:sharesiso4217:USDiso4217:USDXbrli:sharesiso4217:EURxbrli:pureqncx:segmentqncx:leaseqncx:plan00016627742024-01-012024-09-3000016627742024-11-
0500016627742024-09-3000016627742023-12-310001662774us-gaap:SeriesAPreferredStockMember2023-06-300001662774us-gaap:SeriesAPreferredStockMember2024-09-
3000016627742024-01-012024-09-3000016627742023-07-012023-09-3000016627742023-01-012023-09-300001662774us-gaap:CommonStockMember2024-06-300001662774us-
gaap:AdditionalPaidInCapitalMember2024-06-300001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001662774us-gaap:RetainedEarningsMember2024-06-
3000016627742024-06-300001662774us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-
300001662774us-gaap:RetainedEarningsMember2024-07-012024-09-300001662774us-gaap:CommonStockMember2024-09-300001662774us-gaap:AdditionalPaidInCapitalMember2024-09-
300001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001662774us-gaap:RetainedEarningsMember2024-09-300001662774us-gaap:CommonStockMember2023-
06-300001662774us-gaap:AdditionalPaidInCapitalMember2023-06-300001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001662774us-
gaap:RetainedEarningsMember2023-06-3000016627742023-06-300001662774us-gaap:CommonStockMember2023-07-012023-09-300001662774us-gaap:AdditionalPaidInCapitalMember2023-
07-012023-09-300001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001662774us-gaap:RetainedEarningsMember2023-07-012023-09-
300001662774us-gaap:CommonStockMember2023-09-300001662774us-gaap:AdditionalPaidInCapitalMember2023-09-300001662774us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001662774us-gaap:RetainedEarningsMember2023-09-3000016627742023-09-300001662774us-
gaap:CommonStockMember2023-12-310001662774us-gaap:AdditionalPaidInCapitalMember2023-12-310001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-
310001662774us-gaap:RetainedEarningsMember2023-12-310001662774us-gaap:CommonStockMember2024-01-012024-09-300001662774us-gaap:AdditionalPaidInCapitalMember2024-01-
012024-09-300001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001662774us-gaap:RetainedEarningsMember2024-01-012024-09-300001662774us-
gaap:CommonStockMember2022-12-310001662774us-gaap:AdditionalPaidInCapitalMember2022-12-310001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-
310001662774us-gaap:RetainedEarningsMember2022-12-3100016627742022-12-310001662774us-gaap:CommonStockMember2023-01-012023-09-300001662774us-
gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001662774us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001662774us-
gaap:RetainedEarningsMember2023-01-012023-09-300001662774us-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMember2024-09-300001662774us-
gaap:SubsequentEventMemberus-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMember2024-11-130001662774us-gaap:SubsequentEventMemberus-
gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMember2024-11-012024-11-130001662774us-gaap:MoneyMarketFundsMember2024-09-300001662774us-
gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-09-300001662774us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-09-
300001662774us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-09-300001662774us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-
300001662774us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001662774us-gaap:FairValueInputsLevel2Memberus-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001662774us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueInputsLevel2Member2024-09-300001662774us-gaap:FairValueInputsLevel3Member2024-09-300001662774us-gaap:MoneyMarketFundsMember2023-12-310001662774us-
gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001662774us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-
310001662774us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310001662774us-gaap:CertificatesOfDepositMember2023-12-310001662774us-
gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember2023-12-310001662774us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2023-12-
310001662774us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember2023-12-310001662774us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-
310001662774us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001662774us-gaap:FairValueInputsLevel2Memberus-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001662774us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueInputsLevel2Member2023-12-310001662774us-gaap:FairValueInputsLevel3Member2023-12-310001662774us-gaap:EryDelMember2024-07-012024-09-
300001662774qncx:ContingentConsiderationMember2024-09-300001662774srt:MinimumMemberqncx:ContingentConsiderationMember2024-09-
300001662774srt:MaximumMemberqncx:ContingentConsiderationMember2024-09-300001662774us-gaap:FairValueInputsLevel3Member2024-01-012024-09-
300001662774qncx:EuropeanInvestmentBankLoanMember2024-09-300001662774us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:CashMember2024-09-300001662774us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember2023-12-310001662774us-
gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-09-300001662774us-
gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001662774us-
gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001662774us-
gaap:FairValueMeasurementsRecurringMemberus-gaap:CashAndCashEquivalentsMember2024-09-300001662774us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:CashAndCashEquivalentsMember2023-12-310001662774us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:CertificatesOfDepositMember2024-09-300001662774us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:CertificatesOfDepositMember2023-12-310001662774us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001662774us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001662774us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2024-09-
300001662774us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2023-12-310001662774us-gaap:CashAndCashEquivalentsMember2024-09-
300001662774us-gaap:ShortTermInvestmentsMember2024-09-

000001662774qncx:ApprovalMilestonesMember2023-10-202023-10-200001662774qncx:ContingentConsiderationMemberqncx:ProbabilityOfAchievementMembersrt:MinimumMemberqncx:EryDelMember2023-10-200001662774qncx:ContingentConsiderationMemberqncx:ProbabilityOfAchievementMembersrt:MaximumMemberqncx:EryDelMember2023-10-200001662774us-gaap:InProcessResearchAndDevelopmentMemberqncx:EryDelMember2023-10-200001662774us-gaap:TradeNamesMemberqncx:EryDelMember2023-10-200001662774us-gaap:GeneralAndAdministrativeExpenseMemberqncx:EryDelMember2023-10-200001662774us-gaap:ResearchAndDevelopmentExpenseMemberqncx:EryDelMember2023-10-200001662774us-gaap:InProcessResearchAndDevelopmentMember2023-12-3100001662774us-gaap:InProcessResearchAndDevelopmentMember2024-01-012024-09-300001662774us-gaap:InProcessResearchAndDevelopmentMember2024-09-300001662774us-gaap:TradeNamesMember2024-09-300001662774us-gaap:TradeNamesMember2023-12-3100001662774us-gaap:InProcessResearchAndDevelopmentMember2023-01-012023-09-30Table of ContentUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30, 2024OR~~TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~For the transition period from _____ to _____ Commission File Number: 001-38890

Quince Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter)
Delaware90-1024039(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)611 Gateway Boulevard, Suite 273South San Francisco, California94080(Address of principal executive offices)(Zip Code)Registrant's telephone number, including area code: (415) 910-5717
Securities registered pursuant to Section 12(b) of the Act: Title of each classA Trading Symbol(s)A Name of each exchange on which registeredCommon Stock, par value \$0.001 per shareA QNCX The Nasdaq Stock Market LLCIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.A A A YesA x A A NoA A Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (A5232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).A A A YesA x A A NoA A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions ofA large accelerated filer,A accelerated filer,A non-accelerated filer, a smaller reporting company,A and A emerging growth companyA in Rule 12b-2 of the Exchange Act.Large accelerated filerAccelerated filerNon-accelerated filerSmaller reporting companyX Emerging growth companyA If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.A A Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).A A A YesA o A A No A XAs of NovemberA 5, 2024, the registrant had 44,001,643 shares of common stock, \$0.001 par value per share, outstanding.Table of ContentTable of ContentsA PagePART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)7A Condensed Consolidated Balance Sheets7A Condensed Consolidated Statements of Operations and Comprehensive Loss8A Condensed Consolidated Statements of Stockholders'Equity9A Condensed Consolidated Statements of Cash Flows11A Notes to Unaudited Condensed Consolidated Financial Statements12Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations35Item 3.Quantitative and Qualitative Disclosures About Market Risk49Item 4.Controls and Procedures49PART II.OTHER INFORMATIONItem 1.Legal Proceedings51Item 1A.Risk Factors51Item 2.Unregistered Sales of Equity Securities and Use of Proceeds105Item 3.Defaults Upon Senior Securities105Item 4.Mine Safety Disclosures105Item 5.Other Information105Item 6.Exhibits106Signatures1071Table of ContentSpecial Note Regarding Forward-Looking StatementsThis Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "expect," "objective," "plan," "potential," "seek," "grow," "target," "if," and similar expressions intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions, including risks described in the section titled "Risk Factors" set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q and in our other filings with the SEC. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur, and actual results may differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:A our ability to successfully execute on our current strategic direction;A our future research and development activities, including the scope, success, cost and timing of any future development activities, preclinical studies and clinical trials, including clinical trials of EryDex or other pipeline compounds we advance through the drug development process;A the timing and focus of any potential future clinical trials, and the reporting of data from those trials; A our ability and timing of seeking and obtaining FDA and any other regulatory approvals for our drug candidates;A the willingness of the FDA or other regulatory authorities to accept any future completed or planned clinical and preclinical studies and other work, as the basis for review and approval of our drug candidates for their respective indications; A whether regulatory authorities determine that additional trials or data are necessary in order to accept a new drug application for review and/or approval; A the ability of any future clinical trials to demonstrate safety and efficacy of our EryDex and other drug candidates, and other positive results;A our financial performance;A the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements;A the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; A our expectations related to the use of our available cash;A our ability to service our debt obligations and maintain compliance with associated covenants;A our ability to obtain funding for our operations, including funding necessary to develop and commercialize our drug candidates;A our expectations regarding the potential market size and the size of the patient populations for our drug candidates, if approved for commercial use, and the potential market opportunities for commercializing our drug candidates;A our plans relating to commercializing our drug candidates, if approved; A our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any drug candidates for which we obtain approval;2Table of ContentA our ability to attract and retain key scientific and clinical personnel, in light of recent management changes and reduction in force;A our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;A our reliance on third parties to conduct clinical trials of our drug candidates, and for the manufacture of our drug candidates for preclinical studies and clinical trials; A dependence upon the integrity of our supply chain, including multiple single-source suppliers;A our reliance on third-party suppliers for certain of our raw materials and components;A our ability to expand our drug candidates into additional indications and patient populations;A the success of competing therapies that are or may become available;A the beneficial characteristics, safety and efficacy of our drug candidates;A governmental or regulatory delays, information requests, clinical holds, and regulatory developments in the United States and other jurisdictions;A our ability to obtain and maintain regulatory approval of our drug candidates, and any related restrictions, limitations and/or warnings in the label of any approved drug candidate;A our ability to obtain and maintain CE Certificates of conformity for the medical device components of our EryDex System in accordance with applicable legislation governing medical devices;A our ability to transition CE Certifications under the previous Medical Device Directive, to a regulatory framework under MDR;A our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;A the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and technology; A potential claims relating to our intellectual property; A our ability to grow our organization and increase the size of our facilities to meet our anticipated growth; andA our ability to maintain compliance with Nasdaq listing requirements.We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we do not intend to update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q or to conform these statements to actual results or revised expectations.You should read this Quarterly Report on Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.This Quarterly Report on Form 10-Q contains estimates, projections and other information concerning our industry, our business and the markets for our drug candidates. We obtained the industry, market and similar data set forth in this report from our own internal estimates and research and from academic and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates.3Table of ContentDEFINED TERMSUnless the context requires otherwise, references to A Quince, A the Company, A we, A us, A it or A ourA in this Quarterly Report on Form 10-Q refer to Quince Therapeutics, Inc. and its consolidated subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below.Abbreviated TermDefined TermA 2017 Tax ActTax Cuts and Jobs Act of 20173PLsThird-party Logistics ProvidersAEAdverse EventAIA Leahy-Smith America Invents ActAIDEAutologous Intracellular Drug EncapsulationANDAAbbreviated New Drug ApplicationARBAngiotensin Receptor BlockersASCAccounting Standards CodificationASUAccounting Standards UpdateATaxataxiTelangiectasiaTETSTaxia Telangiectasia Trial with the EryDex SystemCARESCoronavirus Aid, Relief, and Economic Security ActCGIClinical Global Impression of ChangeCmaxThe highest (peak) concentration of a drug in the bloodstream or other part of the body after drug administrationCMCCosmo Manufacturing ControlsCMOContract Manufacturing OrganizationCMSCenter for Medicare and Medicaid ServicesThe CodeInternal Revenue Code of 1986, as amendedCOSO frameworkControl-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway CommissionCOVID-19Coronavirus diseaseCPACertified Public AccountantCreditsTax creditsCROContract Research OrganizationCTAClinical Trial ApplicationDebt AgreementUnsecured line of credit agreement between EryDel and the European Investment Bank, which the Company assumed on October 20, 2023 in connection with the EryDel AcquisitionDMDDuchenne muscular dystrophyDOJUnited States Department of JusticeDSMBData Safety Monitoring BoardDSPDexamethasone Sodium PhosphateECEuropean CommissionEMAEuropean Medicines AgencyEryDelQuince Therapeutics, S.p.A. (previously named EryDel S.p.A.)EryDexRed blood cell encapsulated dexamethasone sodium phosphateEryDex SystemAutomated combination product to encapsulate dexamethasone sodium phosphate in Red blood cellsEIBEEuropean Investment BankEUEuropean Union4Table of ContentEIBLoanUnsecured line of credit between EryDel and the European Investment BankEryKitConsumable sterile kit component of the EryDex SystemExchange ActSecurities Exchange Act of 1934, as amendedFASBFinancial Accounting Standards BoardFCPAForeign Assets Controls, the United States Foreign Corrupt Practices Act of 1977FDAUnited States Food and Drug AdministrationGAAPGenerally accepted accounting principles in the United StatesGCPGood Clinical PracticeGDPRGeneral Data Protection RegulationGLPGood Laboratory PracticeGMPGood Manufacturing PracticeHHSUnited States Department of Health and Human ServicesHIPAAHealth Insurance Portability and Accountability Act of 1996HITECHHealth Information Technology for Economic and Clinical Health Act of 2009HPAHypothalamic-Pituitary-Adrenal (HPA) AxisHTAHealth Technology AssessmentICARSInternational Cooperative Ataxia Rating ScaleINDInvestigational New DrugIPInitial Public OfferingIPR&DIn-process Research and DevelopmentIRAINflammation Reduction Act of 2022IRBINstitutional Review BoardITTIntent To TreatJefferiesJefferies LLLCLighthouse Pharmaceuticals, Inc.LSMLeast Square MeanMAAMarketing Authorization ApplicationMADMmultiple Ascending DoseMDDMedical Devices DirectiveMDRMultiple Devices Regulation 2017/745MCSRModified International Cooperative Ataxia Rating ScaleMHRAUnited Kingdom Medicines and Healthcare Products Regulatory AgencyMPEEMulti-Period Excess Earnings MethodNasdaqThe Nasdaq Stock Market LLCNCENew Chemical EntityNDANew Drug ApplicationNEATEryDex Phase 3 Trial (Neurologic Effects of EryDex on Subjects with P-T)NIHNational Institute of HealthNOLNet Operating LossNovosteoNovosteo, Inc.PCAOBPublic Company Accounting Oversight BoardPCTPatent Cooperation TreatyPDPPharmacodynamicPDPrescription Drug Marketing ActProcess solutions(Hypotonic Solutions 1 & 2 and Hypertonic Solution FIGPA) sterile solutions to allow drug encapsulation and restoring the physiological osmolality during EryDex process5Table of ContentPPPProtocol Population is all patients who enrolled into the study and fulfilled all inclusion/exclusion criteria, did not have any major protocol violations, and completed the initial treatment period of the study as planned. PKPharmacokineticPPACPatient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act of 2010PRFPurdue Research FoundationPTPatent Term ExtensionR&DResearch and DevelopmentRCLRed Cell Loader, the machine that encapsulates drug into red blood cellsRegistrational or pivotal trialAn adequate and well-controlled trial designed to be sufficient to apply for regulatory approval of a drug candidate, although notwithstanding the Company's design a regulatory agency may determine that further clinical studies or data are requiredRmIRCRescored modified International Cooperative Ataxia Rating ScaleRBBCRed Blood CellsRSARestricted Stock AwardsRSURestricted Stock UnitsSADSingle Ascending DoseSAESerious Adverse EventSarbanes-Oxley ActThe Sarbanes-Oxley Act of 2002SECSecurities and Exchange CommissionSECSECurities Act of 1933SPASpecial Protocol AssessmentSyringe KitDevice for anticoagulated blood collection and for the sterile connection to the EryKitTA Trade and Cooperation AgreementTEAEEmergent Adverse EffectUPCUnified Patent Court

expenses5,863Å 6,094Å 45,273Å 24,699Å Loss from operations(5,863)(6,094)(45,273)(24,699)Fair value adjustment for long-term debt(449)Å€"Å (1,252)Å€"Å Interest income683Å 959Å 2,393Å 2,464Å Other income (expense), net 150Å (216)(158)(504)Net loss before income tax benefit(5,479)(5,351)(44,290)(22,739)Income tax (expense) benefit(13)Å€"Å (80)248Å Net loss(5,492)(5,351)(44,370)(22,491)Other comprehensive loss:Foreign currency translation adjustments2,158Å 158Å 203Å 309Å Unrealized gain (loss) on available-for-sale securities174Å 101Å 158Å 496Å Total comprehensive loss\$(3,160)\$(5,092)\$(43,998)\$(21,686)Net loss per share - basic and diluted\$(0.13)\$(0.15)\$(0.13)\$(0.63)Weighted average shares of common stock outstanding - basic and diluted43,164,13636,073,04043,090,63235,941,234The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.8Table of ContentQUINCE THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited)(In thousands, except share and per share amounts)For the three months ended September 30, 2024 and 2023Common StockAdditionalPaid inAccumulated OtherComprehensiveAccumulatedTotal Stockholders'SharesAmountBalance as of JuneÅ 30, 202443,276,60643Å \$404,368Å \$1,087Å \$(358,522)\$46,968Å Stock based compensationÅ€"Å €"Å 1,124Å Å€"Å 1,124Å Foreign currency translation adjustmentÅ€"Å Å€"Å 2,158Å Å€"Å 2,158Å Unrealized gain (loss) on available for sale investmentsÅ€"Å Å€"Å 174Å Å€"Å 174Å Net lossÅ€"Å Å€"Å 5,492)(5,492)Balance September 30, 2024 43,276,60643Å \$405,484Å \$3,419Å \$(364,014)\$44,932Å Balance as of JuneÅ 30, 202336,343,632,99536Å \$391,990Å \$257Å \$(305,399)\$86,884Å Issuance of common stock on exercise of stock options and vesting of restricted stock units70,394Å €"Å 28Å Å€"Å 28Å Restricted stock award retirement(54,757)Å€"Å (18)Å€"Å (18)Stock based compensationÅ€"Å Å€"Å 1,331Å Å€"Å 1,331Å Foreign currency translation adjustmentÅ€"Å Å€"Å 158Å Å€"Å 158Å Unrealized gain (loss) on available for sale investmentsÅ€"Å Å€"Å 101Å Å€"Å 101Å Net lossÅ€"Å Å€"Å 5,351)(5,351)Balance September 30, 2023 36,343,63236Å \$393,331Å \$516Å \$(310,750)\$83,133Å The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.9Table of ContentQUINCE THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited)(In thousands, except share and per share amounts)For the nine months ended September 30, 2024 and 2023Å Common StockAdditionalPaid inCapitalAccumulated OtherComprehensiveIncome / (Loss) AccumulatedDeficitTotal Stockholders'Equity Å SharesAmountBalance December 31, 202342,973,21543Å \$401,638Å \$3,047Å \$(319,644)\$85,084Å Issuance of common stock on exercise of stock options and vesting of restricted stock units303,391Å €"Å 225Å Å€"Å 225Å Stock based compensationÅ€"Å Å€"Å 3,621Å Å€"Å 3,621Å Foreign currency translation adjustmentÅ€"Å Å€"Å 203Å Å€"Å 203Å Unrealized gain (loss) on available for sale investmentsÅ€"Å Å€"Å 169Å Å€"Å 169Å Net lossÅ€"Å Å€"Å 44,370)(44,370)Balance September 30, 2024 43,276,60643Å \$405,484Å \$3,419Å \$(364,014)\$44,932Å Balance December 31, 202236,136,48036Å \$389,105Å \$(289)\$(288,259)\$100,593Å Issuance of common stock on exercise of stock options and vesting of restricted stock units270,445Å €"Å 110Å Å€"Å 110Å Restricted stock award retirement(63,293)Å€"Å (18)Å€"Å (18)Stock based compensationÅ€"Å Å€"Å 4,134Å Å€"Å 4,134Å Foreign currency translation adjustmentÅ€"Å Å€"Å 309Å Å€"Å 309Å Unrealized gain (loss) on available for sale investmentsÅ€"Å Å€"Å 496Å Å€"Å 496Å Net lossÅ€"Å Å€"Å 22,491)(22,491)Balance September 30, 2023 36,343,63236Å \$393,331Å \$516Å \$(310,750)\$83,133Å The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.10Table of ContentQUINCE THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)(In thousands)Å For the Nine Months Ended September 30, 20242023Cash flows from operating activitiesNet Loss(44,370)\$(22,491)Adjustments to reconcile net loss to net cash used in operating activities:Stock based compensation3,621Å 4,134Å Depreciation and amortization170Å 18Å Impairment loss on operating leaseÅ€"Å 66Å Loss on disposal of fixed assetsÅ€"Å 71Å Equity investment in Lighthouse, Inc.Å€"Å (78)Change in the fair value of contingent consideration liabilities2,082Å €"Å Change in fair value of long-term debt1,252Å €"Å Non-cash goodwill and intangible asset impairment charge17,130Å 5,900Å Amortization of discount on available-for-sale investments(1,858)(1,313)Change in deferred tax liabilities due to acquisition of Novotest, Inc.Å€"Å (248)Changes in operating assets and liabilities, net of acquisitions:Prepaid expenses and other current assets(2,025)2,272Å Right of use assets, operating leases and operating lease liabilities(170)192Å Other assets(292)Å€"Å Accounts payable(424)(161)Accrued expenses and other current liabilities532Å (576)Net cash used in operating activities(24,352)(12,214)Cash flow from investing activities:Purchase of investments(89,562)(95,116)Proceeds from maturities of investments100,727Å 84,514Å Note receivableÅ€"Å (500)Proceeds from disposal of assetsÅ€"Å 90Å Purchase of property and equipment(124)(136)Net cash provided by investing activities11,041(11,148)Cash flows from financing activities:Payment of contingent consideration(5,000)Å€"Å Payments of finance leasesÅ€"Å (6)Proceeds from issuance of common stock upon exercise of stock options225Å 92Å Net cash provided by financing activities(4,775)86Å Effect of exchange rate changes on cashÅ 329Å Net increase in cash and cash equivalents(18,077)(22,947)Cash and cash equivalents at beginning of period20,752Å 44,579Å Cash and cash equivalents at end of period26,675Å \$21,632Å Supplemental disclosures of non-cash information:Right-of-use assets obtained in exchange for new operating lease liabilities\$232Å Å€"Å Right-of-use asset and financing lease liability reduction as a result of lease modificationÅ€"Å \$(70)The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.11Table of ContentQUINCE THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)Note 1. OrganizationDescription of BusinessQuince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The Company's proprietary AIDE technology platform is an innovative drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Red blood cells have several characteristics that make them a potentially ideal vehicle for drug delivery and our AIDE technology is designed to harness many of these benefits to allow for new and improved therapeutic options for patients living with high unmet medical needs. The AIDE technology platform is believed to confer several benefits over conventional therapies which could be applied to a broad range of small or large molecule drugs and biologics. Our Phase 3 lead asset, EryDex, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T. By pioneering the encapsulation of drugs in a patient's own red blood cells, we seek to advance proprietary therapeutics that hold the potential to redefine the standard of care and meaningfully improve the quality of life for patients with rare disease. Liquidity and Capital ResourcesThe Company has incurred losses and negative cash flows from operations since inception and expects to continue to generate operating losses for the foreseeable future. As of September 30, 2024, the Company had an accumulated deficit of \$364.0 million. Since inception through September 30, 2024, the Company has funded operations primarily with the net proceeds from the issuance of convertible promissory notes, from the issuance of redeemable convertible preferred stock, from the net proceeds from the Company's initial public offering (the "IPO") and from the net proceeds of the private investment in public equity transaction (the "PIPE Financing"). As of September 30, 2024, the Company had cash, cash equivalents, and short-term investments of \$47.8 million, which it believes will be sufficient to fund its planned operations into the first quarter of 2026, a period that is at least 12 months from the date of the issuance of the accompanying unaudited consolidated financial statements. In connection with the acquisition of EryDel on October 20, 2023 (the "EryDel Acquisition"), the Company assumed an unsecured line of credit between EryDel and the European Investment Bank (the "EIB Loan"). As of September 30, 2024, the principal of 10.0Å million euros (\$11.2 million) was outstanding on the EIB Loan. The Debt Agreement requires the Company to maintain a minimum cash balance of 14.65Å million euros (\$16.4Å million) until the outstanding obligations under the Debt Agreement, together with accrued interest and all other amounts accrued or outstanding under the agreement, is repaid in full (the "Minimum Cash Covenant"). Furthermore, the Company may at any time voluntarily prepay, in whole or in part, together with certain fees as set forth in the Debt Agreement, the outstanding obligations under the Debt Agreement. In the event of a default or a change in control, as specified in the Debt Agreement, EIB may, subject to certain grace periods, accelerate the outstanding obligations under the EIB Loan. In November 2024, the Company entered into an amendment (the "Amendment") of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment. Management expects to incur additional losses in the future to fund the Company's operations and conduct product research and development and may need to raise additional capital to fully implement its business plan. The Company may raise additional capital through the issuance of equity securities, debt financings or other sources including out-licensing or partnerships, in order to further implement its business plan. However, if such financing is not available when needed and 12Table of Contentadequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of product candidates. Note 2. Summary of Significant Accounting PoliciesBasis of ConsolidationThe accompanying condensed consolidated financial statements include the accounts of Quince Therapeutics, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation. Basis of PresentationThe accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the instructions of the SEC on Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the management's opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included. The condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 included in the Company's Form 10-K filed with the SEC on April 1, 2024. The results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period. Risks and UncertaintiesThe Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company's potential drug candidates, uncertainty of market acceptance of the Company's drug candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. The Company's drug candidates will require approvals from the FDA and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any drug candidate will receive the necessary approvals. Use of EstimatesThe preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company's consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances, determination of the fair value of identifiable assets and liabilities in connection with business combinations including associated intangible assets and goodwill, contingent consideration, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets, eligibility of expenses for the Australia research and development refundable tax credits, impairment of intangible assets, including goodwill; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company's estimates. 13Table of ContentForeign Currency Translation and TransactionsThe functional currency of the Company's wholly-owned subsidiaries are the Euro and Australian Dollar. The Company's financial results and financial position are translated into U.S. dollars using exchange rates at balance sheet dates for assets and liabilities and using average exchange rates for income and expenses. The resulting translation differences are presented as a separate component of accumulated other comprehensive loss, as a separate component of equity. Foreign currency transactions are translated into the functional currencies using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses, resulting from the settlement of such transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies using exchange rates at balance sheet date and non-monetary assets and liabilities using historical exchange rates, are recognized in the condensed consolidated statements of operations and comprehensive loss. Significant Accounting PoliciesThere have been no significant changes to the accounting policies during the nine months ended September 30, 2024, as compared to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2023. SegmentsThe Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing therapeutics. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating and evaluating financial performance. All long-lived assets are maintained in Italy. Business CombinationsThe Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business. The Company accounts for business combinations using the acquisition method pursuant to the FASB ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company's financial results beginning on the respective acquisition dates, and that identifiable assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using one of three valuation approaches, the income approach, the market approach or the cost approach. The Company reviewed the three valuation approaches and determined the income approach was the most appropriate model to approximate fair value for the EryDel Acquisition. The income approach model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the "Purchase Price") over the fair values of the net assets acquired is recognized as goodwill. The fair value of identifiable assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred. Intangible AssetsDefinite lived Intangible AssetsIntangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. The Company regularly reviews whether current conditions or events suggest that the carrying values of its acquired definite lived intangible assets might not be recoverable. When such conditions are identified, an estimate of the undiscounted future cash flows from these assets, or relevant asset groupings, is compared to their carrying value to determine if an impairment exists. If an impairment is identified, the loss is calculated as the difference between the 14Table of Contentcarrying value of the intangible asset and its fair value, which is based on the net present value of the estimated future cash flows. Indefinite lived Intangible AssetsIntangible assets with an indefinite useful life are not amortized. Intangible assets acquired in a business combination or an acquisition that are used in research and development activities (regardless of whether they have an alternative future use) shall be considered indefinite lived until the completion or abandonment of the associated research and development efforts. Intangible assets acquired in a business combination are initially recorded at fair value. During the period that those assets are considered indefinite lived, they shall not be amortized but shall be tested for impairment. Once the research and development efforts are completed or abandoned, the entity shall determine the useful life of the assets. An indefinite lived intangible asset shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the intangible asset. Qualitative factors to be considered include but are not limited to: Cost factors such as increases in raw materials, labor, or other costs that have a negative effect on future expected earnings and cash flowsLegal/regulatory factors or progress and results of

clinical trials–Other relevant entity-specific events such as changes in management, key personnel, strategy, or customers; contemplation of bankruptcy; or litigation that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset–Industry and market considerations such as a deterioration in the environment in which an entity operates, an increased competitive environment–Macroeconomic conditions such as deterioration in general economic conditions, limitations on accessing capital, fluctuations in foreign exchange rates, or other developments in equity and credit markets that could affect significant inputs used to determine the fair value of the indefinite-lived intangible assetGoodwillGoodwill represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.During the nine months ended September 30, 2024, the Company recognized a non-cash goodwill impairment charge of \$17.1 million as the quantitative analysis resulted in the Company's fair value being significantly below its carrying value during the three months ended June 30, 2024.Contingent ConsiderationThe Company determines the acquisition date fair value of contingent consideration using a discounted cash flow method, with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC Topic 820, Fair Value Measurement. The significant inputs in the Level 3 measurement not supported by market activity included our probability assessments of expected future cash flows related to the Company's acquisition of EryDel in October 2023, during the contingent consideration period, appropriately discounted considering the uncertainties associated with the earnout obligation, and calculated in accordance with the terms of the definitive agreement. The liabilities for the contingent consideration are established at the time of the acquisition and will be evaluated on a quarterly basis based on additional information as it becomes available. Any change in the fair value adjustment is recorded in the earnings of that period. During the three months ended September 30, 2024, the Company recorded a \$2.7A million adjustment to decrease the fair value of its contingent consideration related to the acquisition of EryDel. During the nine 15Table of Contentmonths ended September 30, 2024, the Company recorded a net \$2.1A million adjustment to increase the fair value of its contingent consideration related to the acquisition of EryDel. The adjustment is reflected within operating loss on the consolidated statement of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations may result from changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Significant increases or decreases in the inputs noted above in isolation would result in a significantly lower or higher fair value measurement. Cash, Cash Equivalents and InvestmentsThe Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash equivalents include marketable securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as short-term investments. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term investments. Collectively, cash equivalents, short-term investments and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded as a component of other comprehensive loss in the consolidated statements of operations and included as a separate component of consolidated statements of stockholders' equity (deficit). Realized gains and losses are included in interest income in the consolidated statements of operations and comprehensive loss.Premiums (discounts) are amortized (accreted) over the life of the related investment as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. These amounts are recorded in –interest income– in the consolidated statements of operations and comprehensive loss.Recent Accounting Pronouncements Not Yet AdoptedThe following are new accounting pronouncements that the Company is evaluating for future impacts on its financial statements:Improvements to Income Tax Disclosures (ASC 740): In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." This ASU establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Under this ASU, entities must consistently categorize and provide greater disaggregation of information in the rate reconciliation. They must also further disaggregate income taxes paid. The ASU is effective beginning after December 2024 under a prospective approach. Early adoption is permitted. The Company is evaluating the disclosure requirements related to the new standard.Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (–ASU 2023-07–): In November 2023, the FASB issued ASU 2023-07, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.Note 3. Fair Value MeasurementsThe fair value of the Company's financial instruments reflects the amounts that the Company estimates that it would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company discloses and recognizes the fair value of the assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:16Table of ContentLevel 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active.Level 3 - Inputs that are unobservable. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's financial instruments are carried in the accompanying condensed consolidated balance sheets at amounts that approximate fair value.The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the three and nine months ended September 30, 2024 and 2023.The Company elected the fair value option for the EIB Loan assumed as part of the EryDel Acquisition. The Company adjusted the EIB Loan to fair value through the change in fair value of debt in the accompanying consolidated statements of operations and comprehensive loss. Subsequent unrealized gains and losses on items for which the fair value option is elected are reported in earnings. The Company will breakout any change in value due to credit loss in accumulated other comprehensive loss. For the three and nine months ended September 30, 2024, there was no change in value due to credit loss.Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September 30, 2024 and December 31, 2023 are presented in the following tables (in thousands):A Fair Value Measurements as of September 30, 2024ATotalLevel 1Level 2Level 3Assets:Money market funds\$997A \$997A \$–A \$–A Government and agency notes\$45,172A –A \$45,172A –A Total Assets\$46,169A \$997A \$45,172A \$–A Liabilities:Contingent consideration\$54,788A –A \$54,788A Long-term debt\$14,899A –A \$–A \$14,899A Total\$69,687A \$–A \$–A \$69,687A A Fair Value Measurements as of December 31, 2023 ATotalLevel 1Level 2Level 3Assets:Money market funds\$4,285A \$–A \$4,285A \$–A Liabilities:Certificates of Deposit\$729A –A \$729A –A Government and agency notes\$68,524A \$3,971A 64,553A –A Total Assets\$73,538A \$8,256A \$65,282A \$–A Liabilities:Contingent consideration\$57,706A –A \$57,706A Long-term debt\$13,429A –A \$–A \$13,429A Total\$71,135A \$–A \$–A \$71,135A 17Table of ContentThe Company classifies certificates of deposit and government and agency notes as Level 2 investments as the Company uses quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trades of or quotes on the same or similar securities. The Company does not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services.Level 3 Assets and LiabilitiesContingent ConsiderationThe following table reflects the changes in present value of acquisition related accrued earnouts of contingent consideration liability using significant unobservable inputs (Level 3) for the nine months ended September 30, 2024:(in thousands)Beginning Balance as of January 1, 2024\$57,706A Payout of contingent earnout based on milestone achievement(5,000)Change in fair value of contingent consideration2,082A Ending Balance as of September 30, 2024 \$54,788A During the three months ended June 30, 2024, the Company enrolled the first patient in the Phase 3 NEAT clinical trial. In accordance with the purchase agreement entered into in connection with EryDel Acquisition, the Company notified the former EryDel shareholders of this achievement within 45 days of achieving this milestone. During the three months ended September 30, 2024, the Company paid the cash milestone payment of \$5A million to the former EryDel shareholders. The change in the fair value of the contingent consideration is primarily driven by the cash milestone payment of \$5A million to the former EryDel shareholders, and the passage of time. The Company owes no further payments to EryDel shareholders for development-related milestones. The remaining potential contingent payments in connection with the EryDel Acquisition pertain to regulatory on market and sales milestones.The following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition related accrued earnout as of September 30, 2024 (in thousands except for percentages):A September 30, 2024Valuation TechniqueUnobservable InputRange (Input Used)Contingent consideration\$54,788A Expected present valueProbability of achieving earnout objectives per the purchase agreement0% - 100%Long-term DebtThe following table presents the changes in the fair value of the Level 3 EIB Loan for the nine months ended September 30, 2024 (in thousands) Beginning Balance as of January 1, 2024\$13,429A Change in fair value1,252A Due to foreign currency translation218A Ending Balance as of September 30, 2024 \$14,899A 18Table of ContentThe following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition related long term debt as of September 30, 2024 (in thousands except for percentages):A September 30, 2024Valuation TechniqueUnobservable InputRange (Input Used)EIB loan\$14,899A Expected present valueCredit quality of companyA and credit spreads for comparable debt13%Note 4. Cash, Cash Equivalents and InvestmentsThe following tables categorize the fair values of cash, cash equivalents and investments measured at fair value on a recurring basis on our balance sheets (in thousands):A September 30, 2024December 31, 2023Cash and cash equivalents:Cash\$1,678A \$1,521A Money market funds\$997A 4,285A Government and agency notes–A 14,946A Total cash and cash equivalents\$2,675A \$20,752A A Short-term investments:Certificates of deposit–A \$729A Government and agency notes\$45,172A 53,578A Total short-term investments\$45,172A \$54,307A The Company's investments are classified as available-for-sale securities. As of September 30, 2024, the weighted average remaining contractual maturities of available-for-sale securities was approximately 6 months. The unrealized gain (loss) activity related to the Company's available-for-sale securities is included in the Company's accumulated other comprehensive income. There were no significant realized gains or losses recognized on the sale or maturity of available-for-sale securities for the three and nine months ended September 30, 2024 and 2023, and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income. Based on the Company's review of its available-for-sale securities, the Company has no available-for-sale securities in loss positions as of September 30, 2024. No other-than-temporary impairments on these securities were recognized for the three and nine months ended September 30, 2024 and 2023.The Company periodically assess its investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. There have been no impairment and credit losses related to available-for-sale securities for the three and nine months ended September 30, 2024 and 2023.For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value and recognized in interest and other income, net in the statement of operations and comprehensive loss. If neither criteria is met, the Company evaluates whether the decline in fair value is related to credit-related factors or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. Credit-related impairment losses, limited by the amount that the fair value is less than the amortized cost basis, are recorded through an allowance for credit losses in interest and other income, net. 19Table of ContentAny unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit factors are recognized in accumulated other comprehensive income, net of tax as a separate component of stockholders' equity, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on available-for-sale securities are included in interest and other income, net in the condensed statement of operations and comprehensive loss. For purposes of identifying and measuring credit-related impairments, the Company's policy is to exclude applicable accrued interest from both the fair value and amortized cost basis of the related security. The Company has elected to write-off uncollectible accrued interest receivable balances in a timely manner, which is defined by the Company as when interest due becomes 90 days delinquent. The accrued interest write-off will be recorded by reversing interest income. Accrued interest receivable is recorded in other current assets on the condensed balance sheets.The following table summarizes the available-for-sale securities (in thousands):A Fair Value Measurements as of September 30, 2024A AmortizedCostUnrealizedGainsUnrealizedLosses Fair ValueMoney market funds\$997A \$–A \$–A \$997A Government and agency notes\$45,013A 159A –A \$45,172A Total cash equivalents and investments\$46,010A \$159A \$–A \$46,169A A Classified as:Cash equivalents (original maturities within 90 days)\$997A Short-term investments (maturities within one year)\$45,172A Total cash equivalents and investments\$46,169A A Fair Value Measurements as of December 31, 2023 A AmortizedCostUnrealizedGainsUnrealizedLosses Fair ValueMoney market funds\$4,285A \$–A \$–A \$4,285A Certificates of Deposit\$735A –A (6)729A Government and agency notes\$68,528A 13A (17)68,524A Total cash equivalents and investments\$73,548A \$13A (23)\$73,538A A Classified as:Cash equivalents (original maturities within 90 days)\$19,231A Short-term investments (maturities within one year)\$54,307A Total\$73,538A Note 5. Balance Sheet ComponentsPrepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consist of the following (in thousands):A September 30, 2024December 31, 2023Prepaid research and development expenses\$1,415A \$133A Short-term Italian research and development refundable tax credit\$95A 993A Prepaid insurance\$841A 809A Prepaid expenses\$65A 365A Other current assets\$55A 81A Total prepaid expenses and other current assets\$3,871A \$2,381A 20Table of ContentThe Company is eligible to obtain an R&D tax credit as companies in Italy that invest in eligible research and development activities, regardless of the legal form and economic sector in which they operate, can benefit from a R&D tax credit. Such tax credits can only be used to offset payments of certain taxes and contributions (e.g., social contributions, VAT payables, registration fees, income and withholding taxes and other tax-related items that companies usually pay monthly). The Company recognized reductions to R&D expense of \$0.4 million and \$1.2 million for the three and nine months ended September 30, 2024 respectively, and \$0 reductions for the three and nine months ended September 30, 2023. Novosteo Pty, Ltd, a wholly-owned subsidiary of Novosteo, LLC, is eligible to obtain a cash refund from the Australian Taxation Office for eligible R&D expenditures under the Australian Tax Incentive. During the three and nine months ended September 30, 2024, the Company received \$0 refundable tax credit. During the first quarter of 2023, the Company received a refundable tax credit of \$0.5 million, which reduced prepaid expenses and other current assets by \$0.5 million as of March 31, 2023.Other AssetsOther assets consisted of the following (in thousands):A September 30, 2024December 31, 2023Long-term Italian research and development refundable tax credits\$4,074A \$4,993A VAT receivable\$5,354A 3,463A Equity investments in Lighthouse Pharmaceuticals, Inc. 78A 78A Assets held for sale–A 10A Total other assets\$9,506A \$8,544A Property and Equipment, NetProperty and equipment, net consist of the following (in thousands):A September 30, 2024December 31, 2023Computer equipment\$38A \$36A Computer Software\$30A 30A Lab equipment\$534A 486A Leasehold improvement\$36A 36A Office furniture\$237A 153A Less: accumulated amortization and depreciation(667)(507)Property and equipment, net\$208A \$234A Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consist of the following (in thousands):A September 30, 2024December 31, 2023Personnel expenses\$2,301A \$2,340A Research and development expenses\$1,063A 564A Professional fees\$140A 211A Current portion of

operating lease liabilities101A 64A Othel198A 25A Total accrued expenses and other current liabilities\$3,803A \$3,436A 21Table of ContentFor the nine months ended SeptemberA 30, 2024 and 2023, the severance accrual activity were as follows (in thousands):A 20242023Beginning accrued severance\$341A \$A€A Incurred during the period41A 770A Severance paid during the period(382)(309)Ending accrued severance\$A€A \$461A On January 30, 2023, in response to the reprioritization of the Company's pipeline following the decision to discontinue internal development of NOV004 and to pursue out-licensing opportunities, the Company's Board of Directors approved a cost reduction program to reorganize operations and allow continued support for the needs of the business. Under the cost reduction program, the Company lowered headcount through a reduction in workforce. The Company recognized the severance of \$0.3 million and related expenses of \$0.1 million over the requisite employment obligation period. The reduction in force was completed in April 2023. On AugustA 4, 2023, the Company entered into a transition and separation agreement with Karen Smith, M.D., Ph.D., (the A€œSeparation AgreementA€) in connection with Dr. SmithA€™s transition and departure from the Company as the Company's Chief Medical Officer, effective as of September 1, 2023. Pursuant to the Separation Agreement, the Company is required to pay cash severance, equal to her annual salary, in the aggregate amount of \$0.5 million, of which \$0.3 million was paid during the nine months ended SeptemberA 30, 2024. The severance is to be paid on regular payroll schedule through the third quarter of 2024. Additionally, pursuant to the Separation Agreement, the Company paid an additional cash bonus severance payment equal to 100% of Dr. SmithA€™s target annual bonus opportunity for 2023 on a prorated basis, an additional cash severance payment equal to 12 monthsA€™ of the monthly premiums for health care continuation benefits, and provided for 50% accelerated vesting with respect to Dr. SmithA€™s equity award. The acceleration of 612,141 options and 54,757 RSAs resulted in a stock-based compensation expense of approximately \$0.1 million that was recorded in 2023.Note 6. LeasesIn October 2023, as part of the EryDel Acquisition the Company acquired operating leases in which the Company recorded an operating lease right of use asset and liability in total of \$0.4 million. This includes a lease agreement renting office space in Bresso, in the Province of Milan, Italy. The Lease Agreement commenced on September 1, 2016 and will end on August 31, 2028. At acquisition date, the Company recorded an operating lease right of use asset and liability of \$0.1 million. This also includes a lease agreement renting office space in Medolla, in the Province of Modena, Italy. The Lease Agreement commenced on June 18, 2018, with a duration of 12 years, until January 31, 2030. At acquisition date, the Company recorded an operating lease right of use asset and liability of \$0.2 million. The acquired lease agreements also included other operating leases two of which are car leases and the other a printing press.In January 2024, the above-mentioned Lease Agreement for the office space in Medolla was renegotiated. The new Lease Agreement includes an additional space and commenced on February 1, 2024, and will end on January 31, 2036, substituting the Lease Agreement commenced in June 2018. The Company recorded an additional \$0.2 million of operating lease right of use asset and liability during the nine months ended SeptemberA 30, 2024. The Company recognizes lease expense on a straight-line basis over the term of its operating lease. During the nine months ended SeptemberA 30, 2024 and 2023, the Company recorded rent expense of \$0.1 million. 22Table of ContentSupplemental balance sheet information related to leases as follows (in thousands except lease terms and discount rates):A September 30, 2024December 31, 2023Assets:Operating lease right of use asset, net\$559A \$385A Liabilities:Short-term operating lease liability101A 64A Long-term operating lease liability450A 321A Total lease liabilities\$551A \$385A Other information:Weighted average remaining lease term4.9 years5.4 yearsWeighted average discount rate9.11A %7.95A %Future minimum lease payments under lease agreements as of SeptemberA 30, 2024, were as follows (in thousands):Fiscal Year2024 (remainder of the year)\$35A 2025140A 2026136A 2027130A 2028 and thereafter214A Total lease payments655A Less: imputed interest(104)Total remaining lease liability\$551A Note 7. StockholdersA€™ EquityOn AprilA 5, 2023, the CompanyA€™s Board of Directors declared a dividend of one preferred share purchase right (a A€œRightA€) for each outstanding share of the common stock of the Company. The dividend was effective as of April 17, 2023 (the A€œRecord DateA€) with respect to stockholders of record on that date. The Rights also attached to shares of common stock issued after the Record Date. Each Right entitled the registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value \$0.001 per share, (the A€œPreferred SharesA€), of the Company at a price of \$6.00 per one one-thousandth of a Preferred Share, subject to adjustment. On AprilA 5, 2024, the Rights Plan and the Rights issued thereunder expired.Note 8. Stock-Based CompensationThe Company operates three stock plans as of SeptemberA 30, 2024:A€œ2019 Equity Incentive Plan (Quince)A€œ2019 Equity Incentive Plan (Novosteo)A€œ2022 Inducement Plan (Quince)2019 Equity Incentive Plan (Quince)On December 4, 2014, the CompanyA€™s stockholders approved the 2014 Stock Plan (A€œ2014 PlanA€), and on April 25, 2019 amended, restated and re-named the 2014 Plan as the 2019 Equity Incentive Plan (the A€œQuince 2019 PlanA€), which became effective as of May 7, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The remaining shares available for issuance under the 2014 Plan were added to the shares reserved for issuance under the Quince 2019 Plan.23Table of ContentThe Quince 2019 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to the CompanyA€™s employees, directors, and consultants. As of SeptemberA 30, 2024, the maximum aggregate number of shares that may be issued under the 2019 Plan is 11,755,418 shares of the CompanyA€™s common stock. In addition, the number of shares available for issuance under the Quince 2019 Plan will be annually increased on the first day of each fiscal years beginning with fiscal 2020, by an amount equal to the least of (i) 2,146,354 shares of common stock; (ii) 4% of the outstanding shares of its common stock as of the last day of its immediately preceding fiscal year; and (iii) such other amount as the Board may determine. The Quince 2019 Plan may be amended, suspended or terminated by the Board at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the Quince 2019 Plan as required by applicable law or listing requirements. Unless sooner terminated by the Company's Board of Directors, the 2019 Plan will automatically terminate on April 23, 2029.As of SeptemberA 30, 2024, the Company had 2,288,074 shares available for future issuance under the Quince 2019 Plan. Stock OptionsStock options under the 2019 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the fair market value of the shares on the date of grant. If, at the time of grant, the optionee directly owns stocks representing more than 10% of the voting power of all our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees and non-employees generally have a maximum term of ten years and vest over four years from the vesting commencement date, of which 25% vest on the one-year anniversary of the vesting commencement date, and 75% vest in equal monthly installments over the remaining three years or monthly vesting over 3 to 4 years. We may grant options with different vesting terms from time to time. Unless an employee's or non-employee's termination is due to cause, disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of the three months from the termination date or expiration of the option, whichever is earlier. Activity for service-based stock options under the Quince 2019 Plan is as follows:A Number ofOptions andUnvestedShares WeightedAverageExercise PriceWeightedaverage remainingcontractual life (years)Aggregate intrinsic valueA€ (In thousands)Balance as of December 31, 2023 4,267,178\$5.00A 8.85\$197A Options granted3,602,5001.26A A€A A€A Options exercised(155,311)0.93A A€A 65A Options cancelled / forfeited(165,861)13.06A A€A A€A Balance as of September 30, 2024 7,548,506\$3.12A 8.72\$5A Options vested and expected to vest as of September 30, 2024 7,548,506\$3.12A 8.72\$5A Options exercisable as of September 30, 2024 2,062,912\$7.86A 7.76\$A€A For the three and nine months ended SeptemberA 30, 2024, the Company recognized stock-based compensation expense of \$0.7 million and \$2.2 million, respectively, related to options granted to employees and non-employees. For the three and nine months ended SeptemberA 30, 2023, the Company recognized stock-based compensation expense of \$0.6 million and \$2.0 million, respectively, related to options granted to employees and non-employees. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the condensed consolidated statement of operations and comprehensive loss for stock-based compensation arrangements. As of SeptemberA 30, 2024, total unamortized employee stock-based compensation was \$5.5 million, which is expected to be recognized over the remaining estimated vesting period of 2.74 years.24Table of ContentRestricted Stock Units (A€œRSUsA€)RSUs are share awards that entitle the holder to receive freely tradable shares of the CompanyA€™s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the CompanyA€™s common stock on the grant date. RSUs granted to employees generally vest over a 2 A€œ 4 year period. The following table summarizes activity under the CompanyA€™s RSUs from the Quince 2019 Plan and related information:A Restricted Stock Units OutstandingA Number of Shares Weighted Average Grant Date Fair ValueUnvested - December 31, 2023 1,488\$4.30A RSUs grantedA€A A€A RSUs vested(1,488)4.30RSUs cancelledA€A A€A Unvested - September 30, 2024 A€A \$A€A The fair value of the RSUs is determined on the grant date based on the fair value of the CompanyA€™s common stock. The fair value of the RSUs is recognized as expense ratably over the vesting period of two years. For the three and nine months ended SeptemberA 30, 2024, the Company recognized stock-based compensation expense of \$0 and \$4.4A thousand, respectively, related to these RSUs. For the three and nine months ended SeptemberA 30, 2023, the Company recognized stock-based compensation expense of \$6.4A thousand and \$37.5A thousand respectively, related to these RSUs. As of SeptemberA 30, 2024, total unamortized stock-based compensation related to RSUs was \$0. 2019 Equity Incentive Plan (Novosteo)On MayA 19, 2022, in accordance with the term of the Merger Agreement, the Company assumed the 2019 Novosteo, Inc. Equity Incentive Plan (the "2019 Novosteo Plan"). The 2019 Novosteo Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to the Novosteo legacy employees. On the closing date, each outstanding Novosteo stock option granted under NovosteoA€™s equity compensation plans was converted into a corresponding stock option with the number of shares underlying such option and the applicable exercise price adjusted based on the exchange ratio of 0.0911. Each such converted stock option continues to be subject to substantially the same terms and conditions as applied to the corresponding Novosteo stock option prior to the Acquisition. The maximum aggregate number of shares that may be issued under the 2019 Novosteo Plan is 544,985 shares of the CompanyA€™s common stock. The 2019 Novosteo Plan may be amended, suspended or terminated by the Board at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the 2019 Novosteo Plan as required by applicable law or listing requirements. Unless sooner terminated by the Board, the 2019 Novosteo Plan will automatically terminate on May 20, 2029.Stock options under the 2019 Novosteo Plan may be granted for periods of up to 10 years and at prices no less than 100% of the fair market value of the shares on the date of grant. If, at the time of grant, the optionee directly owns stocks representing more than 10% of the voting power of all our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees and non-employees generally have a maximum term of ten years and vest over four years from the vesting commencement date, of which 25% vest on the one-year anniversary of the vesting commencement date, and 75% vest in equal monthly installments over the remaining three years or monthly vesting over 3 to 4 years. We may grant options with different vesting terms from time to time. Unless an employee's or non-employee's termination is due to cause, disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of the three months from the termination date or expiration of the option, whichever is earlier.As of SeptemberA 30, 2024, the Company had 246,797 shares available for future issuance under the 2019 Novosteo Plan. 25Table of ContentActivity for service-based stock options under the 2019 Novosteo Plan is as follows:A Number ofOptions andUnvestedShares WeightedAverageExercise PriceWeightedaverage remainingcontractual life (years)Aggregate intrinsic valueA€ (In thousands)Balance as of December 31, 2023 310,431\$0.55A 8.23\$155A Options grantedA€A A€A A€A A€A Options exercised(146,592)0.55A A€A A€A 94A Options cancelled / forfeitedA€A A€A A€A A€A Balance as of September 30, 2024 163,839\$0.55A 7.48\$37A Options vested and expected to vest as of September 30, 2024 163,839\$0.55A 7.48\$37A Options exercisable as of September 30, 2024 47,426\$0.55A 7.48\$11A For the three and nine months ended SeptemberA 30,

day immediately prior to the effectiveness of the registration statement filed in connection with the IPO. The 2019 ESPP is intended to qualify as an employee stock purchase plan under the meaning of Section 423 of the Internal Revenue Code (the "Code") for U.S. employees. In addition, the 2019 ESPP authorizes grants of purchase rights that do not comply with Section 423 of the Code under a separate non-423 component for non-U.S. employees and certain non-U.S. service providers. The Company has reserved 1,924,262 shares of common stock for issuance under the 2019 ESPP. In addition, the number of shares reserved for issuance under the 2019 ESPP will be increased automatically on the first day of each fiscal year for a period of up to ten years, starting with the 2020 fiscal year, by a number equal to the lesser of: (i) 536,589 shares; (ii) 1% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such lesser number of shares determined by the Company's Board of Directors. The 2019 ESPP is expected to be implemented through a series of offerings under which participants are granted purchase rights to purchase shares of the Company's common stock on specified dates during such offerings. The Company has not yet approved an offering under the 2019 ESPP. Note 9. Long-term Debt In connection with the acquisition of EryDel on October 20, 2023, the Company assumed an unsecured line of credit between EryDel and the European Investment Bank (the "EIB Loan"). The EIB Loan was amended and restated as of the acquisition date. The EIB Loan provides for maximum borrowings of 30.0 million euro through four tranches; tranche A, 3.0 million euro; tranche B, 7.0 million euro; tranche C, 10.0 million euro; and tranche D, 10.0 million euro. Each tranche is subject to conditions precedent related to the Company's business and capitalization. As of September 30, 2024, only tranches A and B have been drawn. All amounts due under tranche A and B are payable on their maturity date of August 2026. Tranche C and D are payable in equal installments of principal together with all amounts outstanding under the tranches on the repayment dates specified in the relevant Disbursement Offer. The first Repayment Date of tranche C shall fall not earlier than twelve months from the Disbursement Date of such tranche. The last Repayment Date of tranche C and tranche D shall fall not later than 5 years from the Disbursement Date of tranche C and tranche D, respectively. The EIB Loan bears interest at fixed rates for each tranche and is payable on the maturity date for each Tranche. The fixed rates range from 7.0% to 9.0% per annum. As of September 30, 2024, principal of 10.0 million euros (\$11.2 million) was outstanding on the EIB Loan and it is recorded as Long-term debt on the condensed consolidated balance sheet at fair value with imputed interest of 9.0% included. The Debt Agreement requires the Company to maintain a minimum cash balance of 14.654 million euros (\$16.44 million) until the outstanding obligations under the Debt Agreement, together with accrued interest and all other amounts accrued or outstanding under the agreement, is repaid in full (the "Minimum Cash Covenant"). Furthermore, the Company may at any time voluntarily prepay, in whole or in part, together with certain fees as set forth in the Debt Agreement, the outstanding obligations under the Debt Agreement. In the event of a default or a change in control, as specified in the Debt Agreement, EIB may, subject to certain grace periods, accelerate the outstanding obligations under the EIB Loan. In November 2024, the Company entered into an amendment (the "Amendment") of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment. The Debt Agreement includes a provision for additional remuneration to be paid in addition to interest. The amount of additional remuneration to be paid is equal to 2.5% of revenue up to 125.0 million euros, plus 1.85% of revenue between 125.0 and 250.0 million euros, plus 1.0% of revenue in excess of 250.0 million euros, multiplied by a varying percentage based on how many tranches have been drawn. The varying percentage is equal to 30.0% in the event tranche A has been drawn, 50.0% in the event tranche A and B have been drawn, 80.0% in the event tranche A, B and C have been drawn, and 100.0% in the event all four tranches have been drawn. The additional remuneration is payable for seven years, during the period January 1, 2026, through December 31, 2032. In the event of an occurrence of an event of default or prepayment, the Company may be required to pay an additional remuneration buyout fee. The Company elected to account for the EIB Loan at fair value, which requires the EIB Loan to be recorded at fair value at issuance and at the end of each reporting period. Gains or losses upon remeasurement are to be recorded in other expense, net in the condensed consolidated statements of operations and comprehensive income. The Company presents separately in other comprehensive income the portion of the total change in the fair value of the EIB Loan that results from a change in instrument-specific credit risk. The EIB Loan's fair value at the date it was assumed adjusted its carrying value based on using a discounted cash flow analysis with a discount rate based on a yield curve that was adjusted for credit rating. The change in fair value as of September 30, 2024 was determined using a discounted cash flow analysis discounted at the market yield. The significant inputs used to measure the market yield as of September 30, 2024 relative to the date the EIB Loan was assumed was the change in credit quality of the Company, the change in credit spreads for comparable debt instruments, and the change in the risk-free rate. As of September 30, 2024, the fair value of the EIB Loan is \$14.9 million, which includes a fair value adjustment of \$1.3 million and foreign currency translation of \$0.2 million during the nine months ended September 30, 2024. Future minimum principal payments, as of September 30, 2024 are as follows (in thousands): Quarter ended September 30, 2024 Amount 2024 \$4.75 2025 \$4.75 2026 \$4.75 2027 \$4.75 2028 \$4.75 2029 \$4.75 2030 \$4.75 2031 \$4.75 2032 \$4.75 2033 \$4.75 2034 \$4.75 2035 \$4.75 2036 \$4.75 2037 \$4.75 2038 \$4.75 2039 \$4.75 2040 \$4.75 2041 \$4.75 2042 \$4.75 2043 \$4.75 2044 \$4.75 2045 \$4.75 2046 \$4.75 2047 \$4.75 2048 \$4.75 2049 \$4.75 2050 \$4.75 2051 \$4.75 2052 \$4.75 2053 \$4.75 2054 \$4.75 2055 \$4.75 2056 \$4.75 2057 \$4.75 2058 \$4.75 2059 \$4.75 2060 \$4.75 2061 \$4.75 2062 \$4.75 2063 \$4.75 2064 \$4.75 2065 \$4.75 2066 \$4.75 2067 \$4.75 2068 \$4.75 2069 \$4.75 2070 \$4.75 2071 \$4.75 2072 \$4.75 2073 \$4.75 2074 \$4.75 2075 \$4.75 2076 \$4.75 2077 \$4.75 2078 \$4.75 2079 \$4.75 2080 \$4.75 2081 \$4.75 2082 \$4.75 2083 \$4.75 2084 \$4.75 2085 \$4.75 2086 \$4.75 2087 \$4.75 2088 \$4.75 2089 \$4.75 2090 \$4.75 2091 \$4.75 2092 \$4.75 2093 \$4.75 2094 \$4.75 2095 \$4.75 2096 \$4.75 2097 \$4.75 2098 \$4.75 2099 \$4.75 2100 \$4.75 2101 \$4.75 2102 \$4.75 2103 \$4.75 2104 \$4.75 2105 \$4.75 2106 \$4.75 2107 \$4.75 2108 \$4.75 2109 \$4.75 2110 \$4.75 2111 \$4.75 2112 \$4.75 2113 \$4.75 2114 \$4.75 2115 \$4.75 2116 \$4.75 2117 \$4.75 2118 \$4.75 2119 \$4.75 2120 \$4.75 2121 \$4.75 2122 \$4.75 2123 \$4.75 2124 \$4.75 2125 \$4.75 2126 \$4.75 2127 \$4.75 2128 \$4.75 2129 \$4.75 2130 \$4.75 2131 \$4.75 2132 \$4.75 2133 \$4.75 2134 \$4.75 2135 \$4.75 2136 \$4.75 2137 \$4.75 2138 \$4.75 2139 \$4.75 2140 \$4.75 2141 \$4.75 2142 \$4.75 2143 \$4.75 2144 \$4.75 2145 \$4.75 2146 \$4.75 2147 \$4.75 2148 \$4.75 2149 \$4.75 2150 \$4.75 2151 \$4.75 2152 \$4.75 2153 \$4.75 2154 \$4.75 2155 \$4.75 2156 \$4.75 2157 \$4.75 2158 \$4.75 2159 \$4.75 2160 \$4.75 2161 \$4.75 2162 \$4.75 2163 \$4.75 2164 \$4.75 2165 \$4.75 2166 \$4.75 2167 \$4.75 2168 \$4.75 2169 \$4.75 2170 \$4.75 2171 \$4.75 2172 \$4.75 2173 \$4.75 2174 \$4.75 2175 \$4.75 2176 \$4.75 2177 \$4.75 2178 \$4.75 2179 \$4.75 2180 \$4.75 2181 \$4.75 2182 \$4.75 2183 \$4.75 2184 \$4.75 2185 \$4.75 2186 \$4.75 2187 \$4.75 2188 \$4.75 2189 \$4.75 2190 \$4.75 2191 \$4.75 2192 \$4.75 2193 \$4.75 2194 \$4.75 2195 \$4.75 2196 \$4.75 2197 \$4.75 2198 \$4.75 2199 \$4.75 2200 \$4.75 2201 \$4.75 2202 \$4.75 2203 \$4.75 2204 \$4.75 2205 \$4.75 2206 \$4.75 2207 \$4.75 2208 \$4.75 2209 \$4.75 2210 \$4.75 2211 \$4.75 2212 \$4.75 2213 \$4.75 2214 \$4.75 2215 \$4.75 2216 \$4.75 2217 \$4.75 2218 \$4.75 2219 \$4.75 2220 \$4.75 2221 \$4.75 2222 \$4.75 2223 \$4.75 2224 \$4.75 2225 \$4.75 2226 \$4.75 2227 \$4.75 2228 \$4.75 2229 \$4.75 2230 \$4.75 2231 \$4.75 2232 \$4.75 2233 \$4.75 2234 \$4.75 2235 \$4.75 2236 \$4.75 2237 \$4.75 2238 \$4.75 2239 \$4.75 2240 \$4.75 2241 \$4.75 2242 \$4.75 2243 \$4.75 2244 \$4.75 2245 \$4.75 2246 \$4.75 2247 \$4.75 2248 \$4.75 2249 \$4.75 2250 \$4.75 2251 \$4.75 2252 \$4.75 2253 \$4.75 2254 \$4.75 2255 \$4.75 2256 \$4.75 2257 \$4.75 2258 \$4.75 2259 \$4.75 2260 \$4.75 2261 \$4.75 2262 \$4.75 2263 \$4.75 2264 \$4.75 2265 \$4.75 2266 \$4.75 2267 \$4.75 2268 \$4.75 2269 \$4.75 2270 \$4.75 2271 \$4.75 2272 \$4.75 2273 \$4.75 2274 \$4.75 2275 \$4.75 2276 \$4.75 2277 \$4.75 2278 \$4.75 2279 \$4.75 2280 \$4.75 2281 \$4.75 2282 \$4.75 2283 \$4.75 2284 \$4.75 2285 \$4.75 2286 \$4.75 2287 \$4.75 2288 \$4.75 2289 \$4.75 2290 \$4.75 2291 \$4.75 2292 \$4.75 2293 \$4.75 2294 \$4.75 2295 \$4.75 2296 \$4.75 2297 \$4.75 2298 \$4.75 2299 \$4.75 2300 \$4.75 2301 \$4.75 2302 \$4.75 2303 \$4.75 2304 \$4.75 2305 \$4.75 2306 \$4.75 2307 \$4.75 2308 \$4.75 2309 \$4.75 2310 \$4.75 2311 \$4.75 2312 \$4.75 2313 \$4.75 2314 \$4.75 2315 \$4.75 2316 \$4.75 2317 \$4.75 2318 \$4.75 2319 \$4.75 2320 \$4.75 2321 \$4.75 2322 \$4.75 2323 \$4.75 2324 \$4.75 2325 \$4.75 2326 \$4.75 2327 \$4.75 2328 \$4.75 2329 \$4.75 2330 \$4.75 2331 \$4.75 2332 \$4.75 2333 \$4.75 2334 \$4.75 2335 \$4.75 2336 \$4.75 2337 \$4.75 2338 \$4.75 2339 \$4.75 2340 \$4.75 2341 \$4.75 2342 \$4.75 2343 \$4.75 2344 \$4.75 2345 \$4.75 2346 \$4.75 2347 \$4.75 2348 \$4.75 2349 \$4.75 2350 \$4.75 2351 \$4.75 2352 \$4.75 2353 \$4.75 2354 \$4.75 2355 \$4.75 2356 \$4.75 2357 \$4.75 2358 \$4.75 2359 \$4.75 2360 \$4.75 2361 \$4.75 2362 \$4.75 2363 \$4.75 2364 \$4.75 2365 \$4.75 2366 \$4.75 2367 \$4.75 2368 \$4.75 2369 \$4.75 2370 \$4.75 2371 \$4.75 2372 \$4.75 2373 \$4.75 2374 \$4.75 2375 \$4.75 2376 \$4.75 2377 \$4.75 2378 \$4.75 2379 \$4.75 2380 \$4.75 2381 \$4.75 2382 \$4.75 2383 \$4.75 2384 \$4.75 2385 \$4.75 2386 \$4.75 2387 \$4.75 2388 \$4.75 2389 \$4.75 2390 \$4.75 2391 \$4.75 2392 \$4.75 2393 \$4.75 2394 \$4.75 2395 \$4.75 2396 \$4.75 2397 \$4.75 2398 \$4.75 2399 \$4.75 2400 \$4.75 2401 \$4.75 2402 \$4.75 2403 \$4.75 2404 \$4.75 2405 \$4.75 2406 \$4.75 2407 \$4.75 2408 \$4.75 2409 \$4.75 2410 \$4.75 2411 \$4.75 2412 \$4.75 2413 \$4.75 2414 \$4.75 2415 \$4.75 2416 \$4.75 2417 \$4.75 2418 \$4.75 2419 \$4.75 2420 \$4.75 2421 \$4.75 2422 \$4.75 2423 \$4.75 2424 \$4.75 2425 \$4.75 2426 \$4.75 2427 \$4.75 2428 \$4.75 2429 \$4.75 2430 \$4.75 2431 \$4.75 2432 \$4.75 2433 \$4.75 2434 \$4.75 2435 \$4.75 2436 \$4.75 2437 \$4.75 2438 \$4.75 2439 \$4.75 2440 \$4.75 2441 \$4.75 2442 \$4.75 2443 \$4.75 2444 \$4.75 2445 \$4.75 2446 \$4.75 2447 \$4.75 2448 \$4.75 2449 \$4.75 2450 \$4.75 2451 \$4.75 2452 \$4.75 2453 \$4.75 2454 \$4.75 2455 \$4.75 2456 \$4.75 2457 \$4.75 2458 \$4.75 2459 \$4.75 2460 \$4.75 2461 \$4.75 2462 \$4.75 2463 \$4.75 2464 \$4.75 2465 \$4.75 2466 \$4.75 2467 \$4.75 2468 \$4.75 2469 \$4.75 2470 \$4.75 2471 \$4.75 2472 \$4.75 2473 \$4.75 2474 \$4.75 2475 \$4.75 2476 \$4.75 2477 \$4.75 2478 \$4.75 2479 \$4.75 2480 \$4.75 2481 \$4.75 2482 \$4.75 2483 \$4.75 2484 \$4.75 2485 \$4.75 2486 \$4.75 2487 \$4.75 2488 \$4.75 2489 \$4.75 2490 \$4.75 2491 \$4.75 2492 \$4.75 2493 \$4.75 2494 \$4.75 2495 \$4.75 2496 \$4.75 2497 \$4.75 2498 \$4.75 2499 \$4.75 2500 \$4.75 2501 \$4.75 2502 \$4.75 2503 \$4.75 2504 \$4.75 2505 \$4.75 2506 \$4.75 2507 \$4.75 2508 \$4.75 2509 \$4.75 2510 \$4.75 2511 \$4.75 2512 \$4.75 2513 \$4.75 2514 \$4.75 2515 \$4.75 2516 \$4.75 2517 \$4.75 2518 \$4.75 2519 \$4.75 2520 \$4.75 2521 \$4.75 2522 \$4.75 2523 \$4.75 2524 \$4.75 2525 \$4.75 2526 \$4.75 2527 \$4.75 2528 \$4.75 2529 \$4.75 2530 \$4.75 2531 \$4.75 2532 \$4.75 2533 \$4.75 2534 \$4.75 2535 \$4.75 2536 \$4.75 2537 \$4.75 2538 \$4.75 2539 \$4.75 2540 \$4.75 2541 \$4.75 2542 \$4.75 2543 \$4.75 2544 \$4.75 2545 \$4.75 2546 \$4.75 2547 \$4.75 2548 \$4.75 2549 \$4.75 2550 \$4.75 2551 \$4.75 2552 \$4.75 2553 \$4.75 2554 \$4.75 2555 \$4.75 2556 \$4.75 2557 \$4.75 2558 \$4.75 2559 \$4.75 2560 \$4.75 2561 \$4.75 2562 \$4.75 2563 \$4.75 2564 \$4.75 2565 \$4.75 2566 \$4.75 2567 \$4.75 2568 \$4.75 2569 \$4.75 2570 \$4.75 2571 \$4.75 2572 \$4.75 2573 \$4.75 2574 \$4.75 2575 \$4.75 2576 \$4.75 2577 \$4.75 2578 \$4.75 2579 \$4.75 2580 \$4.75 2581 \$4.75 2582 \$4.75 2583 \$4.75 2584 \$4.75 2585 \$4.75 2586 \$4.75 2587 \$4.75 2588 \$4.75 2589 \$4.75 2590 \$4.75 2591 \$4.75 2592 \$4.75 2593 \$4.75 2594 \$4.75 2595 \$4.75 2596 \$4.75 2597 \$4.75 2598 \$4.75 2599 \$4.75 2600 \$4.75 2601 \$4.75 2602 \$4.75 2603 \$4.75 2604 \$4.75 2605 \$4.75 2606 \$4.75 2607 \$4.75 2608 \$4.75 2609 \$4.75 2610 \$4.75 2611 \$4.75 2612 \$4.75 2613 \$4.75 2614 \$4.75 2615 \$4.75 2616 \$4.75 2617 \$4.75 2618 \$4.75 2619 \$4.75 2620 \$4.75 2621 \$4.75 2622 \$4.75 2623 \$4.75 2624 \$4.75 2625 \$4.75 2626 \$4.75 2627 \$4.75 2628 \$4.75 2629 \$4.75 2630 \$4.75 2631 \$4.75 2632 \$4.75 2633 \$4.75 2634 \$4.75 2635 \$4.75 2636 \$4.75 2637 \$4.75 2638 \$4.75 2639 \$4.75 2640 \$4.75 2641 \$4.75 2642 \$4.75 2643 \$4.75 2644 \$4.75 2645 \$4.75 2646 \$4.75 2647 \$4.75 2648 \$4.75 2649 \$4.75 2650 \$4.75 2651 \$4.75 2652 \$4.75 2653 \$4.75 2654 \$4.75 2655 \$4.75 2656 \$4.75 2657 \$4.75 2658 \$4.75 2659 \$4.75 2660 \$4.75 2661 \$4.75 2662 \$4.75 2663 \$4.75 2664 \$4.75 2665 \$4.75 2666 \$4.75 2667 \$4.75 2668 \$4.75 2669 \$4.75 2670 \$4.75 2671 \$4.75 2672 \$4.75 2673 \$4.75 2674 \$4.75 2675 \$4.75 2676 \$4.75 2677 \$4.75 2678 \$4.75 2679 \$4.75 2680 \$4.75 2681 \$4.75 2682 \$4.75 2683 \$4.75 2684 \$4.75 2685 \$4.75 2686 \$4.75 2687 \$4.75 2688 \$4.75 2689 \$4.75 2690 \$4.75 2691 \$4.75 2692 \$4.75 2693 \$4.75 2694 \$4.75 2695 \$4.75 2696 \$4.75 2697 \$4.75 2698 \$4.75 2699 \$4.75 2700 \$4.75 2701 \$4.75 2702 \$4.75 2703 \$4.75 2704 \$4.75 2705 \$4.75 2706 \$4.75 2707 \$4.75 2708 \$4.75 2709 \$4.75 2710 \$4.75 2711 \$4.75 2712 \$4.75 2713 \$4.75 2714 \$4.75 2715 \$4.75 2716 \$4.75 2717 \$4.75 2718 \$4.75 2719 \$4.75 2720 \$4.75 2721 \$4.75 2722 \$4.75 2723 \$4.75 2724 \$4.75 2725 \$4.75 2726 \$4.75 2727 \$4.75 2728 \$4.75 2729 \$4.75 2730 \$4.75 2731 \$4.75 2732 \$4.75 2733 \$4.75 2734 \$4.75 2735 \$4.75 2736 \$4.75 2737 \$4.75 2738 \$4.75 2739 \$4.75 2740 \$4.75 2741 \$4.75 2742 \$4.75 2743 \$4.75 2744 \$4.75 2745 \$4.75 2746 \$4.75 2747 \$4.75 2748 \$4.75 2749 \$4.75 2750 \$4.75 2751 \$4.75 2752 \$4.75 2753 \$4.75 2754 \$4.75 2755 \$4.75 2756 \$4.75 2757 \$4.75 2758 \$4.75 2759 \$4.75 2760 \$4.75 2761 \$4.75 2762 \$4.75 2763 \$4.75 2764 \$4.75 2765 \$4.75 2766 \$4.75 2767 \$4.75 2768 \$4.75 2769 \$4.75 2770 \$4.75 2771 \$4.75 2772 \$4.75 2773 \$4.75 2774 \$4.75 2775 \$4.75 2776 \$4.75 2777 \$4.75 2778 \$4.75 2779 \$4.75 2780 \$4.75 2781 \$4.75 2782 \$4.75 2783 \$4.75 2784 \$4.75 2785 \$4.75 2786 \$4.75 2787 \$4.75 2788 \$4.75 2789 \$4.75 2790 \$4.75 2791 \$4.75 2792 \$4.75 2793 \$4.75 2794 \$4.75 2795 \$4.75 2796 \$4.75 2797 \$4.75 2798 \$4.75 2799 \$4.75 2800 \$4.75 2801 \$4.75 2802 \$4.75 2803 \$4.75 2804 \$4.75 2805 \$4.75 2806 \$4.75 2807 \$4.75 2808 \$4.75 2809 \$4.75 2810 \$4.75 2811 \$4.75 2812 \$4.75 2813 \$4.75 2814 \$4.75 2815 \$4.75 2816 \$4.75 2817 \$4.75 2818 \$4.75 2819 \$4.75 2820 \$4.75 2821 \$4.75 2822 \$4.75 2823 \$4.75 2824 \$4.75 2825 \$4.75 2826 \$4.75 2827 \$4.75 2828 \$4.75 2829 \$4.75 2830 \$4.75 2831 \$4.75 2832 \$4.75 2833 \$4.75 2834 \$4.75 2835 \$4.75 2836 \$4.75 2837 \$4.75 2838 \$4.75 2839 \$4.75 2840 \$4.75 2841 \$4.75 2842 \$4.75 2843 \$4.75 2844 \$4.75 2845 \$4.75 2846 \$4.75 2847 \$4.75 2848 \$4.75 2849 \$4.75 2850 \$4.75 2851 \$4.75 2852 \$4.75 2853 \$4.75 2854 \$4.75 2855 \$4.75 2856 \$4.75 2857 \$4.75 2858 \$4.75 2859 \$4.75 2860 \$4.75 2861 \$4.75 2862 \$4.75 2863 \$4.75 2864 \$4.75 2865 \$4.75 2866 \$4.75 2867 \$4.75 2868 \$4.75 2869 \$4.75 2870 \$4.75 2871 \$4.75 2872 \$4.75 2873 \$4.75 2874 \$4.75 2875 \$4.75 2876 \$4.75 2877 \$4.75 2878 \$4.75 2879 \$4.75 2880 \$4.75 2881 \$4.75 2882 \$4.75 2883 \$4.75 2884 \$4.75 2885 \$4.75 2886 \$4.75 2887 \$4.75 2888 \$4.75 2889 \$4.75 2890 \$4.75 2891 \$4.75 2892 \$4.75 2893 \$4.75 2894 \$4.75 2895 \$4.75 2896 \$4.75 2897 \$4.75 2898 \$4.75 2899 \$4.75 2900 \$4.75 2901 \$4.75 2902 \$4.75 2903 \$4.75 2904 \$4.75 2905 \$4.75 2906 \$4.75 2907 \$4.75 2908 \$4.75 2909 \$4.75 2910 \$4.75 2911 \$4.75 2912 \$4.75 2913 \$4.75 2914 \$4.75 2915 \$4.75 2916 \$4.75 2917 \$4.75 2918 \$4.75 2919 \$4.75 2920 \$4.75 2921 \$4.75 2922 \$4.75 2923 \$4.75 2924 \$4.75 2925 \$4.75 2926 \$4.75 2927 \$4.75 2928 \$4.75 2929 \$4.75 2930 \$4.75 2931 \$4.75 2932 \$4.75 2933 \$4.75 2934 \$4.75 2935 \$4.75 2936 \$4.75 2937 \$4.75 2938 \$4.75 2939 \$4.75 2940 \$4.75 2941 \$4.75 2942 \$4.75 2943 \$4.75 2944 \$4.75 2945 \$4.75 2946 \$4.75 2947 \$4.75 2948 \$4.75 2949 \$4.75 2950 \$4.75 2951 \$4.75 2952 \$4.75 2953 \$4.75 2954 \$4.75 2955 \$4.75 2956 \$4.75 2957 \$4.75 2958 \$4.75 2959 \$4.75 2960 \$4.75 2961 \$4.75 2962 \$4.75 2963 \$4.75 2964 \$4.75 2965 \$4.75 2966 \$4.75 2967 \$4.75 2968 \$4.75 2969 \$4.75 2970 \$4.75 2971 \$4.75 2972 \$4.75 2973 \$4.75 2974 \$4.75 2975 \$4.75 2976 \$4.75 2977 \$4.75 2978 \$4.75 2979 \$4.75 2980 \$4.75 2981 \$4.75 2982 \$4.75 2983 \$4.75 2984 \$4.75 2985 \$4.75 2986 \$4.75 2987 \$4.75 2988 \$4.75 2989 \$4.75 2990 \$4.75 2991 \$4.75 2992 \$4.75 2993 \$4.75 2994 \$4.75 2995 \$4.75 2996 \$4.75 2997 \$4.75 2998 \$4.75 2999 \$4.75 3000 \$4.75 3001 \$4.75 3002 \$4.75 3003 \$4.75 3004 \$4.75 3005 \$4.75 3006 \$4.75 3007 \$4.75 3008 \$4.75 3009 \$4.75 3010 \$4.75 3011 \$4.75 3012 \$4.75 3013 \$4.75 3014 \$4.75 3015 \$4.75 3016 \$4.75 3017 \$4.75 3018 \$4.75 3019 \$4.75 3020 \$4.75 3021 \$4.75 3022 \$4.75 3023 \$4.75 3024 \$4.75 3025 \$4.75 3026 \$4.75 3027 \$4.75 3028 \$4.75 3029 \$4.75 3030 \$4.75 3031 \$4.75 3032 \$4.75 3033 \$4.75 3034 \$4.75 3035 \$4.75 3036 \$4.75 3037 \$4.75 3038 \$4.75 3039 \$4.75 3040 \$4.75 3041 \$4.75 3042 \$4.75 3043 \$4.75 3044 \$4.75 3045 \$4.75 3046 \$4.75 3047 \$4.75 3048 \$4.75 3049 \$4.75 3050 \$4.75 3051 \$4.75 3052 \$4.75 3053 \$4.75 3054 \$4.75 3055 \$4.75 3056 \$4.75 3057 \$4.75 3058 \$4.75 3059 \$4.75 3060 \$4.75 3061 \$4.75 3062 \$4.75 3063 \$4.75 3064 \$4.75 3065 \$4.75 3066 \$4.75 3067 \$4.75 3068 \$4.75 3069 \$4.75 3070 \$4.75 3071 \$4.75 3072 \$4.75 3073 \$4.75 3074 \$4.75 3075 \$4.75 3076 \$4.75 3077 \$4.75 3078 \$4.75 3079 \$4.75 3080 \$4.75 3081 \$4.75 3082 \$4.75 3083 \$4.75 3084 \$4.75 3085 \$4.75 3086 \$4.75 3087 \$4.75 3088 \$4.75 3089 \$4.75 3090 \$4.75 3091 \$4.75 3092 \$4.75 3093 \$4.75 3094 \$4.75 3095 \$4.75 3096 \$4.75 3097

biology for the treatment of rare diseases. Our proprietary AIDE technology platform is an innovative drug/device combination platform that uses an automated process to encapsulate a drug into a patientâ€™s own red blood cells. Red blood cells have several characteristics that make them a potentially ideal vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Our AIDE technology is designed to harness many of these benefits to allow for new and improved therapeutic options for patients living with high unmet medical needs. The AIDE technology platform may confer benefits over conventional therapies and if so, AIDE has the potential to be applied to a broad range of small or large molecule drugs and biologics. EryDex is the first product in development that leverages our AIDE technology and is composed of DSP encapsulated in autologous red blood cells targeted to treat a rare pediatric neurodegenerative disease called A-T. DSP is a corticosteroid well known for its anti-inflammatory properties, as well as its dose-limiting toxicity due to adrenal suppression. EryDex is designed to alter the pharmacokinetics and biodistribution of the DSP allowing for effective and safe treatment.As of November 13, 2024, 32 patients have been enrolled in the Phase 3 NEAT clinical trial of EryDex in A-T. We expect to report topline results from this trial in the fourth quarter of 2025, with a potential NDA submission in 2026, assuming positive study results. During the third quarter of 2024, and in accordance with the EryDel Purchase Agreement, we paid the former EryDel shareholders a cash milestone payment of \$5 million related to the initiation of the Phase 3 clinical trial of EryDex in A-T. Additionally, on October 20, 2024, in accordance with the EryDel Purchase Agreement, no indemnification claim against the EryDel Shareholders had been made by the Company and all 725,037 Indemnity Holdback Shares were released to the former EryDel shareholders. No additional shares are required to be issued in connection with the EryDel Acquisition.We also completed a patient sizing project with third-party analysis from IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics, which confirmed that there are approximately 4,600 diagnosed patients with A-T in the U.S. Currently, there are no approved treatments for A-T and the global market, based on our internal estimates and assumptions, represents a more than \$1 billion peak commercial opportunity. We believe this could allow EryDex to demonstrate the clinical benefit and commercial potential of our AIDE technology.Proprietary AIDE Technology PlatformOur proprietary AIDE technology platform is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patientâ€™s own red blood cells. The AIDE technology drug/device combination consists of a specialized automated equipment including the RCL, a sterile single-use consumable treatment kit called EryKit, Syringe Kit, drug, and process solutions. Red blood cells have several characteristics that make them a potentially ideal vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Our AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. In this way, our AIDE technology may confer benefits over conventional therapies and if so, AIDE has the potential to be applied to a broad range of small or large molecule drugs and biologics. The use of autologous blood may minimize safety risks associated with the use of donor blood and may reduce the potential immunogenic risks associated donor cells and engineered cell therapies.35Table of ContentThe RCL is a proprietary CE marked non-invasive device that allows blood processing at the point of care. With a user-friendly touch screen interface, the RCL automates the AIDE process technology by handling the blood, drug, and processing solutions with the use of the proprietary EryKit. Our EryKit is a CE marked medical device that provides the essential single-use components for loading the patientâ€™s red blood cells with DSP by using the RCL. The RCL, EryKit, and Syringe Kit have been CE marked in accordance with the MDR. Process solutions (Hypotonic Solution 1&2 and Hypertonic Solution PIGPA) are proprietary sterile solutions. CE marked according to the MDD, aimed to create suitable osmotic condition during the process to allow the drug diffusion into red blood cells and the subsequent restoring of physiological condition.The automated AIDE process and treatment is designed to be completed at the point-of-care and includes a series of steps which take approximately two hours from start to finish. This process includes:â€¢Collection of patientâ€™s blood using our proprietary Syringe Kit.â€¢Processing the patient's collected blood in the RCL using our proprietary EryKit.â€¢Autologous red blood cells in the RCL are swollen and their pores are â€¢openedâ€¢ in two steps using two sequential hypotonic process solutions. â€¢Drug is added to the RCL and enters into the opened red blood cells. â€¢Physiological osmotic conditions are then restored by adding a hypertonic solution that â€¢resealsâ€¢ the red blood cells.â€¢Drug that is not encapsulated during the process is removed by extensive washing with an injectable saline solution. â€¢Upon completion of the AIDE process, the drug encapsulated red blood cells are infused into the patient. Potential Benefits of Red Blood Cell Encapsulated Drug DeliveryMany efficacious drugs have limited therapeutic potential because of dose limiting toxicity, while other drugs may have efficacy ceilings due to inferior biodistribution, pharmacokinetics and pharmacodynamics. Our proprietary AIDE technology uses an automated process designed to encapsulate a drug into the patientâ€™s own red blood cells to deliver a therapy in a potentially more effective and safer way. Autologous red blood cells have several characteristics that make them an ideal vehicle for drug delivery:â€¢Potential for improved biodistribution as encapsulated drug in autologous red blood cells is designed to enable the slow release of the drug from the red blood cells traversing through the body, various tissue beds, and many capillaries for desired therapeutic effect.â€¢Potential for altered pharmacokinetics and pharmacodynamics, including long circulating half-life, and altered or improved tissue distribution. The altered pharmacokinetics and pharmacodynamics of the encapsulated drug delivery enabled by autologous red blood cells may significantly increase the desired therapeutic effect and/or improve the safety profile of the therapy.â€¢Potential for improved biocompatibility through the use of autologous red blood cells to, thereby avoiding issues with donor compatibility.â€¢Potential for the encapsulation of small or large molecules, peptides, and proteins inside of autologous red blood cells to limit biodegradability, thereby altering the encapsulated drugâ€™s metabolism and degradation.â€¢Potential for significantly decreasing adverse effects of treatments.36Table of ContentNew Indications and Program Expansion PotentialThe flexibility of the AIDE platform has the potential to provide benefits over conventional therapies and if so, could be applied to a broad range of drugs ranging from small to large molecules, as well as biologics. Potential benefits include better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life which we believe could be an advantage for treating patients. We selected Duchenne muscular dystrophy (DMD) as our second development program. We consider DMD an ideal indication for EryDex as corticosteroids are the standard of care for this rare disease, but its utility is limited by significant chronic toxicity due to adrenal suppression. As a result, corticosteroid treatment in patients with DMD is commonly interrupted during adolescence due to interference with sexual maturation and delayed puberty. As a next step, we intend to focus on generating a Phase 2 clinical trial designed to evaluate EryDex for the potential treatment of patients with DMD, including those with corticosteroid intolerance who represent the majority of the DMD population. We plan to initiate a DMD Phase 2 study in 2025, which we plan to conduct utilizing capital efficient study approaches.We also completed an initial assessment of other potential indications for EryDex where chronic corticosteroid treatment is â€¢orâ€¢ has the potential to become â€¢aâ€¢ standard of care if there were not corticosteroid-related safety concerns. This evaluation process spanned across ataxia, neuromuscular, hematology, cancer, and autoimmune disease indications with a focus on rare diseases. The prioritized list of other potential rare disease targets beyond A-T and DMD includes: 1) autoimmune hepatitis, 2) dermatomyositis, 3) pemphigus vulgaris, 4) Hashimoto's encephalopathy, 5) Becker muscular dystrophy, 6) pediatric lupus, 7) juvenile idiopathic arthritis, 8) myasthenia gravis, 9) limb-girdle muscular dystrophy, 10) chronic inflammatory demyelinating polyradiculoneuropathy, and 11) pulmonary sarcoidosis. To support our drug development pipeline expansion in a capital efficient structure, we would prioritize an investigator initiated clinical trial approach to evaluate EryDex for other potential rare disease indications. In addition, we intend to evaluate other potential applications of the AIDE technology platform using drugs and biologics targeted at rare and debilitating diseases to further expand our drug development pipeline.Our AIDE technology platform reflects more than 20 years of innovation and approximately \$100 million of investment, which has resulted in innovation that creates high barriers to competitive entry. The RCL, EryKit, Syringe Kit, and process solutions are proprietary products and CE marked in the EU, in accordance with the MDR and MDD.Limitations of Chronic Corticosteroid AdministrationDSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. Our AIDE technology is designed to encapsulate DSP in a patientâ€™s own red blood cells and to alter the biodistribution, pharmacokinetics, and pharmacodynamics of the DSP allowing for both effective and safe treatment.The optimal efficacy of corticosteroids is the result of two pharmacokinetic characteristics: 1) an initial bolus to achieve a high Cmax that results in high levels of corticosteroid receptor occupation; and 2) sufficient sustained tissue concentrations that allow for continued receptor site occupancy over time. In order for a conventional corticosteroid to achieve these characteristics, the drug must be dosed frequently, typically daily. Long-term daily dosing regimens sufficient to provide efficacy, lead to significant and debilitating long-term adverse effects associated with HPA axis suppression. Corticosteroid therapy without significant long-term safety liabilities would represent a major advancement in the treatment of many chronic diseases where corticosteroids are already known to be beneficial.37Table of ContentPhase 3 Lead Asset â€¢EryDex for the Potential Treatment of A-TOur top strategic priority is to complete the Phase 3 clinical trial of EryDex, called NEAT (Neurologic Effects of EryDex on Subjects with A-T; NCT06193200 / IEDAT-04-2022), to evaluate its safety and efficacy for the potential treatment of A-T. We also plan to continue investigating additional indications for EryDex. These priorities include the following activities and corporate milestones:â€¢Initiate our open label extension study in 2024.â€¢Complete enrollment in our Phase 3 NEAT clinical trial in the first half of 2025.â€¢Report our Phase 3 NEAT clinical trial top-line results in the fourth quarter of 2025.â€¢Prepare for a U.S. NDA submission in 2026, provided we obtain positive NEAT clinical trial results.â€¢Pursue potential strategic partnerships to out-license ex-U.S. regional territories to extend operational runway to support potential NDA approval of EryDex, as well as further advance other potential indications. Pivotal Phase 3 NEAT Clinical Trial of EryDex in Patients with A-TWe dosed the first patient with A-T in our Phase 3 NEAT clinical trial in the second quarter of 2024. As of November 13, 2024, we have enrolled 32 patients. NEAT is an international, multicenter, randomized, double-blind, placebo-controlled study to evaluate the neurological effects of EryDex in patients with A-T. To date, we have enrolled seven patients with A-T in the NEAT clinical trial across clinical sites in the U.S., U.K., and European Union and expect NEAT site activation and patient screenings to accelerate over the next quarter. We plan to enroll approximately 86 patients with A-T ages six to nine years old randomized (1:1) between EryDex or placebo, and approximately 20 patients with A-T ages 10 years or older. Participants who complete the full treatment period, complete the study assessments, and provide informed consent 38Table of Contentwill be eligible to transition to an open label extension program after trial completion. The primary efficacy endpoint for the NEAT clinical trial will be measured by the change from baseline to last visit completion in RmICARS.Regulatory InteractionsThe pivotal Phase 3 NEAT clinical trial is conducted under an SPA agreement with the U.S. FDA, which should allow for the submission of an NDA following completion of this study, provided we obtain positive results. Additionally, the FDA recently granted Fast Track designation for our EryDex System for the treatment of patients with A-T. The Fast Track designation has been granted based on the potential for EryDex to address a high unmet medical need for patients with A-T. Fast Track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review. Our plan would be to submit the NDA in 2026 with expectations to submit a MAA to the EMA shortly thereafter. EryDex has been classified as a drug/device combination product by the U.S. FDA. We anticipate submitting a 505(b)(2) NDA to the FDA, which allows us to rely upon the agencyâ€™s prior findings of safety and effectiveness for the active pharmaceutical ingredient, DSP.EryDex has been granted orphan drug designation for the treatment of A-T from the U.S. FDA and EU EC. The EryDex Systemâ€™s RCL is a CE marked non-invasive device that allows blood processing at the point of care. The EryKit is a CE marked medical device in accordance with the MDR and the Process Solutions are CE marked in accordance with the MDD.Prior ATteST Phase 3 Clinical Trial Results in Patients with A-TWe gained valuable learnings from the prior Phase 3 clinical trial of EryDex, called ATteST (Ataxia-Telangiectasia Trial with the EryDexSysTem; NCT02770807 / IEDAT-02-2015), which is the largest global clinical trial of patients with A-T.ATteST was an international, multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial of patients ages six years and older. A review of the data suggests that treating patients early can be an important factor in A-T because the rate of neurological deterioration is most pronounced between the ages of six to nine years old. The objective of ATteST was to evaluate the effect of two doses (Low Dose and High Dose DSP/infusion) of EryDex, compared to placebo, on central nervous system symptoms in subjects with A-T. The initial treatment period was six months. All participants who completed efficacy assessments over the initial six months were eligible to continue in an additional six-month, double blind, placebo-controlled treatment designed to collect longer-term safety and efficacy data. There were 176 patients randomized (1:1:1) between Low Dose (mean of 8.2 mg Â± standard deviation of 3.3 mg), High Dose (mean of 17.4 mg Â± standard deviation of 5.4 mg), and placebo. Participants received monthly doses for 12 months. At time points of month six and nine, one-third of participants on placebo switched to active drug, respectively. All participants who completed treatment in the ATteST study were subsequently eligible to enroll in an open-label extension study (NCT03563053 / IEDAT-03-2018; OLE-IEDAT) with 104 participants receiving High Dose EryDex. The primary efficacy endpoint of ATteST was change in neurological symptoms from baseline to month six measured by mICARS (modified version of ICARS) comparing EryDex active arms and the placebo control arm using a mixed model repeated measures analysis. The ICARS was developed to quantify the level of impairment as a result of ataxia related to hereditary ataxias. The key secondary efficacy endpoint of ATteST was the change in global clinical status from baseline until month six as measured by the CGI-C. The safety objective was to evaluate the safety and tolerability of two dose levels of EryDex compared to placebo based on the occurrence of treatment-emergent AEs over the 12-month double-blind study duration.39Table of ContentHigh Dose EryDex missed the primary efficacy endpoint with a p-value of 0.077 however, statistical significance was observed in the per protocol (PP) analysis with a p-value of 0.019. Most of the clinical signs of neurodegeneration are observed in patients with A-T before the age of 10. By the age of 12, the vast majority of patients with A-T have become non-ambulatory and the neurological signs of disease progression slow significantly since most of the lower limb neuronal damage has already occurred. mICARS is focused on lower limb movement and published natural history data suggest two distinctive regression patterns between patients ages six to nine and 10 years or older with rapid neurological deterioration in the younger age group (six to nine years) compared to a much slower deterioration in older patients (10 years or older), many of whom are non-ambulatory. These data underpin the treatment effect in the patient population where neurodegeneration is most pronounced. Subgroup analyses were performed in the six to nine year old subgroup in the mITT population and there was a statistically significant difference for mICARS in the High Dose group as compared to placebo.In the ATteST clinical trial, EryDex treatment was well tolerated with only mild to moderate transient AEs that rapidly resolved without medical intervention in all dose groups. No patterns of clinically relevant AEs were observed. Additionally, there were no clear, clinically significant differences in potential corticosteroid-induced side effects observed between the treated and placebo groups, including adrenal insufficiency, cushingoid appearance, osteoporosis, growth and development through puberty, and serious systemic infections.40Table of ContentFinancial OverviewComponents of Results of OperationsOperating ExpensesOur operating expenses since inception have consisted primarily of R&D activities and G&A costs.Research and Development Expenses Our research and development expenses consist of expenses incurred in connection with the research and development of our research programs. These expenses include payroll and personnel expenses, including stock-based compensation, for our research and product development employees, laboratory supplies, product licenses, consulting costs, contract research, regulatory, quality assurance, preclinical and clinical expenses, allocated rent, facilities costs and depreciation. We expense both internal and external research and development costs as they are incurred. Non-refundable advance payments and deposits for services that will be used or rendered for future research and development activities are recorded as prepaid expenses and recognized as an expense as the related services are performed.Historically, our research and development expenses have supported the advancement of atuzaginstat (COR388) and COR588 and to a lesser extent the clinical and regulatory development of NOV004. As we sold our legacy protease inhibitor portfolio including COR388 and COR588 to Lighthouse Pharmaceuticals, Inc. in January 2023, we did not incur any additional expenses related to these legacy assets from the second quarter of 2023 onward. Additionally, due to the decision made on January 30, 2023 to discontinue internal development of NOV004 and following the termination of the License Agreement with PRF on October 31, 2023, we have not and do not expect to incur any NOV004 costs in 2024. With the acquisition of EryDel, we expect our research and development expenses to remain in the current levels as we continue our Phase 3 NEAT clinical trial and potentially expand into new indications.General and AdministrativeGeneral and administrative expenses consist principally of personnel-related costs, including payroll and stock-based compensation, for personnel in executive, finance, human resources, business and corporate development, and other administrative functions, professional fees for legal, consulting, insurance and accounting services, allocated rent and other facilities costs, depreciation, and other general operating expenses not otherwise classified as research and development expenses.41Table of ContentFair Value Adjustment for Contingent ConsiderationWe record fair value adjustment for contingent consideration primarily due to the passage of time related to the contingent consideration earnout resulting from the EryDel Acquisition. Changes in the fair value of the contingent consideration obligations may result from changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations.Fair Value Adjustment for Long-term DebtWe record fair value adjustment for long-term debt primarily due to the passage of time and the interest accrued for the loan with the EIB.Interest IncomeInterest and other income, net consists primarily of interest earned on our short-term and long-term investments portfolio.Other Income (Expense). netOther income (expense), net

consists primarily of the effects of foreign currency exchange rates. Critical Accounting Policies and Significant Judgments and EstimatesOur management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts. Actual results may differ from these estimates under different assumptions or conditions. There were no material changes to our critical accounting policies in the three months ended September 30, 2024 from those described in Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K.

Results of OperationsComparison of the three months ended September 30, 2024 to the three months ended September 30, 2023The following sets forth our results of operations for the three months ended September 30, 2024 and 2023 (in thousands, except for percentages):

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
Operating expenses:Research and development	\$1,431A \$1,431A \$3,485A 244A %	\$1,431A \$1,431A \$3,485A 244A %
General and administrative	\$633A 6,633A (1,033)(22)%	\$633A 6,633A (1,033)(22)%
Fair value adjustment for contingent consideration	\$2,683A 2,683A (A (2,683)100A %	\$2,683A 2,683A (A (2,683)100A %
Total operating expenses	\$6,094A (231)(4)%	\$6,094A (231)(4)%
Loss from operations	\$5,863(6,094)231A (4)%	\$5,863(6,094)231A (4)%
Fair value adjustment for long-term debt	\$449A 449A (A (449)100A %	\$449A 449A (A (449)100A %
Interest income	\$683A 959A (276)(29)%	\$683A 959A (276)(29)%
Other income (expense), net	\$150A (216)366A (169)%	\$150A (216)366A (169)%
Net loss before income tax benefit	\$(5,479)(5,351)(128)2A %	\$(5,479)(5,351)(128)2A %
Income tax (expense) benefit	\$(13)A 13(100A %	\$(13)A 13(100A %
Net loss	\$(5,492)(5,351)(141)3A %	\$(5,492)(5,351)(141)3A %

Table of ContentResearch and Development Expenses (in thousands, except for percentages):

	Three Months Ended September 30, 2024	Three Months Ended September 30, 2023
Direct research and development expenses:Personnel related (including stock-based compensation)	\$1,572A 1,311A 261A 20A %	\$1,572A 1,311A 261A 20A %
Facilities and other research and development expenses	\$134A 103A 31A 30A %	\$134A 103A 31A 30A %
Total research and development expenses	\$4,916A \$1,431A \$3,485A 244A %	\$4,916A \$1,431A \$3,485A 244A %

Research and development expenses were \$4.9 million for the three months ended September 30, 2024, compared to \$1.4 million for the three months ended September 30, 2023, an increase of \$3.5 million. The costs for EryDex development increased by \$3.2 million in the three months ended September 30, 2024 compared to the same period from the prior year due to the initiation of the Phase 3 NEAT clinical trial. This increase was primarily due to clinical trial costs of \$2.9 million and \$0.3 million manufacturing costs. Our personnel related costs increased by \$0.3 million during the three months ended September 30, 2024 as compared to the three months ended September 30, 2023, mainly as a result of an increase in personnel related expenses due to higher employee headcount compared to September 30, 2023. Facilities and other research and development expenses increased by \$31.0 thousand for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023 primarily due to an increase in rent and facilities expenses. General and Administrative ExpensesGeneral and administrative expenses decreased by \$1.03 million to \$3.63 million for the three months ended September 30, 2024, from \$4.66 million for the three months ended September 30, 2023. The decrease in general and administrative expenses is primarily due to a decrease of \$0.9 million in consulting and professional fees, \$0.5 million decrease in legal fees, and \$0.1 million decrease in corporate insurance. These decreases were partially offset by an increase of \$0.1 million in personnel related expenses, \$0.1 million increase in audit and tax fees, \$0.1 million increase in commercial and new product planning expenses, and \$0.1 million increase in other professional and administrative expenses year over year.

Fair Value Adjustment for Contingent ConsiderationFor the three months ended September 30, 2024, we recorded a fair value adjustment for contingent consideration which resulted in a \$2.7 million charge primarily due to the passage of time related to the contingent consideration earnouts resulting from the EryDel Acquisition and achieving and paying the first milestone after dosing the first patient in our Phase 3 NEAT clinical trial. Fair Value Adjustment for Long-term DebtFor the three months ended September 30, 2024, we recorded a fair value adjustment for long-term debt which resulted in a \$0.4 million charge primarily due to the passage of time and the interest accrued for the loan with the EIB. Interest IncomeInterest income decreased by \$276.0 thousand for the three months ended September 30, 2024, as compared to the three months ended September 30, 2023. The change was due to a decreased yields on our investment portfolio which and decreased average balances.

Table of ContentOther Income (Expense), netOther income (expense), net increased by \$0.4 million for the three months ended September 30, 2024 primarily due to \$0.3 million unrealized gains resulting from changes in foreign exchange rates. Income TaxWe recorded tax expense of \$13.0 thousand for the three months ended September 30, 2024, primarily related to foreign withholding tax, interest on uncertain tax position liability and net of tax benefit from decrease in EryDel’s deferred tax liabilities. Results of OperationsComparison of the nine months ended September 30, 2024 to the nine months ended September 30, 2023The following sets forth our results of operations for the nine months ended September 30, 2024 and 2023 (in thousands, except for percentages):

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Operating expenses:Research and development	\$12,765A \$6,013A \$6,752A 112A %	\$12,765A \$6,013A \$6,752A 112A %
General and administrative	\$13,296A 12,786A 510A 4A %	\$13,296A 12,786A 510A 4A %
Goodwill impairment charge	\$17,130A 17,130A 100A %	\$17,130A 17,130A 100A %
Intangible asset impairment charge	\$5,900A (5,900)100A %	\$5,900A (5,900)100A %
Fair value adjustment for contingent consideration	\$2,082A 2,082A 100A %	\$2,082A 2,082A 100A %
Total operating expenses	\$45,273A 24,699A 20,574A 83A %	\$45,273A 24,699A 20,574A 83A %
Loss from operations	\$(45,273)(24,699)(20,574)83A %	\$(45,273)(24,699)(20,574)83A %
Fair value adjustment for long-term debt	\$(1,252)A 1,252(100A %	\$(1,252)A 1,252(100A %
Interest income	\$2,393A 2,464A (71)(3)%	\$2,393A 2,464A (71)(3)%
Other income (expense), net	\$(158)(504)346A (69)%	\$(158)(504)346A (69)%
Net loss before income tax benefit	\$(44,290)(22,739)(21,551)95A %	\$(44,290)(22,739)(21,551)95A %
Income tax (expense) benefit	\$(80)A 248A (328)(132)%	\$(80)A 248A (328)(132)%
Net loss	\$(44,370)(22,491)(21,879)97A %	\$(44,370)(22,491)(21,879)97A %

Research and Development Expenses (in thousands, except for percentages):

	Nine Months Ended September 30, 2024	Nine Months Ended September 30, 2023
Direct research and development expenses:Personnel related (including stock-based compensation)	\$3,303A 3,405A (102)(3)%	\$3,303A 3,405A (102)(3)%
Facilities and other research and development expenses	\$429A 386A 43A 11A %	\$429A 386A 43A 11A %
Total research and development expenses	\$12,765A \$6,013A \$6,752A 112A %	\$12,765A \$6,013A \$6,752A 112A %

Research and development expenses were \$12.8 million for the nine months ended September 30, 2024, compared to \$6.0 million for the nine months ended September 30, 2023, an increase of \$6.8 million.

Table of ContentThe costs for EryDex development increased by \$8.9 million compared to the same period from the prior year due to the start-up and ramping up costs related to our Phase 3 NEAT clinical trial. This increase was primarily due to clinical trial costs of \$8.1 million and \$0.8 million in manufacturing costs. After the decision made on January 30, 2023 to discontinue internal development of NOV004 and following the termination of the License Agreement with PRF on October 31, 2023, we have not and do not expect to incur any NOV004 costs in 2024. Our personnel related costs decreased by \$0.1 million during the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023, mainly as a result of a \$0.6 million decrease in allocated stock-based compensation costs, offset by a \$0.5 million increase in personnel related expenses. Facilities and other research and development expenses increased by \$43.0 thousand for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023 primarily due to an increase in rent and facilities expenses. General and Administrative ExpensesGeneral and administrative expenses increased by \$0.5 million to \$13.3 million for the nine months ended September 30, 2024, from \$12.8 million for the nine months ended September 30, 2023. The increase in general and administrative expenses is primarily due to an increase of \$1.9 million in personnel related expenses, \$0.2 million increase in commercial and new product planning expenses, \$0.2 million increase in audit and tax fees, and \$0.6 million increase in other professional and administrative expenses year over year. These increases were partially offset by a decrease of 1.5 million in legal fees, \$0.7 million in consulting and professional fees expenses, and \$0.2 million in corporate insurance expenses. Fair Value Adjustment for Contingent ConsiderationFor the nine months ended September 30, 2024, we recorded a fair value adjustment for contingent consideration which resulted in a \$2.1 million charge primarily due to the passage of time related to the contingent consideration earnouts resulting from the EryDel Acquisition and achieving and paying the first milestone after dosing the first patient in our Phase 3 NEAT clinical trial. Fair Value Adjustment for Long-term DebtFor the nine months ended September 30, 2024, we recorded a fair value adjustment for long-term debt which resulted in a \$1.3 million charge primarily due to the passage of time and the interest accrued for the loan with the EIB. Goodwill Impairment ChargeDuring the nine months ended September 30, 2024, we conducted an impairment analysis of our goodwill that resulted from the acquisition of EryDel in October 2023. That assessment included a qualitative assessment of deteriorating macro-economic conditions, including inflationary pressures and high interest rates, and the continuing decline in our market capitalization from the date of the acquisition. This qualitative assessment indicated that our goodwill was potentially impaired. To determine the extent, if any, by which our goodwill was impaired, we conducted additional quantitative analyses which resulted in our fair value being significantly below our current carrying value. As a result of the analyses, we recorded a non-cash goodwill impairment charge of \$17.1 million for the nine months ended September 30, 2024. Intangible Assets Impairment ChargeDuring the nine months ended September 30, 2023, we conducted an impairment analysis of our intangible asset IPR&D that resulted from the purchase of Novosteo, Inc. in May 2022. To determine the extent, if any, by which our IPR&D Intangible Asset was impaired, we conducted a quantitative analysis which resulted in our fair value being significantly below our current carrying value due to the assumptions changing as a result of the decision to hold this asset for sale in January 2023. As a result of the analyses, we recorded a non-cash intangible asset IPR&D impairment charge of \$5.9 million for the nine months ended September 30, 2023.

Table of ContentInterest IncomeInterest income decreased by \$0.1 million for the nine months ended September 30, 2024, as compared to the nine months ended September 30, 2023. The change was due to decreased yields on our investment portfolio and decreased average balances. Other Income (Expense), netOther income (expense), net increased by \$0.3 million for the nine months ended September 30, 2024 primarily due to unrealized gains resulting from changes in foreign exchange rates. Income TaxWe recorded tax expense of \$0.1 million for the nine months ended September 30, 2024 and tax benefit of \$0.2 million for the nine months ended September 30, 2023. The change is primarily related to foreign withholding tax, interest on uncertain tax position liability and net of tax benefit from decrease in EryDel’s deferred tax liabilities. Liquidity and Capital ResourcesSince commencing material operations in 2014, we have devoted substantially all of our efforts and financial resources to building our research and development capabilities, establishing our corporate infrastructure and most recently, executing our Phase 1a, Phase 1b and Phase 2/3 clinical trials of atuzaginstat (COR388), our Phase 1 SAD/MAD clinical trial of COR588, to a lesser extent reading NOV004 for Phase 1 clinical trial, and initiating EryDex Phase 3 NEAT clinical trial. We have sold our legacy small molecule protease inhibitor portfolio and terminated the license of our NOV004 bone targeting drug. To date, we have not generated any revenue and we have never been profitable. We have incurred net losses since the commencement of our operations. As of September 30, 2024, we had an accumulated deficit of \$364.0 million. We incurred a net loss of \$44.4 million in the nine months ended September 30, 2024. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a drug candidate, and we cannot assure you that we will ever generate significant revenue or profits. To date, we have financed our operations primarily through the issuance and sale of convertible promissory notes and redeemable convertible preferred stock and common stock. From inception through September 30, 2024, we received net proceeds of approximately \$303.9 million from the issuance of redeemable convertible preferred stock, convertible promissory notes and common stock. In connection with the acquisition of EryDel on October 20, 2023, we assumed an unsecured line of credit between EryDel and the European Investment Bank (the “EIB Loan”). The EIB Loan was amended and restated as of the acquisition date. The EIB Loan provides for maximum borrowings of 30.0 million euro through four tranches; tranche A, 3.0 million euro; tranche B, 7.0 million euro; tranche C, 10.0 million euro; and tranche D, 10.0 million euro. Each tranche is subject to conditions precedent related to our business and capitalization. As of September 30, 2024, only tranches A and B have been drawn. All amounts due under tranche A and B are payable on their maturity date of August 2026. Tranche C and D are payable in equal installments of principal together with all amounts outstanding under the tranches on the repayment dates specified in the relevant Disbursement Offer. The first Repayment Date of tranche C shall fall not earlier than twelve months from the Disbursement Date of such tranche. The last Repayment Date of tranche C and tranche D shall fall not later than 5 years from the Disbursement Date of tranche C and tranche D, respectively. The EIB Loan bears interest at fixed rates for each tranche and is payable on the maturity date for each tranche. The fixed rates range from 7.0% to 9.0% per annum. As of September 30, 2024, principal of 10.0 million euros (\$11.2 million) was outstanding on the EIB Loan and it is recorded as Long-term debt on the condensed consolidated balance sheet at fair value with imputed interest of 9.0% included. We may voluntarily prepay, in whole or in part with a prepayment premium. In the event of an occurrence of an event of default, a change in control and certain other prepayment events, as specified in the Debt Agreement, we will be required to prepay the outstanding EIB Debt together with an additional remuneration buyout fee, as specified in the Debt Agreement. The Debt Agreement includes a provision for additional remuneration to be paid in addition to interest. The amount of additional remuneration to be paid is equal to 2.5% of revenue up to 125.0 million euros, plus 1.85% of revenue between 125.0 and 250.0 million euros, plus 1.0% of revenue in excess of 250.0 million euros, multiplied by a varying percentage.

Table of Contentbased on how many tranches have been drawn. The varying percentage is equal to 30.0% in the event tranche A has been drawn, 50.0% in the event tranche A and B have been drawn, 80.0% in the event tranche A, B and C have been drawn, and 100.0% in the event all four tranches have been drawn. The additional remuneration is payable for seven years, during the period January 1, 2026, through December 31, 2032. In the event of an occurrence of an event of default or prepayment, we may be required to pay an additional remuneration buyout fee. In November 2024, the Company entered into an amendment (the “Amendment”) of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment. As of September 30, 2024, we have been in compliance with all covenants under the Debt Agreement. As of September 30, 2024 and December 31, 2023, we had cash, cash equivalents and short-term investments of \$47.8 million and \$75.1 million, respectively. Based on our current business plans, we believe that our existing capital resources will be sufficient to fund our projected operating requirements for at least the next twelve months from the date of the issuance of the accompanying condensed consolidated financial statements. Our cash, cash equivalents, and marketable debt securities are held in a variety of deposit accounts, interest-bearing accounts, U.S government securities, debt securities in government-sponsored entities, and money market funds. Cash in excess of immediate requirements is invested with a view toward liquidity and capital preservation, and we seek to minimize the potential effects of concentration and credit risk. Our cash equivalents and short-term investments are held in money market funds, certificate of deposits, and government agency obligations. We believe that our existing cash, cash equivalents and investments will be sufficient to fund our planned operations into the first quarter of 2026, but does not include any costs or cash expenditures associated with initiating additional programs. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. Capital ResourcesOur primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures related to EryDex, the initiation and continuation of the Phase 3 NEAT clinical trial, and general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. In January 2023 we out-licensed our legacy protease inhibitors to Lighthouse and in October 2023 terminated our license for NOV004. We also intend to concentrate our efforts on development of EryDex. Accordingly, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of any drug candidates or whether, or when, we may achieve profitability. We may continue to require additional capital to develop our drug candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with other companies, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. Following our acquisition of EryDel, we anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including: the progress, costs, trial design, results of and timing of our Phase 3 NEAT clinical trial and any potential future trials; the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals; the payment of future milestones to EryDel shareholders and payments to the EIB in respect of obligations under the EIB Facility; the number and characteristics of drug candidates that we pursue; the ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; our need and ability to retain management and hire scientific and clinical personnel; the effect of competing drugs and drug candidates and other market developments; our need to implement additional internal systems and infrastructure, including financial and reporting systems; and the economic and other terms, timing of and success of any collaboration, licensing or other arrangements into which we may enter in the future. If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger,

consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to other rights to our drug candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide. However, based on our current business plans, we believe that our existing cash, cash equivalents and investments will be sufficient to fund our planned operations, which would include anticipated clinical and development activities related to EryDex through completion of the Phase 3 NEAT clinical trial, and into 2026, but does not include any costs or cash expenditures associated with initiating additional programs. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.

Cash FlowsThe following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):

A Nine Months Ended September 30, 2024	2023	Net cash (used in) provided by:
Operating activities	\$(24,352)	\$(12,214)
Investing activities	11,041	(11,148)
Financing activities	(4,775)	864

Effect of exchange rate changes on cash

9A	329A	
Net increase in cash and cash equivalents	\$(18,077)	\$(22,947)

Operating ActivitiesCash used in operating activities was \$24.4 million for the nine months ended September 30, 2024. Cash used in operating activities was primarily due to our net loss of \$44.4 million for the period, adjusted for \$22.4 million of non-cash items, including \$17.1 million goodwill impairment charge, \$2.1 million change in the fair value of contingent consideration liabilities, \$3.6 million in stock-based compensation, and a net increase in our operating assets of \$2.5 million, offset by a net increase in our accounts payable, and accrued expenses and other current liabilities of \$0.1 million. Cash used in operating activities was \$12.2 million for the nine months ended September 30, 2023. Cash used in operating activities was primarily due to our net loss of \$22.5 million for the period, adjusted for \$8.6 million of non-cash items, including \$4.1 million in stock-based compensation and \$5.9 million in impairment loss due to the write down of the IPR&D asset, as well as a net increase in our current assets of \$2.4 million, offset by a net decrease in accounts payable, accrued expenses and other current liabilities of \$0.7 million.

Table of ContentInvesting ActivitiesCash provided by investing activities was \$11.0 million for the nine months ended September 30, 2024, primarily related to the maturities of short-term investments of \$100.7 million, and the purchase of investments of \$89.6 million. Cash used by investing activities was \$11.1 million in the nine months ended September 30, 2023, primarily related to the purchase of investments of \$95.1 million, and maturities of investments of \$84.5 million.

Financing ActivitiesCash used in financing activities was \$4.8 million for the nine months ended September 30, 2024, which consisted of a cash milestone payment of \$5 million, partially offset by proceeds of \$0.2 million from the exercise of stock options in the period. Cash provided by financing activities was \$0.1 million in the nine months ended September 30, 2023, which consisted of net proceeds from the exercise of stock options in the period.

Contractual Obligations and CommitmentsExcept as discussed below, there have been no material changes to our contractual obligations and other commitments as of September 30, 2024, as compared to those disclosed in our Annual Report on Form 10-K. Our contractual obligations primarily consist of our obligations under non-cancellable operating leases and other purchase obligations. We enter into contracts in the normal course of business with third party contract organizations for clinical trials, non-clinical studies and testing, manufacturing, and other services and products for operating purposes. The amount and timing of the payments under these contracts varies based upon the timing of the services. We have recorded accrued expense of approximately \$1.5 million in our condensed consolidated balance sheet for expenditures incurred by these vendors as of September 30, 2024. We have approximately \$27.5 million in cancellable future operating expense commitments based on existing contracts as of September 30, 2024. These obligations will be satisfied in the normal course of business, but generally no longer than 12 months. As of September 30, 2024, the fair value of the EIB loan is \$14.9 million and it is recorded as long-term debt on the condensed consolidated balance sheet at fair value. As of September 30, 2024, the fair value of long-term contingent consideration on our books for the earnout related to the EryDel Acquisition is \$54.8 million, refer to Note 3 to the condensed consolidated financial statements for further details.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.

Item 4. Controls and Procedures.Evaluation of Disclosure Controls and ProceduresOur disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act, is recorded, communicated to our management to allow timely decisions regarding required disclosure, summarized and reported within the time periods specified in the SEC's rules and forms. Any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Under the supervision and with the participation of our management, including the Chief Executive Officer and Principal Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of September 30, 2024. Based on that evaluation, the Chief Executive Officer and Principal Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective.

Table of ContentChanges in Internal Control over Financial ReportingThere have been no changes in our internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of ContentPART IIâ€œOTHER INFORMATIONItem 1. Legal Proceedings.From time to time, we may become involved in legal proceedings arising in the ordinary course of business. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity and reputational harm and other factors.

Item 1A. Risk Factors.Summary of Risk FactorsWe may be unable for many reasons, including those that are beyond our control, to implement our business strategy successfully. The occurrence of any single risk or any combination of risks could materially and adversely affect our business, financial condition, results of operations, cash flows and the trading price of our common stock. Some of these risks are:

â€œWe may experience difficulties integrating Quince and EryDelâ€œ's operations and realizing the expected benefits of the EryDel Acquisition.â€œWe are substantially dependent on the success of our lead drug candidate, EryDex. The Phase 3 NEAT clinical trial of EryDex for A-T is being conducted under a protocol negotiated with FDA by EryDel and our execution of the trial may be delayed, may not be successful, and may not result in NDA approval, with adverse results for our business and share price.â€œWe have no drug candidates approved for commercial sale, we have never generated any revenue from sales, and we may never be profitable.â€œWe have and may be required to make additional milestone payments to EryDel shareholders or pursuant to the EIB Facility in connection with our commercialization of EryDex, which could adversely affect the overall profitability of EryDex, if approved.â€œClinical drug development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any drug candidate that we may advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval.â€œResults in earlier clinical trials may not be indicative of the results that may be obtained in further registrational clinical trials, which may delay or prevent obtaining regulatory approval.â€œWe will incur additional costs and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates.â€œOur drug candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential.â€œClinical trials of our drug candidates may not uncover all possible AEs that patients may experience.â€œIf we are not able to successfully demonstrate a favorable differentiation between EryDex and currently available corticosteroids, our business would be harmed and our ability to generate revenue from that class of drugs would be severely impaired.â€œBecause the potential rare disease target patient populations of EryDex are small, and the addressable patient population even smaller, we may not be able to effectively complete clinical trials or commercialize the drug candidate.â€œWe are a clinical stage biotechnology company with a limited operating history, which may make it difficult to evaluate the prospects for our future viability.â€œWe will require substantial additional funding to finance our operations and to develop and evaluate current and future drug candidates. If we are unable to raise this funding when needed or on acceptable terms, we may be forced to delay, reduce or eliminate our drug development programs or other operations.â€œThe terms of the EIB Facility place restrictions on our operating and financial flexibility.â€œWe cannot be certain that the FDA or foreign regulatory authorities will permit us to proceed with any current or future proposed clinical trial designs. Our drug candidates may not receive regulatory approval, and without regulatory approval we will not be able to market our drug candidates.â€œClinical failure can occur at any stage of clinical development and we have never submitted an NDA or comparable foreign applications before.â€œClinical trials of our drug candidates have in the past been put on clinical holds by, and failed to demonstrate safety and efficacy to the satisfaction of, the FDA, and if any future clinical trials of our drug candidates are put on clinical holds by, or fail to demonstrate safety and efficacy to the satisfaction of, the FDA, the EMA, or similar regulatory authorities outside the United States, or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates.â€œWe currently rely and expect to continue to rely on third parties to conduct some of our preclinical studies and clinical trials and some aspects of our research and preclinical testing and on third-party contract manufacturing organizations to manufacture and supply our preclinical, clinical and commercial materials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, manufacturing or testing.â€œIf we or any of our third-party manufacturers or suppliers encounter difficulties in production of our future drug candidates, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our future drug candidates for clinical trials or for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure.â€œIf, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any drug candidates we may develop, we may not be successful in commercializing those drug candidates if and when they are approved.â€œIf we are unable to obtain and maintain sufficient intellectual property protection for our current drug candidates, any future drug candidates, and other proprietary technology we develop, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize our current drug candidate, if approved, any future drug candidates, and other proprietary technologies if approved, may be adversely affected.â€œWe may not be successful in obtaining or maintaining necessary rights to our drug candidates through acquisitions and in-licenses.â€œOur stockholders may realize little or no value from the divestiture of our legacy assets, and as a result our stock price may decline, we could be subject to litigation, and our business may be adversely affected.â€œWe have in the past and may in the future fail to meet the requirements for continued listing on Nasdaq. If we fail to maintain compliance with the minimum listing requirements, our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock. Our operations and financial results are subject to various risks and uncertainties, including those described below that could adversely affect our business, financial condition, results of operations, cash flows and the trading price of our common stock. You should carefully consider the following risks, together with all of the other information in this Quarterly Report on Form 10-Q, including our consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. We have marked with an asterisk (*) those risks described below that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K.

Risks Relating to Our BusinessWe may experience difficulties integrating Quince and EryDelâ€œ's operations and realizing the expected benefits of the EryDel Acquisition. The success of the EryDel Acquisition will depend in part on our ability to realize the expected operational efficiencies and associated cost synergies and anticipated business opportunities and growth prospects from the EryDel Acquisition in an efficient and effective manner. We may not be able to fully realize the operational efficiencies and associated cost synergies or leverage the potential business opportunities and growth prospects to the extent anticipated or at all.

Table of ContentChallenges associated with the integration may include those related to retaining and motivating executives and other key employees, blending corporate cultures, eliminating duplicative operations, and making necessary modifications to internal control over financial reporting and other policies and procedures in accordance with applicable laws. Some of these factors are outside our control, and any of them could delay or increase the cost of our integration efforts. The integration process could take longer than anticipated and could result in the loss of key employees, the disruption of each companyâ€œ's ongoing businesses, increased tax costs, inefficiencies, and inconsistencies in standards, controls, information technology systems, policies and procedures, any of which could adversely affect our ability to maintain relationships with employees or third parties, or our ability to achieve the anticipated benefits of the transaction, and could harm our financial performance. If we are unable to successfully integrate certain aspects of the operations of EryDel, including relevant human resource functions, or experience delays, we may incur unanticipated liabilities and be unable to fully realize the potential benefit of future revenue and other anticipated benefits resulting from the arrangement, and our business, results of operations and financial condition could be adversely affected. We are substantially dependent on the success of our lead drug candidate, EryDex. Our business and future success depends on our ability to successfully develop, obtain regulatory approval for and successfully commercialize our lead drug candidate, EryDex, which is under clinical development for A-T. EryDex is our only drug candidate in late-stage clinical development, and our business currently depends heavily on its successful development. In the previous Phase 3 ATTeST trial, the trial did not meet the primary efficacy endpoint. The trial saw statistically significant results in the age group of six to nine years old. We initiated the NEAT clinical trial in this population in the second quarter 2024, and expect to announce the results of the NEAT clinical trial in the fourth quarter of 2025, but cannot guarantee that the results of this study will be positive or that they will allow further development in this therapeutic indication. EryDex will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. We cannot be certain EryDex will receive regulatory approval or be successfully commercialized even if we receive regulatory approval. In addition, because EryDex is our most advanced drug candidate, and because our other drug candidates are based on the same AIDE platform technology, if EryDex encounters safety or efficacy problems, developmental delays or regulatory issues or other problems, our development plans and business would be significantly harmed. We have no drug candidates approved for commercial sale, we have never generated any revenue from sales, and we may never be profitable.*We have no drug candidates approved for sale, have never generated any revenue from sales, have never been profitable and do not expect to be profitable in the foreseeable future. We have incurred net losses in each year since our inception. For the quarters ended September 30, 2024 and 2023, our net losses were \$5.5A million and \$5.4A million, respectively. We had an accumulated deficit of \$364.0A million as of September 30, 2024. Before we are able to generate any revenue, we will need to commit substantial funds to the anticipated clinical and development activities related to EryDex, and we may not be able to obtain sufficient funds on acceptable terms, if at all. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us and/or result in dilution to our stockholders. We expect that it could take several years, if ever, before we may have a drug candidate ready for commercialization. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we pursue our current strategic direction, and seek regulatory approvals for any drug candidates, prepare for and begin the commercialization of any approved drug candidates, and add infrastructure and personnel to support our drug development efforts and operations as a public company. We anticipate that any such losses could be significant for the next several years. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholdersâ€œ equity and working capital. Further, these net losses have fluctuated significantly in the past and are expected to continue to significantly fluctuate from quarter-to-quarter or year-to-year. To become and remain profitable, we must develop and eventually commercialize a drug with significant revenue. However, we may never succeed in developing a commercial drug. We expect to explore partnership and licensing opportunities to support the future development of EryDex and other drug candidates. We may also encounter other unforeseen expenses, difficulties, complications, delays and other known and unknown challenges as we pursue our current strategic direction.

Table of ContentThere are numerous risks and uncertainties, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to generate revenues or achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional drug candidates. We have and may be required to make milestone payments to the EryDel shareholders or pursuant to the EIB Facility in connection with our development and commercialization of EryDex, which could adversely affect the overall profitability of EryDex, if approved.*In connection with the EryDel Acquisition, we have and may be required to make additional payments to EryDel shareholders of up to an aggregate of \$485.0 million in potential cash payments, comprised of up to \$5.0 million upon the achievement of a specified development milestone, which was achieved in the second quarter of 2024, \$25.0 million at NDA acceptance, up to \$60.0 million upon the achievement of the specified approval milestones, and up to \$395.0 million upon the achievement of specified on market and sales milestones, with no royalties paid to EryDel. These milestone

obligations could impose substantial additional costs on us, divert resources from other aspects of our business, and adversely affect the overall profitability of EryDex, if approved. We may need to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. During the three months ended June 30, 2024, we enrolled the first patient in the Phase 3 NEAT clinical trial. Within 45 days of the achievement of the milestones, we notified the former EryDel shareholders of this achievement. Additionally, within 30 days of the notification, we paid the cash milestone payment of \$5A million to the former EryDel shareholders in accordance with the purchase agreement entered into in connection with EryDel Acquisition. We owe no further payments to EryDel shareholders for development-related milestones. The remaining potential contingent payments in connection with the EryDel Acquisition pertain to regulatory on market and sales milestones. Additionally, in connection with the EIB Facility, we are also required to make additional payments to the EIB consisting of (i) interest payments on the outstanding loans thereunder, (ii) payments based on a percentage of the revenue derived from the acquisition of EryDel on October 23, 2023, which will be payable annually commencing with the first such payment commencing on June 30, 2027 with respect to the immediately preceding fiscal year, and (iii) repayments of the principal amount of the loans under the EIB Facility upon the occurrence of certain events. The occurrence of certain events of default under the EIB Facility, including failure to make payments as they become due (subject to a grace period of three (3) business days) to the EIB, would result in the EIB having the right to accelerate and demand immediate payment of all outstanding obligations, together with accrued interest, if any, and any prepayment fees, under the EIB Facility. We may need additional funding in order to make such payments. Our future results could suffer if we do not effectively manage our operations. In connection with our new strategic pursuits, we may expand our size and operations through the EryDel Acquisition. Our future success depends, in part, upon our ability to manage such expanded business, which may pose substantial challenges for management, including challenges related to the management and monitoring of new operations and associated increased costs and complexity. There can be no assurances that we will be successful or that we will realize the expected synergies and other benefits anticipated from any future acquisitions or strategic transactions that we may undertake in the future. Our financial results have been in the past and may in the future be adversely affected by impairment charges from the recording of goodwill and intangible assets. *Our financial results have been in the past and may in the future be adversely affected by impairment charges from the recording of goodwill and intangible assets incurred in connection with acquisitions. For example, during the quarter ended June 30, 2024, we incurred a \$17.1 million goodwill impairment charge in connection with the EryDel Acquisition. Additionally, we incurred a \$0.8 million goodwill impairment charge in the quarter ended September 30, 2022 and a \$5.9 million IPR&D Intangible Asset impairment charge for the quarter ended March 31, 2023 in connection with the Novosteo Acquisition. Further, our failure to identify or accurately assess the magnitude of necessary technology investments we assumed as a result of the EryDel Acquisition could result in unexpected litigation or regulatory exposure, unfavorable accounting charges, a loss of anticipated tax benefits or other adverse effects on our business, operating results or financial condition.

54Table of Content**Risks Related to the Development of Our Drug Candidates**

The Phase 3 NEAT clinical trial of EryDex for A-T will be conducted under a protocol negotiated with FDA by EryDel and our execution of the trial may be delayed, may not be successful, and may not result in NDA approval, with adverse results for our business and share price. With the acquisition of our Phase 3 lead asset, EryDex, we initiated the Phase 3 NEAT clinical trial in the first half of 2024. The NEAT protocol is the subject of an SPA, agreement with FDA. The FDA may revoke or alter its SPA agreement under the following circumstances: **â€** public health concerns emerge that were unrecognized at the time of the protocol assessment, or the director of the review division determines that a substantial scientific issue essential to determining safety or efficacy has been identified after testing has begun; **â€** a sponsor fails to follow a protocol that was agreed upon with the FDA; or **â€** the relevant data, assumptions, or information provided by the sponsor in a request for SPA change, are found to be false statements or misstatements, or are found to omit relevant facts. A documented SPA may be modified, and such modification will be deemed binding on the FDA review division, except under the circumstances described above, if the FDA and the sponsor agree in writing to modify the protocol and such modification is intended to improve the study. An SPA, however, does not guarantee that a trial will be successful, and our execution of the Phase 3 NEAT clinical trial may be delayed and even if successful may not result in approval by the FDA. We, or any future development partner with whom we enter into a related agreement, are required to conduct clinical and nonclinical trials in accordance with the study plan and protocols and applicable regulatory requirements. The FDA or comparable regulatory authorities outside the U.S., including in the EU, may disagree with the design or implementation of our or any of our future development partners' clinical trials. We or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities outside the U.S., including in the EU, that a product candidate is safe and effective for any indication. In addition, we are responsible for ensuring that each of our nonclinical studies and clinical trials are conducted in accordance with the study plan and protocols and applicable regulatory requirements and that drug candidates are manufactured and tested in accordance with applicable GMP requirements and other applicable regulatory requirements. If we or any future development partner are unable to demonstrate that our candidate drugs were manufactured and clinical trials were conducted in accordance with applicable regulations we may be unable to submit appropriate evidence to support applications for drug approval and the authorities may reject or related applications. Clinical drug development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always predictive of future results. Any drug candidate that we may advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval. The research and development of drugs is extremely risky. Only a small percentage of drug candidates that enter the development process ever receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any drug candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. The results of preclinical studies and completed clinical trials are not necessarily predictive of future results, and our current drug candidate may not be further developed or have favorable results in later studies or trials. Clinical trial failure may result from a multitude of factors including, but not limited to, flaws in study design, dose selection, placebo effect, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits. As such, failure in clinical trials can occur at any stage of testing. The Phase 3 ATTeST clinical trial conducted by EryDel failed to meet the primary endpoint and was potentially negatively affected by missing data during the COVID-19 pandemic. Several companies in the pharmaceutical industry have suffered setbacks in the advancement of their drug candidates into later-stage clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding results in earlier preclinical studies or clinical trials. In addition, data obtained from preclinical trials and clinical trials are susceptible to varying interpretations, and regulatory authorities may not interpret our data as favorably as we do, which may further delay, limit or prevent development efforts, clinical trials or marketing approval. Furthermore, as more competing drug candidates within a particular class of drugs

55Table of Content**proceed through clinical development to regulatory review and approval, the amount and type of clinical data that may be required by regulatory authorities may increase or change.** If we are unable to complete preclinical studies or clinical trials of any future drug candidates, due to safety or efficacy concerns, or if the results of these trials are not sufficient to convince regulatory authorities of their safety or efficacy, we will not be able to obtain marketing approval for commercialization on a timely basis or at all. Even if we are able to obtain marketing approval for our current and any future drug candidates, those approvals may be for indications or dose levels that deviate from our desired approach or may contain other limitations that would adversely affect our ability to generate revenue from sales of those drug candidates. Results in earlier clinical trials may not be indicative of the results that may be obtained in registrational clinical trials, which may delay or prevent obtaining regulatory approval. Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies and early clinical trials may not be predictive of results in larger clinical trials, and previous results from early or small clinical trials may not be replicated or show as favorable an outcome in further clinical trials, even if successful. For example, EryDel had previously endeavored to develop EryDex for the potential treatment of A-T. While we have not seen evidence of significant safety concerns throughout EryDex Phase 3 clinical development for A-T, it failed to meet the primary endpoint, but showed statistically effective results in a certain population, six to nine years old. We plan to conduct a Phase 3 NEAT clinical trial in the population (i.e. six to nine years old) that was found to be statistically effective. However, further studies in this population may not replicate previous results. Accordingly, the previous clinical trials that EryDel conducted may not have uncovered safety issues, even if they exist. The biochemical pathways that we believe are affected by EryDex are implicated in a variety of biological processes and disease conditions, and it is possible that the use of our drug candidates to treat larger numbers of patients will demonstrate unanticipated AEs, which may negatively affect their safety profile. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, or after achieving positive results in pivotal trials, and we have had, and may face, similar setbacks. In addition, the patient populations under investigation with EryDex have many co-morbidities that may cause severe illness or death, which may be attributed to EryDex in a manner that negatively affects the safety profile of our drug candidate. If the results of our ongoing or future clinical trials for EryDex are inconclusive with respect to efficacy, if we do not meet our clinical endpoints with statistical significance, or if there are unanticipated safety concerns or AEs that emerge during clinical trials, we may be prevented from or delayed in obtaining marketing approval, and even if we obtain marketing approval, any sales may suffer. We will incur additional costs and may experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. The risk of failure is high for any drug candidates we may acquire that are in clinical and preclinical development. The clinical trials and manufacturing of our drug candidates are, and the manufacturing and marketing of our drug candidates, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market our drug candidates. Before obtaining regulatory approvals for the commercial sale of any of our drug candidates, we must demonstrate thorough lengthy, complex and expensive preclinical testing and clinical trials that our drug candidates are both safe and effective for use in each target indication. We may not be able to develop a trial design that the FDA and other foreign regulatory authorities can accept. Each drug candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. Clinical trials are expensive and can take many years to complete, and their outcomes are inherently uncertain. We cannot guarantee that any future clinical trials will be conducted as planned or completed on schedule, if at all. Failure can occur at any time during the clinical trial process. For example, on January 25, 2022, the FDA placed a full clinical hold on the IND for atuzaginstat (COR388). Additionally, the Phase 2/3 study with COR388 in Alzheimer's disease failed to meet the primary endpoint. COR388 is one of our assets that has since been out-licensed. On March 8, 2023, the FDA placed a partial clinical hold on the IND for EryDex related to extractables and leachables of new components used in the EryKit. The FDA subsequently lifted the partial clinical hold on September 23, 2023. Additionally, the Phase 3 ATTeST study conducted by EryDel failed to meet the primary endpoint. Even if any future clinical trials are completed as planned, we cannot be certain that their results will support the safety and effectiveness of our potential drug candidates for their

56Table of Content**targeted indications or support continued clinical development of such drug candidates. Our ongoing and any future clinical trial results may not be successful.** In addition, even if such trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our drug candidates for approval. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our drug candidates. If we are required to conduct preclinical studies, clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully complete preclinical studies, clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety of efficacy concerns, we may: **â€** be delayed in obtaining marketing approval for our drug candidates; **â€** not obtain marketing approval at all or regulatory authorities may suspend, vary or withdraw marketing approvals for approved products; **â€** obtain approval for indications, dosages or patient populations that are not as broad as intended or desired; **â€** obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; **â€** be subject to additional post-marketing testing requirements; or **â€** have the medicine removed from the market after obtaining marketing approval. Drug development costs will also increase if we experience delays in testing or in obtaining marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be amended or will be completed on schedule, or at all. Significant preclinical studies and clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our drug candidates, could allow our competitors to bring drug candidates to market before we do, and could impair our ability to successfully commercialize our drug candidates, if approved, any of which may harm our business and results of operations. In addition, many of the factors that cause, or lead to a delay in the commencement or completion of, clinical trials may also ultimately lead to termination or suspension of a clinical trial. Any of these occurrences may harm our business, financial condition and prospects significantly. Any termination of any clinical trial of our drug candidates will harm our commercial prospects and our ability to generate revenues. Our drug candidates may cause or have attributed to them undesirable side effects or have other properties that delay or prevent their regulatory approval or limit their commercial potential. Undesirable side effects caused by our drug candidates or that may be identified as related to our drug candidates by investigators conducting our clinical trials or even related to competing products in development that utilize a similar mechanism of action or act through a similar biological disease pathway could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims. AEs and SAEs that emerge during treatment with our drug candidates or other compounds acting through similar biological pathways may be deemed to be related to our drug candidate. This may require longer and more extensive Phase 3 clinical development, or regulatory authorities may increase the amount of data and information required to approve, market, or maintain our drug candidates and could result in negative labeling or a restrictive REMS or comparable foreign strategy. This may also result in an inability to obtain approval of our drug candidates. The occurrence of any or all of these events may cause the development of our drug candidates to be delayed or terminated, which could materially and adversely affect our business and prospects. Our drug candidates have in the past and may in the future be deemed to cause AEs and SAEs.

57Table of Content**Clinical trials of our drug candidates may not uncover all possible AEs that patients may experience.** Clinical trials are conducted in representative samples of the potential patient population, which may have significant variability. By design, clinical trials are based on a limited number of subjects and are of limited duration of exposure to the product, to determine whether the drug candidate demonstrates the substantial evidence of efficacy and safety necessary to obtain regulatory approval. As with the results of any statistical sampling, we cannot be sure that all side effects of our drug candidates may be uncovered. It may be the case that only with a significantly larger number of patients exposed to the drug candidate for a longer duration may there be a more complete safety profile be identified. Further, even larger clinical trials may not identify rare SAEs, and the duration of such studies may not be sufficient to identify when those events may occur. Other products have been approved by the regulatory authorities for which safety concerns have been uncovered following approval. Such safety concerns have led to labeling changes, restrictions on distribution through use of a REMS, or comparable foreign strategy, or withdrawal of products from the market, and any of our drug candidates may be subject to similar risks. Although to date we have not seen evidence of significant safety concerns with our drug candidates in the patient populations currently undergoing clinical trials with EryDex, if approved, may experience previously unreported adverse reactions, and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our drug candidates. If safety problems occur or are identified after our products, if any, reach the market, we may make the decision or be required by regulatory authorities to amend the labeling of our products, recall our products, or even withdraw approval for our products. If we are not able to successfully demonstrate a favorable differentiation between EryDex and currently available corticosteroids, our business would be harmed and our ability to generate revenue from that class of drugs would be severely impaired. Our business model is to pursue the development of off-patent drugs for which we would directly pursue the development of a red blood cell encapsulated formulation through the FDA's 505(b)(2) regulatory pathway. In order to receive sufficient reimbursement and utilization, our drug candidates, will require showing differentiation against currently available generic products. If we are not able to differentiate EryDex from currently available corticosteroids by showing a safety or efficacy benefit that is reflected in the approved label, our business would be harmed and our ability to generate revenue from that class of drugs would be severely impaired. Because the potential rare disease target patient populations of EryDex are small, and the addressable patient population even smaller, we may not be able to effectively complete clinical trials or commercialize the drug candidate. EryDex is in development for rare disease. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with

EryDex are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, or patient foundations, and may prove to be incorrect or contain errors. New studies have in the past and may continue to change the estimated incidence or prevalence of these diseases. We cannot accurately predict the number of patients for whom treatment might be possible. Additionally, since the potentially addressable patient population for this drug candidate is limited, we may fail to enroll a sufficient number of patients in our clinical trials in a timely manner. Furthermore, even if we successfully develop this asset, and obtain commercial approval, we may not be able to achieve significant market share for EryDex. Because the potential target populations are very small, we may not effectively complete clinical trials on a timely basis or at all and may not realize any significant return from the development or potential commercialization of this asset.

Risks Relating to Our Financial PositionWe are a clinical stage biotechnology company and have a limited history operating a newly acquired business, which may make it difficult to evaluate the prospects for our future viability. From our inception, we have been focused on novel therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s™ and other degenerative diseases. After the Novosteo Acquisition in 2022, we shifted our operational focus on the development of our bone-targeting drug platform and lead compound NOV004 for development for rare skeletal diseases, bone fractures, and injury. In January 2023, we made a strategic decision to out-license our bone-targeting drug platform and prioritize capital resources toward the expansion of our development pipeline through the completion the acquisition of EryDel in October 2023. We have a limited history operating our newly acquired business, which may make 58Table of Content it difficult to evaluate the success of our business to date and assess our future viability. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. To date, we have only initiated two late-stage clinical trials, one of which was initiated by EryDel, and we have not obtained marketing approval for any drug candidate, manufactured a commercial scale drug candidate, arranged for a third party to do so on our behalf, or conducted sales and marketing activities necessary for successful drug candidate commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by clinical stage biotechnology companies in rapidly evolving fields, and we have not yet demonstrated an ability to overcome such risks and difficulties successfully. If we do not address these risks and difficulties successfully, our business will suffer. We will require substantial additional funding to finance our operations and evaluate future drug candidates. If we are unable to raise this funding when needed or on acceptable terms, we may be forced to delay, reduce or eliminate our drug development programs or other operations. Since our inception, we have used substantial amounts of cash to fund our operations, and we expect our expenses to increase substantially in the foreseeable future in connection with our ongoing activities, particularly as we evaluate and develop drug candidates. In addition, if we obtain marketing approval for any future drug candidates, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. Further development of EryDex will require us to incur significant additional expenses. Moreover, we expect to require substantial additional funding to finance such payments and to advance the development and optimize the commercialization of EryDex, and there can be no assurance that such additional funding will be available on terms that are acceptable to us, or at all. If adequate funds are not available on a timely basis, we may not be able to effectively implement our strategic plan. Accordingly, we will need to obtain substantial additional funding in order to fully execute on our corporate strategy. As of September 30, 2024 we had \$47.8 million in cash, cash equivalents and short-term investments. We may be required to recognize impairments in the value of these investments if the relevant companies are materially adversely affected, become unable to repay debt securities when due, or experience credit rating downgrades, or if the public trading price of these securities decreases. We believe that our existing capital resources will be sufficient to fund our projected operations, which would include anticipated clinical and development activities related to EryDel’s lead asset through the Phase 3 NEAT clinical trial, into 2026. However, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may need to raise additional funds sooner than we anticipate if we choose to expand more rapidly than we presently anticipate. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to: the rate of progress in the development of and the conduct of clinical trials with respect to our product candidates; our ability to successfully identify partnership and licensing opportunities to support the future development of EryDex; the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals; the number and characteristics of drug candidates that we acquired or pursue; our ability to manufacture sufficient quantities of our drug candidates and devices; our need to expand our research and development activities; the costs associated with securing and establishing commercialization and manufacturing capabilities; the costs of acquiring, licensing or investing in businesses, drug candidates and technologies; our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; our need and ability to retain management and hire scientific and clinical personnel; the effect of competing drugs and drug candidates and other market developments; 59Table of Content our need to implement additional internal systems and infrastructure, including financial and reporting systems; the costs to grow our organization and increase the size of our facilities to meet our anticipated growth; the economic and other terms, timing of and success of any collaboration, licensing or other arrangements into which we may enter in the future; and our ability and timing of future milestones payments to EryDel shareholders and repayment of obligations in respect of the EIB Facility. Additional funding may not be available to us on acceptable terms or at all. Any such funding may result in dilution to stockholders, imposition of debt covenants and repayment obligations, or other restrictions that may affect our business. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to some of our technologies or drug candidates or otherwise agree to terms unfavorable to us. The terms of the EIB Facility place restrictions on our operating and financial flexibility. In connection with the EIB Facility, we are subject to operating restrictions and covenants that restrict our ability to finance our operations, engage in business activities or expand or fully pursue its business strategies. For example, unless we get approval from EIB, the EIB Facility limits our ability to, among other things: incur additional debt or provide guarantees in respect of debt; incur liens; make investments, acquisitions, loans or advances; sell assets; make distributions to equity holders, including dividends and distributions on, and redemptions, repurchases or retirement of, our capital stock; enter into certain hedging transactions; enter into fundamental changes, including mergers and consolidations; enter into transactions with affiliates; change the nature of our business; and change our management. In addition, the EIB Facility requires that we meet certain reporting and operating covenants, including an obligation to maintain a certain minimum unrestricted balance of cash or cash equivalents. Our ability to comply with these covenants may be affected by events beyond our control, and we may not be able to meet those covenants. Subject to grace periods commencing when the borrower learns of the occurrence of a breach, a breach of these covenants would give EIB the option to exercise remedies including to accelerate the outstanding balance under the EIB Facility. The EIB Facility includes customary events of default, including failure to pay principal, interest or certain other amounts when due; material inaccuracy of representations and warranties; breach of covenants; cross-default to other indebtedness (resulting in a right of the other lender to accelerate such indebtedness after giving effect to any grace periods); certain bankruptcy and insolvency events; certain undischarged judgments; and material adverse change. A breach of any of these covenants could result in an event of default under the EIB Facility. If an event of default occurs and is ongoing under the terms of the Finance, EIB may accelerate all of the obligations of EryDel thereunder and demand payment from us pursuant to the guarantees. Any declaration by the lender of an event of default could significantly harm our business and prospects and could cause the price of our common stock to decline. Unstable market and global economic conditions, including adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions, may have adverse consequences on our business, financial condition and stock price. The global credit and financial markets have experienced volatility, including as a result of the COVID-19 pandemic, changes in interest rates, and economic inflation, which has included diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability and changes in 60Table of Content unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, acts of terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could heighten market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. Failure to secure any necessary financing in a timely manner could have a material adverse effect on our growth strategy, financial performance and stock price. We regularly maintain cash balances at third-party financial institutions in excess of the FDIC insurance limit. Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. Our failure to maintain certain tax benefits applicable to Italian biotechnology companies may adversely affect our results of operations, our cash flows and our financial condition. As a Company with an Italian biotechnology subsidiary, we have benefited from certain tax advantages, including, for example, the R&D tax credit, which is an Italian tax credit aimed at stimulating research and development. The R&D tax credit can offset payments of certain taxes and contributions (e.g., social contributions, VAT payables, registration fees, income and withholding taxes and all other tax-related items that companies usually pay monthly). For eligible research and development activities, the tax credits were equal to 20% of the costs incurred in fiscal years 2022 and 2021, with a maximum annual amount of \$4.4 million (Euro 4 million). In 2023 the tax credit rate was decreased to 10% of the eligible expenses for certain activities, and the annual ceiling of the credit increased to \$5.5 million (5 million euros). Expenses incurred by the Company for years ended December 31, 2023, 2022, and 2021 generated a total tax credit amounting to \$0.9 million (0.8 million euros), \$1.1 million (1 million euros), and \$2.0 million (1.8 million euros), respectively. The Italian tax authorities may audit each research and development program in respect of which a R&D tax credit has been claimed and assess whether such program qualifies in its view for the R&D tax credit. The Italian tax authorities may challenge our eligibility for, or our calculation of, certain tax reductions or deductions in respect of our research and development activities. Should the Italian tax authorities be successful, the R&D tax credit, may be reduced, which would have a negative impact on our results of operations and future cash flows. We believe, due to the nature of our business operations, that we will continue to be eligible to receive the R&D tax credit. However, if the Italian government decides to eliminate, or to reduce the scope or the rate of, the R&D tax credit, either of which it could decide to do at any time, our results of operations could be adversely affected.

Risks Relating to Regulatory Review and Approval of Our Drug Candidates and Other Legal Compliance MattersWe cannot be certain that the FDA or foreign regulatory authorities will permit us to proceed with any current or future proposed clinical trial designs. Our drug candidates may not receive regulatory approval, and without regulatory approval we will not be able to market our drug candidates. We currently have no drug candidates approved for sale and we cannot guarantee that we will ever have marketable drug candidates. Our ability to generate revenue related to sales, if ever, will depend on the successful development and regulatory approval of our drug candidates. The development of a drug candidate and issues relating to its approval and marketing are subject to extensive regulation by the FDA in the United States and regulatory authorities in other countries, with regulations differing from country to country. We are not permitted to market any drug candidates in the United States until we receive approval of an NDA from the FDA. Similar requirements apply in foreign countries. We have not submitted any marketing applications for a drug candidate. Because EryDex utilizes DSP, we believe it will qualify for FDA approval through the FDA’s 505(b)(2) regulatory pathway and through corresponding regulatory paths in other foreign jurisdictions. The clinical requirements for a 505(b)(2) drug candidate can vary widely from product to product depending primarily on whether the drug candidate 61Table of Content claims a new indication, provides for a different route of administration, or claims improved safety compared to the existing approved product, and may include bioequivalence trials, limited safety and efficacy trials, or full Phase 1 through 3 trials. NDAs must include extensive preclinical and clinical data and supporting information to establish the drug candidate’s safety and effectiveness for each desired indication. NDAs must also include significant information regarding the chemistry, manufacturing and controls for the drug. Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review processes can take years to complete and approval is never guaranteed. If we submit an NDA to the FDA, the FDA must decide whether to accept or reject the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA. Regulators of other jurisdictions may impose similar requirements and have their own procedures for approval of drug candidates. Even if a drug is approved, the FDA or a comparable foreign regulatory authority may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming clinical trials or reporting as conditions of approval. Regulatory authorities in countries outside of the United States also have requirements for approval of drug candidates with which we must comply prior to marketing in those countries. Obtaining regulatory approval for marketing of a drug candidate in one country does not ensure that we will be able to obtain regulatory approval in any other country. In addition, delays in approvals or rejections of marketing applications in the United States or other countries may be based upon many factors, including regulatory requests for additional analyses, reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the period of drug development and the emergence of new information regarding our drug candidates or other drug candidates. Also, regulatory approval for any of our drug candidates may be withdrawn. Clinical failure can occur at any stage of clinical development and we have never submitted an NDA or comparable foreign application before. The FDA or other foreign regulatory authorities may limit our ability to proceed with potential clinical programs, which could have a materially adverse impact on us. The submission of a successful NDA or comparable foreign applications is a complicated process. As an organization, we have never conducted a registrational clinical trial and have limited experience in preparing, submitting and prosecuting regulatory filings, and have not submitted an NDA or comparable foreign applications. Failure to commence or complete, or delays in, our planned clinical trials would prevent us from or delay us in seeking approval for, and if approved, commercializing our drug candidates, and failure to successfully complete any of these activities in a timely manner for any of our drug candidates could have a material adverse impact on our business and financial performance. The commencement, enrollment and completion of clinical trials can be delayed or suspended for a variety of reasons, including: inability to obtain sufficient funds required for a clinical trial; inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; clinical holds, other regulatory objections to commencing or continuing a clinical trial or the inability to obtain regulatory approval to commence a clinical trial in countries that require such approvals; discussions with the FDA or non-U.S. regulators regarding the scope or design of our clinical trials; inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs, including some that may be for the same indications targeted by our drug candidates; inability to obtain approval from IRBs or positive ethics committees opinions to conduct a clinical trial at their respective sites; severe or unexpected drug-related adverse effects experienced by patients, which have resulted and may result in a full or partial clinical hold by the FDA or non-U.S. regulators; inability to timely manufacture sufficient quantities of the drug candidate or devices required for a clinical trial; difficulty recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including inability to find patients with a rare disease, meeting the enrollment criteria for our study and competition from other clinical trial programs for the same indications as our drug candidates; 62Table of Content inability to retain enrolled patients after a clinical trial is underway; and enrollment may be delayed or interrupted or patients may drop out of clinical trials due to or the fear of natural disasters, such as earthquakes, tsunamis, power shortages or outages, floods, or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability or other conflict, cyberattacks, or other events outside of our control occurring at or around our clinical trials sites in the United States or Europe. In addition, the design of a clinical trial can determine whether its results will support approval of a drug and flaws in the design of a clinical trial may not become apparent until the clinical trial is well-advanced. Changes in regulatory requirements and guidance may also occur and we may need to amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to resubmit clinical trial protocols to IRBs or ethics committees for re-examination, which may impact the costs, timing or successful completion of a clinical trial. In addition, if we are required to conduct additional clinical trials or other preclinical studies of our drug candidates beyond those contemplated, our ability to obtain regulatory approval of these drug candidates and generate revenue from their sales would be

similarly harmed. Clinical trials of our drug candidates have in the past been put on clinical holds by, and failed to demonstrate safety and efficacy to the satisfaction of, the FDA, and if any future clinical trials of our drug candidates are put on clinical holds by, or fail to demonstrate safety and efficacy to the satisfaction of, the FDA, the EMA, or similar regulatory authorities outside the United States, or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates. Before obtaining regulatory approvals for the commercial sale of any of our drug candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our drug candidates are both safe and effective for use in each target indication. Each drug candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Clinical trials of our drug candidates have in the past been put on clinical holds imposed by, and failed to demonstrate safety and efficacy to the satisfaction of, the FDA, the EMA, or similar regulatory authorities outside of the United States. For example, on January 25, 2022, the FDA placed a full clinical hold on the IND for atuzaginstat (COR388), one of our assets that has since been out-licensed. On March 8, 2023, the FDA placed a partial clinical hold on the IND for EryDex related to extractables and leachables of new components used in the EryKit. The FDA subsequently lifted the partial clinical hold on September 23, 2023. The FDA may place additional clinical holds on our current or currently contemplated clinical programs or otherwise limit our ability to proceed with other clinical programs in our pipeline. Additionally, the results of preclinical studies of our drug candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials. For example, the Phase 3 ATTEST study conducted by EryDel failed to meet its primary endpoint. The results of clinical trials in one set of patients or disease indications may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same drug candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. This is particularly true in degenerative diseases, where failure rates historically have been higher than in many other disease areas. Most drug candidates that begin clinical trials are never approved by regulatory authorities for commercialization. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA, the EMA, or other foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our drug candidates for approval. Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA, the EMA, or other regulatory authorities. The FDA, the EMA, or other regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA, the EMA, or other regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA, the EMA, or other regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of any of our drug candidates. To the extent that the results of the trials are not satisfactory to the FDA, the EMA, or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our drug candidates. Even if regulatory approval is secured for any of our drug candidates, the terms of such approval may limit the scope and use of our drug candidate, which may also limit its commercial potential. We currently rely and expect to continue to rely on third parties to conduct some of our preclinical studies and clinical trials and some aspects of our research and preclinical testing and on third-party contract manufacturing organizations to manufacture and supply our preclinical, clinical and commercial materials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, manufacturing or testing. We rely and expect to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct some aspects of our research and preclinical testing and our clinical trials. We also currently rely on and expect to continue to rely on, third-party CMOs to manufacture and supply our preclinical, clinical and commercial materials. Any of these third parties may terminate their engagements with us or be unable to fulfill their contractual obligations. If we need to enter into alternative arrangements, it would delay our future drug development activities. Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with current GCP regulations for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible, reproducible and accurate and that the rights, integrity, and confidentiality of trial participants are protected. We also are required to register any future clinical trials and post the results of completed clinical trials on a government-sponsored database within certain timeframes. Failure to do so can result in fines, adverse publicity, and civil and criminal sanctions. Similar requirements and consequences may apply in countries outside the United States. Reliance on third-party manufacturers entails additional risks, such as the possible breach of the manufacturing agreement by the third party, the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us and reliance on the third party for regulatory compliance, quality assurance, safety and related reporting. Third-party manufacturers may not be able to comply with GMP regulations or similar regulatory requirements outside the United States. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for any drug candidates we may develop and will not be able to, or may be delayed in our efforts to, successfully commercialize our drug candidates. We also expect to rely on other third parties to store and distribute drug supplies for our future clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any drug candidates we may develop or commercialization of our medicinal products, producing additional losses and depriving us of drug revenue. Risks Related to the Production and Manufacturing of our Drug Candidates and Future Products Our production capacity could prove insufficient for our needs. Our production capacity may prove insufficient in the future to meet the growth of our business, including producing sufficient quantities of drug candidates for clinical trials and, ultimately, our customers and distributors. There is no guarantee that we will or have properly estimated our required manufacturing capacities or that the third parties we rely on to provide required machinery and materials for the manufacturing process will be able to perform on our proposed timelines or meet our manufacturing demands, if at all. Also, if we must increase production capacity for any reason, we may need to make considerable investments that could lead to significant financing needs or require us to enter into subcontracting agreements in order to outsource part of the production. We may not have access to the raw materials and other components, necessary for the manufacturing of our drug candidates. We are dependent on third parties for the supply of various materials that are necessary to produce our drug candidates for clinical trials. If our agreements with one or more of these suppliers were to be terminated or if one or more of these suppliers are unable to meet our demands, we could experience delays in our research or planned clinical trials or commercialization. We could be unable to find alternative suppliers of acceptable quality, in the appropriate volumes and at an acceptable cost. In addition, these materials are subject to stringent manufacturing processes and rigorous testing. Delays in the completion and validation of facilities and manufacturing processes of these materials could adversely affect our ability to complete trials and commercialize our products in a cost-effective and timely manner. If we encounter difficulties in the supply of these materials, chemicals or biological products, or if we were not able to maintain our supply agreements, or establish new supply agreements in the future, our product development and our business prospects could be significantly compromised. Our manufacturing facilities are subject to significant government regulations and approvals. If we or our third-party manufacturers fail to comply with these regulations or maintain these approvals, our business will be materially harmed. We currently partially manufacture our Red Cell Loader machines and EryKit in our facility in Medolla, Italy. We and our third-party manufacturers are subject to ongoing regulation and periodic inspection by the FDA competent authorities of EU Member States and other regulatory bodies to ensure compliance with GMP, as part of our clinical trials. Any failure to follow and document our or their adherence to such GMP regulations or other regulatory requirements may lead to significant delays in the availability of products for commercial sale or clinical trials, may result in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for our products. Failure to comply with applicable regulations could also result in the European Commission, FDA, the national authorities in the individual EU Member States, or other applicable regulatory authorities taking various actions, including: levying fines and other civil penalties; imposing consent decrees or injunctions; requiring us to suspend or put on hold one or more of our clinical trials; suspending, varying or withdrawing regulatory approvals; delaying or refusing to approve pending applications or supplements to approved applications; requiring us to suspend manufacturing activities or product sales, imports or exports; requiring us to communicate with physicians and other customers about concerns related to actual or potential safety, efficacy, and other issues involving our products; mandating product recalls or seizing products; imposing operating restrictions; and seeking criminal prosecutions. Any of the foregoing actions could be detrimental to our reputation, business, financial condition or operating results. Furthermore, our key suppliers may not continue to be in compliance with all applicable regulatory requirements, which could result in our failure to produce our products on a timely basis and in the required quantities, if at all. In addition, before any additional products would be considered for marketing approval in the United States, the EU or elsewhere, our suppliers will have to pass an audit by the applicable regulatory authorities. We are dependent on our suppliers' cooperation and ability to pass such audits, and the audits and any audit remediation may be costly. Failure to pass such audits by us or any of our suppliers would affect our ability to commercialize our drug candidates in the United States, the EU or elsewhere. Our production costs may be higher than we currently estimate. We manufacture our drug candidates according to manufacturing best practices applicable to drugs for clinical trials and to specifications approved by the applicable regulatory authorities. If any of our drug candidates are found to be non-compliant, we would be required to manufacture the drug candidates again, which would entail additional costs and may prevent delivery of the drug candidates to patients on time. Other risks inherent in the production process may have the same effect, such as: contamination of the controlled atmosphere area; unusable premises and equipment; new regulatory requirements requiring a partial and/or extended stop to the production unit to meet the requirements; unavailable qualified personnel; power failure of extended duration; logistical error; and rupture in the cold chain, which is a system for storing and transporting blood and blood products within the correct temperature range and conditions. In addition, a rise in direct or indirect energy rates may increase product manufacturing and logistical costs. Any of these risks, should they occur, could disrupt our activities and compromise our financial position, results, reputation or growth. The manufacture of our products requires strict adherence to regulatory requirements governing medical devices and if we or our suppliers encounter problems our business could suffer. The manufacture of our products must comply with strict regulatory requirements governing Class II medical devices in the U.S. and other regulatory requirements in foreign locations. Problems may arise during manufacturing, quality control, storage, or distribution of our products for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, manufacturing quality concerns, or problems with raw materials, electromechanical, software and other components, supplier issues, and natural disasters. If problems arise during production, the affected products may have to be discarded. In the EU, our RCL and EryKit medical devices, Syringe Kit, and process solutions, are subject to periodic inspections by our Notified Body to maintain CE Certificates of Conformity permitting us to affix the CE mark to our medical devices. We may also be subject to unannounced audits by national competent authorities to ensure compliance with applicable regulatory requirements. As a result of the transitional provisions in the MDR, some CE Certificates of Conformity issued by Notified Bodies in accordance with the MDD from May 2017, and which remained valid on May 26, 2021 will remain valid until December 31, 2027 for Class III and Class IIb implantable medical devices and until December 31, 2028 for other Class IIb, Class IIa and Class I devices with a measuring function or which are sterile. Class I medical devices, for which the conformity assessment procedure in accordance with the MDD did not require the involvement of a Notified Body but will require the involvement of a Notified Body in accordance with the MDR and for which an EU Declaration of Conformity was issued in accordance with the MDD prior to May 26, 2021, can continue to be placed on the EEA market until December 31, 2028. Manufacturers of medical devices may only benefit from the above extended transitional provisions deadlines if the following conditions are fulfilled: (i) the devices continue to comply with the requirements of the MDD, (ii) there are no significant changes in the design and intended purpose, (iii) the devices do not present an unacceptable risk to the health or safety of patients, users or other persons, or to other aspects of the protection of public health, (iv) the manufacturer implements a quality management system by May 26, 2024 which complies with the requirements of the MDR, (v) by May 26, 2024 an application is lodged with a Notified Body for conduct of the conformity assessment of the devices covered by the CE Certificate of Conformity, or the devices intended to substitute for such devices, in accordance with the MDR and a related written agreement is signed with the Notified Body by September 26, 2024, and (vi) from May 26, 2021, compliance with the MDR relating to post-market surveillance, market surveillance, vigilance, registration of economic operators and of devices is ensured in place of the corresponding requirements in the MDD. In addition, these CE Certificates of Conformity will remain valid in accordance with the extended transitional deadlines above only if either (i) the manufacturer signed a written agreement with a Notified Body for the conformity assessment of the device covered by the expired CE Certificate of Conformity, or the device intended to substitute that device, in accordance with the MDR before the date of expiry of the CE Certificate of Conformity, or (ii) a competent authority of an EU Member State has granted a derogation from the application conformity assessment procedure in accordance with Article 59(1) or Article 97(1) of the MDR. Any failure to comply with any of these obligations may impact our activities in the EEA, the renewal of our existing CE Certificates of Conformity and future conformity assessment activities. Manufacturing problems or delays could also lead to increased costs, lost sales, damage to customer relations, failure to supply penalties, time and expense spent investigating the cause and depending on the cause, similar losses with respect to other batches of products. If problems are not discovered before the product is released to the market, voluntary recalls, corrective actions, or product liability related costs may also be incurred. If unanticipated problems with our products arise, or if we or our suppliers fail to comply with regulatory requirements following CE marking, we may also become subject to enforcement actions such as restrictions on manufacturing processes, warning letters, suspension, variation or withdrawal of CE Certificates of Conformity, civil or criminal penalties. Should we encounter difficulties in the manufacture of our products or be subject to a product recall, our business could suffer materially. If we or any of our third-party manufacturers or suppliers encounter difficulties in production of our future drug candidates, or fail to meet rigorously enforced regulatory standards, our ability to provide supply of our future drug candidates for clinical trials or for patients, if approved, could be delayed or stopped, or we may be unable to maintain a commercially viable cost structure. The processes involved in manufacturing our drug candidates are highly regulated and subject to multiple risks. As drug candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could cause our drug candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. In order to conduct clinical trials of our drug candidates, or supply future commercial drug candidates or devices, if approved, we will need to manufacture them in small and large quantities. Our manufacturing partners may be unable to successfully modify or scale-up the manufacturing capacity for any of our drug candidates or devices in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners are unable to successfully scale-up the manufacture of our drug candidates or devices in sufficient quality and quantity, the development, testing and clinical trials of that drug candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting drug may be delayed or not obtained, which could significantly harm our business. The supply of any of these materials used in EryKits or RCLs may be limited or any of the supply manufacturers may not meet relevant regulatory requirements, and if we are unable to obtain any of these materials in sufficient amounts, in a timely manner and at reasonable prices, or if we encounter delays or difficulties in our relationships with manufacturers or suppliers, the production of EryKits and RCLs may be delayed. If any of our suppliers is unwilling or unable to meet its supply obligations and we are unable to secure an alternative supply source in a timely manner and on favorable terms, our business, financial condition, and results of operations may be harmed and the market price of our common stock and other securities may decline. The same risks apply to our internal manufacturing facilities. In addition, the

manufacturing process for any drug candidates is subject to FDA and foreign regulatory requirements, and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA and foreign regulatory authority requirements, including complying with GMPs, on an ongoing basis. If we or our third-party manufacturers are unable to reliably produce drug candidates in accordance with the requirements of the FDA or other regulatory authorities, we may not obtain or maintain the approvals we need to commercialize such future drug candidates. Even if we obtain regulatory approval for any of our drug candidates, there is no assurance that either we or our third-party contract manufacturers will be able to manufacture the approved drug in accordance with the requirements of the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the drug, or to meet potential future demand. Moreover, we, or our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities, to monitor and ensure compliance with GMP. Despite our efforts to audit and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA, competent authorities of EU Member States or other comparable foreign regulatory authorities to be noncompliant with GMP regulations. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including shutdown of the third-party 67Table of Content vendor or invalidation of drug product lots or processes, fines, injunctions, civil penalties, delays, suspension, variation or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products, if approved, and significantly harm our business, financial condition, results of operations and prospects. Any of these challenges could delay completion of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our drug candidate, impair commercialization efforts, increase our cost of goods, and have an adverse effect on our business, financial condition, results of operations and growth prospects. If the market opportunities for our drug candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. Because the target patient populations of our drug candidates are small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth. We focus our research and product development on treatments for rare and ultra-rare diseases. Given the small number of patients who have the diseases that we are targeting, our profitability and growth depend on successfully identifying patients with these rare and ultra-rare diseases. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our drug candidates, are based on our beliefs and internal estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases, and, as a result, the number of patients with these diseases may turn out to be lower than expected. Our effort to identify patients with diseases we seek to treat is in early stages, and we cannot accurately predict the number of patients for whom treatment might be possible. Additionally, the potentially addressable patient population for each of our drug candidates may be limited or may not be amenable to treatment with our drug candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business. If patients who currently receive assistance from us in paying for the cost of our drugs continue to receive assistance, if approved, or who receive free drugs in the future, will negatively impact our profitability. If EryDex is only approved for patients with A-T who are between six and nine years old, it will be limiting an already small patient population. Finally, even if we obtain significant market share for our drug candidates, because the potential target populations are very small, we may never achieve profitability despite obtaining such significant market share. If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any drug candidates we may develop and for which we obtain approval, we may not be successful in commercializing those drug candidates if and when they are approved. We do not have a sales or marketing infrastructure and have no experience in the sale, marketing, or distribution of pharmaceutical drug candidates, if approved, or devices. To achieve commercial success for any approved drug candidate for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to sell, or participate in sales activities with collaborators for, some of our drug candidates if and when they are approved. There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, factors that may inhibit our efforts to commercialize any drug candidates, if and when approved, whether alone or in collaboration with others: 68Table of Content our inability to recruit and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs, and other support personnel; 69Table of Content the inability of sales personnel to obtain access to physicians or our failure to educate adequate numbers of physicians on the benefits of any future approved drug candidates; 70Table of Content the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; 71Table of Content the inability to price our drug candidates, if approved, at a sufficient price point to ensure an adequate and attractive level of profitability; 72Table of Content the pricing of our products, particularly as compared to alternative treatments; 73Table of Content availability of alternative effective treatments for indications our candidates are intended to treat and the relative risks, benefits and costs of those treatments; 74Table of Content restricted or closed distribution channels that make it difficult to distribute our drug candidates, if approved, to segments of the patient population; 75Table of Content the lack of complementary drug candidates, if approved, to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive drug candidate lines; and 76Table of Content unforeseen costs and expenses associated with creating an independent commercialization organization. If the commercial launch of a future drug candidate, if approved, for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our commercialization personnel. If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our sales revenue or the profitability of sales revenue may be lower than if we were to market and sell any drug candidates, if approved, we may develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to commercialize our drug candidates, if approved, or may be unable to do so on terms that are favorable to us. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our drug candidates, if approved, effectively. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our drug candidates if approved in the future. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our drug candidates, if approved. We face an inherent risk of product liability as a result of the clinical testing of our drug candidates and will face an even greater risk when and if we commercialize any drug candidates, if approved. For example, we may be sued if our drug candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, early access program, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Product liability claims may be brought against us by participants enrolled in our clinical trials, patients, health care providers or others using, administering our drug candidates or selling our drug candidates, if approved. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit testing and commercialization of our drug candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: 77Table of Content decreased or interrupted demand for our drug candidates; 78Table of Content withdrawal of clinical trial participants and inability to continue clinical trials; 79Table of Content initiation of investigations by regulators; 80Table of Content costs to defend the related litigation; 81Table of Content a diversion of management 82Table of Content s time and our resources; 83Table of Content substantial monetary awards to trial participants or patients; 84Table of Content drug recalls, withdrawals or labeling, marketing or promotional restrictions; 85Table of Content termination of clinical trial sites or entire trial programs; 86Table of Content injury to our reputation and significant negative media attention; 87Table of Content loss of revenue; 88Table of Content exhaustion of any available insurance and our capital resources; 89Table of Content the inability to commercialize any drug candidate, if approved; and 90Table of Content a decline in our share price. Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of drug candidates we develop, alone or with potential collaborators. Our insurance policies may have various exclusions, and we may be subject to a product liability claim for 91Table of Content which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. We may be exposed to a variety of international risks that could materially adversely affect our business. Our business is subject to risks associated with conducting business internationally. Some of our suppliers and clinical trial centers are located outside of the United States. We may enter into agreements with third parties for the development and commercialization of drug candidates in international markets. We also plan to seek regulatory approval of our drug candidates outside of the United States. International business relationships will subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations, including: 92Table of Content differing regulatory requirements for drug approvals internationally; 93Table of Content rejection or qualification of foreign clinical trial data by the competent authorities of other countries; 94Table of Content price controls on our drug products; 95Table of Content complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property; 96Table of Content potential third-party patent rights in countries outside of the United States; 97Table of Content different United States and foreign drug import and export rules; 98Table of Content different reimbursement systems and different competitive drugs indicated to treat the indications for which our drug candidates are being developed; 99Table of Content the potential for so-called 100Table of Content parallel importing, 101Table of Content which is what occurs when a local seller, faced with relatively high local prices, opts to import goods from another jurisdiction with relatively low prices, rather than buying them locally; 102Table of Content the potential for so-called 103Table of Content parallel exporting, 104Table of Content which is what occurs when a local seller buys goods meant for the locals and sells the goods for a higher price in another country, potentially causing or aggravating supply problems; 105Table of Content unexpected changes in tariffs, trade barriers and regulatory requirements; 106Table of Content economic weakness, including inflation, bank failures, or political instability, particularly in non-U.S. economies and markets, including several countries in Europe; 107Table of Content compliance with tax, including withholding of payroll taxes, employment, immigration and labor laws for employees living or traveling abroad; 108Table of Content regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries; 109Table of Content taxes in other countries; 110Table of Content financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations; 111Table of Content foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; 112Table of Content workforce uncertainty in countries where labor unrest is more common than in the United States; 113Table of Content production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; 114Table of Content business interruptions resulting from geo-political actions, including war and terrorism, public health crises, such as pandemics and epidemics, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires; and 115Table of Content compliance with evolving and expansive international data privacy laws, such as the EU GDPR. 116Table of Content Any of these factors could harm our ongoing international clinical operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations. For example, the UK has voluntarily departed from the EU, commonly referred to as 117Table of Content Brexit. 118Table of Content We do not know to what extent Brexit will impact the business and regulatory environment in the UK, the EU, or other countries. Changes impacting our ability to conduct business in the UK, or other EU countries, or changes to the regulatory regime in those countries, may impact certain portions of our research and general business operations in the UK and the EU. The United Kingdom 119Table of Content s withdrawal from the EU may have a negative effect on global economic conditions, financial markets and our business, which could reduce the price of our common stock. 120Table of Content Following Brexit, the UK and the EU signed a EU-UK TCA, which became provisionally applicable on January 1, 2021 and entered into force on May 1, 2021. This agreement provides details on how some aspects of the UK and EU 121Table of Content s relationship will operate going forwards however there are still uncertainties. The TCA primarily focuses on ensuring free trade between the EU and the UK in relation to goods, including medicinal products. Among the changes that have occurred are that Great Britain (England, Scotland and Wales) is treated as a 122Table of Content third country, 123Table of Content a country that is not a member of the EU and whose citizens do not enjoy the EU right to free movement. Northern Ireland continues to follow many aspects of the EU regulatory rules, particularly in relation to trade in goods. As part of the TCA, the EU and the UK recognize GMP inspections carried out by the other party and the acceptance of official GMP documents issued by the other party. The TCA also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to accept EU batch testing and batch release. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As it relates to marketing authorizations, Great Britain has a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland continues, however, to be covered by the marketing authorizations granted by the European Commission. For example, the scope of a marketing authorization for a medicinal product granted by the European Commission or by the competent authorities of EU Member States no longer encompasses Great Britain (England, Scotland and Wales). In these circumstances, a separate marketing authorization granted by the UK competent authorities is required to place medicinal products on the market in Great Britain. Northern Ireland continues, however, to be covered by the marketing authorizations granted by the European Commission. On February 27, 2023, the UK Government and the European Commission reached a political agreement on the so-called 124Table of Content Windsor Framework. The Framework is intended to revise the Northern Ireland Protocol to address some of the perceived shortcomings in its operation. The agreement was adopted at the Withdrawal Agreement Joint Committee on March 24, 2023. If the changes are adopted in the form proposed, medicinal products to be placed on the market in the UK will be authorized solely in accordance with UK laws. Northern Ireland would be reintegrated back into a UK-only regulatory environment under the authority of the MHRA with respect to all medicinal products. The implementation of the Windsor Framework would occur in stages, with new arrangements relating to the supply of medicinal products into Northern Ireland anticipated to take effect in 2025. The UK regulatory framework in relation to clinical trials is governed by the Medicines for Human Use (Clinical Trials) Regulations 2004, as amended, which is derived from the CTD, as implemented into UK national law through secondary legislation. On January 17, 2022, the MHRA launched an eight-week consultation on reframing the UK legislation for clinical trials, and which aimed to streamline clinical trials approvals, enable innovation, enhance clinical trials transparency, enable greater risk proportionality, and promote patient and public involvement in clinical trials. The UK Government published its response to the consultation on March 21, 2023 confirming that it would bring forward changes to the legislation. These resulting legislative amendments will determine how closely the UK regulations will align with the CTR. In October 2023, the MHRA announced a new Notification Scheme for clinical trials which enables a more streamlined and risk-proportionate approach to initial clinical trial applications for Phase 4 and low-risk Phase 3 clinical trial applications. Marketing authorizations in the UK are governed by the Human Medicines Regulations (SI 2012/1916), as amended. The MHRA has also introduced changes to national marketing authorization procedures. This includes introduction of procedures to prioritize access to new medicines that will benefit patients, including a 150-day assessment route, a rolling 117Table of Content review procedure and the International Recognition Procedures which entered into application on January 1, 2024. Since January 1, 2024, the MHRA may rely on the International Recognition Procedure, or IRP, when reviewing certain types of marketing authorization applications. This procedure is available for applicants for marketing authorization who have already received an authorization for the same product from a reference regulator. These include the FDA, the EMA, and national competent authorities of individual EEA countries. A positive opinion from the EMA and CHMP, or a positive end of procedure outcome from the mutual recognition or decentralized procedures are considered to be authorizations for the purposes of the IRP. There is no pre-marketing authorization orphan designation for medicinal products in the UK. Instead, the MHRA reviews applications for orphan designation in parallel to the corresponding marketing authorization application. The criteria are essentially the same as those in the EU, but have been tailored for the market. This includes the criterion that prevalence of the condition in Great Britain, rather than the EU, must not be more than five in 10,000. Upon the grant of a marketing authorization with orphan status, the medicinal product will benefit from up to 10 years of market exclusivity from similar products in the approved orphan indication. The start of this market exclusivity period will be set from the date of first approval of the product in Great Britain. A significant proportion of the regulatory framework in the UK applicable to medicinal products is currently derived from EU Directives and Regulations. The potential for UK legislation to

diverge from EU legislation following Brexit could materially impact the regulatory regime with respect to the development, manufacture, import, approval, and commercialization of our drug candidates in the UK or the EU. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. All of these changes could increase our costs and otherwise adversely affect our business. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our drug candidates in the UK or the EU and restrict our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our drug candidates into the EU. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the UK or the EU for our drug candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the UK. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU. We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants, and the loss of such persons could negatively impact the operations of the company. We may not be able to attract or retain qualified management, finance, scientific and clinical personnel and consultants due to the intense competition for qualified personnel and consultants among biotechnology, pharmaceutical and other businesses or any other circumstances that would cause them no longer to provide their professional services to us in the near future. If we are not able to attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. In addition, we may need to adjust the size of our workforce as a result of changes to our expectations for our business, which can result in diversion of management attention, disruptions to our business, and related expenses. In addition, we previously announced a reduction in force, impacting a number of employees. Any further reduction in force may yield unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended reduction in force, the distraction of employees, reduced employee morale and could adversely affect our reputation as an employer, which could make it more difficult for us to hire new employees in the future and increase the risk that we may not achieve the anticipated benefits from the cost reduction program. Our industry has experienced a high rate of turnover of management personnel in recent years. Potential changes in management could be disruptive to our business and may also result in our loss of unique skills and loss of knowledge about our business. Such turnover may also result in the departure of other existing employees or partners.

72 Table of Content

Replacing executive officers, key employees and consultants may be difficult and may take an extended period because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize drug candidates successfully. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel and consultants. Our failure to retain or replace key personnel or consultants could materially harm our business. Additionally, the members of our management team have limited experience managing a public company, interacting with public company investors, and complying with the increasingly complex laws, rules and regulations that specifically govern public companies, which could cause our management to have to expend time and resources helping them become familiar with such requirements. We may lose our ability to implement our business strategy successfully and could be seriously harmed. Any of our executive officers or key employees or consultants may terminate their employment at any time. We have scientific and clinical advisors and consultants who assist us in formulating our research, development and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. Non-compete agreements are not permissible or are limited by law in certain jurisdictions and, even where they are permitted, these individuals typically will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with other companies to assist those companies in developing drug candidates or technologies that may compete with ours. Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading, which could significantly harm our business. We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants, commercial partners and vendors. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-U.S. regulators, provide accurate information to the FDA and non-U.S. regulators, comply with health care fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities. We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, products liability and directors' and officers' insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations. Failure (or perceived failure) to comply with health and data protection laws and regulations could lead to government enforcement actions, which could include civil or criminal penalties, private litigation, and/or adverse publicity and could negatively affect our operating results and business. In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, "process") personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, financial information and (collectively, "sensitive data"). As a result, we and our collaborators are or may become subject to various federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security).

73 Table of Content

In the United States, numerous federal and state laws and regulations including federal health information privacy laws, state comprehensive consumer privacy laws, state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws that govern the collection, use, disclosure, and protection of health-related and other personal information apply or could apply to our operations or the operations of our collaborators. Similar laws are being considered in various other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. These developments may further complicate compliance efforts and increase legal risk and compliance costs for us and the collaborators upon whom we rely. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the federal HIPAA as amended by the HITECH. Depending on the facts and circumstances, we could be subject to civil, criminal, and administrative penalties if we violate (or are perceived to violate) HIPAA. Many foreign jurisdictions, including the EU, its member states, the United Kingdom and Australia, among others, have also adopted legislation and regulations that increase or change the requirements governing the collection, use, disclosure and transfer of the personal information of individuals in these jurisdictions. These laws, and similar laws being considered in other countries, and regulations are complex and change frequently, at times due to changes in political climate, and existing laws and regulations are subject to different and conflicting interpretations, which adds to the complexity of processing personal data from these jurisdictions. These laws have the potential to increase costs of compliance, risks of noncompliance and penalties for noncompliance. For example, the EU's GDPR imposes numerous requirements for the collection, use and disclosure of personal information, including more stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulatory authorities and affected individuals of personal data breaches, extensive internal privacy governance obligations, and obligations to honor expanded rights of individuals in relation to their personal information (for example, the right to access, correct and delete their data). In addition, the GDPR generally maintains restrictions on cross-border data transfer, and as a result we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries. The GDPR may increase our responsibility and liability in relation to personal data that we process, and may also increase our costs of compliance. Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure (or perceived failure) to comply with these laws and regulations could result in government enforcement actions (which could include civil, criminal and administrative penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Actual or perceived failure to comply with privacy laws may also cause clinical trial subjects, employees and other individuals about whom we or our potential collaborators obtain personal information, as well as the providers who share this information with us, to limit our ability to collect, use and disclose personal information. Claims that we have violated individuals' privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations. In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of drug candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any drug candidates for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, including in the EU, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. The PPACA substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. Since its enactment, there have been executive, judicial and Congressional challenges to certain aspects of the PPACA. It is possible that the PPACA will be subject to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures will impact the PPACA and our business. Other healthcare reform measures

74 Table of Content

that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our existing products that we successfully commercialize or to successfully commercialize our drug candidates, if approved. In addition to the PPACA, there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to keep healthcare costs down while expanding individual healthcare benefits. For example, on August 16, 2022, President Biden signed the IRA into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in PPACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is unclear how these or similar policy initiatives will impact the PPACA and our business. Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011 and subsequent laws, which began in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2032, unless additional Congressional action is taken. New laws may result in additional reductions in Medicare and other healthcare funding, which may adversely affect customer demand and affordability for our drug candidates and, accordingly, the results of our financial operations. Also, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed drug candidates, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, in July 2021, the Biden administration released an executive order, "Promoting Competition in the American Economy," with multiple provisions aimed at prescription drugs. In response to Biden's executive order, on September 9, 2021, the HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. Further, the IRA will, among other things (i) allow HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the "negotiated fair price" under the law and (ii) impose rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. It is currently unclear how the IRA will be effectuated but is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration's October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved drug candidate. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drug candidates, once marketing approval is obtained. Our ability to successfully commercialize any drugs that we develop depends in part on the extent to which coverage and adequate reimbursement are available from government health administration authorities, private health insurers, and other organizations. Our ability to successfully commercialize any drugs that we develop depends in part on the extent to which coverage and adequate reimbursement are available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, each individually decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Government authorities currently impose mandatory discounts for certain patient groups, such as Medicare, Medicaid and VA hospitals, and may seek to increase such discounts at any time. Future regulation may negatively impact the price of our drug candidates, if approved. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that coverage or reimbursement will be available for any drug candidate that we commercialize and, if coverage or reimbursement is available, the level of reimbursement. Reimbursement may impact the demand for, or the price of, any drug candidate for which we obtain marketing approval. In order to get coverage and reimbursement, physicians may need to show that patients have superior treatment outcomes with our products compared to standard of care drugs, including lower-priced generic versions of standard of care drugs. It is possible that a third-party payor may consider our drug candidates, once approved, and other therapies as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our drug candidates, once approved, compared to existing products, pricing of existing products may limit the amount we will be able to charge for our drug candidates. Third-party payors may deny or revoke the reimbursement status of a given drug product or establish prices for new or existing marketed products at levels that are too low to

enable us to realize an appropriate return on our investment in product development. Because EryDex is still in development, we are unable at this time to determine the likely level or method of coverage and reimbursement from third-party payors. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any drug candidate for which we obtain marketing approval. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors, and coverage decisions and reimbursement levels for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time consuming and costly process that may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained. There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the medicine is approved by the FDA or other comparable foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale, and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but make their determinations independently and may impose additional restrictions. Our inability to promptly obtain and maintain coverage and profitable payment rates from both government-funded and private payors for any approved products we may develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize drug candidates, and our overall financial condition. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future. In the EU, coverage and reimbursement status of any drug candidates for which we obtain regulatory approval are provided for by the national laws of EU member states. The requirements may differ across the EU member states. The EU provides options for EU Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU Member State may approve a specific price for the medicinal product, it may refuse to reimburse a product at the price set by the manufacturer or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Many EU Member States also periodically review their reimbursement procedures for medicinal products, which could have an adverse impact on reimbursement status. Moreover, in order to obtain reimbursement for our products in some European countries, including some EU Member States, we may be required to compile additional data comparing the cost-effectiveness of our products to other available therapies. This HTA of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including those representing the larger markets. The HTA process is the procedure to assess therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product currently varies between EU Member States. In December 2021, Regulation No 2021/2282 on HTA amending Directive 2011/24/EU, was adopted in the EU. This Regulation, which entered into force in January 2022 and will apply as of January 2025, is intended to boost cooperation among EU Member States in assessing health technologies, including new medicinal products, and providing the basis for cooperation at EU level for joint clinical assessments in these areas. The Regulation foresees a three-year transitional period and will permit EU Member States to use common HTA tools, methodologies, and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technologies, and making decisions on pricing and reimbursement. If we are unable to maintain favorable pricing and reimbursement status in EU Member States for drug candidates that we may successfully develop and for which we may obtain regulatory approval, any anticipated revenue from and growth prospects for those products in the EU could be negatively affected. In light of the fact that the United Kingdom has left the EU, Regulation No 2021/2282 on HTA will not apply in the United Kingdom. However, the UK MHRA is working with UK HTA bodies and other national organizations, such as the Scottish Medicines Consortium, the National Institute for Health and Care Excellence, and the All-Wales Medicines Strategy Group, to introduce new pathways supporting innovative approaches to the safe, timely and efficient development of medicinal products. Interim, top-line and preliminary data from our future clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. From time to time, we may publicly disclose preliminary or top-line data from our future clinical studies, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from future clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the top-line data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our drug candidates may be harmed, which could harm our business, operating results, prospects or financial condition. Even if we obtain regulatory approval for a drug candidate, it will remain subject to extensive ongoing regulatory review and requirements. If any of our future drug candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. 77Table of ContentManufacturers and manufacturers’ facilities are required to comply with extensive requirements imposed by the FDA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to GMPs regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with GMP and adherence to commitments made in any NDA. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We also are required to register our establishments and list our products with the FDA and certain state agencies. We and any third party manufacturers or suppliers must continually adhere to federal regulations setting forth GMP (for drugs) and QSR (for medical devices), and their foreign equivalents, which are enforced by the FDA and other national regulatory bodies through their facilities inspection programs. In complying with GMP and foreign regulatory requirements, we and any of our third-party manufacturers or suppliers will be obligated to expend time, money and effort in production, record-keeping and quality control to ensure that our products meet applicable specifications and other requirements. QSR requirements also impose extensive testing, control and documentation requirements. State regulatory authorities and the regulatory agencies of other countries have similar requirements. In addition, we will be required to comply with regulatory requirements of the FDA, state regulatory agencies and the regulatory agencies of other countries concerning the reporting of AEs and device malfunctions, corrections and removals (e.g., recalls), promotion and advertising and general prohibitions against the manufacture and distribution of adulterated and misbranded devices. Failure to comply with these regulatory requirements could result in enforcement actions, including, but not limited to, significant civil fines, product seizures, injunctions and/or criminal prosecution of responsible individuals and us. Any such actions would have a material adverse effect on our business, financial condition and results of operations. Manufacturers and manufacturers’ facilities are required to comply with extensive requirements imposed by the FDA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing procedures conform to GMPs regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with GMP and adherence to commitments made in any NDA or comparable foreign application. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. Any regulatory approvals that we receive for our potential drug candidates will be subject to limitations on the approved indicated uses for which the drug candidate may be marketed and promoted or to the conditions of approval (including the potential for a requirement to implement a Risk Evaluation and Mitigation Strategy) or contain requirements for potentially costly post-marketing testing. We will be required to report certain adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in drug development or commercialization, or increased costs to assure compliance. The FDA and other agencies, including the Department of Justice, as well as foreign regulatory authorities closely regulate and monitor the post-approval marketing and promotion of drug candidates to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. We will have to comply with requirements concerning advertising and promotion for our potential drug candidates and any products for which we receive approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the drug candidate’s approved label. As such, we may not promote our potential drug candidates for indications or uses for which they do not have approval. In the EU, the advertising and promotion of medicinal products are subject to both EU and EU Member States’ laws governing promotion of medicinal products, interactions with physicians and other healthcare professionals, misleading and comparative advertising and unfair commercial practices. General requirements for advertising and promotion of medicinal products, such as direct-to-consumer advertising of prescription medicinal products are established in EU law. However, the details are governed by regulations in individual EU Member States and can differ from one country to another. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product’s Summary of Product Characteristics, or SmPC, which may require approval by the competent national authorities in connection with an MA. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU. The holder of an approved NDA or equivalent foreign application must submit new or supplemental applications and obtain approval for certain changes to the approved drug candidate labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical trials to verify the safety and efficacy of our potential drug candidates in general or in specific patient subsets. If original marketing approval was obtained via the accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial to confirm clinical benefit for our drug candidates. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval. 78Table of ContentIf a regulatory authority discovers previously unknown problems with a drug or device, such as AEs of unanticipated severity or frequency, or problems with the facility where the drug candidate is manufactured, or disagrees with the promotion, marketing or labeling of a drug candidate, including if approved, such regulatory authority may impose restrictions on that drug candidate, an approved drug, or us, including requiring withdrawal of the approved drug from the market. If we fail to comply with applicable regulatory requirements, a regulatory authority or enforcement authority may, among other things: issue warning or untitled letters that would result in adverse publicity; impose civil or criminal penalties; suspend, vary or withdraw regulatory approvals; suspend any of our ongoing clinical trials; mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners; require us to enter into a consent decree or permanent injunction, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance; refuse to approve pending applications or supplements to approved applications submitted by us; impose restrictions on our operations, including closing our contract manufacturers’ facilities; seize or detain drug candidates or approved drugs; require a drug candidate or approved drugs recall. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our drug candidates. If regulatory sanctions are applied or if regulatory approval is suspended, varied or withdrawn, the value of our company and our operating results will be adversely affected. Non-compliance by us or any future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population can also result in significant financial penalties. A Fast Track designation by the FDA, such as the Fast Track designations received for EryDex, does not guarantee marketing approval and may not lead to a faster development, regulatory review or approval process. *In June 2024, the FDA granted Fast Track designation for our EryDex System for the treatment of patients with A-T. Fast Track designation provides opportunities for frequent interactions with FDA review staff, as well as eligibility for priority review, if relevant criteria are met, and rolling review of the sponsor’s NDA. Fast Track designation is intended to facilitate and expedite development and review of an NDA to address unmet medical needs in the treatment of serious or life-threatening conditions. However, Fast Track designation does not accelerate conduct of clinical trials or mean that the regulatory requirements are less stringent, nor does it ensure that any potential EryDex NDA will be approved or that any approval will be granted within any particular timeframe. In addition, the FDA may withdraw Fast Track designation for any indication if it believes that the designation is no longer supported by data emerging from the EryDex clinical development program. We may be unable to obtain and retain orphan drug designations for some of our drug candidates or to maintain the benefits associated with orphan drug designation status, including market exclusivity, which may cause our revenue, if any, to be reduced. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug in the United States will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. In the EU, the European Commission, following an opinion from the EMA’s Committee for Orphan Medicinal Products may grant orphan drug designation to promote the development of products (i) that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating conditions; (ii) either such conditions affect not more than five in 10,000 persons in the EU community, or without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product; and (iii) there exists no satisfactory authorized method of diagnosis, prevention, or treatment of the condition that has been authorized in the EU, or even if such method exists, the product will be of significant benefit to those affected by that condition. In the EU, orphan drug

designation provides a range of potential incentives for medicinal products that have been granted an orphan designation by the European Commission, including protocol assistance, access to the centralized authorization procedure and fee reductions.If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including an NDA, to market the same drug for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan product exclusivity or if the FDA finds that the holder of the orphan product exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. A product may obtain orphan drug exclusivity for each indication that has been designated upon approval of the indication, subject to the qualifications above. Any orphan drug exclusivity granted for second or subsequent indications applies only to those subsequent indications and does not block approval of a product for the first indication once the initial period of exclusivity has expired. Moreover, even if one of our drug candidates receives orphan product exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease. In the EU, upon grant of a marketing authorization, orphan medicinal products are entitled to a ten-year period of market exclusivity for the approved therapeutic indication, which means that the EMA cannot accept another marketing authorization application or accept an application to extend for a similar product and the European Commission cannot grant a marketing authorization for the same indication for a period of ten years. The period of market exclusivity is extended by two years for orphan medicinal products that have also complied with an agreed PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications. Orphan medicinal product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The period of market exclusivity may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria on the basis of which it received orphan medicinal product designation, including where it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity or where the prevalence of the condition has increased above the threshold. Additionally, an MA may be granted to a similar medicinal product with the same orphan indication during the 10 year period if: (i) if the applicant consents to a second original orphan medicinal product application; (ii) if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities; or (iii) if the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior to the original orphan medicinal product. A company may voluntarily remove a product from the register of orphan products.We have received orphan drug designation by the FDA and European Commission for EryDex for the treatment of A-T. We may seek orphan drug designation in the United States, the EU and other European countries for additional orphan indications in which there is a medically plausible basis, including other rare diseases. In the future, exclusive marketing rights in the United States, if granted, may be limited if we seek approval for an indication broader than the orphan drug designated indication and may be lost if the FDA later determines that the request for the orphan drug designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. In addition, although we have sought or intend to seek orphan drug designation, we may never receive approval for such designations.80Table of ContentIf we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial condition could be adversely affected.Our operations are subject to various federal and state fraud and abuse and other healthcare laws. The laws that may impact our operations include:â€¢federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;â€¢federal civil and criminal false claims laws, including the False Claims Act, and civil monetary penalty laws, which impose criminal and civil penalties, including through civil â€œqui tamâ€¢ or â€œwhistleblowerâ€¢ actions, against individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid, or other third-party payors that are false or fraudulent or knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;â€¢the federal HIPAA, which created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;â€¢HIPAA, as amended by HITECH, and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization;â€¢the federal Physician Payment Sunshine Act, created under the PPACA, and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Childrenâ€™s Health Insurance Program to report annually to the U.S. Department of Health and Human Services under the Open Payments Program, information related to payments or other transfers of value made to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;â€¢federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; andâ€¢analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state and foreign laws that require the registration of sales representatives; state and foreign laws that require drug manufacturers to file reports with states or foreign regulatory authorities regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and foreign laws 81Table of Contentgoverning the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.Outside the United States, interactions between pharmaceutical companies and health care professionals are also governed by strict laws, such as national anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physiciansâ€™ codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities, including compensating physicians with stock or stock options, could, despite our efforts to comply, be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our drug candidates, if approved, outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above and comparable risks, among other foreign laws.We are subject to substantial government regulation that is subject to change and could force us to make modifications to how we develop, manufacture, market, and price our products in the future.*The medical device industry is regulated extensively by governmental authorities, principally the FDA in the U.S. and corresponding state and foreign regulatory authorities. The majority of our manufacturing processes are required to comply with quality systems regulations, including GMP requirements that cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging and shipping of our products. Failure to comply with applicable medical device regulatory requirements could result in, among other things, warning letters, fines, injunctions, civil penalties, repairs, replacements, refunds, recalls or seizures of products, total or partial suspensions of production, refusal of the FDA or comparable foreign regulatory authorities and notified bodies to grant pre-market clearances or approvals for our products or issue CE Certificated of Conformity in the EU, withdrawals, or suspensions of future or current clearances or approvals and criminal prosecution.In addition, our products are subject to pre-clearance requirements by the FDA, similar regulatory authorities outside the United States, and notified bodies that govern a wide variety of product activities from design and development to labeling, manufacturing, promotion, sales, and distribution. Compliance with these regulations may be time consuming, burdensome, and expensive for us. The failure to obtain, or the loss or suspension of any such pre-approval or CE Certificate of Conformity in the EU, would negatively affect our ability to sell our products and harm our anticipated revenues.Foreign governmental authorities that regulate the manufacture and sale of medical devices have become increasingly stringent and, to the extent we sell our products in foreign countries, we may be subject to rigorous regulation in the future. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated revenue.The policies of the FDA and of comparable foreign regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our potential drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. For instance, the regulatory landscape related to clinical trials in the EU recently evolved. The CTR is intended to harmonize and streamline clinical trial authorizations, simplify adverse-event reporting procedures, improve the supervision of clinical trials and increase transparency. Specifically, the Regulation, which is directly applicable in all EU Member States, introduces a streamlined application procedure through a single-entry point, the "EU portal", the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application; as well as simplified reporting procedures for clinical trial sponsors. A harmonized procedure for the assessment of applications for clinical trials has been introduced and is divided into two parts. Part I assessment is led by the competent authorities of a reference Member State selected by the trial sponsor and 82Table of Contentrelates to clinical trial aspects that are considered to be scientifically harmonized across EU Member States. This assessment is then submitted to the competent authorities of all concerned Member States in which the trial is to be conducted for their review. Part II is assessed separately by the competent authorities and Ethics Committees in each concerned EU Member State. Individual EU Member States retain the power to authorize the conduct of clinical trials on their territory. The extent to which on-going clinical trials will be governed by the CTR will depend on the duration of the individual clinical trial. For clinical trials in relation to which an application for approval was made on the basis of the CTD before January 31, 2023, the CTD will continue to apply on a transitional basis until January 31, 2025. By that date, all ongoing trials will become subject to the provisions of the CTR. The CTR will apply to clinical trials from an earlier date if the related clinical trial application was made on the basis of the CTR or if the clinical trial has already transitioned to the CTR framework before January 31, 2025.In all cases, clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. Medicines used in clinical trials must be manufactured in accordance with the guidelines on GMP and in a GMP licensed facility, which can be subject to GMP inspections.In addition, on April 26, 2023, the European Commission adopted a proposal for a new Directive and Regulation to revise the existing pharmaceutical legislation. If adopted in the form proposed, the recent European Commission proposals to revise the existing EU laws governing authorization of medicinal products may result in a decrease in data and market exclusivity opportunities for our drug candidates in the EU and make them open to generic or biosimilar competition earlier than is currently the case with a related reduction in reimbursement status.If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any future marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, drug development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workersâ€™ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.83Table of ContentOur business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws.Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we may operate, including the UK Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our drug candidates in one or more countries and could materially damage our reputation, our brand, our international

expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. Any collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize potential future drug candidates. We may consider collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of drug candidates depending on the merits of retaining or divesting some or all commercialization rights. We will face, to the extent that we decide to enter into collaboration agreements, significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish and implement collaborations or other alternative arrangements should we so choose to enter into such arrangements. The terms of any collaborations or other arrangements that we may establish may not be favorable to us. Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:

- our collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;
- our collaborators may not pursue development and commercialization of our drug candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive drug candidates, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;
- our collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;
- our collaborators could independently develop, or develop with third parties, drug candidates that compete directly or indirectly with our drug candidates;
- a collaborator with marketing, manufacturing and distribution rights to one or more drug candidates may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;
- we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
- our collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;

84 Table of Contents

disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future drug candidates or that results in costly litigation or arbitration that diverts management attention and resources;

- our collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future drug candidates;
- our collaborators may own or co-own intellectual property covering our drug candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property;

and

- a collaborator's sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.

Risks Relating to Our Intellectual Property

If we are unable to obtain and maintain sufficient intellectual property protection for our current drug candidates, any future drug candidates, and other proprietary technology we develop, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize drug candidates similar or identical to ours, and our ability to successfully commercialize our current drug candidate, if approved, any future drug candidates, and other proprietary technologies if approved, may be adversely affected. Our commercial success will depend in part on obtaining and maintaining a combination of patent protection, trade secret protection and confidentiality agreements to protect the intellectual property related to our current and future drug candidates and the methods used to manufacture them, as well as successfully defending these patents against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell or importing our drug candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States or in many jurisdictions outside of the United States. Changes in either the patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be enforced in the issued patents that we currently own, or in patents that may issue from the applications we currently or may in the future own or license from third parties. Further, if any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected. Others may have filed, and in the future are likely to file, patent applications covering drug candidates that are similar, identical or competitive to ours or important to our business. We cannot be certain that any patent application owned by a third party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition or invalidity proceedings before U.S. or non-U.S. patent offices. The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our current or future drug candidates and proprietary technologies and erode or negate any competitive advantage we may have, which could have a material adverse effect on our financial condition and results of operations. For example:

- others may be able to make compounds that are similar to our drug candidates but that are not covered by the claims of our patents;
- we might not have been the first to make the inventions covered by our pending patent applications;
- we might not have been the first to file patent applications for these inventions;
- others may independently develop similar or alternative technologies or duplicate any of our technologies;
- any patents that we obtain may not provide us with any competitive advantages;
- we may not develop additional proprietary technologies that are patentable;

85 Table of Contents

the patents of others may have an adverse effect on our business. Should any of these events occur, they would significantly harm our business, results of operations and prospects. We have applied, and we intend to continue applying, for patents covering aspects of our current drug candidates and device, any future drug candidates, any future improvements on the device or other proprietary technologies and their uses that we deem appropriate. However, we may not be able to apply for patents on certain aspects of our current or future drug candidates, proprietary technologies and their uses in a timely fashion, at a reasonable cost, in all jurisdictions, or at all, and any potential patent coverage we obtain may not be sufficient to prevent substantial competition. Without patent protection on our current or future drug candidates, our ability to assert our patents to stop others from using or selling our current or future drug candidates may be limited. Due to the patent laws of a country, or the decisions of a patent examiner in a country, or our own filing strategies, we may not obtain patent coverage for all of our current or future drug candidates or methods involving the use of these candidates in a particular patent application. We plan to pursue divisional patent applications or continuation patent applications in the United States and other countries, where applicable, to obtain claim coverage for inventions which were disclosed but not claimed in a particular parent patent application. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our actual or potential future collaborators will be successful in protecting our current drug candidates, any future drug candidate, and other proprietary technologies and their uses by obtaining, defending, and enforcing patents. These risks and uncertainties include the following:

- the U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
- patent applications may not result in any patents being issued;
- patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;
- our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use and sell our drug candidates;
- other parties may have designed around our claims or developed technologies that may be related or competitive to our platform, may have filed or may file patent applications and may have received or may receive patents that overlap or conflict with our patent applications, either by claiming the same compounds, compositions of matter, or methods, or formulations, or by claiming subject matter that could dominate our patent position;
- any successful opposition to any patents owned by or licensed to us could deprive us of rights necessary to prevent others from practicing our technologies or to successfully commercialize any drug candidates that we may develop;
- because patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we or our licensors were the first to file any patent application related to our current drug candidates, any future drug candidates, and other proprietary technologies and their uses;
- an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of applications we may in-license which have an effective filing date before March 16, 2013;
- there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns;

and

- countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing drug candidates in those countries.

86 Table of Contents

The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection for such output. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. We may also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or feasible. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court, and we may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. Third parties, including competitors, may infringe, misappropriate or otherwise violate our patents, patents that may issue to us in the future, or the patents of our licensors that are licensed to us. To counter infringement or unauthorized use, we may need to choose to file infringement claims, which can be expensive and time-consuming. We may not be able to prevent, alone or with our licensors, infringement, misappropriation, or other violation of our intellectual property, particularly in countries where the laws may not protect those rights as fully as in the United States. If we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced against that third party for any number of reasons. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements for patentability, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. Similar mechanisms for challenging the validity and enforceability of a patent exist in non-U.S. patent offices and may result in the revocation, cancellation, or amendment of any non-U.S. patents we hold in the future. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents, or those of our licensors, invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more drug candidates. Such a loss of patent protection would have a material adverse impact on our business. These lawsuits are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the claimed inventions. There is also the risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party's activities do not infringe our rights to such patents. In addition, the U.S. Supreme Court has recently modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications, or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our current and any future drug candidates to market. Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. Our ability to enforce our patent rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their drug candidates. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor's or potential competitor's drug candidate. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded if we were to prevail may not be commercially meaningful. In addition, proceedings to enforce or defend our patents, including those of our licensors, could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering our drug candidates are invalidated or found unenforceable, or if a court found that valid, enforceable patents held by third parties covered one or more of our drug candidates, our competitive position could be harmed or we could be required to incur significant expenses to enforce or defend our rights. If we initiate lawsuits to protect or enforce our patents, or litigate against third party claims, such proceedings would be expensive and would divert the attention of our management and technical personnel. We may infringe the intellectual property rights of others, which may prevent or delay our drug development efforts and stop us from commercializing or increase the costs of commercializing our drug candidates. Our success will depend in part on our ability to operate without infringing the intellectual property rights of third parties. We cannot guarantee that our drug candidates, or

manufacture or use of our drug candidates, will not infringe third-party patents. Furthermore, a third party may claim that we or our manufacturing or commercialization collaborators are using inventions covered by the third party's patent rights and may go to court to stop us from engaging in our normal operations and activities, including making or selling our drug candidates. These lawsuits are costly and could affect our results of operations and divert the attention of managerial and scientific personnel. There is a risk that a court would decide that we or our commercialization collaborators are infringing the third party's patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our commercialization collaborators may not have a viable way around the patent and may need to halt commercialization of the relevant drug candidate. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages for having violated the other party's patents. If we collaborate with third parties in the development of technology in the future, our collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability. Further, our collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability. In the future, we may agree to indemnify our collaborators against certain intellectual property infringement claims brought by third parties. The pharmaceutical and biotechnology industries have produced a 88Table of Content proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of drug candidates or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform. Any claims of patent infringement asserted by third parties would be time consuming and could result in costly litigation; divert the time and attention of our technical personnel and management; cause development delays; prevent us from out-licensing or commercializing EryDex, or our other drug candidates until the asserted patent expires or is finally held invalid, unenforceable, or not infringed in a court of law; require us to develop non-infringing technology, which may not be possible on a cost-effective basis; require us to pay damages to the party whose intellectual property rights we may be found to be infringing, which may include treble damages if we are found to have been willfully infringing such intellectual property; require us to pay the attorney's fees and costs of litigation to the party whose intellectual property rights we may be found to be infringing; and/or require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all. If we are sued for patent infringement, we would need to demonstrate that our drug candidates or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity or unenforceability is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management's time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity or enforceability of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid or unenforceable, we may incur substantial monetary damages, encounter significant delays in bringing our drug candidates to market and be precluded from manufacturing or selling our drug candidates. We do not routinely conduct independent reviews of pending patent applications of and patents issued to third parties. We cannot be certain that others have not filed patent applications for technology covered by our pending applications, or that we were the first to invent the technology, because some patent applications in the United States may be maintained in secrecy until the patents are issued; patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived; pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our drug candidates or the use of our drug candidates; identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims; patent applications in the United States are typically not published until 18 months after the priority date; and publications in the scientific literature often lag behind actual discoveries. Furthermore, the scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent's prosecution history and can involve other factors such as expert opinion. Our interpretation of the relevance or the scope of claims in a patent or a pending application may be incorrect, which may negatively impact our ability to 89Table of Content market our drug candidates. Further, we may incorrectly determine that our technologies, or drug candidates are not covered by a third-party patent or may incorrectly predict whether a third party's pending patent application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our drug candidates. Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours, and others may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our drug candidates and future approved products or impair our competitive position. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing drug candidates. There may be third-party patents or patent applications with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our drug candidates. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar inventions prior to our own inventions, resulting in a loss of our U.S. patent position with respect to such inventions. Other countries have similar laws that permit secrecy of patent applications, and may be entitled to priority over our applications in such jurisdictions. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. As the biotechnology industry expands and more patents are issued, the risk increases that our drug candidates may be subject to claims of infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe existing or future third-party patents. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our drug candidates in any jurisdiction. Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our products. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the U.S. can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our products or the use of our products. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents, that will prevent, limit or otherwise interfere with our ability to make, use or sell our products. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent's prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party's pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. 90Table of Content We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, including our research programs, drug candidates, their respective methods of use, manufacture and formulations thereof, and could result in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on any issued patents and/or pending applications are due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm to pay these fees due to the USPTO and non-U.S. patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. If we license intellectual property, we may have to rely upon our licensors to comply with these requirements and effect payment of these fees with respect to any patents and patent applications that we license. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business. We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers. We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and drug candidate could be significantly diminished. As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. We may also be subject to claims that former employees, or other third parties have an ownership interest in our patents or other intellectual property. In addition, we may face claims by third parties that our agreements with employees, contractors or consultants obligating them to assign intellectual property to us are ineffective or in conflict with prior or competing contractual obligations of assignment, which could result in ownership disputes regarding intellectual property we have developed or will develop and interfere with our ability to capture the commercial value of such intellectual property. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors, and invention assignment agreements with employees, consultants and advisors, to protect our trade secrets and other proprietary information. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using commonly accepted physical and technological security measures. Despite these efforts, we cannot provide any assurances that all such agreements have been duly executed, and these agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA's disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. In addition, such security measures may not provide adequate protection for our proprietary information, for example, in the case of misappropriation of a trade secret by an employee, consultant, customer or third party with authorized access. Our security measures may not prevent an employee, consultant or customer from misappropriating our trade secrets and providing them to a competitor, and any recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our drug candidates that we consider proprietary. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time-consuming, and the outcome is unpredictable. Even though we use commonly accepted security measures, the criteria for protection of trade secrets can vary among different jurisdictions. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. Trade secrets could over time be disseminated within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties typically restrict the ability of our advisors, employees, collaborators, licensors, suppliers, third-party contractors and consultants to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our drug candidates and provision of our services, we must, at times, share trade secrets with them. Despite employing the contractual and other security precautions described above, the need to share trade secrets increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position would be harmed. In the future, we may need to obtain licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated. From time to time we may be required to license technology from third parties to further develop or commercialize our drug candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our drug candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our drug candidates could cause us to abandon any related efforts, which could seriously harm our business and operations. Where we obtain licenses from or collaborate with third parties, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties, or such activities, if controlled by us, may require the input of

such third parties. We may also require the cooperation of our licensors and collaborators to enforce any licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business, in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. Moreover, if we do obtain necessary licenses, we will likely have obligations under those licenses, including making royalty and milestone payments, and any failure to satisfy those obligations could give our licensor the right to terminate the license. Termination of a necessary license, or expiration of licensed patents or patent applications, could have a material adverse impact on our business. Our business would suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensors fail to enforce licensed patents against infringing third parties, if the licensed patents or other 92Table of Contentsrights are found to be invalid or unenforceable, or if we are unable to enter into necessary licenses on acceptable terms. Furthermore, if any exclusive licenses terminate, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties may gain the freedom to seek regulatory approval of, and to market, drug candidates identical to ours. Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensors' rights. In addition, while we cannot currently determine the amount of the royalty obligations, we would be required to pay on sales of future drug candidates, if any, the amounts may be significant. The amount of our future royalty obligations will likely depend on the technology and intellectual property we use in drug candidates that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize drug candidates, we may be unable to achieve or maintain profitability. Intellectual property rights do not necessarily address all potential threats to our competitive advantage. The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: others may be able to make drug candidates that are similar to ours but that are not covered by the claims of the patents that we own; or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; or future collaborators might not have been the first to file patent applications covering certain of our inventions; or others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; or it is possible that our pending patent applications will not lead to issued patents; or issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors; or our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive drug candidates for sale in our major commercial markets; or we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our drug candidates; or we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable drug candidates or will provide us with any competitive advantages; or we cannot ensure that our commercial activities or drug candidates will not infringe upon the patents of others; or we cannot ensure that we will be able to successfully commercialize our drug candidates on a substantial scale, if approved, before the relevant patents that we own or license expire; or we may not develop additional proprietary technologies that are patentable; and the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving that covered by our patents and patent applications; or should any of these events occur, they would significantly harm our business, results of operations and prospects. Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we can because of their greater financial resources and more mature and 93Table of Contentsdeveloped intellectual property portfolios. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, in-license needed technology or other drug candidates, or enter into development partnerships that would help us bring our drug candidates to market. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution. We may not be able to protect our intellectual property rights throughout the world. Patents are of national or regional effect, and filing, prosecuting and defending patents on all of our drug candidates throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing drug candidates made using our inventions in and into the United States or other jurisdictions. Further, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing drug candidates in violation of our proprietary rights generally. In addition, certain developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit, and in those countries, we and our licensors and licensees may have limited remedies if patents are infringed or if we or our licensors or licensees are compelled to grant a license to a third party, which could diminish the value of those patents. This could limit our potential revenue opportunities. Further, competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own drug candidates and, further, may export otherwise infringing drug candidates to territories where we have patent protection but where enforcement is not as strong as that in the United States. These drug candidates may compete with our drug candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. In Europe, beginning June 1, 2023, European applications and patent may be subjected to the jurisdiction of the UPC. Also, European applications will have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the UPC. This will be a significant change in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty. As a single court system can invalidate a European patent, we, where applicable may opt out of the UPC and as such, each European patent would need to be challenged in each individual country. Geo-political actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future licensors. Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates. As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Our patent rights may be affected by developments or uncertainty in U.S. or non-U.S. patent statutes, patent case laws in USPTO rules and regulations or in the rules and regulations of non-U.S. patent offices. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs. Recent patent reform legislation in the United States and other countries, including the AIA, signed into law on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, Congress may pass patent reform legislation that is unfavorable to us. The U.S. Supreme Court has ruled on several patent cases in recent years, narrowing the scope of patent protection available in certain circumstances and weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. We may become subject to claims challenging the inventorship or ownership of our patents and other intellectual property. We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets or other intellectual property as an inventor or co-inventor. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our drug candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. In addition, we may be unsuccessful in executing agreements assigning such intellectual property to us with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. Patent terms may be inadequate to protect our competitive position on our drug candidates for an adequate amount of time, and if we do not obtain patent term extension for our drug candidates, our business may be materially harmed. Patent rights are of limited duration. In the United States, the natural expiration of a patent is generally 20 years after its first effective non-provisional filing date. In addition, although upon issuance a U.S. patent's life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire before or shortly after such drug candidates are commercialized. Even if patents covering our drug candidates are obtained, once the patent life has expired for a drug candidate, we may be open to competition from generic products. A patent term extension of up to five years based on regulatory delay may be available in the United States under the Hatch-Waxman Act. However, only a single patent can be 95Table of Contentsextended for each marketing approval, and any patent can be extended only once, for a single drug candidate. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the claim, but instead only to the scope of the drug candidate as approved. Further, a patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug candidate approval and only those claims covering such approved drug candidate, a method for using it or a method for manufacturing it may be extended. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our drug candidate will be shortened and our competitors may obtain approval of competing drug candidates following our patent expiration, and our revenue could be reduced. If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Our current or future trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. Moreover, any name we have proposed to use with our drug candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed drug candidate names, including an evaluation of potential for confusion with other drug candidate names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary drug candidate names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. We cannot ensure that patent rights relating to inventions described and claimed in our pending patent applications will issue or that patents based on our patent applications will not be challenged and rendered invalid and/or unenforceable. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our drug candidates by obtaining and defending patents. We have pending U.S. and foreign patent applications in our portfolio; however, we cannot predict: if and when patents may issue based on our patent

applications; and the scope of protection of any patent issued based on our patent applications; whether the claims of any patent issued based on our patent applications will provide protection against competitors; Table of Contents whether or not third parties will find ways to invalidate or circumvent our patent rights; whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; whether we will need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win or lose; whether the patent applications that we own or in-license will result in issued patents with claims that cover our drug candidates or uses thereof in the United States or in other foreign countries; and/or whether we may experience patent office interruption or delays to our ability to timely secure patent coverage to our drug candidates. We cannot be certain that the claims in our pending patent applications directed to our drug candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that any such patent applications will issue as granted patents. One aspect of the determination of patentability of our inventions depends on the scope and content of the prior art, information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to our drug candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our drug candidates. In the event of litigation or administrative proceedings, we cannot be certain that the claims in any of our issued patents will be considered valid by courts in the United States or foreign countries. We may not be successful in obtaining or maintaining necessary rights to our drug candidates through acquisitions and in-licenses. Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license, or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our drug candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or drug candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our drug candidates, there may be times when the filing and prosecution activities for patents and patent applications relating to our drug candidates are controlled by our future licensors or collaboration partners. If any of our future licensors or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our drug candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those drug candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. We may enter into license agreements in the future with others to advance our existing or future research or allow commercialization of our existing or future drug candidates. These licenses may not provide exclusive rights to use such Table of Contents intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. In addition, subject to the terms of any such license agreements, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business. If our future licensors fail to prosecute, maintain, enforce, and defend such patents or patent applications, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our future drug candidates that are subject of such licensed rights could be adversely affected. Our future licensors may rely on third-party consultants or collaborators or on funds from third parties such that our future licensors are not the sole and exclusive owners of the patents we in-license. If other third parties have ownership rights to our future in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. It is possible that we may be unable to obtain licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, drug candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected drug candidates, which could harm our business, financial condition, results of operations, and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, drug candidates, or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. Disputes may arise between us and our future licensors regarding intellectual property subject to a license agreement, including: the scope of rights granted under the license agreement and other interpretation-related issues; whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; our right to sublicense patents and other rights to third parties; our diligence obligations under the license agreement and what activities satisfy those diligence obligations; our right to transfer or assign the license; the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners; and the priority of invention of patented technology. In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. In spite of our best efforts, our future licensors might conclude that we materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, Table of Contents products identical to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. From time to time, we may be required to license technologies relating to our therapeutic research programs from additional third parties to further develop or commercialize our drug candidates. Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use or sell our drug candidates, such licenses may not be available to us on commercially reasonable terms, or at all. The inability to obtain any third-party license required to develop or commercialize any of our drug candidates could cause us to abandon any related efforts, which could seriously harm our business and operations. Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that: collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations; collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or drug candidates; a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our future drug candidates or that results in costly litigation or arbitration that diverts management attention and resources; collaborators may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current and future drug candidates; collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and a collaborator's sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. We may encounter difficulties in managing our growth and expanding our operations successfully. As we seek to advance our product candidates through clinical trials and, if approved, through commercialization, we will need to expand our development, regulatory, quality assurance, manufacturing, commercialization, compliance, and administration capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to increase the responsibilities on members of management and manage any future growth effectively. Our failure to effectively manage our growth in this regard could prevent us from successfully implementing our strategy and maintaining the confidence of investors in our company. Our stockholders may realize little or no value from the divestiture of our legacy assets, and as a result our stock price may decline, we could be subject to litigation, and our business may be adversely affected. We have sold our legacy small molecule protease inhibitor portfolio to Lighthouse, which is a newly organized, private development stage company in the start-up phase, and has only recently commenced its operations. There is currently no existing public market for the shares of Lighthouse's common stock, and there can be no assurance that an active public 97Table of Contents market will ever develop. The absence of an active public market for these securities would make it difficult for us to sell the shares of Lighthouse's common stock and realize any value from them. To date, Lighthouse's operations have been primarily limited to organizing and staffing its company and completing the acquisition of our legacy assets. Accordingly, it is difficult if not impossible to predict Lighthouse's future performance or to evaluate its business and prospects, or ability to develop our legacy assets. For these and other reasons, our stockholders may realize little or no value from the divestiture of our legacy assets. The divestiture of our legacy assets or previously announced change in our corporate strategy, including the termination of the license for NOV004, could result in litigation against us, including litigation arising from or related to the value, received in the sale of our legacy assets to Lighthouse. For example, some of our investors purchased shares of our common stock because they were interested in the opportunities presented by our small molecule protease inhibitor portfolio, others because they were interested in our bone-targeting drug platform. Thus, certain stockholders may have attributed substantial financial value to our legacy assets or NOV004. If our stockholders believe that the financial value which is or may be received by us or them from the divestiture of our assets is inadequate, our stock price may decline and litigation may occur. As a result of these and other factors, we may be exposed to a number of risks, including declines or fluctuations in our stock price, additional legal fees, and distractions to our management caused by activities undertaken in connection with resolving any disputes related to these transactions. The occurrence of any one or more of the above could have an adverse impact on our business and financial condition. Risks Relating to Owning Our Common Stock The market price of our common stock is likely to be volatile and could fluctuate or decline, resulting in a substantial loss of your investment. The market price of our common stock has been and may continue to be volatile and could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including: our integration efforts related to our acquisition of EryDel; changes in our business strategy; timing and results of clinical trials; our ability to identify partnership and licensing opportunities to support the future development of EryDex; a market opportunity for A-T and future indications; any delays in manufacturing of drug supplies, results of preclinical studies and clinical trials for drug candidates; regulatory actions with respect to our drug candidates or our competitors' drug candidates; actual or anticipated fluctuations in our financial condition and operating results, including fluctuations in our quarterly and annual results; announcement of actual or anticipated reduction in force, including our recent reduction in force; announcements of technological innovations by us or our competitors; overall conditions in our industry and the markets in which we operate; addition or loss of significant customers, or other developments with respect to significant customers; changes in laws or regulations applicable to our drug candidates; actual or anticipated changes in our growth rate relative to our competitors; announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; additions or departures of key personnel; competition from existing drug candidates or new drug candidates that may emerge; issuance of new or updated research or reports by securities analysts; cash runway expectations; Table of Contents fluctuations in the valuation of companies perceived by investors to be comparable to us; disputes or other developments related to proprietary rights, including patents, litigation matters, and our ability to obtain intellectual property protection for our technologies; announcement or expectation of additional financing efforts; sales of our common stock by us or our stockholders; share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; market conditions for pharmaceutical stocks in general; our ability to maintain compliance with Nasdaq minimum listing requirements; general economic and market conditions; and ineffectiveness of our disclosure controls or internal controls. Furthermore, the stock markets have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. In the past, stockholders have instituted securities class action litigation following periods of market volatility. If we were to become involved in securities litigation, it could subject us to substantial costs and divert our management's attention from other business concerns, which could seriously harm our business. We may be subject to securities class action and stockholder derivative actions. These, and potential similar or related litigation, could result in substantial damages and may divert management's time and attention from our business and adversely impact our business, results of operations and financial condition. We may become the target of securities class actions or stockholder derivative claims. Securities-related class action litigation has often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. This risk is especially relevant for us because biotechnology companies often experience significant stock price volatility in connection with their product development programs. Any preclinical or clinical trial results that the investors may deem as unfavorable, volatility in our stock price and other matters affecting our business and operations may subject us to actual and threatened securities class actions or stockholder derivative claims. In addition, we may be exposed to increased litigation from stockholders, customers, suppliers, consumers and other third parties due to the combination of EryDel's and Novosteo's business and ours following the EryDel and Novosteo Acquisitions, out-licensing of our legacy assets and NOV004. These types of proceedings may result in substantial costs, divert management's attention from other business concerns and adversely impact our business, results of operations and financial condition. Future sales of our common stock in the public market could cause our share price to fall. Sales of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could depress the market price of our common stock and could impair

our ability to raise capital through the sale of additional equity securities. Certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in Securities Act registration statements that we may file for ourselves or other stockholders. Once we register these shares, they can be freely sold in the public market. Moreover, we have also registered under the Securities Act shares of common stock that we may issue under our equity compensation plans. In addition, the issuance of shares under awards granted under existing or future employee equity benefit plans may cause immediate and substantial dilution to our existing stockholders. In the future, we may issue additional shares of common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline.

101Table of ContentWe have in the past and may in the future fail to meet the requirements for continued listing on Nasdaq. If we fail to maintain compliance with the minimum listing requirements, our common stock may be delisted, which could have a material adverse effect on the liquidity of our common stock.*Our common stock currently trades on the Nasdaq. The Nasdaq has requirements that a company must meet in order to remain listed on Nasdaq. For example, Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of \$1.00 per share (the “Minimum Bid Price Requirement”) and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive trading days. On June 20, 2024, we received written notice (the “Notice”) from the Listing Qualifications Department of Nasdaq (the “Nasdaq Listing Department”) notifying us that, based on the closing bid price of our common stock for the last 34 consecutive trading days, we no longer comply with the Minimum Bid Price Requirement. The 2024 Notice had no immediate effect on the listing of our common stock on The Nasdaq Global Select Market. Pursuant to the Nasdaq Listing Rules, we have been provided an initial compliance period of 180 calendar days from the Notice to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of our common stock must be at least \$1.00 per share for a minimum of 10 consecutive trading days prior to December 17, 2024, and we must otherwise satisfy The Nasdaq Global Select Market’s requirements for listing. On November 12, 2024, the Company received written notice from the Listing Qualifications Department of Nasdaq notifying the Company that, for the last 10 consecutive business days, from October 29, 2024, through November 11, 2024, the closing bid price of the Company’s common stock was \$1.00 per share or greater. Accordingly, the written notice stated that the Company has regained compliance with the minimum bid price listing requirement set forth under the Rule and that the matter was now closed. Additionally, in December 2022, we received a written notice from the Nasdaq Listing Department notifying us that we were in noncompliance with the Minimum Bid Price Requirement and we regained compliance in April 2023. In December 2023, we again received a written notice from the Nasdaq Listing Department notifying us that we were in noncompliance with the Minimum Bid Price Requirement and regained compliance later in December 2023. There can be no assurance that we will continue to meet the Minimum Bid Price Requirement, or any other Nasdaq requirements, in the future. Furthermore, we may also be unable to meet other applicable Nasdaq listing requirements, including maintaining minimum levels of stockholders’ equity or market values of our common stock, in which case our common stock could be delisted. If our common stock were to be delisted, the liquidity of our common stock would be adversely affected, and the market price of our common stock could decrease. We have never paid dividends on our common stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases. We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.

General Risk FactorsOur charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock.*Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could delay or prevent a change in control of our company. These provisions could also make it more difficult for stockholders to elect directors and take other corporate actions. These provisions include:•providing for a classified board of directors with staggered, three-year terms;•authorizing our board of directors to issue preferred stock with voting or other rights or preferences that could discourage a takeover attempt or delay changes in control;•prohibiting cumulative voting in the election of directors;102Table of Content•providing that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;•prohibiting the adoption, amendment or repeal of our amended and restated bylaws or the repeal of the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors without the required approval of at least 66.67% of the shares entitled to vote at an election of directors;•prohibiting stockholder action by written consent;•limiting the persons who may call special meetings of stockholders; and•requiring advance notification of stockholder nominations and proposals. These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, the provisions of Section 203 of the Delaware General Corporate Law, or the DGCL, govern us. These provisions may prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a certain period of time without the consent of our board of directors. These and other provisions in our amended and restated certificate of incorporation and our amended and restated bylaws and under Delaware law could discourage potential takeover attempts, reduce the price investors might be willing to pay in the future for shares of our common stock and result in the market price of our common stock being lower than it would be without these provisions. Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the sole and exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ abilities to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. Our amended and restated certificate of incorporation provides that, unless we consent to the selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for:•any derivative action or proceeding brought on our behalf;•any action asserting a claim of breach of a fiduciary duty owed by, any of our directors, officers, employees or agents or our stockholders;•any action asserting a claim against us arising under the DGCL; our amended and restated certificate of incorporation, or our amended and restated bylaws; and•any action asserting a claim against us that is governed by the internal-affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation also provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees. While the Delaware Supreme Court recently determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring such a claim arising under the Securities Act against us, our directors, officers, or other employees in a venue other than in the federal district courts of the United States of America. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation, and this may require significant additional costs associated with resolving such action in other jurisdictions.103Table of ContentClaims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:•we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful;•we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;•we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;•we will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification;•the rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and•we may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. Our internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches, which could result in adverse consequences including, but not limited to, regulatory investigations or actions, litigation, fines/penalties, disruptions of our business operations, reputational harm, and loss of revenue or profits. In the ordinary course of our business, we and the third parties upon which we rely process sensitive data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats that could cause security incidents. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer “hackers,” “hacktivists,” individual threat actors, organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Despite the implementation of security measures designed to detect and mitigate vulnerabilities, our internal computer systems and those of our CROs and other contractors and consultants may be vulnerable to damage from sources including, but not limited to, malicious code (e.g., computer viruses), malware, ransomware attacks, software or hardware failures, telecommunications failures, and unauthorized access (including as a result of personnel misconduct or error). In particular, severe ransomware attacks are becoming increasingly prevalent and can lead to significant interruptions in our operations, ability to provide our products or services, loss of sensitive data and income, reputational harm, and diversion of funds. Additionally, remote work has become more common and has increased risks to our information technology systems and data, as more of our employees utilize network connections, computers, and devices outside our premises or network. Although to our knowledge we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, as well as adverse consequences including, but not limited to, investigations, fines/penalties, litigation, and reputational harm. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our drug candidates and other third parties for the manufacture of our drug candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Our reliance on 104Table of Contentthird-party service providers could also introduce new cyber security risks and vulnerabilities, such as supply-chain attacks. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our drug candidates could be delayed. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, or that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims. Our ability to utilize our federal net operating loss and tax credit carryforwards may be limited. Our net operating loss, or NOL, carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Moreover, under the Tax Act as modified by the CARES Act, federal NOLs generated in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of taxable income for tax years beginning January 1, 2018. Under Sections 382 and 383 of the Internal Revenue Code, limitations on a corporation’s ability to use its NOLs and tax credit carryforwards apply if a corporation undergoes an “ownership change,” which is generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. If we have experienced an ownership change at any time since our incorporation, we may already be subject to limitations on our ability to utilize our existing NOL carryforwards and other tax attributes to offset taxable income or tax liability. In addition, future changes in our stock ownership, which may be outside of our control, may trigger an ownership change. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. As a result, even if we earn net taxable income in the future, our ability to use our pre-change NOL carryforwards and other tax attributes to offset such taxable income or tax liability may be subject to limitations, which could potentially result in increased future income tax liability to us. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Item 3. Defaults Upon Senior Securities. Not Applicable. Item 4. Mine Safety Disclosures. Not Applicable. Item 5. Other Information. In November 2024, the Company entered into an amendment (the “Amendment”) of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment.105Table of ContentItem 6. Exhibits. The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, timely and successful completion which Exhibit Index is incorporated herein by reference. ExhibitNumberDescriptionIncorporated by ReferenceA.1 FormFiling DateNumberFiledHerewith3.1Amended and Restated Certificate of Incorporation8-K5/13/2019001-38890A3.2Certificate of Amendment to the registrant’s certificate of Incorporation, effective August 1, 20228-K8/1/2022001-38890A3.3Amended and Restated Bylaws8-K8/1/2022001-38890A31.1Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and Rule 15d-14(a) of the Exchange ActA.3X32.1#Certification of Principal Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002A.3X32.2#Certification of Principal Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002A.3X101.1NSInline XBRL Instance DocumentA.3X101.1SCInline XBRL Taxonomy Extension Schema DocumentA.3X101.1CALInline XBRL Taxonomy Extension Calculation Linkbase DocumentA.3X101.1DEFInline XBRL Taxonomy Extension Definition Linkbase DocumentA.3X101.1LABInline XBRL Taxonomy Extension Label Linkbase DocumentA.3X101.1PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentA.3X104Cover Page Interactive Data File, formatted in Inline XBRL (included in Exhibit 101)A.3X# In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Management’s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purpose of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.106Table of ContentSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. A Quince Therapeutics, Inc.Date: November 13, 2024By:/s/ Dirk ThyDirk ThyChief Executive Officer and Chief Medical Officer(Principal Executive Officer)Date: November 13, 2024By:/s/ Brendan HannahBrendan HannahChief Business Officer, Chief Operating Officer, and Chief Compliance Officer(Principal Financial Officer)107 EX-31.1 2 gnqx-20240930exxx311.htm EX-31.1 DocumentExhibit 31.1CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Dirk Thy, certify that: 1.1 have reviewed this

Quarterly Report on Form 10-Q of Quince Therapeutics, Inc. for the quarter ended September 30, 2024; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant€™s internal control over financial reporting that occurred during the registrant€™s most recent fiscal quarter (the registrant€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant€™s internal control over financial reporting; and5.The registrant€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant€™s auditors and the audit committee of the registrant€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant€™s internal control over financial reporting.Date: November 13, 2024/s/ Dirk Thye  Dirk Thye  Chief Executive Officer and Chief Medical Officer(Principal Executive Officer) EX-31.2 qncx-20240930xxex312.htm EX-31.2 DocumentExhibit 31.2CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002f, Brendan Hannah, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Quince Therapeutics, Inc. for the quarter ended September 30, 2024; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Evaluated the effectiveness of the registrant€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Disclosed in this report any change in the registrant€™s internal control over financial reporting that occurred during the registrant€™s most recent fiscal quarter (the registrant€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant€™s internal control over financial reporting; and5.The registrant€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant€™s auditors and the audit committee of the registrant€™s board of directors (or persons performing the equivalent functions):(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant€™s ability to record, process, summarize and report financial information; and(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant€™s internal control over financial reporting.Date: November 13, 2024/s/ Brendan HannahBrendan HannahChief Business Officer, Chief Operating Officer, and Chief Compliance Officer(Principal Financial Officer) EX-32.1 4 qncx-20240930xxex321.htm EX-32.1 DocumentExhibit 32.1CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)In connection with the Quarterly Report of Quince Therapeutics, Inc. (the Company) on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof to which this Certification is attached as Exhibit 32.1 (the Report), I certify, pursuant to Rule 13a-149b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and 18 U.S.C.  1350, as adopted pursuant to  906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: November 13, 2024By:/s/ Dirk Thye  Dirk Thye  Chief Executive Officer and Chief Medical OfficerA (Principal Executive Officer)This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Quince Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. EX-32.2 5 qncx-20240930xxex322.htm EX-32.2 DocumentExhibit 32.2CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350)In connection with the Quarterly Report of Quince Therapeutics, Inc. (the Company) on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof to which this Certification is attached as Exhibit 32.2 (the Report), I certify, pursuant to Rule 13a-149b) of the Securities Exchange Act of 1934, as amended (the Exchange Act), and 18 U.S.C.  1350, as adopted pursuant to  906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: November 13, 2024By:/s/ Brendan HannahA Brendan HannahA Chief Business Officer, Chief Operating Officer, and Chief Compliance OfficerA (Principal Financial Officer)This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Quince Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. EX-101.SCH 6 qncx-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Cash, Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Business Combination link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Cash, Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Business Combination (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Fair Value Measurements - Schedule of Changes in Present Value of Acquisition Related Accrued Earnings of Contingent Consideration Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Fair Value Measurements - Schedule of Quantitative Information about Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Fair Value Measurements - Schedule of Fair Value of the Level 3 EIB Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Cash, Cash Equivalents and Investments - Schedule of Fair Values of Cash, Cash Equivalents, and Short-Term Investments Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Cash, Cash Equivalents and Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Cash, Cash Equivalents and Investments - Schedule of Available-for-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Balance Sheet Components - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Balance Sheet Components - Schedule of Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Balance Sheet Components - Schedule of Accrued Severance (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan (Quince) - General (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan (Quince) - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stock-Based Compensation - Schedule of Activity for Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stock-Based Compensation

for-sale investments Investment Income, Net, Amortization of Discount and Premium Intangible asset impairment charge Impairment charge Impairment of Intangible Assets (Excluding Goodwill) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Contingent consideration Payments to Acquire Businesses, Gross Schedule of Fair Values of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Provision for additional remuneration paid based on revenue between 125 Million and 250 Million Euros, percentage Provision For Additional Remuneration Paid Based On Revenue Between 125 Million And 250 Million Euros, Percentage Provision For Additional Remuneration Paid Based On Revenue Between 125 Million And 250 Million Euros, Percentage Effect of exchange rate changes on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Impairment charge Impairment of Intangible Assets, Finite-Lived Deferred tax liabilities Deferred Income Tax Liabilities, Net Restricted stock award retirement Stock Issued During Period, Value, Restricted Stock Award Retirement Stock Issued During Period, Value, Restricted Stock Award Retirement Accounts payable Accounts Payable, Current Computer equipment Computer Equipment [Member] Commitments and contingencies Commitments and Contingencies Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Schedule of Nonvested Restricted Stock Shares Activity Nonvested Restricted Stock Shares Activity [Table Text Block] Stockholders' Equity Equity [Text Block] Options vested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value EIB loan European Investment Bank Loan [Member] European Investment Bank Loan [Member] Geographical Geographical [Axis] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Research and development expenses Accrued Research And Development Expenses Current Accrued research and development expenses, current. Income Taxes Income Tax Disclosure [Text Block] Accelerated vesting, number of options Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number Property and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Current liabilities: Liabilities, Current [Abstract] Imputed interest Imputed Interest on Borrowings Imputed interest on borrowings Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, \$0.001 par value, 10,000,000 authorized, (100,000 shares of which are designated as Series A Junior Participating Preferred Stock), no shares issued and outstanding as of SeptemberA 30, 2024 and DecemberA 31, 2023, respectively. Preferred Stock, Value, Issued Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Note receivable Payments to Acquire Notes Receivable Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Payment of contingent consideration Payment for Contingent Consideration Liability, Financing Activities Net loss per share - diluted (in USD per share) Earnings Per Share, Diluted Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Foreign currency translation adjustment in fair value Foreign Currency Contracts, Liability, Fair Value Disclosure Goodwill [Roll Forward] Goodwill [Roll Forward] Milestone Payment [Domain] Milestone Payment [Domain] Milestone payment domain Options vested and expected to vest (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Level 3 Fair Value, Inputs, Level 3 [Member] Line of Credit Line of Credit [Member] Number of Options and Unvested Shares, beginning balance (in shares) Number of Options and Unvested Shares, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Remuneration payable period Remuneration Payable Period Remuneration payable period. Trading Symbol Trading Symbol Percentage of deferred interest converted Debt Instrument, Percentage Of Deferred Interest Converted Debt Instrument, Percentage Of Deferred Interest Converted Options granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Net loss Net loss Net Income (Loss) Attributable to Parent Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Foreign Currency Translation and Transactions Foreign Currency Transactions and Translations Policy [Policy Text Block] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Leases Lessee, Operating Leases [Text Block] Probability of Achievement Probability Of Achievement [Member] Probability of achievement. LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Liabilities and Equity [Abstract] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Fair value adjustment for contingent consideration Change in fair value of contingent consideration Fair Value Adjustment For Contingent Consideration Represents the amount of fair value adjustment for contingent consideration during the period. Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Specified Approval Milestones Approval Milestones [Member] Approval milestones. Schedule of Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stock based awards vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Discounted earning after tax Discounted Earning After Tax Discounted Earning After Tax Proceeds from disposal of assets Proceeds from Sale of Productive Assets Finite-lived intangible assets useful life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Schedule of Carrying Amount of Indefinite-Lived Intangible Asset Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Options exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Goodwill Balance as of December 31, 2023 Balance as of September 30, 2024 Goodwill Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components Equity Components [Axis] Business combination discount rate Probability Discount Rate of Each Milestone Probability Discount Rate of Each Milestone Warrants to purchase common stock (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Financial Instruments [Domain] Certificates of deposit Certificates of Deposit [Member] Maximum aggregate number of shares that may be issued under the plan Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Lessee Lease Description [Table] Lessee, Lease, Description [Table] 2026 Long-Term Debt, Maturity, Year Two Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Deferred interest percent Debt Instrument, Deferred Interest Percent Debt Instrument, Deferred Interest Percent Entity Small Business Entity Small Business Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Local Phone Number Local Phone Number Award grant period Share Based Compensation Arrangement by Share Based Payment Award Grant Period Share based compensation arrangement by share based payment award grant period. 2024 Long-Term Debt, Maturity, Remainder of Fiscal Year Prepaid research and development expenses Prepaid Research And Development Expenses Current Prepaid research and development expenses, current. Payout of contingent earnout based on milestone achievement Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Measurement Frequency [Axis] Measurement Frequency [Axis] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Restricted Stock Units Restricted stock units Restricted Stock Units (RSUs) [Member] Net loss before income tax benefit Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Minimum cash balance Debt Instrument, Covenant, Minimum Required Cash Balance Debt Instrument, Covenant, Minimum Required Cash Balance Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2022 Inducement Plan Two Thousand and Twenty Two Inducement Plan [Member] Two thousand and twenty two inducement plan. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward] Income Statement Location [Axis] Income Statement Location [Axis] Line of Credit Facility [Table] Line of Credit Facility [Table] Government and agency notes US Government Corporations and Agencies Securities [Member] Risks and Uncertainties Risks And Uncertainties [Policy Text Block] Risks and uncertainties. Cash, Cash Equivalents and Investments Cash and Cash Equivalents, Policy [Policy Text Block] Equity investment in Lighthouse, Inc. Gain (Loss) on Sale of Investments Schedule of Outstanding Potentially Dilutive Ordinary Shares Excluded from Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Research and development expense Research and Development Expense [Member] Cash flow from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Antidilutive securities excluded from calculation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] General and administrative expense General and Administrative Expense [Member] Property and equipment Property, Plant and Equipment, Gross Weighted average remaining contractual life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Input used Business Combination, Contingent Consideration, Liability, Measurement Input 2019 ESPP Two Thousand Nineteen Employee Stock Purchase Plan [Member] Two thousand nineteen employee stock purchase plan. Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair value adjustment for long-term debt Fair Value Adjustment For Long Term Debt Fair value adjustment for long term debt. Entity File Number Entity File Number Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Short-term operating lease liability Operating Lease, Liability, Current Prepaid expenses Prepaid Expense, Current Schedule of Other Assets Schedule of Other Assets [Table Text Block] Computer Software Computer Software, Intangible Asset [Member] Reductions in research and development expense Reductions in Research and Development Expense Reductions in research and development expense. Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Proceeds from maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Net Carrying Value Finite-Lived Intangible Assets, Net Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] EIB Loan ,Tranche D European Investment Bank Loan, Tranche D [Member] European Investment Bank Loan, Tranche D Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Long-term debt Beginning Balance as of January 1, 2024 Ending Balance as of September 30, 2024 Debt Instrument, Fair Value Disclosure Interest income Investment Income, Interest Common stock, shares issued (in shares) Common Stock, Shares, Issued Fair value of total consideration transferred Fair value of total consideration transferred Business Combination, Consideration Transferred Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Voting rights in percentage Percentage of Voting Rights Percentage of voting rights. Cash severance payments Severance Costs Security Exchange Name Security Exchange Name Disbursement period Disbursement Period Disbursement period. Total Assets, Fair Value Disclosure Long-term debt Total Debt as of September 30, 2024 Long-Term Debt Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Share based compensation accelerated vesting percentage Award vesting rights Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Stock Options Stock options issued and outstanding Share-Based Payment Arrangement, Option [Member] Current portion of operating lease liabilities Accrued Operating Lease Liabilities Current Accrued operating lease liabilities current. Long-term Italian research and development refundable tax credit Deferred Tax Assets Long Term Tax Credit Carryforwards Foreign Deferred tax assets long term tax credit carryforwards foreign. Unamortized employee stock-based compensation expected to recognized over remaining estimated vesting period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Stock award conversion ratio Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Issued Up Conversion Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Issued Up Conversion Maximum Maximum [Member] Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unamortized employee stock-based compensation Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Balance Sheet Components [Line Items] Balance Sheet Components [Line Items] Balance sheet components [Line Items]. VAT receivable Value Added Tax Receivable Entity Address, Address Line One Entity Address, Address Line One Foreign currency translation adjustments Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Schedule of Accrued Severance and Related Expenses Summary of Accrued Severance [Table Text Block] Tabular disclosure of accrued severance. Subsequent Event [Table] Subsequent Event [Table] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Purchase of investments Payments to Acquire Debt Securities, Available-for-Sale Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Subsequent Event Subsequent Event [Member] Schedule of Carrying Amount of Finite-Lived Intangible Asset Schedule of Finite-Lived Intangible Assets [Table Text Block] Cash Cash [Member] Income Statement [Abstract] Income Statement [Abstract] Options cancelled / forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Other non-current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Cash Cash and Cash Equivalents, Fair Value Disclosure Imputed interest and fair value adjustments Debt Instrument Imputed Interest Debt instrument imputed interest. Business Combination Business Combination Disclosure [Text Block] Preferred Stock, subject to adjustment (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Beginning accrued severance Ending accrued severance Accrued Severance Accrued Severance Balance as of December 31, 2023 Balance as of September 30, 2024 Indefinite-Lived Intangible Assets (Excluding Goodwill) Numerator: Net Income (Loss) Attributable to Parent [Abstract] Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance (in USD per share) Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Ending Balance (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other current assets Other Assets, Current Number of lease agreements acquired Number Of Lease Agreements Acquired Number Of Lease Agreements Acquired Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Assets held for sale Assets Held for Sale Assets held for sale. Share-Based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Other comprehensive loss: Other Comprehensive Income (Loss), Tax [Abstract] Equity investments in Lighthouse Pharmaceuticals, Inc. Equity Method Investments Severance paid during the period Accrued Severance Paid Accrued severance paid Ery Del Ery Del [Member] EryDel. Statistical Measurement [Axis] Statistical Measurement [Axis] Drawn percentage Drawn Percentage Drawn percentage. Milestone Payment [Axis] Milestone Payment [Axis] Milestone payment axis Other assets Increase (Decrease) in Other Current Assets Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Fair value of the EIB Loan Loans Payable, Fair Value Disclosure Balance Sheet Components [Roll Forward] Balance Sheet Components [Roll Forward] Balance Sheet Components Other non-current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Debt Securities Available For Sale [Table] Debt Securities, Available-for-Sale [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding In-process research and development: Indefinite-Lived Intangible Assets [Roll Forward] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares) Share Based Compensation Arrangement by Share based Payment Award Options and Non Option Equity Instruments Exercises in Period

Share based compensation arrangement by share based payment award options and non option equity instruments exercises in period. Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Discount rate Discounted Value To Present Value Of Intangible Assets Discounted value to present value of intangible assets. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province 2019 Plan Two Thousand And Nineteen Equity Incentive Plan [Member] Two thousand and nineteen equity incentive plan. Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Amounts reclassify out of accumulated other comprehensive loss OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Impairment loss on operating lease Operating Lease, Impairment Loss EIB Loan, Tranche B European Investment Bank Loan, Tranche B [Member] European Investment Bank Loan, Tranche B Debt, non-current Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock Class of Stock [Domain] Number of Options and Unvested Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Change in fair value Change In Fair Value Disclosure Change in fair value disclosure. Operating lease liability Total remaining lease liability Operating Lease, Liability Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] Incurred during the period Accrued Severance Incurred Accrued severance incurred Schedule of Future minimum principal payments Schedule of Maturities of Long-Term Debt [Table Text Block] Total liabilities Liabilities Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] EIB Loan Tranche C European Investment Bank Loan, Tranche C [Member] European Investment Bank Loan, Tranche C Options exercisable (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Vesting [Domain] Vesting [Domain] Prepaid expenses and other current assets Reduction in prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income / (Loss) AOCI Attributable to Parent [Member] Cash, cash equivalents, and short-term investments Cash, Cash Equivalents, and Short-Term Investments Accrued expenses and other current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Expenses Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accrued expenses. Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Measurement Frequency [Domain] Measurement Frequency [Domain] Restricted Stock Awards Restricted Stock Awards [Member] Restricted stock awards. Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Income tax benefits recognized Share-Based Payment Arrangement, Expense, Tax Benefit Number of reportable segment Number of Reportable Segments Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, \$0.001 par value, 100,000,000 shares authorized, 43,276,606 and 42,973,215 issued and outstanding as of SeptemberA 30, 2024 and DecemberA 31, 2023, respectively. Common Stock, Value, Issued General and administrative General and Administrative Expense Lab equipment Lab Equipment [Member] Lab equipment. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade Names Trade Names [Member] Professional fees Accrued Professional Fees, Current Payment for contingent consideration Payment for Contingent Consideration Liability, Investing Activities Three Year Anniversary Three Year Anniversary [Member] Three Year Anniversary Segments Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Preferred Stock Preferred Stock [Member] Payments of finance leases Finance Lease, Principal Payments Schedule of Future Minimum Lease Payments Under Lease Agreements Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Impairment charges Asset Impairment Charges Contingent consideration Business Combination, Contingent Consideration, Liability Supplemental disclosures of non-cash information: Supplemental Cash Flow Information [Abstract] Other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category EIB Loan, Tranche A European Investment Bank Loan, Tranche A [Member] European Investment Bank Loan, Tranche A Statement [Table] Statement [Table] Long-term contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Cash, Cash Equivalents and Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Beginning Balance as of January 1, 2024 Ending Balance as of September 30, 2024 Fair value measurements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Other information: Supplemental Balance Sheet Other Information [Abstract] Supplemental balance sheet other information. Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Options exercisable as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Due to foreign currency translation Debt Instrument Fair Value Due to Foreign Currency Translation Debt instrument fair value due to foreign currency translation. Class of Stock Class of Stock [Axis] Short-term contingent consideration Business Combination, Contingent Consideration, Liability, Current Short-term investments Debt Securities, Available-for-Sale, Current Other Other Accrued Liabilities, Current Common stock withheld (in shares) Class of Warrant or Right, Unissued 2019 Novosteo Plan 2019 Novosteo Plan [Member] 2019 Novosteo Plan Office furniture Furniture and Fixtures [Member] Contingent consideration Contingent Consideration [Member] Contingent Consideration. Fixed interest rate Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Other Operating Leases Other Operating Leases [Member] Other operating leases. Tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Medolla, Italy Medolla [Member] Medolla. Business Combination and Asset Acquisition [Abstract] Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Goodwill impairment charge Impairment charge Impairment charge Goodwill, Impairment Loss Restricted stock awards Restricted Stock [Member] Rights Plan Rights Plan [Member] Rights plan. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Debt Instrument, Fair Value [Roll Forward] Debt Instrument, Fair Value [Roll Forward] Debt Instrument, Fair Value Schedule of Quantitative Information About Fair Value Measurements Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustments Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Subsequent Events [Abstract] Deferred tax liability Deferred tax liability Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Prepaid insurance Prepaid Insurance Current Prepaid insurance current. Long-Lived Tangible Asset Long-Lived Tangible Asset [Axis] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Total liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Fair value adjustment Liabilities, Fair Value Adjustment Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Maximum period for common stock shares reserved for future issuance Maximum Period For Common Stock Capital Shares Reserved For Future Issuance Maximum period for common stock capital shares reserved for future issuance. Intangible assets Intangible Assets, Net (Excluding Goodwill) Number of stock plans Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Useful life Finite-Lived Intangible Asset, Useful Life 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Antidilutive Securities Antidilutive Securities [Axis] 2028 and thereafter Lessee, Operating Lease, Liability, to be Paid, Year Four Weighted Average Exercise Price, beginning balance (in USD per share) Weighted Average Exercise Price, ending balance (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Rent expenses (less than) Operating Lease, Expense Stock based compensation Share-Based Payment Arrangement, Noncash Expense Common Stock Common Stock [Member] Proceeds from income tax refunds Proceeds from Income Tax Refunds City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Net Loss Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Geographical Geographical [Domain] Lease agreement period Lessee, Operating Lease, Term of Contract Minimum Minimum [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Schedule of Stock Options Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Maximum amount of future consideration payment Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Change in deferred tax liabilities due to acquisition of Novosteo, Inc. Change In Deferred Tax Liabilities Due To Acquisition Change in deferred tax liabilities due to acquisition. ASSETS Assets [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Assets acquired: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract] Total Liabilities, Fair Value Disclosure Liabilities: Liabilities [Abstract] Net Loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Liabilities assumed: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Schedule of Financial Assets and Liabilities to Fair Value Measurements on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Unrealized gain (loss) on available-for-sale securities Unrealized gain (loss) on available for sale investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Accumulated Deficit Retained Earnings [Member] Goodwill expected to be deductible Business Acquisition, Goodwill, Expected Tax Deductible Amount Schedule of Employee and Non-Employee Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other assets Other Assets, Noncurrent Net loss per share - basic (in USD per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating lease asset Operating Lease, Right-of-Use Asset Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Options, stock-based compensation not yet recognized Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Option Equity Option [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Schedule of Fair Values of Cash, Cash Equivalents, and Short-Term Investments Measured at Fair Value on Recurring Basis Schedule Of Cash Cash Equivalents And Investments [Table Text Block] Schedule of cash, cash equivalents, and investments. Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value 2024 (remainder of the year) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year IPR&D In Process Research and Development [Member] Contingent Consideration Contingent Liability Reserve Estimate, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Bresso, Italy Bresso [Member] Bresso. Options vested and expected to vest as of September 30, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Basis of Consolidation Consolidation, Policy [Policy Text Block] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Schedule of Fair Value of the Total Purchase Consideration Transferred Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Trade payables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Trade payables Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, trade payables. Document Transition Report Document Transition Report Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Issuance of common stock on exercise of stock options and vesting of restricted stock units Share based Compensation Arrangement by Share based Payment Award Value Options and Non Option Equity Instruments Exercises in Period Share based compensation arrangement by share based payment award value options and non option equity instruments exercises in period. Business acquisition, transaction costs Business Acquisition, Transaction Costs Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Monthly installments over the remaining vesting period Monthly Installments, Remaining Vesting Period Monthly installments, remaining vesting period. Debt securities, fair value Fair Value Debt Securities, Available-for-Sale Increase in number of shares available for issuance as proportion of shares of common stock (in shares) Share Based Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares Available For Issuance As Proportion Of Shares Of Common Stock Share based compensation arrangement by share based payment award increase in number of shares available for issuance as proportion of shares of common stock. Schedule of Supplemental Balance Sheet Information Related to Leases Supplemental Balance Sheet Information Related To Leases [Table Text Block] Supplemental balance sheet information related to leases. Operating lease right-of-use assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets Business combination, recognized identifiable assets acquired and liabilities assumed, operating lease right-of-use assets. Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Change in fair value of long-term debt Increase Decrease in Fair Value of Borrowings Increase decrease in fair value of borrowings. Short-Term Investments Short-Term Investments [Member] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Total future payments Long-Term Debt, Gross Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] NDA acceptance under contingent consideration NDA Acceptance Under Contingent Consideration NDA acceptance under contingent consideration. European Bank Loan, Tranche A, Tranche B, Tranche C European Bank Loan, Tranche A, Tranche B, Tranche C [Member] European Bank Loan, Tranche A, Tranche B, Tranche C Percentage of common stock outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Identifiable intangible assets Finite-Lived Intangible Assets, Fair Value Disclosure Car Automobiles [Member] Total assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Weighted average remaining contractual maturities of available-for-sale securities Weighted Average Remaining Contractual Maturities Of Available For Sale Securities Weighted average remaining contractual maturities of available-for-sale securities. Severance costs recognized Severance Costs Recognized Severance Costs Recognized Cancelled (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Royalty rate utilized Royalty Rate Utilizing Under Income Approach Royalty rate utilizing under income approach. Subsequent Event Type [Axis] Subsequent Event Type [Axis] Proceeds from issuance of common stock upon exercise of stock options Proceeds from Stock Options Exercised Balance Sheet Components [Abstract] Balance Sheet Components [Abstract] Balance sheet components. Foreign currency translation adjustments Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Options cancelled / forfeited (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Quince Therapeutics common stock (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Novosteo Novosteo [Member] Novosteo member Restricted Stock award retirement (in shares) Stock Issued During Period Shares

[illegible]

[illegible]

[illegible]

[The content of this block is extremely repetitive and appears to be a corrupted or placeholder document. It contains no meaningful information.]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

01OK=00%VYL12L:H6T6_E\$C#M#M4:17-D1UJ:72%0ZB5:1PQ2_OUKT7XBZ)~\$11W5=NHV.EW&Y8+C40+B*S8%\$1SDS.MGV0HOS'
02=65X?C(616.A0VB:=(L5HI04M6T~A5C.M.9/2=6ZV4DTB1~02=QMI.CTW~OL655.ME2%?BZG?16UY5+Q+W.(AV?56%5BIFU323FNY.NSBL
M56:5Q~YCD.L~W#.#R2~>KKA@Q#12P.4G1=H221MMITC4CH~J7VA~VM=04\$F.MWE\$E.#LGIH0XHXKYZO+X~#OPGKOA=~/MG+~\$MU+HL.LAX.NPII>2>2~
M3WD41~210@+~2L~M~\$=S8W13P&4VH1#Z\$E~#?7ABX.COITU.YL.M.WPGN.M=OI+OUOM=MIC.I+&IAOOD=?.?JGPA?20?71=..?9+VIAOY+I?C~N(KE.F~M%8(VHYEDD3B)NZ.E)~
L=59H.7%?~?GUFU&X&S=M+T#6+BPDM1.Q9FW6.MX&5.Y09D8I[W.#.M~<?<?SWD7_1+X6~?#IKXV~O&S&A+D.IX4G1
M.N~1+1.YXMYX@EC~1~9ZL7P1.DHLS.RVE.W76@H121+HUIX>TNWTZQ21.M+6L~?65Y?2225N2S.2225\$DDDDDD~1V7VA~M2V?P.M30756G32FY.M6U.H)N~H3.C2?&F0P2
M#W@1AAW1~?PCGUOH~&EQZX?QK&K.R7%~?M~.K~<~.1P13IAFE.O.D.B=HQE.EW.B~&#~?2~\$1U+?+X@G.V586.F.M7=Q1074FM.N9?>VP.D523?~N8KPKW
N5_9~X~9~4~K6.PX1.Z9IEQI.MIW.WEMWO=7~1~%YAVS7S.V.V#N1.#15#~\$~X~\$2Q4S~>F2+4M1+&Q~WIM.MI(APOIPE9J(69MS9D5.Y~
~L&GAWC.Q%K~X~@~1M%NULX+~>3Q79.2.O&C&Z7~\$.50\$H.M8K.PC32E=C~W>MHO4TC1ULUYOYAB~OWI.FE~J1~&GSGI0B0XU7A.Z?#%19>~J2TWQ&M.
~L~9K~#0L.6I.AK8NB1P44&L&A&L.P~7E~<3OI.M4U.VU6.TV61.LM+1/KG2I(=H0&JL~2?&CX1EL~K+P&3JO~&QGB~).\$2.M.&ANG~7>2O3K.WE
MO&MYHX9&D/GC.PY45BI@+WIJ.Y.U.P.BE>QISH.P.MB~&~VMV+PG>ZM&ZMFMY>WIO=W+~?#S)H9&DEQ(R.S.C&C+T+PW.MIWA&IBTWV~S)=W(T~M>X.5
'O15E.3K2&R&R&M&S&CB1>51~<2.GPNI~D?F#Y.#~?T1M17TW1\$V.M~F&M~K~JHMMH~0KH~J~<~<~S/4Y.Y~BV2~L1B2X~<6P1L.ERREUS1CT/H3.M.A#=#9?
CDPTZ>+7W.P1SPYSDCNB8&(96)&#&#BEQ.C1DDG?L?Q&XSL=N~M~SZE>641M~<1.LWMYL.WE66&(9IF.JZJ=B\$~I@&C&CBKW0~V2?FSX<UX.MB344KK2H
HDQ1YA2>+15X.BH1.N2V?OBN.U.Q.0~M~.W~?Zi>7.AFZ0~(M1K>?~?H~<N1Q2CG2VGDG.D1N2UPWIO.NV21~<NS&?2~>~VC&I~CM27&2X~1LM0.
XFD01.YES+~?F~W1.VA76~8HGD~1(XD?~?J126.MPMKMI(M@M&6IUSXNWARB.9D3~<Q*GR&I.DION?P.B.O1~<?P.C1~+~?MPA8OX.L~B/013K~<K?P>~>~\$~&ACT*~
L1+J6U~OS/OFFO.F0N?P~?5\$5VIOI.MU?/CA#3~1~<GR&G.C/RM02&65Y.2U~YOYFR@~#F6X.D~M~<8&XK0.P~<?S7.M.M%2C2?>NCTY2U6ITQ~/POI~<Q~N1192
LKJ51~#.~2.OQ8JO~5T.BM1~0~Z?727UUX=M1%~A~U~J.O.AHRT&T~&~&S3I.LGZ&65L?2~*S.M~9.R.M3V~#FCNCGUE?&CXCT?7274.U+~KPZ&SIZM=AL<~I&QGM9~VVOVWW&(2@P1&~
M~<X%XA(ZX3)~<T~T~RV2N1M~RO~J~%CDDPZMZMFZMY>WIO=WI+W~W~?#S)H9&DEQ(R.S.C&C&R&~<?16K~#OP.XU20~#.XJUA~H1~J~CL7MfGIVMF4B65Y960VX
MUUG<4#87&~*U~?7Q4~<?&~<1.3AO5M90HI~XT~ZM+XMK>9~1M1~?#M~MIQ?BY5DD~#~ALH~N~6.ZIA@/811L.AKX3EN=WGRV~&f&~
QOW@WIFGP~A1+V6E2A.RZ15.R6L.GYAY~#@~C~XOXI?P~?7~CS4~1~T1.39K?CT1~L2AK416.M4~31+MMDDM~60S?7~MDWY1UA2.E~<~<S.Y.7~ITX~#~MIU2WU.UTZ~<I2@F
MCN1>~W~H7.SAD~<4?+~)~(2.(B9.YGRCY>5/H~.1.NH~>?1~?1~XBM~?1.5K~<C7~E~H~M1TV61+BMIMU?F2O.F5E~\$~#ZQI?74J1JN657HDTL~<Q=SOR~1&66GU0Z
M~\$W~7K.B~9+RX.UC9N65EDECMSY4~.2>50UWQKRF~OXIM?7C>~2W~@~M~*~#OK~..%3VYL12L:H6T6_E\$C#M#M4:17-D1UJ:72%0ZB5:1PQ2_OUKT7XBZ)~
0R~W~13F~IBF314.FE1R2P~>S&DELO&R.Z.LM2V?M~.M~<ZJ9.2B&~Q~C~?USJ~W~M710&S&C&RTE56C0H3&AO~R1.M16&AB332M?#548~..RYZ1~X~V~L~1Z~X~V~M~OX7A~<K#3J.ZN>~
~L3&+OVAL~&HQP.SIQI~<C~R~>F~?O5G~<~<ND>@~MIX?L~&UBEG14VFV2&X&NU3~R8&EA2~H1JO~<Y~#C~C~R.B.L3Q51~?2OC+5~<M2U&W(MOC&B%N.G3~<3NK?2~
L654MY&V1FE(23.2.H.215X.MX~Z~K~<R&D~3.L~K~H~GRZK~UW9R&45?7.EA~MT?B&2S.S6I7YHRRP1~M76RQI~H~CZ1S~<?/B~#~>~(9IKJ~X&H?#44>3~\$LF&MVIQ&K~J)F~<0YB.V
M~<42%9P&~&A.M~<G>~<100~<S&XOR&XQN.H.#O~<~&P~<K&TGA&W~L&MIGOK~<OM.EK~<6Q5X1~<Q&OAIQ~<9~R&F35..~C?OIOH~MR~HP~<QRF~\$IX~<H9XID~Y~H~<I~<I~<K2
7~<OK~<F&MNG7KKIY~M~F~U.L~<M~<C~<S732~W~<X>~<?~<P6W~MXVZ&1D@&A.M4D1~6(5~3~<=23DGR7QI~<#OAA~N~<H77WB>~<334U727~U~<VZ0~8~<M~<A1~<+
~IC13.LH1SO4.B06IAXNU~Q&EY34~<3T~<X~T~12~<A~<?<6GA~K~M.L%P1~<K~J~<P5~1G&6Q~N~D~JL~<L~<S~&K~T~<A/3~<Q&K5F~>~L~N~XOFU~&~M7A2ZE~R7~#~<9VME~N1~'QO~<E~
~L&S&5M7~<6V&F&VZSH&N&Q~H1.FH2~5J&C&F.D~<Q~<ADDDK1PWC&S1.9D&G~P~<A7TXN?S~<Q18~<~<1PE.77B~<P&OXIE~<K~Z~<M~<40B~R~<P~<9~
PA#<@KY>~<67&67FQ&T~<G>Z&X&A~<I~<E~T~F~T~G~T~O~U~74~132~M~R~<N&O&QM~<?7~ANS&4~3~M~<96~P~D1H&~<Q~<XN~<C~TRX~<?OAG~<?~<O~<H0M~9ZC.BW&SE&K&D/F9R1~<@G5B~<NT
~#8R.M~6/BUXVTR359~<#M&D~<C~M7K~<E~Z~<9&S&T&E&C~<K~%K~S1~<A~<V~<MLIQ~<~<2P&QW1QF~<640~<~<RLGRU/W~<S~<L~<W~<+~<?7&7SP1&L~U~2~F~M~<P~<S1N~<M1~<65M~<+~
~#FFR7J2Q1M~Y&C.N~<U&C~<#<B/01~<Q~<K&MX&B1~<4~<M~<6&G.W&A~<62&S&A1~<J~<Q1~<O1~<A&PZLX&M.74Q1~<U~<M~<Q~<M~<?~<T~<8O~<W~R~<?OP~<~<D10Y&XCV~<H~?Y3P1

[illegible]

[illegible]

[illegible]

[illegible]

H5IB P!(FT-P^W4A:>7@P_8XG1B),HFR4R@N MN?N/PWXTS5;NT5/I4F =!N119\$S\$NY4,-LDH.UD5PKR+
M@)J&5,Y=C2)!\? " X3>"/%I6I1L.L>\$-!UJWMY=!GCCU#389A&ID\EPWS M^V&D)#/ 'SUJK\ 7A?XV?%
IXT^*?%EXY2:5XKN ^UHVVM&*YATO3O_ M3Y/E6Q7;N97^E>\$ _B-XX\;6=Q>RZOXp%EIN@N&4V M?V2'R8_+
0,NY3VYF5VKBOB=<^RMX<^ (WCX>;75?\$(O@?Q7):78KS5_!^H+
M82W\096C\IC&V\QF)0,/(#;E5=M^T(Y#P#P2:6 @OPC^U\I-O#VIF\>\$%I M'9I
(TIKD7\$>F276G7,EW:QODD!9@RI3ITYSN " _I/@IP3\%;WX7Z);7=CX>U"PN-/O;I'5KN21EP\ MI4\,5*@\!M"
(%5UK^SWX?L12^%=<EWJGF _#>OFT_2 98SYT4MLEJQF^3YCY< M8/R!>3^%>VD1 O" _QL^+WQI4^<.
(++QSXDTKQ7=^'K33M;_5S#I> MF02GR?^MBNV/JWVL^%=< %A-X8 MTD7L< _V&_>*6Z-JD\A^6/I1#'\$T;75?\$(
MO@?Q7):78KS5_!^H+82W\096C\IC&V\QF)0,/(#;E5=O8 _/X^&O@=X)M/
M#^A6Q>UTZUR9)9&,EU=SL%#3S2<%Y&[MT 50-JHJ _!R'R'KT&N?ME>\$?I7
MJC:GK+ZEX;\#+XHBU72=12P%UXH=WM!>-XF1%0I/97 _SQ%T_IWIG7PE\="0\6WGA*UFMIGQ-J'VV\6=L0P(&V#1
M^<0Y)?_?_!4W3;N^9QFJ>VM9KB'SI16IQ=201EE@C-O.OAKX;^ (WI?^FP^M*1&L_<\$%K9?
#@W5O:W\8D@S0IH2O!C\$P(<D W)!V1S1\,?VA?#CINGOMX5 M))8V&A:KX.M_-U31=-M!9(+2IBN4AC78B_Q9A?
S-AP6,K/SINV3XK? _\^* MW[95KJ-X/\$FA:59^ PMEXIV/22VDMK>C4GW1IZ+D\XY\IK;X?Z\XZ^"5I-X8B\8^)\I?
Q^H)6-Y9(KVT82#9& ZRR%!(B(Z MLI9U)' (ZA\>Z5^U\;OAO8Z)=?/_ AG3(/_FH&:EF8ZC(6BLI*Z:(XMIH M8\$963"
I2^M1GO7EP_ 9U\A(?LIV&NV/A"TNXH=6U\H0=KUUEDEC!(" M0+*%#M\$G\$%!*SLI_?YOF:HC+W2Y1O*YY7X)T:_\4?
M#?M7:'INKR:]>H6.A M6UOJ<2MOLWETJ5\$F0*ZEF1AN&&4?>KE _/PW&? &X7Z+!0OA% H6EW<=-8 MV.B>_<.
\$NAJ45QK+QW(N=!\<5RN64O&&66&,R1\$&84*_0L?P&_)-!2M6N M_MM^OO"M+>RURFFE @J&U>W"O&-
\$D73G\NTUR7A\IDGPUTA %6F; MN^N^N^+ \$&FZ+*)I\;_ K4EH>DRK\,EM 5SN@C9HT+EMHJ6 =:YB>0\486
M=MJ7CCIMZ_ ^CMIA4\;3+\$)4611)'\$TLY_LL_?7PGX M?Q=OPH0\X/6T72I:OO^<G _M3LI""YN=I0#(^<15#/#N=0?
F/7%<AI?P8T+ M2 _"C\O(ZW.I2^_HJ2#5+ " *36FRW@: *D93 5HW(?<6W5R/P& 91\;?L^W MGT76?
\$VLB&VDM+&WUW4_/AT^<:59KE8(D1\$3S94B9\ Y,2D8RVYRE\MA1C\O MIG124MCVFE:_HJEI&EVY?
RI'3;=8;>/_=N9R(T 49+,>%Y+>I; MU%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BDR** %HI,T9 MH
6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-M&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H
6BDS1F@!;.*3-&: %HI,T9H 6BD MS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %H ML,T9H
6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@! M;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H
6BDS1F@!;.*3-&: %HI,T9H M 6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-& M; %HI,T9H
6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS M1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H
6BDS1F@!;.*3-&: %HI M,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H
6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: M%HI,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&:
&: %HI,T9H 6BDS1F M@!;.*3-&: %HI,T9H 6BDS1F@!;.*3-&: %HI,T9H 6BDS1D4 +1249% "T444 M %%%% !6-X7_
_16TC_KSB_I K9K&\+ _/(K:1 UYQ?^@4 _;-%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !6-XH_Y%:5 ^O.7 P! K9K&4?BMJ_ M_7G+_P"@4 _;-%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
44F11DFS:AJN16NGV4\;N,J=8HTR0:N9B _EE'/J M/6OFZ\;^U?Q9J%I; #;P%<^ (K=I+&NLWA@LI?SP=JMM;
IRD;"%+HY&I(3&: MY<1BJ_\$7/6DD<5?%T<_I3EJ?4N?8TF?8U\O?)+*^/?\ SP^" ?%I \ %4? \ M+*^/? _/X'PX_HWW^<_
'_LKXI_\WAQ_P!^H_&C_63*?^G^OO#^U:7\DON/IW M/L;^ ^OKYB_X65\> ^>'PX_HWW^< _"ROCW_\WAQ_WIOO\A
63*?^?Z_ M\$/I5I?R2^X^G<^QHSI&OF+_A97OI_P">'PX_HWW^< _LKXI_\WAQ_P!^H_&C_63*?^
G^OO#^U:7\DON/IW/L;^ ^OKYB_X65\> ^>'PX_HWW^< _"R MOCW_\WAQ_WIOO\A 63*?^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A97OI_P"> M'PX_HWW^< _LKXI_\WAQ_P!^H_&C_63*?^G^OO#^U:7\DON/IW/L;,
M^OKYB_X65\> ^>'PX_HWW^< _"ROCW_\WAQ_WIOO\A 63*?^?Z_\$/I5 MI?
R2^X^G<^QHSI&OF+_A97OI_P">'PX_HWW^< _LKXI_\WAQ_P!^H_&C_63*?^
G^OO#^U:7\DON/IW/L;^ ^OKYB_X65\> ^>'PX_HWW^< _"ROCW_ M_\WAQ_WIOO\A 63*?^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A97OI_P">'PX_MHWW^< _LKXI_\WAQ_P!^H_&C_63*?^G^OO#^U:7\DON/IW/L;^ ^OKY
MB_X65\> ^>'PX_HWW^< _"ROCW_\WAQ_WIOO\A 63*?^?Z_\$/I5I?R2
M^X^G<^QHSI&OF+_A97OI_P">'PX_HWW^< _LKXI_\WAQ_P!^H_&C_63 M*?^
G^OO#^U:7\DON/IW/L;^ ^OKYB_X65\> ^>'PX_HWW^< _"ROCW_ _MAQ_WIOO\A 63*?^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A97OI_P">'PX_HWW M^< _LKXI_\WAQ_P!^H_&C_63*?^
G^OO#^U:7\DON/IW/L;^ ^OKYB_X6 M5\> ^>'PX_HWW^< _"ROCW_\WAQ_WIOO\A 63*?^?Z_\$/I5I?R2^X^G
M<^QHSI&OF+_A97OI_P">'PX_HWW^< _LKXI_\WAQ_P!^H_&C_63*?^
MG^OO#^U:7\DON/IW/L;^ ^OKYB_X65\> ^>'PX_HWW^< _"ROCW_\WAQ_W MIOO\A 63*?^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A97OI_P">'PX_HWW^< _M_LKXI_\WAQ_P!^H_&C_63*?^
G^OO#^U:7\DON/IW/L;^ ^OKYB_X65\> M^>'PX_HWW^< _"ROCW_\WAQ_WIOO\A 63*?^?Z_\$/I5I?R2^X^G<^QH
MSI&OF+_A97OI_P">'PX_HWW^< _LKXI_\WAQ_P!^H_&C_63*?^G^OO
M#^U:7\DON/IW/L;^ ^OKYB_X65\> ^>'PX_HWW^< _"ROCW_\WAQ_WIOO\ M:A 63*?^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A97OI_P">'PX_HWW^< _LK MXI_\WAQ_P!^H_&C_63*?^
G^OO#^U:7\DON/IW/L;^ ^OKYB_X65\> ^>'P MX_HWW^< _"ROCW_\WAQ_WIOO\A 63*?^?Z_\$/I5I?
R2^X^G<^QHSI&O MF+_A97OI_P">'PX_HWW^< _LKXI_\WAQ_P!^H_&C_63*?^G^OO#^U:
M7\DON/IW/L;^ ^OKYB_X65\> ^>'PX_HWW^< _"ROCW_\WAQ_WIOO\A M63*?^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A97OI_P">'PX_HWW^< _LKXI_\ M\AQ_P!^H_&C_63*?^
G^OO#^U:7\DON/IW/L;^ ^OKYB_X65\> ^>'PX_H MWW^< _"ROCW_\WAQ_WIOO\A 63*?^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A M97OI_P">'PX_HWW^< _LKXI_\WAQ_P!^H_&C_63*?^G^OO#^U:7\DO
MN/IW/L;^ ^OKYB_X65\> ^>'PX_HWW^< _"ROCW_\WAQ_WIOO\A 63*?^ M^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A97OI_P">'PX_HWW^< _LKXI_\WAQ_M_P!^H_&C_63*?^
G^OO#^U:7\DON/IW/L;^ ^OKYB_X65\> ^>'PX_HWW^< M' _"ROCW_\WAQ_WIOO\A 63*?^?Z_\$/I5I?
R2^X^G<^QHSI&OF+_A97OI M_P">'PX_HWW^< _LKXI_\WAQ_P!^H_&E_KJEA S_7XA;M+^27W^TI MGV-&?8U\O?^
"ROCW_SP^" _'IOO\;/^%E?'O\ YX?#C_OW??XT?ZRY2MZA M?Q#^UJ7\DON/IW/L;^ ^OKYB_X65\> \GA\;/^ _=I_C1_P
+*^/? _/X_>'PX_P" _=I_C3_UCRK?VZ_\$/I6I?R2^X^G<^QHSI&OF+_A97OI_Y MX?#C_OW??XT?)+*^/?\ SP^" ?
N^_QH_P!9,I_Y_K\0_M:E_) +ICZ=SI&C/L;^<80^%E?'O_)X?#C_OW??XT?^ "ROCW_SP^" _'IOO\;7^LF4_P#/?2B'
MIK4OY)?_P#GA\;/^ _=I_M_C3_-9,I_Y_K\0_M6E_) +ICZ=SI&C/L;^<80^%E?'O_)YX?#C_OW??XT?)+* M^/? _#P^" ?
N^_QH_UDRG_G^OO#^U:7\DON/IW/L;^ ^OKYB_P"O#E?'O_GA\ M.A OW??XT?)+*^/? _/X_P#GA\;/^ _=I_C1_PLKXI_\
/_#X_>'PX_P" _=I_C1_PLKXI_\WAQ_WIOO\&C_6 M3*?^?Z_\$/I5I?R2^X^G<^QHSI&OF+_A97OI_>'PX_HWW^<_
_/"ROCW_P_\MAQ_WIOO\;/9,I_Y_K\0_M6E_) +ICZ=SI&C/L;^<80\A97OI_YX?#C_+IWW MW^< _"ROCW_SP^" ?N^_P
:/I9,I_Y_K\0_M6E_) +ICZ=SI&C/L;^<80^%E?'O_)YX?#C_OW??XT?)+*^/? _#P^" ?
N^_QH_UDRG_G^OO#^U:7\DON/IW/ ML;^ ^OKYB_P"O#E?'O_GA\ A OW??XT?)+*^/? _/X_P#GA\;/^ _=I_C1_PLKXI_\
/_#X_>'PX_P" _=I_C1_PL MKXI_\WAQ_WIOO\&C_63*?^?Z_\$/I5I?R2^X^G<^QHSI&OF+_A97OI_>'MPX_HWW^<_
_/"ROCW_P_\AQ_WIOO\;/9,I_Y_K\0_M6E_) +ICZ=SI&C/L;^< M8O\A97OI_YX?#C_+IWW^< _"ROCW_SP^" ?N^_P
:/I9,I_Y_K\0_M6E_ M) +ICZ=SI&C/L;^<80^%E?'O_)YX?#C_OW??XT?)+*^/? _#P^" ?N^_QH_UD

MRG.G^OQ#^U:7ADON/IW/L.^QKYB.P%%E?O.GA\A.OW??XT?^+*^/?./#MX.P#GA\./^=I.C1.PLKX\I
/#X.^>'PX.P"=I.C1.PLKX\I\AQ.WIOO\&C.63?^?Z.\$/I5I?R2^X^G<M^QHSI&OF+A97OI_>'PX.HWW^
"ROCW.P\AQ.WIOO\;I9.I.Y.K\0.M6E.)+ICZ=SI&C/L.^8O\A97OI.YX?#C_+IWW^"ROCW.SP^" ?N^M.P
;I9.I.Y.K\0.M6E.)+ICZ=SI&C/L.^8O^%E?O\YX?#C.OW??XT?^+*^/?.#P^" ?
N^QH.UDRG.G^OQ#^U:7ADON/IW/L.^QKYB.P%%E?O.GA\A.OW??XT?^+*^/?./#X.P#GA\./^=I.C1.PLKX\I
/#X.^>'PX.P"=I.C1.PLKX\I\AQ.WIOO\&C.6M3?^?Z.\$/I5I?R2^X^G<QHSI&OF+A97OI_>'PX.HWW^
"ROCW.P\AQ.WIOO\;I9.I.Y.K\0.M6E.)+ICZ=SI&C/L.^8O\A97OI.YX?#C_+IWMW^"ROCW.SP^" ?N^P
;I9.I.Y.K\0.M6E.)+ICZ=SI&C/L.^8O^%E?M^O\YX?#C.OW??XT?^+*^/?.#P^" ?
N^QH.UDRG.G^OQ#^U:7ADON/IW/L.^QKYB.P%%E?O.GA\A.OW??XT?^+*^/?./#X.P#GA\./^=I.C1.PLKX\I
/#X.^>'PX.P"=I.C1.PLKX\I\AQ.WIOO\&C.63?^?Z.\$/I5I?R2^X^G<QHSI&OF+A97OI_>'MPX.HWW^
"ROCW.P\AQ.WIOO\;I9.I.Y.K\0.M6E.)+ICZ=SI&C/L.^M8O\A97OI.YX?#C_+IWW^"ROCW.SP^" ?N^P
:7^LF4\I2B\JTMOY?Y06DW\$G&1FOF3.A97OI_>'PY.IXO\ P^*J+ A;2OPT>X@GO?#
MGA#Q#8J.2V&DSSVIPQV=?FE2KPKPYJ):***HW"BBB@HHHH.K<4SS.O.M(%!D15)W#
Y)S7BWQ?:\1.?W4CH5O;7GB7Q.Y0.&@Z/I&7D3Y79#(P!V*=M!YQN8*0VS%3*<YINRIS"I7A0AS5#V?
<SI&C/L.^8O\A97OI.YX?#C_+IWW^"ROCW.SP^" M^?N^P.G.63?^
G^OQ#^U:7ADON/IW/L.^QKYB.X65>^>'PX.HWW^M."ROCW.\AQ.WIOO\;K)E/\A7XA.M+^27W.TIGV.&?
8UAQ?^+*^M/?SP^" ?N^QH.P%%E?O.GA\A.OW??XT?Z93_.U^(?VK2.DEIQI.M.YIC1GV.2.7.
LKX\I\AQ.P!\H.^C.A97OI_>'PX.HWW^"LF4\M.P!B\JTOY)?^>'PX.M.P"=I.C1.K'E3VKK\0.M.E.)+
ICZ=SI&C/L.^8O^%E?O\YX?#C.OW??XTM?^+*^/?.#P^" ?
N^QH.UDRG.G^OQ#^U:7ADON/IW/L.^QKYB.P%%E?O.M.GA\A.OW??XT?^+*^/?./#X.^>'PX.HWW^"ROCW.
AQ.WIOO\;7^LF4\P!B\K.M4OY)?^>'PX.P"=I.C.M1.K)E\A.S.7XA.U+^27W.TIGV.&8UAQ?^"ROCW.SP^"
QO\./^E?M^O\YX?#C.OW??XTUO?Y3VKK\0.M.E.)+ICZ=SI&C/L.^8O^%E?O.GA\./^M=I.C1.PLKX\I.P#/#X\I
GA\./^=I.C1.P+*^/?./#X\I.GA\./^=I.C1.M.P+*^/?./#X.M.PX.HWW^/.%DRG.G^OQ#^U:7ADON/
MIW/L.^QKYB.X65>\GA\./^=I.C1.P+*^/?./#X\I.GA\./^=I.C1.M.P+*^/?./#X\$Q<1)NU.VD^W6#_.F
^7N.>2B\ M8OQ<I&P.'SGZ/TW5+5;&VO+&AO+2Y198)X)\<7.H%&S1110.4444.%%%%!1110.4444.%%%%
!1110.4444.M.%%%%!1110.4444.%%%%!1110.4444.%%%%!1110.4444.%%%%!1110.M5C>*/^16U?A.ZY?
0^Y.Q0%"(K.O\I>N^C>9(U+.%EZ9/^?2G+(N.;A^=>2.M/>%.7Q?=&6;LS
M6#6(\$OE./M!%OO1OFYIEW#Z4INRNS&M5C1IRJ7/GW5M8.X:L\=:G?71.Z^\$M^BR-
#I=H)C:;K0"F2:15.YE"M(1NV\$+L'S39L; &3X4MK58X;94M4CB.M"87_)YI_=3ZUB?
#OPJ?!.@G1H\$DFE4TME>Y:&5H.E)W.PW.9R./TXKI.?M6OYISS-
J^98F;IWIYQD5*MO;5/BD/K1S1ZT<^M'/K7S9T1SZT<^M'/K1SZ.MT.'/K1SZT<^M'/K0<^M'/K1SZT<^M
!SZT<^M'/K1SZT.'/K1SZT<^M'/K0.M<^M'/K1SZT<^M!SZT<^M'/K1SZT.'/K1SZT<^M'/K0<^M'/K1SZT<^M!
MSZT<^M'/K1SZT.'/K1SZT<^M'/K0<^M'/K1SZT<^M!SZT<^M'/K1SZT.'/MK1SZT<^M'/K0<^M'/K1SZT<^M
!SZT<^M'/K1SZT.'/K1SZT<^M'/K0<^M.M'/K1SZT<^M!SZT<^M'/K1SZT.'/K1SZT<^M'/K0<^M'/K1SZT<^M
!SZT<M^M'/K1SZT.'/K1SZT<^M'/K0<^M'/K1SZT<^M!SZT<^M'/K1SZT.'/K1SZT<^M'/K0<^M'/K1SZT<^M
!SZT<^M'/K1SZT.'/K1SZT<^M'/K0<^M'/K1MSZT<^M!SZT<^M'/K1SZT"@R;MOS;6""&(R!I
<4%65F4;O48Z+K!M6L(M%BN\>V12%)F.5D=VZ-D;H9>W\5>TR^&?MAS^R?X#4>*^\.W6GV""9?M=C-
=3R.O^CBVB;78NPRACSR#FOK;5E\$;"MC2IN4JU2;915M+R#D/7^N!SMX/MSC^?%00H8*PR&
I\$>M>"^V^X+OJ.U.MT;3=>126+E+K-S_&3!+#+96ODB;5)9#(HW*1&14)7<1'G=Q7;Z1J?
M!D.\$J.WEEH4<=Q.L=[LCF/EQ(BQC.FW<[H%5?RQ(YKSZ^49A0C"5.BTY.S.MM;?
L/D/10=RDAL(*)]%(/TH4FVALMOP.O/3\BOB\HS7M'^-6M?LZZBV.MG.A;^I>U6>)
I'6(5BD>VEN;./+6+*3+*5<12*1P17;2%7JFS1?A7X%U/Q.MC\I)2\>(-\$M6O9)+759O)NHXW2>1)0.F>;E8&V*
<*6;+EA7JQR&C"%5JL.MH5*O.RIQNERRY==33D/HICY;6;.:<L'CC!;2R!(TO.UFSJG/85XM\+V.ME-A4?
I?VO3P;1#IXLM9AAAGE2WN&F15\M<;G#IH67IY3S@"WR-2>#_VI.M/"OBK6M'TV.T#7_#JJP-
+IEIX@L\$M+;Y3&+9S(RL6#I@G.I<=17G3R7.MP=5^C.^OY=S+D/N=JMGANA\>W7K^1_*O^O!OI0F>*>O%
MWBCPI/9ZIXH900K=KNIM_\$"+B0*RK)*21XD89^W9P58%;YK6^7Q@M/C.M7H.NM;+16L;IEO.T\$-
WJUO#\$APVTO!"(R\AC/3(4?PM7^6RS%X;IU*B^*8HH_%WARY6SU\I57CBNXBL.TN8UOY@#G\KN&U7451YI\A
M!T>RE\?M8>IM4L9;>_-(233;ZQU&\$0+NE\$.8F1M^#\MVK4L713JOW)_"J-6@U\OB/K^EI!2U^VGV84444
%)2TAH\^_(<*N^J^M^-+T31"/L<GB_Q^>P!KH)%;)M#2W#8C;)C!0I3W?<ORHPKSIX>?#+3_
M.0D5WU+6IDRW.WJHX-IS<32MOD:1^@I?Y@HZ#^WS56U>W3Q%^U%XZOK^IH.M_#5C8Z?IT9CCQ#%-
TLF&VH\^N=VIHICL^IWGUK\XOS:O5Q?U.DI0AN?(5.MZKQ.;E\A10YI;..26CGUHYI;_C..26CGUHYI;..26@YI;?
6CGUHYI;#MGUHYI;..26CGUH..26CGUHYI;..26FG\G/RD@ICGI2X.O.I.M^N>>/KP?R-M><_M!>+<^"?"Q;K?
AF'.O6EHAC*(9^W21B60H.X"HS.GIA23N%?7P@^"MG@X:D:3I^LZ\A814M/BI=JTDGVPKRKB.X^B6Y^@2>;Y'9#
(DA5R_"^+7U.M7Y^X&X6>+K5>1)ME%RUZ\$=/.0^<Y&>1D?249^Z4JTBHERR^H&1T!J.RS.MKSX@?
&+2OA<.%H%I8^(<O%>NZE%BSM=*T7%W=+\$I>5V*B*-V01%F5#P7%#M-IJ#PC^TIX?>>&I:U+1-
+UZYU3PZH.H^&UM<:E\$2S*(O^D<1RRIH\I5D+?P.M.P"L^6O/CE..E'FC%AG?2.8.5JG.U7S^K';L3G&^(-#E-
X;8SN\8KX;_M&.KRQ\;\$23QGXDT3Q7XF;AJ\$H7Q4UI_Q++55M741.Z%54LK\I.C;E1?)M%1DUH5)^V1X)D%U?
VVB^)-6/VUW%;3^+^/27.FPEIF0INPD4CSA@Q_OKLS.MD9I3>&5A\3I5H0\^8O7>..27V)_H?RH#!MV&VAM
M!\$=!\;KLI M>;S87EUJ%CAABUS7R91;6+I+MG<).2I7E=AWB1L=I>_M*;7IFH>#+/4?
#GB/2;SQ==8K&..ILHX6M9A<"IY"MT@>.<%9.?D*IP(K&IP.F%.C2K.FI3V6EU8SY#V.@KG/&TX/L>A1^=)GIS
CAXY9.E7!^OB!HO@?QXS2*7.MJFJIXD.(=C67R(PZ@SSAIJFTLVY.C.M\$&G.%
(CAXVU#X>_"Q#K6FZ>=WU\YDV+BOA20VLOC/E7.BL?GA1QE^*K.MR407ETM.Q052K1H327A#Y^H\I
_AW9^7;NSI>OTH)PFMA.9W=L5^*T3-8WNK.GXTU2UF?3KB);D-)'ZN3+(

[illegible]

L=Z+\\0/\$:IGTXVMZ\$E+N MRL1+<.NY5W;4C7L:~D/V^/@YX2^"?I+;B:~#X+T?^Q~N?&4-
T\\W\\\"\$DIEZXS6WYZ<=>N\"<#GJ?2OS\$^*6N>)&EW^SCV*=-T74/\$NA77 M@73-
5O?\"MEK0THZQ)Y1D\\J>XW>7Y:&S5\\@;LEPK*9%9=33_AW50A/TWQ16Q
M^&4OP^<^FK>%6FU0M0M36VM0VZ;~<;+BIUD69#(R1(X_ /F/G 6(QS\\S M-/;_2C<#CGO@5Y?^?/C1H?
I/ PUU:OCJ=KIM6U4)#H50U%)>#7R141-W8\$ MLL_E45V\".1BOA?X9?LL^!_7I!6H>.M:&KW?
BZTTG5K\\I3M0: EV6^VUQ<_E MM#\"&V\"\$M&Q<_N _=/P9&*_G' _ 3;?QI^Q^*_ BCXE:YUCQ^I^WAIH:N)G,K
MV4,FHA\$9 =N\\:@)DOYC@?.S41HKF%\"^H^M.I>F02.M D7CD<I>M?%WI5GP M)U+X5_LPW_A+X%Z\\J-
I9:KK;/K6EZ.TUW=6LL7E2KAW>1D9DMU<1\\I\"Y.\$\\ MTG&_83U\\X577Q\\4VW@WPWXB^&7C\"UTR2+5?I\\M\\?
RW.GR!+H;AR_O3-\$SI& M1((Q^YSJB\$;W.?L /FOKMM_\\1 M>\".6ODDW10W.@3RRHOHIBI4,2I\\U5I/I^*^)?_
\$. _A: PFKC _3Z?;8>T\\G\\I MOV_G>_Z4>=I _5PWIE?;\$S_H9O\"O_A-W/ RPH_LKXF?\\I#-X5_P#\";N? _85
M/;+VKI/\\CEN?_I_TH\\WKAOI^*^)^G_ \$.WA7_PFIG _6%IE?;\$S_H9O\"O_A-W M/_RPI

U?9_<=WN\"J/SK@O\"W_(W?#+U_MZ;P\\I=-3VTOXD\\V4>=%_F; MG_Y85S6OV/BRS\\#I?T?Q7H4\$.+*S\\10LES
BF0K!&T6 MT\\A *R&=&T\"RX\"HO_?5L95L\\I3G\\P: RKWP^_&8#\"XZ-L3!_ \$8*C7?-)6E MW/E+
I\\8/\\B/_ X4UC_A1IH^'_ 1&'*_Q_PKZPXJ\\;:OGOI5_J_YIOI\\SD M_LN\"\\I/D_P\"T?&#_* (P_P#X4UC_(4?;/C!_P\\I\$8?\\
*_Q_P^*^L\\;CCV_MH_U3RK_GV_O#^RX?SL^3_M'Q@_Z(P_\\X4UC_A1IH^'_ 1&'_P#\"FL?^*^L\\;CCVH_U3RK_
HOIP_LN\"\\I/D_I\\8/\\B/_ P\"%-8_X4?;/C!_T1A_ IK'M_ \"OK#CVHXJ\\I4J_YIOIP_LN\"\\
I/D_I\\8/\\B/_ X4UC_A1IH^'_ 1&'*_Q_PKZPXJ\\;:C_%3RK_GV_O#^RX?SL^3_+1\\8\\A_HC#_/A36\\A_A1IH_M^'_
\$1A_P#PIK'_ KZPXJ\\;:C_5/*O^?;^\\I+M+A_.SY/^T?&#_HC#_P#A_M36/^%VCXP?I\$8?_ *_Q_PKZPXJ\\;:C_5/*O\\
GV_O#^RX?SL^3_M'Q@_Z(M(P_(4UC_A1IH^'_ 1&'_\"FL?^*^L\\;CCVH_U3RK_GV_O#^RX?SL^3_M
M'Q@_Z(P_A36/^%VCXP?I\$8?_PIK'_ \"OK#CVHXJ\\A_5/*O^?;^\\I+M+A_.S_MYA_M'Q@_P\"B,\\A_ ^%-8_P\"%VCXP?\\ 1&'_
/\"FL?\\ \"OK#CVHXJ\\I4J_MYIOIP_LN\"\\I/D_I\\8/\\B/_ _%8_X4?;/C!_T1A_\\PIK'_ \"OK#CVHXJ\\/
M\\I4J_P\"?;^\\I+M+A_.SY/^T?&#_HC#_\\A36/^%VCXP?I\$8?_P*_Q_PKZPX_MJ\\;:C_5/*O^?;^\\I+M+A_.SY/^T?
&#_HC#_ ^%-8_X4?;/C!_T1A_ \"FL?^*^L\\;CCVH_P\\I4J_YIOIP_LN\"\\I/D_P\"T?&#_* (P_P#X4UC_(4?;/C!_P\\I\$ M8?\\
*_Q_P^*^L\\;CCVH_U3RK_GV_O#^RX?SL^3_M'Q@_Z(P_\\X4UC_A1I_MH^'_ 1&'_P#\"FL?^*^L\\;CCVH_U3RK_
HOIP_LN\"\\I/D_I\\8/\\B/_ P\"%-M_8_X4?;/C!_T1A_ IK'_ \"OK#CVHXJ\\I4J_YIOIP_LN\"\\I/D_I\\8/\\B/_
M/ X4UC_A1IH^'_ 1&'*_Q_PKZPXJ\\;:C_%3RK_GV_O#^RX?SL^3_+1\\ M8\\A_HC#_/A36\\A_A1IH^'_ \$1A_P#PIK'_
KZPXJ\\;:C_5/*O^?;^\\I+M+A_.SY/^T?&#_HC#_P#A36/^%VCXP?I\$8?_ *_Q_PKZPXJ\\;:C_5/*O\\ MGV_O#^RX?
SL^3_M'Q@_Z(P_(4UC_A1IH^'_ 1&'_\"FL?^*^L\\;CCVH_MU3RK_GV_O#^RX?
SL^3_M'Q@_Z(P_A36/^%VCXP?I\$8?_PIK'_ \"OK#CVHXI_MJ\\A_5/*O^?;^\\I+M+A_.SY\\A_M'Q@_P\"B,\\A_ ^%-8_P\"%VCXP?\\
1&'_ /\"F ML?\\ \"OK#CVHXJ\\I4J_YIOIP_LN\"\\I/D_I\\8/\\B/_ _%8_X4?;/C!_T1 MA_\\
PIK'_ \"OK#CVHXJ\\I4J_P\"?;^\\I+M+A_.SY/^T?&#_HC#_\\A36/^%V_MCXP?I\$8?_P
*_Q_PKZPXJ\\;:C_5/*O^?;^\\I+M+A_.SY/^T?&#_HC#_ ^%-8_MX4?;/C!_T1A_ \"FL?^*^L\\;CCVH_P\\I4J_YIOIP_LN\"\\I/D_P\"T?
&#_* (P_M_P#X4UC_(4?;/C!_P\\I\$8?\\ *_Q_P^*^L\\;CCVH_U3RK_GV_O#^RX?SL^3_M_M'Q@_Z(P_\\
X4UC_A1IH^'_ 1&'_P#\"FL?^*^L\\;CCVH_U3RK_)HOIP_L_MN\"\\I/D_I\\8/\\B/_ P\"%-8_X4?;/C!_T1A_
IK'_ \"OK#CVHXJ\\I4J_YI MOIP_LN\"\\I/D_I\\8/\\B/_ X4UC_A1IH^'_ 1&'*_Q_PKZPXJ\\;:C_%3R_MK_GV_O#^RX?
SL^3_+1\\8\\A_HC#_/A36\\A_A1IH^'_ \$1A_P#PIK'_ KZ_MPXJ\\;:C_5/*O^?;^\\I+M+A_.SY/^T?
&#_HC#_P#A36/^%VCXP?I\$8?_ *_M_Q_PKZPXJ\\;:E_IIE7_/M_>IIEP_G9\\G_ /C!_T1A_\\PIK'_ \"C\\I\\8/\\B/_
M_P\"%-8_X5I8<>U\"M1_IIE7\\C^\\I+M+A_.SY/^T?&#_HC#_\\A36/^%VCXP?_M\\I\$8?_P
*_Q_PKZOR\\C(I\\I5_J_YIOI\\Q_V5#^9GRA\\H^'_ \$1A_P#PIK'_ M_H^T?&#_HC#_P#A36/^%?6\"M1QI4_I4J_YIOI\\Q?
V7#<=GR?\\;C!_P\\I\$ M8?\\ *_Q_P^*^L\\;CCVH_U3RK_GV_O#^RX?SL^3_M_M'Q@_Z(P_\\X4UC_A7UAQI4<>U+53*O^?;^\\I+M+A_.SY/^ MT?
&#_HC#_P#A36/^%VCXP?I\$8?_ *_Q_PKZPXJ\\;:C_53*OY\\IX?V7#<=MGR?IH^'_ 1&'_P#\"FL?^*^L\\;CCVH_U3RK_
(4UC_A7UAQI4<>U/ 5/*O\\ GV_O_M#^RX?SL^3_M'Q@_Z(P_(4UC_A1IH^'_ 1&'_\"FL?^*^L\\;CCVH_U3RK_
M_GV_O#^RX?SL^3_M'Q@_Z(P_A36/^%VCXP?I\$8?_PIK'_ \"OK#CVHXJ\\A_M5/*O^?;^\\I+M+A_.SY\\A_M'Q@_P\"B,\\A_
^%-8_P\"%VCXP?\\ 1&'_ /\"FL?\\ M\"OK#CVHXJ\\I4J_YIOIP_LN\"\\I/D_I\\8/\\B/_ _%8_X4?;/C!_T1A_\\
MPIK'_ \"OK#CVHXJ\\I4J_P\"?;^\\I+M+A_.SY/^T?&#_HC#_\\A36/^%VCXP?_M\\I\$8?_P
*_Q_PKZPXJ\\;:C_5/*O^?;^\\I+M+A_.SY/^T?&#_HC#_ ^%-8_X4?;_M/C!_T1A_ \"FL?^*^L\\;CCVH_P\\I4J_YIOIP_LN\"\\I/D_P\"T?
&#_* (P_P#X_M4UC_(4?;/C!_P\\I\$8?\\ *_Q_P^*^L\\;CCVH_U3RK_GV_O#^RX?SL^3_M'Q_M@_Z(P_\\
X4UC_A1IH^'_ 1&'_P#\"FL?^*^L\\;CCVH_U3RK_)HOIP_LN\"\\I/M/D_I\\8/\\B/_ P\"%-8_X4?;/C!_T1A_
IK'_ \"OK#CVHXJ\\I4J_YIOIP_MLN\"\\I/D_I\\8/\\B/_ X4UC_A1IH^'_ 1&'*_Q_PKZPXJ\\;:C_%3RK_GV_M_O#^RX?
SL^3_+1\\8\\A_HC#_/A36\\A_A1IH^'_ \$1A_P#PIK'_ KZPXJ\\ M_:C_5/*O^?;^\\I+M+A_.SY/^T?
&#_HC#_P#A36/^%VCXP?I\$8?_ *_Q_PK_MZPXJ\\;:C_5/*O\\ GV_O#^RX?SL^3_M'Q@_Z(P_(4UC_A1IH^'_ 1&'_\\
M\"FL?^*^L\\;CCVH_U3RK_GV_O#^RX?SL^3_M'Q@_Z(P_A36/^%VCXP?I\$8_M?_PIK'_ \"OK#CVHXJ\\A_
5/*O^?;^\\I+M+A_.SY\\A_M'Q@_P\"B,\\A_ ^%-8_P\"%M_VCXP?\\ 1&'_ /\"FL?\\ \"OK#CVHXJ\\I4J_YIOIP_LN\"\\I/D_I\\8/\\B/_ M
_8_X4?;/C!_T1A_\\PIK'_ \"OK#CVHXJ\\I4J_P\"?;^\\I+M+A_.SY/^T?&#_M#_HC#_\\A36/^%VCXP?I\$8?_P
*_Q_PKZPXJ\\;:C_5/*O^?;^\\I+M+A_.SY/M^T?&#_HC#_ ^%-8_X4?;/C!_T1A_ \"FL?^*^L\\;CCVH_P\\I4J_YIOIP_LN\"_M\\
I/D_P\"T?&#_* (P_P#X4UC_(4?;/C!_P\\I\$8?\\ *_Q_P^*^L\\;CCVH_U3RK_GV_O#^RX?SL^3_M'Q@_Z(P_\\
X4UC_A1IH^'_ 1&'_P#\"FL?^*^L\\;CC_MVH_U3RK_)HOIP_LN\"\\I/D_I\\8/\\B/_ P\"%-8_X4?;/C!_T1A_ IK'_ \"O
MK#CVHXJ\\I4J_YIOIP_LN\"\\I/D_I\\8/\\B/_ X4UC_A1IH^'_ 1&'*_Q_MP_KZPXJ\\;:C_%3RK_GV_O#^RX?SL^3_+1\\8\\A_
HC#_/A36\\A_A1IH^'_ M_\$1A_P#PIK'_ KZPXJ\\;:C_5/*O^?;^\\I+M+A_.SY/^T?&#_HC#_P#A36/^ M%VCXP?I\$8?_
*_Q_PKZPXJ\\;:C_5/*O\\ GV_O#^RX?SL^3_M'Q@_Z(P_M(4UC_A1IH^'_ 1&'_\"FL?^*^L\\;CCVH_U3RK_GV_O#^RX?
SL^3_M'Q@_M_Z(P_A36/^%VCXP?I\$8?_PIK'_ \"OK#CVHXJ\\A_5/*O^?;^\\I+M+A_.SY\\A_MM'Q@_P\"B,\\A_ ^%-8_P\"%VCXP?\\
1&'_ /\"FL?\\ \"OK#CVHXJ\\I4J_YIOI_MP_LN\"\\I/D_I\\8/\\B/_ _%8_X4?;/C!_T1A_\\PIK'_ \"OK#CVHXJ\\I4J_
M_P\"?;^\\I+M+A_.SY/^T?&#_HC#_\\A36/^%VCXP?I\$8?_P*_Q_PKZPXJ\\;:M:C_5/*O^?;^\\I+M+A_.SY/^T?
&#_HC#_ ^%-8_X4?;/C!_T1A_ \"FL?^*^L\\; MCCVH_P\\I4J_YIOIP_LN\"\\I/D_P\"T?&#_* (P_P#X4UC_(4?;/C!_P\\I\$8?\\
M*_Q_P^*^L\\;CCVI?ZIY5_S\\I?WA_9\\MK2Q^&NF>')#_*S5=7UJ^YMQ\\F/N0\$2I?:OK+CVH9I9R2_*<>%J
M6OLW\\X_I^*A_S\\P^X<_LQ2:5X@TSQ3X\\U^X\\8^)^+Y\\I:&10NGVDQ2+<\\<7\\I_ M&<.0H^Z=F\\I0U>
I\\VXB5%2)5&W;SC\" =%_ :K_D3<5W#<=G\\I&>>F?Y4\\I<#7U5&_MC3H0Y*%&D>C1P\\I+\\#Z4U8?1116YTA1110_4444
4I+<2\\JZO\$K#;MXQAP>JD_M'M7A/Q&_9BDU7O\\I?
BGP)K\\IOX_\\3WOSW_..AM/NY@DNUY(O\\Y:09*8\\D<:EF<*H&XEC@_#J:PK4;=>')4@I\\I\\SFK8>EB%:HKGR>IK\\;=(O+
MFTOOAKIGB_?ZO5=(UJ^VMS\\F/N3DR\\I?:G?:C!_T1A_ \"FL?^*^K@RGD\$\$\$4
MO7MR7LN_J>OLW\\Y\\Y\\W\\E0_F9H?;/C!_T1A_ \"FL?^*^M'Q@_P\"B,\\A_ ^%-8_M_P\"%?6\"M1QI4O\\
5/*O^?;^\\I+M+A_.SY/M^T?&#_HC#_P#A36/^%VCXP?I\$8?_PIK'_ \"OK#CVHXJ\\I4J_YIOIP_LN\"\\I/D_I\\8/\\B/_ P\"%-8_X4?;/C!_T1A_\\
PIK'_ \"OK#CVHXJ\\I4J_YIOIP_LN\"\\I/D_I\\8/\\B/_ P\"%-8_X4?;/C!_T1A_ IK'_ \"OK#CVHXJ\\I4J_YIOIP_LN\"\\I/D_I\\8/\\B/_ X4UC_A1IH^'_ 1&'*_Q_PKZPXJ\\;:C_%4RK^_1_M>IIEP_G9\\G_ /C!_T1A_ \"FL?^*^M'Q@_P\"B,\\A_
^%-8_P\"%?6\"M1QI4_\\M5/*O^?;^\\I+M+A_.SY\\A_M'Q@_P\"B,\\A_ ^%-8_P\"%VCXP?\\ 1&'_ /\"FL?\\ M\"OK#CVHXJ\\I7^JF5?

^WIX?V7#^=GR? \C! P!\$8? *Q P*/M'Q@_Z(MP \X4UC A7UAQI4<>U'^JF5?R/HP_LN^I/D_I\18/^B,/_
%_8_X4?:/C M! T1A \PIK' "OK#CVHXJ/I5,J D?WA_9,%_IX M/TF01R76D^&4DDFGIW>,'+*S_*VPB,
&6/N%XRWT1X&^>B_#70QHWA3(=* MTY)6E6!13C+*G#N^Y+124M=YW!1110_5C>=%_ \
D5M(P^O+_T^MFL;PO_,BMI'_7 MG%_Z!0:LT444 %%%_%!1110_4444 %%%_%!1110_4444 %%%_%!1110_4444 M
%%_%!1110_4444 %%%_%!1110_4444 %%%_%!1110_4444 %%%_%!1110_4444 %8WBC_D5M7_ M.O.7 T^MFL;O1_R^YK_
/7G+_Z!0:LT444 %%%_%!1110_AZ5Y?%#IDN;Q M \5F^*^@COIJ/P/^((\$T^VMS?Q6Z:A:3PI_A#6TIVEL);C.=H@-
LW'=7T=25_M496N5KD=4_8WU/PIKGB_C_(5)\3ISX4>&/\$6V:\V>D1W<\$%
MP59)))+4M(IMMPV_ZK!4QH0VU8UC^F&C%5I2009Q/_@?!"?#G/O@<>=%O"P
MOWLS=/_R3WP>621MJY.U510L:1HJHC"#^+5^8KECV#^&OE+PS^MQ'?_I>>-
I1\$ _\$15/_A3Q=/_YFH;)I&DVL=S&I6;\$=O=L'+=\$>=BGEQ_H M.,EOGKZNI* <9M-<^P/%IEF
MJ.+^V=9_P!XOEJZ?,X'IS.WY?K7^*^I(?CSXW?"N'PCXU^+5MK5S;ZU!JUM
MK#>=%UMY81!'+\$T7E17^HP+295CT^_.*I/JL1MJQ:5%I.)Y^*_V28=:\? M#N+22\$F_G'6N-U3IB.RUO\
95TKX.WGB1IY\N^NK3Q";IE\$,K3RR%Q;^? \MQJ>6+I_/RTW?>"U'^T8-7I2009QI^SI?_#^+.N>:K?>576;>\AO
M;#5-+\.060#*1NBNHHY"MQ"<.0@*#_A.AE41JMSX3_LO7WA7XIW'Q^<^_I MXC>_7M/I-
@NHJPAL!6TMPJ@>1;KNF3/F@LCA669KEF8_0%#3I1CY4+1114_MEA1110_4444 %%%_%\$4W1*X7X@?^C=,\O^P_-
_Z:I^NID^;Z5P2Q^8+XN^&_M>2!MU^_//3_B57YI9^/7^'IOS/0**N^K1N^K5^0.I">_M&X>M8GB#7;+PSH
MNIZMJ#M%86_LIU=SI2^V_.23@+W_!/'IO)NRNSC?C+8=*^\$.APS74+7M)2:B>_M(\# +7_%5KXH?^%\$/_(U1_P
_M? \56OBA_X40_ \C5>Y;?>C;IFKL:24_M(K+P?X?U77M4G_&E;9:RWMU_Y+2>3#\$I9R\$4;F.T\$>_ME'(^U'^-
GXO \X9=^T5OXH^A1#_ _TG_#+_PQIU5SXH>G_(O#_X MW6+_ _/O@_0^/'IO/P/^+J).?^FL?R-
=M3/VEOAF)+^0+IQ3XDM/L M2\$\$.EQIEU;PR7<_Y\$@C)<_#&XVD3(0W0AQ@ \U7LGV)\J87M^+_S_7_AEK_JK
M7Q0_*(?_&J/^&60^JM?%#_PHA_ \KVH(T4EI54<IE@.G!HWRCJ^<=>I38_MKZCA_P"3I7_F>?^
 \M?I5:~*^_A1#_XU1_PRU_U5KXH?^%\$/_C5>W^9^N^P M9/09^O\ @?RI=RXSOX\XS<_M&*KLB5VY"\$CBN\#J6
#C)&0.CIZT^0/J6'_D_%_YGB'_RU_P!5:~*^_A1#_M_P" _4? \# +7_%5KXH?^%\$/_
(U7N!:=IMS(IN.%Y'/T1@ \ALCIUHL^U'#_R M?B \SPI_(9: P^JM?%#_P*(? \OJC_(9:_P^JM?%#_P*(? \OJOQM,+
ME%)/^S?3.&7W_ \2;?K^=*^U&AV_%GSCH/QI^7_IUC2?#_P_8=)M;73IR_M06-
KXRTUP+&24I&0LZGF(DE^N=BE@<+M!>OH+2I4M_7L8;VQNI>^LKB_98;B_MVD62.5&Y5E93@@CH1UK(A5>\$I-
 \#?;_JIA^Z=>+I^>WG3Y%)SSW!Y#>_MD^D^2NOG:>P+@!);(&V^8B^F MT%)5SM^K3^>QC.>%G&C+WHRV?
8^F***9ZP4444 %%%_%%5_6M_ \LBJOIN MWL;*WC:6;YN)CCC11EF9B<
=2>E?/0Y^=O%WQCOKS3O@QI5M<:?.X@N/%V MM+)%:12-^ (Q2.)E#NZ\$+SAPK,
R;2^IGI0>L;I^XT^ (WAGX.^&_M>G6;JVS:A MX@U.V^1H+
04CDPX4MY;H0R;27B7.TLM>X^% ".F^="HLM&TBP2QTZRC\$,,%_MO_ORIJ#GCN23R6/4^GFDO>^E4GBJLJ4?
=A'=ISR;W_9MA2ZPUQ<>)_C!XTN_MM2>?>LN@W0TFW\$>Q!M\$*%P.0>?E^FYI?K^M=+MI&_ \# +7_%5KXH?
^%\$/_ (U2_M? \N#<C_(6W\3^<G_ "1#_XU7N&Y<\$N!U.^ (L_VV?@GJ^B5M^A^ (FEQ7)F M>#I1.LL-
H^3<D_ \GC&TA/D_ \HITU3OI^U+?#R?B_ \L2_M;P!5:~*^_A1#_M_P" _XU1_PRU_U5KXH?^%\$/_C5>XMM522V
IS0NENCYQP:7*^U# _GXO_ \M_ X9: ZJU4/ "B'_P_ H X9: ZJU4/ "B'_P_ K=L?VDOAQJGQ6/PVLO\$E
MO=^_O/EM_P^S8+>9TR^D4)\Y6Y\$5MPW9I4H<_ \5ZF<+U_/OHIG8/J6'_ M_)Q?^9X?_ PRU_U5KXH?
^%\$/_C5'_# +7_56OBA_X40_ ^5I^?M8:7_DUI?V MIG^"\=LLD^RHIFD=8XXP2?O,I^JKU+_ \2*M;E_OC_2CE#ZCA_Y/Q?
^9X?_M_ \M?I5:~*^_ (40_P#C5'_# +7_56OBA_P"%\$A_XU7N)*KP7P?K1E=O&_D#_M)&>E^*^U'#_R?B_ \SPW_(9;Z? \
%V_BA_X40_ \C5+_ \M?I5:~*^_ (40_M_P#C5;7P^_ \0^"O8\8:GX6)^<(X=U33TFENH88)A^J1RB_V69DJ4;F!1
MCE3D<_?V@_ \P^^(FB^ \I=VYAA^=\$ M^1DR_>(X&>G1?^OI0^@+XA_\$37/_FA:T_2I2Z;C^T=;TGC\$ BG\$,N7=C
MXD88VG<I^?LF^U+?#R?B_ \YW_(9:_P^JM?%#_P*(? \OJC_(9:_P^J_MM?%#_P*(? \OJO<&9%Y+@#
(7D)ST_ZBERO/SSW!.*5@^HX?^3/7_F>? \M# +7_%5KXH?^%\$/_ (U1_P_M? \56OBA_X40_ \C5>XY7!_ @>I^ WX\
M<_ \I=...?FZ=>+!I1P^GXO_ \P_&60\JK7Q0_ \B'_ \H_P^&60\ MJK7Q0_ \B'_ \KW#_CJ]^R?WQV\^O2BP?
479^KDNSHJ#>S2R%BN(^&W^H_!_XV>&/C9H=S?;!-(TUK*8K
MNSO@ (H!CD(TL:DC8P4I6S@A<#)1%>DE=S^K_NGI7RU\6YP46EU#=6ES<_ \,@>.5& (96^!!!!"-6QNKBT44
M4#^"L;PO_,BMI'_7G%_Z!6S6_X7_.16TC_KSB_ \H V:*** "BBB@_HHHH M**** "BBB@_HHHH **** "BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_H_MHHH **** "BBB@_HHHH **** "L;Q1_R^YK_/7G+_Z!6S6_XH_Y%5_ ^O.7_M_P!_H
V:*** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "M"BBB@_HHHH **** "BBB@_HHHH ;T->=%^9M-
U3P_J;VE_ \:~?K;J^3KV_ \8X49MNYT&<8RRJC17HC4F_PIF=2/_&QP7_ M!1O^H'^>?"_3_MU3_Y&H_X6IHW_0.4_ \
A)ZI_P#(U=YM^K1M/K4> \9^SG_<)_PN#0I0_ (A M4_ \A)ZI_P#(U>2_M3?%6RQ?@_XGATV/Q+;7:)\
!/@Z/9Z#H\CHIA&+;RLH(X(8%YV1^NU1^0_M_2M0_UO7F//GO*7XI_"G0M:_S!KU&.+?>
49'.89+J;I9@RODI(TNK6PO=4UJXT>*^+;3;2)IVUXU;YHX\$*)V (PVI^@;TW7_ "0^8A>K^F;G,>\RQ;Q^IV8R
M.A!KSS_@I_ \#^Q?XZ;X8_ \")^&_ \0I9_VD+E=(TV2Z;=I^E!6I2(P=K
M8SC.T^E>C3P)5>7H<4H/DY^H"_\$W7OCRWC;+2OAOX\&0^X!7SGUWQ/>W\$ MD_ \BA^TGXRTOPKXPB\
^";KPIKURLJ_ \JT&HV=A,&_%Q) M<,&B(^IW*(A5B%C5F(3GO^I97B/5/C^XL\$^!+IX>^&+ #PN^D5YKGO^U=
M!&IF78C0PQ;DDC;LD;A1@_ M\$!2^!W#; _07QB_>^+WP#U#PSXL=>!_#=O/M40(K.YL=&U&2IU73V> (L5
M>9+_B9^K^P" (5/E&N^?^VDO".M?^SIG_I^"I^&J>_ \J7Q9#1%8Z9HT2_MW6I6,<%
I\$DT\$^ \W968DK(A^":OE0+O_ _J+40B!^UEI7A/X:;(A/%GA?_M6H_9%SI_M>
(+)^DTJRFB@EB;RKI599X@9&83^9N5\$M9^R_\$S_MIHGOWI7QY;X0_"71M!O/\$_EIHU35I437\$Z6MBA!_ =F&,*
I\$^;_GS\$9U_>@;_ M^_@+^V)JWQ=M_ \7B3QYX3I3Z1^IEV/#5JMU\$7I^PA\$Q<\$9WH!)_A+XF^ (W!7^BOX^)?
UIX/T;:U:WT^U_MUR8Q:B9@D5KYK0+S&IA@D#+/(^6J%?_ \$E8J)G.U3(S#L^6_O&O?RZ_.#@ _M2OG;7KR^H
8ALC%1_M/8\ _&?;!%?WH_F?1U%%%%6>@%%%%_!1110A_"ZSMY_VJ/C?
>D027=0%H\$7W@?H^Q^H_ \# #I^C;38+BP_N MU25GDN;2/88B^<_N0@EF>E9PV;P?P2_Q2_EH
MLT9K0I\$6BDS1F@!;*3-&_%HI,T9H_6BDS1D4>?/M5>?"\$OQ*_9_ \&GAO_MPA<_9_\$&H6L<<"FX;GJLJ/+; _66)9(_
A3YF&(4L1+?#^XH_L^Z%_X-M^A_MH:/@XW@GO^P)JVK7>GO+<_WDK/YTFZ+V_YG)(C4_LB(&VL57I?^C=JO
MQO^T^X?W5W\O_0^NF^<)O%*2Q^58ZC=" _HV<>81R@9@#PIDC^4I\J\$XG^*Q" M^_W!6G@?
3/AC<_L_WOAK4I2NX/M7B;7;2ZCM;_T4M+/\$9(%^S^KC/F2_Y;_&_M@D=A771ORVN%\$=[>>XAO)
MM)OF28A!\$=DB0A&MMK;L;PN^E"\$*4KS^X!^?^OOSX3\;?#^P=XDV/^*OB7^" M=- \1V%I/H/@S3IH_M_S!;F;-
=1VX9V_B6^HWD1J;M16979K/I)?P2UCX=_M MD>/_F^X9:UX_ \CP\IMA5I0NH;9;-E476I^XVD6I^Q M7?-
L<=_P3EU/Q^X^&OB7Q61X2L/A?8WMY)XFU^Z@NCK86WL5D4Q>6I5X4W1_MG8X+C=/_C)(K!A
X\>:UX;NO^6F1?"S2="AE;@; (KXC/_D^Y!%LWR_ MF10S;9IADC#?(^L^#_B7_ (9A? \@CO!IFJ>\$=2URIU*TC;5
M=-DMY(4N+^"-91&ZH74\$MP&_J1G@UP_PUT^U^_@^ \^\$^/_V8=5^ (C72)K MF)^_TOPO;J-
AJBO^MNVVUDW\WJHJQW1\$^8!AY;Z3Y)3DS_.9PC&Q0_ \0^ _MGCKXL>_ \@J_@^<^
CP1X@ \10:GX5AOK>Y6ZDO;=X(G&HX^R')/_OFEB^C\$ MG>=M>R_&CHCXM?LIQ?"ZI:6WA;_2=U^K;Q_J6D:?
>S6NFQK.I#PR_)G/&NB_ \JT6U\)^ (C&XD;+3IR\;_RG>63)FA+(&9@GJ7QJM=)_>_97\8/>^'=9\7-M;7%-
M:6OBZS72INPNI=>_1FG_ =Q1L%*F97VE)9_70IL9WAHRSIXT_B9\ /A=X,T>QNVU^U;6/\$%JJEQ^=KIZN5#1R1/F-
SY.Z_NA00)_Y9JV^VM_MU1M^SSX_ \AR6QMC^HIXH_ \4.LHDL_ \IT@N%_A.G6D4^;D(VK(& \^*(0D&T(+;_MBI?
67QITVUGX%_\$PT^TGOKZZA;_E!;VMM&9)9I&M9%5\$502S\$D_M?M.'7PC\K^XO:_X^&W?P_N6BN1HJC?7

M*:K:VMP6%LSS.&C8YDM@6C0D^9RD>^N/P^!2%/C;_@FV/AW+H_HGB6XLI MJ6+2I4LS%.TJ:G+=102)
(T802;\$0DD85PW3%<=XYUKXC?S\$IF/2_@/!:2!3QE M: ^+8;>QT>ZO[RT6^2(UL&5_CNV<1RAS:+C+
(OIX;7DPOF='^+<[M]3.IA Y M3H3Q19^_OVV/V10R+E0X!5<9X+8K?^ MV-?^4AGQO_IC?_ITMZP?
&G[,BGP!^T=^SGI>D>%-7U+0_#UEH2ZKJFDV\$IS M8072:E<37+FX<\$JF^H,\$C:K+P
!7H/I)WPA7>^/VZ_C^K^K>%M:T00K^MMCDJEIHT-K<:I2@=^/+E90KIEI88)R 2.*UE*/D9/I/ZF=GSWL==X>_:1^,
M_P>O^\$MUSX.>&/!Q(:#=S:?:W'B*ZN6N!F0_.ID(T7E%HC;_+ +@*TF"^5 M?R^<^7?
MX>*!:_9OL_BMX%*VMM^:ZV@ZWINKV\H%\$#&DD,\44L6U")(T
M+,GWY005!YE#X%WWCCIBOPXSX^NH_";OKXVC;5)I2T+6/#IBMY;7T11(\$%P M8WD^SI_LZ.1[I]F=_*"
H/@S^Q%XBV/L?_!1\+>(M'^Q^_O%._J&&PO8C M*[6V];.&1B?)7-RLIX.!_JL^5^3GY8=33WSTA;+;_(E^%Q_!Z/X?
BM- M1\,7UM;ZUXAUTVDMU#;://>0V<I0)_3I^6*.#OAVDY=-7&_#UA=);.7;2Z=:6S;BEQ&L:Q3SV=G\W;9(
MH9<8_I_!/?X>^/XM0!/?^/_ (GZ9J\$B;5#9Z39W^N6+PZDT%M JEVD:DA
MEVE2^I.C0DON*JQ)1A&.@0YY2U/3OVC/CIXB^\$7Q6^#OAO1K+2KNT9ZR--U M26\CD::&/S;9
8BKJ%,\$VA^;=T6CIHWI^H^Q#^'_BA&_#>CV>E75GXVUC^SM M2E08Y#_%\$)K6,-"5=0K?Z2WWMW^K7*?MT?
#SQ1JT_PM^(WACP_?^+;WP'X@ MCOI=!TY"9KJ!YH9,KMRP*O;1*0L;X\$F_*C&O+_C3KGC;IH'XY_;6-.^%/C
MG0_#WAWQ%' +=7FNZ1+!*':ZLWDS%&7\$4*1HI\$KN%8F0=8V-1&\$9UOO.DM8+;.*ZDBVW/FS!)7=4 "QR
M19,4KX=5*CUWID_IHS6_C9E4*'I'G,M\$JE=SC*IRN5?:GS=^SY\4=4^\$_I0GI1EQ!X^2^,M-O?\$T@E;PI:?:KNTG6I
MOC\$LEN67;,H9N;"UWIE,4K":S-RJ>88A)&5 MWX&.1G(Y'=-6<8R>*!/?_&G/&-
EX1^!_B^>^N5BDO;"XTZS\$10222SQF-/W M_-
Q&_<^'. \$8CI2E)\SXAQC1DYI\#/V4_-\$%QXD_9I\%S74<<+0V+6*"W)'R0.T M\$9&>Y2(\$^<^:IA/S,1ZBN#^#?A:?
P5)*_ "&A75HMA>6.FVR7_-M&H03B-3-IW M(R7+DGON_/6N18^Q2C\I,11H04^Q)1115'2%8WA?
Y%:2/^O+_ T"MFL; MPO\BMI' 7G%_Z!0!LT444 %%%!!1110 4444 %%%!!1110 4444 %%% M !1110 4444
%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 M%8WBC_D5M7_ZY?_ \$"MFL;Q1_R*VK_I>:QXJL!*
IN_A/KC*;O2=(C0KI^T M%7IZL3G&R0)M)5D4;@"/W<>[Z^&^_I\Z3#JOA_5+?5+ %EP)+60\$Q,55C' M(_*X#*2K#
(R*Z!HP=^\$8_>SDYXSP.8KP36OV_ #DFM:AK/A'6=<^'FKSV MD& PI<^3"2S% @63'!MAV*RC"@ +6-
I1/5.MA7RT(1T7OY>A!^YIZ,^I>%? M^*C^,O T7/_ M.S \BJ/^%1_&7_HN?_EIV^ \56G;.^VJ^/MGNN?>C
M/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN MN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

V MJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4 M

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_M_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y M:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z M+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4? MQE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC M_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ M (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+ M3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_M_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_ M-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H M_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A M7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C M/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGN MN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ M/MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

V MJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4 M

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_M_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y M:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4?QE_Z M+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC_A4? MQE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ (JC M_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ M (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H_C+_ M-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ^ \ /MGNN?>C/O7A7_"H M_C+_-%S_P#+3L_ (JC_A4?QE_Z+G_Y:=G_/%4

VJ?\\MGNN?>C/O7A M7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C M/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGN MN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\M/MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
V MJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4 M
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_ M / %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y M:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z M+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4? MQE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC M_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ M (JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+ M3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S M_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_ M-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H M_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A M7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C M/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGN MN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\M/MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
V MJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4 M
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_ M / %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y M:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z M+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4? MQE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC M_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_ M (JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+ M3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S M_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_ M-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H M_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C/O7A M7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGNN?>C M/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\MGN MN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
VJ?\\M/MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4
V MJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_/ %4 M
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y:=G_ M / %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z+G_Y M:=G_/ %4
VJ?\\MGNN?>C/O7A7_"H_C+_-%S_P#+3L_(JC_A4?QE_Z M+G_Y:=G_/ %4

%I/N#IT%[;^(YK. M)H[IK,130R9B"9)595 M9F/R>6KLKLH4MZO\\(VS?A?
\\5/!-EK5[XIT;PG?R QW.D:YJ45O;/2C.<;F7 MS\$(Y65< CD[6W(OT"L2*N% QC
';TKP#7_V\$ _@5XIU6[U&Z^'MG#++= \$>9%8
MW5Q9PJ5&W*Q0RK&O3/"YSSUIQE!QY)ARR-?X.?
M0>!OCWXHUW1?!C:AJ)T:* M"XDU":RDBM9HW) ".WS!E8,NV15+,K[-
P1F7Y@_97^,W@GX7_M0?M&Z?XM3

MV.@3ZOXGD%I/>/Y=LQBNKYI\$>8CRXBOF)C>RYWX+,J^VOAW-
_#7PK\|P:# MX5T2RT32HR&,-B@7*LDMW+YFZ1)F)>,KYTINTQE?
+\Q|NW<.:.'O!RR/E_P#;^_:7 MV/>* _AW;_ "OP%J%MXTUWO3=0)(NAC|#
[#2]1D9'6[D+W4J%49-T+S.[1;DD*G:1D'! MKU\1J.P&*/*GR\A'LUW/G_X1?
MH?#+XI>"/;6[SO7H_A*_E!BNM'UO4HK>>
MWD&2<;F7S\$(Y65>" .3M;./"\$+IX2\\$:5):2:E=)* MOVQ62XCB8#9B-
D;HJ2;6:.W9A@J47Z U|A/X%>*=4N|1N_A[9PRW1'F16 M-
U<6<*E1M!6*&58UZ9X7.>>M>I_#_P"&_AOX8>'8-\,:+9Z/I,:J##9H &*
MHJ>9*WWI)&5\$!9LDA1DG%'/!/?PPY9'7|J^*/^"JC(W|/'AIB|*G_E-LXDC
M!;C!)= '=D=|J>^!WK|7SO7,^./!.C?\$3PSJ?ASQ!IT.I:-J\$1BN+:X.%E4D,
M&5ARK*RJP(P05!!! (BG+DGS&DX\T3DO"?
|1WPU>:IH&F>'O&^B:MJ>M027
MEE96|VAGD145RICSN23:X;RWVOM60|<(^WX__8C^,6A?
LW^(O&GP1^)^5Y'X; MURVU2>\CUF\?R+&8K#&C+ND"E%*Q"6.20*LBRC
!*>9|>?"|FSX;_!/5-0U M/P7X<@T;4=0B6&>
|::6YE>,'<51Y9'9%9MI*@@\$JH(R 1-\5OV=?AQ\<(X1X
MW\+6FLSVS*40"\EO*OAF_PM\W4/CKQ#XIGMQ\$-
"D6YBM|EPCQJQCW&25Y(P%1>>0203&LOUUA(M_ "%UX!^%/(@SPY>M;&
|T71|/3KA|8EHC)##'&60G:=OR&N6^%O|+/PK^#VM2: MQX2\
(V.F:M)MVWTK/=3)A60F&29W:+E*45'DIFD8 M|1|%%%%8F@4444 %%%
!1110 4444 %%%!1110 4444 %%%!1110 444 ME 'S-
^VG\:=4^%G@NPT00)|BTUK6WF"7B+S#;Q|/.*,#\LF)%P1SM\$A!#@&O
M&?"/_!/GQ!JVCB\0^*;;0;V;&+>UM3=-M*_O7WHN_<2,+N7CAGS7I'|>?P
MQU3Q5X/T/Q'ID\$EROAVXFFO+6(;@L,@4R3'")">6OR@<|G;JMG"_!%!M+
ML=%L|/QCX>U1=0BBBC%UH|13-
=2*f)I70^4J#=#T5=U<4^64OWC/B\4Z\$;.& M/=HKX3S5-
)\6_L_\$S2;F|O%U#PSK\$I6|)%HV|;ZW20*^Z)MI695=74#@,X0, MP,F?
T83YE'/;)K\VO&7C?7OVV/BCX8T73M*DT>QM8P6ABQ<-.@NGVBZ,C)%A M5
B4ID?-&/GDP/TE7\$;G/3 JJ#UDE\WY/9.HJ3O27PO\R:DD^XWTI:1CA6
M/M76?2/8_+'X2?%;1/V??CA=:KX>AO-?)S&33%N+I1#<&U,JE2B#@LICR-^
MTR9Y6+(V?4?_\.^?)&@^)\G_IVML?^E%8GP1^"|/GOX77%T'P%J-G_9I
MA^T+J5_<1|O-APKMV7+?
W6_,^M>CZE^RA'=)LKF|E\7\$D4<.:9%@N;Z>0K_M+\$.:SEO|Q98X%
M7+N7("XZ\YXKG=2^+7A;2%!N=;M9!_T|9E/_ (YNK2G1JU?
X<6_DHC*5C!8@,O M4!N/S-?+>I_';QG>W7|NYAL8_2WMUA
Z%OKF;C7O\$_C":2T_M*^U*2?CL_L MC2QG_MG|S|*|:GPUB-
ZTXQ^9XM3B|#/_'>G*?HCZZU3Q%INBO|H|4|2R#?= M-U,L?\R*Y;4?
C5X2TVZ%JVMQRS\$<>2C2K_WVBE17SWIOPK\4:PH-OH5|&%Z? M:@(A?3S-
M=38_LZ^)^IOLIN;JOLX) #* S-*N1\W 3''^|_P*M'E&6T?|XQ*?
MI_3,%GF;XG_ =*UZZ_Y':E^TMIT=EYNG:/>3R_\\|@B/_T'=7-ZG^TIK3S;
MI+2|2&W|K+OE?|"E:^G_+,MJMQYE_JUQ#C_5Q1",_KNKH|,^
/@ZSMOWEK M->R_|;B=@_YKMJ_;9#0^&#G|_ZV%|+B3%;S4/P_*YXKJ?
QF\7ZJSQ'5+A+> MXXC^SQI&5_BX=1NZ5C;O\$?
C%4P=8UM8.OE&2Y'ZEJ^NK+P?H>FW"S6NC6%K,
MO"RPVR(PXQP0/3BM7RQ'PHP*AY|AZA NV%2|0CPSBZT^?%XN3|Y+L?
A#XQ MU PI_9-5C_-| VX_|U6G?LV:E)<8U'5;2VCQD?9P9#_./:
M: ^BU3KE5YZX%*V>V*Y*G\$6.E\#2|S>A3X3R^'\5.1XQ8_LXZ3|G\$5|K-
Y/;>,'I3"HR<*O/ M7WKQZV98O\$?'59[=')\!A_X5)
(IZ7X9TC10_|GZ79V/F8W_9H%CW8Z9P!FM#
MRTX^4<=..E.I:X7*4G=NYZT:<?*
P*PE&T4M%2:#/)3;MV+M|,4OEIQ\HXZ<4 MZB@!-H|*,#TI:* \$VCTHP*6B@!-
H|*6BB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH ****

/B#_@I+_KOA[_NZC_.UH_X)M?Z[XA?[NG?SNJ/^_M"DO^N^'O^[_JA
[6C_@FU_KOB%_NZ=_ZKSO^8D^#_P":@_K^4^WJ6DI:]\$^\\M"BBB@
HHHH:;\$&.:1C.>E)Y:9SL&<8SCM7SQ^T?^T%XA^#?Q2^#/AW2+?3[
M3O&NM?V;?R7T;M)#%Y|K%F%UD0!L3NWS!_NU]#
[O>FXD'M/T>"6=)88KA9-/D6?8EI=F3@S%2QX\L_N)?D_M_NM1Y@YD?
7NU>>!SR>*&56SE0/VC_-H+_MQ#\\&_BE\\&?#ND6^GWFG>-
=_LV_DOHW:2&+S[6+,+K(@#8G=OF#_':^A]WO_M3E\$GF'8%(T:-@E%)&
<9'KUIU%(H3:/2DV@8P.G2G5Q7Q8\\4W_@?X5^./,\$6FJ_MDVI:3HUYJ5O'=
LADB@>10RK@E25(S0!V3*/0=<[*4>]>0_LM_%S6/C=\\"?
M#GC/7;>SMM4U,W?FO:NL<<4G'EE82?-L*T:-@_ME%)&
<9'KUI<>U%+0,3%&T#M2T4P&[5/51USTHVJ#G:,^N*=10_W8O]T>O2EI
M:*_ "BBB@_HHHH_****_ "BBB@_HHHH_****_ "BBB@_HHHH_****_ "BBB@_HHH
M*_ /FG|K3XW^,/@O_,(KJ'AVRL;FPO?M-O=_VA"6M5<&!H?F5D(?;YVT;L%0
MY*G_V^"6/Q;_&?/&EU_?%7PJN?
#%WN2,'224M8X=X/GMY#Q#AF=21&S';CY
MONC[3^)'Q<*_ "C3|.Y\\5ZE'IZ74K);JRO+)(P!+82-6<@<<[2!N7VKXH^,'
M[0WP>\\9V)_LWX3QWEW<2374U_J_33GCG=>)"[H2\\X9I'+J9%Y
/) *DA^3OP3\\8?%;PV-5'PQ@U";SC%|N_ML[2X|SR\\>9Y0??&^W|F,?
W:|)O0B;^U'J5E=P36?BQ(HHFBF\$/AT6\\RJPP'
MCD2V!#CU!XKH_&W[7|C\\,%E_IOPN\\#^&|,L8[HVTFHM-191B-T2W*_QC=
M*5RSA@P/[LFL9O_@H-\\1F7'|C>%PA_KRN.W_;Q7![BT4W]Q^>1|CAX^QEB
MI^D5H|Y|S^QK\\#/\$OP?T?7|HQ++%!J&L2PHFEQ;9/LJ0^8_SRHS!RX=?
HH4G_MYB57Z8_^7IBOF_\\9+_:;%\\1?'IO%|N:?
IMFNE_9Q;M8JXWB4S;@^|FOCRTZ_M>M?1_P##UKOI?"C[K+XT(X;,
<5S7C+QQ9^"-)^W7XF>/>(UC@4,|S|M,
UKZ;J5OJ5G#>6LOFVTR>8K9SD5Z8QKTY5)4E+WHFE1114&Q%N
M;TI=QJ\$MLCW-@,04;N/SK+U'Q9I.D3;+[4K.S_Z[3JG_
\$15\$YZ1CPDV|/#^#5S&J?_MM+6**#8Z3!UKY_MOU#|H3Q!).'M-(M(;?',+
|Y7_P"_F57|*Y:Z^+WC+5+<0R:MN4>|O3Z06I3_T85KE+|H=%OO+L-#FN8
M0X?JY_U\\A>UXDQ7V(P_#_\\^U+|H;Q1>V>U&M|&3^|;VK9_\\>+USNH?
\$CQ5J_MDX:77=2CEC7RV\$TGX!^*;Y_:|H|DTV%_)0M>HLH8@DO1X>RS#_
44_M-J*/PIWR|<8X|,4ZO)J5IU7>4FSW*>'I4?
@BE\\@Q2>6HY"KGZ>M.HK,Z!OEK_MNW;1N|<E+13_2C%+10_E&T>E+10
F!Z4;1Z4M%_@HHHH&%%%%!1110_M_4444_%%%%!1110_4444_%%%%
!1110_4444_%%%%!1110_4444_%%%%!M1110_4444_%%%%!1110_4444
%%%%!1110_4444_%%%%!1110_4444_%%_M%%_'Q!_P4E_UWP|_W=1_G:T?
\\\$VO|=\\0O|W3OYW5'!27_7?#W_=U'^=K1_P
M3:_UWQ"_W=._G=5YW_,2?!_\\U!_7|H|O4M)2UZ)|X%%%%!1124?'W_4%
M\\0:~X0^-7|^-NZI,+;3M-U^XO;NZVLRQQ17%@SNP4;B0,X_R3DU%\\1?VJ?VE
M|)TC5O&^B?!^TTCX?P%|B"/Q#_|H|;)E&DN+=;E94P09&"Q81>=SH#(=O\\
M;D4+^T1^RR_8\\49'_@5IX_EQ7VC[5T\\RC&-T4?LZ_'[1/VCOAS#X
MMT..>U07#V5[8S_?M;J-59XP_P!V12CHRLN_JV3M;*KQO|./Q^U_XS?
%+XR^_M'=8M-.M-\\\$ZW_9VGR643K)+'Y|U'F9VD<%L0(WRA/O5YQ_P2K_>?
L|^ (F?Y_MF/B:X!+6!(VQ(76,L|N_MDL3|8|K"J%W^WM\\6?_?BBU\\">-/@7-?
>._*^T"S\\ZC*?MD9RZO!\$D,^Y0@(_M.)&^:_L[3E%P?V==6^(?P(\\7?\$KP))/
3?%3X=Z'KTZRZE>7B:/=1WQ2%98_M3+,0DHB6(JVV/+LRR95'4-
|+X\$^#_C7XC?M#:5\\:_B)I5IX+N|'TO^R|\\+:_M?
>B\\N%5O.21KR=1L/\$\\K((L9WINVF,|HER1Z\$1E.9Y|_P4%\\0:=X0^-7|^-N
MZI,+;3=-U^XO;NYVLRQQ17%@SN0HW\$@9P!DG)J+XB_M5?M+Z3I&K>-
|\$^#_UI_M|P_@+W\$\$?B&!_ [52V3*-)<6ZW*RI@@R,%BPB\\G0&0|?
|/MW<[H(_D1)>7,CL44%F*K_M_".>,#FO._%_:%^/'QUOM2U'X+?'[3KSPG9R?
9EN0\$,I\$\\N\\YF4|O/B0\$Q|2_M8TW|'1N3CK_P
5#G^9/YU|=LN:=8Z3^SG\\,XK"QBM_M('-

?:RPQ+'F5X\$DD)"@#>SEW8]2S\$\DUK-*/--
]S.+Z2X(UCGN1\$@D\F.JL=F7QN*J99=J]/WDA[FO2?C MO^SAXF\8_%
[PK\6_A]XDL]\=^'|+^SH]/6K;SK"\M_=F#NGSQY2>=3M5\Y
M4+Y9&^L^6/NR+O+WHG/_]^/G[0FD^--
&T;XK?!F2'3M=O([2WU;P@WVA+! MYT)9GB(19"N]@\$KT3]I?|HBS_&=|(T
)H=_XK\3>(+G[-I&@ MZ>[(;K:4\YC)L;;M\U<*<
S,S(%&W>R<2O[4GB+X1^./#_A#XX>'M(\-IK9EC
MLO&FAZCOTRZF0IMWV\F9K.;"5\$,LI(WKN^YED\L_:2T?7?%'!0_X9:~?X:\2
M'PCK,WA9VMM86RCO6M7'JHL1Y,N48L@E3V#\$CD"B,>:1/[AIK^TQ^U1X,\
MCOGX\$^#6BS>#K6S%Y?Q6-T]M?I\$8^6*>?,\91BI<&\$[%5]VT99/J3X/_!D\
M-_/P39>* "FH27>FW*CS8)/EN+68*K/#*@/RNH*#:. "'##>KJQ\R;X&_'U
M;OVE(SCIGP%I_IC_
)Z>E=#^RC^SFW[,OP[U#PLOB)O\$T=WJ4FIB\;S^RD%X MHDV[0]\?
NZB7+*)<><[QHHHK\$W"BBB@ HHHH **** "BBB@ HHHH **** "B MBB@
HHHH **** "BBB@ I*6DH _:.*_9OB^/EOH<@U:31-0TEYA%,L(N(VC
MDV%U9-ZYABYW#^*OGWP\ ?CG^S[K [C2]8TVN4DN5C:(^;"S^6)TG
MVE-PD.1"Y(PWS\+GU_-:R^(WO'_-\"*:9V;*]GO;XW5S='3]/6[NE2(P MH#L*.
A,YW-M^\\\$ 8 D-X%8_LD_&OXJW5K_PG.M"TLK&556;7-3_-L;XUH
M\$#NN5VKGJ>(IAYBSPRR_9;:<\$Y&(T_>+C(
DZ\]/EKZH7"K@=JUHJ:7[P]C+88V M,)?)7)*23_5L/:G4C#P]C\ ?V2? '\$A?
X\$_%;QUX\;ZCI=AK(*VU MOJN^(VH\$9=KA?/!P@8^6V'VX*JKX?
4=4^*EMI]C"RO+>7&E+%'\$V5_)9[K)W#:2#CCVJ'PY^PCHGC"R M>
[T'XKV>MV,;F S:~8I.B-M)(9TN3R%=3RXT?\$X>6.P2^KPH0 MMVOJ?
9_AG00X9\8?:AX=U[3M9\D*9?[-NXI_+SNVYV\$XSM/7T-= \$V[H01]BO M
OV7O@!:.!.WUB]L/\$Z>)>K?7H[62*:V\$ \$86,2*XD:0M4/G;8=|<%>H#\$>
(OVC[J3*Z%I M:^41Q<7C[L?|LTZ_]UY;XB\?>(? \$FZ/4=2N)K=AAK5D]J-
OJHX-?2X7AS&5 M_C]U>9\EC.+,%A_X2Y_0Z7XX^,QXH72V4#;[#3F\J-
LY!ER0]_A@J/0H2/O M5K?#7XUIX2\--I=_:W%XT!V685 O&.
(C^)'S#=#|_9KRAG:1F9B6900\$G)/ M'/X #*R:I^TQ?
26^RQTB*"Z_O2RF9/TV5RE]\=O&<^H C5(:)
MK>)O%&^R,^KZQ;M]Z(3S3(?J_6%:>G?"GQ?K\$ N%TBX"?W9L12_ ^1-
IKZZ6% M5/"J/PI2OUJ)<2SC_N]",?Z^1K#A*\$M<3B)3/FS2?
V=M;U!K62]NK:TA(S(O MF&21#Z +A1^#5U.G_LT:9"G_!,]6NKENWV6(1?_
!5>T*H[A#^%/8=,5YE;
M/,Pj;3MZ:'KT>&;Z+\\$?">DR6TCV1U">\$<7%U(S>9]LHPA_*
MNTT_PIHNEW#7%EI%C:3O]Z6&V1';ZD#-:*J1PNW';%2<[1ZUY-3%5Z_\23^\
M]RC@L+0]VE32^0+#&JX5%]*78NTC;,'J,=:6EKF.U)+83:/2C]*6BE9+8
M8FT;LX&?6BEHI@)1M'I2T4@\$HQ2T4P\$I:** "BBB@ HHHH **** "BBB@
HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M"BBB@ HHHH **** "BBB@#X@_P""DO\
KOA[_NZC_.UH_P"";7^N^(7^]HW\ M]JC_ (*2_P"N^'O^]JA[6C_(M?Z]XA?
[NG?SNJ_]B3XA_YJ#^OY3[M>I:2EKT3[P***** "BBB@#Y:_J^\$?C#XF?
&+X#:]X:T=M1TSPMK_-KU>Y\$\ M47V>'[18R;@LC*7^6*7[F]M?4=-95;
<&52&&#D=1Z4]/M5.5Q6/EW_@G[(- M/%_P5^#NMZ%XTT=]\$U2ZU^:]2U-
S#/B%K:W0\$-\$S#K&W>L3X% ^"O\$O[/?C3] MIGXA^,-\$FLO#=#J,^N:~?
%UN(UDBEC8%61U(PRD\$@@\&G]1=2.0_.G MX,?LR^+_ (^6>O?
%OP\4=:^\$-CXWU.ZOVT;1Y9+N3:LLBL))T>V4XN#<&,+
M&2L93Y]S,:H?'2Q^+_ [#[:%XLB^/.H>/\$U*Z>TDT/Q\$)722-<2'\$,DTN4RBQ
MR3*R.GFK@GS<#U._P""=-WX9\2:I>?"WXM^)/AHNI!6N--MGFG4LLLKHJR
M1S0DQ*KD*LGF-RVYSG%=G\(?V']-\\$^/+3QQX\9:S\4_%VGLPTNXUQR8;5
M=T;JDDDC-*KF1E8OM7S%.P.HDKK]K#?IVZG/[C_-]JKX1^,/B9\8O@-KWAK
M1VU'3/'VO_:]7N1/%%]GA^T6,FX+(RE_EBE^X&^[7U)3656W JI##!R.H]*=

MFN-RN==CY<_X)^_!_P_7_!7X/ZWH7C/1GT35+K7IKU+4W,4^(6MK=
0T3,.L M;=Z^HVIJJMG;:XQG%.:B4N:5Q1CRZ'Q?^TE^S!\1+/X\1\;_A
=,N_\$=G' M&+|2;|PCW;*#_3&9'\$6UK:1HV7="56+/AYXCL?'BZ5X_L
MAI5_"GAWPS+&M[K=R8HS;QO.T\T<4#2Y0_O4+J)\$=2DNY/M;RT#A|B|U&T
C MD#CCZ<#|J|+7Y?E'RG<..A|?U/YUI|5Z\$>S1W?L_P#P!NU_8|TSX5_\$;3?L
M5U/:7UK?VJM%,T7F7<\D4B,\8D4,DBL VU@IZ@5XCX"^&G[4_[*=I>^\$?!&
ME:.\2/"#.;C2YM1N5066YY"T2D)/#)&6VH|)ET5F!#9|PG|-HSG SG-&T>@
M|>GX4>U8O9(^)O@G^R|1_%-QTMOCA'2YLI-
;MW^6&)6,NT5|)A=HP!@9SQ2>4K#!52,YY%1|1|U|:#|FNY\ M#R_?X|_
+3OQ:;%ZY\9M'\.>\$O"?A*\BF31(=_+NUOD,BO*I02S>8)#_D;&1
MU55*L\$<|^\^N?M@?LKW_[0\$'AWQ!X4URV\->.]"?=8:DS-
%'\<1%UDVO/&AD1H MF7S(F7<3(-O|SX95N)8E!YW!;=S|_8@^3'TI\ _O
MB3X9_"_2M\$|8>+;|QMXAAWSWFI7_:_0^(?QG^'/C2/7?"NEM?>! M|:S_
'L*PK=)))*0^YYD7;-\$_%&#N5M@"
DDN4KZD5/<_C2&).*/#E_:_7,2(##/H\B7\$4K|3YC!79/*76O _CQ
MG0S:'P5HOU1X|XN_X*):.)#IT8\+>&|ZYGD1P)M9=+>*)MH\MBJ%_=-7<26_9,
M!>M=7^SG\0_C5\1_&,FO^*.*^P^!
|BSQ#"T*VB1R@)M>%&W3RAAD|F;80Y((
M*!*|J)_!_P/X+EL9=%\+;78W=K!Y%O>0V4?VG:%VDM*5W%B"023SD|D_
ML=^\$?^\$^_9G\;^'_+5+9?VAJEU;F>\$N'@=K>!0V0T>X_,5SAE.T'\%>73Z
MMXQ_8;^)>IVMGIHO_#FJL?LBW@4I=6:2?)^4*RS*'\$9)7:/;!*2?)GC?AK^
MTIK7PN^%.I>#M!TI8|K5+N6==5DN&\$ELDD"1\$Q!-
OSJ51Q(6X+8VUYT:G+/4 M_-J.(I8>O&>)YE\W-IOVL?
2/_!//QA'KAY;FVTJXBN8))7+*(YT M<&)5/"J&@8|1QF0^M?8/#BOF3|B?
X,ZM\+/"JZKK<36>K^() (7^Q,2?L|JO' MN,8D0_-'?-EW D\+'D*^|5|_
JH537;3CRPU/MN&X_,UX3X@_M:0NWR-"TM#\$>EQ>/NQ_VS3K_-
JUYEK7C3Q)XRD%G<:M/=R3A(HK90_A8=#Y
M8&U_P"U7T.&X>Q=5\U5J\$?;^4Q/%>#I2Y*-YRD?2OB#XM>&_#+-
#=ZFLUT MN\FWMAYL@V|=VWA/^!XKSCQ#^TG=2,1H.E+Y6.+B|?
=C_MFG7_ONN*T'X,>* M_\$#
(|69T|5#%7OG* @9Z_(/F&?|WFO3M!_9OT2Q!DU;ZFU0X_U:'R8A| OS?^
M/UZ/U?)\O_C3H+LOZ_4\WZWGV9Z4(>RCW?^?_/_&-A;^)?&4@LKC5KB|DG
M"Q16RX";AR#Y8&UL_P"T*V-#^#/BK7|CM9&P4!BK7KE0,|?D'S#/_^|7TSH?
A M?2_#MLT6FV5O:|B"|1Q*I(W3_=X*DH(Z:/OM/W MF/KRG(\?T'|F|1-
/S)JMW/JIO_JU/D1?@%^;_P?KGOBA*=6NM6M%\+Z+\$- M/M|3:9+
<01F60YY9V.XD;5Y_VC|U|!|1NR.#36C5FW%?F_O#\A_?E7D4\Z
MQL:WMY2YWV>WW'N5,AP+H^PA#D7=;GR9_P_*5\8?|>3_P"(O\X
XJA/@KXP MC?>FCR*_|Y;B('T*OK3;|&EV^QKU?A_6G&O3EC_%\SQ?A_4_|A
|/_@UH M.LZ!X3&GZS UG-!,RV\FQL?)PI&#&_!B1BO0PHYX'OQUIJVA:A0(T
4;0-MHX'I^@_*G@CFOEJU:5::=*_^M^*M?NO*TG2;5KN8HZH\FT?
+%O=5+N MVQ%4MAF8#O5CPEXVTKXA>%|-\2>&M1AU71-
2@\$EK=P,0K\G(;<#*5(*LIPP(M96
92*^5OV^|2N_'FH_#X)Z5<36^I^,-72;4I=,D:66TLHV"!YK=<%X=SO+
MN8JN;(G'&4|K|O;3;31_V+_&UC86L-C96L.GP6|M;1B..&-;ZW5410_%4#@
M< <5M|/X?|QAS_\$?1:R-Y:XD#%?O;?X|HYP,G^*K39KYQ_X)|J&_9"^Y8_G
M%|R1Z7\X'Y8'Y"OH_.:RE'ED7%\T2FNUBY)4"0GC_ZXY7J03P:16BW#+, _O
MUP3E2>.,E37YN^%?#^J?%\%/%CIX|C\0>, +RV^\$WAFX6.QTO2R|N;N-
Y)UM)U_MBE4JKE4D>2612Y)"JH4KL|:T7|@OQ+&\&?&NCZS\(?BAK6AZ8|W
NLZ;JLJ\$W M\$&95FD1UA:*21(Y (DF@90PW;@:WE2C#1|D1G*70^S%I&
M>#1#<&:&SYE(!))&0#T88X(-?&O_58C3_AG?0%V+M;Q/!N&.#FUNV.?Q/
MU_H_X)Z_&UM=\-WOPCUN_DNO\$7A>,SZ=W*_B?9/V?.'M5S\A|HFJPD.22^_
Q^4<9!_N|2,\&K%?F!_P %%/BAKWQ: M\0:WX+\-VPN_W@\$P7?
B"|@BC>/^T99!\$JF?>PP&G6)8CM;S\$N2ZE8@Z*G3|

MI*Q=27)&Y^FT,YF(V992,DY&<'HPQP0:M &O)/@+JEOHW[-
_PWO+V:VLK"U\ M):==7%Q/(L<:(MG&S,6. %7[Q8]!ZG-
>@^'O%&C^+M'BU;0[6L]9TJ;=Y-_I M]RLT#[68-
B1&*D!E(SVZ5\$HFG,;=+114@%%%%%%%%!1110 E+110 4444 %%%%%%%%% M!1110
4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!2\$4M(>E &)K
M6OZ=X9TF?5=9U&UTNQAV^=&Z;^VYX UOOK9>'=)
MBUG4FO;VWL(=2CLQ':-+,ZJG,CJ^ 3SA*XC_(*&>+-1TWPQX6\03FWL-7E
MN;BZ:-RK/[G5-D9P>1OF#8/0QJ>HKC?B5\\$?#OP5^)GP"ATF&/[9=:O;17U
MYDG^ER1S6?[P(TA6,LQ\$ M=#^)UEX#OM52+Q%>0B0("?
*5\C9\$S9PDD@;2*W\3VJ-*6 \$K>7#*DD!\MN.)/.V\?-A_=%;\+?K?[-:0E>
M4CTL+BI5J]:C/[!9I&.)HI'Y5A[5L>GT/FOX+_M#3?'KXC>-/#O]A6EWX)@
MAD2WU!89)(I8MXCVR[UV-YRN7-(7:JLI\$G+UWOC3PM8_"[P3KWB'X??
#_1HO M%<=N?)L]/LHK>2<%P6SL4.X 7S/+!W.8PH^8@U9_ SXIR?
LF_\$#Q=X>\5Z5 M=7MG-
B%S91J9S)"Y6.,2/\$!"R/VIJR^6PP"17OWQ&_J&:'HLJ>\$VF\1Z
MS*C^29+>2WM8'_A,C.JEUQO(\$8;/E\E0=U"7OKXVL'B.QF:UU*VL6VQKRS1N
JL\$93C<3DO&XZ+7M1 M'R]<5\=?\!\$]?!VH:7X7\3^(;N-
;>PU:>V@MT8,K.8#*K2 GJC&10/H9%[#/
MV+U6MJ;DXW9[665;E;"PJ5/B'TM)2UH>J%%%%%%%%!1110 4444 %%%%%%%%%!1110
M4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1
M110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%
M% !1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%
M %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444
M4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 VD+'T-0S2+'#NW,%_O C^M<-
KGQH M\,(I?\ M\$ZB<9"62^:#_P #'R#\6K6GAZU=\M.#EZ"7Q=##*]>:CZG?
#CH M<_C4\$\R1Q\NRCU##^M?/VO?M%ZC=2-%H^G_94_>8GF;S9!G[N47A?
QWUY[?> M(\$GCZY:::>]U>67&VWM]Q0;4R?
W:87FOI*'#N)J1YJS4(^;/D\5Q7A82Y,* MG.7DCZ-USXS>&-
!4M_-:7]HMC(2Q'F@_-\#'R#\6KS77OVC-00)&AT?3S:I^ \ MGG?
S9!G[OR+PI^N^N=_-?Q1KLJS7=K#I43",A[@X8*1EP\$'S%A_ME37INA
M_LZ^'K-=VJ33ZK,!IQ\QP^H^;_,>KN]CDV7_+'VLO+8\ _V_\$&:PTJ4?/ M_/?
\#Q*^ \0>('URR3W-J]\LF-L%ON9!M3)_ =KA>M=!X=^!/B?7)%GN[6'2X
M6\$9#W!^8*1EP\$'S%A_ME#7TOI^@Z?H0CL;&WM\$7HL,:H!^
%7(X0ISA=VI33:C)CE&S'#GU 'S M?
^/FO1]#\+Z5X=M6BTRQM[0\$C>T<2J7(Z%B!R:UQSZ&AHP5(*@J>H(XKYVM
ML5B=*]1L^KPN783"1M1H,B?>!1110 4444 ?%OQ04-
MP5!^\$61G;X9N",JOW6IC^I.OO _^"A' _"9 \0?I8 \ IPMZ\U^.C'P?_P %
M\$O@CXFU9_(T6^TN318+B/YVDNREXFSRU+/@O>6XW;/ _^C;K!JO#V6H:U;
C*L#^5?0NB_'7P#XFCOU MT#QAI/BFY LX'NH/[P]=QZC=+\$H!+++!
7=_O(OR?*F8#J:SJ0ESR'2E'DB?* _MBGJE'XL? 3Q]XC\=_L^:Y9RVNJWC7-
YX(NHXK>*7+QNL*;ML+1@M-@@PO'\$2
MB.S&K_PI_;XU3P[\0;7P"W\#7\\$\X6T\13QVR31!E*2)/GR][+(I,9;> M&64
J%SX3^WA\2/'7[1^*\$?AK\,GM_"C^'6@\3Z7%]HCB@:V M!W".4 @W_\
2.\KS7XB M>!;OX2?##X"?
M'>\$E:XUCP[X=T.UUNQC2WC6^M'M8X3*9&3>)&5_LY(5SMDC M8*!#7I7_
57_P"3>_#W_8SV_P#Z1WE>W?!OPWI_C3]EGP1H.J6PN-)U;P?8
M6MW&TS(+B&6QC5P&IW X)'K2C+EI1N+EYIRL-KWQ"D
MESXT\426.LZ[=7:LIR9);^W*0RLZ++F-6#,LA9EEDGP>:F^%/[#/C&R^-NEZ
M#XY@76?@IX.NK[4/#J:C+#=)\$!(7L;QJ[021PV\D?#?>7>A#+U92RAT/-
=S^SG\\$T_9]^%>G>"X=; MN-<-I-/)J\$RL@D>29G(6)I'\$28(7:F!E7?
[SDEGP'O+32_V:AU?:A<0V=G M9^\$]/EDN+IA%'#&+2/ OC
MOX900#MKJ&C^(-V3P_)IKTEX;1M2%@@@VX2.2,R)QIGC_
'3MCY4^3YS7UA MMV>,-6'_"W1+G0]:O-&O)=8B07.GW+P2-'Y\$Y.

[802@(0D=/N^@KSKX4_M]M:GJGBBSTOQMI&GP::>3PP1ZHK-;K:AL
O,)7=2@)4LVY=J!C\YKAJJ'N?% M9I|3J8OV56HZ')F6W M\HY\B(-
DO&Z+C.P)DDI|W*H' SCT|5\0_M5?&'OUXD^+EG\=? MOJEG<6QCR M-
+E:VGN|B2+S #(A!\$:1R1L02@&9"V0BN.M_95^-GBR;QIJGPQ^),MQ;^(+&
M+.GM?|4G<1K\;OO_?-LVR*R|]ZB5RW
K2\$H0ER'5@L3A<-6>%@F|NSEWEV/ MHKQSXXL_?AC5M>U-FBL=-
@,|RJZ!GQT\$>XC+L<*H/#-A>|>=>!/VNOAK\05 MCBAU^/1+QHGD-
GK9:T8('V_ZP_NV;'/RNO_7;|)J6G6NJV,|H>6L-Y:W\$;0S M6|P@=)
(V&&5E/!!'!!X-?-?Q*_81\%>-+BYO=#N;KPE?39*QP1K/9>8T@9Y& MB;GE?
E"HZ(HZ"MI|R7N'KXKZ|'W\,E)=GH>F?%/X!^!_C\$WF>(=,\$E\MK);0 MZC
|1SQJ^>"5.U@I.0'# \$DXY.?.-!_8(^%VA77VF\;5==46Y@%K?W;)&>I M!@2-
LGZUXOX@_P""=_BRGNU71?\$.DW|JL1D\Z\,UI*)#U 15E7'_*CPW_P
M3N\62W.S5O\$.E:99^7Y@EL?.NI?,|C+\$N/^!5S/7|!X4I5*M7|Y@M>|H#Z*
M\6_M3_"KX5V*:?#JMIJ#6UO&(-\,|H"Q;M@567\$2\$+S@LO'X;O3O_C>S\|
M=^&-)U|3&:6QU* 3PJSH63/42;2<.|RK <*V5|5X5\~?V\$?!7@NXMKW7+FZ|
M6WT."T<\;P67F+
(6218EYX7Y2KNZ,.HKZ4TW3K72;&"TLK6&SM;>-88;>W0(MD:*,*JJ.-
!P*ZH.37OGN8/ZX_>Q"C%=>D7J***L|4**** "BBB@ HHJK+< M&\$G?E4
)!!&2!U8YX % %JBJ.S.OP(?T_,#C)\ =Z@9^859H **** "BBB@ M HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MBBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH
***2@! U(?852GOD@MO-F8QHH8LSL%P!W8|OPKA?\$/QP*Z"-HO'OW
M|+9+04_ |M#\G_CU=%'#5<0|4H-G'B,9AL*KUYJ|J>C?C5.X04AM_,F=H54,6
M9W"XQW8|OPKYVUW|HO7=29K?3(8]*R/OE1+
(|H3Q^:&N#NK|Q!XF=?,U/7) M"9)FM\O(-K/A@@@7Y0 ..*^DH\ -
UW'FKM0CYL^..Q'%V&C+DPD)5)>2/HWQ%\< MO"V@KM%Z|^_9;)2Z_P#?
P_)_X|7F6L_M&ZY9<2F=M_KD;4J
MKX>_9|\3:@WG:C)!H\7|WB67\0N%_P#'|J)\.? 7PYD\RY@FU.4-&0+A_W(
M8#DJB\8)_O;JZ7')WFL-) MC%G!\$S*-O7|VN/YUTGAWX\$>)|M8=*A81D/<-
\P4C+@(/F+#_;*FOIW3
M|)LM)MU@M+6"U@7|L4*!%'X#BIS;QDDA\YXQU|:QJ<15(KDPL%!'51X5IU'
MSXZK*9Y-H?|.OA^S(;59I|4D Y23,<.>Q 'S?^/&O4=-T/3=(B5+&QM|1%Z+
M!\$J?D*N#GK@T_ITKYNOC,3B97K3N?
687+\+@XVH4|">2@.0B@YST|^M.Q2T M5QV6YZ0FT'M1M Z"EHI@)M
|4M%% !1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110
4444 %%%!!1110 4444 %%%!!1110 4444 M%%!!1110 4444 %%%!!
!1110 4444 %%%!!1110 4444 %%%!!1110 4 M444 %%%!!1110 4444
%%!!1110 4444 %%%!!1110 4444 %%%!!11 M10 4444 %%%!!1110
4444 %%%'Q!_P %)?)\ 7?#W_ =U'^=K1_P \$VO\ M7?\$+_ =T|^=U1_P %)?)\ 7?
#W_ =U'^=K1_P \$VO\ 7?\$+_ =T|^=U7G?\ ,2?! M_P#-0?U_*?;U+24M>B?
>!1110 4E+10!\Z?MJ?!F|^+'P>DOO#RR6_C?PM(-
M8T.\M=RW8DB96>&)D1L..PTOP^/V@O@;I6F_\$WPO<6+:U9
M6TVKZ#,SVYAU"LF|>7*6C7S45PIDWXVK(2R5ZR8U;&5!PWP V|?A A ?
E_N_VUJ./_1|=A+?V6_AG\%| M?EUWP;X<_L75Y;1K%IS?W5P?(9ED3W
;7FZ2XN60E6,/VB4O)Y1,8)3=MR.E>H|5|>O2 MEVC=G
SZXJ;L=D<#\5O@WX/^ -WAR'0?&^E-K&E6UT+Q8/M<|OMF"LH.^)D; M\$C
<|':Z'PKX=LO!_A_2|'TN\$P:5IMK%9VL0F:3RH8E"H"|'_NM(\$:G;19TZVFO
M+224.H"22)&45LC|I2&4Y|55?XJ|\<_P^*G@7XH1^"E\%V)66QTYHY8O:BT"
MHPC\JUQ_TQ"NP #(_RLP=J^|/C-K/@S2? ^H?\ "?\ V4>' +L"VDBN@720E
M@5V*HWELC<-GS ID<@&ODSPK;OV;_!_I->Z9_|=CDFM6M=UW# 'ZVY3F?
'QG\^ (/VS|; MQW+-)HGA^ZEV!|2**\3"Q^S8E*.RJOF<_?QCKMKLO!VM6?

CC @H%+KFA.VKZ M8BL VRU7,2JNGF N6Z[#
(NU6^X?,7:S;EQS^J_%3JFN\L==M(?AUKMA<:PVZ
M6ZA@B\$T+#+AK5WN2D #'A4 C; 0J5XKZQ^#'.?A'X'1WIT!+F|O;IR9M2U/
MRWG6,D,8T*QJJN4\$J!C(V12IQYW)I;F_O((GFALIXN\$4R,D0+.[*)A%*#M
<#HV>Z M_9#TG6?G[,?C?3M*OY-%UBZU*X2RNHI=C0.UK
REFVML&2%2S95JKI0@^5/ M,>EA,1'&48UHKQ606B2--9C?
AHJP\$>8VVRN95W)'&LC'!'?X;T_:/C M0_LI_%
;1C_A%M4'3M|CEXK:E+ED9SCS1T/GC_@E/\$@_9VU|0BA5\3SA1C@8
MM;1AC\23]2:^TAUKXO\ ^"5'_)O'B'_L9[C_-(I.OM!>M.M_%D%+X1U%%%%8
M&@4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %
M!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %
M%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 44
M44 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!111
M0 VE_&LV\U6WTRW-Q=W4-O;*.9)' 7_OH\5YUX@_:_\Z-(%G-+JUQEU/V9
M28U8#C=(?E"G_9#?2NBCA*V(=J4&S@Q&/PV%5ZTTCU4-
GH:I37R0VYDE8Q(H M8LSN%P!W8|OPKYQ\0?
M">)M2RFG06^EVOIQ)I_S/R_^.5Q=O'XD\>3&V,^I
MZSY;*K1LSSHCHN/XSGJVN!_%MKZ6EP[74>?%3C!>A\ C7XLP_-|/"0E_ ^2/HKQ
M%\<_"V@KM%Z|_)V%FI=?^_A^3_QZO+|>_:US5&-
OID\$>E9'WRHED'T)^7_Q MRH/#O|/OB74'\[4)(-'B_NC\$LP^H7" _^/5Z5X?A
@+XWD\$VJR@QD"Z M?|UN YVHO&"?|^ZNE1R3+U=WJ2_#_(Y;A-':|J/F>
75|K_CJ9D,VIZY M)F25K?+R#:SX81A3M_|*|3P|^S|XEU!O.U"6WT>
(_PC\$LWXA<+_.5|(? MHUGI-M';V5I#;01@A(H8PBJ"6>' _@/X=TMO-
O(I=4D!C(%T^8@P'.U%XP3U#|J|)T_2|+2;6."RM(;2 MWC!"10QA%4\$Y(
P.:L|0^2\$9E>T@GN8_PEB1DS|#7*Z|^W\A-'O/+LX|8UJ,P^9|JL|
M0)\$&_N_OGC;/_:SJM#N6G3RZ MYZM>\$H.*>I|FN;86KAITJ,|?
(XW_A=OO\$ _Z'WQ/_P"#FY_ ^+H_X7;\1/^A|
M\3_ ^#FY_ ^+KBZ*\SGEW/SSZS7_G?WL^Q/V%OBAXS\5?\$_6|*UWQ'J&LZ?)I;
MWGV?4;V2X>"5)H0@0NQP")90V.N\$ST%?=GMAFW#4_4<@G*>"3D|L?
11174?2'Q!_P %)?\ 7?#W_ =U' M^=K1_P \$VO\ 7?\$+_ =T|^=U1_P %)?\ 7?
#W_ =U'^=K1_P \$VO\ 7?\$+_ =T|^ M^=U7G?\ ,2?!_P#-0?U_*?;U+24M>B?
>!1110 4444 ?-G|7'|7,G|+/_ "M4S_) *FM_:JvZ_:T\CR/)
|B%|P/FBN!_X;F^+6/^36/&W_ 'W=?_(->;? \ M%=U&|X2\
|3JV..G_'G7Z&R3&'. _Y5_)!!&<#JQSP *Z>6,;:<&<|W*4CQOX
M_M8^"/VD6U&T\+S7^GZO8\$RRZ9K\$*PW)A^0B9%5W5X\R*IPV5)&0NY-
WM^*_M.GPH|CD_X*J:NG@N":+3(8)UU\;2PDM9IFL2TS3>2@5\$^T")767
M)_B;H46M:99WVF7-19210%'>6ES).UE'+N28JNR9EDW!\A!D?,-M1|.75%>T
MCW,7XG_MWZ=H'C:|&_#SP-
XB^*7BS3I6&H6&F13016HCD>*;+>4\C%9!\$I/ ME^41,I\$F%|Z1&*-Y&2-
MHYI/-R-D; "|7+.JF'_ (K^!|&_LUV&O:??|3\27UU>ZC/(N7+1S/ B
M!NNQ4AR%Z!F'(^:\PA @I-\4F^%5K|2|)BCT|QCX2O+8QZQ#\,%S|F>8J%
M1DQN99Y(I'W',>)"F"QWZ;D,^:7+SGVG6#XD\16'A;0K_ %[4KF2TTO3;
M.:|NY761Q!\$B&1W*("S\$*/N|?3FLCX3^*K_QQ*_!_B'4E2'4M6T:SU&XCM0
M5022P)(P56)(4%B!S7R5_P
%5/'9T/X4^&_"L,MY!7\$#JISS&S<%5J*=/GGR(TE+ECSFYJ7_4#U3Q#?
7,GPN^#?BOXB>'; M>9|5M8ACN(4:5&&<>7;S|059""OMD(?YHTP
WJ7|_7|7|/@_HC39DT(M|""*74-\$OI%:4*ZKF2%U;\$L0D.SS >/F1-
Z9|,^'|/@'1OACX T#PIH41M|) MTJS6U@R K.%&&D=D
4NY)=FQEF8L>37QC\>O#|S\ _V\A3XS\ (VUAIMKX\N
M!IFIV4\$DP6ZN'N\$BND)8T(4!UN('##@RP%W0L"7N*C+W2)./6_C!^U9\1 M?
AK\0|7\Z'\!?\$WC?3;'RS'K>GM7\$@/W17K.-W2G*=/FTB7:7*"?
B|_@HMXZ"Z9'J7B;|GGQ M#X=M'F^SQ7&I7|H\$SE2P7?+9A2VU7;_
(#7<_M4?%3XC>\$O@Q\//BGHYOM\$ MTVSNM.O_

!5X5'E\KPRO;R>4\\H\$!8651;BIN873;EVJ:Y+QOJ,'[87[7>
MB>!:83W/P^^&\$[W_ (A%Q;2+!=ZHK[%A8,IBE4,IB =5+H;S82N&/UUXV(V
M'CKP5XB\.:@|T=AK&G3Z?'?\$5C MXJT&PU[3;F2[TS4;.&|M)D61!/\$Z"1"
RDJ?N]?7FMW^&ODS_@FKXG/B#|
ME^QT^2R^RC0|40-.BE,@8SJ|K=;AW7YK@I_VRSW%?
6O45C4CR2Y6:QES1N+1 M114%A1110 4444 %%%!!1110 4444 %%%!
!1110 4444 %%%!!1110 4E M+10!\\5?
\\%%EOYM)\%,GVK^R!/= "Z,)8V\4A\KRWD7H6P)0I/(!DOT.?3?#_ | M'?P7N-
%TN6VT?
^U(9((Y8=075KAC=!E!\$H,'|#TGP/:F^TPS37&JVT<\,+S2*8OLZDR.N5'[PD?
[*>@KYWTCX"?M(^';
M"+3|+@US3+*,EH[6S\2QQ1*22Q(59P!DDGZFN&5HSD^2Y\9BG[+'U92H.I&
M+YGU>G|&/P@!R/"A'M_:=X.V/^>OI7MZAMJR?F| M//B#K?
|_%_Q(2>'_\$6CMJEEJ,L<9FA7R9Y|>.1EAN;=?F5@R.X,6F8G)5HP#M8"O(
M/#?QB_9G*ZA|JM/AKK#O);B%3?VT5W%L'?
9/%/!^N^M4MY+8>))H'M+:8;0|O&&,2?_ \
:;&_.'K^V5T&PU.R_LORA.-4B2/=YN_;MV.W M_/U,ZV%ZD5VTU'DLC|+
1H4/&.'=XCZ***U/0"BBB@ HHHH ;UZ5X/^T|\6 M/!&E !_XG>&|KQAHEKXA?
PSJ,*Z3-J<.=YO>S;8OE,V|MZ@R&XNFU*|B+-&@B0A8Y@|@PJ+CC/RCTXJ'+
MS:D2V/G#_@FK\6/!/(@3X\$ZW8^)?&.A>';IO\$LT\5MJ>I16LCHUK:@-ME8-
MW MAQ_P"OO\YZBOG'_AWK^S^,?4!T78A BS:YOKR"SA_OW,HB4?A
CQ7GWB#|H#PUHTC06WZU1O-6M|.MS<7 MEU!;6RCF220!?
^^B<5\YZ|^T%XFU\$E=/2WTRV/= %\$TX^A/R_^.5PUM8:[X|U M_-J&LW;:
(C,0T^QVZ;W_P"6:X|-MKZ2AP|6Y?:8NHH(^1Q'%E#FY,'3E.7D MCZ\0?M
^&M&D:"SGFU:YRZG|,L,88#@M(?E A LAOI7G'B#|H3Q-J3\$?:'
M;Z7;'O&HFG_GY?_!RI|#_9UU_4-K:E=QZ5!C C+B60>@(7Y|S9
M.P(7"X^C&OHRUL;>TACAA@CABC 5(T4!5 Z = *F;,-U KEK<1XB6F'BH+T
M/0P_"F'CKBIN;|3S7PW\#O"F@8E-BVH7!_BOVQ?^^!^|_':|)%M;2WM+>.
M*"".&.,!4CC4!5 Z #L!3E4_|.*E_AKYNMB*N(ES59-
^K/KG^|G/6@ERY2QN/M2?G^=9.L^(M+\\VZO9EBB7ZLQ_%<
M=J7Q^^&^FVEQ+#_X+KO\^-5Q)_X*)?#[MH7B?_P&MO\Y(K/VL.YRRS+
M!PWJ(^JA|:/Q_6OB:^^X*1P+=7GV#P,|S90S>4DMQJ?ERLO|D6%E'_%W
MKF?\$_!1+QC->+_8GAW1=/M?*PR:GYUPQD|=ZM\$ O_*S^LT^YPSS|
PWF_N M/OX?"_GBOS.\0?MV?%?Q%|E_L^|TGP_L.9/|.M%?.|H?SQ)G_
+9XKD|? M_:H^*WBBP6VN?&U_D3>8S68BLG)V\$?FR3Z8X.<56U+6+?
3;2>YNKJ.SM88C-)^*GQ4T_4-
/LKSQEXLL5^6XM4FN+Z(|N5\$J%F"8QW!JOH'I._P 3/\$UT
MUM;>=":@*VQRVJ6C6:>6>J|Y=B;O^!5/UG^XS+^WJLOX6&DS|+/^%\\?
#@?\\M_>&?_!S;\\Q=<;_P-G?"_H;_/RFW?\\ |:KXNL/V,/C#>7UI%+X=CT|9
M)=DUU<7|J84C_O,%D=E/^XCUUH_X)|_\$D_\\,5_P#@7UKO|D)_M
&GFD|J|!YK7|?OPXT^_GM;T\1:O#&,B|L|!8XCQV\YXV/_ 'S7(>(O^"CN
MD6DZ_P!C>|"J2U"\\CS#)>7(MI=_|S:J2+_X|64O_3?#_ \$#'_4&^Z*Z M|3?
^">7@>&&"2^U_Q#-?1I^|FMIH(49_|P0QN0/8N:J^(|&G-GE;X(QB>:^^)
M/^"C'BFZ\K^P/"6EZ;Y3?Z1_:ER|SN'HNTQ;?
K\JZB>0N#J5J+N4\$_PAY@S!>/NYQ3|C6_G#ZAG%3X\0 MD?G_*Q^UI\6-
>L9;&Z:WL%M-@F2VAM|:0X(?Y9HD1X\ '!^8;Q7/V7Q&^
M)OCA1HT/B7Q7XBEO(VCETZW0|FY9T(P5:-2<@CJ":_5GPYX#\^\$?._L+PH
M6B"?;YO|G6<<'F;<|=VP#.-S8STR?6MOR8Q@|5R.G
H|A+^87|@XFI_&Q4GZ M'Y&:?"?B5J6H6UDG@?
Q\$LDTVV)I=)>%\$;U>21515_WV==_PQW\8\H3O_M
"J6O_QVOU&|,|BC\#1|5CW+CPY07Q5),_Q?^">_P 2NVK>&1G_*>|C_Y'
MKJ/_P""<5|/;0-J'C2"WNGC\$DD5MI1DB63N%9IE9A|56ONS.*;+=-I 5=I.
M2,<&J^KP.Z.08&.\;GR1H_\\P3R\&PV=NFK>(|_M;? 7P|\\K7PG;:;!-?

W7]H37TMW?:BZ/)M7[-M5=J(@ W/@8XW/[5^
MD^SG).:_P#B/A&O!_Q;ETY_%6B_VB^EB7[,6NY8?+\$FW=CRV (;RU^]TVCI
M1/#0G#D1GB\EP]3#RA0IJ+/R1HKZ;\;?;\$#IDCP;KLFEP>%M7\1-;C;- =Z->7
M\$EN/GP KRW,?F@_WXJR>C-1X)^('I' C'78]+G\+:OX=:X^6&[UF\N(I<_O,
M\$, \5S)Y0']^3:OJRUU_ZO9CR>T]D] >C/B_[\$ES>S]K'IQ_ \P3W_.2T:M_V M
)/_ \$H@K] \$&;YLJ7FFZC\$(-0T^:6UN(E=&^S2J=KKA =P5^ W<\$EWDD+
[\$7Y,9R;\ +VTO:\C\E_M.I_:7UOV?O?U\$ _9#PUXPT
MCQA9SW6AZM8ZS;PMY;3V%PDT8?:K8RK'LP _MS!P>:\V^!/PNMOA#\--*\-V
M\<8N;>(/>S1KM\$]T0#(V=B;E! 56/.Q5':O2<@"O<6Q^MTG*4(NH(=2T44&
MH444E 'YS \!7:[WPF _BW_ +9UW>I_L" _\$[6=-N;#4/VF_%=_874;0SVMS
M;W4D4L;##(ZM?\$,I!.01@U+_ ,%%OV? _!Y\>&^'R^"=";7#I7]H?:BEU!!Y
M'F?9MF?-E4-GRVXK]5XZ5U>TY*4.0YO9\TY'BGP' _93^'O].<+R>\$M/G.KW<
M307.LZDXFO98RYD\$8.%5%!*Y\$:+N\I-^XH".*^+WCK]J#1?B!JIE\.?AQX<\
M0>\$(_+^P7^HSHDTA,
<:/O#WL1X=I!]S^&OJ%HU<8958>XS08UR#L!/TK!3ZF MO(?
&' "SOVUO^B0^"O\ P-C _/EA72_' +2?' _P 3OV&/%*^ _J/TOPYXS2QEU
M#4;.WD#6L<=I=^?M5D>7YC!"/X_OLO=@SM^J]U5U'2]+6-/N] &_LI>]LKN-
H M;BVN(EDCFC9=K(ZD892."#P15*I9B]F?.A P3SO(+K]D_P?%%=17,]M)?03
M]R87^V3/L;'0]9\$;GLPK&_X*.^*+;P] ^ROXALFAE;37;VRL;=8<- \PE\$^Y\
MG(79;.!CN1GJ=O#V/] /GOR_9A3>(+KX&+H?B_PAKEXUT_A'4V,)LI'9MLJ^
M9.N=D44,)E[=)O.Z(^6K"KX?_9G^,?[17QBT?QY\?8M-T+0-#G"VGA"R>*]
M1]AB5PFS;J^6R:6CS\Y'O)UMHU=&4_,&##!%?(O_!6CPK=7WA'P%XC62
6.FWUWI\ M3\$^HK MI]S*"@\EQ,9(HI#;DW[U.Q]OR>I?%KX-V?
QN^%>J>#_%KZ?.ZMG\$J3*5&QU...^*?VR->;6OV0OV=O">EZ??
W>IV&I1ZS= MI%)\$:"2]@^ [M.8B&0O*\$"B4 &\$"+\$2("J%ED
1Q48/GN\$G*2Y#ZVEG,.] ?E M5)!!&<#JQSP *^#O@7:?\-=?M@^(_BY>Q+?
>!!S#3O#8FMCY4\R\$F)U+P+
MNVEI;EMW[R*2:UY.VOH+]K VW^(7B+X/ZOX3^&WAF77=8UR%[*XO3]
(I8\I,8"+C).,=SU/ZFO#_VN_CD_P\$^! M>L>
(+:8VNN73+INCL_' ^E2AB'.8W4>4B2S8<;6\H*?OX/N7W: ^./BQ\ \$?&OI
M1']5/A6\5^&FTKX0>#06MXKNZL93JLXE#EO)7S&\$4K10_QS8!BC; CD;;6=
M/EYM1RV.T_89^ I^! _P+L(I2LDB\3:Z!J6J9BVRQ;\ ^5;L&C211\$A&4 M< X-?
2+1J<,5!*@\XZ<8H6-5!^4<\GC _#[5XQ^UE\3K?X3_ +/?C#6]C4YK M"
]EL)M/TV2UF\FM>"?L7?#.I^\$_[.7@[1]2LHM.UNY@DU&^ACB,
M,ADF=I%\$RNJL9DC:&)]# 'M'RJ!7O5.K+GG)BI1Y8V'T445F:A1110 4444
M% % % % !1110 4444 % % % % !1110 4444 % % % % !1110 4E+10!XC^T;\?K/X%
M^%8[B*#^T=?O]\5A9G(C4KLWR2'LB[T^4?,V1CC\$?"B"%DTW1Y]F
MWNL;BT?GK'LE)VG"@Q%=WWMTB8ZFH?VJ;_4M; ^'/PD^+EA81P'2)
]74%LYD, ML5NUPD,B-)(NWY5>*.+H-WFCI@!N" I*^_9W_;&U+Q?-
XGFT^ ^3Q%). MUP^J0ZM;021NR>7LB*395-F%P#C'2M?_A4/[4?_ #\^)O\
PK! _D5YT;1W MIGP&'G&A2<;N%5G8!YC'^\
MW3'4UW^ [Y<]J^<_V1_"/Q2*\-XJ/Q*N-6G686IL!J>J+>XV^=YNW;(^W[R9]
M<#TKZ_.=O09KNA)]C@Y*=" ,E#D78?2T459WA1110 4444 %,.-&P2BD\]1Z
M];?10 F*, "EHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHH
MH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@
M HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "
MBBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH *****2@!,FC-96JZ[9:-
M:-'P M>(Q3M2IMGFXC,<)A%>M42/6MQ'M6?J6N66DV;7-
] >V]E"/X]F41*/^!'BOF? MQ+ \=/\$>KR/' ;WL6G08D8QVJ8D"\$84.[
[A_L;#7,6/AGO#X]O5N(K"^U6?'% M^Y8Q\>DS'] ^7IL4^
MJ3=F+>3%^);YO_'37F/B7X] ^)=6=HK:]CTV#\$C&.U3\$FPCY0[OR6'^QL-;GA
MW]G/4KIA)K.I065MA&\BUC#2;2/F!D/RJP]5W5Z7H/P7*>'U 333?3=? .NS
MYO/J%(V_05T>TR7+_@3J2_ Y'1S_--9S5.';9_@?-.GX+<)>87VJW&

M.+^1F,?I*W'_CU>@Z/^SIK-S8H^IZM'8R (/+MT^T<\$?,",(%P?[NZOHQ8U
M' 0#*3E2/E%<-;B+\$STP\5!'I8?A3#1_P!ZDZGJ>;^&O@?X4T#\$IL6U"X(^
Ml?MYB_\ ? _= _P#CM>BVUI!:6R0P0I#!& J1QJ%50.@ '0"G*IS_ D5+_#7
MSU;\$5L1+FJR;I6?5X?"X"?#*U""!C5NJ@_A2A0.@I:*Y_,ZQ,#TI:**8#=#Hl
M*6EHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "
MBBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH
** M** "BBB@ HHHH ***** "BBB@ HHHH *****
"BBB@!OXTN:3IUJL905;#MOU! MSQW|CT-,AR4=R?^/^ U'M(l3.6(H0
MWFOO/4Z*^>M8_;C^%>GZ?=75IK-YJT(^6QM-.G25_IYROJ?Q85R=_\%\$O
M!*V|V-.T+7KB|A@,BOW\$.,<6_LK,LKM_WRK5G|:'G_P"B>?\ E8'_ ,8KB?\
AX9\1O\ H%>% _P#P%N/_)(J/K-/N<,\ M^P,/MO|C|S0!
[Tl:OR|U#|L|XNW%|=SCQ-|@\$DV^.R@LK4QJc= GF1&0?|M"
M:Y+6OV@/BAK5Y/?7?C?7A=2*A>*R09+.\$*\$P'\$<3A\$5A\QV|3S67UJ)QRXFP
MWV(2EZ(_65KAU5N.:S/\$7C'1/!^GF|U|7-/T:RW>7|JU&Z2WCW
M'_ :8@9K|K9| "^*GQ0M=.OKNR\6^,+ #YC!=-
!=WL29^|M;Y@,| "M7PW^RY\5 M_%&GK>6?@_4+:-KC<%U01V3;_P"|Y;
(P_A7=&JG/^TPKYA_#G|"004UK|7|ILM-|/|"/*.I7R0NSH'
MD"3=C_ ;VUUOAW_@G;XKN+HKK/B+2=.M/*\P2V7G740F>A1EB7'_
J/:5_P"4 M%F&;5O@PZCZL|:_X>)_#W_H!>)_ 'MO_DBN./_
4BD_Z)TW_@Z'_QBK&A M_P#!.2QAOK=|6\>75|8Q_P"NAM=,6UD?Z2-(X_\
'*ZK_AW?\. _^@WXG_P# MBV_ ^1ZRYL1V"V?
3V<4>,:E_P42\=OJ\$Ql|&\.06,TG^BPRQW\$KA/1H!(@=O|
MU!7,ZY^VY\6M=NEELM5LM#(A\LVMA91NA?\ O?O@[YK|&'|&OPA4.A
A%&/ MF-O?_B:WGS-ZG|IR:Z*Q^ 'PUL;_UM!X%\W\$<482,W.F0S2,%
&YW="6;U) M.35>OK_SA_9N;5/CQ"1^<_B/|HKXJ>)_WA6|\=:G\$D.|LI5L&&
|"G<8502<@ M8SG;|4HY/BE\5M'4P1^,O&&CK/A9?-O+^W\$@_C!
(9=PSUQGFOU?T7P|I7AW M3H=/TK3;/3=/A+&*ULX%BB3<2S;44
#)8DX|DU>\M/|@'.>E:25O|PO|J3_ M (F(D?D|X=_9I^*?
BA;L;+P+JEL%;;.NIHMD)?\ =\W9N'NF:Z|P_P#L1_%C
M6+QQ>Z5IVBDP^8;F|NT:)I|O|EG;TQ7Z;:1SUYZT;?K2^JQ|FT>'_,OBJ2
M9^>>G_\!/?QW)?6J;AJ^A6UD\NR;>UN)Y943U1&A56/^ \RUV_X)PN?^:@8
M_P"X1_\ ;Z^W?+7>6P_QX+8Y-+L%5|7@=<,@P,=XW/EG_AWGX :17;7?%!=1
M@-|HMACV'^CUTVF?L6_":WLX(7\2WI6V6!KB:_N=[;>N|9*%R>^T#FO?_PH
Ml.*V|E#L=\\|"D@AP_U_8K=RMWYEF#.V/)2I\$ M:J-
J_*!Z#VJ2B@!IC5FR5!/KB@1JH "@_*=10(2C:/2EHH&0A1VS3OPK%
M\0>)M,*Z>^I:OJ=MH|BA"M=:A.D4*%F"JI9F_RQ.!SWKRGQ)^V-\&?"|X+6
M|^(%E<2>7OWZ8LM|&1 _=\V%'3=_L|MU;4\7K?PHM^BN92K4X?')
(|P&:=NK_MXC\4?\%0?"-C;:/#_A'6|1U#S?+|K5IX;.+9_>WHTK?
CLQ_M5Y%XN_X*8_\$7_M5X|Q?#GA|1=!M;J'RK62ER^KL_M>=/_,+ #>1^F^|Z
U\A_!1+XN77P_\A9:>&=,T5[XK;5);B_G_M(C\$9XP_MP==I?S\$7D,I0RY&6%?
\$7BK|K;XO>+OLW|H?;\$;6(/LH<#^RY\$T|=NQG/V94WX_MVC|_-
WY|O4UR.N> O&B6(\9ZQH'B_6-W_Q,)M>U&PN/LY,T@9)))V'S|Y)3
MB0M\^2<"O|NX7^JXBG5QM6*_NWU9Y.)S5UZ,X48,Y3<=H7/RCH.PYS_
#HW M':5S\IZCL>< SI**_5.ENA\?97O;4_0G_@FA\8KS5-
%UCX=ZA/#Y6CK|MT>%_M(?F,958T=KGZ/E6T:Q66L?Z!M0^Y=(
MAIN7);?&I&U5"J(6)R9*QOV%_A+)XT^(5YXOOX4;3-"V+;O,F|)+Y@2HY3:
MWEABY"N"K&\$@\FON'XH^ K?XH> M;\,WDGE1:A_8O,V,WD2
@QR#YDR\$< *^W_M/S;<=*S/@7\,;;X2?#G3/#L*1M>01^9?
7\$8VBYNB,RN3L0LH("JQYV*H|5Q>_MQ_?<_0^3ED\?|3^L?8W_
_WCTCRT!SM&@HVCTI:* "BBB@! **6B@!AB1L913SNZ=_6G;1Z#UZ4M%
#3&K8RH..1Q0_M45EP5!'IBG44_,6)%&_B@?3WS1Y*==BY^G^?
04^B@!NQ2,%1C.>GOFD\$;!*?M"2..YSD_J?S- "|%P1M_M&,8Z4M+10_4444
%%%% !1110_4444 %%% !1110_4444 %%% !1110_44 M44 %%%)0

F:3FE%5FG==@R"W"X^;UQS0)NQYK\>OB%X2^'?@26^:Z;_:^D
M74T=M_9GV1;D3RY\Q1LDPIV>6\FYBH
CSUVU\WWG_!OZ+4;6>UN_AC#=#6L; MPRPS:JKH\;C#(P,&"T'4'@UL?
\%#O"MYJ7A_PIKMO'(UAI4TIK=-&K,\?G&) MXI./E6/?
68K\S1C._:JH\#?"KX1Z\X5T04-(\)>&=3TF6",V\TVF1.73\O
MS.ZEV<\$?,'^8\$\$-S7+)592TD?+XBKBL1BY4L/448Q/B7PM\O=-^N0>@
K2E%P6IW9;A:N&4E.:^R2(IK%=V3N/R MU\1?LYM\>A\?'C'_A*/I&
O/I2_M(M)\@&=Y'EC'E#\X(=GDL?E+XPI(KI>8_M^6I(&37Q0?\
@H\}SCX=8SU_XG_^,45>7W>=V,\RJ8:E*G/\$5"EV\SA_\
MA;O\40_Y7^M>YMR!S\FO0I?"?99>X2P\?9R+--_. MPQM?7T%J'#;!--
*%9PHR0JGESCTS7G/B#\H31M/)BTRSFU6;LW^IB_%F^; QV MNRA@<3B?
X,&SRL3FF#P?\;HD>Q;MHZ_G6)K'BO3?#T4;7\;V@8-M\$TH5V"C
M)"J9@%)#\PS\5C:1X*\2>,+A MKNQL9\U)-S=39PY/WCYK<'/^]7TM'AV5)
<^_JJ*/DZ_%?/[F7T749]=K7\1 MFBV?VJ+3K2\U&:,91V40QL?3+?-
X\7FGB7X\(^)=6=HK;\CTV#\$C&.U3\$FPC MY0\OSN'^QL=-3H'\-,TK!\;U5-O
#RL4Y'_,\?^.5Z#I/P=\\(Z(\$*:6DL MHC"^==,91N_O;6RF\W
S6GM\EP\A.#J,P^K\09E_\$FJ<_VS_/FVO\.>('/
M5XMPEA?:I<8^6_D9O+X\I)6X_\>KT3P\^SCJ5Y^JUC4X+*VPC>1:Q!I-I'S!I
M#\JL/5=U?1:QHHX"C*1E'R_*IP*IKR/2PW"N&AKBL.IZG
MG_AWX,^%_#^,:9JMF'/FW?[WGUUVGY?H*]
CC6,850H\A3L;NM+Q7SM7\$5<1_M+FJR;I6?5X?"4<+'EI12^0-
&C8)4\$@Y'%+M!&".*6BL/,ZQ,"BEHI@-VCTI: M6B@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** \$%-/U-
*":A:95Z\OTID2E%?\$2<^J&YO2N&O?C1X%TR_N; &\;Z!:W
MMJWE36LVJ0I)&PZAU+90_6N1U\JKOX1Z%>W%E<^,
I=Y81F5\2">YC_"6)"GY M&H\I\$PEB\/#>:\JXI,>I?-.O\
I>GPWT>\\NSCUC6HS#YGVJSM0D0;^I^ ^ M>-L_\!KF/\$G_47\+V=J?[\\$-:MJ-
IYWEB*^>&UBV_WMZM*W_CE9^VAW..> M;8*&I1'UW_GK2\?YKX1U?\
X*/ZK-8SQZ7X)M,*^D'^CRW6HF\13_MQHB'_M,?KD\1_X*!?\$RZM+F%=-
T'3MT)C2\MX9O,#M\TIOD*_C_:%1\9IG#+B#_0^MV_N/T:&?>@_C7Y;-
^V\180+C:3QE(KR?ZL+IUGA_XNGD\$]*Y.Q^+WQ-U&\M+
M.T\;>*KZ^NI#!'9P:WQC_CUOM2ABE_%78&ORYOOA#\ M3-6O)
[N]\% ^+;RZN)3/-//I-S(DAZNS%,EO<\UT^F_LD?%K4K:*[C\))7B&X
M@#J);NUA<*>SD)(KAO\?4FCZQ/I39F\Q.- M-N?
-.U/[++WNSC_EIY(?;I7Q7(>(?VY?A;HMCYMEJ&I:[*])/+^QV-C*DN\IV
M9Q&N/^!5\Q:'^P5\3-4M;&YNGT'2)6_UEC?7K-+%])CD7\GKLO#O_!.G7+J
MSWZW\XOT\3K\?L^SV-HIY%Y?^ ^SQ-G_@-7S8CL+Z_G-;X_.H^IW.M?
\%\$/ "5M M:WG\ID^&M>O-1A_U=O?&&VBD_X&KR,A_O@UR6I?
\%'KUK.3\#X,M(+F6/%N\ MVKF9_8F,0H67_=>NBV_P#!.GP_:_?_
&\XOU/4/,/[C^S+9+78/IK>9<_5_M=E=;H?!\GPPT.[EN+Q]9UT2V_D-
:WU\LOCU/D)&Q/U)JK8C^9!\!/:WQ22/I M?^'AOQ&_Z!\A?_P%NA
Y(KAS^V=\8S_,SA+_X*K\A^,U\PZ+^R1\)=!OX_M;VU\VLD\?1+ZXN+J-N-
O,4TC*?Q%=@/@;\./^B?^&/_36_P#\16?L:_\ M.'I EYM4_B8JWR/S_U#X?
\$C4;VN;CQOXFCDDG,\S0ZG;/PHI=\$CC1P%3V_Q
M3+OX=_ \$WQM/%K%UX5\4^(WNXO/.J36<|R9%884+(1^ \&.G_XK|=5A1?
X%_*C_MRD7\JA1C;P_/2M/JW\X4>'Y2_B8B1^56C?
LG_%K7+.WOI;P5<+%, "8TNI\> MT9,I=\D:&WF^7\FO+S=.(_7,,'O\
@G;XCNO M+>(/%6FV/EG\U_9UK)=;@1\VI=Y6_MW';,NKL-
"_X)TZRAV/0CEV\$C_RZ1Q*_M_GX;!\M'EJ6R5&?7%.HH&,6)%555%_7H
_E.VCTI.* \$VCTI-B^E.HH\$)M'I12T4_M#\$VBC_I.* \$P*6BB@!,"C:/2EHH
***2@!NXT9/I7-^)/&^@^#I'9K^O:7H_MMDTHMQ6MSXR34-
2M81+JGTJTEN5G_M;R\X6*1%,+;ON\R84G!9:Z*6%Q%?

^%3D_1/*M2AO,^@.,TN37PMXH_X*D^& MK3I)_P
(SX*U;5M|2>=_:URECY04?+M\L3|_P"UMKQ_Q;_P4J^*&O+>VVC6 MNB^&
(KA\VTD5J9|RUC\<P<,\KF)CCY-WE|6SD!*|W#<,YI7W|OJSAGFF%A|H_M_48,2
3%8'B3QMH7A"Q%YK^OZ7HEDTHMQ7GQ\003"(6Z#2|K|#" -I)>.!43JQ^?
|VW9Z"E_LK_!>\67PL_M|3X<:|;LL.\'5+46:!?023%\$W>V|=[UZA>%8T?A?
L5&'|?(X/|8E4_A46S|_M)?
&'|;WP@\&RWEK<^,TU'4|6\$2_9M)M9;E9V\O>%BE13"V|H,O,F%)P66O&/%
M/_!4OPU:BT_X1KP5JVK;VD\|^UKI+'R@H^7;Y8GWY_VMM>,^\$_\
@FS\3=92_MSN-
5N=%\.)/,5NH+BY>XN+5/-6\$<;M&QV_O!^|Y)PS+S7M7A;_@E|X=MOM/
M_"1^_|6U70-+ACLO)!W;O,\$V_)Q@C9BM?JO#N#?|ZM*IZ?A_)|MF=;X
M(\OJ>,^+O^"E7Q0UT7UKHUKHOAB.XDW6TD5JT|Y:Q^8.&>5S\$QQ\F|R|K9
ME>6>* _VN/B|XN:Q:\^(6KVS0,XA2PG&G&5CMW(WV=461EVC&_IS_
'Z_1WPG_M^Q3\(\O"-I#@%R|L=JY/7@>E+^W,IPO\NV"7_;S_M
'.*^H8ZI_\$K6/QWM/V=_B_XU\4%)/_OBF|U:^D:X>^U.QE@5I"V|GEFN_B,
MQ;YLEB2>:|+_,\!7XN>(\$3WT>C^'P9?+%EJN|S\$>7Z_Z.DBY|_|&O
MU86,+T&!Z4A5>A4\$8QR.U%_P#@EMH%I<\$: M|X|OM0L?
+VF'2|".UD\S_KH|2C;_+_S/O7KO@_|@WX.>&%LD)O#DNO7MM/Y
MZ76L7TSM(WFF3;) \$I2)D!XVF/#_ \$'O|&^2G(M>FWIV|*-HW9PH-?/ULZQ^
M(^.M+\OR/1C@,-3^&!A^%?AQX3\"_:?^\$;\,:/X?^TA!/ _9=A%;>;LSLW;%&
M|;N;&>FX^M-|9>#M(\>>&=0T'7M/BU#2;R(Q7-M.Q"%20P8-
U#*5#!A@J0"" M"!724FT9S@9KS/:3"?
^"8WBB;6T_P"\$M\3Z5;,+&0)ET9Y9KF;| MYC:GFI&
(CC/SG>/|A|_2,*HZ*!054|5!KZ7_ %HS;V?L_:?D>1_9.\$Y^?E.+
M^%_PWTOX3^"|)**:;%/#I>FP&&-KB8R.S,S,SEC_!LS%CCY03A0!P.V_Q30
MB?
W5|H|O7K3L\5\M.;J/GEJV>RDDK(6BBB@8QH8VQE%..F1TH\$*+@A%!SGI3Z
M* "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@
HHHH M **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_MHHHH **** &'ZXKYN_:U_9|2_'1O#7_CMWIEG_9OVKS_|2DD3?
YOE|=I1_M&Z;&_P"^O>OI%L8I-BX&..E9RCS'-B*"Q,/9R=D?G6W_!/?
XAM/+MU?PPWF_M',C-=7.|. .,0=0#^H7_@GE|1E;
<-7*@KD;A=W&1GK_R|5ZG_,%#_%5_
M|_AGPMX<@F:#3M7DNKBZ*.5+"%\$ "QG!Y!?:?=@|T!|5|0>\$=)NM&\+:-
IUYJ<_M^JW=A9PV|_<_B6|D1-C2N"2|=A7Z+Q_*H&4|C<,NQ(X=B/
C/E8UE6=N_J^|@CED*-&I6H4DUR|ROM'7%<.?@5\O^B?^%=_
3V_P#\17<4DG^K_M;Z5M9/<|V<(37OJY+?'SXS?#?
X=Z|JGAKPM*_!VJZM8L8;C4;|3;86<+|8_MV^1(QOEP'=7^9/+9?XJW?
A!KWA7QE\!?!%?CS5_A9X/O;_0KF;_0='T>WA6;) M((93DRY(\$K\$D?-
A1M1FPK--0BL/&-XR0VRZM,T-S--) M(_VF-MX>S_8W\=:5_-?V??
%&KZ|>|;VUKK5PT2R2QH|P_MRV<#^5%O<*SMM90"W7/-<4)>^?\$X;JZE6-
:I*/++FM&R|VW<|8_91\9^'/B%
M/VUS10"FE>\$|2%Q|CU.WTFWCACFFC3<"NP_LA\$H8*QRN|AS|YO>
3BLUP6#7|ZHEZ:GMY.!_C6)K'B03?#T4;W|_;VH8-M\$TH5V" MC)"*
(/C5XKUQGA:Y;3X&QO^P_QD|3N.QS\W3BL72!/B3QA<-=V
M%<C/>K)N9KJ;.'S|X^:W!S_05|'2X==)<^ -K**/EJW%7/|F_HNHSVKQ#^TIHN
MG_N|,LY|6GOPY_<1?B6^;_QVO+_ '\$QJ5^(HY(SJ"Z0C!8GBLP8R6\S_*2'Y
MAN|H|P|^S=C:#*O#7AF)#9:1:M-%Y9\$U_MR?-=2O(.3G:?
I6OUC)\O_AQH/OT'_ (YOJF?9K_!ZGLH=MG^!AUZ1X,\2>_M+
|AKNRLHU92S&ZFSAR>|UN"3_05Z=X?_9ON)^@#T
I#&#QV|*X<1Q#B9Z4DJ:\CTL-PK@Z6M;|3U.)\A_PK\->&85-IH|
MHTT/ED37|QU*\@|FSM/TKME54484>PH"J.!@_ =!3F_%;?_U*U2L^.;N?64
M<-1PT>6C%(=M!&,#'I1M'I12UB=0F,4;1Z4M% "44M%!1110_4444_%%%

M!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %
M%% !1110 4444 -+5YK\10VA/ OPJUB+2?%&N#2[Z6!;E83;S2DQ,S(&S&K
M8Y1ORKT#(9G 9CC[P.>.,<'..U?GC_P4":-OC+I+*5^30(D/R?*P%Q/A"?7V
MK"O/V<+GBYMCi8##>U@KR/J;_AM#X0_1#?:_77?_QJC_AM#X0_1#?:_!==
M_P#QJOS HK@^N2['Q7^M&*_D1^OWPY^*7ASXL:-@:|_,%'K.WO+G^R?
IQ>:=\$/DN+[4TMI'/LBQR+_P"/UVQK MPY;W/K/6C(OLQ)GWVD^'JA_>?
V=:*^=WW0_GB3/_&SQ M1]9IF,N(L NK^X_2X&J\EQM#EY54;=W!&\$
ZL2>U?EEK'[6GQ8UZQFL+KQK> MV|M,03);0V]O(V'^6:)\$>/!P?
F&\5C.;XV^*7CU;G3--UOQEXB,UN7GTZ M&^N|O?&>"K1|CE3GH3BL_K4?
Y682XCH_NZB/UJ-P@ZN1^5<2?CO\A MHH'AC_P<6_+|77YD:+^S_+
\$;7+R"QM? VOB249C>ZLIK1\$ _P!^28!/_'J M#3_V;?
C#>WMI'+X"C_@GC|2=K+_WA8!N&'VNXY^O^C5U
M.G_1\$Y+Z:UMSJ'CB&WNFB#O#:Z4TD2R=U5FF5B/JJT<^(I"^LYW4^"BH^C
MPYO^(O|_@HYI-G,O|C>"|1O|7R/-,EY?@ZUM;:_^T_\$NNWNHQAZ?Y-
J87^O2>=|H^V:A?2))G_MAY:8_"MGR8C^9J.>5/CFD?,^N?M|?
\$N^L;NUBCT?2';_5WMC92&1?IYLD B?I7'WG|7
MWQ@U"SF@F:RI;W2/&/*L|2"7!&P|7"*T94LI#CIBOO+PS^S#|+?"C7,EEX)
MTV5I.9/MRM>E=O39Y^|&>^,9|Z|CP_+
#/PCX3O)+S1?"^C:/=R(8WN+"PB@ MD9202I9%!()_/85?
LJWX_|+S&I_\$Q+1^6FB_%;XK^)+JWL=-+7^,=7OY1G
M|+8:G=S2C_@*\$G|:@T_X%?\$G4M0MK)/!'B%9)YL1-
+I+PHC>KR2*J*O^O^QK|M=!"@.(Q7TP<#MQ3^K>8UP_*?|_%Q\$F?
EY_PQK|86Y|@W)W%_|D*6O MWCU/^MZ^|=9IW|?Q)OK.WDDOM!T_P_R
22V|Q<2F82'^\$E8G50/IEVK|&^*M/UI_5XG1'AS!1W3?S/@S1_+
@G#J5S86KZIXSL|#47YF@M.->ZA4^H=I(F_-M17:>?'|
@G3X6M|,VZWXGU>^NPQRVEB.UAV?W?+<2G/_OKO'^S2;|_<7K
MNZ=_6M/80.R&1X&.-'SEX?_&%?A?HK7;:A:ZOK|3\$\$-J%^R|=H_A|CR^#_
M+>:Z|0OV5?A5X9NS=VO@^QED>)8A_!>|CP#D-LF9AN_P!KK|U|
%5>BJ/I MWWH|L<8!
JO90|';'+|+X:2.8T7X3>"/#>H1W^D^#|!TN^C&\$N;/388I5&,
M<,J@CCBNG^S1?||UZYZ=_6I*6KLCLC3A'X8I#?+4?PBE*@XR.G2EHIEI);",
M1Z4AC5EVE05QC;CBG44#&^6IW953NZI=:7:|T&*6B@!H15&H^E+2T4
)@4 M4M% "8|J-H|*6B@_I,4M% "8%&T>E+10 4444 %%% !1110 4444
(,T456 ME9U5F,@4'ID#O!|X;+Q!XLT71KMXOM"VNH:E# M;R^7G&|:S
|?|KI7C_C+|O?X.^%?MD:>(KK7+JU?8+31|*5FF82A,QRNJ0LH
M^|N,FUU!V|J|*.#Q-?|A4Y/Y'+\$48;S1|)?G2|U)>)O|_@J1I-C/NT#P%
MJ6HV/D;S+JVH1V4OF?W=B1RK_P"/Y_V:|4|1_P#!1|XO^(:/R=/ET?P_LF|Q
MKS3M.#R%/3|^|B;:/&_WKWL/PQF=?>FH^K.">:86'4_4Z2X,8+/E!C^|5'=
MCDXP*Y|Q;+2O"G@5K+_A)/%.D>'?M9;R1J>H16_G;1R\$WD;OPK|>|>^/'Q6^
M)FJ26EWXP|1ZK>ZJR6,NDZ=O4CPO2H?|YBXQ_KY'\$|VE4_
MA46S|"/&G|?'P=|*_(T|1W6NW5L^P6FCV4S-,PE"\$QRNJ0LH^|N,FUU!V|J
M|E|3?|!%2M(L;C=H'@'4M2L?L^_S=6U&.RE|S^|L2.5?_!/_^S7F'A/_()H
M_\$*_>Q;Q!XBT70;2Y@|VY^SL|WUS.O|M!'E!/!\$?_!1SXO>(:/R=/ET?
P^4E|Q|S3M/WR%/3|^|B;:/&_P!Z|SOOVCOC M'XV|1(R>||%5QK-|-%;_
&'1KZ6 &1E"(I>#;I?Y1^|102V|D|_3;PW^QM M|&_"|X|H8^!&
|GEA\$.5EFU!-OKY=R|KN_VL9|Z|;T'PQH_A72H-+T72K/2 M--@W>59V-
ND\$,>YBQVHH &68DX'4D|Z'G^5T|JUP2_|>_IE?V=BJG|2J?CMX
M7_9+^+WC+SULO_J1_9S&)/4A.F!">FS|04|S|7E|J|0|_P#!-KXF:REG
M<;K8BYM|BY>XN+5/-6\$<:-&QQ^'|WYB<,R|U^I:KZ"D|M=V<'Z
M5R5.+LP?|.T/1&|.GHQW;9V/^%_""7WAVV^T_P#"1>-|5U70-,ACLO)S
MNW>8)O,R<8(V8KV/PE^Q3|("A'!8:G|,#,|,^"_#_@
MNQDLQ#VAZ;H5G)*9GM|-M(|>-I'H4N50_%L*HSUPH|*V H48
P*6BO*J@|.WITI|%(8WRU/55/X4NT>E+10 F*-H|*6BDT MGN FT4;1Z4M%,

HHHH 2BEHI)12T4P"BBB@ HHHH ***** "BBB@ HHHH ** M** "BBB@
HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHH MH *****
"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH 3%&!Z4M%-'
MSY^UC|"Y_C=X*MGT<0MK^C3-./K(VU;A6QYL ;|J%|J_.P."BC*ABU?*F@_M
M1_&'X(:.?#H&K:8%L|6UA2PM?.\$FCRPO;6T2E%*A!&Q!VGYG,A_=G_
&L_I25# M?7.U<|J7-JCQ,5E|JM3V|"JX2?:6Y^<_PT^#WQ%_:6^)
MUGXC^("W|NBPK;SSZA?VS6|5W;GI!;*A0D.-X+* @5R^=Q&_!'(TP@!|JPQ+
MG"*C;:>|R!G_4 G4G050HITX+!0P<6D|M|MCJ0TM-?|K?2MCTCY:_.O|&5
MG|4?.\$=SX@|+Z|X8U)UD:>WDMP|M>7/WEEX.Z)B_WF;)::2"7|?T'_OZ
M>*KF:1-;|3;)IEF\$'E-IZ2WAW!P?+*N(?E+<|OX5^7CCH/V,O%&I^+/B5|3
MO'VOZU|F@%HC7|SLMON>2219 |RD*D"P/&NX':K%00%.?)K'P?XZ_:|?>(
M|>AGA@A@78&U2X.RQAD9A':J\$3J|NYV|E2QY?G@E|*60*SX"O' U"\$PI.4Y
MW%G/-)&2WE5PL!|7Y#\$S#T21%& N*^L| MM==.2E&Z/K|#6AB,/"|J\$|
X&H:I;P2 ;O(SF8_1! M|Q_*OF|Q%|7/%>OEB=0DT^*7E8|W1XVID_,?
FZU1T'X7>)/\$3*UMIC);-LQ M(D)D59;ES&"RCY2\$!W,IA
>V5YUXB^+_BOQ\$S,;^33HI?NQZ?NC VI MD_,?
FZUW7A_|FU(^=:U9D9EVF*PROT&YL@C_(!7J/AOX=^&_#+++INDVT,P
MSMN/|9*,|YVYZ>|:/%Y1E_^[T_:2|O;^OD9?4<|SA WBK|.';K_7S/F;0? MA?
XD|1,C6^F.EL^TK M&_#OEOL^D6L4L>=EQ_K)!D8.';)"O74>6J# 4
4OR|<8X|,4ZOG*E6=5WD| MGUE'#TZ"M3BEZ(-H(Q@8I JJ .F|3J*S-Q-
H|**6BF FT>E&*6B@ HHHH M ***** "BBB@ HHHH ***** "BBB@ HHHH *****
"BBB@ HHHH ***** (P?J:= MG|*JM<,JJ"PW<9VX.
|UQR*R/\$7C+0O!^G_:=>UNQT>R#;/M6H7*6|>|_ 'F(M&:+HRE4A'XY6-_)|Z-
S>E>9ZQ^T9|-M"LFK|NO'.B-%;#;J6UY'=2?| 8XB M7A
WS7&ZG^VO|)K*TFD@|0W&H21P^;';6NGW7FR,/X5W1JIS_M,*GVD3GEC
M: ^|^@?QI-007RJ?^"B7P^|:;%XG_!|K:_ .2*X|_|%(9?^B=L/^XR/_C%
M9^VAW..6<8&&|1'VSD>M+D^V*_/#4?|
@HEX|;49FL|'|.P64TG^BPRQW\$KA M/1|!(@=O|U!7-ZY^V|A6|,-
'6?"R^;>7|N)!_&"0R|AGKC/-3|8 M_NLP?\$<)?
PJ4G|C|6M9|2:7X=LYK|5=3MM+L8Q|JU>SK%\$OU9C@5QVI_'SX;
M:;:7%S+XZT*18XM|B6^J1S.5_P!F.-FL_P#|00QUO|_#O/X?M(KG70%!=1@-
|HM|@>@_T>NETW|B?X10V,<\$OAE|A>0L|/#.L>%|JU@U_2M3T6XE4
M2K|J4\$D+B/S)%#_J|E8Y|6/K7|_-^6B|!7Q=^V1|?'?Q3^)UCK'A?0FU&
MUAT>.V|;B"/\$BS2N5VR.O4.*F6&:AO<|Y%.E1|H|24Y'Q%17M/_#&_P 8
M/^A-'_@TM?|X|1_PQO|8A H31_X-+7_P".UQ>QGV/FO|/QO_/IFU^SW^R?
M_P+|H&W6NGO3)HLEO?/Y@^Q_:?N*C|HWF)S^|ZU|##_@GA|N,ZYXFP.G^
MD6W_,CUT?|&OPO|2?"WX9ZCI7BFP.G:A-JLURMN989?
W+11(#F)F'5#7T'C M=C(Y|J|:E1@H'Z!E^3X98>\$JU)Q|L<'A:~PTU|QB^'?
/AGPAYW|@^'M+T3S|OF_V M=9QP>9MSMW;_XW'&>F3ZUM?
9X_>:|,=.W|4E%,Z8PC'X58;L7TI=H/:EHI ME|;";1Z4WR8|I&Q<'DC'!H|%
";1Z48 Z#%+10 FT>E&!2T4)M'I2T44)@ M44M% "4;1Z4M% ";1Z44M%
!1110 4444 %%%%!1110 4444 %%%%!1110 M 4444
%)155IB%WE61V'W"1^0YQFDES 6/ 6\$.^YLYM2C%T@*;P! &C,5&X*
6(^|NS7CWBG_(*-?!|03%_9|WJ_B@9< M3?
V38M'|GV|'_P!|:'.?)G=7;0P.+Q'|&E)_(YY8FA#>:/J7|_SI:O?
>4ZR!"29H\$1E"J^!L\$VYQW6O&_%7_!1+XP:|
M|C%C>:7X6&9"W|GV!;S|_=#_&GS,8_V,5|V&X6S.M034?5GGSS;"PZGZJ2/
M(JLQD"@|L.C|N1CGGGFN:|2?%+PAX/O#9>(/%NB:~>21?:%M=0U.&VE\$?
3=M9 M@=O^UTK|?+
|XD_%:XQ;G/HUSXA|4>*I=6D:XDT6TN9ID89WL%M8R4P /N;-J M_P-
;OAG|COXR^+K%;RS^'E|;HLI4+JK1V3@^OES')M|HNWVKU(|,T
M*C'^O,XGF|6I_"HMGWMXG_X%_"#P_I_VFQU?5/\$DGF^7|CTK29A+CUS.
(UX M_P!|/^S7DOBS_@J)/MR^%O ES+#L(M+S5|_IQ(\$))F@1&57P-

HFRX[K7 M\$ ^% ^"8/C.\O"/\$'BW0]L/(W>9H\ \$UW)O\ [NQTb7' _+_
(#7KWA7_@F7 M\A 3UL&|2>(M:7X6YD)_L^P+>?G|H?|3YF /|C%>67W
MQ*^*WQBU*?1KKQ#XH\52ZO(UQ+HMK=33(P!WL%M8R4P /N;-
J_PU^I'A'JD7 MX.^#S=G3_ NDS_-AD&J(=1!VYP4^T-
)LSN&=N,|9|5Z|I^CV.CV-M96%F!9 MV=M\$L\$%O;QA(XHU&%15 PJ@<
#@"E_K!@,/IA,)& _=[A_9N*J?Q*I^ .WAG|C
MWXR>+K%;RS^'M|J)=H756CLG!J?+F>-|O0MV^U>T>% _^"9'C.\OB?
\$/B_1-M,L_)|P2Z1#/=R^9C&-CI\$O3C|WMMK|+ HZXQ2|?
>N6MQ;F,_X34/1'3#**\$= MW<^(O#/_ 2|'\V5FK:|XRU04=0+|O-
TN&&TBV|AY;K,< _|6_ 'M7M_ AO|C?X M-^%|Q|VQ| "V-W/)\$(<:M+-
J\$>WKGR|B1UW?|6,^|>U?9X^NP'YMW3OZ_6AE/ M VKBO
Q&;XW%.J:M)_UY'?#|!8:C\,+E/0?#.C^%=)@TS1=*LM(TR#=Y5G86Z
M00QY8L=J* !EF+' ZDGO6D% Z#%+%+7E-MZL|4DMD-\$:CHH%-
|F/^XO7=TI^O MUJ2BD,;L7 &T8'M2XI:* "DI:* \$VBC:/2EHH ***** "BBB@
HHHH ***** "MBBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH *****
"BBB@ HHHH ** M** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH
***** "BBB@ HHH MH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** &?
C7CW|1GQXA^!_A&TU!8 M!?:M>W<45OH/M9XP5:=^_
<*G&|*P5Y(PPPQKV%ERN*^)O| @HYILLT/@2Y:
M&0V4+7|*^4OB9_P4&U*SUZ:U|\$
MZ)83Z7;ETCOM7\$SM>#Y0LJHA4QH#O)W9)!4_(WRUZE\8OVCO
OAOX'Z@G@_Q M!87%Y>6*:?I5AHUWY-U;B:/:KA\$!> Q)N?YE7:8MORDU|J?
L%_#NQ|6?\$/4| M=O;6&_L-#B1DCG#;DO)&'D38^ZVP0R|<|&;
9&4YZE1N<84CO,9C*|2I1P6 M%J|2?Q-:V/9_@/A M00_\$7Q#I?A0Q-I:Z7K6I-
LMKZUE464CGS"% (9LKQY:+ MAG|QVZ)7U;N90&?&G@W7=&DM|(4531S27-
S;2&.X+(\$%M(0.< MJ!,_P|Y,#|@V?
>,#'RTSUQS713^U'L>GEU>NYU,-7ES2AU+/%#&|4E:P^QC47AFAMY@&F2=I
MN^S9|KDW*9:-"D?+ MJ2WS';@|!|G&Q^(?|ZWXM\RV4MMI_RP2OR|R9)
<@.XV^7T.:^E6|EKY)LYX0Y|L\$.ZNI%PN"H QUVME4^M%6NZG))|=E:C|4C
M8?1116AZH4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 444
M4 %%%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110
M 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%0|D
MCAW&0HB=6<_S)H D5LTUB,J:Y?7?B+X?|+MLU+5H(KC'\$"MNEA
VS7YC^5> M7Z|^TDT:%=&TPGCB2^;|!_!R?| OH5Z6%RO%8S^!OUT/%Q>
<8+_Q:B^6I M|FTB1P@|R|+U9V_F37/>(OB)X?|"
|"/4M4AAN,9|A7W2GZ1K|Q_*OF/6OBE MXB|5;7FUBXCM9BTL-
O;\$1KM|C*C+ ?|56_#OP>|3^(L(FE|ID)Z3WC>3_P".
M'+_^.U|##A^&'7/CZRB?*U.)ZV?*L|MH.3|J#T#7OVE?+3;HNEL>.)+YL\$'_
M '!R?^Z|XU;XL^)_ \$DB3G6|JV@D+2P0VC>2 O<93EL?|5>G^'?V
M)E*I"/QR2^9U7YTN3Z&O*->_ ;B^%OAGR/MGC;3KGS3M3^S2|
|LX_Y:>2'V_5 M|'N5UC|N+X4Z?
|JU=6FM7FL30CY+&STV=)G^GG+&I_|Z%+VD>YS2QN%AO-?> M?
0GXTFWWKY0U#_@HEX(6WN_|.T+7KB|A@.BQW\$,,
<6_LK,LKM_WRK5RA_P"" MD,O_ \$3MA_W&1_|&*S|M#N7(R?F |<8'%?
DOK|/1'Q*UV|N+VY|>:W|HF&/+L-M0>V2+C9Q#"RJ.>>E+?|
@WXL>/&M=400#_C#Q.LUL3'J-Q;W-T/*?D(DA^^O M? %9_6?
|C,GQ'&7|*A)_ (40Q%X|/|>\$|LW|O| B#2|'%P<1_;
|Y+&M/^UW7C72|E1(\$,>EW/VV3=_ USAWOC_@-?GOHO|)WQ
M:URSM|^V|7 BF!,:74UO:,F>N^ .9@_YK74>'?V\$OB EK3737.GZ9H!CP(6U*
M|5|P/WMODB3=C_:VU'UB?_/MB>;9A+^%AF?5VK?
MQ?"G3M/NKJTUJU>:.\$?) M96>FSI_T|Y8U_|'A7-_P##Q/X=|M"|4?| @-;?
)%>1^'/@G7XKNKK&L M^=(L+7R=ZRV?
GWFQEB4#_@5=AH0_!6T@OH'U?QU5-8T5'U_X<@_X>13=OAV1_P!QD?|

QBN+U+ @HEX[MDU&9K/10#D%C-) HL,L=Q*X3T:02(-
'4%>T6' !/WXH6UQ)J/B" ^BC ME\$KV?,WJ?WW)IF(MG0+#9U4 ^HD?
&6O?MM %S4+VYN8=?M|'0_ZNRL;" QC_ + ^K(ZUR/B#H/X MF^)+U)
!OQSK45QM2-/L-T;6)0"7&4@6-7+!U&[T K],D^!OPZC7:O@'PPJ^@
MTBWQ_P"@5UMGIEGIEG!:6=M#:VMNBQ100H\$2-%&%55' 'I5>PJ?SA_8N
M-J?QL4WZ'Y-W&A?%3XH6NG7|W9>+?
&%A|Q@NV@N|V),_>VM|P&>^!6IX;_9> M^*WB?3UO+/P??
VT;7&X+J@CLFW_WO+F='Q_P&OU8|M,*JX7ITXI<#.<.:2^*K)GYI>'V%?
BIK7VO|39::X?V\$>5_ :5|K|L_>V^0)-V| ;VUT M^B_ |\$|_&US?
1+J>O^'|/TYOFDN+,W%W+G'9&6)?_!ZOT'*W! /U'K2|15_M5XG3'AW
QW39|4:=_P \$Y8!J%L+WQQ+-81OF:.#2_)ED3^ZLAG<?*=D==_P M|O|
A|WUOQ_X\$6W_P CU|2M&K8S&#M.X9'0^M.Y|!6GL(G9')<#'_ETCQ%? MV-
OA\$/.!)G\$C;W_.)K>_WJ?WW)KIK'|G_&EC8VMI_P@WA^XCBB"1FXT
MN&>1PH W.[H2S>DR:|)I=M7RQ|?' "48_97W&?H_AO2?#NFPZ?I6F6>F6\$.
MXO6MG_L42;B6::J@_9)).!R2:O| DQ_W%ZYZ4^BJ.A0BMD)M SQUI-H|*=10
M6)@>E&T>E+10 FT>E&T>@I:* &>2@V_(OR|..G&*=2T4@\$VCTI/+4?
PCKGI3_MJ*8";1Z4;1Z4M%(!@C1> H_QCI3L#TL:*8@I-H|*6B@84444 %%%
!1110 M4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 E-
*FG9%5&F&X MA9221CJ1QSC((4138KVW+7X4T_C7E?
B|H3X8^!UU!M9|?:+\$ ^GRFWN MK.WO%N+F.0/Y;+Y,6Z0NK<,H7*|3BO)?
%'_!2/X3Z#>"WL7UOQ\$GD>;JTG3 M@(MW|W|_)&W_
(|C_ :KT*678W\$:4*4I>B_ S.66+H4|YH^KP32|Q7YS>*/^"H
MOB2XT|CP|X|L=-O=^|S=5O9+E/+|_NU2(Y_VM^*|Q|4_|%|/C3X@O\$O+'5K'
MPO-D:HUO86,+P2?O,"4M.LI&0RC*OMXZ5|H'A3,ZV|5'U?| PYY|LWPZZGZN
MF (MQD9BHW!0"Q'W=V: (_A(B=|9HX|&^W^,?
&_DJ+XZ5))=:C|!_*8M|O/^L| M^E=MX1_8D^,'C|K.>#P7-IVG7K^*!EQ-_9-
BT? MV?;T+_:&ASG_&=U>/>+O^"HFH3->VOAKP+#:MYZI:W^J:@9,
(9!M:6!40#=- M'D\38!/#-6'X7_X)=>+;UI1XD\9Z3H_E%|=#_
&5;27_FC^(GS/(K';NKV3 MPC_P35^&.@R6%QK-
WKGB26WB(N)KM8+6XD*8)5(D\$J+NR^T29SP2|'L^&|\$_
M|Y5&OZ|@YLSK_#:)|L>(_P#@H1|:O\$%|Y^GZUI?A_9"8WL|.TU'C,GK^_\$C|
M_?.SVKRH^(_B=|9HX|&^W^,/&WDJ+XZ5))=:CWP'|IBWR|_ZSWZ5^KGAGH
MX2^%|*DM+/X>Z'>1R.93_ :L'V|Y|Y|>;\$?V)OC!XP:SFA|_S:=IUW.8A<:I1Y6.
MVW=7Z0B,+P.*/+ "YP@_
5PUN+:WXFFM|<17\$,|VL%M<\$1|<*L2"5\$!RP42\$CH2XKUCPC^R+|'/!YNSI_
M29_MFPR?VHAU\$';G!C^T-)LSNYVXSQGM7L?
V>+G\$2G(VGY1T|I2E3_=7UKY M^MFF-KZUJTG|V=|_)AH?#
BT|1|/#2+&VLK&RM|*SMHE@@M|>)8XXHU&%15_P MJ@<
#@5:VCTI:6O::;W.U)+83:/2D\$:J_|0!J|PIU%(8WRU_NCUZ4N!Z4M% M"44M%
"4;1Z4M%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%% M%%
!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 444 M4
%%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 M
4444 %%%!1110 4444 %%%!1110 4444 %%%)0 F>#7&?\$GX=Z'6?"
M=WH'B"U6YL;A?EDP!))!)@@2(3RK_0".Q(/6NRKYR_;&^-%Q|,?AM'TVE7,E
MOX@UZ5|:">WD=9((\$V^?
*K*ORMAD3@JP:7>M>&/AK%INJ6.WB'Q9#OBM;V M?
\$=LT'E@QRSN7WR.K9&/DWCJ^_)KBA4I0UY3Y/ 8O!86;J.BZ?-W/1/BQ|_I M.+
_.R^+?B?QQ!!X=AOUU&|2|D6">%|>/=!!!LC(G4M&JF/"OM4|NY)KZY5
M3N8CH1Q7YE^%_A|6_VL?\$=MJFL7%|<:2MP(UUR|VBTM\$&T2-
#A\$U+2'@\$UJ>|T/D/ M|F#X-^*OA#|=/'^D"WO%|\$_-\$#%?
3K|ETQ=7M|.4!=E2296V?(&W|LY3'E'B+
MQIXZ_8P|>>)|'TS3;_A%M>NC=:6UZUS<6XC1F51'AQB55:)) ?F.U3D@!FZ
M'XO?MJ>+M0|::AX>^'=O:-9I<+86|_:Q"ZO;R19"&DMQN>,JV\$5%(8L'W AF

M"IO_#5'QW^&M]:R>*K5V%X&AAC|2:;\$- '9<%G4)Y,,P&!A2P^?_-'<<4I07
M4^!K8G"THJEAW)*\$OB6JUW/6_P#@G?X.U#3?
#GBCQ#/"5TS4IX+6S9D9'D|G MS6DD!/:RLF^6?!+XU:%|:/|_!
:FD9AU*U(CO=-E.9
M+60YQZ;D;.:^R4<'YNA#JOJ3*&7KBNFFERJQ|=E|.G3PT53=XDE%)2UH>B%
M%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%
M %%%!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110
M4444 %%%!1110 4444 %%% #1F@T U\$SE8PS8#+U;C|S0+8E'-(6.>M<
M3KWQ:|~^&F>*ZU19KM=Y-M;CS7&WKNV|)_P/%><>
(/VD;ME/|A:4ABQQ<7C; ML?|;:-.O_?=>GALKQF+_ (=/_0|/%YU@,'_!*B?|J>
|>9MCRQ&5Z@/Q^9K MEM>^*'AKP|A;06K=KC=Y7DVY,S|O3RTW-
7S)K'C+Q'XPD%G/JL|W+RW_#_,^:O#WP@|3>C.(NE/ID+=)
|MC%_XX8+=/+7Y>N7.2V?|G97N 'UIV/05Y>(X@QU?2#Y%Y'LX3A? M 8?
^(G-^9SVA^"=\$|-PG^S|*ABEP0|F-|SYY.Z1CN.?M.
M)KP)3E4=YNY|53I4Z*M3BEZ_%|4FU>?E'/7BG45'D:B44M)0 W)|J:Q_J
MJW DWD3*%SP0.5QV(/>N9USXM^"_#-Z|CJWB_1*O8QS:WNHPQ2_|NP-
3>)-ME*K3C|K:C>^=Y8COGAM8MO|>WJTK?|CE6ZU(W:*?)N-\$0_|
C|+ZQ3|G'+.L##>9|V!O<4N3 MGFOSDU'_(?!?\$NZM+F%=-
T'3MT)C2|MX)O,#M|TIOD* C_:%75Q*9YIY M|N9'DD/5V8IDM|GFL?
K7:#.:_6*4OX6&DS|1M;^+7@OPS>R6.J^+|J#TJ|C' M-K?:G#%+_P!NP-1|L|
<.:<^:=J?V8SWNSC_):>2'V_5|5|M\$Z;^R/| %K4K6.
|C|)7B&X@W*);NTA=5/9TDD5PW^~^I=7HO|!Q.U2TL;JZ M;0=(E;_66-
|?,TD7T|F.1?R>E|:I_(RO|6S*7|/#A3Z=|0?MR_"W1;'S;+4 M-
2UV42>7|CL;&5)O-1A_U=O?>1;1 M2?|
U>1A_WP:X/P|_P3IURZLPVN>+|.TZ^W|#!8VCWD7E_|H/\$V?^ UV'A_
M_@G3X>M?/_M|Q?JFH^8?W'|EVJ6NP?|6|RY^J|*OGQ'8/:9|6^"\$8^ISFH_|
M%'KTV+=YM7,R!^Q,8A0LO^Z|8H&4_B*?
+B/YD/ZGG53XZZ1|0'|LKXS9C'_ "6|EW
M8RVFVN^5F^ZBJL/WJY#4/CQ|2=2O;RYN/&_B:.22.0='5@F0WN.:Z_R8UQB-
:S M^KU/YP_L3%U/XV*;|#|B;KX=_ \$WQM-
%K%UX4|4^(VNXO..J36<|R9%884+(1 M^|&.G XKH=%_91^+FM6=M?
VO@RY6.9-L:W4|/%HR+ _=>.9@^/8K7ZK+&B|*BC
MC;QCH.U+M!QQ5_55U94>&Z*^*I)GYK^'?V#?B;K5E')?
KI&AE9MBVM|>%IEC M_O9@CD4'_ @==;X>_X)V>(|K|2WB#Q7IMCY9_=?
V=:R76X\$?-NW>5MQVV|J^_M>/6D|M>"..G%:?5XG5#AW QWC<^_
="X)SZ8LP36_&=Y?6(C^2+3K-+9UD_
MO;W>48|M@KKM#_8#^&VFZA!E..&7! (|#5^PB=L7-Q\$S
M#^%T>4JR_P"R1BNW'P)^&RC'_ "O_OT_Y|OVZ?P5W./I1QZUKRQ|'="T
M(_87W(00IV0?E0L*)PJ*HQMXX';TJ|%,ZDDMD-VCT%(T2-
U4'ZBGT4#V&^6N| M.T9|<4BQ(JH10%Z_#I3Z* &|%/50>W2EI:* \$HVCTI:*
\$VCTHVCTI:* \$P M**6B@!*-H|*6B@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &
|J0K|THJMYFZ,D M\$J6S@G)Q|X-&K^\$3EREC.>QHKQWQ%^U=|
(?"NGM>7OQ\$T6X3S-HCTR|^W2Y
M/0^7!YC|?|JK;MKR/Q9_P4N^&6AR7T.DVNM^)'B@WV=Q;6|<%M=R!;
|=TCK(O MS_(?W60>55J|EEN-Q&E.E)_*QRSQ="&|T?7:MN_O?G3||8Z?
6OS@|6?|%0O M%ET;?_A'?!NEZ.%+&7^U)9;_,|?P;?*,EXYSG?
7D'B+|N;XUZY)?V_":_M3|:_|S|U8=:;Q^0KNX|N)|IECVJ_H9I#
("N|FOH*/">95/>E%17FSS99QAX M_KGZZ><,D"4YYXSR,=2..
<9'Z5YEXP_:3^&/@9=0;6?'^B0OH|IM|JTMKP7 M%S'(|ME|F+=
(75N&4+|O4XK|G9;/XM?&RSL|MX/%WCJRL)G@AO)H|O4HHG; M
?:S!@'.%R@&>!S7?^#_-@_XR>)C8_|4W;Z!;74*LMWK%|&D<"B,.HEC1FE
M1R3M \$6|&ZE:|_|5O!X7_?<7%?X=3F_M6O4_A4&S|&|4?|!23X4:#>?9|%

MJ;1)Y'F :M)TX"+= = ?R1M_P".X_VJ8|4?|2/\$ES88|> ;#3+S?N|S5
M+V2Y3R^ [M4B.?! :WXJ'PO_,\$OM?O+'/'B'QYINEZCYO^ITBPFNX]O9M[R1
M-G_@/_JJP|_P#!:/X1>'|XW%_ 'KOB 2)@6NHZELB\$N?|;F!(WW^ ^=OM0OI
M6|TE4_KY O|3Q'50/C?QA^WE|9/\$UQJ&SQ"HEE>1-;QVNC6L4<8XV.T|X=/
+|"Z'|QHENHC#J)8T9I4M>=%_ ^"7NOWECCQ#X|TW2|1|W_%.D M:??
=Q|>S>8|D39_X#_P*OT9|M/0>O3WS_.G,H8\$'D5Y|7BQ,ZGP24/1?YW.N
M.3X6.ZN?*7AO_@G)|(|U!KB^37-?61,"UU'4=D0E_YZY@6-|_OG;|5Z|X_
M9U^%O@:WTT:/X\$T2&XLG|RTQ;BQ6>ZC?.Y6^T2|I-
PP.2V1@>E>G+\$L:@*H M'0 =*;C:>-HKYVMF.+K_ ;K)_>=|<+AZ?
P0)!&@Z*!2^6OI?E2TM<5SJ2M ML-\$:+T51^%,^S1<_ND^|M^Z.GH*EHJ;
(8WRU+!BH+#H<E+13 2BEHH M 2C:/2EHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** " MDI:2@!I!|>: ^'_ |@I\$ +CX?@#
"ZAC|#:XK|@Z<5Y)|;OV>/#WQ|;1CKU_J M-H=-\$PA_LZ:-
"?;|O=G=&V?|6*SJPYX>+PLJ-/ % MC\$B|S^|/;?2OI'AWA|O^@YXF_|"+;=
_1Z/^'= _P .|H!UOQ-M.#TKXE|= ?LK_SX:- Q4GC_ %C37"),+
[NUDN)5+%/EA2W,K G^X/X M3Z-7VQ"J^4
16M*4K:GO8&KBIN4,4HJWH =M4\$G%<&WQW^"(X6!X8|_ ^M)Q;=
/Q==W)&)%VGC-?\$ _P#P|?&MZ27N)8X-,UY9(FMI8H|;6F61Q_YL9B;#/C
M*A3|X56^K_\$GQ|^%4FBZC|J7B|PWJ-E+:LEU:?.XKGSHF4AE|E2Q?()!7G-
M?.3?| \$VUD+%'ZMN&#NT;:1C' /?TI?^';Y#,P^ (W-R3_8_7Z_OZYHQJ1W1
M|A_ |2PM!TX8=:^9>_X)ZZ*^G:7XOU%|^RD-Y+;1I9)' M-
6US5+W|%I>F6|M U=7(4D00QIOD8@ YP%/ZU|, ^" \$7QK_ ;PN|?U;0/"WPK
M^&FEWQ&(9UJ,>;WB)2L?H%2U M^>DGCSXR?L/-
!OT2W|=>, +WXD?" +6;E8IO\$&IOR2FVD=56;+[HHI(O*+K# METD0R;?
G+F+| (:@S\$;LI))(R >C#'"!HE'E",N8MT445)84444 %%%%! M1110 4444
%%%% !1110 4444 %%%%! !1110 4444 %%%%! !1110 4444 %%% M%%! !1110
4444 %%%%! !1110 4444 ,ZX-)NZC-#':IJ_.7XN?M:??/0_B= MXLT_3?
\$D.E:=9:K<6-G:+8PR)'(89BT3OR(RW6L:E54SS<;CJ6!@IU=C|' M-
WO^M)GW_6ORT_X:(^,' 0WS?^"NS |C5'_ V3|8/^AOF_|%=G_P#&JQ^M
M4^YX?^LN\$|_4A(KOS_-2V@&Z M3;=21C.%2-/E Z|>!5_Q%^TC-
N(T;352%/O37C|G_P" 2?| Q=>_A-C& M5.F^5|J#MK9|@*%/FG42?
9:L|V:0^4&8A&7J_- 'YFN0U|XM>&O#+/# =ZF)KI M=Y-O;CS7&WJ&V|)_P/%?=
NK>./ \$OC-K>RN|4NM0D=?>VB3:C-ZF-0%/XUS^ MAW.B>()4W>.,?
#%A@,5-YK<"@9Z_NQ)N&?|VO?IY%AL.N?'5TO3^OT/EZO%=3
M\$/V>!I: WM/P_P"">U^ (VD;N0LN@Z4OE'I<7C|L?|LTZ_|?=>9:UXS|2>,
M)!9W&K3WR-@H#%7 MOG*@9Z_NQ|PS_NUZ;H?|.&B6|S5;N;4SC_5*?)B_
+|W_C|>, ^)?^"C6CV| MH&C^"M1U&S|CS#)?7 MI- |*+IHCH'A/2|-,3?Z1
M_:ER|SN'HNTQ;?K|J>1B^|L37T4^5?W3OH87(<%UY_Q/N/0_"VE>'K9HM-
LK M:T!(+M'\$JER.A8@-)4M|I'B'E6=I!+@C8=KA%:,J74AQTO7STL M6JCO-
W/:CQ!@*2|G1B_DC|2^,GC|:3<@SDX|>17Y*:+|4OBKXDNK>PTWQ;XP
MU>_E&?LNGZE=32C_ ("A)_6HMA| @3|2M2U"VLD|#^(EDGFVQ-
+I+PHC>KR2
M*L:K_OL16'UKM!B_U@E+^'AY_3N|^,W@72|0N;&|; ^|2^MF|J:VFU2%)(
MV'4.I;?*C7(Z|^UW)=!OKFRNO&EN|D'^M>T@N+F/M+\$C)^1KXB_P"&=?
C" MYS_PAN3N+| (4M?O'J?|;U|Z|\$?|\$_B7S_ ,3;PR/7_3+C_P"1Z7M:_P#*
M2|TS.7|/A \$^@/\$|^>GPWT>|NS76-;C,/F?:K*T"0AO|O|YXVS_P&N0|0 M?
|%&-M_L?|8'A'4|1|_| ^TKE+3&N|=OFYS_M;*Y?3?| @G#>7%K_VH^- M8+;
|>(2216VDF2)9.X5FF5B/JJUV>D_|\$|O!D%G;HJWB/7=0OD ^T36IAM8Y
M2.F(VC<_ ^/UI?=\$A|V>5O@C&)Q'B3_@HUKEQH#0?"-
AIMZ7XEU2ZEN4">GE MJD7S?| #KD-

=,X^)=_97=M%'H^D.W^KO;&RD,B_3S9)\$_2OICP_^P|^*M#T_MR;
[3]0UZ3SOM'VS4+YXY,|;#RTQ^%=+X?_&5/A5X7O#>6?@^QDF>\$0@W|
M/=QA0<[MDS,-W^UUJ.3\$?
S"^HYU4^ND?"=|^V|^7K[39|:Y|6W\$:RPR0NMO
M9P1RA"N"X>.+>CJ/F!7D5R|C|7OB;J-
Y:6=IXV|57U|=2&".S@UNX>5RW38H MD!D_ BOU*T7X2^"?
#NH07^E>#M!TN^@W>5=6>FPQ2Q|AM;:RJ",C@X|<5T_V M>(?
P+UST|^M+ZO/^8/|Q=3^-BF_0 (Z_P#A|3-6O)|N|^%>+;RZN)3/-< M:3
MK+CP|07Q5),_.;3OV OB1?65LSWV@Z>)(1++;7%Q*91(?
X3MB=5Q_LNU=5HO_M_!?.5YK&U?
4O&MKIVHL!YT%GI|W4*XZ;7:2)OS45|Y8INT>E7|7@=D>|^#> M-
SY"|_.\$Z?"UOIFW6_\$^KWUV&.6TL1VL.S^|Y;B4Y_X'76:#^PK|,-%:|-
M;:QK|S\$\$-J-^R|<#HIA|O@_|>:^CMO|TS7KGIW|:%4+T11|!5^PCV.Z.48&
M/_+I'D.@_LJ_"KPS>&[M?|]A+(|0B_XF#/>18'(;9,S#=_M8S77Z?|OAH-
MY!=V7@;PW:7=O*)X9|?28\$>.0='5@F0WN.:|/;<4<>M:QV0PM&GM%?
M<-\$8Z(/RIWEK_=%HJCHY4MD)M" I-B^E.HH*&F-67:5!7&-N.*/+4|LJ#
MNZ|=:=10_FT#H.4GEJ!:@*/|3J*\$VCTHP/2EHH 3:/2C:/2EHH 3 HI:.*\$
MVCTHVCTI:!!24M% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
* M*** &=.J*32?=K)U#7+72|*>|N|F&TL|>%KF:ZN9@D:1J,LQ8G 55Y+9P.O-
M'+*6D"7*,=S7ZTTM|:9|3_M??:_PA|E^V>/=-
N&N&D\$0TN4ZCG;@G=|G#^7 MUX+|:9|5?|
!33P/T|=ZN@:;!KFNW<4PBM6G\$=I;7:^9C<&WO(N4RX_=9,,, MJUZ=#*TQ:I/-
O\$_\$W|8?QE|7V,=K>?\$. _@A643H=+6 M"QE&T\$%7>!48|,?
E/R|MGH*^@H)9C4|ZJE#U9YT|XP|?@5S|BA,!N"3;GYX M;D+GD9'7I7E/BA
:N^\$/A73VN|SXB:+<)YF/+TN|-|+D|_+@|Q|OOMVU^5> MF_#?XJ?
&+5(M:M=|2>*Y|8FVQ:M+/^"EWPST.2^ATFUUOQ(4&^SN+>!(+:|D"9*
|I'61?G^0_NL M@G*JU>0>+A @J)XLNC;_P#".^#-*T@*7|W^U));_P|?P;?
*/EXYSG?6CX
M/_X)@:A,;%_%/CRVB;>'N;'2+\$RKLW|<1SNZG<8L88PX1LDA|9KV?PC_,|\$I
M?A#X?:Z%|:;MXG)*^6-2OQ'Y"S!?!LPBSN|/|YI*?#>%^S*I_7R\$EF>(W:@?
M#WBS|MOXS>, +?489_&DVfV=Q,91:Z+%:ES+!XQ',B^=&G
X,F|EWACBN';0 M?B=|:'36?|-
|3^./)S8'5)+>YU+CO'YC*W//^KQWZU^OG@WX%_#_, "3:?=:
M'X,T.PO|*+RK74(,;W*J\$*%C<;?+,K,"Q)+9.2U6^)\)A_=MP>\$BO-|_) LIJU?
XM5GY,>&_P#@GW|9=>NS%J&B:=X>/D>=|LU7586B|S^|_M_H|2-
XYC:KU|P?_P \$O|0F^POXI>6T+;P|S8Z18F5=F_;B.=W4|C%C#&'M"-
DD/C-?H7MI%C6/(5%4\$|C@8Y)R3|:|JOQ5F=;|?+Z(|(93AH|QN?+7A'_@
MG=|(|:Z%|:;MXGR5|L:E?| E^1Q|P7|(L|N^_:|F|_%_WX?| @%|"?0/!
M>AZ=>V<2Q6U_!91FY"JGE|C/MWEF0E2Q))!)KO@GS9X..GM3|HSDCGZ5|_
MQV+Q^:HY?-GHPPM*G|\$4*\$5>@Q2>3&>J*>_3WS_#I|%
<=SI6FPWRU(P5!% M(L2*H"HJ@= !BGT4@&A5'10/PI=H|*6B@!-H|*-HI:.*
\$I-B^E.HH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** " MBBB@ HHHH *2EI* (^-
O7.*Q|8|0Z;H.GW&H:G>V^G65O@27EU,L441)4#W@G0X9%|+VFI>++L11R@
M*S2;2KM*OF# R?DB;^>WYK|;?M<_%7Q|H|T@U3^P-'?R8';P|!) !(S2.O|U
M|S|Y|IN!(F5C/RXW9P_@7|1/AWX)U*W_.\$V|CQ1=?;I91J;S>;8HFB"A5M
M&'ER#*_>+<%|_P->O?M4?
&CP+|4/@KH6G^#;I()K>_M'DT=HA;O:1FUF5\$* M\$;65"R*?*W?*
WS)GCE.4X:3/A9XROC*,JM6LD_Y5H_Q,#X_-L2Z|X^L-(|

M0:WJ\$&B>'4M4NDM/IWE09(2T:QI@_NH/Z_
RS[3C*DLVWJ\$X\8V+P!WKA0@ M6Q;X+ ^ G;ECH.G\GJ?]
1XZIOG=Z"NVG!4XV/L,OP="4KTT_>)*3RUZXYIU M-YAZSQ%)5)0<7V>Y-
124M4=0 M4444 %%%%'SU^W7KVH^&/V3_B+>:=
<^1++916##R5EW0SW,4\$RX;J7BE90> MQ.:I_P#!/_B-6_9!^'Y*@DB_
<>NH7&?SKO/VAOA_P +0^"/C3PPUA_:=J. MF3BUMED\$8:ZC7S+
<[MZ_ \MHXNIQT#9&:_X)Q? \$RROOA&WPUOA_97B_PAZ3T;2LLSPL%)
(,8+;2ZJ.B/O4M#GEIM74W?^"C?AJQUG
MJE'7+R\M%N9J]&N[&^L\LK*8IC<1VY(P1O!BN)D^;(RX.,C(I?_9OC7_AGOX7
MX4#/AC2STI_9(S_/FOF'_@HQ\8+?6M)T+X*>%[V2^ \9>(I3LO>:;\$46-
HFAV%%%%%%%%8'0%%%%%%%%!1110 4444 %%%%'!1110 4444 M %%%%'!1110 4444
%%%%%%%%!1110 4444 %%%%'!1110 4444 %%%%'!1110 M4444 %)2TE \$3_==
U^07QH4? \+D^ (QP==U \)Y/R!/YFOU\;IOX&OR#^ M-')9/'
/V'M1_*)*X_9_#/A^*/X%/U..HHHKRS\YL=!:^/_\$.F:3_&3' MK#6>G\ZF,
(W))/IT?-R2?SJA/XVUEHVCEUZZDC;JK7+D^\,UIF_LV_LJ_"O
MXF?!3P\XD\2>&FU35KK\0MS_:%W'N*7,R<)' /N@<=@/204&_8/^"#9SX*
M8X\=7O\ _P"/U\71<9TXJO5G\G_P3ZRAPW5K4XU>97D?F+)J.GJ 'FW!6W#)
MS@^OUJO-XDLF7:UXI7T,7%?J\$?V"?@:W7P1GZZM?? 'ZXWQ!_P \$W?
A/JFK3 MW=M=^ (M&BE'R6-C?QF%?EV_+YT;L>>>7ZUZE'#Y-4TQ%2J_N.O\
U:Q\Y^= M/ "6VO\ SSNN_P#" .YR?UJN/%!#%A8
\$XR?,ZX&!7Z(\.O/A9_T,'B\ _P # M;7_Y&I/^'8'PJ_Z#_BW_ ,#+3_Y&KV*
+A2&\)A_JY5_E7WGPIHWC\PI:VMK_M_:?A+7\W48>;F:VU^*T60^JHUDY_!?
KV/P5\5OV.=)T6R36O!/CG5=2 #M)< MSQ.(&9 ?*5H9X59 <[7:-2>I-?
1*_P#!, 'X5*RLNO^+@R_ =VRTR/I_HU'_# ML+X6+NK-
Q^6G4C#' CVZD=:N2X6E\...RCD\?#_ 4XO\CRS00V MD?
V7O#ANS;?"G6KPOD2?;I/MKW;LZ!/M%PV, ^V, \Z\#P_P#MZ?L_>\${R2\T3
MXXL-%L()&4D\$J66<\$@D_X\A6GJG_!,7X;S6=Q_9_B?Q_;WLB.L M#W\$MM-
\$'\;HQ"A(![*Z'CK7)?\,KI_ \HJ:?"^\$Y_ \U5I&GPM/X7,/W_Y'H>Q MQ\/^'"'X'=?
 \.OA7D'_ (1_Q9D=/I\$M?_ DFE'_!3WX6C&-!6_? \>EK_P#) M-<' ,.KKG_HJ*?
^\$Y_ \U4?\,KKG_HJ*?"^\$Y_P#=5: ^RX8_Y^2_' (T4LT6R M1Z5H? !2KX5ZMK-
I9W5GXDT6&4?/>WNGQR0#C_IC-(WY*U=A_P_- \? D\?&K M?^"74A_XQ7@J_ \
! *V=GP("E1XS;:3DC^QK_ ?_ " !30^&^ M/@7Q_P 5J_ \
X)\0_P#C%?,GBC_@E\XPLV@'A0QKI>L;BXD_M6WEL) ^X5\
MOS_,SWW;:Q/^'9/Q7_Z&#PG_ .!=S_ \ (U;QR\AZ:O\ 6Y?
U\C/ZUF7\A\ _Z"W_7R)^MYA_SY/N?P_M_P#M1?"?Q%I%H%K\0_#J6US_JDO-
12TF_X%'.R2?FM:?"_#0GPL_Z*7X1_ \M!\;?_%U\ "K_P3\$^*JL"-? \ (@CN+NY_ \
D:D_X=A_%3_H/>\$?_ NY_P#D:N?^ MR\DZ8S\#;ZYF/_/A?
>??/_#0WPL_Z*3X2_ \!\;?_%T? \-#?"W_HI7A+_P'_
MMI_ \77YC_P#""7QS_P"A\$;_P;6'_ ,?H_P"&\$OCG_P!"(W_@VL/_ (73_86_M4? \
0>OP_, \0QG_ /D_3C_AH;X6_ \)%* \)?^#VT_ \BZ?8_ '?X>:M?6=EIWCWP
MQ>WMU,MM%:0ZW;/(C?PHJN2S_ \ (YK\Q/^&\$OCG_ -"(W_@VL\X_2#\@_X
MXJ/^8K8=NG_+;M2_L+*A_H/7X!_:&, Y\GZ\IE_R31N3_":_ (? \MX82^.? \T(C?
^#:_P_P#C\8_B; \C\XS>\$ \ \$W=Y \;ZY3SL;=+;:_J?=Z^7" \C\
M??;M\JXXY#@YNRQT?Z^9? \H5_P#H'9^R& \4_P#?5)O3U_6OQ*_X9^ ^)W_1-
M?%W_ ((S_XBC_AG_P")W_1-?%W_ ((S_XBNO\U5I? \4?P_ \DB\ \5J_ \M^&?
MMN/K_P"/_&H1, 0&FP>#C/)ST)XXS@_F:_ \$ _P#X9_ \B= T37Q= _P""
M&_ \^ (K> *_#WXZ^! ?M7_ C7AGXB^'OM14W'JE: ?J%MYVW.W?Y8&
 \&3C/3)H MEPK22TQD/Z^8_P"UZO\ SX9^SGF4FN_P"=78,O' \U:SCPG*? \
#Q4' \RI9S&& \.7W' M\3;CZ&C\$? \P_N_ DFC_AYQ\5?^@%X1_M_P#_ " \^2:G_
%4S3^5?>A_VQA/YG\Q^G' \I^M' \I^M?FA \ \. /BK_T_O' \
M_@!= _P#R31_P\X^*O_0" \ (^%W_ /)-'^JF9_RK\T' \L83^9_+5_5KJ&JQC_
\$F:UU%\2%S_+ \$9AF/_ (6A_P\1? \Z)BO_M_A1?_?? "W_H!>+O_
\$MO_DFC^P>A?G^= 'Y_G7GG_#0GPM_Z*7X0_ \!Y:_%T? \-?"W_HI?A#_M_P

'EK |74 5J | (N8 :TOYE|YZ'^?YT?G^>=>?|"?"W_ **7X0 |'EK M /%T?'-
"?"W **7X0 |'EK_ /%T?5J_|C^YA|6E_,OO/1/S-)YGM7*>\$ _B5 MX4|=-->_|
(WXITGQ%|D*^= _9FH17/D|AP^LG; ^=- YB WF .L)0E3=I+|": M0EM(DR?
0T<^AINX>I_.CH2"6'9A@XP: ^:/VS/VJ+K|G_ ,+VND:"T-UXRUB&
M0VLTKQ|+")<+Y|B&PM7&5HT:2O)F5:M"C#GJ:'TSY MNZ,X8H6S@G)Q|X-
+TLF)!G=1RH((XS7X6^./& _B#XE:_=: SXIUJ|UG47
M:3S;B|7)C#|88DR0L2|D'|_*ZGX1_M >._ @A>K-X9UFXAM/:.5M+N!OL|C|X
M&97BSM4|4(9XP) .AK|JIP7BHTN:%5.78^>CGM)SMRG|9YI*^9_#?
|>WPJO? M"NC:GKNMX;U+4("FCR0S7CV|F|T*LT*_
U,:LF=L;,*Q50R@>>^*A @J%X M0L:/9X?|(WJ&H>;Y?
E:M/#9Q:/|V|&E;|=F/HODZ>48^I/V<:+OZ'LRQV' MAO-'VUS3&8KV-?
F5XP_X*9?\$76(|Q?#?A|1= M;J'RK626"|V<-3.*\$?@3EZ'f|!>(/%&F^%M/DU'6-
3M=(L8R%:ZU" M=(H4+, %4%F8#+\$#@#GO7E7B7|LCX->%|L6MU\0+*XE\O?
OTQ9;Z,C^|YL*:F| MVW;J_/P_P# ?XL?%6|COK+P3X@U.XUK.H1:I?0M"J>&?
+@G^|7/\$%C|HOX|&|/#S?+ ^Q:MJ1,WE^O^CI(N3ZI_P#@-=BX M?RO#.V-
Q:_|= _IG.|QQE3^_%2/HOQ3_P4S|#;:'>KH&@:YKUW%,(H5K@1VEM=
MKY@&X-O>1-/K4-V@>#|:TVS|O:8M4GGN7|SU|Q M3%Q_L|-WO7=^&_|
@EMH\$5YYGB#Q|?:G:B/9Y>FV\$=K,'ZG|Z|2C;_LL_^|>
MG>& _^">WP;T'3WMKW2=6UV<_ P"EZCJ8|@QIY?MC=35;AK"OW82J^
MO| (7)FE;XVD?;/B7|L+XR^+K&.UO/B/?P0K*)T.EK!8RC: "">!48\,?E/R|
MMGH*PM/^'?Q7^,VI1:S;Z%XFI6RZO,JQ:K=6|IQ!:R\$P@O=.NT*H!3);:H&6
M"U^Q'AGX4^" _!=^|HX>|
(Z'H=||1@>YTW38;>1HR0Q0LB@E.9+R,0\$W5AI>G^6^_9DK%.SL2%
MDSG,7S
8V+7W|\$'/RCYN001MPQPHYZYUF(XIS*M|OE|)\$=,,IPL=XGS#X:_X)
M|?!S0=/>VO=)U;7W9S_I>HZG(CB+_GF/(,:>7|8W5|QX9^%7@OP7?/?>' _".
M@Z%>O\$8'N=-TV&WE:,D,4+(H)7*J<=,@>E=*BA<8V@#@<=>*D-
>!6QN*Q|^>H MY?-GI0PJ*G|\$4)Y2?
W1^5+Y:|_*.>O'6G45QFZ26PQ(8XP0J*H)W' [DYS2| M%."5&1TIU%
QNU>N!FEVCTI:* \$P/2C:/2EHHV 3:/2C%+10 4444 %%%%! M1110 4444
%%%%%%%% !1110 4444 %%%%! !1110 4444 %%%%! !1110 4444 %% M%%! !1110
4444 %%%%! !1110 4444 %%%%! !1110 4444 %%%%! !1110 444 M4 %%%!
!1110 4444 %%%%! !1110 4444 %%%%! !1110 4444 %%%%! !1110 M 4444
%%%%%%%% !1110 4444 %%%%! !1110 4444 %%%%! !1110 4444 %%%%! !M1110
4444 %%%%! !1110 4444 %%%%! !24M% \$;9;8:5\$5VDD0#;D|,*! MU))
[5;W94XKYF;:=^*ESX#^&4&C6=S%;ZAXB>2T9Y(P|_8Q\$3.P)&P'.&I2JRV/7-
!U|' !GQ,AEC|2^'K#5VEB|C|2T)2X2 M/).P3IAU7YFX!'4^KY>|=?
+\$|8R&F|&>(9H&15V66N1B53(7.YO.C&5!4D_
M<;DGU^7V_P#90MO%/_'F|*O/%FIW6K7VH%KV\$WTGF21VTA_=@R9)DW#
X7,J4:E:G8 -.'5OCS^SA?V5U>GQ M##I-C"BO:WZT_P 5>'KR=S/IT7(
(=RGZ<' #./? _ (5?N_|A^*|V/_ AERGP>\$CBYPW^_*OG/XT?LA PF^_FI'5KW29
MO#FN22+-JOAYTM)|K+.SB1#&|EGDW,[1^861/FX%?1],8*2/E!*G(XZ'_)
MH4N4+7/GSX"_L9?#+|GO6'US0|2|U;Q#|ZKK.L7"SW-O&X"F-\$1\$1<|6&X)Y
MG|V0;L,17T+M&2<#.,=*:H7)PH!8Y/'4_P"0*?1S!//%7B;4M=O=:|0
M0WVI74UY,L5S"L>^63>V%,)X&3P>U?
3>/6H|NWH%'34RCSJS./,\$86AB5:O' MF/ES_AWC//^@YXH_P#
BV_ ^1Z/^'>/P|_Z#GBC_,"+;_Y'KZE_ #|*/.3|*_MS|C'L<7|DY?_,^4<;|,?
AYIWPG| "VAC2YKNYL; S&-KQD,S>9*TIR5"KPT MA'2NR"KW H55W;MJY&>
<<|?Y4K>M;GK0@J<5!#!?+7^Z/RI0H7H /PHI:18 ME%+10 4FT>E+10
QH4;)**IQ^%/HIC&>4G|T4>4G| MT4^BB|Y8|AOEK_=%)Y*?
W%_*GT478|(R|<|+Z-XGTN?3=9TJRUI;3I^);.^M MTFADP*^ MXX#_
(9|^%W_ \$3?PC_X(|7_-T?|,_ ^"|_*OX1_|\$=K_ /&Z|^BK^L5O MYWH|
[*G *ON//T 9|^%L84)|-O"*A>FW0K48 |(=- X9W^%?| T33P? X(
(

M;7_XW7H5%'UBM_.08_9P_E1X7XF_8R^#BR\%YJ/@'3|>9(C\$5TN2:PCV^O
MEV\HI;.:QGWK_X8)^!O_0C#_P&U|_!KZ"V@9&T'VHVCT'Y5M"XR/_+Z
M7WO_#_OJM+^5?_!Q?5:'!GX'@'_#!WP-VJO_"\$*_OW5_M>M_P#Z?
OZ/^&#?@;_-"3_P"5>_|_C|>_P"W_9%&W_9%+^T<9_S^EH%|5H?MR?@?
(' _#L?X7?|]##XO|_RU_P#D:C_AVA"/I_H8?%_@9:_P#R-7V!CW_6MC;|_
*UW_P!NYE_S_EIYC_9^\$ _YIH^/_/AVA+O^AA|7_|@9:_ (U+_P_.MR?A?
NS_PD7C#/KJMM?|Y'KZ_P!OO^M&WW_6G;_V9_|/^7WA_9^\$ _YIH^O/
M^'8_PO| ^AC|7?| @;:_ (J<|X|X)>>' +O|+_PCWC?5=*V_G#5((IWSA@;_M-
OE^3Y>#G).^ON#GT-(J*",)CK^O6E#/,S@|^WD3_9F\$ _P"?:/@/_AU?<_|
M144_|)S_.ZJ/^'5|S_T5%/_G/_NJOO_'L*,>U;_ZR9I_S_?W+_ (S_++P_MG|A|_?
#J^Y_P"BHI_X3G_W53&_X)4S,N#|3HB;,<'PWV|/^/JOT"Q|48|J_M?^LN:O|Y?
O|E_D/^R|(OL'P!_PZPN?^BH_X3I_ ^2JX_|X)I?.\$?|=>'30\$
MWAFTZ*5UBGNYKF*5XQJUF18653Z|6;_J_3KRQZ4M73XGS6&|6_P
E_D*6_M4X27V3|P_P#AV3|5O^AA|)_ ^!=S_/(U'_#LGXK?|]##X3_|
NY_ ^1J_3S8/M3|]*_@|/TKH_UN\$3^>A_X"C/^O|)V9^8?_#LGXK?|]##X3_|
NY_ ^1J;_P_.MQ?BI_P!|PC_.!5S_|(U?|H|I^E&P>GZ4O|;S?
VH_P#@*#^OL'V/RNUS_M_@F|6M*TF|N|6Y|_ZO/\$_O6-E?
NDK^Q,T;:_FZ5RG_#"?QR_P"A\$;_P;6'_M_?K|>6BW8SSCID4;1Z?
I6T;,+^1G+),,^I^0O_PG|O|<;M.TW|H+2;&"RL+3X
MK6=G;QK##;V|6J1QQHHPJ*HX"@=_.!7G7Q_.X3O^UK8_\$>(FU80;
(#XE;=K_MAK=D)%7YI@#@,K\$#U)|;_ \$FY>I_M^6X_5-@&\$Y&WMSUI?
X9%_ADQO7LV_XSZ|3^9JSJ6GSZ'J\$FFZE:36-_:N4GM_M+G(HTZ7MW-\$
M;CQ%X;U#0|*TMKY|"2/5;B>_.9I4"R9(2%AC,N?QKZ6|+_P#!+?0;6X(UWQY?
M7|@(|ODZ781VLGF?)=:'48_V=F?>OIK|G?
X26OP3^\$^A^\$X/+;|BC,M_G;T^E?BN8<38ZK7FL//EC|D^MUP^54.2,JL?
>/G+P?^P=|/'# "V4DWAR77KRVG|_|+K6+Z9VD;S3)MDB4I\$R_|
M;3'A@,\$'O|AX5^'7A3P(+G_A&_#6C^'A=!!/_95A%;>;LSLW;/%&|;N; &>FXX
MZUO|1NSA<^N;.=|>M?_UL7B,1|U:HY?-
GL0P|*GLD'DHP.44@C!R*&B1A@H|M&,=* =2US7-
UIL,|F/^XO3;T|>GTI1&JXPH&.!@4ZBDTGN_F*_HJ*6BF_E&T>_ME+10
FT>E%+10_4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!111_M0
4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!1110_4444 %%%!
M!1110_4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!1110_4444 %
M%%%!1110_4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!1110_44
M44 %%%%!1110_4444 %%%%!1110_4444 %%%%!1110_4444 %%%%!111
M0_4444 %%%%!1110_4444 %%%%! \$;J=O'%?&W_!13PU_MRG/S-*/_,"CJ.A
|@K|W>1<5|E%N:YCQ\$X0TSQ|X2U+P_K\$'GZ=J\$1@DW*,H_M"!MD&
|_&5@&5NH(4|16Y|_GSE'-,5AH_M*A7H-S75;%O|JCQG#|_|
(|VMCX8CM|411#HEA+;2B2.YG+R,7!<*B_R3&(-_MNPP&|>,J1^FT*_NT#
(88FCM|:P9OLUJY_M4H|!CM,A>,D#XU/4_BC;:=90D&;|N=)2&.
(DC|HW.!N+|9!_MZ|^ ^-H|/?@|Q/>)|I^E_"0=6OFZ6UC;P2R'Z*ER6_6LG^Q?
%O|*O^">GB#3=)-UX=|4_MVNO7|. '>Y_M|\$?LU_LV_P##/G|NL?\$)UMM6\$&
|_ \$+|_.\$|GS,8 =NOF?I7N>><_5|U?L5_&_MK5?BEX+O|+UZ>XN|9T-
X5;|=>9K>7?Y)=B?FDQ&VXGG:8|YE_M&T>E+10_FT>E&T>E+10
FT>E&T>E+10(3:/2C:/2EHH_3:/2C:/2EHH&)BC%_M+10_F*,4M%_"44M%
(!**6BF_E%+10_E&!Z4M%!1110_4444)BC_I:*_ \$VB_MC:*6B@!-H|]*:(T
P%7&,=*?12L|B^)/!|A|QEIZ6.OZ%INN622"5;;4K2.XC_M5QG#|7!
/Y|ZL>' _#_D>\$|+@TS1-+L|TV#=_Y5G86Z00QY8L=J*!EF).!U
M)/>M*BM.>37+?0GEBG>Q'Y,9ZHIYST|^M/VCTI:*C?(_@*WA<:'
M8:=>+J9N/M#7ZR'9Y9AP\$V_N<^8_7TKZ/YV^|1-
&&^JGZU\$HN6QS8BG.K2Y_M:%?\$_C_H\$>&A_P#N/_DBOM7XB_M?\$31/A?
X9O-<|0W"6|H"2JQQKF69R,K'\$_.C.OIX/'!)*J":|_X>\$_#4=/_#_M
(F_|!;7_P"2*Y91G#>9|G6IU#6|/;XKGKY7+_MG4O|H|K|K\$U-

<D8>U.I&.U2?:MCW7L?FIX-|<:/Q1\4/\$^BZCI4FKV-U&V MV&7%LUT
[9]H2*DN0PJA,GYI"#||>#ZKXZ_P""@FF7.C7EIX-V:H=1EBF
MC^UZ@|436LC)B&5\$ E5QNZJVWI4OP+ ^,8_:R|3:OX7^(7@[0+F&'2I;FTNXI
M9Q);JTB(ZAF=RK,'C;=&Z,ICSW4CVW0_V4_A3X>N&N+?P?8RM)\$(:B7O(L
MYW;)F8;OJK&?>N&*JO| A3/C./A\7*ERX"JE2|/<|M_8.^&.J>\$ _!NN>)-3M
MY+9/\$5Q!-9VLPVAH8PQCF&>0\UOE/39D;E9:9Y*A0 !CZ4|<%&:
MZHIY(V/J.)AXX6A&C'6Q)1116AV!1110 4444 %%%%!1110 4444 %%%%!
M1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%
M%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 444
M4 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110
M 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!
M1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %
M%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 444
M4 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110
M 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!
M1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %
M%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 444
M4 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110
M 4444 %-*CTIU)0!\9?|\%\$M/U>?PYX/GMC)_8:W5Q' R*>#A4G
M8,>C8"|==IX(_99^!7BCPOH]_I>F?V|:30J4U#^U+H-/M^5F<+(H#
[@0R87# M C:N-M8_|>GO-NO"?@72_#\$%C;2)XE>5))KN-9FCCB,:\$*A!
8EEP_5-N5PY M4IXHW]/Q(U"RMWDOM!L!+
LLUM<7\$IE|SLK%8G5J*E2|K|-|I#ZD_X8S^#N_' "*9'_84OA
X|7NB@+A0,"OSL'_3U^))/M_(4)\.? @7.E1S9:(I M6Y|5|\$?L|M*7/PF|5>*-
^*VOZY#-?TOQ+).UVLVD:% M<010MS|J*8_FSN;=YF=^3YFZN^7XN?M11C
LO%('8JK_P#(U'|_/71^&IU
MX^/=1|3^*3=_9OL(28WGD[!)YG,THVD[ESZX%>W?V/\$OAT1@Z%XH_P#
:V_^M2*|^'LUM(^PT<+./M%BW|JC7_9)|8?%;Q(?%*\$R#4XQ
::^SSJ&FI9|F? MS-FU\$W?L=4L3I?D^>-4BCCW>;OV|=MCM_SS-
>M8XYKOIVY=S/O!**H1Y9|Z|CJ6BBK.X**** "BBB@ HHHH **** "MBBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M**
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ M HHHH **** "BBB@ I*6B@#XS_X*&^(+#3_#?
AC2KG1|. >_OI97AU!G_'|I M%%Y?F!.1P_FYGGFV1A? M,9A<99F8H (I
!7/*DY3YTSY_\$9=B:E>5>E7<+|D? MG|_P|(^XZ:/X7'
&Y7'_R17Z&QG=&"5P33/+&X\$1C|JFX':QCR;G9@J-> MBI>WJN?JK!M&
8KROQQ^SA|_B/KTNN:_X>AOM4> 0R74=Q+#04_@%O+=?_!ZO<2B^G-
)C;TP* MRC3A\$XZ>682C#DC"YP'PW^#/@[X2C4&|*Z,VE?-GVD+=33;O*SL
|QC_>;IMZF003UHSZ4E:GH4Z<:2Y8JR'4M%%!H%%!!1110 4444 %%%!
!1110 444 M4 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444
%%%%%%%%!1110 M 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110
4444 %%%%! M1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%!
!1110 4444 %% M%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444
%%%%%%%%!1110 444 M4 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110

4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444
%% % !1110 4444 % M % !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444
%% % !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 % M % !1110 4444)0% Z" EHH 3: !T% & !2T4
)2T44 %) @ > E + 10 F ! 12T4 %%% M % !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 M %%% !1110 4444 %%% !1110 4444
%% % !1110 4444 %%% !1110 M4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% M % !1110 4444 %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 M %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% !1110 M4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 %%% M % !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% !1110 4444 M %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 M %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 %%% !1110 M4444 %%% !1110
4444 %%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%%
4444 %%% !1110 4444 %%% !1110 4444 %%% M % !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 M %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 %%% !1110 M4444 %%% !1110
4444 %%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M % !1110 4444
%% % !1110 4444 %%% !1110 4444 %%% !1110 4444 M %%% !1110
4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M4444
%% % !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1 M110
4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M %
!1110 4444 %%% !1110 4444 %%% !1110 F < ^ U - (- + M K @ _ \$ 7 Q P ^ ' G A
M ' 7 I M ' U G Q | X 9 T ; 5 8 = O F V . I : S ; P 3 H 2 J L N 8 W < ' ! 5 @ ? Q % * * E (& U \$ | P U A _ M & M ?
T _ P 0 6 4 & | 9 E N + N W M R 9 6 2 2 V = Y (U 9 @ 3 ' N 4 , (5 (0 % 0 0 M ; 4 | M 1 E J 9 R | Z . A C _ | \$ _
X Q > , _ C 5 | & = : U S Q K K + : W K % O X @ G L \$ F - M # ; ' R 5 @ M V 4 ; (U 1 0
M M . M 9 5 9) ! 3 ^ \$ = 1 1 M 1 6) H % % % 8 F N ^ * M . | - ^ 3 _ : - Z M I Y O W = | ; -
G _ O F @ # ; H K D O | A : 7 A K _ H) ? ^ 2 | W _ Q % M ' " T O # 7 _ \$ \$ O _) > ; _ P " (H
Z V B N 2 _ X 6 E X : _ Z " 7 _ D O _ | \$ 4 ? | + 2 | - ? | ! + _ P E M Y O | X B @ # K : * Y + _ A : 7 A K _
* " 7 _ D O _ _ P # \$ 4 ? | " T O # 7 _ 0 2 _ P #) > ; _ X B @ # K : * Y + _ M _ A : 7 A K _ H) ? \ D O _
_ | 1 1 _ P M + P U _ T \$ O _) > ; _ X B @ # K : * Y + _ (6 E X : _ Z " 7 _ D O _ _
M 1 1 _ P M + P U _ P ! ! + _ R 7 F _ | B * . M H K D O ^ % I > & O ^ @ E _ Y + S ? _ ! % ' " T O # 7 _ 0 2 _
M) > ; _ . (H Z V B N 2 _ X 6 E X : _ P " @ E _ Y + S ? | Q % ' _ M + P U _ T \$ O | R 7 F _ ^ (H Z V B N
M 2 _ X 6 E X : _ Z " 7 _) + S ? _ \$ 4 ? | + 2 | - ? | ! + _ R 7 F _ ^ (H Z V B N 2 _ P " % I > & O ^ @ E _ Y + S ?
M _ \$ 4 ? | + 2 | - ? | 0 2 _ | E Y O _ (B @ # K : * Y + _ A : 7 A K _ H) ? ^ 2 | W _ P 1 1 _ P M + P U _ T \$ O _ M
" 7 F _ P # B * . M H K D O ^ % I > & O | H) ? ^ 2 | W _ , 1 1 _ P + 2 | - ? | ! + _ , E Y O _ B * . M H
M K D O ^ % I > & O ^ @ E _ P " 2 | W _ Q % ' " T O # 7 _ 0 2 _ | E Y O _ B * . M H K D O | A : 7 A K _ H) ?
^ 2 | M W _ Q % ' " T O # 7 _ \$ \$ O _) > ; _ P " (H Z V B N 2 _ X 6 E X : _ Z " 7 _ D O _ | \$ 4 ? | + 2 | - ? | ! +
M _ P E Y O | X B @ # K : * Y + _ A : 7 A K _ * " 7 _ D O _ _ P # \$ 4 ? | " T O # 7 _ 0 2 _ P #) > ; _ X B @ # K
M : * Y + _ A : 7 A K _ H) ? \ D O _ | 1 1 _ P M + P U _ T \$ O _) > ; _ X B @ # K : * Y + _ (6 E X : _ Z " 7 _ D M O _
_ | 1 1 _ P M + P U _ P ! ! + _ R 7 F _ | B * . M H K D O ^ % I > & O ^ @ E _ Y + S ? _ ! % ' " T O # 7 _ 0 M 2 _
) > ; _ . (H Z V B N 2 _ X 6 E X : _ P " @ E _ Y + S ? | Q % ' _ M + P U _ T \$ O | R 7 F _ ^ (H
M Z V B N 2 _ X 6 E X : _ Z " 7 _) + S ? _ \$ 4 ? | + 2 | - ? | ! + _ R 7 F _ ^ (H Z V B N 2 _ P " % I > & O ^ @ E _

MY+S?_\$4?|+2|-?|_02_|EYO_(B@#K:*Y+_A:7AK_H)?^2|W_P11_PM+PU
MT\$O_"7F_P#B*.MHKDO^%I>&O|H)?^2|W_,11_P+2|-?|!+_EYO_B*M
.MHKDO^%I>&O^@E_P"2|W_Q%"_TO#7_02_|EYO_B*.MHKDO|A:7AK_H)
M?^2|W_Q%"_TO#7_\$ \$O_)>;_P"(H_ZVBN2_X6EX:_Z"7_DO_|\$4?|+2|-
M?|!+_PEYO|XB@#K:*Y+_A:7AK_*"7_DO_P#\$4?|"TO#7_02_P#)>;_X
MB@#K:*Y+_A:7AK_H)?|DO_|11_PM+PU_T\$O_)>;_XB@#K:*Y+_ (6EX:_Z
M"7_DO_|11_PM+PU_P!|+_R7F_|B*.MHKDO^%I>&O^@E_Y+S?_!%"_TO
M#7_02_|)>;_.(H_ZVBN2_X6EX:_P"@E_Y+S?|Q%"_M+PU_T\$O|R7F_M^(H
ZVBN2_X6EX:_Z"7_) +S?_\$4?|+2|-?|!+_R7F_^(H_ZVBN2_P"%I>&O
M^@E_Y+S?_\$4?|+2|-?|_02_|EYO_(B@#K:*Y+_A:7AK_H)?^2|W_P11_PM
M+PU_T\$O_"7F_P#B*.MHKDO^%I>&O|H)?^2|W_,11_P+2|-?|!+_EY
MO_B*.MHKDO^%I>&O^@E_P"2|W_Q%"_TO#7_02_|EYO_B*.MHKDO|
A:7A_MK_H)?^2|W_Q%"_TO#7_\$ \$O_)>;_P"(H_ZVBN2_X6EX:_Z"7_DO_|\$4?
M+2|-?|!+_PEYO|XB@#K:*Y+_A:7AK_*"7_DO_P#\$4?|"TO#7_02_P#)
M>;_XB@#K:*Y+_A:7AK_H)?|DO_|11_PM+PU_T\$O_)>;_XB@#K:*Y+_ (6E
MX:_Z"7_DO_|11_PM+PU_P!|+_R7F_|B*.MHKDO^%I>&O^@E_Y+S?_!%"
M_"TO#7_02_|)>;_.(H_ZVBN2_X6EX:_P"@E_Y+S?|Q%"_M+PU_T\$O|
MR7F_^(H_ZVBN2_X6EX:_Z"7_) +S?_\$4?|+2|-?|!+_R7F_^(H_ZVBN2_P"%
MI>&O^@E_Y+S?_\$4?|+2|-?|_02_|EYO_(B@#K:*Y+_A:7AK_H)?^2|W_P1
M1_PM+PU_T\$O_"7F_P#B*.MHKDO^%I>&O|H)?^2|W_,11_P+2|-?|!+_M
_EYO_B*.MHKDO^%I>&O^@E_P"2|W_Q%"_TO#7_02_|EYO_B*.MHKDO|
MA:7AK_H)?^2|W_Q%"_TO#7_\$ \$O_)>;_P"(H_ZVBN2_X6EX:_Z"7_DO_|
M\$4?|+2|-?|!+_PEYO|XB@#K:*Y+_A:7AK_*"7_DO_P#\$4?|"TO#7_02
M_P#)>;_XB@#K:*Y+_A:7AK_H)?|DO_|11_PM+PU_T\$O_)>;_XB@#K:*Y+_
M (6EX:_Z"7_DO_|11_PM+PU_P!|+_R7F_|B*.MHKDO^%I>&O^@E_Y+S?
M!%"_TO#7_02_|)>;_.(H_ZVBN2_X6EX:_P"@E_Y+S?|Q%"_M+PU_T\$O|
R7F_^(H_ZVBN2_X6EX:_Z"7_) +S?_\$4?|+2|-?|!+_R7F_^(H_ZVBN2
M_P"%I>&O^@E_Y+S?_\$4?|+2|-?|_02_|EYO_(B@#K:*Y+_A:7AK_H)?^2|W
M_P11_PM+PU_T\$O_"7F_P#B*.MHKDO^%I>&O|H)?^2|W_,11_P+2|-?
M|!+_EYO_B*.MHKDO^%I>&O^@E_P"2|W_Q%"_TO#7_02_|EYO_B*.MHK
MDO|A:7AK_H)?^2|W_Q%"_TO#7_\$ \$O_)>;_P"(H_ZVBN2_X6EX:_Z"7_DO_M
_|\$4?|+2|-?|!+_PEYO|XB@#K:*Y+_A:7AK_*"7_DO_P#\$4?|"TO#
M7_02_P#)>;_XB@#K:*Y+_A:7AK_H)?|DO_|11_PM+PU_T\$O_)>;_XB@#K:
M*Y+_ (6EX:_Z"7_DO_|11_PM+PU_P!|+_R7F_|B*.MHKDO^%I>&O^@E_Y
M+S?_!%"_TO#7_02_|)>;_.(H_ZVBN2_X6EX:_P"@E_Y+S?|Q%"_M+
MPU_T\$O|R7F_^(H_ZVBN2_X6EX:_Z"7_) +S?_\$4?|+2|-?|!+_R7F_^(H_Z
MVBN2_P"%I>&O^@E_Y+S?_\$4?|+2|-?|_02_|EYO_(B@#K:*Y+_A:7AK_H)?
M^2|W_P11_PM+PU_T\$O_"7F_P#B*.MHKDO^%I>&O|H)?^2|W_,11_P+
M2|-?|!+_EYO_B*.MHKDO^%I>&O^@E_P"2|W_Q%"_TO#7_02_|EYO_B*
M.MHKDO|A:7AK_H)?^2|W_Q%"_TO#7_\$ \$O_)>;_P"(H_ZVBN2_X6EX:_Z"
M7_DO_|\$4?|+2|-?|!+_PEYO|XB@#K:*Y+_A:7AK_*"7_DO_P#\$4?|"TO#
M"TO#7_02_P#)>;_XB@#K:*Y+_A:7AK_H)?|DO_|11_PM+PU_T\$O_)>;_XB
M@#K:*Y+_ (6EX:_Z"7_DO_|11_PM+PU_P!|+_R7F_|B*.MHKDO^%I>&O^
M@E_Y+S?_!%"_TO#7_02_|)>;_.(H_ZVBN2_X6EX:_P"@E_Y+S?|Q%"_M
M+PU_T\$O|R7F_^(H_ZVBN2_X6EX:_Z"7_) +S?_\$4?|+2|-?|!+_R7F_^(H_Z
ZVBN2_P"%I>&O^@E_Y+S?_\$4?|+2|-?|_02_|EYO_(B@#K:*Y+_A:7AK_M_H)?
^2|W_P11_PM+PU_T\$O_"7F_P#B*.MHKDO^%I>&O|H)?^2|W_,11_M_P
+2|-?|!+_EYO_B*.MHKDO^%I>&O^@E_P"2|W_Q%"_TO#7_02_|EYO_M_B*
.MHKDO|A:7AK_H)?^2|W_Q%"_TO#7_\$ \$O_)>;_P"(H_ZVBN2_X6EX
M:_Z"7_DO_|\$4?|+2|-?|!+_PEYO|XB@#K:*Y+_A:7AK_*"7_DO_P#\$M4?|
"TO#7_02_P#)>;_XB@#K:*Y+_A:7AK_H)?|DO_|11_PM+PU_T\$O_)>
M;_XB@#K:*Y+_ (6EX:_Z"7_DO_|11_PM+PU_P!|+_R7F_|B*.MHKDO^%I
M>&O^@E_Y+S?_!%"_TO#7_02_|)>;_.(H_ZVBN2_X6EX:_P"@E_Y+S?

%%%%%%%%!1110 4444 %%%%%%%%%!1110 4 M444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110
4444 %%%%%%%%%!1110 4444 %%%%%%%%%!11 M10 4444 %%%%%%%%%!1110 4444 %%%%%%%%%
!1110 4444 ?+/_ 4 ^,7C+X*!G1= M<|SZRVB:Q<>
((+!YA;0W!\EH+AF&R174G,0.?O-!/?A\HLKQUX\A B.Q^ M+?
A2*SUJP@U*WCN;2%)5BEC1U#!=/9@Z+96=W+!9VS1DQ6|<9=&-PI8%@"
M"57CM7;%2JE>"NOZ?'^ ^G M:2>5+:4^3E#&SQ^2%:&)UW*[E<-
G\HSQ7YY>"?5E^W-^T;X6\476K6?@OPO MX+O&_L/P\J-LVK:Q=Q3>>9!"
(G1&),CQ_5G\0B_%V\,Z7I M?PFN=%T\5;^ \N\UW4I1_P
2^%4,@9(6C=7W\JQDX8J!"88R195(:Q1K3/8
M1\4_6OS\^(G\OQ^ ^!OA&_ |>>&_V@|=|8W>AP->SZ?JO F"\$6NQQ)(\$FN)HI
M651NVLIZ,RX955O9;|K#45_8K_X71IVC17,J?8(Q\CN&?,7RH)
|BB2.&:)5.UT9"6FD M96 DFD(EVOL?'FQ?.FSY,OX8_P#*4'XN?|BQ;_|
HO3*UOB% MXOUZP_X*-"_PU:ZUJ-MX=O/#L\|SI\$-
W(MI/((|OP|P@|&8>5'@D9_=K_= % M:V\|3^4QN_|R8^N-^:-U?
%_|>7Q2^(/PS^)WP1'P_U*9-7U&^OK=-:9A9Z MH\9QOPSQ\T1AF4C<|
(&+!T-'=/U* M\MK.5S)N\N*<3HD>Y>5'D(JDA/D7YJQC17+=R-
N=GWR3\T>M?,7\|O\4%Y\6_M/V>-3\>-Y(:*3PW<7%GJ.HVJ-(MS%;VR3MF:#
<.|PZJZ1L9#"T1D7='(N\W)W*S)%&C M@"?8O6X>T/T!L: ^?"WQ&^)W\|7QF|
(_#OXB^)_9_B5X(7SK9Z)KTA_TZWN6 MF13OWLTA427"!Q)(X"&,QL-
CPU\PYJ91Y2XRYA:***DL**** "BBB@ HHHH M**** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ****
"BBB@ #Y9_X* ?&+QG\%?@SHNM^"=:;1-9N/\$\$%@\PMH;D^2
MT%PS#9(KJ3F,'/M71_L>_'G4_C9\,93XD26S|= ^'\N32M4R(Q"S&#_M.Z/S
I5@RKB2*=44!1GR_|JQ&O_S SX<.T<>*+=AQTV2\YKQG1=-E_9)|
M5_!CXW61@@^ ^'OBWPWI>C>)EB\I&@N9;2,R3+%'"S\$8@6?>YH)
(YE8KY@SV1 MA&5*_4Y93Y)GZ<=J^&?V\ VT-<^\$>NZ=X%^ ^'NI-
I_BF\$)J>JZE\$EO.1' =R4D.=C*GEE=P=@OU-|O/C)X<^&OPIO|
X@ZG>M=>&K:TCNH\G2R+ MG\0DK*D\B;_QS(SQA6W;/G\+!7EI=0" M8-
FSTX:C;%(H_,0O'\$\;BJ^8ZM"EKM88&(HQ7-S,NI*VQ^@/P2\1ZEXK^#?@
M77=8N6NM5U;0K&_NI_+\$.F32VZ,Y"#A1D\!QS7=Y-?/GA7XF:?!|7\BOPGX
MOU.*22VTKP;IKQVC;UDN)C;1)%#E58KYDC1INV_*7R: ^>/AC\,VA?VK-('Q
M"\2_%O7OA?H\|C^QM(T598DEM\R,)/*BFC/EG< CR%Y75=Q.P(S9^SWD/G/T
M*)JZ/QKX2^%OQ0^+O_/Q\T?X5?%?6KCQ9XA0S_&30?
%5X&DDDF9W: +|Z% M=RTDCI#)%(3Y);JXCVEW_M_\$KXNZ5^V)X2|
(_# 'Q\$MM>:YX:6U.G:A,#8H MS2WK/=-\$V4\$D4<(<.HW\$Q!=KJ?+
<|BW(/:'W3^-+GWK\|OB9^S?|?_@Q\W\ M?
\$OB/5M\MTU74\|DO\|D0K%"@>=DG52A)22-0R\$G&\Y'^A?!_B+Q
M+ ^UM^R?8:G9Z\A #GQ#X@C4#4=
(\$CO;O;WVV0ILEC=5E6\$C;YF5\$Q\9\F6#6_F-/,-|S'*TK\$|6+- M;|EVH-
@?;|_WZXS_(*6>-O\$7@/X\$Z%?^&M?U3P\|?R>(H('NM)O)+65HS:W3 M%"T;
E254XSC*@\J^7_VW6E\5\8>-/@#^T- M\8\K5/%>H?
%N7X::A)#G3?!CAVZN6L\6,1HHX\BYC>,M)O9UDE6-OP2FX!\$7 M:_8/^ -?
COQYHOC+P3\0X_A %'\@&>*PN+Y\|D)9\G,A9_88\3O+N>
M@WGC2\|7^\$?'^F: M3'+
<7^FPPQ)\$ENEN|M++ ^YMW(7A_W3AC\F\$<\$BOIK\JG?X :) ^T=|.8?%NA1S
MVBB=|*|L9S\|K=1A6>,|V12C(RLN,JV3M;M#4\SHHHKF.@**** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ #@?C=XDU+PG|
M&_'.NZ/. *^4_V#_VNO&'Q,|27GA'X ME:F;S4-3M6U/PYJ%Q9PV?VJ.)VBN(5*
|!+AE)4JC\|S<98\|E^GOVD\$#?L\? M%# @8_P"\$7U0?^2DE?
E\)_@WJWB+|E.;XJ^#GMHO&7P\|5W6JO-MM_,DL8\> MTG.2RG>8GB65

75=OG;0Q=5KMIQ@Z4KG)4E-3T/V*[YKYZ,:%_:0B_9V^%\$U
MY:W#R^+M<,FFZ# KQ!DN3\$W^DE&5BZ1_*Q&QE+M\$I"B3<./^!/?
OETCX|_#?1 M_%FBS1F*\A7/5;12F1K&Z"H9K:0E4.Y&8C/H#+AA\K"OF?
X1ZF/VPOVK-3^((M^V:Z^&7@.,Z?
X=2|@D2*|OF&6G,4BLF5;S'W+Y<@46#.,|.>\$+2_>=#24N9: M'>_|\$=_|
XQ>,_C5\&=:USQKK+:WK-OX@GL\$F-M#;'R%@MF4;(U10.I^R6?-
<1#XZ^,G|<'Q2UNV"|>,+[X;_" + M1|EHH?\$&F1R1&YD166'#|H9I9)?-
#M#E\$C01|OG"&6YT^:K"9C#@E51@|SO A#\$B6(R>6KH
M<(DOO_ |8'Q&N(V_.\$?C#PAX@O+#+|5;Z;:=K&GS/;3-#-=VVUD92C)N23'4
M9!:>N*CV3T'|1'TEGZT9^M? W@7X,?M%_M&^='|<>+/C3?_ ^2^TNT^P:?
MX=:4+4TL6%:4DM*C"X61/,*R*ORLO*I&W2_O!|1'JO|1W|0V
MN?!_X@?|WPQH^EV=VGC?7X|'"O+QI'-O LUNCB)4(RSB<88G"|#E'W';Z!|?
M-4O-%^!/?Q&U#3|N>QOK7PYJ4|O=6TC1RPR+:R,KHP(*L"
01R"!7P%^V)|" M\$^E_M#_#F'^V3+_H'EV=QD)YEQ)|_>N<8SM&:ODC
MRQ)YY>|=Q^PSXEU?
Q=^ROX&U;7=5O=:U6X%YYU|J%P||NV^G5=SN2QPH &3 MP !7O?|
%7YR_LT_# 'XP?&O|F_P1I6B^.)A3X TU;UK74-'F=|3U:2-5\$F6:-
G="C|OJO@'XV^+7P)_ :H/P0|>Z|<^.|!00R:EI&M7|
MZTUPD:02OYREV+A7,#(UNY(1\LK;1NF4Z2E*5AQG|D3|SI**X?XK?
\$W2/A%X M!UGQEXAFFECT;2XE,ZVT;22LS,J1HBJ?
F9Y'C49VCYLLRC...;>8W/(OVQOVG M&^"_@V/0?"LS7WQ-
U|QOZ'IMK;F|E"O(JF9HOZ_-'%|I?*5 5E63;Z)|#=#| M<:/X)TR?
X@>+ +_Q%XJO|6.6|M;BULX(-/F(+/%\$+9%W;2P1F9Y-QCW+L#\$5|
M\$?!SQ1^T3|3_!1QL|?"3XH>#QX.^=(J'"1VL3M;W1C!E=55M
MWE@1>6ROO=)-KE6'|L-V2I|L.6)RQG>?,?
7E%%%IF\6S^U,2D4J;=I=.#YM>+;:^P+|4-% MT^UL-A
VGO%EC8VL206|K;6|U'%#&H"JB*MJA5 X %=-/%PY;G-KS|JC
MSK_@I'I.C^&OC+/\$W@I1#|7;RY5OLUE;+--=^5)&+&;1-^2Z2JRO_NG|T!
MU9L0A#|A^T|^T5XB|_ %+P3|'_ |W|X=|3^+)|:27Q)?I!)'9VS3.A6.&9E6
M25A#)PPP0%C3<|@H?!O|A'1?'Q!'CWQMXKU3XG>,HI_-L|O6A 5QE%5892
MCR2-).F#M=GPH9,('0/76?M*?LIZ/^T'=-K,6N7G@_QIH@)TW6M,1?,&&1Q
MOY1V\ME8IMD38SD|Z?/#W4.T_>|)_ C1^S7J/A7X(^/?\$|B|X|>/M6U+^SKZZ
MD#;LMAI-U-(&\$-M|BVN!'(|1QF-6PQ?:@4,\$'0_L=^&?#?C3|A7PEH7C&"TG
MT#5!=6=Q:WQ"*|MJDxcc!/S"0R% FTAU<+L(< T|PY^P?9WMO>GXH>/_!-
+M4K|H2|T^TEU:Y<6^F)/&\$:>"&9Y|3@;F#LY_ =G900,.R|+_+)7AZ'|FG3?
M@SXCu.^|0:9;M,6, M5N1%7;)Y6-RA@F!LKZ=^'OPA|_#?X;Z;X"L-:Z|
V=E)920:H MWVD7*RDM*)_#&5F9F&-F6*J#@ \$IQZZARL^8?
V:_P!E'JG;XN?!GPIK\AZ M+7-
4^Q0P:S<6^J7|6S4(XU%RC1B?|T?,:O&'5ERL@9070A_P#LO?_X5_\$
MRUN?#.DV>F^--/M6OK2W&N74MTELP>!Y6MY)F!C_ 'C1|RA
R!D\$#'E%U_P3 MGNO#/B/5+KX6_%KQ)_|+U+9+<:9:M-.ID661HPLD>+
|W6;SQOX_NE=9M=U2,!4,CNTDL2?.RR.K@.SR.3AMI1
M9'!)27<48R|!'_#/_E*|A7/^Q8M_1>F4?S\$E*|!(^Q8N/_16IUZ|X9_9V
M/A|H+Q;A7U|1M)\,HX!_TO3NOY#|J^S_+4+@*.F.G:O#_CG^SB M_P9?
B)|+/%7_"2'29/_^I'4S9_8C.+W|H;2;WF+Y?-
MU_ |YX|?/J9^\$^H7S2"^MM(5VA"L(CY5N(Y8VABRI8IEAED"
M|\$0+71|2,N;4SY9>|H=KI?|(OP ^'WC|PM):>'K#2_%O!>:-%<:|=+/-);,
MDKM'"|Y|/81&Q&&ZY.!7TM^-?*/P7_82T3X>_ \$+_ (3|QKXKU3XF>,XI=H>
M:QQ'L5%AD*/)(TDR;/E=GVJ# 'A |:O7U=Q7/.QK 6BBBH- HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M **** "BBB@ HHHH **** /BW_@JQ_R;SX>_|&>W_P#2.|KTWPK|+
|+XP?L8 M>\$O!FK.\$BU;P9I<9FC5R+:5;2)XIA&KH6"2HK;<_-MVGC-

:G[5W]L;?M-?#O M3_"S>(F,QV>I1:F;Q:/I4Q*12IMVETX/FUW_P-
?"7@'X<^\$O#\$=W|O70| M.M=,CO=@!G\$, (CWX&=N[9S6W-
|D;&7+>9^: @ _PS|0/CAXP|_LP>,L:BPT? MX?WM|=ZMK\$0+27-E'M2\$Q^>
Z@"X,44B#;Y-VC>7MB!;|_|;UTVST7|BWQMI M^GVL%A86D.G06|K;1B.*&-
;ZV5\$15"J% &!7TGY:|0HQG/3OG.?SKS3 M|H#X0-|=OA#KW@=M6&B_VKY
-Z;=KA4|N>.?/E^8A.3'C|XX-'M.:<9\$>SY8 MR/GSXT6%SJO_3&LH;>S:
|E7PIX?G:..!2WR+|C=W(7&5159CVVIZ5|'^R9X MUT7QM^SW|I-
\$U*4UT_1|+3+Q4P/LMU!;HDT3CJ'5ESZ%2C+|KJO|;P3X|L M?#?PG|/>!
|QXM>TVPT>WT25KJ!7COH8X!\$PDC.X%7"D,#P3"X7|U;2 M.R|0@#G *\$|?
Q_ Y2??"(=AX7N/^>|5W?|/'|%OAOX%^(<SQA>ZQ>>- 'M|T'|7M4C"-
(|F2:)/G99763#N|CDX::465P>D|3_LYMX@_:@|(&!O\$C6Q
MT/39=+31_L09;@,MU|WG>9|O_'R?XA EGUYJN:.P>?|\$_^30?
A^W|6V|4MWP-0N,"O8?B5X57Q|_|_%GA>2|:P M36M.NM,>|VY-N)X6C+@'&
<;^*Y_JG_X/M|"?A#H/@8:NNM?V5YP%Z+=K=7|R
M>2?/E^8Y&#)C|YX%9'2L>Y6|46X+9&0/L=YM88X89/0^M7?B%^P'-JWQ:U
MSQ|/_B7K'PPN=;,DNH)8)+(D|C|IV\$J7\$;"-RJML;(1ER/EVHG9_&?)C6Q
M^~)7P#|*?"_2O\$|HHNG>&|R"X@OM0A.HS2I'#+&0V^1<9:4L"N @4(B!<;|T
M.>|F?++DY#Z3|M=HRHR.>G^?4U|7_L-
*#^T+^U\$A&53Q02J|E)N|0SCTK|2 M|UX;|#/V<7^#7Q\$^*?
BG_A)#JTGCC4QJ8L_L1@%E^|N9-A;S&|SFYZC9|P<>
MG/&7NR+E'WHGN7XUXO;?M0>\$9?VA+|X.3+J%OXNMH!+%)
;J+2X_T=+C9\$P<MLS|'S|RJ/D89SC=|/@>M>!?M*?LB^\$?
VEM)@.KF;1/\$5C#)%8:U81@RJ&5L1 MS(?)="<,4RA!#;73S&)(J+^,C?
%#P;X2|=>#M0T|QWIVG:CX>6&2>Y M?
4E58K=51PTH8YA9%+D2@J5ZA@>: ^9_ ^"6>HS77|_|^LPS7<|S:V?
B.YBMQ<M,VV""|_|:/A 3@)N=VPO-9G'4&LV^_P""=?
B#QI):V7Q\$^/GBCQCX:M9?/DTV M6*13YFU@)%:6YF56
9ADH3ACSS7UYX"\$Z-|_|_#6F>'?#^G0Z;HVGQ"*WMK<
MY6)02Q9F/+,S,S\$G))8DDDDG24HQAR7\$HRY^:QU%%%%%%%%8&H4444 %%%%%%%%%
!111 M0 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444
%%%%%%%% M!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110
4444 % M%%%%%%%%!1110 4444 %%%%%%%%%'F'?[2_]O?Q/_P"Q7U3_-(Y*^>?^"5/S?L|>
(2> M3_PD|QR?^O.SKZB^)^7A5/'WPX|6>%Y+UM/36M-NM,>|V9-
N)X6C+@'&<;^*| M_P#V4/VH^%E|0MXFCO-2DU,7C6?
V5@7BB3;M#OQ^ZK;K4N4RY/? MYCX>^+'A|Q_ ^RIXN|= _!|P78_P:I>%?
BN(4|/_FHEC)-<^1):(|V^%I/*)B M=G;<5>VD,B|0@^_?
@)|%=*_9_P#AHO@|3+G|:L(,ESJ4MO'%)?7#L=|DFWJ M!E\$4-EE144N^,UZ?
Y,>2=BY)R3CZ?X#|J%AC0'9&J|8.%X'%\$JKFAQARGQC M_P\$J?|
DWGQ#_V_|Q_Z1V=8G_!+GQ!I6D_#OQCX%NI6L?%^G:|_|>7NAW2/#
M=)"8K> NR.-Q(DB>-E'W& #8)4GWW|E'|G-OV9?AWJA8>(6|3)>:E)J8O&L
M_LK O%\$FW:?'C|U7 ?&;|A'1?B!|00| A/O!7BO5/AEXSEE#W=YH_,Z_-X*.->
=#T'|F3Q#H-|J\$-OJ>MR MV|&GVNX--VTFGW-KX
M9|6|EI=AHGBD6:S5D93|P96&,58|%.?|\$_|"3QU8>*/BM|0=:^+&H6!B6QMM
M7#K#L0R-Y4XDED::+>0X3*C*/NWJY6O>_C|'|S|=?A'KO@%|+SQU_P!#
MB_P'Y5|_|_#!0/^"H'Q:X'R^&+<#V_=Z97U'|_|O"R^?A5X3|+QWK:@FBZ;:Z
M6EYMP;@00K&'(&<9V+OC OB-KAM-
_MTLR_M#_LM;D9MGBEV^7!.T7%@69L
M!1Q7T)^T;,&_9|^)^5(9/'^J%MV/E'V67YO7"!QZX/I7(?M3?LLZ-^U)X8T
MRPO-3FT+6='G::QU6&-IT19&0RJ|6|5=6\$;.!NW*5C;.-R/A?#_ID+5/#7@_
MQ|9^)_BAKWCKQ-XLTB?0UUC5FE>*SM6BD1"ML9G\$A5Y|'RS|_|0JGE|H;?-'
MEB9VGS2+_P#P3W4?|_|_?_X'/VX|_|_JH7|S^=>>>?\$U%_P""H7PC)4\$_|(|O<
M+G';R|3.*^@_V?|X/M|"?A#H/@<;LNM?V7YX%Z+=K=7|R>2?/E^8Y&#)C|Y
MX%=YGR_P#R?X/^6?7 MFCFCS2U'R^|\$_|RYQ7Q;_

%4-.GNOV>=%G2SDNH;7Q+;3S/\$I_T>,VUU'O;T M7,B)[7/Z^T>U!|N.|
(-8(I?36@F=|P(I1(MV9R6#*5V\$-|X92&.(KXM_-DMT;?
|%/#@OIF@6G|HZYI)TZXU+R|N+9;01W M4|U@QD!XY8X\$EE(9C06;,*N2-
-4V/!..SQ#X+FN[3X='SQ1X+WDGG)IL4 M4C\$R;54N[17,*L2JJ,A
<!*|VKV7|FG|D?PA^S+L,QT5IM8|17D*17VMWT864
M@*NZ.%!_J82Z;MF7))7>|^6I&-&F^:#N9NT9^E*%|!2T4_|I/F&Q<-
UXZTNQ>NT4ZB@ M!IC5F#%02.AQTH\$.JQ8*3U..M.HH;M7CY1^5.HHH
;M4X)4\$ 2@HK8RH/X M4ZB@!GDIG.Q<|X|T^BB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BB MB@!NQ>3M'Y4NT9)P,G@FEHH
2D9%9<%01Z\$4ZB@!-HR3@9(QG%-|I/F&Q?FZ M|=:.?10
W:OH/RH"JK%@H#-U..33J* &[1D' R. :%157 4 >@%.HH :8U9E)
M4\$KR#CH*.;>(LC&-"/3@G|ZDHH 2DVKS|H_*G44)@4AC5CDJI M/KBG44-
|M20=HRO3CI2|1Z4M% !1110 4444 %%%!1110 4444 %%%! M1110
4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 4444 % M%%
!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 444 M4
%%%%";1D' R.!Q2;5X.!D>U.HH 2EHHH :54X))'M2&% "E/HH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** " MBVV@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** " MBVV@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBVV@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH ****
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBVV@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M**
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBVV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** " MBVV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBH& M=8|?=O*(G5GAR!;:DW7O17B_@+XP3>)/B'JFFS.WV";A
99.0K!!EL'9| MV|?-S|W&!7LZMN4&NG\$8:KA9!=<|5?!GQOXTTQ
MQ=|H|OD?;V|2LS6T?V6-)/; V#+AB I7E73IE2C'W;F\$9R|'W3JFHP:
M3IMU?WUY'96=I\$T|MS' %&D>+M&BU;0|6L|9TF M;
<(-3|I9H&VLP;\$B,00&4C/;IZU|G?#?XYW_P'T!^P1|0-8UM8SXAL= UG2
M=6F^S)!#H#8 ,3IN/R#>LA5_@45WW_!/?_DS_.Y|D7Q/O|13"X

MK.5/EB:1ES'T;NHW5Q/BCXN>"^L1Z=XB\9Z#X>O)(?
M\$=KJNJ06[R1EF!D M59&#%0RL,CC\JW]-
UBWU;2K2^L;M+^VO(5N(+JTD66*>)E4K)&XRK*58\$\$<-
MVK/E95XFO@T8-8>M^*J)\)Z/=ZKK.L66D:7;E/,OM2N%AMX\Q"H#
(Y"C+,@Y M;DM\UG>#_B=X4^(7VK_A%O%.C^(S:E!<_P!DZA'=B'>25+F-F"
[E1BN<9QQ1 M:07.MW4;JR-2UBWTG2KN^OKI+"VLX6N)\J\D6**")58M)
(YPJJ%4DD\+WK\+M+_ %SP7XXUB33O#OC/0?
\$5Y'#JHEM=*U2"X>,,,H\$C+&Q95+,,!D\=/6CE87B= M+JFH0:1IMU?
WUY'96=K\$T\MS>1@8JMX?4:1XNT>/5M#
MU:SUG29MPAQ\NEF@?:S!L2(Q! 92,INGK7&_M'PO_+ #//Q241KM/A;55(V
MC!'V.08KQ_+8E!::!X!_8\^'UYXDU_2\#L))K^U%YJ%_!'%)*;^Y(4,[*_
MRL2G4;7\#EJ/- \$GF\ZQ\68-->&'6@>-!-
[_ PUKVFZ\H_%_4M8@TG2KN^OKI+"VLX6N)\J\D6**")58M)(YPJJ
M%4DD\+WJ.4NYJ@&G5P._@_&SP%XHU:VT01/'WAG6-2N!F.SL\7@FN'&-
Q*1HQ M+<>@KOLBJDI1W%>XM%%%(84444 %%%%!1110 4444 %%%!
!1110 4444 % M%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444
%%!!1110 44 M44 %%%!!1110 4444 -_&D8\,FC/%@DU^8?Q2_X*-\$'Q)K
M5W;>"EMO"FBORK+!-:K+?>400\$E9_,B!;[_^T1Y&,!VVG?N_!' @HYXFL=;T
MS3/B7':W^A\?*_N\8MK5EO87DDS'*ZQD(8'R;4C#\1NRS*5?ZF?"V9TZ'MW3
M7I?4\O\ M7"_L\GZ0\T MC#'\!KXU_P""K\$2'\G7P^NQ=K>)X
PQP,/B;X4^'QM?_A*?%.C^'_M#=%Q;?VMJ\$=H)MA!8H9&4-
M5U+8SC/-9QCS&AUV#1@US7A'QQH/CW39=1\,> M(-
+OV*S>3)>:9>174\$*H/#*M'BU;0M3MM8TJ9F\$5_IJU'F
<.:>*>H/#=E=RLS,W.,'\W;.:YCGU*>%RKME0VSVSQ7L7_#J7X2?|\##XP_+M
VT_1JZ/9QA&.NYASREL\[*BN&G(V9*D9))&<'HPQP0:LG-?G3\0KGXI?
M!/'5--UK3?\$TWQ)^%FIW,>F1Z9K\Q(6TORV+1V\?P\6\E)%66)#'NSOA79'
MN^~/#?B.P\5:%8:JIUQ)>:9J5G#>VDJ+(@GB=!(CA' 925/W>O8\UG*GR^!:
M1D;|%<3XG^+W@OP/K\$>G>
(O&>@^';R2'\1%:ZKJD%N\D99@9%61@Q4,K#(X_M*MC1/%FD^+-'M-
5T;6++5\+N" EWVFW"S6\FTLK@2(2IPRN.&X*^U1RR#FCW M-
W!HP:P=>|5:9X5T>75==U.VT?
2H642W^H74=M!O;8H>1RH'S,J#/5F4=%/B%J\X1;Q3H_B,VI07/\DZA'=B'>:
F"[E1BN<9QQ1:15SK< M&C\JKYAV.3(%+?=W?P;A@9&1_%7&:%\;/
7BC5K;2\|\$|?>&=8U&X&8\,SU>" M:X<8W\$I&C\$MQZ"A*4AW._HHHI %%%!
!1110 4444 %%%!!1110 4444 % M%%!1110 4444 %%%!!1110 4444
%%!!1110 4444 %%%!!1110 444 M4 %%%!!1110 4444 %%%!!1124
#<9SBD1B,\CQ7RO^VU\8O&?PG.\$0 M/A;5SI:WPNS=E+: "8MY?
DE=HE!Q\YOSKY>_X;(^,'_0WS?| @KL_C5E73K1J;&F"S:ACZGL
MX)GKO.#5=9#R2^_Q^7ID'^\UQG@U:KXK_P""K\$:'\G?0%V+M;Q/
&&.#FUNV M.?Q /U
KHQYYVUI>13/9RY8!)41MRMN1UVM@_NV\#GY1_X)40I_PSOX@4(NU?\$TX
QP,6 MMHPQ^))^!-:O\(_[*O@?X*?%3QGK7A_XC0>-
-0@B.DR:3;>29=*C:XWA+ORV M8F;?
!DK\$H*2?)Q\ERIQBY)LSC.4^5GU_17(>,/B=X4^'OV7_A*?%&C^'#=% MQ;?
VMJ\$=IYVP@L4,C*&VJZEL9QGFM/0/%&E^+-'MM4T'4\75\+N1F&^LKE)X
M"W#/UY-?3/BGXO^#/ M=|EAXE\7Z\X;OVA6X2UU?5H;:1XR2%8*[
["5==QZE&XX-7\W(L7-[UCNJ6 MLK2\9BUFSM+VQG@N["
[A6Y@NK>42))&PW(P89!1A\|P8<\$<8!Q6I6994\|*|E M9F9N<8/YXY("ZU-
O;(_P#KU^9W\?7A.P\SC",==S#GE+9'V5 M%
<-:1LR5(R22,X/1AC@@U9.:.GXA7/Q2_X)XZHNM;:XFF^)/PLU.YCTR/3 M-?
N)"VE^6Q;:WC_>':WDI(JRQ(8\IV=|*(JWWQX;+1V'BK0K#7M.N)+S3-2L
MX;VTE19\$|3H)\$<(X#*2I^|U\FLY4^7WC2,C?
I*X+7/C;X"\+ZM/45TVFZS!JVE6E\8W27\|M>0K<075I(LL4\3 M*I62-

QE64JP((X:M4)O'6@>"+-+Q+KVFZ#ADX5NM2OH
M|>)Y3G"JSL!N(1OE'(V.>W)X1|<:#X|TV74?#B/3?\$_BLWDR7FF7D5U!'*
M"4W1LP!PR?+G.&!ZFBS'L#PO|7/!?
CC6)-.1.^,|/17D2CD)/H|/#&#U(|A^5>C@,11PU;GQ\$.==CQLTPF(QE#V6&J<
MC[GS+_PN?QJ?^8R_@-%_P#&ZKWWQ>|8WEB|M=ZQNC&|=M#_A7TO-
|/_#"MQMCPYI.<.-6M-4|1W#Z786|EIT!*1);1+&C*!E6P!R/F^G MRU|WE>
(P695&J>&4>7KH?F><8;'Y13BZF*E+F|3(T|5+C3M12|LMRSPXR)#Z
M'(_6NR'OD|9J,#67Q_U|Q?|QNN'W,S%FY9NI)Y->E?J;1|7IM&U72K.|^
MT+YEM+S.-"G2>(JTE/E/G3G,|M_A<_C0?|QIO_&B_P#C=>L?
XB:QXU74X-5EBF>S\$>)HTV,Q8ON#KT&-J|M/IU=Q'V#(7YO#>DY|K*A
^)K2L='L-%MOL|A8VMC;_P#/. "(1K^0&*_.<M;F6!Q5+V5"AR/OH?
JF791F&\$Q\$;U;\$NEPQ2RKNU&.4,P>2/Y=L<@^|U(KV?XC?
MU/^T1X6U;X>?!WX<^M(M=USQ!83:=>MJ,4<7|G6|VR!|L,CXXG8;|)
(D1@K,2I-9/|&8_XV&?"NM-?|JD_'S^=?HFUO\$^T&-
#M&%RHX!&,#|*|BI*G&7PGT|./\$^/?A|_|_|
M9^_8+^(NB:PP3Q%J.@ZMK&IVOVE94M)GLG18T95Z".&/+/\$;Z?
+>RIL,NQ5ECW@/(9/F,C@S?,YRN.,_87O++X:_M+?\$KX6>\$O%|OXMQ|
K8IK-A>PW"W\$8D#6X^5XF,0(6Y,+D+ES;H?DV|:B_9ET_|FVQ^\$^F^/?'
M>I^&M7|>WEM=RZM/XLO8|J_DD-S(|L+&6;7<^%7;RIYLBX.TC*8OV2|9|
ZMU^WS|1;_,&Z+_PC_AJ|,K+|J+(6"F-IX69(. *DQS(O)69&(!=JY?C
MN1_*0Q_#FZ;_D_:T|=?)C?75MX!^%|-.3P_#./|<,))\$*(P5BS/:L|C#|MX%"
(#|UX_=8_V!/?A/H_BC0|>|Q^(!?VHZ/,9LZ%KT|+7*,%#))(|/*B%=ZG
MRVC8AY!DY7'B/PQ^*&E_LG_ME_%;PUX_)TS3?'FHQZG9:T0XM;:-
Y9WMVE9T M4>6QN&B:096*2
AB5W.OTQXJ;:"^\$GA"|T6R@|867B34=8NX|.SL/"|G59FD
M>6.,Y6WWA0/,SM.&8(XC61OEK*HQB_AE1Y>Y|G?
M<>/O#Q_:_GNOAU|4/%^MJ>"OAKX4L(KDKIT;7
O|0FC1E9E6)|AV7&%#!P%@DV|3(VWE/B^G|)%OX%EN M?A=XGO|
PCX^TQ5U/1KVPAU>21HQN6+=<(1&'95R^Y"C.O(4J_IGQ(^('\$M|*O|?
U_XX|80-)X2|::3'9Q:C:I*WV-EM'*Q&S\$C)+9Q|HX|S".=&.250_1
MWCK|L'X0?#WP_=:K=^.|&U8*L,5CH-|/?W-P1\$|A1'&Q*Y"%=|A5,|U.
(|_,\$S7_BY_P3W|0>*O\$+1W.NW_A+6HI9;>,*LSQ1W4() "@KO M81 MM
0LQ"#&!7EW|'?|*OA'XQ_LZ^%=8^(C7GBNS O%T?2)+F:RM|&@^US>
M:JK#(&>6;7>|CN22!&HP(LM|&?\$7Q|HWQ)_9#|;*>=,AO+;3=4|':E>107|!
MAGCC:SD."IYR"?
|1_P"\$!^(\$RZ=>:3?:A')%YQN/*"1#R|X%L+B"1&DR|!F7S"&?:I?'
MWP|K7|7G|85Q|(+O79M\$|#^\$;"+4;^&WF'^D,|4;-(J|,><1.5B-F)&
MCEM4W1Q|F6.X5N2P1MU?>WO***-I%9!@MY1<,-RLAC<-
@XK"7,Z7|PT|U2|P^NJ*** MY3<**** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHI* \$STKS
MSXY_\$&|^%_PE|4>*M.LYM4NM,LDX+>&!IMTG12X5E/EJQ#.0-
'ZPZBY.Y|K|&IS|O M)|YUW@/|JSXK?#/PAIOAOPYXF72=(M
PM(38VCK^|8R?,|D1/.3^==/I_P"W MM|;|. ^M9Y/%|_|YOT ^&|/)?PV|!>"
M=*T2^|Z#XHO;6,K+JVJ;-;27%Q(7)8L2F2%+;%4DE5_4DGFNT_X9|^%Q7!^
M&_A/'_8#M?|XW7Y17S_"=SGS82_P!W^1|73R|;|^\$^_8
M|^'7B00I8_VUK&FWPMVF\$@A|VPN9_@? #D\$|3@#(S7U;^S?_,F|_"_+>?
M2O|TCBK YV_X*KQK_P_|Z_"5;Q/:AAZ_Z'=|:|(^?QY^&VB_?X=V6H?\$
M7PGIH|^&M/@DM;K6|>*2)UM8U965I-P8,,=:)G|U*|\$>|W9ZGK_Q'62>
M_A|XE|3L;->RZ/IEUJ0L|^T7#0PM(\$W#.T'9^M?#|/*|)VF?M\$:'?_!B^M,=
|<>--0|3R2&VL?M,|OM\$*O#WB.ZO|NM->6SU&.ZAMY+F&2.,RF(N5'S-
^"G%?-|!|/3'@_MPH,T^%OC&ZA|^"(?"T|P)5UYUMHKC?<.|BJ9-
ICE220AD;G@D\$D2+%G!2|G M))>|:RY>>.IQ7|1'P=B_82|>>?%

C%|,;BXLO#EQJ4.F:GX8-U*WfJREGC65Q M(6AEC@ (Q)DQNS=<*_
(^|_P""A%E)|_*&7PI^FEVV;[0]273;WR[V6WDN]92
M|S%!D;DCB95NT9|9Q,JLLBDJO+?MN?&+0OVD/\$?@SX(_#6|C|2:W2:S
M9OY|C#NAD1%W1ABZA93+))&&6-
8SD\$A_+^NOVE/A?)|7/@;XS|*V44TMY>6; M7%I#;3I\$T|W""ZSVZ;Y
556FB0,#@88Y*YK7FMR>T,N5RYK'D7|?WQ(AM/V>; M300"TO|
:_^I^/+BVT53X-'OR;FZMG=FA2/)N(Y (X& (4BY7+'A6S?V&::#
MX1^*OC/A%IE^S/X=UXZI90=7<,EQ&[J]N8(DGBD^T13"UA4,3|S*(|,F^7\$?
SS D_*M@|"_;&|@6 OKIU>TNMIM MG6*-25,?
[N_:#'&ZX1MFXDK|PU|N_P#!.WP')X,_9AT&XF2^M|H7;FXUB>.| M79MW.
(860;%_ =O!;PN#CYO,+#"LH'U'7/4:YK(WI_"?G1^V8H_X>'? PXY7^
MQ=I|,ZI<9Q7Z+>U?F_|MM7|OI|?GP:OK^|AL;SAT;=[FY?RHXU759R|.Y
M^7:%YYK|9_X:0^\$W_14/!V?^P_:?'*TJOE*\$+&<'&,Y'+_MD:+I&N_LR_\$6
MUUF^_LZS73'N5F|Y(M|Q\$R26|9+#GS)4BCV_>;?
M4ABI'@/PC^*%_P#!W_@F M+:^,-
(A+:EI|G>16D|CJI@DEU:6!)VRCH0C.LI&#N"XQWK"_:\$_:\$D_:;LU^
M#7P7M;
|QK=7=XDFNWVGVY>WCBCF5\$B5F3:8_.,+M<*Z1JH7#N&DV^T_&'|GF M?
0_V%|6^%G@TK?7VGZ9"8G99B;R>"=+JX9(U,C*|KQRE8P2 SJH^6M590C"I
M_,1|4I6/,/V7_P!@WP7XT^&MKXZ^*+7'CCQ#XPCAUSS9=0N8E@@ES-
&&>-D: M61O-WN|;CM4;06?GG^'-
U^PW^UIX%_X0Z^N;GP#|1|XZ<^@33NKV|&2-CL
M5<.L+W2O&Q_>%2Z\$ _>>3U+|D|/K_.'/B3X):#HVN>(M.|&:YX8L;72|N#7|
MZ*!)EB@55N(WD*B12\$R<#*, -K<89_-/B9|4+_:_P_:_^%/AKP3J>F^|1DU
M.|UH!S;7,:2P/ <-\$R(P|M3;K\$LAPLDDX"D+M=E>HZDE->Z*T>2)?
4DTKQ% M^U+|("?
Q'UF|TOX/W5N+V2)I&M;.:2|!G3YY1|XE71N;.||+:ZUW;7X60!DDD=IM|9\$;QLL
MGCM?B1|?/A'#XXO/A5|0=0T<7\$|K%=RVFO11RZ=)DR2I'-
(V8XI%6W27;,\$R M)8-A8FOD3XW>*/
_@'|HCX577|.&L^&|/7:W=HM%N?.TNXBGEM88HKB.
M)C\$L;\$.SK&H<' \$N/,,;&8J4U9%2Y8=3M/V_-/B-I^I?%SP+|*/%?B:|!\$_#R|
MMGUC7|1LD:9|I6:588S&L>
|'"O"X!&|=TZ.|9|L\$>0R1KCSGB9/*8'D,H5,@D+L^0CTS|LS6+CX\$_M:_"KXU:C
MIEQJ/A>VT^32)8K3?!?3_# M7|NR_\$;0Y+0PQ2"VAN3-
>8D(V+|EC#3;^1E/+WI_.\$!@U5Y1C'V9*^*1PO_!/_MOXP>*?
BH|"5NO%&H1ZMJ&E:C)I45X7+7%Q#%;P.&E8L=|@:9E+GDA4W;F+?.
MJ0UYI|%/C+H7QZ!VWBSP_9ZI:Z=//-"%U2W|B1I(VV|E*|HY4(&0|,,?>
M5E7TMJY*GQ'3'X1:***DL**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I*6B@#RK|H#XD:K|+OA+KOB;1;>VN=1L!"RQWC%X2KSQHS?
ZG&U MWQR,E1GBO@?_ (,^,/ _\$. \$W_@KL_|XU7ZA: AIEGJEC-
9W=K#=#6*GS4 M:W(?E_|\$;XQ>,OBS_9G_"5:P-4^QDFS|ZT@BQYN-
V|IR@.FU?R%<57UM^W|X M'|.>"Y?
X|Z|I>AFY6^|:;9QV_F;3;;=VQ1G&YL9Z;CZU|DUY%:;+A4U/S3 M,J-
3#XF5*K/G85Z9X| VE/B3X" T&PT'0? \$LFEZ19|O*A:SM7#;F,A^>2(GG
M<3|37F=?HK^R3|*?!?
B3X!>&-2U7PCH>J:C(UWONKS3H993MNID7+LI)PH"| M>@
IT(N4|&=.487\$8JMRT9|GNGS|H|/;'Q;TV|6YFUE-6BA.V2VU"P@CAD90
ME5#Y2HX8-SP|>T?|4%4B6_9V|.D|?^ \$GM_P#TCO*^GK#X+^_
+OH+ZS|\$ ^'|2 M|MY1/#<0Z7 DD<@.0ZL\$R&SW'-
?,7_!5;_DWCP|_V_|O_P"D=Y7NX2#A5U9^
MBX3"5|-1E|9J&_AAX6U#PY#H|G|IEY/+K;Q)|,/"VG>')M'O(-3O(+F;O;VK6
M|@G=0NH,2P494A/'^S7UO^S@H'|/?PPX'S>%|*SQU_T.*C|H|1_PSW|3^!O

MA?5<>W^ARUUH M5I4WJ\$1VB>1?LB_!7P5^TWKOC7Q!A9-00=?
^)HU6ZM;OPWJ%^UC.L.?V?;IV M\969/+D+0@!O+4*\$ Z&L;QU^Q_X
O_VW/#_PR|+PZM;^\$|K1I-2U>VTVZ-Q) MILJL55Y)\$D,*.4MCF4DYN5QH-
N7XQ|= "JU_:\$^,X^/7@CQ-XFUMM>:+39 M+&;|-'#81
Q6X:\$36Y.Z\$Q,KLT@=65@ =SR>Y?LY_M??LU^#;,@>&O"?AW4/A
MG;7(C#:AK=BJK=XD"QK+'O^QGM_2.|KK+K|@3X?^++++5|_ ,=7>L>-
/&NM!GO?%ES=O!,LYB5 T-O& M1"L2,@:.-UD"@*IWJ,5R?
_!5C_DWGP|_V,|O_P"D=Y7V>RAEP1D5S. X)SR:UX1UKXS_ WN=8FU?
0_!.LK8Z:KH 8SYMS%,T:|E\$D-NDAC# MX5FIK?\$.4_A/SH_ ; M,4?
|/#O@8<Y6;SDBWW\$3));QDL.?,E2*:/JYM^U2&*D M?
(|/Q@UKX. |\$R?!MWX=EGT_6=6OKO1XM3CF\$+V1DO;V:61"4)R4@=,C!3>C
MKRM;G[8G|0DO|1MFOP;^"|K>^-;J|O\$DUV^T^W+V|<4Z|'_L1^/'WA@-
=VO@F|M|6O6ABE,LX5)UN98U)DV; MI;EYCN;9&@?
DJH%:T|)%&%3^8SE|W-8W/A+_P3=^&/AWP99VOC|21XN|5NWVB
MZODO+NU@7(&8H5B>,>6@X#/EFSD|051.*^ /AW6OV1?VPK?
X/VFNS:WX'|76 M\$NHV\$-Q,|I'9(I&61EV8|X"V>-C'M5U9'(^39'I_
/'|M#X8_ %+P59ZW>>*M|'|):A*#%=:1K>I16|JO(.DXW,OF(1RLJX!')VMN1?
G_.&_Q A_:J_:^L/' M'A"%T|)>".*DM)-1NDE7|8K)<1Q,|LQ&TDMT^U)-K-
_:LPP5**KU'S>T06BN M7D,WXP6?A/Q|^W=J?AOXWZS/8?
#VPTGSO#UKJEV^GZ?(TD\$#/^| 7 :0W67|MQ27MXXRY"B*OH;X5_L??
#X<_ \$31?B'_,;K5='0Z>46QTW6&N=,U*WE4_O',MOF/,,-&R|9
N883CCYK'B/X|? KQYXPU|X>>,M2|+WEUX=NRCV?B9;>2T,RQ MH-
T4DH,1D7SI(VCW+*K)*FWYJ^:?.#GB+0O!_P"WOX;|/_ '4M\$B|,,:.)_P
MD%C92R2Z5<%#-.,8@H9-Z6Y3RO)94C8"/&'D!+3J1^0_ =C/A PQ|3
M/VH|KX=?%#Q?JG@KX: ^%+"*Y*Z=&UP+ _%":-&5F58GV'9<84,' 6"3;M,C;
M>4^+Z?LD6_@66Y^%WB>_|
(^/M,5=3T:|L(=7DD::,;EBW7"\$1AV5\$O&VDQV<6HVJ2M|C0);1RL1LQ(R2V<:
M/+/\$"-|4Z3%>6NG:M:I>10:A 89H
MT89^9#SDYSN&Y6&&5F5E9NM:N*7Q'5\$6EI*6I&%%!!1110 4444
%%!! M1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110
4444 %% M%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!
!1110 444 M4 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444
%%!!1110 M 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110
4444 %%%!! M1110 4444)12T4)M&,8XK!'P_|.*H0>'M+!'0H46<>, Y
QCIGFM^BKC.<M/A=C*=*G4^.*?JCG_P#A7OA?_H7=*_|./_J>R|%Z!IMQ%
<6FB:?.3PDF M.6*V160D \$@@<9 X|*V:*MUJK5G)_>9K#4(OF4%?
T0F!Z4A16ZC-.HK\$Z3R M|P;^S|X"^'OQ\$USQWH6C#3?\$NLFX_M'43=SR"
<2SB:7*.Y1,R*,;1T&.G3U# M%&!QQT|:=V|P,'Q5X=L?
&'A_5=!U2#S|*U.UELKJ\$S-'YT,JE7 =3N!VDCCU MK%|)?"KPGX&^'=OX(T?
1XXO"BQRV|>E79>XA>.5FD=)!*69E8L^0Q.=Q!ZUV M|(\$5>B@?
AZ478'@MG^Q|\$;'Q3)XBB^>E2WIFDG:&X:6>V:20DL/LKR&#;R
MI4;)|@8QCCT6S^%?A/3_
(FWOO"M='BMO%M|8#3;K4X2Z>?""0@.H^1F'E1K MYA!;9&JYVJ*|;:-
V<#|/3.*-HZX&|'|@|&&0 *YWX7_LL_"OX0:U)J_A/PC8Z=JLA4K>S
M,JW,F%9287F=VBW+(0=I&0>'9|_3Z)9:QI,BL!#>("W(R>9\$WWHY%5W
9<\$!C@C->6Z#^PI"O"^JV^I M6OP|M)IH< 17|U<7D,G8;XH6C;|PPRO!Y'~?
0-(L:~+DA5!..@|.E',ULPLC M#|5>'+'QAX?
U30=4@|_2M3M9K*ZA,S1^=#*I5P'4|E.TD<>M>9ZY^R3|(?%7
MA72/#FI^"M+FT|1XDAL!;|!>X@C7>RIY|3+*P+2/(P+\$,|%SECF0:-HP1CB
ME=A9' ?#3X-^"?@|HXT_P;X>M=#AEP&DC1FFGP6=/.E?,C|2S@;V.-
Q'>M#X M@?#?PU|4/#T^@>)|\$LM8TF16 AO%!"|D9/,B;
|T0L6&W+132M&W7/ M*YSSUKZ"VCG@<|:18T7)"J"
<=|Z=*0VWN%DM@HHHI#"BBB@ HHHH **** "MBBB@ HHHH ****

"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH
**** "BBB@ HHHH **** \$P**6B@!NT>E)Y,?!V+D\$D<=S MU-/HH Q?
% '@OP|XVL4L?\$6A::KUDD@E6WU.TCN8U< @,%<\$ X)&?6-[VU
M(T@CC(*1JHOMR !QZ4 _1*6BH**// BM& ! QN\0Z!XVTMM8TJVNA>+ ;N>
MWVS!64'?\$R-@"1@.>A->7 _1#07|G_YO^* ^|VYO^)SJ/R#D_O^N0/RKZ.^
M4,3CGUQ2|J:G;87*CR_X1?L|^ ?@: ^JMX'T1=#.K>1|L_P!*FN!/Y.|RR/-D
M?:/WAZ>M9WQ1_98^%?QAUN/6/%OA"QU/58|VZ^A9|29|JJ
S20NC2|5C"C<3 M@# Q7L&U?0>O2C:OH/7I1|1WO<+(P^%/L.OPW^!ZS?|
(/X6M-&GN68O>*|E MQ3RR84RN|'RKQP*|. \$2!BP10QZG'-.VC=G SZXI:&
HC/-?A| M|"? ?
P@U+7KWP=H*^'9=:E674(|:>;RI&3S2B1Q,2D:*9I<+ \$%'3C@8M_%+X M-
^#_ (U>'DT/OH::KID-R+OR1=SVV)@K*/WD3(Q&V0CKC!(KOJ-HW9P, ^N*
M+N|Q61@^%?#5AX.|Z5H.EV_D:5I=K%9VD(E:3R88E"H"|'<3@ <^E;|)2TA
MGCGQ4_94^%_QJUZ/7?&GAE=;U>*S&GB;|=6Y^S@LP39%*@ZN3STS7)?
|.J? M@! T(A Y6M1_P#C|?1W/'4Y-&ZKYYS|J|'# #GX1>#?A/8_8O"?AC2|"B:
M.*::P@1)9A\$"\$>>7 >5|,WS.2?F;GDY|CRU!R% /TI>M+4MWW'9'AWCO|C;
MX.?\$C7H=UIP/97&KW;|1/9SSV1G+%F:1U@DC#2\$N27;+9/6NR^&OP;|\$_!
MW13IW@WP|;:!.5WO&C--
<\$ \$O&9Y7S))MRP&|C@\$BN^VCG@2,B:VR5>3R)4Q)&&V("\$89
M"J.U87PQ_9=^%OPAUA|6|*>\$|/3M38ADO)G>
|EC.QD9H7F=VBWK(5::1N|P< MUZZ45NJ@_AZT;5|!Z|*7,|KA9&;X@|+Z-
XLTFXTK7-(L=9TNX*F:QU"V2>"4 MJRLI9"!5LJD9"!4'M7A&F_L#_ ?
3M1M;RV|"0M<6QL+6)8+>UMHECBAC4!51% M 50 . !5NBBB, **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** \$I-
BGM3J*!61@^)O_7AGQH;<^ (/#VEZX;?=Y/H6<=QY6|&|
M;O!QG:N<==H|*Q/^%%_#?_H0/#'_ ()|?_XBNYHI-)|F3HTI/F<5?T:'_P"%
M%_#?_H0/" |X)|?_P"(KJ-\$|Z9X:TV+3M(TZUTO3X=WEVMG"L4298L<*H
M&223CN2:T**+);%1IPB|QBE|A*X'XJ_!OP=|:O#D.@>-M*;6-*MKH7BP?:Y|
M?;,%90=|3(V)"!ST)KOZ3:-V<#/KBGML:&%X5|.V/@_P_I6@Z7#Y&E:9:PV
M5K")FD|F&)OJ_NQW,=H Y|*%7AVQ|8>'|5T'5(?/TK4|6:RNH3,T?G0RJ5<
M!U.X':2./6MVB@#@/A3|& !_P1|-S:|X(TMM'TJYNC>- +N>XW3%54G?*SM@
MB-0>>@%<|J'P'T;PKH'Q+N? -L_AGQAXVM|A|G5?MUP-U|
(LWE29W,8MLD|/MF)1CK7L&T;LX&?7%(44C&T?
E3YQ61^:_P%_:LTK|COP3;_"XG?"_7O#6LV5 MQ+<":Q@AE.I.|TI:Y<,4^5?
+2*.59)1((^&PJU: ^*B: ^_X*0:UX3|-^!?!E MYHOA?
3+|HG4/'_MV0WV;X42V|91RI4QF)O+#|I7,6Y8DC9S^C@C'(!SUI&A
M7@!5QG/X^M;?6(('_RZF'LCA?BK|&_!_QN|-
PZ!XWTMM8TJVNA>+!|J KGM|LP5 ME!WQ,C8_D8#GH37?4;0#G SZTM8'0>?
>!?!@WX| ASXE|5:|X>TJ32|5|37? MV|69OM<|GVN?,K9".Q51NFE.(PHZ=
<# 'H-)2T >.:?%3|E3X7_&K7H|=|:>&5 MUO5XK,:>)OMUU;G|."S!-D4J#JY//3-
#?A/8_8_"?AC2|"B:.*::P@1)9A\$I"//+@/*^&;YG M)/S-SR<|SM'/YHZTM2W?
<9|^:_ ^PG|"?%J7FHW?P|LX9;HCS(K"ZN+. %2H
MVY6*&58UZ9X7.>>M>I_#_P""AKX7^'8-|.):9:/I.;J#9H &VHJ>9*WWI
M)&5\$!9LDA1DG%=H|>M+3YF|V%DMCR_XK?LZ_#?XX)"|&_A:TUF
M>VPBWA>2WN54,7\$/VB(I)Y09|P3=MSSC-)|+/V<_AM|\$XID|>%:/2);E|SW
M>^2YN&Y5O+^T2EY-F8P=N|&0#B04=HW9P, ^N*
HW9P, ^N*.9|PLCD/B|!|-#
M7Q0|.SZ!XGT2RUC29%8"&|0\$+N1D|R)OO1R*KN RX(#'!&:|MT'|A3X%>%|5
MM|2M?A|:330X BO|JXO(9.PWQ32M&V#AAE>#R.: ^@:18T7)"J"
<=|Z=* .9K9 MA9"|1G.!GUHI:*D84444 %%% %!1110 4444 %%% %!1110
4444 %%% %!1 M110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %
!1110 4444 %%% M% !1110 4444 %%% %!1110 4444 %%% %!1110 4444

[illegible]

M>4NZ7R8V;=)L0AFVJVT2,LRJRI*ZDKN0KD8"!R>*.HK(TK6K;7-
/LM2TRYAU'3+Z!+JUOK:MX62"-PI1T=25974JRE<@YZUKT %%% %!1110
4444 %%%4GF"E@'8,.K*PQ MR1Z^@*!>_% %VBN,-
"\$Z'/K/B+6K'0=*MRIN;W4IJ.VMX-S!%W2.RJN7:->O+!.WS7 M14
%%%.O#GBC4HH&NI;+1=9@O)XXPRJS,D3L0NY MPN3D\M9Q+#+
&PRCI("I7GCC MFM:@ HHHH **Y+QE\10#'PVTF'40%GB/2_#-C+.EI'=ZS?
QVD,LI#\$1J\CA= MY"2'&Y#B+4M*O%N;:78Y1MC(65L,K@ MX)PR|><9H
Z&BBB@ HK\4>+=!%Z%=:WXBUK3J T2VV&34=2NEM|>+HHHH ****
"BBN?T_Q=I&KZSJNAV& MN:??:
[HWDG4].MKJ.6YL_-7=%YT:MNCWH"R|E7<.10!T%%8'BCQ;H_@O0KK6
M_\$6M:~H&B6VPR:CJ5TMO;Q;F"J7D=@HRQ4^M(_A'7J8N@PATW3=?
M;BZGVH78QI')EL*">|JW+=!0!Z11110 452CF|R,F-F
MXY)9AD9*^P|8U^8X/%=!0 45YYXR^.GP^'^>J1:9XK|>>&O"VIS
M0K=166LZU;6LCQ\$E!(JR2 E"ZNN> 2C#L:V/&'Q"|+_#?3K?40%GB33/"|@|
MGV9+K6=2BM8&DQG8'F90S81CCKA6/7-'5T45SMYXRT?
3=:TO2+S6;&SU;5/ M/%CIMUG_)!|A_M/^R?M,?VS|)YOE^?Y6[?Y6|Y-
^W;NXSGB@#>HHHH **** M"BBJ23!BH+L6/1F88X)|/4!N;F@"
[15*2;RXP9&;GD%6&3SGZ8 XR:XWP1\ M.,JLS)\$|+\$+N<+DY'(P>:..HH MHH
**** "BBB@ HHHH **Y2U^(WA6^|6:AX6M/%.CW7BC3XC<7>B1ZC&;RVC
M(3#RPAM|: O\$^|O|: ^HKJZ "BN>T/Q9I7BI=2_L+6;'7!I=X^G7WV"ZCF:VN
MXRIEMY=C86105#(V&7/(YKH: "BBB@ HHHH **** "BBB@ HHHH ****
"BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** M "BBB@ HHHH **** "BBB@ #Y0_X*B*!^PS|3B
3_9N3_P!Q2S_P%8D\1\$BK"N0L<+@+
M\$))NE_X*=9_X8A^)^2LQ('F=5!_YB5L6|'I: M|?| A7X'Z_XK^"6D7;Q3>-
UU:VN9|>)D6YNX=|>+S)(U)D(|9B,^8T)618
M^3_8Y|+>)OB=^RA^TIX6U)/H|=Z_P")/\$&CZHVJ7\$4TH!N?M=?
M):>>|@|JGPP|:3|0?!7C M3Q7H36^L1ZP()KN^@ODN8; 10&JP-+);(#
('R|DZ211L :|6D_;<|8^%_ \$ M\$ _C?X6W.@_ \$W7-3ETSPK|/-
/UVVU*ZUHK\$C><)X1L@@@3>QFED^6%4+DG=&C? M,?Q ^%?B3JF|A'X
S^+K#|1+|O'VF>?* \$MOI=S%-):VS7UT^Q-S*DDJO>1 M1D!BN\G#,@WU:=:
[UOPA^U)H?PY^-%EX*U?XE?!/P-J6JVVOV|=SIMU?64L
M%J&U"R4^7)+;VTJL/R?;/LIQ&'E4 ^D/AI^TYXOU#XFZ-X&^?*PPN/A5KOB
M2*ZD\LFNV^MV^I/H)+N%S;KFW=(V5UWY5OG&|*JK>@_!3XI>(_BAI?
BB| M1^!-7^'LND:|=5;6&L>D?RODQD#!VFOJ MX('GP|A?-
)4ZEH.G:M8Q>' \$-SX?NHJ8M3:RM>0",NR1LV|%/F+Q(L;@AM MZ*>*
_3X|_M('X->*O" A>U|*ZEXN|3>*K. _L'2=,EVRWU|JJPL2NV&+9
M<22O<2.JQI;R-ASMKS_2?VU/\$&O2:YX,L_A/J\$ _Q|T4I-
>_#==M%CM|1C%B M|.ID_9VC|NXA^0 R^8X7R|@|T+^T
JC|N+|DXQMAE_X2W VY_XED8)(YYP M.H|8KR|X.LX_X+?"'\$ (N_P#XHZV#
<|W6C|#\$&@Z=XCL:-MHTEXEZ(|V"RDW)/& LPVO&-P^8.!N55=O+|B%J
MVN^,AV9_V1_@=H-YJNG3?\$O3-+M=5N-)DAA>30;73(6U./SI<^6Q257
56WK M&ZG(8|OX1R,_ASI^AZVMC9ZA:-W=|IAT^(7UG
%RK/,L42E6#\$HKJH8OY;@'NVF ML_-
33/)|,0?"SPQ+I;12VYFN+%;B|VR%|Q^VOFX#_.=K|JR;5VE=HQT^J: MAX/-
&4?
@/=WACFTSP=X0TQI8K>XOVN9TA3)2VCDN927Z|.77|L?;5DDC6RV(&B\Z1U
MUBARJ^:_M7>-_ \$G|4'A?X)_ VVLS|,/\$'Q6#:KXATG6H(9K02+.T47&R6!5W
MGS9(G>,EH69K41N(RTJQ@'(?LW^'_ %|/C_."Q9UW6H+G3_CA#-8^,I+?

MSC;S:O?23ZCI=T(U90L\JR1P86 10A) F EWUZU^VFO@J:JJC|EP_\$0>'SX*
MOXH:|_X2;R3I^/L\$!B,OG'RS^|K&3|[%8'10W|%_P=OB|!*/7T7Q)|?|?Q
M^MO\$^HZ=X?D|#::927E|"C-"L5RLP:W=R=GF@*LK Y4D'ET^*'A3|LSXH?
L M9>(-=TG1|(-%O+6.YM8|0AT^\$RQM [2A5WHLT8D);RVA8@\$C !;
M|5^'/_@YX@_;"^!|_/.IT%?B:87K7VO77@F&WDT.WT)(MU|JA&C2XD#/#&5
MPV9P)&7=:UOVKV|,>_VRO"/C7X^:9_;7P3;PU/IFA7\$^F2WNEZ9J|.7D6Y
MMP|JO(|*/AS%A@8<(QMGF7H++2?V"_CU%?6<5CX>^7Q+O8|6|-U?
LEMX9U M|0SLKQ0;=L5MZ;K\$02'S54P*|DX|5^*
M/|@|/#X;6VUR>UM=4N?"5Y')9/+;1YCC6.%S#"X2;|)6-5),NYLLV1TOQF^+S_!
MKPK::XO@WQ?XY-S>+9?V;X.THZC=1\$QROYSOA@1%^|"EL|73U-
?.W|/#OAZSF
M^,7QZ^('A+P7<>"OA7XIDT2/POYFD#2XKZ&WLY!+"\$M|V.|_M#P7J|@T^|E:
<=44 M|10!Y=X5_;5/BSQ-HNB#X%?&W1?|2O(K+^TM8|
(>1:6IDD">;/)YQ"1+G+_/_LKORW#^7/&(@9(VQL92>1P>*|S|JQS_PR_|
&)5Y+^#M8SN! M4#-E*.^3DGH!0!|S?
|\$_|5N_@F?"WPIUN|GGT+QAX4T_QQX-NKJ5G'G36L3: MMIP9RJ|XYG-
PD\$*\$K%+)) (Y9C7FW_!5/Q3J/Q6T|Q=X1TBX:/PW)|/3|;UY MUA0K-
JM_.EO8V@5@LBE+6>XG|Q&=#N*,H< CW"7X1^(?B#^Q9!|?\$_P^2'_A
M:/|@?0-#UWPR|Q)|F2X9;*%+BOEFP|FXAWHT8DC1V6\$.RH":|V_:"^TW|_|
M_!+KXA>'|9U3_A(O%NI7MIK/B76?/FD-_J\$NK6HED#2,Q::JQQ|L+O|+WLB
ML|"#@ZQ_:0_:7T|G'P?::E?V|QK?B;5IO|/T#PMIP:2|UJ|)54B@4;BJAI%
MW/M; (5G9(VX/P'^V1K4'Q9T?X>?&7X;W'P9U_Q%'O|-S7.N0ZI9:I(LFU| M?
|3\$@1)^5VQ'EMP&59X5DROVUH_\$/P|^ (GP@^_MCX=N_%?ACX;3:N_B33,-E
M O8K*|MHX3=Q1D%76%59W79)'P/CCXWZ1^W"|5/A+X0^"T4WB;1/! M?
BK3?&OB/Q7<0RV6GZ=%:O(|0++\$':4-)LPH'R+|X"9H #U/QY^V1K4_Q9
MUCX>?|KX;W'QFU_P|'O|236VN0Z79;7(TFU+?|3*A1Y^&W1#E=I&69)EC|_|
M9ZUG0/%?|*_|7'B#Q3X)EU7P|_|
XW|5;W>^\$|>|M+DK':PW/DS8WM!.KHJ|D^ M:-T#+RH-:7P;^_.AK|E#XZ?
&KX6_\$|KC2+_Q/XVE|5>'9|/3|00_.VX|4(V M0P0PVSEBAB2-
CD|I7D1<^62>=^!VO+XL_8Y_:/UN;2;|29M2|3>,|LZ;J<(@
MN|_2:=&XBEC.=L|!P&2&|F@!|?VMO%VJ:A^RM^S=X=|)?
#Q;OP+X|O/#MG?> M'1K<:+-
#Y,,|HHN7'F_OBH'VL%/+^RC)Q(<|9X#7P|X5_:#^"2>)?V8=^\$
M'CO6+OQ!::9()Q_P)CX\$W%0,'-DZYZ_K7JG|0(7_AN+|D|H^'4>+
_KD#_B6QCD#KA0<> MU &|X|_|:@|7MXQU3P_|
!_X6W/QBE|/RFP|1:E;Z|::78V-YC<+5)9E83SJH
M)E1!B(O&K\$LVU%M_VW?!&D_O7OB/XR-
QX3F|::G/X>UCP^|BW%S'K4)VRV% MNZXCN7R"4=&V%#YC^6%D\$?
QAXN^%_P_"?A|!/?B9;?M1^#9(%|3^(-0|2^%_
M&EM>ZE)87UE/.A;R,5F05GA+\$MN0|L0Q"^2TO:_\$3P_X.T|D_2/'/P,^&GB
M#1_!O@+XE6'CZ73-;6^BF|0VMO%&&OK-
IO.D^SR1R0N)'"*L<,SE6<_I#7YY_M&?M3> /V@|4_9W@^'MOJWB'3(?
BYHDMWKBZ)=VVFV|T M9(^S&XN(XP9V%R'"(&;8CL=H"|OT,H^)OV'/%&S_
P_X)GZ'XP73UU#_A'M
M(U_5%L@WEF=H+V^D|O=AMN0K#;/:/>EU|_|@HEKGA7POI?Q(U3X#^+
|+X(:@8Q M;^+)-0M&U K)&PCD?
3PV8T>7"K(|RHRM&ZL?,1&Y'|G#|W_P1|U@B(!V|&>* MMY'&?
WNH^|H9'&/XN*=^T9(W_#GW2<)A_P#A#/"H4Y_Z:Z?
QP>_S<8|UT82(/3=>_;>|7:'X=|_:/A=MI396<4S(M|W=:AL|F&W*J-
KD9>618E!(OV;_BOXGAN(_!|A_4M;TG5 M-
0MT\$CVDU_8A(2(|AW4".5R41CMB88+%5;Q;|J"Q^'OQ/^*7@'|H+XB>=8|
M4?L^ZMH|_37^Z|LKG2)AJ\$YM-4DMXBDQM)HY 8SG+)<*Q02&*.0
^OO@K^T M5KWCSQS>^ ?B|X"N?A?|08--&NP:/)JL&J0W6FM-

Y/GI<0+L#K,-C1.%8!T* MELMMY X!?!M9>)OVB-1!*:IX: ^%&J0_#K4K,?
VEXPO-6BBBM+X0,|T\$%K(BS7 M<4|9F#4_)YFA M>33S)=O@7./)FVK&/D
(?DBNM_X)CKO_&(?AJN?#|7OB!K'C*QAO|_2=%0I916
MT+VZW#27UZVZWM<1.N%9F+R;40-EG3YP_9Q9E_X(|ZL GA
PAOBO=CWEU'L M3_N|8_BXK+^)GOIUWX8?LW?LH:-
/XROOAI.O\$GARWM_%'C32M,:|O+>*/2K M=HK:"0*_D2SEY@LBJ9%:
(2J0L;@@ 'T1'|_VHO\$OQ!|: ^*_AUXJ^&|QV/BMI
M&F_VS9>'M2U875CJ5DVQ\$N\$OX(2H03,(WPCE2WR|RLB1^,?LJ_M#?
&KQI|0/ MB-._P'MKC3;|XAR6>O:I: ^++6A
L)HK:QLY80*=2UTT,, \$H_"O^T|A0?.\$*Y:>|O8'U. *UN)8XY5MLJ^W?
M&A9M|J&1XV??_9I^/OASX*_'/XR?!|Q+9:PWC|Q#|4+K6=(T|3|'I8MU9Z@8
M7CN-|;%46&%/M\$QD*E(S_\$Z.J@'H_P"S?|2/A|_#X>?&S5|3P|8?"KP?X/
M|>ZS8ZG(E|+|;320^0AN8X|@\$/FXBC2VB!_90L>6;%/O% MGP/U_P
*?!'6+Q(HO'+:M'<7-M;RLRVUW-IRQ>8D;\$1DGR\$|V+9!P\$|Q81YC1
'O7QM_:RB^%?B#X>:/X;|*ZA|2|SX@6=|)X<3P|
M%+9X=TKG8MLZ3M(UT&81HF|8ZY9:WP/_:NUSXA?%K5?A;X|^&>L?##
MQ|8:9_ ;BV9!&LJ72!=SM),4VHC*/+8;|X*KY=K'@V^^&_Q|_8
M0|*:GNWG_D.8|/PSZ4_5/'G|9/Q(|\$QZGXKC_9W|57OPTV:I#9:DUFD
MHCGNAI\$|L8N\$4'>ZB79F)5=O*5F*T_BMXITWQE^UQ^QIXBT>Z^UZ)K5GA
MX>/RS-#+L,3D)M< KN#@XP.M?)&J?
%2X_;&^\$/Q'U#QS|6_B:GO@L=&UR6^
M%_A.WETG2|,L|:8V6#|Y,%#^| ^%O^1|_X)W;HMA/@_M_5
DA'RC_B06VT|>O X.?SH^F_VL_C!<_W|G7X@^,|.>=-3T_36AL9K6!|)
M&M|V=EM|60I+E6199XF8/'M|K_=KS?|GG|A/X;>#_AWI-|X_P#_FG^+?
B1K M=E#=#^M0|6"/6;F7475D)|-(&C7\$DLJEX|;PJ,|2, |>M?M*?"F+XY?
WQKX M\$ECB:76M-EALY+J=H84O_|M*S)|P5)DBRO?
^\$DL;B_75_+,D#7L%Q\$DC7"N8 S2\$|2S'8TH5 MG(!ZWJL'P7_8, ^'?BWQC%:?
|(-H&I7C7DVF6-S/+>7|9Q':6;2&.*1POW(A
M&H2,,|L<.4X;0OVY_%7A77/'7_-"|O@SJ/P:|)^*OW6G>)KS7(K^V@NF19\$B0
M46)'LPREN9L%2#N4*DC1|K|L^#;^Z\$|T<>?W=Q!|(@G@=6B/FJ MN
7|+Q)XOXL^)|T|/|6WQ\$|_!+TZ|M/AQ|48|+2Q|76*/=0:==Z?9-&
M+2YBC0NKRYF*E=P^5<;L3-|J?LZ^(|W|H#|K+Q%|=O#^DSZ9|+
|/PM)X(T;5 MM2)AEUZ5=0\$|WD\$17<(58&/+|DA?XQ+'\$ 9VF_|!0'X@>,/A,?
B;X+ _&>- M:UKP1I^FS76JZKJ_B>TTO(9;=7>
|6W1E:2ZAB"8\$P0%V61=BLC*?9=8_:V|, M3?"?
P5XN|*VUOXOUOQU;A?"WA.RGC2|U*Z*;I8797=+=;?!^T2L2D&OLL6VJ
MWQS^QS^W1X'^!|/W@|PG>6/B'5?B';B|&B>%|72I@WB!IM0G\$!M9Q&Z-
&9' M:(G(8/!, CD(KT/B-^R?KOPQ_9D_9TO?B1X'/CKPQ|-
SK4WCCPWHNHR1WD-K M?S"998WC*>9|F(5I
C@%D&&,6^50#Z_ ^&G|3GB_4/B;HW@;XI_#"X^%6N^)(MKJ3PVR:
|:ZW;ZD|J@DNX7-NN;=TC977?E6^<;LJJM7|- M7>*/B'|090#?@?
MX4:EXDLM%|277A_Q;KLFKQV5IHPBU"2W5X_.0&|E-
NGVIXH?|6LL";V9^/%/ MV9=/_9!O/CIX7O?
@5X+UW7_\$ED+D/XDT^WUF33|\$W6TH7|6;N147SD|(|E? M)C(&#M->K?
L'+Y:_M\$#Y5 ^,7B)5!0=A;CL!GCL* *GCS|LGXD>"8|3|5Q_I
M|^*KWX4Z;.,3+XDO-4ALM2:S241SW0TB6,7""#O=1+LS\$JNWE*S%><.,.:|
M6:~X6^#%WX!|(Z;XR|(>./\$GA^YL|0DU,VEQ>SI=0W|H:B&2-3"9_)AQ.Q=4
M'FK)&A|MS|OZH|5+C|H;X0_\$?4/'Q;^)|J?&"QT;7):|X7^|\$|>72=+TRSMS,
MI@OXV@|IHTR|2/+YIC98/WDP4|/?|;Y_#'|"?|*WCG|<:CHO@35/!OB/6
MOLKQ"6.SBM4C8JKNH9S+-\$H7/5@3A0S |WXI^_FUK2?@|XA^,_P
MM\$|5M| M3|.T70+50%, =U+IQF4.FH+<6L>&7?.\$%-
HW\$AA5FSM7'M'P_^.VI>+/CH0_A
MCX@|VWAS50"|%GJ&FSQZD|HURQG|PFZBC>&)@D96.*0J946639N.T%OG|

MGXS^&/CMX7^/BGP=+?WOAP_&{0+.UU&JL);5-
1V),6EMA(JNl:M(T19@/WD M\$HZ@DIOI(NTZH7P K
I=E^UEIZ^./B^FO6%IH7PT^"DPWWCF34WEBN;QXHFE
MM(XDAVF2%G:)T65Y!+Y2B/=(.*U+JL[X@>#;4^+/'P(UGP-|)5FA>?Q3>>
M(.6^LK>:2.."6XTN,&=#OEB|R(%WC#-|KE=K+O&J-
\$|>@:9<7RV=Q=+;)=2*I|F#S2#M M:60+&A)+. %8|5|9_LM?LS_
!_G^\$=OXTTO|HFW)W'Q#F;QMJ.GVO@NTU& M,W-
ZBR>9YLC(=S)Y19%145@54,/F8 JFN/VJ?%FN?L1Z?|:O!..@Z1XLUMO#_M
/:.HV,MS+86UM+#'(E)|\$KJ6E\$Z-F\$NF|(VV2EMN|E/V5?C;|0_#W|/_A1
M_%OP5UK3O!>B>"K&72=;|V:G#K_KC1PVZ6|,6G6Z>;&|R.TG|P|8|>R|LO
MDOPT|Z|/\$/^&A_V5=0GL:U_P 9>'1|4^\$;ZVMK724U>:|L'@N8\$@\$VR+;
M+%MCC15-2"=SLC"BKG@_JN"*;|@Q;3X1V>L:CX^|'^!;--1FFT1Y;;2F@:WL
MY7D<@Q,QB-Q' C!|\$M2^&.F>+;S^
MQJ)|06^OP:Y;MJ+\$"*VF6VC'DE|L%)Y)7|NU9'C|W0/V@-6_X:+OOA7XO|(M
MX3>YM)M2|*ZVNK)=6GB&&(@3QJ"L;1W,2LK-HDV@2-
G8LK/976K^7>I9RWJ&.,R62)*JISYLB!PZ1JY!|J^~7QD|: ^ |6TO00A|!*=
M: ^)VOW,37ES_
8FDZ::VRD)EKZ=#\$T|.5VV|>7VB1V"@+O^.OCA|6;WQW_P M3^)'A/Q'H'
AGQ|_P|C>/'\$6@3+;1K!)>67E74,,('I;3Q_-L18^' M6,NJ*S=W^VQ|;9?"?Q|
^"/&7Q-U|X. ""4?#;ZG<>('G2G4-4U!;O:MK
M#>)%|,|EKY4A,:CY7=6R)4V@'OG|./|2+_ '%O%NB: X6U#P#X|)WJV7B#PM
M?2&9K0R!VMY8;A559XI8XV964_*2-R-'(WF/!|/^QY?"OP/_X28:<9
4,9C!R&&,9S7(_L%Z"X7_&C/VE|/CO| Q?JB MH?#7DW_CQS-
K%RKVMQ)%).3AEW_*D@1T01K(JR!U7N/^"@FF6FO:7|!-U"
MVM|0TZ_ ^+F@6M|9W\$ "R0W\$3K<(!;HP(964D,K9&.#0!X1^U-X; ^?
B2| ^&.F M? \$ ^\$4^ .I7^J0Z!80M*"88K>;Y3%V^ QD|K(C)C
M4MN+*GDOQ6|"Z=^Q|!2M, ^, _ @+1=/T;X::KY&B?\$+1K64V|G:P23P16FIV|H
M&NTR0L|JX56+K)A4#22S+P'QK^/%IXZ_::U|P3XR^,OC'X;?#|K+1KCP3#|
M|&Y%|XHFNX2QN8KVV@N&FBW.102, ".1A'M!>%BX!|-?_+96N^+/V3_\$_P
4 M_A|X+ ^T^*/" VNW|1>%O\$EQ)93:)|J8|0?LF?
M3^"M+BU;4/\$5UXM|5Z5!#X@NXIM0ENGL88E M%S.C&-IB|*'^<.4+
|V#E31|_VG_!7Q= _8\$|1^"?#4&K3:SX9^\$E|!KTDVGLM
MOITEOI_V5\$>8_NW>?\$LD01B2D,F_8R|* /-2_::|/? /JFGX%>);3P+J|UH M?
B.'2-(T_P -:#+|NO|%)|. >6W@A|W::IU,206SNPC+X_ :|7S?&;P
M|_|/BA|'=8^&OB#Q/%-<: # =6^JV^L6=U'!#)-<>9-&\$5&41CY\$WO^|3*H&1F
M|B^(Q?| X9:_87B PA A,? @8KT(-FXZ9Z9Y!|:J2_:"56_ ;A_9.VO|RCQ: M
&7(&=-C!R. >>.H|J \$US|L7QUXD^(7B_P_|' @EJ7Q.TSPE>?V/JWB"XU^
M#0|==14D2VT*W,9|XIA0Q'(+?=VM&|G?_LA_M#:G^T|(' ^H>\$QX.M+Z|G
M@T^S75%U!KB"(B-IMRQH4_>B5-C+N_=[LX=: ^'OB_P"('A|JH#X|6_PHUS
MXFZ5X8U;68|>_C^&/@.#7M. ^W?V= MY(+K|5\$;2^|Z202F(+(&5&9BP
3|+_M &)-> ^M| |#0_AM8: H^B>%+RZT.|TGQ5"8=3L;Z-S)<)
<@DJ):42\$)|B MF0KA"i1 #PC|JJO# '@/JLKPCXU^/FF?
VU|\$V|-3Z9H5Q/IDM|I>F:NSEY%N; M.?A=-X/T|1-0,8|0:IX:U"+
M^S(OL<+LN1%(8+;9',78J\$X?<@/AGP)^%X^*" M9ZEX&|' MMX\$|!?
\$G1K/1_!|^HZ8VDV5YC39X9+N.%4W+;O)<)*LGE_.LW_#"15/00#0
M|SN|VWA.+FXM=-E59IP"&\$.*V9 M"NPE) Z+Z-|6_C|2?#|C*30?
A|(|9^)+6<44FIZE?ZI#H%A"TH)ABMYKE, M7;X#&3RLB,F-2VXLJ>'?_ |
;B|_ "OX6:|!*_&'A/Q9:??%_P;9P>'IO &B: M-/J&H7PM88U%S:L@\$3Q-
/..Z12%5BN|0CRX'|0'QHDI|J0Q5|-OBA5/' MPA|*646E'PCIG@/3+J+4?
\$=S<1?--|J@AFDD02&2#R5VH|!, 20N2-6/VJ_C MYIO|17_!-
KXE: !HVH^'-4L;VPTG7=!U.!X|K3=0BU*Q|ZV8LHW%0RD-U*E=
MRHVY%^B?C!^TAK?AKQ@?!GPP|
W'Q:|:V427FLZ;::K%IEMHUM) J3+O"|1W@:YU7X: ^.(;%="|7Z M?

>7HBTJ\|M+(1RVMU%;%6WSB(%2-XPJ|<_OFB/_L_X#_M_WGQ9F\3^'_\$_7A6X
M\#_\$_;PC/;1:_X8DNX|V.U6YC,MK+'=1?NY4DC^8X^9"CJR|*S>2?|%'M:_X1
M/PU\\$_M;_F7^MMI_Q4T2|.FZ3_9|H|\$4=TXBAB!&^5L%57."V*T?V'|/^!ENO
MC2|/^!|@G7|!\.7/V(R^(|0@00|.UXH9@OV-[N5G;R)#,DGR)AF&0>&|2(B|
|QWOP^/ &H_&";Q|H>MZ#;:^\$?%|/@_79M)O-&_M%|J1 MH1%&|%Z-
T,3>1/N=HFV;71,J3SM^?O\$ _QN|_MT?%OX5>\$OA3-?:|X<|%^)K
M/QSXB|7#3IH;6Q^RB?|/9B.<(|/_Y*Y7E%RRK*JR"/_&Y8?B\\$__C'I?CW
MX<6*W0^*NCM|. + ^TLKM; "5=9E23^R|X3B1"UP"Y5)&7|W';,OF)YB&_ ^F?
V M??CQJ/Q\|M_&_J1Z%:Z5X7TC7KK2-'UJ#46N4UV*"5D:|B'E(@MV 4*R/*I;S
M 2/+ ^?SW:/A AZ7MP-O _IK.,<9_MS.:?SKVKX*_#.Q^#/PA|)>|M/D@,&A:
M9#;FXM+=;,>.Y=%4R7!0;@K2/O=N|^%":;#/OB%X?^&|/@_50%?
MBO6(|&T'2XC/>WUP66.*/(VXY9F+*JHNYF9@J MQ7RO'_P4#|3:=H.C>/O%
MGP/U_P_*?!'6+Q(HO'+:M'<7-M;RLRVUW-IRQ>8D;\$1DGR |JXSXD?
M|>&/CA|\$_-9^&OA'POKUW;O&UI=^%IOAY-9RPSZ5>2Q2PW+S
MW#QK'LA =BV08T0!|!|=OVO-'^&!|)Z-X1TW (6CX||8>4_A|PSH
M=|&OVRV9=|7CW #+%;",PE(PV#_+))'8|?'|QPO@_P 7:|1?@WXH|':
MGH,4-U#I&B2)XC?5H9=R1K9O:CYIO,C=;L=<_8H^*?P>
M^)/C+2QJ_@#3_AHOPS|0ZSHA:_M%S|JLZ?
Q5^S7|5/&_P4T37;IO#5L;/IOB;4_#DR:??I),8KJXM!(%>3|(HN3*
M7CVHT8+!DW @&KH?|8OCKPW|00"A_XP?!+4OACIGBV|_L?2?
\$_%OK|&N6|:B MQ BMIEMHQY)?+!2>25^|M61XY?V>5!_ ;D_:T4@8'_"
(X'I_Q*Y*^0_\$%_P"&M?
&WBCX%^+?"WQD^)7QC>3XL:%:;SJ&O^9: ^'+>_>0RM|EM)HHS%(?F,<9|
<_L^G;^W%^U@6D.|O^\$2SM&?^);(.>G/'4^|!_P5\$4#|AGX MG\$
G^SHQ"E'Y962%>C^*/BQ|6/AKX6|\$>&=-^'-|/7_B0^CV|SKM|9
MW*:3I"LD21SR?;IHUA,LMQG9_BAO+W.50!0W
ZA^VQXNU+X(_%35M\$^&W|C_ M !6^'"R+XE|>
(-2*)|!BFDBOH9A'LO(+B,WEJT9=\$DVNV86E|X_:6_:LT M;Q)|2/_|A|
&35_AQ|/\$_GA676T|7^#|/F:_P!7OQ>>6;&_|6&5|9H0L3NJ
M('4%XY1^|39SOP%^'.HWVK_MM^#=&N/%GB35M0|-Z58:9-
X|NU_MB|>;2KL6_MYN)'V^67|V/8DP1T0QK(|.CJH!|A^Q?
|50'O_"F_!MKXV^&5KX"|Z)X(LKF MS|:7/BBTN(;Z.&V@V.|"@"5XF>;+D|
|!Y|^K?MG?\$_!M)O/&V@? ?6=<^#M MK!)?
P#"92^(+.PO)M.C&^6|CTV8+*5.;/)\$CE&E3RSA!(.,_9Q^-GAC|J7
M|DD_!CP2^HCQE;_#270=3FU+3Y8K'3;E;1+&-9|@_J3,|/)'LWDQPREE1EVG
MYN^&_A?|D'PWX7M?!_Q?^%.O:%|;=%4:3J?A.;5|J|U>|2-!%):?9Y1"WVH
MNI1'K|Q_BQO|_*|CS,?PU|M>,(=-TW|H+|AJ'1M&OO#FBQ:1X
M@AL=\$U=#%>:?!_8ULL50*KLS+)&NU&!9F!5LD|U|KA0!@_4?(W|:'_4,
M|A |(>K:'H2>';GQAXIU.\$7|::+DV4-
M9\$R()FF,3AF:1&540'(C#O!WCDZQXCU+S/LED=*OX&E|N-Y9,/+
J#;D;\$9/.W'4T ?+ M/PGE^\$/@GX^_%_PY^U#I>A2_%/7_
|++J&FZ|XXTQ'TN^TAHS|E-G+:Q|2M(M+))OVN?|\$_O MA>%IH9Y3(6)-
P|B\$EE^;@%1@=KKO|>GPB|0:3JG@+XL^#-8TWONDZ:=>?#?6_M-!;5Y=0O
L4L45OY2/!(<+)*4\$+MLW'RWVJKJQ|8TKP+XB^&O|(?|'"AWQ%I<
MNA:U;_%O2+F?3|H|9XA/>WTT:R*!|A|N:+-9_ ^+C^+UO#GB 22RF2|\$_7_'K?
H)F,SQ7,&R03RA#*ZRE5V@5|B>#? M%6I?&S_@H5|&?C0U|GPMXD0?
\$VA>\$;<0H0=*TW3I4^U%|)) ^_N+BZ?RID5XP M",E63'MW|7?|*/CGXF^/!?!
PSUF+PO8>/M-3PKX|NVN&C7|+|%*D|5XL,10S
MS^7'-9G>YW1S)"%1&>1;WQ6|,Z?X)_:Z_8W|:-;: 9-(TFR|3:?.|1.7=8K>+
M28DC0.S%B0BA=S%LX!.30!|B5|J_|-|'_HW7X^_^\$._? _ (7U57RC_PP*W_1
MQ7Q|_P#"Y_|N>@#WKX7^/&^*'|@?2_\$QT#Q%X2-X9H0^7+)%^|A
MR=N|90/'*NIKP?;/^'I>W V_|*SC'&?|)
|PWFH3;Y&D!EF*KNV|JY7@(|H_A%?)7QH^/'@7|GO_(*,V?B;

MO_KC^!N_A0FFPW'V2>YW3-JJR!2L*.P.V*0YQM^4<|T?7WC[XA>'_(8^
M#]6\5^*]8CT;0=+B,|?7!98XH|@#;CEF8LJJB[F9F"H"W%?..I?MG?.\$#P;:
MGQ9X_P#@1K/@;X2K-"|_BF||0V"@KKT/BK7|>WLF,-
S:7&GJK+=K<)"&N(DS)(MI* M! "&5=|(#NKYC|_V_P"PYKNA6|A+|&?
%ZS#=#1.RW\$49|MY(W\$8220EF0A%;*JQ**?=WQ;^_GQ)|_^,I-
!^&GP7UGXDM9Q12:GJ5_JD.@
M6\$+2@F&*WFN4Q=O@,9/*R(R8U+;BRIQO_#P#PS_PSG_PL;_A%|?=
.\$G_MO_M(1'_A_L|W|H?| "1;<P!G;O+_.!;|F=G&SSOW->0_M?
&B37OVJ_%7PV_M^(_Q4|_|NHM1|1W-Q%|TWVJ"&:21!(9()7:CL\$P!) "Y
M/_L^/X,|&?'XHQ?.\$OPWXT|2Z-I?QGU#|1J\$>^ ^UO1)8(893JEY+(-6^
&H>'O&.DV8O|/3;KQ19R:9J_M2%P%@2_B!.*W+;)| (82B^7'YDL8E4UY%^P"|?
4?@_;P^"->U+7_M-4N?-'OXCMQ"DT|]>7+ "/3V!G51<,8;|O|OD5O?LD?
%BZ|>?%O7|/P!XNU_X MD? BWT@SIX@|30R^?IFMR7DDAT^&XGCBGN(Q
X8^9Y|1CR5|Q0<-QW_!.7X| M^'O#7P|_|_L^WUKJZ_\$ _POJFL:?
K6EQ67FPZ="((S2@CS?X_6_P"QM|
<+7P+)X"T/PCI_B/1+ZTO=+TO8NF^((|JUA\$R|_M_|L|WY0.Z1BT|3M\$Y+2%-
U?1'QZ^,\$OP+|!MXP?PEJOBCO|&7=K(T-HVN|&S
M|N1C=B*0J)\$601*X+*41Y)#Q&0?D7XN?%CX>_MC_!:_^"TWP7T:X|<^)?
#WC_M;2=2U|Q7;^'YK9=)TBV>68Q7%Y<1QL\$=S)(D0)#M_P_W|_X!
|H:OVMIO?Q_M+T_X8_#GP=-16_B9-#)J-
|H5CJ<=C|H5D%W>;=74BLD3,63:C|00XRREX5DR
M?|_|\$OB;P|_|);SX>ZMX4|1?"SP_#J.KZ/K-Y&#->-!=3-##*@=6@VVZ%+K
M&)%G5_+"@;./;\$'QDT|/D'|MSXK:Q|3YVT7P=|1|&TC4|(A0);7=RGGZ?#|E
M>T9(H&'FG?)*VUL*HBSS+@5/@Q!'^T;|OVVM*ACU?
PK;>)M.TG0XO|NZS>Y01_:"B_?_N/FV<;NAJOJW|3GC36/_?
P|U;P|!&M;|?;|XHT" MU|2SV\$.HKIVG:9;S0HXC?49T\$4LWF2*HA0;R@=V5
%#_!U|/VDO!_A'_@G_M/XL^\$\$Z:Y??\$|1_#?B.SU7PQ8>'|R2YTSS;JY1|;IC&
(HHHOM\$;RLS@*RX+
M#;6KXH^_5SX7|)_L|^"/&/O+|0_!SX2:E|^*M*U";70#.GS'4-5U)4B7|'|#>1
MQRM;F-1#;?*3E'9'R)4"@ 'V5^SC^TB_QQ;Q;HFO^%M0|
^/?"=ZMEX@|+7TA_MF:T;@=K>6&X556>*6.-F5E
/RDCLN!MBW'S+|@00X_"|1_MG|2^GQW_ (OU14/AKR;_,>.9M8N5>UN)
(|)R<,NX'Y4D".B"-9%60.JW?V, M?"-Y|2?
^"7MKX3TJ>WBU/Q!H/B/2K.6X)2%)IKJ|B1G* @E1N?<QZ;,%E*F-'DB
M1RC2IY9P@D'TSX3|5Z=XT|)Z3XDT:|_UHVKV45|97#H4,T,J*|
<@5|_%ZO>I&@BDM/L|H_MA;|474HN47=(.9CVRM^H_P_)|/3K'X6^\$K?
1=\$U#PYI\$>DV<5EHNJ(RW>FPB_M&,0V|R,2P>-=JMO+,"IW\$T?GO|
\$#^V_AS^W#|>_C?H1U*|_P"%=WGAI?.\$&MDV"NYO=O_+\$_=_MA0CS)
(C%!_F|UC00M)(6V+C|/ #: @^/4_PY^!RZQX(N(|9_M|3>+9+71?!DUI*DD-U?
WH(MI%E97AVJA||&0JCB!/8;JX'X*Z38:_P#MF?M>
M:9JUM!J6GWT/A6WNNK&ZA62"XC?2Y\$9&C<%65LE2IR",@US_|-
O|'GC7P'|;+ M76O'FM'6O"?PWLKG0/AY:S:E-?P|^S+^S_
/&R#Q3XFM;7P_X*^(FK6%WK5Q\$80T<\$5I\$KK'EVW2,@_MVQJ79F954LV*
|_4OVS0B!X-M3XL|?_C6?_WPE6:%Y_%-YXALY;ZRMYY(XX)
M;C2XP9T.^6+S(@7>,,WRN5VMXSI?PH|0?;|E_|:|!%>%(XI=?U'XMZS)9V
MMU,81,T%U8W#1AB,*SK"0K/M4.RABH):O-O#-O|_L:|H5O82_!GQ7+|2D,D
M%|_|-*.N7NLPW43LMQ%&?.2-Q&\$DD)9D(16R|L2B@'W=|6_C|2?#/C*30?A
M|_|9^)+6<44FIZE?ZI#H%A"TH)ABMYKE,7;X#&3RLB,F-2VXI|J5?_O|6EE|
M0/V: _&?Q1L_#VHV&J>\$;|4O|;|*ZF6MY|/4;*RSV+R%,_W,_%SB3)57!C7Y
MY:_^-\$FO?
M5^*OAM|1_BIXX^\$/A2RBTH^\$=,|Z9=1:CXCN;B+YIOM4\$,TD
MB"0R0>2NU'8)@"2%R4|6+LC\$%LLI(-'I&O?|%\$M<|^*^%|+^)&J?_?Q?
9?!#4#&+?Q9

M)J%HVH%9(V\$&S&CRX59'F5&5HW5CYB(WJ7QV.:@U+X<_+\$+P\|-_7@+4
MOBA\1-6M)-8;1X+U=.M\33E,B_:)KR1#&H:5=BKT.,%E+1K)X#^T9(W_YI
MTG"8?_A#/"H4Y_Z:Z?QP>_S<8\&TU"S@B661RNG?:
D)RTDZO"UPL,T\I9^(G@!;MKG M@!5_.I1S26=WH^L30SR1SQ?)*8GB=M\)
<'RY6"^8JAP@1T900;|_9#|>>-MOB+|-4U0Q;<76JZ7-
K\|GA76;ZU2QNM8T+S;*/FBCCC"/(ID_=0AE2)M@ MW[V]_H **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** &^6F|=M7=ZXY M\?X#\J1HT?
&Y%:'3(JP?Y@?E3Z* \$VC=NP,|,TT1(H "*" HP..E/HH ;M7GY
M1SUXZT*BKG"@9.3@=3ZTZB@!NQ=P;:-WKCFEL:* &[%VD;1@|1B@(|)%
_"G M44-V+@C;.'KQ2\1D' STI.* &^6O3;.9STI2H;((SG@TM% #?
+7^Z.N>G^? M2EQGJ,TM% #=B|<;1C&,8|>E+M 8L-Q&"<<_P">3^=+10
F!Z4TPH< HI"| M..G&/Y\$T^B@!-HSG S2,JM@\$ CW%.HH
;Y:C^\$=,=.WI2TM% "8'I2>6N|=M M&|UQSW_Q/YTZB@!NU?
|H_*C:N;;1C&.G;G44-V+@#;.#IQ1L7:1M&#U&*=1 M0
W8O|T=^WKUI=H|*6B@!-HYX'/7WI:** &K&JL2%)ZD#K_)R?SH:-68\$J
M"1T)'3_.!^5.HH ;Y:G.5'R,'CK08U;@J|&<|. ^<_P Z=10 F/:D\M-V|:N|
MUQSW_P 3^=.HH :L:JQ(4 GJ0.O^GOG^ M=-\$\$:XQ&HV\CY1Q@8'Z5)10
W8NXG;GJ1_LP_ | V M=/@7X7^'BZZ?\$0T876W4VL_LRS^=[?A7K7EIM"
|5VCHN.* M7:.>|2T-V+N#;1N|<HH MVC<3@9/4X|.* &>2FX-L7<.0<FV/Y4
M;%SG;.^N/^@IU% #=BX VC Z<4;%VD;1@|1BG44 ?)UU^R;|1_"/B?Q7J/P
MF^/.H?#O1?\$NN7/B#4|+U#PO8:QYFI7,F9Y(I)!&T<6%C18SN(LG<=U>L_
MCX"^_ V??:|_ H.A7FKZO+?:G<:QJ&I: ?&|OM0O)L&2>63:HW8"KE%'W-QR|
M.6|6VJ-HVC"|..E&Q>/E'7/2@!=H#%@!N(P3CG_)_.D\M<8VKC@|/3I_(4Z
MB@!IC5F#%02.AQTH|M=NW:-N.M#1JW50>0>1W'0_H/RIU%
#0JKDA0">O%(8D8\$%%(88/'6GT4 M,|M,D|%SG.<=|8I=B|_HQOV|.E.HH
3:#U%)L7:|M&|T&*=10 WRTW;M|J|O7 M'/;_ 'Y4;%SG;YSG%.HH
:8U;.54YX/'6A8U7D* >G _SZTZB@!-HQC Q| M*3RTX.U<@Y"0^OZG\Z=10
A4,,\$ C&.E+110 A4-U /&.E-6-\$SM15SUP/< MG^9/YT^B@!JQJHP% &.
<#MZ4NT9)P,^N*6B@!HC1*6EHH;Y:|=NT;W|!^5/HH *0@-
U&:6B@!K*K*5(!4|\$&<AHT;;E5.TY&1TIU% #?+7^Z M/7I|Y_G7D?P^~!
|>"/CE|5OB*->&H+X|&C_|2QK(;+|%;& \$R^8?,WY+<(F
MW_:KUZFLBMU4'ZB@!&B20 ,BL.3R,|<@_P S^=.90RE2 0>,&EHH :RJRD,H
M((P01UHVKN)VC)&"I_4_G3J* \$QWQS12T4 -|M=NW:-N GRAPHIC 14 qncx-
20240930_g4.jpg begin 644 qncx-20240930_g4.jpg M_|C_X 02D9)1@ ! 0\$ R
#(#_VP!# , " @, " @, # P, \$ P, \$!0@%!00\$ M!0H'!P8(# H, # L*"PL-
#A(0#0X1#@L+!\$!80\$1,4%145# |7&!84&!(4%13 MVP!# 0,\$!
4\$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04!
M%!04%!04%!04%!04%!04%!04%!04%!04%!3_P 1" /M")@# 2(A\$! Q\$!_10 M'P 04!
0\$! 0\$ \$" P0%!@<("0H+_10 M1 @\$# P(\$ P4% M! 0 %| 0(#
01!1(A,4\$&\$U%A!R)Q%#*!D:\$(T*QP152T?D,V)R@@@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM|BYNI
MQ|C)RM+3U-76U|C9VN'BX^3EYN?HZ>KQ\O/T|?;W^/GZ_10 'P\$ P\$! 0\$! M
0\$! 0 \$" P0%!@<("0H+_10 M1\$ @\$"! 0#! <%! 0 0)W \$" M
Q\$\$!2\$Q|A)!40=A<1,B,H\$(%\$*1H;'!"2,S4O 58G+1"A8D-.\$E|1<8&1HF
M)R@I*C4V-S@Y.D-\$149'2\$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM::WN+FZPL/\$Q<;'R,G*TM/4
MU=;7V-G:|XN/DY>;GZ.GJ|O/T|?;W^/GZ_|H #, ! (1 Q\$ /P#|4Z*** "B MBB@
HHHH **** "BF# 'I1V|J-0|Q|1?-_G%'S?YQ3%KV):*B^;_./F_SB M@-

>Q+147S?YQ1|W^<4!KV):*B^;_#BCYO|. *U|\$M%1?-G%'S?YQ0&O8E
MHJ+YO|XH^;_.*U|\$M%1?-G%'S?YQ0&O8EHJ+YO|XH^;_.*U|\$M%1?-G%
M'S?YQ0&O8EHJ+YO|XH^;_.*U|\$M%1?-G%'S?YQ0&O8EHJ+YO|.*/F_P_X
MH#7L2T5%|W^<4?-G% :JB6BHOF_SBCYO|XH#7L2T5%|W^<4?-G%
:JB6BH MOF_SBCYO|XH#7L2T5%|W^<4?-G%
:JB6BHOF_SBCYO|XH#7L2T5%|W^<4?-M_G% :JB6BHOF_P_XH^;_#B@-
>Q+147S?YQ1|W^<4!KV):*B^;_.* /F_SB@->Q+147S?
YQ1|W^<4!KV):*B^;_.* /F_SB@->Q+147S?YQ1|W^<4!KV):*B^;_M_.* /F_SB@-
>Q+147S?YQ1|W^<4!KV):*B^;_#BCYO|. *U|\$M%1?-G%'S M?
YQ0&O8EHJ+YO|XH^;_.*U|\$M%1?-G%'S?YQ0&O8EHJ+YO|XH^;_.*U|\$
MM%1?-G%'S?YQ0&O8EHJ+YO|XH^;_.*U|\$M%1?-G%'S?YQ0&O8EHJ+YO|
M_.* /F_P_XH#7L2T5%|W^<4?-G% :JB6BHOF_SBCYO|XH#7L2T5%|W^<4?-
_G M% :JB6BHOF_SBCYO|XH#7L2T5%|W^<4?-G%
:JB6BHOF_SBCYO|XH#7L2T5 M%|W^<4?-G% :JB6BHOF_P_XH^;_#B@-
>Q+147S?YQ1|W^<4!KV):*B^;_.* M*/F_SB@->Q+147S?
YQ1|W^<4!KV):*B^;_.* /F_SB@->Q+147S?YQ1|W^<4! MKV):*B^;_.* /F_SB@-
>Q+147S?YQ1|W^<4!KV):*B^;_#BCYO|. *U|\$M% M1?-G%'S?
YQ0&O8EHJ+YO|XH^;_.*U|\$M%1?-G%'S?YQ0&O8EHJ+YO|XH^ M;_.*
U|\$M%1?-G%'S?YQ0&O8EHJ+YO|XH^;_.*U|\$M%1?-G%'S?YQ0&O8
MEHJ+YO|.*/F_P_XH#7L2T5%|W^<4?-G% :JB6BHOF_SBCYO|XH#7L2T5%|
MW^<4?-G% :JB6BHOF_SBCYO|XH#7L2T5%|W^<4?-G%
:JB6BHOF_SBCYO| MXH#7L2T5%|W^<4?-G% :JB6BHOF_P_XH^;_#B@-
>Q+147S?YQ1|W^<4!KV M):*B^;_.* /F_SB@->Q+147S?
YQ1|W^<4!KV):*B^;_.* /F_SB@->Q+147S?Y M Q1|W^<4!KV):*B^;_.* /F_SB@-
>Q+147S?YQ1|W^<4!KV):*B^;_#BCYO| M_.*U|\$M%1?-G%'S?
YQ0&O8EHJ+YO|XH^;_.*U|\$M%1?-G%'S?YQ0&O8EH MJ+YO|XH^;_.*
U|\$M%1?-G%'S?YQ0&O8EHJ+YO|XH^;_.*U|\$M%1?-G%' MS?
YQ0&O8EHJ+YO|.*/F_P_XH#7L2T5%|W^<4?-G% :JB6BHOF_SBCYO|XH
M#7L2T5%|W^<4?-G% :JB6BHOF_SBCYO|XH#7L2T5%|W^<4?-G%
:JB6BHO MF_SBCYO|XH#7L29HS4>YO3^5&YO3^5(>O8DS1FH|S>G|J-
S>G|J U|\$M%1?-M_G%'S?YQ1|W%KV).T9J/O8DS1FH|S>G|J-S>G|J U|\$F: *C
MW-Z?RHW-Z?RH#7L2T5'N|S1N|S3L&O8DHJ/P M_D2YHS4?/^11S|?
E1|@),T9J/GU%/J*6O81)FC-1|31M-,+DF;U'M-&TTK MA=\$F;U%M-
&TT[A=\$N;U'M^E&WZ4#),T9J/:?6C: ?6IN!)FC-1_E1568\$F:
M,U'13L(EHIO%'%+4!U%-XHXHU =13>...!CJ*;DT9- #J*;S1S0 ZBF_YZT?
MYZT.HIO%%&H"TM18ZXXIRXQG.:E2OT#T'T4450!1110 4444 %%%
!1110 M 444E "TF?>FA<8KY-;(:4N/A_9GP;X3N|^);N/- =6|Q\$NG0D?)S_.^
M>H^9%^;C*IX.DZM1Z(| ^-O|4G@_X-R7>GS2'5_\$/E_V78C
MD%D)C|V0_)GY1CYGQ(C;=M?*B?|OKXBZT+J#2|/2_#|K--H|S%;O-=01>
M8.?G?9(>-GW.P#!7S317ESK2EMH?F>*S_&5YWI/ECV/:O| ALSXP_|0XM_
MX++3_P",T?| #9GQA_Z'%O| P66G_P 9KQ6BLO:5.YY7|H8O_G|+[V>U?|-F
M?&' *'%O_!9:?! QFC_ (, ^,/ \$.+?^"RT_|C->*T4>TJ=Q?VAB_ ^?LO
MO9|5_P-F?&' H<6_P#!9:?!FC_ALSXP_|#BW_ (++3_XS7BM%'M*GU?|-F?
&' *'%O_!9:?! QFC_ (, ^,/ \$.+?^"RT_|C->*MT4>TJ=P_M#%_|9?
>SVK_ALSXP_|#BW_ (++3_XS1_PV9|8?^AQ;_P %EI_|M9KQ6BCVE3N'|H8O_
)^R^|GM7_#9GQA_Z'%O_!9:?! &:/^&S/C#_-#BW_@L MMA XS7BM%'M*GU?
+F?&' H<6_|!9:?! &:/ M^&S/C#_T.+?^"RT_ ^,UXK11|2IW#^T,7_P_9?
>SVK_ALSXP_P#0XM_X++3_M.,T?|-F?&' *'%O_!9:?! QFO%:*/:5.X?VAB_ ^?
LOO9|5_P-F?&' H<6_M_P#!9:?!FC_ALSXP_|#BW_ (++3_XS7BM%'M*GU?|-
F M?&' *'%O_!9:?! QFC_ (, ^,/ \$.+?^"RT_|C->*T4>TJ=P_M#%_|9?
M>SVK_ALSXP_|#BW_ (++3_XS1_PV9|8?^AQ;_P %EI_|9KQ6BCVE3N'|H8O_
M)^R^|GM7_#9GQA_Z'%O_!9:?! &:/^&S/C#_-#BW_@LMA XS7BM%'M*GU?
+F?&' H<6_|!9:?! &:/^&S/C#_T.+?^"RT_ M^,UXK11|2IW#^T,7_P_9?

>SVK_ALSXP_P#0XM_X++3_.,T?-F?&'_*%MO_!9:?!QFO%:*/:5.X?VAB_?
LOO9[5_P-F?&'_H<6_P#!9:?!FC_ALS_MXP_J#BW_(++3_XS7BM%'M*GU?
F?&'_*%O_!9:?!MOFC_(,^,/_\$.+?^"RT_|C->*T4>TJ=P_M#%_|_9?
>SVK_ALSXP_J#BW_M(++3_XS1_PV9|8?^AQ;_P%EI_!9KQ6BCVE3N'!H8O_
)^R^!GM7_#9GOA_MZ'%O_!9:?!&:/^&S/C#_-#BW_@LMA_XS7BM%'M*GU?
+F?&'_H<6_|!9:?!&:/^&S/C#_T.+?^"RT_^,UXK11|2IW#^T,7_M_P_9?
>SVK_ALSXP_P#0XM_X++3_.,T?-F?&'_*%O_!9:?!QFO%:*/:5.X?VAB_?
LOO9[5_P-F?&'_H<6_P#!9:?!FC_ALSXP_J#BW_(++3_XS_M7BM%'M*GU?
F?&'_*%O_!9:?!QFC_(,^,/_\$.+M?^"RT_|C->*T4>TJ=P_M#%_|_9?
>SVK_ALSXP_J#BW_(++3_XS1_PV9|8?^AQ;_P%EI_!9KQ6BCVE3N'!H8O_
)^R^!GM7_#9GOA_Z'%O_!9:?!&:/^&S/M/C#_-#BW_@LMA_XS7BM%'M*GU?
+F?&'_H<M6_|!9:?!&:/^&S/C#_T.+?^"RT_^,UXK11|2IW#^T,7_P_9?
>SVK_ALSXP_M_P#0XM_X++3_.,T?-F?&'_*%O_!9:?!QFO%:*/:5.X?VAB_?
LOO9[5_M_P-F?&'_H<6_P#!9:?!FC_ALSXP_J#BW_(++3_XS7BM%'M*GU?
F?&'_*%O_!9:?!QFC_(,^,/_\$.+?^"RT_|C->*T4>T_MJ=P_M#%_|_9?
>SVK_ALSXP_J#BW_(++3_XS1_PV9|8?^AQ;_P%EI_!9KQ6_MBCVE3N'!H8O_
)^R^!GM7_#9GOA_Z'%O_!9:?!&:/^&S/C#_-#BW_@LMA_MXS7BM%'M*GU?
+F?&'_H<6_|!9:?!&:/^&S/MC#_T.+?^"RT_^,UXK11|2IW#^T,7_P_9?
>SVK_ALSXP_P#0XM_X++3_.,T_M?-F?&'_*%O_!9:?!QFO%:*/:5.X?VAB_?
LOO9[5_P-F?&'_H<6_P#!M9:?!FC_ALSXP_J#BW_(++3_XS7BM%'M*GU?
F?&'_M_*%O_!9:?!QFC_(,^,/_\$.+?^"RT_|C->*T4>TJ=P_M#%_|_9?>SVK
M_ALSXP_J#BW_(++3_XS1_PV9|8?^AQ;_P%EI_!9KQ6BCVE3N'!H8O_)^R
M^!GM7_#9GOA_Z'%O_!9:?!&:/^&S/C#_-#BW_@LMA_XS7BM%'M*GU?+F?
&'_H<6_|!9:?!&:/^&S/C#_T.+?^"RT_^,UX_MK11|2IW#^T,7_P_9?
>SVK_ALSXP_P#0XM_X++3_.,T?-F?&'_*%O_!9M:?!QFO%:*/:5.X?VAB_?
LOO9[5_P-F?&'_H<6_P#!9:?!FC_ALSXP_JM#BW_(++3_XS7BM%'M*GU?
F?&'_*%O_!9:?!QFC_M_(,^,/_\$.+?^"RT_|C->*T4>TJ=P_M#%_|_9?
>SVK_ALSXP_J#BW_(++M3_XS1_PV9|8?^AQ;_P%EI_!9KQ6BCVE3N'!H8O_
)^R^!GM7_#9GOA_Z'%O_M_!9:?!&:/^&S/C#_-#BW_@LMA_XS7BM%'M*GU?
+F?&'_H<6_|!9:?!&:/^&S/C#_T.+?^"RT_^,UXK11|2IW#^T,7_P_M9?
>SVK_ALSXP_P#0XM_X++3_.,T?-F?&'_*%O_!9:?!QFO%:*/:5.X?MVAB_?
LOO9[5_P-F?&'_H<6_P#!9:?!FC_ALSXP_J#BW_(++3_XS7BM%'M'M*GU?
F?&'_*%O_!9:?!QFC_(,^,/_\$.+?^"R_MT_|C->*T4>TJ=P_M#%_|_9?
>SVK_ALSXP_J#BW_(++3_XS1_PV9|8?^AQ;_M_P%EI_!9KQ6BCVE3N'!H8O_
)^R^!GM7_#9GOA_Z'%O_!9:?!&:/^&S/C#_M_-#BW_@LMA_XS7BM%'M*GU?
+F?&'_H<6_|M!9:?!&:/^&S/C#_T.+?^"RT_^,UXK11|2IW#^T,7_P_9?
>SVK_ALSXP_P#0_MXM_X++3_.,T?-F?&'_*%O_!9:?!QFO%:*/:5.X?VAB_?
LOO9[5_P-MF?&'_H<6_P#!9:?!FC_ALSXP_J#BW_(++3_XS7BM%'M*GU?
F?&'_*%O_!9:?!QFC_(,^,/_\$.+?^"RT_|C->*T4>TJ=P_MM#%_|_9?
>SVK_ALSXP_J#BW_(++3_XS1_PV9|8?^AQ;_P%EI_!9KQ6BCVE_M3N'!H8O_
)^R^!GM7_#9GOA_Z'%O_!9:?!&:/^&S/C#_-#BW_@LMA_XS7B_MM%'M*GU?
+F?&'_H<6_|!9:?!&:/^&S/C#_T.M.+?^"RT_^,UXK11|2IW#^T,7_P_9?
>SVK_ALSXP_P#0XM_X++3_.,T?-F_M?&'_*%O_!9:?!QFO%:*/:5.X?VAB_?
LOO9[5_P-F?&'_H<6_P#!9:?!M!FC_ALSXP_J#BW_(++3_XS7BM%'M*GU?
F?&'_*%MO_!9:?!QFC_(,^,/_\$.+?^"RT_|C->*T4>TJ=P_M#%_|_9?
>SVK_ALS_MXP_J#BW_(++3_XS1_PV9|8?^AQ;_P%EI_!9KQ6BCVE3N'!H8O_
)^R^!GM_M7_#9GOA_Z'%O_!9:?!&:/^&S/C#_-#BW_@LMA_XS7BM%'M*GU?
+F?&'_H<6_|!9:?!&:/^&S/C#_T.+?^"RT_^,UXK11|M2IW#^T,7_P_9?
>SVK_ALSXP_P#0XM_X++3_.,T?-F?&'_*%O_!9:?!MOFO%:*/:5.X?VAB_?
LOO9[5_P-F?&'_H<6_P#!9:?!FC_ALSXP_J#BW_M(++3_XS7BM%'M*GU?
F?&'_*%O_!9:?!QFC_(,M^,/_\$.+?^"RT_|C->*T4>TJ=P_M#%_|_9?
>SVK_ALSXP_J#BW_(++3_XS_M1_PV9|8?^AQ;_P%EI_!9KQ6BCVE3N'!H8O_
)^R^!GM7_#9GOA_Z'%O_!9:M?&:/^&S/C#_-#BW_@LMA_XS7BM%'M*GU?

+M-F?&'H<6+!9:2&:/^&S/C#T.+?^"RT^,UXK14RK5%U#^T,7_S|EH/
M;?|ALKXQ?|0XO_."RT|C-'V5|8O^AQ?_%EI|&:|6CI>:CV|3MN7|>Q?|
S^EH:/^&QOC%T.+?^"RT^,T?|C?&+H<6+!%EI|9KQ:BLM?;5/YBO|0Q?
_#^EH:/?^&QOC%T.+?^"RT_P#C-A^&Q?C!T.#?^"RT_M^,UXG4O-
'MJG|P?VAB_?^?LOO9|/'^V%|83_S.+?^"RT^,U)_P-@?&#_H<7M_P#!9:2-
!FO%XZEYH|M4_F)^OXO_G|+|V>P?|A?&'*%O!9:2|QFG_M
/##8'Q@_Z'%_!9:2&:|7JQ4^WJ=RO|0Q?_#^EH/8?^&OOC#_#BW_@LMM/
XS3T_:|,|=??&+?^"RT^,UXW1'1|>IW#^T,7_S|EH/9?|AK|XL?|
M0XM_X++3_P",T|X:^^+'0XO|^"RT_P#C->.IW!9ABW_P09?>SMU_|
X:|^+'0XO|^"VT_P#C-+|^UQ|6#_S.+|@MM/_C->/T1U/UFM_,7|M?Q7-
#|E|Y|G|7'Q7/7Q>?"L_P#XS4B?M:??%=NOB|_|@%9_&:|CJ2M.L_K-?|
F#Z_BO|G|+|SV-/VLOBLW7Q>?|P"M/_C-2)^U=|5CU|7G_,K
M3_XS7D\$=21UD|577V@^OXK_G|+|SUK_AJWXJ_P#0W'_P"M/_
(S4G_#5/Q5_MZ&X^=I_P#&:|ECJ2.I^M5_YB_KN)_Y^R^|;C_&K/BN?
^9D?_,!+3_XS_M4L?|57Q/_P"AE?|_|!+3_P",UY''4D=8RQ5=?|O'/Y|I|>Q_|
#|E|YZS_P-M4_\$_H97_P#2T^,U83|J;XGG_F9&_||3_.(KR*I(Z/K5?
_GX_O#Z|B/^M?DOO/6?^&J/B?_T?_DE;_|Q%2_|1?\$_|H8_|
R2M_B*|EJ2.N=XK\$+_EMX_O+CC,0_P#EY+|SUC_AJ+XG?|_#'_P"2-O|
\$4O#3WQ._Z&,_^_O_/5_MY54O-'UK\$?|/Q_>'US\$?|_)?
>>I_P###3OQ._P"AB_|)&W_/B*E_X:9^)^O_M_0Q_^25O_P#\$5Y54O-
8RQ(N)7_+Q_>'US\$?|/R7WGJO_TW|1O^AC/_(!6_M_P#|13_^&F/B_T,A_|*W_
/B*|J7FLOKN)_Y^/|S7ZWB/^?DOO/4O^&FMOB/_-#)_P"2-O|
_\$4_AI7XC_|#)_Y)6_,17EM2|T/&8E?|+QFGU|?%M|_Y|ZC_,-(\$?_*&3_P
D;?|^J3_AH_XC?|I#&?"M_P#XBO,N:267MU|?%_|_Y|XUCL4_|EX_O/3?
^&BOB_T,A_|&W_/B*?_PT1|1?^AC_/)*MW_|
B*|SCJ2L7BL0O^7DOO#Z|BO^?C^|J(X:(^O_0Q_P#DE;_!%3?|-\$
M>/O^AD/_(!6_P#|17FW-/J98S\$+_EY+|ROKF*_Y^O|STG_AH3Q|_P!#*?|
MP"@_^(J3_AH+Q|_T,C?^4',17F_-/JKN(Y^2^|T^N8G_GZ_O/2/^%>M/?|
H9&_|X/_B*/^%>/?|H9&_|X/_B*|Y|I9?7,1_S|E|X?7,3_,7_M|Y|Z+_P
+Z|>_|I#(?_*#_P"(I_|POGQY_T,9_|.#_.(KSSFGU/U_%?|M/V7WE+&X|_|
+Q_>>B_|+W|>_P#09;_P#@_^(J3_(7MX|_Z#++^D',17_MG?-/H|0Q?|S|E|
|*^N8G_GXST'_A>GC7_H,M_X|P?_!%21_'+Q|_T&6_|M_X/_(BO/^:?'67|H8O_
)^R^|A|"ROK6(Y^/|SO/^%Q>+|^@Q_YC_^(IW_N'Q9_T&A_R!_'/\$5Q-2|
MU/|:6,_Y^R^|FOUJO|SO|SL?|A+|^@O_P"0_M(|XBN-J2.L7FF-
7_+Z7_@4O|P^M5_YW|YV7_"VO%7_\$%_(\$?_P13_|MA;'BO_H+_P#D"/A
^(KCJEYK/^U,_=S^E_X%+_,/K5?^==>=?_PM'Q5_T%_M_"#'_P#\$4?|"T?
%7_07_P#(,?|17)U+S6?|JX|_G|+_P*7^9K|;K_,QU_M?"S?%/_\$%O_(,?_P
14O|PL_Q#_T&#_WYC_|B*Y*I>.)9KCE_P_OI?|
M@4O|P^M5_P"8ZS_A97B'_H,'_OS'_P#\$41_\$KQ\$>NL'_+|Q_P#Q%"(CUO&_
M|I)|14G_"?>(O|_G|;_+H_P#\$5S<=6*C^V,?,_I?^!2_P_S3ZS7_F.@
M3QSXB/A_R^-_W|3_.(J7_A.M9_Y_6_|H|17-1U)'6/|L9C_S_)??^!2_S
M#ZS7_F.Y|*>*=0U/6K;VFNM|T#;P?W:#HE>D_=X%>/>!?^1FLO|Y_0'KV3^*
MOV+@^O7Q67RG7FY-2ZZ|\$_U/H<%*4J-Y_=1117WQWA1110_4444_%%%%
!11_M10_4444_8FOZU:^^M"O=5OKD6|A8PR7|PW.(40N|?
+Z8/Y5^07C7Q=J/C|Q_M-JOB#5N=2U:2XN/J9_W|BW|OW:2ZM|BOU9^_O_
"1+Q_||@'4/_2>2OR+_MKAQ"=|3Z-JFA0Z=>>9Y"WMQ.)ALD=/X86'1%=7_
..|?B/C_D+^%L^GGW&?M_1-"HU'T%#*<=47-&F|6N?+|I%?3|?
|\$_|B_JD_VMX6_|")_(S7SEXH|/S^M%_\$NJZ-
>G=/IMY)I|YM_|494DV5\$H2A|:L<|?XK#L|I"U^YFT445-T<.^P4_M5T7@?X?
^(?B7K7|B>&|)&K:CY+S_&8_N?W2G_D|Q_DCYA|D)7OJ_|!/?X_MCMS_&MX7
|Y|C_XS5QA*<>:.*|X'\$XJ"G2@VCY@HKI_'WPS|5_#&^F^)=
M|NM(NI3B#SSF*?|U?|J|S^23_6?/L^Y7NZ?|\$^/B_|88:MX7|Y|C_,T_MN2?
8JG@,36FZ=.F|QWZ6/F&BOJ?|I?|B.5S_:A;Z>?<9_|\$UE>*OV&'?A

M3PMJNNW^M>'Q:Z9:S7TY@N+CS3"&7(_U/L:MT:D=T;O*,E>'+'7'DP_:)
[F?]U;0?||Q(_P^2_+!_Z"CUI M?&#X"ZU|%/LD.N^("NM2O?|1IEC/)+Y/
ST^>%?DSD8_BQ|OW&VUR2Y>>MVAVK"5W2|OR^|U?
^7<|UHHHJ3D"BNB|#_#_Q%|3:_L3PWI(U?4?*>?|,?W/
M|I3@2>8_R1|G_P|DKW/4/V?B;/6=S-;W&AWD|4/^HM|Z3S+C_IG|*)_P|I
MO5QA*<;Q1VT,%B,2E.E!N/<^:J*Z+QQX|0_#76?[%|1Z2-)U'RDG^S#|H^Z
M8X,GF)|DG(/_*!7.U#O&7*SEE"5.?)_6"BO:_A7^R?XI^,'@^#Q'H6KZ\$('M
MDDA-K<7LGFP2)TCDV0OY?.7Q_=DCKR?Q-
X:U#P9K%UHN6@M=0LYO(GMYCD\$ M>O|
G|I5*\$H|#:IA:U.G&M*/NRV9F45TWPW^&^L_%;Q:->'|#M/M=Q_-WZMX M?
XY)9A_EFB?_8)||=I8_V;?;\$?P,TFTOM>U70KLWLIMX+6PG?S1|F|Y/+=%
M_=ISN_ZZ)3Y)(4?<6|/):***BZ|G'S6TDG<****CF0U>7PA11 M11S(?
GT"BBBG<+|!15C3|/N=40K2TT^S^V7,|WV:WM;?|H+<3/_LZ^AM'
M_8)^*.H6-M>3SZ)I5Q*,FVOKR3S;?V'DHR|'K2,)3^!7.O#X2OB5*5.#:78
M^<:*|+^*G|. ?CWX/L9-7T+AI7VWSMUK_9 M?
FD>7<.GW_.7/^KKYBK22<(J4M+G76PM;#QC.JK1DKI|H|O|,****BYS
M;H%%%%5==Q:O9,****+KN%F_AU"BBBBBZ|AKLD|A1114W'9K26C"BBBES(
MJ%%%%/F17?
1Z!1115""BBBIOV%S14;MA1111=#T\PHHKIOAG\|M1^*/C/2O#
M6DWEK::E>>9|G_M#S/*^2.1_X\$;_)YU6O-8JE"=9|M-7=|',T5Z9|:OV?|
MQ%|"/|*&NWFEW3:F)# MC/)1Y/E|_OHO_/2O.|/T^YU2^M+2PL_MES--|GM
M|6W_'LMO,_"SI|KVZFM6A4I5/8R7O=BO17T7X9_8/^)^N6"W%ZNF>'9S+
MG|/J%|YDH_Z: ?N4E3|_P.L/QY^QQ|3?!"^>VDCQ#;6|\$>;K09_V|Y-AC,?
MR3/Q_<3_-GJ_9S|';_96.Y/:>R=OQ/\$***ZSX6_#+6/BYXTL_#.AG%S<123
MBYN"XB@B3_EI+L1O+_N?|L=9QO*7*C@ITY5)JE%>|^AR=%>S?
%K|E'QK|&_M"X|0ZQ9PU*4Z\$W3K1:??3S"BO? M_"/|\$/Q-
|6:0+^8:9X>||9^SZM-)%)|P,)/+1'V;-G(^:G|.IRW::UY;C(P|JZ M;Y?
Q^X|=HHHJ3S0HHHH **** "BBBL9@21TO-)'2|UD:#XZ*(Z*@_J7FHJEY MH
?'4O-11U+S0!%5BJ|6*R*(Z*(Z)>:??3.:?0\$0HCHHCJ#0DCJ2.HXZDCK
M("Q'4D=1QU)'64P)(ZDCJ..I(Z@U)(ZDCJ..I(ZRF625)'4=21T 25)'4=21
MUS3-8\$E2|U%4O-,|2|U%4O-)EECFGTSTFGUSC
M@21U)4<=243\$2|T^F:BJ7FLC4?4O-15+S2F^I
M(ZCJ2.LQ0)*EYJ*I>:@T'QU8JO'5BL@".K%5XZL5B:A'4D=1QU)'4=#X%_Y
M&:R_WG_|>O9/X|;|'|C-9?|S_/H#U|)_%7|EP^|BV?^+Vv)|/|/X(
MZBBBOT0|\$**** "BBB@ HHHH **** "BBB@#@/CK_P D2|?_/8!U#_TGDK|
MBZ_73XZ_|D2|?_|8!U#_P!)Y*(NO.Q?Q(_N?*XM\$****XSX<**** "BBB M@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
* M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HH MHH **** "BBB@ HHHH **** "BBB@ HHHH
***OZ+HMOX@UJUTJQM/M6HWD T M=O!;'M,|FR/|I3?
WN4J,7+2.Y|H_|\$^OAO|_8|'UGQU= ^9>2#3;#|Q)%F%= MCRR=D?
<^\$^Y|OV?|V=U>M6^M:7^U1|#?%UGIUQ:WS33WME;D^?:Q++%*7LWD
M_P"6@^3|/(WU/R_PU4^*5Y|^SU^R_<6%I=;;NTTV/1|*!A8S374@V23Q|_Z
MS_63|'=|KG=SNKP;_@GU0|/-7:YX1GNV-OJD7VZW^T7_"^=%|/^.,_|M'2
M3>V/X;?I_<|>W+|EC|.I2A@G1RU|23YOF?*H:?
9/^6=>J:|^UA|5O#NCV>EV'B|I'IC!';6UO|ALP?)2,(GWX?85N_MG M_#D^
C->:A8HR:=K|7V:T#^7YSR?OXS(W^L^?)Y_L^;MV8KP:O-YI4Y6CH
M?!57B,!B:E*G-Q:=M--#|5/^\$V|0?|_P_P#"5_:/^*E_X1#^TOM7DQ_|?7V/
MS/V?<^_SC/OX5|*?|_E?&#D_P#"8_-X++3_.,UIK+_
_F4G_L0O_RFU=7>IZ9X+_5^(OP|_VN@:|XC^Q: ?9^9Y%L+*W
MESODWR9D=?|E?
H/^S3XSUSQ|_|%/#_B'7+K|9JMV+GS;EHHXBVRXDC3Y\$ 4 M?

(@K\K*4+|C/_DVGPk|;W_TLGI86L3LV1P|B*M6O*F*4>_I_F?S\$S?ME?
M&%A@^,&Q_P!@RT_^,UY3?76H^-/\$UU:~?WY M/|E9E?
9_!/GXDW\$@R:~^O9/_M_M8>2C(?P>O)_B;|(O%7PBU@6/B2S^R"?S#;W-
O^|BN-C|/,BD_\$?NW^?_%>Y M:~^QOBM|&_CM|0/'JZGI7CBT|.Z.LIAT^UL-
3O+7|JR/|6TJ(GW^?F/U_A"UU M7QD|"Z|XK_98U33O'=WIEYXJTO3I-
1GU33|;?%YUME|>|;L=XUV,1M'IR3" M|?EKHG2A).VECZ"MDM&5.
<84W%K;S(V'O">G:~|"/5;?#ZCK5S//<3D)_! M*|*
(!"|P"/./|CG^(U\WWW|97Q?TOQ-=F^UDVC0WA^T:)<:5%%"!MDYM_|
M5^=_L??W?|6ZM'|FG|K7_A3.D_|".:YH|SK'APSO<074\$_[VWW)EXXHW^22
M/S,?QIM|QV^>OJ|M;~^!W|2C"VDN|"2:E,1;PI<#|J|"?OL1;|DVSJ?D^7|
M_P#M4)J4>6#L=5.V.PE.&&KVFD\$5Q=|?O/T&Q/F=/,?YGWU./VR/C
J|1XP;'_8,M/_ (S6Q^U5^S4W MP9OCK.B\$/X4U.7|/!;S2D26\$I_>>7@_?
3|WK_|6_OO|_URRE4C+E;/_EL3 M7QV&Q.E.;3>_F?JG^TMXTUOP#|%?
\$'B#0KO|'JEG|F\$5RL,UTXFI*+LF>
|Q#B:|'\$1ITYM)Q|^O^05I^&O#6H>,|8M=%T.U M%UJ%Y+Y\$%O"<
#U_S|RLROMO_@GEX#M5TW7_!FP#:A+*-(A4@_N(52.9OX|M?.9(N-
GR^5_M&N>E#VDK'S>681XRNJ*?S/16U#P;^Q+|^?LHN6U;4|AI+B&W
MW_OM5O-B;W R1&@_=Y_NJ!|JF^;||O\$WB74/&FL76M:Y="ZU&|F|^>XF' |O
M|_%?VBOA"/V@V?_%1KHU&RN|/MTEN;DK'DVSP-56I_9_X-S|
|J*|A^#O|+_BCXV^&KW6="O= M+M(;>|DL"+^:2*42(D;Y^1&_YZ5I?
\$K|D#QK|+_!>J^)=9U30IM/L_+|;~*X MG,QWR)'_!0K_?
KBY)\$_"|@/Q65T>WM)0-/U0YJ? MSI-YCE_N?/+P_P|S;|H9M^;J_!|_-
/P'O_B':W6A>)&|0RM|<_V#:ZE#?6V MWE|2JB,XA4X^^^QFV*V_?
M;LLY1M3=CZV5.IC#_M+:|_-/_U>7|1Z_LB_&V'X0_\$(6^IL%|_>
(/+MKGA(_L|GF?)<2_|GF2|OF7Y)=V'V5Z MS_P4 ^\$.R72OB%86N4?-
\$#5O(A)(|_RPN#M3_MFSN_:!5KXQK|?#?V>?'EM M^TQ|/|5|)^)0+B_L;9-
/OWR99)X7C_<7A=T8>?| (3U?YXM_1DK2C)SC|_G5 MEE6._P||4>OV3-
_8@^&=K|/_AI>^/_;*6MWK\$/VA;BZ/DB"PCY|SYT7R|Y&
M|B&*LJPM7R9^T|7'^-7Q.N_\$+M|FTWRH|;3K>X\$8EMX\$/^3J7?
S7S|^WS= MN|Y*^J?VW?BTG@/P;9?#K0=MI=:E9?Z1|EWQ?9K1?
E2*+9M0;_+D3'|R)UV_M.*^(/"_AZ?Q1XFTK1;(|9|2O(|/@_S_JA*|FRG6?
V\$PS2H%4|LH;+XO,|7X M1_#QG|;I+J/0+-C80R^1<:G?3&*TMY?+W^63H|^
(^WS\$W;~5W'B|JB+XF M>\$|&.H0_V7X@\$&3|FTF>267A"YD|MT7?
T^XF|N1L6OL_XC_#WQ#I_P)|;P?
M|)+G3?"K;OLQFF>2,PVN'|SRG16;SF>GZ?VEI86?VRYFF^SV|K;_+V6XF?-
)9U|!>&?V\$OB=KNGK<7 M@TSP|.9<_9|0OO,E'_33|RDJ9_X'3_VM;_7X0?
M''7_#%Z;_U"ABUF#R(!&
M|OOGAD_ZZ;_+ED;^_P";)N_V|2|U|H'X|!=4TVUU;3-_|F*6WM|+G_L>U|J M2A
UD_MZSH5|H=G!;7ZU%X: M%Q?H=HS>0P><3|GR<31C|GR_!|K@O^">?
)&M7|#DO_*(MZU|A'G4>YZZR M3#0QT;7NR5|'S3X%_8U^)^OC;U-|
<65OX>@'^H&O3R133_?_.6:(SQ_<'W|MF,C;NKPROLSXS?MR>(_#/Q_U;1?
#>DZ:FFZ7,VGS7&K0222RS1R|),)(OR<M_+|?_'M3XSK&HH1V9|JFE'
T>6CAVVX|^9|;?|!|3P?8:MX|4>())@&U#2 MX;>" 'RSY/FB3>_0_A
NRF>/E=QWJ|^U#^TE|4?AU|9M5T30|5_L/1((K:9&?FNQIGBRWC06
MY7Y/OONA|S\$G|_#|MK>S5O2E'V7+&5F?
0Y=4I5L#'#4JOLZB_\$^5_&W|9GBOQ M|)|CPA?VMJ-
0O!%;7&M6|SQ27\$(QOC|M!Q(^!OQ|FV1UV5A?!O|EWQ5|;O# M-
|K.@WNEVD%O=R6!%_-)%*)4CC?/R(W_#TKVG|H|CO10#WABY|3?#^R-
H= M-ADN-1TR:>2;SHE^=Y(G=V(=WJ8TY3J6J*YC'
5:~/^KYC)MVNK;'P1X|W.A7Q-JNBWIS/IEY)HYM_|
M5YJ2;*|A^)'|'_C7X8>"-5|4:SJFA3:=9^7YZV5Q.9COD1/XH5'|=>?_!H-
MY+)X_P#^P|J/_H^2OT_.;'_!C;X|O9?|I9!4Q|H:D^QPX/+|B(XJ35^
M3;RW_P@_8S7=^S7X4^M|C_P,GKX|(|_L1_\$SQ9HXOY?|_|V^>/^/?59Y(Y/

MN!A)Y:(^SD_O-Z1_P"!D]?#2_M3?\$Q/'P!5#Q%=M;?-
|_P#LSSY/L'_7/!OV>7Y?_XM^[YZVJ.)#GU/;QOU2.'PJQ47;ET_|
ME.9^~)WPA!5_""6!8>)+/!)Y_F>1VW^&ON;|N#PEI^O?N MU>?"ZAHEQ!/:S
(/!9*D+H21|PB3./!:'^\$50_99:|;|D^1/"@M?|A*(MU+'D>5YO|H;Y/(W?
|N_9Y/^L_AV?PXX/V*Y^4X'DM"..|C)^|:Z7<^?M9_8
M(^*&FV5S=P7&AZM<1C(MK&|D|VX|CYR*@_%Z|Q^('P#|=_"_1/75/\$OAW^C
M/EF|@W!OK>0^;Y#;:VE@%M
MXCN+R|CM_L^D"264E|Y>3>BI&G'^L=_DKG?BE^S+XL^#G@_3-?|
\$UQIJ6MW M/;"WAG>66*9XY')D&S;P8|?
(S5^CGQ8^(4'PG^'FK>++NVDO+?3HHR+:#_MTKR)'&!|76KG1A
Z,9EV7X:7L8M|/39?.QY|!)OV9/'GOBM1JFD6-O;:
M*2X@U35I_*AFVG'EQ|\$9^X^<)M_=NN|=70>,OV*/B9X3LS=0VEKXAM?
*DGF.MDS^;+"4&>(W1'D+|A0FX|?2OHG|M'XJ:O|(O!OA;PSX1+>'4U\$3VYN-
/*1?9 MK6&-\$|J)=GR<2#:Z;63ROEZUY_|
L6_'SQ%JWQ"N/!_B;Q!:=:Q;:I#+/827Y M>YF2Y09,8E_YYF,2/_R_NQL^_|
_G3IJ?(9/Y?1Q\$<%-OG?VKZ7|'R?X7|
M/3^*/\$VE;+9'\$^!7D>GP&X_U0E>397J'QC_9>|4_'!PS8ZUKM|H=W!I?';PCIW(
M"@??|O>W^U(|UZM_P4_Y(UI'_8=B_|
1%Q4^R7O>1S1RBC##XJ=7647:Y|A
M?!3|GWQ%|>|JW|@WFEVITL1F=;Z>2(GSO,|O|B_SSK)|1?!_6?#Q6_X5Y<
MWEJNLS75M8&ZAN'%J);D1F/^#?|_M/|E?3G_!-ML2_\$+_ =T|^=U7%?&#_D_
M>VQ_T'|&_P#1=I4JE'DC/N91R_#2P6'Q\$5|S=OS_,CE_%7|&/QA.7>F6\$%
MC;^()|2|S)TJ>00P; "?-DF14CW9PO|?(-;&L_L\$_%#3;&YO(+C1-5N(AD6
MUC>2>;<>Q|Y%0?B|?4O|8'Q3|0?"X:VNI>&YUL|1O=2BLOM7D+*(8S'*Y.'
M^7_EGW|;|_89^,GB_Q9XXU|PWK6L7&K;=_9TFH0W.I22SRPR++&A
D\$=.)_0R6&;:SIL>H3Y5%B|UY)\$DX4#A_+WM_M2.J?
M/U<,=DUV/C,5AY86O.B_LNP5|'X3_95|;:./AF?&ND7.F7NF2PW-Q#IV9Q<
MS"%Y\$V1QK"WSOY8VX?N*|E&|A%P+75IY(KJ_XZ2(L+!#|9_WOFK MD_!?
|*WQ&|<>)M4TJWT7?QR|.W&N^(KK5|;5|V*PN--|TL;8F|N-)/+V;(RC>6_R(F_|
MWOG>O=?VZOBMXD|!:/X5TCPWJW|B_P!MS7!N)|=S'=?
N3#Y:129Q&#YIW<=A M_#O#=#C2<'L=|/'994P|Q"YK4_/<^;_-(D?LA?
\$+X::.^M3VMIJ^FVT4DUS M=Z3_ML="G3?AA)6|9ZO|EMM2UF_ZA-J-
P8P+?3^7C0R;MH38#;Q^7_6?-|RN%_X M*3?
Z|X>G_9U'^=K7OGC3^Q6_9;U|_A'RW_"_P#""W'V#/F?|>OV/|W|_P"?
M|F/O_-6UE|1R|'OTZ,/|3Q%::NXK3|KGR-|2OV|/'OB#6B?"@'AS1(IW,_^S
MQ374|0Q_K_^Y.P^Y_P|-OS_
'ZM^#_V^O&FBZ/T=_P^XOZUK5QX@UFZU6^MNQ=:C>327\$|R!@"5Y-
|GW*^TO^"?/PW^PZ/K'CJZ;|R|D_LZP_<21;H5V/+) MV1|TF\$^Y|OV;&
|_ZOBW1=%N/\$&M6NE6-IJKU&|FCMX+8JIGDV1_?K|/(BE>P
M_L^_LNSV%I=;!NSTV/1|*.W86;LUU(-DD|?/^L_UD_!W':YW<|JWPT?>YF>C
MD-!^TJ8JJO@5_4MPZWI?|5'P,|6VFGSVM^TT|H8P\$^?:Q+-%(7LWD_Y:#Y/L
MLC?4_+_#7YFZAI|SI=|=VE_9_8|F&;|/<6MQ^ZEMYD_Y9U|7?
|\$_^O'W|F^+M M<|(SWC?9|4B^W6_VBX_7SHOOOOQ_!|'23>V/X;?_
+XX+|L|XO_OB=^U?|5_#GQ,|4Z59>+OL5A8ZO>VT%M|
MBLR?)2=XTY>)Z#O7O|_P_\$|Q_Q9?5_^P|+_P"D|O5;|JE?X1>/OB=K,S^+
M|S5-;DOY|10|%MM5MN|Y|R.1\$C|U\$\$\$CE/O!AQ|V|FMO>E22VN>H7Q%;++'
M"S<9>MCUCX4^+T^/'P-L|6U_2A:QZW:W%K?VD,KA.)'@D_/#INVD_P"QD_
<M;C|4?L0^\$M-|5?'19+_X-'TZ2_@PJ-%YJ2(D?#_!)YF|?|:C1Z^@_VEOB|
M;_LZ^;7P#X0T*ZTF:|TH/8ZC!B.VMH3O21XWW|WN\$'S_|TL;_3M;XQ^\$/
MQ.U'X0_\$"T|36A_I?D?Z/|;>?)%%/"_^LC^3_OM?|ORVV5-1PC**|'-F>)A
M3Q.&5;5Q^)GUI^V3|>/B'|+?&V@Z;X9NSH^ES;=H^TFR27|1-YCK)'O=&0;
M%|K|G_/7YNJ5Y#|^W-X|F|ZGHM_:VUYJ5Y#|G@UV_99H_-F;Y-B?)YFS!3
M9MV8W-OKZ0|(_M7?"KXPZ0-)|4;Z1+=X|_2O\$L_DM&*J)-WF-^ZV!QA?;V

M6C^Z/EKF_C1^QOX4\8^%#K7PWL\6RUE_]/@@@N";74(6^?
RX_GV1YZH4*I " M<*=R\$/S=Z M;?3.:?
0\$0HCHHCJ#0DCJ2.HXZDCK("Q'4D=1QU)'64P)(ZDCJ..I(Z@U)(ZD
MCJ..I(ZRF625)'4=21T 25)'4=21US3-8\$E2\U%4O-;|2\U%4O-
;)EECFGTSGUSC@21U)4<=243\$2\T^F:BJ7FLC4?4O-15+S2F
^I(ZCJ2.LQ0)*EYJ*I>:@T'QU8JO'5BL@" M.K%5XZL5B:A'4D=1QU)'4
=#X%_Y&:R_WG_|>O9/XJ|;|" |C-9?|S_/H# MU|)_%7|EPA|BV?
^+_VV)|/|/X(ZBBBOT0|\$***** "BBB@ HHHH ***** "B MBB@#|/CK_P D2|?_
/8!U#_TGDK|BZ_73XZ_|D2|?_|8!U#_P!)Y*(NO.Q M?Q(_N*?
XM\$*****XSX<***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB M@ HHHH
***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M"BBB@
HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH * M***
"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HH MHH
*^B/V'_AW_P)A|7%UR_:0|1?_1|NPT+2M"NS>3"XGNK^!|_
'R;\$CWHZ_NTXV_|='JZ-N;F
M9ZF75*=+%0G6VC^)|??'K|L*/X*^/|-0>'5|0R"UCN)KA=3\$/DRN&_=E-CG
M.P10|)!7G^G_/|1J"34+;|=X'^Q61D_?W%QJGG2K'ZK&85W_P#?2UD^/O&
M^H?.\$GOEJOB37!C4+R;\$_D0F.+Y/DCCR?|D?_
G7/5K*M)RN>K7S|%JO)4Y^
MZWTHM%V/T1_;1|!VOQ&^"@|7:2QO+K1@+^WN;\$^;JHM9=@DP48*4V"*3S
M2*OSNKWGPW^V=XU|/^";?PE<:5H>K:9:68T_B;64DOGPCY/+DV.JA N_D^
MYV^;O7@U17DG+F1R9OC_-BZU.O2W:L_|S|/U_P"3*3_V(?)
|CZ_|,"O1Y77S=OF;.?NUX;3Q\$E+EMT*S;'4 M,7|/V;^%6"OU#_8R_P"3:?"OUO?
_-\$LGK|O*|U^&O|8/C7X7^"M*|;.-I>A3 M:=9^9Y#7MO.9COD=_P"&9?
|I|+#R47=BR7'4,#B)3KNUU;|O|CPJOL_|X)|? M\$;TM|?7_
5J%U;V=U_-0T^WSB6XPFR_"7QV|_
M\$_59=#UCQEJ_A^_O);BP;2;NX>.*)OWAC|N%V|O9YFQ=^S=Y7RUS?
B;X;_M M6/PSO/\$NNZKKXT40_P"D:9<;S;<>X|EU0?@E>>?
%3|HSQY|8&,>K:P;33C_S" M| ^5:~P8P/OR?/'O^=WVM|W973S0UH<|G\$8K
VE5A4J.^ROL>J>#?V&|5|: M?"G2O\$UQJR6WB#5(?
M'|F7|7^C>2^SR#YB;VC^0;|&QYB+M38S54^\$?|(_Q M-
TGXG>&-5U;P|_8^G6&J6U|DW M\$HP+FQLI-M_<^<|(?
Q2CFH|HFA+*)%06491E"|Z|K'K?| P40|6:~?X1|/M>&|^[49]0_M\$X*;8(DC=
9!G<-|R?+@<^6_|ROA:M/Q+XEU#QEK%UK6N70NM M0O)?/GN)A@>G^?
N5F5A4E|25TK'F9CC'B|2ZUK+L?J%^V;_,FU>*OK9?| MI9!7Y>U|K|2OVP?
&OQ0|%;KX8UG2|"ATZ|OSVLK><3#9(C_,4S?W*|*IXB
M2D|HZ/BW3Y|"/B+PWOVZA|J|HC)0+/\$|:(M3&|CL>/YLCCS\$A=?"|:?
AKQ+J'@W6+76M#NA:ZA9R^?!<0C((|A_?|4I^ MSE-DGF? M.D>=_(_C^3/S?
+_M|^*GBGXH75I<^*M6_M:XLHC!!^YCCB@)ZDHB*A_P
_W*Z.>G1OR=3V;>,P M& C.KAKN4BKX=^(GBOPK8_9-"|1:H-M/*9_LMA?
211>:>LGR/3|9^)WC+7| M.|T_5/%NNZMITXQ<6U_JEQ+%_?|
|6|US5%31V|L?| GL|FR/|?HQ|/-^A_L@_|!25-6UR|Y>9%UJ MMW:P
F:7A\$MX<_-LWG8N|>ED;Y=_P OPE|(_BYJ7P;UF|UO2-)TO5M3|G|/
M;W>K022_9_|GIY6QU^_G|H|XQ?M\$>*CF?!7|H#Q%|"?
|6.A6>EW;:F(Q.U|#)*1Y/F;N.G_#TK
M7#R497L|S>V_/S1;=N|H|D>%?" |1WC+5FTV*||=4KCFXUB^N|
M6&'FSS/;=3G8F|NZK7#_"/X_|C/X*RW4N@7C+832^?<:9?0F6TN)?+V>8
M1|H|^_F|RTW;LUZ/K7|>_Q0U.SN;2&WT/2KB48%S8V4GFV_N?.=D/XI71*I
M&3O<|^IF&%QRC4KSG"2WBMF=A^SW|_
_\$"_M2W.F_\$LW6OZUHFD275C<:I|)< MIE+B-
8|B)W^^G|V0KG|K=E9/D|" :&^(WQPT_P"(-KX9^'_AVYM-/V?R-:M M;#
|6+G<,2>9(X:&! QO|_P_|K=NVO7Q|H_C|Q#8^,K7Q5!XAN?^\$BAF^T'4
MKB;S9/D^3_6/_K/W?|OY_P"#Y?

NU[9K']>GQ/U"QN+."VT/2KB08%S8V4AEM M_<^<[(?
Q2B%:\$HV9&%S/"0HRI*3AK>_5GV+XZ_ML_LNZI_PD&[A)?|A\$+C M^T-
WE_|'U|C_>_<^3|^?N?+7FW_3S_P"2-:O_-AR7_T1;U|N:?!M:>.
M[3X?:MX.O;NU\0VU|!<6W|HZMYDMSY,J%7^??CN=F_?
U_N@((O@Y^U!XH^"/MAN|T?
0K+2|R&XNI+XF_AEEE,CQHF/D=/^>9K3VT.=2|'9+.L*|72JWZ6.1^_
M_P#R63Q_P!AW4?_\$?)7&5I>*/\$\$_BCQ)JFLWHVSZE>2:A.+?!U0E>3?6;
M7"[-W/B|14YJDIQZGO7|.H+G_"^*U[4[C53I%K:S1VVGWGV=)1/-P|Y3>K
M_)&?_(H^;Y'5F:W^Q3|5|+OKBSA|VVK6|8R+BPO;?RI_KYSJX_[XKRKP/X_
M|0_#76/H|.:M_9.H^4|'VD_O?W3'(C|M_DDY'_L|>YZ9^WY|1;&RMX9|70K
MV>.'7W-C)YMQ_TT^29%_P"^\$K2#I2C;8|C"U,KK0A|834X|>Y|,_%?4K?X/
M_LFW&C>(;M3=0^'(_#Z?9VW&>Z>W|C|UOV|'|+|_
VQ';;VKBO^"=NM6|WPZ|_M1.;G=J-KJWVF:W_+LMW7O/F1WO/H?
7(5(K|W%6|V>F_%+X|_\$+7/CEXIBL_"FJ7AOM8O)|>Z^S
MG|+Y4DCS1_OG_<_<(_C^|HOWODK|/;X_9M|5C_&K/_P|+(*^//%W|;GO+
M|6.;;"^R_#_)X(^TZ5!)%+RA4Q^8|MLY/WTV-P-C5B^+/VK/&OCCX9_P#"
M\$ZQ;Z9?:9-#;6|VHXF%S,(7C??)(TK?_EG=|G|_P#_R>OA/PO^SA
\$37O&UKX?M9|C4IK*3|+;P|Y|,^1)-F#!/_CY?OUM>?VNO&?PW|
6OA#0K/2S;V4,G MV>XN());KYY'?S/O|/D=Q_!VK9|,MR?
\$+P|HUKI4PTO5390BW%UJT\$DUU.?
M61UF4.??'^|U\$|4I**OL34QF78RG1A6F_<5O7;_"H_P#;N|80^'O@?-HA
M9?M6O74=O&%E'F"- '\$SN\$ _C'|M\$Q_P!-1^/_L&^";&S^&>M>)|)U4KXBU":
M2PGMYH9/LMA*G*9CWK|H_P!9&^?|R3:A3+
|OC'QS|0/\$7Q,UK^V_\$FKC5M1_M|J.#
|2/W/H|3DQ^6GR1|G_V>OO/P'X:FOOV/+2V^%\$G|EZ|?Z=&YN;<^3+-= M
HEW^|?^-_+DC5|@+|FUD5592G/GGS';@<;#,327\$&I>?MYL5_^|>2>9_X_|
A_|WYE^>OHGX8_##|IC3_B|H|WJ&K:I8Z;;SXFN=8UN
M_|MO*P0XDMTF;S#C/ON_B3|Z7A_@H-
X^T>|AT#PK;&TN_\$%E,=0N;G@RV\$>MS'EYV<>:'WXW?|LH_E_|*NLN:'-L+;
(QKX:=;MS0E';FV?R/<VS)!_PS?XM M7N39_P#I9:/GX&>.C|.?
BUX4|03L5M|_|Q.TUN|I\$+_N|B7Y!O^2.26N|^M)7|8'C7XH>"M5|ZSI>A0Z?
>>7Y|65O.)ALD1_XIF_N5X57/6J7FI(|3-,TI M8G%TZ^'=W#;3SN?
H%^VA|*M6^+O@WPMXF|(AO\$2:<)|@V^GA)?M-K-&C^;\$V M_P"?B(;43?
I6C|4W/G/0>.R^MB(XV:?.OLVTOW.M_:1^)&BW/|8'A?4/MC1Z;X:GT^
MVU"Z|V,>3<^=(1LW?<|S8W|6Z-TKWG|N+P?K7C3X2Z?
%H>F76KS6>K1W-Q;M6,'FRF+RIDX3|S_/'PG/X U^<%>[?#7|LKQ|H-O#-
KX?MFTS5;>S_U'|K0R M2RV|//>CJ|+3^'_OG|NRIA54N:4YL-F|&3'|^/_6#
H>2?&#_)WMO|L/Z_P"B M|2N7TO|;-^)NG^_
;GQ%/>6NK&6&2W_LR:"06\$|S?B*._T^=/_N;WWMM_BK\$ M|A_Q U+XJ?M-
>%? \$NK6=K::G?:H7VC^SQ)Y7R20)_&|?|_GSPY8POL:R
MOV%J8:CA<,|8S_SU_\$^P_P!N+P;KOC3X3V,>AZ9=:O+9ZO';*8O*F
M3B/|S_/'PG/X"O+_P!AGX-^+_"?CC7O\$FM:/<:3IW|G2:?.#;C')!+- (TL; MDB-
P(O@_X#TG6_#MZEI=MK%O!,MO#YL<|ESNT M6A;V?(5;H|PKY-|6?MO?
\$WQ7HIT^\$Z7X>\$^?|)TF!XI>4*&/S'=MG7|Z;
M&X&QJUJN,)YZV85L%@|;'\$5I24UT1L?M,6|Y|>V|;?POX<^S2W=K#|IVA
M;D-%|@>:=Y#P(|GF2HZ?,W|O^|E>7_&?X#>(O@;?:5!KWV6ZAU*"0PSV,_F
MQC9_K(_G17_Y:1?P?M#57X#OXIC^,7A9O!WV7_A(A+^X^W_J_U;_T
MS|OS=^SYO|OS;*|F;_T^)%AXL|.:3H&F-|M.@0W/VBMYM|EM,4WV_U01C/
M;|YM&&2N>=IQ=7N?.U(X;%X2MBY_'>Z/ENOU#_8R_P"3:?"OUO?_
\$L GK|O* M|U^&O|8/C7X7^"M*|;-I>A3:=9^9Y#7MO.9COD=_P"&9?
H|1AI*+NS')<=0 MP.(E.L|75OR_R//O@O|_|EE^'|_
V'M._P#2B.OI_P#X*1X|SX>8_NZC_.TK MX^|+^O_="_B72|9LANGTV|CU"
7'^J,J2;Z|KXU?M>(OCLND_V|9Z7:2Q(M(&L8)

(B?.\O?|H\ V YYU2E%4Y0|CP^*A' 8C#7|YGU|_P3U&?
@KK' 8WKY>_8T_P"3DO"/^|>?^DD|0_!W|J#Q3|\$ _"|HFA66EW<%S=R7Q-
_#)+_9 M'CC3'R.O _/_UP?PS^(6H_"WQH/B;2;2UN|2L_, ^S_VAYGE?/)'_Z_|H*;
MJQ?+Y&SS##N.\$5_X>_X?Y'U=_P%)3^| ^'O^|J|A|2NZ_8Y^*.F_%'X1R>#-
M6-
I7O^ ^|_|ZX+1=9U#P_=VM_I5U=:3J,0Q!"|CAELHL92.3SGY./D5PS|O+W-
LJU|_V#/%WB3|9)XPNO^\$2MQ%((+>" M>.ZN?.V#9)|GR;-YS|_?B/-
N=61X;_&|_ (H:'IZV|ZVF>(9Q+C|3J%CY
M9#)|R&8/#R^(9%M8|B>==3\$/DRMN_=E/+< MYV"-
I(*^0O@| ^TEXC^!NDW=CH.E:%=F|F%Q/=7|#^:/DV)'O1U=KOM_P"N
MCUQ/Q|<:C|2_&6J^)M=_P"0C>38G|B'RXOD_=QQ_P#(_|/I*1511ARQ)CF
MM#|X#DPVDV|J|SZRT|_@HQ!)J%K|N|\$?8K(R8GN+?5/.E6/U6,PKO^FY:
[K]M M#P+:?\$7X*_|"6Z4QN[K1L7|M=6)|W|3:R|!*4<*4V".0O|WR1>|?
GA7O/A MG|LWQIX>|%V_A.?2M#U?3+2S&GXU>RDE|^\$?
N_+DV.J/^| ^3|G^|WITJW-#D MD/#9S'\$T:M+&NZDM--CZ1_X)Y_|
)%M9'_4WKY/U|QY=_#7|J3Q#X MELF_TS3?\$_=|_:QAB1RR-_P!
<|OR|HU1_":|J3QE|^=(NM&TK|-JVGB7|1;V^K022 M&W_YZ>5L=,|_|
.:?/5VWUG5OB0/&|E:V_A7Q%YOG_:M#@DCC,O_"TD M|MW;|_|
|: ^ ^I5*18|_(AD^<)>QP6^ZW>OE#1_V^/BCIUE;6D|OH>K7\$0P;F^LI/-N
M/<>2ZH/P2O,OBA|>?&?Q?9H_\$FL&|TV*:2Y@TN"% (HK??_N?
ZS9_!OWO_P!| MO5PJ4Z?PFU/&9;E|G7PBE>2M;HCSZBBBN, ^,WU"BBB@
HHHH ****QF!)'_2| MTD=+S61H/CHHCHJ "I>:BJ7F@!|=2|U%'4O-
\$56*KU8K(HCHHCH EYI|,Y MI| 1"B.BB.H-"2.I(ZCCJ2.L@+=\$=21U"4D=93
DCJ2.HXZDCJ#4DCJ2.HXZ MDCK*99)4D=1U)'0!)4D=1U)'7-
_U@25+S452|TP'U+S452|URR ?4O-15+S6 M9J|7FHJEYHF66.:?3.:?
7..!)'4E1QU)1,1+S3Z9S3ZRF:DO-/IG-/K(U)> M.:?3.:?4 2|T^F.:?3.:?
69H2|T^..F.:?3.:?2F*!+S3Z9S3ZY2RQ4O-15+S0;#ZDCJ.I(ZPF!)4O-15+S68#
MZEYJ*I>:R-1|2|U%4O-*8#ZDCJ.I(ZS% DJ7FHJEYJ#0?'5BJ|=6*R (ZL57
MCJQ6)|J\$=21U"4D=0!T/@_7_D9K+_ 'G_ /0'KV3^*O'O_*|O\$EH?=_|T"O8
M* <^"%;+9>B%%%%%%%%!1110 4444 %%%%%%%%%!1124 <# M|= ?^2)>/_P#I
ZA_Z3R5^1=?K|=?^2)>^|/7^P=0_|)Y*_(NO-Q;6C/SOB MI>_3?
8****X.8^%_KK_D%%%%%%%%',|=?) (****.8/ZZ_Y!1111S!_77_ (****
M.8/ZZ_Y!1111S!_77_ (****.8/ZZ_P"04444VWZ_Y!1111S#_KK_
)!1114Z=A7>^E_1 M_P"044457/_^NO| D%%%%%%%%3S=B;7T>WS_
_@HHHJN8+);?K_D%%%%%%%%',NQ5V|6 M|?G_)!1114Z=\$+>|^OD_P#
(****KF787|/_ (****.8->K_#_R"BBBITZ(
M>^_Z_P"044447'S2VNK>C_R"BBBBBZ#36_7U_R"BBBG=\$^GZ_Y!73>
OB7XJ^ M&=|-1|-ZM:O? MI|'KFM?M8?%?7+2|L)_%|VUO-
T^PPP6TH^DD**XKRO4-0N=4OKN|O|S|9=W^@4445%^YAS.7Q?D_|
M(****KF786NZ>OS_,@HHHJ;|@4G'X?R?^05?T76KCP_K5KJMC=_9-
1LYH|B M"Y/>9)-|?
WZH457,NQ7/+25|5UL_|CT'X@?'WQW|4='M=+|2^(O|8T^&7S_L MYL; >
(^;YVEW87GV2 MYAF^T6|U;_NI;>9/^6E5Z**7.8W=N5/3Y_Y!1114W|
I./PV^Y_Y!1111<7F MGK|_|@HHHHT|!=|H|'_)!1111?Y_Y!1111CZ MKR?
^044447|Y_|_)/_ ""BBBBXN9K6-K^C_P_@HHHHT|(#C)K5|^C_R"BBB
MJYEV%JMG^?| D%%%%%%%%',|=?)@HHHHY@_KK_D%%%%%%%%',|=?)
(****F;CW#^N MO^1)'2|TD=+S65X|S2_|_:Y#XZ*(Z*BZ"|_6O| D%2|U%4O-
%T%_P"M?|A| M=2|U%'4O-%T%_P"M?|B*K%5ZL5EH%_ZU_P
@HCHHCHT" _P#6O^1+S3Z9S3Z- M!)V_|Y!1'11'6>AM|_S_P
B2.I(ZCCJ2.L|2|_S_R+\$=21U"4D=1*_P^? MY_Y\$D=21U"4D=969H|_S_R)
(ZDCJ..I(ZRDKEZ=_P_|B2I(ZCJ2.BP:=_S M_P B2I(ZCJ2.N=ILUC9=?
S_R)*EYJ*I>:G4!|2|U%4O-8/7J ^I>:BJ7FHL; MZCZEYJ*I>:B6H|LL.:?3.:?4?A
/_ (4="7FGTSE MGUE?^M?|C:WF2|T^..F.K\$=9_M)_<&HO-/IG-/J&

[H]Q44T2T^F:BJ7FLN9&MF/J7FHJEYIM-A9CZDCJ.I M(ZCE8131)40-
15+S6'O=B[#XZL57CJQ46*Y0CJQ5>.K%8ZEVD\$=21U''73^&
M?!MUKR^;*OV>P[#^L?H*Z!%@<3CZOLJ,+ORV-
J5*=5^ZCHOAMHYCM[B^F./ M_=1?
[HKOZ;\$@C41^U2U_2>6X"&786&'AT7WGUM*G[*"B@HHHKU34****"BB
MB@ HHHH **** "DI:* .5|?>%QXT\&^(/#XNS:/JFG7%A/H4;S%YL93?M/XS
MG|^*^1_|AV|-W^(:@?| 8%/_,DUJPTM3*\$9;H|[\$9?AL4TZL;V/A_|X=MR
M_P#11%_|\$I_^2:/^:/_4^+_X)/_MU?9J|%'U6EV#^Q M,! S|_% YGOA_P
_|3_T/:_^"3_|=1_P|S;_*'M?_!)_P#;J^SZ*GZI2|[_ M_+_%PAGXO_,^,|
AWNw_0|K_P'''7_|=40|P|W/_0|?^4K_.W5|CT5'U&A M_*'|BX'^3|7-
)GQU_P|Z;_H>_|RE?_&ZG_P##0|O^AZ_|I7_VZOL*DI?4 M,A
RA_8N!_D_%_YGO|_PP&?^A|_/_*5_P#;J=_PP(?^AZ_|I7_VZOK^BC^S M|-
_*5_8V!_Y|_B_|SY" X8';_H>O_*7_/_J?_PP6W_0|?|_E+_^W5|=T5/I
MG8;^47|BX'_GW^+_ ,SY\$ X8+_ ;_H>O|_RE_&ZI/^&#W_Z'@?|_@K_^W5|;
MT4?V=AOY0_L7_|/O|_%_YGR1_PPF_\$/0_P#!7_|;JD_X87?_H>1_P'''
MO_|=7UG24O|_PO|_*5_8^!_Y|_B_|SY+_P"&&9?^AW'_(+/_MU/_P"&'9O^
MAV'_(+/_MU?6-%+_^S<+_*)|D8+^0^4?^&'W_P"AN7_P6?|_VZG?|_0M_P!#
M\$ _D*_LG!_R'RU_PO4_0W)_P'''S_|=3O|_ABQ_^AM3_M_P
%G_VZOJ.BI_LG!_R!_9.#_D/E|_AC"3_H;4_|%O|_NIW_#&DO_0V+_X+_M?_MU?
3|%'|DX/^07|D8/^0^8?^&-9?|_H;4_|%O_-NIW_#&|O|_T-J?^"W_M
W5|.45|CX+^0K^R<'(?_P#POW+_ -#9'_X+?_MU+_PO+_T-J?^"W_|
M=7TO11_8^!_Y|_B_|P_LG!_R'S5_PR#+_P!#9'_X+?|_|2_|BR_P#0VI_X
M+3_|=KZ4HJ?|%P/_#|_!/?^8_|+P?|_(?_#)+_P#0VC_P!A|>H_X9)?
M_H;1_P")_|CU?2%%'|BX#_)|_B_|,?|_9>#_)#YR_X9-D_Z&P?^1_^M.TO-
RA)_T_@_|(_!VOHRBE_8N_P"??XO_##^R|_' "'SQ_PRRHW_0
MQ+_X!'_X|3_&5F_Z&)?_(_':^A**7|B8#_GW^+_S%_9>\$_D/GW_AE<_|
M0QC_,_A_P#%TO|_PRVW_0Q#_P_P#[.OH&BE_8>_Y|_B_|Q?V5A/Y#P+_M
(9?;_H8O_)/_P"SIW_#;+?|#"/_#'_P_77O=%+_^PLO_Y|_B_|RO|_PO|_M*>#?
|_Q'_H8A_P"7_V=/_X9D;_H8O|R3'_ ,77N|%3_J_EO_/I?>_|P_LS_M"RGA'_#;
|?|##_Y)?|_V=/_.&:V_Z&'_R2_P#LZ|THJ?|_5_+?^2^|_YC_M_LW" _P
IX9_PS>_\$_,(P#/_|.G_|#;+?|#!_Y)?_&=>X44?ZOY;_P_^MEH|_Q_V;A?
Y3Q#_AG%_P#H8A_R2_^SJ3_(9W?_H8/_)+_P"SKVNBE_J|_MEG_/E?>_|Q_V?
AOY3Q/_ (9W?_H8!_X!_P#V=A_&?)/^A@'_@'_P#9U|31
M4_ZMY7_SY7WO_/H/PW|IXO_,,R?|_0P#_,_LZ=_P*!E_Z#X_|_|
M|.09J*/|6|_Y|K|W_F'|GX;^4|<_P"%"?|_487_,_LZ?_P*)_ZC"|
M@'_|G7K|%3_JUE?_#Z_&7^8_P"S|_*>0_|*+/_\$&%_P#/_|.G_|"CC_M-!/=/_
/_P"SKUNBE_JOE|_SY_|FE_F'|GX;^4|E_X4@?|_H+I_X!_&=2_M?|*4/_07_P#
(!_|BZ|6HI?ZKY3_,^?)I?YA_9^&_E/+?^%+M_T%O_""?
M_BJ/^%+M_P!;_R"?_BJ|3HJ?|5
M%O@_X5_X23QEK%MHHFB^?!"HN/D9I9,X2*-%9W/?"CA0|'"H::5P.|HKCO
M?C_1/B5H-MK.@R75SIDP#6|U?6-Q:?:_41TDB\$T:M)&5DXD7Y3SSZ=C2_***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "B MBV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "B MBV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "B MBV@ HHHH **** "BF-BN6|9>.| |:0^J>(M4M=

(L8\YFN9=N?D9MB:,U\H>,?V/_NA?;HM"TG5/\$L\>PP7##[]:3G^M/YW-
'B;!\U_=?>]OFKCC_P%(Y/^B=)_X.C_/(U8_6*7<|F6<8*F^651-^5MV?
<%%?)/A?|X*">#=#0^QPZUI&I:/=228G;#R/FVA^?|_F!D=QLP>\$[GAJ^B
MO!GCS0/'^DIJGAW5+;5|&3&)K>3./D#;'XS&X|P?
(V&&>16D:D9'50QV&Q+M M2FF^W7|CK:****T.|****"BBB@ HHHH ****
"BBB@#)UC6+70=/N|1U"|@L M|.M8GGFN9Y?
*BAB09=W<| #'Y5|!>*O%7AS|L#XM" _|'?CK2O"7P(T2;|1H M^F:O?1Z3=>
(08_W7|C)?M-) &)T_6| N_\$FL6V/^D:I+?W5K|IE'?RX9E2,JZQX*UZ*6XL1? 1_|
+OY|=T!L/F;/+EM6=-BNWS-|Q\$3| M\$FKGG'E=D;0ES*XM%%0:!!1110 4444
%%%%%%%%!!1110 4444 %%%%%%%%%!!1110 4 M444 %%%%%%%%%!!1110 4444 %%%%%%%%%!!1110
4444 %%%%%%%%%!!1110 4444 %%%%%%%%%!!11 M10 4444 %%%%%%%%%!!1110 4444 %%%%%%%%%
!!1110 4444 %%%%%%%%%!!1110 4444 %%%%%%%%% M !1110 4444 %%%%%%%%%!!1110 4444
%%%%%%%%!!1110 4444 %%%%%%%%%!!1110 4444 M%%%%%%%%!!1110 4444 %%%%%%%%%!!1110
4444 %%%%%%%%%!!1110 4444 %%%%%%%%%!!1110 4 M444 %%%%%%%%%!!1110 4444 %%%%%%%%%
!!1110 4444 %%%%%%%%%!!1110 4444 %%%%%%%%%!!11 M10 4444 %%%%%%%%%!!1110 4444
%%%%%%%%!!1110 4444 %%%%%%%%%!!1110 4444 %%%%%%%%% M !1110 4444 %%%%%%%%%!!1110
4444 %%%%%%%%%!!1110 4444 %%%%%%%%%!!1110 4444 M%%%%%%%%!!1110 4444 %%%%%%%%%
!!1110 4444 %%%%%%%%%!!1110 4444 %%%%%%%%%!!1110 4 M444 %%%%%%%%%!!1110 4444
%%%%%%%%!!1110 4444 %%%%%%%%%!!1110 4444 %%%%%%%%%!!11 M10 4444 %%%%%%%%%!!1110
4444 %%%%%%%%%!!1110 4444 %%%%%%%%%!!1110 4444 %%%%%%%%% M !1110 4444 %%%%%%%%%
!!1110 4444 %%%%%%%%% #".OK7SC|9/V1=/^,GQ+@|3ZIXA
MNK2P^RQVT^G0H7D8IYF#'(ILD?| K-HC(UA^|^X?2-(>AXJ7%,Y<1AJ6*C
MR5E='S;|0|"/P6_9G|%VE_??#VTU#3[S4?LP!LHKZ;S7C=|E|E_N?N_|^*|7
M|,ZUX,|:./=Z1H-WHFL;::PBVFT^QEAN(88638D1C0|0A0?SRRG??|H_|<->#?
\$?X4^ (OV2/\$W@CQ!#J MUI>:G_-I7^C&2+|H"4,UOG_EI"XD"?
P;D+_ *E*?!5G)=3S&>'3_9QVMR(G_ 'DC(|>(|B_ MS-SM^4|<;|D?
X5>|H_ &=UXT|\$^+KK5-/BLOLOQT*|A|N|L)9A&Y-RT;JDO,<8QG|B,_P!|9U|Q
M^C?/6O| "NQ/P;_- =1Q?M'32CS|ETM;^|I|U4M,W-2|UZ!|O<=14>|_-&
|_-I!|=R M2DI*3|*!CZ***"BBB@ HHHH ^3_-
N|X,>+/"OA;PKXY|""YG|: ^!;TZE96 M=MY0Q1LC^9(CV|,BI_\$HD7:
|%%KSO3_|@J-X=T?PTUKXL|\$>(:+Q
M_90R07^EVT"16HO4_ =F/S))/.C&_&X>6|IROSE/F^|*2MXU%RJ,E>QC*#O>+
ML?%'L,GP8|5_\$?|:|1?M"\$7PY_P (A=7PEM|&|,SK*EU;D1QVOVF4-M/^
MHB|OYT^?S9&"HNS?|K-3J*SG+F=RX1Y58****@L****"BBB@ HHHH ****
M"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH
* M***"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@
HH MHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****
"BBB M@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH
**** M"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@
HHHH * M***"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****
"BBB@ HH MHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH
****"BBB M@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@
HHHH **** M"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****
"BBB@ HHHH * M***"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH
****"BBB@ HH MHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@
HHHH *2EI#T- 'MSY^U|!
|OXV>\$;)D)VGO'HLDDUDLO_+Q&^#);C)V)O*1?._#S*Y579J^=)MOV:?
CM|8M1@A|<7364&G6\$MO8W6HWL,HR%&Q!Y+N^|W WR-|Q7|V|HJ5|)?M
M2?'VX^!|AG29='M;:|1:G<&&UM|?Y2Q+@R2?(.>?+39O3_ %N|^BOENR^
M-W|3&HV=O=V,&OW-O<1K-!=6_AE)(IXG&0_ _!|<=<=JXJK| ^Q|5FBP7UAJH
MS.3MS*/D7M)^/QX|">+|GX@D?VMK&@3>;!JHOA?
RZM"1Y<@C_C?|WQ^|V/M M(V_-7=_LW_#GQWXZ^_VI_%3QUIEUHT|F^3#
<0FU|^5X_ (L0O'O|E(N"_P"%O?M2\$ _|'KXH)_|%:/A ^1:_0V/=M7?R?

84Z:BW>_6Y>6X.A M6FIT^=*+O:75/S&\2^)M-
!\$Z':>:SK5XMEIEC"9IIB4X"@?Y_-'?)_C/I/OI9M M7_LKX?>'?I6N99DMI>|U/A
OY3+LO%;H-|FL;?G1_W@^2OK;7M#M?\$&AWF ME7|N+C3|Z&2UN(&
|PNA1U^7V)_L+P|+?"WPUTUK/PUHUIH\$\$\$GSR^0O|Z8_
M.1YLC'?)CS#C<3M_2NB<92V9|/^+IXJM*U.?+'O:Y|?1_\$KIJ/QSJUVVDZ3>^
M'(#/IEDT6&UMC@(F/O\$R3U.-^?^T2?\$KIJ/P+JHHVK:3>^(IT G^RQZ+#
M=6PR'3'F6:9!Z'&/_:|)9;_:L|1?&?QMJA_7|)TVT\$6G_:X+G3A)'G;(
MB/&4=G_YZ#G/;_OGZH(W \$_/I6.8N7VCQ|-A?K<.>CB9,^_/A|^WM=6^K76
MD_\$CP^-+GAN/)-UI4\$O|D|T39)VYP4/F%_FW<;=F: ^MO#/B?3?&NAV>LZ-
>M)>:9?0B:"XB/#_Y_#%8_CSX5^%OB58+9^)=%M=6ABRT0F7|
|!"E:?"VT^QACM;>|><0H@1%^;V_*M(|T96O<|)?!F
M<91;56HI)>1LTM%%;'J:1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444E !1
M3-HV^PK"|0^+M%|*V(NMSTBSDE\$(N+ZX2*,R'HF7.,G/I-V5Q-D)R;LCY
M3_X*&:%:7GA_PKJW;%?N_M"O|;/PSU31;&YU76F\ZC+#+_
1IMQ93R^1>WF(FQ|8|?|CI^6NL^+WP+|
M(M%V.@7NJ:M=_9|**2:RFTBXC|J:.<1GS#N1P_"J?>O.E_X)|_X(P"0
MUXF/TN;?_P",5B_:WOH?+5J6-I8N=7!|KYM|L|9?VS?@|_%XM8GU_LJ|_P#C
M->VY|P#_R08@U|N?|.J_AOG_)#7B;_P)M_(Q7U.JB.,!1D"KI^TC|=CU<
M%+%34OK<8_|;HIQM%(0#&P'I3Z.U:GJ>70_*F|T'XR3_\$BX|;VW@;7M(|0W
M%U|N6YT_1+B**"5QCB/9_P|H|^+?
O>00%^+W|48%'KXHQ_P!BM'|BUZ)M|:OVK/&VH>-M?|%" "
|33=3:7(|O._&G|/B|Q)-CQ3XKT|G%C!-(|-LMX7|O9"GSG,DF\$ _B.%W|IY?
M,4&Y64C|^I4*,L1*A1Q\$TU>|MM/S-C|D?QE|4_&|5'XD6^H6JP?9_|/^WZ5
M|A^|9_,Q|B^9C\$7TKZ.9@.2:|)_9/^_EW|;/AZ;C6#:MX@TR?|/!AE-
>A!6CW/LLOY98>+4N9=Q|%%%4>@%%% !11 M10 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%% !1110 4444
%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444
%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444
%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444
%%% !1110 4444 %%%% !24M% # W'(KYS_&K_-GG7?CQ9Z=#U:U
MM;K2Y;C-M?;UAN(Y@G|:*V-OE|?(>O7^|H'44FKJQ\$XC#T|53=*ILSXM|??L
M9^+O\$7PJ^|A72|8TD77A^&|%/|<%XH_,N'1|Q!
(V^Z=W|WM^'GO_#OGXC?|M! ?PM_P"!\$|+9KV7|NWXK:WX"|^-|/T*|N-
)EUB>;XN-1L)A'*(H1&!\$,? M. |RQ_.C?*DVY^>O\$_.8#^(UW9VT|SH5I+
/W-Q?S^9;_/_3/Y(77_OAZ MXJD4Y6BK_,^)QF&H3KRIT:4IN-K^|;?

Y%K_AWS\1MV/[7]*C_MXG_P#C-?H>MJE55<\CK7YYC_@GA1S_.,QCPJ/K/7-?
!\$2TDG^K;Z4HZ4A;\JZ+GT6Z/SL_9!A>>'?@GX_15;+XZ'I
ME:S<2Q:?.W4\OYL5O.LCQSV_GH6V\G\K+_<=?_W*Z#|E;XW>%O@S!|O\$LI
MJZI:V@=5GGL--,Y\VX_T6#RQA\$9DC=XRGE;-HKT/Q)\.?A)^V-J6K:MX:U>
MX3Q!96|<%Q>6-O)\$,N6|B26.9%W|=AY0J^T;=W";>:TG_@GWX?T5;G4?
%OCF MZN=-
AB:X)M|>.Q\$&WJ\DCO*NP(.X&.NZN'DG%WAJ?"TZ&.I."PZ4J<;^|Z|Q
M_P#P3FT2XCTWQKJP@TVELK:&7/WI8HY'D/_D>.OM%5VK7E'P+|=^
O%7AV MXTGX>&-=*T%TM6M/),1PZ!Q(\$?|>\$,3(/
<#>Z2'YOO'U<>M=5%-0L?59?0 M6&PT:<7=#Z***U/1"BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_HHHH *M*** "BBB@_HHHH **** "BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_HH MHH **** "BBB@_HHHH **** "BBB@
HHHH **** "BBB@_HHHH **** "BBB M@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_HHHH **** M"BBB@_HHHH **** "BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_HHHH *M*** "BBB@_HHHH **** "BBB@
HHHH **** "BBB@_HHHH **** "BBB@_HH MHH **** "BBB@_HHHH ****
"BBB@_HHHH **** "BBB@_HHHH **** "BBB M@_HHHH **** "BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_HHHH **** M"BBB@_HHHH **** "BBB@
HHHH **** "BBB@_HHHH **** "BBB@_HHHH *M*** "BBB@_HHHH ****
\$!B7=Z"G9I+47J/HKE_'7C"W\|\$^&[K5)AN,0Q# M&P9I,"#\:/OB^W\;>&
[75(1M,HQ+"6R89,*#\;Z/8U/9>WM|E|7\SF^M4
MO;_5K^_:|O(ZBBBBL#J"BBB@_HKSSXF?&CP=|_|-X2S4_|*^VB0VQ,\$TN_
M9LW_'\$;|O'7UH^&?QH?'&#^TO^\$3U/^U?L0C-R1!-
%LW|JGWT7KL/3TJ>>M-[7.?ZQ2|H'FHL>AT4451T!1110 4444 %%%
!1110 4444 %%% !111 M0 4444 %%% !1110 4444 %%% !1110 4444
%% !1110 4444 %%% M!1110 4444 %%% !1110 4444 %%%)0!|;=
/!0Z|T6'PSX3AO+&[N?\$\$TU MR=/NH9_*B@B01>?Y@S|^P#=:1@<P
7|#\EX;_X*(;H>B6EGK?A:(MJ4\$/M^D:E#>FV%QQCS/+|EO+_,<^|7U?|6(
EAX9_X2#QYIFF7FF:9|OVK4;#|_M5Y/F2(@VIL9OF?R^@|]*^4/#_.T#|*O%7Q
TC0=+^!^AC3-2U*UL(=1O;_TB MES+(B&3R%A;A,_W^UQJ_P##R.7O|.U/
M_<:/_P C5|N1L#@|R,U|R>*==^#O@WXSZ1\|M1^'.DB|U*&
(_P!IMX>@\$)F= MPEO'_J_G#'^<-Z@JK87^_L^FU/?VK:%[M2=|'L9?
|_:U7JE>D:I^WW\1KZSN(8;:0;:2#_%UM83B2#_H|SK_P|H7N^K?\$3X,?L
M?:|=Z-I&DWRZEJ4:3W|KI<[W7V<)Q&9!--^|SYA^Y_P+^#;?_#PKX=|H%|29
M_P"O:W_~/UY\RAO4L?"QH_58?59XQ1:W5K_ (W*?["OPG|2^M*|4ZQXCTK
M^Q|K4MN(+>X0QW1\DS;WECQB,'S/EY_|=V%OK3(*BO)_@C^T-
X<^/7|JC0K/M4|-M+|HSKJ\$4<9>|H-F-CM_SS/Z5ZSC;UKT8644?99?1H4,-&
"5UW'T4451 MZ(4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% M!1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 % M%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% !1110 44 M44 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !111 M0 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% M!1110 4444 %%% !1110 4444 %%% !1110 4444
%% !1110 4444 % M%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 44 M44 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !111 M0 4444 %%% !1110 4444 %%%
!13:0D=Z5|;AZ#Z*C_"C<*2E?H*_|59KRVL|!Q5;^M'3;^1Y|;-
_,%0^_JOS_(14HKPW4/VE|/@GQ8:3<74>.6GF\$?|&KF+G|H#Q&UY
MB&UTPV_|
|_#Y_|#KTZ>0YA4_Y=V|3R*W\$V64MJE_Z|SZ8S1N'J*^1H_C1XUNK M,1_VMS-
T)ACB_P#9*RH|6|5^*=UC|JU+5?|
GXM_/DE_|>9(|_H&N=U+XN>%=*N/+GUJ%V|+<M_-+_Z
#7SMIOPE|5ZE9^9#I-UG^|/Y<1_|?VU)KOPJUGPOX=;6-4%M:|>MOYX

M\S_XCL7^_P#=%;4\CR_G5.KB>9OHOZ9RU.(!RE!U*6&Y8KJ_Z1L?&KXBP^=
=M0MK72[TG3{0|,R1B>5_(C_.+JW|?&HT/Q*=%N&"VFHP\$|I?7_@?_P;
MKRSGTH|O<7-K?>;!_H=S!7V,LKH/!/!KX;?CW/A*><5EC_KTG|U_P|'W717(
M_#_Q5;>,>?#_GJ0P)S@38_AEZ/_G^|75<(11J
MTG=/8EHI*6LC<^(/^"DW^N^'WTU'^=I1_P\$V?|_6_\$'Z:=_.|H_X*2_Z|X>
M_P"|J|A_.UH_X)M?Z|XA?|NG?SNJ|VW^TGP7_-0W_KX#|?HI*6O2/O0HHHH
M****"BBB@_HHHH ****"BBB@_HHHH ****"BBB@_HHHH ****"BBB@_H
MHHH ****"BBB@_HHHH ****"BBB@_HHHH ****"BBB@_HHHH ****"DI
M:2@#XM_X*,:U/#I/@C2//TV|EO;F:'YEBCC2,?^1Y/TJA|8/A_X5|#_\$_+|
MG6/PK;VC6MOJ5LOV^UAC,M|'#'+8D)99\$3|Y_>W_|?
O7TG|:/A+IGQF|%WGA|_M5C):@RB>UNHN?L|R9V2;/^6@^8G8?
P*MAA|1ZS^QW|9O"E|9P:8G|K6|M+|O_M@N-)U2..*WEYXC|RGCD_=Q?.B?
W/F^2N&MS*3DEL?%YEAZ|*JJH<7R6MO_M&V_K<|W_
(*#:U;6'C;P2=/NOL/B.SADN?M%N?*E\$?F)Y'S_/72.7;S|IS_M'Z^Y86)B4_|-?
&GP#_8XU6P|:6OC/X@WJWFHPS1W|O:P7#RRF|P9"|R_JC_M-QWW,?
O;)_%4GCK.K:G%# '<6|O/?212W!>23S|@|&5W"_NAG=_RU_M^;JE;O|+_P
!?!7Q6^'_ (VTG7K1K3Q_IMY);BZF%Q'+I^Z(I_3'O5'''/%+|_MG_3/Y|S|F'7?
A|XT_!:/>?*#<^I6FJ:I9:.(I+OK6.*_Q-(GVB02+-+YA|_MX1_W
OFD*K=5J_'C|B#4?&7C6YU_P7J|K9C5)9+F_MM8GDXF?_621R*CGY_|
MA^Y_#|OR+P*FW#F2YF?!4<&_J|:M*DJK3DGW=_/R-?|_8+|9:~?K_(0U;2_|
M*M++6M*FMXKB|LK&*V%|["PD\$'F.G^L=-DN3Z%>6;=7UOUZUX+^RW|
;GX\$>&_M|4CUB|M;OQ%J=P)|FXL=_E")01'|YYY,K|IB?ZW;_#7O?%=-)2C!?
&+P;H|PL\$VL0_M=.L,,DL7_?
Q4*_K6|/#UJOP0;^5_R.6IC,-1_BU%'U:7YL|VBO&|0_:1T&U>
MY%O8ZE=K"/W3^6D<RV7AZVM9^@|_X,B#_@.U#7J4
M|EQ|3:DUZV7YL|BIQ%EE/>LGZ7?Y(^AJ3//#MO<&.7M-
@FCZH;R,'037RO-X;|4ZXQO)M*U*_M|:49||0R2F,G|M|:_V'A:?!;_%1_KYG/_K'C
M:|_N^\$E|_|ACV:|_|^//A&TM3/#=W5ZP'_O!_X<_3?M7|:P|4_:6TA+7=9:
M5=74_P#=F*1?KEJYCG3?V:M:DNB;W5;6V@|+;^9(?_9*Z+3OV;,*?)?|U:|XN6
M_P"F,.*^@ML#_(|X(HQ&?^_MSU|(%IOP\$)V%GY\$UM<7C?|H|A|W
M_CFVMO3_(7^%;&W1(?#^GD@?>GB|R3_+|?YOSJO|0RC#_PL/S>O|,7|DY|
MB?XV*4?1O_(^93XY|5ZM?9AU75/M,TW_!|03R?Q_P#3-*98_#OQ5?7Q@M|
MU+=UVSP^7'_WV_R5|G+&@Z(H_"G;1Z5F^(E3_P|WP|8_C_D;1X5E/_>
<3*7X_M?JSY8TOX^++Y29K.VTL^DT_P
1NKH=+_9GU*:S_P!_U>UM+GU@@|T?^R5|M#T5QU.
(LPJ;22|\$>A1X5RVG|47+U?^5CQ:S_&:=*AMQ|LUG4;F4?>|E8XXS_M_P
VM72:?!|'P=8_9G;2?M;|X|Z>0C_OC=L_2O1:2O+J9GC:WQU7|HCUJ
M.2Y=0^"BOFK_)G.V'|@|0|+O?M5GI.GVUPHOY|%M&CC|0*W@F.,?TJ6BO/E*
M53XW<|6%*G3^!6(^%KS|XH>+GXA6UM;Q:N--
BA+EU|GS!+D'FJE/1HSQ&'IXJDZ-39G@W_#;/_4Q_P#DC_|;*/^&8?^IC_|D?|
|97O_M-%>U_;V8_P#/W|_%_D>|_JUE?_/K|9?YGGOP0^'UQ|/;>YMI-
8&J13&H/)|L_M18'A;9W5WRJ-
S'|ZDHKQ:U6=>;J5'=L|_#X>GA:;I4E:*V%HHHK\$Z3X@_X*
M2_Z|X>_|NH_SM:/^";7^N^(7^|HW|JC_@I+_KOA|_NZC_.UH_X)M?Z|XA?|
MNG?SNJ|_F)|@_|FH/Z_E/MZEI*6O1/O_HHHH ****"BBB@_HHH,B@!;.*M*
"BF|J-U*X#J****8!129%+0_4444_%%!!1110_4444_%%!!1110_444_M4
%%!!1110_4444_%%!!1110_4444_%%!!1110_4AZ4M%'QM_P4,|
M8:AIOAGPKX?@8&PU2:|XN+I07S.81'LB./X/WAD_WXHZJ_MD?\$_+4?AS|,?"?P
M_@|1?:|2OK+R=6U3SO|_29XH8TCRZ?_,|^3/_)|N1?G&ZO0_P|L#X>^'_B)
MX0TJWU?7|*|.>)+>5CI-UJNJ?9(CDH+A/^FG|OGH^8)GY=U>4_|_P#9%|>#
MXA:-K7CW6"-*|_31_8;?|:J686T@>W|KC\$<'(X/SXRNQ-VZN*49N;C'6Y|9
MC88IXFK2IQ=ZG+9KIZH|CF|(^/V_-%7@KQ3?W=N+K4MYN-
T^XQF%/+;|O+M|FS):?P;_G^9?

N)7Z=H^Y5!J,FOES\HGX"^-+/C9\40!L415O!,2XOMLT<,MMOE\SO|
=+G?'Y2IC=||?S!%^>OJ+RQCGC(KH1<=#TLKP|-4K0C?D7PW)MZ1_N-
J*5:8V*U/H-6M#\H?_QD@^#_QBN?%/(@;2OL_AV::2W_L\49O-E-HTO M\$9^
MB.\$_9K_:1;|H+^WP_AT>'SI?V<@_:17^M>[BN9|->!/#_@T7 M+:%X>TS1C-
CSA\|G';><5^YG8.<>|=GN:Z(J5K2=SZ7#1JTZ2C7E=KJ.HHH MJCJ"BBB@
HHHH 2O&?V@_C)J/PI,Z59^%M('BOQ_P"(KU=,|Z\$)Q^E"%Y
M)Y1"@WN_NFYD5|Z|9\5OB1H7P?|>L>?,?
\$OV@:++I0)S\O.695&: ^3+3X=ZW\0/A;|8?C|X^MK1=>|1^#:P^&--6:2Z_L#3O
ML\$^PQ.7V>9.D@=O+13S)|SSGB32G'2|,|>M+2RU M35?M(N+?3U>*<
(>7<20@@.|MG;&#|H07L-?./!/?_DT#X??2^_|3A<5|&5-
M56;78(OF5Q)%%24%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4
M444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!11
M10 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!11
M!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444
M%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444
M444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4
M10 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!11
M!1124 %1+GN!3N!;;DE%-
W"BDG<8N:6HQ2EJ%)2^%@.HS5=I@/O2*/RKE M-0^GA2QMWDFA0:<<#
|L,WFR?|)|WY5I3A.|,7|QSSQ%*E\)/%6NL+. +5=2NVE' M^H,|DIG'^Y4VF?
#/Q5J=UL@|V7(7UN(?*_|0|M=L>'J='^/B8K^O4X?|JN M(_W7"RE_7DF?26J?
%CPGI**TV06|'3|OV<^>?R3=6!J7|0GA:RNO+A%U>""^
MNAAP!_WWMKS/2_V?O%=|:>9<"VM#_P
^MQ,8Q2?| ^|C&N7N/VB/%|P1C:|\$D3_|H(FZLS'B'QCT&I>(!"?^
MFEUY&^OK;3?"NCZ/<&2QTJTM92,%K>|\$/Z5M;00&,4_|>P|^!AHK^O0E<-
MC\$?|YBI/^O-L^0;'X1^,KRU62'2+SYAG=/*D3_BKON%=);_|>+9+<,+K3;3
M//D":3;^>ROIREK"IO-CI?#9?+_,|:?"_C_|!6Y^O|P\$>%.?|LOPI<9O_M|!
<74/800F*3_OYO8UOZ;^SUX6LKKS)C=7AQ_J9IL ?|;|6HKRZF<8^IO
M5:|++|D>O3X?RRGM13|;O|SB=,^%/A'2XV6#0+8^9|H|1F<_FY:NATO1-.TF
MU\$5E96UG!_ =AA\$8_*M2EKS*E:K4^*;?S/7IX3#T?X=-+Y+|\$, "@=A^5-.?7%
M2TE8|HG3809I2*6BAZC(LX__%T;O85)10 M%%%, HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ^(/^"DO^N^'O|NZC_#M:/^";7^N^(7^|IW|JC_@
MI+_KOA|_+NH_P
|6C_@FU_KOB%_NZ=_ZKSO^8D^#_YJ#^OY3|>I:2EKT3|MP**** "BBB@
HIFX4;A1J3S(=GBOD?XF_M;^)-'^/&@>%/""ANTN_"4?B?3O
M"VO^)^K_,D7VRYP_V:U*2+^|A02|RV|8_RLB?)OZ'|H_XU:Q8:UI?P;|!;GX
MH>,|69::XGGDM(=)LSY@DO/,3#F14278\$^;,>|KL27P#XY?!|1?@7\0/V1O"
M>@6|NHM/\$NZ^N|:#RVOKOS|,\$EQ*"S8+D="QV+Y:|J*!TTX:V9E4=|C|%J
M04\$5S=;&Y\:/Q^VA|3_BC|4-<|+?+X>:5XCTWP|+*MJK6K3"2"X&_8DD3H/
M%'&'<2|/G=Y5^;:FQZV/AA^V)X|T'XI:5\/?CK|.AX.U/6;S|-I.MZ0DGV"X MF?
R_+BQOE1_G?#21S/L:6-61?F>O/?V7?B5!^Q!8^(OAG|7|6Y)K-J4NHZ=
MXE^SSW>GZBWEP1ND11-""&3_MJ5?RG38T'QHU+1_P#@H5\6O
WAGX?'5;SP MWX8EN)|>|2^0;6U%I|/_WW4=TI^1|W.3F=M|>Q
M^BE)17DW|0F@_%'Q!X-L|7X2^(-+|.)#?
(9K06(5DB^R^7)YD8_|JKKXT_&3Q1KLWP
^'6F^)?!6F3BT.KZ^OE_:IL\$|X|H\$|@'_M'^K^9E7RV;9YFQ?L7PS_
&Q_PC>D_P|O?9/|=^S1_P|H?V=O^S>?Y?|SR=_S M>7OSMW\XK|Q?
V*?!O|0GB'X8ZO>?"/QWX?|_#?APZQ(+FVU>"*6;|7|G@WR?M|>LO|E?Q_|
:^E?VX/VFO%O|-OBCX8:AH7V>|T2|EU_ZOI=P(P+^-.!;|!O
MVF2,_O)=KI_&1N1U^6NJI3->>SB^%OASH|H|^*>D^(_'_B
M3PK9>"I8|U_X7TF#|H_3;\$)&':%GRDY1W_TEU^_M;;A*|M|1_M-?&#|HKXN:
MSX(^#_:7I&@^'YS|H|97_EW,,X3S\$),FR6,1RO|ZI(T=W|K?O1=Z)DJ=|^1
MLY65S|THK|^O\$OQY_:&_9\1:/A8?|^-^(?@G5)XH9|3TJ"/_|L<2>9%(J0

M8D_Y:;)DV.L6U77YW3Z*:O^*NI>! ?V8_\$/CGP5JUL-1ABLM.U6W\$=U&8IK
MN"/S(IX9'#1R"4'(IJ3IRNDNKL*,[WOT/>Z2OA&S!:_M&M=._!_"7P!;>'?
&T<)N-?13:@?^?)5I^W_-%?E\$!+S.<_NW1F0;QA|_FGL)#YMMO,^!:_*^%?
AY^T9!6/[@W^T1I/PF^.%YI?B&#Q_8CIVO:=!^!F_CM_+4HG!
MOSXI8_GA1M|N_?Y:5|S^M8SBXM+N-2O?R'T445)04444 %%%%!1110
4444 M %%%%!1110 4444 %%%%!1110 4444 %%%%)0!|:?! !0S0;2|_|.^\$|3GU>
MUM+NSFN;>#2IA^|O?-\$6|XS_+
0;LX7\$OWMP57U/(@C^V)|V=+^%_A_2O\$FJ
MR:%J>FVL6F_9IH9|GS1# '&GFAT1L|NI_NY|_ 'F|<^_O|/'AWX! ?V3_:/WJE
MF=+|T0-ITTC?|Q7RCKWPM_9CVZA/ITWQ.|0/-%|YM:/|3&O_X
M;5DKDJH&IS0/C<5'%8/%SQ-%PC&=OB?8^E/^&S_ (/:O^1L?_P67G_QFO<|
MAE|1UKXF|_LD_!;XG6;ZAX:|<:YJMO#Q*(+VW,L&2^/-1|;>G^K.W?H'?O
MIKJH50/2MX2+GB+6>UA^X#)Z5P;?'3XWPY_Z'SPS_X.;?! ^+KX^|2?
L,^/'|HLSK_Q M(=,UDPX|XZ?>1W/DEON9V'C/O738|&OFK M|D/X5:|,SXH?
0OB#IOC@WPMO/&G|_6^PS|_|9L;_,|_P#//OV^E!73%|RN M?
0X2K.O14ZBLV/HHHIG8 %%%%!1110!|_|_MB?#'XY_\$#XN>'KKPYX9TSQOX#
MT>*/4;?0=1FBBL/MF)\$D^UHUUS|R0,,OW4VR;-O^MW|A6OB1^UO=?
#'Q;: ^M)?AAX4L/#R_>K
MR#|EOX8ZS|\$_@/X<|&:|=VE|JFE?:3<7&GL|L1|RXDF !=\$;_V0#|O;O8:FM
M+FDWW+C'E5A:***S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G^|2WV\$W8DHIF12\$ _|5-6> MP|_H^EJ%5(/0"GG_
#Q2VW%>^P^BHRRKU('XUEZKXATS1E!O;ZULQ)WGF2// M_?
1YJHOE+1(F4XQW9KYHKB-2^+GA72;CR|C6|=V| (TO_H_
/4XIRVGM)OT3_6Q|0YI#(O=A^=?'^I?%WQ9J5GY4^K76?6 QQ' M_P \$PK UA
:5U*:SS9:5;6MSZ3S^:/_9*U|_|_9IL(:@F_U>XNHL?=@ MA|K_|_*KH-/ _&?
O"EBA%Q;W6IG^|<3?_\$|:CVF14-HN0*CQ)B-Y1C|SRG5/ MCYXKU!<17EKI?
O#!_P#%|JY:^^ (GBF|OA//K^|;A_ %!-Y4?_ 'PGR5|-Z9|+ M?"FFVODPZ%:E/|L|
(E_5MU=5!;P65J(XE\$\$.? P,8IK/,OI?|OAD_73|&#X>
MS+\$ _|UBFO3_A SX|7P/XJU6^Q-I6J&YFF_P"/F>&3^A Z:/6|8_ GQK=712:
MQM|;CBXGFC\$9_P"^=SU|7|1Z45G/B7%/2G",?
D;PX1PW_+ZK*7S7^1|YZ7^S M/J4RG|;JUK:G_IA"|O| Z'MKHM+_
&;M'CMMM|JEU=3?WX D7Z8:O:Z2O/J9 MYF%3>JUZ:'JTN&|LI?|
+I/UU_|_SL?@+X/M;4036=S>L|S<3W#AS|=FU?TK
MI(7P)X>|BI:*Y3LY4MB#J?7|:-I|&_.IJ6DDH| #LGNAE-VBI:2F%EU0
MU<9I6QWIU%_4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M **** "BBB@ HHHH ****
"BBB@#X@_X*2_Z|X>_|NH_SM:/^";7^N^(7^|H MW|
|JC_@I+_KOA|_NZC_.UH_X)M?Z|XA?|NG?SNJ|_F)/@_ ^:@_K^4^WJ6DI
M:|\$_^|"BBB@ HHHH ^=V@/V)_!7|1GC*T|3>)=7U^QU&SLH|/4:3<011B)9)
M).?A?/;IJ_!|V4_#_|-MCXKB|_ZQJDE_KD41^T:|Y=U%;R0B3RSLA6'(S(
M2R|P7QPR|;|HJ^9VL3RH_-KX6^\$?VL?A?XJ|0>)_P#A5V@^(_%WB&?.H:|K
MH;RW1AZ_9XMEZB1Q_N_N1I_SS_A1-G&?
M&>,OV@|J4^*'P=N_'O@;P_H_B6R MUG?X9M;&YC|F_N_M%I^|E_TI|#>
(OXT_UGW_.Y^JM?.G|2'P#|2?&#XH?|S MQ_
H|UIMG8>="=9_M'44U"9XI9HO/M)?W6Q&!.+>0?.5ZBNB-7FE=HPG3?1G:?
ML|Z|4=?&7EU6O#^E^'/\$AOG\$-
IH|PDB^R^7'YSQYU@L\$TLA^SQ|XE:2,HXW>8&.Z23^'8HQTMSFG,^;E/_

MV!/?@#X"!?"_,\$/Q:9Z5X||7ZU?7HU"YUD_ ;S;_ O!^/[DCD=XS(^SS_,V(^VY
MQJW|V;^WS|+_ /|!=)|\$_%3X:V-MX"|5V.LQ:<+G08(K:'RFM[B3,D")MD/
M|O9 MI*ZMN7;LZ2^_8U^+'P=|3W|U| ?B?;>/'/#.IS2SMH>O^9-%8;Q'Q%O2
M=),|/ONB.B1QKN?+4Y?
V'_ 'WQH|3>'|;^/OQ&M_\$|OH"5VVU|GUOX%UZ|1^#/#FJZAI5SHVH
M:E9V|S"C_+\$ _P!|1?LY_"_5_#/B:YTN|
MU"|UF74@^DS220^6T\$\$>/WB(<_NO3O3?
VD/@)XC^,'Q0^#GB;1|K3;.:P|\$ZS M_:..HJ\$SQ2S1>?:2CRMB,"
<6|@^)^99YK<2@R>5);P>7(4Z@/Y4NWC_EFWH: ^X>*^+OB?^Q7X
MWTCXP7OQ1^!_C>W|(^)-2N)3?;.:K)>2V_?&1|B0/LD|P/(8G|B1&16!9678B
MKG3DG%Q;W*G=.YV?_!1#6(+ #|DOQ5#/=V|H|J\$MC;6PFF |Z7|9!)L0|_R1
MR/@<[8W]|<9|>O|E%_I7_8L>&_ \$;8UCV_|#OQ.^,/C31|<^/_ ,1K7Q+I
MNC;?(T00XU!GBB'EW\$ MFW_M'1|'LM/G-N/W1EAMTC?R^%X^3BO*OV;_
(")>)/@_ |4/C'XFUBZTV|L?& MVL_V CIR:?,|LL,7GWB@'%Q'J|PMT-
9Z>_P"86V|CSG|N;_DXG|EK_L:/M_:O3Z^T*^=?
VC_@)XC^,'Q0^#GB;1|O3;.:P|\$ZS_&CJ*:A,|4LT7GVDO|K8 MC G%O)|K U%?
1?X|I--)=C1*U_,=1116984444 %%%%!1110 4444 %%%% M:1110 4444
%%%%!1110 4444 %)2TE 'R3^W|3-4|)^#=(|.:3)):C7GN M!'YI+D6D7)FA<
R>6F M/GES'M'^_C"Z@O'BE(1-KR2R/YO MF2,?)SO7GR=+GUN?
\$XM8:GC9RS&/-%_ #I=&7|1/ FI_L4_\$|PMK^@ZN=4TZ^ MEDQ;@^3-
<0K(@DMY?O*^)|)(OWG|_Y|J;\$K|&8V^09|,U^;6DS>-AVVOBA|_
MKVQM|&T^*(7PL=|K;P|_P|Y)|SR_OWY5?|_):?P(|5^DD>(TP!|WBNFB|I
M#OR=W=6=)-4OLW)%Z<|:..0&-H8;E(|JZ+GTMM#|U?AU|_.\$?
|:OC/Q3K^N^M(|_*SAB'SO^:8-^|)!%&'78B%)?X^_|:|
|UE?!?)JENY^-7PR|0^)^M/U;|'J M-E/<6UOIAL?^/B9;='CP|S+Y>_S-E?
3GP%_9VUWX0_' +QM>VI6U|"W4.VP@^ MT?ZXN|(HKX=6=U/X<|33&<-
MH.BQW'D;?'9!(FQO+V>|I^ZRY_W4|V=ES21^?/+U3BJ^*IR;7-S6;U|=3T
MK|@>Q|*_|
(9J|_HK78UNXF@M|6MKNXBD/F1^84ECVHK^6WF2#Y^|:K|VTLWU
MJ*^5/V\$?A3K?@'PUXAU?7;*XTJ;6)X;>WTZ_A\$4RQ0B0F7GYQO>63Y'53|FI
M'SU|5;MN3Z5V4OA/KLK|H|4I^T6D)124M:'JA1110 4444 %%%%"4M%%38
MHHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BfKCM2-C-
>@|+46X M9IU(5UT8^DJ+1@C|S7,7WQZ|'VMJ9X;RYO7
XMX+=PY^F_:OZUU4| M)B:SM3IM^B..KCL+0_BU%'U=CTREKQ35/VE=
(CMMUCI=U=3?W)RD7ZY:N=U3 M|HC4IE'V+2;6UA
TWF>7_T#;7J4|CS"IM2:|= #QZO\$F64O^7J?IK^1|&4;A
MZU|H7WQV|:W5T'AOK>VXYMX(8Q&?^ ^MSU@MXX|5:K?9AU75#T\$TG|?
M_3-*|&'#6*>M2<8_ |F?%V&_YZ@LK4R2L((8^3DX KEM3^*7
MA33;7SIM,2GZ?|.S!<0YEB|JUPK7K_PQZM?_ +0/ MA2Q0&WN+K4S_
'>_XK;7/ZC^TM80W %AI%Q=18^|/-Y7_Q59&F?LU:E+9X MO=5MK6Y|8(/-
'LE;|G^S9ID-N/MNL:A<2_Q>3Y<<9^D>QJ7L|BH;RRC|J6I?
\$L/V>_%MU;JTT6GVH/6">|X/KL1DKH|;|F.Y-IB?Q&#/_ M 'OL7_V=>_T5Q5.
(6_5O|+'D&G_L|^&;:Z|^YDU" M|OC_ (|Y9L1CZ;55OUKI|^-\$?A72;CS+?
1+=V|9RTO| Z&37;T5Y-3'8JK_\$ MJ_-Q|%/ *
<#1_ATDODG^9D:5X>TS1E(LK&ULQ)V@A2//_?(YK4"JO0 ?A4E%
M<4I2EJV>G&\$8|(8/;^=-9B#U J6DJ=MBK7W&8_V:7 |*?13=GN/T(QG^|3_Q
MI:*7J)*P4444QA1110 4444 %%%%!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M?

\$'_4E_P!=\/?JW4?YVM'_3:_P!=\00JW3OYW5'_4E_P!=\/?JW4?Y MVM'_
3:_P!=\00JW3OYW5>=_P_Q)\'_U!_7\H04M)2UZ)\X%%!!111 M0
44VEVTKH!M+1_%7G_@/XP^#_B1XD\6:+X\7::\!^O9I=ST&BDS1F@=@VT;?
>C;1M!:#'4F;4TK3T\$ M+CWHVT+7>!?
C#X/^)'B3Q9HOAO5_M^I>&+W^SM7@%O+%JFFWR)LRZ*K_/%*
M,H6Z=>:5M&UT\$|#O^/6CBEQ\TFVD,7=1NHVTF/:A)"U'44SM1TJA|+BY-
&32 MT4@%HI*6E< HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH * M**** "DI:2@#YH :R^7BKX(OX5O_
Y:6UWIMZ+FWO5U&UDEA\$O\AH,K)^|MQYNT;_F^?^YE?.M-
_;"^%'Q!O+67QW\.%I>::87.JC!J<50%\R.BN?OR?(B
M/W]:^GOB\6O"OPGL;2\|5ZK_94%W-JGMU\F662=L=
B(SGKZ>G\ZOBGXN?M
M& "/QK8O_9WPE^W:I^7ITHGQ\DDCVSEYQF3YH_7_P")Y*DG%\ZI
MCY/JSPU1RC6BGTBUM_^
?:'PT^)W@'QO86MMX,UC2\B"&#,.FVV(98(E^0 M?N#M>-
!C'*8KT+'IQ7Y: ^#OV5?B;+1KPRVOA'_A%=.FFD_Y"V^UB@_C\O8^Z M;9_
KI'_-[HU?J-'JP#UK2DV_B5CT,KQ=,%4VZM/E_4GIKG:K'VI:&&Y2/
M:MSVWL?'O\(/QO\::?%\XJ>._\$ _JSGPR(\$#:_)/YHMI7?IQY?R#&Q(Y8VQLW
M?(S;VSL^B_BGX=UOQ5\I:TGPYK!\V:Q>0XM\OSGRCP<>J;@ "F\|F7=N7YA7
MP9JDWC7\B7XGZM#I-K\IT;48I18B^WSVEQ#O _=R?(7\I.%;^YYK_P
#HU:W MQ%_R\1^*M'DTKP\I">\$S<1R03W*WGVFZ'_7)\BB,\GGYSTV\&%
<4:R4/?=V M?&T,RIX;#RP^*QJ'&\|O7S/^Q?|\\$|5^%O@W5-7UVW:QUCQ!-'<
MM:3<&"% 3'YB8^27+R;A_N9VMNKZ9!'-
=%)^|=GO99\7ZK!5_B'4M%%:GJA1 M110 4444 %%%!!1110 4444 %%%!
!1110 4444 %%%!!1110 4444 %%% M% !1110 4444 %%%!!1110 4444
%%!!1110 4444 %%%!!1110 4444 M %%%!!1110 4444 %%%!!1110
4444 %%%!!1110 4444 %%%!!1110 M4444 %%%!!1110 4444 %%%!
!1110 4444 %%%!!1110 4444 %%%!!1 M110 4444 %%%!!1110 4444
%%!!1110 4444 %%%!!1110 4444 %%% M% !1110 4444 %%%!!1110
4444 %%%!!13<^J&Z@!KQE_FXV?)_OD\U6O;=-U"#5-/M;N#:T\$T8E1LX^
M\SG\I:Z^!K8:E3JU%I/8\G#9G0Q5>IAJAN:U)FLO5;-T\2;3S;V\MK.#^M\-,
(Q^=<|J?Q6\|Z7&K3Z_:GS/N_9\SG\D#5RTZ-6\I,&_D=E3%X>C_\$J)?- M?
JSMJ*|IU+|H7PM977EPBZO#C_70PX_|HVU@:A^TY"EQBP.W%U#W,\QBD_
M\H&->I3R?'U_J3^=E^:/J<0993WK)^EW^1\K25\QW'\1/BV2W*FUTVTSQY
MYAD*_EOKF\|XN>,KRU::;5\SYAC;!\\$D3_@R)N%>G3X9QTOBLOG_D>14XNP
MX2<_3_@L^OMP7G.*Q=2\5:/H\|P(H5;2TE(R%N)TC/ZU\|D\O\$/C\$8(SNGE2)_
=6_|@X>C_'Q,5_7J<3XHQ&(_MW/"R?|>29\7GQD\Z?<+!-
JL1XZPPO+%_W\52OZUS6H?M(:#:_M_M*W4FGLMEH%M:S\!Y MUP9\$'_
=JFL35/V@?%=|;+;%K*Z\|R8W5X2\A M4S38
[XVUOZ7\)">DHRPZ#;L)/O?:!YY-|U/Z\|DV'_AT7+U_IA_9_\$>)_ MC8A1\|A
ACYMU/XF>*|3NM\B&Y" _P!VWF\H?^.;*AG|->*M=8WDNE:E=M*/ M\|>
Q)3./I^OKS2=%T_2;4165G;6<'|V"\$1BM(J\T&*T\|PX;_,74MJ*?
JK_GE2_AQ2^2_P AH7%(:DI*S<5+XD= G-&T4ZBAJX\$>
M*:V>Q%2T4Q;;!2T44#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/B#_@I+_KOA\N_ZC_. MUH_X)M?Z\XA?[NG?SNJ/^"DO^N^O^|JA
|6C_@FU_KOB%_NZ=_.ZKSO^8D^M#_YJ#^OY3|>I:2EKT3|P****
"BBB@#A/%WQ7*^"?&/A+P\KVKV^E:QXEED
M@TFWN!)BYD0)O028V(%&1^/\K5XE_P %&_"|XZ^)W\|/?
AG4?/73M:UFYT^|N?WWDS7 M%A'(8^&
|25\|KW\OPBU\|P3<^&!X\$TG2;::U%M\J>FV,<6H0!1\|D@N-F\N#_M 'RV_G?
OW.#T*(.I.74PO.|78|?TC6+77M/M=1T^|@O-.NHDG@N8)?-BFC<9

M1T<<\$'C\Z^00V&?^3B/VI?|L:/_&[U"J'_3:U3Q'X=LOBM|+|;N::|A|
M%ZT(+ =K::27\$KR3QW"1F0C|WOM_,7Y\$):.61F^_5_|AG_).):.E_|&C_-N|
M0JG|04T3S1\$COL_=2_M_O-FSC;FD^\$_|07PZ^_
PNE|%>+ +75|F\$DW%K^|_@NP%"9D|B5\$DV?08OWFS9S MMKRSXC^!OV-?
B5=Z3?^)-.*7,|KXHG.IS"*3RX0+:S?>_E^9&=I
M1&*?.BLL2|\$_^7_\$WC'X/Q_M;?!KQ+|";NUM+J|UF+3M7M;#2Y+6V@A>2.#|I
M!-"B1EX))D?R_P#?^1_G>8TXRT'*HXGZ4>(/\$ND>%-
%NM5UW5K31=,AQY|I?
MSI%#!N.S!=_E'S>O>O&=!_;H^!GB35K;3K+XC6<\$|PR/|0M;BUBZ;^9YD5\$A
M_O-7B/|8^@W'Q|_:O^%'P7OM7N-(|*3V4FL7+:?_*^XD'V@N#|^W_5VA1'*
M?)YTGW|/*^AM1_9'^" ^J>&5|V/7'PW|K8>1';&>VM/*N@\$Q_R|IMFW?
NQN?? MN;^(^J4802>\$9/|GVMQ=1=-M_\$|*,C|?W6KS+|02|M_@'^R-:>\$?
=I:>'|#O;VW|M!;EXOL|JT<|T@|S=_M%Y7S|IV|9)-
WW|PY3P(WP@^'_AFWTJ#|E+XD:N_09|GQ|X&CU"ZGE"1H9/,F
MD;J(Q|B;\$'|*J.*<(1M=DRF|V/MWP_XETCQ7HMKJNAZM::UIDV?(O;"=)89|
MIV8#|I^;TKXH_91|<:1|/B|^UQX@|1:G::3HFF>)3-|T3PIX||'_!R^LC?Z=I?
C#3)(3#>!X%_UC|N<M/*J_/O9(DW;V3-9/|/+?PC|_=\$_|
: @:_%N_\$UFVL6FB^)|I3;Z+>D2Z=---<7
MZ?:9H/N2.B>;&F_.SS9/XMNQQC&*DKDMR=M-
SZ=^&G|6OPK^,'B6#P|X3|7V MVJ:W<02SPVEQ9W%H9PGW_+|Z-
0Y'78/FVAV_@;'MFZO@S|O?|G'PMX-^\$|^(_M_@3PWI?A+Q'X>O;*XFO-'WZ?
^Y|THGE1P83S//DA??C?MCQNX5:U/VSOC)XC ME_8@|)ZY:FVM-
0|>0Z=::@(#)\$!%I7M&K|VECUS7OVZ/@9X%&1^/|K5ZEX"
M^(GA|XF^&::6O"6LV?B'39U7%W8S9_)1^|N09WQR;)
=CX9AWWA+2/&.I*WVBZUO7M*@NIKB4XW_?#>6F?N1IPH_O,7=O!/AMX!
MA_95_;ZTGP3X00)U|)>-'EN9=.G,C?9@D=P|:?.>^9):.(|_W|G|VOT"_BKX-
X*D>!?#VF"72/\$L'A_2K?Q'>^M)+:WN=4@L8Q=W\$7V.?|=RSXWN/W47?-
)9IZ5%|+VJN:5;|FA|("|H3X7 M?&OQ-U/F3W9#|!2>1\$COL_=2_O-
FSC;FMSPK|(_W@6|:|^|>#|!|. MZC)%|G-SI.EP6LIBX/E|T1(|9N-:
MN+6#1+Z'SK&W_=QOYACD=,")((XD;Y46A_B::4:46G+HB6YJWF?6?PO_:D
M^%OQCUAM*)^+|^U7(VV'|L.G M@SPG|S|40!EE;^_\$GA>:VO_8-
O':17&^Y2./|FWRY\$DEWK(GS'&UL_)L^O M/A'XJN?'/PK|^)+T6XU'6-
'LM0G%N?W0EFMTD?R_O'-
+1W|.=O^T%9Z\$PU9=*OM+>3|/<_9_M,9BEV;P4WIG/EQ|O M6OG|P|A ?
CM^SWK4|_@"ZTWQ!IMY,&G\$7D+|HBA?,8ECFV>7O\$DW\$+|^Y7
MKO|6WQ\$^(?@Q?#&F?#FVN;B_OOM-Q<#3|_|.(8C F=@5_DS M!Z=^R7|:?
BI>VB^.=5:TMK"; N=?U,W|GDOCS/*1'?|N?QNF|Y/^/"(M|F.>2"V4
M_9;2<_P?(G|Q-G;|H|_+YKZI 2.,+C |L,U5*,X_P_0|K+8XZ,'|=|O(L4 ME
D)/|6WTKI/9>USYW_&: :>|)_"?|5X?EV-VW;%=6KQ#P7^VCX#|_
ZXM|;?"&S|.VTL4D4^I:%Y'VKRP1^|V>3% MO&_ROX^>^>U8?
|'_@7P|:OB%XHUGQU_Q-M8MYHM0M|6>?RHKB9I'DGG,"!=X M5_*RA^3|
|/R_/MNRRQR)/(_(\$=?:(8\$9K>G+GAM8^EP.)^N8>-9JP^BBBM#T HHHH
**** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** M "DS2=JB;K|RE?N*Z6Y/135:D;-/U" 8?163>:K::38O&-
)4"WN+C5I_,|C%G#T; ??;GZUU4<+7Q&E*#?R.'\$8_#85W'|J?,GR'8E?
04>,'7+6NU#YW/E|5Q9@Z3Y*"O MX'T|KGQ(|.^' 1>ZM;F3S/) ^SP?
O9,^GEIN;|*|ZUCH6VCM&_LS2|BXGPX'
MVS|UV^4@(&W9/^|7GFB_!GQ3K0MS_97V:WD&6N+X^5C_(!A?
BE87BS0|;P MWJPTS|7|KN(>9_LYS%YO|S7F9-Q<7%Y>^=?.?MES-

6KINJ:] = 6ITFQN = 2NX9A(/I/@F?./XQL3Z_MK6.<^E:OA?Q!/X9\26NIQ#*Q3?
[R/_+XK]/\$4E[+W(*3CM<^"P]2*K6G) MKFW:ZFCIOPT\5:E=;8?
#ISM_O7\$/E#_O_ ;73.;^SYXKOK027'V>S/_/M<3U%/UN_S9P5G\!?!N
MGW#3PZ/!TZ3322Q?]^V@_*D;=V_D*EHK&[.JUMB)5/|I-*6|5 M)24%;
[C:3.*DHJ;:H]QNZEL.*5@"BBBJ **** "BBB@ HHHH **** "BBB@ MHHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M*
"BBB@ HHHH **** "BBB@ HHHH ^(/^"DO^N^'O^[JAI6C_@FU_KOB%_N
MZ=_ZH_X*2_Z[X>_[NH_SM:/^";7^N^(7^[IW\JO._YB3X/_FH/Z_E/MZEI
M*601/O HHHH ****
/A7_@H+K7_".&C|FW5EL;O5/L.OW%R+6P@|ZYGV7% @ M_E11_P#+21L?***
['7O|@I-'K#P;6K_L_|G\$?M2_|C1_|M=ZA7VG7;.%X#|. >&|4U74=)|-Z;I-
_JDWVC4+JQLHX9;^;YR))G3F0_O).7S_M_K#TI2J|W-IN-
4|6UV/S>_9A^,'@+P/A3/B9J?|0IMS|2;?6;=AJ6K67|J>3 M-
:/+')|E|J|_(|F1!^|1|FWRU54|BM_XZ?&VU^./|0'|^J;:I&J6WA&W|6?
M9M/US4/W*ZO,FH6B3O#%|1)Y<7SOMWM*Z;5;-J^|_%7PC|#^.;Y;|Q'X.T#
MQ%J,
<7V<7.KZ5!=2B/D^7O=&P/GZ=|UL:WX8TCQ%|D;5|)L|6^PW<>H6WVZW
M27R)DSY(O@Y|=OA|^T%I&CGQ#IVA MVG|CW|KL_\$|7MM6T+P'
MX8TG5+7B&|T_2;>":+<-G\$B(&&4XK/F4DE);&O*TVXO<^>_VM_
GBW|I;|DG M2M1L?#>I:+XEL|Y?Q%_PBTI\$"+6|I>:J/"7B1?W%|9+97%S
3GB2)TC?"/_ :A|O/-+M&SF1T+'<4U425K\$NG=WN>;_LW_M +5\$/|2VK>(?
|!'ZMI7AG2C&+;7M0.?EW\$Q&)+%/ @#^T=^T+
XR75;31=8|626ZZ|/8R36MO,EQ?OY_
|W/C7X1_|%)/AAXF|#VMWX|U4>\$O\$BCR+ZR6RN+F\$G)Q M)\$Z1OA'_+C_
#J?E^;=^% ^OB76/VN/VQ?^%Q0:/=^'O!/@^RDL-/N)K<;
MKG='(D<4C|_|9_IDT|>7O1\$\$.M|J'?|&|0?!3X=>+-7N=5UWP'X8U75+KB:|
MU#2;>>:7;-G+NA8X3BNIT?1|70=/M-
/T^T@L|.M8D@AMH(O*BAB081\$0<#" MY4<|/%?EC:X>S;MS.|C3_(J^,A
@J5|J\$J|/.6CS065S=V|GXCMKFY:WBS| MGB^SW"!Y/|@WR1H#=?
D2OM&LK6-'M=>T^|T_4+2"|TZZB>":VGB|V*:-QAT= M#USS^=9TYFO9-1T|
MQ0;=SY^8_+20QQELQS1VPV^67='#JW|?D_?/A#X<^\$ _+71|_|&|*|F|OI
M1_9%C':^?LSL|P1HN3|Y_|I_%7@7PUX|TX:9XG|V:7XBT^*7SA::K91W4/F_
MWQ&X89^<_2K4XI.-M&2XMVUV/A'|K|A:RTS|HK1;3X_|!VRN/&^H^)|8_M-
MTL\$D7D;)|!(B1H(\$_YY>8|C_(B?|WA^YOA0X//@#X>>%_#!N_MIT73+;3?M
M(B|OS_)C2,2;/FP3L|>|+X0^'/A+P"UT?#7A020#90/+^T?V38QVOGL|I;\$.
M: +S|Y_.NMI2DFE&*M8%&SN% %%%9&@4444 %%% %!1110 4444 %%% %
!1110 M 4444 %%% %!24M% \$* @MGI^%?+?|1WA/XU0^,T|7_#_
%:233+.S|K^QK< MB0-A|DEO)NAGX|!OX157*[S|54AJ9)R./%898J'(Y./IH?
^C_MX>-/[7.MF>-!O-3MXHQ|WF:91|2S*G94|2K>BO|>?(FL?MW>-
?' +6VF>"/|/V+4KB*3A?,U*Y^YMQ)%&B*D_>.=ZN#CI7J|I-_A/XT3>,G|8?
\$'5GCTR(L_)L6^G)D+?)LDCMX M|L-OQZC?
RZLN7WCZ3TW2|/2;_VL|&T6VM8(A#!!"NR.*-0 % '3T_"M0X7M5
MQIR^U*YTTW|M'7S(|_D4>?F;.:?P|O5V^7?MKV)0.@KYP_9,|8?
%7Q@_BC_A95KJ%JL'V?^S_|M0TG|'"F_,F8^1?_Y95|'L0O/8UZ%-
IJR/M|%.E#+#0=*+C'LU9DE%)2U1Z 4 M444 %%% %!1110 4444 %%% %
!1110 4444 %%% %!1110 4444 %%% %!11 M10 4444 %%% %!1110 4444
 %%% %!1110 4444 %%% %!1110 4444 %%% %M !1110 4444 %%% %!1110
4444 %%% %!1110 4444 %%% %!1110 4444 M %%% %!1110 4444 %%% %
!1110 4444 %%% %!1110 4444 %%% %!1110 4 M444 %%% %!1110 4444
 %%% %!1110 4444 %%% %!1110 4444 %%% %"9I
M:BP/:C|J|\$M%1_ =SVJAJ&J6FD637%|=06T,0R9IF\$:+^9HC|SY8ZLF4XP5Y:
M(TZ*|WU|XX>%=!Q&EY_:L^/NV|P?|J|_<_|J|UG|I+59+E5TO3;>SMU|S

MYKTF7A G=Z'AXK/'3/'?:0;031C)@\$P,H|JB--^E?,&J?.\$#Q7XJNQ#
<:M<70D_<"V@ M_=>?O_Y9^6G^LK0T'X.^*\$_./^1|EMSTN;[|U_XY|_,-YN-
|QB*/_?X#/A^5Y MIJWQM|5ZI_J;ZWTV#RO(+6=>+YQXZ'+|/^
T_K&2X'^%!U'YF;PG\$&8K|H4|
MGZ'S=IOAWQ#X|N_.AM+G59YN/M5Q_L1_|J'KM=#_&==;OOWNK7-
OI7&>/WL
MH^H^[_X|7TNL:KT4#|*6N:MQ)BGIADH+TN=^'X3PL7SXJ3J2^|M?
Q/)=\$^M7AG3K<+>BYU>8|!NN)S%@CL_JN?QW5Z)INBV.CV8BL+.WLX?
|L\$0C'Y5K45 M|6Q=;\$_.|2;?S/J,+EV\$P4>3#TU%>FOW|C%.
|WKA|H/X/^\$|2OKFYGT0?+/AK|9/@+HGAK5_L6E^*/*\$'V'5|7R_M(I?
M\$7GV:>7|Z,R?)))+|PK|: ^I/>FXM13|D*5VUV'45'C)!KY#_9)^ (G|0GB
M_P"*'C:S^+7AZYTCPIY!#G:=KC3\$M8|:|_ \$=O:R#_CYC|OS?WG|W_51G?|_S
MD5>_D4W:Q|@44WCTHX|*D+CJ*^6?VK/C%XL^&OQD^
NB>&M7^Q:7XH|0?8=7 MM?(BE^T1>?9IY?SHS)\DDOW"OUKZD|ZMQ:2?
EK.Y8M%)TKS M_P"-7B"|!) !GOUK6E7(LM3TW0+Z_MKD|9|:#-';R.CX?
Y3AAWJXIL3:1Z#17 MAO|/'Q"|1?%/|G'PIXG|3WIU77+|WOVBZ|F.(MLO)XH|
(Bj|^2-?3|:|OZL: M))Q:782E=)|Q|%.:A:18^BD:D6IOK80ZBF"G&GJ_M%%%,
HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH
P|:U|3/#FGW&H:K M?6NDZ=%S-=7TJ10C^'EV.!^
>&6'|:GPZU3QGI7A02AJFKS7E|;V\$&IPVB1V MOG2E%'WW5_|EH/X*X?-
(*>+M0TSPSX6|VV|/U6>XN+IT_>;'=MGWY MCL3UKEG4DI|+R/J?5/CEX-
T7XF6/(@6|UA|XDOH MV*WC+F;5MCTL+BI5:M2C+5Q
M_\$Y/XD#Q*O@;Q"/"L2W'B\$6;_P!G|_E?ON=OWT9,@|C=|K\$!6VK|P^-|7|L
MCXG?";5_|#^(OA+NXACD)^U#|[%?|;Q_-X#P?|
Q^O1=>_91^%/B:Z%U=^# M+2VG6+R-M@9+*/;Z;(75:-
!_91^%/AFZ:ZM/!EI&1U6%\$ M_P!6A|Q/ER?F_N?8_P-
P#A)6|#^'AXKB6W0FS0ZBJ3B7\$W&|B*F2>3M^
M522J|E^8|&AZ#I7AW3|?3|)L;;2K""B&UL84BA'7"*,#|*V=OR|:UC#EZG=
MA,+7H2<|15@KB_\$'QH|*MZ\$=O|H_9L9\$%IB0'_@?W?
S:NBE0JU|*4&_DIZ%F@L!U(%? M/VO?M*7+9BT/1QS_
_O%^2;/E<3Q9@;_O9TKSGV6GXL^I-|<:)X97=J>KV|N<9\$ M|/P_1|!QK@-
>_.;T:S/EZ597&JMV8?NH_U^?_QRO(|\$^\$_B?7<+FTM?_M|K-^?
*&WUV|A^*|_#T7|FIV^S2ZKJ|H,?OK>SA')_WW|?|KK^H93@?|>*O-
MZ'G/|ZS+_=J*AZG+ZS|>O%FHW06SD@TVW!D^:&'S"<=,|MV?_'Y*WL?.\$'C
M|Q=2U.X.R#|3^|D|CNA|S_)9^M?2>D_|WPKHB_N|*@NI|)G-T/'!|L; MY:
|R-0%X7%+^W,'AU_L-!7|O^OU+CP|CL9|^/Q#2|(^9_#_|/?B+52|JGV72
M;BKBRL::S\$G:"%(|_P#?(YK6 M91C&./:G4M>'*3EN?2PIPIJT%8:
*0T^BH|#0****8!1110 4444 %%%!!1 M110 4444 %%%!!1110 4444
%%%%%%%%!!1110 4444 %%%!!1110 4444 %%% M%!!1110 4444 %%%!!1110
4444 %%%!!1110 4444 %%%!!1110 4444 M %%%!!1110 4444 %%%!!
!1110 4444 %%%!!1110 4444 %%%!!1110 M4444 %%%!!1110 4444
%%%%%%%%!!1110 4444 ?\$'_!27_7?#W_=U'^=K1_P3 M: UWQ" W=, G=4?
|%)?|=|/?|W4?YVM'_!K_7?#+_=T|^=U7G?|Q)|'_P_U
M!_7|H|O4M)2UZ)|X%%%%%%%%!24M)0!|+?|!M:_P"\$>^-'|NK+8W>J?8M>N+D
M6MA!YUU/LN+!*BC_P"6DC8^45%|16_2N-
'U;QMI=WI/ANWRJU!X%TZ*VO| MZVB3*;- V=TGDV#?
_KOGS|J*VV*MS|N7_DXC|EK-
+&C_P|N|/K|0KK:4M3P|H|DW|H/_A|'X5CQ//I1T;4|6|DT|4+4_P"L|<<X_|
(|D_89_Y.(:E_|&C_V|U"E./+* M20HR?NW.6T'XX_M%?M::|JFJ?|!Z5X%|
:7=RVMOJ6L&WEDN)5|@^5,-EP^_MRWWC8B*GFR(SNR+6?
JG|17|4WPU^*6E?";_TCP9X|87=F=0L+I8?*_M""|X MYD+B>"--
GERIS&G^K_C^>|/|@+I7Q,|? \$WXL^'_@%=>&+'X?>'|=DMFT+QO,
M99%NR\$CDEC^S!|_+'V;RXO,?:R==TB/L|_|

AW^SUXCU'XMVWQ;^*NKZ7JWC M6RL?|/TW3-
A>+3=*B_>))M=SYDY9)9/J9|PRR??^39I)1CTT(C=L|E_X*#:
MU_PCWQH_9MU9;&|U3|%K|Q2: M;J%J?|29XXXY/.B_B|MX Y8SA^5^|/^
|^Z'J*^+O^"4_)O/B'_L9|C_-(| M.OL|?O5C6BE)I=#2G|
SY!_:H_:H|6>"_B!|PE^\$FD0>(?B!JD1,JP6CF_L MX21OY0|O?Q)C|SS?
(B;&9763*<#|5HOVJ/AG|%/&DOCJ_|#/Q0|-ZCIEQI MI_|
V3\$8|0L0K>>,W,>RVB0HCR1.^4?Y8|_(N|TW/AYJUM8_P#!4GXE13SP
M6|_X:CMX/.F,TOV;39/+C!(AV12OOR%C?WQ|.?M'_/O?Q0_|%?5?_2.
M6M?A<5;Z+|,_P!@OP|XLUM_L>FZ19ZE0A%&?F.87&)' M^?
>|,KR%.?|6|_(A8?*FX/LRO^<O_X_|NP5|>_LOZM::I^SC|+Y;*XM|F>&
M=/@W0S"4"6.WCCDCSGJCH4;_&@>AIS7+S2MUL53LXI7V/?@?| M3?
\$;P=|M=D^#'QVM+4:W>
<:1XFMQ%;17|9=XR3E4D27F.+RT1|6UTW.^SJ_VI/CUX|T MSXF>%?@W|*
|6WMO'_B6:A;_E^8O)L+0|R\$?=G_(JY=_RAH^179_DX|JM
MS5;>|;|H7|F335NK8:A;^)!<36IN!O\$3WEB\$?
R^N6|J7;_P!_|%|3ZIX'^(.APBVL-3YA?9+;OQ(/*N Z;O;_>OR4KPN|
MVW%>5K7.\$^'UO^UAX\$|:::/^,W|+_\$_PUJE|'J%UIL|5G-H|X,F?+@W_ZS
M?L"2EO*V?)OWUU7|47|1>M_"74"/"?@_P#X?MO%OQ)|33'|IL|?N;>!"#)))-
M&KJ_S@2|3|B?NI79_P!SM?
A/%G|1'CG|E#QMX4T/XOZKH_B_P3KAN(8/%.G6
M#VFJP%#'^^NK=/W/EH9|FR#YB@#_'OD?AOVGO#|MXL_X*#_
RTK4/\$.I^\$ M;:|^|>1_:NC7WV"|AF:2_P#*2*?'!=QY?
^UYNS^.G&%Y:BE.RNC8^P_MI^?
M#*^+K_Q'X7|7_8|07\$ _@|V,+='L|BQ;?|FU#3KC)-M=HD;O&),_2_9O|&W?
AGPS>:G=Z=>7KZ@3|T.-#RB)Q MB,5E.46KFL5(|8HHHK\$V"BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHH"
/&OVCO@?;_';P4-/2X2QUC3Y1<:?=31_*9!UBDQ|P MC;^+9Z(WS;-M?#FO>
/CIX=OO"MM?^'=>NKO09OMNDF& ZG'8?

&|2^SW/VC4+\$6TT%H_|R|1&)%|Q.K_*+_B5+|H-REN4CWB.(A/
5O!|Z|HFSRMNW<|.G4LW#SM'|.G:"YN-7\$<> B(Y(V. M^?| 6_*/O,WR_7Y2_9|
Z9^TM|0OB|XJ|=|^U6.U_LBS3Q9EEDD*F.1) XC M1+?8J9;Y)KQ<4E"7-
;3^7OZGT5|_/B5H7Q7|+V>N:%=?;K;:@A M@1+!|(##|4J?
P2+Q^>1|IKMQC'2OBS_@G/K5Q)IOC721,#IMG+97,,>/NRRQR M)(/_
"!7VD&R,UT0ESQO8|;+|0|7AU6EU'T4459Z04444 %%%%!29KYH_
M1_:*U;X%^=")T_P?:F_|>>*+PZ=I%OY3S2#@>9)\$FQEED5I841#GYI0=KJCJ
M?*E_X)CZ/XN|M?>._B+XFU?XCWEGC4-4-S'I>%YI+G3M
M>U6"3|5<6B7'E OYSO(SD/YD,D7W_)')'^?;Y=?;-1.+@|{#C+F5QU%%%%%%%%04%%
M%%%%%%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 444
M4 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110
M 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110
M1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1124 &12U J=
M?E_&GYZIS2,Z1_Q8D)J6VH725WH2TE<#JWQA|*:'^|U:"Z
ME|GS|MK^|R/7>ORUP&L?M+/_*3%I6DJG'|FXO9NI_W\$|?|Z|;#Y7C,3K3
MINW?8|3%9W@,'I5J*_9:_E<|HQM!K"UKQ+IV@68EU*(MK) &|/^;&=OIG|U?
M+VN?%SQ5KRD7&IW-I:>9YN+#|T-OIO3YZK;+|-/0?B"S\$EEI-T+;*/|C+_
"Y_X#6SH?|-M=Y)@ZOJ5JBF3)MK.(2XC|/,,, Z!7H^@_!7PMH/S'3?MDV,&:
|(DS_P#|OY* M*T|KDN"_A1=1^9BZ/\$&9?Q9>R_^;A_PD'C ?|Q+Q
(3_MW7D;Z|'1/V?_\$> MH+OOD@TE?-SF>;S9?|_"?+G_
(%7TO#;V|G:B.)1;PQ<# QBK5<|7B.OMAH* M"^|/*|=" _/BJCG+|E^9X|H?
|..@V+6|NH7=SJDP&|C|U'|?D^?_,?KO|+| M&Z'H(7|H-
M:L(O*|Z&+|YCTW_>=)25|7QN)Q7|;:;?S/JL-EN#PBM2H?C
M^8Q5"|@/PIQ7UIU%<)Z2TV(ES_>S3_Tl:6GZB2ML%%%%%%%% PHHHH ****

"BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH * M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** /B#_M (*2_P"N^'O^|J|A|6C_)M?Z|XA?|NG?SNJA_@I+_ *|X>_|NH_SM:A
M@FU_KOB%_NZ=_.ZKSO|F)/@_P#FH/Z_E/MZEI*601/O HHHH **** /G^H
M#X"^(_C|A4/@YXFT>ZTVSL!:_L_VCJ*:A,|4LT7GVDO|K8C_G_1Y!|Y7J/K7
MT92|?>C_|T.3:2|S|J*3;|GSK^Q|A_?\$/|_?POU;PSXFN=+O=0O-9EU(-L,TD
MD/EO!!'C|XB'|/KT|USGPY^%OB+|F+4OVCOB?
JYTS5=,UF>Y|1Z=9V%Q)YOE M0_:YS%+NB_=EQ(@^3?SFOJZBKYY7;?
4%%*WD?FQ|!_V4?AS^V%HNK?\$?Q_XE MN++Q9K=
|_!WQ|XH/Q&U2|C^P_.2ZNKB N#'|D,:9C| ^.)/(='W^'_5O7TQX
MY_X)K?"#QIXDN|7MOJOA,S_-/:^'|F*:U,GF)Y@2,:7R|9X1-J+CY5KL_@5
M^Q;|,OV?|<;6|#L|K5?\$/|U;?5-8N!--;Q_OEQ|\$5(^_P^S?|O)%W|'#M'
M7|2%^:_^G8PE&3CRD'|2/P%|1_&#XH?!SQ_
I%UIMG8>="=9_M'44U"9XI9HO/M M)?W6Q&!/ ^CR#YR04?
6OHRG45QN5TEV-E&S;|GSG^Q|A_'Q#^S|L_-6|, ^)K MG2|W4+S69=2#:3-
))#Y;P01X_>(AS^Z;/O7T2OWJ=2TI-R;;ZCC'E5CY_.:4 M_9!UGX@?\$S2/BA|
/_%L'A'XA:??%&,7\$0\$5_LDX>25\$9Q^|DDC8.DJ.GEQ|57 M)KG+|HE?
XS_%3P7J|H|8?BA:^(|K|!>VVDZ#H_|HFF37;QQFVN+N2&")W\$<
MZ&01^4^SRD8-|H'^U**T522278ETT|^9X7^S|_|Y_|/NE_"WQHUMJY%K?6
M.H?89I/*N(;B>=S&)/DD_P!7)C/R|_|!T+|CGXZ_.|U?3_@K|4M+L_"FIR?
M:39Z|#^|MY_WG_0P3Q_<|H-(FS?_'!L2OO*BE|25VWU=PY\$?(W|/'|&NN>!
M_BE|A6/B5XM_X3#XBW(D.ZU,GV6VE?S(WDW_
"^9^X(C2/8B0C*JK81EZ+X| M?L^_\$3Q%XW;Q|_|+?B==^\$O\$PM(K
Z7J"QG3)XD)|M,(F?D|^Z<>.OBYX5|076D:9X?BQ%E M)/,_YXQ)'F2.+>=CNZ?
+O38E>L_M2?LLZ)^U)X7T|VN|7N-&U?2Y)'T|5H(# M,L(?
9Y|4L&|0X;RU|JRM&GS?>5_H"BAU)-W)5.*5CX6C_9|_&N-6T6S|:M
M|:M)L|\$ M|6>ZTZ>0W_D|LS)YXM8ID)/^>R;|?._P_|U|*?_3X,V/P^&&E
M>#=#/OKS5UM#)+/=7TAS-,YWR&.,?+% 'N/\$:<#J=
|/%F;U6BB5235A*E%!1116 M1J% %%% %!1110 4444 %%% %!1110 4444
 %%% %!1110 4444 %%% %!1110 M|N|:ZTNRN)YVN?
WO|QT22X%U&9!;7!'E|,9,|_(?E!_A%?,WAO|;|!^!
MOA6^6|T3X>7ND74L7D>=IVBV44AC_P">>8Y|X|NE<-
:;>9WE:Y|;F6'I^UG& M5=1C.W,GOIV?0|4|+_ 'S3M0_:OM/B1K=LVC;:-
+^ ^MK=S<_9_P#0_LN_.O2X M_CX3ITW5Z+|+?
\$5M|6_VZKCQ7X;5KS1HXI+@W\$|>7B);/I*9 A/1I/*_VP)/ MF1/FK.;?
OW\$|LKYWJWS<= M: ^G/AM|)?"GPKL;JS|*Z4-)M|R7|3<'SI9D)VQU+N|.?S|?
|U3"F GK&5|;F> M"PKK348UE-1GSNRZG?TC?=-+2,
<*3|5Z|JL?!OQ:_9J^(GPO^(%WXK^%)NFT M^;S=0:UTZ9(I;8B02;/F;?;.@Z;
(T5_|K+_|?K|#_#WX|7GAV|!%:|X?-MW|T_@W_|_|J|_|KRP^&4);3K2X MD^S?
V3I?VZYN(OD07\$F|&|OK_<39YFUM|9W_ M|H->?LOB@?| M7RTN;ZN?
G%>.\$E5O#VENMMO/T/K'|G/X&P? GP6=.DG6^UG4)3<;A=0Q842'
MI%&3|QC3^'=ZNWR|H|A4#H*^ED8RJ).T3K?V*/V??\$7AG6/%OQ=|?
V=M|CCQI++WUK;>9WFF2//_M_'T:|U;|H3P_9H?L45SJ?|K8_|K*
|W1_V;M4DN"VJ;E;6D_|OY;+,A|/_&X+LS M_P
#KN65Y7@O|YK9F&I;G<'?/|F_>2>1V<>7_P LZ^C-#^!OA716
M,C6O|HS8Y: ^/F_| ^X/P6NWT|2|31|!%;:RM8+;&(86&%1&@_(4UG6_PJY<#
M03|V/^P,RQSOCL0UY(^9_#_P)|1:M(KSK;Z5;'RR3,/W@W?|,TZ_|#VUZ)H/
M|_6CV6)-5O;C5&|J?W4?_P_7_P"/U|-25Y6(S|'5|%/E79'LX7AG+L+KR|S|
MLYK00!&A^&5Q|NCV|HV,&8#|X?
JYRU=#CC@<5)2UX,YRJ_|W<^FIT84HV@K?
MA^1\$BX/(%*V|/:GTM3Z&R\$I:** "BBB@ HHHH **** "BBB@ HHHH **** "

MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** /MB#_@I+_KOA|_+NH_P|6C_@FU_KOB%_NZ=_ZH_X*2_Z|X>_P"|JA
_UH_MX)M?Z|XA?|NG?SNJ|_F)/@_^:@_K^4^WJ6DI:|\$_^|"BBB@ HHHH
|_^,0Q
MT_X_##Q'XQU#_3+;2;7SUMLD&XFR%@CRB.4WR/\$F_9A<|CP*30?
BWX>|0?#_M'2OB#/?#PWX;O|. *X%QXA'V VZN0%,F|1|Q
4Y*/D%&=75C|T_MSAOBY4/
M@|_|"H@+MM:U/^V=8^S_N+F"T0.GFQ2/^|_U?V|JF&?_*?|#|*_X*#_|)GWQ
M!^EC_P"G"WK;EUBNYES/7R/BVNJZ%JUIK6FS9\B|L)TEAGVG9@
M.GRGY02MZOF_@GO_P_F?_#_.E|_P"G"XKZ.J:SDN6378N,N:.*?|_
&I>)_\$.E^'= /EE|D7>JWL=K#YO|P2.5&?D/UJ#PA|10"7CXW2^&O\$FE
M>)_#9F/|1_9-|'=>1OSL|PONV"=A_*OSV_9|!Z3^W?|_M#?\$OQOX|NM2UGPS
MHLL=MI.AW#>1_HLTD_V>.1X7_=B&.,GRT/S/)N9C|^_W|4/^"=_@/3?
&GA_Q_M-X"U;5O_5WI5Y\$;BUL+^XECN(|&>W_|
M(|RN<_X)Z_&^R;R|^"&NO=K+;Q'6?#_U?|_V>\$W.G7"1W21>6CM^|V7'GA
M|I"R2*Q7R:7LOW?.F#J6JQ_MVL/F_P|P2.5&?
D/UKH^BU^6'|=GC;Q+|>/%'CJ+0|S'PX^%9MH-07|1Y<4^I
M33BW|S9L5S)YDDL>?G1\$M9'5OW^QU2I^TERMV*J3Y#|/='UBUU|3|34-
/NX+MS3KJ))X;F"7S8IHG&4="7/YUJUXA|*?'&D?#W|EGX?>
(/\$>K6VDZ)IOA'3_M;FXNKK(4
6D8^N23|J#YF;"KZ'T'X>_\$_+P_|50"%GXH|,7G|J:.%?&46|T;,>2_M+=LD>-
R\$=5?|9'(ZBLW%HM23.NHHHJ2@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@#XK_P""
MBC:C_9'@H0?;/|_|V|_|_|D>;Y4>S?|_P|JGG;<_|_.VZO2O#O|/P:O-%M)_MH_#_
/:T,T2?Z>-3G_T@%|B7*.J?;#_O/_%9W|8WP|^ (OQ(T;P_H_@NR-|
MILLTD^KPQ3P1'Y?*|G_6.F|?ZSC:/U"U|ZZ+|_|VD?#|G:Z?I?|_|VD;,<0
M6|CXBCBA'.|B77UKAFK3|Y7/C,4_8XZK.MAW4CZ7^X^LA AC'X/;ACPDY'
MMJEY_P#'|JR7:N%':OSK_P"%3_M1;L?;/%&?^QIC_P#DJOT3CSM/7'-;TG%
M_#&Q|&75*=3F|G1|G;?2UR2DD_U;?2F%@ISC@#->8^#_ -H+X?>._%4OA?
1/_M\$=K?:U'YA6WQ(/.V??|_*D==DN.OR,WR_-|WFMG)
(|6=2\$6H2=F|O,^/OV:_MBQX3_9V^)GC70-
9U1M7T6|FC@M_\$_=A%)+%F'S./+";SO|S^#?|_W=Z_/7T|_MPV7|'&'S>+2?
^X5>#_VC7B?_S)^SG_-%>'_A1Z?|_\$_4?|_R?LZ?|I%=_'_M_(4>G_|Q%_M+_
(1+5/|4_M%B(S<8MYH=F_?L^ ^B|?+|/3TKO_X>M>\$?LV?"_P""7PY/B,>|?%O_
DIO!;B_M^A_:O=?9|GF>7Q"J^7N|R3Z|J|VVC;TXKHIZQ/J|+.7?%
|JGOP!|>&TAO'A|_V?|*\$_@L?|_3KBV,'FE/,_U,B'G_MRX_RK@O^>_P|_|^
O_*OJ'_Q^OHZBJYI6LF0X1;N>._"J|EOX7?|3Q<|!3LTM>@MMQ^;_*BP?
04N|;U(%/4GF1+17&ZY|2/#OAU<7_MVK6YD\$GD_9X/WLF?38FYOTKSO5?
VEK6&S;^R|)N+F?YP/MG|KM|A_0-NR?=:M|'#Y;C,3K3INW?;|'|DXG.,#A-
*M17|_|D>Z_XSFLW5M;T_2+4RWMY;V<_B_MGF\$8KY=|0?
&KQ3X@S\$|V=,MB,'|&?+_'_W|X?@U8UCX7|4>,KW|3!;ZGJQG_M_P"7B?|_U?
R?|_|)7OT^'948|V,JJ'XGS-3BJ-:7+@J+G^'Z'NNL?M>&=-M_MF:R:ZU:
<|_EMX?+P1U_UFW|-U>?ZY^T-KEYF+2X+?2^,;3B60?0_=_|':=H
M_P"SKKMPN;S48+4>5C="|,D_ZY_PK_X|7|L.C?KPQI"@W%O=:M<>;Y^;R;/S
M?|B|4_2M|Y'E_P*=1_?_D(?'=WY,|W)Z/^SC86UUYVIZO<
M7H.S\$,\$/E*,>OWOTVUZ#X=^/AWPR!)IFD6UM<|
|G;YLO|T+O|U=92U|_B,PQ_M>*TK5&UVV_ (^GPV58+";TJ:OWW_.XSCMBF,#
|5+17GGJV|\$:|O7-.X|I%)7Z_M@E;8****8PHHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HH_MHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@

HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@#X@ M_P""DO|
KOA|_NZC_.UH_P"";7^N^(7^[IWA|JC_(*2_P"N^'O^[JA|6C_M()M?Z|XA?
[NG?SN|H_)B3XA_YJ#^OY3|>I:2EKT3|P**** "BBB@#XM^
M)W_*4#X1_P#8L7'_*+U.O0_@"_)GWQ!^EC_Z<+>O-/VAL>?V_/@/XQOM
MUUINIVDGA^"WMQ^_,W|^\$2'(5-F_481|_IO^7.S=Z7_P4)_Y,_|B!|+_'TX
M6|=VZ;|'-?2;\$_X)|_|F?|_P_|I??^G"XKZ.|:~!|V//VQ/A!|*_V*MM=M+.343I<-
E/:2SQ(44F-|E(H|Y(T^=UY/H,U%6\$N9NPZ4URI=CR+XK?L/
MZP/'VK_\$CX+>.
|OP1XVOKN2YGM;J=_L%U*|D4DF70,P3S\$DD:.1)D=SMV(M<
M9I|/7WQ:_9Q^(&D^\$_VA-'M;CPY>"46_B|2L;H/^\(^T8A^22-/XHQ"DJD)M&
|+N^5^K^'7_4<|/+?:GHOQ>T#40A?XALYI/W%Q8W\$T8A?8|"21B/SDD*2
M?W-C>47W+YB)7F/[3?QGT_|;BOM^\$7P@LKO5[FWU2/6)]?N(?
LUC#"ENZ>M;A_G\$:&Y.YW1?FB"JLOF**WA&_N5%=?
UU)E+2|'8|_X*K_|F|>'O^QGM_|MTCO*XOXK?
#74=#_9Q^"7QP|\$BY7QMX#|_.*;@?;)Q'<:VU|HFOX>:J%L;W6FW?A
M/389|6XA|R.:|_|/(AXP>?SK_,N6%P:O4L>_,'/|M.TT|/E3P|_0_"5|;6
MGB3Q="++2+:X(E^SS#/VMC&^SS/(N1|,V,N_P_OY2CUP?Q(^"?_H'_@FG
MXC|/3C_B=SBQU#6>1G|7->VOF1_?=/D01Q_)|C^5NQ|YKHO@|_P3=?
#3|H0>M);_6+2^'^&EW=SJ/AK0UGDEDMKN;8\$,LE_|!0C_M)-^('TL?|
TX6|6I1C*,4R7%N/,S1|_#?#/1/C!^Q_X(|(>)FN&T35/"6DI_M-
|GF_,@9+>WDCDC(|H|8;GY./F5E.*|?X*_!PY|O-KX1|,?:#IL\$TD|75
MTR&YN)7DW%Y71\$#G&\$S_'(XU|5A_!Q!IOA7|E?P-KNK78M-
+TOP;8W|S_:0|&7GB;PS9ZG;;;:7KZ>PU>&.*4RI'&
MYX1WXQ(*YIAI;2@#YV_:P_:O/M@CX9LH=(M@?.\$&LM)#_:W=P/W5N\$*;W
/_^L?.\$@V+|WKN^|L;Y\$|0?|+W)WWA>MUU;Q)XHL;KQ-+Y.E6T^N2>;
<2_)^|_UW|O|UD?W|E?1'_!0+P#<:Y|_#_B_MB_9@T">6VN;?&/W-
SY:|_O#|/Q(TV?|_37A_:_:|@T+Q5XF^\$/P|^|(D-G<6G_MBKP^+?4;FT@M|PL?,2-
YY3_X9LQ31Q<'|J>9N|5XJD9R;?8^,S"E7J5JJE.2_M4\$G'E?W^IX1'I/QMM?
B:I7@K7?B#JOA76|0B|ZP.K>(9_*FWOL2/S(GER|^5
M*%W|_P#;9=WZ91YV@GKCFOS)^,|0>J_M&^)?!-MH^A?|(_KEC>26|@;:5-|
MD|LLD'E_/LB|OYX_6OTU7F-5/7'-5A^OD=F35(2E54)2DM-7YB-'OC*@U|Q?
M"7|BNQ^\$OQ*MO%<'B6ZU*VL1.;#3OL:0E3(DD?|V0-^|=R'^%/G^;C|M?
3T_MNXQ'9R:./#_A4?|4I|A_Q|>*C_W-,?|_E5M4?E?W7UKZ.)'?KT*7PGV>
C".&C|_'M(NSW):*2EJST@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BF@4\$4.HJ)?
>D9CGAA10L)W_M70FHJ)Y
O|0%):Q^T=86MUY.F:3<7@._,T|HB48|. &_7;7G>K_&|Q7JR_NKZ
MWTV#RO(S9P|_H|S?I7T&'R#5M7'E7F?,XKB?+|+ISVBB&6FF81H/Q)XKA-
:~.WA?25Q|/=:K/YGD?Z""#|W^^^U/UKY^T
MWP|XB|=77GPVESJL|W'VJX_V\$YZ/7:Z%^SSKE|B75)|?2|C.>)91|1|W_QZ
MO2_L?857QE=-|E_3/%_M|_:_|8'#67=H=J_|16N7"XLM.M|8>5G\$Q|R3_KI
M_"O_(|7\$;EXO|0^*;Y8I|5NKLW@C_M_ ^64^?N?(GR5|MH_|/_AC3;<+>?:M
M5F^3YKB;R^1_USV_KNKT/2=%T|1|4165I;VD|/V&\$1C|J?|_N681_|D)1YGW
M?|_47T_|R_H/P7|4: ^1(EH=,MR,C|8#&/^_/O#|5KT#2/V: +6
M&S7^T|6GN;CY"?L?|KM|X)8MNR?|VO=0H|*6O/Q'\$&-
KZ1ERKLO^">UAN&.!M1|ZHN=|W_P_X|I?AMX<|.J#8Z1_9!)YWVB?|
D|GU|Q|S_K75QQJO1_*FI*^M>G4G4=YR;/TZ="E15H02(U49IYTU%9>IN-
SS2DTM%, HHHH **** "BBB@ H HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH ****

"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH ^(/^"DO^ MN^'O^JJA
[6C_@FU_KOB%_NZ=_ZH_X*2_Z[X>[NH_SM:/^";7^N^(7^HW M
[JO_YB3X/_)]#^OY3[>I:2EKT3[P**** "BBB@#PS|KKX(GX^? W5_#EN
M,:S;XU#1QZWD.=B?2<>AHVFJYM\$NQ/*KM|SS;_A MFWX2_P#1+?!?_A.V?
_QNM3PK\(? _@: ^: ^|. >#M!|.ZC)%|G-SI&EP6LICX/
ME|T1\$ _QM6|2^&|*|2&S|S|/_ &M8QW7D M;|; _"Q(C8)V#|JG|^*^!/?
#7@/33IOAGPH?AW3Y9?-H5E':P^; _?*(%&?D M'UKJ***)VLF'*KW.9|5>!/?
#7CS3AIGB?P|IGB+3XI?%.|HME'=0^; _?%;AAG
MYS|*T='T>UT'3|73M/M(+|3K6)
((:"+RXH8T&\$1\$'0#C|JT|U&ZESOX\$EAGVG?DQO|I^;U|*WJ6CL,Y?4!
<^%O:|T MGAK0|>[N-+L9%T_0K(=7TW3X\$BM-.NYTC,EG;1HS 1Q",1K|
[9|O=G|HM>VY-)3YG9 MKN1RCZ*;FDI%#Z*;Q2BD 4M- H:CK8!U%-
_AHZBF+K8=12<4M PHHHH **** M "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH *2DZ5'-)M|J/K0'J M>=?&'XN:-|_%_#A
;NNK=26S3K!!;6<7F2SROG@.ZES)D'=O M^?
<#N^:N6ISRFX)V/F*|3%UL5.G1FHI+KK> _^1JZ'^V+X+|.WUOJ.D _0|
M)U&/_4W%C<01R==G\$B6W'I7Z\$0J!D@Y#IJ20;HV'J*WN M>L|H>Z?
GEXGU?QW^V5|1/%6C^%M6:W|%V9W06|T9(|.2\$,D<9EV0|F=WC|Y4
MF^|E|OW,UWG|'^D7^O?LO^.-+T357TC6K04;F"VN|5C%Y\$QL|<(-
VUO+ZCE/ MF'5<-7F?P| |:G^Q7|2O%GA_7M(J:??21C|2089IHDD?R|B+
[ROO227|W_? M^7>(K|4;B>WN|R".WWP(B2?/NWNCQCY-
MNS_:KS*=1*5Y,../6HPQ\$9UYOVLE/F7;LD?07|!_P 2+SQ;X!U7PY>W=Q=2
MZ#-&(&N.2+22|W&'/S962.7M|J%%7IA?JE;T!KY0_8*^&>I^\$_!.L>(M62
M2U_M^2W-M:RP@9AA|S9/Z_/YG_D/>/E>OK)5"C'6NVC)N%SI/*XU(X2"K;^8
MZEHHK4|4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ I*3-,8?|.:|0-MR6BF@TOI%&.M#|-
MINU/5K>V;&1!N >'Z(/FK@== :-T>RS%I5C<;J>S#|U'^A 'XY7?A|#B<5
M_!@W|K?F>5B#='T^='^O _=M.+S\$!U+4|@|(?M/SR?9^ MZ'S/^6?
K7T%+ARLH|V*FH+|SY>OQ92ORX2DY_A^A|)%Z| |?^!UFZ)^SUXCU
M!K62|N;?2K<#)_Y:2C|\$^7_QZO0=)_9|V/648^VR76IGRMI\$LNR//|)%?GS_M
,"K3V>28#XVZC|CF53B',OX:|DO/0|1U/O_XH|470AGU:YNED_<"V@'E>?O
M_P"6?EI_K*T-!^#OBKQ\$PQI/V6V/2YOOW7_CGW _!ROJ32?
#NFZ,I%E8VMF M).T\$*1Y_|Y':JJ%Z"IEQ%|"/+@Z2A^/^103X7|L^;&UGA
#|3P?1?V:4R) M-:U4#/6"SSQ_P-NO_?(KT/1?A?X6T&9I+'2;8W1"?-
+F7&SIC=G9^%=Q25X. M(S/&8G2I4=NQ|+AOYW&*BKT %-
=1D';D_6IJ*|MJ|N>U:RLM M"+;|4G |!4U)3WW"W8*6BB@84444 %%%
!1110 4444 %%% !1110 4444 M %%% !1110 4444 %%% !1110 4444
%% % !1110 4444 %%% !1110 M4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% M% !1110 4444 %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 M %%% !1110 4444
)1FF<_6DQ_LTK|T*Z):*C_*C)|:8R2DIGI7!_%GXXK>' M?
@GX/NO\$ _B:Z^RZ9#A%1!NFGF.=D<;9^9VY_5FVJK,+A"522A!7;Y5(TXN4
M|\$COZ6OR>|;?|%"OBSXBU@W.AW|OX2TT|0;;;V5O='_6?|M9)D;S)/>/8O|
MLK1X)_X*%_ %GP|K N=V/^L_Y920HOER>|F|?|EJ^R_U1 MS+V?
M+1|+ZGC?VSAN?DU^X_6&BN ^\$ _Q7|. &SP?:>)O#-U|KTN;*LCC;-!
M,:XY\$S|CKZ?1EW*RL>|VGFOBYQG3ER5%9GMQDH2CU)**2EI%'Q!_P %)?
M7?#W _=U'^=K1_P \$VO| 7?\$+_ =T|^=U1_P %)?| 7?#W _=U'^=K1_P \$VO|

M7?\$_+=T|^=U7G?|,2?! P#-0?U_*?;U+24M>B?>!1110 4444
?)'G6L3SSW,|OEQ0QH, MN|N>_, E77RJ-* -EN8GDB@_, -<|&7'AO4-3TRXTR
MXT&^FEBEMOM%P;+S,O K_/OB=XUUCPO M|/AU;+>+Y|\$FQ?Z|K%Q&=A
EDDCQ%LF2,|_ -U(C^=O9/, _=?)NIOPQ_,6| M;Z3|8++X7?'#P1;^\$?
\$FI7\$0L=2T8/);?OC&EO&4WR^8'D,J>?&|(K *RKL= MEZ|_ (OR^'|.T;|E?
P|=V%E|DN=7O+V_OV' "VF%P|'F?7RX(U_X#7/_P#!
M2|P%;>)OV<;S7R+=3|+WEO<6|T8!)
(8H% @DB#|8PWFQ.V.&|L|BN_N>T| MG;K8S|HEYKGV'7'?
\$/QYH_PU|&ZQXLUMQ::?I%G)ZGJ6@V_--W?"?*,L>W KY%_X*
MQ^+CI_P_|\$>&/LO8:GJ5QJ/VOS<""|-\$ (IFSN7^V=O| GGC^_.L:=/GGR&DI
ML.8V=A VI/VA/C_:MXC^#_PCTT^"GFEM|:Z|03Q^9/LDOY@_P!*@[8X3>BN
M)%|U_P"#T+|E'|L&+|H&^U/PIK_AV;PEX_T./??;H>(I,V& MA?YURGS/^WZ
|_ ^'=,|+>&M)T+2K1;72|+LXK&UM@3(((8T"1HWS<)@<^E M?%/|5WAZX|
_MO| P*|>>'|F"SU'Q%>1:-?B"QCRVR>*221S_K-|%/|Y?/S* ML2;6^|MMX?
M*?M8:1^SWJ'A_1(/#MYXN|8:WAM/T/3IHQ) M_K4C_>_>D3>))1%L1|
|1.O%>)^*OVJ/VG_@O8CQ1|2?A%H(|)03^3=*Q/@5J&G_\$S_@I=|2|=O=-
IGZA:07FG743P3VT|7F131,..C MH>""/YT/EI-)J|P|ZIL|', "OXD:%|8/>C^,/#?
V@Z+JD/F0>? 89 R2-') M&XSU1XRG&5..JS*=OE7^)T|C_X)OV>H^#?
\$OQN^'DVK_ ;M+|,,: '!;@6XC!EWW\$ \$DF?O?/'9P_ M)O?978^_OV1_AW|).A?|9?
&.F6EWK'B>^T#7KG^TM8OGNIK;SK.3S(XRQ^OI
MQ|THV3=*^|TH6>LRZ:%TF& M2.'RT@@DS^|=SG|HZJ^BFKXO_X)3_|
)O/B+_L9|C_TCLZ^I_&WC?2/AUX= MU3Q#XCU6UTG1--
@^TW%U='Y5'|R2>%0?,S?*OO%1?O+(TIOW.9GF_P"U9^T5
M8_LZ_"^|UIC:W7B.|)M|&TNXE(-Q,..W^3YO+C3,C?=Z!=ZLZUO_+U3XBZ
M|X*TO6_B(ND6>HZC:1W2Z5I&F7-J|@'R_E3>?,|/)M,88;\$V,'7Y_O5^?'A;
MX|>(?BK|7#|,+:|X+:|3|4TZ?^S|'TS2O)/|+T'"\$AT/GI#+|HN/WLCY=\$V\$
MAE^^GD_87|.W|:7ASXZ>(+KPA?Z1>>|B!8E_.T/6&Y8I(^.^.*3",|B)'EXW
M1&&'P'5':M)4W&%DM3.,U)WN<=X?|2:S|#/VX-8|,.)M6NM5|, \$ZTCFT+4M
M5N))OLTT.CR?8Q(^R.--|S=(D\$>|CS;3^ ^|?9-?%O_!26|@|'^#?AM|0::TM
M|KQ-X9|66|6#7!D,()CDG>-XU=0=|VT/^UP-K1KZ3I*F47(YL1AX8JD MZ-
3X6?G8/^">_P_1S_S%?"X^L|Q_ |9H'_!/?XCG_)BWA?| |W'_P_9KTW_M
(*>,-1TWPSX5|/VQ'|FZK-<7%RHWYG,(CV1G'|&9/_P|^*.OJ/PGI-UH? MA?
1|.O;UM6N;.SB@FU"XXDN)%C"&4CGE|\$_B>MMR2D;
|IHD).8V'M74>Z>#IXN^&/QY|=>(_ 5YT"ZSJ.@Q MR0,VHV052,B.X^S2??
0H_EHQ^3LR|A|U>,>*O\$'|_P5|<7FDKX(;7M0MT%O
M<>2HU"UAD!_U0%S/L\$B<#*+|F2FX?,M>;?LN_%KP|
=0^()|2V+6OB3|\$5L M+6:
(B42Q;_,L|^UGCWN(N=FT>5|WW%K=_91^!OA|XKZ+XL|=?\$ C5=.@F>#=
M<7LD?(W8)|BXE<;><21_/O| ^>F|HN.)5*E17BM3X/ZW/%QA|,?:MRYM/A7
MF?:?PS^).A_%3PG::|H5U|JLY?E(8\$2P2_/_%*G|\$B|?S'RFNW7'7UKXF_X)
MRZA=S6_C^R^TA|**6SN(;7_EF)G|_*|/_RX_P#OW7VO^&:Z:4N>-SZO+L0|
M5A85::DM%)2UH>D% %%% !1110 4444 %%% !1110 4444 %%% !1110
44 M44 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!111 M0 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
% %%% M!1110 44T48|T>H#J2H@_!,:CU"?>-5"+ MJ.T%;M_7F='17CFN?
M&:#9&>+3|2XU2=1DY'E1_3Y_G' ?%<#KG|
M0/B/45VV+0:4GF@8@A|V7_B/\$EQ#F&,7+@,,TN|
G7/VD|R8\$:1IEK&OFX^TWD0F8C|GRTV_M_P#H=>=ZS|2/%.O69CO=5N1
1(V_P"Z^|T^YMA|RO:-_%9ST&Q:WEO|RXU2= M1C@^4GU^3Y_!^O1=&|
::H%F8=-M+6S3"#|S#C.WUQ|ZJ_M+*L#_NU'F?G
M_3(LG.LP_WRM R>FOZH^7M#^\$GBC7@#;Z7RASD_H|JO^
5|I@#H**XJ_\$>.J_P-J/HO|SU<-PIE|'WJ MJDP7,OD^1FZ_>Y'IL;Y?
RKN5A2/HH45/17SM6M5 MKRYJLFSZFCA:&'CRTH)#

N#T 6E.*=16%NQU"9I.*=119 %%%, HHHH *** M* "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M2@ I:8 *4GM2O;
<-1:,U'@48'J/RI^@B6BFXHI#'45\$-V?2G;J3DH/L=AU+3
M,BD)YZTT^;80^EJ'<.^!^-8_B#Q%I7A?2;G4I8U6UTG3X0#+=7MPD44.
<+DN M_Y/>J492=DB'*,?B:-W-+7F_P#PT%|+!U^)/@_, 'MK_| '*X(_MY?
OMX MX) [A5_ /&:ZJ>#Q-3X*;?HFS.5>E#XI+
[SZ\$S1FODSQ)_P48^\$.B70ALDU MSQ!!Y>[H7H@ (XL_W,30\$_|
X[M]ZYOO!_P4I\#6NBW,ND>/%\$%WJ0'FUU# M|/:Q_ VT1Y?T1JH"GDN8U?
AH2^XY99CA8_;/M?--+7YI_ \4F_P"B7_|E<_ ^MY:X+_AYM|4_ ^@%X/_P#_"
[_^2:|X<+YK/_EU;YK|&<|LWP: ^U^!^H-)FOR8| M2?| !0CXUZY?
>=8ZUIGAZ#R,?9| #2HY8C TT_?>:_P#X_LKF/\$'I:'QH|1:/
M=V,_CJZ|B;H=/_@M|64<:_P#60HKQ_P#?==T>\$<=|N<%|W_D8/.L|/A_-(8I
M:QJ4V3;VUCJEY++/L&|_NT?TJ'4/ M@A|5M8OKN_O_
XRO+J;:2XN+FXT.|EFN)G^_)YFRM?|58TW:OBH1_'149O
M.)/X*3?|>A^O_B;XK>"/!=V+'Q'XPT'P|>R1&86VI:G!;2^7_?VNXXSWZ5S6
MO?M.?"CP|H|SJ5S|1/#|6T/_L^ ^CNY<_V<40S#)_=O,CQX_NA-74>%O|
@GC|8?\$.!N1?V.F>'?*,8 MSK%|')Y_O'IF|W|G^WLZTWD.54_CQJ?I_P
_RO|0QL|J+/MO_AO+X&?|#RQ_M|A_ _P#&:X2|_P'''E?PIT^ ^NXK?
1_%%W;P2N/MEK8VXBGQ_RT>=7_WU5O: MO"/_P'''8_Q'EO+2*_|
\$7A>TMO.C^T7-O/<2R^3_P M|Y?DIYA|MZ?|U=M_MPZK;_HJ/_E"/_P
DU/U3A|COB)/^O)\$NMFL|J:1M>*O^"HWAFFW:W_P"\$:|#Z MIJPR_G?VO<1V'
^YY6P3^9GG^|7S=^U!^UG@:>/_#ESX;M=,GDN9|4:
MH+F*>9_+|N3R|B9V#S1_VT>OJ72_ ^"9?
P|6QMHI|3|0>*+BZ|M/.G@GMXHVD M^|1:Q9S?:+C3;^>.4SVN'
M|P11)"OF/GR_D_B02|0|;%KOR_\$M?65?SQGM:GB,PK3HN\;Z'Z)ET)T|_
%5=Q|%%>(>D?.\$'_M_!27_7?#W_ =U'^=K1_P3:_UWQ"_W=._G=4?
|%)?)|=|/?|W4?YVM' !-K_7?\$ M+ _=T|^=U7G?|Q)|'_P
U!_7|H|O4M)2UZ)|X% %%% !1110!^>2+_7>1L|LI"/|JOK+'%=,JC|E%)|'/R+F;
|G_?#7X+^"/@MH_P#9 MW@|PY: ^'+:8_OVM|F:?!=QYL|%)D)-
IEDV|W.W.%P*|=^+W@'|H_6/B#JUUA. M?
B)X9|/>\$)O+%CIVI01&:#\$=G^U|_P#%|244U4::?87(CY;_."_:
|G2+R^L+|1_RQF-P|_E_7RYXV_X%7/_/!2|Q|;>&?V<;S0";=M
M3|47EO;V|J9Q'|(H9%GDE"=9_OE1(V.%|U_|@U/O#^QGX^ ^&/C76/%'P^ (M
MMX0GUN;_H.L6|8T_P":223,6R%XQL_ =1HGD|U3S/WOS|::|,?V*?&^K_&"S
M^*/QP|_V_B|Q)IL|1L=-T8O';?N3&|O(7V1^6\$D\$K^1&BHS\$,S-O=6Z/<|H|
M2_6YG|W+RV/T'X*:#>^\$ _@OX%T35;866IZ;H% C87-L-
KB&6.WC1T^3Y3AAVZ MU|B_|%8_")U#X?|_@CQ/H* C3-
2N-. ^R>5D3?:8A)YF_L4^Q_P#D3A !7JW M|_L?
BS|HCPWX4L_# 'B"TTK^R|V2XN-/U6:2.UN=Z)(=B/^|C(^7Y/^6C_ M #K_
!>U^,OAKI_C_P'''>K^#_\$UU<:OIVJV|G7-W/!!YQ.S_CX_U?EB0A
MO%.S:K@;5_%9TY*\$^<1:S?F'^^CRN^>*>2.1 M#_JID% EYG/S,LJ;5^|NU-A
V6_VA/@S:MX<^#_Q"DFEN+:U|001^9|0 MD5Y8_P|!%G|8Y38C.9&\I/X_00V4?V/H0V?
K|4_>0^(I0%OC_7(|E|J+-(K M<.4DG1=|%Y2\RY:9_G;"?*GS|FN6F^9.Y,N:2M8|2^!6GZ?|, _|@I=|2|'"0
M=8-WH:A=P6> MG6L3SSW,|OE10Q(N|N> /Y5XA^TI^R?
I'|0FH>'|;@|17GA'QAHF%T_7-. MAC,G^M23|H|V1|@CE,6QTV-*
|1*RU6FW:P>|3V5RQ_P3=N|1|9^)/C=|OYM M(^PZ7XGU^.>W(N!)B7?
<3R1X^|D=Y#|^Q-J?4'|1_|R;W|4A_L5|5_P#2 M.6KWPK^&^A?|_P !Z/X.+
?:!HFEP^7|Y|YFD+/(TDDCG'5WD+|849.U548K MP|H3X0?M&_\$KQ-
XIT_PIXY|+Z3|_-9M|/|&DZE\$#,(7MTCN\$WBS=OG?\$7_8SW'_I9TO_
5*U"YTH|G'1X8+VYM+ M>||1VUM MD6-S>&_N+<*9OWS1H&7+36+O|R*/C-?

9_P5/AOH7Q@|!ZQX.|2:~HNJ0^7M/Y\$YAD#)(LDTW1\$4Y0Y=AWPJ|)>? WPW|:-+MX3DM|GPU96,8L+V;:K<1;1<;TPLADSYC2?QM(6[U\6?M1:6-/ :~@GP>NMO#27EEXDO/H.GU!=~M_+^T0"|>- Y)'1|TG^CQRI+O3Y(8OO,N0FWX5_97:~?M^#%B?"PV^+N@CPE!/YUN- 8@_>G>,R8C>VN/+^?/R(^S^/ISO7J7[-?|17P.MCUZ|:~^O\$-QX|^)% |'&HUR_,DOV%?)C22.*21F>0|%/?:VP!55_7WM24'>M|QOM3!K"7PI&L- VQU%%9&H444M4 %%%!!1110 4444 %%%!!1110 4444 %%%!!1124 +24S=P*3H<&G8.|MCY^_:T^!-W|:~"-F^D|?^\$BT222:S67_)>(WP9+<9^1- Y2+YV_YYEU72R+6"TMK>QM->TH:2"%/W:"+(WDR./GW?ZO_'Z_M2? Z#%+L7J0#6\$Z7,|WL>'B9XLM-4MO/%4TL=U)T&XR3&L:(D5SOD5(@Z\$? +|R^0YW_:0_S@YW_?)RV=U>:~?LC_#~PM|;O\$?BR;QUNU?5(M88|BVMYKZ2*6X+R2>?.=C*[A3Y0SNA_K?F_@K<_9@^!'@GXI?#_::7X@M M6L_'NFWDEO|:IA<1R:~NB*0\$Q|U1|CQR_)TS^:O/4Y-W@K'Y_3JXJ57VM" M,(NKS?=YOOY'MO|'7BCP+?>&|7T#P-::|;PZ7-'<7L^NB+S;B2;=S|C|>%M| MGW5P.^ZOI1N.2<5|E?L%^--.10>#M6THZ39V6M:5+;Q7% |96,5M|M482"#S M73_6.FR7GT*|LVZOK7MS7715HGU>5RC5PD)WT|B2BDI:U/6"BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ I*;2\$9|9HZ:"OW)**B7/? %_.8^XH>@|AU+6+JOB+3="C M!OKVVLQ)T|Z9\$S_WT:|ZU:|H30+.,_88;C4OW6X&*+8F?|A#?/GZ+770P>(Q M7|YN)S+"8/2O429Z|2-(J|6_&OF/7OVA/\$6J9_LHVNDP'^+'F3#Z%_E_ M|=KB;B^U_P<7F9QJ6IW!WS_&|Y)|G|./+P"6?I7T5'AS\$;XF2@OO/EZW M%F&OR86#J2^Y?>?2FK?&3PMHJ_/JL%S+Y/GXM?WN1Z|U^7|15P&M? M+29N8M M+TM4X_9MY'KGQ<|4Z|I\$^J7-I:>9YN+\$>4- OIO3YZK:~|_~%GB"S\$ECI5T+8^6?|C(=<M/U^M|ROJ+0/ VC>%|C3M*M|9L8,P4>81Z%S|U=+~*E/B&G0?+@:\$8E4^%YX MI^TQ|>3|O^'N>:~#^S3=-B77-7_Z=|'|_WZ_|15Z#H/P7|*:#|W|F_:9L M8,|X1*#_,^|~2UZ!17@XG- <9B|*M1V|+0^FPN1X#!ZTJ:OW>I3M|6"QMMD M2B"*/@8XP*L8QTJ6BO)=Y.|:/C%07+'1\$:~7-(P&>M244O0O;8*6BBF 4444 M %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 M4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1 M110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%% M% !1110 4444 %%%!!1110 4444 %)FCK32M&@#LTM18'L#1N_VOTH|1:=R M6BFT?A4Z|!CJ*BW |C15:|@:9+13-WM2?C4IWP@245%G;UX_&D,R_>JM27M)1W9+2UP6M? &+P!X9U2YT05O"A_1M3@YFM;|5H(9HMPW E';^E>TTM?-J? M|_!&RL|F6'Q3<:C?#/_H6?&7_@':?_"37;#*,PJ?#0E_X"U^9SO'8=?;1|B4M? ^N_P#!M4BRM:~N8M)^'EU>:~?C|S=:AJJ6TAX_Y|I#|^C- 7,^)/^"I&O75CY/AWP/I>E MW/FX^U:A>R7T7E=SY<:1? ^AY_P!FO0A,YK5^&EH7^9RRS;!K|7X'Z/45^6MFI? |%*/BSJ%E<0V^E^&;&2&3|_:6,_F0<8\$GSS.@Q_M(RUQG_#=P<P#H M? #_X*M/_/C-=L>\$=0?P4VS|JMRKWKSP_M"?S_HH_@_M_P 'MK_|:3^"WA_5Y|/MN?'EJJU",M|AMKBZBZ;N)(49&|ZKE_\$G_!0KX+Z'8- +9;GJ7B*Z|S'V33M+MDCDY_CS.(DQ_P+=|5|O_/#LOXI_|!SPA_X'7?) |C5TGAK_():Z|=6/G>(MO&^EZ7<^:3|EL+&2^B|KL/D>+_T#A M4_J'#E)7>)D_P"O03Q68SV@D>L_MV/.AGV|,^,? .T_P#DFN"X>J'_HEW_E=^Y:TO#/_2XTB"|LOB+QUJF MKVOD\0Z? 8QV,GF^OF.|O_H.?|JNK_P"8?PS|^)O&7_@9:?"-4?18O2Z2E M^'^0? |*M3JD>+>)/^"GWC>ZN0_AWPGH&F6_D8-MJ\$|_|+YOIOC>+_P!_P"! M5RGB;_@HO|8M=L?(L'T+PY/YV/M&GV7FR_|7A/?*G_CFZOM3_(8-^!8-

MYDAC P!Q: | CU=:X; &4 A#X7L&M+'X=:%/R2FG | QFN P"& M@/B?
P!%&|9 ^#R| P#BZ_8#0_@WX!|,|:|H7@CP_H^IP<0W5CL\$,T,X;
M3AT3^M=S|H|4_P#6+_0_@X&/W_|#^RZ|Z|C|6_\$WPO^_C*^%|XE|(^_
M\$-U##Y N+ 2KRZF,/ />Z5H^&?V/ C1XKLQ=6'@75+.VBE|@?;_+L)3C_IG,
MZO| |#^Y7|+8'I140B|\$*/+3HP7R?^8XY+2^W-L_)#0_V_C5JVL6|K/X:M|
M)MY!G^TK_5+?RX/8>2|KG_OBNO| ^'97Q3_Z#O@|?|O|U_|(U?J|17-+BS,
MF_<:CZ+_()JLEPOV|OYGYYZ?_P2SNYK6UEO_B):VESY,?GVMMH?FQ>;_P
M M/G,R>9DY_@0?|-=7X;_X)?| @^UT_P KQ)XNUW5KW>3|HT^"WL8?+
| #8Z2_ ^MA_|
: ^XJ2N&KQ)FM;XJS^5E^ATORS"Q^R?)&@_|\$U_A7HNL6UUDKAJ9OF%7X
MZ|O_)HZ8X+#1^PCRK2_P!FOX6:98V|H%|/"XBABCA7S|,@GD(0#&7="SG
M_:8|N_>NG|)_#SPEX&:Y/AOPWI/ATWAC^T?V38QVOG|<|/,V(N2-
YZ^M=;GV MI*|Z5>M/XY7^_P#S-XT:SASI M:GG9AB7@L-*M%7:Z'>^_
_A|^S!|0=:EUS7KOP>VHR_Z^YMO\$"6GV@|_|F2>3 M,GF/E_|
6/EN>M'@GX>_LP?#_6XM:??&Q?%K?#5;OP+>FS|2V<7VVF|F!)?M
3EXMCH^ M2Z9V;<'=L^;;G.IV5)^SBY'S=_P4E_UWP|_W=1_G:T?
| \$VO|=|00|W30YW5? M+OQ&^,GC3XM_V3_PEFK_ _K_
&+S/L_|BWB^_P"7YGW\$3_GG1|.OC)XT^\$O| MK?)
")ZO_9'VWR_M'|BWE^YYGE_?1_|GI7C^UC|F/R|YIAUFOUS|/_+' M|
|45X|^S7?>,-: ^\$NF:YXUU=M5U+5V.H6_ ^CP1^1:/CR\$ _<(^Y!YF?O?O M=O|
#7KYKUJ?J%*?M(*=K7'T4E+0:|1110_G6C%+12 ****8!1110 W;1MI
MU%*P#<"CBG44_P:2GT4P&XI*?10 WZT-3J* &X%&VG44K
)UIM/HI@<)>X1^
M%7A7P3XR|6^ (M!T>WTK6/\$TL<^K7%N9,7,B!|DACSL0Y>0L4
WL2S98FNY)I MU% EH% % % PHHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@!A M 46"-^&VO(FY:JD9 M=U?\$_P#P4:T^ZFM_%
| |F#64,MY;S77_ "S\$S^1LB^ O^7)_P!^ZRJMQAS(M|S,J|/A95*7Q'U'|+_&T?
Q*|:)XH&F76C|J\$|F^R7H_>+R1GA:-C!-(L|K2X99%_M'5A(?
M(&/GC177R^DN-^|=E/NGY M:|2^,/|1W@3P|/#+M?!_B'3)
|R|TY;#2M.TJ|F:V\$D>U'')\T'E)E_F5<>7
MM^5C7@7|!OPUM_%WQ\$U/7|^SM;NS|Q1F(W&
<_V<^7((Q|F42.3 _=:8R_|& M%2I*4E"#/ %QF-KU*U'"8>>KW>YZH|
_VH_B'K6F^&_%NEKI6KWLIM|?4+&8 M+:3S?/E"COOC_P"6:++S|W|^?
6RL#@BO@K|OZWTS0_&O@S6=(46GBN:*6>X
MN=/G|NZ_<^7Y\$AV=_P#6|7/_#S_-CY/N|8_D0@9.W%:4I2;<7T._+:U7GJ
MX>J^9PMKWOL6*#TIB_=YZT%:#|&?#GPC^*7C'XG7'B%=)L|7B M(-
O=\$Q6UL9GCDF>221SDO,F5^YM|PIS|N!/|BO| LS:|9/B!>ZM|+O'/A>|
MN;PRZA?:7<:KYA@F|P|Y(O*\$C|'=_GW_""^|_|OF>@^#?&7|97Q*U|5_MB
M6EE'+^Y|S|J\$^|&U>1Q';Q1IMW|5,@_A5_+=F97>N| |: ?|\$^?\$FCZ>|_A_Q%
M:>(+@0R^?;30_8I2,?)'%|)|QZ|W7^>.%RE/X(GPU2K/%4IQIX:|/5|H.|H M?
Y'T1^RQ| |GX%>&=5CU:|M;SQ%J=P)KFXL=_DB) 1'|YYY|U|^Q^A 6|?X M
:|YX-?+_P"Q-|:|^*7AK5=&UYOMUSH/D!=3D;L|4GF%|+ZNOEGY_XOXOF
M^=OI^3Y?FQDUT47>)|/ETJ-3"P>'5H|B2EI*6M3U HHHH ***2@ I:Y_Q|XE
MT?PGHMUJFN:M::+IL./O;^=(88-QV8+O\H^;UKY7US_(*@_!|1|7GM+"Q|
M4^(+: ?|A#3K"(0R|=/WT|_|/?2"J492^%\$.<4|7/LBBN#^&WQ4|+?&#PK_M
,))X-UBVUO1?/D@^T6_F1LLL>,I+&ZJZ'OANJE&&5<5W1ZU+T+'4444 %%%
M%!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444
M %%% %!1110 4444 %%% %!1110 4444 %%% %)
45SWB3Q+IW@00|S6M:O4L MM*L83--<2GA0/_CFO*Q^VA|^"?"C
CM_9=Y_|&:4I1B|G-4Q-"BU&K-*
MZON>ZTM>%C|M#X.| %K#_N%WG_QFK&B_M:?"CQ#K%H6G>*31^|JKS1J
M|/,(Q^=:)3Y4KG7*<8*|G8U:*|GUKX_>&-+MRUD|U|QW_+;0>5C'7_%FW
M/X|J|^U|HK6|H|UI5M;Z2,8P?WLH^A^|_X|7N8?)<=B=8T|+N|/^#^!|WBN

M(MPNDJB;[+7\M/Q/I5B%7EL5PNL_%;PMH-L99M5@N_O'R;-O./N.)T_X%7S
MAJ7B+Q%X\O/)FN[K5IYN?LMO_L1_||TK:TCX*^*M47||80:=!Y7G;;R;O_N)
MN;|:|>.0X:A:6.K+T7|?H?/SXFQ>?)E^'E;NT=QKW|2L;YBT72|N?|EXO"
M>/|@|"?^A7GNN?%_Q3KQ)&K_9+<|::Q_=?^/|W_|Q^O3M'_9QLK:|/4
MM4N+Q3LQ#|\$ (E&/7|WZ;:|\$T'P'X=|/_&=[^2+6";,8%P8091|;V^;|:~?U|
M)|#_+O2YWY_|'(E9;G>9+_&FK|/T/E|2_A_X|4W;30:5<78D/GFZN/W7
MG|_ ^6GF/_K*|T?|FW5)+AFU34|:UMQY?RV.9"?|/^P79_X_7T4%Z_#|*6N
M2OQ'C*FE*T%Y(|/#<*8*G|U=N;|L|WT#X'>=%S(|:DV.6OB9!_P!|8V?D
MM=K8Z39Z78K;V5I;VL,0PL,"B-!^0K3HKYVMB*V(=ZLV_F?44,%A|-'DI027
MH-7Z?K2G%.HKFMV.T92|4ZBBUM@"BBBF4444 %%%%!1110 4444
%%%%%%%%!M1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%%!1110
4444 %%M%%!1110 4444 %%%%!1110 4444 %%%%!1110 4444 %%%!
!1110 444 M4 %%,9=PI-N%Q2O;5AK>Q)13.,>M(/847Z 24444P"BBB@
HHHH *3--R?2D MS|5/,EN(DI,TVBJ&/HIF:3(/\$&E>&-
)N=4UG5K72=.AP9;J|N\$BBAS|N2|<#D|ZY4_M"?P?|U(M|'G_+CEK_|
%UK&G.7PJY#J0C|4E|YZ/17SS_PWG|#/ ^AW/_@JO_P#XS7)^M)?|@HU|(-
%NA#9+KOB"#RMWVO3|_119_P">>)WB?_QW;|UZ\$,IS"7_+B7_@
M+_5(YWC*"^VCZRI,U|4^(|@|HX%M=\$N9=|*>(;O4A_J;74/L|K\$WUD1Y<
M?@C5R9_X*IM_T2|_,KG_P!RUWT^',U|4&O6R_-HYYYGA:?Q2/T"HK|R-0_
MX*;?\$.2|NY;#P|X7M+;SI/LJM/!<2R^3_P_L_P!YR>8??8G^[7'>)?^"@_Q
MJUR^\$|CK6F>'H/(Q|GL-
+CEB/_37|HYK_P#C^RN^/"690XXJ/JT2S7\$S_+/B)X4|"M:CO)XDTPKPZ;PR?
9_P"UKZ.U_|;|_P_O>ZY(MWCIZU^.^H?_XK:Q?7>H7_@7QG>74TTEQ<7-
QH=Y++<3/|^3S-E=98_L4?&|_M5+.UNH/_UV+::*.*?
_2+VSBE^89/R/,CQX_NAU"X'='N=2NOB-H#6|/+?V??)=R_W>
(X2|OSZ*:Y;_AO+X%_|#P3_M_P!PF_|_C-?\$GA7_@GC|8?\$.N1?V.F>'/*,8SK%
|')Y_O'|F|W|G^WLZUT^MG_|!GXC\$7EI%?>(?
#%I;=>'|HNK>:XEE|G_EH/+/|E/;/MO3_>I_P!DY%3^
M/%M^G_#.3QN/GM22/=[W_@I9|*M.OKR*WT?Q/=V|\$KC|9;6_BGO_P_M_'G5
MPA_?56|JYGQ3_P5|_6|6_ C?@?5-6&7|/^U|B.PX'W/*V"?S,|_W:Q?^
M'59_Z*C_.4+_P"ZJZOP_P#|\$PO MKHMM%J_BOQ!=ZD/|?
=:>+>UB;_MFZ2X_M_%VJ>3ABCK\$2E|G_
)!S9K4Z)'\$:A_P5,O)K6ZCL|AY:VEQY,GD75SK?FQ>;M_P_L_D\$*>9SC^_
!_M5QG_#S3XI_|+P?_P"-W_|DU|,>%_ ^"=?P?|/_&K|_M=;ZKXC,S1X_M2_:,0
9!\$?V?ROO'^_NZ5TMC^PW|\$|(OK_|MO=O+<03)GV;;O|^!U^JX_9|^%O_1-
'"@BM?_(W76>'?#^E>%| (MM+T;2K72_M=/AR(;6R@2**/'S8"+P.?
2I_UBRVGK2P4?Z^0UE=>>|>1^ND^/OB|/3/M>B
MZ3XC|>>+O.AE^T;;WUY=?N3|DGFQHI?N_WGEU7L/V=_BKJ5Y:6D'P|/4?:9
MIDM_|TNXBB^;K^|= \$2/'/_1_DK|J_M-J^@_*EVCTK1<73|_P_-
"/X_P"1<KKM"_P"";GQ9U;1|2ZN;G0M'GF&3I^H7_M\$B2V|OW,,J?D|?
JACVI:Y9|6YC+X>6/HO|VRUDN&^W=,_-'PW_P3|_W5T8_M_\$7BS0-
M(R+G3XI|^7S?79(D7_*_,KJO|AU:~^BH_ ^4/_Z: 02D
MKCJ<39K4^*K^"_R_XY3@U|G|3XI_|.'8GPS|^)?&7_@9:~|_R-76>'?^"?OP
M8T?2|2UN= N|8N(/ ^8A?:I<"::Z^2|:9_P" "OIFDKSIYQF%3X|_O_F=2P.
M'7V\$>&^&_P!COX,>%|TWEAX!TNYFEA|@F_:6^BQZ^7,|KG_|^|HUUG_#/?
PL_M_P"B; >\$/_!':_P#Q%>B|4?A7#+%XBH|SJ_-
_P"9M&A37V41^4HZ*!28/|X#_M|*?
N/O2|CZ&N;4V4>79"#Z4N|2|>M+Q2:ON5J-P?3|:3'O3^*3;2L^X|B;O>
MBCCTHY|<4"&;3_<_6EY|!3MP|X'XTQI4|ZC|Z->@G*,=Q|&T5PMY|9/_G7E
MU:W_(X|V5S!-Y\$UMM8_;<^\$^EV=U<6^NW6JS6XR+
M6PL)_F|AYJ(G_C|!_MEFLG|BXN-4|J5H_5HQ"VSZ;FKGO\$7_45|27/
MV3^PO"&E:4/^6_|:;|EWQ_!|SRO+_|'ZCZS3|G)+/U@B,T|S;(X44\$EB3T|?
PKEF_M^.?P|'_^%_!U;_P#Q=?FMX=_9G^*OBK|5|@|#:I9^2'/LL\$LV3=

M8N>V&E_7R/MO6OVMOA1H%_/8S^+H)+B\$<_88)J(?| #AC9?UKEM?
_N^%FB_M9OL5SJGB#SCC_0++R_)&.O|XQ9'^YN-?/P_X)Z_\$<_+7|+_P#?
^X^,UTF_MA|!..?5YK6TEU;QK:6.H?|+Q!9Z:JU"?
H(SQ_J@J>:KV*^M9U4VD)':ZE_MP4*|%):3?V?X>UVZN1%F&">*WAC,G8%
:_9_WRU5,|KZU_X8Q^#G_OI_P"#2|^/5TFC_LZ?##0|&VL+;P-H1_
MHJE!%)E^Y=\$WH?|,/LO|N^(M4U?R?|1|OOI+K|/O_P!9|^OU_MIV/
W|)^\$|HWFB>&M+TBYDA\$!N+"QCAD\LXU?1GY8_M6?","?"
XL7265HJE\ZO_H@?(_=0;^)(M/NJF%D'W\$/R)+^6-
^SK|*V^,'Q:TG0Y03IT)_M#4,'I9IU3.|7^9_*3Y/F7S_M=W|%?=?|6WPA?
XJ?">YELK/|9XAT8G4+!1%^|F"|R0<(|D.@^XGWWG2.L?|B7
MX5'P%|*5UR=6.H^)|FH8Z_6F#|G3&|E^XY?/RM^|"M|RO-^KKVQ|#+)I/,|6
M_='T@|H%513ASFG4M>DM#|ZVUA*6BB@84444 %%% %!1110 4444
 %%% %!1 M110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110
 4444 %%% M% !1110 4444 %%% %!1110 4E+24-
 ^|@UQ/Q*^&VA_%CPO>:%KEI|JM)OF
M!7(E@D!^26)_X)%Y_/!^4UVWWCFQG'ILKXR77PO^&T6GZ1=O9>(I>D-
O!=O9_MR"-,>?*/DYZQO|%6_>|E^Y4S:2NSCQ52E1H3J55HCS/4A_@G-
%+J%R+#QM_M|CLS)^XM|C3/.E6/T9Q,N_ZA5KZC^&?
PUT+X4>%K30M#MOLMI"=Q+9,LTA/S_MRRO_!R-
Q^6!|HK|Z=#^#WQK|06=K|0|"TURZN)(M4&N?VK_IT|E|W7S^
M=)OC^|_>OC;U%>E^"?V|=4|+_#;^R|5MO^\$A|70S26|%U<\$QQ>3L^1Y7^|
(Z_MO_N;U_BWUQ0K4X|JO|A@L9@,'4.K:MU|.1:C|ON+>|"0W/FPQ;X(MB'S_
/5_ZO:K|(OXW^>OK98|IB^;H.E?F;X5
M^'7Q;_:PUZTU/7+RZN|&:XPVO7X,=K;1?V??K|-HX_
M+C51R!711DVV|6N>WE4_::=:G3Y8O9O=|J!DC"/+DYQ7Q*W_4BF.?^+>*/
M^XT?_D:ON#;""M<&WP+^')_YD/PNA_N"V_P_16DHREL|'=C:>*J!5YAO
MRN?GI,?VDV^\$OQ&U_7M&V/+!X?UJ3SKGPV98|OC|XZ>5,D*^6%>27:-F-
OR_M_>^:O8M2_P""C5U<65TMCX%6TF,!\$5S&A_P36_P_16*HU(_#
(|2G@,QHP=.%=M)A_NGS7_P_\$|:|3FT+O=:P:..UKJ4.EN+|4IKDR&Y+^?
Y6P0>*YSPSX\$|/>#ENCH/A|3-',^/_L^SCMO.V_2-CWL%AGA<-
"A)W:'T4459WA1110 4444 ?!|A_P4_|1W'C#Q|!*/@MI_B&MZTB#Q/?
(=8MH(2'YW;_O9.|.:^)?VT-#OK7|NOX"ZW+:M@Z=>W6DV\$%T"N3-
%JA>1/|WRI<1^W|VOT)_A!KHJ-QIQ4.IS0BN=WZ'Y_P#P
M3T>?|EO|OC6/AEH5K=CP-XTL_M-C;7,R2"#R|>2XCD|SYG(1X|N!\$?
8Q3YFW_M|\$9_T!KX8|<^(-
/UG_@J=|/:6QNA<7.EZ#+|I_M/^HE^QW|XC/UCN(GK|G_B
MJ*NMC2FAU%)2UD:A1110 4444 %%% %!1110 4444 %%% %!1110 4444
 %%% M% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!24M%
'A?M|9_"::XLS_'K+'@9!7Y@5^H'|:/_"::XJ_WK+_TL@K|OZ|C&?&?F/\$|
MG|:A%6^\$*WO>LCPW|0/#^J\$VH%GJ5O.?/.(ODDC>L&K>BZ+<>
(-9M=*L;07_M6HWDT=O!;'TYKR;(_OUC2E|.I&;5|R,
(OW;+5GV=K7|54>M?;.^M+MK=QA_M::QOK>+'OOW|Q^#UR=KXZ|_
^(+R|)\8:#|H_X^+BYOM;MX_"(HK7A=|)"?
MB)9WEW:S>|I>:YAE|G_1M+N)H<)T/F(FR0?
|E5I/@G|0Y%|O_A7GB<#U_L2X_M_P#B*_1T:~X^L=#LO_%U;A|7^+?@ZSSY
M9^SP;W;RC_T-?UW5Z-H|H!M'^6?Q|X7U6X|S|1NO?\$5L>?^N:NJ?I7YQ^(?
M^H>%|S|+KGAVYTFXGA^T?9KZQ|J7R@<&3YTK,_LNV_Y|7_
+|5PXC_B+ZSI_M4J32|)6_X)Z&'Q&#PFV&3?=W?YJQ^M?AWXO?"|=:Z7H?
C3PJ|RSBWM|/3|4M_MBS2LY_2-\$.6FOL?C_P#|SMP|11N'J*_"V3P?|+^|Y4?
PA_\$^?M^0*ZX4LGEOCK?|PY#_UHH=8_C_P#|UMP|11N'J*_"63P?
S|WE1|(G<_P#3_MI793P&455>.81_|7_F/_6:E_)^/_
/W>W#U%&X>HK|'9/"=S%5?_A&|2_Y_M_|T77;3R7+JOPX^/W+_P"2-A_6.G_
"?C_P_>G>O|X?G1O7U'YU^"W_M_C>I?|/_G_Z+JO_&7<_P#/G=?|^*ZH|

X.7PXZ+^|_.2+CO G|A?^!?! M/WQW+ZC|Z7 MYL=+N)(L?< UB)5_ZL89?
|QL?N_^V+CGJG|%. _S_. ?N;N'K1N'K7X_^9^T MW_>^+?YZI2|_ -IS^|H6_P
|4KD_U: ZB8?>=2S=/_EVS|?|P|:-P|: (#=^ MTYZ_%S_RJ4N|HWU^+G_
)_5*7^K3_P"@F'WC6;7_.7;/U^W#UHW#UK|2M0^ M-WQ6T>^N|"
<^,K2ZAFDM|BVN-9/OO^7OJO|+|^ ^)O| T43QE_X. M|S_XNNK_%1K|*T?
Q.?!A (?M|N'K1N'K7XA_|#0'Q. Z*+XS_ /!Y>?! MQ= '
T|!3O^BB^, P#P>7G_,75?ZG8G_G|!1_VY2_E9^WFX>M&X>M?B%_ MPO|
^)W_ \$47QE_X/+S_.+H_P"%_P#Q. Z*+XR_|EY_P#%T?ZGXC_G|#[V
M'|MT_P"5G|>|AZT;AZU^ (?|PT|!3O| HHOC/_P>7G_Q= '_#0'Q/_P"BB^,
M_!Y>?_%U7^IN(Y_P_\$.SNF_L_,REK|0O| AH'XG_|11O&?_@|O|XNN_
M_P"&|_CG_P|!#X?| P5:~P#&:PJ<(8N/P58/|_|(:SRA|J+1^OU%?D#_P_
MW_/_H?#_P""K3_(S1_P-W?'+_H>S_P""K3_(S4_P"J&_GAI|_/D3
M3^VL/V9^OU%?D#_PW=|'QS_Z'P_ ^"K3_/XS5?ZG M8_|GAI|
|_P#D12SK#1^)/|C|?:*('_AN|XY?|#V?_!5I_|!9H_X;N^,7_0 M|G_P5:~
/_&:C_5'&_|/V'WO_Y\$?|M8;L_N/U^HK|@?^&|OCE_T/9_|%6G_M
/_QFC_AN|XY?|#V?_!5I_P#|9H_U1QO_#|A|H_ ^1#^VL-V?W'Z_45^0/_#=
MWQR_Z'L_ ^"K3_P#XS1_PW=|/^X_4&BOR^ M_P""FOQ3_P"@%X/_/_|_|
DFC_ (>:_%/_*7@_|+|+O_P"2:7^K&9?R MK|T'|L87N_N/U!HK|OO^'FOQ3_Z
7@_, +O_Y)H_X>:_%/_H!>#_|P_N_M_DFM/|4|U_Y|K|U_F5_:^%|_
(Z@T5^7W_#S7XI_P#0"|" /@!|=|R31_MP|U^*?|T O!_P#X 7?_,DT?
ZIYK_S|7WK_ ##^U|+W_4&BOR^X>:_%/_M_H!>#_|P
N_DFC_AYK|4_ ^@%X/_P#_"|_ ^2:/|4|U_Y|K|U_F'|KX7O^!^ MH-%?E|_P|U^*?
0"|" ^%W/_-'_#S7XI_|+P?_X 7?| |DT?ZIYK_P ^MU|Z_S#^U|+W_
/_U|I*_+|X>:_%/_H^#_/_P_N_|Y)KM-/ ^"IEW#;V ML5_|
|6|N?)C|^ZMM<|J+S?^6GR&%_+YS_&X_P|JL)<,YG'_) =_BO|,TCF MF&EU?
W_,0VBOS^X>JG_*);_P"5W_|EH_X>JG_HEO|Y7?_+EK+_5S-?| MGS^*_P
Q_P|J83^?|'_D?H#25^?W_#U0_P#1+O|RN_ ' +1_P/5#_T2W_R
MNG_Y&JO|6|U_Y|C_',FF\$7V_P?^1^@.:,U^?O_|3;_HEW_E<_P#N6C_A
MZDW_ \$2|_P_KG_W+1_JWFG_/G|8_YD_VM@_Y_P_#|LT9K|_?^J3?|1+O_M
"N?_I_ T2|_RN?|W+1_JWFG_/G|8_YA_:V#_G_0+-_M&:_/W_AZDW_1+O|RN?
' +1_P/4V_Z)=_Y7^|EH_U;S3_GS^,?|_/H6 MP?|/^!^@=%?
%NE_|%./A|)86TFI>'O%%O=>4GG0006|L:R\$?!)YR;|?|B_
M|M7O^'GGPS_Z%KQE_P" =I_|DUQO),O_.S_|DFE_8N8_|^)?<'|H87_G
MXC|!./3%><_%CXQ>\$_@GX:N=5|5ZI!9KY4C06N0;J^*G|D49.7/SQY(^5=V6
MVKT|"_X>=?#/K_PC/C'_ ,|3_Y)KXF_:8^/>I_M!?\$Z|U=C=VGAVS_<:3IE
MR<_9XL?O)!|_C?|H??| |NYU1*|;+.&|9B<1R8F#A"U|LX|5FE&\$/W4KR/IV
M|_X*D0V|H>06/P|N;ZR|V007%QK(AF: + ^%FC\$#;"?|H_A_M5|M|OVS!/GOVU
M8:|!#|J|V>#)_|.U\$H?M|P?-2VD1_WFS_Z|C|?FV_>V_DA5C3|0N='O;34;_M"
|NK2YAFCN+>ZMY_*EMYD_U:_%/_H!>#_|P_N_DFO@H|+YG)-|B5N|E_F??
VOA>Y^H-)D>M?D\$?V M|_CF?^9|/_@JT_| ^,UQ^N_M-??Q!K%U?3_!&U_P
^7H|@OI+6+^Y_JX=J_M1_|?%=|\$.8_P")4BOO_P_CGEG5#
|6\$S|K=P|12;E|1^=?BG_Q= _P"-6B_|MS|XZT6*?_H|O|6"9(|
@2>9Y_8|H|OYI=S++#YX^P+)?1;?3S(4=<_P"S MG=|5^>O_PA|<_ ^A\$/_(-
=/_|CU=Y_P_R_BG_P|!SPA_X'77_P_C4O| (MR:F_?QG-Z?
TQ/'8^>U)H^G_\$G_!0KX+Z'8M+9;GJ7B&Z|S'V33|,DCDY_CS. M(DQ_P+=
|5SO_|H^&G;PSXQ_P#_T_ ^2;|G|_|\$MM= NK'SO\$?CC2M*N?-S
M|ET^QDOXO*|/,D>+_P!_P"!5TVA?
|SM; &TUJVEU;XB7=WI^/WUKI^DQVTAX M_P">CS2_JK4_JO#-+3VTG|_
_B4ZF:3VBD5/^'JA_Z)=_Y7?_N6N4|2?|!%0_M/&|S=>9X=)|:|IEMY&#:ZC-/?
R^;_OOO%_Z!_P_"KVG_ (=A_#+_*&QE_X M&6?_,C5WW_#!OP_P"A'8_|O:==
/_CU+ZYPUIU6'D_O_P#DA*CFL|ZB1|:: MY_P4B^+.K:/=VMO;Z'H|PP-
0T^Q<26WO^ ^FE3|TKDO^&|_CG_T/A_|!5I_M_P_9K|&?#?
|*/PA|+6#6EC|.|"GMY)C.6U"#|=(?^!S|WQ_L9VUU&B_!WP!X M9U2VU32?

WA_1/3@XANK'28(9H=PVG#HM2L[R>GI#!7]?Z8_/[QL]Z[1^/W_M
T!|3O^BB^,O_!Y>?| Q=:&K> ?B|/3/LFM:MX<|>>+O.AB^SZE/8WEU^Y/
MSQ^5(Z-^|_>>97|6;5]!^5+M'I5_ZTTZ>M#"0C^/Z(4!M4L|>*4P#|?
Y=A*2|KG_OBOUOP/2BIEQEC_L0@OD_|RXY+0^W)L_+P#X M=E?
%/_H.^#_/_N_P#Y&KM-/_X)9W.-4U493R?|)MX|#[@??|W>9_.)_P" UV6@?
|\$_A5HNL6UUQ"&7Z^3%&_P#X_7UO17#4SS,:CNZTEZ:?
D=\$,NPM/X8'SY_PP;|_"^A'; M_P&U_|
_JZ|3/V:_A9IEC;VD7PY|+K#%#"OVC2X)Y"\$ S(Z%GA M.=WM?
O7JU)7FRQF*J?'5D_5MG5&A2C|,5|QR/A/X=^\$_K71|_|^'|)|.F|*?:/I*
ML8|7S|N=GF;\$7)&|?4UU.W'3_"G;?84?E7*Y3EJV.**CLD@&/2EVBDY|!1
MD^HI6;W+|6+QZ48/84|BDVU/*NP(,TE)|O:CFBP,3GTH_4N5|OSH,B^H_.B
MZ%IT'?I3+M#|+6:W.MZQ9:1:22B\$7%|<)%&9#T3+|9.#6'_PO/X< M#_F??
'X:S;_ /Q=5ML9.M".|E|YWU%>&?| #:/P=_Z&UO| P5WG_P 9KD|= M_;
|^&6FWMU;6|GK^KV|/_+U964?E2^P\$LB.?^_:P|O3|G(|PPB_Y>Q_|"1|/
MTE?('B#_(*(>%|2Q_XD?A35;Z|#[@"WU":*UA|ON=Z-+_P"@USY_X*22'_FG
M2_|@|/_C4>W|SCGGF74_BJK|?|C|@I*_T_|%"OB1_T?"X^D%Q_|>KF
M/\$'_|OQ7UB|6:SUFVT"%8|_4V-A%+&?^FA|T2/_./UC|I'(^ (L%|B|^1^ MG-
&1ZU^4/B+|J3XK>)|K|I)?^.|KJ|TMO-|_|0/+L)<>GF0HKUE:A \$ _XJ>(KR
MWL=,|6^,=7U&X&8K>QU6|EEQC?DOH_I1|:AV.:7\$V'^Q3D_D?K@9\$7^?(?
G7*_M:|120"GA6Z%GK?B32M'N9(3.+?4+Z.&3ROP7P|= />ORM_P"%)?;_H1?
%'_@MCN/_ (BNLT_|D7XO:A:VUS;>\$3|GEB|_2+V"*3+|@COO0_|H5|:?
|AD||Q4_M_APLOZ^1^@NL?M%_# '0|*YO|GOSH/CB:|MX=6U|0;&P_?
3V;3W4K'_<9(|_T.H|K6_E'_:&:U-L,E|O^">P M'_@H9|/>VC>)|/_:W_|
C|6IBYGO|Y+:02?W?+_M1)<_7=6=_P.W9O^BAJ/^X*?_DFNGTW_
_OZ^"DM(?|0|OZ|=7(BQ-|/|+;PQ_MF3N0GE-L_P"^FJ?WQ7_"Y4Z)'%:Y_P
%&-7FM;N+2?|5I8ZA_P N|Q>:D|U" M?K&J1_HXKFS_,%"OB.?
^81X7_|17'_OZOH'0/V\$OA9HOVG|:::IX@|XY_T^M|OR1Z?N1%D?
|^XUU.B_LD_"C0+^" ^@|(|VEQ"/MT|U\$/^32,OZ5?+5|C
M^JYU4WJ|Q)J|/9WQ?O-0N;B'Q'IE@EFP+:WTJW|JV_Z9_.CO_WV|QG_#DK)
<7/?\$R_KYGY M/VNN?%+XH6-
Y807GC#Q7IG|LW%M!/=WT|)|Q#+|W=/E_P"N=16/P)^ (E|>V
MEK!X'UT7,TOD_P"D:7<0PX?J?,-D8_WZ_7C:OH/RI=H|*R^IK^9EKAU/XZ|
MF?EL/V-?C"W3P>W_(|3_X|76Z=^P#|1|JUMY;BXT&RGDA_U-S?S^9!_P|;
M_DA=?^ ^K|'*V^JTC:/#>_"^W=_,^!/#O_!.KQ)<_:|=|7Z5I0_Y8?V=!)= M|_|
RO+|?KH=/_X)R0QZA;?;_"VRS\$G|^WM|+|J5H_19#,VSZ|6K|;H
MH^K4^QV1R+_+_EW^+_S/E?|X=Y_#KOK'B?_,":?_XQ71Z/^Q^)|+L|6WN
M-"NM5FMQ@W5_?S^9-[GRG1/_!ROH6DJ_84^QUQRO
Q_Y<02U_F^^Z.,>=OV?1:Z&S^#?@'3KRUNK#P/X?LKF";SX;FV
MTN"*6&4=) 0@(/O7>T5MRKL=DM/I*8PW4G%+2T)Q28|J=10 S|J?UI-
H|ZDHHU C7GD'(I&C^|7(
MJ6B@5M&AGE+Z4>4OI3Z*GE0R".-8OE4=:DS|QIU+5\$|J2204444%#>G6CK
MU% @HHHHH&%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444
%%%%%%%% M% !1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110 4444 %%%%%%%%%!1110
4444 M %%%%%%%%%!1110 S./PKXA_X*2?Z|X?'U74/YVM?;Q QUKR7XW?
L|^'OCP=).NW M>IVATSS1;M|L<9_>|^=Z_ SS'ZUE6A|2-
D|'DYI0EBL)*C#XF82_MG?"#: M|/BM|@8V_P|F7>/_ \$37Q|X"|3?#_|
VBO&>O|C<&|)S7EY?Z>;BWGFBBF MF>|C>,F-\$W_<|W,;IM_O5|)?
|_|OA|_T&/\$W_@1;_P#QBF_|_|?AY_T&?\$O_M (\$0?
&*YVJLOBL>'6HYKB'!SA%|VI|0^#ZX">*CC_+!=Y_|&:JQW;E&
M3|U|3>./V5?@-|XW/B+OSJ>G7:0I|_9H|ZW>Y;-GV>8(%AWR#/&=AK|:CQ
ML&.E=-/F:/;P%3\$RE)8FUULD2"F-CO3Z23_5MZ XK4|9W2T/*?"|1GP|^&NM
M-HOB+Q"MEJB1),8(K:XF(#9_)M&V_|UZPQ^VA|'CU|6M_X*KS_,_U|D_|L
M^?!33_VA/B|XV_X3C5KK2M;LY?M\$UO;^7;7-Q_|C^?)Y;I|^"2'YTV??DC^Y

M_7?!.|AYWUGQ.?I<6_P#|8KC4JSZ?B?*T|9FF+_>T81Y7M>Z?SUT/9_AK
M|:!/WQ>.I#PGJG|J_8A&:@BWFV|J^S_%B+U|L|/200.OTKR;X(L|^'/@:
M=5.@WFIWC:GY0G;4)8Y#^ZW|;\$7_GH:|9'<8KI@^97/H<.ZWLT|00>?8?
11 M15'4% %%% !1110!|W?MC?LMV_P"TMX M+;3VMK3Q=H|Y;2:FZN)
(|7:|D?VB M.78C|-"GA=V^-/FV|MW DG_#5W|0_@7PR?#NN_
#5O\$7BVQM/(.N:>)9K&>; MR_W!?!%'B MKXF_%B<70Q\$|3?Z,W|_S9;: 2#?
YCQOY)WF.'9&@Q"D2*I^=D7ZY_BIU%9RE MS%1CRB4M%%24% %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 M%% %%% !1110 4444
% %%% !1110 4444 %%% !1110 4444 %%% 'B?|7&B
MW_B#|G|Q3I^E6EUJ6I2FV|BVLH7ED8BZA? 1>20!GZ"OSH_X4O|\$(|!'B?
M_P\$EQ_|17|!8SVI-B_W1^5<|6BJCNV?/X_*(8ZLJKE:RML?C_||*5^(G_0
MC^*/_!)=2X:P|.I&?-L,7:J@8I>/:G45UV1|CH1^7_G_H|L? MW0?
P%24M5<329RWB+P#X=|7+; '7/#FEZP8?|2-0LX|CR2WWL;^GX5E?|*+^'
M'_0A^&/_36_P#|17?4E9|J|+|C%T*3^RON/,-8_9R^&.MV-S87'@?0X|>8 M?A
8K-+60_|#BVN/P-KW.BE|.)D|AWO37W'A M?_#%OP>_Z%-
A_P!Q2|_ ^/5Q1_P"">?PZ_P"@QXF_|";?_P",5|4TE3|&'8QE MEN\$E_P
NH_=M9|3?| @3;_ /QBN5UK_@G+;27TLFD^.+BVTXC_Y
M+>_TN.YE4X|.CO_ ^@U|ITM.5.,E:2,993@I?|NSX>_X=N2_|%\$7_,\$I_P#D
MFN?|0_|!./QA:W2_P|A^*|*NX?)YN;V| |:02^NQ\$DX_X'7Z T5E+#4I?\$OQ_M?
^9SSR+R^P?G9_P|U^)'_06|+_J_P"X_P#C-97B3|@_XH:+8-/9)IOB&X\$N M?
LUA?>5?*^FG|Y(DS_P.OTGI:4<+3C|.AA+AW_|/|+^|+_AC/XP_P#0G_-X M-
+3_./54U'|D3XOZ=:W-S<^\$?| 1XHO/_T>|MY98+AG!Q^"4E|S|?O|
A2OQ\$ _Z\$?Q1_X)+C_P"(K:|. ^" _C+X0^U_V%X>|= MZ3YW-
Q|@LKNUL_9_J_N5^L^T>@HVCT'Y408/^9F:X;A'_E|(_'|_(75|1/^ MAX|4?
^#NX_|BZU= _:)^)GAVY:XL?'JW=PT7D'|;<&^CSZ|)=R_^|?K7Y: M_P!T?
E08U_NC|JS^K3_Y^A KYB7#|9?
|Q+^|_@GY7=._>*K_P#"B_AQ_P!""X9_|\$UO_P#\$5?L: MG_/QD_V/F|A T\$L^*O|
AX3|1_|H\$>%? _>?_X|1_P|^(_0(|*_|@//_M/'J^M?\$7|+_
_*O%'V87Q@72;80DD&P#67WASGR2F_Z-65_PQC|/A H4F_
M|&EY_P#'J7LZW|_|_R'+9M';\$K|_ ^>&Z?_P4X*>2^S_OMJF_X>1-_T3E?_
=_M:Q^Q%|*4L|FWM|"NM*FN!C M|58WTYDA|QYKLG_CEJ6-X7(^SZ?
+#=1>7V;>|1?^@UK_|#POX=|0%|2 M_P#@/_!^J.I?
|\$/|!36LW|G^((=M;DQ8AGGFMYHQ)V)3REW_|J+7+_P## MMV;_
**&I_|@I_|DFIYL1W\$ _P"VX;1BSTW0/VZOA5K?VK|;9YP|?
W)EP|/::WO^&S/@W_-#6W_@KO|XS7BG_#MR; HH: _^"4 _"37 M(7_
3Q|?QWUV+^O!H5U;>;_H|U7Y+^6?^!O5>TKKH4|5GD/BI
M19|3: + ^UG|)|>OX;&#Q=;)<3#C|=;SVL9_|:31JOZUU7_"|OAO|_|#YX8_|
M!Q;_/Q=?%7_|X^)'_ \$%/#'_?^X_ ^,US?B#|B'XL:3>+%9Z-:: "T'^NL M; ^**,:?
+3, ^:8W_|9T_BP|S|Y_X7E|-V_YGSPQ_P"#BW_ ^+I=: M^\$/P^|3:IK*|1?
LN_%7PS9FZO|P-=7=MYGD_Z#Y=_+M|?+A=GQ6L,16A|E_>3_M
&SBE|>%;^1^C'_#/OPJ_P"B<^#_/P1VO|+12_|L|"O|Z)QX/|!':_M_\$5^8O|
PI/XB_|0C>*/_!?'SX1KY?|_2+_AGKX5_|\$X|(?|@CM?_B*/M^&>?
A7_T3CPA_P""_U_^(K|Q?^%V_\$;_*KQ1_X/+C_.+KHO#O|4GQ6|V
M8M+#QS=7=MYGG?Z?Y=_+M|/F1GI?VE4_F?
XA#B+"2WHM?)'Z_|_|_"S_HF M_A#_,\$=K_|\$4?|_|_"S_HF_A#_,\$=K_|\$5^?
G_#9GQA_Z'%O_!7:?'&: MT?#_
_W|!6=)NVEO=:MM>A:#_4WUA%%&/^F@|H1O_P"/TO|3E_. _Q-UQ!E|^
MR_N7^9|Y?|_|_"S_*)OX0_|\$=K_/\$4?|_|_"S_*)OX0_|\$5K_/\$5|9?|
M/"OB/_T"/"W_'XN/_CU26/_4-?QWUH;|P_H-U;>;_I%K;6|40E>OF><M_EG_
(_|/ ^TY?SO|3?|MS+NW_DK/LG_(9Y^%G_\$3?P?|_ ^".U_P#C='_#
M//PL_P"B;^#_/P1VO|_|KYF_X>2R?|S\$Z'_(_N:C_AY(P#T3I?_=G
M_P"1JU^O/_GXS=YME: ^TO_7_D?3/_#/7PL_Z)OX/|!':_ \$4?|_|?"S_H
MF_@_P_\$=K_|17ANF_|!0OP0|H#|O|_#VO6ER8LS0016|T8E|@/YJ|_/OE

M:O?V/#AW T!O\$W_ (#V_P#|>JOKS_Y^/IS?Z_EW||Z^1U^O?L5_! ?Q!J|^
MHW"@6T2ZF&#|AN+BUBZ;?|7"ZHO_'S53_A@OX&?|]"2?_!K?_P#QZG:/^VY
M)|4LK6YN-?NM*FN!DVFH6\$YEA|CY2.G_ (6E_PVA|'?^AN;_P %5Y_|9KM6
M:8JUEB)?^!,KVN6=9P^|&7_PP7|#/ ^A)/_@UO_|X|1_PP7|#/A_H23_.#6
M_P#_ (|73>'?VHOA7XH^TFR|<:5;>20"+|FQ^|.,><\$W_5:Z+_A>WPY_Z'WP
MS_X.;?| ^+JO|2QG_01+_P "?^9K'ZA+X>5_<>;_ /#!?P, Z\$D_ ^#6_P#C
MU'_#!?P,_P"A)/X-;_ ^CU>HZ)|6/!'B*^@T_2/%VA:K?R|QVMEJD\$LC
M<;N\$1^>!78|AZC|Z?|H8W_G_ " |"9O'#X67PQ1|^_|#!?P, Z\$D_|@UO_M
/X|1_PP7|#/ ^A)/_@UO_P#X|7T")%|12|OOH_M"?| / ^?_ (\$RUAKZ"&EX|*?
M:;>.ZUY?^!A_S%|4P_|S|7W(^??^&#/@5_T(I?^#:_ /CU'_#!OP*_Z\$<_
M^#:_ P#CU?0&#|4<4_|3QW_ / ^7_@3_S\$L%A?^?2^Y'S_ ^#!OP*_Z\$<_|
M@VO_ /X|7)^)O^""X/*V_9-/OO+%G_GIF=)7_|'MOM7U;M_MHJ3=[5<,TQ|?
^7|O_G_)B^HX9_|NH_M&1ZTO|;S+_G_ " ^|J6&_E1??| #L/X_M9_|OR^,O_
RT_|D:C_ (=A_#/_ *&7QE_X&6G_,C5|A8-)2_MK,?^?|OO_M#^S|)_S|1|??
|.P_AG_T,OC+_P_#|+3_Y&H_X=A_#/_H9?&7_ (&6?_R-7V)1_M2_MK,?|G_+|Q?
V?A?|GVCX|3?| \$N='N+X2^'/'>J:1:>3S#J%C'?2>;Z^
M8DD7_H.?|JOCGX^?|F|^_O-U3PE=W5QJL,,\$50#J4UG|F\$|3Q|_#(4WM_R
MT|V|_WXJ;_%E&*|H^_GP|^+?'|PW;:3XEMID>UF|ZWU&Q?
RKJWR07|MV5N_M'9""O_) %9?=ROB?%8?
\$*6+GSPM;4|_ %933J0;H*TC|8**^S/\$G_!./QK
M:W0C|. ^+O#^J6WD9^U:A%/82^;Z|(TE_|#_X#7O?P#_8)|*_!_Q1:^(M8U>Z
M|7ZS82DV1FA^S6D|^38X@WOF1,':^|;R/DWHCU|UBN*C)R?:UCP*64
MXF<^65DO4@^\$ _P"P%|,MA_Z1_PEOAR|U7Q'<017%_|:M3D'V:9T3S+>|/.
MZ)Y:./A;_WWZUZ/X;_8Y^#/A: ^ ^V6/@+2|F:6'R";|H+^+&?
^>#D4H7@U^1U4G4K2?:F_|S|2&#P|5|*9YW_PSU|+1_P_TW|'_M_/@BM?|
XBO0=JCH%J3)HS7GRG.7Q.YO&\$(_#%+Y#%C7^[06_|XI<'TL.?:IM-
+6VLA>:.*=D48%3ZCV\$Q2<4?C1CZ460)ASZ4KA|WXR>|-
O;NUOO&^@65S!-|GFMKG5;>*2&5>L9!<\$'VJ?1B)_0_>W_P#CU<=J'_!1N""_N?L'@?
[9;+)^XN+C5/*E:/U;_0ML^FYJP^L4_M^YPSSG_4_BJK\?| (^VLTm?_7B#_ (**>);C|+_8?A+2M*&3Y_|
+ \$TEWP?N_M?<|K9_X_7/:E^W| \1|RUN(H+?0K.>2'B:WL)_ ,@_Z:?,/Z_|I4_6J7YG@N|Z'D
M^6XBD^;NGS?|'_V=/B;XCNFM|'P+JMI<+ #YY^VVYL8\^F^7:F?:K|0+I_M\$F6?5_|EWAI/^00_20_
(7I\._E_YG|PR?|_N,6_P_77+ZU^UM_*-|OYK&?_M0=;R7\$(Y^PV|JUG/^!P0LOZU|ZZ=^Q?|8+S4+;WF_.?
9;>6;|)N9|5M_*MO_|MII|CN_|WPE==_P|W^)'_05\,?| ?^X^,U/M:K^R2LTS2IMA|'T3X@;_F^%
M&DV'FV.I77B"Z\$@^V6PLGCD/^WF;RDQ_P*N3U+_|@H5X(6TF_L_P|KUUP+^/_M5:70>'_ ^6IBX@L+%+:02?
W0,=Y<_3;3YJ08/:YW4^Q&<_M?""D">ZE8_P""KQ_ ^M@5|_#_P_|_AWWUGO-_X\$V_|_8KM/^&+?@_ -
"HW_@T0/_X|1RU>Y/U?_Z_MG_+V*/DOO'^W?|4-:L&@LGTWP|<&7'VFPL?,E'_3/| \J9_X|7/?|-E_&'_H
M<6_|%EI_|9K|YT?|G/X9;_'8VUA;'^-#DMX1|GVZR2ZD_|FEW.?Q_=#H/PU\)
M>;_HWFb^&|*TBY>\$0&XL+&. &3RPQJ_S%K*LSG0B&C|K0^%V? \$4_M|SSXH_|!Y7%_J?A/QAK&HW_Q+<7VEWE?
KD_M(U_NC|J7:/040JS_)A?ZNN?|; \$2?X'Y0>'?V7/BKXFLO=6'@:ZM+;S/)T|
MR|'7;Z^7,Z073^'0V(/BQK^VT5YHMMH\$'P?ZZ^OXI8S_-,QY1D?_P_?Q'_Z#^A7_+W'_QBNR_X=MS?| %\$7_P
\$MI_|DFON"BJ^K4^QUOR#|X_8_%YGO_X?X)W^%|2Q_XGGB05;Z|#DFXT^&*MUA|OL-CK+_Z%6_H?|
OPTTV^MKFX0-?UBWBZ6M|>QB*7W)B1'| \WU7U#25I_M|&GV.N&4X*G|_) ?U|SPW_AB|X/?| "DW_(-
+S_X|7:_|*)^'_YD/PS_.":_MW_|B*[ZBKY5V.R.\$P|/A@E|CG_#0A'1/"MDUMHFCV>DVDLIF-08V|<49D/5
M|(\,E2459TQBH_"AGX8I>/6G4E|6PS:*3:/3|:DHIAKW\$XHVBEL:0\$M?Y4N|W_2GTE.XM1.: -M.HI#"BBB@
HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** &'%8^N;|I_M?AW3|C4-60K;2=/AYFNKZ9(H1_#R|'_
_&MDU|B_MX?"_07X^L_"FI^&|*N|7_MM|+6| %R+ # \$D@|WR-A\$?WY|
5G|E14ERQNCBQ=>:'HRJTH|S70T_'|>G@;P_MZDD^ANWN_%EUY;_%MX?LUMRV/++R?-G;S|J_-;/|S^_0V0?
BMXZL|J2"/|AW_M3?W<\$Z\$#80W0|QT_?|_S0&|^7TWIN2/_?K%^!00_ ^'0@C4MWC3X?G0#YDD_MYU
3"7R(O+ \M\$^R0^ZD^?_EHY'^M_P|B08_VI0C5X^ ^)OP- \.V'|@J|59|/4K_M,G21|JEEH0(G3RPF-
GR'+ZWCNA;6X|ZY,+GY.GR1EXR)-^|ININ3KC_M|\$ (5"QAQ^7|Z?%?|0'QDU_Q+ *?#MQHUU"/M|N;_M""Y^RR?,-
GF2RET2.>;^XG_33|_SN_6_|*?|_VI?^?KQ1_P""3'|_E5R?PK_:
M.L|/C|0/%6H^\$ _#UU=>\$|4|/G0;Z^CBE@ "2?(_F; &^Y^| ^3_*_,|[-]>PG_M_@I)+_T3I?|_P='_
_1J|F,J5K|S/S2B|NDI206(DI/>S=ODK'IW|)/@WXJ>_M\$#XJ'Q(N=1NEG-0_
&?|0U7|=|TS^9CYV|0/[KZU|&X&T?-TKP0|FK|I|0V@_M/^\$AW>'1X?|_ [+^SG_C|^TB;S0,Q_
N/|7^M>YC&WIO7IT|)(GW6!|D|- 'V,G_M*'=|DM+24M6>D%% % !1110_4444_ %%% !1110_4444_ %%% !1110
4444_M_ %%% !1110_4444_ %%% !1110_4444_ %%% !1110_4444_ %%% !1110_M4444_ %%% !1110_4444_
 %%% !1110_4444_ %%% !1110_4444_ %%% !1_M110_4444_ %%% !1110_4444_ %%% #: *6BF*PS?:

>EVGUI]49'^-Y4^E MIW\$-VBCBG4E(8G%+NI:2@!G'M1\U/HIB:OU&X'K1S29_&G4M(8S:3:0<#J MDI*+
/(4CV [((4NT=U%244"LNQP/ "C/AS -"!X8 \SU0_ /\$T? *+^/_ M \$(7AC_P2V_ ,37?45/*NOBJ%+^5?
MUB/_ &SAD5:J? \,7 IW_ %*%0 !K>? \ QZ0_8 M2^>M?90L=MJGA\0L3_H%[YGG#T ?"7_P!S:;R?^!>?
PZ_Z#/B?_P " +? \ M^,5]445/LJ?8YWE6!E_RYC[Q\?>(/!^= AB[LT\ B1^*]5LKS>" +C4(8KJ'R
M^XV(L7_H58/_ [:D_Z**0\ X)#_ /)-?;U+4^PI]CGED>72_P"72'_ #/A MC4/^!<=[#9W)L?' ,=W-Y!,-
M<:;8HQ+V(?S7V? \ ?#5RA_X)Z_\$8?\QCPK_W M_N/_ (Q7Z)45'U6CV,9\Y?+!'X0_ ,.P \ !/7XD? \
06\+ 'M0*+.XAG%Q; MW50I=0%+;S)TD^Y6EXB\ :?&;P? \ 9/[=1>/-)\ [-CW^WWMY: ^?L_P!9]^OU
MGVCT%)M7^Z/RI?55_ ,R7PZU_#Q\$D?D!_PN[XC? \ 0]>*?
_!YT^UMK:W\7'[/%Y'^D64\$LN4[AW3>Y_WZ_5/RU_NC\JO]:T'2_\$_GW&GZ_MK86NK:~-Q-
:WT*2PG^+E&' /XT_8S_G)60XF.V+E_7S/S/_X;+^,/_ 0XM_P"" MRT^ ,UT/AS\N_P"*&BV @07TWO#<"7'VF_L?
+E/_ \$S_ '+0)G_@?=? "B0_MAS_T(GAG_P_\$U0_\$4G_"B?AS_T(GAG_P_\$U0_\$5/L:0\PUE.91_YB6?%
M7_#P?XC_ /0)\ +_]^+C_ ./5I>'_ /@HAXPMKH_VYX5TN[A\GBVLI7MI/-]- M[0]Q_P_KZ/_ .&+ @]_T*+?
^#6\ P#CU' _#%_P>_P"A1;_P:WG_ ,>HY:W< MS6!SE? \ +Z/WO_ (\3_X>22_1\$Z7_ , '9_P#D:KNC? \ %&
[.2^ACU7P-<6NGX^ M>XL_5CN9%..Z.D?_ %*767 [/PZO_0NY;?4=?S+[E_D' _#PSX>_] ;Q+ P"
MT' _Q^E_X>&?#W_H#>)?_ &M_P#X_7-: P#\Y=)N;K_ (DWB^>SMA\$! ?V* M7,AD]? ,1XL?] \UG? \ .VY?
^BBK_X)#_ \)- ' [L4ZF=Q^ROP_S;/_&T/@]_T_M-S?^"J\ ^,T? \ -H? ! [H;F_ \%5Y_ \9KY_P#\$7_ !.77+>R/_ \
8/B^S0+CSN+;_ M_LY+6+R03>CR_P#H%8'_ [U^(_ \$%_ "W_?^X^ ,U7-5[">+SM? \N8_C_F? M8>C_
+1GPQURQMK^W\ G\R? \ Z9_ /\$B\ [;URG_#&00A_MZ\$Y0_!G: ?_ 'J7M:0\H3S7,X? \PUS] (0#?CSP_P" ,!
<=.08[G_MR2WW,[#_ #KI"Z^H_.ORY/[&WQ@'7PXJG\>%E_7R/U_# +ZC\Z7&[T3PYXRT>
MXFA\@W5C8WD4HA'_/E_ (E5M9^)0Q3\ .WEQ8:IXL\8:1J, _S-;WVJ7<403?Q&[M^E1]:7\K-
(\1/E0/_#R1^MKMMW'/_ '60R0^+WQ< \ =: \5_&EI9> .==M[; '6;R_M&WMX-4GBB@C2=QL^_P!<5S=C\
<_B'9WEI=0^ -] =-Q#*9L7_ J7\$T_ %ZCRW?9(M/[^N2UK6KCQ\K-UJM]=BZU& \FDN)
[D=!* \F^3[E<]>LZB2M:QX6:YP_93@H1_M<#I?^?U?\$/ \ Z'CO/_X_ [C_XNE_X77\1/_^AY\4?
^#RX_ ^+KCJ^Y0:32Y4SYN_M_.*KK[; ^\ 4K]E0Q)JOC3X&^%=5UR\;4]3DCN(9KB8_ .^RXD12? \ (@"#)ZMC)
MKV/S%+;\$_A^=?D%X_ \9?\$_-0LOA_PIXA\3G_6>1IFDWMQ[0]Y4:240^+ , *5_M^(G_ \$(_BC_P27'_
17HQKR4; \MS\JCGM2-&G&G1\$0" MMV+/6 \$FEZ16. " ^;_ I[USVL?M&?# +0[&Y0[CQOH*7+]@C000_ [] =%
MX= _89^+&N?; /MUCIGA[RFO_I] \) /M^0^Z^W(_P! [;3]M5_E-GFV93VP[/KW_M_ (;2^#_ \$-C'_N%WG_QFN-
U#]0_ . '-GJ%W%;;?KMW:PR8^V6]K_ (IO]M0\ MRN!_OH* \;T/_ ()W^.)KRVAU;7]!L;_ #]]<69GNI6/_ \ N;D?
H=2/\ @FY M_P!%#7_P2G_Y)HYJ087UG_ZG_+J*-'0!_P_%&=)MKS_B2^\$;B\M3%S/?WJ6T
M@D_N^6B2Y^NZN?US_@H0J\UK=Q:3X*M+&_ \ ^7>> \U) [J(_5%2/] '%=QIO\ MP3U\ \$+ :0_P!H>
(>=NKD18FG@EMX8S+W(3R6V?]] -73: !^PC\ + - %U?; ; ;5/\$_M'G\$'_3[WR_)&G\DI9'^_N-
'+5[A[+ _ZGVXH^?/^'^A^Q(_Z! ?AC_ + \7'_ QZ_MN1U^]M#XP7FH7-Q#XC^RV\LV!;0:5;^5;? \ 3/YT= _ \
OMZ^T+ ']C_X2:9J% MM>0^\$D:>WD\$ZK/>W\$D>Y?5'D* \ \#!KL_ \ A1/PY'_ ,A>&C_P!P>W_ ^ (I>R
MJ0[1/]F9I4WQ%CV/\$7[3'Q5\5_9?M_CG5+/R2#_ *!_H'W^G^IV^9_P_J-K_MKGQ3^*%C>6\$-YXP\5:9^/_
Q;03W=]#R? ,0RQ_ -W3Y? \ KG7ZPZ;I5II-E:V= MC: +;6L\$0A@@A79'#&H_ "8'3T_ "M+80\ _='Y57L)=9&DR
M>;_ ^P\E&0_@]=1X>_P""=?B6X^U'7?%NE:4_ ,N/[ADNN#]_&_R0+ _ \ 'Z^_ M:2M?JM+L=<=>'<#]I_ , ^)=/_
_."!]N_M0.() - ^#??='&/_ + [/HM>0T50RKL=D<#AH?#37W'!V7P: \!Z; >VEW8> "=LKF_M";
[1#31^%/HIA;S\$XHP*6EI#(_RH_&I^2G<0GXT8-+2T!8****0PHHHH **** "B_MBB@_HHHH **** "BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_HHHH *** M* "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH M **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_MHHHH **** "BBB@
HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "B_MBB@_HHI* &;LJ#6;JFI6FDV-
U=W\TMM:P1&:>:8[(XHU!)FD\$[6_!-I' ^ \C+CYLM))VPR"16ZX; .I)0C_MJ< .,Q"PM"=:6RZ'M_CGX.^#/B5'_
_5!X;L\14N9(4@^UR1; ;E(U??L\$ZX=!G MG_8?P5XG=KA8XP+;7X5DW2[_G(N(E^EY3C_40_ "V^U?L@
M^# +GP9\# = %U>M0;F^8E>Q%1R*HK_MVL<;P_.'Q"] ,ZU)*35_/[S\R(0\$WQS_9UUQ1?WFI?9]-MK8RVMS-
_JNL(;5GV(_MDFQV2#> \?EJ1L?&=M?I0&Q:-2: /#XR:EJG[/ ' /67_ "2G5KJXT[4YHM1G_F\ MV6:S>39-
_? .53CRY=J?PJ(_FW)7Z'J1L![\$5G0>KCV. ')HJE*M2N_==K/6Q+ M244DG^K;Z5UGT[VN?(WQZ^ (?
P; ^"MXVCI\ .?#0B+Q#Y7G_V; ;Z9:Q1V_ _UL
MFQO++IEE^1NV\HKJU>7Z'^U1*GOHDU;X%Z!; ;>1^IN+"&TN9!QWC>&+ P!" MJK^Q_P"!?
#0QJ^ (7BC6? '7_ \$VUBWFBU^WM9Y_*BN)FD>2> \K(^'I?6L9!XNA*\$5T37YZ; '3_ UL? \>AC70!%AI5EINJ1I*
MUUI=G';>>JD@>9M5<[OBW_@G/K5Q)IOC721_#IMG+97, , M>/NRROR)(\/
R!'7VD&&_UT4GS0/ILN0#Q6&C5M8=2T45J>F% % % !1110 4 M444 % % % !1110 4444 % % % !1110 4444
% % % !1110 4444 % % % !11 M10 4444 % % % !1110 4444 % % % !1110 4444 % % % !1110 4444 % % % M
!1110 4444 % % % !1110 4444 % % % !1110 4444 % % % !1110 4444 M% % % !1110 4444 % % % !1110
4444 % % % !1110 4444 % % % !1110 4 M444 % % % !1110 4444 % % % !1110 4444 % % % ***?24:BL,W?
YS1N_SF_MGT4PMYC>/2CCTI]+49%\WK_ "HRW\W^52T4:B^8VE^E+0,CX]!2Y%.HI@, M5-OK^=# >U24E
GKN,VTC1JW4" I: *6H- *2LRK-# 'Y;? ** (;XS\?&+Q \!_T'
MM1_]*)*_7]D#*0: \4US\DGX4^ (M:NM6U#PPUSJ5W/) <3W^VZZ!:1WWN3MEX) M-0
M27&^0N_SN6< .Y/)KIUXKU(_M048V/T3" T51HQA;8;GZ4?+3Z*HZZ)N%' +2T_1X/H*.?45)13N!%Q2Y'K4E)
M2U%86BBB@84444 % % % !1110 4444 % % % !1110 4444 % % % !1110 44 M44 % % % !1110 4444 % % %
!1110 4444 % % % !1110 4444 % % % !111 M0 4444 % % % !1110 4444 % % % !1110 4444 % % % !1110
4444 % % % M!1110 4444 % % % !1110 4444 % % % !1110 4444 % % % !1110 4444 % M% % !1110 4444
% % % !1110 4444 % % % !1110 4444 % % % !1110 44 M44 % % % !1110 4444 % % % !24M)0_WI7R%_P
%# /!EQJ/@OPYXF@W&WT: [_MDMKBWBB!_ =7'EC?YG_+ /]Y%\$G_ ;60KN/C@# 'UK^UW1K3Q^HE[I6H6PN-/087
MMKB!N_PNA1U^7U! /YUG4CSP.#&8;ZYAYT5U/! _V0_CMHOC;X?:#X:0+^WL_% M6DP)8_V>Q\$?GPI&?
+>\$;0WG[M/FQ]UU?Y54K70&MZ]I?AW3[G4=50K72]/AY_MFNKZ9(H1_#R['
KX@^ (G_! /W5K&26Y\ \$:HFK6B128L-5<0W.%CXBC=4V2%W, MGW_*")S_%7!^' V'_BQJXT5[HUKH\$ @SYU]?
Q2QG_IF/*_K_ \ CE< \;M2* MMR, \ "GC_QPT%0>'0 \ /I- /- /+ MR[/- \DC?<^6+[R? ?K]/UPL8![5X! \ " /V3=

^"-\\NK2W/"0^)/\\C^T)H1%' M .F88\\L8]R850G;H=H179:|]X;@G(K6C!IN3ZGH97@ZN'4ZV(705'=DU!Y!I
M!CM22?ZMLCM6Y[KV/@GXQ?LO^/OAFXTU?Q/*5N4TN^CDN)+;2+G/-=6/\\;P M"- '7S(_*&0;'CD_P!4
MDG!'[M] \\?\\ M5+^S+XLM?V>_C]K7A[Q5JPMK6>)]GN+><36!NDDC\\N24@\\ M?\\M4R_SIYGS;?GV?<:' 'X<-
_P S[X8 '6+?_P"+KSZ<:4 ?08^(PV&HXV,I M*HX*6\\;_/
.: 9S^!L'P)\\%'3Y)UOM80Y3/J%U#%A1(>D49/S&-/X=WJ[?+ MOVCV%0.@KF_#?CSP_P",ENAH7B+3-::#'G?V?
>1W'DEON9V'0[UT>X;S5+240-)[C-QHW?YS3Z* L(K=:&]:6EH&)2T44@"BBB@ HHHH ***** M"BBB@ HHHH
***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH * M*** "BBB@ HHHH ***** "BBB@ HHHH *****
"BBB@ HHHH ***** "BBB@ HH MHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB
M@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M"BBB@ HHHH ***** "BBB@ HHHH
***** "BBB@ HHHH ***** "BBB@ HHHH * M*** "BBB@ HHHH ***** "DI:* (P#TS7SA^UQXR^*?A!0"P^&]MJ-
TLON/[O M_L_20MWW?(\O/R-Y>?WOUKZ3I"H/49J)1*,]B0'_/(M?H?&2RC>!NKY<_X>\$?#? M=G^Q?\$_W_
(#6_P#\\?KZF1@XW#H>E=\\;W97/7RM17/RU_:?.XA;8F:X'X;_&
MCP;\\70[3_P"\$4U;^UA9",W+^WFAV;]S_6(07RST]*[V0;E8#N.*_VV* & M#]E?XD>(+7P5X?
NM=T6[F,T) LR2^@N8OWGD>:**R.F\\[MNWYO[Z]:TG+E6 MQOCL5+^S@[7B] (7X; LC^#?
B\\VICPG\\60[6^QB,W) X1Z>+;OW^6/GG3/\\ MJST]/>NX P"':,?BIX0 M50AQ:ZG="8Q"-CI?V
M P"YY@C'W&\\O EK7JG "X/VI?^?7Q1 X2T? ,BUYT9T;629\\31 LV5+VE;# M-O\\ N\\S_ %/IO[FW]FUOV?
3KY;Q&-?\\ [4^SC CR^S"R?,P,;VSGS/TKW7A MA7S?^R7XR^*OBY0% ^)%KJ-
JL)M_/[&H;5]A^\\9 ,Q[B]\\8B^E?2^KV[5WPM M;8^\\P"H_5TJ,6EV8^BBBM#T0HHHH ***** "BBB@ HHHH *****
"BBB@ HHHH M ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ MHHHH ***** "BBB@
HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH
***** "BBB@ HHHH *** M* "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M *****
"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ MHHHH ***** "BBB@ HHHH ***** "BBB@
HHHH ***** "BBB@ HHHH ***** "B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH
*** M* "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH M ***** "BBB@ HHHH *****
"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ MHHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@
HHHH ***** "B MBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH *** M* "DI:* /B0_
(**6>IOX?\\ !=W!@;%'=W\$X\$\\[\$?GO&GDYC/_NTN>?X?^!5
MW'@/\\EOX(^*0^&CZKI>EMX@M)X8VAU%M4NE;?'5Y KJ-^0=R;5VL"NU:ROV\\ MOB9=>\$/
NE^&8+^UG30*;*@3W\$V)####L)\\N-OXSYBG?U3'R_59?\$_M_8"^(M]Y:6TL]SH-G-+!_J;B_G\\RW_.F?R0NO_?
#UPU%>I>W,?\$XEUVO? MI<^IU_8R^#F>?"C#V_M6[\\ CU>YJH5<*.U?G?_,.]_B-NQ_:A?\\ [_W' M_P
9K]#HE\\M0G4U03>GP\\I/>6W?^-^X5+T_X8=@,O!IA3/W\\\$5/170>UTL>>_M#?
X^*#/\$\$VI'PGI7]E?;!&+A?/FFW;-^S_6.W3S#T]:[[Z5]24D1"G&FK05B M+KT;]*?M.W%.I:/006UF%%
PHHHH ***** "BD^--+4!U+3:2F ^BBB@ HH MHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH
***** "BBB M@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M"BBB@ HHHH *****
"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH * M*** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@
HHHH ***** "BBB@ HH MHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB M@ HHHH
***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** M"BBB@ HHHH ***** "BBB@ HHHH *****
"BBB@ HHHH ***** "BBB@ HHHH * M*** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@
HH MHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB M@ HHHH ***** "BBB@ HHHH
***** "BBB@ HHHH ***** "BBB@ HHHH ***** M"BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH *****
"BBB@ HHHH * M*** "BBB@ HHHH ^, \\ @H=K5M9^'/'6G3Z3:7=W>374/&J3-^\\LO)\$6]([O MMAQNSE<1?
=W;63R71/V\\B+H>BVNG&TT&]^001VWVK4(+B66?9&\$DLGG?O) M&Q\\U?I^*0#U&:3RT NK^5<\\ZOA[^UJ_ *WZ
MBT445J>D%%!!110 4444 %%%!16!X@\\2Z/X3T6ZU37=6M-TV'GWM_ M.D4,&X[,%W^4?-ZUR^G_
+0'POU34;33[#XB>%K[4+Z9+>WM+76[>66>5_N) M&@#080074'[L;(_P!]
M#Y+/"GC32;3P[\\10"U[):W]GI[P/)N%61 MHS)&7=\\(XV/[].8VW_/L3Z5-
?|O["_A04_B+\\=/BA\\=EL+G2_#F0S7.GZ1] MHLHK47T3W_D\\SY.Z"WB1G^?>\\DGLSR/7WE3K)1=D%-
NVHM+1161J%%9\$0B; M1K?Y)=8LP?\\ :G2@#7HK\$ X2C0 ^@OIO @3' C1 PE&A P#07TW_,"8_P#&
M@#;HK\$ X2C0 ^@OIO @3' C1_P)1H? \$%]- \\ F/_ !H VZ*Q/^\$HT/\\ MZ"^^F_P#@3' C1 PE&A]!?!3?
F/_ &@#;HK\$ P"\$HT/_ "*"^F_ \\ @3' (T? M\\)1H? 07TW_P)C_QH VZ*Q/^\$HT/_ H+Z; X\$Q_XT?\\)1H?\\ T%]-
P# F/ \\ MQH VZ*Q/^\$HT/_ H+Z; X\$Q_XT?\\ "4:'_P!?!3?_)C_P : -NBL3_A*-_#_ M_@OIO\\ X\$Q_XT?
\\)1H? 07TW_P)C_QH VZ*Q/\\ A*-_#_P"@OIO (\$Q_P"- M' "4:'_T%]- \\ "8_\\: -NBL3_A*-_#_ Z"^^F_!,,?^_
' "4:'_ -!?!3?\\ P)C_ M ,; -NBL3_A*-_#_ Z"^^F_!,,?^_-' E&A_ \\ 07TW_P "8_\\ &@#;HK\$ X2C0
M_P#H+Z;_.,?^_-' "4:'_T%]- \\ "8_\\: -NBL3_ (2C0_ \\ H+Z;_P"! ,?\\ MC1 PE&A]!?!3?
F/_ &@#;HK\$ X2C0 ^@OIO @3' C1 PE&A P#07TW_,"8_M_P#&@#;HK\$ X2C0 ^@OIO @3' C1_P)1H? \$%]-
_ \\ F/_ !H VZ*Q/^\$H MT/\\ Z"^^F_P#@3' C1 PE&A]!?!3?_ F/_ &@#;HK\$ P"\$HT/_ "*"^F_ \\ @3' M (T?
\\)1H? 07TW_P)C_QH VZ*Q/^\$HT/_ H+Z; X\$Q_XT?\\)1H?\\ T%]- _P# MF/_ \\ QH VZ*Q/^\$HT/_ H+Z; X\$Q_XT?\\
"4:'_P!?!3?_)C_P : -NBL3_A*_#_ .@OIO\\ X\$Q_XT?\\)1H? 07TW_P)C_QH VZ*Q/\\ A*-_#_P"@OIO
(\$Q_M_P"- ' "4:'_T%]- \\ "8_\\: -NBL3_A*-_#_ Z"^^F_!,,?^_-' "4:'_ -!?!3?\\ MP)C_ ,; -NBL3_A*_
#_ Z"^^F_!,,?^_-' E&A_ \\ 07TW_P "8_\\ &@#;HK\$ MX2C0_P#H+Z;_.,?^_-' "4:'_T%]- \\ "8_\\: -NBL3_
(2C0_ \\ H+Z;_P"! M,?\\ C1 PE&A]!?!3?_ F/_ &@#;HK\$ X2C0 ^@OIO @3' C1 PE&A P#07TW_ M
,"8_P#&@#;HK\$ X2C0 ^@OIO @3' C1_P)1H? \$%]- \\ F/_ !H VZ*Q/M/^\$HT/\\
Z"^^F_P#@3' C1 PE&A]!?!3?_ F/_ &@#;HK\$ P"\$HT/_ "*"^F_ \\ M@3' (T?\\)1H? 07TW_P)C_QH
VZ*Q/^\$HT/_ H+Z; X\$Q_XT?\\)1H?\\ T%]- M_P# F/_ \\ QH VZ*Q/^\$HT/_ H+Z; X\$Q_XT?\\ "4:'_P!?!3?
)C_P : -NB ML3_A*_#_ .@OIO\\ X\$Q_XT?\\)1H? 07TW_P)C_QH VZ*Q/\\ A*-_#_P"@OIO M (\$Q_P"-
' "4:'_T%]- \\ "8_\\: -NBL3_A*-_#_ Z"^^F_!,,?^_-' "4:'_ -!?!3?\\ P)C_ ,; -NBL3_A*-_#_ Z"^^F_!,,?^_
' E&A_ \\ 07TW_P "8_\\ &@#; MHK\$ X2C0_P#H+Z;_.,?^_-' "4:'_T%]- \\ "8_\\: -NBL3_ (2C0_ \\ H+Z;
M_P"! ,?\\ C1 PE&A]!?!3?_ F/_ &@#;HK\$ X2C0 ^@OIO @3' C1 PE&A P#0 M7TW_

"8 P#&#;HK\$ X2C0 ^@0IO @3' C1 P)1H? \$%]- \ F/ !H MVZ*Q/^\$HT/
Z""F P#@3' C1 PE&A]!?!? F/ &#;HK\$ P"\$HT/ *""F \ @3' (T?)1H? 07TW P)C OH
VZ*Q/^\$HT/ H+Z; X\$Q XT?)1H? MT%]- P# F/\ OH VZ*Q/^\$HT/ H+Z; X\$Q XT? "4:' P!?!?)C P
: M -NBL3 A*-# .@0IO\ X\$Q XT?)1H? 07TW P)C OH VZ*Q/\ A*-# P"@0IO (\$Q P"-
"4:' T%]- "8 \: -NBL3 A*-# Z""F ^!,?^-"4:' M -!?!? \ P)C ,: -NBL3 A*-# Z""F ^!,?^-" E&A \
07TW P "8 \ M&#;HK\$ X2C0 P#H+Z; .!,?^-"4:' T%]- "8 \: -NBL3 (2C0 \ MH+Z; P"! ,?)
C1 PE&A]!?!? F/ &#;HK\$ X2C0 ^@0IO @3' C1 PE&A M P#07TW
"8 P#&#;HK\$ X2C0 ^@0IO @3' C1 P)1H? \$%]- \ F/ M !H VZ*Q/^\$HT/
Z""F P#@3' C1 PE&A]!?!? F/ &#;HK\$ P"\$HT/ M *""F \ @3' (T?)1H? 07TW P)C OH
VZ*Q/^\$HT/ H+Z; X\$Q XT?)1 MH? \ T%]- P# F/\ OH VZ*Q/^\$HT/ H+Z; X\$Q XT? "4:' P!?!?)C
M P : -NBL3 A*-# .@0IO\ X\$Q XT?)1H? 07TW P)C OH VZ*Q/\ A*-# M P"@0IO (\$Q P"-
"4:' T%]- "8 \: -NBL3 A*-# Z""F ^!,?^-" M4:' -!?!? \ P)C ,: -NBL3 A*-# Z""F ^!,?^-"
E&A \ 07TW P " M8 \ &#;HK\$ X2C0 P#H+Z; .!,?^-"4:' T%]- "8 \: -NBL3 (2C M0 \
H+Z; P"! ,?) C1 PE&A]!?!? F/ &#;HK\$ X2C0 ^@0IO @3' C1 MPE&A P#07TW
"8 P#&#;HK\$ X2C0 ^@0IO @3' C1 P)1H? \$%]- \ M F/ !H VZ*Q/^\$HT/
Z""F P#@3' C1 PE&A]!?!? F/ &#;HK\$ P"\$ MHT/ *""F \ @3' (T?)1H? 07TW P)C OH
VZ*Q/^\$HT/ H+Z; X\$Q XT M?)1H? \ T%]- P# F/\ OH VZ*Q/^\$HT/ H+Z; X\$Q XT? "4:' P!?!? M
)C P : -NBL3 A*-# .@0IO\ X\$Q XT?)1H? 07TW P)C OH VZ*Q/\ MA*-# P"@0IO (\$Q P"-
"4:' T%]- "8 \: -NBL3 A*-# Z""F ^!,?^-" M- "4:' -!?!? \ P)C ,: -NBL3 A*-# Z""F ^!,?^-"
E&A \ 07TW M P "8 \ &#;HK\$ X2C0 P#H+Z; .!,?^-"4:' T%]- "8 \: -NBL3 M (2C0 \
H+Z; P"! ,?) C1 PE&A]!?!? F/ &#;HK\$ X2C0 ^@0IO @3' M C1 PE&A P#07TW
"8 P#&#;HK\$ X2C0 ^@0IO @3' C1 P)1H? \$%] M- \ F/ !H VZ*Q/^\$HT/
Z""F P#@3' C1 PE&A]!?!? F/ &#;HK\$ M P"\$HT/ *""F \ @3' (T?)1H? 07TW P)C OH
VZ*Q/^\$HT/ H+Z; X\$ M0 XT?)1H? \ T%]- P# F/\ OH VZ*Q/^\$HT/ H+Z; X\$Q XT? "4:' P! M?3?
)C P : -NBL3 A*-# .@0IO\ X\$Q XT?)1H? 07TW P)C OH VZ* M0/\ A*-# P"@0IO (\$Q P"-
"4:' T%]- "8 \: -NBL3 A*-# Z""F ^ M!,?^-"4:' -!?!? \ P)C ,: -NBL3 A*-# Z""F ^!,?^-"
E&A \ M07TW P "8 \ &#;HK\$ X2C0 P#H+Z; .!,?^-"4:' T%]- "8 \: -N MBL3 (2C0 \
H+Z; P"! ,?) C1 PE&A]!?!? F/ &#;HK\$ X2C0 ^@0IO M @3' C1 PE&A P#07TW
"8 P#&#;HK\$ X2C0 ^@0IO @3' C1 P)1H? M \$%]- \ F/ !H VZ*Q/^\$HT/
Z""F P#@3' C1 PE&A]!?!? F/ &# M;HK\$ P"\$HT/ *""F \ @3' (T?)1H? 07TW P)C OH
VZ*Q/^\$HT/ H+Z M; X\$Q XT?)1H? \ T%]- P# F/\ OH VZ*Q/^\$HT/ H+Z; X\$Q XT? "4:' M P!?!?3?
)C P : -NBL3 A*-# .@0IO\ X\$Q XT?)1H? 07TW P)C OH M VZ*Q/\ A*-# P"@0IO (\$Q P"-
"4:' T%]- "8 \: -NBL3 A*-# Z"" M^F ^!,?^-"4:' -!?!? \ P)C ,: -NBL3 A*-# Z""F ^!,?^-"
E& MA \ 07TW P "8 \ &#;HK\$ X2C0 P#H+Z; .!,?^-"4:' T%]- "8 \ M: -NBL3 (2C0 \
H+Z; P"! ,?) C1 PE&A]!?!? F/ &#;HK\$ X2C0 ^ M@0IO @3' C1 PE&A P#07TW
"8 P#&#;HK\$ X2C0 ^@0IO @3' C1 P) M1H? \$%]- \ F/ !H VZ*Q/^\$HT/
Z""F P#@3' C1 PE&A]!?!? F/ M &#;HK\$ P"\$HT/ *""F \ @3' (T?)1H? 07TW P)C OH
VZ*Q/^\$HT/ M H+Z; X\$Q XT?)1H? \ T%]- P# F/\ OH VZ*Q/^\$HT/ H+Z; X\$Q XT? M"4:' P!?!?3?
)C P : -NBL3 A*-# .@0IO\ X\$Q XT?)1H? 07TW P) MC OH VZ*Q/\ A*-# P"@0IO (\$Q P"-
"4:' T%]- "8 \: -NBL3 A*- M# Z""F ^!,?^-"4:' -!?!? \ P)C ,: -NBL3 A*-# Z""F ^!,?^-"
M E&A \ 07TW P "8 \ &#;HK\$ X2C0 P#H+Z; .!,?^-"4:' T%]- \ M"8 \: -NBL3 (2C0 \
H+Z; P"! ,?) C1 PE&A]!?!? F/ &#;HK\$ X2 MC0 ^@0IO @3' C1 PE&A P#07TW
"8 P#&#;HK\$ X2C0 ^@0IO @3' C1 M P)1H? \$%]- \ F/ !H VZ*Q/^\$HT/
Z""F P#@3' C1 PE&A]!?!? M F/ &#;HK\$ P"\$HT/ *""F \ @3' (T?)1H? 07TW P)C OH VZ*Q/\
M\$HT/ H+Z; X\$Q XT?)1H? \ T%]- P# F/\ OH VZ*Q/^\$HT/ H+Z; X\$Q X MT? "4:' P!?!?3?)C P :
NBL3 A*-# .@0IO\ X\$Q XT?)1H? 07T MW P)C OH VZ*Q/\ A*-# P"@0IO (\$Q P"- "4:' T%]-
"8 \: -NBL3 M A*-# Z""F ^!,?^-"4:' -!?!? \ P)C ,: -NBH8Y!<*) (CFIJ "BBB M@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH ****
.1^(7P1)\ %;PA>>% \$!G :F@WQB-Q:BXDBW;)\$D0%T9 M7^ &#P>U>4Z!^PY\\$ "/B32M;TKP*+75--
0(10MK@ZK>2>1,DGF)(\07. G M&#*^A*2FI-\$N*9@>(/\$NC^=%NM5UW5K31=,A0YI[?SI%#!N.S!=E'S>M?W
M \$Y ;P\3? \06B L1:9=]-+6Z\83P0\ @Z6B2# ,0 'MW/[67[*MY^U!I^@: M8GC>Z\];=I4MQFHM8S6MIFL7?
H.HI*6I*" MBVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBVB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** & M48I]% #**=2T %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 M %%% !1110 4444 %%% !1110 4444 %%% !1110
44FZC=2U["N+13<4 ME,8^BBB@ HHHH **** "BF40K2 =1113 **** "BBB@ HHHH **** "BBB@ HHHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBVB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBDH 6BF'Y10.E^XNMA]-W4<47&.HHHI@%% % !1
M110 44VEI(!:***8!1129% "T4WBC!I:@.HHHI@%% % !1110 4444 %%% M!1110 4444 %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 % M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 44 M44 %%% !1110 44W-&:5P'4E(M!&*.M@'44WBEI@+1110 4444 %%% !13 M5Z402EUL M%%,

HI.W-'W12Z +1113 **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@# \ M]/C'\; /CGK7[:&L?!_X?>.+ /P];3^7IA74+"W,46-
/CNG >&"5R>):ZC40!_ M[:7A6U M2#QYX7\7/9R(P#8=0!:1 ;A0 \0?):P8'][]C;1K[\^OB/OA^+ M&B_!?
_@I=JWC37;:\0--TT1F:VT\1R38DT>.<2.B?7D OU[+K 5<^'=0 MH=U+HGA'Q1>ZG@?
9[74%M[6(\=Y\$DE=/EY_U;5WS@X\MENKG&5[Z]'J0[%0
M[4D_[37@05I]J5L[.P\2Z+>F#4+73Q)Y/E/DP2#>6P3LF390?_5;_) -Z(/I1 MNE?*7["/PU_X1GPWXX\<
<:AXNT[Q9XN\9WZW.0-I%];W5I93)OD\K?# \GF?Z0 MSOL^4>9&JC:@=SXG?"/X\?&3X@:M:#XBVWPL\<
6!;FVT;60B!>OI"ZY<30&:'YX(\1E\$.PL;@?0,[T57V+NVLD^R?, MDNHU533?8^L:.*^*)-
_9A:.\$&E];ZMX3^/\<=>+M3\$R+/IGC:.*?[#<0DAW'^ MLGP3Y83Y\$1]I?:Z?
Q=;^U5\;0&NB^, !7PC^%M;:X@^)]UR=200]3I]FA)W M.C1G?YS][E3#VG='U/25\)-^RG^T/X#\<-
KXAT+X_ZMXB\ M6V-IYXT/4#+-8SS>7^CWW\$SH_/F;'DA^|LSLQN3WKID_P#:# X:2^%7 "3S
M24VC:G:WDFG:A:G %)GC2.3S(0XMCORQG#\K|WY\;W \$K|EGOI/\ \)7=7 B]M30K72-4U^ \DN LT0V*
PH74.\$/GN9\$= P!VY,>V/?QY M;G8F P";E/\ @E3 _F|^(\^0QGN/ 2.SK0 X)I^, _\$'CGX%>(+WQ)X@U+Q%J
M4/B:XM5NM607NI1\$+>U(C+N6X&\ G6U1?&9TY6MYGV#17YM%^]1^/7QV^,'Q
MB^'/A/OU<=>'0"NF^+);B P!8>./?Y?R) HVS>GF/O M9\4U^ -7["?BKP_XVN?
B+JWQ2\#WEQ_9]];:S>2\R0\QC,/ [K1 M.K+M.R6/8ZVN5]7R/THI* \3 _&IOCQ%^SG\<
(=3\6+;6UWK4]Q'I^DVMP9##/ M=N/^6FP?P)'+)@E=WE; Z,XKP'1?V4 VA?B%9G7/&?|06J^\$M=0?*>7H^FR
MQ6R^7' SPF@ACDZA@B.F06W00K*,+[LN4N5V1]UT5\H?LM 'GOYJ?Q-\5?!\K MXJ6M0<^/ #4!U#^W; Q>3?
VA>/DHFV' _!\1;#L3Y3\ZHR?/|6 =J)1<78I. MXZBBBD4%% % !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% M!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 % M%% !1110
4444 %%% !1110 4444 %%% !1110! \ _MP M.???X,?'CO= M%\ "7[#3?|!AUB?36TN.ZBF*3W;S^9^[\<
[9Y%0\ ENNQ8RWR?>K[+^'?CS1_B M5X+T?Q9HCBZT_5[.YM\M'YG3F.38[*]\$?*, (P*U\&?
MM;9;ZU^WS\ '= /O MK2WN].08-%MI[:XAS\$T5Q"^J7&^1#Q78 LP7< [)?[0'BOX\$^*+JUM?#/B*<
M: SX2NYIXP9]\GDQOR[(U >3)%Y?S[%#VNU%;SDW|DX0)=SEA)JHT^A|YYK\ MX0%W[< BWQE^U]X4\+>]>R\<
'7['19 P!S9746K#|8\$N+B*38|I&Z2;%V/ M|R/=\C/7T1^VU\+=OX1 _\; -H/VJ?
X@+^C)I^@6FGPR33Y^1)9(|A5|Z)*-F MPE0-DC^1EW8^; BS\&+3X"^*OV. "5NMJ=3@|2>?J-U"V!>*>PZ=I%0
MY3RR#@>9)\$FQEED5I841#GYI =KJCJ?);#|D/|H/Q-X: MW6/V@M?T?Q=>PR M3W&AP7%Q|EMYG)>.+S(9T2/J
WEP[4]^7>J+OS5/1-0>?*?XM/MTT33+G40 MLS2^7Y_DQ/(8)_S8/R?
K7P9\:/AC(?/V3=)TOXEZ5\9M7^(VE:3>1B_T_6)[ME80*?|VGF0=-2I<1N\H1B-CI\C+TWIZ ^TUX>\1_M ?
LVZ3\0-)\8ZKX\$TV# MPI<^(-0T&Q\V2/48IK..?[-*Z/%G8(Y\$^=' _-: ?DH]GJM=&+VCY6[:'K [+ M?
Q.UGXV? ?PYXSUZUM++5-5^T"XMM/5XHAY=Q)"" [NV=L8/WN]>/_MD>,\$ M7A;X\?LX6&C^(|3T73=4\3?
9[^TL;V2***B^T6 \N5\$ _U@Q)(/G _>E>7?L M4_LX^-0\$7@#X>^/=^,VOZ1X;CNO/_PB%0\ _:/LAA@09-
_1 TE4 ?;#N = \ MM#|]OU' 4&OMIT_P"-7[-]SH^E?VWJ,&07%Q;Z?|H\$7VB9+BP\N+S'^2/>
M^\$|P =S60(HUN5&7._97/NK-+7PG\1/V8/VD/\$^CZ0XL7XU75IXLF\RYA\ 'Z M! /F>D=0#/YR;/W8'WX?0-
'G^]*?60V(CMK/[07P8&L^)K2 :YI=|)I\$ M|W;+M&H;\$C<7&P#|V6\$@W ?+N&X;<|QE3M^R3V-HSN|-
'TCVKY0^/?[2/C2 M;XM60P8^#.F6]|X^D@_ 5]4U*!_L>CP/'\DI'3*^9\$YD(=!|B!)6?:OU?@&N M
|. !GPEx1\<(>?&.DZ/L\2Z_P W^ISW,MS+;! RS'FNWEQ|/W;:4Q'&/X%V
MQ"26Y4H\W4^0_&7CK|J_ |F6S'C+QKJ_A?XC>\$K8QC4+6W\N\$P;|B"/JD%0)Y MC^:40A)E3EG7[M?8/PK^)&A?
&#P'H_C'PU|H.B:I#0@^ ^PR!DD:.2)QGJCQ ME.,K0\K,IS7P|\;?^"A6A?&?P8WP^ \V-SXTM;"*62..3
M.SS#M/_P!,MM)M?(:Y (-Q-DM/_M)AW5|F_"YVC@5M4BU'FDK&= /1V/0Z***YC<**** "BBB@ HHHH **** M
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@#SWXV: >^\$ @SXYU02KD66IZ=H-|]?
VUR=KB&5+>1T?# *<M, _%?*W|!0[77BWXH>)KOPK\2;QKW5-1L [2T#4IK**T^U1(|QW\$:%-J28>/ MY?
+3 EE<;F/EB0J#|H _)-['^' _&*J \ I'+7Y> "KX,ZEXB_960/BEX+ M-I9>-
OA|XJN=1^U9C!^R0V=I/ &G(SR)(PZ([=AG^5V?9771C%T|,Y9MQJ7
M/V+60GK|L3|HJW_9T^\$EU>P.S^)=8\$EAHT0FB\ V^8QG-P4<-02'@G"-ES&K< M/NKN0@C\8-\$^ WPQTSQ;H-
S; '[5\$!>VD,WG&QNO&IDMY#M4DH3U^C>I1U^5U M)^:OA3J50^V'^U=< \$9/M-U\./A|%)@T'[1
_45SJ+ \FX\$3|XR5P9/\ EG*G M^@EEK*FFI/F6QI*7,M#0?^"? P_8 %GOL^#FKZYXSU;^U]3AUZ6PANE@AB =
M);V|[#Y*(G#R2|J^HLU\8? \ !*C _)-Y\0 _|C/U001(DV;OGV| [G#FJR MZ)\$4Y6@I/J?H52U^=7Q#A^/?
[#M_I?BM '.J?%WP#-/_&-8 MG>?(WJ(G>5 M[??YGR3H^W>\$61?
N*_ IO[>0QFUOP[^S(X)\; /]NUZQN;4K'='YT# MV=Q.@EC;_610B+;ZV/LBDKX4N/V8?VC?B-9ZMXK\0?&
MRZ\&^); _/TFW\+Z#<7'V"W _':>7;ETG5(MC@HVQ)NA??*S5V/|'"QF\;^/ MM)\6^"0^V\|3^
[N/3;C43/YLER1 MR/-#?/GGY@SNG3T;3V!5 M-4K;G;>.?V@M9\ _ME7.I:AJ4HD,0^KNC&D6/D0B2V&[?
MNV^; _!L^?0\]H#4K02?@7\0]1L+N>Q0|'PYJ-S;75M+Y"0 <P _-?0?>VJ:++I \$34IM^U;X M35B_FP1-
I^SRA MOFE. 8R_W \ EH:UE",>77U:ZU?5KC[:] MHO+^:2:6;9>3H"7D^< (H_*OH%B;_.7]FKX6_&'XV?
LW^!| (TGQX?A;X(TO[M;:;?4]'FEFU75YA>2?0)/+>+RX\$R6/R] P!^+; '<7KQ8DDP4Q
M&/++0\ZG9&=0S%5/*M78W;LKGE?|7G|2GB'POJ^C?"[X2WP0/BYK5W'F""WB MNOL%0@0@F3Y(W?@Y='VQ"1VV?
(|?00@3P_J_A+P];V>M^+K0QAJ@&^YU. |MK M>UY\M _EQP(BHF\^P'WL-Y! =N* _/|X#R?M+6-K=?\$GPS\+M, \1:
[XNA^TW_B M;Q=>Q :KB+S,I'#']I@^SV_E^5L39\ _E;M_E^2B?20[/*]/8\$/|0- JGA77_#
MTWA+Q_H<>Z^TYED,4X0I'.Z[U#0%)FPT+_ .N4^9_GV]-2.C2Z&*=[7ZGT_2T M45S&X4444 %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 % M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%%
'YSL/^0-/?\]U^0T!UC1[77M/N] M/U"U@0-.NHG@FMIX0,BGC<8='0\ \$'G\Z^3/C#^P?
KG0&^ .FJ_\$|0_BG=^!|5 M03\$L/|GZ6_G0;+>._Z1'Z==12

```

[1]KWGPL^&E7EE!;Z5HI;U2A\QWDDEG#B>TD?ROX\Y7\['[9-0^C/@/'SG MX/\ V5 M''?RV^%?[2?
[/FG1_$303X[U&?0+;7$]KXPUT7\MC']LM DD2!% M\0?B7 ?\K 8K[,^~7P5\! 'RPM/#/C;SM;N\BYN=,>&
<0W\N/DCDEA]0GF0 M[L[DWS/)=%! .D:WI=[*?L,V2 MZ2>10V?ZSRG9TV2MY4?U @I.HG:SV"--
IMVW/$ CWJWCW\B/1] \6:-\1=> M\=>$I=8CMK_PWXP\N[FG+07#R/'?A!)&-D46V/;L5P6^?YD/! ?
M/1>%/&7[8 M7P;UCXF;-=:1\0$'AF-;C^W -L/L\5?:W2WE=' 'G\2(R MN,X0"492V.0_X=[-
!_Z$( ^#;4/ _C]=Y\! "? 'PY\!>"VA^%R68\ .7UY+J MN+& DOXKB; ADD\UW?/^JV?>_P"6?
M7S1#_P3H\67VBV7A[?7V@/%.K^$(A; M07&A^1)Y)AA\0]W$CW3I' _JAM^1]F?
NFOJXCX0_"#P\|#/!=6X3\)\V/V;3(?$/ _8SW' _I'9U\%^RM^SK _ ,R?#V\]\+G0#_PD80-3DU+[_ M8;+
[(10CAC\OR\[_ //+\U\TO[* _].0\ PS)\;/;WPN?$/ _"1B\U.340MALOLA M!>.&/R _+W0\
\0703G44N;S(4)*WD>- _L _\G$?M3' _*FC_P\N\0I?^"J _M _)O/A[_ L9[? _-(\R08?@? \
LZM\&B'\3 _$ _P#PD3;NWCK4_P"TA:M9>3]A MQ)<2&/?YC>9 _Q\>B?ZNE:_J_9W_X;:<^'MEX7'B#_
(1T6>IQZC\L%D+0.R.; M/R+_WI _SU\>U'M%[9/H/EE\+;4> _P""I5A3^X-\D: _WY$K? \#_L7_LV?$ _PYI?
B#P[X2M=6T34H15RN9M(:ZUG MQ'?Q16\]KE\$_T@!"8XD_P"64>\&3;EFY_9WV)M\[-8U+W0%[JZM/' '@J:76-
*^S^>)K@!-[V\0C_Y; ,8XG3Y&;?B+_09 MJ0\ _0D_9^*Q8 _:(\"?$ _A+0\(_X16[#_P_2L6)E^T?9KR2?
B3SDV; _V?<>_M0I#;6\IVM;H8>SW\S\^ _V5=+U/\ ;!^~5W\= _&EM;P6/AB&WTC1M,BBCEM?M
MB0B1Y/F _>8227STWC<&N8\LO\GGL_P\N; DX? \EK_L:/ _;03Z^T5K0#XX?LZ_MM\90B)\,/$Y\1-
I#>!=4_M(VHLO.^WYDMY/+W^80E _\ 'OUPW^LHC44I\VP2_MARPY=SP[_ @H)?1^&/BA^SKXKU$W%MX;T/Q-
)/>ZGY$DD-0\ _0\ _^2F>2D*=(\ (2BY@M\# \B3R1#-0 _=RHETB2?ZT\OD3?C\HIQFDF\6&TX- _MNU\D?P
U\30B%_P44^ ,7B\PW=C6?#JZ#'_IPU6W!;U$R_8(-+$GW?G>WV\W0_M$67>G-;GPT_Y2? \_Q<[_%>W
_/16F5\G\! _V< _"'\_ 'AJZT3PE:S; ,Z;[1?:_MI?
&.2\N6! .P2.B+ \Q3A5"!>0\3NS90A3\G50#7\3_BWXNGQ'\J'B'3\]/.A_
M8L>1LCM$ \SS\^7_X\NFS_EKUXJG4C=M=K$? _=?<57??"M"?"$ _';X0^(!/ UA=%_M3[_ _0,3! \I\@PW$<^?
+WIGF, M?Q=Z0^'0AEI^D _!02_AWJI.KZ3;Z!%X>N _%,/VB%+<02?=?='03/1_ES\]06
M2=HJ)KRZM\SS' _@G0_R9_P##_P"E\ _Z<+B0. _P\N; DXC\EG_L:/ _;03ZA\ " _M_P#!.NX\#^ )K2WA^+WB? _A
(-3_M$^%[_+S+7\1LD1X\+.DVWS$>.+ \XD:/B/_MY=C;73VCXW_LZ-\90B)\,/$Y\1-
I#>!=4_M(VHLO.^W9DMY/+W^80E _\>^,X_M;_65HI14^>YE:7+RV/;CRM?%_P#P2H_Y-Y\0_P#8SW'
*1V=?:_WWKQ+ \E7_M\G; _ (9C^'MYX7;Q#_PD:WFIR:E\I-L-C\ID(WQPQ^7Y>] _^>7KWK)2M%Q\FS6M
MSV\(%* _#'\I_P_&?%KXJ>+/_AYI:ZG:>(0"\MPEPE _;0^3<+<#<1))$Z.X^2_M3R^)-C?01\0#[_/:0,U\T?
M$ _L6^'_/CIXBM?% \AJ\YX(^(%B4\G7-^7EBDB;) _M)8\HSR(D>$D1T883)=41.4%[_CD^78V/VQ0\0@ \Q\^S_
..=0\5;7I%Y3I' _GN$CC"+ _LJ*\TT _@G7<)> _$UK>?%'X0^)_B_IEB? \_M1\+N#)$ _2\9<&1YY7"2)_L?9L?
D? \M?86CZ/;:> _'\M-.T^T@M-.M8D@AMH( _M0+BAB081$0< _#C\JUG)YE34F\MM&M117.;A1110_4444_%%_%
!1110_M4444_%%_% !1110_4444_%%_% !1110_4444_%%_% !1110_4444_%%_% !1_M110_4444_%%_% !1110
4444_%%_% !1110_4444_%%_% !1110_4444_%%_% M% !1110_4444_>: ?M(? \F\] _$ _P#[%?5?_2.20GC _()4?
\F\^(?^QGN/_2.S_MKZD^(_@ \^ \X>>* /#_N_L1U03+G3?M)B\SR/.B>,R;/ER10_20/0V5?V=_^
M&9/A\>^%SXA_X2,7FIR:E\I-L-E\DOOCAC\OR\[_ \ /+U\UM%I4>7J0U=W/AWX_MK>'?'G\[*?
B;OK\ '/!5H;WPU\5C% \X>*M*(K#SKCR'M_WVY" _ER>0\]\VS\/+_MN3[E?>G\WP5TCX!?'#3/!FC'\68-
\Q=;DT,<4E\, _+R2A!\$49; _D<:_FV5_MZI2TZE5S225K?B*, _4^+/\^"5)_X0Y\0 _\C/
MWBV7B^QUZYU"YT*X'E7<$ /EP0>9Y;< _(\?EM _=-WMTS\Y^RM^SK_P _R?#V_M\]\+G0#_PD00-3DU+[_8;+
\]C?'#\L\0> _/_+U\UY _\:/V$=#^('0#_P"$ \$_>_M+=4^&'C22?[1=;EHX)CG+1R))((T>)XY^ \P;G1PK?0-
REI&>KE.,I25\]S)0D_MK>0W_@H\XOT?0_V9=?T: _P!7MK/6=;N+;+3[4\2W'DW4$TN!SPB)\SG" \JQW
MG0'QW\M;3[K2?V\0@WIM _;7-EJ-C/HUM<6D\ .R6&9+_G$DK_%ZZL3%\AM\87\T _@D/ER^8\KR1\Y-
_EAU3)DW\U=DSR\Z? \]7M1&<8M10_MMU* ,I7TW\;0:0B_IAG _).(_ :E _\&C _-N\0K\2V^ \]>( ?
_\G50@S\1/B?X_MG'B(ZPWCK5/[2%J; 'R?L&)+B3R\ _F_YG _'QZ+_JZQC*R:[FSC=I\QCSXG< _\
M%0/A) _V+^Q_Z+U.OHC\H_P#Y _\^*'_8KZK_Z1RUYI^T0^QWI_P"TT_XB\/>*[ _M#Q]>>"/% ^B^7!;ZI;0^?
^Z1W>,!-Z>7(DLA=)$8>^ _Y-E_P)^R _/X1^#/C7P_MCJ^C050\0B3QI:7-0? \_B?5I990FDMS!')% _\S@;
(_+S\^ \] _+^_M6-$TDX.*_ME?8A1:0IN50^"? _' "9 _\ \Z7W _*7W%>> _$ \C _(*@?"/ _+BX _\1>IU_M\
_L\] "$ _GX0^ _' _0=7760\+^T_P#$Q$'_V;SS-<23Y\0>^_9# _!=JY_Q7_M^SN?0$04'A+XNCQ'\E'A\3)-
/_&A_8@?/WQW2>9Y^_*? \?/39_P_LASS24ES2_MEW#E\U1\ 'N'<5\& _\%) _-TRX\=?_C4/$UK=? \
(3;ZU<6VL72PR>4L,DEH7B+_MI\X+QI^5V?/^ \?;7WG7GWQ>^$ 'AWXY^"\WP\XLL?M.F38:"X0XGMIAG9/$^/_
MDD4Y^0*MN5V4YTY)-% \EA\DD,0&W&R22*%X_M_G8/YC9_A3HI?
^"='BRQT6\ \;/%^T\XITCPA*+F"WT/R/)/)$ _V _\W*B72)) _MK3N^1-^/NBOH0X# _+.?@ _\90\
#5UHGA.UG8WT_P!HOM40C')=W+ _G8)'1_M%^XIPJA_07^)\W9M;QIUW07T\I! =0/= " _MK#S(MPR"?
K5_&,GJ;:NK"4E)-IDM%,I# \BC4=[;DE%?'0C3 _(*5?"[P+XPU_M_P _WND>*CJ>BWEQI\P; >SMS$TD+E)!&3)
(L_P#//%M)^*<= \NS _&JT\G/L3SQ08^P**X7QA\0K?PK\+M> \_M;6_AU03M+T:XUB# \/_ ^[OHH\ /QV^$/A_QN=
(71? \4^T _\2X3 _;?(-, -Q)!CS-B9YC_M/\>JL\7)0K8\0HI#\T"INABT4F^3BBZ _=1113_**** "BBB@_HHHH
**** M"BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH *M*** "BBB@_HHHH ****
"BBB@_HHHH **** $I:C;!ZTN\%(-1\%)?>E>'3>&3\.-50H\7S\F _E\W7)&\=/6K/A?QKH/C;36U#P\K6EZ
M _;QN831W$0D'5-Z9YY%:_.$E'GL\>A/_& _+4Z2EJ/KUHY\8K.X\Z7)**_M\H _:$ _;#\ _LW^#+_Q-
XFL\3N\ .N\U-/_TB&.6420'(XX=T\1FNP\#^*; /Q5_MX)\>)\M-
^T)I^M650J\L)Q^ \F.;_2()/_0=G^TJFFE<9T\]-X1:6@^T4FVC%+_MF0^T4W;1MIZ _I*;2\30
ZB0G/X_MK>"0V/P?K7V04H+2^ZN+_N8)(KJ/_G(.X;)-C_(WE.ZHGPNZ _\)\X9_P# \S; _M _!=0Y).QBZU--
IR2: _.^HK&^ .WPY\>/_/#\ \X.;? _P"+KH\#U\3/$FGV^HZ5_M>VVJZ?
+S#>6,R2PG^'AU.#573=@C6IR=HNYN45&I';F0*_V@_P\H3P\^S?X,ML_$WB:RU*
\
```

0M10+*/4%.DP02QF) MI)(\GS)DQ5\$:Y/_ 5: ^\$^/^1<:\;? \ @%9_)5;>SE9.VYFZD;M=C[2I*\;
M^"0[3GP^^/B0'X/UK[9J4%I%=7&EW,\$D5U KYR#N&R38_P C>4[JAQ\WSKGV
M+&*B2Y=RT[JX^BF4N:0QU%)12N@%HIN:-U%QCJ****8@HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ I*6B@!E8NI>*M'T>X\J^U6TM)L?
=N)TC/ZXK;;TKYW^* MPG\0ZMXPNM4TNS@0+>],9.V1(Y8-L:)QNQZ'07HY?0HXBK|.M/D7<:\;--5B,
M'1]IAJ?.^0[%P+ \--P S#IJ]OD?_P 569KG02\.:;I-UW,46 M1;Q7<>^0@<)\NXUX(/@=XT"Y_L@X]YK?
_P"+KD]8T74-UBZL+VU^RSP]#GC M^ \ P5]7A\AP%6K^Q'-
;HO^'/B,50)F="D0;8;D3ZN ^1T'@'00/X= \=#5[MSY%NYG%\%Z8;[!_,D?WQ6^.08S3)<-
B&JTYJ\$4?/Y/GV+PR^KTE[240/_ @'U M400 \-'_)CVF#_M\C ^*K5TG6M/UBU\VQN[>\A_002B4?F*^7/^%'\^
&Y&D M- W]@ \ BZ]9^"?@/6?!<&I2ZM'#;F\ "?N%F\R1=F_J?N]\W07QV.R[!4*7M M*5=2?8^]R[-Z#]30
M\$7[:GQCM?A-XCTKP]XF%]K7G76L0B2/[]_: ?F1C,0\?E?P?\"KWW40V3?V M@_C7?6ND?
% X06@)\0X:>T\,9\$ET/-C?9(GD01 \L ED?SMCXVIRU>747[Q2 M;/I:;LK6.>_9,UW4-
8 X)U %JT0+T7\$&F6>06%EC \F'^SQ-L/J= \K?C7MW MI".L6FA?
L: ^"M00[NWL]/M8M2FFNKB;RXH8TO[@N\CGCWYXZU0\ CKX;Z)\ ' M_P\I_C_P
;^\$/#1N\$T72 "6JI#]HF,LA9[>XDDDD]ZEWD+'R< *JJ,5S _PC
MK%IH7[&W@K4+^[@L]/M8M1FFNKB;RXH8TO[@N\N>/?TZUE.2E\V6\ C6"Y79G M&ZC _,% M2\17UU-
 \+0@UXL^(WAR"9[=M<@AGBB,RD\10I!-QL,3C?L?Y\Y\R M)7K _S+^U#X; _;< \-WE[HUC>:-JNF+;C4--0@"+?
S8R1Y%T/]J_5/%UK9: ?\%0@OKWB[PW;PRPP:E<&/0=*\$,HA3[]+(C)(.H\ M0Y'3R N3H>CMRI>1-
DMYLEM""\]W&8HB _\$SMXD_V\$&Q?EW5]U@5\$^6M8TCS25[G M@G[2/[6G@S]FBQMH=76ZUGQ'?
02W%CH=B4\T@!P]97_Y91[P[]V&:DE4?8^W MR03?^" @6I>';ZUF^*/P9\6?#GPY/-';KKD\\$_L0F8CB2-X(>-
@E?Y-[_+0Y M4>N"UK A8_B#_@I!\0 ^\$%'AB]U01=!M_L' _FXGEM;&%K>TW_90(>-R]0 M+^\$L_P#?
KU/XA>!?VG/B1X/U?PEKD7P80-_U>S>UN2HU,2#CB6/>C()\$TGU"6^N;GR(0/.E^V3 MQ[W(^ \
)'&F3SMC3VPU;,&][.03]Z783[F[]M'1?CIXFU;PCJNBW/@7Q082 MR*-!U"X\PS!/]8%D:-/WB\$/NCV[MGS_-
A[G1_M)_M9^#/V9[&U@U=;K6?\$FH M127%CH=B4\T@!P])7_Y91[P[]WS-R=J/L?;XC^V5I+>' /VO/VWUMJF
MIZG%H\ _DSB*+R40+?0C=ETO)D<9^9#MX&X.GAOP[IGC0_@IYXX30+; _VP?#> M@V^HZ-
;ZD3+%83+'8% 'B3.T; 'N)G]GEWCYANH(Y_Y*_XN:5N2_S+EU_P4/\ M\$/@V\M+KX@_ 005X/\-S3_9FU6X,F3-
Y'=5M=6T34H/M-0=6I^5@?U!\X9#\RM\K>R>./!.D?3P[J?A[
MQ'I=KJ^B:E!]FN;6Z&0P_F"#RKCYE;YE]OEG _@EK?W.I?LXZQ#/>W-W;V?B. MYMK9;B7/V>+[/;N4C_N#?)
(Y']^1ZS?+./,E8J+E!V0<^T;***P-PHHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M[GXH_"CQ3X2L;ZXTJ\U2QD@ANK>;RLRX&U)'VM^[\<@ (XP=R%U[U5-1G)1;M< MSG)QCS)"_P##0GPMZ?\
"00!Y_[CMK_\77D'[3']77A[P'*[N]\ ^+M U;Q M3>S1V%@UA>6] \;=G_P]9<21H_1(T;:?:
F7>8]RE6\,TF+J#5;/R;G/20;W1S_P-\$>N/^ (W[,/Q,^\$ _AI=?\3^\$KJRT:.5)(KB& M>WN3!N/R>:(7;R_ ^NGW-
YV_ \M*_1L)D&4^VIOZW&7EI[VY\U5QV,]G9T[?; \ M\U_7M1\3:U=ZKJVKW6KZC,/W]S?
SR2RW&S]W_K'K0\\$/0\$?PVUK^W/#6L76 MCZE!_P_050/_ ---_ER_ \](_W?\
JW^1ZY^B0U.IAZ;I>R<%R^A\GSU.;60[MWJ?KW\(_VL/
/_CKX;Z#K60>+/#_A06[]J#>Z;J&IP6LL\$Z927]V\K,\$WH73< M<["F: [@?M!_"L? \ -1 "'_ @]M?\
XNOR0\)_LA?%[QOX9L=?TKPC=7FGZA%Y M]M=3WMO: _:(L?ZPQNZN/]C/WU(;[I%!=!8?L&?'&^0[2"X\
(6MI;S31_Z5<:I M9^3;8_Y:'8[N/^ ([U^45N'\J4G)XQ+RNO_,^MI9AC;).DSZE_X*K_\F\^' M0^QGM_\
TC0^*A_V; _DWOX8? _8KZ7_P"D<=?*7_!1/PF?_G['?P\ \-&Z^
MUG1]8TW30M7D^7YWDV%PGF;/_FZ[,XKZN_90_.3>_A? _B0I? _Z105\+42
M5+E3/>BY.I=H])^ [7Q5XR_X%:= PFUWX8^W@35_B]=6)E^W7&C0^Z_01CS_M(0+25Y8]\FSS"BKDQ[-
ZN'KW_P"/^HW>D_GXAZC87<]C?V/AW4;JVNK>7RY_M894MI"DD;]B",Y^E>+?
 \X\$0"&CZ'^S+H&LV&D6UGK.MW%S+J%T.);CR;N>+& M)YX1\$PJ#Y>6;[SN3G"*47)HTG=RY4QWP8 _;0T/X@?\$3_
(0300X2U3X8>-))_M_L]KINL\$F.8?; \H,= R?:8V8!>: \1_X*AZ%I^D_#_P_MCXYLK-;+0?8Z];:?:;
[_;MY5W!#Y< _E^80/R/'YB_P]TYV_??/1 _%0 =UJ_M?
P3TGQYIMPNGZ_X,U**Y@U);B6.6"*;1(W6S^/SQ:29ZKY7RL.C:1C&5NER_M'*20Y'T- \9?
B7I_P8^%_B/QCJ'^F6VDV0GK;9(-0-D+!%E\$)-^PA<[C_MP*Y7]EW]H;V_:2^&4GBBWT;[\ /W\$5[]IUS9W-
SYP698XW_=R87>-DD?.Q/F#_M]0F;P']L#0?K/QY\ _?;P5I=K=Z/_P_+.N[74K@V,SW2VL*1PR2)(B! /M\$:"
MY\ _JG_'I0_W>H^"QZ-=?M-P2?M46?P:TWP[-JC+9?:M5UZ"5]NG
MMY,DJQR1^5T_X]AYF\+NN47[WRU[WFOBC]AY_QIV-[NY%N]SJ5D^BVU0<7_B^T270,.\$\Y?8CR2;!R5B?_M
'A]Y? _ \$Z_-P#!)S_EZT>ZFL ^FD,IAN=8_6.: "7Z,D0\ =>J5YTTI%749_M\USLK_ _X*)W'B;Q-=6?PM^#_B?
XC;98G_2-4MQ)\$_2\@C(C2"5PCI'03?L? MK\GRUZ!^S0\ MI>' /CIXANO"%_I%YX'^(%B7\ [0]8;EBDC[XXI,
(SR(D>7C= M\$88? =4=JZ0]D?P?HW@S]G+P##H6E6UC _;6C66H7PMU_U]W-;Q0)+)SU.0.^
M%""N%117@'[8VAZ;X3 _;V_9R\3Z/8G2?\$FM:] 'IU_JEDWE27,*3VD8BE*?\
M3.XE3 _;0[&^7;1; ,I.%K6)DY*/-<]0\ _VE0VI-' _&?; ;2;*WTJX\7>-]9GC_M73?#-A*1/.'?9YA.QM@S\B
(S._RJ0WV3A/A]^W1/J0C31_#70%^%0BCX6W> MOWD5AI^U?PR2PW,W]SYXHG^^\4?R(_ ,F6V*-]6_V@_@?
X^;]H+P3\;0A]9Z5_MXHU+P[:?V?<>&M0G-K+<0M).CF*< (_#Y=Y+[_;M\H'] [G973^#0VJ(F\=:/X
M'^ (G@_50A;XMU1G6W^W&.ZTJ_E_39!;7Z8260I)%QL7Y_P!W]
[90BT7" T5*M\$%\%R0)+-7 _; \^\$^D>&AI5[]J50H3WVGVB;S)M+@F/VYY)3%\XDV6
M\6UT_CBC_N5ZYJ^B_M3:_I]YIU _; !& \TZZC>":WN(=5EBGB<8=)\$/!R/SS5_MJ,8)-J]S)RE-M7M8]W\>.-
(^ (GAW2_\$'AS5;75]\$U*#[3;W5JG>0HH]*YI^SL=,7=7%HHHI%!1110_4444_%%_%!1110_4444_%%_%!1
M110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%
&5J>J6NCV=U=WUTMM:P1&:>>9MD<,:@DN2>G_UJY8_M'+X= P#0^% _!U;_P#Q=9G[0WP]U3XJ_"?
7/'^C36UM?WOD&)[W<(5*3QR?_M-M5C_P_L^P/60@; _ (8U^,/ _\$)[?^#.T_ _CU8U)RAM&Y\]F&.Q.'GRT:+F

M>F?M]>. ?#_C/_A"?[?#1:5JXM_MHG;3[V.Y\G? \ 9]A^0FODJNR^(0P< \ :? " M7^R?^\$ LTC^R/MOF?
9_W|0+|SR_, ^X[?|?|*XV0&K5^*?8_-&[770#_ (<^VZ?>9Y^R+VWBQLDV291W1_OOUK1G--.\5* MPE7|S!R?
8_2BQ^,0@+4KVTM+^QMH%[1#;6VJP2R32GI& '))|J^?:?^"J MW/[//AX|0^\$GM_ \
TC0*|3T7|BGXKZE>V|G/X;MM)MY!DW-|>V_E0?3R79S_M_-|5|9_P547;^SKX<7T|3V_
*1WE>QA)SG/WE8_0L'BL1BX3^L4^6WXGT3^ MS? \ |F| " \ |%?
20_2..C|I#_DWOXH?|BOJO_I'+7R1\) _^":_PP\>?"[PG
MXGOM8\5#4|:T:RU&Y\B^MO*\$LUNCN8\VS498;=W0R8MEX^05V\D.?XCUN:7)L=?_,J?^3>? \$7_M
&,|0_Z1V=>C?LX_%3PYX^~*?QBTC1_>F^\$;_P_K/V74=5L&3S=7F\^|02S_M;(4YS%(_SNY_>UYU_P_\$J? \ DW?
0%_V,|0_Z1V=)^PS_,G\$ _M2_|C1_|=ZA_M535W/R)IMKE+?C+_ (*%:= PFUWX8^~W@35_B|=6)E^W7&CM^Z
01CS(0+25_MY8)\FSS^BKDQ|-ZN^K-;_@IMX4\._YL?.'7P|9>\$0\$T!)OM+:VBE^S<;XQF9X
MG^>/RWYC7K|;JX7|F3XFW?[*NL_\$#X1IX0U_XHV&B:S).W2
M..6W_P"69_ =S;LR_(\4B?/LWUZEX3|\$>* _C=^U7X>^~%|X:U3P1X3\/:+ _9V_MGVGB&)(M4U"90=QN3
CDVP3|3)G?G=Y<97|Y*\$E^+VT!2D^IG? \ |5?_)-Y_M\/?|C/;_ /I'>58^ (?|75YI>M:P?
A| \ , -6^)'@_1F>#4/%VGSRI>DL8WS|9_M4@D3RT3|\PN0=L;-CO!_P58_Y-Y|_. \
8SV_I'>5|>:/H|KH.GVNG:?:V|G_MIUK\$D\$-M!%Y<4,2#" (B#@_ ^=D@&' 'RNCHOL=?\$/|
V|FV^B_'7|IK3K&UM_M|33K+Q+;_6|K;P"&*"%+B_V)&@XK|=6LJL5&5D;QES^Y^='|9G_*0SX'?|P3
M_P!.E07Z+8'20SJ_,_Y2&_|N"?^G2XK|%1ZUK5E|D#"G9SD?|_P#P4+_9_MUT?1?|!'
M_PG960ASQ;HE| '<7UWIY-J;@37'%S|B?|?'3R12>9E&V>9N=|_MJ_?00P0_&B-#|6?LY:/\6/%S: ^'M--
CYVHW=POEQ0RQR>1,(TW.^'GC;RD_MRSME,ZN1;OZ_ \ 0|8|XOM\$,DE_/&)(^LD;XBD7
M_MF|7"/M:;4B93Y&VNA|??:?%#_\$/C*^N|KX??_S05XQ_-PS_9EU6_R9\$WEQ_MNT_MK?
&;P%HE\$ _\$+30\$%E^IVH: !-J'|GW=K^YC3?&|_N_OVD/SGYOWLBI/XZ|*^&_M/|3^D>.0&|^_|
<|. :0X\$|>PV(N|H>000A+XH727|!.K|+A\$>_.3Y|+04%U&U7_MV)J/);*N4KMVN1?M(M_>#|V: +&VAU=;K6?
\$=_%+<6.A6)3S2_'DE?_)91_M|P(|V&;DE4?8^WR03? \ @H%J7AV^M90BC|&?%GPY_.3S1VZZY/!/+)\$F(XDC
M>"'C8)7^3>_ |0Y4>N"UK_A8_B#_@I! \ 0_P#A!X80=;T70;?|!_PFXGEM;&%_MK>TW_90(^>_
R|Q+^\$L_|^04_B%X%_:<^)'@_5_"6N1?|B|TS5|-|6Y*CAQ(|_
M_)8|Z;@D1P'3^XP#52C&%E);F:E)WUV/J;1|8M=?T^TU#3|N" \ TZB2>&Y@E_M\V*;)QE'1QP< \ ?G6K7CW|+?
PQUGX)_?PYX,UZ|M+W4|*^T&XN= /9Y8CYEQ) M,_
Z(V=LF/NUZ^U.M50KFZFTG_2;BME^95LME*5%+7NCP/\8CKZ|HKT:_\$&*Q_*5&HHV?D_M>5AN<'A*T:|*V4D-M-
OU2!XS%(R|)-\8W\5|]-\M/HK6_W/-W_7|9_MHI1DXQMYW%RZW/S\^!_QD^_7PQ_: / \
"NP_9^U2|UW2H;JP@UVX_P|_TSS4_M>1DD_ _\$GCRT^W'6?#|G_VYIMEY_M>EF5I+/_
\$:'3'_+RY8U|S|ZZ1^:R_/7VS16KJW09;DJG:VNO_%CX5%;_M|F?|H'5_BM^*M^N?%_@_Q'-
|IU_P08^9)+YK2Y?Y/G=RTDDL21H_D^9(K)Y_M7WNL\,_'C|H;XU>*--+TWPV\ (0^%6Z5#>1G5M=\7+)+MA\$@?
\$; ;I_TF|(I8V" M;_ \ 6Q_/ %|^0LBBI=2ZLT/D|ZZ9\2_M3?_XF^#?C59_7X,(M|K2VGD;|H: M@M+?
Q11GG8|_+|^'CCCC|B/8^ ^.-UW,=R9VN?M6?M"_\$"Q&A^#?V?=5\ (Z|>_M>: %U37_-ECMU\N3_)
|PP0QR="I=W3(''|WU|UT4*IMS*|A.G>^NYXAXT^Q_MK=?LM>*=\$1W<'B/QM<=>\$;VVN7T>R<+
<7;VDB#RDZDD^B*';|J)G80S3|\$&_M_P=_P|F^X,^&M^U#X)W/C^0_*W: ?_9\$TD>IV^GSSS21W4")*^U=
|^5A>STL?_7CK|_MI3|H/XQ>&|KPKX*^!7BKP+KFIK;^W; \RQ&"'8YD\N2:&W2"1L_>90_|SYB_MKK|(?LK_
'B_9S^\$>F>\$WN;:|UF>XDU#5KJW\$AAGNW'_+/?>X\$CBCR_N|RM_MY1&'K|0=#4H05>HI14E:2/S9\ :?
|P_%T6M'_A%_M/%NE7FB#_CW_+> \R.ZMQYG^K^1&23|W'_ \F|^XE:7PK_P"">I60BFTNOB|
MXATNYT2"6,_V9H9DD_M_8),7\$>92I^S|H_M>1_96%Y^?E,C2=)M=%T^VL+"VM|ZS@B6""W@B\$<<,2C"(\$|
#Z5HY/_>2I_MJ20F7>6LCUE%(^/0^"EG@WQ|XX^!.@67A0P_J7B+4H?\$U0=-:Z39/=2B(6|T_M#((T#
<#>/_SKA_A5^UI\6/_/P_P#"0AG_(9F\9WW|BZ9:Z8;DB|B|_R8HX_,_MV"R8_P_'ZU|14E;1J)*S1FX-
RNF?._P9^)\VM_M)>%_&NA>/OA!JWP|TQK2.P_M;WUB6X'|H07\$S?'0|AV_P|4*)X&U3XN^_I
MKBOZ/_8V\^0|LA^'VC7&CZ.+J&XA|V:>|N':2_- \M45A\$GNX_,1MFR6#;0^_7:_ \!1KX6>,-
<_X0SQGX#T>XU76+:'4?#^HKI%@|_MS?2VEW;|,_)&W|M(Q=)D<:Z^3YGK|AI:T|J:_ \|FD8\ _MJL?G9^W)X/\
&&_>0>+|/T&RTVY;^R;">6-|H;^>;RS(D;|{C_M'?R00/^&Y0BQC_DUKQI_P"3?_R#7VE16WM%9)K8R|EJVG9?
6J?_XU?MJ^_M*+6Y^*(;X6_#BP\N_P|/T*SVRW5QYCY>(7.R=(/W?F3HNS^&W^>;OK/XH_!_
MW1_B9_'18^'K6UOH^C7=E|DM_L\(\JQ,>#;/_&B,@_DR1Q.\$^|B/;TKTNBI9'+YJ
MRY3Y/D="LD<4CR2(GG>7&J1Y7W?0.EK1U;WTW(C3MU/FCX|_!%^. 'PL=)K_MWAGP+;>/?
APMI'!+I6GW\$C_HLPR#*_\$WC>\L8V(ES^EMN_=;VKYV\8>'?BC^MW)\60AZ/\$GPAN_@GP0>9U9=?
GGADGAFDC>X=XXG=5?Y/_MT@I*F-3D5DBI0YNI|B_MF?L|^0^7BCPK|3/A1|/C^|GAG_1E_?
^5+1_)&PR3;XW&|DE=6/R*C<=%^V+ \ ?_9T>TT02_VV_M2_@0|I_MFG9YDAC>%/+3G^.;Y/XF;8: ^ZZ6A5-
\$FMA.G=MWW/+|V?|/^(|C|-=,7XI:0_M:ZIXPFWSW#6M'_'Y"ORD4I0;))\$Y&|\$1.-0S|=-|T^I2T5DW=W-
(JRL%%(MH****_"BBB@_HHHH_****_"BBB@_HHHH_****_"BBB@_HHHH_****_"BBB@_MHHHH_****_"BBB@
HHHH_****_"BBB@_HHHH_****_"BBB@_HHHH_BY7T%+N_MSWI|%)ZBL?_
W|6W|/OB+X\X6.@7>FV@TL7/G_VA/)%GS3#L_V(W_/U\ ? \ M_.|OB/_T%_"0_
(\$3_P#QF0T3I^QE1A)W:/#Q62X3&5^5K)MOS/SL_P"">WQ'_M_P"@MX7/_;Q/_P#&:^Q/V>_AWJ?
PK^\$VA^%M8FM|C4;+SS+)|8|0)80/))QN5_M3_RT|@=*|0HJJ=-,+X33|Y3AL#4|I10?U&>G?('!2SP;X@|=?
K0++PWX?_MU+Q%J4/B:WNFM=)LGNI1\$+>Z^D"(&X&\?G7V%171&7*[H]:4>96./V?|-N|_M)!^?P\TZ_M)|&_L?
#FG6MS:W,7ERPS);1AXY\$[\$8Q1^T|IMWJWP+^(>G6^I_M/?7|)|X(/_P_"
M/\$%EXDT#40#NI3>)KBZ6UU:R>UE,1M|51(4<+P=A_*J'|+-CJ^P0^*7|40BK_MQ;I.I>'?#0_;4FI0:C?
64Z17^I'<7\DDL7R?0_\$G|WN|>M?:-8^B;P|IGB_MKPUJV@ZK;"ZT05+.60NK8DQB>&1^DB?
+ \W*9%;>U0S;:F2IVMY^Y_?"P- \ M>0^5UXX^ (WP6\/_EI_
MTB>30?.Y/NUTGA#|CGOK\0_&FE>* _P|H;Q09^_3HF\ :?X?T^\$ "PQE'\$DN\$B1_M_G'S)Y/S^5^N=U^2NCFA>
|V,U&2Z\$W_!2SP7X@|&_#^I>(M2A\2V_M|TUKI-D|U*(A;W0,@1_W_WC\Z^P!WI:6N-R0%1|^0HV;?<^/?V-
_!OB+PM>_MOVCK_6/#FIZ+IVJ>)OM%A=WUE)%%?1?:+ \ ^9\$|_ZP8DC/R?| |7V_M_HI3ES
MNX1CRJQ^=G|T5DFMC+V70-I|GP%JGP/^_M-/|:OBJTN?BB&^%OPYL/*0_3| "L|DMU<;WS^ \ 00\DZ0?

N_ G1=G\ -0\ \ PKZ M(:1 9RL0CC\#;KP/I\6ND7%B8KC0MT\CM; &:=%D:; (\#9L\R/HX02;@C;% M>[44G4E=-
+6*]G'7S/(@+P)^TI^T'\ '?#KX5\; KQ5XZUS3 M0_ &[8&64S MP[\$,?F20PW"3R+DCS-
^ P#, &9NC_99^"'Q- \9?&N\^ .00G1; '6FM/(T'0V! M66PBEC'.Q' <(DZ\ "'^\$0#,, <, %GJ\TD5UYL&^:'
8+)*?/N/, W[\$ MBVQ;/G9/G_02BA5.562"4+N\ SXF :F^! P 3? !00JL CK\&\$^UI;3R->T-0
M6E0XHHSSL= WZ/' "'Y\$>Q]\<;KN8[DSM< :L :%^(%B-#\& L^ZKX1UV\T M+JF0^;+';KY&'&.3H5+NZ9
78^<0NNBA5-N97L)T[WUW./^'=KXDT_P M7H\IXRU2VUCQ/;VJK?W=A\Y4,\W

+H MY7-^]LZ]?&Z[MC:-?N<*WVTVRNU>Z=K>0C@Z.XH/WI05NJ4')R^?;]5*7^0V
MX_:=PZ>3!*4R&]UX8Y0"Z>6+H\NSIZ\NZ'U^X>] &W_KL[X(H65C[B3Z\K5X< MG1)"NM9E2Q
4_K015[JN"1#0^#G /\$I;TL+\[PC].Z8=M"R4UU>V_H>IV06+ MHR='1:67JJ0;]_ ;V7W6@YQN"5]K:\
[_%K;Q[\>BH*#0?VDU8# PVII' U>? MAVS\DI], #' \[#@G/&6S9B+%^K5KU\
[NQMX>AM0*, F%1>#>1, 0T*Y;AV^-5C7 M0KP6811V65R;56.6IE1-6UR6I>V:UC2KXIVM36FT?
W[28C]:=5(&V*[\$]0D! MV'\NOK=-N ;%FZ;2U7#]"?!,R)Y'9%^=WPGP6F_GQ:/367%^>GYQ![Q'B?A' M#._1
7@35!; =;GPK8.R /<4P0+08AH>&=!30U6E?G\$ \$" :W>BCEW_ZP]FW MI\ NP/8B87MQ%_1_4E2_>SBE?
+&TXM7M0%X6"DVKP]K#1,K[6:KFATM*"VD MWGA=T5_A1708FD8UI5%UX5L\@'VWOC!-67>5+MH
I*.'V.+ '#M]H@NW45G>M M*?VL>-N4\T(U56'PTNW:UC7P0FT VW<+;RJC/'/"<%Y=U#<"M=@\$I6&^-K4\$"
M+8:;,&Z_8-?ABK6YTL="Z*71M8&6.;;<%665.Y+PG_AW)MVD/T-XUJJM,*[3?
MFPL]%M">K7)XSS0,V%6\$.%Q#NR[

2;R/,D2-/DC5G)WRICA>,BMW M1=:L/\$6DVFI:5=V][IUY#')00CDC=?0HP/7N*^:0\ @J-_R80\ M3?\
N& ^G2TKA_V?MPM;3&9[C] MYI,KB/R99_,D,<@, #\Z#_E0%%\$?6'@/XH'^?B9_PD/_ C6K?VL?#^LW/A_
M43Y\$D7D7D'EB>+YT7?L\ P?.F4.?0=:[:0CG\CS01I @?PI^U)XDUNY-EI&D? M%CO/J%Y<^2\GDPQ)
 \DFQ\0.\$!/&>E8>G_M'?M,^-0!5Y\50!'PN\,0\,1+] MJTGPOK1NQXIUC3DV\$W\$.Q5"'F3S9\$&TMC[B7'R-*?
9.J:UI^CP&:^N[>Q@ M^&V^T7\$PA!EFE2../) C=WC11_\$0"]36S7Y] M/_ !\9_%X9_70?(-5T
M%?17C30CHUDEGXBL+B.[_M:*,E0'D>//VE/ MB% \ ? &EZ5\4+KX=+ \6/%VIW%MX;^Q7]Q8^';>UCBB,EW?W-
WM, :0F0EHTR\ MN8TC7<[,@!]>45\6_]KWQ-J00J\.?#WQUB^0C"Z\6Q7ATG4?A-J\MV-/
MFM80/D2_CF;A)H\^4Z?Q1N-IW[T]_P#@KKWQ,UK2_\$\ 01\:/7X;U*WU^ZMM M(M='NQ=13Z:@C\B3S-
^9'<^;RZ0MP,Q)TH_13HKYW :&^/'BSX=?\$;P#X\$ \% M^'= \1>)'?5GJM0I"ZC,8;6" \M_LC :+F0/_
,> \=0)=2.B(\K^5&B;=YKS; MP[^U%\7_ !1XT\4_! *U/\^"?^> '8H\2NM3FN+P>%OL#?9V#QX3[49]EY%'
MY> GWY/- P"61 /J P 8>*M-\\$%=7\1:U= 9-(T>SD0[VY\EY/(BB00(^Q,
MN<)D\9/%5M(\>:!'K'@&R\;Q:M;)X30--CUJ+5;@&UA^HT7G^?)YFWRT\LASV MF-0.ZOERS^-0BCXU?L8?
M'IXTTS2= \ \%A.'Q/X40FT(R?8+F6VLY"98A-\ M\;?0-GSD_P"K+?+OV+YMX\L;OXJ?IG]B;X(XSHGC2STW4-
8+7\MM%<:=IFEV M\109RB'YG\Y)"Z_.NUXH_P#?0_1\ P"'C'[.7_ "3_P[@?+1TW^T?MOV#S_L M5Y]C\W?Y>?
M?D^1Y?_3;?LV_-NV\U]!;+K5AXBTFU+2KNW0=.0(8[FVN[68_M2Q3Q.-\,00L(-.GD";PF%,I=NAH_V/AW\=0
008\6>-/#WA76/[6UGP?>G3]>M_M0L,\7V6;?+'LWNBK)\ \ \$OW"W3WYROCE^T]\,?V;3H[?70\$WAS^V1!OAW-
^OKK'[.'QC\3:S=6EUXLAD\+^/[G5\ M>.UNII\3,^HV^EUYWS"2&#2;R?,L((T^2-& M:9J^N@;1IUQ#-8W-
P=CO^ZCN\$1Y=J1R0+W;!!]&16Y\;?VC?AW^SKH^F7_Q M
 \26_AV#4I0LUEN@DGEN"@R^(H49RB\;GV[%\Q\G+J#\OZ]XP\)?MF?M'_!W
MQ#\]+U6^_X1'40[1UWXX0V%Q8VT%G"A=] &S*(0/>@^ M.VA>(_ @[\^V7H'Q5;P'X@^+7A2X_-
R>&Q;>&.&.^U3P]=[WD\$ L4"HK>6Z>8GF M%]P-Q.K.J^5\$X!]&?!_X\>_ CUH1U?X?>+M,\3VL'%PMOF.ZM\R.D?
G0/MDB MW^7+MWJN[&Y?EKTNO\$ @'\8/@\]=;KQ9XH^%][I.K:C//;6^N7EK8/:7\Y2/_ M_1S*M-
 \ \$%=7\1:U= 9-(T>SD0[VY M\EY/(BB00(^Q,N<)D\9/%>#>%?CE^T'K'B;1[#6_V8_ ^\$=T6>]BM[_51X_TZ
MY^PP0(!).8D3=)L0[]@Y;I7H/[5G_]K?QE_[\$W60_2*>@#I/A? \ %PS\80_M^E>,?INJ_P!K^&]2\W[-
= _9Y(? \N1XW^215<'?'(.5YP:I?%SXS>#/@7X// MBGQUK]OX?T99XX#=3\Y/.E?.R.*-&>5N^\$7.U'?[J-CY
_868?L[>)0A]X&_M8;?'Q;\':?XKT#C_4;Y#I]N=6M_XW?S8_+N0,D9(DV^7&I.;\V_X*5:Q??' M;1_B?+I]S-
+B+3M \7> (R73X= M2=R\$ LKH3\$N^FXVN_% WE\UH0#Z\KREOVBOAU%X+ \<^Y? \$M0;>'0!.H7.CZ_
M=W\$,B"VO+* "GP"\. &6 MT3P7<2Z=K_BfQ_>1:?-J2.]E:B\$AR_.YR"0\ NKY33><_LT^,M2TK]F+]
MKGQ1K7AS2[;6H/&B_4;[PQJ12_M%F2QBDDLY2FU;A-^8V(X=?J*_/K_%3X MS^#-&^&(^)= [X@M;/P5_9L6L?
V0V/90=B\$"[C7_ " M_P#;8"" Q>\4:+X= \(>.;36-:UJ>YAL--6QNXIC]GMO/)E)(5\ M/+ .5=]J0A MU7\;^-?
V;_P!E)0#>EX0L=\$\7: SX/2I[N:WCFM+ M.2V3*G3=XE\ V-MS_ "0;02AKU.'Q]\4/#W\07P% _-
_#KP]\,M5\1^(+0Q\$+? M5/#5C=S3:?:0:?!(AM9[EM\4DC^:D0\ "R>6/4T ?8M%?\$GQ2_4US4/B)X@
M\.'?"_P_5_"3PY: ^\$[N31]7U+XJZY)82W]XA_>1VENC1)Y<)&QIW&UWD/E_*C M.VMH?[]6FP?
L[ZGXWU;13XA\6Z;XFD\#6VE>\$6>[M/\$&N* 8082C<_V>9,2* M[K052543,\$\T ^C_!Y\4?
#OPS_X1[_A)=6_LD^(-9M0#^G'R))/?/0_,\$\$7 MR(VS?Y9^= \(>?>Z5VU?F]\
<];_!OM5_9SB^,GAOP;8:9= \$ _P_.W,%SX10) M_-T^[4R?Z'=QS.XD=Q(?WD+NB?9I/F?>E?I#0!Q/P0\
BAX9^,7@?20&/@W5_M?[]7_-ZEY0V:[^SR0^?YE M"VGU+P_H/B+4[>?"F(RPW=](GF;20R\$Q^W6LK0=^V-
^T^X'^\$>?';4/ACX+ M/PCOH;[:P"\$;M]:N&UVVM;A_D\$ \MQL\C8\LD3_)\$[A945D5@[H ?<%YK%AI_M]
[I]0<7=M:W-],>WAFF\$9GE\N200Q@R/LBD? R=L;MT%;%?#7[6GB+XXV' M[6GP1\^/\;[P6VG+G-
JFH;#;:19W\$>+VWTR2.?[]&S/(BP7,WES'9\TI61& M\M';H?BE^U9XT^%-CX2^'FN:I\,] *^_.J66W^9(VV-/G
/L2B0E#]F+J]C6_B5\3=2^& C'50_/B30'!H_ M_D50KWPPU22^TK[+YZP/;2F1M\=PCF-_P")627^#; \S?
V7/CS\80VCI/P5X_M\^ASPAX?^U19FWU%KB>X MB^Q(XW2>>TC1VACM_M?[]M4F8R[(I&_C6@#ZQH
MK_/#'[8'127CKX_V_OPTCX=^ E'^^EV3W.K:7=:G2GDQXW?.Y0+M< ^@:Q[/6+#+4+W4+>WN[;ZN;&86]Q#
M#;.)#!+Y<@CD_YC?9+&^#@[9\$;H: ^F\!_N:4>7R3]D3Q9^TUXM\;?\$G4_M)KGX87.C0_\$JXL/%!NH[^.
[\RWBL[:=+ #8_GEK;Q1)%YWS[A^H ^O\ X8?& M+P;\;-)U740_OB^V\1Z;I6I2:1/=6X?RC=0^6\@CD=?
WJ8DCQ(FY&#;:U>A5_M\A_"S]ICPW\!&G[0?CKQ3X?TKPYHG@SXAZUIT_ B^EF.;4-DE0''),N_]
MY=S221HTAVJ?D+;.%&ZN9U#]H[]IGP/X-M/BMXW^0AD?"]IC
MWQ4TW4;C2+C6+B6QAM_+@M9X+R3Y=Y@2&661X=JRM@*K*PVNGP/^/GQ6N/VA_M-5^#/Q?

1,^&70#;Z!_PD|EKW@^|N&L;FS\^"!/(L\VZ3?YKS;G9U_U?W-N' M<^IZXCQ!\3-
UX4\;:>?!NjZL;70)XL^V?V/;^1+))I-M&);C|XB;V(<_M.R^BYKYP^*Q>;C\";/X@^(MM\0-GX!T7S-
0E|+;IJ<\GB0;=#)^>2>%MVLTD;-9)\(S%(7)\R;7J?;\$#QM9?\$/\;F_8G\6Z8MQ;:=K^F>(12MX;CB41
M3:/!)&)-I8;\2#00!|HU|??\$|10+X# "7Q1<^'?\$GQ\$TzVUN 'SK6QM|B_ \ M(E61XWBE>VCE6.1'0[D?
YEQR0(JU^VU\3-0^\$/[+/Q*\3:5]J&I1;;|@N+> MX-
K+;S74B6R7\$S\$S^8,8YBQ3[U:W|,O|. A|]G+X2^' #UEH>D6GB%= M,MH-
>U+3XB3J^VD9,DDD(CS)\$\R2790^XLFU51?E !V7PV^*?A7XP>[?Q'X M)\0Z9XDT6< ?;[&?S##(4C?
RY\$^' (\$D3=')M=, C&=+CC00\$.K3&1X(I7C3+NQ,K|W# '6;=[NJ/Y/ M=?M+?']GU?#GBC|H#P?X-
7X;:ELM|6U+P)|KFN_#,\FSRY+U'=T>/>3&WD% MOFSM=FV1S 'V017RU\6-VB?
B^JGQHE^\$7P+|.Z3J_BK1X5U'Q/K (NAN(|& MT>.6/?!;GR=KR3S9#KLW8 ^Z_P']:'3_&= VB0%?B|XA>(?
A/\ %?P|;>& MBMH\$4FH?2B*5M*UC33+LC0;21]Q'9DC1D=MP;:_|V*\$ ^DJ*^"/ O|20|40 MQH^!5M\50
0@3XQ@MON)) 'Y<4#N7W1G M+LKHU=|XH ;R\|R? 0X:~*|!.D6GBOXC6\&CV_B:|^R;5I\|. \$0Y+Z|=(_W
M%M)\GR8>X;8L2_/N4 ^NJ*^+?@?^U|XFU7XU>' /A|XZ\1?"WQA=>+8KPZ3J/ MPFU>6|&GS6L7GR)?Q5-PDT>?
*=/XHW&T|Z=#|. CM\8?C5\0-7L/!WA_P ' MV'A+P?XP00#0BC5]>EG\$U_#?R 1Z?' '|?0\$L?)=Y)|J/-
<8556-L@'UC6-J MFM:~H\!FOKNWL8/AMOM%Q,(099I4CCCR?XW=XT4?Q,004U\I?%#X0?M1^!- M'\0?
\$6V^'W@&S\ Z+YFH2^M4U.>3Q(-.AD ?/)/" [6:2-&LD^\$9|BD+^9- MK\K^V+|6/B1XD|\$ _L^>
(0AK?;' :^%/'?B3P|T&G^('7|4;QY8|VP6YD21T^ MS|XX0-\$>V56A^5W61E4
^J 'WQF|&?" 6?"FF^+/\$5KI6H>)|2BTC1|/\$DDM M_ =N=@&Q%8A/WD8:0X1">YAN3/HM?' /Q.^('Q/\ GA?
X3CXK^'/AAXB\2ZU_M\5=)TBW_+)L;N|M+&UF1|ES#|I=7COD=)=DGW57'')KT?X? &#Q3=?M.?\$ /MX4>-#I-
CIMGXA\|7%A9212WVFN\D=0)-F:5-\,WE0_ \LF?YW5-I^4] HKY M,C :|N-%USX|^,?&0|F_ |*6^'-
Y'HE0=Z;822:G?ZL\$@2ZM_GFQ^|GD^E*I+ Q1!#-(B'', MA_LUQ/#Y@=|FU'\J3:R?>4_1"0-?B)\=0
OPG\6>" #WBK6/|)UGOA=C3]! MMOL,\OVJ;?%'LWHC+'|||7WR07VX|*K| |BE|*8?V_?C'\=;6SNKJVT/P+H,
M?@S0+B^AD^Q_)\|I|I|U)QOCDC=?OHP/7N*^1|) _4|;?%# @GVWQ M0^'WB/2%\<:/H\$K:|<;
[9I*5NK2W<7V(H7V03G_CXBWHR,IC#1*LF5/V6-;^ M/_AC|GWPIJ6K>&?!?
C+PE#X)L6\+Z'X:0;BUUFYF|BW^R)=3W;+;1IY'F&5T MSR/D5_NL ?;-?&| 'KX_P#P3^(GP_L_C-X=|
ZGX1\9ZS^X8@U+P%->+=6& MHS' \$?SD0^&-|2#Y/N@%MW''I+U.M?M'ZS\&0VC#X0^,5_X/\|^ \$5G?
9WHF=T\$@20;9|T2/MPN7E|J(]<^+GQF|&? OP>?%/CK7| M?P_HRSQP&ZF#R>=**^=D<4<;,|K=|
(N=J_ W4;'H=?#0Q;:_1|5>(/V)?'WQB MU;P)X80/'6H3V4WAGPCXNTJ6Y,NG ;X(1^,|6L:7HGPA|-^%|QB-W?
>)/&UY(-/49V):1P6S_ &AYV_UF|U6)5CV| MG9_D /:*|V^-GQW\?"L|)%|/Q#|0-
8'A|1;B|CL(+IK*>YS.TJ'Y6=XDXC_@HYXFT_P '>%0@EXBUN|^QZ-HWQ5T74+ZY\$3R>1##' M=R.^Q,L?E'09H
[GX8_MY? ?XN>*+;P|X;^(FG7.MS@>3:WU0<6'GRM(D:11 M/TU;Q9XML]>MIU^(
M6FZ9=VJ^!XA(CR7CSS)"2|Q02|=(Z|VBW;0-CA#?27Q:U0\ ;#00&DFG_";P
MWX,TK1;**,W&N>/KRXE&I2N/N6D%D|/&D|1WGV|FD^5=J;W_/?JX7Q1\4?"G
M@_X>7/C|6/\$&FVGA&WL4U'^W0/\$EL87QY^- 'A3|C>ZUGQI9?# '5_ASI0PJ>[T;3;6"EN|G9IZ26_M\5_ '+^Y>-
H!(!)43J0P0RF@#|[-\^*M-|;=>=(|1:+=;|)(UBSCO|*Y\EX_/B ME0/&^Q\.,I@|X/-=7R-
XN_::|0_ "K|F;|G0Q5X8\ "Z1K>H^,IM\$T<=>|/F_ MLRT5KS3Y'CM|20|DMT6=(47?N39E>^|6^\$?
CY\3Z/KW@F|N(HK8V=0)/<1RQW.YY'XA_N+^|^_S*@|!|=T5\;I>0C_/&S_MXB?;\$^S^#/AWP#IGA'P9K,0AB?
40'LUXUU?ZC"? \2/)2S<|(TS&/G^\"&WLWMU|AM= AGBB6TB?R/W@F=|2>9', M?E8KMV?Q;A0'V'QI_:-^'?
|.NCZ9?_\$#Q);^'8-2F^S66Z"2>6X*#+XBA1G* M+QN?;L7S&M".K_#|Q=IGB>U@XN%M\QW50F1TC\Z!|LD6-
MRY=N|5W8W+|M?.?QVT+Q'\?'VR| ^.;>_ \$'Q:|*7^AN3PV+;PS8QWVJ>'K0
M>|@EB@5%;RW3S\$|PON!N)U9U7RHG|8&/|1'P/\ 'FB_#\$XD^"|9TNYM|+B\ M|Q=JE0I4E0?
&*W@D>.2Y1X5GD1(Q*\$_.QL|'5,|&% '0|?%&/@?X|?M-? M/B#X'^?@P^'\$TINM'T/Q;
<7=MXBUC3T&?,CD3=;1/<|^49,(F1_K(|LK^H M?%K6_P!H.^|:2:?)0#?
@S2M%LHHS<;YX^0+B4:E^X^Y:063L\;0|>?;N:3 MY5VIO< |(^*00\, !WP/JOC'QEJO|D>&|
|K|3= 9Y)0(|R1(T^2-6=DD\$C2)^ZB0\68N^\$ /KRN)\>?%P|,\ ^\$>_X275 M0|)/B#6;:P_IQ\B27S|R?
S!;!%B-LW^6?G?"#WNE>1?LG_M;:E\;I?&GAG7_M;GPQJ_BWP7/9+?;
|X(00MF@:C%=QN\|EJ|_/00)) 'A_CC^50F*)QW_!1S4- M2T?PS|\$+ OM*70#K=0\ %;19;'2_M*6_VZ=
(|HQV_F0\L>|QLWG|N0: /L2B_M0D.Z;\$^_ PC^_W@?0?C#X>|&VW@'QSJ5QI&E:GX2.HW,NFWA.;."ZFDA5)'
MFSY8VQIN.^3Y\$C9:|S|G^XR>*/'GB3XI^" 'ATJT\;^"M=^SFWT>RDABETV> M!)+^|>4;YAYKE-Y9,!653|X
^@*X0_ (6AX9_X6A_PK0\ M8_ \)=_8W_ "0 M?V9Y\$0\ QY?;?(|WS-FS_6?)LW|_/9QS7F?
|*QQA\4_ '|PWXG\9ZF=+ P"\$ M)FUZ|MO\| ^GV4D4U|IL,|QI>3%Y6.|R-GE^7'RF)VV_0\$V\I_P_Y3\| NC/_ M
+G*_ /JNB0_ C_ \6_#WP)^&>0^_.%9N5T71H1-.T\$7FRS;I\$CCCC3^|R1H, M|5R?F95^:0F'4/VCOVF?
_@VT^*WC?X6^&I+VF-SJ_A?1C=GQ5H^G-0(GEW MN(2***1_E1L\$|TM_G:(^XJ*^60C!^UEJUJW@;P9|\$-
&M_&_CWQIIE0X@L_M;C5H+B+2=.T23!_M''|(VOL;E%0?-N//S;(I>E\|>+|CSX>\|^+9/'?@GPQXK_M\26<4-QH-
OX#U7|:-ZL7WH;:3|>RFW:(QB1Y/NLDOR*SQLK 'T!7\$>' (G^ M&0%?C3Q5X-TK5C=>)/"?V/\
MBU\B6/|;:F,RV_|QTV/009^1F|&Q7S<_P> MOC_ \\$_B)\|/|XS>'? .I^\$?&>LQ>&(-2\|37BW5AJ,Q_T?
SD0^&-|2#Y/N@_M%MW''I+N_L?>GR_M;:_| -|4\0^R-,T_2KRU_LBJ2W\$T*+;QPM(-S|OF_M\58Y6-
W90#|!J*^>/%0>|/OA?P1X(^&|MH7B74|-T>W&K^_. 'US(MI=2PQ_M)#Y8@>D>Z>XF<&=I'^15RN|W?
Y/(-=4_::^,NK?!KXZZ(;+PUX.^_ P_*K?{3_MJUUS#)=Z5?;?+;SSP3V)\S=' /Y\$?F*)T=-PC5T7S66\$ ^S-
%UJP\1:3::E15 MW;WNG7D,=S;7=K,)8IXG&^2-U^C]>XK9KXY_9&|4?%GP3\|"/#7B#XG77@_M.S^\$NC>
K74=/N=!A0Y-5@ABM('CDND<;#BW\$I<1|P-0>;ZM^WYXZU#1|0 MQYH?B'X&V7@>&"34;?
P=K_BMOXMN+.,;_*/D.\,=W,B?) 'A_*:1\$?/V9;=>8[*>*6|=)#B^&UG
MNY)8TWN|1(D9^:=7N7PN_P''\$U_X0;2?^%A?V!_PEV9?|0_X1C|1_9_ \K)/+ M\KS_ -Y_J_*W;_XM_M0!VE%?
??'!1|4?V8?&&F>"0 NCZ7K/BGR40|5N- M79IK6RA<.(|?RXI5?SVQYGE=J&/Y7|S*>|_L9_M*1?M5?_02?&
<|G;66N0S_M2:??J|G;>8(8+Q,?Z0>,[^C>*3&7V^;L+NR,: /2?'GQ1_.#/_A'0^\$EU;^R
M3X@UFV\Z:WXPTW_A\$-2N_P''SK'6|)\$NH6UQ-\^4C_M-JDN?|1+|9CVYKY>^\$WC_?L*_\$/XOV'08|
(^(3H7B;Q)+XB7XNV>E&^L9|2X_M)\J+4)+:/ (D63Y-B(5\VZ?:B1|7>S^UMH_PS^*GP)_9QTOP79Z1=?" |Q#|3

MJ&MX;308?L=HUK<:TN(@D6TQ/EY=X^5T??NV00!)]5Y[K'QF\ '^'?B9X=^' MVHZ]#:^-M?
AN+G3] \$Q)))+/#'CN\GRJ=B823:9-F_RY-F[97CG['0CJ;P;X\$ M6_ " QWJ]K:ZY\ 'IO[-0=3N?*MHI]\$ \HS;+?
2%!Y4"&U&# 'YCLGD[I&#/7S)\ M/#K?Q(:@ GONU ^U+(\$*)\3 V! I5[YD7V#0K/2S'8?N'W>7)-YLUP_EN\
M3^:CK]]J /U HHKY4_X: ' :9_P" C2S_XE>? \Y3/^Z, P#N M;+-ND2...-/ (S0)&@SM7 M)^9E7YJ^, I3_
&^0' /@>T/C709X@^! VJ^"XYH9[GP?X0\527_BB"&:1\$<9# M_9KB>'S [[-J/Y4FUD^ \H!^B%>
_%K6_P!H. ^\ :2:?) 0#?@S2M^LHHS<:Y MX^0+B4:E^X^Y:063L\ :0] '>?;N:3Y5VIO?R3_A0#Q+ _PSG; ' "0?
^+Q_P#" M: ?\ "M/^\$: \^+^S _/A(L?ZSS?_ X]L\XWYW_N] ^W]_0!]LUC:7K6GZQ)K& M[M[Z#SYK;
[1;S"8"6&5XY(\C^- '21&' \+ KU%>(^# =0 :;N-\$\5Z9XGTGX8V MOB2&S^TZ^K^G7-_/I<\Y?
LY;1PLPQY<2@+YT.V*7:XKQK @G;XF^/WCC MX; ^#/\$NLW^@&Y^&FLW>LW]]
<>5>1^ ()YY;R[>20H@%MS=D]A^Z/]Z@#[3UK6 MK#P[I-WJ6JW=09:=9PR7-S=W4PBB@B0;Y)) ' ;
[B*!U["0#_AC^WE\!_BUXHM M0#0A0XB:=?*TB1I%\$]S'\$LDCNXVHGS-GA>#1^W/\&?\$?QZ
M_9E\7^#/'5SMUZX^SW4%GYL<<6H>3.DAMY)'1MF[9]I#)\ \<>YUCWUQOPT: MH^\$7Q NO_/P_ \<>!KCX7>-H)
[.X\/^! &WAU[5;::*/;:RV,CP^2BK)YL\$#_ M+IV>/:J+05: /KNBOEKXM_M\$ \$+5/C1+ \
(0@7X=TG5_%6CPKJ/B?7 %T-0' MHVCORQ[X+<^3M>2>;(==F['W7>M#S (6:P^)\$VB_M%6'BSPCH7A0Q7\)
M0#50=#[#/+=6>HWC6EY<:;_*Z6S1%;NL&?-19'#.6X0 ^Q:*^6?A/\ M->* M?'W[!=\[:;-0M-
*_L_%D.@:WJ2VUM!)]A\$MG)=I&-F[I-A/B/= \ KR*N \+/\ MCQ\20A? \,=5^& A^PA :F0\
AJR\0ZMKWBZYECTF": :WC?[':6\#MJ^Y6=XDX?X# M. ?%#XM>"]! ^+^JZ3X\) !2ST: MXN=?N;@W^-+ #XC?
#_P[XNTV.XM].U[3+;4;:&X \$HBGB21/,VE0GPXZ&@#!TGX M\^!->^+F0?"[3];, _C00[/\ M" TG[!
<#R(7\$)\$Gf%/? CXXB1S_K/K7I=? ME_ \ %3P0J6B?M;?M' &?
PW:F[\5 ">]\,;T+8S)']0TF32'CU2TWO\D>^W&_MS-CN0D[8EW/7U'^TY\
<[F[^"0A03_A??:0%G076WTWPE=1&6*2"&YC\R342 MBE9XXX+=, \Q\$M_#XQ>#?
C9I.JZEX%\16WB/3=*U*32)]JW#^4 M;J^RWD\$)\$W(P8;6KT*0S[_8S\3^\$0V1/V=?V@K[6+G5&\ (^"0B5
MJ]BK&'SKNXCC%I;6\8"]4,CMY:9^1 S_ #; %YJGJ?]?7CGP/: '0KXL\0? [5 M?]<:X\]3T5\#^+OVQ0V@0_P
)](^.VH?#^P6?A'20VUW_ (W M;ZU<-KMM:W"!)Y;C9Y&QY9(G^2)W"RHK(K\W3USX[?';XC6_P : #WP<^#0
MAW0[WQ?=Z/)XHU#50&\$LBZ79:<)'@3Y(7\$TDCS@#@';E/E;<[1 'TY17GWPB MU+QWJW@3? \$3P_I7AWQ)#-
):SVV@WTEU;7(C^07,9=, :3\$&1(\NR(4#00WH MGH- !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
%% !1110 44 44 M44 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !111 44 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
4444 %%% !1110 4444 % M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 44 444
%% !1110 4444 %%% !1110 4444 %%% !1110! \S? \ %\$0^VM>-/V M0/B!H?
AW2=1U_6;C^S0L^FZ7!)239&F6.\$!)]A7(+HV"WOEW^CJ2P)-+I]VAS'+^0'UC< JS)+(F]=]>PT4_?#?[(/P-\
M9W7[,00V^'/CBUN0#GB+Q!KVLZ1<:K-!=SB^:73[>TDU6,W3A[A]Y1+/OW*K
MN7V[\%5/K!/M_B#39K>W2>86_P _D3HZ2^5"X=G\M)5#?)\$ _MWQ10!\W>E^ (+G1[>SU?F6_
MAB\$>R\&U=F0]Y']MY4_ =G;*XYKU2B@#YD^ .7A76=8; \$ _9FURPT?4K02-&'B M?^T=3MK;22WL/-
T]\$B\V3&R/>XPN_P" \?I7F_P_*?A_XKT_ (*J?&30;-X< MU6U\^WWA6WMK?7)K"2.PN)?+TK*17!79(X,PCFT;
[7YC MI%_Q-#L3R'/E[KC9L0'=\ZC\$ _BC^TY: ? KX1^-=&U+P?;>(EDU?XB M7?ABWN[JQL/L^6^WMOM>/LW[Z1)
(KNXLY?L.F^*?%9N=+FNT&^W^U1_9N8Q*(RV/FX.WYL5B^! M-: ^ (7QD^) ['WC+07X&\4:1KN@0^)
[#07/J.ASVHMKHZ?' ' ' <2EH(D1+G_D7_M8-@:00*S,C5]ZT4_?(OCCP?JG[- '[1UK\40! ?AVY0?
/CR: +3/'6A>&]'GO[MZ&[2.X>#6(XX=V\$R^R;8!U+;)I9?EZGXJ?M> .0@M\4+K3-5^#?B?QQX)OHA_M-9KF-
^0[B2/_BRUG1[N*_L+K^V]0E, T4@DC?8\Y0X_M<9P1B01?VE] *0] <_9S^*NF:997-[J.H>%-5MK>UMX3+-
/,]G(B10QH,N[G_M'J*]5HH ^3;K]GW6_BK^Q'\) #EE,WA#XC>%] %T#6M\NM7@86V,R! :X'X\?
LJM\&_P#@FOXG^%/ @/2-0\7ZTILY[@V&E^9>Z_M0='4[>2>8Q0J6.\$'RYW,D42+0;9NK[PHH ^6?VQ?A_X[A\4?
#7XT?#S1K?Q= MKOPSGU&XN/"4F]9=7L[R".&X^0(0_+=(T.Q-K;L\!V18I>"UK7/'?]:WQ9^' M&FZ=\.0\$WP0\
>!\>L?&.K;UX^TJ2Q0[Z\MWD^SV=K;[\.C_R;GW';G)V;\$2_MX^XZ*_ /ASX;^)?
&G['*QV^+^@Z^ ^WC3Q[X8\9^*0^\$JT#7?"_A1S1>=?G_2_M(KJ=
[E(8\$A>.*,%]G\$;ROM1TK) ^"0A'Q]'0%0BG70^E! MH,T,DTLWVC3T\$<=LZK_I* >9^[22,:70\M??-%
'PWX^'^_BJ^_90_8STJW\ M:M<7^@>* !=QJ]K'8RF;3X8;-TGDN\$V9C2/@.7_V9^%;>D_ '+PKK.L?MB?LS
M:Y8:/J5WI&C#Q/_VCJ=M;226]AYNGHD7FR8V1[W&W_ 'C]*^FZ*_ /SFUKX_M:P?LY_&GX@2> //V?
F^_A'QGK5[XITCQ-X;_QZSJFGRS3(9]/N8Y?N1IR4? M>,Y++NWND/1?%GX>^+?
&G[,=IXE^'OP.MOA9K/@0009^.] \ \$0V5MYNNPVT; M;)+FVMEB^SS0^*Q;#YY0] %H99TK[WHH
^"/C=\3/&G[2&J?_E]"^!_Q&\/>_M']^) ^D7^K:EXFTM+.6#R3U^R(\LWD;+B1VN"1)Y>W*](_X)7:IX00?
#>JV?BP^\$ _\$MM_8=Q821W[3327_EQB_IOW00CVC&6R*/_MC]X \5Z0_P_\$KM+\(67A05;S08/"?
AJV_L.WL)) +]9H9+ #S(S \$W[TV2;AC*_MX-?*_! /Q<^_Q:T/PAJWCW30!^I: I8ZKH0AVVDN-1, -_9^7]
MHBC1&R,12??9/G, :;@'WIYM\;0"/B3Q/X\#?M&ZS" 'E\<^+C1_P#A&]=^ M&NLZ7'?ZY86;7\LEIJ,-
N=T9N/+DB+P8WQ>8\3-]^6']! ** /EG]F?4_#UKX_M@7= _X2_9@N?A!X?;39+>;Q/K.B66BZC-=>;&[6?V2,>< \#
(1)YQ;87CV[=R5_M=X)V^%M:\%_L@?#_0_\$6DZCH&LV_P#:/VC3=4@DMKF'?J%Q)'OC?##*\$>Q_MKZ9HH ^&?
@#X \5Z1_P2NU3PA>^&]5L_%A\)^); ^P[BPDCCOVFFD0_+C\$!3?_M0??'M&,MD5S^Q?T'Q]IWP!_9;T.^ \-
_\$;50AM!H,-IX\ \, ^!+>0:KG>+[\&X] %AL[]RGG,UQ,BJCV\ "9V)0\ -EW1+M^5_MG^XZ*_ /@;0?
V9_%7QB_9] :C^']S:7/@_4_%'Q.U?4M)N-9L98X;B^+BSG@E_M'0_9Y3;[/,0/U+*^V;:/&0[00QF^~WPC0?
A#%\!/%'AKXG>)H;CPWKNM:Q80_M%X4T^)XY([N\B0 [;T*99!SS(-K7&Q5F^ ^;* /C07/@WK7?>XZ?L9:386>I>
M(-)\#Z/K6CZCK]M8N+;)I\$ \$4DV-RP&9X_E#/R?E^:NK_X177/^'CG _DG_M]C:G_P (Y_PJK^S0[7^S/ID^U?
VOYGV?S_N>9L^?9G=MYQ7TS10!^1:?!_5? MB[\-/'"?%#X+?%QS^T)9Z9K^U_PDWB":Y@T6V*/+Y\$A)#-
LN\$R=\50#_ZR_MRR%5*0?.GTAX;\ ^*X?&W["\$DWAK5D@.\ ^%=2M=:F-C)_P_2F5]\$MXXX[G*?
MN'WKL^?; \P*U]R44 >>?&KX9V7QH^/BSP1?+;BUU[3I[7\$]0\ :1;RNN(Y_M_+ /!>)PDB\C#1C#
(>: ^7_A7^T+\30VOD/Y<41V.V]LEV2+*)7W'10!\4_%7P_ \;OVF/AH/\$L'_M@C3?_NL^\$/&6G>,?
^AZ]/YMUK,5M;G9! ?QJX6TD=Y2<>8-K?NGV;/M#\G\7_M/B#\1_VZ_!&E_!W00A)XN^&5KXA^SW^BWQ-X[TR2WM-
(A@DAF,=B(?CYXL\,W7PZT_M-]"?P9X:\,;M;R1ZK/9+>>>;R[C] <_.9 =L>/NG^ZBR5?7=%_ 'Y??L=_M*?\$

M#X;_+0@P1X1^!WC+Q?XDF%Z/#6M6MN)M N/.U"=1)=W".0V;RY#,&C? \ MAB1|Z+-03K/'/'[%?BSX5?L?_?
FZL=%T#X0;G\)3JESJW@ [4++S; ;78+] _N(M[; > &WR0 \ LMZ9? ?9N587^S?@/\ !71/V?0A3H7@'PY>:E=Z/I
N/L|QJDL< MES^&GDG?>41%/SR' 'R|/SKTB@#XX^!>M>%0\$WQ8T&;P/^R/J7PZ@LQ<" P#%
MWB3P0I_AVZT[?!)Y7V9 &DN/,Q+&_E[=GF1|OE>NM_8M*ZYX3/QX&MZ5J6D M-J7Q6U_4;
7UN\)N;5 (\NXBWC|Y&^#M<94XX-?35% 'Y%I\ 'J5^+OPT\<)\ M4/@M\40'/[0EGIFL77_ "3>
()KF#1;8H\OD06\$D,VRX3)WQ6\, #K++(54I!\Z M?0GQD\ ">-+?}BC|G/5=!\
(ZCK7B+X;WOA3Q>^%0(N%U&X^RVR0R6R1I" [B0 M/*-WR *LNGPQR>;>W5NF[]&LCRI\ \ ACC?.UTQN?MR>'=
!JX,NO! ?QL^#WANY\0 M\$'PU/)I- I|I \HU#2;F-PZ7,\$.V>X2*<0R(B/A&D>3;QN7Z|HH ^1-2_80U
M"3_@G- \ , ^Z?J|M;:T=,C#:I=9EM#?B\2|D0856\AI, C5|F|\$PVUV'S>1^ MG->TN\T.W\WG|
WVKXGP&2VN;5? !VGV^AN>>)F\$DD>IS*R)&T<9=>'#-L17 M? (=0T7HH \|^, C* P# ?PK\6^(-
"TRZUKQ)I^F7\$VE:=;6,|J|JNRF+>,PP M#S'1I/+W8^ZI+,R*-P^2_P|GC_@GW?1?"71-9USXS?
&/PWXN\30)X@UZQTC7 MO[,4:A&[W5] \9:Y%<74<&KW-F|0=1W|Y%:[1]*Z>9EW^5(H\;Y9L',T3X
MK_&WQ)^0'=>!?!GPC|>>!/&0A+P9;6!U748/L%XT5-[0\$]?HK10!^5C? ?
1=9\4? !S0I\|0@7\30#VL670+T8>)?%/C| [6 M=7U|/, \Z>\EM/,E0QLX\R6Z=841|BINW2"+Z.^-/PPN?VV?
BP_@/7=)\1>' ? MA/X':6XU&Z0|&6TDU_5IK>>WMY+"1T7|W9_09/.W,DKR1J8I(|KU|BT4 ?GC
M\7H_B_X| P""?0Q*^&'C/PAJU| \3 " \VEZ/|HTBW0-0'B6V2|M)(M0MI"A\| MWC20RA6=U;-VD6+?
L7H/VUM+UK6?CUX+ M#\|OHFE:EJ|; ;5M U&_%C;0; ;U3S_N)=@_ =0ID;G.%&>37TU10!\H?M'__M
[UGX5_\$SP^T|\--' -|K5CY>C^,| #T02Y+R \ \$&CS3VZ\$PHAYN+;RPZ'Y M' [>6VTFVDD@/ MGW-
 \/.M3;7"222I_I+*Z+)|Y@5!%M_1>B@#X/ 99_9 \1; ;^S#^T7\, ?^\$; / M@>ZUGQ-
XDT| [16^:X;T\$,UE#;!R13S(LD|0V6?9\ZQ;MN|BJ_P -/B-X|^ (G M| %OB/X;7?P6\; ^\$|1\/_ P0='N;G5|&2#
[==I9_9K2WL8F7SKAID\$KM\G|I M@B?/YB07WQ10!\ -^/0A_XJ00V; V,|*M_#FK7%_H'B0P7<;0:QV,IFT^&&S=
M)Y+A-F8TCX#EP-F?F07I/QR*ZSK'|8G|,VN6&CZE=Z1HP\3_P|HZG;6TDE0_M8>;IZ)%YLF-
D>|QA= WC|*^FZ*_ /RM^+_P -?&?QP; ^/&N?#?PGX\|6>'; MS6(#.L7'A/X@67ANSN);33K>"XL|JTN;9WN-
CO,-_W&63Y>[-|D_L7^/|!\ M7?"&ZT;0 _/ J_A"]9N_"M|X7^UI=Q6MY;\$&3R[A! I&[S_6D/S,_F!=
M_#^C+ /).+6\$0)YTKXWR2R2.SRMV MR|9VHB?>1< 'F/Q4; ;. \=?!;XH76F;K|&_\$ CCP3?
1"YT;70AW90J5W#M2%' MM|ZU.WRWW^./RK@ZE- \L#F 'Y-K;G4)\ MC.8HN7; ;
 *ZCXZ; :H\5:3\8/AA\40BE\ -[B/2D\ \$Z3X1YT*WF; ;I<7-W(D\ M"ISK,94\$DS_+ '+)0_ =^4;_0VB@# \M/\
A1/C'PW_, \$ _/VE?!&G_ [U;TU* MX^(F>6;5WC6;Y@ "1R;9|@WI&6.*|2^ .GPIN/A/^TWXC M^)WB7X*60Q\|
>/(K.WGM=.\ /|ZKK7A^ \M+3RX0*@?=YD\$PC^=QMYP&V[\$6; M|YHH ^ =V6+FQU,>)|1T/|G|_A10AVX^S?
8+BYL+/3+ _%@KYJR?; ;*% =|OY M+YV>8S;UEWKC-< ^W7X2\;>)M#^\$UQX#\+77C#6M"^(FF^(1I<-S';J\5K!=
MS2>9._R0(>\$W0_%(B_ ,SJM?5% 'Q1<^(/%0|9WQ; ^'5B/ACXR^' 'PV\ "ZU; M^, -1U/QI8?V5J%_J,
F^QVUK^ \Z0'0.^4|US\T3!/-Y|_@H!*?' \GQ. \ \$>*
M_A0=6USJ0C|3KCX2ZSIU| " \L|M+R.>9+C8D; /&D6+J:63= \ @AB^1E\W=| \5Y
MIX@^ "VC>* BYX2^)&IW>J76J>%+2|M| 'TUI4CL|66YPD|0A\$ \$CR/& /+ ^ =V0+ MRJ;OFH W?A[X+L/AS\/_
[X1TV2XN-.T'3+;3; ;:X(,IB@B2-/ ,VA?GP@Z" MOE7XT^,M9^#/[=]I\0C\, ?'0C?P|/\-D\ /F?
P7H4FH""Y;5'FV.?B= \M, \&>-?A=J,L%G|GN/B^H9L(KB5;@_ M3QQQ!' " '*X">*/#7Q. \30W'A07=
M;UBQ>+PII\3QR1W=Y> !VWH4RR#GF0;6N-BK-| \T4 ?#7C#X6^//V5?B!\ * MB9X4TBX^*FB>' ?'!%A\ -
0\$FB;39N-5^0Q2HXU"UB#L) ' \S&Z'G:H^|M9I8>A^ M+G0=^-/Q?_9J^*NI>_ ACXP^'.HPV=K_ ,
(U/J,M0'K6HQF;9?XL06DMY8XX MY?+^80*)\$;+Y|E?8E% 'Y6-|!|UG01\ /&GP^! ?Q. \ /:09? \$01AXE\4^/0
MM9U?4\$ \SSI|R6T\R5#&SCS);IUA1'V*F[= ((OKCX&^%=9T?|L3|IG7+ _\$?4 MK32-9'AC^SM3N; :2.WO
"M/=) ?*DQLDV.<-L^Z?K7TW10!\S? \ !1+PMK7C M3|D#X@: 'X=TG4=?UFX_L| /|INP27-S-LU" WDDV1IECA_2?
84G|87P!+CX=:+XHT'3=-. -6^K3W% MW:*9M.NTYNR' \QTDN\WWD0,D3ET5W54= P!#J* /B? \ 9Q\0>+ /CG^S?
_P * M4U[X6^, /AB;+P#)X8U#0-XCL?)MA-|G2RM_LL3| 'N- \?FS0|P1&)\$W-YB07E-M?PVL;#X7^&;7X;^/?
V+AXQ^(NA@; -:ZYX? \ !|G=Z)K06-\$M;F74ID =;P1Y_MLCAMGSNVUMT*?I910!\C>-0"/B*Z;) 8^UB#P-<^'-
-T;3M>75| -TZ+|38^ M'S-I<\$<=J|T*>2B(X;:'Y4;R_EKZYHHH ^./VT/^">>C?M>>*.*|5GQCJ7A'
MQ%9V<>F;A9)>6IM8Y)Y,>5NC?S/,G/[SS-NT ;.=U>S?LT_L_P"B_LS?!_1_M_7A^Z-^MEYEQ?:DT"0RZA=NO
MH>B@#Y\$ _P|KSXH>&[B|\]*_* P|G?QGJGC^UG_L^WQ?"-M|K\.;C*43R[@7\ MVS| - \A^;?
0\E/OL71T7RR#|GSQW\ .?V8_V4/!&H;-->> (?#WQ/TK6-7M=) @ M>[6PA>[NYY])73/R1"YC1WY0,. '9<-7Z'44
?)G|60| %8 ;5|; ^'-6L0\$' " M-6EQ9_ \
", ^+3##YUUI&D)=1WL446_1YDCR/\|C,Y.^20\MODU\N_&GOEK/P9_ ;OM/B\$?ACX| \; ^'I_AL_MGA\ S^" | "DU
17+;H\VOSE4'R)TW;OWD?R|YK|8HH ^1/B%>;C^WI^SS\30A| MIG@SQK\+MIE@L_L|Q\0M#-A%<2K<">.,
(([DIFVV.X^YYJ,%?|I|C|, ;|I=Y MH=OX?0/V!OM7Q/@,EM7|0'A74?'7|5'BK2?
C|\, /BE\40A0<1Z4G@G2?" / .A6\S1E+BYNY\$G@_M2.=9C*@DF?Y8Y9- [ORC4?| /0@770@C| ?
BGX>U'X|7/C+0!\3|0-SX-SYP3_M1\$@; [5; " |C4ZFB?9XUB&U7F<(WRM7Z(T4 ?' ?|).DZ| -|6|?U0PGX*\8_ "
MX)MH_P|F_P"\$\; /Q;:R_VX|W|<27-A9N\0V>W\N4AA&8HF>3A'\0Y, ' |@WQ- MX|^%0AG1_@-K_P)0%-
I/X7U758; [QE<0/#H, |F) [B9+BVFF17G=YY(HTB1/ MF0^=N&&20N*B@#RSX^>,0'P| \ MXE| #>\$+?
QQ'S<26|U=68CDW_ M_&5T5_WZR>4^S8^| (Y%4%W20FOX@>+0&0|80C+X2Z;X<^\$7C7P-H7A'Q0IOB_MK6M; ^(-
DFCJL5L)2D5M#0>2X=P9?N?<;RMWRR;D^YZ* /B;Q=K'B|JES|L#X M@^ -Q\ /0%WQ% " ?\$;1|.F9_!>B&_0-
/U&QC^S)!) ^ ^' [LQ&23>ZC6ZM|673|N".3S(S+ #YCP>_M7)C+JC/MR^SG|NKS7P; \ %| \$| \$?%;X@? \$&Q0M3;6?
&XTXZC;7,L9MH0L<'D1^ M4!&&! *9+;F;GIMH ^%/ACXH^(0@?|A?Q3\ " ^!70%0?'&FZ^KUAD<" \S1D)\0ST?
\$#PMXJCT;X\$:' \2/AW\4_% P\$? |I(?-UV,1^8FJ1(\4P2-/*=1(Z|98_E_Y;5^FM% 'Q)^P|&G;G_MX, ?&
[|H*VM/AWJ7PY\)WG|@'1;2XGDNH0+^S7#R8NGW+) (CR?00CRK\$A17= M\$5VU0V0_A#K>M? \
!.^S^&GB^SU+PAK6M;-KVD3QZM8R1W-C|IN;Q(Y) (-C_M'Y) _P#N&.>, ?B+H8&C6NN>' _?9
MW>B; \5C1+6YEU*9/W6\ \$>; (X;9\|MM;="GW_ /#V&:V\ ^ TN/#UOX1N\$TZW
M\$WA^UFCDPTH^6F; :)TQ&4BQLS?'N_EKK:* /F3X&^%=9T?|L3|IG7+ _\$?4 MK32-9'AC^SM3N; :2.WO
"M/=) ?*DQLDV.<-L^Z?K7/_ +. /| "ME\#/C)K'C M*[U>UUG3M+AN-
' \#Z4+4!=#TV:XDNG#2/NDDG22XN85DW|0*+|F/G; (OKNB@_M#X&T' |F?Q5\80V??VH_A_4

MV^SS\$#J2RAJFVL'POKVEEFAVA^A^8&^U?^\$ R6US:KX.T^P\~SSQ,PDDCU. M961(VCC+KPX9MB*[Y#M^B]%
'YY?M >=1\=?M4>*M)^,'PP^*7Q2^&J0'I2 M>=")\(\Z%;S-&4N+FfD2>!
(YUF,J"29_ECEDW_N_*/-/@'\\"/>\$7@'|C0|J/P M>/!&I>';F?6?%4.C:'!!
<71N(6T^*&W%J\R+)=QMLV))L'F\'[U?H#10!\,_ M'[P:XKU?_@E=I?A'R\~ZK>>+!X3\~6WJAVJA)?)?K-
#)8>9&8 F>FR3<,97! MKO\ Jk+4=_ MBUT[QS^SIJWQ=\\$S:9)##KWAVRMJ6U"P0)RZ/;1VIVS0)Y<0
MD^U1NF&\M?08~?4)% 'S_P#LAZ5X\L_AGJEYXV.KI;:IKU|J'A03/\$UP|UJF MFZ)+
('L[:^=V=-/4>830DE=%D16;Y-B?0%% !1110 4444 %%% !1110 4 M444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% !11 M10 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% M !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4 M444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !11 M10 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M !1110 4444
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4 M444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !11
M10 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% !1110 4444 M%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% !1110 4 M444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !11 M10 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4 F444
%% !1110 4444 %%% !1110 4444 %%% !1110! _|D! end GRAPHIC 15 qncx-20240930_g5.jpg
begin 644 qncx-20240930_g5.jpg M |C X 02D9)1@ ! 0\$ W #< # VP|# , " @," @,# P,\$
P,\$!0@!00\$ M!0H"!P8(# H,# L*"PL~#A(0#0X1#@L+\$!80\$1,4%145# \7&!84&!(4%13 MVP!# 0,\$!
4\$!0D%!0D4#0L~%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1"
1."1H# 2(A\$! Q\$! \0 M'P 04! 0\$! 0\$ \$" P0%!@<("0H+_ \0 M1 @\$# P(\$ P4% M! 0 %) 0(#
01!1(A,4\$&\$U^A|R)Q%#!D:\$((T*QP152T? D,V)R@D*
M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM(BYNL+#0,7& MQ\C)RM+3U-
76U|C9VN'BX^3EYN?HZ>KQ\O/TI?;W^/GZ \0 'P\$ P\$! 0\$! M 0\$! 0 \$" P0%!@<("0H+_ \0 M1\$ @\$"! 0#!
<.! 0 0)W \$" M Q\$\$!2\$Q!A)!40=A<1,B,H\$(%*1H;'!'2,S40 58G+1"A8D~.\$E\1<8&1HF M)R@I*C4V-
S@Y.D-\$149'2\$E*4U155E=865IC9&5F9VAI;G-T=79W>'EZ@H.\$
MA8:'B(F*DI.4E9;7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/\$Q<;'R,G*TM/4 MU=;7V-
G:XN/DY>;GZ.GJ\O/TI?;W^/GZ 1H # ,! (1 Q\$ /P#14Z*** "B MD(S28Q0
M+4;'%,;9%ZM0ZY);LFI:@2XC Y^8?G30M"?WA^=*Z!2B|4R6BHOM M"?WA^='VA/[P_.ES(.9=R6BHOM"?
WA^='VA/[P_.CF0'YT'YT?
M:\$_0#\Z.9!S+N2T5%}H3^\SH^T)_>'YT'YT'YT?;\$_0#\Z.9!S+N2T5%}H3^\SH^T)_>'YT'YT'YT'YT?;\$_0#
M\Z.9!S+N2T5%}H3^\SH^T)_>'YT
M'YT'YT?;\$_0#\Z.9!S+N2T5%}H3^\SH^T)_>'YT'YT'YT?;\$_0#\Z.9!S+N2T5%}H3^\SH^T)_>'YT'YT'YT'
M:\$_0#\Z.9!S+N2T5%}H3^\SH^T)_>'YT'YT'YT?;\$_0#\Z.9!S+N2T5%}H3^\SH^T)_>'YTIAS+N2T5%)D_04:
< MG]]:5PYEW):*B\Z/^|1YT?|ZF',NY+147G1_P|ZCSH [U,.9=R6BH0.C_04 M>='_'J YEW):*B\Z/\
09_&CSD|1^=3<.9=R6BH?.3U'YT>H_.CF#F7>G|Y?SHYEWF7X<|>Y-D49.0^;A_C6CS\$_OK2YH|Q\R)LB
MC(J'S\$\$_OK1YB?WUHYH|PYD39&14/F) ?7|*-R?|}%_2GS1|AS(FR*,BH=R? M\|%_2C/<.:/'YTX^9=R7:*
HJ+SD_OK^='G')?7\Z. M>/<.9=R7:*~HJ+SH^|K^='G1?WA^='/'N+FCW)=HHVBHO.C_+X_.CSD_0#
MZ.>/TCW'=R7@49.1>='_'U_.E\Y/[R_G1|2/<+HD_6D_"HS,G||?SI/-3^
M/SH|I#N%UW)OTHR*B\$T8ZNOYT0G1_P|Y?SH|I#^8+HDS2U#YR?WE_.E\Y/[R_M_G1|2'<+HDS1D5'YR?
WE_.D\Y/[R_G2|I#N!+2U%YR?WE_.CSH [R_G1|2'
MP7):*B\Y.S+^='G+_>7\Z/:0_F"Y+147G+_>7\Z/.3^\0YT>TA_,,DHJ)KA%
M_C'YTJ2B3HEK08A&:*1L<(T+*W?,W.OK;3B+|J3X M\6GP2\%KY9E.OZLLL.G>6@*Q,H4-
,Y8%0J;U.#G<2!C&20YA:A=75]?SW-[< M/>7<f>;--+
MKR.]UW4;W4[V./R5F0[F2>01AF95W.S\$8WGY<^>LVBO/]K*6K9^=U,=B;K; MG-A1114-R>MSC7<****/>
[A>7<****/>[A>7<****/>[A M>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>
M**/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[MA>7<****/>[A>7<****/>
[A>7<****/>[A>7<****/>[A>7<****/>[A>7<* M****/>[A>7<****/>[A>7<****/>[A>7<****/>
[A>7<****/>[A>7<****/> M[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<
M****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/ M>[A>7<****/>[A>7<****/>
[A>7<****/>[A>7<****/>[A>7<****/>[A>7 M<****/>[A>7<****/>[A>7<****/>[A>7<****/>
[A>7<****/>[A>7<**** M/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>
M7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<*** M*/>[A>7<****/>[A>7<****/>
[A>7<****/>[A>7<****/>[A>7<****/>[A M>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>
[A>7<****/>[A>7<*** M**/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[
MA>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/>[A>7<* M****/>[A>7<****/>
[A>7<****/>[A>7<****/>[A>7<****/>[A>7<****/> M[A>7<****/>[A>7<****/>[A>7<****/>
[A>7<****/>[A>7<****/>[A>

M04.M4_F*YGVW9(0N)^%F?U>T?+-7+1+WK0_A5_KM1^D?+7U0"U:;>.H!_#*\LRU M#<+N490@_G/?/08
FB7PB;M<+71J[QL?' 'QP\121LSV6ES'2;?=%&A7R=) M5D?+?0FF;G^ ^ \@J:\U"YU2[N;R]N?
MEJ\^H4444P"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH ***Z;P#\~?%GQ2U:?? ^G?VE?PP:;) (3/!% ^Z#HK??=<
M\LOK0KMV2+ITYU9\DS>YS-%=U\1/@?XX^&-A;W7BGPW)HUG?2^1'!=!{>;,/G MY48Q.V-P
^]CH<=#7"R@M0S#V[=Q1*\78JI2J4)SM^QS\8(^3X+,G^RU_9,,9_/6;CC M/2L/_AFWXD\)\7_PC' ". _\
\$]~P_P!I?8_M]OC[]YWE?[]L?>I^RGV\$!\B8_M_?3?W'FE%>SK^QU\7Y,1X+,,?^RM_9*.I_Z3<\8ZT0_#''Q?Z?\
(>W_@RM/\ MX]2[E4_E*_L_%=;:\X\7HKU07/V4?BCX;TF\U35/"7D:~9V\US/<-J%LWEQO
MQLYX\$W^R.QZ5Y&JD)DC@D[#_+;/GOW[FH<7'1G+6P]7#;UX\HM%%%(Y[FW^\$
M**GL=/N=4NX;6R@FN[R:1(XK>%-[2[F]"5&TDL<\!2">U>LVG[)/Q9U"SAN;
M7P:ZB9(V*3WEM\$P5U#89&D#*PS]UAN&>:<8RE>R.FE0K5U^Z@W\CQ^BNA\7? M#_Q-\[/Y;77 _[=Z!>&0I#+
<6Q2*785.4< K+@E<[?QD9ZBNJ\\$ _LW_!&^
M(WANSU[P]X<;4=*N0PAF^WVT8(1VC/RM(&'S(W6A1DW:PXX7\$2G[/V;YK7MU M/-**]H_X8W^,/ _0G-
_X,K3_X]1_P0Q\ _&#0X/8?[]Q.T_ ^/5?LJG2)0\ V?B0_M^?N.M< M96,^:#LSDG2E2ERU59A160X9\&:
[X\U)=*\:/:1M>CZE^R7\7--M;R^;P=--'! TS+;W\ \$K%>22\$"R,
[\$C(QM.JKP@V00\AHJ[K&@WWAG4)M,U'39=+082K207,303#>BN-T3_%?E M9>2!G*I5-FM&:>\B\$D2+&[D,
MK2*P._%48*\8I\LK7L=\$**6HN:,&UY*YY=12(#Y8)'!')V^K\0;G\^YI:1AH%
M%%"UV!7D^6*"BBBEKU\$]'9A1113#0***53M9&"10(&^19'VJ6/_&_.6DWLD4_MDA**[3X>_!KQI\28W?PQX?N-
4@M#(/MBE8(6E3&Z,2.0@V[Q]GGC071>(/V_M6_BOX5TV"[U#P7-.I=8<;Y=ZZE@22(XF+\
')' '2M72J6ND=4<'B90M@I!0:~8D/;DI3VI*!CD[T_FF)WI_-2!)#GFE?M20YYI7[M4@!.]2+WJ-.]2+WK-
[@.I#VI:0]J0\$BT[FFK3N:_%703J:0>G5+*0Y.]2+WJ_M-.]2+WK)[C]\$[U(0>HT[U(0>D_]>M2^E1+UJ7TK-
[FBV]/2I/2H_2I/2H94= MR3TJ5>E1>E2KTK)
[E0<*E]*B%2^E9_9\$R3TJ3TJ/TJ3TK(9*02GIWIB]*>G>LWN:K8D704B=ZC704B
M=ZR>Y1(0>I\$[U&0>I\$[U#V+6P\5+Z5\$*E]*GH42>E2>E1^E2>E9@2'H*?#GF_MF'H*?
#GFI92)5[TI[4B]Z4]JR>X\$T=-./:F0TX]JSEL:+8?Z5*02H02I5Z5B4_M/303Q3\$[T\4P)?
2I/2H_2I/2LWN42>E2KTJ+TJ5>E80<2W'IWJ1>]1IWJ1>] M3+8W%/_:IHZA/_:IHZR^R_X]J?Z4P]J?
Z5ET*CN2KTIR]::02G+UK(T9,02GIW_MIB]*>G>@1(0>GKUIB]Z>06LWN3]HF7I3EZTU>E.7K4,U)EZ4Y>M-
7I3EZUD] MP)EZ4Y>M-7I3EZUD]S1;\$R]*>G>F+TIZ=ZS8R1>]= _\ "G_7:C](_P#V:N_7_M07? _I_UVH_2/\
]FKZ[A3_)&U+Y_DST,#_&1Z(02G4U>E.K^ASZ@9)VID_MW^I;Z4^3M3)0]2WTI2^%D2V?H?B@00?
[J_R%.I]!]_NK_(4Z0\$>Y^\$U/CEZA_M1112,PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!5P&SR& MXPR_>'S
C'MD+G@_9K[[]_80^'C^'_AG>^)'N3<7&02X4P](X(6DC3/R+^WF_M4G[WRA._!^\$ _#^A^Y\6^)]
(T2SEC@N=2NH[. _2<_N@TCA!OX;C+#!L?S07Z+? MM%:S!\&_V9)]\$LKA9/_L8_#>FM_9/_+H(B'"A1N\E9&Y
7([C"MU(TJSF^A_M]7D5.,/_:8J]_, \$70B+9Z;^U!^SK=>&D21]1MA>:6L*;*TGA?_5Y)(4[T>{0
MT&X]5Z_F0KQCRY(3-(J[4'R@;DV@\$[ISGD9]G@GDFON?_@GUX^_I>?%\$/A"[_
M=FNM/G2]MEFNTHJ;106488S#T\925VSL0"?[; MOCWP?X:T;0K'2-_%EI=6#8Q=-VEP'*Q1A!N/G'_TU]N?L=?
\$+40BC\ (M#]3_MZ0%;PZE>&<31V:;L8V7\$D?RY8]D'I*3<3LX>QE?\$5W"I*]D?/GQ _;D\=^%?
B#XET.RTKP^UAIFI36,4EU: MW _/ ^%E?)K _&+HW]L_V5_80_'0<>1Y/G^; MN_UWK7G _;/_>2R^._\
L.70_H]ZXRN9U9WW/GL3F>+]K)>TV9]N_7]L3QK_M\3_BWH/AK5=-
T*'3+UIPTUE%,LGR022+MW2D<[.>*]B_:L^,FL_!#X=:?K>A
M6MI>7EQJ26)34\$=T"M'(Q;Y&4Y=COWKXI_8W_Y._/\ 'Y_077_I'/_7U!_P40_MY([H?_8?B _\
2:XXKC4DZ5^Q]3@L;7J975KSE=H^?/&[/;WCKQEX=UK0;W2- M!-CJ=I/8.UK:W#YXUB?3VUF76&1K
MA[6V,3/&(2HWJ!"Y#!?F9F<98;17)" +JNS9\SAZ6(SFIRUIW4>I\2WGPE\=6_MEC-
<77@W7+.WMX0,N)YM+GCAC5>3(6Z'@C\JY-<%A(<)(R*RR1\\$KN!5@/0D
M#/_L*^Y]+_P""A6AWGB>"UU'PG>Z;X?>X,4FI&Z\$\R1X8H[P]\$>HVEE5R5^8# M<1AJG[<7P-
TR'P_ ;.^.]\$TZ'3YK;:R=8^S0*&E2:166Y(5@&83\$JV\$+0YI).\$
M%:RP[WB=6(RBDZ,JV\$JW7C"X,5WJ6LL8H+A\$&Z&VB
MD9=N[8"&:1&+#!"19Z5Y]X _;S\8Z'XXUF0T71])_LJONIK:!:^TN3>&K?PY- M:>(-3VPW_G,5U:6\7F@EXV*
[I&*@\$ \$QIM(+;@4&[S_X6?M@>/_A;X.TWPWHV_MGZ'/_IMF\@62]BG>3:_AEW,PE4\$G? _=XZ'D&H_CI^RCXD^"-
M%JYNK?70#[(_MV08%:"",E5SYB\$L\$^;=@AV_BZ;L5XBI0M+@ (77*EU&"P!&,CMW^7\>]/DL9B[PP]?
GJNTDC]/OV4_C)K/QN^>H:YKMI9V=W;ZB]BJ:>DB(46.)P_MWS,QS^[]:]
<^/[/8WC;X7_%C70#.DZ;H,VG6)@\$VKY@_;*7;^TAXP'^U:??^D<%=2HX4TT?3X[&8B
MEEM.0"70_P_C5^T^XC^_S:~?%?I=K_9?G>1_9J2+N\S9NW;W;_GFN,8[UYC_MN^HY_*J65D7@Q\Q(W#:"#SD
X."E7(8%7DC;(&Y3A2-PR#D8)(S@'.3_MV[CS'+FDG(^G4GB;G-6=]3]/\ P?X;T _9=^ "V[WUQI5C)?
7[6Z\$BYN_M;I&9E0?+NPHD9JZ+(<_6.T++B!V):_E_MP_3GAMI.[././&G[_@/55N9_#]J]J&@SML:W@E?
[5;1!64/\CXD(8;LDR8! ? M=T.#ZCC)J\&?HV(6)G0A/+I6BEL?/W[4W[1VF?'%=#M=%TVZL-
/_TS?,*%*',=Y8@@;_3X39V,M]J4-II\\$]U<32^3!;K\$#-+(W(50%
M/7!YZFN0^+OP9\4?176H=+\0V6P7\$;RQ7EC*9;:_[T([@%F4D@HRJP_S]U_MAGZ!^_W[2WPW^#^'P?
D">'YAXSEE;[9960=F0F528YC/*Y_3:0&0\$%7]S;%@\ M\G(ZDWSL^_5.>*Q.MX5URQTR@QWDUQI\Z)&Q_M^7#/@
;JY>XQN_M^'G_.ZE=IOL)5NFNH;AE0R2+D1HR85<_.#R#@[0_P_U?MG?"'3_(8_\$*RN
M]'TS[%XZ_L*_ "G40">E>*?\$&0:5+I>IWES'8VUG?>T4]0;Q_.2'/S%7\Q

URSMH(0,GGFTN>.&-5Y,A;H>"*^X/V:0A#X9^%/P;M 'FM6MI)J\}@VLRZF M8WG>SM3&{QB'
Q<0N0X7YF9G&6T5S6C\ !0?1+S0-!;ZCX30--\27!B? M4C5YF 'E? \], =;^U?V!?
AM?:9=>)]UC1;NQDDM;5--0;B...*X@E,C2; MQVMD0Q\$GMQTS40[='P2TR/PY;^,-
&TVWTZ2UN"FL0"JQ>;',^:S6#SA/NVQQMY@.Q>,R\$=/X<] MZJG1Y*C39TY;EM+"XUQJRN^FFV\ "&SX;+>+H_B?
X\U50!VLQZ*FI7UR;]-.E M:!(/-=C.&5-I(!9N, 6N3N_A#XZL;">:]&ZS900JT\JR^GSK!'&.22<#IS^ M=?
4'QN ;4\Y0' @)0"), : VAHDFI+JFW: LD?FF/RL@YQ@ ^0/%>K?LF^/M- M^*P-
MM(U"*WDNM'C71[^QDVLLD(&R 0&[,2LL6T'SC4DTF80+\
M+B\3*C3GKKT V/S=C^:= '\R.%FCWAL\$!T/R@YZC.XUTNE?#70?KVG)?Z3X4US M4-
/F#&: '3)Y821@%A)TZ)5[QE\+=6*_%'4/ @+7.J07R6=HRF* W!E>-82
MN6*KY@D1BI;C7A,N4XUI5790/SC8;2P\N1!N.#)PV.F".V"#^== MA\(?
)^*Q*\ />%S*UM#J%V!/.C;&6"-6EE"-AL.4C; ((. <8%<^?TVUV/P>\>M\,?B;X?
_2K;M+=8W!::)59B87402;5! :3; (= @ M8@;B, GL<:=N='E8505>' /L?
H!^T7\8#^SS\.= 'ET+1[>2\EN\$+L+2"2&5;.V5 M5P0VQ1D +A4++NP2,[#CQ#P- P
%"]435'B\8^&K9]/==R2Z(&2X3Y6+?N7D M8."=G.10 &/ .0^*GYK7P#^T7X%ABF.G^*]#>19(Q'(?
W,H4%064AXI%#@\$<- MARI'S8KYT\? -/! /FTATN&3P3X@NK>]#2;H-:V2)-N.OV^.-2G =BHC?<3@;
M,LQ].KS?9/T3&?7HM5L#+W\$MCMYN^,WCL &CXN7^M23I;1->S)96=C#!&9I]B MA\$)*+EG;8<[LD
*H9E536^K'P0\8>'--EN\6\+:W8Z9"?WDMQI\Z)&Q^7#/@ M ;OUK>^'/A?4!/0?A+1M6L9M-U" T\06<4MI-
C,6+A-03@Y7#94E2'!4[2 M^*^10VSD4?LW^+"!@AK3 -+(:XXTW-. \93KXFL>CT^1^:.EZ+J M7B+6%L-
(@FU74IH)\<-G TFE5ZX 4E0N"K&N>\$==\)Q6[ZUH&I:(9%D,7]JV MOW?49[5ZG^QFH;1H P@",C?
= ^D4U>U \%(5?^?>;>,I MJ6? "6I1IITW*YRT"GBV_A=K?=- F?)5Y\/?&E;"NK7GA058M%*)*-0
M;RF%LR.PV-N;Y1N) 'N5HL_A[XHU706U;S\ -ZK+HJH\IU!;*8VRHC'>VY?E. MT@^X:0TDTB'0/\
AE/0+K0+I \ ;FBV'AJSU*YL@ 3,+: ".X"A20&YB'RL= MK=&^4D'B/@ ^V38_%3XGV_@^/PK-
8PWAG^R:A\I1RWEQLZF1,80%4;E6DPP" MX(^8;?5XW20N>H\DH7A&56SDNQ^?
^BZ)J/B34XK+2;*; P!3GB\R*&SMWF>2 M,?-N"!2>U:.M> /\$ AW25N=8\,ZQHEE)*+<76I6\$T">:WS*N)%'WN?
N^G/;0 M0KXA>+0!?!>'>CZAJ6D>'Q+?^*;; [7%IMN?B(5\$W\$JHVR*W^HW'A\ZTM/M8_+#'F2', 'SF0>;]F??
@ =VA?%+6&[UG MPSJFD1.PA6X0;&2WA,FQWVB1_E)9 QQ_LU;^+'@4_#7XAZ_X9VR)#I]Q(D F M97E:
Y;!W=>&+1-'V'<'I7Z=?& 40#7A+P#%XJ\3Z.VL6'A^ZA0XH(T#M'.3 MY"2A695.SSF/S=/O
;E6HITN;FN\CR\#ED,1[55'R^S\C\0+GX?^)M/T*/5[MKPWK46BE\$E--IL\22*X&R0N/E VN
".N*IZ'X;UGO/JCP;+IESXB0(HOM!M M;*&25Q&0[0<"JG)' '7UK!]/@-
^U#I [0>J:MX5U#PG_9K+8FY\JXF%W%/;ED MCE657CCVX\U1@A@1N],', ^('Q:\(?L9Z-
I7@OPWH4FJ7EUYVH"UFN_) \$<,DC ME6DG=&,A#RURK/LB)8_*-U^Q5N:YW+)L,J?UA5?=
[V/A+Q!X+>0>#EM5US0 MM1T5)[RVQU"R>W:4*06(+*-V"PSCID>M9" +(C".20-\BR/M4L> ,=Z_5+0
M=5T7]I3X(K=7-E<QZ5X@M9[>6"?RS+ RN\3.I(VDB1"4<@] \$;:.WYX?#-0#? M@;XR6]I\1=
(MI]'LKUX+VQV%Q;W*, \$!'1N%?8X(?.\.C'Y6) &=2DJ=G?1G)
MCLJA0G3Y)Z3Z01',Z+ \/_ \$ B/2'N=' \, :QKEC'^*; :05,N(U(^7C M[WKQWK.UC1=1\ .ZE)8:09W%AJ4:JTE0=0-
#(JM\RY5E&.IK[:6_ \% "-\$TW6 M);;PWX3F\1:9'\@0Y+Gf&SMN* NXRC DK[W!)5B21LW+A00_B1X9\ -?M1? J'
M7=,M'N[E[:6\T&6,"&:"Z"%/)+M\NUG4QMN^1LC\X1ZTC0C-73.B.4X>M"<< M/5YI15V?G1H/AK5_%-0-;:-
IE[JUU%\$9WAL;9IY(XP0#(JEA@LHX_058_X0 MCQ(/\$7_"/_V->IXAV>8NE_9)'NE3 ?F+9NY
!Y]:] ^_X)^JLGQGU8_++G096 M\$JJH# W%N2.!G &,'0GZU], \$[XM> OV< \$.IZCJ,5Q=: [XHN8[N>WL8HI+H
MQQVZ00MU4B(&+"[S]YI". V(C10'F;,<'E&MAEB*LN760^?7 "H?'GV/' " M!^*;;L;/[&N]V[|^=F5%
<K.B: CX=U)[#5].XL-2C56DM[J!H9%5LLN591CJ M: ^X?A; ^U=I'CO]HYK2.0?2="US2X-.@E0C&)S=0M+
(@8B0J%8SRH-N\LZQX8 M;L'B/V_0AM+8^(-&\;6T%0;P7\7]E7[%0&50SJS?Q2%T!7[H(\$!8<"J)=<
MO/%CK9716&=>A/F2>I\ M:#X9UGQ5>/:Z+I -]K-PB>8]M8VLEPVW+:ZSI=]H]PR>8EM?6LENVWYQ8G_0PV\$A5E0}
[>10= M%%%8'A^2"BBBF 4444 %%% %!110 4444 %%% %!110 4444 %%% %!111 M42V *5>M)2KUKG
E/04@I3T%(*#1;\$A[4E*>U)0,G\TQ.1/YJ6!)]#GFE? MM20YYI7[4@!.12+WJ-.12+WK-
[@.I#VI:0]J0\$BT[FFK3N: %703J:0>G5+* M0Y.12+WJ-.12+WK)[C]\$[U(0>HT[U(0>D ->M2^E1+UJ7TK-
[FBV]/2I/2H_ M2I/2H94=R3TJ5>E1>E2KTK}
[E0<*E]*B^2^E9_9\$R3TJ3TJ/TJ3TK(:)5Z4].1,7I3T[UF]S5;\$B]Z
MD304;1ZD3063W&2+WJ1.11KWJ1.10[C1;#040I40J7TJ>A1)Z5)Z5'Z5)Z5F M!
(>@I\,>:8>@I\,>:EE(E702GM2+WI3VK)[@31TX]J;'3CVK.6QHMA_I4J]* MB1*E7I6)0].1/%,303Q3
E]*D]*C]*D]*S>Y2)/2I5Z5%Z5*Q2L7N);CT[U(MO>HT[U(0>IEL;BGM4T=0GM4T=9?9
<>U/] *8>U/] *RZ%1W)5Z4Y>M-7I3EZU
MD; ,F7I3T[TQ>E/300(D703UZTQ>]/7K6;W)^T3+TIR]::02G+UJ&:DR]*X\$R]*YHMB9>E/303%Z4].19L9(0>N_
KM1^ MD? \ [-7 +WK0_A3_*[4?I'_.S5]=PI_P C:E\ R9Z&! C[!\$7I3J:02G5_
M0Y]0,D[4R;_4M]*?)VIDW^I;Z4I?"R);/T/Q07H/[U?Y"64U>@_W5_D*=7B/ M< " :GQR]0HHHI&84444 %%%
!1110 4444 %%% %!1110 4444 %%% %!11 M10 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110
4444 %%% %M !1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 M%% %!1110 4444
%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4 M444 %%% %!1110 4444 %%% %!1110 4444 %%%
!1110 4444 %%% %!2J M=LB,\$C>0-\BR/M4L> ,=Z2C>\>UD=H0F&9AT3@X)]><=<Z6[L!14?L" #2XU M?QU?
^++FTW:7HD#VU0>\$,N;QSM;RP.&V1F13D<>:/60I0X0Z? \ '?FH6>G?\$ M35-% M+23(8K>\U@V /A%\#M/@00%?
AVV MU!HY-60H+?4!) *6)X!AW; ,6(1(44??7@ \$XS\ -^/ %JUX^ \9: SXC0\$EBFU2Z MDNA#-
,9C"A.\$B\$A^ ^J(%56PH(48 &*[^94Z:5MS[YXJAEF C3BN9RW1^BGPT MT'X"?#GQ*MYX-UCP[:;0?)_9V8]?
 \]I0]*PB57F8\$LT:X &3BN# & /AU!J MW@G3?&\$ \$7EZCHUP(YKL-%#MMG) +EAEU240[<= /-
;UKX(D!D4)YJHA;+JYQ\ MN"N>,\$L!@\$?>K]) -'^-GP^-GP5CM/%N:-I-SJNGM%J&FW=[;Q36THRKLJ
M2,04*Z&2-B.BHU:4ZBJ)Q9=' '4N_2R:0S'OK*YTZZN;.]C2:XCW(QMW6168.26!4E7& MY&P03D;3N.:_00\
9-^*0@[PQ\ 0#ECJ_BS0[#48/MDLU0<:C!')&INYCEDW MY YKGP[K]YWZ'F\ .2C2Q,W)]#XA^ -G_)90'?
&'+W_TH>N,KK/BY?0:A\6?& MEQ:RI)M'UZ[CUE+IX--U"*:1 M8UMYU90D8],1Z!* =09-'UN E#^R*T&]6?#L^?

+^3B4)N!7[^\^NZ?CMK]>90' M#77PK7Q=H.GMK+3Z/ :FGV"MMDN=T!ECB!P<%N!T[U^1*QJTRJ7D8=89)(PK
M8/(YW#.1D8P?7H#7UU^R[^\^I0@WP!%X5\<37264#M]BU.,^?%:0;6/DR!0' M^4C@J'Q0V_*L8-
98:HHMWZG)D6,IX>4Z51\KELS2' !1U0F>'X?1E&/ .M\$. M.^6'V?C((/707\$ &;1M27XP?#G5?"1\<
(PZ*=1,06\753\$%:,5)1E?(7(/ED? M>'60>[KP3^S-JWB)=6EN !GVM9ED2WMM:C2#<@P%*SK*
(B07& "6A0W4>FR*;;5?L D1V<:J 8[>(E6V\$J8R'"I\J[0WR M%=Y-Q5DSU,9+\$PHS]IB4T[+::GS08>&=:0-
!N-.3 M*+Y)E (W.H&3 &:[GX? M(?\$+X,"\$:7.ZSV[00C"1*6#& M+"G:.*9P,L, CZ(9^ :H^&VB> [?P-
XCT^XT2UM;:2WDDF0WUI>Y :;A5+ M!I&>9RFP#=#C8*[E/A P#LS+JPU/[7X5-VMS]H\$*Z\#
7#;R%@,YC5,J?D MV[0%(QMR*SA3Y?>4CCPN"BU"KAJZ\U<|%9^(\ A,OV8]>UYX0(.J>%)KX0 M[BPC\RS+
[02H)QN[?@0=* *]> \ US'\07UM^T ^UYH_C/PV_AGP'+>/:7\$B M->ZE*IM8;J
JK>3\$&7<=Y8Y9@N3'LY63CY):-.?<;Y%!SYTD4>YN.>NXXP,# M&!ZC@BHK2YG9G)GV(I5JD%!WMI< 0; @G?G-
(4 KI_ZCTW_*3V]?./[91S M^TAXP_WK7_TC@KW3]ASXF^\$ "'PIU2WU[Q+I&A7HG=F%
M6E+*Z=-2_K4\II.%)W'YTM6M)N+&SU:RN-3LAJFGI,GGZ M>TWDK=+N!,,.5!
(W#IG/. *|Y+F:15>\U%:)E^YT'Q%X-.BZE<6H:.976 M]TV_EMS)M((DB8XSC(R01C^*HKWG]GG]JCQW8^/?
#/AS6=8 M-2-0NH].>W MNS#RH\TQ'G?:1EFQ0^ZQ;T ' +I[MHO[27P>^./ARVT'QE%:V%U,&+6'B!,11 M2B
LSQW078FT-(J2%D?Y20_35KP : LX?!NX'B0017\PW%K\$4U#K\$FH2JC M?
+1J&61MW(RRJM+=B:1*\$>5WYS[K"X%T9*KAZ_NK=7_ \$*/ !01,^\$.@.K MLLJZ_"Z\,6R())\8
[YP,\COUQ7(#? \ 8] \% #WX?2>* B0.SRVIL\W:QW# MIVEIDIM7]T1)), -
ORL58R8"N0C5XK^TM^T4WQTUVP.FIJ&G>&=BS#IVH;(MW-P<[YV09PX5Q&JLY ;&R"0J;1/CA\-/VA/A#-X?\
&&MZ?I\$UY:0)JMK< M7'V%H[H/PT+2':X\R(.GS/QY8=?FP;3C.:.JG6P>.Q?RQ4_@W70@'\
_B%I\&DWUYXFUJ;?R3KIECEM=-258TWF3= M'\$B\$NY,D8+K^R[B,Z>\$' [.?F* ML=I.T]>0-
3*WLVB,74;RVK2FX\W3EV/4_P#@GJ, !C7_ % M^; TFMZ^*OCA MG_A<'CP) K1K=\PV_?P)I.GX[?
SKZP_8;^)7A7PE\)=9M];\0Z5HUY)JLETL M%_?1Q2>2;> !R&
(.U?)7Q9NK;4_BYXPGMIDN()M:0)K>Z@D\$D4BM<28*L'P M<@8_1^@-8UI?NXV/.QTX?4*">K1^I?<
G(0/A:/%^A6+:RTVC_-IZ?8J= MKW6Z_RQ0@X."W Z=Z^5D_P""CA#&2+X>QF-B< ZSAQWRP^S<9!Z]ZS/V6_V
MO-, \&^'\$\^*.);I+.&10L6IQGSX;6#;Q\F0*_RD#14/CS"ORKK\$SX(9 MEU;Q -5FN !INUF61+>WUM\$@+
(,13;I*(B04LA0JQ9L@13V.ISI69[KQ-3&4 MH3PU51M0>QX/\90VV'^+GPXUCPM)X.72Q?
>3BX&I^;MV3))IWR!G[E>V_P#! M/;1 "370WGF&^WI/FQCI;6PZ?A7B7[4G[0'@'XC>%=, \+^%- 'CEMM/;,%JC
M0-;BVB"JIAM47:X7<-AW+L =#:C?R:7[&7[0&B #NWUCPMXKN0[(MKZ\6XL M]0FA=D\$TBK&Z3M_, !&#\$
*YD<8R>=2;JW;/-P^)Y#?&[DL MCP_11V^/ DQ)7J7[\$?Q'E\ _ !:&@RW\$-MI?B2+[-])-*L?
EW"!FMV&X?,2Q M:;)D F5>I %>Q 'K2/V>]2T'Q-KC:YI, 'B+65(2_T.Z^VW"W D#1P*Q5"WE
MX9P\$W>8X+J9"3\6^HW.DWD=];-]CFM95GBN_S0M')&5VD2+\R@%1\PYX!P. ME9?PZG,CQ\1">6X^%:,KW=W-
)'Z=:M\\$(+[[I300B.A\NUM](FCFCA2-1)= MC\$2/(3\TA>&=U&%!'D("V"%KY)_;D^>47C7XL)HUG=FYL?
#T36SA?+;-;I\W M3!67+\$@")PT; >
(M2N]6U"3SKV_GDN[B0KMW2R.7YG]:G2H>SI?;=V4ZFL[&XU.Y@M+19);NXFCA@A@IGDEE9@10_M0)RV.GI4-
>A ;XF:3(_B-9>)-8T236H8\$*P3%);9GPK2JN-K_NS(NUB! MEUY'4<\$8\S2V/A:,%4JJ,Y61SMGJ'B?X9Z]
(8GU#P?K\$<:I/%'+;RK\$0DFR_M0_ARIS'P3CV-?9G[&G]1WB[XH>)-3\+^*W_M.2&S?48M2\E(7'K)&AB9\$ #
M^8N#C/!R3GCIK[QY^S[^\^T)8Q5>(K01S>VL4;2-JTK;:: M*+^V9\+548_32;_E-E[5] MI^V=_P
FV^+3_M6G_I9#7YU_\$[XBZ0_%QMJ60:L[R27\$D@MX1*LGV* \$XM M1M4?*@W D!=Q^8\MD>G@0\:%^%P
:/AJ^G>+8BTBFNK5(=6TK69/LL6\ MYW-&9&&Y=T>Y61BR#83M;(JH34W*/<.!QE'\$RQ%*]N;: I8^2?V,?
^3D/'^' M = ^D4U>V? \ !2')I\|C40 ;:NK_%:X _Q=8Z3X2@AFU#5+E;2XU? M3U-Q% ',6?-
0)6/[K@JJC,JF-@0K"0,OV]/'7AWQM_P@X\Z_8:W#%]N63^S M;R*?:S"WV*2A(7=M8\A]*A)*E*-
S)T:>%RVI0=1-M_J0\CZ*7_DRX8_Z\$; M-L*^*OV.\ DXOP;]+G_P!(YZ^I_P#A:G@[_AD_^\\$IT?^U?
^\\$/\ L0\ M9 \ :\$'G>=]@_P!7MW9W5\C_+*NLV^AWX^>;W5+^'3M,MOM;RW%].D4<3_ M &28;6=F [U-
25JD&NA.-JQ>)PMGT[60W_!2\$52?#]S\FH?SM:[+ @G; R2_M'7/3^WIO_2>WKRW]03QUX;\<2>!CX?\
\$>GZU';_&XW3;1<1731*?L^"Q1C_MMSL.,\<'TKK?V&?B5X3\("G4K?7_\$VCZ#=R:R]TD&I:A#
(T;6]"JWSL.N. MU:1_CMWT.BE*#SJ4[]%1X'^V1_R<9XP'0;?^D4%?;W[93'_(9J]5#_*]
M_2N&0A0]J36M/U[1H+Q/J.DZG9WVGSFT\FXAG26!L6D.Y0,!(X"G^Z^MOVK/ MBKX0\3?_Q'0'I>E>+-
#U#49&M&CMH-1@EE;:PD@)NR?NU,/MQ.?#U:;6,UM> MZ/#?^">H)^-&L8_Z_4W_* /MJ7_@H6Q;XTZ0?
^H%#_Z/N:Q0V'_%FB^\$?BQJ_M%YK6I6>@6C:'+"L^HW,=NID-Q_VT%B[DC)QWQ1^W\XJT70A\6-/N]\$U\$SU^T
M70XH6GTVYCN\$@N)WVDH2,@ ' ';-1S?[-<\$I063^SB^0?S/KG]C\$[?V;?'A/ M3-Y_Z5SU\FZ'\!;...[2/Q
M4N#I^@V&NW,FIWJ,/,56NI=D40SG>Y1L,0 M54*Q()VJWJ)^RC\5/!0A0X ^'M/U?Q;H=CJ,/VR66UN-0@BDC4W
M-?1G]H#P_P#"OX _!,&M7BQ^&M1250G)3
ME1S6KY9PCS'MUGA:U+ #TZ[7*M3T'Q9_PSS^S5.^B76A+XC\11^0]Q"TT U&XA
MD\MBLK>:1\$[9#%8RA(D0[=I4U[_/!7Q3X>|:?'W3-6\]Z.=!\3I*+;P;W
MB@,125XW&R)B@^9">#WKPCXQ>\$0@#XJ\63>.]? \ &L/VE1_U[8Z;J"7(N-IV M+NMU628
J0&,>W:J!LC:6K0/@S^T\ \)Y0 =08Z#>VG@f2=-8V,.FZ0=P6\I"
MJ0S*ID9F!+C+DY8Y))S6L&HMI;'70G&C6GS.\$8M:6W/F0\ X)ZG_B]6JC_J M
R_^[G_P#10K_DMFD_]@&#_P!.*+BL;]B;Q=HW@_P"+VK7VM:WIVDVS;+--" ML]U=1Q1\$S/;L-
KLP#%EYQ_LFD_>:\6Z-XR^+6EWNB:M8ZS:IHD,3W%C'=>T_5[*;[/?V,JW\$ M\$VU6;:(ZMNPV5."H/(:IG&
+-23X@:%'^TQ^S.DVGP1'4=2L8=3L(!)'.>[M3:YMUE)558,)("R\$9;/>050CVM(
TJ1YX7<,G=Q@@=.3D],5]W_P#!70- MK>I^"0\$VD7R2-I&G7D?V"Y8R,!)0\V,;@53;LC?
803SLG[XK+R0>#,'^:T M?:RPDM5)7.C_&G_!8_!]?G&V\6%)%=7EI^H=D95CGFDMXT59FD4E?E, M0,;:
-K20\[%&RN, 8'J<@DGN2?20?0VS0BL_Q"^^TVCP_+
MIOAL091KG(>X)'VAQE%8?.0E\Y4^3N7[YKP*IQ\$G*5ELC@SK%+\$8CDA\,58* M***P/ 6P4444#"BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** MB6P!2KUI*5>M@I!0:+8D/:DI3VI*!CDIT_FF)WI_-2P)(<TK]
MJ2'/_*_:D_)WJ1>]1IWJ1>]90U+2'M2_D6G]1IWJ1>]9/<9(G>I%U&G>I%
[T@'KUJ7TJ]>M2^E90E2KTJ+TJ5>E9/YHMB1>]2)WJ->]

M2)WI/8M#040I40J7TK/[(F2>E2>E1^E2>E9#1*02GIWIB]*>G>LWN:K8D704 MB=ZC704B=ZR>XR1>|2)WJ->|2)WJ'L:|+8>*E|*B%2^E3T*)/2I/2H_2I/2LP
M)#T%/ASS3#T%/ASS4LI\$J|Z4|J1>|*>U9/<":.G'M38Z<>U9RV-%L/_2I5Z
M5%Z5*02L2AZ=Z>*8G>GBF!+Z5)Z5'Z5)Z5F|RD2>E2KTJ+TJ5>E80<2W'IWJ
M1>|1IWJ1>|3+8W%/:IHZA/:IHZR^R X|J?Z4P|J?Z5ET*CN2KTIR|:02G+U
MK(T9,02GIWIB)*>G>@1(0>GKU|B|Z>06LWN3|HF7I3EZTU>E.7K4,U)EZ4Y>MM-7I3EZUD|P)EZ4Y>M-
7I3EZUD|S1;\$R|*>G>F+TIZ=ZS8R1>|= *?|=J/T MC \ 9JX|>|=| *0|?J/TC \ 9J^MX4_Y&U+Y_D>A@?
XR/15Z4ZF)W|J?T.G= M7/J|DG:F3?ZE0I3Y.U,F_P|2WTHE|+(EL_0_!>@_P|U?Y"G4U>@_P|U?Y"G
M5XCW/PFI|0|Q1WNT%%%/7N-ZII|0HHHHIB; M?1A1112|&/FET"BBBEKW(MS.\F%=[|"]
TWQ%\5/#L.M7UCIVCV|W'=WDVHR MQ)\$\<9W"(K(ZA_,8)'M&3AV.,*:X*BKC)K0+&BBG4;J.YUXW&2QE95):
(****3/.|0HHHHN|@3.V"BBBHUI MDQT>H4444|;6';2VNH44447;ZC^+=00****60)_#UXGM[%
|L6|G=Q5&>|E7|V MA2!V:4!V2+=G&V,-P,? E%:0ER79Z6!QSP/,XQU>S|\$U|J%SJE|<7E|)+/?
M7#F>>XG<.\S-SYC,.K-U.>G|U+ DASS20VI(<|TK|J0_G>I%|U&G>I%|UF_M|P'4A|4M(>U('1:=S35IW-
"KWIU-703JEE(I%|U&G>I%|UD|QDB=ZD70_M4:=ZD702>06I?2HEZU+Z5F|S1;\$GI4GI4?
I4GI4,J.Y)Z5*02H02I5Z5D|R_MWN.7K4R|*A7K4R|*SEL(#VJ:.H3VJ:.L2H|CCVI_I3#VI_I3-'N2>E2K47I4
MJUC+<0|>|2)WJ->|2)WK%|FBV)%|U(G>HU|U(G>D|BQXJ7TJ(5+Z5G|D3)/2
MI/2H_2I/2LAHE7I3T|TQ>E/306;W-5L2+WJ1.|1KWJ1.|9/<9(0>I\$|U&O>I M\$|U#V-%L/%2^E1"I?
2IZ%\$GI4GI4?I4GI68\$AZ"GPYYIAZ"GPYYJ64B5>|*> MU(0>E/:LGN!-
'3CVIL=.:LY;&BV'^E2KTJ+TJ5>E8E#T|T\40.|/%, "7TJ3_MTJ/TJ3TK-
|E(D|*E7I47I4J|*Q>XEN/304B|ZC304B|ZF6QN*>U3IU">U3IU ME|D|Q|4_TIA|4_TK|)%1W)5Z4Y>M-
7I3EZUD:;F7I3T|TQ>E/300(D703UZT
M0>|/7K6;W)^T3+TIR|:02G+UJ&:DR|*X\$R|*YHMB9>E/303%Z4|.19R|W5C=M|^&:;%^N|3>'_P|;->G?
#6U6/2Y|E/NS_M-\G^Z0^I->?+:ILFK:E#;Q\$!RW6-LEG;00IC"JH^E?IO! MF6RG6>:LH|>9|F7TWS_Z-
!I>? 'J_M/^&+ @|_T*:_ /@T0/\ X|4_5Y\$?ZL80^>/W0_ (+^B0U_X80\ @|_T*:_ ^M#2\ ^/4?|,7
>Z%-_!I>?_ 'J/J|@_P|6,7_/'|W_) 'Y?T5^H'_#%_P>_M_P"A3?| \&EY_P#|J/\ AB_X/?|_0IO_.#2|_|
CU'U>0?ZL80^>/W0_ (+ M^B0U_X80^#W_0IO_P"#2|_ ^/4?|,7_!|_H4W_ \!I>?_ 'J/J|@_U8Q?| \?0^M?
^1^7|?%?J!_PQ?|_!|_H4W_ \&EY_ \>H_X80^#W_0IO\ ^#2|_ P#CU'U>0?ZL80\ GC| |P_C|OZ*_4#_
(80^#W_\$*:_P#@T0/_ (|1_P,7_!|_H4W_P#|_MI>?_!ZCZO(/|6,7_/'|W_D?E_17Z@?|,7_!|_H4W_ \!
!I>?_ 'J/^&+ _(/?_M)"F_@T0/_ CU'U>0?ZL80^>/W0\ R/R_HK|0/^&+ @|_T*:_ /@T0/\ X|1_MPQ?|_ '0|
H4W_ /!I>?|_ QZCZO(/|6,7_#0^|_Y'Y?T5^H'_Q?|_ '0^A3?_M_&EY_ \ 'J/^&+ @|_T*:_ \!
@T0/_ CU'U>0?ZL80^>/W0_ (+^B0U_X80\ M@|_T*:_ ^#2|_ ^/4?|,7_>Z%-_!I>?_ 'J/J|@_P|6,7_/'|W-
) 'Y?T5^H'_#%_P>_P"A3?| \&EY_P#|J/\ AB_X/?|_0IO_.#2|_ |CU'U>0?ZL80^>M>/W0_ (+^B0U
_X80^#W_0IO_P"#2|_ ^/4?|,7_!|_H4W_ \!I>?_ 'J/J|@_MU8Q?| \?0?^1^7|?%?J!_PQ?|_!
|_H4W_ \&EY_ \>H_X80^#W_0IO\ ^#2|_ P#C_MU'U>0?ZL80\ GC| |P_C|OZ*_4#_ (80^#W_\$*:_P#@T0/_
(|1_P,7_!|_M_H4W_P#|_!I>?_!ZCZO(/|6,7_/'|W_D?E_17Z@?|,7_!|_H4W_ \!I>?_ 'J/_M^&+
(/?)"F_@T0/_ CU'U>0?ZL80^>/W0\ R/R_HK|0/^&+ @|_T*:_ /@T0/\ X|1_PQ?|_ '0|_H4W_ /!I>?|
QZCZO(/|6,7_#0^|_Y'Y?T5^H'_Q?_M|_ '0^A3?_&EY_ \ 'J/^&+ @|_T*:_ \ @T0/_ CU'U>0?
ZL80^>/W0_ (+^B0_MU_X80\ @|_T*:_ ^#2|_ ^/4?|,7_>Z%-_!I>?_ 'J/J|@_P|6,7_/'|W_M_) 'Y?
T5^H'_#%_P>_P"A3?| \&EY_P#|J/\ AB_X/?|_0IO_.#2|_ |CU'U>0?ZL80^>/W0_ (+^B0U
_X80^#W_0IO_P"#2|_ ^/4?|,7_!|_H4W_ \!I>?_M_ 'J/J|@_U8Q?| \?0?^1^7|?%?J!_PQ?|_!
|_H4W_ \&EY_ \>H_X80^#W_0IO\ M^#2|_ P#CU'U>0?ZL80\ GC| |P_C|OZ*_4#_ (80^#W_\$*:_P#@T0/_ (|1
M_P,7_!|_H4W_P#|_!I>?_!ZCZO(/|6,7_/'|W_D?E_17Z@?|,7_!|_H4W_ \M|_!I>?_ 'J/^&+
(/?)"F_@T0/_ CU'U>0?ZL80^>/W0\ R/R_HK|0/^&+ @|_T*:_ /@T0/\ X|1_PQ?|_ '0|_H4W_ /!I>?|
QZCZO(/|6,7_#0^|_Y'Y?T5^H'_Q?|_ '0^A3?_&EY_ \ 'J/^&+ @|_T*:_ \ @T0/_ CU'U>0?ZL80^>/W
M0_ (+^B0U_X80\ @|_T*:_ ^#2|_ ^/4?|,7_>Z%-_!I>?_ 'J/J|@_P|6_M,7_/'|W_) 'Y?
T5^H'_#%_P>_P"A3?| \&EY_P#|J/\ AB_X/?|_0IO_.#2_M|_ |CU'U>0?ZL80^>/W0_ (+^B0U
_X80^#W_0IO_P"#2|_ ^/4?|,7_!|_H4_MW_ \!I>?_ 'J/J|@_U8Q?| \?0?^1^7|?%?J!_PQ?|_!
|_H4W_ \&EY_ \>H_X80^M#W_0IO\ ^#2|_ P#CU'U>0?ZL80\ GC| |P_C|OZ*_4#_ (80^#W_\$*:_P#@MTO/_
(|1_P,7_!|_H4W_P#|_!I>?_!ZCZO(/|6,7_/'|W_D?E_17Z@?|,7_!|_M|_H4W_ \!I>?_ 'J/^&+
(/?)"F_@T0/_ CU'U>0?ZL80^>/W0\ R/R_HK|0_M/^&+ @|_T*:_ /@T0/\ X|1_PQ?|_ '0|_H4W_ /!I>?|
QZCZO(/|6,7_#0^M|_Y'Y?T5^H'_Q?|_ '0^A3?_&EY_ \ 'J/^&+ @|_T*:_ \ @T0/_ CU'U>0?
MZL80^>/W0_ (+^B0U_X80\ @|_T*:_ ^#2|_ ^/4?|,7_>Z%-_!I>?_ 'J_M/J|@_P|6,7_/'|W_) 'Y?
T5^H'_#%_P>_P"A3?| \&EY_P#|J/\ AB_X/?|_M0IO_.#2|_ |CU'U>0?ZL80^>/W0_ (+^B0U
_X80^#W_0IO_P"#2|_ ^/4?|,7_!|_M,7_!|_H4W_ \!I>?_ 'J/J|@_U8Q?| \?0?^1^7|?%?J!_PQ?|_!|_H4W_ \&EY
M|>H_X80^#W_0IO\ ^#2|_ P#CU'U>0?ZL80\ GC| |P_C|OZ*_4#_ (80^#W_M_\$*:_P#@T0/_ (|1_P,7_!
|_H4W_P#|_!I>?_!ZCZO(/|6,7_/'|W_D?E_17_MZ@?|,7_!|_H4W_ \!I>?_ 'J/^&+ _(/?)"F_@T0/_ CU'U>0?
ZL80^>/W0\ MR/R_HK|0/^&+ @|_T*:_ /@T0/\ X|1_PQ?|_ '0|_H4W_ /!I>?|_ QZCZO(/|_M6,7_#0^|_Y'Y?
T5^H'_Q?|_ '0^A3?_&EY_ \ 'J/^&+ @|_T*:_ \ @T0/_ M_CU'U>0?ZL80^>/W0_ (+^B0U_X80\
@|_T*:_ ^#2|_ ^/4?|,7_>Z%-_M_!I>?_ 'J/J|@_P|6,7_/'|W_) 'Y?T5^H'_#%_P>_P"A3?| \&EY_P#|J/\
MAB_X/?|_0IO_.#2|_ |CU'U>0?ZL80^>/W0_ (+^B0U_X80^#W_0IO_P"#M2|_ ^/4?|,7_!|_H4W_ \!I>?
_ 'J/J|@_U8Q?| \?0?^1^7|?%?J!_PQ?|_!|_H_M4W_ \&EY_ \>H_X80^#W_0IO\ ^#2|_ P#CU'U>0?ZL80\ GC| |P
C|OZ*_4#_M_ (80^#W_\$*:_P#@T0/_ (|1_P,7_!|_H4W_P#|_!I>?_!ZCZO(/|6,7_/'|_MW_D?E_17Z@?
|,7_!|_H4W_ \!I>?_ 'J/^&+ _(/?)"F_@T0/_ CU'U>0?ZL8_M0^>/W0\ R/R_HK|0/^&+ @|_T*:_ /@T0/\
X|1_PQ?|_ '0|_H4W_ /!I>?|_ MQZCZO(/|6,7_#0^|_Y'Y?T5^H'_Q?|_ '0^A3?_&EY_ \ 'J/^&+ @|_T*_
M;_ \ @T0/_ CU'U>0?ZL80^>/W0_ (+^B0U_X80\ @|_T*:_ ^#2|_ ^/4?|,7_M_>Z%-_!I>?
_ 'J/J|@_P|6,7_/'|W_) 'Y?T5^H'_#%_P>_P"A3?| \&EY_M_P#|J/\ AB_X/?|_0IO_.#2|_ |CU'U>0?
ZL80^>/W0_ (+^B0U_X80^#W_M_0IO_P"#2|_ ^/4?|,7_!|_H4W_ \!I>?_ 'J/J|@_U8Q?| \?0?^1^7|?%?J!_P

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

```

:3*92/IN/061%"D:@*J@#Z,5Z6"X)E&:GB:ETN MECIYY:E9S>IB^&?#MMX?M?CW/(V-DGWCCU-
/M*!^%/7ZCA\2PM-4Z*LD> MS&*BK(16S3J0%#>74,:W:D;&:=2T 1Y Z4;0\YI]+0(CW?YSIN_SF6FDP: L M-
W?YSIN_SF68-0%AN/...-W^XS!/K M1M/J:DSZT9%AD>T^IHVGU-29%&1189'M/J:-I134F11D46 CVGU-
&T^IJ3( MHR*+!I/I1S0+4CVGU(HVG^:\D^M&10 S M&W02_C3J6D S\31CWI]%%&8\Z3:76GG>DXI-
VGUHVVGUW%:'R 3:76C: M?6G<49%.P#=:I]-:I]-=D49%D,9M/K1M/K3\BC(I@,( &F_@*EI:!\$/X"C\! M4U%
$/X"C\!4U% $7X"CC_9J6B@',8\0PH_STJ2B@1' )Z4?YZ5)10%B/\ MSTH_STJ2B@+>$7Z?
A1^/Z5+12UFC(QGL:..76I**8$?/K1SZU)10!'S1S4E%("
M(YH "I*,BE9\PT(Z*DR*,BBS[A9=B.BI,BC(HL^X678C "C\*DR*,BJ"R[#% M\Q2>E.X->T4!H-
/TI/PI]+1H*Q'C\*-M/HVB@+,#,"CBGTM*P6( _I_+--+SZ MI3Z*8QG/K^E'/K^E/HH 9SZ I1SZ I3Z* &
<^0Z4<^0Z4^B@!G/K^E'/K^E/ MHH 9SZ I1SZ I3Z* &8/^12AJ6EJ7?\XHY_P_XHLP)J*AY_P_XHY_SBBS
FHJ'G .*.?.\ .*+,"BH M>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X
MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G
#BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG
#BBS FHJ'G #BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_S
MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\
.*.\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?
\ .*+,"BH M>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P
XHY_SBBS FHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G #BC MG .*+,"BH>?
\XHY_P_XHLP)J*AY_P_XHY_SBBS MFHJ'G .*.?.\ .*+,"BH>?\ .*.?\XHLP)J*AY_SBCG #BBS FHJ'G
#BC MG .*+,"BH>?\XHY_P_XHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\ .*+,"BH M>?\ .*.?
\XHLP)J*AY_SBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_X MHLP)J*AY_P_XHY_SBBS FHJ'G .*.?.\
.*+,"BH>?\ .*.?\XHLP)J*AY_S MBCG #BBS FHJ'G #BCG .*+,"BH>?\XHY_P_XHLP)J*AY_P
XHY_SBBS MFHJ'G .
```


1/\$ \ '1 ^1J/^'D MX?V\COY P7^1J\ \/(Y?^B>) P"#H \ R-1 P\CE P"B>) X.C \C5\644?6
M*0QW\ X+ (^T P#AY'+ -\$ \3 P=' Y&H X>1R]\$ \3 , '1 P#D:0BR MBCZ05[A ;V. G !?Y'VG P /(Y?
^B>) X.C /(U' #R.7 HGB?^#H " -7 MQ91118JJP M\?'S (+ "/M/ AY'+ T30/ =' P"1J/\
AY'+ P\;\$ \3 P M=' Y&KXLHH^L5>X?V\COY P7^1J\ P##R.7 *)XG @Z/ R-1 P\CE Z)XG M (.C P#(U?
%E'UBKW#^WL= /'" R/M/ AY'+ T30/\ P=' .1J/^'D) X.C \ (U' \C ME Z)XG @Z/\ \C5\644?
6*0QW\ X+ (^T \ AY'+ P\;\$ \3 P=' Y&H X M>1R]\$ \3 P '1 \ D:0BRBCZ05[A ;V. G !?
Y'VG P\CE Z)XG (.C P#(MU' #R.7 *)XG @Z/ R-7091118JJP M\?'S @0\C\3 . 'D) X.C \ (U?
%E'UBKW#^WL= / \ @0\ (^T ^'DQW\ X+ (^T ^ M'D1R P#1/\$ \ '1 ^1J+**/K%7N\}08[? \ !?Y'
MVG P\CE Z)XG @Z/ P C4? \ #R.7 HGB?^#H P#R-7091118JJP M\?'S @0
M\C\3 P" 'D1R P#1/\$ \ '1 ^1J/^'DX M?V\COY P7^1J\ \ #R.7 HGB?^#H P#R-1 P\CE Z)XG @Z/ P
C5\644?6* M0QW\ P" 'P C\3 X>1R]\$ \3 P '1 \ D:C (>1R \ 1/\$ \ '1 ^1J^ M+**/K%7N\}08[? \
 \ % D?:? \ P\CE P"B>) X.C \C4? \/(Y?^B>) P"#H \ MR-7091118JJP M\?'S @0\C\3 X>1R]\$ \3
 , '1 P#D:C AY'+ -\$ \3 P= M' Y&KXLHH^L5>X?V\COY P % D?:? #R.7 HGB?^#H " -1 P /(Y?^B>)-
MX.C /(U?%E'UBKW#^WL= /'" R/M/ (>1R \ 1/\$ \ '1 ^1J/^'DX?V\COY P7^1J\ \/(Y?^B>) P"#H \
R-1 P\CE M P"B>) X.C \C5\644?6*0QW\ X+ (^T P#AY'+ -\$ \3 P=' Y&H X> M1R]\$ \3
 , '1 P#D:0BRBCZ05[A ;V. G !?Y'VG P /(Y?^B>) X.C /(U M' #R.7 HGB?^#H " -7091118JJP M\?'
S (+ "/M/ AY'+ T30/ =' M P"1J/\ AY'+ P\;\$ \3 P=' Y&KXLHH^L5>X?V\COY P7^1J\ P##R.7 *)X
MG @Z/ R-1 P\CE Z)XG (.C P#(U?%E'UBKW#^WL= /'" R/M/ AY' - T3 M0/\ P=' .1J3 AY%-
V^'B ^#H " -70;1118J\0?V\COY P7^1JG3? \ %'I MVC9 ^%?I7^'VB, C\GKXZG^" ?Q(X6U\ . =+ \4?
8Q8?;FF T<3>;LV321XW M\5S\STK\B6Z#Z T-?J#^Q? \ FV^\$ K= P#I9-77AZLZCLSZ/(L006,Q\$H5I
M7TN>XKTIU,CZ4^N\^ZWU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M**** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH X3X\ /) %0'? & K\ TG>OR' A3 '17Z\? ?'
_DBWCO + 5\ Z307Y# M_P *? [HKS,5 \<3 \XG_BT@HHHKS D?# /<****8@HHHH **** "BBB@ HHHH * M****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M**** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH
**** "BBB@ HHHH 1N@^0\#7Z@_L7 P#)MOA3 >N 2R:OR^; MH/K \$-?J#^Q? R;;X4_WK0_-
+)J\(\ \3/L.&?]ZEZ?J>XQ =IU-C^ [3J]5 MGZ8MD%%%(84444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4 M444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !11 M10 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 <)\ = P#DBWCO
M_L!7W_I.!?D/ "G^Z* 7CX\ /) %0'? & K\ TG>OR' A3 '17F8KXXGYW MQ/\
Q:04445YR/AWN%%%,04444 %%% !1110 444+G<=H8NJEUV\>, \X^ M7@GGMZBCK8:5W;^KA17Z2?"0X"^^?
WP\(\ :3XL\/:#?^);YI(GNKG2X9I&N M6\$UQ)"TFU_N*DB[RW/E]XT\ /+ 'Y\$N M3"59AN?:2(V;)PRE0\
GV."HKWW\G\XP?"S MX>^ [ZQ\<^!V\3:I/J\$MS!9*ZLV&20XYQFQK+PU:?! [70A M+< \$>S^'FB)H<^%I=7QB?
1;9;@K;M(^'4 C/[LXYK6&4U?F-\+E\$,7%.-57Z MKL?FA17UCX\ :'^ ^L>\$ \$%CI?PP;3\2N--
GAMK(^PK&+R)'3;&\2;EP[*V M1TQGBKNK\+ '3\G ,3>[)*T*W^B17>J7D-
C\]HT&P\I9)&^+N(S=NWE<9\Q>F>AZ5\C +17Q)^?'Q'DT\$^"? BZVGVC\8/[.M\3S] E M^7 JF.[;M?
KTW<=314I1IK?4C&97'"0DY54VNAXW1139,, C;RC57U;1X*6MAU??:7PD^ W@;X5 " ,?%/XBV46L7-
Q:17RP+"US^ M\'.JA(A^G;* [&0;F< +A? [IE9DWQ& 90^+.CZAI^H^&\\$F%#+!<-I\5K*Q6
M.4DQ0; %PS+ \Y\$4F=S, (S\$ "NKV^E>3LSZ\9/*-., JU11D\4NI\845] _?XQ M?"3P\X?U2T\6?
#^77\FXU*;YM;E[*ROY(H#''B-I)#&25*N#M0#.3@9P/J\ P MU:?!W70A+< \$:S^'NBQZ'#:75\8WT6V6X*VY\$?
\$.GZ1\,6T_5+G3IH+6^;0K"RI)\$V1M MN\ P, /G=>@KY/R>A7;@#]>09Z\^ I6%2GR;.YY.,P\,-)1IU.:5=
HHHK(MX/0**^A2V' "ND>+OBSJEGK>FV.J6D>BS3I!>VJSQK()H KX8\$ @%OSKE/VK
MM!TSPQ^T\XLTW1\.#3=/A:U,=G:1+%%#FTA)VHJ@_D]>U:C=K'DM%%&T%26&4Z?
=W88@A3CKU(&1ZUFXNR//<)V;4=@HKZC_97^WP\ M^&OPY\8Z3XOBS>ZA/--JG_L\7'VVW\G: +7>JD/AEE&V;
_>^A./+?@OX3T#X MJ?'?2\}O-.DT_P /ZCJ\$S\A29B\&D0V, [^Q09)ZL\26
M!CRTG"=W/2UNIY=17IG\2/@02?A \9 \$VAZ)IZV^C60MUBA5\Y7?! [99R6(M+2\$ \G; \W;O\!XC^.GPLU#JE?
10"1T]-9UR&RAA33DMC ;>\5300/, V# +W^ M4DMYNUP S@4J-
[I08(8'WZL*LN5P/E.BFQJ% C4&/8^!D@GIVX\= KG/7-.KF ML\7/+4)23Y0HKZ= X)\QK)\:-65AD?V%-Z46\
<1^V^HC :0\8*HP,VG_I)# M6KIVI^T/2E@>7!+%\V[M8\9HKL/A^XD\ />\$0B^I>J^*M(M\ P ;+.UWI_P\G
MCN/, !@D53YWQ/^*OP)^&/CB \)Z0\ M, ;>ZOK/R5=K/P_921-YB\U"EF4_QCJ\SZU\< %SQ)X? \7? \$+5-
5\+;1_8.@7 M*P-;Z? \ 9H\?RP((U8\ (V^C+*W3TJ;E-06CN+^9?#")J-52;Z' 'T445@D\GC
M\K=E;5\+4****OE94HU2TTT)4 MZDI**045\]?MA?!'P0\ !FQ\ "IX=L6M9\Z*Z6\F:9W:=HA!M8@G:#^ \;[H'7
MZ5\VU/[*S M6,8MI["0\$E">WB?RI0?F&[GG78445\]?L; !; \% "C60\$T_BR1;">\MX4L\1-J9C&%=0,B^0-(-
Y;,\#;?: M+Y((7.M.' /+E.K\X=8BK&G-N-]+M'SK171?;\$6M" \I>/M& MK%D234)Q'(\B\UCA'S3.5+*& C5SMW
GH#G@_HGX\^"/@+Q5H?B'PII'A30+ M'Q/_ &0T,DGF_9I#/\N5 D@; (4D_+@C#C=U4Z+J)L\0 Y7+&TYU+
MV2V\WV/S(HJ>^TVYTW4+BR08)(M2MY#!+ #-\$DMG4A=C#H&' 'D,S=NW;<9\ MQ<8ST->(Z\A?
0@1<=>, =+U" +X9&/28-.O+>XM1H-E^ \FDDMFBD\0?AMBQ3*0CQ^S_X5U\5M#N?A7%+=Z7>2V\$LD'A_3_*,D
M;E&"I_2,BB6'BH\R9H\EIJG\5UER08^(J^V?&FI6&L>,->OM+L_L&G7.H7\$
M\ M; >6L7EP0(7B78N57\$;)T)K&KEY7T/FI4G&32UMV"BM3PIH40BCQ7H^C6PA
M;ZU*ZBLHA.Q"YED6/+;5+!10R6' QGD\!^W=:\# =9,*Z\$GBK0)/%>LZ_MJ/*-
Y<6*7<\K1X,DP6=0+A0;T&Q30(*<,4+ #:G1<_BT1Z>"RZ>,3GS9\GT5^EWQBM_A!\\$?#UEK>0?#G2;FUN;E; M-

5L-&M))%D969?E;;V4]">E?)00_+GPN^('A6RL?_@T^'=5M]2CEN9VTFT MM#+\$(W\B,D;%AEI(S@=
<5R'H3TKL^KKEYE(^GHY+'\$4W4C66GX'YH45\8ZQ\ M7?A9\0/&WPXL/_@Y0#.KV_B\39KFZ;2;2U,D(D
,9=&)Y:2/COBM[_@HT\$W_M_#\HNU?^)\@,XQG'V;/ZTI8=+DI7L8RRJ*H5*T*G-R\D?
&%%UPHHHHTZ@HNZNNG\ P4444:W22W%ROX;/F"BBBEK90L+S:=EN%%)Z_[0]13
M:;L/E=KRT%HK(^X)\PK)\%?\$1VY/\02_P#I-;U\ +T'T'\JWE1<4GW/50.7
M0#T:=57ES+L+111P5;;K187@KP6P45^A'\,/PB\'>-?V=/
M#L^L>\$]'0+Z\6]@G0/LEGDL9BJ2,\$4RQGYDEVAF*[T*MM9B1G\YS714I.FE+N>UB\LGAJ,*]]),Y MJB010V?=
(12?&KXEV?A]GE@T]89+F_N+80B:*.0%.S?W9F1<@'!8-@f>/L? M\K#X7>#/#?
P&\2:AHWA/0]'4(FM(X\JVTZ"-TW7L0.U\G')/?MT%53HN<7.^ M@|-E<\1AIXENR1^>5%(0W4(E:7*D]
[.R@\HHHHN* MS:TWOMJ%%?2/[&WP1* &GX\7MXKLI-1M-.AMT2V\$SOH?-,I+,4(?(\I<88
M#DYSVUIP=1V2.K"X:6*K*A'XOF?-U%=K\%BS &KP,TC1L\ZY8NRQDE/)\R
M>Y(/00S7TY_P4>4! AZ0NW(U#_VVK549.#EV.VGETYX>K60\T'MW/BZBBBN6_M5XV/(:
<=)*S"BNC^'_P\UWXI>)\P[X>C=KZZ#;IE.U+:/&&FD;G;&N<\$\3R_MR@?,5#?H!\#0V5_!'\@70Y=-
UNSTS03XEE@BDOGOHH\ D11MN5\$C5URL9*2?/@ M&1E8GH%7IIT95'8\ C 9750VM\(-RBNJ^,5E;Z? \6?
&=I;0BWLX=:0(8\6WA_MV1!\\$N)"(T4* 3_L\ P"?U)\(@?X#^?PE/Q1^(\K\K\$LE0%J"V\JTM0"DR!
M8X_*^Y+(S2J"TB\5.W^X964;:DVKF>'R^=:0*BFM-WV/C&BOT\$&Z'\%0VG_M OKUMHW@Q-
%ETOU+M#80V%W\$[I]LD26(E#SYHVLQ&4)=2&4GX/\4>'I0"7B_M35=\$NI5E0-.NYK2N_\$LFK\0FZ#Z_T-?
J#^Q?_P_FV^%/|Z_/2R:N_"?S\ M#AG_'J7I^I[C]\VG4V/[M.KU6?IBV04444AA110_4444_%%_%!1110
44_M44_%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%!111_M0_4444_%%_%!1110_4444
%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%
!1110_4444_%M%%_!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%
!1110_4444_%M%%_!1110_4444_%%_%!1110_4444_%%_%!1110_4444_%%_%!1110_44_M44_%%_%
!1110!PGOW_Y(MX\ P"P%??^D[U^0_\ "G^Z*_7CX\ \D6\= P#8_M"00_\$G>OR'_
(4_W17F8KXXGYW0/_%I!1117G(^>X44440!1110_4444_%M%%_!7K7\+/PWA^)\WQJT*PN\;[5I]B7U*[0&?
NXUP_X<'?&TC1QLB\ D2#L" M1Y)0"L.H8XPR_>&4C'MD+GVS7WI^Q^X7L_AS\&];\=1E(+ M2U\U=S?
(/GW>:3U^4)73IASN\>Q\>3X=8C%1YMHZLX;\K3XZW7A_\H+P0_9\ M+(W@659R!*8?M1F6.26'S%8C8\&Q1E
=V\ '*G)V/VY_!FE^,/!\A7XG:,K7U_MNZ06\ S,D);S+&8>9#,2V/+ "OP, 9^T'/2J\?
|\&'\PRGX>@')";SN8C:6(MX\^,<\9XQ7K?@7XC6/[7GP? \6Z?+96^AW\$GF:2HY!!/?!!'X5_M^A'PB/\ Q@-
?_P#8#UG_-&W5?_FOZ/<^'->0\ (OH9+>_L9FMYX796\MD9T*_MAD&TX*D<%NF,XQ7WW\)&'_#
]_JAZS_P'C+FN;"WCS*9X.20E3K5H-ZJ+^ M_/C^%/IT5V?P4_Y++X%.\ F.6/\ I1'7&=E_P\T5V?
P4_Y+)X%_[#EE_P"E_M\$<=-OGNSPL/IBH-E)C^<K#S"53*9*[B<<9'T-_P4=;9_MF?"?1M5^&^E?
\$01/#3,"^ZXBSD_M7_E:)2XRXWMNR!\OH/QTL/V@+?QB\U--1CU'P\=1!ULU2SCELI%50T9:X7]
MXKG+AMV02RD_!<^+?M_6/QZT;X52S^_ \$VE7VBWKP7&CD6BSL[-051M@4,5_M*9PC.>,D;5)KHJ1T<4CV\9-
2IU*7LV^UDK+YGI'PE^~WPM^*/P3T_P"OC>Z_MATEK:PAL\JSU2X-K%=1P>6\$D2;:JN^V\A'N#\,-I4\$GFOB-
_P3\%G87-_P"#_M->NKJ\MXBT=CK" I(;EP2>)UV!,@J&W\ R\G\W+Q.N_L&>.K+POI^IZ/=VFKZ_MH\ L#>=Z3,
(X986;:3\$CEFCDP2X+>D'R_C.>:/M-')1A+>I4\;0UBM)'Y^7_M\G/I\|<6MY%
<07T,ACN8;E=LD<@ZJPP,.._OR>2:_0+X1?)\ @U_P\!@/6?_M
\$;=5*_#\$7H/%'CWQ)K%K%);V^H:G,\8([5]U_M?"-A_P_#WX\ P\AZS_Z,N:G#N*K<-09U.WC_M6RATP>3=7-
M'-)'=62R+\6FJ47\XCNBG;DY)\9KFI_MZ/),[FRR:70@f\A^9NG7G.0>H_\$K2_CD%9\$E!PZ28W
C@|C@Y()XXY\^?^%T:M_V_I0_\THMZC^,<9D_ SM1MR? \?T7#?+Q\MH2.? M8'I40_!/?_DM&L?]\@&;-
*+>H_BT V\|0>T(Z_V\HW_HNUKT>6]**74^THV_MLZC?^='T-^TM\3_#/P^U000\$ESX/M\= \3ZBCV=0?
32)#\FMX0=Q\$N0W4G\40_M0B\@MD_*&Q0BQ^HW\27*4_C&/2WT\4;?3\K4K'\3"))K>2_L+B%6!_Q)Y3H
M,XX97*Y3:0\$_\%(B=WP\SZ:A_*WKM?A*R_\#_M^#U_L/6?_\$9=5T>ZYN+/_M7G5=3%U_-99?
[=F1#*N"5^S6^WL">,=0#\(<"N)_MX)_\$@ZUKP,-/:1I?M&0?VD)\A0^/>'R0+XQG/4=*[?_@GNS_*7UP*
:_M\+Z3V\>&_L"7=0:_&J\6:.*&2XT:6&\$22_&50,@&1<+-IS6_U0W^TYN+;.[R0*.=OF=-W_M:M;XPLW_P/I;
(X#KH&BD-D(3B2TRWM_P#7KR#\K\X^>.[SXI>,_&UOH,ES
MX:"07'\H">%U58\6)'\@'S3@H1VQMWU\ \6E' _#!\^G/YK)\$NAZ)(9(6*L4\$ MEL3SUZ9\Q^
)\7E*7,5\3\$U)XI5M(V=MCYQ_9S^*W@X)GAC*.HR_RG>/,S\0?S0\ 90T>3P3^R@/&GA;PC\JGCJ>W
MNG.V\$>?.5N&0;@I#%0D2.84(+ \H^8BNV_9\$ \0?%/Q^IOB6X^)?VQ(XY((=. M6\TZ.R\$ _VF0&FA->"_&E6-
)\IZ3X_++>0IT'3D,<9.,X)SF0,?VQ_ ^3D0&/UM/_22_M&0:0V8R!\^VA\4>;:I_Z<(Z\6;:).?VD0&&.1FT_I
(X:PK1<\IXV.BH999? MSL\7KZ>_X)ZG_B\K_\ 8\F\]*+>OF&0IW_@GNP7XTZMDX_XD4W_*46\88>
M7[U^CY.U]=IWZ.Q0'[8PV_M(>,!\VG_I)\#7LG_!_R.-S\06=#)M&GX48_P"G_MGU^G_P"KK7C0\9'_
"ZTNYUQ\059;FY>+RYY9_M4:(R+)\07;D*0B!, (55?70A_\ +=+_9N^>G^>)KCP7<?>0B_T
XT^T>ZN16&WABM?'OP/ %7A#X0>,0\$%E\10!;>)\F_G3\+#!_M=&UFCF*R1B\B\$89Q^&3E>,B3!\@9J? \D/0?
M7A+Q[XWNM\$ L/\$7Q\$AUN^CAF:6']_,L2LT44
MP_>Q>9++*AD3Y3N&=RJJU:1)4V1E9(\$4L22XY)&S/4Y'S0\ /JR_9U_;"0_M_#^FV10-
*U*ZBTJUA:8PK;1W8R#V7V\ /F'QM\9_&7Q&_MUJ;Q\I\|IGAM=-:6*WN-
+6RCCNI)\$*10\U\$KA4\$HR68#^ (YVE0#/C=J5MI/[M<27UQ*(K&UUS2+BYE<@10*L=J7D8_P"RN/SIU.5J-S3%-
RIT:J70*?:VA\2?_MM'_M%'X_-X>C3P_&^=8\$Y&;S\ -Y9B\$7&/+? \WF=.,;>^>.1_9^N+7XI?#?
MXB7E_IKP6'B/Q+J,\ \FLS<1W\$,)9/-4*PX8_,N"/45^V0_" /QC\69/!9*_M:_.FL-IRWANPMW';E"_DE
'9U.#Y;C@&'&T'C0/^P'9SZ7\)_ \$]C=0M:7=KX@N_M(+BV>/RVAE6",_A'8CC0WQVJN:7/RK8W<_P#!\/?/_M_N?
5B.@T&7_- 'V\<7^V:W_!DAXR/?%K_Z10BL_:R4.8\ZICJL,'&NU>?-
M9:=-3U\|0;X9Z9H>GZ#XUTC2K.RN;BZFM=2%N'22Z=U:=&L'L'8\ K+ND/S<@_M9(&!\Z/_#WX5:1^S;*;#Q)-
X*0%/CLO#>ME:0=W:W\$@,UU^K>,0%7QD_M^!MGXB^>M0:3XCW17,UDPBG.Y5\EL2T@*HV20SD8;_Y59-
XMQCS.^YZ4*=&_M&+J2:7-:Z\|&=H0D?M3>%=9T\Q\|->2\ (WEEM2UN;J,B15E^;=:3M&C*X:;%2
MZ;=N/+ #:PQ6N:_8M_'!0A'XX\+^ (+>W,>07NEZA_LH3#"V@CEC#18*X.X;E(
MR06!Y!+_X=\/_M6ZQ)=I=^(K#0XX67RSJ4=C^>!\ /RB&7&T@9W< \OEQC=-MK^P_?7VI?#00G=:G>/+;P%#H?
@0\ X102KB.8:9-%,BCY4:3Y\<1\ M8@0'(V,X!_'(Y'D/Q#5>>(P?MY)*49V3\CZO_:'^.!^!?

@ZPUS^QFUM;N_2P M\$(N?(V;H9)/,SY;=/+ Z'KVK\X0B)\0C\5/B-K7BDZ;=(^WM\$/L9D,GE{((X
M_0E\$SG;G10F0N0\ ;V\ \$ZY\ ;/A)H\$?@FUBUU0ML.H+MN(HE-0Y\$N)E>1@I^
MHQU^8'H#7Y[^(#.#,J^#=8NM%UK36TG4;.0QR6ASM3@,, 'H<@Y! (.01P148F M4M+&/\$%>0I%KW--;?
J=!\\$V''&;P(3T&N6/_ *41U]W?M;?L_P#B'X[?]\(G) MX=0=-L0[,
R+EM0ED3*R>3C:\$C8L/W9RN5S0SW'PC\\$ ^2S>!\#V_MRQ_]* (Z
M^N/V_0'>0^\$5\#'_0=>U'18I50FN5TZI>W;8*;8+D*PW8+'&>F3ZU5/\ A2YB
MLL\DL0JJNDX\CK/@1\)+;J E3P#XGUWQ9XAA\VZ\N2_F\$F; .WCB+B,1DH'=F,
MI'W+X/K>K77B''CC%N+F\>2=R@R1&0S'D%CU\^P' M\2M-M[#7?!,\PM]5N[N35+]F8?
Z4&C59\$08PK1^4IVDY(9B_0K\$. ,H2:BMD7 M@;\AL5B*5#EM''*T6]ST03?
C1<7WC*#P,/ @OKX\!SR)HZ7\VF20P+;NJQ M:/ M MODX.Y0ECRQ48*#B0^%/Z? \,?VT/
MUHNGIIN@ZW;7MQ%"C)L2Y6VG\$R1(M<,JA6B., #< ORKM6'6M' :KM_%TMAI>MP7FC :0+M]:\K3XHC S?
>>,Q^8I M48.548YW !@%:JWAV/XD:7^UE\--^ (B'3]>GAM[>T;3_*0('MIE/5+^W08X9#EHUEDNG"?=&
<;NO>0-/^"A"A?C1I!'.="A/_),7%=I_P3?D M\$7MY+@'C?BW^QK\1-6^+VLW6CVT>I M:#K--J']J&>-;
(SR0(Z-\$9 [;=W&T,#@MM)8J*M=7BKDP\K0PSE@8Wfy. M72YU0[5GP6\':A\)]-
)0@BSL]@A2UFD6QB^RP7EI,5\$1,(5090TD6-VS@X M8G8@7MO"7AWPU^R!\SW\XCUC2;>?
Q1Y.VYD41KKRJ9^K1YR=LB, MVT5:4\$WR+4ZZD*5.K4G"*<^3IW.J_9@^-VD?&Q_%];>\$[;PSKD+VC7TD#QS
M/>1M\$XA:2940LR^7(FUA\H48)R00P%:\;/^2S>.0^PY> ^E#U]B_L% #70+X% MTGQC?
^=(\$N\&CU%K: .U^W@1SR"(S\ M\18NA&8W\05*Y4@GXY^-G_)90'7_8
MWN\UIU.C7M\ M**BY'Z)%T, !2H49U>62=VK7N>6 MH?#9? ?QD0+^TBD3 M3?
\$*G4U)C8*MP6*SJ').]BP\$AZ;1,HP !GSCX* \ED\" P#83C.XV^W\!SQ\< !?8W MQH\#A?, +#7K('S5VMG[1&
<'UP3C/'3&!MY:Y:D6JD7\$3'4/99A"26DW<^G?^ M''CN-OPZQTQJ' MK7Q;7VC_P4.H\F =KE\ -NS?
G]_)OBG5;]A&Q8MWM9E!2>[^61Y&PIN"KA=C JPF M.10@^Z? \;;N^ \66_@E?@OKX\!SR)H\>H2Z9+'
ELZK\$"UH\"A;?/!W-PF6* M@90>; \ !/\ ^).FP6.0^"I[A;75KJ\DU6S,C#_2@T:I(J\$&:/RT.TG)#L0
M""8C1US2_P!JVV\53;=IFN6][H0VKRH-:\K3HHF@+##/&8_4J."JH0SN # M*U=E+E\FG8]
[!2I"B1MH(4J0T#K5U\(/VO]-TBVN-:\$>MQ[UM+7 M[6+74;8L\$>=1"Q82#;%M9@KK\C;2-K,/GWXQ?#WXJ^-
/BMX*\#>.\$>GZ[J- M^LGV*?3UM\6L3[C<2M'MA;B.\$G:P*OL(4DAQ4/CC\AGXA^'=1A'AJ.V\4;>3
M^ [EAECM)(@N&&]9) H&3@;"V=A)QD"H4I\STT.52JPJU(TJ%Z;M=\$GQT_80U M#X9Z'-XBT+4)/\$6C1N0GC6S
N; .W.,2E5;\$JC^(JJE22^-I<+U-EBY?;9-I MSM8\$ 8.!QP..<#CG(X:OT*U,WOP6_8MDT?
QG<\$:W)I%SIBQ),)'66;S%BA4N MWS>5&PSLR@6%R0RA:/7_6%-L7E@H7#-]Z0\$?>]AD\$#UP3_%7/6AR.+6AY>9
MX6C1Q)TER!:=NI^@0\ P4-&[X-Z V,?13Z'_P!)KFOB#X:W^B:7\0/#EYXD
M@^U:#'>P ;H2R[3"9/F,BE'+1K@,R@?-M"<;\C[= P""A3\0@0X>QT_MZ'/_ M (#7%?"0A#PC?>/?
\$VE>'M+1V0\ 49DMX00! #N+>BH8A0H+,<\$;?%-/\$W\I M%)&N)M4\0\ -K&VMDCMY?MTVGV36=0)N93\$!\$00
MS@;B6"#" (=F.,+X?7H0QD^!/B3X(WNFPZ\]G/%J\$;_9Y[*=I QC*A@P8*0P# MQGH
=W'20.JYJB?,>!CG4E6DZD>60U_NG_=;^1K]!/? @H9\0P:T!A \2>YKHHNU*?,>[E- J.(2 M>I\8?!!/"Y0
@_ZC5C .E*5][?M3?&31?@MJ'@_6;KPJ/\$N0L+V.PD>?R5 MM80+C,[!]KX=L1*/ESM+ ,/NO\%?!' DM/@+ L-
V/_I2E?3W !2+ ?7?#W'IJ M'\K>M*,[4G2W\L]_4KNQ>10HE\$4 MEI GR\EZ[6&-R_48%;GPG8+^P)?Y_P'@'K/_
*,NJB_X)[L/^%*Z[GK_&[- M_P'D\06UKR6FY\ZC&)>IU6E=PU/&?'G\1&E^-/!]Y\(? 7@J.RTVXNX;#1;N
MSU !+D)=H\3!6C4*92!N,C[@TAW\$GD^U:|^> V& VD+:>4UKQ1?1^0D\8 MV3WNP0_)7E?<8HR?
+;RE)&2N%P&* "/@GQ'_P (?X0T37_)^U#2\NWOFMMV MWS5BD23;G:VW)0#=-M.,]J^ [OVJ?A#K' [0G@/PEK-
()GBU4V<3W\$%HS""[R" MX\$161'?:\$950':0,AVY! #1&E=16QYF\$KU:*U6*3J1^T]"[X+ \0?#0]LS
MP9KC<]\=.%175_LD_!76?@7X.\3:MX
MTGMM)FU+R99+225&I#!YN9)9@VWYA(>GW5498DD+RW[%/B^PU_XD_&&]MV- MLVK7T= ;V-
SM6Y6(RW+?,BDYVB2,':G:6"GM6T%=QT-^V<5/W?^\$ZQ_Y4*]M_X**6<,E]\-80M<>GK)->H]Q,K/#&N;;R?M)W?
B66WL(?#4/B4:ZE\UTJI)']KCG,HN7\5&1EE M'DHV6'&0 !1I3- PK\ (L:3D:B<3L,#BVS\HSG!*G/'3'.
[!P>D):'\$\4I8 M3\$>UBKMW7I<[?X]?\$# AE/P+X5M? GA#38=+0[F3[3-- QAC9(E'A\A5I)I M-
WF.S,?)/#9W(0Q \2>&(V>;\XK^(? GAL^+-4LK5E34;2!S=3RJL:;6RS.
MF/WBH6W>60S;&V=UI7A/QCX0^\$GA/1_AIK^AZT;6\$#19XI6>=+F!@9\$, :1J>BZ7.;C^R- >00VB^6_9V6
M10SE".#N;&YVH9!6LER*YWXGFIT9S;>S (4UK_E2+(@UV0Y5MW6UMB<^ P!/60F+ M\IC'_).0\&XZXNO_
\$BFH1'C4\$D!=R@+C:&VXPBUXDWW?Q_H: ^GO^" @V?^%T; M3G_H!0_ ^E%Q7S"V=OX_T->?
72]HTCX_,X0IXRI&*LD?>G@SQE? \ P^_8(TK0 M#IC2+?;?PMUFD*JIE-JQ!9)#&KG=1*%9L-B,"@?!](?V6?
V8]7=;D+90\$>NJLMK;L5 MY!#?8HL*_P_ZX9YG*8<(\G7RZZGXV7\^H_L*V] =7,]U=S:+H\T\]PSR22MY
MEJ7+,QW%F).6)W',>U>%?MM_&RW\>>+M/\.,+J"70A[0T6=S;SAXKNZ2L\EM#(\8M%B3>T8 MD?
\$3B0[2GF[6954FNC^%W[3'A+]I#Q1#X,\5^!8+2=\S6,-]MU&UEF1'9QEH ME".(]Q4]"N\ \$J=JF?
P';C]I']CJ/PQ972Z5JD5I#I4FZ/'BG3;[!0J^%_A+9?!W]N;PQHVF29TB\@N+^
MRMY)'FDCB>UN049F'&V2.7!)) *L,LS\$F01?
CQ\ZC' =+>Y.Y8@B2.K'&;?'D@JF54_,685@ZMXNT[Q3^WYX2AT^0S'1[. ?
M3+B=65HVF6VNI&56!/*^%:8'D,&!'<< P#!0A@WQHT0!X'A^+ T?<4VW&+<
M48U*GU7"U)45JI*VQZI^V\X;T/XE? 330B986_V2[M[6TNH99\$ EFLYR@ \IB_MIZ+YX;.6"D-C[Q)]\$ _9(^(?
G7P=L_)<+&3P^8]#8?;%E,Q@MXL29_&S< M&SM.2.0>N0^+FV3]@G3PTKQK_8>C%G&"6'[RU/'X9K._X)\:E%
<=""Q#:0R1 MF]35VN7M0X:14DMX1&S#MNV-CZ&G%RC41UJI[/ 'Q<7\4+]-SSG6?VJ0^%]>.
MOASH;>%CH/V7Q;IM^+L:B)MX679@KL4C=YF.">E>_M0?&/1/@A?^#M:N/"B_M^)=>
(08[!FF\@6D7EQF=E;: ^';\$2_ =Y40\ P^Z_R%X7^"/CCX3_%CX;W7BS09 M=.LKKQ'8PI?+)# ,C/YZ81C&[;=P
ZXS@^AKV+_@H])YDGP]/R[L:ANVGC.+> MHYI*\$CSHXK\$4\7KS5I]JUS0?BI;Z+^TE^RK+XNBTP:9J5EI]SJ%F)
(A));3 M6Y9;B!&. 5?RGC!8_8*N4R@_ /5BV[:])9)(E ">9G=C'!' /3'4 ^V_*_0?X_M0L/^&!
[\= ["UG_T9=5^> \ "G^Z*YL4ERIGF9Y&,_85;:M:FCX<1:IX1UZ_MSUG1;J2QU2S?
S(:F'[T>"QY^4J5RI5L@AB""""^U/V ?\$FI^+0\$70.UC6[N_M2^U2\;3Y)KF;[TF3=;3Q\H4*0H5< !0
*)] %T>Y\1:M9Z581?;=10)XH+ M:W,BH'=Y\$C'+?[_ZU][?L4?![QE\)&\9/XIT/^R%U!+(V \ I<,PD,?G^81Y

M;MMQ03KC.?8TL,Y*NK\BW/B_P"-WS?&CQZ@*AGUJ_4AN R?:'RN M??BL;4_'B'7-%M--U/6;S4-
'MGC\G3[NZ=[;#9D1E5?C<-Q / ^8]17I7[M16P;\9>#/\&GB7Q1JNB&QT35--2F\D9 /7;S@=Z^@/V30
MV4CX=FM?&GC73\$ _MG"R:3IDZL3; *-L\p8<3G!P02/[Q <[4<:N.%\&OIWABRD_XEVFG4[3>_1^_F_?
%6EQNSV16*KN)9 MV^2_\$7AG5/!^MW6CZQILVD:C:-Y4]I<,69&!S][HX*E2''#*5-57YDN5=#3-
M'*C3C0A!J\$=GW[_B9U%%<604^6"BBBD,**** "BBB@ HHHH **** "BBB@ MHHHH 1N@^0\
0U^H/[%)MOA3>N\ TLFK\0FZ#Z_T-?J#^Q?_,FV^%/[MZ[]+)J[\)\3/L.&?|ZEZ?J>XQ=IU-
C^[3J]5GZ8MD%%%(84444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% ! M1110 4444 %%% !1110 4444 <)\= ^2+>_P#L!7W_*307Y#_,*?[HK] M>/CO_P
D6\=_]@^*_P#2=Z_(?^%/[T5YF*^.)^=\3_Q:04445YR/AWN%%%, M04444 %%% !1110 D@00G<>A!
(Z_+WX[]NOKT6Z;:&^(5YX1_X1)0%!\&@_8 MDT];!;2&'="J+'M,RHKKD*> 3N^[\QGGSNBKC)QN:0K5**?
LG: ^X@ZD90J,; MK-E5P,*0W/'K^'\-=G\/?C%XL^\$>J?[\OJDFE'4%C\$S);V\@+(6*,3,!"C> M_
_09_AKC:*B+<7=;E0K5*+YJ3LS5\1>(K_Q9K5YK*XR3:K?3^=),L4<)N)# MM7<4CVA>
<NHT7X[>_./# @5?!MAK_V?PR|M/;FQ-G_P:*.7PYC+'Y
MI&ZD5P5%7SR0=%10%2G)RI.S>F)'L\L;3GG('H0;CMW['KVBZQ=>'=7LM5L
M)A;:E9307%M.8EDV.DBR=&|=GZ52HK/T,8R<9IZ;X7_:2^)7@/1/[(T;Q;=6]E!L\$50>)#=-\$%4(55
MID8JGR#"A1SCK7,;OB9XG^)NK0WWB/4;G6941EC6Y;]S'G#.8XE^5<[%SM
MZX&>U)KBZL0#0@LE\$+GAOWBPJ/,/[OHW"\XZF MN!HH52:5F!|26\2H_V3D'J&7E_?=YH0QV<^'
MJ^#;#7_L_AE[;:W-B;:![@T4XM8X8HK;-6--L<,:H =J* M7SC[I]Z9XQSQ%5&3CLQ0K5*;
<8/_BQ)IP\3;W;:;NG@K:]EAA"/(5#\QA3U6/KGIV[V='^_GCK0? M
B^#-.UYK7PV\ \$L!MC:607RIBSR#>4\SD0)7!T4N:5[MFGUNNI,:EJ]WW1WO MPW^/7CWX6Z7)I?
A36!IFE7\$WVE[7R+>00)M122SQ\$ <1>XKC-#UK4] NH=2T MR^0+4H0PBOK"Y^S3#HQC([U5HJI5)W33V)>(K-
Q?-I';R/2_M%0[2'Q\;;*=UGQ)=2V#,[30V20VWF(=ZL&:%5+H59LQG(.G'&:_I_ '/QW MK7@F+P=>ZQ#>>&
(H(818R10JFR:E=%601!L*(U.&.[]*X*BAU)]S26,Q\$FVY MMW.V^'/QN\; "W1[ZT\+>)6L(+F9))H?
(BD1I0@S(J3:PNX\$#*!<[>E>;T4>TGH[[\$ MQQ5>,>6-1V\3L/'_Q?\
%G@WQ1J7BS2]:CT_7M5,K7LZ6L3M,LTJRN^PIM!+ M+C(3M6IXP\7:OXZ\27FMZ]>&^U6Z\LRS&(MP6-
47Y4"CHGH*QJ*GFE:S)EB M:TH\DI705TG@/XD>(0A;K\$VK^&]5_LJ\E@^RR/Y\$ZWK]X;[5KKRS+,84BW!8U1?
E0*.B> M@K7^'?Q>?7?"F2_,\$6UK^QQ?JHN,VT,PD9-WEC]XC8Q0?ICKSVKCZ*M2<9_M3RW\$S.(EC#N\CR'A?
3?^M;?@/XF^ M)_ACJ,M]X:U:[TN60_2^0V8GQG;YD9^5\9;&[ID^IKF**B+<7<4*TZ=7VL'9_M^IZ=XH_:4^)?
C00SH^L>+KJ>RN-XFM[-(;5I0RE K-"BED^,USOP\^ M*_B;X7W%U>^%-7ETQKU42<1B*6)B-K*HA8,@(^;&U>,D
C><[G160M9W33V+ M>+Q\$I\JC=0,] \$0?M\$ _\$;Q!JNGZM>+KX7NGR![5H0%&B2?.N/(4"-F*RLI M+
(KZU<+>:I=@/<2/"N"ZQF)253 (4 *_E!(5&Y. M:R**7-+N3+\$5JEU*;9ZG9?M/?%2ST1M'M?%HK;NLL*M: '&
M1A\C:#GG;Q1\\$_M#?7P'!=6VA:]:0:AW,GF='\'/?B5XD^%VI2ZQX>U?^S+V:#[]+/Y\$ _M,IDB+QLV%*D
AD_N]ZI^-&M^_0\$%[KVNWIO-8NMGG71AACX6,1K\H"C/R# M^&LBBE[2=6&^YA*M5E!0@? \$+X]>_OB?
81:7XI\0"[L+>;[1#:'1!&1 M,%=5 *(I/ROW)_#0B_#WGX>)?AA?/>>M7N]*+JJ0'"S&)MHP0F1M\CX.[&>
MF3ZUS-%)SDVFR_K%;VCK<[YK60<],\6?M*_ \$KQIX??2]9\4W5S8R\OM\$=FD5_MHTB\$%2C/_BDH59B5;
(.WD<51^'0QT>_ "W39=)\,;W_9^FS3&Y:W6T@*20M1 M=X,B,V"B*."HXX%<#15NI/FYDS1XW\$W4N=>:_@GQ?
K7@;Q!8Z[H=][DU>U\ MPQ70AAD^5HFC;Y2&'5C_U> \??\$K70B=JD6M>*6&J7<\$/V:)FBCA7RU,C*
MKHJJKY+G@@#BN:HK*\N7E;,:?K%;V?LE[]-* M(\$[P+HZZ+HGBBY6PA\09: MWJ171A"
[4P'F1BJ9\J+@#^' /->?:MK.H^(+^34-60;04M0F'^';=7URUQ,VU_M0F&=NN-0;C!
[53HJY3E)]7"IB*U>*C5FVETOH7-&U>Z\ZM9:II\PM=2LYX MKBVN#\$LFQTD20<-
N5TG0\$^+WB[XK26!\4ZS:XL^86 ^C0PB-GV^9_JT7.= MB=<[.].106?[7'Q>L[.V@ \7/<+"D2#SK.UD8A=J[W
M=XRS-QR6.XG![5PVC?;\$Q1H0C2W\5V^M7LOB;,:?[20I!>S\$>286!:52&([\$ M*0 <=JYJBM0:3[G9/%XBI92J-
I->?4Z3QY\2/\$7Q2U:'5_\$FK?VK>10"UB?R\$ MB*Q*[LN0@49RYYP.E7/AW\70%WPIDOSX6UG^QQ?JHN,VT,PD9-
WEC]XC8Q0? MICKSVKCZ*CG:ES\$?6;JJ*JGJBWK.KWGB36KK4KZ5+04+V:>XN9VMP%:1VD<\$ MJ0!
[T]>I!'203]+:N^+,C:5'IUEXN0&AC9A&;Z."YG"EB=K2RHSN>>IQ@8 M SS7DM*%\$YP09A'%5J;:;IS:0V-
37_\$VM>+=1BNM:UN;6+I5\$=M=ZA(T[JH+,M%);[H4EN!QR:Z7X?_'#QM\,-
+NK7PQXD.BV5Y+IEMGBBG3S.0Q3S\$8)O[GC M[HKAJ*492B[IBCB*L9 MK;!&RE\$^95X7'7= _\$*X76-90?
\$6L7VK:C)YE_?S=-7#?N96)+G8@"KD^E5* M*(Y-8L;%EFC MM!1#;Q^=>81HNI;D=,K' 'M5W)' ,
[/(4CIFTT5I*3 MGN;U*]6K/GF[3T+PW\? _! X/\&P^&-&UMH]"CBDC73VT^VF22*5F=U.Z,LV M6=NI]N]
<5HVL77AW6;+5=//V'4;&>*XM9A#%(D3)(L@4'&#@H>WOWJE10Y2> MS'+\$5I.+E)NWF=E\10C%XP^+#+:=PE>M?
VP-.1EM_P#1H81&S[?;_P!6BYSL M3KGIQWK: **F[>K,ZE2I6ESU'=G8_#0X0>+0A2^H?\
(MK7[CC4%47'^C0S"1 MDW>6/WB-C&Y^F.O/:N;UK5[KQ#J][JM_+G4KV>6XN9Q\$>L>YWD:3H0\ _O_K5
M.BJYG:Q3K5)05.3]U\$MI?3;:=07=I/+;WT,B20W\$,FQXMK:BRG<"&![@J"1V MKUBS_:V^+EC9QVE0XN>=
(4B0>?:6KLP7:N]Y'C+,>.K'<3@]J\BHI*4HZ)ET ML56H*U.5D^QHWE_=R;&GN;^_E>C:
M#^U!\4_#.E36=IXUNI0TWG WODWLHR -I>=&; & <>U>6T4*I430<=/\$UJ; M;A-J_F=X\^)GB?XFZA%?
>)=6N]3DC!\$0F;\$4><;0+C'RIG"YV[<#TKEI2RQ M,4^4_P#[3Y3MR".C>^*=11*4I.
[9E.K4G+FY3KU)352/\$P5U491%)^5^:X"BIN M^50[ETZ]2C%P@[7+6@ZQ<=>'=2L-3TR;[]?
6,\,]I+Y0D\$310&_1^_3&>GI74 M_\$3XQ>,_BQ)IY\2ZW_:4MAE;5?LL, 5Y"@?!C53U5.N>G;0QE%";MRW!5IQ@
M22?N0=>'>Z/_'3QWH/@-?!FG:\UKX:>"6W^S&SMB/*F+/(/, *>9R7DI/AU> M/'GPQTM]*\+;N--
TJ>8W+60D6\I:3:BD[WC)^Y&OI7!T5?M)Z-/8T6,Q":ES M:I60D&YUCW21B4L/+ED12I8 <+TY#?G7: #WXS^-
/AC%)_PC/B"YTNVN"TC M6: ^7-#YC,I9Q%(&&6V#!QG@@\$;N>+HI1DXW:>IA2J5*,N:,K/R9W/COXX>._
MB1*Y7B+Q/J-W9,GE2012>1_Q5FD_:&55C[D9[9.WCF?#?BC40!0B"SU02IC MINH:?(DL4D955QACR&Z?
ZSIWK,HJ54JWBA@@\X_' "G8@ ()!YR#CVJ76/CIK_CKQEX70/'UY#X MDT51K];IK5[:V0S6YFCDF38BJKYCA"@,
<_,1@D9PWFE%7[2>S_ KV(O=S;VT? MD?I)XX\#0^T2=+\3> ?B_J7AZUBA\$%0;:;-
(T#_*'F1)+\$T4X\$0S!N1F,%0_M5JIKWC>R_9<^>I: ?K?

[illegible]

!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4 M444
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %:-G4UJ M,[Q!_P @:]_ZX2?^@-7DG\/-
(UZWX@_P"0->_]<)/_ \$!J\D_A_P"!&LYG MG8H...:R6QQ!S1S1S1S3&'-'-'-'-' !S7E000^_
W "FQHV=&750[2\[# M=-^0(+\OMY;:L^9[8Q[UZES7RY^V[N(\%@!6R;S*MT/^H_SU%85I1VKOM4^+E
M]H_PCE\;EO(/%NESH_P *M3U>T*DBYLIY)DR "1N2 MV!./^!?AWZKX>?M,^' &GB"UT#4H;
[PSK4I8+;ZK_J3(,8C&<-0.3CYG&5>.'CB,>Z['M_CWQUHWP\|.W>LZM(] MO:0*R^0I432S^3^ZB<+"4C)SD8
)R"#7C;?M87L<*;H/ASJD0A090^0]ODCV MP-(5W+^Z\$>[('"8TLHDL3JEN?,#,FV)&>#"A-
MK,0S,3G"X>JE.7,57QS\HHWY5:^USZ,\&*(/&GAG3]//#>MW4-CI_B/2-0FS[50@HREFKM'C.M?M67W5K:}S)-
Y< MACX3R.<:/706WH?Q[\6:0KVfV5U\)]>L;]>[NXK>2ZF^T!+4,2HD<>0 ,9R/F M7[IzUX!>:-+;X?\ [2F0>
(]0\]R;/6-25HK9&:4;S+'T/_ ^ZC-?3OPT^/V@ M?
%;7IM*TBTU*VNH8FN@UZD:JX\$BJ<[7;IYG<#KW[1&3DW9GAX605K2:G/9V, MGXT?
M\$ *B\46NACP _J_G6R2[UNC"0Q=T\$8&QRWW-W7CS/>L. \ :DU#QUAN M/%7PTU;2M+E*K]N,[MDD\$0A%D2-
&8L\CYP1U .*\R ;,\N/XEZ=Y95%30XB9 M(N\$7;+,&R?P>T '?XM^\$5^% B"SL\4TK7+Z\5K.#3TN(W<2,"-
QVJVS8VV3 M+#+ EE@\$,14<[O:XEB:BG449V4?()]\&^+=/\<&#6] (D:33KQ/,3S\$*.CYQ
M(KC'#!@2XMEMX;W4IKJW91@2(4C0MCX\UT4VY1NSWL.-=2FI3W#FCFCFCFM#K#FCFCFCF@ YHYHYHYH MLZ7=
,A.S_Z[+ .JD7^I'U_H*MZ7_P_A.S_Z[+ .JD7^I'U_H* '!)15N+2^GMU:V0[NXK>2ZF^T!+4,2HD<>0
,9R/F7[IzUX!9^,K3X> M):YXA01.;>SUC4PR MV\>YS0>:/C_00U%?3OPT^/V@?
%;7IM*TBTU*VNH8FN@UZD:JX\$BJ<[7;IYG<
M#KW[8PDY; ,^9PM>I6DU*>SL9/QH :) X5%XHM=#'A^/5 .MDEWK=&\$AB[H(P M-CEON;NO'F>]85]^T]X@T6-+
[6 ACJVF:43&L^H/-,80&S#&&:5!) P"R[O MN[AFO-/VS_B_\$K3!'Y>T;+ /W?
W:4FK[\&U&5>M6J1ISLH^1R/PW^) A[XIZ7]>Z'<2%XY/*N;!U5)XI-S;3(
MJL1@'!R>A&3MXYGK?'_10A[JG]@VUA+XG\5S;8TTBW944L64*KORP)#,0% M5L[3G'&?#["Z_P"%4?M:2:?
I\$'F:=J=W#:20IQ^INDCD\$;MM;:B.P*G'(C"Y M_8U0^)50KWP4 :&E\4W2G5[>XD0+"X0BVV>-
B5DC5@[#]WYCISG#;&"D.%- M<\K6N8RQM;V;=M8NS/90"?[2+=/\ .ZSX\$U00KW4I5CMH_0FR2*2ZF9U? MRF2-
3'@G:=V>V.?:V9[VUVB=AQ0CW -R1D]N.O/>0&0AS^T=X1^)6K: ?I^H M6W]C:]N"V]=W()86D^9
(IPN,E=JE6526<@%\DUZ3JGC;00#MS':ZKXATC0+
MSRMZ0ZIIM9>5_H\D_D@AY4C)W;3TW^E>.Z^U3XA\26*W>C_"_4]3LSC%Q93R3(
M3@9&Y+7M[DUU'Q_0\:/XH_9[\2W6EZGI^J6)-NHGMIUEB+&ZA7LQQUKQKX#?
M'_0/A5X/O=*U>TU*YNIKYKHM9)&RH/(C48W.07R^P/3MWF4FIJ*>YYN(Q4_K M"IJ=DU<]W\+ _!?
U06/"WBW5]9\\$:AX?_L:Q:YBMKZ21/M>(Y)&VEXD^[Y0S_M@-] \=. _!>' VM-:\63SC1_A=?ZH;
<9E%C=23>5GH6"0\$KG!QUS@^E>C:]XRM M/B%\""?\$GB&R\ \07FBZD%6Y3:XV)/'S_WQZF0#?V/?%6C^&H?%0\
:NN6.C-- M]C, 0)XXS(R^>"5#,, [=PS@'J,\9HE)J25QU\55YZ=-3T?D>0?#?H[1?B!K
M\^AZ[TS4]'UR4MMM+W_5HZ?,>N&^X'^\J_CV];89D=AY>P':GE_=V_>7] &? M'OC'7+/XE?
M6: !+X68ENX.1=+!() +A\ [1]V, -'U/^J],5]AR9^T29_M^ GG^E.,FW9GH8^I.LY2VDVG26I^Q(K."7C<=9%_N>]
<[Y-2LGN>!F- M:I1J04963/J#P#:\:/ \$?BSQ19:3>_# +7/#-K<&53?7TDCK"5C9SD>0@YV; >0\ M58GQ
_9E\ ""/[OPC9>\$Y=-N+)?AIKWAW3^9D^TS;V.XHVT*)(D1F/ M/\8(76^1MPW+PQ;DJ,.3E%I7W^E7JX.48RE?
FV]>QZU\0/ MVC],\,>+X9T#2;CQKKB-F:#3Y-D,/RLS@85F:5=HRH7IDDJ5.9/AU^T /&W_MBL^%
[SPEJOAW7BV[#IY\,,>U6\$DQ(5DSDC:5Z^4V6W8YB4!<[2>A!'56']X=3[M7 _&GXJ+]
(/"MKK3Z2=9\$UZMI]G\]85^:&5\E_MBI_YY]A70:QX]\-:/J%S9:EX@T02KN,@R6[]>0V\D&1N
<@4R&W8']XM_%7 MC? [7FL6^N?"72+S3]2ANX9-8C59;:1I(I/W\$X^^-P/7U'X]KJ5^RWOL>EBZ\
M:5*3A+6(FD_M/>([5MX]1L0A5KEY:S(["XLIY)ED/S1A0WV8=-N>IKT+P[\3 M-
5U+X;^(/\$NL>\$[S0K02XKD_V; >R,CW(BA\$HER47KMOT/3MW\3^# P"TOX6^ M'?PYTGP_J6G:U+
<63S'S+2.%D!>XDDXS*#_'Z5[IXVUJ#0)\%0\$6K6H=;:^ \ M/7%RBS)MD&^R+_
WWZFLHM\MTSAHUJDJ3J.>MNNWZGE?A \ :TUKQ9/.NC_" MZ_UOP#=#+&ZDF\K/0L\$@}7.#CKG!]*
[+X;_M':+ \0-?M_#MWIFIZ/KLI;%I? M?<5T^8]<-]P/]Y5_'MY#^Q[XJT?PS#XM_M77+'1FF^QF_7D\
<9D9?/R5#,,[M=PS@'J,\9JMXQURS^)7]5GA^3PY% 8;.\LQ+=P7]W;]Y?T84K&F_P#'_P_ \ UPF_1%M5>3_7/0-
['S^2T0:Z\ M@L6\OC.?3M7E_@0]K3PEX;\#Z]H]UI&M?;:,QAMVD5+=H=T<008_?Y_@/_:01
M/VH" &"/B1L*,_9L+Y>U@OVN+&?_ -9K./-RWN<\$:\U0E4A0DXQA_L:A# \+15\ P2\1KDIWQ_>4^3#B_ML0\
+6\,Z?+X>TC0#;+>1J2WHLWD7_E0'(A2,0'8PJHY^L/[]2DESW.XRK_MQP<1SW78]0\>^ .M&^'?
AV[UG5I'M[2]67R%*B:68J?W41;@2D9.V.I"NY?W0CW9) 7S#EAMW&N5^+J^(/B[M_ ?"7BU_)A8B1=3@1-
+JA:&6<87(1HI3]PX\$S'("G-CX4?M8Z7I.FZ/X>\ M1:=);VEE\$EB=4MSY@9DVQ(SP8X4)M9B&9BMK! (;CMUZ?
K_] M8UA:+XJ]/IX/L-;L=0LK309(\$\BX\W9;JN_N ^X;0" I7!P1MVD#;RS3/'GA0_M6]J&QT_Q'I&H3.698[?
4896?Y3]T!B6_I6B:ZL]E55""C*:NT>,ZU^U9=P^_ M-7\,67@. ?
5;BT0I[=6MKW,DWER&/A/(YQL]>];>A_'CQ9K>NV=A<"S6]-M[MN9() +B8S[+;) \$KIY2CY>6'(Z&0 +3QI;?
#_ /:4UWQ'J'G&&SUC4E:*V1FE_M&\RQ]#P/O^HKZ=&?Q^T#XJ>()M*TFTU*UNH8FN@U['&JN!(JG.UVZ>9W_Z]
M^V<9MMWLS\ -6J59/GGU.9^(7[3LW@0XA70A*S*-K=U;- '&GV>](DF+11R85
M/*8C;YFW[QZ54/[5MQX=08AXQ^'NN>%[:56:VD?-V?349RJ4XSENPYH MYHYHYJS8.:.:.:.:
#FCFCFCF@>S_UW_6_]!-5X_ \ 5_ \ 0\ V5:L6? \ MK0\ @+?^@FJ\?^K_.! ?^RK0_0-'-'-'-'
!S1S1S1S0(\0) C= \;A\ '1HJ'1 M0[8;53,BA;S[.T13RP&' [MMW,@XXZ?Q=*[CP9XLT_P ?
>&:/7M.,:2]36R@%8V4\ \ /OY_GU/SI^VXLF[P8R!CQ?(^U-YV-]G[P/7H?P/49!P_ ">N:M_M^RW\5W\>
(=1:X*WS?:";+ + !D9(YT49^2?(P? [Q*J=JN0C#CE.U1H^H>([R_G;-)\$)F@#@_NS'D)YRX,A>4[%
M51D\$&K=3=G110RC*4IRT09^MW-'-?;/C#XA?^OX'W6F7_BS4--\7Z5>2FU>W
MMX2D*,K;B#*L:; "Z;]APV3YAPQ4UW/[0WQ.U#P0*M'\2>%-3D@CU" [A_P!_ M^S[B\#Q22\$E'5N24C;(
Q@#Y<R\TY/DINK-\$S'1F!4,8R<' /U)R: ?M%U*HXZG5?+:VE[G; MM7,=AI>OZ/JE^X9X8]>\BN';CYBH!).
>04\$CWQX'I_08^(W_MQP\8:Z/ NLZ5X5T^R\HPZ?JJPFx96=@9F;RI_TF_:'!@#='RV2['53EV1=;&
M4J2CK=0L?3G-'->,:0J7Q.L?@+J&J:J\&C>,+! /M'+:)#(PMXU =IEX2"+*735\$0.8P!'P)H7X! M'S=N5

JBZF?UZFGMTN>X\U@^//%UX4\&:SK-I T\TS8VLLT2Q[, [0&V"=SH- MJ@EFYSM1L9. ?
*/V7/C%J'0\$L]:T\7KQ;05K:=9[?;Y<4CVD@QM6, (JD*Z(Q MQN_UP'&>>^%P
5_&GCGP[\2/\$MWK#1:1FEW4NEP+;)) '#-Y;&/;<('S\$ MBKD9(>@GK68;D?HW U]+^*, @ZU\1=1\ 'Z;?-?
ZK8VWVJ9[? (IH MVWJC(W^V- S74=UYO\ !/Q=XW^+'PDUZY368K+Q&NIR06U -8H\$ \$<3-&T*
M(ORL'8%MK\$;AP:\2^&.C \$*^^, GBBWT'7+&R\71B\ : 09\$41W2BYC\TQYB., MR^7(!M7
W\ "ES6*"^G\ E9D2=D. \5CRJ>9G, N^4*B MJJY!SQM^#[7XS:#XJTZ/Q'A%\ -?C-
K/C+XT^* "E\::?;:5I:W91H/, ^T.8IUA^;< M\=/8#J>0;V8AU:0/YFX.P> >P#@?RKXU\& \);-
^T9X[\@%1V*ZE/+J, 4MY MJ0, =L/M:8R=.2&6(#Y6'/*8SG0/A;\6/'=G\9I? 7C:2WU265Y\$::."-[81
MPO/'L*(F0R\3R>, 0#G.:E8\ #8Y)\L^ [7XGT=S1S2LKJS>8)"^XC?+|Y@"< M4G-
=2/HT\JZ#FCFCFCFF, 5>W^ \0\Z]-\# \ (M6?T; T-J\R7M_0+ .03? _M (M6?T; _-
#:JCN=6&^)F_2TE+6QZ84444 %%% !1110 4444 %%% !111 M0 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% M:1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %
M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 44 M44 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !11 M0 4444 %-:G4UJ , [Q! R\KW KA) P"@-7DG\ \ P(UZWX@_Y
U\ P\!<)\ MT\J\ D A X\$:SF>=B@YHYHYHYK); '\$- - - - , 8 MOI7/53DN4\ '4)8B@Z<#G?
AS\2?"=C\."?"]G<^+M% @N8M)M#)#-J-0&\ /E< M;SN\&>WT-4/VCM8L=< 9^ \1WEM>IJ-K) |E59+*35%< :8L8?
<G>NE X5AX: X0' (0 [% 03&SR L/VB7\WG=>U MWYJ;2M:Q50P^) G0E0=M58\7 &2 &?AWP\|-
[^TUKQ'I^GW2ZD\&. [NHH'0> M3%C)?@_H/4CC. '^T1\2K+XN7&B>"0!@DUN8WC2R3PQ-AI@A6)5F. !LPTCL<[
M1Y:E6P&(!?D_9C^&C-(TWAM0I8G9 :-T2H8DC!, HV]?X0<| ^U=?X3^' 'AGP' M+ "-
T&SM98U.V>/YIT\ZY< , WXDTN5\0(81P==T%A\ D<, WBCPU^SIX \ '>'= M?"WQ%X#N]; TRYT:
M\ \2W3H;5M.FVSL99\$DD:2./YB/*\W+2X*YX4, 1GZ*U\PKH?C#3VTW5M, BU*U
MD+, '0/OH3\K, A_A8:AALC'XUQNC_ +, OPYT?4HKVT*6<|TAQ\$+N6:>' /W"Y
MB9V5GX'SD#IWF4U=&E?"U91|E!*\$5KG, ? CP*N0_ +/MIH0BF634=*U\Y)(K
M&5&MVBA\ <@&U@65BCR\CU\TX^7;79>&?@9X*\ '^ (X-9T?00LFJ6QDDAD_M&
MZ;RU<, IX+\$<[Q^5=V\!&\$41<, 9R64XS\VT;> !G@40/EY(W*'7"], OSMY_/N M*<(I*S. |86-
*G&+BFTCXJ\%:MQZ#^UAJ-W>7D%C;0:WJJ=-7, 6EQY"S@YYD<&. &'4;>1Y078=Q)0QGZBN=U3\G7X?ZUJ
M5UJ%YH/GW=W(;F90MUP/GD>'CS3 ?\ 04NC_LZ^ M%U:SU&P\ -^7?6DJ503 M :|B3RY%8, ORE|IY
^|Z4HQ<;V1Y^%PM>E)VMJ\GSQ^V1E?BKI1, 33L-)0JC M'D?Z3.>H|@A%?0VB?LY_#S1+RWNK;PI:7-
U%Q";Z6:XB&<*6\IG9"0>A(&/ M?MI^+0@WX1^(FJ17^0:/|K0\$B@2_ :I\$Q'YA8? (DH7_6. _8UV:\J&\CR">J|
M>P(Y^A' !G@4F7YV\ _GW%9R\&<[KL?%/ @05\30_VL=00;V|@L+--:U4- M/7&N?
M'5\|PQ7UAI_Q)\WUU:6=MXNT6>YD<&. &'4;>1Y078=Q)0QGZBN= MU3\G7X?
ZUJ5UJ%YH/GW=W(;F90MUP/GD>'CS3 ?\ |2Z/'SKX" T75K/4;#PW MY=|:2K-! /|KN)/+D5@R_*7VGD#
[WI6, 8N-[(\3"X:M0DW96;N?//|9;%?B98 MEFD0KHON8C"+|HN, DGI7TYJGQF\ ":3!-
<7/B_3!|;ON:"WN(IKA7#JN5B0% MB|F^ZCX'S0)6/: M_LV?#JSN8YT*Q3>6?, V37.KU+
%K0HKJX0, HGM?, MY7SC M.Z2% @S\|C/3GU-)1:W-88.K2@TFFV\OS/ESQYHNA7WQ\T"Q^'DFGVWF30/)-
MI<1N;>UN#*TAE4%BC; N :H")@SDM+*>X MM|F6*.>25FG:YA100L<8"+T|:YG|DSQKX>|. ?#B^M-
8\1Z7878U)SY%|=QP. MH\F+'WV&?PZ?C70_ (I\+Z;XR\WFCZU\|JTNZ"K+!YC)0(=7'*L/[IKA'_9
ME^'#2.3X;P6)8) _:-T=H) ' !?CKVJ94WS*260SU<'4|NJ| -+16L:7CK05HGB M;X8>-0|&UC3\6\C1;SS?L-
W'/Y>ZWEV\MC'&<'&N#Z5\X_LK " _PO\ \$B'Q M.?\$NFKJ"67V40_OY(F3?
YV\|1U/.Q>QZ=N_TWX;^# A+PEINKZ?I6C?9;35X MUMKU?M\$DF^,
[HQR0.,>: >A'6K/@OX8^& AQ)>CP IOV\KQ8Q, WGR2>8B;0+X
M9VQC<_0#KW\4X*34GT&\+/\$5H5:JMR|BWX4\!^' _#:/9^'| -MM/A?:7\KY MG?&<;W/S-
C)QN)ZFMWF CFCFM8Q26A|, :4:::BK7#FCFCFCFK- YHYHYHYH . M:::~::~:
#FIK7.Z7 KC+ P"BVJ'FIK7.Z7 KC+ Z+:@'+^\$?4TG-+ "/J:3F M@ YHYHYHYH . :~::~:~::~: #FE!8# 5>8,XW?
W<@C^1-)S0N=P &DW9\$2|'&^, ? MC\X0^'M ;Z=KNL?8KJ;|;J)?(DES"243[BG'*-UK)T |HWX=ZEVU#3|>-
)M)!*"VW[Z,Q"D-D?, #@8W+S.;OH>\$L;B)5*BB MERP[G? \ B_Q\IW@KP; <^*+P VEI=N(RS6*1R/)0D15V-
N53\TB|QUJ7P+XTL MOB%X7L0\$&FPRV|C>>9Y<50&JRKLD;-MVUF7[R-T)KY=|+ZG<7W\&'BJWED5X
M+/4HXH54Y\$8:>UE90>K O(S;CD_/CC_574?@|XYTSX< LS:%KNK23Q6L)N%' MD0-
(7VY>8|PYHYKYYO_VK+024M|N? MX<;Q:Z|=2+'#J3NR^=&3NS&##M:1HD+A5=E(W?-C)'ME|XTT2P\ .OXHNM2@M
M_#HM/MBW%Q&?+|@X*', P78Y"B/ .X9X9L#7G2T9Z-/^4ZU^5|&US1S7@?\$?|5
MTNH27.HZ5\|/ >U+0;24K/J|, WF0*H^<, JQ0AU!4E3*%PRDE. 1WGB#XZ>% # M/P^T?Q-WL=1"/9V!M?
N\HAA\XB=AA%W#=(&VCTV^B7|+= -, DRC:&?:8X_ ,3:W+8)&?ND8)F_ ;+ A5^DL(/8ZQ\$4 M\ P|MS&WF.
<8/[L\$MQCQ|T5E*I'5|G&KC(NC*<'L>UZ%K8BJYC=01NPQ|YJ_S7S-X> :200""PZ|. FT|\$;M?Z-
8Z?;VUQK#+|GB5E M(A(C;9)N4L\$7&1|[[@Z'V|1_B=H_ P" 8_&4UU%I_AY8))GFNH2BC;VUAL!R
MYW@H%ZL1@'." ;C.)>'QE.K#SMJ=7S1S7SXW|5U|J 0\ 4- ^'60:QH|H6\W5 M))"&CV;6=|
(I5#JF7P688"D\OV;|; ^'?Q&TKXH>_QK&BK-#9B0Q&WG15, ;X M#D94D'*NK=3|[\ * =WH:4L91K24(OXK
MR|OV8?ANC?^\$;W_1C7MQ'9V\6K:7OFF MD:- (OW=0)\ '^@9_H: ^E/#/P)\ \$^#=:M|9T?0?L^I6N|R9?
MD3QW4Q81%L!%^ [D*5W/A?F) 8 MY\7_ &9_!>L>+ /B#K/Q&U;3;>V@N)[B6UD7S(EFNYF97, "C|T01I(|QW=5
W_MLK8]?T_ |G+X=Z;5=B0\7>00|. [5(\$6"S@;4 MM8V5\$
7^)=0", /+X/N::BY24GT&L/6K23F_AV|>YY58_&SX5_\$TW6G:C<;:D M%0,Z%0\$=NGDR
\$1|U:7C#|P#8D.+ 'H5G(' \$UJ_M6GB6% (DZ@R\ D.YEC\$AX& " |J^C?\$/P%^' BJ\?4=3\ .6KS.?GDMY9+=I-WS
M;F".I+ '=R^#N|L<| #X4\!^' _#:/9^'| -MM/A?:7\KYG?&<;W/S-C)QN)ZF
MIE|7.>>'K59KF2230>VY@^*/@;X.\8^)IM8UG1X|[5;@1R3E;VXA,@7&URB, M\$.45/F|X|0:\K :B\, Z?
X+^'7A_2=#A%0IMKJRI%: ^9) (P+17+M@%CG|PZU| M'\UA>+0 >C?\$.QM|.UVS^V6L,ZW42^?)%B8
HGW&&>' ;K52BI1Y; '=B6?LZ^/O#FA?!_0K*)\4Z'I-U&UTOCOKZ-64>>^(M*|3?
M'"#Q=Z/J5GJMH='0QY|C.LJ\$ _9WST8XK)_X9F^&[/\ PB'S|=OF?;KCUV?W_M_6NJT/X8^?' "WA_4?
#VG:9Y6E:B|F|C\^23+R@0R_#_@&T>S\ /Z;::? ^"T0Y75. ^, XWN?F; &3C<3U-5/! ?PQ\ -_#B2|'A_3?L

M#7BQB90/DD\Q\$W>7PSMC&Y^@'70VZCFM84THZH0!8*%""4TK^7^80I6-2/,N4\ '498B@Z<4<[\. ?B3X3L?
ASX7L[GQ=HL%\$%I-H M9(9M1MXWA =P(SV^AJA^T=K%CKG[/WB. \MKU-1M9/LJK)92>8KG[3%# M[CFK2?
LR_#A9\$(\-Y*D,4 M&Z&X @G@/ST[UT0\ PK#PU_P@/_ "'80^*8V> M7]A^T2>\
[SNN -9V=K)' -3P^(J4)4=-58\7_9+\9^'?#WPW0[360\$>GZ?+= MJ3L8[NZB@=!Y,6,E^#^@]2.,X?
[1'Q*LOBY<:)X*!&"36YC>--+)/#\$V&F"%8 ME68X&S#2. QSM'EJ5;
8CU^3]F/X:, TC3>&U"EB=G]HW1*AB2,\$RC;U_A!SW[M5U_A/X<>&? '=?"
MWQ%X#N]; TRYT:\2W3H;5M.FVSL99\$DD:2./YB/*\W+2X*YX4,1GZ*U[PKH?
MC#3VTW5M,BU*UD+,'0/OH3\K,A_A8;AALC'XUQNC_LZ_#G1]2B0;3PI9SW2' M\$0NY9IX< <+F)G96?@?.0.G?
LY*YK6PM6!5U _9]M-%\4R MR:CI6H/))%8RHUNT4/G[D_VL"RL4>0,>0FG'R[:[+PS\#/?!7@_Q'!K.CZ%]D
MU2V,DD,G]HW3>6KAE/!8CG>/RKNP(PBB([AC.2RG&?FVC;P,\ "EY\0)&Y0Z
MX7IE^=0/Y]Q3A%)69WK"QI4XQ<4VD?%7@K5K/0?VL-1N[R\@L;>+6]51KJYD
M\N/(6<'+EACIWKZPTWXD^\$[ZZM].V\7:+/<2D&.&'4;>1Y0F7.P[B3CC/U%<
MYJG[.OP_UK4KK4+S0?/N[N0W,S?;K@?/)\^/'FG^_P"@IVB_LI[^-#UJPU&R MT'[/>V?+DA@C/(-W^Q%?
3'A0X#^ "MTE]8^';87<;?NYKB62 M^>+FI?!WPKC/BX>)[K2,ZTCQW"S :IDW20J&3Y%E" M_=C'8UVG/EY
VJ7;*]6C; M@, -N+?Q,=W)]A1S1S1S77IT/8M8.:.:.:.!AS1S1S1S0 /_5 \ "]E6@!>:.:.:. M
#FCFCFCF@#Y=; > P!7X. [??] VA7MGQA^UA\5/"]083"&/5+<&3KEP= MT\;?" P_?.\$IK%?
\$.G?;09[Q"WGR1^70*!N%= M\6Q>) M;[2(WU^%UN!0;OM>(/"NC^,M-;3M9TRW0[61F.VX M)S\$QPK,AQD-
RX;/'XUBJ=E;N<5/+;L8M1MH[GSM^U\00#?B#PCH>CZ;J-I MK\$S-?
_:9(["XCFB@5(Y\$/F%.A.].# =..,5)^T9I=UH?[/?@G3KZ&.*\L[FR MMY?+^Z72UF5 -'P]>L^'0@-
X!*WXU#30#EJEP1^62:62;;M P"6BHSMB3]W M K0!VZ]NB>9!>=#^(VFPV&MV2Z18Q2>3YC28W,6;YF8L?
F+=;M12-*>&DZJE+ M9*UCF/#/P-\\$#^0\$D6LZ1HSZ?JMLLTMO.E]/+Y6Y6!&QWVY(7[-]H3R0/C3E;>
(*)0K,%V/%OVX/EJ<@CZT(C M*,)3M&Y#*,X^;:=W!|OR*]\U/\
9T^&^LZI)>W0@^U^VNV'CL7F@B8_Z8EG@*)NC M>4DR\$AI" -^\$/0 M,UNZL;#SM+\1^'I-.51&8!9AHC
T,17AFC"10Z]3@*HPP[X;^\$W* _LGZ\] MP&6[U;2+[4W7S%9-DD)6%DQ "T2(W.>6/3[J^J>- /A?
X8^(D&GCQ)I0]IQZ> M?W&Z>1\$WD*#G;Z[ON+U!_#G.Q>Z#IUYX>ET*>R_XE4RE3APQW MW2>A-
'LVM@IY>XUS^E0S1XQ^QC_R2_40^PU_ P"B8*X7X0^(M)\+M+>/[S6 M=1M=/M&EU*+-Y.L22901E\$G3IT[?
9/#?B-/#*0VJ;'Q;XCCE70KJ(2?; (T@9?LOD\$.=H5G500 M%2<*8^Y%>^/\70.3ZYI^EIXBL;F\OMWEPV-
PDH1E(!W.GRJ2"0#<+?#2^'-6T9)]-4+L@)<+!"!TVN0S#/L>PK*\(!OP;X)U 7>C:#%;ZHR
MXCEN/,N'7:K*QEO*SL0WSG&W/'7'#Y7?0UIX?\$4N90M9NYX?\"%0]J#XD*_.M50J1#?*/U7_P!-
HKWK0\AGX4\,^,-0\Z9IJQ:MJ,DC7MU M]JD9B'E\$DF4W[>H7J*7_ (5?
X>7Q['XP.G>9XF0*!>?:IDVJ(3%]06*!"/RH M4#/ZG.G&0YK63_PCZ4?PI>:Z4>Z'-'-'-'-'-,!5[?
M[R_SKTWP/_R+5G]&_P#0VKS)>W^0\Z]-\#_/(M6?T;_P:#;JCN=6&^)F_2 MTE+6QZ84444 %%% !1110
4444 %%% !1110 4444 %%% !1110 4444 M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% !1110 4 M444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !11 M10 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %-:G4UJ ,[Q!_P @ M:] ZX2?@-7DG\/_ (UZWX@_P"0->]<)/_ \$!J\D_A_P"!&LYGG8H.:.:.
M.:.R60Q!S1S1S1S3&'-'-'>"?MF?DQTG_L-0 ^B9ZF4N5-]CEQ_-Z01E4[M'0?-'>6_LQ?D\/-\
_U_Z535Z;=7508VLL][/%;6D0\R2>9U1(]0S;F+, M JC'+8../6DFFKDTZD9TU5>ER7FCF0-0^&C/AM_:WV#-
(2.U\ S=]G\IR/* MS_J ,\WR+\0 IIFNMU_0SHGA;P\NM7EZ#H3,I:\M[>2ZC?S""K#R=V5+,N&
MP,X/7""YGT*6(HR3=U9&YS1S7/:=X\T+60!(\5VU[\&OAXP27)0\$MW!\$:%Q)F M(IYG6-
ZE\ '^=&^(FDRW^A:E :&GQSK 9?+D3;-L#Y' ;[CIV/2CF74IU*5 MTK[[(W.:.Y?
0_B=X9\4^(-1\:/=J/FZKIR.;R/R)(\)\$1#)RR+GDKT) #OR M_P'T\ P'P+\3M+% '&/LV&DZ,5N8_9"+254C=?
+A?;\T;C^/KCCT.->3018^*0V6=' +?7#>PKI=Q\$+Q;Z5C&/*QYB/)YC#8_#D%A@%L%MHX7_ M (:,^&W\K?
8/^\$CM?,W?9_ \F3RL_P"K]SS?+\0R_P#IIFKD\T6\5U:7L36;(TRW,?
\$<2/0,&9(90*C8_*6,IC\L*,\MGCCUHDUN:NK&*4G+1GI'-'-5? [4T M[^ROMWVVU_LG;]H^W>='Y6/19YF_S-
OE_P#33%<19_M_#N\UP:9;^*]/A00_MVQ)+@21P2E.I6;:(V\ V_*I3:/IZM([W\ \$M ""#0/#?PFTF+3 M=8%_X?
M\$D+:M<[8(S*LC/,P5PACB63>H+ X '^U1J,NEB)596DE;EYCN^: MCF0(=.C;ZN9BM85,L[2;5C6-
>26<=>P0*X"W_:"&]YJS:6GBJSBN =@>T9 M(9-GREA*8_+9>.&SS5CQ]XLT#0-\,?&K:7K%KJYATJX69--
GCEVDP2;,E& (MYPW8=*T<]-#5XFE&+LUMXMIUE7S/OD9'H'% M:/-?+7[-/Q0\+?# [X6:G%XA\1VMC=-
K+*MM(K-("88L;@JL00^U@' ZD5]& M>\$_>B^/-'35?#UY>.:7:+=Y3Q2"1<;0,1U5E;D?
*P!Q@]Q41J;.: \N_:=9%?!?B7MQ;']Y]W(NHB/Y5X5\! ?V?]"^*Q@V_U?5)] M2A08+W[(1:2JD3J(X7V_-
&X_CZXX)#GARGRRY4C+\$8R=*NJ\$8WNKGV-S1S7R M;XGL?%7[+&N:;>?K%QKQ@^YEDA&GW;ND, #AG0IDJC[
Y612"VUAM_RK?4= MEX@TW40#E0KANX5TNXB%XM],QC'E8\Q'D\QAL ' !R"PP"V"VT)5;[F^'Q\$;M
MU5237_#E_FCF0-0^&C/AM_:WV#_A([7S-WV?S0)D\K/^K]SS?+\0R_ \ IIF0
M0[2ZM;RWBKN2]B;S9&F6YCF7RI%.&+!Q)M*G(PV.>?2G>+ZG5&K"20!DW-'- M>;_-%?
#A=6.GGQ'\$C[S\F2&;RHV/REC*8_+"C/+9XX]:[FZ\0:39:&VIR;G MI\ .DE=X0KBX5('=_
2RB3:0=WRG&6Y]*I22&JU)J,00+ -'-<'H7QZ^'WB MK40[/TWQ1;W-
VY_Y>4EA,A;C;&B@L30X4\$A0PK0"J1X5(E7C/F(NT' 'R[20 M\+#+R/<57,NA4*M.>B8;
[/[V"#_2HD^A\$E]H^,OVSF,?Q.TE]JD+HL1&?0;OM-P1C\L]1T MKTZX_98U;7'BM_\$0Q)U?
7],B8DV.Q\ '* ,B,CR/(JL"00"9(SR,5L_&+]G+_A M;GBJSU;=
(27^S0(M%M_) \CS,89VVYWKCF>A_#0[*0^K0XV\80TSR?FQ[Y] M37/%6FSY^E@74KU'47NL\;^ .WA?
2/!0].&MZ1HED+3K9;=880Y<(I08V(4D MYV[V<]ADG_K ^'GQ.M_A3^S'X8U:>""
[>:6[MH+:WQF2;S;ETW9X"YCY;!*Y MW_ '%>M_\$WP/_ ,+(\\$ZCX=^V?V?])L\0_
\$K9YGE[)%D^N7.=FWJ/05QE[^S M08ZI'=' /\!WNM3DZ;*]W#J\$, "[7D+2D;XSNRJB8KM#<[?;JE3?-
=&M;#U(57 M4H)64;'DG05^(?Q,\;?"?5]10_ ".GZ?X+OVCN!<-G[0D#3*8B,SY*[MF&L! MN2%&>8?\$ U)?
V_ "0AEFEB_M.3[88=V/+^TW/^NOCY/. \OJ!\VS'.*]:B_99 ME00#-SI7B#0QK6N6QAB72D?0@G55M_\$>F>5-#-
&Z%!*KRM)M\L\$["I;AMP("IC<;8]F^QQQP>)K26?.W8_CW[MV>_0F0GS]K&QEG^,WAR5\$L

M1.ANK6!8+5\$5\$K(E;A|W|F;E*B(%DWY%0BNUCL_P!E&L%N=/T_P"(>IV?A^F
M9I=,MK=HVFOCYUBJ7):WGN>4>-/@G\9/B M-I=OI>M^*/#NI;:'(MQ'E-JB0%E7_5VPYPXS@}14_P"TOI,_A\1
9)\(:7>; M#>V5[9V\|0[0+++RK\N\YNW<"K|I'RE=:A'IVG^(/B%J>N^'H(, &F["HC(
MB94\L.\JOE=W&00Y(. WR^@_%XOM\4/!=GXE,? \ AEV\^Q^?|E_X2P?:?)W;?*^SQX\W
M\ 'F^5U_BV8YQ7LNI_LCQWLD=C'X[U:7PC!)YD&BM'YVTG+2&/\ >*FYBT0_M "R./,Z-
V\9TOX9^'K'P'%X,EL8KS0?LK6TB7&MOV#_A'_[&3[7]WR/N#[1YV/X= M^S,^W?->-?L19W>-,
[0M[6#_BAX3^(C3#0-8MKZ2+<3\$NZ*8*I +; &"L8P2/W@7'/ '>HH:BYX=
MO?'DOA5+R3_A)D+K):RV,T3,T<9SMH(70 M@_Q5K&CZY C^5/>2C&2C#R|T,:NH?
[I/S#:6^5C@'3_9G^+>L>, /MWA/Q3|I M77-*15\$TD3BXN\$4A&:4<_08V\M2YY8%GS.+:; \$Z?FCFN<\8?&?
MPQ\.:VN-?U,;:;!<2M%&DR-) (2,;0E56;:RN6VD#C/45'X/^*A?XA^?_P (MYK%K?
2Q;MT7S12A\|I:RV56;:; 0;0#GC034DRE6I-\0,D^QT--'##?^V@>/M,2\T#4K;4(@B_M0)Y3X=-Q8#?\$55H\1
[3C[L79?-*N|=@%04A."?QI5_UP^M?&?|%^ \ \$ _ \$;:;7;2)%RI^H7-GM%Q;6\ \ \$=\$, C&;2_&\$NI:|})
<\$Z;:;>9\$MHQ=*T_MOF3%2)R"J|9,C.37I'B[XQ^\$0 _|^;+6|<2RU!S\UFGF7\$T'RJVUQ\$KEIAPIN
MV|3UP<4IZ&D,3%INI;3<[1=V| +>I"<\$_C698>*M&U37&TJR\1:?.2X0?|07IG'?T-9.B_%+P?KCVD=GXIT?
[1<9\NV^VQ+XJF/0,=HPH!S6&S\.:|%=74*%;C_L\$D;\$2_MVT%D7YAW4\$[M5*Z.J,XSBVG?H'-'-?"MGX-M/
MB% ^TEKGAZ|,ZV|YK&IEFMY-KC8\TG'?'H:|7\5?L0S^"-+0-9\!^)|:M-0L MX)99;:,3;9|Q%
(8PH\^JX8[25!#;G5!E#@UC[378\JCF%6IS24+I-K?L?2?-' M->5?LY?
%R;XH>\$Y1?)&FOZ6XANT1&0SHX)CF\M5V(OPX9_3C8#A0P%=%XN^, M7@SP#
<+8Z|KMK:RN2WD1;KB5,8SNCC1F3J.I&>>N.-E=-ST(XJA4I*IIJ=GS_M1S6%X5\?>'/'UDUYH>IQ:E;*55TM?
EE!.=NY#|R|J#C('0UG^,OBUX1^'=\EG_MXEUV*UN91N\$'D22RH%QU"(Q_B|1^/8NGU-98BG""G>R>AUO--'8?
A/QUX<^ (M5G)=:;%>VNI0Q@;Y%7YX\Y4*Y9^;%=2_L_40%%0;7_M: 'EV268QE>-LCQJ2I&SE20%_&GS)\$_6(*-
V|.YWG--'5=+U6RUK3H;S3KVT_M0[2082>RE\$|L38^7[X8@GCD8!'>K7-6GS_-=P%0_\$ \$U7C_U?
0_95J09_Z|_@+?^@FJ|?^K_X%_P"RK0_0-'-' M-'-' !S1S1S150 @N:3=MRQ+(54L9!PJJ.N37R; *_V8]!^(_P
MOL==GU+5K2_U!;J))83&8(W6:6)=R>6"ZY4942(3TW#.1T_|, C;Q+#+\1/%G_M@00#>3Z\;
(221W4TSS"W>.400L=QN"D-' \IP!MR%7=BLE4N|C@ACI-1E*-D_M,|WT/Q5H0B;|0NCZ09ZG|F;:--':SQR-
"Q5|X+TS@XSZ&M7FOEW|B&-&30DK0_M*^!9_OV7<.MPFT+ _!,<\#V-
>Q^)/COX""*74ECJ7B*WCD4^7(+>*2+A)25SJP^*A5IJHVHW|NQW_#1S5'P|X@L?\$VEV^KZ/.+NR
MN@7CD^;=)GCA1Z8|C07,^+0C%X.\ WD=CKF06MK-(2P@3=,XVX8JRHC;&.!M_M5B-V&0G<+;
(I070=+G;ZIJUEH=C)?>E>1:78P|?-NKAUCB3+!5W,WRCYF7K1I>K_M66N6,=|IMY%J%C-N\JZMW62)\,5;:R_*?
F5NE>: M(7<-Y\!-?N;">&[MI!; M0')^"\3|KB)MR;&*NO/#8&:X|X((&#P=X|^"?ABTUW7;>T>0W2F.+=,\?
^D. M?G5\$;R\|MQ&<'&<'&\$<[YN6YR_78JLJ4GHU<^AN:.H^'0\$%CXFTNWU?1YQ=V_M5T"QV?-'-87A3QYX? \1
'UH|YX?U*VU""-H?R0E=,Y00_M0_,N<'&X#H:W>:<97V!5(S7.@YHYHYHYJVKFJ08.:.:.:.:.*#FCFCFCFF_J
M|0\ >7^=>F^!_P#D6K/Z- Z&U>9+V_WE_G7IO@?)JS^C?^AM51W.K#?&S_M?I:2EK8],**** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B_MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "FM3J:U &=X@_Y_M_U|_-<)/_0&KR3^'_@1KU0Q!_R!KW_KA)_Z_U>2?P_\"-9S/.00|\UY)^TUX\$U[XA>
;:'3?#] MFMY=PZG%&FHK,K7S[B-H!')#)0?"EA081E/*+!6/**V#Y>#C%M0/. >2PRH_M*+TM=D'Q
^!7A#0_@MK|E9:.D5|9:1,XU;RHV0\ ?&I<2/-L^8EU;3"ED<17*D\$DG(&,%2.G^\$M_M<_
7QYX|\,ZA'9:K<6^A^^,;8DN)8H#.(8SG@!)9_0N6\0=B/!%2-^S/K'_M_"^H|T:7"/!_U)=1:YE2'R?+XD-L;
<2?>W?N"Q'7;71?M.?17Q!X\|2^'|7T_M/2Y;Z6.V;W08Y;B|(XT5R\((9D!9@SJ1\Q_V=ZUC*,KZ'\$J.
(4'5MK&R1-^ MQKX9.F""=7UEEGC?4;L0IYR!DCA!Q(J_8&7DE7AB/D_P,'/8_M_P#)#_\$G_M;K_.E4==|\-
")\!^ |\$T_Q>7+9VX\$VW)0S-\|I!(SS(SMZ?-QCH,3X\>&_M-4\8_"07M(T>SD0-0N4B\$:Q/_&P"SQNWS2?
*/E5NXK=:05SV8T9+!.GU:._#_M_&, ^28ZM_V&IO\ T3|47[:%Y#'\-|)MFEC%Q+JJ2+!N^XUBE#LJ|I9>>V
M1ZUS'PYT/XT?"C1;W2M,\#;:>6\US|J_TN>(R;B(T4|EN_I^6->F#[BMFQ^!_MOC;XI^*_
,UOXIW\;V,+.PT>SE4M%\WW"8QM5&P-S!W?Y0"P)5U6LHSR2(!)!EE894I/\$Y7!Y
MC7'(%>V^/_@7X0T/X+Z[966CI%?66DRN-6\J-K_?&I<2/-L^8EU;6\$LJ@-NS(N&^4_M[XU/#&N!\+^+/#?
@[PROAGXE?#IHITA,\=Z; \$P:@RB3?^|+>6VJWF*61P,!4_MP225^D/!_P_+]=^&7PCF\|\
AF|L1XGF)=KZXW"U,C.,D#^9!&J-MVL5C+)|@_MUY9XF|+_
!0^*GAJQ\.:|HFDV&EJ\;RWTK0BX;9&07%|4B>:*S5#\$DENHB,"D,N|;LEX3
MH#CY057;Q/B2QFU3X;P&=+^"FKZ?<6XBD AU<02R7(92"QD=;=!(61I,\$,%P_M,JH"8'T'\1/@3;^_
/AMI7AEKL-JF@V2166JM#\I>*/8P)(9UC;:K,B\$C.Q_F_M"XKC+90VA;/2XM_AL=,F:UE6W7Q-
/)#-.\$63B1MSYD',F\$R\$ _\$EG.3+@|WN_M+\$4I2J.53FL|6LCT|X%#6\$^\$GAZ/7+2>QU**_
X9+>YMOL|J(W,:\$Q\8S&B<|_M1N^|DYX|OFLKPM;:M9^'|&'7;NVU#65B7|1=V4'E0RG:N&48'/7/0=,)&,(
M7FNN*LK'U%#6II,.....HW#FCFCFCF@"SI? \ R\$|/_KLO\ZJ1?ZD?7^@J_MWI?"\$|/_KLO\ZJ1?ZD?7^@H
=S1S1S150,/_ ML"WW_I|)75GSR1F,<_ \#|145'[MCG0_M\$7*E)1W/C__9Q^>M^/DU_00&&H>\$_LGV?S?
L/F?Z1N\W;NV2Q=VG&<->_M/30N?'WX4>(?!/A"ROM8\=ZGXHM);X6_V:|S9\$6AE(E^>63IC'&/0=^WI7|
M+GPQ\2_#B3Q0-?T|I MX+3R6\^_3S'3S0,X5VQC5,K?,S!1RR|:YE#|W;N?,QP;^I.370?\\$|Z|QY?
MV&0\AC+\$_?N_NJ!JF_/Z_C52;P|K'B+|C71?|(?<+*6>|N|?)_FP1W,Y;C|K_M;3A|K==0'S_5V1^&?
B:3|E,^#FT?_BI6W.MKY\?0W[R']Y0V?'->M)-/U.XN5ML)*K!)/M9N%W,CX(\J-N1R#MX/41K8J5.<6W.^D#
MR^X\4>\$_%/PKTSPCHW@B9_&8**;ZWA\Z5@F?,G\$B@R2_QJ09&V-25!_C20H_MS2_DGP^_9JU32I?)@00|!0)
|IHE_WW+0N|H04E6,:@1|E."%7_07GFE

!PF,;51L#_L0>)=!T MF_)G2]EM[1MPC580W< \L)95 ;=F1<- \I#QJ>&-3ZIH_QWU?P0/X+N[:QEM&0 MV,F0_;
(Q8 MF1KZXW"U,C.,X&.R"-4;;M8K&63!JN4J,54J7460=MZ^9\Y>\$/%0A?P9X>C\ M, \$ X9,K^262[-B8-
0E!DW*LIK[.<*<=/, \/^ (EA? M^,M'L++P[\%]1\W=I,-E]I\4Q:X@%"61_W*YRP!\PEN0P)R26^0_!-UJ%YX
M-T*?5=YU2:RBFNFFB\J0RLH,@9-HVX?>-OMG07BEC>?M"ZS!8;;-:Z7H+JNR M75&6&5W183\TR;Y5 ?[Q5\$4?-
G R,_0%JD\=K%'=.)KQ1B:58 +1V[E%RV%] M/F? 'FK6\$6M6>IEU*49-S)>.:.:.:ZSVUL'-'-'-'-'
!07MWJ\WGW! ?M&^ (=5U[QMX.^'NBW%W: M7U]<1W]S/9B0RQ@.RH\01@6"!9)&7 IFK9&SG.3Y=+' /6J>Q@W^!
[fS1S7@/ M[f3'Q&\2?"ZW\]0^'M:>P@GCN(9W>*5Y?+\K:Q:7<)IU*WU M?
[2U_#8[SFCF0!0BU\30\$WA;XZ>#/#VG:CY6E:C]D-Y'Y\$A'X]0>(_P#5@9W,"<-TRG\/'Y]A5*39M1Q%*K.45?
07FCFCFN7^* 'B@>" A MWXCUK[9]AFM;&7R)?+\S\$S+MB^4J0?WA3K +- /GTW-9RIPBY0H=1S1S7R3X9 M\5?
M!>,-&MM ^VV%\$)A?DTZ/>H?:QVLHQ@*>OKQ0B0: SXZU7X4 !NVU0Q MW) :7B%*?]
(0200F>=I3Y48*G8<)AB%5 E1R0=N#G&HY'!30E.I&6EDM;GI? M-'?-?-7A_4?
CS\0="B;3K[2M%M;B,09:4M0&KS0[5^:\$3QL=K L5,D@# LV MI#UW_P + BE%\=/A_K=K9W7_ CWB-
+:WG"1\$"V,B-MFB 8952CMPVX%23E ML%CG;=BHXVE)+FB +S/5N:..! 9+\47T-KK?
@75IX[:4M%NW6VA8@S,K0)Y ML0(7#[9\$=0,W,&\W_P%&??5*E?W9D"AB-DOWE/>G&7,KG;AZZ0\$.9"T%?&?
PY_P"30;S_+ #6J \ M07V5) JR<98\$&KTRG\7/Y=07R/\M+@8 M!Y7WB#X: ^3-I&I,9)-#:7[. I#
MX"@;%, :N04((=^WD%F*E)2Z\$8BK[:4:BBVETL'X=?M7>#9 #T\$.D1 M:A]B?R+!!#\$TTAMI0B;,%-
Q.XY+&F!RP_N '3R AS^T+X3\7+*UCI\]850 MKY#0@ X0\9 \$Z#Q0\0X;73&L?GCTN"; M?N**HB;% S+' 'YC,V
Q)9'!\^* [7]I#X8ZE\20 ,=0IMH0\ PD6GW27,-0-Y M:22H>)8 ,=AL4LWG'&<[
F#BIY9=#ECAYSH3:C:TDT?/0QHL+SXB^./B/XFM MKV:VL/"[VUB+2X^9MMWF"!0+7/R() %D?{XW8
QDFNB^+.N+\; %7PBT61Y&I M6L5Q=S:3)DQ^=,\$N!CG'E?9Y\G& /X:11^!_P %Y/#/PEU+0?<\$46JZ_) .
M+N"/RVEBB>-HEB\$J[MZX+N,E<:;1@8KA_P!G3X"^(! CJ37 \$=G':Q6L.+1 MGG629[AQL. C' 'RA_0
=>.)QE&S9B\ /63;&4'Y!R/8#K7R0) %;X1 M^/; .-E[XN]-Z#'=VJ7-I=V\LUU;M' (8H[(OVJM4U33V-
W8V]_J-Y-- M'MO]G(D0XSS@M*X[LM>A:G? X*VGPETH3.D.H>(:F)40-70N[,"0?<C/W0+X.' (!)PS!<
M#;+BY-21G64\?4@E&UM307]G/P_9 &?QYXN\3^*XH]2U57C=+:1 \0: ?S2&5 M75@0%543@& !B#@\$.^(6CQ?
#S]J;PA+X068L\&?!_QGxV^*-KXV\?Q6NEW-F1)!IMO,SC=&JB-XD1]L< (=G; M8G>C\$@KFDH-
*S.5PG%1BXWES708Y_P"/7A0Q1X=^,1\70X> X3+PL(UDCL)H M'GMT@2/;LB[3Y7S;G#,"!0)P2K8[_9 _1
&WPZ\6^)-3?PWX;C\ \ B2:V MCG0TAME6(,@E\IT;:%5RNXA4+Y5B0%;7Q"0?C#H_BZ: \ (VNF: IH\$T)BBM+
MQE65?F0M+.SLA#;|Z85R"\$8*<[L0X)? "WQ1I'C;60'/BC^S=.0-3A>(:3I2 M"/RU,@+[CN"*!L7DLQ)
<=B&5@TL^+-4\3:E MX/0/B?K)"NWF([00,Y.#(%B? V ! 2!\W#\$#H7P>TG0+9 M#+JNF^!|4\)
MZ#J"3P7%E)9,(:2(PLX42\$# \U(R_N%&<*,|7J7PE\=??"QYJ'B7X8+;WF
MEZFS0=:)/_HL4>\, >\$Q&I0,04VNI&YIC)/8_#"/XNZCX@.H>,Y=(TK1=A1= M)MX8Y6R%78RE""^,L9,[FD;
<#F,KA%IF%"A4C5M4^_8]89MS94\$K_ " 564 MDD8/?K23_ %ST#>PG-'-' M-'-
!"V#FCFCFCF@H/X3]*^)OC)8W&J?M1RV=I?/IMS-?[XMGU]HR#Q18Z10T :I8W9N?MM0\ M.L4<)?C>I_Y9#L?
P[\U=7L>)FE%XB,*=M+W.@_X9U\;[A;GXP:]M&S\$ _P!H MP5YRQ_TDCG..G>0+/V+V,G00U1]J@-
HTQ./0;0/A)S^>>IZU]E+ ,>S.8/- M.2?+R.\$ZKSC'7WKYH_9M^#?B[X=^/=30]>T?{ }90ILL
E^U10F3S(V'R)*6 MU:/V%3)6E?L,UY_P"\$=2T/X/\ C[Q'8?<SP\?\$NH\$QA;E8X;P@\$"5G*3D*RR(1(7)W+N'!
MW-7M?PK^%_B3P0\ 'SQQAOM*-EHM^+TVU[]HA'NK7*2 >6'\S/EAL;L#DY(M]^8?"W3/'0CKQ=XR\2?#_P
06&B6]WJDDAM]29))75I7D0M&5DP, X)!')VL M?FOE+U."03G%).][0\SI?V5?AQ<_)JWC.ZT:73--
NT>COW4+/A)0&\V.1 MP'95BPGFD8D\[@DJU9/PI\+Z/XF :2\=1ZIRZI9VESJ,L'VD%T#?:MBC;T? M\$-M)^-
\$ @#0=/:ZU+&'6>WC1?L\BVIFW(XB4G*!& M_P,=36A\)_ACXI\+ 'SOAX@U'39(=)0T0&M+J2ZA=69[J.6-
MBONY4'L*J, M5)(ZZ='VJI*,;M/J<1HGAVQ* MF)IFFPPVMI#(S+! 1L1GL"IX ^5/F90D3 MY5Z#C%?
62_PUX'_PJ_Q_0[4Q\8#30,\,HR@WGVJ%-K#3A\]QF+=2:|YD&V,< M;V4*N>G8=QUK>/5'I8.\$X>TYELV?
&WPY_Y.10/^PUJ0\ [<5]B:A? M0Z7IL][<3?9X((R\DK?<50">?Q KY-N/A1\3 "0Q@U?QCH6@P7"+J5Y<0?;+
MJW9"DXD"Y'GY'^N/I75^)^M*^/?Q,TVXT>^L=)*6\$T3"YFBE)BND+#[VQ1YV M_ZDXV*1N#;^
,HRY;Z'F86JZ%.I&,'S-0IIJ>9?LSMJ&@7?CSQ-I@NXM%T& MZ)NIY-L'V@21JV&#;'"(&)P#]VN_97^'Na>-
M!\1^*M>L()>U&Z0I;59-35 M;B+'EQR,QC=1F0DX8L3@*<5[+|-?@_HOPT\]3;%:6L-\+F'9?7DD2/\ :V(Z
M.A.%AY91'T'L,;MYW>1Z3_-?B? \! '5+Y? T50XH\ -W08_8-0E!,+;U/FD%T
MVR;2Z\$H<'R\MCA1*C9;%1PM2@Z;FKQMKY&-X.L+;P+^V+=;+H[];:7="99;6 M58PHCDMQ6[
M36L=N[+Y.V9E94D4;(U0CGYE (<8]*^\$7P;U^'X@W?Q"\;0;)K\$QD:VTJVG\ MR2#F#IC"MM
\$1VI\\$_) *N<<9T_%&K?&[00&&LR:/I>@^(M&E/F6?GR*D=M&L MA3;=SQ.7(VLP8LIW *,3FN5VN90"N-
%N=UK==4VU<^;?'V: '3? \RK\([+Q R=3\$B M3:JS0*71@Z?N&6V/EKN!)(.=RL"2-HZV[X. #4-
&\&^*++Q>UF9_%(A\^QL MHHU2\$*KMD;4\$<; R!E #1HR J&+"L#PUX1^-?P;CGT+PSIVG^*=&=,@F0)/
M*>W9L@JJ/,AB9@%9ERRA0NMNSF?9MZW,ZE/\$-0G55K=+&C^R/I?B70;'Q-I^ MM:3J6EV DMY[+^T;-
H3(S*ZR;690S8\$<8((XX/\ %7T'S7#_ GL?'=GH:EI^H:E)Y;(EFB;H!Y:YC=T55;'&;@,<,P(QW'-=5-
6C8^CP4>2BD@YHYH MYHYK0[@YHYHYHYH GL_]=P%0_035>/_%? + -E6K%G_*[('W_H)J
M0'_J_P#@7_LJT +S1S1S1S0 ^.0KWKFO(P!IOP'K/Q"^^]CIVB6?VZZCU...:6+>L>80*
MF50F9@HY9>M8U8WBUW/.QT93H34?0\H^%F0 !FC^%EC:>#?#.D2Z4?M'V'4 M)WC23B>3)}>
<+]=U3'J#7I_P#^ 7 "IY=1U?4M0@U/5+Z(VODP))BUM\G^ M=PK-
G9'U4\$;>2< \=/\ "0#>J^#_A7H>CZU9_8=2@^T/) %063 >YF8?,K%3P>U M=XV1\$[&#SP.203L2.?
J!W%8J/NJ104<# 'V2G/506Q\J?L:+8KHOCXZLT-QIF MV5^T1W"(T2QL)RQ<-QMVMSGCMWJWJ7CCX""^?
MF@Q>&8=8M)!#>7]K;BZ0E MOW12*>1U?;M2,_NP5.,C&>WP2^"WBSPOX5^(FDZK91Z1>:U9I:6UQ-=+Y9.
MRX5MQC:0J.,G4#.?;J7PM^'GQ<^&M_H%CIFD;.:7DC>?XDNBEQ/&%!571?, M#2*-I"AD !8\$X&2,US6L>;J-?
V,:/L^MK]3._9=7:CH'PY^)']9\1^)&'Q!K4EZ]D9-5 MC\VS+Y<4C.48,/,=I&)9MQ!&(W-GI/V=?@_K?
@%0&]AXIL8?(0A!:10'.EQ M%=[3.C_8.['U6 <*6U>H8# T?X;?%;X*^)=8M0_D%KXJT""0F%;^9(U63.
M!YBET9) %925R&&TD+PJ:1B[:FL*=6\$*=2I"]KZ?,T/VCO#^F "SX9W,7A#3 MH-
#@UW58;: 6V58C<1&.1F0L2WEIE,E\$R-N[C]8-Y9HT.[X92Z+8_174-6N; MVT+KXD\$&CL9&7Y)8W%N01]
MT.TG0-26ZAENW@5K@2":6%71RIV.%6/;ZDCTK= \; >"0'7B+X!:AH.NWD'B'Q

M+=20MNL=D2.%N4<@NX6/>J*Y;Y4/ ^4G+MYIGA7XY^? (\+Z+8:;:7\$#3
 M+>VUO&+W3U=M/Q+*SJJD'L';>\$D*B0E7/59LTUY%.E-3JZ#-H/E/|EWQ=?^' M (<\$R6,>U9-
)M%OH;>;:8Y)0)E9A(556(JM; M:GJ6K?>);%T(B *QPD2??CR9,E@&. \J=PQNX#2?AK\3 @CJE\0@;*W\4>&f
 MXL?L&H2@F%MZGS2"Z;9-I="4.#Y>60PHI1TU1K"C4A[%U>-M?(00"-C;^ MVP+01M(4PZ/<^:);:H\N-[:
 [-4<;?EP7\0 '10M?5TROIYW?P (/H"<KF0! M?@W\&?AE].4>93ZAS1S1S1S72>L@YHYHYHYH&'-'-'-' M'-
 "KV_WE_G7I0@?_D6K/Z-_Z&U>9+V_WE_G7I0@?_D6K/Z-_P"AM51W.K#? M\$S?I:2EK8],**** "BBB@ HHHH
 **** "BBB@ HHHH **** "BBB@ HHHH * M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
 "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH ****
 "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
 HHHH **** "FM3J:U &X@ M_P"0->_]<)/_ \$!J\D_A_P"!&06_\$' (&0?^N\$G * U>2?P_P# C6\$-#U#
 M6M2.RRL;=I1649<@?D4' 8L<)N!8f0 >WF^PM^)WB750@fKGC6Q/!8SVT* MW-JIJD!4RQ0B1R[-N;
 WJZ+N4,!DfMPQFYI.S.6==4I--]+GL?-'>5?I.K MX;:=\7IM3T^2SDTK5K-&GDB-QIH1X!A6VOM3.#
 (0&P8R.3VZWxG>.6^'/@C4 M?\$1Tf[8+;0@6_F>7YVYTB^]M; &T\$-T/W:2FGL1'\$PE2=9/W5N=1S1S7+?#>+0
 M0_PLCPIWB+['_9_VSS/|]W^9Y>R1H_0;5SG9NZ#[U=3S5+S-X5H5(J4=@YH MYHSA>F/F4;^NWGTW#/\Y&0!?:
 B9^U-_P *Y\<;EX=_X1S[?]C6\$^? &EY>[S(MDD^YY1Q]_P!;F&BG4=DSWKFCFO(/@0?KCP^(+NPC\.?
 V7;V<' MVEfYK0SU#;U5(_4C#-N;&Df3QP2&^/OVD-)\-^*CX;\:/-=->=25A-'!;
 M2!\$BVABZ<%RTB;1E57&TLVX;<4.2WL91Q5#V2J1VN>P\T/-^+^M>% VBK?PO MK?
 E#PKJ'M'#9)%CfSY(D;:C,&:430;E \A.S_P"NR_SJI%_J1]?Z"@fW-'-' M-'-' !S1S1S1S0_F*P,
 <2K,XV@;=PD;8=HCQ55JE..N27f(Qf7fCKP+&
 <6\LE_K=XD%=%L]*TNQCTZSM8 +2WAW&/KG<"6)R<\Y)/J3QCR/X2_M- M6'Q,\3-
 X>U#2)]_0Y&W6%9+6.XBE::Z2f^T"!50L'(_M\I?XPB->'WZP_\$Wf83^&?&\$NK:-
)X5CNY-.NY;5fI=2\LRLCE6)3RFQD@MfX_M?K.56\$3E>88>*YE^MKZGT?
 S1S7RZWf;8;8&\&R^2Z@M'JN63GDx\CT#>Zf; MXP?%W70AA\3?!GV@QVGA.X5A>.'61YF,GENf?
 (S'R5DADPNW."#G(P_:1LY! M',*4TY0EHMSVSFCFDW*TC%#Y@8!Q)ECN7&%Y;D\#K@9SG02\UHK/4f!6DM>H
 M3fM:""6fDN8f==D*MT138%SCZNS_)5f.R-Y M<;MN\0C'F? _//&f^GXU\R>.(K7P/_
 MAZ#JEW=>?'JJ08C_P">)ECDLU7_M +Z13^85-SQ\PO:FUTDON(?VX#&L/@LR-
 L7_3"S8SA0L);@?;V<8VCUSSC! MP'_ (7U'fF#XI67B7Pf!) PCMT7*C9 MAW_>_P"03/_W?%_P3??
 \$CXVVER7/E@W=S\$TBG9(&2/<)1L!D\$8,GSX (VG=D8*_LP_#>V" P#"-[0>
 M"WVZX..0!QYHfXf&M3X0_\$+5 ASX;Mf3T?PM=:0(TP-TT&_9;P*H>3>Z?.N4
 M'#'*KM)8!\7Mf[H]*E1fE2&LK(\;\4?f+QW\)!KZMX8\>ZE-!HI^V#3=LE MI"D:\$RN1F9E9@,Y500_R\$8;"-
 K?f3/_:8_9U_BM_\$EW/_TS@CFN(0_'55_MHI?^F1\$@f(ER/'/[3J?
 \$SP=)X<_Z/JR^)=9M19F""*9@48,\ZIM7,FX&56_M.U,J52+M(07K'P'_GX2?#6.WU2XBTZ\>CJ%^\ER)
 (+9BBC!;"A@UB5CDC< MKG+ @5'+R00X:5.G6JNG2?NVU/'-+^WCKX1^!H]"2>!KF6;3C)I[KJ'W')
 M#;EHXV6-'0)MD&U5\2:IJ0f4GQ..LK1YKX^!-,F#S.WfL@f\$)6)',S_M+N2+('RN-
 Z\X3f7Z7I&GZ+IU0IEFWE6=G"88U9RT;(BE%')SM5=H&23@=>P_M*;;ES/H/"4Y2JNHW>\$-\$?/_ \,M%M?#=
 _UAXfM+3_5MI\EV?K+;2M_X\5_Mf%-G,/VA/B1XHDN8fVUC\$EHUT.KOM*!;A/I';#/U%?1Q9V:0
 M00W%V/[SfV""YAS1S1S1S70MCU@YHYHYHYHYIC#FCFCFCF@_M_YHYHYHYH #FCFCFCF@_YHYHYHYH
EH-5f+FCFCFH; MNfATVWDNfB=+;*WfI9)9&552,*=[%B. %R2fU_.2fDC-Z\$N5DVV3V?PUI9N)-
 +C@'ES3&.\$0M)69MN\$C1R2K9,IQ)@_#;^# M/[06G?&*34+!M..C:A:QFY"+.LLJE)-ZFRK4_:^P3fZUSJ>;
 M.....X7ICYE&_KMYf-PS^1J^9;'19QUBPYHYKP7XF?M3?*\Y\<;EX=_X1S[? MfC6\$^? _VEY>
 fS(DD^YY1Q]_UK<^"0f05Q\7->0f*/PS)ID%G:&XDOUN_/'"
 M>H5/f6N&/+ #KGRSTQ62J;V1YTf>QZfS1S7E0Q4^/FC_[U!-!M_M;*7Q5XGF_2+2K=E1=S2
 !)'Y8.P9GPJMGG..T/_Wf[1-MK_BB+PfXf\,7W@W_M4+U?] 34I6V76690"&1"C%HU5"1fV6P<@*SYU?
 4UEC*49^S;U0;R/8>;:3_MUSXN:5X5_+C\+ZU"l/A;4H4BL^I9F?.V1F",6+LD^&T#>N.2"QfMDRLC(?
 MOCENG';''';Tf.SJ001CTYYSD>H/&/&/\$Wf)G@'Q! M?--8MV2251T<*36G_Z8_J;XC?%37+7XL>%_WA)+;
 f5W7MVRA00fL2%2Q.^7fS'05?2f4MM:T_M>TU*SG^TVMZ%GBN6/SE&(V93F?F8;^FfGTW'Y"CFM-#J7J' M-
 '-9*d?W^WW_-\$->"fMQXY%:/P= MM8 ;MNH^8T:E#D@^1SS@f>U92G!..S..MC:.'FH5)6/J/FCFO'_B=\?
 IOACH7_MA>^N/#GG3ZY"fQ)9->^2fDRK%>Z)V-NP' Z#&.^>/6_>Vf3_PA/G\YV?VK_MUP"?>'M1*
 <=>B)9CAHRY*DM_(&HN:;\6L_C1K/CKX^)^0\$^@Z;_&7J=A(_M*0?:0/VH%1I&Y\$;C:DC-\Q(.W!'-=9\&\$?
 B(WQ.^'MCJT_P#R\$HF:TU#WN4_W_MMPJK\p96^4;1NP"=M"DM(f;fL<33G**3=F=fS1S1S1S6JV.
 f3f+FCFCFCFJ_M#5fAS1S1S1S0,.....)f/_7?!\;;-!-5X_f7_P+P!E6K%G_K0^M_Z
 M":KQ_P"K_P"!f?RK0_0-'-'-'-' !S1S1S1S0_/D^&G@74-=,8N+J/\$5I;8),fPP/EIC31,"R9Q5@,ISDf>B_
 M='-&SXX'X,R:&?f&_MC^TC.,>?Y?E>6\$^;&Q_L_?f1TfCFBUS(@I>:00T7+>,PYHYIK,Z,"%8@_EF122BfJR
 M?0>XY_60#?B-^UEH/@G7\$Tf[1+1?%)C9EN)X;@>3&V.-Kf&WD-
 fFUBD>>XM2Q!"E1E56)R>3C)***JY/(\$fI+L340-.DKRDSVWFCFO/?A7
 M\9+XG07MI/;2:9XALI&34=&0@6F52""0=J\$H-P#D_?2?F4AEW2?P_C7K?B#_)Uf_UPD_0&KR3^'
 (\$:SF>= MB@YHYHYHYK);'\$-'-'-'-' ,8\$VE9\$ZR2-;&1V?;SG_M=fYK#;TVX0?A-!<16_VF\$SU6"6=-
 ^W\$;1RQY_ff=%_X%6S:74%W^RJfVUO_MfIC7PB\3/OW?0\$M=CC_@)4K_,!KDE\3T/
 JZXf:E_*)GA/PIXBT'P.GQ)_M/ZAL.C7S07*^&M1MCV'.1AU9I0&4@C.1@f\$CZf^('Q2T_XJ_L0:_J-0/NU*
 M%+./4;9D;_03BZB5AM/52RL5;))&_3E2!;_8fM8;fX3Z0;3VT=[%-J\|;VLZ
 MfHI%,&\$00.0f1fC>G60'/CE_.M8^#6IZI;Z%')X*UR1%/G.6571A*4E!Y\$
 MBX_>_TC+,VX+EK%'C^Sj8>@Y0^"2LT>Y?fN\|26/f,NBR^\$f*#4=>'G?9K_M:Y=51Sf0;=G++_f0_B%4K?
 QA\Y&P0@'Pf;?(Q7S9XfA_7Y0/f,f_)Z_AWM_MfOPS>>+OV;=TFUU:Z\W5PLD2ZI%_K80M^f?<
 >')V^0854M_PfG7QC,VQ_C_M

HSY'\ ' 'U0\$/B=XNLO&THFU6XE\$\$V MN3+)+('9F5ALW,DQ/F!@3G;&2,\$LNU\-[B3XJ M7:IXITX2)IUGYCX
+JY& M+=K9&BPH'F289AR< L,U>I M'^,0#G@WPDFI:IHVD^(-0?S/[-LK^&"14D/+ M.0WS^6F 'VXRTB
E<@B7'30\Z*J2IJ0)^!Z>9XMX\::;? \ %#!I/P7=^HY M-5L[-2SMA,\;1B;RYFF=D5E#!0I;KCG=@
8+=K^V;I!09Z;X/U^TD6!)=)09; M9)X]>)G"NCI[(D&#_0BI?V3_@^- 'TN/QCJ]0'+JMZ VF[E8-# \$"P:3)QDR<
M'/'<*I[X" ME:E+<+:X5T&VL9+R74+^6Z1SR50' 'Y?EJ0?(N"?^ BDE:-NY\$8 M2^JRJU?B*T MA>2>...X#))M
6*196S]!1F_X!5/|ERZMI @QH\$\$\$LST2\CGB,00W2^2^ M)8R/09 Y. ,]!C!/- L2X\CQAF1H@SV*[DSN&1<M!?
% M!0 S0">"9NQ)(>,)C S\OX/;0?09X M)^(\ /FOH>+ QX6DNYK<1^2MY<11+(# +8!0LR
GC@{MP}75!!MW!L%I7/(;)Q@X3_ (\$L&C_ '[P!J>MWV MF60B*UMWL&9<3,
((9U1U.Z*^@)^4889#\$C_ /K7R;XBU*^XQ?M5:;!_PCL0G66BRVQF086)66 M&"8SRR+P.=[>2"!@N8V!
((KV#)HSXE#P!X"NELI?L^K:0FT@6'!:',, "9& #! MPL:@8900'\$8/44HNRLD987\$.-*I[5W2>GG^!Y=^[_: +
&B_X+[-P-X=/T@G* M_P#?0'5YE_V=T47?' '!'X3^%MA?2P+#J&M?Z;-]PGR\D08*J,(8MCA22108)ZK?M9:X^
MC "&:W2/>VHW]M:EE?YXU#^<6"?09,(3VW^]39ZFNCYKF0AK9S:?._'!M/ M; 9Y[?2K2"1638X9(\$7:1_L@ ?
A72\UTQV/;P!02B (...:HZ YHYHYH MYH ...: #FIK7.Z7_KC+_P"BVJ'FIK7.Z7_KC+_Z+:@'+^\$?
4TG-+ "/ MJ:3F@ YHYHYHYH ...: #FCFCFCF@ YKS/XZ?A/C'H>F6\<-C?6=VI M6\N S*L+D>:BH&
9R5C=058GRB@V[R:;YHYI-7,ITXU\$U+J0V<.'(554%A@Y Y'0@@3YMX([B22W%JROU\N:18GV?
[>)"5!P*]"YKS?H[3;G5/@EXGBM(7DGCCC MN R2;0%BD65L_1490^
5E,X<= N]3EWY3B0A:9P67[)]&J/"D*RRZ7J;SB#I/ M(KSXD/N41! M?_?A/PIXBT'P.GQ)T#4-IT>^:*=E?
#6HVQE#M(PZL\H#*<@ MC.1@ \$CZ,&EU;3_L@ZK!+ '(UII6JV\JH^XJV^9AGZJZM_P*C]CNUA00A/J]
MM/;1WL4VKS00:SH&BD4P09#\$Y 'U&,9Z=:Y>5R:1\Z2K.C%.SM^)^4^('02T
M_P"*W[,>0ZC;S[M2A2SCU&V:,QM!+_J(-IZJ65BK9)*X!_5('4?_34(/V<
M='ETJ%+K4E@O_LMM,^V.2;SKCRMW(Y::>OG_XY?#K6/@UJFJ6^A1W2>"M M1(N/W?WCM(RS-N'^=?
/3KG5/V>-)L[>^GTZ[N+;]MDN ME_UT7[ZY^YKAI598IJHM4F8R>+ V@ IW^!/#N=OX6=(KCP[XBTP
MZ!XBM5D*2IE\$EEC;\$J>4[;DE'"<5)I / \6^&T\G05:_NU3Q3IPD33K/S'P W[R,6 M[6R-%A0/,DPS_9.
6':L91<6<_N8>+H40H+PR" M'4(UCPKIWA:5M7-NTXWQP2
MQAVE,054,BJQ(",30C#)@]E^E/C)XD\>&!/MQJWB#2;+7K:)P]MITZ0MYMP MY942,-W7/\
6;&UM[07+C3+6SC\J\$R-\PFB M0?*(DW%5_Z;B>=F22B^8QK8>IS0#4W>[OZ&Y^V59WL&E^#/\$D;"P?3[ITB1?
M^/F)Y421)%IAY\$@/^)*^D)!^].V0N%RNW^%3N)/XDDD_60G;]LC4Y;C1/"0A M^UL_M<^H7TMS\$B\L&CC\OR@0?
=]H8_\ =W\5?0^UU^60Y8<#P=VWME>W.1^ M%=4%9M'J8-1C7J+KI^00-'-'-'-'7'8]F-
[:AS1S1S1S5%]S1S1S1S0 PG-'-'-'-' M-'!V#FCFCFCF@H...: #FG(NY0G_-6H+?CM*_\
H+/3>:6//VB/'W\ M?UH?PLRELSYG^\$NH/XD_:R\;ZEJ%I'G2)*07!0W*8 M_BO_=G'EMN?
23GAG"766IG?IGXA:G\%0%]\ /0'-W';;&.F\#G/?!Y!."]+_&@? M@NG06_
RSZ=IB#09;1B2UF\1FX&0&C<'J2N200;@N2!G/SK\#M4U76_VC-* MN/\$4MU<:MBXMY_MF#,-MK+\$HE+
<[JJ\$SG*G+\$YQ4KQM\$BK&="5.C)W7-=?Y M'T-XX\2?%Q\4WT7A?
PAH^HZ"17[+%==[>"]T[P[HUYJLL>H0W, MI21%C1<&+JYD[B#YW964
_6*X&?/S\70B=\\$='V0BKP9:2:'#%80I\$0\ V M14AVJK2K++&C84G&P!MLA
ZD>W^/_B]X2^&TEE::UJ7V*XXNV\JW\$9EV*JE= MQ*C*+_ "Y)V' X)'F'[4'Q<\,7GPWET72-
8LM40M7N(U\$<%P&,422B5V8*& M)*(@4GD.Y!_U@,I13=WN9XN\$*4Y5J4>2U3ZGM_A0Q-8^,/ #NGZW9R2S:=?Q
MI)!AE,K9_&'VEA04@ACN.3GIT'D'[50CVXTGP_#X1TEG0]>UF0120VX)EBA&
M/DPK;R\C.B!55@07!QQGL/@MHD0@7X/:%;:U<_V8]M:0//0WKY\$;R//A]VTH MRA_F!RJE-0>0'?A+-
)\=V@M:\:WUN\ND:6HEL\$VQAK91N6VX'/**6 MDN)&C5N^WS0?^!BK:M.*+J05.02@CZ+YHYHYHYKJ/:C:V@/_
%?_ M+_ -E6!>:.....: #FCFCFCF@ YHYHYHYH ...: /FG]MK698M!\+
M:/Y,,M0=7,]V^[_6%HHBPBJ/]@B=MWT6MC]L*WCL?A/I^0;6VRUAU*&.+].V(M@AF)0>H!X_G]TX?
[:F7,FF>%=26#?:V[W<\$DC/M16=\$<?*JD,I_X#6[^V M)=V^H?"71[NTG^TVUQJ]\\$0;" M0:?
XHT+P'JFDW45]IUPEXT,\1)#C\$'/(_C (8.I_*D5[5H7@?2_B+_"NA MZM\$);:71;216'\$D+K-
LL;=G7/OP6R&7<#\6>/\ 1_\$W@0[/X1U^40:Z69);
M!1S&R2D9DC;NC>60IRK9"MN41*]\%9=3@K1J4*"IOX96MY'W;\4-2\6:5HD=0 MX.TJSUK415/'L_*
M,#_IG;Y_3]>WI_Q0\&ZKXWT2.RT?Q+>>[N&Y6X\$S9;M\H57\BXD7KG/?[0: M0,+C]G7QC"VQ/C]XA4(B0^1\
[>3MR6&+D?3D'I6_0=CV<3&JW\$P;.^DT#Q#\ M1/A1?E0IH'X.Z/\ M"/1_"\G7\$U_=7WVF2Z0I^#-M\$(4A?
X1\ S, %YV[L9.. /K]PGHK^? !L%EJ^N MR:H+'S!+KM_)L#]I7:#DL>F[N>YKYL;"\5:%XDB*-HNO:?
K!MU03/+IUW' M,L(/D?7V_=S@XSUP?0UG4MHV88ZC"5%2J0:V[U/J/Q=876K>&]:L=/NFLM3N M+.6.TN-
VU8I2I"ON"EE()&&'3-?+']_Q>\,"G^WM%\5V[>';W[3]H>Z>V=
MG4KM1K>0(OF)LC_ME64BW[6]MK=JUSY*/N98A:N_L@[,]8 ?HPKL/ MV;?A"OPY\+?VA?P1CQ%J@\$IG:-C-
!"47;#=#SGJQ/'*)*[S[+U+, 6S^)-)S2M&Z22;_+\$@;8ZKU#* &S^(-)S79+V_WE_G7I0@ M?_D6K/Z-
_P"AM51W.K#?&\$S?I:2EK8],**** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "FM3J:U &X@_P"0->_]<)/_
\$!J\D_A_P"!&06_\$' (&0?^N\$G_M * U>2?P_P# C6-M):+3A-<6T-K/(D4S0,6\$H/EX(3<7*N&;?
N;&%"9]GYHYK.4.8Y)T M%*I[3RL8/@_P'HWP\TV73M!TW'S;&27SF3S)),R;%7[SL2?D2/_ .IO%7A'1
M_&^D0I>MZ='J5J]JZHSLA#*0>&5E8<]",XQWK8YHYJG%-6_9T^7V/8R M0"WA72_!7A^RT718)+73;-
&2"!W9PBEV?AF9F/+JQQT[5J\T0;OZ-S1S4N*EN93HPJ:SBF9GAWPKHW@^Q73-'TVSTZTC*N MWE\$EI"ORJS_J=
[?#!7B/B#P#X MD\;?M'6>HWVE;0!FAQI=6,WGF.-Y2"\$; Y,HG4%L_+MCBW=J]0YHYI.!G4P_MM%R085FW;.)
P0#:'^",DC!' /WN./FI.....:T6QU+8.....:8PYHYHYH MYH: +.E_A.S_P"NR_SJI%_J1]?
Z"K>E_P#(3L^NR_SJI%_J1]? MZ"@!W-'-'-'-'!S1S1S1S0 +?AIJGBK0M3L]GAJ"Z4VES)(J
MM<.,!I\$B"LS;XUB)^;"<+Y6KV[FCFLY0YFI=CFJ4(SFIG+>!_A?X<^&P0\ M^P-
+DTM[QD\$Z2W,DS.J+A#\S';RS\ "MK7-!T[Q1I5WI.L6?V[2[R,Q7\$6_V M5R#TW_J0.1R*0\T3V:V,#P;X%T3X?
Z9)IV@V?V&W:4RR1?:)9L, M0!UD8L.

..G16_S1S1S3M;8J,%!62W:3=\VY@CJ2QWGNP59\%79\900+\0C)QN)QDXZU4\7?#3 MP\XXURTU#7\].DOS9'-
NS74S0QL<90\$&\$?.U>QZ5U'--'+E)>'IJCR\<+NZ&0\$?C=X!\2_\$;XF>\$-%ET\9_!JJK76H74CLJ3
M?..!LFUL() *QIC#?0FQ@9(\NYHYI2C<5;A&K!4_.XB\$M\$A,:H^6WLS/QD%
ML]\\$>_KCH%YHYHYJTK(W2459!S1S1S1S3*#FCFCFCF@ YHYHYHYH. :FM<[I M?^N,0_HMJAYJ:USNE_ZXR_+
HMJ (0X1\32:7>Q0SV=Y!); M2PL6!=74J0"N&&02,A@>>.M6^.:F4>8SE!333/!_@'\-/ \$WA%?&GA'6\].\S
MPE)/Y,,SR;'N-T;)) (B*I8[XA&3F0!.% '*07K/@OP+H7P^TJ730#E@^F:=),
M90LLERTY5MJKG<6;JJ+QGM6_S1S4J%K/L8TG1 MZE:NZNJ,[(ORD'AE96' /0C.,=Z?
X6*Z7X*\ /V6BZ+!);Z;9HR00.[.\$4NS M\,S,QY8\6..G:M7FCFA1U-
%2BJCJ\];6#F@B,HPE.T8SD,HSCYMIW<\$'' (HYH MYK1\&C3TN].OYQK' [.OPYUC4I;V\ *6<%TYQ*+26:''/W
XC5U17Y/S@'KV\ M\GH'A310".GKIFC;:9Z=;H58["I\$F,J&<-]JOE/S\$G-:G-'-9\IA'"T8-OE. M3\
<-"OPQ\1KV*X\2Z=)J*6I!@1KV80ACUPBNJC\HZ].W?I\>UAT_3X\2WMD
MAC@55CM#RA_NJ#Z\$X)Y/'U+S1S5*.K*5-)\5J>(>(/ /B3QM^T=9ZC?:5N\
M&:'&EU8S>>8XWE((1L+QEZ@M #MCBW=J]P9MVSAPP0 J^"!R<8*+S\]CC MYJ3FCFIC&Q%'#0I-
OJPHYHYHYHYJT=0HZ47%PB:FSRA(\H^CM()0\$VG^(-5T\KG6K".-H9S-H %EEI&S7E9G%Q MY\T6S*,A^1?
E_C\5UW-'-'*C:5&G-KG6SN-C7;&@49"@+OZ[B >> 2G\/? 7X M?^%;Q-1TSPY:I,A^22XEDN&CV -N7>[\$,-
0#X&WWSQWW-'-3R*]VCGEAZ4GS M2BF[W*6NZ'8^+-'N=+0"TUA=+Y50#%<,B^6?G^9U969F)&2",J"IX)JCX-&G
MZ-X%T&'3-!TN/2+'S #7X<:IE\&BZM.60+YES UW 6]!-5 MX \ 5 \ 0\ V5:L6? \ K0\ @+?^@FJ\?^K_
.!?^RK0 0-'-'-'-'!S1S1S M1S0 T7XA:*TXLUS#;R&2"14"NL0E5-GE2"% MRI4 *I8\BP'K/-'-9N%W%?
B/J45SX@T*.XNHQC\2)Y(W925 W!77/(7J#W MZ=^LYHYJK+J:SHPG\0FKI"+RH;R/()ZKU\ CGZ\$=S2\TA'6J?\
PIWPA)XM_P"\$HN=(WZRO\S\3Y\TN\]/N,[+V\@?CV\3FCFGR M\A+T^7DMH+*RS&1BN,KM3=A54
\$G(7\N0.Q!\^00^' 'P+XDM?\$'C#QGXT M\V>N:K.]LMJ\XD:*\$,6FP\G\$8*1HGS,-D2X^7:3\?
S1S42A'A4J1G);IV M0I# ?ZWS!G(7^D\OY\$4G-'-'-;[3:PW^10\,03? _\ R+5G\& \#;0,E\?
[R SKTWP/ P BU9 10 OVJH\G5A0B M90TM)2UL>F%-:ALG % #J*S\C5+.W?9-<10\$? \ /5PN?
IFHO[:TW_G\IM? \ M0\E N9+=F11D5E_VWIH Y?;; 0\)1 ;FG?\ MM_W^2C^W-.Y ;;; M_0\
M_/[;?] DH_MS30\ G\MO^ R4!SP\FID49%9? \N:= P_MM_W^2C^W-.Y ;;; M_0\
)0'/#N:F11D5E_VYIW / [;?] DH_MS30^?VV_P" R4!SP\FID49%9? \ M;FG?\ MM_P!_DH_MS30^?
VV_ [)0'/#N:F11D5E_VYIW / [;?] DH_MS30\ MG\MO^ R4!SP\FID49%9? \N:= P_MM_W^2C^W-.Y ;;; 0\
)0'/#N:F11D5 ME_VYIW / [;?] DH_MS30^?VV_P" R4!SP\FID49%9? \ ;FG?\ MM_P!_DH_M MS30^?
VV_ [)0'/#N:F11D5E_VYIW / [;?] DH_MS30\ G\MO^ R4!SP\FID4 M9%9? \N:= P_MM_W^2C^W-.Y ;;; 0\
)0'/#N:F11D5E_VYIW / [;?] DH_MMS30^?VV_P" R4!SP\FID49%9? \ ;FG?\ MM_P!_DH_MS30^?
VV_ [)0'/#N M:F11D5E_VYIW / [;?] DH_MS30\ G\MO^ R4!SP\FID49%9? \N:= P_MM_W
M^2C^W-.Y ;;; 0\)0'/#N:F11D5E_VYIW / [;?] DH_MS30^?VV_P" R4!S MP\FID49%9? \ ;FG?
\ MM_P!_DH_MS30^?VV_ [)0'/#N:F11D5E_VYIW / [;?] DH_MS30\ G\MO^ R4!SP\FID49%9? \N:= P
_MM_W^2C^W-.Y ;;; 0\ M)0'/#N:F11D5E_VYIW / [;?] DH_MS30^?VV_P" R4!SP\FID49%9? \ ;FG?
M\ MM_P!_DH_MS30^?VV_ [)0'/#N:F11D5E_VYIW / [;?] DH_MS30\ G\MO M^ R4!SP\FID49%9? \N:= P
_MM_W^2C^W-.Y ;;; 0\)0'/#N:F11D5E_VY MIW / [;?] DH_MS30^?VV_P" R4!SP\FID49%9? \ ;FG?
\ MM_P!_DH_MS30^ M?VV_ [)0'/#N:F11D5E_VYIW / [;?] DH_MS30\ G\MO^ R4!SP\FID49%9? M\N:= P
_MM_W^2C^W-.Y ;;; 0\)0'/#N:F11D5E_VYIW / [;?] DH_MS30 M^?VV_P" R4!SP\FID49%9? \ ;FG?
\ MM_P!_DH_MS30^?VV_ [)0'/#N:F11 MD5E_VYIW / [;?] DH_MS30\ G\MO^ R4!SP\FID49%9? \N:= P
_MM_W^2C^ MW-.Y ;;; 0\)0'/#N:F11D5E_VYIW / [;?] DH_MS30^?VV_P" R4!SP\FI MD49%9? \ ;FG?
\ MM_P!_DH_MS30^?VV_ [)0'/#N:F11D5E_VYIW / [;?] D MM MS30\ G\MO^ R4!SP\FID49%9? \N:= P
_MM_W^2C^W-.Y ;;; 0\)0'/ M#N:F11D5E_VYIW / [;?] DH_MS30^?VV_P" R4!SP\FID49%9? \ ;FG?\ MM
M_P!_DH_MS30^?VV_ [)0'/#N:F11D5E_VYIW / [;?] DH_MS30\ G\MO^ R4 M!SP\FID49%9? \N:= P
_MM_W^2C^W-.Y ;;; 0\)0'/#N:F11D5E_VYIW / M\;?] DH_MS30^?VV_P" R4!SP\FID49%9? \ ;FG?
\ MM_P!_DH_MS30^?VV_ M\]0'/#N:F11D5E_VYIW / [;?] DH_MS30\ G\MO^ R4!SP\FID49%9? \N:= M_P
_MM_W^2C^W-.Y ;;; 0\)0'/#N:F11D5E_VYIW / [;?] DH_MS30^?VV_M_P" R4!SP\FID49%9? \ ;FG?
\ MM_P!_DH_MS30^?VV_ [)0'/#N:F11D5E MVYIW / [;?] DH_MS30\ G\MO^ R4!SP\FID49%9? \N:= P
_MM_W^2C^W-. MY ;;; 0\)0'/#N:F11D5E_VYIW / [;?] DH_MS30^?VV_P" R4!SP\FID49% M9? \ ;FG?
\ MM_P!_DH_MS30^?VV_ [)0'/#N:F11D5E_VYIW / [;?] DH_MS M30\ G\MO^ R4!SP\FID4C5F?
VYIW / [;?] DH_MS30\ G\MS_P\MEH#GAW'> M(\ D"W0 7"3_P! :0)/X? \ @IKUJ9X-4L\B*";-LH06C(?
&;Y90AVY8\$;F1 M\HX,/ V0J))00X\!IU>)QW-'-=B/AW+ P!10? \ ?G [.E X5U+ -10?]^?
M_LZSY)+HQQ0-'-=E PKJ7_H*#_0S \ 9T? *ZE_Z"@ [\ &='++L/ MV-7L<;S1S79? *ZE_P"@H/\
0S \G1 PKJ7 _"@_P" / V='++L'L:08XWF MCFNR_P""=2]10?]^? \ [.C
(5U+ T%! WY_P#LZ.678/8U>QQ0-'-=E PK MJ7_H*#_0S \ 9T? *ZE_Z"@ [\
&='++L'L:08XWFCFNR_X5U+ P!10? \ M?G [.C A740 _\$%!_P!^? LZ.678/8U>QQ0-'-=E_P_*ZE_Z"@ [\ \
V=' _M_KJ7_H*#_0S_P#9TQJ]CC>.: [+ A740 \ T%! WY ^SH_X5U+ -10 M?]^? LZ.678/8U>QQ0-'-
=E PKJ7_H*#_0S /9T? *ZE_Z"@ [\ P#V='++ ML'L:08XWFCFNR_X5U+ T%! WY \ LZ/^%=2]10?]^?
+.CEEV#V-7L<;S1 MS79? *ZE_P"@H/\ 0S \G1 PKJ7 _"@_P" / V='++L'L:08XWFCFNR_P""
M=2]10?]^? \ [.C (5U+ T%! WY_P#LZ.678/8U>QQ0-'-=E PKJ7_H*#_0 MS \ 9T? *ZE_Z"@ [\
&='++L'L:08XWFCFNR_X5W(/^8J/^ / P!G1 PK MV3_H*C_0S \ 9TQGU1S&D \A.T_ZZK
#JH0^K7 /85VL/P]=)E9G&H"(M_P!,3 \ %TQGV.*YHYKLO\ A7NH"7 +8]/ 'Z.678/8SZHXSFIK7.
MZ7_KC+ Z+:N0_P""=G G\ ' ?G [.G1 #YD! NOS -, ? LZ.678/8S\ '\$ PC MZFDYKM&^'3\5U_1 \L>0_C\ -
_P""=2]10?]^? \ [.CEEV#V-3HCC>.: [+ M (5U+ T%! WY_P#LZ/\ A740_04' ?G
_SHY9=@\C5\ '&\TQJ]CC>.: [+ A740 _\$%!_P!^? LZ M/^%=2 \ 04' 'Y ^SHY9=@\C5\ '&\TQJ] MCC>.:
[+ A740_04' ?G_P"SH_X5U+ T%! WY \ LZ.678/8U>QQ0-'-=E_P_MKJ7 _"@_P" / V=' "NI? \ H*#
+ \ 9TQJ]CC>.: [+ (5U+ T% M\ WY_P#LZ/\ A740_04' ?G _SHY9=@\C5\ '&\TQJ]CC>.: [+ A740
_ \$%!_P!^? LZ/^%=2 \ M04' 'Y ^SHY9=@\C5\ '&\TQJ]CC>.: [+ M_A740_04' ?G_P"SH_X5U+ T%! WY \

LZ.678/8U>000--'=E_PKJ7_ *"@ M_P" / V=' "NI? \ H*# + \ 9TQJ|CC>.: [+ (5U+ T%! WY_P#L
MZ/\ A740_04' ?G .SHY9=@|C5|' & \ TQJ|CC>.: [+ A740_ \$%! P!^? LZ/^%=2 \ 04' 'Y
M^SHY9=@|C5|' & \ TQJ|CC>.: [+ A740_04 M' ?G_P"SH_X5U+ T%! WY \ LZ.678/8U>000--'=E_PKJ7_
"@ P" / V= M' "NI? \ H# + \ 9TQJ|CC>.: [+ (5U+ T%! WY_P#LZ/\ A740_M_04' ?G_
.SHY9=@|C5|' & \ TQJ|CC>.: [+ A740_ \$%! P!^? LZ/^%=2 \ 04' 'Y ^SHY9=@| MC5|' & \ TNW@ \ !M9R-
(+E6)1D_U/JI' \ ^H(?AR5A51=@CC_)8^P_V :ERR M|!|&>UCCN.: [-OAV : \$7 ; 'K_X_2? \ *ZE_Z"@ \ |
&=/EEV%|&IT100- M'-=E_P *ZE_Z"@ \ | \ V=' KJ7_H*#_0S_P#9TQ00--'=E_PK MJ7_H*#_0S \ 9T?
 \ *ZE_Z"@ \ | \ &='++L'L:08XWFCFNR_X5U+ P!|0? \ M?G |.C_A740_ \$%! P!^? LZ.678/8U>000--'=E_P
ZE_Z"@ \ | \ V=' M_KJ7_H#_0S_P#9TQJ|CC>.: [+ A740 \ T%! WY ^SH_X5U+ --!0 M?|]^?
LZ.678/8U>000--'=E_PKJ7_H*#_0S_ /9T? \ *ZE_Z"@ \ | \ P#V='++ ML'L:08XWFCFNR_X5U+ T%! WY \ |
LZ/^%=2_]|0?|^? +.CEEV#V-7L<;S1 MS79? \ *ZE_P"@H/\ 0S |G1_PKJ7_
*"@ P" / V='++L'L:08XWFCFNR_P"% M=2_]|0?|^? \ |.C_ (5U+ T%! WY_P#LZ.678/8U>000--'
=E_PKJ7_H*#_0 MS \ 9T? \ *ZE_Z"@ \ | \ &='++L'L:08XWFCFNR_X5U+ P!|0? \ ?G |.C_A_M740_
\$%! P!^? LZ.678/8U>000--'=E_P *ZE_Z"@ \ | \ V=' KJ7_H*#_M#_0S_P#9TQJ|CC>.: [+ A740_04' ?
G |.E7XG_ (1 MRR|!|&IV.3L_]= P%0 \ T\$U7C_U?_ 0_ &5:[B/X>M&"! =KS_P! , ? LZ8WP|
M?/&H+ ' VQZ ^/TN678/8U.00?--'=E_PKJ7_ *"@ P" / V=' "NI? \ H*#_ M+ \ 9T^678/8U>000--'
=E_PKJ7_H*#_0S_ /9T? \ *ZE_Z"@ \ | \ P#V='++ ML'L:08XWFCFNR_X5U+ T%! WY \ LZ/^%=2_]|0?|^?
+.CEEV#V-7L<;S1 MS79? \ *ZE_P"@H/\ 0S |G1_PKJ7_ *"@ P" / V='++L'L:08XWFCFNR_P"%
M=2_]|0?|^? \ |.C_ (5U+ T%! WY_P#LZ.678/8U>000--'=E_PKJ7_H*#_0 MS \ 9T? \ *ZE_Z"@ \ | \
&='++L'L:08XWFCFNR_X5U+ P!|0? \ ?G |.C_A_M740_ \$%! P!^? LZ.678/8U>000--'=E_P *ZE_Z"@ \ | \ V=
V=' KJ7_H*#_M#_0S_P#9TQJ|CC>.: [+ A740 \ T%! WY ^SH_X5U+ --!0?|^? LZ. M678/8U>000--'
=E_PKJ7_H*#_0S_ /9T? \ *ZE_Z"@ \ | \ P#V='++L'L:08XWFCFNR_X5U+ T%! WY \ LZ/^%=2_]|0?|^?
+.CEEV#V-7L<;S1 MS79? \ *ZE_P"@H/\ 0S |G1_PKJ7_ *"@ P" / V='++L'L:08XWFCFNR_P"%=2_]|0?|^?
M^? \ |.C_ (5U+ T%! WY_P#LZ.678/8U>000--'=E_PKN0?|Q4?|^? \ |.C_M
(5|) T%1_WY_P#LZ.678/8SZHXY>W^ \ 0|Z| \ - \ #_ / (M6?T; P!#; L-?AV?- M#-J'F|\$?ZGIG_@1KJ-
!T0^Q|!;7S/- V=|NVKC'N;T*X|4 \ 0%K\$YK9 \ 89_X2.]^J \ H"UC_M04.: : : : : >H!S1S1S1S1J_M*Z
=12+CM2U0!1110 4444 %%% !1110 4444 %%% !11 M10 4444 %%% !1110 4444 %%% (1FDVT:
.HINVC;1H_ZBFX_ZFCCUJ;H!U% M(N.U+5 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
M!1110 4E%!6C0_I::J|:7:*-%HI-HHHT_6BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HIK4=A0_ZBFKWIU2_M_44A&:3;3 =12_8I:8!1110 4444 %%% !1110 4444
%% % !1110 4444 M %%% !1110 4444 %%(1FDVT: .HINVC;1H_ZBFX_ZFCCUJ;H!U%(N.U+5 M%% % !1110
4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4 M44A&:0"T4TC%)0ACZ*: *7'02\$+124M4 4444
%% % !1110 4444 %%% !1 M110 4444)W%1R_Z0 \ Y5)W%1R_Z0 \ Y4!U/+ &&?^\$C0?J0_H"UC_5?
\$!:QN:Y9_\$S09_\$S.UWQ\$I7AG3VN|8U*STJT#>??3K\$@/;JPS6_M.W06 \ &DJLGC3P_=,Y4#[-?0G?G|N_2?
TKRS|L^9^NF \ ZQ&H?IM)@G_Y & MLGX) /P7XZ^%6F:IJ^F2+J|]'= (|
|%=3NW,TD:ML)V<;2>0W.W@|*YI5.5V
ML>)5053VTJ4%LK|V/I'=NPP+.64,) #RK*>F#2 \ U \ H_LI^(\$ \ *^./&GAE|4M+
MG0K:UF0&0XY|Y2B"180.3+,L:/NPS\$XQ&F7|UZ3XD:T \ !^';V2SLTN-; ,99_MQ/ID"2PEB<
10(ZL3 \ IPRAE.#@D_UI&H|:FE' '4YT?:3T/9>:4%|/15Y@SC= M =R" /Y\$UPMM_7M!0/AG-XTLY|05|
(B7S+F+3X/,NDPZB4,OW=T:GS&R3A49A_MPHKYF|\$_M"6VE?&370&&N_VG1U/(^*-I4Y02^T?5VJ?
\$;PSH/B;3_#6H:CY6JW(TN;:/YAF\$DHQ5?='*-| | M \ .]=*Z&*0H#N4_ \$- \ ISG :7@U \ Z>*M4^&J?
&'P)K|_8^()=FY5C'S' M;E,?L^ &C0_M&6DZ5X6L+/51JFE:1\$|GG|/(<0QPPN%D \ PMN!)
(RI.WISBH0\$7|6W@C0M60- M-B34-1%J|#[=:1Q26SR*Q5F10-0%0_1T'(. 1BE|2-MRUC*7LU4_P"53^&?
%.F>+M)M_M19T:X%YI,AD,-P(W7>(W=&1MP!_A;MCKR: ^4/VCI2I#;0J7G\$A_MV*D; \ EG+<)R|C'7GTJAH?
B#2_\$5J9|'U2VU>VC8Q/<6TZRKYGWR,CT#B0*0V_MK0^H \ -? "N?2H\$^RZCK\$JV4,2W'E,B_AI&QU92,1D>DU>
<LC: J'A00AK7@W_M4DDLY|F_7446IF1669_6; ,#>7>)U?< ?DB7CN)+- M%\+R6IUG6M-T87!81/J\$ \ <0;
18J78#@'T/45D7'Q0 \ (V/B#3M\$FU5\$0-2@6_MYLXH=QC>\$DA764*(F(/<|^;0BIY'04 :BT/08K2'4--
M9+73KU?M',L2\$R_MW*N0=RLN^17_)^X> D. 013YC-8V3?R ,V1J190E"ECP#|V0G7|J|XOS; ,8W0@?2X-3TC
M4/,BDGOW14AN+4QMN6-R=VW?L0X ^Y)R>T_@_P",V@^_0@|K'A*RM-2@U'30_M"\$OFN;GRS
!#;I"RA0,+ 'Y)=1TVTG/6UC668*,I4WNE<|0 \ ^/-&^(>FRZCH_M_H_VE8QR^25^7)'B38K?
==01 \ CQ_E6|S7R#^S_ \ '/PM \ +/ACJ%KJZS7%]<; MQ))%8:?!YC|'#&N_+A5"ID;.&)Z<8R1| (_#CXHZ| \ 5-
'DU'1)&22%_ *N+2?8_M)HNNUB\$9EVMAL;68?*>H%PJ0K5TY"EAYF \ C; /*V|O|QZ^RGI7R|^T%JDGQ!^,WA?P
M!&)YK*VN8G0K>S90.+2L0FN5;Y2R0LI!_A&YNU%27+J&*Q"H0Y| \ NQ| ,3K%_MAKV FV|]I=[!?
V,Z;XI|>=9D9E6^;^;0V0_\$EYIL/B/P.K\$WEWFC_MNURL;2^:R ,T5TFX?+M \ S8X |R,?
XJ|@^('Q8T;X=WWAV&LPW5L-;F:WA0(4_M5HHMICC+2Y; .W\$B|
??'=QG|0, .ABHSI>TEH=CS1S7B\$W|87@5M22*5-5D1Y_M1% ; @C%M_SLN \ ^?
YFP8W<1D_+TZD=1 \ 30CMH/PQDTYKZV0-4T_5(S)9_AIW_MDR6SE0"0_90P/SJQPI'S|3R
.:6YJL51:NF>C \ TL9=7#+M)Z;/F+-GT_Z_C6_M/XR \ 7; ;X(\.7^N:H?*L|906,/ M?#.AW;V6I>
(|&L+A.3!ZOK&A?;-5NW1IKG|;U'3/-TG30M9LX_/DCP \ 5S_#^RI&>"W4FLIRE?8 \ ZMB,33FHQ2LW8^L= \ |
M&GAS5K.[NK'7],N|:TVFXN;>_CDC@W9V^858XSM;&?|IJC_PM3P/M!'C7P|+ MV)75;<# \ MPKE-
<^&7AGX< "WQU_PCND?V6;S1+D3MY \ DOF^7;R*0WV., \$OT| M: \ &_97^&/A0XC)XE_P"\$ATW^T/L?V7R/W \ D6S?
YV| |C#.=B|?2CF:DH0J95L_M35IU(TG:| \ SZST+QIX> \ 1Z@MIH_B/2|^|^D^18W<<|L_P!QCC \ >0X5=U36-
M,T/2|F^U" |33|/MP6FD09UA5!D_Y90EZD=:YCP; \ &_ "7@+5);|0-*_LV^G@- MLTWVN9_D+*
<89B0+*G60'/VQ/&5Y-%H^|@368W.J-|HNK2&.420EML "<95D: M3S21M(W)&3TIRERZG55KSP|+VD| =;?, ^B-
)US2_ \$%NUQI6KV.KQ*^QWL9UF5_M6P#RR_+R".GI3-= \ 1:5X9T|K06-2L|*M_P'GWTZO(#VZL,U \ X_6ZF^&/QJ \
M3?#N0R+83R%|**XN!*_F(" \ ,@ \ 0";Y+YL-*JMUT/4_ ^%K># , Y'0POYNS=YWVZ/9M_M_P" ^ZV-
" \ 1:5XFT|;01|2L|5M"Q'GV,ZRH3WZ,<5X' \ "0@7X(\8?##2-8UKP_MY|NU6Z,YDN/MUP,C|1)&.-

P[B0SU/[,VV: .UGCD:%CG[P7IG!QGT-:,UY#IT;75S(L5K" MIEG:3:L:QKR2SG[N"!7R-
K.C^!/" CKX3R_#:#^+K<:DL-W>17>^X.YHD!F7/ M[MV62;*
[_\$ UC+C&0.J\>Z]J'[/1/C^/P9X40E'@:S*_VS<1*%C=PQR!,>'7:H M6-2#EE9\;5W*HSOHTZ0\
\$SPYHW@V_P#\$\ .J6VKZ1IIVSW%K*
MMP3(V<(H'5B9\$4'LS"M;PUXDL0^AV6LZ;_QXWT2S1[FW,/X65F[LK*RD=BI MJE>^
="F\%W'A);:.*#1Y;4VJQ1Y)QOLE7))>16PQ;)RPR222:\7 _&+ _!)+ M>>#]8T
EG@TN>.:.%C/015FWY1\$_@7=\$S^[/2/Z5=>4>YU^VG&K"F_M'T3S1S M1S1S6R/30?4...:8!S1S1S1S0
_\@F? M_KM_[(M=36T=CW:~P(****HT"BBB@ HHHH **** "BBB@#A/C!\8?"/P3\6
M>M^,]:70=,N;M;.*Z:WDFW3,C.\$Q&K-DJC]NU>2/_P%!0@ (L+\$>/B%4[0] MB:@Q!VA@-OV?)X*G\;^E&
[5\R?MV_ \$^*TGP#HGPY\7%M!XN^)%^/#UBUX76 M&.!RB7+R\$1N"A65820#@7&]/FCJXV>EB)76J9[)X1^*?
A3QUX @\;Z)K\$1+ M-'--2N\$>UB\$43NLLC^:.*%ICD^9L 8R:\YT0]MGX(77BF3P_#\1=-C0\$EEA
M,DRR06:/N,A%W)&("/W;@,) -K^&#EA57XH_LGZ3XY^!0ACX2:5K=UX3*:5
M=VCWAMXE:74+>-6#I(%,:"625A,9"CCS4WE"37/_+7V0_#2^#>N_#0Z;9^
M)0\$RVR6V@>"M!@2ZU&T0!;F2UD2TC^>!847S"=H7RE90'WA&I14G8GF:5V>\ M>-
0B)X7^% AV760%FLVN@:;C;/M%ZY3S'P[>6@Y:1R\$=@BY8@=*Q_A'\=0 W MQPTN_0/ ?B*WUR&QE2"XS%+!-
\$S+N4M%(B,%90=KXVMM8 G:;^??'A06?AK MX5_9BUSQ5I- =>&/=JB^*-*@@?
4C9W"Z8\$A094B#1LMJ\4CM,,LA*F,,607 M-:3\ B!\>-L+Z3X;^' !L.CZGKT=@T)016:Y@:(..)7V0+*86AB+L
MR[-B!RJ;&I\J%SM'U5XG^-7A+PMXY\/^#[[5F3Q7KA!T_2;>VN+N:1,\R.L4 M;"),!0GDPH578G"-7>VK%G>
(-00-8^*0C] M+RW\;>*E*0:/J\$:&3P]I@FE:WL8V4 KE&5G)"DD#<@<.6^@K;_T[@H\N_L_)@MG<.%
[C(R#^'\Z^*=;:S^% \ P400_ \$?C_4K+3]"U MCPLR>\$]2UC(M;*:;-,>.6&*5QY<+86Y8A67BZP23,H-
QBFR)2Y3Z;^#GQT\#? M'#2]00/!'B.'Q!#8S+%=;8I(9(69=R[HY55PIYVMC!VL 25;%CXL?&3P5\&M
M'BU'QIXCL]"MYMP@BF)>>XP45A% @,DI'F+G8K;0V3Q7S?%KGASXD?MP>\$M; M^%H.K+H>FW+:V
M;+U_XN:0JLVLE>6\$6GZ1IMS &AT:(0HLHC=BQW,ZRME/+ %Q*"K;RU4XI.Y M*DV;/PM_:(^'/QL6[3P5XOL-
+FA5C)9KNBF51MW2^3(JNR?0%'F_%"3C.0:S M?BC^U\ "SX0ZNN^*0&-E8:DP+/80QS7< \
(PK!I(X(W:%CYB[0X!/?/RYP<= M/^+ [C1S_ ,%#0A];^%K)T\1Z/>0XNN=-?Y);5[8BTCNPK'E)!&V9%5B);;:
M;"80K7XK>#_V;_ \$G00TGX0V%X]UXEUZZU"QNI-(ENH/\$&F-;1&*P2>1?+D\A
M'\EXY'2*/S@BG;DA\L6+G9]C:~JUIK6DV5_97D%U8WD<^%_QB*?%S^W'*:M_;<.DW9L;J[M]>860G+D%
(IV01S8Q6; M-K(W =,_'?P]USQKX1_9]&?P T.RUS1/BGXFMY[^U" '&#^'- 'FU"9V0IF M(
\PQ/L\$8*.&)9) B0]H?"_P%HWPP\ \$Z/X6T"'/I.EVR6L\$?EJA;+G,C!0 M
7=MSLV!N9BW4DF^Q497T.NHHHJ#0**** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH ****
\$:N\$^,'QB\(_!7P[;:WXSUI=!TVYNUL8KIH))MMTS([A,1JS
E8W[=J[RFM2ND]A'S4W_!0;X"+ "Q'C_ "J=FW^Q=08@[00-OV? M)X*G\;]E\ "?\$+P]\4_!^G^)?"]VVHZ)?
>9]FNEY(0,"2M&QVN%8?.C=0,@& M0%/V[0B)? :3\ /] \$^' /AZXMX?%WQ(00X>L60"RPQP.42Y>0B-
P4*RK"5X<"XW MI\T==XS_9[M-0_9QN?A!X7UB7P?I_V"&QCU.*\$2RE%='G,L<;1;VG59EDVD M;_ -D8->
(.UM+F;0T,[5/VV?@C:~*() E^ (NFR7CR00B2%)I;-7DVF,F[CC,(M'SH"WF;5.6IAMH2KR7\$D MRG\$B
8E!;Y2,CQ+20A/XUT']A0X2:9JGAK5+Q]!\1VFL^(0"4NE<^E0A/^TW\ -C3JE]IW@SQ)'JU]
M9Q"XFM6MY[6;RR<%U26--&&#MSC*D_??/0? \$XP>%?A.NC+XGUA;*[U>\%C M86E0!+)]'P3H6II"\$L=.98Q)J
.TD37)5N0_1'E0\L;1,\$XZ7^70^F MK+&U\,#@@0?NG XQV_(59JM9QJFXH<(0/DQC;W_) \$<=@!5FLS4****
"BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HI\+ABO/;' /MS M GBI:* /GS70VY?
@CX0\0:KHFI^-1:;EIEW-8W4"Z9?2>7-(T+M.\+^%_IU37;\R?9K9=-NX]Q2-Y&.Z2\$*,*C'D]JJJN
MV55#,54+D[G('X]0K7R-^S7_&]GA0-%TF4>\$/'T8C1I((419) M[ILQ!U:03*4(;>JS3(X(
QI%)Q;_I73W/JG5M4L]!TZZU& N(M.L;2)YI[B= MQ'%#\$@):1G;@!5!8GL<\5R0PS^,7ACXP:0=6\)WMY?
Z/A7C0I--NK:&4Y<% M8I)8U2; !C=6\$9;85PV"17R[^VE^T1H-YXJC^#T7B>;P08I/!<^,16#B.2/37 M
W65M'L>6:642HWR1LFE6)C\ [R0? V<_ ' PM\8>_QH PH0;*;PYH&VP;3[> M"6![:< PW1RHLLAW
D^:P.]@Y)+!J.2R3'S= ^*7[4GPL^#^L#20%7C&SL=3(M.^PAAFNIH0
I!=8(W;_GS%VA\;CG;G!QZ9I^K6NMZ39W]E=P75C>1Q50W-G, M)HIHW
*E' '#*P/!'J,5\88GV",%'#\$@LD@17KD1/.78GP0^,/A3XN'6 MW*:M_4.DW1L;JZM[>86HF7(9(IV18YL8SF-
F^5D;@.N>ZKD0A;X!T;X7^" M-(\+>'X/LVDZ5;)_P1^6B@N09&@" NYRS-CYF8MU))ZVLGN:1=T%%(H**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,7=4M-\$T
MNZU" ^N;>RLK6%YY[B[F\$,44:C+,[GA5 &23P!7A_@W]M3X->/?\$VE>'&\:6
MT^K;G.M09V]U8WELLSG)QYDT*J')4@*QR7VH/F89Y;_@I-X5\1>*/V:KM_#T
MTH32]0@U+4[:)G_TBS3<'#*H*LL;0',=^ HA+Y!0&N;_&DOB[\#?&/[.,^@ M:?'
Z/XGNK^W@M/'^@&T66^MKYHPMDRVT9\$D C/EAE*K\N(BK;_*;:,9+S, MG*SL?6>H:M;Z'IU]?;A%]!\-
HLM];7S1A;)EMHR)(! M&?+*#57Y<1%6W^4S5-:;+SL3SZV/IQQ0\1?#7P0T";6?%VM6F@Z:K>?>3\$;Y M-K-
Y<8^](VV-B\$0;CM)QP:R/A'\=0 WQPTN_0/ ?B*WUR&QE2"XS%+!-\$S+N M4M%(B,%90=KXVMM8
G:;\&^)6F^(0!VA_LU>*0&UCJ>JZ#X-B#^+;/RY=4F@_M0/[-"IJ\$Z*9%=;:5)7:CL&A.H:LUS
T4<20M>64P0#\$79EV;\$#E4V-4\B#VC1]5>) _C5X2\+>, M?#_@^U9D\5ZX0=/TFWMKB[FD3/,CK%&PB3
+YY,*%5V)PC5WMJQ9W.#LP-K M?F,>N1CG/K];\ _9N^'GB#4+S6/BKX_2\M_&WBI2D&CZA&AD\/:8)I6M[&-E M
*Y1E9R0I) W(' #E0H*VSM.X*')R=0Z?IBHDK/0TC^Y-1114EA1110 4444 M%!!1110 4444 %%% !1110
4444 %%% !1110!7NF*KD-AMIP,9S^> M0G2'_@H1\ ?
FOX\R/[W]CZACITR(, '\#7TDPS6)X0\1:=X/T&^US5[DVFEZ= M;2W=U*(V?;%&A=VPH+-M4,VU02<'
_*I6ZDN< \X^&? [4WPP^ -F03Z'X,\2? MVUJ,%LUW-"VGW406\$.B%BTL:*1EU^7)/. <84XJ?
\$?]K3X4_"/Q9_PC/BCQ=# MI^NK"+B6SBMKF[: (,"R^8T4;*AVC=M8AMI4X"D&0,OV-]'U/QSI/CGX]W=E9
M70C+QU>7"Z=:RRHL=G8VSM!#:&=(\9)@59& =6\$,+ [2X(-7_@G#J7A35_@I M?W^FWMM=>-
[04+BX\57,DC0>S20+,U0+/0&YMT>,,AF\YB3(9:TY?T(YI:(M^E_! ?C/1?B-X5TSQ)X>0X-7T74X5FM+VT!
(D7=@@Y_9&! # (V&4AU(RIQP-C M^UU\(-<^ (%GX,T[Q[I6H: _>3QV\\$,6^2VE=U\$BJETJ&!F*D
.+ /VI_#7P>UFUTSP[<16G_"/M87DRZ?9W]Q9W"2S0%.(E^T*&W0_P

MI'L^01UYSX\^(^A70Q^R=X9^!&@^\$=47XNR1I]F0A*XT-K:XL;M626YNW,BI
M%&81/(90V2MR6?"M(RCA9V!29^@'BSQEH_P^\,ZKX@2:C'I&CZ=;FZNYR M6\$8'&,\$L21M557+@\$@%B
:'@70A10C(PQI^0Z//)=5J\$*W%K<26\D/G1G. MV0+(JMM8?,K;<,"""00:~;?;\$-Z_[6'QOD\)\V":I\,0
>H(0\$G)X9\7:7IOAZ?{1"!S^7- MGIGDS\X@++^\SR'[8R,U[-\? ACJ007\%VFD:5-8V\L.H)=/+?.RJJ5*5.-
J MLW60=-; /P?&ZAX!^'.C: 'JL7&IR7USY+7-[J5U;TT0PC<7\$TT]SI\;QWLB0!)HSIN-*@
M0=ZF9^Q'TD6+Y@J2,)@Y"GIN"(>@Z5%\! ^3H/B)_W\$ \ MT0200?V??
@SJGPDN0\$JW]W875IJAA&GS608\$A3,=SJ1\F=PRH9L'/^ 7-;Y\ M ?'.A_\$+7?%7@+Q+9:;VJK-+-J6Z0-9Z?
J0S;MMME(8;EW#?0;9N&[9B08_B%\%/\$GC3XM>\$%(0)+FT
MW3([5;K.Z%W:.=I',2C>NTE0XG-Q.K)\:/@B0Q.N++Q!I-])HWBC3HP(;B1F>
M,H0S0[F\>P>7]S#\$B9VY.5;C%.+8I8:M4C-ZI"/C+2-;TK4[MSP=I6C:GI>]5NM-N+=9?F?4+
[-*I60^A4E>I^]79Z3\+ BYJ6M:=<=>) _B1]EL[7;+&VCP0' MYK&2,E9(+C:7Y)?]8L@&?\
5D;LZ'Q*^""M^,/C/X4\56NHV,=CI/V9+@7/ MFBYD>*X>;%ER.26M[GGW[;U0']J]*79AA^TR)=PM
M<+'MD=%:,JI_V SN5_WVKK_VS \ DF6G?}AF'_T3/6C^T7\&=9^+W_"/HUY M:VYTX3^?}LDD5I!
(80N;4;IL/7;U'7MU7Q\^W "V/!Q75;V2TN8YA/;R%;T M,DVQE*0\K-
MVN<+QUP=N# 'LV[JVYV3P]2UGRT=0R0[PKHW_D?P#T;2/M' MV1=0\ -0VC7#1>8J*]KMR1D'J1R",?
WA7SWX>N/B'^S=I= INM>%/[<\(75W, MLL>%EBD.'!&,J@%E M-;VXE>U<1LD9&Y\$S&JX^0ARYPP=
&+\A%K_XA6MUX?GF-I+/* M2;MHS(2V[,18M@OE#)M* +0VUC M4I2KX5Q;N['Q[I6L/\ M0Y9.-
09 &;\;* VD?"WC1Y,6&I[&NI)_WJJ!']GNL;1Y@ (MRK\@_> W1VG[
M/OP!U3X5^(M4U;6;NWO+RXM5@LWM7D9=A?< FAD7'^K7&"> 30T0Q^~^#?%0
MP3!;Z;)9P;G9WGVBY\$^1U9B)8RX5F52&#*\V6B3CC(YW\N-[GCK!U/JKG;W M\H=- 9/LQXV^)GC#QK?
+;M>KF01PVK; (I+IW=I=OF4*JR1C/4.07&3=^/"J M0[3WP\LR-&KZ1U9N3T', \$KX,ZSXR^
/A30797>GVVE;6MH'6?S/M#F* M=IOEVHW3W(ZCKVJ*?+8Z?JM2,&A\K5N[,W]L[DE^F_I AJ' _-\$SUT[!&_9;
MB\ P2!1X1!WQ>4_8SBM+XU?"]/BW\..D)>R6ETD@N+;23_5R2!77;)\K-MVN
M_1>.N#MP>7\)_#;XDVOP_P#\$WAG7];TK5+>XT=M.TR&)&=@0NB@.\$1E0+MZ
MB3/+&#&T=HE^XK\$W!./PQ7K7P""&>J?"WPC?Z/JES;W,\ ^I M2W4<^G3L;
<*8XT4\$E5R08VZ+6#^SI%\];^\$7 "0-K%W9W)U+[/Y*VKR,R+&9 M?0;D7^^,8)Z'IW(TW\$BGA7&M1E;;<];U?
4[70])0=2U"X-08V<#SSLF[/EH- M[D]?FP\$5FX[A: ^)?A? \ &;1/#_Q-UKQ5XR6Z0-00-TD,%E\$K-&LK;MR-+
(C! M0@L#/*,W(Q@_4_QP'\:YX^^'EWH>A3;;;S7,L;3RZGNVK\$F9/DPK_.72->5 M/RL^#"BIO@Y\-\A
A4 @BUT)YDN+W<9fN6/=L:1L8V98 (\$*"N 0" \C.:J5Y M^ZSHQ5&0B,3"&T?J?%5Y\5-#MOVAK?QOI,-
U;Z6]Q'->17=M' P\$G[NX(5'; MA@SL200S, '<^B?M0?NG\#F>' [0%-TXB;[K./LY&?^ UZ? \ ' X/S_%KPY9)
MI\]I9ZMI\Q>&X0=WE-&X&^)L9ZE48E[9KA_B'^SYXN\;>!/ VCG4=)34 M/#D-09W/E0,L8DB,>\$/(6*)"V00S,
<9&,'LVDXH\Z>'K4X5(?=%Z#_-L# M1[33?A5X>%0IT:R6.I)';, .L"&&0-L^I7GZ"K/C[P!;^,0V8]
N;1>H':NO*Z:G@_P7I^AJES;DZ5I<4%VTL["WC,<["W)*KA
M">1Q24;MW.M86[646K)Q/D#6/B;=> // @GX)\\$6,C7>057SZ?+'YJPJZQ&-(\$ M9-W,
<@ECP7(>0[@#M./L;PMX/N[!1@LY "[F.7. M!R7+9.Z0F#]EKP;:ZY\2M<^6Z?
8/8Z!ILTD.FK,C;P\C,8T5QGG0Y?0"0EOX\$? \)SWQ% [B M7_IQBKZBR%)+%EP#ADZC_/T->-?#7X,ZSX-^
/B007>W>GW.E:HMV\$6\$S/M" M&6=90FW(07V)Z'IWTFVWH;XRG*I.\$DMF=[\50^29^,?^P+> ^D\E?)'[-P7
MT?X0-KPU6;5(FT)(1%_9DBJQ\$HE#;LOM_=7'30UK[(\;:/=^)0!GB/2X#B\0 MK2XMXVNGVH!*C(-W_?ST-
?.W@CX_%0X;B^&@>*?#NF; "GG*NZ4-LSM_P!9 M;G&-S=#WY[5C* .I/H< .HREB;;Y;KT/UGN6N%
MM!]S;BBC!V(0!,0ZYZ"OE+ A;VC:A^T5-XQUF> \U72K&9UL8K;V6=P(QM@9E MD=>I(F) ;]Z3D=" ;H?_P
7]0T/Q%IOB#QIH.JP;CILME;QB+'I+(51G(2W M3=B)I@%+=2#M; '&Y^S']\ 'Y/A)X9NXKXP2:S?
RK)/);EB@B48C0\$XW8)D);:0 M+.,<540?T" I"IB)PI4URQ30\SYG^+708T+QA\2-\$\9>\$H;NVN[5HVEB08HUR
M\3;XW9DD=B<84#LL: '=4L8FD@0-0M[F-EW>6JM;W#C^ M('IC[P/MWKT0XQ_#,%?CP/=;\$DR6]
[D3VDF[8LJ]=&'R%"ZMD-PW_SBO+- M2^ /C#6/@/I7@VX0=-!-[I^I?;(9X?,\$30LCD>8PC!#B6=EX0?
*J9).:S<910 M%;W,)X>M#VL7KS(YWX0?LR^%_B)\.=)\0:EJ.M17%[),/+LY(50E+B2/C,1/
M\ 'K7T]H.BP>&]L=)M"[6UC;Q6R-,^Z0^7&D?S?]\>@KP+PM)*0C7X,T:TTK M1?
%GAFVL;995CCV>8F69W)W/9ECAV]>]>0\ PSTWQ;I6@3V_C#5;/6M1%ROA M0+*-51H=B8'")T?S.U:00U,=
QY(Q3C9V/"0VW0!7X. [??_ &A7T]?6M0?0 MW-01Q;E6\$FTJI(PWEL>0,(6_AKI_AWXZ00B#\&;#6=
D@G\008+;R)J3[M(DNHP%E,@B+\$+0!88)#)RI<,IM)L4%[/%55+6Z7_# 'D0Q,TOPO\=-0B*_#
M#25;X@:K*L?FV\KSW%E_RL"%G=]T\$A#'\$&,(225RC#.\.VOBW00&5W\+0AAX M@L[0Z+;_&N]U>
[8.]]='RP\@S',\$\$;NJA%_U&#,YZ^0 "7X0W0@_5-2\4^ M*=1360^IN()+D2N\=K\$&5RBH53+,57)*J%"H_N
"<+X@?!_QA_PL*?QEX"U MZQTW5=2A2W0(-2A\$F,! 1&PBD#A'R&_!@'D@SRMNYR5,+5_CJ/0/9=D;OP
M!^%S\2/#^J66N0]B\0;/.+&\9HF1=Y0(K," *Y*3!HP?E*\$X7=M' _LVWT. MJ?;\$XNWM0-]H@GU2-
XY5^ZRF2Y/'XDUO^#?"NG?LU_"/6-IN@;B]\$0;Z;-2 MHFN"%BBB4A=QB+MM4MN!+.0JY(7(_8)*C2?AI-
KCM&]QK=R9_RSM(?*B'E@ M\$'I^\\$S=3][KV?;3]'1351U:2GNKGN_-'-'-'-'-'=*/>6BL_-'-'-'-'
8GX]>: ^+/V=2W[M3/[47C'XV7!\SPQX<+&/'@VE/,PC&27DQNC0&EW "1DQ-(CJ&(^7.W(#\$J5(!%#X2#70?
@_ M\ /M'\ (^&8Y\$T?3(VCC,TF^1V9V>1W.-S.SL0 "< 4I6)<;G-_%SX\^&_M_@B?
#!\1P7D%MKN1I2YG=D2%R2=QW\$*Y56"OM\Y; "^^WPP MUSX/^._%7B7P_I,.L6>FS7D&M[5MKE[Q;=X+7?
<(5:4Y,2)\$08%0&UL(![1 M\5/A;X5^,7AC_A'?&CV^MZ2TR3BWG+*4=3PZ.A5T8_D95@<,P.59@?" +7]@
M/P3<6NE;;XE\;?\$'QEX7TME-0XW6FH6F^TF8W%ON(MIGI_##X80?7GABWL[Y]_BW6K6?'[P/+ "0TQ\1/
 \ /Q(\ "ZUX5NM2U'2+76+8V-Q/IHB\$ZQ MN_LBH9(W493*DA<@ \$E2K;6%SPEX/T;X>^%;#0?
#]A#I6BV">7!;0J2BC)8L< MG)8L68LQ)))+\$GFFI).X+K.[M/F/-
<7212VCP%VA"1),T!10JGR=NW8S1']'+?.6)()./NGC\!750=?L3>;S
MQ197UQ/X@G\,:=J0U6T\#2ZGGP;W/S-OCM"OR#?([F,\$+\ICRV:, _0MGN#
M2!B.,8&TKU).>I]>0J#^! *2:N4HV+5%+%8K8L****8!1110_4444 %%% !1 M110_4444 %%% !1110_4444
 %%% %>[R_K_2'9E_DQSC'??&/A?0;#X^?M ME_%'S^)E0#?'P3;VOACPGJ5Q!9,S7H@P1*3^Y%=0-G?2
M((Y(S'(VUE;*R8WE=Y557(4\$&XR29G--K0\8^+WA>V^ / [4/P4E^>@MHG_" M8:GYD#;0HW4UR;[3-

6@A>17&!%&WD;UC5&"JN()_FQG&+:VP%\$<*!44\$*"P1FZ+;-BXU.^E<)!;0 @EF).3M#,\$1V" MMM(K@_#?
{)I\.^(M+U4?&/XKZE'87D5U_9FJ>)1-;7!B<-LE7R071@H:4GH> MHKN?%7P/T+0Q\2?%7C'Q")=4N?#,<@T?
3Y@ALX+B4H6NMNW>90\$51N9D3:K(M%<;AGI>Z+Z6/E6 ^'/B309/!NC>-IK01=
<^, _B22Z\=ZE'J+:/PP0H[VN@)(M&!43HXMU*2[L(R:I\$"J.]^#7@?3 _(\$?M=ZQ\._!UU=V'@C5/!X\3GPY/<-
< M0P7H05M0.A:1F=0R(20"3D@\$X5%7Z!^(WPUTGXL>%SHVNWQW\$9\$J75G>6*=7*B[1^)[MH7FHM"
(T1(1%4*@\$:_PY._,X50M.2L2H6=SV*V #-MZ\$*?0\$ _Y[,?C9<'S/# M'APGPSX4&TI0PI+R\F-
^8I'E\N:)A I^ Q\F0H_XT_&C0_@3\K0Q?X@T_5; MG3+9XX&32;432;I'"@DDJL:@DY>1D7@ \$LR*VY\)?
AGH/P@^'^C^\$?#,%[_P]XBT^'5=\$U")H M;JSF'\$JD< \$\$\$6#;65E(9652"" 0Y2Y68(JRL<'10A?
|*0B|X9.M>,-(T'7 M|)+E',N0S-\$CI:1MYX=+M""D6,N2KJI5V|'%'>8 _\$[=9\3ZS^R_H,GB1S/!; MW5S;:5>*
|_%KFS1B_9=SNR;9?.C4#;M2&,!0 -SD_8'\\$II8T5/&7CP>"C<:_ M8 _"%OX@9=)C4S _!&(U3?M+|(C)N.
<{MW}^@=-*6F@^'|;PSH33:'965BNF MV#6I\$SVL<6Y8K(? ML'X/_"/PU\$?A_IGA7PG:20:7 H=II6#7%Y,5
_!S;1N=L#) 4!0H55 _? M\$#|CGP;\00\$&I7E? 00%?>+0@|X(US4KE;R_U+0M/0+BX6,)YDTEM&\C855 MRQ/
4 >W0=W69X=TRVT72X;"SM8;"TMD2&&RMD58K=%4*L:10 % _' P M!BM.LG0H:A1112&%%!!1110 4444 %%%
!1110 4444 %%% !1110 44 M44 %%%5KW<5 5268\$#;C/_UX_P#U=#0!|T M?;\$_40" _PUTSP+X:3|1XN^(%
MU_8=E;|E3,#0&EP=TBf/YA*D/S%2/M&|6'EF07/@S|+;/X) "WP|X-TMTN+?
M2;=8FF;>JW%PS%YYPK,Y3S)7D?9N(7=@=*RM2^".DZI\9-/)>JZUK%|K&E6
MDMOHV67%XD>GZ:9\$,Q'7Z\$=:_OF|VQ'+JW<^5_P|C3P|X;|XB?'W6H|:PD\6IX|U.RGF_W7<=B)0\
M*,N28T:42G<-^P==@QC>(0#MX=P""D7@%#.GS:8^H>&R|\0PZ=9'&UE M1WNS'/<21G,C0<>7N\U_ZP\$
|_|\OK?Q,95\._?;\$;QQ'XRM|9\2> _\$|6AT^ M|U3P=J?V">^BXVK<,%/F;2JX8\D;01|B;=+X-?LT^#?@=?
7VI:1!>:MXCU0R M'40%&M7|N=0N|T|3,='550"S')15#;\$W|R :T(Y+KQWJ<>HN|K%!"C0:Z
D@8%1,CBW4I+NPC(&D0^H^J0%GP M1\|>./B1X9\8:Z9|5N_#;4G|E;|<+|DMKF5E+76
FYY<1H!N9E3:&558|JU M/B)\--(^+/A=M%UZ*XC _'J7-I>6.?|7|FCPU\='4UG6K;4|;\5>*= M7VB|1>|
|H7FHM"(T185E"J%0"->V3C&2%4|+|;|MI+ |B)|5T_PQ\|_#|/H3>& !OBSQ)!H_B/Q%;WL5N|M;ORT|WJ<+
(GFLTf M0H\$!1PR2D58^_7|_GPS|+ !3Q'JNB>!K#1|7|+;/<:EH^IZ.QL|0BN;:WD>&
M7|5&5D=@P#S7(90ELD GV_XJ "WPK|8?#'_ C0C'1X-;TAIDG^SS,R%)\$/_ M#HZ%71@PRK
X9@,0#>F.GV;PSK^0"73EV* MRQ|(XXXFC;:-A"CIM"KGYX|XZ^)WC3Q)^R3|!;+Q/>WGAG
M1/&NJV^B^)^0%"W@MI0L =TB9C<;VQ=6Z&X>8ML(1MVY)R*|N^_7|_GPS|+!
M3Q'JNB>!K#1|7|+;/<:EH^IZ.QL|0BN;:WD>&7|5&5D=@P#S7.YQELD GU_MQS|_% !?Q&\#VW@|Q%X;T^|1-
VX@%0IL<".V\H)Y7EE6B"K\HV?E)4_*Q! M\43|@;P9)8Z7I0B'QKX^|9>&M,=/LWAG7|>\$NG+L5ECV100Q-
&8T;""3:~7 M.Y_G<7*[W._|9+|4:_XR_9R\ ZSXF66/5|JPV+/_YH>YB25HX;A0,9
MF8S1)%*7)^8R;E/SUY%JNNZ0^T7X^U'Q|;^'K040AA\,70KSPQ;V=|^_Q;K5
MN1MGC6(. '@C:&2.*13RSX >|Y85^D0&WPST_Q=|-+P-%/X:T:~L%TH#08H
M8G@MBH0Q1*|;JB>7E.%RJDE2K|2-+PEX/T;X>^%;#0?#|A#I6BV">7!;0J2B
MC)8L:XNDBEM'@+M"\$B29H"BA5/D|=NQFB/Z.6^Z_8F M\ WGBBROKB?Q!|X8T|4AJMIX&EU//A^WN?F;?':%?
D&^1W,8(7YW3^ELT9^A M;|<&D#\$<8P-I7J2<|3Z|?4'\^4DU-+E+S5Y_*#_9--B+R%RC8#;FAFD^1U8_9-
@SYG^V M'^L0JA"OF?P@C)/;I^/7G&0Q0QH%C =R22JA!ECS@GFOD|]MOX;?|KPSX>N_\$M_P"-*U|XCZZ
MZV.A:3:7-W9R:U>23\$DF.T9?=-6FW-)PS%E0NA9#7V-Y08J57RR1DMM |?SY M.<5Y/JW|_?A#09\;M/_B?
K)0-8UK2K9+/3-/0?+-G8%"2CH@C#LZLTK!I6? M:9=R|=L>RE)I|Q+C=6,3|CG|6F|/G?X3QZ?.\$;Q3K#1W^L3-
B|)S&H^A64L_M72(|@-SMEC(XPL@_B_:3^*^B408?"WX<6GV\$X@^++68"|_R|2:%8X"27|S|)|
M\1&\$6,9<9!+*L,Y'-'<+X^""0A_P7|0/%7C MA5N-5\6^)|5^U:0?>4TT<"JB16T6Q\$58E6)#C!9BH+LQ5<'--
K=ARZ6/F0P|_M!_! BWXKWOP3\0V|Y PKOX?%;7&C>&_4)H)=6N|N22XUCS(VB=EC9FM_D M#(KSN|Y?
*5ZC^P|<7UGX'\;^%KG6+W6K#PAXPU#P|IR^+G|/^C?%C5+61K/B#P;XDLX_L8\0>%=0^P7TELS|S:N^
M&5XC(\$D"LI*L,J1N<'H/@0\ _"/PW|\$? MEX5|*V;6^F0_2/--M,UU,0 _|TK* M|N=MH.<
_54*BJJU*2L*,>4|P=Z6FK3J06QH%%%, HHHH **** "BBB@_H_MHHH **** \$|BHY?|7^?|JD|BHY?|7^?|J
ZGE_C#/_ "1W0U7_P!_6L;FMGQA MG_A(|WZK_P"@+6-S7+/XF>+/XF'-'-'-'-6AE;4.;.:.:.:>HV@YHYHYHYH
ML)*V@IYY/4G)/)-:.'-#5R)4XN2FUK M:PZ3K\$,=QIMW^YUB41016X_C6-0_N_.N|T_P|P!40-'-%B.17N'-
'-'-M-4;!S1S1S1S0 _\)G_.NW_LBUU-Y3^!|1115&H4444 % M% !1110 4444 %%% !1110 4444 %%%
%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 % M% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444)W M%1S9\L^F#4G<5'+_*Q_P"5
=3S0Q5':R;Y<^=++\$P*_P"K16S|B|;:0KKL70L|A_S|77 _'YC_P#BZ/L|A_S| M77 ?F/\ ^+JCS1S0&G80?
9|_#_GZNO^_,?_Q='V>P_P"?JZ_|Q _!>4>.: M T|[%|/8?|_5U_WYC _|BZ/L|A_S|77_
'YC_P#BZH\TP_Y^KK_M+_Q_P#Q='V>P_Y^KK_OS' |75'FCF@-.Q>^SV' _#|77 ?F/_XNC|/8?|_5
MU_WYC _|BZH\TP_Y^KK_OS'_P#T?9|_#_GZNO\ OS' _/%U1YHY MH#3L70L|A_S|77 ?F/\ ^+H^SV'
#|77 ?F/_XNJ/-'-: =B|]GL/_GZNO_M^_,?_P_71|GL/^?JZ_|Q _|Q=4>.: T|[%|/8?|_5U_P|^8 _|
XNC|/8?|_M_5U_WYC _|BZH\TP_Y^KK_OS' |71|GL/_GZNO^_,?_P_75'FC MF@-.Q>^SV'/_U=?|^8_
(NC|/8?|_5U_P|^8 _|XNJ/-'-: =B|]GL/^?JZ_M_P",?|_71|GL/^?JZ_|Q _%U1YHYH#3L70L|A_P
_5U_WYC ^+H^SV'/_MU=?|^8 (NJ/-'-: =B|]GL/^?JZ_|Q _|Q='V>P_Y^KK _+Q_P#Q=4>: M.: T|%
|/8?|_5U_WYC _|BZ/L|A_P_5U_WYC ^+JCS1S0&G80?9|_# _)^K MK_OS' _|T?9|_#_GZNO^_,?
_75'FCF@-.Q>^SV'/_U=?|_?F/_ _+H^SV' M/_U=?|^8_P#XNJ/-'-: =B|]GL/^?JZ_|Q _%T?9|_#_
)^KK_OS' _|U1Y_MHYH#3L70L|A_S|77 ?F/_P"+H^SV'/_U=?|_?F/_ _+JCS1S0&G80?9|_#_GZ_MN0\ OS'
/_T?9|_#_GZNO^_,?_Q=4>.: T|[%|/8?|/_U=?|^8_BZ/L|A_MS|77 ?F/_P"+JCS1S0&G80?9|_#_GZNO^_,?
_71|GL/^?JZ_P",?|_75' MFCF@-.Q>^SV'/_U=?|^8_P#XNC|/8?|/_U=?|^8_BZH\TP_P"? MJZ_|Q_
!>='V>P_Y^KK_OS'_P#U1YHYH#3L70L|A_S|77 _'YC_P#BZ/L| MA_S|77 ?F/\ ^+JCS1S0&G80?

9[#_GZNO^,?_Q='V>P_P"?JZ[\Q_! =4 M>.: T[%[/8? \ 5U_WYC \ BZ/LIA_S177 'YC_P#BZH\TP_Y
M^KK_+ \Q_P#Q='V>P_Y^KK_0S' \75'FCF@-.Q>^SV' #177 ?F/ XNC[/8 M? \ 5U_WYC \
BZH\TP_Y^KK_0S' P#?T?9[#_GZNO\ 0S' /%U_M1YHYH#3L70LIA_S177 ?F/ \ ^+H^SV' #177 ?F/ XNJ/-
'- :=B]]GL/ \ MGZNO^,?_P_71]GL/^?JZ[\Q \ Q=4>.: T[%[/8? \ 5U_P!^8 \ XNC[M/8? \ 5U_WYC
/BZH\TP_Y^KK_0S' \71]GL/ \ GZNO^,?_P_7 M5'FCF@-.Q>^SV' /U=?]^8 (NC[/8? \ 5U_P!^8 \
XNJ/-'- :=B]]GL/ M^?JZ_P" ,? \ 71]GL/^?JZ[\Q %U1YHYH#3L70LIA_P_5U_WYC ^+H^S
MV' /U=?]^8 (NJ/-'- :=B]]GL/^?JZ[\Q \ Q='V>P_Y^KK_+ \Q_P#Q_M=4>.: T[%[/8? \ 5U_WYC
/BZ/LIA_P_5U_WYC ^+JCS1S0&G80?9[#_M)^KK_0S' \ %T?9[#_GZNO^,? ,75'FCF@-.Q>^SV' /U=?]
?F/ ,+H_M^SV' /U=?]^8_P#XNJ/-'- :=B]]GL/^?JZ[\Q %T?9[#_)^KK_0S' \
M%U1YHYH#3L70LIA_S177 ?F/ P'+H^SV' /U=? \ ?F/ ,+JCS1S0&G80?9[M#_GZNO\ 0S' /%T?
9[#_GZNO^,?_Q=4>.: T[%[/8? \ /U=?]^8 BZ/ MLIA_S177 ?F/ P'+JCS1S0&G80?9[#_GZNO^,?
 ,71]GL/^?JZ_P" ,? \ M\75'FCF@-.Q>^SV' /U=?]^8_P#XNC[/8? \ /U=?]^8 BZH\TP_M_P'?JZ[\Q
 !='V>P_Y^KK_0S' P#%U1YHYH#3L70LIA_S177 'YC_P#B_MZ/LIA_S177 ?F/ \ ^+JCS1S0&G80?
9[#_G[N0^,?_Q=(T-@L;C[7= M_P#0U2YH/^K;Z'^1H\$Y*ZT.) \)O-%ID@TY%ND\YMON)/)(X'0(K_*XK7^T:
MXI/^@Z>1 M7TG_QFJ'P]_P'03/ \ 1=0 &1:ZFMH['L4_A1B :M< P'?#3? M /D_P#C-'VK7/ \ GPTW_P
#Y/ \ XS6U15&AB :M< Y|-- \#Y/ (S1]JUS_M_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3?
^3_P",UM44_M_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/_M
(S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3?
^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|_M-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5%
&+J]JUS_GPTW_P/D \ C-'VK7/^ M?#3? ^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6U10!
MB :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ MC-'VK7/^?#3? ^3_P",UM44
80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/_M (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5%
&+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|_M-- \#Y/
(S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+ M]JUS_GPTW_P/D \ C-'VK7/^?#3?
^3_P",UM44_80VK7/^?#3? ^3_P",MT?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/
(S1]JUS_GPTW_P/D \ MC-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3? M
^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5%
&+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80V_MK7/^?#3? ^3_P",T?:M< Y|-- \#Y/
(S6U10!B :M< Y|-- \#Y/ (S1 M]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3?
^3_P",MUM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/
(S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3? M ^3_P",UM44_80VK7/^?#3?
^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5%
&+J]JUS_GPTW_P/D \ C-'V_MK7/^?#3? ^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6
MU10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/ MD \ C-'VK7/^?#3?
^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/
(S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_M_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3?
^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5 M%
&+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/
(S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/ MD \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3?
^3_P",UM44_80VK7/^ M?#3? ^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1]JUS
M_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_M_80VK7/^?#3?
^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/_M (S1]JUS_GPTW_P/D \ C-;5%
&+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/
(S6U10!B :M< Y|_M-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^ M?#3?
^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6U10! MB :M< Y|-- \#Y/
(S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ MC-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3?
^3_P",T?:M< Y|-- \#Y/_M (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPT
MW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|_M-- \#Y/ (S6U10!B :M< Y|
-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+ M]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?
#3? ^3_P",MT?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ MC-;5%
&+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3? M ^3_P",T?:M< Y|-- \#Y/
(S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3?
^3_P",UM44_80V_MK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1
M]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",MUM44_80VK7/^?#3?
^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5%
&+J]JUS_GPTW_P/D \ C-'VK7/^?#3? M ^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/
(S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/D \ C-'V_MK7/^?#3?
^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6 MU10!B :M< Y|-- \#Y/
(S1]JUS_GPTW_P/D \ C-;5% &+J]JUS_GPTW_P/ MD \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3?
^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5% &+J]JUS
M_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/
(S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/D \ C-;5 M% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3?
^3_P",UM44_80VK7/^?#3? ^3_P",T?:M< Y|-- \#Y/ (S6U10!B :M< Y|-- \#Y/ (S1]JUS_GPTW_P/
MD \ C-;5% &+J]JUS_GPTW_P/D \ C-'VK7/^?#3? ^3_P",UM44_80VK7/^ M?#3?
^3_P",U=TV: ^E[S[;!;080L^SSM+GKG.47';UJ[10_4444)W%1R_Z MO\ Y5)W%1R_ZO\ Y4!U/+ &&?^\$C0?
JO_H"UC_5? \$!;ON:Y_M9_\$S09_\$PYHYHYHYIK8@.:.:.:8!S1S1S1S0_B_#W_D\$S_]=0\ V1:ZFN6^0\
R'9^NW_M+(M=36T=CW: ?P(****HT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@

HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH ****
"BBB@!.XJ.7_5_G *I.XJ.7_5_G *@.IY?XPS_P MD=[15 \ 0%K&YK9\89_X2.]^J \ H"UCO-)?VS !I9F-
IX@281JXDGBB*#N M?>V3]_H#GV-1SI:,X*F+HTYN\$16:5SWGFCFN;\\$ \$3PU\0K.:;PWJ*WL=LP M6:-
HGADB+/(WQNJL,X/)&#(X)Q72X\87/AJ*^@N-<*4K!*<8 MNTF;/-'->6>+0CE9^\$?BUI?
@JXTN2[34A&KZ@TQC\$()MVR?,(F4D<; M>-0/J2EBJEY?-D<;\]/ESCIV^8/3:..:.-:-
S6S0&=%NM4UFY^Q:;;C,UU <4 +CCYCG/W5^8XXZ4[]R&U&//)FAS1S573=
M4@UROM]3M^WVMY\$L^'0&WS*>>1G)^5N1WZU:YHNA*:>J#FCFFOD([,%,KNV MMT)!! \
00 <5YK>?'[PYIWQOC\ZI;:KIVHO-!');B1P7C *NV,J1U M _'M+E8BI6A22YWN>F*/\$UGX1T#4-
M9GB#X^6N@?\$W0 _'=]H,ZR:K%"LD\ \ @C-JTX9\$CVC*38)0/T9EYV MC&PY.97L8_6Z46XR>IZSS1S6?
KVO:;X9T.75M9KR;R8K> KYA &6?18?*OR@MV+ M*.]' ^I4ZJI^]/9+?]?LN:;YSP#0-+^)OANWUW1S-
]DFRFV['K/&5."DB! MCL8==OH0>]= 'S3NAPG[2"G'9AS1S1S1S1Z%:AS1S1S3HRX)VRF,D8V -M;D= M<*>
U(H"^MF-YHYKR3QO^TSX9^'0BB]\:/:E1NL3W%GY9+6T<+)^B23C=*/[_ M *5@ P##9G@G H#Z_P#]^+?_
./UFZB6YQ2QM",N23/>>:;X+X6 &;1/BY M:?\ 8UG?VGIG^5YQVZ.-=WF;]NW9(W]PYSCJ*[WFK0?
8ZJ=3VD>:;P,M"\,7FDV>M7<<\$VJW^V:S@V[WEEOG MY5[8X< *N1GJ*V2'^*7,@D*@LDK;F4Y(^] %TZCY?
3034DR>>.MMT'-'-'- M'-/T?N'-'-'-'-&I6HV:QE\9: '>>* MKWPRFHQOKUK;F1NK9>L< (4Y^I6,XW?WL
#^0 M%)S5(K7J'-'-0-G ;, M\%R,?,TSO!<2[4(%S:Q/M4C=N(,; /I^N*3G%:-G)5Q5&C+EG*S/=^:;Q?"
M7C/10'FBPZOH5ZM[:2C&?G5D/]TH_P_Z_P# B?;BMKFB]14=\$9*:4HNZ8<*3(=0 ")T8]LU2:9
MIS;WV\$YHYK'7QEH=YXJ0?#*;C&^06MN:NZMEZOP A3GZEQ^5;)+\$?ZKROG&[M^]@ ?R HN@C.,DY1Z^A5UHT'-
'->7?&SXX^X,R:&?]&_MC^TC., M>?Y?E>6\$^;&Q_L ?]1T[1048\E54^9,H20W([C;GV "HYM;&\$*T)N4;ZQ#FCF
M0%=>:;S\(>&]:OM)N](UOKFRN);9VACMVC/ER/'\0[_&/2J*?MG>#%DS'I
MOB.%MC']U!#N("DGI/[5/M%U,)XZA:\KEJ>\ ;LW_P#/>J^YM5TN+4([&*Z-H\$N45968*K]I&Z;_ ;K6 M9\5?
GAH^PEOK6VU=+S5;JX#\$VM@D;2PA0" Y9UP3GC /W6Z=WS:7-9UZ=.G[M23]UGH/-'-9?A7Q-
:;>,0#.F:U8M^);WT(N%>)]P&21L8#HZX^;GN*Y;XI?&; M1/A' _9G]LV= _=VAYOE?
88XVV^7LW;M\B_WQC&>AHYEN7*M3A#VLGH=[S1S7 M@^8%6YCV MN/+E>/G _+X]30IW9E#%4:0\ -W-
[FCFN^',WQ*7X5^!+C6A\$ES?--';6-K)N MV33N3@/C^!4#R^YDSY>-WS8-/Q%\9],\ _#
\$[7_%=C+I&I:A&MQ^I: \W+ M@? (Z("Z8S=, "'Y)&RI8CE77G<=K^&X9P3M#?B1\8=\$^&0V"SOTN]3UF_8?9M+T
MA!+=.@(7> Q_1#@*.#@D',NA7UBG9.^YW/-'->T[2 MFNKMWA4QWG^"VH?)"#3")B-
H(\$10(5R5R3T^!>&0\$EIXN\ /Z=K%C^M0>VZ3*^ MV?NR1\R^9D;U<.&Y)W YI]6HXUHRDX7U2N:??-'-'-
'-6;!S1S1S1S0,.... M:; #FCFCFCF@ YHYHYHYH #FCFCFCF@ YHYHYHYH
M#F@_ZMOH?Y&CF@_ZMOH?Y&@SENCT7X> \@F?_KM [(M=37+?#W_D\$S_]=0\ MV1:ZFMH['NT_@044451H%%%
!1110 4444 %%% "'>C K \=-^-%^0A? M4/\$7B^4HM*T?3X3-<7,V2H&0% !9F+%555!9F8^H)(%>
7/[=G@'1)+.??/ M#?CK0?[]Y.8;/Q=J7AR5-,NE:-I(BA!,KK(BEEQ^D@L -Q#LQ774^GL"C;7 M^&,?
%EIX#\ 'ZWXC0X[F?3])L9M1N5MU#RNL,;2L\$5B%)*J%:9^VU M9ZMI=0?:=\ '?BYJ-E2P--9^1&K8F8IMPQ5=W!
M8<9S_@['^TAX7^,FL:QHEE9ZXK7\4Z6R=-^'/MB++41 Z*4G\$0CWL.J^(0%E] UU8>?#MB[]JEW&I^9UC
"K@;F M^=ERL;D9*\$4TFQ^K] %>\$ #']JOP5\40&-WX.1-8\(^-;)C9^6#JGAWP\+JRFW(M _=R>:-V-VT\
<,K#M1RNX)W/;Z*^9\$;HT""OEX8\ -Z0\ -B1X5U#0^>II^G M2> (=BM(I97DCCX9I^0&D3.
<;AZUT^02 :W* ##6M7TC A' %GBR]T& 7& MLKX:T5KF/24,2RQ-<.S(B*Z^F!R5 C]T5R7A^OEI^C[P0I?B+
MPWJ,>L:-?1?:+>YC!!D0Y7/S8VL#D%6 (P00",5SWP)^-NB?'30]2UKPQI.L
M6WANWNFMK/5M2MD@U+;S^SVZ[S(4&T(-1ATK1].A,UQ<39*@9 +,08JJJH+,S!5!) HU\$VD=#17R_ M=?MV>
M\$DLI]=\>.= \ (7EP8;/Q;J7AV5-,NE:-Y(F0F5UE12RXCR006 & MXCZ0CSM+!6DR
&SSDD0V<<5ZHWOVT^2 A"GQ*\46FK>"- "BW& MYM_\$6FRPWUM^ -NADAC#LK.07
]VN#ZFFXL.9^JU># #/]JKPU\10^#^"I M]\$1^ ?%'V3[?9Z3XPTK^S[B^@RR[K=" [&3:48%1@D E?
NMCH_BA\;+^%&I M^#='N=*U70%X@57C6NEZ7H<*2RRF-0TDI+LD:Q*&3)+# 8.<*KLA8H]5HJM M:;>> K[5]
&.N3TSQWJS4@%%!!1110 4444 %%% !1110 4444 %%% ! M110 4444 %%% !136[5!?,ZPEE^C)^8X
]S[?_K[4_6:*,^)G[4^A?X= M^)]0"\%EX@;\ ^+H8\$N[C00!NE-J%Y9POD">9!\J -Y8V\$F3]XAVE6)%WX+_M
M->!0C9<;E1NAW^YI^B#20,;4 #NM0?9;_3]DKQL94R02^0EMK-M\0 ^UF IN M+M M\$"AC&,9+YD4[2I]&G!\$?
VA/"/QVM]8A\ /Q:E8:MHLWD;OH6LV+6]WITC2RQ[M)ADIO]AE8@.Q^&
[!.*.65M@YD>N45X%\4/VNO"GPQUS6]^_X1_Q;XNU#0(A< M:W_PCFB-K MZ-?Q?;+>ZC&#(ARN?FQM8'(*D C&"
1BGRL.9^645YE\ "?C;HGOTT/4M:\+Z M3K%MX;M[IK6SU;4K98(-2VLRM);J7,A0;0,NB8SL^ \CHGIM24%%%
!1110 M4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4E17&[: A <\ M#/ZUY1\2/VC_
= \+ &WA^PIJMQ0VVMGIM@HEEC2601K/,&("1[V4 M=2YVJVUL-*XF['KM]5&-756VF-9&
(P%)P.Q^0(8)]!]*Q^)' [1W@[X7^-0" M/A35+BYN?\$7B:\AM;/3;!1++&DLBQK<3 D!(P[*I<[5;:V!*X-
V/7:*Y^ M* _Q8T3X-^'8-5UPW\$KWMV++3K#2[26ZN;V\:-WBMHHXU.7=HF))*+G)!ZX' MP=_:0\+ !DUC6-
\$LK/5?" BG2V1KOPYXEL19:B('12DXB#DE&#*\1ZQ;-?NNEP(UOIMF^9/M5S*[HJ M1EE8?
+N;*XP6:-6],LU958N%\S^(@Y)[_P!>G.,XS1L,LT444@"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ I,U60-Q:-5&6P6&& M(R1C@X[<\UX-XT :X\+^&0%&H^']"\.^*OB-
JVD71M=8A\#;1)J"Z6YP46=\ MHN6^?A-VUHI#_P#A)0!][>:;0L\JW\$ M#Q203"->)PW!9?,)0E<\
G!J]\8?B1HGP@^">M>,/ \$+2#2-)A\V6.&+S7D M+, \$2-5) W,[(H+%5&
[+,H!8%G>PFSMJ3;7#?" X@+\30^ECXFBT/5-\$L=1BB MN;*^50L_G36[QJZ3_0S285@V,,0^0?
EZ%0(+/\NKXD:;&LDGDKYLDLC&010QH" -S.R_9(+\$D@ FMGP^XCF\7^&;'6KC1- M2\,27T^RC3-82-+N!3G
E6.1U#'[V-V0&_8 @BBVEQWUL=%1112&%%!!11 M10 4444 %%% !1110 4444
]W%1R_ZO\ Y5)W%1R_ZO\ Y4!U/+ &&?^\$C0 M?J0_* M8W-;/C#/'1WOU7_ -6L;FN6?Q,\6?
Q,\\$_;,_Y)CI/_8:A_P#1 M,];_ .SNUDO[/>DMJ<44^FBW0?M4=U_Q[F^]3-YGF?].W/ZU@_MEA_ \ A6&E

ME8C(1K\$9W?-M7)Q/UPP_4N+^# [,0A7XA?#S2/\$6K7>L&2>?=#;0"D9\NX MDCX+0L?X.W/N*Y-I00^2JJJ\?
+D@I:~?<5/V79Y(_B5XWGT.UU'^P\$L9I(;/7(M^8"1?(4AR\$,YB\W86(Q^\.V\PHFJ*?M3 M*H;)\$ /F1L5*
[3M"MT92S' (/HUKX>T'X+^"=70M!TB"&WL+*6ZG!3\$EPD<;\$J M\K\$MNP6VL25&6^7F0%?
#0Q"^\+/Q@L=5\1:/KF@>%/ #EB[6IDU#!BC/WR)&D1 MG-\I'+5W0{#DAF7QFYW9+V>X/MW*V)\J<=QT/ I? M@/\
G0?#3_N) \ I>E1*3DDT.9+;;? \J*""VUOFY=AGFNJ^,WQ\A^>I)H6B6HU;Q1 M.55+4G
ME/\$2R@+0:0[T(C7.>>067/G/QU+?~2?#G;T4:;[?07TF/UQ7+ & M30YX?VFY0_B2?PI;ZBD,EGJL&
[, \$8LQ\$#PPZ0'(G7^,G*33V+GB*E/FC2[V/ M3M/^/GC/P;XNTK1_B7X8M='M]7EBBM=0LI?+2)"=LK3\$, \9&_ :&
=< DX(88 M0?%?XZW_, -?B3HWAZ'2(]9TN[M\$FV1Q/)M[\$^J M&?\$/X=>)]+M '_A6VL[
M2Z(>862RQ\p),4@F>-F!X D\$! ^68*LU7]L* \6M;PV-[96D?A'[7]IJ4 M.[SVF\$;
[TDRVW.~/QMC^YLRPZ'3]N#[0@ \ [?? &A74 MG_P#),M. [#,/
M_HF>I;>K;V'6E5E3JTU+56_) \$ P7]5>.K3P0!-XJT>PTSP?8Z# '<6]TN?/94 MCC*;0W\AV^7N;A_24_XW\$'
/Q\^)WCBWUG6_! ?A*PG[,6:]> \ Z7;ZU\&/"VGWMM]HL+50[6UN5WE-TRU/6-&.AWEXN9=*.7S6AS)TW\$* MP;8
Q1E#)PI)(./F;]KK3[KPM\30#7B[3;BVADF@5HYXHQ(YNK:3<9G4 \ */ M&!GCY3GC->] !'Q??
^/0A7H60ZD8G0+H2K))&A7<8Y6C^8?W0EYQ@;LX" =& M!'TYX5D\4?">^DABDDN=*E74HV7:\$4(K+(7)
[>6[D8_B"]>AJHG9,[,5%8C# M*47MU.. :N^(50)\-?#]GI=U-+XC<7BND_59[1%63H305C))\$1@X5LG/!Y
M+]GJ/50A'\;]5":E=-<3W=DL3?8?WBM/'%YRR_.A-AF7I][^'07, !=M3^
M) Q*[\$:~/<7(TSPQ:R32N;K:~?]:G/8>@ \$ [XC77ACX]>"M M*BT31S/>BVA?5=0MFDOK8RS21R"*8,0 #R8&>-
T0!KF/V.-%D0[KQ=XLOE>\ MFG*V/VN2579V;=-=\$@=S_HY)/4DU%\> P :<^'69?,&=. (7^[G4)#_(BM8WL
MF=%,T:/MW0*1'V%=>*)CL+FSL80!GVV!K.^M]QF\$WE/0CD);E0]:?N'Y20 M-
: A/60B)>?"'7+;7=%M.-\1^#9C8W4'^08_9D6,'])P8V=ON# [G;M;]L[M_DE^F \ 8:A_]\$SUU' -K? \
W)0_+9TI>ZWJ4Z=L15= LW/! @7XR\?Z# \ M=:L !0@Z#5(K>]YGO+@ [X9(S&HC2(%6=\('X=L;L;?FKW+X
_&J?XP;7J7 M]HZ= 8P_Y)EJ/_89F_P#1,%010@LK=G6%=VZ:8LJ01@KRNRYRHW=0OKY#^!(^ (T,VK^+?#>AZ9XB
MN;EFM;C4]40AF60!9)\$V"5&;+8.XY)QQCG.E1MZ(TS"KS2A03;N[0T.Y_9GU M27X<_%/Q%\,
[^ZFEN;B5_LLDT30^;-"6P/+*G'G0J)
%5M[> &33KQY_MZLA:58X_+80&?.4!0+F; &1C=:7<%UAR1Q4Z>'J4H\IZ?,T/%G[07
MQ4\#PV&L^(/A]9:3H&HW!E2WFWO(\$X=HF*NP240K '\$,LC_N@0PKJ/C3\['!_P!6>6ZU^V?_P_D MRT[=
+#,/_HF>MV\ \#I!00V;=&T@6[7?W_PC]K/9+'L#_ :4A4QA6=2_6_8SR
M#MD;%5S-.R.E.0S3I1E=I)F_ \20BM:~# /A?)XQTPQ7\=Q! =.6X?8DIE" [& M_W,%C9GV \K\$W3&X6?
A#XFU0QCX#T_60\$,\$-0J-]NF\$4%I) B1;BD?+NQ?
8&P,K(HYQD_'WA05=5^*0A/P7\+8)5MFAU*XEE\M(GA92GF^UMK*VM[>QMOL=G#\$L<=NL>U\$VY&!P,8
VXXQU.:4).;U.C!5I MxB3E+9\$J >%?+?P(_P"3G0B+_P!Q+_TXQ5]2+]X5\M_C_DY[XB_]Q+_--.,
M5742TT'BZ<55I\I]\$_.M7?P[X+\0ZM\$(3-6,KF+8B2,5S\$J\LY.0VT#! MS] %;_DE_C/_L'W?_HEJ\0_&+
/DFM_M^_P#VU-C_ +]P9H;:~?@K\ [K1 MA"5D7/B9^T))I?BX^" ^D0>(0\$3N8;@9'V>VGXW1[5/S/P=VZ1\$3
9L_/B/_MP5\>=>C^(\$7A#X@^&[71=2N@!#
M]F_:~5Z,WBM_"&IZC=W1M+E=V+A9IA+~;MAAPT14\G[RKCG%>E:~? \ 3:~? \$K
MPU>ZU\3U\0:S93PWD5CJ,7F7,L<,N\QH&N3\FU7Y_X*MD\$YK/VC[GGTZV)G- MN.R=CM/'GQ(^ (D?B"
[T7PA\Y[FYM-H>]UD)'!<~*AC\$^X_9R) 6?<,2KL&- MPI_"/XVZMXF\9ZIX+\7Z0FD>([0L\('E
 \8'S1;2S.9<-0#C(:-F^48W-RFI M?%SQY\1/B=?^" !'V70UTF2X674)I?,9UA=X0(M7LM:UV-
[A;NXT_Y(<64B\1A5Y4_*K+J8S]Y%Q M?6W_3+^+6I>/YOC1X;?Q!IG;^(:>2TBL\$M_ \43;9I#&S9!T3
MO[!XY^+_ ,1?A_ \ "V/7M?T+3K37+C5Q8I8E&:,P- 0W\$K\$(80_5Q)&(9[EE,]Q"S_NRR?NV<*-C&-
EPT8RX(,L&N?M& M? \$'4/#UYXLTPP=:1>#H \$> UIRK2_00I8H)%*J"WEE!052K#S#M^3=^)')G
M5G_V!M*_]&6]'PW_.3.KS_L#;K_.C+BG[WICC4K<[3ET0_,] \& &+1/ M\$GPY3QE=WG[DV\$2R27_VYUF-
0*IV/'@ [I!A-FT\$LKJ^W+*H\GL?V@QB)XY. MIWW@?P5 ^CZ:VH2%I7*G>!&?-&9,J1\$:[P"P&2&&>0^'NDW6L?
LC>.:8;(_ M1MEE+*+A,!P4;(7'4\$DJ:7/-:"EBJ]3V<87/:?" /QUM/'7PM\
M1^)=,LC8ZQHT\$UQ)I,Y:8Q.B&1.1M8QL!XJ/F6103LK@-_: ^)GC;PFE_X M3\&6^I2V,
<@U:~:])O(D^8E(K=#/ND98@A9_TF?E&T9 :UX)^&.F?#_X/?\$R[
MTKQ79>*K74M(E!GL8T5\$:. "3KME<9(D7T/'?MH_L8? \),M1_P"PS_-Z)@I^ M^[:
[E>TK2E&\$G9EGX4_&SQ'\40_.N-IVD6UOXNT9E;RYS_H-PK%L8!DW+*52 M08+]0IWC.U?
#_AGK'Q#LOB]XJ0=#T6V0_%4INWU"RE_U*;IU\p)^_C^42!HM:Q&Y6/[BR!'0"\GHV>Y^IK0YK@_BI\&=\$^+C;:~;
M-YJ^I_9_F>5]ADC7=YFS=NNQM_<&,8ZFN_D_8R\%;=PUC7&P>%DGM]I8@9_M"0 M" _P_L+7Q)KFE00
7*7%I)*D\IC:X<,0D+ \ '/'(XXYJ7]M)5'POTQ#M_Y" \;B M7S-S_-! 80#[FRL-4T9=K6=L^UWA!QY_"@
M"IG<[QDG>S,?0"0!/@QX%U750%>M>&E\9WW@76X<0BSC=V;Y=&E65>)47*\$2
M'G)Q*V,#=EJ3BM!QJ5:~*G3I_ : ^@_A3\<-1\4>(M0\%~* #Z:-K]I"7*V[M\7)4Y,<:-G;)@J04D=6
9A@&9\ \ ^"LDL/[2_Q+E2/[7<(-2F2.\$G,G^G0850 MQ"D[MHR2 &)/%=3 \ \ X&V_AGXS1;K-
 \18_ \$'B&RW^=IUQG[=AX1&^"ZX+8_MVNNW[QMCCC%
<~\+>7P0\=_BUK42M>PZ;I^K74BSX!D5+Q"Z!OX&QG#9(' .0 M>*. ;FU;
(YI_NU6T=S0M8^+/Q;U0WM]X;^' /IG:-:AS\$FIJ?M; (JMD^29(W(* M[#M567(=0S<@}#/_C%JGQ4^&=
[J0AZQLH/%=B1YFGW1_P!&=PHRZ@R;BKJ' M",6'S1LN[Y,GSKP_ \00BQ\8+/5?
\$6C:YH'A3PY8N;4R:C@Q1G[Y\$C2(SN51X_MR6RJG(V@*+S1-*M+GQ5,UVU_ ;7\$FV"%FG7?
L_>#Y1(''WS\C=37N0Q" : M%G\ "Z=H^BP:~?;WGCZXMH15M#TNR^/7C+P?XLTW10B;X:L=&M-6DBCMK^UD6- M4!
(1S*=[1D>9LW_,N!SC#>71?'3XZ-_9M/T70+4ZMXIOMDD4,X=HQ;EV4\$X M.' :1@^R-
6PS(Q)&T*_GGC+]G&YU" \TVW\1?%MI[ZX##3H]6BWG+84I\$&N3G)
M,:%0.U9GC&XL/#_ [8_P!N\1B*QTAI898KRZC;R@?L7EI(&/0K+N_> G;Y M?M6D92V-?;5XTW!M*\K70MYG)?
M'>(_ '.M+H-0XXT*UT:YMQ/) :M8D-#)&XC_M^4\$,XRNT?QD@,H('WG^WY/_6-7RQ^V]J\$=S-X.A-Q&UTL-
U.UL&^>.-S\$%8_MCT)20_]JA'_-?4\G^L:M*=^=W.[I^057-?_ (8(_P#6+7RY^Q#_ *0QC_VY_M?
^UZ^HX_]8M?+G[\$/^K\8_ \ ;E_[7HG%.25MRZ].*05&*V=[G3?MGG'PMTPL_M,[_F#B"?H1T_&K?
[.W@+P0KWP;T.\U/POHNJW_M#0<#SK03H9'.)Y.KGDUD_P"(S@FFL>U%*S757/9M.U*TU02[2_M96N;2Z5;J

M''Y#1R9;17Z2'G P : ^3(M&G : ^/WB>\(@_L>SM;BS6[D9KN&)%)! T&,8 MS*PF4%EX\W!S@'W\XY>+
[7X9 "'5/L*-8SS1/9;=:V0\@)-(A7=&X5MC(NZ3 M(XC(!!(SX%\!+?XG^\$ _#\$^I^"?FEZAINK3><[
[=SHN5CE*X\$9N8@BJV_ MP2S\$&C&+J.^B+QM55*E.@]8VU2.Y_9%\6/#8^(? VJ1RVFH;7<2W<8FW*PMM
MQBEBV'[NR3DX/WI&R /H/0UPVGZWXD^\$ M?Q\ M=<[5:8FA3:DQGO[6TG7RPD[F.23
=]W[W=)MW'/E>U=Q^V\!L\#-\$@6+ M_2541)AE :W&#VZ8^7MGWK/FT]#F=:3P4Z;W3T.R^'W[1G@#0__ANQO-
=J MZL]-MK>XC^Q7'+QHJ'GR,=4707N\$;Y4KYWG\$ R]-N=JCCW!'8=*T^'/PU\ M)7_P/[*7EUX1T=
[EM+LW:\:RM_.=A"N'3U]:])EC?RBL2B-T4#][PD:13T'^ M>E;PVN>W@6W20=:?,^9_VE+RU\1?&+X=>&
[ZTDCM%EC>5H_07"3S+& Y)"__ M 'U6M\>K&Z\\$_%;PG\1M0T>350FF6Z6EW;VVT56[AY<2,&1&5WHRY'WU4!E
M)&<;X\6LJ_M,?#R[^R20VD\^GB*?^"4K>G=M^F1^8KZ8U"\M]/L[FZNKA;:" MW0S.[''@*-V26@+;7_%K*"4+;
C9R1BNY^ GPUU.ZU>?XF>* MKEFU76%,UHBGBKS?A^UG :0^(\,OC+5-/BN0! MWA\0;V.B33%Y-
1G4;QD;MBR\$[68.P7"1&P*ABOG&G^&6\9_"KQ)\4=5UV_M/_M%GZFA6X)Q\$@\(:)D7,<:/N
E"J58*I4;E0(=N7PNZ/-51T?>DK00IZ'U[\2= M!E\4^!_\$FE)IZWUY<:7+';VJD!?._=\$%^Q(4^^\$T+
MMFTL\1F@LUPHV0[(WQ@^ MO(W \$L@B0GS@!T64H) H#0#.,G@?V.MO\ PJ_4_*^ZNL2H=WWMPBASG\,5
MNI:GM*S0=.4>L=3W0FCFCFCFCNC<]F+N@YHYHYHYH*#FCFCFCFC@ YHYHYHYH M.:.:.:.:.: #FCFCFCFC@
YHYHYHYH .:.:.:.:.: #FCFCFCFC@ YH/\ JV^A D:. M:# JV^A D:#.6Z/1?A[_,@F?
_KM_P'R+74URWP] P'03/\]=0 &1:ZFMH M['NT @044451H%%!!1110 4444 %%%
'F70\^!WA0X]>&])T704]]_9>G MZG'J9MK&7RS=(Y\$,+D ML9)'SY95 [K#G/G?=[7CS2/ G[,?BM]3M+747UB
M\$;1IMK,I*0*0%- \;/3+ M8[5BB >>[F(]2WA3(WR/@X&1C!)(4,1\ P#P^'NK?M%>[+^_.Q.BRIS+X-
M\ '/&XMM^B+8^U,&4":.3: '60J1@I(& U2P:Q080DU>S) C?IOBKP#_P3VN-' M@TR>WU_3_"6GZ;J-
G"1<^1&@M\]2RAAM6 SYD&0!N?XW"YX5 :[\&^"7P MGX;U;P\X_P#ACX>D>WT2PU+Q=H?
V6Q@8*5AA>8R0R1'C=\W&7)"*[K\]XL= M:#X%TJ'40%7B'30%#C+*L"W6J7D=M\$TA4LJ!I,#0?*VT_%GA[P]
M^S)X[?Q_D5S'?V\$NF6EI(LY'*B)F'W:;>FPK+N5?VC/_ M#?B#30'OPP^*6B;#>>+%\%W&HC4-&TUXQ4#
M*XW5Y)??%;7M+^+^'B;XZZI\[/]=T'OK+P[!X+T#0=: M-8US4IKQ)D2&V93L4
M,\B%E+G8A9!)AE3Z4^# !,FNN-#&E^&+(WYU'%L+/R[6,2>:7.(RF M&W;B,\$')XKP7PW'XJ_:;UK50C-
:;;HNH: !X:M=3M/ACI-QO_- ,0%E"1J5PS M>7LWR6P"Q2#Y<(P\$;())'%VT'4>IV?
[,^FZ/X)US6SXR\5Z3)\.S+;;I:>+AA;Z0+K!0-UU_I.Q9)6C;[3PQ;*0! M\G;OK]&
[56VDN/FP:D=#_704U%U*C+H6J*:M.K(U"BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH ****
"BBB@""YCW[#UV]L9_'USC/0]S7D40PI M\%?"0XC>.?C7>7%U'JEYI@_M*[N) T-E9V\2;Q^&B!CN6WCSNW'}V-
I&2&]; M059PH4[3S\ VW=CW'(Y_QKP[P7^TSI?B/X \ C7X3:KILOAW6=' \HZ:MU=)) MJZ/\$997C6-
2\$V(48*9#(R-DHA1P*C?H3)H\C\.\$?/0/VG/VM/ ?BCX?-ISZ) MX*T_4/MNN7%S'!=;B)[=42-+-L71BA:*
[N"S40#I[QPA1=RK\$WS M-\$LR1JQ!!F0YC#*U>F_MH_?40A; \#KS_A'[:_N?
\$WB*^B\.:8NGP/+ ,ES/+/Q)XC00%&AZIX;MEN(KB6>*-I+>Y6-W>W6-JD2R,&F&8(F#[7^S#\&
M;3X#_!K0/'L21-J2Q :]5NXBK"Z09.9G\ P*ID4'"(SC<(HXE).VH?VD?C5_P MI[PC:;)I,=GJ?
CK7[F/20#6AW,YC^W7DLB1C.,?NT\ P,S^D7[J]T,BFCF[Z0/_ M)I<^5M#T/Q=I/P7\,?LW,8=-:RLO[3^(?
BN+5%6'0-*FNY;@VWG'.? C[Q!:0? \A?5R9+BPL7B M(/F6KSEDV>4\$ =ABL1D.>P^'7ACPW\/_
03Q!X;\%V\GHFE7'@*4-5TC2Y M%CM/[02\1(Y)+=/DC<0.A"JJ\2EL?0,ESM:X0>NI]>45%"VXMU[?>_G_)]*
MEKG.@****8!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% "' M'>0,OCU\#?#70[\-
Z3H0BJ2^_LNPu*/4S;V,0EFZ*1R(87(!;8R2.#Y95 [K M#G/IC'I7"?&?X0>'/_@CX%N_?BB_-EIEJ=J00@/<7-
M\$ \#K#;6=N%0)8M2@L JHB@,L MI\$ L8VX#!CV.<'S3X#?#]50VB_\$FF_'?XG1_*09?0@YXW^MHL1;'VI@R@332
M;0ZR;3P4D#?ZE8/IC70%6G>\$])EU;7M3LM^TZ+:LUUJ-RM0!'N944F1L*K%F M "DY)8#-.MM:6,TET9\>=
?JJ+PM\&0@3X+TR\^'Q T#P[9V=LMYXBFT1FT MJ-YV5IKDSF4LT;RS,X95!/FJ?09VU[^T;X3U;XG^
_!/_B#P5:V_B[5/#7B7 M3/%EA9P74.,6L)%P5CG9PD8:.=G5_F4A.^ \&N \ B%\00".D?" +5_%FKW-GJ MGA
Z6UVSK)!+?#P,FY\$CWGRY/.'!H"0S6D() M>7")) 8=\4E\<212!/ [KHZ,# \$K@]Q3?H39=SS+Q-\5]0\;?
&+PE\4-3\!^) MO_G@3X7:;JNHZA=>,8\$L;J^FNX#!' :VD))65]ZQ[2]/02;#L.Q9.H^!=1:6? MQ+U3XB?%G5=
(*?%'QC'!;: !X30-=5IM/T9VC6W@C@E*-YDL\3. '+\JQ9 M\$ \$F? \-E?%LR8T;5?@5X!U0R*
[L+D: K"VP!XP,6\^GMW*2'0(CCR0,[/P9X MO\=?LE_&?QC\1=.L9_B7%?:U;-[J:IYVBZM"=EK9VET2S"--
EH(T6613YFS MU6*Y_9UU6\USX%_#S4K^ MZF0[J\ \-Z;3Z-6#.A.ZN%%%(84444 M%%!!1110 4444 %%%
!1110 4444 %%% !1110 UJANF*[,; 3D;G&=0 M<'P.X^M3-
4%X00ED[MH.3MR/S]NO!Z_7&1;@]CQ*S\\$_ #0!E*S^(WQ%OM10 MK"WU[45U+6=50S)<^69)V\$4210)_JUDN7
_TOE_F9@!M\ R_9YUS3/CA^U5XN M^+/A:#3[3PM;^'5\ JX0(60]0E^UADNI;9"9(%*6S(0GA9&18R,CY8_20@1^
MTAH_OJUQQCX8FL6\,>* #6IRVDV@W-'/_=0;1LL1N&* (0)0Z.J/*% %VWK MGR/P]8V>K? \ !1"Z00ARVGQ:-
HOAU/[QI/I]FHCENY9YG\ EY% C(-RTOV9V?(M.+;52P; ;(=H[-' .[7/?0A? \ OPW\)M=\T+2;=-
,^'H0#6IZA\$=KW6H MFX1C(ZE5.[5AF@R-LN'"LHJQ\;OC]J0Q-^)L7P(^\$6JBR\27)=/\$?BR))'
MCT.W12TR1; ?WY^X6)4([K'N\$AW0^?!\X2^&_@CX!L0"GA>U:&PM>9KB9MU MQ=5X >:=L#<[;5YP
%4!550!W2N-*+/GK3?%GBG[E?7/B;8K\, %OC^T\2> M([WQ3HFI>' +9;B.62>&(R6MTL;L]N(Y
(UD97,GS,\$_ =G/GNAZ'XNTGX+^&/ MV;F:'36L;(ZG\0_%<.IJL.@:5-=RW!MS,=Z :9;(JRRAE*L?
EDB=I(OJG]I# MXU? *? \ "-I'I,=GJ?CG7[F/20#6AW,_EF_0)9\$C&>1^ [3S_S,61?NI00R*;
M^A];?'"/4 !UWX-LM/\ >K:9JWAG188=)MSI=\+ MV.W\$,2!8C*&;<5C,74ENGB'PWX+M[/1-*N/ 4.H:
MKH^E2+%;_P!H)>(D)2V/GW'ZWA;=GKV^]U_S_ (5C+; .^,WQ>\-?_ P \$W7B0Q5=-!IMO\B0Q /-
=S\$92"&,D;Y6P M<#H &+%5#;/B70#\{);TFX%/Q8\DW'PI^+/CF:&?XD M>=
_B7X=D0\$BL/*&E6@681648=1(C"/RTD)P28E!!9&DD]Q^(' [F,WQ(^5KX" MN+WXUR1^(?#-Q/>-->R^+2:UGN&
<^3<);]B20Q2>6';S!QN41EGW^4 M+ " MWXNZ2?A:-? \ C2?%C77C_2K73)%\)VEJ-,NW\T17?
R.?,> ^'1L(F8/%-60 MG=GN7[10A0Q#IOCCX6_%#1?#]WXI_P"\$N-2&HZ'I;1BX-I=6I26XB+N0F/\$
M(AB!06E:10"N-U>0WWQ6U[2_BQXF^_NJ?#_7=IT*R\ .P>"] T'6@+36-X0? \$MU:P:
M;\$T6]W5W1#Y48CC*KG(!V;B>375?X;C\5?M-:UJWQFMM-T74- \-6NIVGPQT MFXW_.F7BRA4U*X9MFS?);+<
(/EPC_1L@DD%+H#C?4[3]F?3=&\\$ZYK9\9> M*)D^.'C*Y&H^(-#76\$FGMAAI;:TB@+TCA@D^;[S?.Z"/;]
(6KAM^T[@? MFW\$ \Y/. /P!'Z5^<7C_PM\K']@70/B1I)@F\=F6TU2T\67#"WU>76#>;KK_2 M-

BR2M&WVGABV4@#Y.W?7Z-VJMM)IJ+J5&70M44U:=61J%% M!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% %2^SB/!V\!M MGC&?Y>N2,5YG\#?@/X9_9)\&R^&0"P0)H)+N74);C4+C?/<32;?F8HJJHVHB MX55&(QD,?MD?&34?A#\/-7N++X< M;,\$P\7>+K=2S:A'G9|CM9-I0+(WR^8W\$@64J) (D(FN*,IRCL:/[%>M6GQ^ M+'Q|^(/AW2X-/\'Z[K5E;Z==6K"-;R:VCE,\ABPC(\HFCG.11EIWR2P>0+?B M)\==,.*^/T E\'Z|XY^WPZU!V.C^&=,FU@ZY?,L@CNI5B<6Z0(T1:,NS,Z MN5".LTBP_=7@SPGH_@'PGI_A[PSIL.CZ-I\ (CM+*)2%1<9(8'DL2Q)8DL22S M\$DDGY(\X)ZZAHMK^S)#X9M0L|KXLT'4+JW\26'D&WN[6[-S+L\^/S'8D:*0 MX(BV<=>7M&M)Y6(=DK7.P\& %0PA^V9|\$0%>G>#]:DL0M^G3Z5?1W4*B[TUKB M)XTF>%7(((*DNN"5;:5W!D?;X%XN0-B-\00V?!=!_9\|P@!1:)X0>VTW2;[6[F M-&T"V@MA#)]I%]'020% (4S\$,,"S('/*-W4?!"L?' '[?7Q6\8^%6MM5\ -6WA MBUL;07;'4X;FSD0)%M&B6- 4P57R[>0'EPK0M|Z|@|3]I+QIJ_04\3?]*#| MWNFC7M:T^>3Q9J\$Q\$CZ+I)54?%;#;)+,)P@3=N"NI/EB19HQ> |(+A:@NH>&-*\>:I9:+Y-V|Q!%9@0NB1,S-|F MZ1V&"D MAZJ:0^!MAX!|*6&AZ7--<6- J'\$4MRZL|*TC/SM55ZL>BBM_FCFDHK1Z1^R;X#T0_MQ#;ZJ|WEY;6UQ),FDWLT9LV3+\$)@Q|R!0/#.2<@- D'!|EYHYI2A%NY\$\ -3F^ M:2. (^&WP@.\?'V^UB?1);Y(M3>.0K/(KK;NID*)\$<;MH\QL%F8GK|XY;F0'W M|,./@SQYX@0M:EM|S2|NZ3RYTTUXEAD8J0S_0(W>G(Z>Y^|7KG-'-'(NA/U_M6ERJ*6SN>?>)? @EH7BGQ=H0B>YU'5(|0TA>.:15D1D;."82KY0FJ|[N.Y'TS_MFMKQ|\ -?#00.L8;+Q!;QS%)M(M)?)DBR!NV2 \9PN005.!N4X&.GYHYI|J+ M^KPE>+6YXQX;_91\!>'15CU&5+S74C(:.& :)HU=74JY6-%#;?4DKS|P=^J\ M7?|?2/%WC03?>->WMMJFDF!(H|/RQ;_D,PF!*NC\$? _2H|_*|WFCFCE%'# MTU'E2ZW."^+P9T;X0+IL64=_:38*\$2!ID?)V2(G>3MN_M>9^_0V???"_P^T_7+..XOM3BUBT-E+=WBL""K @HBIACNY;.:KE-W3CR\B6AY|\+?@?X=^\$^IWEUHT- MS=7EPJHLMU)&S01IN4>5M1>N3G)/WIT[|'Q""^'.B_\$SP^NDZJ+P6BSBX2XA? M;_D@!18 JRGY2RG(/RNU=3S1S2Y%8S^KT52=&WNLYKX>^ =&^&/A6WT/2MK6_MD#AGENDC6663=N#2%4'Y0JC@<**R? &'P9T;QEXYTK07>W>H6VJZ6(BV_E_M9W\$4_G?-N1NGL1U/7MW?-'-/ETL4Z%-TXTK;(P?'G@02_B%X9N- &UJR0C|.X M"E"FI(D@^|)&J7_UBS^QW1D0%?Y2&! M)1\$"|_F'+J^,<8'7U'FCFIE!- W9,L/"3YK:G)?"WX7Z; *=!N-(TV>|DBNKM_M|R1M0F4SJO6-&PP1%(Q&0&TX_&L|X4_!C1?A&NIMH|W>7/\ +IB\Y;J2-E1H_MPP^3:B|=YSDGH.G?ON;.:C9I|@6'A>+CT.6^(WP|LOB;X>_L34KS4K.Q>59 M9|/,?:TNT\$JC_*?DW!7_-Z-*T/' 'A&R!\^&|F#0=-W"QL8Q%)'W.V279W^4 M?;S,Q;W-;/- '--- K4KV;_WMJTC=-.16KZZTWX5_#|S/1U=-'S1S5.*:T-/8KWIP^)JUSYM_9+T6;Q%KWB0XA7:6\5|J%Q) (K/=Y2 MR2.L\H.< (%\I5PQ^Z: ^D@RM&# 'Y>W>Q =_R6R?YT#?'_J^*|*[U"YU75!.'6X\0|. @EG\|Y=J M+U|R>@Z=^|YHYI\IM.DIM2?0HZYHMMXGT&|TF698K/4(YK6?|.ZJQ63);;E3_MW(KG0AK\,='^%6@S:3I84J,9 M24K'\$?&KX-^%0BA*)M=TEUU*-2(|0M7VS@-'7.5|J#K=^G?G0_7|,?@KP-JD M>HV\%UK6I1.CP/J0P8?,L:1JK- SP2N1C@C)SZQ51S4>S74S>#P\GS:9XFT6*2T0|/@,"6,,ZFU=C%)\$&!;!;S")&SMZ|6RS\$GTCFCFFJ<> MQ/U6DY89'(!&Y@< MB? _9V\,7WPUT|P3)H\<\$JLL<\?VA(XF1TZH5^&@Z@_M)*- #^&&EZ#\3X(MKR9)'D@GM6EDGC^T/'*SN_1_0WW/0#K76\T5Q._M)T'X->%0" A?40#6DQ"UM]4@-M? 7*7(DN)XV5@,R,"6P2> %4;N%&35GX8?# M'2?A7HLVCZ1//);7\$WVN1KF==ZL51&Q@#M&04'M76\T-A%)&&"E- J+S|f=2?;!0G#\T2*TS0)(< #YF?YCT_B_/KS4W-'-'-7J=6MK,Y'XE?#?'2_BOHUMI&K3_M7U0#%/ _DEL7565A&Z<|E9>DAZJ:T/_?@_30_'A&RT/3&NKRMM0XBDF=9'>_M-I'\>7>&_P!G?0_!0C!_\$FB:QJVG M74T|R/IT36_V.19#\UNT/D9:(;0%4'.%|7Y@*L_\$3X_^\$/B=?B^U2VG@U8. M;VQ98Y)43|JR;@RGJ06*A!\0""Y| (YHYI.G.I./ *XZ'G/PV^ 'A#X9ZH M=0TJTN+06\$+NES>.K2(&'*IM"KM&|C^D^I/&&Z+\!?'#>D^)/\$6N :|ZZD\11_MW5M?6UU}&J>5<2F5U79\$K0\ AM\(/#GPL0M9N-\$E_MODBU-XY"L_JNMNZF0HD1QNVCS&P69B>3|XY;M^.:./900<4,)|1INZ1Y-XX_9 MA\ '^//\$UUK174-'0I|IEBTB1(XII%.2Y8HQ#G^+!_Z;L\XZSQ=|+/#/Q_T*U_MT06K4S) &%K=2W+K;.:7LT3|3HV:Y=SQKPW^ MR?X#T'4D0Y40M;2-U>..EB\$*NC!E+"" %GC@&E6Y^08YZGXE?!/PY\50LDF_MN17MG?6^8XKJQ*H|(22\$)96&.X7&P11T/&0^&2_M_K^&|? 2E%|%)YL<|:PCJ;FX9_ ^T%GBVJC;B&V!<|1G.!CV5\ -)0",N\;ANY&_MTDX_-N/P'6CFCFJBN4THX>E10R1M<5 &.:2HR.6W[6"@C./-1K@/A3\&- % M^\$:ZFVCW=Y<_VD80.6ZDC94;.,/DVH07>E_%70(=)UB;\BM(;E;K_0757)".@ZQM_?|J\V_X8Q\ ' : =0VSQ/YGE M8_U\> ;LV? _/"0=^:.;BF|V,982C.7M&M;6/&9_P!E7PK-X4MM!_MG7H-* MM|V34(X3=1J))6C2(M*/(YPBN!S_!F07M/TN+0|&WTRV@>WM;.)((8WW\$&_MJ!54\$^P!X_ZU8YHYI%/9'#? %>X/Z%\6|/3X|9D0+;33Y&DAN+&<1L%_M9<,K!E9"I(0\@G*C'>J?Q_ ^!.C?\$.PT2RUC5- 8:/2(VCA0%D1;BY9EC5VF+Q_M'+_1(.%48]>WHO-'-2Z<7==R98;G-/F6K/_Y/V,!=>WY=8UY@<@KY|0N/!Z? MN/ZUZ|X'\&VGP)\,V?AVQ,S6|EYA5KE|SGS)7DY_[|]6|S1S3Y>PJ>\$I4GS_M1W/"0VN/-SXH\ PZY9^?+ H+/-+;P'YI;>3;|2|CEDVK)DLJA4*)M6\,S31";_L;&>.V#L3NV\$.KX09+*I8\$&+N^=!7HW-'-+D5 M|L/JL?:2J/:6C7ZF?X?T/3?"^@6FFZ6EG86<*&%8T&U5'_+/,5NI. 69V8]:_M\JUC|DWP3JOB:35R=0LQ) (LKZ9;NBV^,DNCAD8E3P3M(//_@/X=Z^H^&0B;UU_0/_MG!JD2#R|W4+BY06A*0&ZNHN'<)("B8_MD&'!7 R,U|K12YG:P#M,\>=&=0\:/\EQ=Z1?1?9YK>*XFMFF0C+*S_MQ,C\$-M8,JG# (2#E6(.AIVER;+9VFGZ?;PV5A9VZ6MK;6L06*%&\$544X5%50_M-N, _\$5N44KL?2QX0_,,L_"0_(6A_P +\$ _X0[3?^\$P_M#^T?|0WS>7Y_ MW?- \CS/) \S^+=C_6?0<;^:|>LPQ:1G.6X4DJ1DC/(SVYXY-6:6AZC"BBB@_H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN,[1M+_M@Y&:\N^*? |./PZ^,RPOXR)\V>07\$.Q8KH^9!=*BAPJ^=\$RR%!YC';G'.2"0, M>K447:\$TF>5?"0\ 9W^'7P36>3P9X0L|#N+@/' +=8:>Y=6\0D;/N+EMW"G_926YZ<<#GJ.GK7-WWPYT#4/'& MG>+G2UN]=TRUEL[*YFFD9;592#(8(RQCB=MJAI&\$\J-IR.*|2EJ44YL9AA)%X/&";<_@CE2% (|90:Q/@S\ "!'P+T_MW4K#P3X>CT.W0IEGN6,TL\TK_\$*'EE9W()."Q&Z1S@%CGT6BJOT_****0!1_M110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 UJ\W^,'| M/?@#X\? V3_PG.@G6_P"R0.^Q_P"F7%0Y7F|/,_U,BYSY:=DT&B|6J_M\$U<^;) ^">_P#;J/_);N/_B\$L-QX.".17? CZYI;:E)[L7*CY\..?L+? WP|K_M4.I6WP_M+NX@W!!J%W<7T(+*58/#/*\3\._V-RG^&.;5KVN^L8=6T^ZL9I+D1

```

MMW4,D4AM[J2"548$$I(A5XV&3AE*S<'((%;5&13YF.R.3\(>="'\>$;+PUX:
MTRWTK1+&'R;:SA0[%ADD[LD[BQ+;2S,S$G)?! MFGZCXAB$(-Q))(JS"
(DJ)T5@DX'"^M#;E"JPP*EI:5V+E13T]=OG-C!D;=U M)[ =^AXYQ]>|7***104444 %%% !1110 4444 %%%
!1110 4444 %%% M!1110 4444 -:H+I P3*[A]W:.N3Q6\!FK-% 'CGQ_9;^%7QDUL:GXL\%6F
MI:GM.;Z!Y+668': ))(75GP(U0Q/R.Y.WJU=!\+ @OX-^#FCW&F^#/"|GX>CF
M4>:UN6>6?;N*B2=B9'P7;&YCC)QU->AT4W)}&*R/FR' )[_ $;@/ 6 , M:Q?XZ=<"?
"N@#_L; "X6^+-/\5>%/";Z3X@T\2"U0{J3NY"GF1M&_R2 MRLC?
(=[5..HYKW.BGS2[BY4<7J7P[T/5/'EAXPO-+%YKVEVDEA8W-Q<2NMLD MA!YL9AA'7@
M\8(QMP""5(4@J#74TM)-CY4>=?!GX%""/@7INI6'@GP 'HE0?S+/7Y W?-|CS/)\S^+=C_6?
0<;^:] =LPQ:IG.6X4 MDJ1DC/(SVYXY-6:6D]=P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH ****
"BBB@ HHHH Q/&'AW30'_AW4=!U>$76EZK:S6%U;VT30RH4D3(Y M&4+=">#7A$/\ P3[^ ,D:D> <+C 'J]K:@-
N.V//[?20I*DIJ3CLR7%2W/'OAG M^RW\,/@CKT^M^#/#7]BZE/;-:33'4;J8-"71RI661U RBG=@'C&
<,HZXT2P37MOD;>8-2UZ\%WJ=[-+--PE:>V832P31,0 0DL3(Z@'\ M <#=&AP2JXZ3P-X-T/X>&[PWX;L+?
2=%TV)8;:QM_NQKR<|226)+$GDDLQ M))KH**00*6BB@ HHHH **** "BBB@ HHHH ****
"BBB@!.XJ.7_5_G_*I. MXJ.7_5_G_@.IY?XPS_PD=[|5\ 0%K&YK9\89_X2.]^J\ H"UC\_@F?
KM [(M=37+?#W_D$S_]=0\ V1:ZFMH| M'NT_@044451H%% % !1110 4444 %%% !1110 4444 %%% !1110
4444 M%% % !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4 M444 %%% !1110 4444
%% % !1110 4444 %%% !1110 4444 %%% !11 M10 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% M !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M%% % !1110
4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4 M444 %%% !1110 4444 %%% !1110 4444
%% % !1110 4444 %%% !11 M10 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M
!1110 4444 %%% "04$8 MFFR-!U@!,P*VH4AN!R=X;|,5J-I$TS$IK5 M^OKM6W ^-&MH|'M4_A1MT5B?
V/??]!S40^;? XS1_8]]_T'-2 |YM_ (S5 M&AMT5B?V/??]!S40^;? P",T?V/??\ 0)-
>|PYHYHYHYI(SL'-'-'-'+ M!S1S1S1S0@YHYHYHYH"P\_@F? KM [(M=37+?#W_D M$S_]=0\
V1:ZFMH|'NT_@044451H%% % !1110 4444 %%% !136I>U "T4 MW-&ZE= .HIOWJ7 I,#-,:!*04M !244C4
+2TU:=0 4444 %%% !1110 4444 %%% !1110 MG<5'+_J S E4G<5'+_J S E0'4\0\89_X2.]^J_@+6-
S6SXPS_PD=[|5\ M0%K&YKEG\3/%G\3.!^-/Q47X0>;76GTDZR)KU;3|/YZPK\T,KY+%3 SS|'0 M,|;JGQ!
<:;_ &0; "S5]]_*F:74%NY)($B5MC$D6V&[">^!SU'?0_*+K\, M=+9=I/\ :18V?,6;,$_0#K^-3?
L_$;P0X3^"NC+J7B+3["XMC=R/#IMB\Y5 M$TK,/*_6S\H(P"<@8YQ7))^\TF?
-5L156*='FLK7._\&'Q@T#XNPZC/H:W$) ML62*:"\C19%# E6!0E2APVW!SP<@5W'-?(0[+*W-L?
$+QG@TK3X;_Q^PS^1 M;>8L<<$LTJRP19 ^11Y_"\XF>(7C-\,M6M=U*#17&.G.L9G>UWQL,??>(1[?WH616
#;=H.T!@!X;_M\,-'^(%)\9/$\&B;J8Z?XLC^U&_OWB4QW7^DOK(%S!)A6E9&_M>01:F4^I-
M7,%>'+|K0]_ \:7&/7/#?QKT/P?:Z3'/IFI10|[B/S/M,A6NF1 M:JQ@A$5Q<27+1SD,5XW;
<<8^|TK9^,7QUU71?5IX&\ "Z9)?^*9$5;BX6W$P M@9HMR^6I;:05&5MY^5-GS AN'S)*|>0%+>SUNI]-
/&VD^ /#UQJVM2QK9J0GD'EYF/(5%[MQ_D9KYP\;?S$XM?! M/Q5HPNE?9;^7&(K@*0C0|_+HIN!$FTXW9>
%5L?M@Z;XKM[6& M^N\7CN_"WT0MM)\I5EMIMDBGD*<,J0("SC|Y 4@9,2J;_5C.IF2|E*26J/_ MI3PWK4?
B3PYINKP0R0P:C|!'>1I)PRK)&CA67LPW<_4=L5H" "4 M?B+Q7J|0J?@ZR\QW-0:6JJ;D*D<;J
#!'EA"DN\0/)SSC(XWP|XZ^+WQ@L- M>U?PIK>EZ3IJA/(JZ-F W2HJ$H(RT1!,F6PQ=:01P=@!%-5-
%H.&81A!ZW4=DN1?;<_Z| M!Y?R;%S_*R/N?PKTSP9-K\WAJRG\406E0KLB%[BVL<^2!OR_,\YX,!|*|BV
MTD5\T?ME:#?Z3XF\,^*;34+F-/ +^S+;MY;6KQ9$Q) "Q,A(' ?RSZ4Y-[CQ MU:I&@J]/3NCZ2\<>+|?
P)X/U+Q! ?R :8[2$S?9\/^ ).U(\)RN9 IG! SN_A MKE0@K\9+3XR:)J$|EG^IM|97$<<|I)
<&X7$G"/OV*.6\Q, D_NLG&X9\S :F M\;S^(/_/@QRTBUO#)XFGCNH8X3MDE18XWCCD3^-
R\T>#@Q#CG(P/@f8GX-? MM'W_ (*34+C6;:>U)J9XQM$DGBY5_*S\Q7YXU.3A6//. !FZC08Y98Z2Q,+?
M#^MCUGX0_'U_AGXKTKP|9>'90$.L7L2S^4MT(E4M+Y2A 4?=NY:&"<< '=Q0 M\3_&70-X;^,'AKP=_8J-
9:G;0M-)%+)) *TDC2!I8206*+RP2716(AIR1:=J0L#DX|#DUJ^$|&^(5G\ (=9EL;=/|
[U/_/K8UGC*GM)P71'H7|/_ ,3M5^*W@Z|U;5X;:*Y@0Y+5 M/LR,JF,(CCJQ[R&03>:~.?@/%\4M0\
Z0%X+ETC3+&&>[:6Z5#/M?LQ_%S6_B9H^K6N0)&]_I9B8W:Q"$SK*TIYC50HP4 M(R
">X!&3<:EVEW+PF,3C"$|W<|LYKSGXS?&2'X0Z?I;<1JKNL-LZM*NT|=T|<[\XST/9U9:'1CL0Z=+EHWO+8|T^$?
Q,M/BQX+ M@UVVC\B0R0!/!YK2^2RGA=YC7?\_*5;=S]_':NSYKY7^ 4S-&2FY3M##H&
J,^6%S.EC5&AS5=X|^6I[AS157RQ\00 M&WQJ^%|KI?B#5]:T22P0;D1_V,[?QT^* M?C#0?
_@WQ=X;U&33M/U:V4W=C+!#HS,LQ\LLNPM%&K|MOWBR$ ,< M-@&L/|M#P?J\TFD^(K,Z7@
M|K000$D":3XST,:1#+%|FEEAB-U;2DPL)-T(4LL1S$%0J_#8+8 SESOFLF>3
M5Q4_K/LY2Y4CZ$TC4/[5TJS0/LMQ9&:))!;W0VRQHRAE#H"55_F.X#0D9.*M M\UYG\ :0CA8?#3PG;ZI!
FIWFK1L=-6)0,MY4QW<>--="U:_ ,VD:UZ+8+: (A01720QY=(P^-H8X
M.X9"G'&:J:I7/&_Q2^(6I>'0AND=KHFVR/' +K31?:5;:9!N5P&78|J H_9W MV^*^<%&%&?
*K6,Z>*C&DN9WDW8^B...<^!0Q@9^" _BC9^!_B!):ZI+?.(X M=6@MR
CR(/*6$K'MFC+AU^X#N=^< **TI/BAXC3|JX>#I;^0^'47>MC);1J4 _MXES3']YM+'_'%CXG>)0" _Q|'\>'
M|/U>.UTV_6R$S;26L+J6>[DCD^|UR/P|L_C!IWBJ.R\6WFF M:UH,P,DVJQ|/,@;+%4BQ'"Q_U?@[_M]_ \ :%?
4C?ZX_6L(J5W&YY5*6(=:/GVM^)\ \ZY^U7=6WC+4 M0#5AX^EU>XL|J2W'V2^+/-L8KN">02=V-
WWC|ZMK0_CUXLU;7;*TN?A;K6F6 M|S<0P27$WV@) #('N<1@=|<^M?/]GXRM/A|^TEKGB&|SYM|/6-
3#+:Q|G_| MYH/^ ^_45|0?##X_Z|\5?%QI6D6FI6UU#_ |T&04C57'F*ISM=NGF=P.0?LZ_M7-?
4^MMCTWB/>D16.:).%7D$_9+8SDY(5>G\5>|>% VLM-\3?%& MT\IZ/Y&EWFH-:V>K?;MV_/%NWE>3 RT=4|_
,==^T9XJC|(?'"66A_M|C4 M%DNTNBCC=E=Y=R/|WD8C6100|<=Z^;_ $GPA0-) 9MT7Q_ \; %A=2:BR?)&(+>
MZCC16PHPQ+16IZ$C>50QD$ZEF;8| $U:<^2E?W5=^A|03MN:0*0DQ@9_V>7NP M<'C/'|WI_!7S9HG|7^J^)=2-
KH_P|0-2N\_' $>QNF9R,#+8%N<9^M>T_"KQ MDGQ"\ "Z)XAN+>:^BWSK&FV-9@=LBJ<\@,I(Y/R,G/8?%W|/_
```

(AE_M.-58B0N5VXD;^ZWIVZU MT0C/6I?#?@_7]8MTCFNM/TZXNH890]7(R1EL-[8]JDVU<|2C)>R<[W5KH\W^
M'7Q6U;XB_%30+:::MF_@72XUA\Z2#>TCC?S&X=M?M.0 MP>)KNRT'PWJ7BW1--*#4M;TV0,D*D,9&3]VRF-
55BK,Z*Q1SNQACE_L8VUN/ MAGKEU)%#!--JLFZY4A9,!(BJDD?<0R-MSP=S_@]#R-GH_CCX3Z#XJ^&R>\${C
MQ3IV0B5;76(7,;1?:8C"7?((15*J=CLH7'WL.I,\TFKGEJK7]C"I?XKZGT?X M7\<:5XL\#0^)^H9U;1YX'NI&06
_8R,K(=P4*K!E+*67 (W8)(Y/X? &::;XG> M);^/0]##^+;.7#Z]=3^4DS=!&
(]@80UX_ACVDX+%;#X3))J^K>&]\${^#4- I]H MMLLUSXAU4#,5B%GDG\AGP%C\L[2VUB0FJ(]X"F0I/X6_(SI?
AFTT3PAK50K M%CIK(L\A4##.P=CD#G(4"A20N:4\5.M--=%]SA/ ?Q)?!7B)X[82\$C1;=%C)"H"Z*
[J'9GF@Q(P9S@YP%R5'M1*YVH-NP;67W/ MS_>/9@.@Z5\X?'BQU#3?VA0AGK%KJ,EX ME0\ :
(UM(VU,I7N>F_ '/XSZ=\\#?;R:Y=Z;>:U=7UW'I>DZ3IT3 M22W]]-GRH!A3MW;7)8Y^[@:G*(WC7BCXP?
M# "S1/^\$W\7^" "I>!(91+J^ MD>'9KF77=,LF4[Y2[%8)6A."YCRK 9'EIEU/VOK'_A(/V@?V:="N?;\$G_C^
MF2>(+S4IA)/LBGFM3;26Z;6<(\CR\$0KD\$ Z0V,Y*M]*>)M:L/%0AG5-%UJT% MWIFIVDUE=6K9_?
0R(RR1'!SRI8<>GX\|V22\Q)07R/*/B=|>KC3=-\ 6GP^L|
M+Q3XE^(1= #\6ISRVEK]G%J;EKV8^5N*Q@QL8,I(RN^P97 J?!.XR?\${'^+. MM_#Xf:)I%EXHM=.77=.U7PW*
[6%W8;UB;*S,95<2-LR1@X?@!5>7Q;]G'X2 M:0X\ 9/^"?B?PGJ=GH'C?PA:E;27-
I,DMQ=PR6TJ!U*+,#&#*9T5 M6V8+?& Q] OA#P=I AW3YI=+TFQ66&6Z0)GE0 ML?)!::;YU<
DG:Z\$I#5EL3S21[2GQDU QW\>I_!'P^;0;KPQX9BC?Q=JUTTMS M-;W,DCB.S@1&4"
<")|SDLL98[P&B\N3WJW^X.<|-]W &P_ 7W^E?'?PA^/ MWPV^ ^EZ-X,>7Q'J.D:EJS07'060-
-4:+KFK2LQFD^U[R9&,L;Q[SOP(LM(R M(\H^P; /<6=F YZ-NW=R,9P/R]2?QRFN4N\$N8LTM)2U)J%% % !1110
4444 M%% % !1110 4444 %%% % !1110 4444 %%% % \$-P3M 4@,3@9 SZ9KQ;X|_M M0^%/ @>D&FW0N-
;|9ZC"#I/AC38))|N]9W6.,\$(A\$89V ^8Y8!MBNR[3[+?J] M0E5"DD\$?,.,@^Q]0_ -7>N,@^\$W@]/B%+XV_X1?
3%\6RPQP-K'D(;G\$;R*!YA M&X,5E8Q\5*#?<6JC;Y,EIH--M; ;3]2U(W0E@TU72 M)! 'N77Q:N?A-
|+= \$T04?'UEIXOM400\$,K MVVFZ5&?)=0Z(/,FRLR_ZIL(9HSE_G"M_X)^OK_PR+X!/E,JX04\$9Y(=TZX7=
MN//W?TKW.U\Z5IFM:GJEA15G::IJ8C->V\^"->,"%8Q(X^9]JE@NXX&[W-
M# =I;&:0;5GA/PT^,GO!T;XR67PN^+OA01]-U?5K:: T+70#KW|T 4?+2-WA1 M90["2-?-
+L[I]U1L/F(S0: \80BU\00\$7C9/@[H'A:ZTCP??RZ35MDA9"CHI9AR0A;7-0_:3_ ;L_%.@2M)\,?AG;75
MM::Y#B2UU+4+B+R|A8G^0GB098&5 +1",+<*3U>N?!KXN?#W7?&]Y\&]>)\V MFD^+M2GU>ZT_Q/!
<"33+YXD26XMYD\W>TKKYI21-B;54(0S5K|MUY)N^AWOP MX: (\,>,_P!G_3?
BYJ#>X>T&:TDN+D3RF06[I(T4D::, &3,B%5PH9SM^56.T M2?
LU^,0'/Q(\ \$GQ=XRL=&T>SU09>: 'I>EB1Y8+%@6C;XE9R'=P00%1 2H9 MF1/DFPMM&T/1M/\
A_=:]JFI?!_X6WD% CJ=BNC^9=^ -? \$C74D@TR&++++&L^ MT>0>F0S%UVW\$?U9\ '?
VE0#/Q>UC6=|@TW6_"WBC1]KW7AWQ->BT0Q 41EG2- M7IPZ/HNFP-/&/B7HL&D^ M*M"L_\$%C!=17\ -K>
(K!9HF#(Z@]G:0?E979&RKL!%;^HGMH>!!?7]KRY^_G M[0^J^%])TK['X"@T&74M+U*\MY(;K5&2\2W^T1JY&
(,LZC@DE"6*DF./W#XK M? \$S1?@[X#UCQAKTCQ:/ID>^5;6/S)9-["-\$1>,L\KQKR0 6!+ F0&M&TNST
M7]0JVTVPMX+*TL_A3';V]K:Q+%'#N]@1JBC[J@# 7H !CN!|!>*?#>D+=# MGTG7=*L]:TR?!ELM0MTN()-
KAUW(P IPRJ1GN >U:3:B910(^80^P?M'ZY MX)M?B1H?@/P=-X7N+6'5K?
PJMw<7.07%J0"WE3*!"7DC)=3M+!6 \MF^0]E? M?M66,0[/0@_XAZ#H;Z_J0BJ>STS2_#R7#PK/J\$TIBDM?
M+0[4\$;)/^]941C\$ MN"/,7.C^U; \:0^%+ "V^;2Y] CG6\;7X:TV,E[JJ0]2D:R1Q!' \PQ&0/@KM8
MJD>09%KC/ [*>J+^REX! \!7FN2: !XT\ .W%MKUGJRVZRC3-0^T/#?C% \5/'/'0F\> /BQHGA VX?
Q3:7,VAZSX/:86 MXDM8VDGAN\$N'+YV&-@ZJ.65?F^=H]0XF_&#Q#/\ % 0?AC\ -)="0?%/D/JGB
M&XUAI+B+1K!2@1FAB=&DE=I5V()%(4L D@=?&0BG)\30AWX@T?XM_%^T. M\0:##-
H_@;PGX'L+FZCU'6+^*2+-OYJK+MV*N41^1"" ,/DMKX?_ !H\ -?LV M_P#"1? \
"4W'B/Q_XEN]2B_X3CXB:3I8N-'T^)^6)K.2Y!4JMLK(/*53L,N% M5"YB2N5;HE-
MV9]HV?/F,"2K'^+.W3IQW[U9K-\ZE::SI<% 9W4- : M7*)+>VS*T5PC*&61"I(*D'@@D\$8(!S6E6!NM
HHHH&%% % !1110 4444 M%% % !1110 4444 %%% % !1110 4444 %5KYFCA+*0"H)RQPI[D^G_Z^U6;K
M74C*\00_,2< \]07'Y?G[Y !\W?M,?MC:#\ \$;34] T9CXH^(<=I]ICT6SADE%
MK'Y;R/=/;,%\$CCC:0QAA)M"L2J\$I\$]F^#0BF\ \;?" PGXBU,6Z:CJ^CV6H7\$ M=GGR%>6!)&\$>[YMF6.-
Q8X[F0+ C5\ '0!0A7X0 &GQ)HWAU3M.UW6/#FL3:A MJ509A;F=I+0^8" 8-Y:;%@/0.&< .SD]=^SSE?V??
A>7VQ.WAC3!M1SMY8>/ M0^F>00#K6FG+8Q]Y3N]CH?B]\2M&^\$7P_P!7\7>()+A-*TR(22+;1EYI'9U2 M.-
/XF=E49(7GGC)'G'[] QOU_X|>#/\$NK>(#=A\ -7>F^([01X],B1A):Q1I M\$ZQ5;CGS4,A5CM4?+RJG(KSRWT\?
MF?%9M8U010+\ \$ _!-]R:9<7_B;[N!)]JE\ D:-- M;V\2^7Y30L600*VQRR!60!V'??#C]HCPQXR^
F%\$4&7P]H,UI)<77VB4R" MW=)&BDC1@,R9E0JN#.#=OR*QVC@M=^#/Q>^'?
B#QKX632[UXE2:YMYD\WS#*X,A69#&A10JL'; 'A5C:Z/HNC:?? \ #^ZU[5-3
M^#_PMNX+'4[=%='R[\;^)'NI)!ID,6666-9]H\AN1D,Q==EQ'7*F*4FMSZX_M9K\9>.?B1X(/B/QE8Z-
H]GK6R\T/2]+\$CRP6+ M&UQ*\$S\$.[@@@(B E59F1 M/7:\8^#0[2WAKX0;SK6@6^FZYX6\4Z-
M>Z\.^)K46=^(&1&6=\$5W5XS0'\61 MU(PR%08K?=M(8@L#@[?T_&*QEN;QV):***D84444 %%% % !1110 4444
% M%% % !1110 4444 %%% % !1110 4444 ?@K^UU@ &.]1L920<^CFW>9E&54P<;1WR.3^.<_A7SM
MK7Q\ \5^./VBO^%:?'R+1+01] &MI9/%/BB\MY+Z'2[H^8(K_ ; ,^,L? !?X.F_\,6DUYXNUK48-"T98+;
[0RW,Q)!\$8R68)&^U= MKAG"!D92:\ \'+Z;^T!^RG\, [65_MRD(8^2P"Q"0J?+&)S0 ;[PGX8*:39:YXW\7W4]
MKI^CJ5T]0:1)#;M++=2NL9W)\$0A,(8.ZLQ3)7 P0@_\ &3X@7?Q9U0X8?\$S1 M-
(L0%%KIRZ[IVJ^&Y7;PN[#>L3969C*KB1MF2,'#\ *KRT=?TU/VF_! ?PX^* M_P ,=:AT;7] &EN;=
\$2\URQDDA/F126US97\$0D 0.ZJC2HK%1&YC/SACY/XW MM?BE\.'S>[?US2;SXW^/H%\(>#M/\ #NGS2Z7I-
BLL,MU>3/*A8^2"TW SJ MX!).UT)2\$274ER:/:4^,F0\ COX]3^"/A\ V@W7ACPS&_B]5KII;F:WN9)'\$ M=G
B,H\$X\$3[G]98RQW@-%Y4?8- MGN+.S <] &W;NY&,X'Y>I/XYS7*7"7,6:6DI:DU"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ "K?-(J@Q> /N.W;N?;BOE?00VB0B M;^T<:W??!#2/"U0X1T64&TX:
[XTN+G.IR!\$D<6\ WQ*H8\$F3DI*A&UED5/ MJF[!9H@-QY/W<9Z=>? \ //07&ZC?>#_@C\.
[F_E330!_A/1HVN98[2V6&VB0 MN68)%'U9G\$[J*
MSU;3(Y':*0M\$I2X1MNU8Y'\$V\$#2[516WLKHQ\V_>:_;0T0X3V^LZ'X!M;?Q? MXTTFX*ZFH@FET_2(UDC3=*

M+=],N/B%J-M<: ?IUQM CT^V1TMY0ZA2ZM\$ZJ-R@N(^YA(&JE^U \) !OPK M
&_B/!X0\,Z;XY&GVZ1F5CJ4+C<5ZA3(P5?NHI"J H &ONJ=D0[V MN?3GB+Q!8^\$?#FJ;|K-
W|CTK3+22_0;L1LPCAB40(=w,<(IR N3VYKY6UC] MI[XQ^%? NC?WQ#X(\/:; *[PVUQGTVT3SA"(5X04,
<2AT M)=EB5B&)9'F"0.Z/=VB/C1_PI_P;%'HT'MK'C06[E-* \,Z'=S%60;R1UC5F M/!"(95+,61<%
9(, #5Z/X#CU^/P08KXJGTRX\1!,WS:-#)%:+(23M02,SD M\$##_BZ+CX@V/QB\8V7BCQAK>KVEU_PA/P^.:
(;J|T;0S,L M;:E/!D^7+-L1?-60!UD*J77"1?5WP5^,'AGXX^!;/Q5X4U' [=IUP_LD,G%Q:
M3!07AF7)V2+D9'0@AE+*RL22LK%1=SNZ6BBL4:!!1113 **** "BBB@ HHHH M****
"BBB@!.XJ.7 5 G *I.XJ.7 5 G *@.IY?XPS_PD=[15 \ 0%K&YK9\ M89_X2.]^J \ H"UC/2N&TKX\$>
M#\36^0: ?X=MH|2AE^T0!;B01Q2,"0%CE%"AF90%.T@ M\$T^9N' /-QP0?F&.G)-4/@_X@TW MPY^TM\0+G4|4M-
(@:7446X0KA88MQOEP,GJ3V%?1WA'X<>&/-YJ=QX>TM=+ M?4)\$FNC:..?W@N0-F|:H!=U 50, #D 8R?
&'P3|\$>-M;DU36M"CN-6;:|W(N M)8E?;T5@C -D\$|-QUJ>1G-' UJ=.FNS0^XG\=G5/VG/A[(TH>/&G3*T@C57
M'VUR!CT;:'!|D"N?_&@/'FF:;^T,USXMN+RU\ -:RD!(DA>(HCCE"<%6YP2>];?
MB#PKH C+36T|6=,M|^UD9CMN"(0A?X:\3>*K+Q.J5@MWK&G.!LUTMU)&#Y3-, M
41U7<-',F6()/&>E5R#C@I*%N1+6^AX)^W!|WP? -00 M"NH :/S PK73 "
MW (9BX7@G|S/WKU+QK\+ #GQ*6Q'B#3?MJ6KR>7^ D3RFU/X1Z';RZQI>H6UGHED-3M7GAD6WB:#
)>%Z;#M/W@1A3|U|>+ OP M^T/P|<>, / 70%DTB^MED:"QNE%PP=@A\$("I/&0KOMWYRI3)0!FKZ8\(?!WP
M=X(6|&BZ';6D&H0^1=?;) &G4PL?F0K(SKM8J,K\JG SG QEG|G/X:3R6*X.P1>9Y?EX4?NP-
0IWJ1;L9U,'6G"/-%VM PQ-\ ?\$% M P") A#X?U'4|V2_OIA.)|G\R4|Y(U+MM!+:47.23ZLQRQI?
M(>\$80&'PA MUU&|0|5IL? \ :K0=E.^\$%GV =7,7G*0NPZ=1Z3:VM08VL4%E!%;6D0\N."% M%1(|OR|5"J
JC'"Y..?6B|M8=0LYK.X@^U0SJ5>!N\$=>^3]<5M0&QZCHREA M 8SW/B7|G339/B%\4/#,%Q|E>'PS927,<4?
F1|PDS218/=Q+#?NFPY-G*+5DN)\$DBB:;3S8=ZA@Q)'FYX/09KW+P/\,?#/PY2
M|/AK30|-2^96G19Y)\$++N0@,|8^|>@'70VT/%7A'1 &^D0I>MZ='J5J|JZHS MLA#*0>&5E8<
|",XQWK|4|+7/+AES6&E3E|3=TSY^_8M\..FF>*?54T-K=S- M<+:6THR)X-F7DPNT*\$)F7;@D_*
<|JK 'Q47|J;P|Y8D*E|-.^3|S'|?)FOHW MPKX5TSP7X?
LM\$T426.EV:E8;9W9P%W/)PS,S'JW5CCIVK+USX8^&?%7B#3?\$ M.HZ=YVJZ6MCJ|GJ%U9^#5%S;6\|J0?:-
/NV*2VV3|S=3SC/IWKE?#/P4|\$%^|34+7 M2M"CM;?5(6@N,SR,YC965D5C*63)P?D
SM&>@HE#6Y53|U95)32W5CS_/8P M_P"29:C -AF;T3!7*L0_ZOQC_-N7_M>OH+P;X%T+X?:3-
9>'=,D@L9YC M=&.2>25I)2@1WW.2W*Q@=1|VJ |GX7^'/AJU\0A|30L 0-@F;SY)/,V%P0#. MV,%GZ
=>9QC9I|A0PM2FZ3M\ -P^WC)?A_X|UC7FMUN)K;,)J=N//D81Q; MLLOR;V4M@| :^6?@#\..?B1?:=-
XB|\$7FE:5'=\$VHEU9,M<1HHW,I:!\H2QRH M8Y9 ?X:'K &7@71/B!ID>G:|9 ;K=91+'%|HEARP!'6-
@QX)XZ>M:&AZ#IWA M?2K32='L_L.EV<8BMXL!<+DGIN)ZD\GDT2CS.XZ^#E7KQJ2;LE:Q|9?%P,
M^/0AWXJT/QIXGN-)UZ_6=&6Y@4(?(='C^T 11Y9CD!L|JC#M76?M@:Q%XB\ M- #K5(/,\$-
|:W%U&LL>UD21+>15|] W|X\DU|,>*0".C^-|)?2|;TZ/4K5W5 MU1G9"&4@ \,K*PX|Z\$9QC07-
7GP%\#ZIH.B: '/H\DNEZ0DB6<3W4V(\$DD#'\! MW+9;|XMC&T8P\$K;^1PG|9_P#R3+30^PS#_P"B9ZZR
MS\|KXZ_9RTC0C'')-=^+;|/YI946984>)G9>0BNJN1@YV8|UUOB|P%HO0\$T
MN*PU|1_M=FDGGB+S)\$Q)Y94?.A#?ZMW|FDU"XC^'_@F4Z1I,|Y;Z;:59:5; M%IGE95 @0-\|]>
_LP^!=2M;CQ/XR\46-|!X@U*9|-X|ZT:|A#GS97&Y5SN;:< #& M!70Y# ?
ZWS|G(7^|D:0Y\$4Z4+;F>7T>2#J2W9P7C;XW>\$0AKXATC2=-N)XYK
MN/|6MQ"A=88.50,!DX8HV/E(R!F0GW|IRS^&'P-00GB91 M=R|3AJ|>ZLN7N>!\&
|P1XA@^"OPXU#4I/M\$NE6SP7LBP&WGM -\$11?+48"H(MQ"68AL|006/#+'X9_N;PS;:S)X|U"U\$BQR?V?-
=VWVF%G(3:|NENSJRR%AP MNU0_Q)7I|*4KJ MWH>0?'#2=
T/|FGPI:>%;^;50#J:NIL|V<@0(&CN'8'Y5QAV;@J",X/(-?0/ MPI_Y)?X, P"P-9 ^B5J7Q-
 \./#OC;0|71|1T>*XT:VDW0VL.Z%(75&CVJ8MN MQ=A?"Y..>G?8T?2|70|M-/L8/L^GV:QPV|MYA?;%7\$?
SDEN@|D5<8V;.JAA MW3JN796/FCX#_B_M/;\$>|<|14J07|0TY^F<+|66LW|G'Q!8?;|QMXI|>+)
MKR*SO\Q)%=2R(D3/#YIR&9E 5Q(KIR>(|-TV2# M5+W<|U/'=3,Q|QEE*X+L.6*=AT|]CQ=|* "7C|;?
^W|'M|Z5&R)6_J1Y)^5/F=?WC_*04|9KZ)\ ' " P0\ #SS_/A'-M:&67=NE^:64H?F*^8 MS,RQG9|W<0,
<=Z@ \;?"?PI\1+BTN?\$FCPW|Q:J8HY=|D;-(CXQRKKNV|)6(M.W+=-W)R0\;DRP%=KF;7,YJ_&|PY|-
0%FK: 'IWC/68|#UNW);P|H-0:SDLXG5VDF0'K MM9F9M0HN2!SCJ:Z90H7|V)"I8G?
+|YCWK6\$++4Z|)0EAXM2>Y|0?M0?Z0P= MV^ ^T*^I&_UQ^M+>/(6^2/R|Y0-PKKG)5.H/3MW
MZA?|30,'E?,I\0)Y?&5YQGI|TN6TFR*5|TZU2I_-;\#XJ|Z0:;'^UCJ%|>W
ML%A;IK6JAI|F3RXUS|HZON&*^L=-^7A.\N+;T@4:)=/)(FSR|1MY"|E@!Y M9WY+Y/'0BN'CS3_?|!1I7|_-@
M#0|4L|1L=!^SWUG,ES!+|NN&V.C|E;:7VG#!>0K40C*+=DN.>@KKP_ER"8"1U).XOM(?/7"M MP?|
Z|')K=EPR^5:4YUI:R|/H?,'|'0BFZL;K0%X*OH'M|R'4WR(T;|B176& M8."3P (U P""K@|!7!_LE^(-'\,?
\$F|NM4U+3|*L5TV53/E M?550\)?"-GXP/BNSTKR=?&|E0//FAV9|D8;48+R'/3TKG0\ AF/X;|>@'MZ*
M<#_3KCT&3|_N'->FBLK'Q3H>K74GS". MQ0HV9A@8PFX|JD^(6FWFN^ _\$VGV+3WEYIMQ;Q6\|/M M<_X7^!?
@KP;X@L|8T;0?LNIIVI9HI_MUP=@,AXW'^*[G: ?LK(%C:-8_WDD@
MRI"J%;KUX)XZ\|=^UUC&Q|5.,Y4FJBMi8\!_800+(-#/4|07'FRKJGG-;Q/N
MEVO#&J,WU;:C_@)KJ0V@/BU= #_3\$T0P_.+WQCJ#BWM|:.*%I)K93SYFT*=[@
M|0L9^|Q!PVS:>>^\$7PWU_P""P :?%M;:=CP5>P!T0I)@B98LT,:-@L=A,D
M)!*LPS(Q)**WJ.F_"PMI_B|_%4G>9XFF)=KR6ZEFQD ':')\$>,!=B!5 10 M H #8\W#QJ_5_86M_PY|S?/_|
!|]G^STJ)H;N35M5CFU2|5_DE81R M-%;JJI^|B&W/./G(:;-Y"Z^V>A>% P!H;P?; "J|AU"&^AVW\=E?+
<1A0SB9_MA()V^=(D9Q&0=ABAX;.%^H?&@:=XJTFTXT5()+NP0#LEC?@2'KP>0&/4=:Y M|P1|*"??
PYDN;CP|I0TM|Q|+>=))945F P-S/M7<%90NJ0@SDA<0X.|R98& M4*UH;) @>2?'K4K05/CY|,-
%M=,\$DMK/%J+;7W!0,E1V ^4<*MLW?^(\+W^B MRH10D'>#0 ?BK50V@/\$GC#Q1;K;VFG2M9Z/\ .S!D M*A8C
QPIB+,W 75'DQSNKV|\$A0I|S>?F/F|=W|T=|91UK2*Y=3NP<9RG.4N MHO-'-'-'-(|)!S1S1S1S3&-'-'-'-
!S1S1S1S0_B_#W_D\$S_ \ 7;_V1:ZFN6^'0 ()G_Z| M?^R+74UM'8|VG\ ""BBBJ- HHHH **** "BBB@ HHHH
Y;XE?#P_ \>?"=WXG M\47W|EZ)8F,3WOD0+Y6^1(T^5%9CEF4< |:^*_ \ AL/X1_ \ #9 |<'Q5M\,? M|

(\$NBF_33;QBEW_:'G^3L\$6\ 'R\ 'A0.>: ^ #1*3CTJXR2,Y1;>Y\G?M3>"; _M_+0A3X7??SP%:S^*KWP?
J%MXHM-)CF\$#:I8,8;ET13&S>8PBAV@-@0A78J MIS_B=^VEX<\>:"[_,% #ZV\0:I5=>B?
1[+PXEI<:9?;:'\!X5TM[F_N1. MBJ\ S.TTD<)(CX>61DB4@,5,2G+-SR'PA^"?B?QQI'C/XG>+M3UKPU\20'FE7
M6F6\$-Q(V_P)Z=(6-M;PHCIF1#Y&4H(?*E2)I_5W7\$P?<%5 MI1^C-0G+ @ @#H./P-
38%+1*7,\$8\H@[TM)2U)84444 %%% !1110 4444 M%% !1110 4444 %%% !1110 4444
5[IEX!;:2./FQZ#IWY(_0(OBI^U M'\+ _ ('^(HM#\>)UT34I[6.^BM_L\$S/^X>1HQ(3%&R@U=RTAIK1B=W
MH?\$\$!/0]H/X?R?!_P! "Z372WCK_30^)/]AG5B1<7%Q_K?6/(B*M)\X\$<= MR*X/|K#|K[2_&'Q&B^\$-
CKD_A/P);7[6?C;Q-Y4D9\ P??"0]J \ 9YTFW\, #WP7XCM+&\$W\$.E:9I%OI
M5Z(S))M1=SPCYG=LM(Y/S\$LQ))V?VEO'FNW-]H?PF\#R7: ^./Q_?:IIK)
MYWA[2U=%N=0DRRE/E:1(R"A9B?+=9%16^A\4<5/,K\UAJ-CY&^*WPCL_@/X= M^#&K:%97FI_#WX=:I+-
K.DNIN,1SJV_6) %)9[65GN (X3@RR%I&|PGP9\<6 M'QX_:\UCXB>#
[6\0_!.E^#QX8/B*>W:WAGO#>K<^3\$)%5R%1\@\$Y)&&1F^ MNN#15>TTV)Y-;W(:7R]\B1K\J*S'+NHX!ZUU-
%+2]P/@+_AL3X1 \-D#QP?%(7PQ_M_P (\$NBF^33;QBEW_:'G^24\$6\ 'RL'A0.>: ^COC)^TWX8^\$?
P1M_B3(:06]/ MU2* Z/:6L9634))XC+"G(Q&I3+LS_54\,<(WMUG*TYEV,^5]&?FS^SC^TM\ M+Y_\$^I?
%KXP^XKCXG:A-);Z9:IM]/!H.G|,+:PHD+(CD,Y9MS,489*L\H/ MVSX!\^.'@KXI^#M4\5>'-
=M[SP]I;RQWFIW22VM0;0^LSEC.(D5'1M^N. M!QZ8,>E+3E)2>P1BUU/E/X%>'=1^/WQ"7XZ^+(-
TFQMO,M? WA049_B6ME) M"L43?%C2?@1\ \$B-\\$0%-GJ5U\4=2DU6WL% MM=/DFN %OU"1HX-
2+*IOL[3^65>5W_T&?!\Q/^>I^)6M %\FA7EE_90\G7+;YKBS)B M'F+\$8QN\$L?S;L#/-3?
LK_+X: %KX4^%_A08:I#K>KZ;X2M8=6T6ZL)EB\$, < M\$4\$Z.9(Q'*NY|I7)#!NF_37U#160,N7EL1RZZGS1_P
?@,S,K^ C;B,+K M6H889\W8\$X^8X\!+=?L4?L]^ -/\ %GQ'\2VV@K^K?A?QYK.BZ5>2 M7<[&T6)
(@FWS=C\$)+(NY@6^?M7VYG%_M'9H?*NA[_ M+_\$#6[Z^T/X3^ M!9+R/QOXN.Z;4M-
93+X>TL.BW.H2;F5D^5I(XSE"S9V2+(\$5N.^*WPDm/@+X M=^#.K:%8WFI?#WX_7Z\$?Y-
3BEJ6[LJ*LK!1112&%% !1 M110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% '++\$KX@>' (6^
M\$K0Q/XH00[,T20,8G0?)>7R]\B1I\J*S'+,HX!ZU\5 \-A_"/_AL@>.#XI" ^ M&/\ A
ET4WR; ;>,4N_[0_R=@BW@^7SPH'/_-??E&T>E7%I=")1;V9\ S?M.6F MM?\$(X1^
?' /P^T^3Q<=:U_2_&D&G1.89\0M(XW<+\$I0_0"LRL%*[L X#MMC? MC/'?=['PZ'??
#/4M"!\C6/&'C+Q!IEQ;V/AVV\0=2V\TEHY7SXG3RY(HSPZ MIYF5#?*ZY-?
9F/:DP;?.K6L3R:WN?//PAT^W_91_9+TA/&\S6B^'M,E0\1#2 MPJT1M_A/3I"QMK>%\$=,R(?+F9SL?<-J.9&?
ZGI:7-U*Y3\W_ '/Q\$L=> M_99TW\G2PT'4;'XQ0\AT6?PA9V)C9;B"YCF0#*4\$/E2I\$T_F*[KB8/N"JTH
M_1FWSE@0_0!T'X&IL"EI2ES!&/(.]+24M26%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%%
%%&)XP\16'A#P[J6NZM=26NDZ;9S7=W) M'\$TA6*-#(];44L2%1L!>3G !)%?FS,([J&Q;3?[-NE
F@083,@E:\$0Y58I#U.=0%?=U&T> ME"DD^:P.,FK7/+?A-^T^X ^,ZZFW@7Q
VN+I9C^ULEG<6ZH)/,6,\$RQKD\$Q/ MRF<%.V1GQ_XA6-Q^UG\7F^YGU:#X5>"9M_BFZM)8DM_\$&HJ(GBT_+=
(M+72 M?\$(DUE)=+I4]N")-5(EDD GRUV<"-2T;8#E68=1^P];WU[X%\<>*;G1[W1;# MQ?XOU#Q%I<.H;1-
+93K\$8964,VTD+W/S8W_LK*S?1_U%'2JZAS1S1S1S M1RAJ'-'-'-'.PK=PYHYHYHYHY1_...7*0=6'-
'-'-'.PFM-&'-' M-'-'-, (KE7F'-'-'-'-&PN7N'-'-'-'-%AI/J] YHYHYHYHL3R);!S1S1S1S
M18KE2T046H_P#()G_Z[? \ LBUU-;1V/=I_ M @HHHJC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BB MB@ HHHH **** \$/45'+ *0\ P"52'M4 \@JX_P"N_P#[(M=36T=CVZ?P(****HT"BBB@ HHHH
**** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
ZGG7B04'BUZ[C00_*RY\RW#_P+W(-9')IS>M0_ , :?_ \$5 M<89_P"\$C0?J0_H"UC+-0F9= M.;UM \ P#3_ ,
(H M.;UM_ #3_M_P"(JES1S2N1=EW^TY06W \ -/_ (BC^TY06W \ T ^ (JES1S0^V7?[3F]; M?
_P#3_XBC^TY06W_ / -/_ B*I4UTV[&? MM\$D03/3>QQU[5=HH **** \$[BHY?]?7^?JDBHY?]?7^?J
ZGE_C#/_ D= M[15_] 6L;FMGQAG_(2.)^J_@+6-S7+/XF>+/XF'-'-'-';\$!S1S1S1S3 M_...:
#FCFCFCF@ YHYHYHYH ...: #FCFCFCF@ YHYHYHYH ...: M: ...: #FCFCFCF@ YHYHYHYH ...: #F
#FCFCFCF@ YHYHYHYH ...: M: #FCFCFCF@ YHYHYHYH ...: #FCFCFCF@ YHYHYHYH ...: #F
MCF@ YHYHYHYH ...: #FCFCFCF@ YHYHYHYH ...: #FCFCFCF@ YHYHYHYH ...: #FCFCFCF@ YHYHYHYH ...: #F
#FCFCFCF@ YHYHYHYH ...: #FCFCFCF@ MYHYHYHYH ...: #FCFCFCF@ YHYHYHYH ...: #FCFCFCF@ YHYHYHYH M ...: #F
#FCFCFCF@ YHYHYHYH .:#_ JV^A_D.::#_ *MOH?Y&@SENC7X M> \ ()G_ .NW_LBUU-[3^!!1115&4444 %
M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 % M% !1110 4444
%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !
M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444)W M%1R_ZO\ / ^52=04U]\$?2'-'-
>7?!'X[V/QBF0+=8%T35K3:@L3-Y5_M2Q6=]URJL&5MRE>,J>^ \$C1I_B[XH:GX+TVT:ZCTNSDN)KZ4[\$>=
M&1/*V<8QYA._ (P<>M5*<5U*G5C2Y?:/=GH/-'->/>-/\$0Q)LOC3H&FZ-1KWW

MA2:*)YY);7=%*NYUN'FDV)LE\$88!?-,"\$.#G:78F55VA&608SOZMUZ9QR!^/ M.
[GL'S(5.LJCDENG83FCFCFCFGS(TYNP%-;'B?P0I&LK#)D& MH6D-R+7KY(>-7V[0X^7/S=;H-
7FES%*I.I./4.;;-Q"MMVK*!N5VY P1D8 M[9!^]D8Q[UX5X^_.GB;PG\?
[;P9>:3ISZ5=7MNEK_#K60\$"CYK&\$B*,(C'S9&\$2; MLL-<_M&SM+34+";:/,MC&5B,40">=GSN67[P-Q
MMQGG"YU>PGBJ;J1I7U9ZUS1S7A_QI^_7B#P1X^T+PMX=TC3KB\U**,JNH*Q^ MTR22F*-5(D3^)
<'V8G*XYM*_ \$7Q.T XP>'-*L+(:GH+P1#4)ULV^R2,I=;M MRQ"4=HD*IYIZHV7W[2N?6Q@;\&[C%-
M.Q[+S1S7?*%#XD:9\?*"YUB^1;= M(EM;0?Q330DJF_'R@!6^;G!W<[\[*JZQXNN;SX*ZAXJT\ _P!EWTN@0?
VZ;/-^ MS.;?S57E2LGS'[S=?;HKYUU.F6)IQ;3>RN=KS1S7DW[-?CS60B'X'U#4==U' M^TKV/4Y(5?
RXX\1^7&WW44 ?. \GY5ZSS5*46KH*57VL%. (E# MDENQUJ*-U)/1'K?--
>\$W0[@Q+JMM*8KV./Y0&))5E0R,RH5 M*CYL?,LG601^:7.GL*65:*FMF'-'-'-5S(WYDNH(8V@0@G
CVEG8XJF, MA3G[/J?1/-'-5-)FN[C2;_6^L%TR^;,>?:*ZN(WZD!@?F)*[N =0 ZU;YJU M)' :Y1C;F>XS9UW-
'-?+ CCX _!;^&PM]5\ (Z' IS7\$(NIN%U:2.'>@EV@7)QF+=U':L?:.VL<\$,PI
MSG[.*= 0]KYHYI6*_+L#8VCE^I S]32_0NZ)E4C&/-V=
M;S1S65X4UL>) "'^D:RL/V0:A:0W(M>0DAXU?;N CY<-WIN@U>;+H(U(N'.G MH'-'-'-'-
%T5S*10*X3)CY<;EXP%/V@];T P :1^#0B/X?30-9NF\$<-[:+F-L\ (FP,RG+! G5B./45FJAY
ML1^1')EY;F2&3ED; M'&WH1^/;WB/ %8&=S G#=#,I #0^?84N:[L<]/\$*I*45T%YHYHYKS[XQ?&/3 MOA#I%K-
<6SWNIWK,+.U10+ #A -Y,F/EON7C!SGIQD'-HWV-;E3V,>>;/0>;. M:%;,<=>\$C0;*2;>X!-1U/Q!?
2:M=Q:JUNK100QLL96)B=J)@&=+U03 M5M0\MQ?.JN\X+G&#.A.\$ \$?0=Z%*ZN<\<53E255)V?
D>E\T' P#A)] E_8?)D^Y/F?M6*12^&N0_%'5]3FB\8^'M*T#2C; M;TGL9E\U9B4P,":0X*E\1?
C4.IY'-2S&%; +%Z.VQZ=S1S7REX1 :2^)_ P 1 M-2N=.T+1/#]U=P00*?" M.CV&@R"YN[9]SJ!"P7'^D-
_\$(X30JEPI9A"L AZYS1S7) %SQU_P * MW\!;KK-Q)=+.%/:/0- @? \ M!;I\00%=YH'
MB73;>0N9(([NR2V@:)IDV;0+0.Q^9@R.FWJI9C\X4W4MH=,\92IU53;1YGNG M-'<;\9/&5[\/?
AYK/B&TBM[J]M%>'SDD:(L\R)VY^Z7^RD<@UXUX+^7QA M^(6DR:EX? \
(: #>6D4QMI&_U:B0*K\>97Y7V/['ZMYN= F;L2R=,)CIU/7MV>J:I%> MFW6I7\$[6UM90/[FC]-17C/9Z/;
[7\$#':R^7^25MH1HE5E=5)+NP&]B*]0 M^T7XWT*SM/\$0BGP5;6W@S4W,=NUO<,EVA9F;.:XWXI_%;2?A7X=?
4M062?4;AG2UTJ Y>>;(S)%&Y=SY M^4E.I(#9 @Z^^ (7B;X>;E=ZQ'I^A:U?6S'2H1!+&;=R"4-R6:3Y\
[6V*H*A/ M4D+IS*^A0]9CS.'5*_GZ'H7-'>+?LP^/M3\4>'=6T37)+Z;6M"N1%_\@F?_KM [(M= M36T=CW:?
P(****HT"BBB@ HHHH **** "BBB@ HHHH *2JU[C,8)8;LK\IP? M7@^0'J.,GM7R=X#6?&+JJC1Y0&?
A3QK; "'+P.UY+^HH&DV^JW^HQ*?+>2Y\ MQVCB'R(^\$CY)+Y)5\$=Z4;JY+=FD?
75+7SG^S7\;M=UW60\$WPS^(D%I: \$[P< M(8[Z6QG, .JVS(#%=PHH!.*E&=-JA?
-0X3<8H_H:W)V6<07'!Q^GZ8HDN4:= MUIZ=#Q@]>@Z?%=Z]XRU+3C?&*58G@AMHF980SA\?
0"N]Z44>5EJW@GQU\6?A7\= MM&^&0Q%URU\9Z-XJL[N;P_XEM].CL[E;F"!)9;>;)) JI&B2'<\$D+&5"&(\Q
M(Z4>8FY[4\&C:*^4+CQ)\80CQX@^(4_PV\;Z=X!T7PGK%UH%E;7>B)=SZG>0 MPQ^1?LUP_\$2^[\\$?)'\2];:Z
MUS7Q'J\$6A1Z?'9P:)"ZETM@IC68R_/A_.9BI4(,[6>3UVD]!A112&%%!! M1110 4444 %%% !1110 4444
%%!!1110 4444 %%% !1110 44AJM?J M6C 1U24YV[N?KQW'K^?:D!9H07RI_P)M\6/VA/&WC+3/AJKU0\
##P?X3U6 M319->N=-BU34-0U"\$E9H4@D=J8;#.L>G\ (?BQXP/_%?5/@Q\
M5;BUU;Q(MJVK:#XEA2&*+7;\$RL"K0_KLGC"0^[0'Y8W)R\$6273EZDQB2HY&>0Z=S],G\Z^6H M?B/\4?
VA_B=X]\- #[6X_A?X5\&W0]ER^(+S1AJ-YJ%^C2I+'\$KMY"Q ?/CF M0#[.0XE9\$:5R7*Q]7TM?-
'P+^)'Q!TSX0^0A%\4+BRU04;'2EUS0_\$=G:1P M?VC8FX:)WN\$F\$?7->PPQF<7H0Z%'I=G#HD#J72V"F-
9C(^'\YF*E0@SM9Y M\$XV&I7/7:*1>]+4E!1110 4444 %%% !1110 4444 %%% !1110 4444 % M%%
!1110 4444 %%%>-?M5_&[^!'PUAU;2M\F\2>=(40X]'T?3XHS('094 MD,995978#8<(GS.VU
5W[U!'LM%?'GQ,M VE?A;X1U#X@0 \$?P_XJFTN'2_U M3P5_8,=M86Z&)FF\$5WN\$[BP9+J&9'94!))PC[I\1?
CMK'B2Q^\$>B?#XQ;+K? MQ.BE0;74=:L?-73;+!/[1+(8TDP;E5DA*1L6C9@0Y *DWRLGF1]'T5\R!GQ
MI\1/"GOVUSX0_\$/Q#;>/7.@KXHTW0'%91:?.(1-'0;R01#9GS-SJ020,\$L2 MX6*WH/Q#13 &?X^:M8>#1?
N=!^' @68Z?KKC2UWZSJ>Y_M(IY@P6.\$(F\J% M<%R!E9\$D1W#\$_K,V&.T^N<'Z\$0]U8Z?:F+PY;:I%-<;!
M[F+S9^4B2)R-R[W^*:N=0&?20#]GXP^?@WQEXF^GQ)G^).GZ=I[ZC\$+?0+ M?3I+-((Y9)@HB?\$C2%_WD
:,9^] M; \7:~J.AS16&H:E\+/+?2/LULEK=>7\$B1WGSS^:#-\$Q!R%X?M+?%K M6_!>AZ+X5\%/Y7Q-\;W7]G;
T]E)<0VV&C%Q=S!5P%@20.[T5S_@71]3T#PU96&LZY<)=5AC_P!*U6ZAAA>XD))>7"B(HYP !P 2QR
MQZ"H+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!XJ.7_5_G_*I.XJ.7 M_5_G_#@.IY?XPS_PD=[15_\
0%K&YK9\89_X2.]^J \ H"UCMZY-%JEFEPKV=M8 MRF1B9Y714+87<2W&6 XYXS65^V4KM\,="A0?
[7C._Y@R_N)^A'3\;M?L[^ M0#6N?!S0;_4?#NE7D_FW!^UR64)EW"XDQ\YY-<ZE\1_7B
M#40\$TCB"QT_3D:26XP=ZQPG8RH7=G"1JIMP2?0#E[JLB,0HX6"I.[9]+\"/ M&6K_
+J^&L^'+_6KW2M>L1#Y6N6Q_TAHV4M%0;*= \$L?&5YHHNV/VN.YUZS1FNK09<+&VXB5<%RRR-^ \/*'ENW?\
M[#NV1?&L;1+YYTGQ(UCQ#X5^/'PU, M3>*]0;TCATR&\ 'VJ01W96Z=&;1,?, '7D\G&1S5KXZ?&K7D\;Q>
/'^H60AB9 M /M^KWC1Q1K0B\PI'9"#Y2!'7D#?S\O(P, MQS)\$8FC616)\$@'+,J<;A0Z8R-
'>^AK*5=1FJ6B4B.X^(>M? WQAH,D7Q*Q# M\7DF+RUDN?M\$@'R'S%#2L5RC.4<,-Y3H0JFNG^_GC#Q;H?
QT\ -Z5H.L/9R M7VGI;BWDGF-L)Y9IXA)(@PIP60C*-S' 'PW0XTDW[/)U33+'3],0-5N;]TM=U
MJMZ\$@W;0"V]T;YB0<1 D\$-P"0*L '(I_PTU_.50*A4Z;NC&=RY0W(SGV(Z\$C MTXI:F=JCIRCS75^AA?
\$Z3X@_L \ B#P[J/\ PG5SKD%ZDCJM[+.T;:602)+# M08%2LD;\$JRE2V[Y" QW?VP0"%
[90IX@_X2&\DTJZOH85T:;5W@MY@C_08\#" M@^45(P07=R#@@_]N#[0@_ \ [??_&A77?MD6<]U\,;62-
)/)MM4BEGF2/<(M4\N5_Q^4]7=\$_P"!U-I--"E3]RK!7TM^2(?A/X6U0X9^"SXV0/%5_KUBGA0[M3:;&[2+!
#"DJ@ \$NZAE*E ?+! 8D \B0-/]XL^UQK5['\4KG00\$H=A;>& M;:26**3\$0*K'M-(@LGRE=S*K#:=@)' '(R,^
_6X^#'_B;PC=ZCH-YJ&@>)V;S4TU('= M)I&D4J7!A1,#[\J1\$;_#Q#J5K MK.JQMBY0EB2..202;\
+P0.F "E^6P,U\X MJ^\$91=:#XG0,(FCDTR[D>15C M\$F&)>5SZHT_Z5[!^SJ+L?1P0]N-S]J\F3(0.)_GF0Y6
23L\09M[;<8)&.2 M?'SPU%XG^\$ _B".2*.2:SMVOX&:/>8WB^F2\;3[>13+!/M6)(]P8*J]YI8CD'/EC%4
MOA_HJ !?JIX>' +?J3;:J;JL\$BSE_M _JK%\70VL-2U.0VNJ66G3R7\;0S,J200-'#:&.16.YLF!00DDC@BNK^_
'BK M6=-: (\!V&FZK?6^EWK6'VfV2YD2"?>.K0-%_&&VH&'<*:L?L8^&I['POKN MNRM(B:E@Q/CO\ \G/?

#K_N& \ IQEK M6-{} LZ(TYPPZJ* -)W?WC/VO_ "-Y:VL'B3_A(;Z33;N\MI/?^Q;GS/*MYUB;I
M{&. =H(CVE<'!1I\$^R((WMD?; ,R'E M0&3_ %8^16Y^V-9SW7POM)
(TD\FVU2*6>9(I\PA3RY\$#^Y3U=T3_@=1^&?B/H M'BSIGNIT73];@DUJQ\(-'<62QR+
(K"U(91N4="K#CTI2W>A52*C7J ME?LF_ \$+70&6F^(-/UJ^ .IIIK0R6UU(Q=V64RY7>6.5!CX!) (R1D@*!)^Q:R-
M\,=3\LR\1K4^3\FN7_ &(?)7XQ_P"W+ V01&6+"TG"K0<=FM3ZBVL MQVK(4=0E"IU?V/MQ^>V0E'39?^%Y?
M427L%P;C0- FM&A>)6: *V=0@CQOL> MX, 17\ 'P7T^V-=/@R9DC)"N2DR8Q(TR[2HQMXX(K2
MIOL=>8.56I"A%7C>[\S6%^]\OP?_ &D? '\$@V;8?#^K3*B>5*!'&K)Y\H%9_F MYC;RRASN:9N2
_=/^U=XXUOP#?>|!_2|^6V2.ZN9;FW\$LD45PR&%U22+/*@, MY(XPN[YESF0-?
CG\+ \$0PLU#1/%=WXG0/%S\I"C4+Y=KP3IAX!M>63.XHS9 M" \>7[UI?M5>*H/&WA'X;Z[#)YK:A:7-S*?-63;
(WD[TW#^W7W+C QBL8WV/- MGS9-\7M ^)/PETW1? \$ _Q\$0-80IKN,3VL\$CB(76/.VK\$S\$6B& MUQ\T:
*\$RF#\NY^T.JWB6_ \ AGX, \; <56_))"B*2\$2@9+\$<-N7N?@QI.J;+|-]*'B.[F0-8N MEW0\2_0/F7\$84%>@8-
C.'+NYN; MZ&69G>.,&)98]V: 7A1?DY4S, _ONQHPA,2B295(!\MA&SD+V.XX)4+P../ MQ\X?M;?"'/6?%3:?
XFT*UDOKNWB%>00\VDQ0+1M\$B@EA M\JV.?G7@C=CF0!' [9E]80!#XRT0[?81QJ@0=)C:&<;%9L0&6
+>VS. "@&[@ M*)+W#74=A-\$ EXD <*[(K/NE8;47ABCGJH)JI;F M>IPXI.C4=:E+WNJM>YZE\?/CL/A_X*TS4-
!_TJY\00E["\ =0D<%OY:L)&0 M\I\$ L9"%,\$, YPM>+ "/AF#QA#\7K.^ \3QS++=^&[*_2[2(2.4V1*K,
MKMETR@0(H,A4D(A.]\ ' [J'4U4!+=CE0)]2V \V,9 K+U(/F E2 MI"[CM&=VW9&%6=257WI**TW=CJ0C)\4-
3USX ^%?\$FD7=I=I=Z@BR"QG> R M,L5S&R#;) ?%6D? \$#6 \$D< AR\CDODT5;R18PK MPLD.V':RA1N7!+9{(W?
-NKGOC\#H4?[- A! # -G-I^AWSI17-M;W& S462.Y M<[MQ]ZL?;T)&*]Z^%/\ R2_P9_V!K/\]\$K6M-.
[.JE"=20RSD\CO?X, ^*-6 MU+]H/O\IEQKVH7NE6X0&@L9KDR0H%0(E!CC9B@8)AW@O'C>WU;Y@LJQ
MM,5.U5+ #S_07(IV\=F#C(C405253EIUF^1MIFYX<\7>, ?@S\;-/\ \$Z\XBU+Q
M+H6H31&'4+C\$LSF4+&DR%FW)B565EW ;2S! ?F! -P>*-, D: [71]M;0[?2' 6 M33TGD-0\VF%WPF I^" *3;T
M,4GFF5D(#1_ Z0\3G) &?FP\$ \<^([+X?_M>2; K-M)'IGIH?;H8Y%#*UEY6\ M
?,0'W*=N6!0J%8@"B\[\&*K."7+?E4_P.L^ -GBW6M-; &\\$;?:ZQ?6MA-]B, M\%0=3+
(QNW7;\2L%.01C@]ZF; >^*FHZ'XDT;P99ZJ_A03[Q(+N_P\8L58W M\$*- *R (JA7(10[E4[F\V@&\$YX7XB^.-
/^(G[1/@?6M#2;_TA-1L+ #^T3 T<\$ MDZW*M(\$)R20)USGGD<8P6]>^.'B;X9+J6B>'?'5B+^22)KZVN61\MG&5*
(S. MA#&\$HWRGAMN2/ER#5G0W.HJKA*VI%\) ?B02]=M=3A^)Y\6^\$+J+,PD9KKS MY%9_DA;]?+?;W^K\ '?
+ [_[0KZD; 7'ZTXKWY7)P]_K%;FOY?*;BW675+FX;:Y0ID%C%'+*/W+\LF\G13Y8+ 'Y>P;N\^(70%\1_L^
M"71M*0[R360%5Z;J)-7N+C[0BQJ[8?R*LD2*C)T#DYP >? \ @1_R<| \1 M?
^XE_P" G&*NC; " \#ZCXB\+;9K>G02W8T5IC" .CE MB5"\$UA9VN>>J=66&G4C=S0H>
<:UK/B_PCX;M_&/_Q=L[WQ-' .LMUX;LK]+M(MA(Y39\$JNZNV73*! B@R%20B&0<;?Q%XR^)_PIT;5? !>H:?
H6H7L12ZN-1MW9 M\$VN8W,7WQC?E.<^+P:U^SVGA6* _N- NH-450\$TM)+R24MOP?+8R! M67J0=X)4J0NX[1J?
&CQRW@?X9^ (/A_>>&0#VK17%V\$((FC3>DGS.YWIO^ M"IP>0"012N^QE1DZ47.;NNW8B^*&A_ \$+X\VNC>)
(_B3J?B*RENO!+;:D92ID M:-W*F, .Z,A"-N.%D;A@ \$1_M2:5-K'A02/'5MKEXNAZT\F&AW\$LCQVS- S
MQRIC*@\$ "D+N!=W. \@@#S/X@>&_ &D>; "Y\&ZEK7B/4(IE2YNKF%H;6V^1A MRC("LK\$/L&YN%<\9Y\B^-
]B]Q^R[X^DMHV-0;K83W%S#^N2(&V9=WW3P79^ _MLAH\XQES3IU(R)4=0^S[\.=>\.V>D:
[=>,+S5]/0= 'A%0I\$@D\NV5TC= A\W M@J08\5^]W\>1?1.7_A/_ (SZ+JVB+XTU'2-/TNX%Z^I++)=78"5
M" I(P7< #*I/0\$>[? 7XCZ\XL\%^&] %T_6X)-:L+=M([BR5)%D5A& RC, _+,@4?
8ALD^ \I TC-.S;2.UPBY48P;Y;:F1\ \ 5_B9XX\1 MZC\ -6\;091:2]X\YK\$:0/>N4F"E8YF9)' D
5<[#MD(SP%'3_!OQMXL\ (_%W M5_A0XKU277(I'E:QN;J4R2/(B"6.7S=Q98WA5FV-+NT@ \5Q?
#SPG; 'S09;Q(;M\%MI^ \AF+=64,4_56)+!7?I/@M\ M3]:TSXLS> !-8\40^-=.FMY)-.U>-
FEW,%:X90.!W,"A8,I9@FT*N% SYGX= \ M+^#_ (9? \$[5_#7Q5TF6\L6(-GJ;331H4#/\ \ 0-D7S-NX &#M**G
4L/60@< M? !Z\)L%MX.T'4H]8LHYKF#4?])\$#KM*= '^QR&@ZIX\^(7Q6\? \ @W2_%MWI50)?W%RU[/]
<2R6]0'-D;&6/= M\RY" >XVMI_# 'Q%XN\% M"7G@36/\$LFOV4WG1.=0G:9440F6-T,C?NW(:,-A M^?<
J0_IM%:;V-(PFX MP=WK/\#D_P\K+P??>&-T[4YM>U#5K#49KJ2TT[4G9VTYE,19(R6/#,Y88"
M*B^)/'%YXF5CCN-UUYA6WB@#.VT-(W7 !P!]P>U M>4 MK6<R>"IXX&EB1[J(LRGR][&!E5FVD_D(Y
/)VG'OU[EX4\?>?%BQH]Z M-(NXM;L8W\$5U:W%LZY8@MND5U!P2S 'H=IQ0KJ31V4(1^N55?4YD_M-?#5I"
M6\4^4Y0%8_L-P;+6&=K650(DCQ, ' ? M\ZC/#KTJF/A7X+X\KP+X9+X(,;:= "JD'KR%.?QK9\ \ ANW20#-
G'::/IMGI5_MIN)\BQ@6) > 11FM^5V9W\N(BI>TV/AC\G0XF:5*?%UUJ^KP7,]M/8/9(MM M\$LC+
(\D; !L%EZ\!#SGC/0UU>H+<_M7??%3YM/TB:PT#3]>*&0&E5V%I'-(Y; M<\$&93N;8FULD'L"RG[&>Y0B1J*XC*?
V4[/Y@!4+Y\ /!Z\, >.0ITJ2_N+WIE MWXS3S0;W6_F%;6'-
MK_PYW/QV^-7B!/' ,7@#PQJD/AYX\?;=Q: ^/&& _=^'85 ' TXLV/W? \ Q_OD\$;67<"#CYNFV06/B=X1\?
>+M:BLM M%\560A/PTRJ);JTM9%U(M@E,\$MMVA@,[&3Y2V=W"UY1<&1?VG?AN(PJLC:; MS0#);
0I&Y!]L=R/3BL7XW^+GUKXTW'A+Q+XG0-* \!6AA;X2UM_NKY,,NTI% MG<6?RP'96\L6(QDY2;B]C558P4Y23=
[+ \#=\ / ^ (/ %_P/ ^, 6D>%= ? \5W'C#2] M;2*/? =;F8/*65)-SR'8!)D-M<90KQD*J\C^UIX-U#PKXCLM3N0\$-
UK=MJ4]U M+!9W;L_IGN#\$SQQ\$L?E+ /N&_0"KDL; A#)XX&EB22ZB+,I\0>WD,JL
MVT@\$A' (!Y.TXZ&GJX, YE%U\ -433T>AT6KW>M?LS># =4U/5?%-UXV0-0GALF
M;@7\$%H^R7#G=*3M(X.Q>2BCC((\076/%6I> %>+KQK>_&2UL]?@A^W0^&UU%(Q M)'& RAX4DVAB
_ [CRF5BJ*P\!D8#TKXS7^F M""?&_?P5?S:Q/H]XEU-9PVL@ MFD^1RQV-M8D&0LN,[A\$P_) (KS3P/JWP*/@^*?
Q+HTMAKUM\$5D ENY&N9%"C? M&4<(%;!.QB3H25P\$!IOFN74D[I1GI:R/2M' _&CKBV^ (\3:A(EYXGM[K^S&
M6ZC,=M=7(&=Y !(14*,P!128RH\0*FN&M?!/Q\$ \1_";6?'-[X\U*U6\LKB8Z M3J6_R9+5D?S'.YR%#
()"B)&R@&-@R\PR7?'GA00/\$0[-;WO@'0IK328=3;4; MBPNQ(7=0AMI&4,6Y!VN2K;%5&).X&[I7Q_ \ /ZE\ "I?
#< \=]_P_)0^EG1+?3 M[2&25\N8Q^5&Z,B@!3C<0P!#;@0, E:V-')N* \MHZ>9T? [&/'PMU%!#&@D>N, _20>?
MX3]*Z8? >[EUE0@]5U/EW_F]S_@7_N/KZCC^ ^GTKY<_Y0<_X%_ [CZ^HX_OI]
M*SI[RN<>"NHU>9N\VSX%_9_ \8ZKX)\875]H_AJ\ \47KZ\ ^%7Q&UKXB7&K0J7A+40"0M"K1-JWF?
022P<#]V03:0KS(*^4_MV9_ 'FC?#WQM>ZCKEY]CM9M-
>UB;R))X0(FFCF1&V32LB0JY"EA(F9"W;:XR#VQ0C5I)^!WQ.\\$>}
M])1YH([2*UVW3DR3R6ZI*)#@*FZ!HQN'(. _ (7C. '\/_ _KG\0'Q6U_Q-:Z

MG/X;N(PM0#J5KM)M\X:..&%00%\Q+(-R@YV\FNL^+G[. _BBV\\$_ZK?3_\$'4/%
M,..F0BY33M0\$@3*':Q+0*=I6,DC(YSMZD5,0>=T<130'-B5&[3T/4_VE+B/5_M/@)K\DTV.D> M2\56
ML]\TPNK+S-L1>"-3"-L3],9Y*]>;5M_'D0C'\D/7/[:>1;FYTF6VL\,8Q(L) MN8A\$S(JC:-
I:,9)SY!;J340[,GQ@(\(?#WP!?:=KNL?8KJ;4I+J)?(DES"884 M3[BG'*-
UH:Y6JS2;E/\$P:G:Z/H_P/XDN_%WAFSU>]TF?P<77F,VEW/WX<2N MF3\HZ[?3M7?*M&:G!/B3?> +#PSXP?
0]%\&>'G24>(GD7S6CB!CC M"!7)D.Q@44QQLVU/NLVU060V7M4MM0^#.EV\;-2:=>7\$ZIG=Y@E>3_Q_L2
M(3CG"FN-\8:]\#Y-?M5@#\#6.D"VA5K%I8=D4A(R#(V0^S/;->?30YJGAR['+X'DG6*")(?+BFN!(2C0C8-J
MJAES'A=@9:5)XD&XW5@PM2I1J^SEN\WUL-^%NA_\([^UA\0;3[1]KWV4UWY0_M_7:>UF0^&^0HYL[C^%?._P
'[G5/\$W[2_P_1]=EM(\$MH8FT[%M]P2^_P#()G_Z[? \ LBUU-: ?M+H9/V>OB:H)RWA?5%_ '?-K)T]\907\$ _L1Z?
HMK^RK\ /4T*ZFOM/;3WE_M<70QLNFFD>ZB_V#Y\$G>:->0R^OS/]X^S^,/#MAX0\,ZEH.JPM/I>J6LUE=1I
M(R^XI4,;J&4A@2K'D=.N0<5\F_"00!XU_9'\(CX<(>?A0XD\8:'IEW- 8GB# MP'8B]^UP/*9W\$S\$'W6[@S# [X
; &"* M*X0/ADLUU) "'\$:>0:HL8D+ CC M\0='M_#GB0QC!#;66@H9?-TG3D5%5)68@&67RH&9"JE?
+&0K%HX_IJU5IE@F_MTD#/RX\3U[\DU\$M[&B)Z***D84444 %%% !1110 4444 %%% !1110 444 M4 %%%
!1110 4444 %%% !115>Z#,T>&*CKP>3C!QCIVH_I^ (M2M=&TNX0_M\ZXBLK"UB>>Y0)Y^C2"%1EW9R?E_)) [
'IUKY)^%,>J?M-?M0#XQ*E[;?## MPE:3:9X3DN'>W^WW+(8Y[G[.^?E/FS!G
B;]U;J0S(ZIYU^U#\0/B'\40B]9_M>#[SX;? \$"X,Z'JRMJ<>B'^+BYE\0>1*Q)W*R_0L4"IM?A72?YFV)'[_
."? MVG+:XOM"\,;?;\$?BAX?LVDM[&VFN_"@M+&R0E8E+9"(HHU(!P"54?=. #6J]
MU7,G\5A/&G[,WB2;7/\$VI?#CXI:I-K;Q5*UQK6D6^EP7-N93_D9EMMIB>UF
M;:S0,'+LQ3E2BU\^64.B:>/#UYI=IX@00A7X#U>VT#X=Z#'Q>5X0\3FXG/V MY[@8VQK,-P;=Y.W=L
Q+;GZ)_ :6L?%?Q,N-%\$WAG3;U-' \2?Z1XJ\31-+ E MCIB2(9(8)POE-<3C?&(_G.W/F1F.0NE/XM?!A0
,/PI\5_#K0=Z_#.[G]\.6 M2F0S290\UV%./<_S-YFX2.RJ7&6EV)QU.B^#W[0-_X[\?:SX\$ \9_M^"KKX? \
C;3K1=432YKU-0ANK\$E5\Z.X10A9)6"/.F4\$@!V.\)] [=;LIRH?>0
M!GYL^HZ=N0: ^7/@W)XF^+7[36L_%:]\$ZWX)\,VGAA/"UG!XHM_LVHW,WVI+ MHR"
@E\$&2N_6LY;FD=B:BBBI*"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+U5[]2\+@.T M9*E?,3[RY[C@ \^G%6&JM=,PVJ%;;PVEE!..1Z)9(X[\$&-&;JP4R2\$>F\^M+M#M_F
MM>./AAK&I/JVB3^#[0WM]9S2J ;2: \Y2[(L4*(3DX)7)9GF*IL_#P+XC^,W_M[0\$GQS\8^&9? !VGV% C)H?
A30]126+4GBWR\KNZ3>JJQ26=%B9#PY/S"-)9=Y_M;W,EJK'U?'W_,]JDJM9,&4XCV<]N^U6:P-4%% PHHHH
**** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M7-_\$QEH_P_M*:AXAU_4(-
*TBPB,MQ>7).Q!D_# ^9F9B%55#S, 20#N7BJVT^59B"HWK_M\0.. "??CC0QZ5^<'C;XB^.?C5\
MW(C*1S7JMY:LWS[R,0&@3R@KAY9#I"/,S,>Q[=^R0X;\4? \$SXL^-?CUXHM]0_MTK3M>MUTGPII]Z3&XTI9_XE>
E_+50%"PVL_S-<2!=DL9/5^-?V8_<\$^N>([M5^'/Q/U3X;IXL=I]?TZWTZ&[MYYC"L7VBW
>,VDSA2SS(^YVV*E :V/ / [3 M">./%UIH0^GQ(\-K=+(YU370#AMK" K&TG[Z82-L+;;;<[F4=ZS/VE;'09
M\3)M\$^\$GAG2;RWT?Q!^]\4^(H?-MDL-,CD3S(8)L>4;BX4.@BRY"Y\R/9(72
MKNXFE:UCYVLHM\$T_A'K02K30!???"OP'J]MH'P[T**_B\$7C#Q.;B<;GN^P%
MC68%V[R=N[:!B6W/T]\' V@K_QYX\UGP)XS\ \$W7P_\&NG6BZHFE57J:A#=(M6)*+YT=PBJA9)2\$0\UT%./+/
#-YF1([!3E !M0\$WQ:.;UGXK70@G6_!7AFT\,) MX6LX/%0]FU"YF^U)=&00%2409*DY(;' '=NW)&Y-6(C>]D?
4EJRMN ?>1U^;_M/MT[<@U8J&[S]=I3/&T?GWZU-7.= 4444P"BBB@ HHHH **** "BBB@ HHHH MH ****
"BBB@ HHHH **** "BBB@ JM?LR0EE(!4\$Y8X]R?3 \ 7VJQW?/ _M_P"V)\8/'?PM\ \$V5M\..?!.N>*0\$^L-
+%%?;5IPJY;-V4@F6,-ZCXN_9UTW5_/@?0M\$U05/#VN>!8H\$.\^)K:*&2\MVCMS_M HE!C"R1.-0G0KL60*
2HZ?/'[_Q*B^GP]:TU#X-?%06/&.I2F[\0>(&(\ MR--J5RQ9Q0>2#/\$<5ZM0<36 MOA?4M/F@U26:-
WCCB>*))70R,H.0K81]0& :VEIHC*-K7L?,0C#X<.,/'/0&_M30K;X@:QXW^-?
CZS73W\4V=0%9)X7\,Q2P.:)TM%_6ZG8>9*KW;V2(TJ10QM[@,L=C;-)0"111%! MLW2#W'M[4NH'ROH?[,?
Q:\)^(' -WX7^-L/A#1-? \370B"*TA\,6]Y(3_M<;&F/.QV[<&/:N0PA60%2Y1>G_9]^(GB#X@6?C?
X:_\$W1K.;0GX.%OIVM/" ML4UAK%0<0N8)E0+QYD2LS0%,0"[FBCQ[/]K#Q=I^S>:=XQ^ 70\$^L=<@F"G
M_A']/CUNR\ID1Q_I2&)"30Y5=P7'+DA@NI^S#\, 'VB>)0B5\0?B'Y.C:YXV
MO;_' /Q=I3ZH/"5WK\$.F6WAGPS]K"P6XED_C:0N(\KL6_M3Y9"RQ00:;T0Q)\.10:.;.4L/B_PY-: "?P%(RZ?
#J)FBCUW5#'_NG>WD4+ M);0*TD:L_Y9\+/') (BGC1=<_9[^/'BKX@V?A#7_!UX2\=6-G%J^IX9LE0= M2M-
3M%:.';#NCO;M;YRQ\Q0,0Y*#8#>EA6=[GJG]/OQBM/C=X#.N1:=>+J= MK=2:=J^E:@A6>ROXL>="<@9
RI4X\VD;E1@RCTVO_0V-_" /B;P]X)\7:WXKT MA?#^I>,?%]XH72/.,LME'+/XF4=7T/2_ \$LMO
MJND6.KQ*^] \$OH\$F56P1PK?+R">0I3]]T>PT'3;>PTNS@L+&!-D4%0_L**N2> M%7Y>I/2K?-
'-3RF'LX\ _M.MK"KNW @-Z^DY("L>V\%>' [370JUOX9TBWU=P_M4.I?88?/8-I!=?F&(M4%YJ_AK2]00EVLMS?
6:W,@QT8]# [MUK\TJ:M%JEQX>TZ\U"%=D6HSVT+W,8'96/0>PZ5_M?0K6'4+6:UO+<7=M*
'@N8PT<@'9ATX_K40-' -59_H0BVTMS'T;P9X>\.20< M:+X"H[<[?FXQZ5IU7KRSMKZSDL]JW^Q;_JHUG/'NA916
(Z=S4W-' -) (?)%7LM MS,T'PKHGACS?[\$T'3]\$ _'G?V9:1P[]9QNV_>QD]>F3ZU6_X5_X8_MC^U? \
MA\$=' _M/.? [2^Q6_VG/KGK6YS1S4N(G1IMN11S1S56-+1M9+0RM# *Z+X9%PVC:19Z8+EMTTEK!'&TS#/WB07&3C
M/J:M:II-EKEC)8ZE9Q:A8S;?-M;B-9(GPP9=RM\I^95ZU;YHYHLB>2*7+8J;
M;I&GZ'I\5C8V2Z;I+\$0064:000\$LS';J_*,LS=/05! ?^%=&U37^U6]\,Z?<_MZK&!LU">".2X0?
[);IT[>@K2YHYH<5T#V<7'E(KZUAAU"UFM;RW%W:R@!X+F, M-' (!V8=./ZUF:5X)\,Z3#
<6NG>'M,TBU05\N\2RM(8XYD.1B11_K.6XSTR?6_MMCFCFC0;A&6K1G:'X>TGP_:0;:1I4.EVTVYY+.U@6)&;
[C^E'LB]?>H]#_*Z_M+X9%PVC:19Z8+EMTTEK!'&TS#/WB07&3C/J:U>.:.7*KBY(IKH9VN>')] +\1
M6H@UC2[;5[: -A*E0YL;.SF\.:4.BY;.=07:;]!6_S1S4E;'-'-.P.G&\FNJL>+?LU? M"G5?
>LZSXFTJXB\47MV<27DZRRK\$%!,@ (90G9W<-R?N"0:%"A?W8D*EB=\ MOWF/>EYHYH4;*PJ-&-&G[-%;4-(M-
=M'LKZR@0[=^6@N(,1L>J;3FL_0?]> M@>'KY+S2/#FFZ?=%1)96L<#(.^JC]:V>:..5/=! [*-
[VU",*0,25%"23(MW+\$GKQ6'_P_*P##']L?VK_PB.C_-IYS_:7V*W^TY[<]:W.:..5=!NG&6Z_M0\KF?
KWA_2_\$=N(-9TJ'5[: -A(D-Y_LHW_N-JMEX=T^VU60'?J\$ \$ \$<=P
MX_VB07KW\33]5\:/5XBMTM]1TR#5;-9?."ZA;K,/,^Z&"E3\PW2RL9C>=%_MF-A0T'3Y?[/W?8]UK&?L>[&
[R=W3=M7.W^Z/:I=9\ /Z=XDC2WU;3+?5+6-Q(ML=];K,H? [JL\$*GYAN.,>IJ]S1S2Y1>QA:RBON*&D>']- \ -

```
P#G^E;:::7:R.9 M%#9VZPHS=9BH4?=-HS^%7^:::..2CJ6J<$K11E:YX5T7Q,+M9TBSU,6S;H  
M9+J".1HG./NENF<#. /05JJIE^K(FU FU0,(08 =/_ U4N-JMEX=T^VU60'?  
J$$$=<PX_VB07KW|36E&%7F)9BA))D;EB3UXHYH MYIP"B/[-Y"B"15^4*47Y1  
MC'ZU9YHYIV0XTHQNN72UC+T/PGH7AM9UT;0=/TUTT7+9GELX(T>4C/W|0WL9/7U/06IS1S4\NMQ*C3  
MT=MC,M/"6BZ?JL^I6NA6-G?SKMG0+>UA2:9<@_Z_-P<8^II90#.DG79=<;0  
MM.BU61|TM||EC:X_90VL4M;\Z?XBC2UUC3+/5;> M-Q,%0+?SQO\ NJV&4@L-QOCU-)HWA_30#  
<;V^DZ9;Z7:R.9&CL;=85+_ '68 MH%'S';,Y|!5|FCFG9|[.G>]C,M/"6BZ?JL^I6NA6-G?  
SKMG0+>UA2:9<@_Z_M_-P<8^II90#.DG79=<;0M.BU61|TM||EC:YHYI,-  
R09PO>2U#FC;NRI#.64J8QRK*>N11S1S3BF MKW+_ ,6J;,0?:!7A_P|?B|T?  
P[I]G=L6/VNV@CCEY^|R07\;DUOPKH?B..)M3 MT>UUB.%F\0\ M*UCGY;&| 92?  
X1TK5YHYJ>4R|C|+E4=.Q1C\,Z98Z0VD)I= MK'IS#)T];<"W;ZIM %5=&|&>'0#DKW&B^-(-T:Z=#&\EC80Q,R?  
>*EUYVG;S MGVK8YHYIJ*W$J,%NKF;=%='U34[?4|[OM.OM3MT\N*^FM8WGA3[P5';G;\W  
M&/2DU[PKHGB;RO|;T'3|;\G/D_VG:1S;;XSMW?=S@=.N!Z"M/FCFAQ17LHVY  
M;=:F8WA70YO|/WZ#I\IT=|DW6L9^Q|L;0)W=-VU<[?|H]JL:QH|AKVGW-CJ MMC'?  
V,Z;)>8;N!949<@|HWR|0*M|TSC9I+W83RUSY>V3/E^7Y&/W>S'3'2L?0 _!?A PW=0>Z1X?L+*X=7#W%K;1  
M1RN#RP+K\V..GOUL\TS:TT>PM]/MC(SM%;1)$A?H M3M3C/' )ZFM*,.S!5"@|= _P  
P9<>A'3\;3FCFBURHQ4=3*_X1G2?[6 MG^R-. M^WYV _;OL4?G _/?WK6LZGS&C=3(S*0\;?  
<(+/2;_.5S|]5|WXW'&>F3ZFJ; "SP6RAF\(:!"T"?V5;| M5QZ#9Q74\TQ#P|%N (MC*T/PKHGAGSO|&T?  
3])\ _;YOV&TC@|S;G;NV M*,XR<9Z9/K5^~M|>\T^[M|R!+FTDB*RQ28*.IX97|^4H5+ [N.?K4W--2X;  
M6+|G#EY;62/&0@0&|<&|XRTC5#%J'A*^G"VFGW9\UY(\LVY@6V1MY;!&!  
M5BWECHH7/JVC:!IGAVU>#2=.LM+MI)&E^SZ?;1P0C( &%15&=H7)Q5_FCFB,  
M>4OHX>%)6B4=6T+2_$%NL&JZ18Z0$K;TCOH%F56P1PK<=">O15*\T)M*\&W6 MF>$[>UT6XAM)(|-  
EBA6&&VE*LL3|(%XP)'&3|T#.<| [-?'--PUN;.C|MNVK5 MCR|]G0X6W/P0\&SPZE%;QZSJ#P;JY6(;FA7  
58&E_C*$ /P/E|9L9R2?4>.:. M.:&V@Z5.-  
*/+$...:..I&FPB #W D$S P#7; V1:ZFN6^'0 ()G_P"NWLBUU-;1V/=I @HHHJC0** M** "BBB@ HHHH  
**** "BBB@ I/PI:* $ "EHhh **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@  
HHHH ****74|JTM+13 ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH  
**** "BBB@!K4E/HH :!FE Q2T4 %%% !110 4444 %%% !110 444 M4 %%% !110 4444 %%% !110  
4444 %%% "=Q33UI| % GJ-6G444#$H MI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  
"BBB@ HH MHH **** $;I2=N:=10 @QVI:** $/:EHHi (.]+110 4444P"BBB@ HHHH * M*** "BBB@ HHHH  
**** "BBB@ HHHH **** "BBB@ HHHI=0$>EHHi@%%% M !110 4444 %%% !110 4444 %%% !110  
4444 )W%1R Z0\ Y5)W%1 MR Z0\ Y4!U/+ &&?$CO?JO * M8W-/C#/ "1WOU7 - 6L;FN>2U/#F->  
M8[2^!!1115&H4444 M%% !110 4444 %%% !110 4444 %%% !110 4444 %%% !110 4 M444  
%%% !110 4444 %%% !110 4444 %%% !110 4444 %%% !11 M10 4444 %%% !110 4444 %%%  
!110 4444 %%% !110 4444 %%% M !110 4444 %%% !110 4444 %%% !110 4444 %%% !110  
4444 M%% !110 4444 %%% !110 4444 %%% !110 4444 %%% !110 4 M444 %%% !110 4444  
%%% !110 4444 %%% !110 4444 %%% !11 M10 4444 %%% !110 4444 %%% !110 4444 %%%  
!110 4444 %%% M !110 4444 %%% !110 4444 %%% !110 4444 %%% !110 4444  
M)W%1RX\L|Y|#4G<5'+ J_S_E0!YUXJTRZGURZEBDD5BH =HS8PB^E9'|D7__ M #|7/_?F2KGc#/\ PD=[15_  
6L;FL)2LSQI6YF70|'U#_GVNO\ OS)1_8^H M?^\^UU_WYDJCS1S20:.. NB|_8^H?\^UU_WYDH_L?4/^?:Z [\_  
MR51YHYH"Z+W|CZA_S|77 ?F2C^Q|0_Y|KK_OS)5'FCF@+HO?V/J'_/M=?]^9 M*/['U#_GVNO^_,E4>:..  
NB|_8^H?\^UU_WYDH_L?4/^?:Z [\R51YHYH"Z+ MW|CZA_S|77 ?F2C^Q|0_Y|KK_OS)5'FCF@+HO?  
V/J'_/M=?]^9*/['U#_GVN MO^_,E4>:.. NB|_8^H?\^UU_WYDH_L?4/^?:Z [\R51YHYH"Z+W|CZA_S|77 M_?  
F2C^Q|0_Y|KK_OS)5'FCF@+HO?V/J'_/M=?]^9*/['U#_GVNO^_,E4>:.. M NB|_8^H?\^UU_WYDH_L?  
4/^?:Z [\R51YHYH"Z+W|CZA_S|77 ?F2C^Q|0_MY|KK_OS)5'FCF@+HO?  
V/J'_/M=?]^9*/['U#_GVNO^_,E4>:.. NB|_8^H?\ M^UU_WYDH_L?4/^?:Z [\R51YHYH"Z+W|CZA_S|77_?  
F2C^Q|0_Y|KK_OS)5' MFCF@+HO?V/J'_/M=?]^9*/['U#_GVNO^_,E4>:.. NB|_8^H?\^UU_WYDH_L M?  
4/^?:Z [\R51YHYH"Z+W|CZA_S|77 ?F2C^Q|0_Y|KK_OS)5'FCF@+HO?V/  
MJ'_/M=?]^9*/['U#_GVNO^_,E4>:.. NB|_8^H?\^UU_WYDH_L?4/^?:Z [\ MR51YHYH"Z+W|CZA_S|77_?  
F2C^Q|0_Y|KK_OS)5'FCF@+HO?V/J'_/M=?]^9 M*/['U#_GVNO^_,E4>:.. NB|_8^H?\^UU_WYDH_L?  
4/^?:Z [\R51YHYH"Z+ MW|CZA_S|77 ?F2C^Q|0_Y|KK_OS)5'FCF@+HO?V/J'_/M=?]^9*/['U#_GVN  
MO^_,E4>:.. NB|_8^H?\^UU_WYDH_L?4/^?:Z [\R51YHYH"Z+W|CZA_S|77 M_?  
F2C^Q|0_Y|KK_OS)5'FCF@+HO?V/J'_/M=?]^9*/['U#_GVNO^_,E4>:.. M NB|_8^H?\^UU_WYDH_L?  
4/^?:Z [\R51YHYH"Z+W|CZA_S|77 ?F2C^Q|0_MY|KK_OS)5'FCF@+HNG2+ P#Y|KG_  
+\R4C:/J#1NHM;G)' /%07WJGS0?|6W MT/\ (T$MJZ.\)W$>BZ7(FH3"P ?,4^T%8|PP.F>M:8\5Z%(2?  
[7T\GONN$' M|:I?#W_D$S ]=0\ V1:ZFMH['M4 @1B?)1H? 06TW_P)C_QH_X2C0 ^@MIO_M @3' C6W15&AB?  
\"4:' P|!,3? )C_P :/$HT/\ Z''VF_P#@3' C6W10 M|B?)1H? 06TW_P)C_QH_P'$HT/ '*VF_\ @3'  
(UMT4 8G \"4:' T%M- M\"8 \:/^$HT/ H+: X$0 XUMT4 8G \"4:' -!;3?\ P)C ;:/^$HT/ H+
```


M:; X\$Q_XUMT4_8G_E&A \ 06TW_P "8 \ &C_A*~#_ .@MIO\ X\$Q_XUMT4_8G "4: ' T%M- \ "8 \ :/\ A*~#_ P"@MIO (\$Q_P"-;=% &) PE&A !1;3? F/ &C_A*~#_ Z"VF ^!,?^~;=% &) PE&A_P#06TW_ , "8_P#&C_A*~#_ Z M"VF ^!,?^~;=% &) P)1H? \$%M- \ F/ !H_X2C0_P#H+;;_ .! ,?^~; M=% &) PE&A !1;3? F/ &C_ (2C0 \ H+;;_ P"! ,? \ C6W10!B? \)1H? 06 MTW_P)C_QH_X2C0_ ^@MIO @3' C6W10!B? \)1H? \ T%M- P# F/ \ QH_X2C0_ M^@MIO @3' C6W10!B? \ "4: ' P!1;3?)C_P : / ^\$HT/ \ Z"VF_P#@3' C M6W10!B? \)1H? 06TW_P)C_QH_P"\$HT/ _*"VF_ \ @3' (UMT4_8G "4: ' T%M- \ "8 \ :/\ ^\$HT/ H+;;_ X\$Q_XUMT4_8G "4: ' _-!;3? \ P)C_ , : / ^\$HT M/ H+;;_ X\$Q_XUMT4_8G_E&A \ 06TW_P "8 \ &C_A*~#_ .@MIO\ X\$Q_MXUMT4_8G "4: ' T%M- \ "8 \ :/\ A*~#_ P"@MIO (\$Q_P"-;=% &) PE&A M!1;3? F/ &C_A*~#_ Z"VF ^!,?^~;=% &) PE&A_P#06TW_ , "8_P#&C_A*~#_ Z"VF ^!,?^~;=% &) P)1H? \$%M- \ F/ !H_X2C0_P#H+;;_ .! ,?^~; M?^~;=% &) PE&A !1;3? F/ &C_ (2C0 \ H+;;_ P"! ,? \ C6W10!B? \)1H M? 06TW_P)C_QH_X2C0_ ^@MIO @3' C6W10!B? \)1H? \ T%M- P# F/ \ QH_X M2C0_ ^@MIO @3' C6W10!B? \ "4: ' P!1;3?)C_P : / ^\$HT/ \ Z"VF_P#@ M3' C6W10!B? \)1H? 06TW_P)C_QH_P"\$HT/ _*"VF_ \ @3' (UMT4_8G "4 M: ' T%M- \ "8 \ :/\ ^\$HT/ H+;;_ X\$Q_XUMT4_8G "4: ' _-!;3? \ P)C_ , : / M^\$HT/ H+;;_ X\$Q_XUMT4_8G_E&A \ 06TW_P "8 \ &C_A*~#_ .@MIO\ MX\$Q_XUMT4_8G "4: ' T%M- \ "8 \ :/\ A*~#_ P"@MIO (\$Q_P"-;=% &) P ME&A !1;3? F/ &C_A*~#_ Z"VF ^!,?^~;=% &) PE&A_P#06TW_ , "8_P#& MC_A*~#_ Z"VF ^!,?^~;=% &) P)1H? \$%M- \ F/ !H_X2C0_P#H+;;_ M .! ,?^~;=% &) PE&A !1;3? F/ &C_ (2C0 \ H+;;_ P"! ,? \ C6W10!B? M \)1H? 06TW_P)C_QH_X2C0_ ^@MIO @3' C6W10!B? \)1H? \ T%M- P# F/ \ MQH_X2C0_ ^@MIO @3' C6W10!B? \ "4: ' P!1;3?)C_P : / ^\$HT/ \ Z"VF_M_P#@3' C6W10!B? \)1H? 06TW_P)C_QH_P"\$HT/ _*"VF_ \ @3' (UMT4_8 MG "4: ' T%M- \ "8 \ :/\ ^\$HT/ H+;;_ X\$Q_XUMT4_8G "4: ' _-!;3? \ P)C_ M , : / ^\$HT/ H+;;_ X\$Q_XUMT4_8G_E&A \ 06TW_P "8 \ &C_A*~#_ .@M MIO\ X\$Q_XUMT4_8G "4: ' T%M- \ "8 \ :/\ A*~#_ P"@MIO (\$Q_P"-;=% M&) PE&A !1;3? F/ &C_A*~#_ Z"VF ^!,?^~;=% &) PE&A_P#06TW_ , "8_M_P#&C_A*~#_ Z"VF ^!,?^~;=% &) P)1H? \$%M- \ F/ !H_X2C0_P#H M+;;_ .! ,?^~;=% &) PE&A !1;3? F/ &C_ (2C0 \ H+;;_ P"! ,? \ C6W1 M0!B? \)1H? 06TW_P)C_QH_X2C0_ ^@MIO @3' C6W10!B? \)1H? \ T%M- P# MF/ \ QH_X2C0_ ^@MIO @3' C6W10!B? \ "4: ' P!1;3?)C_P : / ^\$HT/ \ MZ"VF_P#@3' C6W10!B? \)1H? 06TW_P)C_QH_P"\$HT/ _*"VF_ \ @3' (UM MT4_8G "4: ' T%M- \ "8 \ :/\ ^\$HT/ H+;;_ X\$Q_XUMT4_8G "4: ' _-!;3? \ MP)C_ , : / ^\$HT/ H+;;_ X\$Q_XUMT4_8G_E&A \ 06TW_P "8 \ &C_A*~#_ M .@MIO\ X\$Q_XUMT4_8G "4: ' T%M- \ "8 \ :/\ A*~#_ P"@MIO (\$Q_P"- M;=% &) PE&A !1;3? F/ &C_A*~#_ Z"VF ^!,?^~;=% &) PE&A_P#06TW_ M , "8_P#&C_A*~#_ Z"VF ^!,?^~;=% &) P)1H? \$%M- \ F/ !H_X2C0_M_P#H+;;_ .! ,?^~;=% &) PE&A !1;3? F/ &C_ (2C0 \ H+;;_ P"! ,? \ MC6W10!B? \)1H? 06TW_P)C_QH_X2C0_ ^@MIO @3' C6W10!B? \)1H? \ T%M- M_P# F/ \ QH_X2C0_ ^@MIO @3' C6W10!B? \ "4: ' P!1;3?)C_P : / ^\$H MT/ \ Z"VF_P#@3' C6W10!B? \)1H? 06TW_P)C_QH_P"\$HT/ _*"VF_ \ @3' M (UMT4_8G "4: ' T%M- \ "8 \ :/\ ^\$HT/ H+;;_ X\$Q_XUMT4_8G "4: ' _-!; M3? \ P)C_ , : / ^\$HT/ H+;;_ X\$Q_XUMT4_8G_E&A \ 06TW_P "8 \ &C_A M*~#_ .@MIO\ X\$Q_XUMT4_8G "4: ' T%M- \ "8 \ :/\ A*~#_ P"@MIO (\$Q_M_P"-;=% &) PE&A !1;3? F/ &C_A*~#_ Z"VF ^!,?^~;=% &) PE&A_P#0 M6TW_ , "8_P#&C_A*~#_ Z"VF ^!,?^~;=% &) P)1H? \$%M- \ F/ !H_ MX2C0_P#H+;;_ .! ,?^~;=% &) PE&A !1;3? F/ &C_ (2C0 \ H+;;_ P"! M ,? \ C6W10!B? \)1H? 06TW_P)C_QH_X2C0_ ^@MIO @3' C6W10!B? \)1H? \ MT%M- P# F/ \ QH_X2C0_ ^@MIO @3' C6W10!B? \ "4: ' P!1;3?)C_P : M/ ^\$HT/ \ Z"VF_P#@3' C6W10!B? \)1H? 06TW_P)C_QH_P"\$HT/ _*"VF_ \ M@3' (UMT4_8G "4: ' T%M- \ "8 \ :/\ ^\$HT/ H+;;_ X\$Q_XUMT4_8G "4: ' M _-!;3? \ P)C_ , : / ^\$HT/ H+;;_ X\$Q_XUMT4_8G_E&A \ 06TW_P "8 \ M&C_A*~#_ .@MIO\ X\$Q_XUMT4_8G "4: ' T%M- \ "8 \ :/\ A*~#_ P"@MIO M (\$Q_P"-;=% &) PE&A !1;3? F/ &C_A*~#_ Z"VF ^!,?^~;=% &) PE&A M_P#06TW_ , "8_P#&C_A*~#_ Z"VF ^!,?^~;=% &) P)1H? \$%M- \ F/ M !H_X2C0_P#H+;;_ .! ,?^~;=% &) PE&A !1;3? F/ &C_ (2C0 \ H+;;_ M_P"! ,? \ C6W10!B? \)1H? 06TW_P)C_QH_X2C0_ ^@MIO @3' C6W10!B? \)1 MH? \ T%M- P# F/ \ QH_X2C0_ ^@MIO @3' C6W10!B? \ "4: ' P!1;3?)C_M_P : / ^\$HT/ \ Z"VF_P#@3' C6W10!B? \)1H? 06TW_P)C_QH_P"\$HT/ _*"V MF_ \ @3' (UMT4_8G "4: ' T%M- \ "8 \ :/\ ^\$HT/ H+;;_ X\$Q_XUMT4_8G " M4: ' _-!;3? \ P)C_ , : / ^\$HT/ H+;;_ X\$Q_XUMT4_8G_E&A \ 06TW_P " M8 \ &C_A*~#_ .@MIO\ X\$Q_XUMT4_8G "4: ' T%M- \ "8 \ :0: JECJ7F?8 MKNVNMF_ V>57VYSC.#0T/Y5=HH **** \$[BHY? \ 5_G "J3N*CE_P!7^? \ M*@.IY? XPS_PD=[]5_P#0&K&YK9 \ 89_X2.] ^J_P#H"UC \ @F? * [? ^R+74URWP] Y! , _%V]D6NIK: .Q[M/X\$%% M%4: !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 44 M44 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !111 M0 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 % M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 44 M44 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !111 M0 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 % M%% !1110 G<5'+ _*0 \ P"52=Q4_5? _0&K&YKEG \ 3/%G \ 3#FCFCFCFA-6,7)1W8@UVP MYHYHYHYIWI=VE>0&QJ6 V1?>8]J8UW" ^H7% H+N.>[MU4S0? QQ!L=[WUP?R- , #DH[LDYHYHYH MYHYB7]7#FCFEC+JX9=I/39 \ Q9L^@'7 \ :IVNIVES=W-E!=VT]Q: [3-!% .K0%N MSC>@ ^YG:<9ZX/I3Y@4X]>]BWS1S1S1S5\$AS1S1S1S0_P#()G_Z[? \ LBUU_M-;1V/=I @HHHJC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ I!TH:FTN@#Z*:M.I@%% !1110 4444 %%% !1110 4444 %%% !11 M10 4444 %%% !1110 4444 %%% !136I32>@ "T4T"EI@+124M !1110 44 M44 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !12- MVHSQ2U 6BFK3J8!1244 +1110 4444 %%% !1110 4444 %%% !1110 44 M44 %%% !1110 4444 %%% !24C4E #J6FKUI?XJ3 6BDI:8!1110 4444 M%% !1110 4444 %%% !1110 4444 %%% !1110 4 M4A \ 4AH =13* 'T4U:=0 4444 %%% !1110 4444 %%% !1110

4444)W M%1R_ZO\ / ^52=047)D;A MB*X+X??" P
= \$;X=VWB"P^*/B"&X0XYA#9W%U*^E=XE+.)SA2R*"00XX[D M5UW[9;*OPPTS>S #6(VXV[>()SDY],=@:X?
X5_&;Q?X2^%MAI&A?#;5]<:U% MPD.M0QSR1.[3R.I*)!EE7<I3CC6JC>BT.W_9[^+WBGQ5X MH\3^%0&#^?
K>G!YDNFA0K\$(I1#-\$SQX1QN(*L,Y;MB08];\9^'0#%Y|CUKQ M!IFAW17S\$AU*]CB+'>WN=5M38M'>^ M?
*(9P99)9\$;)E]71R_Z[@.2,4U.RU1M3K5<-03FM,^C[K7M-M]#.JR:G FD M?^*3?
+.HA;+JHVN>A. :.=V7IU'A @W|H8>)/C1XBL=5UK3M%\)6MO);VMR\ M(BN)
(YD&])21G>F]@.58'!ONK!_9+N(/&G@GQ-X.U^-=4T*S^SR"#YLD2"0
MN!\W"PA]R*K!I9.N>.1^# P0\>)0CYXR\ -ZGI7V_1].B01;1^9)'M"SI&H MW(P;
[AD^9N3WZ4<[M<*N*K3]G.DM^IN>I^./!\B+|H#PEXIM '&DV,)BMA% M;BZC^TS1"638D"H!YL4@=AC(W+L.
<;3[G=7M09V07%Q'X.TTP,8[&)"S>9;ORL<.Z@M\ P53\Q&\ *V<&95&KN MPEBHx=SE):WMN?6&B^*M
_31RG2==L<6%E65=*NHYBK-G;N" =Z-UZX/I5B MX\0:=;Z\FCRZM;MJT@RMAYZI<#)SM+< ,Y|/QKX2\3>-
_!V@^)-!\1?#;2 MM2TM]-4R2V^I,&6=E("Y;S')#C>D@. HP.I/I0[2>GQ:K^T^X1T|I[3A7:P=Q\RL,R-
D\$9!;J:7L:~?VI*~6IK6]CZ/TWX@^&- M=08;/30\$VE:E>3A0(L[&ZC:8A008",6R KYQ7!?'[XU1_#?
PG<1;)>6B60A^Q\216,7|037T^I-<(^ M&:-8I&4NNX!SE(EW'J%5S[0L95,5B'1J0M9JQ[!\, /B)I_B|PKHH?
7K#4=9 M.GP2WT=K("/")4D,4?FAHE^8?02QXXR7QCH-;6/'WAK0|0FT_4_%&E0WLE?^7Q:~7:~\ M,?
VA[(R^*-2M_#-Y-:WKV;7\$DT:PN^RY!B;K\RS>'8XPUI?& P!L[P>;01M)\40V51SV MEP;:~\N!I/-BE
"22D9P%9%494--,0T:JEW%- '3C9REAXU8|T3|HKQPO@;X M6Z0?6|T8K^*V^K(4;#RR,6+*5(P5B61AV#!
<<8KSG|D/XF:GXF&N:%K6J7> MH:E&JWEK)?2M200",CYA6#G[VAYL?' M#1/!^A>
(KK1;>18+6[;W,B+PT^"S2V6*ROM3=KV8!V4I\$,!I(Y#E"TCLO:2?)%<+^SW;M\3/CYXG
M\;^9=08VLEQ+;K.RH\8FW1VR,-Q^|_74 = ,#@^"KQOV,;?M.?#V51@!M/^>) M&7:?
MQV[B>0!'3WIW>XX3YXRKU-G^R/1_CQ\:%&WA"=-\$0;&Y\1M<)91(TZ MM-;!HV/Ry6&5W - M\Z)UZ9K4\ -
P ^&?@#>>(+^2X[+6-1\ (N+N^DDF*N6M0,8;2^U^G_Z_YI M-N[1T.>(E6G".W+W*?
|(^0;1H/PEU*XU^6+71[^TN]@Q[&=-\4]0.LR,N2.&7Y>H/20E'|F|X*^\$0B5X+UG4M M\FNI&#<
(793;*J1L'CV%*R7=00D].;)?[EU>SBEM9\$C M=]T:R/YWF..V\A4W8]JX3VCW#"8F4?
9TY+XOT/IXJK1D2>7MWJ/WGW8UW&\$;:=F_ZN>H?LH_\$J| \=>#;ZP MU662ZU73)5>6ZD^8R)-N0/E\$?
7M[.J7B#3='FM+>]U^TL;J]? MR[2*XG6-YW/R[8U+#.SNIX8G9?N*54^Z-T]J^8/VD @ MCX6^&0@72=4T
W<%TMW'I\|D[R^7*NWF.&X\$H\D8V\4/FW;SP,8'3UJIX?U[2/\$ELT^E:E!K^K&WD/<
M6T\8Q!*D_20=Q7R_ \50C4?%7[-.BB26(-IK\$K6] ;HI\00LS@F0,H58Y& MD6VD(SD1R\$8.VOHCX9^#3\ /0 >BZ
;AKN2U@)FE+JZ><[L@0@ [0S^&1QR M; <7S,ZZ.(=>?LX]K_P# .+|; !?Q-XM\37VKZ=\3M9\ -6]T(V&F6WG!
(=L2) MD%;D#G;Z=J\|/"Z5XV\;?%Q^X2_X65X@M0[*:Z/IH>?<2; "IA#T\T8_,] M:~S%~\^*6 @1_P_G/?
\$7_N)?^G&*IDM3SL91CSPNG>3[GH<^@'Q#\ _AWX[N M=0\=ZGXHN)M(F-M>7,DB26A2.8-Y9:100?
+G&/N"0%/@?H0CCXR?VZ6^)0B' M30[->, M=7\$Q?S&E[>;'MQL|Y|8Y^H0BM_R3/QC_P!@6]_])Y^*2/V;|)^(
M&IG7F\":WI>D-&L(0%U-%99,B7RRN8)/ND-GE?0#KVEZ-+N1BH.E7ITDGRH^
ME0AC*/\$/@G7Y|W6/'>I^*+2;W:W^S7WF>7\$6=")?GEDZ8QQC[W?MS/[5WQ.
MU#P5X)L+33IFMM8U2XD:*YMOE\J. ABJ.&W*[_8AP#^K2=._H7PST[Q=I.@3 MV_B_5;36M22X9X;S3XU56A*
(,#"R&,G;UKYR\6ZWH_Q*:_J1-:NK*S_-;%(M|K)+=SP11%H6E;8WFC#QM<,R|
"3&4..,ARE:~)0B:D/,>IW/[,WCC M6E\4^*0_0B#4[K5]2TV5YH+JXGDE+LCK%,6+M68259?
E'#^KVU_VL=>U^PS\ M-].N=\$U:XT>Y&K*/M&FSM"W"2@,./IZB0*/BUXFTSPC?~]&::!K%KK-M)]G
M>YEM+^*Z*| (9@NSE08-K88D99@#P0/20VSF_P"+7Z.;:)92NJPW W^LRMO.
MJ^G<#N^E2]U^1QQQ,0JM6DW>4>IRWPM^%?C#XE>#=.U|_A:0B:RBODF/V?SY M)GC:-
WCW;0/[^7CI7NGPS\&ZMX(T":RUCQ+>>*+N:Y:X-S?;M\09\$ BYD;IC M/;[W>0G|X0^&_C#>?
#G29?"GB|1=.T(0-|EM|M-SH0VB3<#_* ,W\>^,U|/
M>'X|0M|\$L8M5F2ZU)8(0M5S"FU.2;RT\W; \H_P"6F MWK2&QZ& IQE",[;]| MGD?
[66N;IH^P|TZXTO5|[2]FU2->'>0G;%F7RI3RR -P0.GK73?L|Z0J&N?'" M0+
[4[R: 09Q_Y5XI^U|XVUCP[H.B:/IUR]G:~NTXNY(',(P^ M/E50,8L>,A2I.UF!\\$ \0:C\+ P#A
H|/T73|/0#6N70L-. \1:5>3EB/LD=[^9=PZ (.37E6@:~?I_P_8/V>0#EYX MN\0W6G6Z1R)->0WVW>*7;_DQ :!
(S10DI">3N#E=H->)?%B?X3:~?I.D7WPU M09[;6K>|C#R1 :26C)WK*3.0,@?:!M9IESU|'M!U,;*^4EVON?
<3L?,~1V,; M*A)P6'EJ.NX^@? \ UC7B?|0'C;P_XC^#?B6RT?Q%I|Y=J;.27B|AW< M+T_&N\ \ VBOBAKG
I_P=;QM!;7/B>V6?49K9U\$9C\F-I(U#\$YB9YU;&\95 M2A!#G%+XI?L|^'/ OP.EU,1R2>*;_*-Y|Y;AF%Q-
+.J3?>*/JTA"G:/E(R20 M<\$JG0PQ&)J583C26G+J|I&KX9\ -IX0\ V.M.TV/5K;1U>5_FUB=8;4D:B^5F
M8JV%YR,?,%Y|'U3X5RV?@?X/Z,M_P"*;"^M+.)0-UC[9_HH7=ROG,S81/\ M5*
>5C7@8VCQS(;|AUG^E\|':FTY_M4YR>_6GQ|0^&'TV(6<\$D;>#C^TR""?
M|0//T%1&3_4RA6="TTKM0/H&_P#^WA325A%|XFT03'FC6>)K^AB\ V-ONN@/ MWD.#@BMBU0+2_L8;J"X^V6\
M33509%;RI#;QR*@S|WM\R1F/;+MNY560->R|G73Q|2K**DMU<|0U|QKX?\
M#NH&RUCQ^I]G=L5^V6YGCCEY^|PW7*V-V|/ # LY90PD/*LIZ8-?"WP _.= M_P!D^*0^&DKJS^*VN)E59/-
_TL5;.-0 "VWABWG<9"YXW5Z=^Q5\ .T:" \ M&-[; :7:5;?1KF??N\$: ^9(N|^%MT8^7CQVLUQ:6MQ<+#+<-&
VV(D\$EBQ1<*"/! M^B^*/AKXA0=3TW[;26)HVBC@F0A =C8D+GE6Z9XQS4I/FY3:0.LL5&,=04 M^E-
9\0:=X;C2XU;4[?2[61Q&LE|<+&I?|RJ'+ ;CM.,>|)I'B#3?<\$<,EQI6I
M6FJ6L;F,RV&8/#07^S=4:TA:UB+,T=M-) MY#1;V)9SD"52)/\$TW[1DWA03?%>L:);W= _8VX:V09A'%YD<,?"*P
^_P"0:0KYE16<(P;: M-I9>C\$9^8>Q&#^>)KXT^(W_)WMG_V&M*_|MZ=;5(>:30 \ +3\;^ _A;|K_.&N M-
7^S :/L_P#;FK_0)^YY>9|OF_|,_, \K @6RE/2WF8U4L'4@Z;M=V|GI_P5
M\!MX;^+WC^YN0&%IJSWTEPKZ;~7R27D3^=N\ZyB550*@(1N^&Z9\8&,^M: SX MV\.>'|CR-
9\2:5H|XPW^7J%|'\$Y|8@'8S>V.%^W>;YW^!?' "=#^10+ \S;G M4-
WfYw>5|N3KCGT|LYS7FF@ZIHMCX\UVW^,VB;AJ>HW\$B+)R,XXV.'A:W5[00^YK6\M+^QANH+C[99S'\$&?A;^SY
MK.L_#J|?5[6]BL5Q,@Q[N21(1))'L&0&(B/8_P6, [M?Q+XGAN0\$-
[J\DS^KJ|EC,961T=BZ0AI2ZLQD8YP448;)>W.QW_6:DI1IP5Y M-
7M<^F5;Q\$\56C*48QNXJ|U/H6Z0^TZ&6ZFNTMX85\QA73+-0/D!MHAME5H@ORY\R9_0>@QWJ7/6R0?7*CY?9J]U?

<<GY?%>DR:(MVL-K-J=*7;008YU,1RZH,2ECR=Y48[L.G5?50!0!0P\2?&CQ%8ZKK6G:+X2M M;>2WM;EYX1%
<21S(-Z2DC.)-[-!> 2I]H]SEJ8J045.=--;NVYZAX]\(V0B'X^>%0%*>-M% MLK<6\#0PM>QI=RQK)+Y<5LJ
>:DH/EJQD;[[CG[I]PN_\$6GP^((I(EOK6'5I MU\U-/6[59SP305"5RF >W7//8?+WQ?
TNTT\]HWX7:=80_9;"TBTN&"#?YFR- M;J15^8L6/
'6C[I/3UUC]H;PAIKW%Q;1:A8VMA*]JY5_*GN)H9!T*X99"TW*
MP^;D\$9!.=J[[&BKNA*4HK6]MSZ/T[Q]X:U^ZCM=/\3:-J\$T0*6UK?1F08)&W MRMQYSG-6_\$'BS1_#;0?
VWJ]CI9N6V0P74ZQ/(1C[J0Z;A]WU&>U?)7[37PYT M/X1^(/"FI^%UDTZ2X68[@fL 8W1XRF\LV=DI4-
M^084'<6Z7]M072'P6LDW MVAE2[196^R@0_9'-5SFCQ]1.2FM8V_\$^DM<\0Z3X?M4N=7U6'2[:;:D=Y=
M3K\$C-]10K'VINGM5V'^@0D%Y;2EK:2/SX9HRIB\H -NWC@YR>0I7A?I9_P#R M3+30^PS#_P"B9ZV+CP7H?
C3X\$>#8?5&LW>B;:#H]HTDT-\>+%LPH\$P?Y'7S M/+QGY@VW;U-/F-98J:E*-
0A5]ST310'WAK7=1@T[3/%&E3WLLIBBM([JY3(M 2?D7YCP#6#6/BU9?#7PS>W4-S9W6LQ(DEKIMQ>)'').&
<1G:GW_)0SN0>" MJ'[0WU^5?C!)\);/1]+00AG=72:Y:W(\U;:/3NE@VE_,+S8;S ^S[C 9<]>* M]B^/^CZ?
XV^!;/CC4M)M7\2)IUG/%=VSMA?.DC+H/F^=0&&YA@ 50WC'L[DD\$8Z1 M+DDY K?L0_#PY_P@/A0QD-
(QXFS<.;S[5,F-)) (A\BL5^Z5K@?V3]<;PKX: M^)VL10_!FTW3X+DP;]GG>5%.<>9SLY4#=@XW5,9:I=S-
5IQ=%S6Z/J/7?%.C M^&UB75]7L=(\$^3&]]-1P*VW&<%F'3<.GK5W3=7M=>MH[RQOH]^W<8\$UI()\$;
M'H^X@U\L? ;X7Z1\9K'Q)XP\=M)K\|7367V<3- @98D.YF5E;I(L6P;<;3US
M0+\,;*3X3 M7:AX2T\JVF79:,I")%V*8/M'E 68^8N2H+\$Y"M5\YT 7JC4:G M+
[LMCZ4;Q0H\$)OF_X2/3"UAM6Z4W4>;7?G;YK*PV9VMC=UVGT-+H7BG1_\$BR
MKI&KV.KB#!D>QNHU7=G&2K'KM/7TKY4^'7@720B^T1XUT/6\$ENM(AOKV[-
MA'/Y=0<3QW+1QNX7+\$@20C0DMSC<&F\%&[3P#^UH/#^B7T]MI9,F8&WDA6L M0--)?YL!JF-
V6_0,QR:ESUV, P"TW2MN['UV&\$?SE?IGS/[F0>;G!W=L>] M?.'[-MK-\1/B#XN^)VJVOV=0-^RV\$+)"RP?
I=00"0\3H,D>S_% M9V;X8>-0,\LR'2+QW9.I8P\$MG\4:ISK\$Z@SALP09!QU_W
M1R1GKC:::0.W#:#1/,^QZ/8>9&WD M+YS*R\$HIWJ8@S,CJ6=0EP A]-T/XT_V3\ +#QKXD%0=7;1/;10Q^7
EY.LLD M2;3@;="K2,5&,*2(SC:,SQ1^S7IT&N;OJ>C^+[KPCX5N0YNL:9:\$"W(;S<'<
M=M2(JS8#*RC+XPI51XQ9WVC7NGV0BS4;*Z?X?>&97T?10#]P[2S:G' MDD:&"*E%D>\$D?,V"5
#_+V6+@CC;66;X. M4W%M+J'D:7XMWR*RB1G\$DTC MM&411]X7&](R2W[N7KG('=<^/CT_G#Q@0AG7/#%]X-
UV\02V*W6YQ+@NVTIH MTX(0'<1@EF7 V#/+?M!::;+80A)JL,48NKG5(K:6>-RRNL=S;LJXZC:97Z\ M-
]J*J6USKG.'L*-)S7 M2MCZ%.ZN'-'-'-'-',H.:.:.:.: #F@_ZMOH?Y&CF@_ZMOH?Y&@SENECT7X> \ M@F?_*I?
^R+74URWP] Y!;_ %V]D6NIK:.Q[M/X\$%%4:1110 4444 % M%% 1110 4444 8?
C/7['PKX:U/6M5N5LM)TVUFO;NX8.WE11H7=]J L0# M'"'\#%?'_P_@GHW[7/P]M?
BC\9'0/%FJZQ>74VF:++>7-KI^@PQ30"(K>W M21,%Q C,6SD*F\GT?^TQ_R;Y\3"7T8>,%]4SR>?<
17X(QR#SGZ=#7'?L M3[:>(-V6?AW=6VF6NBQ1Z>;1[>VP 9H99(I93\B-/))&9&X/SLWS/\ >;1: M1YC-
M@V\$6L>%=3UB%0/?2W\M9899,A M)EBDF2)'7/*2CY5547ZJMM?.,CZ]8:Q_P %&-9M;.=9
M;G20ANEE>QKN<3'4(9Q&<?ZJ>)N/[I]?
4:=#]:F71#L5ERI9=S?;/E4@98J#X#^P_HGBGPY\8/CC#XYU.;50%\D'AZ^U:ZN54 M/'---;SSM!\C,FV\$R&)?
+)0K\$"N%(4U6XT"6?30 M"7A_2M"Q::;8S!<7 F1E2=Y0F)Y=%5AAY@(BEKX%_'[S/VJOBS<- \ "N/' MT
157/A^V'FZ'\^E;+5H0-000)@C*GS%.6RH8D Y%="CRQ:.>3=R]8_"KP?^ MTEXB^-.H?&*[0?M7AGQ!=Z?
96,VL3VD6@:6D\$8A0DA9PL8G2,3-)(&BD\H.! MC>#;^'/[36K^%_V.?A[K%]J">+?B?XDFDT?
P_I^I3^7+J=U]M>UB,AW9=8T, M>^21P&*KND5Y%8^I?M"? SX(ZYI6I^_.B7XJD M7WB'7+B4SSZA>-N9V,K
_R!VD*@A?0LQ&]W+>05\T?I?0E\1!_QZUKX2^/_ M!-
:_^PVB)XETSO'8QZ?,D'F1VSP20QKL)\W>1@DXY+?,%3Z/M6W*3M*]/E M]/;J>E8RW-H[%BBBBI*"BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_HHH MH **** "BBB@_HHHH :U5KX[5#Q'7?"PKIG[<.L^.?&?
CW5[KQ/X(T[Q!^H ASP09W M%Q8Z?'#" T5\XC=9)I([@#^A=JM)D;614U?A9]M_9<:5L_@];7&HZE\,0%
MFGW.J^&X[B]I/[(NXS)]<6<^E815><-RC+!9XX1RWRPIR/N+M?%SQ!IUQ^W-^SY MH<-
PIU.SL]=0IK8*P*0SV3+\$Y/W3N:WG'']SGM6^EVD9+8^G++[TG?G[V1SU MSG'?.<]=ZM4R/0\
Y["GUSFJ"BBBF,**** "BBB@_HHHH **** "BBB@_HHH MH **** "BBB@_HHHH **** "BBB@_I?2>7LQ@,
<@'T)(ZW[+\$"YV!EN#*=RY(DARS8+/A6?PI_' M(^0C1J/QCF0H[SPSK]U865C M-K,]I#H.EK;Q^3?
1PM*4C\$Z()7D?=%(8MX4#>I]-_9A^ NM^!/[Q9\1?'\> MH_\$CQ?() [V-I>._B7 MX:TL1Z7 TMSK+/-
:R,NU4420"P>=HJH&#L"P"#+8/0[*_B=XCFDT?P_I^I3^7+J=U]N>UB,AR"RQH8]\DCJ&*KN MD5Y%:0=?
V:/@78_P_+;2.^I>+5*WQB'7+B5II]00&RSL9& 8H'=RH('W MV8C>
[EOEC0=2UC7/%0A7Q0IFF:=I7C/Q]*WA[X;VMWH_V=0"0AFU\YIKT0L1 M%) (T)618MXRLJ]&,30%7MWP7\9?
\$;P?>M9^\$00 \360CM6T1/\$NF>(X[&/3 MYE@R.V>"2&=A)EWD8).!DL=P5%);:\$Q;OJ?
3%5[4EE8[203CT]NIJQ7/Z MG2%%%, HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH M
:U5;S/[M0V-QP5/&[Z'L>_X'ZB6Y8KMP&./_E'/^?K7RC^VYXA\876EZ\X' MT0PIXXF\]ZU(3X@U0P38K>3_&-
!M-C&@8,K2LR_NY10I;'GJ9\$#BM29/30\ M4^(GQ*]3?'CXK?#30Q;S:C9_"&P^(VC:1X8@N+_8,XDPKQ&./<
MA4+(%C=90?HGJJ)[C60'/P>\ "ZG?WNF> ?%.L7UOKM];WLMEY["U+_ WA35YM-^' MP\&+XEU?3;04!+:Z7?I-
%\$SLTC;X2;;;(P8C(=6;(\$>W: ^\$GAN']J#XH2?&C MQ%807/A'1G;30_%]IDDAE6.;19M4D@*A5E=UPA(!
125W1Q2'S3Q5X+&*%> M(]=^\$ P[L=/T/X>^'V7Q)\4-0CBN;L/!9LLD.FI-N9]0;DQQD>60Y3D?'!-8T>Q\!1?
994^<>FPQ06^DRRBVM5B0H@TAD;V\@^5 M0I=0D_ =^4:DM">9WL?<]FTCJS2#;W'&?
U]C[V;4WE1DX7>>,U_E_\$[6+GX_?M11?L>)+S20!>@:"VK>[},TM9
M;::4[AV1/L%Q."#Y!AN8798\AE=PS9V,GUQ)V_SVKY\$%^MVUO\ _%0CCH_
M]EPS7]WHVEW4>J\$XFMXHK>T62?E^[(9XV;YU_U"\-U6X=3.1S?Q9^'6C_L, MZSH'Q4^&D&HZ5X2EU""2?
%_AR(0>6ES:.SA;L0--^ZEC(\M69PNZ6-?W8:02 M; %C@QLP&TMRRXQ\W.>/KD?A7S'_,%&/\$%EH7[*?
B*V0;A+6\UB^L[&RCR? M](E^RDS+P.ODP2M_P#K7T:JJEL_5?_0%K&YK9\89_X2.]^J_@+6-
S7+/XF>+/XF>)_M9:'JF M0_#03[?2](OM7E75(W+&^IF5?E'*K\W)(Z>E=-^SWI.H:'\(/#]CJ5G-8W
ML(N%E@N8&A=6^TS'E6YZ\$=:]&YHYK/V=W<\ZL0;N0Y6,'OYI=UKW@?Q%IEE M\$L][??:<6T\$3,JAY&0A1N;
7G'.X5\J?"GPGK?AQ]1\WOPF_M55[^YDBCUK M682+&%7;V49?+5P^YED!?'(')VX^R>.:4J?>

U,\1@HXF<7)Z(^=?V4?!GB M#P?>>-[-;5M"0]+WM:(BW"'\$J(TY=T?E6(R0*DCG/W2*YS^S_!G\&?C5X0\ M\$47@F\176>J+=7\$!TWS1"ZSS"56W)'B5<'J_&?E!^K>:,:7L=+7,EE\ (PA M"+^W/F[X0>&]:US}HCX?:S;^'|3EL(H{&6X98#(B-]L>21998PR!E![, .GI M@G2^- 'PR\4Z-X^M?B- X(BCU76+> B]M8U9Y&"0E3*JL [S=#F,JN'^8%02./ M?^:,:?LM&NY4L0@T]=6[GA6F?&3XH>)MB7U_ID T]}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a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

%\$L5YX@UN9SLFD0,(X84P L40=E7Y1G/ 50L:>RT44-\PTK:!! M114H84444P"BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "B MBB@:K40:EHH8>9BK*%!(+8)VA' &+X.Z \9/&G@^PU
M#4X;/X8Z7;+KUU&ZM!;SQM%M%NC)0;+L).!L4JL@T?C=);GXD6 MF@:IH5W'HWC?
PQJ2:0HFH2JZ1/)R)+6=X WGV:="5D1""0 6#*#GU^C(HYAM M7/GCX-!WQW9?%[6?
BE\4=8T*\67&EC0+"Q\+PS)IUIZR"9PSRC>6:52V& MSM.[#E65(-H&VSF0X8
MGY^OU'/3\JFI:0!1112&%%!!1110 4444 %%% M !1110 4444 %%% !1110 4444 %%% !1110
AYJ"\8KY>,\$DXVGI]> ?Z M#FK%#(YH00@;X^'/C30+XG^#?B+1K2V\4W@0=3*^+HKB>Q%TX)ENX9('W MQNW
\AA_%M2)\$V/@;\#_ \$7A0QIK/Q^)FN0ZY\2=<@-BZ:>\BZ;I%CO5EM+ M0. 2I8(S,W)*C&6#0)[]BC-:-
?"&G7^IV[I M,])N5U+6)=0^9-KUQ&Z;/VTT31!;(4WM\B0Y&Q6577W"BE<+'C 00^\$MS M\2+30-4T*
[BT;QMX8U)-7T2_E5TB>3D26L[I^'\S3H2LB(02 "P894\M\& @ M[X\L0B[K/Q2^*.L:;>*>[C20X?
T^P\+PS)IUGIZR"9PSRC>6:52V&SM.[#E6 M5(-HFBGS.UA<.!NR-W7Z]>GY58HHJ2PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** \$;M1GBEHH \A:;#^>K_% M3X;?V3U&>'>,90T/(KJ?
B1;^*+KP#KE MOX.GM+?Q0]I(NG76JR;(()6&T2.1')G8"6VE&\$ \$'&0>#[+X/WGB\1Y/@U;74:;C%-
+XBDL8R9HK;1I%: &- +C610!MAC.W M;NB/V51NIJ3)Y45[/&Z1&&\A0F&#W' (SUXZX'&VJS114%A1110
4444 % M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% %>Z56P2FX M@'RY]#_
\$'Y5XE\8/@3J?BSQ\HWQ%\#>(0^\$6)>:-:-8":9#-8ZM9Y=A872 M@AEC,K\$[XSN0G=@LJ?=-:3-
-.Q+5SY=TGX'?\$WXD?&30/\$WOKUS0;C2 "TR7 MNC^&?KW,5G)>)N(NYS/AF=#@
;L8)'RJ95F^F;5BWF9P"&Q@=-. ('^%6: M6B3YAV"BBBD, **** "BBB@ HHHH **** "BBB@ HHHH ****
\$[BHY?I7^? \MJD[BHY?I7^? \J ZGE C#/_ "1WOU7 P! 6L;FMGOAG A([WZK P"@+6-S7+/X MF>+/XF'-'-'-
'-:-; \$!S1S1S1S3 .: .: .: .: #FCFCFCF@ YHYHYHYH .: .: .: M.: #FCFCFCF@ YHYHYHYH .: .: .: .:
#FCFCFCF@ YHYHYHYH .: .: .: .: M#FCFCFCF@ YHYHYHYH .: .: .: .: 5B;=4'-'-'-'-
,>04. .: .: .: !AS1S1S1 MS0 6UPYHYHYHYH&' M'-'-'-'- 'S1S1S1S0 =;PY9?ONJD M_*OK65_8'_3Y; \ ?
^L)1U/%FID\$;5%8G\0VG\I\$4 \ P N/_B*/[?M/[FI ^ %0_P#\$ M51J;=%8G\0VG\I\$4 "X_P#B*/[?M/[FI_
@!4MT-N, M:() (NN>F\1GIVH NT444)Z5')\W\ Y5(>HJ.7 %?Y_P J ZGF/C#_)&2 M]^J?
^@+6*W;MCQAG A([WZK _@+6-S7/.70'BS;YGJ'-'-'-'-)&?0=PYHY MHYHYIB|[N'-'-'-'-
>|W#FCFCFCF@/>[AS1S1S1S0'0=PYHYHYHYH#WNX|W#FCFCFCF@/>[AS1S1S1S0'0=PY
MHYHYHYH#WNX|W#FCFCFCF@/>[A MS1S1S1S0'0=PYHYHYHYH#WNX|W M#FCFCFCF@/>
[AS1S1S1S0'0=PYHYHYHYH#WNX|W#FCFCFCF@/>[AS1S1S1S0'0=PYHYHYHYH#WNX|W#FCFCFCF@/>
[AS1S1S1S0'0=PYHYHYHYH# MWNX|W#FCFCFCF@/>[AS1S1S1S0 M'0=PYHYHYHYH#WNX|W#FCFCFCF M@/>
[AS1S1S1S0'0=PYHYHYHYH#WNX 5? 0%K&YKEG\3/%G\3#FCFCFCFFMB YHYH MYHYI@'-'-'-'-!+8_5?
_0%K&YK9\89_X2.]^J ^@+6-S7+/XF>+/XF'-'-'->" ME MA \ A6&EE8C(1K\$9W?-M7]Q/UPP_4&N&^%?
[,>@_ \$CX7V.NSZEJUIJ&HK=1) M+\$8S!&ZS2Q+N3RP77*#*B1"<8W#_.1A[7E?+8\6MC*D:SI0A>RN];'UGS1S7S
MC^S7XT\1+\00%G@GQ)JXN7E5'BD\EUC9QN&X-'C. NTX5?,Q7J M'B7X[> 0"=TUCJ7B*WCD3]U)JG22@^\
<|9KYZ\& M(6,0QGU_40\$7B66#PC';2V]A%9P3&\$]H0%*(@ MK-YKQAF.X=#@<\$5JL8Z!5Q=.G*"?
VCZ9NM>TZ'60I\$^KV?|IL WV&2=4GP. MF\$/W_P.GXUH2%V"?\$%]XL>S0[ZWT
M^ZLM+^Q7#1S;G_T9XVW8@4L(-P!WM7!R><|>Y^)/%.C>#;5M1UF^MM+MXUP/_ MM#ES-
CYBJ=V;Y1A<' /X5?.A0Q\$9*3ELG8TN:.;XOP? \ &+P3X\U'[%H606MU MJ*L#'_Z-\$Y# NRK01%M'0?
#^@Z0'8^*VEA\$ MV8#0LX9(VD\U)"NT,69!N!8K|WC&0G4BDV<|;1C%SYKV/>^:.;\R#^'Q: \ / M^-?#^CZ-
!K4FJ^([?38?ML\$B3HVVY8HQ(6D?AFW')8 \ (QGJ;FL?' P""OA;6 M+G1]3\5F'4+24QS\$13R;)
Q4NBD8P!D@@#01SZ7-(XFFX*;.;2?F>@|T(K= M;0|+-;-;:S-
!90>7(J%|DT>>XD6.9S UVI3GRV,L1B_8P4XJZ;M P3[&YHYKR MC|IC08?"?PCU%N7AN=3_P!"@G2-& B?
<9E;?QEH5D|_WG>?7?L7^+&6X\0^ M&YMOD,\$U&,) &% P%296^8'YD:;,<|?
NCBDZB3L92Q\%65'OU/J=BH7\X9'I8# M9%|YCVJC=:|IT.MC2)|7L [38!0L,DZI/@=,(?0_
(= /OKY8 .";_A8G\0 A MWPO\$NI3VUB;>QN8X8|Y1)' :266;F&/ *E0MN4C\$?-0X^%\^'+/X|>\$)|0\2
M'1KZ""U6P_.K8S21,8Y66W:.0JT<2?(J^6J!05+ -4^UULD9_77)OECL['0 M\A=G+-M!Z;/F#+CU!Z?
A44UY#IT;75S(L5K"IEG:3:L:QKR2SG|N"!7A'|2W MQPB*:#>^'= U6.Q\6)(ZBN[E/&0YVOZI' ML>A^(-
+|16IGT?5+;5|:-C\$|Q;3K*0F??(R/0.*T>:^6_P!F?XI^\$0_/PCU!
M=>UVTTVXDUN3RH)#YDCCR85#,J*Q52ROR5(S@=2*^B_"?C/1?FCIJOAZ\CO M--M%N\IXI!(N-WF(ZJRM/R/E8
XP>XJH5%+8VP^,A5BK05|9YHYHW*%'F"1 MHU8,ZIR-H!W\$CQ@\$G*^8?VGM;E\;?
\$'PE\,+6|C@ADN(9;N>/\$|VTD5B*/Y M."NO'#[=P#>=D=%;
MFWFESE|2S8%)BDC,98A&\+WNE:=JFI2:=P2:;0@S JIW,JD|Q)|Y^!FA30'F%0Q4*U+VST-
_FCF0.&.:.^'DFJK9- MXHB6\D74;3)C6=[>>1@|]'V MDXSM)P1E&'!4Y.8T52#?+?5_D;/-'
>2>./V9?" Q\$|47WB#4|1UJ*X01&/+ MM)(50^7%'%QF(G^#UKYZ^&_P9T+QE\;?%?
A.|G0X|*TM;LHT\$Z :&,4ZP_-E M&_0#OU|9RJ2CT/,KXN02FH*G>[L?<'-'>,-\%]'^\$'PS^(XTJ;4YFU#2;L2
M_P|I.K,!'!,%QB-?|S9Z|J\&_9Q^#.B?>Q-?_MF\U'T_L [/Y7V&2-=WF>;N
MW;XV_N#&=30ZC32;W(K8^K2G&G|/5^9|PQ\,PE7DU5FGN@QQ(ML; Q!HQA&@D"N""|/21WJN?
K8ZJF*=&C|6K'K:Q|)%T;X+J|)%T'MB\;J DTL1Q^Z)[>M>^#/X9Z7*M FTG1YKR6SFN6N0|
M.=6<\$HB'I&0|SWHC/F1IA<150,5/DLGYG7NZ%NESU+FCFHKJZM|UEG09XK;TB'F23S
M.J)'M^;7EW;Z=9QC;\U\ZP1 ?< MW!PP7GMP2;XC1?V@0AWXDUJ'2]/\1F^09R=I,4T>2>>'=0,?-
P22#VIRDD*5 M>\$%S.2^_4|!YJ1JFK66AV,E|J5Y%I|C#M\VZN'6.),L%7M3WT\,E MP7%S<3_9[>|!-
YN6VLBKWR5^]^-?/?QN^-W@?Q0\)?\$.E:%KL=WJ#F%8HS!) M&LA\$S%OVED7...A/4=.^AMX?.M'6K5-\$D;8NJ+
M/'|G)+-&0)/N>&K',;:M|GL?M ?#_1\$MC? \ B".W:[MXIEC6VE6%T#)'=NN00?D*A.|'/ QV-
:*;MN=E.02J/DBR_S M1S7 ^(?CSX\$|WW|G70BF"WNU<(T=M!)1V>F>)-*0YI5#B"._B>50^ ABQ^A Q^_
'_N@1Q%.4N6Y0\TXMY)4EEC"X5TR^QN=."1G^ \,9KR?|G?X\;==Z7/ M8^+?SUTGB74M5;|- 5FD*AUC"
(C*NU4\S=A,+MYX<<5/M%SU.\% % M'PK\0KDKX=UZWNIP600*C1S.!UVJRJVWT; !YQT-
4ZD>YJL124|Z^)_C)HMOXD :DETJ|+BV0;^QMG:%|L@ \R.&/Y? \ 00T-
M9U*OL[6,_,9BWA8*25|NQ|L\T7NAC5U#_=)^8;2WRL< Z?[,_P 6|8\8?;0"?BG|2NN:4BJ)I(G^Q<(I",TH

MY>QMY:ESRP*Y&02S52\DNYG30C\I&G5CR\Q\ES1S7,^+0BAX7\^QP1ZWK\$5 MC+*QQ\$-TTI3+<8XU9CEE?
JIZ58\%>/M^>:?'>'M2M=101JTB12-YHW@- MT.U63\A^HS@XZ&JY[L\76AS\G,C>YHYKC/%6Q@>\(>
[M; '6-=BM;Q@SK!;^ M9<.@&-WF10(S)U&,D9YZX.-'10B)X;\1^\$;CQ1IVI;-&MHWN)YXA(/LZ1@E MV9&^8?
+NZ@'@XIN?0 K+S=IMTN8TF=[8EVD49DD>, MN-RD#G'4UF?
M:>*M&\9Z!X"UG2;MK_29TU%83Y155PT".V),#\$=NR2HK%U(Z
MM]#RJF815.=2*ORGUSNW88%G+*&\$AY5E/3!I>:\^NOC_/#VUUH;5/XKL[F\ M;7:XLQ-) &8Y53,%,>1D\9&*
[JFB;#M/)<1R!2HA?>&SG;M.XC\@*UC),J2G M6IRT4KLI:YX@L0">DW.LZE>1:78V:[Y+J;3:L>2 N?
JVUIZEE'\52Z3JEEK& MFQW.FWD6H6)8I%=0R;EDV@*V/HRLI]"K#^&0! VL-50\600"?@;3M3M1+JU^
MJW<,VX,A#(D(E890'F5V/!Y1>E40C);IJWQ#\ \$ "7^T9-!\'3V,,CM:_ZR55 M,B1P%W*@G,2HG3#%#M<@8S?
4QG).6FSL?1 -'-?.7PC\WX: &CQ9X)M M]E1W,/V^020VQ,<,SR;F7:B 0Y&(4*&W;FQM)JGI P!L :D^(DSW
M9N\$^&N@7+M: [=Z)?.IVACG8?,*, &4B^3 :3>S530N..YTDE[SZ>FY] >+ / M&6C>!=&DU77;Z.PLXV7#L-
Y9\@@!!\S .Z/KVK855"JP5XV8#".>-F %(!^
M;GGYCUZ=J\R^/G@73/\$7P=U:R2*VMK/1XFU"S:.W*K\$D\$3X5%50%40!E Z*' M!& H @_9G\6-
XJ^%&GI)0>XTF1],DE>-5#K'@XQZ1NB\]=N?XJ=[RMW-%6; MQ"IVW5SU7FCFCFCFM(['HIWU#FCFCFCFJ&'-'
'-'-!S1S1S1S0 \@F? * [? M^R+74UM'8]VG\ ""BBBJ- HHHH **** "BBB@ HHHH **** "N6\;?\$CPG\ /S
M9CQ1XHT7PX+L2&#^U11AL -"%0Y0R.N=N],XSC>,1140Q\$ \76G@'P7KGB?4(M\F:PT6PN-1N([0 RM%#&9&"
D!GPN I8 YKY8 8Y^# A;XK ?@^)GC 1+ / MOMXU\67-0/J&I: :07?E^3/+;QI
CIMA39&#L"Y&\+R*-4I+2Y+>J1]>+J MEGK6GP7VG7,5Y87,:SP7-
NX>*9&&X.C#@@YJ 7R/^SM;ZE\# P!ICQY\%K:;
M^ X0!1.3Q5X;C0+Y)Q900*L=0%' \N :T\L@N> /)W?,TCNWUA:DE6.W;TX1/ M;J;) +E!.Y8HIJTZI*"BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "J]TPS&I.-S<8ZEAR!^0-3-
7RS^W5XRE\CX8 #. M& U32X B#XBBT04KG3-B,VF[DCN(0,,2A^(T=X)-&M]3@DNE9!EU,(8NI
4\8%=C;N&W[6++G M.6/.3SC\ 17S9\7/V\ P3> "&^T_P #^\$K3PUX0TBW^U^M4\A++4%0X\$S
M;AKDX:0,54,TCG))^_93^)^VH &+X""^/%FKHR:I=V[P7;\$I^]F@ED@ M>4A555+M\$6*J,+NVC[M#C9G?
M_)]/4,#(\9^M \!Z=%?> (M3QC\ZLUF6%%!!1110 4444 M%%!!1110 4444 %%%!!1110 4444 %%%
!1110 4444 %%% %>Z8;HU M)QN/&.I8<@?D#7':? \6 FK>* \ A&K+QKH^YXCC=X)-&M]3@DNE9!EU,(8N MI
4\8KQ']NQQE+Y7PP&4- JFEQ '\$0%I>HW&F;\$9].W)'<1>8&0^CV VOP]J>@!++4%0X\$S;AKEL-
M)N*J&:5SDDN<.JNM\NWF1S;^1])VKAM^TEESG)/.3SC\ 15B0(V4_B=J7QB M^
0A/Q9J\;)JMY;0!=LQ3,LT\$TD#RD(JJK.T18JHPI;:/NUZY4E(****QPHH MHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ KG0&?C;0/ >G17WB'6]-T*TED\F*?
5+R.UBDEP66,/(P&XA6('L:V+S+;4 MRR@@Y*G'IW_R?3U'Q;^RGX<\+?M1:W\2/BUX0TP^,+J;7[G1]'L/\$E0#-
#IN MFHD,D4<=MAD1B)?FR2,-'AU;0-5LM9 MT>XR(+W3YT6@DVDJ2DB\$JPR,<=P:V2:~/0#^@R LV?MC:-
X3\ -6=Q9 #GXD: M==W2Z4MPGV.QU2V5I9I+;+;E5\I8U,:A0?/&"5A1(K>T8>.,>.!LDG'.3U
MX_G1**C:W4(RYBTM+35IU04%%, HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH
**** \$JAK6J6>BZ?/? :CGVT;3SW-PX2%% M&XN['@ 8J>^!,>
<,R@E\$ZM[#D<^G^2/CSQK'H [00];W "L \$RWMWX/\\$: (MFMMX?
N!&EA?:H9H6\V55YF3RKN(;7(&X.I0J[B2HQYB7*Q]1^" B1X3^('VP M>% %&B^(Q:" S_V1J,-YY0 =-9PL_#
M/QM^&?A>#P ?>' [Z"UUW3]%2&PM[_2I6PT4L>S!8RM&H=5)7S,D,(U,?V-:J MZY#]0!R "<=>GX=3TI-
65P3N[%JBBBD4%%!!1110 4444 %%%!!1110 M4444 %%% " =Q4H->K?M M-^
J9^(7P_L=.T2S^W74>IQS2Q;UCS%Y4RM\ S, %++UK?^!7A05?!_PKT/1]
M:L_L.I0?:'DBWK)@/I27UNUK<*4E\BUMU[# P!C.ZN-4T'QEHU] MY5WIBM;NU0<0;MWFPR1R!QU96\M 18?
P7\+;-JG[07C[3]0T6Q0],M1 MJ'V:R>U5HTVWD<;A4/10&:'UKT7]F;X6>(A?J7BZ/7K((9VMX8;BVNTECG\$
M1GWG@[L?,I&15)! QE62N800AK\20AK\7/\$?B;P;I%GXBAUF*>>">9EA"^^?/ MYKJ8S)&R;
<#YP3UYQ #*A=:HYU1E[*FYONTRI\<+. '3?VF/AK;6L<200)ID= MK\$=JQ8%ZZH
@^[A0YUS'OXU:]U[!HC^R=0L+0Q/9Z=]F>RT>W9E^5[>.5PC* M&;! ?
=N"KDJ#AD.#7I0Q4^&/BWQ/\#]433/\$NGQ;-LTHA9T1248R;-0G%6") MLHRR#) !S\$HN^AE4H5I1G:]KW/#
!]#KNOZ]H^K>&?A'? \ A&[TDI,IM;.: M2*21762,L%&C12"&YP20RY. H'8 M%Z7%KG[1W@?
3;M5>UNK;QAFU4Q,RM< MR!@Q'AE&&7D<\UW.EW'OY\1>(M,6\L]%&V=0,M5<3826*X7S0'C(WNV-NX* M
T>#NRR&H/BY\,?\$7BKX\>#?>\$>DZ89=%L5LVN)C=0Q_ZJYDD;"-(K ;53^'_ M
K2,7;40Z055)] =4SS0\K_P3H'A;:PE-I6D0:2M0'4T>%!' / [MQLO]YL -T%=Y^V5H]G)X)T_4_L\$50JLNJOP0?
C:)6B\$,S\$&GIDH*L?M/?" Q M'\20^\$5'A_3?MKVK77F?0XT\I7,.S[SKNR%DZ;NG;C/6?M"?#?4/B=\. /L>E
MJMI>VMPM[%\$04"? :C9A#EE 9BQ(PW\)Y'49N.K5C>IA?@^)M2\ .1PKJ44 BG6>6V3:
[3+R5#F)SW&S<.0*^;0!>K67PEM M[K0?B'\.FNK&]G<)=?90;J-MBQR"&60?,-QB.Y'3;NW_ #!E?
00PE_X6;IG_MA>\T37] TK1%TG35M-.N9+HR":9(W0"41R.67INP58%4PC]\$XG7-+^/ /B;1:
MGP5K6B;+>6EY*+;?5+F2 EP9LB7;N*IM'.Y80, 4\$;9!SJTY)6,:U%N%-PB[MKR/:OAC?Z!JG@72+KPK;FUT
P^5;PM'M*E"5?>R5Y-B\#.W?MW?Q8S@5H^/?#1\9>"] :T1(K26Z0K62&W^V_P"J
M2;83\$^=IY60(PY'2M9+W3V:D76PK5M;'R;K&0'X :I\)? "P:[7,L+?VG;/7J M0*5+;+@Y?{KJMNTQSG/G?
=?'S=A\1\?#?JK#0?%-TLSV6L)%NFDWI0>9#]E M;][G:77".VTC_6#..&-0]F?X%:
[X'\3WNN>)=+2QDM[1;>R23RYSN88>965C MY85%,?
(&?,J]J7]IKX4WQ0*\%V;Z%?:;]4TZ\VP*\WE.\#@!DB4_LQ:;GCSXL>*/&HM8[6.W>2X2,2,Y2XN'
M8!\$8==J*X.?:@=!K?'7:W[4GP^67SQ08.7^7>I&H.J]/91UKTS]G/X977PW\ M SIK,\$&G>(M0N)+F\@B\MB
JD(N]"0R_)N' Y=N.YYKXM_#0-XJ^_G@SQ#I
MVG>=I6F_9!>2>?' 'AXKF2:3AG7/!7H#^'_&T2M\$(9G()/3)05NV?A'0=-.9PN=3L]%L[#4[CPEFYGCM
M8Q/(39>807_BR1'],5K_+07PW0_ (F_#EK+3)1#J%K="]BB8J!,JJX6\$.67 M#-N., -">1U' />#M^)-Q\,?
\$7A30%X8L].6TT-M,T]X+Q7DGD\$+0_.ZEL M EC'CC&' :K3DH05' (_LJ?#GUX0^'.M7>KZ%;ZC//?0:]I0\$R:
M.,00D*C'F/#R-G9UXST0?L/Y:/QHY#([/:%HWW\$KS.1RW)X(KTG]FOP)KOP M]\ :G8>(M*DL[Y]4FG%G)
M5#;PO-)(W"1QJ,NY;^#:.=W:0C3X5?%#P_2/H_X[:/XD\1_#>_T;P0I4FJZEJ#I!(D=TMN\$@Y,F M22-

P8#RRH(RLC9XS7/\ P9^!.B>& -G%XT+2]4URX=KBZ>\@A0/)*P%ClR MAP@15^7<<,7f8K22.L*JR]#;C V\c
MY5Z]P1Z5U/[0'[/50XJ\ -V40@S1+=L-2M+C]Y;6\4-I'<10A S2(AD(4M@
MN\$M2MU6ZU'0M(M;Q%8\$C[.88VG4#>H! MQY;Y()Q\$R#& GM?VDO >M?3\$P'IEAH.C :{Q-
2BG,7F1IB/Ry%/SN00^L=>Y MKL !.AMI_P ,/#^BZ09)]LCTJ"TN-/D?S\$90#M=78,5*'# XJXWE<[(X9JI*
M+6CB?,7CCXN7'CG]GWPC\;WEWKNLW9T^]C@A,C2K 4*C+@NTf&2V;*@A]KK MD8KZD\!^\$8?
0A#2]#MY/-60A6*23YL22D\Y'PQ)&]W9RN?E+D8&*^6/V:/ M&E:U\7-
50M/CDU#PWX==Y+.\;R ,+EF%N[;N=X0&3C^.-*^QV#\>8BQN1GRU MZ(IY 'MDG\ZJGW+RN#FW5J/;3Y
0WA7RW\"/^3G0B+ W\$0\ TX05]12?ZLG&
M6!.*],I %S^7<5X\)/\AAXF[* '30GXAU'30)TK40M8LY//CDR\MS'- 'PKMC M@-U _'M52\GH;XN%2 ?
\$&GV8^UWEWID]0# M'TVO+%M'/UD/<=^*:/A=X)^,?PBUD4:-X0T^6 \$/G-?74+8>/?]T"X&/0\
M.1Z5G*,F^ASX^G)XFFY1?+Y'T1\, !6I^" #\]AK7B2\5W=Q<-,9[\-F)6 M1,1L3(WW2JG;QG=66%?,>H?>?
0?%7[37 "0>*+Y+?P]HK^7 P665IA!EHFB> M(%F9ILS;CA<\$@G@ ^L\)\!:-4\^-);?
5/!FGVTDFFR16)TN\CAN#H8, ",\$=ZWQC/\="\$2> +V+PWH6EZ7KENZW^L]G!#9^:1D-&[A! ME"C-\NY^
MDF_XE5IYVRWQ<2)N&+D#G9Z=J^G= T^XTK1;&RNKY]2N;:WBA>ZF P!9+B-/
MG;YCU^M?/'@%/CG\/"NG^='&:&]K9K,89+VZA9BK.[X.V\ "NQZ"0:OAG MJ7BW5-!GG\8:59Z+J)N6\$-
G92*R+L3!X=^K^9WK6!Z.!.<:8II\UD>8 MF? M\DOTG L-0 \ HF>NI 9B P'2'^& ^WK -*IJK?M,^!-
>^(7@&QT[P 9K>7< M.I07\$B^?'\$PC\$80#\TB=ZX#P.005^'GA#3 #]CX\$TB\LK/S1&:BZA90+
M=W=BBVZ"]6DZ8H^V9U)3IXUU7^VM8F ;4UZ L]%\ -;5;W9@L=0EG:ZAW!5GV M&(*K<\$D?
0&^7D\$D'&0I7SKQ)8S;G\ -X?#.E !35]/N+<120ZN()9+D,IRQD= M;=!(61I,\$,%P,JH'8'0/C+X8ZU\:/A?
9V BVVM=\$\960GW\$;0".2.&3>^%+M M>PC*>46"L>45L'R\ 'EK=QVA;/28] AL-,G-K^MNOB:>2&:
<(LG\$C;F >#G&3 M#YA !)9SDJ4+RNF<>)I.=5RGS6V?A>;X\$^E^+=JEA- #]C'X2\]R:#JT-VK>2Y#'?
Y1R58\=CF08 CI& 'C[PCX6>.YT05M=TJ*3[=)#'JG2Y6 M00\$&,\$
\$CRR6RR#"C;J#Y%00&WP[^+GQ.^'=G9;CH.C; !#I=VBVN@V,JJ\X\$ M;HI\PNZ+&FXA03@G?
GH*B5]B;].M432AHK;VU,[I]I'QQJEU\&0A];2W<\$IUZ MS2[U"120L]Q'!!MW<*ICW2;F!7.8D((VG/3 _!G^#?
A?P5\!+HV^BVG\3%M MHX]26W\$5Q),]Q' (Y^9FY\$DA"DX4' YK3^)'P/O/'0P1\]Z>FVW\2;+8P*(
M[HHD;@11B6(' 5@DQQD-G;E0. 69>)8+&0L+>)6;YDV3 MZA?>6K/\$C2!RI82)\$&D8H6!4_
<[IU=,NI1J2G*%2#>XW^C?F/D 2% B;' MD^R P!I +^F%_Y,? (D""'W0']Y5 M/Y0TS74+!,0\$#AI>
[Q(S;E MLEN(65 ;L2X\$H.W.PMD%FQQTZ!/?^%7^)/^&3_P#A#/['P"*E_Y]/?/C .?S MS/\
6;]G^KJM7KY6+^KR0=I !8YSP'\-0"" ^RW?;U=Z'9R:@UAJ^R=0D3]^ ML\SDH3# ,/R0K]?
PK0_9=T^ZUCX^+M.LKU8M2N;J[BBG\UMRW#V4*QDR+\ MRX+9R/3UQ77^#? >N:/^S-
=>%+G3/+!0MIE "MGYZ -)(TOE_0 E]&3K57X M""^'-4^#/PQUZ7Q+ITNGSV=UD^*=
 \;^"1J6N?;I;=3LBD(8*R&\$,& 1AM*@ MCR\AACS3X!^# B=<=>";W4?!"B[3-
%TFYN&B:&X=97WHFT[D;638,8SD D; . M,!2?4/@1\6/%FL^/?\$W@006T&KW.EM.T>H0QJH3RY%A;&%7Y3QCY1T-
3'1F& M""M[5.;Z0\ST?X0Z39ZE+ %>2V4=X(-,0)XIKR)93%+Y+ .%/< D9[9KR+JD M'PEH.K^;
[4KS1+*X0X=4D2*^N;,>.2YBC6*\$@:Q\WR,=P Z'^>]^-_"X23P MQJVCB3R60[*>T^U>6S;5=)(RV1T
.W.2.#U'4>% _OPG\5/ACK7 _C5QX;T MR?PQ-?R7=WJL=R%= _E\$6^/;(S \$1C:/+(8DK\F?EU<5)\QZ5>G?
%1FHG?*LX M^'K#XT>./%WB?Q/&N]WZR10\$DL8> -,)!PDBMG8(U1<@94X.T\$-^(>C6_P\
M;G\ 'R;!9Q:=#J1L&>UMXUCAB664P7 1548!C5BW_0L0?%WA008[NU2YM+NWFEFNK=HY#%;EMPW_C_5#06E M2-
TCMS2\$U3IJ,6VG=GU7M10,62;].K#8LK?=5CP, AF0CGX.1MXB ;VOM3L9 M/M-E%J- =23J<*
(C052#W>.BX VL]%- =J=Q\?0&ENNE2Z1HWA>"Y^5]1LY MUW8V-\I>RL>S(@*0Y9R04=Y\#_
(*VGPETH3.D.H>(;F)40-70N[, "0?^C M/WO+X. (!)PS!<#;#BY-21G64!>
4@HQM;4^4 ASXAU360%VK>*-3\ '7'00U; MY=PVN;>&1B0QE18GP0!L4\$@1[6X;"X]\$\#^EZ]:?
M!#5+3P/K'A+P]?B2.>Q M%DWEVD?EEU592F%>JA 7;.=B@*:ZC4/A+X^&0CJ \ \$7PU;RU'3KYG^UZ/
M(P@4;0,8\$@,JE S#8 ZL,J/F&6/8?#&'XMZCXB?40&EQI>DZ/Y+QQZ/9PK)) MN_0H\;1L2#N\\$.^1CG?E2-I7-
1<7J<5.G4C-J2MP \+<46^A0FV\+ MW=I)>0615 R+'.HMF;:25 CE88'!W<]E^&WPO\ BK\'?
%6I#2="T#550@D3 MZI?3(T\$ 5@?FJS^V9I-EH.F^!;33+)*TMVNS M!8VD?EQ#)MW;:(N\^E=E)\20ACX[IT?
XVI\00"&FVVM0*, "X"JL,WD+;!9 M\B;0E*X*L,8.1F&&10\C:6=3IUJ:5K0]3. ;I^'/AGP?
 \.]\$N=)T.SL)TOUM&FM MX5222!H9&D_Q_0/AHAC=TR<=37N0PK5E^&0A#,WF#^QK,A?IN8\$/\B*X_P#;
M2\!ZU\1/ >F6&@Z/]K0\$U**"9&F(+D4 .Y" ZOU[FNZ^>EWFB #WPQIM M\ /L-[::;:07%M0\
,Q(D0W?,&*GE6^]3C=2LCTL/2<<1*7+9.WY'SW\= _P#D MY[X=?]PW_P!.,M>[?S\$X8:#\4M'33];6>-
H95D@NK+'VF(\$@.\$^5L@CJ-I' M;JHKQC[K;SE\ -ZIX+\;=?98ETV;R7F;E<1LD]LI4?,")+G MP/!=> M/?
6;K4[8?9=0WP]!;6[/YNR5@V\@X7@% =#E\5+]*_AT\3SW\$(BU[Q1<;KB5?+D,@C;:@154B\$DIL)<1(7!!
M!TM!^.?B0P_X-&H>%/!UJWPXT&X@L@+F3R]S".@.];(#YKNZG(4A6E7@Y67S/E5HHE#08.X-(N#G=67(V
M[G'+#U;:C5CH_P CZ6T'5-,^(7@^W0;:(7>EZK;AVC9P1R15XW X#(XVD98@ MA@3Q@>/_ +&K*_POU%HX?
LZMJTCM\$0W%8P0DX_#%;GCRUTGX _LZWFB2A)(O M[.ETV">RQMEUJ
MB_#W_D\$S_P#7; V1;ZFN6^'0_()G_P"NW_LBUU-;1V/=I _@HHHJC0**** "MBBB@ HHHH ****
"BBB@#SG]HC3[K6/@; \0=-LK6Y0;N]\. ;E;P6]G\$DTLTC M6L@5\$5?F+-G &2< 8)%<-^Q5XP0?
&7[+/@ "P!12);B.R?34-LC)0CM9I;> M-\,2=QCA!)S@MD@ \$5[I>Y+1J".<[\$\$]"#GJ/3KZD?C\XW?
])^L>"]4UN]^# M_P 2;[X6;=KEW+?;GHHTFVU;Q-PP4"2VBFQY#;LD@%LC8@'I'&JZ)IKE; ,W?
MFNC/T#6/^\$A_X*)>*GM+2\>'P]X#M]&0[IX?]'CNIKJ.ZA3?VW1N2!W*/Z5] M20KMS][M][K]/\^M>8?L^?
71?@/X90;.SN;K7-?U.?[9K?B74G,EYJUR\$OVA/V9] M?TZS6>V77[K1IYIH">)?#?9K?!=)[?P'
MX*UKQ)J(N)-/T2PFU"=;>/S)I(X8FD957C+G;<=<2 .M>2_L#Z?>:9^R?X\$A M0;&73YFBNIEBE0IF-[RX>-
P#SAT9'&>H<\$=:Y060V2_%WCK[-X>\>?&?60W MPU@NTFD\,-IL5M/>11D^3#,Z*&C&YQG"Y_7W/M]:8'R?_P
\$VM8UBX_9YG\ /MZSI _]DW/A?Q!>Z*+=8FBE 5EF82JPRK!YY\$/3'E@'D\$F_P#%;5%UG\NOX'^^ M[250+B?0]
(UG5]0DAAS;P6MS;M;Q.3D[1YEN4([M(E='XN_9=N;7QMJ_C+X7 M>-KGX7^)=>:-
=8CAT^/4-.ORFXF5[5R@6?]3\$JL.CG!;5V.0\#0V;[+X5ZEK MGB?5];D\;?S'Q!(SZIXMKN<0RS(-0\$
MUOX#\%ZUXDU\$7\$NGZ)83:A.+>/?-+'#\$TC*%XRYVG' Y(ZUG?&CX3^&?C5X M'N "OBNS^UIUT"8Y48)/;3

\$K-"Y!VNH7#QN ><.C(XSU#@]Z^A*S M=#T^#2;.*QM+6*SL[-(8((('Q''&H(1%4 *%5< !>G3M6E6F-
@!&Q< 6-XSHH9!N;GY<]NY]R/20 ?%G[+ES; M>-M7\8 "
[QM< ##Q)KS1C68X=/CU#3KXIN8S/:N5VS[B0[U6!X"UN;=K>%R?GV'J,||CUSF0&/@;^S=9?"04M<3ZQK4GC?
X@^()& MDU3Q;=6PAEFC. L,, :DK!&%5.%)R1QA51\$]KM]VT[@ Y.3M_3<8I2MI;H.% M]VAZTZDI:@T"BBBF
4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%%
\$%TX5,E/,P"VP=3CG@>N<5\E_#+5M5T/_ (\$*_&/09;1K M;2=<1/Z9J\$D\>UYOLT50;H\+9^:/=/>C>C1^]?
6MP#M!4 L#D9 SZ9KQ_XP M?L\Z-\2=:T;Q3::C>>/'VA'CI/B;3<":'Y60'.K?)<09)W1L,E2ZAE#MG2#
M2TN1)=3S_P#X*':MY/[.-_H,%A^M4L='L+2QB,K/,UPDV-JC<25AD4! MX4Y'X8_#?2?
A3X>FTC19KZXMKIKHRWVW MON'-.-.-.-.%@LY;AS1S1S1S3LA\JV3#FCFCFCFBP*ZTZ!S1S1S1S2<;A*[MJ_M'-
'-.-.-.%BKR3#FCFCFCFG9\$J0HPYHYHYHYHL@MYL.....:7*EU#FH+
M^VBO; ">WGACNXY1L:UD0,LBGKR>F/Z^N^GYHYIOX?JO[' @2\U"6[MCEU#28)&W?9K25"B,>N!,C./JYQ[-
QCTCP'\-?#GPSL9+P_:+\$T@4W%R93- M)-C.W?(>3C<+ !1D[5&374\$--\>=>1T'5H9KBQOH_* MDB@&6X.Y6
/4JRJV.AVX((!MZ!H.G>&-M_*TF&SWL;50D<4!)7H'S,3U=F MW,QZG<"0HSR1_PMC^!D9U8]1N!!!
(W[.TM;&Q@M]*&SWM81Y<44,>04C M&Q1CLH(7'0;2!@ 2\T@8[4M% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% ! M1110 4444 %%% !1110 4444 (:3IU%*P"4M%, HHHH **** "BBB@ HH MHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0X[IT#':EH MH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ IO&3FG44 (,=J6BB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** \$/:HY?N?G_*G2#.*8^&'&E,7>YYAXPS_P)'> 5? 0% MK&YK8\8-
0\17A'J0_H"UC\UR2::U9X=24>9V;#FCFCFCFE>/'-.-.- M'-.-.-/FCW#F7=?>'-.-.-.-.-
'N',NZ^\,.....:/<.9=U]X MX M'-.-.-.-.-'N',NZ^\,.....:/<.9=U]XX'-.-.-.-.-'N'
M,NZ^\,.....:/<.9=U]XXZ^\,.....:/<.=U]X< MTX'-.-.-.-.-
'N',NZ^\,.....:/<.9=U]XX'-.-.-.-.-'N',NZ^\,.....:/<.9=U]XX'-.-.-.-.- M'-.-.-.-.-
'N',NZ^\,.....:/<.9=U]XX'-.-.-.-.-'N',NZ^\,.....:/<.9=U]XX'-.-.-.-.-!U;?0_R'-.-.-.-!SY;?0_R-
'NY+DKK M5'HOP^ Y!, %V]D6NHVBN3\ R*NF7)P?. \ 9%KJ/,3^*Z(ZH]JC./ (MM23;*-
HJ/\$S_0"CS\$_0"J-N:/S07\$+E'BD6W-0\ H<-? P#! MM/^%J>-0\ H<-? M_P#M/\ A:GC; H<-? \!M< M?
_%T?|+4|;?|#AK /X-KC_XNOV'\E/[B_E1Y*?W% *CZL_Y@_U;G_S_']W M !/OX_X6IXV_Z'#7_P#P;7'
_71_P_+4|;?|#AK_P#X-KC_+K]A_)3^X0 MY4>2G]Q?RH^K/^8/16Y \ W]W !/OX_X6IXV_P"APU_,&UQ_
_%T?|+4|; M?|#AK \ X-KC_P"+K]A_)3^X0Y4>2G]Q?RH^K/\ F#_5N? \ S ?W? \ \$ 'C_A M:GC; H<-? \
!M2G]Q?RH_M^K/^8/\ 5N?_ # ?W? \ !/OX_P"%J>-0^APU_P#&UQ_ \71_PM3QM_T.&0\ M @VN/_BZ_8?
R4_N+^5'DI<7\J/JS_F#_5N? \ / ?W? \ \$ 'C_A:GC; H<-? M !/M/^%J>-0^APU_P &UQ_
M71_PM3QM_P!#AK_ (-KC_XNOV'\E/[B_E1Y*?W% *CZL_Y@_P!6Y \ /] = M_P \$ 'C_ (6IXV_Z'#7_
_P;7'_Q=' "U/&W_0X: P#^#X ^+K]A_)3^X0Y M4>2G]Q?RH^K/^8/16Y \ P! = P3|>/^%J>-0^APU_
_&UQ_P#%T? \ "U/&W_0X: \ ^#X_P#BZ_8?R4_N+^5'DI<7\J/JS_F#_5N? \ /] = P3|>/^%J>-0^APU_
_P#M/\ A:GC; H<-? \!M2G]Q?RH^K/^8/16Y \ W]W !/OX_X6IXV_P"APU_,&UQ_ \ M%T?
|+4|;?|#AK \ X-KC_P"+K]A_)3^X0Y4>2G]Q?RH^K/\ F#_5N? \ S ?W M? \ \$ 'C_A:GC; H<-? \!M2G]Q?
RH^K/^8/\ 5N?_ # ?W? \ !/OX_P"%J>-0^APU_P#&UQ_ \71_PM3Q_MM_T.&0\ @VN/_BZ_8?
R4_N+^5'DI<7\J/JS_F#_5N? \ / ?W? \ \$ 'C_A:G MC; H<-? /!M/^%J>-0^APU_M_P
&UQ_ \71_PM3QM_P!#AK_ (-KC_XNOV'\E/[B_E1Y*?W% *CZL_Y@_P!6 MY \ /] = P \$ 'C_ (6IXV_Z'#7_
_P;7'_Q=' "U/&W_0X: P#^#X ^+K] MA_)3^X0Y4>2G]Q?RH^K/^8/16Y \ P! = P3|>/^%J>-0^APU_
_&UQ_P#% MT? \ "U/&W_0X: \ ^#X_P#BZ_8?R4_N+^5'DI<7\J/JS_F#_5N? \ /] = P M3|>/^%J>-0\ H<-?
_P#M/\ MA:GC; H<-? \!M2G]Q?RH^K/^8/16Y \ W]W !/OX_X6IXV_P"APU_M_,&UQ_ \ %T?
|+4|;?|#AK \ X-KC_P"+K]A_)3^X0Y4>2G]Q?RH^K/\ F#_5 MN? \ S ?W? \ \$ 'C_A:GC; H<-? \!M2G]Q?
RH^K/^8/\ 5N?_ # ?W? \ !/OX_P"%J>-0^APU_P#&UQ_ M_71_PM3QM_T.&0\ @VN/_BZ_8?
R4_N+^5'DI<7\J/JS_F#_5N? \ / ?W? \ M\$ 'C_A:GC; H<-? /!M/^%J M>-0^APU_P
&UQ_ \71_PM3QM_P!#AK_ (-KC_XNOV'\E/[B_E1Y*?W% *CZ ML_Y@_P!6Y \ /] = P \$ 'C_ (6IXV_Z'#7_
_P;7'_Q=' "U/&W_0X: P#^#M#X ^+K]A_)3^X0Y4>2G]Q?RH^K/^8/16Y \ P! = P3|>/^%J>-0^APU_
M_&UQ_P#%T? \ "U/&W_0X: \ ^#X_P#BZ_8?R4_N+^5'DI<7\J/JS_F#_5N M? \ /] = P3|>/^%J>-0\ H<-?
_P#M/\ A:GC; H<-? \!M2G]Q?RH^K/^8/16Y \ W]W !/OX_X6IXV_M_P"APU_,&UQ_ \ %T?
|+4|;?|#AK \ X-KC_P"+K]A_)3^X0Y4>2G]Q?RH^ MK/\ F#_5N? \ S ?W? \ \$ 'C_A:GC; H<-? \!M2G]Q?
RH^K/^8/\ 5N?_ # ?W? \ !/OX_P"%J>-0^APU_M_P#&UQ_ \71_PM3QM_T.&0\ @VN/_BZ_8?
R4_N+^5'DI<7\J/JS_F#_5N? M \ / ?W? \ \$ 'C_A:GC; H<-? /!M/^%J>-0^APU_P
&UQ_ \71_PM3QM_P!#AK_ (-KC_XNOV'\E/[B_E1Y M*?W% *CZL_Y@_P!6Y \ /] = P \$ 'C_ (6IXV_Z'#7_
_P;7'_Q=' "U/&W_M_0X: P#^#X ^+K]A_)3^X0Y4>2G]Q?RH^K/^8/16Y \ P! = P3|>/^%J>- M0^APU_
_&UQ_P#%T? \ "U/&W_0X: \ ^#X_P#BZ_8?R4_N+^5'DI<7\J/ MJS_F#_5N? \ /] = P3|>/^%J>-0\ H<-?
_P#M!]@XC_H(?W? \ \$ ('_A='Q#_Z'?Q1_P"#NX ^+H_X71\0_P#H=_%' M @[N/_BZ_7[|.G]Q?
RH^SI<7\J/83_G_K[P_L'\$?]|#^[_@GY_ \+H^(? \
MT_BC_P=W'_Q=' "Z/B'_P!#0XH \ '=Q_P#%U^0WV=/[B_E1]G3^X0Y4>PG_M_#_U]X?V#B/^@A_=P_\$_ ('_
(71\0_ ^AW\4?^#NX \ BZ/^%T?\$/_H=_%' M (.[C_XNOU^ ^SI<7\J/LZ?W% *CV\$ _Y_P"00#^P<1_T\$/[O^"?
D#_PNCXA_M]#0XH \ !WP MG /_%]X?V#B/^@A_=P3\@?^%T?\$/ \ Z'?Q1_X.[C_XNC_A='Q#_P"AW\4?
M^#NX_P#BZ_7[|.G]Q?RH^SI<7\J/83_) Z^\/[!0' \$\$\$/[O \ @GY_P#" MZ/B'_P!#0XH \ '=Q_P#%T? \
"Z/B'_T_BC_, '=Q \ %U^0WV=/[B_E1]G3_M^X0Y4>PG_ \ U]X?V#B/^@A_=P3\@?^%T?\$/_H=_%' (.
[C_XNC_A='Q#_M_AW\4?^#NX ^+K]?0LZ?W% *C[.G]Q?RH]A/^?^00#^P<1_T\$/[O^"?D#_P
MNCXA_P#0[^*/_!WPG_ /_7WA_8.(P"@A_=P3\@?^%T?\$/_*'?Q1_X.[C_+H_P"%T?\$/_M_H=_%' @[N/_
(NOU^ ^SI<7\J/LZ?W% *CV\$ _Y_Z^\/[!0' 00_N_X)^0/_ M NCXA_]#0XH_P#!W']@XC_H(?W? \ !/R!_P"%T?
\$/_H=_%' @[N/_ (NC_M_A='Q#_Z'?Q1_P"#NX ^+K]?0LZ?W% *C[.G]Q?RH]A/^? \ K[P_L'\$?]|#^_ M]_@GY
_ \+H^(? 0[^*/_ =W'_Q=' "Z/B'_-#0XH \ '=Q_ \77Z_?9T_N+^ M5^V=/[B_E1]"? \]?>']@XC_
*''']W !/R!_X71\0_ \ H=_%' @[N/_ \ XNC_M (71\0_ ^AW\4?^#NX \ BZ_7[|.G]Q?

RH^SI <7\J/83_G_K|P_L'\$?|!#^|_M_@GY_ \ "Z/B'_T_BC_ , '=Q \ %T? \ +H^(?_0|^*/_ =W'_Q=?
K|JG3^X_M0Y4?9T_N+^5'L)_S_P!?'>|]@XC_H(?W? \ \$ ('_A='Q#_ .AW\4?^#NX_ ^+H_ MX71\0_ \
H=_%'_@|N/_XNOU^SI <7\J/LZ?W%_*CV\$ _P''^?00#^P<1_P!|_M#^|_ ()^0/_PNCXA_ \
0|^*/_!W'|]@XC_H(?W? \ \$ ('_A='Q#_Z'?Q1_P''#_MNx_ ^+H_X71\0_P#H=_%'_@|N/_BZ_7[[.G]Q?
RH^SI <7\J/83_G_K|P_L'\$_M?|!#^|_@GY_ \ +H^(? \ T_BC_P=W'_Q='_ "Z/B'_P!#0XH_ \ '=Q_P#%U^OW
MV=/[B_E1]G3^X0Y4>PG_ #_U|X?V#B/^@A_ =P_\$_ ('_ (71\0_ ^AW\4?^#N_MX_ \ BZ/^?T?\$/_H=_%'_ (._
[C_XNOU^SI <7\J/LZ?W%_*CV\$ _Y_P''00#^P_M<1_T\$/[O^"?D#_PNCXA_]#0XH_ \ !WPG/_ %|X?
V#B/^@A_ =P3\@?^?T?\$/ \ Z'?Q1_X.M|C_XNC_A='Q#_P''AW\4?^#NX_P#BZ_7[[.G]Q?RH^SI <7\J/83_
)_Z^ \ /|_M!Q'_ \$\$/[O_ @GY_P#''Z/B'_P!#0XH_ \ '=Q_P#%T? \ "Z/B'_T_BC_ , '=MQ_ \
%U^OWV=/[B_E1]G3^X0Y4>PG_ \ U|X?V#B/^@A_ =P3\@?^?T?\$/_H=M_%'_ (.[C_XNC_A='Q#_ .AW\4?
^#NX_ ^+K|?0LZ?W%_*C|.G]Q?RH|A/^?^_M00#^P<1_T\$/[O^"?D#_PNCXA_P#0|^*/_!WPG/_7WA_8_.
(P''@A_ =P3\@?^?T?\$/_ '*?_M01_X.[C_ .+H_P''T?\$/_H=_%'_@|N/_ (NOU^SI <7\J/LZ?W%_*CV\$ _Y_
MZ^ \ /|_Q'_00_N_X)^0/_ NCXA_]#0XH_P#!W'|]@XC_H(?W? \ !/R!_P''%_MT?\$/_H=_%'_@|N/_
(NC_A='Q#_Z'?Q1_P''#NX_ ^+K|?0LZ?W%_*C|.G]Q?R_MH|A/^? \ K|P_L'\$?|!#^|_@GY_ \ +H^(?_0|^*/_=
=W'_Q='_ "Z/B'_ -#0_MXH_ \ '=Q_ \ 77Z_?9T_N+^5'V=/[B_E1]?" \]?>|]@XC_ *''|W_! /R!_X71\0_M0_ \
H=_%'_@|N/_XNC_ (71\0_ ^AW\4?^#NX_ \ BZ_7[[.G]Q?RH^SI <7\ MJ/83_G_K|P_L'\$?|!#^|_@GY_ \
"Z/B'_T_BC_ , '=Q \ %T? \ +H^(?_0|^*_/_ =W'_Q=?K|JG3^X0Y4?9T_N+^5'L)_S_P!?'>|]@XC_H(?W?
 \ \$ ('_A=M'Q#_ .AW\4?^#NX_ ^+H_X71\0_ \ H=_%'_@|N/_XNOU^SI <7\J/LZ?W%_*CV\$ _P''?
^00#^P<1_P!|_#^|_ ()^0/_PNCXA_ \ 0|^*/_!W'|]@XC_H(?W? \ M\$ ('_A='Q#_Z'?
Q1_P''#NX_ ^+H_X71\0_P#H=_%'_@|N/_BZ_7[[.G]Q?RH^_MSI <7\J/83_G_K|P_L'\$?|!#^|_@GY_ \ +H^(? \
T_BC_P=W'_Q='_ "Z/B'_M_P!#0XH_ \ '=Q_P#%U^OWV=/[B_E1]G3^X0Y4>PG_ #_U|X?V#B/^@A_ =P_\$_M_ ('_
(71\0_ ^AW\4?^#NX_ \ BZ/^?T?\$/_H=_%'_ (.[C_XNOU^SI <7\J/_MLZ?W%_*CV\$ _Y_P''00#^P<1_T\$/[O^"?
D#_PNCXA_]#0XH_ \ !WPG/_ %|X?V#B/^@A_ =P_M3\@?^?T?\$/ \ Z'?Q1_X.[C_XNC_A='Q#_P''AW\4?
^#NX_P#BZ_7[[.G]Q?RH^MSI <7\J/83_)_Z^ \ /|_Q'_ \$\$/[O_ @GY_P#''Z/B'_P!#0XH_ \ '=Q_P#%_MT? \
"Z/B'_T_BC_ , '=Q \ %U^OWV=/[B_E1]G3^X0Y4>PG_ \ U|X?V#B/_M^@A_ =P3\@?^?T?\$/_H=_%'_ (._
[C_XNC_A='Q#_ .AW\4?^#NX_ ^+K|?0LZ_M?W%_*C|.G]Q?RH|A/^?^00#^P<1_T\$/[O^"?
D#_PNCXA_P#0|^*/_!WPG/_7WA_8_.(P''@_MA_ =P3\@?^?T?\$/_ '*?Q1_X.[C_ .+H_P''T?
\$/_H=_%'_@|N/_ (NOU^S_MI <7\J/LZ?W%_*CV\$ _Y_Z^ \ /|_Q'_00_N_X)^0/_ NCXA_]#0XH_P#!W'_
M|]@XC_H(?W? \ !/R!_P''%T?\$/_H=_%'_@|N/_ (NC_A='Q#_Z'?Q1_P''#NX_ ^+M+K|?0LZ?W%_*C|.G]Q?
RH|A/^? \ K|P_L'\$?|!#^|_@GY_ \ +H^(?_0|^*_/_M=W'_Q='_ "Z/B'_ -#0XH_ \ '=Q_ \ 77Z_?
9T_N+^5'V=/[B_E1]?" \]?>|]M@XC_ *''|W_! /R!_X71\0_ \ H=_%'_@|N/_XNC_ (71\0_ ^AW\4?^#NX_ \
MBZ_7[[.G]Q?RH^SI <7\J/83_G_K|P_L'\$?|!#^|_@GY_ \ "Z/B'_T_BC_M_ , '=Q \ %T? \ +H^(?_0|^*_/_=
=W'_Q=?K|JG3^X0Y4?9T_N+^5'L)_S_P!?'>|]@XC_H(?W? \ \$ ('_A='Q#_ .AW\4?^#NX_ ^+H_X71\0_ \
H=_%'_@|N/_MXNOU^SI <7\J/LZ?W%_*CV\$ _P''^?00#^P<1_P!|_#^|_ ()^0/_PNCXA_ \
M0|^*/_!W'|]@XC_H(?W? \ \$ ('_A='Q#_Z'?Q1_P''#NX_ ^+H_X71\0_P#H=_%'_M_@|N/_BZ_7[[.G]Q?
RH^SI <7\J/83_G_K|P_L'\$?|!#^|_@GY_ \ +H^(? \
MT_BC_P=W'_Q='_ "Z/B'_P!#0XH_ \ '=Q_P#%U^OWV=/[B_E1]G3^X0Y4>PG_ M_#_U|X?V#B/^@A_ =P_\$_ ('_
(71\0_ ^AW\4?^#NX_ \ BZ/^?T?\$/_H=_%'_M_ (.[C_XNOU^SI <7\J/LZ?W%_*CV\$ _Y_P''00#^P<1_T\$/[O^"?
D#_PNCXA_M|]#0XH_ \ !WPG/_ %|X?V#B/^@A_ =P3\@?^?T?\$/ \ Z'?Q1_X.[C_XNC_A='Q#_P''AW\4?
M^#NX_P#BZ_7[[.G]Q?RH^SI <7\J/83_)_Z^ \ /|_Q'_ \$\$/[O_ @GY_P#''MZ/B'_P!#0XH_ \ '=Q_P#%T? \
"Z/B'_T_BC_ , '=Q \ %U^OWV=/[B_E1]G3^X0Y4>PG_ \ U|X?V#B/^@A_ =P3\@?^?T?\$/_H=_%'_ (._
[C_XNC_A='Q#_M_ .AW\4?^#NX_ ^+K|?0LZ?W%_*C|.G]Q?RH|A/^?^00#^P<1_T\$/[O^"?D#_P_
MNCXA_P#0|^*/_!WPG/_7WA_8_.(P''@A_ =P3\@?^?T?\$/_ '*?Q1_X.[C_ .+H_P''T?\$/_M_H=_%'_@|N/_
(NOU^SI <7\J/LZ?W%_*CV\$ _Y_Z^ \ /|_Q'_00_N_X)^0/_M_NCXA_]#0XH_P#!W'|]INV|V.W.U^(S-N
SIOS*"?^M8G;>F.. /6N" 8) :CUW4KR_ ^!GQIN[C20C%X8F>WMX|615FU*S2-"B^=N(N) MU|9|Z >;%LE5I?
WKT ?<|?)G|=3;E_9SRZNV "Y?#FXH_ G_2><> \ +%?2_MGB_Q5HG@?P|UVB;4M4NH|:WA+NJ)NDD(5^H?
#GACXC;-JEQM2TH;RVN=/\$\AD6-8XFN(XTDE+NFV)0#.YB=V|)Y)Z_P''+W|9/P=^_WB*10''CW3]*U1A
ME|.ABG0;JV;9&X|Z.!)&B#1RIM,FW=DD|AG: >|T5POP|^*GA/XO^#|;Q#X, MU_3_
!%I\$VS,|A^K^7(423R9%#!H90KQDH^UEWKN%;G@XA>?B3I4^I>\$/ \$ MFE>*,AF-L|H|I]=PI*%#F,0&Q
8^Z\$CKAEH_Z:B0_ C=|"?|/[O?ABT\> M/=#^B#1K6|74(K4W<|L%G5'17WPNK<+XQG'-?F|^V9^QW\
(_A3\>/V:/#WA_M;PC_ &5I^C#Q*=.UJV&I7EP+NW%S81!=\LK-'B.>7|A'7V%_'ZS45\|?" \
M83^!GP=|=:3XP\ '>|O|^|1: ?YBVM| ;%|<" ,0\$\4B|99V4Y1W'*|Z^2I0@;X_M* ;'_P'''K/QH|_
^/|!_MW1; ;PU; :E; :M=SVVV=; ?2D#|H9%;A99. >| 'Z?4_M5\^P=? \ @G7^SUX*|2;)XDT?X?+I^LZ5?0WUC=?
VYJ\$AAFBDD5HFV0.5;YE3A_MAB0?/&'BC3_ OA/5_\$6KWJVFE;18S:A?7;*S^3!%&TDD@10S''JQPH)XX! /!_M
_BHK\9_V:?\$7B+X/_&;X=?M, >+-0M|'PC|8M=UN3-<73+, +9:;DMQ^| \$|U, MVV%#=[YN^RL-
FQWN=Z+^P^*R>4IV^<;F|;FQG_X'?GG_ "@#1HK\F0_ @F5^_MQQ\ (?VC/@/K0B^X@^\$AX@UFR\1S; ;%=?
VE>V^V%;6UD5-L,R*<-*W)!-?>/P_M>_8T^\$'|/'BN;0% \ / "7_"/Z0=6CZ?-=?VI>W&Z^W1BFR;5UY;-
#T!^6@#W2_MBH+?/.4V_@'&>Y)S^004| !116%XV^*Z;XY^+;MX;UJ#|7HVL6_M=#^A21-Z\$, ,H6^RG/-&
|17YI?MV?L)_SX-?LJ^_&'@SP3_9^B/338FVN_M|70KC900K>)QLEG93\DC+RNINXK00@)_P3M_9| \>?
KX=>)=<\ ;:|9U;PSI_MNH7MTFLZ@OFW\$UK'))+M6<_\$LQ.W_49Z8H_ ^|Z* \ ^\9_&+P5 \ /?%7A3PQXD\
M06NE:WXLEG@T6W0@0EW)\$ \$WP^;M**V9(P_!|F9U5=QXKE/A?^U? \ +/C1XYU3_MP;X)\96WB#Q%IL,MSD>-D|-2?
%31Y;YKB&W66TBFFL09%4J3>1HT_3YQN?S-J;<_M-MVL:Z7|J? \ : TC|FWX.ZSXXU&|@L-3^SS6FB07=K--
!:=E|GFEMK:00C(5_MBG)+N%/S+UH_|OHKX1_X)W_+9/A#QM\)_A|_0\$GCR|\0?% \ ^-^|74X;V
MYN)"MQ=7",URR&-@MNBD? \ / *_%X/%>WZ|^VW\#_09^))=8^(^D6,0AS4)
M=)U^39#)|MCNHI%CE6.UV>?,JLW^LC1E^5VSM4D_'0\ 17A2_MB?!U_A" Q1_MD|=Z:0_Y3R|WE_
4&ZNA^"0|0WP|_:\$TW4_M;WX?>)|?Q!#IDRP7:>5/;RPNRDH7BF575& ;:<;69' .48_|4HKQ0XQ?M2?_M^KX
>2GC00I8^'KNY56@LF\RX0)\$82;9?L\ "M|(B87->8"Y_4G)4'7^#_P>_M_A_ \>0#|FJ_#_P_6: ?XCMX2! ,+?

=<6X+NB"6"3;+N,;[?,5=P0LN1S0!Z; M17B?B[|K;X.>_ \$GB00/\$GQ TG0=9\,103ZEI^H%HL21":
(PJ0#F[&Y<@'M=%?GC^W=^VA8?#0X\?'7P'I/B^XT.'1/%-GJGCE=.6\BEM; M-
1;R)\$SQ@+;/R03S.*J^3\$G3H?LKX('3P5^T!X:00\$/@/6_P"W='M;QM/F MG^QSVWEW"HDC)MFC1C\DL9R
1\|T- 'HE%?*W_!4(!OV'?B0N[;?^);>N/^ M8G:<=A7G/[/? !. _JGSQ0\!/AQXEUCX?
+>ZQJ_A03;^|N1K>H1>;++1M^*U M)PJY9GX4 4 ?=]>\$Z;X5^\$W[#?P=UV^T^V7P-X#M[M-00Y/,N[X+/,T-
N'R M3)*2Q\$*@ 8!P>!FLGQ!^WM^S_P"'?>-AH%U\6="FN[X1^5+IYFN[9"]M&0FW M4"M%=@KR)'4J0S-A6!H
^C**\ ^+'[/;P5^"/B] "7B_0S::1KZPQ3RV-097 M-VT^*R NF_P"SQN%8@;@A(8B1&QAU)|DT06+77-%M-
4TN[L]1L+RV2YM[BWG\$ ML,\;KN1TE&08R""&Q@T ;=??.WQ% ;J^!'PG\53>'/\$ _P 1M-AU2WW)=VMG
M;7.H""02-&TU6\DL+;5;6YEN99XE!D5K1(0.0JK(09HU4"6\$|)(\Z_CK|L?X, #/PKH. M0>('NG:39>
(+*#4=*M *FDN[BUN(FEBG^S1HTRQ,\$?)X54;AM)W8% 'NM%> M(^ _VN?@I\2K729M!^)0AJ\FU&4P65C<7ZV=
[*YD,2H+69DF#\$Y W)R.1P03 MT70C^/GP^ V@KJWC[07I ANVF)\$*7!:2XG 9%<101[I920F1[0+4[0P+8'-M
'IE%>_ !S|J+X6?M +.0@'0K8>(+ZW50.L5\$E0>HJB,F46\J+,8MTL8W[2F M6(SE2*J^+0VM?
A!X!\2>* #WBCQ_I'A_6?#4\$^I:9?;\9\$)H (5@#V45XI&0VM/A-^T)J5_IWP|\7V^0:E8P+<7%J+6XM9Q&6V
M^8J31J\BA@;:"%WINQN7\RY^W=^VA8?#0X\?'7P'I/B^XT.'1/%-GJGCE=.
M6\BEM;-1;R)\$SQ@+;/R03S.*J^3\$G3H0#|J*|\^"/QT\%?M >&K[Q#X#UO
M^W='M;QM/FG^QSVWEW"HDC)MFC1C\DL9R 1\|T-=[, %4\$KN70D\ >M \$| % M?CK^V!-
XF^_7[0WQ=^*0@+4(4^P^ATB&R:QTR26ZN+B.[9Y9^BE4C;+3_P+H
M/) *04V01C8REY1^K/PC^)^6B_&'X=Z!XR\ SF?1M9LHKN M*CO^N7YHI-CL!+
M&V4=%/!VJ;'I_B^0^I.C:AJ\K0;9;:A?1P2WLN44I" MC.#(P\Q0=H.-
XSC(SS'QT ;*^'7I.^DZ;J^Q!\4V AR+4I)(+)&BEGFN&5=S ME8H4:0HHV[G "@L@}RZ@_!W[5_QZ^'00Z ;
_8[U7P^XJL/\$MK#XRQ.ML6CG M@4ZAIJH)K>0"6/<8W^*8HW",E- M/B^XE\ Z?K+/XR\ _JFCW50-;W\$*\$@>;
<;>;%\RGS(\KM>-A\BIFY^-'0 MT\# +/OA>W\0 \$+60[#T6\04T^.<6<|T&N&C=P@2)';!2)^V ET5P_M_P
2/BGX3^\$'A.?0%XSUVP\ Z3\$C8NM0D\$?G.(WD\$42D[I]"B.1&@+G:<"0/ M0A#^V3\'?
CSXBFT;P/X|T_5=44933IHI[*ZN6V2.?)CG2-I0L<3[C^NVX!(4 M8W '0-
%>9;|)=0A_X1^(:^!=>|3Z;H0B4Z/)XA2UU!S#&|C&9/-G\UPL65\J M9B-VX)&
[GY02,#X3_M8 "GXX:1XHU3P=XPM-3L?#-ND^L7ES#<6,5I&RR,)) M))XXP\$Q%*2PR \$R>H%
'ME%?,7AC_@HG^S0XLUZTT:U^*>G6|S,74-JME=6-
M0@1ER7FN(T2/@8^=AD *,L17L0Q&^*7ACX/^\$K6Q#XXU_30#VE0AA\I09519 M)1&TGDQ(6W2R,J2,L: N0. 2*
_XHKP?X/\ [9?P9^_WB231_!7CS3=6U8\$" M+3[F*:RN;ABDCGR8[B-&EVI&VXQ[MH'(7*Y|PM&W)N
^1&@&|VXZ|,YYSC'6@ M"Q17YX?%\%1/'^F^ _CQ^R;X=UJV^V:/J_B6XT^MMS)YL,MUID,M3&F>'M-
:,W=|'S3A""BQ?*+B5G^9I%" (Y'.* _ZHKAE^ M*7A%?AS9^/)\$ _GZ;X/N[&VOH-7_M
Z;J^!'08\50^/'#^Q&TV;5+C:EI:WEM)Y#(L:Q0-<10I)*7=-L2Y=N M2JD9P ?1-%>9?;X|^
0A#JOAK20'BK3?"EYX@P=.;4&:_V?R\$1IMUPR^5 M^CS(\%RNXL NX\5P^A _JNWX#>?,?
B);^!|"^(|A>^(KF).GV\0M[I+>>96("0 MW)B\A|VTB/8Y\$C; A8NN0#Z,HKY/_ P""AG[2]K^S_P#
76[*QUS^Q?'/B2PE MM/#\?EW^FD^9#^6LBR1310\RNC#[RG/!K M1;M]: '45^7\WP+\\$?M!?\%8/C9X<|?&-?
T:V\,V>H16QNY|;;.EMI2^*Z% MT;A97XSWKZA\+?!\ !.W|G0P3XAT?Q)H_P_73M9TF|B0[&Z_MS49/)^FAD#12;
M7G(;*#G#%# 'T_17YK_M8?"WPY\90^"I^P@&\&+],&M>'M0\&2&[L?.E@W^6 M-
6E1M\3^RXD1.C>W>0<-4 X)J_!03|/NI?AY8ZS\, _&2P.NG>+M!US4#>Z?* M5"Y7?<\$%2N49>Z,Z@H2&-!|
<45\6_L. 'QW+XS\7? 'XNW4-[1? 4230ZH MLKS0JNGLJ;9Y7(Y=|-;GS&97=;E=T8=)&K@0^VL?|-.?
|_%0\$ _P^*(FM3Q?# M;0=|CN+'PE:ZI)I\&N7;165R1=A^WW+QB6258U*[1:JPP!*7 /T/HKYB^ _[M#G@0X)?
%32_&/PPU/7_!5FH\050#\$ _IS7.F:R/*N5C:=96>3S4DG1U"!J_B/4/MHNKW^UKZ'?Y=|<1(-D5PJ_MB-\$Z_4 ?
I517D7P3_9;^&0[-G|LGX<>&/!&L^2;|?M|U<^?Y(D\H?0Y7VX\ MV3IC.>& M|^,L/AZ8=-S%(&
<,SKNM;@8^EL_VA6D,C1;V_0&Q8/'N\$BR@89>A&,@_E0_M!9HHHH **BFZ+|]?
Z&0S<:T^WAOXS _%30A^X\7:7 _&SX=U^P7)|KLO/E MAW^7:TJ'?\$RLN)\$3H1Z=Z
/THHKY.D_X)A_LSMG BW!^5<;AKFI'' '>X). M !P>!F0)/\$%KI6M^+)^9X-%M(X\$)=R1!-\F[2BMF2, M
P9F=57<>* /0;^*8KC@H=^S[;WFL6Q\? _&I])#-?76G;-J%S;6T8G2_3 M&6.^X|AEDB429V,73!(=
<_0FB:M9Z[I<&IZ;<0:EIUY"EQ9W5K(LD,\+HK(Z_M.K,I5@001P01[&@#9HKYA^,7QV\#_%CX%?
M)>'?"_M#5=:\ '^&|9L-4W_8YQD9^:6SLHYIE0S69E>39YLCJV1F1)7+?0(I)8T^0"WB6R\; M^%-
&|0^'[L7VCZ090W|A=2*Z^=#+&)(F*.%9&KCXIZ++?M/#;K-:Q32V*>8JE6^V1QM!MRZ[F,@5,\$_05:02/
MB#\=0 _PK^'\^0_1:0';^\$KQD&'7=(M)|0@;_49AD+6TJ0K<6=S^\$_C.U,CV^B7P|K M=VUQ
[PR)L<2S,3&?,!=8VC=@"! (H9L@^V^17EZ _KP00QB7X77?B#[]XY:T M^WP;9>VDL
N8=H(,\$SHL=P<%F(A9B#'*./<#6^)7Q2\,?|0P-?^,/ &6IC3/ M#VFM&N^CM9IPA>18E/EQ*S _#-
(HX!'(YQ0!W5%>4>./VC?AQ\OA3I?Q)\ M0^)[?3/!>I06L|AJ4UM,6N0M"[X?+B^&1W=&+|0L%#LV K\$<-
"7|LCX-? M^37)M"&^/\ 3-3UB/[MC<)-8S2XC=R88YTC;;L4C,T>=@)QD4 >[T5^9/ MAW_@I#X-
E;D\4:0KGCVZL?@W!X433=\$*VNHK;W-YYMM-)++;! "1.&-W\$)/ * M7Y8D7)SE00V/XH>%&^UEX^N]?LM*|
(7UE;ZA!K6KSK9P"&XV&!W;;Y98R1 MC#XP2HQVH [FB0G;X=?MU? CXL>*H?#GACXC;:-
JEQM2TM;RVN=/\$\AD6-8X MFN(XTDE+NFV)9^@N5W%@W^B@#TVB0"?A[^V1\%?B0\ \$:Z\^"\$_ 'FG:WXDA
M\$Y%H(IDBG\$)^?[/;Z+#. 6^E,V41G&54L,?PS^WA\"/&GCNS\;\$)\2+&^|0
MW5Z;"WC^S7:0SS@XV17+Q>2Y8J1^M<^82BH277(!)'457M6)9AC: JX1C\PS MGKZ_7)[^E?!? !:;C_AE_P
|9/_ F-L1D-JQGM /TH ^_^4% P"" M80[- D.?AMMR#D_VYJ2CJ1VN!C(/L/203)%^'|'/P-D4\$>#_ASX<.
[<3=7G MV?|1=#_KI*Q:--OPT9#!@X.,\$>0 !K7#;2G."30G0[?GK7.^\$?B!X4\8ZIKFG^'0\$
M6DZSJ&D2K!J=II]]'/+92Y=0DR^Y; 'RV W_9V^&<'CGB7|0#X#>#?B%=" M-;^(NG67B^V01874;P730VTK\$
I)^*XKBVOK2=9HIXG0-49^1EX^E2""00002,4 ?H^137 MZ"ORJ_9;_9B^&W[1W[3 _UH?
B%X:'B%M%\9R_8/]-NK;R0.0=1\$0^HD0L&\$ M:=<|.,+0:L'| ?[7^P:LOAMJNL6WPY^)^6I2Z/?^!Y+V22QM;A
MS:6_VJ-YC(=^98)>1YA-N4#B.7:GV!KW[3WPK\ZYXYT76?&EIFI>;**_U_MZ00DE22""54>-D#>B?
=YL2XB#M0FB0X=U4@^L-^>3?"]HKX=-&3P)J0CGPG
MXDM=2\+;3<30:AK#W!-8Q6QBC2640|H1"JK%&2 _XR20%(!!Z7_,%!/V=] M6\:/X:M_BGHL5^L\UNTUU%-

#00Y:L6;[9]&L&W*-M82/R I)9:/I6JNH-B M,#W!VXZX(X'(PC07RSS6YENXIH;\$F-26(0)(Q 4^0[7]S;^["
[MR Y /;? /O M""*_\$G2I2\(>)-*429#;;9[W1[Z*[A24*',9>-B P5T)'7#+735^<__!)+
M01I0@K[CGQ_XAUNY%EHNF>)-0U""NEC>;R(8)/LI)'4\$G;JEL \$|NHK[B^% MWQ2\,?
&3P39>, /!MZ=9\ /;EYIM;PVTMOYNR1HG&V55<8;;KRH'R\9H [-B0, MOAU\>/ 006\2>--?
#WA76AJ>K>#KW[%KMK]AGB-G,9)4V;G51(2T\$_,98?+SU M&>4^,'[9?
P9^!/B2/1_&0CS3=)U8DB73[;*:;|N;=@D;CSH[>-VBW)(NTR;=P M/ ;#8
/>*>\>G ;B^%L7P;N/BA'XPL;OP3:B 7&K;|2T %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444
%% % !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !
M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 % M% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% % !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 ?*G !4 M3/\
PPW\2<#/\ (-].=ICC06)^W-^S^K?CB>S^, PQUG4M!^+ @>S>?3Y+?' M<#4K>(2N;/R@K?0"7E"J%99/,>*12)
4|\$;U^% B;XS_LK^-?!0@_3#J_B+ M4A9&ULQ<10>9Y=;20\ /?RH,)&[?;PSMXR;|P.2#Y>Y#SE@I^8CC&.
<|,>N M (=)?)^PWFRXW%8V= MF\$C([1,6.Y>="Z.HZ?|KJ2S^+ [W|/OP5U^VN&*6T%UXJO(%G5[;4)%CN
M6@CGMF0HR(;!U8L&+1W3;FR,50\$M[#|T,DBH7D',GF.SCS/, .SWC|K+|G7Q3\7-6^'GC7P#XBM- M ^GP_U)
[-2X=3DE33;N*8PB@N3"0FB-UAVY3(93)&P_>;XP"W^W;\.=!^) M?[*/*M-:MA(- (TFYUVSF"+YD%U9Q-
/&8V=6VY"MG^W#%))5!7<2/F0XQ?&\$R
M^+G !&V;Q)J:7(U.33=+LKJ;\N6N9KB6UUBWM'GDE95+/(UN9&SD@OC+?>/ MHGQ,M_VDOVI/!&I_#2?
X8V'P1T36?)AU;Q9?^+X|5F-D)\$\ZW@M0KF61;I=Q1P01R11V [NWB5(YVD#LQ)FB"\$A7KSCX8?#GXZ_
ML3;:JW@GP+X*B^_GP_N-2E0M DF\3QZ5J6BPLB%|6X\$Z&\$JS9*?9P 665V"F M544 E_8Y\#?
&'P/\?/B1=ZY\|K#X3_"KQ");6M|>';#5;.\MM.U"!(+?\$,=J MX56FC\$DLC>2N3'%E0EPW0?|+G|,OA?\
93\!;AX1\):CK&I:9=ZD^IO)K4L4_MLJR0#%&OK1Q1C;B%3C|Y)Y|'"C^SOJ7QJ\17?B;7/BSHVA^\$M-
0#"N@>|]G- M0=;?&LUR7-W, 4DD>-K;|C1:L_X\OW?^L|[[WS>0&V@#Z|KX_X*/?\)T?|&/\ V.;?^ENE
M5]_U|@_MK? WQS\5/CM^S1XC*:;\$VK:/X/\ \$IU#6|E;N""|)"03W#|)'5I M,K#-P@.-0/49
/KKM^/|*_,&X|(^- &?_!6#XUV7@'X@?'*XUF/PU93RZK_8 ML.J>= +72@T'E3,%7'->T:VT>U/_ "366E#=
%A0DS*S,-KVSC|CYS0 M!|?%!6X4 % P-XDN+SQ \;#\2=&DM)(H|7PA9:2(+AG5A/YL+%GP%E79W\W
M)Z5\ ?\ !6SX M60AWX,;!\-GF@L'^(&HJMSJMY'(|M:65I/!-*Y,6Z0.)&ML M8CDRBS
#=MSZYX6^_0|06I>*=&L-< 9F_P"\$>T>Z0(H+W5_&^TZX%I 7 DF M\I4#2;\$W/L7EL8!%6XN#(
MRA))HXK;1LQ?/?M_I)W[;J,;KB(\#_&M VCOV6?B_&R;/\ -?#0CM(|OP| M90W'AF!)=)U5ECN;6
I#!0DC7)DC\R#=-,S!?- ,C\$LH-?80[%0QP?|H3|G'PEX MQU*:";7S&|CK'E31NRWD#-')(D:J(9)5"S>6%&U9T
W+AC|6R>7&S @!|A9 M. HYP.P&#@'Z9SC-?*0|) P;|>_L_?'3X0^%FT"W'P6UW4G\1^'=3M7M+;.*
MUN)1'YEHEJC&8(\$*Q*QVHLLJH\W@ ^5/^"9_P * B|XY^!&07?@#XW|\.- \$ MC\23P/I)\)66J?><+:6K&?
S9F#*2IC79T'E9|U^D7P/\(^./!0AF|L_ ' CX_M\$?69;QIXM6.BP:7Y4!1 MOY4+%6VL';?
W\S':0AW|C'P_P#M,?LB_# +50!X_M9U_X3#|;K,FJ?VC_,)QIEEM#000B/86D)OY&-_\$U
M08_\$#X(M\,M%CLWGBU8>+K'5?/G#(%@|J%0RY1I&W|!Y>.] 'MEPF|8?U.ML*SJ, #;QM4_8
MY./TJ00!\0_L<^#_ (/^'_B=J5Q\/_V?0BC\ (M;:2)\$FUKQAIU|!;SVYG@W6_MZ>=3*TA;RVOL^|&_ (|_
&M;AE+A08YW\$|_|^|6**_ /E;_@J)_R80\ \$0\ M|AG_*+=2040V3/^360@|_V)NC?^D\$-2LJ#"HOY8\$XXK0?
V=?#.I^"0@/\./#NM6_P|CUC2/ M#_F6%|;^8K^3-%;I'(F5)!VLI&02#CB@#XK_."K0@^R^(GQ>_9=|*;E---;:
M=KF07FFW,|JZQ51Q37&FQNZ.R,%(5B02" <\$@X07J0|47@KPE^R/^R;X|_3? M"OP=X;|'|>
(K/2(=\$@UG3K'R+Z.">Y@MG=KN,K.TJJRR!BY)E1&.\C%3_+;W MP-\<_%3X|?LT>("FA-
JVC^#_\$IU#6|E;N""|)"03W#|)'5I M,K#-P@.-0/4
M9^D_B#X+LOB'X""|1^\$=1DG&F;|I=SIETUJZI*L<|31LR,RL_V'."00"!P0#0 M!\)_LU:|]6/_G|_
0AKPMX6_9%T060""^KZ-#=WEU-XUTV./7_+5 IDN9X)4) M_?|AF-|P1 (AA0H'H_['/_@WX@?#OP?|
&31_B|X(TGP)\,|K5+06='TG4;^U M0+*PT^Z-Q)>6;".1HDM8E\$?R%8T/FS'G) J_#.T_:3_9=|_#Z;|--;?X8Z?
|;| M\$T42Q:3XJL_%L.F2?8C*WDV|Q|>|F\$D:#@1L8EC,,;DF,M6|XN^#7QF_.. 9 M&\?^\$|B?J7A?0?&0B6: "
|TNST82-9:9#\$MI/'|;3-R2QF@F\$CJTH'G;E9E54 M|Y+\50VF0@0J/|)WBWX=?"?X;^+0&?
P^A\ -7=C;ZMH7A2671-'NA""B&YFN" MC++\$YAN7E*NP+B0NSDUT/P"U*|U7_@C_*M-J%|/J%RG@?Q+
)KB1I&\$480X_MHHPS'|J1HB*!P%10. *F\,Z#^TIXX^!.D_!&X^%7A_X;:, GAV#PSJOB_7?&4
M,I"2R%JMI,+:SLR&2X=3YB|Y#%|K(S9*D=Y^S9^SSXGT7|@N#X0^+E_X1+7| M0T?6=)ND9X|L6;7=Q=!)08GV-
A9T;8KC)&,J=PH_L_ \!+___),6^&GUU/\ M]. =W7A_ 3(\)Z)K'|7_P"UKK5_I-C=Z0H_C1_|-
U"XMT;>R\Z|U2.7R9"I M;_NGRG:1N"!|5Z7^Q9X2^..?P2\.>%0A+XC^'&DZ3X0\ -SZA+?>-#XCCN1JD;
M37\$L26=K&!)\$6DFA8&;""5%+N"NX_M_L9_WQM\)?CQ^TMK_ (OT---T?Q=X MC74-#N%NH)_M4
N=0D,FR.1G3Y9X_E< Y8CL: /+?@IX4T6T_P""P7QC\02-
M/C>R\,KJ%LOV9%;WNIXM,,UPN!A9)/M,X9U^90. ?/#'/0>/M2F\ (P#!7SX= M1:*MKIO_E7@B6VUKR;>/?J
07\B&1B,EE:RM10&VVZIG;|I|3X<_WQOX_M?_X*/?%;XJ:CH)@\"UX;@TVPU?|5"WFSB/30R>4)#(0-
0,=S(^%7D\TG0(^ M!GCCQ!_P4>^%/04T|P^UUX#T3PW/IU_JWVR!/*N&CU)57RF<2MS8\
<,09", \$*5|I"6|F,K|A\ (?#|0R7|LZ#Q5\| \$M/^\$ _@;7M&FT|Q1:VN065
MW%>7:M<7,>H2);.F^Y>1TB+0'*0CRG=\V5WK/X2_&+|EGXL?\$/Q+\,- M?BU
MX'|?;I_ ;5SX70M>&DWNCEZ(\CW\$|,CH8'MSD*<*)2#_N''(6=2?@GKWQ_P#&_M_P_1|0UGXD^%=
&G_@*&TDMK'PM:ZDNI;I+=L;5UN)IXP8VB7;=J_IC/SD.C M@X
/F'P1X|\ \./^./^"Q'0QFUW28=6_L+0+/6=,6X!80726VF0QW"Y(5F5968_M,<[6"LOS*K5U?|T^&_P/\;Z%_P_%
(0BA\4M0T7R0_6N^&X-,T_61>6|> M?,(I-!3R0YD7YK>9%-";5M'\ \^')FU'6_MKE;N""|'_;NP<-Y.,B
M^TO//4|0\YK|!4Z&0D;|NC|G_P_8?&C7/A|\00_|G;,>)-7^&^N+JK^%|FZ

[[5^N [5#9 #WPMIO 2TOK6R\.:+;WW MPQ76;Q["-8[B^&DI+|LE50-TV^*-0-.7#(C=5%3 M#:#7 -
IC|C'Q P'& M;WX6-X-\>ZA>V=08^' ^\$AL[[[1;Q75I.;CF0-D29Q*/++9 =KN ^%;>) M0^&# P#A77V# BK
/A6?|A?V7|HCQ|IM LS|/Y& =M UGR;|VWOG% '#?|\$T M/'NBWG|'0A"TGTPBN;77#JAU;VDA21-
09KR>!OM"X(E|B|S(SNS\BHI! %?+G M| -0QN\7^ - \ @D|\4|4TZ_5+ P .ZS-
HFD31@P080W;V7F^6T>QO*KW|S(CD MDJY' .U M?;O["0PS\4?|G|E?P9X-
|8Z8=)|2:5|N^TV7GQ3A=|]/,A\R)F0Y M5U;AB1NYP:\H_8_98\7> _V2_B)\,?BIH|QX?N/%&J:BDL5K?
6|\|QM;C3|: MW,B2QM)&&67&|)! % '%_LTZ|\6? O| -/AGPQX5_9%T060">LZ+#=W5Q- MXXYT8M>-S
0FW,T,REOWRLI,/P- MX4N/\$\$NM>%- 'OU&"Z%E#=#25//9Q>1*4CBB =%5"("TLI .3CG AG: ?M) LN^ M| | -
^&M0\,= / ^- ^B: *)8M)\56?BV'3)/L1E;R;>X@0 S'2- !P(V,2QF&-23&6 MKWG|GI0BU<^#+_4?
C!_8%OXDOKP75IH ALL;?3;3| - %MV9L|I%E69F8/(I+
M *Y7:J@'P;_P28_9I^&WQ\$^% BG0|XG\+Z=XHUO^UY=%@CUJUCNK2UA2""8, MD3J4\TF;#.06
3Y2NY@WH\707^&7|& |<70>?X@V4/@S3?#N@:" A34;/3!- M#;V-0;?9IH\$6W#20HTL" 1| I^S#('|O=Z-
_P33^|OCW|GGX#;_H'C_0VT36 M|KQ-&M+N)/\$T6E+H^I'+ M=6V(\$N2PWW AD=VCP58S8VB9P?5=6\??M#?
LU M0?"3PGXI>V QI* \$">: MP-0'X?M|+NK-HGB\$|SMMHF.V*.5)=Q>RD*F#*(A.)\E5,ZHQ:8! #SV^T?
M|H7QE^U/\,?B'9?L|Z?|-X;2\DL0>HKXFT^|?5|.NOLT,GVKR7B>;|/'7C M1M^&6/"G9AN>|\#^
=|!1=I;:7\$DP&0- MT:S,5+9*D*Z, U?OWPY|9?M* \$3XK:7<^) A|H/PF^&Vfy;4K.76HM5U34G
M,%RBK#+\$IC6-) &MW8,L;9C&V1P6CKE0A0\ "7&_A0 @I% \40BAJ6B^3X\$U|PY M#IMCJWVR|O-
N!' INY/*\$AE4;K>8?,H'R|P0: ., ;FOIO!W|8 | (OB'2H;73 M|:OM?N|)NKZ"VC:;>SEGLX&A>>I|?YS7H?
|9GP-|<_%3XY_LT^(O"FA-JVC^# \$S:CK5RMW|!# M|C@-W8.&N1U9_DAE^5 <8YZBK|/|='|/_C#XD:Y|
(/B^X'L|;Q)J_P -|<75 M7\+W-TEF=4A:>UE?9! ?MJ?_00
MW^TI\0 @|X0LM|\SX4V.KKK/BVZN|JWA@=%JD,963|5YWE?:E =JJ;KF/+ ' M|:, ^= V. VDOV90A-
^R7#\./&OC2WBU#0#!=MXHL; ;3M7F29KD%&C\$BP94B MV,4+>40NY&9"?00Z#_P2=^,5CJOAWQ| \ (+;7H-
;TWP=J4MSX:U4A+2> TV>; M32R2G?,RAHVQ&K.18)'0Q(M#@0V6S:?'#|05|H;Q|J| %P-
2|"SV_A/1(+BX%Q#90|B&:2>A,4CFS8_NR@ M"W=P#N+%CF?| %#_*L8?VLOV0=3CL;5-4N?%P3721JCRK'?
Z>8HVD_RRH\TK M|23M\R0C&XY|+QM|\$_BE\ OVH|>^,7P6*6'C;PYXRM4M/\$?@IM8CTMW009#
M|LB^18%QY2\$R.99"JS"/!4*?;_ ?PFLU|3^(|;=3=QQC5Y49K%'9<1RR(!;2QJ0|M-VN|0F0> MS_MB
VW :!_9T|8>\$%TXZKK#637VC+&T*2IJ,2L\!228;8_8>4S9!N6I= MRY)'! ?L& !'X@?#?
PQXT|7_%Y#/\4 &FKM>ZE=E M6(86.2-#C9L0 ^>?BIX\|9^+/\^F>KZ=I?PMA^+Q^'6@6\^A^'Y|&EQV4LB
M6D|ZQDN&:)YE>X2|H.\$MVOQ@#50 'JS :4^+L^!0\$WA|JF?3?"/CCP0K-0 M?P^|O^\$RTV(N){6})U?
3IG0Q2FWD:=0,C\$F&&|<98F0;_P|H'X\$>.V^,7A?X M|?"V_M;|Q3X?
TV32=3\)ZI>:/6FLZ;F:7R(YD&GWR';)@8@YC=B!%AZVE?\$ M#|J;XB>--?
#>G+|)=!^\$0AJW08;G7=6UCQ);ZS)U4D ^>OV0 (4Z|\=/'^H'P?| !GBF":XT'40"0GNK>UN?+-RL+:I<
M+&7QE59HMI*D-L)VE&P5^@_VJ0V1;/Q9^S/XY\(| !PSH?@W6M5:UN9;+1M- MM-
/CUC|/,)%MI7\$>"" ,F/!3#A0T@1I <_P"(OP-|>Z|_P4?^%7Q4L-#%SX\$T M;PW-I|JZW<(\J9HM1"Y1<2,-
T)\R\$(^?|W&|!;|?KSXIVGP :Y^#6G^&M3 M\503":6P\3M,D5S;B)R8X?+=,3E_) "F1T0 -EEZT ?-
/G|L3PI8'PKX" :) M^\$K?!(K5M)08X|"NM6TH/X>^TVABA26QFV%+;RWE.UUW0Q1.2;@AQGS;XJ^0
M&GBK @IEJVFZ9|+|;X0GX< '>700#LFN)I<-A(ZVD|ZE^&9H6E#W"H|M!PM MNP&Z ,.|^,7PK^<-
G|=4GA/P/\1?A;;?|OP!I>I?VYJNL0^(|75|Z|=(FB2VM M4B \$;,)Y,M(I5>&S\GER^I?'_P"!/CR3XV>%/CO\+
|ZW00%GA_3)-'U3PGJM MXUG9ZW|N)90*BECR\$F|R4A?/W1;Q\$YVB+\$@|XC\=K/\ :3^+6N^!?\$WA_P#9 MHTWP?
XW\+ZS;W\B?_A,=-N|B:VB697TZ:1&AE-0(T|^9&),-Z_0%J_0^U) M8NY4#=@AE?<,"?|
Z_PQ|!\JZ7|00VI/B%XT|-Z=P *IT#X1^&8+Z&XUW5M M9\2V^L75U;"ZA:2WM|;KB-
WB\$R9DC(.|8>)U|/U39YPQ+EMV&&=0 YP./\^G M'% 'Y|?| %1-/U/50CM^R?
8Z|K7 ".ZS=>);B"SU3|,MS|DF:ZTP1S^4Y"R;' MV-L/#8QZU|AX7^!O|0FD^)-(N|?<
&FQKB6EU#|J&EMX|T^ 7UNC@R0^,O\ A |8N=70K=-4M;' . MV:QEB3?.X^ |G<956QCG&1G?;|H+|IA65E_9-
Y4Y./B+IC=,C'\$8|/Z=Z .- M_P""B&FZS\+|6^&O|2/A;SM|3^>I?9|9MU@ABG0-,N2L3HUQ("P4\$WA50C
MLOVYI^V|2:3|L;6)/VD/B0\ !3X'>&+RWUSPOKTL?C'Q3|E:Z^SW.AP.C0EK MFW;8U0<\$3!
<9/G):D,F58_3'B3P-%|= ?@K<>&0'.A-HY\0Z0D.I:3' M\$0#D+:FD|V.EVZ?- \$L<#-
L3\$6V%)WEXI7(!BSQ|XH;4^#7PR3 MP);_ !1T&TTN7Q&G@N74QI>JWC?:E#30(3\$5@6U\$B|DY#3HQ99"HU?
VE(V MC/VA/AY)HW_# +U0X<\56=Q#>:)XN7Q0I4|H|LB7,\$SM:/M1HF?R I974XP23 M@_ ^|?M9?LZ^*?
B|JGPY|;^ ->M0#W0!\ :B| I<>J2RIIM|' ,T7VJWN3"/-5 M'2(*=A.Y6DC9<2;TXS0|4/VMO'\$>@^%?@AH?
PQ0|L0&_BSQ)XLM|8@LT|E MP"(|;=?;|S>8RA9)%SG?'@LR@'B/_ 4 T>^^)GC|JBO1_B-I^K|J.NZB+;Q%
MH|O*R1+//+I27=NCQNS*FYY\$#*|8R&. U>W?|%, /">BV0|"?C&TM-)L(+70
MSI?|D6|=NBQV.V|MH|!G4#6(G>;,85W7A207?ME? WQU|5?CA^S/XD*Z(MVKZ/X0\2?VCK5RMW!"+,
W>GN&V.RM(-D,0"!L; >>V>| ;N^&'B;XQ?LL>, _M|7@S3SK/B/5/L/V;T\^*#?
LOH)7;S)651|J,>6R=N|S0|XU^UYXHU3QQ_P \$ MH|CQ+K5R+S5M8\,>&;^|N%1\$6:>6YT^223;H_7<|-P.!@8
KZ6_9, _Y-: ^#W_M_8FZ-_Z00UY9XT_9S|0?|\$|@#2/@|/=6_A|Q2/"6CV3K=,) (8+NT6WD,+M&Q M^00;F-G7=@-
N ;&#?_9)NOC-IWACPYX/\=?#33/ /AWPKX=M=*CO)=AU"ZU
M2\B2&*)XX|<>7!\$B\$F9U=F):.\$(3M>@#Z30!E!@00&6"IC+8'0Q^?'20Y\ _V M^/&WBCQI^UU\1)0%?
VJTDI_4I-,L+:1)%\$.GPL5MGBCD)VI(F)_EPK-.SK|^
MOZ!95+1 *B0Q|@A/J>_XYKYD :0_P"">OPJ :;|;0>*=;BU;0-?6\$6| MU>>'Y883?*,!'G\$D,@=T'RA0EXGD
'F2-@?-P_%54554|=,BA0Z|AR> MF>@ZXZG\ /6@#|Q+CPCXW\9_ \%8/C79> ?B! PKC68_#5E/+J0|BPZIYT
M=* M#0>5,P5=S&\SJ/+QWK|, ^# /PJ^+ @70%=7?C|XV?|+)T:6T>&+2%\ (66DB"
MX:1&^T>;"09\!95V=#YN3T??.GB#X>?'#X5_M|\$WXP^\$0A)_P)|X)M&L-;_9D.@:=-7L-M M>ZP0CS3|HV4#.
|QY*QY?RQ\^T<: MQSCK^?I|5^@'^/\ 20A7|I3X3_%VU ;F^'?QJ|! ?#/\ X3W2_#0ALV\$UI ;E MG10F30\
;D*;IFW?*MTC|@A|QCC|KL|6^*W|5?CS3|00-'^!6C_#/5M0@>*V M|6:|XSM-3M=-<+D2&"")G=L9V?
*P#LC,K(KJ0#S/X1J&_P""Q'QT^4,W "'6 MNW04/VH/V _"?|0WBRR\;Z1JVH_#OXDV7DFW\0Z*JMYDL
M3H\Z7X4T+XT?# MC5&SI&D6.J0Z#>: +Y83!FDG#>: 'R!OFEFW-7_<9|I@#Q#P3\40CW^QI\?0A

MM\,/BIXHM/B3\//&H/I^BZ^5,^H1,9&BC#.SK(&,EU9M)Y{3*L;*L;DJ17T MS\30C)\
< "WC: ^TWP; ^ST? /AZU9#; :Z?&=E8&ZW1*S .C2H73;|. @R3GR\ MCAA7G/A?
X% \$?|I#XZ>' /B7\ ' 'S4+ 50V.?B/=Z[I(\ M/ZO<> M2EN]+^T+>?
89VTZ4R0>'=%M_M>M:OX;U*PL;"/TGQAXK_P"\$WU^U,HN|>&F1:<;K+NT9^SPDJFV-DCXY/E{N M]?F9_P \$T/
AHH? 77S\)\S\, #X= _P"\$CG^T+X0^W :S>?9;3=L^SCR|GE^3 MC/.XMFOT+^"WQ\$^)WCP:T?
B)\)C\+S9B\$V" \)\):0\ ;|V\R'|PH\KRRD?W M00>90|TY\@_X)B_KQW^S\(! \$/A/XA:+=86MW7B:74(|?
[9#=:X6M+2,2;X M7=>6B?C.>* +/P' _&4_%B_&K6?C9\70%.G^,OB7>6HH *_E/
MAI^S,8U_XPM^<@QU70|2(^N1?C_XXZ\^?L<^#_@_X?_ B=J50\/-G| MXH "+6FTB1)M:\8:=>P6LJN9X-
UNGG74RM(6\ML:/NQOR.V|10\3C#>D-ZY M^|3S@Y_0_&OSC:R\.^)/%G_5.^\$6D^\$?0_"#^(KGP8XM=
<_LN^4A;X_M_M9I/|'E(5MT:NF3TWYZBOTANN4_|)G0QD9&._%?"[2WPK^+=0^W9\OC\|/_M (;'X@Z-X8\.-
ITEM;EGIPDG=K|&3=,VX;%ND;.PCCM0|)|+ @|<?"CK M3M4|8?M#_P#="^8/-:|T(>";*P%SNA94_?
Q,63;(R287|VS\|1KYH_X*I>#_M|/_B+70V8/'M_--:Z;K>OWFF74UJZORQORW&FQ.Z2,C_\$*0P2"0,@|2*|
MR_X:_:7^9C^R:6;H|@?|_3/_'UYXK+;_.^! ?CKXI?7|FKQ#X5T% MM5T?P=XF.H:U\$!QCW% 'IUU^QW\
(%^'.M^#+=M^'0A|1;'5-(;0Y|K2|-MUQV@.TAC:1-.C9H^#'|H_T7:DA"+&W(C_M'^0T)G4)#A73)4N?
^\$T|1>\$|>2>(9KZ:>2ZE0;JQF8?;/_99EA\$<@P/GCY"@L|J/F(SGC&3|E?LPZG^TQ^SC\?\$?"0PZ;|F>3Q =
(^TK :. M^/=,MO-\$MS+/GRL.\$VB3;|XYQZMB@#UK @J) P_F+ \$0_N&?^G2TKY|_ :Z^ (MFL>
_P#@E;_K+2)TM1XGT;0-"0+@EUD2V?2C,X1U(VE (\$;LAHY)5(YR.| M\8?LQ_0%|LSX@&-9^
_1%AX%^%.D!KN+X;Z/JSW^Y+WL=X| MVEA8I8" |QS2;'CD=TCVLGE)#"1M*JS4-)^('|6/PS\ V?
A!_@GH_Q'\0:/IL M5G#XSB\90):7TBQ#R|B:"Z"3NX.WS2S1EW5RK_\$8ZGXBK^T;%^SW9^%=-T02
M0\$/Q6\1R7NGZCXHTK408:3X=MYII-L\3_R73/%!)&D>Q6<-"SN790)@#XG^&_M>J>+OC|XD\)?L@>*|57_
(0+POXQU33|CQ|#:70?&ME0V>M7VI100')%:6X1?W3LZ^S(R8P%.3M,4 MX!@?MR:A;2?#SX*?M9>#=#*0Q?^&
[W3-6NPES^8W\$^B7@21K>XE4,Y!=XH0J, MZJMW<(REB-3|K#0,/VIO'_P%#^WA2|,M>\$_%?D^
_%\$8A0K47'A|&C>W:5T_M_V0S8F4(VUA,MMGRCM-?5NI>!" /A_X.77@S5/L|A\|/|07T>XCNKQTA@TR.
M#RG\$DY<.@2%2#*7|&"08'&/BC_@D+)=3T|P|X@^+.0/1000\$GDZ-H|UT\$FG MCT^Q4P|5G+L|<;.B1>254
6,1Y4QX_/2/VX0AG\3+CXF?"7XP^!0" ?Q'A| MSWDUWX.NO^*ZZJXN;==A9YAY7RD,|+)' :M'"2)-W3_
G|JWX9?&CXEII^H>% MY/AY\+?CW MX\| &FCW_P -0 7AWXB^!S L-
_HMQJ; ;K)N" LQ;B33, +=8!_HX.Y7D)+@*,
M|E\L^&/P+^ (GQ@ :HM_CY\50#>K\.+CPUIG|A>&0".G:G#J4LJM%-ON+FYCS_M'M!NYMBH\$;E<[1'F8
X_X0E(_P#@K _'!EE6-!X/MAG@=(=' S|9';';\.= M ;N\6> (_%|':7P9^&7_""P_%>0K/2Y?
\$*>"Y|4A%JUX10F,K">7>H9_M<\$- ,AW+(P/H^COX0_%CX_-MK>)?CI\/_ +|\5|,|8Z&FDSZ3 ;, &C3Z9*GV
M)-S/_N\Q&H""HSEI_54*K/W7|0W|./Q\$^+6F_"30QHWB#1="^,W@&:_&UI MX| #0YI4@%|!(4!N!
WD|0>K1EHW7|YOC_/&VE(VC/VA/AY)HW_R|;^/_ M%5G<0WFB>+E|;Z5/?;+(ES!,|6C|4:)G|@*65U., \$DX
_.'^W5^J?C^XH?L0V_M_C_1--75|3U>)/&\$BLB36HN);C2!=6^PLZ0%N+I@LX(!^9NI|C\0?%#|K;QQ
M!'H/A7X(:'\,;^|+00XL|2>+>6(+/-)< B&W7S/,WF,H621%=\$;5|'\(>)/|1UJY6|@A%G_03W#;'96D&R&7A
V-0/; M(!Y?_P_%B?"NC:/^R_X"6RTC3K!-+|2VVG6+6|M^&+2T-CH?%\%,0">BV0|"?
B^UMM'L+6+0QI9TNUBMHUCL=M|;P*8%_Q\$1_M\$|QC;C",R=)|?|_%0@1XY:_^_A|PY\/-
_M_6K30+;ZC+;_&R"VV0K_M:W:-+0F=|!^5.-0/IT-=0^W5\,_%'QF_97\9^#?|VF^50\$FJ_8?LUEY\4 ;9_M?
03.?,E94&%1FY8\$|>,F@#T;|G?Q1JGCCX%_#WQ+K5R+S5M8\.:9?W=PJ(BS_M3RVD4DDFU0_NYV;@<#_P:7R1_P
%I"1^R_X5(_Z^&VXS_P!.-|S0S7UM^SKX
M9U/P5\!_A0X=UJW^QZQI^AG3+"|M?,5_)FBM4CD3*D@|64C()!Q07A'_4Y
M^!/_C;|H3X\$^'_#0@+00^\$AUFU\207\MM+R&U*P+:W2,X>9T7AI(QC/?H<4_7 MF_9^:_8P0?VM#GGD?#?
3>F<8_P|9C|,TS_@IXQ;|AWXD'A\ V=C=V_XF5J&|.UBRDC\V/49|NTC-P|PK_ ^9OWD-N&_H1_-BJH^*_V
M5_CIXB^'_P#P2G^*VJ)-<7%UX?U*|T/16L)?L/OA5\8_#@TIO\$VN7-&QP*/80V%_AKH?PY_9-^&|KH-
LL(U;2;:7KZ;8IDFN|R) M9I|"[*J|MN|8U+994AC#.=F3X%-P3-TFPT'|HK|KS3M+M8;#3K/Q3#;6|I;PB_M**&-
+S5%5(T'"H !TQCM6M\8?VJ_@#|-|. ^%)&?AWQVNEYLM(\=S>+A'
M901RX:%IK>5/M4L=LSNNU^C)BC5(U.U7??\ ^"?_SS\2?@A|3_ (_ZI\0H_M^N?^\$FUBWN;'7U:W3^V-MQ?
M):EY(A^S=0|;NW_|_3/'>0U3N%#X4_MOMX) ES^'U|U\C_L4_WQS*_CM^T0XC\5Z\$VDZ/XP\2C4-
_N6NX)OM<(N|0_M^/GB00-4U#PP9\$|/_ A#P0_M;0)HUI(8TVW6;D;Q+NWR^Y-
X>&!A*%18U\^B^!_A^XZ_|=/B9I_C?3VUS3- M#TFSUV/3YMMH|BX2TTV*-)T(>|
3EC^D|BBAMZ|E;|+IT4*^7<.3TST^7' M4_AZU\@_#GX>.-!_P""D?Q2^*.I:&?;
P^K0AR#3+50M<)\$LXCTT&/RM_F#
MYK>;DJ|QWS0|YK^WYX;|+;!: !#X\$>'0#T/@OP0\2/'\$)UE0"@AT|6BBEM|=MT,,
<6R4L;J)P7|VM:QY5L#;|E^./A^X7^ (GPEU7X;7NEVT/A6^TW^RELK6&-
M\$M81'MA,"LC|C|S1M&P4A&C4@94"N\$;_"_9|0?VC/A^!HFB^(|CPIXJT;5(= M?T^5(6*+?#0K((A(RJ9\$7;
(WSQ_,C;7_8*4;S?Q3XU_:0|<>&=:|_V_PBT#P_M;K-|8S:;?B!%XR|T^!0+970+6WA0W<6_!,(+>QLT9?."*
/C?_AI05_ ^'10| MD|+_/M#_A)0^\$\$_M7^U)/-^R|?MV>F=GD?Z^Y&_5PTRWE\+6&F?
V4; &Y@B=:N(ILF,ZJBK(969VE.T;V=B1EB*\|2?L.MZ/<_L2GX#6^I+?W.F6DL^F:Y?I^#Y>J&62X2;_C?
R(FFD="\$#.L,CH'))YWM_P/X@:_SB\^Z7\,M6^'^AZ+JME%_9,WQAN_\$D.H6ZQ1_K:_L&)GFG>%=RB1E
M#2.K2+&A9%/_?V#|?|_#KG|HLC;>/_0RJ@9QH5N.U?4_P#P2_ \^3%0AI|=M3_ \3G=UQ'|"/|+/BSP+^R?
00AA\4M-N?#>SXGU^4(I(|2|MI95L|G3|:W, MJ/&TB^R|9-
V<%,D\$8^9_P" T|/I|FGX7V/PBL0A)X4\56^G3SPZ3XUC\4+;_M: ?#|ID,PEFMGC%Q*L,LTVX1K&SJNU_3AW
_&_9%\<#X9?%#|00Q>;"34QX?U_MRYU8VDG?LPVGCFFU/Q3XY_MU&^U77-4U!EDN;B>.ZFMU#3;
|(/*:3#EB^GE(|SXJI^P7^SU\2/@?|_ \$SX_M:I\0|=;H>)|8@N++7D:VC.L|9|I+CR(96\C?
Y\4GEG;M\$FT9*FLGX6>|_CS_M^Q9 ;WP^#_#D?'^X:R7W|I:|J5QXIMM(NM-610WMG^DQ*_H;|TB^S/(-61
MDC_/M#PWX3T/PFNKHFED?I|H7|ZA?V?;QP?:KJ0KYEQ+L'SRMM&YVY.T> ME?\$7_!%G_DUS05_V.=U_Z0V-?
3GP&3XM7=KX@U;XJ^0--EU:ZCGT?PUHH:;3_M1K7RD^D7^U\JSR;@VXHFT/YC(|(ZI%U?LE_"#XY?LGW>H_"G3_
FC>(_"-|_MXM_M-OB+=:S^#_9|16PF'|GJ3<&X:.*D&256:09+1+08_ ^|J^KVH3#;G(;D_M-DG/XGM_ ^005B@

HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH KW2DLK?=
5LNH^89QT]?I@}0 M20F?QY^P?X \8>/K{QSH.L>+/A=XLU%IFU34_6K/I\FH{VC+><")%#\$Q@ML
M"^8[.\@=L%?J"B@#YT^#?[%7@#X.^/)'_DFN^./'EQ0'"4^--2_M'48E:* M*/8K{54;5BV+(%\P+
(Z;MAQ7T%8KM0Y14;^(((<@'TS{?X59HH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M**
"BBB@ HHHH KW3%5#%MJ\{LM@>N?R!KQGX9_LQ>%/AC\6/'WQ(M[_%C6 M0%7C*,-[-=:U-%<@
M\$)/;G^=3T44 %%% !1110 4444 %%% "' &SX7Z=\:0AOK/@?5]5U71=+
MUJ);>ZN]%N%M{DQ>8C/\$)&5@%D"F-U(.Y'<=ZM?"/X;::+\(/AQX?\&^'K=K; M2-'LX{6%9
HEDQDM++L55,LC'I'8*-SNO{UV%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 % M% !1110 4444
%% !1110 4444 %%% !1110 4444 %%% !1110 444 \$4 ?_V0\$! end XML 17 R1.htm IDEA: XBRL

DOCUMENT

Cover - shares9 Months Ended

Sep. 30, 2024

Nov. 05, 2024

Cover [Abstract] Document Type10-Q Document Quarterly Reporttrue Document Period End
DateSep. 30, 2024 Document Transition Reportfalse Entity File Number001-38890 Entity
Registrant NameQuince Therapeutics, Inc. Entity Incorporation, State or Country CodeDE
Entity Tax Identification Number90-1024039 Entity Address, Address Line One
611 Gateway Boulevard, Suite 273 Entity Address, City or TownSouth San Francisco Entity
Address, State or ProvinceCA Entity Address, Postal Zip Code94080 City Area Code415
Local Phone Number910-5717 Title of 12(b) Security
Common Stock, par value \$0.001 per share Trading SymbolQNCX Security Exchange NameNASDAQ
Entity Current Reporting StatusYes Entity Interactive Data CurrentYes Entity Filer
CategoryNon-accelerated Filer Entity Small Businesstrue Entity Emerging Growth Company
false Entity Shell Companyfalse Entity Common Stock, Shares Outstanding 44,001,643Entity
Central Index Key0001662774 Document Fiscal Year Focus2024 Document Fiscal Period Focus
Q3 Amendment Flagfalse Current Fiscal Year End Date--12-31

-- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted
submission.

+ References

No definition available.

+ Details

Name:dei_AmendmentFlag Namespace Prefix:dei_ Data Type:xbrli:booleanItemType Balance
Type:na Period Type:duration

-- Definition

Area code of city

+ References

No definition available.

+ Details

Name:dei_CityAreaCode Namespace Prefix:dei_ Data Type:xbrli:normalizedStringItemType
Balance Type:na Period Type:duration

-- Definition

Cover page.

+ References

~~No definition available.~~

~~+ Details~~

~~Name:dei_CoverAbstract Namespace Prefix:dei_ Data Type:xbkli:stringItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~End date of current fiscal year in the format --MM-DD.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_CurrentFiscalYearEndDate Namespace Prefix:dei_ Data Type:xbkli:gMonthDayItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_DocumentFiscalPeriodFocus Namespace Prefix:dei_ Data Type:dei:fiscalPeriodItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_DocumentFiscalYearFocus Namespace Prefix:dei_ Data Type:xbkli:gYearItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_DocumentPeriodEndDate Namespace Prefix:dei_ Data Type:xbkli:dateItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Boolean flag that is true only for a form used as an quarterly report.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Form 10-~~

~~+ Details~~

~~Name:dei_DocumentQuarterlyReport Namespace Prefix:dei_ Data Type:xbrli:booleanItemType
Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Boolean flag that is true only for a form used as a transition report.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Forms
10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1~~

~~+ Details~~

~~Name:dei_DocumentTransitionReport Namespace Prefix:dei_ Data Type:xbrli:booleanItemType
Balance Type:na Period Type:duration~~

~~-- Definition~~

~~The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document
type is limited to the same value as the supporting SEC submission type, or the word
'Other'.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_DocumentType Namespace Prefix:dei_ Data Type:dei:submissionTypeItemType
Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Address Line 1 such as Attn, Building Name, Street Name~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_EntityAddressAddressLine1 Namespace Prefix:dei_ Data Type:
xbrli:normalizedStringItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Name of the City or Town~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:dei_EntityAddressCityOrTown Namespace Prefix:dei_ Data Type:~~

xbkli:normalizedStringItemType Balance Type:na Period Type:duration

-- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:dei_EntityAddressPostalZipCode Namespace Prefix:dei_ Data Type:
xbkli:normalizedStringItemType Balance Type:na Period Type:duration

-- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:dei_EntityAddressStateOrProvince Namespace Prefix:dei_ Data Type:
dei:stateOrProvinceItemType Balance Type:na Period Type:duration

-- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityCentralIndexKey Namespace Prefix:dei_ Data Type:
dei:centralIndexKeyItemType Balance Type:na Period Type:duration

-- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name:dei_EntityCommonStockSharesOutstanding Namespace Prefix:dei_ Data Type:
xbkli:sharesItemType Balance Type:na Period Type:instant

-- Definition

Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such

reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name:dei_EntityCurrentReportingStatus Namespace Prefix:dei_ Data Type:dei:yesNoItemType
Balance Type:na Period Type:duration

-- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityEmergingGrowthCompany Namespace Prefix:dei_ Data Type:
xbrli:booleanItemType Balance Type:na Period Type:duration

-- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:dei_EntityFileNumber Namespace Prefix:dei_ Data Type:dei:fileNumberItemType
Balance Type:na Period Type:duration

-- Definition

Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

+ Details

Name:dei_EntityFilerCategory Namespace Prefix:dei_ Data Type:dei:filerCategoryItemType
Balance Type:na Period Type:duration

~~Definition~~

Two-character EDGAR code representing the state or country of incorporation.

~~+ References~~

No definition available.

~~+ Details~~

Name:dei_EntityIncorporationStateCountryCode Namespace Prefix:dei_ Data Type:dei:edgarStateCountryItemType Balance Type:na Period Type:duration

~~Definition~~

Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

~~+ References~~

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Regulation S-T -Number 232 -Section 405

~~+ Details~~

Name:dei_EntityInteractiveDataCurrent Namespace Prefix:dei_ Data Type:dei:yesNoItemType Balance Type:na Period Type:duration

~~Definition~~

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

~~+ References~~

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

~~+ Details~~

Name:dei_EntityRegistrantName Namespace Prefix:dei_ Data Type:xbri:normalizedStringItemType Balance Type:na Period Type:duration

~~Definition~~

Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.

~~+ References~~

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2

[+ Details](#)

Name:dei_EntityShellCompany Namespace Prefix:dei_ Data Type:xbrli:booleanItemType
Balance Type:na Period Type:duration

[-- Definition](#)

Indicates that the company is a Smaller Reporting Company (SRC).

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange
Act -Number 240 -Section 12 -Subsection b-2

[+ Details](#)

Name:dei_EntitySmallBusiness Namespace Prefix:dei_ Data Type:xbrli:booleanItemType
Balance Type:na Period Type:duration

[-- Definition](#)

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange
Act -Number 240 -Section 12 -Subsection b-2

[+ Details](#)

Name:dei_EntityTaxIdentificationNumber Namespace Prefix:dei_ Data Type:
dei:employerIdItemType Balance Type:na Period Type:duration

[-- Definition](#)

Local phone number for entity.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_LocalPhoneNumber Namespace Prefix:dei_ Data Type:
xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[-- Definition](#)

Title of a 12(b) registered security.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange
Act -Number 240 -Section 12 -Subsection b

+ Details

Name:dei_Security12bTitle Namespace Prefix:dei_ Data Type:dei:securityTitleItemType
Balance Type:na Period Type:duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange
Act -Number 240 -Section 12 -Subsection d1-1

+ Details

Name:dei_SecurityExchangeName Namespace Prefix:dei_ Data Type:
dei:edgarExchangeCodeItemType Balance Type:na Period Type:duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:dei_TradingSymbol Namespace Prefix:dei_ Data Type:dei:tradingSymbolItemType
Balance Type:na Period Type:duration XML 18 R2.htm IDEA: XBRL DOCUMENT
Condensed Consolidated Balance Sheets (Unaudited) - USD (\$) \$ in Sep. 30, Dec. 31,
Thousands 2024 2023
Current assets: [Cash and cash equivalents](#)\$ 2,675\$ 20,752[Short-term investments](#)45,172
54,307[Prepaid expenses and other current assets](#)3,8712,381[Total current assets](#)51,718
77,440[Property and equipment, net](#)2082340[operating lease right-of-use assets](#)559385[Goodwill](#)
017,625[Intangible assets](#)64,52863,6720[Other assets](#)9,5068,544[Total assets](#)126,519167,900
Current liabilities: [Accounts payable](#)1,6222,033[Short-term contingent consideration](#)0
4,103[Accrued expenses and other current liabilities](#)3,8033,436[Total current liabilities](#)
5,4259,572[Long-term debt](#)14,89913,429[Long-term operating lease liabilities](#)450321[Long-term
contingent consideration](#)54,78853,603[Deferred tax liabilities](#)5,3825,3040[Other long-term
liabilities](#)643587[Total liabilities](#)81,58782,816[Commitments and contingencies](#)
[Stockholders' equity: Preferred stock, \\$0.001 par value, 10,000,000 authorized,
\(100,000 shares of which are designated as Series A Junior Participating Preferred
Stock\), no shares issued and outstanding as of September 30, 2024 and December 31, 2023,
respectively.](#)00[Common stock, \\$0.001 par value, 100,000,000 shares authorized, 43,276,606
and 42,973,215 issued and outstanding as of September 30, 2024 and December 31, 2023,
respectively.](#)4343[Additional paid in capital](#)405,484401,638[Accumulated other comprehensive
income](#)3,4193,047[Accumulated deficit](#)(364,014)(319,644)[Total stockholders' equity](#)44,932
85,084[Total liabilities and stockholders' equity](#)\$ 126,519\$ 167,900

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which
invoices have typically been received) and payable to vendors for goods and services
received that are used in an entity's business. Used to reflect the current portion of
the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name
Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI

<https://asc.fasb.org//1943274/2147481372/852-10-55-10>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_AccountsPayableCurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_AccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-14A>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI

~~<https://asc.fasb.org//1943274/2147482790/220-10-45-11>Reference 3:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480016/944-40-65-2>Reference 4:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480016/944-40-65-2>Reference 5:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 6:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 7:~~
~~<http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-14>~~

+ Details

Name:us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481231/810-10-45-25>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481687/323-10-50-3>Reference 5:

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6:](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6:)~~
~~<http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7:>~~
~~<http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8:>~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(12\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9:](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(12))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9:)~~
~~<http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10:>~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(8\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11:](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(8))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(18\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12:](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(18))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 13:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 13:)~~
~~[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 14:](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 14:)~~
~~[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 15:](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 15:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 16:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 16:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 17:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 17:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 18:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1Reference 18:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23:](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23:)~~
~~[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24:](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25:](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25:)~~
~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26:](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26:)~~
~~[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(11\)\)-Publisher FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(11))-Publisher FASB-URI)~~

+ Details

Name:us-gaap_Assets Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

-- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled

by an entity as a result of past transactions or events.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3)

Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25)

Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)

Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3)

Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28)

Reference 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10>

Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147483467/210-10-45-1>

Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(9\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(9))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)

Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1)

Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7)

[+ Details](#)

~~*Name:us-gaap_AssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType*~~

~~Balance Type:debit Period Type:instant~~

~~[--References](#)~~

~~No definition available.~~

~~[+Details](#)~~

~~Name:us-gaap_AssetsCurrentAbstract Namespace Prefix:us-gaap_ Data Type:xb:li:stringItemType Balance Type:na Period Type:duration~~

~~[--Definition](#)~~

~~Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.~~

~~[+References](#)~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481830/320-10-45-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479130/326-30-45-1>~~

~~[+Details](#)~~

~~Name:us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix:us-gaap_ Data Type:xb:li:monetaryItemType Balance Type:debit Period Type:instant~~

~~[--Definition](#)~~

~~Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.~~

~~[+References](#)~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479668/805-30-25-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph b -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479613/805-30-35-1>~~

+ Details

Name:us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant

-- Definition

Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479668/805-30-25-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph b -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479613/805-30-35-1>

+ Details

Name:us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant

-- Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482913/230-10-50-8>~~
~~Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-24>~~
~~Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-4>~~

+ Details

~~Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

- Definition

~~Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.~~

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>~~
~~Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-1>~~
~~Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>~~
~~Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

+ Details

Name:us-gaap_CommitmentsAndContingencies Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>
Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_CommonStockValue Namespace Prefix:us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482525/740-10-45-4>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482525/740-10-45-6>

+ Details

Name:us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>
Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482548/350-20-55-24>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482598/350-20-45-1>
Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>
Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>
Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>

+ Details

Name:us-gaap_Goodwill Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType
Balance Type:debit Period Type:instant

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482665/350-30-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482686/350-30-45-1>

+ Details

Name:us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28)Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(14\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(14))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B)

~~Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481404/852-10-50-7>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481404/852-10-50-7>Reference 21: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-30>Reference 22: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

+ Details

Name:us-gaap_Liabilities Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType
Balance Type:credit Period Type:instant

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>
Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>
Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481687/323-10-50-3>
Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482907/825-10-50-28>
Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>
Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481203/810-10-50-3>

Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481231/810-10-45-25>

Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481203/810-10-50-3>

Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>

Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481687/323-10-50-3>

Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482907/825-10-50-28>

Reference 7: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>

Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483467/210-10-45-5>

Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>

Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>

Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>

Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>

Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>

Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>

Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>

Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>

Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>

Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>

~~S99-1BReference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481404/852-10-50-7>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481404/852-10-50-7>Reference 21: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

+ Details

Name:us-gaap_LiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_LiabilitiesCurrentAbstract Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481568/470-20-55-69B>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481568/470-20-55-69C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1D>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-4>

[+ Details](#)

**Name:us-gaap_LongTermDebt Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType
Balance Type:credit Period Type:instant**

[- Definition](#)

**Present value of lessee's discounted obligation for lease payments from operating lease,
classified as noncurrent.**

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>

+ Details

Name:us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

-- Definition

Amount of lessee's right to use underlying asset under operating lease.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>

+ Details

Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

-- Definition

Amount of noncurrent assets classified as other.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_OtherAssetsNoncurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

-- Definition

Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.

+ References

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.24) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

+ Details

~~Name:us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

- Definition

~~Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.~~

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

+ Details

Name:us-gaap_PreferredStockValue Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(9\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(9))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB> -URI <https://asc.fasb.org//1943274/2147482099/360-10-50-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB> -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(8\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(8))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 360-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB> -URI <https://asc.fasb.org//1943274/2147480842/942-360-50-1>

+ Details

Name:us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480016/944-40-65-2>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480016/944-40-65-2>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480990/946-20-50-11>
Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>
Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-1>
Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480008/505-10-S99-1>
Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

Name:us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>
Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480167/946-830-55-12>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-1>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-2>
Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>
Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>
Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>
Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>
Reference 9: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481687/323-10-50-3>
Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482907/825-10-50-28>
Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>
Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>
Reference 13: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>
Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480418/310-10-S99-2>

[+ Details](#)

~~*Name:us-gaap_StockholdersEquity Namespace Prefix:us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type:credit Period Type:instant*~~

[- References](#)

~~*No definition available.*~~

[+ Details](#)

~~*Name:us-gaap_StockholdersEquityAbstract Namespace Prefix:us-gaap_ Data Type:*~~

~~xbrli:stringItemType Balance Type:na Period Type:duration XML 19 R3.htm IDEA: XBRL DOCUMENT~~
~~Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sep. 30, Dec. 31,~~
~~-- \$ / shares 2024 2023~~
~~Preferred stock, par value (in USD per share)\$ 0.001\$ 0.001Preferred stock, shares~~
~~authorized (in shares)10,000,00010,000,000Preferred stock, shares issued (in shares)00~~
~~Preferred stock, shares outstanding (in shares)00Common stock, par value (in USD per~~
~~share)\$ 0.001\$ 0.001Common stock, shares authorized (in shares)100,000,000100,000,000~~
~~Common stock, shares issued (in shares)43,276,60642,973,215Common stock, shares~~
~~outstanding (in shares)43,276,60642,973,215Series A Preferred Stock Preferred stock,~~
~~shares authorized (in shares)100,000100,000~~
~~-- Definition~~

~~Face amount or stated value per share of common stock.~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name~~
~~Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-~~
~~02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1~~

~~+ Details~~

~~Name:us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:~~
~~dtr-types:perShareItemType Balance Type:na Period Type:instant~~

~~-- Definition~~

~~The maximum number of common shares permitted to be issued by an entity's charter and~~
~~bylaws.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name~~
~~Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-~~
~~04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-~~
~~1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name~~
~~Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-~~
~~02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1~~

+ Details

Name:us-gaap_CommonStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_CommonStockSharesIssued Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB> -URI <https://asc.fasb.org//1943274/2147481112/505-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-2>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-1>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_CommonStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

-- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-1>
Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_PreferredStockSharesAuthorized Namespace Prefix:us-gaap_ Data Type:xbtli:sharesItemType Balance Type:na Period Type:instant

-- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481112/505-10-50-13>
Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_PREFERREDSTOCKSHARESISSUED Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-2>
Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-1>
Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>
Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_PreferredStockSharesOutstanding Namespace Prefix:us-gaap_ Data Type: xbrli:sharesItemType Balance Type:na Period Type:instant

- Details

Name:us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 20 R4.htm IDEA: XBRL DOCUMENT Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD (\$) \$ in Thousands 3 Months 9 Months Ended Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023

<u>Operating expenses:</u>	<u>Research and developments</u>	<u>\$ 4,916</u>	<u>\$ 1,431</u>	<u>\$ 12,765</u>	<u>\$ 6,013</u>	<u>General and administrative</u>	<u>3,630</u>	<u>4,663</u>	<u>13,296</u>	<u>12,786</u>	<u>Goodwill impairment charge</u>	<u>0017,130</u>	<u>Intangible asset impairment charge</u>	<u>0005,900</u>	<u>Fair value adjustment for contingent consideration</u>	<u>(2,683)</u>	<u>02,082</u>			
<u>0Total operating expenses</u>	<u>5,863</u>	<u>6,094</u>	<u>45,273</u>	<u>24,699</u>	<u>Loss from operations</u>	<u>(5,863)</u>	<u>(6,094)</u>	<u>(45,273)</u>	<u>(24,699)</u>	<u>Fair value adjustment for long-term debt</u>	<u>(449)</u>	<u>0(1,252)</u>	<u>0Interest income</u>	<u>683</u>	<u>959</u>	<u>2,393</u>	<u>2,464</u>			
<u>0Other income (expense), net</u>	<u>150</u>	<u>(216)</u>	<u>(158)</u>	<u>(504)</u>	<u>Net loss before income tax benefit</u>	<u>(5,492)</u>	<u>(5,351)</u>	<u>(44,290)</u>	<u>(22,739)</u>	<u>Income tax (expense) benefit</u>	<u>(13)</u>	<u>0(80)</u>	<u>248</u>	<u>Net loss</u>	<u>(5,492)</u>	<u>(5,351)</u>	<u>(44,370)</u>	<u>(22,491)</u>		
<u>0Other comprehensive loss:</u>	<u>Foreign currency translation adjustments</u>	<u>2,158</u>	<u>158</u>	<u>203</u>	<u>309</u>	<u>Unrealized gain (loss) on available-for-sale securities</u>	<u>174</u>	<u>101</u>	<u>169</u>	<u>496</u>	<u>Total comprehensive loss</u>	<u>\$ (3,160)</u>	<u>\$ (5,092)</u>	<u>\$ (43,998)</u>	<u>\$ (21,686)</u>	<u>Net loss per share - basic (in USD per share)</u>	<u>\$ (0.13)</u>	<u>\$ (0.15)</u>	<u>\$ (1.03)</u>	<u>\$ (0.63)</u>
<u>Net loss per share - diluted (in USD per share)</u>	<u>\$ (0.13)</u>	<u>\$ (0.15)</u>	<u>\$ (1.03)</u>	<u>\$ (0.63)</u>	<u>Weighted average shares of common stock outstanding - basic (in shares)</u>	<u>43,164,136</u>	<u>36,073,040</u>	<u>43,090,632</u>	<u>35,941,234</u>	<u>Weighted average shares of common stock outstanding - diluted (in shares)</u>	<u>43,164,136</u>	<u>36,073,040</u>	<u>43,090,632</u>	<u>35,941,234</u>						

~~- Definition~~

~~Represents the amount of fair value adjustment for contingent consideration during the period.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:qncx_FairValueAdjustmentForContingentConsideration Namespace Prefix:qncx_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Fair value adjustment for long term debt.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:qncx_FairValueAdjustmentForLongTermDebt Namespace Prefix:qncx_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483589/942-220-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-1A>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-1B>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-5>~~

+ Details

Name:us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-3>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482635/260-10-55-15>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480175/815-40-65-1>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480175/815-40-65-1>
Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting

~~Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 6:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 7:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 8:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 9:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 10:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 11:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 12:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 13:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -
Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 14:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting~~
~~Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -
Publisher FASB -URI <https://asc.fasb.org/1943274/2147483589/942-220-S99-1>Reference 15:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting~~
~~Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -
Publisher FASB -URI <https://asc.fasb.org/1943274/2147483586/944-220-S99-1>Reference 16:
<http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 17:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting~~
~~Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147482689/260-10-45-7>~~

+ Details

Name:us-gAAP_EarningsPerShareBasic Namespace Prefix:us-gAAP Data Type: dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-3>

Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482635/260-10-55-15>

Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480175/815-40-65-1>

Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480175/815-40-65-1>

Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>

Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>

Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-7>

Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482689/260-10-45-2>

Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482689/260-10-45-60B>

Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-4>

Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482662/260-10-50-1>

Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>

Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483589/942-220-S99-1>

Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>

Reference 15: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482635/260-10-55-52>

Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482689/260-10-45-7>

+ Details

Name:us-gaap_EarningsPerShareDiluted Namespace Prefix:us-gaap_ Data Type: dtr-types:perShareItemType Balance Type:na Period Type:duration

-- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>

+ Details

Name:us-gaap_GeneralAndAdministrativeExpense Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 2:

~~<http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482548/350-20-55-24>Reference 3:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482573/350-20-50-1>Reference 4:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482573/350-20-50-2>Reference 5:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482598/350-20-45-2>~~

+ Details

~~Name:us-gaap_GoodwillImpairmentLoss Namespace Prefix:us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

- Definition

~~The amount of impairment loss recognized in the period resulting from the write-down of~~

~~the carrying amount of an intangible asset (excluding goodwill) to fair value.~~

+ References

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 30 -Topic 350 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482665/350-30-50-3>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>~~

+ Details

~~Name:us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix:us-gaap_
Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

- Definition

~~Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.~~

+ References

~~Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482765/220-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>~~

+ Details

Name:us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_Namespace
Prefix:us-gaap_Data Type:xbrl:monetaryItemType Balance Type:credit Period Type:
duration

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit)
pertaining to continuing operations.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-8>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-9>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482685/740-10-50-10>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479360/740-10-S99-1>
Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-22>
Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>
Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482659/740-20-45-2>
Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>

+ Details

Name:us-gaap_IncomeTaxExpenseBenefit Namespace Prefix:us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-22>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7(b)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>

+ Details

Name:us-gaap_InvestmentIncomeInterest Namespace Prefix:us-gaap_ Data Type:
xbli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481687/323-10-50-3>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482907/825-10-50-28>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482765/220-10-50-6>
Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-3>
Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-1>
Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480175/815-40-65-1>
Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-8>
Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-9>
Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>
Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>
Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-4>
Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480167/946-830-55-10>
Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting

Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147483581/946-220-45-7>Reference 15:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>Reference 16:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-22>Reference 17:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-1>Reference 18:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting
Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>Reference 19:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 20:
<http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 21:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)
(A)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -
Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX
210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic
10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX
210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10
-Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX
210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic
10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX
210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 26:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)
(B)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -
Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX
210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic
10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX
210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10
-Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-30>Reference 30:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-32>Reference 31:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482689/260-10-45-60B>Reference 32:
<http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-31>Reference 33:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-32>Reference 34:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting
Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 36:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting

~~Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37:
http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-
gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification
-Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-
gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification
-Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147483589/942-220-S99-1~~

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType
Balance Type:credit Period Type:duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_OperatingExpenses Namespace Prefix:us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_OperatingExpensesAbstract Namespace Prefix:us-gaap_ Data Type:
xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The net result for the period of deducting operating expenses from operating revenues.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-22>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-30>Reference 3:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-32>Reference 4:
<http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-31>Reference 5:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-32>~~

+ Details

Name:us-gaap_OperatingIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

— Definition

Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-10A>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-10A>

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeRecla Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

— Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-10A>

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossTaxAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of income (expense) related to nonoperating activities, classified as other.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>

+ Details

Name:us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 730 -SubTopic 10 -Name

~~Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name
Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-
gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20
-Section 50 -Paragraph 1 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147481283/985-20-50-1~~

+ Details

~~Name:us-gaap_ResearchAndDevelopmentExpense Namespace Prefix:us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

- Definition

~~The average number of shares or units issued and outstanding that are used in
calculating diluted EPS or earnings per unit (EPU), determined based on the timing of
issuance of shares or units in the period.~~

+ References

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher
FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482689/260-10-45-16~~

+ Details

Name:us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix:us-gaap_
Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482662/260-10-50-1>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482689/260-10-45-10>

+ Details

Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix:us-gaap_
Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration XML 21 R5.htm IDEA: XBRL DOCUMENT

<u>Condensed Consolidated Statements of</u>	<u>Total Common</u>	<u>Additional</u>	<u>Accumulated</u>	<u>Other</u>	<u>Accumulated</u>
<u>Stockholders' Equity (Unaudited)</u>	<u>Stock Paid in</u>	<u>Comprehensive</u>	<u>Deficit</u>		
<u>USD (\$) \$ in Thousands</u>	<u>Capital</u>	<u>Income / (Loss)</u>			
<u>Beginning balance (in shares) at Dec. 31, 2022</u>	<u>36,136,480</u>	<u>Beginning balance at Dec. 31, 2022</u>	<u>\$ 100,593</u>	<u>\$ 36</u>	<u>\$ 389,105</u>
<u>Increase (Decrease) in Stockholders' Equity [Roll Forward]</u>	<u>Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares) 270,445</u>	<u>Issuance of common stock on exercise of stock options and vesting of restricted stock units</u>	<u>110</u>	<u>110</u>	<u>Restricted Stock award retirement (in shares) (63,293)</u>
<u>Restricted stock award retirement (in shares) (63,293)</u>	<u>Restricted stock award retirement</u>	<u>(18)</u>	<u>(18)</u>	<u>Stock based compensation</u>	<u>4,134</u>
<u>4,134</u>	<u>Foreign currency translation adjustment</u>	<u>309</u>	<u>309</u>	<u>Unrealized gain (loss) on available for sale investments</u>	<u>496</u>
<u>496</u>	<u>Net loss</u>	<u>(22,491)</u>	<u>(22,491)</u>	<u>Ending balance (in shares) at Sep. 30, 2023</u>	<u>36,343,632</u>
<u>Ending balance at Sep. 30, 2023</u>	<u>383,133</u>	<u>\$ 36393,331</u>	<u>1516(310,750)</u>	<u>Beginning balance (in shares) at Jun. 30, 2023</u>	<u>36,327,995</u>
<u>Beginning balance at Jun. 30, 2023</u>	<u>386,884</u>	<u>\$ 36391,990</u>	<u>257(305,399)</u>	<u>Increase (Decrease) in Stockholders' Equity [Roll Forward]</u>	<u>Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares) 70,394</u>
<u>Issuance of common stock on exercise of stock options and vesting of restricted stock units</u>	<u>28</u>	<u>28</u>	<u>Restricted Stock award retirement (in shares) (54,757)</u>	<u>Restricted stock award retirement</u>	<u>(18)</u>
<u>(18)</u>	<u>Stock based compensation</u>	<u>1,331</u>	<u>1,331</u>	<u>Foreign currency translation adjustment</u>	<u>158</u>
<u>158</u>	<u>Unrealized gain (loss) on available for sale investments</u>				

~~101 101 Net loss(5,351) (5,351)Ending balance (in shares) at Sep. 30, 2023 36,343,632~~
~~Ending balance at Sep. 30, 202383,133\$ 36393,331516(310,750)Beginning balance (in~~
~~shares) at Dec. 31, 2023 42,973,215 Beginning balance at Dec. 31, 202385,084\$ 43~~
~~401,6383,047(319,644)Increase (Decrease) in Stockholders' Equity [Roll Forward]~~
~~Issuance of common stock on exercise of stock options and vesting of restricted stock~~
~~units (in shares) 303,391 Issuance of common stock on exercise of stock options and~~
~~vesting of restricted stock units225 225 Stock based compensation3,621 3,621 Foreign~~
~~currency translation adjustment203 203 Unrealized gain (loss) on available for sale~~
~~investments169 169 Net loss(44,370) (44,370)Ending balance (in shares) at Sep. 30,~~
~~2024 43,276,606 Ending balance at Sep. 30, 202444,932\$ 43405,4843,419(364,014)~~
~~Beginning balance (in shares) at Jun. 30, 2024 43,276,606 Beginning balance at Jun.~~
~~30, 202446,968\$ 43404,3601,087(358,522)Increase (Decrease) in Stockholders' Equity [Roll~~
~~Forward] Stock based compensation1,124 1,124 Foreign currency translation~~
~~adjustment2,158 2,158 Unrealized gain (loss) on available for sale investments174 174~~
~~Net loss(5,492) (5,492)Ending balance (in shares) at Sep. 30, 2024 43,276,606 Ending~~
~~balance at Sep. 30, 2024\$ 44,932\$ 43\$ 405,484\$ 3,419\$ (364,014)~~
~~- Definition~~

~~Share based compensation arrangement by share based payment award options and non option equity instruments exercises in period.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEq~~
~~Namespace Prefix:gncx_ Data Type:xbri:sharesItemType Balance Type:na Period Type:~~
~~duration~~

~~- Definition~~

~~Share based compensation arrangement by share based payment award value options and non option equity instruments exercises in period.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOpt~~
~~Namespace Prefix:gncx_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:~~
~~duration~~

~~- Definition~~

~~Stock Issued During Period Shares Restricted Stock Award Retirement~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_StockIssuedDuringPeriodSharesRestrictedStockAwardRetirement Namespace Prefix:~~
~~gncx_ Data Type:xbri:sharesItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Stock Issued During Period, Value, Restricted Stock Award Retirement~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_StockIssuedDuringPeriodValueRestrictedStockAwardRetirement Namespace Prefix:~~
~~gncx_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480483/718-10-35-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481089/718-20-55-13>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481089/718-20-55-12>~~

~~+ Details~~

~~Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServiceP
Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period
Type:duration~~

~~- Definition~~

~~A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix:us-gaap_
Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.~~

~~+ References~~

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>

Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481687/323-10-50-3>

Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482907/825-10-50-28>

Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482765/220-10-50-6>

Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-3>

Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-1>

Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480175/815-40-65-1>

Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-8>

Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-9>

Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>

Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>

Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-4>

Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480167/946-830-55-10>

Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483581/946-220-45-7>

Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>

Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-22>

Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-1>

Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>

Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1>

Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1>

Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1>

Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1>

Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic

~~10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 32: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 34: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 37: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 38: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 39: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483589/942-220-S99-1>~~

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType
Balance Type:credit Period Type:duration

- Definition

Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-10A>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-10A>

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeRecla
Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period
Type:duration

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-10A>

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustm
Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period
Type:duration

- Definition

Number of shares issued which are neither cancelled nor held in the treasury.

+ References

No definition available.

+ Details

Name:us-gaap_SharesOutstanding Namespace Prefix:us-gaap_ Data Type:xbli:sharesItemType
Balance Type:na Period Type:instant

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>
Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480167/946-830-55-12>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-1>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-2>
Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>
Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name

~~Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>Reference 9: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481687/323-10-50-3>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482907/825-10-50-28>Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 13: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480418/310-10-S99-2>~~

+ Details

Name:us-gaap_StockholdersEquity Namespace Prefix:us-gaap Data Type:
xbrli:monetaryItemType Balance Type:credit Period Type:instant XML 22 R6.htm IDEA: XBRL
DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) \$ in 9 Months
Thousands Ended

Sep. 30, 2024

Sep. 30, 2023

Cash flows from operating activities Net Loss\$ (44,370)\$ (22,491)Adjustments to
reconcile net loss to net cash used in operating activities: Stock based compensation
3,6214,134Depreciation and amortization17018Impairment loss on operating lease066Loss on
disposal of fixed assets071Equity investment in Lighthouse, Inc.0(78)Change in the fair
value of contingent consideration liabilities2,0820Change in fair value of long-term
debt1,2520Non-cash goodwill and intangible asset impairment charge17,1305,900
Amortization of discount on available-for-sale investments(1,858)(1,313)Change in
deferred tax liabilities due to acquisition of Novosteo, Inc.0(248)Changes in operating
assets and liabilities, net of acquisitions: Prepaid expenses and other current assets
(2,025)2,272Right of use assets, operating leases and operating lease liabilities(170)
1920Other assets(292)0Accounts payable(424)(161)Accrued expenses and other current
liabilities532(576)Net cash used in operating activities(24,352)(12,214)Cash flow from
investing activities: Purchase of investments(89,562)(95,116)Proceeds from maturities
of investments100,72784,514Note receivable0(500)Proceeds from disposal of assets090
Purchase of property and equipment(124)(136)Net cash provided by investing activities
11,041(11,148)Cash flows from financing activities: Payment of contingent consideration
(5,000)0Payments of finance leases0(6)Proceeds from issuance of common stock upon
exercise of stock options22592Net cash provided by financing activities(4,775)86Effect
of exchange rate changes on cash9329Net increase in cash and cash equivalents(18,077)
(22,947)Cash and cash equivalents at beginning of period20,75244,579Cash and cash
equivalents at end of period2,67521,632Supplemental disclosures of non-cash information:
Right-of-use assets obtained in exchange for new operating lease liabilities2320Right-
of-use asset and financing lease liability reduction as a result of lease modification
\$ 0\$ (70)

- Definition

Change in deferred tax liabilities due to acquisition.

+ References

No definition available.

+ Details

Name:qncx_ChangeInDeferredTaxLiabilitiesDueToAcquisition Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

-- Definition

Goodwill And Intangible Asset Impairment, Excluding Operating Lease Impairment

+ References

No definition available.

+ Details

Name:qncx_GoodwillAndIntangibleAssetImpairmentExcludingOperatingLeaseImpairment Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Increase decrease in fair value of borrowings.

+ References

No definition available.

+ Details

Name:qncx_IncreaseDecreaseInFairValueOfBorrowings Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Loss on disposal.

+ References

No definition available.

+ Details

Name:qncx_LossOnDisposal Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Right of use assets operating leases and operating lease liabilities.

+ References

No definition available.

+ Details

Name:qncx_RightOfUseAssetsOperatingLeasesAndOperatingLeaseLiabilities Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

-- References

No definition available.

+ Details

Name:us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

-- Definition

Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(a\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479581/805-30-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(a)(1)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479581/805-30-50-4)

+ Details

Name:us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfConti Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-24-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482740/230-10-45-4>

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Namespace

Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI>

<https://asc.fasb.org//1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 1-SubTopic 230-Topic 830-Publisher FASB-URI>

<https://asc.fasb.org//1943274/2147481877/830-230-45-1>

+ Details

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncrease

Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The current period expense charged against earnings on long-lived, physical assets not

used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482099/360-10-50-1>

+ Details

Name:us-gaap_DepreciationAndAmortization Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481877/830-230-45-1>

+ Details

Name:us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEqu Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period

Type:duration

-- Definition

Amount of cash outflow for principal payment on finance lease.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147478964/842-20-50-4>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479041/842-20-45-5>

+ Details

Name:us-gaap_FinanceLeasePrincipalPayments Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

-- Definition

The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>

+ Details

Name:us-gaap_GainLossOnSaleOfInvestments Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

-- Definition

The increase (decrease) during the reporting period in the aggregate amount of

~~liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>~~

~~+ Details~~

~~Name:us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~- Definition~~

~~Amount of increase (decrease) in accrued expenses, and obligations classified as other.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>~~

~~+ Details~~

~~Name:us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type: duration~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Amount of increase (decrease) in current assets classified as other.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>~~

+ Details

Name:us-gaap_IncreaseDecreaseInOtherCurrentAssets Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of increase (decrease) in prepaid expenses, and assets classified as other.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>

+ Details

Name:us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>

+ Details

Name:us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-24>

+ Details

Name:us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-24>

+ Details

Name:us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI

~~<https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI>~~
~~<https://asc.fasb.org//1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Publisher FASB-URI>~~
~~<https://asc.fasb.org//1943274/2147482740/230-10-45-25>~~

+ Details

~~Name:us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:na Period Type:duration~~

- References

~~No definition available.~~

+ Details

~~Name:us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

- Definition

~~Amount of loss from impairment of right-of-use asset from operating lease.~~

+ References

~~Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 25-Paragraph 6-Subparagraph \(c\)-Publisher FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 25-Paragraph 6-Subparagraph (c)-Publisher FASB-URI) <https://asc.fasb.org//1943274/2147479365/842-20-25-6>~~

+ Details

~~Name:us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix:us-gaap_ Data Type:~~

xb:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (f) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-15>

+ Details

Name:us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Namespace Prefix:us-gaap_ Data Type:xb:monetaryItemType Balance Type:credit Period Type:duration

-- Definition

Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481830/320-10-45-11>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-13>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-11>

+ Details

Name:us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-13>

+ Details

Name:us-gaap_PaymentsToAcquireNotesReceivable Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-13>

+ Details

Name:us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other

comprehensive income (available-for-sale).

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 11-Publisher FASB-URI https://asc.fasb.org//1943274/2147481830/320-10-45-11>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 11-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-11>
Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 12-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-12](http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 12-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-12)

+ Details

Name:us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 12-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-12](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 12-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-12)

+ Details

Name:us-gaap_ProceedsFromSaleOfProductiveAssets Namespace Prefix:us-gaap_ Data Type:

xbRLi:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of cash inflow from exercise of option under share-based payment arrangement.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2A-Subparagraph \(a\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2A-Subparagraph (a)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A)

+ Details

Name:us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix:us-gaap_ Data Type:xbRLi:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9>Reference 8: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting>

~~Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480167/946-830-55-11>Reference 9:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 205 -Name Accounting
Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480767/946-205-45-3>Reference 10:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting
Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147483581/946-220-45-7>Reference 11:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>Reference 12:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-22>Reference 13:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-1>Reference 14:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting
Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>Reference 15:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481231/810-10-45-19>Reference 16:
<http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 220 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482765/220-10-50-6>Reference 17:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 18:
<http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 19:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii))
(A)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 20:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -
Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX
210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 21:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic
10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX
210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 22:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10
-Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX
210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 23:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic
10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX
210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 24:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)
(B)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 25:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -
Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX
210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 26:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic
10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX
210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 27:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10
-Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-30>Reference 28:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-32>Reference 29:
<http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-31>Reference 30:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting~~

~~Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482810/280-10-50-32>Reference 31:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 235 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147479557/942-235-S99-1>Reference 32:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting
Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147483499/205-20-50-7>Reference 33:
<http://www.xbrl.org/2003/role/exampleRef> -Topic 810 -SubTopic 10 -Name Accounting
Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481175/810-10-55-4J>Reference 34:
<http://www.xbrl.org/2003/role/exampleRef> -Topic 810 -SubTopic 10 -Name Accounting
Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481175/810-10-55-4K>Reference 35:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482790/220-10-45-1A>Reference 36:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482790/220-10-45-1B>Reference 37:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482740/230-10-45-2>Reference 38:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -
URI <https://asc.fasb.org//1943274/2147481203/810-10-50-1A>Reference 39:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -
URI <https://asc.fasb.org//1943274/2147481203/810-10-50-1A>~~

+ Details

Name:us-gaap_ProfitLoss Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of increase in right-of-use asset obtained in exchange for finance lease liability.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147478964/842-20-50-4>

+ Details

Name:us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase in right-of-use asset obtained in exchange for operating lease liability.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147478964/842-20-50-4>

+ Details

Name:us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>

+ Details

Name:us-gaap_ShareBasedCompensation Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 23 R7.htm IDEA: XBRL DOCUMENT Organization9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] OrganizationOrganization

Description of Business

Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases.

The Company's proprietary AIDE technology platform is an innovative drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Red blood cells have several characteristics that make them a potentially ideal vehicle for drug delivery and our AIDE technology is designed to harness many of these benefits to allow for new and improved therapeutic options for patients living with high unmet medical needs. The AIDE technology platform is believed to confer several benefits over conventional therapies which could be applied to a broad range of small or large molecule drugs and biologics. Our Phase 3 lead asset, EryDex, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

By pioneering the encapsulation of drugs in a patient's own red blood cells, we seek to advance proprietary therapeutics that hold the potential to redefine the standard of care and meaningfully improve the quality of life for patients with rare disease.

Liquidity and Capital Resources

The Company has incurred losses and negative cash flows from operations since inception and expects to continue to generate operating losses for the foreseeable future. As of September 30, 2024, the Company had an accumulated deficit of \$364.0 million. Since inception through September 30, 2024, the Company has funded operations primarily with the net proceeds from the issuance of convertible promissory notes, from the issuance of redeemable convertible preferred stock, from the net proceeds from the Company's initial public offering (the "IPO") and from the net proceeds of the private investment in public equity transaction ("PIPE Financing"). As of September 30, 2024, the Company had cash, cash equivalents, and short-term investments of \$47.0 million, which it believes will be sufficient to fund its planned operations into the first quarter of 2026, a period that is at least 12 months from the date of the issuance of the accompanying unaudited consolidated financial statements.

In connection with the acquisition of EryDel on October 20, 2023 (the "EryDel Acquisition"), the Company assumed an unsecured line of credit between EryDel and the European Investment Bank (the "EIB Loan"). As of September 30, 2024, the principal of 10.0 million euros (\$11.2 million) was outstanding on the EIB Loan. The Debt Agreement requires the Company to maintain a minimum cash balance of 14.65 million euros (\$16.4 million) until the outstanding obligations under the Debt Agreement, together with accrued interest and all other amounts accrued or outstanding under the agreement, is repaid in full (the "Minimum Cash Covenant"). Furthermore, the Company may at any time voluntarily prepay, in whole or in part, together with certain fees as set forth in the Debt Agreement, the outstanding obligations under the Debt Agreement. In the event of a default or a change in control, as specified in the Debt Agreement, EIB may, subject to certain grace periods, accelerate the outstanding obligations under the EIB Loan.

In November 2024, the Company entered into an amendment (the "Amendment") of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment.

Management expects to incur additional losses in the future to fund the Company's operations and conduct product research and development and may need to raise additional capital to fully implement its business plan. The Company may raise additional capital through the issuance of equity securities, debt financings or other sources including out-licensing or partnerships, in order to further implement its business plan. However, if such financing is not available

~~References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract
Namespace Prefix:us-gaap_ Data Type:xbli:stringItemType Balance Type:na Period Type:
duration~~

~~Definition~~

~~The entire disclosure for organization, consolidation and basis of presentation of
financial statements disclosure.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480424/946-10-50-1>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480424/946-10-50-2>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 810 -Name Accounting Standards Codification -Publisher
FASB -URI <https://asc.fasb.org//810/tableOfContent>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 205 -Name Accounting Standards Codification -Publisher
FASB -URI <https://asc.fasb.org//205/tableOfContent>~~

~~+ Details~~

~~Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureText
Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period
Type:duration XML 24 R8.htm IDEA: XBRL DOCUMENT
Summary of Significant Accounting Policies9 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract] [Summary of Significant Accounting Policies](#)
[Summary of Significant Accounting Policies](#)~~

The accompanying condensed consolidated financial statements include the accounts of Quince Therapeutics, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the instructions of the SEC on Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the management's opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.

The condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 included in the Company's Form 10-K filed with the SEC on April 1, 2024. The results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period.

Risks and Uncertainties

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to: uncertainty of results of clinical trials and reaching milestones; uncertainty of regulatory approval of the Company's potential drug candidates; uncertainty of market acceptance of the Company's drug candidates; competition from substitute products and larger companies; securing and protecting proprietary technology; strategic relationships and dependence on key individuals and sole source suppliers. The Company's drug candidates will require approvals from the FDA and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any drug candidate will receive the necessary approvals.

Use of Estimates

The preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company's consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances; determination of the fair value of identifiable assets and liabilities in connection with business combinations including associated intangible assets and goodwill; contingent consideration; accruals for research and development costs; useful lives of long-lived assets; stock-based compensation and related assumptions; the incremental borrowing rate for leases and income tax uncertainties; including a valuation allowance for deferred tax assets; eligibility of expenses for the Australia research and development refundable tax credits; impairment of intangible assets, including goodwill; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances; the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company's estimates.

Foreign Currency Translation and Transactions

The functional currency of the Company's wholly owned subsidiaries are the Euro and Australian Dollar. The Company's financial results and financial position are translated into U.S. dollars using exchange rates at balance sheet dates for assets and liabilities and using average exchange rates for income and expenses. The resulting translation differences are presented as a separate component of accumulated other comprehensive loss, as a separate component of equity.

Foreign currency transactions are translated into the functional currencies using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses, resulting from the settlement of such transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies using exchange rates at balance sheet date and non-monetary assets and liabilities using historical exchange rates, are recognized in the condensed consolidated statements of operations and comprehensive loss.

Significant Accounting Policies

There have been no significant changes to the accounting policies during the nine months ended September 30, 2024, as compared to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2023.

Segments

The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing therapeutics. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating and evaluating financial performance. All long-lived assets are maintained in Italy.

Business Combinations

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business.

The Company accounts for business combinations using the acquisition method pursuant to the FASB ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company's financial results beginning on the respective acquisition dates, and that identifiable assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using one of three valuation approaches: the income approach, the market approach or the cost approach. The Company reviewed the three valuation approaches and determined the income approach was the most appropriate model to approximate fair value for the EryDel Acquisition. The income approach model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the "Purchase Price") over the fair values of the net assets acquired is recognized as goodwill. The fair value of identifiable assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible Assets

Definite lived Intangible Assets

Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. The Company regularly reviews whether current conditions or events suggest that the carrying values of its acquired definite lived intangible assets might not be recoverable. When such conditions are identified, an estimate of the undiscounted future cash flows from these assets, or relevant asset groupings, is compared to their carrying value to determine if an impairment exists. If an impairment is identified, the loss is calculated as the difference between the

carrying value of the intangible asset and its fair value, which is based on the net present value of the estimated future cash flows.

Indefinite lived Intangible Assets

Intangible assets with an indefinite useful life are not amortized. Intangible assets acquired in a business combination or an acquisition that are used in research and development activities (regardless of whether they have an alternative future use) shall be considered indefinite lived until the completion or abandonment of the associated research and development efforts. Intangible assets acquired in a business combination are initially recorded at fair value. During the period that those assets are considered indefinite lived, they shall not be amortized but shall be tested for impairment. Once the research and development efforts are completed or abandoned, the entity shall determine the useful life of the assets. An indefinite lived intangible asset shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the intangible asset. Qualitative factors to be considered include but are not limited to:

- *Cost factors such as increases in raw materials, labor, or other costs that have a negative effect on future expected earnings and cash flows*
- *Legal/regulatory factors or progress and results of clinical trials*
- *Other relevant entity-specific events such as changes in management, key personnel, strategy, or customers; contemplation of bankruptcy; or litigation that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset*
- *Industry and market considerations such as a deterioration in the environment in which an entity operates, an increased competitive environment*
- *Macroeconomic conditions such as deterioration in general economic conditions, limitations on accessing capital, fluctuations in foreign exchange rates, or other developments in equity and credit markets that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset*

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.

During the nine months ended September 30, 2024, the Company recognized a non-cash goodwill impairment charge of \$17.1 million as the quantitative analysis resulted in the Company's fair value being significantly below its carrying value during the three months ended June 30, 2024.

Contingent Consideration

The Company determines the acquisition date fair value of contingent consideration using a discounted cash flow method, with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC Topic 820, Fair Value Measurement. The significant inputs in the Level 3 measurement not supported by market activity included our probability assessments of expected future cash flows related to the Company's acquisition of EryDel in October 2023, during the contingent consideration period, appropriately discounted considering the uncertainties associated with the earnout obligation, and calculated in accordance with the terms of the definitive agreement. The liabilities for the contingent consideration are established at the time of the acquisition and will be evaluated on a quarterly basis based on additional information as it becomes available. Any change in the fair value adjustment is recorded in the earnings of that period. During the three months ended September 30, 2024, the Company recorded a \$2.7 million adjustment to decrease the fair value of its contingent consideration related to the acquisition of EryDel. During the nine

months ended September 30, 2024, the Company recorded a net \$2.1 million adjustment to increase the fair value of its contingent consideration related to the acquisition of EryDel. The adjustment is reflected within operating loss on the consolidated statement of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations may result from changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Significant increases or decreases in the inputs noted above in isolation would result in a significantly lower or higher fair value measurement.

Cash, Cash Equivalents and Investments

The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash equivalents include marketable securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at or less than twelve months from the balance sheet date are classified as short-term investments. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term investments. Collectively, cash equivalents, short-term investments and long-term investments are considered available for sale and are recorded at fair value. Unrealized gains and losses are recorded as a component of other comprehensive loss in the consolidated statements of operations and included as a separate component of consolidated statements of stockholders' equity (deficit). Realized gains and losses are included in interest income in the consolidated statements of operations and comprehensive loss.

Premiums (discounts) are amortized (accreted) over the life of the related investment as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. These amounts are recorded in "interest income" in the consolidated statements of operations and comprehensive loss.

Recent Accounting Pronouncements Not Yet Adopted

The following are new accounting pronouncements that the Company is evaluating for future impacts on its financial statements:

Improvements to Income Tax Disclosures (ASC 740): In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." This ASU establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Under this ASU, entities must consistently categorize and provide greater disaggregation of information in the rate reconciliation. They must also further disaggregate income taxes paid. The ASU is effective beginning after December 2024 under a prospective approach. Early adoption is permitted. The Company is evaluating the disclosure requirements related to the new standard.

Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"): In November 2023, the FASB issued ASU 2023-07, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The

Company is evaluating the disclosure requirements related to the new standard.

All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.

[- References](#)

No definition available.

[+ Details](#)

Name:us-gAAP_AccountingPoliciesAbstract Namespace Prefix:us-gAAP_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

The entire disclosure for all significant accounting policies of the reporting entity.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gAAP/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent

[+ Details](#)

Name:us-gAAP_SignificantAccountingPoliciesTextBlock Namespace Prefix:us-gAAP_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 25 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements9 Months Ended Sep. 30, 2024

Fair Value Disclosures [Abstract] Fair Value MeasurementsFair Value Measurements

The fair value of the Company's financial instruments reflects the amounts that the Company estimates that it would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company discloses and recognizes the fair value of the assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active.

Level 3 - Inputs that are unobservable. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The Company's financial instruments are carried in the accompanying condensed consolidated balance sheets at amounts that approximate fair value.

The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the three and nine months ended September 30, 2024 and 2023.

The Company elected the fair value option for the EIB loan assumed as part of the EryDel Acquisition. The Company adjusted the EIB loan to fair value through the change in fair value of debt in the accompanying consolidated statements of operations and comprehensive loss. Subsequent unrealized gains and losses on items for which the fair value option is elected are reported in earnings. The Company will breakout any change in value due to credit loss in accumulated other comprehensive loss. For the three and nine months ended September 30, 2024, there was no change in value due to credit loss.

Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September 30, 2024 and December 31, 2023 are presented in the following tables (in thousands):

Assets: Money market funds \$997, \$997, \$- Government and agency notes \$45,172, \$45,172, \$- Total Assets \$46,169, \$997, \$45,172, \$- **Liabilities:** Contingent consideration \$4,788, \$- Long-term debt \$4,899, \$- Total \$69,687, \$69,687

Assets: Money market funds \$4,285, \$4,285, \$- Certificates of Deposit \$729, \$729, \$- Government and agency notes \$68,524, \$71,135, \$64,553, \$- Total Assets \$73,538, \$8,256, \$65,282, \$- **Liabilities:** Contingent consideration \$7,706, \$7,706, \$- Long-term debt \$13,429, \$13,429, \$- Total \$71,135, \$71,135

The Company classifies certificates of deposit and government and agency notes as Level 2 investments as the Company uses quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trades of or quotes on the same or similar securities. The Company does not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services.

Level 3 Assets and Liabilities

Contingent Consideration

The following table reflects the changes in present value of acquisition-related accrued earnouts of contingent consideration liability using significant unobservable inputs (Level 3) for the nine months ended September 30, 2024:

(in thousands) Beginning Balance as of January 1, 2024 \$57,706; Payout of contingent earnout based on milestone achievement (5,000) Change in fair value of contingent consideration 2,082; Ending Balance as of September 30, 2024 \$54,788

During the three months ended June 30, 2024, the Company enrolled the first patient in the Phase 3 NEAT clinical trial. In accordance with the purchase agreement entered into in connection with EryDel Acquisition, the Company notified the former EryDel shareholders of this achievement within 45 days of achieving this milestone. During the three months ended September 30, 2024, the Company paid the cash milestone payment of \$5 million to the former EryDel shareholders.

The change in the fair value of the contingent consideration is primarily driven by the cash milestone payment of \$5 million to the former EryDel shareholders, and the passage of time. The Company owes no further payments to EryDel

shareholders for development-related milestones. The remaining potential contingent payments in connection with the FryDel Acquisition pertain to regulatory on market and sales milestones.

The following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition-related accrued earnout as of September 30, 2024 (in thousands except for percentages):

Contingent consideration \$54,788 - Expected present value - Probability of achieving earnout objectives per the purchase agreement : September 30, 2024 Valuation Technique Unobservable Input Range (Input Used)

0% - 100%

Long-term Debt

The following table presents the changes in the fair value of the Level 3 FIB loan for the nine months ended September 30, 2024:

(in thousands): Beginning Balance as of January 1, 2024 \$13,429 Change in fair value 1,252 Due to foreign currency translation 210 Ending Balance as of September 30, 2024 \$14,899

The following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition-related long term debt as of September 30, 2024 (in thousands except for percentages):

FIB loan \$14,899 - Expected present value - Credit quality of company and credit spreads for comparable debt : September 30, 2024 Valuation Technique Unobservable Input Range (Input Used)

13%

[References](#)

No definition available.

[+ Details](#)

Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

[Definition](#)

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

[References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>

[+ Details](#)

Name:us-gaap_FairValueDisclosuresTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 26 R10.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Investments9 Months Ended

Sep. 30, 2024

Fair Value Disclosures [Abstract] [Cash, Cash Equivalents and Investments](#)

The following tables categorize the fair values of cash, cash equivalents and investments measured at fair value on a recurring basis on our balance sheets (in thousands):

The Company's investments are classified as available-for-sale securities. As of September 30, 2024, the weighted-average remaining contractual maturities of available-for-sale securities was approximately 6 months. The unrealized gain (loss) activity related to the Company's available-for-sale securities is included in the Company's accumulated other comprehensive income. There were no significant realized gains or losses recognized on the sale or maturity of available-for-sale securities for the three and nine months ended September 30, 2024 and 2023, and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income. Based on the Company's review of its available-for-sale securities, the Company has no available-for-sale securities in loss positions as of September 30, 2024. No other-than-temporary impairments on these securities were recognized for the three and nine months ended September 30, 2024 and 2023.

For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value and recognized in interest and other income, net in the statement of operations and comprehensive loss. If neither criteria is met, the Company evaluates whether the decline in fair value is related to credit-related factors or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. Credit-related impairment losses, limited by the amount that the fair value is less than the amortized cost basis, are recorded through an allowance for credit losses in interest and other income, net.

For purposes of identifying and measuring credit-related impairments, the Company's policy is to exclude applicable accrued interest from both the fair value and amortized cost basis of the related security. The Company has elected to write-off uncollectible accrued interest receivable balances in a timely manner, which is defined by the Company as when interest due becomes 90 days delinquent. The accrued interest write-off will be recorded by reversing interest income. Accrued interest receivable is recorded in other current assets on the condensed balance sheets.

: Fair Value Measurements as of December 31, 2023.:

Amortized	
Cost	
Unrealized	
Gains	
Unrealized	
Losses: Fair Value	

Money market funds	\$4,285	\$—	\$—	\$4,285	Certificates of Deposit	735	—	(6)	729	Government and agency notes	68,528	13	(17)	68,524	Total cash equivalents and investments	\$73,540	\$13	\$(2)	\$73,538

Classified as: Cash equivalents (original maturities within 90 days) \$9,231 Short-term investments (maturities within one year) 54,307 Total: \$63,538

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//320/tableOfContent>

Name:us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock Namespace Prefix:us-gaap Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

~~No definition available.~~

~~Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:
xbrli:stringItemType Balance Type:na Period Type:duration XML 27 R11.htm IDEA: XBRL
DOCUMENT
Balance Sheet Components9 Months Ended
Sep. 30, 2024
Balance Sheet Components [Abstract] Balance Sheet ComponentsBalance Sheet Components~~

expenses 1,415 - 1,132 Short-term Italian research and development refundable tax credit 995 - 993 Prepaid insurance 841 - 809 Prepaid expenses 565 - 365 Other current assets 55 - 81 Total prepaid expenses and other current assets (53,973) (52,281)

The Company is eligible to obtain an R&D tax credit as companies in Italy that invest in eligible research and development activities, regardless of the legal form and economic sector in which they operate, can benefit from a R&D tax credit. Such tax credits can only be used to offset payments of certain taxes and contributions (e.g., social contributions, VAT payables, registration fees, income and withholding taxes and other tax-related items that companies usually pay monthly). The Company recognized reductions to R&D expense of \$0.4 million and \$1.2 million for the three and nine months ended September 30, 2024 respectively, and \$0 reductions for the three and nine months ended September 30, 2023.

~~Other assets consisted of the following (in thousands):~~

Property and equipment, net consist of the following (in thousands):

Software 30, 30; Lab equipment 534, 486; Leasehold improvement 36, 36; Office furniture 237, 153; Less: accumulated amortization and depreciation (667), (507); Property and equipment, net (\$208), (\$234); : September 30, 2024 December 31, 2023 Computer equipment \$38, \$36; Computer

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

Research and development expenses 1,062, 564, Professional fees 140, 211, Current portion of operating lease liabilities 101, 64, Other 198, 257, Total accrued expenses and other current liabilities \$2,301, \$2,340, September 30, 2024 December 31, 2023 Personnel expenses \$2,301, \$2,340, Total accrued expenses and other current liabilities \$2,803, \$3,436,

For the nine months ended September 30, 2024 and 2023, the severance accrual activity were as follows (in thousands):

770, Severance paid during the period (302), (309), Ending accrued severance \$(—), (\$463), 2024 2023 Beginning accrued severance \$341, \$—, incurred during the period \$1,

On January 30, 2023, in response to the reprioritization of the Company's pipeline following the decision to discontinue internal development of NOV004 and to pursue out-licensing opportunities, the Company's Board of Directors approved a cost reduction program to reorganize operations and allow continued support for the needs of the business. Under the cost reduction program, the Company lowered headcount through a reduction in workforce. The Company recognized the severance of \$0.3 million and related expenses of \$0.1 million over the requisite employment obligation period. The reduction in force was completed in April 2023.

On August 4, 2023, the Company entered into a transition and separation agreement with Karen Smith, M.D., Ph.D., (the "Separation Agreement") in connection with Dr. Smith's transition and departure from the Company as the Company's Chief Medical Officer, effective as of September 1, 2023. Pursuant to the Separation Agreement, the Company is required to pay cash severance, equal to her annual salary, in the aggregate amount of \$0.5 million, of which \$0.3 million was paid during the nine months ended September 30, 2024. The severance is to be paid on regular payroll schedule through the third quarter of 2024. Additionally, pursuant to the Separation Agreement, the Company paid an additional cash bonus/severance payment equal to 100% of Dr. Smith's target annual bonus opportunity for 2023 on a prorated basis, an additional cash severance payment equal to 12 months' of the monthly premiums for health care continuation benefits, and provided for 50% accelerated vesting with respect to Dr. Smith's equity award. The acceleration of 612,141 options and 54,757 RSAs resulted in a stock-based compensation expense of

approximately \$0.1 million that was recorded in 2023.

- Definition

Balance sheet components,

+ References

No definition available,

+ Details

Name:qncx_BalanceSheetComponentsAbstract Namespace Prefix:qncx_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//210/tableOfContent

+ Details

Name:us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 28 R12.htm IDEA: XBRL DOCUMENT Leases 9 Months Ended Sep. 30, 2024 Leases [Abstract] LeasesLeases

In October 2023, as part of the EryDel Acquisition the Company acquired operating leases in which the Company recorded an operating lease right of use asset and liability in total of \$0.4 million. This includes a lease agreement renting office space in Bresso, in the Province of Milan, Italy. The Lease Agreement commenced on September 1, 2016 and will end on August 31, 2020. At acquisition date, the Company recorded an operating lease right of use asset and liability of \$0.1 million. This also includes a lease agreement renting office space in Medolla, in the Province of Modena, Italy. The Lease Agreement commenced on June 10, 2010, with a duration of 12 years, until January 31, 2030. At acquisition date, the Company recorded an operating lease right of use asset and liability of \$0.2 million. The acquired lease agreements also included other operating leases two of which are car leases and the other a printing press.

In January 2024, the above-mentioned Lease Agreement for the office space in Medolla was renegotiated. The new Lease Agreement includes an additional space and commenced on February 1, 2024, and will end on January 31, 2036, substituting the Lease Agreement commenced in June 2010. The Company recorded an additional \$0.2 million of operating lease right of use asset and liability during the nine months ended September 30, 2024.

The Company recognizes lease expense on a straight-line basis over the term of its operating lease. During the nine months ended September 30, 2024 and 2023, the Company recorded rent expense of \$0.1 million.

Supplemental balance sheet information related to leases as follows (in thousands except lease terms and discount rates):

asset, net \$559, \$385, Liabilities: Short-term operating lease liability 101, 64, Long-term operating lease liability 450, 321, Total lease liabilities \$551, \$385, September 30, 2024 December 31, 2023 Assets: Operating lease right of use years Weighted average discount rate 9.11, % 7.95, % Other information: Weighted average remaining lease term 4.9 years 5.4

Future minimum lease payments under lease agreements as of September 30, 2024, were as follows (in thousands):

Fiscal Year 2024 (remainder of the year) \$35, 2025 140, 2026 136, 2027 130, 2028

and thereafter 214, Total lease payments 655, less: imputed interest (104), Total remaining lease liability \$551,

- References

No definition available,

+ Details

Name:us-gaap_LeasesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for operating leases of lessee. Includes, but is not limited to,

description of operating lease and maturity analysis of operating lease liability.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//842-20/tableOfContent>

+ Details

Name:us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix:us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 29 R13.htm IDEA: XBRL DOCUMENT

Stockholders' Equity9 Months Ended

Sep. 30, 2024

Stockholders' Equity Note [Abstract] [Stockholders' Equity](#)Stockholders' Equity

On April 5, 2023, the Company's Board of Directors declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of the common stock of the Company. The dividend was effective as of April 17, 2023 (the "Record Date") with respect to stockholders of record on that date. The Rights also attached to shares of common stock issued after the Record Date. Each Right entitled the registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value \$0.001 per share, (the "Preferred Shares"), of the Company at a price of \$6.00 per one one-thousandth of a Preferred Share, subject to adjustment.

On April 5, 2024, the Rights Plan and the Rights issued thereunder expired.

+ References

No definition available.

+ Details

Name:us-gaap_StockholdersEquityNoteAbstract Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

+ Definition

The entire disclosure for equity.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13)
Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13)
Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14)
Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2)
Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2)
Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6>
Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6)
Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1)
Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(e\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(e)(1))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)
Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//505/tableOfContent>
Reference 11:

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 12:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 13:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 14:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-14>Reference 15:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-14>Reference 16:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-16>Reference 17:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-18>Reference 18:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-18>Reference 19:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481112/505-10-50-18>~~

+ Details

Name:us-gAAP_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix:us-gAAP_Data
Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 30 R14.htm
IDEA: XBRL DOCUMENT
Stock-Based Compensation9 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract] Stock-Based Compensation
Stock-Based Compensation

The Company operates three stock plans as of September 30, 2024:

- ± 2019 Equity Incentive Plan (Quince)
- ± 2019 Equity Incentive Plan (Novosteo)
- ± 2022 Inducement Plan (Quince)

2019 Equity Incentive Plan (Quince)

On December 4, 2014, the Company's stockholders approved the 2014 Stock Plan ("2014 Plan"), and on April 25, 2019 amended, restated and re-named the 2014 Plan as the 2019 Equity Incentive Plan (the "Quince 2019 Plan"), which became effective as of May 7, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The remaining shares available for issuance under the 2014 Plan were added to the shares reserved for issuance under the Quince 2019 Plan.

The Quince 2019 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to the Company's employees, directors, and consultants. As of September 30, 2024, the maximum aggregate number of shares that may be issued under the 2019 Plan is 11,755,418 shares of the Company's common stock. In addition, the number of shares available for issuance under the Quince 2019 Plan will be annually increased on the first day of each fiscal year beginning with fiscal 2020, by an amount equal to the least of (i) 2,146,354 shares of common stock; (ii) 4% of the outstanding shares of its common stock as of the last day of its immediately preceding fiscal year; and (iii) such other amount as the Board may determine.

The Quince 2019 Plan may be amended, suspended or terminated by the Board at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the Quince 2019 Plan as required by applicable law or listing requirements. Unless sooner terminated by the Company's Board of Directors, the 2019 Plan will automatically terminate on April 23, 2029.

As of September 30, 2024, the Company had 2,280,074 shares available for future issuance under the Quince 2019 Plan.

Stock Options

Stock options under the 2019 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the fair market value of the shares on the date of grant. If, at the time of grant, the optionee directly owns stocks representing more than 10% of the voting power of all our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees and non-employees generally have a maximum term of ten years and vest over four years from the vesting commencement date, of which 25% vest on the one-year anniversary of the vesting commencement date, and 75% vest in equal monthly installments over the remaining three years or monthly vesting over 3 to 4 years. We may grant options with different vesting terms from time to time. Unless an employee's or non-employee's termination is due to cause, disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of the three months from the termination date or expiration of the option, whichever is earlier.

Activity for service-based stock options under the Quince 2019 Plan is as follows:

Number of Options and Unvested Shares Weighted Average Exercise Price Weighted average remaining contractual life (years) Aggregate intrinsic value	(in thousands) Balance as of December 31, 2023	4,267,178	\$5.00	8.85	\$197	Options granted	3,602,500	1.26	—	Options exercised	(155,311)	0.93	—	65	Options cancelled / forfeited	(165,861)	13.06	—	Balance as of September 30, 2024	7,548,506	\$3.12	8.72	\$5	Options vested and expected to vest as of September 30, 2024	7,548,506	3.12	8.72	5	Options exercisable as of September 30, 2024	2,062,912	\$7.86	7.76	\$—

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation expense of \$0.7 million and \$2.2 million, respectively, related to options granted to employees and non-employees. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$0.6 million and \$2.0 million, respectively, related to options granted to employees and non-employees.

The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the condensed consolidated statement of operations and comprehensive loss for stock-based compensation arrangements. As of September 30, 2024, total unamortized employee stock-based compensation was \$5.5 million, which is expected to be recognized over the remaining estimated vesting period of 2.74 years.

Restricted Stock Units ("RSUs")

RSUs are share awards that entitle the holder to receive freely tradable shares of the Company's common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company's common stock on the grant date. RSUs granted to employees generally vest over a 2–4 year period.

The following table summarizes activity under the Company's RSUs from the Quince 2019 Plan and related information:

Number of Shares Weighted Average Grant Date Fair Value Unvested – December 31, 2023	1,488	\$4.30	RSUs granted	—	RSUs vested	(1,488)	4.30	RSUs cancelled	—	Unvested – September 30, 2024	(6—)	Restricted Stock Units Outstanding	—

The fair value of the RSUs is determined on the grant date based on the fair value of the Company's common stock. The fair value of the RSUs is recognized as expense ratably over the vesting period of two years.

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation expense of \$0 and \$4.4 thousand, respectively, related to these RSUs. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$6.4 thousand and \$37.5 thousand, respectively, related to these RSUs. As of September 30, 2024, total unamortized stock-based compensation related to RSUs was \$0.

2019 Equity Incentive Plan (Novosteo)

On May 19, 2022, in accordance with the term of the Merger Agreement, the Company assumed the 2019 Novosteo, Inc. Equity Incentive Plan (the "2019 Novosteo Plan"). The 2019 Novosteo Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to the Novosteo legacy employees. On the closing date, each outstanding Novosteo stock option granted under Novosteo's equity compensation plans was converted into a corresponding stock option with the number of shares underlying such option and the applicable exercise price adjusted based on the exchange ratio of 0.0911. Each such converted stock option continues to be subject to substantially the same terms and conditions as applied to the corresponding Novosteo stock option prior to the Acquisition. The maximum aggregate number of shares that may be issued under the 2019 Novosteo Plan is 544,985 shares of the Company's common stock.

The 2019 Novosteo Plan may be amended, suspended or terminated by the Board at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the 2019 Novosteo Plan as required by applicable law or listing requirements. Unless sooner terminated by the Board, the 2019 Novosteo Plan will automatically terminate on May 20, 2029.

Stock options under the 2019 Novosteo Plan may be granted for periods of up to 10 years and at prices no less than 100% of the fair market value of the shares on the date of grant. If, at the time of grant, the optionee directly owns stocks representing more than 10% of the voting power of all our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees and non-employees generally have a maximum term of ten years and vest over four years from the vesting commencement date, of which 25% vest on the one-year anniversary of the vesting commencement date, and 75% vest in equal monthly installments over the remaining three years or monthly vesting over 3 to 4 years. We may grant options with different vesting terms from time to time. Unless an employee's or non-employee's termination is due to cause, disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of the three months from the termination date or expiration of the option, whichever is earlier.

As of September 30, 2024, the Company had 246,797 shares available for future issuance under the 2019 Novosteo Plan.

Activity for service-based stock options under the 2019 Novosteo Plan is as follows:

Number of Options and Unvested Shares Weighted Average Exercise Price Weighted average remaining contractual life (years) Aggregate intrinsic value	(in thousands) Balance as of December 31, 2023	—	—	—	—	Options granted	—	—	Options exercised	—	—	Options cancelled / forfeited	—	—	Balance as of September 30, 2024	—	—	Options vested and expected to vest as of September 30, 2024	—	—	Options exercisable as of September 30, 2024	—	—

intrinsic value -- (in thousands) **Balance as of December 31, 2023 310,431 \$0.55 0.23 \$155** Options granted -- -- Options exercised (146,592) 0.55 -- 94 Options cancelled / forfeited -- -- **Balance as of September 30, 2024 163,839 \$0.55 7.48 \$37** Options vested and expected to vest as of September 30, 2024 163,839 0.55 7.48 37 Options exercisable as of September 30, 2024 147,426 \$0.55 7.48 \$11

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation expense of \$48.7 thousand and \$145.6 thousand, respectively, related to options granted to employees and non-employees for the 2019 Novosteo Plan. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$96.0 thousand and \$226.0 thousand, respectively, related to options granted to employees and non-employees for the 2019 Novosteo Plan. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the condensed consolidated statement of operations and comprehensive loss for stock-based compensation arrangements. As of September 30, 2024, total unamortized employee stock-based compensation was \$288.1 thousand, which is expected to be recognized over the remaining estimated vesting period of 1.49 years.

On May 19, 2022, in accordance with the term of the Merger Agreement, the Company assumed a number of restricted stock award ("RSA") agreements with certain employees. Each outstanding Novosteo RSA was converted into a corresponding RSA with the number of shares underlying such RSA adjusted into 0.0911 shares of common stock. Each such converted RSA will continue to be subject to substantially the same terms and conditions as applied to the corresponding Novosteo RSA prior to the Acquisition.

Restricted Stock Awards

Number of Shares Weighted Average Grant Date Fair Value Unvested -- December 31, 2023 175,763 \$3.30 RSAs granted -- -- RSAs vested (73,010) 3.30 RSAs cancelled -- -- **Unvested -- September 30, 2024 102,753 \$3.30**

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation expense of \$0.1 million and \$0.2 million, respectively, related to restricted stock awards. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$0.2 million and \$0.4 million, respectively, related to restricted stock awards. The compensation expense is allocated on a departmental basis, based on the classification of the award holder. No income tax benefits have been recognized in the condensed consolidated statement of operations and comprehensive loss for stock-based compensation arrangements. As of September 30, 2024, total unamortized employee stock-based compensation was \$0.3 million, which is expected to be recognized over the remaining estimated vesting period of 0.99 years.

2022 Inducement Plan

On May 9, 2022, the Company's Board of Directors approved 4,000,000 shares of common stock that may be offered or issued under the Quince Therapeutics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). The 2022 Inducement Plan was adopted by the independent members of the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules ("Nasdaq Rule 5635(c)(4)"). In accordance with Nasdaq Rule 5635(c)(4), awards under those plans may only be made to an employee who has not previously been an employee or member of the Board of Directors or of any board of directors of any parent or subsidiary of the Company, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The terms and conditions of the 2022 Inducement Plan are substantially similar to those of the Quince 2019 Plan.

Options under the 2022 Inducement Plan may be granted for periods of up to 10 years at prices no less than 100% of the fair market value of the shares on the date of grant. Options granted to employees may have different performance goals or other vesting provisions (including continued employment) in accordance with the applicable award agreement. Unless an employee's termination service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of the three months from the date of termination or expiration of the option, whichever is earlier.

As of September 30, 2024, the Company had 1,666,694 shares available for future issuance under the 2022 Inducement Plan.

Activity for service-based stock options under the 2022 Inducement Plan is as follows:

Number of Options and Unvested Shares Weighted Average Exercise Price Weighted average remaining contractual life (years)

As are state intrinsic value -- (in thousands) Balance as of December 31, 2023 2,333,306 \$2.98 8.40 Options granted -- -- Options exercised -- -- Options cancelled / forfeited -- -- **Balance as of September 30, 2024 2,333,306 \$2.98 7.65** Options vested and expected to vest as of September 30, 2024 2,333,306 2.98 7.65 Options exercisable as of September 30, 2024 1,361,094 \$2.98 7.65

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation expense of \$0.3 million and \$1.0 million, respectively, related to options granted to employees for the 2022 Inducement Plan. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$0.4 million and \$1.5 million, respectively, related to options granted to employees for the 2022 Inducement Plan. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the condensed consolidated statement of operations and comprehensive loss for stock-based compensation arrangements. As of September 30, 2024, total unamortized employee stock-based compensation was \$2.2 million, which is expected to be recognized over the remaining estimated vesting period of 1.64 years.

Stock-Based Compensation Expense

The following table summarizes employee and non-employee stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 and the allocation within the condensed consolidated statements of operations and comprehensive loss (in thousands):

Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 General and administrative expense \$ 786; \$ 945; \$ 3,096; \$ 3,014; Research and development expense 330; 386; 525; 1,120. Total stock-based compensation \$ 1,124; \$ 1,331; \$ 6,221; \$ 4,134

Employee Stock Purchase Plan

On April 24, 2019, the Company's Board of Directors adopted its 2019 Employee Stock Purchase Plan ("2019 ESPP"), which was subsequently approved by the Company's stockholders and became effective on May 7, 2019, the day immediately prior to the effectiveness of the registration statement filed in connection with the IPO. The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section 423 of the Internal Revenue Code (the "Code") for U.S. employees. In addition, the 2019 ESPP authorizes grants of purchase rights that do not comply with Section 423 of the Code under a separate non-423 component for non-U.S. employees and certain non-U.S. service providers. The Company has reserved 1,924,262 shares of common stock for issuance under the 2019 ESPP. In addition, the number of shares reserved for issuance under the 2019 ESPP will be increased automatically on the first day of each fiscal year for a period of up to ten years, starting with the 2020 fiscal year, by a number equal to the lesser of: (i) 536,589 shares; (ii) 1% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such lesser number of shares determined by the Company's Board of Directors. The 2019 ESPP is expected to be implemented through a series of offerings under which participants are granted purchase rights to purchase

shares of the Company's common stock on specified dates during such offerings. The Company has not yet approved an offering under the 2019 ESPP.

- Definition

The entire disclosure for share-based payment arrangement.

+ References

Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//718/tableOfContent>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(2)(i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(l\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (l)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)

[+ Details](#)

~~Name:us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_Namespace
Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:
duration~~

[- References](#)

~~No definition available.~~

[+ Details](#)

~~Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_Namespace
Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML
31 R15.htm IDEA: XBRL DOCUMENT
Long-term Debt9 Months Ended
Sep. 30, 2024~~

~~Debt Disclosure [Abstract] Long-term DebtLong-term Debt~~

~~In connection with the acquisition of EryDel on October 20, 2023, the Company assumed an unsecured line of credit between EryDel and the European Investment Bank (the "EIB Loan"). The EIB Loan was amended and restated as of the acquisition date. The EIB Loan provides for maximum borrowings of 36.0 million euro through four tranches: tranche A, 3.0 million euro; tranche B, 7.0 million euro; tranche C, 10.0 million euro; and tranche D, 10.0 million euro. Each tranche is subject to conditions precedent related to the Company's business and capitalization. As of September 30, 2024, only tranches A and B have been drawn. All amounts due under tranche A and B are payable on their maturity date of August 2026. Tranche C and D are payable in equal installments of principal together with all amounts outstanding under the tranches on the repayment dates specified in the relevant Disbursement Offer. The first repayment date of tranche C shall fall not earlier than twelve months from the Disbursement Date of such tranche. The last repayment date of tranche C and tranche D shall fall not later than 5 years from the Disbursement Date of tranche C and tranche D, respectively. The EIB Loan bears interest at fixed rates for each tranche and is payable on the maturity date for each tranche. The fixed rates range from 7.0% to 9.0% per annum. As of September 30, 2024, principal of 10.0 million euros (\$11.2 million) was outstanding on the EIB Loan and it is recorded as Long-term debt on the condensed consolidated balance sheet at fair value with imputed interest of 9.0% included.~~

~~The Debt Agreement requires the Company to maintain a minimum cash balance of 14.65 million euros (\$16.4 million) until the outstanding obligations under the Debt Agreement, together with accrued interest and all other amounts accrued or outstanding under the agreement, is repaid in full (the "Minimum Cash Covenant"). Furthermore, the Company may at any time voluntarily prepay, in whole or in part, together with certain fees as set forth in the Debt Agreement, the outstanding obligations under the Debt Agreement. In the event of a default or a change in control, as specified in the Debt Agreement, EIB may, subject to certain grace periods, accelerate the outstanding obligations under the EIB Loan.~~

~~In November 2024, the Company entered into an amendment (the "Amendment") of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment.~~

~~The Debt Agreement includes a provision for additional remuneration to be paid in addition to interest. The amount of additional remuneration to be paid is equal to 2.5% of revenue up to 125.0 million euros, plus 1.05% of revenue between 125.0 and 250.0 million euros, plus 1.0% of revenue in excess of 250.0 million euros, multiplied by a varying percentage based on how many tranches have been drawn. The varying percentage is equal to 30.0% in the event tranche A has been drawn, 50.0% in the event tranche A and B have been drawn, 80.0% in the event tranche A, B and C have been drawn, and 100.0% in the event all four tranches have been drawn. The additional remuneration is payable for seven years, during the period January 1, 2026, through December 31, 2032. In the event of an occurrence of an event of default or prepayment, the Company may be required to pay an additional remuneration buyout fee.~~

~~The Company elected to account for the EIB Loan at fair value, which requires the EIB Loan to be recorded at fair value at issuance and at the end of each reporting period. Gains or losses upon remeasurement are to be recorded in other expense, net in the condensed consolidated statements of operations and comprehensive income. The Company presents separately in other comprehensive income the portion of the total change in the fair value of the EIB Loan that results from a change in instrument-specific credit risk. The EIB Loan's fair value at the date it was assumed adjusted its carrying value based on using a discounted cash flow analysis with a discount rate based on a yield curve that was adjusted for credit rating. The change in fair value as of September 30, 2024 was determined using a discounted cash flow analysis discounted at the market yield. The significant inputs used to measure the market yield as of September 30, 2024 relative to the date the EIB Loan was assumed was the change in credit quality of the Company, the change in credit spreads for comparable debt instruments, and the change in the risk-free rate. As of September 30, 2024, the fair value of the EIB Loan is \$14.9 million, which includes a fair value adjustment of \$1.3 million and foreign currency translation of \$0.2 million during the nine months ended September 30, 2024.~~

~~Future minimum principal payments, as of September 30, 2024 are as follows (in thousands):~~

~~Quarter ended September 30, 2024. Amount 2024 \$— 2025 — 2026 11,190 2027~~

~~and thereafter — Total future payments 11,190 Imputed interest and fair value adjustments 3,709 Total Debt as of September 30, 2024 (\$14,899)~~

~~—References~~

~~No definition available.~~

~~+Details~~

~~Name:us-gaap_DebtDisclosureAbstract Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration~~

~~—Definition~~

~~The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.~~

~~+References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1CReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI~~

~~<https://asc.fasb.org//1943274/2147481139/470-20-50-1>EReference 11:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481139/470-20-50-1>EReference 12:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481139/470-20-50-1>EReference 13:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147481139/470-20-50-1>~~

+ Details

Name:us-gaap_DebtDisclosureTextBlock Namespace Prefix:us-gaap Data Type:
dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 32 R16.htm IDEA:
XBRL DOCUMENT
Income Taxes9 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract] Income TaxesIncome Taxes

The Company recorded \$13.0 thousand and \$80.0 thousand of tax expense for the three and nine months ended September 30, 2024, respectively, primarily related to foreign withholding tax and interest on the uncertain tax position liability.

The Company has a history of losses and expects to incur a loss for 2024. The Company maintains a full valuation allowance against its net deferred tax assets as the Company believes it is not more likely than not that the benefit will

be realized. The primary difference between the effective tax rate and the statutory tax rate relates to the change in valuation allowance.

-- References

No definition available.

+ Details

Name:us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix:us-gaap Data Type:
xbli:stringItemType Balance Type:na Period Type:duration

-- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480990/946-20-50-13>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org//740/tableOfContent>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482685/740-10-50-14>
Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482685/740-10-50-21>
Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482526/740-270-50-1>
Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482685/740-10-50-17>
Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479360/740-10-S99-1>
Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479360/740-10-S99-2>
Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482603/740-30-50-2>

+ Details

Name:us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:
dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 33 R17.htm IDEA:
XBRL DOCUMENT

Net Loss Per Share9 Months Ended
Sep. 30, 2024

Earnings Per Share [Abstract] Net Loss Per ShareNet Loss Per Share

Basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average common shares outstanding during the period, as follows (net loss in thousands):

2024-2023 Numerator:-- Net loss \$(5,492) \$(5,351) \$(44,370) \$(22,491) Denominator: Weighted-average common shares outstanding 43,164,136 36,073,040 43,090,632 35,941,234 Net loss per share, basic and diluted \$(0.13) \$(0.15) \$(1.03) \$(0.63) : Three Months Ended September 30, Nine Months Ended September 30, -2024-2023

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented because including them would have been antidilutive:

: September 30, -2024-2023 Stock options issued and outstanding 10,045,651

7,469,163 Restricted stock units - 2,975 Restricted stock awards 102,753 200,099 Total 10,148,404 7,672,237

-- References

No definition available.

+ Details

Name:us-gaap_EarningsPerShareAbstract Namespace Prefix:us-gaap_ Data Type:
xbrl:stringItemType Balance Type:na Period Type:duration

-- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher
FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards
Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContentReference 3:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482662/260-10-50-2Reference 4:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482662/260-10-50-3

+ Details

Name:us-gaap_EarningsPerShareTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 34 R18.htm IDEA:XBRL DOCUMENT
Business Combination9 Months Ended Sep. 30, 2024
Business Combination and Asset Acquisition [Abstract] Business Combination Business Combination

EryDel Business Combination
On October 20, 2023, the Company completed its acquisition of EryDel, a privately held, late-stage biotechnology company with a lead Phase 3 lead asset, EryDex, that targets the potential treatment of a rare neurodegenerative disease, A-T. The acquisition will drive Quince's next stage of growth, as EryDel's proprietary drug-device combination technology platform and promising late-stage clinical asset represents an opportunity for the Company to expand into several debilitating rare diseases where chronic corticosteroid treatment is – or has the potential to become – a standard of care if there were not corticosteroid-related safety concerns. The Company accounted for this acquisition in accordance with ASC 805, Business Combinations, which requires the assets acquired and the liabilities assumed to be measured at fair value at the date of the acquisition. As part of the acquisition of EryDel, the Company recorded deferred tax liability of \$5.1 million and uncertain tax position liability of \$0.3 million against Goodwill.

The acquisition date fair value of the consideration transferred for EryDel was approximately \$66.9 million, which consisted of the following (in thousands):

*- Fair Value of Consideration Cash \$2,615;
Quince Therapeutics common stock (7,250,352 shares) 7,164; Contingent consideration 56,120; Settlement of preexisting notes receivable 1,000. Fair value of total consideration transferred \$66,907;*

The fair value of the Company's common stock was determined based on the closing market price of the Company's common stock of \$0.989 per share on the acquisition date. The aggregate stock consideration consists of 6,525,315 shares of Company's common stock issued at closing and 725,037 shares of common stock (the "Indemnity Holdback Shares") were withheld by the Company until October 2024 for general representations and warranties. The Company has included the total fair value of the stock consideration within additional paid-in capital and common stock.

In October 2024, upon the first anniversary of the closing of the EryDel Acquisition (the "Holdback Release Date"), and in accordance with the purchase agreement entered into in connection with EryDel Acquisition, the Indemnity Holdback Shares were released to the EryDel shareholders. As of the Holdback Release Date, no indemnification claims were made by the Company. No further stock consideration is available for issuance and no additional shares will be issued in connection with the EryDel Acquisition.

The contingent consideration arrangement requires the Company to pay \$485.0 million of additional consideration in cash, comprised of up to \$5.0 million upon the enrollment of the first patient in the Phase 3 NEAT clinical trial, which was paid in the third quarter of 2024; \$25.0 million at NDA acceptance; up to \$60.0 million upon the achievement of specified approval milestones; and up to \$395.0 million upon the achievement of specified on-market and sales milestones. The Company estimated the fair value of the contingent consideration using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions in applying the income approach are as follows: 15% discount rate, probability of achievement, 0% to 100% each of the milestones and future revenues from commercialization over the contingent consideration period. No contingent consideration is payable unless and until the milestones are achieved. The fair value of each milestone after the acquisition is reassessed, with the subsequent change in fair value recorded in the Company's consolidated statements of operations and comprehensive loss.

During the three months ended June 30, 2024, the Company enrolled the first patient in the Phase 3 NEAT clinical trial. During the three months ended September 30, 2024, the Company paid the cash milestone payment of \$5 million to the former EryDel shareholders in accordance with the purchase agreement entered into in connection with EryDel Acquisition.

The following table summarizes the allocation of the consideration paid for EryDel to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date, with the excess recorded to goodwill (in thousands):

- Preliminary Purchase Price Allocation Assets acquired:- Cash \$560; Tax assets 10,107; Other current assets 644; Property and equipment, net 238; Operating lease right-of-use assets, net 302; Other non-current assets 14; Intangible assets 61,096; Goodwill 16,929. Total assets acquired 20,051; Liabilities assumed: Trade payables (1,685); Accrued expenses and other current liabilities (2,943); Debt, non-current (12,564); Other non-current liabilities (854); Deferred tax liability (5,098); Total liabilities assumed (23,144); Fair value of total consideration transferred \$66,907;

The purchase price allocation is preliminary and may change as a result of additional information obtained regarding assets acquired and liabilities assumed and revisions of estimates of fair values of intangible assets and related deferred tax assets and liabilities. The Company will finalize its valuation and the allocation of the purchase price, along with required retrospective adjustments, if any, within a year following the acquisition date.

The fair value of identifiable Acquired IPR&D intangible assets was \$60.6 million. IPR&D was determined using the MPFEM under the income approach. MPFEM calculates the economic benefits by determining the income attributable to an intangible asset after the returns are subtracted for contributory assets such as working capital, assembled workforce, and fixed assets. The resulting after-tax net earnings were discounted at 16.6%, a rate commensurate with the risk inherent in the economic benefit projections of the assets. The probability-weighted, projected cash flows were calculated based on projections of revenues and expenses related to the asset and were assumed to extend through a multi-year projection period. The IPR&D has an indefinite useful life, and as such, is not amortized but rather tested for impairment at least annually.

The fair value of trade name intangible assets was \$0.5 million. The trade name intangible assets were derived using the relief from royalties method under the income approach, utilizing royalty rate of 0.3%. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The probability-weighted, net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value using a discount rate of 16.6%. The trademark has a useful life of 21 years. The trademark is amortized on a straight-line basis over the useful life.

The excess of the fair value of purchase consideration over the fair value of net tangible and identifiable intangible assets acquired was recorded as goodwill, which is primarily attributed to the assembled workforce and expanded global market opportunities. None of the goodwill is expected to be deductible for income tax purposes. Goodwill is not amortized but is tested for impairment at least annually, refer to Note 13 for this assessment.

The transaction costs associated with the acquisition were approximately \$2.5 million, of which \$2.3 million were recorded in general and administrative expenses and \$0.2 million were recorded in research and development expenses in the consolidated statement of operations and comprehensive loss.

The Company has included the financial results of EryDel in the consolidated financial statements from the date of acquisition.

– References

No definition available.

+ Details

Name:us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix:us-gaap_ Data Type:xbtrl:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-5>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org//805/tableOfContent>

+ Details

Name:us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 35 R19.htm
IDEA: XBRL DOCUMENT
Intangible Assets9 Months Ended
Sep. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract] Intangible AssetsIntangible Assets

EryDel Intangible Assets

The following table provides details of the carrying amount of the Company's indefinite-lived intangible asset (in thousands):

December 31, 2023	\$63,197	Impairment charge	Foreign currency translation adjustments	867	Balance as of September 30, 2024	\$64,064	September 30, 2024 in-process research and development: Balance as of	

The following table provides details of the carrying amount of the Company's finite-lived intangible asset (in thousands, except useful life):

					As of September 30, 2024: As of December 31, 2023: Useful life: Cost		
Accumulated Amortization: Net Carrying Value: Finite life intangible assets: Trade name 21 years \$460: \$(22) \$438: \$460: \$(4) \$456:					Impairment charge Foreign currency translation adjustments		26: 19:
Total \$(464): \$(475):							

The Company performs annual impairment reviews of its intangible assets during the fourth fiscal quarter or more frequently if appropriate. As of September 30, 2024, the Company did not incur any impairment losses related to its EryDel intangible assets.

Novosteo Intangible Assets

In January 2023, the Company decided to abandon internal development of NOV004 and pursue out-licensing opportunities. As a result, several of the assumptions used in determining the initial fair value have changed including discount rate and expected cash flows and thus triggered the need for an interim impairment assessment as required under ASC 350. And so, the Company performed a fair value assessment of the Intellectual Property as of March 31, 2023, and based upon this assessment, the fair value was determined to be significantly below its carrying value and resulted in an asset impairment charge of \$5.9 million during the nine months ended September 30, 2023.

Goodwill

As part of the EryDel Acquisition, the Company recorded goodwill, the excess of the fair value of purchase consideration over the fair value of net tangible and identifiable intangible assets acquired.

The Company evaluates goodwill at least annually, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. As of June 30, 2024, the Company performed an impairment evaluation of goodwill after assessing qualitative factors that indicated a possible impairment of goodwill.

Under the qualitative assessment, management considers relevant events and circumstances including but not limited to macroeconomic conditions, industry and market considerations, overall Company performance and events directly affecting the Company. It was noted during the assessment that the Company's market capitalization was significantly below its carrying value and a further quantitative analysis was conducted to determine to the extent, if any, the Company's carrying value exceeded its fair value as of June 30, 2024. The quantitative analysis used fair value based on market capitalization adjusted for control premium based on market comparable transactions. This quantitative analysis resulted in the Company's fair value being significantly below its carrying value, resulting in a non-cash goodwill impairment charge of \$17.1 million being recorded during the nine months ended September 30, 2024.

The following table summarizes the changes in the carrying amount of goodwill (in thousands):

		Balance as of December 31, 2023	\$17,625	Impairment charge	(17,130)
Foreign currency translation adjustments		(495)	Balance as of September 30, 2024	\$-	

- References

No definition available.

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org//350-30/tableOfContent>

+ Details

Name:us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 36 R20.htm IDEA:XBRL DOCUMENT

Subsequent Events9 Months Ended

Sep. 30, 2024

Subsequent Events [Abstract] [Subsequent Events](#)

In November 2024, the Company entered into an amendment (the "Amendment") of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment.

On the Holdback Release Date, and in accordance with the purchase agreement entered into, the Indemnity Holdback Shares were released to the EryDel shareholders. As of the Holdback Release Date, no indemnification claims were made by the Company. No further stock consideration is available for issuance and no additional shares will be issued in connection with the EryDel Acquisition.

+ References

No definition available.

+ Details

Name:us-gaap_SubsequentEventsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

+ Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI

<https://asc.fasb.org//855/tableOfContent>Reference 2:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483399/855-10-50-2>

+ Details

Name:us-gaap_SubsequentEventsTextBlock Namespace Prefix:us-gaap_ Data Type:dttr-types:textBlockItemType Balance Type:na Period Type:duration XML 37 R21.htm IDEA:XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)9 Months Ended Sep. 30, 2024

Accounting Policies [Abstract] Basis of Consolidation

Basis of Consolidation

The accompanying condensed consolidated financial statements include the accounts of Quince Therapeutics, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.

Basis of Presentation

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the instructions of the SEC on Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the management's opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.

The condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 included in the Company's Form 10-K filed with the SEC on April 1, 2024. The results of operations for the nine months ended September 30, 2024 are not necessarily indicative

of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period.

Risks and Uncertainties

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company's potential drug candidates, uncertainty of market acceptance of the Company's drug candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. The Company's drug candidates will require approvals from the FDA and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any drug candidate will receive the necessary approvals.

Risks and UncertaintiesUse of Estimates

Use of Estimates

The preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company's consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances, determination of the fair value of identifiable assets and liabilities in connection with business combinations including associated intangible assets and goodwill, contingent consideration, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets, eligibility of expenses for the Australia research and development refundable tax credits, impairment of intangible assets, including goodwill, and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily

apparent from other sources. Actual results could differ materially from the Company's estimates.

Foreign Currency Translation and Transactions

Foreign Currency Translation and Transactions

The functional currency of the Company's wholly owned subsidiaries are the Euro and Australian Dollar. The Company's financial results and financial position are translated into U.S. dollars using exchange rates at balance sheet dates for assets and liabilities and using average exchange rates for income and expenses. The resulting translation differences are presented as a separate component of accumulated other comprehensive loss, as a separate component of equity.

Foreign currency transactions are translated into the functional currencies using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses, resulting from the settlement of such transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies using exchange rates at balance sheet date and non-monetary assets and liabilities using historical exchange rates, are recognized in the

condensed consolidated statements of operations and comprehensive loss.

Segments

Segments

The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing therapeutics. The Company's chief executive officer, who is the chief operating

decision maker, reviews financial information on an aggregate basis for purposes of allocating and evaluating financial performance. All long-lived assets are maintained in Italy.

Business Combinations

Business Combinations

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business.

The Company accounts for business combinations using the acquisition method pursuant to the FASB ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company's financial results beginning on the respective acquisition dates, and that identifiable assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using one of three valuation approaches: the income approach, the market approach or the cost approach. The Company reviewed the three valuation approaches and determined the income approach was the most appropriate model to approximate fair value for the EryDel Acquisition. The income approach model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the "Purchase Price") over the fair values of the net assets acquired is recognized as goodwill. The fair value of identifiable assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence

costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible Assets

Intangible Assets

Definite-lived Intangible Assets

Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. The Company regularly reviews whether current conditions or events suggest that the carrying values of its acquired definite-lived intangible assets might not be recoverable. When such conditions are identified, an estimate of the undiscounted future cash flows from these assets, or relevant asset groupings, is compared to their carrying value to determine if an impairment exists. If an impairment is identified, the loss is calculated as the difference between the

carrying value of the intangible asset and its fair value, which is based on the net present value of the estimated future cash flows.

Indefinite-lived Intangible Assets

Intangible assets with an indefinite useful life are not amortized. Intangible assets acquired in a business combination or an acquisition that are used in research and development activities (regardless of whether they have an alternative future use) shall be considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Intangible assets acquired in a business combination are initially recorded at fair value. During the period that those assets are considered indefinite-lived, they shall not be amortized but shall be tested for impairment. Once the research and development efforts are completed or abandoned, the entity shall determine the useful life of the assets. An indefinite-lived intangible asset shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the intangible asset. Qualitative factors to be considered include but are not limited to:

- Cost factors such as increases in raw materials, labor, or other costs that have a negative effect on future expected earnings and cash flows
- Legal/regulatory factors or progress and results of clinical trials
- Other relevant entity-specific events such as changes in management, key personnel, strategy, or customers; contemplation of bankruptcy; or litigation that could affect significant inputs used to determine the fair value of the

indefinite-lived intangible asset

- ± Industry and market considerations such as a deterioration in the environment in which an entity operates, an increased competitive environment
- ± Macroeconomic conditions such as deterioration in general economic conditions, limitations on accessing capital, fluctuations in foreign exchange rates, or other developments in equity and credit markets that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.

During the nine months ended September 30, 2024, the Company recognized a non-cash goodwill impairment charge of \$17.1 million as the quantitative analysis resulted in the Company's fair value being significantly below its carrying value during the three months ended June 30, 2024.

Contingent Consideration

months ended September 30, 2024, the Company recorded a net \$2.1 million adjustment to increase the fair value of its contingent consideration related to the acquisition of EryDel. The adjustment is reflected within operating loss on the consolidated statement of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations may result from changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Significant increases or decreases in the inputs noted above in isolation would result in a significantly lower or higher fair value measurement.

Contingent Consideration

The Company determines the acquisition date fair value of contingent consideration using a discounted cash flow method, with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC Topic 820, Fair Value Measurement. The significant inputs in the Level 3 measurement not supported by market activity included our probability assessments of expected future cash flows related to the Company's acquisition of EryDel in October 2023, during the contingent consideration period, appropriately discounted considering the uncertainties associated with the earnout obligation, and calculated in accordance with the terms of the definitive agreement. The liabilities for the contingent consideration are established at the time of the acquisition and will be evaluated on a quarterly basis based on additional information as it becomes available. Any change in the fair value adjustment is recorded in the earnings of that period. During the three months ended September 30, 2024, the Company recorded a \$2.7 million adjustment to decrease the fair value of its contingent consideration related to the acquisition of EryDel. During the nine

Cash, Cash Equivalents and Investments

Cash, Cash Equivalents and Investments

The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash equivalents include marketable securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as short-term investments. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term investments. Collectively, cash equivalents, short-term investments and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded as a component of other comprehensive loss in the consolidated statements of operations and included as a separate component of consolidated statements of stockholders' equity (deficit). Realized gains and losses are included in interest income in the consolidated statements of operations and comprehensive loss.

Premiums (discounts) are amortized (accrued) over the life of the related investment as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. These amounts are recorded in "interest income" in the consolidated statements of operations and comprehensive loss.

Recent Accounting Pronouncements Not Yet Adopted

Recent Accounting Pronouncements Not Yet Adopted

The following are new accounting pronouncements that the Company is evaluating for future impacts on its financial statements:

Improvements to Income Tax Disclosures (ASC 740): In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." This ASU establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Under this ASU, entities must consistently categorize and provide greater disaggregation of information in the rate reconciliation. They must also further disaggregate income taxes paid. The ASU is effective beginning after December 2024 under a prospective approach. Early adoption is permitted. The Company is evaluating the disclosure requirements related to the new standard.

Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). In November 2023, the FASB issued ASU 2023-07, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.

All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.

Definition

Risks and uncertainties.

+ References

No definition available.

+ Details

Name:qncx_RisksAndUncertaintiesPolicyTextBlock Namespace Prefix:qncx_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:xbkli:stringItemType Balance Type:na Period Type:duration

Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name:us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix:us-gaap_ Data

~~Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 05 -Paragraph 4 -Subparagraph (a)-(d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479515/805-10-05-4>~~

~~+ Details~~

~~Name:us-gaap_BusinessCombinationsPolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482913/230-10-50-1>~~

~~+ Details~~

~~Name:us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the~~

consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483426/235-10-50-4>
Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481203/810-10-50-1>

+ Details

Name:us-gaap_ConsolidationPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(13)(b)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>
Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(19)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>

+ Details

Name:us-gaap_ContingentLiabilityReserveEstimatePolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org//830/tableOfContent>

+ Details

Name:us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482548/350-20-55-24>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI <https://asc.fasb.org//350-20/tableOfContent>

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 30 -Topic 350 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482665/350-30-50-1>

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name:us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for segment reporting.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482785/280-10-55-47>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-29>Reference 3:

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482810/280-10-50-41>Reference 4:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482810/280-10-50-29>Reference 5:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482810/280-10-50-29>Reference 6:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482810/280-10-50-29>Reference 7:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482810/280-10-50-29>Reference 8:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482810/280-10-50-29>~~

+ Details

Name:us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482861/275-10-50-9>

Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482861/275-10-50-4>

Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482861/275-10-50-1>

Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482861/275-10-50-1>

Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482861/275-10-50-11>

Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482861/275-10-50-12>

Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482861/275-10-50-8>

[+ Details](#)

~~Name:us-gaap_UseOfEstimates Namespace Prefix:us-gaap_ Data Type:
dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 38 R22.htm IDEA:
XBRL DOCUMENT
Fair Value Measurements (Tables)9 Months Ended
Sep. 30, 2024~~

Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September 30, 2024 and December 31, 2023 are presented in the following tables (in thousands):

Assets: Money market funds \$4,205, \$4,205, \$- \$- Certificates of Deposit 729, 729, Government and agency notes 60,524, 3,971, 64,553, Total Assets \$73,530, \$0,256, \$65,202, Liabilities Contingent consideration 57,706, 57,706, Long-term debt 13,429, 13,429, Total \$(71,135), \$(71,135), **Schedule of Fair Value, Liabilities Measured**

The following table reflects the changes in present value of acquisition related accrued earnouts of contingent consideration liability using significant unobservable inputs (Level 3) for the nine months ended September 30, 2024:

- (in thousands) Beginning Balance as of January 1, 2024 \$57,706 Payout of contingent earnout based on milestone achievement (5,000) Change in fair value of contingent consideration 2,062 Ending Balance as of September 30, 2024 \$54,768

The following table presents the changes in the fair value of the Level 3 EIB Loan for the nine months ended September 30, 2024:

The following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition-related accrued earnout as of September 30, 2024 (in thousands except for percentages):

Contingent consideration \$54,788 - Expected present value - Probability of achieving earnout objectives per the purchase agreement

0% - 100%

The following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition-related long term debt as of September 30, 2024 (in thousands except for percentages):

FIB loan 514-899- Expected present value- Credit quality of company and credit spreads for comparable debt

~~13%~~

Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name> Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb) -SubTopic 10 -Topic 820 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>

Name:us-gAAP_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuation
Namespace Prefix:us-gAAP_ Data Type:dtr-types:textBlockItemType Balance Type:na Period
Type:duration

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2)
Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2)

+ Details

Name:us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbtli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-3>

+ Details

Name:us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliation
Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period
Type:duration XML 39 R23.htm IDEA: XBRL DOCUMENT
Cash, Cash Equivalents and Investments (Tables)9 Months Ended
Sep. 30, 2024

Fair Value Disclosures [Abstract] Schedule of Fair Values of Cash, Cash Equivalents, and
Short-Term Investments Measured at Fair Value on Recurring Basis

The following tables categorize the fair values of cash, cash equivalents and investments measured at fair value on a recurring basis on our balance sheets (in thousands):

September 30, 2024 December 31, 2023 Cash and cash equivalents: Cash \$ 1,678; \$1,521; Money market funds \$997; \$4,285; Government and agency notes —; \$4,946; Total cash and cash equivalents \$2,675; \$20,752; Short-term investments: Certificates of deposit \$ —; \$729; Government and agency notes \$5,172; \$3,528; Total short-term investments \$5,172; \$54,307; Schedule of Available-for-Sale Securities

The following table summarizes the available-for-sale securities (in thousands):

Unrealized Gains
Unrealized Losses
Fair Value Money market funds \$997; \$ —; \$ —; \$997; Government and agency notes \$45,013; \$159; \$ —; \$46,169; Total cash equivalents and investments \$46,010; \$159; \$ —; \$46,169; Classified as: Cash equivalents (original maturities within 90 days) \$997; Short-term investments (maturities within one year) \$45,172; Total cash equivalents and investments \$46,169; Fair Value Measurements as of September 30, 2024 - Amortized Cost

Amortized Cost
Unrealized Gains
Unrealized Losses
Fair Value Money market funds \$4,285; \$ —; \$ —; \$4,285; Certificates of Deposit \$735; \$ —; \$ —; \$735; Government and agency notes \$68,528; \$13; \$13; \$68,541; Total cash equivalents and investments \$73,548; \$13; \$13; \$73,538; Fair Value Measurements as of December 31, 2023

Classified as: Cash equivalents (original maturities within 90 days) \$19,231; Short-term investments (maturities within one year) \$4,307; Total: \$23,538;

- Definition

Schedule of cash, cash equivalents, and investments.

+ References

No definition available.

+ Details

Name:qncx_ScheduleOfCashCashEquivalentsAndInvestmentsTableTextBlock Namespace Prefix:
qncx_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of investment in debt security measured at fair value with change in
fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-9](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-9)Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-3>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(aa\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (aa)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(aaa\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (aaa)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2)Reference 9: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2)

~~Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 10:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 11:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 12:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147481800/320-10-50-3~~

[+ Details](#)

Name:us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix:us-gaap_

~~Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~--References~~

~~No definition available.~~

~~+Details~~

~~Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbnli:stringItemType Balance Type:na Period Type:duration XML 40 R24.htm IDEA: XBRL DOCUMENT~~

~~Balance Sheet Components (Tables)9 Months Ended Sep. 30, 2024~~

~~Balance Sheet Components [Abstract] Schedule of Prepaid Expenses and Other Current Assets~~

~~Prepaid expenses and other current assets consist of the following (in thousands):~~

~~expenses\$1,415: \$133:Short-term Italian research and development refundable tax credit\$995: 993: Prepaid insurance\$41: 809: Prepaid expenses\$65: 365: Other current assets\$5: 81: Total prepaid expenses and other current assets (\$3,873): (\$2,381):~~

~~Schedule of Other Assets~~

~~Other assets consisted of the following (in thousands):~~

~~September 30, 2024 December 31, 2023 Long-term Italian research and development refundable tax credit\$4,074: \$4,993: VAT receivable\$5,354: 3,463: Equity investments in Lighthouse Pharmaceuticals, Inc.: 78: 78: Assets held for sale— 10: Total other assets\$9,506: (\$8,544):~~

~~Schedule~~

~~of Property and Equipment, Net~~

~~Property and equipment, net consist of the following (in thousands):~~

~~September 30, 2024 December 31, 2023 Computer equipment\$38: \$36: Computer Software\$0: 30: Lab equipment\$534: 486: Leasehold improvement\$6: 36: Office furniture\$237: 153: Less: accumulated amortization and depreciation (\$667) (\$507) Property and equipment, net\$208: (\$234):~~

~~Schedule of~~

~~Accrued Expenses and Other Current Liabilities~~

~~Accrued expenses and other current liabilities consist of the following (in thousands):~~

~~September 30, 2024 December 31, 2023 Personnel expenses\$2,301: \$2,240: Research and development expenses\$1,063: 564: Professional fees\$140: 211: Current portion of operating lease liabilities\$01: 64: Other\$198: 257: Total accrued expenses and other current liabilities\$3,803: (\$3,436):~~

~~Schedule of Accrued Severance and Related Expenses~~

~~For the nine months ended September 30, 2024 and 2023, the severance accrual activity were as follows (in thousands):~~

~~2024 2023 Beginning accrued severance\$341: \$—: Incurred during the period\$1: 770: Severance paid during the period (\$382) (\$309) Ending accrued severance\$—: (\$461):~~

~~--Definition~~

~~Balance sheet components.~~

~~+References~~

~~No definition available.~~

~~+Details~~

~~Name:qncx_BalanceSheetComponentsAbstract Namespace Prefix:qncx_ Data Type:xbnli:stringItemType Balance Type:na Period Type:duration~~

~~--Definition~~

~~Schedule of prepaid expenses and other current assets.~~

~~+References~~

~~No definition available.~~

~~+Details~~

~~Name:qncx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock Namespace Prefix:qncx_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~--Definition~~

~~Tabular disclosure of accrued severance.~~

~~+References~~

~~No definition available.~~

~~+Details~~

~~Name:qncx_SummaryOfAccruedSeveranceTableTextBlock Namespace Prefix:qncx_ Data Type:~~

~~dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482099/360-10-50-1>~~

~~+ Details~~

~~Name:us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Tabular disclosure of the components of accrued liabilities.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfOtherAssetsTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 41 R25.htm IDEA: XBRL DOCUMENT~~

~~Leases (Tables)9 Months Ended~~

~~Sep. 30, 2024~~

~~Leases [Abstract] [Schedule of Supplemental Balance Sheet Information Related to Leases](#)~~

~~Supplemental balance sheet information related to leases as follows (in thousands except lease terms and discount rates):~~

~~asset.net\$559, \$385. **Liabilities:** Short-term operating lease liability101, 64 Long-term operating lease liability450, 321. Total lease liabilities\$551, \$385. ¹Other information: Weighted average remaining lease term 4.9 years 5.4 years Weighted average discount rate 2.11.% 2.95.% [Schedule of Future Minimum Lease Payments Under Lease Agreements](#)~~

~~Future minimum lease payments under lease agreements as of September 30, 2024, were as follows (in thousands):~~

~~Fiscal Year 2024 (remainder of the year)\$35, 2025140, 2026136, 2027130, 2028~~

~~and thereafter214. Total lease payments655. Less: imputed interest (104) Total remaining lease liability\$551.~~

~~-- Definition~~

~~Supplemental balance sheet information related to leases.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:qncx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock Namespace Prefix:qncx_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6~~

~~+ Details~~

~~Name:us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~-- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_LeasesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 42 R26.htm IDEA: XBRL DOCUMENT Stock-Based Compensation (Tables)9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Schedule of Stock Options Activity~~

~~Activity for service-based stock options under the Quince 2019 Plan is as follows:~~

Number of Options and Unvested Shares Weighted Average Exercise Price Weighted average remaining contractual life (years) Aggregate intrinsic value - - - (in thousands) Balance as of December 31, 2023 4,267,178 \$5.00 8.85 \$197 Options granted 3,602,500 1.26 - - - Options exercised (155,311) 0.93 - 65 Options cancelled / forfeited (165,861) 13.06 - - - Balance as of September 30, 2024 7,548,506 \$3.12 8.72 \$5 Options vested and expected to vest as of September 30, 2024 7,548,506 3.12 8.72 5 Options exercisable as of September 30, 2024 2,062,912 \$7.86 7.76 \$	

~~Activity for service-based stock options under the 2019 Novosteo Plan is as follows:~~

Number of Options and Unvested Shares Weighted Average Exercise Price Weighted average remaining contractual life (years) Aggregate intrinsic value - - - (in thousands) Balance as of December 31, 2023 310,431 \$0.55 8.23 \$155 Options granted - - - Options exercised (146,592) 0.55 - 94 Options cancelled / forfeited - - - Balance as of September 30, 2024 163,839 \$0.55 7.48 \$37 Options vested and expected to vest as of September 30, 2024 163,839 0.55 7.48 37 Options exercisable as of September 30, 2024 47,426 \$0.55 7.48 \$11	

~~Activity for service-based stock options under the 2022 Inducement Plan is as follows:~~

Number of Options and Unvested Shares Weighted Average Exercise Price Weighted average remaining contractual life (years) Aggregate intrinsic value - - - (in thousands) Balance as of December 31, 2023 2,333,306 \$2.98 8.40 - Options granted - - - Options exercised - - - Options cancelled / forfeited - - - Balance as of September 30, 2024 2,333,306 \$2.98 7.65 - Options vested and expected to vest as of September 30, 2024 2,333,306 2.98 7.65 - Options exercisable as of September 30, 2024 1,361,094 \$2.98 7.65 -	

~~Aggregate intrinsic value - - - (in thousands) Balance as of December 31, 2023 2,333,306 \$2.98 8.40 - Options granted - - - Options exercised - - - Options cancelled / forfeited - - - Balance as of September 30, 2024 2,333,306 \$2.98 7.65 - Options vested and expected to vest as of September 30, 2024 2,333,306 2.98 7.65 - Options exercisable as of September 30, 2024 1,361,094 \$2.98 7.65 -~~ [Schedule of Nonvested Restricted Stock Shares Activity](#)

~~The following table summarizes activity under the Company's RSUs from the Quince 2019 Plan and related information:~~

~~Number of Shares-Weighted Average Grant Date Fair Value Unvested-December 31, 2023-1,488 \$4.30 RSUs granted -- -- RSUs vested (1,488) 4.30 RSUs cancelled -- -- Unvested-September 30, 2024:--(\$--)~~
~~Restricted Stock Awards~~

~~Number of Shares-Weighted Average Grant Date Fair Value Unvested-December 31, 2023-175,763 \$3.30 RSAs granted -- -- RSAs vested (73,010) 3.30 RSAs cancelled -- -- Unvested-September 30, 2024:102,753 \$3.30~~

~~Schedule of Employee and Non-Employee Stock-Based Compensation Expense~~

~~The following table summarizes employee and non-employee stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 and the allocation within the condensed consolidated statements of operations and comprehensive loss (in thousands):~~

~~Three Months Ended September 30, Nine Months Ended September 30, 2024-2023-~~

~~2024-2023 General and administrative expense \$706- \$945- \$3,096- \$3,014- Research and development expense 338- 386- 525- 1,120- Total stock-based compensation \$1,124- \$1,331- \$3,621- \$4,134-~~

~~References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace~~

~~Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration~~

~~Definition~~

~~Tabular disclosure of the changes in outstanding nonvested restricted stock shares.~~

~~References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Subparagraph (c) -Paragraph 2 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2~~

~~+ Details~~

~~Name:us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock Namespace Prefix:~~

~~us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~Definition~~

~~Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.~~

~~References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriod~~

~~Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

~~Definition~~

~~Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.~~

~~+ References~~

~~Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (c)(1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)~~

~~+ Details~~

~~Name:us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 43 R27.htm IDEA: XBRL DOCUMENT Long-term Debt (Tables)9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] [Schedule of Future minimum principal payments](#)~~

~~Future minimum principal payments, as of September 30, 2024 are as follows (in thousands):~~

	Quarter ended September 30, 2024	Amount 2024 \$	2025	2026	11,190	2027
and thereafter	Total future payments	11,190	Imputed interest and fair value adjustments	2,709	Total Debt as of September 30, 2024	\$14,899

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_DebtDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbtli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Tabular disclosure of maturity and sinking fund requirement for long-term debt.~~

[+ References](#)

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481544/470-10-50-1>~~

[+ Details](#)

~~Name:us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 44 R28.htm IDEA: XBRL DOCUMENT Net Loss Per Share (Tables)9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] [Schedule of Computation of Basic and Diluted Net Loss Per Share](#)~~

~~Basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average common shares outstanding during the period, as follows (net loss in thousands):~~

	2024	2023
Numerator: Net loss	\$(5,492)	\$(5,351)
Denominator: Weighted-average common shares outstanding	43,164,136	36,073,040
Net loss per share, basic and diluted	\$(0.13)	\$(0.15)

~~Schedule of Outstanding Potentially Dilutive Ordinary Shares Excluded from Calculation of Diluted Net Loss Per Share~~

~~The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented because including them would have been antidilutive:~~

	September 30, 2024	2023
Stock options issued and outstanding	10,045,651	7,469,163
Restricted stock units	2,975	102,753
Restricted stock awards	200,099	102,753
Total	10,148,404	7,672,237

[- References](#)

~~No definition available.~~

[+ Details](#)

~~Name:us-gaap_EarningsPerShareAbstract Namespace Prefix:us-gaap_ Data Type:xbtrl:stringItemType Balance Type:na Period Type:duration~~

[- Definition](#)

~~Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.~~

[+ References](#)

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482662/260-10-50-1>~~

[+ Details](#)

~~Name:us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTe Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration~~

[- Definition](#)

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482662/260-10-50-1)

+ Details

Name:us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 45 R29.htm IDEA: XBRL DOCUMENT

Business Combination (Tables) 9 Months Ended Sep. 30, 2024

Business Combination and Asset Acquisition [Abstract] Schedule of Fair Value of the Total Purchase Consideration Transferred

The acquisition date fair value of the consideration transferred for EryDel was approximately \$66.9 million, which consisted of the following (in thousands):

: Fair Value of Consideration Cash\$2,615'

Quince Therapeutics common stock (7,250,352 shares)7,164; Contingent consideration56,128; Settlement of preexisting notes receivable1,000; Fair value of total consideration transferred\$66,907; Schedule of Fair Values of Assets Acquired and Liabilities Assumed

The following table summarizes the allocation of the consideration paid for EryDel to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date, with the excess recorded to goodwill (in thousands):

10,107; Other current assets644; Property and equipment-net238; Operating lease right-of-use assets-net383; Other non-current assets14; Intangible assets61,086; Goodwill16,929; Total assets acquired90,051; Liabilities assumed: Trade payables(1,685); Accrued expenses and other current liabilities(2,943); Debt, non-current(12,564); Other non-current liabilities(854); Deferred tax liability(5,090); Total liabilities assumed(23,144); Fair value of total consideration transferred\$66,907;

- References

No definition available.

+ Details

Name:us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.

+ References

No definition available.

+ Details

Name:us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition

date; and (c) the fair value of noncontrolling interests in the acquiree.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 805-SubTopic 20-Name Accounting Standards Codification-Paragraph 1-Section 50-Publisher FASB-URI https://asc.fasb.org//1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextB Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 46 R30.htm IDEA: XBRL DOCUMENT Intangible Assets (Tables)9 Months Ended Sep, 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Carrying Amount of Indefinite-Lived Intangible Asset

The following table provides details of the carrying amount of the Company's indefinite-lived intangible asset (in thousands):

		- September 30, 2024 in-process research and development: -		Balance as of
December 31, 2023	\$63.197	Impairment charge	Foreign currency translation adjustments	867
		Balance as of September 30, 2024		\$64.064

The following table provides details of the carrying amount of the Company's finite-lived intangible asset (in thousands, except useful life):

Accumulated Amortization- Net Carrying Value Cost		As of September 30, 2024: As of December 31, 2023: Useful life Cost	
Accumulated Amortization- Net Carrying Value Finite-life intangible assets:		Trade name 21 years	\$460: \$(22) \$438: \$460: \$(4) \$456
Total		Impairment charge	Foreign currency translation adjustments 26 19

The following table summarizes the changes in the carrying amount of goodwill (in thousands):

		Balance as of December 31, 2023	\$17.625	Impairment charge	(17.130)
Foreign currency translation adjustments		(495)			
		Balance as of September 30, 2024		\$-	

- References

No definition available.

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xblli:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 350-SubTopic 30-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482665/350-30-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 350-SubTopic 30-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482665/350-30-50-1)
Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 350-SubTopic 30-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 350-SubTopic 30-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2)

+ Details

Name:us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482548/350-20-55-24>

Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 7: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 9: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1A>

Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-2>

+ Details

Name:us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix:us-gaap_ Data Type:
dtr-types:textBlockItemType Balance Type:na Period Type:duration

-- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482665/350-30-50-2>Reference 2:
<http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b), (d) -SubTopic 30 -Topic 350 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482665/350-30-50-3>

+ Details

Name:us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 47 R31.htm IDEA: XBRL DOCUMENT

<u>Organization (Details) € in Thousands,</u>	<u>Nov. 13,</u>	<u>Nov. 13,</u>	<u>Sep. 30,</u>	<u>Sep. 30,</u>	<u>Dec. 31,</u>
<u>\$ in Thousands</u>	<u>2024</u>	<u>2024</u>	<u>2024</u>	<u>2024</u>	<u>2023</u>
	<u>USD (\$)</u>	<u>EUR (€)</u>	<u>USD (\$)</u>	<u>EUR (€)</u>	<u>USD (\$)</u>
<u>Line of Credit Facility [Line Items]</u>					
<u>Accumulated deficit</u>	\$ 364,014		\$ 319,644		
<u>Cash, cash equivalents, and short-term investments</u>	47,800		14,899		\$ 13,429
<u>Line of Credit / EIB loan</u>					
<u>Long-term debt</u>					
<u>11,200€ 10,000 Minimum cash balance</u>	\$ 16,400	€ 14,650			
<u>Line of Credit / EIB loan / Subsequent Event</u>					
<u>Line of Credit Facility [Line Items]</u>					
<u>Percentage of deferred interest converted</u>	2.00%	2.00%	9.00%	9.00%	
<u>Deferred interest percent</u>					
<u>Payment of one-time amendment fee</u>	\$ 20€ 20				

- Definition

Debt Instrument, Covenant, Minimum Required Cash Balance

+ References

No definition available.

+ Details

Name:gncx_DebtInstrumentCovenantMinimumRequiredCashBalance Namespace Prefix:gncx_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Debt Instrument, Deferred Interest Percent

+ References

No definition available.

+ Details

Name:gncx_DebtInstrumentDeferredInterestPercent Namespace Prefix:gncx_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Debt Instrument, Percentage Of Deferred Interest Converted

+ References

No definition available.

+ Details

Name:gncx_DebtInstrumentPercentageOfDeferredInterestConverted Namespace Prefix:gncx_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of

cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>

+ Details

Name:us-gaap_LineOfCreditFacilityLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name

~~Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI
https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 3:
http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting
Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI
https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 4:
http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting
Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 5:
http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name
Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-
03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-
S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -
Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX
210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-
1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name
Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -
Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4~~

+ Details

Name:us-gaap_LongTermDebt Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType
Balance Type:credit Period Type:instant

- Definition

The cash outflow for loan and debt issuance costs.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-15>

+ Details

Name:us-gaap_PaymentsOffFinancingCosts Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480016/944-40-65-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480990/946-20-50-11>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-

~~04(17)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479617/946-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480008/505-10-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

[+ Details](#)

~~Name:us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

[-- Details](#)

~~Name:us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type:~~

[-- Details](#)

~~Name:us-gaap_DebtInstrumentAxis=qncx_EuropeanInvestmentBankLoanMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

[-- Details](#)

~~Name:us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 48 R32.htm IDEA: XBRL DOCUMENT~~

~~Summary of Significant Accounting Policies (Details) \$ in~~

	~~3 Months Ended~~	~~9 Months Ended~~

~~Thousands~~

~~Sep. 30, 2024~~

~~USD (\$)~~

~~Sep. 30, 2023~~

~~USD (\$)~~

~~Sep. 30, 2024~~

~~USD (\$)~~

~~segment~~

~~Sep. 30, 2023~~

~~USD (\$)~~

~~Accounting Policies [Abstract] Number of reportable segment / segment 1 Number of operating segment / segment 1 Impairment charge / \$ \$ 0\$ 0\$ 17,130\$ 0Fair value adjustment for contingent consideration / \$ \$ (2,683)\$ 0\$ 2,082\$ 0~~

[-- Definition](#)

~~Represents the amount of fair value adjustment for contingent consideration during the period.~~

[+ References](#)

~~No definition available.~~

[+ Details](#)

~~Name:qncx_FairValueAdjustmentForContingentConsideration Namespace Prefix:qncx_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

[-- References](#)

~~No definition available.~~

[+ Details](#)

~~Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:~~

xbli:stringItemType Balance Type:na Period Type:duration

--Definition

Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>
Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482548/350-20-55-24>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-2>
Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482598/350-20-45-2>

+ Details

Name:us-gaap_GoodwillImpairmentLoss Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-18>

+ Details

Name:us-gaap_NumberOfOperatingSegments Namespace Prefix:us-gaap_ Data Type: xbrli:integerItemType Balance Type:na Period Type:duration

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-18>

+ Details

Name:us-gaap_NumberOfReportableSegments Namespace Prefix:us-gaap_ Data Type: xbrli:integerItemType Balance Type:na Period Type:duration XML 49 R33.htm IDEA: XBRL DOCUMENT Fair Value Measurements - Additional Information (Details) \$ in Millions3 Months Ended Sep. 30, 2024 USD (\$)

Ery Del Business Acquisition [Line Items] Payment for contingent consideration\$ 5
- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-5>

+ Details

Name:us-gaap_BusinessAcquisitionLineItems Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (d) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-13>

+ Details

Name:us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Details

Name:us-gaap_BusinessAcquisitionAxis=qncx_EryDelMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 50 R34.htm IDEA: XBRL DOCUMENT
Fair Value Measurements - Schedule of Financial Assets and Liabilities Sep. 30, Dec. 31, (Details) - USD (\$) \$ in Thousands

	2024	2023
Assets: Debt securities, fair value	\$ 46,169	\$ 73,538
Total	46,169	73,538
Liabilities: Contingent consideration	54,788	57,706
Long-term debt	14,899	13,429
Total	69,687	71,135
Money market funds		
Assets: Debt securities, fair value	9974,285	
Certificates of deposit		
Assets: Debt securities, fair value	729	
Government and agency notes		
Assets: Debt securities, fair value	45,172	68,524
Level 1		
Assets: Total	9978,256	
Liabilities: Contingent consideration	00	
Long-term debt	00	
Total	00	
Level 1 Money market funds		
Assets: Debt securities, fair value	9974,285	
Level 1 Certificates of deposit		
Assets: Debt securities, fair value	0	
Level 1 Government and agency notes		
Assets: Debt securities, fair value	03,971	
Level 2		
Assets: Total	45,172	65,282
Liabilities: Contingent consideration	00	
Long-term debt	00	
Total	00	
Level 2 Money market funds		
Assets: Debt securities, fair value	00	
Level 2 Certificates of deposit		
Assets: Debt securities,		

~~fair value 729Level 2 | Government and agency notes Assets: Debt securities, fair value45,17264,553Level 3 Assets: Total00Liabilities: Contingent consideration54,788 57,706Long-term debt14,89913,429Total69,68771,135Level 3 | Money market funds Assets: Debt securities, fair value00Level 3 | Certificates of deposit Assets: Debt securities, fair value 0Level 3 | Government and agency notes Assets: Debt securities, fair value\$ 0\$ 0~~
~~- Definition~~

~~Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>~~

~~+ Details~~

~~Name:us-gaap_AssetsFairValueDisclosure Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481830/320-10-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479130/326-30-45-1>~~

+ Details

Name:us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479581/805-30-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479668/805-30-25-6>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479613/805-30-35-1>

+ Details

Name:us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69B-Publisher FASB-URI> <https://asc.fasb.org//1943274/2147481568/470-20-55-69B>
Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69C-Publisher FASB-URI> <https://asc.fasb.org//1943274/2147481568/470-20-55-69C>
Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1D-Subparagraph \(c\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1D-Subparagraph (c)-Publisher FASB-URI) <https://asc.fasb.org//1943274/2147481139/470-20-50-1D>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI> <https://asc.fasb.org//1943274/2147482907/825-10-50-10>

+ Details

Name:us-gaap_DebtInstrumentFairValue Namespace Prefix:us-gaap Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Fair value of financial and nonfinancial obligations.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) - Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2

+ Details

Name:us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix:us-gaap Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_LiabilitiesFairValueDisclosureAbstract Namespace Prefix:us-gaap Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecurities Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type:na Balance Type: Period Type:

- Details

Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type:na Balance Type: Period Type: XML 51 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Changes in Present Value of Acquisition Related Accrued Earnouts of Contingent Consideration Liability (Details) - USD (\$) \$ in Thousands

	3	9
	Months	Months
	Ended	Ended
Sep. 30, 2024		
Sep. 30, 2023		
Sep. 30, 2024		

Sep. 30, 2023

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Payout of contingent earnout based on milestone achievement\$ (5,000) Change in fair value of contingent consideration(2,683)\$ 0\$ 2,082 \$ 0Level 3 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Beginning Balance as of January 1, 2024 57,706 Ending Balance as of September 30, 2024\$ 54,788 \$ 54,788
- Definition

Represents the amount of fair value adjustment for contingent consideration during the period.

+ References

No definition available.

+ Details

Name:qncx_FairValueAdjustmentForContingentConsideration Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliation Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>

+ Details

Name:us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabi Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>~~

~~+ Details~~

~~Name:us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiab: Namespace Prefix:us-gaap_ Data Type:xbtli:monetaryItemType Balance Type:credit Period Type:instant~~

~~+ Details~~

~~Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type:na Balance Type: Period Type: XML 52 R36.htm IDEA: XBRL DOCUMENT~~

~~Fair Value Measurements - Schedule of Quantitative Information about Fair Value Sep. 30, 2024 Measurements (Details) \$ in Thousands USD (\$)~~

~~Contingent consideration Schedule Of Available For Sale Securities [Line Items] Fair value measurements\$ 54,788Contingent consideration / Minimum Schedule Of Available For Sale Securities [Line Items] Input used0Contingent consideration / Maximum Schedule Of Available For Sale Securities [Line Items] Input used1EIB loan Schedule Of Available For Sale Securities [Line Items] Fair value measurements\$ 14,899Input used0.13~~

~~+ Definition~~

~~Value of input used to measure contingent consideration liability from business combination.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>~~

~~+ Details~~

~~Name:us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Namespace Prefix:us-gaap_ Data Type:xbtli:decimalItemType Balance Type:na Period Type: instant~~

~~+ Definition~~

~~Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -SubTopic 10 -Topic 820 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>~~

+ Details

Name:us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiab
Namespace Prefix:us-gaap_ Data Type:xbrl:monetaryItemType Balance Type:credit Period
Type:instant

+ Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 3:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 4:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 5:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 6:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 7:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 8:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>Reference 9:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>Reference 10:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>Reference 11:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>Reference 12:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>

[+ Details](#)

~~Name:us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix:us-gaap_
Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

[- Details](#)

~~Name:us-gaap_FinancialInstrumentAxis=gncx_ContingentConsiderationMember Namespace
Prefix: Data Type:na Balance Type: Period Type:~~

[- Details](#)

~~Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type:
Period Type:~~

[- Details](#)

~~Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type:
Period Type:~~

[- Details](#)

~~Name:us-gaap_FinancialInstrumentAxis=gncx_EuropeanInvestmentBankLoanMember Namespace
Prefix: Data Type:na Balance Type: Period Type: XML 53 R37.htm IDEA: XBRL DOCUMENT
Fair Value Measurements - Schedule of Fair Value of the Level 3 EIB Debt 9 Months
(Details) \$ in Thousands Ended
Sep. 30, 2024
USD (\$)
Debt Instrument, Fair Value [Roll Forward] Beginning Balance as of January 1, 2024
\$ 13,429Ending Balance as of September 30, 202414,899Level 3 Debt Instrument, Fair Value
[Roll Forward] Beginning Balance as of January 1, 202413,429Change in fair value1,252Due~~

to foreign currency translation²¹⁸Ending Balance as of September 30, 2024\$ 14,899

- Definition

Change in fair value disclosure.

+ References

No definition available.

+ Details

Name:qncx_ChangeInFairValueDisclosure Namespace Prefix:qncx Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Debt instrument fair value due to foreign currency translation.

+ References

No definition available.

+ Details

Name:qncx_DebtInstrumentFairValueDueToForeignCurrencyTranslation Namespace Prefix:qncx Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Debt Instrument, Fair Value

+ References

No definition available.

+ Details

Name:qncx_DebtInstrumentFairValueRollForward Namespace Prefix:qncx Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481568/470-20-55-69B>
Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481568/470-20-55-69C>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1D>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482907/825-10-50-10>

+ Details

Name:us-gaap_DebtInstrumentFairValue Namespace Prefix:us-gaap Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Details

Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type:na Balance Type: Period Type: XML 54 R38.htm IDEA: XBRL DOCUMENT

Cash, Cash Equivalents and Investments - Schedule of Fair Values of Cash, Sep, Dec, Cash Equivalents, and Short-Term Investments Measured at Fair Value on 30, 31, Recurring Basis (Details) - USD (\$) \$ in Thousands 2024 2023

<u>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>\$ 46,169</u>	<u>\$ 73,538</u>	<u>Total</u>	<u>46,169</u>	<u>73,538</u>
<u>Cash and Cash Equivalents Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>997</u>	<u>19,231</u>	<u>Short-Term Investments Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>45,172</u>
<u>Money market funds Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>997</u>	<u>4,285</u>	<u>Government and agency notes Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>45,172</u>
<u>Certificates of deposit Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>729</u>	<u>Fair Value on Recurring / Cash and Cash Equivalents Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Total</u>	<u>2,675</u>	<u>20,752</u>
<u>Fair Value on Recurring / Short-Term Investments Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>45,172</u>	<u>54,307</u>	<u>Fair Value on Recurring / Cash / Cash and Cash Equivalents Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Cash</u>	<u>1,678</u>
<u>Money market funds / Cash and Cash Equivalents Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>997</u>	<u>4,285</u>	<u>Fair Value on Recurring / Government and agency notes / Cash and Cash Equivalents Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>014,946</u>
<u>Fair Value on Recurring / Government and agency notes / Short-Term Investments Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>45,172</u>	<u>53,578</u>	<u>Fair Value on Recurring / Certificates of deposit / Short-Term Investments Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</u>	<u>Debt securities, fair value</u>	<u>\$ 0</u>
<u>\$ 729</u>						

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an

entity as a result of past transactions or events.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 820-SubTopic 10-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 820-SubTopic 10-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482106/820-10-50-2)

+ Details

Name:us-gaap_AssetsFairValueDisclosure Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(aa\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (aa)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481800/320-10-50-2)
Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481830/320-10-45-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481830/320-10-45-1)
Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(6\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(6))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1)
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147479130/326-30-45-1>

+ Details

Name:us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

-- Definition

Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

No definition available.

+ Details

Name:us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

-- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-3>

[+ Details](#)

Name:us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItem
Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:
duration

[-- Details](#)

Name:us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember Namespace
Prefix: Data Type:na Balance Type: Period Type:

[-- Details](#)

Name:us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember Namespace
Prefix: Data Type:na Balance Type: Period Type:

[-- Details](#)

Name:us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix:
Data Type:na Balance Type: Period Type:

[-- Details](#)

Name:us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuriti
Namespace Prefix: Data Type:na Balance Type: Period Type:

[-- Details](#)

Name:us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember Namespace
Prefix: Data Type:na Balance Type: Period Type:

[-- Details](#)

Name:us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringM
Namespace Prefix: Data Type:na Balance Type: Period Type:

[-- Details](#)

Name:us-gaap_FinancialInstrumentAxis=us-gaap_CashMember Namespace Prefix: Data Type:na
Balance Type: Period Type: XML 55 R39.htm IDEA: XBRL DOCUMENT
Cash, Cash Equivalents and Investments - Additional Information 3 Months 9 Months
(Details) - USD (\$) Ended Ended

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Fair Value Disclosures [Abstract] Weighted average remaining contractual maturities
of available-for-sale securities 6 months Realized gains or losses on the sale or
maturity of available-for-sale securities \$ 0\$ 0\$ 0\$ 0 Amounts reclassify out of
accumulated other comprehensive loss 0000 Impairment charges \$ 0\$ 0\$ 0\$ 0

[-- Definition](#)

Weighted average remaining contractual maturities of available-for-sale securities.

[+ References](#)

No definition available.

[+ Details](#)

Name:qncx_WeightedAverageRemainingContractualMaturitiesOfAvailableForSaleSecurities
Namespace Prefix:qncx_ Data Type:xbrli:durationItemType Balance Type:na Period Type:
duration

[-- Definition](#)

Amount of write-down of assets recognized in the income statement. Includes, but is not

limited to, losses from tangible assets, intangible assets and goodwill.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>
Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482130/360-10-45-4>

+ Details

Name:us-gaap_AssetImpairmentCharges Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-9>

+ Details

Name:us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A)
Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A)
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 11-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-11>

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period
Type:duration XML 56 R40.htm IDEA: XBRL DOCUMENT
Cash, Cash Equivalents and Investments - Schedule of Available-for-Sale Sep. 30, Dec. 31,
Securities (Details) - USD (\$) \$ in Thousands

	2024	2023
<u>Schedule Of Available For Sale Securities [Line Items] Amortized Cost</u>	<u>\$ 46,010</u>	<u>\$ 73,548</u>
<u>Unrealized Gains</u>	<u>15913</u>	<u>Unrealized Losses0(23)</u>
<u>Fair Value</u>	<u>46,169</u>	<u>73,538</u>
<u>Cash and Cash</u>		
<u>Equivalents Schedule Of Available For Sale Securities [Line Items] Fair Value</u>	<u>99719,231</u>	
<u>Short-Term Investments Schedule Of Available For Sale Securities [Line Items] Fair</u>		
<u>Value</u>	<u>45,172</u>	<u>54,307</u>
<u>Money market funds Schedule Of Available For Sale Securities [Line</u>		
<u>Items] Amortized Cost</u>	<u>9974,285</u>	<u>Unrealized Gains00</u>
<u>Unrealized Losses00</u>	<u>Fair Value</u>	<u>9974,285</u>
<u>Government and agency notes Schedule Of Available For Sale Securities [Line Items]</u>		
<u>Amortized Cost</u>	<u>45,013</u>	<u>68,528</u>
<u>Unrealized Gains</u>	<u>15913</u>	<u>Unrealized Losses0(17)</u>
<u>Fair Value</u>	<u>\$ 45,172</u>	<u>68,524</u>
<u>Certificates of deposit Schedule Of Available For Sale Securities [Line Items]</u>		
<u>Amortized Cost</u>	<u>735</u>	<u>Unrealized Gains 0</u>
<u>Unrealized Losses (6)</u>	<u>Fair Value</u>	<u>\$ 729</u>

- Definition

Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

+ Details

Name:us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period
Type:instant

- Definition

Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

+ Details

Name:us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period
Type:instant

- Definition

Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479130/326-30-45-1>

+ Details

Name:us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix:us-gaap_
Data Type:xbli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of investment in debt security measured at fair value with change in fair value
recognized in other comprehensive income (available-for-sale).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>
Reference 2:
<http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 320 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481830/320-10-45-1>
Reference 3:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>
Reference 4:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 326 -SubTopic 30 -Name Accounting
Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147479130/326-30-45-1>

+ Details

Name:us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-2>

Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>

Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>

Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>

Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>

Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481800/320-10-50-3>

[+ Details](#)

Name:us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_Namespace Prefix:us-gaap_
Data Type:xbri:stringItemType Balance Type:na Period Type:duration

[- Details](#)

Name:us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember_Namespace
Prefix: Data Type:na Balance Type: Period Type:

[- Details](#)

Name:us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember_Namespace
Prefix: Data Type:na Balance Type: Period Type:

[- Details](#)

Name:us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember_Namespace Prefix:
Data Type:na Balance Type: Period Type:

[- Details](#)

Name:us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuriti

Namespace Prefix: Data Type:na Balance Type: Period Type:

+ Details

Name:us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 57 R41.htm IDEA: XBRL DOCUMENT Balance Sheet Components - Schedule of Prepaid Expenses and Other Sep. 30, Dec. 31, Current Assets (Details) - USD (\$) \$ in Thousands 2024 2023 Balance Sheet Components [Abstract] Prepaid research and development expenses\$ 1,415 \$ 133Short-term Italian research and development refundable tax credit995993Prepaid insurance841809Prepaid expenses565365Other current assets5581Total prepaid expenses and other current assets\$ 3,871\$ 2,381

+ Definition

Balance sheet components.

+ References

No definition available.

+ Details

Name:qncx_BalanceSheetComponentsAbstract Namespace Prefix:qncx_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

+ Definition

Prepaid insurance current.

+ References

No definition available.

+ Details

Name:qncx_PrepaidInsuranceCurrent Namespace Prefix:qncx_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

+ Definition

Prepaid research and development expenses, current.

+ References

No definition available.

+ Details

Name:qncx_PrepaidResearchAndDevelopmentExpensesCurrent Namespace Prefix:qncx_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

+ Definition

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482685/740-10-50-8>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482685/740-10-50-3>

+ Details

Name:us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of current assets classified as other.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_OtherAssetsCurrent Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483467/210-10-45-1>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482955/340-10-05-5>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483032/340-10-45-1>

+ Details

Name:us-gaap_PrepaidExpenseCurrent Namespace Prefix:us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type:debit Period Type:instant XML 58 R42.htm IDEA: XBRL
DOCUMENT

Balance Sheet Components - Additional Information 3 Months 9 Months 12 Months
(Details) - USD (\$) \$ in Thousands Ended Ended Ended

Aug. 04, 2023

Sep. 30, 2024

Sep. 30, 2023

Apr. 30, 2023

Mar. 31, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2023

Balance Sheet Components [Line Items] Reductions in research and development
expense \$ 400\$ 0 \$ 1,200\$ 0 Reduction in prepaid expenses and other current assets
(2,025)2,272 Cash severance payments\$ 500 \$ 300 Expenses related to employment
obligation \$ 100 Severance costs recognized 300 Additional cash bonus
severance percentage100.00% Share based compensation accelerated vesting
percentage50.00% Stock-based compensation expense related to options granted 1,124
\$ 1,331 3,621\$ 4,134\$ 100Option Balance Sheet Components [Line Items]
Accelerated vesting, number of options 612,141Restricted Stock Awards
Balance Sheet Components [Line Items] Accelerated vesting, number of options
54,757Novosteo Balance Sheet Components [Line Items] Proceeds from
income tax refunds \$ 0 \$ 500\$ 0 Reduction in prepaid expenses and other current assets
\$ 500

- Definition

Additional Cash Bonus Severance Percentage

+ References

No definition available.

+ Details

Name:gncx_AdditionalCashBonusSeverancePercentage Namespace Prefix:gncx_ Data Type:
dtr-types:percentItemType Balance Type:na Period Type:duration

- Definition

Balance sheet components [Line Items].

+ References

No definition available.

+ Details

Name:gncx_BalanceSheetComponentsLineItems Namespace Prefix:gncx_ Data Type:
xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Reductions in research and development expense.

+ References

No definition available.

+ Details

Name: gncx_ReductionsInResearchAndDevelopmentExpense Namespace Prefix: gncx_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration

- Definition

Severance Costs Recognized

+ References

No definition available.

+ Details

Name: gncx_SeveranceCostsRecognized Namespace Prefix: gncx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration

- Definition

Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479830/718-10-S99-1>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration

- Definition

Amount of increase (decrease) in prepaid expenses, and assets classified as other.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>

+ Details

Name:us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>

+ Details

Name:us-gaap_OtherRestructuringCosts Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

- Definition

The amount of cash received during the period as refunds for the overpayment of taxes.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-25>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482913/230-10-50-2>

+ Details

Name:us-gaap_ProceedsFromIncomeTaxRefunds Namespace Prefix:us-gaap_ Data Type:

xb:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>

+ Details

Name:us-gaap_SeveranceCosts1 Namespace Prefix:us-gaap_ Data Type:xb:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.

+ References

No definition available.

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVesting1 Namespace Prefix:us-gaap_ Data Type:xb:sharesItemType Balance Type:na Period Type:duration

-- Definition

Percentage of vesting of award under share-based payment arrangement.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRights1 Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:duration

-- Details

Name:us-gaap_AwardTypeAxis=us-gaap_StockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_AwardTypeAxis=qncx_RestrictedStockAwardsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_BusinessAcquisitionAxis=qncx_NovosteoMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 59 R43.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Schedule of Other Assets (Details) - USD Sep. 30, Dec. 31, (\$) \$ in Thousands 2024 2023

Balance Sheet Components [Abstract] Long-term Italian research and development refundable tax credit\$ 4,074\$ 4,993VAT receivable5,3543,463Equity investments in Lighthouse Pharmaceuticals, Inc.7878Assets held for sale010Total other assets\$ 9,506 \$ 8,544

-- Definition

Assets held for sale.

+ References

No definition available.

+ Details

Name:qncx_AssetsHeldForSale Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

-- Definition

Balance sheet components.

+ References

No definition available.

+ Details

Name:qncx_BalanceSheetComponentsAbstract Namespace Prefix:qncx_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

-- Definition

Deferred tax assets long term tax credit carryforwards foreign.

+ References

No definition available.

+ Details

Name:qncx_DeferredTaxAssetsLongTermTaxCreditCarryforwardsForeign Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

-- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3:

~~<http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-25>~~

+ Details

~~Name:us-gaap_EquityMethodInvestments Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

- Definition

~~Amount of assets classified as other.~~

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480167/946-830-55-12>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(10)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>~~

+ Details

Name:us-gaap_OtherAssets Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType
Balance Type:debit Period Type:instant

- Definition

Carrying amount as of the balance sheet date of value added taxes due either from
customers arising from sales on credit terms, or as previously overpaid to tax
authorities.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -
Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX
210.5-02(3)(a)(4)) -Publisher FASB -URI [https://asc.fasb.org//1943274/2147480566/210-10-
S99-1](https://asc.fasb.org//1943274/2147480566/210-10-S99-1)

+ Details

Name:us-gaap_ValueAddedTaxReceivable Namespace Prefix:us-gaap_ Data Type:
xbli:monetaryItemType Balance Type:debit Period Type:instant XML 60 R44.htm IDEA: XBRL

DOCUMENT

Balance Sheet Components - Schedule of Property and Equipment, Net Sep. 30, Dec. 31,
(Details) - USD (\$) \$ in Thousands 2024 2023
Balance Sheet Components [Line Items] Less: accumulated amortization and depreciation
\$ (667)\$ (507)Property and equipment, net208234Computer equipment Balance Sheet
Components [Line Items] Property and equipment3836Computer Software Balance Sheet
Components [Line Items] Property and equipment3030Lab equipment Balance Sheet
Components [Line Items] Property and equipment534486Leasehold improvement Balance
Sheet Components [Line Items] Property and equipment3636Office furniture Balance Sheet
Components [Line Items] Property and equipment\$ 237\$ 153
- Definition

Balance sheet components [Line Items].

+ References

No definition available.

+ Details

Name:qncx_BalanceSheetComponentsLineItems Namespace Prefix:qncx_ Data Type:
xbli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used
in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name
Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-
03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-
1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name
Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-
02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-
1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards
Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c)-
Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1

+ Details

Name:us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period
Type:instant

- Definition

Amount before accumulated depreciation, depletion and amortization of physical assets
used in the normal conduct of business and not intended for resale. Examples include,
but are not limited to, land, buildings, machinery and equipment, office equipment, and
furniture and fixtures.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name
Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-
03(a)(8)) -Publisher FASB -URI [https://asc.fasb.org//1943274/2147479440/944-210-S99-](https://asc.fasb.org//1943274/2147479440/944-210-S99-1)
1Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name
Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-
02(13)) -Publisher FASB -URI [https://asc.fasb.org//1943274/2147480566/210-10-S99-](https://asc.fasb.org//1943274/2147480566/210-10-S99-1)
1Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 360 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147482099/360-10-50-1>

+ Details

Name:us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix:us-gaap_ Data Type:
xbri:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets
used in the normal conduct of business to produce goods and services and not intended
for resale. Examples include, but are not limited to, land, buildings, machinery and
equipment, office equipment, and furniture and fixtures.

+ References

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482099/360-10-50-1>~~
~~Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>~~
~~Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>~~
~~Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480842/942-360-50-1>~~

+ Details

~~Name:us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

-- Details

~~Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

-- Details

~~Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAsset Namespace Prefix: Data Type:na Balance Type: Period Type:~~

-- Details

~~Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=qncx_LabEquipmentMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

-- Details

~~Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

[Details](#)

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember
Namespace Prefix: Data Type:na Balance Type: Period Type: XML 61 R45.htm IDEA: XBRL
DOCUMENT

<u>Balance Sheet Components - Schedule of Accrued Expenses and Other</u>	<u>Sep.</u>	<u>Dec.</u>
<u>Current Liabilities (Details) - USD (\$) \$ in Thousands</u>	<u>30,</u>	<u>31,</u>
	<u>2024</u>	<u>2023</u>

<u>Balance Sheet Components [Abstract]</u>	<u>Personnel expenses</u>	<u>\$ 2,301</u>	<u>\$ 2,340</u>	<u>Research and</u>
<u>development expenses</u>	<u>1,063</u>	<u>564</u>	<u>Professional fees</u>	<u>140</u>
<u>Current portion of operating lease</u>	<u>liabilities</u>	<u>101</u>	<u>640</u>	<u>Other</u>
<u>198</u>	<u>257</u>	<u>Total accrued expenses and other current liabilities</u>	<u>\$ 3,803</u>	
<u>\$ 3,436</u>				

[Definition](#)

Accrued operating lease liabilities current.

[References](#)

No definition available.

[Details](#)

Name:qncx_AccruedOperatingLeaseLiabilitiesCurrent Namespace Prefix:qncx Data Type:
xbri:monetaryItemType Balance Type:credit Period Type:instant

[Definition](#)

Accrued research and development expenses, current.

[References](#)

No definition available.

[Details](#)

Name:qncx_AccruedResearchAndDevelopmentExpensesCurrent Namespace Prefix:qncx Data
Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[Definition](#)

Balance sheet components.

[References](#)

No definition available.

[Details](#)

Name:qncx_BalanceSheetComponentsAbstract Namespace Prefix:qncx Data Type:
xbri:stringItemType Balance Type:na Period Type:duration

[Definition](#)

Carrying value as of the balance sheet date of obligations incurred and payable,
pertaining to costs that are statutory in nature, are incurred on contractual
obligations, or accumulate over time and for which invoices have not yet been received
or will not be rendered. Examples include taxes, interest, rent and utilities. Used to
reflect the current portion of the liabilities (due within one year or within the normal
operating cycle if longer).

[References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Topic 210 -SubTopic 10 -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-
02.20) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-599-1>

+ Details

Name:us-gaap_AccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-599-1>

+ Details

Name:us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 710 -SubTopic 10 -Name Accounting Standards Codification -Section 25 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483070/710-10-25-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 710 -SubTopic 10 -Section 30 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483043/710-10-30-2>

+ Details

~~Name:us-gaap_DeferredCompensationLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~+ Definition~~

~~Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

~~+ Details~~

~~Name:us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant XML 62 R46.htm IDEA: XBRL DOCUMENT~~

~~Balance Sheet Components - Schedule of Accrued Severance (Details) - USD (\$) 9 Months
\$ in Thousands Ended~~

~~Sep. 30, 2024~~

~~Sep. 30, 2023~~

~~Balance Sheet Components [Roll Forward] Beginning accrued severance\$ 341\$ 0Incurred during the period41770Severance paid during the period(382)(309)Ending accrued severance\$ 0\$ 461~~

~~+ Definition~~

~~Accrued Severance~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_AccruedSeverance Namespace Prefix:gncx_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~+ Definition~~

~~Accrued severance incurred~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_AccruedSeveranceIncurred Namespace Prefix:gncx_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~+ Definition~~

~~Accrued severance paid~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

Name:qncx_AccruedSeverancePaid Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType
Balance Type:credit Period Type:duration

- Definition

Balance Sheet Components

+ References

No definition available.

+ Details

Name:qncx_BalanceSheetComponentsRollForward Namespace Prefix:qncx_ Data Type:
xbri:stringItemType Balance Type:na Period Type:duration XML 63 R47.htm IDEA: XBRL
DOCUMENT

Leases - Additional Information (Details) \$ in Thousands 9 Months Ended

Oct. 31, 2023

USD (\$)

lease

Sep. 30, 2024

USD (\$)

Sep. 30, 2023

USD (\$)

Dec. 31, 2023

USD (\$)

Lessee Lease Description [Line Items] Operating lease asset \$ 559 \$ 385 Operating

lease liability 551 \$ 385 Rent expenses (less than) 100 \$ 100 Car Lessee Lease

Description [Line Items] Number of lease agreements acquired / lease2 Ery Del /

Other Operating Leases Lessee Lease Description [Line Items] Operating lease asset

\$ 200 Operating lease liability 200 Bresso, Italy / Ery Del Lessee Lease

Description [Line Items] Operating lease asset 400 Operating lease liability 400

Medolla, Italy Lessee Lease Description [Line Items] Operating lease asset 200

Operating lease liability \$ 200 Medolla, Italy / Ery Del Lessee Lease Description

[Line Items] Operating lease asset 100 Operating lease liability \$ 100 Lease

agreement period 12 years

- Definition

Number Of Lease Agreements Acquired

+ References

No definition available.

+ Details

Name:qncx_NumberOfLeaseAgreementsAcquired Namespace Prefix:qncx_ Data Type:
xbri:integerItemType Balance Type:na Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many
axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name
Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI
<https://asc.fasb.org/1943274/2147478964/842-20-50-3>

+ Details

Name:us-gAAP_LesseeLeaseDescriptionLineItems Namespace Prefix:us-gAAP_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(a\)-\(3\)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(a)-(3)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147478964/842-20-50-3)

+ Details

Name:us-gAAP_LesseeOperatingLeaseTermOfContract Namespace Prefix:us-gAAP_ Data Type: xbrli:durationItemType Balance Type:na Period Type:instant

- Definition

Amount of operating lease expense. Excludes sublease income.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-4-Subparagraph-\(b\)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147479041/842-20-45-4](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-4-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479041/842-20-45-4)

+ Details

Name:us-gAAP_OperatingLeaseExpense Namespace Prefix:us-gAAP_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479041/842-20-45-1)

+ Details

Name:us-gaap_OperatingLeaseLiability Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant

-- Definition

Amount of lessee's right to use underlying asset under operating lease.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>

+ Details

Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

-- Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AutomobilesMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_BusinessAcquisitionAxis=qncx_EryDelMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=qncx_OtherOperatingLeasesMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:srt_StatementGeographicalAxis=qncx_BressoMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:srt_StatementGeographicalAxis=qncx_MedollaMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 64 R48.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Supplemental Balance Sheet Information Related to Sep. 30, Dec. 31, Leases (Details) - USD (\$) \$ in Thousands

	2024	2023	
ASSETS			
Operating lease right-of-use assets	\$ 559	\$ 385	
Liabilities:			
Short-term operating lease liability	101	64	
Long-term operating lease liabilities	450	321	
Total remaining lease liability	\$ 551	\$ 385	
Other information:			
Weighted average remaining lease term (in years)			
4 years 10 months 24 days	5 years 4 months 24 days		
Weighted average discount rate (as percent)	9.11%	7.95%	
Operating Lease, Liability, Payment, Due [Abstract]	2024 (remainder of the year)	\$ 35	
2025	140	2026	136
2027	130	2028 and thereafter	214
Total lease payments	655		
Less: imputed interest	(104)	Total remaining lease liability	\$ 551 \$ 385

-- Definition

Supplemental balance sheet other information.

+ References

No definition available.

+ Details

Name:qncx_SupplementalBalanceSheetOtherInformationAbstract Namespace Prefix:qncx_ Data

~~Type:xbtli:stringItemType Balance Type:na Period Type:duration~~

~~[--References](#)~~

~~No definition available.~~

~~[+Details](#)~~

~~Name:us-gaap_AssetsAbstract Namespace Prefix:us-gaap_ Data Type:xbtli:stringItemType
Balance Type:na Period Type:duration~~

~~[--Definition](#)~~

~~Amount of lessee's undiscounted obligation for lease payment for operating lease.~~

~~[+References](#)~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name
Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147478964/842-20-50-6>~~

~~[+Details](#)~~

~~Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix:us-gaap_ Data
Type:xbtli:monetaryItemType Balance Type:credit Period Type:instant~~

~~[--Definition](#)~~

~~Amount of lessee's undiscounted obligation for lease payment for operating lease to be
paid in next fiscal year following current fiscal year. Excludes interim and annual
periods when interim periods are reported from current statement of financial position
date (rolling approach).~~

~~[+References](#)~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name
Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147478964/842-20-50-6>~~

~~[+Details](#)~~

~~Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix:
us-gaap_ Data Type:xbtli:monetaryItemType Balance Type:credit Period Type:instant~~

~~[--Definition](#)~~

~~Amount of lessee's undiscounted obligation for lease payment for operating lease to be
paid in fourth fiscal year following current fiscal year. Excludes interim and annual
periods when interim periods are reported from current statement of financial position
date (rolling approach).~~

~~[+References](#)~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name~~

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix:us-gaap_
Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be
paid in third fiscal year following current fiscal year. Excludes interim and annual
periods when interim periods are reported from current statement of financial position
date (rolling approach).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name
Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147478964/842-20-50-6>

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix:
us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be
paid in second fiscal year following current fiscal year. Excludes interim and annual
periods when interim periods are reported from current statement of financial position
date (rolling approach).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name
Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147478964/842-20-50-6>

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix:us-gaap_
Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI>
<https://asc.fasb.org//1943274/2147478964/842-20-50-6>

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI>
<https://asc.fasb.org//1943274/2147478964/842-20-50-6>

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_LiabilitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease.

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>~~

[+ Details](#)

~~Name:us-gAAP_OperatingLeaseLiability Namespace Prefix:us-gAAP_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

[- Definition](#)

~~Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>~~

[+ Details](#)

~~Name:us-gAAP_OperatingLeaseLiabilityCurrent Namespace Prefix:us-gAAP_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

[- Definition](#)

~~Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>~~

[+ Details](#)

~~Name:us-gAAP_OperatingLeaseLiabilityNoncurrent Namespace Prefix:us-gAAP_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

[- Definition](#)

Amount of lessee's right to use underlying asset under operating lease.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479041/842-20-45-1>

+ Details

Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Weighted average discount rate for operating lease calculated at point in time.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147478964/842-20-50-4>

+ Details

Name:us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Weighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479589/842-20-55-53>Reference 2:

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147478964/842-20-50-4>~~

+ Details

~~Name:us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix:us-gaap-
Data Type:xbrli:durationItemType Balance Type:na Period Type:instant XML 65 R49.htm~~

~~IDEA: XBRL DOCUMENT~~

~~Stockholders' Equity (Details) - \$ / sharesApr. 05, 2023Sep. 30, 2024Dec. 31, 2023Class
of Stock [Line Items] Preferred stock, par value (in USD per share) \$ 0.001\$ 0.001
Rights Plan | Preferred Stock Class of Stock [Line Items] Warrants to purchase
common stock (in dollars per share)\$ 6,000 Rights Plan | Series A Preferred Stock
Class of Stock [Line Items] Preferred stock, dividends (in shares)1 Preferred stock,
par value (in USD per share)\$ 0.001 Preferred Stock, subject to adjustment (in shares)
0.001~~

- Definition

~~Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many
axes to the table.~~

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 505 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 2:
<http://www.xbrl.org/2003/role/recommendedDisclosureRef> -Topic 272 -SubTopic 10 -Name
Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147483014/272-10-45-3>Reference 3:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 272 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482987/272-10-50-1>Reference 4:
<http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>Reference 5:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 6:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 7:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 8:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 9:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting~~

~~Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481112/505-10-50-14>Reference 10:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481112/505-10-50-18>Reference 11:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 12:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 13:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481112/505-10-50-2>Reference 14:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 15:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147479886/946-10-S99-3>Reference 16:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147479886/946-10-S99-3>Reference 17:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147479886/946-10-S99-3>Reference 18:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147479886/946-10-S99-3>~~

+ Details

Name:us-gaap_ClassOfStockLineItems Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481112/505-10-50-3>

+ Details

Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.

+ References

No definition available.

+ Details

Name:us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: instant

- Definition

Number of shares of preferred stock issued as dividends during the period. Excludes stock splits.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481112/505-10-50-2>

+ Details

Name:us-gaap_PREFERREDStockDividendsShares Namespace Prefix:us-gaap_ Data Type:

xbrl:sharesItemType Balance Type:na Period Type:duration

-- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_PREFERREDSTOCKPARORSTATEDVALUEPERSHARE Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

-- Details

Name:us-gaap_PlanNameAxis=qncx_RightsPlanMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_StatementEquityComponentsAxis=us-gaap_PREFERREDSTOCKMEMBER Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPREFERREDSTOCKMEMBER Namespace Prefix: Data Type:na Balance Type: Period Type: XML 66 R50.htm IDEA: XBRL DOCUMENT Stock-Based Compensation - Additional Information - General (Details) Sep. 30, 2024 plan Share-

Based Payment Arrangement [Abstract] [Number of stock plans](#)³

-- Definition

Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans

+ References

No definition available.

+ Details

Name:qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans Namespace Prefix:qncx_ Data Type:xbrl:integerItemType Balance Type:na Period Type: instant

-- References

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace
Prefix:us-gaap_ Data Type:xbli:stringItemType Balance Type:na Period Type:duration XML
67 R51.htm IDEA: XBRL DOCUMENT
Stock-Based Compensation - 2019 Equity Incentive Plan (Quince) - General 9 Months
(Details) - 2019 Plan Ended
Sep. 30, 2024
shares~~

~~Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Maximum
aggregate number of shares that may be issued under the plan11,755,418Increase in number
of shares available for issuance as proportion of shares of common stock (in shares)
2,146,354Percentage of common stock outstanding4.00%Common stock reserved for issuance
(in shares)2,288,074~~

~~-- Definition~~

~~Share based compensation arrangement by share based payment award increase in number of
shares available for issuance as proportion of shares of common stock.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSha
Namespace Prefix:qncx_ Data Type:xbli:sharesItemType Balance Type:na Period Type:
instant~~

~~-- Definition~~

~~Aggregate number of common shares reserved for future issuance.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-
02.29) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

~~+ Details~~

~~Name:us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix:
us-gaap_ Data Type:xbli:sharesItemType Balance Type:na Period Type:instant~~

~~-- Definition~~

~~Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many
axes to the table.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480483/718-10-35-1D>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480483/718-10-35-3>Reference 3:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting~~

[illegible]

~~-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 26:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB~~
~~-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 27:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB~~
~~-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 28:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB~~
~~-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:
duration

-- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvai
Namespace Prefix:us-gaap_ Data Type:xbri:sharesItemType Balance Type:na Period Type:
instant

-- Definition

Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutsta
Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period
Type:duration

Name:us-gaap_PlanNameAxis=qncx_TwoThousandAndNineteenEquityIncentivePlanMember
Namespace Prefix: Data Type:na Balance Type: Period Type: XML 68 R52.htm IDEA: XBRL
DOCUMENT

~~- Definition~~

+ References

~~No definition available.~~

Name: gncx_MonthlyInstallmentsRemainingVestingPeriod Namespace Prefix: gncx_ Data Type: xbrli:duration ItemType: Balance Type: na Period Type: duration

- Definition

~~Percentage of voting rights.~~

+ References

~~No definition available.~~

Name:gncx_PercentageOfVotingRights Namespace Prefix:gncx_ Data Type:xbrli:pureItemType
Balance Type:na Period Type:duration

~~- Definition~~

Share based compensation arrangement by share based payment award grant period.

+ References

~~No definition available.~~

+ Details

Name:qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantPeriod
Namespace Prefix:qncx_ Data Type:xbri:durationItemType Balance Type:na Period Type:
duration

-- Definition

Amount of expense for award under share-based payment arrangement. Excludes amount
capitalized.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic
14.F) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479830/718-10-S99-1>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix:us-gaap_ Data
Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Weighted-average period over which cost not yet recognized is expected to be recognized
for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for
example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen
days.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo:
Namespace Prefix:us-gaap_ Data Type:xbri:durationItemType Balance Type:na Period Type:

duration

--Definition

Amount of cost to be recognized for option under share-based payment arrangement.

+References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo: Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

--Definition

Amount of tax benefit for recognition of expense of award under share-based payment arrangement.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+Details

Name:us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

--Definition

Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.

+References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod
Namespace Prefix:us-gaap_ Data Type:xbrl:durationItemType Balance Type:na Period Type:
duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many
axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480483/718-10-35-1D>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147480483/718-10-35-3>Reference 3:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -
URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 4:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -
URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 5:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -
URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 6:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 7:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 8:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 9:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 10:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 11:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 12:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 13:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 14:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 15:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 16:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 17:

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 18:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 19:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 20:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 21:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 22:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 23:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 24:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 25:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 26:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 27:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference> 28:~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:us-gaap_ Data Type:xbli:stringItemType Balance Type:na Period Type:
duration

- Definition

Percentage of vesting of award under share-based payment arrangement.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)(1)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRights
Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period
Type:duration

-- Definition

Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format,
for example, 'P1Y5M13D' represents the reported fact of one year, five months, and
thirteen days.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:
duration

-- Definition

Purchase price of common stock expressed as a percentage of its fair value.

+ References

No definition available.

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCom
Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period
Type:duration

-- Details

Name:us-gaap_PlanNameAxis=qncx_TwoThousandAndNineteenEquityIncentivePlanMember
Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data
Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_VestingAxis=qncx_OneYearAnniversaryMember Namespace Prefix: Data Type:na
Balance Type: Period Type:

-- Details

Name:us-gaap_VestingAxis=qncx_ThreeYearAnniversaryMember Namespace Prefix: Data Type:na
Balance Type: Period Type:

-- Details

Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type:
Period Type:

-- Details

Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type:
Period Type: XML 69 R53.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Activity for Stock Options
(Details) - USD (\$) \$ / shares in Units, \$ in Thousands

9 Months
Ended

12
Months
Ended

Sep. 30, 2024

Dec. 31, 2023

2019 Plan Number of Options and Unvested Shares Number of Options and Unvested Shares, beginning balance (in shares)4,267,178 Options granted (in shares)3,602,500 Options exercised (in shares)(155,311) Options cancelled / forfeited (in shares)(165,861) Number of Options and Unvested Shares, ending balance (in shares)7,548,5064,267,178Weighted Average Exercise Price Weighted Average Exercise Price, beginning balance (in USD per share)\$ 5.00 Options granted (in USD per share)1.26 Options exercised (in USD per share)0.93 Options cancelled / forfeited (in USD per share)13.06 Weighted Average Exercise Price, ending balance (in USD per share)\$ 3.12\$ 5.00Stock Options Additional Disclosures Weighted average remaining contractual life (in years)8 years 8 months 19 days 8 years 10 months 6 daysAggregate intrinsic value\$ 5\$ 197Options exercised\$ 65 Options vested and expected to vest (in shares)7,548,506 Options exercisable (in shares)2,062,912 Options vested and expected to vest (in USD per share)\$ 3.12 Options exercisable (in USD per share)\$ 7.86 Options vested and expected to vest as of September 30, 20248 years 8 months 19 days Options exercisable as of September 30, 2024 7 years 9 months 3 days Options vested and expected to vest as of September 30, 2024\$ 5 Options exercisable as of September 30, 2024\$ 0 2019 Novosteo Plan | Stock Options Number of Options and Unvested Shares Number of Options and Unvested Shares, beginning balance (in shares)310,431 Options granted (in shares)0 Options exercised (in shares)(146,592) Options cancelled / forfeited (in shares)0 Number of Options and Unvested Shares, ending balance (in shares)163,839310,431Weighted Average Exercise Price Weighted Average Exercise Price, beginning balance (in USD per share)\$ 0.55 Options granted (in USD per share)0 Options exercised (in USD per share)0.55 Options cancelled / forfeited (in USD per share)0 Weighted Average Exercise Price, ending balance (in USD per share)\$ 0.55\$ 0.55Stock Options Additional Disclosures Weighted average remaining contractual life (in years)7 years 5 months 23 days8 years 2 months 23 daysAggregate intrinsic value\$ 37\$ 155Options exercised\$ 94 Options vested and expected to vest (in shares)163,839 Options exercisable (in shares)47,426 Options vested and expected to vest (in USD per share)\$ 0.55 Options exercisable (in USD per share)\$ 0.55 Options vested and expected to vest as of September 30, 20247 years 5 months 23 days Options exercisable as of September 30, 2024\$ 37 Options exercisable as of September 30, 2024\$ 11 2022 Inducement Plan | Stock Options Number of Options and Unvested Shares Number of Options and Unvested Shares, beginning balance (in shares)2,333,306 Options granted (in shares)0 Options exercised (in shares)0 Options cancelled / forfeited (in shares)0 Number of Options and Unvested Shares, ending balance (in shares)2,333,3062,333,306Weighted Average Exercise Price Weighted Average Exercise Price, beginning balance (in USD per share)\$ 2.98 Options granted (in USD per share)0 Options exercised (in USD per share)0 Options cancelled / forfeited (in USD per share)0 Weighted Average Exercise Price, ending balance (in USD per share)\$ 2.98\$ 2.98Stock Options Additional Disclosures Weighted average remaining contractual life (in years)7 years 7 months 24 days 8 years 4 months 24 daysAggregate intrinsic value\$ 0\$ 0Options vested and expected to vest (in shares)2,333,306 Options exercisable (in shares)1,361,094 Options vested and expected to vest (in USD per share)\$ 2.98 Options exercisable (in USD per share)\$ 2.98 Options vested and expected to vest as of September 30, 20247 years 7 months 24 days Options exercisable as of September 30, 20247 years 7 months 24 days Options vested and expected to vest as of September 30, 2024\$ 0 Options exercisable as of September 30, 2024\$ 0

- References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalD: Namespace Prefix:us-gaap_ Data Type:xb:li:stringItemType Balance Type:na Period Type: duration

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

+ Details

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisable
Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:
instant~~

- Definition

~~Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.~~

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

+ Details

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesIn
Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period
Type:duration~~

- Definition

~~The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.~~

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

+ Details

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitures
Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:~~

duration

-- Definition

Gross number of share options (or share units) granted during the period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPer:
Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:
duration

-- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding:
Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period
Type:instant

-- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding!
Namespace Prefix:us-gaap_ Data Type:xbli:sharesItemType Balance Type:na Period Type:
instant

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the
end of a period.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding!
Namespace Prefix:us-gaap_ Data Type:xbli:stringItemType Balance Type:na Period Type:
duration

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance
under the stock option plan.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding!

Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

[--References](#)

No definition available.

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding
Namespace Prefix:us-gaap_ Data Type:xbli:stringItemType Balance Type:na Period Type:
duration

[--Definition](#)

Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

[+References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndEx
Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

[--Definition](#)

Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

[+References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndEx
Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:debit Period Type:instant

~~Definition~~

~~Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

~~+ Details~~

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndEx Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

~~Definition~~

~~Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

~~+ Details~~

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndEx Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant~~

~~Definition~~

~~Weighted average price at which option holders acquired shares when converting their stock options into shares.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

+ Details

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesI
Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period
Type:duration

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeiture
Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period
Type:duration

- Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPe
Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period
Type:duration

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisable Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstanding Namespace Prefix:us-gaap_ Data Type:xbri:durationItemType Balance Type:na Period Type:duration

- Definition

Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndEx
Namespace Prefix:us-gaap_ Data Type:xbrl:durationItemType Balance Type:na Period Type:
duration

- Definition

Weighted average remaining contractual term for fully vested and expected to vest
options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents
reported fact of one year, five months, and thirteen days. Includes, but is not limited
to, unvested options for which requisite service period has not been rendered but that
are expected to vest based on achievement of performance condition, if forfeitures are
recognized when they occur.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndEx
Namespace Prefix:us-gaap_ Data Type:xbrl:durationItemType Balance Type:na Period Type:
duration

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147481112/505-10-50-2>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 3:
<http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 4:
<http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480008/505-10-S99-1>Reference 5:
<http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting
Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

[+ Details](#)

~~Name:us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix:us-gaap_ Data Type:xbri:sharesItemType Balance Type:na Period Type:duration~~

[-- Details](#)

~~Name:us-gaap_PlanNameAxis=qncx_TwoThousandAndNineteenEquityIncentivePlanMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

[-- Details](#)

~~Name:us-gaap_PlanNameAxis=qncx_NovosteoPlanMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

[-- Details](#)

~~Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

[-- Details](#)

~~Name:us-gaap_PlanNameAxis=qncx_TwoThousandAndTwentyTwoInducementPlanMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 70 R54.htm IDEA: XBRL DOCUMENT Stock-Based Compensation - RSUs (Details) - USD 3 Months 9 Months 12 Months (\$) Ended Ended Ended~~

~~Sep. 30, 2024~~

~~Sep. 30, 2023~~

~~Sep. 30, 2024~~

~~Sep. 30, 2023~~

~~Dec. 31, 2023~~

~~Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Total stock-based compensation\$ 1,124,000\$ 1,331,000\$ 3,621,000\$ 4,134,000\$ 100,000Unamortized employee stock-based compensation0 0 Restricted Stock Units Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Total stock-based compensation\$ 48,700\$ 6,400\$ 145,600\$ 37,500 Minimum / Restricted Stock Units Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Stock based awards vesting period 2 years Maximum / Restricted Stock Units Share Based~~

~~Compensation Arrangement By Share Based Payment Award [Line Items] — Stock based awards vesting period 4 years —~~

~~— Definition~~

~~Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479830/718-10-S99-1>~~
~~Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

~~+ Details~~

~~Name:us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~— Definition~~

~~Amount of cost not yet recognized for nonvested award under share-based payment arrangement.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

~~+ Details~~

~~Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo: Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~— Definition~~

~~Period over which grantee's right to exercise award under share-based payment~~

arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type: duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480483/718-10-35-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting

[illegible]

[+ Details](#)

~~*Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:
duration*~~

[- Details](#)

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type:na Balance Type: Period Type:

--Details

Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type: Period Type:

--Details

Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 71 R55.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of RSUs and RSAs (Details)9 Months Ended Sep. 30, 2024

\$ / shares

shares

Restricted Stock Units Number of Shares Outstanding, Number of Shares, Unvested, Beginning Balance (in shares) | shares1,488Granted (in shares) | shares0Vested (in shares) | shares(1,488)Cancelled (in shares) | shares0Outstanding, Number of Shares, Unvested, Ending Balance (in shares) | shares0Weighted Average Grant Date Fair Value Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance (in USD per share) | \$ / shares\$ 4.30Granted (in USD per share) | \$ / shares0Vested (in USD per share) | \$ / shares4.30Cancelled (in USD per share) | \$ / shares0Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Ending Balance (in USD per share) | \$ / shares\$ 0Restricted Stock Awards Number of Shares Outstanding, Number of Shares, Unvested, Beginning Balance (in shares) | shares175,763Granted (in shares) | shares0Vested (in shares) | shares(73,010)Cancelled (in shares) | shares0Outstanding, Number of Shares, Unvested, Ending Balance (in shares) | shares102,753Weighted Average Grant Date Fair Value Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance (in USD per share) | \$ / shares\$ 3.30Granted (in USD per share) | \$ / shares0Vested (in USD per share) | \$ / shares3.30Cancelled (in USD per share) | \$ / shares0Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Ending Balance (in USD per share) | \$ / shares\$ 3.30

--Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0: Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type: duration

--Definition

Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:
Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period
Type:duration

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:
Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:
duration

- Definition

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:
Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period
Type:duration

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

-- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-- Definition

Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:
Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period
Type:instant

- References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:
Namespace Prefix:us-gaap_ Data Type:xbli:stringItemType Balance Type:na Period Type:
duration

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that
vested during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02)
-Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:
Namespace Prefix:us-gaap_ Data Type:xbli:sharesItemType Balance Type:na Period Type:
duration

- Definition

The weighted average fair value as of grant date pertaining to an equity-based award
plan other than a stock (or unit) option plan for which the grantee gained the right
during the reporting period, by satisfying service and performance requirements, to
receive or retain shares or units, other instruments, or cash in accordance with the
terms of the arrangement.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02)
-Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstruments0:
Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period
Type:duration

-- Details

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember_ Namespace Prefix: Data
Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_AwardTypeAxis=qncx_RestrictedStockAwardsMember_ Namespace Prefix: Data
Type:na Balance Type: Period Type: XML 72 R56.htm IDEA: XBRL DOCUMENT
Stock-Based Compensation - 2019 Equity Incentive Plan 3 Months 9 Months 12 Months
(Novosteo) (Details) Ended Ended Ended

Aug. 04, 2023

May 19, 2022

\$ / shares

shares

Sep. 30, 2024

USD (\$)

shares

Sep. 30, 2023

USD (\$)

Sep. 30, 2024

USD (\$)

shares

Sep. 30, 2023

USD (\$)

Dec. 31, 2023

USD (\$)

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Award vesting rights50.00% Total stock-based compensation \$ 1,124,000\$ 1,331,000
\$ 3,621,000\$ 4,134,000\$ 100,000Unamortized employee stock-based compensation \$ 0 \$ 0
2019 Novosteo Plan Share Based Compensation Arrangement By Share Based Payment
Award [Line Items] Maximum aggregate number of shares that may be issued under the
plan / shares 544,985 Common stock reserved for issuance (in shares) / shares
246,797 246,797 Options, stock-based compensation not yet recognized \$ 288,100
\$ 288,100 2019 Novosteo Plan / Stock Options Share Based Compensation Arrangement
By Share Based Payment Award [Line Items] Warrants to purchase common stock (in
dollars per share) / \$ / shares \$ 0.0911 Award grant period 10 years Rate of
purchase price of stock on fair value (as a percent) 100.00% Voting rights in
percentage 0.10 Stock options granted maximum period 10 years Stock based awards
vesting period 4 years Total stock-based compensation 096,000\$ 4,400226,000
Unamortized employee stock-based compensation expected to recognized over remaining
estimated vesting period 1 year 5 months 23 days 2019 Novosteo Plan / Restricted
Stock Awards Share Based Compensation Arrangement By Share Based Payment Award
[Line Items] Total stock-based compensation 100,000\$ 200,000\$ 200,000\$ 400,000
Unamortized employee stock-based compensation expected to recognized over remaining
estimated vesting period 11 months 26 days Stock award conversion ratio 0.0911
Unamortized employee stock-based compensation \$ 300,000 \$ 300,000 2019 Novosteo Plan /
One Year Anniversary / Stock Options Share Based Compensation Arrangement By Share
Based Payment Award [Line Items] Award vesting rights 25.00% 2019 Novosteo
Plan / Three Year Anniversary / Stock Options Share Based Compensation Arrangement
By Share Based Payment Award [Line Items] Award vesting rights 75.00% 2019
Novosteo Plan / Maximum / Stock Options Share Based Compensation Arrangement By
Share Based Payment Award [Line Items] Rate of purchase price of stock on fair
value (as a percent) 110.00% Monthly installments over the remaining vesting period
4 years 2019 Novosteo Plan / Minimum / Stock Options Share Based Compensation

Arrangement By Share Based Payment Award [Line Items] Monthly installments over the remaining vesting period 3 years

- Definition

Monthly installments, remaining vesting period.

+ References

No definition available.

+ Details

Name:qncx_MonthlyInstallmentsRemainingVestingPeriod Namespace Prefix:qncx_ Data Type: xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Percentage of voting rights.

+ References

No definition available.

+ Details

Name:qncx_PercentageOfVotingRights Namespace Prefix:qncx_ Data Type:xbrli:pureItemType Balance Type:na Period Type:duration

- Definition

Share based compensation arrangement by share based payment award grant period.

+ References

No definition available.

+ Details

Name:qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantPeriod Namespace Prefix:qncx_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Issued Up Conversion

+ References

No definition available.

+ Details

Name:qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedUp Namespace Prefix:qncx_ Data Type:xbrli:pureItemType Balance Type:na Period Type:instant

- Definition

Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479830/718-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481112/505-10-50-3>

+ Details

Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

-- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

-- Definition

Amount of cost not yet recognized for nonvested award under share-based payment arrangement.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo: Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:debit Period Type:instant

-- Definition

Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo: Namespace Prefix:us-gaap_ Data Type:xbli:durationItemType Balance Type:na Period Type:duration

-- Definition

Amount of cost to be recognized for option under share-based payment arrangement.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo: Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.

+ References

Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod: Namespace Prefix:us-gaap_ Data Type:xbli:durationItemType Balance Type:na Period Type: duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3>
Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)
Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)
Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(3\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)
Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(i\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)
Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(ii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)
Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)
Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iii\) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)

[illegible]

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:us-gaap_ Data Type:xbrl:stringItemType Balance Type:na Period Type:
duration

- Definition

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvai
Namespace Prefix:us-gaap_ Data Type:xbrl:sharesItemType Balance Type:na Period Type:
instant

- Definition

Percentage of vesting of award under share-based payment arrangement.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRights
Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period
Type:duration

- Definition

Period from grant date that an equity-based award expires, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 718 -SubTopic 10 -Name

~~+ Details~~

~~Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod~~
~~Namespace Prefix:us-gaap_ Data Type:xbkli:durationItemType Balance Type:na Period Type:~~
~~duration~~

~~- Definition~~

~~Purchase price of common stock expressed as a percentage of its fair value.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCom~~
~~Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period~~
~~Type:duration~~

~~- Details~~

~~Name:us-gaap_PlanNameAxis=qncx_NovosteoPlanMember Namespace Prefix: Data Type:na~~
~~Balance Type: Period Type:~~

~~- Details~~

~~Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data~~
~~Type:na Balance Type: Period Type:~~

~~- Details~~

~~Name:us-gaap_AwardTypeAxis=qncx_RestrictedStockAwardsMember Namespace Prefix: Data~~
~~Type:na Balance Type: Period Type:~~

~~- Details~~

~~Name:us-gaap_VestingAxis=qncx_OneYearAnniversaryMember Namespace Prefix: Data Type:na~~
~~Balance Type: Period Type:~~

~~- Details~~

~~Name:us-gaap_VestingAxis=qncx_ThreeYearAnniversaryMember Namespace Prefix: Data Type:na~~
~~Balance Type: Period Type:~~

~~- Details~~

~~Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type:~~
~~Period Type:~~

~~- Details~~

~~Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type:~~
~~Period Type: XML 73 R57.htm IDEA: XBRL DOCUMENT~~

~~Stock-Based Compensation - 2022 Inducement Plan (Details) 3 Months 9 Months 12 Months~~
~~- USD (\$) \$ in Thousands Ended Ended Ended~~

~~May 09, 2022~~

~~Sep. 30, 2024~~

~~Sep. 30, 2023~~

~~Sep. 30, 2024~~

~~Sep. 30, 2023~~

~~Dec. 31, 2023~~

~~Share Based Compensation Arrangement By Share Based Payment Award [Line Items]~~

~~Total stock-based compensation \$ 1,124\$ 1,331\$ 3,621\$ 4,134\$ 1002022 Inducement Plan~~

~~Share Based Compensation Arrangement By Share Based Payment Award [Line Items]~~

~~Increase in number of shares available for issuance as proportion of shares of common~~
~~stock (in shares)4,000,000 Award grant period10 years Rate of purchase price of~~

~~stock on fair value (as a percent) 100.00% Common stock reserved for issuance (in shares) 1,666,694 1,666,694 Total stock-based compensation \$ 300 \$ 1,000 Options, stock-based compensation not yet recognized \$ 2,200 \$ 2,200 2022 Inducement Plan / Stock Options Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Total stock-based compensation \$ 400 \$ 1,500 Unamortized employee stock-based compensation expected to be recognized over remaining estimated vesting period 1 year 7 months 20 days~~
~~- Definition~~

~~Share based compensation arrangement by share based payment award grant period.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name: qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantPeriod
Namespace Prefix: qncx_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration~~

~~- Definition~~

~~Share based compensation arrangement by share based payment award increase in number of shares available for issuance as proportion of shares of common stock.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name: qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfShares
Namespace Prefix: qncx_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant~~

~~- Definition~~

~~Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479830/718-10-S99-1>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

~~+ Details~~

Name:us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo: Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Amount of cost to be recognized for option under share-based payment arrangement.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNo:
Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:debit Period
Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many
axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3>Reference 3:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 4:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 5:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 6:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 7:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 8:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 9:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 10:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(01\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(01)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 11:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(02\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 12:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(03\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(03)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 13:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 14:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 15:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 16:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 17:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(01\)-Publisher](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(01)-Publisher)

~~FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 18:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 19:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 20:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 21:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 22:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 23:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 24:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 25:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 26:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 27:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 28:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -~~
~~URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:us-gaap_ Data Type:xbli:stringItemType Balance Type:na Period Type:
duration

[- Definition](#)

Purchase price of common stock expressed as a percentage of its fair value.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCom
Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period
Type:duration

[- Details](#)

Name:us-gaap_PlanNameAxis=qncx_TwoThousandAndTwentyTwoInducementPlanMember Namespace
Prefix: Data Type:na Balance Type: Period Type:

[- Details](#)

Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember_Namespace Prefix:Data
Type:na Balance Type: Period Type: XML 74 R58.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Stock-Based
Compensation Expense (Details) - USD (\$) \$ in Thousands
3 Months Ended
9 Months Ended
12 Months Ended

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2023

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
stock-based compensation\$ 1,124\$ 1,331\$ 3,621\$ 4,134\$ 100General and administrative
expense
Share Based Compensation Arrangement By Share Based Payment Award [Line
Items]
Total stock-based compensation7869453,0963,014 Research and development
expense
Share Based Compensation Arrangement By Share Based Payment Award [Line
Items]
Total stock-based compensation\$ 338\$ 386\$ 525\$ 1,120
- Definition

Amount of expense for award under share-based payment arrangement. Excludes amount
capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic
14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-
1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -
Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_AllocatedShareBasedCompensationExpense_Namespace Prefix:us-gaap_Data
Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many
axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name
Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI
https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2:
http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3:

[illegible]

~~Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 26:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 27:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 28:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB
-URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>~~

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:
duration

--Details

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: Data Type:na Balance Type: Period Type:

--Details

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: Data Type:na Balance Type: Period Type: XML 75 R59.htm IDEA: XBRL
DOCUMENT

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - 2019 Apr. 24,
ESPP 2019
shares

Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Common
stock reserved for issuance (in shares)1,924,262Maximum period for common stock shares
reserved for future issuance10 yearsIncrease in number of shares available for issuance
as proportion of shares of common stock (in shares)536,589Percentage of common stock
outstanding1.00%

--Definition

Maximum period for common stock capital shares reserved for future issuance.

+ References

No definition available.

+ Details

Name:gncx_MaximumPeriodForCommonStockCapitalSharesReservedForFutureIssuance Namespace
Prefix:gncx_ Data Type:xbri:durationItemType Balance Type:na Period Type:duration

--Definition

Share based compensation arrangement by share based payment award increase in number of
shares available for issuance as proportion of shares of common stock.

+ References

No definition available.

+ Details

Name:gncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSha
Namespace Prefix:gncx_ Data Type:xbri:sharesItemType Balance Type:na Period Type:
instant

- Definition

Aggregate number of common shares reserved for future issuance.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-599-1>

+ Details

Name:us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix:us-gaap_ Data Type:xbrl:sharesItemType Balance Type:na Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480483/718-10-35-1D>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480483/718-10-35-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480429/718-10-50-2>Reference 13:

[illegible]

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems
Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type:
duration

-- Definition

Maximum number of shares that may be issued in accordance with the plan as a proportion
of outstanding capital stock.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstai
Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period
Type:duration

-- Details

Name:us-gaap_PlanNameAxis=qncx_TwoThousandNineteenEmployeeStockPurchasePlanMember
Namespace Prefix: Data Type:na Balance Type: Period Type: XML 76 R60.htm IDEA: XBRL
DOCUMENT

Long-term Debt - Additional Information (Details) € in Thousands, \$ in 9 Months
Thousands Ended

Nov. 13, 2024

USD (\$)

Nov. 13, 2024

EUR (€)

Oct. 20, 2023

EUR (€)

Sep. 30, 2024

USD (\$)

Sep. 30, 2024

EUR (€)

Dec. 31, 2023

USD (\$)

Debt Instrument [Line Items] Long-term debt / \$ \$ 14,899 \$ 13,429 Ery Del
Debt Instrument [Line Items] Foreign currency translation adjustment in fair value
/ \$ 200 Line of Credit / Ery Del Debt Instrument [Line Items] Provision for
additional remuneration paid based on revenue up to 125 Million Euros, percentage 2.50%
Provision for additional remuneration paid based on revenue between 125 Million and
250 Million Euros, percentage 1.85% Provision for additional remuneration paid based
on revenue greater than 250 Million Euros, percentage 1.00% Remuneration payable
period 7 years Line of Credit / Minimum Debt Instrument [Line Items]
Disbursement period 12 months Line of Credit / Maximum Debt Instrument [Line
Items] Disbursement period 5 years EIB loan Debt Instrument [Line Items]
Fair value of the EIB Loan / \$ 14,900 Fair value adjustment / \$ 1,300 EIB loan
/ Line of Credit Debt Instrument [Line Items] Maximum borrowings € 30,000
Long-term debt \$ 11,200€ 10,000 Imputed interest 9.00%9.00% Minimum cash balance
\$ 16,400€ 14,650 EIB loan / Line of Credit / Ery Del Debt Instrument [Line Items]
Drawn percentage 100.00% EIB loan / Line of Credit / Subsequent Event Debt
Instrument [Line Items] Percentage of deferred interest converted2.00%2.00%
Deferred interest percent9.00%9.00% Payment of one-time amendment fee\$ 20€ 20 EIB
loan / Line of Credit / Minimum Debt Instrument [Line Items] Fixed interest
rate 7.00% EIB loan / Line of Credit / Maximum Debt Instrument [Line Items]
Fixed interest rate 9.00% European Bank Loan, Tranche A, Tranche B, Tranche C / Line
of Credit / Ery Del Debt Instrument [Line Items] Drawn percentage 80.00%
EIB Loan, Tranche A and Tranche B / Line of Credit / Ery Del Debt Instrument [Line
Items] Drawn percentage 50.00% EIB Loan, Tranche A / Line of Credit Debt
Instrument [Line Items] Maximum borrowings € 3,000 EIB Loan, Tranche A / Line of
Credit / Ery Del Debt Instrument [Line Items] Drawn percentage 30.00% EIB
Loan, Tranche B / Line of Credit Debt Instrument [Line Items] Maximum
borrowings € 7,000 EIB Loan Tranche C / Line of Credit Debt Instrument [Line
Items] Maximum borrowings 10,000 EIB Loan ,Tranche D / Line of Credit Debt
Instrument [Line Items] Maximum borrowings € 10,000

-- Definition

Debt Instrument, Covenant, Minimum Required Cash Balance

+ References

No definition available.

+ Details

Name:qncx_DebtInstrumentCovenantMinimumRequiredCashBalance Namespace Prefix:qncx_ Data

~~Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~[-- Definition](#)~~

~~Debt Instrument, Deferred Interest Percent~~

~~[+ References](#)~~

~~No definition available.~~

~~[+ Details](#)~~

~~Name: qncx_DebtInstrumentDeferredInterestPercent Namespace Prefix: qncx_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:instant~~

~~[-- Definition](#)~~

~~Debt Instrument, Percentage Of Deferred Interest Converted~~

~~[+ References](#)~~

~~No definition available.~~

~~[+ Details](#)~~

~~Name: qncx_DebtInstrumentPercentageOfDeferredInterestConverted Namespace Prefix: qncx_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:instant~~

~~[-- Definition](#)~~

~~Disbursement period.~~

~~[+ References](#)~~

~~No definition available.~~

~~[+ Details](#)~~

~~Name: qncx_DisbursementPeriod Namespace Prefix: qncx_ Data Type: xbrli:durationItemType Balance Type:na Period Type:duration~~

~~[-- Definition](#)~~

~~Drawn percentage.~~

~~[+ References](#)~~

~~No definition available.~~

~~[+ Details](#)~~

~~Name: qncx_DrawnPercentage Namespace Prefix: qncx_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:duration~~

~~[-- Definition](#)~~

~~Imputed interest on borrowings~~

~~[+ References](#)~~

~~No definition available.~~

~~[+ Details](#)~~

~~Name: qncx_ImputedInterestOnBorrowings Namespace Prefix: qncx_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:instant~~

~~[-- Definition](#)~~

~~Provision For Additional Remuneration Paid Based On Revenue Between 125 Million And 250 Million Euros, Percentage~~

~~[+ References](#)~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_ProvisionForAdditionalRemunerationPaidBasedOnRevenueBetween125MillionAnd250Mil
Namespace Prefix:gncx_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:
duration~~

~~-- Definition~~

~~Provision For Additional Remuneration Paid Based On Revenue Greater Than 250 Million
Euros, Percentage~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_ProvisionForAdditionalRemunerationPaidBasedOnRevenueGreaterThan250MillionEuros
Namespace Prefix:gncx_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:
duration~~

~~-- Definition~~

~~Provision for additional remuneration paid based on revenue percentage.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_ProvisionForAdditionalRemunerationPaidBasedOnRevenueUpTo125MillionEurosPercent
Namespace Prefix:gncx_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:
duration~~

~~-- Definition~~

~~Remuneration payable period.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:gncx_RemunerationPayablePeriod Namespace Prefix:gncx_ Data Type:
xbrli:durationItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Contractual interest rate for funds borrowed, under the debt agreement.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name
Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1B>Reference 2:
<http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -
Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

+ Details

Name:us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 835-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147482900/835-30-50-1>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(f\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(f))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.12-04\(a\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.12-04(a))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B)Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69B-Publisher FASB-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B>Reference 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69C-Publisher FASB-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C>Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69E-Publisher FASB-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E>Reference 8: <http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 69F-Publisher FASB-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B)Reference 11: [http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/exampleRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1B-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1D-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1D-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D)Reference 16:

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25>;~~

~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1I>~~

+ Details

Name:us-gaap_DebtInstrumentLineItems Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.

+ References

No definition available.

+ Details

Name:us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.

+ References

No definition available.

+ Details

Name:us-gaap_LiabilitiesFairValueAdjustment Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-599-1>

+ Details

Name:us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Fair value portion of contractual obligation to pay money on demand or on fixed or

~~determinable dates.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_LoansPayableFairValueDisclosure Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~- Definition~~

~~Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481568/470-20-55-69B>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481568/470-20-55-69C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1D>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-4>~~

+ Details

Name:us-gaap_LongTermDebt Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType
Balance Type:credit Period Type:instant

-- Definition

The cash outflow for loan and debt issuance costs.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482740/230-10-45-15>

+ Details

Name:us-gaap_PaymentsOffFinancingCosts Namespace Prefix:us-gaap_ Data Type:
xbkli:monetaryItemType Balance Type:credit Period Type:duration

-- Details

~~Name:us-gaap_BusinessAcquisitionAxis=qncx_EryDelMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_DebtInstrumentAxis=qncx_EuropeanInvestmentBankLoanMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_DebtInstrumentAxis=qncx_EuropeanBankLoanTrancheATrancheBTrancheCMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_DebtInstrumentAxis=qncx_EuropeanInvestmentBankLoanTrancheAAndTrancheBMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_DebtInstrumentAxis=qncx_EuropeanInvestmentBankLoanTrancheAMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_DebtInstrumentAxis=qncx_EuropeanInvestmentBankLoanTrancheBMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_DebtInstrumentAxis=qncx_EuropeanInvestmentBankLoanTrancheCMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

~~--Details~~

~~Name:us-gaap_DebtInstrumentAxis=qncx_EuropeanInvestmentBankLoanTrancheDMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 77 R61.htm IDEA: XBRL DOCUMENT~~

~~Long-term Debt -- Schedule of Future Minimum Principal Payments Sep. 30, Dec. 31, (Details) - USD (\$) \$ in Thousands 2024 2023~~

~~Debt Disclosure [Abstract] 2024\$ 0 20250 202611,190 2027 and thereafter0 Total future payments11,190 Imputed interest and fair value adjustments3,709 Total Debt as of September 30, 2024\$ 14,899\$ 13,429~~

~~--Definition~~

~~Debt instrument imputed interest.~~

~~+References~~

~~No definition available.~~

~~+Details~~

~~Name:qncx_DebtInstrumentImputedInterest Namespace Prefix:qncx Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant~~

~~--Definition~~

~~Long term debt maturities repayments of principal year three and thereafter.~~

~~+References~~

~~No definition available.~~

~~+Details~~

Name:gncx_LongTermDebtMaturitiesRepaymentsOfPrincipalYearThreeAndThereafter Namespace Prefix:gncx_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

--References

No definition available.

+Details

Name:us-gaap_DebtDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

--Definition

Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.

+References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>
Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-4>

+Details

Name:us-gaap_DebtInstrumentCarryingAmount Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

--Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~
~~Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481568/470-20-55-69B>~~
~~Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481568/470-20-55-69C>~~
~~Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1D>~~
~~Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479440/944-210-S99-1>~~
~~Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>~~
~~Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-4>~~

+ Details

Name:us-gaap_LongTermDebt Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType
Balance Type:credit Period Type:instant

- Definition

Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-3>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1E>
Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481544/470-10-50-1>

+ Details

Name:us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant

-- Definition

Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481139/470-20-50-1E>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481544/470-10-50-1>

+ Details

Name:us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant

-- Definition

Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.12-04\(a\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.12-04(a))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-3>

+ Details

Name:us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType Balance Type:credit Period Type:instant XML 78 R62.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD (\$) \$ in Thousands3 Months Ended9 Months Ended Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Income Tax Disclosure [Abstract] — [Income tax expense](#)\$ 13\$ 0\$ 80\$ (248)

- References

No definition available.

+ Details

Name:us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8> -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-8>Reference 2:

<http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9> -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-9>Reference 3:

<http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10> -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482685/740-10-50-10>Reference 4:

[http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB TOPIC 6.I.7\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB TOPIC 6.I.7)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479360/740-10-S99-1>Reference 5:

[http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(h\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (h)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-22>Reference 6:

[http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(9\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(9))) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>Reference 7:

[http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph \(a\)-SubTopic 20-Topic 740](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph (a)-SubTopic 20-Topic 740) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482659/740-20-45-2>Reference 8:

[http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(h\)\)](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h))) -SubTopic 10-Topic 235-

+ Details

Name:us-gaap_IncomeTaxExpenseBenefit Namespace Prefix:us-gaap_ Data Type:
xbrli:monetaryItemType Balance Type:debit Period Type:duration XML 79 R63.htm IDEA: XBRL
DOCUMENT

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net
Loss Per Share (Details) - USD (\$) \$ / shares in Units, \$ in Thousands
3 9
Months Months
Ended Ended

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Numerator: Net loss\$ (5,492)\$ (5,351)\$ (44,370)\$ (22,491)Denominator: Weighted
average shares of common stock outstanding - basic (in shares)43,164,13636,073,040
43,090,63235,941,234Weighted average shares of common stock outstanding - diluted (in
shares)43,164,13636,073,04043,090,63235,941,234Net loss per share - basic (in USD per
share)\$ (0.13)\$ (0.15)\$ (1.03)\$ (0.63)Net loss per share - diluted (in USD per share)
\$ (0.13)\$ (0.15)\$ (1.03)\$ (0.63)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit
outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3:
http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting
Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -
URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4:
http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting
Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5:
http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6:
http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7:
http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10:
http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI

~~<https://asc.fasb.org//1943274/2147482662/260-10-50-1>Reference 12:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482689/260-10-45-10>Reference 13:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147483621/220-10-S99-2>Reference 14:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147483589/942-220-S99-1>Reference 15:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147483586/944-220-S99-1>Reference 16:~~
~~<http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482635/260-10-55-52>Reference 17:~~
~~<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI~~
~~<https://asc.fasb.org//1943274/2147482689/260-10-45-7>~~

+ Details

Name:us-gaap_EarningsPerShareBasic Namespace Prefix:us-gaap_ Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-3>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482635/260-10-55-15>
Reference 3:

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4:](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4:)~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5:](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5:)~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6:](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6:)~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7:](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7:)~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8:](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8:)~~

~~<http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9:>~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10:](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10:)~~

~~<http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11:>~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12:](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12:)~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13:](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13:)~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14:](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14:)~~

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15:](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15:)~~

~~<http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16:>~~

~~<http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7>~~

[+ Details](#)

~~Name:us-gAAP_EarningsPerShareDiluted Namespace Prefix:us-gAAP_ Data Type:
dtr-types:perShareItemType Balance Type:na Period Type:duration~~

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480678/235-10-S99-1>

Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481687/323-10-50-3>

Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482907/825-10-50-28>

Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482765/220-10-50-6>

Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-3>

Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-1>

Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480175/815-40-65-1>

Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-8>

Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-9>

Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>

Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-11>

Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483443/250-10-50-4>

Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480167/946-830-55-10>

Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483581/946-220-45-7>

Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483586/944-220-S99-1>

Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-22>

Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-1>

Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483575/946-220-S99-3>

Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1>

Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1>

Reference 21: <https://asc.fasb.org//1943274/2147480097/470-10-S99-1>

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-30>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-32>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482689/260-10-45-60B>Reference 32: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-31>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482810/280-10-50-32>Reference 34: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483499/205-20-50-7>Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-1A>Reference 37: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482790/220-10-45-1B>Reference 38: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483621/220-10-S99-2>Reference 39: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483589/942-220-S99-1>

[+ Details](#)

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbli:monetaryItemType
Balance Type:credit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetIncomeLossAbstract Namespace Prefix:us-gaap_ Data Type:
xbli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

The average number of shares or units issued and outstanding that are used in
calculating diluted EPS or earnings per unit (EPU), determined based on the timing of
issuance of shares or units in the period.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147482662/260-10-50-1>Reference 2:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482689/260-10-45-16>

+ Details

Name:us-gAAP_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix:us-gAAP_
Data Type:xbli:sharesItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gAAP_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix:us-gAAP_
Data Type:xbli:stringItemType Balance Type:na Period Type:duration

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or
units and other shares or units not deemed outstanding, determined by relating the
portion of time within a reporting period that common shares or units have been
outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher
FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2:
http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting
Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI
https://asc.fasb.org//1943274/2147482689/260-10-45-10

+ Details

Name:us-gAAP_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix:us-gAAP_
Data Type:xbli:sharesItemType Balance Type:na Period Type:duration XML 80 R64.htm IDEA:
XBRL DOCUMENT

Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares
Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares

9
Months
Ended

Sep. 30, 2024

Sep. 30, 2023

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of earnings per share (in shares)
10,148,4047,672,237Stock options issued and outstandingAntidilutive Securities
Excluded from Computation of Earnings Per Share [Line Items]Antidilutive securities
excluded from calculation of earnings per share (in shares)10,045,6517,469,163Restricted
stock unitsAntidilutive Securities Excluded from Computation of Earnings Per Share
[Line Items]Antidilutive securities excluded from calculation of earnings per share
(in shares)02,975Restricted stock awardsAntidilutive Securities Excluded from
Computation of Earnings Per Share [Line Items]Antidilutive securities excluded from
calculation of earnings per share (in shares)102,753200,099

-- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could
potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the
future that were not included in the computation of diluted EPS or EPU because to do so
would increase EPS or EPU amounts or decrease loss per share or unit amounts for the
period presented.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name
Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147482662/260-10-50-1>

+ Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:
duration

-- Definition

Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many
axes to the table.

+ References

No definition available.

+ Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems
Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:
duration

-- Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidiluti
Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidiluti
Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidiluti
Namespace Prefix: Data Type:na Balance Type: Period Type: XML 81 R65.htm IDEA: XBRL
DOCUMENT

Business Combination - Additional Information (Details) \$ / shares in Units, 3 Months
\$ in Thousands Ended
Oct. 20, 2023

~~USD (\$)~~
~~\$ / shares~~
~~shares~~
~~Sep. 30, 2024~~
~~USD (\$)~~
~~shares~~
~~Dec. 31, 2023~~
~~shares~~

~~Business Acquisition [Line Items] Share price (in USD per share) | \$ / shares\$ 0.989~~
~~Common stock, shares issued (in shares) | shares 43,276,60642,973,215NDA acceptance~~
~~under contingent consideration\$ 25,000 Business combination discount rate15.00%~~
~~Specified Approval Milestones Business Acquisition [Line Items] Milestone payment~~
~~\$ 60,000 Ery Del Business Acquisition [Line Items] Deferred tax liability5,098~~
~~Uncertain tax position liability500 Fair value of total consideration transferred~~
~~\$ 66,907 Common stock, shares issued (in shares) | shares6,525,315 Common stock~~
~~withheld (in shares) | shares725,037 Maximum amount of future consideration payment~~
~~\$ 485,000 Amount payable upon achievement of specified milestone.5,000 Milestone~~
~~achievement related to market and sales\$ 395,000 Payment for contingent consideration~~
~~\$ 5,000 Discounted earning after tax16.60% Intangible assets\$ 61,096 Royalty rate~~
~~utilized0.30% Discount rate16.60% Finite-lived intangible assets useful life21 years~~
~~Goodwill expected to be deductible\$ 0 Business acquisition, transaction costs2,500 Ery~~
~~Del / General and administrative expense Business Acquisition [Line Items] Business~~
~~acquisition, transaction costs2,300 Ery Del / Research and development expense~~
~~Business Acquisition [Line Items] Business acquisition, transaction costs200 Ery Del~~
~~/ Trade Names Business Acquisition [Line Items] Intangible assets500 Ery Del /~~
~~IP&D Business Acquisition [Line Items] Identifiable intangible assets\$ 60,600 Ery~~
~~Del / Probability of Achievement / Minimum / Contingent consideration Business~~
~~Acquisition [Line Items] Input used0 Ery Del / Probability of Achievement / Maximum /~~
~~Contingent consideration Business Acquisition [Line Items] Input used1~~
~~- Definition~~

~~Amount payable upon achievement of specified milestone.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:qncx_AmountPayableUponAchievementOfSpecifiedMilestone Namespace Prefix:qncx_ Data~~
~~Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~- Definition~~

~~Discounted Earning After Tax~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:qncx_DiscountedEarningAfterTax Namespace Prefix:qncx_ Data Type:~~
~~dtr-types:percentItemType Balance Type:na Period Type:instant~~

~~- Definition~~

~~Discounted value to present value of intangible assets.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:qncx_DiscountedValueToPresentValueOfIntangibleAssets Namespace Prefix:qncx_ Data~~
~~Type:dtr-types:percentItemType Balance Type:na Period Type:instant~~

~~- Definition~~

Milestone achievement related to market and sales.

+ References

No definition available.

+ Details

Name:qncx_MilestoneAchievementRelatedToMarketAndSales Namespace Prefix:qncx_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

-- Definition

Milestone payment.

+ References

No definition available.

+ Details

Name:qncx_MilestonePayment Namespace Prefix:qncx_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

-- Definition

NDA acceptance under contingent consideration.

+ References

No definition available.

+ Details

Name:qncx_NDAAcceptanceUnderContingentConsideration Namespace Prefix:qncx_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

-- Definition

Probability Discount Rate of Each Milestone

+ References

No definition available.

+ Details

Name:qncx_ProbabilityDiscountRateOfEachMilestone Namespace Prefix:qncx_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:duration

-- Definition

Royalty rate utilizing under income approach.

+ References

No definition available.

+ Details

Name:qncx_RoyaltyRateUtilizingUnderIncomeApproach Namespace Prefix:qncx_ Data Type: dtr-types:percentItemType Balance Type:na Period Type:instant

-- Definition

Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDnHnMnS' format, for example, 'PL1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -

~~+ Details~~

~~Name:us-gaap_AcquiredFinitelivedIntangibleAssetsWeightedAverageUsefullife Namespace
Prefix:us-gaap_ Data Type:xbli:durationItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts Namespace Prefix:
us-gaap_ Data Type:xbli:monetaryItemType Balance Type:debit Period Type:instant~~

~~- Definition~~

~~Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 20 -Name
Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher
FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-5>~~

~~+ Details~~

~~Name:us-gaap_BusinessAcquisitionLineItems Namespace Prefix:us-gaap_ Data Type:
xbli:stringItemType Balance Type:na Period Type:duration~~

~~- Definition~~

~~The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (d) -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147479581/805-30-50-1>~~

+ Details

Name:us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmou
Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:debit Period
Type:instant

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets
transferred by the acquirer, liabilities incurred by the acquirer, and equity interest
issued by the acquirer.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147479637/805-30-30-8>Reference 2: [http://fasb.org/us-](http://fasb.org/us-</u>
<u><a href=)
[gaap/role/ref/legacyRef](http://fasb.org/us-gaap/role/ref/legacyRef) -Name Accounting Standards Codification -Section 50 -Paragraph 1
-Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147479581/805-30-50-1>Reference 3: [http://fasb.org/us-](http://fasb.org/us-</u>
<u><a href=)
[gaap/role/ref/legacyRef](http://fasb.org/us-gaap/role/ref/legacyRef) -Name Accounting Standards Codification -Section 30 -Paragraph 7
-SubTopic 30 -Topic 805 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147479637/805-30-30-7>

+ Details

Name:us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix:us-gaap_
Data Type:xbkli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

For contingent consideration arrangements recognized in connection with a business
combination, this element represents an estimate of the high-end of the potential range
(undiscounted) of the consideration which may be paid.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479581/805-30-50-1>

+ Details

Name:us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueH: Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Value of input used to measure contingent consideration liability from business combination.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>

+ Details

Name:us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Namespace Prefix:us-gaap_ Data Type:xbkli:decimalItemType Balance Type:na Period Type:instant

- Definition

Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssume Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:credit Period Type:instant

~~Definition~~

~~Amount of intangible assets, excluding goodwill, acquired at the acquisition date.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-1>~~

~~+ Details~~

~~Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed Namespace Prefix:us-gaap_ Data Type:xbnli:monetaryItemType Balance Type:debit Period Type:instant~~

~~Definition~~

~~The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_ClassOfWarrantOrRightUnissued Namespace Prefix:us-gaap_ Data Type:xbnli:sharesItemType Balance Type:na Period Type:instant~~

~~Definition~~

~~Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~

~~+ Details~~

~~Name:us-gaap_CommonStockSharesIssued Namespace Prefix:us-gaap_ Data Type:xbnli:sharesItemType Balance Type:na Period Type:instant~~

~~Definition~~

~~Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.~~

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482106/820-10-50-2>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount recognized for uncertainty in income taxes classified as current.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_LiabilityForUncertainTaxPositionsCurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (d) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-13>

+ Details

Name:us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

Price of a single share of a number of saleable stocks of a company.

[+ References](#)

No definition available.

[+ Details](#)

Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType
Balance Type: na Period Type: instant

[- Details](#)

Name: qncx_MilestonePaymentAxis=qncx_ApprovalMilestonesMember Namespace Prefix: Data
Type: na Balance Type: Period Type:

[- Details](#)

Name: us-gaap_BusinessAcquisitionAxis=qncx_EryDelMember Namespace Prefix: Data Type: na
Balance Type: Period Type:

[- Details](#)

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: Data Type: na Balance Type: Period Type:

[- Details](#)

Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: Data Type: na Balance Type: Period Type:

[- Details](#)

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: Data Type: na Balance Type: Period Type:

[- Details](#)

Name: us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAnd
DevelopmentMember Namespace Prefix: Data Type: na Balance Type: Period Type:

[- Details](#)

Name: us-gaap_MeasurementInputTypeAxis=qncx_ProbabilityOfAchievementMember Namespace
Prefix: Data Type: na Balance Type: Period Type:

[- Details](#)

Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type:
Period Type:

[- Details](#)

Name: us-gaap_ContingentConsiderationByTypeAxis=qncx_ContingentConsiderationMember
Namespace Prefix: Data Type: na Balance Type: Period Type:

[- Details](#)

Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type:
Period Type: XML 82 R66.htm IDEA: XBRL DOCUMENT

Business Combination - Schedule of Fair Value of the Total Purchase Oct. 20,
Consideration Transferred (Details) - Ery Del \$ in Thousands 2023
USD (\$) shares

Business Acquisition [Line Items] Cash\$ 2,615Quince Therapeutics common stock (7,250,352
shares)7,164Contingent consideration56,128Settlement of preexisting notes receivable
1,000Fair value of total consideration transferred\$ 66,907Quince Therapeutics common
stock (in shares) / shares7,250,352

[- Definition](#)

Business Combination Settlement of preexisting notes receivable

[+ References](#)

No definition available.

[+ Details](#)

Name: qncx_BusinessCombinationSettlementOfPreexistingNotesReceivable Namespace Prefix:
qncx_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration

[- Definition](#)

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 805-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(4\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 805-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(4)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1)

+ Details

Name:us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:us-gaap_ Data Type:xbri:sharesItemType Balance Type:na Period Type:duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5)

+ Details

Name:us-gaap_BusinessAcquisitionLineItems Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 30-Paragraph 8-SubTopic 30-Topic 805-Publisher FASB-URI https://asc.fasb.org//1943274/2147479637/805-30-30-8>
Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-SubTopic 30-Topic 805-Publisher FASB-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-SubTopic 30-Topic 805-Publisher FASB-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1)
Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 30-Paragraph 7-SubTopic 30-Topic 805-Publisher FASB-URI https://asc.fasb.org//1943274/2147479637/805-30-30-7>

+ Details

Name:us-gAAP_BusinessCombinationConsiderationTransferred1 Namespace Prefix:us-gAAP_
Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479637/805-30-30-8>
Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479637/805-30-30-7>

+ Details

Name:us-gAAP_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
Namespace Prefix:us-gAAP_ Data Type:xbrli:monetaryItemType Balance Type:credit Period
Type:duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash

~~portion only of the acquisition price.~~

~~+ References~~

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13)~~

~~+ Details~~

~~Name:us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~-- Definition~~

~~The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.~~

~~+ References~~

~~Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13)~~

~~+ Details~~

~~Name:us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~-- Details~~

~~Name:us-gaap_BusinessAcquisitionAxis=qncx_EryDelMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 83 R67.htm IDEA: XBRL DOCUMENT~~

~~Business Combination - Schedule of Fair Values of Assets Acquired Sep. Dec. Oct.
and Liabilities Assumed (Details) - USD (\$) \$ in Thousands 30, 31, 20,
2024 2023 2023~~

~~Assets acquired: Goodwill\$ 0\$ 17,625 Ery Del Assets acquired: Cash \$ 560Tax
assets 10,1870ther current assets 644Property and equipment, net 238Operating lease
right-of-use assets, net 3830ther non-current assets 14Intangible assets 61,096~~

Goodwill 16,929Total assets acquired 90,051Liabilities assumed: Trade payables (1,685)Accrued expenses and other current liabilities (2,943)Debt, non-current (12,564)Other non-current liabilities (854)Deferred tax liability (5,098)Total liabilities assumed (23,144)Fair value of total consideration transferred \$ 66,907
- Definition

Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accrued expenses.

+ References

No definition available.

+ Details

Name:qncx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCu
Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:
instant

- Definition

Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, trade payables.

+ References

No definition available.

+ Details

Name:qncx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCu
Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:
instant

- Definition

Business combination, recognized identifiable assets acquired and liabilities assumed, operating lease right-of-use assets.

+ References

No definition available.

+ Details

Name:qncx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOp
Namespace Prefix:qncx_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:
instant

- Definition

Amount of assets acquired at the acquisition date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssume
Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period

Type:instant

--References

No definition available.

+Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssume
Namespace Prefix:us-gaap_ Data Type:xbkli:stringItemType Balance Type:na Period Type:
duration

--Definition

Amount of currency on hand as well as demand deposits with banks or financial
institutions, acquired at the acquisition date. Includes other kinds of accounts that
have the general characteristics of demand deposits. Also includes short-term, highly
liquid investments that are both readily convertible to known amounts of cash and so
near their maturity that they present insignificant risk of changes in value because of
changes in interest rates.

+References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -
Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1>

+Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssume
Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:debit Period
Type:instant

--Definition

Amount of other assets expected to be realized or consumed before one year or the normal
operating cycle, if longer, acquired at the acquisition date.

+References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -
Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1>

+Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssume
Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:debit Period
Type:instant

--Definition

Amount of deferred tax asset attributable to deductible temporary differences and

carryforwards acquired at the acquisition date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed
Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:debit Period
Type:instant

- Definition

Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed
Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:credit Period
Type:instant

- Definition

Amount of intangible assets, excluding goodwill, acquired at the acquisition date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed

~~Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant~~

~~-- Definition~~

~~Amount of liabilities assumed at the acquisition date.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1>~~

~~+ Details~~

~~Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed
Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant~~

~~-- References~~

~~No definition available.~~

~~+ Details~~

~~Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed
Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration~~

~~-- Definition~~

~~Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.~~

~~+ References~~

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479907/805-20-50-1>~~

~~+ Details~~

~~Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed
Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant~~

~~-- Definition~~

~~Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.~~

~~+ References~~

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssume
Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:credit Period
Type:instant

- Definition

Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssume
Namespace Prefix:us-gaap_ Data Type:xbkli:monetaryItemType Balance Type:debit Period
Type:instant

- Definition

The amount of property, plant, and equipment recognized as of the acquisition date.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479303/805-10-55-37>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumed
Namespace Prefix:us-gaap_ Data Type:xbtli:monetaryItemType Balance Type:debit Period
Type:instant

- Definition

Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479907/805-20-50-1>

+ Details

Name:us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilities
Namespace Prefix:us-gaap_ Data Type:xbtli:monetaryItemType Balance Type:debit Period
Type:instant

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147481372/852-10-55-10>
Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482548/350-20-55-24>
Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482598/350-20-45-1>
Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>
Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>
Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>

[+ Details](#)

Name:us-gAAP_Goodwill Namespace Prefix:us-gAAP_ Data Type:xbrli:monetaryItemType

Balance Type:debit Period Type:instant

--Details

Name:us-gaap_BusinessAcquisitionAxis=gncx_EryDelMember Namespace Prefix: Data Type:na

Balance Type: Period Type: XML 84 R68.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Carrying Amount of Indefinite Lived 3 Months 9 Months

Intangible Asset (Details) - USD (\$) \$ in Thousands Ended Ended

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

In-process research and development: Impairment charge\$ 0\$ 0\$ 0\$ (5,900)IPR&D In-

process research and development: Balance as of December 31, 2023 63,197 Impairment

charge 0\$ (5,900)Foreign currency translation adjustments 867 Balance as of September

30, 2024\$ 64,064 \$ 64,064

--Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards

Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 30 -Topic 350 -

Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3Reference 2:

http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -

Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI

https://asc.fasb.org//1943274/2147482740/230-10-45-28

+Details

Name:us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix:us-gaap_

Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

--Definition

Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.

+References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher

FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2

+ Details

Name:us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbtli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.

+ References

No definition available.

+ Details

Name:us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss Namespace Prefix:us-gaap_ Data Type:xbtli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:us-gaap_IndefiniteLivedIntangibleAssetsRollForward Namespace Prefix:us-gaap_ Data Type:xbtli:stringItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAnd Namespace Prefix: Data Type:na Balance Type: Period Type: XML 85 R69.htm IDEA: XBRL DOCUMENT

Intangible Assets - Schedule of Carrying Amount of Finite-Lived Intangible Asset (Details) - USD (\$) \$ in Thousands 9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023

Finite-Lived Intangible Assets [Line Items] Net Carrying Value\$ 464\$ 475Impairment charge00Foreign currency translation adjustments\$ 2619Trade Names Finite-Lived Intangible Assets [Line Items] Useful life21 years Cost\$ 460460Accumulated Amortization (22)(4)Net Carrying Value\$ 438\$ 456

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix:us-gaap_ Data Type:xbtli:durationItemType Balance Type:na Period Type:instant

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>~~
~~Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482665/350-30-50-2>~~

+ Details

~~Name:us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

- Definition

~~Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life.~~

+ References

~~No definition available.~~

+ Details

~~Name:us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

- Definition

~~Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.~~

+ References

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483147/928-340-50-1>~~
~~Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482665/350-30-50-2>~~

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483154/926-20-50-5>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix:us-gaap_ Data Type: xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147483154/926-20-50-5>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482665/350-30-50-2>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482665/350-30-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482665/350-30-50-3)

+ Details

Name:us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Details

Name:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 86 R70.htm IDEA: XBRL DOCUMENT

Intangible Assets - Additional Information (Details) - USD (\$) \$ 3 Months 9 Months
in Thousands Ended Ended

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Finite-Lived Intangible Assets [Line Items] Intangible asset impairment charge\$ 0\$ 0
\$ 0\$ 5,900Impairment charge\$ 0\$ 017,1300IPR&D Finite-Lived Intangible Assets [Line
Items] Intangible asset impairment charge \$ 0\$ 5,900

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 926-SubTopic 20-Name>

~~Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147483154/926-20-50-5>~~

+ Details

~~Name:us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix:us-gaap_ Data Type:
xbrli:stringItemType Balance Type:na Period Type:duration~~

- Definition

~~Amount of loss from the write-down of an asset representing the future economic benefits
arising from other assets acquired in a business combination that are not individually
identified and separately recognized.~~

+ References

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards
Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -
Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 2:
<http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting
Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482548/350-20-55-24>Reference 3:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting
Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482573/350-20-50-1>Reference 4:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting
Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482573/350-20-50-2>Reference 5:
<http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting
Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI
<https://asc.fasb.org//1943274/2147482598/350-20-45-2>~~

+ Details

Name:us-gaap_GoodwillImpairmentLoss Namespace Prefix:us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

+ Details

Name:us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-- Details

Name:us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopment Namespace Prefix: Data Type:na Balance Type: Period Type: XML 87 R71.htm IDEA: XBRL DOCUMENT
Intangible Assets -- Schedule Carrying Amount of Goodwill (Details) 3 Months 9 Months
-- USD (\$) \$ in Thousands Ended Ended
Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Goodwill [Roll Forward] — Balance as of December 31, 2023 \$ 17,625 Impairment charge \$ 0\$ 0(17,130)\$ 0Foreign currency translation adjustments (495) Balance as of September 30, 2024\$ 0 \$ 0

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI

<https://asc.fasb.org//1943274/2147481372/852-10-55-10>Reference 2:

<http://www.xbrl.org/2003/role/exampleRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI

<https://asc.fasb.org//1943274/2147482548/350-20-55-24>Reference 3:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -

Publisher FASB -URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 4:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI

<https://asc.fasb.org//1943274/2147482598/350-20-45-1>Reference 5:

<http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI

<https://asc.fasb.org//1943274/2147482573/350-20-50-1>Reference 6:

<http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI

<https://asc.fasb.org//1943274/2147482573/350-20-50-1>Reference 7:

<http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -

Publisher FASB -URI <https://asc.fasb.org//1943274/2147479853/942-210-S99-1>

+ Details

Name:us-gAAP_Goodwill Namespace Prefix:us-gAAP_ Data Type:xbri:monetaryItemType
Balance Type:debit Period Type:instant

- Definition

Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482573/350-20-50-1>

+ Details

Name:us-gAAP_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix:us-gAAP_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of loss from the write-down of an asset representing the future economic benefits

arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)
Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 24-Publisher FASB-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24>
Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1)
Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2)
Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147482598/350-20-45-2>

+ Details

Name:us-gaap_GoodwillImpairmentLoss Namespace Prefix:us-gaap Data Type: xbrli:monetaryItemType Balance Type:debit Period Type:duration

-- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:us-gaap_GoodwillRollForward Namespace Prefix:us-gaap Data Type: xbrli:stringItemType Balance Type:na Period Type:duration XML 88 R72.htm IDEA: XBRL DOCUMENT

<u>Subsequent Events (Details) - Line of Credit - EIB loan - Subsequent Event</u>	<u>€ in Thousands,</u>	<u>\$ in Thousands</u>	<u>Nov. 13, 2024</u>	<u>Nov. 13, 2024</u>
	<u>EUR (€)</u>	<u>USD (\$)</u>		
<u>Subsequent Event [Line Items] - Percentage of deferred interest converted</u>	<u>2.00%</u>	<u>2.00%</u>		
<u>Deferred interest percent</u>	<u>9.00%</u>	<u>9.00%</u>	<u>Payment of one-time amendment fee</u>	<u>€ 20 \$ 20</u>

-- Definition

Debt Instrument, Deferred Interest Percent

+ References

No definition available.

+ Details

Name:gncx_DebtInstrumentDeferredInterestPercent Namespace Prefix:gncx Data Type: dtr-types:percentItemType Balance Type:na Period Type:instant

-- Definition

Debt Instrument, Percentage Of Deferred Interest Converted

+ References

No definition available.

+ Details

Name:gncx_DebtInstrumentPercentageOfDeferredInterestConverted Namespace Prefix:gncx Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

-- Definition

The cash outflow for loan and debt issuance costs.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org//1943274/2147482740/230-10-45-15>

+ Details

Name:us-gaap_PaymentsOfFinancingCosts Namespace Prefix:us-gaap Data Type:

xb:li:monetaryItemType Balance Type:credit Period Type:duration

-- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147481674/830-30-50-2>
Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 855-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147483399/855-10-50-2>

+ Details

Name:us-gaap_SubsequentEventLineItems Namespace Prefix:us-gaap_ Data Type:xb:li:stringItemType Balance Type:na Period Type:duration

-- Details

Name:us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_DebtInstrumentAxis=gncx_EuropeanInvestmentBankLoanMember Namespace Prefix: Data Type:na Balance Type: Period Type:

-- Details

Name:us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type:na Balance Type: Period Type: EXCEL 89 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4\$L#!!0 (">);5D'04UB@0 +\$ 0 9&]C4')0<','087!P+GAM M;\$V./0L",1!\$_\IQ0;=!P4)B0-!2L+(</>QL0D&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(C(I(/ !47BK9.7:=N')=HI6-Y #0GDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " GB6U91 L)=.X K @ \$0 &108U!R;W!S+V-0&ULS9+! M:L,P#(9?9?B>R';*8";-I:.G#@8K;.QF;+4UBQ-C:R1]^SE9FS*V!|C1TN]/ MGT"U"4G_\$(09L/ M?420G-^#1])6DX8)6(2%R)K:&F4B:NKC!6_-@@^? L9UAU@"VZ+&C!*(4P)II M8CB/;0TWP_0CC#Y] NQ+GZ)W;N +LDQ^26U# ,Y5#-N;R#@+>GW-^RQK)Y:H0HA#57DK%'Q1?04^N/_QNPkZW[N#^ ML?%5L*GAUUTT7U!+ P04 " GB6U9F5R<(0 & "<)P \$P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:MK03621A'^_1S80RY8-[9)- NIL\!"SI^Y%1^?H.'GS[BYBZ(: (E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AJA4!P"I DQEJ&&^+3&K!'@\$WVW0@C(WXV({ZM0FCU7 MH5A)VH3X\$58:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)}7 \:V< M/!T3\$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@\$_9Y>PTG/Z(++90VX?H;5,VPLC0='U!=*Y \FIS_I,C0' MHYI9";V\$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P' T=HWPJ0X@L Y M?RY]SZ70N?0]H=*W-R-]9\ '3BU0>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+', <\$X>RPP[9SR2';9WH!TU^ 9=NOCI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\ /YZ<5X&N(YV02Y?9A7;>? 8T='[Y\%1L*/0/)8=QXCRHB'NH8:8S\ -# MAWE[7YAGE<90-!1M;*PD+\$:W8+C7\2P4X&1@+: '@Z]1 0)256 Q6\8#*Y"B M?&R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8\$V>KRMVEL<%5'<]56_*P

MOFHJM!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?}%U#KG[VW>/Z;I,
[2\$R<>41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPDL UC6'ODRWSEPVSK> U[F M\$RQ#I'!/?
8J*!&K8KZZKT_Y)9P[M'0Q@2";-;;I/;=X Q\U*M;I60K\$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ# 'F
6/,H68XWX=%FAHSU8NL.8T*;T'5 M0.4 V\0-;/8--!R1!5XQF;8VH^1."CS<_N_-L,+&CN'MB[\!4\$L#!!0 (M
M">);5F]XC8FY 4 .(> 8 >&P0=VJR:W-H965T&UL MM9EK4^,V%(; BB;M=-H90BPY%T(A,\ ' ENDN&PB];#0!
(&PE\;OMN;*Q@XBC)+EL+K=/S3B?S%R+FV;E, M10)09E+%7,.MFG>R5 D>%%\$QU&&.T^_/\$Q:HX0BV42-
+F2NHS 1\$T6R/(ZY M6E^)^2*^N6[2U>_8SA?;/.B,+E(^U.A?TLG^NXZI4H0QB+)0ID0)6:7K3\$] M]UQF
HH0?@_%*GMU30S^LY1?S>:9\&3T10CHQ67KK\$4",>-YI!_EZA>Q!>H9/5]&6?&7 MK#;?
=KLMXN>9E0\$V&\$H0A\GF/W_95L3K %H3P+8!|T K?L%=0Q@%J";DA58
MUUSST862*Z+,UZ!F+HJZ*;*!)DQ,,TZU@KQG>@+&6!V*Y 5PP5G(KTE+C."6\$.ZUK* MX^'A]W)Y2IR>+?Q-
<=RR?MQ"ST7KY^_QC:=-}([ULMX3M8NJC: ^GG,\$0U>5J6PD:*AU.G_6!# M0J,:(05*I-YA2
Y5UJH:\$T>12J5MN'A4EKEMDKQT*B&>/T2KW\8WD2H4 9F M%!*8!ZR-ARN5XZYVX*'Q#3D')>?
@P)ZI."PAQ0I0WXZXUHQ'F;4AT;"&@&)?VH#1J4: E.G6E:=0Y"A<%)! M-
^6FQYZ0J8:02:0BGLP3K=;P/[#6P0[UZOL;_1[4%/F5DZ'"(#_Q%W(7P%@- M9Z?>
<=",=>H DT&E3F(T<=VCE18.;\K**EQW".PX"4(>.N+T@'^\$[\CFQMLRN MV:>4?(<
NLN)K!R4]AJ+,B4)^06)@H_S'QIA3Z&3:*53Z*XTWD/78[KB9)+,T=9R7%- M;VP%/89YHI5[HKCG>0\ZD9GF\$?<
DK3.NG+EQQV'7.K L4'M>4M#)2%<_1;|= MPTZX'@P7Z-*>L8MHE60HGB9N>C]*&})@N98+YBC\@0G'U00
=60F.X)EK9 M)HI[GJ=0@V.2,T+9C\ \D;GP;E29G>SV=(4 M30DK2F[-Q^Q1_&+<-
XGAX5%/.RBNQ@fS270); \WFSFQ3^0[PPVQ MR@VQ@]R0V<;!R0=3,)?*.AGMT;F7290[0@_9\$<
DV@E;>8Q@A5ADA=I 1FL8\ MBLA5GL'KS-YK<9VZW H>UA20LC_L(/MS\$PLU-Z/R RB /86E(N6)05UQP=K<_M
Q[7%+1R/PPW+[MV7 AH1PP/EZG'.X8+8I4+8KB!V4VS;Y;X:9'R)I]S#9XV M,0NHE?<
@;^9MM/6S4>H6;_6)9CKI=L!]?+NSMEC;&R@FQ@S)('DRG^BS?71*(M%_*KL#?C0D02E*C/!@-[0X89H=59H?<
A7J5,!=["YA!_0PBP:K?PT#[0X&*U MAPS',#YN97S76*!; \XG U([Y)<
M56X.%,NGY0^NN#BV[?2?;TY_ /W&S7F8D\$C,(-4X',.&IS8^JYD;+M#B3?)9: MR[BX7<
@>"&4^@/:P]^@]02P,\$% @)XEM64*9K\$E0!@ MQQH !@ !X;"[W;W)K;%8B&1'4D+!6;#JYQ(=5MM%Z^L<
M*\$D;HSQ;(_\+%SEA06QUV3R[JU:70)89^*A=:42=YZ1Z_\$@S?KB:P=63@ \JL MNY/ZP6)U69(M75/YM;RKU-<
WBZ"5E.2T\$XP6HZ.9J=@T0;C#2!@WB+T8/8G - M="CWG' 3_Y_2JYFG&=&,)E*[(.IG3V]HEFE/BL?<
WSNGLV*8V!'X_>?^Y"5X% M'9WRR5NZM9/_ ,IW9 ZDY_YX5?;!11H?PG/1/,?'#JL-P-)+23/.V/%<
M(&=%^TL>ND0,#*_88 Z_12]P9X";0EED3UBV19'59\0.H-%IYTQ=-;AIK<
M%0TK=#>N9:7>,F4G5S>\2%6GT!2H*\SEA*I;CZ2C!0)!60M6(!W7PM2ITR] M>0_.P-?U+7CWYCUX<
U@!ONQX+4B1BLN%5^RTUT72M?VQ;1M-M+Vfy3G WAP@ M#_D6^QNW^2U-<
E#ELS/&I^4)EX9@*=\$P%;0SAJ534544+"8@0*N8+6SRM]_N M0,^X"U&2A%[-U)02M-<
K3V>KM3S#T/MBB^T',3F+%QUBQR_OJAH@=4+T&\$GU! M0]=L3S(50+476U=AXTH0" _L5"J/@5&<
CJ@3F0Z1IN^DN=[02IY) M6N5JJ.VID/D4Q]9/,&C>#V"\$1B1-5.!C+[*3#(XD_R?)NXJ6A*6_/I1Z)HDF<
MKUSN:*4F\!'!(V7@!'B,<1W!\$VP0A'\$,[Z_#(.G2R_L(ER5Y_#13!B,8CQB: MJ"CR?<
<[.,3I2C)Y)K%*K2CXV"=5CM-3=/P<%E3;FD9DE;\S3@L&^G65\9!D[M6?ZI.!+))BBW(J-<
(34&GA...;LUK=3.,@':-S#-A@. MHXF%" YT\$KJ[N9G0#GK0:'<9>.&8G8F* W]B!,)>N: !3++K)<
[""'S(Y#80#'_ M \Z&"Z.E-S&182\W\$+]}(6S-&[EG&)*-V@85.V7JMP0XH;Z=!]}(^W>IUG22\ M5GH%20)<
(U."V!FQ*\$@S16+@?!Q.T_ U M#H%[51SGV-J:E7@HW'994\$M@G5KMC6L9X@'^G0+=U0-5Y3(.G#<
<[E%IKH%.!X09E:4-Z&!;+!] M Y?MBL%."P\8ZA!89B M.+4H5Z[D^N];GB>LW:[U>X3GT9L,L77Z<^NM<"Z+?<
[0CDYC[N40!JXX>J\$0A>ZW P[P\=S%(7ST_N;Z'TT7T;J\$0S^ MCPR:I8FYP#H0ISGLBQ?D+EZNTY1I-<
56+;,'PPPJ0D)*I1==*TZQ0?"_P8W], MU8: #(8XGZ/:E#^*7,JJHK?,Z:R9)5\0R7\$WRG3XLWU-%7]U;-<
P_(4J;XQJ;_ MAO+\"17#?36#W=7,D'9*-VH>6^M\$;-8E9SA4F10GUPJ\$RW!J=X\$[f@: [2YA6<
M; \7DZFZE;18I0K_\$XUK& HL#+YZBW!#KPSZ\$\\?I-JR0JBR>Z,,0?-(9:J0YJT-Y*758>'>RXESY0+'26*0 :H<
M]00.Y=-_I9Q_'!U^A=02P,\$% @)XEM685%0VK_ @_%L !@ !X M;""[W;W)K^DXV03RH!T.17<
MEG(UM1*M\VO;5E\$"&54]D0/'F:60&=78E2M;Y1)H7(*RU/8<9VAGE'\$KG)1C M>!>[9*M!FPPT.E.5[<
_9#/)?)LAB5F M&7#%!"<2EE/KQKV>N26@C/C.8*.VVL18>13BR72^QE/+,8H@A4@;"HJ/-;+Y_6A@<
M^"1J0*?;*K88&R1J%!:9#48%62,5T_ZJT[\$L#M[P^X<-]%>#7 +\T6BDK M;=U13<.)!LB332RF4:9FQ*-<
;A@WV[C0\$F<9XG0X\$SS&38&88\$N)E,548>6 MII1'0!;&6)&+!TZ+F.'),F84PE<Z]91--<
+I& \)S91"8ZJB:U1DV&VHWK] MVVI];_Z" \A[Q>NB.=X_0[X[#\#B*\$NR7<;_-MS\$23#J])AU?R]??PS?\$0<
M@928 776XK^J"D-Z_0.G1ZCN-.[/6V MJ6-1+>U^H]T_3WNU)X06.A&2<\$)XZ\$:[11?^0^V9+E.] =01?<
T)@RT*_L= !_MDP6F5'%-X,& !., '4VG*8\97QU0/CJH%-_%2/6Q4#P^J MGHDLPT_H&X_X*0C?BRJ]3QHA<
=G"#_ [? = [C^UNRD^);#D8-0Y&YSLX[7B/ M7FGJ^UXP^#K#'?\$=@=XX\#UWT*U]W&@?GZ_]C),^/M5_1^!<
Z[S7MR^L=-Y<1VD,075M,W^E>, *Y+"\$H%.+T_&615A54>+0*QC M'H7&JJAL)EBX@C0!._+40C[W3&G4E,+A7U!+<
P04 " GB6U9#:["ZG0& M "6' & 'AL+W=0B_":WG"ORD&>%0!YME=I=3B8RW0*WET3;24.R&^Z90WR?<
7(T2WB&8^5IF#P[_7/,LT\$[3C[X9TU+Y3!QY?/[*_ MJ\2#F#LF^4)D7]-<
\$;:_]'LQ%)^KM,_59W/_&T&IYHM%)JN_Y+[[.B,2[Z42 M>1,,+W- MDIR].B>02%J0+UNQE0<
FKR8*&JQ?.XF;QKVM&T=[&N>1#Z)06TE6T,@B5_. MQT<#\1-(5)LM^IBMMW20\<
(;0+HCG0";4H3[2GL7SPSU,S0][^J^WVZ2#*\M M':_B\WKXFJHH-H0_['0-R4NLBVL2'R?<
1\^"EW+&87X^@IB00#WPT_DG-W1^ MP?+[DF3+ER1;01#924_X;4_X0^SS\$ \#(RGA;C7WD!I9=5<
M\R3IB4X)2>)7CZI. G\$T+D7^*!MZ(CMVSB&_ADC&8)AH##930733C]]:G;CL/[#K%;\$ M(D>GLH;AI'BMD8R<
HB_R=H@ZD567R,H/_1[E';FT!UT//.:L0+1B8Y;T;T M^6M2<+QS/7NY"EAC*#6:F;_05.'VR.R?<
F#ENQ/V#%R0380N-0 MU?PQ_8H]P). "KU-Q:)6^#K(&- \,PLU3:(^K,>R9T]A>!^;XWM70B.\$K!/[=<
([0R:..QW>]U4C.S[Y"*EH[L_=]#M_=?MWXNR M+5^4;?52;*>]TME[]PD?";--NBE(0"]+7L3?">R("IFQ^G-<
9^:#/B\?.,S*!P+#[\H&R]>:CLZ9TV)I^ MK4X/0#L[P-9KPV0=U9=N&"TY3!A2B?<
@;\$7LE%2L2024]+I\;CN?)=I4^C"/? M]"2K\?7TL[7TF%?^V,Y.RZRH:S9<
M1K00:S:R+VL8)YXUA!//VN3HG"7GY:8ZX)*0@'VAZN_F[/V\$.U-=71D/'_K<

M7BY")5S,87FE04A6'VCQ*XYZ;D32HF\ MNMQRE0!2 ^#WM1#J\4: H#V*G/\+4\$#!0 (">);5E03>.A< D-
E0 M 8 >P0=VJR:W-H965T&UL09S;:9 M.B(.I,34]LR.!,Q.IX=,LM->='K!2+##AB*U2QDKMZY+\IM
M4JNGY<.TVI4R6;>=MMF4!.\$TW29I/KF[:5][6][=/%LZ2W/YMD35?KM-RB^0 M958\W4[PY.L+
[]*'3=V\,+V[V24/\KVL/^S>ENK9]*BR3KG,[F4_06MXG^ZQ^5SS}(KL# M"AN]59%5[?_HJ6L;3-
!J7]7%MNNL1K!-!\/?Y',W\$2<=#W3@70=R-.M.M
MC0YD=J8#ZSHPHP.;G^D0=AU",*Y@XZZ#E\$[X?):F=ZF=3)W4U9/*&R:;W4 MF@>M76U0-
<=IWF36^[I4[Z:J7WVW*/URA.Y1NI1563I.JG5D>U^J,2J*Y0 M<: ^>=:M/FR);R[+Z
^* [=/"WK0(4_VZU2U0D+7Z,/[]7K0T07Z":4Y^G53 M[*LD7U7T8#SDSGE^+.LDZ1\ M:J]5^N_:6?
Q[09&EFMBM602;9C4^200F M705;B:;HQ5^*JKIR!!## RSE?;I*:UUDJE+@F ?DF >D565G5%+AS3/T_Q!
MK=,LR5<205"S4&V24E97**E5J-5+1/\$?&0D(_PU'P)Y?;![&P%6M.CH]W-, (T80/@90IX:BQD5_XI)H#\$-#?
IT4TZ_MTLTA#AXTHY-)QT\$00E2?\H7=C\$:&*XXF@Q'H=Z,V\VNR3S6&PEGHSD)^W;:
M%+'C%&V(STS16H=JBMQI?)%5F&U)7L*2G7_W9-'8-, M?DBQ):08A0030&*:^1_="[-0-
Y4U;Y=%^KJMC<.ZK&>:0>R,^R7*55^U[W MXJZY.E1(7=+0HZSJ9F&I-]6PZC)=-2?
B0[M]GJH+YLF)TY4JWH&-3970.D^2 M6<"8L="6D#\$YI)@ \$M.2(#HF0?2CDL!E?&1YA;%Q.5MX!SOVZ0\
(R'#\$"B_Q MSVE=>N7'KLN9-??7\$27FI70)&9-# MB@D@,5+00F]HSCN;&Z0&'KJX!_3ED0 \$DIED2'RV)098<
MEE13PJ^;4^5.%3-)?#[DJ*++T0VJ0/"3JJ0,B:TK\YK8B>4S2+/F8271?E*A* MU(,T;^XF6M;B-
S;R1U'IF'>\8PV#%*-#SD_152-ZR''JA// XF:]1XY#3 M9A'7A+ 8FQY TH,EJ!H'51.79T2WH;<6V(\M>+
[V\$*CW9]?F#-0J(!MJM!D M_2R.3:X &I>#J@DH-=W4GBU@/UQP(MC+1MHU^SR:S\V\YZZ9/_EM*1KC.#8)
M@*,="6=F\MN-KFD0T0@,A<5]V8YGS\AA,6@5#ZJV!%7CH&H"2DU/@K[Q_Z* M_P?B6/_ (1F>,305F
8V9N38A@W)0-0&EIJ="#QJPGS0\,Y3%-CL@)C;RCWCT M:>!R1_X:44"IZ1\L]2^"&G%=Y-90 [HCY9M@'
=LIEYR5N"1N6@:@)*37>T MYQ0\$SS>^"= 2FP/8A-8?>.Q2&Q*2@X844&JZ,R>[./P@8PRG)789CZW;:.\$/ M-
J1(3\$Y;\$P!I:9;TD,-XH<;WP*KB8T@<&@M&4A>L_15XT,.0\$"%U/WI\$070 M(PI(6\$ML1H #:T6![N\ 5>-##D!
A=0-ZW\$)\>,2'ZPE-KJX#FEH60!)&I:@ M:A0435R<\$-V\$'F\0/[X3E3K5Q]]2^=
'6Y4"QJ7@ZH)*#7=T1[\$\$/\&BF] MM<3>YN!"M5TS+ZUR2#E1K:;=C6H=C;RHE02@0A!Q:AMLNXY ^4-Q.8-
C,0S M2K")>D'C1A8J+9K=IK\S-P&Y)!B_8ZH M5;K8[6C_3%;K:*6R/XX8-*:#4=\$MZ M1\$'!B.(\$!*U"WH26-
_H_242H&I\ R \$(J)"Z/SV1H'XB_8F0J%VPX\C0J&.K V-T9GY5P0]BM >@8)435R>\$=V& M'CG04CU
_ '%#)+>+ M#H3!8I/<+;IFWCK:)16\$S*S)N:;=9=@Z1SF^X4\$C59B?JZ-[X\$#' @?/AC_W
MI\$%N\$A0!W\XD_J0<3FHFH!2T[.W.,1YM_F<'#G]- (9N]&8%\$^2"AB-S_U_CG8XF)L4R='JFH;SD!W]K,>
(#>C!2)>@3(!4+4EJ!H'51-0 M:GH2].2_P6U48(Y- YB8H-4?<+1U0V)RT)@"2DVWI" \V?}MHP*S;W)B[U3P
MQQ_M\$.A.A4%('!BZ@Z= &3%\VU58(Y/^F?6F@(%_Z!J?,@!"*B0NF\$]&&#? MOE6!N3Z99[%YW^N/,-H"t%(?
5\$UJY[!RYG*J?+P.WJ')W6Q:W_W[6-1U\6V?;B1B;J];AJH_M]^+H0[ZI/DIN>.0&=[]#U!+ P04_"
GB6U90W&BU2LF7G M\$@-9[Q9=8)L&3??N,RW1-F\ET14I)[E?T-T*!L63S00F0+[@D#;?/#&?FF:%U
M_2CJ'W+'F\$)/95')F]%.J?W59"*S'2NI_"CVK(+; \$1=4@6W]78B]S6CN5E4 M%A,21;-)27DU6EZ;9_?
U\HTJN_5NZ^1;J2UL^?6"\$>;T9X]/+@3[!=*?U@
MLKS>TRU[8.K\KZ&N\E12\Y+5DDN*E2SS.]EHA+)&*E*VBP!R:OV MDSYUCA@L #WN!:1;0,X7))X%<;<@-
H:VR(Q9GZFBR^M:/*):2X,V?6%\8U:# M-;S2V_B@:0@0AW5JN1)5#I0"
<@174A0\IPIN'A1\p&XIB<0&K:CH,0Y)[FK&,\$:2P9/6! MC9;=>>1?}RF?Q.RDXDM
M;'2B0*B[!N_9=0T/3?PG92=^&EV]-,LN(\$/2F0_3,'429*8!%)=1UV&=UJ MF@YV*IX1?
+:=ME""X\2]F>D19!H\$^9F!Y1FG+4%4.:EJ!7_G0=I:H' 5MPY M9.9NF/,CS'D0YM=R3WFM8ZZ-
,\$\$,J(*!CUU8YQ:..H940*8GFY-P>6RKR6\$-Z:\@KK3FU MI!#5=JQ874)0M59.S,1.,#*U,-
M2/LP]*>,@Y2W01#4V97TK1/[(B\+4#%XI M,(60@0-
_D"/>IVNVH_76F9W=5YV6\$A0;H62+31>1SY*>77&87F\'=4Y['?(U M\$PT_UG7P0'E!P9PQ-/UC2&
(VR!)W%"5V0./Y='YNBTLLOK'F)Z1<9#(I]J\$ M[3BK;Z@VBCX-0Q_E\$S_RS2#K)?\Q>H[<1!2,1%
(]NGE9+=%QB3Q97M/GW@6 M[@"-4?*>3!%U\$3=P+H/IM\ >P;FN;L+'_3LM[87[Z7MU\$,]=^,P>= 7#/(L
M1^Q)-Q>L=8N_VEC#' 11-'L)OULL_08>0?I^>;:8H2DQ+.Y/9_C,*&X5?0 M&#!-!+_#.:5W]IP^0%C/;4H?
VQV*0PH0?&;UU(#W/^'<7W_Y3:-C\G"JMNA
M=N!TM.NYGH2Y_C8S04VB/7W6A,:61=YVSWT0;J1/Z7H"\$>X'!IH8V19KNZP+1\$P>#SQ?3 MF;5A#KG%&-?
J/543\)4?U^+C&\.Q4IJ6KJEN! ?@=WF:1Q%*4G/L=MR\V3J_MC;6>T\$EX(+X3BNGC
L8/WAIDS[CGI=LA,I[Z^D'2)\$R>PWC=U[K6P!RG'R:#[F>0]]^)UL6,=GUW2<6^L.VID82I_M\5@A
>\!AK,TREY1 M)>.@*[_Y-/*=M)UZH.?H.\$S1]_393'2!8=0I_Q?E1M%YHCC\$/D2][0&9^K3R<"D;
J2XN2QA3I/F(+ '9_MPR5[8G7&V\Q0'XN]&7:X>0KQ&. >T*-+Y]=6]GNRAHG;=U)FEJ_M ;?%YKZ]Z-
DU#K/KE\V&92;\$V5/6#M40V0QEW2P*6Z#MH#ERJKS73\$6X"&#Q@4SR/T0.>P"5'R"))/>A[
MWHW#0+ORH454H37;\JK2(:.9CM5DY)@C>)EPRLZ/=(85GL2]3>UZ.%T%J>VCV^\+);_G-CCX#*X1LZK:=K%X.
M^WC5_Q@-A<9-K)/P.J.R.9D8B\ VX/YE_8JTHB)G1[E@8 MP">H8H]0/;!([&:6'.J0_C#ADG/WTF80VW#3-#V9?
D4_C.TZGG303D_H0RW MLBE;:6P%2Y'S#<^Q_!F07XU"\$R3L\ -G0Q^JB]90350,\$AD#C3;G[>/3X]0
M2=R:=P/.GG_"5Z0V78=>3?0JQ>^TAD(CP; -J(P^IN#XNGV;H;U18F]>""@+
MI41I+G>,0MNC!>#_&P&S37>C0^#X3LGR_U!+ P04_"GB6U9VC\$2'K0) M !?%P &'AL+W=0*Y4T>4GD_9T
_HAE@C_MIY>MSNH\$9DC*MU>9% MXF#0Z-QITXTYW5AWYRNE@OC:U,:?#:H0VC?CL2\JU4@_LJTR>+.TKI\$!CVXU
M]JU3LF2AIA[/)I.3<2.U&9R?\MJ-,S^U,=3;J!LG?&P;Z>X05&TW9X/IH%0X
MI%=5H(70^6DK5^I6A=; &X>G<7]*JIME0+9&. +4\&\RG;RZ.:3]0^=(6&[_S_M6Y
G"V00Z.&Z/!M,R"!5JR+0"1+_UNI2U34=!#. ^Y#,'04H2W/W=G?Z>?
8#T2IEC+6X9/= *JR/R_I0,+6G0^*3=X[&8@B^F";+ P+ M&FW2?_DUQ^\$I_K,L,&.[DR^V\DH&>7]J[\$8XVHW3Z
>[RM(P3AM*RFUP>*LA_M%\X_NI4T^K^20G0Z#CB1UL=%EKY(TK/02/\B/E@3*B_>F5*5^_)C6-*;_,^0,
MN9@]>N"M:D?B:#(4L\GL^)'SCGKWC0B\HR>X-Q27UGA;ZU(F0)A2W#CEE0EI_MP2[>VVD*;2LQ2T6%=
70/C7?&# W[?^2A"R8#CPP903;WQK2S4V: E76ZM_M!N<_3
]F;Q]Q+WCWKWCQT[_P^P]75I<*5\XW7: !N(@>N[T7?X_:%\$I\KI23
MK8I!%WXHKDTQ\$MH+*6I\$Z84/J%^QT#:HHC*VMJM[4=BFE>8>%5+J_IM*\$:R(

MIK;%G38K\$2HE6KM1CI1)T<((Q/JG'U/[IJ]>>F\$WAL[CD\ \0#V =)EA\$2< M=\$J4VBM4I!^1>
<@N;_R+%ZVSK=,J@&7\$/KJG=BQJX7%Q&5LOA';&+N6Q RB M='\$U+M5;PUU80P 4.!J]1*AD\$!'Z2%&E";
[!6T%10K^*5/(UD<*IRB Z\$ MZX<==!!>U-;6H@ KP8M/^PNBDC#+JS5"7XNBDH1!Y;2G)"1K&6FG*#@-J4#X
M30!VZWNA2P6IM:IT42N.(!M3JAJ>(BJ\$?10=-]!4\$KE])>,TKVYD@:9@2
M@9/)SEQ[7#Z0Y\II\$6,9'#)C5'2V5"N\$RN4Z2%4U%/,7GT?B M%&R!1PE\MV M:U?FBN2^--
D\U;D.@5G<2/05Y2!%H%/C-K):12R+ADG=_B;+6@2%=ZZ7:AR7C<9=?1N(W 27JDB3H MV\$L)\ "&3\JCAE#
[N_2#FJ%8%-&1W[7UB2]*!'J5XEM(7XDER@;EX&R#VN#(M4WEXYEKZT_8M2GUM,<'X#.^@353T.R=,=>)
(3E;6\27^HUJ57! #0! =')E[M\AE=%KUM@9KH6NV0);8NE\$Q011\$;QE])@XXN-%/OLZ.3X]\$\$\$PTA=P\;1N'U@
M=*B'#5F1G>L!KHQF?;5S4 MQ'0+92JW&[\$."B8\1K9T/ M5+PNI,\$!AI\,B7809\LFLJ"^HAQL74Z TGS@-
K'N.2:67Z#;WH&X)/_E+%H M9\$3)PY2B'QOOL.PG1-]/B",,1+3+Y*M&CU09('!=T3)U(\&8L3'(EB*_BQ%
M_V@/'WG;?'0B]Z5 MT@LN8A\ P'P%>P.'GL<'WB,;&ZEBNFW@[%V-6RURJP#(=JJ5F@X5U-3VL04A
MNWU);E^BTP&GH>>9]]&1W@8]81]!\$C;RG>N\$PXK8MUK:&88F!6U)W/R1U&_1@ M1582^:#^'KI;@ \$ I \$M%
[OZ=#%2&H0WVAR.UO\18ZXS'D'6^1H@NQLXF29I M1J9137,U!F?K(=N'!JJ7FI-OT!9"7\$..^KCX#VJ8>VUV:
(6A6V6"(?K,,2D MQOLT#[9HANU 0UJ:5/=ZM]HG-U/6@3#@GI#KQ M!T;J=:Z9@S!)]/A7:2(-8%,NZI>,V-
B*3+Y*.C XT^Z5*G+|YZU#D6>.L@0, M836,8#16.#H20 00=D1[ZEL;S;X#;,4/"9Y@%9(!:HXW0L]Q@@
M#6&R+'6^=2ZT2&G"WS0Y1N9QCHQ 0YY@^'G060-H)2Q'X=D [IWZ:]8X 7Z@47.ZHUM='A9#+)E*@/M[(^+2,
<:G!0834[MPRG/0'L!3N-HKKDT@?:M?B=,N+!#0-'NR\$/K+6/ LQ/!ICF5'Z"5NZ*JV+:0G
M(1\9G*8G<3\$0FM#D4=U5IM0 74RG8;-1?>5@Z:.0:\(?SWC\LC[L,A(L]C MW(LA0\G286Y[.8PST3/M-
G='1"W.B8"B>\$%ICKZXDE/CHD64[Z0=,N9A:WC MDB%GF,X?=>7NZ\$[)B1Q=8T(7V\&2*8R'74M>,J\$V%
(8'"R/- \$R2VAA#M4 MSW13I70;+K1YBNO#KA2F0][+M'W^1D)V!\$D"7G/W9J%2U?(^D<9,1A'\$+NL%
M\2H1BA\='E0VWOGHV2C<K M)40GHUB J9 #U!+ M P04 " GB6U9V6 X:387 @2P & 'AL+W=0J5F[2JV^N!-
[?M]MYU9[VPFMCMN>V;VM?8!(M2\$), \$0I =E0Y]?N=[&3W=%94M&MLF@2K(("S81VYI;8M7(0ZG?
^X,4;08]=01-V0= MZDE6S;\$#\$'2C&H0.>0:G/SPY/W0\# '1M38,]9KRWJGZ"#07V/B)&,;;)N:
ME;TAE&I@4';.T1?9@H"MX67!)L6 MVB57R;(Y!)3P F<(06GUQ2\$@5=M?8][NW9:\TL-G\$FQ\$5>0R=5/H,
0XH]' M7X\$+@E_Y"?8-"?
@@WH)4I=W]+R(Q(:60W(J]S3I79.RC^+'%16)W\M%E!C6070ZM(C150#.@ =8UD4.0^V\$4'YS:] M&PE#4
5Q&0A&ONVTCI.Z1VB0QILFLHX/Z*W:M)5I")CBP MRZTS=2'0+L1FIDWQZZ3HF.) W/;0(0 M^X1?
%B)70H"5%"KNT<*773@;.9HQ=0,2>&_)^/P1MN]:I-XM1>8/\$VP+ MP*9989H;6X,,530=
(X6070+>Y<#GQ7<(EM;15%4+M2]4W1+W\6S=V-JN\$- I#V[U MRB"U)(
^+79"01*;\EH&/.F^*3%&Y,U47>PBDA+MG.47CJMMO:P(W/)Y5T MCTC8=EW'K" QW0NYQ*307E^FZ*2<6F CF!
*L&8@K170([L <62)EM[?(!UD MAZ4@.!K\$,FA)Z1E9-, @4<=>%L[T,KY LB1:3<6,=9WCB7&AD!F.T0_8E]J
M@L:>)N4.B99Y\=SS-] =ALFFA@C>=\@G]CGU7V2:7J) @E%RCY6# SU6=)\$ M3-
FH3_!9"0WB*]&XV8K%"96]H0-#ZVAOM4EI.M[7+12L-FIA:M.RMA\$@LET\$ M*?H\$J6I*R+PH\$P"\$
,=N8DDHDS(24@).E+B'**JSL;XM?%:B])AW_G#T^#+7 M!*L87BMDGHX+@4P4G/-!>IU.V& M-7F:^B#51F>A>-
%YQ#;/U&T688/H(MG,0;<@LV6VP,NLS![:E;45;>LLYWY, M>AG5(B U<#[1K-BU+99'=.G*NE(
MSC;V9:C"4DT052-3P'DH'DK'@H+0%M:A\$(3WK0;R%)':@:P M6U\T-X0G<@EDIEE>@T!Z1LE-
CIT\$::@X2/0]\$Q M#T)P];9AFD&[%EZ5QI7=QK?!. /8JIMNU ?/(=?\$W"ZZVBW\$(97*.2ZZV9PR?
S0R(7%E(6F@!)>R.;AD/)%'V\$2HE:U\$(8IBB2]50& MWM"-I0IMY,\$*?E0/4%0I-<'Y7?* &1-WK_H>\
(4'R7(:\&PB4<=&H"! =MD.-0%X3)I150.F>EM(*VA20L4BY@?+B\^8YZR]4^WUD0VP: #>)B;/%Q M?
CT0*H9+I\$G\$HC^7:VBU9FL'L':0:60SRGPM-@X\$V50J(T=(M<^2&F&L-GG M02\$M \$4H33087R+7N,\$HP5W&80
M!;@B4^T9F=0=XFIK',V7[V"0TI(<+>+3A]0X!\$ZE0:@^)*D\X#@515M;,8A M "V'7.N)OX^&A;*T.?
[2I@)RX"QSZ#,6#[(BQ3DES[A^&V:* ,0=E\E'>V[M1,A(\VQ(4\$U= M5#V\$8(E=0
]RV!6:\$ET>822P2?;3FYA :E,PMA#YQI<2G% M['M.'0-^XU_OUIT
7W1P 'FD\$WX&R%9K02^E!E11ZR)2:ND5Q3+4E7J!>PL M1![(C)>[\$Y9!9B.*Q;_I+/-+8&-J34\7-R@P-24-
+Y"SP",TXZVM'%#>:=' MJT+@Y6,02LX=V=X-'4<=Z!10 \$&YLT+Q0ZK>A\UMY^"N0U!\$HE,>/:2(04B
M>^Y]NW8,%K8C?-1 L?J3X=]E@?)?-B*8-3>Q69=I5GH[FXPI8DKQ*>4,+(M?L_.\$1@E/6+
(T)VT7'W1%K=KS:~!1(KE>_XL:V,%Y0S-&';-4UES\$:-/CAFU MHY?&H=Y CE#0)'&\$7I/9
968UR,Y74H1KKCVIYRB[WH/\$WUZLG*6%5,H+D/K MVW"-4D(77?1WV(PZZWJB/'! \ ;?;LM\ -
0)JH(N;%6]DTH(U=-KJ=C1AF_2G MFC%+)N_1 QGFLG,LDV&]8[+VOF(13L@N*LA:Y1QIMEW0"13-5\$''%
(Z]'[NW MD)13:8]#JJ/I)!617N^93W84!"0\$,2PDS_NE6&80:2VJN+R^*C[D93%D]-0:#\!1KT?
*_ ,9%=5T.L\$,:JDS03FR:@\T M\#@I"?Q*C1XVT0/MU,G\;J%7IFGD6"1FY+;\$DE,7.E#2SZ:4?ZILC>B,LC@J
M&.CY,'P"3&8B*J4G^_02B<^HA.U5Y9!=Q]U<=I+)\$C1@;>D.%A\$0(9U<+IX5"QQ(K*CN[F-
HSE(_!0U13&12W2D+' M)NVV=53KXT&E; :5]/ SUQ\YW3'>0G&[UWCQ,K?N#Q,;";S4/,H+0[X(:^G4 M5 *+]
(6(J:\$'C'PK.T69]3SBTY6MH9J>=4K<IAT+N90Y0M^3/K+5.L8C)4'8 M->!LBVA%
>9S&:+VV/4.VAKB_\$*I_X!>IG!]?0KL'0H_>"%=0\$/RI_GAV;.' MA;T)Y6L/,VW3Z';*F^DT&ZF;
9:8#!'GYS\$S3'(:V^R (R&I M8W.H(MB@8_6-A P66U0!_R-J!+4?;%&>CCV"0*[SD=*[Z*8@L?G%*4 U<
MQJ7P];4&_08&(3G-^(6QE^%6FZ+,D*Q,/:ZEYLVA[U##7X3#BIOF- ET3",6 M(15+ZA/[=4
2CI%2LT0#MU#QT#M;5?04BH8PZA40]RVJV)"A3SZ1L[SNA52 MXE;<]8%FB?\$/XCW7@!DJ'(J"?NN*8D?B
M022[:Z@1'',/<1GYH600+M_WQ.RP#P7[XUQ(HJ4952M0["'9H^P-6&6-./T9 MQ9^D3L,0
#JGA9#G\$W':4M5E%\4G07;J,(13[2TGC2,!]+,10SZG\9;>+,,2 M96#/'Y'Y"]V((L]>U\$5/),JI?:PED8 >-
@10C&<20C-E\&#IP)JEQ^UO\!_NL M/.0GG0(!54.NJD-\$B/;2TI0*9Y"20TM:.0L-W)6S0\$
4&N9Z'S"1"SSS(J M>NL0S7A6)2* %:VB5T.]HQ])_X@ZGJ)R"RC+;\RT2'DI "93GGFQ>N^]@_,
M/7@&ZW5>X-U!=ICS\$0X%/]"[0#J63HMFKC/UK]*N7S5B6(P.\FXAP.\$^E'G4>+/-!<4H:\$KVA 8!G]
M+TQA8X,!=J\]QW""1JGU,]0)!J\TD#"AXWH4(*SELP(R_\$B,31H!@C0JW*
M%3+@ PP\$31MT.Y[=YXX06L1]MAZ7L2.. 0;,&B\FWY5M%K0HE,?D'MQXF\$;=0<\$^A^?%C],BW?
=3,GHW/2'05#+=:Y^! M;M\F*!RWE9=S-CD @I=5M^F4@TYWD>X[CKZQ^4WY5U^1*2BE2"GY;R81A3\$
MJZ:9&!@59JCB;B(%>,)DI?L20NEG.KAQW]?BH\.!D1X3UP_#(2KS<3K5 M2CF2D)X9:G] /N/1!BI

Z.RU3C,1.^:#S&?CRV=\J?AJ5)"#4_UR77;MMP] MHUW"D&YCK(3.,GNSX@>+W\$#(IZ.?X+*D@AH413TK
ME&QK;*B60@]!:-S?&A<"&1Z+ZE-&)&X[=V)GD"*) (53^PIY92SQ_ S&E"L.<7>0U\$@FA5[SSWG"@F3C9]>_59: #
[XZOU238TC M!.\$AYP:}H+Y=.2#WWSHP(%(ZIPLA<8CH:M!MRXTDJ;^?}"7CKMWD7%(<"BR MWD'*)D);?
28%ZX0' '@R"V 5=U.'FFXF7"J20RWWSN=.52%!03 H'N5XYL?: M'*^6\6@LZ_F?@TW?
T9J \YK0^S7B1";0#.C\$'?-M"'\$:JI110,6N'RCE^G?7 M]_I!}6)TR*>E8A[2D<@_:#RJ/,2^U'A\$*-7IEQF-
(HC61@^P.<"F S+UG MNG-0C%*%S0{&-M0Q%VIX/4(:S'3E=76: !Z<,D]K2=E&'C&L6DLW4HIFX5<,:
MKLG? !8L/ 8SM"UEG)JF\';M,/ ?\#!'!}|TM/1L_ %K*3VK0;^#7 P&4.H&(LP-\$Q+SX]R&"U'-?@LM:#)S4G*8QTI
+}RYM&E^9 M&%JYY\ S*59]H3:5D3.<09FUE8,+
M&N]'2AD\$&Z<<,WRV:B>4]I@,AW#ZBIC'0[/R6')T]M1TWZ6BX[-;MBD#7@J! M<@ =R
IG^GG@A: .5H "U6?'=C\FH A;#+< XW^(-)(\WTEV;M\ V-CE?<D ; M.>WY&
(7@TWX&J\F<^S7,1.0,B@^&X#0@".S;TK% , 6>LY7ABR;5\$E5L0! !J MND=-4,Z?I,:\$A"H.N'(C0: :
[0^>GT0=SA. QTLZRA ,R J/N&0??T@,N57K09 M['VGF^H@/F-J0VW+^D+W0<*T\$ \T!??
V]C[\6NB=Y90AXUDV>3?:6=)5!H ' M]2PQF#/Y]E;3U9S],[:IR3;7LT7J-+&L?
\$PYPS\$V2HB/\N8?]/,;0#0N=- MKVQ=R^DMW1+=5Y39 6S#/. \$Q/T.=0IMOPA^QW200P1[\.A_7GQL8,8UY^' I
M@XY[ZRCE&\QP'AK\ S 8! [SG^EU*T.R9&?}WMR >40)2F?3@QWM]}9SXEPK?, MZ+ P#
!\-3U3H>\$=')A!Y0V40D[G'^Z=FCZ&P;4X,^ .V:>.17L-B--)@\"Z M,[JNLK&P!
M#', \$OPU+WVN:\$AL,ASJ+C! ?F*6#^AMK@/V&EY7=T@X\<6#IF@.73#R1<3L8
MVQRN3SV'K,.03P0:= \$61ZE6Z;F:E\3!UK^9I\79#=YXB;\$07]XG'']IG""> M
(*"4*WT^.+TX5.ZVYTF0/0;NCQ\$1?=J0+>E]4>0.>=OCT_ /"N.[K?+ \$CF MKFA]GY5[9DAV<22[F308&3-
]LLTWIVQEEKLT4!E^,8![C6\$T@X^2Y?9C#X;< MCUR'\$ \$QFTD'E\$+*!0A?
AFKJ<)5&?:H5H\XN.DW"DM\6*Q]T<81KG/F,XS\$J MH&_L5DA+(1P4+VG49R? [J=K;?GJO!Z@SEM \N3*A64?
<(Yw@#J?A2>0X0*:6 MA%4N08MP^4,1[OU861J/>L-3#8IT-.7=B0B[0]S7-QC).82IU0ELHIZ'CD=D_T"7V+U@?
Z! !\$^'^ ML '*=?3/+;M@/+TG[6.Y\%:B+T#+20YW<4T@%6JK]^ **+[A2JM_V:E[S:"JE MWW(%=?QS#Z8?
RAK_QL70H?UIH@K/Z:A:=.QP,*!&TTZWf8#ZNP<5=47@^(QT ML3?QK#" .]C)/2FXZ3/W\ S4GVJT4;
[5; \VTQ\R:IIY0>,TM/T\T^7\JM'>OR MVU'?* [>B]*;62RP]G3 ^YJAP\GM,\J&U6_X-
I(5M6[0A/] =:P2_1" _B>?HPD M?J -TH]B0?P?4\$L#! !0 (">);5D=6;2V;@H)T? 8 >&P0=V]R M:W-
H965T&ULS5G9;ALY^0T50NWNB0'9VFW9;10PEIXTDH&1 M.)F'P3Q0593\$I(HLDU66-
5\ YY*LS9+LI*I^0+RKN<>LLY6VGRS2R^R M]I0FRIYWEGF>G?9Z-EJ*E-M#G0F%-W-M4I\CUBQZ-
C."QVY2F02&_?Y1+^52 M=2[.W+,[2? MLSN#NUXE)9:I4>9JQ8R8GWQ>=>/BDD M\$A'E)('C[U%\$
M89@P='K[A9R6-SSG%V=&KYBAT9!&%\Y4-Q0*245!^90;0)68EU^ \Y=*P+SPI M!/L@N"V,@,=S>];+(9R&]*
(@Z,H+&NX0=(^:)40+;M5L8C;\WM0JM)L6&IV M-7Q1X">1';)10\N&_>'X!7FCRM*IDS=ZW=(;:-
\$D[&6 >MR9G.#Y/CW-IN] MR/%VD50PIS;CD3C0H""L, (^B<_+3X.C_J]0*#RN% !Z_) /U'00.'!+ '[I6!S M>0?
HWNDYR 'D6J<95^N_63:7BJM(\H1)!1!5?A:JADK*NL\$\U85RUSQ0SF;" MYA(U(\ (KF:,ZBR3&
[\$B@#"&115JI4)LKF2 ==,L3IPA'05H+3-*&97R]:S@" MI^Q<&#>%)9+/9")S-
QP2M(F^2=9^%/=39R)?":%00N8;Q&?J'D?X3WS:9KG4E^;*FKQ.#" M2K6 _DLI##?
1/P5<(3[AT+3G_.'=:YVR!IBT>1L\$^3V7;?>8;T0J0X7K7TC.J.SY+:0>0\#@}8
MB6C,H04""0DDN/92:P1T(QFV3*@C1#7]N7D M@0FV%-6F6G WC64"R7T9SMUHPB7/%1I*
LX@4>00S/5#X/"PUIAC7&&1*MG M.E9N;D2 M&PD>D, (())TDF*),LE1E620^N^ZN(Z2(J9""&&4JC*^6DKIG'#
MPA/&9 M,!\$^5JH^>^9JF-;/DD%UNK\+@BYA\TX@KS8\2&(1,PDMH!3/PED)A M!.SRV:A5,W%=EE"2.%L"!-
IM"=E8J1&,%LKL1&*G&C>FUH0"ZR>1(^\$I9_QI M1S[3B:00QU_X<P+5(
MN"6]\)+-9(*\$ \$I5CC7@H)+7HE"0P0S>&\(U_ \$^QK\$2^" \$U1\@%0 "M\$M%X(M-3(*8QVR!S4L !\$UY3=4L(=C#
[FHIH^4.MZ&H2[]2 M-?J0^W(4W"!:"]OVSTHF"9MAY6_8(3%Z4G0_2X[]0YI@""*P#E+(MX.H2%* M)-
Q#\C;SWH8H_EC"=&D.)29BC;Q\72\$L5_ '2#DYCB]E7:G'MR#=[+3F94^45
MOB4Z<%3:F@&T\$#2P&ZAD"\2B)6:V!B1\A>&61+DVM\Y\$*,D=U7\$#%NJ?#MS3 MD8N>X
JK]'4MW%7A=0Z0%0<"UU8"+'[IVP7L]ZY^+W.X;.2%93-MN0\0/TV'@^&OC:0?]*,PRF\$D&0B\5-&:^B6T'D^Z
M@^A-?39K5G&P,#H^]?G0LZ*1[-UN?/7RY7AL10U_",>X
M.YQ.&0^;6ET+H#U1(J!6S[3@SQV/*QM;5Z_%,*C:7>"]!EU3XX' [&C-
L&RXEV61<^<&0=GDJ<6+S@.D2_#*A6V/7F5\$ \$VB7!^HM^DM(;^5 MJ23V\$C#.ZL)\$&#\$W.G4*
<0<'TL0'U"+7;BJA!7%-\$N*A_Z41#>K"X0GX<)%+ MZD9\$BM!S9J:FXJYB1N;EE3'1\$7JKH29+589T+)-
R[N0<6^ =+E?=VYQ+J!! MFU08 +*R- Y#Z3_0\$+S:&D_GA:U;(NA.[&,'P<[7MF3-EJ=NN=+?SQ>IMMM: M6+
<'0X-*L447- M(KIN%=']9A=I'Z#X9NM:2&@_M;]Y3;(PR?=&_!3X)_8A2X\ [XEVE7"]^?)' M#,U,V;9S+0?
\$^Q4= ! [Z2. MKXD-M4T)%M;[*^0&LA18#">)C_Z'<&2;??[^SZQU\$V70NGE.RUO>^;V >BU>5?-099
())0&7ALXWH\$G8^=#.#.^S7,90]X ;R M'M@GE=OKYP8TZQ:[6L>#C3^8J\$[,J2QF\874,9YA"B,
<20&B;_EX&R3PK<5 M18'Y0:ZG0":%'\(AYXD[]].06..!IJ:^VP_P=B83+/- (M*
(%]L0\$C5T1, SSJNA4SSH!0:'.%)9FV-^;CA^(P\ \+XQ_K.9.#;?%D.H\ MIJ+7&8T[*&&FTCC M
0VZ.IDE<^DTV&[H\AQ/_?>DZICTH0"\26P, 3&S_V[E8E2=-&P;?A76A^B MT3CM>IV)=T-"QV9>
(HPQ#D>+HC@-023]A);9GZI&0]]><[+ /C?U=@==[*-+ MVC?^YC/0) M;5E_.:4:#_D ,H9_9 >&P0=V]R:W-
H965T]I?>KU_V^2Y>JE.[< MK%2%- [FQI?IXM(N^6UDE,UY4%QW18'#1+Z6N>K?7//;)WEZ;VA>Z4I^L<'59
M2KMYJPJSOND->\W_9[U8>AKHWUZ0Y\$)]4?ZWU2>+I_Y62J9+53EM*F%5?M.[M&[Y^ .Z'Y/.%WK=:N]5N0)7-
C'NCA0W;3&Y!"JE"I)PD27X_J7A4%"8(:7Z/, MWG9+6MC^W4A_S[:#EKETZMX4_]297]
[T+GLB4[FL" _9K/^NHCU3DI>:P0&G M6(>YXZN>2&OG31D70X-
25^%;/D4_M!9<#KZQ8!07C%COL!%K^4YZ>7MMS5I8 MF@UI]((-Y=503E<4E">XJW&.G][+]TR\$?0I?
0I:ZT=9J,H[(:M,?*@>E?,E M/5_W/? :B%?TTRGT;Y(Z^ (?=*?#257SK04Y6IK+N^#QVWBHX:1=^ .C@K\HE;G
M8CQ(Q&@PFAR1-X;/F9YXV (>R^U%;_+HE;BG79I85QME1/_NIL[;X&5?Q^R M.8B<'!9)^?/:K62J;GI(\$*?
LH^K= OC#&+PYHC"DZW"DV/2_T^DCLH]K/7W M;29^72J1FP*9K:N%\')>P(6I]&IAK/Z/\$I[>DZ,?
R=%.F!Q023)]"K4G6;NM\$JD MA70.^E%@,?(H=4&@.4-U.7.P53B*K?9:N7-Q0Q8\CUO"N%HSX9(@6+]0LJ
M0@2+%-1#.50#<1!W%\$C"CNXHUJ33:F7-D\8R56S\$A2B9QL[9KKI"W2L [\$PL ML)4X_6NXTU!9M-]

@T*21MZPAM\$-[/C9FQ?,%9J\E18UZ%(P=-\2-.ZK,,>M!A,L+"V1M\$LJDH^*UIM2L:Z6'(2/R@BG%Q5# K'NZ
^/6\$\$F8'?DE,\$T>F7" MYJP?)D0';EYV\9XI5]:I1A6B(:*'A2*"L&A+*2)E'Q)0*+C#>HJDG;"2+3 M6>&3-
T@V@:EJ6I"5UH.%C#[W316U3RK:Gf?K;JD?H)B-/A;!U=50">WC\ MA4!7['3!B8G.Q)'-!X%+OYA@A5G?
BDKI^Y,A:JD]#83]N05\\$ (UT4RQ;X5 MT[\8F0-V6HN5LMID %2!#)\$\\$'\>.VB4[V?@R5G9&-
"AD[/KZV8D;!QBS-6C M 9(9)5-\$2C F\$, -!UMR:2!K,YWG< 05A;GR:Z5"N+G,05XL*3F(&Q!7@75S M%#-
XY&F%MC&D\A004./"\R%GD]8^J GR)7>GQ0ES\1[\$*PC.G(Z4S8D=G 8 MTU3'F)C\0<,
(C88(4KG2S,+>UBGIFHA'77EB/@4\^9!X"V465JZ6.B6%4T442CHT=+(\$S\7)"\$0W@K= MLYBU:??#_2ACP,
0J&)2HS%/XX>G]6A<%82"% M-8,E.&D&R\$4BZ! WA8PMKZ+I6Y0;MC115*06]T!-)D/4#H(8-B\I;ON(#9
M^:P9R6,.PX !B#@ 52J4QH= -=I%Q) I"<8KI";;U>2^8P74DX]16"/EGM: M%\$2DC)N!!
(N="E>+)1KF@0R%/:. -CA:\$/E,[P+35TLJQE@Y8C)JBQ6'0>* MX[Z : 'R0=6GD):0*;=.U;[KI&=\$GB
+2NT#) L=@W.-= \7<.?TVB 7\)< M3PBS1 H@%,0J%<6DDX?W/<3F^Q3Z@LP1(\)S^X1 Q&3-
66#%K<'ESE=9'Q3 MT7; 0L&I3'46E6J@)+NEF#I.(B&-G#?IP](4
MA+J8TWR6X&@6%,TU,FB F454/W>;0)8JRX?=DYVA M] M#&\$ A1NPY+ E"BH.J]J"YD/QCS2L<#;:;
<&I@33AB[/@KQ 3AWV[LM0:Y,H5%4 M-2>C>@IU&P<'C)+U%\$];LY'10L;3'#;N@S]6[^=-AM5E6 M,KVV(IEQ?E
,<0X>B\$QNW*X-\; &9V]=FI :N5,8\G0,Q\$7\$U\$8T7-#W\W1&[MM-M)@6DQJV+[OUR];9Q;".0>()P?
NMZ(MY<(5V#TXY#?0X-H73I]#!<<\6C\ MC0. N-MBX[==NK9^M@4^OXIXQ9<1[:/[A>]>>\$28# BJ&K[B&>N
M>C>@ZC98< M0@X1)\7PDMBH20]_3/FD-;'8_C\2FD7PGM*[U;P?F:;0W\ \$MCVI;"&VZ7# M80W0]F^!WL5;H-
EXNIU[7_Z0@#Z^2T7CXI^+?7BQ-
5N]#MW4]E0WZZ6R" X7@ZFQE[&w)*K\$8YK=]Y;5E7Y^NC(I4LJI.N;DC3>S(TM9(5;NSARI269 M^45%?
C2(X\E1(97N79SY9W?VXLS45:XTW5GAZJ*0=GU%N5F=]Y)>^" #6BPK M?
G!T<5;*!=U3]4=Y9W%WU&G)5\$';*:.%I?EY[S)Y?35B>2_P2='*;*?TOV).9
M,9 YYFUVWH09(,HIK5B#0.6!KBG/61',^+H['5;\L+M_UOMOWK?X].>R&@NZ[5Z8%;_4>//F/6E)G?
^KU@%V>&D)]+:5:9H%L."0NEP ME8]-'+863.,G@R: !0-0=]C(6WDC*WEQ9LU*6):&-0['N^I7PSBE.2GWE<5;
MA775Q97,I4Y)W/L*N#9%;33IRIT=5=#.,D=IH^DJ: !H\H>E\$0#.Z6CKQ1F>4
M[:X @E6=:8/6M*0\LPK0J>R+81R)03P8:/-OV+DZ]/J&/^BJ^/?ES%46]?&? M?
5X'I:]/2KEG7KM2IG3>0U,XL@_4NWCQ2S*)3Y\Q>=29/'I.^P]EYZ]I\$G>6 M2JDR\>81?>
[("DS\;Y:DA77M;60\$9?.T98D;4L:+YDVDC)(I@9-ZRIAY@*Q
MQ=SDZ'VE^)^0:3PQM<-2] *U0(HK*F;0T.99W%#:/ \$G\DV&W+X=7VG3I]\WH M 8!2%KQK9]"!2*)1,N;K<
A7C:U>560+\;:2N9+Z:16 @EIG<.-,+,* . Q5XL,+692G-]0>2\$X,+U/8 M#5(;<&JS=XT!?W->\LG0@_#JCX<6,
M1.TH\S&S8SQ\$V4-N40 MJ1WVQ>_FP;B*C+BKH/>VRJ @ M/-RR:>U05FS;9\$> \[/PT5Q8-_*66%H#'(+
/J%0/@WH6K& M;9%\$3:0Z_&+9]R/6;+VCB)\$'NM]Y.&EA0=] 9#-/V>"W]J]^+& MP8\$81?'QR%]Y(#
FA'!ZR7\$T'(^ TJ/)+4SY4JMjW2]J0""8?,ODD,TF<;>4 M8),I 5]2F0,_4#I]
<3SEGR882\HS7XQ.00N+7Z:#9' JDK@9'68[5@?B)!K' M\$URGT7@TPD1B5(4%[!D;X_V*Q._ Q)UWM'FGJ?
K),YMKKN9*[';A,3;E/Y/- MRWLSKU;2\$C3QSZV<;BA!D< MLQ<#&'>9IK:F9Y63K9(SE?
MAV8D_TS[YE0A/YE!DG=&:\FVR!#H1-[1B%(L/ M_Y->)5&,A[/?])'-
\$6%\$CH<]\3MH&"1)YWG)T49@87Z8\FQZSJG<\3*!= 7 MHI:<3,5@?-Q4N?RQ>'F6%_]=832^+491=\UUUCU!C
=G \TS]0@;?&<9RU6 MA""3KDF'^R897IN/^!6(@M;L=>0(1BUL''@V\X& K!''/L&T!\$T93(!N>/C
M&#;W:ST\$?RMW.)P.4,##^.'0E'\ ">VK?=\$4 V2<1[+?XA=0\ /S:QJNN?
IBB;R?)W)TI5\$A\YMNJ4]3(TF#^'^0U&F'#,KI60""FA MKIWM.N.Y_OY3' (=T8\$596P=A4U>ON&@>Z:<65
1UG1C;*> M<*)J2@:\:/52<(8-6\\$,PLK"]])DK\$+RV'+0KJ^"4-() (5JV230 SX&K"BK*W*Q#EF8@2*\$*0ND%
M4W;,"':57/@R,E37BTN445Y. 0Q6R_H3!1]W 5X@+QJY =*<"TD/T.NAV(M2\$/!Y0(,RQ0&W%0\]-
\$B_L" T?B7?&K/YNZ2^'K)[+?Q"?WF_67];K:0D M]"4;FC)4!F^UA0;#SI]^QR?NJ\REBA'T
=S6P]D>ZK&KU>*@ (9_J ^&F MF(T\$S>>!63=L:8-2'6&ZXWZ07!VA+?>YL1M&\$&.?!N.1GRR\RXJY"(!QS,
MP\$0/*;3F.]_8(*' M8F%PL^Z\$%, \$1K08^*@5!8CY MH9!Z&\ @9:; Q, MX6IC!+&^@6<2!"" :9\MS5@R:Z#>
[M]#5'#B9Y!>J+L)1#GB4H_Q3IF@-!(;8 M-&=U%\Z #+""*4\EKQ0_2DX=R"E8R#>;D^T9JSH]LR+=AH,"<)1AA
RJ=GF;F M3)!E& BFG(#T.-1= S.\.'^DF0=U7D#-E*XRJ2?7 \$GV\SC\$- N;-HZ)?0I
M*@*F)J0=V'0G\ZYA!E=;1:T^D;<]V'0:.L3;\$'()W]H900#0X20L=W3[E0V M9?B\$N0\$/'\)\Q3@)U<&!+\$-
NB_!%_!4\$!L#!!0 (">);5DU./'N.04 +4- 9 >@P0 M=V]R:W-H965T0&UK M26_)?\$2 T[3 M8"D:)&BZ%
<.P#[1TMHE2I\$I2<;Q?0SM2?HWKKL.P+WJA>'?/?/?"T_G"V,]N MCNCAJ5#:733FWI?
#=MMEHC*+BT;:6"U\D+.YXX7VZ+P4,WQ_VMY
M;^FM0=:2RP*UDT:#0>E%8YP.+WN\ /VSX3>+";3T#>S(QYC._W.07C80!H<+,
MLP9!MT=\@TJQ(H+QI=;96)MDP>WGE?;KX#0Y,A\$.WQCU2>9^?M\$X;4".4U\$I M_\\$L?
L':GS[KRXQRX0J+N#>ES5GE0"EJ84)02!W0XJGF840@-/F*0*<6Z_3< MT5!
>26\&)U;LP#+NTD;/P17@S2!DYJ#^N M?94DYT?0D5QRYVU/NGBEG=5R MEU&N\Q6Y,[@UVL\=0-4YYK0R;
<*P!M)9 ;GL '%7X@&4+NDD3.DFG=T1?=>U8 M-^CK'G4,_AA/G+<4^S\/^1A5] ZKX'H8NE)D>-
&@A='H'[\$Q^NF'=)#\? 1@ M;PVP=TS[\$>:/RAU&57M[H^\$N\ V:"EFGL-D\$X*(7U8*;*YPA0]?(*%8RS+Y5T
M,I0%+[\Q12GTDDJ\$UBWF0#50A9=Z!BHJEAH66-(VE!-G KE=!-N"%[2S: \$ B#
M\5II9@JZ9^Rf!LI\$CP6SF'(^IH. ?4\$ 778,:YF5)00#=\[IRT8^A>S6HN M/#;=,
f(B1^D>1T(Y\V^(NL7<*""4.,V5RU.*?4_6NT@CI:;")K@0IYX0DK]@_
M^DP:TPXL45C7A(K@*^@G=\$7M0^:NF_P_W'6VN<--IN]QMDLJ>4@P[/-R\ 0# M>F-)"
(N0";OZQM89? !054%h9P\#5ZEIX^YW3Z M1J6'0PD+*G0*_
_Z,ET1?'KW4="CN:}KD"QV)>1XHIRJ,&AG[3GB0<6(#U)CH
MA':_ \$0;".6C2^4XM5_HJ..V/)I"L\$XB3)T(^%/(MF-N1Y A\=S909JY@:6JL
M4,13#/D4VZKfU4'T'-1,R[^ (06@.GV@XHCN/%\#G#)M_S1V;1P4J48IJ#)Q' M6S_N22FV!
[H%5]\ '*K@4^_0!*N&ZWT#;;QT/55FJ\$ CBI'"\$AG\$\98:PI84=C\$>329:;B/D2*W*0A M(4^N,*M78H)U88V*?
AX?Z.5K\;N II-<\$A=CXG8#&@+Z;K&9>N9@ M)UXQ+WW>T8>TE_#-
+N@!].Z"&LG*Y:)_ U<3#V/,&E0A^VU&X,\Q9J:Z1!D M458^-!(20#J17Z9)

[U4MM<P]I8Q5H>&N/;6*%V@G84?!\@>!\[SA5KU?7_R3C M.(IOMLO"G#8#XQGL;\#BG_RJT0(&^3XWQ
MJQ);5DFLM,T?@, . ' 9 >P0=VJR M:W-H965T5 MTFX6E43U61R[K,1*N*&I4?-.86PEB*=V&[O:HLB#4Z7B-
\$F.XTI('G;5LA,,+H[+G,I9=I!CH5H%'TQNX_8Z3GR>)E1 M+OS#KK4=GT20-
8Y,U3DS@TKJ|BMNNS@<.)PF3SBDG4,;+<'!9;0!8GYU)H= M6&-;'X0I
90)B>U3\J;+.]*J/YFDQV51J5HW5_P.5U(^EN&A,C^TXZU"6 M+4KZ!,H[^&PTE0XN=8[Y??^8&?6TTCVM9?
HLX!KK(8R3 :1).GD&;|S+' >\ M?^0"7\900BQV#BR?#G^?4QVBSIY'-47S)FK18:SB"0"H;W!:/JQ>@X.7^&
M\Z3G/'D.;=3\ LHKUZ'3^!0AU 119"?QN.!(ZEWK;(3"PIY69JN(J=E[.?JVC.H20 M/.F9[(0#+
H,|0X\8>M6Y^BD^0J00?>> "&.&:7+U8\$|G)ZGD)\?5#)DVE.[M('HXV_HP'RH^0SJD62M,X#BU+8Q[B5WC7
M:"636\"?C9:.) ^#A2SX01E@&W[)NX@_HF_K\U!+ P04 " GB6U9;UNW>((1 #52@ &0 'AL
M+W=OP*B:1R2N;|^WGM] "!!B7*B:"0C#[9(H/OUNZ_N MYLM;5?
Y:K82HV9=U7E201JNZWKPX.Z02E5CSRE<;4<";I2K70(:0Y?59M2D%
MSVC2.C^+@F!RMN:R&+U^2<\NR|01N'(/O@H
MKU&E"R4^A6_0,M>C0)\$2.0BK1\$^AS\WXGN1YP@ (T/AL8([L8(+U5Y1?^S6STVB4K4'6%4=V03RK_3J..4L-I#
<:4G0 MTIS|I(IZ5;&W12:R OPSP,JA^EG4WD1W KP2&Y %@<>B(\$KN@!<[4F."%0^"
MM^*E,*1>\BUH5LTNRI(7UX(^ \ %HJI+4)/-'2)>PTZ&8:/I0*@V/!601F-;
ME2A00.CU7 \23H+S.S!/'.;)=?)*20@1^7@EZP(LM_XL0>2TJ5J]* (5B% M<|@FYT7%>,74DH%D:K%>B-
*)YP7[ZU|F430YAV_AG+W|W,AZR|X5*3_6K(Y= MPFQV\M^-
A">G1XU|KVV45005'1U%, "QK4BV0/LQCUOU0L!|JJC%/\$/\$0_J|; MRG&E<'I>:9)7*L|]\$ "310-J6Z
8:A2)S#B(L&-F\$7G--S?+\$?P_-3C_\$B8\#9 MBTTIW4?E M=B73%5N(%-9@8KD4Y N--' _B6S;5V&EN9/
D^8EJQ4|<#,*4=\$4?%B*;XGV M0NI#I)!4EC(' ,F3!4E44Q07>RGI%<|Y=?0!)U4J|_4,6UZQ"JP0FWW"9\T4N
M&_0:)JNJX4A+ |PJ=YAR*TI_/&(88|N|HMUIM<;86 MB9F\$=6M5&A@LPK"89!;>SB@*UK)8\$8)-?-F0'K:|
\$D#XK&AJ&?#+KWA- MX|:@>"0.(*0G3|-06;\$P|*;CL9>\$,S07*-DNZJE:KTG=@!\^V +J@42N;:3V
M4+A7K?:D?ROS'!'F10%"R|J_842J|561CDL03IV(L&7>6\$R|>)QTN%& ME_)S&_7#DN\LFR#;
@LLHY!P1M0C=XT8^T^&|)P&%R#K(^@XR:0>DYS MR\$<8?2%/;|P\^#NI,D*^V:| PL|8(&HJZ_K0F9(Z,&
(N>*, "Q@3.:):H(5") M_JE#PBYS?;%M:#"1,.;WM#X'.6^@+'-ZB([HUFZ8!DB;M6('WZK8P^02J
M|B6'!6G_6@&S#%(.IQM%|S;J5KL0\$|8=|DS\)|109 U*:*8*"UG%IK(2FF8; MN"KA>+J&2H(KC:>)|@QW&- 'C
(D@W|)J/8 ;EY05!S#?Q107\|HGUY WE*2(M*XY9AXL=J)>TI"@ZHKL1Z_E0@_%+)%V_6)9JK3DDM
\$A7J(PJ2#*R\$-(.M&) MQM\9%*J\$() 'G' :=. @3ILH+RTW'\, #Q\$9FI!04:C'?8:JQR*"R"1/"<+UNC6
M0<1&)\|>Y" "G6;7HQDQLB[1@WSVBR]-^F&X3\$D4Q"!E8B9G8ZLLYR!=40 M'1+|=;X\$U,H*X&^T?EKSP
M,N1F9QI&6.*&0@L3<)(F\,@T(_FE"] M\$4;G|J|=WLK) (1T+@|4Q;X\]|@-G(S=V!21R|6%.NHQ4DX&7NS"
;8&.=^FF M2'@01.0%D|B;AXC-U)|-X+|I8FE)^|4&|H.R(M" F0-0B=']T5IB#GJNI# M9S7;:'G:K?21Z*
(B5_\L|=L#;9)_3%8\5GD1_8!%2 ;7?E6_R6<|.KA_E_M ^M(BW\K:9-=TH)'(VSVT\$77S'@!>B2_I_0;:
(N2;*;1#5*23B&0E3%X8_MG6W_M3G<^89'M.CU8A-0."E7D0+S)&1F_A>S<+Z8YM6Y("1,/0%88FV%+V")6!F
M70*,W,;09:\.Q(8\$K8#)! (YP_N9H5NJP3=JE*JH/.20()E\$|9CDS76S78|1;T|8M" |V'
2KTXI"0/W3R|&#;&'PKG?R>> (#!^\$<4P3|)! "X+>#X0_M=4,0F6'\$3?PXZ/-0-|312P/IA*:=F:UX7-W7F?
Y@2AD1|509U^!D)-6B5PA MG^TK0M|[[<.XNWES|]H=4^:5WV-QR +0;-.3>I0
M8,>T/6TMCYY.Z2TKU"3(>!\CZ" :')X4*)N*],R|2|DE&60F=SIBN@6J)Z M|, #Q66;?
3C^&9_|JR"7W'*,XDJPX:6*4>.\$Z@1_PQ"4"UE"2|2(|W#SZE_6_MC6;Z003ZE\T".5E+W?
G#=A9N^NA^@>GQZY8Y5;2\$=+N3TN?+L"1Z6T,7*3"^ M(GA:07^7?8&^B4_X&">)-X?R|]"&[P<,
[D_2>AZ@|]&:5\0!|]"B|6;T2|' M@6TVW|GI'933MY;OMY;OMY;OMY;0_UN^QV|J)1-0.I^= \$MKWV%|59|Y.-
K| MR3K-<1AX210"SIGXXS&^?#L&00'X|T^VXM>TRC&>0WGD>G&K8=.\$ N:33?
MM|*|C>9P\$GNS>&Z)F0H)E070|+?UF2W4F8'XE^MYF3J)=^D|ZTP?)B.)GY_MTYWZ,DS&_N28T0B!<=63T-
V^125|7SB!SND1U'WV1|&#K?V|!_3GHYF,S_L_MR/;W|U"':,DF:WB|= @?05&N|'0'=W68GHX|7Z-3*/
,).PI%"G+J@/G*(|KK/UDI" |V|K|F#RJQ<=W#E?5>N_I" M|S0<>0|X?>SIV)M.8MIEI9|TQ5V=|(NVDSV-02
_3C030K:5'0:1-0T|%)YF_M_S3L;S(&1^V?#E06DVV41KLT)+^%AL_MFQCD0E!'!0>/*;:'Z!_0" +|=|
0|_J#BJI@ZLWMMOK-;A\H7,DWHJEE6IGN_M_/!5=.09I3ML1DX_"|00AS)HDZEJ2FG",61#WACMZfZ;\$
MFVBUI?2IZ)QD8_MGN+9_6K+4H7M)&J:(_=5D9,(UCRC(-CI+X#""; PW?_ \$N|B1D/C0:+'TQF\$7_M1-
CPT_*GI0BJM\$W_A7V9M2]=RY3LLJ3@*S/9;><8K?/P;N9S_%:P=E2_0*M_M6K>9,PFx?|P6_?
#!I2#6K(5D5.MR)/96*=:P.20!NX|K"21AR>E>\TF/#C>_M8N\$RG|X>'4+1
="ND\DJ=61)>P6/;,'(EQ,\$%"7Z|IC:(MP93&L'W06.@H1" |JB1X*6ZR&E6Y?N/^F> /_|V1@24>UA=^K)
[P;N>B5Z,A_MBA1_VB9>=[_L60%9/[@P^Y#20N50<\$!|7<[N#0U0*+ M0#B.09B.84;^?,9F?A+LM?
&^ONUW|(Q':0|MD3?U)^. |Q;^J_ |B"/@SXJ\$9@_MZ,63T_M @8=P?)IJ*>Y7&N%0/Y+9-
K^&K.YIZJEDE\KQXU+Y'|'D>^+^7K>N_M?
XSWFL1M"1Z\HOW62/7GNP]-.HIV.\7WJ^_RJYP"#220|T|":*6S;?"1*E = M5W:R&XD>@'L0&2|OSVP@^-
[I.&.]|KM4M1RG_ZN|Z_UN8(, @YSU?E&. &8|_M8|,9^0|Y@K6Z*7G1L/4A0+M6Z^R#AY%7EY>|=|_1BK
P\$)|X\$.^;=L!_1KLP|5\8./> M|75SN&30ZGK_+NNC7F-WY*(W@)1)FP@LIX_@;:G|6|C|^7U#Q#Z_YN"FO:0?
MM9>UX.0XR)=I#!)038/W.RSN"E"9CZ|>V*;^7D&EV_TY 'S@#JJC;7_RK_QN_M>W|O^G1+^#F_
Q+0_H8!\$|(' (F^-,U*?)%#4!4%F!W\2B_6P).9W:0F6+08A. MAH%WPD\$X617\$=G-LH8^J=@5F?
&|JM06*.8Y5FMYCF\1W?A\$@|.817GB*#06<_M#0_J@.;(,9?-[_0|@9:]M@YJ|Y;W3U_=<|. <5N&=(*)+7W>P!D|
[XD\$S>Q'= MY_|!%X: ^D6XIV;F07E5\$W0NZDCZ.)|YX-C>DF@0HX7>|M?(.5|M|/X:F|LUS_M_*XMM'?
3'+YW+IH;1/:XW3F9?L0MZ0'[W8G>\$K2-;|^?K\$K57*|(5TNI":-. M)!!B2S3MUSIG^?1%)N_|1F+;A\|X+('?'
@_T|7>C'Z5)60*|@BJ16I?|]|J_MMZ)N'2TOW/!!#1_ZH9JSSB\+K7\$'\$7_"5%LBK_R)!
[ZGZBZ4+_,E\$|7/^ ^ MTT^ \0(:*\$N2YA*F!|QV/-&_LEUIMZ">*&JH&6Z"/*|\$!30P_|Y=*U?8+^N!^
MN.KUOP^02P,\$% @)XEM68,|86?M"0_J|H_ID|X;"|W;W)K&ULG5G;DMNX\$?T5E':\M;ZB-
9+F|AE/U5R\B5/KK&-| MDX=4'B_2DK_&"1H_)2M?G|,-7C72V)4'>WA!- IRNON_NME8|_60E_KB6VX*
M_V:T"J%\?7SLTY7*I1_4A5XL|_NEP&W;GGL2Z=DQD*Y.9Y-)N?'N=3%Z/:&
MGWUPMS>V"D87ZH,30LISZ;:WRMC-F|TU#SXJ)>K0_^. ;V|*N52?5/BC_.!P_M=|QJR72N"J|M(90:0!G=35_?

G1}Z70!/K3:~^RW(D\FU7^CF7?9F-"&#E%I M(T2?};J01E#BF&#UUKGJ-V2!/07C?9?V7?
X,I=>/5CS+YV%U901Y4AD:B\$K M\$Sf:S5]5[<9Z4NM?R_V,2ULXN12"L?;%X+PX)<%_&0%;'H2=P.3D@,*L%
M9FQWW(BM?)1!WMXXNQ&.5D,;7;"K+ WC=\$%)^10^C_.R_)5X;XNP\N)MD:EL*'\,6UJ#9HU!}[-G%7Y2Y5B<
M3!(QF\Q.G}%WTCIXP0I.#N@CM\2C]JFQ0G)*_/MN[H,#&/ZSS\FH2W2_+BJ0
MU[24J7HS0@5XY=9J=/OS3]/SR?4SEIZVEIX^I T'40&L '[KADK%NT*DMBCJ MDMCHL!)AI5 ;7ROM-
3^T" '6;1^5\$;CY/OUVKAR2P0DY27CY@U+66R%]*AE ME0E9B*KP*D5\,T%FD9(4-
SJ(N0H;I8I&IRPR50&VS"N/M'G/.Z>RU\$\$. 5]6L;B MCH."P@PJ)S TU9D (6;:AD/:R];. \$A (KL
M6M!_A0U"261WMAZ@<-<0@E-M MQIG8PJ50&7! ;T(E7"H>SF:[4ZMSUJL+;(4Z%S(@8-\07L?AI@)6_3H@Q:B%
M(8AV(-0*?)/[HJ\6SY5T?'[V-##GX],N,"A#;5CW(#QSHYN
M+H>6);MUG:~NZKM',2486U[3E'RS#/#C87_VRVX#344K-A;ZHH(0%'K73V>3Z M?>WV [G]8->J0 0@=]/KEV(L?<
JT<[90;IX;S-)=;R@\'\$L07K*V!:=)I=-F2 MFTU"&VY6EM#MZ+J4[HG#J7*<@('5"=H
6C[0#]I3I8G^_H\HCXE+T&.U)C0@ MJ])APV2:~.F*ZT@SXPC.FH1MV6V1N[80\G-
RM#_1:H>6X&V*ZE#;S">4,?17 M*MH?]*"I*K;][TA,'KD-%X #XJ1PHB01&Z8<##H^VF^:YZVJ:T)R\$ZA<\$YH
MZ\U*H^H)L#I=K)J]0(F=YV^RJ'!(\$E-N+&>,V:ILQG=Y!,@'L4 = MIV,OZ &19L@LTA3T2J-S,(Z8+G2\$)M_(-
)XSN^LXG4?;[24-@))50"L9R+%U M-4(.V0PX8A\$H0(0&S6!;\$,35"P*P32=T4]7ZZWJ9E;V.NNS:'"+DN
MGY[I]/4"[E1>%50Z]*[Q][.S9A4];L(0)XF=DD0]!S3YFG[AV6Q\QK%VU"N(M S&0I[.SW?&(^6DJ+Z;CRZ%
40!7.=#DWZ 853]@NA6J/BGY Z(#0 MHNFL8%V;'B%-MG12\39V80SJ\ISJ%.U50##]J70?%4 MMM3]Z02>JX;+<
<+LH:2@7!WV;5UL,'JK>&(-VAM!WII)IBD7SL(.Q)"0BR7U M?CPJG9IK*R.
PY8G*1N[BNF5]Q50HP*+N\$VL\VN%OW#L=W6KY\F MXN74BC[SK:E8<;\32?Z80<(>.-IC]'2FK%//(*)W(V?,<
[H6WW\$2[M]=!.M5 M7;A7DABN!USJ9; M208GSK<4;>R<2A?|2!1KNQ"=UI=\$N+1G:%'\$;:XN#-
J3!\$;W'C47V6^B[W MGOXIMEH9"%9NK;+#;\$>S/Z&U<4H2M4RI^%GISI# M=IT&D:C#1-
V=SIDUF&K\O)7U]_08YAI]>/^R.>Y#E^~;^8#;%+. 'NUP,CG MK#YW(OT.TA'O(YS'KIJAV+2A'H0H)YK1D=<-<
]6@Z/FF'*=D)9002(^H.'*>D M-[*I0*)= ;M= Z"0AG6GS'BM[VGGM"Y*5!>FU-E=]2N6[E/#J>86IFD:~!M
M#;=-#J.M/*SV+U^+?T02=W!S4"XN(X^XA/ ='8=J7G0YE0,I\GT:D+7%TWf MD.<%Z6[6?>96M(C.-
*8W@N]VS^(J8 QIT @A'[N3RZDKL M^TQ]W/OU(=%NR;^1H/>0P_&'A/9I^S/,??SUH5L>?~,!Q5W25%#J
=')^.)L M!*3R[R+Q)MB2?XN8VQ!LSI);5DQ;W@N+0, /D& 9 >&P0=VJR;W-H965T51E!C4G'67;4-
DK;9#&+9]=^,7,=&6WQVD/HFD;YS1D:MYHG!\GC MP8U>UB0'Z6+6JB7>(GUKKSWOTH&EU
W:H)T^C]4\,3TX.9N*?33XKG\$5=M8@ MD>3.WM0))(&B"~2;+9@5--KV_VJ] MS<,.X#A[3#>
L91=^HJK00I!8SfU;@Q9K99!%#C6@6IZT4Y98\WVK&T>+2 M%JY!N%-K#+,4F%'.TV*+/N01XQ?0'^!6:H#?<
+8EED_Q*2L9Y(P?Y9R-7R6\ MQ78\$DVP?QMEX^@K?9 A0\$0DF;X8'%SH4QH7.(P\S0-Y?B%~/1=RSSA]GE&:<
MY"2TJL!YPEOT#]@LGC [N H^_2*WNF@= H:~Y0E^~\TW-4(YZYIE=UP]Q3.
M6U\$B5'\$&') "S3UC^86GNG:FU'8978L3 M;0F9@H
;5]QWMD!//&.B1>N"CCUMM,JUT;09/0FW5@54U)J[QV\D(JY[X)0(MLP164!
!VA:=9T.YC8&*]=,,M;\$K?!5G3'PH\$RG^GEB>* IU@5J*18\$FFDM MSU\$>"NB]!"G1L&<^9T6TPYNCT?C
DC3#&.6(4\I0IM'WG# V538>\H(B,\$>+ M%1N0-(0(D?.HC/Z#92^WS^&2EV0:Q11.=(*L<~>\FFL153DN0
Q%7(52%\$7 MTS1<]26*&1*+@K4LD9/U7.RCY][Y=&<<->B7<>@&*%QGJ9],P^DPUT [~3&95<_2X\$0?#
MUV[Q~U!+ P04 " GB6U9>+VRV:~# C" &0 'AL+W=0/>#&1PD6R4NG>+GZM%\$M"*+T#H'1YP\$ H1 .B&C\><
_ M3BZ=X5 ^HG UL5,L&V;PDQ+?>67K17 90(5;U@E[J_8 X2&>PN&52AC " M> M-XL#*#MC57,P)@8-
E_V7/1[R,#"X?,L@/1BDGG?OR+/\S"Q;SK7:@W;:A.8\$ M'ZJW)G)4UU T49 S>H85TSC?/(\$JX[C-D;>%^8EESN
M!D'"[U<;8S7UQ!^0Q=0#Y: #N7LR,RTK<1'013"H'S!80G^7C../9\CF)[+Y M.?<
3_6)' BP\$K9G@)3%90<=%9K\$'2DG!*+2F5JFGHDABORPTUMD5-49ZFR>
591!LC<|V=.#6>| Y6/W('E#317Z!98 F@;'DUYE7G3ZBD%.NJA"8@:T2 M-!L,?#@AP?<
71[P PH0CS:7K12UF1>"G/PVP2>S%-Z9QV/Z-4E)[> 0LA_#0&?2 MNM6J\>4KF2@P?<
QD5=07>ZIO)GHX!@6G\$W=EI%>8,DZ0^TF'?JA,1H:XYVH M!LX9\3M2F[U9V+55Y3VHUC&B!C*F<_6@/<
VC36)*=Q&.BP0F83Z>4BTRN\$6: M!+QTC(P'Z22W!MZ_NTR3]"DX712_%) [9FF:)(X#2>%ZRN"GD[A3EDFG)\D<
MOPSS."<_XTE*Y9R\AJBP>"F;MSYY\E0^W32]C\^M'MZ : ZP?^LWC^?WYC> M<8IE P?(0 M4\$L#!!0 (<
">);5EUL&P0=VJR;W-H965TW15ZZER=; M[ZMG9VJBD';_6N5F]]D;#U|N\%F3)RI@0].9]10)D3 JI7*6><
M)\$C\=Z/>J#PG05#C:Y1YTAY)&[N0&^D L>VP926=>F/R?^K;U^>7)R(3*UE MG?0?<
S>X7%>U9D+S4Y([~%;NP=C\$ _\$6GM0"GB9FA0Z#+\+V^C'SH;+L;W;)C&<
M#5/6.QS\$6KZ57KYZ87=4\$Z7%)1/WN);C7W^U>0;X1/GQ!M3 MK'0IR540SCPDT_=G:93R,DB9WB/E4GPPI=Z\:<
[,5-;??P:-6K6FC5J0IP* M_*2JD9B-\$S\$=3^@/X9CY\#%40<[<)<5/U\@0EXI2]42>0?00ALAP_?!"<
(>60\$ "'IWQVKORY% MO+/[MRH7@]]AC^I-RME\$0V.R"P1?JMH427+04CQ?ZZ\RH3V#G5V*591\F)<
MD**R^D9ZE>_%5N59(G*\,74>I2]6VGB5;DN3FTV01W)WVF^Q+P?6B.LM2D_<
MPAM)04N"Z%0217KAI=TH'\$^*59!6>BUSX0'4'ACB214IK+1*E*JV)E,;52HK M"1-\$IIV"~^1B<^0T#5BI_-<
<9)86_KW69:KGF;K1J2)>#6R]W[(*_@&8);3E#L+;!)N>GZ M*T50=0K[V!<
1\ZVDKP/IU>5L;XNM=+B.F%RANA;BN2JTN\=NH&/H!U:J5S M[:\$)SF\$G19E=*A>TRZ\V-\$ I?%'YYU:14[(A)-<
KY2E1\$ U;NA"SQD:9 MIJ8N;5FP70=S4I>\PF82FT.,77UZ(Rf&BV0P UT""^AT"R]#"/S,EK'CHV"+<
MH\BE]'FN);M28QW6U_6^8]M%_7_60-2+M=16W,B\502.]F6PB_S@^DW D")<
M2EH_~%VWNKHQMHLPT%#H3LK2B5[>MHKM;=NCQ6B";I+G#0S6Y\$B/'LYK*Q-/<
MZ&\:CQ:'31LL=E[\;Q&!7*W;-BBCJ'1_3,Z8PKC[+>RM)%+2E:\$8=VR!]9 M(?)<
50=1\$@X]R.;IL3F\BPK(<13H*7YL<+(.2^ F9LC6U@W7NZ3/Q\$RGR1Z/(<
MFYX2;Z3;BD=BFBPGBUCB9(V5E:J1?8]JM, Z-./TBWARGDP7XV2VF JW1=:Z<
MI^(\F2SG))3JAZJA;^1BF4RF%P(\$Q^>J_2-4K+J%\J0L,AWI@K@I(.0J5V*2 MC,?CH//!><
<;CCNYWWR.07":7XW,.Q%V_Q^QH,;EG\$ _Df X);, R((IH#GY8A M8+EA^_%G^P*L<
9"EWRK22^_L2[^(/0)\ZC0(.04YL%D M5>/71(1N=0>TN;_4-F5B())\$YH;3P5U\$Y<'_3G#9EG !XVUU= GK>&^<
06!M4 M8S#0F,29L\4&V,]8'2T>-"E!H4,E/F>-]AW2.I>ZB(<4,E-'F3,2'XU8UY;Z<
MXF!\$J;0=2)TS;E!.4:JSE\A0./_0ZR;/F="@(\6B&'#2<-!"J;WP1SGZR9\$ MH=.G<

JHH16NX#T=46B'G6%M"FI2HL> MT(#L(4DK"&2>\$I8U=/+CNZO/!S;E+;A*TUP(\$ZDXFBTH%'5KS6:,4(!X:\$8
M'DV[>@!@/KZ]HEQ5E:5[MLI7. A@3K^6(P?^"AS\$!2[BGHG)XG%K/,@UX4#-'09S_AZ@E80R8 CP9CQ\G
M0I&\Z/5#M-BL=>UKQJ4;5=;X;(TY@8%;V119K+^%D![@\!-!0W/6)F.- MIE+8LX/K,B>"'\$@C-
+5CW6R;A=EH@NP2>UZ(=<^*MCCZ!0QHMCX@TFQ0217 M(!)?U9P2V!#P>C(;ZE03(. [G*!T)M=9&"0;=GGC-
JFBL:ZI@4B8[9T^X2Y M#^T,-?*VMDW, _1;]!MG+EQZ*+CW\$WVJ8TUQ9]!EY *6FG0XB'OVW'UL;S1^*C04Y?
ZOK3@F3,OB/!:=S" _%;R'^Z9V#""8@FV3\WZM':-? \+B MV<4LGE*:\03HI,D<1 J-;Z,I<,WQ&&39'FQ>
(H\$2BT1&75;H5XC/IJ>([K!?)#)-+N>SI^*M M6I'']'2.>3*;)8CE_.F!?'3\#%8D[!;Z?
K)Q@I+B^>1NN&DNC)=)9,YI#P/\QW M;:6%<:Q3\$@35G;PB5Q0@71\$N:;Y&-HRDA/>Q]/C-H?+XK;Z3*F%
[N.3I75]TON\;ALQ][CKC?GZ\$+NG[!>DV=3E MSE'--E"=:YNC(UJ.R-#?@&139K\$]QKC0Q8-B
M0>7:I;K[AZK*DW="?D/= . M.< \/) [4\DHXPY"'=5G _ ,+06#U66YZY1RD+=5T2=B\T@X.\$MG!V* '@AT M"XM
5ZT##[=F+W/&Q4*AXV?WUQ0F0Y:H_8TOWGG7/J08!/^/9H_C;-0.%WA= MQVN(!EDC!8(7G+SA_.4'(I*
[80L\$P.S* ,+8.E>-N:U V=1[;Y@Z3-B)WHYJ1 M_6 /I.6 R9+-7B0ZI#PD&%60.J0*G40TH90F\9*?
[K&R,+SMRLB,F7(X.I,V M?5]AE V8E72ML\$^ VF%]5>3VP] ^H0NZ;OL:Z.M-0Z-Z:\DQ7C?D MN+EU8?JBB>
[G^[:3]%'J".4;5),\#6UR9\$G>S/^'1V%,%C[2W!.M;UDY3B1, M3'W[I 9R:F!>Z\$6*I8?C-2V,HY\$ _=S9?
A>T\.%W E9"OVP@%QMHASR9S#I/ MK7@ IGUM(I1.I0\$VG*['L<)@VJ>#VB[4>W3]4-Y D#
([@U" S@A^Q\>S=@B, M-YZ'6;JYIV;XSJCE4^(Q&>J1;B#I]'XI5";240^F\$J)+&%.%0;&1\$4MR>\$S_
MSBG[P;MR8H<_Z_P^ V/UAG^% M0K<1@(?P4XWVT _:' +E?A]OV'Y>%7,A^DW6A8GZLUMHY'YXN3@)0-&V\J_K7'
MRGA0"GZY50_02POP =H@S>(;.J#]'<^K_P!02P,\$% @)XEM6966I# ; M!P A1(!D
!X;"]W;W)K&ULK5C;M\$9, "##*?<\$<0>+?+5U3GG,@P/A8G(7_HIU'#L==T12.6^*>C(0 M%\$K' _)+S4-
KPLG@0@FC>L(HX(X+!900I)>7Y];LA>71B,8_0JIA-L IS45Y
MYRV>*LSSES?:2[U4BYS\$W#GR[K50\$98?I,Z0%4,,7H@Q*GXU6B_C1@.^H[(GQH"M&@]'DD7CC)L=QB#=-^(-
_/OJ1KE>="ZE3L M)20>*)?DQ6660)_SA?,620GK\$ UQEWJ](9"9'&RN]%(RH]*.6Y62 M0R-
XJ7(G3"8\QB72V@T/DX6IM_>0C9%*?7F)R<4M)(IK3P]R]&6*6XTZTE> M3SQ5&G-,Y5 U=W0FH I/Q8)L(PU@?
8_"3DG."%IDU6H<4JW<)L2WN'/Q)7, MI4XX*J-
X04D=9!B"C,4/8C;N#D^/Q0VP*Z3LWUW^T4P,3\5[XV4>%N);3XZGH=UI41)EK=2!Z'J"N/4W?*6;GG38;*5
M=_M)BK2R02E!-Y7U*U3=)0CRN9+6HS3&"K"(IY8^5PB9;X3*A"RAJM(JT-Q[
ML,K=MIY\$JE*AC0<&)"WX3@LGS-(1MUPLG#ZA[XHVY1;')'/'4&RU> M2_!@-T%2.R
H02N\$!>0"P@7;B\$Y6(^-6BW,^;W[!;!A,00.7E760"PX@:(;\$
MCP^@S)0EU%5!08I<(\$&R96#K[@J'4:8AZY8"ZJHNN;.:&X2;B9N1+';?+?LL
M184I&2@1MT&>*WE++""]#%.20\$IY=(H"A8:UX"K@HR'E3B08E\$B' J+[7;C0 M5Y6#LM1R29:3QC*:\-
JP?.8N2K:=6!^G:M_"BZYXID5K-6*^;MK,9X.D"MB M.W.?V5J\$&"S;.:0"UF2@8C@P_2]+12U41-90:F0[-?
CMU@VZ(0D^ (%!:=AN ME&M%C !:BZVE:WB-15Z0<.@SE:E\$!NTN^,P8Q-787PT42\7RQ?J G^AS:J^9 M ?
2';> \49Z<\YWM]1#*2>B7<'8A/KOLM]6X)YK3 T13HLVVU-1ZGR>@W2G6 MRWV.+27&H'70\$ \4'Z-EJ,@3X/C-;
(JZ[7P AF M:_ VPD:R[QXRB0+IW?,CXGC0IFMP"HD6)PE[CA:5;[I<\37Q(-Q?
D>: .PI!GE#T[EDB4A:4[SUN@PU\$?:D8@QY+^X#96R\$WP&92>^>)&!.*M2[VN4*##
M!M52L&Y704XGT):U4LK8'J,:>7D89JZ\Y#<'L)IX@]TB@,2Y! .KSH3-*^P@ ML!6 _%;0G/H1.8UCM>&W-
%U+CU2;JL:YI,\$[#& #@UR[^[S=^<>B\H&@7!6J M-MM")M: +&T*E7#8-*@/VSK 8R^"EW)\$0&-](G]?2A@3.
8C.T3&(P0;4\24 M0BD)]Z#, _GZ!JENFGM43-SXT,* !5*NG6A;2%/WND++%)\$N0E6\W>PIT'8T/
MR^*]#R#-0A^2SNVA8V#YW X9J5*:L(:E^&+V(,^5(?WIKWI[H#<69(;EKB/ M&L+^G
MN&+CG= GUG4! =L_4\8.#^DHN>M"=6SUPLFX [I]Z#_/N[Q/"X.QM-#QPJG^+) M<#PX^0;3Y-/)Z?3H6UXGMN?
40Z^9 _=:G@8(A#^ <' \@U?B5H+G;?&.9QT\+ M=\C!QKL]TN^0U%.&:8.>L?
3CK#QHT> \! *8, 'QH6QGM3A)\KPJG< \@ \SPS< MHK[@!9H03Y? _% !+ P04 " GB6U9 XZWZ;H" @!@ &0
'AL+W=0 M *'PS85DIFM@L4>C.+CJ/=PB-?U'P _6[LWAA\)KG63WYR6\ZBQ!M"@87S"HQ>: [Q\$(:P0V7CN M-
:,AI"?NCW?JWT+NE\$0.+YJ\8N7KIY%9Q&46+6N\$>]N<\$^G0.05VAAPQ,V
M'38[CZ]HK=.R)Y,#R57W9B_] .>P1SI)W"&E/2(/O+E!P><4=AH[D06;<=#+#J)]!V)<[C3
MRM46KE6)Y; \F.P,GM*=IT5Z4'')S0C&R1&D23HYH#<>GR=<#7B>#U\DA]8]IC ^4
M@.*7(UPHT69L^(')JDHZ'8#W1@ \J9*X+X^"FU*I@JD^*CJP&A:4]0>R58& M47I)^J%!SW#Z*(!NZ;-+Q=WV-
<"R9G0TL"\$D56X(5H+3_7YMMEA!^3:44<)PYI:!.H/H/U*:[>;^ ##GT+V^U!+ M P04 " GB6U92>25;>H5
#+20 &0 'AL+W=0(MA"2L*4(+D#/_6_OI[NAL 08G2CGW.Y4N^V".* ;#0;W4^ 4L]OK?OLEUJWQ9=5 MW?
@71\NV73]].?'E4J^4G]JU;0#-W+J5:0'1+4[\VFE5\4.K^N3]]/31R4J9 MYNCE<[VWKU\;KNV-HU^ [PK?
K5;*;5[IVMZ^.#H[BA<^F,6RI0LG+Y^OU4)? MZ _;3^KN#IY-\$I3(KW7ACF\+I^8NCR[.GK\X>T@-\QU^-
0079WP5M96;M9_KP MMGIQ=\$H_JL.&V(&2UM[_K>XE7L?7AP59>=;NPH/@X.5:>1_ M]24((GO@R>F>!\[#
^?,MRS\$7+Y6K7KYW-G;PM'=H\$9 _%;Y:3!G&CJ5Z];A M6X/GVI?7!T4IR? MGE\\$!TWNPA[
[8A0_[_ND/9X].GQW@]B)Q>W&(^LM7RAM/9W9E&P]V^T4J/L;EM] I/BXUS*6T MJ[5J-
B22TN+8&J\K^B04_@&,KN'T#6JJTPKAN#GX^C% 3U<*X? [3,.\$7442!-ZTR^+ / MEY?0"V"\ "-FL,EJF\$>QG#
(6PUYWS'6\$%:_F,30,CZ8+PL0FZ=0WFJL#MA)0%
MV>GQS_S@I<.9U[IX0G=]T(NN^J+7Q_ ^9/3=E['\$5=E00)G1U4U2V;&R;- \$M! M&<(#V\ S-K6UQ*_3"Z5\
[0[N=;?K=D31KW>I144VAC4QT1IHX)+KVIS\ \.3][M _S[6IL&:TQX;57] F 6\=ZC\$S">@<,V-0-
I0RS5X*#LG*,0L@?N\Y&92A-K MC88&>X)?8DX5AT((JRFK%Y[!]"C85B%A@>)E@;<0TTR[!+I\ -0M(9
HXPC-.P>DEN7;P M550? \XNG=9\4P,C*5;B-#0YC1\$6^\$; \ \> K>(%'+3\#:' _"/AQ00:K2;0Z)
M3(R#Y*ZQ]U>"9HFLXX]>]8M<9MB9D_8)=K9^I"J^V(S8R;XM=>HF.Y)_ ,W M@ W35(B* \$+=MGGL%:+37]:
(8TD\6_LF?-G>^\$6!FOA2X"F#.G1MYTBIFPZ2 MS8!>T.*0-WR40.&C@V[L@_&?Y:0^ 3U\X?@>="'
Q<>)Q<<' *7_R M+-XWP&L8Q#A07T!>=4(\ZP"QMS7M+G\$3W42F2EC4>^7@R'SFED@G5NHSM"*Q
M0=)2'KG56A2R72I]WP.I0G:M+:.UE:K%) 'A?MTB"*N-FIG:D(P%6\$C9_/T
M"5&9)I=' #K5FY@.\$D#81DED.FHDI(<<\$,HIB-20KV\)G^4;/>>?WV^?02TVX MB@!6P;<[COFRHV"0>J/J3B?
 \Z9\$#K*X5:[R&6@:3Z%-23N_ REX<60^CKTB MJAG?73C51F=@-^L\E,K3[E:SL\$,FSE: \-YBFRV+I57-
PFS17UA;W9JZGN32 MCV\$%DYM0@.=@Z8),% @H5R\YZ4K?(!=?K^0A3PJ (YAW-?B^T:P8M6T6Q_2I

M2CJ2BXW\--2CC\JB:F0*. GA6>GXH'.!H,^M@K;1!1R=&?-4:}&1/N-.N<([J M"[Q*90237#
L^K!L#>_)40H10AJN'454]'0D&>\$ 1\$<'P5%95.J\$H)<=97(*:&L>WD\YL6U+,.=#RL9R'T"0=6)M.X2AD-,4=Y
M4&\;V.@2P:5U,)J:=X!TB#;-*MM '@#0S@?M12+ &0&;AZ<@,\0T&@>D;Y38 MZ! B3
004AM\HZ.G@9/VMN\$18^]:9%4:5W8KV)T8QU9,>KLT\$!Y!%W\ SXWR& MQ R0(AG\TE6+X,=GMA-*I5SG-
+P.65XM&- " F7!9U((0?Y2K2F7P8[F5J]" M+KWM7,G98MEV'(+AR7'Y4!&A)+Y/<4)9K\Z!CLI
,XY!;?))SY*#0(RA M 7S%9(!G-VF^\$C9;MU;S\OUS2-^1/"0D% 9']KCM20C/[I-R/D\
MZ(DWG; .2W45K:HK7>\$BY@7; B\ @.YX+)VSI2MIZ(TP3Z;)P4!;?)I>3Y\$& M\$EWR&*0W^DNYA-EIAA,0:[]?
REHH0S' P>5!5>X@3-\$&J;@!_ ZF[5R6Y\$DWCP*X(M2WI!)G0\$<;6UC0#J.X#<+<">D./%FIX]7@*S.I0<0?
^N6LNH\!P^W;6-A"/YY M/I1:0 F[:%C(3)KCWUM42 [0/*<^X>-QNK2(D7[K(Z+0DU?PK\$?
\$H\!W)@;L3GH,92F@KWB^1U1X:&+D*C\$6.339*V3IA>PDN!_C0?G\$ MQR&7X,I9544N*^T(;,000;E3*7*
5GW\N32:(@==B\$U@U_5CI:T<4&YIV>K M@0?EG@5%Z([T^X9:"7L2<@;I0BT63B](G7K?N>X<(#%X1D0[I9:G)
IQ\$-E, MCY -:5GHI]1+=Z(X5C'JU%!P)2KV'I'9YI!VG)WVC833PU7,*/BK+*P=[11\ M
YV\ZH3MD^Z40#YQ&L11 @)S,K 9PSA [A'-WKR;YIO@[@IN-C^KZQR\$0K9 M(?)F*!X+XXOH;7+.J (Y-
PX)\$(*6>B.1K\$B1 ICG0'), \$56457\1&.G%U4D*7*)=*L MNZ 3:V>IXA)C2BZ+G MS\XC\$P4*Z>([@CW-
%!\^>W2 L3YIIF4:W8VB>Z[A/U001\1W*4;]G1E2? MDFH+R9:KC!MR>'!\$0W#MT+*R<4
CU9]@VW,6\4Z5+&.IZJ3Y%4K,0\$^SDC0> M9\$G(('=V'NOEZ9QV;?8 \$!S5L5I5\$6WL8\&5D' 066U0!_R-
J!+Y4<;"C/10 MK%J^YR.&5Y%0H5[9901'*R-GV5S\$F<'PYH,=B[Y;\$9#HZ^D4;S6. <#PY0X
M; >&7;3C&J2BDID\F8I <U"@-W!' 'Z3DT;L !6GR99C8B;\$ITF-8Z&D&E!)
M#804>008@A@U/YU]2:%Q1&=2Q;&1*I+!)U;X: MRF>WGKJB0;%*S@3AJ12 [Z?
%WT@'. /? ,6&&7&.Q,5^3#D@SBMKN&*N0Q!A+H MROM]0\$<,,0
M0#K?'S'/S5A:4M5E%X\DOQ4V8"DVEL.7G<.H&_+^#6<1CQZ>,C2M@&N\$ R&
MJLF09JJ\K.T(EIUY\JR60H>\U!E*,9!#?&#MP'VX ;JFB&7L?>P00/+0FB'V/ M,D17U<\$S170A
0F.9&F1&EK02!LQ2 E+W\$HX(0:8J0C'@(N8D\$1H/0;,%:W\$Q =1#1 ;K=9[T M'MAV&#51"04BN;%C^1381P]Z H
BLR@E)EHHW61[;8 M1EYZBV94V<77B*N7S>Y9[AC@X4V\$0C"EG%2-L>!S3I\$:0J+>]#SB+XW0<-*%
M&EMY4R\VL'7J*U!>0I1J\UF#BXW(5,+X"V<\$0HQ(W\$J)?J(D#-SI@ZOX)! MTP;=AEU8YX? %RWB+D00IM,
[&@,-MC5^F+ K09U\$IB&'56TJ! ' &)H,\-)ID MJ%KP^*50D?U,\ '0)3B;@? M/<.^?9NHL-
]67AJ0TE@#RJK;U/ZAMC?2#L?>-Q;=*0[L*P,*0F@AS&EII .7 M JJF<0P8/&6\.-8D2N.7\$DW %GF\0A5?
B<73BN=' (/ -27F)4(M+A&WS&FB M]=.PER=H<9S:??E&DJUGAMI/#DR*SYKUTE-3NIYP>-?JQ8;E(/&^/(9-RHU
MD"H%]D"JSZY;M^7F&=U*;<1"]=Y,>FQAX"!0}?(R"WNZ@;GN,\.(9,=[D"Q* M RZ?
6DX!LB23&R1G02B4+&MLR-I"+4,W-\8%QX9+H0H4T0D,OPKU1&(\$4:30 M <8-K!<9AD,A@I;H8>6@BJA[+-
#RX"8WAF50) M>2=0N([ZG7&,(/4SMAL,2=\$SU\0/A/\$WUF#N< =Q^G RT1[*L\[[/.0\8([T MY
ACZ97=WNT2'\X'4)1'SMA65U@'7/\->7X8[G]H=3^4(DJK;^4^NF^+6I M8N4TBU"WZT2"V;%TL./Z6Y[#R&(-?
\$)\L*8-?;7COX,+HQ)#)Y?JX]GAZAK2 MKCG-D/,:' F<9;WQ7'HCESQ:^^[59Z:Y%]G#8DWU,\0 0\D-
2F)]U7:PW7_K M('"XTX-5I_ZMEK.#KZ&0.H'Q*YRWSB*CM_P1LL^@-#3B;J1_%NM\ Z.M,6 M9S6*K+R2 J]0
9E(3C BI 9#1'9&['.=U,21?RG!N:0 ,R\ AD!NA\$V SMOQ7P98MQWZS&#. =LDGJ5\$ ML.E;:-
;:CV'(6VUH'H:E;U8\2[Q2G8LDN])MZA< /C,9?I>8/;G\"\$).!RE1Z MIM][CU\$2]4G>:X#)Y(<:;H^4!0.
>>DA36M3\$X\$=!#NK0U Z"?%XJF*-0/"/ M5J@)DP,J!2?+&(# /#NIO'(^3^V9/10D2K*GB07CEU*S"*T-
-/;>RB5&&*YKR
M#IWM4'L%+.&PJ4HJ===4*%.50(?;K^=XF>>CQ@LD16,Z4LNDID8(!H.&YXK.&7\$AP;7%P8&.^1>P3+
[+@=4M\$I G@?>P#)ND=-J/K M0B/8TN-1[=WU/8<0MW\5[^SP*W57L*9)0?>6;[J^\$T0,+QM;G1X#6@4?[\'
MX0'P1J%X[H LS6()5:H-GJ;C[9]A<[#.++BG V6"8%C74T.Q5F!7;W[6?%I\ : M(\$0-L>/V3.+6 \$X0]="
[_ZK]S,R>4@0M:X,LD6P%'R\0[5:++Q';RM033SKD([U\$GL- MB(-% V^Q,;JNLHF:8>LR;4Y"1<
_PJ;*C%Y.8KCUK?\$2!CORA?V[;0%FH&R M0&)A
F"+8!@!^"XB/>2G^E>7SPZ =/Q!TY#8X\$5 90%%P<2%E; \@WOP06/IE
M9>'*JU&/17V7D)D&2V]V<*3/,0^W<8J*P7CX?\$KGL^0]GXVTZ;TW2@7+EBMH MG+2.0\$KTM'@+24/
FU++Z>3*G047Z_K\;4GZ#&^(\03N\ I1>&T[MW_2N@ M/*9%KQ)A2Y?7G[#-*7][?/K#I#BZVRK3(YGLHN?I8-
*S0+)W9;*7L09#;:;:/ M\$?EE,5N9^2;-CX;WXXF*&(8_N\$G,+^=D9 @EY0T0X60BI5'R="0871">?98N M\$96
%G"*0^DX:T?F52QXH,X1IW'*-7KM+ '(-9L'H1\;SPT',G8:)-K*>JKWM MYP-
[@CH3"4VH*Q/J8"0]T@FN71I^"3J.J*DY<96?WD5XWT41[W@6AK >L/S M"HIT-
4PDKBE\$;=0MJMM0"Z5Y/GY,6W\$J'2Y5U2KEJFEN-]A80%IS8Y7M.G0 MI BCU<#X&* AGJ>.3
_T.V\$5B"TO\$T276];\0K<.ZGCA+ MW7T"0DX)L+X1?0*9[C#%04]\$ZJNKN0=6815MELL^RGRKB7*;
(\J8ZT^<9 M^H=@4.8BQWA)NIY2-2C^ >ZQ/""[<\$08SK]R07V<-)IMKV\,U;"<.H; \U MI"Y"14,/=7)+
(17V4FV_A\$U#R(8;]VVOYC4/OU*6L*;6Q,A0")A^[&0WAQ/^ M-[0_S6SA.C6A1)5[+&X6&62EW8)_18C?
*VM;^:F==#7]4M&E #Y/?[0\S-\$[Y184A=5ZCD=/IX_A M0IW\,J;+0 \Q !D
_IX;"]W;W)K&ULSSA;;]LV%/XKA)=V";#6DFS+ER8&8J?=.K1 UJ3=P['2CZVV4JD0E))
M0%^='CXG=M'TJ=W2G\S:P#+[K-4FK/.VMI\TNV:9 T9 M-Z]5#A*_+)7.N,6A7G5-KH\$0W*
(L[8;^'W4S+F1G>NKF+07T5!4V%1(N-3-% MEG&]F4&J[LXZ0;>>^"16;TL3W>EISE=P!?'9S?
JEQU&VT+\$0&T@EF8;E6><\ MF,PBDG<"7P3=48Z7W56R M?HLR"L%HO.=[F10WG!+9^>;G7'- \$FC-NHX4]UJ
M!"7*:0PJ<)V=0N-"LR\+8!]!&X*#>AQ;]CQ-8]3,">G78N[F&PWJ33. M2HWA'HUC]E%)NS;LK5S
X0'Z+J)K((8UQ%EX4.\$5Y*]9S =8Z(?) _IZC2*S;@1ILW2@UC;+7T Q1] I5N@3!%_03(D<\$L"=^0_94
M<;SR&EY,\)P>NP:6PBVD9+Z0>8'"A8\$%]E%0LGZL)MY@=7Q52#ND2M@-LYL< M\$!>MQDRRD,6@FW1R.UQ
4LT&;K;'N ;FS).VW(A +%6*%\$;@K*L=-NP^J,*@ M\$G,RV>0W09M?*XL^^^", "ZHVK-I>=>)E1.05?
H;K]I&Y!2]K=&8CL*I,-D\HBZ0["X9A(_ID6*\$J&HU&SJ&ZKZ0]*KEY9T!FR:6Q9T/= & MX_&.
<#5=XCMBT=B+1NW&-Q\QV,WZ0\A' 'TO' VVVEU4<]!6+&7"*09N^UP9 M8=DP?+!UNW\HA-
'(&V#Z]+S0,&1WQL,>0L". .QY@]X(.R,0'\$3DFP%"!\$](LTJ
M/18M%.F0SU+%1'14].P]\$1#)*"0_I#AR3AN+'L34SJ+7N0Q#UQZ20QA'0,F: M8V@,\5%3A61HF4\N2D\$YE-
Y5THY\19/\$EU@"UQ+1,2)C[6#%YH=H&VT/I1S6QM\$:TBMQ-1= \(\0D,S-?F\?3_#

M(N/R_W)V5:JMC@J024)V@3TZSI7&BZID5#..H? *)4U:N2T8_0.G500_H.2C MIN2C9Y?\KP5FL+ "
<+0|80>4SAL"=QY0Q>\Z(MI(^0&=;K,N7C0@3RFC?;\$,1 M6U"\$3-+"N8G\$VJJM+FGT.(G,599SN?G1/*?
N|_0\47HPN\$|0Q&58#CI!-^"A M0_>:EI7DL1+[-21K*6|0?VT\Z=+GN!Q\QMH\V7 "-%7S|CY'RD\CTGN4JNX
MIBA'>%37Y#/-!70% A^;[R@&J2)-S8GX786 R"0E,FEJ;H_+YW@DXA4%?59| M/2F-1GYXT5:GW:V':
9ZY9|;!E<5TI90TF:V>=&?EP_9! 'R|X"/7"-9&;SZ M+W&I WJ()ZHNG|CEP*KNVDIDB17*,S?
P0)&;,UXXBYG=NY6+F2AUQ@N\E:## M/&?RX1(SL9\|0G/8N..;5)L-=S';L@TN47_=WDI:N0U*PG,L%!
<%2S/G00_M_#(R)^V%;QSWJ04-QI*5\$--XDLR=SQ##.,M4%@]-KA%6:9 2(:/VI,IU%I M!-
0?+_1/UG:R9<447HGL+Y|H=.Y,'\$APS5>*,MKIMEB)L4>I+E-.;#FFJEB1P0 M3%"66M(I)SF|N&
(J'8!YPLN)J5& MU(UK!9>5@N 7"J9P(PJ=*0A8))@E7>);,X.#"^(X"+G%|!J\$W@,+AD?P MPL8#H<4+?
X'WB7\$)WUA6(EQS%6="E1(5_VQ4EI2TOS397,%.>R&-(5TKK8L
MQKE#E:_)0|M:90'_GC|P/1P@/&\+ #8^B+)|15F4F8(8@V/Y)59=D=S8,.Y3(74 MI_104%F#\$Z
Z18:4,'<85Q*R8L-7#+%59<;CA+M=L-|BK 6&34#@ZQM M6D',-&Z\$Y/\B: '-N>.P:JV)KE7D"/LM1WK(D;UGRB&
L8=0^#K:L C"UF4Y2F MGC-6Q BV?BC+>4'Z1:D(607/@5)-8|Y"V>0;7&-<|AV)ZR|;|@|WA>'9V M/QB-
)_8=|;XI!WR@ \$I;?J>6N2|(\$T^D8AH-@ \$L%GL4-9&'LL)+7%(GZ 0FCR MQ/MWD_/H
'\$R'(|@7FF65TB|MI""@09%Y>X-Q%-0)H\$T"M-Q&+%JON8F M!M;="6Z%XI H\$#QI/8!Q,CW(:1@-'\$
4#B(RM; *F.0416'WY!*+A(/3&<*0F MHJ8FHC?7Q,6.\536+VA(8R M-
%1#XT6JM4JOKLC*6\R&I",1+W+R+BE+X&M!/?^/L^6<;\&7&G=B<;T?
X*U3*%!>!*8D"*2MFP|\T12N,J84Y:0IYD,=M1| MU"LV0"!E|%\^N'3/=4I>G7J0L_?
5KRWISGKH010D+|\\$# ,MG_ '7,,Z^,Q?-DY M'D-X)91N!\^S35.J0?
&G4(J80A;4JHETA|4Z>U|LUW6QC\..HN=L;|5\M^-&\$ MFMD\$* |Z KA?+8=0|B8&L70|L20'KT@|
>;X>3 "KX_'02A_U00K_M294W# MJZM-N+W)*T>YL?,E_<|56>AJ"&MVFO'VHIK<'J|7\^-DQL3|0S7).J=C:DM
MR6JFK|9;;.TP7_P%02P,\$% @ M)XEM6> =:C0'!0 80X !D !X;|"|W;W)K&UL
MK5=M;|LV\$/XK!S*=-!53'U|0I+ MN:D8^:-=0SU?K8WMF,S/;|;"|9H_ZCM%7Y,.)><5"LVE (7%Q>C2/|M*
|7PW MX3/'C3YX|V0)4LH0|N,FQ0AY5B\$L,3,6@5'SB=-8EA:(U/BZQ1QU(NW"P_<=
M^J_.=K)ER31>R_) /GIOUQ2@=08X%:TIS+S> X=;:>V.)ELM3N'S;MW'@V@JS1 M1E;;Q:1!Q47;LJ>M'PX6I-
X+"X+M@L#IW0IR6KYGALW/E=R LK,)S;XX4|UJ
M4HX+&Y2%433*:9V97|&2B0QAX1AP+:M:"A1&P_#\$6Y:H3\XGAL38R9-L"WG5 M0@800,[@HQ1FK>&R#'?
QV\$U.MT#-'8Z7@6#@_ NL3R'TQA!X032 %W8VAPX0 M? *W-?UTNM5%\$E+ |K&Y!HWY0NWG.=,TRO!C1|M'H'G\$T?
_0&3|QW RI'G\RV/;|K"3L|K2),96LG-\='2B1U9:5V"AV!/X|\V+9A2&&5R00B4%5P M8UC)F7@9@E)
(W++=##L"3*%,3*LVP MV:44G(L#\$\8Z4>PXW(3F&:VJ=U*:RQS,EF*H", MT-^20,> >^M^6!//35\$"7=APGR?
0\$CF./_H>|1+0<>6\;0B-1'E4\$9_52AX|4+NJ#)4+5G1|1GQ|Y@6SULC,=NB=[K9S5V M?
J1CODW>&Z1=R_2620H9D1R:8\L5KK@0-F*|(.QAR;^1)M|\$@RC3* MKK!*4,"YS('F3:?
>@Y/E^VU83^|070|9(I\H(FR!2WU3J=4_55|H6D_C*S= M)6(I#5U)W.N:|H"H|
0: +Z0TNP\KH+M5S0%\4\$#!!0 (">);5D|B:L@ MF@, (4(9>&P0=V|JR:W-H965TDK#BMX^Z+
MQ,>|Y|S'H:CI3JIOND0T\^A70L^"TIAF\$H8Z+|F>B ;%+2SD:IFAJ9J&^I& M(2N<4UV%212-PIIQ\$R-147>*=
MW7-U-,2*[F;|7&P7|CGV|+8 MA7 ^;=@65VB^->*9F&/40 :A>92@,+-+&C\$DV5F|9W!GQQW^F,-I.UE-_L
MY&,Q'R(:;\$%:8&X0_Z/6 [|&J+!""%6^&?24U0%P0\$>=KE3+FNF\;VL00+" ME+/@*H "-ZRMS+W<_8%=/B|
7%;:/6'G;4?C-/)6&UEWSA1!S85_L>N#@<. M5|K#DGGD+BX/9&+|@,S;#Y5<@?
*6A.:';A4G3<%QX5MRLHHVN7D9^8W2"EI M./0,UA7J\VEH"-1NA7D'L/0_R2L_8|B5PI0:?
A<%B_10PJFCRC91|1,3@*N ML!G ,+J)\$K2\$WC#/L.APQN>S0#QQ5H;12+XYUB.'B(|#F\$/QDOW+,=90,K7
MJ!XPF/_Z2SR*?CL18-H'F)Y"GZ HH!5MA2 WL&J;ID(206\$5+%G%1(ZP?L!XRK3LF_QW@!TSJF:GRA60:-
K*BPTRJX0), M*50-1*\$!'W-LC#<#@ZHf6U% P74N6V% \$9 ^GP UV&"|1M5W&3Y@WJW\$;F4(M"WZ1Z
E\;I#|N-AVN,J>,ENIEB;,&EV H)C?0):-Z3F\RN"&LS60N.%(*M2 M*0/.A@/R.ZRJLWN".(IAE,*-%-N?
F:99!,,DAL_2%N|E+A&Z0.(ND\$^FI)P. MRCF!K^XS005E#\2PI830?CJ?F1Q|.AC#*\$S*E(1NDW>@'SQ>%A?
\$@CN\$M7 |& M&;P|H\G! '7NRZM'PA0Z^ZA876X5.5\$<5>9+0
M^"GKJ.N.VM>HV5.WCMHOLI:|2M2>I1|T=@\$|5/BJ@DF;UU13:NM?5'&OS#/? M'TM#D-
1/UXUSV^#,6F00IY\$=C" >CNS@D@9NY\OI? *LRB|Z(YU/3RX&FI46WGYB9.,NFK4T=&VY84G_":BL M
>UOI#3|B27H_SSF_P%02P,\$% @)XEM653)A@7A!0 |Q(!D !X M;|"|W;W)K&ULW5A9<|LV\$/XK?
L6=HBB1X2(ZM M&3EQTCSS<7TD#YT^P.1*PH0D5 "4|/|Z+L!#BG5\$XS9|Z L)@GM|"WP++"'V
M%/*;F@H\ECDI3KOS;2>G_ ;[*IU!P90KYE#BGXF0!=/X*:=|-9? ,JM4Y/W
M\^)^P7C9&YW90FLY.A.5SGD)UY*HJBB8?+J 7"S/>WZ0|;CATYDV'?W1V90- MX1;T_?Q:XE>_LY+Q
DK%14DD3,Y|8_T(C;R5N +AZ5::Q,3R8,0W\ S'Q^R\ MYQE D\$.JC06&KP6\A3PWAA#&GXW-7N?
2**ZW6^00;>P8RP-3\%;D7WFF9>| M08|D,&%5KF_ \$|E=HXHF,053DRC|)LI9-T&-
+*2V*1AF_"U|6;_8C,.;PL#; MH1 T"H'%73NR*- \Q549G4BR)--)HS31LJ%8;P?'23,JME0B7HYX>W6J1?CNY
MP+@R\E84.->*V>\$ZNF,/.:CCL|Y&-T:XGS8F+VJ3P0Z30_)E'JFR&690?:| M?A_A=1B#%N-%L-?@+M?_
A|LP=YV"\$/_M|UD?W6).9E4.1\$R(G3GR>6YF2Y&Q83?73|L0|6Y'7%KCF#:\$|/'4SAYL".F
MK%_1^*UPCB71,R"_5;Q,>?('Y+KG)6\$*\ (4&L@Q=4IN;J*!Q1%Y"UF5F;D M0ER TFC63HHB7VT:X?X
1)7!7+Y"#+E"LBUI RK_ZSY+\\$L;/R#J5,&4:"\$<)C@M*2A8LKU#B8XG81:40"@I>,,2-3A V MPGP'*5C(U+?
4HR1T@CAQ_&1 7I'(|3PR< <1MOUAT@4U11X9?-2)0<")4,AW M@YB\F40^,&;|MV*0Q-
>1H|'|*H|Q\3SQW23C"..MG4@,MSE.V;>9D UU80 MCIQ!C'H^=;U-3|\^A;FDFZB:A"*)\$X4#1!IC)-3U
XPJ"4R\$G>-FBLQ\p>,< MUU\^T,)V^V)V931Z'K=98W;:"!PO#IRA;| D|B#&1V)0MJ&|@*66GE=B(3_B
M\7_E*?4|)Z0^CI3G1A\$./?8A2Z-H@Z7/R7((3(D;100.7T3!E>G= MA@|BHN_0V'<\3,5M&/>4'U%7?
D0'EQ|7HJ7<#;Z05)9|EM@-!>5)'0|;"|) M|C!|ZBPPBZBV0U\$?)?A?
Z(VUZ;9*)U//LO+)#D#R1I&;VWM,)"F*|?6*F34) M.3.!|+ (^| ^#@GVX&>|RK 'PWSRSF3:>|8E^6*3K,0;
MDRTIY30AP"PFH4N|&ORN|+\$ &TM'5NUX36N5\$L_UUMQ0X5,KM=IP-T9B0&0R M450|?_X0)9&3Q-16+C;
<|;Y!&J\&*:&.YWO':VHO'24?R|PDZB#L2;.X2|/X MX#2|+. :Y> *P|,2<.^DZ=I|<+A|-&
|:EW5Z_+TH|6,=7(KZNPVYRS8:7KN.# M&I_=%TTBZIEL|1\$0*>K#(YC#X|;Q-

H)V[DW#Z#,\$E]:FEUS/>E[L3;';-K78 2<>06 \OPE,-^=-<5W2#A07PP.P[P] <.)\"P[A^
M^Z')/BP@TYG5SV !N9C;^J%5IA3+&E2/@@7%3 PR)W0Z&_G%+VR8J%14UM(MXG\$F,._0\6FXE>3]M4N(
N347K5@6HFJU/5]1-?;W>:,ZTN,E7A1%?2)R2F6 M(B2'':IZ;H+;A:R05^H/+>;V2N-
!;\"T*VYP:PW7?\".#_B1\"Z_3 .NCNNT=]0 M2P,\$% @)XEM6&ULA530;]HP\$/U73FE5M1)K0J
4*\$2B[:I56J6N=-N':1], M_2.SG=+^]SLGD#\$)V!=R9]||[?@ [;K+2YL46B [>I%:V&A3.E>,PM&F!DMES
M7:*BG5P;R1RE9AG;TB#+:I 4810%@U RKH)D4J\]FF2B*R>XPD<#MI*2F?=K
M%'HU#;K!9N&)+POG%\]D4K(ESM%]+1_-96'+DG&)RG*MP& ^#6;=\\77?U]<% MWSBN[%8,WLE\"ZQ>?W&?
3(/\"*4&#J/ .CSRO>H!>B&3\7G,&[9\$>N!UOV.]] M[^1EP2S>:/&=9ZZ8!L, ,LQ9)=R37GW\"M9\+SY=J8>M?
6#6U_4\$:66=EFLP M*9!<-5 VMOX?M@##: \07@/B6G=S4*WRECF63(Q>@?'5Q.:#VFJ-)G%<^4N9 M.T.[G'
N^:S5\H-#(^\$6%PY.G]E\"H#V;A([?4F8KHFN&Z)X#]\$('K1RA86/ M*L/L7WQ(HEIE\4;9=7R0<([E.?
2B#L11W#_UVN=]FJ^WAZ^VM\MMZG0MC((M/V8+ZPR]BI^[S#9<=U2XK\":7A*N4E\$U\"R=^H-
9W>)/TB_6_0_S^D LUX078M# MN4#3W@TP M)FK@6UN(53KL_5NK),9?9L#%\J9NB% ?J'L0L_D[I2KHF/X>1H
M&'?C*Y]>:\"<#Z'8[W5'DXTL@;CH\$:_0[EGGM3]ZP=:&ULE59M;]LV\$/XKA\"H4\":!&
M[W;LV@;BI,4&K&D09^N'81]HZ6P1H4B-I.+DW^](R8J_.E[WQ>;+W7//D<_0 M--M)] :A+ \$.>*R[TW\"N-
J;=!H/,2*JH09 T\"=S925=3@5&T#72N@A7.J>!\" MX2BH*!/>8N;6[M1B)A0#F8 [1713552]+
('+W=R+0/W\"/=N6QBXS\$BUE-M[\" M\WM]IW_6]\"@%JT'H)@51L)E[5]TF5E[9_ '0YT>C(G-9\"WEHYW\6LR]T!
(\" M#KFQ\"!3_GN :.+ = 2./0#M/K0UK'X7B/_L7ECKFLJ89KR;^SPI1S[](C!6QH
MP\VIW/T\"73Z.8\"ZY=K]DU]F&'LD;:635.2.#BHGVSYSWY_ S#G'G\$#0>;2#'
M\H8:NI@IN2/*6B.:':A4G3>28\)>RLHHW&7H9Q:W>.^_2;W)'2BR*JD\"LU0&)P%74%<0
M)/1)',;I\";RDSS9Q>,D;>)^I\$DQLA]G^>;761J\$X_CJ6;PN7'H>S!3/5-; 'H*?;'\"
BP:#D1NR+6LZL90)V2<+JEF.:&B M(#>,-P8*N,]'DOG=,!7U*)#%8C*+6J-
J+FL*@R0W;\$QC=HWH%\"2;+=^09Q0,RF3A\$ZK)1G)\ M/C0YZY&90!09:'33YU/R4\"J_D1%
(^!;HW,K8)ND>BI?:LP^Y, ,1K=-A72- M5%-WOB[N>W*6^>DD/F]'21:Y49KZR3ATP5C&25R]
2'Q>%K []T)D/\^@330 MHU'J1\F()\",_\"=^F(9V-9R\$ _BB)29+YDS3RXR1]I640R&'Y]I'ZUS4BJ? B
M2LZ[Q>8&T46X7QDEYR?TF05ZS7Y:K]|\&^=Q) \ (PROE+*U=\ALDWA708!5JM MXI4\Y[RQM])1LB+7E.<-
[^7^ T1^FN4#\"JM5D^4V//=ZP+/8\^SNI\1K(VL M0>\" J)5I?
DCV: .VT18,]=\"!LW&/AK#&:\AIH[&LA\$70\"J#\"CM;P8A\"<(K\] MM>F; EX9F3\265M&6\"A;-U9WJ(=AME&
(LLK\41:1L9^.)JBYA-P#0H4LMXRT M VD\$,YI\>'<91_\$G\$0N3R/,UL_\"#V9D =I*+=QH0323\,4
MXXS&,^FK=?\$E^IVC+,G,,& M7<.,+2I\"M=VYG1A9NXZXE@;[JQN6^\$\$\$#RAK@_D:B%+J)#=! (BW^ 5!+ P04 M
\" GB6U9E\$*!GV \$!S\"@ &0 'AL+W=0@#>+8TM8BE2 M(:FUW=_/D)*0]1IHT1=;0,SES)P9SG@MU80.
0S9%SH22LWIAQUNSK-H:#Z M3I8@&0I54\$--M6JJTL%-'
\"!>^&0I]T\"I\$;SIV>W,U']]=^,9@K8^B46RD/+>+CYFDY90'0(.J;\$:/Z]P@-P;A6A&]\;G;V]22MX
M+W3_MYA1RP+JN%!\C[890)):] B&2QIQ\$3'M.7^? MX*4B(S.ML01FZ?>*:>9V_YPM%
(F[\N0:\$V\$UTV8TMI\$N:PJ2M:)!04)K M^0-/0>+ _<@5\$M <17=,^?<+2S\"H.1\"
[]>\H4^49YY58F!_(L#>5D7JDT1[HB M4*R@#%0-]5E1H9>@U'EV:E17[5Y&]8PFZ5'8,FJ
+*U7K\=>I2=NF(,; !#L+ M>:>VXC#DD0D]\J)E(.7HZG)52&I1KM% 7>PR),
M7TB[]X6Q[_7BD.B<(OP.Z7M!\$EFE!DV#,&<@X\0+P@!'0F8X%/8<7<# P0:= MM\X*:4!C:TN!0=J*
(X'G^W[M\R%X+IUOA^&)(DW]/OD\"K'B/;'B_T L;9>N M/G1=(
LK9E/C\"X8Q[3C%3ROBLNDNFKS;5(=DFI<.IW@_V-QFS.*9ZF=3@N
M4JRD[(1;1KI+@*&WW,HN<)36&.DQ1GZ\$D=88\"37U]3/6(SV9R6LKF]0V&4RM M5-@ (K?&5E-D:>?
P/BLX5<(:M'=- \$0]7.%4,VS@X89Z>^C7;LC1.?/-/S0? M]X)!GWQ!)Q2^'\@0I%USED01ZL7W7)FMPP:HJ[3\$]
(C_YA?V!N1+Z>*\"0>=@ M_5#V5;N5R]M*[^]37^X->HT5(<7MF:4@ (A^H6+%;.)VYI'=PX1\V,4A0-J&
MPZ9=G8=^Z'M^')PPK(G^R/:P#\"#\"_6_ =*D7;@)8.X@]1,586BL,&)15L!A\"A/_ M G&ASS\"PN(M\$.0B].HLX%?\"
<*!G%DQ9LZ-)B\$W?&6M&,\$.^@T MZ\"Z1J!WV0\"!\"#?]?CN7>!/H\$\"U,J-.[:/5<+4,\%=>S]1S>I!XG\"!\"L<^4[5B
M0B,-EBCJW_60BE4]XM0+(TLW5BRDP2'%?>8X%8*R%_!*\&[-0MK8#]G3G\ M4\$!#!!0 (\">);5EJCD!/P,
_L*_9_>&P0=V]R;W-H965T\"B\$-%,0M[8< M^Y)^;4R-+;J! !& 207S_N0=FD7K01LXFJK._2
M;S28JBB8WB00J/74ZW[F]A8]\E5NWX,\F)50A+=I/Y8VFF=^BI+Q_;;B2H#&; M>0/>>]!&
[_6!S0S7YM\$87\"1+I;ZXR74Z]0)\" 4FUB\$P^MSC)0KA@ (C&7UM,
MKW7I#!^/=^COZM@IEB4S>*G\$;SRU^=0;>9!B0BIA/ZKU+[B-9^#P\$B5,_00K
MYFP\ \" \"IC%7%UI@8%PV7_ ;P08='!J/@B\$&X-0AKWHVCFN45LVPVT6H-VITF M-
#>H0ZVMB1R7+BFW5M,N)SL[NY:6R15?\"H2Y,6@-G-TQFIG.Q>]>[T]YR19K MT6\"!I NX(.2-C?
PDTPQ_ ;N]3[Q:_C0^(F\$B=&-3WZ,U>0^K%P=L3,41M#-\$I]-DM/I]8HDPV03J01K\"DRZ9_T9IV9@5\$\\ M?.+0
&MR&'6#.((3TABTTAC\%VF\>ZDL3GK['V3Q DET 1\2NEVH#&:5, \$S M))G,CUW[_\$C^/^W-
B8BQ,\$^2JJ@HNT2!KE);_K7)]*]\$H;WDST04_ *@R4CC M[6E]9@QWFJ4(DA4(80\V)&E#>HGB@'[/PK#C)OWI?
BFJ5P;Q\"?&^6,1A#>T+ MN%.6B=J14VPT')R2:]S*-7Z>7]H=5>I#\\GR).KS9=FT(?PK\";-68T[7CZX6
M'1/G:0?0\;08_7-1Z0V[<3@XD)H=VM>V\YDW#L3_>M&T? *XN#0C,R#0X'U+5T\$TKU\$RL*N0V M8ZDL-3/U,*?
N\$;4[0/N94G8W<0[?>G3V#5!+ P04 \" GB6U9]KW\"AG\$ \$ M ! &P &0 'AL+W=0;0 *YB >-
S,F4V9)B4@\"*2'S^3 ^RAYQ>*#[CU_4\$?Q0AKS[(CV>=Z.9Z!PRP5-BF!9@X2D M^2_ ^7C3\$48#C0!#@%
_.I0%N\$>]!>&N 5 =ZE 9TBH'-I0+<(Z&9MGS=6UM(^ M%G@\\9'2/F,HM:>HDTY5%RP8FJ?IGS063=XF,\$^/?V
JGY!<^<;[R06_2\]?H MS:N^V_7>(Y*BW]=TRW\$:\\60TNI(>FD)60&',L\"CL+B_,>:&P+W1W@VSW&CF6
MXZ' 'N8^N7K^MP4S:8*:/#^BJJ&\\=S&^S6%S@USKIW6:ML'\\K\$Y!,\\R'4,+L
M#.;6U\F4GD093BG;R;CN\"]Q/,HWH\$DT81\$2@ (0\+_KK.94 MKYZJ^KY;0L\$AC
S9N7%@.S#&;U[97>M]G5N=,%\G;*H3%FB\"53R[I6>WB3[^ M\$(:;9!MC_9'J94E(1)W61DA;K3IA?@[K9C_U-
N[&\\DVR;&]H[HZ%Z2PSJ\"G3 M'G2]0YD5%5ZIPFM4,<%\?8U\">43P;4MV.(94R*Y4=J\"(KRD3[P2P1/:K.^B
M4??J3#66T=:43IB?PSI'K>;U^I9U(DIGD8\$F6\$5GI]39:=3YB:;KW%@\$B]J7
MJC&^K2J=,+]SILKV^H/!B2J=10:=LW?*=CUG4/] *=4L'W68'U5'L7S2]0T,0 M06F=CD946QTZ8;Y.V%0G+-
\$J\\CME7)[0V2*TM/I62?,UPF;ZH0%FF_5S_W2_M<_] =J2-\\6V-ZH3Y_?..U';.QKP\\U^ XEV6=Y@HT5:SB8%

Z0Z^\$Q2DFR3 M?':RP%.,0Z@ST4AI:T(GS!^\$GM3^B7AR:PCM!\$D!8 M7HFRJTNHG;H4S.,9@F.=J0'.Y@>G>?
SFNK7VHG4_1!74M0WY8^8(8B M^4NNG)>2_+/!/?D"\$4\$WV>>%!16")MGI&G \$3&60!Y>4BN>\$^F)!?C0;
M_P!02P,\$% @)XEM6?M+?Q,P P V L !D !X;"!W;W)K&ULK59=;HP%/TK5E9-G;0U(>&C8Q)" -7ZT
F5=7N8]F"2 M" &:V)EMH)/VXV<[(>,CI'3C!6+GGG-]CZ_CTULS_BAB (F>TH2*0A5+F75M M6X0QI%AC-
G/,52#?G"%AD''!E0FMBNX[3M%]-J^3TS-^%CRUE0BA, M.!+--7\UQ 2MNY;#6LS<4\6L=03MM_+\
*F(!^R"5]2#VZAO.7I!D\$ H-0-6?RL809)H(K6,GP6G M5;:4P.WG#?N-
J5W5,L,"1BSY2B(9]ZUK" T4PQ\M\$WK/U1RCJ:6F^D"7" *)U M'MM6P>%22)868+6"E-#\S\5.FP!7/<(P" T
[JD KP!X>P#/.0)H%H#FJ1E: M!<"4;N>U&^\$"+?XVR-N(Y6;/K!J&_02B]"=9],)5=0B<?)?YKW!V)S-"4+
M2N8DQ^2B01BR)96\$+M"\$)20D(-!E !*31+Q!%XA0!#EF2X%I)'JV5_01='98 M)!WF2=TC23UTQZB,!1K3"*(*?
%"/?U^#MY4_I0KN1H6A6TLXA>P*>U8YH7MDZGN'UC0!6]C0@.(QJ=AK<7-:[CV:FQ_M4];8J:W01E6(5CA9
L+1#V4#3+G^%J*0F4^NJ9XINQ:9GE.6ZX@(G8.E07/; MUJZ>\$(-1^T(<1KC.M;NG0QU-KH.]95524)NG/(-)
YB;)KYRMYK2A ^.^]N:' MC>ZH43\$?*-N:N\R_] +GG05.10JA "JHYJ8YSXR'TB6&:,T8U+9+0,8 M^*L-7
>H]W/&Y&:@\$Y1FW0\#4\$!#!!0 (">);5DSM!U86P(&H%_9 M>&P0=V]R:W-H965T\$&HL'">0?10
MC=>HE"=B&2];SJA+Z8'[ZOW];:B=:WD2A=-&_92E6PVCKQ&4N!"-Q8C>>,BVWF<9LY/9"Y!U.CW8K@
M1I=8 HN/N8JNE'17RC@]2CC'^@QZR6=(D[0/#,)G)Y'.L+;ZUK4"[S] [PW_M]@TFJ-ZK\"C0S],5U+:
8<0#0VC7&.4?/YQ?)-^R.IWLOJ!07= UK@A]A#! MJ'AI](6S@E\ V =W#B0Z_9[@_G\0/,@\$#X[V<2;=>-
T"ODM0\-%+0?0F+TF6 M;:/U>D]SRWH16/T;L\X'6;S>%Q+0W?[*{3},.3%SHUT["IVW>TA&[?S\#6]?
MH:FP2ZD)%"X8FIQ=U[S M/U!+ P04 " GB6U9/_'-:08& !1-P &0
'AL+W=0?' ;N'@M=CQ3[ZQ^0HVE>IH_C(M=SN-5-6B;C0%D\$H2W<9*-%0/J
MM8_Y8B[V,DTR_C%'07Z[C?,?;WDJ'J]'P>CG"Y^2AXTL7Q@QYK0X@=]Q^67W
M,5?/Q@W**MGRK\$A\$AG*^0AZ]" :YN0E8.J"*^)ORQ.'F,2BKW0GPKG_R]NAY- MRHQXRI>RA(C5OP._X6E:
(JD\ JU!1\UGE@-/'_]\$?U>15V3NXX+?B/2?9"4W MUZ-
HA%9\ '>]3^4D\ _L5K0E6"2Y\$6U5_T6,=-1FBY+Z38UH-5!MLD._Z/0]<7 MXF1_0#L&X'H_/G<
J0>0BN@QLXK6;2SCQ3P7CR@0HQ5: ^:"Z-M5HQ2;)RFF\ MD[EZ-U'CY.)=G.3H:YSN.?K XV*?
XW(Y"7"\$TPMPV_@X;= \J88'U7!B#A^KB]1< M*=Q<*5SAD0Z\(_ ,K&X_C0&H?6'X1KXI=0.37(_5-*WA^X%/_
[!X>0/&RM/_ M8_9'TG D\$+JZ90<2%7RYSZMI?8G697DU4*"E4"0ZBN=QN2C;2(>M*!WH-
(J>S(V9.+FN2B8049Z(?.!S7:_13JMK-GM;@98@BJ.. "@RTR@:@P"UN>"Z3 M=;* ,I; (5RGJL^\$X4B?
7;"R,Y3]\$EA#?0RAN0P;4(BK8S3T]H)D^MVP\$LW*ZE M"*(Y<[?H?M=" 'FC9#T"Q7?PI#CS/2M]
<^6+5_63+'R@3JH*ME+SZ %]H)G?M M!()P<-F")L*9IRV\$@'L)5S+MNT9* NF^D:V@X+(U9V.]:*U-XB@,W%
M>W![@*0JLF8\$CG6?%\$YK)4_N58#;X^KS:%%]H9N>I?0H&_4&W6:S'P4IM"8HP_MZS#76)L*'/Q2NX-!3^+
<%GM",\F>-/\]ML2AY:FA3J_WY.F40"%FBMI!8+AY M[V]W:@_P,2C\$3\$Q+/A[8J^V'+?R@4+;?
+1>8UB0Z]41_8? :WA@..="0H1@_M8RW8>+!@8Z^" [00-Y*D%&WL5;-068LM":E'USI8':[7&9ZFUJD>'Y@?
&=)ZL_M2^@XUCJ.!^LX]JKCOM#;NZM:QPFLXZ[W5[W>@R!M&]"QE!+M_0A\8T&7KF,3
M!.,Z4[N\$.2#:')#16P/\$ZST*7V@FSY/= ; ; _UVPQ)"9M.@HRRUXR"PXSB6_M);8FY?6&@B\TDZ=V,@3><8
*SZMI\85F\M2FA< ;#IT.DK0W#FQ]MB4L9#C" M'76F30:9_E(+1\$"/XCP)GM!;LMJF\$-BFN+1_I+T_T?
KJ0R%FBMI'\$ '@#H/\ % MJ@'_ Q*_0<[-2"S\=V, !32)3K0:25[+-1TL
MU]2K7/M",WEJN:9>Y9KVR5488F9YLI%_EE:=[3\PI0,\74+%J59Q.EC%J5<5_M]X5F\M0J3F\$5=ZU'K[9W"6<
=7.@\$:#_M"]CK;0I?:"9/;2\H;"]<"[AM]&SFU!(64L9(QV\$D[3D8[#F.M4ELF<\$CG8\B_M7>)P]-
>AL'[\$\$#U,:^VQ1>:R5/;%@90071Z2-: _WP"&F/EH>\ '@\$PN]Q]V\ M'EOPA6:2U2Z%P2[%I?
EA[3T+VYDW6UCWH3=V<@JQ9WNCMPFJ ?K.0=G"N@^^ M,>T#V,!NGEG:=,09-
TL8831G[F?;@E#;@K#G&\$)3NHXM\$8SK3.T2?B'4?B&D@\07Z[!T+
M7V@F3VTV0MALN);0\$2T\$EE,PY)CE^_3W3N6/S3[\$^4.2%2CE:S5F\GJJ(/+C_M] []>.3Z3853^!NA=2BFWU<,-
CY>'*/7^6JBBK)^40ZIJ?D6W^!]02P,\$% M @)XEM61:5L>KK_P_7!_!D
!X;"]W;W)K&ULU5C;CMLV\$/T50@V*!-BL9/FZ6]0_ ^A(T118PUMWDH>@#+8UM(A2ID)2=M_?
L.*5GQ1:0LMGKIBR52/&^KZ.MI!0_M?2U3\$/AD+55"#0[5QM>I_AH[4,+], AZ?D*9\,9#- [=0XZ',#&
<"%HKH+\$FH_M>IH_E_N1U (. \$P]LLS5VPA\4[J!)9C'=%PY)>7>MV_F- M7>]6?&:PUT?
WQ'JRDO*K'7R,1UY@-P0<(F,9%YV, 7.+1%NXU0!Z94F+?#X_M_L#^P?F.OJRHAJGD7UALMB-0X)\$8UC3CYD'N?
X?"GZ[EBR37[I?LB[6!IZ), M&YD48-Q!PD1^I=+ '8X_R%,-" M> [H/_H%X#V2RUT"D#GI1:Z!<"Y[N>^
M.^FU-#Q4,D]478ULMD;I[Y#HUY,V#09&H5/&>+ , ^-EBGRF/_R#U1G"C)
MC";OR1)3,LXX\$+DFTRT5&]"\$";)0H'%@<%G=]W&C&GFPOX_G!J(<2Y2&5[G_M5_E,3NTXI# ,61"+MYK%H*#@#?
6)TQ3@S3^3M#_QE7+]# \X_+&7G[YAU8XW^ MN969IB+60]^@TW;K?E0X.,D=#)]QL\$WNT?16D[F((:[_S^KQ-
S5X'\4N%0\/_MBD_"6L(EI->D'5R1, @[%?N90AS>KG+GOUF?_VOK)V*TR_1K.[[V3]/OJLP#
MAHE6Y&),7%)%F5*8.F1"-=-7Y%'(E0:UHR0,SH\BS8Q=(T6\$;)=25V1*>93Q_M/+>^I"<\$RPK>ZKB0ZLR*-
]CIWJ/ME+?Z11&,()2F_QJ!][XUU]:0>"WJ0_U_M239KDFS>\$-E)H#MEH#MU[,,%?<)"8.M
]*,.0%X>7*5WH4X8!RQY_0_#LF6P_M<16H*F*YL9XS9C^N_'] ;A
\$0W]W'(K;+:TV%\$V2S1LB.PE%MPQ%MS84>3&W_M975MW[[-H9_?128Z+M!5^N<6NL?
ZA[U!^TS_[D64SB(TNUP1!H/P=-&\CN9\$_M@5ZI0*]6@4^869Q45<])??"UI:!)LEF39/.&R\$[4[Y?J]_\'-;=?
9*";))LU_M2390B.PDT(,RT(/:UVP"&R9\$'D1.1815W9T\$ _Z_BPYZ\$M)X]A4QJB5\;G2;) M9H.+RM?
M]X/>6E[#>ULN-!]5)S/+@92%:@Z@Y_DYN+2MOM] >#_ML[]>:_ZU>K[(Y+PAD[F>_E&[E(#:N#Y5XTN<=
[H_Z/.^YXJ? ". QG30-* VBJ/02VHGON>>YN_ANM.'B_M4:X0%3S%42+'SDJ],QU9;#"F,H63S'1;Q93TW
MIBQQ)B/[]9,1CQ3\$40P5H#,XIB*'Q<8\B0TSBU10A9C(AE/0.!B])R3LP02,0;VQ_/#C:RLP4B9<_YH-M-
P['B&\$488_M* -!]=\;+S&#*)+F\;T=4J?QK"ZWJ]?6_%:S)Q*0.31%Q:JU=@9.!#B@F:1_MNN.;]U@ (ZAJ)\@?<
2_L*F..LY\$&12\;@PU@QBEN3_] *D(1,7_] <8^(6!;WGG
MCBS+*ZKH9"3X!H0YK=' ,PDJUUIH<2TQ69DKHMTS;J:)0AW""5F4_ =M!3(WRWK2[?0'@Y&[K0'?+?UW#\HV
M_(0;EK_XB^NH-&(>+&+>R;CW3'G0'4%OU31;XS[-\$GU+9%)#.N8Y;;=2JJ] M^C0/2G>#@]-,G_:EN1'SP
-2\;#9TKS\ @JB+=K)MY_) +HPKF:;U&>;5-H7_M:?
3X;GH!\$:>U%W:SZ:'!V+46XC[34LDQ6@_9]1[2V!3^Y=HND*KW-ND,AL,] M:=XU#M+<.Y26+DQ(=4[I\$7:?

WAW*V.2&3E0J%BR1\$*\$"VWFM?JZ,D4^Q>4; M05,[.];5GT M*0;1_@ (H) 9 >&P0=V|R:W-
H965T981\39%RK<3QW=V\$X_I M*E%FP@W'.'+''.:JG|8/0(|=2B=,,F4PY X'+B7/E7TY|:V|7/*>XE;5G,\$*L
M.'\Q@|MXXB&G'''E&RD@0_??:Z34*&F.WZ6H4_DTA07GG?JM#5X'LR_2KSG|
MD<8JF3A#|V)\$3S/4&B'.*P)=06Z5'*D'XAANDT(&;NRG,<*'_@=(;*
MI>2>P0FD#XG/)>\$07+L*HUIG+E1B30MD(#2".XYTPE\$FY8C/'?'JX.KXH0
MV,4X#5H%Y|B^@ (YW#H\$7=.%I/H/3D|,6W4Z5NX|5|1S0M7'?,:E\$;I)V7D_3 MST=.*>B-LR4B_M64A\$*
|VZQM#N.E7),()XX^;1+!%IWPXP> |WUN(>|6Y-TV_M|7"*JY2QE*U@2BAA\$0*1IK)?"Z7HJ#
|JFZ:3|S0N|+'H#)0B3E)AVU7AM>GLT@3\ \ %-K M /Z0SEZIW/-'X7-K|2E#L;)-6\$+\$/=/^=02P,\$ M%-@
)XEM6;X\0-^1!0 ^RD !D !X;|W;W)K&ULS5I=;|LV%/TKA%<,+9#&\$JD/.W.,Y&/=- C1;D*3=P|-'QJ9CH9+H
MDK33_/0Q(V55%&V*B086\ (MMV?<>WWMX21U>:0)\$V1>^)\$2 ;T5>|M/!4HC5 MR7#(9TM28'Y,5Z240RPH*
|'"0E^00R%>,X'GE5.1#& 3)L,19.9A.JN|NV'1" MUR+/2G+# %|7!6;|YR2G3Z>#.MM@
&9K+FA1.\L(BJS"29_S:2?F%Y@0CP" MZA7\^G6=;7!.2L\$!+N?@JMP0+HKJ^CVXDP4T7^<\$T_7X@#,&/N-
|3;BZM&,< M52!W2|K\$^W0'''@/OFF""^9F0.L&BA_3FNMV2V9BPK'\\$YYAD';R^)P%G.W\D8
M/MU=@K=0WH\$W("0!_9*NN?P+/AD*281*9SBKDS|?)@T|DKXCJV. @B, 0A9 MW" <|I=D)MW#RAV9|D-)?
S,&L!D#6.&A#KP6_6><\$TG/F63N8X8?LCP3&6G1_M|6>;(&7U!RW9#F-?
Y3XX\$J0@0|CXV8;3&0/1BT;)WR^9^1T(-<%3MB&#*8_M_00FP2\VICR!&RAAC?D0I?C" |
5|E7+|V!A2)RHXBTY;T%2RHPM;IMIE\$2_M)N|<--.-\J13\$;-59&I%\$3;>2,|)X*G-
MBVKK%+\2T;^6(*6YBBIT05?-5_M3='=B6N+TPG5MV8\@1E9)TW6R2'-M<0G;Y| #-|2AK?4YUQ+|RIV/\$YWJGK?
M)A0#%-JK>M3\$.7+&;?V\$)TX00=&D|@1LKC|N7Q(97TV"=0GL,WL):Y_M9U'7;9J'8,\$Z3L^
MOM#,E+4P"@|*&85>I9\$0-),|+8Y"K^JH1G,0V1:C"(|BCLK6ZBATRZ/?Z(:P
M4JW4E2"1V\=R|@Q**HB|Q)UH08?)\$YJ9NU9A8700>Y5R?E",|G36BYT2I|>_M)9Z\;OW>-
TM&L=HH6JM<*ZC0+;\$N"!/9(IMAL=TVS\F*^D08(W4B|1XE3VAF
MWEJ1A;.#JG"0PLX7FLF=EG;A4P'UKG"0XJ0&, _:=<&R?|E"+|N@675WMGG|! MKQVI^U|ZMS\$\H9F<;&D'PT.;
(M"K102%9G+7;IXY=51W;Z7V;Y\$K6CD6H^Y6#M)J#+G56/=-\<#1Y
M^DX,=PR|!>'G&&V#C'104T,KYK2%YK)G=;4R-TX|LQ|@|2@|UIL6\21N,H_MZ9@76L\$AMX+
|0_/B|9L%=P"||_9'=/;0EI#HH(YID5>-Z00-Y\$YK3.3UJ!;M MG\/-@L6LQC%:<=#"\$BK.N16=8|@KU?
VF|2>&T&^D(SJ=):\$QW402_R*C|] MH9G/WVCY&7D|ZJW1\$>L>=PF*RWQT=MI|,4X|}%7F/VF)4);5G\8A3%7,
*P+ 9 >&P0=V|R:W-H965TW"3:V-AQ\%V6K: _?F^K^,4!-6G,H<,_RRE M\$M3@4*U\G2N@B7,2W.\&P=
7E&5>.'9S5RH):|9*C9WPPW%.5W
#YGM^I7#DUR@)\$Y!I)C.B8#GQIIVS^|88M*)| \DC"2QIPY0_ \%AU|ET'OM"OW*H? _;%0:5@T0=+W-WQ\$74T'!"L
MY(8H:XUH|L.Q|F|R1+Y;9?7)C%/YEZ&?"&=7I1V*?9/Y0L#7ED!E-;):0RVP-
MV@W/B'3)&%66LKQ1|D_K=!'\$1C*N#Y&D^W\$3EZ?SSV#09FX?VX"N*\#*+| M0A_| \DUF)M5DGB60-/A'|?Z?
6_Q|)*1FI?0\$RGFW%? &|E/2"SZ2;M#M-\0S_M>|U|KRF=UM|_N;5=\CHU5NDY_|Z+^!=4*;(+>4%D(CIF\$M=*-
#DQW2AC<)"_M_|DD>_G9;X:TA|'9SFD,\$P|/-PUJ#5|XX5UG&'QI80N08-\$AP>8' M01I5_K
MTF|##^<(@@)H6M0>*;CL6T0!I:M2(SE8*4IL%JQ4_N%I8N2R27:8K72!8<3 MK.\$3C>5.-,2509.0K3'\JY"!'!
(0:V1D2X"|"13683#VU|M*|+6(|EK, MVRQVN!G6W_Q;N9D*6=C;1D',J=9LB=D7QC\$0QX4H.+7;72)-
"K>X0'52V|&L MP7'81\$2YWJ%"B+T6T5Z+>90%#A&CFHA1*Q&7(L=#UUZ|)\$ZI6C6K/-JK\EZ+ M:.*_%0,VB3,
|?:C|\$8+2V|].H\$(I97C/U;-U:3EU'16S^0',VZS3,1|B*E1WC_M7_BRC_V&Y-
@RXK#\$I8+3\$8J@RMZP'!B9N^9G(0VV4NXSQ78:E#7_TLIS=/_M+E WZ.\$?4\$L#!!0 (">);5G\$ZK8U_0)8:
9 >&P0=V|R:W-H_M965T/GCN>|AY*DP/CCV(#(-/_M.\$K\$U-I(N;VT; _<0\$5! =M"HLZL&8^I5(?
|P19;#G25.L6131PGL&,:)M9L MD0YWRV<3MI-1F, M1V(70Y0_?8"('!86MI|_ ^!H^;*3^PYY-M00!%B#0MK=<
M'=DYRBJ,(1\$A2Q"|"=2ZPI=SU|\$J<7W\$ ZB|!0I4.X9>|0'-ZNIY6A&\$,%2
M: @BJ008PARC22(K'CP54RJ^I'R_N+96:/_I'FI046T43)GH9%Y*KLZ'RD|,Y%90W_M2'^BWW_LPCV-
(|\$"T62%;I(|)"!FGQP.T4_6TVD6_V!I=[6D8T?L(|JJ.!@0E_M@Q:PW/%0AB#0VVN0ZKQXI|SN%M?H|9MWZ
T*\$_1MPW9"(8N)+15U39C0_M'&F2%IH+V%X@UWF/B\$. \!0>YV?T:ELH=I^YNU=U6"K-F00^#
M^:TI"3V!55+BYBEQ3>BSJYAQ&?X+*S1G0C:%>00/4G_ =7?8S+W"P,|'WY1CJ_M5D/7|T:Y586V"7H"#TWS5K=1B
MNBV+.01*+6?49TIZ_JND9)RG_M9/P_*G1'A2GW4;/'8N;JY/|!0SU3\$26VQ4+Q0\ QZ7AVCCU#,"G;L8
M?:%5PRY)"?Q*)9I=J*^T|(1634NA%;!Q|KY0IIESI9/Z>\$A.*K7|S/=<9|A2
MJL74QN:Q_84E*0\$)7|46X;UKDV<&4'.7H^>T*HA%UH >Z|5ID;5<79;>D*K
MIJ40(MBL1%X6<+BN,NHMM<'((R._I4X+,8+--J2+@L-UN7&JDXPF56J%','%F
M/ =))PF481FXFDRJW0C1@XP!^J?>,NBQHW1348MVS52C')B'N6=^E"&8>I#_M#28#W"
(T2#%UB7D+;NY\$F7/EX4#"#B+U#;A>6*^%7#'|B'GVS4\$5WCI<4M5|_M|
_N%6R9")M+T(AT|AW7\$UHU|F*JDN"U&I%Q?)^=EI(|JFDI)CHQ3_0.C:C7_MYPJD/OF';LN\$)<7L)^;9WZE;|?
HP@-2E0HN" (85.(&:=T*VK|:H.2/VQP"!'H_MCL,M9KYK?B9@|G|FYW,#R-
J#U')^"0"N_320+^Q^4+Y@ZH2%,%:>3D7004_M/|X\$.1Y(MDW?(|PS*5F<_MP_70'7!NK\FBGQEAHW5Q/YJZC9?
U|+ P04_M" GB6U9PA4,|0<" "Q" &0 'AL+W=0_M6ZZU0?#>EHG2%QP5- ES\$"|E.!,
|MAB5D&N60\)P(68^0>09L\$NMX4?&>P_MECMCHIW,.7_3DZ=X;#E:\$*00*<5K.D!NZ.M^R?C7?T
M,J<2)CS|P6*5C*W_(C\$L:)|FJ9|[^_K6?0N;+>"K-+UG7M8Y%HE(JGM5@5)"Q_M0/JGF|H/_P"W=P3@U0#07(!?
WQCM%)F;#U21<.1X&LB=#6RZ8'IC4&C&Y;K_MISA3_N\RQ*GP@:8TCX#,3&0F/"MX#KF2Y)K,_,#%QF0+A"S(54%
6DT\;C(\ \$ M26@>DV\J_4\$FI1"((/=2_N(N'T%1ELHK9'B= /9++BRMR05A.7A)>2H3)D:U0_MN%
|>CFJ1#Y5(|XC(&10WQ^<\$,_Q>AWPR6GX(T0(=PW*M=-JM_6.UG0",860HX2Q_JL\|T|=!|'|+|G\CV_M_/N-
?_>4>|@-@V:F(DI,&&)8X9909#H*4*>DJPL5|_-.4N8Q6G/V%=V02\$#,5)>9
M:LG^CL|;VT,0735'0/0;+ _VS'@#+92ET%+NT|50K!CWW0%M'C7/;K6W0;|N<_MI>U4!@:M9?
N#P|:U:_R=FCUIPT;:_\2T;K^*Z0V*F0VJ2|ZP+>|07;LD<+0%_M!8VXX*2X%XZI),5!|TPT^9FZ@|9;XP?#PT?
>+0+\EG9|YT#1A_E7*I88-I+" M_F'.S1"=B^J_K":*%^:,F7.%)Y89)0A- 4(7X/T%YVH|T<=6\Y42_@502P,\$
M% @)XEM63QV+BJ(!@_DSD !D !X;|W;W)K&ULM90;:N,V%\$5_A7"+H@5F8DN^)6EB(+&N0*<=3'IY*/K
2(PMC"2J

M))UD^04E9<6V;)F), 7M>\$D067CR4M\@C'? 'JB80/\8J5^IL'+@JJ]*98]&4E&\$UK49'WW<@TB\H509F5_6^CV))
ME!D0B6 /U(T;YS)V:T%Q)\9>Y(FGXGIRCWGG\U&G%W\B8BEK-\$&035_Q[9
MG.6Y(>DX_FV@04V;1KC[^84>U)W7G;FGDLUY_E>6JN5U[[Q'409_5(GZQ)\B
MUG1H; '@)SV7IESPUQPYZ)%E)Q8M&K", HLG+JGSXW)V)'X(R."-Q&X.X+QD<\$ MPT8P?&L+HT8P>JM@W
C&;Q5,&L'DK7V8-H+I6ULX;P3G^X+)\$<%(BH;#^ M>H?WZ.*SJX\$?R+' '*UIYD/MH?JM?_L-
&:_4T)_FVF=FMW2G)8)(W?UE37G_M1<5+5BI)WI.;-,V,(6E.XG)J61E[_N@Q1;-<_J0/^>/_
(S)^_Q/YGF0E^7W) M5Y*6J;SJ*QV9X?>3)HKY.@KW2!1#H&7:BF)7Z8L[="=0W%:_K8KG=<"Z"0
M3^GF0+H0Y_76M1)05HLS,AB](^['7:=\$+0^CE5G9#BHY;_.N?=V>5?K_B0!_M5\
(J#^SR#J3(G:/R\OZ'GU=VW.[W&/)L>!:1AAN+K!AS1N>>H']_8L^DL2* M%?*>CC!OUJA1-
];,@>RH@F[(NE)3C+QR'JS'[YS)H.?NIR&A'E(F(^\$!4A8_MB(1%2@,@K7\/-KX>62CSSZQ=%7G*=_^89/1;
(D>MS7.<:C3IXJG0HIPIYU_M.B99E[&M%_-089-:IA)[YGH\@JO^XZ]?#8_:_\)\$A!4A8>!B[X^YW,'JU
M@S\$HII9CQA0'C_F&&8S:JHEK[X0];&X6K)A,YVA##6H5(RU95\$W%K;_-=4Y
M2)B'A/E(6('\$A608>=H[4T.=ZSX^%1KCMUJQP)BJ0ER,G&D1.K(^=4+HG4_MHY6HI^:.*?C%5J?
E)>7UGC\IM;&S0524B8?QC[<#_Z-E@B(1%2@,@K7\ M-MWX;6KUF_RV_F64\52HCAA197SVG>\$W^?
9HKZYZG*%>7WJH(>\$>4B8/SV<_MZ_ZLBFPPL,(B)"P&P5I6/=|8|=QJU;0-J)APJ8QC\$[XHL_Z[ZIOK:Q308F\$
M>4B8CX0%2%AX?C#5'@SP\$;+!&_1K>?-BX\T+JS=W'D@E9@:_Y^5*[L[C3"1Z_M/*6+SMN._=L9[(XP>Q.YM?
E3'8B\$^4A8@(<2%2B\$A,4@6,NJSF#[7'5@'TB7_M5+Z.7RJA|+)"T>;R?L%P[UN0!CTRJK&R\XMRFI99U!V=
[6?>?<'L^I[H72_M?"@M@-)"**"V"TF(4K>WAG=J_8>PXLGGIQT>;N[>=-97JT?"BWT6*RZLP5[
M:Z>F"PUM=^YS'/_/N/7LISFJE5<.AWL#0P^+(&2PHY^#B?N7@^BCGZ.G.'>
MV8B[SL9.0M"VB;NUB6NUR6_5L7L7N_#D7Q0)\Z_T'TH+H+002HN@M!A%:UMW_M6YQQOE^UQH&69Z_T#TKSH;0
2@NAM_A*BU&TMK.W91K'7J>Y.4PSWY%R5=PS_M0?C#RW3=;6UH@09*^Z
T'TH+H+002HN@M+BA[:8D\$=U1LZ13&);*7)>*05) M);+\$>+;/_WE;8W)F7RC_MU_)9IYA#;1Z4YD-I
9060FD1E!;C:&UG;ZM9CKV<|16I!;28!;5Y4)H/I050_M6@BE15!;W-!V4X0Q;#J>'LDLMF4MQU[7^I4_
M'[C%KYU!^7C*9,F/T_M]P^;L?U!+P04_"GB6U9)P8C%?0"#E!P_&0_'AL_M+W=02ZXT\$,0-Z:\]'V=YE!0?
29+>+BSD*J@!J=JZ>M2_#DBYA!N:G"J<^8V7_MC!4@-)."*&,05'G:I]>N<>R6!!*VYNY?H;U'IB
MZR^57+L06=>V@4?22AM9U&!D4#"Q^=/G.@Y;@&[T#J!;[_I_"PAK0.B\$;I@Y_M61-J;#)04;"X(1T@V[4_A)?
AD\@17C'P<_W;QHW3J-VI+B;2ZK)KZ>->K;=\$M1A<786/TIDS4B(D.BGD8W2'+_M%-C*LFRCLM!'6Z?
&8;Q+;=\HC'K04(L;:0%!:E^>*F9>L'96H\$WA,@SKZ;_V_M'EM+0*8YQ6:50F582KD^(<#KE]_MH_XBG;H^5M-
V#Z_WZE;_J\$)AP7"@K,^BE;_1V4S;_?)T?7DN#79Y-\SQ'09E_M#7!_(:5Y6=A6W[SLR1J02P,\$%_@_)XEM60Y;
<%.R_P_[A(!D!X_M;"]W;W)K&ULM5AADY,Z/TK&70KHS/K>CGWJ!\":
(U&D*>\$_R!A^Y6%K;L3'^CM5NH3=K#,R2UL0'[,MK[D:V0U+1%/(!&49XA"0K%?X?(T7&E!&?
**P?P?'2*=RPJ@W/7@7K2Q'*X(\$_M0JDIB/K;P1J21#,I'='J4KJNYIP8>'M^Q0RF35^G<\$_%KEGRFD=RNK+F%
(HA)_MD<@;/_/\6ZH2FFB[DB2A_T;Z.=2P4*D*RM_8K!2G-JG_RHR[\$_0!/'@'X-<#]_M4X!7
[PRT4I9F=8ED218H(VR3%0D@B,KKDR#I<_!GEZ" M)#01SQ3FX^82/7W\#NU&-\$/_5DA%\$
L;_FDZA0:82WKHI+E/B!K_D9\ISG_MR'7<20)\;89?0JC@N(1[7;BM"MI4R6VJY)9\WM_J?;E2D>B=A%1\
[BYR\$L+*4FM0_-!%3QYA'WG95_.(Y%U*N_U%?!;,\$5"'&N%EU8I\$5"
M)\$2(I(Q+^HM4JU'9(@)UWY"6)_IJ4=W+V^@GRZ[X(70SY;V[C#^GJ"ITP9U_MM\$:_
[1.C]HYHYH350!K)/9T4V/9#@.0,CF3TQWJ1?Y;11.36JU*XJ)/!689\X
M(\=00XU\$UDG7;]+U3[.D_#&K,!)9IP*SI@*S0[!E7\JS>V[SC@W9\$^+W^W'>
MR)0_F1\W+)9[PJ%/F9%BZ&2,1-;)=M%DNSB-'1=C5F_DLDX^L-.V_LY(AJR)_M.G9SCAQICNE*/.A6L/DUI&
[1YD1/W0^QF+K9MMV'?A\$;0<M>8BZU;A;_S_MP.;68X_M07N6FQZ\ENML[@=-
Y@|*W';8F!SCW\$%ZEMBRY((T33G;_R*"C]C%CL76KT'8RV-@F##&H;WI-U\D88[H2VU8#FWN-M?
^_8JGF*"YY16?2_R\T4@^=D)+9NPFWS@N(%XX2;7QIIC!JMMQ[?G[*2A;["\$F_:_+GG_M^GLNYW-
'6ZGN=0%&R\$/)A1Y[A3'5I>_KK("2Z@M9@<_G2ZE*G'I5KZN%-#<_MB4KN1T&0^"5EPDM'[MY,I2.Y-
IP)F"FBUV5)U<|KX'([ID)0=^_&K0IC;_CI_MJ*(KF(.YJV8*5WZ;_6NB76RD/+>+C[D_M8R^P0,
A,S8#0;_-\3(!SFP@Q?C0Y0?8GK7#>I?JG?..7A94PT3RKRPO=@;
M>B2')5USR%JXU3HQLF[%N<&X5/&>I,>DTY_M%1F0N6N9B2PK*4_835Z1.79,0N9_Y))<99E:0T[>/F#[:_-
"\$BIO_-@4H,EDK_MAOKR0=\$X\PP?'H^!4,9UR\PS=U\2L[7I_SP@2Y+>1;HU:/?(/TEL'/&M+K
MFC1Z@G0.U06)@YAWOR6CZ#%.6AD>/Y3[6K"U2;P;-&Q5_M5KA&S6&#XZHJ;9N>HJU3J0=
PB")#VB/@_I)KONVW\+V3]=2R25H.Q@I)TOH_MANL?
P^T5J68[CHG"LL)LM:=F2DVR[5U)Y>8N#@,_0A0U3*P(!YR@A/_>^5W@_M24=5#U0@_:_IF@Y:
[L%);C>J6%/[&]4K9C0^%*7*_LN_M!NA?U:=@03"R<@?)0AH\EMQE@7<0-D_?+Z4TNP6[FQJ_XJDOP!02P,\$%_M
@_)XEM67H+FX#\$@_Q@<!D!X;"]W;W)K&ULK971;ILP%(9?Q6+5U\$IK(4!(UQ&D)MVT7E2JRKI=3+MPX218-
3;S3>C>_M?K8A-\$THZJ3=)-B<_W#K9/W'#Q*_L_A9Y*RN3<*92J+EQ79@646)[Q"IA^_ML^*BQ\$H/Q=J5E0"
<6U%)7=_S(K?&A#E);_N11+S6E'"X%8@69,9(*"0*>_]=\&ED" I,=(80SM/IU_2"'>?M^Y?;_XZ_MEP-F)-4%]
M6/N/G[HZ[_BTS[#_P3^0B!\11!T@L_FVI+9M*ZPPDDL>(_\$B=9NYL'6QJIU_M-H29KY@JH=\2K5/)
E/,_D"TW3)+7E;<_5,2G;)4[YB\IH#X"EUFF;@A1REL_M0%C!\14H3*@T9'WZ14Z/CI!1X@P]*W@M<0LE[&K-
*!9QLTZF\$4+X[\\"Q'= M<*8*B3ZS'/*7>EY=0EP0A.T!<[L'!_!_MOQ;
[YQVG%.E]V6"1_QHJ7&L<#AN;HWXA*YS!W-%G68+8@).?S>)0\$]#6?&G_MLQLZP60J/EM3"DJ@!4@2
_T)LO:8[RQ\0'H;_9J\P1CUC-,KX_M?!(K3-Y(&AU@G;_G_A[K4)#W<1AVUL/.1F'U>7[S%Y^~?_V6\#
BC"9[@.[_ME5B"6-M.(5'&:Z;_Z.?[901I;V#]^87NDFU/>79INUP-UCHK2P1A96V],YF
MNF:B[1KM0/'*7KP/7.EKW#X6NM&,"_Z_8ISM1V8!K6G?P%4\$#!0_(M">);5E8&P0=VJR;W-H965TZ:Z
\$]*D2R(UP5>KU*Y5N[N]F/;"#4Z"+N!/\^C'Q7>Y9DRAES3)Y,19*[6Y=%VY6+.4_MRG.^89G^9L>I'%6_JNTJWG
M#'=1M3006\+0M#1"MSQ3:XE(%K'(C'=UK^NNXWW79)@*0%NH<J3SOR#LX1[Z_M]ABBLT^?
49(/J*UW=M@CVVB85\#Z>U@+)CP=T[-@B!T3LL7QT"R2]>ILJPIN_M[]UL2\D8*I*.0B87(MX4:?
[11M^)KA5+Y3\MW9V5V'X[-I_+N6&+MC\$T;_5_M9.*9.=.??('WJ]MF8"\$A9_P_@QSMRD<849TJU98+
M*Z9K+DK8H(#E1>5Y&@2CL?M*#%D@^2XP=XPJ!LTE_MJY8).RB4Q?8J36+VV_MJ6=%=560A_6&>0X;J2

;-), 'IZ@UJ10961Y8IA!|T2N/0!'<)7J*0&I-L|9I M:V9%=550<*2>[WEQU:L<#?
CH'@+4*4.]BUJ]"ZMZHJ06D\$ MBF:*W1A+W^XL9QHJ^1<|P=#D59>&JDBT2@UJ+D%I(2B-0-' ,G#26U0\^J!;
M&EA06@A*(U T,T,-
+?;MOOCT6G#L8_0'TQ.D@M!"41J!HYO>EQDUCNYL^N038.5TS4M&LZ|T0M\$D"13.%;IPQMOJZ M;B7
SNHLM0_3BX\$;9) T4RQ&Y.+|2;7+ %V/V!=="=8:U!"#T@4S4Q*8XCQ M!WV9Q:"?9D%I(2B-0-' ,#4N&@-
|GZTXUN]:M2MM!|D:OC(K6C4'VT,|Z M@YI?%*JIOWNP\$RME8E5L@9-HP;>9*G:R-|?G_F58;I9K,.7>
M05LJ5G\$F|>*>XI|GL|<:5X6ARN&8V8R&_00R\Y5_N3 M0(%Z4^+T/U!+ P04 " GB6U9J7Q0IEL\$ (\$@ &0
'AL+W=0AZ -C7=0"2")*40'X[WLI*?(BFI@&SHLM2KQ'YR|D|=1DS<5WN0)0Y\$>>
M%7+JK)0JKUQ7SE>0,WG)2RCPR8*+G"D:7MW2L3:H9_R5PEKN7!/MRC/GW_7@C:BZ8LZ-
K4U>I,6.HVQ\$0@T13LUNP>,@207 M),8"2:H,"%0N"K+##.9BF7DAF6LF
.)ZZKZ7#2EHU/P"!E3D!:#%20MS=@>* MI9G\B(!?XSMR|N\$C^4#2@CRM>"59D- S|(PQC*")X)T3 MW-
#@_FMW?P.YFA.-@W|S%6'4!|N ^35>< 30.HY_?XI-;C1VH=E.+|A<#&SHLR\E",OPL2293BL1>BE<
M\,5%A0,F)2AC&A0000VJ=X^7612-) ^|+KEO|. <\$HZN;LL0T|MJ\$U(?TZS M5*4@KTRTPE.FY41@>XY&G:-.1-
2WQB@MUH4#DA!|D*&MCL\$%H\$&-F)./7J0 ME_Z<06A.RZ|C.|"R0>?
%TDX6\$V:B.^A1"2/0@&Y_3N!3,|AQW=HY?0\$|68G M0+>^GPSLT%#PAX'MSSE:*..Z^Z..W?'
MUL1\JSLQ MAGV@G6TA%Z.ZB(|PR:S_2;D1U,P|&\(&TM"/9+S0JTD\4.2L(VI M/& M4%\$+%5J1|N)
06VK|0Y?))4SGE5*(+K"\"@9DP27VAS;MC\$(+3KU=XK1 MN_3&|+!FCTPNMU64_N&
<_*Z>6_.R0/;;,5Q3NXJ('|?/TLE M4./|8_2\$GK*X3X6V'Y.MGJ#67C|3LH:
<-46=X,) &_84+0*XC0#W>H':A<0Z%)DI!|T6U%XN+?;L= *?:LFJ+6':^X#(>PSST8'')_#WU
MMP*!VA4"CBQ_/H G=UHR0|UN_3 M)-_5ZZ0>ZLI62="D1)-CN=#*:|(
MFI>5;CQI@6D!J8S>C'K>7%"OEYKWD!)TJR6H03^_0>6UB':99YC4UWGN\$C%= M?R/YDXEE6D@DL4_K|W*
(L1/-9X=FM'A9G|R?N5(\KR|7P+!)Z GX?,&Y>AWH MCP'=QY_9?U!+ P04 " GB6U9-FA%5%8# '\$ &0
'AL+W=0M+3W M-B): \KUBM,"-
+G/_I_=0%Z,3=\$XIS3S15V04Z+ZIM\JT6@0\R(P+ETE=Z0!/F)S7\=04?/P*_*L4(M@ME+& ?C24?
XNC|\B^4()H\$-GW:\$Q_WA,28Z/.P:W=>6&E7C1M78\B:/\-, M2_E!|89_/|./X>W"G/YN4M-
!9MVPPTPZ7\J2)+CR=+Y%? ?THC_".?|/UVB M7,)B1|"60\$DC<="CS8ZK5\$(3\$\$.BR^A)
(.A.T1GM,"KKB2VL0 M?JIC6"K:P,/,/>8B"41"\$2_|PZNMW%#% ^X2%CN"M33.&HTSETDY%YK@|FFZ8V-
U/.&!'R3'Y6(\U/DF4>!\$[H]:|TQEJSA&L96|1F%L, MR.(M"HH2KIZ2SKWPEL17C<17P\|8
ME!YHBD4J;1Y7;W.=R5MQ9R?)^M9N.X=>:@D1|"6I#|X>/,-?N^K2,T_\JP
M|I_&4&>N:&UI)^5""\$1IVTJ:W-|T36<.3I(^D47++HH5.?V63U(.#FGKGV:VC_Z"5!+ P04 "
GB6U9,)4XEQ(" |! &0 M 'AL+W=0X#J-H*>\$ \N,FDL>I+L-UF|^9.VE4I'9?FAE|SIES|'&S3IN=;0<
M>99"V3QJG&MGE-JR @<?*61C*'J=E2VQI@50!)09,X0J62<14565A;
MF2+3>R>X@I4A=B\E,R\+\$+K+HVET7'CBV\;Y!5ID+=0"&MR/=F4PHR--+Q24H
MR|4B|NH\FD|GB|37AX*?'#I|\$A/09*/USB>/51|?7A (*)UG8/@YP!*\$ \$0H MX^_&8TM/? T/K)"=
|1RX996&K0BU>NR:./\$:F@9G0AGG3W (-?&\|7:F'#
M+^GZVKLX(N7>.BT',"J07/5?|CR*X|I>R=@W.>)|@E":3I)=*&1B\K-@+CHXCY_=N8
MV9:5D\$7IJ#Q|C;WXOI<;,\$37Q/K|"=BSXGL:6X" MC7|0AR+-Z.&T,SV9!?'^L0C&SY

QCVH-B,+>22/\$E.FK\?)3M>MB;9BRUIY.\$YE\$1--TH_FA+1
MPI.HI)D%I;7U=1B:K\$3!S*6J4=+*2FG!+\$UU\$9I:(\M|D*C") (K&H6!:)J%/4K. M!4K#E02-JUEP\$U_-/) \
|?|.WSCN#%|8W!*EDH|NLE=/@LB1P@KS*Q#8/1;XRUG
ME0,B&K\ZS*!|Z0+WQ50T|UX|:5DR@|>J^LYS6\Z"JP!R7+&FLE_4YB-V>D8. M+U.5\5_8=+Y1
%ECK!)=,#\$07+9_|M3582\@B8\%)U_XGFWB3S+M\RR=*K5_M!K3S)C0W\%)| -
)'CTFW*|6TRBG_I@|698\7<|*5PZT2M->&^7)=0!+%K^'= MKX;:+>S)#*6K'RPJ|N'L<|/)'U"B9A6&7.=Y'.
<1I;XN@RA5G' M9|FR28|P>0WW2MK2P#N98_YW?<\$C:>H')3N__0GX@/4E#*)71"H9@BF91G,"
M=M#7;>|A!|= @'1_1V|.J!0VZH:GT--|L1%(X_5A<;" M6039B"5J4*NNA&!+9ND@;F&)P(UI2%|#6Z9I
:\$^L0=MUI'/ZMK%.HWC6@T MC*^FX?H_WU'/=W22+QU/ZDB&F.CG3-F:SB5;5@C4PSQ71F<7F(%;JUI10VU_
MW&F4*2'(9MS=@#/"?)?.#TD:/9.4Q,/Q8#0\K&C<*QJ?5+1 |6X<|<5GA*BU M&LMDSF5QB%"+&T=[C*++Z
B=24|GJS?EC2PX;:;=#Z2BF|F|@\$_5.9_@902P,\$% @_)XEM63>% M,@W7!P_*DL_!D
|X;|"|W;W)K&ULQ9SA;YM& M&;_E9,W3:VTU@9L)\T22TDX6*55S9IVTS3MP\6^V*C_N7!;XFE_.Z &,[&
M9|,|4KXT|M_|>^'N*??>^;\461?|P7GDCPE<9I?|!92+L_Z_7RZX_G+WXHE_M3|4W|JR)+F%2;V;R?
+S/.9D50\$0?>P6#<3UB4|B;GQ;Z;:'(N5C*.4GZ3D7R5_M)"Q;7_%8/%|TG-
|SCD_1?""UCO|D?,GF_);++\N;3&WU-Y19E/_TCT1*,GY_MT;MTSD)OJ_.*%K|_%#%0?";Z5.Z\$^*HWWL\N>@-
|1#SF4ZD13|UYX-<|CC5) M'<>W"MK;Y-2!S<_/|* X>74R=RSUR+^/9K)Q470M\$=F_)ZM80E)/|/,JQ,;
M:=Y4Q'GQ+WFLV@Y29+K*I4BJ8'4\$2926?|E3U1&- &>X)\ "M MSM@-&> *|* M\(|-,*P"AEL!|KX,HRI@=&R&
<14PW@X8|PDXJ0).BL\$J>|<8&I|)-CG/Q"/) M=&M%TQ^*|2VBU8A\$J9;BK>LT, @;X@Z<
M=X1^6T5R3=ZG4YYJT9";F*7DU: ^K2.UYK5H5_/)QJ8-R\KGDD5QKK_YE.FR=0#"M#0&Z/\$1WSR%ZY(-(Y2(G-
)WQ64L\ MM<>_.Q0?VN,=UP+HJ_|>=+K|W.E7KI5XN9J_)8/ACZJ+7: ^M0^SAMWSYEG# M(GS8\$NX?'|Z6G?
Z_|,'_RQ|:PWT^5>%.6|@Q%-Y&_U|!_8=SH)EG+3H_S++ M6#KGZJHKR=6:--
0=L'60^_*193/RYP*2=Y+GN1_M9S/59E_V)Y?SS1G^9)- M^45/324YSQYX;_#=#YX\%.;,) P'PFC2%B
A(4@F"&0X49>0QM|4DKD@>'R>#MZ+S_T!Q:ZJN@X^\$420L0,)"\$,P8_-%F M\|\$?6P?|L|
(M)7LRP=\658|JXPk3)P,KK>JTH8>.&I!Q'7|&F0);&GF>8S:B_MNXV\L;05*-AM-'2\K71A2|K!8-
/&Z.70II?'UEXNRA1=E;1UJ#6T:XH;+>K|V3&\$_0S-. ,:C|E8%5! MZ8>4Y1|35XA\4_|00TC8F5W%
7Y4!H|T'0#_<=>Z'&\$)JIDH;KYEC/L_++ M?MR|.B"ID*H0),GX5,S3Z.|6Y^K*GJ:S<\$K:J/_=31JU.>5()
Y:44;6W,& MT)PABF8.OEL/OG0823-A|(HE!9_:2&*9BJF-BF=EW8I_M':A-
":7Y4!J%T@ (H+4313)G59J5C=RN|&U9V8&?9#'?FGY/=Z6>WT7B|\$6UI
MY+J|LTI+J\%VJQ!UCN:@U":B8W<1WZ=J\$#B1|(|G<|93?1VIQ<:- H@-J(SJYG

MMS,D\Y00PTV"PTU"U)F90U\$[C8[=:0R2LD1D40<[X4YD-I%\$H+H+0013-E5EN@CMT#_6_N%]0*MA=)*
(T>Z#VGF-9;10)U2%\$T\^&GVB)U[2;?L0]%V#%=0&E^5 ;K6A;SW^X M6P^ !-
"D(8IFJJ"V0%V[!=HL93X0,GY<,6.'=M8\$DN9#:11*"Z"TF\$4SI5,; MJ*[[PL6,"W5=H30?2J-
06@"EA2B:*,/;:=76M=MM_*V;LS,[*@1J14!H]T'0> M_EMYT.,(4313);5IZMI-
TZ.K&:A5"J7Y4!JM:%05S,E.-8-,&J)HI@IJE]:U MN[3-:N9#E\$;)*FD5 =2:A=)*
(U":0&4*J)HIE9J&]D=0W3Y C6*H30?2J-0
M6@"EA2B:*,/;:*W;M70\$G)CD1[V2YRJ8+)*2*RS*)IL:>X94&4X.Y9E)\$'%J\X M><5RPIX?670=*BJHCPRE^5
+K6C&!,;L/+0&S1FB:*98;G_8M3^A6=:ZH0H9 M7_%0J(KJ).0)SV2V%,U42FWQNG:3L0@M
M9+PF49I+%=Z5LK+FYIRP1LW-H]8*D%]7RC-A]+H@2ZU+96@QB^*90[4LC9^
M/;00:Q3)Y:6E31=V2E=0&D^E\$:AM !*U\$T4RNU/>PY+UPD>U K&4KSH30*
MI0506HBBF3*KK63/_BPNND8VI^LL*JAQ*#71BF86R5LE,C1CB**94FF*> 8 M.[A[B6S'=-I8\$]A4 V'<
V#00]BLPZ(&\$*)JIE-H2]NR6,*Y\$MB?JK!VH:0RE MT0-=:0EA\$/OX0A2ME\$Z_6:>A&?
SXJ5+.9F*52K+EY1L]FY>['190,YH: _U M<^8[+?NI5;I#ZP;*X\$2&)^KU)I [U7WIUXWI!B6;P7Z\$Y(*9+B
MXX*S&<]T_7]01#R>4,GV+P>:(04\$L#!!0 (">);5EV+"\$>^@@ "U(M_9 >8P0=V]R:W-
H965T=CL0^7K#P CE M\3\6U165D'.0ZE01RAA#]=SJ[M#]T]AGE4A[C^'/^Y>/Z4S;UC_?
++^B'GT4GX;AW\^ZVQ[.50.T)H >8BF/M6;(/Z190"L;BPAV073\U M2)J+6 -,S#7#9 .LV(&4#4@]1E;(
MNO,R[^HBB5]0DA\MK.4?BMP4K86;(.J[12%+0%#T2Z[>LAB_/[&Y&(-;J- M=V)TI%Z1W_?
H00R9]2'D*'Y"UWV@^PK\$@,'%6W0[0\N!2]N>.9%X3I6]'D MT\,=>0/16_0]6J]TZR4\14&\$/D5!EKX3/XK/?
V[C0^I%Z_1BD8GP\R_6?AGJ MS3%4?";4?HUUCK)MBGZ*UGS=T?X6;F]CP,!''Y*U*'CXE[P:#%A_X?HZ[10YA
M"SM= <'-[[@FMM%&HI:5J*66*#]? M>&\$H1"WR:\<3#S1Z;=DAD-\$E:PL\$0S_4N*H\$KL8X"7FT'G
&KA3A+G66U&(M MX>IQ[3.UH!SSLOVM:8\^I8UIKZ M:S1D@]W:H_MHU+9K MPNPY;@]8V+>I-@E&-
D0&W5.LACJBK/F*)]6-P4/V1*(;) V-.9:#:5.1S^2 MN3+SP*&82I7D8\HTWM^=LRW&N*/3I=U3)C;N"V=
J=P4X^D&9N!\VUS*76] M7@?Y)R]S=T'JAW%Z.,.R]DC_4BJ;_G]LR3\V#\$!5IWEIR8\+T#D_>B+!5LB
ME0H'D9(P>#IVZ?N)=W7SQY'RV-3M\$2[XT)0K]?6WM>N#-]JFK*MDRW68;J9 M\$,E.-@Q/UYM-PC=>QL6*.4N"*
U\].R%A^[K[+]RJ(>8J<,V-7 I -\$Y R MJ79&MU)<,R4]T(_A,,.2>3#(%)6.DMORC.-?}MS/OV1Q\7,?
MY4>^L\$-#L54 MJL0;#.-J\N\Q[724N+=6688GBE3(^P;U-I\$E^P'K[T]6+_U: !TU',U@,,Q
ME2N)!@\BFJHG->0119X[7RH#>0JDP1]IL!]20+WII?GJZX'0,UXLQ8!"W\$V/ MNR\$7:MB4:68D_6&8@+HZ?E
F8/-NF8G5*1/D?*"FJ -AB4Y8KQ(TVA!A0==1 M.")3Q9*3*!"T?"N=Q6%[3H8'(&IO@D^& :?HH+]6_P
M)R+AB>C= !^6>] \$G> /H]/ZG9[6[_C\ M
K['U*DH@D%3S81(;G)@;AI4XBYMU1>NQ&V/7048^S@K>TUTJM#>37NTD;= M]4>-VU.U!G=0&1V*J5+*
HU<6&E#B=M1=0H[K*/>P M8<>FPB2V.'K8\0H"=^FH[W(P!-NT&5A"@2B\$H&HWNTXTRIGC_DAF8!-
F69"DA/5JP*--4:HN@=)N8S"(9E* MEIQ\$!]6)AG<^5BF@7=N#0S"5*,F']NW20AA]C-
8'G^]XE&E7N6&S0WEX+&0- M)\$BNHA-MXJ:C]N(>RUHS"[5]W-]H([>*:IB(_Y3M""!\IOHEJ]1-W-3E=/:
MRW?8H:D@R6ATY*W5-P&)4<1K !-FZJUIG. MG'_]]S: ?DI_4Q4;?R,U&W<@]EK6F?LE.[!MMY"
[]UE<7>+YJ/R(#1V>J7F(4 MFV(0-U/0N2G/R4S!3DRR\$YMF'S?K0] \$&>S95)H&(3; ^'FZGWRQ254P /D\##
MOL7V;:9NW^XZ)7N.:DJJ/8\VS0YN-NH.[K&L-9,@N8?]7SNX>QR=5N]NM7IW MSJ]>>TR=RML.: *J9\$E-
-,0=W\$S=GJV\X,R,05\$ MN1*BW-??RQN4&?6YMO;E!X[(5+>D+'?X/;U!"M6MW8K"40%J47LARXXGF^ (] M-
0+NXT.4'=-40U:000GNG@#S\$(>?GR1SJJ]>(A;J*0KYDVAJS?.N2([OICE^ MR>)]]7J7QSC+XEWQ<
M&I(F=XCC39I-B[(]-)G00DC@C=PSQ?9IB M=I]3A!ZGFJD]#]S'FZW(!_399(4Z(X)1F/:88864^U&W,<
MF\$XN"*S^B,F1-YY10I0_2A_SEZ_15#/R&9&\$A")'8/G00!8D27*2G,<_%52K M?>,"Y0,S/2@6+Q?
S@#E9T.3/.!+;J3;24\$36>)^(>WK\E50+&N2\D":\^ (N. MI>WP6D/AG@N:5F(Y@S3.RO_XJ0I\$0R_Y_0*K\$E@0!
M!I5@%\+@0B)P*X%;Q+X,5A%I#PL\F\$!Z1"RWEK3\H4A7H98!CK.\LI:"R4]C
MJ1.SI:#AXY>YS\$V\$C25!)+J3C M7*Z'E9-YZ<1Z08F-;FDFMASY642B'KVGUE^ I0_4>M-2
'09L3ILUG/8YI:2 MN"2[*V0;/R/+L)R>"2W>+[?]{X0%]W0W0_QZHY1X)I=SLD[=B;=\$HZ+/?J<"
M)X@7K>FAR'?8J(N^#)<M^#EF^EA9IJ68QC&1#]TD]=C9]MF0[KVMFNU;7S MNW.:?2]!CU^#:-
IUHK3H([30!FG5893RD3\KXP027<)/1%R4=A* * OK9=;4JYSF^,XG4=Q6ME%&_C+\$]W*2H/0;]W M*HF7?
E,@81XDS(>\$!4"P5HY-X_QST_C@]EE-*@H0&D>*,T'I050M'9A-,XA M3.770_RFE^T3YXGFZ"#
[0]QMT(ZPF/;]]^<KF1?G&I+F0;%>"YT(9GU=S0>= M1P!%;^?5.N?54K=U '1Q6U4 MYH'2?%!:
\$5K%\;Y.,=4G^=6V]7,B.-23->V.]CJ*W0\XC@**5>=4;UP@I M890BPH?+'S/[3]3'N?5H?:ET4URE0!B?
F^.%V3/NF6._0#(ZX\L;K%0,-G'& M44+6TI50-1QHB)670N6+H+0B\$N.! "D'3XG%< \$18;B
_7U,JGE]R!_75W.0_ M4\$L#!!0 (">);5DJM=E:'00_%@4_9 >&P0=V]R:W-H965T<?7P/0_A966),V!R90S
M)& ^#J[QU90,C8!=\9C"5NZ-D7'EB?-G,_F4C(/(((,8F544/W8P UDF=&D M/8E3=1R' P#E,"_0NE0S^B+
M>2;M+]J6:Z, Q6NI>%X*;P1YRHG_5H&8D^@0VH\$2"E +.["D\$5Y2Q6=C_3?
M(F%6:VUF8%VUTAI/G\ZGV*TW/-?)EM2&ZQ5-] Y(MUAD@/D?WLP>)*\$0TX*JB=[>@:)K)]Z-
0:00&4QB7]J:;/5)C]Q)]YDPM)?K M\$DA>RH<;>^4 V3DP)5Z%,UA=H\$YTADA\$NNA"%*YI
]D^? !8Z?0AZE@+W1H+ M]R"52&.E(V2CA1Y8JN0QU[UZ3'U=R16-81SH_I(@-A!,?
0H!]Z.?/2B[%I;S,YG0TUJ&\%NX5 'H6@#F--A/<'0Y'X>8(['X% MN^%_8N@S&2^*8;^ 8;H.
(!!!6#@!?!HP]+8_N#_GE]\$ (85AJ\$7PXU)0Y:U M@#%L&H;+"L+E/[-]/M@UK??,95/
.'(G: ^2MR" ^6\$730KC@<-, ,ANY>0/J8! M?:2I0(\T6\ /1(S0Z0:'B/4K S6.]\^+0KH7G9J4\$.<9:5S-
+0&1QC0\$ \$00V,\M>;:=%4RC&N%'\ '(= @+P5\5^AM M,74;1\B1!F[!&NVWXI'#H*U3!;Y^
Z<U@S'H1+@.AR,=XB>=]CU&J;!)-!Q!\$#]!G+K-((*H MA'1.U&R04WRU\$:4D4\ S53Q;U/];:Z-KLN+H0<\N+.
[3,5NGHDRF"N1: +@0ZG**ZQBHGB M*WUJ],25XKD=+H\$F(,P" ?<<[6;& /59>+D&U!+ P04 " GB6U9@5)
MG9D)_90_&0 'AL+W=0G0L:SQ,*-)/KB^K([=])>7?"72)&?W!2E7
M64: +]2U+^7R]IG#TP\65Y7A/PPUEEF0L+Q.>DX(] M70UN[(08LU2&*L70"7LIM]X3=2J/G']5'S[-
K@:6*A%+V50H!)40S^PC2U-% MDN7XLY\$. -C%5QNWWK_2P.GEY,H^T9!]Y^D56[=754
M=>E30:\0" Y""I5:TM2;2A!5;EF%2:ZT^R *^=] \$YA/7#X)/0_Y*VM_1C[R_M3/XD2EJ]ZF?
B6/;\$!.'^N\$K\$FG_(IRY7*R'U*<+N;_R9EX+Q]^2=SP1-T0+] MY5#(\BCJ<-K\$]N08SH'8+KGCN5B4),AG;-

:/S3GGQ5+'Y0SVXX!,,)1?Y.,; M=%Z_S50'2+Q9S3\0R_M)?G>.VU&@C^;L=W1-[F5VVR\$_D"\$I%[1@9?/2]06;
M>0]L^8&X5@7TR)<'G[S[X?UA6G_ZS7VE==4;M%_1IE"Q&>.SJ<38)HPF""?S
M\W(KKGNH>_JT2,?/ZZ8H:~#YGLA<0Y'9-MM/=TW5U^.,:%C/RC[!*)/DD6%;^ML^.\;NOX7G=\U?-
=E\$Z95<#V;65K'AF@^L?_V*/K5^ZY(F\$^4A8@(%2%2B\$ MA,4@F*95;Z-5ST2_K07VS\$J1Y'-2J\$Z_ZP=Y6U-
LJ]*HL='SM?5A=#E\WE:2_M,51?)2%A_1(6(F\$1A:~#8)J21ALEC8Q*~HT+FI*R&EH\5FW;=*0MZ]*4D=>W
M%4/'!HVWA*[,;3N>95FZX(.=*YK[Z4+]]Y8V<_7;2?SK/=;_AQ1US+VDZF_MU>!X4X-
C8PU^R6G&"Y'\2]8=RY8I7S/6JT*~^+X5BH3YX[T0;+'"H^\$B_M9+@8!--\$<[81S9E1-
-6\$X75F4\$T4NI1A9/15!A+F(V\$!\$A8B81\$2H~@FM[.M-WH[?^/!/]3E2JTB8CX0%2%B(A\$5(6
R":5J;,+0Z,;:-=1;DJTR0N?S@LVI_M8"1?98^L(/SI=980%E20C*!)(R-)6:ZD6E?Y3"81"~T:6:MGEWX>GR;?
&_VE_M6L-
&6YW6R/,FYSN#?!\9,T#"0B0L0L)B\$P3H6VUJWV648:RF>=%ICN931MXE>2.S]T;~!F2/U51R4YC>T;0\$[W0AL3:
M],>@9GN:A6!-;~'MG@@\$-&T!I(90606DQBJ;+L%W^M\WK_W7[-U=25")>+>/>(M#[KH?Z1(MB7'H%+T68T=LB
!E!9":1&4~J-HNLI:B\(>02?U2H*?VH;NF61_M3*LC=5,GV[PGFA3DF:8K.:VE):~%*C6HC2]<_@5MSN-
YZ'.~;I'0-&S)B_*6%_M4%H\$I<4HFBZ\UN:PS3['[WS+(2>R0VU41>>L4U=0QZ.AV;~;6=~XI"~IE0&DA
ME!9!~3&*IBNK-31LXQIT01N/_JB6W>@'^#4)-,V_GC[2WZ_M=L<9Y\6H\Y2K^36'7#,D'D'0?42\$?5NRJ>KQ!-
~R"PA_9H7\K*[\$4"V2:I@R_MJI(=;Z/,Q>LM&BK_*4%4%IXI%KMJC4F(Y+5^~<=E\SHNGO[-M2=0-%T.;?N
MA/,=[L1GJ4(Y\U2"K/01:0FCRRVLP>[MD9>W;^AWI_M/3!=UI/,ZTL6HL]4KNW4#"//2^YN/;\$^
Y3F0VD!E!8>J5;~;MWH\$QH='?U##_473A=P;#H[9<*A'=17ZB-1L+A597\&MA-LI/*BAT-!L;8K9
M99I"PP906@BE15!;C*+IZFI=!QD.-&@_I8506@2EQ2B:KJG6&W'-B^B='?50BX)]M7U=MCM9;>E"K
TH+H+002HN@M!A~TQ7:VAVN\9=M0LU1*_T'TH+H+002HN@MM!A~TT6[=<V9+!>=CF0'W%>:38[N\$.~5J.M
\$H+H;0(2HM1M~J(PZV'~62LF%56\7_MC,Y8H1+(S]Q+EX_J";1Z!<P=02P,\$%@_)XEM68Z.HW]]!0-B0_M
~D~X;~]W;W)K&ULQ9I=;~]LV%(;~"N\$50PJT_MM2C93I,E!F+KHP%6+&C:
[6+8!2/1ME!)U\$C:CH?]^)&4(DN.S.;K>J+1*)X
MGD/QO.;',;^VC'\5*THE>LRS0EP/5E*6E\AB%39T'6\X\$NL\WPWHQ6;7@_PX*G@_M4[I<25TPG%Z59\$G0J?
Q2WG%U-VPH29K30J2L0)PNK@TJUH_M72/]*@^,?=4WM\GUP-\$MHAF-I480]6]#YS3+-\$FUX^~;~FA\;L/V]1,]-
~"0_M7N:!"#IGV1]I(E?7@_<#E-_%66?R\$]M^H/4+C3409IDP?]&VKNL,4+P6DN6U_ML6I!GA;5?_)8=T3+
~M'~#-S:P#TT&!\Q!&H#]!]@=,1@5!N,#@S<8P;CVF#~M4@^3VF!R;#
Y8G!>&YR;8%6]:T+C\$TFF5YQM\$=>U%4U?F/@;:Q61M-!20)=<M/4V5G9S>2Q9?
3M3P4S0G.5*X8(8C;Q%KN.ZZ+9(UC%5VI/H+B,%_0.I)&DF_M7JL*7^Y]=;/;J-
7J~T@)]7K&U(\$4BKH92M403AW'=AGG5!0=(&SSTD15R)5!0_M)#3ILO_L]A??LH_L]MBU
(:J0YM>=9]Z=>9:B1_)#CD7;TP7]06'W?J>EN^0_MYQCS48^Y_W)SKZ\W0\]]^'W>[~NY3V-
EC00.,Y'P&GU[AN<=;~Z*~(IZ]'W#_M.2F6E;~)G.]2N=T=VIOAF2WB"0Q5(=&MI+GXJ^=]9I7_4;~]/9-HT9>
~QM]^IE)DB%A!M\$'_M(YZX);(^N5AYI~JE@DT,3"~Z-E.,]9=VTY9!3R7/P]U*P?~*WL0]J!0^KS3"~MWH&
~J,=>XS1U.KT\;GIY;~WE0IFHKV^ME%/]A+F0\("2%@"8N_8!V13!J1_M3'[P2#^!E!\$!9"P\$!(6
<Z\$~CIOY'5N'8-NBUAM]035:~]UBG3]0CM@"M"2TF@79?5~E0]0,("2%@"8N_8!T]7#1ZN+~#&A.15(\-
MY9K'~SW4E#R-34DU3*~C08D%2CC8D6U-TID87HG43JQFL=]RH0&&G010]&#*L_M#3I5(I"~P!
~60L(B(^A'(MC9YVLN8VI;>W;"M\$~6Y.-R&@+H-7NHV!~4;0=&ZP6~EZS#P=M,./#G8^/DV\7_9XH.Z#~I7?
Z%YD\:/J5T1MLT#PD*,T'_MI06@M!"4%D'1NN+99R/QZ_?G0#!H_A*4YH/2_E!:"\$J+H&A=F>W3L=B>C~T?
MRQ#0U"PHS:~]IG;3VX1P3@+H,>USB\;'/'IG-~K]?~JVYM.F7PJ2Z]256ET@_MFI<9VU~Z?
\$E"~TL:2U4J66M9@MB&1R8XYV')3/\:6/>~H#?!E61UCV^I\$54?"EVDA4\$87RI7S
M[EQ]LWAU2*6ZD:PT9R0>F)0L-YP!0ZENJ;BS&PI259_R3)2(@J;A7~E_MSR+;D@)E\36#
SLZ1G(IMX3UA!GDN2F,=#=1H_M?4KA\?\$C/5*+~XNY00Q6)/^6)3Q=&!;#);#!NYS?D,-?T"QH+'DQR9GZ18?&
MUC)00&.<%(U8S*#(R0H?WS>!.!(3K_~01.5S_Z(W;~@?M<#Z-&,'JNAW\$C_M&'<~WAF!UP@~\%?LZ6"K2
>~8GU-R0%1;"YH\4.E2:A'@K)25M>947,V\$COMK_M3N*=[TN1FP2M2]"\$*EF&5~G=H+~HXV>6_R:=~000Y3&@-
P~PG.7LK1!^60?H_MS~NWZ!7*200Y)3N&RX3-32[F*~V:<3.W93TWY\~S<7/2)E#QE*~P32'KTP;~!^M^B-]-
*RWG0&_*0+=1MMYC/;2&22NH;I_K04G_MHV~Y_+&0VWWRDUBZ;>6ZBN>>FTZ**;">DKRB%);\$~V/H^4#.K:
~Q@]J^J_M:8+~^5L@T4<.!?NWKSIK_Z-^~[+ESUB~8U@8HJ&KD>D['*~QJ-
++=CKNHQYUEM38G@fW@1D/!N8#E\$!%;\$0;_M1C@13Y&,<8KE(QU!W;_~[@C/(!?&GYZX0%.F&A3EBD"7:29;~
~L0>;&Z*GLR)T_MP@*=L%_G+-(.\$ZF(R[8B+C4WQ)HW/FH^EQ.OTP^?VDQ'XTX[?&K6M,~*.PS
MLKOM<'"/QF_2IN_R6#\;@01TSA5C3.~!0?@.J]3M,M_U!XD004=TP@*=L%_G_M+-(.\$\GQM,WQ]#~WS;G.BM
~)"W3"0IVP2!/LI")LZ_LWL:6Y;S;_D<=]I_MG'U&W>X;~]B-G4Y[~7N,Q(NKU6F=PZM\;13-HTV&
NA6;0NOMG:T_MW7*Z4ALMG?&E/509/>.!/00K#:70^'I_ZQ.FVZQD*(~>~<~&5=7(IG!JVWC.H3
M3BJUQ7#+,.">%DP!)T"~E@;B^(80_GD@'~[<=;S]02P,\$%@_)XEM6;_N_MYK?#_@_J_8_!D
~X;~]W;W)K&ULA57;~MLP_M#/T5P0.&~ECC2Y.L[1(#2=MA!5;~;+~#M8=B#8C.Q4~T\24Z:0Q~E.UZRNMF+
MK0MY>(Y(49.MTL^F!+~#D17!IID~I;743AB8005_S4!5(W%DI+;C~J5Z'IM)M"~^D>)A\$T3@4E,D@G?BU3*
<3550.)&2:F%H(JG=SX&H[~#>)@0_#\$UJ5U"V\$Z_MJ>@;~F"~59G&6=BA%\$R_~\$Q)HF\$U#6;Q57SL[~+W!=P9;2BF
M0>0(8?<_@2*OPW<_N<."&G\;C&#~+JIS/!SOT3]][:AE20W<~QZ#%;~;AGTT75N7/%W/459!;
M)3#7A0KCNB#WHN)J!T"~\A\$>~#"^K](-_DPP\~ABFI!G.,\$J*~@3E72J4H\~.5;JAP0Z5\$UTYK*_M-6!563+?D4.
~C.[\FQ+=4%~?D5(\F!~F%]]LIKXP_[X[B;=F(KF,WPJAC0_M&PC2]^~B-Q_7P1ZK73!K"885NT>
C"~M)-7VPF5E6^M%RV5Q<[FAR4^):"=>ZOE++[B6MOW>.4_@%02P,\$%@_)XEM61W~+<1.M"~P_H(H~!D
~X;~]W;W)K&ULM9U=;~]LX&D;_M"N\$~I!AV@C:T0)^DD!IKP8P*~TNT\$[W;U8[5CT[~&VLN2AY*0!]]L
M+J5^NE)9\7@Y"80+WQ)[Q=5<~)P7@8_!~!C..Z0;/\$/U+U6&X})06FW!7%~]K)S>QR,*I~I#(UK6J\$~-/~]J&N5
M937)]..0%CK8K+~NN/WXA)R<~#8@,S67ZZSZ4CS^MH=H-2FK>M,C*YB=Y;)<~#K!;~\?_Y8_V#['5(0?~1"V#
<~)C_M&T1M@^C8!G';(~#ZV0=(V2(YM,&X;C[~]M<~HV.&T&Z_F0VPP-E96<7.CBD>AZ
M:4.K'S3CV[0V(Y+F=12_5MK\~C7MJLFG(K)_7RF])%3=5>0]^3B;I75(9\$9N_M\N>HUY%Y2U4ETZS~C?
SZRUDTCG\G:4[~^7!3K4N:S~AUYXSR_&~;F;_4:AM.V_M'~^RY'~^\$K_3@GGXN\6I2\$Y3,U<~]L/S39M-BQ~V;"KT
0\6_~P0H+H'0E'84R^M?~7D[90?.0IUW0?~0GTA;~]L_0!>~^F%_GU8G!M3_HH,PYH=]5:L3\$HT.;B#0</p></div>

M@SG4)^&'434UL*#=P,X^,8,9;5(:=-SH5:()YDU>5GIM=H,5^=K8_)>\Z8J(E)SW(D@81<+8,VSDG4Z&RKI'T-
NP[DD@81<(8\$L:1, &" M.,D8;W(QAE:&,3(L2!A%PA@20I\$P 8(Y83G=A.74N0,0)R_FU"0WQ]5:JWSZ
M1"HM\S)[/L*5L_8P^TF1.90=BY331YDME:0%1#0J0HF"0FC2!A[AB5;>W-S MEKM3/I
K%"8\$Y"S34#._(<.,?JRNAD%"9N76'0M7(H3:;!H;J*VM%WPTQ)U MIZI'I7(G4S*?D3 9)% M[%XK62E-
JH7,_X]D>306.UE(&FUI]0[2=9NKI KY5":0-'<7%F;&WC]W^2+ M&Y\G>9>I.A:I,>L,
U3G0FGTP):>DB%P=^T;QB@- JE,2B-0VD"17,#8MU0&\$"K30C5M% :A=(8E,:A-(&BN:&Q M+C?
TNUQN)S28(]MJH4B]G_ED]C.037#P WO'!NI@H336TK8G.03Q^=XT!^A* M!8KFYL\$ZV-!0)K?RL#7SY;4H0
TLE\$:A--;2G"A\$^TF VE84S4V"M:VAW[:^ M'&^8P7=?#N3 -6M4!J%TAB4QJ\$T@:*YB;&Z-
<3JUA"J6Z\$T"J4Q*(U#:0)% M+ H"0E4)I MT=P,6+\$. 'A"KSJ49G>, /U:E0&H726\$MSKI,(]N?6MHMMAR[8#YU
]@0U%-":.RE.> <<S SCW??^?&XV30G?LS M;&-D;6-TG&W<.- KWSW]W4 N.-
I1&H30&I7\$H3:;!H;G:LB(RP(C*"BD@HC4)I M#\$KC4)I T=S06!\$9^44DU?
(Q/S#]TX H'12H>HPZIG NSOV\$KI#:#:0)%2 A<#MIN34.YV9FBNMMTY9R;3('Y2N
M=N\^TR8HZ307"IT= 50BU. 3WN/.50Z0FD"17/'W\$K'Z, M6X1>0T;\$3^V=\$:CWA-(8E,:A-
(&BN=FQWC,.H44HACIO*(U":0Q*YU":0-'< MT%A;&A^8I7ED\$8)*42B-
MK0#I\L,NE(.I0D4S0W!UOU,06)L4M\Q8Z5,U;F2 M^?=FR08[\J>6^72AR\$?[\,H^0.[Y:;Z [WS
6C4!J#TCB4)E T-V;6C\;8 M69TQ=%8GE\$:A- :E<2A-H&AN:*Q@C0\ (UB,^S?4C>@<%J/H9:7BB-0FD,2N-
0FD#1W-!8RQL?N)[^F%(\$-;M0&FUI.Z5H]W:%T'5R M*\$V@:;XW!%ACFOR>RKI;BHZYILV/[1L**
(U":0Q*YU":0-'< %BUFV#GLB90 MIPNE42B-06D<2A,HFAL:ZW03 US6XZYI\T-Z1P5J]8#*6RB-
06D<2A,HFALCZWB3&M^H,862J-0 M&H/2.)0F4#0W-0?B>6?T7K,&8\?T3LHV. 'ZIPM&^T6'^PW7V&^NIGV-
?S MVM?;\$;U WB\^^;NL,!=3(0FD42F-0&H?2!(KFAL>:V^046W*@9A9*HU :@](X ME"90-
'5MUH!X62J,M[<"MXQATI1Q*\$RC:95H-: ^ PN' #QW
PW'0]*0AP'=20#RUF&ULK59=:YLP%/TK%JNF3EK+5SZ[!*E)5*W2*D5-NSU,
M>W#@DG@%S&R3M/] ^UX:RM"6DB08"-MQS?,XUW.01EHL'N090Y#%- ,CFVUDKE M%[8MPS6D5)
[S'#)\\$W.14H53L:]E+H!&!I0FMN=S@3.[9HE8"IED/", " MXK%UZ5Y,ASK>!'QGL]4[8Z*+=#E_T)/K:&PY6A
D\$ "K-0/&V@2DDB29"&7\J M3JM>4@-WQ\ L5\8/>EE2"5.> &"16H^M@44BB&F1J%N^_0J5GZ[F"WDBS95L
MJUC'(F\$A%4\K,"I(65;>Z6.5AQV V]D#\"J]UZ 7P%\8[149FS-J*+!2/ M M\$3H:V?3
Y,:@T0W+]"XNE,"W#'\$J^,:SU9D"D9(9+!4Y(P0\3J(B<)CC\$[K"1-2DG>'DD+R,^)[WPFGN-
U&N#3=0@,0H2[!NZ_A-N8G#I# M7ITAS #Y> DP+S,FPX1+G8V?ETNI!'Y^0YJLE5R=9B/]2U[(G(8PM0"?DR-V
M8 4?/[@]YTN3T?][L*V7]0VV]B#/0>D2L0FZ3J3JVZ MJVJ&
[E/5)UMU;=/:2ZUZ2Z^T:UZ[K#U\I;N8]4WJN5]PXI[Q/\ MS8E: S:1&"M)DY'>P?
2W+G.DB7YMHM]JXHKK&EQ6>SRJK0UV>B_:S]:%S02 MRJ"V,FBU' LJ)XKGI0TNNL)N;X1K/6R!T +Z/.5?/\$]W2
MZQ-<[!:=02P,\$% @)XEM64089>N& @ L0< :D !X;:"]W;W)K&ULK5513]LP\$/XK5H8FD
9)D\!8UT:B3=%X0\$(4MH=I M#VYR;2P2.[=M00W.SMI5B!TU=:7QCY_WW>^_.=NL!+R264 FJR+G*NADVE=
M]EU7)1D45)V)\$CB>S(4LJ,:M7+BJE\$!32RIRU_>\"[>@C#01P-KN9#00EL M:FR(X*126A0-
&6]0,%Y_Z;K)PQ8!:=;H)?D/P7Q+\"-PA!0PCV]1 VA'!?!?#^<-
MP8;NUK';Q,54TV@Q8I(@T8UL[#9MVS,%^/FG4RUQ%.&!/W=\\\$040![H&A0Y
MCD%3EJL3IS\$Y/CHA1X10\I")2E&>JH&KT:FANDGC8%0[\-]P\$)!;P76F
MR(2GD':PX]W\3S0X+@;:1N00(A[Y.P6G4)Z1P/M ?,\/.^XSWI\>=(7S?)XG
M_ ^S]63*"MOR!U00^6GX2,Y7D0E42R/>KF=(2_\, NNI=*X;=BJ:0]55)\$Q@Z MV+@4R"4XT?
MW0000R#RD6'U)L(RQ>0R60(J1]>MJ Z0G>K!Q4@%[:Y*Y*(MBNOZ/:;6=KY]#GN,\Z@>'W_DZV%V2^6"
<45RF*,K[^PCMDA9 M#XAZHT5I.^!,.RG=IGA3 5I '@^%T)0-L9!.Z6CWU!+ P04 " GB6U9 M/,B[I*(#
#N#0 &0 'AL+W=OJIVI30RXB1L*" =A%,K]:K5T>U]]B:&1)0\$J>W]=]W[(0L9 U'
M6 H% #+/8\ CB6<W3/^(C)*?I6%I6869F4]<2V19+1DH@1JVD%,00&2R*A
MR[>VJ#DEJ0:5A>TY3FB7)*^L^52//?+YE#6RR"0ZR)%HRI+P0Q:T8/N9Y5J' M@2 Y-I-JP)Y/:[*E:RJ?
ZD<./;MG2?.25B)G>)>T,[^NI-5I.RUP1\YW8NC M-E*>/#/VHCJ_I#/+41NB!4VD8B#PMZ-
+6A2*"+;Q9\=I]4LJX''[P/Y)^PZ^ M/!-IEZSXFJJ0\$NII+DA:@'KJ=UC.[>W:-WR\$9"
MS0J45^BIRJ5X#X/0 CUCC0!&,:4E>*3V92?=[A?M[KTSN\?H,ZMD)M"J2FEJ MP,>7\=\$%0 U*]G)Z!SD7WD7"-
:U""#00D>=XOF\$ _R^0AV.3.?UM]]:]7/Q\$# M] [&-1\^%UM-23F1C\$],)]MB?3-678\349.\$SBRX_P3E.VK-?
_S!#9V?3+> MDBR^)=GJ1F0G!^#W!^! ?8M?YT20;B9-! [V1P,4%0IP@)-WU>;2\$S M/.M4@<9H#6-
YU>NW!P%#,^=D/?Q>\$@4M\;XM 98\!L;+>CWT>CU<=8NA
M&@H,T94HK\&C"H0^QJA)2]P?.\X(Q.FJ!_HDW_QM02P,\$% @)XEM63-#?TN/ M P L \ !D
!X;:"]W;W)K&ULS5==;:]LV%/TK MA 8,*[!%GY;BS#:0.!U:H-V,&%L?BCXPTK5-A!(UDHK3?]]+2I\$M1Q\$60"C\
M8H0404?G'/)*0+.]D]J!Z#)4\X+-7=V6I=7KJ02'>1478@2"KRS\$3*G&H=R MZZI2 LUL4L[=P/-B-
Z>L2BYFH-&<%K"1159Y3^?T&N-C/'=]YGKAC MVTYTV\$YB5M(MK\$'_7;XDCMP6)6,Y%
(J)@DC8S)UK VKIAR;!10S#8^*.KHFI M!1S3Q4L M!?' ,KV;:Y<.R6!#*Z[0Q/X#-(F!B\57-E?LF]B/8>DE=
(B;Y*107KQ)^Z43T(IL@)UCLJ@?Q&UKA9LHH#\$10R5Z65ID7&BBU9"0V% M9I3S[^26\I UR"YHRKM[A
M0@L_W]Z.\$ G;!5GIU0/W5!;X M;=>?_V\$P.2CAEQ]ZW.Y9A'ULS OE"M5TA3F#KXQ%,A'5\^+GS/
MCRXC#?,X[\$7+P.3. F",&GC.C(GK22PC@%Q:T!\%H41CVG82& =PY+6L.0<"B/I*0P0FL03_Z0P7@8F
M43SUX[" , "Y;F9>#;N] :#\L@SEM7=B2PCN1I*WEZ%J4P M'=,PD< ZA0G>X>CCG4,Q-"R.-[EW4@8](<\$TF?
07@7]TMO/?5@9T3V76? \ : M1'KKNHZ%UM4=' '0'9U\$+8VQ3!L)K60:X8SI#Y[(?E@UA#W?
AB"9A*H]\E!;FU+J\$@JJD+7!_YVMFT[KVVS=3)_8]I1VU,=8.I>]C.5 M6X8'+
X;A/0N\$B0EZ :P'FA1V@[K7FCLU^SE#EMJD"8 [V\-\$-D[-P#R@;=(7 M_P%02P,\$% @)XEM6?:+56\B" 3SH !D
!X;:"]W;W)K&ULM5M;:]LV&/TKA#<,'=#&NEF.N\1 &JU;@*4+DF9[&/; M2'1,5!)5DLIEZ(\?=8DH6@H3H9]?
\$LNR>@<=?1]U#B']\XQ_\$5M")'K(TEP< MS[92%N_G,?:F^G"7',Z=J\$4E) M+"L(K#[NR"E)TPI)M>-
K"SKKZJP*]H^?T#_6-Z]NY@8+SPQE* MR :7J;QD][^3]H86%5[,4E'_1 ?MM\NEJA503J5ZK*R?
6'4J@S0J!3EMW0'- (4G>5-=%4 0(F(MQ#05/Z,?T1R)+>9\$()JCZYQ*\5:=5,>?
MZP4.\$_ \$T5RJ!E;5S..V,:=-8[QG M&N.C>[4G\M:2B M?J#HGS_4.70F22;^'6GIAP8R&(>L>J'WHL

Q.9ZI;D80?D=FZY|^<\$/GES\$2 M(<\$B(##RJC,K"AKZ^J9X(*3F."WE0!KYYX07CSK'Y&WWHQ-49J [ZLP:N>
M^&[M'*P.5T?SNSY;UB9,90L(S&!KT;&UL+*E^I),A9KJ0.(0:[MN0HB2)#5[MS9F*MNPWS%H[C[\$20M1%3
M(P@S.!KV?&UM/+5=5UQ[!644!&S4K&E:")C)#68KF/D6>_1-219:YY*\$A"8
M0=)A1]*A05,J2\$PW5"7525P=J=>UNU53>8%" M,XGIZ6S72LR0!%)!VEPUIR:C"!HD50:"9KGF;-@_--
%A.*3TBT" K-Y%, [M M>JDI73V!#.U1M#X@>44G0#4RH?1TGT!U)HX:P.=U,45.%#H9GD:(WOVD7^
MM9)F7/G;0&:G8&VXV6D*1F@:=&2@RAX*S61):W07+NX_8LJ1TAHE06R#))-* M=ACR%4F.
<|'\$V2AEBV'0'ZZ,DU1Y=24W&,HP_T(DPGF"!\$|'T|4;&@--<*,)KP3;*\$4-
G.N9(T)AN!M/H!H?"LTD26M\SZ[QSW*)\UM:|6%8""'+,\T? MBC#760V(=7W4&@F,5K?>W9]?>D><2H?
Z^%#5\$JEZ?>|;5Z@MSD|8.(Z_RPZH MKH=" ,|G1NMZSZ_KHI='5MOS+R00JW*'03%:TRYZ5/W8^/PCJ(B'0C-
9U">+LX0XWQA+[FF:(0*%0%0K M'&X(2DA2QK(B=)2|Y:/'/&@!4-T.A6:RI'6|9]?MW6_7UH-=;QLWC9M5\$C\$3
MSW3GAP/!Z0W'(>SU3V9K'W+=TW+=L\OU=D!5V;_?2*YD4EI+2YQD*F.%K&33 M':GC+1?CT04ZA
^%D&AF@:|\$4FLFG50B^7>_% 1V*W MR\$9B^X/MM< F:U|B'0?BWS?+0)U8E\J=,SC;9W9B?*4*2MJJV1):SOXY#
\$ M-090:":00>5 ^U@/!+L@'9%T#|\A* |A& W\$|^3UL-I V^8U:#V @K-) \$0; M'|N+W16?
^8X(>@3SL; '@.PXDp.,U(Q H9D<:C/BAWM(8\$@C<0J*%D&AF7QJ M6^+;;0- #TN*?%|.#
HH60:&9BV^U(0GLDPMGB5)]=\$/KB9G!*,SHBMNQ M)4;A(& M|4Y><[L/F0%HFQ&\:HF1RML+SF|:1005M-
5);T;F&SI7!KF:'0R& M3B?, -MCKGAJ=H&@1%)K)NS8LP1X6*06@/@44+8)", G4/B5X:0*C*&4UM#HZ
M.!|,%R8-LAK494"AF6ST=A|87<9KL|J=|)^8U9_6X004+8)",WG7AB58|"&K M0"&KAXN;W-VL|K4>4&@-
&->#KR,\-MZ)V.U>Z', M9;_9KSO;|98|J?<(S07E55;+<00:2Y02C:JJ'.P5)SP90=B|T6RHM|/=|.D
M9%E|N"7*40/J_07|AC'Y|*6JH-M#NOX?4\$#L#!0 (">);5E9^76P\ (M \$T' 9 >&P0=V|R;W-
H965T'R|TR,N-65_XODYS**@^DVL0^&8I54\$-;M7*UUV%-'" M!??#((C|@C+A)4-W-
E/)4):&P,\$S1719%0|C8'+|,\'-VR5&W0@)\,U M7<\$*\$. -GK=-K3%K!W?6S|B0G.,JRH!HFDG|CFEC'8<=@?
#|&8P M%@@==V7(44ZIH5\3A*|1?4G-& MPN_4?V&7W,VGY/CHA,B<*GBAS<=8-
\$)FX"\$3GMW7P&Y3'63#/GT_=/>\$:N M#13Z1QM0I;+7KM+VU85>T01&'C:;!K4!+WG|IA,'|P|
=00@|B'MR83J0(VI MDHJ=E&W-31+&G6CH;U|L|1I;08.V0I9,I)C ').|AM*P5)-4%&6&""LU?2#'
M_=,P"DZ|45AGY*0-K3(2|:#U.W&0'2UJT*+89#",+ \$"89:HIQ|;|\$=|J.J.X M\$P|: >(&(#X(@/+/<"@L
+8))AH>F;9(1\$@#&B=8"FQ%#QS:D.(|I\$X0!.U\$ M_8:H?Y#(-
>ZF:5S7M' %AI@_0=H&U=\KH3@^#_KM5(.&:0"?-83SH2X>\JNU ML2NZP7X58>UAZ;W@|W>FH_W0?
*9JQ80F')8H&9SU486JAG>U,7+M!N9"&AR_M;IGC|PZ408#0EQ(36F_L#&Z^H,E04\$#L#!0 (">);5D/?
>=>T00_+4; M_9 >&P0=V|R;W-H965T3@ >H,:=0L06Z'TC/9;\$ M*|\$Z4.5|X0XSW-
B;S@!\KTG2T7.5&Z*':^/ A*DE*4 M9SX*@LC/25!|V7"Y_3W5Z9" YZ M>2
f>D_5E\.=T"6_<4G2G#*9<@8\$W:Z\WB%\$3**LL;7E!YEYSLP7=EP_LT4 M/B8K+S MHAF-
E;\$@^N.1WM(L,TZZ'=|K4Z_YGT;8_?|B_J'LO.|,ADAZR|_- MTD3M5|(< PG=DB)3G_G03UIW*#1^,
<|D^1<9W0U="WTVU3JU0"JF02 EN>;Y)&2E_C FXU^,K*3(*^!9\(*D_7TE64F* MUU)2)<%U_+U(!4T
80GX*R6;-&M5JJ0H^T6NK(|_%)\$TD^TW9=[#-Z^>0?> M@)2!AST0I%;)I:|T#TP|_+AN|4W56C32VGMZN
#3X#U_9H-R&_ME M?#H@QW;YIUA=:F0W-?8&_H88|*0^F(7TV2U"20AGA4#K-A!|,H7,D#B>G* MT|>40%(0?
600\ H^&V(CDL\$|,CLA-RT(3>UN:_X#PYIEDV1*Q21J72K'J/_ MZV#I/W8Q|&0
RPB#I|6PM04_V;|9T|!9M7^_BV>_Z6#WK,)S!X1+,^S(|_18 MV +_ =4"EV2,VBE^ N&R M@7!IA?! G@_IA|
0"JOV7!0NS7!E%G97L@#.+X=AS!L80E"F
M+&BL+N=B<6F&YSTLT6PV#&710%E8H=P)' ;6>B|C#M6KS\$&'7_4>,*J&V%C- MSF7CT@P0>FS0=#|,!@9MB
SL0T:ST=&1|4!&=0@'PJ3M"=|."EVH1M_H*KOU MN:R^*WB1K:(S6F&Y,5VR?^(!BG@=JI&X;|2#V!.*
(S&'0=MK(;V7-W/OC\:/DZC MM5,W#/OA>C(/1QBA-ETC>|K&=\$N%.6I5>IOZ@N=Y|+30:99VZH91/TM/PF_0
ML0=_;9I&|C1=Y8"L_ \ ;!.0T3CMUPZ@?IR=H"L=VKJASS&R/U.4!_J,YP#?G_M|ZKD%7,FTZ3?
MU3G0B\$J:#0;SE7+P7S(J9Y M4|?^%U!+ P04 " GB6U9XP76GYL# " ! \$ &0 'AL+W=0:7?*R\$.
_C3#.A7@/XIP#L#<"N ^UH+7@7P_M7FMA4
\$*U^W2|T*XD&H:3*38\$VE6(YNY*=00T*@7X^:@++7\$IP00.KCCF0(- M6Z5_ ;I4"K<@56>|IC+
(|GG94C>07E/WA#&R3^)"V"K*8S6Q-6|>;&.JHW.RHWVSVS4)9|\$ MUXDB"S0?-^##=ORH!6^C: +5R_2?
E90U6PB7DU\1U_B1|I^U|&?^>KC;Y,Z0_M65_ \M/4C,=SZ&+D^GWOV&WE4D2@%&8/!51&"
<\$XXRN|PUR48V;1XZ:8EZ0> M,ZM)DF.5TPBF5FYHY0ZLX.T?/= _YT"1XEVIAEV2+CLB.0N/5H?' :V(.|+*=,
MF@B0**R_TUQ*"G@L)\6W:!,|%WA^+< \$7XPQ6+ERNN|B/G>=61?X/:0T&| M?
_|V"!%D*Y#|\$9W|ZL0:"2^-2I=D84DV.\$@>0ML; MW9RDF(Y,'LD|K.4>_GJF;:6X5. NR<+A"X%/_?
PDOP|JE4;M:J&|3Y6|QR+ M72F|1X|\$2|I52LL^(0Z*-;"1M+%D:&6^5.PNR<+1"S&'_NE9|H|Y|GP
M=RY(#E@0ZBH|G"J907EX0GP/ M5I'(- \$E65S/UOWR;=\$EGLS/>N-YKV\$^-/UUT<(|TY?-^2=,'8PKDL(:3367
M-WB*9-G0E@,M|J*A6PF-[6%QFP"-09H% ^PMA'X:& /UOP|!_U!+ P04 M" GB6U9W_0;(VH#_#|"P_&0
'AL+W=0&4M544-GJI-J&L%M&A%0^3*\$K#BC(19+-V|4YE,|D8S@3<*:*,JJ+J
MZ1JXW,Z#. 'A>^,PVI;\$+83:KZ0968.[K.X5GX>!2L_J\$9E(0:>MYL(B0EG^B M!6W\$5P9;07-;,"H/4GZS)|?
%/(@L\$7#(C;6@^/<(2^#<.B'7|UI,-S3"G>/ MG|W?M^EC,@|4PU+RWUAARGDP#4@!:_|IP\UEN?
X4^H8GURR77|2_9|K%10/)& M&UGU8B2HF.C^Z?>^\$#L"| '\$+DEZ0' K2(X)1+QBUB79D;5HWU-!LIN26*!N-
M;0:@K4VK0FR8L(|Q911>9:@SV:TP5&S8_P>RT!J,)F=DA7NE:'!%KLF2*07\$ MQ(8L*MD(8Y?>,\\$,G'W_VA?
D4\$>WH"AC.MW:'2_NB%0W|PC;P@3Y\$LI&TU% MH6>A07!|^S#0(:\|R.0(Y"7Y*(4I-?E%=%
X|N_ \DX\!B%6;"A;\ERVZ\3K MN(+ZG(RBGT@2)6,7D%|^ SG*XU8^N",AJLW&*#_%Q-PM'S,5DB-
F#FPQP\$R<;553IK_%I*7 M5&V<;)W%9.>^T0&9+V*/QVX4B\7MD-L=@*|C5(@\B=B%|6:TZ|-%G|B\$|+0
MS04Z'/*?_MYUL|/64=3F2V5X?+H0Z7WN=|KV'=<,+9V0G*^,5)3)Z_*M=.67J5_S&I.'KY
M\D9>LJ7400DMC|S|Z;_+|\$&3(T'|2#0#0.0%6N1Y4S7XZN.&PP^,NSOM@TX
M,>-7!&=)*),3=/G>9*^,H^DAGR-HDAX AC0C5078N.W4J4EN M!Z)NTAI6A\EVT_M|K#\$Z1R4#<#K:RG-
\XF|P3#09_ \4\$#L#!0 (">);5F):L>#@, # - M_9 >&P0=V|R;W-H965TQW' M|JT9?
Q8!@%0044A%WPBDC+NF*;P (BRN6_04/9DS'F&INGOABI@#|A-2%)IU
MRVJ9\$2;4<'K)V(0|/;:4(:\$PX4@LHPCS/T,(V;IOU(S-P"-9!%(F\$X0Q@N8

M@GR*)USUS\$%)0%001A%'.9]8U#KCCH:GP'^\$UB+K3;23F:/>0.V.\;EIX0 MA.!)K8#5WPIN(ORUD)K&
[TS3R\$-JXG9[HWZ7>=>9EC+0M_\$%\&?;-C(!_F M>I*G*1[;^"IF?
IM;S6"B27[1.L6T%]I9"LB@CJQE\$A*;;^"7+PQ9;Z103ZAF
M_I;0.\$"P,X)]:H1&1FB<&J&9\$1+K9NH]29R+)79ZG*T1UVBEIAM)A.VRA>A M>IU,)5=/(B>))9TPEI@LR"P\$-A
IT"4:~#[15<0A&M-T*>J:7K@,0G%9P5Y MFKKHXNPS.D.\$HF\!6PI,?=\$SI9J2C:]+/PP#5_-\$Y&#XS*0* 1]
<\$0X+0E M_.L20JE2D>>COLG'L%XJ.(7X"MG6%U2WZHV"^=R>3K>+[/Q?]-\$_111)AITO
M#C01LP_HW1%*)\$S>JU?91_LKY>>]PJ.OA\$C*BI]*MXH%M<;8%?\$V(.^H78X M
7P%AG/^J=:R;HKR7J686Z78J"*QG0HU\@HURM2W7U\LBX)(%/ "U48ND1=@ MOH"BPJ2:K413?
TA6CM4S5]09/HIPCR)&^XCFM?4*V0';S/TVR_V>8J]YU-Y1
MA)LBFEN(6KMF0[6XCSK@KY7[:Y7[FSR>XRB^<8M\E5+?^SY5*>96*3;J2&PG
M^T\^V/W/'/:55:H2C&W2K%116(!>KD>I\ P(Y7J0G>PE0IYG:.[J/[B()) MU-PZ
D:@LJ#/W@)Y;\$EE^L'/1/_C_2 YU;X9'] :ZM[6"<5==!]+3^ZM>I=X M4\$DG5*
0YBJ4==56^R%/S^=I1[(X.8#.F%3'V:09J"L-< U0S^>,R4U'!\@0 M2);5ES?-NE+P, /H+ 9 > &P0=V|R:W-
H965T M0,WITPXT:B>09*V-S&LP1I S4;WI;:W#%@!YV@%!#0@> GI[&\$-") JH5<#>D UT*!\!
M9>INE7LI7\$P-C49*;HBRULAF/TKU2S3JQ82MD[E1^)OF: MO"1,D.^97&LJ4CUR#09HW;A)' \Z\ "X*
MTZ@3W*LS"3H)YU"F/MF6NB'KM1;/H.14%36#LX-FF0=V \$[UZX0^ \VT:'Y(L
M/B39[\$!D.Z01:U;CU\4>32BG(@^"M=V6,220+T"1T-];;-9-.PN>NRB')XHIL M4)+9F^TF\H>#H#]R;
[:E/I#+';G[C=S]3KG/\X(RA1>D(4E&U0K:!. [E8:W MF\+T48NXLNA061S[0S]\8#;K(MI)<-
D..A,\$+P#DD6# Y6L ?N85T=R...[,-&]N\$SMC\$>V:;>Q N/ M E?W9@_F) M?SKU6^9C;&RK/00/?
=457^#&9D(3#DMTY9T,L7!4U6E6 R.+LI5:2(-6?F9 M87,.RAK@_Z64YGY@'33M?00;4\$L#!!0 (">);5DPR-
&+D0(+8& 9 M >&P0=V|R:W-H965T'+@&JV!3VY#VW^ :4)1D]&/27L#70N?XG(M)"=="
MWJL,0)'/ (N=JXF1;E0>NJ^("JH&H@2_*ZF0!=48RI6K2@DTL: B=WW/&[L% M9=R)0CLWEU\$H*ITS#G-
)5%445#Y=02[6\$V?H/\$_E 6Z.G]D_6> H94D53\$7^DR4ZFSAG#DD@I56N;\7Z M,[1^K,18Y,H^R;K-
]1P25TJ+H@6C@H+QYDT?VSIL 'S_!8#? OSW H(6\$%BC MC3)K:T8UC4(IUD2:;&0S UL;BT8WC)NON-
250GB=+2HE@H>*N":7-?X5.1P M!IJR7!V1\$ (%LXE(R51"PC1.7-]B4I1GJAC MLK\5AZY&T69K-
VX%7C4" 1<\$?A/U@_R#8^)[_HA&<5R2];N1L-A?K=Y[FA&_73F9M\H4H;P\3!JZE MUN!\$!W0#L7?
9Y_D_66TY#SKGP60LT1QDC(;QPIMS@0<')X5_.8:<#--8L%K MD!J20BHTU\$/P/P/-
#M]ZT]U;6ENYI1W0TJN[97TK+QDF?SE&0@0,= MG6]E;>D\]72>0EY?^E28 X7%10.-
'900G\$FL; ,I0)>A0)\0XC0[8AM4L;] M*8U2=Z.KF([^E6QE :K]D0G&^0#JBV@?
5ABHQ+XGY]QC^R9Q.BC4BM/;.:7*6:9<%\$-W MKE3^P?.*Z9RFI+C(=^_K M[?
A9"9R[GE7T<@_1BTX'P80\$P_W\$]^EC4GW[-) ?0U&IJ-%=D](?U.X//>=4
MZQC6*4:++#1M0V5"!R'W.G9R9YV,&@Y>Z[@B5\$Y;N(MTUSANY5A3P:.)EH MZSEP34#KDY0Z#X0/W3'A;''
(9L!*2,KXRX2X\$IAG/I*/TA:03^A I'@WLFQY< M8Y5.RD0FR]PF@_F=5*=0 74/##+.&X-
=UP1&@YPH1:6XUIWRY#X!'*J]MTJ MUPYGDJS\
[J7;\$LJ#3C+)9\$QED\9WZ]\HP&D"=B2;S>&HLMF#4*DLU8V8D5DF M2.FA9E0-+3NEG-="#>A[LJ&]3-
96KJPIT32UH:II9\$P']-?5C/:Z;/@B72=G M#YGM-##\$64?JHW>2)JP9=E?)HT!3-
W'U4F> \]5'SF8BI6;P>R<<#4C-<^:9 M9(\Z&Y3*5 >H=)T'*A6;KD=^2I+?T:6JR VF9X)Z[1^CYW\ [SC
HJ"5\WK60 MD&?YQ8Z#WFM9+N\JVX:M'JM=Q:&0#P&D^\$QF#R*FNP?OLD@.GR/U:[TP\$WV
M7NW. AR3 C&8!ZD2: :4ZYM7#>VK4W4@=>#H?L-7C=XF]29+!A73*2].8MC M*I[L7K6\
(A/14KZAK\^/:4(67-TUX-!MVU]I5:9IU)QU Q-1G=6V0\#P]%;X M?C?
1N9B(Z9+&XZHK9Y.RZ>B&SEI]@+'-7)?ZG M\?31\1@,\]:W(GV4TT<:\$/N\ 2.*[*N-Y0\$&
MM@I8[4!^>QZH*3LG"&!5,6_8%8PC480A4(OV&@U#9'9"^<K7![M*@B"*[A@ M=@=!@"P->((Y@
<8\$&0E, !K>>15S^G0/8 U: . 4\$L#!!0 (">);5F7 MBKL!0 A" \ \!X;"W;W)K8F]0:RYX;6S\$FEU0VS84
MA0*X9MUP#K;^DH;Q 'RN07(VJ#ND+;_8S8E0 MXNC#]*,C\3SDH4Z>M'F8:~W ?
E2ELI/!LJY70\AS9>BX09/01+*9EK4_': M:9K%T*Z,X(5="E%7Y3
[:C;)AQ:4:G)YLVKHS0W]#UR*OI59N9[0C7HHG^~MX MN\>I94S63+H_B_@%52R4J^B&(R&
V87>JG0[61+UK50)SF1I?E9#!> M'[@7II;YSNYI" F5SVRWI^:S+IR]3 :9R#4XE\;6W1E=^]PQ/@IW\GJKJ?6U
M+&MA+GDM_C*Z64FU:~)M05S'T+J.+P^9S'<1C\W_ "J.=SF8M+G3>54/4ZCD:4 M+;"R2[FR_Z9X)2:~#"" TH3'L]
[@=NB06UU0[*BY0YENZ N2DZ/\$H450AE1<'< M?U:7LG Y8!YD!""C T)^BSS(&\$&#&X&-8/\(;A03]HW:>G ?
=0'X@>/V^4?K/W+KKXW M\I&7+10CJF WZE'X&7N\$40:(%G.3G#03N3Y2K;3:"N(8*H78*;?NQHJ !KEC
M3"R/:;WSAZ4N"V'L;]U]K9]]-J2,,;\$S.K;WYWR=ZRK7DMU.*&-DBS&Q+FZU M6KQW(Z:*78I9[5,A/8R)-7"C-
E4HX,0> S:3:>;Z0#;,\$-KAQ W^U:'^4G5DKPA2&1# F-L&T MF5G007\$GL;0'K=P:H=P?\$>=^*/E@
!?; .S<;*H-=&<%Y!/:;% MP@^CB301\$6MBG !?P^EC(EM\$U+;H0+^YQI [6\$@7\$;\$N]DFV)WK(!&Q04+7
M]D81:20BULBNX'H1D4TB8I0TF:X7\$IDE(C;+C0+Z"&.DF)A8,?[,EKV[%#67 M94B'S!
(3FP4+T"\".Q,@L;,%9]@GP/3LK"ND/I6-8LR(VRW[,J6N]\#&166)B MLT#,L "(3!,3FP9C!L\F,DU; !J,F?
B8R#@QL7'PX"R(K).3&P=C!E\$&WDG M/F1MZU0JEZ>1?) (#U;9>,Y*/B2R4\$%L(8+;YW<=\$DJ(+02C&>3-
!%DH.=3\ MIL/T>WH"UTZ(+800_9Z>(< LEQ!;"F\$%/109*J.<[Z]GBZX#('>6ERT3KIL(2 M58(LE!;!Z"=F-
R!JW+]"1'7DVJU796=/'1!9*B"W45^7N';PG2\$()=5EMWU1\
M)VVF2\$(I=9%M/V8TZNJ2/S&1A%+JJ1#""#!=SD832MUB Z:"W&
M87Z9_NN7+%,DH9180C":X4V'2_B'*KIUSZ:0]!1)*"66\$,2,@F@B":742_OP MI@?
11!)*WT)"_9A7U:KT,9&%4F(+;55:MT<@_OLER\$(9L85V,/T1R'7C8R(+ M9<06\E=C>T<<69)/1BR?GK*U'T@?
\$ \DG(Y8/Q RR>H;DDU'/@/HJ[+ _ZCX^)MY)-1SX#Z,3?Q]# 'A&V3\$ \H&8X4U'\LF(Y;.[8A&D(A\3R2=
[ZW<)?,PPFD@^ MV9N0_P3^ \5\E1/(Y(I8/C.8%)S&1?([(5X.VWM/H-= 1,M!19Z!A=[(]/2G\$ MW'7*XI-
KWKK].2_S.\/:C_6;,\$G:3@#G35E>N'V?U:WFO>8E\LT+ *?_ 5!+ M P04 " GB6U9K&U05SP" "0*@_&
'AL+U]R96Q5+W=00,UYOVR'IJ09=%MZ Y*>?- DBL>A[=U/ M2!?) ([.83?
%9R5%_8/P0]3'EWQHQUW*KM]70:~?Q\ .IK*K=.: _ZKJL= G8 MEKNNSZ?SD4TW'-
000!RV==^NW]MMKF6YC'JXG5\$]/=[.7+Q^]?E_)G:;S7Z= M?W?K/\=-&0\ON/[HA0>RRWFL%J ML,WJCJH_#]??

=I;YLTUUY"<"007U%[*]!746 KUE\K!-H+>@WD*AMZ#>0J"WH-Y"H+>@WD*AMZ#> M0J"WH-Y"H+>@WD*AMZ+>2J"WHMY*H+>BWDJ@MTY>EA#HK:BW\$NBMJ+<2Z*VH MMQ+HK:BW\$NBMJ+<2Z*VHMQ+H;:BW\$>AMJ+<1Z&VHMQ'H;:BW\$>AMDY?='H; MZFT\$>A0J;01Z&^IM!'H;ZFT\$>A0J;01Z.^KM!'H[ZNT\$>C0Jf01Z.^KM!'H[MZNT\$>00D8R6!WHYZ,X'>CGH[@=Z.>CN!WHYZ,X'>@7H'@=Z!>@>!WH%Z!X'> M@7H'@=Z!>@>!WH%Z!X'>,? G9A\$#00+V#0.] 08- [T"]@T#0!05N"/1N4.^& M0.\&]6Y^4N\R?AURN?9\K 'Z/TGU>#XW7R]_67[0G-R7"] [U;45Y^@M02P,\$ M% @)XEM64!K%[H @ QBD !, !;0V\N=&5N=%]4>7!E&UL MS=I-3L,P\$ 7@JU39HL;U;P%1-L 66' !DTS;J\$ELV0;*[7%20)!!2H2;].H MM3U0XI&^5< NGCW%R;9K^[@HUBGY4\9BM;:;QM)YZO/*TH7.IOPUK)BWU<;N MB(G9S+*#]8GZ-\$U#C>+ \)]*6]J%-DZMM_CDVKE\4@=I83"YV&X>L16&];Y0* MIKS.'00Z4\KT-;';)\<[<=WX>)0W%.S+A&'E^X#7/%\$)3T^36AG1MN[R+ M;5L6TW-+L=Q?XHL>W7+95%2[ZJ'+1\KH]DZKHE2UY:[HD? [DU.^8=I]\H/S MQS+[- 0/.V^!\S!;+]/NXMY\$,IZ<^Z*0FOVO^)Z820_?C1,NZ;ZA\GY>I]< MV(SSB&0\''['V?70^7?0B0/B1('PJD#PW2AP'I8P[205%('R<@?? 92B,H MHG(44CF*J1P%58ZB*D=AE:.XRE%@Y2BR"A19!8JL D56@2*K0)%5H,@J4&05 M*+(*%D%BJP215:) (JM\$D56BR"I19)4HLDH4626*K!)%5HDBJT*15:'(JE!D M52BR*A19%8JL'D56A2*K0I%5H);5E\$"PET[@ "L" 1 " : \ !D;V-0);5F97)PC\$ 8)PG 3 M " &UL4\$L! A0#% @)XEM6;WB M-B;D!0 XAX !@ ("!#0@ 'AL+W=0);5E"F:Q);P8 ,<: 8 M " @2<. !X;"]W;W)K&P0=V]R:W-H965T M&UL4\$L! A0#% @)XEM60VNPNI!@ EAP !@ M ("! 1@ 'AL+W=0);5E03>.A< D -E0 8 " @:L> !X;"]W;W)K M&P0=V]R:W-H965T&UL4\$L! M A0#% @)XEM6=HQ\$AZT"0 70< !@ ("!<# 'AL M+W=0);5G98#AI-A< M " !+ 8 " @5HZ !X;"]W;W)K&P0=V]R:W-H965T&UL4\$L! A0#% @)XEM64 Y MI1H,"0 RAD !D ("!EP 'AL+W=0&P0=V]R:W-H965T);5DU./'N.04 +4- 9 " @210 !X;"]W;W)K&UL4\$L! A0#% @)XEM62;RTS1^ P X < !D M ("!E'0 'AL+W=0((1 #52@ &0 @(%)> &P0 M=V]R:W-H965T);5F#/6%G[0D M *@: 9 " @0** !X;"]W;W)K&UL4\$L! A0#% @)XEM63%0>"XM P ^08 !D ("! M)I0 'AL+W=0+VRV;,# C" &0 @(&*EP >&P0=V]R:W-H965T);5EUL&UL4\$L! A0#% M @)XEM6966I# ;!P A1(!D ("!!ZD 'AL+W=0&P0=V]R:W-H965T) M;5G@'6HT!P4 &\$. 9 " @&UL4\$L! A0#% @)XEM63V)JR"; P A0@ !D M ("!!=D 'AL+W=0\$% #0\$@ &0 @('6W >&P0=V]R M:W-H965T);5G,E{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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= { };Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=(window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e;Show.hideAR=function() {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p; if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerHTML=p+a.innerHTML.substring(1)}} XML 91 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited {

```

color: black; text-decoration: none; } /* table */ .report { background-color: white;
border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial,
san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */
.report th { background-color: #acf; color: black; font-weight: bold; text-align:
center; } .report th.void { background-color: transparent; color: #000000; font: bold
10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left;
vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-
wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width:
200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover {
background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf;
color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color:
#f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; }
.report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro,
.report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid
black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black;
} /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for
numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; }
.report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /*
styles for text types */ .report .text { text-align: left; white-space: normal; }
.report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display:
none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text
.small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes {
font-size: 1em; } XML 93 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3
html2363521false610false8 falsefalseR1.htm00000001 - Document -
CoverSheethttp://www.quincetx.com/role/CoverCoverCover1 falsefalseR2.htm00000002 -
Statement - Condensed Consolidated Balance Sheets
(Unaudited)Sheethttp://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited/
Consolidated Balance Sheets (Unaudited)Statements2 falsefalseR3.htm00000003 - Statement -
Condensed Consolidated Balance Sheets (Unaudited)
(Parenthetical)Sheethttp://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaud/
Consolidated Balance Sheets (Unaudited) (Parenthetical)Statements3
falsefalseR4.htm00000004 - Statement - Condensed Consolidated Statements of Operations
and Comprehensive Loss
(Unaudited)Sheethttp://www.quincetx.com/role/CondensedConsolidatedStatementsofOperations/
Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Statements4
falsefalseR5.htm00000005 - Statement - Condensed Consolidated Statements of Stockholders'
Equity
(Unaudited)Sheethttp://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholder/
Consolidated Statements of Stockholders' Equity (Unaudited)Statements5
falsefalseR6.htm00000006 - Statement - Condensed Consolidated Statements of Cash Flows
(Unaudited)Sheethttp://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUn/
Consolidated Statements of Cash Flows (Unaudited)Statements6 falsefalseR7.htm00000007 -
Disclosure -
OrganizationSheethttp://www.quincetx.com/role/OrganizationOrganizationNotes7
falsefalseR8.htm00000008 - Disclosure - Summary of Significant Accounting
PoliciesSheethttp://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesSummary
of Significant Accounting PoliciesNotes8 falsefalseR9.htm00000009 - Disclosure - Fair
Value MeasurementsSheethttp://www.quincetx.com/role/FairValueMeasurementsFair Value
MeasurementsNotes9 falsefalseR10.htm00000010 - Disclosure - Cash, Cash Equivalents and
InvestmentsSheethttp://www.quincetx.com/role/CashCashEquivalentsandInvestmentsCash, Cash
Equivalents and InvestmentsNotes10 falsefalseR11.htm00000011 - Disclosure - Balance Sheet
ComponentsSheethttp://www.quincetx.com/role/BalanceSheetComponentsBalance Sheet
ComponentsNotes11 falsefalseR12.htm00000012 - Disclosure -
LeasesSheethttp://www.quincetx.com/role/LeasesLeasesNotes12 falsefalseR13.htm00000013 -
Disclosure - Stockholders'
EquitySheethttp://www.quincetx.com/role/StockholdersEquityStockholders' EquityNotes13
falsefalseR14.htm00000014 - Disclosure - Stock-Based
CompensationSheethttp://www.quincetx.com/role/StockBasedCompensationStock-Based
CompensationNotes14 falsefalseR15.htm00000015 - Disclosure - Long-term
DebtSheethttp://www.quincetx.com/role/LongtermDebtLong-term DebtNotes15
falsefalseR16.htm00000016 - Disclosure - Income
TaxesSheethttp://www.quincetx.com/role/IncomeTaxesIncome TaxesNotes16
falsefalseR17.htm00000017 - Disclosure - Net Loss Per
ShareSheethttp://www.quincetx.com/role/NetLossPerShareNet Loss Per ShareNotes17
falsefalseR18.htm00000018 - Disclosure - Business
CombinationSheethttp://www.quincetx.com/role/BusinessCombinationBusiness
CombinationNotes18 falsefalseR19.htm00000019 - Disclosure - Intangible

```

[AssetsSheethttp://www.quincetx.com/role/IntangibleAssetsIntangibleAssetsNotes19falsefalseR20.htm0000020](http://www.quincetx.com/role/IntangibleAssetsIntangibleAssetsNotes19falsefalseR20.htm0000020) - Disclosure - Subsequent
[EventsSheethttp://www.quincetx.com/role/SubsequentEventsSubsequentEventsNotes20falsefalseR21.htm9954471](http://www.quincetx.com/role/SubsequentEventsSubsequentEventsNotes20falsefalseR21.htm9954471) - Disclosure - Summary of Significant Accounting Policies
(Policies)Sheethttp://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies
of Significant Accounting Policies
(Policies)Policieshttp://www.quincetx.com/role/SummaryofSignificantAccountingPolicies21falsefalseR22.htm9954472 - Disclosure - Fair Value Measurements
(Tables)Sheethttp://www.quincetx.com/role/FairValueMeasurementsTablesFair Value
Measurements (Tables)Tableshttp://www.quincetx.com/role/FairValueMeasurements22falsefalseR23.htm9954473 - Disclosure - Cash, Cash Equivalents and Investments
(Tables)Sheethttp://www.quincetx.com/role/CashCashEquivalentsandInvestmentsTablesCash,
Cash Equivalents and Investments
(Tables)Tableshttp://www.quincetx.com/role/CashCashEquivalentsandInvestments23falsefalseR24.htm9954474 - Disclosure - Balance Sheet Components
(Tables)Sheethttp://www.quincetx.com/role/BalanceSheetComponentsTablesBalance Sheet
Components (Tables)Tableshttp://www.quincetx.com/role/BalanceSheetComponents24falsefalseR25.htm9954475 - Disclosure - Leases
(Tables)Sheethttp://www.quincetx.com/role/LeasesTablesLeases
(Tables)Tableshttp://www.quincetx.com/role/Leases25falsefalseR26.htm9954476 -
Disclosure - Stock-Based Compensation
(Tables)Sheethttp://www.quincetx.com/role/StockBasedCompensationTablesStock-Based
Compensation (Tables)Tableshttp://www.quincetx.com/role/StockBasedCompensation26falsefalseR27.htm9954477 - Disclosure - Long-term Debt
(Tables)Sheethttp://www.quincetx.com/role/LongtermDebtTablesLong-term Debt
(Tables)Tableshttp://www.quincetx.com/role/LongtermDebt27falsefalseR28.htm9954478 -
Disclosure - Net Loss Per Share
(Tables)Sheethttp://www.quincetx.com/role/NetLossPerShareTablesNet Loss Per Share
(Tables)Tableshttp://www.quincetx.com/role/NetLossPerShare28falsefalseR29.htm9954479 -
Disclosure - Business Combination
(Tables)Sheethttp://www.quincetx.com/role/BusinessCombinationTablesBusiness Combination
(Tables)Tableshttp://www.quincetx.com/role/BusinessCombination29falsefalseR30.htm9954480 - Disclosure - Intangible Assets
(Tables)Sheethttp://www.quincetx.com/role/IntangibleAssetsTablesIntangible Assets
(Tables)Tableshttp://www.quincetx.com/role/IntangibleAssets30falsefalseR31.htm9954481 -
Disclosure - Organization
(Details)Sheethttp://www.quincetx.com/role/OrganizationDetailsOrganization
(Details)Detailshttp://www.quincetx.com/role/Organization31falsefalseR32.htm9954482 -
Disclosure - Summary of Significant Accounting Policies
(Details)Sheethttp://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesDetails
of Significant Accounting Policies
(Details)Detailshttp://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies
falsefalseR33.htm9954483 - Disclosure - Fair Value Measurements - Additional Information
(Details)Sheethttp://www.quincetx.com/role/FairValueMeasurementsAdditionalInformationDet
Value Measurements - Additional Information (Details)Details33falsefalseR34.htm9954484
- Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities
(Details)Sheethttp://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssets
Value Measurements - Schedule of Financial Assets and Liabilities (Details)Details34
falsefalseR35.htm9954485 - Disclosure - Fair Value Measurements - Schedule of Changes in
Present Value of Acquisition Related Accrued Earnouts of Contingent Consideration
Liability
(Details)Sheethttp://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPreser
Value Measurements - Schedule of Changes in Present Value of Acquisition Related Accrued
Earnouts of Contingent Consideration Liability (Details)Details35
falsefalseR36.htm9954486 - Disclosure - Fair Value Measurements - Schedule of
Quantitative Information about Fair Value Measurements
(Details)Sheethttp://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeIn
Value Measurements - Schedule of Quantitative Information about Fair Value Measurements
(Details)Details36falsefalseR37.htm9954487 - Disclosure - Fair Value Measurements -
Schedule of Fair Value of the Level 3 EIB Debt
(Details)Sheethttp://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueofthel
Value Measurements - Schedule of Fair Value of the Level 3 EIB Debt (Details)Details37
falsefalseR38.htm9954488 - Disclosure - Cash, Cash Equivalents and Investments -
Schedule of Fair Values of Cash, Cash Equivalents, and Short-Term Investments Measured
at Fair Value on Recurring Basis
(Details)Sheethttp://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFa
Cash Equivalents and Investments - Schedule of Fair Values of Cash, Cash Equivalents,

[and Short-Term Investments Measured at Fair Value on Recurring Basis \(Details\)Details38 falsefalseR39.htm9954489 - Disclosure - Cash, Cash Equivalents and Investments - Additional Information \(Details\)Sheethttp://www.quincetx.com/role/CashCashEquivalentsandInvestmentsAdditionalIn](#)
[Cash Equivalents and Investments - Additional Information \(Details\)Details39 falsefalseR40.htm9954490 - Disclosure - Cash, Cash Equivalents and Investments - Schedule of Available-for-Sale Securities \(Details\)Sheethttp://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAv](#)
[Cash Equivalents and Investments - Schedule of Available-for-Sale Securities \(Details\)Details40 falsefalseR41.htm9954491 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets \(Details\)Sheethttp://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpense](#)
[Sheet Components - Schedule of Prepaid Expenses and Other Current Assets \(Details\)Details41 falsefalseR42.htm9954492 - Disclosure - Balance Sheet Components - Additional Information \(Details\)Sheethttp://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDe](#)
[Sheet Components - Additional Information \(Details\)Details42 falsefalseR43.htm9954493 - Disclosure - Balance Sheet Components - Schedule of Other Assets \(Details\)Sheethttp://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDe](#)
[Sheet Components - Schedule of Other Assets \(Details\)Details43 falsefalseR44.htm9954494 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net \(Details\)Sheethttp://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEqu](#)
[Sheet Components - Schedule of Property and Equipment, Net \(Details\)Details44 falsefalseR45.htm9954495 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities \(Details\)Sheethttp://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpense](#)
[Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities \(Details\)Details45 falsefalseR46.htm9954496 - Disclosure - Balance Sheet Components - Schedule of Accrued Severance \(Details\)Sheethttp://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedSeveran](#)
[Sheet Components - Schedule of Accrued Severance \(Details\)Details46 falsefalseR47.htm9954497 - Disclosure - Leases - Additional Information \(Details\)Sheethttp://www.quincetx.com/role/LeasesAdditionalInformationDetailsLeases -](#)
[Additional Information \(Details\)Details47 falsefalseR48.htm9954498 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases \(Details\)Sheethttp://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInform](#)
[- Schedule of Supplemental Balance Sheet Information Related to Leases \(Details\)Details48 falsefalseR49.htm9954499 - Disclosure - Stockholders' Equity \(Details\)Sheethttp://www.quincetx.com/role/StockholdersEquityDetailsStockholders' Equity](#)
[\(Details\)Detailshttp://www.quincetx.com/role/StockholdersEquity49 falsefalseR50.htm9954500 - Disclosure - Stock-Based Compensation - Additional Information - General \(Details\)Sheethttp://www.quincetx.com/role/StockBasedCompensationAdditionalInformationGer](#)
[Based Compensation - Additional Information - General \(Details\)Details50 falsefalseR51.htm9954501 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan \(Quince\) - General \(Details\)Sheethttp://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlan](#)
[Based Compensation - 2019 Equity Incentive Plan \(Quince\) - General \(Details\)Details51 falsefalseR52.htm9954502 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan \(Quince\) - Stock Options \(Details\)Sheethttp://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlan](#)
[Based Compensation - 2019 Equity Incentive Plan \(Quince\) - Stock Options \(Details\)Details52 falsefalseR53.htm9954503 - Disclosure - Stock-Based Compensation - Schedule of Activity for Stock Options \(Details\)Sheethttp://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforSt](#)
[Based Compensation - Schedule of Activity for Stock Options \(Details\)Details53 falsefalseR54.htm9954504 - Disclosure - Stock-Based Compensation - RSUs \(Details\)Sheethttp://www.quincetx.com/role/StockBasedCompensationRSUsDetailsStock-Based](#)
[Compensation - RSUs \(Details\)Details54 falsefalseR55.htm9954505 - Disclosure - Stock-Based Compensation - Schedule of RSUs and RSAs \(Details\)Sheethttp://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDe](#)
[Based Compensation - Schedule of RSUs and RSAs \(Details\)Details55 falsefalseR56.htm9954506 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan \(Novosteo\) \(Details\)Sheethttp://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlan](#)
[Based Compensation - 2019 Equity Incentive Plan \(Novosteo\) \(Details\)Details56 falsefalseR57.htm9954507 - Disclosure - Stock-Based Compensation - 2022 Inducement Plan](#)

~~(Details)Sheet<http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetail>
Based Compensation - 2022 Inducement Plan (Details)Details57 falsefalseR58.htm9954508 -
Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense
(Details)Sheet<http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedComp>
Based Compensation - Schedule of Stock-Based Compensation Expense (Details)Details58
falsefalseR59.htm9954509 - Disclosure - Stock-Based Compensation - Employee Stock
Purchase Plan
(Details)Sheet<http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePl>
Based Compensation - Employee Stock Purchase Plan (Details)Details59
falsefalseR60.htm9954510 - Disclosure - Long-term Debt - Additional Information
(Details)Sheet<http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetailsLong>
term Debt - Additional Information (Details)Details60 falsefalseR61.htm9954511 -
Disclosure - Long-term Debt - Schedule of Future Minimum Principal Payments
(Details)Sheet<http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalP>
term Debt - Schedule of Future Minimum Principal Payments (Details)Details61
falsefalseR62.htm9954512 - Disclosure - Income Taxes
(Details)Sheet<http://www.quincetx.com/role/IncomeTaxesDetailsIncomeTaxes>
(Details)Details<http://www.quincetx.com/role/IncomeTaxes62> falsefalseR63.htm9954513 -
Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss
Per Share
(Details)Sheet<http://www.quincetx.com/role/NetLossPerShareScheduleofComputationofBasicand>
Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share
(Details)Details63 falsefalseR64.htm9954514 - Disclosure - Net Loss Per Share - Schedule
of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss
Per Share
(Details)Sheet<http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotential>
Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares Excluded from
Calculation of Diluted Net Loss Per Share (Details)Details64 falsefalseR65.htm9954515 -
Disclosure - Business Combination - Additional Information
(Details)Sheet<http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetail>
Combination - Additional Information (Details)Details65 falsefalseR66.htm9954516 -
Disclosure - Business Combination - Schedule of Fair Value of the Total Purchase
Consideration Transferred
(Details)Sheet<http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTo>
Combination - Schedule of Fair Value of the Total Purchase Consideration Transferred
(Details)Details66 falsefalseR67.htm9954517 - Disclosure - Business Combination -
Schedule of Fair Values of Assets Acquired and Liabilities Assumed
(Details)Sheet<http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAsset>
Combination - Schedule of Fair Values of Assets Acquired and Liabilities Assumed
(Details)Details67 falsefalseR68.htm9954518 - Disclosure - Intangible Assets - Schedule
of Carrying Amount of Indefinite Lived Intangible Asset
(Details)Sheet<http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofInde>
Assets - Schedule of Carrying Amount of Indefinite Lived Intangible Asset
(Details)Details68 falsefalseR69.htm9954519 - Disclosure - Intangible Assets - Schedule
of Carrying Amount of Finite-Lived Intangible Asset
(Details)Sheet<http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFini>
Assets - Schedule of Carrying Amount of Finite-Lived Intangible Asset (Details)Details69
falsefalseR70.htm9954520 - Disclosure - Intangible Assets - Additional Information
(Details)Sheet<http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetailsIn>
Assets - Additional Information (Details)Details70 falsefalseR71.htm9954521 - Disclosure
- Intangible Assets - Schedule Carrying Amount of Goodwill
(Details)Sheet<http://www.quincetx.com/role/IntangibleAssetsScheduleCarryingAmountofGoodw>
Assets - Schedule Carrying Amount of Goodwill (Details)Details71
falsefalseR72.htm9954522 - Disclosure - Subsequent Events
(Details)Sheet<http://www.quincetx.com/role/SubsequentEventsDetailsSubsequentEvents>
(Details)Details<http://www.quincetx.com/role/SubsequentEvents72> falsefalseAll
ReportsBookAll Reports qncx-20240930.htmqncx-20240930.xsdqncx-20240930_cal.xmlqncx-
20240930_def.xmlqncx-20240930_lab.xmlqncx-20240930_pre.xml qncx-20240930_g1.jpgqncx-
20240930_g2.jpgqncx-20240930_g3.jpgqncx-20240930_g4.jpgqncx-20240930_g5.jpg
<http://fasb.org/us-gaap/2023><http://xbrl.sec.gov/dei/2023>truetrue JSON 96 MetaLinks.json
IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "qncx-20240930.htm": { "nsprefix":
"qncx", "nsuri": "http://www.quincetx.com/20240930", "dts": { "inline": { "local": {
"qncx-20240930.htm" } }, "schema": { "local": { "qncx-20240930.xsd" }, "remote": {
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-
linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-
2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd",~~

"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
"https://xbrl.sec.gov/country/2023/country-2023.xsd",
"https://xbrl.sec.gov/dei/2023/dei-2023.xsd"] }, "calculationLink": { "local": ["qncx-20240930_cal.xml"] }, "definitionLink": { "local": ["qncx-20240930_def.xml"] },

"labelLink": { "local": ["qncx-20240930_lab.xml"] }, "presentationLink": { "local": ["qncx-20240930_pre.xml"] } }, "keyStandard": 289, "keyCustom": 63, "axisStandard": 22, "axisCustom": 1, "memberStandard": 33, "memberCustom": 24, "hidden": { "total": 7, "http://fasb.org/us-gaap/2023": 2, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 236, "entityCount": 1, "segmentCount": 61, "elementCount": 536, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 808, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.quincetx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R3": { "role": "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R4": { "role": "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-

US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-44", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-44", "name": "us-gaap:SharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.quincetx.com/role/Organization", "longName": "0000007 - Disclosure - Organization", "shortName": "Organization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.quincetx.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.quincetx.com/role/FairValueMeasurements", "longName": "0000009 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.quincetx.com/role/CashCashEquivalentsandInvestments", "longName": "0000010 - Disclosure - Cash, Cash Equivalents and Investments", "shortName": "Cash, Cash Equivalents and Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span",

"div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.quincetx.com/role/BalanceSheetComponents", "longName": "0000011 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.quincetx.com/role/Leases", "longName": "0000012 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.quincetx.com/role/StockholdersEquity", "longName": "0000013 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.quincetx.com/role/StockBasedCompensation", "longName": "0000014 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.quincetx.com/role/LongtermDebt", "longName": "0000015 - Disclosure - Long-term Debt", "shortName": "Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.quincetx.com/role/IncomeTaxes", "longName": "0000016 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div",

"body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.quincetx.com/role/NetLossPerShare", "longName": "0000017 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.quincetx.com/role/BusinessCombination", "longName": "0000018 - Disclosure - Business Combination", "shortName": "Business Combination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.quincetx.com/role/IntangibleAssets", "longName": "0000019 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.quincetx.com/role/SubsequentEvents", "longName": "0000020 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.quincetx.com/role/FairValueMeasurementsTables", "longName": "9954472 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R23": { "role":

"http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsTables", "longName": "9954473 - Disclosure - Cash, Cash Equivalents and Investments (Tables)", "shortName": "Cash, Cash Equivalents and Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "qncx:ScheduleOfCashCashEquivalentsAndInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "qncx:ScheduleOfCashCashEquivalentsAndInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.quincetx.com/role/BalanceSheetComponentsTables", "longName": "9954474 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "qncx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "qncx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.quincetx.com/role/LeasesTables", "longName": "9954475 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "qncx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "qncx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.quincetx.com/role/StockBasedCompensationTables", "longName": "9954476 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.quincetx.com/role/LongtermDebtTables", "longName": "9954477 - Disclosure - Long-term Debt (Tables)", "shortName": "Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.quincetx.com/role/NetLossPerShareTables", "longName": "9954478 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-

gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.quincetx.com/role/BusinessCombinationTables", "longName": "9954479 - Disclosure - Business Combination (Tables)", "shortName": "Business Combination (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.quincetx.com/role/IntangibleAssetsTables", "longName": "9954480 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.quincetx.com/role/OrganizationDetails", "longName": "9954481 - Disclosure - Organization (Details)", "shortName": "Organization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R32": { "role": "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.quincetx.com/role/FairValueMeasurementsAdditionalInformationDetails", "longName": "9954483 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-82", "name": "us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities", "longName": "9954484 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities (Details)", "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34",

"firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } },
"R35": { "role":
"http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcqu
"longName": "9954485 - Disclosure - Fair Value Measurements - Schedule of Changes in Present Value of Acquisition Related Accrued Earnouts of Contingent Consideration Liability (Details)", "shortName": "Fair Value Measurements - Schedule of Changes in Present Value of Acquisition Related Accrued Earnouts of Contingent Consideration Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettl
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettl
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R36": { "role":
"http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout
"longName": "9954486 - Disclosure - Fair Value Measurements - Schedule of Quantitative Information about Fair Value Measurements (Details)", "shortName": "Fair Value Measurements - Schedule of Quantitative Information about Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-83", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityVal
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechnic
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-83", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityVal
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechnic
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R37": { "role":
"http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebt
"longName": "9954487 - Disclosure - Fair Value Measurements - Schedule of Fair Value of the Level 3 EIB Debt (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value of the Level 3 EIB Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-86", "name": "qncx:ChangeInFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R38": { "role":
"http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash
"longName": "9954488 - Disclosure - Cash, Cash Equivalents and Investments - Schedule of Fair Values of Cash, Cash Equivalents, and Short-Term Investments Measured at Fair Value

on Recurring Basis (Details)", "shortName": "Cash, Cash Equivalents and Investments - Schedule of Fair Values of Cash, Cash Equivalents, and Short-Term Investments Measured at Fair Value on Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-94", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "qncx:ScheduleOfCashCashEquivalentsAndInvestmentsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R39": { "role": "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsAdditionalInformationDetails", "longName": "9954489 - Disclosure - Cash, Cash Equivalents and Investments - Additional Information (Details)", "shortName": "Cash, Cash Equivalents and Investments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "qncx:WeightedAverageRemainingContractualMaturitiesOfAvailableForSaleSecurities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "qncx:WeightedAverageRemainingContractualMaturitiesOfAvailableForSaleSecurities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale", "longName": "9954490 - Disclosure - Cash, Cash Equivalents and Investments - Schedule of Available-for-Sale Securities (Details)", "shortName": "Cash, Cash Equivalents and Investments - Schedule of Available-for-Sale Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssets", "longName": "9954491 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-3", "name": "qncx:PrepaidResearchAndDevelopmentExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "qncx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "qncx:PrepaidResearchAndDevelopmentExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "qncx:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "longName": "9954492 - Disclosure - Balance Sheet Components - Additional Information (Details)", "shortName": "Balance Sheet Components - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-7", "name":

"qncx:ReductionsInResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "qncx:ReductionsInResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }}, "R43": { "role": "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails", "longName": "9954493 - Disclosure - Balance Sheet Components - Schedule of Other Assets (Details)", "shortName": "Balance Sheet Components - Schedule of Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "qncx:DeferredTaxAssetsLongTermTaxCreditCarryforwardsForeign", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "qncx:DeferredTaxAssetsLongTermTaxCreditCarryforwardsForeign", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }}, "R44": { "role": "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDet", "longName": "9954494 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }}, "R45": { "role": "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri", "longName": "9954495 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DeferredCompensationLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DeferredCompensationLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }}, "R46": { "role": "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedSeveranceDetails", "longName": "9954496 - Disclosure - Balance Sheet Components - Schedule of Accrued Severance (Details)", "shortName": "Balance Sheet Components - Schedule of Accrued Severance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "qncx:AccruedSeverance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "qncx:SummaryOfAccruedSeveranceTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "qncx:AccruedSeverance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "qncx:SummaryOfAccruedSeveranceTableTextBlock",

"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.quincetx.com/role/LeasesAdditionalInformationDetails", "longName": "9954497 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "qncx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["us-gaap:OperatingLeaseExpense", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R48": { "role": "http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedToLeases", "longName": "9954498 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)", "shortName": "Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "qncx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "qncx:SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R49": { "role": "http://www.quincetx.com/role/StockholdersEquityDetails", "longName": "9954499 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-129", "name": "us-gaap:PreferredStockDividendsShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R50": { "role": "http://www.quincetx.com/role/StockBasedCompensationAdditionalInformationGeneralDetails", "longName": "9954500 - Disclosure - Stock-Based Compensation - Additional Information - General (Details)", "shortName": "Stock-Based Compensation - Additional Information - General (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-3", "name": "qncx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "qncx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "unitRef": "plan", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGeneral", "longName": "9954501 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan (Quince) - General (Details)", "shortName": "Stock-Based Compensation - 2019 Equity Incentive Plan (Quince) - General (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-132", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableFor", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-132", "name": "us-

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableFor
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors":
["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef":
"qncx-20240930.htm", "first": true, "unique": true } }, "R52": { "role":
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt
"longName": "9954502 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive
Plan (Quince) - Stock Options (Details)", "shortName": "Stock-Based Compensation - 2019
Equity Incentive Plan (Quince) - Stock Options (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"52", "firstAnchor": { "contextRef": "c-120", "name": "us-
gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentag
"unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-
20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-133", "name":
"qncx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantPeriod", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span",
"div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-
20240930.htm", "unique": true } }, "R53": { "role":
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDeta
"longName": "9954503 - Disclosure - Stock-Based Compensation - Schedule of Activity for
Stock Options (Details)", "shortName": "Stock-Based Compensation - Schedule of Activity
for Stock Options (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": {
"contextRef": "c-138", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors":
["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm",
"first": true }, "uniqueAnchor": { "contextRef": "c-133", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors":
["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm",
"unique": true } }, "R54": { "role":
"http://www.quincetx.com/role/StockBasedCompensationRSUsDetails", "longName": "9954504 -
Disclosure - Stock-Based Compensation - RSUs (Details)", "shortName": "Stock-Based
Compensation - RSUs (Details)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": {
"contextRef": "c-7", "name": "us-gaap:AllocatedShareBasedCompensationExpense",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"
], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": {
"contextRef": "c-164", "name": "us-gaap:AllocatedShareBasedCompensationExpense",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-
20240930.htm", "unique": true } }, "R55": { "role":
"http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails",
"longName": "9954505 - Disclosure - Stock-Based Compensation - Schedule of RSUs and RSAs
(Details)", "shortName": "Stock-Based Compensation - Schedule of RSUs and RSAs
(Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-146", "name":
"us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThan
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors":
["span", "td", "tr", "table", "div", "us-
gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body",
"html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "c-146", "name": "us-
gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThan
"unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors":
["span", "td", "tr", "table", "div", "us-
gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "body",
"html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique":
true } }, "R56": { "role":
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail

"longName": "9954506 - Disclosure - Stock-Based Compensation - 2019 Equity Incentive Plan (Novosteo) (Details)", "shortName": "Stock-Based Compensation - 2019 Equity Incentive Plan (Novosteo) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-120", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-154", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableFor", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R57": { "role": "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "longName": "9954507 - Disclosure - Stock-Based Compensation - 2022 Inducement Plan (Details)", "shortName": "Stock-Based Compensation - 2022 Inducement Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-176", "name": "qncx:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesA", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R58": { "role": "http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpense", "longName": "9954508 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-187", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R59": { "role": "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "longName": "9954509 - Disclosure - Stock-Based Compensation - Employee Stock Purchase Plan (Details)", "shortName": "Stock-Based Compensation - Employee Stock Purchase Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-195", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-195", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "longName": "9954510 - Disclosure - Long-term Debt - Additional Information (Details)", "shortName": "Long-term Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-213", "name": "us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "unique": true } }, "R61": { "role": "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails"

"longName": "9954511 - Disclosure - Long-term Debt - Schedule of Future Minimum Principal Payments (Details)", "shortName": "Long-term Debt - Schedule of Future Minimum Principal Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.quincetx.com/role/IncomeTaxesDetails", "longName": "9954512 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://www.quincetx.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLos", "longName": "9954513 - Disclosure - Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share - Schedule of Computation of Basic and Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R64": { "role": "http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShar", "longName": "9954514 - Disclosure - Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share - Schedule of Outstanding Potentially Dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "longName": "9954515 - Disclosure - Business Combination - Additional Information (Details)", "shortName": "Business Combination - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-222", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-222", "name": "us-gaap:SharePrice", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor", "longName": "9954516 - Disclosure - Business Combination - Schedule of Fair Value of the Total Purchase Consideration Transferred (Details)", "shortName": "Business Combination

- Schedule of Fair Value of the Total Purchase Consideration Transferred (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "66", "firstAnchor": { "contextRef": "c-221", "name": "us-
gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",
"us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-221", "name": "us-
gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div",
"us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm",
"first": true, "unique": true } }, "R67": { "role":
"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLi
longName": "9954517 - Disclosure - Business Combination - Schedule of Fair Values of
Assets Acquired and Liabilities Assumed (Details)", "shortName": "Business Combination -
Schedule of Fair Values of Assets Acquired and Liabilities Assumed (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "67", "firstAnchor": { "contextRef": "c-3", "name": "us-
gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3",
"ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount":
1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-
220", "name": "us-
gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndLi
unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [
"span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm",
"unique": true } }, "R68": { "role":
"http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIn
longName": "9954518 - Disclosure - Intangible Assets - Schedule of Carrying Amount of
Indefinite Lived Intangible Asset (Details)", "shortName": "Intangible Assets - Schedule
of Carrying Amount of Indefinite Lived Intangible Asset (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "68", "firstAnchor": { "contextRef": "c-7", "name": "us-
gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table",
"div", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true
}, "uniqueAnchor": { "contextRef": "c-231", "name": "us-
gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table",
"div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "qncx-20240930.htm",
"unique": true } }, "R69": { "role":
"http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang
longName": "9954519 - Disclosure - Intangible Assets - Schedule of Carrying Amount of
Finite-Lived Intangible Asset (Details)", "shortName": "Intangible Assets - Schedule of
Carrying Amount of Finite-Lived Intangible Asset (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order":
"69", "firstAnchor": { "contextRef": "c-3", "name": "us-
gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-
US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body",
"html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-
gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-
US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-
gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body",
"html"], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true, "unique":
true } }, "R70": { "role":
"http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails", "longName":
"9954520 - Disclosure - Intangible Assets - Additional Information (Details)",
"shortName": "Intangible Assets - Additional Information (Details)", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "70", "firstAnchor": { "contextRef": "c-7", "name": "us-
gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "unitRef": "usd", "xsiNil":

```

"false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table",
"div", "body", "html" ], "reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true
}, "uniqueAnchor": null }, "R71": { "role":
"http://www.quincetx.com/role/IntangibleAssetsScheduleCarryingAmountofGoodwillDetails",
"longName": "9954521 - Disclosure - Intangible Assets - Schedule Carrying Amount of
Goodwill (Details)", "shortName": "Intangible Assets - Schedule Carrying Amount of
Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-4",
"name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US",
"decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ],
"reportCount": 1, "baseRef": "qncx-20240930.htm", "first": true }, "uniqueAnchor": {
"contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [
"span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock",
"ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "qncx-20240930.htm",
"unique": true } }, "R72": { "role":
"http://www.quincetx.com/role/SubsequentEventsDetails", "longName": "9954522 -
Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "72", "firstAnchor": { "contextRef": "c-54", "name":
"qncx:DebtInstrumentPercentageOfDeferredInterestConverted", "unitRef": "number",
"xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div",
"ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "qncx-20240930.htm",
"first": true }, "uniqueAnchor": null } }, "tag": { "us-
gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": {
"en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label":
"Accounting Policies [Abstract]" } } }, "auth_ref": [ ] }, "us-
gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit",
"calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } },
"presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": {
"en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable,
Current", "documentation": "Carrying value as of the balance sheet date of liabilities
incurred (and for which invoices have typically been received) and payable to vendors
for goods and services received that are used in an entity's business. Used to reflect
the current portion of the liabilities (due within one year or within the normal
operating cycle if longer)." } } }, "auth_ref": [ "r28", "r685" ] }, "us-
gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr":
"credit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 },
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": {
"en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities",
"totalLabel": "Total accrued expenses and other current liabilities", "label": "Accrued
Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of
obligations incurred and payable, pertaining to costs that are statutory in nature, are
incurred on contractual obligations, or accumulate over time and for which invoices have
not yet been received or will not be rendered. Examples include taxes, interest, rent
and utilities. Used to reflect the current portion of the liabilities (due within one
year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r31" ] },
"qncx_AccruedOperatingLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.quincetx.com/20240930", "localname":
"AccruedOperatingLeaseLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri
{ "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } },
"presentation": {
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri
}, "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease
liabilities", "label": "Accrued Operating Lease Liabilities Current", "documentation":

```


"Accrued operating lease liabilities current." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri], "lang": { "en-us": { "role": { "terseLabel": "Professional fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r31"] }, "qncx_AccruedResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "AccruedResearchAndDevelopmentExpensesCurrent", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Accrued Research And Development Expenses Current", "documentation": "Accrued research and development expenses, current." } } }, "auth_ref": [] }, "qncx_AccruedSeverance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "AccruedSeverance", "crdr": "debit", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedSeveranceDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning accrued severance", "periodEndLabel": "Ending accrued severance", "label": "Accrued Severance", "documentation": "Accrued Severance" } } }, "auth_ref": [] }, "qncx_AccruedSeveranceIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "AccruedSeveranceIncurred", "crdr": "debit", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedSeveranceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Incurred during the period", "label": "Accrued Severance Incurred", "documentation": "Accrued severance incurred" } } }, "auth_ref": [] }, "qncx_AccruedSeverancePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "AccruedSeverancePaid", "crdr": "credit", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedSeveranceDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Severance paid during the period", "label": "Accrued Severance Paid", "documentation": "Accrued severance paid" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDeta { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDeta], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated amortization and depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r59", "r158", "r531"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event

and circumstance from nonowner source." } } }, "auth_ref": ["r39", "r40", "r106", "r166", "r528", "r544", "r545"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income / (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r5", "r17", "r40", "r437", "r440", "r477", "r540", "r541", "r718", "r719", "r720", "r727", "r728", "r729"] }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-lived intangible assets useful life", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDnHnMnS' format, for example, '1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r121"] }, "qncx_AdditionalCashBonusSeverancePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "AdditionalCashBonusSeverancePercentage", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additional cash bonus severance percentage", "label": "Additional Cash Bonus Severance Percentage", "documentation": "Additional Cash Bonus Severance Percentage" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r101"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r405", "r406", "r407", "r556", "r727", "r728", "r729", "r802", "r822"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecogni": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecogni", "crdr": "credit", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r71", "r72", "r371"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net

cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpense"], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation expense related to options granted", "terseLabel": "Total stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r400", "r408"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "gncx_AmountPayableUponAchievementOfSpecifiedMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "AmountPayableUponAchievementOfSpecifiedMilestone", "crdr": "credit", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amount payable upon achievement of specified milestone.", "label": "Amount Payable Upon Achievement of Specified Milestone", "documentation": "Amount payable upon achievement of specified milestone." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShares"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from calculation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r215"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecurities", "presentation": ["http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShares"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r48"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShares"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShares"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for

the period presented." } } }, "auth_ref": ["r48"] }, "qncx_ApprovalMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ApprovalMilestonesMember", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Specified Approval Milestones", "label": "Approval Milestones [Member]", "documentation": "Approval milestones." } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": { "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Impairment charges", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r11", "r57"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r140", "r162", "r190", "r222", "r233", "r235", "r272", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r430", "r434", "r456", "r523", "r593", "r685", "r697", "r768", "r769", "r809"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated" }, "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r154", "r169", "r190", "r272", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r430", "r434", "r456", "r685", "r768", "r769", "r809"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash" }, "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities" }, "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": ["r87"] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": { "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities" }, "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "qncx_AssetsHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "AssetsHeldForSale", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails": { "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 1.0 } }, "presentation": {

"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Assets
Held for Sale", "documentation": "Assets held for sale." } } }, "auth_ref": [] }, "us-
 gaap_AutomobilesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2023", "localname": "AutomobilesMember", "presentation": {
 "http://www.quincetx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us":
 { "role": { "terseLabel": "Car", "label": "Automobiles [Member]", "documentation":
 "Vehicles that are used primarily for transporting people." } } }, "auth_ref": [] },
 "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr":
 "credit", "calculation": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
 { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight":
 -1.0, "order": 1.0 } }, "presentation": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt
 Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
 "documentation": "Amount, before tax, of unrealized gain in accumulated other
 comprehensive income (AOCI) on investment in debt security measured at fair value with
 change in fair value recognized in other comprehensive income (available-for-sale)." } }
 }, "auth_ref": ["r245"] }, "us-
 gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr":
 "debit", "calculation": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
 { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight":
 1.0, "order": 2.0 } }, "presentation": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unrealized Losses", "label":
 "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
 "documentation": "Amount, before tax, of unrealized loss in accumulated other
 comprehensive income (AOCI) on investment in debt security measured at fair value with
 change in fair value recognized in other comprehensive income (available-for-sale)." } }
 }, "auth_ref": ["r246"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis":
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt
 Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of
 investment in debt security measured at fair value with change in fair value recognized
 in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r242",
 "r280", "r521"] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash
 { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 },
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
 { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight":
 1.0, "order": 3.0 } }, "presentation": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash
 "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitie
], "lang": { "en-us": { "role": { "verboseLabel": "Debt securities, fair value",
 "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale",
 "documentation": "Amount of investment in debt security measured at fair value with
 change in fair value recognized in other comprehensive income (available-for-sale)." } }
 }, "auth_ref": ["r243", "r280", "r516", "r734"] }, "us-
 gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
 "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": {

"en-us": { "role": { "terseLabel": "Short-term investments", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": ["r240", "r280"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399"] }, "qncx_BalanceSheetComponentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "BalanceSheetComponentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components [Abstract]", "label": "Balance Sheet Components [Abstract]", "documentation": "Balance sheet components." } } }, "auth_ref": [] }, "qncx_BalanceSheetComponentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "BalanceSheetComponentsLineItems", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components [Line Items]", "label": "Balance Sheet Components [Line Items]", "documentation": "Balance sheet components [Line Items]." } } }, "auth_ref": [] }, "qncx_BalanceSheetComponentsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "BalanceSheetComponentsRollForward", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedSeveranceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components [Roll Forward]", "label": "Balance Sheet Components [Roll Forward]", "documentation": "Balance Sheet Components" } } }, "auth_ref": [] }, "qncx_BalanceSheetComponentsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "BalanceSheetComponentsTable", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components [Table]", "label": "Balance Sheet Components [Table]", "documentation": "Balance Sheet Components [Table]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale", "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale", "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": ["r85", "r86"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other

Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "qncx_BressoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "BressoMember", "presentation": ["http://www.quincetx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Bresso, Italy", "label": "Bresso [Member]", "documentation": "Bresso." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor", "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandI", "http://www.quincetx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quincetx.com/role/LeasesAdditionalInformationDetails", "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r424", "r677", "r678"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor", "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandI", "http://www.quincetx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.quincetx.com/role/LeasesAdditionalInformationDetails", "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r76", "r77", "r424", "r677", "r678"] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition, transaction costs", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "presentation": ["http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor"], "lang": { "en-us": { "role": { "verboseLabel": "Quince Therapeutics common stock (in shares)", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "documentation": "Number of shares of equity interests issued or issuable to acquire entity." } } }, "auth_ref": ["r134"] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor", "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandI", "http://www.quincetx.com/role/FairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r424"] }, "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount", "crdr": "debit", "presentation": [

```

"http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Goodwill expected to be deductible",
"label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
"documentation": "The amount of goodwill arising from a business combination that is
expected to be deductible for tax purposes." } } }, "auth_ref": [ "r83" ] }, "us-
gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname":
"BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": {
"label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [ ]
}, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor
], "lang": { "en-us": { "role": { "terseLabel": "Fair value of total consideration
transferred", "totalLabel": "Fair value of total consideration transferred", "label":
"Business Combination, Consideration Transferred", "documentation": "Amount of
consideration transferred, consisting of acquisition-date fair value of assets
transferred by the acquirer, liabilities incurred by the acquirer, and equity interest
issued by the acquirer." } } }, "auth_ref": [ "r0", "r1", "r16" ] }, "us-
gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "crdr":
"credit", "calculation": {
"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor
{ "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0,
"order": 2.0 } }, "presentation": {
"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor
], "lang": { "en-us": { "role": { "terseLabel": "Quince Therapeutics common stock
(7,250,352 shares)", "label": "Business Combination, Consideration Transferred, Equity
Interests Issued and Issuable", "documentation": "Amount of equity interests of the
acquirer, including instruments or interests issued or issuable in consideration for the
business combination." } } }, "auth_ref": [ "r0", "r1" ] }, "us-
gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentCons
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsider
"crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 8.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "terseLabel": "Change in the fair value of contingent
consideration liabilities", "label": "Business Combination, Contingent Consideration
Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation":
"Amount of increase (decrease) in the value of a contingent consideration liability,
including, but not limited to, differences arising upon settlement." } } }, "auth_ref":
[ "r428", "r721" ] }, "us-
gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
"crdr": "credit", "presentation": {
"http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Maximum amount of future consideration
payment", "label": "Business Combination, Contingent Consideration Arrangements, Range
of Outcomes, Value, High", "documentation": "For contingent consideration arrangements
recognized in connection with a business combination, this element represents an
estimate of the high-end of the potential range (undiscounted) of the consideration
which may be paid." } } }, "auth_ref": [ "r82" ] }, "us-
gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation":
{
"http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitie
{ "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }
}, "presentation": {

```


<http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities>, "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r2", "r81", "r427"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "en-us": { "role": { "terseLabel": "Short-term contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r81"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout": { "en-us": { "role": { "terseLabel": "Input used", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": ["r452"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "en-us": { "role": { "terseLabel": "Long-term contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r81"] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": { "http://www.quincetx.com/role/BusinessCombination": { "en-us": { "role": { "terseLabel": "Business Combination", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r132", "r425"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLi": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumed": { "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLi": { "en-us": { "role": { "totalLabel": "Total assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": ["r79"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract", "presentation": { "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLi":

```
[{"lang": {"en-us": {"role": {"terseLabel": "Assets acquired:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]" } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": {"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesOfAssetsAcquiredandLiabilitiesAssumedAssets": {"parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": {"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesOfAssetsAcquiredandLiabilitiesAssumedCurrentAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "calculation": {"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesOfAssetsAcquiredandLiabilitiesAssumedOtherCurrentAssets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherCurrentAssets", "crdr": "credit", "calculation": {"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesOfAssetsAcquiredandLiabilitiesAssumedCurrentLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities", "crdr": "credit", "calculation": {"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesOfAssetsAcquiredandLiabilitiesAssumedDeferredTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTax", "crdr": "credit", "calculation": {
```



```
"crdr": "debit", "calculation": {  
  "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedAssets",  
  "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",  
  "weight": 1.0, "order": 4.0 } }, "presentation": {  
  "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDeferredTaxAssets",  
  "lang": { "en-us": { "role": { "terseLabel": "Tax assets", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date." } } },  
  "auth_ref": [ "r79" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",  
  "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",  
  "crdr": "credit", "calculation": {  
    "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedLiabilities",  
    "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",  
    "weight": 1.0, "order": 5.0 } }, "presentation": {  
      "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",  
      "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedDeferredTaxLiabilities",  
      "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liability", "negatedLabel": "Deferred tax liability", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r79" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets",  
      "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets",  
      "crdr": "debit", "calculation": {  
        "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedIntangibleAssets",  
        "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssets",  
        "weight": 1.0, "order": 5.0 } }, "presentation": {  
          "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",  
          "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedIntangibleAssets",  
          "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r79" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",  
          "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",  
          "crdr": "credit", "calculation": {  
            "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedLiabilities",  
            "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLiabilities",  
            "weight": -1.0, "order": 2.0 } }, "presentation": {  
              "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedTotalLiabilities",  
              "lang": { "en-us": { "role": { "negatedTotalLabel": "Total liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r79" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",  
              "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",  
              "presentation": {  
                "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedLiabilities",  
                "lang": { "en-us": { "role": { "terseLabel": "Liabilities assumed:", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities",  
                "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities",  
                "crdr": "credit", "calculation": {  
                  "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumedNoncurrentLiabilities",  
                  "parentTag": "us-
```

gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
 "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "negatedLabel": "Debt, non-current", "label":
 "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r79"] }, "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities", "crdr": "credit", "calculation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
 "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "negatedLabel": "Other non-current liabilities",
 "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": ["r79"] },
gnctx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseAssets
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseAssets", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
 "weight": 1.0, "order": 6.0 } }, "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets, net",
 "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-of-use Assets", "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, operating lease right-of-use assets." } } }, "auth_ref": [] }, "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
 "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label":
 "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": ["r79"] }, "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
 "weight": 1.0, "order": 8.0 } }, "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandLiabilitiesAssumed", "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label":
 "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": ["r78", "r79"] }, "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedIntangibleAssets
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":

```

"BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
  "crdr": "debit", "calculation": {
    "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandL": {
      "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
    "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandL": {
      "lang": { "en-us": { "role": { "totalLabel": "Fair value of total consideration transferred", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r79" ] },
    "qncx_BusinessCombinationSettlementOfPreexistingNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "BusinessCombinationSettlementOfPreexistingNotesReceivable", "crdr": "credit", "calculation": {
      "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCo": {
        "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 4.0 } }, "presentation": {
          "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCo": {
            "lang": { "en-us": { "role": { "terseLabel": "Settlement of preexisting notes receivable", "label": "Business Combination Settlement of preexisting notes receivable", "documentation": "Business Combination Settlement of preexisting notes receivable" } } }, "auth_ref": [ ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": {
              "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r75" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": {
                "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash": {
                  "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": {
                    "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash": {
                      "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": {
                        "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale": {
                          "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash": {
                            "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": {
                              "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang":

```

```

{ "en-us": { "role": { "terseLabel": "Cash, Cash Equivalents and Investments", "label":
"Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of
accounting policy for cash and cash equivalents, including the policy for determining
which items are treated as cash equivalents. Other information that may be disclosed
includes (1) the nature of any restrictions on the entity's use of its cash and cash
equivalents, (2) whether the entity's cash and cash equivalents are insured or expose
the entity to credit risk, (3) the classification of any negative balance accounts
(overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and
whether the carrying amount of cash equivalents approximates fair value." } } },
"auth_ref": [ "r46" ] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": {
"http://www.quincetx.com/role/CashCashEquivalentsandInvestments" }, "lang": { "en-us": {
"role": { "terseLabel": "Cash, Cash Equivalents and Investments", "label": "Cash, Cash
Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire
disclosure of cash, cash equivalents, and debt and equity securities, including any
unrealized or realized gain (loss)." } } }, "auth_ref": [ "r733" ] }, "us-
gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": {
"http://www.quincetx.com/role/OrganizationDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Cash, cash equivalents, and short-term investments", "label": "Cash, Cash
Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on
hand as well as demand deposits with banks or financial institutions. It also includes
other kinds of accounts that have the general characteristics of demand deposits in that
the customer may deposit additional funds at any time and effectively may withdraw funds
at any time without prior notice or penalty. Cash equivalents, excluding items
classified as marketable securities, include short-term, highly liquid Investments that
are both readily convertible to known amounts of cash, and so near their maturity that
they present minimal risk of changes in value because of changes in interest rates.
Generally, only investments with original maturities of three months or less qualify
under that definition. Original maturity means original maturity to the entity holding
the investment. For example, both a three-month US Treasury bill and a three-year
Treasury note purchased three months from maturity qualify as cash equivalents. However,
a Treasury note purchased three years ago does not become a cash equivalent when its
remaining maturity is three months. Short-term investments, exclusive of cash
equivalents, generally consist of marketable securities intended to be sold within one
year (or the normal operating cycle if longer) and may include trading securities,
available-for-sale securities, or held-to-maturity securities (if maturing within one
year), as applicable." } } }, "auth_ref": [ "r717" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit",
"calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },
"lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents",
"periodStartLabel": "Cash and cash equivalents at beginning of period",
"periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash
Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount
of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or
usage. Excludes amount for disposal group and discontinued operations. Cash includes,
but is not limited to, currency on hand, demand deposits with banks or financial
institutions, and other accounts with general characteristics of demand deposits. Cash
equivalents include, but are not limited to, short-term, highly liquid investments that
are both readily convertible to known amounts of cash and so near their maturity that
they present insignificant risk of changes in value because of changes in interest
rates." } } }, "auth_ref": [ "r45", "r116", "r186" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecrease":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncl",
"crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },

```

"lang": { "en-us": { "role": { "totalLabel": "Net increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r4", "r116"] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashMember", "presentation": ["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash", "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": ["r156"] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositMember", "presentation": ["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale", "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities", "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": ["r15", "r691", "r692", "r693", "r694"] }, "qncx_ChangeInDeferredTaxLiabilitiesDueToAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ChangeInDeferredTaxLiabilitiesDueToAcquisition", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Change in deferred tax liabilities due to acquisition of Novosteo, Inc.", "label": "Change In Deferred Tax Liabilities Due To Acquisition", "documentation": "Change in deferred tax liabilities due to acquisition." } } }, "auth_ref": [] }, "qncx_ChangeInFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ChangeInFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebt", "lang": { "en-us": { "role": { "terseLabel": "Change in fair value", "label": "Change In Fair Value Disclosure", "documentation": "Change in fair value disclosure." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r151", "r163", "r164", "r165", "r190", "r209", "r210", "r212", "r214", "r220", "r221", "r272", "r305", "r307", "r308", "r309", "r312", "r313", "r344", "r345", "r348", "r351", "r358", "r456", "r549", "r550", "r551", "r552", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r581", "r602", "r620", "r637", "r638", "r639", "r640", "r641", "r704", "r723", "r730"] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": ["http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]",

"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r163", "r164", "r165", "r220", "r344", "r345", "r346", "r348", "r351", "r356", "r358", "r549", "r550", "r551", "r552", "r672", "r704", "r723"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase common stock (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r359"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock, subject to adjustment (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightUnissued", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock withheld (in shares)", "label": "Class of Warrant or Right, Unissued", "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r36", "r93", "r525", "r580"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGeneral", "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock reserved for issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r37"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r687", "r688", "r689", "r691", "r692", "r693", "r694", "r727", "r728", "r802", "r821", "r822"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [


```

"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in USD per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r100", "r581" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": {
"http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r18", "r100", "r581", "r599", "r822", "r823" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } },
"presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value, 100,000,000 shares authorized, 43,276,606 and 42,973,215 issued and outstanding as of September\00a030, 2024 and December\00a031, 2023, respectively.", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r100", "r527", "r685" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive"
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive"
], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r41", "r174", "r176", "r180", "r517", "r536" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": {
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDebt"
], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [ ] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":

```


"ComputerSoftwareIntangibleAssetMember", "presentation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDebt", "lang": { "en-us": { "role": { "terseLabel": "Computer Software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": { "r656", "r764", "r765" } }, "us-gaap-ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": {
 "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Basis of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": { "r84", "r659" } }, "us-gaap-ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": { } }, "qncx-ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ContingentConsiderationMember", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout", "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Contingent Consideration [Member]", "documentation": "Contingent Consideration." } } }, "auth_ref": { } }, "us-gaap-ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": { } }, "us-gaap-ContingentLiabilityReserveEstimatePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentLiabilityReserveEstimatePolicy", "presentation": {
 "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates." } } }, "auth_ref": { "r137", "r138" } }, "dei-CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": { } }, "us-gaap-CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": {
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "http://www.quincetx.com/role/OrganizationDetails", "http://www.quincetx.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": { } }, "us-gaap-CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": {

["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"](http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails),
["http://www.quincetx.com/role/OrganizationDetails"](http://www.quincetx.com/role/OrganizationDetails),
["http://www.quincetx.com/role/SubsequentEventsDetails"](http://www.quincetx.com/role/SubsequentEventsDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]",
"documentation": "Type of credit facility. Credit facilities provide capital to
borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref":
[] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri":
["http://xbrl.sec.gov/dei/2023"](http://xbrl.sec.gov/dei/2023), "localname": "CurrentFiscalYearEndDate", "presentation":
[["http://www.quincetx.com/role/Cover"](http://www.quincetx.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel":
"Current Fiscal Year End Date", "label": "Current Fiscal Year End Date",
"documentation": "End date of current fiscal year in the format --MM-DD." } } },
"auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType",
"nsuri": ["http://fasb.org/us-gaap/2023"](http://fasb.org/us-gaap/2023), "localname": "DebtDisclosureAbstract", "lang":
{ "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt
Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": ["http://fasb.org/us-gaap/2023"](http://fasb.org/us-gaap/2023), "localname":
"DebtDisclosureTextBlock", "presentation": [["http://www.quincetx.com/role/LongtermDebt"](http://www.quincetx.com/role/LongtermDebt)
], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Debt
Disclosure [Text Block]", "documentation": "The entire disclosure for information about
short-term and long-term debt arrangements, which includes amounts of borrowings under
each line of credit, note payable, commercial paper issue, bonds indenture, debenture
issue, own-share lending arrangements and any other contractual agreement to repay
funds, and about the underlying arrangements, rationale for a classification as long-
term, including repayment terms, interest rates, collateral provided, restrictions on
use of assets and activities, whether or not in compliance with debt covenants, and
other matters important to users of the financial statements, such as the effects of
refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r125", "r188",
"r314", "r320", "r321", "r322", "r323", "r324", "r325", "r330", "r337", "r338", "r340"]
}, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri":
["http://fasb.org/us-gaap/2023"](http://fasb.org/us-gaap/2023), "localname": "DebtInstrumentAxis", "presentation": [
["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"](http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails),
["http://www.quincetx.com/role/OrganizationDetails"](http://www.quincetx.com/role/OrganizationDetails),
["http://www.quincetx.com/role/SubsequentEventsDetails"](http://www.quincetx.com/role/SubsequentEventsDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]",
"documentation": "Information by type of debt instrument, including, but not limited to,
draws against credit facilities." } } }, "auth_ref": ["r27", "r97", "r98", "r141",
"r142", "r192", "r315", "r316", "r317", "r318", "r319", "r321", "r326", "r327", "r328",
"r329", "r331", "r332", "r333", "r334", "r335", "r336", "r466", "r667", "r668", "r669",
"r670", "r671", "r724"] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype":
"monetaryItemType", "nsuri": ["http://fasb.org/us-gaap/2023"](http://fasb.org/us-gaap/2023), "localname":
"DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": {
["http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails"](http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails)
{ "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation":
[
["http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails"](http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails)
], "lang": { "en-us": { "role": { "totalLabel": "Total future payments", "label": "Long-
Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and
debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable,
bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and
other types of debt." } } }, "auth_ref": ["r27", "r142", "r341"] },
"qncx_DebtInstrumentCovenantMinimumRequiredCashBalance": { "xbrltype":
"monetaryItemType", "nsuri": ["http://www.quincetx.com/20240930"](http://www.quincetx.com/20240930), "localname":
"DebtInstrumentCovenantMinimumRequiredCashBalance", "crdr": "debit", "presentation": [
["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"](http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails),
["http://www.quincetx.com/role/OrganizationDetails"](http://www.quincetx.com/role/OrganizationDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Minimum cash balance", "label": "Debt Instrument, Covenant, Minimum
Required Cash Balance", "documentation": "Debt Instrument, Covenant, Minimum Required
Cash Balance" } } }, "auth_ref": [] }, "qncx_DebtInstrumentDeferredInterestPercent": {
"xbrltype": "percentItemType", "nsuri": ["http://www.quincetx.com/20240930"](http://www.quincetx.com/20240930), "localname":
"DebtInstrumentDeferredInterestPercent", "presentation": [
["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"](http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails),
["http://www.quincetx.com/role/OrganizationDetails"](http://www.quincetx.com/role/OrganizationDetails),
["http://www.quincetx.com/role/SubsequentEventsDetails"](http://www.quincetx.com/role/SubsequentEventsDetails)], "lang": { "en-us": { "role": {
"terseLabel": "Deferred interest percent", "label": "Debt Instrument, Deferred Interest
Percent", "documentation": "Debt Instrument, Deferred Interest Percent" } } },
"auth_ref": [] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType",
"nsuri": ["http://fasb.org/us-gaap/2023"](http://fasb.org/us-gaap/2023), "localname": "DebtInstrumentFairValue", "crdr":

```

"credit", "calculation": {
  "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitie
  { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 }
  }, "presentation": {
    "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebtI
    "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitie
    }, "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "periodStartLabel":
    "Beginning Balance as of January 1, 2024", "periodEndLabel": "Ending Balance as of
    September 30, 2024", "label": "Debt Instrument, Fair Value Disclosure", "documentation":
    "Fair value portion of debt instrument payable, including, but not limited to, notes
    payable and loans payable." } } }, "auth_ref": [ "r328", "r455", "r668", "r669" ] },
    "qncx_DebtInstrumentFairValueDueToForeignCurrencyTranslation": { "xbrltype":
    "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
    "DebtInstrumentFairValueDueToForeignCurrencyTranslation", "crdr": "debit",
    "presentation": {
      "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebtI
      }, "lang": { "en-us": { "role": { "negatedLabel": "Due to foreign currency translation",
      "label": "Debt Instrument Fair Value Due to Foreign Currency Translation",
      "documentation": "Debt instrument fair value due to foreign currency translation." } }
      }, "auth_ref": [ ] }, "qncx_DebtInstrumentFairValueRollForward": { "xbrltype":
      "stringItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
      "DebtInstrumentFairValueRollForward", "presentation": {
        "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebtI
        }, "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Fair Value [Roll
        Forward]", "label": "Debt Instrument, Fair Value [Roll Forward]", "documentation": "Debt
        Instrument, Fair Value" } } }, "auth_ref": [ ] }, "qncx_DebtInstrumentImputedInterest": {
        "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930",
        "localname": "DebtInstrumentImputedInterest", "crdr": "credit", "calculation": {
          "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
          { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } } }, "presentation":
          {
            "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
            }, "lang": { "en-us": { "role": { "terseLabel": "Imputed interest and fair value
            adjustments", "label": "Debt Instrument Imputed Interest", "documentation": "Debt
            instrument imputed interest." } } }, "auth_ref": [ ] }, "us-
            gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType",
            "nsuri": "http://fasb.org/us-gaap/2023", "localname":
            "DebtInstrumentInterestRateStatedPercentage", "presentation": {
              "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
              "en-us": { "role": { "terseLabel": "Fixed interest rate", "label": "Debt Instrument,
              Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds
              borrowed, under the debt agreement." } } }, "auth_ref": [ "r33", "r316" ] }, "us-
              gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri":
              "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation":
              { "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
              "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt
              Instrument [Line Items]", "documentation": "Line items represent financial concepts
              included in a table. These concepts are used to disclose reportable information
              associated with domain members defined in one or many axes to the table." } } },
              "auth_ref": [ "r192", "r315", "r316", "r317", "r318", "r319", "r321", "r326", "r327",
              "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r466", "r667",
              "r668", "r669", "r670", "r671", "r724" ] }, "us-gaap_DebtInstrumentNameDomain": {
              "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
              "DebtInstrumentNameDomain", "presentation": {
                "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails",
                "http://www.quincetx.com/role/OrganizationDetails",
                "http://www.quincetx.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": {
                "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name
                [Domain]", "documentation": "The name for the particular debt instrument or borrowing
                that distinguishes it from other debt instruments or borrowings, including draws against
                credit facilities." } } }, "auth_ref": [ "r34", "r192", "r315", "r316", "r317", "r318",
                "r319", "r321", "r326", "r327", "r328", "r329", "r331", "r332", "r333", "r334", "r335",
                "r336", "r466", "r667", "r668", "r669", "r670", "r671", "r724" ] },
                "qncx_DebtInstrumentPercentageOfDeferredInterestConverted": { "xbrltype":
                "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
                "DebtInstrumentPercentageOfDeferredInterestConverted", "presentation": {
                  "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails",

```

["http://www.quincetx.com/role/OrganizationDetails"](http://www.quincetx.com/role/OrganizationDetails),
["http://www.quincetx.com/role/SubsequentEventsDetails"](http://www.quincetx.com/role/SubsequentEventsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Percentage of deferred interest converted", "label": "Debt Instrument, Percentage Of Deferred Interest Converted", "documentation": "Debt Instrument, Percentage Of Deferred Interest Converted" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"](http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails)], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r34", "r63", "r66", "r90", "r91", "r92", "r94", "r127", "r128", "r192", "r315", "r316", "r317", "r318", "r319", "r321", "r326", "r327", "r328", "r329", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r466", "r667", "r668", "r669", "r670", "r671", "r724"] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsAdditionalInformationDetails"](http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsAdditionalInformationDetails)], "lang": { "en-us": { "role": { "terseLabel": "Realized gains or losses on the sale or maturity of available-for-sale securities", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r747"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale"](http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale), ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebt"](http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebt), ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities"](http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities), ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout"](http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout)], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities Available For Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsTables"](http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsTables)], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-Sale Securities", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747"] }, "us-gaap_DeferredCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityCurrent", "crdr": "credit", "calculation": { ["http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilities"](http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilities) { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [["http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilities"](http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilities)], "lang": { "en-us": { "role": { "terseLabel": "Personnel expenses", "label": "Deferred Compensation Liability, Current", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": ["r67", "r130"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"](http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited) { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"](http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited)], "lang": {

"en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } },
 "auth_ref": ["r411", "r412", "r524"] },
 "qncx_DeferredTaxAssetsLongTermTaxCreditCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "DeferredTaxAssetsLongTermTaxCreditCarryforwardsForeign", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails": {
 "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails": {
 "lang": { "en-us": { "role": { "terseLabel": "Long-term Italian research and development refundable tax credit", "label": "Deferred Tax Assets Long Term Tax Credit Carryforwards Foreign", "documentation": "Deferred tax assets long term tax credit carryforwards foreign." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssets": {
 "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurrentAssets": {
 "lang": { "en-us": { "role": { "verboseLabel": "Short-term Italian research and development refundable tax credit", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards." } } }, "auth_ref": ["r73", "r74", "r801"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r11", "r58"] }, "qncx_DisbursementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "DisbursementPeriod", "presentation": {
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails": {
 "lang": { "en-us": { "role": { "terseLabel": "Disbursement period", "label": "Disbursement Period", "documentation": "Disbursement period." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensation": {
 "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r369", "r373", "r401", "r402", "r404", "r680"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "qncx_DiscountedEarningAfterTax": { "xbrltype": "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "DiscountedEarningAfterTax", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails": {
 "lang": { "en-us": { "role": { "terseLabel": "Discounted earning after tax", "label": "Discounted Earning After Tax", "documentation": "Discounted Earning After Tax" } } }, "auth_ref": [] }, "qncx_DiscountedValueToPresentValueOfIntangibleAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "DiscountedValueToPresentValueOfIntangibleAssets", "presentation": {

["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails"](http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails)],
 "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Discounted Value To Present Value Of Intangible Assets", "documentation": "Discounted value to present value of intangible assets." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": {
 "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023",
 "localname": "DocumentFiscalPeriodFocus", "presentation": {
["http://www.quincetx.com/role/Cover"](http://www.quincetx.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel":
 "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus",
 "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or
 other fiscal year statements having FY." } } }, "auth_ref": [] },
 "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri":
["http://xbrl.sec.gov/dei/2023"](http://xbrl.sec.gov/dei/2023), "localname": "DocumentFiscalYearFocus", "presentation":
 { ["http://www.quincetx.com/role/Cover"](http://www.quincetx.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel":
 "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation":
 "This is focus fiscal year of the document report in YYYY format. For a 2006 annual
 report, which may also provide financial information from prior periods, fiscal 2006
 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] },
 "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri":
["http://xbrl.sec.gov/dei/2023"](http://xbrl.sec.gov/dei/2023), "localname": "DocumentPeriodEndDate", "presentation": {
["http://www.quincetx.com/role/Cover"](http://www.quincetx.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel":
 "Document Period End Date", "label": "Document Period End Date", "documentation": "For
 the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest
 event reported; for the EDGAR submission types of Form N-1A: the filing date; for all
 other submission types: the end of the reporting or transition period. The format of the
 date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": {
 "xbrltype": "booleanItemType", "nsuri": ["http://xbrl.sec.gov/dei/2023"](http://xbrl.sec.gov/dei/2023), "localname":
 "DocumentQuarterlyReport", "presentation": { ["http://www.quincetx.com/role/Cover"](http://www.quincetx.com/role/Cover)],
 "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label":
 "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form
 used as an quarterly report." } } }, "auth_ref": ["r701"] },
 "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri":
["http://xbrl.sec.gov/dei/2023"](http://xbrl.sec.gov/dei/2023), "localname": "DocumentTransitionReport", "presentation":
 { ["http://www.quincetx.com/role/Cover"](http://www.quincetx.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel":
 "Document Transition Report", "label": "Document Transition Report", "documentation":
 "Boolean flag that is true only for a form used as a transition report." } } },
 "auth_ref": ["r702"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType",
 "nsuri": ["http://xbrl.sec.gov/dei/2023"](http://xbrl.sec.gov/dei/2023), "localname": "DocumentType", "presentation": {
["http://www.quincetx.com/role/Cover"](http://www.quincetx.com/role/Cover)], "lang": { "en-us": { "role": { "terseLabel":
 "Document Type", "label": "Document Type", "documentation": "The type of document being
 provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same
 value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": []
 }, "gncx_DrawnPercentage": { "xbrltype": "percentItemType", "nsuri":
["http://www.quincetx.com/20240930"](http://www.quincetx.com/20240930), "localname": "DrawnPercentage", "presentation": {
["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"](http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails)], "lang": {
 "en-us": { "role": { "terseLabel": "Drawn percentage", "label": "Drawn Percentage",
 "documentation": "Drawn percentage." } } }, "auth_ref": [] }, "us-
 gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri":
["http://fasb.org/us-gaap/2023"](http://fasb.org/us-gaap/2023), "localname": "EarningsPerShareAbstract", "lang": { "en-
 us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per
 Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": {
 "xbrltype": "perShareItemType", "nsuri": ["http://fasb.org/us-gaap/2023"](http://fasb.org/us-gaap/2023), "localname":
 "EarningsPerShareBasic", "presentation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive"](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
["http://www.quincetx.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLos"](http://www.quincetx.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLos)
], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share - basic (in USD per
 share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net
 income (loss) for the period per each share of common stock or unit outstanding during
 the reporting period." } } }, "auth_ref": ["r181", "r198", "r199", "r200", "r201",
 "r202", "r207", "r209", "r212", "r213", "r214", "r218", "r445", "r446", "r518", "r537",
 "r660"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType",
 "nsuri": ["http://fasb.org/us-gaap/2023"](http://fasb.org/us-gaap/2023), "localname": "EarningsPerShareDiluted",
 "presentation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive"](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
["http://www.quincetx.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLos"](http://www.quincetx.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLos)
], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share - diluted (in USD
 per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net

income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r181", "r198", "r199", "r200", "r201", "r202", "r209", "r212", "r213", "r214", "r218", "r445", "r446", "r518", "r537", "r660"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.quincetx.com/role/NetLossPerShare"], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r206", "r215", "r216", "r217"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecrease", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r458"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail": { "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unamortized employee stock-based compensation", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r403"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "presentation": ["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOptions": { "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unamortized employee stock-based compensation expected to be recognized over remaining estimated vesting period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r403"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOptions": { "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Options, stock-based compensation not yet recognized", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for

option under share-based payment arrangement." } } }, "auth_ref": ["r800"] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": ["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "lang": { "en-us": { "role": { "terseLabel": "Income tax benefits recognized", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": ["r400"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShar", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDeta", "lang": { "en-us": { "role": { "terseLabel": "Stock Options", "verboseLabel": "Stock options issued and outstanding", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r699"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements

for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r699"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r699"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r703"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r699"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r699"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r699"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r699"] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r18", "r152", "r177", "r178", "r179", "r193",

"r194", "r195", "r197", "r203", "r205", "r219", "r273", "r274", "r360", "r405", "r406",
 "r407", "r417", "r418", "r436", "r437", "r438", "r439", "r440", "r441", "r444", "r459",
 "r460", "r461", "r462", "r463", "r464", "r477", "r540", "r541", "r542", "r556", "r620"]
 }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit",
 "calculation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails": {
 "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Equity investments in Lighthouse
 Pharmaceuticals, Inc.", "label": "Equity Method Investments", "documentation": "This
 item represents the carrying amount on the entity's balance sheet of its investment in
 common stock of an equity method investee. This is not an indicator of the fair value of
 the investment, rather it is the initial cost adjusted for the entity's share of
 earnings and losses of the investee, adjusted for any distributions (dividends) and
 other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": ["r225",
 "r271", "r713", "r751"] }, "qncx_EryDelMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.quincetx.com/20240930", "localname": "EryDelMember",
 "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCo
 "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandI
 "http://www.quincetx.com/role/FairValueMeasurementsAdditionalInformationDetails",
 "http://www.quincetx.com/role/LeasesAdditionalInformationDetails",
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Ery Del", "label": "Ery Del [Member]",
 "documentation": "EryDel." } } }, "auth_ref": [] },
 "qncx_EuropeanBankLoanTrancheATrancheBTrancheCMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.quincetx.com/20240930", "localname":
 "EuropeanBankLoanTrancheATrancheBTrancheCMember", "presentation": {
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "European Bank Loan, Tranche A, Tranche B, Tranche
 C", "label": "European Bank Loan, Tranche A, Tranche B, Tranche C [Member]",
 "documentation": "European Bank Loan, Tranche A, Tranche B, Tranche C" } } },
 "auth_ref": [] }, "qncx_EuropeanInvestmentBankLoanMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "EuropeanInvestmentBankLoanMember", "presentation": {
 "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails",
 "http://www.quincetx.com/role/OrganizationDetails",
 "http://www.quincetx.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "EIB loan", "label": "European Investment Bank Loan [Member]",
 "documentation": "European Investment Bank Loan [Member]" } } }, "auth_ref": [] },
 "qncx_EuropeanInvestmentBankLoanTrancheAAndTrancheBMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "EuropeanInvestmentBankLoanTrancheAAndTrancheBMember", "presentation": {
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "EIB Loan, Tranche A and Tranche B", "label":
 "European Investment Bank Loan, Tranche A and Tranche B [Member]", "documentation":
 "European Investment Bank Loan, Tranche A and Tranche B" } } }, "auth_ref": [] },
 "qncx_EuropeanInvestmentBankLoanTrancheAMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.quincetx.com/20240930", "localname":
 "EuropeanInvestmentBankLoanTrancheAMember", "presentation": {
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "EIB Loan, Tranche A", "label": "European Investment
 Bank Loan, Tranche A [Member]", "documentation": "European Investment Bank Loan, Tranche
 A" } } }, "auth_ref": [] }, "qncx_EuropeanInvestmentBankLoanTrancheBMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "EuropeanInvestmentBankLoanTrancheBMember", "presentation": {
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "EIB Loan, Tranche B", "label": "European Investment
 Bank Loan, Tranche B [Member]", "documentation": "European Investment Bank Loan, Tranche
 B" } } }, "auth_ref": [] }, "qncx_EuropeanInvestmentBankLoanTrancheCMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "EuropeanInvestmentBankLoanTrancheCMember", "presentation": {
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "EIB Loan Tranche C", "label": "European Investment

```
Bank Loan, Tranche C [Member]", "documentation": "European Investment Bank Loan, Tranche C } } } }, "auth_ref": [ ] }, "qncx_EuropeanInvestmentBankLoanTrancheDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "EuropeanInvestmentBankLoanTrancheDMember", "presentation": { "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "EIB Loan ,Tranche D", "label": "European Investment Bank Loan, Tranche D [Member]", "documentation": "European Investment Bank Loan, Tranche D" } } }, "auth_ref": [ ] }, "qncx_FairValueAdjustmentForContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "FairValueAdjustmentForContingentConsideration", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveIncome": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveIncome": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensiveIncome": { "parentTag": "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": { "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r448", "r449", "r453" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": { "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r448", "r449", "r453" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniques": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniques", "presentation": { "http://www.quincetx.com/role/FairValueMeasurementsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Quantitative Information About Fair Value Measurements", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r19" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": { "http://www.quincetx.com/role/FairValueMeasurementsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets and Liabilities to Fair Value
```

Measurements on Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r87", "r136"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcqua", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebt", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitie", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r328", "r362", "r363", "r364", "r365", "r366", "r367", "r449", "r484", "r485", "r486", "r668", "r669", "r674", "r675", "r676"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash", "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r448", "r449", "r451", "r452", "r454"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.quincetx.com/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r447"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitie", "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r328", "r362", "r367", "r449", "r484", "r674", "r675", "r676"] },

"us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities", "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r328", "r362", "r367", "r449", "r485", "r668", "r669", "r674", "r675", "r676"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcqu", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebt", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities", "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r328", "r362", "r363", "r364", "r365", "r366", "r367", "r449", "r486", "r668", "r669", "r674", "r675", "r676"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculation": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRe", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcqu", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcqu", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcqu", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": ["r20", "r89"] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending

balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": ["r20", "r89"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash", "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlement", "crdr": "debit", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcquired", "lang": { "en-us": { "role": { "negatedTerseLabel": "Payout of contingent earnout based on milestone achievement", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r88"] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcquired", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout", "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance as of January 1, 2024", "periodEndLabel": "Ending Balance as of September 30, 2024", "terseLabel": "Fair value measurements", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r20"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofChangesinPresentValueofAcquired", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebt", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r328", "r362", "r363", "r364", "r365", "r366", "r367", "r484", "r485", "r486", "r668", "r669", "r674", "r675", "r676"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash", "lang": { "en-us": { "role": { "terseLabel": "Fair Value on Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r447", "r454"] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.quincetx.com/role/LeasesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Minimum Lease Payments Under Lease Agreements", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": ["r808"] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0,
 "order": 3.0 } }, "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "lang": { "en-us": { "role": { "negatedLabel": "Payments of finance leases", "label":
 "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for
 principal payment on finance lease." } } }, "auth_ref": ["r470", "r472"] }, "us-
 gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation":
 {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale": {
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash": {
 "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities": {
 "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout": {
 "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label":
 "Financial Instrument [Axis]", "documentation": "Information by type of financial
 instrument." } } }, "auth_ref": ["r241", "r242", "r243", "r244", "r245", "r246",
 "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257",
 "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268",
 "r269", "r270", "r275", "r276", "r277", "r278", "r279", "r281", "r282", "r283", "r339",
 "r356", "r442", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489",
 "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500",
 "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r535",
 "r665", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r747", "r748", "r749",
 "r750"] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype":
 "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "FiniteLivedIntangibleAssetUsefulLife", "presentation": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang": {
 "lang": { "en-us": { "role": { "terseLabel": "Useful life", "label": "Finite-Lived
 Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible
 assets, in 'PnYnMnDtnHnMns' format, for example, 'PLY5M13D' represents the reported fact
 of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-
 gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang": {
 "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 }
 }, "presentation": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang": {
 "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label":
 "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation":
 "Accumulated amount of amortization of assets, excluding financial assets and goodwill,
 lacking physical substance with a finite life." } } }, "auth_ref": ["r160", "r296"] },
 "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang": {
 "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major
 Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
 "documentation": "Information by major type or class of finite-lived intangible assets."
 } } }, "auth_ref": ["r293", "r295", "r296", "r298", "r513", "r514"] }, "us-
 gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "FiniteLivedIntangibleAssetsFairValueDisclosure", "crdr": "debit", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails": {
 "lang": { "en-us": { "role": { "terseLabel": "Identifiable intangible assets", "label":
 "Finite-Lived Intangible Assets, Fair Value Disclosure", "documentation": "Fair value
 portion of assets, excluding financial assets, that lack physical substance, having a
 limited useful life." } } }, "auth_ref": ["r803"] }, "us-
 gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit",
 "presentation": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang": {

, "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang

, "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r122", "r514"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": { "http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang

, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r513"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang

, "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r53", "r56"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang

, "lang": { "en-us": { "role": { "totalLabel": "Net Carrying Value", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r122", "r513"] }, "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure", "crdr": "credit", "presentation": { "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment in fair value", "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure", "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into." } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": { "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation and Transactions", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign

```

reporting enterprise in a hyperinflationary economy." } } ], "auth_ref": [ "r457" ] },
"us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "FurnitureAndFixturesMember",
"presentation": [
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDeta
], "lang": { "en-us": { "role": { "terseLabel": "Office furniture", "label": "Furniture
and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores
that have no permanent connection to the structure of a building or utilities. Examples
include, but are not limited to, desks, chairs, tables, and bookcases." } } },
"auth_ref": [ ] }, "us-gaap_GainLossOnSaleOfInvestments": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"GainLossOnSaleOfInvestments", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0,
"order": 2.0 } }, "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "negatedLabel": "Equity investment in Lighthouse, Inc.",
"label": "Gain (Loss) on Sale of Investments", "documentation": "The net realized gain
(loss) on investments sold during the period, not including gains (losses) on securities
separately or otherwise categorized as trading, available-for-sale, or held-to-maturity,
which, for cash flow reporting, is a component of proceeds from investing activities." }
} }, "auth_ref": [ "r11" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive
": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 4.0 } },
"presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive
"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label":
"General and Administrative Expense", "documentation": "The aggregate total of expenses
of managing and administering the affairs of an entity, including affiliates of the
reporting entity, which are not directly or indirectly associated with the manufacture,
sale or creation of a product or product line." } } }, "auth_ref": [ "r110", "r604" ] },
"us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname":
"GeneralAndAdministrativeExpenseMember", "presentation": [
"http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
"http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedCompensationExpe
"], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expense",
"label": "General and Administrative Expense [Member]", "documentation": "Primary
financial statement caption encompassing general and administrative expense." } } },
"auth_ref": [ "r108" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation":
{
"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesOfAssetsAcquiredandL
": { "parentTag": "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
"weight": 1.0, "order": 1.0 },
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesOfAssetsAcquiredandL
", "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
"http://www.quincetx.com/role/IntangibleAssetsScheduleCarryingAmountofGoodwillDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Balance
as of December 31, 2023", "periodEndLabel": "Balance as of September 30, 2024", "label":
"Goodwill", "documentation": "Amount after accumulated impairment loss of an asset
representing future economic benefits arising from other assets acquired in a business
combination that are not individually identified and separately recognized." } } },
"auth_ref": [ "r159", "r287", "r515", "r666", "r685", "r754", "r761" ] },
"qncx_GoodwillAndIntangibleAssetImpairmentExcludingOperatingLeaseImpairment": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930",
"localname": "GoodwillAndIntangibleAssetImpairmentExcludingOperatingLeaseImpairment",
"crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 7.0 } }, "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],

```

```

"lang": { "en-us": { "role": { "verboseLabel": "Non-cash goodwill and intangible asset impairment charge", "label": "Goodwill And Intangible Asset Impairment, Excluding Operating Lease Impairment", "documentation": "Goodwill And Intangible Asset Impairment, Excluding Operating Lease Impairment" } } }, "auth_ref": [ ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r286", "r291", "r666" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r14" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.quincetx.com/role/IntangibleAssetsScheduleCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r290" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive", "http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.quincetx.com/role/IntangibleAssetsScheduleCarryingAmountofGoodwillDetails", "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Goodwill impairment charge", "terseLabel": "Impairment charge", "negatedTerseLabel": "Impairment charge", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r11", "r288", "r289", "r291", "r666" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.quincetx.com/role/IntangibleAssetsScheduleCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [ ] }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } },

```

"presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive",
 "http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails",
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIn",
 }, "lang": { "en-us": { "role": { "terseLabel": "Intangible asset impairment charge",
 "negatedLabel": "Impairment charge", "label": "Impairment of Intangible Assets
 (Excluding Goodwill)", "documentation": "The amount of impairment loss recognized in the
 period resulting from the write-down of the carrying amount of an intangible asset
 (excluding goodwill) to fair value." } } }, "auth_ref": ["r11", "r24"] }, "us-
 gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFinitelivedIntang",
 }, "lang": { "en-us": { "role": { "terseLabel": "Impairment charge", "label":
 "Impairment of Intangible Assets, Finite-Lived", "documentation": "The amount of
 impairment loss recognized in the period resulting from the write-down of the carrying
 amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": ["r722",
 "r766"] }, "qncx_ImputedInterestOnBorrowings": { "xbrltype": "percentItemType",
 "nsuri": "http://www.quincetx.com/20240930", "localname": "ImputedInterestOnBorrowings",
 "presentation": {
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Imputed interest", "label": "Imputed Interest on
 Borrowings", "documentation": "Imputed interest on borrowings" } } }, "auth_ref": [] },
 "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "InProcessResearchAndDevelopmentMember", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
 "http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails",
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIn",
 }, "lang": { "en-us": { "role": { "terseLabel": "IPR&D", "label": "In Process Research
 and Development [Member]", "documentation": "In process investigation of new knowledge
 useful in developing new product or service or new process or technique or improvement
 to existing product or process, and translation of knowledge into plan or design for new
 product or process or for improvement to existing product or process." } } },
 "auth_ref": [] }, "us-
 gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
 "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive",
 { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation":
 {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive",
 }, "lang": { "en-us": { "role": { "totalLabel": "Net loss before income tax benefit",
 "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest,
 before Tax", "documentation": "Amount, before tax, of income (loss) including portion
 attributable to noncontrolling interest. Includes, but is not limited to, income (loss)
 from continuing operations, discontinued operations and equity method investments." } }
 }, "auth_ref": ["r109", "r720"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income
 Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] },
 "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis",
 "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedCompensationExper",
 }, "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]",
 "label": "Income Statement Location [Axis]", "documentation": "Information by location
 in the income statement." } } }, "auth_ref": ["r299", "r300", "r605"] }, "us-
 gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain",
 "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedCompensationExper",
 }, "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]",
 "label": "Income Statement Location [Domain]", "documentation": "Location in the income

```

statement." } } }, "auth_ref": [ "r300", "r605" ] }, "us-
gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": {
"en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income
Tax Disclosure [Abstract]" } } }, "auth_ref": [ ] }, "us-
gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock",
"presentation": [ "http://www.quincetx.com/role/IncomeTaxes" ], "lang": { "en-us": {
"role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]",
"documentation": "The entire disclosure for income taxes. Disclosures may include net
deferred tax liability or asset recognized in an enterprise's statement of financial
position, net change during the year in the total valuation allowance, approximate tax
effect of each type of temporary difference and carryforward that gives rise to a
significant portion of deferred tax liabilities and deferred tax assets, utilization of
a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r191",
"r410", "r414", "r415", "r416", "r419", "r421", "r422", "r423", "r554" ] }, "us-
gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit",
"calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive
"parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } },
"presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive
"http://www.quincetx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": {
"negatedLabel": "Income tax (expense) benefit", "terseLabel": "Income tax expense",
"label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax
expense (benefit) and deferred income tax expense (benefit) pertaining to continuing
operations." } } }, "auth_ref": [ "r145", "r150", "r204", "r205", "r224", "r413",
"r420", "r538" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 11.0 } }, "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase
(Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the
reporting period in the aggregate amount of liabilities incurred (and for which invoices
have typically been received) and payable to vendors for goods and services received
that are used in an entity's business." } } }, "auth_ref": [ "r10" ] }, "us-
gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit",
"calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 10.0 } }, "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current
liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating
Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and
obligations classified as other." } } }, "auth_ref": [ "r721" ] },
"qncx_IncreaseDecreaseInFairValueOfBorrowings": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.quincetx.com/20240930", "localname":
"IncreaseDecreaseInFairValueOfBorrowings", "crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 5.0 } }, "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "terseLabel": "Change in fair value of long-term debt",
"label": "Increase Decrease in Fair Value of Borrowings", "documentation": "Increase
decrease in fair value of borrowings." } } }, "auth_ref": [ ] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and

```


liabilities, net of acquisitions:", "label": "Increase (Decrease) in Operating Capital
 {Abstract}"} } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0,
 "order": 16.0 } }, "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"},
 "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label": "Increase
 (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in
 current assets classified as other." } } }, "auth_ref": ["r721"] }, "us-
 gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit",
 "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0,
 "order": 4.0 } }, "presentation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails",
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"},
 "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current
 assets", "negatedTerseLabel": "Reduction in prepaid expenses and other current assets",
 "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation":
 "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } }
 }, "auth_ref": ["r10"] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudite
 }, "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders'
 Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll
 Forward]", "documentation": "A roll forward is a reconciliation of a concept from the
 beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
 gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
 "http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails",
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIn
 }, "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets
 [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation":
 "Information by type or class of assets, excluding financial assets and goodwill,
 lacking physical substance and having a projected indefinite period of benefit." } } },
 "auth_ref": ["r294", "r297"] }, "us-
 gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIn
 }, "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets
 [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]",
 "documentation": "Line items represent financial concepts included in a table. These
 concepts are used to disclose reportable information associated with domain members
 defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
 gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIn
 }, "lang": { "en-us": { "role": { "periodStartLabel": "Balance as of December 31, 2023",
 "periodEndLabel": "Balance as of September 30, 2024", "label": "Indefinite-Lived
 Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding
 financial assets and goodwill, lacking physical substance and having a projected
 indefinite period of benefit." } } }, "auth_ref": ["r123"] }, "us-
 gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit",
 "presentation": {
 "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIn
 }, "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation

adjustments", "label": "Indefinite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails", "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIntangibleAssets", "lang": { "en-us": { "role": { "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } } }, "auth_ref": ["r54", "r123"] }, "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsRollForward", "presentation": { "http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIntangibleAssets", "lang": { "en-us": { "role": { "terseLabel": "In-process research and development:", "label": "Indefinite-Lived Intangible Assets [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": { "http://www.quincetx.com/role/IntangibleAssets", "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } } }, "auth_ref": ["r292"] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } } }, "auth_ref": ["r52", "r55"] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncome": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncome", "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } } }, "auth_ref": ["r111", "r223"] }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "lang": { "en-us": { "role": { "negatedLabel": "Amortization of discount on available-for-sale investments", "label": "Investment Income, Net, Amortization of Discount and Premium", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } } }, "auth_ref": ["r112"] }, "qncx_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "LabEquipmentMember", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails", "lang": { "en-us": { "role": { "terseLabel": "Lab equipment", "label": "Lab Equipment [Member]", "documentation": "Lab equipment." } } } }, "auth_ref": [] }, "us-

gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDebt", "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvement", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r124"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": ["http://www.quincetx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r471"] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": ["http://www.quincetx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": ["r471"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated": { "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r476"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r476"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated": { "lang": { "en-us": { "role": { "terseLabel": "2028 and thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r476"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0,

```

"order": 3.0 } }, "presentation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated",
"lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating
Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's
undiscounted obligation for lease payment for operating lease to be paid in third fiscal
year following current fiscal year. Excludes interim and annual periods when interim
periods are reported from current statement of financial position date (rolling
approach)." } } }, "auth_ref": [ "r476" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated",
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0,
"order": 2.0 } }, "presentation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated",
"lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating
Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's
undiscounted obligation for lease payment for operating lease to be paid in second
fiscal year following current fiscal year. Excludes interim and annual periods when
interim periods are reported from current statement of financial position date (rolling
approach)." } } }, "auth_ref": [ "r476" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit",
"calculation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated",
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0,
"order": 1.0 } }, "presentation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated",
"lang": { "en-us": { "role": { "terseLabel": "2024 (remainder of the year)", "label":
"Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
"documentation": "Amount of lessee's undiscounted obligation for lease payment for
operating lease having initial or remaining lease term in excess of one year to be paid
in remainder of current fiscal year." } } }, "auth_ref": [ "r808" ] }, "us-
gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit",
"calculation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated",
"parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0,
"order": 1.0 } }, "presentation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated",
"lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label":
"Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation":
"Amount of lessee's undiscounted obligation for lease payments in excess of discounted
obligation for lease payments for operating lease." } } }, "auth_ref": [ "r476" ] },
"us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract",
"presentation": [ "http://www.quincetx.com/role/LeasesAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Lease agreement period", "label": "Lessee,
Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease,
in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one
year, five months, and thirteen days." } } }, "auth_ref": [ "r807" ] }, "us-
gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock",
"presentation": [ "http://www.quincetx.com/role/Leases" ], "lang": { "en-us": { "role":
{ "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]",
"documentation": "The entire disclosure for operating leases of lessee. Includes, but is
not limited to, description of operating lease and maturity analysis of operating lease
liability." } } }, "auth_ref": [ "r467" ] }, "us-gaap_Liabilities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities",
"crdr": "credit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }
}, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": {
"en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities",

```

"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": ["r30", "r190", "r272", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r431", "r434", "r435", "r456", "r579", "r661", "r697", "r768", "r809", "r810"] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": ["http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated", "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r105", "r143", "r530", "r685", "r725", "r752", "r804"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r32", "r155", "r190", "r272", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r431", "r434", "r435", "r456", "r685", "r768", "r809", "r810"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueAdjustment", "crdr": "credit", "presentation": ["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustment", "label": "Liabilities, Fair Value Adjustment", "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r87"] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": ["http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities"], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUncertainTaxPositionsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilityForUncertainTaxPositionsCurrent", "crdr": "credit", "presentation": [

["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails"](http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails)],
 "lang": { "en-us": { "role": { "terseLabel": "Uncertain tax position liability",
 "label": "Liability for Uncertainty in Income Taxes, Current", "documentation": "Amount
 recognized for uncertainty in income taxes classified as current." } } }, "auth_ref": ["r31"] },
 "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems",
 "presentation": ["http://www.quincetx.com/role/OrganizationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of
 Credit Facility [Line Items]", "documentation": "Line items represent financial concepts
 included in a table. These concepts are used to disclose reportable information
 associated with domain members defined in one or many axes to the table." } } },
 "auth_ref": ["r724"] },
 "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
 "crdr": "credit", "presentation": ["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowings", "label": "Line of Credit
 Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity
 under the credit facility without consideration of any current restrictions on the
 amount that could be borrowed or the amounts currently outstanding under the facility." } } },
 "auth_ref": ["r29"] },
 "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "LineOfCreditFacilityTable", "presentation": ["http://www.quincetx.com/role/OrganizationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility
 [Table]", "documentation": "A table or schedule providing information pertaining to
 short-term or long-term contractual arrangements with lenders, including letters of
 credit, standby letters of credit, and revolving credit arrangements, under which
 borrowings can be made up to maximum amount as of any point in time conditional on
 satisfaction of specified terms before, as of and after the date of drawdowns on the
 line." } } }, "auth_ref": ["r29", "r724"] },
 "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "LineOfCreditMember", "presentation": ["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails",
 "http://www.quincetx.com/role/OrganizationDetails",
 "http://www.quincetx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A
 contractual arrangement with a lender under which borrowings can be made up to a
 specific amount at any point in time, and under which borrowings outstanding may be
 either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] },
 "us-gaap_LoansPayableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "LoansPayableFairValueDisclosure", "crdr":
 "credit", "presentation": ["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value of the EIB Loan", "label": "Loans
 Payable, Fair Value Disclosure", "documentation": "Fair value portion of contractual
 obligation to pay money on demand or on fixed or determinable dates." } } }, "auth_ref": [] },
 "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri":
 "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel":
 "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone
 number for entity." } } }, "auth_ref": [] },
 "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "LongTermDebt", "crdr": "credit", "calculation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
 "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 },
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails"
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails",
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails"
 "http://www.quincetx.com/role/OrganizationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "totalLabel": "Total Debt as of September 30, 2024",
 "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized
 premium (discount) and debt issuance cost, of long-term debt. Excludes lease
 obligation." } } }, "auth_ref": ["r27", "r142", "r327", "r342", "r668", "r669", "r819"
] },
 "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":

"LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit",
 "calculation": {
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
 { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } },
 "presentation": {
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
 }, "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt,
 Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund
 requirement, and other securities issued that are redeemable by holder at fixed or
 determinable price and date, maturing in next fiscal year following current fiscal year.
 Excludes interim and annual periods when interim periods are reported from current
 statement of financial position date (rolling approach)." } } }, "auth_ref": ["r13",
 "r192", "r332"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation":
 {
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
 { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } },
 "presentation": {
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
 }, "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt,
 Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund
 requirement, and other securities issued that are redeemable by holder at fixed or
 determinable price and date, maturing in second fiscal year following current fiscal
 year. Excludes interim and annual periods when interim periods are reported from current
 statement of financial position date (rolling approach)." } } }, "auth_ref": ["r13",
 "r192", "r332"] }, "us-
 gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit",
 "calculation": {
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
 { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } },
 "presentation": {
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
 }, "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Long-Term Debt,
 Maturity, Remainder of Fiscal Year", "documentation": "Amount of long-term debt payable,
 sinking fund requirement, and other securities issued that are redeemable by holder at
 fixed or determinable price and date, maturing in remainder of current fiscal year." } }
 }, "auth_ref": ["r726"] },
 "qncx_LongTermDebtMaturitiesRepaymentsOfPrincipalYearThreeAndThereafter": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "LongTermDebtMaturitiesRepaymentsOfPrincipalYearThreeAndThereafter", "crdr": "credit",
 "calculation": {
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
 { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } },
 "presentation": {
 "http://www.quincetx.com/role/LongtermDebtScheduleofFutureMinimumPrincipalPaymentsDetails
 }, "lang": { "en-us": { "role": { "terseLabel": "2027 and thereafter", "label": "Long
 Term Debt Maturities Repayments of Principal Year Three and Thereafter",
 "documentation": "Long term debt maturities repayments of principal year three and
 thereafter." } } }, "auth_ref": [] }, "qncx_LossOnDisposal": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "LossOnDisposal", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
 "order": 14.0 } }, "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"},
 "lang": { "en-us": { "role": { "terseLabel": "Loss on disposal of fixed assets",
 "label": "Loss On Disposal", "documentation": "Loss on disposal." } } }, "auth_ref": []
 }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": {
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
 "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout",
 "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails",
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail",
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt

"http://www.quincetx.com/role/StockBasedCompensationRSUsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": { "r301", "r302", "r303", "r304", "r368", "r511", "r539", "r571", "r572", "r625", "r627", "r629", "r630", "r632", "r653", "r654", "r664", "r672", "r679", "r686", "r770", "r811", "r812", "r813", "r814", "r815", "r816" } },
"qncx_MaximumPeriodForCommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "durationItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "MaximumPeriodForCommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Maximum period for common stock shares reserved for future issuance", "label": "Maximum Period For Common Stock Capital Shares Reserved For Future Issuance", "documentation": "Maximum period for common stock capital shares reserved for future issuance." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": ["r450"] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "qncx_MedollaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "MedollaMember", "presentation": { "http://www.quincetx.com/role/LeasesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Medolla, Italy", "label": "Medolla [Member]", "documentation": "Medolla." } } }, "auth_ref": [] },
"qncx_MilestoneAchievementRelatedToMarketAndSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "MilestoneAchievementRelatedToMarketAndSales", "crdr": "credit", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Milestone achievement related to market and sales", "label": "Milestone Achievement Related To Market And Sales", "documentation": "Milestone achievement related to market and sales." } } }, "auth_ref": [] }, "qncx_MilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "MilestonePayment", "crdr": "credit", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "label": "Milestone Payment", "documentation": "Milestone payment." } } }, "auth_ref": [] }, "qncx_MilestonePaymentAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "MilestonePaymentAxis", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Milestone Payment [Axis]", "label": "Milestone Payment [Axis]", "documentation": "Milestone payment axis" } } }, "auth_ref": [] }, "qncx_MilestonePaymentDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "MilestonePaymentDomain", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Milestone Payment [Domain]", "label": "Milestone Payment [Domain]", "documentation": "Milestone payment domain" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout", "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": { "r301", "r302", "r303", "r304", "r368", "r511", "r539", "r571", "r572", "r625", "r627", "r629", "r630", "r632", "r653", "r654", "r664", "r672", "r679", "r686", "r770", "r811", "r812", "r813", "r814", "r815", "r816" } }, "us-gaap_MoneyMarketFundsMember": {

"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "MoneyMarketFundsMember", "presentation": [
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale",
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash",
 "http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities",
], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money
Market Funds [Member]", "documentation": "Fund that invests in short-term money-market
instruments, for example, but not limited to, commercial paper, banker's acceptances,
repurchase agreements, government securities, certificates of deposit, and other highly
liquid securities." } } }, "auth_ref": ["r773"] },
 "qncx_MonthlyInstallmentsRemainingVestingPeriod": { "xbrltype": "durationItemType",
 "nsuri": "http://www.quincetx.com/20240930", "localname":
 "MonthlyInstallmentsRemainingVestingPeriod", "presentation": [
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail",
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt",
], "lang": { "en-us": { "role": { "terseLabel": "Monthly installments over the remaining
vesting period", "label": "Monthly Installments, Remaining Vesting Period",
 "documentation": "Monthly installments, remaining vesting period." } } }, "auth_ref": [] },
 "qncx_NDAAcceptanceUnderContingentConsideration": { "xbrltype": "monetaryItemType",
 "nsuri": "http://www.quincetx.com/20240930", "localname":
 "NDAAcceptanceUnderContingentConsideration", "crdr": "credit", "presentation": [
 "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "NDA acceptance under contingent
consideration", "label": "NDA Acceptance Under Contingent Consideration",
 "documentation": "NDA acceptance under contingent consideration." } } }, "auth_ref": [] },
 "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecrease",
 "weight": 1.0, "order": 1.0 } }, "presentation": [
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"],
 "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing
activities", "label": "Net Cash Provided by (Used in) Financing Activities",
 "documentation": "Amount of cash inflow (outflow) from financing activities, including
discontinued operations. Financing activity cash flows include obtaining resources from
owners and providing them with a return on, and a return of, their investment; borrowing
money and repaying amounts borrowed, or settling the obligation; and obtaining and
paying for other resources obtained from creditors on long-term credit." } } },
 "auth_ref": ["r185"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract":
 { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"],
 "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:",
 "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } },
 "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecrease",
 "weight": 1.0, "order": 2.0 } }, "presentation": [
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"],
 "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing
activities", "label": "Net Cash Provided by (Used in) Investing Activities",
 "documentation": "Amount of cash inflow (outflow) from investing activities, including
discontinued operations. Investing activity cash flows include making and collecting
loans and acquiring and disposing of debt or equity instruments and property, plant, and
equipment and other productive assets." } } }, "auth_ref": ["r185"] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"],
 "lang": { "en-us": { "role": { "terseLabel": "Cash flow from investing activities:",
 "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } },
 "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "NetCashProvidedByUsedInOperatingActivities", "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-
 gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecrease",
 "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },
 "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities",
 "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount
 of cash inflow (outflow) from operating activities, including discontinued operations.
 Operating activity cash flows include transactions, adjustments, and changes in value
 not defined as investing or financing activities." } } }, "auth_ref": ["r116", "r117",
 "r118"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },
 "lang": { "en-us": { "role": { "verboseLabel": "Cash flows from operating activities",
 "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } },
 "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit",
 "calculation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive
 { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } },
 "presentation": {
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudite
 "http://www.quincetx.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLos
 }, "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss",
 "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of
 profit or loss for the period, net of income taxes, which is attributable to the
 parent." } } }, "auth_ref": ["r107", "r118", "r144", "r153", "r173", "r175", "r179",
 "r190", "r196", "r198", "r199", "r200", "r201", "r204", "r205", "r211", "r222", "r232",
 "r234", "r236", "r272", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312",
 "r313", "r446", "r456", "r534", "r601", "r618", "r619", "r662", "r695", "r768"] }, "us-
 gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": {
 "http://www.quincetx.com/role/NetLossPerShareScheduleofComputationofBasicandDilutedNetLos
 }, "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income
 (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": {
 "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang":
 { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements Not Yet Adopted",
 "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation":
 "Disclosure of accounting policy pertaining to new accounting pronouncements that may
 impact the entity's financial reporting. Includes, but is not limited to, quantification
 of the expected or actual impact." } } }, "auth_ref": [] }, "us-
 gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensationTables" }, "lang": { "en-us": {
 "role": { "terseLabel": "Schedule of Nonvested Restricted Stock Shares Activity",
 "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
 "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted
 stock shares." } } }, "auth_ref": ["r26"] }, "qncx_NovosteoMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "NovosteoMember", "presentation": {
 "http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails" },
 "lang": { "en-us": { "role": { "verboseLabel": "Novosteo", "label": "Novosteo [Member]",
 "documentation": "Novosteo member" } } }, "auth_ref": [] }, "qncx_NovosteoPlanMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
 "NovosteoPlanMember", "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDeta
 }, "lang": { "en-us": { "role": { "terseLabel": "2019 Novosteo Plan", "label": "2019
 Novosteo Plan [Member]", "documentation": "2019 Novosteo Plan" } } }, "auth_ref": [] },

"qncx_NumberOfLeaseAgreementsAcquired": { "xbrltype": "integerItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "NumberOfLeaseAgreementsAcquired", "presentation": { "http://www.quincetx.com/role/LeasesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of lease agreements acquired", "label": "Number Of Lease Agreements Acquired", "documentation": "Number Of Lease Agreements Acquired" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": { "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of operating segment", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r732"] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": { "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segment", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r732"] }, "qncx_OneYearAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "OneYearAnniversaryMember", "presentation": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt" }, "lang": { "en-us": { "role": { "terseLabel": "One Year Anniversary", "label": "One Year Anniversary [Member]", "documentation": "One Year Anniversary" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive" }, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive" }, "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive" }, "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive" }, "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive" }, "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r222", "r232", "r234", "r236", "r662"] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": { "http://www.quincetx.com/role/LeasesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Rent expenses (less than)", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": ["r806"] }, "us-gaap_OperatingLeaseImpairmentLoss": {

```

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"OperatingLeaseImpairmentLoss", "crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 6.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },
"lang": { "en-us": { "role": { "terseLabel": "Impairment loss on operating lease",
"label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from
impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r805" ] },
"us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname":
"OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
", "lang": { "en-us": { "role": { "terseLabel": "Operating Lease, Liability, Payment,
Due [Abstract]", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year
Maturity [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_OperatingLeaseLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"OperatingLeaseLiability", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
{ "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0,
"order": 2.0 },
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.quincetx.com/role/LeasesAdditionalInformationDetails",
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
", "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability",
"totalLabel": "Total remaining lease liability", "label": "Operating Lease, Liability",
"documentation": "Present value of lessee's discounted obligation for lease payments
from operating lease." } } }, "auth_ref": [ "r469" ] }, "us-
gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr":
"credit", "calculation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
{ "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 } },
"presentation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
", "lang": { "en-us": { "role": { "terseLabel": "Short-term operating lease liability",
"label": "Operating Lease, Liability, Current", "documentation": "Present value of
lessee's discounted obligation for lease payments from operating lease, classified as
current." } } }, "auth_ref": [ "r469" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
{ "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 },
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
", "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities",
"label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of
lessee's discounted obligation for lease payments from operating lease, classified as
noncurrent." } } }, "auth_ref": [ "r469" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
"http://www.quincetx.com/role/LeasesAdditionalInformationDetails",
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated
", "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets",
"verboseLabel": "Operating lease asset", "label": "Operating Lease, Right-of-Use Asset",
"documentation": "Amount of lessee's right to use underlying asset under operating
lease." } } }, "auth_ref": [ "r468" ] }, "us-
gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname":
"OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": {
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated

```

, "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate (as percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r475", "r684"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated", "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r474", "r684"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": ["http://www.quincetx.com/role/Organization", "lang": { "en-us": { "role": { "terseLabel": "Organization", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r96", "r135", "r546", "r547"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri", "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCuri", "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r31"] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails", "lang": { "en-us": { "role": { "totalLabel": "Total other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": ["r139", "r161", "r522", "r697"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCuri", "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCuri", "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r168", "r685"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r161"] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassification": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAc", "crdr": "credit", "calculation": {

["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
 { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } },
 "presentation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited](http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited)
 }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on available-
 for-sale securities", "verboseLabel": "Unrealized gain (loss) on available for sale
 investments", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before
 Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of
 unrealized gain (loss) on investment in debt security measured at fair value with change
 in fair value recognized in other comprehensive income (available-for-sale) and
 unrealized gain (loss) on investment in debt security measured at amortized cost (held-
 to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r170", "r171"]
 }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr":
 "credit", "presentation": {
["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsAdditionalInformationDetail](http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsAdditionalInformationDetail)
 }, "lang": { "en-us": { "role": { "terseLabel": "Amounts reclassify out of accumulated
 other comprehensive loss", "label": "OCI, Debt Securities, Available-for-Sale, Gain
 (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment,
 of unrealized gain (loss) on investment in debt security measured at fair value with
 change in fair value recognized in other comprehensive income (available-for-sale) and
 unrealized gain (loss) on investment in debt security measured at amortized cost (held-
 to-maturity) from transfer to available-for-sale." } } }, "auth_ref": ["r170", "r171",
 "r172"] }, "us-
 gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfI
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
 "crdr": "credit", "calculation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
 { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } },
 "presentation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited](http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited)
 }, "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation
 adjustments", "verboseLabel": "Foreign currency translation adjustment", "label": "Other
 Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment,
 Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain
 (loss) on foreign currency translation adjustments, foreign currency transactions
 designated and effective as economic hedges of a net investment in a foreign entity and
 intra-entity foreign currency transactions that are of a long-term-investment nature." }
 } }, "auth_ref": ["r6"] }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "OtherComprehensiveIncomeLossTaxAbstract", "presentation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
 }, "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss:", "label":
 "Other Comprehensive Income (Loss), Tax [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr":
 "credit", "calculation": {
["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {](http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited)
 "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": {
["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"](http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited) }, "lang": {
 "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other
 Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other,
 due after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r35"
] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense",
 "crdr": "credit", "calculation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
 { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
 "weight": 1.0, "order": 4.0 } }, "presentation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive](http://www.quincetx.com/role/CondensedConsolidatedStatementsofOperationsandComprehensive)
 }, "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label":
 "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense)
 related to nonoperating activities, classified as other." } } }, "auth_ref": ["r113"]

, "qncx_OtherOperatingLeasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "OtherOperatingLeasesMember", "presentation": { "http://www.quincetx.com/role/LeasesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other Operating Leases", "label": "Other Operating Leases [Member]", "documentation": "Other operating leases." } } }, "auth_ref": [] }, "us-gaap_OtherRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherRestructuringCosts", "crdr": "debit", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Expenses related to employment obligation", "label": "Other Restructuring Costs", "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r11"] }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration", "label": "Payment for Contingent Consideration Liability, Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": ["r9"] }, "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities", "crdr": "credit", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/FairValueMeasurementsAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Payment for contingent consideration", "label": "Payment for Contingent Consideration Liability, Investing Activities", "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability." } } }, "auth_ref": ["r7"] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": { "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "http://www.quincetx.com/role/OrganizationDetails", "http://www.quincetx.com/role/SubsequentEventsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Payment of one-time amendment fee", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": ["r44"] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "negatedLabel": "Purchase of investments", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r42", "r182", "r239"] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor", "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the

acquisition price." } } }, "auth_ref": ["r43", "r426"] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor", "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCor", "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": ["r43"] }, "us-gaap_PaymentsToAcquireNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireNotesReceivable", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Note receivable", "label": "Payments to Acquire Notes Receivable", "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics." } } }, "auth_ref": ["r42"] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r115"] }, "qncx_PercentageOfVotingRights": { "xbrltype": "pureItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "PercentageOfVotingRights", "presentation": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "lang": { "en-us": { "role": { "terseLabel": "Voting rights in percentage", "label": "Percentage of Voting Rights", "documentation": "Percentage of voting rights." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGeneral", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDeta", "http://www.quincetx.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGeneral", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDeta

"http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799"] }, "us-gaap-PreferredStockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendsShares", "presentation": ["http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, dividends (in shares)", "label": "Preferred Stock Dividends, Shares", "documentation": "Number of shares of preferred stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": ["r18"] }, "us-gaap-PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": ["http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": ["r687", "r688", "r691", "r692", "r693", "r694", "r821", "r822"] }, "us-gaap-PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in USD per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r99", "r344"] }, "us-gaap-PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r99", "r581"] }, "us-gaap-PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": ["r99", "r344"] }, "us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r99", "r581", "r599", "r822", "r823"] }, "us-gaap-PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, \$0.001 par value, 10,000,000 authorized, (100,000 shares of which are designated as Series A Junior Participating Preferred Stock), no shares issued and outstanding as of September\u00a0030, 2024 and December\u00a0031, 2023, respectively.", "label": "Preferred Stock, Value, Issued",

```

"documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r99", "r526", "r685" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurr": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurr": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r717" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurr": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurr": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r167", "r284", "r285", "r658" ] }, "qncx_PrepaidInsuranceCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "PrepaidInsuranceCurrent", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurr": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurr": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Prepaid insurance", "label": "Prepaid Insurance Current", "documentation": "Prepaid insurance current." } } }, "auth_ref": [ ] }, "qncx_PrepaidResearchAndDevelopmentExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "PrepaidResearchAndDevelopmentExpensesCurrent", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurr": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPrepaidExpensesandOtherCurr": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "lang": { "en-us": { "role": { "terseLabel": "Prepaid research and development expenses", "label": "Prepaid Research And Development Expenses Current", "documentation": "Prepaid research and development expenses, current." } } }, "auth_ref": [ ] }, "qncx_ProbabilityDiscountRateOfEachMilestone": { "xbrltype": "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ProbabilityDiscountRateOfEachMilestone", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Business combination discount rate", "label": "Probability Discount Rate of Each Milestone", "documentation": "Probability Discount Rate of Each Milestone" } } }, "auth_ref": [ ] }, "qncx_ProbabilityOfAchievementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ProbabilityOfAchievementMember", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Probability of Achievement", "label": "Probability Of Achievement [Member]", "documentation": "Probability of achievement." } } }, "auth_ref": [ ] }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIncomeTaxRefunds", "crdr": "debit", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails": {

```

```

"lang": { "en-us": { "role": { "terseLabel": "Proceeds from income tax refunds",
"label": "Proceeds from Income Tax Refunds", "documentation": "The amount of cash
received during the period as refunds for the overpayment of taxes." } } }, "auth_ref":
{ "r47", "r117" } }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit",
"calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0,
"order": 2.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },
"lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of investments",
"label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
"documentation": "Amount of cash inflow from sale, maturity, prepayment and call of
investment in debt security measured at fair value with change in fair value recognized
in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r182",
"r183", "r735" } }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0,
"order": 3.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },
"lang": { "en-us": { "role": { "terseLabel": "Proceeds from disposal of assets",
"label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow
from the sale of property, plant and equipment (capital expenditures), software, and
other intangible assets." } } }, "auth_ref": { "r114" } }, "us-
gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised",
"crdr": "debit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0,
"order": 2.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },
"lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock
upon exercise of stock options", "label": "Proceeds from Stock Options Exercised",
"documentation": "Amount of cash inflow from exercise of option under share-based
payment arrangement." } } }, "auth_ref": { "r8", "r23" } }, "us-gaap_ProfitLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ProfitLoss", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 15.0 } }, "presentation": {
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" },
"lang": { "en-us": { "role": { "terseLabel": "Net Loss", "label": "Net Income (Loss),
Including Portion Attributable to Noncontrolling Interest", "documentation": "The
consolidated profit or loss for the period, net of income taxes, including the portion
attributable to the noncontrolling interest." } } }, "auth_ref": { "r153", "r173",
"r175", "r184", "r190", "r196", "r204", "r205", "r222", "r232", "r234", "r236", "r272",
"r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r429", "r432",
"r433", "r446", "r456", "r519", "r533", "r555", "r601", "r618", "r619", "r662", "r682",
"r683", "r696", "r720", "r768" } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PropertyPlantAndEquipmentByTypeAxis", "presentation": {
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDebt":
"http://www.quincetx.com/role/LeasesAdditionalInformationDetails" }, "lang": { "en-us":
{ "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible
Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used
to produce goods and services and not intended for resale." } } }, "auth_ref": { "r12" }
}, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr":
"debit", "calculation": {
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDebt":
{ "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } },
"presentation": {
"http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDebt":
}, "lang": { "en-us": { "role": { "terseLabel": "Property and equipment", "label":

```

"Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } }], "auth_ref": ["r124", "r157", "r532"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 }, "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r12", "r520", "r532", "r685"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r12"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.quincetx.com/role/LeasesAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r124"] }, "gncx_ProvisionForAdditionalRemunerationPaidBasedOnRevenueBetween125MillionAnd250MillionEuro": { "xbrltype": "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ProvisionForAdditionalRemunerationPaidBasedOnRevenueBetween125MillionAnd250MillionEuro", "presentation": { "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Provision for additional remuneration paid based on revenue between 125 Million and 250 Million Euros, percentage", "label": "Provision For Additional Remuneration Paid Based On Revenue Between 125 Million And 250 Million Euros, Percentage", "documentation": "Provision For Additional Remuneration Paid Based On Revenue Between 125 Million And 250 Million Euros, Percentage" } } }, "auth_ref": [] }, "gncx_ProvisionForAdditionalRemunerationPaidBasedOnRevenueGreaterThan250MillionEurosPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ProvisionForAdditionalRemunerationPaidBasedOnRevenueGreaterThan250MillionEurosPercentage", "presentation": { "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Provision for additional remuneration paid based on revenue greater than 250 Million Euros, percentage", "label": "Provision For Additional Remuneration Paid Based On Revenue Greater Than 250 Million Euros, Percentage", "documentation": "Provision For Additional Remuneration Paid Based On Revenue Greater Than 250 Million Euros, Percentage" } } }, "auth_ref": [] }, "gncx_ProvisionForAdditionalRemunerationPaidBasedOnRevenueUpTo125MillionEurosPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ProvisionForAdditionalRemunerationPaidBasedOnRevenueUpTo125MillionEurosPercentage", "presentation": { "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Provision for additional remuneration paid based on revenue up to 125 Million Euros, percentage", "label": "Provision For Additional Remuneration Paid Based On Revenue Up To 125 Million Euros, Percentage", "documentation": "Provision For Additional Remuneration Paid Based On Revenue Up To 125 Million Euros, Percentage" } } }, "auth_ref": [] }

"en-us": { "role": { "terseLabel": "Provision for additional remuneration paid based on revenue up to 125 Million Euros, percentage", "label": "Provision For Additional Remuneration Paid Based On Revenue Up To 125 Million Euros, Percentage", "documentation": "Provision for additional remuneration paid based on revenue percentage." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout", "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r301", "r302", "r303", "r304", "r361", "r368", "r396", "r397", "r398", "r487", "r511", "r539", "r571", "r572", "r625", "r627", "r629", "r630", "r632", "r653", "r654", "r664", "r672", "r679", "r686", "r689", "r767", "r770", "r812", "r813", "r814", "r815", "r816"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout", "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r301", "r302", "r303", "r304", "r361", "r368", "r396", "r397", "r398", "r487", "r511", "r539", "r571", "r572", "r625", "r627", "r629", "r630", "r632", "r653", "r654", "r664", "r672", "r679", "r686", "r689", "r767", "r770", "r812", "r813", "r814", "r815", "r816"] }, "qncx_ReductionsInResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ReductionsInResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Reductions in research and development expense", "label": "Reductions in Research and Development Expense", "documentation": "Reductions in research and development expense." } } }, "auth_ref": [] }, "qncx_RemunerationPayablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "RemunerationPayablePeriod", "presentation": ["http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails"] }, "lang": { "en-us": { "role": { "terseLabel": "Remuneration payable period", "label": "Remuneration Payable Period", "documentation": "Remuneration payable period." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive" { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive"], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": ["r95", "r409", "r817"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedCompensationExper


```

}, "lang": { "en-us": { "role": { "terseLabel": "Research and development expense",
"label": "Research and Development Expense [Member]", "documentation": "Primary
financial statement caption in which the reported facts about research and development
expense have been included." } } }, "auth_ref": [ ] },
"qncx_RestrictedStockAwardsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.quincetx.com/20240930", "localname": "RestrictedStockAwardsMember",
"presentation": [
"http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails",
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail",
"http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Awards", "label":
"Restricted Stock Awards [Member]", "documentation": "Restricted stock awards." } } },
"auth_ref": [ ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember",
"presentation": [
"http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShar
], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards", "label":
"Restricted Stock [Member]", "documentation": "Stock including a provision that
prohibits sale or substantive sale of an equity instrument for a specified period of
time or until specified performance conditions are met." } } }, "auth_ref": [ "r48" ] },
"us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember",
"presentation": [
"http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShar
"http://www.quincetx.com/role/StockBasedCompensationRSUsDetails",
"http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "verboseLabel":
"Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]",
"documentation": "Share instrument which is convertible to stock or an equivalent amount
of cash, after a specified period of time or when specified performance conditions are
met." } } }, "auth_ref": [ ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
"parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } },
"presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
"http://www.quincetx.com/role/OrganizationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "label":
"Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated
undistributed earnings (deficit)." } } }, "auth_ref": [ "r102", "r129", "r529", "r543",
"r545", "r553", "r582", "r685" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"RetainedEarningsMember", "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudite
], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label":
"Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings
(deficit)." } } }, "auth_ref": [ "r152", "r193", "r194", "r195", "r197", "r203", "r205",
"r273", "r274", "r405", "r406", "r407", "r417", "r418", "r436", "r438", "r439", "r441",
"r444", "r540", "r542", "r556", "r822" ] }, "us-
gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit",
"presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "negatedTerseLabel": "Right-of-use asset and financing
lease liability reduction as a result of lease modification", "label": "Right-of-Use
Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of
increase in right-of-use asset obtained in exchange for finance lease liability." } } },
"auth_ref": [ "r473", "r684" ] }, "us-
gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit",
"presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ],
"lang": { "en-us": { "role": { "terseLabel": "Right-of-use assets obtained in exchange
for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange

```


for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r473", "r684"] }, "qncx_RightOfUseAssetsOperatingLeasesAndOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "RightOfUseAssetsOperatingLeasesAndOperatingLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": { "http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "negatedLabel": "Right of use assets, operating leases and operating lease liabilities", "label": "Right of Use Assets Operating Leases and Operating Lease Liabilities", "documentation": "Right of use assets operating leases and operating lease liabilities." } } }, "auth_ref": [] }, "qncx_RightsPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "RightsPlanMember", "presentation": { "http://www.quincetx.com/role/StockholdersEquityDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Rights Plan", "label": "Rights Plan [Member]", "documentation": "Rights plan." } } }, "auth_ref": [] }, "qncx_RisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "RisksAndUncertaintiesPolicyTextBlock", "presentation": { "http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies" }, "lang": { "en-us": { "role": { "terseLabel": "Risks and Uncertainties", "label": "Risks And Uncertainties [Policy Text Block]", "documentation": "Risks and uncertainties." } } }, "auth_ref": [] }, "qncx_RoyaltyRateUtilizingUnderIncomeApproach": { "xbrltype": "percentItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "RoyaltyRateUtilizingUnderIncomeApproach", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Royalty rate utilized", "label": "Royalty Rate Utilizing Under Income Approach", "documentation": "Royalty rate utilizing under income approach." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.quincetx.com/role/NetLossPerShareScheduleofOutstandingPotentiallyDilutiveShares" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": ["r48"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": { "http://www.quincetx.com/role/NetLossPerShareTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Potentially Dilutive Ordinary Shares Excluded from Calculation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r48"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": { "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale" } } } }

<http://www.quincetx.com/role/FairValueMeasurementsScheduleofFairValueoftheLevel3EIBDebt>
<http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities>
<http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout>
, "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Available For Sale Securities [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252"] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": ["http://www.quincetx.com/role/BusinessCombinationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of the Total Purchase Consideration Transferred", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValueoftheTotalPurchaseCon", "http://www.quincetx.com/role/BusinessCombinationScheduleofFairValuesofAssetsAcquiredandL", "http://www.quincetx.com/role/FairValueMeasurementsAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": ["r76", "r77", "r424"] }, "qncx_ScheduleOfCashCashEquivalentsAndInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ScheduleOfCashCashEquivalentsAndInvestmentsTableTextBlock", "presentation": ["http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Values of Cash, Cash Equivalents, and Short-Term Investments Measured at Fair Value on Recurring Basis", "label": "Schedule Of Cash Cash Equivalents And Investments [Table Text Block]", "documentation": "Schedule of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.quincetx.com/role/NetLossPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r731"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.quincetx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee and Non-Employee Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r70"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [

["http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails"](http://www.quincetx.com/role/IntangibleAssetsAdditionalInformationDetails),
["http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang](http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofFiniteLivedIntang)
`l`, `"lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible`
`Assets [Table]"`, `"label": "Schedule of Finite-Lived Intangible Assets [Table]"`,
`"documentation": "Schedule of assets, excluding financial assets and goodwill, lacking`
`physical substance with a finite life." } } }`, `"auth_ref": [ "r53", "r56", "r513" ] }`,
`"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype":`
`"textBlockItemType"`, `"nsuri": "http://fasb.org/us-gaap/2023"`, `"localname":`
`"ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"`, `"presentation": [`
`"http://www.quincetx.com/role/IntangibleAssetsTables" ]`, `"lang": { "en-us": { "role": {`
`"terseLabel": "Schedule of Carrying Amount of Finite-Lived Intangible Asset"`, `"label":`
`"Schedule of Finite-Lived Intangible Assets [Table Text Block]"`, `"documentation":`
`"Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical`
`substance with a finite life, by either major class or business segment." } } }`,
`"auth_ref": [ "r53", "r56" ] }`, `"us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype":`
`"textBlockItemType"`, `"nsuri": "http://fasb.org/us-gaap/2023"`, `"localname":`
`"ScheduleOfGoodwillTextBlock"`, `"presentation": [`
`"http://www.quincetx.com/role/IntangibleAssetsTables" ]`, `"lang": { "en-us": { "role": {`
`"terseLabel": "Schedule Carrying Amount of Goodwill"`, `"label": "Schedule of Goodwill`
`[Table Text Block]"`, `"documentation": "Tabular disclosure of goodwill by reportable`
`segment and in total which includes a rollforward schedule." } } }`, `"auth_ref": [`
`"r666", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762",`
`"r763" ] }`, `"us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype":`
`"stringItemType"`, `"nsuri": "http://fasb.org/us-gaap/2023"`, `"localname":`
`"ScheduleOfIndefiniteLivedIntangibleAssetsTable"`, `"presentation": [`
`"http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountofIndefiniteLivedIn`
`l`, `"lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible`
`Assets [Table]"`, `"label": "Schedule of Indefinite-Lived Intangible Assets [Table]"`,
`"documentation": "Schedule of assets, excluding financial assets and goodwill, lacking`
`physical substance and exist in perpetuity." } } }`, `"auth_ref": [ "r25", "r123" ] }`,
`"us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype":`
`"textBlockItemType"`, `"nsuri": "http://fasb.org/us-gaap/2023"`, `"localname":`
`"ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"`, `"presentation": [`
`"http://www.quincetx.com/role/IntangibleAssetsTables" ]`, `"lang": { "en-us": { "role": {`
`"terseLabel": "Schedule of Carrying Amount of Indefinite-Lived Intangible Asset"`,
`"label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]"`,
`"documentation": "Tabular disclosure of assets, excluding financial assets and goodwill,`
`lacking physical substance and exist in perpetuity, by either major class or business`
`segment." } } }`, `"auth_ref": [ "r25", "r123" ] }`, `"us-`
`gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype":`
`"textBlockItemType"`, `"nsuri": "http://fasb.org/us-gaap/2023"`, `"localname":`
`"ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"`, `"presentation": [`
`"http://www.quincetx.com/role/LongtermDebtTables" ]`, `"lang": { "en-us": { "role": {`
`"terseLabel": "Schedule of Future minimum principal payments"`, `"label": "Schedule of`
`Maturities of Long-Term Debt [Table Text Block]"`, `"documentation": "Tabular disclosure`
`of maturity and sinking fund requirement for long-term debt." } } }`, `"auth_ref": [ "r13"`
`] }`, `"us-gaap_ScheduleOfOtherAssetsTableTextBlock": { "xbrltype": "textBlockItemType"`,
`"nsuri": "http://fasb.org/us-gaap/2023"`, `"localname":`
`"ScheduleOfOtherAssetsTableTextBlock"`, `"presentation": [`
`"http://www.quincetx.com/role/BalanceSheetComponentsTables" ]`, `"lang": { "en-us": {`
`"role": { "terseLabel": "Schedule of Other Assets"`, `"label": "Schedule of Other Assets`
`[Table Text Block]"`, `"documentation": "Tabular disclosure of the carrying amounts of`
`other assets. This disclosure includes other current assets and other noncurrent`
`assets." } } }`, `"auth_ref": [ ] }`,
`"qncx_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": { "xbrltype":`
`"textBlockItemType"`, `"nsuri": "http://www.quincetx.com/20240930"`, `"localname":`
`"ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"`, `"presentation": [`
`"http://www.quincetx.com/role/BalanceSheetComponentsTables" ]`, `"lang": { "en-us": {`
`"role": { "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"`,
`"label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]"`,
`"documentation": "Schedule of prepaid expenses and other current assets." } } }`,
`"auth_ref": [ ] }`, `"us-`
`gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {`
`"xbrltype": "textBlockItemType"`, `"nsuri": "http://fasb.org/us-gaap/2023"`, `"localname":`
`"ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"`,
`"presentation": [ "http://www.quincetx.com/role/BusinessCombinationTables" ]`, `"lang": {`
`"en-us": { "role": { "terseLabel": "Schedule of Fair Values of Assets Acquired and`

Liabilities Assumed", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": ["r133"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGeneral", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt", "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails", "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDet", "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedCompensationExper", "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r370", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.quincetx.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Options Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r21", "r22", "r69"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.quincetx.com/role/StockholdersEquityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": ["r60", "r61", "r62", "r63", "r64", "r65", "r66", "r127", "r128", "r129", "r163", "r164", "r165", "r220", "r344", "r345", "r346", "r348", "r351", "r356", "r358", "r549", "r550", "r551", "r552", "r672", "r704", "r723"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r698"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": ["http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r700"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.quincetx.com/role/LeasesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": ["r237", "r238", "r568", "r569", "r570", "r626", "r628", "r631", "r633", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r655", "r673", "r689", "r772", "r820"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [

["http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies"](http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies)], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r226", "r227", "r228", "r229", "r230", "r231", "r237", "r663"] }, "us-gaap_SeriesAPPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPPreferredStockMember", "presentation": [
["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",](http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical)
["http://www.quincetx.com/role/StockholdersEquityDetails"](http://www.quincetx.com/role/StockholdersEquityDetails)], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": ["r714", "r715", "r771"] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeveranceCosts1", "crdr": "debit", "presentation": [
["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails"](http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails)], "lang": { "en-us": { "role": { "terseLabel": "Cash severance payments", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r11"] }, "qncx_SeveranceCostsRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "SeveranceCostsRecognized", "crdr": "credit", "presentation": [
["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails"](http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails)], "lang": { "en-us": { "role": { "terseLabel": "Severance costs recognized", "label": "Severance Costs Recognized", "documentation": "Severance Costs Recognized" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": {
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {](http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited)
["parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,](http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited)
["order": 9.0 } }](http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited), "presentation": [
["http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"](http://www.quincetx.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited)], "lang": { "en-us": { "role": { "terseLabel": "Stock based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r10"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail",](http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail)
["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt",](http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt)
["http://www.quincetx.com/role/StockBasedCompensationRSUsDetails"](http://www.quincetx.com/role/StockBasedCompensationRSUsDetails)], "lang": { "en-us": { "role": { "terseLabel": "Stock based awards vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r680"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [
["http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails"](http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails)], "lang": { "en-us": { "role": { "negatedLabel": "Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r390"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [
["http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails"](http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails)],

```

"lang": { "en-us": { "role": { "terseLabel": "Cancelled (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r390" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r388" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r388" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, Number of Shares, Unvested, Beginning Balance (in shares)", "periodEndLabel": "Outstanding, Number of Shares, Unvested, Ending Balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r385", "r386" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [ ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance (in USD per share)", "periodEndLabel": "Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Ending Balance (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r385", "r386" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance (in USD per share)", "periodEndLabel": "Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Ending Balance (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r385", "r386" ] },
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptions", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Beginning Balance (in USD per share)", "periodEndLabel": "Outstanding, Weighted-Average Grant Date Fair Value, Unvested, Ending Balance (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r385", "r386" ] },

```


"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptic
 "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value",
 "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
 Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
 [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThan
 { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptic
 "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" },
 "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-
 Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other
 than Options, Vested in Period", "documentation": "The number of equity-based payment
 instruments, excluding stock (or unit) options, that vested during the reporting
 period." } } }, "auth_ref": ["r389"] }, "us-
 gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThan
 { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptic
 "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Vested (in USD per share)", "label":
 "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
 Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
 "documentation": "The weighted average fair value as of grant date pertaining to an
 equity-based award plan other than a stock (or unit) option plan for which the grantee
 gained the right during the reporting period, by satisfying service and performance
 requirements, to receive or retain shares or units, other instruments, or cash in
 accordance with the terms of the arrangement." } } }, "auth_ref": ["r389"] },
 "qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantPeriod": {
 "xbrltype": "durationItemType", "nsuri": "http://www.quincetx.com/20240930",
 "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantPeriod",
 "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt
 "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Award grant period", "label": "Share Based
 Compensation Arrangement by Share Based Payment Award Grant Period", "documentation":
 "Share based compensation arrangement by share based payment award grant period." } } },
 "auth_ref": [] },
 "qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAv
 { "xbrltype": "sharesItemType", "nsuri": "http://www.quincetx.com/20240930",
 "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailab
 "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGenerall
 "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails",
 "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Increase in number of shares available for
 issuance as proportion of shares of common stock (in shares)", "label": "Share Based
 Compensation Arrangement By Share Based Payment Award Increase In Number Of Shares
 Available For Issuance As Proportion Of Shares Of Common Stock", "documentation": "Share
 based compensation arrangement by share based payment award increase in number of shares
 available for issuance as proportion of shares of common stock." } } }, "auth_ref": []
 }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": {
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGenerall
 "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt
 "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails",
 "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails",
 "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails",
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDeta
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails",
 "http://www.quincetx.com/role/StockBasedCompensationScheduleofStockBasedCompensationExper


```

1, "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r370", "r372", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399" ] }, "qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": { "xbrltype": "integerItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationAdditionalInformationGeneralDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Number of stock plans", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Plans" } } }, "auth_ref": [ ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGeneral" ] }, "lang": { "en-us": { "role": { "terseLabel": "Maximum aggregate number of shares that may be issued under the plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r68" ] }, "qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedUpConversion": { "xbrltype": "pureItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesIssuedUpConversion", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail" ] }, "lang": { "en-us": { "role": { "terseLabel": "Stock award conversion ratio", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Issued Up Conversion", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Issued Up Conversion" } } }, "auth_ref": [ ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosures": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Stock Options Additional Disclosures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [ ] }, "qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstruments": { "xbrltype": "sharesItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndNonOptionEquityInstruments", "presentation": [ "http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ] }, "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock on exercise of stock options and vesting of restricted stock units (in shares)", "label": "Share Based Compensation Arrangement by Share based Payment Award Options and Non Option Equity Instruments Exercises in Period", "documentation": "Share based compensation arrangement by share based payment award options and non option equity instruments exercises in period." } } }, "auth_ref": [ ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails" ] }

```

```

1, "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Exercisable, Number", "documentation": "The number of shares into which fully or
partially vested stock options outstanding as of the balance sheet date can be currently
converted under the option plan." } } }, "auth_ref": [ "r379" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntr
insicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntr
insicValue", "crdr": "debit", "presentation": [
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetail
s", "lang": { "en-us": { "role": { "terseLabel": "Options exercised", "label": "Share-
Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in
Period, Intrinsic Value", "documentation": "Amount of accumulated difference between
fair value of underlying shares on dates of exercise and exercise price on options
exercised (or share units converted) into shares." } } }, "auth_ref": [ "r392" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodTotalIntr
insicValue": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodTotalIntr
insicValue", "presentation": [
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetail
s", "lang": { "en-us": { "role": { "negatedLabel": "Options cancelled / forfeited (in
shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Options, Forfeitures in Period", "documentation": "The number of shares under options
that were cancelled during the reporting period as a result of occurrence of a
terminating event specified in contractual agreements pertaining to the stock option
plan." } } }, "auth_ref": [ "r383" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossTotalIntr
insicValue": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrossTotalIntr
insicValue", "presentation": [
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetail
s", "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in
Period, Gross", "documentation": "Gross number of share options (or share units) granted
during the period." } } }, "auth_ref": [ "r381" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
"crdr": "debit", "presentation": [
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetail
s", "lang": { "en-us": { "role": { "terseLabel": "Aggregate intrinsic value", "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value
of the underlying stock exceeds the exercise price of options outstanding." } } },
"auth_ref": [ "r68" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
"presentation": [
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetail
s", "lang": { "en-us": { "role": { "periodStartLabel": "Number of Options and Unvested
Shares, beginning balance (in shares)", "periodEndLabel": "Number of Options and
Unvested Shares, ending balance (in shares)", "label": "Share-Based Compensation
Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
"documentation": "Number of options outstanding, including both vested and non-vested
options." } } }, "auth_ref": [ "r377", "r378" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
"presentation": [
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetail
s", "lang": { "en-us": { "role": { "terseLabel": "Number of Options and Unvested Shares",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options,
Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a
concept from the beginning of a period to the end of a period." } } }, "auth_ref": [ ] },
"us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExer
cisePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExer
cisePrice", "presentation": [

```

```

{
  "xbrltype": "perShareItemType",
  "nsuri": "http://fasb.org/us-gaap/2023",
  "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
  "presentation": [
    "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails",
    {
      "lang": {
        "en-us": {
          "role": {
            "periodStartLabel": "Weighted Average Exercise Price, beginning balance (in USD per share)",
            "periodEndLabel": "Weighted Average Exercise Price, ending balance (in USD per share)",
            "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
            "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
          }
        }
      },
      "auth_ref": [
        "r377",
        "r378"
      ],
      "us-gaap": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"
    }
  ],
  "xbrltype": "stringItemType",
  "nsuri": "http://fasb.org/us-gaap/2023",
  "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
  "presentation": [
    "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails",
    {
      "lang": {
        "en-us": {
          "role": {
            "terseLabel": "Weighted Average Exercise Price",
            "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
          }
        }
      },
      "auth_ref": [],
      "us-gaap": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"
    }
  ],
  "xbrltype": "perShareItemType",
  "nsuri": "http://fasb.org/us-gaap/2023",
  "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePrice",
  "presentation": [
    "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails",
    {
      "lang": {
        "en-us": {
          "role": {
            "terseLabel": "Options exercisable (in USD per share)",
            "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
            "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
          }
        }
      },
      "auth_ref": [
        "r394"
      ],
      "us-gaap": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"
    }
  ],
  "xbrltype": "monetaryItemType",
  "nsuri": "http://fasb.org/us-gaap/2023",
  "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePrice",
  "crdr": "debit",
  "presentation": [
    "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails",
    {
      "lang": {
        "en-us": {
          "role": {
            "terseLabel": "Options vested and expected to vest as of September 30, 2024",
            "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
            "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
          }
        }
      },
      "auth_ref": [
        "r393"
      ],
      "us-gaap": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"
    }
  ],
  "xbrltype": "sharesItemType",
  "nsuri": "http://fasb.org/us-gaap/2023",
  "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePrice",
  "presentation": [
    "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails",
    {
      "lang": {
        "en-us": {
          "role": {
            "terseLabel": "Options vested and expected to vest (in shares)",
            "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
            "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
          }
        }
      },
      "auth_ref": [
        "r393"
      ],
      "us-gaap": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePrice"
    }
  ],
  "xbrltype": "perShareItemType",
  "nsuri": "http://fasb.org/us-gaap/2023",
  "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestWeightedAverageExercisePrice",
  "presentation": [
    "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails",
    {
      "lang": {
        "en-us": {
          "role": {
            "terseLabel": "Options vested and expected to vest (in USD per share)",
            "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
            "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
          }
        }
      },
      "auth_ref": [
        "r377",
        "r378"
      ],
      "us-gaap": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"
    }
  ]
}

```

Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } }], "auth_ref": ["r393"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStock": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": ["http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGeneral", "http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "qncx_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardValueOptionsAndNonOptionEquity", "crdr": "credit", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock on exercise of stock options and vesting of restricted stock units", "label": "Share based Compensation Arrangement by Share based Payment Award Value Options and Non Option Equity Instruments Exercises in Period", "documentation": "Share based compensation arrangement by share based payment award value options and non option equity instruments exercises in period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail", "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOptions", "http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails", "http://www.quincetx.com/role/StockBasedCompensationRSUsDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails", "http://www.quincetx.com/role/StockBasedCompensationScheduleofRSUsandRSAsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Award Type [Domain]", "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails", "lang": { "en-us": { "role": { "terseLabel": "Options exercised (in USD per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r382"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails", "lang": { "en-us": { "role": { "terseLabel": "Options cancelled / forfeited (in USD per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r383"] }, "us-

gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": { "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Options granted (in USD per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r381"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": { "http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share price (in USD per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accelerated vesting, number of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Accelerated Vesting, Number", "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": { "http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetails": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOptions": { "lang": { "en-us": { "role": { "verboseLabel": "Share based compensation accelerated vesting percentage", "terseLabel": "Award vesting rights", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r774"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetails": { "http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOptions": { "lang": { "en-us": { "role": { "terseLabel": "Stock options granted maximum period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r681"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue", "crdr": "debit", "presentation": { "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Options exercisable as of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r68"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualLife", "presentation": { "http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Life", "documentation": "Weighted average remaining contractual life of options outstanding and currently exercisable." } } }, "auth_ref": ["r68"] } } } } } } } }

Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
"documentation": "Weighted average remaining contractual term for option awards
outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported
fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r131"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedTo
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVest
"presentation": [
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDeta
], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable as of September 30,
2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining
Contractual Term", "documentation": "Weighted average remaining contractual term for
fully vested and expected to vest exercisable or convertible options, in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one
year, five months, and thirteen days. Includes, but is not limited to, unvested options
for which requisite service period has not been rendered but that are expected to vest
based on achievement of performance condition, if forfeitures are recognized when they
occur." } } }, "auth_ref": ["r394"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedTo
{ "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVest
"presentation": [
"http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDeta
], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest as
of September 30, 2024", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average
Remaining Contractual Term", "documentation": "Weighted average remaining contractual
term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS'
format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and
thirteen days. Includes, but is not limited to, unvested options for which requisite
service period has not been rendered but that are expected to vest based on achievement
of performance condition, if forfeitures are recognized when they occur." } } },
"auth_ref": ["r393"] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStock
{ "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPerce
"presentation": [
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt
"http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails"],
"lang": { "en-us": { "role": { "terseLabel": "Rate of purchase price of stock on fair
value (as a percent)", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase
price of common stock expressed as a percentage of its fair value." } } }, "auth_ref":
[] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudite
], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)",
"periodEndLabel": "Ending balance (in shares)", "label": "Shares, Outstanding",
"documentation": "Number of shares issued which are neither cancelled nor held in the
treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShortTermInvestmentsMember", "presentation": [
"http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale
"http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash
], "lang": { "en-us": { "role": { "terseLabel": "Short-Term Investments", "label":
"Short-Term Investments [Member]", "documentation": "Investments which are not otherwise
included in another category or item that the entity has the intent to sell or dispose
of within one year from the date of the balance sheet." } } }, "auth_ref": ["r634",
"r635", "r636", "r657"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"SignificantAccountingPoliciesTextBlock", "presentation": [
"http://www.quincetx.com/role/SummaryofSignificantAccountingPolicies"], "lang": { "en-
us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label":
"Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure
for all significant accounting policies of the reporting entity." } } }, "auth_ref": [


```

"r119", "r187" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis",
"presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.quincetx.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation":
"Information by the different classes of stock of the entity." } } }, "auth_ref": [
"r151", "r163", "r164", "r165", "r190", "r209", "r210", "r212", "r214", "r220", "r221",
"r272", "r305", "r307", "r308", "r309", "r312", "r313", "r344", "r345", "r348", "r351",
"r358", "r456", "r549", "r550", "r551", "r552", "r556", "r557", "r558", "r559", "r560",
"r561", "r562", "r563", "r564", "r565", "r566", "r567", "r581", "r602", "r620", "r637",
"r638", "r639", "r640", "r641", "r704", "r723", "r730" ] }, "us-
gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis",
"presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudite
"http://www.quincetx.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Equity Components", "label": "Equity Components [Axis]",
"documentation": "Information by component of equity." } } }, "auth_ref": [ "r18",
"r38", "r152", "r177", "r178", "r179", "r193", "r194", "r195", "r197", "r203", "r205",
"r219", "r273", "r274", "r360", "r405", "r406", "r407", "r417", "r418", "r436", "r437",
"r438", "r439", "r440", "r441", "r444", "r459", "r460", "r461", "r462", "r463", "r464",
"r477", "r540", "r541", "r542", "r556", "r620" ] }, "srt_StatementGeographicalAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname":
"StatementGeographicalAxis", "presentation": [
"http://www.quincetx.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Geographical", "label": "Geographical [Axis]" } } },
"auth_ref": [ "r237", "r238", "r568", "r569", "r570", "r626", "r628", "r631", "r633",
"r643", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r655",
"r673", "r689", "r772", "r820" ] }, "us-gaap_StatementLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementLineItems", "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudite
], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label":
"Statement [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [ "r193", "r194", "r195", "r219", "r512", "r548", "r567", "r573", "r574",
"r575", "r576", "r577", "r578", "r581", "r584", "r585", "r586", "r587", "r588", "r589",
"r590", "r591", "r592", "r594", "r595", "r596", "r597", "r598", "r600", "r603", "r604",
"r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616",
"r617", "r620", "r690" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement
of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } },
"auth_ref": [ ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Statement of Financial Position [Abstract]", "label": "Statement of Financial Position
[Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_StatementOfStockholdersEquityAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders'
Equity [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_StatementTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"StatementTable", "presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical",
"http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudite
], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement
[Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash
Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other
Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r193",
"r194", "r195", "r219", "r512", "r548", "r567", "r573", "r574", "r575", "r576", "r577",
"r578", "r581", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592",
"r594", "r595", "r596", "r597", "r598", "r600", "r603", "r604", "r606", "r607", "r608",
"r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r620", "r690" ]

```


, "qncx_StockIssuedDuringPeriodSharesRestrictedStockAwardRetirement": { "xbrltype": "sharesItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardRetirement", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "negatedTerseLabel": "Restricted Stock award retirement (in shares)", "label": "Stock Issued During Period Shares Restricted Stock Award Retirement", "documentation": "Stock Issued During Period Shares Restricted Stock Award Retirement" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails", "lang": { "en-us": { "role": { "negatedLabel": "Options exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r18", "r99", "r100", "r129", "r382"] }, "qncx_StockIssuedDuringPeriodValueRestrictedStockAwardRetirement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardRetirement", "crdr": "debit", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "negatedTerseLabel": "Restricted stock award retirement", "label": "Stock Issued During Period, Value, Restricted Stock Award Retirement", "documentation": "Stock Issued During Period, Value, Restricted Stock Award Retirement" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Option", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": ["r689"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.quincetx.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r100", "r103", "r104", "r120", "r583", "r599", "r621", "r622", "r685", "r697", "r725", "r752", "r804", "r822"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.quincetx.com/role/CondensedConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Note [Abstract]", "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.quincetx.com/role/StockholdersEquity", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r126", "r189", "r343", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r357", "r360", "r443", "r623", "r624", "r642"] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": ["http://www.quincetx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": {

"terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]",
 "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": ["r465", "r479"] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "http://www.quincetx.com/role/OrganizationDetails", "http://www.quincetx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r465", "r479"] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": ["http://www.quincetx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": ["r465", "r479"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "http://www.quincetx.com/role/OrganizationDetails", "http://www.quincetx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r465", "r479"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails", "http://www.quincetx.com/role/LongtermDebtAdditionalInformationDetails", "http://www.quincetx.com/role/OrganizationDetails", "http://www.quincetx.com/role/SubsequentEventsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r465", "r479"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.quincetx.com/role/SubsequentEvents"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r478", "r480"] }, "qncx_SummaryOfAccruedSeveranceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "SummaryOfAccruedSeveranceTableTextBlock", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Severance and Related Expenses", "label": "Summary of Accrued Severance [Table Text Block]", "documentation": "Tabular disclosure of accrued severance." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.quincetx.com/role/BalanceSheetComponents"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental

balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r712"] },
"qncx_SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
"SupplementalBalanceSheetInformationRelatedToLeasesTableTextBlock", "presentation": [
"http://www.quincetx.com/role/LeasesTables"], "lang": { "en-us": { "role": {
"terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases",
"label": "Supplemental Balance Sheet Information Related To Leases [Table Text Block]",
"documentation": "Supplemental balance sheet information related to leases." } } },
"auth_ref": [] }, "qncx_SupplementalBalanceSheetOtherInformationAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://www.quincetx.com/20240930", "localname":
"SupplementalBalanceSheetOtherInformationAbstract", "presentation": [
"http://www.quincetx.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelated",
], "lang": { "en-us": { "role": { "terseLabel": "Other information:", "label":
"Supplemental Balance Sheet Other Information [Abstract]", "documentation":
"Supplemental balance sheet other information." } } }, "auth_ref": [] }, "us-
gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract",
"presentation": [
"http://www.quincetx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"],
"lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosures of non-cash
information:", "label": "Supplemental Cash Flow Information [Abstract]" } } },
"auth_ref": [] }, "qncx_ThreeYearAnniversaryMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.quincetx.com/20240930", "localname": "ThreeYearAnniversaryMember",
"presentation": [
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail",
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt",
], "lang": { "en-us": { "role": { "terseLabel": "Three Year Anniversary", "label":
"Three Year Anniversary [Member]", "documentation": "Three Year Anniversary" } } },
"auth_ref": [] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [
"http://www.quincetx.com/role/BusinessCombinationAdditionalInformationDetails",
"http://www.quincetx.com/role/IntangibleAssetsScheduleofCarryingAmountOfFiniteLivedIntang",
], "lang": { "en-us": { "role": { "terseLabel": "Trade Names", "label": "Trade Names
[Member]", "documentation": "Rights acquired through registration of a business name to
gain or protect exclusive use thereof." } } }, "auth_ref": ["r80"] },
"dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri":
"http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [
"http://www.quincetx.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel":
"Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an
instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-
gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
"presentation": [
"http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale",
"http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesOfCash",
"http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilitie",
"http://www.quincetx.com/role/FairValueMeasurementsScheduleofQuantitativeInformationabout",
], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]",
"label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that
imposes a contractual obligation to deliver cash or another financial instrument or to
exchange other financial instruments on potentially unfavorable terms and conveys a
contractual right to receive cash or another financial instrument or to exchange other
financial instruments on potentially favorable terms." } } }, "auth_ref": ["r241",
"r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252",
"r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263",
"r264", "r265", "r266", "r267", "r268", "r269", "r270", "r339", "r356", "r442", "r481",
"r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492",
"r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503",
"r504", "r505", "r506", "r507", "r508", "r509", "r510", "r535", "r705", "r706", "r707",
"r708", "r709", "r710", "r711", "r747", "r748", "r749", "r750"] },
"qncx_TwoThousandAndNineteenEquityIncentivePlanMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.quincetx.com/20240930", "localname":
"TwoThousandAndNineteenEquityIncentivePlanMember", "presentation": [
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceGeneral",
"http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOpt

<http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails>, "lang": { "en-us": { "role": { "terseLabel": "2019 Plan", "label": "Two Thousand And Nineteen Equity Incentive Plan [Member]", "documentation": "Two thousand and nineteen equity incentive plan." } } }, "auth_ref": [] },
 "gncx_TwoThousandAndTwentyTwoInducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "TwoThousandAndTwentyTwoInducementPlanMember", "presentation": [<http://www.quincetx.com/role/StockBasedCompensation2022InducementPlanDetails>, <http://www.quincetx.com/role/StockBasedCompensationScheduleofActivityforStockOptionsDetails>], "lang": { "en-us": { "role": { "terseLabel": "2022 Inducement Plan", "label": "Two Thousand and Twenty Two Inducement Plan [Member]", "documentation": "Two thousand and twenty two inducement plan." } } }, "auth_ref": [] },
 "gncx_TwoThousandNineteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.quincetx.com/20240930", "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember", "presentation": [<http://www.quincetx.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails>], "lang": { "en-us": { "role": { "terseLabel": "2019 ESPP", "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]", "documentation": "Two thousand nineteen employee stock purchase plan." } } }, "auth_ref": [] },
 "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [<http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofAvailableforSale>, <http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsScheduleofFairValuesofCash>, <http://www.quincetx.com/role/FairValueMeasurementsScheduleofFinancialAssetsandLiabilities>], "lang": { "en-us": { "role": { "verboseLabel": "Government and agency notes", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": ["r818"] },
 "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [<http://www.quincetx.com/role/SummaryofSignificantAccountingPoliciesPolicies>], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r49", "r50", "r51", "r146", "r147", "r148", "r149"] },
 "us-gaap_ValueAddedTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValueAddedTaxReceivable", "crdr": "debit", "calculation": [<http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails>], "parentTag": "us-gaap_OtherAssets", "weight": 1.0, "order": 3.0 }, "presentation": [<http://www.quincetx.com/role/BalanceSheetComponentsScheduleofOtherAssetsDetails>], "lang": { "en-us": { "role": { "terseLabel": "VAT receivable", "label": "Value Added Tax Receivable", "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities." } } }, "auth_ref": ["r716"] },
 "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingAxis", "presentation": [<http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail>, <http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOptions>], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799"] },
 "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VestingDomain", "presentation": [<http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanNovosteoDetail>, <http://www.quincetx.com/role/StockBasedCompensation2019EquityIncentivePlanQuinceStockOptions>], "lang": { "en-us": { "role": { "terseLabel": "Vesting [Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799"] },
 "us-

gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive
 "http://www.quincetx.com/role/NetLossPerShareScheduleOfComputationofBasicandDilutedNetLos
], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares of common stock
 outstanding - diluted (in shares)", "label": "Weighted Average Number of Shares
 Outstanding, Diluted", "documentation": "The average number of shares or units issued
 and outstanding that are used in calculating diluted EPS or earnings per unit (EPU),
 determined based on the timing of issuance of shares or units in the period." } } },
 "auth_ref": ["r208", "r214"] }, "us-
 gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
 "http://www.quincetx.com/role/NetLossPerShareScheduleOfComputationofBasicandDilutedNetLos
], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted
 Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType",
 "nsuri": "http://fasb.org/us-gaap/2023", "localname":
 "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
 "http://www.quincetx.com/role/CondensedConsolidatedStatementsOfOperationsandComprehensive
 "http://www.quincetx.com/role/NetLossPerShareScheduleOfComputationofBasicandDilutedNetLos
], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares of common stock
 outstanding - basic (in shares)", "label": "Weighted Average Number of Shares
 Outstanding, Basic", "documentation": "Number of [basic] shares or units, after
 adjustment for contingently issuable shares or units and other shares or units not
 deemed outstanding, determined by relating the portion of time within a reporting period
 that common shares or units have been outstanding to the total time in that period." } }
], "auth_ref": ["r207", "r214"] },
 "qncx_WeightedAverageRemainingContractualMaturitiesOfAvailableForSaleSecurities": {
 "xbrltype": "durationItemType", "nsuri": "http://www.quincetx.com/20240930",
 "localname":
 "WeightedAverageRemainingContractualMaturitiesOfAvailableForSaleSecurities",
 "presentation": [
 "http://www.quincetx.com/role/CashCashEquivalentsandInvestmentsAdditionalInformationDeta
], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining contractual
 maturities of available-for-sale securities", "label": "Weighted Average Remaining
 Contractual Maturities Of Available For Sale Securities", "documentation": "Weighted
 average remaining contractual maturities of available-for-sale securities." } } },
 "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-
 gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30",
 "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role":
 "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" },
 "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
 Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)",
 "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r3": { "role":
 "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30",
 "Topic": "805", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r4": { "role":
 "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830",
 "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481877/830-230-45-1" },
 "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
 Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic":
 "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-
 10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
 "Accounting Standards Codification", "Section": "45", "Paragraph": "10A",
 "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
 "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r7": { "role":
 "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
 Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(d)", "SubTopic":
 "10", "Topic": "230", "Publisher": "FASB", "URI":

"<https://asc.fasb.org/1943274/2147482740/230-10-45-13>" }, "r8": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482740/230-10-45-14>" }, "r9": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(f)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482740/230-10-45-15>" }, "r10": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482740/230-10-45-28>" }, "r11": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482740/230-10-45-28>" }, "r12": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482099/360-10-50-1>" }, "r13": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147481544/470-10-50-1>" }, "r14": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482665/350-30-50-1>" }, "r15": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147481047/942-405-50-1>" }, "r16": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147479581/805-30-50-1>" }, "r17": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147481203/810-10-50-1A>" }, "r18": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147481112/505-10-50-2>" }, "r19": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482106/820-10-50-2>" }, "r20": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482106/820-10-50-2>" }, "r21": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147480429/718-10-50-2>" }, "r22": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147480429/718-10-50-2>" }, "r23": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147480429/718-10-50-2A>" }, "r24": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482665/350-30-50-3>" }, "r25": { "role": "<http://fasb.org/us-gaap/role/ref/legacyRef>", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147482665/350-30-50-3>" }

[illegible]


```
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r44": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" },  
"r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" },  
"r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" },  
"r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" },  
"r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r49": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" },  
"r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" },  
"r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" },  
"r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" },  
"r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r54": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r55": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r56": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r57": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" },  
"r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r59": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r60": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r61": { "role":  
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" },  
"r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
```

Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting

Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role":

[illegible]

"https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(13)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r139": { "role":

"http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" } }

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r271": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r272": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r273": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph":
"(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-
4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r275": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r276": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" },
"r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r278": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r279": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" },
"r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r281": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r282": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" },
"r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "9", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r284": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r285": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" },
"r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB",
"URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r287": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r288": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" },
"r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r290": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph":


```

(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r309": { "role":

```


[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

"(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }


```
"https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r422": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270",  
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",  
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482526/740-270-50-1" },  
"r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",  
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",  
"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r424": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name":  
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph":  
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-  
5" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805",  
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",  
"Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r426": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name":  
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph":  
"(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-  
50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":  
"805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",  
"Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r428": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name":  
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph":  
"(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-  
50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":  
"810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",  
"Paragraph": "19", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r430": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":  
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph":  
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-  
25" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810",  
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",  
"Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r432": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":  
"Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph":  
"(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-  
50-1A" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":  
"810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",  
"Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r434": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":  
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph":  
"(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-  
3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810",  
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",  
"Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r436": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":  
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph":  
"(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-  
6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",  
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",  
"Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r438": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":  
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph":  
"(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-  
20-65-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":  
"815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",  
"Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI":  
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r440": { "role":  
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":  
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph":  
"(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-
```



```

20-65-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r442": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph":
"(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-
5" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r444": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph":
"(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-
65-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r446": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph":
"(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-
1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r448": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph":
"(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-
2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r450": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph":
"(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-
50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r452": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph":
"(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-
10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r455": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" },
"r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r457": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org//830/tableOfContent" }, "r458": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" },
"r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "17", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r460": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name":

```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

"Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481004/946-505-50-2" }, "r639": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481004/946-505-50-2" }, "r640": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481004/946-505-50-2" }, "r641": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481004/946-505-50-2" }, "r642": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505",
Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481004/946-505-50-6" },
r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948",
SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99",
Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB",
URI": "https://asc.fasb.org/1943274/2147479851/948-310-S99-1" }, "r644": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r645": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r646": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r647": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r648": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r649": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r650": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r651": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r652": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360",
Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479438/970-360-S99-1" }, "r653": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310",
Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482856/976-310-50-1" }, "r654": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310",
Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482707/978-310-50-1" }, "r655": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification",
Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic":

```

"944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-

50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r694": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r697": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-0", "Number": "240", "Section": "308", "Subsection": "a" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-0, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r704": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":

[illegible]

[illegible]

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI":
<https://asc.fasb.org//1943274/2147480097/470-10-S99-1A> }, "r770": { "role":
<http://www.xbrl.org/2009/role/commonPracticeRef>, "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI":
<https://asc.fasb.org//1943274/2147481139/470-20-50-1B> }, "r771": { "role":
<http://www.xbrl.org/2009/role/commonPracticeRef>, "Topic": "505", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "[https://asc.fasb.org//1943274/2147481112/505-10-50-2](\"https://asc.fasb.org//1943274/2147481112/505-10-50-2\") } ,
"r772": { "role": "[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\")", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147479806/606-10-50-5](\"https://asc.fasb.org//1943274/2147479806/606-10-50-5\") } , "r773": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "715", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480506/715-20-50-1](\"https://asc.fasb.org//1943274/2147480506/715-20-50-1\") } , "r774": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r775": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r776": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r777": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r778": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r779": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r780": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r781": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r782": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r783": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r784": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r785": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI":
[https://asc.fasb.org//1943274/2147480429/718-10-50-2](\"https://asc.fasb.org//1943274/2147480429/718-10-50-2\") } , "r786": { "role":
[http://www.xbrl.org/2009/role/commonPracticeRef](\"http://www.xbrl.org/2009/role/commonPracticeRef\"), "Topic": "718", "SubTopic": "10",

[illegible]

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r804": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28",
"Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r805": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r806": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r807": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r808": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" },
"r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r810": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r811": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r812": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r813": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r814": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r815": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r816": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r817": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730",
"Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482517/912-730-25-1" },
"r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480832/942-320-50-2" }, "r819": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479440/944-210-S99-1" }, "r820": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B",

"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r821": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r822": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r823": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } ZIP 97 0001662774-24-
000011-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001662774-24-000011-xbrl.zip M4\$!0 (
">);5F.D62;'='0" /;X&P 1 <6YC>"TR,#(T,#DS,"YH
M=&WLO6MMWDBR+00] PJJ]#XSU6N!20]W5S=G41AW,^RW8;:V?~^V2N1\$J,I
M(=&ZV&9^_8E(B9L11@()4I"SUG09T"4SXHG(B,C(B%^[10\$E%ZHXQJV]>M? ME20YKQ*U-%LWK.=?
]KN=WJ10 [?UG]0^520_S]>E.NK\$U?T(M3^HXE'A4 MEUX;-RQY8RK|TW9^&'!\$>C2)-[*=2:D4W-
;QIS/'>|Y[DBJKE?EE\U^=:UU5 M-:(VZZ4*I;14J=%RJ3EJU\$NZ4E5DVJCJ%;5;?+X>*4JY6J0JI>9P-"Q5&DJJ
M1.I\$+0TK1!N-Z@VUII&B?EU5*V34&,HU6J,571DU-+TVI%JCHJL*566907?L
MP90AWI9[; ;OY)9=J00; &GC>]_0SY|?7U"CY?/=LOGPW+-"R*T_[L.<1R<5;\$ M
SI|5F6E6I(;I;)2F#_'M2NJ4E][SM00;:LYQDNE\N?PROF-QI:6]K5_I M&Y9&0;D9&BN1^ ABT&]
M;1N/4EZ9W?QRG2Y?PJZ=\$P)^P!&5%Z.!'XV/IKH^CJB1*\UF_,;F+^4-\M M/1,R75P\
(NZ071K^L#8"U_\$V+X00UX<)\$_RQ>7XZ_S2C207)X0_#XE+5PF@ MOR-6>'M<_#CD@=>|(_OI MD?"Q)OK >?
FUT+\$M#^2R-)A-89A;\.G7@D??0,^,S)];_5?_6+9W@F;2'X M2G.,?
(Y^/*7S\&CA|8^:_VB&R^2Z\U,^FM!-IRI26;7EFU1&(#Q=HT74B?X MT|!U:K\$X?=[4 Z.H070?
_,>Z.C7@E8"*;'(!)]\$C>NN!;^;=6.IT#C%[ED]? M_DYG!8Y+D@!>CXM0!PNAX9;U00C8B) M@ S?UBBTV!?
[0|C#.\X:0;J6?@,J?0&*9J%5 DR"TMORDEN': A@R;>,X!7N MF#C4+;Q_+>HUG6K&!\$;:Z\$\'T4HZ-
<=D[CNP^BX?Q &Y\!Z<)UP]X%U#ZCR, M^E3S'<,SJ-LAIDGUK[,NT<;KUQ8DG, \49X/OH; N@)@S8<^'^0VL?
NN#FSM MXPPV)Z"L3D".-8'N&W4TPZ6/0#&Z^-\$_?W65=1Y; J2DVUXI?\$04C ##M2((MR^:4/J_+I4-
'%BK43="G;:JNW;9^@&SDYA60/9 B0#WC,G41)W'OAL[./DU
MS7'UYNJ@5]C[EB\]W^G:OL,^L=7B&NG^AAYB80[|A!+7=V@K^!3\^,OG]=_F
MG_\$9&\#/_FT\+&QKK[_W;Y(^:_\'S^8^@' V=KE[*8\$\\V]GSM10WXY MAS\F>J!]
<16/?!S|[*='#8&THI^0\1Y5^A6V--0^<^_IVR-G'\!'+GD4\$= MB0DJC;16.[V_KZ^=
[V]>C&#|Z5.V=LT_@>'F>*CVV?I8DI42ZLSWORV&J:]< MVBRA+;'_R_SS "6?U^8=30:5 S(\$JP7S\$P!
(E07#PI_V6=F9=YFML;S0V96 MX6MFY;F=5*W "-#_3X9RNF1H(:)2F209&Y5T?=/WT,K-B3J6W! M1W==)
<'W\$|LZBB*JI:2(E,P-XHQIWM9U SUR8CX20^]9'3(U/&FA0Z96^)^9
MTU_3 (E0XC|@>S>F#E|GT#\$^|87V+,V>T-SP(G/?(6->/%&^!;5N\20#.09 MS0WA.7-MTIP: [X-) J5 W-
4X=|?XE_9|\\"X\$S/VIW&MN'KB4N;MW/09]6H&\$ M)7/?^E56GVSHK^;=I^7 OD^-_%WGW=8]MWZ=&^+P|N<=2_.7T'
|U|/[L*11 MF03/W*^<|<6?)B_R|H0?5?&G2?C,'>K332W0+F>F:QH'FVIJWKW-TT3>3L2L
MW+NI)X^\\G890Y;S|MT>.0)V(2WGW?(_H@*7E|);S|02>R_%+C?ZY=X|/|X"E
MOHN\.\/'=L!2(WSEFGN_III;WS=KCK6FIY0N7^\\TGF9-2X ^N?>I3|ZFI<>+ M0+NL1U{34B-\\}>\\NY_\$B;Z\
MG8)+>?>\\C^6EJ"D:'G?|CV%EY(F_?/NF9 :2TF3%WGWV(_JI:1)>|[_MF8T MM;0|OD=-?
3C!0=IJCWDDZ4^G()9N?>63^Z G8AQ>?>LF=QP* M6NZ6;(8)PUIGS1WPY6\$47+&#+'?'=T.'7@^6?
8<550S>QRII=7W'GE)B|:P7 MZGKXXU=B ;BSB967 P95?KUL?^C2/WV401?X#U8.?5?&90V"M)@MP*4H):6<
M"KCX#2<(CY|I;C(LT^**_N_B/|>QKC3X70;\\WU4AD|M0VDZ2?^_9K|00\\)?
M.K8SM1W6^L!M6WK|F<*MU^T6>L\\-/|B-EN5K/3Y/<' ;DX. V\$)B0 ME?P\\P<%M /\$8RPH ;:
VU'8,!VDV1#CK<,^9 MA002Y/19AW0.--R7(0_K (9[F6|ZY8F&_B- M/7& ZY8F&|@-17WU7<.BKM06_00-
EQV073T+XA&-?QKI\\(4#0@,G|\\9EC&Q)ID;HB=!4.Y"ZM\$ M,92\\'8;&9>A9QV4R,!DXJ C6X#=<\\J&HY/^4>
(/;6,178@+E:7],J7=G;V1I MVBW"^^<0=@Z^/_V!1AQ=BPAMV.?K|2.LW2ES?8=4C;AUV=EB;:1'5E40=)PP^
M.*!C[?| :3(#?X#70(Y^&(0!2)V2:WL1V!/, [3JE+4?TUN0UL"A9RC,\$U= MR&ID3Z PQSMB;2I*;B.=
J)YAFB;6I2|J##'\$,E(:0C15|Q%E 483J<9N(U& M|Z9\\?VP|WH ZDV5X\\Z*7KN.G#Z>IE;@-L0L@\\@-\$-
#5BCG<;3U)0Y MWI@0 .45H"EJ4\$7F=@.#0XQD(C3<*M%YG8;06#AZ'KATH+Y'(EACH/4^=9_
MW(9>N<1\\JNJ&VT GAYA/E?#\\!A4 /(_YQ;|_8KD?M] G-00ZK(0; ;8>.*\$R.!*L@9DY14-=AA7N(VQ/&)&M^/-
'F\$%\\6!QOH5YBL_X.M0L)81= MY'R/.HN+_(, (?K K?N-(>\$3Q7QW#K3B130'24N'=NFWIM, M'?
N%YBN8I'#K6'/.A%0E@5L_.A\$3;GW',CS?H7#AK?&&?^5(\$+CUFOGF0;IR MD+F/0%>PH|PW6%!)*X2C9NZK|D&
(!DPP)B%6+SV,\$-SZC&UP-02(7LN>K?UX MF&93/F+_, -:C|&\$6|=QG<<88;Q\$W4|Q| \\JC/&L\$LRT(=
<,"9S!S(OA.#. MH<,"-GT/)H37_T;M9X=,QX9&S!6D?H6%VMT5^XXM"ZZ*:>V;G+G :>G90F),ZC<|@,0*_
TQB>L^C *+>=V|@9E2 MM_WHT!%UG-"H3D0IH13>D\\F: ^6X\\CST7?\\C>9@4@4+7,9DLFVY+! P08*
MN(SC9%M)7*!@ P7"SZ+TJYD:MHS2N/G39P# M.DYT,J5";3A*H./TRVR%VWB60,?ZRA)7=Y331
>WX3;!CKU/MZ:'CEP\$^(- M[6S!W;N4P^6X;E/_>]GNF;D(J27;F!7!\\WXSFT0|]3
M8DDGX\\XIO/6JB.6<3GFN6\$1J2:Z6E&8J%E&5NPC,V5&8NUC'!4G-FMI\\Q|6/_ MU.:
[2P|3F|P%/4X6|!+02AE:W(9WCID4)\\!V'+!Q&ZTZ;J:=@-MQX,9=K.YD M>X,"6NE"J\\9M%/"43D^:@?
9:WL)LYR1B&>TEUO(6G#LGG0*0)5P3\\3\\NA#I5 M13IW;\$ P?0I"FC5_/2S#F#-<0'KR(>EX"-Q? M_Y/HVKS\$;?
#YS! M=SU+|S563/0X|KNYS8BPP_I-S?YY?B;_'(ZF_QU;L,L_/ I^V4EZ@+ M#T4?3L'L-\$-
LC;Q\$Z7&2<*"+1R\$M\$ZJ*0D9\$UT. V_,0/_ MZ7D(\$S>X#1/QRZ>3*,^\\A',N2GGR\$.AMJ;K,;M;D-

K04BV=/U*7\$T<; M\OZ0DV;M8\JZ]6LR6W(MAWN.G6@M:W(:M^&>8Z=:R;B-X'#/L5.M8]S&5ZE<=^\$Z
60^CX(JT EPW=.CU /F.CP-= 4G7=^PI)5;/>J&NAS]^)=;/,S0[G *Y MI*;S9=3D-021 RX/'&
(!;=KYX3:W09/\Y"_)D7[,M)1P=[L"NL7%'CM_JI8?8XZK,79 H^*V%\YQ(H),N9%Q MX=LA?K@+>>5&8PC\
('ZX#=A]]5W@I>NVM3]]PS66 >Z],[LAIJ<(2J0:Y"(- M
F8>'SHF[/,*00&F/!R&F(H9+X8E\$+D;D2*4&A>1[W\$X!V',)\$]L XTXP*B+2
MFYD]+N"W&W[@^C+G\$LPWIV'ZG3'Q.' M?IU%/^#0LUUY%2?N IIGSN?3Y&JJ"K>!QZ/P^62-
%TXBT|P&&,^8UZ>2;VZC M>?*@[9G*,|=QL3/D\8GD6.4VW'1RMR;-_5>5V[/#*Y8:ZU,R#B?\$6^;1BKPP MF;MX
I.K;X8)JXMMT4Q=8:T^GCOU"S,4E63L[.AGSP)CYMW;'OU[2(9L+^9AU-;&!GUA MUQ[Z^NP3
\]K9>Q9,\MD8FK3M MNM1S0\Z^D7 ;3L0&#*!AP&]:YW0<" X?H%(^#I]8+ MX[RXS6V
YPA"G"Z3Y65NXSV95SNY4(9S&WDZT<)^,&02:@*AEKG-^LD/:WC8
M)RESFQJ4'SYFE\$Y4YB[\=00[EB,.CKQ5^]EXNW:H M:_L.3#X.*8 /!R\;KRT?
H'_,/8:5;5"1HVA7*,U6M&544/3:T.J-2JZJE!5 ME0\7S;_E/:XW,X'-X"V5QMIX'G07E>K4^_)JZ-[X6I'E_U-
@U[5^<:?\$FE^M MV:;M7/\&!)!HR\&&1I1":&.;0^ZP"8ZDKW]5ZLB?\$^F01)99;^X .!Z^",1%NQB*-
M'3KZM?#3;LK7"ZT! 3!+!DC"&"0@ZY?/!+B!M)TS99,UQ'D&[QMS[,GUPH, M-0S&LZ?7-?
@X);IN6,\EDXZ\M2\<-GS\AHV>F,;S=:W!6ZD%/384,*7&T' MYE,"8IIDZM+K^1]?=,=FF0&"H>1A-
WT97U(B)<7ZGB&1LSP)>Q]P<+!*%W) M 9P\ *VGS]\< GP%/WW> +[9N&K*T3_)5PK[C-
[GC/,61:>>H5V#TP\$R30 MKX5RX=UDP^'#E9)N^T@,1-<&<M>R!+1>0. SF_EV]B SRELH045TX'W[P+7Q
M#J[U"+@66M_O>X/NC=0?M ?= CK"5@:/RVC[W<[WI]Z@U^U+!?!J?L_G=; M]!]UI<[#MV^]?
K_W<' "":BQIO#/=0 WWOUO@X?{HG1SU;F25+E:;9YNV)48 M6JW0DN8#3)=D<51JH?6 > Y0*U'?
49>T'W[\]/1-^@66;NV[OT]/\$23PI7] M"9<.K:04)(N@N:53X_K&UMC9&MP7!%?007M!2Y]
=;/^)=:/0EX'0->60\ M&C6?0A'GA_1@T9\C!I2+Q;N\<^V.;0;L?E1H!FQ;\^>KNCI|PW5]53>@W;1! M
WN:NK+8R7:E@A1.K"?^', '= &-T]D2GMN,5I)'M3(@'0L";=STRWJA>\AQ MH4K40NLO/S7KE=J7K=K\$TW-
/QC^MY\&W:>[?TE/W<>'IX'T^/VI [U]/Y & M#0*8&P.P*22E+T\24KUD_ZS]' K#7[02BN6R,
(*;7<&^+/2+%?62/2089C] MZA-/C]S:CN2-J?3G"92X&1*X'M2?8]UZ9'=W@T\UW6TZ?!-:0*/&.-M)9W,
M2C-PQT04FJ.0#,8>G7I!!* L^R6,+0&SK,6DZ<.3T,E")W]DNSGP.K91N%TI
MCXCI+K1R)=3*E7/5RDQN!D M^WZ/Z5ZAE@.U|"V0,M?+(\>>2.JL4LFSWW\5 MQPLZ3D0BWH0[]F1BN!COE6X-
4)2 ;U@#KA,L0%T6C\6;@W0GLE/%<+12*C<=: M39F?I>22/*1304^-%YM)"K\$G^LQRARP/-
W;F,*N!5>D;ED:EP9@Z9\$]4*IN M4>I9VA4_L(OK77;?
B.9).#\,1R]G+!%7ZD^IACLYNF18DN&Y4F?;,=-3U1(M4R;QAN.:DLWJ54VN);4DJ\TK18TV&9.:DN7&5:W>/*
(I&4R<=<P(-U.V-0=- MA5ERSC3\,!J3AWJ1'\3P1/F?IEM4+K1MJDE?BT[15 M67I6Z!GQ8\$#>N'N=Y"CN&Z?-
JMIEQ2P-&5R\T8Y#T#K=-WTKF*BQ##JP26 ML VFL"/]VW<,5SE=/5 TK*2QBX_PR=#ZWUB5"NK>0?
MYTTS)%^6E@ MLE05/=0,6U==S #.?@'JRLJ< 72++1JBB+!J+T2F;25]LWZ0M0]*+4]PT0 M+
[5>CFV>GB').GB0S!G8KX0%#BMJ]FW?&TM]F,0M5BHU7,U^3Z1B8M0/_)01
MC%6GEL&J<[08R\$Y18L[ITL' RT\ -5:E <26/FG0ZMBTJ6ZG].8%R09, YB.,=-VNQM*0344N M5>M*/:Y4GRXN?
\$D1C A94.>R8%AH&%[7@&R]5*?Y/ATG>I;+DZ2PZ2".E27 MIK[C^AC \FP)KF VJZ)^&0Z,BA,#]6W-
NY8.23TZU1IUS@95KE05&^6,8E;'7\$YWYK"QY71@>\$'B,B7:6-(P M S_%L-.0<"F^)>?E)K\)?
WMUI,8V+NYBBX5'E!|Y;X_FQOM\Y.;N_C\$]3C+ MGTC.]VZ81-(W;8S%3218ME['!GRS7-
N2A%W6<^.!I)KFX8>I,:'/^<(B)^Z7 M03(03BD/FT!)%F((C8B9H@Z9:ES8I-
5@I008P(I\$%J4I<:0780I4^F_,V%P MFU]RQX=\$VM>9)%]5E\P8L?
^M5/L'S@(>2ZX,MXHYMS!^99[AY8^*]'_LK M61\E#C&X.9S#ST6)6+KT20WF. 0DP.#?\\,'IV*=R\$HPB?
@XF8+AL&\$R1Q M/:DI2SJ9N5>!\$& [;]*X<=W' A7D.J)RM4CGN\N<-HHM/Y%W?>X7'MALJ#/_ M/^\$=2&
[W(&R]91)JB0?N;92_MT].%CMFC"2!4U058@09+TI M9%W(^DED'<2+2"8,FTI\$TT#6'8("B_!W<.F,_%8"D)8B?
W_GH"3@+L'U\|P016@&0WC+6^96&>@R<.9+ZMS^635ZKN+CY,A1_N95HY(X
MR@W\I16:;US)Y70>I520&DW^1J5>U9543CDMZDGP>H8GGOM[%RV_)SZE=/_R MP.9FGW@6:.*I?
0\$22^[/+*K02=]2@4!H4/ 'Y9 M"B=0([C^CQ>A 2>)[0VST M0>P],Y@C0V;&*HRSN+A8&]9-
@MG^VX0MP*N!J5Q(DHSV Y[ESG#E]\&IX MK63!U&Q<_%\,EYEL%AXI(2:ZR7@8\$R-&>KTZ<717PH,?
AKXMY;3\B?P<&8(2 M8=+TPJ3NF)KF'#72)\ ""U8&!IX_#@5NWTGX%W7Y"6AS>>73DB1Q+8K0B/V
M2E+^R';E45C:++19 ;[P"EP!7ZI!%:[BIHY[95M>H)]\RPB(QS+8P+A? M)ZA: \$G2#+# W5\+0?
0;B+UREAS'DC58ZV7WP?>8;@1.K]/;\B47)7HYF>]#_]-G]9UM.>;4(^=0.5M]KAYJLC]-&6?
+E\$(*\L^4M9.C;IN]M MOV6=Z&4M+\$BGZRRZYZ%M0/OX!'HJ,K>2Z\30]=-RKD#&W?> M%S09Z-SIXTPW^M3*
(ZQ=B0ZDI,WB4Q3T#H);4>M;AF<6-_. \$ZRM.&A@,?V MTT#J744L:4<4RE/8*E'T.Y6M\0%8DC'TMG??
ON_TV6<2>&LZ+.G2,;7M?J'1GNT*MY5VM 1(:0JT)M786:JT1 M4ZVQ](.Q;<(KW+>IM3]TS>\F=!G.==G6&Q?
Z#.AS\Y!GY4K,?59A|ACZ=:T M7X4]EG/]A207%*' A (["P56QP.-'HS)LZ5%!'%;HM.B
0]"G^5_E\$^CIA>U9X6.3B/W M!=GY:QX(-3QVW(7I6_C"G']&=6W:KH^GFMIV?FY6Z?#/>'T,%G(,V5C&.7
M0@FGSC9E;BM7A!(^ R6L! D]G@,<8PKXT;SUJJ/.%1KV#\$3UDC3LF9Q#P9XJ MP4\$4<1+E7+0LL/1A\OW*?
UC*\$G+0^51L,]%S?&8TSDV0@Z!U])F9@-K&Z M_L)N.@."Q/#5?G@8%0SNLD))H9DK%/\$Y2+0BBSWP MW/&M?
MH]<*&)4]?\$P-\$;B(LS>C[%#L*4LNPG14-++3M&4BMT+;YXUM9/NUF MM]"V:6M;Y.@WN-?
LW1\$,W:T*]GHE^!H]VWL3\$TQ)'1LQ!/1:XE4:LU M(:\RVBST.H#:8DGG,MSD-
(F2NF')1%/W^5GA;E':JRR2>LJC\$E)H060 NZ\ MZ 4D>@%EGK3/>@'UIY0= \;Z'={3?
28.:EKIUG9>X<_2G6W_P,^KI3I6Y_EA MKZ
CBV#0VVALN'B:T@&2FC.8\$7;JEF+9S21%+GT!^ME1PS+Q39T;))F.\$EW M,C";J%8]=2S?3U
M]1=A([Z0Y+;02",?5TWX?9T5)=_0G M2<,&=UASQ2U*4Y-8.*:I0S4@&AN0Z\%HPCR'09>> P^'&V
(E#C:F/VJTQ=J MVE,<,+L]_# A\DCY06_2:;\$ @5< MG/SV2^%=,VE(03/#)V-D (6&.^G50@:N,.00#K,PA'D
8H%"3 ^PW]>#=/ \$ M?ZD+\$X9GX= (= \RV=]XN\$S[/V8?
4XUS" TFE,7FATI!@:2&02_KRB%6P9L'8'!HTJF0@PHY:|V];441 %I HW0 * M\$=!>(4\$L;|0-\$@!8
\$H@:"0QF1*\$ HC=NDHF-D:*(5AMVIX5#Q4X"2W2I(>5*9962P_YBD. M!UEE:R#^Q>!EZ/'*S8)P"
[4P4UTZ3HYEII:1W(#ZTQC"=B/M.3M=KIMF@ ? MSRH0'(K:P&/"B%,T095[3&L7UV055=-US.;#Z[U-

JY6YW6E@83;0NJ363Z;% MF:37DC:+3M,76*.-6KZJ(BU01,D0%(4W0U\$*S9:1CR"B;U0#+_3|2A)J;D,#
MW#F!A0LB^),1?Y8&]ZC'^0700*"S66<0;.,[: M'"09S+!?'=P4,Y-=5R N*\0AU5?^\
M;2&+6(71^CYXUZOM_& A#1P%^*-&@ F'0AA !(:@\$"S,[|N\$"KL<;C;P)G<; MN'&P=H"C\$3AX0BED!J;7,?
T(, #I%IQL79>;NXQ.0(ROKN!,H \P,\$,6?L.*9_ATQPL@NF9:I#Y2K!N\;TWT]'1IA,006;> M2VZ0-
XLR34I7"Y/DJ'0:VE?- WPV6FKX;]*YBWA' 0/WT#E!V+;H"PC7P4\$0|]0!|N MPU"MY?F0/U M0@R3;7RC^
HY.U8(DCHOAD8#|X\$./7!33>-Y9?MG@J"W^'_@S1@L9,2V.(CK MVK#X(3 M/9E0!PT9&*4(.9Q80|;1/W8AS!
(,87|6<#6GJ*[R9ZU M)8 \$V!B%SB#5V45+ *!&7H85-UY03S'.Z%N!#[M^J_&?>9J)0,\1T1.DN01I
MCX@:.,PY+UB @|)\C,(A%ZY8*"0;L'4,\%- ,D9%RX/XG9HB!3
M40DCD19BD(X0I!&N\JCK<:8Z20"X,P,!3K%N#5%#/A3.T@SQ SM9R?H;XUK-5 P<0W/6-JHF-
I/9NTY, +%&EV*01#>HPK0AM9E_G:0##MGI4-> M%XFH[CR8 XP7>Q5'7#IVY2\$NT00M2+
(GKVZZ;"2>0\$D@&R&;03;LMU 9 F: M*#\H*8'+C70G9,K629:.,@:N<\$0|>T?"DSV)S0C
G2^8,J450>Q?/MHP)&J'P M?-4VZ=0D,|;ML*A,Q9B*30.MS MQ|:IA|;EVLV+C&-W?CCBN\7.)
|'"3H:M)=3C'|&=I0(Y6W:=@R QU<86S/|Y M)L* F3%YF;BAF<28K.<'(&2@8RL)/BQ0F6AX>QC, GU
+5(-8/6&.3 7&7_Y@I'8>36|,A|XNKD3_!L@K5N M-2?YB0**!H)4D|FMA^\$0,)R!?
390MG@K!;,%\$L)R!.*P:19B,|F%')W&JUO M.YG^!;10QUAIAY'!P=(/;., EHU(H|KS.Q|P:6JM=P8JIK--:0T
Q'\R?P , 5 M*0\$1JNPX!206W!EB50T8Z\BP4XBLL@66G_+&[-#W2IF9!9 ?Y2/&?R=AV?C\$ MM2VT(HKX<%C\
<13/P&C05)2^*T\$%KC^&?H(3S\|Y^%EQ|30-CCD,?*,|E10;4J(N'1/"Q,LDKL'"\$>V*S'(0 M@#!)4<&BP-
0\$)"RZM5*?);C8PBI^X; 'XU|[# 4D!|WJF>I.3A;NT,&82F(2Z|WH.4'JMD- \%SA(4-
R:5'PE_7.>:!B4S5IY7I@0%I! MC!UM720#M%++N 2,X|>+2;+ #NZ=+4|#!>'CE1H=[:BP=HR"=./YF|?7 <4
M!8?ST|&XG^_ [+W06/&N>J0"F2_0J92V!8M6=78N"DV=J:09E5>&6I&7XA0D\$
M1<3@B07&X#*J\$1867^'1@DJ+>0&=Y|2:4%#7.CI-, #H#@Z)CAF=SMEI9*Z)4
M4B!>H:C@|0&G&I&PIY|15NA8|9*P,TTH1HA5H_1C&!0B14:L+X_QK27=^@Y"0(AVK^00GCL\
M#\$4+^C*XS5_\$J0\$M?AH3-UP\J;5\|V7#&EI'E>&=7\$JI\$')H,-' %D +'T_A M@M+S<20LYPV7
6L60&F%5IN2NL#*=LUT<8FZY51*WY9Z=NSSN|EJ03M3?>V M=| ^|D0;=IV|]SEV,
|Y8Y+R^(M@10<&Y=A|5I7PT| %P2,Q&5'"V(088'%/WQ8 M&FEQ7ELQ_!8?U0&?&%3>^Y|>-
R|VW<4WL\$:%7X+66G\9K|X=&QT, +!@1^E(, MF5(_R!_H6=I58!D\$)?1
+3'+1<<5U#5T@SA&:,80T|6#=#GU_(\ONN'"RV;7AL4XSF|Z\$CXL7 M0E|TK;_D)_AYJ>:NY\$#5A2T3
MPC>' /U_!3Y\W0R_+5Q54WA\$ _R5=*Y/?;'E6K7Y4;'S|J1Z.<=S7^)?RW#M%-9" =.P6--
G>XR"/T|P)I6!CBKMZ'P6X9V(! M4V4"+>%PWS=TX(P*T:T;_0*34I._Q&#QV4\|'MM95/8= 9/: MFA?
LXT0W)U_-!Q_9L|=)%XN (C,07*(BA6?KQS!;IBHFLE+? , M?@Y24Z5'QWXQ,+HI\!5EQ'0%NF)2*J@+G5?
F.,KL+1)H5Y;@>D>J>XH&<]* M_0GNO|0G%0(@ _LWIJ\!73%)9SX;-
M4I0MZ8EB>HGM2%|-6 _LAC/HM%.MW!+ABDDK3;-|B28!|3'\AV/RM8^N+PQ\$" M8)\$ ^RX =@# OK.T-
P&M*'J5!@);,4GED3>#E ;4)+!\$8IZB:Q !JBA*#0:T MSP.NXI%#H97-Y+[AK8^"X_*!'VG| D V0T? M*!
+A=A00B0&)=683@QV=N/;HNPD>K>8\$NP S02^(0'U(/ 5U|(+)"|RNP^MA MY2BV@%@DQ/H"8C%)Q0X>L+-
R09D;|)SBS&'R F?6#MCM"ET51+S@|H%.!MGCT MZLW/MCT%K= 8=|64YJ-&FL@2R98%5@7:(N2U8?^P|+\$E,!
<@D74-DL|5ER: M;CS>: M7ECYQA.'#1(<9=\$B2";@%,+I240\DD8\GN85+D2P8Q?)!F(=3+J+%6S5G5 0 M-
|?)#S?8>|G|!-"@%UI\$9D-.\DG>E^/@A|3?+1=W|%\>P|]8@7*V0\$ID0?8A
M|5Z0Y@+,C\$7M: ^Z/E9(A1'C"1K78Y=^)=:/8EC88:780:(LDFU)#YIG#ZDC MJ7(1_J^6)58GTK+F%7?
7EJ=Y8;+,T6J\$70JG_S\5RT"*|0\$JS _M3IS+B4LKK!38#|H^?;.,!<\$'8^*M-
'+&3\$0VN1X&MN.;V&\&JFEBLF\$I|6S?\ MB?0XMMW16)R;B"995R0PQ:74W%T0>U@?T^F;B+\$DA13+(', '*S%
(;*_P_/)(&L M*' (QUJ_*QZU(NME|J^F5VWIT|Q=ESF3+()QC3!8P7Z^EF@;00Z1'YZ3&H| M8:8(9IQ+6\$-
\$HH02(=C?<5=0^8\$/K\+0J-F3 MH6\$%AR:FCHVM
EBKM"5B=P!68@4F5N%^|*W=/&.X|Y4;Y.:9C%LV, ;>3\@)6^P25*08EU06HV04LOUN1_0)G5KX\HCKZQ?
7"J&S0A2':6IQK6PM1 M|# J43P:3%PF0+ N'V! 27'96NG1\ 'S#(\ZLU-8=BL5=/P\$ I M?Y;.,X98)A1%;V?
1B-*(;.,! *PB8?7T%\$S*9?A%*S:X2E/'UL#B6A9D9V _V-A>A"E45\ (J\$ETBYC0T0,+H\ /S2ZGNB+ <\5
MB;9;R37@H35T/DC\$SD=* YMU@A'K8!2- D:9.4I%*X6D!)/N|CH"4A\$4NL.
MQ|;0BJ9KB2DF/8Z),R\$:JYQ%\ \$0_S|*N!,RBB-;_)0_5DU24N)|4_|/'WI'? M*!\$)B5%4^B;2+&*3BC@_*
(N\MMU07\$|8_>64_3KR0;>V" &S%)950>G@41&J| M&K5P^-*+1KM1=/J1L J+JE8UV03XZ/L&.6-X6"Z_HL
5C2PQ"F0/8&U//TA MJ;|)2_UR05_7\$(NaV\$0D125!FZT&4)\$9<3_I?Q=;0 FS^?\.X|;MR4KA>);# MSU+-
/0M'X-*M@0MAX>51&WY#S#XV.V**\$82CZ#T"#?; .E8"PCW0+G\$LF(<+ MD_0_5.P81='MGK@Z^5.@+&:KY#&5
HI)?<_6?DA!K\$-\$^|>A|],5T(I)*GA,
M9TPGS\$ _H6I|AB=Z)D702I7N20"JHTR,BKQ\3JML6>1/) &GP\CHE+I7+8B003 M/?4=/.%A;%)W-
(*)HY=NC>M)#\$#.SGJ4|VQ4G(2/)9+_8KD=M ;MD|!)Y M.UM)|-AI/XCDZ+C\$ "LX,=>P)0'RV6I3X
<;HXI4B5_H#J F; /RZI",N57FPD M8>D*3)H6\$8I(:HE\B|B4"0)9;7UF82T*@:9(- (GFU;%IY5!7PT*Y?(3WV?
L.Z//,>.PN68&=88IKVJZ0CXI=-80\$F?!@ (A6>S^HU8-'LZ MGKE&\$*HCIF2|\$|LD#E8|TX,:CV',+CPW+-
HC1K,1VR,N4|9\$>\33C46T1|R, M|HBYT.R/HKIP7\$I1AY5#M^&TJ,|G2|8AHN+F32%3R"?K00ZQK|G#D@5U27#
M@K4.%S'7_6@9.?(-T<&^Q0,RS-|&%YLS|3M_0"0Q"7#)|4=*!8);M26/R
M0B6,F\$S(0VT'E|I@&"^P+K)1N\$7V;&QA9U+;,<-W&F&E%@\|7U:M=AID&X7| M|<(QN1*
(0651_4IDM44R_N|'1))YQS_@%T|XQUL4;KLCW./X8304JJMM*%C5
MX|\$ (ILF,F@|FZ6+YEF771&DX8^HMK.7(KL'"|NKJ0S0N_+;E&:9!UJN_*+* M;!07GFX%8.-
N<#BZ3Y>UJVYML/M%&M-6<@U\$MF6R_8T!=292|PW^=@6HHBDE M2NXE(Y>HLY>
6!V1DA0;5|K4H>#BWMDSIA6T@P708_07PM_\$6PG\PEM9*)BY MRPZ:<;V\M'@=I'(%\$W+\$|YNR#RR\P&H^,;?
G=/JG#PAD MZN\5_%<"W\ +PS>,F)).71@F?K2E(95+"Z%X0/QX9^Z PY,&/#\$>WE MHR5+G.!.:#UH-
FKLB3C*G1I-0W8\$_.(:&5^9K8"FAD!3%(GZ(MP87YG|BJ\% MG?|PL&S|E3BZL\$"C8?
5=P&I/6&'|'"8&J%+U146YV*2" 8MZZ+B_1NH110AL2B;NGAS:2SC61=@;&ME,.2)|04"UN%BOX;
MD6#K"H|PKT|=?:KYCN\$986V0|ILV)M8SB|)-#%=LH6U=!A9D\$XIM3ZH%C;C+ M90&P*%*)WL>Q236E&NNW-
T_Z%!UI/Z;7#\$%^4.G0AE!<,4D6%/EEFUC\$@B'9 MA&TU+?=A<3=LF7Z'UP7YP\ '!'LVVK/#G,-NYZ\S>DU_

[1^ VWI3 "IEI61 MFBFM'*('&[.K! [G;SPZE00UMHUE71#0BXRL&% 'J3JCSC#0ZB\ 'JPDF\$!;E
M83T*9S2^,\KVQ! ?E* 'Q'8"J24/W'@>C G2" MA[F"/&%R5; ,R? \$^8&=N<&J M\$R4\$DI+W'PE<4U\$S8#L9,3,-
[L?3.L1PQ, '\#P[FU!8?S, ?1&QJ0A=VGQ95: M09SF/_I8CGR: \0Q(5N/(\$BA]=A^&D@|EJ;J?KGMW; ?0.
[WVG=2[0WUX^M8> M]! [NUR>6 , ?-PFXZG&C6/8].).5*NC4L8K&P'%N!T8=PK : =L*K&F# WC/_C
M>^ ^ ^TY4&OW>?VH = [X->IU\ \$MG"0 L_-=[Z8] M@]?VW=MG%']VYWT.=A%NR)UX8';]-VZJ9"Z]-
WB_@ZVH, YW'T/4MBW8+! M>G4E^J9IM'W&[-3N!, M#NMMG=>I2)\WF5:/22%KII-:X4BOU5"J=*.6KIJHF
M>M3V[RMR+;U! '59^A6@_GAT\ .UL* @3EB_ WMO"& \JQ?< \ "]AU(A/X+S\I-?E+
M'&^"_DV=NE79BGV07+I9\$@=J2P7)556*VE, 7<:)AU@Z6] +=4"VDG, (HEVS7 M>
(, \$FD; IQR2(\A6S(4!S%P&"DUC]_NKBFP00X61W>\ ^)D?2.C/0>GV!D&>C%
MTW\$Z6BEV?, =AP2K7I9Y[S8. *2.W^E 25Q7<;5^4ZYYPD; G!J7, , \#A"S'1
M\$WK/TR33EZ4<8/B_#YKAZL08(") "GJ?UB0U;MG7KD&!'W[<, [PDC'+ZK%W"K M'P?/OM!*&R=:L:\$F.Z0! ?
QDD0G%*T0/A\$R0\$1_X ^X2&E4I-A2.I44!JY&*]JG(B-BG9/SE90/MCV_%*) (!?, JP7 MX.DD:05LM/H06:5%;4
M0JM2+2KU@V7E \QFL<3\$, 780'EH[E'+&T"H76M5*L2S7.8'69?DQCPZ=\$G#)
MZ=N46FYX5,0.ZJBL.:M[>:XUEJN06>'9@XIW T(# ;, U*WS8BZI\A4"JUR ML5%7.#%^QW. %36F:P0K "GC
I>EH&M#, L1+I#H MN=EE'Q\B(34P491B76FD9(D2W; CV"Z^5+ #MLI@/_5N]T*K7BY6*S#W8+LU2 MQF,X7M#(
@/_K%)L4;+H]K-V, :R92Q6AG59S0.U'DU@>F#G=.<'0J16\J5B;Z<-G0A;3Q>T04/2/N%+'D;?P=M\$LFX*2\$4&\
[C;Y"1\)R+#OU.D28&B%KE MQL&[U"+.NP?7?[-M_ =4PMU='0_C VPZE."?
@NCLW,MZH70H/=>P(N*N8!HQ!&Y\$'ZVY;VUY9#I59H-8M5N<:)R2',U".Z\&G@IUYH-8K52EHQ M4DY,5IYU9Y
U\$*T[,]RTY8T,\; /JD\W];*0_5E9\$4G%0@ (NJUHI5):V8[^DW MW#ZPT(4X"7%*E/>15)R:
(\$ZU>K\$ I7TS&!\R<\$#=@LTMWC+06+=]#"?Q=AI[MY]#.RHJ*/GA_UVM [=WU!KUN7VK?WTC]P4/G[\ _W-
UTG_IA\$U*I^?WWN! ? MXJ0VKYS] ^*"] :9"A8;+C?*N=MD]) \ %* [+ "\FU-8]60I"F9X4FD0P)SYVF) MG:>]M
M+L3AL09\$5D[%(^N0F0M8,?"G;^AA#PB05;+G:0'5=^'0KMNQ)T,C;-+>6="X MLTKBN]JG\$6*T\$NL
MX],/S\R0^)TB@VA_Z0[]?+@!0,20%[5^4_-Y<5!5XJ300=, ?>43_ SEHM\$Q]L7D;C5].?W\E"3L? [I MP?
E9(J3+'U@2'7&/!Q8\YJZ>8SF]/&G.5+?/+L*<2' [;.\3)365%06N-\1)
MSS,\$60J[:/L# #:M/EXLU;C8'+L000:\$C"FS3)8^ \ " =LV!24])VC/TNP)'9"W ME> :JVV63#HJ&,DM-
WCID"\$,W^-IX9215&5(DL_LB&A.U&OPTMYK,0&11UC#PB6\F:C"ECWR\?JX**F#CFR<8QN4W&08B,R"(V46)#4?
&H56 M0RFF(!TBI^ \H!8_IR IU)H -;784-*JAL-]-@'/:KEC3R9&T!HPZ+8[#P1I M'ZGH(VY/*,'UUN5F
MF9ZL\UX8_G21ZT7I0S\2K4?J],? \$H1\;7;W\VXB.8<;&+0>B?/@]#WB4?T? MQ/3I\JGA0B@0Y\$[]6-
2WC:>2U7C*A99\)QH8TE^ 1C=4\$!HEQ)Q)7ZH*#@ MBK;T-YBE[4@=@=J
FC6F06[141&SL/Q]%;GJNZ[^G2\31RB5)&D<1EL3#;B8> MUC[4>0]UP,+&-@5?VP-
^2@DVV]L2J%EV;0!'1_ ^!N-<;L:F%]@24APN7[=, %= MP0U;ZN.?JFZD=ZI:Q-#Y@ \NEK<'0*?,&W2.
[<3RZ/F@VV];! [D]NQ;1X!4) M?8S&1P;Y 3[8?H.I\N#PK S]0)NVD=SF3D#70P>W-+B3&=VK+D_6LXNR37?/
M+'V[>6-@6RW W;,#\ [E2+JKU6K\$648 ^PL4\$@RUKB._G69RBS0QZ/9"01/, M[8I;:-;!ULKFR=Q-.G-
K35]\$-9RS&@ M4>8(&I>5B->&02.QB0D6FZ%+AB5I9&IX9+^&C!?'A'>ZJ\$K0@Z2-0M&=U GJN MB\$'!'(F^
5N5JL- Y.5A7! !0[@M*M@4.IPJB*+ R?[%VF;DY?ENG96B1N<';BS73PQ\# : MD+>DPE-C9;
<.;S0C#%G^D+6[=%N6R*HCLN1*6@FEP@>5RGK=&1HQH65!JJ> M'!'%'!>./OSU7F*>J\$?@37J7.! :0PUVA\DU
Y*1" T@_AJ56*LK)I"0\LK. \ M8VI#^1X-4TW E-(LUB+;11X=4Q=YR,7=FF(JSKRD;A^OYO-V&9\$3RHLB8^VA
M2K%9YK^ \H3C[PH/AG +DE\$*K42W*AT? SN4,#(R>HC(.A& M4T#1V_1 RIR-SHE_M+-
MZ2EH(#6C'L, 'L9/3=EY"AH4,IWMF-AT9+F?4V/CH M,L.R,C,\>-E6;IZRL9%5.B/-L6,%
[U74!TBC0WTD;&8H\AP9[XC5N4!G:QV!1 M930FQE0B&NY_\$&N&V3R6[:%X<#7EF3
6)\=MC7M>)CEXXVI2P%1Q-<-C-0! MFG1L>, / ^8N1E
+R181%+,YAG"5^PPYS0\$G06J!4.J%*%,40MEVVV7304))@9
M].75T+TQ3!!'NW!7R')Y>0L9P@A\; LM1V3#5@FMPICJ[W*=50Z+HT5A,:IJ MA8P:0[E&:
[2B*Z.&IM>&5&M4=%6AJBS_KUHMS&\;.\MTWF=:&CJ4 "B1\$4SP MFIB09.8B8E?A"=A<)?I[>FVERFB4#54
BH&,@.JP@T)^UR#KU,&K8\$R\$F[%(M8P\ '?>GA M5GIXA'D->G !Z K=>?
CV^ -3]'6[K ;,KW3WT^SQ, ,Z%J_1]KJ9 SN/H>Q:L M-K8/3]7=HD3?-(HK^#A8F71I2IWYIPEK<;I]DN]D"J;
(UNWE0L*,!)BJ2:8N M09[\44WW*E)9M>&Q8;' ;0H2/BQR4VF6\,H1/CB M4.U>P4^?-[^05*
[J=27R)_DJ^OMMCU+4*U56\$SUJ^ <5Y9P'I5S5*Q4>!]7X M\%\$9Q+P"?7 2J!I3;)ZH
M2XF#-94L3%5]H;8]G;#HW0Z9;B?>:XLY\ \2; ;3QLFL6<6Y)=L_K'NV9S@+0M_M_68)CVZ@8Q-OF>'9LV+S\ -
JS_.3<"L\$X5\%H'% ,PL!)AL5(^N*N>\$ PA&D+ MAG),P:AAHE207MNLZ2\$D@QOT",D(*)*_
Y3,FH%UJUHSPTG;G7(Y=QX3%;]2B MF\$R\$?A/1)X9EN)[#DGS.Y:SU\7V-
D*8@'NTUBNXK(7B\KU@KB[[6YXBE'>9Y MVEC".F[%6HV7ND("2T>T; %/&DB*#35LNJLVLT60 (,/\$ \$IAU&8-
I@4@('J<\$+ MF"XL@/Z; ;>N0AFE*QF1*# <->DD; \$^=Y/SLPK@N8;Q'990>&-.TM2(J54.(7
MQ58445#]K/&SR_8]F&# <5547^#FF01<# /S%6Y@JLS/6B4BH>IDLZMY', ;0=-,WVD MS5R\$D@A-
+36A\$;XUA[#;8?AE!JNZ@-4YPVJ' /9@9K!H"5N<,JQTFX@&PBN%] M- NM:AJU*418/=8F0E#I\&Y_L+%R:J
MYKEA3;ZKY0FGI;U=(\E92Y#V@N"WMK/HN>YU5JF=5)Q4N=12B[7&YQZ?*!3+
M';92L"@/1=2'Z[ZJ\,; ;"TP=P9P\@I92440)C8-+J0I8<0BK+>9DMJJ*NYV0 M(OUFS* B:DQ(!"51[8WSC.=?
0?KX<KD5I>V.D+=5Y4 M\>KCAR@/1UR5Y7TW^;]+=1#^1?
3R<,35"JU*M:C6A9(3D(L5V3P<N, "\!6GDV).Y30JNQ""!RK,2FE3#F!0BLVP#EUB_&M0LTL3Q MRM-KZY3"
Y<+0 V;-\$/@->9IP)XEP>\# =,T.^"5Y:U6JD#>Y2%OPT+-\$'G* M5F.5(^2=?=QT^Y;
[:50/)8\Z\$X#<+].K/E-6#G,0MVYQ7 'M!T :6^ LE&R MH6)WOT,\$0V0V<>C_) \]U7\=)
[/VGV9: 'I!>5H39P7\%*8E5>CG@)C_8TF[:)48/[%1\$U^\$4(- ^ MB;W9FA@P*JJ9A@#,F0\$F]AYI8L"4"ZVJ?
\$@*B(B-Q>)/W/1A<)B;H#2F8S'1N MDGGD#;ZQZ,C8;[05XM,'XJ;J+; ,&X*_ @Q/ZC[>#CVY[G&\$.? -5H>V"] ^
+ ' M-DTF/_OY.15VVJ12YSK10*2X<&8@'AFC5<1HN;K9RD9@]/(P&M'8LC23# M=2D;D+?
00_P:T#I*0AK82.%P+_/T*ER<1\QX2WL+I&*G_52:::?)"-#Q"+HT M3*
[*J7&@U#K%!:8XQE1VIF@L;+ '3*90!>]ZTUL6\$:D5 -LN +%!Y_Y-< M597%5YN'I(>+L,"Y0"YN?/4PR)5%N%1
+FFX]##(55CTLUP7T4^!N?@FYV&8 MJ])@9J7)M9X[^V!FD<+>3)PZ= Q^@_%"F4UZ0=4HC3' [W?

R(%I#W4@QLE./M[-)J^ML.?+0DS7<<:FDSR7/@:2:KB+52#6-XN\$X61^0.\$6.[2K
>#6/-0JLL\W(&^,)ZE'ZW' K# M^_5I6=B6-(G=.9^EM >?2&&B>E()3!^2BXP37(I6*Z&9Q562N#,Q>H "[4]
M)SG(5Q\ (WE_0>RE(7UF:_A/53.*ZQ@HM"YH[@>25L/3?06TZK[G;\$?XS&%W M@%6:,>P4@)V\&;<3L,L_-
XP5#.'1XZK*55_UW CB?8'6"[9@Z[MCA:U03)L=K6Y(9'-
GE"D*'%GU/|WLI/G6W|DD@T4H43VC0K7*N#G%D\$)\+R! MF4*(14B:D+0|DJ#2E#1V@E0^~RP\ (6E"TO;(-4I3TO
<;+G8;!Y2VT6(&E^@ M\$Z*66LI;FJ*&IWF58JUQ2-TMD0"76KV<*74D=TP<*I6D(7\$-32*6+NF&Z7M4
MS^94S+FICV23S['Z>*1.'Z'RH1>J;M4B7>)80_9W_IB; &0+)2\$0E43CXS:A:
MR@/YBKB/&D:ST)*0(DY6G_D)12'F0LPCI*N1KG35Y?V\$?,JA;-56(
MN1!S(>;K_G<*8J|N)^9|N#,2\76LI51!:@\$',AYIQ?SL|]?_R3Y072(P)/),@YB#*|DCW/2>V#@@6_LAV;
[G>L3" M2<4)2"2A5"2;0M#DTKSV:~P-^+7#TC-GT;8*HVAATX0'6V5:~4JL4E?)F
M##/BB_T1N<11H'X71AJG:#Q'P6W4AQM:HC'|PVUHEP0%^7*9M:'0'P^\$*^< M\$D.-
CV(|*8XW'0EM*\$S'RTVY6"MO9E\ (Q.<#|*XTT)\670\=5B_MLZ(4U?+FR9J/<^JHPYN&,J\$OUS<(DUOP?
\$LCUX'^Z-P0_&.NS0TQI2AP/_190_M3%T*/"6^;J!G_ \S4L00A^XOYA@2_'AD6L30#;@0_>93E75\MZ/>>6N&
*E68_MP|1V#;3VM4/Q'.(+?)JZ-X8)HBC7;TKE'YY>0L9P@@_R#M0.2(;MLIT%<;4_M6"?
%ZG|QM(A/HZ16R*@QE&NT1BNZ,FIH>FU(M49%5Q6JR0+ JFA2!3>-G?D, MIB EI:~#R8\2&<\$KXGY2F8NZMA5>
(V5XG^GEY;J3(:94,5&@((R"MLL,R_M|J|!|5,'KX(Q\$6|&(HT=5%P [>8/^\$P#5 \H-AW4>9;WRV?
2BF(|'YHC)\$@| M4D_ \;UWW^E*@|^|3^W' [0=|K|,020#5=JGF9>2=A_N;[GV>R/!7_V'N|Y- M>P ?
^@/XYUOW?M"7'F|ATT|G| _W-UTG_I_E:HPV\&_>)A90FW^Z?M<_<^ MQ|'W+%A@;!^>JKM%B;YI%".XV
QTE?2=L@K\$K\$+/W3|)=V(\$4V1+|7+M8/8A_M3-4D4Y=>S_XHAONU"2S:~BPV,W?0D?BXXJ##?
AQB1I,'/2UUZ)0?Z-(QP_MAF_.?|Z"GSY0?E^6K^I*(_ (G^4I)^'U%KB6Z8|N@FE>U:EV,;=>8&E>52I6S
M,2GR5:/6Y&Q0/#(/OE3|^~W1VQ7-M^I+*E&+_7\$|T<;N=90ILE0;0?;?_N|0
M*DW@^K\$K43",=D/>IJB;R;5Y;*DRFJ\$Z60XH|SI-'D+8W7^~\$:@H/>* 100_M1&^!0R7X1-#UTUZ=
(:SR\$,GV*/JXQY5"GM0>W#*L5|C5_PY_Z*C:|B&L;+M0")H2B>;!D7RF_M\L>V"3-R_OIG!5?
W6<%CKM,I;1;DF3.X&@_M"60&80E78A)+H0)A65E_ \RT:U'J9^S&'E\$;/OACW:375#L'_= M^WY+ \/-
R@K;Z%;KM6)-CDIF2I?C9Y&)'(_59Y:(?""^HT|YRQ_70EJUN|I_M^H8WBSA,W*@B?
KEQZ29\$1XA.FJ*SHUIAE.@D.Z3?P'H8:N7!APX.BW*+T1*BE7?12E;9J1RSWDP*0M; A,9&L:H>4CU-2!A78+M(
M"4LD8)7,%Z\F6(:U8K,6^T;:_\OFF_+=+HKBJKQ=?QF?>(\$V\$;K!B;_>\$B6
MY9Q/IM1R68XN#V' |/,1C_)30U74#965&KERUIPI\$=%\$ZRPNN9/(6JA^;"VL_M-
H8V,MD',S#Z5D=,L5D9K8%P3109T4!/5\$P+ES#HWWJ0!@:~82YV/H3U>QG_MBSWE'\3T:5+;HXE!?
XJ*>G#G'P|!>.K|SU(8A*KBF3LI=B/C3E,I?&FJXW<#_M/)E-^+,Y|2F3&2|%1#|'#'E!9KCNB0Y?@CN!.
(@>F=IK>OPF-;704HLIM#@7_M\$!0*0G#G2\$V,CZ@?RGSIAPL*H,=H&X|,E%C;<,-ZH:&3*0+L(L#_V?(CHE:"
M.X(|Q_(>LNZ^W*P46DJ=E_'A@)U0"CGFSI\$ALQU0I4GG7!!6PKS7GEBST#L
M&7"VA(B@D^~).X(|@#L_<279\$9,, VW)\$!;!;EI>F5..1:*|2JQ4HSA;_A_CX\
MP>#IK,AB&E6(SHDDG;X07EFKAU435PE/>_M3\$ZA&N^ (EJ)B:&)H8F@10|N40/V6XN%ES:T_53..UJMRA?
6%+ZOU8K-9_M%=%Z85@>+RJR1Y'63>.QBOCEWG_4HB-\$)TW1R=XIJX%<-158%_XN'BZ\$BRN<
M">':)50[U%_ =E)|ZH:56#ZX.+F2'*QA=I.PD"\=0E"/,+AR/U<'E:K'1H7='ZMY|H^~\|9(RP3C8VL758Y
M&OZ@;|31#)?|%GXY17ZYK&LY%KR_R>*/#OSI&!HV_PZN0Z2)(W\$9!>_J6X)W_M?UK:6Q"Y^_J^DF7;<8CU3-
DIT|GRDD)4T|EP)|'"NR6Y^#!I9I5I_M|Q3IC95;4<#IY*4"E0"?4_V".X(|)U?
<.=#;_*D=Z^X(J|SZ|=X<(LA:~),|P_MZ-X%QN,D/)QEB9|M@<*|'"3D""J|5+_0':!\$(#Y!QL.2<^PR)I)/"
[8E|G;*_MA5:U4JQ'Q.L3!Q(Y"!>~\I\$F2Z>N9-LL^##I3E:_MG"NT0~-U=8+,6WN<(*_MZ>8-
/T*Z!7<\$=XZ@>X^G>JM\J-X+VBM*M:7H!6|TB-J'(F!V9MQ)PRSGM%&?_MJM2P45^YK' 201-@%*I"
<\$=PY^2*/&|Z0,Z7'K^@G9_L&Z|&\<=%RR010A#!_M)<\$=P9TCN'<|20UEU5!Q<|UOP'I_>,\$@3&A
01W400+CJ<_FCPI@_0:(#AJ_MRU2Q@2_V\$&3<27!'<(>/U?^0^S_C|HBJ*H-%(/,2_!2P\$THAQ|PYDDN0N4Y0
M>-(%)|0I<%#>+5!'U%U%_\$542W!'<\$=RY3.XD2LNa_%9_0(TB|Q=9_M5|VL9%U770WKJE?*Q5I\$8Y,|N9LB1-
=#3_-N03T%&VPT8+K#T*UJK|%)/_M1|.D9#L(|@1\$^U-@|N@D-!48N73RWLD,PN1\$B+%R'0DVI:8.#H8B
M%B\$A,3F5F&0AGXT^_YF52E>Q5+HB%~05S6X>6WUW(5="KCB9>2*QVNA_D+HT_M88'T#+U@VPM6"@^~I
M%0ZH4H4Y3&V7'7:~B@F/;_0+Z^&|HUA@CC:U;M"EL0+6\@01N!|VV\Y(ANV_MBEX5QM1<)\J??
W&T*!)&5:V046,HUVB-5G1EU-#TVI!JC8JN^E25Y?~M*X7Y_M36-
GJ=?;6GH4/*C1\$8PP6MBOI*9BXA=A2=@N*/[|W|3E<;_Y|:C|VOP|ZG7Y1@J^V2S40(^~\W-|T|_0=&PG^ZC<
M|6|;_C0'_W|KW@|T<N?'CI_ WA|J;|U/^KU(79#0|P\P2:0-/W^>;_M^>
<|CKYGP0)C^~!4W2U*|\$VCN&B/@_5(EZ;4F7^:V#XL*=LG^4Z,L),XD\5U_MJP&F:I*I2Z_G?
WS1#7=JDMFU8;'AL9N^A_ \+%QQ4F._WNI"DP<|+77HE!_HT_MW%\$+WQS^?_4_?=[\OBQ?
U95&Y\$ _RE9+P^XI<2W3'MD\$UKVK5NAC3SC\$UKBJ5_M*F=C4N2K1JW)V:~X9!Z,J?;QNZ.WQYL9=D.5/-
Q_,7&KG64*);VT'S7|+@_M%VD"EX|=B8)=I&_NM%>8NM|H;AY2\|W9K|8#_7R\$UN711)T8NF|2K(FZ+=LL_MRK?
=GG#PP7PC,Q:~."_C4#(Z|:,3|.|BD8A#LH7W)#0\V;%?8Z=.[47TJ-C9_M@N0)+~RMHSH"J|~|799%VMM(/?
44L)Z39%BY'7|8B>J=,RK\$A4=>M37-G_@F_M"ZRQ,T/Y1=WJ8:?
3@ES,W|*=62X0|@R@W5PFB:4MP,HAVY0M1E'F6I97V4I2P76A6U_MV^R7BZI2S;P?
>#I^HW*Y:BED%6/R225IJM;!.N84Y6R\$Z_C1_M68A./>LTR+(*T%39KQGJ_0_|.U'8=8S^P4T|?9
M|I)',L.06+?FAX"U;4N_MZW@0R#G/0N8Z|, #4-T0\$&|/"GJ|)0X:8@\$N5PL_M-S<+((@F:~+
(W|EP)|'"NZ5.SV'BS^HM|BG3FTMW0=!2U\V= \7=X\$EQ7U_K+>8N2ZQ#,KI5"P"(5EFB519G*XOHN\+?RK+-
)^~U_M1WNYB?M2-967=BQG"<:V8Q!S7PBR_!|"0?"L(1W>.9."HX!K|J| (0.E02|H_M^R5LG"QI8>=DR5LV2Y;(
B=B*T7TVN)LW1\$!*<\$=P9U\$3MV.^0(?=,,UXE._MN\$P,
<)4(7MFV|,%RS5B;%A^TS@30LJ7*!^>^~XP)#2"XDZ)?<#P%H/*D_"YH_M6^"|Y5
8PG^H+CT3PY(^F:S^!MKZ\W;)_Z+M)+C!,,BQ,L6)NHM@V\$-L&G*TO_M(NXDN".X:
[QB>0=WE@0^5PM)!GZAF\$M8ZH<*33KB@30'@B82.@8CZBZ@_9TN(MB"H)|@CN".
[PS)U\$Y\HK&QU*MYPKAT5Y:7HESK"H%EJ52K%<3|!H4>_G#_C9_ML- \S@4^~
'_A<2@W#B)8@HHKAD8\Z*XVLJQA6ZE@%KJC6:\6:0-EB6E0Q%_4W_M,H0\|%\$M:G-E: (@JAD)T+DYT-

HI! I5VLIM+\$*H;58B4'U6J\$< GA2E&X5#EK MX:JR\P85):VM!2%:??*#L(D4K4;1
C1LN2\$'(!.'R6J4H*Z**H9"P/\$M8HC*A MF:]=*0%->S6J3?(5W96"0;ON8P)M*\$R Q-#&TXW-[UXLV.%Z
C125-TJIG[B%60JT: SJ,@'5UX4PL45SBY2N)+ETVWTYDL0 MX=R4I%JAI38V|PE\$ %, (T+D*TS: 'ONRV'+L>Z-
15*M"PH2\$Y5G"\$@E8YEWZ MJHU"2Y'E8K7)?V;6!1VK\$ZV.^)73+2&9GY;'56;L+C6Y6*EDE)S|(L|CR%
M6 ', G21+;W5+:AE' '3-J, JS=RF8P7Z"/2_0)W2"X(|B30>;>DG#/D^)>6%+< M%U33|.F|1T20M^ H>89#|RY>?
K'%@|8'" ?RD9 CZ/A2 <9W@!?! 2I#T0. ML.H'L =(M25;T5/E30!6T7I=K" |0+W>D15
M1A\$Q.S/NI&6&|H\$|L(8EZHI*^>!Z%P*, 0E4(|@CN\, R=%&Q\;05XC2\|)?D\$|
M(5DVX(|0:A%51YZ>58JQ=:99F7+BT"8T(#Y)|@|*?H%QU, M#9X4P 5M\$!RUF:080!
;'"'+N)+@CN,/ 'ZG^(_9|UX\8:%B|0'ES81\!|. * 7!
MG2.Y!%GKA+K,DTZXHV!@YJYBJB B/J+J)+@CN".X, YE|E2+M8BNK>DC8=C8.#, "A*F29E\RD941Z,=@>98=73K:
M3U=[G2]4*812"&4J0KGA:*1=0|2.->2;Y6*Y0&DF"K\$58B0\$=A^QW:, |X*9D MU@JMJ B(64R&50BK3";N4-
YH995;ROH|9THI|ZRFAT M,V^F5&46HUR42D?7\$0_0%++8JV?/ Q&%.):%@1A5@S((ADV1Z\CSCPM249
M,-9GAYC2E#@>%LSWQM2E@'"BZX;'2JE8.K6"HBH6(R !KT>&12S-@!M=#|Y@
M2Z07"|: ^IU8XH\$H5YC"U779: |MJAF#7_0K\&KHW@GB:%?0"EDN+V\A00B! M|VV_Y8ALV"J3U?^#
|236:;'Z7QPN"HM152MDU!C*-5JC%5T9-32|-J1:HZ*K M"E5E^7|AH9W?->
'F4YB29UH: .I3|*)\$1S/' :F*|DYB)D5 \$)X%RE^GN";27+ M:)0-60"+@9" ZK =E@EU#
<).':P*QD2X&8LT=E!9_K2;/V"<#-B0_9";#NI9 M/"0,6E&LYT-U;-M|88KBC^^|TY7&QS>?
6H=K\>IU^48*OMHLU+R/O/-S? M=, [W1L] NH_W/5NV@/XT! _/1^Z|X.^|'
K==K|WZ7;NX= |GF83T(E_NG| M7"'_G, ?1|R085VP?GJJ|F0, ,X!)T4+MLR4=AF0^/_;> 4EM)\$L8_5<4|/0=
M.X)B>#<>XDHE^W9FL_M\KKG30L_WVF_P\YFG?01A M:"2C\ EX*#PHDC=0+#. @4AA"@&@WV|W#@F'/Q(P+
'!G/_K;G#A>-4?.G>[- MM*GE0'K;U'7FFK-@J(F#?8K>@A(#U.I\ S MZBWVKDRJVD\$>+R|/QP-
9*'J0RH_) "1Y=9VIZ>^4L8GUE-UZ9U!"S, ,?/* M\$JISM(.D+^|,"<-
F";G+)5'">@TL=),S7E/7 _\|)C.G0(+^">B00@Y|4|ILYL"ZPKRP51MWZOUV6?EY M%= ,%
9M6V| #TN0.; ^VMWVGJV17(E\M8X M5&|MXS8&TRP*P(EB&6:5*L8]>SS9P\$ \$>XDGV^*_
K:7%XRCN_GR|TTT4;A%L< M3MS_L!C(0*6' |L@K'R002^3P41JS MB%|L#(F!9AFX/2V*;2/ZN', ^M&-
M+NW/^ _,&-U|=Z>-)3*N:/^*4 =M#GV8Y/)A^E|U): \".L<*8WSS'"HC+'&
M6R%1"EE&3>"E^XPN5LKF+NE0, |U^QK\$#E(LY!:- >|%QLZ!9I0YD6NM3I;Y>L=C
8=| "'BS0>7?._, FT":YW(;SOXN" ^=5V\ (Z(; M?EWW|NT^2PN:-DJ&FL88=.Z>G.8;GRD=-VS1|D-
HD*+E6@1BU MJV9|79>2'4F'I&2P'/OYQF?N'/#I*7|0Y45J2&4Y), ^<=\$5|X'Q [VW/P&
M:9;KP_2|X|K. *P"F< .K5"\$-E|790;P:N-. |JX=,Z9\5.^+2>^W:K9KY=EV|^ MQ;%0&/OV7&,5|.R*/W
M'U@RB86+I(_6#.CR-MDIK0/NP7:KD(!6L>/_RF M?&L;|R&
(;Q'"4;#DX\ ^) %2! \|J(IA;EU#0; ;ZJV.RFVX0'1;QZY/@V|8DZP^ M:E8%VZY+FXXGKZ_6;9C>!&VFQ"C(&
|C1FZU'05ZD1K1?64_2IHU\CKP3^Q?F MQZ_A8?I!7 +0X5>7ST4F|Q M(SD^##9EKL L,S== QAW?
FA\$P+*01)W\&)F\3A3S|B _/B>#YS|H@_7H5JM\$X3 MEQ|'#P+TW_6?GR/ ?PC8=^*12M\^'8>^\$5*0(TVEB36-
W'R'? M+:6Y^NS76ZE2I.PW\H'\$^'="AN!\|88\8YEC-MH1:=X_KI\$+ZA*8-X:&ON) M!5.,7|B#
(U&U20"4" _;2->9!EFL4K;J*!= E< S(80^**\VB);=\$T4A\$|E# MR>W>Z5FF\$K.'|&KEM
|X\$|;AF+1Z>U"5A(7K/+ #07.(KL,%L+CG)*+)4/JVH(5":0 M/@0B80WFJ"KI!]>E.Y,<5>IQZ>HQP?
6.60|234DC?@|TD0S\$5|INU9"EU"# M-KBRK8>RT^Q7S4-Y7?KL|80B-IZVT)<8C56JZ=|]%-
,4(H'\E<,XBPP&M7&W MG>YWHY31LT:9W3T'6Z ,ADK|E|-0'P8IANPM=Y:52UT")54 #YFBTD_6F2L MK;?
31K50+V/_N0J\$5A*9CL=H|T.K5A/0:I#N' '*N85*.'-56Q%V:>^ZCSJ| MQS#'\R:F;15=N
\$<+0#5=5Y,@QGOE|_#38 |*. A-KR&HC&.%D;2N05.1E'/_MKL-(JSEN5.%CB,W#N3EPS2?B_H3\$);F-I0U07N@
M?&27AV2;N/_1D*P|TK|;|V584BK<>XP."S| #<4G,?+F^:_\A=60\$K/>UVE59\
5IQ'I/2&#.LC7L9+0V4FGM\$-3?>K/P:|P|/J-| ^3.\$3(T"/_M'BN<4-
92): ^7C\$H%M=@L5\$JA3+M9&X|4AYA3.V\7+D9P_25EU#"0A0L4C->E MHA|4C_M5_/BKI5./CH\2QEDTT<*<
(ETI(0#"4*;J,%D(9#))V+LS|>DZ), L1 M^-:>EIF1T7T4U\$M*/BB10^:D'-Q+Z.^>MR
MA)7(GCE! ,.KD=4U@386NB7A7(0T5*#VW+^H3-_8!C1*H\NP-KXP9|@9L, |\$ MC-;T0(X*"F _\|F#VW\$F/|1@
?|D/YD|,7GL@7_L+*B9I@KDEA'(18@<(!^ M%) VLLAD5!NW,UHFJECMV6-+D5CMEMC2P5!M54JXK|7@-
AYGR'(\J;+;XQ?= MEN!9Z+1JXVY], -BG?>W!:Q05S6T56'^<1)\$SC6;LV'J8UX|U,J
I%\$8G9SPF?!>+J/M,FHC\$|X OR?A5"+EUIYI!_F'X407V8170<4)Q5)5ABY!7< \$D9V:V.P_BJ/_MD|?E?
T8EWQ1-DK" I#BG\F)! _V#1C5Z7. H@J0Q>%/45SN\$8Z7Y68H!FG'8Y M/12V=|(\$@;+|VA-| M-
FT;04"8QT\WKYSH>>377:|]|:EG%22B_1!1LS|(:+2F'/_#GCVG#*J':L#;N M=MN|05DJ?
T44^TU,&TR2"G) LAEV+\WCU ;VB51-K?S00V2^&AW2JQ\$(P5ESO_M9T0HJN8\+L% @442HB#
DPEZ%J+^+D*)GVIR@1|5 M5.CS#VBJL&K.T5B*P3_M7HR:L'"20#+V\D% @T|TMG;&?'#=#| \.4R2PW
'OUJG,HE^HTVQ(?WPJ,MRRVZ_M;56)5" T!1,ZD*.\$S*6:6FLNHT1+@ENYI.OSI!19E%/\$?SAW#G,+9\$A6G5Q\$|
M/C(+CQ>J|\$1XG0NL<|H;JZI&GH5|)N>C|I19M;4'P:0)HUL;5V% @/_FA?_C8_M'506|<02UN|7|!
|RTJWA|A<;N(ZF:0W=6G_MPZ=FG_59UVA-AQ.C _\0FPZ|1;K%VL_F_V#\W!BR_BYQ(@ (TX0); ^'=
L<_%7L">],G01_M9B|R0/_8?#|P/=^1/2#>+ _ZJ.HC|.N_J0X.LAD#/_|^_V7NX:| _Z^_WV_MZ\??
0| _?/=8U^"B?C*NR\R\WS\^:M\?M+N'+Q|^?GG\^ _']?CP^?| #|7?X
MX|/_|E|LO=>WG|7'| _#!;Q^? _'4WOPN>=K;| &WHT=TR: ^5!*UV^?UGMH4) MMIO0-
30AU+\\$V\15, " _2!XI\|TT^2 MX3^&/_Y#Z|K|J|JX;SF3'Y\$0|]5\$(YR &;>^^ PWP\$#@+Q"9W #H/KX!*?+<MWE?H"+X3"|*/HQ?AHAF0:M=.(<|:6@F&J4@V|D_B25|F0"8DYF-FSL>:D) M-01T20-M5% D? >4#40=5\$U ^=
6SBMSJ=TWZ"2""8A&5M+@5T|S7FU/?#Y6#1BB8G;'X?%WC|KRNBS;S>7>IW=Y _*C% MH+8 >*)=2/Z'P5Y,N_R
|1,0*6%2^ (0_TWTQY"G|E_CUZ_5P8@QP51*71RP.|B/:KE.* ,LOR&MJWY ?;3(=M M>0RT:M-0?
='|1W@XR&* _W,|1\,KVZ.KW!0:)7L99_T_P>>6\$S+7K_M+0\$)SL1>^'Z!>4T!X27(PHW"?ES\|@4|Y-CP%=_|
<3GQZ!1C-X,0_N##M2T6 ML!ZMIFM/KJ; ;0_D8M,"6"V"R61H0Q2: !Q3&3U7G%_77T|> +Q? MJ5%T!|JU)!G=
(U;6/_0(#^UF'SW"36*CF9YQP!9D^/_XM@EU?A&P,NY3<_8B_M;G1R(5T0_8ZQM8!RH'K&.P90.4*.N_T7|=N;
|Z#*#PVX;_9(;9?"TX'D1_MV(08X+=CVM0" |A5IC0T@##!>J!E'G*\$T%H0X'#JU^I_OW: ^-.0|M(^|0TN&D+

M_M'0'E?@ZL]<)P#QLB4@ *9HP!KQJP+J!|P#5.+DAP_8(*H6B=X|^&FR?X]-
M#C&\\$0CE'+YS@(&0SZB>_0@R#3:G2TP^S4"N(8I1UY_8P|F|\$(<)^9P)UX5L M:1\$\62B-
IU/.+|_@C_%7|>:0|U?Z%~M7|_RJ\$GF*|@2@/!X072,9B4B@Q7+
M8|XND+8//6EAS+|17&%.1J.JI)&\$N|KR9X_HWH"?-XY,< M|?BC>EK8.8|XKN_PZ00HS=G(?&@-
NX.&NF.0!*'ZT(K,7VIWB#?MU"CT;Q@ MBL2!(< ?&@*BJH8H#*I%M)Y&6% ;B#::K^2A57)^; P#5?
AWE(>52|U^T?R7W92-I^J|V"B'\$"GW1"*D"S^>V)B^\$F#RZOW3Z|C\$@%!,- MM_2J
+D/0<1BF(4B'D.7'X>S#E;?-(M2:'|7%I7G0Y/>_+S^>|IW09_-YA3 M+U)GH\$3&WQB|18|>_+"900=I^P^-
%H2;\$4 2Z,2'@G!4*&0C+Y< M+M|>BHL?Z.7;B9!/@8L GX-VGF3S?)GUEZ0X\WQH%|P| ?V\&K1QSH
M&4B\$'"04%-;L)6.?=.!.%:|DZK,+ (V_ =|<-<;-NK6Q7'R-QH M9I.H7Y |<8,Y%('PP>|@D4YF<.FW=.WO\0|
H@)>2Q:W,.)#P)D-=GYM."S&1 MP@&8K0.;|@+Y1&A.. 1?L!MBY<+"^0*&ZJE9-/F,'9H/|YWK:%4,T(7%TJ
MGF|FS&(&06I69;?.\$)%=U?0J;;@.ZTVW%?&GDH00.?>>"<'6:A/1VCUK|I M<8N:2I,-&Y-&T25"_XMN-
|'-(-("6DY-&Z.NWA!RMN"VET=.S?'|C 1?D|Z MK? !\UH9LNB?1/B23'MN%,25A_SEA+MKU5(7;ADR*:G&
A@6RH

+0_L=*- /0*LZ7:~E2*0'I M0!..?~M,V3I6@L985HWECC-=!|0^CG1A8(V JJ?J|F|&*:Q9>I2I^*I2^VB34N/
MP+;HTL'V;R<3= T Y+~\Z%0J9071"4B|C(:F7D9#T&,SG:#J@=S%Z@Q:|0I/0
MV"E=J9>9KM3CU%#H_(ET+=K3,N/4_=7SG4.H|;WNF9|@+=9\$*Z|\$I?*L"V1.
M"YV%A9&)0(1_0.L=!:0#06<+J&'.*P920.#),PU3=P\$|P= #5D6FA,RZ2AB0 ML5"7R-IY00<\0V02I1W2^(Y)-
HR&%<- KA+UWRPW2%=I>YF#PX:TR.)U.> M&R+05 P00RER#7*
|EA9V#5+0R4|FY~WM5\H'(\$0UY|&U8A7VA+"P\$7#P)=N M')-L:X' PLA_'BG10"^/L\MYI>UFC?_30"
|Q<(64-*&")U0|GF%SW>_'\0 M>#5(MKEH,*\$7 3Y=:H9#UHS02N2#V'4E4N9.H|/"TI">=I&=TJ8I'%?)8=
M2I4NVGEH T993@03IJ ROELW @AD3/P-S=3D,|<=VUKRI@RP)0MV@#DM-"0C M>N!M.
(23888+9CVB>)^2#WB3FRZB9TB:|IB|JI+0:M64CN7&"%>A_|
M\$>X+\$!I5=T\$@T>=0MPS+>3.&Q:F;LQYRUHGQA@RP J*X;(:F.H_./1U1AB^8 M)3SYS,;
(L@CR,TIWR=D' 1JCV04V1%DJF!;'7\$^@H70_'DG&2BVR MDA#TB M/7B9SM-HR=>1S6I%PY,H L+)6S#=(A(
_U"V4'."^;\$6#^BTAE=3'KE/0S M @CLU20&(8:RWX;7PK<*AV/HTQ' 6S+=%5"3_GX!M);
(>9!4*H^~FHLD^>K M@5=;|+-P1US>:++
<+U|1\$M*'+W5|9'&2'~W3I!D+6A;\$VTZ;L>:24%7|GKI43'+F&+MY*/.TT)":!6-D\$ M8MHOC06"E0@\
(\$,.)AB&@CB&MHG,%<5V0T\VOXG0|8R2)B|=|(2R-WP,4Z M|5^8^ \$I\$B\$U0:"R@#43+B|2H/
BIZ|PQ|0|ZMI3X(?42B\$Y|0?48YM>|G3) M_-P3 ">5#?BX.M|(.#)C.* P&E
)MGH\TXM0;H<)F;J"TS|UD|/;|7047HW M%5-\$0J74HH!./U"~3S %-9XIM|ID:B&4W_9|*IQ<|&)0BN M*
(B9SYW|*/&9E-1BH\0' 2@Q9/7PPH#^+V/X?1G8"G<'PX7@+Y|\$<=8("NE MG=0:#|;YY(MI!!*V'N8E|# !
|)&*)EP0\$:7(.R3W^PD5-P1Z+-7PTX?;4(1 M79|1|+A *';BMYA>UC 8=S7|Y.G<|Q#A_*,MT*HSN@E@*>
()8AD_~#8.0! MRQ=BC|S34;(T*~^JK\$|N7N)\P4V?J1(AR>I9'V+VHIE|;V MYOWO'GN8?
@0T0.+Q(@8^D=6_3L?7QH>YPR4>6YT)XR:51S?QBU^Y4D.)A(L M8P9|F-D766X\L>| '*!\22#S\$C)FAHI"*8V?
\$H'F& \;'YJ'#B|=@J?;JM7# M(@/0.SW*TGEE:15ZG E@VG|8B2IRV,7H=MG1C9A/M"
(G^;GC^93G+WW|T=+QK?JK|AI>3\$N7X5_*?6Y< M"@Q=,/S4) Z4??JL<'D8Z(P5\$<8CJ;"2_?<
T>7*";C^;~L_XZ|7*8>A|ZT M0&FY.D<(Z|IN/DAZ GF"-3Q"J8!YK:|,;+EF,W^!?!H@C<;"1#~*|R#\$A
M42.&@'7AP9BXLKGCDA.ZSBOI GACN"~^!9Z|5VU8>Y1_YE4/.IQP&@ D20 MQ;I"XL-40"BS.?!YN65FF0
Z4U9*2:0.%?7; "4<7%8^?R&\7ZZ7UR99U?C MG@!-35<&DU*W%-^T0*Q?97(
0|!)2!IWH<.8\$@|@CB:/@(/.3,0\ (LT%3P" M&@]-*&NCQF0Z@2>P5V@5(JUN\$L-KN"#VHG,:3;*(> 4!-
VAPJ(ECTYFC;+F) MZ4Z"N><+XEAQV !T,5\$#R_D)@3R)G&+|
M*\$5"G)4)90|M5C3+0)3"1S(' +9&4@ZVA&K)M57#Q*J6E'Z9Q7;"|A@>*G,
M@D1F04=E^E1@+|?;+*!8:E:\$M5,TP0J)*_!W6"AI3Y;?8P&S6|N@/X4-DN>N
MZ#?/4=L5Y|;DP;7848D3QB%Q!JKP5#@2,=|,'BE')>;1U)MT-)680:Q7XM\$5 M*:IM|0,\I+L)T?EW+Z8;QAT-
T:>2F_*E!8AEW030C<>&9M"ZJ(ZB4\$I,C.7S MH!*>>6ZHDA,06VB1|X66TGD9_~J2/ Y'2D|L6_SUY9P
VS#FD6_7#S/4P(!I_94.3.PK7> :55B *)9?68|<ER096 >_A49@~6\$MC:H<&<@C:F1E6:;+D#~0K2VD|"
M#R"'<0N"U*/S+<3YXE436X=RB*-Q_Z#H;H*T%7MOYHNNH/=03QT#J?L/C,=(
M=X+V5BPVM6V|J|&'7^~1D=GT35:GK, :Z9|E9\$:<|0S0.+34.<|0IY|Y;QD M"CL@7VYUA\0A3>#_7ZX
M@T=&0J*H@/F7X#-A E|V0&(R,0GZD|@D\$'%A8"18J@ :K7PA TVT+02?AZ!& M0ZV+H0_%9*|>3EX Z?
Z: 0SL8IN8N\$=E\$;B@RPI B07TSY<<<*[9L]>0_@EU&?(F((@-<9KSK&3F^_0ZH/Q|).A.05 M&1-
D>&1YQ#5I6R7:~3PM1<4=MF%;D) I6AX%TNK M2SK0\9-GUR&FS4\|;\$EU)L4?
T*7F2GU9QYY,S!|STJY W"~VQEZWBY@E1\$A M:&CW_*5BV "6.1-5JW&
F5X&I.PT2#~60_C3FK+0*AG+,&/Y@SI=8<;=Q=L= M11"0%X'
"='44+IG2;\C!4XXW#~H69YR,PC1R0*CL^\$YD5,;Q&:YIYJ33;3_=/K|7;A_0M.\@IR;+L-E#2<11
M!7\08X)U#.=A5Q' MOLTU4N_B-^C8@FU@>F(L'H6A?1V+A|/(%|EVQ,=UD70+TS|\$A|+~|:-PX8?)
MH!!7\$WBSS#70%(\$KP?V,K|U05QE?AF+ITX6+44;<8L*HR)0^_ \$F1C_BYI:F3 M;E#\$|KZ(KY>&+;AYRB\
(^/E0|<;^\$1:02JR|K"AF)17F8|@A'E: (B5L(I MSM0L&4(*_2* |R\$^\$D\1@,>25!-|6'+BEL4?
S\G0BE,"X9\$0)6S9A%DC+=6 M^!JX\$VKB^174(!;U5W@1@;-HS? U-0.S9\$T1,9F5&S@E\$
M&D6Y7*RU!B(;Z:@_S"MH>TH@3H7#8UL2!GK8+@S/B77N)\$L< C(LE|\$S+\$VS MGT'?
M618&J0I#3C',X4\089*GB@#=#UC5F4@|_Y\$S30I7&'NQY30.25S|7|Q>E?IR1 FII%>;X'1HR M-QDG-
Q*KAG&G285((J;U)L89I>JZU#.U@J8)R3S2ELQC2&'%Y7R\$/>-7S,|;J M(&4B)XG C#-#(WE|Z72:~9Z-
&-43E_L8K('0&|K (&<@_WML*Z0H">|+~#-1L M0AC(8PKSYEY|M<\$2>9GP'2@>P(KLN9*3CIP?T-YA"V,DU
M(|&2XI\5< H45"#N;>,R50C4FW.U".K/(S6)'4UQJI!*V AA)J#,&<|0K83& M'S> WJ_/W34L8>A)13.=
U6.U;6:JQ<; M->44%;AR\T^P*~>6H7DR>*+4WMRMLRGV9_3V|^<(;MZD765Y,AK:ARBD&F_Q M|,<~:~#
(WKK3FV*)ZF4-(*)"1|HCU.2'P?"!HX<2,U(^&|L"K*-A&4(BM\,IF M(P9;J;:@\$N/+042J\$*EC:
<54*J2W=0HN4^QL_2%Q9|YQ1@S\$T|0\B? 7R% MI8-3J;AB=;8(=*/|'4^FE06&+;S'13G?>19I 9A"5L@B?

%U^1>""\EF_P9_M2S@P_H=[HQ9T9EQR,YSY!(3KWI:A0W84)?-??'2.[+F!*L0;FC_G7VEJWR* M-
Q3(+I5[MXW4P6&;8K+G#0Z+?=KRO&;2#FV^ZF/3B98")G6__7T_6_2,*F MW6GT\$!;8=S&\%3(@^0@0EQ<[H-
327\,T="R_T9\; M; ,U#8=>!\L L, .LQ&%RH?#RPE8D41:NG\&DWAA)"A56: F*XP#B%NTFZKU1C M97I9G=M87'
84>7W2V(=%<'\NN??)(GK@!J("=.3N!-8WF[J;0D0+D0+>*B^ MVC@<2_\]"BB+B&8=!' : =6NR'#1,SE[-
E@X5A9BI1 ^(#CJD ? Y,!P]LYHV M'(_UI)W 9072Y%>K
;2*]V',I@)YF(I[@^0V,0&3^X\62D1BZ009%1\@5'Q MK&CXNF#XNJ2.\ /TSW50G@^+S+5?<4.G,"FZ6R6!
[RKJ7\ZY",Q^QY Q=J8N M;MM08:5B4%Y8A\$E[\90F0GSK)LL^J^Q96?L%K?
T0/X^H/:N#5HM')'=LD@:0)]P9:P MEAZ?70(68&9F741J3XR2UR,I;&V#LY.3F!9(N\$FR@E+ /!?
5R'!'F9.2UW MCNPV\5DD&'V_@0AP7YALUK(JB3,ZB/7/M(-8='CJE!QJ^Q4GT[C4".6!ERE<
MT_E0F;U#9%FK%LMS"!U.(D%5#%C)4#(3S1R<)\0>"K&:LCLISY"DC-' BVL9 MN089\5VM\$]JG0/R15/*IK&&
(9<_BN,5/^,R_Z9G?HF>X5,W8IMB.?&/-;AQ M; &C%V^D\+;-
F7A1R6D:9M%A"MG"=)YD3S>5UF.H<=0Y,98G(W!F1#A0QC.S1 MDF9\M"2VHXPQB-
QKE*. '8JF@P'/BERI^+E=*)&6)A[+"#HWH,0\$SVCB5EWX M(\-TDHRVQ,3&XK.X43E#599B"2H[ZN">;%>-
*>\$YYQ&L]!6M*VH MD:Y,!W5C^=BA@]<1^I1H#1F/Y64(@[RIG7\$AS". \$063K8,,09VHNB41'-'<; M'NV3XT:<-
,(B\Y,[(]JXW9CL&\$49 RHI!%S;TJ&HDMB-@^55N@QDPH3-T\$J MD4J.*I L0Z:R%C3ULXZ
MOBK=U(=AK"CZ5Z7CU,+*ZHO6*X?5MI2#JL3MI#(:!R07=([2[RZF3[17]/ M#9\X2J/8R
+DN;\07]d*;AA6R9\6)\$JJ)&3(76/.'%Y>@6UKV8L4-K(+7&P M-Q(R=*"-[?-<
BT6GNXB4M&M\&UBT\T+ZB@FPY ?D17SB6*(N,FZY M@A++RPEG0?8WSI38^Y"RH.#;VU:0SS1T
C>!UJVG6=\$@;G:87"X>I\&KL MC(3"T4SWJF<40FU223@>U>X@NB#ZF' VU'S#\$W&:<%SSF:J1@)N)&851+9Y@
MS-16DM IB\P/XKPP[BXJ5=6_Q6FJ D'[KG6-90&00)]L(DH]9[>BG5/&BJOYDZ\$5> /2 M^ ;
[3_+S;TW05'P)4M0Z](XFF77F=0F*)E;+LJ!LZ,]:T'-MM
MTL<;M/,G10^VH7U;>\YX:7(XKE=4G18^S\8.495CEU]!6IK!W . ">>,]W:E M5.L-M00%Y-
A8Y6E6+5:\$G[*=0\$*+6YK,,F*5ZLGBK0#TW,<'BXV?>\$>6Q/\$D
M>3\$K9=0\$CM&' \$4TGD9VH\$Z@,]RDJ:U<6%*6U![CP07SB<,>QJ6JN8SOH)IM' MFD>N_M\$^1_WC&T,00:
(-6>+,VA?'U_X0,-];PP'3R*@X:5%MM8.MI,FE3;7G
MKXG>8,G3A4'26\$@TWG;' "4>Y8/0*1\$X/%*:U;M\JQ3<409^S'%.@3RY@Z,0 MD;"_ZS^!\F4/>.!*Z&D?
=)MOW^&(-,=D\$+3;'B9I98&=UH-3;Q]\!11KT!4US M5-=JV[VE4>]/!+ _#YR*?
KT77%6H?'>M,G&HN8D:N6>N<[ACE=AGV3Q!1&2L81 M)?4-,GGED3+H\$3F#;'Y3NH\8PNUJCEP44U,2^/)_QCV?
P8%["\F^Z4@L]2> MJ2F*BSN5\9VDAAAS(
LF1Y(662.@CF7J823C3S(G9:X0:YH_ZWCWJ/V'F&;BH]40ZLCG8NN,@M4AWU_M=-,B22.\F#3[FE:\<
7BYF\$EAZ&[E9FK%..*CV++V^X)44([K@[HFFJ]I83\ M[0V/4+6'1#TKE!!U>@N?3-"=D)-XJ>(5L0T\$4>
(77&L])88["POT4.B29PM] M.GP_\59KHKE:W@76,=]GSN=FR2GSL1")\$=L][P02C[S]M:/A\$U\$V"3)6T7DI
M8S>2"D4T3X(_@>G\$FDWT=5'+1B\?15N]>FRH6W(0ER?=3866ZHIP*\$M2S_JY
M@IA&ZLCVG0:G(.N%C\B0H0:*Z&]S\$?;I&2+>0SQ+ID?0Y^H?
ZF!\4@0&B9/J)K+0@]9/(MN;\$+A0EWB/UM.&.]7?;X MI^B\$\"C'6-
Q&4IS1C7UH)-.*.F.]N\V19R0G_'6=A6#%]_79?#]/=E0\$D?Z M2N(F=[H72W/+4':CN22R5%'Z@?FPJXQ9-
V1%ZC0*%':00Y:E+--
^+CLM\QKM:@0'R\59YL2)'N\A2ZMN()' "24WX"&Y_/TU+=)EBAGCE!@+4]KW5M9H(QZDYF2Q&T1X9M^N%Z,B0&B;+<
93^:#1 MZL\TN\>GSYYG:#:5RT3B\0_PS(U4 PX.HRYWLR@9P28ZE9 M'(H]<68J;XF_(9GR[3BP\$9/A1B-
BC&!+;>5R M*I@W%-08ABB+(OL!-7K385Q4]\$?LJBE^!01PSBD^", \$L\ M=M:*QW0]THD\$IF1:-V
S1:Q&".2R661*I,Y\$YG"L;2J0#,H37%OKVA4#<#L" ML&Q6"EM)PC1D\C'^^>;I^"YE#JX_3;*Q.??&5APP?
^FX]14F>B(\$JFH<;B M-#0,R& V7\$'=6<%E/AH\@FE#]U)Z2P"UU[15I,AM'!H*J(ZV*7+9%9)
MIG*WUB+PPPJ0#/&=FQM0:90R^Q9:-0%.=]T(:F1STD/D;P><)*(8A(C2&CD MV5U:SPM>42:TU+HBQ)B(GJUY-
P2?D)>R!5(D+>#>K8MU*%?9TP0J3):4QDA*W:;=S;%G8Q0G^0?7:X+5V.PU;?4A](+<
+8\$GNE]U2H#),]T[:CI3]D<,5=H]L:H\!\'EJ M0
0\S]]@,2;ZU#N[IS08;.@@7'F<5M0]F':8D9Z\$#T^A1^4>';QZ(N%= M5B\QT1X>2Y1E5L(V<\IHJ-
+N.\$TN<^0@'1U\6^QJG\D]48(FB5KAA#(>[&^8 M[X.D^1XK"3(\7-48@[%^UEHH]7*
<'[&TMG1P4:]'(AV*08V[9PYI6QNI)-WH8(:;X@Z>]H2<-(IH M>&^+Q'%%X\$(:^NC,NIG@Y,&%0]I)?_QJF-
["TI?03)N_3P_]A83W@&TB%8 M2\;&L/S)'N1?1\9RH\D-9M^%_S?DF\77#?CJ]'G/N]U&I]?_ *K9:&5^GK=4
MJ]UH#K,?R5LJ_-NLZ\V=?Q-]=8N]0_"(Y=@,!(?"?J0K5,+<5R?_,!VQK9Q M[JC3E/Y/VDSOVHN?6DMV(^&
(C&;4*G)S0#Z!6ZM+'4J0281D[A0)T]9;>QV7 M>^R.<^#AIA .G3F/+>=77K ML'!H(A0\$!|I""
0_I(+QP6'<5C^.(P[RPJLL_-#M)G8]DVNOP/EP MJ*LV?K*_%R:^R82Q-/^I^+ #1F=0&3K,5ME^
MDWNFO^UUQ/C17%RU4F:VM8GQF5!MW>_76H+T0FUF#M8<0Q-NXAQ1:15M'EUS#9FF22Z%4%5&J M?
1I,-6PI3G7):-4Y/J=J5XU375D\$@G(E5F?^;FG;.!<\$0E]>0#7PYWV,0< M"(4R*N8+"YD.")E^0=4?
E61U;YVK<&B/U0YA5D6"B@1C KJ[,PVFR:Q;9G1\$ MT9BBL0NAL=ZQY%R0+&-*T:"BP*A=8& M_\A[;+<
[&/._.F3]18U_'SAF-\$\ZQ+*Q1#FKC7K<^& XKDJ]00D:/0K"MK?^]
M,6R]0E2Y;!B%7<>T>P^,72.%71>-71LLNB-(QU&S8M+ORI+2/H<#B;#>D,I# MVU61Q%CI?<
=C0+72""': '5FW52-Q0& M'5,A+ &#.@J#>AJ#-BA]94FR;L4DV97Y"C/;[6P9+!&-XU;=KRK+<
M;%' '8W&C\$H+RHUYMW!_5^\.2\$V/VNLSCA>PSMIF.E90QJH/ M_.%A0&N>BJ,6[N7\$;J-7\C&KRPW\$'.K=
(Z8!=T*2"Z62 [2('LCD<#&%9\$H(CD7 M(CEZC^QNLW6!*;R*0BZ50@8':?&\GD(J5R9Q9>G)=[B7*>S&9R)"L'
<[<[" MM.LHUAR4UK\$Z30V=VGC0+JNSHZKQK13: '*0K]7KFVE5EXQ>-4J5UI\$ZC3D]Q MHHM%FTU]4@_ B4K/'%?
M!=3,F\ -3RJ9NIX?RJPUJX_ZPWFMW*V(4J8(F6WNNMU%I=(EH=?AJMU6Y_5U7
MYA148V]4+ +MN,/N(S>*9E6JS8>=.]J3EGMZ:I66ZC&_2@2W%%;XIKET:#<
M[=IX6&_W^HH\$%0DJ\$HR1X'!3X+PT\$NR K=6KMX=J*HZB046#"1K<);??RI. MMU5Z0%5-
Q5%3<=1PF00=^)5YC=14G++>)X?0^]JM]6KCWJ ^:)9EU:ECLZA5V5PJX-MTQI..P8M+QRM+6U%2<
M,TVZ[U0#Z=.EQJ1^QN&ZMV6_569^V**HKOF(! MB@4<3@]SPG;S%XX[@/D.CZ6^ UQE+OX*
M]J179B_:S\$6Z_P^SU^JT^%3L_ZK&NTIL.)T7]BDV'7:+>8N]G\WT%M_)U&

M.3E3#>/%@#S^0||G'6+*X@N>P,/.LA.Q#?,N/7EII|W:AAE21T;0-B+.|QF# M<|
[AS4MM8NF>9TZ!YVF3E<90!F\1NU!GO.[A> @&3%S03/M%^\YX7P9/_:B MP(.?_AG \$X:V *X!?
P%#U3P3#JB|\&M,Q@;^%;@3^,74=>;T(=VT81G3-6X6 MNNLOZ5'@9AH< 047:6AXFG6 T&"0S-4M";@
W__B\|VC<#SW24 'DZCNX;V M LR>W^C<,9C%]_8Z,R" CRA"||U*EKS(33NIIA MNF5BP|0@>7B-^*NN^8X&D
%9X3, ""X\$?S3%|3P0-)X'8(Y?>6&-%#|<_!3P M9LE?'#N-:4^LP(#NG!1+L+5=W6#WQTL3+"&/VR^*
(@Z+0;0U9?:(S(<> ;N M590K/YB&H@.AHE0:'X'QS" 6H=L*Y@0\QH,?&@R/)T^L#>T7T>I;_AEAI)
M:CL%S="*[TP?1,AD?:HY49&8@2&*HHD8AI\$A8^3S11BN;IWF;FZD0]@G] % MOVJM*E2A%A6#BQA!93S8WQ
#77CE>|TS0= MB)CN\$='A:\>>P%.TB^_PF0>6 M,_D1Z5>#%,.%SW 3#^2Q!>H#;L"JRGZGCF4YKT@ ?(@@B"H+.
5GF9.9#A?A M 8\$#F3 /KR1D\$/KDS\#D&I&2A00F#Z9P\$%-C>FN|2!0@M|-V1+7R:(L8UVTZ31HEU
MWQ4@K.8I3CL-0:M87G#^-KG.(S0#AY[9:X7E)<|,P+':>4E0 M2(MQ EC"\-
Z>8FS284Z_I97^G@&|VLAMWNN6;H/BPX/YJB]! M(5K1AX2:I#WI'N@N:/*9%MAF#F@U^F1F@KHS)P_
5:460RD423T,)>80XB/S M?8L/K2U,CB,@QSI +D6-;\\TG:02Y'9'A@0:+4F01IXQHNI BQ-1F0/AH&VGE.#2J-
6E/:T5Y MEHJ-'A8TE\N^AL:\$%="N>ZT0)IWZX/AWBW_2D2" X54*^>U_!"XY*XD/[|+ M5CR _PI
>Y9\JIX(##;=2P+HQ/H|S1=S|<6@!N,0BGTX=<9:.)1 OR\?:| M-H%7(| TWS5UJZ'=V^C?
A*L@U0@*., ^@N/S!+NXT\J,F-V@Z&0^1& 3.!!8IG0)GNLIEC 3YX/\$QC>G%CM@5X K^SV-\$-?
>M01B|]RD,&/0QONCH:V'9(X0-;G5A6|R;4YT;Q:S7Q;ZDK8# M|_|:(=LZ.8JF0TK^7 FZ^5I&2-CW%
&\$7|S"6U*M(N1V3>|C+/H7 XJH6' M\$?&F %NJO#QI8Q!@\$JK+=)94(##7AP XQ(. "L"-
<,T79FM/R\M%B\$X) "%&G M"!VQ#MWS|&<,9;C29/S3>:7XIS8-7(KG"@!Z^(L9H!!\$0,C),X"?WI2UD=-
R!Q9\#>*WC+LF=P<=B MXW\$|@*07WTL9T3P>|+RUC?5A/?C!%|=V\$ + WS+, IU-9K;Y9\
|RKQ(A_%|R160|B/,#W9Z#R7S*@(Y|1 A\$TA?2D=LL)Q\$K\0@NT M_ ;NW36!PU;!(2A@M\$:30V,\\)(|P&S
-ORI,|;BXOI=7J=-K|37DP0^Y&\ MI?(_[S;|E|NI=J01&JR/?
IX(4KTJA&2/\$ZI4D5DX;MK+4L;1=^TE>%;@ "X6Y M%DIS!;LM81?WFVCD.%&@VQ)TW\AH>D-
TW|WF%'|13;|M4|<@+26%RL@2* MDYZZD\$V_83AL-7R\0;)|\0 =*H!#7?91^|CLN0_ZF\|6-M?U
;MS)2C'Y9*2 +M=|J1?X*UHI\$33@_0)MPKJF0XZ499^*M M%9(G58R1':61=4 ?
| |KQGTX0:).0A5*J\$*)RA9*E"7-\XC0| MS%;NM#Q9<.&>"E7Y45W'Q=DDIQVI
VAG6%8'4%6|<:|D\BLKRBA\$)#D9G)0Q MSF%Y;Y?0UZ:#'='K|=[>^&JKF)K//@04(<%N"CXU-;0VTK|)-
WP7%K54*451 MRL":= A7@D1RA B_KOSB0/^3L#|>P3V# +I8@%JRSWM9(4JGRB2CJH*I_8 MI7RB)
VUVP+9VZT/1V7UJ*|8 42RAYSJ*I?H*C=47>4JL)LY5 MMKM<1?*>+0=7DL/'5/IS50IS\4ST(R1-4G :|)M_%
{XVLV.QV|HUH%6IYD-\S_X0A, MZS:T8FTG|G10A0 _\<!.Z(>;FWM0\$;|;A .#Z&@PS2322Z&4TDNAE-)'#|
MNH; U6*0H0X:| |%\$B_38FRWRGOGK,C;1KFW9?X.BTX^3&3,"BSU,L^\$1VV9. M0XUN|RQ;9W@;SB-Y=M!Y0)*
S?0MZ5K8 MH@0|PIHT,<,|7/B#AY.|&92/&X|E-K+9Z!3.
MXJD:A%S*&&V8/7 |HIL6FOR?'/=1CWNU,'4X^BL+|X>U\6@TJ\$B|P8X(GZF4
M*K09;:A\W!YM"0+346W'9#.'I-|*, -VZWVKQ51-\KT8RF4&FWHDW&X>R|0=EZ6.'J^P|0,|:D: B
MP1@)|HY%@AT@P69|L'_ CBT0I#G/F@>P8_%<+G<-
|.8L75(8NP5I|XV5E0|\-9#T'>YE:F*^%Z5V&8RJ|%60|5K"1Z,-730. MX @E>*M1:T.G09=J-JDF@:A)X&!;3
M:I:6!%20QPS+\$ETE7NP1;*/\;:8]:7M-'Q0|4.R@(#LX47)7;T0C|CK-07,&
M3\P.*CI,:6.):|2T,%ZBJKM,FUBZYVE3\$PM5X1.) #=>PP3>>CE6DX:TWM-MU M|0SK5"S+MX*K 1#!P-1<-M=-
FL>|R(C7'H F!,@C5J7);^M>J|WBQA8+U_D) MZ.4S:[EE/3>5,?^/V,|MW\XWN9N|:#._A7MYF.930
+GX2XF|XS I5%+(9KW MF|50?Q4A0#BFA0:=^DNZ#'#J+X#/,^Q#>V,YG0=60UIXP:X0V;TFR5TX^'7# M|6BF)
|I9,D/.CDHM,)D\$|X" PX\$?|-X2+ILQV^.=,>01GMU\2|A/X6R\1/L MI9?5DS@^Z"JHOPG(!,|0G
4L"GVF\58X2#4^VS79!AGVJ?G8*F|*GVV:V- M;2IS:-0/\$78ED^X",XB|.)^Z) M3>|EY?/+6^./@
N:++|Q_F'|7?Q:YV%ZI!'V*\$ 1+)?53G&|0*A,XQ0F&9;\$' MY E"4UIJ2&+Z'+124*%H0.UT:|GZ70%P MU6D
LHWQ1.6IY;QBJW+11 |TU">^A*+ YV%#|AKGV\3K"K\$B(GC^0WM\$|]'6 MXWK(1:@!%M=:.<#(7\$@<1FBV?
(<"A:66.|\$7)KE7?3>8X%|KVHM)|=.YG(S@ M@ZUO ""Z50?(P#7^&5 \$S,4\$D+J877TQX^8&-L_@
M';NDKCP#>P=@ 3#<6?+>? F4F4MX'R+"W0RP05"V07^T!Q, Q(8&S3TD^T\$V M5-!V;!U\0^W2E-
H8"TGQCKBM>7B-M>H,'|2/+"C0\$(>D\$-7MN!6?*\$E)J3PU M7<|7 S%XHR18F B^<93GP R'0, E|D\
(|)|@FP\$LO\@4X.%+L8F|=^/C| MJVE9R&Y=K!9Q^=^QAG8_U9A)VQ*C MI2>P!D_0|8IGW:6Y&+1;' #2.
(HS)4KKD|5-90Y4@9X/B S|0Q.XBQ\$/T4A,Q.Z M&%X9G=P61P_/'#^+0\$7V0DW78Q=(HA.T0:2!Q*A(?
#Y&5)S;N0G4R'N(|\ M\$. (#V(H-YN,/ +I5-3V , 'J4.G|L@Q>A84DSR>2; C\0M0() (FJWLPD*=@_G M>0-
UTEWE?' 'A9\$)(P;L% D1XM\$3KDG '\$T6\$U6D 6GDH|&U#*)(>; -D.Z/& ML^+"DN05<20XFN39|Y)
2ND|=;"&N>ES|<6/E|VBB97IZ(F#IS4.CGyu4HL0 MPUSD6\#3G. 9*|\$T';L 40\|ZKFZHGUL0,/ &ZKAE-
4DJUONV-5*3I"JPEV-. MDA+|1BLGZ&^! :|(|U1Q7&*B@EIDL#J5Y! MT*W&'H#Y?DOZ.9&Q02S-;' #4-
7.*4J1.G4S7ZHUX|GA 8CM!CG(%P,"PB+| M#%3,1>
"|^9!+Q#F0#;3)0E8.!)0&!M90AE",>GW"=6LA6.98,6:)-+93VXH MZXL%?
\$I\$#.CF!G0'X@(|(W4&>S%9J#"7TU@NM ,Y)2G5N0,B|H=B5N@90"V/ MW3C3*:">;6A:H#NS'85+HTXKJ:
M3DI: #-,\$,(E|\$,4\;-34#I\$ED|_0">|*ZFVC;D<(MM(4G5&|0_9%Z,3T@G7NW M:\YE>M\$J<#1|],+?
H%/%H'0+1@20|>|8D(5:FF|)/@*3T|]YT#G+ LVKH_6 M,ZD+;|+<|38Z0>[ESK53FRJTJ?4|L@^0B'0*+L,[E?
&V6V=[WNQ:52Q\$UZ@2 M78L-E4A%?|+;52N,*%H?0>_8DU.A"IKIMU+SHY\$T=Z#|'18H)92CGS.X?P\<-
M,H(WYK_DEV\$|@)<.,|_!F_KMVJU5|A51?H?/_Z8).\$:D9J-*|IWA\L<3%0: ^T
M'B&*5A6M*EK=@E;1&MB)50L72ZN*&!4QEDN,|;H#0;GH:MN,&5E_>.L&:J M^37^ZAK:~J@)"
|MPE7|!KA6;+>%BY>H#WKVBF3<^VP|]"GT*@N|MK7VTF@U
MJHU;0:KTNU,X=0XXM:M5,E038Q2^:|"3R|!5MH&]|\$&|;E;>ME>^;469YT.9.QLFPTXI MAHDB1T6.BAP/:-.5-
SFB:J2J:%'18JFT6)J|VR-EM=600G2\AGB*FL&F-KZM MDU#-M2M,7G?Q9L"7-<|NVI^!NEPM^H6?>.
S#3M9+|I; (9@VK(>_.T^PN34 M_.L2G|)\L%,YM%2CY.3X@?;!LL6&_5*RQ:H5E#H-5H^VNOCL\$;C:FS2C=6RF
M+9GN|L9IJRI/+^EY-8NMU3R5?V%0L1E_UZ_G|A9\$|/5B=.W/;VG,JSE8:@Y6
M17W)P|)\R25>:TE3L%2GK/CGE>W I#;U|:94IRS5*201*>L#FXA&62UJE-5) M-HY1&'&XMC9K%; "
|:YS=W4\$!\$0VU\KK,EGU\$R1Z@0\$FT.??->E2T"06WNI< M\209 TTA6+5NYP(0;+7GVZ6@6)6U*=7Y317DJ-S&=

<5\@Q-7Y(QJXVZ)/>Q5 M/L=150 HRCPCRBR], =RH0+)N1:N*5A6M'K!<9|2Z6%I5Q*B(L5QB+"0&.FJ?
MBRI[#8DV=[@7' SJ,Q%#H=F5J059_KCKUL&@(\ZM?&@LS>!E)0JJ]H"50A]
MRK=7RBM950AV)'Q[4P6\$6U&ZTXC5JXW[*91*I9@K;#HU-AT2F0K4AXSZ(/3: M5>F|>
U!D+);WUY'(<@=|I0P&@ '?58[[6%:E'4'4N%*0G3M,C8:U?|= ME!5*55(%/!.;50!L9URNN)S>QU0H=,%
<*B2'(>|9E,(OFY%N%1)_L\$K;60; M*)?JTH(.00Y_.;RC>U+=N==LH6.UWN0NK3L7S00\M-^BS-B\HDQ%F44FE-
5-\$D|PM5X50-4RGQ0=JX-;JW.ZW+"DFI MMK;5E;>7|+Q*J&PU3Q5-[|?&06Z|TU0=N8\
<0E=Z8;6>W|*65UUK#P2:RV'F MI|)'!V6YDDN\UIU0+))KK3C0EV .US?A?R/03300Z834V@H!8?;:77TZ?&KV
M69|UC=9T.#'Z3VPR|!KM%FLWF_;;|>V:H9[6#1+|6]J8R/<+X|/M%Y#^__\$
M>5>5A56,>@P6"XMZ8.K6>|W2|0E|G# 'F?S'|B>5@?TS0.SS^WG(F/R)T&7*\ M!1 RX|87G^'B#%|K \$I,
M3S'4!'19')(.07(B(*G3&1%I/7.W" FZ9LP!=JK'U?*HU A<|D0HN)09H,TQW)S.2& 9[89:S MH.I%*4I4#T?
5|*;P3!'20@2*?1,8|CK7APB_I"8F-+"BYEFK61NWZMU6|10> MJ'YPBB(KX" 9@2+31-
?'0/*RZEDKE%NW6\#N=, (|JZ|1V,;=I KQUV&K9C) M1//UG|K\$989J1;7|E*P/;J /HS0^D_I-?
AY1S"|TUUW"5+L57<-|Y/CP@;L M+)"JX\A6U8?J\$G%G@Z|Z?|SI(.Z45=ES)L'%T|M(INT%+KIM50>7?0R!>PG&
M-1I&MS8>=JN2^*-.:'!09,=T&0WJ ((A0TPZU19% ;=RJ#(A>0|CYDQ%&5)K@K'R1HKFJQ;::)|*2:
|7UH%BP.)^*MBSB9-MX\$?0'.9!;|82)5L|7\$W-3X4^*8 MS>@1 0D.%?CYCZ22R\$Z EIANVFZN3\$^_.7?
FRMTL|&=V\^0R <>-/H7-0M.M M5WWI(<3C.;2F?1,'X.K9SM3+4|Y!JV Y T,=9MQB"?/R?
3^X MDZ^;V^_3_Z?/'KAU@^ .CK85K#4)GNBX|@_#|<+3?9 %GA"|7;U.%'S|IK6,SS9+*Y|9|8Q&_I
M0;A>VYF;\$|UC\$|]Q|0V0,Q-6A=\N-6?|X/|9790 CI^8S;:PS:GKP+,9|VAH MCP\$^&7|@T7..#:=X8EK@,8-
@,.)T"|<6^I(7.,/&)L A\$2|PJ+!D|\$Y=\RG MV :T-ZSQW*#@ZYV8V*DW_EU=^?M=UP,T8R?
V/1|CK+;E.%'I@U@9;0L%#/_ M' NY=NQEW&R"0V^(><(V39 -/0|ZZ\$H"+| M. N\3)0# 'F;6\FU#T^+7|0(\
MGVUL2 ?-(|)WSX<6D)+F&MXZ+|5ZDV=\$+*|1.#F6_BF>WMM6E\$H20N1*&W7
MOLUSNO&T|G|AX;80/H5VVCK43H&F6XUV_DX!IPG#?>!.+9M(\$U^4T"%P+T,
M+0%SSPL|8PXWS;L/)0.#),PU3=Y=(MZ?+W|-0/= 4|F<
|D/-4,|^>T#X\$+G'#W2BG3@_&V|^#18MRC&8 &V|C\$|*9,&9X MGP_H|13,X0S?%"!>%J?H%VU5D,-
==WW_8%MJR<@*3\$S(U'1!Z0|9Z"ZHL8A) M2!XY(->SURLL:5K-'&ZV*S2&*8'2<03)M^M"X2#> >?
8VK&I/2WW/ID')@W\ M: 6(<"PP'SSV@?' 0;:>%2NSQS*MV:S#C|8?'G4^N*#?2)&3I3"-T|_.@D6D
M/#JW>W)-5>QY<6><|,P+*:*4_@40_LV,|E MEHNNHC-5<;9=ZG>JY %1\3M@XH;2AV)!F4ZK-
N|6FX.RAIB=/0JJJD\$5;1XZ MZ?Y(M-E&VBRA:DF5C>Z+.!BMX#X;E.\JE7_7|*)_ZU; ;@V#2.=;"-#^E-&I
MC70U3F|0J:5R_2N(0QM24\K"H2YFI77|JB;T2"CP|<_]|>)+MFFK7W&7Z_7 MC6E?9SI43F5\$P05
MGJ19_\$7|^E2I1-&RW,(VZ*@V'M5|S?Z9=\K?S3=_G,HH1>Z*W |49EV4W+0- MVGA8|W5+&K95L0+J#-+?
OKI8*.\$0*9"/=C"%\>0P0G^/;#BYZE=+M_U;VP@7 M3B?#=#5,S+JJ7#)< \$HN 9#/_ S%=K4^BP|E1IW
+EQA/EGGAIW2M|5(C7NM(.HG?DBP"*4#*H M?#>54|.NEF.TJ>U_C0;T3]?
QLJ(2W79M7/;@N=;;R"H|35'2|DIJ-V,X>LH#(PPC|PZ4C?*Q0IAV784\$IUK":V|,0& MEE&%L.4:=\$?
9@2EP;6JU="GJXV'0?5_RNO>;M7&|,ZB(1G#%N-AT&58-KK@_MR-1>6;602H'^<1H'TO'>;/ID\$|X_WU-
3G#FS0+|Z_C0>|6+APR?3|I:B66T+G_M38DIH|<1C#_\$(K_MAC^ ^CC-@;Z7-K)
(IMV;=S0I|GL6Z5^GC5&;;#/#XE1_M6&S=K
|&|^X:3HL2;U3M4ZJ.3G\$TV'R>\$;7U@FZ^AB|_ ^2TS.J7MV@JA,4 M@9YP;DLQ_NVA3;|J\$:I0CP_JG!N_T?
4QWD*9-Z,5\$W>TSZ;^9%HT):*4AKWB_ME;%E<_KV|0K5+U60\%03@MJ*#GK^U0NC46/8'>Y00-#LE-1"M|0HM4?
5*U|H M=K'+EXX97+ZM9J85"9USM;R+(U_M*.;P_C:1MTWJ5|L=)R?V|C0YL5G6W.;*F,JJ2;|BQD-
+PPC^EM>*|T^27WA_J;2.:R27CM0;M1Y & ?/LAUY:06SGXY0\$@C\$CT/T\$UN+ZICZ_M5)J"48'PE|*5
GDIHJRS+4*FG|_B=(M*X@Q6^B6NV!,MS966N71*C_P_M'*LTR?U;S:."|FNPNP?|
<%25KOU*DSRB)ED<5_J@2?:J4I|3DB9Y1LW,|4+Y_M*T5%D\HP/"QH+H>0;.-?&R&
(I03S!_0\$.X!HVR (\$5ST|>.,VDS\H)2BJB%\1_M_P'<4R40_Y"F|Y56_E|AUS/\&X%LV@H!-)I.*BNICQNZ
|W_PSF46_/^* M16VJ?TDFW(IC-J-'|)"ST)_9S9/+
M|!|W^A0V^TZW706EAQ"/9^":|DT<@*MGSSWA='JP/&2.X#XCDNW_0YPE;GX_M*|B37IF|:.#,7"?
X_S%Z|JT^'3|T^Z|.NT9H.)T;_B4V&7:/=8NUF\W|!2E-2_M.+HZ|Y!78%,9?
9QUBRN(+FF|.01&LF6..GES'H/Y7'>787|Z(P/ZT^T)R\E.M|X^JGYW^R7\$IS|R&;
|0Y_'SF:0RNP|#"U7.^63^*JG_F(Y9I^<|"0-N)Y"| M_#P")VJ^,A<^|40*NWR|MM\?-=K-
DC+8.XUNMU>U#';P*8DC.9*#" M&-*IC0>#JN3.7KR)\$5Z|MM#-LECB^>;S%6KI5H0G?@7H9F\$|SBH9MD_?FTVE
M.I;*&D6881YJT&22T>E1XQH2Z^TC?W<+*H/V% 4VT647+^_\$Z69K|T2U-U_M|5/4JJA54&0.I)&M/;HX3:=?
7LK-4IZZ9MN8R_M;^'8'M-\A|P=ERW_WG'-L%VZZ"N'K2=T>_EW3UN8"X;KQUK-
X0|0+;#0#QD*'_I@+;>#V"77<'_#F"6MHWV//PUF=9|R| ML9). ?0Z6|%)!TGE0)=JKRB70H-C>;V0FQ1-
0|KXV8CG?>J ?Y:LM4^)'8'% MT%\+WRA5'"QCGN"|,APIQUG;7B\$&TZSGW#&@#VN(|, _T|GGVELOK"
<)+;Z,JT5QT;,\ZQ;3D<'3Z^!;JRB.H:6H%\$EA-QBMO@.?!\
MSI2|]5CVCL1""HK3R8"B=,T'/.|\$)?'3E'E0HKABV\ .PR&N"E09K^3/L_NLML
M|7\$. _ZYK0S4^- .K:UQG|SQM<'C6V=0/7Q^CY6_D|?>7Z|2T""& MZ; -^|+K)W3;OK\|W0(^3NP;5].?877
2X9S+@+.78M16+NY+RL8-I&R>KF4_M5<=-0<|,R:S@UK(WQM/K\$KQZ%&+K.VU-G_J)-
A5S|_6*6Z<#42L&*X5+NQ) M^!(<=+>+/_ 5P97K +0A/VQ507AKP?7^?/3!|H<-
TNCDP&3W82XFV>C/D<)|XTXYNKHV5T&D_ ^"\D^M.\$#RR4^9)0^!DC-6)|LARI%6|_ M1PGMDG|ZTCT3-
(P,;*T!4*LML\$.|7:H&|*\$%D'?9W_SF^KT4Y+T%K&H"%!+M)|<^,9M-
39>;N".7DQ\$-7RFI|L(J7@&+X>3)ON(W;IPO&="G/?+Z"=?^6EQ
M7T'+H0_\&P0L4,8WE!3>ACNC21L95Z:#XFXQ#0(70A|GX*B%_GM%J*;0%#DD_MCH_77|2"|
<1"FHNH#P|CY<&5(*MW'_Y5!ZHHA,*@'T1=[5-74\$S_B&6<|?:_M|59&E!_0.E):"Q^|7?FC|P|
|N05!1@FG|NWQ%D6F%UA"K\),=&?RXX9V0RJJ
MW+%.!\$ _R#X">_S&=!E0=G862\;;\%JF."A"2K05P\$G&D)ER:3^!F74G^D^
M"2;4^5V#'_YA4C96D|D4TNY'\%P=4FGY#*|85'J=_ ,9;L_MH."E<^V'@UIDZMWZXC-<+IF!SY|/%\|/\$+R"67H
0E_&2=A43^^|M|0',:-1H_MN;Y/&I\$;-I;_Z"X_,\$N|G7#B"-H3(>^"#UVI8V,1|8L*7|^BAE+* T'76T\

M0JX7?&W@H;:MD3PWPJ+A)>FJ5&I<7-'M;C E,QM0++H=U@P<:38JTG,/DQ_MJ]@M-B\K
V3+ICM^Y/(3%)TF7L?>"@PLRQ;@CDPT+(COPN?+PI8B,JLK;T' MCNLYH;WQ%744X7+XS;1T4.[0X3:67#;3]B-
E-'DR_ ^\$D2*18C6U^G2SK[!! MU+Q%]STE#V\AZ# ^ARW!,X9P&KKY:%2<Q5JE85!HV91#"KTZLT8-&IE"Z!-
M& 20=W9!([IL?0F&X\<@]GZ]HCTKP:LL]:0D C^2TJDCL;:JDZ8(S7:*>AE MR8WOS)T_3+%;#\$&14&2
S4[>P?N63'G[]*'\$ M.1HY6 ^IDF!32.T/VJ>[* MLY!['D#"CXH6L\F)>X\$RH5%Q5^9]/1
9PJG*OW)>6\$W"\$4X.=SB*I^1[0X< M]B4TC _&1MV0+I2Q",3?@6^(D(VP=(^L2>7MLI%7[>>DHTKK*-?
MU[S@2PM/ "ESRJ?:9J":2+3(<4)'N);:,@UQB6QC7Z1;E&H5=OP34&!:E& M50?
\$C7QY)T=CQ>DM,U#E"8B\$]CBWVET='[RA2"*YWZ+@BP]B%T%G^MXJ7!0: MAQW@ME*#G\$)\-]9L0;# W!2=2F!?
OCM@5-2@*.FU.2&Q-2)R&^ #U;:;%*NV M\$!78RS';0@B'3I&V\$(N%1>)9M][K%87'F>.^?ZKS'X1
M_6:S^0TBXH<%/D^GU3P\+F@DX7G#+'?'37/G\$80P*U?@KCA@SL R=:W[JF;NU,#'3A6[>"
M.)>&!'2JG686;MG,X:P 48D)A\$?*)JKE3I4W3'?]L-'BK6LV\ \$FL\$NY?R9X_HWW&F<,\-
H>3WU^X<5V^FILVGN168772RN%!TV^#*%4XM.NEE?W;L MYT.PRK/L[7,D50G^L2?Y%- "KC;L9R?
*J%=3YH\MNW'([N03!-&A7I7-8F<.- M"/Y59IU\NM^&V9A7TDES- 0 W!LF'\$EB9!' ^+UAJA>MHJ
KHZ#=A&@6!0W+ M]*J=?>/9DR+ 'C,1TL&XU<80IW;"=G;-?CGJ#]' /-MG-0?K-AZ:45Q_#?3Z M/_0'IHAC-?
PS]CR9ZZ8=>0 0I5"&X R<;,#L7+\-\$DI" I8#\IN\$8UA0U-I8 M9M10CFKC;F.476=4A?
#%^=]B] "WV&J"1A\5<*ZYQ6L0\$BD.D\CG5.&:=8T M\$D9F,R*3E">1@4G&57"R0YQ05JT^K7-
N10V&YU>M[(C)7>SQN:F85CL- , M/YG(WK3 "WIBJ-XE##U-.D/^7C+N4V[F%HTU.F\LI[N7/V M)-X[?
@ [+5>' ^AX!]@16_0S+KA?WF8 %^%N;W:N-6][2I+7N@_GE*M [Q7277 MAOK(Z+^_9DP=Z;?
Z@/&=OF+VQ\3X@6+V1\X&=BW63@_0)Q77/ZH.#^4C;E< M1@U\$%- ,!@E\ "JF=,;M(P7VR"A3Q '\$D444H]JX
MW]0;[BUT04I@9&,\$7N,[S9P0 MXU'6>W>*G" N7&87FENY#%[,;G3-C(_
M) #36QK+DD\$D[2:6RJ4EQY%FFUZCT^A-7,HM>]J2)1UG;.*9>[V/.C3Q4H3L M]AG,[58I-0
GF9ZXPFO6AY[WFF@QK/ASBT'1B1;/...DYEAP']Y'FH6#ZV#> M@^5X@9L16<M"0D2C;>(\L%\
M!1%!04;3#MXL['UE9BC0-AW"#0MGKT[3X^,16P-^8EA@-^H2:_V0?=9N)W5 MF5%>#([0.=
[85Y,S+= "C/M)\$GU[V[CKOJ_C'#9:@(' ,CR; .87H>#@ (E%PN= M*+:9A081 4(KXCQ\$T[?
\$3\$Z7/9L>GX_]R0&G') IR80PCWA_] (%! X&HXL MBL#["%@/F[0%_MTF7,17'3FKN>#5VR';:
(0W=1S;HKWH5L#6MS'^REQ"K12B M=A)30%+B*HFFL<'>]]&GH4_XSFC5-\$Y2,_YF1F<(G*;)CYN<
QD[&MV/0/_Z M"H+!5?+6]&(<,:A>0FOF@79E8>JC_H?)=WX(!\M&S/8E+G*E\33>X%HG^U M=#0LX2\^\$TA-
SD.>P,1^+G"60(ECI?K=B@0A85\$A'(E; ' @2S?<267II!&4T M_4SZ1C)\$G.QJB8/W0U/E^%M(PJ;=:?
00%NUF;R047^W> MQA1B5\$V(>,[Y[P:G%+U5L#\! [+X+\!7F;.@?SCHM]L =B.8\ 'DQA7'^L' *"
M5GQG^KIE3K80[271\6E5NK"+-\$U>;W6S#=#6\$R4/S35^\$8'/<%M G%QHT_0Y M?A*IT;J8N<>'TY,""0
\$48G#5.IH89%F3[]SV0T*T=@[N'+IR0]R(1_3Z/DE M%\GM\ *G3X\$2">]
(F8>_Z4MMP'? 'H6'H.%X9C2\$Q!SM\PF;>)>]T#;HB)D7!T M%#[@R;3X/*35.?+XS/W7!VXJ1HYB81SJ+
[I14<([6L.H1=L ZY")X"" ,P- M@QN7^U8_Z?
N2]B0'/&\$JOPV4HE%RAZ?;-6.B004;-63K&7(\Y:X29+EB'3 MJ:HALTK1P;#@_JF"]^9&.[]AD^/0P9DA@PU^1-
DRV!*W.!>G-J MHE,0_CUP5?XWB@].QLG=<%R0H=VN+Y+"E">Z3ZJZTI^?@94# M^]9X]2_!2^P!_7MSD
9/3#HV\$@Q9-U<8T#F&L[6PU*W\>.Y\$ZM6RE6/CGN M/Q\$5"LY+
[]='M7&K51_T>05N;YAA7X: ^S:S;B0L[&R"ZPPF_I2 -\H!5,(M3Q,,GW#@(1"S9>'XYHG+R+\$A9DA/3=?
S2;:;#>\C-/.4E3E0*#\ "+9,D)BDM M0@,T 61Y6M+40@JP:PP)0:(EAG>)K-Z8;\N[/T\"/?
BY/=V/@[<"Y#>E]= M9^&XN+3\';F>X+I(NRN*)YTFB,QZJ]N0=WKIE(<,%_B0 +YU\,LNYVUU\CPP
M>Q./*/\$%H?XP?8B"\$021WSB_R"K [;1JX_2A?Y%4D0IK>' +8"(>H(=D9.D1
MQN+/S#FHQC@.U\$+;%#1X6BJ&OK\2!P1@_C2] ",I?*(JOURA1?/H\$[(S@V% ' M%9 HYS#R,47R@B&'AH07>
L^H!%E'AV,[]@WNC8Z,2WX0/875U*28/#2F"= MX<"^;Z2:\$ZY37GVYB'8A0Y;IH
M_05ZEMIVE5PI&1RJ\L.I!438=@_Z6" G61]GZG3*42U(M=?Q*[[[<>JA#?+?JS.P^1G)>3.%49+
<:,2]0M.WB;D!W&S7@:??-QGU)J@ BG_M?15=)M2B-3U_8#MP['2I2J@&3%&J_
[]8+X(H8L0I\$Y@""^33] 0M8/2/*TC MP&AR,:!^? WG7Q0]&!/&\$!/KY]46_CL4)SA(G?&9ZG,'R'XW0"?
TK78" I>(: MT[\=?!\$;/!&="J!='C#2_7AP^ -UY48!R!_0G=R\$ C3AC%1:E5Q(PQY,3-;G M&+VP?#T6TM8\
'4*-09?Z.V% =#+!,")\ S+ ->!D? L@6#4H<9UL93 MI)'LTX3I0"]\;:I^9HMP#(' :RG;A[0'"5-
\$ _#%7\$8<&92<1D,@EB!%IONA;D M%W&/G*MNN,G^R6^RVZ2DNILE-5Y)8:5M CYZKNL,F67^C2(.%[[,034NLPNF
M]"#W,DU;N&&_A_DS\0: 9+ LWAF)2-9/1%JD;.10,PDR>5=[X M-IRIEQ#20_\$5[F/
"IM*)0; \6;GK@G+72>URLR+;/=B&NC'?2U+9;&C_PTB) M%DYP(>:(SV>8TRG#,1@A6/FP;\X04=%",QW^-
S2P07&2,A!L;:B7N%2\$3Z2A M3_\$%3S,"6F*B!QY#7[4G,N_028/I_JP.&CPRI]ACZ_@%R0"4@3KY#);ZC9<
M**&+(SP\$]WL">*:,I# J5Q)%_0\$6/*]W6CG<[4G,)P1?([SB(.+:L<@J#*\$6 MJ<(BULN01N_6
TLD[FKIFRQ#G,XPTL)ORD*>Y_2I2P.6\Q3)S?E*[,3>7 MNOUT?E[UK%5Y,%*0!9+>\$"*LA(W6^,I-
+];8[N(ZT75+[\$37;C2'V8_D+97_M>;>Y0J>=VM1!-
M4KMY'@YL+@4TZLSRYCVV,.PYX]I@0DD^2^PC]C'/Y(N, M@>;RPZJ?X""*&#C;,_QN<_WJ;_(PLK:LXI)V!
<,,G*'M%GBRRBN?79[0^C M]/B2XU3A0,+YS0?0SQSG0Y_6V9X_#5_TYP6Z=:9GL,PIT]Z0=^FMXC0'\$%4R M.-
L4<8\$K#=#SYR<[0DHEIB!]?L:L;NB>;N(:<:W[9U7Y.RAWGS9\$&_NX[-\$]ILB5ND>7]G'?Z];E#+'
M\$W7#2KI.2S06*6GBZ/88Q',ONH#;N MUM0]0;TU2-<_E#T/L0BY7&A_MPOITY;?_6>X.=.B'(1?F64F02;D-
,G"]"&. MC,S{8#0-LVTU770CXN5%]D>E1?8W(E68MG\$76?;&J#8>_0_L07ES_MVUAZ+_Q54\$HZL>JEV-
P7.Z^J9\$GN4=*V-+8\4_DK!9*@B&X08&.10/GT]UG. M_0X(@^2X@A)NY4Y;,\$@FB?=
M>\$ (B2\ '/;'/<;K];\$.FYHP0SLT.MN.-]B6;NXP7,>\HX%U8-K&]M[ZUQ4MP_M]8EX=Z([#?7\;R\]G:[?<
G;9K'1JC4H[Q10I!^4>P\$!-;=8FT:\7\$22TTAM M-T#*5A0'G8(D[G3'\
<6W28*\$!=#X5%Y/>3V)Z]E1T/'TC)2PI'L7?LY)T%CV M<(R-[10L.;XC1);:P_V[!;@ (2JW'ENIDE-
L,P2;6=K02K"<1A1,#-'86I]C;_M3+G2"EFT0B1E;&R(\$.!TOWE4?R^_IGN_5+B9IBNOIP!"8H5PV'W<)R\$<:+S/
MZA!0&\>2%40B0,L(T!_3M!8B_'5W54B&HP.[E7:K5VFG**J3*'HXJDS:<]'# M"=IEC8(6DK7[9Y?-<
+KU1\$>X+"3;N) L/;!2M\$*R3@T+R;J-DRPD*V5J(0** MC>(4DG5P\$'-!9.L8KSH%E5\$S'H-NMU9YL\$%J<
ME7V^XJ0X90L_Z":0;,0HHWM\=/!76UQSG<;.K?GW&VXHHOF[FG!R6L6=YFZL

MX@(&P=Y: 'N705G%N6LLREM, Q1^/&4X8XR MW'\$2-
K3"!WEMZ"YX7=7>UGG^, K+ \7F5H; %K; QH; &5%ZUVRD\$SJ4\$WJ=+L 4| M* '0?-
GCY/UQ; +X: HXM &+ Z3Y@TPU*0@DA< \ @A^)6AW=6RYRH. %@ \ (D8Q M \ #FJ<\$GQ%3#S2>7+G6D\$+7&#I/-
KQ98.X+ /VA0B 4KK8|F0ST| [D(LE6+ M\$61B., 2593E#G"N9; A3< \ GM#(NJ\$1-2M8:-
\$LB|>@Z.V<%EX(CG76M_76NM@ M8%>3IK5<*PVV105B/A06' ' ^R=)\$; R#=\$JZIM3A7-0U)%8U\GW4"J2!IRVU!%
MX: #Q\$MYH|QFH3 K@5Y_R#QY>DD\&C_0K9L(VQZ7|Q66DJ M@:RM/[NMG%; !*L%V^!VT\^Y@A1HY_
XZ>7>P0N0=?@?@| 'YS4L(|N7^AF39P M+^@<_54; \/(\ 'N(X, Q; U22FX%\$')#-ZL2F4E)B<, ^']#
->!:9V; P("86 M: " @>7&, "WP)IJ\$F.Y ' (H"S5I"N- E5MU%RIE9_8+7G00 MIR)I|H("OCEBI
19Y1XUD*E_0W8\ _YOC_Z\!KY7'KG8NI^DA FA+!N|+F'SIIJOH#MHA|@XMXS=S@| \V<8; <3&-UA^?61Q^3"IV!-
>F'6HH&# M -SV; V: |T=+ '04&M8W2, UJ@^|@U'G8\$Q|+5&C; K1J-7^#_0\$S9U#0L6@%A#/_ M?
VJ7Z; =X@*A2VYI=#\$2L3BA#G|; .M), .GKB^0/?0X-4 >Y&4<; CC7 ;J. (^ M8! "C4?0T <=/C_Y9_W1>
<\$L; EPJZ40P_UW02E#B^V|=PGK=0&23\$V4Y&*0\B MWD"- .P9WTIIKOJN/>&J>&"X^5IU&"NIT/WFO<=
 \CU*H@*KVF!@E36L"Y<)* MEJ=7DB\$/H@V4A@?JRA-#N-=YG?@Z#^=\$PZ+*; TCUE: *AT| %T9GV5=DJ?-+W/
M\; XQW=.K@1!-!*|XZC/JG56M/G\YYN+77L\; J'N-@077FFJ@9Z0^(7XE=&; |E MQ0S-7B, IH7J-
4YBA21Q%TR|IWBR59S"%Q<#%@-0EB, UHA.8B Q! A'-1\$P, V MT?Z6P0?
3YBM&9; *NK\$NBSQ| \&: 07: VWZWEG; W: ZU4: CNYOAC: UJLY?^I_P3 M)=OU?-18NJC&H2=*BY|MG|
17\ \S/W@X6|WKB%#&M&*0; ; @3#9A1P5'3@ MG8XHv=&(EA. ;Y!; .&158UY")+(311"Z\$1)JMV M@ \ /50Z#-
_X_8R*?W, N!%3H'5+LKI+KNHJ, 1Q| NIJ+S|*P!+^ M#&+W<; +; (GP:NAB; 55KV\$/ZQTNH=?^++>J13M+D%Z?
23N_IGSEG MK@:RW@w\7F|UV#V; >HQC*|, 1BL461R@ \&F**.; |; I9#L3\T^3?: 4G(B M8C-. +0M9T|T5U02|"?
N2; RQG4N#LGC2\8L\$V| |\$IES29E+; E&|2. "J8S|LT M*/NU=VE0KHQF'PL_X#00; 'BJJ*U@6|VSCX
M=D=3%' ; 991\3|/4=QHE7Y\9&ZN9\>0"Z-LJB7?1(IRLM<7Z/EE0.S)\PYW"
MET;)FMEX3UWR&V^KDZGNT\; B3)W31R^++<%Z VS| C M3FN>7?H0#C>!))'M">EX2?23|Z/-5\$E9'/.; MR+J
VJCY/WDDU0^1N&V|7= M+ '&=2SM=08U2GE0&HX\$^< (ACM*2G&*|08R8|E2|R=0TH.|]TYN^RL/.A-
MZ*9QE.UTSRZ; W93VOX7|K\$4WN?LL, XE">0'IC=SMELWEA|FWAL)4T=)+\$RT%
M; LM/V, ZD\$: @#&U6|<|&'IWM: ^ZG, FQ'J?'+"%1 MP3YD?
3@ \$|4T#53PI* I9IX8?/XM|60YP=LXV4_ (0VLQUGLV1P=W.D8T&B03=3@()XH-I#ZT
M+5SLQA80C7| \$XD+ \ %8|M. S8E| \F_ GU? \$S_ IL|F+; %'R(9^FIVI!%X_2I"K%E
M!; TSDC=XCLB. \ "M\C_IKT2K&HB+; GF4\Z<. YIJ\4W, <; 0| .K6B&/IQH3E2; M'CU_77W8W<5-
+0(SH7UJ\ 'W\$1, P, SI<%RQ#YW. 7V%EBF#K|P4=XY_ ; 8BT)B ML<. B9| %!|JV|XWS&\0/" /G0BK5T|S, 0L(
M0%+KI\RU!F| .Z0SB4XZ=JBR\5> ; /@#E W^!/_ \$J_ =-ZM+#@_ 'T*; .J M1 : 6Q(4|0\$ IAXIIX2+320&J?
MG. IS7+E)T\ .57JL4G@8?*&\4L-W: 5Q208W0W8| \$D|ZR; %M(H6(4=, B9D_9%
M\$W+8R'ML, WW+W0XNKEP(!&0DGA-Z^WMUNIG
ME_5: .B(&26H@=%)X2, L: T05(3CM; %MHB|9"RN=6RPJ|P5_HVJ0: W; B"
M!T9F*!=A^)>*@F<%00D(>&WH8|SL!)!S01CIS', Q; 72&09)2, !>8V; 1!R%H6&60I, %X<_V8M#B)6?
DT>WCK\TH^I MCJ_ \A#0E02%H=HP5UC_Y<"1H@0I7FT>=?2VH7L0"-P%C^)\&F78B@B.\$+43_M1N9X; +A(?
0)8V; |E/D; UCY8Y_#>TJ\$&=2\G\GW00JJR&WT@|F5"8/&T4T".& M>N_!=8\0P=FT, ("WQP9NC^I".
=Y60HX')TM\$)N0F!+C3N2D^RB38#* 'I . MYG(|; ; J_8R&YC>E(I!!" : 6^D" T@%Q, "0KS'X3L%\$)V!%
(=@+H+KKY; =, - M54Q+L&8M|]" ; !D|L|S @S8Y77Y MZXANW. I4N0T4-
&9AX^HRKD!FVIC>1| \$2\$3C, |H86H^0EF%X, 3*|=&ND58" T' M!M-KI8+I"4S=M. ^T.@ADM?
@=^&VCB(!6\$JF+\$5Y9!8D#_ #8WEK M8U4=')D^*^M: 8Q|+ TW5: E6; |=9N4*
_U5H0+P15UN|; M4ZYJ, .0JGUH\$*|C M@L_L" \ /I/2\$U99_0%R6Z_/8@=0&KML9?JK; "L+ 4_66(1 M-
>PGNWy9#; %1N+ZD^9+F5V| /W&#;\.)|L#='; %^, 63W8-EC@WM T6/STNY M: #RC-; M5. (\$0SNXA22Y+ \
JQ/IR\$-/*2|! %827D; !5V=WU7@KB2HL M'; N. (A"/ACMMK%\$|UCJ| |%4; B8JV4J; 6, G7-
)0*X+; 4NZ+T)TSL9; H@#338C M(^7MQ?@EMF=5; NJI_ N8|GK0 > MU*VOBV6| RZA. (Q|_
I*J(\$Z*, I>W3M>UL4R\7=2RW3|040DN\$X#Y, MU_ =+G>*^RNLIKV=[TV6)R71"ID08; G+
(P05'W7GNP06KK1K'%N_]"FBB2, M: T
M4I(\$TG^S4; 2W286; Z; KR>@H@)%: !4>X\ 'I00#@22MS(TU*B=7?; S, !3+R-!! MS*MP\
(GV: |2X6\;) CA4G4F97Y!|VTFWL&G'_ ; IZA33"4JAC1\&BQA)X^#(: M44P2+8-%Y?
7L.5BTRH3QG5DA2L|V, X/HW=6<-8M><|9_ \$+E. L|)K|LN; L|(^ M8NN; LV9!; \X; K3<; +7MKT?H5(&.UDZ@Y;
|3/+K055J^L.2MEZJ8U9\WBU)PU M.CC. I"#" \YT&%@4X(&)HXFR?H<"6)?C)WIKMR5; BQ8%PIZA0BF.U\
| #0*QL1 M=^D>'QW\U?; &?'?' Q0S|C344T?I=339YC>+>; HSB_D; WFA>Y6!&<6Y: R|*5 MTX&WX|9R?X>V
M0%R; HGLH-, %|W; 2PE\, @|!%NR@T'W: '#>X->5U.D?9 M3^_LLM%80; ' #4-
XCC; 9.H0X<6B+WCR/L=#@J'. F+2DJW<\$"XZ57B< *'. , ; M'(-&2\$|, T6CB; Q7>CV/A'1PDIK|J
 \, VQJ; 0\2#'^@6'8*@F; XKD, .(#-=&Q3 M'9S. <|0A/S0I#| |DS_R>A2- '<4|GKC&.; ^'T>4)7ZI^KVJI!6=A8_M
J2E3QW0?|A0>=; 9+ \#A|CFIL|: <.F_%.W_P6)IT&0WF"(! LBL\; HE1_WX- MM/#- \?_7@-? *8U=
|, 7, 3=Q^(N|>K9ADB\$7'SQ\$<&>0TI(P|Q)MV4 M; E^ .I^ -YQ&L, 4QX*WL|0"Z*!YDN?H6?6\, C; =5
) : 5X)&)H7\&'R|W3\$&R^ MY7J?6*5100|6AT/' '5&=+ \$T8E+/VI'SX; KA/<, |73Z#ZD/_B"@TD"AP#2'=E
MV#W(1; " &AWXXA4G'N| \$^G'W_ <75VKNGR26*DX1"L5-V, IA0"@|_J0'0J4-|0
M*L(CB%>'>. ^N3T(("%. '7|@HCQW^/'U, |B9; F9@QITR|I>'I^&E|]|\$?@A<+
M. |&ST|T(: FXW590CE_ =C; L+FYNR?LV0: NP>/2_G?M.H80JGU4WR-<(ST>&'(M+QTWG41TK'R"EA7.
A/\KTZ*#P9X0; |) \ |9Q3K4^<-1_2I; R"<, YA7_M4_+!VV\$ \; T8"1PW/'0*= _@T/E0AGKFFL\ .5! 'F>-Z7-
D=S#*ZR! |*>, %" ^S M*)I(HVB\$ _; =X-3K+|KI: 0^(3; YX+PCR=E%8^/BCGD_N2HS>OBHQ; L%D_M|^=W-
FC(@#R|>| #DW<); HNX1>BV; U: AT6J_*|YM5|J=YM+--8CGJ*E#M, I M*'?J<, W-GRC?+"WKZ.VGK&-
|UEG(M9..0!6!&B)>=Z@P30/LLEEM)F/; ; ; &
M<; W&G0GMS; *C; |02_ [CJD1\7JD@^T=3D'&TWQP@+; U6">]SU'*_I'TPE)\
MZ#3EL#Y)M8N&^_ .VO)TE\$GIA^0?%D/FIVX%A|G. \I>=#=&\KQOI, ' ; ; SCJS4JW79AD@=; D=; ;
M3BUL=S0GRG/+M&5W2_SHXR0>V06WEGC85AV435L%: MKJQH>AMC=M-1%TWXGH

MGKJI4VIOX:@MZFS(W1;3;>OKK33\$.CF;2:YU2<+=>LFW=RJ=4)WFOHZTM?Q(M-[G^UK{6VL:U)D>M;'/^V]?
XMZ"LGLI+06UEU/1WIIOT@B0@X27-,8CPCMT M,U+W<-U<&S8CM;MX90W^6LU(2\T\$H:U;V \$P<[C1XB/Q-
A!W5/C_2[R45E@_MM>@K^@"8)"SO[*J^0805A]6L"*L3^QTE/^=N'(U,[!L+P:NH?}YH8}AL1}U MZT6?
>VB(J386&%CJ_2[N/7.'X_>:"XV*8&Y'999'[G="3X%:](+LQ8-+ +@ MMG\SVXV6/NX-
+AVC8[1&]7%0..H,C&&0-6K4C4:M]G] ZH_4YP)\BT B0#S_M]:M^F7:+&2U!C2Y*.-G)--+KRY6\
[1VH4RG(+R63&UCSMSAX%0U9 V E\0MV% M87.A8K[]IZ=]=E!1PQ7>F""V?<>ECC_7Y/8HN|TN*_C4V4N[W9T]!
(;WC#L[MWGAW]:R;%E(@B&ELPL-\$T)7WX#HS5-&.+3]W/[ZFOCKJ!\D=ENJ=7;8J<\$WX_M_]?
MW8,SUGUMJL]1&SKCL>&B*G1!56*K(#?&0%XF&!> MP7ZK6AJU:1_P.V=I?SH[9ZLN]6MHA^@C9X8Z=\
M@28L889V/GQF2@:/)TTW MI@ALTW0"G_?#=IP@##"9H&+QTWMAM\#\$ 'M3K/[87C^H74NG_-)-]T;Z7]K0
M)JMX_)2G?<#X>Z/V2?QOX:OTQ_HGV,E=L0\U_2L58=*&1^J \$3N#/7MT^HYM MT15,]1\$U2NI1.RL8+PX8H)YF.
[X&9N.SZ00>?=JP8Y^#;^,#BI]/C&,<^B/Z M0P/YOU'T1_X+F-%DMKK4H&F.3-V=RT<*=JS@7\<.&
0>&8Z/,W6M;\$)BX], MI BD@"Y8W*?TQ^!>NJK*IHYUB:T'6]"AKZ\$0:.4[;7P?8&EK8-9G208)
MG@6U_ZYX(3T>B* W3(^>^@&8Q@JHNSRT_!3./L"/Z^ M]2'#PI*P"@ \$+JMI/F^Y4\$=M@V2#GFS8;G!
[ARAW1MPS/T\$,-,R?1(=(T/W_M)04@;CP1Y7L(3L!^?K9
0#^QPIKVSX8R]VT:DVW11,&.%W&^A9H^M@^%NN\$47/J0"*XHHG^@;F)ZKFJ84 MCKK69X@%P,;A=P,OV\$!7_TN
-0?2DLQK*';JP(R53J=3Z:0,1I83J MF-Y(9B\$1^W+)7%UH\LSPJEH=\$!%I
_42* 45".N4I\$S=AH=M;33R;!5K"9 MY'U\;Z@,K5:UV6Z]<52&)^:~8Z5Y3HG2RNBNSNADUR\1]S7RN0M-
~1]7"0HE1 M[\#]1]5(7E(#_#0.\]!/Z)P)@GGZVS+&A?:"8S&[5*5\69L]Y=2CDV504Z*W MG^P.GF.
0)%D*2C2NW#5\;>":66Y^03!@8SL_HJ15V]!S=R15=H^2=K(7=YSC_M?4MT42R=3VW@=Y@N8"3J!?
7]'^CJ9/NL6!6EY*%U1HXHVZE076F)B>/ M;]:5U&F<738JS6:STJSM=N[<\^LBV30AT[LF:Z]3+8_A"
[#5(!=_06,;.=EGLHA_?XKBN3A&,D^'N])' MM^(>'QW\U?:V#V'!=YK%C)V7([7W,M\Q=Z. MYBNN8T-&
<^5ZK?2Y3C:J=50ILHP(,?J\$G?L29*N9P_M#>.(B.B"3E13CTP3TC\$0Y23[\A)&]'!BC
++N!^0=8E"6ILX*W#QF0 "04=X MUV>+Q@:*R^C7\$A,KX7>X\$@,H?@9K\=W *,+~93DT7_Y,0PEF,+BX"">)*?(<
MD_B'S"T37%(5C#>W=NG3!)^(<_Z_Y3^&=T.RG-46\M]X\Z ^F"FF&Y,#PFX0R7 M\WF%LTOS>;OE?-X"K.7
~WD[9UE_9:E7J])%+_7:U@~-WZN109T M>OD>M62.4+-9+NK@B^H0?}0[1F[0[V&\$07X
G=>#LWXD:~4K&RFW<2,%L]Q[MJU9Y:P?Y#8V]-<_Q0/QSF.,XW@"\$D\""+1_N^'\,@30R
F\>\$W/=RDZ(.,F>5.IZU'#VI5,1SV=W)5,;VY^ M96;YJ+0.EVKJ+B\86#?5E\$CR]\%M[_;2_2;:)?
C7EE%KIO[!>60+MI#NWC) M<>^+XWK[XKC&V66_E96_/5F.*UFJ9*E5++5BI,0NZR44?FN>738KM7ZIXTJ&
M+!DRQI"80SX"0[:((>M9!5G%8&\$?-_1_6Q8SHSJI#(<_MT_WW69X0_13W92.V@46:QVW=SJ^7CMJ=>T)4LZ+X?
W.JZ0#5;._+EU132*II M[HMJNF>7[<;6_FA)-86DFM91++P>=@;7&UF=\$ (08J"BX\SR5_UMZM4] M^>_63=SN:-
Z.B-E18B*G@.FS@-FQ"[G5G1XNXK,6+L*.0T*E)"@EP0I)L*.\$ M22Y)T*LQ"\$FS_KXD0BD)BBL)CI&0[=4:
M9Y>M2KUYZM9]8>*,GMT\$R6;U"PJVVU MJYEK6AKVXS=J]7X,[.(<_>VSH[04&'YCNI;0=UQ/TT?..#/(M)\$6D
OZ(MV[_V M_2%R&K5/_D?#P_T<_W3N>Q>QXY^+QAXQE^!8?067--G,]=YAA<,YNIB"&JG M^GC& XC(' #0ZL_8
M=I0,H,Z(0"E_UN=95MS2"7YC3J3\$R@1_A+;!K[,1U_MZ(_A5VW#\R36@FL\B3)4QXZ:9[60:3&:
M"i;0S#YE0ZSMW#/<-_A-0[GP3 M&PI'W)W_5P!4-9XC5"2/NP-I,G.(,3%.>E-0A.#9T:~0E<@5?0:C3E
MNN^PI-G6>+V[1L*_!^A08!_R1>A[^0UT -R3^K/ZH1RD45'J\$A;_L\$,N#'
MMJ,_L3A+FA"R*#C"A=,'_!5W04(IKM^!1F@_F(TI9+2V.6C8U7?,0%0.,
MFGJJ\4/X9<>F8X=EXF_C2^7>91_P.AQ-&>/^@UI",3R8301\$*XP\$H1_@,^
M!%>2%W>RWUZ!.PEOF3HVL<*U/D,APH.>OXLW?G'<+P'.P,.)T#&#*B>N9*_6_M1)>N#QS;Z"01(C1>-0[0D%8B:
K/SQ10%.<=N]B42[<)]A*?))X9'MJJA]\%M M6Q8"49CVT#4HV@IT_***%_0@P_Y&9NNYQ-
KPD[,':3!V,3]\$EH#0457L"F" M&3+0QU_V\7C5_W5G_3\$5QBN\N1B!,OH!(1PXNYI'5V"1S.&!.+ MK?
\$5E!TNP6R\$8J)1:134K590UNGRP_V4\$5(T62"1Z!(^A_,\]V1*QW/QIB/_M=^)>[VS&1KT?
~SE>/>NFA0H=#E(>X97WX#HSA'A!Z_C^W/U8N8G<#-^NVPW
M.Y5VKY]~I_@L):=EBT075.H95^@LD"!V&NB/QGW8P4'F080B#3#V0R5^D\,S@=2=Z@>0T2X\8#7]F]:>0X"<-?
H9#@U/S_F!\$07<)&3_R0+M, MP9!8U,^IQD**,ER_JC!E-/)X6\F8)X^34@1N"90S_'5[,]&/"%GV&A_\]1S
M:,Y(<_&Z0K2FA"9RHE]~IY5F5L1/\$/X!RS3')CP3X3-@XP\$N@P\G7%12L:~#* MFQM^9,7H=0CQ5+F;Q-
4XE@'<6,MDU)(F+1+K:HR%30>L_'9PN@G_S0&CHU]=MH5P6I<&-,?10@ (4LQP.5D<"_Z=6Z"?
P;^%T2_~9WQWZZ0+;2\ (F90*-+X"?\$ M8U->UB@B0,Y=N06L#_~*3,9Z02Z]=>_") (3#::3B\NF@;::,;@'X
MU\$.XD)&&;R;I"#^8/H@;_P51T<2#)8K.;0#Z"4QJL(0IHJL_,^Z_2?;S&>W
M=Y^UWQW=/CMG;I<_D^<"\$]6/3X+A(M/2#MZ*&34';\$867B",%_95V[*;D_#_MA]LEW""/>1*JC_C2-?<
W>589[_#>8#JI=/_XH@]-R_3G00M\EF%\NPC^XL^3 MJ&2]6N_LLEE+ 7#4)\$@+;H)Q?C8"4#8@6>3E
CBW\I5Y6_J^WM=?;V&Z,1KK_XZW^I!;_.]W]74P;U82U"?F5+&%F[Q;J.]W M"XUUME#5;M&[D7LP*>3Q!\@_-%
0K\MD**X9V\$W&\$" 60@DB99JT, L^D8_4Y MP.S*F/\BE;_2=]&Q0P.3?^E=T2,^*Z"1(U=_P;:>_Z=/G0!-
K%\$0^GF2B\77 MT/B;Z7,&3R);TT11!CX4G!?)/%S+5? 4@_ \$*[^ ^")3\$2(^XB3T"W^AV?TP;
MA*EEA7AE8+#+:/ "A8_1DP&MF+H&]V+4TGH3/- (7PWJ6R'())/,2QZTQIM[%-RIV0E2NVPWLF M!V+9EF,\NG@
2,0K;~^YR?95",A>';SQ!%H[^ ^8K=IVQF3A8[(('*)]IS,<+G MTJQ"#!""^
BVY1%NHUPV5_!P/UQCEG@E_!+C^H%J(\E=Y,WD]/%;=1B%8^) MC_4:H'?>FZ
~)W,GM04=W0J#;)0(CTUS5^0M=&WTBQ*X67^E[7VN%!SK?NI* M9QB)M&%-~*5H)))RVFGM%5CBZ_@=+
<8IK*Z:ZCX'.@6Q22]B6\$P,^J@_MCIX1VI_5A3F=!92\D_R[[.K2"3-^4'Y=<=>E]1X;X7(.EJ0L*W,1_B^J>-?
~C_##%Z74-\$3[0U1GJWB2\,[B) M;:BH%5<<, >EP[3P;-FCTK_S>[S" T36_C_/_2=
IZ2]Q6!J>DB9/,_R'5;40@8M0GCJN M\$8\Q3/4YRA2B9V_B]=FQ8&FZ:U(^\$6VC"K[P9>*@;G?QWQBH7-RPS>-
*8\$% M!JA!Z2V43G;Z>6UPRI3/H=SFLT!U1]#YL1Y80D9YE>&\$C_A.9/JN8U5H+80&M\.):4%I/<.:J_R,V]
2T8HB\$C5?!&P-+F0)YZ^U_:H)J&&!/ *P69#G1*UZ+S-6#"7D0_%1RN:0,<2:)?PWQ_MM^<#>XZJVL_(TP.F#4-
0X187XH2X-W*KPY/QA,I"PB10R<(Q^Y2QXB2]JJ8\ M_5+%'C08?I8Y!>>;21D\$N^2%&69)?(H&1C%_G(D0?
A/G3HBD_BZ0SM85W).U MYB\$BZ;M^;I,E900WEB@4-4]U8X#^ZT;6S#6_W!BEF3*-QMEETO@+,U4\ZV%0
MRUY\$VJ"XG4H"N,0UL,4PBE(]L>LM/X:~E6.5H%E0U9):N\200JHG) M'47J9'0K#W)+7QPWTLO?
E54\P.NIEN/>%M5T/V>/3KW1_LI^\$*8.0>61ID8;

M1_DD_412C:XHT6/S")Y;K<6#. !5M9@7>EKMN;;WKSYPYC39^98\;f5J.4\!"MEFI003'(!"T?!(Tf:=?
VN.*>L9/,0TC5ESS9*2&'Y3;2G)6G"K 7WMEMP^RRG60!J8FW#=#WVK=
MS=K992 /NBN8IH.E7R>7CK .N_QZ;;0E4PYYC?530DHM24CG@BQ!i&1M4 &N
M2&/%RU#CDH0>DB.9UP1KP<,j9!68*EZDJ):-N^"=2EB3L>!R-QLI<2);44Y#34'(EH=8A#S\:#2ZCU,?L>2%
fD<u^0\^G0IjB@L MG8Y""DP\$5>TWW<2@A\$0S0.!UP\&)&@HZ\^H2SBF8;
M_KKC(U?/N.!E?'R1E6EN.790. -8^6D?9UIG6N*8Z'&*P)CGCT0F*3T7' MC3T*\%Z@9I\$75F.B9AA:N!
AT:&L(G--[\]X\$CBLRHA?6!C(@B!1K9@L410] M\$7BR@V:HNZQU^6NASL;ZCB>,V9H>D1>.>(:AQ0A8H0@A2@]'
MS]"UN6E8\,7 ?39XPf0.^7ZD5KDI'2E'C# -3T'=Sf]<*>U6J00>;-'*7\5I M 8 "";1&J^:U>."@TQ14YB
MC!-X7*HA7#57=3GAFSDGJ#;JJRJHX*F>4&M?X+TT23VJBTU),C6;E#U+*=]?'M'&T:~9\J+1(!RVFU.3?
36%4.I@P!LPT0' 05^'fT0;20GL^.:(-CQ3N'B M0808FE"K;(Ef5CC;-
^<>5J3J0 #;KL7+,J\$J.S 7DWN9KWE(:YT)G9_15NV/M M(9;51#GS)A-+0W+!C(F=)&IA
D5FDH7854fQ1XYRWU&8&H^*2X21Y556"#94 MY;HGQI:N&-19H&\$&9+MSB#+/),>NUJ0-W8U%
G(>YF*%ZMMWQ1!1V*M\L1 M-G GK,BB'-!"2CWF'*:3&@9T15'2G8P#VF@TN\$H:TULAHW'3YT,)001C =H
MF/!W74>VVL^RJQJBT0V2E@V#=#;*@j3KWPTLB!MAf^P7:L\7RIB5I.S5/)f M2_#=#5)00)I=')\(CF?
C4T&XL6EGKK26U\TM?>FV/8&U?L.&> .@:/?:3N M")f\$FH?K>COCNJW >f?
@KX -6YUMU/f&0)5R5B50+>4MU&*+/TY>3*LF M(M;6* 7^UIC8Z>1=JJQTMNK*D*-K4&%1J<\$S.664(,S!8L1@.
([RAX]A0>6 M0X6U:J4*.Q;^)B#?/):CZG3M0!;WR0?I0<57HOT'\$=B\FJU5GW'6JUTT;:A
MDK0%YC]*S:3EE3;CS(/;JL'%YIZXfV4N;F0@8C)W5HRS5BJN?VJ.;HB7LA6 M;1G^/Q5@fY.,W^X9S0G415-
Z"WQ.840E#Y5>?VMI=134Y@4IED1MC@&6I7;X MK(<2UZT5'"6N7LL+\$W=')6N/^NLRK+A6*PG?
UFHEL>X81H\54A4@JZ%\$FG\6H;>#45\$TP65)#EF&M*V9& MY%A<)Z-<.UH<5GSIKf)^,RQ*]3%J0"M?
NUHG#GU3T; L9 TF50'52L %9B8U"A&(^5H\$/";*MC.0 7 3fA)WPJ&\62 MW+!CE4_9>MI
N:R'M9f>0YE"\S5#0EGVGIfUW6E##J9f7<+K5790S@ UUA*J=
M8C6E(.RV4A!VOX&X !W%+SQ*HV=M9CMUR7;:L&AU<3N?=<1<7MFC&0/%S"BC M=K75*WfM*NV\$9/Vf}T+ZB?
3=C#LX""H;-XUJ*(XA#KLQ1V\$=L?R> !?GUQJC M"QT<\$NQ(5)\5A0 +==\$%58N6PX9/?
=EULJU5MMENfJV;-6TIfD!+;8\E&:VQVHP+T0M'%=A7H:Q #IIT-;^> F\=L\$'DfQUC2Z4'I]f\$#I
MW7W/1J4GI@V_3%<,Y 7K/KQj1WTYNZ*V=V4f,ITHBfFL-K0'YY_E MW""\$-N4GKRUR=)I6R5VA.@/6V4E\$=
("K48)P32X"0@QBES5Q<@fE2EU4fV MZY\!ILHI WSW35HN2VXX=6fH'8(;VC7DAF8f.3FSY(8B4\$S)#5E%
(70AA0K9 M9:M5:7:3)2,E.Q2!9\$IV\$.S0/P@f(!f] VRE FB'fQDRN#%L9VK:6P<-CNWF MEMf_W\
f\T5M@K:R-F\$7f>QU^X".>B29TIf/9*E07%L4_)K_AX0Q%\\U8
ME,M0"8UW"QURWL\$6f>9AUI8*%7+Y%YM"ZR9J7>;57JS4Y"=:7\XG@IE+=,MLKTCDDf, *0=&8-
USBZ;G4JMVZS46DGGHR39 Y%L_8@DVSW;:G=&LCV2LK5^ MK=)I)H.I)B&3f1R6" F'6NQL6Zf1
RK8K_5:}TF@FQW8N)fDWXH"NE7.C M4F2Z0@I"i.
<+EH_2./0&HE,'f2DN;E1+E0ISSAZE/f92@%"!008#T=LRWR^(?NU_&\$CG6 M(@&2G
U7"i!2@)0"9'<"I+YSSET6D=Kf0C(E&0V7K)462"E 2@&R3P'2WfD M618?W/U",@5(#RV0SEL2(&0-
&W8QGYE^R9%3<f7M?.8@%(.I6f9>Z8E_@fW-7NR6F)V#U0#/7 ,\28--'f/M5>G, :
M*2_7E1MfNHWF+;0"M/(?!=]'\$>^8"/TL<)YW8DT_ ^#f]:7YLQX0C..E388T'#;BK5M1LV=\$'!L>@JX
M46\M30)0:3;G :"'!M\$4ZW7*K56Nf}):8ZB(?@GE>+SN^YX"WSS'L4HWBA.YD6#;N7-H7E!f7%HN84V
M7J/2;:f0SD=J#WJ;A+^X0,XA-!&;Q:L_909\$ NPTB@GT5NK3^OX,VEV\$\$/9 M-H?
SICA@>9G^<>B_0fYNO=6KM&IE=#fH(!D,&RGWG!)@106W!^' KOH*7>Z MC4JCV5U#fNfQC\$ZGZ&-
T&GG1X#\"'CS*\#>fM@f#B>R;*.!MY>\$AN_VDM#P M\K&:\MR-P.'YX2F0;fPIH9W9EI]^+;?
N, :PM/356,@9'UY -&%"f]9V/_2= M<\$I-@Z?4-"N0F2=#^*fET)Q' (@R "LP09_99ZSQ)BN:CK-,664?
fZ!,#&M4 MT7_8"1P9fG\$/3*#0X<2&3WQ\ "Y.-T&f]@8^DAfF.B>H37YfQJf4N%OU;\$
M+!6X9)S'0GEf62&@^:ZATWQ)7fJNN9C=MXW =4;&DV\$CCB(6#XQ,SX#f5f2K MBT>>NZ)NaB:SC%S\X-
^#TOX:'D4TNI_@2;@ &D'\^C0(R ^A#P>=fB8U@ MX,#F#9fFN;C!\$PBT9W-(f>ORPC5E_S,X&12#E"*
fTYA)?>3>EY#N"i4(GP2 MFFN("06X,F@4\$*X'WT"&) M(&T%YQXK TGKF.3Q\$#MY7B^X3J@fJ+C-3V-
ME0_I,\$K)WKB(ARLG+Qf>D"85C'DPM0:"X-C!,S""\$SAE> @6F>#.Y/2? M(?UN%
f(=D6.53)0*Y'D@SD:\=VT*YQG01_W8"%0> S3" 3W.F)\=K;:J70'Y MZ*Z?fC>5N RT65ZQ<47A0"?
f6JYf6HU&+083TUY#3WR'-3S9.,?H;H04,#91 MfUf1H5V),fNR1f]fIW7^AW4CUORHORI_#5_)f(V",!73698-
!'"#HTR@AM9_M-?MJfVF:\$.P3SF:&fYDC@VfJ) V 7D+5%f.L3.4AXCN% M'06;#=#6=@IB#-
PI>0IDB%/<+3B,;@8!^f7(@Q9;3ENJY^2I^ f&RZFGT!&90 MIU--AB8D04Gf1fIOU4&"*W4=U=Q>fNR67K0:K?
=V5S76>+0#f/9T*;8S_J@SfQ\!X= M82f*;6AXWPS ?HPDfBW)0(B\$/4I&=E(:
f+>:#+VQIH(fJ@Q%I8M'7.#G/S9(MYAR)KMCK1A_!f=LR@f5f(?
f;Y5"S6VLRDDEQXK0f}B7f}+,X%0XES^ \$f-U M03NJXKM\;fHM<0010B0>:.9019&,00M6J793F+ABfZ'\
f@1EE"QC7S4D2I0 MWfALR6%8If}XZ>*fRVG.+6C9><;V3S);D%#W% D0f&<,Df&7C+EZFP;J,FU*, MXCURTQ)-
_9Nf 5YPKW-VV>Y4ZHW>CM1S093PJ?#(f#\W+4,&S6>N8;R:'D6& M;0?'Af0fT#"?4?AMQ#707 ?f90f?
fQ10=.KWX?HS#%UYWT/3SPW+W7f+NL5_M.)92W1R#8Kf\$ XM8%I,=6BP1T4HX@>
f;Q/7<(JB'8>A*OY:LSfC*VRYB@W\A MTQW)f(:(%fYZ9@SC5D=-5Zf[F%BP,;TB.50*AHVfZ?A8T9_N-
Y#5^79LF_G M&HV&2KD)fPJ40/> RTMSI/B;4^KV4#f\$C4ZRfVMI@3\$f4 3T^N\80I(MY&7'f+
M0(F'N\L=@:BMB\$!(G#f)?>GVR9=\$/*0"S MJf0fLZ5fW0WXGfH+\L: =f\C)?^TSH9+)II4>J0
MJTZLJ&2#:PSH/%fXWZ:Q4-" U10, .&%PD0\$;fDF^3B-27f^6/(#LPYf]fKLUT MKIU#5%B),J55Q0I
f):=/'+)W,KW^D,@WSV8B2<f_ \$8XM" M=M>BK^@#D-2fG_V51fKH""JW#6MJUA9.1_G?
B1L^3Y^,BX^KZ'f>Z&-8f\$?=>M>M'G'JH154> @E /<'f0F3LF,U@ACK"&A&f]f(RA@P\5/P9KTPJQfFf@H M5?
YMC<),T(*4B^8\$'18D =>0^F7:+6;7&392ZPR;1:QPN+-C4J>Bf3.AX\;F MZ_G fC:PINMA,9JL=A!"7?
PHRAN4V'=. , (fB+MA88V8=@,*4@K%"HF3M"(K
MJ@<+W'"\$5fNF@5SG\$0+QLB'HTDY2J;0Q#T96R&*YVRA3f+)9=7AL57REf(KD_M@2_
5!ME=ARZIXfJFHU+H0>,P21DI6_IYE2f9*J/C_6Y7f6^.=HX<+&.+54> M8S7:Lvy:1)*H\$5"fT2GAP<\$+
fTDM105(X,J853#BGfUJHYRC6.99P.,P*R M&NG")Z:16.6=4LHXTW.7W.009V\$6F>7C:5'!/8V0_EJ7A#9;:K

M;BW907B'(HR?MM V^!"UM>Y2C^@S\$IN3E,)U_0#I1A65MK'\$3K|10@W<[/P=^\$AXPX|?]6R[|AQ#|^DZD&V
M(%K\$=,%9,!^&!(#T3-J1"W6/IK>K((&N6%-K:<VWJC P+WPXZ2'F1*\$R6 M9=RAPX\0CZ3WB =G
3BZ6)+M\$#<4S!;LIFR5W\2>+R=,UW."\$+V%9]"T48 MQA1>@S=0|76CQL?RIS'GNFD)EF,CZ5AS ;6'?A
6D1,YP?EKZ,+X[ABT?N8 M[9/:E)]?P=V-&4|1"=[(\[S.]P4|BX-)TG9AT:BI"(',NR?=
[5 ">]|%*5L%KLZ|ASLD,,TF6 M8^9G3-1LI({A%"UL4>#Z=@PR+*[-#473B)DJ+E5H2^'G-?)/\$S\$P\$|D8FQ5@
M T:5R,KT F# OP):X 3-'N10Y?EA\X&0#,C8+P5N?13?(.I' 4*?W:SB=/B/Y()6Z@Z"*2P.'B(ZM>"OPQ#U-
]G<0:20 M='4(2HCLLJ1-EM;\E=;X)7J|G%,+BC@U7H_%"?9>Y&WG MOX:0#5PSBPGJN^VY.!684"*F!|>P3)Q:
[LZU|RED*=6G784L_9Z;+*[B4FBK MR>X;
5H4[D28\$5+8X9U5\,5JOUFW'J|PNUR_*BAMBV^INJ>6N[IGX_YL:KNQ MJ2P>3")TW9(E/_U:
RMXRYK#XX!OZ: "0"V+VHO!,PJF 7\Z9PE=0|9DG*W> MKDKHRHKX7)1U3|G<(2,W;,-<[Z7V_9 *B6^%/TD7E<9
K;+/+3J0LN3H*Z3RX M&-GUY00FP45^C!,Z@: ?&E,A+476YMZI7K:A^CN M;%^WGT5,/I5>4I&8)
[H805%ZG.BVQ!+, '9+ KKYZI=;0E-KJ&)0F|ZW43ILS MV,:TC^5BG4J_D6PL++7,H<9++!9A;*-IMNB5?
^,LLDL=M%GLNUX[N^S7*K64 M88J;*9H"@;6=M@KZ/5GQM^4-0F)DQWL3:RZVDXDJW_=F.6=#^!TUA".R"\H?
MZ)9\$9U1^859'.)Y.+UF->E|:R LMEAH.76R>-%YGANV)"GXGEM=3*CC?F55|
M,LPG:0%67&)N|F00\$,I6,L*Z/ON5)OLF%'9C##C%P572 56\$*L\BJ@J?_0=
ML9>#7>*UY;:R;!8I5%IIT"=",E5:[46V>70?8VK%0JK,T4
M5MKLI%)K%82'LL9\$Y515|;/+=J7630:SE)KJ\$"'HI19BY%5J|XKBGK>KV U(*?Z7 *5X+1&S36\P/(7,-9,FTF
M, (&.+3\$#'\\$ G5'A+&T;KN C=|Z-CW", \$&D%8\$A0#|\$, +TH[E8*B6^S@-N M8Z;-E;|KKXW#2!BP|CV;
<%ITAQF?)6 TA.S:9-('/&CK, G'-@OH1,(S#U< MDN\ZB&U^HY+UT1^!1R- 00K.ZX5W5T*,66UNZ*Z*QY
&K%R'RZ;+2P*7K9?@ ML@58RX'!90L)(Y0\$C3(5%:M)|:K=/7S #WTZ^W23(M\$0CS\$GLE|W.3|G%0.^ M;?P,
|)\H:40SEI W\$;0-#.1UUS\$#"2 MB^_@7/?%\U6ONT!&|Z|-T%|>, /!04V)6,1XP/0 "1^!^!'/=/?*] M
J_0WZ<#1*+/'\ '722D@UIGYB@J.0LZ*A04I1J4=G "P>-0^@B,; \$>\$<;0#P9X\N(00704:0B-%?DE%;%1'%I(-
LKT MA857A*!SU%,G<|K2>A 01H)*\$%G>()C\$8F\$5;WA@SL*+KS'6+S.VIX4^<4;TK6B|#{0Z
M%SZ%0S5G%E\VIF,#"?2=GXV0H#_E"PD"^(|6|\$/416|Z"/ #SC\$ M8L3PL2^V #HD|13#=#^7UA.:ME1|I&_D[
[!2J'_2&04&X.07-HC!'%0L? "%5%: ME7V?@N81 ((2.#VFAT+0/A|-#;<: S2R5D3[0/40>S\E7"\$] -1H(8
A_%L" M&\$I4=HK*F C);,U#NS9NI2S8G-*JT0G |,D"26!)E&EG-H/+1&:B&,A>T/\5 M9\$Z)/\$?
GX\KD@&|,6_#=-)CBKJ-UIG ME|)\M(<@U^N M:8I5X)|'2#R.AG,IM7I3Z!N3@F!P,)H#NHB>|)@K"
|L\$SQA^6^04F3SKF|GJ0V|H),'/FG#2,A|N(Q2ZB M%:0G|0R24|S6. M%(JE)W|\$(|)PY7.-"!
VG',;"YC=|\$:;+ SNI9GL&6CCJAE-\$">Q-&#I4J|7 M-ZW0E!
[JKDM31W2RYA:FG/ZGI\2_P(|X9KCWN.MX*@#> 7ZUUL^/W|VJUCH| MPN|N5K0-\$K|
[@;|)0#VMQ8;\#D=5A',R|H'008H&X|2/!I|R >)(3 1(-^|V MC/*|E|{|;1J_(A_Y9MWC\HG^&V,H*+!:%-
C4MJD\$7KMR;3|<5PP@|:/N+9^W M5U|>@;,"KI|1=\##F938)\$F#NMN5NK|7966;58B)BYLQU7IQ98"=U'8:S@!
M\$|HX?+04"?%)8P6?A(>9S\$VL8)*4.*G"'W4TEGJ->N/349%WMF"0DU637QP7 M?
K1%M_QPSB^42U081E6!AV^1>D-\LUR_B"NX%C?P&W ;|II ^YX:7"(\,|+ M7J=4*,S?
IV9=QX3R\37Z@43_GK6S9+|W!";TGJ-(|LU381?+|22P\$ \$ MV\$QI|_ ">-
Y9AR_LFRJKV6%5|HZQJ+!|: #EC5+E,I&V8@EA0-960?FJUWEGW(MD7FH4)\$0"#JEM*G V8@-
QXDVF5Z:WD.8=U'|:N-6C/7D|)_WZIURC65:RK7
MM.:6F46<.,LX/0:99BJ4K|?;V|U3(5*B8HAOVN&\HC7'Z\$*Q)|I61Y, _?)
M,S)S|\8D|Z(F@V=).UXV6.=.CNS@!|R4*7/\$3C)7=8|K:3.><3 5?4Y77,Y/ M#KB\JN.L-3W^LU!#-
+HJ^AL^@V\ FL9-*"VL!TQ;:W:CHZE%(VE:"Q%8RD: M3XI-5XC&-U|5RM%T|N1-M'\$>JI|T?
3UYITIS|PLO|LI.|DA/=N\$'7-DN: ^?J M_2)+X,<0^&0-!&'RE:AD \$9@0G9=9*\|P|!#-
=C8PQ*Z#05M7, YYPQ57:%M|2 MR51K>+2|#6C7@B-(*EGAC6J"=#.H50>J;R?A2\$^+|'8L2I?
[|DJ'IC52_P|EFJ6326 M>C|YQZTQ.PY0)EU^?T.)M;Y/=>(2:V.W8R.TE%;K|+)1%*>D2)1XZM\0.6FE M|M\Y+
[7/+N0|@0#2^W'P;:1ZZ=07Z_MKELT=9DSVB414=WDT;T>;R|\$, ^*P
M5)=T\$&BFG<^RWCA,DKU,H6|V7+_|%K|?BKA20.U&Q.VZXJ;5!1'73'FG-:3@|CNN:N3C5JZHM(&GPY4LXC8H*
MKZ6-3)Y5:=K#P,41|IB<2Q2?-8NKCF<*K2P| (,0Z,GKC|;YI0S|'B^X:R: M+E,X8KNSM?_6@;3<.>%
[+PI")017Y<^T.V10V-1#=<&(E)G9P&)?+0_1ZW6_MHL\$+L\#U<#IB@+,BY1C4A0F\$5S@MD^+=533/>*8I9-
\$(U& ZXP%;-,?5M%,& M?L.#X"0*-\$;:Q3J7&\$M\$Z#G0-/T&@/!FNF(5E&V+
MGRYV;DYCL_|'\7T:C7,4LQT)/5'|^G&M-=LUV"L\WV/B)ROX&F<_JGM0'B@. M
^C)L"Q8+W+ @XNS0_RYP,?|2K,N)#0+Y'FV=?|S+\$7)PQ6%L=7+@QJY\F(M'LA//CM@!*
MS\)=C2;*M7IGE^UJ5@!&CI531*N-XU"GL(.)I0DT>C-=6C9/3ZC),SS^PI>* M,) E,U|HDF.\$4E&&"|99+YP&&
(U<|0LQ\$|8 !+*V76+@;D&@1H-KTP: ?ZCBD M'/\ \$ YT8-HIY#<=@^S0CFV4U#5P "(8'T8CN-&#/J3XG-M4V/
LQU1>|Y2F0EOP/@R'0;11&|MBJJQ';H4L?*EA!25XA0?#T83A9P#\W' M'(-@<%PQ1|RT1R-R?
1+6,S|UZ'J5YRL/+?QPR)_AB'AUNZH>@5?H3SP.4S(\$ MF79PBG26=,\$T&C-
VK9%.Q@&Z>' ^6.36%,3C5AZX3#A>' XZ(=;T*GFW@^6"? MX!/%/, ,8'\)GB 3@PA;NF;'D4>7SFD;
9D/4:_IX#/^0(EQ\JZK=^:0486FP
M*\$7&*VHYI,D(55:N29^19.6257I0#F4*9@":Z'#R<.HX_E0<.YA:#IZ^*S#/E MZVQ|P.
[3SX2SY*D0JW0.A9.AI^:P33Y75P|,;8Z>)@FE<.;T|>CFB0+T+_* M(@T\A_7NIB(>B;|
_P=HP[X@NS&+KVVUQ5-?;N|(-1S9/9P|RF68|,\NZ|UJ M?85EPX<3ZL@-#)W6@A|;\$,Y:|CH)6|VNG29L-
7@U.,_17X;'2BU2?QG@U2&) MG^HZ&8C6JMM^AF&|DFLH60_K6AJEX^^'F,J"\H)7R#C9I MUU\$|53J-
'8>6|Q4\?A=SRG8SR.|T2X)R-;BMJ*|;QE03V*1!;%)0)IL^#|D M|GXTYE|G|9UNM?QV|(&>%OPKBT\V^I-K-
|\N6_VD"EF?-PI8%U|LWMC=;+YX MN4@YF^@)U1L";/ #8JX-1N2V6SMKM|G|S>VI|&'IM+WT(,KE?
PW<7R\SHP_0 M;T1?,WM\$'RX7J60UW+A.#3RBUP3= M4N8D)0C;9K\$,XL,87?
GB=_BD>&@V>I+&CTH*HH5@<=ID1'YRR0L:10S^WG-\$ M|V^.-4(%H7TW,#%J:#>Z;W"5!J82AAAB)X0JQ?0G|
(TPSZP_N08GV\$B^|;1" M44*"DV>GH!|GT0M^@,|N8*[5-2@/1YD4D182Z7 //S*!+QBN)Q.E2Q9I.YAW
MP_=@BH2N8FCIYE2\9(K0K(-Y/'0VS0ES6)X/M+*0+<=BE&?<M(B5, %D>EX0 M9NC@A:CS\).Z6"V\X/?
X,^R4D=>*1ML(D0GEHRX;^0@<=A U1V:9)80?H.* MM+XYSVQN)Y/.*HE0(0X0SHB(YP-^# V;1NW3E?

PM_5S_="XIX,88^-I52'!T MK+=WG[67B3F<:"\Z*&].6'PU;7,:3+5K3']=PWIL3/>.76<:EI!Q9+E--OK,
MPLRD#B(7ZPV30>AV!2L!\\$,C+,*?@TG|WP'ZR2T*\$6-,"0EL,MQL^'F(F+
MV.0'9+\$6YELHI65A70A6J%&MVIA+PP;L\7 N6Z%.2EMSZAGSE4.PPL!3Q:0S M_)Z*
")21&8+OXDU\$4I&C<[6Q>^9SBAKS4 5: .9IF1:R'>!"!+AK)[5CXMB\$% M_% V\4CWOB=[8& OK-
X,%RTHL#>N! ?&&,#W' L\$3;PN* YY=B[+HQF(,>0 M-CMGETDDRE_D;?C84K6_92\N56PC=:&@P9,57;=
B_@17-J'%2>P0(P_#'=P MZ5=T[9]%7=Q,GY/(\$K6S>).A !J;+GP7/D\$,--,(J(#M>G->NB"2_@^DU\$!S: MV"!
[(H ?TUZ!)03 " !H%#!L L@,AZVL&7JL17]N0VL7;D.047H-I=>P'Z_ASC>F6J,*,DP6>E%TI/0)TVY,
M;QAX'L7#0:)=R=P!IO.+,N[=P ENIKQ_,R^PNLW#+=@PRW GAN49+Q.TZDU1 M, YWJ>/@ZM
F0G7V!52(5J]=)V>]<\$4RU\$6DW\)-A?9>T*/^*90P1_/IDAU M9Z((D9T)W, 5]14D_ H_Y*/@^G_.@JAX2M90?
#C+?L+9.1P%;BG4D#^,(9A MV)!:[Q]Y2(@-/NF)N]/M=E_W%Y+: [V"3[Z:N:8EC.P6FL\$6EBQ3]1!;"K(' M
+-?MB+Z5\$%&Y@YABC!7.>&A=DN%B%,THI8B?SUWP,X2F/QMR^)WP2>_7N
M6/P23E|^EE:'K^0'8K&AJ\^,P#>'7@6SWZ;Z_8!,, UUK5C!7@UT58&)8\ [22W#65 MR280[&!>TV'#VZ@S
@X=A(@\PB?%TX:'RB"#JFG MCI[5P'(X)>/E 5 MA9F0%'S7' 3<.*;"/"/Y60:V,Z389M#^A8UNKEPY093V#=
Y>[HM\!K)[HU MOL#I<54-KVSQFDQLO<+\$.%,S[-W&,YXBG;/ [&&ALFV,L289CQ@-#]JI#81\$ M,
<0IO/^9&16DQ_2C@BT* **X\$T^#0\SED1:: "T!\TP-.%SB)XN:W#RN\LZD M)NRX
!V#\C9<%;6_4'C"%H\$17HG4;N:8VM|HF1/= \$XPJ;D.XU6"\$6*8(SF@# MUP'KOR6-"(?@3;&D'S9B457U%&X-
CI<)F= ? W44GBVI1CE*UZ[\$C!P'2SG MY ;&J)F2"- \BKL#R8">%>NAT/1*,#A7-C[6;'P\J>W*
(&7@8/N\ \$WB(0: CX> MJ1'E) VQ'1,%X0R(00GH.A:0&1(-6S=7%8Y7>BZ(&H.Y
M2&R"=1USQ'T ?]HH!RC62Q:@;UZ8|MC2IR!9'! !>,^YG!(*)!0KAAT>PL0L* MM)&=UZ)[RBX@KOR H,&[%*BF
+[,J00X[=&4\$N=Z4K5'-1B0D M2!@/#, &G(=NF!1F?Y *8FF|NHWZE\$;PN-):L"1<*?
AFBPQIA>_I8A,Y(<"D*0/MVF)(60B;&L#=#"/MMA&&-+&AI:W)%A&EB3|JQ5:91Q+,2EJ)1\;A M ?
=#W^\$DAR31_)0-2EUI^I..+H+Z_1 J|B?ZB|D@);0%3CZ(IRX09*W9S9N% MRSYURILE4U\Z/40TE+.NW#
(+5CAJ1|0? \A028Y8AFB=9'&GP'.)CU_D#18G8 M);#&!,;ZSJ-X"XF2N|_ X^Y*^RKLF6M.5'ZX>04? \
&%0H\$*S7NP0!%> /C MSIF-^\$L42F! ?DQ->: .68U"(J6_U>+&< V^*VN\$K4 M)X>600C' !Q+2Q/)J@A"
4U8U)\$ (X/M0=C1Q]_4[IQ+(%\P6C/=RA7>I&JB9;F59+2MXUBF MN2Y9ZZ*B!
(\#@[KF@:5B8H,J2I|PD2AWV1B/_ \$AT.@'7&+H2=*I4 :+L\;EL[S* M65[F)'.#I>0 "D"Y(G
_R2;Q;08@Z=#H6-6\$00 PI,=1@3.!YRVX"14T/|'7 MGJ(H6_KJ*2!CH
LWAD\%39V)T*0+SJ; .BF[+R+C5R&M(Z,\$WF63*.X>#SE M*7_2>4>@HX\$X_R0 &F=H\$EN%MHIXRLBQ\6CI
=SQ1F8J5-XIDDNA0R0DM2D[P01(3)[ND0]&DP53E0_+.%01C#6^P1Z#'? M"
<"L|X8NNG9D+X_UH5&1"CU4^RP|292&(>|(.H,[")I09\$E3@%:4HL()6D)J M\83\$HS4K)\|F 6L]_C>?
4G0R,DBK'@JZ#*#4><'P3B\$E8^;(%-1.Z\$U8(/3# M5,F"0;48&0E8_@+=AQXBN7#"H!;(&G-X+X5BT:)
(44;R'#@0|Y\KR*>6=SL MT3[\;0YBG|3V#_%+K?X?^G3VJ4%0@S\;[L+?'^Y^>[&Z)X]*/=002I,/KRBK
MXB5Q:%&LYP;V8TY%T1W:<(C88*# @N--'5_%I5'+^)^0\$"1L@5,Y()I8Y'@)L BXNJU^UD* KM%*?
H|LZ1A#T8Y#^WC!KAL8 M:BA 8? +9WPQ)!?"XL^Z_@-4(-I<(%WB^ M3D%)+%0P08E E)%KE"18"V:C@Q8#-
^M<8+_90W9+-J%A\$;KV/UXTND>["KOR&HF,>9@RB| += M,KF^/B8RPN 97VDR7E;>SKY\$9_QB2UB-
S&|P,W;8S()F-C\)#)I)9-U*7F*+ M7| HAO%U*RRHPRM>0-OR:0?)> SV20B1\6J+%> .I:FE-
R!.R9T1G)07W10 M\$I;C4(D6IK@8ITVG-+F\^Y)1]W;:/V>4"B!00\E=\. *H=B1)N>+5XY
M!YHQ,884YAE,#/B;:1F&U'(E^5B4J2J+;%F3&+ M"A;-17KE7"MGSS#D)NIMI!RG!XHJLX2-A*!>0
:"P76=X(E#D@/@JHKVK+LD M&\$2"24K#>'Q7.M0E)ID@>DA!+TS=Y!-E.@>HGC6,/V7&(\$XH).
MXL1E_1IMC/F(L|;PB| %IA9PD9'E)S8<7F=3WXIM<>A&35,DL?%(?BT(S)*!G MQR2*)^(5&1Z1-5=?4=
[Q8>XXS0K"^\BHQ ") -3-F/F;[PC2C;Y@V!GD06V4E
M&:"=2AK8>' +U45C)\$U('2B|INR8D4FCT3<&Z'#B6Z4UI&>)A:Z>C2K+9FFSB M@GYDD*"GN-\$(K1E16+-
V":M)RZ*7J.BE4Q:|& M;Z;H)6=@!1| \QW..!0, M803!=4".3K7;5U@B%0J\$/% P0 JA(5C&JS1/8@ \$T62:
<6I(HJE=R%SD.)4;" MLH)&#K0@C|2X1=E^TJRH"1%!X&8 MU#AS"7NFR;) L4|U0*
(;H>BE(0_\$J(|(*=|\$PXEXXR9P,-C_ =Z#B?IS"9S M|X)ZY,W3JV.0/PG?<8*;D*/01D*W1\$"(*
B)57\$,\$L'\8S7 M@'I. "\$43;/59^ES]'*# 8ZA%NT\$7@"\$\74:(;/LHDYQ\XP((TV4)*.2YN M#FLL-H?
%@CMBN)R\|6DT*V)\$>!/G\$ E5K;/P5KZR\ (I8GP3^9CV/'&B-AEZ MUU3_PW\$5P88'.W-
FPF(G0@,Q9_/I40,S6N/#33E,KM1X*ZI1X5!&II&L MD\T('N5(Z_5/Z\$-EE,+ #JHSP8WJ2P\VO:,ZB%CI,\<7?
=R\$['T6H!&YP;+CA M2#)EB&!8\$0%W8%.YH>M@^9N00YIZA5NKI9BK:!,#^Z\$Q6@^LC03HBA@4.' :B
MCT"V7JNG)-IB0S9;+)XI%RDB51,[2W@NZ4>0/HUT1<.^M"8HXR5;6@D5F1= MG%8_5YI6, 0@=@US M[8_3
B,79DCDQZ\$S1^N/W%Y);US;3K7/4R_F[H&^N(9?|L_1WD|N'@RW9&5
MIGPJ6KUV'E)@K'|]9\$SGH)1MH70=:PY.L0G?=&B&Q5|P .MP9B \0"A3:;KN
M#H&>X(CPGAR2_(3"\$X29"D6WF3.#TL)&:"128B5-6K@4 +7(\$'\0F9"1'
MBL_8*/B\$RP_EUFA1%DMYDR6+EU*00J'4|");6Q>40_C1=2=)7+4JT_K0 MN# II5LE CC0?5X?
ZR\RV0BZ)*>0JA*XM73\$H^7W4'09G-9.1%1X8N%X6!0FB M/M:&C1"N>)"@ (N1J&:0*MI !_ FXK-IC M\$)*!
[KHFEBOYK"\,GUOVX7GN/*78/-8ZE|HTE@!%P@;3!NQDG3JF/Z9V5[^ M]>8[?>?KS4T!KCNHG_F["D\+GK.07-
=QW7D5ZXH|_B:7 R/L!F5D!R C:_0G MJKET6KB]'D_2%V>JB"4K:P(J2_+ + "1"3_0C;DT8R>;2B1FZ[#\$LJT'Q;
<.(\$ MS@|+(CJ.%V?Q\!;K"-BNBNI_LKB3,*9P 737Q" T MQ_*2Z\%QJL8,5;XS'
8S8CB&PP.#R0LB_1UX""0=A1+(P+1]"1,9=42% W0) M#C|Z/MA5P 46H0UIZL6-HT\$
43NG&HT&+1G|T(|P!0'" /2MT6 M&' ,T)'Q\$ \$ UCENX7"81A/D.#!P/INHD(@+\[|M,%HHGS+_ K/ CW";:)\$)W1
M-?G.7A(%0;4.2CM>DN+L4H;N).M5<.([W8@:YTA86E9XMHNIBL7FX+\|7G&@ M(GEQF;N@N61Y\$7|#"?S8NZ-
7"1_-,CE0A|*?>+> (S]?9R<@VM"0\$94\$0B!7 M?@@U&IJ-PC--"1_I%L*XSH5BXLXFCB4BUD"9D8DR,MTR(U.
M1P^ (V-.GS3/ M'3*P_P4B/=7ZS=K_/=6K?R>SM ""0_/?E@@:L00X@S2|-9GKY0,I^YT:K-7
MFH^5%>U=U2)0_8|""0K!#V IKA ML_2-\$8>>J G)Y("M&7J4&(%<"Y" L(F%:". +NPS<,WE <0;N-
U%E)VX[P2BW>@WR%T\$[7L2"MV M19!;8NM1>%4)(9,%J,1U.,(?HHFE1U7)N_:B* 1I:C&,HYCGUXC0"J07;,
M'())X"C'B-FR3[3;*\H|5Y1|W,J^ X2ALY=(L?6!8LI7\$L6,IAM9F=3CE1:S3 MKRQD"2-C2CL1KV49-
J9\$M22P5\SG2D3+J;V=5,2S7| %S<#Y7L0_29<"D&[8 MAE7>USJMYL9,YM9UADK,PG850B?&_#1GP

.W),IKVAU+S-?R{09U=X&+,;K(M7E%L,> ?&QS|B3DC8PR|=."W(4XK>UU0?
>,D14N|C%X^EC7G!XI8(5;2,'P?&0,XIF/5\,8'WP\$|CR M0V/@7* M+|{ 9IWJ-.##[=-KX>#WE^2*
4BC^'1H<&**=0 ;KJ4K\AS2CM" M4<40 A:CS: 'N1*:NP/ ^3Y63\$K>8 #?@7'|:,ITH<,'IT12I)0&X+^\$
MU45=DA3L'1I8IX.&\+-(-C#)D;C#6" T.;V\A<=GKI.R3P/4|D\!K; ;0%1!+4 M&BF7I7VH?ZR?8|W?"Z):21?
0E;=624F3-FI9;ZN'F597(#G*C CABQ,8"0\ M|&3!;QT'ENH&RD&1L<^(\$J&PMB;J\$Z!0K6D3|#1/;,*'E-
'',/K8*Z./!5C+ MFZD'7ZK%Y"AC ^C>I-95'+R!|3Q<'D&3>U.=?%;JA'U"4D<(1>\$=5Y3+'@(
MHTE@0C\$VH@PKI)"JA!|SXCNKPG0#R M OT|OKJ^X\|V>.L"!#B0 _3!S?>?|O
3CP_|II@>|Z:W>|X(*;>=^-)ZPH MP'H&FGC+
UF|@MMN1)MI!NJB<>;)F(<%EQ(;;%SB9'(0IL+D)_8,H1%>ER/S.<(Q(?7('0@_50&IZ:LX!?:=S)
M%V281Q>'0W"!2%2 |@1AB>N/N8?S-E.'DZ69=/BV| =C 17!; \H%A+, "XI%E
MI;Z6ZE0&+H\$S9@V'BD^3BE:2L8H0GC0:(R#;Y64*GHUE0J_@+DJE,N=FJ(:C&T"SFCC| \H@J.W M&HH?
C=H7V>U!|N\ FSE)GL-QB=@(GQ\;U|)2)/RLKGV|NI(X8;=?KY!;7*11
MJG0FG1).3@K)9PB2WC/'V&2C>P(/)'5TG)A@)?2&9\$0.5-ALV/J"%WU1_|^N MM3\,SC\TSFD+8F\$*-P0\$7RZ|
<=&@#F: "\$&\$/V,-Y6\$)%1(8GB-R%;")-I97 MX2HG@HJ70*5SX9.H!**,>'(-0=XS>+=ZZ&05Y1MDDY/U\$=-B-6
M';H&+0\$)5GP^\$="A;I/, +TQ'50% |!Z|D"/YHC!"\$1 ML\$A8.|4K3N0#8<*JZ8GZJV,6TZ3-BQJDXC84\
(\8I3029HQ/D9A<1H*lwQ&7 |?K4.L0^ .K\$Z M 84N#)^-'(\<9ESPK&*2<,I;,#|K|
<|8*SA1\$ "VL\$3@P4DX'H|)%!/:;@K*"G M&.P%M06S2.\$,*-U--\$D'=J52DL@+,QUAFN4B09;R
|H"S7:G66LW(UM@B;9 M|Y-V OM! ?WJG\$5%0=;*+YA/%J5S='VRY+;@^G|Y&BDNP\$6""\$XSIC|"F9K(
M'\$64H^:;.&L\$|.V,. -A(J*Q,002GL7@64SNT!10 NN560=KC9Q7A#U04+BC?I|R?B3#9|#EE\$.
M: 'WW.4)VFI\$B>\|L&GMP\|#>300/05%|7Y5^HP/ Y)V:C|"8E!%C/C0R)
M9(4%;ZX1>V^RYFM@C|T!)J8S.EV|5M4^SV. _7#Z^!E3J2KF5/)Q8K@B@1AA M0D6?
#F1%@2\$<6TLURZ16:B0A'MJ&30|CB@*"G-HL,LGC@\$^ P>)Z#C\9#2\
M1_H4EX|)|GF*F0W.'U"H9L>@Q*Q>=>@M-06&/;!)FF1Y:A3:AC%G:Q/08 M5D?
Q>EFIX,W;0Y&##SNQ>:W\$D/6WJFA,&S6'|'9XM(@Z.ECC 3UIR< MX"RFL(U_PAL3XPXJGU&*X#+.\$I
MD5S\YF4C%YT829I9HH%9>->2-42-981E)AJ9DQ2># !4L?6-|X,90B6#1A. ME!G*,MN%DZ&Z2D| ^67QH>0?
XJ"Y\$D+ '+3*VK/& %H?1PL*: JT.01=(=/S:2
M0&*I7IK|L8MBI69&L5(CM6NUWMQ_L5+62EL9*VVFKK1VNF55JU F%+\Q'J&K MA!4Q(>>\R H4-G1#E
)"5H3EC=BU&7%Q,E?S25N5 4)0M%A8I0*6XK/X.D(6 MR'0VAIT%T@4YI "R44BY6% N1%(.T^1BR?
1,4>Z";R,FE-HHI3PIPK2#10B(M.;<|*9VQ*#(6E0PM(.&9-L.;>@(.@H01I3I4XX1TG,9(#4>(W:DPC1)KQ|1#
MH V\$EP E@K.R\$/5!GX'S1FB-%0V7X!1IB90=.0RM6NDP%& M!W(8!*'68;\$+8CK>^%47C5^92J;=H61:
MZ4IF4W78:FP&XM"O'Q7\$86D.|(MI@VA#07L/!X IH,*\$"|,7?!U-F*?Q<Q< M!/^EXU|!|A-SHF;
(9;.P<;7&38K%F +*XM\$G7#1AEBT\,3P?V:B+/A9P&)| M/^|-07
\$N<*;^P|].OMTLXCT\|0|^DI#C5\$U.'8_@|N';RQM%|@|_8M!Z6.*3^52\$!E;?*0I./ .EC MJF\@J)"9/N=F.
|3L#-?#EUGAU3K#MSZX9\7'/ EJ\$ _;TQG04);"QU8ERXIC M>Y|.+&=NX',M?8"Z\$B,%V
|LF30E1WQ'M!E|%3H<3.-3M; G\V|+|H/WX8) M*-E64<\$X/T6R=<|+A*\$Y+|C,@HB@|LT20I?LB*/%82@C,0?
A1&8'YYM@78#2 #4'F@&QYAJ0B M|*M8#%JDG/!#B|W?^R|:7/;6)(N_%<0->X9^P:L\$J6>CRWJEQC MN|OB_?
0&"!R**(&XMD|J^_N9T%"RE2,D50QHVVTV61!,Z2)T\N3SZ)UCXY
M++HBB&,WN"UHC\$@P+1";N'5XW)5""T/T;4,(5|@G7\<61DB1#Y\ 3R/?PG*
M/#6+\$FCV1F';UD,,W\$A##Y32+7%0#&:QB^6W9;SS/'.;2ZYQEY"IRTU'N:7J
M7P',#D,CWM/7'SZ>7%P\8WK;#Q_+/BX,AZB7J*(@1N-24|K7)-D*?E,)_/;A
M'\?'7!%|0|V(F0\Y45<8L:7^4\SS/(LG6+>/G>3+;9;\$F7/B>63NP&!00^#R M@/|;\$".3@\"'8_0^#8|09?
U/D%88(@:K\H2JEB,,SF4ER|B'X3 '!F!6SDFV M,2FD#!>A!Z4#&NXL SX!C XFR%N.L_# \$A '3B_%.K?*
|K*B3^HM0)ES6:Z!^ @.1 A+#,L53\9^7:U M2()PN4C&,FY4S677U*E KZ\$,@U7)-
@1"X2!ZRL|"/|9Q5(XJ7., "4U?IKK9 M.;/ZDGD0FP@0IR!+G;ZDZ(%H-0&,\$ WE|/L5KC\$J8UN"BO@TDSL?
Z6W-*C^ M1F^AGJ3+'VM|C^5C0<>U ;>-J/, \$X1R9&P:60L&M/W0>P(J^9<\$VB|D6,- MI!@.A56. 8?RY?
8U)A5,%>*&%9YB(;%!"\$5)=78UYS1)E#6IF0F|3F!A8 M1|7(,IIRP@0K Y0 ?5_)JZ1Y%/LC=NAT&*&88;P
33?Y)N&C0.ZYM6CU\ S M>=R!7LF&=@MJ*SH2S ^@G/QE|&?%225(4|VF"YA 0*^EM=*4N\ \$R\2VM0
M'7F0"6)F.? 'LZ#4Z8M6+LDD27TD%,K:F%D@>S?>A>F*D\$#5W1'H":18 3|,'8KL-%3;B<@| M^X&6A|?
5>RKAZ&>T4/N?R J0M+.QWE/ECGS%MO: 'LH,(1H.S%QQL0')|U7@
MS.C8='(0;IC9.^U08N\U\FMCD.#2^E._@^B&.M/RR4? \$ \57=DX|=(NB)\$ZY M0\A" P4- 1\ _=#D<8#;L8J\$?
^I\$9@2IYA:C*>&)&+ #0 LMZE\$PP%*#7T,7A0 MC0('JQB1 60?A6%1)2QXNB49H281',A_TW^,7CW3/%SX#C>
(5R (/ZBBF., 'R"9;"|0?V0%|R)03 M8XT",Z',@R|PF+1\$ \ (HZMA.3;3#2CV/G\$D,.YC@!+.<)>R\K2XI)|QF ?
8PT6 M|@N8A\$G#@>ZD\$C5BI2!3Q\ PCLK6 _K6Q|?U.7QTI%'
MFWU_79/%SK2V+UNN\ V"19A^J3-. *B#:8@SKUWF' '0='Q\ ;<4UMJ-E>|%>S M/8Z< VLN,"ILU'T+(10+=>-?
G.Q >6Y0ZFZR\$IPYR9 170+J'8K9D MM0FK4 M^ Q3)D_IV(+,W\!A0WF /Q"1TLQ&(8P|F<;-9B012LI(&*"
<=>A1|#D6>@:++ M00VD ^,5W\$R+)%C^%*>T!/2CNR"11L?'1\<=>'QT>CSK^0>M1H?'1\T?V358|: ??3X_-A4
\ J+.UC_J1)(NE" P08 M3\)_ 7!BP'23(/R": -HT>BY*8DK_3R/W?AH00GHC36;0AIF;XLV2_ :T5SZU-
M|4:GQ'"/"/L*<|S*J3 ?EP4ZW=><65"|" %0A_C,HA@ M?;.%1!#HRF7<(J.Q\MV|7W|*=" LXLZX>%&UIV#:7C
M/^# MAHNG+9DRT M1@0Y5QZ.NZ\+T99-7 @TD':|(#)V*X;M:X). =Z==+>-CT;Q/#D7I'0:I>RSB
M\I=#\$9>M|^@P5&I|8PND8 @D--:982&V QT)R4J\| |!>6FLZ%U_ /XQLIR/| M1L:L1_|
|2/06WU_3YF_N1>4W2GEN-3>S6W M4 _EZ+S;7|F+&\V^UMAZYS/,RR=N*?7IP=K*R9
MWX^W,R8ZY:Y_FS,^/=W#UNQ0GKG^IS?;\$N58;6XS| \|^%65ZJL=+76"70'.AR(ML)_XYR?'6XK|FEW?A2;:Q'-
ZG)MSZI^?GPR;T\ ->3KRCT|.G@T;T|N-&8? M=E<.X.K6*)PT2|5J*?H>0_704;+|V3SOMBZ-NI,M+=B&_].Q?
WZQA48?/+('MVAB""8|?#0YS/|=G.#<|W9C1\;:NW1#)V" I)0->4UV?J|-VF=KA/!&,S",2! MB/^9?
W%7|WEC*\$C? ;='M:'G_0'+;6.SPX;V>\$.?CD|&6_0J0=G*.Z)\$0KM- M/NW+%A^D97+(J)Q?LD+X +-VU>
 (= @J/ZUR0?;*UV|1 |?>- '*K'M9EDFPR; M^2@VG+X<\ M=N^VY6Y9CV%
|AE/S/6_+|CF/|P0"\JU8"/8:4##LAW&=J_-'| "B<7VR;SAA2 MK0^T-2_/7@Y;T\^M>3I^<3Z

\$WJX+5N83P,NX7#NZ'7KHU M3\>C+6Z%85L>JA[I?~MZ[V%K'JS@Y?R! QX'>6/? ,U^_0^CX;W_)YBPGRAD
MC]!E\A;^D:AK?+2[^*/-&9 [IB^W-U]ZD!XT_6;XC%ZA,P[22CG N,)[X^8J,*]~)'";8=;5^20G_U-
V#COW'Z M?][C2/F[I01_.H=IAM_B#P3JY+S)A7S.F/A,Z>G)'HU1:X31V_AXGHT\+=#<^
MOV^Q,OT^)1A&>KD%6/12C<.:<*FR_C MMV!,06_&XLUR-?VO' [M]K;.%W[XZV?JQ)I-L:-R24T0@K]V[>(!M
BN]?%X M8_MX>&^%WVNLV/'D^SV&%0FPYJ;.*N[>50=GLYJZ)[PZ9\ M0_?<0S0GWU5SUZ%[[HX7^%
[=YW;B3\>/6C_)EMCQNB#K+6*[/S(&V#M'U_FFT;U,/=X M[W9P';EJS MU[GNL/WN!N;A7D\$8S!(3-
=RQ,"0*>S6P.4"!WP//Y;Z:.*T%_051R^&G>GG
MSCP=07@@/I)A5[;9E>/CA]V6@[R[!Y;\$WE]\$YWW:0*N_;>CT&V6EAM]_X]]-
M5T;I[RH0LC15B4<07Q5Y3^,T3"J<"8PE"/\GP2%PI68H[3:K.E[!ZY@A_Y M9R^V9> 8;M\ 'VYR3T;:-:X;-
>:.-&9\ /6]/7K7E0HM;'9[AN?+ 0=>K0@C!.. MXC*&)Z+UFE\$,ZE:#]N&[#.SW'"CG9ML?N\$!M_L-CX@S:
&+9FBYS2'5L&#CNS_M\YT9\DF/,%SW.2N#9/0[>T-\$EY31G<#61UF%17F[8%XXD'3_MUR;?I^A4_E_MZ(X<]-
]B=?:DW@UG8C@3ZZ)*IU0;-X=U)E8/4ZR!..^';AS,UG*EU(+33B[-' M?::^\$2]H]S0;ZV=2?GX
'V5\>FVL9<=K-7A.CLK:7P>C.YD+5G(Q]L\>]& MY4]&1Z=W?}B)#V/%3C"Y"@JBF'ERT!:W)/M;
[,TR5\$(4T<:Y)J:V[MGEC398XL[%9*:]UV6;5.XN./RV"N4(2F#B+0&F>S>F/' AG[BU!"KRH40JK
M<1J7,>62<870+[- /<+E/0->7G[V0I@9'CJ0S.,@.?(^S^+"[LE-4.!C8<5A_M ?
53ZS^11<#=&SNBA5+XY/CHQ/P!%KR;!F%9Y9C0IA_U?8L_5,2TT\C:\WSK
MN^M,=\$L*H4M<3[N:4\@U@U17H;M3\$/XA3D\$9X28(2F_M2DJ4/U>9P!%K[YS1A"+
(,YB'RCTU7R39\$EX^4T\$4P0U7U@:W8A1]%^Z[I:.. M6FMT=&PHJ.YT7=QKI|NZI[''.8Z=AF9GJZ?
2@PVB)V[.3_8WE:H<-"I.Z#*: M@Y8MRIS(U#V?[/GM%;HW!D\$]1G8PZ=
<"0, !LW<\$FA0G1^UJ@ZG%',=E8)^="^2Q_M-%6J\/\$70B;J#2A15^9+H:..*Y;UFK9?
WF=^V(@BJ*^=QBPQTSS^X0@_J8JSR,9>U3D%18_MIJ@*2V^!1&F*:V??V5H)]U&L!&N+0&X[R93*P"VA_SH\??
(NB'/O'T\$"@G@9_M_5D5):EZ/ S(Y0CKA0^\$ _ROB\-[(1-S_%-??:7=0!S<*)#-\$!Q4V&NX)6))K
M6I*0B2A79+071+09A;#A3KY^XE^\$ _JY@98*F*PUFLKHTF"9;.+I0&
M>5'B:.%519BE,'\$E5P840ZE[8P)09;_\$_R,'S7>0G[%Y-0=A)^R=*KY[><^^-
MFI3[G]C>Y#^Q"Q'10G1+;_'C[F\C]:3IR1>%X_4@JR&>:6L19EDL)@W<3EC_M_7_^\&)V'LL]-
VXEM_QKY4D,UII0%LWRL80S0=J][/U%1)!(<4@6K94Y"UC_ME42%E[&VBM-K)<(<MDXYS4!&18;9U=\$_"^
Z1]&:#Q= _W>YE'+JK4] ^ED;<"A?<(F)^V;]M: MB+5*X4T)C#ORK@+P]9K&(RM4C/'@NV\$"*7*%LY9%
0R8B+9^#K_L?^EH1_M^<,QP]#I%2\$AEWIT^M!E&[+8_2:3+6XL\$FB%+ZSF4X2ZV[3'YSL_M?W%NS>N!^9AD-
U27J3C! !YX)FIFYW>W,[+8YL9N0&1XJ"G_+/1X>;^."85";_M#FIH\;!YBX=#FVYW[X??
4*4.K1^&U@}#ZX>A]K1\&LOZAMT/? M3]UC\$9>AMT-?RD\$EN.-@388N#L/(]MNF47/*[-6E20\2.N&P^HZ?
T#MXT=C_M_7YML5E]Z[!N',[^ =CTQ^\$;4=S._>/1P]*2S/(VG[(!L;53\ MNJG<16]S1J-
];\$U0BD^\$4GN!A;C_ERLU<4C#T^"NU]9/_''+^](\$ _OFFBO_M;)Y[MW\OAMWIZ>Z<;=U\:=B:AR*_VL/&'_.0%?
K^0SQX0\"R+;N(D>+Y(HAS_M0N-SFEAER<"5ZW0]RV)[A\#R2W7G8#HJ'? (T?JA _/BV#_M]"I&&'%0(_O
M[G.#]=PW4,3Q<&OV,+E\U]NK92&S7F@S7E*N_ _/?N&C=GE
M13[XXP=VD;_FNSD._/30_[009#QZ^GF#&YZK[=G.#L]WIS:2]\Q\$'FON\$IN_M39.U\$,GW<N:/7VP&]MJ(0[
)WE4.SH^]<] ?0AQV]!'Mz+%_M]N)^#0GVOZ-W+\$GXW0;ZHE^Z^"ME/L%(?9JK_R2%043]F5MBIP[1!H>U=EX
MRL;*YA'2K1;A _RKQ[6;.*@,N_E(=I.,E,/=S1W8)X]QG[>V3W:[SP=IG0Q: M0??JY\$B="?L[PSH\'?
GCL_&OK^W=Q@P@E%Y0SW!N>KHQ_\[A&_*F]2ZTT.AC_M\ -WA%TY>'FYU_*/?G-
/S; >/:P^8\U'7]8K2U5S_LRLYW9?LPZ/=W2Q\@8&%=M?
XS0SK\^NQB\A/YMR]GQ%F'>85L>:%M.3@>BA9YNS=/S+;)<@TM]8*4#0\'- MG&#?:?
J*PC9"^NYT.0\$, "WR3P3_WORRU*G/J6)!Q2@;64[!A<3(D\!+;H[\ ML[/M7?W>[.:0P-]HGU_>D8]V2. ?
=SA0;5*3%3A70;)8P3?/KW800QZ _IO_M@,QW%4%<] I'/6SG/:/=X^U#@;W9RJ'T8<-
X[\GVJ)#!++D0*&%,^;FAA(\ MN;_U*OU7&SM_CU/1IP6Z&X0\MUB9?I\2C"*=0+AS%.D^*[/GH,1P&H;3L"X*
M= _KRS6&X30,I^%1G8:1? 'BSC'IGI^&X[R60'/;WZ@^B<^+U<*SCZH.+3_M&Q?
EQS*8)\$KWN'1:ALZ#_'I.>>)CD+R=C9B>^%-6V&',4BKAQY0:\UI0\$ _CU"MG605/C0K?
4U]#M>#ZJX7*L1EK<*6*9[;) MYNW[0#MFI]KE\$^:7!(M"_:3_XU44%XL6/X4IS0F^M\$K>9B(^MFBG8E'\>6/
M7]W\$43E#5^_HF-P][<[F^7C(_CHQ_?3T^/3LY..S\Z/AIU_GW5HT;CH^.+ M[I^L>M3J0Y\>GP^#>0A!G:U]U
Z")?0L1[ZJL*WK.CZ6A]NM9D^K^OV;((=M?M] M(.YT_G?5(KY7FD\$8L<:GNUM&K?
M;/[H%/OE&"WQ\=&878A/UNZM5?BR*^#VQP7T3*7D>V_MJ]OF,2WIMZS'&)WW^9B]S9=OU-=[5=?-
/VS5TCGCA0,[W5N%_ [+T;_U;&L\$ _M=N/9/DR&020+VNCUC_WAT1^[_87-V03E/
M:7<>B,1AV)AM:D8>K&/J(5_6]XSE[/6R9D:LJ]!\$[;_.B0%=GC_4]M'HCO#\$
MP7'8^>U]0&W'K6%K'NJ*>+E%5>&P*P]7Q/6PNW*0]_:A93C?I\U[>B#]'>5%UF:J@2D/
E*%7E/XS1,*IP)C"4+0SR?!(7"E9BCL%,7_MMY;R>^3Z<0_.7Y0007A\MUFW?A:
MW^04WP5AG,1E#]\$]HS6CL-.M=NQWED0Z'='^QL_@0"M_YI7[OH_3@P]9L<6J&_MQ%Y/=V8TVL/.'_.35WFW3]#
<4]3DK@V3[^W0#4A(I?S^!K8^R"H0I= \ \$NGB),AT/Q/1^*\SL@EP[K3*P>90T+VQ0@#6=J_M. %/KSM2+L_&C/E/?
EI2L,S?YZRM2Q?'V]S_M5;P;E200R6A=.'!^Y,X2XD\$K)PI+T6JG'E&5#FJ3I7#(G-R[I^O(FN%35C+(
MX1MEYCTY/SJ^[\-.?I@JMK0*55_H+Y0BX\SOCE;2DPEE^>:U,8[\$]!'%;30>J?'Q_M]?_XH>=?
B:&/) #IU_! "\$)[_# 'X:]7>1PDJ\8ZWFBLN^997/MR5P^BVBN"N4)"Q3B+0&F>S>F/
M" _AG[BU!,7M1INN42'PY:S*0=]GJ!U/0->_ M7G[V0A@'7I^>B:MWY'V>Q855H3=!]@6\ \$08+IZA?6?
R+00&5[<30RNAL'\N38_MN1CBU(,5JJ9:6%8Y#H]^UU;*0/9_<])_N-?5WSXD_IR#!MSB=J/UAF.<5S@_M;_.9! !
(94K10^XBVF&) X3M!3\$(TJ4>]F\A[!>R*00R7[HDP\5T8PV_M\$%\! =@?
1Y4<6WG\SE1)Q\$=L*T/,@[/>5\$%;6%[S(\$Y!1\!#_@QR5PG)>8"[_M<Z4@-X?E+4_Q#ZD05L%4>--
J>\$YTT^5N*7TN#-'I]C'M45"FZE]%^B[Y?D;_MU^;I"1C.FI/W+E;X?7: _?4<\$]0T,#07'FT//7%SNM:_J53EH--
Q0I<1_MJ.NX*'-R@QA_[GM%;DW!D\$]1FLD" _WV*&?-CHY.KF/TT<&S?U'2=-T&T?6"%V06WQ=/V#]
: ^:J@)ME5N6@TS)[%JQ44E+6MA%%1? _MU\$() \$X\$%;P9*_.6082=070Y=' "2^XGX%QA-<#SA\ '5ALI_L)9%9GH
MN/[S?(&^%_ZRJ/(@#>4!ZY)W09Q[_P@2D,/+Z,^J*\$G)XU%X33;D%?X3_K.(
MP6ND6W'_4UQ_FVVO"!@S=\$ _QB\%<\$7_BES3B@3U%0GMBH3NBG@WLOAN2K8Z_MX!EX:KPG8<;"6>P-JI]

/LFC"HHBN"(A+F\$A7&^I)--=UQ40AM*191>Z5%F?C MI9&7FWB7X3^KF(-#? ;#6:RNC>
'2VVD3>.*'&T"FPA6#>*MX#A7M2_L(W ML\=\JR.W?RGY9@?AERR]>HY^D?=&35G
<,\$,\$.=I!LMFA1BM!+&BK"JO!%!@ MNV Z:TT^*_P%K)HP6) T_8LU0)E_A-:&1&. GA:H"1
MPA0U4\$D(T,)K*1)\M*.')HH*R>*K-)[^E-(21CP!A_2&0AA6.;EW89#G=*1 MCXX\[(^>"J#&DW"KK?5H&Z56,
MD?]+D"PP-KX#W76RE>Z*[1+AX2N][^]/=@0GCU9I4V6U1Y.!.WY;?L.BM* ME?
G>^S0\0MG_-5CB(,;; 'D7[VN:FK3V<76'CL\$S,)14.>=M1=G; M
2YCE40%Y@SYWKO6XEPNLKR<9C!H23;H'P37*DZK(Q+?# U4*SP8?'"YS%<1I*[^% M(D;I8G@;#&G%!I
L=^1P':*93:0\.?BZ_Z&0%8H '-,)TP\$B%F0.W40WF 3# M1*5J&I?R0/%]DS,B%[6@> (RP)ZC,\$!M
M7WE)'\$PPE[B4] I;FLX42%K=C#/' +?X#80)3E>>RAOHY<: ?DQM%_7#[C3PZ M/OFA!T+3+=V_Q/^LXD@0U&N.
<7@?50'70-C[5.6G&!,\E\$0+0PX18< (9I M M)!00T)71J<6^1.HZ(VA!-2G*0(=9X/|HMU%-0?9*#AI-
XQ3NMYBK\WA14#@G M5-((^),')350P+8,QA\$Z3U] >'CR<4% M7!DV5_#>^W3YYL=?
+]|T050H27[X>'9QX5,ZU\$4N&"Y>+PPQ" B-U+P0J@, M9%2-!W&P#?X"*TXS\$;S?6LS9'[])I!?
J7.%C,'H9+KYCCALVS!)8EP4 V;"D? MY5D\B4ML-URS7#1V2G&X+Q'V8T:7Y;*3?3"RMA-
95K(J:@B280>4LSRKKCC!%,2468?5XYB3" (8992 M1<>\$E<\$X EU]WQ/2S.08E0(?CKQW:"J@Z%-\$S(SD
MEI2=BJ E],!H0J4B5L(H'%[C0*9@4D].CD <.)4.0IH)PB\V&[9 ^ SKD^JY
MA+PG)\$@*!Y)2^#JUV]UKRM08%_@+*9J/(& M=: \2F>#WE8YB""\|+WUA'\.TB >4 STA[?0?
_9^R8+TAV=LR>I DV\=S%GG ML-#A=80_*#IR1'0*&D] Y1%'B@'Q\PI&I9K#093G!_FIYP<.W4P"D9J9'**
MYZ=\$V,M,%: T?WF70G?2^(G)\&??>['RP]>^VJ^|160DGSC3<7BPDO RDE<<':P\W&IP4W">@+^0J&N\]-]
[\$Q:3* M'[[\$/TQ!G; H,ISDHWG.&YW@-!,K9CBN*?X?NCF#/(EI."" <)R2:W/[&I56
M>YE^8E%9*>%W)\\$MKZZ)7G,@*\$,RC#-'K-TV@!7/1?'BRLA"\$@KWEB""^ ID]'(N03/2).Y\$B<#-\M \RIO:C9?
4SAP'(*A MR(PR*,U'1%*"HLUZ;+Z!+V42E>2)0"(NF/YXN*,US:X9_RM#5XH.^&SA^X MTT00.D0@!+,ALZ
#BD\$, [V:6)62V(8HTR*5T(Y"OHR= MAPLPY\$P>VPGP!_,A6-)!E91@6IH8"]VG99[0%:=C)AH.;MY'CR@HV-Q2'
BP_MLG4F0K%,)ZA3X\$Z3P#0_C7[AR@]*#CVAH>!2%X, LZU2C:&5& \$EXCZW&0\ M10X=FOH?M;
4M*IPL18Z7+7JI>C:H[Z.&30EW^+"&19"/IRLE&GA-WA2(6H? M_C8^,OL+VW7B4RSPKZ/Q6?-\$PI%-JL(; '5W4?
Z M%OX)[N;XK'633)T;5W M"9= P4F=93=8+>D8N2WC%C540\EU]1 Z\$7_1J110#F0\SD#?VN?YWMFZ+W<;
MV+YWL>8W/IK6&&JN_PS_#%+?^BT9>JY[TSWK5=K8,<\$(F8(/91/1]YR".*FH MU8 5+IL\|XV#|08X^WIN", \$B
M_99=|]*Q/8IKJAKSV2#(I,/9SJ-R&_*@Z?XF=QM[8Z/7UWJ0]*_1Z^>:8^Z M<>=378'F!N.D;@*X?
0KZXJ|Q2N[T:X0408;QI.@'D55=W_\$SC0\$M=*)=>SCP MPH8\$C,|3|)?9,J0?@U9RD69\$9+S|19_V/9Q
+,%OK\$^#<2"3,RA0B*93T M0%+^H1;\$HGYZ7(Q\A1\$L\|)589..(+!Q1Q<8(R\I'"%#5)@.-?\
M\$C,1SG&AM;:W-3>I^;OKNVI/CX@++XDZH=C@W9 4=^R#ZX@3%W6\$GLRV|CYMM
M\$GC76I/+T,#6(R?,A!M"\$=C""3(T3.U#7@2.RL@AEH_JU?;\$1G1V?3Q >,0!(MZ<11N'D&1XP]7
N2D4S\$"Z=>D8K37IS9M'LSIO"SOLY=2*:)>V\$1(*,A)PHT MS[6R.' 'U-2[HD\$MLJ*:82J\$K-_.F5 M!3E&I92-
N:C MOQ|]|JZPY#&E76*?[[=>B#6EYIO/BP7.#I49(0?Y%YS'3=52%Q'@7L_L7S.F
MU7'&X0E<13\$N:6U'B&\#Q0P>*]&!ZQA.29G=|#D&L|WL018(K'I0^37I=Y-> M*I3Z@M*
A9YS3\$21N:/+###E#:)12"8%#4:Q,NC!'!0/X^+W:%-CX:[+>VU M\GRH506BY-LEBR>LQ-@P*8A[.<\$ #
[]_9<#_VQ_02NU#^NZMUVI+^8V!YH MACN(T<*7HER7?-6A*3NID%_9HD14XF/4)98N%KT[B]Z"":=JV>*
(@0CP\$BA MD\WK K0+U=Y,"|L%IE|D%*PXP|84JS|67T|J@|80Q&25W_4V>I5V85W*F#M05GV3&7N9:XNY8+-
'I?'WN8MNS0CA+*KRN8!V:CB@ M-0""!.X7?|HRGD@&IEZ.Z**!Z%F"!D(#B%* I,."I."X;ZH=&D850TF1MPU
M-08GED1PG\$),C<"VD+=B,|Y&[*M5&)(1F?YP/D DP!G#F\LJA#_-.T0H\$;& MNI)?N2|L@DR,E*-6KZ-
-2+^#L&\$ WI?_3DW@400E0\$5\$8*R|SZ/)D,K1:L MF|A0|N6D+PI"0=/:T1XVEX<@?X)QBM*PUL1D IF%
>1*CS() "7XG*1^,T9Z-2;.'T"NVA+(&K+1-% |@)\$V04PY0 M6P5P"?/?V= F:Y.&R6_DS_25"*@WH#>/
8|R|KJX)09/TF0\$;R#|1V+N&^2 M(UL%D[A*PA>:BU\$P M+6BY5*B)? "JULA(0T77%TV4-MJ=TBZR(8T
"S(\$*)(/A>C)-5>5&I.G"-+6Z0MRN|\Z0J-\$/NS DC!U#M%HO!A8-^B.B&:.#B>2'F7Y6X%\T^;
M'#=L3R4\M\^1(ONGLU/-!ORCMU7^]'S\8F\GD@)TYX;X|^&4%^;\0FR!/_ P M5Z9(!L5!,37 &\$,
<8T4(NI*6=@J|8J?7-!WT*IP;P@Z@\$XRH5!R !XRN7MFS(M914J+>2K;EV0S: ?0I.XT CSXHL0Y8UV'WY\$*
7|5RI\$C\$C&0:"9VF(<'E+)OH=V'[0G2ITP|BMGI])WB.)HA737\$G14|JP M2R_5\$E**_Y,2'"5ZAV,PS-
Z+!;N[1>_.&:;#YPI8!L079%2WB\R4Y+226\$8E#>B2/,+GX!CPV5_VF'F@M+OR)\B**49Q44F.%
MH4GVR^L|ZL8B\@+B4L(Y!//\$J09(RE#4(J,&4*0YU\H\#LM&K;=[^AOPM(:- MQQTJ\$A@R|Z#MFW"H/N708-
MB.'"(+X#C;#C=J,;>ED'Z9)L9^L-M4!VU54@
MM1/RC;G*KS!08H\$!\$7.A92,:E\$1GUH\$H8;_80JFOH+U,B=T'S>VMLCCP4?U*E^KLK0,:}RZ_"HD;@:B|Q,;J
M%&M6I]"\ OEI<%.60<%-3VE80-V>X;BH2:|0JJWQSD+A VUV#HL#.51'9JLN M%FQ>RLY^PIAS3
G&G/@2UDV+.\ (/^4AN)S630ZU*[QCB03Z6QN&! 270#Y_0(^_L!@0C M?6_R#>!TNP'D:
(P#"YH"W.AHV1A+@KUD_Z/5Z#9 MX(P0?XI3FCS|Z)4\3,+-&&)M=|CHY4GW1\='H\Z_KWK4:'QT?-
'|DU6/60WWT^/S;S>HD|6/H0:HLF9WZ>'; MT3V7(W-3>/|^M8'Z6*CKK#>K7/-=>|>|^1;^HW.P& (R0\$K(\S?
UAE|L'U> MNSWN=[| F|>!0[UW=E\6HB49M!|8L|';9>CLZ?U=+?#) U P?9+ M #X8=+;UL+;M4N].|MC;
<,J|>.<;S0K)0:;H3HNB+|V:V|/QJ7|IR-GYVGRGB ML=AJJMM?&5V'>!"T@Q*TT=@?CTX?7-
>=:7,1'0K=;*9^'B[B7<>F_]UFCD M'Y^NBW_+?=Y9XIL\$VOD<>[.4]B>T>G%YB?_&^W,H|?
&WIG,V#U/_J879@|E MZ|1 \>+L\$*V71[XQ%^=;JN/#NN[WNK90#=2JUB+\$]!!!8AKPTK\S(^#E^3X*
M@6T6RGVDW0|;|Q.|8*A0DENG(DQ_0).QVW5G^U|;WF:0:;4? M9.#_JNX>AR:CC*(_JR(.0T_>#
(>_U^%W|K>PHCQ=^'|4[BJ[N.^!0YXN6 MDX?0Y);+GCG5<(+T6^0ZBC2)J|]-
@#AYW.,*^1/N:V=!MLQ[4F|1(IY0X30Z0@G0BQ@!4;?-N\$E&BN+I!L#?U&.\2 M22UA-
9\$^72W2;F?'#G&^BRB_6"W*WV^1^L50I-Z#L3P: OPM[2N;SPL^I! M&TEM0>?4X5V_@^:H4=!BZ=84^V;A
MJPTEE>?053U0/"GLVL7=HZT!ZK;[K'=)U\SIZBL6%;)@\ (X-J0550?";MS)_R_G=S16,N%3/:#PX%&?
7:R^30F=;9 MY;565;W|BA2CZ A&<1%61:\$+NZA@-'?|5Z29;?>N<\;B*X?.6F2-M3"JJ7I% MI#?K20T
'Q/):JZ0%J0S0|&|HRN./+SR,DTKHNM&\@C,7;_+P,88'3_0SVX M+VXM%UZU8/9RU13=NMMWBV6/
PMIJ!*N0;31#>PG47.R|L B\10D45ML5_Z07E\$U\72_-;+JL@%;IF+G!L5,?|0*^CZCT59 M1;\$L9,EV%#
(8I!62R%)3'M|99&P!\$>0Z2NEDSF^Q.P,;@:P-1:VG89W@BM2F M)K@R?

(J%GP[\+ME+E2.+G^6WCN\$Z1^]I(,%*D43(-&=E? MZ^8]S-@[\.?+^MT+FA)+9PE&*X ^)_0<;0I3IJ%].<M^95JNC\BYIO\7#)*U M!%X!9S4A0F+-007JGFH%\0[%*2NPCQ5HF=%X\GQLSIO&T8&;)TD;88RI-^@E M:UW:9\$Q1-Y" FN\H+8\=*V#9=0,(NFN(8U-A^HU[\+LR8!B&NE0V*79?P[Y,005@=T&2XK\$Q)[PT%0(!+,-#CFW MGJ "F<C\Z>JF?(GJU^0A-\$,]/?<%E@P7-G38>4N\$V)00Q2XCT8R^-/B:^(DL@ M%*ZB\YH\$] [6^V+!7L]4+!^5 T?-KYG,[[A0:66HB\YRI1IV96H?9>E).[VK= M&' M=H@U,+U;QYKQ\B>]AR8^LE[FRAH:2R^)OZ!Y56;M' C;#790JD:IGAVO M5JK;^(1G/PRJ^+&KXC;;TIZ_- \O/W\|VWK]'VNW1^-6'S _]]J/W_K=W'S[^ M>OGY_8??[A\9N.AY9&- TY/T"/F7"#K]'Z\|WOLP\RB&C^XM1V!B;B1DB9.PM MAHB0++EFKS:AV2WL[. 2B MFQZ: [A9I^(L=E.^3.C44E+!="H4[PA)#F\$;GJ* MMT@I87TB0&Z\CXUW _;9G*YPK !%]D:2;HLF:RK,OZ:I05KKH7@\$%)&!A+C M,\$F7-6=PZ'+S4U/S-- 0#L2IP]0)I!^RV+"E460IM0_3A XF 7\LT'?:4+GZ MMDLD-]4;<^1X)09PF%*LP"-)L\$D _;*73U,-SOMXU'? 3]0E\$<6WL;T9S;4W M)ZU[T]\HGD0=GMUA]V;4:Y0,3@R;.F9>J(,GVWY%/92!\$ %\#V3Y1RTSHH<7F M\^N=* [HZERYKS7\Y09N^K# DB@401Z4#@\EQ(=\$6)>+F^01YV>4HX4>%D":[M%BGUM-;\$WX\$H &<1D)MDQ M+UX5;F=D5K\ (CZ^]*B;8)M .!3T+DYMJ940W4E3#-M\MFU^0.)V**>"/0 A2 M-ZD\$;4TS>ZG^C0;'/FFD? GG];3RMN?7ZY-E^TAIM*5PVCF,ENP7ZDK-(&\=VA^)-F6;MAENT9U+; M9MMS4.<5LMCYA]@30F MG!# :.I:87=X HOBUP0348#\$@WXRH0;1H+;PBA\V M>-<;K,]F1\-\$MY-\$^X:;]LD-PEG,CV8 3GLW&OUW- %K55HON\&.)]9E%'Z,! MU;*8R/VZ)024D10^E?.\$>&KD=I^I7^I M\&Z5ZE9!Y%T7@H1TK- 0^KCH!F^K(\$15;!VP:QYVCB/CC*.9-%^DKC5/9RFD)I<.<0JT]]N@TIA\!PI>2QM2Z;E#J^VY M%0=)W96D? K0;A\$(4M\?(M65TSZIK@ZK4&VQZY4R4-+;70AG! ^;J*B9G4KH^ M-<6 %1L^@&PH4IYT2Y;R. (:.\$7%4@1EF^"3C(>Y%9I]@#G>U%GJ*M*)JNF^X M<]SR3-I (0@<=A[.D\$]I3]P.\Q4A M(X^?"0. MNXX]=^)#.!I_Q;&^3:^X02YV;M\(#=]+LW% 78-197)+M4PL\NWLND(QR(S MNJY-AMW;U> [97I0DLXDN=@.\8^TI1^<=>2H,N43 Y4K%5M6 ;7"#5#;+!T;)QL[K? MS7.IZ[-!?G8<(0X\0\]?7L>3& (0IG*4PM*NEJ30A^"C?_K;W*7@',W PP\$9P M?0D*WL2E32R00#"5\$>0USQ C\H18Q3&^LZEY;#0N_8P)- SFI@B;;.\$IHY-) M%E UNG6SMJAW2S;;;.BZ\$.P03<0;L.: [M14=Z0^X'2FIB[7Q.;E%MRJ4UK\$ MVX;5(\$]A1[MJ_*5^X:5NU<9LZNQ1;3K^V\D.TK@K;<10&[K7/T-%?X]M4R/<'GAP- B/0>C.4!89"#,KK;U0@7E%BR.BM M_@YJ)DQ-8ZUUEL- STEI\I^"IGF3!'T=I^RHF*]@HIMD70GIA0",^1RS\$S9@& M9*@OZ;BT>E(.XWEE\FLM\$ M-A)EJF0,Q;R;*/SS8/'L.8Q^NZ@YJX*BY,*71478';]/F/6&+50R04>YT<;0 M#245P50)3E:A0Q;\$2YT99YJ0()0X0Z_U'#^.DX1:1[6<]^YQ\$SAFY2A1Y<\$@ MO\D0R5K\]9(>6H!IGP3Y*J4,VJ_0? = 3\F#_80,&@7].,I(_9'1?X/^!U/E M8%@%#;UKDV\SCL:* [(QPS>PY,3,HZ%W;!R;02F%.DEC".WI""16G3^M-'Q/, M3M,^Q4Q.)F XKQ#D^V[A*H1!"UN ^#/\72#A\$ _DIR* <*\G F);KV8:7FVDPC M,YCG#0ZJ&GU4@Y&*3 ']]L>#V*[(MELUA^W:L=6\$UB.-"0Q<9&.VNBK9DX.@@ M,X]\QD6VKNP:E0>\$I68^R+Y#B+<.\0&H\]:GP\NVY;7ZU7R6U/6ZS3<>KM- M?P@^7;36E49^RAC\$16(6XS] F2(I&=(;U9'^FM+,T87=L:;;04-RD\=769Y5 M!0BR2B5FY-P=&!'"+@EPG39R,F<6TTDJ MT^VDT02F68- !S1.R5,)G&,'8\^-8;L+\\$UA14-'B#A*^PDWU5@L#GX\O E: M!0XS+F8,/Q4XA\9=A<'Z3B0NV2#P56NA.^K028HMTI!01/,X^B8-<51A\$<, MBV;FQJ8B060QUH:M9VD^D2S\$B\$.T,/ \$E9Q0&H..#Y9^M:#%>2T1 %\$)1H;Z, MF9<&[.U\$,;VG(\$" (J+@4)*0.Q.C@1\$N%.JY QV>1 RX!^[?;\$\BXGC72CK-C! MBV)AA QA^#KP>^L(XX)\$U4X*[^<\"R)? (W@7<(ZPD\$54J)N9J.<9FW^LW0<< M&@H=*VPB4-*SJU^#M;0] =FK%[\&AZ^~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

!.,, #0XLI*6304<[>&EP8/N5#6&830#"<^))!D9M1@P>"I22# M4B=\$Q\$K3+!IK&HKZZ?/G?
W>XFJJ%_P[R;7H%80AZU%L0)%0,?]+7(02&63U
M"VL!BX\$Q4[V"4PTC23\$*F3A."P,A<3496=,R)\UE6N^RJ?/@%!,<1T=BD,#4T_?+%2:+ ZA2G2J!RVG.0\$Z!
(&/-#7-4D^XZD6I)B6F"2,Q^#4\$[GLZ"U+ MV0FQ2D=AT[0;:@GG2TXBE"POVRB;X?LI@T6F_\&S>NFANG& MNP?
R?Y?SWRI#)B>=L!JWEZ!W(IBQ MX2KWZ^";>H9M(YP"MQSCJ9%(U%6610P5)&P_"/\$5=99ABH/>QS_ZOX06(--A
MD;K2SZ_8|37 PN.M74-=:ABE5=HWA!X3T80CD8FFF!&UIK+YJY"RW^KO^_X MZ&+ #U!5G8E
T>CICUF@8!'!IGOK^X_#FORZHWWWJ[M]:YMQWNF=5R10.A7 M"NR>C-
@7C7WW[)K[*Z3U6=0\L)4UF&-.R86FG+(V4;,:=<,+0C3Y%>AN+- \$B MS:UKH9QB& L=I5P-
2BJPLKVW6!8%8:&UL.44:X\$3X1E801J)*;5P" M?>(J+>5>0DGWL3>(U!BYVAMK@VPIC,Y4UA/P!GAO;TO+
[F^0S'E77<:09K1I MQM,AS=B#L3RV-.M7 [6\$'U3!S/@3?L&4UJ034IK [;:!E@;7Y_4!THZ>]]H>
M_JY;WN\3I*,0YT: "'>D=Y*JK\C8::&4,41!>D]^EWY%@WT6,M!_Q[% AF'+0.0C!I;D),H+ _\\$ /G=S8N8MEX
MPC@/JWE!.:CBIX\$,?> \7P) \G(%W6V+^&,\$5X'C"ON17IHLWX200^ ?+ #M@ M @.I4#92*8+"EB
[_F*5,IXJRYUP+E8=P2Z":< &(I\4\$?%?<^*I%eH"/F, M:1(N,0&P=)L_(C_"09EIJ.&!
<1?/"*V6RDUB2:#X13G;U05Z:M!R'8E9)BX M1MHK|B0HG< GW;U06-;0"4#%\$'%XRG@IH\$U>X|2C/>*##57T8.
<\$ /CMF M"UL^|W(;"(,XA0SH8I -)@)0S"EA0@B0853U3!3F>XP(K|CC'K:Y"Q*,(EKJ_M,PP8/TX,H07I3S-5E
M#%#66(3W)*QT+\$F)5)^(IB;UP=Y"X(9SH|;N48>(+9ADUTSEJY^E;:>?T3M(Q MQ/V\p?8CTJT
A[=L*/S.L<=,'D90" P;S F|P" _EXL4F'[8;:1UE&FF!NY M40H|;=?V^_0X*C&YS<6C>5->JICN^N23G.
MAXHXC.1)*W?5-:GFNM.WUBY>QJ4E^MJ8,)=ZOB26.2\$+%!H(A%;AJV;J76I
M(R04;H>Y600M[!Y&|J+9|\ZM2G8>U(-CM&5,R02/:07J(8|.PR1Q.50Z LR/ M!5" I G'S7P<,[GN/'NEZ
2\$6F#8P"5]4V*CK= *RP M./#-V7R1-B9T&8#-0C@T+|B0K58|E="> \T\$Y8IP|!-|%\";N5.75EK@\$@C
M.K:P|^"EH8) 8X.>8?JC7^HXQP M258\$@;|(&4 4!A6 FD-\#)[FVK1\^Z^U_ '4ZRQH;&N2.G6,|6>Z6Z^X-
_BHF9|V|ITGU\IU#G@|C5Y@42.=U-96DL0J9RPG^AF29
MG\$ _002G24#)7(AH0;\$"CIX=NOTITD3DU2)|D8BGZ!MS-N&|.=,/00N9^9CZS M^6A7YNN\$.R*!|\)68M#BQ?
LU\|Y X;>W;ZHZUNL,>Y^94A!6LX65:N)*F160K MTS93F!"\$<>U64%C,<[(T=>(-K ;&2HB4E P?BYQX_>\$?
| | | |' |WT", UC\,C M|Y-4HW.-NS!8TON190>60^)V06":@V;*A<* \$7D(=%+E) B_6#8R0NP<|'S<
MI52PT0<*7I.V3=8YXJHTV/T0Q-IIE)1-KLM.4F4\$;,N B*%E9B":CHSC'1^K
M|CZ4|1YV#7XF# 'F)UM=XK5H+2MNZLNN4U5!)")|B"U|CK*K!) -? (#.M0Q.[
MXN+09]0\AA4U#BNPY11+*6",A>-9Y5!\$H"E0\$>0RLX(.5UZ'40(?E=/OZX+ M49 @\XPX)F"<6:YTFRJ4069|
BYT")AN-*RP(568! RJX%M^@#L8N,/9 '7H MP5@&|RAVYPA\$YCRP@P>[K0XZY40'?R_3'LIY0ADGRX7C6;NJ++
(%&_66TZ6 MZY2?75&74T9@|X;B%V\QITV_>I;2+L(JUKHR1798=#H7*W;BK#.R%FHIB'J
M,\$EQY/::6,I6!0'UQ=Y^NT.4U4E9U>4T=?\$><<4/)I*Q#2+5KCMU@F\MT;+ MW+7^":
|YK\$LQ5JTND\A;/B,1V"DELB(3IJ'NZLBFA =W\$PX-+\$AL>%R[8*\$ MG)Y&0<"\OJ/%<3&ZF@V*Z,'&U%]-
SD'+'+(WJ;.:0J9|R(MM&17ZV#;F5D52 M)LILT;53*,.:=[6/L>F8|#@F9Z!F*I#+=:B,J3WVH2R
8\$NKL |K_3Z'@M= MJGYW?KWW3GRKEB-@D!' '4VGX3":J|TFJ5BC2MTU\$S0&/NJ==\X7SJZY &X?5 MA?
+90,GPH/&|L\$Z#HE!K7IHKCLI*T^L98AS<8FA<\$+UZJ;';6T-IYR,;.'EQ M*)')40^9NH!'E_%/J8FZG# ?
>3QF6+;.\$N|;40MP1,3|QPR|+,M#BE<&,3'I M0#9Q3U0*++D8#&Q(3
N8H7ZI|I'7\7 |R+&W@60.,09<4 1(:\39-L?D|'-@ M*AHMU|6_ACN;FSHG5 !X^Y3=G+
(6P=YR/0,I0:%JSJ8"F3K|0BJCA..6VZ>XP,6:546=H%9I66,?"T5&.V16Z_YD-R|6|:ER^K=VSK24N\$ _? M|]=?
|6Z|+;1&/)A05BN\$H6!;K-D6;:C-U;%.Z*VK!8(V\0G5R/DEIDP0>0Q& M@&PI0Z|1PJ/-
0<'0%_U5C8N3'U7&,9*BD<%R!RC^Y'K&30B;ERAQI%>>XAU M63L7">EZ'LL^54WLZ05?S|/\@EV;
(V58_408SH1<,*121+N\$H01Z6?KRU3Z!#EZUY&Z4#E>96Y<7.<8-V|^ M0,G?Z@P<@X?
%S&L;V29Y+K:UCK=FN<%DU;J/MQT|0P;:NE&K74)NK"2<'L%2 MCE@/|,GVK&1<8T@,;BU:(GWP6AV./-
U;F9;%=A7S.',NVYMT12|\50)T)?M8 MQQW1@Z6|/:F';6\IBR4I(-
" \)55=,8FP0|RRPW#A>VFCL1YZ+)S^>K02B74 M&V.LN'0#3>XL=?+. +RP%W^K?
U|BC#&63|_9\MEEERD_\$QES+MKHGP6_H\$B M6!FOT/I)64;11I'RLV>'!|"%=?-S*^\$8)7)1,#&7*EHF5
MITO*VGGZE03598UUNI:87|5BED_8S:AG'#KLYY&A;NY&T.'=IEL-E&B'E2Z@;D4_5D/:J#L6,9;1&'T;
Q/M/APVA759A.:?H"C;DMDT\$.M\T#S0|F M>?U|L"1|USN0F|=?"+.W#|^P=2PAA\$*T4%<(00;:
<*I;3RTA8=KE?UA'CI! M.RC2^%I&.F"+=7|DHB11M1@T MFHU584DEX5G_-
RXM!A0KMK#V@X0QB;>Z#''EP" P7@F;J6KTM!FC!>W-'?(7-M*JPY"
(&DN%G8|2'PI155H|64UJ)Q;HQ\,DHN5WH=C,7J/'4Z\$|JH7/,^D#LL M7E/\|/TESL^'0'D/00)}),
[9R"*M5\L)ZN.M&;:C|BAW-N7ZJ)8)^&) C0R ME8WK46N5SCKY0EL^M;"/D|B8U0%4|7Y|K'I=?=01(%
(J66ZQ5L50UJ@J-Q1C ML51.,I.;C+GI|V+!"Z;#CR#|NVQWLC8,=.I7^\$%&P60S0J=M4ZTFP/1>1-/
M;:MHJ|6H#"!.C2\$|P=MD917/TGU!5Y|#?6_0\$|Q74L,5YCDK"2K0V9"S#2|0
MM4;X&JD_VFR'ILYA(I|K6AQ'5SFXD2.W (WYZ9N|4YF7N19J%_H (1!1D\$L#7NSH[W!;[4:U<7!
MA0:G6Q,|6%0%7@,^8:^IC00X|E\$>W'0|T;VG5:3+5X?|W=G^ZAX%|@%SC&FJ M"
FN6#5WI01KW2>1L"7/B/S(1@ S \ ;=0&A=I&B8V!*J<14/W,|D"IJUEC% MF-X(H7>8:D6K%BFSD2LSMM M
+*B?&ZUJ+;WW&|NY.89-F9'&T. !TK^(: 1T52PZEFM\$8+N7T\$@CG6V3=\ MDS?-^Q&41!GTPB>!"Y/8#
MU%&AT\$D7Z7_A|"'=F#U\#2DR|A'JSU,[TJ+09(P80 I=P-1A5A.(2Y%V%8<0N M3U)J(RDZ\F+Z+P5QWH2^_
_V VP97RW9+DM<&_1"2U;:&=\$YMK-' :XTEV<1 M3Z&40)*=1V@CVDNB9"3>'(:/NRV/3;6D2;:QAJ+MM9K6J
Y00S^9R>X,QS\$; M087NHMSJ?'!1AERXS3Z*[J7PN\B)-=F(-+6J|?+E%|3&-TX.*0<#H<9A1.
MBMZ^3M=#KRF%Z\$.LY0X,^,W%L+@U7<==1Z;!'LX)&@=&+MT19V\$ZL=X&|ET/Z+/)L%;^,+> M:QH@AJ
E67I%1HID+2R":UW!A7|+ #,785DZ))U9M4PTZP;V0G0H\;SJS(U4ELY:27LSP|Z' M;3&
<>Z3IS1YF(/|SJXL7F2DY1\STU2\=0>P=TT1XKL;|.V%3"H/S74|FK]-R M%LV4G+DJ@JXNERV+RUSQG
9M0I@NLXVZF-ACQ#-SC_?06,\$")EX,@(D>C.71 M " ;N20>V/C.GT|125T5*S!0HF?0:E!K5\$>|15|5="_
:_^6"N%DB11JRB6_U\$ M*\$C;")|+:-JT(N5_S9RXQHM1+!0=,;) MG\$13?RNJR?TR<9D7XU9VRU<\$^TZ+:-26-
%*=^EK4:S5_ARSDYCU,HR M^U"&05';5'.)G/Y0Y,=T5U1;2B/=-"I'J?E\$)8"ZH,\$5' (%Z8!7#>0DTE:8
MI|T@,Q|C"AP#AZPAL"JT)\R^E.V-9M)^XENLP:3PH6J6.ME'V?)/V|C"RM>G M:M6/!:-

J#%UF.RG\1E8DK:=,M&\A\9D!FL% MV\$D2:#{<' ,?V]-Y40\$JA=ZI9,6/:G-7D2!5?6('8E)"LB&8G"YQX(88T
M.?#>Z#; '0>2\$?FP+#PSK)ZTR@AG, "ZDM\$/-1-J[<'X:E#RBU :LX5,XZ\2S2< MFNJR1Q1R1Y(LWY"W")W?
N1)59AW7:6, (N0JYM;#10T\$,D"%0Y\$?{<')VM+ M>\ BRRACWP7EJM4'.0P9440Q'T'C9<[V9*F_P<.I*6
P=F+-DP7Q@;,-]C9T, M\RS&/K4P! N0\80R:HV3\$5P*6-/4>1Q(FK&S
MM#8A70>1=)^I#%, 20X&APP5HQYG^4+Q9YT>UA[G,3YDYFWQB MZDD/1SY,1(".)C+43(5_J^#L-
-/PHP^F ^!X2* 58P-4J='5&(" ^!7K1I&RW MMP09GX.2^08ZN\$!B#7+Y=*D=/7<7RI@6#M14+MT2-
/N>R0,LAZ'BWFL/6\A0XJ1HDVF^HK[];A^NT2Q9JLN;^:U^>K[G:MLP) MGH&<6+&-
^LDN6ZTMLNHNMIx@_A7EEJ?>J\>S-JN)H'L] \$&E=4E1:EJ%2]P M4%+KTM=, (+>ZM)/'PZYJ?
Y3NK3U[I2<9ZM9W!K?RNV1F]C^-]0E>B/?+TU-L['2:RZ%BR2A MJ&BP(.8N0^@JT >GDUT"A[I.?A;%P55*
<5BZ1]N\$ 99C(U)B0**[8.^+RZEN M7_) ;=HV6=N9=.DV 0=)M 6!\, "; M((\ \$ _BRJ,%S3.'K-(R)%QC,436?
T\$'ND;%<[\XL) 2P11 ",B-2 R(T^\$/= M?E:I7=B&IW7(:INL]L60U>[!6!Y-5GL]G^JZ2U*,5:-
B=0Q#YQHHM4*ML;MO M4*\%?*<^:\$A+Y0+ZD5?Y.M(9?T-6&-Q-ZH\ \$K_U+"OU/D@;4F?*N
M\$)F[FM\ \AP=M\$A2G&#)YA'0S5!*,K T;3>*W:YEXR9SKLS-6"=2 VS)]<< MX+?99"Y2-^UA&QY3RZQFIY\
^8Z:UXI?#XER3IAAA5QIH1G;IA[;**)MG<#BU18W\!FBB-\ M HESG<:JR0JVI*Q5#6"L(@8PAQL'KA2Q)%-&>\$5
W;10QW>E\$H.<70&=- @ M] \W(([/W'#95I D?.WK!2>-%*VZ@A,W8R7U2=4-2HCQ:R76W4'##RK9D/P]B
M\IE!A>FW4*X>:V081YBE-2H,\/YKQ*!PUD+-84[P8E &4=,%-I0B\$"T@?-&
MG[^K/)]@[%VGH&/ 6[GV@0D4ZTWH\%/(/ZEM)>SZ<8)@X*RVKC8C4TT1P / MM 0F79.
([D%\NL\ .K\$PRPP!28J1!2P [;QNC#47R:H>'W;N/W4RHZR;=#S/(XH&RZ)7S[>0>>TE>Q"] ;HNZB]
MJW.Q'UKZJ,JNA?.425ZQ5S&F]JR;Z^*2/\$0@J73NS@S+5:[^&DS."]S
MG4CH#')I7(6D.H2E<((7\$EZ\52[/#DI^>\<=3F?S8BA)XC:RY:HURE^JJ)6 MY0?:TO#W3+EP0"?DW\$?
60X& ;)%I,1W(ZC=:1QB+0@MCC9+?]?62>DHY^+= (M3NRD8#E@K+ZJL"J5MOW@#8N,,H6V4N"2E*>A(/SW?
QN='[\Z.28>PE-60)'W MY/3T84'LTxD (+*UF>5BU)-H7\14;+VGJ,\2#F0-+K^HY.W* =7"H[30Y1D
M(N9980F1Y"=NN#14#SD*6IZK;4 \-W*N& Z@5G4NZH%MMT+(0
MG#==ZM)D'T8\=WQV@FM7)>4YL#J3#R8^9LM,%Y%LIJT&\$G MBL\$J-:A2ESI8>S9=MOJPH[L\G]*S[CM=-
JQV!L?8A&\$MQX@FTB<[)+-2>74E%D(:?B MN*,7.=AR+ZD"(U\$Q6!SHN;6B8D&K!Q%XLWPNA]U[D-
TCSA;\=RBH[!B\$!@;> M1[=T:HIZ@G,)!-Y XIP+C8 M&5% &\$&E' S-J9!F5"EZYQ02I4P-
"3<^N>*U',#=#Y^WN;1-&*;:XD=Y8& M5]8(:48)&0NWKQ\$,PH85*"?)L%N[0 .4L.-, '?H0+E-
<R!RP<;) \$A#2Q!,XK[BI*#0B+U] [/WCL][^NV+J,6T&=U M(Z\N3*D+04*J:L)UN8^R]*!1G C-4@;3S,
(OLKX^WHV9+?(AI S2/L%E5[96 MWRZ][U+K.*Q.AF.X@QF3P @.G70#M<>\$D\ 1#+.0>[#]G7>4P;4R&4#EH7
G)6C-IFJB0\6%44+[OCANY""!K'+A3 ME6!G7EL7IO_51XBD47>)/CHAJ;[<65=82V"\$QEU@5 ,6J;-!<\H-
##8-MP M\PL-DU3-QM-5FE 9 /*H..T9J;H:YNRW=Y\0,T5C]#Y&\5"0"]\$A]J\9 #6[MNE09HNSX+Z2JB:
A0V(WVT&T>2_B#P?3=L<;D\1@E0[AQ%TM,M?Q6YBP[U8G
MP[^2+..!6P*B'[9B9UM1,\$E/H89DQX[EW2VY(6L5[5FX>JWM;J)3L/2(PXMT M(:#
[0_2:V9"/U'PA!P:L^BH/9\2B1&T32L'=,L,E F@%^4WNPk#3N]II'9U M,B:I@IZIZ(I[=<"[A.MTN, ?8@?
0_43&4Y1[0UML3QEU4LFUA9\661(+5]=P M/AY@=]SS(3B4TSH#]C076Z
0Q&7\$E]=DP5B"*8^P/+C@EN(PP\$5&R)] MZI66@EG S<.1;- \ \$G:YR#,3I]I?2?-P\$.! :3[(\SVX4-
6S,40/..: 11\B;\$ M&.Z; []%C'967+!WA; %6W\$ZS\$(OM?J*<\$LB9,?6K11W,!B0C*+5"= /72K\$!
MUJEQ(98L/F73#RYN [DISZ8M=#B:L3Q'.A79>XJ^3(,J*6NIY"! .I('(@M@] MD7!S(:6)"H640%'\$5W)@2U=?
F5)8[/M%W)0AD00,V38K.AIY0X^T KTZ MFVVV^947YEE1/)>A4FA3&X8.U(1A1.?KJ#T*S89N
=,%E\X>KY)GJH00 M^#J=2,\$=:(9CPCZD%HUG\$DCETZ,IPV*7V'9#JZ7'+&D;\$0+P@QG\$.2:)^!8G\NA
YN7LTPM8F8F"\5\$*"AQ 45(YTNL0_04F%BIH.:8"K:0+"S0X ML"2&*S&B%
(CL*WTSS=+G<\$ZI92+JSRT<BQZ4DG!RMK0@5I&D-/B>I@'4B IOG9843F9>R1GEAA"-FN1BM-IO:_6+--!7-
[:ZPF1]7,R0 MM5[0/!]*F0CGI66,J@LAI0PG-^>H%-#B1J4#URX2ITN7NI)8\;EUM;:J
M7*ELD2\$6,#2W'CAZ,&#!\$ \VYRYR\ . \IT41*A0X=*(:S#4IH"H6>)U)7?S,
M#*1%_H\LD_"#0W_)D3;2MR0@\$0+;I9 YEELLJNUQYM@/1(LX5P&V]!0TU,PZ MV[GHI=*F+F^W2EWKQ+E#C\$*F?
5]'-S4U;%QH?PUQ(QCG0%+- (Z?,\Y'X! GF?7T=* M,E5['>99JYGF]=1'< M7=+V@\$XT]<IF'=VV\$?
@&Q@7D"H:F?+>H>/D]=""5JVG@-X?)EUN^32ZZH+- M*KYJ/=LPSZZT:[TU]:N-C>E7SNWW)UB7\72Y/QHCYB+
(: :4D#5! '8DW%!ZU MAHOSZ#E3J'8;K"1K7S4\$E9LE07^-70&I)C0,N\$2ZXQXB@RSY+;JJC F2[@FS
M>%\$(0:#F6;(:C8H- 3BP[\$0,1! ;OK]*/H) YL*]A,(@@0!#M,;"B\$S6CN#/ MZ"R)_A0?
2YB9=']I+=0.*Z;:YM6]-MU-B,0\YN 13CB6-B2"JVNJVHI2R,R M"\DE NO!-
/.) ;M.B!Q<*U13Q!Z\;%L*GUKS(4HIU MC_ ^, '-43FW3?6(\$#@J3I""A[?@7?-"J)>NE:
[.K0[77!=K!WGND%+3)/LIC!M MN#J\T\XL\WI ,;J)KX5VF?-CZ8KE0L)!<.V"? .GVBj#UU0V,W*T@5 W2([M&
MC4_DI 95B-+Z]=_A'Z>T&_X=M<^0)]V\ '8S[T@IN9GI8?MAZK\$X"D[R]1?8
MQFR_A8R/;#HMJ"F8(,HQQ&GGH(Q)X4 CGJJJCJR,D\$],;3_S07]:ORZF:B/NXF:DMBHJ M8C7\$@/
.G#" *:}@D8@)OI.XXH: J_E MW+ %N&B,'N; >\$EQ34AH->!/ \Q\G6[YGGPE5(I8(=4AJ07G_CD].C4T\$@^?50E
MF6?^_8PH;[%91&-T3!"&?.N:*Y& X", [2#-WPUH]=2+C[KQ-AS<>6:ABW:N4
M)L00TR5")HG9T=G=LCV/Q4,OH_00]60-&LDMK,^83@47BP,@D;>&[C4B9GG M9.1+ \P]N9J*7T?
3S0^KW,BNIUY('"+28DCQY:Y./WR9] &M!4!IV!CIR_9G6-^=WV5?MC?6S: MN^RCI8;[J.B0H0!
<.@VQT0RDUB"OZSP W-[%Y# +A-0M;B1LSJ]!"-VF@T*M>][5?TXJ;C 8("KJ<4-,\$RADKS(E&EI V6R0E%QY(B
M6G5"31!-=.\ \$X="L<[+-^/C =3#\<;HP2!JQQ/+L M&PUTZF5@ZEN)%[2&'8X65E;%R]R"G)09& 7CZW
[IL#HJZVZK MTH:"VZ3#X]]\^MUW@X-QR>>5[5SV,XAW52 [7?JXBX/\$/Z0.PIBV\$-+MVI<= M
=0[]6>50T4D]8UL3IL+I;; '0"UV',TV4K#HUQCUO '#""G246HTCS/?:/2?
MK*F\$7A\V#_8"U9;V!LI6,^TA"VRSP*,A"]R#L7P?66!RV0MNO8MQ:=' /OBY* M-8KZ ['W[LV1&\?VX%?IV(B-
D'X!TIJ1WX[8""HTML: ^8\UJI/7?8>;:A <- M] 70Y+0_5:>?%16_2_Y\J74NFK (0_);CSJD96/D^?
@M\$*IN#LP*7RY G\J M " W0&63:'D)OFF:@-Q:+5(2+\QV?BF?. 6\V8-S\$X[EX,L?AM%&(SHJ^ [Y* M%#?
LAV!,2R^AV2L,NVY1)C38KY*NSMAA.XK2D>4,\$R)_I(PI@40A""<>==5< MKN(C)^42K\OD'R8<7&50Y?
7U;:6K&=XV5:\2Y/5@:2)Z[N!2&['YC\$ \#B4I* M"XVWQT(RD'!_4-05,

Y1V##,8;J=BTU'ZN1>?) +2T=YS>"S7(B00\$CX?*DDP M*0B\4JU-?=J:-!PI>K#(8J.B=>Q'ZESZ "RG"0!\$>J
@BD,7V+0DA8EJSJP2@_)C\$?<=,*1!:D0P!4)V%N\$=UMTA048;_ '>NG=%J(F[G<+P4R>DS MC >TCB2GD)[!
[B:X!=XE60WH50#0NB9.Y;F./UMU"?6YBKLAFL)Q14I;PMPE9=9H6VSZ M\0X4ZM2?F"!||I3.0F
#4<]=@/)&C!.*\7AHHGQ<3X,5YZ+,(. !UII8;:=+ MPA#2;T]@!\Y-:.1DW\$-)^GC?4=R!(KB1)
(06K):,9E%G48?/ M%8\,DB-P/@.LJ/. 'GC0C [M@L.WT* ;TUZ 2NP*>P)- %MD*B"+895*\]^(
MV7\$S\$C0N<)* \/"J\)/,BJ4I_%6,13@A>C;B\$LWFM)[Y @A.45K]*0T?.,
M8,'51CD8N+!\$FICM).6007S[GKMT#@-G7_3[] L2HE35'V=Z^#WJK7-^0-;,"
M@J'C;SF,3R(:Y;09UVWE.*YF8(^/6,&'49%I:3/I/9I%1\$J62\:^60M0BCZ_)2[&K M_JJI\ C
#H1\$3\E2EDW0F&0A1YH8[,D&T*("N&0I,/KVD>Y#BFU??B/P>._S_MH1X-
%J7ME'*)>\0;:=+>2TU4T73D.G(G/DQ'6*BF7^N^B&SMW[0%B>C1E!-R4! M[RAC-V9Z=-VUA4;Q_)3_6(F..MR?
T!21'.&8LX[|V?SY%I), "OREV:VIN)BD!ZC6;\U0/2^3\$=093L|LVW?T9"AJN\U(H)WI*,)IES M"M6([22L!#M
6)]X8N,90U7W#DU[/ON?FX3RCH#M8>X.K0FCT\XRE'W:#C) Y<^6\%GZ4?1Y3 M:H]+KL[02'#0NEY@=,&-I-:1
@Q=ZAVZC-"ZKY%RPAWIG?*QOM\$21=7(M1":<='0(RUCV),KATOR(70[VZ>49^W0"SW*61CMM\$YMEV>
8LR6KG/%CEK9I M0F-@AK*P9<[\$G\]+?&MGBX28KI: @C<1X0&/-FGTR4W?|0EW,5>5D-8L;2Z0 M2H3*Z-
*BDFH|E,(:G%E" N?&&^#V 0!6=3AT(;7# :@V!RN.UZ= 5SBYPT M'&^;KMLP@FY'),DX;?
>'ZZ9>KVZKLB\$9G[X&,\$\$0HB16G#VM|C7_5*PB6PM] MI79?,7:7@E
P_I..F\1C')0>9GV\IKZ)L5Q \#)&RH\$6\2J.L5/(,^\$L,!E-MWQV4U#,:8D1^BX@+:HW=/[W(G"Z-/|A?
@'X1&^E4.%YCAFQB-"C7#0J7<*I& MK!FU6&@;' + R CI,P7CL|Z|0UY3W-
K(/W"U" \+@>T P4:IYHI%A].AULVGW M5=-U M4/P6DF%NH73(8QU"=1@!OMXH)!A=?@Y:>9)NYFV_-3]*?-
(&W/Y?GJF*3F?V2R MP
K\|@H7C5CE6C0^S.6,^9LXFMS^V_DDYZ%2"E\V: \N;32Q5@,>Z(^W@s'_400+=>HEI;^ M=4?
<<&\$YIYT;>|UJ5:3 D\$ 87,-*>C5>HXDCS9Y.WJ5L(TI9\ -4_K"@G?QB4 M:HB6[I;H]83(@Z(: *0DG@E+>J)-
M;="79]^+CSC"1PN#ZZ?>)|14W+54#0D: MWWH|4*2<- 'P((YC\$SBT-8W;26]Z-
;*\$M&"\$ _0L9<4|Q'GJ|3*J\AG.0?D;I?#1V@YD4#=: #4I+0-*#|>8?7W'6 M>3S\N|Q!,#JN/GOUS;=?
0[WGQ=H')!A91\$UWJ'\$@C/4(-*FL0S/>|%*U02- M?- .NWH(RY0=*+ #1Y60FJ5/9(TGGLB
*JCV'\F;,.254=#^YU_%@[KXP6VU_&#0J0T(Q7IA20HR7HQ.+5;< MG?.3>6\$)E-.17D1^!N\!3Q'-
J9+0X^#H+%U0EZGY"?;U0F(&^JCH3%2&8(^) M+""^?X,V|'C(A%25;(6077;(B) M"H/'|BEZWEQ\G012N%
<^~^E00Z:G/\ \ # M9)N,0LB=E5^NKK| [KGK_G=1+(FK|^JCJ!:=D0!V%3""WA9.V^V;?U4H,YQXE M?S-
IV2&".)H+S9>1/\6G:32\L +4X#%S@#0A;+%D"S#D AV/'\$-EJPI((!
M#5T7(|6C=+41_)2M'PV0&C|]E>MJO">#\$\$\$&,W-FU:+L/)9L7TNL|!TA0J=|
M/*XIQIT^W!|]'@Q7,QGC+*'C)%!3V+.N8YZ(3D9&Q[VMC.DIGG;AH)-Q<\N7
M4G._"5XL>UGAS&H|Z_)2YD*;M" LJ+""&X0"FFGB%)W:K,LSW-65%,3>2"E0*(?C_%V M1%\34
P'SY6A8&:5@G83V5*3 J00ZMEIGFEP]?LFYJ:4.7|0KNMT0/"DR;4 M0F-@/.QJ20E05M3-
C'@'+3GM.^@9W^E'L*ZI|=0[AXIM1WYMMEP;%^'93HM.H-V!4THUJ)^?5QR3; ;D=B?DD:T=, #F@F()YTPE-
\$5UVJNAF20+ MU'\$0F&NCGCL6?9\J+9*^ZL"V9(. *U8L)D\$>0I8J,F#.I!"|+|%(KP8@56A+
MTAZL!W0 |RRNT8REH!ZT?0>.0Y(AGCAY@#MHA>90Y3TNN\Z3R=23>#9PB#01B^/\$,83N!9 M?
AGT+4G|Z+L6|=0)=6HG)!U,^N":Z;PI,#?V(,3("S8283!Q|'+;IA9M:6R] M-%X,WDS(@1LVQNH&/_0J\$U-
(\4/?#,X|3@'M/9^ "1K-';,0'SJ.L5SS0^D^ M;#[K890Z|7:V+CD.5;-5X_N0JMM39_* *24 UVBB22>]G
[H7"0< 85&> L\ M 1'%^03!^E"-0P4=K!X4D8G^98^;JC0.GTW5UEQQ2I|(\$4; L)4W#JRL-\$.VU MZ""^XX
=7LX5H^Y;S2)U_7'Q7'K\$MP" IHY2H4<&<'<6E\Q)0|3A#H_,P@Z^
MFJJ,F:RSQ;EVR"0,%@|C>.N>+ '9S/\;?:!0GLZ04@XB3;|!|IOE\H=@9*C\GY(N
M^<|\@1E9(B);":::8 [817S6M(ID'=W&|=Y!'-'*/BNX>:>|V>|YN\$D\$|'"@% MYQ,II4TP30UDZEPAX\$5L*
(C*PF/4LXS1= D<3J!)?FX5,ZG+|L(0J)&5S=5 M. *C.G4Z^828WA@P*ZI")@LS"92*R?
K^0>MT&FDQ)RHD M|+|) 6E!\>B2);| MJ|??, \N:Y98M4!JNK(9/25RRG4076N|"%0_(%!, :K0AXMY20,S?T*U*
@E. M)U8)PQ2IA/"")PNC%7X9\LI%B_84X"D5%C.R>. 8@I7WJ>D.9'7_L3WQ3=8
M6T(VS0|>9"H8"04HA; PR0\IB0".V4M3J@L2"3(*J5Y(8_1^L9/_'"L2U)-R
M%7AY=V54HJN%3839J+CB5XIJPWSWZJH>7-X=PAHA)&@FW7,BMB0VZGL@!#=
MB)*A2\$)6;2CCNEQB1*M6)@!_B)5.4:S1=M^W)7I30UFVY%1K5L75RRI:.U
ML)8\Q@+'T0D;0>QB#U\$&PDZT2C8\SR7-@QI%A.\$K*L'TE^UN60,|<40T;6*%
MXK'CCA0HSH29H.F.\0"A+^#Q^A:X(#8*4>.I)*=,NHP<1 M?" /T.H8=6|T;@/#!:P&1(&E+VC4P/0,=Q\$ "UATD-
0D3L0"#(ILSL M6 "R-K6(@@FTZ9:J1UGX HU6P&&D?F'G\DUBMO|Y-K=4\("9PC; MI?
EFWD416%J:Z@^PQ&M%", '9'-@EQ+^=VSA54>|6\$6#/W|F38^IQ: '6ACRE M\$--"YH)(!9=WN8\$A|;SP-*
|3%.IBL\$!YPEG).0%Q%D0^8W+KI7L>4!DF#D5\ M**^G6.VH^CF*-.A!%
[U0|V"FHJ3>|)KM'E)5DGW>6B;#K'\AH/;(HY@J!EK"C& IGHY!=#X7\ M"S>*!T#3@4"8/=-|7Z/8S-
XD;B_P|=-9%(^J"47F|W?|Z@H'?)N&WSQ0D'?8-
HTMY|7>Y+G!WC#++>6/V" T7!5PZPK0TZ(MC4DD.Y@&GF&>SY[21RU,.AVN-+9)@ MEG&?_8:%#2CD0KW-
_#0X>F9.3J\$7Y=-+21J;,.0.M2<V7, 'I31(=^&D MZ.?M<|3^\$VTSUA("GY7D(SEA5)V&\!RB64;!P0QC0
S*>#9"ISLZ'6G+=P M"JOJL8 >Z/>X:1CUWE;RC#T-,A5*9|)&%0N*B4/,0QG;^/+;#XK\$S#N81NWN-A'.0N:3Y-
IFBX MS?@:FL:+V"=7BIB*D91K+2VL64I" THL?%8.FAUM30;D!:L8K67|7M=AYF^T MZ42B?
MYB%#94@FV)XJK"B(EL%)|C[FI\,XHW460/Y#-I<%7X_9AT>"8\ZLK M|+"T*54R#38@WU3:^.GWP0\ (P-
/UYQ=GMC.<#^ .TIWUZN'023E9^E9!]=.NO M70<^ \:RHVR3U; .M_2HUZIR*=,XW@G);#R?
3K/UV*5_K+,LX>M%0PZ'PJ@K0 M^%]=21Z@Q+D_-R^IN>)S":J1V^K3=6^/#?9&NC:F\|U"JM|
M8V69>DT)C;V@L1UQ)//\$87_YUL7MZO7WX;G0Z.'48R>80.MN(PE2T2&*M1"K M4A3,MA.SF|.94:?:L
UCT;%P|Z9;'SC'&;|'WE/=IPT*#0-%\$,FSYKDYX\$0_MFXD -LE9(8
XPTN:84X; **30>0)F14;HJ8@UJV1M6\$: _VQ<@K&\, '-EBJ0F.%Q^%8_UW+R4CH_'6KF/0J/_XI894#'_M740
9JMH@DQ';!25M+MZ0S6C?!\X;.KT>7+TYEA"V42]?&XH3B0WGC059RZS M'\!EUE1W1YR:9G\E\$7I/\1H)?
RC/YUGX-DX_Z@-'QEC@DW N*| [BK.R=?NO M@^ MSC/P;#/

1YY4XW!60@X()PDS)\C1D\3.K0]MOBB>.K00712)K=0C4(?XJDW04\VPJ@ MW'LY1I \$9:R(,(&M:
<4ZC^=Y^/\$<=8*!E"(M2MEV=!!IJYQ']ET95C_U)#H
M)0%*8/033]7\$!B)TLG(*40(<,2^_J<)B(L>H;+@H#K7WPRC-JQ\$V%5NY30 > M^1: _+JFQX'+UET-/MIMB%LXQ?
ZB.KH2F%6K?5'5=&=6DRU &>[.0R?%)PU21 M...9.)-KZ2I?
I[5D8>=T9: _+H5:&'>F4\$A4A(0EF*2D0"84(80Z- MR&L*VIF;)).DORB]\$[]W[>J'" :D_] /]G-2EH3AA\U]
(#F38BTR^NB2EE M#SPY8X!:.],)U%H'-B-;WU1I%."E7.0*S)QXJ;QZB\,!Y LX6 !GL")>G MKL#
(;3D31JZLUWJ<:+>%R]Z@;8>= [X"= \A-N: ^5GD1K>)NJ"3:ZCZ0N.=E; MYS@CN??
QY"MWWW#1%8T4RA=LY(!QVRB@FX:#?0EEDV2C\$S785Y^A=RP<,\$/8>05^..S,VZ&MQZ1+R%_X/)W/N)\$B@Q50
ML]NZ @)J(';*YCSRSS;RK,UF':W;N\$4V!XX=SH/_?#B7CM@YX%-#H.Z MNM5ACW# \.3!YU_?NC"
\$GRKX3B,U8[Y^X@,3!BBQCX\C?&7)-J(7[-_XJ) M/*8]X4F7-"3B'D"TE5%;*47)+2*T\+LCBY44VEU?
#S2MG,+.+%6*! MYPN*G).]EJ'6W%D108]B4IM>B'N#3R#H \0W61Y@F^:SC4J)2T0I'??)
MG6)8.DV74K.IZ#F2X1Z.'0.KL:4AW#R3,964TP7]Z_G(=0)QL87'"!P#B(X_*05_K26^&BZ[+?4.?+&T%#?
\^EG&]? M_9?01LC63+%Z?T27U2K\L8A#1V41*A (CV+:>C#38X#*="WN']W(;0B?N\TQ
M21AZ]7KUJNI'30IQT\&KKJ6&?IJ./>'DQS'"0\ (KUQ_0)N&+5-'22F+V!J@N M&8_K=?*(4!HV^X
D8E8X#\$D^'PSQ')SP^EPU,W2E?DJD@UTTB,P_5<: ?&N M'C"?8DS>?05MP029#\ \?5CK2MWX%",9^CNS0]5=?L:
[-VS!W+[]X\3M>?>Q2_M,=U@)>UZE [-IWX+\$:<77)042D+^!.ON?E6M&;0_Y0M\G>P-6H0W^ &^M,U
MH;^:LN7>R;E#;0Z:0^?^"NOYNU9A_RS]3>QR0'S"74KA2U23!N@G7AE[C&Q. M4UW:]R>[=6N?E_2=CC\)?
0T#+*;90H>&?A,&C>*M], \$SHP_?+I0!5_M8(8,\$%4S(6-Z_?
I*JN9+LW[IJ("D9S=?,V2\$NA8:EBP]J/*U!^V]JV*,0+3E_M(D5PK1+_..N,\$4B^./UL1'0D;TS_M4&]ISH(C'I9
+Q@ZM\9^;7"1'9.#/3+DP:9^%FZ>7Z1L/7B8_LNFV]RHIER^ MMQQ?JJ]R0_WCI&1^*#\$PM,7YN^EAFBHU?
VD\ 'CX^..SN[#ZXK\$2+4!VE.NS_M,'2"RY0\$9GHA5B"8Z;LJ[# "F=)S]Y5U]4\L_F2\UVJTJS\$,((=<"9.J\$L(FH
MGW0;W0T#H%*77;+LSR0\YZ#\80=B>J80+*%Y,0IM)QM; M&.)@1JL:=D&M9++59965,VMP<.,] <9?
EFZSZN\$>)\^1,VV])>8U)A?_3;[(P5_M,JS0;\]8H1-XE0\U6*&'A8T63C?!,;(XLVR/%D;#Y#??QJ_F
U;..1*=')0G, M>Y2A:'0#PK\-'GZCJG3G0/J0(H?#\$1<\$85XF*;?&S%Y_3(^H0_0 [_,+<
MFI,_EC+J@:3=W">0G78!IZ1W^W(JR1?7%CVH%*^15(-/]V/-6A\$/GWP(A(1\$ M=G9N?C[J]F]S
AU)X09*M." :]Y6.0;/_]&\[D%T00:QU:FW)'2K\T5=((\$6_
MDG2@,\,Q8GW<1]0I9"KVB5'"0228NH\$KE)>D\$'9NM]/I)7(@_%4:T+<2WP@0] M*)9W"+4I.J3?
52!G90IH(F3H""LJ6I)' ^7- [=#V[H0C@' *#RS'@]=EY>K]UR4_M>I3]Z:'B_8NPN-
\$HLY:J8KEPXLAX3L"CQN_R""%7/8;H45*Q= !D!MINI90.PNC92DY_MEQVA'A(!T6J5TS&\)^M+U,H1GNZN-
78YJ5<,[@FL MG\$>K;Y&_39*4&Y%@]M23"]!APG8WIJ=<;41XR?;;CE;/7M)75'T>9B\CA&:/
M""!#ZWJLYE7MPU_0:0G%7IZ<1\$ZJFI1NMCM<'B58^A29-BGF4-\$N'E+JIY
MI, _SJJX+GN9\$*\$, @+;2B:3D[.>Q&"; \$4Z (?A/AR\U_*3T?1I(=[*#A+1I'5_M&^ Z(0THY--+*%Q
A%H5(X8'%Q)WF(EP[\$EQ+7'>[.K8!7R\STVTHY160?E1_M),NDQV=,M6T>X(\$4Y>AY+8
3WRQ0'(&M)A0GK[B@RM@9#:"YL\$:3E8\WW\$#- M#WIS92(91NJ;H/!WT)[YFG+GT6G0:F-@8N8288M=%R8>
M3%M#>-?JXK"?H:=,(- OM!S\$UV,B1VD!1)8VH71D'D>,W6S;GV:=I4]]4HFW_M9W6!P>J-
JJ].#D/*AYJ,P<*;+RAGYJ^9DMPW&L_([BNC[,X12*@[/*.+V5_MW#.7*X'W
W^P;K?;4V;]+8R4XG1E+JM*0\M"00QESOM;?##TQVG]R\$30'(L
M6*>N)S3EGB16P\3E8DG@>+PG!BK2B:X&/I6X.H_!_?;5?]FRA2PI/TF\@%YU_M7CZ(_9(00=R5]2*:I'
HG'1I\,LN/6XZX>6.'"I)]J0_MP3ED'!QV4]>,6X>]X#L"B64WK\C!V<1M*(-+S^1'5^8Y;R6*+F,X3P\M629A
MA\D8A>F:.L,N7X_R=CZNK'*+"D_..1RV(%.&+PPC)7+*NX]9S:&_FWKWLWV4_MA3]U\6;:6!0[U\#\$:6VT4N3-
!DM%'L3P75P*6I9,E36P]W_M!+:FL_V(*[=0HYRGN3TY'->4EC0;5B29Z)REK1@20R3JF_5YD>] '2C2DV7_M?
#E*' ST4(6NL^3D-*G5B[610\ X\3LX_I@T6P'H?X]"_E_*45_M"K]064K1!_]D&MITZT":
[-HY6K?]3&/U7#9VK01*[SE'%IJ(C=[!QGLQAQGC_MK1/CT5.V5G\G_MMY+W0EJ/)A]D?
WK0'9L"D^;_R^]VY@N^82-)EPQU9K&>0=1ZYEJ'L9\$2+3^#RM<&G_MKY1\D#PL1(Y"*:_CL^A);Y?HEP?
=C78Y5IR_D1_TC7R> >:_V\AN(,'>&_M:0"W:HC_NNC7UT?SH%TL/HDA_M-Y*6F-1I>\$8:0_#_/_CID!CRX?
8P;KI[:P_U3W(N,UN9^7?G,0,)/,LOH\S, M]H[95+M"IS"5NCI1B4XU-J&*"([YMTB)T,N)/)ZT]3
MD>P:A;_NMI*&.V\$GE[1NJ_006HWEQ_*T\U-?%\$R:93VG+2K^@+L->U,#_%_W
M'6>7PSBQME1K"MZ5L"RU_]GPBV!CG(62/LC\])*7"\^[/7434L>YUZ"=JST@
M8>KX;:Y#&'69=,HG"M.7;+6J/Y70'-T52361/BM-6*L_5YQ?A[M_B=E1;U+!_MP=Y'@89EEA8\9V\$;C"X
2=*4+&Z_/4:2%.ST->^',@ \$L*U[SMF1P@!81PBK8_MAG&7,EQ<'B>P*!XCZMEVZ\.'0'E.)=9DHYU#Y)VRU,
<9%0;8JA4W2EQ?X<5,/_MM!V#6?IK3=\$H\$H0(L;<'.,.,>XW4@1&WZ#=7*BZ*4<;/3@7W)
ZMZFFZJABY]]EB%>!;_D];:F(ICU!_M+J01?S\$^C@U!,C_QHD0XX)L=#XBDF(2S=,K79?
BEV._T8;=*GN@9,^46XH3_MS&0G]1?'\'-=5F,0@ (M44J./>2:L=90I3IQ\Q-GKHFF1)SW'!8.?C\$ \$\A4H.6
MG8VHJ]03>;;3I>F_E+%=96,4= JQN98L\$24E\$'I\URZ8\BLB=,&+]+Z6%&
M"=>_2R0LI:KB'@=:!I2P"4%9&*@&"(\$;K6\$2AQA%_53T7!,-0H6<%W69C\$N0_MP0TTR0K;D>%_BTLWH#02'
_CIFJD(F-+M0&U9\$_2@TC23VPW;E&5Z]LE&SXM_M56CRC\$QY>"OUYT_!:-0H&=:02!778H]\\"# "F@T/;86"0
JH"[ODS!1K5*94_M7;-R;9/9P\CW%M9T!016&^"?)#8.^V\ _Z-+F%P^@L>'T0]EVK\$S_M053FH0)\V^>V?
57)93)=-4D+WR_,;Q(\$8V*<6*0^^-7U4=:F<#-6Z;/0TP\$ M"GKQ'1X_UJH:[\G<#/'5'GK@P4JMC6-CA,LT&B
3-*6)U<-50539A&C='_6VF_M*RZ8AUJ6:C7)DRX>\PNN\$)&H1@_%66CQ59R/0ET>%F%D78J.9_M+SPVHJ"?
P!MN@-!J^?7JF-'IB1*ZN9RH*EZ_M*HIF40*709PKJ\@LB0.4=17&=:;_!3)+=1_)501_A"
[-XA>&AW3!3;]A*JRJ]_M34=&Q\B>_8\$Y?LR7E(X\CKADTA+:X+K=]J5A06)XUG9>+U65)L0&6J38_YOV
M_^\ICB[7U8\$I.R9[-#>QUM0]773>0?X:3YH52-+*1,0-) NAK]B_S*Q1[K<* _MAZ6LTQB-2!W%5M?
LU[0^IFPUX(494A#H=C"TV5=\$D]TBMVY]M[G8#>IHX9\$/_MRFQ@=3#>GC.\JCDB\$M6,SIM6,,)+2_M!K[@!?
RL]\1WU0FJ5):"%\1()0P(Z>H04J3NV%/S!P73_@T@&/YY)IYZ)=(H1\$PXP!'R^_B#E-+%DY;:Z[P/M
M88X+X,%&D-G44*#I@!"FR,[6N^M#\ (49DV7-%;+L"FMN#XYR6?>#ET]1"Q.)_M]L[+X)F6
3,L.\$52MM4V\AZ0I2&/U]\$1G]CUR52;_]K.YA:/_R(?2Y+\$&!3!_M)I7NA?-V."^\$'VTA)!L844D%05-
&C%/@UXV0C\$].GBVW#>Q"\$S\$,%; "R9(C<&_M<: <+30,Y>]>4WSB&H^<Q\$S_.'_/_4Z]GD>MYV6HDQ\$3"9?

A[^RYX^H]-J'OG M!J,S@4JALZ(AIU8:UV)T>Y[IYYQIFB3XDGE%DKUSVJ&4B1D\$A")*9PX[&G/\ MYXEZKHG*!
<'!^\$=7*ZNV\$+&ER412L3.M=WE:ITX(*P)703-*7VFG+X=X@R+J M\$!H^8?9>TY_HRG7'U#,[93@C\$* 1Z?
MF0;F5JF, ML0:3JVNHI!Y&*GC!%V6H;8VSC.A.-[2+1)D'.^\$R\$JVEF\\$. G<3@.^EF9R M0>T\$H0/S(GDV-
07". 14T(L"1L*=03W\$0[>NF;\$-Z6'R/Z2@1V.JRGY3!)C/ MCIIZ(0B-4K#-100.=W-D6R8K.4C23C8.&
)X7*UFYLO:/9=P-HA)>KD>?(0B MIJL&[E4AU(#51+CSSBE=H8)#DC, >'!CZB'L8LH!E'W='(T)1!&*45"?K;,"
MGM16^6==08@38X85+01KCP,X7;B0*Q@'26(B%ZF>I06_,S6#[H;XP5 MSJ>G->?
RM7E1A\11^!HB1ZQ.AZ05VAA5/8L>D:6:D790%C+ MXE,*\ \$NE1DU)|B\$S\$ /GX[MG5(U->7]<#\$8#Z
WT8:;,+PXC&C8D8T#<\W, MD*5T0-5I#5)6N!Z#%T@WT"P_LH2K;\$^1JU"\$ \$KTLV-L@,) &0.J M >"%HF
)M4QE4UK">C0 E&[[(Q(U1*FJ6H_1\$NQ.M!IS3>213#1]?Q#"Z)7^+0TL*#I1.JB7Q("L\$M2K7)Z&,R
M<0B/CYWIN M W,M12 8=*)5K6@P"N'!I\$4CLCP)0 8:D\p<4HX3F_@D&!.RV85+#!*&+K!X MT"FR\.=L.;[B-
W+D?=> *%8]00-(!'2=60E\L..!5R4>;M4)KSH "78;YI" M=AW93;"A6EH13(2 3)(V-7X) ^1<[5=@6&X6X
MG>R7JV #*N\W#>TE,4+A<80(!+*Q!^JY.8P\$@"WFUYCU>9[1&,\5&F\JI:CL
MA,B"U*,H:8:6\27LZ3FA15P3D68E9HUKB6WEY@E75#6T=69ESY/U7)-54[.: M&5?'ORJ\$!M92?YZ#9U1_ 'A@8*
(>ME1N#\$/C\N:(<@7>00)J4X.YAS=!=;H M>5 \[D]#I"N6GA3V\$,XS\EPSXKW&7==6*
(>43+6)R0SD* '&[.,=I>397BUPH MH[>.YSR&ORFI)W(28)]>9R89^/'-TPA2NFH'F MEFK@R\$^1Z0--WBFEC>
(>#Y GD9TE@*ETZ-\$?SZ345("R:CK75\L8#!^?&] M;+Q(W'-
S7HHI<9GFF69FJ9H7L0,/1=1X^Z00D\DHXN0LN9>VNE#JPA 17'= M'(9(V>&K2C,R(MG+
(<5Y!AH;T/@/9Z#Q"3S+X,"T.!DVH.OC9PI\$(5L%C&U MDCH9?T3"Q=00
M;:WDK+QD0PFNPQKSY!'L."KB.\$EL/>M\B2A* B'/;F.N)16(M;EJ8(\$G>AJV MG1!0.(%S)!/!/?
^T\$Z+ZR(2Q."\$/6^>F' MYE\$7P\C04AIW(;K/P;\$LH@+B<N>'RM"8;UW; I1\$Z"87\1_?1[19ZS<
M\$PKT8P3U3B22E'NN,(T2 * (/&ZL3ZEXOW(#5-^/.!\$QKAQ#HW # C#HJ\
MeTY2@0BX@%\$.70X8 2ZV[(\$7YS0-S^M)T)PD YXH(['XS0X,2-(A1 L#\UY M9GZ,F4F);X;C,\$);6PPC?
R;I/Q5R5' R>-8%+DA\$JH;8N;?&5,[J*.;I>I[M
M9^5'B?),%&5U\$P0)"?. '1 [B3Z3+\$WYN9"02B8> 0/B33&)-++VE=\$4.TI"!
M^+D!\IW8IZE_8Z/2Y(TRY9+VKWS0-OWC)Z3?0_9 F'7;MD-=;J/=]>'(+*/5CF\X#D1.8U&Q4?\ABXKF=)
%LJ00!B#)%7QJ ML#Y*)IF7E83^\$E1WZ)RH10NR]1'.L4A(NZFI1^!YKUZ0[MJ0S
XC%1];!NMXVH%EV7!0=M&6-16JJB,E,QE0,D!9=UW MY=E7?;,\8JPG<,E")JUE][G5 8G]<(!>D
[)8<\M[0'S;*1)T03B0U7MV3.3 MTL"6I IHQ6C;Z*& J\+;7Q.5N 0\$B&^XJN0WH%>D1KXKZC!%W=:UB FN6"
M[^I!"ZK,\A8>[;J0KTF#(/VS_VD[>0<1_Q%' M//;6"EZHSYNL.?(#Z^,;M"J6-
#T\$*!Y4=Z.@BI4/&.Y7%4+&4K MOKWX;UPU= IT5-A'0EP:02');?6IE!-D5NV;)#6=*M]0\$AF?
23@!A,1D%=U3+<.'+R)2%M4)"UAN%>WM.Y1"86'.C M"LOGUZ7P07R^.\!IZMF[CK/S U%PEN]U1!
4;4N>0W4(A@Q^_04I,1Y0)8 M4+//;[4"7#MZ1<[K^QZ0+PK*"!NNVZR&E)KN4]I+DYXY,I# (D@,X@?+>P!Z:
M,@AE%<:304]SE[\LTYE"1,2QW8RF3=5=Q%C\W*=8VR(F(79E,,UNG X[+T+0 M?
@&=VW\$*3BQH[L07C\JA)"J5Y\$Y5V8^W_WTH M/]#5[KIF':PU_7,\[F\[/-6V87';VW"R4-
N5UI'J_L0D^>, &_A6I^5@= &-X M2E",IJ@U0\$[V?? "U0Q:045")0WU]ZN_?07NV\LS"-Y \+_[X@R"/X%G^66
MX!/M=%7!6@N0J6BT/V"7N)_S_A\(>PD)_ZG,X7_U ^3&32#U&6JIN+0A%"3 M,+//X_
M[V\$9#N0(' (A8NP:M&=4+5(69SY!'H@6(QFZK7F4]!JU_KDGJ->E5AVC6.. ' MMKL'GQUW: XQ!JFC+-
D+"#;I+Y45G6JVKNZ[JJ=8[[_N^%/9F2R,6HYW+U
M2DM;N+J"QU(V);2+^;A5+VP7#&>G71. UHH9Y!"KM#)V4^] \$6K(#![%]#X10
M_)82I*U0I'7R\HDT^DW5HN9BC^86KCV:6^ _OX_7',00WR0??GC-FA\%T/- M0X>YV70[8Y-Q!%EN^<5FH3)R
%0"<[7-TUW3=M=ZV;V9Y.=+6MB4)RGBRA M#,A*E6ZLTT&BY6' LUA\N \]/^2/;/.FZ>YIV?
-6*Z:K!KP*%2ET00[^ (OSE MNU=7.A D/+RK8NZ>&PNHT6/-IW"[^EN(. (EWYD6Q>0G%RQ=1.!*)69PC7..3
M;T0[E+!06TN'\$D\$2*WC8%HS000WF GJ=I=A:K53PP[^WI*;YA@6\(;A<_) M-
0M7,RM.N"2DD\$=3RQQ&^GA,FM0B2T^C0-.^8T0(VJ5X+&A1<3Q755HE%QEI M&5 =V "D890JTY&MN.&
*@9A\$ "DDK6A+LEZKNL+RNF '@N%H9,IE8]8!MT-C2 MP^/?P44[,1]#70RV>OVIL&A]G[=C8UF=/]?)?F?4\
('R# 'Z/I' 'BLGF5AH% M;:CE+04W?)^:*=K+\,BJX>Y>]YYM7=AK PX#9,S,[:^ZHWX,(%DC6G@=MT=
MIOYR]8]@ L-\M* LW-%(H@&# W< I9EK E-@XY@N!KNGL[@%I\KS"[4>?)R0\ M\$M,0!GK
Q_5Z6/C3*;2"VDU+'?Y ??N.RNG[2K1PUP!'H)5)H?Y\7# X5J_A
M-.C(A*!+,\$PX76T3UA4W>-0#J'&GEXG+\$9U(54M=D)0GH0[J<,0<;FZA;&(<
M^I2=E3,181=0F2BXK2PMVZ'G)X1M(KE7\$SP>1L13K?BCKEK?LD=02G_)LPDY2QY0\$0
M;^70UE06[=DPD3EA;P0C30/XZ,6^9I-@SY\L0A)^90@MZI%2AV6:U\$02I1M5&_&'&L[<1Q< 0L]@BDT^
M=V\$?!\$?,\$\$=-0_6\D=J'FJA M]@;R:^EX<.9C.%S0:NA/\@HF;\ "Z^0W3&,?0Y[U"TYN_Y!M*_0P4HT:UX,,
M\$MV%-UK=\$&]S_!Q#<\$JJV> D!3+R;2B7VEL- :2WG18ZR:(%IYCZE3_E,%/A<1P[?3"C TPL35N[N/+W\ \$S_
+ \T[_2 M,+36Q[NT]\$!H#N?59=7-K91IF;1D_UFWFR&LVK_TP;VEVIGX/'RVV&] TE3(
M0ZF@YYZ9>D@T'00JCKCU:2@G" E=WX5 J&ND+IDG,SE(7SA<\$./Q1X\$K;+.P
MEKGE>G0!+8]\G+E[,M2;#A35TNGPSQ@07MGG_@;)6"R(<;PDSJ#X^>60>4&!
MMMWW[TG2:ZI55>X/4;]@3(J61Gw+;YWP F 68GLW4T,AV0=1#? YB)&B\NZ9B M'YA (0TF5A/"Y\FAN?
Q)U]AD)9G24E_1XB.X(IDW\$GUC H#PW!>2>)K-"#&+ M/[Q-,>&:<%V]_?K;*^UI@*?4K3-
7/SUB]WUWS\L2*3UM+^9MUYY+V6R6*^+ MJ*I&CD@PQ&UXG\$30B&,PR V.PWCDSV"1VLL000@U\$N;A0F39-
=5,/C=CU;UR.B_YET7Q TE![#?JA^)W7.,06RKT M5IK@SFYHH;]SCO#%4:PQDX;]E3,T)V6CZ.&\$;]. [ZUW>
M+\$]V)]/['3SPB' *P/U**EE:94K8T)#C"K+L5J'U M""U<_F_68T=Q1/06L9!(E872>!LDAN^#!1DC30(0!1
M<:5(*!WF\L+-)>G/TXHA,1WD36KFM4LI("11&GLSW]U29N#7C,#0[B^P1/B7
M7S[TY9./Q]\N:2FN2M?7\$R/&9BN:,F^J/G0_)DSQBY> >0&'%[_]W!LMW@68 M=(3SE!6SS%6R6!^+SY-<%;
(Q(MXTV_7U%(R?9&,%&A'BORN5D:*[A;'ORU^BF="#097"6\$V?ELY^?;EZ7Y.7 MD?W:G7&LE46>
<_04YT"Q^LVW[PI. ?,K 1LJ!>CQN.<,W9*-3 \B6,DX(E3\$ M,P9!9!#YTTI9M731^]M.JKA-
V*;;H[00L!\XS4LB:!)*)*)2#(QE! +*">96 MJT>B,GSTU;]\I86=MU?L@D6(R5+"DG@5[NH-
%2A>0[RB(*K%=M-JL;MPYE- MSV@%ZK=7N/ZKK)^^*UASSSX,A3AWDJ@H60SV3\$&\$;+J,KD]2*8W_B J>W;P

M2\$&04BG\$[#6T=L?>LIN6.TL+(F3JRJ^0Y46=4>B)+Y86DQ=OR?D.HLGQD4S
M&UN*.T*>Y#''&E>=V%^^-8>JVS5R?D:0:;6^N=L_-]=U'']-[-,LPY(C%#F M,W@
UAY0:Q[PS6YP1:1B=7V0>0 URLYA!W:T!^2V^>ZY3S/&VS':?P33<|EH M04XB!D9,3++8*?
&#/@E*3T(F'M'9?)TR.G7UXHLB'%*7J^ W8K*0M7ZX\$ &/ M7\:<!)E)+Q80-2E-
)..X5=M%A3]/QXHO5L2I[9]:4. J..48ASYGR MP8ECR:Z2>G&,D_3%EG(>&AI\$0 F5\F:V[2#-32-:2Y1\?
K[U5=US[K07)YS M,01/6\$J8D:4.J&N)5*UN*KM>FEE(T3-35E@'6IMBP/*\$XY@2E'K-6=(*(V(E
MNBR+XI/D/=UXBA%X_!U*E@+H0B@*M/[H0]>;S/|8IOGYR\^-|MDAU5X:6A? MG2#%:D69C2I0_#''-,#2&-R&
_V:\>&B0GE,) * !ZG:&D'8I<(%K6L(:Z7\$* MR?)&(^77 *AV7QX0QHR6A&5-W14LC5]/5M7=U5 NM->6CQ3>1
ME/#6*TDG==GP*^Y@)G_IX+1SA3B7/\:HE|L#Y&JY.ZYM*T=X-'(&G!JQ'MYJ
MLIEEBY4>V2U>W<#)08GAOP!=W6@D\$YT!9V
MIMD1!UNS)XV+H.66L9#N(LU1*\$+!,C)Z7=-DD5G'0.BL)S.MHYUNANT!E0!0 MI%)H-T!=A?
#6L%@J90!72F0GDDJ/;PC%Z';0\$C>"G+"FCK*=-#1-,W"ER5V/)
M"60F,&@(XNP<3XC50]F,,KC'ULY.OEK6#3U(.NP"2!6,*X/9@Y@;U1@;\4,M)E\$-J\0]@X.WA04,;!_37'?
#4.-XN'T-G VV>(':/L0F35P18@"PC8U4) /E ML3/K,+TG)7_8;SRRJ&0G@LD,9,U+#4J'KG:#F-
W"\$ ' [4,%)W(@V|2(#\!9 M?*PCG3K5XV)%>GQ>#R\$W6\X <>!Q\ 7#7|0C"8S @\?M &CKR'6]#IQ0,U=>
MJ5QAW\%''#-!FH.V44M00CG78]59(1QB4(!3:4%F0.?R94J@(* K#0#),&@W MQ,1\$5K-
<5P?|K%AW02X=L91D'M@>I"3I)]V5)+5#>:T9<;F<%(2,-MGU%.S&)9X)8D>.5<8^|.=-.)0^7IG] M"0>
@VG;C+R&2# MEC2DX+S\$0B%.5\$UV8/@+URA4KMJ#0MWM,\$NIDND%,-G'N@H;\]:B,HZS-82 MIL*72/MSU:
385L]'F0=4M=44VUN*FW|K<)12HX|;46V0]75L9-#P6XX|V8(M/^L!.UB6@SNCE?!#?T79G+*IY&DA!S,7NGB-
S@5?/Y^GSJ0.P)LD#-!*2*C MLL\$*9DV+6P)54U09N<@4G<4-??#L-+I"0\$W5458*\8!0S0+6P&&)\$LT1+\#
M*FE0F\$3;]>1S+2R6M@DVI#^B_AFMY488.)E\A\|X0|]2*)YM_&BG@3NA[#+G MRRY7[Z]&6_2WW5?
7BM*2B\&J38D=Y.C@R!YE-\$/T&5WB86>\$S;:/M2-\(GJ M7|0R0Z:VBC0@>\$;_Q=YJYB:
<82%W\$PEV55BPM\$9<7!VW5X3@Y*'R^B^OP/KR M7&]@6)6IV VD M<^BC'(62D*=>1G*4)?;!!'!Q0Q';\$QXK?
H/;.*#UEAVC1;Z@^L?76RWFL/BUE M0I@DRK8D&Y4G>;M)NBDX">1B;P\0W7KE(A]-^>B|LF(RL: ^XQ2+]
M/AJ4XHM,DO!&G^!21_8LU-+/Y2.:/&NT=H?:6)4[KJ;IP+CYQ.?8&Q2,GD3- M!>>AQ%=DA=/D
P3FJP9B>;!,_KXYVH?978, \$WY'=- 8LDR+,+6AG]/W0{)R3 MNT/U!
(0_].Z<:T|0C69S|WW)RL]>NS/51;CU8T>9NY+4' W)J0<|_Q1=S:4\$1_#;ZZ'KIQ:|4!CE, 3? M2+(U
AQ\$*RV9R,HIKIZ>G&9,>V;Y@J'W\$Z2!YB@Q"Q9\$ \:C1M<01J|PLV1 M,L/SQ8ZLW52N1?
V04,>.Q#!KS8=@T=\$6END4:(HM/DK_ J-K+P3TX24%]5GW MM"(D"4JW[Z-1N
+I\$LH&@IWQB@E"4));J':"\|PQ_5PS1!L,|A@J)*39CSN M9200T5'X#B;6HF^X1-
(FZ_DHD|71:XYBR#QER21_2 MU;Y@C.K14A?8Q_Q1310E.0YLP"XJL^9+#523!R"]=<&?H7REOP MDH-
@22ZKV*\LEY;:,0HX5W^W0GT*BXA-SR|_XW5) NY6,,T=?0 =PI"1)8=> MJU\$-)CBLQHW,2=7>4'J: KIZ4-
83JV8\$PPP-+7#2W6%3>:!J6(@Y)YEOG@V/ ML0'# I>KBF,83LP2BA,H)JY7%J:'N4_00^9GR!W(GZLI;:
(*!^7QXV<9#=- MP(04\/_T3%^NWB;W8(.C/ !6HP8T#FZ?.&PJ'L!4 >2H1"\EZ?7?J*,<72J
M'V"+82@L\5Q2(8L.UYJ\$VW:1AN&Q" @'4-9#&F0>392-K\FA05=^|B+-9C* M=X@_D_07U
4C'8Q_/"IC\$HV>/C03:F|'F#9<\$G0=-6&GZ.'R)BW\$#67#M#\& M="*: ,N3>/,H3^W?
UH(/P#>B8""&|#_+;Q_:-S4LCX&KG#++T17]?H#]=91 M\$K)JMB\$,+1M|1%ZL-,8UBK1"
J_.0M&9L:R|IA\$=S6US41AMS38L"[_OZ1 MX#TW2#HKE7P^1MPA@Z,%8\A^
JH7876\$40EN*.K;M'ZYCDS).X>UF!_FR|5K MRV|&;2+93>XC0/^-%DW9(DK4F"P38"]B!REQ?YE;SS#,G3<9NSF
MLB&4U%K,L6JU%JE.Y%Q>J%\|&U678E'K()/AEJS_|f6W25
MV*0;HCF!_\$.#@UD2C!E3#0F)RB8MJPD506@1I%^9IQF02!1JELIL[G/08' MNJEH| ^#/'Y'|.%)1ANCK-\&0-
W+D\$0C\$0YP,850BRJ&C&SZX|0V5*T,0U04" M7H^ED23*9B\01K?JHWP|+(.05_#\$6NI:JSF,B@CG8[=L8@H3?
L=6Q_,L-Q M+BQ=/*,2G.00|/TN,YY QXK|J GK;S>LA3V9#@7V=;D)SB?Y' U%#Q@,\$&H\$ MZ\,.)@X?
7PE',>;XX5!|.WGN<\$5SP9+@WF*V>:'.9GU)|B0AMV\8=XT:WAE%6 I82M MMC|D=:VNPUG%N<.^WC&@N
K_Y<@&-_FT3&H]5W_J HI3#C25DE+3]3Q!UKAY MCA(*.K7>T3N!F7VL5@YX4!].H1*9%05E'*Z@4M&10EMU"F)
I+2PT24IU*\@_MCZG@|N@M;6%UGPLN W/+9 VI\$ED&Y(2N@8(.GP7XKMO*%7:U."S#+1T1GZGX M"4U"8;*'
Q"X_*YY(Z5\$SMZA0,+=^MF#?G#V%R^8(5'4L38VJW|f5Y'DZZ
MJN+LPH/WHI4V(TA=N^MZX62^@ET0,&AY8504\Q\$*/=7\(_0|T=5U+!\$SIX@2 MS*1"6N@B) >!J_0G;]=+
[A]Y7A=SW)7LE6ZK#=_G HT94C P6>&G;_0/ZLOJ MLIC_&^,AA4-&>V M@6WUB,-U/C^AME;_(*Z!-
W*9B@&N1MY\$7IU*@"DV(|f9B"@!& _@Z:[\$RR0|GC']:(LD.RL,>&YAW]"K4CCT/^,04T=PJTJ)\
M0['\$|&=Q5Q@#N, !2NPK 4>EU\XH0VC5?|XRRE!W?/0#5, 1-\$T?N;-T|KY^
M\^|JRM%N&G'F^|>0_KZ>L\7"G8X10**D<7!_@G0)P'-L5^*9Y'|[H3/Z.]J..N,Q6XV M;
<"1@H!;.,.'9[Q&CQ|J)@@"#S@U;E,P#J?KDE'RV6@)\$+SMF#_@F3A ,7EI M|JAG& 86,K_SMH_J\$&3CL RD.
<#A)" ,#9=B8._./#7PX>QQF,Y7P3\$1I,%KT M095=EGL.GMN>H#)S!OLCA\$SR:-++Y7\$1(AJD6!((; /C:A
0Y+^63 =R8*0 M7JBMLYV%9G>W6;409YUM9+*MR=]/?;-R'0=\SP)*DF[V! JH61 :\$|^MC,D
M26;:@R9L9B\D7/%"317^#9H@?Q=/L0>PN>--3V1NF|8#08A0*\$112' A=2A#>,B;H]> H4?
Z!/LR[G0_",Z'^YJU M5;VD_ :^04XTM\$/_K1VE*4:QT6I4\$>,I:S"9\$TS9,23,V)N\$-7YY!#[:YF0#
M2.XYR5\$P+8044S954QG6"*=UYCK0%;"D),_J4K"#5=?8C0NG?|\-PT5P2^CD MQFC%C M&V#62S('ZS!3/6
>FVG5.: IU\$7N3UECGU>^TQ="6Z70C1:FNMJE MC&,2-IN!] \$5\A|INCW@?*8!.
[f2IVYM7F4H"Q3'V7F=T7I|2@XUS6:CQA>^ M_&/2M6RP4D57&3K!6Q6+#=V6\$5RN4N=EV(?
SRJ0/%0/*T6|]T&W|_,?--),.V4?YX8I'R4?Z\;MPTC1 M++#08Z'(8'R''*'FD\|-
#8Y4/CHVE22!E\$0Q\|>>"RNY4@U,2<^@14X%C\QN M\$V\QOP.+ I,XXP">OV+F'N^R]:LIZ-
YC%@4\4449R<&D]2>4SY4'0\^QB1_Y MN;V+W7*M;_9^ V(^:;\$&B&&=M&=N@^5E^TGGD 5;:3F5W-
8+SEZ(H["IM@3| MC8LN;HSITL0@9')U)U3B^,3BU:OHMG.\$#L@-X3N%08!1RKS3S^XDRW(|>PD4
M4H^UE=2@PV?!FQ#U]2:^A%'5W,-+CX90GBLS8)=':B_-6D ^M4BXR?G&'D
MT*YC^M:Y8'D\$VM;8L!1LS_H*S(I&59@|+EQ|>MIX. !AK 3QG)IC|(#^,GRN M|'TB=,]' E0XG>'0F:,\$<-
AFUS?QX2QPZ.GY+%H.0WCA7W-8S.C\$YU;.675 M"(MIP%HE3ID,04N.:YY.FCZG*0CPHD;U3N"&^)

()GP1;%X[_F03= ML%05TT M\//)^RL+#3 <.&.!5923/>N-
2E0XDZY,\+*5#@W(\$F*1)L;G>T+&K*XR@:W7\$6;5!9\$G20&SDAI76:.\$Q>A7W<&P%\$&/G@ "2FQ@'K=F;X:IDP1AH
ZS8 MQ=MFN7V^R2&8"B*AH,2#8?#R00P\$40"L=4NT 67V,[DF%:C9&GN M,QF>D'G3.(7\$V'-K,90T?
BK.=U^E/8MI*V\')IZ'/C#W1: ".Z4A31*\$FG># M35/3#X.7NKM.U?\$ZJG\$ Y#/&HW2F7B|EVMB+
(18WXI;{\$PNW^5!5^XEGM=H0 MY#LXEDWE7"G'I>R^H)0,VKPPUEJ% \5N5"W@6##!36ZL_T?ZI8.X+(
M^(I;Y4+L9C616/>BAV|0-'^\&53+8P-7I-YH1<(G,?:'/IPY0_0<'E)6<*SJ;GKE'T206|MNA8I|Z92=98
MDX5\$ HW9.R*? 4K|'<(0AAW;BFM=-Z+Y3KV?IKN/HH\Y&'M|>11?JQW!XKC MQXMN>
|'0UL1D"U84GG1^\$ZAI.ALM[04I1%'6]I; &T=D4)F>Y>SR=GUDW>6 MP0FP3SZX3|Q)8|' ".^H:0T0?
S:)+3AVRD10@W3G'JA0_3000'-6H9B++FQN* M2T&N*#PVV)JV7,)NU=Y:ET\$C A;P)+_ \ORG0%ISM@?Q@+-
>P|H=#V1I=[9\ MFYMJQ"G2=PWE%&GK+|]XP4K/M(FX-BI9+-6-0@%;*7WP2VZ,E7*I_*\4HQJ
M1!'S,Y50L2[Z:L=@;|70U#?4A,M &S#H6V0|8CT ZG7*71')'X< EA28P03 M;6E/G .R'|C0K-
LXGC'IZ>S8|M#ZKD:D4G,TN/4L;<*+2,JMI APHV?0 I\$G M#QX+N(\$F0,I,+KN3 ,U=KN?4=\I5L(40?
I\$(F#|1M8CD7000L.Y#5-,>A:^(ML\$BY\$W6J\$4:6B8 (^A-U 2;FBX6SFV5FT"(0?,SU^#CT3CS.(-(I"2A=Z
MW5)UI<|S1LB|\ .Z=/6@C\()IY9\$E+F9/+M9B8FYU)SB%!'X|N374B5X*KP^G MB*X|X|)!22PZ\$ZY"5-I&I\
(!\$0NXM9CIZ JW36|Q/' ;737>=AMMQ;QIPWR4^H)A+Y\$L;AL/:D#U3@-Y S.4D.>"T64"2
MFJJ"-0=.YP^>|F00W|0W@T/'K&|A;H(&|80 S0=K71.3U%X&P4!C!5YA#159 ;C.L/JL IW:G
MX%+0U2&Z=-.1"R%8%1HJ)\DHT%T:|?;E(SRSK(5JH+YC?A6>8:6HT50!Y6 M*!#++|I?: D+/.V0Y9FR,
(MK"3FVY?R|B7F#NW8A5'|<05"T H@<(#|",8,7 M8.P5=WE2.Q.@-TC #9B=U0N--@*H|/5B:D+J:6-
S^HPA\$)PW%?7.&-RGGH= M0:>/#CNF?Z:'S'U5U.|;CG;X|32^BFMZS0KI6RG.H-PQ*(MGY0;4"QF).8<@B- MI%
Y^&;D00+JB>H8QU)/YB+;TH|IM0U)EC%+@UZ-L9;|X7AA M-AJ?Q\PGM%03I|B.;ULIT= .'= #V|7SU;
(Z).98^/8H&-CH,J2N@*/KC?W| MKK1ET"40, 'HG\$=%Q0T2+4)BM.?BH.D ZB 4|R1G6Q+|HFEXY;'?L_D Z99 E
MP5,T'UP6X-3+* \T1+WFYH>%4"5?78|GV|(("4YH7|]T0 U9+B1J& 'Q?P|B
M7+Z|CE>5*GG7M|\$|+;=&5BKNUH M,JA:=&X0*(QC?2VVWEEL;*F+Y"868./Z6HNB)!D?8U-!9:QKJ4Z*
RW388\U MF3)^G\$RE@S'.BN?+E19 \$3S1T^">D4=3D!USWTT*U 5@W!
M2,MJR3PF>:7M9,4*0I/5V3R"A\$|;R4|L(: MIM/XR,%H(|3,9RFM",HKJ>MORE;5X\$Y@QA|E-
OY%SX|7=LX|T|,L?*>0/7|@1 M@P0X=RAP5(*2|CD6|X|E5K1PR*|;|F;X1'|D "E5DSF9\X4-
(OCR\$PWX^IZ|-5BV0A M#62WPZT,>DSF>P"M1GJD"(6TX#0<,)T|E%WQ^#?GX0\$)/,LOHNB|8!5BQ"V)
M#K|,^C/@A06A|>X1**;F^#G|IV=C-L|2M#&@940XJ PMQGKX3#)R) M*J-803
+|T"B3@R>53D*?;/(W"G5:L1%8.T(!;HR@VH&17,0,:6 >/\$"(|#A
M&*9>KT2QA@6N9B\QCTLKIVM<>&&%@G0YV-%-X|TS^D^YAV,Q,':1&K*QMDHE
M*\$|VEE.+ ,L1Q|#3#B,1M1./+2%VN7D7DX;R0Z%|;|!M&: _#"1/E^K M6F_F>=H\//9Z?
GHFH);"J@BD#C.!0"0,R^H9S=!S|=9>*FI"F#BW1'3I3=4> M>= ==1^TU|A0)=8#90W@FYI&3RH?G;+91E_4%?
PHQ=@Y" (^5_N\$%20565|8 M/W;('7+^"" &'51|I0:#!S7N1EAB7FB<(A:[U\$MMSK.@3:V!XR-(9@1,
MB!;+"9)L|'T/+T\$/' :\$=M@*F(HOM9";D/X2\,DC M@|(YBX:%HT)NN.F\$/VP)P8P"3WR)8;Y<#XP
MIZ|8.V%,34X%VD84:/+|#"32 W|=@BU7"RIP05FE)_T#(:K9'9*0%IVM,%6" M\$.A/*5?
U!*E|R<3ZL@XZ2+@I4\6 'UNUC=-*\$J7Y"14;(9VK6|7JB0M#S_WL M<.<.A0L&ZW(C'|>)2I"\$V9]?
^2^>+.F#HV)G0 |I0/\, I#| _VSLBLX\$&FTTVH MT\$*|!\>^0CX(.R)|%V76.CG
+GDXA=7^V306|B.V7YN|2^5|+QFK-&EZ)H+2S MICMBH:-
*,:G..)|]*KST\3MPVBF22(M^3A('HZE9C|BWJU'X)V00U&/L_)>% M=(T*7Y7=RX9\$LOJS2H"WX?
GV%+^B%)&X*)9KCRRX M)D?PCQ3AP|:#KLW0_5XZ.6)=; MC>:|\J/E_2-)%4)*I'TE9XOKDL-
5IU4&6XM2SE)" ;4270/4"H FWD BAH1) M#L|9EX0/!:(P8E(CJX^8H9"C4CJ^>+)|7L1>
<5T>7'8E|&^Z|A154J"*#?Y' MX3 PIQ5=RCM036':X04\$F1=+B2PDE(BB4TUW#^//#@)?2+#=B>&T+CF#2 MX=
(*H:2GU2'?=>GAKA-T1E:)/W% X4WLI'Q|R+KMDUM YS3*Q.R1 M \CGJQSZQD7|+.I;DJ-/*JX)K0U&
_L*M;@K|\$7F/NB^&W3*Q:I6AWU|&*HT#U%&@(/'- (Y M+' .8P\$#)=9)L510>011L.CT--SG3X01:
|Y5T3.#?,@9#+. GY>9\$;GRE@G^S M+Z-7X*@NN(?TCM.@P|T>R*2HN!"8XY|\$|!
M5'1Z=EHYWMJ>T6AY<6W98\$U&PE/Y,>920#|]W88R98I&|- '#^ B=|E5?#;1 MS>)HG=X9L*UPF
+0+)'YT*V)Q-H:;ES";+KK5/X|-85)E|V,A60DXM5PY.>5 M9#"?-
'AZ!&7L7Q*N\$|K7CPRGG%;!06Y'4U(:9LS\$H-9+U+ZR:D_"YC69\$7|@ M'
ZP_%0NF=-7|5TB'2:0,Z#VU&9/ASA6H ##CKILX?' .M6*K%?_V7"L^@6?Y
M9=2*,ZL0/.J0JC7_CMLV0HVUV'|T^-V07K|_4MR|FC3HV6-; ,97<(.HKD-M M<;|Z^>M?D5M.[7L9I/+U|W(V?
>M Z&Q_L.LTXP\$>,C3,!.^,DC; 7!L M20@Z|XG?%;E*Z'@=<>P&>L)DP3VQ*,"|<,@C2?B" 'M|Q40(D-
#; ,UZ4A-3! MZEJS:3A4I:SN'V&D^W.!@|VKZXFX+!IE>(Y0";:@/)'*8;;30K%D .HR|A(M?
H&&1B"\$U;L0Z6<;NXGF(T@#BP_N9/9';N.ZA9);Y.|I|Z20A30\$>3,VLW M# N'HBI\$=VF\$Z27\2"Z^>3QM&?
9^5|U-2F2^V=\$T0^82.?*W\$;4;LLW< E| M%17DN KII60+55!^E*H2@#"0L.=:\&|8^|B)HICRJ|.1<-
=U=\L+*1\$HXQ2 M-3667/*1,(G-,2%QHH_) "XFX_25%)F^>R?|9,W\$DH%"]@N@/'J M3LUGU>7-9?
2P"KA7Q@=IID^+EG3IG=|YR&PNJ(#D77+0L=*+ZEE3_/4A!S
M'H_Z4_4DU'0M8RX=H*@(0%=\84|S5P):B#D#QW(^DS=@+ -Q ;SK?|7'VMDE7XX|]7;|F;H+!| +S>?X=5|SN-
IJ? MXA5LWG<&SE3H\$5WS_3KX=E3:BNUF(%W:'KQ_JPX|0^0R_S1M7J,*A?1_6E
M5|2D7G|/GWJL0|5T)"%0Q6&C\$WW+@39086?'92 M N1*=@DM+ 8P^>I?=[DE\ \$PXR27-6UFIPVM,SX9NIQ!0?
R+D7(I"-'+|'_ JS MG'"'" = \$?'>DN.KF%XR15D;3-28"H0RLM. ?&.7#Y7N ^'^?>AVXRJ>(-F95 M9GV?
&#PK4,N1.)7AD.(TUQV-A1IX= HYRC07(:)Y;-G7L,P<7BA;0RN2:91BTXU|K_-U>Q"EC MBEW=NYX-
5A5\$MC7\4Y-|]#WY'#&2|]#H.0W'?45\MMJ%@RJ=Z*Y-BT5\$@0J#>2
MG>VPT/2&/'*T%H#E0|:Y;^&X;#;* _8\6*F=VKHP..M(C)_|6'I&91",#0< M|L>Q<#@3I/*D?
0@2S+Y&|%1Z1|-F2QH_+U;)%P/B8-:@% M)#N_GS;G|K|F|.RD26M+^CW'A! ?BIL.H>>>
HV!RFP,H"P9C&%_B3B).\$R/ M' 'H,X*12W5CEQ@0&+ZJ=MJQAU_4&K'+&F|U|TI66W?QH-0SLFI)PU@;6A\$0
M"\$;AT9,TK\$2I'.AR7KMD7W9<).L%N|V*7%;M'D<;\$*|'#UG5|---262>X0 M|P|:(N+S:Z'/H#)V?I#?
\$"!#_SK986(F=7R' ". \$1IHU7JMGAC/1/9 MS0A')\$SH!+K0.BX(30V6R&98'ZE?

OR>X@?;)JHFG7%BB7Q!KK7&HY<,4+PG M/=3H#D]*!.'%[!OI*-C4U6[*MF/\$](,6(6WB?+L\#A0XD
8W!.WVQA1FAI M%#,(+)5\$>[--/9)\$)D-LMW=%A4^>@P]H3 >WKL^Z1,&RLTA5V+B3A02^PEB M11\$YBBM
P1[>0ZR4LRR8\$DQD2P@73DMV696L9A#S\0<0]?/@EY^E/Y\$R-+ MUSOP '@#6:UL.(\$9+1JJ[CR-F[EK;
[IL\$4@,P\$%&1'6^1B'VN*;7Q[*!D8D\14P'RC. 7A%.? A6.D@_E#?Y)TLGA."P8:# B M#:J\$)+>
]F":L7(380B&X3/].2/7!)%^3P\$0)0880P%>UJD)2AAZ;<5LIM MHGTEOLG%766UH#P%--
R4QBQY\44J^..13HL7S-'SPN3)JE='?G2NC) LOY#* M:.)KEK,%FMA-^ 6=[77ENTBG:C?Q1\$G-Q8XYN5P'@?
@"3S,.WC05!-JS_E7E M;%)L70H"TLZFB0I26*2>H/#0?WW[;0!42<@J4&HE\$TUG69Z,6WFK)#8\$8Z6
MG9MU"S=\$F5H%R+/.1+ "HTC7RRW'D(KLK4?4;*K2??:/[ZZ(N\$GQ0"JC\MN MMSC:+,E\$M0C6__E,&;
(D)P&\=?<\$B%=I0@2(=[M&T10G ^B4"M,C4,(9 MI:;*)BBF!-EU!.GU2B]#];8QR, JB'J-4Z 8>:0VGJ2S
0?6!J!\BTE+(A* MO,=L4JE/Z8#. (HI>W* QD?B&,?F=G8R>9TMO\32 /*&?66/'Y[CW__0^6_Z= M]CY0*C0S?
&YIW;JW34"C\$OPY+N;&0+&(EDVV45934:%)IOVJ^4+-U&I=: [CG-+3WN M[8S-
YY[<;D6%36Y#C#)MF#8QY3DC)NZC=#*WR9/_^DT+)GW)4]8TAQA01;F+4Z? M[1.?
F\),)S;.,H:TT*U^]YLOQ+@HKJ]D>VK5EBJ#"Z9HR=00>#5K:#W\,>YKE M^L0'P-L[CE7K#G[0I^ZK:]KN>-
Z7...!ZTB&3=0\$)JR;Q'OPT: [\$H@= MV?ZG'DW\95Y.D)\$Z2ZLASR[.B"VZ\X-
[A2@K8\V)79\$D7YAI=40Q0ATOP>36 M_V8^P+K[E\X\C3().YE<(V4"P%[)\$^(A((F2(5%\#LPKQ55XN=[])
[30Q)3\$ M3,I!%N+/4*;M["#^W!Q\$247G(R>G&W=] 9Q=R!/?,\$Q..%CB%HI^+(W8B2C>1Z-W+R==N8 M:?
S,=SIXV7A.0;J]G5(YEZM0J7[WFF00.L%032W7,\$B?2Q5<VDDW=WLL=(^V53Q*4-P MJH3%-Y+!8Z(XA\<,U-
.,3-1(%X,,)EFJF#%5XH:--):/PL%0N3W)L-LTKHB%
MO'3.0R)2AU'Q6W\+)J(6!FXEC7]X'%8H0S2V5RJINK94HI15Y>4P'?N'+54Y MUB?HQM311WZW[!-
_#>WL;NF;ZU8)TX\ VX>6;RQ8'K1H8T6BHI75'Z#GQZ@&MY
M4FG!'OX_%8W200@_3BWL,41T\$8P4!U./JYFSZ.67+[80?Z3682S%034TWSV7 MS20J
Z^_OU=SF+'Z@>@/YEYZ<;X>ND!/!=7MSM\$X%^G*HA5*61FVJLA"()\@ M0ZMR\$SEN8(<9D)J]
[J&%;*\$TC%:=&N02CPP3<]/92B1YN2@^_0)BPAB;M<- MKI"(@?IM:B>Y#?NPMQ['3"&EH?
IS;#/FRJ=7B?'X.:TS):G_%X M;5*V)G2/M!W"B+18!YG.C\$088-TID9\$0;T0CIJ';, GTX5XTABR8&8@L\ -4
MF)EY?B]B[;C:,Z3L)3E _EK2PPBWIS.2B^_0=NU=>-DJ?U0ZX29^C9?3]J0EF MB[;5K!T>*HSFH.G'/GV;@MFM
/8CF6#N! M)"J+B=VYJ(R/!=1R1V6Q0XJT\$ETL]UFQC5.4A;FTBLD6/W6!2]]5K/-JMC8E M,SL6/%!D-
XF!:_A@S,JL'I%ZWQ-P7]?@T:,MK-'U Y1K2QU.9&1LB\$W7)3MZG7J(-\$S7I*%;:ZJTL>G06Z:C15IY^4?
H>"^4,%6)IF M-OCU2]=\$_ !8R+>V=;^+?Q%QS&4&Q20"KB[PJ]L5#]#LG>NS%ME_0?
GROP)/,LOHS)/2*:YV%GHS,!KYP#RA_9#2XQ< MFJD0WX"- "14C47&('B*54\$@Y]#3KMH=V)^&'&*7J+BM-
=PSW,[JR M &RIARSD1LL#PPF'Q*%2)%2T/D0=)T<3\$UI,8&V6C7 DV(6V1\R,FJ,8RR6* M'!5V0(\$ _0QF:B;
0Q4PJF79J1*<'KK4Y*-T-=WR2P,". M@IZS\$.X\!\U!\02"TE)!S@2=M-I JHS#&]@UZVHE(M)MTR2.Z44#?
TA'#/G M.7VN.4UG"!\$KL_V4R'D)U1@UU9!GK6S.#LEB72_,6:UGM)/=,A;A\$8>%/X5?GV7CFPS-
/_4RG09"\IUX6(KR/\$QA@ MM2 %/%NJVfJ&]0B.BV8LH* I>L3;X*Q=QX@"[H* 9@&B[+F9/
M"L/TJ. 21X\$8;G6>ZY0E_26.?2J.0N7C&H=*E[W1 /B^?,5^3AJ/HT!-]N*G M+TGS#V+
B[!3XXYP^A;A49KRFI+Q,D[+V4G'&,VE/D%U22I,%.A#V')3-Z71 MDDW13QGG4\$89EH"9D\$>N-
G5)! !JW^V5X6T-3A(PVVB2S6^="4VA <\$YNH3 MN\ .05G\IAW^U7? B/H11H0?CEX]PZI1;:0[C0Z0+
04^I,J*6,:.92@:Y[5 M"B ;J%-#>!Q&?FU+M'0E^CK3'G,S[R[0-'Y STL_8LNI0AY9H8% ^NC D
MJ/)9+\R'%GA%!>X],^WK^G5ZB]LH*XAM<77QW>7219UN@G)=:=@F)9Q0!F5% M3R0#/XS!3"7(S5R@:4]ZD/0#?
Z-@L]I4=VC/'^AY 1#+*N1=S.OZK!M]1B M.)&ZWK S:&=<>*^,X%8<806*TC&X"3=.K *?
@7K#L"@=(T\$+D=&UJT,X@4=K MP2,=%6ME3P: ?UD3'%K"IM]4%4TDA##H7BC?8&VZHE_Y7N5X\)^A6X3X-
5R,JC<7%R:NQ381G*-R): M0CZE*YL6C[0:..H2\D"V?4F2+Q.J&EII9!DLQ_0 YF#F%@5:TC*K"0@:30,[
M)1KCDR!9)BUI-[9\$K" \$E!S0@AG%&&JM B=#8(/0%Y!T0?X,N2? :9#^R"#K M9)%ZCFRZ?D\D78(=Y8?
>2!A]9 C9.&. *.D!>4SHU:(K \4N;HZEFXB'+5I MWP>(**J/X),AY)A'R+>B)CV-N(,) ^#YJ?9W @?
W@4?'M'/Y=923^=>CK85-/ M&N,6TS\MJ4SRZE>J((30<*&NL*,V',5'1:<((INEH(E^[[=L 3NZA0^ M_5U?
K,=W#L *+XPC'[UAAN6%:)\0,12#Y#^YNX.-1.;:@LT%M&HSWY\$ MPOS3=Z\$%NZWNE7\NY1=?&\$V9PE*4,"?
0<8-S/L3+D%8! RZK\3P4\$]QSN. MCJ2UM/.:J8+R'?4HL)51(* P0R>2)CIT<[>U%A8 /A#
(W,V@,%W]AM;M>9T MT4N=UCL(PPF]+LT=\0/R.9UJK9Y1888*^ \,9%78"S_++0(5%4S: _MH20&F0Q"+
<>LMQ;DAL.%/D#_E,:#TZB!C3R)(++ P7W9;X8>4'WIT]P[8AZ*_/R6?
WYRJ33[:S7.'93ES=ML.+HUB?/S7H0DR"KG,96 M=.3?]ETK9).;ZII#0C3N^E.X?WB
J@:2#>08M:E*KI&F\$12N.-.W7!9?0>"C MG300I"]E5+T!+=F-#8D;Z,[C&Z]*J\$VXKJ.EZ?
SU^_.,5[Q4PGNK[_HL: M)04(WU:T&@@"DRK(.U_!+DQ\$KC4D)M:0.>5/6%YA-# ?Y)2(>EP3(8P; .5 MDYS?
^>\P2U\$E_HGSE+0!\WN3I +XI=UUZ[BD"88HA(68';DE/U0AVT^S6';1@PKA('G3-RNS2?
%U19;#!\ .I(9^S;SU*^?V3 M3J*?M&,=\$25A(_"QX-P+EUV=LN6HR5J9D^N3MT2",MR[G;:=T'EQT]VBG0
MIT0'E(H#"H'-IE;%1[: -'%S\$M6:'P0;=7(,FVK@H(X%0CIY:QWK7/Q>44>9
M14\$:/XJL"NN>\$NB,6\p=:,%0\$0X"\LX\(% ,P*HL^@ZKEI? ;ES9",@,6B%2B MB%3Z(ZBGZ]8X9M9U0S[L>-
M%7P@\$_0<"8]<[f@=(2_52MDK-5\QWS(R&5*!T M!\$BDP0U*;'6CGQZX"LT/C1P]G%C@,&NH; R2Z#-:YF
M&\$5T/N+\$ M2[,N6T"IUJYEA6<4<S@D)LH+L.JY#+GDN/HW:>%Q2]-F-0=&^FI "H.@Y, M'V 'U]'*00
F(N9UTZT)&\2+86N<=[V;E@Z%=FLR76/^F>DRI6MG>KCGF! ? MEZLH\$:0G,TCTYU-^9G4>VNVZM"\$@-
HIB';8W;VW.2\7CT]&0+UBI \05V 6) MK:CI!N<^\$EJ.IY"i?6H'/M:K^-];\ \$E9%B,'F'+4>4+\
M!4=*X='X[_BI7]Q:GSNT!*D=S MM5U3YC0RU!6U6;U[\^Z29,F\$*NRRJN ELT[[@DP>HX([J9<=9JW"-
G3%&B\$(M8G%&LNI6(1?Z:/,SC09B#P5M_UIXN5')P4-3K=:CHNU 1J]H?XH,U13F9/7 M-
"T[58^KMV*\$Z!,:Y7G>]L%.@*QVD3')CME5@/-1]Q\+=.M#RRR805/Z+BY MNT[.>Z@3[, (,C=RJG-\NYI,KBG?
XB)#GMY[HQ2< *D:]AN9HXNZ-J29H]('I' M4-6JKL;,A, QT+Y "B]+*-!- THZH"(W\$0YE+LC>]M5
+A+)K*B^\$8M%KMY> M:;'+^4A' S)],-B8 @F"YX6IIXU+[Y8>7M:; ^(\$=M77V-L!(RD'N06ZMW M\ -
@8.P,H>0RYLD= _1C?M"5,6ZWTP\$<=YSX\@BY(ID!0*([LW"6>PE:]NYJ"W M"@/?4%;DYE;'&1JTA/#I"TZUI**
(1.Y""6D\&K02ZI() ^H+D/RKPB]9R\F'B?^L)F)F\0%B1I4X=TA&%,\ \0@2H\$BD<0_UU
MZ5[SU31)=\$62'GN&2.+*)#8F358]:NC:%D\$P5:U4A :9H*8\,%\G;)PWC,+ ' MZZJ*,; '*F+7'+) *'+/4TV0-

5, Q280:04:F(T9&3Y#5;)32+00))<1UVYT5)B M'FJYX,511:%3="^J%KJ(L2D9/B7B-S2U%\$XYH77*K=%YRQ/8E
D MO'PPE+24QM/'R,4J<(8<,6-S+QMBH)}&E=)J^61_8-%&FB_R"28D9Q5394F/
MLPI%K&K^_HMS5?,\$GN5_357S4[5T%_D17#LCD7XY=IY@Q#CA,I;MF&!Z#;0] MT8W29,P<9[-Q_0S\--
W?)*U'.9&?-0].5'ZV?7E@1LSR^C X7N!\V#DF ^N: MZ7^*@%[:|J3|BV>NB>=JF-%90 J+_N+0]?
K#-4\$KR:,Y\$(\)>U?*IS;,\8 4 M5A\$M%9/>/C3Q"H#GF@!Z3<-Z\B&8XP:1U2V*ARNS")&V3T%^I='3N/#5S^T
MLB0\>S#][8,\N30X5Q0+PLU*58X& A8+W,>\F*R-J5'^@,%4(H^ ?]0;YS8QY7,/-%/' M &EA61WRXM
_CJ05RPC2:FBJS8T%\@,OLY70(X:#QH8&+4U(7R#K#\18KK@6
MU,*&&&*U]6D&/^Q:IR##.X3QDPI:&6++LMYY+J'1.(KB(_2]V\$(8'.1 MWHME>/@C&,@0_03?AWHUECO\1
)&OE#N,4P-M5UT]U70?|9Y#-4AL2K6.@6
M5M,1;^FC/2<&6/J"D#\2W)H!7V2#Y(\4:\00;=FB*\MX#*1H6ZF=* MR]SX%?'UFW=75T;8
3#;:02M9I/4/M@,*R,0/++'MFGJ=E4?H6[8,4T[2 MV;QM^6]8C<,Z+!/D<#:5^01'[RTHPDI< 606U.8+RBQR
9"@13/;DU2VJW9@ MVA&Q\$PK>8*; 73TP&-1PF[S=*]AIU"!X)Z)HIE6S]H/UH=A[\$28NF/)%BH6 M/?
ST:"HL^PUZHDQS^T@9;Y9\8A@HW[^(^(\2P[HTR/36]?;HDEUD112>2!:" M GW8TSA.4JX/UB
R+'JAH"W"H=YL6)N(T6<&9;:F5&8#>%HCQ@ (9X3AP4X' M92AF0:"FU&7BOK(K049W-
A3/92C\$.!"V:&^4\%\$0""4+\$4 MUW#>/>RMQ.E+1M3;2/DM 2!H84#&0@%#6\JJMP+6=I];A["&UO9M!W\$#UP\Z
M>4A-H\3>K\&]S7"X5E(3.^0#IH>TDJU(25S0I-#4WG6-5/X.'%LY67>L_.CJ
MA+W#N/!MC8270*6B9^P7/*>IP[XG+E/2 P.4"_AX%PTLF?<@]#"7NA^@1^ M<-Y6/\;Y^TX9[%?
00#""^/[1#.\$8K=N;U2(YGS+MW5Z^N"FLC>&S'^?^&K%, MOY+U9X9"-?T* VJ+F(FT&X0:Y3
3]U/1RRKW_)Q3AUK3\$*]NZV;35ZW! _F MI?F&FGY1D7\G9WK4.2I;T3&5W?#]Y?0+3,%'KD)/_4A0.+J0>
[4.'#?A+A& M1WG0VQ3)IG"<#7018 P\$;+0] ^R]:Y/CQI4M^E<8)^Z-8]]]Z@EVS,3^J1I M21[-
M2U=27/\&46"55"# V05>+^IM[4?N3"1852U5B])X3DQ8W4V"B7SL
MW(^UU]K*K#&Y!K3+\$AV";04[10=\$[H;9SS8#C G-1 [0? M&-LRB5[L.@0=PUYLT.\K6[WS>B*KWVGVO 9D
&UY<'\"\$0ZMGTE,55X(NTB;Z M&Z8]9;JGI*N>/)XQ;_R]Z 4ZXN0@?%!S021#E"
<)"A3IFI&0GL4TEEE6*W>B1)+"]=6TE?.\$,2 M#%@YHG-&""BB57.-PI(H8E\.=C!;V5)
(I25&XND\CQ10ID759M;T%0025A8 M(YP@0;:S66(T4#R.F[6I#3REG()30\$ZMWG83K\^2N^H*=
['7R%G%99BL)0W5UC*!8SE \)2BF[,+^2T1&%#EU/@@ZMIA?":A50!ZS(T M006,4(;<)>7[W40@H1&*K4W&6D=
[.6<8R%1Q3JIT=5DUYK\$[5=1ZS5 M?/%XV^*/!]*(*V(U/:G937-XH/ZPQ=L^)KM6)4L\2E^&ES#DFU=
<>KTUHBH? M>7= +(Q<%J15G\$-@J_B-2?,2X['C[+ES(177"#NIV[Z* Q2>M.&*LJF-\$3VW M!8A*%&P?
R^FWR&2M2*S)Y>>,LW95),DW(K'@]Y"B*?63J=[0Z6^_LISMT\$ M;RK^?-6:P\$4#.4
,>S"QZ>!ZVL70NW^HQ'V*2XFT%6RH59/+>99* "X; _"- M*;B/Q0>N])"7PJVGVCQ
5#%LT1M^C*K.1_M.PG7,8&=F^W!\7#^A:G%BYAR+ MET(N4\$P>B!,D61"/'H[C+PUJHC"\$+4#6UG!}RLQ"K?
DY:9 MW+F+&ITX9/-J&^,FZ<\$7,H[H6\$Y**F\ MA)U"RKF:?)W)XA.W0.0W'R^4YJ\WVID3Y*N2%--
/V<\4X%8)H^M,2EZQ;>6> MX2K58AN6\FX^8[A0A4Y%30Q57&0L\$ 52S;+.'3EECKF-. AH):N*!RR*,/ MK"
[G&EID=XGC9E5IM,=B0"A^63R=[5]PKJ,W?# P&KA8JF M\M&ZR03Q-J: 6_33M=6U]4TX%_D2SAFK=%
('"=]\L7:RY.U&6W)!K7ASRBZ4 M>(\$0FTZPB,\$*H> BG3S;:D2%UZ'D0G:F2=[0:7\$QV,NM[5/PP::]#\$%V5[
M&[;XJ5Q0M*= AA >,8&#>,I]437H? [K-ZEW*.0]U(18FH?Y3-@P>D\$7,G= M-<6TH+OUMM)= GLC"(' *1H.&
(Z; "B<+\$X=)Y5]]JDH8**'0)T?A=M^CBN@LU M6^8E>MW, RX#=%3;3_3]*KV;HH@/N5@Y&C#<&74[\G]0&4
8TTGX!6XT*QI(MHK3]G_ZZM.+P/MA.+ \$,NXZ!17\$85^U(A0@IQ=R,I\$:XTL6H7;6\9&L&JI= M Y7 *1X:-
I(TY:;[X*^(!#\$\$!YA)Q0\$#)Z.[L- 00"\$=\$]=^L7H;V]8WDAN@ MIJ,K@H>UNY6.FMQ.]&DL""OU_.0%&-?
27(A[ZQ*957B,6>6<>CJ]:0*;.5TUN)+%M=+HE:0Z]#*Z X.\$WQW\$3-E4(
MMRKC^H>A^T(2MKI.&T.1GNDEPP&EE(KG+F&W^,WL?9DBE.A:] MOHD*,>G.H%0'U0S022?
0*SS*%^3VE#?]EV*7EJY8K29(635K8I5 FU..J\$??460?4Y]A=]WS17-?
MK%IP,L"0*!X;:1VA=:RXZ,L8U:X^); L6*>PNZU2.)/<^7NCM#M[(FQ:!) \0S5-
*KYA1SG24NES7^:\;CEG)1ALCH25UNX\$5ID'C:\+7P]0M0?)78+B1-\$8
@Q6V(BF[OUY])XT&3*U"S_K6^LD0IU/LPG/..-D+!),8)N:0 MP""Y0#Q,)!JFXMLGXH3Q5:PMAG)-P1*'M^XI]-
H;/2_L\ \K_9-0=W]+ Z+ MM J"W_+?N4J+2RJ@K0Y[?=?=?>I/3=8<9BES!EBITN-!V<8J2B8XR*Q*V M>-
P#>U;:(H+A.]GZRWJ)VB[LSVR<5-A0TGAVV1\$N5[3=[D?'T-JD MKXSA7(085L3^&K\$0H"Q _-
P*YQU3/ANF^9W6SC]A.=WS7@4\$Q%TB*\QW_GOGME-F5PXDFASMJ[(;+YH8J;1P'39Y?,(6)&_1JB&7
M6F>TW>A9(%8YM7=2K6QL#97LR2,[-]\$=0CPDT"L=[@C/;4SK& D*]'&DV500 M;EV!6;SI((\@!&PSSU\$-
FT9S+)05""^0%ZS"2,IZIX0GP?P^!E/A37D-A_Y5 M46P^BDZY800!?"W\VZ;!"8PHQ7D"E2<]_3)[
_6/#R^;+@[E,>6<55N?<G\$?5+9][3&&)R&H^H]=XC=:G;0U.7G M1X?@LNWRQ_WQ]>H_A
R='/_0*YT:5.M.)1+2;L>\$"H&(-)-)G=Z-(^)->6>CH!P9(20Q6: +>*?>28,C,V;C8?FJ.J0\$G-U'1J-"7 M(43V,
(S0%M;ACY<>2G[%GC75ARF'G,V]209\$>^#K<;YN8^_KSVV\,GN!\ M]D5!..?
EH0V8."5)4,+K&\Y:RR6'*/@V+/F_67IU/WW\V77"VW[6057Z"VD[C,3?%5@(^-\$-0P0U24X)@F'!?
Z0W@]:DC=,+(-J9LR9Z;:^03Q\$!#N MFU\):WR2_NU7GX65Z58? _D;E!+U7[T9]MP-
3KUIPV0L=28_#FBN5;JI=^Z MJ'S A3DUDOMJ)P&4))@J%Z STD!^2Q-:U.;'0TI^8#8)Y&X7!ZK#FY9^/-R<
M*/1&Z%U*\;LY0I1M=XE,#:=\$C1US J+E)6WY M_5'485\$U&M8M\$-3[A[2KX83F;9@^Z1\ (05#(\$-\$\DS-
J2D=\ 'TEV'FX6"RL M= %;&8Q>J%ITPP-W?101X*;>NTHU>U>Z]65XF0-PQCHN6G+9U_1C-QE5PE M\LN@L);?
-#%#9Q0C/M(2N1V@,5\$'N:!] "0,I'X>EY/J 1.%*0PCV[#M2LI1: M 7Y<.783L_6P#/>(J!LJ8L%_KXKD9:
(^7L!\ _/+[Y+VXX :6!U4H3M8_P,D; M=%B.E*19-?TML5"7&.2: KX=!ZDK:=-T9?
@187F9=H8T=S'P*1;.'.3*:)DH06WJT[1=&0QF P!> '+1QB!+=+6SU^JK*#94W>48ZFK M&"7!Z]0-
=!,];2\$SH"U *_\2G>IA9EQ3*1@< WCHF?GYR6;Y/V3MIM!,DC"\$\ MGBN8:&. ?PA?"NU61>-
M'06LYLA4,0%9\=N<^Z-QANFDVE;=CB*Y3I_AQI,F'(_AU%BC>YS#UZNOT\<9=%/*'V2 MZX?!\!(K-X87Y
XQ%8?5_H7DT.44G#H\$QC8Q2!,I:]A_3]J@!B).@ !M'8)V M3TK1XM-;H^PAZ1.,_XK5\$FT&@H;7X]?Y4'DILW
!;@'HR2+.^[C?UT96! MCI7MJ:*0YD@>0Q08JV= 8E/L2+ZY&J3'*1MW/!ICL6>K83%Y#'=K(IRT<:
M%D+H9+)]\$18>20<@02H-[QZST^)+@2!L*PCV*_'0,XT5"L%58XL%!
L<*'/ \$S828*4HBV)E3'\$)I',G;Z7Z[_]W]1_RDY]1\$^?W M.K(8[1BOMS%05\+ B/^155KNT=*FIW"8&Y. Y]

!S?Z L-7+=%00_2H'_I7 M:&AP&*!4B%PP2)%:=MOPT-9_DG^67%=22'0'5X>+T#YI)VI"
MZH%\+,.@=FV:_NAF&=^JFTAVOY>[U^BC%7W@/P6\$%4\^V:P38A0*2]L29;-6X M'QSI_@UD;-
F;U8\1KK5U= B!@LFEPLV'3UP: ^P\$4;6F#@>)>U MD0%5=^W MCCQHHT6:D8M:\$H5/;8=>+;
(EF1T.)+V7:4P\$= 4LD4>=K.>7*6\Q]=LIW<^4: MLU89\4X>'VZCD\R4^Z4L(>7@BY\$2C?8D@7?
7,70_W1=0\;247^V_2#IM+6(V M4?,"7QD[.VE(C08*8Q7N12 =6N(+NNN)8^XDS>#EGG<&M94Z@>-WP]2,T:U
M>)0&' ,0KS7DPQ]\H,/=ALF;D.FR=51C*B0V:[Y41J=8M_UZ]7_48;C*?V7632:(ZBE1RZ=EB@INEP M-
/+VV21Q77I H+\$A25Z9EYB+J+*F*6T90 @R'K1@24,A!7BM9)3N)Z)^D%\$ " MJ&V'SF@+
f>N.W2\$VLHI+CDM"@>,90"1)+T,0%WT+JW&6+;."&"Q_7-Z&"@J+
MA;J9;QB/1V'L3/1;58B@)!S25EM>G9L1('WZ3f&J@I< [AVI44DF5/GHZ@-G
M!WFK**X = G.C&NS"*1#I+&"'\JC3SS ,D"G*%GNHB?
(1W7298;JYM0S0A@LYW:C080ML:N>U<(L":)9\W'CTA3R:SD^_9>? \L?J(D#V"\3N MW&3SS9T:=2XE.\,?
71Y+;KOD&Q?YS7NW\Q/)0"IX [TT=(L3,KA\$-[K#9%[M8>LS*4H*+W\)UA<#]DCW
PDR90WT^A>"B%:R^QE;D=ETT*BN%*:23.YL91. M!K)IWEE%5IAXXX. N([2UV[5\$<5+H1()-DZCI.K/-=+,8HF
MBR5:ELZ44?F6J%_8DJG4IV8_#ZPG/!*54!/.4PSV0A77N /LZ16:CF.U-N> MU[B*]W#).X90!!6WF05!;!<-
(XR<"&='KWEU?4G5"U+A&<86G->'=B*PU"6 M%:_1MU\&G6 >+(34J_*[6(9YQM#YZ
=/'+'*>:W8J4.70K@8>H^0(S#V(I"! M\$%/9U>H8 X6?N-&:"Z.<204#560"!RC;-I@&1 S@ IR_WH
/MP\X,;2K\$95 M6?F1RGLF(JS[@1&IV>Z,,G8'B@.R?PZ;ZR;L- #ETWT'2HVF/JBH,,6V=%Z*
M93.FH64T+.%5-;^#K?TN5G''70!UYWU87:6YAW82>(4FU\$2L>0.PL4YU*>+;
MF5K\8WWKBS/('&,0VHP&9<7ZHECLEG5Q>*5]YQ]-' M;?#.\$CF7:DA+;\$;C05;F&
(>)KRIRT:\$R.HXGKM4?)/\80?3K9GFI56)X"Z8@ M4N!^X =!'AY)].;Y\$ #1(8"(\Y?#60+A1V7LNNH0?V'56&4
DO(R;J+WPQPU.)G17J.N(FH%2SC9JZ)4EG8C"C3M0(K!66+^3'(ML,'3I"0\Y?A0G6/*>_*'9M@3"?W_B&+0?
7#)-TK'^.Q!,8<+I6^8I6^TCHM M;]+?^K[F#U=\S06,Y9=FA;\;W_/&EV#0!_6(F'E'>=,%NI^Y8VS>:N@!
<1\$*E]OP;U?4(A(D-ZEVLZ*QV"P@TA<#B1I^YL,\$61XTVKTBI)KB!, M8WTKN?
G#@;EBTV3;]:I_ ^:L^=(^3G4.P5!10J=';_5W>N0GU9&0*(A'6NH;\ M&NY%3KIMCR/CE9ZP];*>Z\$=WX76'?
#AG\$&@*6K=7!%]EK\DT>\$M)U,1<6/M, MP=&GAMU*V\B1?I1^Q'D"/.B%];(8@U?J)\V6<-
/*X[[]JMWVX7())MI55#-S M-37-2KMV,U?>PY6SV#P#U%'LU("2]Y.A'9!0/L0J_9:1H%\2R7"U;>N38M@
MB5_YK?R-;_5?_DW>JXN8BJ.Q[UQ060EXTZ6'R0;'"?8I08#>(?-22"PJ%[- MY-
E<\$.@@'IY_/3*B3.LPCDAU\ \@(@?WS.2]B.R)NQ\$H,(=08K)U&8&3FUJ% M1M/0H,JZYBLY/-
T[QP,H[#W(9X#&B_:=<[%ZB MTNT(SBI)?9WPOWCE" #US:6F=B/X;+^7J3J5-1>3Mf&KWTGW_-Z'6(,9@"_H
M_,C8#\$\$DU1LL@245G86,Y5Z!(1F^UH,@BB47QL!DI)ZX]Y QQ;^W^J;#F"QJ MSNF?Y+(Q_22
=5QRVQ['7/F=V#;G574A77,KRBA; MR0S^XT@5067F%,)4K"MEJ/GSCDUI;.C\A5^A^)-
)9/\V,"APDK<(M]G)"5H> M40DIT5@-^W)X8,Z=[,5TE8DI*YS%98/"#-T+;#E*K"?6E&GC3%, "Q>\7#7)
MMUZOWCJF#NX5.<2U8#FT,2H;1;2V_T1Q/-&*1WPP*LRBK8.OL,BFY!&*QB7K MZ7PHDA?/)]:+J\KA,68C:!=L;
(85%A:Y>T+,4LE\A)"V K"!];*FY"ZI@9 M!9SEH;42%PEN7!_CK,_KU9<< 0-1V9]L! ^^KT8?0&
[0AFSU1C/5F/=C[PS& M##J=7=GQ:??Y!)HJ':B_PIN5&Z.,R8)=&VE6SM96@M6
MBX\$JH'KL1E7.B1H<6=1]HSY50#)J0@%2W'[DJB!R.#B_"NV&Q(6/I*L8^UE
MMY4\$4F:QKZ!IPK:DZZ'TAI@BW060C(CMYL2=%*.= \$0&4^1/D;MKOW%@\$R89 M-
D,HABL0'DHRKE^4/_40B4]3+)<+F7XU=QEV7:W37"?G9Y?7"50ORYAL(PYN)0.!
4('*G^;VB%T6^U6Z.A A91L?<@_E9N9#9 M'U)9""8FKJGP%X2V[)!8MIL7C/[P.-I0.MA*0;6(RD_]!U"5^L
MRN-B6PLN.,#-2: ^.TDNYZ"5=E^E^C:(LAY448@5_TW?IR:+ON,];0_1V(%N#Z]+ MU\$:5](?B4Z[?
5%1\,I*+8E3_5#:_RYB00TLA#,ZUYFP?&A'F2WHIT2^+JM0V ML- V9FI5%BE#*99R:-PJ^EA5V0Y--
/N\$!;Y7U@8(J(^/E:ZE]-F"##BZ/I3% M]\0'KU?_3PT8#IX2/@'C&L?W<+^S:E^5(M>Y7=?S%A53QX0P'Q\$J\$
_7D]W M*" [37;\B)J2!(1D\$[JQ463"11C&%6B+(GUQ!,5+9&7LH'.?\$)WZANQ@P60T
M@TS'&]*'+12%11>B8M75/I[2URUAWG-7DW9\$Q80Y\;9PE@./N%CI6XQH"@ \ MH;+;
\$N6H;C\ON2EY*TD"OUY]'KN+D]+A^K@\$*0V=3&*9N\$),K*K6SU/&,0Y,60\$)7,60PJT0]K)Y3HF0
M:D>"54@,H)ZS[^K>@5Q)U6H2_[F021!6VV#BI!&\)\FG5EPI94S481'J5CF\
M%.'*#Z7RYE)0"\$T;PK!-1%N6GCIP>P5=%Z">= QU))IF,QS>4=8I/2C"0I1=BJKEI*1:;6(S0(3\>R
M/OEYE5T'E*]47%(503F50ZW\$/ "9SU\$S-TK0Y)A/;C82-"%^^B)>TKE&@?4; MV?AA0;XG2!\$!;%=?H]P*,_S?
WWW\$=>\I0?UV [,C=[,M-WU -TV/;B_M4- MAKRE\$T0JB@0D\$14.(@50+J;S/^VH1-Y,@(.VYBJ=[?
A;F)W\G=,'F C%9V>VFNZ1K* M625.T35Y]5(;0'1UJM/@=H#+1-XTP'\#(71=EY==EQ2E):BL#(B_V@ (3FHT
MLI9"4GQELB'=T*X%6,\(I0%)>8\$FKU @H169+L_5_K39F6B1"1(WEI
M\$>'. \$N_T,,2,,8.>M""0'D/6JY1\$K+7G'?@#=[//E\$ MGD]1[<&"0]:8-B_?GV]&H0\$5X;J2.I)3>]T]+
[5[%, 'ZK_S6;I@.L\8!902- M74K",;0 M)'_SR76006#233CV;])0A!1,6-9.3&,FR MAK';/- /JN#,0)G@?
KI2*[PL4X?>J(/T^M6E>]@B"E_0ZZ@.DI#!\ \V&GBS MN,QQ#PG%8+"P@<,00KZCEFR^)8Y]HT5-
_ \$78,70JBSKVJVJF&"+]*FMF9_,% MZ@5U\$AZ)0>Q5P3#"S0YTA9U=P%C^;10,G]S5/883N3[F-56HP)E><4&LP=
_ M!02,..@;>WB#;F"EQ0#Z54[[]'N>I[M@15K)/=%#BM[CDQ+80;_/_=XH,L-G&ERJQ)>5 MN"0S1R8
?;!8G'WB[;=?X4S3QTQ\ M]3?;>&YDRJN6\1Y<68*V.93@!X/QM' M5C",G(.V[DKD? MS%2V58);J8
F.SAKC%"@SV[E>!H,JY!;K T0(AI_%&K\8I(2W#G MYQ_C4HS;24I8\$;]H3? [2/ZQ#QFI\VC>?)K+
(W@=DEX=4(^PI\$.=Q)=>MZ& M7[QK97B"LG /T5KNLV\$V*^"\Y2@.I[T(7;.2!,1T&H(Y')Q>/-0JUW8KG=3
MEJE@BP-%)I"7<4V150%R MCB5B&!/TVU8)V'2LIL0DVJ\$BLY-RH\$2^FI3-H^I!>I\$K1PR*BMW#-TW7-0=-
M811D\IT;%>60PW5!QM\!-;A@).A)? \$U9?C@(;37DQ=,X#;ED_/[]U=QX
M.AN72CT^8CW=)C;,"/+E'CA;U0I=@B [ZU=WP< %HNF?2MOW=)(("RV.;[?M1+Z8\$P3IX
M9AKS.\RXI,WQ0/JB>Z0J;I!C[P6_C'0%6S0EA[\$G,I1>5;">%(0;MU, 4N M)H>G)@YLVZ^/8X94GLAD3/!#
4@)+Y:2XEJ.V'@R1D?LIT;8S0,YC04+V#:/ M! R)408UCC-< #C6"?Q%QZ.=,@L=41TL?9KLHVHU
Y\PI0\7JQ)Vf.JQ31?; MW-*:5[BU\TX_8\$%XJ(HP_8JX4V.P=1\$*'/#WU_?#:+WA^LQ^3YG?BN'9/-; M01!
Y?*&EK0A:ALE9D1SPXK [DSYW\ZFN06RWU@D]BR94Z885&=\$\$E)\)]-L M[)OD_#G"/C=,1H\6S@M?27791U-
RD#B3MP/?4N%\$&A: ^[F.Q_0A\>=I!DA M4\7;@/1G[MO-,>(!Z=-WDO(WNMEZ>L?#\$#H64I?

G)\#?,2(!@=76R."D+** M1FD5Z>[J0W*];@5;'(&6!&U,N/TTKQ<-36D:%=#+4IW8S9&WK+EEIE1C\@E/[
M[U]2H\AAB*AQ:L]WW\7K62*"Z[AV??->:!H,N.[YAOH(NW<@!0Q>;--8 MQ60B\XRH\$-\
XC\ \$ZG%+!YNA9RF"\30F#><2Z>'VI7!;:NX)V@K5,J\$?:N"= MT<.R8?>%]T37!NJ3?<.A&>!! ,BL%GW8Q1D>
+ \$Z&/79\$6UEU[67B)< M^[T*#6N) T2^:/-C=I>]7GTG#]HU)%G73CN>3%UX/7I^1ZVR24[;1MH) ,X%
MHB@#QT2H)V-P[P<%\;X)&]OUT9K588HVJ06.\Y,^&\?^;N@R'C&6#%6'TZ#K
M2C2H.P,W2'IDYOLH=U=5^UNC:A5#!T5D#G8R\==T>\C5BA)0;\$>CI@<\FK--=09^X!RS=YUGWT[(85-A,
MR,CD<&0W@(>S-\$EM,,^_0G91;I\PKYE,:WKY\TOS[= \(*B+1'.7\$%:DJ<#;\$ MU!2 V"*5!9XF
A_&X#&LV42VJN.SWN)VQ:9)>U#H7MW*]0[/MOD>LMB,"Z* MMG"#6UR0K(PJMZ0PXK+.=&FI'LQ)K:LJ7)
(V=_M\$A;:UV9UQ@.(UWY,0'00-MXR3SR(^4X58V-8D-R\X;IQL5LBI_0['9'ME9*8Y.JL*WC#^,L^ ^8U3ICA9=
MID#7PA.OJ8KTXI)P!>^[XY[NT]5;#)7)&<(5(G!5]#7GKDA44:A\ \$QA\$V!<0 M^G*-0"
[I1];AXX]6IZ:.01RCLZCZ-XE+2!2-;?#FXMIJ\$U3& 6Z; J%:_!&#
MB]34SI^CV;QTJ "5QZZ@Z#&V\ZY_3<)&CV%)*8\A3E29NK C(\D' OGPM M)89/@'L1XV)97-
GYOINO')P1.3@C0?0YQ<5XG?A82W8\SP6#ZS365PU6'XT2&Q5XZFP(T^3@ FR1
M8SA4I"" .I*Z)1VJED5\$A*:DJK;44([P(EZ4;K1Q1"ULF_60%:_=&-;=@6 M,)%F5D'WZ?
QD1#+G,& DSRF#QS(W\W2B/G2P&0Y9Y!7,\$QT=[+V04ZK M\[[A_\$186>TVC.]HK_9Z]=[^)I8M"4N8K!0-
SX*2Y8G BP8=34WBD\+.,6Z)[X MAW;M-&L>5%ETF0A>3\ZZ7KA12 ?Z=PG5U.]HSRT1X%8RE=J;LBH(0_3'A;D
MV\PI\+Z0>IF37N;X3GW8U!S\N"* (EA[ZT\B2G7 F^[L*519N">J"-." :6 ,=VEVR=U!1PA83ROR/;@V#6NM-T
M\$+4/ZHFE009FBSL(&1>E0\X0'E'7H[[;:'IY\@TN\$N/9G>C<@<:1^=^F;--, . MFE>I]=IQ(*KLA%*LO#XDJ3%
"\6<);B1[+,C0_*,\)YR>.K H/>RUV!:\$0-6 MG41.IG ZV++-4JL1N]
61B;R%0J!M,Q+0XWS/-:]LDOH35B>UW9:E2HAN"0^>
MCBNY>#1/+26Y"" .0Y)"8VR:"03;UCHAB_<44@G)L_8=ZW'!\KDE-EPEWI=,D M)"
]AO"&A!ZX\%V;N.7>)/@MG,BT6T\$A%LL>J20P\2?H\ KD(0GF502.K51'BJ?T9Z81IUGA?8M\
<[Z+W;J""\YP7P0J;^+=V4Y]U09;CUH4&HF2%5&CM(<[KN])6A),0X6 M!\P^.-_3%[\$C[H>C^E#9M!0!
(S,.,\$+\DK)6L3AW?K4R5;*H2G5[K*F8TT@E MKFP??,X#A_@X+5L34Y!RVRF*-VIUZL(7* E@4J0KDA
1!AN1T6E>:"CIG&>H MW5\$K&&7I\$%I8]\0F2:7>J<(B2I@H/5M-?UL+P
=#E;Q&QBH3NDF'<'73ZGV"?.,5F,6\!^3Q\^DN*I5_CVJ-#SJF@+<^>YQ#3&=#=]# 'L%'1@B:M.ZDW=-Z\$
M,P60;I9YB@F?PT#F'T :+*TD2<.F:GPRR0'P6,=2XX3\&-;'M&P_//DI?VX
M'RP_FR7K+&KL6KG9,JCV?.*>Y9)D36#1,UD:%.!+I5%]E2ZJ('K1,,93NFEV M/34%SD>M7J@V})0'74
!^YI]=EVC\ S(5E*6AIW*Z85# 'B<&WHA\$Y4#HY6-UK MT3D6G?_M6G2^@+ '\-
HK.X01V[5:QYA19*>2T:9&J&P0XD!D MGTI?@Q,9K@I+MWS_ZP_.4(><8D2<\V)J!+PRI(*:8M2]("0Y-
[\NT(L1!*PZH,79,:NW',00X4M25#- MO S'@]'W%9)"]%=?C*?/FQ^C/ HBU0S>9L(!)
GT\K&NF7T[\LT./@IN]\$9- MO**YJE!D\ .FYC5;T*!2G@G;]<-T>+W=->1"S=HH3V- GEQS-000BI60II=J!
M5VTZ0(I\$@#?UU%X/[P=:/4I(:0+*),HN']]=?5LMN+!^N<]HWW< W[A349E M; &C=]2>YP\$UY27M\$5#F.-
]N7PD!1V%8URWSX;:,;)+:'L6]B4G+;"" ;0JEP^ M7_\$KX!\R3!H5Q\$/HB>XPZ<*;CKN]AIWV[*;
M83AQIB:E@7F]\B)VOM:SQE<&2#J\2/4HYTNL7,; UL0[(3JF4C\)"\$HUKM++X] ;/?C'\$EZK61V]5^
M90'K,74\$=\$8W*6_R/A(SHRQ)<0Q)/GYS(12N#J9^-"NLC_M)VV?
R[9J<6,'4\LE/0\$X"7ZF+#@>Z,4I!5JB&WV?DEFV0A:N7>'0PK'=<*0\ M@T^<@QMPCL#S8*[]109&)%7M
VKJYZAX>.FYHU+S<.4P2U< M@/7DC(*BPH%=00_.E*W MC-X[,26#
<1&'M2.RG(H0A)0F4C0T4YK09!CR&V2^[J];X_6WP)E+ 18W9GPB M.VU8G,K7;04B@)"\$FFR2_\$8#'"B2-G,[
@>(.2%Y5RMJ5H*0 Y170NJ< H:7U-7&0< MXSIV:3)8H!/AA];!J;R-. (BV-Z'=L\$&'W=%6V,.=ZU\$'R(X*'Y/1?
4B_CB01 M&#,55->9%5](3L#^/<7W.MG[ID5@'Y#]X\$:4ZL1PP M=\I\Q+I@?8YGDIDQ\$5S_PHQ['AJ4) M\W^;V
*U*E&=-M V2\$%?1P7ABAFG3NNDK>.G7!>\$;TN!7:1X7D]
MC"\$.. "2Y\VD7I@J3<.^E#2M7S*EA30]BCF]@+ '\-C"GDF(KMN@8UCZF_/A@ M@f0^LK[5AY+#7^YJI?
0=Y8CJDM\IS00^YX00U41)DA:K:"H7PQ_N&6&J;W1M MQ#J.N;2P>4JXQ&^7&\$E_9_AON.7!4P>6?1LRE3?C4\$?
>0LHTMQLTH,0/_B2K M69!&^06F/[\NL+M\$>S*.HR2WAG\8U4,=:VWVH4G2F/,@8L78'6_%Q/NGIS0
M=:_XD(@#7I9;7))QKY"5KH3<#^([M72Z[TCKKMS]'48F[PC">)*XNX,8>@(_ M6Z&U/JY9&_ ;KU=^ .NV8\$L-
L=+K!YXM\$BP9<)'3 W[W+^P/B6.50;=!NX!;09 MI9(DV[&=Z_)IJJWL]D*+YP(/9')1&=
<:K3\$[<8=6S!E3]%V2K5<72Z_A: M(B+K72WF)8AY\N394V=ND'34*!F?<+5G&7#?>ENRR8W(Z^4/>EX*'.--
"MGO M&)*WP(\^X'0@B,*5T_GURM-F^U=
0=%;3&='1^X#)M8=8ML!A,D(<4JWNT1"KEA[K3;W)#Y7BADU6X)' 'G3D_Y+
MS]4*:JW(NPS0ZLTJE7BI1U(_IW)N)/DC6R_3Z^;:B;XENQ)^Q?U;Y9BEN%XH MY-?
T4;^2QL>0LZ[.%)6^/J1"VUSQE%!.B(%U7FEM#I;>CTF4=" .KF89"03!*<
M'1^M^3'(DP(85R*G=>DWUD_A)>,4UH\%UJ\G49*%9YVT-.WYXI2AS/&2)35G
M\ E6./Y&H#&P['Y"X,;9Z7\ "&>#^2# ")5!,RID_+]U_N]EJTGDI E<;GHW=* MD:.8/]\C\21J;+@[9I-
A<_ [A#J]>['!2S#^6XLEELI=KJBK[?N14L+9VU>6F1K MCIYS91.9EJ% CJN/MBB<65^3\T4HS;QQ-U;D>G_8'4?
D96P(COV (0.5RK0) M9BWI1#8(&[PW_4J(;UFBV5A])3,5!MPP?Y6%@3.<)S,R)WD+Y=4D*KV4\$@.6
M=3:Q&7APRO*-&>!PS&/0XA-\$;8=G@G4T25>\$84'-M9#4Y*/9#B0#%#A43E=*GB[
/A=DHWS.CN@*V\;I%!HG0(A07.^P^7;J8L0)L%
M9<^ .QIA)!H;: "/]80W/. "Y#^V03!&I@(<'!'! *D8#A+GG;^0IG@>^C@]"BVJ[I[FE"SHP%0(\$MAB=B8NC*OHCL&E,
MT.MA]@5A*IJJ20GP]>JMF#0^4C/D@]V0-Y)62B4_Z4MD'L>(&(\$TIZRM7(9,)
MSWSK7PWT)M=60FB\B,]Y94"1>+0^XWJ74@9I):=&\$GTA;C=WGD8HY*-S\$Z<
MQ&V:USKV1!/:*&M5;:KHASLU@]:GJ9I3\$\20U;#;))L#E\$PE):R^IEMDT!D M?
U7^ /<76H%]0V+J\TNHX;SZ)HFG%6+LW/S\!9=7Y8++K[/2PB-PVI(6I[,3 M,H_"BD7W]_0TP,+(C0SIM0#^-
HEGT\50Y2;J4HJ5Q)46G6, :--A MZY5.HJF4#^&I&J M\ D%IIX4NQESQU,D.(
74P@?!FBC1%ZICF["_N["]A041N56*.>06ZMYFYA+6X69RWU MP] %9*K%NVW\$W X).23H/N:2TOCN7G.?<
S99_.W%:U, W=>UDVDLG MM!Y/2R=3:[6XP2:N"JCH3"E.Y>=//,\$R1V.S/T)JFN(D3-/D?B%\8=0 .M0=
M)ER%R0_6)ZFG\YRX6->BI17^AB5*4.&L]Y,E.\)5R,9#7P9Q\$47.>,6P\$:AU M\$#]-N7E.[ZZ#D])#(&^%

U[/':--32;]Z)\6(&71C):S_NY2)290L#FH1_M7+ \G,GA\$II[\$>Q\LOOR\S&.!%XI4V40\7KUG\-\#
RF6@R7G@D]_C"DF00#" M_G.;B0-8>K5+7D'5Z'@QTGI4\$7F3P0UPQ;*TEQ48,05M*0N9T+K\$2DEB60)F
MC\$ _NE95Z5D-75TJKZ(A(N%H3&X(AJKINQW!\$*+F\;AY1_\$ZKT1>D^/U^9>5B_MU3&IYCR, P1JB-
ZK905*DV0D@K^7Y?}\$N4(M9MJ.L^=!4(A%XBB-0L_.1XWZ_MR!75LH"FOC&
0"2&V&G9M8M*DN,E+,EC8AQR?,3"UJBY^:,V7W='2WKZFKJX*}(-I2BUTT)*0+KD#F^})7};&)N
M"\$B2B15+D02PVRFO=J31KIS?}\$ZV#2'ED>Y,DNU"F[M+]LIJ_A'&JY#^\$%GD_M]'?HJ-
9)IK60F\X%3:THV[B\:_GFLGW+J((04PI1A-WF3!_AQ(YF^SG;Q^/Y_M;79NH\N@51I08>3I)V3H_)LIW2Y?
#3W*HQ!@Y"\$PNIKH@2M?1F7D16_!&7_M8D0>J5*SYTR_9A@B>1,["&[4A'P:I84'MVQ/UV^-\4C,S' [=3N2M_.
(M\$GL!_MF"B<0Y'M#XS],-=\$4K0T^XPW'\$97<|5QT!-CL,Z%1_SHSJ&*D1"G-NP(8)?_M";?
WEB0#X\$:4!JL7EJ1)13>*56YBX01\E6-=[P73XH\$#T7HM4]F]70W%_?"*
M^0;,_JV)J471.%"3"IG@K8G3\48[8:1^L@E)MW#2A\$ _K94:9(IN)3A)&#^M^
MCKTM78@B0,N"MYL" _Q^2CR84S-5UY\4AV=-&WP3-=KQ)CD@J. _M\<:+SH\@F'%K>GM8)20BT0ZIE-
I*#J7&I8K@4K._#U\$;_U^,(N#XND.,)#Y_MC-->|
<@V90B5HZ0Z*^87\DG4\DVZ\NHJSI[/R9:D'8'7B'8E_J0W0\7L.Z/ _M^7>("FF.DY?S\G*9IDI:NT;,_Q|_8K0-
'KJ>;L(+--75/(B9'639RRB&IA#<\$8_MIZ9.W)B)ALH#<77B+9Q"6+X|\ZLH\5LK?
_14ED1Q?;^)C\$FU@N+U0'&&IK*I_MX!Z]S&"9VFG00IN([(17RB-WHUV&P";_9T()5>+:3FUSE"C_6RV\7SDBX5-
@J_M'_@V6#K0J[[V#2-+S@[+=QFJIO[V=P|VYK039#HM<3?1WXA,[F&\WKU>=AA_M[4%U>:5GH1*@^&,%#9*YY
@|3G>\$>6R.Y)W^2.5N[;SB7W&?5EBS1ZJ70X[%_M<-_THY+!6@S#\JP&Y!*="W9W2-!&L-
QWCSQIS)GS75\I2T:9N+*NVAQ_R3U_M>1KLEY]_5A\$B8_==D7J9M^'!0BVC*"LIS>QMA#.WG2VA_S?
J%B35M\$Z^Z" _MX+ _WR.:1>-I)WG>SUIIQ)C@V4<,_LL:[T.A3JOEG\Y^@|_K5I;U?K-M6I]_M_6/Y;52MDPQ-
J@LD'_A"/T07,_)6)R-SRH;8KZVM%\H>N184"EN"NIH: !_M0)%@JUS!8<82\LQ74;=F%B'DL91J\B)
[Y(!+ #B.5WYX;Y:">' :\$ZTA()Y)+(_MXWF;-:_V%B,C[WJ;3VYIM!NJ";W&F[TF:LPOV/U@G7SLY5\IV(>
<=0@Z:5*_M#_ILO:HWGZ.HJE<%XMW?;WFJA6\$<,_^)\7L*_M"S^-(?^('.)J.7A%KQ\@^SEV1?7(C\$>Y-
_EO;*_C=K[\$YVYX%B)5\$(2:F;-[@8=MQ4.SGRP K0^_1/57VL0#07,/7J_VH]-XU=)Z1'" \VW-;|B?
&)4K%10BAFVH_M/U4_QC5J;=;R.B.,S8%_I205U_]""[X>5X:|EP+27A\$;+%1"89ERRORS;:V
MU#3=W*;RX*E|C,_)GP3L#%W5+4BT"M>1_#0D;DFR^!B8<+0S:&%V_MCS7(\M
MBEY,D!X/^^SW3\,_^I|7C+BIMLSK\NGIP7V1%TY-26,W5LY8SM='#3C7PPGF>_M^,!G?0@S:K1.-
:_\LW[L]0\^&07+2|9A;_8I&_LL\$9VZZ0#UW!MI_Z^VN[1,_MQ]_%&"G*X0A\$TJKNU6=-
&5FQ95A^X&0;QYJH[R^,S:_^1VG"JSTNCI/4+D89_MQ-)*WI>8R[]/-S/+)B,[1;X.SN,T-8HFHJ_)I66-
H(<[=,4E[3=,]8J/D^,]_MHR/T0U@X^K]_="M"Y|L)=^&VM_T?)LND=;<"-WI<4#*IL_9[N"GDQ]8%IVT=
M7FG7KA,Y1R|9K907EWXHOV?352IU9:41ZS&B:VUL):?B^-SQ#,OS),F@)/-D_MJ_WR@M
8AKR0PVWZRHJTM5LVB;8FM[:@[3"S%'. \$@LM]L!M-_"VNZZW++]=&:#23X:PF_R[2_P48YV5R>N
MI&;HJ[UHE]A#!\Q5.,;_*^5T1^2'(DB\$E[2Y<%(C#J SX)CE?QHDJWG/_ME=AUF"%F/4+U)1:>42(KA#'9(4U
#+/[3@I^Z&#%@1<);(&N/JDT\|M;Y.76_ML8IJY;K#0#40"%ID*1!;ZA;>^0|GVD-G[\]4I/A^NZ:'3!&IXEJ;
N#=-G_7K!EUBPAJD<*.9R8AVKXKD_MA!GNMW!@4PNVU>I95WW.J0.W;^CL*2H%!SCGKVQX.!8.82,):+5]:#
[95_M=)M&=#3|T,X)3W.[=A(V*3*8|;KXF_07JR4\V\$;8<+9*@0SE'0+S!N0X|5P|.Q:BI#+,?X>?@2:/?
&Y0;R\$48_MKR_-)Q^@)4;GHMX\$BL(OHH(&;?+EEMKL4-X/R1|]S'T-XTIE9"R1+P>)8X.
M*!W0M>^:3CDP'>0+Q15*1TV-^U8TW;OZ'?V/RA2BJMN&V/@P]-:M.,7\J,0?_M4P?7M#W)L_U0LB&[!6#-
[;KTH&K3<".=)0R70W"3|GW:Z5S/EZ2:4WIE1VF)_M)K-ZA(Q-.Y,S^#L2ZG9#L&=+BF<-
&V[F>.EK0..17GGFR"I&#1T<<&%X_MQ&UJ??CZEHO?52,R>V0-
I"?;=*F|3WYC,\=R7@065K#^&^JP0H"Q_#8*UM(5_ME_A/WYP30[58/T5;-E\$6=WZ5_?6"DCTX3.N&
[<GS8^09+Q0BD:-?QMD,UBF_M4V3'B49*JW;L7!V8WT:VU*768;)+X'1Z2J_5>=P.X;@>|B9?*9X\$I|Z,T
MV&*DX*"ZB+,.<>&0(-"84/5Z?R!UX>CG*0?
\$0',X00M0(4K0X*AJ&/(_A\$7MH3(OF'-09N>38%ZR2))5T_WEZ)NX=&H6_%)3*:EL4I<[/4"ZWFH(.>-
P7!|]852)"\=I8ZD'Y_M24BK;YRII^#G>4RIRT8N\$3F,\$5#'_LK7.H7,#>/DCYM&LH-NZ/D
M,KTU93XV463TK+@|:K):CE'VT;/?@_OMR,P2L&K2919"H_L>;-G'*Y4U?2L7*_7]=S&PM46SQZW6"?
%|6&5'LID1:R%IDHC#IPR38.6\ _MRLV|U/(>=\$J:-#?%>26\(/<_"*P|@\$,P9#W^VL@G/QLI1;!0H%MQZF]*V
M>9U=3(Y=-\,E;@;B!CT0*J.7B3AF<=-<%_0#&._B\L\$&L-25-N^#3|C=I-A\$ _M:D([H(FY9<,P\$C@NR3/|)B+
<5WV%U.I+7YLER0\QV3;V9: ^5<%^0%_M%BNEHGKJ+:@>V5W3;5?C%K7"3L46R[_M,IERDX?
ALUSAD@MJ*CJ4\|BR=E9"*210RWXE_C@)AH>Z7@6YTIB|9=<"=Y'
M7[G+;_ILQJC_0U*OEY3;=5,|I,\FZ;E@%IC*H:2U(<@,|]?+=P\$24BKK,F@=
M,Z|F5\|)8C**FQ7|A\$S*RG!N3J";6_HZ;MT)<)>M_|0TRET)@%F:|18>=6FX_MXY.|[3U4SKNI/2A6BM
M5JJ|D;_8+0BUBM@":*,Y|H<7W^:@K?24:1\$6.Q'M&PM+Q|MFD_)F|RNTPNM_M4|%,.N&F_A%"SH2KPKZ?
B3+ #1V,|6ZX0|ZB=-\$SR|9!)IAM9^UA<IM=302U0_ML3[I]/^2
J0,PUYLF4")^:2(KH20<88,5J977K\$HW*=H5W3=7D#1\)|D%5>T0_MBJ(BL-3T5E\$')<08.^4M2/#!-ZH.HYT?
#J#V:-TQM[MHFYS\$]+K=!) +5@-INLXYIG88:*(\Q01,3Z/#M=|D+"J^\$JMP:(<-N_MLC*#BD)+?
S5K_\0[4^]'WZ]MB1F+[*-
>I1!7#\$>>_X=A|'Z^7&3@7,T1\$:0;S0*J>/"3E\L|Z=@\$:_P^,R'<+V@08SW!VM>")9+0.,F.K
M9[,M00:1RKT@E9[0,_)3)|E:W34*3EW.=']^7F/BYNU=" (P?U^%GZY%1(" &
M=>RFP=HV0!E(S9/<9LAS\$C52B4E> (QJ\ \$II]W8;R'L,ELG_Q,?'=/_PDU5_M6)4Z\@,\;:R?;GI5!"[*_]ASK
E#;!WNE_-IT;"&>ET6TU69Z[F1_MUX*\$F\$V&8.:I|-\3,R_ ^ADL\$*_+>TXB9K;N|>H;E|0(,G4S@2JJ[Y|\1KKT
M3Y,U" _Y6,XK,#W,P<(/S0839A:\$ _[YQ1L:,*_\4&0-],OK_|#V4;VJ8KAF_M*"71-R7B\,>^'L?
A08A8W4NFHG_Q@<@_3=-1W2D903_|^#/&3M(B)KH+04._MH1;Q&"D#E'!3M" _0|A^,^;%U13+U|2-
5G@A=Q%UA!HD4UC=4?=>,*;5_9&Y;:_M3'1R'#7(KZ2!/_QC7QSI-:A\$&L8#;=+_0;-ZDVU^0BCCS^IY-^IS)-
LPUD M23L&&Q.A]"?1I"6_>1N6.+@,2\|%,=AH/(8|W_BHU_-UY\$37*SY58<48V\$,F_MCWP>#D_D+8+M
XNB>S=7_SP190(Y:F#E.90S5'7LHR18=:T90P;0"=*)LE?LXE|/&= _M/1)_;H971)-;:;?UVH*>
ILGNW%Z|427E"VOLKB5,EC|1NZ?Z3C"6)G"IR>C_M&1.9V21(F!5##_L'E)+(4\

<22NI/(M43'UVE\$=/(D7F\$UF5(X&?VN0ELL"E M)G3>XIBS0*U45,J'Y0U0B';/>L2&;>LU*A.;
<',"IT=KR3R7MCR#3[ST\0: M? =E&&*B6,0J(0G07U/>M=4)CHRW(I&5ANX4=7\1JVKP3-E M#
(+'N\$Z,5X UT;:84 ,>QIF2@+ P|VYQ12-3;4* L M MVJF,#^9-RE+JR!%;/J13D#-MAWC9 %V
J_7KE#W[0')4Z/YW]*G'7/>IE\J&@E MGGX;0%Y|VZP;PZ:M\#8[>M|VZI2B^:P=*F90Z N???
59!6]&.3)J(7G?4<\$ MY-"J?0,G0*GF R9; UX7V/*-I;?0Y6W VRLQ ^%:8KZ L?PV2LS? ML_W0CHHIT;>?
1TB(U?VM%4R-9J"TA\2&8!'J'P?(-3K=[/A M6;().#3\ 'H#+ 0 J.2>9H #:0<,\G>%^P2)&S&-[+IE
M\7\$A1'5CL_HKZN+A20FD,MY!N8CF5|B!!--7PJAQ.UM+ S84GIM|\$)[<\$N^\$> M1(!?00Y0%\G-
-[34S(X9%2>\$UV=GN?%=(XH "[11%\$9@5\$()-
^"ABWD,=&0*%A'U%P4NK&|FZ0L)=|4I(4&^&C=239KXUBM@%EE@I&/I8 M1Q!)ECM,|&3HLDL@/3PS>?
A0A*\20XFS8B'4&@Z^%.=J80^?.7GE>H@AW M ;OY_9 WHH_PUY+72USWF9IYB)D/HU,VS\KOC^ \$+F"F'M,
[7F+KXWU)JX9 M%P58EK#(VN|A.&=IK3;|0J_06BZ:\$/["CUSU!=@!?"NW"(3^G%27/D<=&='%\$I*EF;%05;
M*X?<,\BJJ12'0/IZ795*B'DP[D9.C|\$^0|,B?D 4%#P|0:G9_\$BBWM8_4|# M, @R=Q"@3W0W734BI?
UYBA,*N'\SU@|69\$ITR*BUU7@(+@*(MPOG|FB8)&
MRXHE'9#J:>>F)'04G0^LEMH(JX0K(WRZJJZGGDTM10.C09.C 0^1(:6WM"UL M ?XQ&\$,\$:MX2V|)\-L,JD=8-
;==VT|T)0P+?E| B*#QA,T>BM- X'D:Y\0K>"C.SKF;1B_1%TXX7-ZQ>&8\);@9%G@H(J9\
M&;JHI";35R)C\HK(CI<|0)+@8;>.,2II#|>(%&C0=. 'F'32>MU=>0!=:VJ00
M707LFY0GBULL%.R|.?)F4P1R#0&G0^JI)9,Z,|+5\$8N16H<&7WW\\$:X5B@/ M(9?
(NYN7.GN(OYB#175*IT&X&+;DG2N.\$4A.%NP\$&\$>CWO.YH<=S#0< MMH";=NP"\^-|
[G]>H(@5C/^L#^N|5ZN_US^&P|[Z;'UPF7F6|59XGF55L360 MU6NK70_06KV^@+ '\-JK7, L; ,3OPT&-
0E6J01\$6S|,C:=T7HE**2;+ DA*=F M+|5J|Y626"*1.P46DK0=-QF.*#-
EFZ'A3@>BA8=B1TK/M|JA16Z1,GZH52; M\$5\$)Y0-R)^CZOU|A1*0L;I3!U=HN*4>YN(DG6E)N:=T7#!22"?
6\$ +ITF?# MJ9@5?W8AXFCW74QV8/[R]X9/4+@92TE*6C8J|+63?%L MVWN@^";L*3I>%!4E'V5D
Y6C\$I=SQK26Z/[H(U0WT/V0K]?G1|I|#,Z6GJ'Q MT=*D:HRLM6\$8M7FE0*'?#>Z99EQ3I,J5X0BZGJ?
#H,JB,A0["IJI==,|%7^| M\D9|S(0T,3198X3E6ST|LV2/YBY;:(@;|I"WK8IB_E/3%1H^I,\^EV4-2+
MPPG\$/1 S7=K7MXY*2_#2+R 6>ZZFSS9*DM-\2V8.A2\JX|3\$Y507AKSC W\$> ME_N;XXMM5/4B"'6PVW?
*N"3^8M!5ZPI'J3?='KSF%=R&MW)\,T7,-&/)J/G M701NEH"P?GI:@H|-(+
WTF&*X\$G@L+8(I"P@2\,=@<'8"DEC8"N\$2 M.,!&30/&V7I#|3|^1H=D4VL M0AWNZC:6/|F2W2J6#BT"
|L^+N_7UZNM|'1V|09RDJJR(.!\$JA&I&9K0|PM?S MYN>LA=%67T!|}@P;HN=
"QV/&,*\BS\6@E!'H|(X&H2^YZ01'0Q)=I:,5E#G M|9\$<)QHHW+;|X>&Q46BV?
T(:6U+;D6'1_0ZY@>UTC/"U,T\5RLFT+?^9MA3 M*5N(:F.!E\R-[P6Z'88-KN2\3E8N/5CBV
%MK3GY29W8D_F/GFZ.'Y!02U92G.?H02N; M9^D0_2;WBXYCC #1@T0IG@PF<[%COUR^FH7;@R<:PV4).?YY>>?
Y1*>BE75 MHW4VCL@K*8B)YP'H0^(>P+(PS;8Z|5WUPC|6A|.>6GS M^MQ+V=-E1NWUL>5'1HAS|3:
(*@4B\01CJ+=>.[T4K/1.Q@,S1ZG?'*Q|> M)#P;:6(!5H^L3'0S;- G5A?
COM\ 'S_H'@'DH:G)B!_I2_M"67S|F2+U.*7B. M\$D)8CQF/1P@-
_6(|@#3&);U%L0+8,A@19|*E;C;%6QDN;BR'7V:LZ ^"+-;
MF*+8*N59!XA)88D1YIE6XQ5>X<1^!YWV7/&7T#X@X3<@K/^4' RA%\$AGB4FN\$'Z8VKZUCL72|f8
M&=K/W|2/=MZO>F%W35(S)=Q|A7(I> >?"3BU5KY=##Z@EM0TC2+UE06Q| M (,)=<\$<^W
V|^=,6AGB'|GWD\$|((1885CI/B*2@2*"2>N)R#"N99UV',8F ME?UBF|B+3&(QR;T N|8YT.)"^((\$:SMR3^@>
X617\$K20M!MYMRO7Y*H1%7)*NA00=7!6)7TPP M;M *8K
/1L<'+'#055:N0E)2Q*I3C)SALPAML"KN0TBTG"2.!IY_R12#QHYZD*0G;@V7\Z0K+N("Q?
\$!8QM5,00S)1(@:>0.R|-MR0U :^?@ M*=DH^V2UJ3F/Y?
5F^4|+)B)46*LE)2HE^G1I^N7K =EEIZYK^A/65,\$16DXU M^8%4""=+U^|+W+(2+\$0#PIQI-
B659)JI53(2%A\$,&^6Z\A "3RQY?YFBH|/C MP,+%(E3&:XAZ&|2P5%?ZF@|@JHXR7&XUX-
A;0&2.>>RY|3^CZ<=NH!B)IDV''+\$52R? Y6Q,\;\$ M)YDS:8ZPY+.?R?
:'>R0E6T|,..S8YU9?|XVX|0:DE8Q_#7*"Y@'02:>P1R6 MTTKTASDKP>7M_N!Z|'&F0@RIG%\$5_N+-
IY3A'\:|=8Z8A#B\$R-/3L|CP"UL< M&J6PZR<>V_2.9=%3PA,BI#(
)S,LA#_0Z|67N\!&Q!,M)RK.%|ZM"0%,":R|^|+D?AJ+&@_U,ES8D^+;QC>#\$,SE6% EV9 M)*R:#66499;
[0A%@] B/AW!=P|Q(P:P|C&U+2./0&BK,I'P529VTB:|Z\$HB1
MA\HY&LXD:VS%48==!,|TD|/)YZHTMIM2I2ME|0= &| ;--I2*RSM++9%2VT% M=\HN; X060P.6QCUX2Z>I;+
(F30@X@H/L|J7VD#)%H\$I%.*&:%AJ#;72RUK MFR92T2K+AR;^@KJPQ
M70^M^DG976LJ)A1JEX98_1J*1E^A@0:UJ5; M<6QY>RIEN/JCES!E3Y./8X)DXR*W7%YP|-(3@%?
R7EX0(@#28,5WR"\$ 0Z M+AB|>-X37''+?GBBTX:J9G3;,-2-%=(XK\=45F>M8+>;C,HSCC8=ERE.S6(*!
M*#LU/6'TW%""I#5X4*10P#_GYLZW|/8_U144HMB93_M3UCL=;TGNY.A%E5\$U|0D_2EB0R_>#TI<=/5>^BB-
EN\$#X(IY^#JZ|>,> MQKB/R<@+<('Y'IQ"B3-B(@53=|,P/P,_98'(506I@_.4@3!5!@Z|M%JZ308C
MDC=C\$ZR)\$0J0VSD=E&;2W/BN*|?J1"/>63+=?;6(G'ORV*/Q3^%L9|\E\$!T#
M|7'C3IC^F|F#F0U|BY8K=4FQ;\$8KF3=(?A#GS\H@LSH>P=T3920T4%!AUB-"; M=ZYM*VF8
B7;T/EF_BI1V8B,|8U?'G68/JH2\$)Q|&\$1\$'\, , 5R=P).KU& M|\$MVJF7'>G@TH_S8\$*2A'Z_9Q3SU3
SMNN1NY*'*B(R*;1KF6/C0XTTI."0E93=BET< MGLIG08#4XU/AAC ?;B7ML_0_E1"=,U5E-
Q8BT53AKGP<9Q0;N7!G,5_3J!;B M\$'0!7+TILI#).P?C+=I.\ZGAB/6'LG?6?&Z45A;_G_UAF_9^5.5#
(IBSEGE C MPP|)8#8,[U;|KEXW:=8%R180I\3L"1%;-QN;(S@?!2Z22[?/,X;\$0I-/&D-\$ M8#
[CY\.&OK|/#9@>T M\,7|F*4CL@R?^U%Q|;B;Z+=XMI|.FYBI)W(TY\D-YB8|89U800BYXM"\$:UHX M
V9B\9F#GFC5J0R%R0X\YC&8;\>08>ND.01|C|D' <=F\$N9;.\$J/Y%<C|0&R M_R*^"\$\)-)?
F(37Y|^6QUH^F|Y|8U|PUN&_P\$3YEY4DL^S!EWWL;BAY+Z M|<-")47P\$8G?[%2B%|IG^Z?@^%EG7(')S?
%0Z.Y;=J?G<<\\KTOYAS'R:&L# MC_U&!FG=4;|. /H;9;N""7B05C|3.7!&_SMWHG\R" S28 EI):!7+E_?^6Y
MH: _=RG|C; '39Y;=E\$R1.?UTPE?*\$SGP1PCH)509_2VN09:WEHQDQDF>/;Y> M64TB4DP10Z;MZ-C\$>=0>:PK"
[Y6:53&5U M=NAY3X2/AH]86P^CBA?6T'F)P
M*W\$[F::SD3|EZFWFY50*E9&9VE%9,ZQ=2#!=PY_Y|+9X8<0(N^:I*2<*0BY M%,:6Q)+A0-(LX00(MB?

NG&17YVZF<-MX,*Q*E+NV-15"\$L@/QWZMK7]W[4UKK77Q=QOW[*GN M^,>J(A(@_10I\$)C
1<1^<' \GBZ[X51WVJ/^+U;#(P#.9,Q8_52K("\$">7([M@,K+<=TNW6Q^/M<[N6D.#TTP;L?)
[K#9;1VE/,H:F8LBZGG\$X!*VUQ;#](* M)SZ/XMPBP^UL;3))I"B"~TJ998 KN:+=7QS-
+LI[/S(7X2:FIQW\$/B!\$7(L M"6>K"ZUG>:6B=W1!9,&_PQ+H[K@N^TLM>Q*UAH70DSF7*0/1M+N&KD0SDDNS
M:8/_ \$RYE\IZS)! "PL(5?94"54IYI6=>E_&#G#"HT&ZY44R@,FX9KX0PDFY)
M+L26RKXX##W]V[M^>'A%]' \OZ\$5YP(U@#@E_VF-Q0DFS8A4=2.6F6KWGS-6'E);TK%@\$DSKTK9%)%QF/? M-
3]RQD#K\$4YJ7?L, YE)/TW\$B^K56J+_1^(*#DPYB8'4W6Z(?DYQLK=-*LD6IE#;:R4]X0IJQC\$(6(QY9]+N20M
MWB]?[;(&!):@:PDKGX8!K7>3;6<:6WVZA:"N#(>:VQN/D\#L/Z-T8BE:0;:8N6X#C/H9^>GH/[R:OPSY(4#[^X
M;P]VJ%_=%K9!3_3YP5)Q\$Z:@32/;N):JA7GL5&)DAX1-+*;11ENZ!-I[UQ3_M]I4=I>'8[
+AS\)%K=0/?'='^TN,P]J&-/D"\$!M8&_&[0E'S0RW.#D:+U\Y M14Y6D8\$HUSH48,H&^1!W*DYA&-&&#/W
D%:G7.0(^H7>3"D;JRL(*8*0_NT* M0KJ_L?
PV0\$@1YH/^'"H_ "37KM63[C&G\ \$JXME1^EY7ZI:JF&.ZE_YMAXND#J M?1.,P3I=W=8: ?B7R9#S,K-P0?0B
MG/=8/:7U* <46^*>Z4EC^H>X(@'890^ZA^HE";-(W?IS[/?/"MV0^1[WVURU M*^1^]6."-XU^<7(?
%R4\$X?):X.9&B+2UAKZD10ES:KPC2/MR.\$XB")HV&2+8 M_15PQ7\67G5&3IHPH#C0=: '1E1=_J0SG?9V)+X\
&02A7G7U/>MHH\$:TR7@ M!D/+;"BX00E81)\$5RXL#PV),25I!\$AXD1* M@:&@2K\/'C\$-)19^
Z88"!^HUP3;!^F"6UG@9N07V\)\$6J%:"+(1VE#>43 M&# 'B-ZV9S;KL8&.K>]R' N/M808Z#
<.HZ1>2"A7_9F*J#:"#5(\$=3M:1_!Z MM1W624-NMMV<=>%(R_DH0.R,+(8"B](5PTH?JJR/TCH,Q
W1/U60J>%V\$9]\H M^0MV./1&,\B&Y >&SW 4P+M0X;S6I[[8#N>KWZ:+;J[&H).Z?84A7KV000R MG>!X;-
<+)QB+*# 'C47?B0*+1R419_%G)0)?KHK_4HM>)H\&+86J0.5B-!8=\$ MBHJ.L.,
]S!C8#*PA52K27:L)5@\$5"U(?T(,E\$Y1)6MAD),B9E7I@3]IM: M:04?00.GM;1E(+I.UUWR8E@:+3X
^53LZ)0YK)Z[0-/BQV6"(&Y>0"[A!_9G M4-:_%K6)1(NS\>9'DXKI;M9K"EYUAC/Q@:]T,M-97;L)\0P
B##!X#8)4R M3WF>)[E9:-Y%;DQ(0)^GT%1(\R/I# E47)4M>A:<7^NF_2E-NGF41AM=E_0 M-JB5692I*-
D;3E@&N?[(V:SJ<3?]?#^3_JXF#^E>8E[;C(AL0&E512MQ=L/< MU2(Y5!\.4JY/PK_K%GMY.XA\$BM*.N#)56
A4@_W?I=2#-5,G0]<^YD*5SXB, M!H>]63+T['X[I%+=VCD M=UK=Z#H4:D9M@]W50*H]N;CUP MY@+FXWP!
VZ2M?E:5[\$X13X-(U*#[G"R2XX5;:MXB?SFZF:B07P-; \E16# M6E2L?7IP/759(J\$J_5#WP+>^7H6Y
MS'8"0Q0>F3H\UP%AH*LX).KC\@"WMUNIH>1>,HF)\H [8>UA'FD(>EAD-SP:28* M"U+)T+.#C/-"1?
X\6']];N[H=L TUJW/5V98RT/' M1)@#] ?L>FXB6)B\>JK^C <*Z,/=K['=8JC SZ!EU2VK<(WPU^,
MAU?'_6I_!S57FG%2@QUZU/'7G/^&U>K7D/6>?-E;J-T)LL)^>T?7=23/VJ,/
M21D+MM+K+=W5(Q= \X_0\;U0]=D/ /&^9)2IRU\$(V^CM7/)0AV?[]BF>[+ '\ M-0!L&>;0BQC#4 MM>N>:E
DS13A0NGEM@MC'5;:G1N?89&+Y5@QF\H,Q>;!A_B_37KE5)\$S;" M1G]Y"#<4
I+9+97*N?!&3FHL Y&5HF=W: #;UF%_D10?G4_*0C(>-B?J:4H MJ=U% I-!570+ [Z.H?;XWL2_-
AHV&IH5N#A10_G8R6""CN>;(ZL*80[1U==VG M (<)?/Q%_)!+P6^? \([J":&X,^(MN.("YCQ#=\$)545[=64]%E
)V+))\L#&7 MA=_XV]?_YZ./_E"))Q8S?2ZAJ[P>QX0HUW]@;"=KJP.D@S%U@K+ ZE5P)L)+ M;\SSJ+N%5T_ \'-
Y\$S8\U'9#,1018\$R0W\RV=(ZI6SK<;:P.C=DM^P MSB=5""D?:HYH9)*WQ;XY_2_Z,H0/N2,L@VDIP%)5F>I\$>?
\$E"#INA0AGL-V'C']09(IXZ0>6,4I_#GZ//73]J]?A#[M7_Z00Z5%7WWK\._%?/R
K0)'S6S8IW]\$Z_+0\MR8R+IM49@^R>8(K5<88'BK176:V)#4\$4;1T,Z#48A M"";5*VW2!R*)H
0^5M*W""G)V=ABW7>K0?S&>/F^Z:V7S02J;\$16<7%'J-5]G_M_L5H&D0CN]\^L7,195IFY30]+FB,7JYL@F' *4*(-*
[,A/0R#TU^-0?+=)DH\$ MZ_7CI]=Z^DNMHO@<6E8Q.VS5]] [G_QARZ]:\B-;:#@BG6?N>;N8.+A*""!T
MIQ/3H2' F;S]V)C5FP[! "Q,H1%ZDWEZ[#[<:GJ>A+4R[3^N"RL:38Z003*K MUY7[8.?0<-
(48J[;/:SK4DJFD(+PW;00));FL9CG*3WH'\=P:0(TCCIWW0]9
MQ)&^>UWHES.XG/HV3;:BPD/.0<'UHC815Q.\$4"AF\$SYX7;H/L72L06_ \$#'3A MM>&?[^6(69XXLZ0707FOR.
^F+ .LX*HG0MS=@R!\#_+ M'1XI'H@(#LZ/[ZU?AS4:=LW(]=@AQ]0/'9GBEZ_K]P%23L_FHS_*;Y.)+)"T
MN>QD7E?FP[J.68I00*8C*TPS4*R@TW=-I0_C/"SY![E5='EU(F(P[@>7[PI_
MS[R_! !0^CH*JEAXF[MC&UZ7]J60-F8\(\$\$[68?MZEUS(E321,7M:SWD!3N] MA.J\$%-<(E&&(W4*J
P0M)6D[1]*,\$+^+VZ@:_V\$J16DHMT_Q:" ([C<2\T8U MX['9H\QX< (0RKJON]-T-
640>)#J*3@)QYZZ^;EUYK\$\$_& \.BAY&=L6B7\!8 M/B_6_6I*WL.4Y"EGQC?^+LW:4\$S_ M\N-)5YA\$QJ>G33
V0;,>#HW7@9TSII;:_0%*Y@SW5N(ESWM[W0T?IE_Q>G< M=8L(!I: *5%AY08==^6E%H4I!XKM_#ZCX
'OU\5XL<6@Y@Q!TI)9NP\.'["Z# M0FHC@]Y?P4I&F?K#6,-@RA<[LK:VNMSZ<5V]%P8AN7H1W2][HL:NU^!-![(E
M'"2X+[-=3P6FZWI\(&B?\$=GE)"E_JZ=-_8\5D4KLCCM_Q0GT_%[U:ZKS11=)
M3L\$J!&3]L&07COW&G:2K4MR+IM!Z(Q+I_7D]D9-WP\2<^&B0F)A'4>B<]2\0
M04GE2R9;HV:M2C@=R+_1HCV:M<@7#?.\$'.DC/W[](['*#EXIE<=]*[&GA?W#(M
'XD)I;:RB')03(7S"E&KV@ZF[*?';:A@G>]U<=>HZ=>+.-.1V^IAQ3).?BP549@4&MY^
_ _%:K_4!1&MUUQ;-L MY-^\$-YHF?J!V?'(Y42N<;:ID1ZWX>7#_0=60Q\$NIAT.W3="SW0X;65R,0;JM
MP3W22W)7,J)S0\8>-LK8/UWNXP)LP/Q1A:6=9DMKS\$P%MCE6X?^(/X9*WKY3_M5
EB(C7LU(:7J4??]>T7-. \J]RNYJ7?UK='!G70]"VL)B1] +K-%S9M-(RV0_M=J0F.GU\$S:/%+M5??L4?(Q3B]
<7A0J<_ ^L=1\$"\0,RS.PC*'S[4[\$B2RK[[2_M!5VR!J_)@MF&Q;X!D]K!Z_+^0I,%VZ"FW9(9/;LELT#5)
(ZWSBC_MDA:05Z3.X]L#""(^0= 78UK4>)CTY8[X9D=WSK'?U0<#AA_ _GN_MZK,\$L3(<#Z]<+U:)'@/?
%KX&]FL.IWTC/29&<)DQ]\[NT.J,P7W:Y?G/;:'*? M>;#:WD10TS/A! MD'%&ORQ7H4S*'921-#. ^)QR_%I7#>
[WW5RQ0=UZNO_MD7G2_3?&[(5?KY@_1RC]2+8VF_Z0(I:VA9>I?A_&Q;J;!GMVN_&BSG;V5G\$+_M)B0@7XK
-2+*BZ62104ZJI]\$>;JK+U_?;R8>[V%#;A'\F05#/8;_#7HF-GN&_M_AJ,^[_9[;0AU#0Z)S?A5M^&
W3P307,&#M;A)@""-X?\$_1AZNNC_B@9]P]P:Y2Y;'0MTE0>4_M)079,Q'KBMS-CAZRMPY@^8N\$^?C@9P-
Y"S+^_EMHRO"[ICD(Y78LV>_NUJSLQJHZ_MP61P0>?U2M)P]I2E^A!\IS/%H6KNQ4A\$MFF8ARA-HSTN6\TDA.\$7-
J*I.,M;_M_C\7?M] ^G<](I#^F&C6SH=-KZF)\;_^-0\$FRDLQE;:R@NQ"TI#E0K>#7D\
M.Q:\$!0&36^:\$'E%XB^RC-\22^\$?_# 'CWY7_YW;WZ0/V0\4>Z6]#NDMOUP_MTVZB0_U_07G]T4?
DH40\$\CMZ0=1\OKTK_*_PA?^_9?^#;^(C[SYM/?<^A: M&N*_0?GH=^0?^Z3W_NL]\KA;U-C&.\$MZ-P]0?
XNIR@90-M)%;?6T=J+CX^ MM>2QZ>4^>0AY@3_AW.DC2(--L/D71%BWL!0[U7\=^V;U\4=5^+^/_U"Q^RT0
MP8>PPI3*ZH<#S9_-?M;_AKVQYC)Y1%?^_(SV#K9**K#Y'JX8V8LM")L]+US9^

MMWGZ"!K&%D.&1U[=RBJZ4;ND&9#Z2C3>S/THDWI'Q_.0/BRN'B>B'53<\$KXS[MAE1X_%-1\$>696/%LQ3.+4G1.
(SN\$,/VFWK\$Q,2E MEI>#A;E=NA[.3A28DV=?KIZQG+!X1.M_6'4-+6EN:BPJE&B%UH^K2R92R_T
M>3@!R\$>\^5<1%V2 *,*('@XS2FRRW>7ILC2P_-KN'9>TI|J7\$GOSJQ_JK-!-0 MQ;H0')=>,!,7+X\$Q6<63(-
!0(_G(ZSIQ^F= M42]NST43/S?M5@1NZ3']LPV+GM;2LH9'?A96L:.Q?X(D@G^;3_VJ\$1=XCN5
M7HAJ;6.^*N'-OB^A:6[J];0;<#C[S209/50\OT\ _U%XZK\NAND\$>-/(TSXVY MY8F!&\$D=69@T&DF"I\$L_=
DX1W);R&#>4-Y10;Z8' 'YEQPL@;U^..R7Q-->H6 M610GR%B?,%*2JI@K4_ &\7@7\$195)/T@6;
[YW6V\$MAH,&HEX:08-#. *BQD?C M0-& *K^F\$,XXE_K15PT? "MLQ[I@QZB&OLZQ;H% ^)RW\$S*NCVK=(3-MAE8
M%8)2)MR&PC@+^:9Z".%_FZEIL.?D5%&>90K;!'%MA1.)LC[;3+B;RN'L]+#<
MNM'Q%Q;I3;.'JC+MHT:*K4%P[!IO-K\$;+^EV2T,DIU^5@28PK(G/S^0K!MQ*:@:K!|KK7_0E8B#(
MGQ|IL]'<:FV2JU|IC%,J50\$0>)\QP-C@0;#W!^07MX;.)I^;L*7'>K|YD=0%??
LC/M((QMV:G'^DPVD(@1/XXHM4H'<'-'?XOWSZTEC MUF&V-H+R)8PJ8|ZH8(;<@4\0/)<@;>+2-
V].Q'9T!@*^W;[P2ZU^.?PY\$6MP M^A6IF2DBJM4%\$97VN_FCGH_@S=V=2(&M8G5<_ITN5'4L*'6D\$EG)?
B9E)V0R MS):R|T1?9|\SV004\>E_6. \$5_&E^I4X(0>^\$>1\0)R+IQ#.E>SVY_C3E)U
MO"4@!/(U3?/J%.YWJ#Y=NI>KM7W>+@;1E9Y*[LJ0-_PQ".^K89R3%4USBL_MV0V@<
L110,B2"Q#^#@!3E/+&=RC\00T(T7%Z6A=OL#HQ|(M#02,S\$GUTWP_M@H<5JE^TD,'G.
I'G"RM.+NPN+4VN;XDL,X-,;'553&18SE2@YS\<9&/-<M"0?
UF@!JC>45"C>0@#2V(\&OW0T"SNZZE32_H;R\$C&16#|K2#KRLM@S9.%J@>G./MXBBJR8+HR-
9B1=WE0>N/0L/[5%^\<L2X1ND?'(W,M)LHNDSSSEBG4Q1.
(5!P97>D5^).%K/7/:H.+BLA7% ^X7XG=|;' 'WVBMVQEJC4C_182"T"Y%NR^H(6+ E4P&=TK2'Y#B."K&4H6K(QP-
#=W>'9"[XDSEYU=Q"&([M:9(T?4_Z@EI=OP= Y4*E0Z7,XH=^WGN"\$V:5LK@&H8KK*'E|H:K=2V+(>_G
M0/5A/-?P%[4?E[JX"UKM]&=/, #5F9X,N6\$!W,Y)MOX%;)+W*%P1?V.D^&@& MP1U'G)ZW=W31C">U*M\=Y
FV/5HN;\$Z#E+2;.'1?<+;\$U98".U|+V(E\$@ (NN MBW+B-\WA ?PLUN.<61??"0_/9?
891;.%PYZ5@SX72LG8%MQ^,FQ;N2QR8#4,M MC-#W.>/->N(?)*K\$08&2|0ATQV017L
_+TAVA.!4D\^1B)@0A.2&=TT20] MY/;8=413\$QP[;!10-?_YH;L207D;G_\$EK\F_2UAVN'3!1^,
(CV|>YOMA5L)7|79;M&|V0SKPQA^ M^DDG|1=T;:Q'B9T4I(JS^|)\>,8\$SAR24-
GYGYK*5D@%Q3:6'J(=L+0=:VR M=Y:02/90C382F|40?A1X#?%!),ARG6CR*=EAA??3;_3>>|PC<;*.|8=C.)'!
M(Z4U_%13-/QJ6P9YRRNV6W;-J>#2;I_K,@47=|>&'3)AL\$PF&-G3<'A<_7KV0! ?K|X3-\$9PI7GDHC^^ M{0*2\
(Z^3(_]VW|&2, G_YV2YLPW5MZ-'2?MI:R0-%<'-'F=BC(|A|>@B9_M/&%K!S0>1|TSS|Q1P8PT,^
I/\FEQR1_IR;#KFWNFUF@+;N"*4&.R.7% ^F3D MYC+B|K4E#*2|0='HJ?8@*19&9& MF9ZR-6MN,.
(L&6M/H%3:W@XCLYJRS<-#;56T.1"/\Y5J=^GV _W|_B5C;=EI ME9V.2:X2<;
(^-4K|,T\$B?..F9%T;..L+_F*,F*B?4WX9FTSV\09_7)%6=U_M_6/YK;+>0_6W)ZX3"A)W?2R\$2B4P1:9;&I<-
!0H4L#Gw==M)"Q3=5!0B2/=>^ ML ?\$N+T|\$G=?..VY>D2MP\$E;1)+06MAU7|ZAWPY'K3|NA;T|N9R"A=>F^V00W
M<9PK+HFWGK;5Z>J=6S34&)'#0L_H\$Y++WA&\],E.:KOU+Z(5G;?_.&/5MD|
MG|=QE3SZ3'XZZMNQR>@8.3#MF?X0C':X&<|<(K^2UU3|2^5XGG-\$N,[6C/?" M+0!?!<&#ZT?
^_060M;=0(HG^%&*Q-B!1HB3KX: !;,'?9>ILFJ9U@^Y4B1081
MB53YL*W^~IU|[\OP2%&RG8UM1IP"BVXMBIKG?|=SN#U+S_EOX:D2#">@!6W_M=B!40%DV,*@8_/T_1
<85';\$R_I(N,PBE3,X/33_J/8)0A_Z?+E)'_10%/D_MX03_BDBY@'6H80@A".UY\!DC:(A?2|?
3%_WBB(*%4:%HI1"@T7N"N4EJ!640_M2S!3PEIH*:M1&L08!X@#J+99:\$F0EL3W40-A(C"
HR!'6!NPAFX2(K3W'>)0_M_7CJV|'Y\|XQ_@1;_FJBK0KN*4=R|SQ0A5',9G\A@60Q_UR=)F@8(|0/(I2_M-
RB)=0V5@>^PV=YGW^Z00JH&\$.ZK*)X#ES9,1,2'&S)0\$N:W)\$#J%BE;@>[J_MLQFCB8HX?0BY]*9-(?NN?4V;
#7-|%T=\$W8\$K2(-D>LM^T#5L3L&-B_M3YRF?'2_?D)L4|D*-U6JLQ!_QB(\5/WB_2G#:"4=UUT_(+L4Z1>V=
(GP7ZC*_MKE!'HCF&+W@,T7BA/E_NLT3/Z*|J0>DYQ(0DAPS8*9@|'^\$0|!+B_A#*UN:~Z
MH|'I3E0G/#3MZA)XB6(F5GA04;6Y;-+~+V_FX; '@YE\$S?=I601M*:!51E"D8XQ'7&8LW9
MC"D*I+6H'F*E4LR\E;,"7L2X0G-%8DFUN(.)L+>46H)I094"-|>W,42|9Y_MM>N1;/TIL)>W((_\$D@ZWV-
Q%BMQ.W%*/LU6JYP^4YM3P\!/\:65A'C_PT;2_M;!\$1<2.V\$F2BK2":!;4X2P^B0!!"%KEH(|+OP*-AH08*\$
-"N2\$66K2\$*P_M(1CB8DU:'G-9(20BN&?JNZG;(H<7\$J)BOY_VUIF+F0_6!:9ZS_.06Y%K(6*G_M
B(!.030*56/\S7TR_CE8?_M<8D'^^49\$<(PB(="1?N"J515-*#U!FBYD" ^M0DD)JI#(SK\$A9!@E?QJ,6
MG\|J#D!'LKA4.-B26CJ|*Y_E-\| ME+5Y0X8N;_49E=)6EM#(7Z2<
+\$7" LXQ.GT/'=\$EJ|H@F.10|YEU^,PVPU8%_M5|U|S+ZQ7\^*,7C;RC?M-HCYG4B.<,D@*LFU
G|SM,0(I9NF_)X">U(T2^|\$_M?#17%/Z=*S@3,N(9@JKW;+G,0H6AG'|(?3.;>QB|L@ZS_6(|D:16DU=YB6T
MU5#,#WH,XCB*CS_9GY>|,%,R0&K&#<*.V1MU(IE2.J5Q"3?@P5S_0;H&7(_MY\$J5"0|
UZ!;W8>,^\,C@H*0"/@@I(P"4^K5HB81D5J0MELU,M+)>("8S+. MMHH0P|#_ET)%0OP-X9D%5R46T(AN'WC1G.
(YHF@ (F!L3Z7_'(;+Z\$IQ@3M^H_MWVJA^))"TUIN\$4!1GF7
F'SBYB0|7LU;S(>46I*K'JV#35(FT2NM28W;^'CNX_M:/Q66+FZ"4R.5>GNE/@Z\$_%77,\$2Y2?
>0|006+7(\$/(V"F^B(D|7\50)Q@ (B_M+I1;:L".57*Y|L7VDN_M*JI>(?CX0,*7EK9HT?
|0(/>ILDVLR,@QHQQ2.2=0-[*.M&)K4Q7A7T('IT835+JW_Y20|/(JUG&|Q5'J\!\$;H2M-
09_KH<|='&0T(>BZJJT-@6"!+\$)\$%\$HF_>P|_M0S28GFX#F#';/W|ZT"K-S9,UXD@Q^&+,&A;#_M."GTTL=H-
D-&'#H>Y!'BFNG'G8MXV4%#YH\TF?U,=E#\$^D.0;8A%B;:HM?|J_M7|0T7JA&XD-!-B***CP#8LJ>?,%SB
*G3/741XHB9X1N-K9@Y74<='|@_M*0!05ZP&VH;|+OP"3II^17#EYE4?.\$!YEM1_P7_)?4%>"^U_MHYV?
7EU4J0IE!>IF!&SX5('L^Y'2_M(*_R1UE0&\$CQT,."C;N\$PR961YP_M*M^:[|BIHF2S<3J_MCWMX#?
ICA|0#>)BK^UQ7'XKIU!&??_|L@UKCXXQ3RJ_M_E)">TM:U7GX|IV'XK_9RX_T(GU_M%7+#URP\$XRK?
M/I04&J=*HOM^>|JWZWY5@UL(-%C_'|-(/_|30GDS=FB?LVW_MZ-BV/J%BNLS#('7?G\$N-NW:3M|;0;P0@8@J-
6B>/_I5_583/'MYRRK=>EAA2_MA>'%Y9FL0'T;=)(>\MQ-Y0S'N1T'24^,N!2\B|XQ)7%7LAN\$VQF+--(2
ML|*CU#M6\)^F^*VH0JG^&,#|3|M7YH,ND2R>B*303-<7B^F#Y)!6LRP:NG4+?3*.6#F/P3Z^5%*2IUVB";-83/YM
5C\,^\$[|U_MREVCH?57AF1<.!)%BSH+80Y= _@0>_#_#^-70F-W)MPG7@'_VFCUSQB:+"UN
MBQ|}BV505\$G27|@6T_2M)4B.MR=(GB)NAP?/E5:1S_\$I>FV^;!_1/4FR)1>)_MZ^VK|NHYE\|PV3V"
|;YY|0\$^=R*F:I/>U\$CK#FWK@0:B|I;0%\SET#B!HH-X_M0V=9';)G_(UD&HB;+|GEH7E=-M_8+ S9RXG'DJY%-

P\$ M\=E"]\,H"Y& R#0E16U!H(I!"")\ "A9C'6_BPH%DNP)9]15/UE)5.\2%I\5K0Q[F4L;LD
M:=*8_ \^70RP^MQE'G^#[O!)W]@VIL'0'HW&-104L7T\ M?-
J;GG],#G\5Z+Y;#6IBC[N3^HW)Z>U\4P6(SMRZ"I"*\K&]8Q6!]ND0]<>08KF0"-
)"+S'2+%7'>? '#R;DH9._8>V MIPN;([Y1^WB2T]_0 7D7AQ@I8-:@^563J>W;%7_UB=?MR[]V-A?0E>R?]^
D/]Y*J\ VX?^5:&J*4%9;_0FBLONW4^ 2 M? !B1[WN]PXB[!RC"B/,T724GG<[=W9W-QVG?1+>=T]B;0ZJFP_P;-
^Y P7# ' M&0Y[H]&@P\?K.).^TSMV)L[@># <= S18-0 '0GLON_8\W1Y\ /940QVXDJ@#
MYT64PDN[PJ]W' 'Z7=Z76?2R-GSF]3NC\>3;B-G M0\>^7= N&4UI-
72E+U>KSL:#T<=0S\8'CL]35.6E+*; \MZAQSG4E4<[]*C M+=%@"W>I]E-EJ2BCJ)G-&PCI>RXXW1H^QLX>:-
@]U;!]HV"-0IVIX+M]7!% MSQ!3T:C\$1LIHQ*-2MQ#E>B8\ .P>ZL2_0N^#77ZW4F->_NN>.XX3D*P(3/ M;:
SKMR%=7'/0 Q]P\$ \\$T%K N+[*H&' +Z;MM9W#H'I'F!&X[Y]@7?Q+5X3JQ
M9L.592.RUF;J9NIRZG]6:4DY""7D3/6^/V))S&,0\]@>V3LFR-X(>Z?WH+WS M/@C=\$&ENC;UC-
)^9NIFZL7?,8WMF[_1LYQ_&X&F P=/[\$0\$>:>],*XT;M(&< M,>+=G=LYG6W_N\$0,
(GZT*E.CR8U/]PNVQA=C'W^WZ=4& M#=:C9NI-G+JOG0;SL3VRGGK&>FJ\$] ?0CPD7&>C)ZUS\$=3-
U83^808SV]=;J. M??GQNH@!9<(3F7]>7;UP;H,D03I1-Y%7K9\$++4&RJH&BVDS]29.05(Y_2" M#43Z]?
F0#1?I7]S[* (R6: ^!>I4"- "H#HWIPM72/C&WK;S=2;./7]E?'GIO^, MC" +^'-W 03>&)#[\$(3?
IL!^:R1^,^^^F7H3I[Z \$0_ =07LC\W/YS=2;./?5]?F#!HI[(&J-K< N#; ,NX92YA&?ZSDU=" _@!6A+Q
M[:9(5VKIVN\$P"+U%YM, 'DN2.*\ZC1EZ*!LL#,W4S]5P5=)! =AR"02A/Z# MRS#+];PH]K'
\$.F.B>NTZQ0.CP[]0:/#(, !FA"MV(U.7U^W?L!7A^N*<_WG!
MP.K]&"6VU>^WQ\FW&#_ L#]J#T60\;&' ;PP+;&TZLW]V0BU0N/
5UL'"VL3R"*\X;) *T5L#> >Z+' (2>I) _FH] \$Y^1F3KPY*]11[6G0R'1 MF%%S\9U8T/I, <^G9/20G! ?YM_AL^\
(P3&[?G";;KQ_ "H'E?=:8N%%48I\%F+ MUPARQA[W1CR+-G01W\RL_ M\$
Z8NMZWFSCBF]H61WJ&_ [SY;3SF!TS^X0^? *AVG5YKM'UD_5M(7?0'<%1EZ=E4,J&2I3'9TT3VX,
\X2B_W_1[G_0SW^ ^S]B><[C'[HG+PY[B]'"+68[= /JA\S3ZU'W?^]X]Y97"Q^ZUW:09Z>Q?0NF>\$D,
[96W+:09B[?]>U3\Y/CLG[<_NL= []M]')RZXS-L32;0W0?>6B'3I7_I6S,RQPA,
MH_[ET0_0F7&^N#PZ>GEY>?-R^H9YTZ/>?')T;^ _W#W^HIVHK.00;QNEEV// MCIS#.10 M>9M[7;Y:\$#^?!EX?
B=="3JJ][?-H]/4E+L0F;+"WF_ "A\V4&8< \9\YQ\ K!N MR_0'+I \$]'N 76?B\$!LBP24"ZXT"J=
<<>U/"Q^(Y\1?8(@:>^/@+0@(@9[Y@_M'D=4(9U@?RQ5]3TNR\$X[* 3SCEF8RQ@5)?
W8*J7\ \$7&Y+WYUQ;\W2]_N')E+ M#?5N%,-
)IY<7%P)03\$+&00?.C[@X)+014VVWR:3J08#B4.= PCK73RN:CV0\$ />G-]S";E7# M@<0*W&VB7I"/X#UR[
^=:P9#P0X2SYX>!L4=NI09%HZYQ?R2 /QX+/\[0=UD MU-A&DNJ/HVS9#)?)_ :0?
I1_9ZMT1!P5*2',.,68;K,.Y9)%#V/GE;J4VH0" M,?
SA,]>0Q:CY"KNBCWZ<\$<+]XH#V^#B1&7J>' .66GAZ@,DC.)>L\8F8HS1W
M%+% '(7_TZUK";PRIWS:ZK>V\C31L69650DLA&;H\$0Z_0%H0SX2"AP;
MAWS8'CF50LV8:0//OP78^:K^T"B3H0V'\VW"(2WQOU\$H\Q_!^>A<8W_VR640 M>V@3D@^?D._N/X/=
[V*&DV,I198IQB]! :3_7\$ MN)K1*A_54&MQ.=<2E=9ZNI?U=\$C8(K^J\Q/C[ENE MU/K[5.FJ@0>23%KD]:0
=RCQ?6A(OPZMU*#G MD6J]KTQ_8RXHQ:9%_A^ YG3JC^W2]WUB/EI7Z+2>5Z:W'"0L4\FB1VQ^#L4^ ^M!V#
[7.529)"IW-[3YFV]BQ0R*-5;C=)HNTG-6>2HKNX.#\]>Z?;.,U3=,C7
M^*\VY;1S\$VXC#"W+;CF[B(46,&5B7)"Y0[^&' -N\$C3;S5@TG4W9:S)3)M5DZ MKXT0YF?
FJN*6RD,+EC(' +\KQM1&>, M7#8X-&JW[UIAD@!M0Z.]TH20,F]M!&+]ZD&*0XQH#
MD4>J14&9UZ>YH%\C/FU"P"QS4A&;:DRUJ"F3^RK9F!9BFIM)Z=NVY(=_ 16G MJ]>I<]49:
[5D@!%B9LN2@2AE*0#PK&+0\$ET.W)FWR'[IU:#G;#G@53^ \! !M8\U>/6Z7(I=1'D?
XH,@#%D@>:000AA'KZ%X=8EN-F7\& M, QPA' ' /)-5%X#&X-9>TWI#=6KPV\$I6,DUDDIA7:Z#.E2L5K)(?
(4KJY^#6; M\!FY(\ \$/;T=7(D<4\W]J5Z0-EJ4I)AA;YJ4@E_B1AXI'ITB4"! *I[4P,K3K
M73G@1>>I5++ ^&?/XB'CS' T\$B8V31D)T;E;@>= %7&'?J=I.-4EE;:0JN4/# M9<"BX%T?,E-Y_"Z92(.ZPJ(-?
K%- "&^TC+*CC@Q#TK)#+<@+J3KFE[L)T4;: MDA(UCK3#U'.;YK#_#,X1.4WPV",4?
13U:)LY:*TR=6%RL>4QHTR#M%;D"YIT MA2HHT:65D9._ 2&!#B9+ "^S8MTNQ?
DH\$PD,8A'C7T/9"P7"&7S^PZA2IC10C M8U"92(F40+\$6,K"D'BA29+U"<(B:R(5U]#9;<:-
&@)*J+HF!0Z=BW#3(VK"7 M%B""LQ9D)6=M6-'#.GVHRR7-L;SF; 4-H.AH%Z)?_4JJSK!WE**%WWPK7+;=
M#^7*]GTM^7>Y5^ (0#2I.<6(W0W/>?D6C=KG:B%\$2R881L\X,%X\,VK[:80CF
M(WDFGBBXGUA1V&M#0LGH5@R)M<16HA[N?JUC\$&C_28NEN@DOW)Q[&.(ID"4U
MYS%8+;+;P;&;KF4I/T4+9)R%M%LA6X= ;0 H*\+,C9 M>I/W(5RV1^ ^0DQ\>,"#R\$#
(_/F34"SZJ;ELK9*"%.4TDMY]]JV%94E*,6N1WN M9T)A3.-N@]I6_C2HGA^K)W>+ #GH4=05=%
D]@+_V5N_XY"*L\$0/ DHK="??0 MM/U30EMG\$%01I T&]4QP<3 (P7&E7XL6'[!:L5\H_ ;=#9%0%3)
(, %Z)'RJ!\^T(RVDQM>2P20!\^ !83KT2CL'4?GCLUUUC@-J
M!Y; ,90@_U01]\$5LMVDK.MA3M7@ \E&0'[J+C\ \$8FG12#R6U]X6 M(7UG1RW+
<;;\="JE\5G;@8Y+,X5P)@Z&Q!P<-T7\$#;/Y0<>8.4LL'N/5]N< MG=I%A!9L)3>G@+UQ5D
*19%4M!;+8KFMC('4E<45H\00(7)2FUL#>+K[E;>Q^ MG5C#)0N-
L#VJIHU\$)7&GC<24MBBE+HKU#8E\%&N,A,HHI;-@SJK\A6&RWJYLV\B[0.P\ER;(M..(\8A_%>-
(:_N.I@Y&'J3XCG\$70W\$*A% M0#94U\$V=^:%2?NI:ZI3,+3?0?TBI=0BM0FQ]-@F/6!=,-]3
M6%43K0TI)4]9*:3D6>CHP\$FLCW))3J12*\,I>YU?:@B,/6\%_7U_+NX48Y,!
MC023.^CP[0QAY1E306*U8:3D.=7K!S-C[T@/%"HB'B6J(*F+PN,00:50?0KQ
MT; ,7J8T< 4=#})\$3JM\$]1\$UAAU-0Q\JW\$4X>[^M62/-P/8UYM.Y"MDI\9LU\<
MM^H&QVW9:W%64J>E]3NG[R\$3PAX?\$)"=9W:BW_6@_4^ ;!>'5'9^85W!G8 ?A ML< \];/\$/G0EV?
=)!%,)]ZKHP,RX4ZH>X""1#AWL!,%F./=>Y7!#8;8PZ4/' M#N*RX;MQ>-@#7I"QPSO(!WRYPP-
1YK/'@L6'3E@0.M9Y!W')'PR9Q20]U8# M>" .8=XXJ.D,LGH56WY:LY(%-TJ;:+9-NZI\$!SQ,7-
XJB5ZND2+0HU'_!GAUM M0>Q3^RNCX8]XZQ\$X*9"+1[+=XEF.3_P!09>6%KKP1ZM1.8X*CO=E[G.?.I=0 MUA#?
[Z++ #07!@IG['BN\$V,XP\ /V V#>!N.DLU#C,:C\0L,FQ.+&E,>F%!* = M\!;!8@_0P0/50S5?>0E^0?

XP8MG4AE0L8PPI#S06S,=NH>G98DTU9T"AFF&Q M?2S\=T#70=QPY\ ',,4._,C0\$Q?
%A*0\$4M= USHI:IL&MNI/#C3 M&1}.G0QHRKJ)J.@\ -Y'DK"QTSDX\&^NI@IO((A>DG1\$J'OI"1[60/I2+SLL(
M? ^;0.0)E/I@*DIY_ W6U8@L^94+/5T)T";\$M9MH2S^9+00I4>& M>5?H]M6/8^K-
WX%CXWR2N62QGW?)8F6W;,.T*9X)OUXS5"X/,G6"*7UC[#6] M1V/\$4E_-' '\$KHP;XJ';0%P-
AVE2JZ\P_7;','/U"YF/B%?4 >KH]&FBS.33+ M!M:)7% R+[YFSX1BRJ/=MP\D7)4635R\$82'>U1G1S7>HV-C%?
^Q(<=,0F >* M\$V1X"LU:/_B#\3&:F:K((T+EA@V=(HAKPI^J1@5BU"!RD|(*AL98FAV(743 M#+WU5C?
\$U=3DC3)-J+4%N>QR,S1\$3;!K,W#6_, 'YKJ?F"<2+T7&F5""^]I@| MGCNM4L6B;03SER;IDZV""\0TV-
@SA3&HX%8;X@MLRY>LYV|)KJG0^1<1\$ MF=A],32\$D*B@POP NU\PCVZC'R:WYG_*WII?Z+\$.>)RITL1\$!NZ*
M9A,/Q"?8LV8PF|@1G|YABS E%J,6GHT"0R NI"(.<4AD:KY1MJ M7W|21,X+JN59(I(:8M?
FE|.5&\$X\$8S+80NF/[QTH|Z&SI9K0)>>M?0CE9I22 M-,&F_*"YZ6F4JNEYJ"3.'\386 M>' M02SW04W"4:X?
#0A+!I/;L6MHEQG;#\ \$M:.06S'H:L&FVG2'Q^L0,)3W M-'DEF]#!1,G?
W8:LU9ALC^6>FZK0BL*5/T,OZ.F;ZH#\48-!2L.\+4'-E% M#AV*J8(-;7NRB@ZH^+QDR>BAF*"I
Z2L00;X>&9A M-='2|:FE=B@G4^+ML- K\$4DMRNHVME3G\]J=E-R6Y(M;P#1I"Z5<\$R)RZ[W0
M<4@*XHS0760KWLMMKVIXCU[8;,'8"<:FLV/CM0[|",VY>K0\!BJS^:E#)-X2 M.Z 0FN\$&\ /1Z@-@4+2IYW0>?
R&.>8!V7&XJ|B*!WEFF^D.L907V\$Z&N|:' ME/PO3.3ZE\$(>3Z,9S1=96'Y)L3<: 917"5[RBB:8-'68?
H920!|G6C98-Z MM;C4%I8 F1C#A;UF\1)4(<&C%D\$'C\$9FSWSZ 5>KN#9Y@W353IW#8LFV+SSX"SL!\-S
M34^+(<97|;58H\211|/1&E;W%/3K05W1Y<3&063,J0F0| 40Y36N4J@#\KT> M&EWCA0-
MV/KP' &>B2@27L4:C["*&\+=.;|^ QGOUHWWZ(J-1-;1*- KZ)-
MK\WV_)IR:4)@%.|3CK47C65DP+9;GDM8_1P^V-7PG\K:76'^N; UK--Z^I "
MVL=K;UIDK4WCC\./)|\$N^0+ANMY15^ VQF(2Y23K?#;G*0N8RF"70J|SWV M|(A!' 3TR583F!P%--
IS+E:1Y!!R2! (,Z\$!>5J,V\$G0 NH#^)%/H&&UGV M(*D1>UZVL>N*!\<8C":F05_;.S_^
1ZM*/FG|]?!GCV"H#9%H6JJL="6@'Y0/L[A+]W" M; <Y9>096V\|P-&/HGK+]=VL?
C=R|&AJ35RZ"0(X_R|3DV_I5-'U03+POLUHV;_0\$#GD3/X>10020GXA!| #400 M|JK*C|J|\^KK3;|0663!A;
G:I/*US96X-!8+V1;E^*DJ5*P^3:E@G-]=<,7 M|'TC'+IXL;.\>,Y:B4=C/9%JF\007%W'\ "\$X>066S-
|;333!./S0@5", '>C;A5,(#" \$3W+5\;,% M|,4BSG/VD.F&&W;@V-
G&+,>FY.S;P:9;W28.3BZLC|:R|0.^F+*YHS=[#UP5 MM^Y-A8;>-ZC3!=%1F-2+D8=M\$@T0?
PP,6AV;.B/>KQ.B803QJ;U7@D+1XM7! MD!#?^|;S/' '7_X?4\$!#!0 (">);5ECTU/@6", .%J 0 5 <6YC
M>"TR,#(T,#DS,%|C86PN>&UL[7U9|\$R#0)|@CA9F5_E4KG47_M
MV^GHV9<\G0TGX\|YYS^QY\R.\$[2_.60_P/@/U]] M^..W9FTD\|WC^;/7TXSSG)Y|'.ML M>-
.;Z6/YB_ \; > /\22?(@S'LSF.8WW ;/CS;/'B;Y.(\P77|Z3KV=9WU)|@
M_3:H+P\$7(/E/WV;I^= \NS9DAW3R2A_R.59_?^?'|Y>N2_SH=\$V\$S;3W%R
M^J^X<7KR3CE\2PG^F8V&0U3%?0K'-45?#S)>3|{SX;GIZ-\0JUDVDN?W0^KW'\!E7RS\$M6R?
J?]_GX\$S_6\$'\$4ST<+E0U&/Z> M4@GN:CGYVSS3GRX9N29C-(F7WC2J8IQ,UW\YPI!'BU<'YS/XC'@V^&V(83@:
MSH=Y|OI_.J7-,PA(: "4L@76\$6H6\$;+2,005@0\D4>S6?K5RK'Y8+;VZE8,G?_ =;V,
<7(<^GL>XW<,H|Q>F|#,ZJP\$ MN*(Y*)\-, "X=?9=T%(@'" 6^MILIN;R^#?B\G,9GDVG*4U)XSY|]S54YK73?
MDBR4XW<(<P'V(H\$J1AM ,P1'#1 M\,H489%+9;EJKWQNF87P,C'"9@V FB&APTZ!L%EGJWP|)%DS6>*!B>L
PQ" M*:88MZ5#T|IP)6N.NF2=|9\$<7YYHAZG@(>AH(%M0JS_*,>DC^PJ|L:7WD095 M\$!-(ZW;HG8P_?K3TS5
A"5I+5D#<+<47HWW UM+>>'Y/ MC=QA ML-+;'FVG9A>XZ\$<&ET; \;X;%-[ED>GQZ.XZ3T_P)0VWZEN<#Q;.
(.B"@XA*4 M%@F"i#"/(C^OI##D.-G&@+B#I^U081X9^E1*H1DT/LXG\9\GDQ0Q=;/+0\Y) M<0V\),|8Y@BA9
;*"0Z(*M,:C6(2A52^|1'?-2H.7=?|Z8K;BX_ ^QR=YP'3 M6<52#&@>"S*8*0"9 F.*E).Q7EHE6A|(W4!&GX*M
Z5_%>&',KT9JLE.GT|& M&U1\$6|0P)8,H*"@P(+4;E\$0@K\ HY&HV/K5RSDM?#4BZ&R:3S(Y\E_RTC|_-
IE5J_RND*\$>H'*=QYB M/#<%BI,Z0^44<,\ "XE)65H|2/,P_F@,!. -9:46-81*EP",I!Y%D
9K5!'3;PRBNZGJ4_C5&#>-1=). M^7YQ*.V1X@8M\$%+"#\$I&6JLB.DP*:%(),4G96K5L\$G"PJX6SD_I?=@7 M'-
\$GSC|DV7PZC,3G^HN7XW3YA8UW#BPY!\$H9"0QU(NV0&01+/Y:HA/#)}MU<
ML1Y\$<)<^<1_U0=,U_YH,VVVB+S@J(7R?3CT3(QQS/IXM0NB8"?ORT9D_.MPD2*K\%|;4%9AN"3XE_/?
(7W0;29>P.GH*##CF"EHERJU1_AV>0IG:N\E|^N8;L3Z
MC0+6'RH;WY4_.;500XX*RX5TL\$F"5F35@5\3A9<)J_ ;^6*<*YWFK*\OU#_S M>! 8 M_ |F=C.Y_V,R25^'H|'
FN"MMP\$TM|Y&P^3(^_!,YE\1|Z(B,:B7C^|3\=7 M#:2| %TN;"?3M>(|CST-RNE< R_-?
0L71>6W|N;," ^1DBAFX2F1R+'EJ(6H. M2>9"CII!P7QC8>|"5Y_.HQH H;DH.CJ^0J.B\$=*0VU%SS^2X
_*DR*7F)EL6_MLVV>\|UW'_.L?' \#L>_ /W"ZJILG;0.%H-1B58B!;HT*A|27# 64I(%(.7ALZ
MT+4N2KR+I@Z*&0H;|9G5(' @BZIIIE=Z;_,'JPHSC28?6A^YWK;LW]=6'X^(J
M|@ \40"T8\$M07!F>6>RPPKY/84NGHM^7Y4UK/H;S M&E'7U5V49\9*4%1,&D\$>&\$FJGBKJ2/%4#,"-|9JT;_ *L=
<7C+>3T*93I%!.M M1'(%(W|]<9500|'/3?NA\|IZX+P25F%Z01;K(082#|7M'/|9NE|GMU9)_7!
MG&C49GU#T0\BX>^%J&V*A:*J1!'3_X56@M1&,ZE4T;)UA7RMY#3Y!AF2XW# M|F5*R_1_SV>+K?
8JE\F4\|)')L-RW YA^#'|W\42BBM0\$.DC6>3 .6, ^>\ M(5WM%1/1%M1VY9'JV*)#=>1ECQ^ZT*_3L
MS_'V2;95,GLV0(LE&Z;.)C!A!F52'"N5:K>B80\ .K/|Q58FU-1*N4P=03,Q0. MZ19;<-@5)9VU";@F6Z&05ZFI
E+Z**1+VL76>?&;*>F3|3\, =LR"P=P0F'- MZRS3Q|3JL#?Y2QY-%0GLU3('2K(8;R;;1PKK5-
UI**4%CD5KY|12V;8&PZT\$ M|!9MD%", *Z!X37,KHE3D M'#!BX->BM^MQ|/T?VR?SUP8-
';.^7;HYC^GY(P+KRW0Z' |G\TK-E|S&J\LA M\4#TA(0&E(X<@N<2HL6NF\!F|J;.
(H'AP&BD|1:F\$">7S8.HUU+P+[E-!N"Y|NY-11R)5<,DPE
M#;6*F\$A(%/4Q:R!F(;FRND33.@MP2\BU3UW^I/HNR5|WT^F"RS-Y]-A.)_7 M_Y|/DUI01!J?H\$&?)E\$DZ=Y-
A\D|"\$X8C|7/->FS (N%0:YA"0CKUGJULV/ MAU'<)R|^?R1=+PDYFA0;5A2M1A:L%,0RV \$@J40C?8Y:1&?
8@&C=#'<*T,\$=-|S M-|/2I_.3!|1,\$U%U>0J8) IPKHZ;\$IHB?
*\U(\$7|+M1\$'E|1N?._WTJ3B72:4C.QR4UWF@T2I&B^4^-9G_M_7=Z-2UR=4F'F#BS=2Y-J6?GQ%LA/1COB-
DB,|6^5N#V7-V=0EJW>050X6_U MP/9B^C^=?!G2I|WZ_N>L MCDAR?K^KFG>("H+ N:062(1&)\$
M'"78>03"10J"]*4UY/8CM4^QZK&0=P2A=H; =X5>2>>5\$ZL\$TL!G)KF21(BN M\T,8<)|)H8
%I22|)%0IG0: ^FZH^50T\\$*X.%4| "%W5M%L'; PBXUI\$2SYD MK.U(F!Q%2)F#-TXS1X@7S2^-V9VZ>T:Z3|-

*MI==]CZ8S+/LP\YYN&7JD4' M67"7=\$E@>\$B\$>:(SXD0[X.(6%1DNG7'R5TTW;/X&GBZ! YM6M\$/&2:WOL
M'4{JB/AIG00S)B_?W'P],NW>(+CS_D#Q6F_%&);0:--*AM04+Q=&_1,'9:)-M-
D.P0E(<[734K0.'XZZP01'(36#\=3C&<;P,1B,);MD[D,40&+GQ]=:T#+YP MY8+1(38?
K8[=7U*V048XSR*R*KI>D-\$J+WT\$0K/ MY*?KX)1N/:5CWP.0!VY'>03P/%3\7QWX\,&&HND4Q'D@S)7!QI'
ME8A5SM)"-/<=(N/-BRXZ6\$:74JB/'/'/#:B'4-RU-(41<\ "J7,0B;20"P5B M0B50B@TVMPY6]U7<]~?
#FWPVS7&(J\;@EZS&KF_9KH&V??#WA)VA?F 9,CGM2K:IRM,RD] MUUPY&8)HGNLZH1=EJ^_*J\ET.OE:
[TL:F&"3(\<5 MN(@65&UA09<<)++'16IA(}NM,W0'! :I5?(8BJH+.71T.\ "5<1,QZI!E2<"X MH8#&J@#!*P2?
E8U%HD37_ ;I6^CIT_3@ (RF;9N)IHU+6;;ZDVZZT 0\@[: (G M>!OM Q28# L!A#*>Z":&>,\MN?
U2^~I&RK6=2>\$T(6<75-FG@:H'DF\$S9?7J M?#80T#,<+AFZ9>?
%R.JW>X2)D6#N%*'6>UR;V+7^R=AZ \P%C.@8N M#?C D#2QR/4B<\$X;*TBF#1>R^0T)1UK:~+F!W3P/L?09-
NW0=3W":7^&B00NT MNIVKB2_2I9B)53'484!8-V; .9"B\+-D6)TUI?=-)W,R6[X,T_+;PU\$F'\>?+ M&*?
G.5V>![V(4WZH^HT1WRX%HR4G1FCR+E2Q#GR=S4> SKZ6E*)LWYAZ&,T[
M':^RIX6YH\JY6W16=3M[C]\7A5TH@HZH!"1B0IU;HR%H:2'1=D&&F(I0;8C0-M)&HG?
#VQ\ NVDFH3BURY3&UUVV55=P/W2*YMPY]9&ARR"<;6CLOJ0F%&")0:0 M+(U*3.X4@10 Q\$XX>BHG^T>56&?
S&HA)FZFK=^7-<+;8!D3Z^VD^'9Z?#EC0 MI##)[\N8"]EYQ#P+1VU50T/E*~K5P [QB'\$H*TRB:~+G9+~)UW^W)T
<*RZD6,HGP/8VK(? MJ@R79W=>Z^)E\I" T4*3/) *N#(@KH*!1GPK0"FS>K7#Q])^\$ _D2/X WG?H;.[
M' 'J_0#QNE21*07@570+'M_05R)*VBIPA7'+7>T9;7V-V2YT[807\^2L16.!
M=5WR=5.IN\VN*\$'VBGM6KV7##,[G2JX-7M;QCV64Z=QMTU.*Q+08?-5]^HT%
(&X^Y(+&>.XPFE;53:WIJ(:KI(!2*LUUD(TW^ .T4'2]G?V'+!V2WR7DV E*.M6"S#K\VBSNU M"V8=#4J1&S-
A#S+[5,??\$%7[Y]_W\$V SRUDG+;T=S^;3\X7/N&;#(#D32>T& M<~\$X(H\$;H.A?+>I5@@@VR.93"
[>0TB^;0S]RN8D_+'ZR?A#G<9\$ _L+G5S@; 'F)B^T1^DQF% M/5I/%R9_Z6+A047-7-G4BIZ4R=
M>H7\Y5U]\$P^EDAK-6""XW4,>P0G-%KC-;6F^QSZ^LU=R;N3V:~&0IU(Z>^
MV/R+/5*N[Y%C&.V[GW]DJWM/AK0RFU=4U64%M [^X%ULSCP8Y\ AI4R9!+\$M%@_ -2A47R&UMGA9H0WJL42*?
P0,ML=R_W M9C9[7])KJOX'Z2[XX(K,%#;J4MLG.7@F\$8SBV?0L;&A^!5D3PG0E"SP&Q.X0
M\IX0N]5'%BQ*PZ(%6UP=^\$*<5Y;1B;CR][7JKU\?74&KNKX+Q6B'."8MGQ\"[^T,W8T55>R;L;@IJ+^D&>9
M/JJ>_KS)7_)H4KB/_ '=Z M;I]. "0Q%+1 M;)57I+B" L]#;G0^YD
6M^ZZ.%~/9IR&;7MJ5#V;6]Y+RDK.RSLE0@"E3 MKUC*2.J1*PB91ZPW+K'FY;QW>5@/.]JH:YP<~
(, '#:DV:.\P8[R*]9?L3_SJ.T.C 8 M""E"UBP!;BRT*5(BA\FH0BE5BB6-.2NXVGNC:1_033U9-%*07^3K>
Z*E:)-P9C=KLS>[_E]BF":0.\$(8FCF M/JRN[DX+;C?
N\$0H43D>\$#A3Y"MSX0\$C\$B^*R:4X0]YSZ[58E+Z%,L<"H^6 M7&]WH0#9U?GWW_/\9+*9\QX4]~*CJXW
6'L^4@&TS@"/Q7---'.I][<21+;3T M*>9H!8\$67' @L_CE#7:X<7G='WG>Z?'[K4\ \SHG[[HMN=LB^Y:9 >NY
_V48 M:@TI"UUKR@UXU(8B4(Y:>8]>YN?.&^GIT' 'X,V?0N1D,?7DPHDB(VV^8ZUV05&?0-AF.+FA.["54-
KEI7\DS3_2^AN MNOIDE-N@95M>HIET6MKENMXZ82C/9D06CG[-/Q8ME+;%DR'(. =2T?;W;_D34 M<;
(,P7G&80/205LIZM/94S=8:2B1-H>4*X)V2]GZQ(I5L4#)#LEHBT+D100! MZ2(MN_ =3^W3BU!84W0J@*3ZVSK]
<4V:~\$S,%#;#60:E-&,P@Q<+ < ML[7:*V%WS\$WL]L ^4)UAXJF;&^~OG=C5EI*)%.@ZWE/-T?;
<3'\S,*CZJFP]F0/%V7";3)3\ MY\$6T.9\L_ : **0=PUN\$5QVQHM4P&/). 'D:D?;!ND
MM0JA>\$5[V7\$'7N@50DX;#S9'A:W;Y_>GMD\16B>XNZHMC38909V5Z94"C]]
MG0R\SB^BD#7, #.04""; 'F4C0GCL1(K-:MIXKXKP87!&P,F#
M.DL6K?/577%\$*SFBGHD(*3BE\$B\^0@=6B6R3_ %C [!V;S\$^"-I^G90/! \:Z
MI)*/H\$;AGI&#;1^,JQ4YR+635K06<<5]:>Q35-H[K-U;B\$>'VA_D/7_ZFD=? M^N^3\?QD-C
BU'\^D"7: '2[6.RR#]J6#4\$4=.&A(' >5UCX%N;V"WD%"[>@Z MVXV!A-H@JE!
)N!0A\$0LJ70G(A((F54K'7)R!92.EKA^@Q"N8PV!P&&UW; , MZ VX.HA6L&28=R8[; 'XJ="M%?
0I[6J#C]AMZ#Y)'U[0@C\DXKLB*RGKA:X=] M;1!5*05_1P\$Q2*// (34_%Z.XGJ4[1R1*3L*97'<8_XN%
(%=>0CQ_ 'OUR'B M578<^QA1L(C<7+D7H7VRHIV@5YN9Q-0=NYS M" I2)H>+@112@?&;@4I+@G& AZ6HBD6P,
[&7^>Y^GI M8B;1C^G&Y_/S:~Y].!Z>GI]>NUKBD)S< 8]K8D!;+;+>1P;P\H7S1F%;0!UDJ MD6R<<2ESL!\$72H1
8EP!GX(ICG%??NLTFTW'&P85WUX]1F_XWPU_NI#/EQO M^5VY8/W-R1@TK*B@:~>E6\$#9R@HA/6CFF?>2T&YL?
B7%@33WR5PVP]HU\$WE, MP;8[)-R=ZK?C:X=*T9=B2KW+S_:%KR*!('P:~ZVPAY]]FZ
S(>I2N)\$\0HF!0/' (=E#"B>=0,/G3V*1/7#\SM(\!6 MESG03.9%G0#E. 'TZR=.,A5RF@3&J.,
(4A)PX[1&!\$((/H),5CG/IZ?6=*CX/ M)J5/6;?FN'H :76BS 8Q9[3>""B~*DBI\$/MB("8C#3>R5Q\$Z_0G-
Y]_X"B/ M3:F^/3T[G]<+ (BQ>38?6&MV4R1RNN=G15UY7MJYC4JA;>\U T.031 .K;1TE[5V\F'%G]#JM=XZ\'
M/CPY%]#-!=!MT^CUJ^=NN IJ4N8G^=-DCJ/WY]-X@K-\Z5:Z3U,F0/X/+=_0[BLFZ#U7N1\;Q MPI0#V--
=B\$)HFWP>UTN*WB:"X[,_* (NT_GR)CI7,0.EXB7X6HY?W3ZE OE^ M;
)HA28)G; .5K5.H[5=QJ"W_QV220@Y'HX'TFG/C(GAKR1.VM%>=< @Q"B91 M2(6Z=8)]]>R>ARG'Q-E5"
[Z7>+H,5/9FQJ)- T=9[8HWZ*,TTE# E3V"TM'3 MLGB X@V6Y"6B/\$+XT691/0]J'A+. 0)4+ ?)I203%FL<%"-
XS9'1(FJG\$ "ND M!22>SE8QW7"H)07PW:[HIX'8T]EAQP(I5YNCVL3[0-]2-ZT/FSH=\$\$]CS*?
RN8X#&B]W!MOQW,0'FQY3^=X/C"BZQ7 M\PI>#!3E##?'U:ZFR(B=69YD467UD[^41?8IT;@}
[QWV@*MLX/%_5W+2YT* M'RI8WI4_9WFM*)@(210%=G&E9R1+ZI62]=!<Q""*2TUBHDK=,UI9C^W) M]17MLD_L?
Z1]TD,H[7][;)_WKR.RQ+F'X+P %:(!)Y(&YRC:*I@,WT^:#[H MV@?W_S=+/X#UT'MF[1K>N,1Z-
4>@6\$N%""%5Z^PJC-@;:W2UIB]"#))T7H: M3\$=+Z9-66M\5FKU/2)%M!4IUGAP)6C
0I"6W+JH6Q>@=YWK>I1YHJ:[H\$NE MLP=N'EK#W+B.C5<&(6K\$TM505:668(5*~I[XQV/K0>^WD[1H2K^ED]?-
G5B MD#[:@F"UIR@HUXM2ZX&!<*EN<)>)<=> \<[=M\>=?",8@){3 AMH;)7 M29""054+^>UH2U>OUR\!9_G0?
_E_4\$#L#!!0 (">);5E/#]19!'8)2. M!0_5 <6YC>"TR,#(T,#DS,%]D968N>&UL[+U99S\Q;LB2<)H"U
"HMOK7WRP0I#B!Q_*J@,6A(UHF M_1 KAZ^J,K-R^! \X^/I]]\Q0EB,I0^QY_X0[, ?8/3-,N3Z?0_ ^--??_ \1
MW) ^YW ^V[_JC_ \X/] \] \ZG;[Z?I;./.%U^WJ.88GYFW].EA^67[;_YK M-0_ [Y'/XYM?3L"RS^4>
_US]V>09IR SR?L/RV\\$\$^KB8Q?050^ _L*
M\$4\$9E."+LY"YY@R=SDKH_ ^]GP0G4AN=P<<203EN(=@@(*J02K%.F'3^I:>3 MZ= _7/^)88'?
\$'03Q>K7_ C3A^7RTY^ _?;? _SG0_ \1YZ?_ /IN_ U8P)K^] M^/2?UA_X];G_RE7G^>^V]7[UY^=#&YZX/TM?

S;_/_S3/^E#_@QP&2Z6(9I M^OH >GQ>70/A56KTM^=0TD<7DS\05G__TRR%Y4I!#|+PS<9/U_@XF-07P(N
M0/)_V.1_2?_--->2",TGYWB.RS?K'\Z[LWMRF=3]??YLG';|>?^3:< MGA+%JV|8?
0F\$ _&GQ>3CIU.\>.W#',M&ZB|8KD3I2L|_6|_MV[UI^D"\$S--9 M1!*7<5HAWI#&N|Y|?
YH00PLREG!VNFQ(\>W0;DK0|&.8M|3PK:|N0.WJB^ C M?HPX;TGJM>^|0N<%D3.W#XC+Q5^GX2Q/Z-5?
PYQVX0^XG*2PQZ/@T1 M3U>OGIPMX^T(GTY^6|+3ZY&/._;^G%QXFP*4:_.CT\A(4(HE'"3&0|0B2Z:8
ML*K<1LKB GDE+.(**^M'\$&:\$_!9/EXN+5ZHJY\$H-FZDX%W0#OGX/\11/4F#9 M,YD@,I=
94E'9|@|0'7|!*IN5B;X73RL*K0/S%3JOYA>6FT=?TZG,\+ ? 0I.3 #KR_.IDM"|0^GJP?2
M2L;W|8=F2'A|&A;+M^6WY2S|_ =4?D\5)CLPGR0J@-QJ4-R23Q!-(07(4TD@C M7"|0W"2F(3|N.?
COPS>^GKED761\&|427"|5IP)_|45KB#QS**XP^BPKVH1^JOUKYN@1 ME3|Q\$|V4_A0.)|AX|2LI#^=SS"02?
EX9JB=)%PP\TFDHA*0^MP#GDH>L#9FV M)?KB3>0M?S,Y+6%PEYU_&P/|:NOF|M|
(U+=1P/9%P76:R*A^_U^M@/RW<'J& MO^+\MP|D:)^H\$K5EJD#,R1#WR4+@-A*5.IG(/8M1-@;\$_=I0='AN-
S<@."N@. MDQ5)BU=GRP^S^>1?F\$ 06F\S#Y #6E! ".2";2 69E!QQ5EF7>%QDZ(G!HN| M!-
|A|+B+NC>+01E1)I6*63 #&(TBIA,CH_8#G&>GT!.YKN|. <96:)PF#^01|
M&P*B|P3>GBUK.+0>\$9PH)K5004(N@<|+)_IY2MY"=BX7G4,REA\ !U=(>I)@ MV%7DMQ\$A|_8B9A\ SJ;W'V-
&9\,E057\$3.PS^B?Z%, @F2T^0UM=*B&Z+AUFB4R-(N*0)L<.\$09:;02%:TRF2R:1YONH>?I86!78=\&@EW?|WU|
M0S9\$^-^;7F|>BF0Q.P \$?)B=\$@6+'^COEU\N|P&;77%N^|Q>UYP|\|=00JI,' M;P-C&;1D
12Y%."*M"!*YL(4X2W3C^VJ,V0#>* |KQ@N0-D2@(|Y"6E=*6Z&* M48ZIIWK5.42?#UQU#A^CZ*XZSY<3;9"?
9M.ZV%:1?9N-I,TA0TIUPRTR0D@Q M BJ7I.%*D:AZ >,N@D9RY3E(T9LPL|?_.\20;M" T#0%00U2GF|\|
|'"3KRY>?^ MBI0UDOK!(|!\$-BY8%#3;)|\$K&#%Z0Y4SZ MM^!?
C>;UW5P6/F2F\$;2P9"DK8<'%6\$/M0I!MKE'9UC;0+2(|XLT4,YF=V0' MR7:XSGJ5\TJ(X?
37.,E0IJ #I\DRG*Z)D|OXB\; T|J#JND^0J K:3SQHGD M1.0;K'L)>@H0;"?Q#B0_54IG'\|.JQ?
V=0D!YY7Q.7ZHV^1G?#;EOPW7A)+= MG+Q.#+
(S'^3@ \$7QR\$;CD2@0'.3;/B|N:N'0I@:"#C#M=8YQ,==600D&&4:N)0)K1Z9 5*%<'*R_0CK8,. M
TD<1;ASG_A\$3Y5TL#YNAV1=L5P|KV@+\$Q\$4+S76:QTM>]DT#(G\$U0' 'XX? M|.ZJMIOAB+UDWB|/|A:K)R45|_
EK"-PS4"(*B"@EY&P+;;\$^HFN?='^3BB<_ M@_VDWM"0J+<2YZC|+JQN CY^(BLGG(MZ'J;05_OC=U^>?
N37\^6^|)*H*X>VG M^L'%JVG^938|_ ^6* M FF/5|Y \|\$)"BLR:D,GB*+POX',I0/)!J&N92W4?
W;H\$|0+8/("4N)!|U,Y#^;R"&*3(> 1V\E,LQ1|X.H M+6AX?H|JK9@.&5J0\0|16RQ7V^?0LPWQVM6ZB#=#W|G=
(\EM,E0@;SC|/\$IZS M |3|/VY7E?VD&FM: L.,8-SA4\$2U@9E+6>Z=997;YZ>)|I!'B8B-
MJ6B|(WY3B/FGV6)!|L/)^^GKL_D|BY0IC\0HN|Z/C^V4FTJ\$3@&NHU M\$:@4R0643H%TFE;IX-
GDULD\UPAXVJ#;7=9W1-<[W+P\$PIH4JG82E 1%K@*0 MV^!V6 L2Z5PW3JKXX\$|EB:7|LKS+(+R8#5Y#BJ(
!|S#61GR|G+"D0|G:;| M+PV:U@2|G;|/T\F_5C0+|_4B^!2Q2ZK_75_3(|/0>H:)|>;7^|&WY?
4&|]|;+UA=&|!.T+| |N^_#P3 MF50"M&('"'2^EJW1=N+0@<02 M/;:-':UMA(S^&2^-0I_N96W4;.8TGM0\|'
M^C>5|R--\$**F^Q;:;\!V"=T6221ZE\BAU2JU|VMVFxEA) (VT>S.'8=3F_0D;VGI09//<(S%G) MHPF:R;
|+XA)^P?1_0#Y=M#YU0UNG1-H=)*J) \F*P4JTKD84\$3@PK%(?DB6 MH77#LMM4'*%/V=|:N<X_'JQN*S,5:
(8HD.9FM.*1UC\$0LY MK5'H("1*YEK|\|>I>%JG^YY2|I!@?9VB7\)'7,-|&|HZG?";: #K.*;^0SNZ% MP)X"
| |#K;Z2/1Y^|2PQLX_R4000.K:'|+N3" P;%K;W@PP+A@1/_4#@8(N>& M^E_=J0|P-
I|]PC|],_V,ZQATF/|]IUF8KD\I!%Z%3!E2,73R|54|84YL1^3* ME6CSS2S|/#4D-#SWI\|
(=|&X7,>DFS1X+\65S@/|YJY>GG6HQ.?!|:"-9:L+195 MYRL84\$02D
6"4&2(@D019&K>D^)|N4I|6Z=|"WATJ;>X@;XW\;0CK9 -L).I(MU?HM5/X_:B6K>R..P@'BH
M90^P>|@|0XX6|]|>/FN49.B ,*6 JB;_G W\$N69HHM-6Y LX8.):ET\$A1|ZM
M!REW,!%NUH9>*1S^GB2=)|L3GE\$86I M.CPH^ETC=-9!|Y2|#HL|/? UE0IS.%WU+IGFWS|,YLO? G()*.:-
TT:+%FXV*-T09AC|Y M*:B_0\A;ERQ>)_977|=2?V-|,ESFF>CVC;6M.|]|)=RH)*0UX
M\$QS91:9VV,4"7CM4P8^A3Q0E|07?NL#0.KTW:5S3?^*=(|KD:\$< MDP>5F(.H383:S9<+.N(\$=SM
8\|CGB@86@BW0V/S=97JXFWY<4(|6B)|^/5L M039,EC)XG1DDE5>36@B142K
|_59M5S&UI>5FVAY"HAH*N^-171-,UE_#)/Y MJMSI9PR+L_-:0\77:JHWTSH4?=\U^\$/:9
%NR=GC7)D0SM;\$*06Y^Z>UYR= ML|'&F->(168%,8D\$*B0#(3,++%J7LQ*A\VF8XN14@
MZZF4L639WL';*K"*.VB0(1 MT.GKP|G)%>+*#SP|/_G7J7EY/_JP0@D.2<*QM/0AM0QCOP5AH@7U#9(HMV
MV#K(0A?|HX|1&R/V<(K;B+K^70>%J3;|B|J\$TU>+!2X789H0^"-V600A_Q; MRS/?A_M6@Z8N;>7-?
0: ^XIF|5+QAG@E);B,%EP("I*.6C^FDW+-2|:'\$-@B MI?E*?X4;#SQW%J1W.A9#QX#V|6Q/=6P?XY
YK:Q@6#2N|9:X|5D^&V35#2|W MI3VWU,58_/;+G>|"|Y<_J)|>GS|. '+3_@93\|SQG-\$028#^#J&0666Z1!1
M#^AMFBBEDLFUCA-M1|FQ0/KF>)AUUTL'-^W.<^0V01>5(EL0V\G' 'T3HC|/|=+9F0)>?+1M4X+08>>Y M
607+10H!Y%KTEQ0)G#N@!M%LPTLG3ZHE^T=RM%H_9#8R|78XXYKR M9+5T@6G:YK5&4,D7\+FV_G1:&)5CR+9U
&G\2'W(|;1L|4(H M>\AYQM!II:0.&Y??_0+|/|.I^>U2?-/_L_.K|JR5^19(&+KY;MQ>QJ)8AJ MEX"Y6EI-<
>?L@:4Y(!P@T7^UKC:@2NW@2YQ?RU|Z0|]/%07%D\$SM M5Y\$D\$|)RU?;|U+\$2+*1 &RUR'"^0KXYY>AF9S:W;?C|
(U!\$:'ASL>KBMICH< M?9L%<-T?/Q\$QY62SA)2B "5+)-?;|Y"1!6<3;|>V=7/4;6D|/(|:J_4F:'KH
MI,._QMU\$*)Z%85IC6P&T@PJ*C\YCQ.IRLZ)2?8QD MU%7A/Y15>B)S9K5*&YCBB4Q_(R%H4>@?
&50V16C3>L3#F0>HX;V0<8W5_/T M4E?W;K"7@CFQ.3K.!0?)R(M4M8>E,\J#UTFDP*,GHCND2|Y!RI-
\$2@NQ'_S\$ MJH-5Y^BIXD-AHJ86,CET.6"+S^4,>1 MT\|XZQP7|_-;JH|-RI?
+B':Z:G;U*:7YVW@9M=K96P9J_)8H)C.P3H/^+BPFB|].9W&!|_53EQE-M3!N-/:'B-<
M+^B)V1@;\VI2^6VKN8:AA#(@Z/=8HL_8?-)!#SZ:)>/L3|-Y^D'(|00/R,\$V
M=52>5P*BKGM1RKQV3N8=87I7&Q=:;IV^D0@_@_CUY=TR03U)GSZ"/CD
*K;_.5"5JYE8+71.GKEI1VQ|W8W4T<\$ZQ-T0!H I^?*_ MN+(|_-
=D^>\$6,X0KW"RN\WX9=CD/\$8N,T05#12TN:")BN5# M%&|N5%57!8M!S((-V&J0T_8;+Y7D\$8'\$2"GF%*#GH6%-
D66_0 M:T0_.1L2>A6Y;5X@U(V;E\4P2MRT^I1PR=:K'_/SJ=S;&X4=<+0\61|_-0B M@HE@E>H ;E(S!I?
G0PGF/X8U^@>|!"%=9CSU^<\$P4*.20HAM6Q|Z=01WCCDQ>?_/@N\$DR61|AF0|/_<7:V0/_-/^|UG|DQ*_V0*_ M-
E(Z2E^U.J&-JT1^B2&?1X6@(|6 MH="U"7.!7"*/0@6?8^LTZ\$?;5VT(7G;IJS9\$%Z.Y@=M0N^F5T\$B',^ABZ-AQ
M,H SWD)P\$;ET/J|L/4?N\$=;_#|+XE07_0R0_|FKJ;7AYJ?_?9)>W \$C/LNI= MM#MVQ*ID@M\$8_7.=U9A9@9

0JKI?4;I['3KQ-00(W7'^0_1'6(4ELW@=_@MK*X0CYC*7#)FH8180!ENP0<9:YMS#,*YZ+<P@]P3ANG7,;?'
A>G??YJ%'^^X5=HE)T"GQ&J%C2'+@AAGIH8#%&0S5;M>.A)S04;3370<--8S)DT6V5 MX4G?
>N4HHM^^^D/7'0C4C.W=I=DP]GQ)Q:I9VY QQ^K>1KGM%_0#ANP>PK^I MOCTDUV-MKLF)]2[/>-
H=. 'I0P=:AS[7+4;\$Y*:5'V&ZVS[\$5N,&^:Z^ (0)K MK+?U; .8U(38&%642H'0M>#8A@\$?IP J4L90D!6YUB_ ^
YJX]]' G[5YBG[60 M64-[;45(^,*(30+;\$2) M''/??C4F10\$V<+ Q=4^<^C;0E20[D=);\$LY
NMW;6GT@NSN\$'Y\?7?(?4LATJ MS: ^POV+W1&907/4\;5F3YV)I109K&6176S,Y9I10G5;9@.RG#-5#:W7C/600
M'6(7;_ *[_@.>9S; \.:[ZI!UG! V\$,/ ,#UL(.='N>.6/BDIN09A5_WCK070
MM:ZC\906612'K4L\1W?' +8CKX+2\$Z&H29?0%HI &2@Y'6/26VQ[-,![E'?<0
MO.QRQSU\$%Z.YX]ZNIBAZ'H(+M'7[FDP?'@.R007YNRSJ;+3CY65VV%YXV*UP M=(A>CE[4MPVQ+X6C+36^5W7?
+NHZ.L:25VA*(.TL.%]RY ,BZ''M)'*,Q*+\ABOC%Q *1P= MI,@!A:-#M-#Z GE# [2K2?N20Q!=-N''89J#J"
(UL&_I ;N.6S MQAY4V,6H[B'F#I&L39WP0BD\&N)1'N=J:55'W+((GB5C#;/:J-9;Q-;\$'91 MV9:=!X?
(NWF*TJ13V90I7>WNN+?9R*1HD^*9H)^P0M^!\%8'G:P+-U00;\$I0 MV0R0IZ'AIJ)L7?FV@>?0S_#W&3&-D-?
3UV?S.4[3EU5ZSGD-UPDWP1:;%AB= M@/7*CY,<6(9<@E9?W>@BB,C):@K?*M.X<>SHT#9B_#HL[/? \ T%N?
R2(@VS!,\]<L;M''R+5K MXYU]MN'V7SY.\X 70G[B^+*)]6-FZ6S>X3>QT1^@R#^F-CI<1WPM<1UU4?_ MU33?
7X9+' AE-IW?N!R]L%0+AN29]Y!CJDUNL@9?5 \$FK>>V()K4K5->"P:: M>;U[\$',>V,1@
VUL!203M14T*M@UV]":X,@CM09/J2P(L< "U(/."=QPWRCG[3T4:U6\2B6^CE2! *,0**)1D[E-
(/(Q:#D):#NUI;P'KK&<9NOET*WN?;:1QL]>OUM*\$M\$P427 M)(,H:XV?0H1@%8(PZ&W"
[/\$/S]A@C:V,P\$DNG@7XZ#-0I6HJX#2\0S0XVP;0% M0'K6D.^BW;\$W.^!.NF)9!BT]F1%29 !.,7#6FR'XU#&UGD
_?J3NV.Q@-\$ = MMH0. *U!U[5-H(71'44"YZT E1,GF\ ZL\$DYXY2)19K&\ /KZ]\$=>USY(BS:9,-
_0^I)*PM(%*=WBG(P6'BNU@V/P&N?+29G00ZI4;9U(_7@F; ,B86B_61M7:V#>V*!SSS0V-BB,0[M.=JT-
=Y([G'M MFPB]@[-]=W+;N35M'0HC'9#E\$T EQ<\$)1\PK%3/GAJRLUB;K9FJ>#!@:"?Q@ M>\-
=2>D06&F#J3,S:EW1K8D[XE7JT1/;^FBPPZZS MN7[J>0GX"1-)9YTY1"D3J(@.7*2%QX2WW%EA3?.KV&UI>\Y
ZZ*_#E0:N:#N MK*L)A>J\;A<(.7V M CE\$D<;#SS]LE<5 >1RE:U)FG",K\$NB?
7' LW, #,: :Z4NN8:WS)9;HCDQYYZM TO+ER
MFVR^@#IF8.TBW;'CECG<\Y;"+#!"U!.UT0*\$L!&ID/4BJ%H;5,.'ZD[)LN- M!JA#E-H!H!N2,?D\Z,&:7>
[*_@A MJND0;=LEE+88G;V,!@PGDU8IC^"T21!S;0I/JQ!CZRS?YYBNUQP7#
M/;DWDMM9#R(4#0V]!%6W!IV)! "HQ&YFRL:MTS293X/T-B3S:8C0#Y0YQ&- \$ MPQT#BS;!2HY,9"@,HROE"V0%
(Q,>^E\$[QU M10&L?>'GF?V].N^CI MNM,->E,Z^WAV2@Y7_LM\MEC\=3K'<%H9^ N)_MZ94X&!\G)7LZEY4
I^4! MJK;.C"1"D,7(:KW3PFQMLC0A !DCL8-F#[_];63B)_KM*Q,ZHG0L1/"9UZ"# M0' E:T"-
_ =0T9K;=U.D#P/;:X2_P;*G9#B[^]LF&&EE"+T![*>H%D27')0K:
MY:4@LZ4P,B>>3;+H\4#61#\;B^2:901=M71?SSY^FDVK4?HJY]4WU] JK8&/
MYP;P[GE[.SRE07;>0KSMF8.W:F!^~PU?86=#MYCA*A" 55*J/U/' 3NA,X: MBU;R(>EN\Z"]VN#?
_ =WG(547M0BIAE15J#XL;.(A<@DQR500DOBDDWH.!@V2_ M-=?
4M1[VK:0WE@RWBWFOKQ(MN<7D:]1,6@Q"&Z0<^@JBK9HWC-?=1]P](LMWD%5_G"->A,"W(+7[<-#Q!WI\$J%*K>
MQ_YZ. I@1!%,HB7_SRI:)2EF<@)]KC/G?*S(@ML?0-^)* \=#%Q%)P,\$7_K M64J_S#[/%DN<7;0A4040Q
@A)0E &P MNV@A")^<Q#F^U8U-CROT\DC-;T_F\#0!:76A\]7K9WX-7U;)JY6#KVQ, M\Z\DJ5_"0\LUL
5/G2R%'OPDER2 MXZ",\!SIG/>)UZB*-8U3TN^1<018KE'U^U-L.VEF(8&V,KT>(>+Y7R2EIA7
M=*UX_MH2DGO.R%]+1G11=:A3\J"C)&;4I043F0E2]_SD&<,B*;R;^U60<- \ MEE9)\6^F1"/2-
]=LI. K/_W9IRJ2'_ZHPL,3SS2+FFL(6-T023^Y\$@0X*)5,
M49MT,^G(TJV?.2!IY1V'^^ VD7\$'%^W7^2PAYL6/))@WTS3[6*\VWV&I93HG
MZ*3)/GK@F50#HFVA!ET83[P'#@Y+HV/E?OH>0+@:"[V#N8'T3-'VB" Q/_ M0IG^.L=/84+H+3B?
8UY#E_# \=0D!Y^>]2DY\#BX*4^?I)^\$)06(?X79HP;N'W075D9K4.ZV\@Y0G10H6P;V-[65M7L?
C.TRS]]:2W52M-&R6 ;1 M%?+JG3'@!+,0=3(L)&6*\ 04VTZ"M]6J]U+KUX296L7PW6QZMKBD M\U>(<)^(!0,
<3H8B[2* +I1#39.S6"PB\$B'I9+TTH9KL[F^V>]U14WD&ZMP% @ MFH1-XSWN]MK;CG=ZVW^C?
8IVJ'>3]Q^6BZM,D=7K@K/ M4J@M%7@LR^@A<):
MI&N,;6U'=F'D'6!Q/(J^C5Y[/ /2FA*>T%I=XP=H09^=UX%FE0"X:2%02>5_G
M6IZ!)1&Y*LE^WMI=:L[\$"VH;*?@V8MW>U^FGJ\]@OC0.>1%1\$BI)A706Y!1B
M;:M'XG)!U]XJBC\$7'V\^F4[R1X0MCJHXC9@, %2N[1V]/UU/ON\$ \^67,,VU M-
'45J0P%E\W30+=^8K>4[]UX/D3Z= _F1FT4%*DL%*010!<&N!=,*U^KSL>= M_JVS8X1X,D2ME#6^),
'KL%+\C6EU:]][5R[L:= #]'4UNG?0Z0WE030BR54 M]\Z6KZZLH^^^7%[C;\8-
YAC!A3J[EJMX7.GGHY\$H2XE<8\$78 % MXVI17;*=,01PUJB\$K0 <6A0!1X/ ,
\E48T#.\$'7TZ')#>^S9\$N>7I%VDYZ 0 MSNL(3-=I9KHX<,I)TJUB(10H4+<^DC:09JN]GDIH',.R0\7)#UVZPL
MR=G'-]-EF+Z?T,F[NAR](+*HQ#AQFGT=W2P%UI&G\$JQF0FN;'2V*3L"XE["G M''Y-
V^FB=+ 53B#;*/%A=IK??/PTGWW&JPV7HDW62%X[\$CLDV]L6(JUH^@FE2B9;-+;Q MLK^'G*
<#A=:R[Y"H\./9G*1[-J^Y,C]. J@_75"6"B:C=(82R1E3P7N(%;^T ME+TJ):)AK:V\$S=0\5
TDGS#Q(4'.5_UA3FQ)8HDH3,'.\$T,W+23;\$01*X# M2KT7S9MEWD_1R
+LNT3',HB^1V'CUQ9!W^G.;)NF'(IU-<"7R:U^W65J]0 M9,;\$D6BT8!ZX51F48J%>/W
@0\%%'43DHGEWJ\$;T/R&P'46=APR, (++)\$YXR MC\PJHLT:VJ*EA" E XZ.EE(QZ)07"-U'SQ."3S.Q;
[1VFUX!KHPYMI/VDTYKT-7JT*)X)\$>NH3[]3>"X0,QE"1A>0
MDM!2[OKZ\0L*LL5#"8H!2X8@;8HA2]TF\$%9JZU3)*%L/B;V' MG\$--06R)@=M^41MI'_LZ<#%?GORVI'-
T9:GA[/T\?/HP2>'T/,BLK#"<1,)3 M[:7E8:H?&V5S%GF*N: 6\7DZ2E7,\$._?
<7+000<:PA%,^W.6DNYH0VR(NH< M/5=)NK@YVH*H(3=Z#T%@\$R&'0;MKJ*A9+RD?#
)8?18JU0%QV'BB@, @Q/DF(M:\ "X])>'H M'Z9%1N&==.HA4 +6MQ[.5V@HY5D+;\$7N"?
SYMGI:5A3@K\$DFZ0!\$1&KR;+ M12+,N,)E8<'YN%UUQK60?73:VEU(!^J05<0GAFWQEG0*[(D#^#1%-I2B%'%
MF#2V]4CRD336[&56M91XAWNKA[0&;4/@2V_-P:HF,L%HQ5-8 M72(HYA ".MHA02N8BQ%\$ZM, RHZ]-?
0B9(CX6QMM\ \R_?(^GEQ:)M%J0*>J+ M=62/)>@>J@P8,!CAF'0W6Y5ML_.N?
NL8^VH.D0BLA;CZM&QY,)^/:2N+X!Z" M,@P4@V.6P'\$I;0E)(. '2W\ \7JYU;TNAM28ZI#5L-4@? ML; "[])\$"

<[:DE0:B45HX7,HL8F47<28@A\$KRS*X;746ZA=?G[+2*> MCOK;R+G#<7 =C:NN#F_+7Q?GZ=HG4M3D/[?>
Y"K=0?L"SA:Q.J'TVA651.N< MN'L).CP@>MX3MY-
JAWA.G\$ 30*! =K+%\AKVEW7#T,3YH)I51YVW9470J =S/*%\%6BH),DNM""^B!C9RM7X8\$'/0T]-Q?
IQF**IIFHJ[HM1P(YXMJ M-R^_)& NOG+&N2=;DEIHW33UZ=AL7A;5@_]"@R[,N"4!1=JIW!)=P717@U%
MQ1)+ED:9UK4"=Q*R=^,URQ&J^_][L0J*>?16\$6'\$LM*0<@5\$&6(0<"\$AU*2 M-C*SJ%3KU-)
[R#E4:NG^~K[5^ZR1C(^=4'KI9:JG,JRB9R;J.CO#@1#DXI"5 MDB\$D-Q,CF-ZU MNV8VJ'@/L?
97MDY1H:7JCOM2)V&@J]>S"6Q./ HK\$K.[E04QKPLZZ7B(-%M? M
+Q;01)!ZY"EY"5X\C8AT49%IF<@8HSA(+C3-A YQ-M6U0S-;SY"0'_3-NDU9#I\$;S208K-'E4*,(M3')@SB*C\F06@?H#J7]!T[J@RE-B(@[/TWG\$]P\>K7^7J&T(JTBT.JA%*D
M(EIH9R/2G(9(_BC8*",QG:7GK;5 #SF'/_WU=:M83UM1-W3'C@/=WVMF5\A M/LAL&?,(.M7YA5@;LXC @&=&
[_^@2N&N=[W,004_6+MA;^AUR"F_0M%X'VQ#5 MR3RXDZ
C6PC[*V[62^H=SHR[B>,6)=.I.D>1@^(Z0I3&@LC9&Z]0>=_:L<9AMJD7)*!:)6H&2D!0,T(@==Q+PI9+*UGH(_#:
MHMIGW0*MTLEPE6:0I][6F2@.9IT3>
M4NV(%&A12*5!U.3S%_]6'D#Y<^P)4RJ7\$!;!G=NCN"C@&1+4;0JTF6H69?,&S?L2_M_13P=5C-10ML7B?
JAS (Y9LL_-?Y). 'EFXOUNPM^\$GR.R T#&H\$54=G;&1, M@5.!>:Z+E\W3FG(LW626F_W/V^X?
9V2),\ZMI_H5. MRR7B] Z#=:U;=:9.6A3D1M2:"7(F8FNEF74"GV1+98MAY@.?/#14]H&*6EV M(
GWN.'>U=*Z#>LHJZO/I/'4L^['V?SOU2G]0\$8'DWM&E5\$(/LKD!\$6_0>0
M3423?/+&MR[4Z,7+X<%X;/MW#*!HW?5S9Z9HU?J]6F'S_IJN_P_F32F&0!KBTM6.%91_\$K?SL<136>N2,;6C
MCH.?9[,V1B3S01CJD1NWJ01^>0>,@[OR:]Z>[9<+.F0G\$S?GU_FAC\F'\^ MGD@Z"TN*="@J+J)X)/08&5-
(F0>M6B>7->1GV>S/D8'CA[7]E_7X.OP+;,(MI^>K\QTN>NV_M'X.)?80[:0&T=ZKK/[D[:K0?
G'8RY6[GGR<&Y8'93">:09M0_!)&4*X2^2! M%CKDI:!(I/>JU2*:=W; "E=LP0;E4E,T4(5%I34M<^@)_\
[_&"8%SS*Y@5; MS_"90A*^UVS#%'V**]97+(N,#I1BKAYKE82MTUZ%+B@4)'&,!Y;2%F'.=HL10(7IG
M;L9^=YK^=0G_YWFL[R/SAB&C2R+6^-N&C(:S'Z\^0#3'G<4_DWU[2&Y00,<
MKY*3E41I8P9G5"9R1#@/_/DE6.+!99NWBNA=6X'WS&QLJ[\A_FNLMY])4A/_M/JX)T8GS[\$L
*14""9R9#@,0:V^9.I<.YNWB@H+EK#SWL&,"=Q3YK(;& MQ^8ZYK\FA"BN'30K2)H0JJ&0(HM
9TL4B>K8]SJ6N@AY5U]Z"-4WLXRZ^#=_M_T7M=ON;B/!0(P8Q_'6HA<5K0)0G0&,4DKGC13-VYI=>?
SSM(/VU4.'I@EK_M4BYFDVY!3*?@QC5"CA;/V%DM=ZMW#YGV6_L7_IGH [R69*.2CK:S2%Y>;1(4
M"A:KRM1=8Z\$^YWTL\$&LJ11 MTBJR-/2J[WJVCdz-Q-9AMSTW%"[FJAF; /*M9_M,2[4?6G#?C@))#Y8*
(4TF03NN7\$-0*>M[6UNRXVCA0HF(:P41!>V9CFXV3 MM""ID]G6@Y_C6']][P&1HPMVA='R,3--
=>"0>1RX\$<62#KD7R\$0)&"ZZFINM\$ M/V/S_0J/!K+1.XVMRV@W\$C/"?,_NNK[9/*Z)HD93H;(JK0D5YY-
9/B&2LU>60&(L_MV2Z8'+AL=1V1&3W9H4:J[:Z26U_S0JCU26D[COYZU0/&AWF(M)+WS^;I0[CL
M37,EQWJ=V' B:>E8\$TJ->6A:6I*!SY8#!0*18A!%-Q^!V8^;9X/LD0&C=4SK
M:M7)WV8U3'#>2^E\$"X=84H9B>*@ANP).9P\H!&.6G\$"4VU4^;WK"LT%0.SEW
M*.G9&=8_/@I,E][>+UQ)XVA>*!>2@3+ 03/1@M(E9)\.];IV]UXSX9X/% MXZJ]PXW;SG)
<...C)ZSPD\BSV1[((\$))=42[263W,A. 2:T9MSQA&DUGKS0H_M?
YXH/H;R>X4J=UF15WE9SY.Z/&M.'*#*#QYA;[4PCU-IH7T#%CQ,3HR-Z1H_M/J*A!R//\$]I'A<-MC.N]+,V?
9]/EA],0;Z:+93@]744]WF%5!1%Z;2F>!"N-M\$C9!SI(Q)KW>Z^@SFNZ5U_M,
<(\202*FPP06D94DAT=:M)FMBYRE2+9(ZU+';>C[-G_JJ/";L/*-@M3X_PS_M^>1WT_I[^.,
[G)+*EC^2E. B(A2A(B>/083:C,&5!%[74*FF%[105NC6+>S;
M4/[L8'D\$A=^&K3L(; '^933_3%H[G=L#B]QEM\5???SU;+'^9+?;E^PS=Y/_M)_]:3PE8-
P4X45XZ)4*M,V<1%/>>3_2MP0AA42MC6?,!P=A[7T1X?+[37A_M1[LF5@V@'V?S]40U<_P\$>2PF6
&2ZP(JZ4BJ" :8(8M(2V>Y:QT@."R'+ZMD_M/
"Z[13/#M9)YR*9;%9>I>7D[V3YI>^0\N7I]00IU@1:YJC]BS73N42G(P"BL^Y*%&2+,TO_M,)YAQYPA*.W8,6>
LD?9,<=CD#H5"S)X#2I&_XE!]S1ZT4\$KT+SJ8I/JV/. M\$ 3G! "4E#19&&YP/*0_M'?
XH.^8,4M(^'7.&2+AU)NPOL_D4N+L"CE%)]&4(V!CS357T=?60X[,)LUU
M3DQ'L9W";W_WX]7IGG+JNXA_R=AZ@N]]F:;S]+*)+E"IPXB.\$P*8JI7:Y(G_M\#9&,%B204(7-105C
YXZ.-5=")=LBHNUXBPk%D*;(P2W!L69&,><4>)50_M.QZRD*V+;9Y;,>
(>=OKNNNB5;MFZ"F0;GEZ*\$0<5(PZ"R2&JNG;1\6,I1I2.
M"Y9ILT[&>U!H%WN["!9[Z14PF/S2_3'@]M!08BC@^T0U1ZV&(&U))<1J6J_M98\>P7E/=(?)?
Z7D(AI06J.RUMCD"MYF#"K1D@S\$G,U","E#07?H+6\G3D:(W<[7#\<'Q+AA?C[< MZT19'DUB_9@.C(ZB&CJQ&
3+SDX'TT]>(>]H4P\G_W1%<_P._C3&-;ELS
MM*I47KQ9\$S_193Y;+X\$4UN%;9',EQ%19BL223X!"YQ"8]=ZW[C?4@8T70(_M'CVB#M6JJH.\,'']-K],
[5^QL;B:W/+#_SA/\$^+KA.N\$.1H.T:W:F@1?N_71_M86F<82X8Z6[67^P/Z,%40N"UOW+5*^Y9H2D5G!2A]-
=+K.30-YM%*A_&U=G_M&Q1R/@A@('7*!3V3H?EX]@YL0_!Z!/ X1@^ZP3:4]P)0PLWT2_Z\$TN,LJD\$0&[6-
V)W^XOVL.JU\$41(, ML0S5J82(VH+F4G_AI"GRX\$9N._9>5M2^*^I(4!M5GL0-9W<[;H-\$G;PG)X49
M,AZT)*W4N8L>LU4VLB)XZX+7PW+XLK9ZKZU^@#M&!.8A;N_PL>_E-R5C,1H/_MW')R5Q-*],
(EP&3)BY76E#*Z]3:0QY+>P^0UD4:0_*0]>Q<5R'M+R1!N. MJT9:(2/)06A%V[= 2_RE#(F,I-BZ^JXK0X]H
QM'V*=</,;4U/7!)7K9)^SU_M;+IB]2R<_H[SC[7V+0?,TD*N*E"<97_B1W"9EY@+YZBZ)'(>ELU'M\$[:_155
MB\(#H6SED@(\;1")->_G;?>?&I:NZ]CHA]_G]67;F<&<"NT<%K3>2AK)ZS_(#)N_M0#0E,&07R5?V7K9EK>7-3-
R/(TPBK+>VH9Z9HAS4RVWBD00I'4Z:BLM<\$" MC(\HLHUHU-C,K%M,0*R\$L2"D880TPRWM>^.)0'@G=?' T-
!R9P!+SC]*A1W_MW-N\$UHQL?>S'\I38Z]!LOA/W5W:8>[EGTJFB?!VW+"1Q7XC[J,EB#4%+ MPUU4?
>)G1^/X9>4]2NQUZ,>_R!Q\+ZS*:[(3R37CGG/P85J\)]@(*;H;(3(MF^Z1A(E9-HY:N6.&FT@T]-
L1M'IYP0)/PR09RG3-^(FR412/Q@IYV\$5YK_M)I/D(!URJ:3,*72YZ.K"SZ>(9#/X:@M_0CR'*0;0C\5\>?
N\K5J[AB%#%PY!3HH_MDE\6LE[)&N_BI.@^HM1;U9[3MUZ! /WV9[7'0CXVP8/T05L7YDWS#6\)&+=
M!'\$; ,H9T^-T&_NU[4S[+558_M1TXT,FN\$;*&Y:P\]G!.UE]AG+636L*GEBI#PQ05"7\$RE%&_>B1"/+'CZD0/
MEI33N2@?U;EAP\I[I^I#Z'R=I99AS3[ZXVM,_E11:RT1^0)D-0+B0*#7_M'!WQ:UO'1I[8"
(5=;*]=3&JU@#W]*[>AJ>7\$0J#1B@,@LDA>M'0HN-1-8RY

MAS=G8\Q",RC%.%"8: '7+0K\FZ6312MER\"(*)T>!VT B%T<%VB&H/P/4=+I;S
M2;VC685' TH*6;S[[;]K(X\$;:WVH\$ZQ-D] &Q*FC*!%J M 1RC2RQE:7/K00#;4?;LP-
=!83T%'N'\R3AW;3^,IM^/D^@J.)9K(H=K[[M>K98 C); C*UDR2AYS>^M4G0)A E" I**88ZVKGKHQ M\^S
.PY8; '3F#Y M# /WAM^'Z.*QA'^WX>DE_#XH_#X()H>(8^ZBXT>#7Z\$3,I;!9^WHG,D,G+*> MSAG,S0*
<< /KR<>#VT'A] '!=H!J#Q]^CUA68P^(C%H-X1%B(6>.&^090S' * MOH3?.^M6/A]@,
(:1BVK WN3LO,HP9HN(V,J#C,8KVNJEE?@#4<0!A.WT:=D MU4,N]4,/;>@:"K_?6T_.\$?
9Y/EES=3XNQL)="WRP\X U#F*YK5RZ#4E>G MPZ'SA'->^W8ZVX0 M.E\$5Z0N: MG5^9Q))?'*MIT02LI!")D%?
WPKY='U,#L 2@^H': V*,Z>JY/ M.SHQ)B K:,&&,\$'Y.M&()8126TUY-\$G&T=2J#^3M924=927M ; Q-6-
^D,_S M:0U+/@0M#^5; !KSPFE[N.(1,/DS)PG@1F938 .[B0+R]+*2C+*0] #:F3LT/
M\KD>8'2%56%YB;73:"PV@2JD"J^C ,UL4!J#5^G@<[':L?>RG(ZRG/:#V9AZ M.
V9HVB3<(E"UD+^4K5'7NKXD-NBN61:R9'T]MY/W]IE%JXT3%K92.]Y;X M8YC,50U+KBX>
(57@]'H6A50P@C:YGD 'VG+ES\$EC*-)W^TC@D>T/SZ:,%\$W M"#XJWW=[<9Q(6;P(S\$%*M2)
)#H;@D4(SNBB;+),/L(0TX-\Z*U-P;PCW A M#T+NHUJ]]\I]OD,0FNQ-TI\&:('%9T\$SVN//)Z-9-%GT3Z;
<"S,0ZSC<:[C MGAA^Q-&SAP7A40>!EH-DEM29E:HCJ@1Y--[FPIA.9C3SFUHS [*80[F8>V+X M,4;P:F00AZ7
>-%6< 823JA0?('J/L&XOZ [\$#!F) M7XXF8/03^&K^DM+>.!E!.ZP['A<0E:0=)401LBTJ8^MD[>=8\5<\$I?
UJ_H8H M>RPU?Q>)>SJM"#&>DUYIL]FA8G8\$IR@)=/3EF\$G"W@LN?6.T7GW^XZ_X&X2 M62--= ASWFQ-M
4UG4KUQE!DM[MF-JAX#['V5S87L4B?R>"-M*&JE"S1A0FL M2\$X:EUV
UNUK1E"UD0'0Z394+>KXI,+[\$.2M*XYR2)F3\$F"]AKXJ\&0]J0 M%'F0/K-@77[(S-
[PW8\#1E/K G (.0:~Z B^0Z-0 7,BK#,>LNE88IM5?CS."8W[*R\G676P0U9] H\-\")JC0Z:TX1U *
M%7BE,G"BT"64PJ36/LB5Q5]/.VA?/72XTUV34I^U^EGK^C*_DPXVD*6"1.%X@1P\H=424)UQ&2+CUF+.W 2=
ME28W/^/1ZK*1V/J/64IDUVDI(&E!QJ-@#\$+-0.39L60D-IZUSG=X8GT>][&V M=M?
%,?)0=AK!LP5/+WT>AXU9&@*3@X09VD' 'CZ7/8 *) &='IZ[P@7SC'""F M4H>H1<\Q)D]'K/%[; 02V.#
[1#5]AS\4//&SA/V+H+8FD64+H+A-8[&ZS1' MP13H% UB#(\$W[&XD9@1)09VU_6F400[*>J001V#4P6]8:"#
()8Q.@B%:?'9 M:~UY83Z]';<'1A-Y=]A9WE]&A;+M^6_0A7-\NW\74W^>\$/,HXG" R5B;,+ M-Q?K=Q?>Q&
(BW-*&K\$74=?JK@>@=!UDBCRX&SG5K3V G0D<(O+XIB0W5.+:& MB>=>+J9NV>+5YS
YK6[6C[/Y*F0])]+#D+4,'12D+BAG:7EV2!X%*H'.G=F:D7Z12K\$ M;D'-L\ 'E163' '7"8")D MEE95V@: "
<@R4=M:\$K(LJK2]C^W'S;)] ,F TO!U>K=DU#>\$]D?:W68W7GYL] M)[4'I]+2@8DUR& #R8II!
[*F+R1C@>I]JWUTTQ,>#8+;R;E7J'H76/_PQZ?) M?/7A]<;M+5&;A(-4!S0IF2)\$5I!0K&S-
JT'+NE1LMR#^V6#QN&J C5\JJJ'8 M46N?.)D=&)Y>HP'B,C(#.+:
(#!>&)S6:]B%WT/\47P,Y=]LGC:1GR5E_ ,S MY>M9<*4YRDC ^=J+4>LP^M1!V#\$DX]>I9B[],AMSAT^38C:~
[#5.US@_#/F'V?S'\J2Y8W MB\59F'8'D<)Y4R\ (KSV''^6W!D]./>.(R&I''^RKG\0Z;8#])>#>QEZV&SB]"?
Y_1>KGZ_N0980G+;/G?N'R':?9^ M.0G7^N)TW:KH1)@LL/:.DZ[Z8=%D",H'!>5XN"=(C=/8P16T(,4-
JCL0LSFT:R..SE\ M62;C = =ZV7G&ZK]KMBNW_M60P0S75^]KE*9UQ3\$DR*XX'0.00:,@W),@.,I M5\&" M-
4A<>]XMW; ,U,\&[>."01V 5P=L2ZG\$FVD^2RMQU S*#ET\ -SVB8^/.K;@: M3Z_ .P+7EEMS\$(G0)
<@L=EXA&*YY-]7AZ=?J02[U9,-,J8/= M GB-'#!;[C-WCK6?
R<,>W4.06F_7IU#E#W*7IW29*,%G5:IT+F@!,MDSAL& M(9D< 0F^SF_5GF8 6I]6K\Y!" +B05^<03?10W[@--
<^E5^<@S=S?QW\$7L?97 MMC:~7/KD@2FLHR]I#9&/;T 5CCJ9Y')NG?@Q@JK"7CH>(LW6.>2_ W/V^X?9
MV2),\ZMI_0V?M%=:H=>NVY_KXB+A>!#D!!"=(MPY2SNP
DNU0,G.~7%9AB8P8K0UHB1@G/3FEGCBF+!YWZ/!K>#&C.,#K9#5'00Q@RHT?(8!;!@R0JATP6"
MMQ&*X"49DJ,Q+XT9.NIZZ\8,0035NC'#SD&R-],T1WKQ571SN>M%KMFKQ:_S MV:?
90'[UQ>N56F=6"4*SV0Q*ZL5**8'D"P0M.+<HR*1[:5FS .?D8([S[! MSA')?!"&1K.,KI;E1IF4U)P!ED+
[@]"TNUB?H+8S%D%Q\$T3HNP@>>UGUX2&\ MJ YZ&:Y]JF>U#UH+.NB,D[2T0BS@E_Q@#80)Y^B,&TV)R],LJ]
[K]FH]:Z*~1+):3"BT\$G!F0/GM <;R7Z+V?* K?/)GT?QPCX [:0&#LW>M\R%
M]R&*:+6\$DATYK(R6"/FG#F00A9-ASX-MG0?{A(L7]D%8!X5U:~1PF&1TLHQ- ML"Z!R*
(./LDUS;:6*A;B7'L6BFM=0_52N] #U..#2X?F P?./~*17:A8Q@I>N M@SJ\EB\5"4F\$P!QM#
[SY/(>7TH7'N4KV!~]#&%<'R(.]N+F;NX9YA&.P2E=)HARA[+&FT;Z:TC>%02W)=
M2M?15/^@,EU00@VBPZP,2%GJ3:B1\$*UB4+S,/-)0B:)U;]EIR'G\&3B#\#K MHZ<,8>\$-I*U0-+2
5Y3CX&"Z#KCX"TYQ'DY?3?_K_)&D0%C6YH2? M<6TAKY,8G"6.74X@A\$ BTF7P*7@J;8H+,8\$UAH?
60%V>' ^WH3)G0371(3&X M!NWI"S\0E= _C9SR=?;I2N\$ZB<*7*/NX8AT4 MMG'_.4 \$[%I"WN55=X^"\>?
U"W*-8S'\<2U1 HI.?'+%K*I3A1VS\$!)+D)). MK+ 238P0<:V-KFQ
4Y0X.>!)>U!9DRM+^B@D1XN^%VQYS4RRE[A69Y3VBVL- M4?
98XEK7RB)M""RI:\$Z6<<6DS\$20BZ0(!NEXB#0[EH?_0D?E\$G&S&7KAB?*TFMR&7(-06?.() (7"EDG+,F6;)E[
MR/3>]=E'+08?I^H-Q>([Y-PA-+1#GF>PFJCR8'5MCAX;L:SY M_ ,3GD:Z[C^G:5XVM2W-
^#6],/IY]0,S6&4Z]U%99R22(C#7[B"RKH\$S-./8F M>/JUL <# VU(>390.X+F1C-ILVU5G\$-?G P1#-:
7Y!8J^ (D9\$]>@T\$>;=YN MQMPX^'E>*V <,A^\$H6-T%-DDA:L# =^>+1=+,I4FT JVRX[+F/ I>@K6Y9 M
M'^;].#MR;"TSJGJ4\68R_C2'Z9>7\$.97*2V^SX]>C -D^F5Y=GCXX47G[ZYP M7' '8.BH=4)2'ELE,T^0%J>L-
#Z.RW(-)T'P4E66.+>)'13=:1!&>5IJKP7 M;(%R])9Y_VN764(37!DUE4A6-!#IC)".D4PRG1,:AYCJ'THL
%&7^G]&CI^ MN-<<*]5SR;[?7\+9;"*5%+N_46(LA^J2SH)9H:U 6C@IB#:7XUQ@>2,^A8[?' MKD_\H:EQB-
0K90&[>5S0H\A2=+4SHI+E2D2PI28A96*IX<()P?G#HM9#J7%:
MU^/D9N40@??.BI1:P.=E[.XMWF);&U\T+A0S3V: M-
_1/941L5CA.%"-2!09@>>VN:X[1])^+/%X[DZJBK9A\G\$WG@?E" L8R@^Z* M%PL(@N&CTP-B
MQ:0N,/:Q55V46?_W&V&CQ#^0_4=(;F*&^]#.%:KD\$+.1,F\$P4060()\$JV*,
M!V5T]C%W&@QS:@5N.,7U];>/P"KK[3>4U) ?K+RL@N&5P'H,@U/LR^QTA(39/ MD0;:,VH\1H85-'?0H?
V9Q:/\$/JDAL\H<<'6-<+TB[%W*N_009ZB\@V768J3&=9C!OZY+YY10Q:"0AY ICGM(3(IP MPSR1N:J"5!
(D<\$NE"RJ\$ZJWWMD]Y[IY.34DWZ,B^ =9ZQFL'8*TF4FX#>9IT M1175[:;,\$7+09V=8UW-:YF.Y1\
(8+>=<2AM)P2T),1B:.'#%J]?D[9<0.U(8 M?)A'W&WY\'; 7\$71*C((5DB3 M(-7N9+ ^RJ4X!S4DW6
TQ298Y8]3N&FUT0%@(R=A)[C3. M55-F!'L?KH8&Q MV T4 U.1HK'\$IQ(U207\$>16)\$UEYF:Q(U0?

MG8@H.YR(T'D'_%70STU?X2 M1N0S_NSS8L8P@,#=4EJ.0'())@ZU/7AK0Z<\$1V+8+#W>^M7|0H++\$)S7\$U<-3
MN'0LLC[-6>40?IE,IY,A^-/+_07_&3^?0"1IM+U@H0<^G!\$HFW7! J.SA;U?:LQLI:RF#)Z2DR5*YS:
M6R0S4'26 M*ID,4=:7V[F.X_HI)8'I[- #5KSZ]-'NZ)XW.1IKH\\$\$%J%('V%5 C\X%PL
MK6DTE(N>B3\$20&\$DFV0H P54U"X|0_0\R|)#|P1*M>&J^V*1>?_EZC5Q;L^M M^,;HS
+4,T\!E^4"0I)4.1*B%JB?X')2++B'=R&V;.,|/.1YJ|.J""L">"BSM MS[V%0IA\@f\$?
SU='CN|AX=RF%W|V^1<-602@4C:FI)4EPE% '@J/UDEBQ.*B M 9NEH(9U,^= [/OD"2-!4V!4S0A0
WFT0\Q(R3*>W9'Y1IDU.D=T#)2)2."E" MD;HHCXA,ECP3W*MER%\$S%;N5.QSP\ (OC1WV1;QW0684B#S&N\=
Z=5!A*] MI,OMS>DH"?X(=#D.5|&;A>CTN(NC00VQ/E:\.;K?;\;+WU.QM G6(NU@L\$>AD M-I\>
>';"@F#\$2XZ+=<4-+=V|@P)&,R^C|JMW/MZ"Y7ESH:JD'S/ '07JOYM. M0@U+Z0/7R?
2VX=5|(^')=9CJ50|WSP|3H409V_!|0TEW#QZ\?)HRKW\X:C49GE M<3V=S.Z\$+T%I='2X(<4=6J8M
@@@FDU(|+B1ZRO+|/P:.Y_#9C|>02CN:LM84Q5SN_DMK,&Y4C"3@S&@ M= U5,Y)V0?B#4|SMX+D:U|\
00X1E0;|'904VU>0'LQ6D7 UP^0_Z|I>#F>EC>;U M% 8L*^6\$S*6E<)FEDBGQ'IW^E"4%AGQDNE.-RU|Y|'"#
|U<3Y;P_Z^B3_*9*S M!B*#X"24N3S>*9I0S,J8VG=X#\%Y&01JKJ\$-M-(-VK/_#0.WDUEQ6Q=-
Y|RZ\$+K_Z*H^MR@0U% L*/X05H87@G>?'/ M(#WX|B,Z09\ '9H6F|2>7;J7^U<(*W|0;R>+G;.-U6|'TG
YIY_OVS|))=) ME@;W+S+9\$VT>!#0AV;XKOVZ|%.NOY05HK;Z4C0I4FP5ED M\$IA,Q*J0K/;
0*Z=D|@*I0 \$0UV|35H(04%QT7N8S;?#B!'J MI'E/+L_1\? MUS70U MGE26@:4FZ!(K0@5-
H!71@S"GF?.V"P2#GPK">DQ_]*WVK5:N:.U7"R/Z M,!P00|A6GG"Z|R,JY*R/6E6E?/,&,NO;*AJ?N(DQE-
XIZ-|\$(D%+4D64@?+ M0PBV|M0_%)YZ>>\$-3YEA3'"[MV5>)>3,@;=,0)13)!\$"<;0T6@8K04_&9E;:
M7NZ+L:;<;C6>;,7-E#*N61DM|6LT(%*9:0B0J9R549A_&!--(CQ9E53DP2'2.E\$AK\$|&. M
8D2M^/2'#6S/C:6\VT6U)8G^XB;.,@HUQ27IB>'EZ#43GRW;.,HBM|'3 M0+M=:S_W9D%
|27QKLZ!|0%6|WTN<1 MXJN| |6Z!QM&@4'4T2;9D16FU% M7GW|.IU\Z;.;+/UJ
Z6\$K,9".5@B524\$LN<(9E'YI4)RM!NS;>V/;'GR8(U M9#^I+;@&IV2_@2|W@I<|G|Y>WW:=
H(6!,CYE=&GDNN(A-64"!E9UIS+FJG MM|9AN6A37%41%?L0/85KW1VV_|)&@?
=V5*>)N.MHKP,ECA!|@UC|"82T0&\$@ M".\FT|"JN+D;Z*GX?P M;8%Q/2PY,N-
%J6D#_\$4Z%HC7@/BBU2"3=E&E3M|!T\I/_NI8Y)&UE6GLMT M.OTL0**6ND \$S8%(;4M/(/1:3
)G,U42"=WE|3|WP82|N "'B|9BD|Z'HBW;-VJBFP4RC+0#0Q -=#;*ENP\$=YJD266E=J/,D1KI;|NY
M"Q2\ C6C5B+8,T4KCB3=HXRC3AC,1'0:\$ET&9'2F5DS-F#T743K%L0;?."G#0 M!4=0GBWZ!PF)5C-
+PE/(EC/&9.K6EN0)Q_2?8*FLDTD3@38XEND|7DD7W@R M+7HRH|* M.\<:M=,
|@GQA_!36JJM8E/UCG|0P=XI!NH"N9\$?#;TIS=' EN%6'"5C9#1)I!AK M7P|N!*"Q_UZNYBA|1JK9^&0AE0^[Q?
F5CE!0TD42M)M(P3;QSB4".+";'\M"U MP|8|X/T0_E@K=368<(\$U(V06A>XC?
RP/;&>Q@=K10KN%*NFMP;6<%_8T3(, M>Q4GW,1<*J^E"?
@S8J(63&K';:Y|G^/.T8!_DL0(\$ "E7'|)#^\$\$/ 'E13I4TJ2K0) BM.0BQ6QR|: M'9?_85U?1JE3+
(,AB2FTXYPZ8K7.)#0@5(E<,FS5?>RM<'X(1ZB6.BJ.])H! M;7V-K@.X9NFF)X"=*K%428W=Z'&\$#IH\$|^!U-
QOYCTG)09<93.B5\0DG:20 M*8G1-D9PKH%/S81_0->/%W*+-61E?C=)6^H)1G\W*2\PU>_?45Q;: ^MHA(A!TJ-
(3F%,@?).^(E|J/&L8P+|\%8^G!|]-#|Z_3M%8J>;,B>M-=&F,>"& M|
)|B"DIZJ5CA*9:!)Q:Q\9;.)T@'5)5*FMA0;|RA_780;_MNBZPON\$0-W<,I!7_2Q&@ "F(|-
P2&XIG'90PF?/@4VUR;('R0|BN-=3PF|T' M#P9| M:ZW4('8(U96AJT;U_TXWXW'488 M>*^SY-
\$0YTTGTBDT|\$H|C"Z3,H+'H^AM@MP^_8+4?Z!(&S2<00)^F8P7PP*6 M RA?H0&\$-- Q:\UX*0-J%&Y6Y?1+5
N2.TUA%VQ"<\$- MK'(P_C; MY_BKC-.WT_/1Y_G\$|7(*3S<5<)E)(S>EY))XJH\$DEIAD(;+L M:F?
RGP1T27RH)0&-9;:3=2F&IZK_0_3(F4|6Y0IORVC;DLJ>|88A0Q_<5D#
M&:0W9>@ (RZ)T7E.6!,8%410\$*,U5C*\|_%KN"BZ(=R=4;<6RFF6G0\6PGN/GXMS7A060B\S7|A8B!'Z2;1H
#RA3/+AL4E\$- O!RE6,8XH2\$|@&|G18&(I9\3= MUBI)+(J!&.MB8CX)+(NU-
^|R\$LA1!L95|SZM+%'Z\$!FKXR'2|2-Z'@G*-? M\$B6*N;0#|U;&A0!PV^~^+T>);&*1X#WP=S9;=[#R,\A?
9C\YJ?_A/G5./WA M\5|-P'OF0#K"=0A\$,D-Q|1H=Z\!Y^Z,4I0;*<-Z2VCNM1?Z=0
MW\0A+!;:|!Y1EDEB\?.M\>'9 E.+QH^E1"HP16S0C#AA9!296ZYX)RYT>|ZE MT*"!="#;\$>I.)DBPI
5;\$ZF.8|T-X0<1JJ)H-3#HX!|RP M|FL3#VDUA04JSV'PZ?
UX#^CJJ,E.HJ(\$1L(\$@*;>I8RHPXC^_1P|_06|VGK M(RY Y15EN\$&U+1*Y|]^>\$CEM_/N,C/?0SWR23|.1R-
!AYUKQUH7)|C&"1: MA9MC8(0|8Y(P+%DKV|M3|19X_7P|?V)L> V.2Q. GWSWH_GW\$L_<G"/R?^,+
MNDA5+; <+^;%8&0SL#0%YC":Y1&C62FC*CU1 V\$F@I6\$?EP@F9?M\$56T=#>V)*M M-0:|&: ;&?9\|*60HJ6|-
Y#CZ-+8|0;WA.OVWU".;'\$/_(:AP2?X.(-\|7HS MS#"03C(I0B)4.4#|H:C5958&M#6HJVXG0Q/?
4EI&L,1LLR%X=R@^R#\$%(Q8F6)1Q,D M\$CC&\$\KCOAHU1S>T_@FK+N""6'DZQ6ZX
ECMB0V=U;R8S.9E8L|RY7N%SN+ \ M^+;HH_KCV<#%04#GS'84>5@0%-
+G/,8UG(4:Q0RN.H7!@^\$>MG4JZZL#21; M9?/_U|>2!_7|<_%!XN?%PF|A_P?Y?>/[U_?
2/|/|/_\+T0WCC#_Z|_09_S; M0I0;0I1U->0DW^11)AFCC0^3N1^M7|MEVE?PMP|1|/|JY@-OWP=[3SK;07E
M;|>RN2^S%9Y|G#NAE."0.:! 'G_ZS^DYRRWI@&!PD\$XE.PF-X(+Q"7";X|K* MJ)' \#V>\$M|@N;Q
Y+4;&.98358^!ZE_MR7>6PT-BX+NPEJZ|NL:T2X_&Q75|P1WFN+Z*JKL0(_C|7_2PEA(MGI5)V@X\$)=
(H!,I\!)="L8ABZR=J'UB8BRH^C^~#S91_RU1Z6\FGY_";-5
M*;AF04N=#8FBU*J)TN#UF5KZ;ZP+Q\A8C+/9HY3&\$V7Q6_78U3^6B: 029%+H.BIE'E:7_#!000|
M7,MZ5J=N>ZF_XZG;/FHXR2%*X_3|WV5N7>IRF'Z.\$DA,F<8^""SJHSN_|+
MS4H+,2I(\LR+Q&0(#\L5GBM1#COU:\N3?<3?]-0M,"6EUI1XX41)A3#B=/3\$
M2..3%#Y1|W=YV,_BU&TOB6|=M'7&>KWKU3T*9_1+G_ZM59I8|DG490Q0K M3.??WXW\>+ZRB(M1?
P/AN'%1.A(3Y412I3\$(3I%H|XT&)J7)YSS!9N0"?KXD_M9TNCBB?FVZZ*'+S"MU\7|P'&G|Z_G\&B\?
K;_'%VTXH@&|)+5_9&-2J"0L18 M#Q01,@N0DTB9FDX)E?XP_0PCESI)_^(>0M-C|WR?C>-
RDBX4^A:)HG6\IPC\C-N>W;|TU=6E6| V.Y#A/I;Y\$0.G?^,9KI1Z!R98_M5XZIQ7*FDN72HK\?(RHG_5W._
3W-E|TY|,WD_&G#S#| M\A+?"*!YE"!0"L54^97A;X\RUZ'MPZ|S/?C8M= MGFP6;K7,'/U<7GH0E+9EWC).
(Q2U\$0:J|=LZ6=E/U^=,V=3PVKIRG>C|GPX_ML\$)[9VG =;' +*6-I1A&H),KP|'&)5,\$Y7Y+80*J?
|H9L^C,#X;0+DLK8|%. M)F*P6\F9 @LN6J*2U3>5L^V&MU:E>@UU+^9FCK:KLK?%VU7X<#|^,;|M- M0/#3Z?

&XQ,F*27X\73\PX\$^6(7ARU(53HP\%4*I5Z<#S\Y-DOWN_S_YA, M7XS\;';[4N\K8+RT'+?S8-
#G+0LG%YYD;TQF+HE0W>@>@K->SXX=3U\V\Y"" M.0TT\$04R2D4F2YQ.GJA,H\E*EY+?9AT\NB#LJU\']=(#?
J#G(W-/T"VE*@_TH5TV\YT(_X J.,+;\$HDI*.F*=I/BR MVBA+;C\#=[DT9T.['=U'SIYU>ZBN""=0>32<1H\W,
/\YE*J 1*^P6BRJ"E: M-^50,0>/HI JE=8>E!)0G"4\)\0CT: ^3Z9\^F@;60'+*6F(TNA#2
+Y>/&0B/=4YY)RU,/WN5'?0G1V=ZL<(\ MC535/ZE>_15'UVDX_G1S\1KP)7,^<9)%4\$2RP(A-
4A+' /2\GR5JHV@>J^V(\ M.X(=K.]:'6T\YX9@!/=&AS?8A\KT)> M58,ON.19-3=E!|E-Q##/W'XTV5 M-
JDH\09)ZNUK_SB#?#UZ,\PP@"BX9F6M5)>&KEP3:W4D*J244\2,:|0;IG*+ MZZR84L?|D>^3FDJR^3Z7SX\T7>
<2"8MBGG6!LK0V*7V9F!1R&.\00 M"2XRZ(\X6U#^6%2JH:H&1Q5/("XWZX"JJ)P+Q*N
+IS@D3CA&=&F7+"WV;M8 M^|SK:40 %FGV54&+LX,G#MZ6R\$<^<#\$/ *GWG #^5DJU-?(8?Q'1ZG+3+\L\%
<\PGOR^QNVB_G>,T M4N=K&\=G>@BW#U>..(3;1R'G<@BW\ UUZ5(4D,N=.L U)HF.8RCW@2'C\|KR
MZ&M/VGEV%4\UB7)DM=,^"CN3";TRPZ\$XLR04C\1 MDB=H+6R*)&.!>00")U^[\\$]#9T*YRM5/?K-
M'=2>K=K(N>*/0J A3.IR66^H^ M.462L%DSQZ5UM>^R7%"UTUXJ/JC:;1]M"A,V>M2>E 4+* 0&V3)],:HB*7:
M\$!43 %%-E:E\^'?FM0/-(X)V"FK IC6.6\'+ I(X2!;0QRW0"1XB>|3TL0\$
M1"L=T^!KEP)L1G*! *@@JVVJ6KBZH_K,(- 72/ 5] *X.0C-TC"RM\EC9\$AUC\|?XSB9)F=HQ4\J2K@ M.I.I'+?
40K5\|L+ID9YF\$UX3I-H.5973ZK^"\$'W1@+K@Q5&\$R0+- "B= W\$8S1.A
MG.\$B,V55\20+ 2E 1\JC%|W0(=\&.B^F\|VU>(EMW^ !H\!QN95\|TA\ @D) M8Y?
DA1401,9E\>LYCU'T'Q<./")E;0GF?2D,=0-'G#/8@%?#/S/U)Y'W#,A=0@! ?)A M'W&WY\ '*;FE!T40)2Z
4#K#5Z \$""5!E M0)/#720(A+L6541'%JFUHER0J&P;MF%YYF2H*N\I]U"M?EQ^"7X& ^=_'|0 M2P,\$% @
)XEM6=D9D=N/X0(A4 # !0 !Q;F-X+3(P,C0P.3,P7V"0WD&E\$^F\1D\Z\$Q"0K00>D5XC
M74\ZKZ'WDE!A)3+^Y0\WW/= 0/"LCSUAE GZSK#7G&,'. M8\< |125U90!.#@X@#>W'P\|V": (P,/ %>NY;?
BWSQW".W?P\>|0\$Q#<|)20E M)B4E(28A(2.GND=&3DE.0G*/|AXE-0TM+2TI\3T#^0T#%0TMS5^;X.#=KL&=
M0W3G#A\$-&0D9S?|TP_X\$4!+BCM\|X,\$\ ,!2XN\1XF\|>P ,X=G+\;X\|- M! <6XUT"0B)BDML)#?<
N#AX>+CX>' ^A0AT-0AT'X%>H>|X\OPNM"7MX^0GW\ ^,>(R*CHF-B4U,|IZ1E?,K,* M"HN*2TK+RBM^U-4W-
#8UM\1V\ 3V\0 \&AR;G)J>F9V;7UA85 |ZK;(GLH>3J+0(>&UK\&3GY0UT=(SNQ2KV>*6^G-B4VL%*(7I *
MNKR3\$Z7>^F4&;;I,;6E()1;U&;67;GGDSN&!> ^;/|Q=KW\^LNPM\0@|U+D MCL?
QG)RFNP9=^*>F\$USST=|TN7C\|D0Y9%; '*N:S/MKS!A(3=3V#!6@IG+EB
MIMU!1#J1X6 ^2LH1;03%E#* D<""W *69BXG;US.7:"X< T@*;24-E80(/" M^SUP\|CZ\|TKT#TLP!2R/X#1Q
(6\QN\|C#9L;8)OMXX&55M=;&(!#|& 8^TE
M:7\XTUCY%C2T5V\$6?.V.!:2"\$*7'N;3(3"5V<\SI!ONA\$5H2"QB\$W.@A1F-1 MKPJ2:D"^<(K+2DP,:
N*+K^Q5PIYJ#,7JC*GT(;|\)],**4U=N2)Y1X&3 M-%<=3R9-0\$)1^0>;/DHR,) P/DJJQ
*|R=XVX^C(3+"#N/_ #7ENY?F39< MT:F*3UFNFDLF,@?Z_4Y1\5WC*V/DRN0^&P+|]4PP+<6 <7;+;
=<ZZEUCE\2 M'8GQRR3(7)]=\$JR>UJ2IS6NV?4.H8%K^-|SPC9+<7(I_5A/E0Z:/@6\^"I;P
ME_2I#HL/BRM\|;+Z=%-76I\B&JG+1\Y%/1+AH?|NHB1500D_FT|2G>DE@K0Y' M\$W%A ?^2F&|
9\|C7D,\$7/:*6C)1LD#W\Y\$6\@:><'(5B!&AV3PCY1-V+HMJZ'4^/' ;\@I MJNW_D0496=RW,#Z'LOH?
T*;^,X#)-MAH;>G>;\$#';&JP<|J\$S/@G^K<^SGQ M6UP?
G=|\|F#K |LAB_L\$CQ7_8:E^I0^P5/|,HW_Q;G_YM -E5;SWVG>5?3 M731\9\ (ZXU>PFG/.DD!.4.0K9\|)?
FU);.I>0D\ -0<.,_X S_C\=10^+M3)S MJ&UJ]9= A? TY1#PL+ JVV9"B;S&B20*0\WWW4K^Z*Y\|;E(:>D
M/9>'RD\|X4)F'4VQ *,IOV.#42GDL:|<@#X6X'"K\RS@@ ;UU"UKT-^LE +\$@0XR7X\|1|C:040%JI2\|?
QCX9,0!1@!I@X+F,K_-|0'H% M_4')5,S0B\|<6CV;ZNY98U)H%+CB00/T20\69W\#=#M1=HH%_F7YAX@06P(^|@
M_575KBK_L.!M_Y^>|M:QYX+";|Y9 M'8!A\$^W M9A_ARY2P+-|X2%U6QL;P(E)?
B./;KEEAB\$'0EHCL4"SOY=6M&\$ MU1?ZK.#55' !XLNJ65\WUA /W1D37\I'J/XJ4A_976Z;1('6:#'?VQ;^L%>
M1F.T\U1_54R"I-|:);K7P'38\$',#C7MX>6\$S=P7YY\1JSLA&NJ?FD8>1RY
MOSI+\.GE8_1W7X\9V#HCO\|E3NPPE8\$ PDL2@K;/R6ZU23*CSGR=*YP)Y>F>Q M@ R%/Q)_JVI-W:7-
V&U>FM<#9,>)\S8WXB ME()I1 Z!+LMO QP(0 M02 GD.??\0B5@C9NY8\$.3\|0L(M+
!>A@748P% ^|5\5\$'S:03D3/@V-;Z MU>17;A^Q:RV+^&L,51Y 1D:NY5Q'9P!;!U>)+'/\J."V 0-%
|&/0A(S(1J MZR,4KV? 5L, OC>E'/ABCAR^0V">S6T)\U%\$9V7T:;,<='+/L,9?I:0GL096 M45*T4-
T\^GFU=2EVK7=CX;19'#(: (I9)=*=Z(SQ)C2=1Y%H*/#1T_L3#5T=|
M9B/^94>QK/3B'%KA64\$L_Y@PZUDP+ W&VL,T:Z\|'#@RA\$|R)\KR=#H5\AH MY0GQ2VCHX.
+DM^#*B\H\|P"> \P<;##'3\YK"8T#8_XN\>8&460<5KSC\H M-#\|PS@VV;J Y.G-N(G+NB'5N.8K-4"'\|;*6-
+EY\G?8 M;23.)C(9I"(??2D20EYU\$%N>P.4^T.BE _R/|S7)]'3'*?X\5.^8U7^R;*|,
M7:U!.,+"=>Z\G0Y"&|FZJ4G=\$\|9*93\,+ &+LH\X1+Q^D+OC^T;2UG#7\|E M',%8I1V-
!=20QV"8D.P8JK8.#949K\1.(!SJRQ\OR(COR4WOU2_K&W)>=L
M1^KFSC=0QOM:%&|3Y(;JMU;@39\H._R*^D?WB\|CXG2=\$!3KHC\YJ\KS!\$G" MH5TKZM\|:3;8=)UEGI-
'0#P.EL.88..92I2Y*@L3-|10?W?W">3JMOC>; M%OP^6(!(/P>20<91@?1".HJ(\N\,0\$4E(YH3%'C6=0Q?
5SSXF@I*3F;NY6B M)&0478D%.+I2HPAFVJ4> 9T;+L0J'K(V;F MB212Z493[VV;*5,.GKV+=/=N, ^-
+H;5V3E4X>^9!1^4 AKYJ&.407&5JQ M:N\$>A8;=+HI\?MT#8A.MEM/C\KJZ*K\22^CYT\6>LY?YES<;60;
|YZ#S.C6 M7N ?R&>H9S_N\$!00\>#|4B5A6C_&T-S5\8B2-9H@_M/=YUV28J?YA%XDIPM1 M""""\|K*)CQF>;?
BN._PJ,V-\$X\T05=K15ML32U6#03Q\ (XU-1P%9M1LIE%AK M/=+1'R\|R4H.!|@ (M;-#< #2AXW\U94W7MH=
5_6/JGQ)_H.T8KDCH "K@&[\\$ M>]T&)9)!W\UJH_F<4?RF??5T=3&"/U&<=2'ALR+\$7K\|:2/0A.VM4X1,S5?|
M9,I\$-7R /LL:BXU=, _"!-X/A@-UD\$') "UV5CG#FF-.':7U?HP!5H=UT'\$V/ MV(4_/\$(V!)N7@!7Q>!'4-
(@20C9)?L=)YU:)D\|M"K&5WJ^?#>XL*!9R*/'X M+TORL +W;R*-?|-,*Y?6U< 79.|<%@<5B2:%
<^SLI'EV&SWI+(39X-WD! M>1)X>DR04T.L9A)-I>SHJ@X>E9L*BDT,KT"\$RH\$+2\|;GPKU,JN/>P\=BKM5B M3X
BBHAA.KLPW=(|R9GZ;6.*H5F(,3Q,'X@2Y;Q.XDIE.E\B\MR=?E&PZK3& M5"9F/+
|\|;VR96D7VP.14\$MZ5Z;>,A76R<|*GP4J?H8!%!YS@JN#\V\|'.5Y MYMI58!=
(EZG7G1,)<C>\A=9S)X^9T=U07)AK?+P9L2NX\B=WC=%/-V+1(*)2+ MI1L.^AJ837F7?
\$6\6#DH\NI_E5!RK""V=;.W"OH KPWD:NTRV=2&3C/6-7\$ M^BQ"NA1HG(/D\$S\9L_6F)?V6-C>=, :ALB'
YF9\N\ /<>JP\KH,\$A5)W% MWXF\ELHX_5)1*+T41JLA2L1;Y%AY\8PR, A6EL5250-E'_@:*ZX(8E2\|IL

M>0+X/IU)/X=T'8V"R_>---AFN20[N>V?,V8G^N'[_AFP;[_^C_:#Y69JDM.@ M-D?M8ZD8BI#?
&# 'D[&+XWKC/L*'BH&G?<,&H9":E/H><57?I RE.%P)&3DXY M^3B8U8;PS_RD5?*IM\XWM>'%L!-
OW"),54;@=LLYT M02LKCF;\X!EZ:'FU+@Z9!CDE)4@S0:QSN([,<\$7,1&X.MOUJTM>^?YW_I%_M
M]=--2S@!]YYL\ 'R^AD0IUG= 6(*1(DKY[2!<@N/& J;\$MV-Y3@)B1(2)Q5H4X
M\WEZ]P<<'NX8NOW^44V)ECD]X9XS [#NT_2ZV5.OH_28TYE&?_N/"N_RH]DD MQF45JAV;I'FG&K)=&
[_@F5U0A]N:X!3K;NSR2S!)>4C]WFEWCK7!0!C_5XQ_? MX?CBYX)GZ0UMWWU2&*/O/RWGJVZVL;DGG61Z-
98TUT0'K77M]GN;9US0#/3* M\$06@4]JG^0,QZ[/;(&A#J#>A'>3PUV@.KK*:LGT59EL(B&>9JF?9V^YY_-^
MKB=-%D]%5#6-;Y5GK)MS\$SXL*B0(W#UD9/W78974R_HD/G5?CZ".AEJ4\4I
M"D^EI9*-7*L[]_CY"NZIF,XC3T70AM\$#H]*#.&P!;,:T'@,3'^_1?*>F?Z
M4=+.9S<^.=Y>BF\$4>.R;.,.)?''.0XU0_\$A06,.)7@S0!0N]802GC09B'WZY*S> M03S0'0/]R)]0!T;H5J \Z!9
1\,X=5W(LH)MG,[_*V(4:TSHTGC?5^LL'-' MB@H&NGD/./4K@JOM[\+
(. "?!WEZ'Q'P0KJ9W+SKHNR5/JZ+!8GE4A@U(ABN M\!-\$B'H=U_MT_^K)@:EN0T=KHCJQR)?
YL]1!F^4MX\3>2_F]IA\$&)0]0@ MV088(ENP7KA^?>5UE
!K2TT'E>M:\UH2J&V,VE#4'@="^@G\$JN44Y]DK)97 M!+;\$L[VEP3@RMS;Q-
E_N9_V06F='I;G>Q0+F]6XS'I7BE\<.CM_ZXA!;>53C_M30*(A\$.X;]-
>.,>-7%/&9=A??!I=.W(!G_#MG)\DR-&5_M8L7Q-H^+^MBN5[\$08=W]>-
DQ>:Q"E@QAX^K6[/BD*=XF2;NL7,%1.PI\$A7I^ MH^T7:##NA=8]U%9T1.>7F58V=.3-
LME=X;T'B> (M(9#B\ V_T?/*>,NX2\K* M5LY6[*LMJHMK=Z'/& :+ \ (1/Q@^Q=GME9Q[M5N"?G
MV'5H8(A)RAR;\AFK]M?;!AY:\#TZ)T7_MZ^DL<9>UW9V8_N\$U(W%A=Q!08(IH+B(@)[V@15+A*[U?YA426(^?
>9.,Q:7_MV0*0MB=@-[NU^L^**Q;P+@8+F*@V]^U]Y'6;QMKAULK:=IZI<GUA';2-47_M)!-T?
QI/%\XVV7U9G)RW(VG:<.9'K1@_Y'?<@29?L'8H_AFF#G2+,D*6W_M4[8C\$F%
(_C#CM;E>.#+=\>]5F_IUT]9F!]JD*;\2/NS\KR6VBZ*"0IB8S
MJ&Z^0@LNKMZN*1V!4&%PD' 'K(1GKSB\PMV=VM:P;?;UPVRNI!F=#%\[7[A4_MFP^ADU4H4W1.D!G,57]<0"S<-
EB^*;T>,Y*]=??94(E("W.,/A58L#<='X=M)MD90KF6T5/?D6S3_E.)IBVU[W_YA%>=:R_H_*2='@94DT?
5NV.*E>H\$WU_M;+&5/JGS)7[/+/0,VZPY'D\$U=Y6G/LJM?'IN3YH%9:2" (=2K?T1'HJ>['/Y_M!\@F*\ADF?
#6%30!000{('D+[C\$]0_8?-! ?I8H35W!^EAJ;]\3*\$M.??_Z*OE+>U_8!]+\$I_PRC?
VU]D0)L38PA7FU=4F^ZPVFBJ-IL5_Q79Y9SB7_MV#]"A7#UB>[VW_H]?PF2ANFO:\$]{}R4)UR7,J?
N[3K=UL;G5:SJ5[L4:1_MPZT+V[U/_M@LS#W4V(I>P0;_%L0\C@4T-AA7>DHN,\$J+
<#%7.86TKA7@EJAN5"_WJZ),3_M508RTI?Z6\7^Y=I9UX(7<="UG?{0Q:4"%DT,>||S%H%>,*-IC>85KS/U!
MG/Y/SE\$T%'\7/_DZON(WUQLD)S[CNU4R0K\0<1[Y(5#4>!] *T0"Q.Q*44?
MW)/[GUT;S4#9Q4@JM>?!ZYKM\$E1*9%-
F7/">]PZ^/%XY&0WR"GN/G0.1I".JE0]E,^KRL0AE\^K[/:E*XNM&M:\$4?J#!1SN0R[P:_K_
M'_U1G/W0,YX;S.FC]?+PK!W-#I*P933M]_OXSC0BS@X=0F^XTG%C_YSW^V_M]&!.+/_\$<]GP
*6\C'I75898EL;&+&]\$.M>+.#T\$09_C-JZ7>K.?0^0#?Z] M^RJ08<3]IM9I?._(#1/,H,9&@IO\,/ [2D+WK=>]
[-?]Q(;)0V@#N]\$[-!T MK5R\ : [?0QJ7Z^A56)B-Z12_8^)]B_N4:.L> \)=#I5Z*X:0#1&GJ+;916J["
M01.H^QPR:F,N%F6P-L+>G552B:C&4^5[7X49H_(WTR_[,X,G0:KR6]0T0F%! ML7^5%/EV8\2J;Y5WNCWN6+
[-Y>1M4IFNTI(Y'1ZIO_ =YM'3^2<\$_ ;P%,5I!C_M_-TY+)V0F&^B!KVO_C0LA/HJZEG"N;& :)1&
<,WJD,VTJU#>B9HTZJB0>>P] M_FS,WAC5KP2@8(#?U@!M'A@12QXE;EX5.TU9@P#15D_W3H2S^7Z0-YR_CYWJ
MDJ83+M_D6V7^&5(("H9;_H! *1]>Z-6S?3-V"GE90ZMUS9S9/'HX:W^V08@K_MT"Y1:F-
E)4RUJD+KKBH@Q^B.DI"CY=5T6G0U4]Z,YKE0&V0U_!<5!+]">CX_M]6M3:GAN2%H[0&U0#>]/12-
A#RIDP7N2/CYAU2Z0D*;H9V= V@](Y#V9\A[\ M"N=>_ [1L]>K(D>\$_?
%=9M\B>01H/C^%GC7ALT.2)0I5A0Y_5JY53Z-S0"3A] MM'"[28T5D'DG>:3,2LT[/EN[+4&XA/0V?"PV[0:TNVL
MM^'R9798, *14&VQ%&?(XX:>)G9/FW\9Q9:Y9I1EA1RV@\$<=)\-FVE76!F7I MRTU_,LL/EW0
MN@#%K/PXJ5J9C0J\44()P\%]/1^1MV^%.L6,ET4Y3'0'T2J;::;)+\ I_1 MX)>G.GV]&-P4
R)*: ^&E\$4\$<)0M^ZM#N:X5PP5.0K5!\C[A?]Q'=7X;*K!XI
M,ZCD\$:VA^7<4XJW._.#,@B"CI'%S100X+R#U>68UNW)5E*A9YC:9,8\ MV]?50RU&5[15&'@QX[,T#'^JX)A\$C-
*!7_6/D/3DW0]7F9'5\ 'R3_ZX!M0;) MK\$IBZON%1Y>FAU7#HY)GB0Z&0,
2=TMd7>_.9A=I['NX[+YTOZ5UI024WS= M/7@90S.I1;7-^+FY5\$M'!+3QLXX%K=E2\$L'[_.\$5
2&33)7.&9X]LB"K3>UP_M* -HG0N^A-&+Q_JDI=QL!AY /8>]*K7Y*VI)GSY8CV MD72;+:^-ZN?
T)*!0JPP6D&R_GG\ \$A%-L1\$6]F1.DUIRX.(R@,E.KU((W=+/%_M5T104?C@R2DKN3/E_X0R[H.HHSZPJ_JWJYY&?
XL(57N=T&W@&5KGP./>_]@S_MC!#LA05\$R'P+\$H.-]>P@S:@C\$ZMZ06#[@4.\@R0#"UZ*S]%0C"2R25:J\$ _1
MPCFT4EVQ<)R%- "K%^KH7N]V10@RPD@M_J\D3-[EWJA]Z*0D3N8]>/4D,/ , M1VNN=?X^!7^%N*%>6@,?
#=1X9U"="<^+&\$W6HA=9=JY:EV"70PZ>*I^0KE0 MH%?6B? UN4^*WZ98,5QY=T,?
^@/Z(<.D9=P.YC6E2!00PRN,"/^4X0_N?/\FN[EJRF#9-,<5S9/[FM]?1-A_M,8_W=8 -" #W+[VMR^H@1U?>%
<=,70(<4ZL^GA\$& ;([#@>2E\ _IE8'^NV?SR_M7_%9YFH&9?TY82-(>X9MJ>)(/,V*!8#.09K
D0/<@P#6#6/D* _F+&H/D)\ /Y=H9K;^T_ID99H- MS3]K/UN?
J>=" \9*;*I5A6&L&VNDLJCP5D<>0+7BZ<6[,25B(>=U37-95/H=,B_MT[2T3]24G:0AL6C#+%_R#-
)C]:'S/K(8CF<\$BTSS+UDZ,#75Y)I?;@3HB4' M_-BJ1_G%M*0]A79I930C#20LGQIYGD[. [BU:K&1N0!DZB?
PRUD+:7\$0\ \$@3- M5Y1MFUI_9/^_M24@8,2). IG5/*R(@39@EB#"' :S#2;6ZZ8N\$GXG0YU21=V'
MAMQ>W#&T#H>Z/'4.2'"UR0-<*>X)Z5_(@LD@_SA]WRI77([TWZ^4@9X05N:K5QYTRJNO_MW@Y].
[_@K^2=FHW2AQB=KPC^GMDM9L07SKN99G^7RH)GSMG/#L>?G; (0F0#B_ M3T,;Q\K<43JD/-
CE2EPB@WH0H='W/)VRM=, #: ?9EF# [BG';BSW,DNM6UF (MJUEU0>F%D8B9&M?
0C3MGX70>71K0.3S(5STD=SH+T56R:L[]2_P^,NX5_ ;Y0_M%E@4M/B&I%)XWT1]#CMEZL'<") (NV00G0SU?-
_J21S,@IA;96H"XC8_T(B1_M?ZURTR48"5ITFI00/_9!505X#+F-5JW3389KF:*CV%Q[7]N1
]V0.N'X(&@T;R4XP='89INQEZ.L2?5M_MP3HLADAC^XKPI1]^T ^:X_E-S":(' ,K\$?'6[(W1U>RR>V
MT&8:] "X_I-9&.,:5DW\?8W_K^LIH+J2ZRY.)<-N"7/YAD(40?J^H: ?ILGGZR_M:JH\$-
MQ*5)]#W\$,F^7H2%X]&'G+5F8TU-?PNH%W)409Y-W?>]=,%#,C&#B*=

M;QA0BLC,KTK5IC7918[G"8A)I[IVNW4*8.7'C0(@;L!L1=C2X>06RVHUQ-B MEU4%50M-L@ #UI+&S[])??"("(
80JTZ1>JWt/5:D*G7;\$M!>'IEN9-!M/# M\4(\L;WZBV\$-
MR>+>.YV6I<:VSU*Y*8L[MP^6AW3W4TCHERV_2EE(TS,0* MMWT6-@80@? !E* >[,+1K/V%?
@7FTIJ !^,0;8PZ_7N=0]I>H\$ M6])C 3 ;\C\$JX& MVJ"R>\$37BSG50H,61X*9+JMG"+NR2 \WP1=A5+4.!]=?
_N"1:2'AJH]T6W@ M5&CSDW^N\^UODG "MJZ1TJ++K >,+RK8JN],5ZM.[3BUNZ@]Y^F&+OCV8P'T
MPMZJ%WY5QT?U2U\$-V;J=:85-COIK!>?J?@?"VFWL&6G3X*EK%'\$A=Z&FBAN/ M!+
<:VU<0@3>,I)I4>Y@SN/AQGTJ^\$5F2G9N!D._6S4'>5=.1L-\9VYR0%N** MTQF0\$N-]OV-
'K=I7=T^0XT^AJS!+)\$&#/VC@E!&8 &- #ML>Z-94^1G"H0E, M+&*TN&+0E^M]05;?#WVJAXHY+0??
W,/!B]_6(J8 !&(!IBRT/U""L@]RH2*Q M:9= RWRRZDG4'\$2QJY,I2/@VWB#4*M^0+L/'0A&04F2^JZ['WR-
I8PM/'0'\ M0_1^@:R]X4">KMW>B=!]>Z6S'@/0,\$KYEC1)SF2\2CPT\$:J+=C\$/=/L&28%UT MF!T]DW
06N95\ANX9M]'9YOML\$;FL,/3CU@ M1<[Q<%B7L;""I /.E6C&9M?/^?M
Y0L>3AM8C"4N6<8"\G/+6%VGJ]0R8S'O MN5-
COML>VG*1U;5G;+YT0Z)7FW3I\+M09J')ROWT*3'K4233_%10,F=.,=M
MC/AL.7/L\$D=7FR3L<4R@GA'U1:C&G/ 2FLFLG*@Q^7&0*BN>K5:W)"/^FP/
M!R;S&T0#4+;:MU44#A0IK#7M/48>' V?9+349?1..S'0?#M.\10Q (DBUV M>^.*HC9]CVZ*#SRJ,'Q-
+GF7X2Z2C^ 8*9RJ)H4G^F3-3"0<+T)%10.,HG2] MIFU:6&B7]LU'>)Q%SV;R9150 \$%:6;-
G>0+AS%V<16X=6]DGN! I! 0\]SAL[K"(C/E@ X0H71C4< M:I,M0%7\$RYK;-A.-H\$F/"REW+CE_XWQ8F?0:&L?N
0&'M\ Y0A9,[4S""I*5/6+-07IW\L^TRM(@8SW+'@/T5NV3D.\$(M.63<5R ;\R19=0*FND9)8-
#>WLUXL2A0(C/W\X/0G4=#=:0P&3M0#>06W\$11 MT4F=WVLT4GR0%=S(M.7H.G?MU2 M#S?
8C7I8&WKJZJWMZ]/&,3I+;!!.%]2H%6 /5KRPZF96P%]'D2%_Y1\$UP[6^ ME6(!]LOH@M->-
+8NT8)5\WJ<9U+J\$BXXG=L0>?N=\$\$V -[07W)!E4AZ2Y59I MY(\ VLPL?!=>!\T4:A/0T*/MAS\$('\$D2L0/]
(\BM6KKV\5+NE^A7#X3D7X>\ M?I(NMDM/IT"- \$KGA0V;K272RN-[9;RU;#!Z=> (1;%*0J4T));73SN;9Z9*3
MI)W=#V&<;>X>P0^L24K#C-G9;3F9E)FIH0TB>D-CR79]U].V(.WHWAL"9 M+>R(5#)N^%#7 ;,RWE*QQ2V
K;#>T/B^D>C3]+0;WY!5;4HG92]PF>Z\$1K0[\C \$#^&RVWV](.Y6P05>PDQ/\W>,-ZTM0R\K>2
MQTQ@7BK4J\3_GMA9=0H]^0"F0D6'TA9+4U52AI];CPRLNUWL2W^F-J]S\ 7M M:#W^
AWTK^G1QL\>80^7S6<6Q0(?F'\S@_A<*!I=RG*Y27>808+@R:ZU_.; M9??
7PBVO_F4]2AQ;>'U"UJUI990/U2\$K50W8_KHIGCZK&D#04\+<1Z=,ASY; M!XLW_ ;[@VYVVDL4[]3*+3+C#_+00?
T* 1G =FHT%J"09*S0-H#(&L(#0%DWG M :0_/*PYA(S8
0)5E/CCI[58=I!X>+ @S74..5VI,D4L&X^W:ZYH\$)K!V^CI3
M35<:*J(\L4\U('_.0A;2M3+*UK/#9ZCN;45A4 "0,GUI9+JC=^:[(MS[IC]+K-?0P_=9[I"K*8-705MX@%](
^LI%\@2+C5&-B\]/ALEM61% ;Q<(-7/^I[/*/), '9:JAQ594%V5B"53U%'(88
M67&JF+_NDN\)&Z(Q0B^06&1\$.#RN_NW;\YPD@7YMMNLNX&Q+D!\VW<=>S^MJF MJ1X-
UBWQUS4<4=NYZ6)X[(_6@N^X8,8Z]9''/\$D\$X1@.I,^N#FPMT?CD4E!] MY%G"2YM')G.4HXS"??
\,+FNY\4&/QER_?GV6[\$]&#]>SWY1!]'B6U"8H37(M]([N6_HT)!U06-M>RFBEZ7LAIR[D]>Y5RS*6?
F;^0TWR!NRR-XRD@'=@, 1 MWZ[\>[(\119F^C9S[N8F+PYJ@X8^!AUM6^T.M7[G= 1'!JD5#Q3XQ1E,??L\
M1IN[W+C/VV^A,02Y.4U\+;:/;J+7@&UCLF%8P/ILW!ISW/:2X'8J)V472;
)7_.B1ALB30:Y+KCENDW(NL_R'-A6JT.:3<]1*I1 M>[6K4DW-
0%&0.I)@05CBVC6B@>0F5T:W'LYEZIR?J3Y*P4 9YZK@3?#33!(M00ENC?" NW:-
Z#W[/C.2=6&]:CAU(Z]RB1&/\0HEE6V4,=3J4,KG9"0:Z6F M@:0P*_))A%+*;A?;?G29T6>'4I>,K7;5U
M=F9=-V;:T?;4ZQ"MOJG4U\$04,LSYD?2LHI)>J8>+7.3=BU/"!T?[@#) MWT6-3\$<(BF\P&[??9#-KI*?
LX+/4/9ZG.6;)K?(&?PL!(/=1_0"Y39E=YDZ01I< H/^PQU.H @Z.KHSB]45XT'2QR_;
M\El<[] !F\XJ_XH%#,E[0VZ(0,?3!D>K3Z>K0,^2V'\$ML8 W:EZ'0Q[X2PN M29WR8W@9D^:--IS!44LZ>*I9
MZ];GY)FT2\OY^;Z?SX9!/^&G5@IJI.EGLKJ%2@+0#2:Z2(M8]JE86P4 YP(@ MD2&R5@.H;
[]0J&S)IC2TQH8!;F\=?;T\@?@EU5;:P3F%D;I7F M!D5T'M=TC5==@?F*U8A JZ?XIL0VZ]8/'A?
+UIK1PP)U,=U]YM\=XG:6.08> C[\T0!H=,MIF+!;],4;3=\G+5F,S>]/_0@'EFZ]/X=#3K+YHL=X.^&_.Y?
2ZF^Z//!/?BDNWH/(:3 MC0#!&R"']I;"G^ (AK64/T4M)7#U8@-S'*S[]?P>+B%5:_ V L^ IFLL#@D M8-&EV-
HUW\$UTH1/*NN:>E.B>\5HP^B8N317V"J ^[\$ MZ>TB);, H'N-
(\V/MM\$RYA*^F+,DIF7;,T "M2!.XHR^J^879#\=W< \KT M[\$&/: &10W@\$8)=AI=G^9!IMR#
(99W%TN01KQ&;?6K>8EZ>]06).*,:@:G+FS M*M2(C*M!X2\$#2YTDL@A0G!)7/HATMF?>+=
(Y9H5ETQ9IGW'RCKW:28\$BV) 1 MW# /3@K]?>C\=+\BL:/OX'W^& >5)L [TG!); 4+/7+ ?(4C"6045EFG@I.1
M.V9V%2?"I<2X,%C\YMT+6M_E[T&D&:W8!73F,E26[X,\$\$&T5:P\NMDN>G9 M9!:T5?9FK>GHIMH)RL
U*5:I85P(._XM,Y3\$>&)]I!8F^ MD3K,,DHD_U9@LC]2>ICUH6'*JUJ4)IDBW>R..!\?&EZ-
+'1NM@U\$_.TC^YOKKVB/\$];J@:GNQ=J0^&RE;-N<0,A 7DS,7K[=IVRY/6UD\$\$ MQLZ\ E[G!I'TD490&8HE7)^\$
V M\$W8TNVK;9%VZY(#A4TATW.6XPAX7Z*)\$.BKJXX-=DLI^"]>&UBRT5NZCUL]@ MYNZ
VW@G:\4X[!Z:K"\$LJQKDP]4L9L,N==7#YH-U.WM?SJYG!IC6&+ MEA!Z%'#\ (CI)"-K+YM10-'\$U#W8=B%A
^MYB_8R,L);:T MA*2AD.TWZ1040"GZJ5I4D4W0[+/:[3Q>I,EF4BR41M:(=;L_7HGD_2IN8K+ M&9=0R6.=!T-
46G?E@S07R_RR\$6_A^1]1(0(-[0B2,N?<- NF^LP\APS&=\^? MD;\B>;X=6EZN(1PP,D\$&MMPF[X\]W[@]/ZL?
5[.PA8WD/D*[K.[-B,BM"@09I M#08+ 0-^,3%"60 1K(+776^0Y0L;*BYS2C9I:@SN_0NTTJ7883E1)C4^I
MTE[=]>SB^01\ ##'?:.B62,%NRR&1@G76]!KAA -IJYJI;8/..T&CZ-[/9: M5NM2T.+[HBX*RUOH:YR&>
=MJHJ6E7*N M@JWNR)#YXH6A)I00.GOH*A<(\^I]0^[\CA6%G;ZD/RI,_VOVXZ%TS<)IEJ/Q9
M##I4U@P[B08Q]I02SS7]ZE_0;:EP95I05Z(RX^VC6-U'@3^F3DKJT*GV#MQ^ M)B>OWK]>2Q/YH#*>R*
<=+NX)M,)#N98L*+L(6^3;\ Z+0S,'R&E-Q6XF4I#Q M\$)N#LU[0=%P0[+0J2:X[2!#]!
(W*+OV1\$ #/2X*=ZL[4I;[E3 >EVE_3QU* MEV+J6(2">-WIEW>?3KR<1\$JL"<>@;
N5*IZ]/W*VVV%0 #4T*7SUP#]33FA]Y6U2RT_15&(^4CHAU93YHUDQJ>B*DGJ?"%S"648A\V^X-@W1-
M.J4S11PN"#G/06R+5\$AVJ[Y-WDF^5I>5W4W.8579YA7K4]=L%,+Z-30T29> M?R9:&!KNKA0GFHY8,ENJDPT?
@!!Y@Z+\$&U,/C,3UBH>_C)NVU>*3GK?0M4\$B
MK,Z4@KPQ1_G77\$:"\,DKX^EV&R%0"S9G1MEDVGJ/YN"]HMRE.3XMLT]\$_<^N M:DK7C5#)5JR@-AY,#.U85_2??

X*JCJ:2LMDI[,^\\OC7ANUTFIT\$>R+=A/_XU M: '20PP,P?*,R,]<:PE,UFWF_N01BL-&(H'1?\$/+_JYF)[,9?
S6N. M_06E/#7@K<:,06X;P^9:0<=?'FU2F2Q[?WYL?F/2A^'^Y1_WK6=QC,9S+;X MKS,S/XJ_\$GEV\$'TYIAB
8*A''VQNVUR+JR^85UP([J-73ID4S)! (Q9NGX]U*\$ MCJADWMAK-M[8GG4]G*? Z9\\A)?HUP+B3U;U>/@'6ROUC
M>U13=0*6D;\\XCJL:'''>\\U:R'Q'4<7/1:G232&^E /[^:IEO,X\\N+XZ)+L
M0/5NJ+/9EA'%GZA^&0SLH4060IQKZ)'Z5"!S>E*>XB=D_L7%_9S%!C<@F(5 M.\$35:2;9/=4]'5=
(5\\CM[1MX"#Q(M4Q@D7^595_N4!=K)6&J[]0);!(04JJUGXJ\\:7CX!"U8\\?1:JG9
M)CAVE1^9YEUBX9=JE*K; ,07VGN6(M@IU_X DTKXWPS3(2'M'@Z1"FU6JX(;\\;/5 &T[J:ZL@.WA)^6:; J,E M_\\
(H^A*ONS>Q<:H%D%.-/XZ\$CDD&9%YM<.9[F%C2>ZK/-G;5F:8JY"TYI*\\D7 MNS_S%T5>8);@15@-%?
BTJ@%"U9T,ZK8H?E:[8EHQ\\+WBC[H7).%S)=G0Y'Y@ M'=S^F'5-(0I*'J11@%3ISQ-\$)E<"&X_?UR%3-DRL?Y
6D^)N"?W4\$?HI=Q5 MI85'T^94VA1_4_"25S MG0P)J*Z/ M/>4;+D[+:Y&@KQ1?
LK8]#X:NLF=, #A!FPB\\#/:L)0](+T8:/A= FE MR.X#.7FNLTV3MY'V20VX58D1/_%***@K4V#0WE-.I\$K?
V\$8"OT5[T]R6&VG M/[FE\\W)3)N3!,RTB4L)?! T>%WH[Z5D9 @;^'JN%06U.%0=' 7V[QP9PH]; M
5Y=FPW^!C1 M@.7YPZ_Y+F '/F/]N6:NUUIT_%JE]LW+ONS;I&K[/].-3=7 MM4E1EC/Y'^6/I./AZ_5;
5Q('CS6^X## MR?AS[+DY+AFR7%,G>:??@/GU!+WLU(Z(=-.FF!HQ_D +)6^' M.[]UVE0\\BM+>]/DZ,R=2RQ:H-
KR%.)Q&)VSP3/AY\$JC: W]-!W35B_3L[1 MP0;10<#Q6(=]2WJ6]#&<=!%A8Z+I1-I*!G*&.[Z4=; ,?
_9V;QYJJ%RD,TL M. I%1&9NG#@27AMJG50L?FR\$X0CR@> VF1D[!^EL:.1J33Y<;10*[B(^:TK
M90!.JNM^U^5B6!)]-=T4F6FVD"5NM7W1. M+^OB2QC&^S*?USQLKT^+(,Z&00NY&N0JDSY>GK;G0&?>V?
&B[);0]4@DE1868A5KJA2D>2B>AH,#" (%ZT&[IF"#1][?XWNHTKJEG<&,86D0K;@BRCY&MKM /.@C-
CN3VP>?]2 & +W MH2\\U,H]1=GI:J' 'TP'=M;ZT&P'6G'[#GU90F65F/K, !;&H:5-QMLS+34!; M#V2=1L0:8?
@AG>>75RT;C>UGUN9#7Q:7<,"V'389-JJ1/1L9, :C@C5^RFF_G MD,OL&F7T2><836!0W>< ,B]@P9T-0Q,:F5>
<2_J.I3R5;7.^T.FC=@MX7+^E M)-PV(^8RP<>QX8;&^!A\\O)FXJ)IF_./X+.W9_ =I=L%C+)L6B]89K4CVCJ(5K
M7X;\$M\$WA^^^I.(8ITUFBT(E ;GG7&R7.Z)ZN^FM)XZ7^9BK4 ;.3K"5Y6[I M/GL]M!=-
T.WN!]2&[Z_4)),JV,>*Q@J+/X)_ '*^B<1-DN'MA[M/C.4?;(LV MA1G]XC3F+IT#-H*!&A'WZR#1
B(OR_HRR!ATM8QS![AV4\\V]:3P']^8U:"UU M=-*4)\\^#Q>5D^MGK!WJA[Y/'5JA<4(N7H/*"V\\B&9Q1,_WB;.:
(A@T(E1^[/BRDL)=V)-E%E57=R.KL?V8%>UC 5V/-)DN07HVY"V#U6? M4=E2K0))U66@SX62>?
G_WS..4IU%MOMGPJ?>J[STB]9LXABHOUG"F M"!)GNHV14Y9300;L,8
\$-37UM":9SNJG]1G=W%I@D9YR=9P4D="<(\$;=WFN/G MY/G8W78B^,8 A'01AG3M]67RL%2US;)F\\>@=#?
B>J&2+? V!0E0]& NPPP)" M RCZ*DW4\\'!+_BG]-I=:=/,A3 M#I8HJ-M)\\=762Y2,'<\\N9VS@F3W!_0QGD7,;
W&=G(ZMFDDQWBV77T2_W: ^7 MX(M)"6UR=WS2,;C8WB+'%VRV*1S?, :81SZ\\,D\\!D9K0/C;^\\Z1FI661)(+\\
MI\\V: ".7/'"X8+B@77-<-P>.MFGV.-Q8%AN%J=1K1"W7:"A C]+>]! ?9'^[&P MUJ;?&2*!N;3R=
<3N8%X9_5:H5WW=F;0P7M!+.\$^/A?V-48[TIW]R<).U+!>M
M]ZA/ZV.^'KD0E&96]SIE_,XWJJ0\$.Q_!N4=+' :E=S605UZ)\\[7B9*FI9UCZI
M#E[6D,\\8'/23IV10!PL=7[&"DC""N"-,\$?'C6"C&TV0YBSFYBP M@K/QXU_H1:&0@\\LQ]3W1I\$77C9#P=
M][R][SGCG/OCWG'/!=^/E9&,K+G6,Y\\YUUQSK0?-F]R_&\\2A3Y,\$03A+?+;8
M1#>%Z!E0GTGLA**BMD5KV"5:&N>^9,8 OSV^4?X+P-N^4/CU=X<"(%(LI99S MP?\$9UU2_=3AH]-
SQ\$5@,R.Y+HWW E_Z"19+&[C-)'XI\\BI@GLC?C("M-085"8 MV%'(-+_%QY/05>^Y?)A3!
[4YGSXLUB*?:0@90'[0R]>J]' "]7HA7&LEH60 MD9*FK!8+[:.S%IF#4T-
,B>4\\-8U:GI5Z9TP+#SL7.2/C=X4',#,T?UU5-0 MO\$';1-^'PVX'VZ?#MH.'LFY?=@0FK_@&RHAD;KA2N5A
6H\$39_M4;0(2\\HJM_M,YUPU_S4U>>)#R-G).2?VD082@BW;RTB]7_%7<.K=@0H1FGBJL/1\\XP#X!EU
M!D25<6_*7^5L*\$Z<:B&'/X%G'3JR_M&*SHT-13SKXC?EVR: ^\\R?+W]VCV#,0#P'M:X0\$4]J@A%2G?
E@0,JVBG3]4)B_MZ8S)JQJ3_7&Y88>@A.8YD")5FPY=RV(-[(U'?01!YW:F03V]F:V'K,!:,PA
M>67M.6+QY5X(&Q8A%E M;0BR9B"%G\\XP8GXD6/A61"G-ZT!;UQH[*XL\\Z]0.>1\\VM=PZG0;=;<4371>
3^VJN*+V+\$%-05X+PL;/:[X!?!-6&-?%U3U>L>-R]'^Z;]2(M+URH@?E(QCP8+;C"BO7Q+J&KC<+KV6J-
+FED;D:S+101GF"5CU0@C/8HIN'E_MZLP+@'9R5Y*FRIN(V/Y9^AM]2IGOLQ"ITV5/USSS/+(%_D0,''+:C[I/
M['?>]"Q*U\\G/L()M&> C\$%0%=(X\\HW;0%K9)?'2MJR%G7\\SUE,Q:@L (.9 M9D,#&!/!>'9()IA>
UYL5ZA0EU/5I(;PF-IN&W.20VAD.:8>_S8J\\^8&(2E\\& MBR;+@.OK)X?%(#\$S40TP%Y?%6SIWIB0C'-G?
0AY^_DQ2W8[B(:/F^4V0(J, MC(X^.\$#8&_T+)3C]<0%XA?&@YJZK.Q,3\\1^TI+(:H()&4J6LTCK1YU
MKM!+GR9R%F]BAC=AC#BSMBPJF);' A455&2]#M'O(M?))-+%L//R=Y=N]/[O MN8,V=^>
(<%\$GB,A7P9GGFZP\$,.))-UG.*ZK5_M>U8I2M2!W20L[SB]L=Q:EV!+!JXN@&\$SY^N_>VHOF\\?[DNK70[F*
[E0&IIJE/ MV:4_EZ7\$SP\$;+7;W9;%\\3_%\\3G,= X\\/^7(1IITN+N?9_\$[(SZK0TZB=%=PP_M\\L7-
&_E]Y%WC0%)?+5+H1-<_I6VC6Q/K:_1A3V1@&CR#L*BQ?;0J(RE+;Z#X5/GI_X M2?CW*NRB+;%DK<1'PPTV"
[>VG4QJS]X4^/.D+L_#%/PR""S?YV(O_JR<%G?Z MX\$LI MU6;:K\$H>\$_FE19
M2QWTOVM_33(5' *+3/5FK<=@@NR+ B:=2)L??3;Z\$>)UN' M*T%KZPPVA.ME?\$C\\ASUO"E\\
[^Z6*U=2.\\.#2"OTX<@=]<.3 MVE+K7XH,#1!L.\$]Q*(V:R4MYI.OU\\A2J,/GT[]_T_]AIW#-H6
M.#DE]4%FL05?KA]3P:6+[KK5PZ_M*2N1&GGYJX(ML]\$*0GA3R@*J\$&3R8.YPH0&Z,4/>#*T0PPRB,J:G:V[?
7/^P M_*@QV>:0=UJ'"?(/[/\$"Y1\$91N_5S'K12NX!?:0S_M5M%S_3AF5IT7'@7>]
0H2!3SV,;]3)8100K\$H7>P9.&1=_Z^C6_S4_D=008 M!;-N[CN\$R;?MX:Q@8[\\'1^Y73QX-HD\\S8A!M\\'IP
2%K%^XC328H!S*/0EH_M&[Y\\'-:74&?T0TXMD]NG[W78(I[4)FP(&!1-JD1W?&Z^XKN%\\M-6NCOFE+
M;1VZ]J'1["YC9;?V!0+WRG8.0KVYHG,PJ.,6^J\\[[85^FA\\3/1S5XUN3]\$H6/D.\$P7PU0M] M;
(\\C4W>*CY8'DAW>GXGIG;_0\$Q58=R[[- M>BD-KIQGHQY8>G=-MNE[Q5\\M,YLXCWB<6Q5R*;C<(3KR
X.C],GG_ ;BG(*3@_MA,&"<65=I"6^:&&!]=E_2>G]MP^H05YVD(=QV0+\$UIH MI/,QI\$JAH,U2\\ =.I;#
(0]BB7)C9KZRB-4VNZG'6P^\\&H1Q[E'X8AD09D^R1_M#K3GL9N_#"K-?YJRWAR?N
"YBZ\\ "MMV0*8F']F\\)S[1&W.+1J7NB#+!> MMWB\$. 'M*>(:[2D5S\\5N_AM8,Y>\\C4KESPMGG2C5RWD_=
PK)T<@P[3\\00F%2_MAZ3;YBI+*6HU!E7.U#5:E0TY!)U_"WAD#FGR)0)F]8:8TAG/T\$6';M8)I9F<
MTMQ@+3<_4*1I4_<&KF)3-Z2PA#V?0=,3:D)?C837]I3"2RKP4GR!1K0'1K>/_M8@.I(NU;2(-+8MQ*
<%ZM<=3>>+L6R^&_&,\$\$XJEN=3!]>6K\$!E_8NH>P=XF02Y;+38_21CY/1X=G?C_M;?%
('6QGX0QB0206#&11!G#@V90"3[W"D/).)ECEP_?U!TKC;TG<+&[*9EB_M5M[L#]Z0"?\\JF8W.NG?

@{KEN'7M0;('37F\$6?XX)<1A2>FVV4V6I2N3E6P!6,9)C/? M1&. ?/1RA+?!D7X6QRZXP@SA56RL]_1R
MF,9D(@6&Q0P0^\$<9AEW=>/:34'0THPLS#V?MQ?K&9YC9%FU4;^V332U]?W M,H-69VL@-
0=9!.'(L6UQJL@90M%W'LRRVV,BAV4KBU(LS^C%'Z/%0PMM59# MMPG6:05>V0Q@&\$#8XBBKYSI+'NQ98M2]
(CC>W2[GCF;FN)L0U-D#VR-YN#)+ MA33.9KD-*P@1U'[BBNU\ Y*/(MS/Q6]& MU;>DV%HIOP.]#J7XKWINM>
(HJ-B0?..U'XV[+F?;46%P (<3LS9U#A0I>)& M*Z?1LT=);@LN7IN]Z_MR\$1\$'S
K%+F29;F^[C'LU;1UE)7WT\]Z70F+W]5 MM(7X<+A!U.<((;*C*8T+[QD\+WCS;
[!Q\IK4\)]I62:2)5LW/CUM5JZ1-ZE? M7R=CX=JSV(9&.'C-IJ0L#-] 1#)ES;T2J0G MTLC@05(X6+-T-
;APD=0IMG;\[8]&\$<.;!0E6W< 7#?*) ,H8W^X =/I/EXW0D@]&IS+V\$M\U;.;.75%'<"9N683C- M^=D0L00
1,>|\2?H? S3I'I#Q9NZ'V\$Z\$??3BX1EQ M!4THVA&8AT_)I'?4TZJQ4_E@_6MU[Q[C'3TA&L(O@AH9+KL^+;H
W(& U;F\$ M3SA*P-LNG F\"@W)- V,2D%P71L/3UCBJW\"CKKG\G7VFD;S38 M822%Y#&PL[#@;.,3H*+;N;@L2:>
M3R0A[''S'0\$]KGN5=94_6C6Z7HG207@Z M/I \-;.\$9-* *WN\+G*WH\"Y&B6Y%WCZ-W<:1ZTA#484KL&TL5ZM?
==A>C58]/MM&+5X;<9R;Y7R%2^] M+Z0\"PH;/C5[MKP8-PSI87- 56;\1WMN'@=>5 M?GJD+?
5UJ;\37@*0/ZI0H(/J_XP[1XCZ#,L]STG2GL*P>)P)<.,\M8FN_*E!X>PDECL;S MS#0 FSX1%)-
!Z&2=D5=UPQ[G3VI4W\0\$HTR5.9,9NW)PYULXR%\$S M-\7R3D MWQU1F.!WDGW6B[\I.;[9XP@[CMRCD?
A=Y\"NTRK\2\3E>'UF6W1'1IA \"UC0 M5>\"];>?N!7W>^ [A-J0XE^G'\"'I M OA.\$\"^ PJD;M/^4H()M6:?
5B%-8ULE;1^%S@I6WI G@I?1UN@H2UH\R&U1 M%:=2?)Y4%Q/M/)%5T2WY90ZENC-0/NS1
4;..0;)F*'\$=6YN%, \$E\6# '5R!7:8+!;2#(R&4,)T?.8'9'7Z83JH#A\V) N*I*[IGV<+RD\"9
MQZ,>0;U'84!0#.0?WY]EW4)PSBQN\ \$H/DM[F6N%\S6M]U(1P8XK)K\N2B3& M0J IR@[BP@922;)\$X^J<0C6+
[:JR;F\?LMM +\7NZ@YS.!UTBG[1Z]@UVEX3KA\"' @ 0\"FD40Y M'.%Q@A20^(. JU7NX-WD=(NB=D-
Z\Y2T0+;VZA8V890.7ICY2QE>#X*,@] M[S*=T[0%9\R^R#!!^0 YM+G00A92%0WJGBZ;BR&9]='>G>HDK@P-
DN<68< MEKP2\$&H*,\%609T]'/-&H)C7)64\$)XS)L4LQC!^6[C+R?NBQJ^QLRS:9WFX MJG => Q>@9E
A\W+D\"N@C>/4X]R>8;<>9K%D25.HL\$13Y^!|Y1X;-Z\^DJ<* =Y 6JL\DDAVDH%(6\$TL^WXS&NIE#EA(?
0#]DS[R/A^*2 MYV/KL66Z>(/%LPR-H9:DZGBM/*A>\XMF0>\$,25Z^Q(^.BLU=2G=<8CU7]\"L<
M'/'9'.%H^[Y/,W\$/LV]=45YL3U4:%SK+KDW^P)ZZ^P\"<,NI:8:A\"AM0EC<5
MW#&D,\$!1>&UD0T/4J^T43HZ:?\$^[C8CA;@-1C%F:ZW[:],D4&Q'LD6X#CF MT61KG6?&VZJ!GG*0NI
GUS0=6CS&!.EXK_I4MSE%SU)50H(ET#>(#!;3/763 MYB6IL?7?V]=N)M]69R8KYWCLPG)!&#!#:B?&7J;S6U=
@(M@9MT)054TG M2?,&\"AB5W,9^WHW] MTH'M:-4)GKET7@1L]^6*L(];6M=?QP(8
MP^8[MJGFG+9U(E\"4N#0=P0\>L46LV;VNLH/A\$]B?5Z3>5_A%?F8%\H2ZZWG M#]/J3A6F\"[>\"P<^:Q9>RZ)P@
\$1I8B; M%0XQ6?&56W0Q_3TR.)U.+[^8NCL VI83.)5YW>W([Z^E6 C'U@DC@Y:251, M3+8Y\C]2J7V3J&?
=Y'F3_G[A+Y;.,Q'U0W#<|<-Y43M1I[A;\"UG18X%#-<5=\ M*^>^GF0MSVW;G)N(GB)I3LH*#-:\"6%1(SN00
M&;4,=5&^5Z^-N-Y^E\$2_&(S^)]\$ JA/)#8^AYQE-9SG)+JJ:F\"UPF)\"9CQR7N8:/H[7..7-1B-'P8[3]1RWK=F\"
=](HZ ^YK1]*1* MRXD,'Z0_M;(KX[%B_CL^Z[YW05N=9CA/9;15:2 (\E=UXN\"#/-L,1\"'Q@[A!F7SKP&7 W
M5ITK]2QYD;ZM[R8>-- ?\()Z6%5JG408-2BTX=N#SQU([W9+F)\$[H!X#J2#E.8/0(M^X=W!YL1EY]P\"J\$7Q1?
OKSSB[>]J\"E-: ?2 EC?9R=-6I'L6'/2/L%0S2 M]+SRE6GX;\=;>5P3DEBE[!ICD',Q!|7KD#8I^&BK#
[08]&M, MY^MP\X0PG(P_J^8G[1](!3^_X8J;4H ?!UQ;KV+JR_*;KRU),XK:JA <;W5I M!
<: 5[A9/<550%>2S_@HHTHUU^RN2HF-MGZ4AE 5!I6,\:16M3W3LL^B(-+B MT_2P29^PW>KU./+PRF4RW;
<+H:Q2-6]SWK+0C5V\JAE?3^FRSS8310[+@F> M+2Q6;8*KJ5XPXF, !F\"E.4!_V M@-S\$EVE5F\|E-
ZD2,F5^*?) '&_3*RN0UW^76U\ 'VG0>6!1JJQ&-Y@|0%108] ML# >|.EX#)=KI9\$R.* WBQ(F>@8RM?--
0].6;0_6&SXX0[<#F?804;03[!K@ M\7LF>FT'0/Q)&9C55M/^I]
MUYBCHA&0770S;\Q0,3Y[)]\"L3\"Y&ISJA_LX MY'9;1.S5AM=[#MFMEM97/&QL.4H0Z0WM4A)=<\$%-
MB9@C,=;]DG_P|P|@/% M.V#D]C;BZ\WRZ]4IOEE (Y>T:/.-M]CEAEMMTL);]\"^R_JD\$/@3F9K26442Y;/J\X2
M.T\$Z,P_W]&*07R&+-2F<4IS4)S+,\"DQ9D)J%5\$1=MHCR(GSL (2 HFBP[& MD+!
(3^#90^:~.*/*..D\^KZ)6[LB*MGX@-^5X_NL3E<!(175+28H&I@U0FV^ MV,[2C]60EH
ZP1F0C+E!C.K&D6UG\"WCKUZ^=\$4:Q3<^ C2=FAB[S0DG>PU MJ?@CI\"1-8:~&6L]B9:[\"
F,Z^4+L[KI,55!V6:A85*,>B]W'0]53I4:~#?ZK0,6 (\"7L>0:~[.AZ'M\$ M-
N^^(S^G4\"\"U.+2,0B++977,W0.H3.I50QTV0.-^1>\$5&\$TRT'6@DY:7*A! MP!]/.%4#7_\$&0<'Z:6IBY.G(H-
TB37U#4^#)2V%7(6I:Y<80^MKW-,\"ST9T MWAS.#7\$)SLE9!T^XN1VB(0,\"GYMF4088
OZVIKF &Y@%9JZ@=7#IFZU>R5 MZ.:9TF0V@E%:NG':Z/>2PR \.2Z23-^9RD\"IR6JROC\$=\$63A;YBG9V/WS(
MQ)?]#& DJ]UGHF@W;BU< \"C006T2].V8UYD,#T&Q*CQ!->&>C)5;\";HV!D8 M3NC;3C?
PN6VIHS^3NM^DAFOAH(X%#^_OF#QV%HU>S+DH M\$G.FTL-98)AP(J_W29D6Q+/_2IE6]]*_MH2\G1!;Y>'Z\"
[#004D7 M1P%\"))!-Y^~W?@V1AN\W!KSG*FSI@J],\"A!+CW\N.@DL8LV7^~64?^W/M?Y0.BKR?Y0RQC?
[C>]FV^B49KXBN;F\"NV !PH MDP&]<2 JQC^/%_@KM9\$BAGP&G&X !_YMN. 805>\-M_UOX&;E7/<\"P>:F3\
M%?W68<6/3SG]J[\D\W \-C'3ZL\3;\A -\"*N?'A)TRG/)M=.M3J_2ZEEF]!3IKVT!\$2BP@J]\$X[\<)89>7;'
MX&_9DN-RQ9K<8+07;5/\GCF\|V@\"..?/PIMC\7\$7@.<7@#9%&?M!6\"!^P(0PHH#\$DE!(1*.U72[M +2\"-K=I_?
7E6\Z-+U9Z@0_6M;?Y]1=J58D* .QN2CV\"\" M(DZ'>.,1CH\|)\^)*U*M@1<-PUX+M1M.2-
]4KQ[)^E\+\$+UBD60N_C\|N#L7UQIL\PI+ GBE\/=T MCCGU\">U*758X\$U4[\"2 H\"63)A9-N-
5>LT>]\"I^D5Y6#^Y[D\:]@OE+8,, YH;+?\\W7+\"))ZC]TD(-1XZ/B3N[2#P& M00]J9,&=?
A]##PM^R=WGV:Q>0\$/+P#]00MQA+OF?ZU[B.?'W24&\"Y(HGT0] M!]>^C&[P!N<\"5?PHIU@+CH[Z\"USGURVY2-
3)=Y\"HTP%>57BP2'PN>!<^E[GX M#YE('0]GBG\4#ZWB\" 22&ST*:X*\$^UP /E&USN*Y:DC,\6QBS1;HSZ]G/OKW
M42 EAH87 -N.DZ!SD[4 :?BNCCP@CAR8K#.0P]R+## MIO-0H%.DYC]T2H9BX1WH XZ_YKTJ\"20HOT!>AWE=
)Z!PM%8(\6_Z_J&#>&0 M6T[&+@ C=9!]',EA.W2\" V1(XPJVO0\"6?] -R\8\"U][@:,BWBSX.\]!5V3/ MTO#LI
V\N!*]NDB@ZE'&:RW&G=Z%/25A(SD0/C)5,81-DC2(+ (3\$ \D\")+/& M#^C0:3AMEU\
_B&E*4P#XJ!K^E@+@!84Q*6NP: \"S7U,\|/L,OC<3SCQ\$5J% M^SNQJ8\"P5788D\$P@V*]:\$Q[CLLYORNP2;
[TAP;!WQT,6!4]ID;,\$>STD#\6L M6= !-\X%3 =YQ\T3\9/#M\"W8=8D93-)B +^T?C4E !&?
LQ1,N)Q,80'\"=^ M?\$X2V\"8)7 NHW_8P645KL7-ET6AUXQ&T5@+R;^0REK@]TB.A\$# YU!.Q\$>H M09P*F\"3)
MT=QP\N *[,B)ZP1VA*F\"EI&E0%:9H3TC09 :SX,F)(#&EN \"<) M*\"0'S_L?
257\RRY\S/T\"D)%U1[!EE@>7U\$\"G[N\")FAIH*G^+L]GHV47@/0 M_QU5\"#?

ZQ)>X!#H24%RU[:@UIT,:KK^QB.3VM*2)7J'NX;C,:YV6\$2I J5L M3,00@>;K!6!Y\^SC!:"\| | (@J<0H:/([YG*B!>(BG:,MPYET4-[R/'Z) 9A/^G.3N\$KA<;>7J|+/2'M/EYR=W/9|T%,>,:! ;8.+*PR@BGVS9'<M926R?]+Z?*_VK_: W:-;P5X@R U%,!,T,(E5N7+#!]P<.,/=| PC+=YU;ML MOR<|MQ%'=+! (TONVP1XTB;@SY\$K@4+,G'>XV'!>;-!)VV&Z/G>]EE/-VH?# M(U;L:LJ7.8!,0#|0*J789-- X|NWOKL/N|C'='OH.-Z5WV|UWQHI;D|})(X%4\ MIDWAIH6A:9JE';*PET)6-GT-88#*8>|VV08.K-Y8+L V? P%X,-B^;#"B/Q4 MLJN:%3)<6/G!\$RN3#V,'&>@E-NG6971T/RKNUQ>E3F#/_V|Y,'IBJ#Q+D/F M|^<89H%%CNF)|]?*#\$+I>+=RM)|78=\$OV!%WE01M WAA'N33SL\|ICRKR,6XS M= #:|V6,4/5\, _^? @QLOPE'C3\$5=JC:|'|>F^B_MECB8\$?JZ;KM_+!) S9_[G MLIFW70GF\S?*DY>U5>- SNYLCAUH\|5ZE,6Q,6*)V<6FE@(+%G:#UU/%8|13 M8N\$CA.EKT@*QN:/)NOC=><2CY9>-9I-OH-R|GRLUE/C>&UUCR+@ 2 X%];S> M?T'KY%NL=3CI3U0Q8"E@Y1-7WBP:|J\Z&UBK!'VY +0|W|^EJ\PY?%QY;<' MULN"\$R)";C&3+H'2TZTQTBNFQ0L_GFCK1X2\$&S8A:NT|M./CF^LV0"H!.*78 2LE@P|C7 5\$)|K> M=Q'- 00R:BV\|2|'L\|OX/SEN<|30+I0&80 :V/+Y?TYK2"(01>0)CBXU2^) MA_>?N &\$&I4VI>:|.Q(VWB/& <7XT@2?|Z;F M\@W&2AY=%M|50IS5WBQ%QV1|*L W!5B9%82N1'6!."4KUP'=G4GNHFFDT\$,ND M_P=K.,\47TR;7U4?+-+@H=Z; K:S9@=1?A X*|I/E2I1STLN|WN2L|/Q9G01ZULY#=5)>X#;H^N*>SDV3;D| J'|@U9+8/> M.EKXPH7|8DW %U#|T5WQ\< 904Y=D.Y5:2Z@7VQ-&T=694>P=7751Z5"6:V, M ?X;=?PLL%D%Z7 !X4#GN!|F7@ .J504ZJ/) M/+1EBA9BS7*U"2\$SIKRF&,4*U6EE6@V"05IPNKQ07%7WHZ'QW5A) +B 9NY& MZ%:TI"+/Z6J^S\>MUU&/ -V710"%M5VDM4JVON^Y9U*F(|QEHJ+D|*GB5I MFAYUH /YU,@Y@A.NN"63;%BAR?N8WNOK9:QI>ZGUE=>.,+H96W%|T5V\&V ML>X>PY6%8#5)ANG7%F7,[V\8L|6P? U,5WU|B#BTTG9 7DT:,'I?F'1XN6C MEG%XNK6=7:0L3'R 1V=[6|N M+|5,E:PM,3|NKY|6"#4LD\W7/7QC,B3*P<<7GU(C8YY&|18453J477JFD\$W MSB5>UJR\$SK;>2C+Q->]>IX#\$W!B22@< PRU^)&G3@V| MHS2\$+K'944ITFAK\$|905%UC54HG%&P;ES@AD^PF.^|V'M95?;1Y|*\$EES= MNJF,S 0F /O Y(OWRU +IUU|9L&\%)TG D6VV" KI+ C@|+ON|0B4;J;2#Q MUAHXMM CER,\C(0\$)H2W5=HC>U/!|A:I^3HRE\$90JHZ\$A==>[0L I3\$?C^&Z MM-Z*ZZJ>.L(C3J*+E/1U% Q8^L UQ;(QX:J*ZAP*ZRH:8"=Z,RK%*W.00WC MB,9VT\$U/3RM90P5Z6HMOWRGTX? @X;_2DD^,45*9\$IT1'!56QU|N)8Z8.+@LI MW"IN;K=(\$=:;MCY*P'H=)8|K0L*|K+>S;-E &.:;J12*9D8("3)E),=AA6ZRS M|)Z#Z96/LV;6W<*7;P'FEFBNK|G@3WFCG-C.%/9I93 MEI/7<'SL)X&Z -1'"? H@.0T)1YX6Y&D>0ZT&SI\Z@P-#DHO_Z3!@S.&C(; M,*!%=&0J5V470A "'S MX_YVE(4Q0^? +M0)I03|Y,N0T:0|'3BW598)A0\(#G +U!'76*#UQ < M8J9HK0=E2_WNTS,_N !4ZH0@%A\J_Z;S-.G^FQHG>I@7%AUT^A'1FE9Z:*L36R7N!/WJ? ;0:QL\5|8.YQ\$ MUL)ND%V178+/: (6%\I>0?NVD;/)!L:NANS5A@>A\$57 M_/|^"S(FI|:VV^UK|Z8M,RJS?#@0H*B"JG P-3@01VC M\$|DMLG":*10-GXI?EL7:=1?|1Y=#NKZ@'N-'YDCV3F>A%/N;YXAM16|KQU MCS;L*"UH;V^:-5+VP2D#.%L@|X%>X2J^QCY1V\$RXVV M^AC^!LF|J0UP|,). |{277/#=+0!9(5&Z:M^MC/DY:_OUW,#D1 |VZVG,8546F423P' W4U*35/<=T29"T:#, M|\BUIL10)9|? |*,H>WPG+NPI/F2>|L=0_!|S^R=|BVJ|JY0?6&ANEN^HFK-! MQ^24<;+/\^XY=NB)!#4,S62N*M0Q:=GE06C@|(-96>|7J#^Y%C3\$5@U K: M;QW/>KAGKL5DV- CIIU|V,RS"AT024-+HPTH:5E T+G;/M^M'J-0A"CS|4HF\3-+"|K0@JHWOHMS=N|S|VX-*-/|1XW@5WL3(2!YGC|OV MD)-1N#R-#ET<,7 M)-*^S7C;-F,DCET@NO|ZK>7Z7\ |6QU.IR^KK8|6'>J\$,P4D+PK(MCRZ51RC M<2@WLD>GH=*PM_2#?2?AESS?8\$%,-K>;M, @?,%?>Z?P0>M*K! (*EM.(AT& M*V/^ZVX:.*M+^P8,X1 YMU"J4-R(0>GV8)"L9GEI1J> M<)%EM(7J?&? #%Y7%M+S*9S#^GK/\|UTD_XLV+TWAL|3XV&WV(?M(:*I|:NYZ M,=Q^(0+02H7IYS_%|UT-I,FN>.Z:8^(4^- |J4BX^LJH7I&|8S%2-?F=L7F6. M50/8SB)|LM|%-&T6+@ 3-R\ QD,I\$X,++7PKCT>QJ#+F M0Z6MWM/YJ*Q(^S0SE)X' 0YYH:56TRSLJCTA@2A8/6:| "C|. &"V6>(4%0 =7DH|X>/OA|4N7 MCH6:FI9N? P+H7,T#J.QF6|T' TQ4]=0JEF;S ADN++Q;>7&U.|%J0F%HR> M|/AR=RZ=&17MZ42E)@?!GLZC*>U|T4RNI M|WS(|WP"^\GW4%)P0\$|!.XP;#&!. -DS(L3|>S9T?,!(R|]>U&!=FUA%3'2(M M0+40'4;OV*C*2\U^0>Z)"8;- '_Z+2W\<;;%MI/G! -2EYJ7'U74=J=-/B, M 184JA/MP2JU<4\8K*TP 3C'L(C0>|F=- E|+9K0P8Z0_*+ N5#C|+|+8VC| M\$6CHL+.%H|N^7=S:F,8@3" 1G3()& <34;@Z#TKU!BYA0F\$6I;P9\:+QE+\$9Z4DA0B#^V@.%W+%'&5?@>'U)&M!78J(:|5,7.>S>'|ME=F MLDWZP?:\ \$86R;XD7@)JUW\$ 6&\.)7%#%/OVU5LHV_Y*4.9&%DN#9,XL,W3> MRW'6*0;\$-_%>?U? SR=Z%QP7WW=BFYA?CC08)0|UV*,2@|A0<#RMB;OP\$|>;NH M3?V^1+|(E7%I0VA6NF)MI,MR|RG7I>VG5\ |.7I;>R;H_AK/TZY-!PVY6 MK\$=CM';M,M\$71\$I766W/JFF|GONGH)M"3C&JZ!P0(>S03?#M\$9L?6+S= MY M(- ;;?1S.-6CLJ&Z#NHE_.'5ZFURX@9>="6 8B/3K.IW /2>JY;53\$|TZGH M(Z8|SEL0!SQV#@;6"4U5RTL74\$WH-,U.0&P\$ AY,QU7YI_M S|UGX_ 4,C|Y MUP="7KQ8I.<|'|)U\$0Q29",5 @'P-E'N\$MUVK+NND.NC:~# MDF/XCWP30D(7A0F^ZE^:T9|?FUN-'@6&|2C@0:VI!-\7%Y._'W++>) _GEHE M5KR=_%NM|J|T'S&B=|9=YGA%#6R,>6;N ,Y;*02D;L'8ECR2=0\,DVR!W'@8\$GE)/B? KX;=E\$0@TW+,A3;RKA|5#G|)KWV(H,I:++<,P??=Y|-(RF M'KH?F|A!|"G+,9^!|#D|*I1 C;9L_|3X+)>2.QKY,X0K0#3PJZ\$5-#*4^*J. MS_214=+3/MZ\I0- Y>0IK|\V%1W'8HW:~&&/U6R\TVIPNA\; \C%|0 #A0LL0A0>IW154+Y?#1JL M(Z5%0JA|P\;:&&X_ QDMJ JP;41Y!|DP|,R\$E M7/S,&05G0R1&"&:CZ>5XD|; .86- UQ83)W37J;IQK?.2WG4GC:B/T-*9\0L < M-EB!?\U28DC\5C>9"55;D5)7<8TQ>NM4VJHIT*ZB&UVHL3^IU9L9 M.2_W)?5DBD6N|_EY'*UK41 =M)"Y9Z*,B_ #0>P3W5D@U_:@=L%7ASM'UH M>A UP")A7*1T/?P70VZ- 41|7'-'@1D3Y7R.NZJJ4U0 M#F2!;)3=CSE697'^M0JIFN?7F@S9\ ?+ICETA"\PMK*X^,S&#"UR94'V* 4\ M Y= H(H0U?W%(!5R)=Q(Q_2EST/QR,.?#I#%VYX&D!L,(\%FWX8MM0.7\$JIG MMCP,04F=9VK>"0(FIF&-WE';DL6 /56T0#T0RS2+ZV@KH\)?DX54=P0|P?'M M*%]-#7/-FEUZ3|f8|VX.\|)-CC:;-|+\$@77Z2#H_T3I7RL#>ID<@L? H"\$+KA MZ0X2F =&@('1!|(90KU>@1,8Q;?TFLM?G\$63EJ*MTP.AG_|')R-N?WZXS|_H M+= (P@|84+GM/) &1(Z26XS&K%&>;4*MZ#:0W F&WS+2W%*L8WM.\Q1^F6?E C M|Y\$-ZP|*%#4)8,6?S4- HH+AU(?^IA@K%Y-L8X:N10KV *|+L|C_)(6"W\Z? M-XI\$BSYG5*+|)(PJ2%GD'/;+5:XHW'2..*R_!=,+\C M(^;TY_?;XB|Y()78H!'(Z?*/'JCXGR?+@#^(EEX M'G<@M9R=-;:LJ:A?)4HHVLP\$')L6./<:

[J%R@T#NNY*D(+9A;"06(E9*F*DZ M0^S;&KJN#<^ '1KU,/NY!X;LHCM9&^D69B\M81>GIF?
4\$2W%WNUG(N85Q7SW MY3YK_7(\Y/2>\[S<:-,*NE^+0WQ*;;(^VDV4?!E\ _K5W[19+C_9W02_\$BYO
MG4=5\'\$6#\QT]Y163;N+M+^T"6GS-Y9T4BYRJ?=/6/?/,M".W.>#3[WTS.% MA.1TNW];>_3F[?
08;XY1#Z9)6>[D1WG?(03\K<[U:?'P']\S4I6L)76:CX;<\ MK9REIVMN'/_-5>85EV:&,EMK-
ZPWX,U61YPYJ"FJ32_[SQ^B_05_ ;I5:@X_M_YY:D]&3#77YJRZ6LOBV^0M
V' 'Y."0M*JU==V6F5^A/I.\]_E^W%[^Y;90. M.,)KY]&1U2_%UM!VPJTH.[DF#0;[\$%((+=7V.2C.M
F)@10714TX."FT*0&W_M=<6W=B4<^?SK#1(: (D.V(PK#EN0P3C3;+^ ?W2= MT^*G3#?A'\$*K]^3J_Y,-
UC*02+X1((1/6^1VGZ6>]G:9KTV<.,=,=\AHXB!K_M_4?XRYN_!3\IG[U9_*IU>F(LI/ZJ1G&A@(-Z)VI_IYFT-
#;6>TL3BB;Z#R0R=1; M:>[-%R?WFL-<+S^..^-]U=U09LSX3>X_VGT].D:+\2N+K2*PY]B[4-S:\$0;X_M+JHK3-
-6)(?Q;L0MS\UHE^/B<<5Y,!Y*I/XTOY^?NWYSQ:C:AS6RG&/GMIFS_M7&98;5&5X648\ -
MY].3;CVV<=>0LKC,_C?0*?N-[P'W]Y_2SOT[;EN[WT=X7/ MPF26(P.G\$5:'9Y)>ZT75UL_A+A]"
[!.'7NX)'_ZJIOZ%-Y#,S6-L&DJR*=-MXC+.%Q=!\9S6S\$*=-^A9/V8W":'=\$[C4CJ454TJ]?J\$>E6--
D^/J08YC+#[]'#['5: M7LJSCT\0^7NOR8#J[8@4_P?H.S.;2;.!QH7>];99/6X+@2.;:'[.VM11G6+
M\$5\$1XE**ICAT'/:JZ?;#J=L%FH=775B!.7TYLM9UQW*4T-/AOH%PH2*,3J_MW_HM[CG1X).KJ0\$:
I0S'@\$+1NR_M,W*#73S5Q0JZABSW,5J.AU).\$75'"0MQ89;\82V@I.IDW>M+C1+>G,FN\9-A_M%'N%2W?[(U?
2VBQI2)LE3,:Y_N<99*S*/\SU9-:N;V;\&'7<4S_8F-R"HAD@_MKXE?X+P_8N2V" ML(5W-)K1V'+B,=Y2ZF
M940F6LE%-=%H-) \S(&SVN%)=]K1YX>1<+:4<8Z.#\$#K8SB=.08\$"\$9#,(H3VRNFEE512VR,#&Q?F59C-<\$Q-
N#T!)>EY7I/_M>^E+V-/ TP\$*TW?V]&<-:,HC8"AU\$X+;<_MZ,T%H%_>5X^CP)
[JW7G571#A%=-CY.VJL="ITT6D[Y3"E?[MPQA-P]@. !V(N_M=>B&DXS2RH-?[,P_9"C?&UIFD:VE_L-
VW#69!=DU:R@Y@WH\IQL1P0UIL:@QCIV)K- MZZ3V#)PU\ /PB>)_G\26%R7#"IAMHR/T"0.OMIUD]K,!K-
V@2&K.,L7^Z]=<8ZYWOL_[MS.>=<\VU]\$(+14/3KRTTCZEBP^R_U15?E6_&IWUV7:B+S">/_VXH,YZ,2F1
M@UM1PGFPT]2']\QJF@V5_&CL9""^:2]F/6H#=. @^',;@P92NT37)ZTEY_OG_M,['21CJ<7-Y;V^6&26L(J)!?
S)\EK@8[KV<%0D:\$JN,G%K_L"]J%+]"9_*G_M\$5+,_/UM_J2(8-
4JH0/P6+6)AWW!%;3K*1MW_QNZZUGC85M*?IB!<.6'1>U_M0-J:({;=?
^E^&QH+!/CAK.EL/1N2=UI<8@JWV#WPK, M6RB'\. !GD"DBE6Q: , ,9IYV;.Z2=UL9#[1Z2A-> ,=ND&F\-'!?'
IB\8KA38_M\$[#FL>SITFBHG@ZW25^7WD_- "3H8=&P;+UL4%V&K%(D)Z);[{]^/^3U3R_M,:-!%-
\$A!^QVM6K;R"]+:Z53V+P5;0D/CLAP[;]QY>LU%?F+':0-HJZR, M(RG1>^8&6F,>34*5
M.9_>4E\,TA+,*+6_Y)TDQ!XJ-VBF:09(T%*W*;EVT,C%-4F*W+LP[FG&]JQW_MM=)K%Y0XJ?LM-?_3?K
G0.K9Y_\8-M_T>/FKU'5Q@A/\$:#UDQ_M5FP\T&(:K2[*&!#5"Z"R8^4K?
>PMPQR2>IH=14:L:}S2HV8PY]!.^(&.!2A_M<= 5[^P+TF"TT#)*W-!4AY\#0LQKB&IUY6=[2*24\X/"
MY5T>B>-60F9"59!0=;^!1.=D%X9#3W-F(M+ V-XQW9:02F#;:>Q%UE3:UPL8>"PWU0#)2KY_M^\$;=(0"7&6VN_M
'G,Q?C2!3WL^E+&7")CD()\$ \$L?W#@[3[[]0VT:\$+PJC_!(\4*\$;^YHVCX@Q./?_ICH59S=,/Z<>V_MVAZ>Z6M-
0SL,!P4[JO08V!34;:#1:>187NI2X,:.HR*ZR15-FD)6&089P0KL'DKD/VO=#M9=%5P0:[I]KP"/!78J
M@VFWHQ5IZF.8.HZ%(_20_F*'\2AG:UD@7Q+LDM^!10#[5X*.X/[?%P7!7VS_M>%M\$H>Z6T0=
[MA0,X7/..8.:?:_M4?=H_X7)\$%C+830C?SX+U00J@[R=+D2<[0C<]LE@?^>68^8B5*+
[!]MX4W*2T"A[E3K\$]Y>]8[N&Q/+GSR8*B+I38)AHXH"%];_MX-?2GFT(N;J\XSK_>+E1H^J/_Q"VN*5-P0='-
WXH-#U.*'-_03'<84?S?K_M="J0C<@QNN(<45X2?QH^W[9Y4*S+W9QG@MQY'A)56R455VBP\E+/ZXTQ7W@
M*5R.T+5[H,[GM%JQXV^:0A#V60ZU0#B?1X>P_MZU1@1=UJ5>87RT/WY1C-;G/DE\2.<[\\$()_"[UY+GR3^17^-
Q!K\)>J+_0B_MBS0.+CBY30PGE*1)+^WMLB]17E4Y;BU4>%7]2;0Q8G@Q]0S]Q^=4.0"!;-/_M^FG0>K-
_RR,\L%8VAN6"QT2KON'",GE;+/>Y30X7K([CT_MW5W'+!H#9AWSBC(0)WR&!]!+V=-?4IH80Y-
W#MOD#US;#3%!.#_9HIX+E,06_MA;M85A";DB<[2?=Z'F@F[IXJG7_V6M-08IU8R(ZC&-^F)W=]!FB/U=_97W_M
,^E]G?6F5!N9&R60>_4%>3;5JN&2-&0+;8G#CA0F0>U5!3-S0"1:Z@YE1%-
M9DSCM^@'7SVD CJH\,BF*]NTEJKB+J]A3MF:A[DN&2(/+/TY%-?
32F@/P120HE^JF58,13\$!BRK0Z]??)@FR968K+UUZ1_M3;*1R')+!W0:KTV<\$90\$EW,\>0\0)}'269T>+C+5C8B
/_=D?&93):_M;CIU013-X3]1\$5JUIPT<7\E\WOFM@\@S:XL\D\OS'X-MDX6F9F&=TD,=-9EG>B.:?-5JX_%,5<
A^6S(B.I'GU=8ZW+-+0)+>C(QX>@_MXWNA*K12I*'A\$6TYC[+X/3FB;H6: !UICY:#M(M:2/93T4\$?
8Q089PP7HB9E;_MS3ZSE7MC^0EZ"R@9=@5(1&BZ_OP<_JL#C5NB1HF/\6Z06A+V.C7"!_T\$6GIV
MR43"/R^S^DOUM9U59_E7MMXE"8^#KKIU>0D)(EB0.]2'7("G=G&[T&^6)6_M("FDS/8^I=Y0U\G-
U9+90Q=D]"4>0_O&-EJZ]Z>&7@XI\\$&"G108\!9==6RT_MY^P28[>8?&AT5MIUUDV"R>\\$@C%#]R%[6Q(07&
[59BI7@XZ\$M^AV]]YX%N_M715<1HE+A')\]' +R/X'!>0!*OP\$P1*A3#Z+8@?*)?T0Y
MDWMM!QIEB!\=10T<;E-?T_4!%VJT65YIW?@9\Q!Q[2_06FE-,0C[K@%GF)
M[\$GC()]H1/@H3I4B*5[G0;ZUA"*N_SN;I%0, M\$55J&'>IE1?22C9*Z)GLFY[K*;C#LK/;
(PI0X=LDMU"0F1+;W!': '=T:))YE_M%[D7S@3-DMZ-7,G%QF\6[%?A=AK<9[=-)S'EJ0"\$2>P?
#Y/E'V_4\0:Q\$[#3_5L_M+09L,&A[7\$X/>]JY(/:,R>%U+&Z1+E9KG_'C9H,:>P_S]V@P,[Y7:2)0_.A2
MD\$]V>0%"I(_L&;-UX=PN%YK^M-S8Y',_D0.SL@*'VF(;@4+Y7_8,271J1"%2_M9
MV=HL\$TV07SF>!8H=R:8M!Y:*FA!<.D9+0DKXFZZI;JB/'4,6!XK5AK0ZM_MM_U?
R!KJ^;L]M*?'JU;\;'93:3>Z9"K%G.FV9^'\6?T[CT\$-G4.G7[_R^_Q
MM0.22\30/+S/_HN:GP=>914+WJT9;*YS@'^4%U])7^JIUX!@.R5>YC;_ME8I._7K\
(%8+UNUFI<[;L;=/:39\6<@'A;USIAT/-M-JM^D9+^#!(1S370G:_MNS-RB>.I?]/CD^A?1'[*"0^4<2G\p?K-
AQ:[RV[2JR[Z3@/)FM945!HR@_MB1U.1Q>MC+0FY%\SWMA6S2\$5GTCCZK-(RET-YQCP7-+6'?Q9&-
^!V2)GUE>BVF8'5%UG3#0_*L0Q::]U6Q&EY]M@50VI(&K9A;LZ>T_MI;D^*:QW(N<(0TF5SK&#%UIF_BU7@/8?
4)?AE54-18/1F_EX:&/_3I2KK4S_M6"RQ0>4I^AEN8#)"L"YX_>K1U"/',G>G=.[!4&7]0ZM,)
_D]'B&UL9T3J^7%VFQ9P\B!/_SRQ/G_M+JM+T)ALM\$1/A%V6?#S0*N@7-.002ZPU_#>BDQ2L&\
[M*S6;2W*0%DE<[4__FOL7DRNZ9;"DX/H\$20G&[P6/(\^Z:KK/(_W
M=R<1C=#KCL8MK!\$6\$3JF,&Z;1[C?"5)D=,"<%PZNPDB-J&YK"H+LLEE.FMD8_MU8&CB;-
Z_*;Y0<:]]6VVX_%AW]*E7J5ENIK&)0,'(QISLQ-LF?\$.GRWX37._MW>K1?E;4?SAEX\[/Q/'"+4FT=
[8FM5*'.*P_EQ,V0.#)Z_M5._B2HBKH?WT*Y19J=UR,?WCH1W79%DWMK5C&/YNR20_-\$C<>_0+D%R/\$(?.(K)&

(=AEE,,TKU#& M2?KE;E; ?N!L,]^T%^-C07:--W\$U[\>[0<3{0??^E))RBU]02[(RX/H NFQ MNN,M\U> VY?
563Z[^\0U1BL=#LHKW3.1\$ H%T'K=<'JEA9.,1%]SOZU:&:Z, M-
JLB/B/A4#;U46"4J,B;SQ5P<^K*S2< !TPV;LK1B4I9PJB^31WGV;B!I:/S! MV90;[F"!SXTJ4/%93SQ-\$W?
CPW0*U)!A%1P7CY?2F?(\FNA(C>I MY (8IU;9Y&5',)2W'(F\#6-[XIJ*, "T;KC27!5!A3Z TF=H0K\QZ
9@_N;3 M^!M[EDAAHN_%H^:C;; "D<*R?^D2>L3LH:0+,%]2(0AVUP'^V2(1L;;>?STE8 MQ,PE&
K^2=S0R=MANQW6---#7QRE#[N",DN<7XA1(E#LY,!1^UP^: K;
M;3ZHW\5<(@T]CM&#D57<)46\6_A3N5'NOU+Z4U^G?JU9SH>B60/797/FFHL9 MKP(IE,Y#Q?
P@]UR9,YDA+AH)VAKJ/5.(C7VP(JXP.00(M@-X[2XD;>!)3H"]7]ZW4\Q\H*H&DW0EL 2?+?"
\$'43HX2DNV/+_00TN'3< M:63P-S0M<&:>.))(Y'0*BW M-5.I,6/UU,BA=[F?I\?
7MR49@9H7F^K_LYN79I.G\GC+\$E?%;6: .6A@*.) [2 M463K\$A-'C+;P0EKHFX\N2XPG\3X64?
U2A=0JEC^0K; !RW=06'0PJ:\3;%X\$ M/[:F=2[J]FEAK4LD#[:K0:],?^U[1D]D5S?(O>CWRKY6W'C0I2'Z_L>
(GB2: MN9%H IQ4263.6];X'2?&)63X4(3U"Z"@E<)<G5PRMA&Y]JR'3.3KP+ W5_91 M.?
9,*U#392<=E8,T4S9Z".*XK M A^;E\00N=-;YA>0WD6>7(8@7Y]" MY+V"B\-" AB194/&.GS/BP0\$R:??,&
<'5>F/TNLLN] MF\(\C:WSC4C5>. \F#8C%'*Z?006&06;\[UML QDD6; MCZ5K9,@-0QDA"9?)'A5X.U*1+/
"9%0]0:NAX8D;:*5SNM05,0'Q+^*0S+, MH-/-)H/F03(\@XL.C
[PV6LZ+G\$C4.=LI9*W1/D6*7L6SN8B[XE00;91N34Y MN.C>XYF:VL#D'!'IK]YS'QC,+7M44[, 'XXT-
4DG/G[/0SU#1A7]7,;FU73-\ M2\$F04> @TR'CGXNRQ+[U]'I];&MG*P5\$0C51=32GID?/F(2Y MN0!FPQ?6-?
8R() (6Q=0R6Y[85J^+)N+Z?^'Y('P[]'87'CS"\$(NV1;GIX, M-8^2'E<=, [&]BL;&UKE8IW?
US@DEVD6BG[]SL_BIC5,D.QG96T[\T)W?GR8N MHV/R(1,+XK;10^18(D)#9R-SL-NF==C6& 4>ZP'Z"X[T!
(V15Z2LFEP KQ," M:-IKZ);CN4)S4/G,S)E,\$K:[:P%41U2ZR% T('W.*Z_8Y0\H):@,+.NY5;/5
MV(("SD^Z)*CQ=GV@6&XCJ9"R]]Z\^D*1G7Y;NKT)IS\M-])6DV6P%J/T6<=8M
M8LZR+SL^)\&3[#D_@6%8/AU8(?,&5C"UN*UFDNE);4I)ZY ^+ B 2&EKVBL
MX%*MAV\$5BN5,0\$M#U.:.6#D5/)\R>\ S25=6DF2;]/5A[]]3]"N(=/,>\$ZP0'
M^ '0"U@"\$Z0'5P"09%*Q,+I?42- RVS<@GN_N49^G7ES\$NKLK3+A MV,0W5F\$Y&\$CCRRIF.Z0\$+Z\V&2^PXX-
M8I[R0?1\N.ET<6_N^=!L!;-CK6(P M&[041K]HU1V);^R0TXDJWZK^/OF=3'?&R\$8>1;-;2=#G5,
[="1FFJ:T8KYZ M'LIG&GH/;>CW.9<:;U0/^1UDH16@]#:=6/N2+G\K9\$R*=C0K;JDE0E=L+^U
MQ3063:/J7D@(:DV&WE==2LZ&:"ELC7"]5R"> 8P74B5L?GS/A#;:"1H"U0> M/S8E@\$8H%Z%SURWT[N09==
*!0HRNQ<*6[YT5>]_(\6L?+^XV4F6-ZW\8(H M;Z9TZ?33C# 'H?*00\$/PEPTRW3+VX.E G_N526*KU
ERR0]5@B"@L.1,8@-TZ M>,U/%CQ20_WACB..&1&N\PN88VM:V+C^NS^5Q@M0S)JFCM3ZI3PW\$UD#D+@
MK\$)QH/849@ELXJPI#5![T@A1^TX6"FFNF67-0M)4^RV5N3W\$^Z"0714+PI*/QX@6L;]3GS.)E2=,P0IWX#+<
M!@:#3UX'?CRKX1 7SRKH"0CR&+70]_ZB07Q,JJG@T7M\Q.9T[XGD-8%&-?5 MY,W@0S7KQZJ6#G?V:-
]6[]6/B:; 0:^Z" I4 !IG/'Z109MDL
M[WIG6&K2*>4IIS_W"RYZ6GD^V\>725IEWM%:0Y'<]!YP59A,4\VN0S.^7*S
M4(^F*3B8\$D+73=5CT'07\^UTFWK['20UOM60. 8*H(3-EDQ)7?ZQ#RZ: ^\$W
M>L\&3IGFLU0;F\$V0T4'T;^6E@T\$2";^V6X,S'6(#7^"N0UB6[T^ (M731J:F['R N<
MI!57V#H:/TGLR/LPZX%,0];+8MG*.*'LKL80')J/>67P==?YZI6[FV_]KA1X
M3A)F8D_RU8^TH;>\$0(KM[V]0/FG :\$8!1=4G*\L7R.0ENF[PS[3"41_!U[M35[+?;@HLN![0P
GIH"K9G3;C"08& T^W0"UY;507HV/J-/0%K;HV2W*-X>+ M:+:@0/D)]WJ("F8FT>!LP.E]V.VP[]>
3A9,0SG_T+0;B C5X@<[JC.,[18 M8#=#IQT>C\$-\$G[8!@FFF3<970SFHWKD];IQ<<0:\$NR4-)0R
7K2(Y&\V(E]E M>3],(OK?C M2V6Q&\$:U6'=- 0\;-;0SL)^I0I5*J/8 =AGXVDC-EY%F%NJ/BF:RQ?:0=9\ -87
MC-THY>:"B<+X7&<6E##HP;RV0 607RS^N29CR%/[>&H;>VE>S^?,Q\H0\HN M6P!VC8@9PTR%ES?
19##L6_YJ'/7VF0!7VL*>GSY[!(+0<[VR?Y-F9NH 2KA= MXJ48E\D.FVAZ<@6X@ SX! !L;MG0GRS< C
M=4[/Z%S(< FZ_ \^/D-+ ML043(L\$[,1I[[:28J1[KA]Q5\$-^EQ_Y6Z5W?UW#,Q?&0MZ=K24 J0;'!;/D4
M).5G* HF6"C2^@Z,#Z2>KGI9LM3X;3S>].LU2.*:\GJ)RSF)68#:%4]\$SJU
M<;ROV3H(U\$X90 ,]R@#40[XB.Y0)[TCNR"19Y0I T,%=(.\$L5_2! MI0I;61;26;>7&C\GRSE&]X[[]=H_5JBJ-
I02-I=GT'C]YD&](L>-^\$#-Q BZ(M:1N>0_ 'C#W_9PERQC5WF)U472I: ! M@MCCHE""YM+V
*/5KRF"LD1#WIS9K! /FCR@=6Z;R@WG9?MC#ME'!'4%3@.C1 MZD. GO) V? \9,V+R-*0%
[D5'2]'*]/3[1P#71\U76(>UCP&J+>1?ARP*MX3 MP#3'\$^Y@U'/B->0\N.WMV6[<]P^1U>4*<&I80F-GK4F0
!00TJX -^&*!->? MP4P\$J^%>)XSV\$'JAP5'D_YR8J>)C>9AIH,OK7R7L3GYSK3UE#WY4N]40*T
M\$,*WA.Z,NIN^(/R=(;3,G3G@ZX_9S\X*;YY!SP]) [D4I0#^JU0?);CC8Y994%,8L*G,*\ U("PB=)?NLA!+
M]47D2;<6'X7&HZ7[WMM9)QXE>DI^-8,]RW:AT5YKWS(2+."7KD-U_')>5N(ML.Z8Y#([0P
W(@*UL,JLUKJ@ZZ'(.%8503"ZN+Y%)! .FVRBQ&R7#5%0+@^: M1D/MG4P]+U*,?TMFLZ^/FQ0']
[;6>@]U"\AL=Q.Y\$0MQL=^;:J.JJYZ2WHP\ MB=>Y)SS'80G*6<'5K\$PT(=S&8)9?03"+0;.K0/[1.-
EV!1B:P\$? B^:VBRNAVKB>'U"1Y[0BT7002WSIGR.')7EU?DI7 MAC3?%=^T9100T-
#L612)3L+L/=13=M7]9T:S@XSVZXXWL52BG\$09@_0Q/9 * M3M*;G([3; XSG[-*!BB3'C1@>K8V!^
A7KD5X6FM]C9YYDZ88Q4>;HS] T M_MNKT1/EN+G9URJJA6&=>27T]JE6&,OK?) -3EC9UUC)L\$"! ,C2\$0#
(-)IG.0 MWU[NT4@?_PEB^HU=IA&ZHWKHMx<\$KD;.9\$Z!,M0T;DD[YIZQ<2IGDQC\$B'\E M"MQ<@40X%D;:R_?
>T(>.)DPF(=\$I#]F^#++EDC(**T\WY.MXWB0G"P8(,6F%DI37Y+GFQ\$@G1,D?HR_1^B;Z[C#^*:G M[]WU^F%?
D&N+VH(IHX*95>5HT&DR?34F)5\1U=@+X(:Z+"CI(-'AKV+;\$+7NG53?9V=(FGC'6J7S_^- (03UI@Z"
<>'@;"MJOBATFE\ ML%_XXE0RJ4[V2R?%\$UCF#>G^29@GW<'> \K\$VJ?WKRFKO>\$+WD\$"VR-@E7%
MLMQW.QX*R^0>;I+\${(ITOM9ZL7>AY@Y>4?5B=S)FW&2_UK1*5FVY):<7=+
M&X4/[WXP]2E(7([KBJ.&F/0H/@CD<%AJD"-?:IS=AHB!9IW0>I,YU?'+B%39 M@A]V)RH^@5\Q]@Q"
T^UNYML6 @^=24Z:A#F!GEC," A9Z\./M%0#E M/4+L.<]L=[97_S^_M:V:E;EM;7-:M+\
[B_IIL(]+HJ3^CC!3@J*,Q["/0XJ,CHF5Y@U MKJ]_U1PB6Z;Y&<63->,E^^?.FVKR2K=@)3?U)>30^5!
(H:P&&L5+@]4W*UO M!@MM*C(T48*JG**?9ET[:<[:>W!78&-8;./=@C#; F@71V\C^]C" **&/< M*
E1<1^ \G>3@ \ '<<&@Z<"R]1RBL]Z\6D58-\NU77\=LJ^/@E\$,M]1TF0;Q&P
M<-4U.H:@]C=KC^XQ;6.Y7&#-6\$D%]:4=-22C@R;_ [X/?_ M6A,=C!L\@%>EP7W^\$*8WT_T--0X0J9#RRP!C+4J-

3-S4'VZ VKF;SQ,CZ"-6 MXS /Z -)J,-F*-\$L;05]- (W_2^!U4Q0RM3_QSDEV"!4C1F52=L_GZF)#GAY\$
M[Y76;?8KP(S)B*K-I8=S777Y-,17 S^+OK(G9A^J=FWE)*;5EIXGMF2*5)
M40"8.45>52!//5!B=%E/PC\ LZ7(@K)2>00\$>CI'F4-99EC7,;#Y9KN0\!<^
M[X;TY+=PE1W+0;05BK6ZGZ@S7K72. [FK\UX-%Z4>;K<7/?2I7Z> YV:R<#C
MN(9&:9HY\WGE(!#Y' (6^0BW*NWT^B(4E+! .*YSV1G?KXJ;BB HEF\\$/\%V
M+9"UCG,DZL2DK078WXYZ/'I' (V0V?59+<;#*^)%LC,+E"YXLGD> MOJRS L*-S= #798C;[JM,<]?
>L. U+H'YU:2)0[6_4030ZC59;!R/S0-3@@(M7%!%GMDBNU%E>"',K9Q;K24ZN/'I"U.NB-
;:=]ZP+00/'\4BW>.N"PG\$YH: M[/K?_1+/HG\$6V;1B@V-UNC@4J.)T1HN(LU.P/M0<6FSW),H-ON_TQ.DI68,>
M,ED-F9(^*?S;@7-*8G#6:0P[-1 DC6H+^E(.5%-@R"[M(K^B%];5+-0@2<^ M9V;'@>?
TFH=0]E3J#;,:)Z\RXC\^+KJTR 'LL?NG[(IC!APZK)YBDXY;"FCF
MR]T547(\#I4ZA=9HC=&N,H[JSZ'2EC\LEA#@07]C/@+\YT[HA*:JO"NZO- MB:U:ID'4RH'2&)W'^-
YEA[X&*00K8*CO8#>G6HF=J6\N!088;10C+=90;UX MIX[+;(3HS<60^<;^>D\$X65N%N,&RC>61?VCURZIOF8<-
^6H M[4&V"AF3 E[L)Z@)A^ YS.P?Q"6">":.7'0>UIC9?E PRXU=G1X49PQ& MEOSNR248IKGM5UFQY
6N>/BD)%0-]-/;T[^(ML[?>;\$^Q=YF#;E=7TLX-!%E#*K"J^J;(9'\$:000%NDI1INO;+;M[8ZWN+*
M9S[<+A1WDGJ>=3%E:;')5'T,IB6(XB0[+ 40K&'C8IU+#+4J%>(KFD'N5)>9 MEK(C2.]>)^W&]EF X3-
^GE&'QB<9F;+6,[[@U;J]Z<8R*Q^W'KNEC*-B;) M24KJK6038WBJT;?S ^"0>1'&
[PEFYBKL"6W5LK\HM#WX^@6:(%[-+(:CBDM< MDP3EI:@JZCZG;'SD1;+>
(J?)3@=P^705BE0JV[&^>NX+^S#ZDV0ZT[M4/[PL MYRA S<):3*9
ISNDT[],>A50>E\J/#;WORN597XFJX*4"Y>IM\H2V-L3Z/B MLBUA2^3M"P5;(VD)>,!-
@=/GE9K\$1\FPDEET91R&2716??SI<.5P-;IF >3 M %13Y:WM-NG\FG=-5;N>+!&V!>\$L#1H<< \M,K
)JV5)?B]M%1@CP'Y.;819(M:R](7G[%].X\HN)9[/O .+N'D M=R=SR\$<77KQ-L+!C\$#@M!04\OJ\+
[VS5";J;'*05"\$V-TN.R9^9PD8L>8, MU,1)P"EC;09^Q&PS"2EI/1JT)G-.A4<)+L(1/_+MV'\8IEPH\$PT-
'L<&&]\@ MJ8_?4*RAB;TNF87D=2&FOAQGV&*^0+IC2V-[>W^2?>Q?^K+J4<5GS*M@C>, M #1L\|R).#K+
MN7H)G"YI>-XRUB\$T-4'XJ<4V18F^MVI' Z"+M1Z9: MO+EM?
#>C:"ZI[F\V:>:=604@19HFT>S9S03+A3DMSB*WDT9-34:RJ,82FS9. MI1MZM1\!|OTT@+<.->N%84H: ?
CTJ6;-CZ*I1/|A4'YI.7-A>X\1>[:N8[\$ MK?F#&M';6 I,)YZ11:@ (MF=\$DR)+W/ M'XY>+E4B",
/<SM8S3*8%HYNP7 M, '-3-72@H^?L\$G);TP%0;Z,9AMX-&N)P:6]E%8(-"2A>E1 MN\$6,QC\$,9-
Q2&Z4]XN:Z"KEF)"*B3"9R[U<.@7,01=?LZ3%URV,]]DV-H49 M)W#3RWUYK:?)_4=/_9FUH/3CH'&?>S-TI\$^;
C!7@)@C#L05X--L.U'N;^QK M-K@1"N%?.]G]F[1D152>)%SI7CS!M89ZUZ35>6*PGUH G-AA\$*KV(3QVUT*
MPF,P)I\$N4;]?+!|V-F*J9:KWPW7 --SYN1++R[U:6\K= +3>-R\ LJU5WSH
MNW;L&QZH5P1IU20.CZXY[;X:LTC U;K\4F93V3+ZP!JN TS9>>I;(/,AWE-\ MJEC?DSICG-
'Y3!_+;4\$I<=*,U]E4IA|OZ0=:UAYZUVYWG%BO06[4,-05N4[MY]2=LW IAS12C@]GT9DI.K40 MIB4#?B%0-
3C060AK0#:M\8XQIVTIOOZ+R)T;[IGA39Z+[RH6*>]2WN&K"O\$@ MW>'RH_J"MH[-
<^BE+:\Q]IN+EQ_RDWF1ZW)?=>0FD>W0^Z9.P8Q3"KSXW'< M\$Y\$,M2H3F5P^L<.M,T?X]]F92N3IE,=-
F&;>:0:OLS/#N@AGY5\$6 51(.05 MAZ-^EBCFA^--NG+RX+
([WA+)]IFS,KW+OV\$>_,\U+KTIB_RQBIA,E2/&\0;*N MQ0:;]7'?K_DM 1D!&JIMK=0C.\%*D.'.^LL
K9SGL3^&5I[P,/L|>0QTUW] M[&1VVU;DO(-9'2ZBZR)*]3f(W)? 1J2JG0#"NWCS9(?+9BF\!^:IW#V[>WX
MIAH)ZZ)-\$R)#8Z1_}2#^ -'2%.9&N2UU7;>6@-N4B^R@H1Q#^19Q<0R<\$'B09UJ(T>LQ"!G209CM M%\$X-
\$F;PLF\N7?9Y@WC-[F\Q\E]KN[ZZ=T]X/%FEKEA?#7CG82^(5K&CJ* M^75^EF?>AC2JX];#=
[QW]^[OHK2V4N#U!PORB\+Z/07WI\$F+=ZT%G,Y[;G(@ MPV<*,%.N3^#XCXKA"0L7104-GZ<9J862-
]E^E#;4\$E8?Y!\8]M,?2*)*XJ ML81840\+B,^+; -K:Y,U8P09>Q>V: [1:Y!05[U#(7;H>.2+00*<*9)G333
MRP%-:(,WR?Q*#&=,@K*)"AU0)^04R\5Y9R,\$F',)]SZK&Y4NI_FQJT7;N_ M%X]9+|XN&J9J0Y?
XAD^.#P0(B?00G% @+-;H\$!VT#>U?;[6>T+TX2_T ^0%1JF!5I!5]A Z.
M.=2^9+NU=JTY%V2B|T6H=FJLXWN^=\BSL5Q- :M&.YL3Z8UXDR\T-
MO?:R/LQMXX+;7.3A=,/K%W=OSPL|AVXI*LB"=3E2DNM=YQDK HN^+;\FR\+
M\$)T*.1+Q;+/+]']@E5+VPV*N*=3W PJ632;W&[W0]>7)QFAKTEGYA6N%=[[MD*6!|V-(EB\=DXR) "/4Y%
(GHV\.>#%C07P%F*V]B&/#MU^H.20>">9NSX%V M""NTYD)MH2"@>E&)I,06A[T?A39:P,AS4]HM];"*E
76QF*BY&S^,?1)KB5X%K%WF=024W84^Q*3>I;M:;&\$H^H3 M ?=-#40)#%]P-R00NZ=>XHI5MNYU@'+[S?
1_7*4V*(.)'WQJ"0 /3P?YF([M]5V^0);I6.51YWI=EN-(18[IS- ^V)#K@P?%PK-WKH%SK2L>F"W;EFI>];**
MY7+!VM&^QGWO9H!+4%,Y01(I;W2DN;|NZ<-[&<\H-J+?ZUG2%;1>.YW.2=N MH0Q:/Q7%!^&W%??
*1.G/=ZM<\&Q%5P|[B-60(3.\4CS&7J?3C=K//4,2;PK M[\^&S0K9%?T#AU,M7_.;0W>.CR/"7%IK
H7S4'8L#C7A_%#;\$ZC&6AS._D#N MGF)SJD0'LWIEAZ.F*.0LF31MU0@R'7S>F_#?>L>Z.0)XZ9,[R9]:-#+8-
L& MEL@#%VP:Y;YVZ%G6)I YE"LC9W,4&HR2((P;/RM>\$'Q/W"+;'!6)E-0PU\$I
M*Y\$+@MC,I.4J"FM'_E<;Z>4ZN|K85> %Y302&\Z&5EP#L0>?>G=3" ^A"80 ME
+F!+UC/Y0.EH(,RNYI(E\9G"??SY\$;\$B"]3<;>I0:< @-14+ M7MFK3K>Y0970SZSLZWTV\ 'NO_%M7ZX
VK.*N(YQVRVI %G0!-7&T,+2 ,V*W!GTB#+-@M^ZZ'*0 M?I"@/&L[WZNWXT]54<\$'GDD*R,C-L@_X&0<59%Z
90JAFBB.GKI)WV#>BX0+ MK?C3E!00%0_.'@;?XY/L2M&07[K4@'S/KY[M]>TL!A>1'E;PMN%6,JT_B;^ \ M
KRN/ONJ6.%EDB+ T_+&C\4\$2?NJ'P,.A3 6^UI[E-LU0Q>4f>Z(3@PGNX! ME1F0]W:M?R0-
]>HY4K'NFX9J;.)38K ZH4 7I\$T*IF34.(S?0:S1_-E+S3ZU\$ M<#?S?
@=>,K""P+125E#CD]I69)^VI,;^DQDL]:%XB;U3&V=I<9S4'R"HS'E\!;B[Q1>-
K^838" 4%,@FQZ+)4JQF^3^%K0.8YV7WKC0Y>60MU,:WB-,&([+<'WWB_9SA6EQ)9 T;I3JKELA. MV10\$-J8Z?
F;>2ID?R;5/?0D*, \$0L&]G/WZR[PWA@8%G5(2TW1*;6.M?P5_PC M#;\ YI@26=M-Y&_K'+0V;?MXRFG>F>*AK#-
W;C/)#16DQ0>K. 6812'C]Q_KI080=RK/F&[K ^UG65:0470(3V]6%*/W MDB_D?7!;^+AJ*?
L3YIN#RG]6R9F&(TGV8!9;SR^KQ' &ONI9|GCW**;' ^WP M7%UZ0_B2MS4N_Z")I20SJY'LL"?
+9!KV1\$>R'6\$' =E_)DNY:0550'#C.H4: MC*Q< 6S6B9>M)+FYD7S#ES9Y*QJ*LN
M1%KW%JBB2AY7@\$S!D76",L.@N/5NNDT/?9V+D20_Z->?]]?+IT[MKP#Y-@DD2/'^F+FW>@_M8)5X"GER).3;_Z^
M31EPB KAVY17K^U-.&_/AO|. #J7B";RUN?^(D5_3>P3C%240IIN5!WOK\$ M:.HB1;_U-

VL;6.&^:#\05DB\GXV+\$^3-;/;203\G89W\!C@B0_74_^\^@,0Z 'XQ6_R9M&JN1@/+>0 \C>QF9
HV;7Y;*,!,>R0*,CV M0W+AKA_0+(UH2+>\$J8.C?Z8'K<*M/<[!>[!>BK \K_AP"K4*HC^T!;D^@^:
M\$%_J#\L3)*" &YM\$%DH0Z2> ZL:/1@%*[3=*,HLKP# ' '6\$, &5R-#J1\$.LB MYE?6[@LZY(>\L'-
?"A*83G:KR69//Z(C)E5;[G?.R*%0;<80.X56=A0+0 QM M"@9>4/8^0^Q636Y6.W'["]P(W;+U^K/Z ^
0"]ARN(LKA\Y@\$_=20 /Z*Y_KW;DAO MBU_.0#?YCWC_04B#(@0)83AVH>1I0GG=J\$V\$KD\Z0UP'-6,0T;
M\7A876L"E8A?#EHS1)!?"?6;N:K5,%*+BA*Z& M#Q'"S:/?
G@5EI7]]DS.T&YC#^3^PD]]+%UU,3]PJU*EK679X]P^.,0G1\$^7I,K!+
M=^,+URF3FKWB1Y)MT^C+JUN)*MWLK\DGDDCY658-&84*3:# M_17.GYM33DE90GS.FFP5-V/FS&?33TH%-?]
1K=I4G[.X'9.E#[GR[X'A/ED M'3V>4.2#\$D4M'T/S!DKQC4:C^9-NR62Z/1+*H7ZH=C\%*]ES8W&10*"TBDGD
M:49R<4_FK6;3WWKFRL#DC<6*A_M ;+72LXLK@'XU)Y,G:@2'A5AD]@X0[!B56Z'8\
>V5L<.2&XA*PZ))47.2.' '29YY': M+* 24I*V:&BL\Y\5@A)OXG0%4!HP.(! ? 9;%_JG7BM;?N%UN6.ZA\ 'FS-
E)1 MV1#;,(\W[">E43;\V1\$/ *5"9?]>[8J"?])J]FPC6F=!\$T MLKIN3:7E+YJ5^R^]B?^&'*JF=92\
=I>A(N:=>\M)8)">V30R!CN+]]GA;-%=07P\]G0SQB?Z)DE5K5HQ M+7G6,P&@ #A\
<(I/#TCZS\ S3]";,)V6VE^U]0_OX\CTM_2CV%R@&5/)*I@E
MTU3BKSFS^?'K0&U4K:N:/6\$/F;A0ZYSUT>M'DQYG/IQAX(#,03=3HTV\$8J_A M\07
!S'TST.80)]' R6N+K*9,%#V\K2T)>]/J(SX>/U?4\DC\^G(V@C!*'\S M'B0Y<'-
&B4VFS=0UJ"EX UR +!&S@40U-Y[U'N=>]\$VE\#^J<]L3&/G//4+
M.X^2A['A';Y6;&!7H(AJ\$R@G&70GQC'30P.>Y](- /01# M:6F8\$=W=/ "EAIS[THR<:&Y4(_C=Y:I(N*+>
(_*9D09R6))0\$E1E,]YL\A >19]YJL%;X6E@M]#T<"LLY6M59,I\0JJYKI5QC-(70EHJH2UV' M-
]F]8G/3*R_B#]]QV=H\$V+XU:SWM./CSIU],VMR+0#040/\4@]=; (E\K_=J M]_04-
3796[1RQT^;&9K+TWA6W;LG@YV"RW?/OV&/+9WW[^5FKNQ7]IY\^- M_F7)' .2E993RF]0_R:(5B8]0-
]8D'J2?G%4/N\$0*QHB#FDG;S]<*, -0_RK9E_MZ?=8/_P5V.I4\$0;671]XY#^7N*IZ+DL'RF+VORS01&^S2<7?NA-
/Z[CY.W2@5H6+ M&FNR;<1^W#)L%:ANJR2XT !6_H2J.2Z ;PN1+XV07G\]?<+H^OY\FVAK3\ M&?
8*DL58MX,Y.[;V#1!CWD',Z*#Q*0XW=M48[?5X]\/,]9SUZ,,W+9NX5A1\$1"47N*6IK2(M]!K9;D!\$0%_I\$
44(0+20TML"%*E*U4Z2(GTGDB7+C4:>BBADU #:5]TGW0N M>]]WZ/[^S:88\RYF
_N',GN8\ "-4H.3:V*540;0L,<"/3VIX<)/ M17CN:P&]7K,I#%-. \$CLH(JC+M96,8Q3V(C/&H MYZ6QQH\$^TP&A-
0QW&G<=<(RQ>+^#T0%^^C);)FJ+)=4]N<>LNID;Y*QJ'9;2S[M9Q60J\,.\$&<C/:<\$#LW6/P]
[H5Z \7Y]J0@9H_)@DL>UJ!NFL"H/%&V9%F' MQ7JR/V:*Q#F./C*^F)U3DK7TY\^N\$0(-
GE6/!S."CN^<8_@&00'1F9M+;N0 M=KA2S]MQ]W+[%QYE\$PX]R>!FG7<"LH]N-
2Q2#\$G0<6H0(\$Q_9N_>D'Y8*W8M M9[1,Z^H2;2M)-7.Q=;T;9- = \$?7IA&?Q'X(4T\KI=
[LR.ACY&42F"AI3E2L MG04RD2C6,VK0A.MJ!K-@:Z!B?%A0=4VHDL/C/<#R0#EJ-)S2T
5N*;]BH0!N7919025;D-#9 M0!6'!X>@B]^3+G\$8FD!,8=P= M%LA0I(0T#MLI""GP0I1?KT>]7_\#.U
MIRD,!ZA-0UC'0'\<]ZP38)Q" \$!6!"Z2Q^Y%5=]\ZHM;7!F8 C[<;9UM&J% M@&[&C;B**)X"97E(A,]Z)+?
1A-SOP5_F^\$%&LR)L7HD[>GNJ&]-EH&=-;C7
M@X]C3M0.I5CV[W]2ENUK+6HU6&65+\TJ,A)ITFVXZ0EM^^&,=6R_31@;\;Y#L MA#PBV>>G
&T>VW+.K1=*GH8(+D]*-M: \0\$W(H3V+[FA\5#=1VG=U;.0'5A^L M_YK5#KZ=C=W2^F888<449N=^-
+B']^ \CUVV'T"SA&=.T GX\$FA0,Y&]@S2%!] M?>?=1#_KP?
J&L6??:CLD1^1\$KI9<9E*9[0W0)TKN5KU8N4M6:D:>8A'E,Y*Y M%LB/CI%[/;,\$[TCG6Y\VVIMMCPU?
FBFEFZ50CR!+3/ =BQ'H/5XU7B-%^M(\$ M>@ZS7DU1^6XYP4;2\6)1W6@^2ZKK-
WL!KEA:S@Z" I,07%9YQUSEQY*C#>1SJ ML2L;Y2_J.\IMWUGPB45L97J0#0);M',B=9;];*L'1V'-
X>L<@!/[3]8V;,) \$ M[G8VUD4;^), \OM0]16TZ2[5Y:]DX(&0XIUC<^MYW:BI&K [10Z*XZ]1PN
M1IK"15K>*R-53QLPM1S(,MA#-]VP5N]T&1>@?>#-0E>]E)Z:WZ\$^V.937@W\$ MQR*C4>%N?
G)UO!X= \+F]JAX93@><+0T>#):/*RJ6L:[8<&T,"#<*!EH+7&03[E MA1C4= DON!I)6&.D])"DOE*)&H :
(^S:V)G+971U0GC/[>K;Y MCW?UKX%-U2FS]X'2SEID:]*>1?J-3U\;5++'8;L&1F="+D'?U^;N/S]WS%'X
M5%09"9G+;N%S01V<"7:B(9%\7B/CL8:\$>4MJ3EYGFK=I\MT6B6&WK3CQBY7< MW:A"9R4XX0TN_GF
3R&L9!?'HMN<>'!85V@G:<6[0^6(;>T]80]JL!H0' 'H2;
MHGMLKE27L&*6(. *>:33Y\]D&+"3J2WJQ+>6W4=20X/H&6#GLUX;]G"1D+S4
MK7:"&+3, !:S7#6[]V(ST7T>F3\!L+63HSZHEWKA EK7]NK&@.=0]X+GC6*KC
MAUPYDBN["ON%_C_T0[<5.*ZN:0@D:\$@OF#U_K95=W]++>8^4';*H @]S2#A\$7 M"G\$K!1G#ZM*!&;H"?_Y54S-
N;'CUZMR,WCA4#?#0!E]JYT>7IX?1%\$FAFSC0FTGF@0"- M3.E000>!N1.2>E+0;W&^-0(=TU-1W^?
MS>:"*;XBBE<"I:VV]YMUVO=7-F]Y!F>W%A>-X2.BWDL4GUZ+]) *0D-EJYW MQ9YM3>=Z A>"Z5'^F!\$4-
]8@'P;3+4:7B0'U>E62)V;%KN]@D!.]UT.5\<*& M[#&XF1MW\])>I6K;
[V<\JBLW,7,%^!GG(;>Q[@NI0R9["E.957D0@D.;Z4^Q M7-+^#_N-
^6_2U\JL#=#EW\#MYG5[E/RW5=I,ZTAHG#)(-!0<;-%:*AS/ =^2 M.K32^A?
+RHTDOI. 38QUFRDD@P.F60;V&81XX].K!M:OY>^9HGQU#XZ.. \= MX^,6?FC+(=+(A!1-
MM8MLBX.;HXZB4HI_2LQAM<J?, D\AN0G=X(#!];'ND', M4\M;\$_F.T@_Z5A!Q
IHC=FEN0P)"T"#2;1Q_KP..-4=A,M8MES]D(< @Y?0%)^;+U8U_)!DRJ5,;
MF:R(G:%=]*5&7\$3V^3"22D907<3@Q.0>)4J7V3B0(N5,"JQ7[VNUK)FHX 5EFQ90@2,H\$3CF M]@HW]
\$AJ]DU3VKUO'0@0YP.SYI:Q+)]]'@F'5"G:IKWC]8Y0&MK&ZH0#0_S M^#Z97H^Q2;.@.42?JA1X-
)Z3MP>65I"S;,-&A38\A/KDP^_6E#9XQS3U91= M)0_5D'7'9LGK%1R#Z*8;\$B[2!.*\$0HB0\$A&.H]I M,
"UL3\$MT@1#!]'?9Y-0UIIJ.J0DW\I/LSF5H/*EG M4A<[<.]K/HP9*)= _\$#E4,YFK)]@%(F?
E^-9817%+:3NQMV0IF==ZW*DHP6[7 M556-%2S-2MX]2!/<,CQ_0H24[59A%P_2M6#E]=CTX.U_Q2:V2C-
]BF<'4]),912_TZ1\Y8N66X3BW6>9,;F+C[.L:>F+H[I\$FU MNVAN]70\$K.L\$R&L7.) DJ3W:H.<9BFU+W5G>-
S&8+Y#D0=*VP#>FVJF9'@ M957Y2>FSP:\$-U@_MB)9-%N*OBRYOFH\[^DBLB3SWU=%.<[FLU]\=%4#,59)H
M[6:1TAVUZ\Z<:Y#9T7<-LZ8#I)F>%RK/SA0559(\!Y0:(UNT2;4X?@V)ODD@ MP"6QTS6.UFKV]Y=G=*
[(L@LV&GC3?@T7^P&X""R4W:P]"=B\<6IB<:!>M*)L
MLMUZEE579#)/W>N;90PJ'?!/EKB8%6L[8W@&5J,D7S1<4"D(*K3P=7*[6W_G_MK7)>

VAF0C%@>=1!^YX,L=J)TDY^[X@0#5MI+?&:A=VSKH6&N#LY1'7#L K^Z[EA>%=BI6:N.;XU-JI@.8^T]U
M"]DE[2I>N%P3_EKI30:PNG=MVG;GL8\$>P2Y:0)475>;+=_*@,,B5EVG)'^4X\#<I,ND(F!F%T*=%LX\NRWZ+
[K<8_GT3\89\$[D!4FC!D*0!PCWH>I_CRL>@J5ZS@ZS6-.7A"HTC>JA20N]NN<:<4[_K<1^M^/]-
M.*Z_D&5/T>P!:#>A3X).=Z.#;5@&*M?@ZZ/B(\65S&WLV+.G.,Y>:6MPD5)R MH;\$W[6D1N-00_A2M\$J?+
28\$G>"98FGI:JSUDL^-]2V7(P\8=*.8H%96\UD M'_ENON:|EBVM7.C>+H@9E8[#
(+J07;KAUKII8T('L*8'!A\$[VEC\R/JHH?3/ MV)SB^B^E805*TS-- KXP0."[G0U+"]/P2A
SZ:Q^3\$N+*7:X7SY_=W>_A\?V MZ=B]2-^,FT\1P!-\$J_5C"W1+Y >FT\$S\$0Y:4(U'\$@Z4?" CNX^A0M5^\$;P!
M^NJ)U" (RA:+D%M%LVQA2X^0COP51('%+IM0! S47\&S%='M\$M M4HF<10P\W=S'%XJ2XC3&H,45-
J;C*WDFa=W+XI<6ATR&#BJ&()H='TF_B\$<- M?V)PJTFU7&: VD@;S_=G\0U-
;W*,Q' 4:7/\$"Z*!_%X;7X3@[3Y@*K*JJF M'_UR)B3K>VM8@KA\:/!FZUVS (\T]:'6*0XT]+&,EU\$Y19+P89
]Y_L?J(BI M3MX6%[+3W!>C8F1I/S81-M0;)M<.75[Y(?<)3G.;ZEW&.>5!^6H55.2J(Q(M"]@;X%+<# <
GY2;D;RWK-)V3\SI+?JP. WG3]VH%3A"E. 6E X#-G*D!(J MV3 =UV#-,X,*4^PVBP-
Z!5@G[AL7J0:2/WV2@(. /UE>\,2B\BH06IC?XY!&OE M&UM="1'J@MD13\$@ (YS[UU3%DUJ/' +8)Y;HTW8]3B(
SG^96TA#,* MW54-K-Q[U2":0:R*CWZ\$[6T7 MC+A/>C0"Y:7YQ:4M!IR'.Z0+37;L<]1R\FI+BJ4Y*\=WIPZ3-
DR(UFNM?%!! MH.VCD1HK"J-KD>['I]YSIWFT^ 'AUU\$@4B1SIVW4S&BIU/7Y0](:N@%1'9@ M--BB[??
W.,UIB@.,S=)J_Q\$NVCV-)3@?88+%?&\$Z[1W:00.E>OKMQ\$3@I*# MM-9V_*Q\!=0/0%+WZS;G3?
+*PHSC=\A\E)\$*#<0L5Z,WBOMKX7& M\ 9\$5[E&7532!6%QN M"<+LQD@&\$9#1KH-]JXF8V"7/?
TG\Q.A)0 [V:9Z&= M^XB\$R@9C.=P.,PEKK!714Q72* K/-)-K(UN^>C0G(-0BA"TN?(W0.4\$ M[:N-
!DZFR[1X\$ (?N49H6]6'X2H0E_78)T@=2M*Z<)U2E-#V?K\$5[8X0'!) ME4%8'M-)V^GQH?%0,
<[(\72L ML['BY?FFZI] OT_8;K*VN>@U4:/, @(>V6E%/#5 M<;7,U4!US"7W7=>..?#XPM*9TFWE[-Z_6])7'0
M;.;>.;[9X;\P(' ,SY3JW.X(S"ZCHBUA SMB0C0:>M9EU4+5>S1GSW,3S=9QG M]3[C8R-?EKBK\$,VM09=PDQ?
420%,\BK5M^LLZR?I@ 2\U>.D:/RIIN]SIWK M;* &A\Z*&H;_P4>4)/Z&:.F0^PU:V=[X)ROU W^KJ?-
^51KMJ\VM.>W,M0- MZ=G\PR0K?"RN@H:2S\UU#5&W_@C#XI1W@*7./>G*PC\DI/\M0=@7V;+!\$>!(-'VC4
_7A*GI\$,85 ML0)#6+V<< PT9,DS1LFWA75I "WFHSIW,
MMU(R2JY/U_TU4.9!#;Z%L/*6@]2TC!E].H"MY,)WA;ZUDIN^FPSU0L<0*28, M6X*,X--]09'S(-
!318RE3C];)-1J0VD:5>9J[2>66<"Z+KOU2*KN#TS_* MV9J X&Q@SX1!|1T_D\$5'&>)VTV"!;2+?.'+6
T^G&=[:0&) =A1!9B'B5A MX&[#':A(JIS:)HBJ\$<' /#8VC2]!]:7NE0Z2(+@&=.82U,YYVL#HUHN3]K?5
M_8E[G<*'+UR16[%Y_NL:P8*&\$HY[S?QA8*'E(IB9(NV5>RV [UF0/Z ;EN>X MZUEUN]272,.1->
_,4:CK_7#G2A03? M1N%RQY=;50KM\$QW>ICQ'4HBS?N HL).!4N0-)% +Z/3X7[L9'_20PJ)K+U.1 M-
9/BXAK#B#K)M!+=T((W>=JVTSG,*(>+DEN>UL!4E(.VZHC=_@L_*8YM= MC+5\M2%^Y=-N,Y,
BMQQY9P=/([Y&)Y;_0@008[04U\4SV* M^EO>UCM6M^'W'[N3]_%U3,T,NNU=
ZHC""N(I9SUUX7R]"U:~MFS)0JW^ MLLU"U'_A=(#%CNNO/1]J\$#"JD0)Z:R_AH@1]
M:TJJ0L[_S5%0,N77H)#QB_G5WP&(>Z>JYXXR7MQH\$N]WT60AJ/5S@JJ=, 0 MQ,065 B00;+150Y38I-
J:M\$EKUK16/A#[(]AR_K3#S'[/<%S%086,=4I0\$F M5+HX=L8GJ.U3[;M0YQLCL'6G1IKB[6NDSU6%0]?4",B0,
(.4(XJ':?7I]10&(\&_SM)38%=[M09)R&C-I]B=G[:8BV*!7RK3?FEBMZU36&!5\$+ZX9(T,#3 @)K?4J8,)R
#N+*C-A7>6FL@?=DA-47'Y1N[# M\$.6IFK_+!)\$6WV5DTF3B'H:]]*@S2DJ0S (-TZZ^D\5FD?49=S:.H:7*]0T4
MINX->6#4F6<;+=M\JL\X:9Y#?^50WB0"6%:I?.&'V]0X]0,N0M/_0V&7>QH4
M!E'8^BSE\]#M&4,+^A8&7*>6
M9(W^C+;,Z+Z:,C3_=M7B0/%1N"S6AW^X4[A6FP[P]\$0:D<-R*JUR,0S1I&F> M SPL-PTBUQE0D=8E?
<,4LPK=,0FZ[1U@G4]"M'(X[<*&D9*0(ZG*,2I3/%, M%FEABX?R;FP#?X% ^P@87+!8W&37#"#@GS4.\$A.AB6-
ZM'U/-476W3[, \$2>7? M+ '4%K/^V, :@H82EG='>30*U8 M\C[|AR\ 6L+=8([V#A5A9&>3E=7280P]3?
5"=A03\$0@T&@#_C?XQ9_074] MHDV'416*D/BJ(E77:E-JS+RZKN&.8%B#_8/) 0^<:
MMWYC>3:)NV)77+])V9 +:D :|E&Y#=#1#HD2E1IQ%G%(Y#?,0G'&&H1+W< ? M.TUL)'ZMH390MWM+V*:J0V(
M@TZMYA(H9-]XS(VJS+=6\$]WQ MW>ZON! -#*'WBWZF?Y"U&"#IC7H6(\$!C8QBB M+K71BB4FH=>2AR-#"T65[L
M>DM!X\$J]C[:_1_2=76NB;KN&G3'F">H"B6&)Y\$/X=%Y0,)2\AU>CSU^W#\$\$= M%;'UX??9DM5]Z8#0]VBE.U-
%U^ (EW;>N01_K#MRA5&BX0N]\$WUE(E]YP,?! M0I*F"K[!SLT"*00X\$L,]C10/>A04<(68?3K]!^7\8W-
'PW&%0QN\$#I(2 M^<(P47_/_HRWE4\SX=9ZZ.0\$PH9_S-", "FT[LGSI.I\40/Z& [T:CN=;0F0
M8UZT+D\>I3(D7_KKH'X+3.&J602&-7YC875\$,R%)+\ '60#4:+?X]!Y/W?EI MAA:\ 'W\$N=]W(2AD+M)*B.6%]?
31?&!TB*L%LBP?_XE!&SN^Z\R'9_P7N@N M5J]3Z=\[B9_D)#*X*00EKNL?F#^QN&_PE:3FZJ7-T+7.>W,
[2Z9P&5CAK\$[T M-/KT. 5,, DKAL4L<5:&J;V,;!8E=QN;7'D8UL/?S3*&?074(WIAZGB_\$3',
MDE@Q2+GQX\%?-44-[RW_&ISWGL,+_Y I"6J2K77GD15X3#M*POUW5A\$6G!1?)*J1?B0C]0=^N=1
M5*6.TB=S_@:]^P]0.%[J?]2PR[);LGI[13*H9[B-SA"D9\XUI< M63.%_6S4!-X<2*5+Z_NQ(7?
039,MBBU1P)TS:F82J7YUYI&00Q^XL?40CU6C MT8;^SYHBI"\$-E^HB-60,949>]9T6WVBVB-^414?_I"4
M2+95*5]JM4L"-:GF@TA)D)6H=/S#Y2T5;*D4[|S0I-J"PZ_7\ M<;7%KC0Z_9HZ)A!=_?
G0_A"+W3_JM,410.\$HE14_TS<7_LZLJA;?"_Z56:]D MKEX4]%8WTC\ 961D&XWV99^7D;B:0.
[\$^K+JJ:XT^T*M"B/4 M-V]]3CQEH8*TLRT(U[G&W]KW=, \$"?U'CD_K]1?BW4LZ86U-6]9B.<>S'\$9H M?
#M#^JH[R\,I>EUW7'6+I'96BY'[3EZT8\3)8ES]6(@8W\73PKXCT*+QP3F M6-!7?C;V%>:QX%86B!X0-\/?
=4;PS_T2D=2 [(F:E^?%>73Z9#2?^7!A4N=F9STH0I99U8GQ>SH5T^N1?(9R28U#E6K567Y+N5/)BX'.0[2:3J!?
M")J,@C^2]QILDf/X0*(T7[:[RWB308C2^*R/U@MX[N_UB=(4B?@UY4DQ3"[D M-
8K/4M_1]BBU4B!;:XM]8K>RTT4JTH=02+^6;V \W0LYXWL:>)3EZR! JU- M+!W K5U9N>)5.V11:7[+:BBY; '!
[S3F]/J\1/>\$P0\$+YA=3MAY^GZ(SNP&*; MC8XN>[_&9U+,-A/?/S@F7J#I\IT6KS=
[M=K=DH('Q\$R4:LJ@H21./FRER^ M8_MB5\GQUI&1"!Q^'B]JBM0;K&JUA]4-
S_^[5^23:>2LCGHD+SGR\M6L2E[) M1VX_'Q/-T-CVI*^C@
.:9L60V5IN5L0[#DBW.*2U!0'^GTMVE;R._JGM@#ECY MK% \(:K)! \BJ+IBU@MUI90\XMLP=*EQQWO-F-
Q>Q_FG?NF)4'X"]-MZER>@ MFEWB3!OUD?H;\$(-UEF@@UFW_E"3S)\&\$5\$6W?>E#,X^PDDX_%1L+AU,9UU
MY]KQ?NBF0> "S4<6BLL+5H_FQL# 'Z#>6]9)6WRV,.DM]ZAB-T/S/8ZC-H; MIMJ_'&BHF8P"Y&<'9>!K=]G?
M\ZV_DL'Q5-(\L_+X'5*334I>9F M>&9*/GAFV-/-10>D1*=-. !#.IN]M>N6FM;0"C233OK^D\$7T_U@U8U>HX0-

HT6 M[*C?<\$^K(ANF&RC0 =)&CWY9H8#_AR)D\$>3W;@7N^?D?
[-R\$@12BNRU0/8UX!HNC"K">'@TU^7'3K+L.].W.'U^3 MGYX2S\$"Y&&E]P_C^JE?Z!U&N-
9VK8D)29T2==T90 "Y1_N!C;I:CKW-[ID(6SUU5N6&Z0_T1ME\$;LZLC X(4H0;HD)_QCM+/!C.^&(!
MVTLD+^3EW[GN8K*W=@S'%L9U D6)2!>>1;?;WB*"U3[N#EG2LIE7_%U[Y3 MB,#_1#3;@Z9^?
KNRFX=<7EQ,Z#'_S;TOS00LN /JNZ2K/AN.&%) .H6!NL M))0JAU\$ --MKVE;-T9(/LR! ?BU3^ZXV;6TUVRO-
GYC_#S^0_?7BRVEC% QAJ M@;I0GP9Z@_H [IAU2LY?-=%2;^ 482A?0%._@-C07/ZRBYF5@,_;G<1M*HM
M^#Y5/F8\$>MJDG'.J7^H<>J F"/'Z60(PQ55_#SM-1\$L27)X>JI%NT&5_!7
MZXC^5+)V^L@5\$(MNWHD'7A[W<A8L@I>.XDS'E,\$LP59<&7@BVC MA+UJ^?
I*9*_K_.I_P,F2N05LA'Y+G5AJH,-,\IH)-&="M,*6VAC68IHHAJ\$5?
>IZCIXK[.8'OE&\$WZQ:99%\BK2YU"Y+;YQY;-0PU^Z M+N?7YX5F^86T7-[7F'
M0030%*E*U(6T0W<1)JJEV)].;&GE!3Y)'F* 9.R=:.'81Y7>ZI'F_JJ/6'C> M5YM?JMZ&^0;K?
)ANTFU7W#P^C97^9D',LR(0L>60=VQA\$2@_LFR<@(@G M=L@9Z*18(B[XY3:'MJ,%VNSR#_KA'HF+[-G-
V1\$EC'Y2XB&RL1 M8A8E!6^;\8&NHL0KJ0K?5KN=#.0F.2^9+Q&6BA-*L*Y[BWXC_R'\K\$%AZLX% M)(3ND*M4
PA1V.^=D5T9K%9,N_64_/=E!5]DNM=0![:7IOY) V";#BAU\UP[M:7=A?- ?H]K+M;EK;[D2.W0-
KC^J\MF=RH@86E_E \6K[@526#HY*D!=84'P3%]L JUHXB MS^U7&/GGA2'8* M"5^!<^U>K
VK/\K>REXTV?;#E!N+7%YC *75AX=4<^48 K%(VM;MY'>M, M]59\,S,J]@5-&^60U>7]KX-\$5Q;(SQ:JO;\35
GABLOMI*[']'2\;> L\$= MX5V9K'4- 7*KWU\$*+>B+BSFX/<^E: ?9#\=2 =L)&R=CC
M=&8*2*/._"@&^JWSY-\>:9ZW;V!;4')V U08GJ8Z@E*!(G%SB=HC:VGRUII8
MNWG+ (@;^TID:]C[:/0%E17/104L%_[]"K' MQ_&EAV)>8RT]K+V8(*P :DCZKZH*#;
<,60MQ+MU^3+/-;EZP?)PFL()A[> M==#7B&/[00\$900/5,;"Q! C4K3F\L4[@A:T^(/??[W7KU@I.
(VS04//XP:? MTD0Q W[;VDD5XY>!QI07H1>S7?X]J64>S\$G1)GKH81BX8POR=/:Y#GWH6*+
M'WVV;_P=YY\$>&57&FIIT)'"(IAC02/ISRBZ;G8^G&K%LXM35YJJY'<[+*F
MCU8/-8E72=B75*L0V3URU\2!^A!B[1;XC3PBW 8TM"J?;C>->91M&KT'NHH MVG7L)<;V3?NA=28F
5YY[0IOE75M>D8R5!ABF2@*\$)Y2?H]BGPUP0.\&)\?92\VD6NHY-+'ZN.# MK(?H4 &4!(PU<_F*
[-6^<8B@I&*,^RM00V@+U[<0Y2R*!VL>=D\$! ?*UK7 M20,]B[B-2R*81N]-05D?
ZTIU.F#WV:@7U0C7\$4P1!K8>(0RU5//<K<;?,P[! MF#*+%;%NKH3_P1(Q/D> M?;+"XH
=CF9(0_6'^!D8]@;W+= *R#>S;3/2; M;#GP'1,= /?B(F:>*U\$_#!?M3&X-&53-H>/[_ (S0U0J><.S8&/J9]%-
LV"!0MHF8R]7E'6)G_];5MQ325^+=RRI",^]QC[*] M5C?KCSZZ= HC[R<#0YV_9VHR,>B,#XSS)?
0!6#&;>@>FQ+1D(3UT<6 IY!P\$ MT3I+.Z7E*N0A^,XF4'\$IB [8%H9 ,0J""Y3^(Q)[>6_2J>K0]=(>:'H#L?IU
M+&G,'4\C 8PI&0L!F@.(?0[W671 IR>M(A'=0 K*15^VRJ+I ,4VT'/;]9T: M-#ZM0!EH>(+FU69\$G>^NA]
(!HE'[0-<[U!']=LC ZH#.'YF!@;B,9VT7H*YK: M7CE/&0X=*6(3TIN'7;L+WNVYV7;A*JYP*";AX1\$F?
_R5Y]5HP][\(?R;P\$?@_0 MSV#;6'3DI?#PK4/?QH#>+2.4M1\BC[HQT?!! 8/19'\$0Z"BGL@^\$)J](B-'
M/B#C4 JTW@.V-F=?1").MKQ;A'G' OKS(21?9VZ(\$S43 _S_[] M:>>#F]#GME>*
[-P]2<"2@%?,9GD.9;PERMN1L]=MCNLH8K[3V(@EP;-45A:[]
M%FPJJJC#0IJ;YAR>,K_0*00=@X0K1NW!%@M!S(K]6L@Y1Z/WQ@KS._L3+[_SD
M+RWQ#Y9/*!#1X0@'8,A4N4VM4ICFV>7JI)+H01*IP\&I=D=3R[3W'&ZIIY8+
MI9QV*>F'1Z4@SLZ"L9LE.X_I@+D!_D"!^CCP 5)W%\FY7/#=[])9XB,%]/2^ M^A2SHS@M-
002>9460^70!,*.M:1S5*[4J%_"H/8U)5;WHUT:*08/#TG6%ZG MMUCDT7?(&J(=
([M([B\FT!XFV[:@G/<'DOMC&WT[F>M9H5G1#85S.![\$D&= M%7NKG@H]L*F]&!@,0L
MMG/0U9ZVRCH5DX3[(VKU_/A\C@[(R?0R,=K9=-;PU;1NXMT0/38"YI HH\K M)0:0X"=X[K9-
Z;R0,^X\$;0@8.95/!VC?I@,. 3"9_V48Q,QIA.-@@(>8'F) MFT;ZB;['_2W&PC/50U)G*BET\S*BU;4.<7
7W;/KEMXFR2;BVA\&>3=-HIR2M-@I_25#-AFQU&*!AX\$KUAH\X#V83/?F:0=R
MZY0/HF%!4R1@DKTNW"L>IT7Z@I[15X/C.[]EK\$<3WJ+GH_6(1_"#J]9T0!J&
M(\$[32%_2IR%QNA\2]:E_H6>LXL&3007*=_;#;U[(WP[5[S;_GT_%5C T;NJW- MN2*DLB!-
!YR0+;\$#EA]N/="=->U>WN*B_V*@"E-4L.\^XZV?'S6J-H0S012X M]\9W/5C3C&/[19RM*V[4PK;DNAWFC
9\$F*S"F*FH*Q#;X(ACQSBGW\$9,74U: M;BMV>(&/D:7RU#6^+S!Q.;I@>DE]ZM22
8;*R[W)0XL0_[]&BMPKX=VZ17(3 M\$AUYR1V3WS"UX"&D2)V;_% HC8[.E21?%HH[#U\FM;GY.QGITO"#@,0-
_ZM=F MWC6Z6!-IRX^B3M,VVH0NA@T^AM .;F+8*&V00JE]T?YKM W-OW0<7^^" TKQH\7TA;UX/TQ=; MD/?
1V1V[D#,P>S0^[]B+M\$,&WCM?)AFO<,"N?<K,#;\$#IC*BYJV]'KRR:B"N M,0+?
MU2>CMY.F14ZP.6M:3+L!;@B+W(*2?%C8.[9,^@M!\+KEC25(&C4=&(MC5=%I2M)\$F"&VQVTH!J4[75?TJ>
#^Y"%GV\RWQ'/W5BW"7AMCD?^4ZG>0?G MZ5%7'H]MW39=&7BY\$.KP7J%;+-+.DHJ/5%=_W^J5L;)=/
9DA4.8V[@IQ"0S M.H"XB2CF3F\@08/RZ(,^=GH"K^Q6%#-06;U^B Z(< M#DP?R5\$GH74.7&S4A>15S+18%#E=
<&51F>.,;"P,^T=;;'@P8U9,B0-%;&\$=- M2CKGT,!KDCVZ\$=0W\$TIB2+1Z8.8;Y)F[0@L/VS^<N-%;&K4&
M!Q%5=\91'B#ZB2G2UT@!"5 ?Z3(0X\4=,6U>*S M7'VAM5'\[]\$T\$FS9US5B<_Z+1I[+6;_>IILC]#
MW;P\$06RWA29.2PX5]EC2],(QD&TR'D\;V23;J/#A\$RQI9'3^AX,=1E#?"Z: MRA4RZ,WB,!W0?[%A#)\BD'?
R70I[,6)-%_'(CH@Y9GI(_&94-HV0BW#%!)J M1"ZC%!^(\>#G"0VW\$?V_.8QM_8H?
8!B(>@;W%#0\$[<_F]Z7G@T?K_"ZGK0.L MW]J!)\7(]52+[/\'.B%BW*X(R<=&)J%G]++)H^Z_[]C;^?
0<]G&E/^&0=NN M9'0(AB\$[-#SG\$)U\$*R_P9%R],NT.'2!7E4C.B0("]0'G/+<[LSU_F_%9CC0-#VU="N1
'Y+<"/!.)&\$V,Y'?UW+__.J]._* M\ZJ0L1G&DD<'JA@"08">#H7_>9;XU>YV)I^T<'87)_0\DX MQHB\>\$0?
9S0)*VQA]^M63]_K\;55I/'^>#W;]>[LKVCJ]GND',T625U!S"5J M0/9?S=,8
;+I+ZAA3RHSDFP*"/=D9,"W<?"=G6(G/"7PQ["?F]04;Y#>9[3* MB7_KLH>]-C]TF6(P_U&'R*3M[7#-
L]C/*Q>\$:F);2AN024+?6]JYC,_.Q.P^ M1B+%_SP@R-/1,Z.YL0-8D@L+0_K_UAB'].8]P@=\=/T*AA_HP-
^(BT)W[&] M:8SPBDQ!(U,R4>2T=.USIB6PCK/%#7#Y=0]/+/.:2)-J'=UXF;T5()FC!-FV
MAWRQ.S!Y6(%P(B)#N\$0&E!D,@GJN_)U937-]Z=E.!SQ(W/0&#C:\$@_DM@?MH
M1MPJ1^UYUK0#99\L%KXG0=F"V5Y'X"N^=C_2W[F?;J2;#GB\<\$*>8*;Q6I\$2_M]D]_,A07/0]*@!\$!F;=&7Y-
B>^G@XN2P2_M.5]_#->4(NDRHCRD>,6M;[#TV]HBOJ-5EU]ISO:_UK"HI7AX@\$W,3096!<=T(H2;H_6 MD0-
\$9(P2#]N015XVZ@I+.42%GC4CT_IFEJ2S1CS'>J_H0^<8/M;P'>EF0YP

MUSY[?.Z)P.5IS,J^S{&9R]MQ;A[NR{G!0NZ5@@_'0!0<)IZ6?L"K3;I:'S:X*D{IT"5VF SZK06AZR!Z)BWE-
^>4+VK?Z#9HNZ/>?C8{>-MF(L M]GV [''%=.6Z)XBJK+R9>,E?{='M[K*M7M%C4JT4PJ\$P0Z+H74ZX!/%=-YR
MJ=!\VL+21>J\$"G!)D"'S5DSQ:6#IPG*(J7D\ -JI3\X?VK M-E^-6R2@XTB2_,21NZ,?
4.E&0RX; ,Z60QJT{G8}>2D2I/6M5GA:66#T MS01JFC\$^QL>\$#&KD^L-^*.3WWPJX\#Z-
\\Z,NR#4YHHBLP5G3NQ7)W,9U3^
M->J07JF.>56^.. "PWNJQ6R51.T:2C44;-.%DLAUW(V8<_EJ)4|92>)C\44&.QP62PN,R-[@8D_0?
8UQ*N\HLD.>4'Z|"A:70:<_ MHV7UU8RSGS'QUA9.\$;8V@M*W <1@VB\$L@V<-X]NFPJ=Z9KE(/)>3|YZCCQ@;
M&PN%&"\GMB{(QJZ0_9H&6RV_89S.2+0:V,"<*X2&\$^-^I9N\\$_L;:_QNL.
M7KM^84=MN&A.P7E%53H@VPN'5LP00@WY&']#EX"HU?J11?1V> M1@>T]*.X\$%^/M-
)3(RTV*F@;_ \$0',G|KYAY@KBERC\3)352\ P%ET;%AZ7Z4 MA4&<-DT0=(W|_ \$>9K?
81_!%M|/+Y0&:ISW1IUFM@FS/>;29#Z.\$2(6ZQ&.H MEXB95-L.JUI_4Z{5-
WW!G@_X8|820.400WKG7!VB<+4&.'ZEZYR>UM!86# ME*HKY9S#3'%D0?
8X@Y9)^1W0/&:5JQ55G0\B=0|TA86Q=48DW{WF_@, C"&S M &N(?3&TV@))=
[-;0VF_LK^0F^(4PB|J(G)>&@1)>-?'<"0_#".U|X)#04& MH>1KB"RC+[E?
*2QYC9FU50/9.L;R0{OU|}JZI<_ %EB,QLE|VBAP|N7H&"L?7 MT&V;Z(QBJY7+'X?2"Z;_ =,%3B_,15)\$'2
M_TWF0SV+*T>?ZPG\$2QWJ^-/-?'3'D*5+EKV"<<:5 M,Q>V>R3%. N-[X\:-0+UP<)5L5/4X/,P)\@-
X/I,7!I")UXCW7W3W M318{0FL2;V4=6>/):0{Y5S_68};P_V"8X*S#^0Y')OUF#M50_@L*-K/N
M/2L_2Y*A3001G?SZ(;*#N06*10WU#"Y8Z_E_OIIP&P/JD-25Y??E_6KJG!>_]^0./[+G^*)Q3:6MX+9
J10*RN6\$SXM%IJ5_M0E!;YNRM3Z&^?^#|PJHQ#5MM<-
YEK%#>S^C^A^MLQ..7UFL/VI:KK\$1CF{LOMN&"7J6)UVA*CL;0-5-?A44XJ*?Q.#^W;91%>| M|
_IK{KXN1:L'@2H<>| #L3|+-G-U!ERSZ?.">ODKVPV,>LD8?8N>S5F7Q** MS|B|=>@JX+{Q@';
H>W_XY\$\MVR^6RZ;>&"MFA'SA8'#(Y\$131X7GX4/V, MU0F7=T:5(N23&_V;#A:2'ICM6JYT\ZY-I|
_!W2I"B0=D0G&5< MM@7Y=;Y*.T0\3_M4'96TCS|'P?L=\$YD_@P\ M\$R">!\W.K8RN'G7-5*R+B+UNQGG?2.^(>^
U_MT(?&53,Y&&7X/QU>A?*SB8;)_ Z"*145-KAQ"|'6BNC0H#E>(IX\$IS!7._ H M@!FV04_0%_Q0,E#,MU?
;T<*HA;-S.VLV\625%<1I!=?PI'#PZ0"9 M*NP3/B%RA /W*9Q)JM:KHDB=4Q_*??
=W6ISX+UDY+67<@|Z9XD\$*\$UF\|M>_MHW."1WP'..Q?._B9KW1I_ ^{&+-BR0&9^<-
(ET4#UUWJU_-7\$DW*!6!C*(P_MR%#P(R-2,OP|'<_)ZN^|)1C@>!5LNCB"(7Z%K?@L9A.J%_B-BHQ%Z>RGI._|F
MPDFPA# <7P&2GMIX%&^FB^V.3W-0":(C.:# M)6GV2&<#|YJ.UV00VZVQW\$Z&YMW=(HD+?8W" [=4G18T1<|2
2<"<:QE\H\9_M_OZ'/6ME2|!N=X;M|>+ZW@!;E:5E:W\$V/I0,& MT_?#\$XQDE#P&M!3P>BZ6TT-'_B_:@_?("I-
0#E|5@RTZP)0)M=/_?6",#FC+ M9Y@|PV-TP)\C0:%6@U!R#.6)U_WY;A|T1@%E0?0_6G!;@|B|U/R0EK
#L;J2<7I|<@KWY?M_D2I'QHXB4DC
MAB\2CC|X:;78V,KF4_"S_7W,.W%16|8L|:2^_E)CFH7QFL9YPO@W\$*V(; \9 M&0S+1-82IFZY,J_(5J618
MD01'9D)TQ>V)!|K=;K!)Y)[X\$4'WDWCII,7B2Y0Y05X6VP.YOC5!/G,/NZC\$ MJ=Q+NF/1-
B&/'\$)3,_C;70\H;SB'3.(H2J7;&*#3M"C>=-P2' MBMANT'-QCVUMMIJ958|DL|J_]*9H4=7B+(F08WC01:?
AH(>GKX";4Z-T@>| M-C^*;>W_JP&PL!-"ZY\!GJJF&\$K*\$9UN5"BT(\87?F:\$C7IE|,>T<@?2*+B<M);:
IN:;RU3L15IE9^ADUAIPA_'?Q6D:'|1AC03:4CVXF-GHT:Z<>AQ<_7-M M,\'LX-
Y';FFD0%KN>2=!\&%@7SBRQ!4\&7'|?KYU|E#>?Z|G3XXAH(.Y636WU_M8<|1FA2^ATPFT?860|<%DYS
Z|0"II<(GT"<_ %W9;K^XH.Y,[H|Z440R%&>=84VM3;N0_MLA4148H%C\$I3*1&EJ)38\$ _\$A_@)2HR)=0*5CS-
J*@H"8+5T0HE01_:F1&I\$F M(*"T" B|T_2D)*\$DD*RA-FE/>DI"CG8@'KL%/U.W>WMD>3#UJ'M|8PG\8?
3B1=+P@7E|2|C6,0Q^ATMG%;I:EXK|E:S; MS@VFD* (KGKQ,:Y_%CS;9W07^>_5Z'(1CZF@NYYX*,&|+8?
Q^1\$GHQ\^50X_M?GQZ95/ZZ!40^61R"1+*.4<#XNJ;=Z!GFN@DMMADW.S,C(8-+03H)9WD(58| M@I\$ \$AHQ7?
A*8*P90L?\$NU_45B>Z,4H,X+)EYS&E<+XN!73+F(?;\4P2'4G)" M)-U?;IV_%|^ABZ".D)2T
M4WZM/'\$W\$+E^R^U@{XH}>6?U0Y_0Q467RC9^S7+Q:BN_MMOK)G4LUQUBW/M8Z\UD;+
M29C@{4Z;5+7Y5XJT}>0N'48-*W'E'\$JHP?G^E0+MN|A!|/;U9UD?&7W!-TR6_MW&0\DF0D3_XX*LD=JWF*
<2I\0PZ)5?ZY<'3VZ7(KH%IE?FE:KX)_M';+XHL"^\J, &%Y\$IQ.,{&CD!X|2Y&<@7_N@|IX/F?NL^_2N|E2L!
[US)_L MF(ZH(*MAP8#;_*!^&I3L@8RZ/1|=>|XRB|I8AI.YB0|0M<: M ;?GSBLA!62YU,
[-<3PWT:TGF#^8=QL\$P""X(D|:C1\$4HHZRJV_ME\A,!/UX4""3;R9" I^ICY^" <+7_M2VY4AK%<1LY5ZB(@-
!T+!HPWR8|(R&6D",PV_'8Q.J5_0L?=(2.\$EUR=#:_\ M
[9/8!CZWD;_5G"R=K=8U,UBYQ0(0"*R5NT|BC6H=A3P&K87*/\FJ#;+1|; M;G0&+I&)U&.'7B|?PF^|/E7-
\$1ZB\$NFA.ABC5MG(M01NIP)[8T2FZRW_XPK+ MT-7ZX8Ww6;)-HJTR_/&ZXAH^/_ 3=H=\$.M!#C(3Z499\$+(EL*
[F%FSF;S0X>' M8"PQ,T\$R-Z-6_"LFN'?LSGAQR+U=?
Y0390VYT|K0&\$[*4F!>1:SS."X@6*J2RUG!,"JS"?;8W=R0\$U^2*+;8I\$;?!1V)24,5%A^"2KI*_UY M|!L,?B-
70#I^07?/Z2V76G;HFE)I9XZ;-UX#=/EUBTL|Y15+ XH?9IBSJ42_ME=-#/WWS57;X.44"0|.S21-LY{3T
-7W;|=Y0_Q%,N,U451WQ |KYD|\EB_8_M?_XLR0Z//?IE|!|] GJFTJRJ0Q5/|9UI2RC|^,4^|1;:SI0(X:6*)
[6P>'0_M|^|M:QESQ2:\$D0H'FEK065P! M#)_N*,M4,_.6-!LA^0_9|]8J!#G.B0BW0_03=(M#I6-
JIT>QKI\GM^,X2H<6!TA|G2\$*J/ZG<+;Z"|#5Q: M:X|1ECC8:>0*P_Z+*%7ILM%Z\6@D|FOLD|T\$M79B7!8H!L-
\$461+49!A_MV1,KIHC"A4_7F(6:0S\$S*\HOV?814ME\$HR_'0MESMP1W+(QCA^KV^8;^K7E%_M;ZN");+:/[HE_-
"+\;DATI,)-#CVZ?P"(HK!|88V;YBA_5\^G+=N84%X/YU_MKWf&&D>XT?4^2R"M?L.579,WGN9QJX0K@
%MU\EXAD?/ML'LC#J|=2JV(@X_MR8|!M|U'Q0JCMVAX!/X:X:JQS\TE_91A?;!"?B(Z0D?..0"Q+GY7DH2>X#;#
MM/W30ZCW" L2PHGG!>GX"E,E?80T&Y?-L]*MUWA_?YZ(Z)?|D+=VY^>7/^6\ M;AX,[-1QEWL'[L.I4_"B?
L4\1'720KR(>J/'6ZF'_\A7|/-"UP2_E'R9=01G_M34];"!,->F7;|VI@=[^&\$B*K4NLH_.|N2ECU;0>E0?
K7ITV6Z|'">#96Q7_MFF'1_505V^K.4D4&WE-LXE,38I|Q_:Y20\$1K1E'N|UJK6.8IK&J|3B|^#V\$6
ML;I'HJ62L@UK_5I_/+9!Y-GU0='HD=\5WUT&EW/72&P%6XB;B@CB_4ZS+(/K
M"EZ)GM6S!3H0^\KZ3P*B|*M_%8BTGXW.Y'|8#A"->/Z74V2*MM\H??X_M#-
\$@P=9(9"HG0>J/W0*#PE+J:N)U+|9MK.%^-BN7I)?5V0K108D/3:PK.A6?_MEQ:71U!-RN*=%)-6/3S35"
[VVWHQV1_0U7+U_NZ:|+;,XDYTY1%W)2;5&SF_MU|Q+WG*W59J^%5-
QJ|W/&>;JBK7MZM,2=;:2LP^2Q*)R@TI|)\K*3J0\$_1" MI"@%SSG":6K8WWMCE<9M_WEJ%0^Q108^>E_KN'K+.?</p></div>

-W=-?J]YG^7FZVXSD] M?%&DQ#'VN;>WDB]X/KY9BU0,Q=G2--
WPHYW5ELF.,O&-' /7E[3&U*2AF1E/WI?;FW5B#3IQYWMF-' :734P M)% 8<,0EE@03>K_G3>\; ;[';LN)2W]N
]!.,.J*Q4U^2:4%WM3@]37]_9GF9+ M'L+3DFJ"?
FWD5K2NX!NID@'NK^]'I7S#U!%.+ZL,M^L>.:T>3[A:X64R]* M8HV6-;0]!K23AJT*&HVE+Z-
0;+;S]J"Y,"1DWV,W\!'#R;G*DPGCN]X9.% . MZ4H7+3[04+?B,XV^*5%TMW
SG]]X8#B,1=&- .0%D%1'X=1)G%5.-IC(U_TZ M)RCM4\$R70%U3R**]&/)]ZL8@'@T9^KK<0.WA%,?
@]4G:CGSISF1RM#MUSYK2 M'[TM]]9\$]B2*DX7T-N_NY&B\;G6\EE,8,'Y[KN+U=Q\$EY3%I1>V*!1XBD.M^
MQ^,UOH6\&;?*0XB>&B"1,-'S<>P0[I!5E]:U+XNM8>7'IH9M)'B\VG#;^H1
MXMLL=A]F*H1>UT%ML9M:'E2'F=W0&E8BYFZ=GGHM[=&Z*"V*VR,X[9\$-'G
MYZ^U0=8*F85B7J73WN+H2JJJB[?:'2F?K?0\^N/@J26S-]EJ[3:3M\5%Y A7'
MR]R3^F,M27>:8@X&FEVD?"T#,"61\$MF\$]YKB;_/#TZS6
MI\$]8IA7&GMW5ZQ4A<(KOF>J)6Z[37]Y%YOVV76MOKQ.*'CB480""WU6_0[KK ME0]QGY3;[BK;29:K"QX073,?
16U\$6%\>(#5C[FE0A7&.N45--DF*%&^94M*R M^)10IL&.&(&J]020];?<\$5,:UQ0%),9JB&(N9ND], [7'.SL++
4TJE53CKPH M7BNTGM^N:>V:@003M.0DDX>8^#0KLOEM6]0HM]>K?^GZQ;RH;*?W5.DQT+&[M5/
=>2T'3=>N I)6K4N3Z03&NZ Y\$*ZH+OYCWB/\\$"<<>9E^RA4\['.#Z7N M:= 2VM.V49K#4'RE1_(\<,
,M,U^5:IWK":4*6HA2[\$F@LU#8M\'+\$P0G7T MLFY;]AENY&7Y;=I3E+Y\$6@AE\]-
]BY=HCFDML]U9:MW"JM770IP=>/FS1CQ M+D(P_H! ?X,F.N3 M"@HITUM]040(MW;?
2"U>=S[D10_XH;)YCNKAC#=/,0[R]&BW& @5A; CHQMR]8,)< M+!N0.WK4WV(QP0^;
[GP.B296/R.!.T> 2=<^<1I,XU4-3+[CMZ&I ^[C5."-I MH;%-*6SVV&).!<-:V[\$ _VC&;Z^KW-
*95_U^,HW'R5>.1TQ_QOUT>2^.!F?ED[:)]+3Z670UU\^R,"F+3N.FC1M?
MGOSX0]!%'P@!#Q=]HGV^3'Z.^4Z:00/ =]9\+J60H=R)PMPVA-80P!N..DB9&NC MF"7=0=IB?;QV=9C]\M'??
R06L[@?Z'^Y@1'/?E(IY55_#(L"7H=\$L/E>0;GKJ0K0E.= MM_E0+[^X=F??L0!4;5RGUD;R)SJHW;UG:2]+
,G[C2]J^;)-1ZK66JU@_2H MV#>Q9\$BP]QA4V-EUV\G=0@/?ZF-[5,B01/0[(RKDDN#7M=M[K%CO\ '/S^C>P MT
,>@;X[%X,YFJKD.]DN!5^<2P-M;70J+VLUKTUE&S]P7JU>FCZ_*_KNU9J- M["G'?
K\&%07U"UC1R2P@X^2"J]R+S//216';&0[W=KULYFK7[GV'Z4C0Y.5 M7"W!S*PZ1]?
DV,5\0XW1"]DR.P@MIA=%)TZL*;(1+Q_R0,C.TKK4JRWK:.]1 MFS73U>5DJG1Q.,U)KFS20I.'T/K\$K1>T#;H
MA-DQR.-8;_OHX)0NSQL^Q>BNK<7*P)>_51*QE;W4* M,-BDS[:8Y]^_VV=;U<9YQ-G-
B*;*+E1L:9\$+D!ECEFB03GLXWJEXF M&080-3K0*2,]268,7XS>0N5QF2_]5JC?V%/%0_8:M=TRN?<
%VG2,T!%_Z^DX ME0_1%[QF57E;;SYBS;'),%S-%U,/(4]C@]MW?ZR9X&C7%#
M,81"F_DC;\SZ^I?]DWAQ2KGNX'+KYG[G&!'L?3V36DXM4W?H2M; M=X%C)\@N2]\:MS^)\1&SDSKJT]+MQ=
(^G*Y IQ3\$;V-J@N T"FKPA.7,3)) M_K1 "0>ZRSEQATJ7\G;.&#*HZ[8!8)M0L]MXFYUJ\%J?Y-/ADPMW_9H+<
<5\ \ MY&37[/6L"8@E%!F85!UW?)#*B#R?5_&VPW.[QV\$:[7]HFY[^EAKY*Q<' +HM.
MQH].XC90];,\&G3VF1:7#;C2C:1UW;J3(BWXB&P=^<(W[.&F@T^UW+,9W'Z
MKKLC;PYJFA@G=07A/\MG;=VW/G97\7!%4W-->3,VU'?+N706.\$Z)JAXG1-KK>]7^R!FP\NI7Q5;
(S;>:RC[JH/_^Z>DR,A@+]2-UN0J+X MWfJ\'\$4#[7:\$'5&=-G'\$2K)8J>3>H;4#JR(MS"KW=5Z7(\HB
MY(+<2L);,*3V<"9J;FT^,6/]1E\$V)5\$';RJ3E&@YD]\$WYEXW1\HH!:W2I0-<1?@A.Y0UNVV56SL^+^&_F_Z-
IWYZZ;%SU&YKTYL\.[M?U'ZUN&+=.S.2ZP\$[\8Y]07K15:3^CL<'X_J.RE*2/K;M<;N07##XM:-OK-^
MN;JSE"D5&EFP=SSWIE0&9\$]=M*>W? [IK?,G;&\$:+Z^]K6W8X7(R*4'.PC^3K M#6W<:._\%;BSL?-
WU,IVNZEKA5E5+/7IINT?ZL]>\2._\YL0L-FBN!*7% MCS02^3K&2/L\H1%L"K4E5CU>" N^K7[4=K-
F*/M903K/49JFU9EKB MI-T;BM0=51;H(IFEQ1T>MF;DUY?CE'Q?ZI/:BH_:J^.-[6F-)C;JM'7C87L
MI6^*;YZE[&5P\$D=ZY8-:[KPY+OWGIO.TS7;WZU.+68]H"6@[\G\$FM(:I+US M#[6) '(V+5%MBQ'E\$-7 N+?
XB%\ M>H#(Y58C;@YY.-G0-EAK@.0A=+<6HR^+EF![4MY?7?U>)F@.0SK:0:![KK5X
MBOA8KLK;S=.\$+M)A,A'PH#_CIKBNABLIW).WO.>A_Q;3]U\M^:YA-R<;B! MNJPV8;LNKQ0*%_3-
]\F=;@^*GSH>.CCN?NF(7F. 6\$_9[:FULGQ99^KL; M'52Q5='(:B[RJ/:+BX=6I=9Y938600M.90CQ?T-
'I7XZTLNDD7RT*2)\^X M??W1XF\$G2LC6^L6P[=8(3:.-00,KTIHT2P[V-G"852ILG[(02[C<=V,_)?=
M;]=?'FEY97P_TL?,<:PYMU[!K@J]R1LE<)<K^VZ3S2Y9EV^CGSH7F=!ME>KUT M^E'U +V*AN?JO@YX\$M-
X"/>NG;3LPJ'!.ZIZ:0Y&Q3L^EK/V. M%VH&%&=?^5F5PJQ[,-4NYZ5:.0QCMD<,RQU<7NI^\$K?P,N\?
Y\$<_60\$0.+WVOC)T>05!E'K+/P(M=3?]\&[WEDV.ATH7]XB7A7[JA8QX<>W9VA'0R;9D?
BH704R\$<=VCD&RTW&! MJ!X-R^94'\71VW%IE[=J[WKJ\^C0Y100IK:/%N/N9\$&&D37_G+#+JCY-!Q4\
M30NV*NTPXW=-9!RL>:/;D2=!]>0+=T04F5I*3Z@,Y[CS4L9]UY?-"#H6X-++Y8 MIJZQ0<90G?
G&8L,;MM.KFBD!TC/\$D7:I,?[%C+*1MC?R[,J \$PTOPFH>DKB]*ADUB%M\!Q.?5#UL_0,=]GR6'R*0W3%
MUPO*M4:AVFM"-F@?T\$H=2<6344SI]-\AW31+IIJ-4\X.K59T]]CQ0-Q5@139T;U-
JW'!L35.K*HY\$6&C\$^N\$+_IN4RC<>IXCY6)3 M^?NU3WRUQ#<!\;=
2Q56W'E\&L4\$*/JQ'MP86\$+E(0:>W2BJ(0JI]#CF?RW? M>AGD)K!#EXU+H%=4GY\]C%
[\3;\LDF/QT>_V8M(A^IE\$DM5SCN2QM'PNM49" M%QC+CL*PE823A+BCV33=.Q[%
/7@.GEB&8NPS2=67XX5XFEM!(I+\ \["(:)J%44&&IZG&I0R0G0:@0X1I M8N0%0"1C>AL/(5%[)E;%S4-
N0\$03U*Q"K^19_"ZP%/S*(8L)UC]-2;R\],I
M/\)M^,5_MN\$'_=V&0XZ=W#4"0=/XU.]:SS9J[%@N:Q72'L^\$3F3QTWI",* 6 MW(-E3WH>X2&&A@\$]N,-
Y&RL9I9L,+(\?L1;&[Q2LX"&\$N[^9L?*\$ICR34KWF MJUAA[TO1X>7VGNF3\?8YV1F_0/7VV\#<^Z7?
&@]I2[T(8=1\$KZB;5N!_KVG MB\$D&WC05+XH_/OR9\KZTG>6-D]&@ JJ#;4Z+_6ZL#
(A=ZNTeg=1CL0W/)LMYICTH"I /]"/BMA50U"V"E6P;!K^*EUZEMY"*?0P2A? M?8<#L&/IX&
[C8I)JANG)+ZQ6J>D9F[0ZD7R*L(K!\$58<8!9= M.[/N:_U@G[LL.:INET\$IM[D-3]?
E=B^"\@9G+&ET#>BCE3%1]Q]IXV.S_2C MF3+I'?]MT(K0CM0QWT&]\0^5\$8,P5QA!W*J.GHVMX/-1F]?
3\$!F,G M@X(/\$6>KHH/:3J]U^AE_=(^BGG1&UQSH;L4WP\$^?21P0X\M#K\]=@C^80
M[5KBG\$JQORCVD'+FBN+G,G90B\$NFX;B'C+CL,\$BS#NL0DPF+/]EP/*?M;(Y M'G)D?NQ]X,/'I);':R_\$7?
=#C/)=3%*DGR%/]3[G(7Z0@UVIBHVXH:CF/\$W\$LW'4QZ>@L#6A5+@&:\$6ETW^EY
MC\$#S.\$X2;KX@C.OZ+K<^C.'G(32^2P'->?I#N3^4G030W^4&>D)G/D>7A]A<

M2"XG;\8RU"/WOH(*7TC\ "S<5H**W,H/Z1QPJ1E9RMK"2-7M?24ATA?\$(B04R<)[,0;D+/B9IB?
U>XK(DV6_NYLZZPA\0:\$GG\V5!M#0 M5(M8,&#"DSS!-P?/(L'>?)[,[*\$Y\A#U'\#H-,Q0NZTQ%_VQ)2DN@-
BQX1R MXEG'Z9ER';'T-"DB!_#37 +@=)';0J@!(V(2E>_3IT\$./80N29]L^3?/SH.>BE<_X,)0HXMG:^^B2I
MB?'PG^>#SU3'<4&RSZ+K?859/+Z4 H%"7<^_@&=Z3H0#:L<8+,[-KECY;> M1^ #F:9TJ0I/G G(OK"?!
4VUR)8ZKJ%'F;E',4)CT#1BPD\ [44_?@V4(*MC M.8^32L(18)ON@6W:D_5SUBZB/U%:0?JA-B5(IWF8&
(B>2]QW+HS]D@. MN306C 8=3<4:7Z)G(" -/A>PV[9_6A8,N+WZ:TR0_***KR2=3L5W+*=T_DB#? MLQ^ H9I
(09-!YW, :NY;+9H1JQU^609_FQ\$[?ZFCT;/"7DN6V">+@ M816U:FP9'1.Z;RY>#)9754:-6(=FR).BK6:D^A
+LJX4A\$ ZRZTAV]0XC'81 M]#%/&TW/G=@9C309) Z3!=!] "(I4:NGDBB75FX/@3L(R^=7)F\0DAUWA\+3*
M&*;!?"^FF.[^#"W/(CYBR2]A)ZB_P0]4A:3]LU^M"5M17,93U-@*N'_;RKQ=A)W-+B'>N_ M5_I] <*B?
APAS&I^4K&WSQXMU\$KC'/Z!5))>Z*CO!KEK*K#8>+74912WC5E)1BT6Z?Z^)/#<+H[R\?"W_1N
M2)38WXG70?:R%P\A#@SJ;6_3L8= MY08M!D0/=1BA9YYKWVP=R\$+-Y,+NT@-(I(=H'ZA!'?U_4C9][XHFY?
_5#;7 M\$KX77V0"AC#&JNN?P;Y\ CCTR8=#&%K.7L8., -H5;KJ9&T=7N.W" MN^RW0(I]9CY
90=2^)\$'T+4HAN+ /Q1R:%TD;RD2A5YBIE3/SE.. 1F_15^ MS+HD: ?P'A13D8I5,Y"BNBRG;!3D(<
^NP+0]BT/T4[FYH]!10=.]E<+3@87 M,OGQ&S? ;T(\$SZS1VA'6-4)%3J>
[YHK]QS#=\DA>V\@*A]Z*3P4L(10BA3-8 MMA"7?_09#6K001\E%)@1\$8L"L(R-\8/CY&-
XXNA_S#R]RK/B(6I70[\$#KR2@ M&:+[?VXKZ7H&1UKIJ TZC,?^+KAP-/F9UMCZ\$]ZZ7^X<7K=;
MX,_6!CAG>"Z_W_QZ""I7X'J?M%0'I^V>R>7&HK[.Z_K9R=:@_RX]#KV? "V6[AH#5[Q!WY MQ_
MU6_R\$&MK6;,*+>/9?L7K[)Z(^0;7FG10^\$K\2&E+@EQE!G:5%,SR-R\$; MS8_X\7:)^]%Z7JZZ9R?
UQ_. W:2]00H&#>8= -7F>EU!)G#8A! :*ABV9+ M8V&
[/92\$S/3+C,E'505\166GIWFP9#*J?7;=+*@\47"7F*<2HJ^5%EU>->^ MF<*;PG-_9=0)8]F<#2MS?Q!-
VZXSRC(W02[Y^'""@#0WDX>>KIWZ0@K[LB=S M.8B,Z \$W[<:(+D,P'JC2N@B%PGMV'/FWQ:'8*1Y"C/-
M5UB3[1":.668 &X(MF\W?#AT\B8-E9'JP.\$7?T9,]E?FP\J]PW+ ,;F/150]W(UUI[18'? "NOM^(Q
M^GNY;.'P@NMMI+B?;.@A:[;5]I/\3(X*552J_8##I>FI4US: ^B/NMU>=G\WE M;,'
<3"I)30@+]ZT.-=PD=5VRK&C-R^4^*\>R0)9:[SY_3DH*4S?2"6BNS)9 M"/YG?
M6['M*9#K&D<,DHMJ=QG68^UDLQ/- [+75203BV<@^+6[S@(\$C=7 MP5,W)Z%#
0;L*XZV2E_)8JX5LK0VIZDC@'8%VZ>8C@RQRX[1]R3\A@*9.[9(W? MAF&Y% (+E)"S0^&IIP/Z;ZUVE%: ^?*>
1@;CIK\$1A&4%.YA7U"-RSZ\3XS7"RU M"X^/A6VW-;2[L^B3^H_0F<);8D1!JI4\3N^>BT5^>P\DA?
Z]>Q8WTR-M:0 M?63UV'52 LKG#[]^0!/U]1SP6]T!+4EW=.N!SU0>>0P8D(> Z1\$Y8Q77-(6]Q^"/MV\$'&
M9_0'605(G&[7?0F5+.Q3QCV@2EEK!RDX9@XZKV7=(F8Q-X?B/06T3JOYF0-! M\$/HIN-UUIT3T]_C%,#/=Y,U5*
6?0"KR6^>".(PY^V',D5]M!ZX);6#>EDT8_MZ%,B?['G);/089L[17KJ_2M72@XG-I:W/-R5-%UEEY4YB\$^L
F@1.!L 1@ (MPI,M35CP[&N/33P\$? ("39H0YS3E^>6?;YU\$Q0JZ' X]L7;T*Q.V@MF9T=GO M6/'V-?
2Y6&QDVR0&LS_*/[*F+G: @C,8 P-'QH[3QUB"-AX'6H8>P4@3LBP_Z5K-F12XJRW6>6#X1ML(]#
M9[UWB: HX4B"U]GK(0!0?>]PQ1>DTH^&-/(0@P)ES;DN'V'L,1],*GIN0;5V MK93733?^F-?
7\V"Y9I/#UX75E?5=J0R0VVQTV=IP]H?760R\$QMFD*)% ^60Z\T^,HS>^*=90>N^?0NA=:1_MGWZF47
MM,SV>),TL_Z;(:QC=+L\ 5HE]+RX)\&B]L]!M\$U=7E=' 'D97B\1<'K344^[,
MP1FE_/BU\$SN["ER@&+%6]=;9)_E]/=/'K)_Q\$'E+2T:./XP\$'3(OH3)/%?WM_MINCB"G%QR?<;
MR&41SB'6:5JK@*W%..GXU.<2@#J9GUVWN37J_L;./SYW\$_.F]=W?H3]-B0% M8]N-PV\$.ZC4_M6_M*J9_?MGY-
7/(?),\$[C.5\.(CQ.,/8]L\%-D[!>!)^ ^UNM=S5?>]OHR?KBJE
M4RXT)=^Y!Y#V7\$U[SNC]N&.M\$&/L!5]_Y)>6C'=4;L],B/T*%LD]-WV/_>M=C3=?EA>^]/?C
M8"TLS*X\; /5(K: MXAP[4E@V@T\5YKYY*5!VUD3T06PMG(S3:]YK0>75NZF6B\Q'% "MZ9&U\<30]
M3*]=@W_@#KJF4CWAC+]#94<.[N7_&R:]8%V4ZK4=+;>.3D8^>@PJEM!=+]#7_M+H!'9X.'!
[G'5@7U6D]02/D0;STP7AM>9?-UZ\$VF/I7"X!H&7"124.JJ;:7I MX+0[D9_YZ66D[8._\]-
=2L96Z^X.AIM;0,VM8H3-'&=HWAEG^C!U-KTQ\ 1(0V.V_V6V] M3GKXYVKOT]6Q%V\$Z?Q;Z=S&SGHUPUMK-Z4?
Z_V/9'UNAP"GLTP6\;N* MU74D@\$L0_B04_"85!_ ^+&2<1,Y<] M:.\$QZ90Z6;+F_YX\V8^)]L-3
R_/OZ0LQ='W.(R!D+>F^AY\$#-;_&IM3IS_M\U5M)<2'2-5H>S'.?.5=-
+R]16_16_!R#15*'Y@;QH/2RT=^; ,KY"'+>RVW" M,NLL?
G2+4W25DRX:CB5GJC2S^\$;R.F@P9WNTMPD\X/U\$J#\739@\$X=XZL5\$? MRHU':S'-H(-:==Q'0\$!
[06<@G+>I77"ICSEP,4?,EQ,56C(00\G=,'X:C)/# MXW@ (RXR?EU0 YT\$'9M5(3GLHT" T-4@PK0K7&V"0_0,^
%:S8);J^N_K5+)]I?VF71>8 M>;LH'3A*YV<"Z\$?Z)B?9! OM90LK@ (=RJW#X-5DN7C020U9B));\$^7WS)?
=MY:]I^RDUW+2"4]UEP_%G&4*]0\<5_M[.@GS[?]&B(TNVB\$/.# '>A8K\+!>17A0T=531X?
_1N)J%F/2+\$R2ONZ5_MC8UMX>R7?K4GZNYK?@\ /KR<,-@>890UPQ6HM-QUW+TOMGEBXJH+=M[N6@=Q
M; ;TX\F8SKI9& (*MZC]\$YWNX]Y.'>[F],?K@GE+P^Y&V_M9RG';V502%\A8D<+U^CEWUG9Z%+HB^Q1]R[HS369?
4GD5:34';7:F/HRST! M1C/\$. >!'0T:C^9!8 LZ5#FN"- "AE05^K_5<;K,W44#RJ9>%-8;?@^NQ>81E]H!K>8CZ
JYTW)^=UR< MOPI+0L43_4M3=U\$[E#(A8UI-PT" "9., "<'Y#!.].6H4&<,0T;PQ+_8,.P8Z_MZOX]?
B67Q/)&Q@ [T*>].5<>[UQ7-9VHD[@8QT[T?J]'Q*0-081>'F,EY\$;(6 MD+V5L@VYGUR;R_AM_\$'LL]@!
(CMJ#NAC,60XX4\$94N0_,R(Y%#!@_,/\$4DK M#3A\$W12[F; ,^JH05QB[:L:5^Z4K?+0./H*%0J>TZ\
(#\$_EE@!0XH:K7HF>C5_MA!WXZ>7JB"67_<3%3_0>\A"CHA:W(H,83Q)XM00H\^!\$U&.LZTC+K>)^;NBQ
M>.L2SH6-\$*B40_?0!,82WQ\$8!>+8C,U@(!Z'A'4;&A2/ [62:L\C'A93;G_M%7EN>HH-91]Z9Q4;+.!>RC)
(\^A3\$ M1(83A7\$!G; ;KZAT[-IJUMW)7&S8>RFU185*,>1IS\7,(U6BW&L^HTX5Q_ ;00,TCG>0F92+B<'M>XS@
MZNU"-@S#HP1&I#).G5VNT3;/'>= 0/K=!S#*A8^AX'16-,3*52)Y6^ \#E>%C+,=S";QG!I/Z0%
M+79UU/*\$ZL_ [8L/R.06=M55(!-?3\$!I94"/-J>C"QU*]J1UHW\QH3^9B02@M_ -T>WUE;19TH[S@_3NF
M7&.,K\$%99/H7&[*T20CL_D:MJM0.->/\$5A<->8R\$8.9ILNAUG(@TF9_4P_PN_E
MYD6Z5"5I!+9W4C;'4K^9AQA'<5H"CAN_XL2"4>0/&@:P7_5IEG3,\K@2/+>Y_MA-LW]J^JEC_09NJ?
VP#\8=85+3M,@0+\QU&5W'Z_H>H0Z([!14CEU6D_LY.7_M.;#&M;4*&(N^#_G(P<5'*4R'ZT.D'WO^
MK*XB544QI9R/AYIBQ41ZL)' 'T9AE77'.?)8%./OY8*K<,4!K[,)N.5VJZ- M@5P[WIB+_A_ ;#@!
<;163DM2"3\$82F+";J(X" ^5/>0CZ=T!07.*^R\>_0TY_MGH.-T; />@>2, "QND*/Q8"UPNZ2T^X3NUH_R&N,Y3-
M%QY@#W^F[QJ9+8^ +&1',L#!"4Y:WX+\ / MU#" \ (KNI%+KY28A!HY(' _A1[H_ML.(+>G^Y1B?VE^DI];>

<28N4R9(=@-(E0/;\$!C!..0:E0/**L-*1M(00,#L=0^PK>@@,W70YI[8[000F MI7YDAR\$T0"DF+.,<=!\$!
< **HA[\^M)3/XTD7&\-P-.[ZUJ5+ '* ,172@/ M%(MW'\$10Y]^QC;R% ^QV.8 G2CY/1\$
MST2MC0QZT#=#Y2'\5+J!L?1,+;U A/\$0 X(-/,2A3-B=(JTA"AQ'0LJ0&?H2 MT'VDSFC<'R\$S,WY)
[X^_S_S=>E?^'H0Q- /\$YK '2"*_FW; MP@I*J!;Y60].U>0#0A21%L0>SD-
LW3SS6U_=#4;Z'AZ'#'E#^:C\$G)/67>9 MSF9&0*05-XB+[VZ=RTZZ/HP 4;!*R;G553&4%P2Y['=?
V@<\$!5HFS*T4)TNN&X6^+;5Z]<"4DLUK+6AD7.VQ[P/-J:AGY8QW+ M\$X[FZIKG?-!A>>GC;
CJ*V'Y[7]D[(0 U!TTS!7\$T='DN9CP87;65=CW5Q!K MG((P'A^@#QM B=\$W9#D].&3XNP!,X8EC-J;@N
3<!)!_W MLR[[3=Z.<=UM"/SN00Y#I)7ENH@_#E!Q'08"1R73")&HD48/\$0#EKU-K'GG MS!AD0R@F!
(' _\N/V'[7.F03HMN3(0"!&+>\ "&JJC,#-5>/CP2\Y-#*:P? \+ MUXW[NXP8^M]1[#'D@(\$+R-
3;JS/*4C/!+HB094RX!U4@PA2D MF=)&9ST%WIG._*Q;>!.8UGR43U4;LTK0L.S1* /5XLXB_=<&2F1"DVOV<9_E!
MOT@>8A^*959W5S;QA7,;-\$-"CRNDP0]<()NCGA8&WL>16-\$?7A[@0%EJ33*5J M16MK@+%;9VJFVS;;6VQ?UF]=
(Z,EA\$0AAT6:N='4-5H9D' M?G83Z#3ASH3;,%&5NI#_VYQS]..51@??'XT.Z)FX/UFL\$1B(=86E_)S@T!*
M'5!6/CM<&1_E0-) ^\$ E>\2=7)RD,0].+1PAJ&QIN-/AI^X=6#0F]^/.0/EK M-
>1D#>>7U;S),^&23)PL'+,+X)B=\RW"OT?A/K&?!&-4Z0:=,;?C44!_1- M605;0?
#0_Z>/+LHM9)XPS\$,.,!+&PNGA7\$#\$CV@#/#/ HV].9S\2I(R,'N8?1 MTSTU:'K518T54<&_*?R7F"'C+3S0"
[:F7]^?^\$:@C?"A@'#@N+ D=8V+V&G3W_%!C+R5 'GP-ZBFA? M^L[/Y+&<9^-L+2>6+]/MQE>&KP-
#6KIS*5<@JL16A"-E?N0-#;V*WD B@I" M(-)V!GJ91F\$MIF6%Q\9"/-;5#?I.]@#FXS;:N/#0E0'N2T!0"CS
;,\K@?" M1C;_VXVTA1%_?9DA'\N\ (Z7>BR MY^G/4QKJR5^+ 7W M/)FV^VWU!\L;M4&;;X^6?,M2RYC_YK?
#!NUX(-?10].4AYCJ5FW3\N+F0)97 M)HHZ:"9],,=I1\SA(MJO9N7GJEMMJNK&SH5;30Z?AN [N4VJ9L\
<%X<[,!]XSY#&BWC<\$V_&JZ&R5, MK,96**^00J[KQ6!3JZ#U^+;0J2:ION()#16V;#>4"0FPSTD0U:UBE4LN-
W* MM1*55_1)T00#W\,ZU7KN\93L6Z?3[LMGJG2_[\$AQ2YE_!\LH+>1CR1\$Z"MY
M/)DA5[B1*MAX,T;7>7#1T/X,['\5:A&F^UE<2XH5^Y?B14RJ([:K#L "/13
MK:J2J5:&2X^+!X1)#H^]\DW290XA!KM5#X\=EF^J8Q_ZJ8?H]>8=5/LD9 M,&)#3'CZM^/%(:0#A:E0VF6IPH?
P/GK@+9* M(N:>;?1Z+>NW>OG@)"<4^Z:"V TX)LI8VTVIQ1IS;Q[<"JEBPTW0:U:J^E M\$/#U7<
5[C/.PA5I3X!;U8("L>XFX2">U&Y^"> 9VY+/R&%>4&/7Z/--8Z_RI) M@RVOW VO>%Y+9-
&176_C1ZIT&G1F\^9"F'9IHR.LK^_9_Y=,M/3FCTSTV(T? MF:@JS!CX_V(KUC',>K02TV>8BS*QS N:]^S+
(9;?.AB1U:_;-L^6(\Q/8F M\$(@=Y;>6+T'E")-
)S3_Y*>'S214H.-.@K"JX6BG@:]D0MZ/9:\ZX*]L7IRT!3Q,U#TCGYF/@:ALK\Y6W F()./3R7,?U8;?
023Y:U\$LE\YB9I))H_L?QX4LZ3#_T+=61M>B M&F75_1?%V-V<'0;_;"?A'HYV[=I%.M"_C.7U])#
<5"X0;5%!*>?FZ6C=ST8_W(\$\$YIT\$VVABQ8N"SAJE_0F2UA\TCLD_R'6]\]
M@:]7)KI@9,_2@?]/>#0&@D)@86D4]L:&0:GX?0U9#**>5J"6+KT,*S(<[ZMD<
M;YRL[K@CEYJ=8:CGZ'YR@S(&LU8D7=]^%I@*[CKXR)V,WZ0ZB=?_7.UVVX
M;]*)>0+'[DLA\+KSLQW^PX8[*_0:501,6[Y_9FR7?
V4V<)\GPW<;>INN'^&2K4UA[9_E_9Z\R5]JHF>XQZ6LX!14L?B6TB'SB=/HWC M,9.GMN]?
Z_['.01=E6Z_!*/"+0/J6Q8VI_T]9#*V02YF;.! JON'S.MUXA\M+]%T7G^WZ,YK%FLL=_%D.P
M5&_*%\RCEV^ANVO?&/?:^6ZM@8VFTLA#41J@]E%94)*K386WNGP(IWGTI_SRB?5X52JV#WVS[%-
!5)+Q9W+7V/=YO[_;#*3.^;I0&\$^&PUD35_&WB@H9/B%ZQ+BM3I?.U]251Z
MMWUXX_D*/F^9PD=1>0(9'^:CK5=C4(+83=\$'0VV9W3D?TGXN%((EP57N=8 MK9?0ZM#J+22
M4,2RAS)/RD[HS<,4IL'1V-S\$SR/C('K(:KVG^V>L&."YE0#*CL.XK\!U! ?0 M=9\$S6E*-M[57]@9"Y#?
\"#Q.D?#G.(7/U3^;5*\L0(2X[U*JE[D1NZNMGA(@ MPJF]@M-:>21(_\,FMA*RK?3@%[B1UGI\$5-GI7G?
*7:Y1E.:72.9LQ.@\$4;V M:DE)] N5K3R@H<_Q#ARZ>(WCIL?H:9;7L-I^&D30EPQN_3
MXUQ<6[#+_FSQNI\7>7G]\U0 M9\E,*N CTF&A#NR!F_.07@0+QBSC7&TX0: M40+J=+,.X]PON3HK81&_?
[:\,M(7BF3E?1SH,3_U/'I6=04&!PK."Y%>E M)\D="U36*/Q\$,+Z8!^V M:/-A\EP:>
(:\)\86)VY69N[R1"H]UE+G^LV4-56?T9WMS'IS>;%X[\W0#]*E MV;5X 1XB30-&'B.2_UF#)-+J?
UHQU5('KYAJ_WR:IMV|BB6I[81[\$1'T=J](- ME4K_6FS52?CQV\V/)7L2(EI@4KV)K@SI6 MUMWWF!\$H2W+4?
[D!EMAMZ<8@J]>9'7N-GZ0%(#_X M"!P90:Z*R4N.[>=0;\X-A_/[R]>3S4_?
LV/%TJ5ZKNKLF6;BA)"BL@V=16R MA^S+) \$E,3+(S9EJ18D(HVU1(:\$R6L0Y3UA"RAQB[[:#,&,\.8N3^CNK[IOG^
MZ<[\]-Z_0!7I?E\YGR?[^,\S^,X3D8M-(:S\$F^S8,%7H(SIS&8VZ_V8L_]
M4Q0Q(\$)%36"K0\^/I;-08@D+\9.LJ^WM/";_T"-BFDR;BC6HP 4P\7ZP?-\$ M+] M7%\$3CW-_#S#4_3#)TE-
NA_9HY8(A7XYR[K_6] HC8;7&*,_MV M2XR MSI)-ET[|Y<*KW G:\Q(F%FC+[>
MIU:F^;_'^V03!ROM#N_YZ=LV>0/T='9]PB26:6/8YI,A00?"0!\J/I0>\$,>^":L&1_L>^\$,CB>CNL6?]}#0
M%G[T]?4A7,6NCNZU!_#Z#@"/%H0S!&Z\G8D_-Y57-
I>/G*42=H^EIGLSVXR]*W%KJ]1>NK)0')**&A1H'_]1T%S>* M,("0E@72.\$5H^JBTD]
_396TZ+,B'A.0[KHZ%CR.=16G%E-L&N0)G\$D=BJ?" M?:LN:@+?>8,[H1Z\&42R-@MHGK;(*80+&2H5Y
IG.&2S>U\$+Q-RJ8;'5RX MB\$?}VD,VB\$*&8(&_ND/5#}QR_0'NB:+^B1%1*:4;137<\$PK,00*J^"[:>4"
M#>+>G7&EM0C4?S8,'/GFGN),#N0DS7A#(&^Z'6&YNN-^6+"1_1?J\;5WZ^ICX M["UD8Z"+/8N=\$*
KL2[C*QL;]"G&S#"^VH]04. AK]@2[YHR GS;%K*00Y# M3H[.!0D_69/7)]N<@:M'/;-HBS@_2@ (RZL?
QC2,Y+/@W>[7D(4P_/14X&8;? M3P;F>Q^QQ;A_08]H1T\$4ZS+^#<_)U,1,^I&0]CJK'V)11V0X?K9YFA;;W.T
MY8VE\TB"F\2EY1.PQDKR]?D9.2Z5\$\$(G_0!BRRVK8V=8>"#3#4)3=EU;SV*D MD#.LV'1[F)D#CL-E<-
'74P*_8J(&]R+^!J]"QV0BC_S2(&/%8BPIQ2=M+RJ MT_JN./ZC]3WS0?6=/\10G^4V_.\2/\=;*\$%!!
(_E+K>>I\ '#L(Q_5;_%Z#P M2^00:Q'F8_!\$W-M#;H/VK]F>1H="Y\$/\$@;S>)(WZ+[']+XG_P=L/\\$2U1FC
M*QN*?ORGB:CTTV>P\$[RE;LS?6_>Z0:8@BWJB8W",,\$K<#^R&C&%X/QU3N;!B M*(WZ(3K"S,US#(?
3A5"D,T"!D\JTR6Y"ZC/0%A:X0B091.KI9&5:BB9',FK+ MP3BP:>_*\$/MY!5SE3 IE*>K\$V;Y:R*"&[0T_;
(4W5P8!YD_"/UTZ:)=!U?_M,*F*VQ:%TS8H#:3^,&>18550"K[QID]96F>6ANKXR@6,08!<7D@ (69H=,/V
MD52*SKRZSE!8N8<\$:G7LI^4]]?+0.' -P/10KX'/%.]U;TPV*./[1#RQ*I>A M'6X79\V^/<<&B?'"=
TX(\$C@A:R?7W0@+;_RG=B;S(NQ5^N\@7'5G2CU9)KQ5#Z*Z0.196Y/=;'_U&%_I=)5+K3.ZP04#6 M_N^N@.\.
!+B#\W@4X0._R&C2*366F\$%,*UT@UF0H>N^0W0^/2?Z_I7J]WU_M*_IWJU10@Y.7@(*?,Y(#LISE4H0?

JW\Z@3+JK%4LNNK@H37R7%PZ2D-A MM;=|X\NT0//Z1 ,/950X??C8&EHUU+-@S%XQ|'N?..^C>R^>6QN&-
T!PC > & MQSNZDXC+I(73\$;^=)&V@.,?
V:;!^4]*3G\L\ 4R=4BAC/%@:=RI>./9/\$K@>G'Q#6I8S@IZ'IT!JI0.F4!;J@N 8XF&<;05!YU&H]?1:4_%W
IT"@D8GE\ 'IRB2PCKM"S60!-FK/XVL!S#*&W!7 M*0S%'TU%K0#7Q\FXR*=9!'!0+K_PZXSNN?
\$BM0&T^00"=":#/)/L+Q!Z>N M9YU3Y *KJ:76#@-]:CA3F TZ'CCD-"9)3V=IK10]5=I_%7X4=#/'UPBT0V.
M=E"@6^>XJFH @+FF3BI_YL;4V,2FT?ZR06 =\E[<00CVQ0G8@B(5&RPN\$&" MX-Q!_W2M."G>[-3;YG<&
[-*8F*B4R\$@ZQ?#II;L9\4Y\7,5L[:;+:}\$0%*>A MMV('Z8F2-4'NOK:3\EBG9.Q(P<(L[=400=676_) [3G"?
A7I_6S%,N9?6,YF MV %S=-ENV ?^>;7GJP?F^Q=!EH IT\MJJ]*AQI@WKA9> LJV%CO\K#N23_;< M'F1
;^YF@XZ:!.L.Z"?)I7[I]K<5]/5KVSLL-'<=/(=)Q9+-&8]:#\$\>CC+UA.9,TBUE>A%G#+
<@!Y0@Z\W9MG:R'>.!0MU MBWCE \Z-/1/1V?V-X3'L\LE0'J'\9^3Q]H*0?D@3M5:\Z.%UO()K_W0\GX\@+]?
8]@]787#(S\380! M0>J6A*8M\$!\5-;L4L_R_5I]9%8(6P"UXT:M15<\P3V\$>.,##;#+U+G2)Y53
M!:"M:W>.M]QWN[I]K1SY.RY!KEHE.KQ# 1^U)5GTH;J6G!LEB8C^23!.\$-5P=.5 M<.LC<1\$L?
>/GBY@9DLLR^#9K,UJP/\V# -IR&1NTI[#;#Y\$S[(ZR)DUUG&9E\
M[WAU0GH.ZS= IN.J2L'Y>B0H5UVG(, <R#@P9]U\$/490^6 =AZ2.L[U>/'\CD?U&@PZ'\0CD7LVW'NA8,1?
M&M_5"D^W\$^ M8L#M@!;Q)+% \X&BLF+-ST.NNGS.D78^./9;.F*\$^]@YW">&HP2I3!;7%S< MY0Y'/?0(#BG@
(!!AMB@R"5C?D,) 99 1:MXYY#E\I.I.0/7-[I]YX++WA M@I:'07/!6!@:/NANNG:-Z< [PN=?1@S4,"NR
MU5C9LY/\$K<^CFA=3T!E?HAEM.-GH4V0KUK.>VRLY@T+U:[\$03FX .TP4FD*" M6Q?
[&N5W0J?;^]XRVH3Z>BFAV.J5XMHN(P;@'V:IPW')H0XQ'P8[R\$RJO MH^&:-V9V6ET3CP4?;T95YL50_?
754TKN4AJF7'BNUG%-3:CN1)7<#7%XVD#Y%#^7%=I RT#-^V-'!0S\$08=:.&E\$*S,-XPYX@500U MG3Z]?
T09_\$C+6:U!*64P(:F317\$.@L3.C+*+;395R5U_9E\$)SJI3'WFMHMY5
ML/#)7#5"5Z9I\4[RDG^I^R15>B6E/^(R M0678MRQ(J =RIZ_0SS_[A^\$1-
F@UH.71WZ_RHSQB\VIQZJD'10ZV/(\$L1? =MZ]S[IT!^4#_E3.7KI9?A3C,S8ZKY5*SP2I\G_YIIQA@:&U77E"@
M\$3X0GF\K[F/Q(?) +KG,=BG^0)GR(#;0!;KDM*I.1/\$KU'T:PEM4K7>%*X.VD
MZSMV+09=*^G/;S;J0B4J8+XVT/S*.W-6%H7?+C,G.RU>GT3FWM>\:LW3,8>1
MANF)MZH+!H.)+0%7"Q+"4]CF;<@5-&-9(\D'E-1]/, +*RK0LX_1+'B/@+2 M&=-E-^;ZE<\$M'X0C#XF3^VP-
M^U35&W"UK3Y7B7Z<.Z:]MX6_M MN5;RU:1><35=?PR2,BNT\H!\$M-U09 M^W[N=-
CPL([H\#=:>P[QH/ZI#W5;A'*,FHT&9LI&@;+;+;-^%,ZP%004=9+K M=U8(#%"25:@.EYYV6\$ _L7/N"+
[(609@W1P/9\$';S6A[EVWM93G#_JT.<5\ MMEH(4!^<7.DQC1GC_RMKG:3G BE>M8%"5;ONYGPSWN//+!>L-
W0/P23X-6;;@.UUR\ '3GMB8+4\8-9KCV"HYZ M:)0)/73V?W,Q80_A #7Y0\$C3P+*
W^+78A=!Z=@)FQ.^=\MHDLSR\$H^E6>2J M6*Q=#<=-WIKC)I\,D6PR)7HAKAN14'-NA._J=W]3K;_)K[6?
MMG=W=X=6M M%JCX^MUW;@>\$E\IIM(0"/PA[VSG1\$UA)2M';/N+Y.M[!N)\(:1S:QY\$3:(
M\$/@_RT&/CM6852M)E*:#J Q*1BU_2C8X)0C;C_\$LVPVU?QH6G(RTE"2F^!0
MU^7*ITE+7"N6NHK(&W*AJ5+09D+?(E(KF_DL!]>.\I5=[79R8Z6+(Q>H1 =M90)QN>50FPBMQ8."34AA
E^KL723VV;:KZ//+V07*,?ZF60;F6*)^/\98SA:7H.- (GC,^R9EZ9I5B/G0!Z:\$WUL-/ MVQ'.F?XN'WQ-
K>ANJ]8)^L^C9@>;+S.*' NS1:B1SP:I4 _TLM,*2CT"U5T MJ,?BUL*\J%/?<3@N_W"4<\$H0<%
([CW'MJ@6VF7'L18#E=IHDU\679X-I3[K M>.GWB8&=:\SR]>KJH6G\7:R&VWX]19(25^Z*G>07*B<\
<,R7\HS(\$B)"@I] M_*^?TA6A-2*J7Y5R-&2EI8BXP47V'%#YWI87[NVJJK>2SG]GAH;+/-<W,(W(%52MAH:5J
M0K0"=0^ :FA\$>CSVVR0A>[9#QK\A%4@=. [ZK86,S'+ HC1U/IX*\$BGN3Y#9 MM\X7@!I3YNLXI2M[^-0E-
Z\$%.J%5-F]&JUJA:=)-.U1AR!*2DC&?_T0,15G MI:GAK-8QRWIT;-C
&MRIKN;\9Y0'LAZWM_7'LA81'S(1:F0I+(&I M0%MK^D/'A=:R])<"];ZG[4X,CW+=)5Q&F6P0;0!*!E#
V,47%6N+ \$5.*R_M? ;D%.)#Z0G-N07Q]-AA6+]>2V50;\$6H7!:-VHZ#>(?)@B\T;2_0*QZ-W+3Z
M^JT_JJX7]]#>Y H2<)G0@P\4!%@\$ 1CJ#@UY=?TI\6'2WBA'>%9^Z0B- SL3?/P1:6S2%HY)9E.MDC^96-
;^E<;/9D^T'W M=ML_0ST+-7E&YF7+9@XQ;Y\$=I\WJ[D-J?3 P?]\YKT,Y!R0"19V>- '@YY7W MJ,V5Q+?
YS\$KWDB[1CR9\ .^>&-U'B^:9Y XKIB7?@J<W;.,SU\$ \,E57:)?G! MIBFVOR-
HS%YU^6]9S805'W,DN:/+W^;FCC*R-CJE>%#K3:]XP#:@U8T8.!U
MPUV:BMN>FUT04SBD4H1S\L.]*EFDA2),TN@IM3(1,N9Y'2-7=SHT#QT!) \18 M#VQ@ "-TAU!?
4J@UEFBYV,PIEJ#"WT?NCI@6R\$7'W'D0A@<[L5N;KWAK7@%F_M*)SRC8"04RD/BSM\$]D0%7R=9U+^,9L
M2*TVEVI[FNTXUJBQ\$%\0.5476XIYM?2)+C!6V,G1.]DDK>N=1JU8BJP.L2V7 MW^T^1,-RG8[-I^WWKY-(-
/V#>@5&3<[I[S-D._LWSUXZ_5K)<6PAYHMMWD[7 MOPSN&?OX?+8_.]Q' '\
8\K^=;6\LX57<5B_)Y0D2)TTFMZ7ABY_%?M&>A MMZ4L]([:I:SN=0(S)W#CWI(N]&I"!*H0%],
(^H94;IM@U0>K'KYKKHN85SK, M\K06Y&R0/-84QK6[EH:FT@7N%18>*-FN43]M:9J^N)N3PRL.M)HX*I?[B"
M_G-4H, :5A*YEM?2DRT]0?@F5;)2?:YH]DA*NS-3@,2= 11J'>A?>0&9B-_*C
MW2++1W;I5[\$*6S/RR\$W+N1K5%\IZ=X;<&^7F0(D[SKNA'\$XPB>+GJI5;J]3 M&;RATV!V5N:6J\$E??G!?
FF^C*L3CX9)F>5,YT1.T\7&J**J.XWM\$)>&X;]#7+EKJV\$3&I_4 MA*'#W J];WJ133G?@:LZ-
SGI=]Y)LJ \DR\6'LHA=DCW!4%ZWGLU7MK#IRL M'X%>M1R&KA-/2N\$Z%C<9*\L%DN\0:3Q]\
!\$X]7)J00"BXH[!'K\$S(_EL]W MS.FNWI3J;NLY?^!:*TJWYJEF+TRVB"A]R[KV04.U\$ MF =Y;N6@P\$WBZ,
FKS*GI#M%YUH329S\$5'4YNW1?M?4MJG[6MUG\?'MNA, >GT0@3N="V": M2:1\$]WVQK9URS)[.%]52J1P
N\$ZM5D6U# =VZU-,5G<7JL(?S+D0RC3V/?1(M+3WE2FN-]1HKW*16<44%7.EV./;4.@E9]Z
4_'E8FOSSADHP\80K[LI!L? M)[^ (08ZN^HZ5=>-79P(U0#CTR=,!?FTMHSU?1SZ_*8Q6@^H"ZZVJDX/+^U
M\X"^ M"8>B+U].@6<%FM<2XDPL>R@6)^.E-+[OH",5RC?6#Y]Y\$7054[?(9D
MH]S5\IZ*B!NIR'*3&;KN:.)4X&^2CC_RfA T*-6\$@=[7KW,HA)>;^)8GZMYA\
M9BJX^\"&&00_U0^H&R>XL.N%5,RXH^WK8(4/H^8\]U..=?@\$BR8)NYVF+QH MVQ<N> ^8/[@U-?
>M85RXZE7)K, '#)K*]>/S7C6;KWS#.AF6&WF2 MECMO;Y\$Y8JA3Q=KS66Y&_710CKX/?
+^_.49RC=C0/=MT(K302:WA: ^ZGJ& M\L\$R0:V3?B3#E>B VMKB0#I@S]I0?B--P:B)M%/S#"F^GZ\$ M
T5\$X%8-N KK<"&JX2\$D(ZT-'P(<@A94'&(\$ID^U,*K%>0R5-90,;YJ]'@" M020T-":YS[Q43-
5GWOY+4M\$^H:=F>@MQ*8M!\$ U-%R#IILQ&0Y21JV1%3/\$ MYP&PA9(>^C)'FY'H039_X0!P+@X60*E"S0?,
[/_KCS<)U' =ISKGR>FQ,; &DG0_B],:7?U MTKFY)>&0STZ\]F;N .KJ&LNB0]PT>8F?JZK0WG+PW\$=A

D%M.S !E.YK+"C M)\JQ\$55DXIX6TY9D6\0N',MA7\> \V7<8NQZ25%)NM7<#&&NM89V>LB\(\-
M)# "02HHK]*L7+,5EK C<^JX1G7TCC#;4-[7Q;!(3?R ?TNM4!QZ:%5JAJF
MRFH*I,H0" :U7/FPL_RHM.L@7(QU>AI-*\$K93'8KSS^4\+SVMT^4^;WDU]T MK07@9),\6-
HM&^>.YH(;;IA>)&Z\$XQM8P@U? =4M \EP]VT*)-T87M*I4X_? M3,2T: _#HC;-
!0RZPPH&3G7*.9,W,60_XN;;/#X10.Q@IKA&X\$I00-N9?&I[, MQ]BMR+G5:L] -U-= M3K7KQL-
'[S8CL]"0!ZS]KP H.V7VG"YLMY\M\70\H_RP@JR SB4.?3X:H6! M;P*!IX/C=THV\|F-
R)#.D+BE\FV7ZK/ML^?V1H\9D@;0UPK+;3/\$36:~?WC68 M518R1F/+>VR]:?BX9%+[HI, /!0SN%!DH
M6R&_JOZJN@0G+JFQ;:H75TS^@L37+?DC6LSZ8G#=#6"=68%FG]T'BJZ&@W& M7[#;8KI]3N61&[L4])+:4?
*R(=\(A6C)!C@WB#4RCE4?(7/NBM%/#57>AWG80 MH]W>'@>\$Y#?63\>1.2SC,1MD@Z-
LARA_*\$U@]YA.49I5KWQCWSDM_M#JA:~ M #6>30+L>N=@4;-C-
8P&U'C+DU^HUEVL4YT(QY>PPEY.JX,W0&G,.L?00BU(M*'_G\$8&#(#6V0 ;EIYLVQFIANV'N0:RMY\$]D-
JC7,]WOTRBF2BYGE=-87?Z/ M(5L):3>+6L,Z&K]6Y@V^?ZWXD?RC@4-WNP:_.5H#-NH^GN66K,IY%G0\$?KS[O
MU9VYTAG&=, \YCEE\$[&>?E?>LY43+\$^S-*NF+SF'K9H8^C"8E%Y> Q9""\|
MHS;2]7[L,8/A_A>Q:SVH\$P0='J'9E@KDB3\$RP035LC\=_9VS(\039RA IZ' M07/A\K.RA%V94WL.SY1\$:
[!!!V4;GN2^^[A"PPZ98AL=):4LY2 'A9VN;4^:M
M8%V[6U#YM&ZOH6T_1I\TTP_OZOX6>.IWE6\CTWEX]IP.A3\4Y3+4UV\Z.;,S MPI\$?
|=/%S, =8M1[DMXU<8>#+;.6AW>M8TL=L:6\$="^ZTUP_49CC.2YH=,ZA MQ0A\$0J
\$\$/CVD8^U'4.7"]X5(9C\$1AFWKT7XPN#&4L@<,V!XR[H5:SU#B0=W
M7[UD78J:71X%0TBA"U^*'=@\$[F'='_.C2PR?K/,XH3&=3L\=NZ5 M?;]^@+K1\C3MU66N_/?;R"0^DU^Z?
\$Z\M;NN]TB/>JNH7*PH:* 162B7XG4W MV; :U/?U2]2MX&,%=D5!WB7?JB*Y]<81ZZ.X*S]&<602?_RC)YBT@
6J\]R MK2'LRCH3%U_5\$* \|05Q.\30,>8*2F@:%SNRTPM7?Z.3V ZG]#?UV6% -\|^ (KYE !?Y(I>2XT8Z"" M?
FWU4L*DGZ<_YPMXL43NL6H"P WQW.IN^BI^SL5.]H]"!H!K_OZJMMT@D\A M20)&!YUU(
J3*2%Y<7\0DCQ/V3W4G]5>3!U3# ""@ 7/HC(9FZ9Y MF.^47\ (BTC?T3=W;=(UOX?@K*C]
:M^N3K"iWN)#7"MQK M'T== N#<:WB/NMH\$="A2[]O *4YSU3E)E7"JYY.*\$W JP1[]:"601L_C-6:/ M]
>,@^K+ML7X>);ZWS:S;:8F,042N+E&;+>[[]S?0W%]%) ; M>=,GJ^Q"0U7 M=W^K'_'S'_EM.8>[=HOUJ-
VY@7PJ\$JG*=?&!@)XJQLX0A;39 #D,\$VF^XN* M&#Z2?\$F7.Z0Z0Q%8B?
*>190)1E0Y[/.T^F\86QVV81&KTL>F\$70CJL!(K,;W MCG;:760.4"X=2L'[,^VBXBYEKI\$X(T%_;/%/78@%
(*&*+Q-TAI=,[H/3@,I M49R"4YXR']C4F3=F"0-A+0?2F#PFXX(^SZ5W5;CP @C3^AID2]P*'_G\$D9KE
M_Y2:C+6D #JIMJ;A\07)*?/G_AJ0(E)BR9X W;_.G+= %:0;UQ]_0M1F&IGA#%2P58;<"0;XNBUR"F%DN.@A_
8"G/%5_MZV7_5XVJ.L5PR%A'!#;T0"3*8\$N0Q]2;[P2W/GW\K-'GU MF=BB.SZ&?TOAQI\UB;&VJ<@LU&IK:\
J_GVJD2Z20T_OK_MM!P\4+XEM7W< M&7JJTB)9M]+H,_X'LCG/!NU&N_4^640(
Q*H+2\$"G#,2%G7MWA!N9GFJ+>Z M65;]UP4^KWHV20P@>KZ(O/ND(ZWIR('T7B00U;-^K'U6&<9<;I'+G^N%SE+G
M0671)\-:P ;HP(D0LT>Q1X%9@U3I_X>* (X@)M=PDTYUBF:%^[DJ6N".PA1!';^R
M\;X#^QE1P<8>M3F%6PF957]CSTF)FC"8"3]_IH^B7).@EYR00S&JA^!]-;:*Y%.9\T#1^K32*MMV,H]
M8R.2H@^9_Y-WCUN^>)BV(#I_/D "P3=G\Z[4;3FNX>YDAM*MKM7TTEZY&AD]? M>CUS8SJ724TP/K(?0)IEN\
W=IQSKVKF0LI)';*W>18@5[0A=Z(^ [H]0QA MPQ-A3I\$KFP"88&'%JOK\|M%M@*F%H9#M36K\%?0_Q5?
Q)_+IJ5TRV-G/ MI3TY>QS?+:5+-LJD5S6F)2^.\$1WJX#^BDW/F?51?Q?DPA7_XDG=8LY:1S6;P^M_0S6)
MJYK\$9:=,YX94]W50PVVYG)>-3\$4SD M5V]*73ET>0H#Q_80\$.&CL5M4
MW2/7,/"':801UG,@XE"29J=3TGIX#.1 'YK?I\$1;00C24IFX%L.5I\$40_XG, M*R[\LYN!#,(CROSUK
H06]B0042(-0ZLW6]Z;]//;<#ZP*WZ;:6PB[]X]Z_6 M&;TT=KF,II-2_>>7JW=2_5YA\$4A?NF!#]::F?@=-
\$YP0E!%4=G -+8!N5_M6P(*662AAD MD5!,7H0.= RC5D?WV6L\$X*KAO%#7C\$J_N%Z^@9<^,@7CM>J,
ML+^E>GU#3@NC/6KQA^'IIH2LA):S'^:-\$.DZKV:#YD?AE@I57J:5_>2>M>>V ME@=-?2V-
MV8WS*>N^Y>N^ \VBVM >HYI"L \$.N10U>W0MOS+7^]X7U\]_KMD' M]U>ER82U&!%,LTQA\$?;XM%C;4?-
)XKSXZTGZ_VBYM M[2"7Y+(U=KR _!L);!TXG=%<0* FWNTDJG07;N!43;H.59 EM0PX33TA8GA
MF8QB@WR[#K)!D=OK?QL>=?E5\$87<4@Y%0<4Q98-?ZL#>%I'TB M*S3,=<^:6EN<5',^]YD;,')!ITE?
K,,N\N8_A\$,#>VPE&Z0S2=M]E(PYWKZ_M))53L=)'GCHNQP#E=7[J]@3G)M"KM2EMNGTC)B+QK@X]H0
MH6L61W\$/KL07?@MKB[!RETA@3/&::%V]\:0I&^<'T;AJ,HG,E&7S']?IFSK9>[C^E1IB0=#)-
QS^~/&\$ZN;.U%YK-C!M1UU017/-(7Z M\$2J4L?(06A'&-&5.+5'9I[&V>>S"
[JS=F^JN08Z+0FK1.Z:)9#Q3>1B\B1YS MH1WAW7NC" IEY?T1C;^;["Y\>7]8+]=%L.5-KQ?X_V[7=#
[B,F4K<61^[_65 MT,C+;;_R[06T=AYZE0^PXZX^R'I?+B@JQ?A3\6C10#R\D24VT;@JN<1":B'A
M8Q%8&!,JH+P\$X@YJYV6:B&K4K9;<_4/5KOK*_0>0-CGEA M#?R3ZZKNKQ5&;77X(?U
J%U%:/62PGQZGN4!*C'U8RD?>^KQ=MCZ"JA.T8S
M8W.)R\S@;D[/N.//*8Y.'DHV3P0D_>19S"M"V0>*4XM*/O(!I70P(V_+GI3 M\0+PJ).>'5Y<7M&2_#7%+[2@1
W_5F>];];]Q@4(V\L^8)G)<'&FQ6GZL;C\$+ MLYL%W_T<-8'_(7:0">%)N
2EV3(%&,F=X05"TZ0U2'F.*S]Z^*M[\$T)N?;<M Q\#D'Q/5&-;*0==20;8N@UC/!D4]\$'4U=P#J!CWH^'
QCHB>&0M00ZC*.W]U.JW^ZG9YF\CFMC=\$7@(\$3QS-L&D\37BTA M?N3P#]?
ZK\$)9*M*AW[=K8U:N?;=X^J(S^J60KOW&_Y'/JG]HF_A5 M#<&_8,ETWS\$.>7[^J_DWKN(BAQ?
^0B/2994:#4JL=)/_>5B? M,G"\$F;K"!CV]U,YC& \!>'YLD^@R_0XX<7#6_/4.RS@;:2N\4LP&/;QES_89
MW&,[SQ);YZJ_]2[.BB/UC!??# _&GY8LH59=8\&CW6H=SH8+R;388S&\/' MJSZ@_EA2J"CHT-?0S-
_LH0\$96-I;Z\$]NMY%\LQ:%=;:&B^B'#Y0\$TLU4&ZA,0A26<[I>G.+:57AFC#([@
MS8F&5"5342T7^U("H0Y*G;>TW2")CQ=?7";YJ-Z[\;S+^=#R/)/Q@%*IZF?6S0_MR"#*YG<%PQ+X6#:
_R^K,LS(!/T\$10%;_M.)Y;Q10F#("8D M8'YQ#3++&:%BKZ%51IV9_-Y'6=,QC8LJ0"(-;IE8>9ZR>WU'0S^J-
8JS&.82 M8N,83W^C:Y?) [W9FL36Z5%6>520K[!-YI3^VB@_MF@EEB&IX=@D91F8.PWE[M2#U])_-
NX(I3T^.\$H(Z>)NW_.VD=XJ?K-,8.S<="04K%/((<[R^X_W7I^V20&R_MZRI?Y4+(=08E*G4IFGH56_.,F[!!*/-
Z,'K\$H?VW-27&UJWW7:0C]6>1853*
M<]_=:Y4TPA&D,S<"F8W/769RY[;JATR)\$:IJ2\$4F>9I=UM@%*_Z31'0LY>
M(NBNJC.#R6(Q!_/I]]:PKSTN\5>9)TT\\$:#=ROG0\G(6>G6C1Q(OX@RC(/LH_M<+86I;Z?

K<-6;VKQI>Y4Z+BC<>@|10|PT>5RQXG!\$*2"S3UV*#[0.5\\IF: MN3"?+S' "SE?6/+Q&V3D:PB3
03'7F0/=,], 2P94@09I17VY*BK^J-\$V>+ M.GM#69.X,ICP1IF@0<\\;0)X#U:WE7'B({<,, "[!E3;/<5%.01?
K/\$F[D+=0#^X2/=MKEVU+VZ;B_=\$*\\U] M|CA>ZX_966N(NC-V_J;9BH=^K|];&#X&;\\U7R/AG_
MFY9JL<^NT;N|U#CWZS-R*2M+2MYRS&AHRYX9\\9LLG M|CORM|=XBICI);ZZ634?
TQ\$,JU;"T25;JB+.>5F1IDMMEZWFG*+4?^CV0^BT M0*J|\\0*6TE+8-);[+MK*KM>^ D:V4A3WZ(%
[XQ*W(TE5\\Y92E\\Q?'L'G0^,9 M^W9:P(P>CQP|\$5WJGFE+U)D*OC-\$&0 GUNQE@XH\\I\$?=QM#_P1P=#ZNKGS|
MB*GF?GKHQ&'LASLCK*YB8X6G.T4CTU40WPHNM<#T0F X|C5Z)/Y&LJ:M<2)
MUBS!_%;5,19:.8!=FWU7?:W3W)CDZ"(L46#9< CS200Z=BF.E^T36^+HG^D4
MR7EUDZ&PX&L)QJOCZMVU%#8|2IAY<%@JQX<-"A7S.;3-4DV6FQ)YX2%\\,'Q) MY:/@K\$4HDY?K\$X4_T0?
KSP_3SK7>#+F#F3N@D(P5K_/YC9F^3-/I@_/C10,F0J|\$E:#"B%)DHSUSHN,RQ;W78E<8&??@;*>HP
M!/-N0ADA9|I:++|RC6)|U7(?A1V;T11|MZDRBI(BXC\$L5 M=1/=I|JH|K\\OCIUV,MCM>B?
6'|FBMN2*="FA;RQK#+^7&S|N;)D6=2U*V7NQ M ^24%PDN\$8HR)6F/MSSP^?_
^QF'4|<(Y5NRW4M&E|)/%\$COMS+TLCG\$Q*|W-% MIKSHK,F\\(QM("JS=!!N|2G|;^FJU<\\PXQF/?
6G*CS G\\N) \\?E5\$.9 M: '%\\704D;KR@.M4|Y 5VVYYLVPW,;;I!&< 8;=9>0+0
MA"44FLF5_)L)VYNYDY=C4G2>@A>;7/P;(.J5I5EL4'M9T>C)-:E<.U0-?\\P\$ MRW&(R@;=H)J29_,@<|@/1*JLW
UU_1K'B(T/*5(W1EA=06|/K KD,(=9NR @CEU*)6*>KZN09;GY6B0G;ZWOSC**_G0&|N8XH^K^
M&RV3KV\\T*"V^SA3TUX|U\$JR':EN)\$Y+-,0"TQ#JE/^6.= "C_|4>J775>?
M=&H,V:"@Q>0#54PE20KJ4M7<^FT_P;|!>&;%747\$?@/#'IN1+Z?Y'\\+;JBU
MC|6RV91YGD&0!Z!E|W4GCGL '*0V6N6^(^,JJE.A32T7R ' '5"Y7YN;=NM+<* M3-MCNW\$5:,GW|& M|
M="R,85&9,X+806(9N&%X3>?5/\\^6HQ_(&=%9M'@BX2-)BIBT@#,0IP4P#96 M0/H-ND6 C&@!&8"BY1G|
|UB'I5 ^0++\$|;|)H8T|[[88*Z04F>28F3_&Z;XGN% M#>H?705_0,VB;_G'57_I3E0PUM V2G1|@|<;6I
12., 'WK\$38_>8G=0NAC ITR9 M-8+\$Y*%-=?9.F78(^GW+9ZYE09&L\$RC&W78N76W6M>20!4.)ZYUBF#>6\\;0
MH2,MH0BU5S5.LA40U;07_OI_H%0G\$3PA!A^..4P198->J3DBA?5=CJV(+85 M^ 7D++5-UN8K*<+WR?7:KX\\8-
DGFYW61-\$-' "L4;^H;409*'W?WR.G'+4P7 M#0?_
Q5.H5IKOML7*85@U.7BQ>F/60BSJ,6*R,B;'!'|QB'W/J2(9A1-MW_=2BS
MIJ<@X6E03W*#ORM:/V1D(G2&J9LUMI5IWB^(NI8 (+/VCN0#(M(!27W|V8VC|1>#FF3N1.PA'Q M
\\>YQR2\\FG16LN-N+5C/!Z^0\$JGR:UY-C)+VR"YZH&W\\@F8R&Q022ZYCTJ=(
MM'%YUFFKE:*Z%AX2+!|IQB(P(3WFX|5=0 \$'XT60"X3MV5^F^\$N?&LHF?U(V MR2XP(%\\0X38+,3T|]>>|R-
H"S(XQ0,"QF&^TF3D7X_)LCY0'A^G;U ! M1#"95?|"[HMSY2K1+JFZZ'.'.|DW+SY9L:AC*F:\$0":J+-
@H@**TL#("A78 M,=;@X>0G:[M,9#RDA+@-0FP2/C+0/\\02(=*S1VBA/0,\\ U95SIEI^5NVMVD|
M7CS'U2RA&9LA,"LUE!|!93553RFXA&RFPU2J#C>%, K;*&X@E"1"7
01I\\UU&2518WDFK(|,FPWMI\\F80^DHX.M??(ZWB&LQNUI*"J V MK+7_P'\$1D?KN<&f@:V&#*NUZ,_,
[6"W+\\0G2#).Y?J*G"E4!7408'AY;^=PM M/"(YIF),4|\$I*:DDU1+=Q@ XN\$J|/L1"^^,!7J0)LD,C; \$U-_V""-
?^;PD#, MD\\)K/4|KQ&;F0^Y6_!\$P?WQ*@D,("PV!F_\$!PA5@|LH*D
^SWE|&IM6<(47KBEX_XWYQE+=32W:ISFOM M)(0A<')6JD_);\$EYC88'\\-53@1"0.LVU5RP@.|!
[=M|0_SF="G0(XR5KES0# M%OZI('|3T|4I2|1R/OD'M|I&9|9FEZ0\\X|R>FH_,SH7?#%QX/UUR|F=- MN;
(A!1.Z|)"@H-*Y\\+J+Y3Z^S> ^YFFZ0=NSK0"F P2@SG|K MR8DQED&|IZ^|H9YL>K F&\$+5J9B" @\\6-
"PKMG9C26'+D\\3_I.YPQU'Z^8A MV!NHC>&\$2\\AZ@_E3+-<+*G97DE'+?-0<|VPH6?2E9N0F1J!805.=D!-?3LW,
M2P8SHYE/|!|1W:++TIEHMZ(@^9L_B-2P0%+3>@8@0I37F5<7|G-IB5UPK@,3 M4FM(8
0\$=UW@%/|R8(*NE' "'A52N31|T@'-.|7TTC|6HKKC9I0IHEV5|7>*R MS-/\$:UX1?;JUG!77\\98-
ZK3+2;L6|6Z,"FJHQ4S'>>K=+-..M@0L|R#-S\$?=: M0JFG6-;-|YX> !-R00K-
=*|MYTL+/_XBA#0I0K#,>VEAV|Z@;|WZKL/%\$?:I MUQY6@1HN.\$OX;?Y+YXJ,-;G"WE1NKU&3GT(&
<=!.2T>Y39*&-..->\\VJ8-00 M.640|GBR7A|S_2^UY;N+ \\19NON.BZ.G:Z9B|MS725|G@&LH8@HKEMK\\,M/&
M|136*|AG5VS>D|>PAYNO;SNP*=JS_@|2Z4K\\|BZN)-.Z7P8^0|J%+%4I7?0D MW.AGB0'YZN0T;B?
S,ID8|B>6\$AC ^.XH6&@GT%.:08T7?5W&6H)81JF M57EE3IK8|7|0C&
(D/M|6E;2U5WN^3FEASO/C8/=G8CXQ4M@43_CL\\07_Z71) MN,5IN;3;|U?
0W9N/F82>3AA5.C%YS'=KJIY41DZA;T^VZ^N,SM&ONL9*CQJI M0IX>ABIE|J=PI7|=|0MGXI8I-A|\$CM>^JQ*Z?
^\$S*.0%99#;|NAPF1'E3@RR MH'4+K\\D%1RW>BYM^>\$_.15PF=T)'LRU(1GV?9QE<0^6X./..P|I\\C:7
M=5IE;N^S%;ZP%0Q4#+ST^\$J4,|X2HBE|V57WV'WBUJA\$>Y0|?,OP"\\S%E
MP!'.;W)*L/;CM#22:ZD/SS=\\6A1|HQ^CW^D02KE= GY2,1@W^+G&:=W|5@Y M&Q9MY0-7?
=G6X0" KYBI'DK3/G+@M/S'0F0@4,B^..76S8?##??+W;|_Z+^V
M_19XY(G'7,YBMHS"S2/%KBX+CG'65^MKQ<|4V#DEY6;F((69V02@58R(&VEW M:
(B2J;JM6=V;KWWTNPO#K07E9R|'REZ*,*QP96#3YAT^%.N9N0! MY&XZ<3Y.1XW)<87%ATCD)_G>JL7"E-C0=@P?
_M"NZZHK|48& C(1E|YDB%#Z7|/0^_*R1_) A/=>[=#|^N9IC%M;|UA3^;*5| MVY*K<;IU?
&|9C@%"M+6IT9|MD5E_MHC#L6?W4G501Z):=/@XW'=NAT2%447 MMVVW<#UP)U%\\|C"W0L3F:
>W\$,V'"#9/3T|V0+Q#\$I;9%*'L1>L.R M|BP"&?9<|6-JDX0FSC2W>-
T45@02|HI5>=.,BSTL5J#6\$S.\\>IEOC##_ \$A MIYD5UMS"1I#:#|0H0" MM;YN-0SB1Q&;1\$V\\3L
Q=.,GJQ&72#2B=J0ZI,H0T;S MY)#1B..W348@_0.<;DM/<;T!9\\^B#A^R^G|;>/T_@X;1WK.'T7-\$D=|V^D'
MY3YC6/TL%V.|^>JC3-+6*1BKLFBT_97N;8X>^?.G&U'SNA01C-[X2Z51X(E; M*BML%DD)S|\$,\$?UE-
%6/LG!+IW)*KM="!N*_ \$< DN'P E|'Z'ZTFI'U9\$4WCV\$D\\0/GE^,?)Z^-C M6"MGW*8F+1*7H*',/XY.:VFCC?
*/T?(>H(0|/\\L&J2|R>%.M&VT|UI<0YRC_6\$+L MN?9|SE"DAAHC?9\\S0.7,&5;'VA=[4!-Q+S> ^"PASSB4?
G>^XLR8.&97D0\\QNUJWC?K%L9-)80#Z?&'.|KN(7NU: MD!|_7?)E#C+<&<\\&07\$U9M|\$^OC|IWTSSZ0,%\$4J4-
;SIT_UEP|(#|<)-?J MD?S_)9.00>0EWQJ=I0Q|67GD&:1QZ&+U3TU,ZD6KNM\$>V|JU+YVH_|*!BU(Y
M5A(!G6#%/NKIY!TTI)"%,?B9|07(-U=DB%_' Z3>/6G);8!#U#K>H/H1^\$V MA3*F6?
>Q#+0DU\\4_WN8CFYR<(:\$|YD|;PVTGA@K.;^1L+!|QN@.#ZE0_6; M6+5WQ?@?-YJ,N7EUM9|N--
_UJ.UK"A9D'0EPJ_A0&K%LI=#K-^&-7V,KA4,RLV*|/VJB189C6RBB7G3|V^H>\\!F4D%QMF;K:0'3!\$WXS<
M:8L+E^E6=XJE!TOV, |E!-K6GV_9U:UT\$'<|+7!&99F|ZRB^2N>J3(,Q59H' M'3 NI670UUMA+A\\4.!|?

H60'+9@,%G[4T2^M["S+\$_@J>FIFS6D)S'36M7X0 M<1IJ+T]:J0-JS[J?20/+56*8D!FJQ58W9N%
J57QZY\Y^>8Z?N\$ W!RQ@0UZ M\$04<8H., ALK:'4CQ[DPZJ';F-M85?(/*3Y0_C CM5<9HX7QP7.NP0U\$9F^
M&9,)[D]04(3I_&_66+\U%411X:_FZ^EEHL6HD*=E7JQM)S.RA!+:10@\XK\$=7 M :J9Y93P?
W8\.*1U*]JH/]./TTTB^\$H,+\)EF,ZA-*\$+QDJ9F)V3[K^:'.B M(T=8QR81;#%C'QC&7U@_FU^<8@DS,N-
/H31Q.E#WB*5(W:K57UU@RK*=0L7'JV?3\M?EJ MV;/B=C'GJP;AK>".\#SN/J3>?4?=
(%D5<0&I2LZ3Y'^J!""%)5;T#0;_H>V1 M)Y>|\%[*VF,4S[0"C\R?
H9L.B!++>2ZY>!1UY*K>\$+RF0G,TQ*"'7SP-B06 MQHEBSJ?S^]+59&]P=B-FW*WLQ/+
J&3M/>*]QC!"K\$KD)CQY9 X\)"!Z@SS/6W#[3HR*]-U[5V0LS).21YL+\$^"YND.V-J[>WRB)[+V*X_@_M0AB?-
+4\ (E!CF&7Z/[E/OS3!6,S:YNMZ%4S.E17_I6;N&G[;' ^59+*S?+}\$ MT3Y0?YE7"Q_-
QQ,I"MRK0A1IX.64=_:RSBF:0\LB\$@N0+V,\$ E_G-G88YZD M9*0+6,%(^/N-",Q*#L[R]ZH0MJWE7GGQK&_UD"
[-,+=HLF<*]'*7+,*9RE T M4XWJCQZZU @C@U"/S)27?*<7-7,.H?OUNC*=*SEB5L5MN#TT%'E62N\$\55
M&1[2R=99_B4>+(GT#CJFDBB^:+B;Y-"!WZ53J?J@=.#MF3J8=PS?55/5=P;= MUD.H00BA@I1#77"
<@'7[J+_C8:S6:V\0'8H]0=!?0;A67DFM3#B22]F[(*N0 MW;ZT)='86J_?)NUVU)&35"Z[N]A53>8I"A\M3+-
G,%FP-AZ[I]0A_I]IG>/_8 M^LD)]\X>\XIK:N>S0>]:@ (HM*D1@5\$14"0HK38 \$:121(BQ1I 0(B/1 5 M
+F1)A)*E"I2(EUJZ\$B7&JFA]Y(02DA"\@><[IG;[W F[Y\$#YL2++8>\ZY MQEBS#
(<9I(*L94I0/#X/WS502MAMNMZF78K77'I'W,C;^4D:Q=0^>[DHA-0]N8;^KD0]04DB*X,1>7UF>JDE.L8M
M3X@*0=QM&^;UZ[T,I?F<*SE]@N AK&*9I40?635\$3(:[2RX-Z3@!M).DZ ^C(1*_A8Y,6,&Y?ZX665U.)+;
M8._='=8D@7^0)ON*N8SC @)"?S>I9>.65DTV0?CHKL+I(KL^+9WN>[&25 MV7IX VKX0&KC 0WW#@USSJK39=?
ICY04-;50,&=8MU[MUGS*;(G5P^9"7'S% M8C[=J"DPW1 ^P.HM0L1AHM0=-[.)EJ S;[R4DP=V-
G;%7[\$A\7])N(.3^#-VBBV16]ZY)=6*1.YA\$P I#[J*')!+!\$@OR1U7?0)\T*D8/H(7<.)]/KTZK%?
ML.S\$5A=M?TBZ1R;HIR'M W#1C,N*7+^?U2IDTIKBB-U+H-Y*XG%4."Z&A@2Q M[\$+
[-*D;U4PU\I:A>>1]] MSPB502Z;9JVR%-81YHY.=355AEBW[-S&;HV8 MC.]C*D_?#]U?
M0V;\&A/W+-9B#^X:9R_IM?&*?
FY"ZI(XP/[DB]'*0G=L0I/!' \43DF3IKTCS,Y07])8K7TID>02FE!H^APV^WU<>42
MF]&.;\X!H50'&8!C=CZ9&4*??-/L=^*)\$Z(#3;FPRU91P<+"0,-H\$-0BU26W MI8>+ 'IJ?
IR5;\P?'#A5*2@?K2./!/K^5AUX-XU+W(2X1;\8W5(M46M[%"LY MNYB9*"6ELGF/L%5!-,1.(%+%2VA%
[S=_6PZ"VQM#[T^='E\$5^NJS>BG0071 M_OY[36;#59I3*F(&Q!2L5<.YLN--@IVGAND\A56?=.P(N5V\(
MM2@\$;89%",HF0*B\]*+X&&'3ZH]:P S@C5,MY;%0]V&R[P-6R6()F1G9UX8< M3YIW73]=<\$< \^,BZ5?
M'\$25/VU[!3ZYR%7;-_8/^YWL'&A&7.ZPGT2/"5'Y M"RADN',K@HZUS]:2R-TZ?
ES<[X*07>R8FDSC_6AX9AZ\N\$S3#>VWV26<]>4%XL;&-I'\$TK](M>68U%IR9G M!YP-
N_4B9T^0*9WAF[HC^Y8!L">QK-Z:C>TXZQ;MRX+JZ#7?Q.' I])8D?U-
MYPZX0[C/00ED[L/CZN30_7T064>_V3"9,K MI5? P3E U U#C04E9(0]R5' BK6 M:TL@;#?%3.N] F0?
P]3X5H@M;K#;VLLC>3K"]&_BAS:0I&00=T0)AZ7S&N M)/?=>J39+YQH[ZUTR_GE5Y.N\ [+91(5WBK?
\$@K.7.9[C\F\$&E*V7ILW]SSY M\ \$ K_SM!L?&.Y(-3E1[7
BH#S.>A\$]WL/QL\$Y(>Y\$V&TA\$:]^04B]Q>2NJP3R.PU3G_(GJ6R M303+X:BQ!]+BPI=:5?
@%KXI'\$R\43;%IW,%E]&.4\$X>* _117A\70<3^A);M M]8'B0WWY9'YLJ7S-;5.;#-,'M\8VZR\)\H0X,9A\ND)
<#?7/4GX(30_ ;W\$ MFVW2J,G,0CQ1Z%NUJJ8)0YG&:V]'A.-X09>F8QXKBVI>*-\$84T8@%J:9M:' MAYG]UZE?
AA=[\2G88*L.F0T4[#19H_\$]A:LTS=7??=G.;3.G=>)-,8_VV2?) MI6?UE4M)-
_ZTG3SB,\$9.SH\$:^[6\V=P#&M+;XA_U^[]?]*9FT2_--?,>[!UV+ M.[.S)2_43#Y=L/=3X@B(K^8WB
B_[!9=\$JW]K#KP.7.)\^G?C#:RYA"GO(
MWE_63XIJ*%5)\VN4/Z[LF7JHX<764K5G20&L7M/00&VULJ[IT^@X/;RYC\!L%
MG0)J)ORWQ;G:6%Q+'CXY:73IZ&5%40_4L^DU^]V#NH&2D7VVK*&=5:FFA/"S5_?J# [!:/U)80M8(]J:5
M59:9R70^K028WI7X<:7VX@,!*[!:-ES=6 +F#0B4#^0: /O.HC90D/WGW0\$] M'L,4E\$>/?
48W;Q%Q/E1*;L30\);)\GGW[RLIC?XZ*S^Y)6(CU6& MKQ_ZS0L)4*L\2C+9;>9;M-2%7MF?
=5I!IB>.ZJMK6*IIPR8[+_1\0&K0>## MH=?"@A52[TSN0),\PH\4\$ 3MI91 \$: ?VUM0IQR#F#1#RY?
&P(FK^ZH20 MJ^Q!3,/@<-QVEJW5A:*L784BA&U"4D6Y5>G)!;XG)S\))\(\ CPS6D7,"K]
MM"D10G/UEZ(,/[!%W-9!W;20S0:VEJQ = Y??ILM" "49!X%?%6[P1;8%.X/ M].UMFVR,,9&(M;QA],+&
[]N(#RIE0KY"8I;&@^-3>;/S]>[19^L2]6@YP3*_M> \NZE@X2)72&0#(>7/%L'"4T&9?
9B6]XL6**X)-3N_T\$N1XH0F@^],!V^IN M1&>5JXG(>0%UEW*@5[3"Z9N_I_A&U2Y\M!FPD(FN!(6_+5*AT?
FFNR; N"J M0,%6IY^P;=;PXX;KT/#('2={0I7(HP_GZ<<%CBP^L2?C^])+X0=HEWT72^,"CZ)P+?R/=>
MP117\RVKVZ^OGK0:Z(1Z6GG!T!- "OUB>WW&Y; 0J^HQPF1)4V>CXI_Q7\$T MGJ48%(7+?JHA/._>YP[?]
RN%6Y>W9K)8W4^W6+"C^&G]>VT@BZCQ]J^U5_#K# ME\$!":ME8#/V/*YEA65IZ1H^'Z2,:/BMD^%K7F-]WJKR-
L2!N_1,*RX!Q80 M2!H^K/U.&F_E9EZ=:^;U^GBLF?C]/IC3]FQZ5;]UF#U0X&\SQ^PNE;::;XQ5R;N9?#L!+32C
&H8P!> M;@T6EJ HSZ/MPW3X06T*45BC140BWIM0R0M_QZ4:]U;F;+G,6Y2*LWR)B>IUC/D^(^2#JQY=W"Z+
M,6EW=6+=&,\$F'&\]8Q/R57U6[%.=L'"!G#Z0=6&[\$V[1ZVBI,\$1]HFT-M.MR
MFWL*W],SWXYFEU.YX[>P#K\G*^H M,ZK(1>3<05@=0YWQ1.N-NR09?F\$E.;J!%CT\$QG?V.N NK0A,+KW\<6
M.TB_-UTR'J]>1'L\$ M7GDLY%U^>V?## 5K6S=C^R3H-;[:K&L.;(UT^KG+E08)7TK?+54;W_KY>?@K
M4EIX]*"!030/(M6@4."(^?&8FX30Q-Q6RX*%^(R#K5#NGVF&@5E0&G^ PGX_MZRLM-4=79&&!*,
X;ZB;F\I@X;+!M1&[L I\$[NH@0\$#%6B2S+G1D4@#-S.5 MP1@K7YD[_7LZC.GW)I5\S\$X,JGJR=0>U)B@TUF:
[>] ^=VV6LS(C-"<8L7;CW:QPW9GAK'?51QP* MTKP0VH35HI%1:?,>. ?U.5E#%Y&+)@#G'9AE@.G1_?
Q]I"CJFB;XX M*!0H*!T]9[3F=KX6:7<6'KT\/:):,F_K56%DRCF@D=L7:C:BMV%,0VH\$?WU<
MD!"HH&G_9X;8T(6R+0_(M=&%U#;TSWRQ=10P/^;E_A4!(PN!B0\ '%/%?RXV M(JV6ZXYF0N)+BD
ML:7Z,]_6>&\^@B:/_:=X;*!CC\$Z:X0HG_#TLBN(%;R3MI0I9\XS]40_.I+) MU/*+PB=69ZB@8&4H\ '89^*X?
K[IXSE\GU]^97 MZD@%H.>QJ7(6V+2!V^(% M.1#XIV#\$?P<\$3M&4Z^4VJN S/B>Z9[,&L,S_*+
(W1CC3,5F/N+,02;#Z)L(V4AEJ2;102%_G>#_ 'V6/^ZH;0_ ^C
MNB'\7^KL";\D9Y[\H]FW>TICZZ_2Q^;_*7U41*K5X\B+B&B1K3W!MH+X^?9 M28H^:1B->3N?
+ +\K.7U2RY%=97\ -7 =GRW5R(R^P0]=,\$F[-1I\@7U MKRP# M[-2C-EE(3J?UBHV\>!7IVS9,:JP

3LKV>CD4G8S4SL MS7P3|9B5FJ0\$6R3L'A0(>ADV=[EFA]-^4W&Q,5*31)B/;F^K\$G57-,#D7:U M/A|F+|3,
#B'(/X9Q?U U|P#PX?%0#0LM(5C/*02K|J)L|K|(\$&'A#B))A>\$ / MI7+?|;=5 B5(N?
*/(.40S76IT|K+GV40^+,LDPS AQR\$# ,^B48R?|R9HZ|B M-WR35=RP)X5)<,%LY%_CAL!J?
YV5E0|GK)1V>R|MKW15@_ ;|:H4Y|+7+%+T2 MK\KZK/R?80&D<)9EZ-
M>:RHXI\$IUS&.A'D)= J/2IX5EMWQVC,F6/^/E'N? M&T*L|K*0N!F :!,YS)[*+FA7@&|S:?" .\Y!
|):T|QGF_G'OE,P =,E ""*3 ML!NQD#&WOL^IH50(,W.0'<2I*>=>^V>(4Y+V^|JJT-/ _D&*KS?L;3?
4;0,P#D76!0%OK!M(DD|\$4&(&'%@,F;YM;2=M0_7=AW M|G\^*^@0EN|_*NQSG_JKL_YJ|_08^<-
I(H3?|4C8D+%)|,'#_|5/3&=\$;_.JRD^X|^?FZ8@XI"|>48GL*D&I M5D;%D|CF4@:,.NWN.@UZ&^_.
)1IT+I&>0@C*PS |A B:E'V MH9K/?+C+@|9M)YZ64YM-30T(0+T9)&AZ ZZ4D?67I%2^N%',RC9="9G5>1R!
M=Q#'|DUO.\$JDT5>TL.^X9BQ ;W'6#;!F-B)J91H4A/; ;C+Y7H)E.?JD_WJS MT)F8_H53Z&9IY*R9G)NJY-
YXWF2YGUOI J^EL9G? 2:L#|4P %H:W|SDTC6F M*Z87_\$J|D0?3KC_3_TS_X_I;2_)&\$QGE|
|EX*DR*4K:L\$#*=M|&|Y MI|R*/I9RNT?FVALR3:J.:AIS^THV1- :36WB093.WF|XJBGA|A MVLAK';\$(D*?WY-
#?LF_Z9/ .:C|DV58ETVQK'K P;?%#"F0=P@"(%"# |ZVH5 M?JR,KI00|UC0_Z1TMU^80E45MIN=,R#8Z.|>5<
>&01+;M0Y-L5>S^_%|Z? M0.D5>WG6G=KJ'"MG?APG|B..M?#<+|6EMA6W4U2V1ZRHOERU
MW0&WEU<@UB55_0+RI7ZFE^0_EY>7*0Z73,2+K0ZX^BY2VJ ;T.| RT?59X(&J?=[C>A>QNU .<:<3KJP%7L
M.FB#59< &8/,4P*|PP20+!=*!\$ZYS;|3&0_4,|(OEOKU' JA(/=0%|\A\$ZW MT%VCJ2L>S/L9FTI?3DEB&F8&,
|IUGR%UD^_05/RF02?SZ &9YEE1ASXY.TZ_M8_NBP&Y9&U|=Y3Z01%8JY;|HJBU%0F':T ""^9_ =U"APCW <%0
M-C_|HT|HM7G:?!>BBVB^M^GJY7/M4^=,%_7_=L/0GLQ7!*U8\$Q(-Y^BE0\$6@G M;WT-0\$F2IH|3R#G;W&08-
R;-9\$0G|V>#M|C&N2#B&4+Y&3R_)R9G^0.Q?FV| MZH949FK(+|GC+(ZCS6@9, _&S@:>PT#E(#);|@9_@|
MN4B_))U^JYWWG1L*5@BR2D3T8!5UDY%?&>?L@CKVSMXIPEMJ8U/K""W,^# M?R%'FY277-
I7C^#JZY|^)G>XG\$)U6|-18|0"S\$NBY? |YQ|G33|MS5/0G"|C90ER M*:0 M/7%*64(U:U!
1C=+B;"S4R8#\$\$_1FW,T|2_5E, .Y\F-;1GKS8C?JP^ZU)D MQAD+W CAHW\I^@H.'#
GVOW^W72GR\$^"6+H*%&,WBV(XT-S9&&9E\$G02,/ M&, %2DX@&(#*CKQE4G03D@5('"<5'OU|=30A|
;J5EF;NB_=09),I;,<^VBT M6.KA6GWKR;A1/647D_=4'UU|S?,-<@|1|89-?Z/ ?Y3M;:=60\$RLLNM_M?
26U;::ZLW-+;UC""*D:9=4MPN;LA6\M);;B="3^@FRI7=(_9ARBEO') :490!. _BSC#W?)1.^5?=\$\ZS?
Y;:LU3A")JG9 MQ4\$/8_K\$A/_5\|3>DG00FUNU@0|^8D/EK" _9 !.R-U/1/_AY9U046' -4U(MNOUR@+GWE-
20R>3CEK!B*)C@5^R!>|A9H^0; ,GDZXM:1&5KK#W/=*_Z/|V. MN?F5W#G!|H"|T 0?4';HI4=FS@&+E 3^0A ?
\$=/*L#>Z=N8""B:%F>.;M:8CPNB4?L@KXM92\$|)N^,UXV)BKI?9P \,REF M?0-C|AIFR*X>N;.,0#7L/-
T!.,@TAVP""@6JFBUA.VD*_ZRF<%#C:N|Z0B^;F M*?82""Q44%)2@W;Z(WI#>;K?W/-
!"*WV(PQ/S=PUB4_L""^DF3J,|LT4N3MEG6_M"90|07YI|4+L2\$R"MT/PPC7TK-D>_+#!%'(8JE00%U#C.VE-EX?
QU:5!ZS(D:3P?K2Z_S-+;<="S M3_XI:WX9DAM,^#^^(4)YR:6Y>HZY:Y=T^Q'*508F|Z_WBZJ_5?
7WVL<677G>S+^ M40I#MX4QEM!ISHS;Z%43. @. @Q@ T+S?|A1F PX<('G%I0T9X+YAI>'TE|VI5
MPH\$=70=U,S_DZAZA?H%=7L*C71B\$+;R#A\$6KSU7:S?|V8\E6DAEY;>/7^I|R*+QI=.9-'?VDSM|QYY%!YJY?
5@2\$P907_M\$0WQM&|&YXG|-B|FA/C*G/PB;B"(@: =6_2N4L?P*Y00FC.A30=JBK95^,' M3,II74X|Q3F:
(U(0MZ0X)3UG_4C:RT'@%|#D_ML1?&|YDX42%X)'_LC#9S_WH*ACV9+.IH3HU-ML4N1':_3|P:C^I^)^8YLV<8@
M&N2\K.B(\$AAUCX,-0@Z3E.>8.+Q:IL.?Y<9@_
M\$Z.%4B*R|C3N,Y|Z:2A4P,8WX9'YJD=Q/#XCXJN14FR_|:0U#AR+*|-PC0- MWG7\$WTN2HET#!X'FJ?
OUU#T(8L462KR7_K,#-\$|2|EX1**+#[Q]&D,SG&=0D_M6_\$;D9,JZG3L72-9X;|)6P0PWT?
3J*900S,PXBB2(_T+J_=L|J8#7|F\|)8 MAQ^T=PLY1E|^3X5,VB2N<|) BK;U+6%_C@_HP_MKMYO"6Q?
WL1A\$+*)CZ|++ MG/|7MM2&YE6I+LB,Z_V8?XF((&^C1DTLTVESZR9A5":|6Z;GA=0%*U9_UQ
MQR^U+.6_U;+.7Z27|)(5TD4*_M^C|5)F0;:Y7;:=S1=X>|^=KL|)GM/#39!L.*Z-|0P4*D,G=&|Z%=_|W|01W
MD7C5=09|L74_I05<;VU_HEXG.P_7S|FMESP2<;WVV=ZR^:;(|M|8Y|Z;C\$7G6D/\|
<<_/WA6QK0)I'4B6HTJEM"0AI;EJ^A1(<=R(|C*0\$B; MNWUJW0X#^A2#C'?A=YJ7YIILRY,NQ\$*KP?
0Q+DJRE|E_F\,MZB|)=(|^*7UC?"E5TU+C:6'+2ZW7KM2*X<\$9JK(JDX_)KS+- M|C/F5@&RM;
_22WX0K|=2K0F|E+). B:7'B5*\$4L2#93X|TH\44F0RE00F_M>M9|!N#?MISK9#(|#-|<U(1+>V+-R30?Y+F\|
AW-^4_7MN" ML+40|H>LFMC0Q49;|!+)|6B,7^[N087^F/%I,*&MM=)2'| -I!_OU3|K(\ MQC0|K>-
_A/"S|RHMXC'H,0K%L/LWTUZI_E(|M1NC*4NLZ)W0^|QN=|SJ,KPW
M=P>1R"T60/'98#922\$FJ54AT'C:TTS'L&N#M"/.K0J1.?M\$-!SS\$';\X^7N,";?8C|>Q
MQ/.S_10US|98BELZ/,HV=M;1QJ1I.\$,"/P5F&:8(L5QJ227I;2KZ7\$S-????
MFQ*"@I>8P/(NGB3U\$5\$1KQC&|G3&%_MJRBHTM:QV:E=MK"K@!N;=:P|Y-
)QGJHW+!RJYK=^35S0ZT;|.\Z#RS|BW^DJ_M7E2S'^0*!R>E6,9;TI=KY
9U/Z""WUUIKA|6LL^W1'WQ_) +CJZ(1BY*Z)^9_M,1HVB--*Y>9_M^T_H
R'\$GQ5?)M!1VNN>BG5H|;#,#5G%X6N%E=K^T88|G8- M+K51!L_)0P^=2TWEL*0JD|1%&J\7B>S#4KVW2\|
MT<+P?8M/08.3SIX-\W'L20Z+QV\ ;|4>;SQ@|J|P0F|<%D9/\|1| (KW"(|IB):X3//V:I,S;:MYD8;\$W
M1Y_QPYAV(*K(R&M_'0?%R_6!T5YAS3X:+TM@G,0PLPJ4'SF\|VY|N*"720+ M8";Z'L
'E:2^V4>'|10MV;7>YK(5LV:&&5D?-JYY\$)N_@CT#<'I+.T)1BHV, M;BAS'0DK-D-
H0Y^A3KL(GN'6E_%|IW>|ZX0*7T5L;%Q/G6ZNN\$9*8H5R.Y-S M2\R'3C_C/>;K-.\$L0FMS>
(,!\$+I72I<|.N^@|ZCY>>|6Z, #_ ^CQ/>)Q"/U MI4+G>ODT^F!Q*=QQ\M(/FIYK.!0@8@0-5\J08-
Z6RI5+|)6/C=32A#EM_R# M5I^G2,;LC)\ES+;LB"8@F&B4TH\|J6R1358=T8R_3^C<"4DA/0CMLELO.NC\$
M/_^BLVX7+-209X,8_*|MT^WPDV;76Y_WQ*S:|LAVF1Z*NZ|7_M9+|4L|G)OC|>G;5/XTNEOW-SA583P72?0V8P
%GNL_Y;RF"[X|>|#&C07|W= M'*'Q?_5V=|/_57SS6!DH-ERE-L6?4DG0P,9"|GSF:.0\$,3H/L,X\$S8&P80"L
M|U*5TJE2Z'FGC>1XI=)|MS(5)5PB36H0<|6=04P5/0\$2A%YM|RA=|&.OH^:#+UV0/SO-VN7;:(XHMB|Y(
MIR|>CVI3Q_8W=TON,1|N+TT=0W'N^<3874U+8G|77G'S+&7?E\$?-#XS= M/\$DC?I5_-1R|)7JL=0R_*L:/D@3.
G|@*|P1!QJ:I*4=1.Y+A/'FTL9&|R0(MTBI* 6JC\$'RJ\=01Q&?PX6E-U78,1'/_M/X&T^A:F\$|N:QR7!'|42H\|
|NCX5&"ZQ*/N|#6(V7=*B9_M^7\R:E4C4V7-[3#A9I+|(1=*K8+)A\|4^FM?5MP36NQA*N,^PIGM+>I-P"
ME049%'VLX3FQ6,KU200'/^*^\$<%U%(RN4=+%;'|KIYR/,^5, .^*189M6NIX_
MDI5U)^>+XHR_1|AGC;^FSX*-507|Q/(H'V|\$60P19QB 'X93MY\|H-(KG, M.D+

(T\ETWVG' \$Z/E\$>VZYMV3<^90./ \HXQ X#BG?!6[; &XE1HN=9FXS>F\$*]N=NA8,@'1M%E:56T8WWU5G %P7
M^Q^J^,1\$/A^S^1-\$<)>LJP[?Y"7')!J^\$;#_KF8-F"&5;#;(C'=RR+J]VY@9ZL;% BWA ^0TMP\$'S^#!
M;Y70N.&2R%M401J]Y)&N%3,JKQ/1#>M,X%G(P+17.G3\LT?NYTN>E=01&_)6 M^U07E6AJ]"USJTE0X@-
""99&J=[6F*?0[ZI";+M5C@1\$=\X8<3'^(- 4GKT N MKL+3QW@H@M>!\$X,;8
+@U1K[J&_AK_,SX!F@)+7))9*M]\DTX:EXGX; B;@Y MU>N[<.NOB.Y>\$]?E\$-<]\;[E|TP0XL/\$[%DS- "A%L0?
2!23=UCN-] &T0\$3X M9+&D]D>0L*Q1> OSVJ: [9,-4C3BMZ" !X=A)W2V(5%- 0R U^NUU9V0_Z% M\5-
!U<#D3P[2#(/#/L!JM'R68#_Y&\QBB3'XL- M8VQC;FSD3C/M20A&R%?
6HPZ(CC,13I8SSUY0T2JLY4Z0'7.K1Y6\#|:0V\$[S M/!P8:T22E+0^U9QP]H\.+X\$HW&"U6Y.3J(?W-
/P_6&>"ERKR&K\$&=J7T_XF M1*'Q(:MS?@0\GL5@YJ3Z%',0XRP_,0GZ*+=UVU4=(GA2*_\ @XB8ZU]G3UB
M^ZL0H^!\S5V)^GJ^XT^8%TM2I/;.T/X.(; *V[R4=M8)?, =JW %8,SDF 3H M[VRC_6,_5="^F'06F/.
[@%#\1K4[&MSC>2')%V]COTY5HN4%\R; _"0XUFI MUZJ(U2\$F%LI650T Z/_#2MK^9B7%6/8:I0-
/\$/,EH[V(Z1F\$%@QDIS@.I04L M(3JPB5WX&\$6'BZG55BW*+?4(>S)SZ#Y@77L(^3ROEM-X!-,P"?WS8I>>&"/
M>1^MR/>["%XA=>],.(\1GT;?P2UYRJS*X|. \#HWD-L?2F/7L7W@V]F^C>1?N/J+=NUGZ";ESZEY1W-:
(G^==L)G)4*Q\?6>85V\6!3<\$-]JK]JL)M (A,4 MN(AMM-0W??[.>/ MA>\$U/-&0W6E9/08 ^6H/6L1#7U<8\$C
"/;R57">Q'Z 1E07WDX/Z'L#[K_9S M>B?H,':9:0A(AI\$D %E0-BT +TZ,N90\4]I&> 5"?*V8]J;N?
Y:JC<-3Z- M;_EHV> :-6N9-^X\$FGUOWPTEx0,W +Z0F7'^ZSWLAC B\+DE8CQ;D@'(2!@* M9 !>?
'Z5PA%J7&"<[WF/Y!K=SW'Q=^X.\$=W P,_)V(K:T3XL&T/VC1Y"F MVLA%<[2Y.CMY
(Y>=J.D="F1.>\$X^@>Y?#SFB0,X"Y,&A=B-;%)B'V')9R MPGZWGPI7S/N >!0T;- \- %W%4!?
(%;ASU_YB3P0V0G-30V;@;#J;U7"!R=9LQ M]|\ "'9 T&)<'XM68(X,?
0RB>'K0@1(8%7#IFU9"2W.4V=S\,G0ZERS6]RC' MVS>8M_Y:33PU4&-^]QLB:N2A&M=RB02<.<N!B|E-'QL05
U&93LX^0= T85 MQE<%) "W+S0LE/ ,.5LM7)961];? *QCBQ=WYV@L* VGL;L'T64C>PX=C@0'UJ MY_*
[,*A4/XC8BG^)'00N\T!N\$;K<0#B;-#C\RYIR.M'2@NTEV&0*IB_LM?><>X5Z<\$S) *?0T7^Q/?/X:(0+?
F^X>TIB\ M*V]8=LKK|E%>C/ 3Y<2,A!OE)R-D@8
M!A\]*PST]=#0034BXNN+J]=19C"IO\9Y)M9IP"0V[%='N%YC '[%,@ \$PSB^Y M>!:|[\$);0%;0X*K@43P*-
PM>|\^;H7&T3(XUSY4.PC4<6LY BF\N@ Z>0!C/ M; ;')8KH!;|F@_ [2_5;2.=>?K K'G/WCYG?Q;NPBQ-K
|/201L=9\=W0]3@6 M)R7A!GIS^PQ.3I2,;44?|0+=YA]PQE@B|Y%?.EE#U2KQVSQA4.Y:T]RL/LRB M&3M-
&M_L)'Q\$@YS;\$W<(0|N/<2*TW*!^*FA!^%"4)I71]A45,710XR8>NC)^ MTCS.],R9+ U#@KM2 YMHT,
(&)0NU7><[CIOCPI_P: M-%V;& \$DFJI<6;2U4;ZND\$;WG|/;M_?@:C+P_>L76JT>C"\$M#^@9W M#KI-
9E30%B\$+3+Y?7P*]V)\;N?310Q==[!&#+*5=H=ZWDNR2Y1]E>JRW2"U-
MS0^CYB/4;':A6X\$J6>S/;D!WNC:|HK?=1@Z#?K\$'HW -CYPDHJ+J=Q5.PEB MT>4>):I-Q0Y9-
Z*6=G+*AQ]W4WG45A,D1Z&WMTZ0> \;0>;FECG8JNY"@. @E=@{
M+, ,T=) V\MAHM\$Y5YQB8,J;9W'IV]7K;1UZ, "V* [6VAJ^ S^*H8?CQX-10 M[^V'JJY]-XRG:?
8\$T.06+MA=\$ F*IEAV_&#;!:1V(/" <9M? \$1YR9G<&+] SQ MG&01@0+#7\$ \GS27&8\$"00L "P_7;:RC?IQ&
MK:TB'\$ \$!.PD;- %N6B>F=4C 3YBP\9*DC@%9&""U-W I]XV3% ^E0S+U.>>!\$W
M_K@YW!">DBRNOKY]B:SBWD8VUK9*BCF1X=X]87W6GRN%JS|. |*)QUSI\$0M/5
MM2M|T#40<[B0JFT=U3_LWPLYCD\$,D-?0FKM2E_>%2FXW/;]A)R=,4",T&J(T
MIJI/W"V.)IRN"! =APWN2*^>1QHT5>Z_HW*-6[3HV(T!2&UF <#?@W9L(G]Z MUJ&Z0]9>%
^6_#P]EL7;:&1\$B^1"S+[:F00:Y.:K!;?B]:I!/T:.0VY\$*"85 M6X@Z^>[&X?
5/S'A4\$5>1'=GV8["41K%Q60I\>!B5Z-Z,(D]_J^&V5J51P6C=X%\31
M29FS\$B24;:)40XCQ]9^]4.R[%&U0STN,+N:E7/<0> H2M+7LI(J?NJ;25!LQ M>],03[4RK7TZ?RM%.]^<4%?
|\^/EU\ \$4W'!)N(4%P= 2 L_)1131D3[VK0; ,Y3 MCV,
=/8A;U^3S8<6+51V0/INEM|Y|)U5GSEE[PV3!1*B6T+WR-X]>LF&CY?X M=DF0EA^Z\;@G";::;ORI2-QTP)Z7G'!
<):&WC>G; #H%\CUJG)YS80/EY60V M."LT) WEI?-KH7&],B3>5=%@?#40BRVA3V] J4CY",ES;^N]> \ /H6?
M7\$W5LJNPDT\YQA=8W%0%1'V%PWJ)H*M| (Y'7C(.W\ \G4+%NJQJ3\#0.6AC08 M<- \-
TWE"&K0AU0S.!HX4BUEC_5@QH%'120)SD)+:/S4/^0JU&WY99@4QF+A4 M#9Y][8-E<\$<9L P<>642I:
(WZ:N.^=!L|.7B\0S\$0I<>V1#X!<2["%=P%Q W MNF!K\<=((%*?EU]3[,9;JSPW0]3\TF#[6XY|(U/K*)NG5-
|'S-,C. ^M%/" MM2&^H7%"Z /UAN%BN7>91GXE(V27IC78B:9Q7INL;CXT# Z1B!R-'0PJ, _#
MTA*AM;E7K3K/Z19^J/0+4A^QR\8/H7P8A-\$F21G@PNS&D:86FX6]Q,= V10 MC;L]4SSHJ#6E_#10+
(EB4WV[>_L'6<7[*Z+>9\$8)<6C807=Z"9Z'S?/^R7N1 M1%*"DH7F%.1K'V_#XZ8VZ<_*5TLZS/S7I^1B\$-
TZ*GT;<)>RH+56?>K%F9)8\ M?>^LY6"7%,]\N;I]9KX]Y"1->AHI8+?AY0;I*\%>0C&=9#2:GJF<#W8Y0(' /4?
[M]=) MR),[V4:C3T;:14N_1:2^0]83]^J0 UE<)>S>VJ+M1'!-(=5%&(; -FAR?>9E M)7|^_.4,0
E&MMV;:ZH8>H<[CC_N;D@FQ]?+QX_6.4KU]3\X\$N*U,XE\$5KD+ M)>2U>DY62G&3-1HWEL;/; !RN+?
E6(*T,M*FR/"[HDPPIV&SB/##-Q][0+>#5/A4?
K&Q//, '.0BAX=HIAQ^2/2=!H2A(BQ2G5YDY83U@519RR0CGL&Z% M9\C:6KX3]X!MPQ?5Y--
MIATR&7UVAV8KP!4]-T]URXPTB.2[1&7;J-9;XYJ8 M6Z3N==00GN)\$XB38 - V[Y]T6YJ@30]CL1. MXWC?WDX
ACD3Z67ZD5+4J;.(;9\Y--&"I,P*J4ZP_#]3(!M1UJI,IF:SWKC# M6,GTD69*C+T0L"*Z:VA=6*+BTI_*I?
RW%JAZP@('1-0V:J9*RRB[W]:03HPG5E06NDP.-\1 M19YOC+ B5*7Q=]G]%SU07WA%1I/_JH>PR\$R1\$+M :+ &
M,3-@2@*Z#?W:NT6] 7NQ>F%) "5_4D;\MLD3.M1P%B@IT&?;H"7GIJWX+\0/44B3>\$-MPI M;6A6
|^&L.2@^6/0>)UPM'7\U1B*QD_L"J\$*E]6Z8UW6EN)C8W6J=Q<@DM-
M(EB]'M,>,@!'9SN;T5/+G6"=;RG3C8J2):[7:V|.M@RG7F\$]/0E^>8^V;%*W M
SP.EZ+*D_UL^T9,!I50>0KX9**?31U\)E#T*;8Y/EKVTU.D1==1WK,"KE%; M90.09-G9R-2;Y3W%\$@J:*. (L-
_31<3HP\ +!9VV0*K.7S?CA5PE0>YRB-^%] MD*-D)L^UX61YX.4G&IJ"'I.),20A[WP^3DAQMG,D_K6MFF.FRR?
U+I[9:+)A M2#011P7B!\--L1]SZ/8F4+4+0D\$BX8@3L?3+7HZMV#311%1B6V1[B+W/J;< M.-R\!*\$#"
[&CF4A.JD<_KC4L,\$!:Z;(\^;RD4X:C".P/2C&?
K&D6/4Z^955#KE]2K<;E@=\Y^[:;EZD;)A"2_P0#0C0E<,T:21>X=/'*GBIYRXTN>M2Q*.
M;QB90_&7)! \F%+P_0M9/K MIE*1CFY.LT+HF7VW -=[_EC^)CSQDGGT]^GU-AJSP#K6AY![(86C/V1&:T6
MF3]' [+>SJJ0"C_Q01F?>*QD9(#%?WKC_E44_B.@_M: *(<(AMG3V,CF^;NG\$39M/XR1Q1V'["4JJP(. [+>|=;F.

<+4MJ!{0J;I15:8! M!XJ7045+?+APV:'U.9)9U;RF))?)#9;I}(V\$0.:BL:&MJ+!%T85A/) M:4YT"3\F]-
=1\29,ZIM2V0&8,!,*0E!!L2HB)33{81A5; MJE*SH?_Y|TJVCAZ'"Q!.*#%6\$)M-/1&BJW IVZY//W0('P|V?
S'BN5,RD.>K&LSD M;FRK58>G@&^%1''^PLMSW5-RR-#TDH+0Z_11AZAQ1>&LBG./| MLBFD<9T-
;P*Q,JL5ZZ60:\$AS3:7//*_Q'=H00QU7FZ+@58 M@40%B?TH'BKY|M)HZ|*5:6CLP8^G3WWS=Y|+N4&V%8<_*"-
FS&50K| (*ZX\ MSB|\M! IFJZT(|CT\V!RSD0 W'N90(@CHU623\0,DY7RK-<&UR1469U7\U0<
M=:CZ7D#ZZ>Z7|+/%A0^YNA)8EN13C.K47P;74P1?Q5H-UKBS?Z;=(TABB=&RIP1.BK\ M+;
<==&S!!Q\$:\ATL2H;.:f5 #;|=??CGR;NU1'G=958 M%>:-?/0;J0F;4<'--8YK6P8S5J%'E?%+?
0SG|!_*3@"N0ZYU?WPB0)>7*R2 M+V0 +.W'/;|)M|< ;?M\$J.->56DU=57>6>PW63Z>^/=,B?
V@IALP|:A/XFMVF MF=.DHN @)TEW|MP%BB|RV\$-.*|M.^\$)"C1M#)JF@R8.I3K>GU62GH--'/GP MG5?
[WI^Z;NAX99)IV:M\$G7X;.:P%VDQA!70*_7E,Q,+Z77@F%>L|KFC86:9UY M:G0(.C(+18U>KE4|4U/6=|<:;!?
C>B(>^55#(0Q^Z8=FY8 @F>8C8RVW=-&U M-?P5/T;4\$ALH:A5*)YXYJ6I?1(V66S:/%_.8*1"
[ON1F9MZT0R^#BJT&1N- M\4|1P36G>J9| M:&JI\ C6+Z0\100Z(@K|DC|2V:7X/4A|9_++J\0^M4K&="L-
^VJF0Z|P332X MT,'%5@MUQN=FZ+P+,|2AU\$Z? M69>VZ.'!W5XX/,CY6G3S\8.-/C?!,>2
^HJ@/&):9PE1/2|5 +: :+BA(\I MI^DC^|ZVA'< %88)L!(+J?8A)[02R3BXD;6PEW9#,(|
[G0102"B"P* %,SP@28AR|A-?=HC|N#E,)|@!. (N#J7ENI+5NGUQC MPJ|+B(1I! ?M2-Z=R2@1|,DJ38|L1:
DU. JB3>VLT6/\(,5;.:R3:|J+J3P M3&F\$3/\0KG0^Q-
X+\$NMRS5I0#@J=>N%0&P#3V^&39P!;:NDE/3|:9H9&L0:| M:@*|'"<%44 P.>%^|8=-6'?
CH=24Y8SMCR'LV"?'| (K-SX2HX GLUAN28*>| # MKV\^S"0.56CSNEYX9 MS^.:,"E0%DEM
Y.XQBY>4DL+DK7@%?-D %YIT|H% MR683*@XPME81!'/U=GDN>!%YBL61V8=H5"<29CZ
8P#JL3C\$0@8YBP\$X4(RA MW\J!'<:FJ"Z|>V*P&A>R\$45)|<)*WJG7H @|\I)RH".^?JJ-JU+F,Y%9V(I M-
;DF\$)DM '|!YF+.1> NQ)^4^XYK&3|?.'V:0\9DL7)\$,NN=\$PL)|U)|3#R, M,("-
|OYLS(M#;.)Y'7P8&KC\$0%L"|S_0TKBS.7')0AVDG:%&:T9\=N*TG|_ M+H|_-
<%H;4N'G'>;5V@RZ;2"YH=:XC;Q^2YVX|S;+F_6ICF@-BM?UG++E#RE! M|S\K\60P97V/\$\0|
\$S(,|G0=UD&@,MD-T614&F5'<," (8.-5)CN^/0#U MH8?0LS)"TXZH|V\$FZ?;>4&04X^+|RI42|I#IH CFVQ,H
G(+KN'P);;XAL?DU MBY5=R?5\$+<(G8W_T@U)|Q1>*B9+ '5!0A>NI:EZ,V*| 3X>KCR?6=B .9GNZ
M1VK|)#PS.\$)(#LAHAIT>"6<=-/2@6#^AZT|X=E%X|B 0D<| |&@3|>@'|2&T M)/?3VV-|(|?;
J/#,G/ERU7U)J1H '(|X|/9_0.-=\$W1_70IS00V |%,9@*9=0=F+ M=190<6S1=@: ^W_9WDYRLN0Z_0
2_|>2%S/_#WGM&--5U|<*Q M*5W@)2E29=N@T0 M\$1%0>A'IA(#T(\$4I)<("\$B7CD) >N^|2^EH9=
0@T0PHG/>=XSSG/[G/>| MSX|0?.,\?Z8?S)V|EYKSGG->:V|IR+CI:#3_)09^X"D+ GM3V(5FQ/(\&Y
MF8&1E-3B'|:4L#LYNVI5R4|C(|,TT08!%FZW&ZH+!5\$7 .06YQ+>2 J?#2HK M9*Q?
UT0G;|N7GZ\$ 70%*,+S|XC/<9:KUL|9^60A+QLRAKJW5IVE?3=% MRH7"2./&-+:03D/LR/X@5J0/?#
@V5M1W'VE9+F|Q:0Q1E:D|TJV(UNEF>0 M/.:RHE3S|<+P|NIY:8+P#,8HL 'U%|\\UGU\$DM4^V_[GA^&?
R/XJPW\)/| M<| 07L.: BUS??0" V2|K".7D-7T;|K3ZYK>8C0&E;\$57E-X*KL;E)K)=W
M0IP7>C&\$T)3TZ_\$ "8\$*BZ20<)FH&4Z'|ZJ'\$035Z0<:=S|Z&)VQ+(5PP) M#)P9|;P
1':I0Q=TFN>KW)=S0E@=BEX EKXQB6#6LN*/.T^|:YTZS?N\$/B(MJK6Y\$HUNAF<0+<9!?
IY.&:@WL,)\8'8.RD+/^F@E97|1|.Z\$,PC1;'F207S MSHA&S*(BW#70?^9-
JER7N&W\0MG+^EJ)I>:;\$X'|K:JRM_%,|@)^63F/S M.CJ3ICQ?<"|:|J*@",ZRC%#^8;G6
1^1!U8P^C"X;IIZHJ|9;5|>)7R^BZ(QYZ"A MK3#,Z:.\$I2+2"ID\$1IJ4+0410AG<;^"!GW;^: M0;00
F)D(4|.R<\$E|I(|EG^!N9\$DF|H M N#;.=IUH|CXU83 S3WINPJW2=? G5;S/&3" K=U0>^?
@2(#4I&^7T'|JH<7@ XB_YI M32B'8RG2.IBYI" (?TK R%@'EH_1|\$>DU8%>(V:;%Z%37TL3|LMR7K,9ZX?|4
M5#.%|>6<|!E0|K=I6N-*6RP7?|!^69;^\$^|, P'E|&XP|4D#Q6CGV:??)8|:'JR_#Y-09_M!0#IP2U?.)B\$ M
_OY_K-Q3|)?0I'P\$#YS5#Q6U!XAY.XWR_@+P#I84XEV/=5LS908A4N06+#5 M5!0DX-
DS,BCM=;WM@:5EYTH|S":T?=-H/<5Y0.B7WKW 2--%KI|SY/^0-IR<|f|SD.1!T60K<6GR@
1SCQJ#*U\$ 8"C1#,22IYG>*LS/E MJ\$8,4C';K;SS X'H@;I9J U7VT=|f|D'ZH".*[AG&-+W)(J8->W?
N@D2Q#4" ML0GU5Q6Q>ZNYM&QV9;:'C2IX)010|f, :.YF8|^V34;H@<:|_2)FPY,T*ISD M?(XBSOT1:
@4B5\$B()&*04|_G?^GC W<:;>3*P\$)0'PVQ.KVE@/8/SB MG/C|WW6X0G#7V+!_#0#5S|
[XP(DEALYD/_S;)&ONDE0_A&S+ULAG8/3R>R)EC1.PM=,6ULT^\$A)[ZG6ZEUGL7BEC->S)\SR8-,+N|)XD>
MJ9?1 ^FU*!.680|X M61\6SH?NKAC#V%|9JB%#?3G7DG:G)A#|N^V4/[L1Y!+V)JP=Q.8BPJ>E(|8,
M:ZG\SOM'\$EAYS^AY2KT9AU^_%N9XY-'<'3X9M?&_G2X/@=XZGG?
6D0X=E.A*FEYPE0P=BG)8UDAWC08\$YY)MQGZ^5G0*(D M2*5)L70"\$*AP!9088DJAZG,|F';YE(8:\$?@Z&4G00&-
^;FZ+G(N-.)|JZW| M782<(\B9/[GZ0>5TT0-)4XR!1H0!62'>JWS\$PR)X79)6GT31>^3^|10|C MM?
*|_LRFI,NT<3/K6 &F3*M9E\$B5.I!17^,JU5/VPWX7'P+U1<="(IWM!WS;2 M)N-*NBPAXE,KE1')'Z1HE0')
+M_A|9\0ERQ8T2Y;*^\$;"5%*G@_!DA8K8 M%17*3ZY;0F(|4L4GX<9'=0177-BR<+BT|,|9?CM|:5AE^P0
6@4A_00SP_#2 M*CA_2= |F9<7@.980IYF@=0="6Z/:9%Q+57B3YJ(\$SAQF YHMNAJ;E|H4%*| M
!#WI^&.1A71EDZ\$-0&_0>CCVC^>[H1@E=FA"W7Q\$E<_SHQY664I?W)MRRZ4
MK>:>JZK!8&QBUG/_G^'\$L=HY(0I4?S7?X,TGRMK_&5(>2@<9Z|!H^('CF8A M+I|@+ZM>,TK+\$1W"?|SQC-
P9_0S@>CPJ00 ()A \$Z|K G',Y7DYG+1RG+DJ MXC\$<|?H6'2?T+Z0()C=B&I-?I?U0;79%;ZU7@N)??
L|, :I%QZQ@4G^M|B\ M?|2(,0L5WGPU_?@8C6,5SWA>|P7@D|4@WLL.B!6M(H24+|f|_L7QC*_AGG+\\
MYN)|EFA3F7MW>Z8CFJ^R?8.)!N/XSX\NV*M|VF6I^' M>W',7W3-
|Y>'Q,*51!A^8E5>\$!A5IA?|U_8%J_1W4B*:+X QNUI_#'"NAKSB M^ |+)\$1X1F7(\$*
|,Z'IPI|/'62X@DJSW>Q9XE "37=*>W(N!_:^00 M?|B)JFT&,[BV]"^W?
*6)550/1>J/H\$+\$J_#Y#,\#'|f2##UC9F,,!YZT-|: M
1?;)TE\2)UWALW&9:5KX0A:C|P+*|YZ.0M/'_!SS/WA+\$F\ ?96\$4M1NUD1 MS3HZHP|f|f(=7'3<,:;2I892?
M@613S.\UI<>EFM*, '^@H?A CM-N .04'C#^ M|9X9_LVGX**09F<6"N8)P-|&*N.^|\6M>|Y;#JJ\$ZAI&f?
VM:B@C*\$9^QH|2# MP3+|/=ONY:SC3#)J_+IZLV3Y'|#- ->!Z933M)EW(PP9,VV6HT^&OZ'?CR_ MJ"
_BX:+>^?EX)_LRO_A\$BE@E>+##T;/5P)4S!L"+|G;[H07<F"@ "\$!H0
M|A5_) \;0;1&4LRU(WCG#&|PX+Q)3Y9+Q,G>"/|T/RZJ/Z_Z:"@R&ENNN-0 MZ.JM <&=BP/,*L\LZ_B'|Q?

MT"I[KK/]&T?DBM9Y#*YT \-B87BJ./N.*\>F-T=\$)NN6, HWOF;D!"2 ^;,>:[UK5!J8J2ZST+G&[-M)""
\$P- '&/R.H9=7.T5_U)6EZ8U*#N9-S0979KR B;Y:JB8")99UV@C>T(F1) M(=%\J:~W?X%?J2L07B/\$0%^:W3!
<\N7U/VSVCO:4T"J#SQ3EUU650=T=>A>V
M@G>\$/#>3\$1NW5#0Y= *R*F%B _>+:JD=>B2PGSA+GS1:#1\$2^C\$????*RF==
M'E9_C&"G#I@SW_)KUKL\$8KBK(I3^KN>=LRCI*2\$QB">67IwV^ <>S#]*F>>
M^]=AQM(6^1_,_,_@P^U88MM1SAN(1KZQ3/_Y&NF[5WXRAVH3T[: (JRCp6]]PQ MRHWTOW|D@NQ) ^[_]WH;VLI75?
 \TT=Z7K.'.-MO)]_E@+154'5\$=QT,='^[_V)0" M &0 4N/M-'6='J _0A[L#P_0I@[[7\3&\W\1&\2)PN&_1?
F,H\M?DX,0.GAC MP>9,V1%Z7BNW@"*-F%)M09Q2ATK5V(.F/Y;#F,([]Z8>%>FG325X5C/DAC0
M>F>WZ _'=&=+X%K260GDF|T\4ETU 4U6G<|3<,B*0&|"]\3/4F-&Y/|S"I< M\0/A-
THJ,M\|),KC|(. 'HS _|P\|C?27&80@648!1<^ M-\$B;8&^R:FB-RH)D^L; %G=@9;AN-?VZ^(.3<5#;
MOM!CY+7 +T?38>LUJv'00-38|UF/S*YN%GR%=-9V\$>N=\=RB;3> (=R9&CU_M
5#!6'U'+MS<>@GQ;SL>'YH4.'+GZ1D?'V.H"N4ST=-S2#P|8&Z;L^]*A^Q\ZDYU,.HwBPPY,&>WHT8,
(&,U>;9B0(K*\$DM6G(M%4*5W28 |X=|+4\$KF%17RWC*M;WK>2S2,4LA8AS@
B3'\$8'0\$RV2TZSPL8YQW5P34003%HP. M#CRQV8DZ30_Z#_,/|RX!7 M30\
|S#J.=& P963|]3BC/T005;1XPdV8\$0W4(;,;') M|5&
<\$@%ZR^^/TMFKJL/5\^4KD|4ND09XSG1<(NVXSE^JQ@ [|&2 4F9LU R4 M [| QN1NX-
[XY8C3F(\$\$7BB1^,C3(\$E-,8D&D\^ 1R <;Q-GH"\#VR0_AEG.5 MIGENC'IJKAEW=^//AF'QH.*:DAHI=5?
N.>ZVS3/+NZ_)01\$|J L|\$ (K.1@' M,D,6,4&B1|H(#07BSHF62\FN2', \$KZ)N/> \:Z3/1(R)H-F-"B|1V9K M
7|I-+SLY!^?B8M4;2K1 /X+N83T+?>#E #:CHR\$1> 6|V(')+ ;7\N)%1
M.*HMM'NE(\;Z6/,YBOE_+:8@R!'0!1 MX|9D *|KN|OG(-AUW93W F>6*Q/9ME!|K%
<13A,-7@LL@U'9UER+2R=M|N;> MB>\$^",^U->6#|W\$0-P\LGG1M1(*-U06IN(;\$QRHP/D%@^\$SI>8XY8HJM9X5R
MCNUAW3|U%XH,Z,T7*@DM724P;(EN-&UD>|QGL'GC&'+(M'#9S00_YQW.'?
761Z5>90MV,0&|>)2<>W%UJ8(;**UPI'^>I'5T>/ZRW.R\7
M5'L9S7&S5^1)N("3'|1JC%/I=2\5?;0J3RW3@\$Y#@ KX42C?=[|_LA??&@S&
MY)"".\$>I@P%@D)C8&;!6A>\NXSU_-1AL18UN^S\ MH"7"MBQEKY:'75^);(E@+|9E4YV7LT'D0W/
MW@N)'|""MK\6 _|: \F|J1T? &1&\$QN ACT8+P^,5-K/-TYIA/.S?WF"LQ3@G5-4
MFD'IJ_) \KRTXVQ&YZ)Z\HF8T01JH^MO^," QAU%GM<>'=\X|C|VB?>="K8+ M<;&.9S^T--H5AZU\$Y=2?
RP))Y|B_KH6PKXQT\%7|83\H/F?!|OAB F(?@_BC!34T/|B)U7?W.AV|1V &06: M^?
4#.*L:0B54SM@S9P92VA%74QDD?J|,JBI@|^I8/#0;3>;W5 ?I*#\V9/PZ M.)+OF)9QB?
V@FG|ZE:5PANW|WX9N/^2L93HH0.SI02^0R@3BS%L5L2LDCM99 M-723AIA_IC(3;MjG7|UROyD=EBC4P&5W>@,
|_Q0=65\X;>0!E..?89093NDD M|U7P^0=VZKJ5_7|39_2384'KM*KW)6,| (G| :X*+=8'IE.SM^N08_GF|M6
MOC-JR='CYM!_KDNu8RK#0^9<^V69_JUAX77SXX\ '!F\$00SKS)#"".&;(*II
MP_:\|:/; '8+28"NQ&7%JN1C6+3%Z@9VSFC<4 _.=0TTP7V*\; (=|EA!\$'< K MZS4.I7"[1/K0]+KRfK() "<,
(I8PJ/VIOETZNG>V\$2V.?J8+N/0+CGP'UXZ30_MK8: ^3).0_(Y4KC(,3VZV0;=M=GNN+3AW9L:S|LF(J/@^?:S?
W9U9&J%&H0\$ M@|'"0LNU7K_U""^0IZ";GEP_ \;4L2+=NPDW07B7HQ#Y3,@SY""^#:56GH+V\$C0_M:
(1YE9+B|2;EM6N!HI30SW>-HDNL)/@?081; ',4S.%-4|L.0_DR\B; _;C/1 M_Y9 _%;_3=9G
_CA51'!' ^C8P37%J>,\$| %20YU!(-; &JXA-;"&F\$<Z^:#)ICLE%ZJEW\0EW6A-R) _=|#0*7N5J""=W
BJ%8%5K/C+AJ-<;R,R#^*-M|JR'0S#G? !YT^IPT,W:5-3(W^L* MG/) ^% 8ZV_NY#I(83L_IS7,?
UG=5)62KZNZD;*^\$PG9NZMY'UC_+^<(B|")0_M2:)+P0@CPFXW9P8TK!A?6!- HVF8V00WXLU_RW_+?
RJZB9#|HRBL\$WJP|:9- M*B=&P)VIP*9\$0F1Z4/I! *W|5)S/@*?MB\J+_?+U0=-P+\$>|?|Sj/^1S4\IZM
M&/J*H|I00"05*_/_|:|+: \^KX30)A^>E03M,60NU10XJ21> 5AL<|P4@G;" _M0./1B+."8<% ?|^#^Q>
%:'C'T#X!/@"<\$,6T7E^ZP) ZKL8-W,!," [\$TWBT MPDY\72\$A:E@Y06_6A] 7(-[06'4>Y)'K'8|B+|?I6C?
Z!| BTMUB9MLFX91 M? *0,Q%N0#<"V/%'&61!<&,[(8"&:'|XAX8< T0*P\$)83D5"5|YOT|,>) M
_,9JY""V90WG_M*-&) ?ZHI)B<2('PV""1EXQ(|&_2ML&)QNY;9JV>[=UP1%,&045YL63&T#=1I
M:/1_6H.A:V1+,G3FIK+"B_%2-;XAA^E7.)HV""!4\$7S_M(KM3^'CZ&02HD',#K6\$7U:5GS_5>?;#%?EM)0?
4NF2>7L/9W'+7;-;3E@G_Y M4YQ4/09%^T\$MHU!! TI91610?K0XHZ=3U:&29"4<9/5/N9B/%L@/PP9I(1IM
M!K0!B-%R07)'?WAARI%-SMFCC "E?;..[Z78A.Y!GK"1BN;=8|\$&#MPKC&XK M7&;-L!:M7CX8>#"9'J-
= %V9PV;F6#6308M;6R^8I*B

5^[XYT"#_ [7|(2_M;B>] ?"305N*5',WR6CV:'G%ST2=:*X0I)"X:5,1|ZY,@>XXLA_+\$/8F+,[
M16W|+FW',JG5N?,&(&!=>4G\$R?8T.&4;TUQK#S/)H|VN-R?|+F')0^| \ M;I*68<3| N" ?
\$>;,Q=CC7*R1|B;:PU;A|7\$U:0&714N,+";PIMT19K*2F3_M0,,E6_@L'\#T\ '(IE:@N"\$=V1@RGJC87*^-0)
|&6%_B_R3&H"(BD"R/7?2; M'"8J?-|H(\$|V'|J\ST/\$09HXH_E\$TVGLCY+9/A(M?6|^WDR*8HV9FGI:UE_MJ-
?:=4|SWW|.3#ZU/ H#PVVDF)0+PKY/&QM*P*>??Q!L\$46|:W(*0+I,:3|@ ME*A/5UU>09)*@551#*ECS0*)\|
0IRL56H1Z6Y>D.> (V\$V8(L7"CK.!_XE0J_M"4KY)J?Q^3JR,|&^
&J"N381(J>1C95MT<%S!K6LWB|72T(9;G.OV<0Y|DP| M\$?6,Y+3@|00QWKS"YL06@2|M-*\$= M=)I^_4_69:=?
(JCDI,UA|MZ51\A.@- M+P|P0/U0.5_580W@,,^9;Y=&A'MHCJ2\N:E B?G\$1&,"L|?P.NCEL,)LBUN(
MV3YJRBI8&<7\$SC'^I.'8PBX=Q1!-@8 ")IOXF+B7\&6L">L|NP8V_M_|:7QG8UN9,X+/:R9L@*6:A\$R05N?
7|V@41= \>A36MNIXR=|G#3"WP.9_M1JWBR3Y\R' |8X=<-YMHK-
!|4E75Y""NY7S;_K\$E/*I^4=&0QK>UD=HV/E%| MV5|]!"I%/(2F)%9*83+;|BJY|G^;_1\KG6!&QMT|I_RT!W/
M-')XIGY%": -3%M,E6_ZCSHY+NOSHE:S\$4GLQ3-QBDZ|K<#NGHEN(- MB?-G^ZTFM\/:?RHMU=/?)
E4LYQY^/#G;^JYG^-%1_MV?#|3DOWZ|0|>Q!JUP_M-(1*C00+048H4H,;.(.T1LLD&B@J:CRF,I)0-T)IZ?
M=F' (&D=:\X;MU1.0=0>GZ-GCV\$9RE&0)E,+VDXRAH7(AJTK,T=-^ _V^TW)U)U19'QH)F8EWE\ORI\$|NU5B,
|1YK"U9MF'ND&,5LK30TV?A_MTG3WR6,/Z:GPQ)JU)EL)=/QKL',_60AX7W#VD^|4TM!8YWC;3ME,JG0/ZNNY=
MBFU|[N+P'7\$30EX)NIKMPM^61E.GA_#>M.W|@97AD^/WS6_/?/Q#)9|_GH0; M'/5\\$/ ,^@PY*%A+VX: %(Y(-
%5U@PF^PH7\$'_Z_N"H/|6<:1,S_YB\ (Z:PIS(N_M27S&D^Z^F_U@8_10:Y|?SL.WWGE_OILN\+J\$!HHRN-@
&S*4C1#R>3MLV_M4"TT,E"#(6;%_TTGT>|C_LWE|F#30V@^3?M_G)F>B=<(8:|V:8G1CH!QG.0_6

MR!;10/KV=*G-8*I2CR-!LHVKRM"3R78V*^@VMW9Y"/JGTNT+@SW8()7P)Q14
M\$2'F!0=;^JXZ"8/8/9TMPL\$#RJ%L0K,>Z+K+0AS\$\\5Z&JP6@5773J#NP'
M5J5=LD:G\$0QM&NMSJJZF*A57^7/&?T5U10 C[GS']M23@'?+M/;7>=%!38: ^ M1)L^E U!>G&;WK2'LDG=0!\\
<1X4Y\$V@-7;4'M-;[:] C?K7W*421+A) M%D[4X2XBV9B'>]:(\$4 M.IOL9,\$H4C;00,X0
MA7'B8/Z.!N:DQTP!8^N1^RW'E"X57@F\\KJ*%W (6UB2KQP07H^HN7NSIHR
MUD\$9D54\\-6Z,6[FL^"2H4>76?.\\+GD3Y3@< MY,L\$=^N5IQMI?=?MDW@!'"R5N "@B-?V&EKMHH3C.1BZ/:)?
0:QFF%Y3%*(T M)?"#ID:T7W.1RM%"I: =EM3["FB:<,_ ^@D?\\<22J<7Y)P: ^N],@;*WT>A%A@ M,U&CW?
DJI^3M;9L]07F0I#_7-DP<_\\20^>H=3^08AVOV>93/Y/M-WQR7*?NV
M:@16&JQM'R,T: #:PHACWE"79(HKI36^L80QV;\\&W1#"E+0\$'E^*YV6P,73+DD6*WZD1*G"G]7>U37
MRZ^OK[A<5GZ?0K08'TE(4T\$RIA\\<&FY0#\$'L!E^\$/?\\,*6HS\\GFKE'F;\$I5 MZ\\Y4MF00N-
W5S5^V&)&@0**,'\\?J8?UR->':\$'\$@70V)>3201M9Y=]/*/9?
MUD\\WBY*J(E)I\$RC()9D: ^@N\\+QMCRP5/IZ=\$&:W9MG4K!PE2%0&'<[]KPX+ M0ZDR#*P;Y8R*5I=^?
7WA_F>YC,(6TS2&F<&?6/=CK5\$Y13./ MNA#: :L7P+0 M,E /11M#3^N6-]T.AK2!7!J]RP*:P (MTUE*-R76)Z
+V+I' M0:0>/TDH>"^SJ\$S2,ZYK%*RM,>\$-@)1C.\\J2C=<(&:^"!E8&V?KG05#35E4
M504]TBCV&ILOP4^(0*1BZ\\Y\\^+3(2BZ\\#"QR#,0S;BC.-%CC.-ZGC];M%B^A
M\$B)=IV!BQ[Y;^\\F5BEM>BH30V.-Y4XNL6X:TWM0%0,SWN2MD5?9J&),VW\\N,0T&
[N(X3T6070]NEE:*,0PMPFAY(X50-7DBP MIX!@*K[WN>110?AXZ M=L1U206J;^N;?
^X"RIGW=LSE%KITD.\$)8>5\\J56#+9?A!&[#LD"JP+D1[TZ) MH*2'0#9*Q*MJ)N9*XA9-""^L.UP\$7812; M"G?
*1P5PP+RIV8UAPPW!JS!'1](GGWL39L4^R70\\WMN&A#V&)+@ D2Q "MNAW.@ WP\\2"W@YW&"I=
[1.C.+6]?.S8EB@^S8 N.DTQT- ?BY.^]H@[P! MUJV!IQ.^H6'ILE@5C6\$/->TTREIKR'A!%B7-:/;-
0%0.]WQ\$R@=2&RF-! MP)#RE-L:;%XU&UVE\\@0+C[J4X?NHN\$>T&KM&0GN CA>RNJ08-80'CG>AC*CU
MK+VB/K#U>6GJEEZUWLOVI9.2G*B!0:GYM?;6D \\L 1'[K3<.-\$)-*=]@T09K MZV\\8=KM.)>HYP!W3'Z# +F3Y
J)@N7NZ2MP01\$5%Q1('9X]]YZC-(!U6#A2 M@QAGU]"(F?
L!\\54:KB/WR!_W6"J2PS(/_ \$0P:.0AP(7KLTVNJ0SF,=\$#C[' M]A=-
@=CH_ =0G*8):3WU#296R!ZU_G%=8)#\\: \$: 7!>0KKE6&P017C'LC90WL M3*" !DQ@=?YFZGV,.-
/N\$2RP\$"KF9IMCF_8FJ#M.R5=4?N19#XYEY>0-A\\Q. M_HYJ6"DD,IRZY5B!'Q/1T&B)L+(MRP.
[PHI])MC4'L7,J:[]]/1\$XFX_R4Z2 M?7\\)/ + "L\\3VN\\@V-
9:;%*]Q%"Y40Y<^0_0VGX+ #)X95S>'>I2\\K]S]6R/M M!N@PNJ^MW%0@;I;?I Q,*Z>+7QIDW%
QN+ \$UD!401*AZVQ_CI5P1U)?1Y. MMX6CVT4?*LK:K)4#6J9,P4#MCB(X8^&(\\[G0BW+^_GZ:&\\S?!MR*?711+P
MVBLS>JS[YKI&/,N#Z!QNZ?*AFW,7#7D63K>/[VR'+5J)S\$#XB)Y9<.00E;01=-HRMU MS+:KZKE4;9Y=
MUR\\109(&C&^0, " LFR1DA6_U9F'?*U)M2/;GV/:80QVN5)/P5<5+B]BS\$X\\ " M5+E# #
[34RT&27C96C^V\$)T9,;R9^FHB7\$U!
M3JJ)E<:&2.:HL<3R5A=)CM6Y%6+7D"HM%P":C<1R?,)B&,K'6%:CV\$^;"43E M';HQ0>/6)!"
U+BCVC&V3]R;9^H\\44:NIC]>]IUS;,_G_88@0Y^B!K;UYB@1W MU.50U@X0[W0W\$;F_@Q1)8WBWD] 3>N-0\$6_SQ:
(;ZQM9=D!PE=]"ZU&3*6^, MP%MZ#MT;3\$HQGUM%(L7\\6"R9*X6^(>CUPG+5=HZJ \\#]M9+#/N(Q3AY9E/C
MV\\#7(20[//\$]_ %BSP*2HHOZ.X\\W350E=1!)MH4%0B1& &FBU)*M@U_ ^HX=S@V M(&YL.
[DF9\\JGMW90D!DFT\$%%YNW?2-U!GWT15A >/9;6X[/Q(U4'7FGY=*D M'&-%U2)JXZ6G(NNL%<8>XAEVL/%
(2@+_MC4_,WSDKW0&C,+G]T9;[W0LG)2N MF3M"#:E@,HCP8_5@I33=\$LC#_1:72=N\\RTS M9UZ;0M_]-
D"569F\$,]D"-X\$4#0 P(1FK8_VVR>3=4)F--6UUK[%*^V\$W?Z4& M(P\$?:W(V>0I'69!;L^\\M]3YMN<)B/B4EM/
0)G*/@Z]E36/S50/4IVP"B[0 MSV*\\D28R[1[=3F*+ M_.'[K""#@:;2#KNFD:10#,E)+Z+XM6K
#0/ZZEMJ5V(#1:,[ES_\\9.E[XB]\\ MK*=",L=37AV=EW @2+M0%88):SLJP0!WNA@;:K(QCARHL>KTMK9TN%5=-
120 M\$;\\Y,0##><:H@-?CZJ5PM@E\$4=L@/?;'DE9QFJKQ(^2\\K?P;F\$9JT9K7)7G MC5X*H:6H+,BH
UFRPB(Q#*Z6,YY])^?](2T26&Z<4IB> :&8/VY=0,<9="-[M)6*4]A9C4.8]:0 ([2,0\\[MC8\$57S?
M[401#SR2F)85U]GS!%6/+>^]C7%4]8K)M=6-T\$ZEY;#\\0B*4MU@,);(U!F M H;T]'9DBLR^5F5U>>60HD-
@I6!6SCV,H6'7L&'K\$/LM%+X9P7[L3#^B%31 M\\3K^IOL_05YSAOZZ#^MP H>VUXV8F3T[/OY_8^BVWT_?L
D*:CB3:ZW2-%N M9[&L'V_RKPW20HVP\$0A5G_0!>"3"5*1;,.]YKPSWM*90+\\,)9KTJN\\P!5R
MY*GHXT\$TVUCS_J36F<:V V7%7!X8)LT7-'P"?D0NN=/1JUP?YV4=)5:}.YID MLTRF>\\
[Z142+V/XSWY'S.N%!3/QM8!\\>["8PZ+UNF+ B@C4>?]J)&-82,0+
M=E1/U?/N7>:00K87>='796*]M4J2UV^ [LRF]Y-X0HD2_76\\;DU?PZK;:2V M6HT>30,-J^(9EKC]P;
L^NN<@129P:/T=]M=U=-WP;57\$@W2-#1+BW!0@R. M ^P/P X7@&?H!MW@SD]N*&?
^/, 'YUQ7WX'51#VEFCL4M+30YR10,(02N,K0, M%< N+ &#Z)D:TN S&P8=F=P524XY#1\$YQK\$?YN;D:
[F*.7NY\\": %CNHNNH? MI;,:/<],2@=7*/==ZC& #0Q/\$,'Q&5GZP>RHQCCG-3IG'0\$6.U^T,N0I?TK
M@EG[[7^J MBME&)#N!^@IR\\54/>(C05K/0U:QM'R,'@RNE\\J7"A2]0'L??,#94KRF)[PML
M(KH4!9XCLWRJU3=MZ_1M*,*']*H/[13)Y@)\\;0W&Y=[_ /ZH
MV,3.26[*.^SJFRM(:8)IN^#F634*7&4EMFYRMSU^QPE-ZIVP==L4R]P&CX3@ M11#G 5:-AZ^'!;:%;HY[?
6<[.HQ-+G0GX/\$T/7\$.5V;*ZKUNZ>?JH5T: MW40HH\$ZFQ@AQU\$LOG0>)1\$1/*ULZ3X!7ILK[0
GP!MCC&U:C>/D*VLU^0 1 M#&MWUFY"4H9-6&* !1["J.1T=[*&LRMC8XL\$4;%<:2B*#FY5GR> J^QI
M25Q:+VMMI"NL1PYT([;8Q&?&\$G/*,VT]4AF]'[<:/)>)RW3SS#52H?NVE]#3
M>H,T>29/3SHVT<%P!YJE*\\7;F<9H=^H] \$2P.,J9@)7\$#0J#>+0ZSMM*^6P8KZB%#?'R(:[MZ\$\$_>[G7>] \$M-
@6).WQKGWN46FB4=5SUWC6]89VU M@?@OT4= 29!JWK<,"8'+2[-ZE^FMJCQ&HSR5VI'L-%PRI0UV79^QW\\ "-9S?
\\ M'EN)A-^: ^KFF40\\[-NPR&]FET1ZP2AX8S\$RNLXE51#)6/RX^4/N>D076J=F\\ MZPK_1Z(3.[^4&58.IVR;?
A\$#W\\APW,9*J DZC#P8%4#J15 MFF1Y:L>PG0;[R7: [-IRDU^?(>(0W;^I!^6PH92D2#U&S< MP++:=<,
[EC\\CD'Y6?E;A3X.WMS]^(+*U:N[J+F+%5A-"#?MY)A.K'B(-)U!A
M2LP;96]>K&CAXL&W+S6GQM9W,,>VR08ED[3BJ]2MJ[>@\$M0#*>_80D_\$5,Y=-
YZ.IHT(\$S:R\$ZBYOXKV^V[!Y5I8DFA;5DHS"3@I[>V.V>YIEGO:-?PU MD*X)721_\\(\$ZTY9F.2C7-
F[3,F)5M&%^@A4KMZ04QW M,/4NMAK#W!#*+=.X !#7M_DP#J/&(M5%]1V-MAD\$\\ "RLB7A)
[DM_G(88C"' .3HD6&#V^MR@L#P'+^1%X'CI5W9[BW ME56YA2LQ\$[5?;F[7R^RGA&%>/ [W+7--

"A@Y]+V^: ># '@!/[JF2 M RQU>&JRL_) \$US!V@ "N8]T[+9V?^*5'0#(6"Z">!DM'*KY2N)7Q=!,A\$VXZM
M\$-9U# /WHP=936S)PN; '*TY'"#QU,) \$)F-],/=6[5#(35W;PXI#P3BQ[,FM8S;CV"XIR9&R'K"V&"Z:=VKY_&06
MZ(S?D(:[\$G(]1B?M D ""Q;0*G-#5WYRC!XXUJCUTVEHT*015>=R\$4@W8U?_M])@EJ<=[9?;>1*%JY(7S@
3,20C&[S\$0&)"-R:Q(:?HF%N>U>_ML& ; M/'E5GVQFLK(7L& Q0@DC& MV\$U_ ;CZ#_G)@S9GQ>T_.0*3+N:NY0:
CY-,Y^DJW_QA8IAAJG03B%Q,II'RL M:NQVXYB]G,AWNZ,^@1V=:WLH0?TL#3\$ (=ZK6+0<%
[Y:83N"M.D,,99./4' 'Q M2 %.@A;F[UM6[F5LU[,XV\W=)G6E*Y@NN+7L4:=7?MK7*PSL(T=:FVQ#0)6L
M\$!Y4.+P,)?0BG3>Y3!UL<;HP:4GXYL:OI^KU';&9=H,4VY]2];@^=K%6"A:H M; ,7,U01%
/=4<"X7@#>RN^=4ARP-QW=TA]14V/RF"5NU>*C4%\?YZ,^:,0MDTCFE9G01JNSF_%0*26(<#@# M/_0AUM>-
)RQ/. / 0[K#'SYPPB1P8]C)T0;DI>13S6%1\6(3=*)\K-8-C\$I_D M80?2;L@%\$J.G&#L^_I0B>^4-[#."VWT??
9]"[&=.M@ZMS51GCT^DU=Q:BV/(MD_.0G]"7FJ^IU&J: "%\ 2 W;#&Y!6M4P;+F(&7D-]2"-ZN+1])_5]^[5VM*:
M2; ;H1-N^SGA#)ZG-HWM)U*D3XHA,B_2Y#5EH?C=M-\[TW/TTYWON)HG3MP5# MTMW;#;L4X.RJR*<>7-^N?
I9682Y9N@RS.J:744C(J"-M\ :62>PC?"; 6%*! M"3V&JXFL=Y-YGK:/-01TKPF:;M[C3+R]_ \Q(MGN5C.K%2-
6E5_59R'Z;@5#E M=YM?\$(G0D2M^?D+C[W!3FYKLRI.WF2_VK8\$0,S-+6, _!])W9TZ^4V=@,I#
M1AZ1VP8)D#CU*; <0/A(,52G+ UDC1?D7K2F#%\6'[2RUFN*Y&[M_6=K"9W1/K,U*0V034[-
#7\$!8('T"Y0A\$*844ZTNCCF"926F\^(UX/KI]B+ M&;)Y,M/-*K8_/Q0/@-/IC,7;(HNC>!%(:?<
[#\?'10XG01X%QPW; '-Y'"\$%8. M?C31X!A8R9QHM^N0; LB9!^Z*"ZG-PF,7P!LR'7N0^_DVDK%'1]/1V3/S>T4
M6R/(=?!\?;>XE(';6(:!*W'.S/V^;4A#P?)PNZ8=.1C11; MBK0X?0\OT ^{A}(P7!@NSK"=>V0'2U0_IN1D)
[^-?-?;3SN(' \$3\029;U4[;0 MD[V]I8E0U\$'2I/5P_TZV1\$>;>ZFK@G#F+@:5^K.6I=(5[PY-%7G\8XR<-,M\<
#)I@)9>_Y##!\$R_/U*?^Q.5DU_9Y"%)!^7)T5._*5Y*T8FA1']S-E7U4
M['(+**!D6H:0P2!%NI)4EKC6)\$X*Q@L+EUNK#P%YH%I M*E"-B4]RJ/),W3\3'!&(5[!]*4;51?
9A\2[+0*%I10C=3Y+\$VF^[7"0QVJ[T M9Q1/56E)7+=?G.3,T3T/KV>\=)K-YAI(#3UIF#CRPZ0%03G3
ML6EM<35TF=;%\$(,EXXJ1@W0/>%9E(M^B\$W/?7AHT_D0'RBJ6
MCUY!&\SNX^_N%\$0,D2N_R\$EI8T4^*U;BM;XTJ0\$8W5T3NZ/9M -\;L5>*6" M",YJ6T.Q."5FE9V]IE<=%<
(8TRW%KM4.F,C;H(NA3[;"U>5U^4B!(!PJ(''_MP-
M4*;%PVRK:5\$C[50==AFQNE8\$A!Y*]V*LQ1AZMC9\$RQP% X5JSLPU]E4X77 M8Q#R"0C7L%:#U(+I3]%92>!H-
+4[H#;3+8N%:!P/#6%2I[=0]-I;/?R]4/DE M2D;(!:!M>L9FV.;4+B!S7BA-L#<
_M])_2RYG6CJA6W])SR\AUIW6N9EDMIK! M>GLK'Q)ZAA!,A2/GG'M?
160+13JQEL6M\K45\$DM\$_%T[^%9B=9' \-3,W/6)&JCLU0PQ)OEFRUHC<
M&6HYKCMK*XRT199+CC2@>4&,W+C6AJ0"#;H?4UQ;D=ICN[0[;*93',82=E?@_M_0[KU\^=':9?
*"LS^[_ HDXZ1EPD]F=#!;BW!R+ \K>T&X6QL-648BH]>^;8Z M.G'() (\H=V%R\$A/LBPCCB>6UDI!9-
%RZ'1AMPM0IY@!;]+A00_M0VSY#ZQ\$#GH'=JM5_CA83LWW=XTF\4XZ0,"6+F^=D^Y([YU1CR^DC];]X&V3
M]JNDAZB;UF,TNGX0WTX3L0F?.[8&L?UM[]D^06_7P'>#'_YJT\KR/;.-E3=B M()/B5ZR".%X,5TLSI<
+/\^0>S=^JQPAE(LZ2;NE^Y8YG5,):WZ>FL(;]X%1R MY%YI=3E:(U;:1V_M%5*=9US-)E9]KK.[0I6+"[<
[PUR#;HD=QJZUFW [;F^P4:;S:G32?-UR9S=C M-F7Z"RHU56@T:-Z*!TJ_%>H;#J \>CE@?29_0ZB"X I&!W?
Y6W\$J&%"C(6" MX_1<^S&!MOHV'T=-V4F*&3YVW.T*9>2-9GR2;M:41!S!DG1\$F>!])LHT-(VJ<
MG%Q;-7*H3LS1MA_2]AJ-2DCL0*H*JA?*\$6PI9M&UR]QB(?@T<_!JX#Y"]OC#_\$((=5=0;H@:/<
[<4)0^M:%; \RFR!;\$8%=#':YFL MTNL>L:9#^005+.XE39H" *TT,XQ4NRC\$NFV>8\ S-E'P]T:T![I6YX=2=:S3(<
M*2_S)\LKY+%%? +(Z!^#08-210!(Z>/_NEM7I^,NT>=; M/!/YX<^&/8[(!Z03AL'+0<[/<
I70CC5"MW.C.W)\N:8R(J[[]>[] @B4K@C MH2ZL,E0G+)F)9'B2""[^&+&2TC=<
BI017PV\8Y1L42."9[[]F[[]6T'E'FM>4M MI\$ZC I^T<4\LS+:U1*1H0S; ,3V@+VG92!56#*TX,H5-JRY4D<
80)&4D/'1C3 M#D(RC<:V<41YF]-L,)Y,>+;_D?Z&-C55MV1 [RV+?>!M!A#=-0/@",<
MUJZF2K6Q"6),VT@'KVZ%\, L,U27I_0*9GC*\$@K-;6X>T2;:ROTJ9,SD:LL+<
M>'C%BRE;0<1HZ""=KF1U.>>G>E-B0C19C!8<*UXA,0W5MN/E8+2] (?P4NR_M/Z]CA9)6NZ>+TY#]:DL:K)<
I(F"HZX1?J5FNB\$5/L",A]K\?1P/1^@J>(E60Q: ^A]/NKS5_%9Y8 +;YB5K07D,E8?+%GXJ M248C\0/SR-
D7Q=S-R9\8S>N(\>[-]TZA21BUQ\,2@];G&-X1M^6_A Y7FHU MTU+;D?,0YR7/N\ .F,C53TSAXI_.GMD<
Q_=G;WMQ*GB ['YY*; 207QTW95_9 MD,+FE#8"">](X\J&=@N]-80L1=J,40G6+(:CFAED ^?I=;#-WPDY<
XP\$72L0_MJTSM;&&*P:9RZPI:YUWB(G5DG/L@U>RZ(/EB+/P'0&=[%PQ+ "IKFDJ80JZT M_LD5F'!R&-<
U/X0*RK6P\H'XZ2C&5,C6KT7'DTX04QG'V\HA(-S^BU"ID+C? M'OMX:3_89[ITM;)BF)!GW+<
[/;3@])&"L(D>AZV=9,7RV00\2^';I\$[&;*/Y5 M\ SXK+5("(!^MK0]",^KB%\$0;X=9(A^("79-IVR-
3=*1 [F; ;M96+40Z),9. : M2Q5RAEJ2U.%M7]>SKX9NQF)+RG"W?/UUT>DIU0>=6J/F\$YD!+, 'V,5>9B06F;<
<\$9I/L1NwZ0\4H/, M+D[R%!KUB#N4I+ #P^+*E6' M^-=5^CC[;=H. [!XG2_E,_AMXA-E?D5KKNWV@4KYPE#;N?<
42'=P\ M\$>@KM)?([L2INDS.L\$0A6+0=-B*^06084-K3?A%/3^ XXX.6Q T9:)[+BX MZ2V)5-<
B[',2VJ_)P(7MR,\0,34,F M=Y'"82; \(\^#M0?^AC/\^0TE:J+W%D0G6G11(Z)%#: +W/L;H-081C-X901"=<
MZ,RHH[?H893HC)+HHX^;D\]SUG>MLY[0+^?YX?P'UWW?U]K[7K0?>]M-FAZ MF<,Z9V6-1?<
>H1,>.2(7^LG'*/>H!; MCI3XEF+JI%6BA83R0-Z1\^N7LD_,72R30PC.>0(_0<
MG&YW6T7J1ZW022<K,JCC+D8&/K(:?0_+5A]X8^<
M\$80]584' '#%8XEU5V/D1K3"D0PM6FZV^\$R[ERK2I6AH.F5\L+2NR7!K@EYAT MJ]S^_Y,8_\HX1@"(L=[?-<
MVFX7\$A/Q?'U)=\&01;>-B&_%KE= Q?4_N7\J0):K!.%?E#([&A_MF2LSS'Q_M_I4TZ#CJZ#E?<
V0\!3:/F43)BJM16D?W6?9\$CU@9739!5L@0WH_1D-V[]AE: MQ;0^T\Q8<19B0CH!+EJ7NE&_E<
E'0*SWI36#@M#75+K@GQTY(*&)) ("3A], MX_G0/\$D#X^> /-?! "U#2FX9=4U>?R\3P[^1Y]1P690.^]9-<
1*.,*2@?U,Q M+J-^,MF00(*Q&0H(RRY-J#4?0F%@P=+308S1>D(BEZLKS:]:0]-<6S]\8#2F M/,-<
N2G(\MOZM.B5F% '6QTRB2",]S9Y%=1LGW+\$@,.=FT%\LBN4 \GP-X8--B[[]5D3MI0&K>Y6;*<
M72+F/UX6]+%%,C+YVY\ _+KTb\ :W_%XY1AJ&T8"-AI*P6AZGD'>M-4C3+ZR1- MC4"5(MH;36C],OW=>+QF-<
'W!;?KW^NMA2Z,-JP\$A^0V;J\$]K_5V_] (PQ?6_2 M##X30YAV=FA,%0N[A*5JHI1MA-=?4#\GZC*U'#^2_X\?<
\P/_B3R]^<[4>+! M'!Q:AMS+ D'I:7!5W>=7;MQJ\$:EVJ94M33\577%QG-A['P1<D1.?)K^8I%><
MY*P137KB1_0_\$_-([E" ^9\]=2:+C,FU@T0+[=%GQ(-0V4B:/>0G.0&S& MQXC\A'L@LXL43.MXXP<
00BD9WX:F.#>PJP*?-8XE5S94<*BT-X/PN1_Y\$VT% M1*Q1R&J@YX>87]:W ,W^8I'M2U_DYKB8AH0%!

[H_Y4I0@!4.KFQE)9()]@B= MT ABL44C040QB@N#M93!M[4A4\QLZ/P('P4R%]-GCHL/._NJIX(' -6*M>2??^
MC, 4ID&.0-DY"1\$%02GL=N\7:4870PG9DQ#9H +GTST&[6:B^0BDY^&TY-6I B\$;&6K#I-
\$/MH^N/2@G@Z@IJVAQ=+\&H4 M:W17NV0\IG89Y4'TX"*\$=XD)0?P%>8 #7AW+2!XX&:=<>R+0Z[\$WZ_L,D+!
M1A.:HNGESGN5&=!SL!V\$+RW7%(0."8V7?}G8@;Q(T/)1E07R15EH0+XE+0F* MNC9'E;Z/XY_[]\TP_3?
['^MV\;+ ?'\$<8XZ=N./\JUKN)C/<[V+Q^RK!OJDS0-X#-N(,3^6SJ- MP+M6VD-RH0Q4B_TS21;AR4R,T6 G-
YHYGQ@-8G G7 N8-YS.'B[(/%RU7\ S] MI0YU?\F%?8@G)"2C]#)-@;:>]"FQ_HEV-'NV9;U+50L(5* *DK\SR0-
WYBBF' M0\$3?WA8Z6+=F#/&K76L'0%J# OZ,M1: !WN^E@?G1 X/PX. JI8U:H0[WN8' MRZS(W+% '[W!3YT-
3MUA?T"?768HF0I"CW%) V]AGS-&@%X?'^D,VA#5^H)X)0@FQT#AFH9P-
EBB\$3C50GG%:W(J\ S]W3Q@GX;X8,;E&>ZV";N=^R!I_L1@_]"N]LUKH MP.8R8;^)0?
KS_.PZ6B49+LAK';]=W^F63)H#/?!>MK +L#*;X%VIJ
MBYI2'V>&RC3P02C8K8_HE0<99V0=4,3^W:\$ \$8.6:%9TREY#GTV)Q[<HZL%9N#-^<1 M%)A42"R?
7W3]7B2W=2PNP*96N M\B@Y"-R/)9N5>[+%.2^>:J6KDSBX*(WB*?&,?W9288QZJL&.B/*-0(#]V00W%-
#3C0K0&#05%!
P M+0'![]?;&V%Y#@'G(SBNB^L,^XJI4IKU]",YC4FP6<; <9AM%2H2A[/M(DE"J
M(0J09VZ:X4YD(7;Y6-\%-UO-V[AIU:'8&+YQN< ^E5646% <5B MX/LEC+=*FPUSID-0L3E][9E;0Z;9AE!R
]X9U9+(\$V%*";4R'FTA#[VX/SYZ M=XSH@2&(-J2TR[Q\$*-
!L0VZP/9@3I=VRN.^'I) Y]/+E9GQB!/)") R!%+@KC+SL?MZMC2P#2?1:Z A;IXP03I(+4\J=3\$>
(WOUUVDU8ZDM2F?(ZI " M&]18-6B=X S^R&GK, ?4GS,KA@-JJ\Z1"H2Z1]PH#\6Y7^1\<[-MZ8+/HF#; M.
P1PF(*SD15DFYQHWI5!/>K02<3+JM!5DY)KBM0*5N)@Y9!(UG^1;2R846?47: ^,9?)Y? MI9JYH%S+R5.@JM;9-
5L2PBK2\$\$.!0C-,B94(<5R(>EE\?X@^RH2UD6I M7M)9
KR\$(H4H=6'R=F69TGA/ V+QTG<[KF]Y3[>N4=QQ3L%WX;^^&2(=Y@1! M7+/9>& KSG;(!_ME*E%<
P#6LBNQZ>6TU&AI-672;VTTA<7I9#1<@S# J" T M5C5"%-MYB@-
T&10E\$H)A>45R;MSV"0'R7W;5^T2Q66AQ!UVWQ+0C5U?/05,9A;
M\J>3!KW\;B9N:1^*=NRI1F[(MA.1T(F\$,!P\$"=(U.G390GX-./(JCGU,N= MN+FAMC_5-, (P?
G04M/[+VL:S^99\$/ZKNT0>0-[>Y:;,[(238:7:=4H HFNO.A0+KJ3DSB@N\VWEPM,7:,8MA^M&-1?R+#E4IV3=)
M"H_<3D&>@?PK2AM% J? !5P 1S08G/06.&\$;GZQ!S.YS8LA/50=H\0028)(,K
MF;F+_V)D:1;@LJ&78+LEEXU"/?%#6I)\$>,.B00K\$B\$&_CU@=&!ZZ4YASATL M*M?/S#H]?>I=,"D *0)Y-
" #4!2HM'/R&L8_C1S;ZE3*&J8IH!=PH7*2-KX3H M][C1S?V\$4 [5QEIB.Z0-(W/-\S3Y@'";.\IH>T59\$ \?
[Y9S,'3=YNQPC%F)9 M<5_J+9V2\MAC7?BLXUOH6WU05U8RJ4>0GX6++ DVVA.*PQ.2_5JA_&/-
R2MX^/CCYYU]77%6SX_P>_G M0;!7*96H>SLQUU+?[^1303Q#FFHYL@=D%-LQP/Q#182]Z#WHPE(YN6J^6\$K^
MNK!@[_0H%N[]? =EX*9!B+],*A =K+JNFJJVIWJ>JH1C8R=F<65MA!+NAA"B M[-
BBDS0DS1@LD].V(YBIS1R_UIPW):X/V--9: ^?XV2/TF\$[,.J;&+;H^I M8TE =@+LU.P'Q:;^0!YNAF90_4-
=X^'0LBMZC2A@1TY_2']?XH8ZX?H_)4)U MG(_Q;]1!LI/\$07L_.SV?
=3W7NKNKVGPV&_3*)8=6&JDT(^Z^@.S5#PCMEV#0 M@F5;S^44K^S2G&EY>_KCY5#W4GN"W#E*I2AEU-4BK
^QZP8SNKJ3<)7+]BY3 M=[TM\$TRE^MNRKW1;6W+LW3LY8DTXG,+L0#MHN'031CX%UO+.R3\2!ID(7:K
MOA@6NPVE7@):,F?!)*9K8+_KG&8.T:EB#>J7T7T5(SU)R'^^;*E#^UF8[LPV M^\$:[B/:>V 2C..8IM;2LU-
\$7]RMMK^<4@&=: \$10:HBT]6I4\^#+#N@3?M\0/ M6VJ9ATIW_V+A@.E+VV0_*DV*K
K<:;@4&>7ISS!.Z7:+4+=7I2]Q?J"@AFA1_MF3N]?\$ =;1]IDN)G<4S_F-:(+K9_M/)QYJ(R*,/-1^ [B:;*>6!5
M9TY"14#_994@8*(E6BF3<5):L"\$F'/VPIT6K M:T6\;[JR92@I#1K(+;YL^L,Y SKD@M@#BFU?
MQJJ*V&M2>B">L"-'\V^F Z" MY",W.F3Z7JX,E"[=9PD>[71^<7=: \$:NR5/D7[(S3PKH/<(7! B6UL?G]M0,,
MHPLU>?/R=F=8WL^U6I>N0GS=E+T8"/1-?Y"W2IS[:%B"LJ#9UTCJRW=-!#9/ M';&I#]?PO,-#^*ILA-
BR)/0]V[(#LV#""4?E,?QZ8D&_AP\$;HTP7C/PQN9<&/ MD_X!YLM9!)_G>' ;B7\?62TYH?JUC#-%
[M^W7,3365'^H@ (X%J/:?8B(6L2N' M[<5^MPCV,WIL]
[I.K""Z?]/_KGD1F= G3F*,83[N^0E8M8+46&?/GI_(MM/0 M^^,GD!Q.E=)]*G_]E/!;ZS_*@5:A.7)
[@/WK4229,0%\4CH1_M (HKG5TULY4Y@#C#
[\$0.: '#BXYNQ\$>#"K^NF.PV:B^WKQE:3\>M@:#,9S'']*VMA"#IB/#.J@QF ;5&@"G<[&NZ'/WNPB"?X1X:)!_5
MX6NV-;_3/AK->BNJQC_ (=GN*0'2MR*A7\$VMLXL?"CC"&BV<+N 48]UZU3LL< M 41EL# [+MH<)Q
 \7A>9ZBH:Z)XA1P0@0W:;BA+3GEY;SP\7 "0>PVG2V%:K MKV[[FP!0*^P[IK]?>TUDQI:"614+HV7C MI4W5
9I0^Y%70>9FCZ#01V)76R!N3WGH;VRFTRLA &Y)D5E;XM MRC*X5KC3@;3G%M^F\G*E"4)\
K:)6ATF>IJS;\KB\$*J;AW;=IH<]TX<(L0?)
MU)%1G<35]Q_SWJPJ[8P*!Y<%)B1!V2U:661L\ _D/@V)/%H<:,?,]\$@ \0T>!%
MBHDY7"6ZU\$&#F00P,+ \^0JJR9IUA[93?J=ALD>]R<:\$G#Q\839@^R!XD0; M-\?Z[;DT3R8<\$W\$#CT?
4ACRDY/B&[M11D_0N>?+HJ\A:-]@3A\$XA)ILFW**I
M,9M/(G93;89>\$SKH%/Q'3[, \DT0"/)P6\$YMF*E(\ ;%H\$9X\$Z60\ P09" _F)I MGTTTV]!DAMY>TTXTQ?
0DZ<#]61K&^\$<;;&-4PPDALL9 '10*-%^U1+>IL\ MY^E+E(Q9%M02MKI:M%@6<(NL_"C%
NQ4@8!2LI00U(^Z4 MN'L#W0NL]A3- M/^]D2@B7S/CB_*4M+1GG7X0^6"IG??C
[/J,51! !'. \$FE!H\,,X\5&)VQX3. MJ(V=[W^_FRKX+5/H8PKC4CB -:?0S\X:
QC6AJ)0KC_)G1W9YV08_'R@P5GT) MSJZN-
>_Y+ !G#FUS=%NS90"KK]CM*&0C[;0:W\G"'^\$=1\$X0!SK%=@J"5=#% M#P*4?[%ZA3Q9(#[M%B&;HPVM>#N+?
EE:WQU#4] >RN9WR80?6:UPBY=L3B;Y MRY-@PIP N+/0ZD*) KPUHP+SR^A\01N@H<"34JK_ \$+
M\$N=+F6K]]:\$(N'%W\$&&E>N3*P-XJ8#%W-G=:PZ.G;\$E6I#BVYC5_V.? '1>\$6 M\J\$[-4S[]P""^?
FG9\$#\$ (D^5Q;S;*2GP2 KM.M^B12*F@>KQ2G#ZX-]5B.TU- M&.6H/#%7)/.G?
YMYJ,E9@>ZSK#&M9E([!;B8E7,7FRS0-P2\;=
MYUWHTUMIC2W7A4FF[I" '9T"S6^RD)U;]3BE%BMYG;P)81ZUQ0;X)R77\$+K_
MW'/.YKYC4M.ARL\$V4UVN*M6K^Z:X4CRU@TY%\$/F#<2DFUJ@-U_RGS]7]Z*]0)]3+@R#BFN9:=MA*A,W?
V64:DFS'D_0MAVN&G^L&)(KJ; ,EVAP(T5/%4"A.\ ^TWK^2HD;%F\$*]EF'F&/^'Q&QP MC81?/.9.D@VPN#J+>P@?
C!,8J!X?2*/6B\$BH4>FKV\ :F%6X5R.RF7EBXLS@Q M'](\ \$4M07D-' []/-@^;W9U*.']'T'8 _N]B6V.UNIASZ8
!Q-J>V_HZR5M_MVJ1TV^W:WMJGQK0-;<%-"-3PC)T,YBAQA. ?R(2" I/UK0&0/WZ-G1,)KPU)T

M9PHD=YJ8I"H,^9JI5@G7;CN2'1=*BJ*A;), '[4^\$ M7.KWZ_Z?'T0"VLX,T07UGE#AXPUFK6\5B]T&GZ
M&SY]<[A>RW[EM/RJZ-\$4T+XQ\$;GI6R_1E5;=TY; .S!*P&#D0.? .B&_1#WNK;9#Z0Q6@[,=R+
M!!=\N&F50"PX!U.@!\$AK-Y?&=#6NS_+V[6P=1MC;"4]>T_Z3\<*MVP-;#P) M<9Z_Y!\$A]F?F0416!7 /&R-
UX<@>D"M7>4C_\$ _9 MESIL5[51?2%6SR^+]2RA0IF@"R-QY [591,W*'NJ0EN*H#FXYO=^C7S;@8>
MYHW8L=V7DN0M7_\$2=4?[(\FF=+E^7^"#N&C#M.'B_-FKV8\$B6%1+?>]9H<\ M"
[J=!FHYK[&Q2]4GTRS_9SWBYT(1#P*SLA8;[VYW1B9/K:Q#8/? .M9L1^J -".!,@JURN
M+F9I,D+@!"!A+CN0.8^0I7093HB,'XTH!<3;!.9L!Z!9.Y/>T>(%476;K5MA MAJ,=.WBR=>(2JTEMW\$N> P-
'Y9,LW^G.;.QIY019\$HXHVS%530:%LM9]7A?Z MPK%\$1RKQA%\$>X!S7:UDU]H%]_Y^D"\HVS?
TIZCNK/AF/E01VBM<_B?Y*-AT M6;QS=*I-1>N[?T\$/\4CIJQ+Z#C7)7 G-0*-
E?7612L+EDULUQP^=Q[,Z_416ZB_2(< M'M]-L6ZS9?E(U=)J+_Z6%TG^QYUSZB%IA20C;I[C]I%<?)?OZ;J(
AJ&A\$ \C MTPC(L_T)[T(%;.1(JL'\%JU*^I4L0UX^)_MC4%^4]>@-@7.[:QLXH0SH70C
%8\&9]3KP+IN=#C^U88T,0F^WY:HSTNKJ+& ML<7G=>RI.E^C#\$A7DD*]>UA\6Y[U0J@FM-
X7%-0'] =C[^+0FQ\77CD:/LM' G#&&V" <7!6&9EZ=F:R9:6V8NF9;,'=/? MVE<8ZE)
@M'IN+8&"5M,K42BD7KZ\"4&SXX4M_];Z9JMT]V% .>95J2G(.8N
M>\Z,'!#H*S=;17.Z.0XA#+0H^BR)A:>6H8CU^"5N8&9?*/_A?PS#-MTL)7J MS)TRJEIE9W7?>
30R2#:'I\ADV_L%(Q0(N9^;U3WQZ+N-DL]!7PU]A-1N_4B ME^@BKI\%RX1ZV@0)9C%&"VHZ-
2PJ3@Z+*=RZ392@T9;ZU,UP']K-EV9]]'YI:81:_P30,QZ:_0BFZ
M9P[U,S&S:N]C7H0U\G#^I+"UX?;UZ^42J_XSR.Q?+-] &WM80_YWR/_-J#A7 M'W<\8(@ EU2DXD:IP'^D?
WBU/OPD2L_17!,V2;DT)3\$AK]/S_.\=:!!IF;
M30T\$07T@GJZ59?'<"H_\$0(!0DG69\NT#Y="C2W>U0%RQ^+5N'<\$V0/@^@-K M)#Y"C-
40,^MM&G%D08MGVC," ((%AEC259>G'&%F+D<60T"5R1Y\ ^<*2]_9XC0@'[W-9Z@FC=Y.7 MGW<1PL0=0_%
(+0NV5_!@KKU;G>94N<7(G/;!>@955D<(KR?+6,]/K/&6]\-B MSZ:MIWL^GK5L)WF;+W4]!M/, M?>2"20?
OY#-G.F8'MP/:X-0%":X1Z1"CV ^ (IQZ0EZ;_ZHVZJS?)MB>];8I M#T7;-#?<\\$3-7X)8!,4?
BGGCVM)B^2FY_YJ%+X?(CY_!RC',/;[-^Q*R%-; M,8P#@4Y;[YH]!>HL>QVS=)LEFT=?[%;?
\$K*K=G=CRWRZBN/V@#\$ _W+I0)_ML2(R#_3]*D553N\$=YR>*B?EQJ0.U/WZTI\>
(Z+""E0(NBN9:3%!!0&2VIW(M\W8_4@>1L@V=WCD-^F(4XL\X&0HC^*^Z?"/""*IPJM"2U;W!AS^?-
[_Q&Y3I15=+Z"T MUR;?&2VU"-17?;K#^WTL%2@!/_2,#?JV[LVW#;186#3]*]8+5M(FT\$-3Y6TV%,8TBTJIP*?
8G&+F0][MS.VAN*28A/0IEXD?9V*TC0.X?>(\&<\$1\,LKN MLYS1^ZGS'^['G\$@PZ_?
5H8I1/JV&55;7Z3@Z'/9840S3"E-WA+J5RY?EN)] M9/:M/LGC-&J]\$9LJ!@:-\IXC08(%WAP2@# [=WS0*?
QP)*H9>0-IN;4VC>X"+R\$3(&\5&ZWK+ M6_6][HY>#^R1JPZI!JP
[LD=B]:4\5%7/J=;GZ_&EM5G@,W&:DUB3" _ZA\$W M;W3W]%;TD:-]H)*,I/XN)G%YHL(9YG!:\Q3> MDF+Z5D;#
T_\$!T[Z^8%\ICJ5JZZM,>#HJ+;H#0F7J90IW_[_2T:[]R!505Y MMI^R+P01,B2MY<;+^Y*2U:7+
<)>C(K2TYC00JF2^]EV>0M;RVKQ2E6.[TIT/QV2[2".LK^I>,8K
MEXUB@UA4F_MT2/]B@9S;&I96!D*+EH(3YXSAC.DKI,X['Y*?S) G%@I&,G=BN:P*E.FE>G.VQ/^9
M=^'Q<\,4NH2X\--XEQ[T<=<*!!M>PP6%*0=?90)Y?U]*A&]EA:IV/B&*9U M^K5\K9N.[H0E)KNC:V#?B0
0%F#WOK%Z ;KSN=D08V70KERFQ .:VWRW7-?NI_5R8CQ_*J87[H0(+0:P%.&M\$#+ES-J>3N+Y3I M^
C5'#/H,T*LBS[KY?/G9;HWA8-A80\X;C>!\X9I[K8@S^&GB[3EI88H-Y/T,XG M4<8<
]HJ49'!+!,E*DI(EN5#%KIHT#^4I(XMCSV/1^#@XLEVFYDYS@K&=4/]M6Y-3G>.&*I/7C\$]^*?
(8C[7^E\4=1"-."I%GG\$%(RD>*QU>4:05S%2MW+*/' MF9_3\1BWNPO[.[B66\$J=!\X^1?
Z\9D[DLCZX:'^7K]/5R*0.7L-;A.&ZYVL2%]K- U B-'ID6A+& J7%2_YPS P\$ _]
M#)0:;UNF\$ "GU"AZE'2A[.[-VXG?L\@0:]N^=R0(-I\$+0: M+=VFQ%0(SI>A-\+ 8+%/Y-. '@GNP?\$3_\$7JS<-
G73'[07'<*>^VJ'#00TH MOP@A.>[U#??+*GW(%.+]=CV]"*RA\$Y6_7#%J[D0 TUY+>?#>H))?J6,] M=R-
W[F\$VZ>3.,5(+M^R3/\$]7U;1_Q\8)Y&.L'I)?^"777N[?B+;_L MF@0WB0J&^Z;UI3X?)?QL'J(\
[>E)4]EQBN*A1K_13%3& M9",10C?F"Y9Y& MN7&,H-BM?S-\$YYS.PY [14W^FT-DK];7,+V+P@R#2,# ^:3CW"?
4& ME+%;PV*66<1TN08"R ME\%00WAG"Q6DY[[QUH44N4<^S9]=E?0J0!WI,AQ-*B")@20DV
MCWCG>Z_R0RD#!ZVJ=E_5]/(_US&]G)6K'J'L<S>GH=K4W M1<%VY:FG87(Z[V?X^><6]W7)J008)>;
(N7YTFQ_J5@Z-X%IC&C=((7=.*(M+ MI9/*)9>IQ3A6WV)@R)0C'4TPKU1B\ZF)>W,J3H@-!X61!S:I\"(
%7T)VVR M\$+I(:A2ZZ\$!;IB/AQ2)+Q43RSK,+S0V)+./62V\$#0;3]23283.6H'L,0EB2M M.
(/Y\"6R4:X*RG'JMOM\$E)] '^1 CB@AP.V0C)6-B0=6T4=-?Q\>702'\0 /0 M;LUT0,82GM#Y1&L/N7/#
["OK]83\17)+5. M(IL*66>L!OPS;:5S^0_7(NI_?.;,VP:M);^(:?>3)UJFZ3Z+JTUBY@H?RDY, MPK[
":M@12;X=#65?U1+?;5\$?^RX3>S.PQ(A/ M00RL*&6! =G:[356F H?
*>Z&GX):/^/_/0J2A_@;QHF<%XS)%4>2&8629SB7 MS: ?DB0H4L_18-
[24=#IA!\!EW0;&-.,HJH%;ZL)=B>CCY7&V?K_4UMGL<=9XFD[=L*L0]/\@DU%\-CP=6 MUPZR/'!.9@0FVCD
F2N#4>1%"6;&Z)V"DB6M1_796Y-,N7W%W47*L-H0'YJ^ MOEPY];%BK)6U*=L-P8UZ,P^[%WV?-
E]U"*3(B=Q)Y8WCHXR>WB;(:_@Z:-% MP-@R;)>AQL+H1L+C+5!/U+PNNTG<@:\X[I(S';\$4D
MOM]C;8(. \1N/4!UAC+SSR"TV/*??3PJNGMW9\$>XG_K>0QM_=>03D][? M,D;_9BCW.\$NA:>3 S6'JGX2-2?
S5(8=XLIT')3H_'24X>FJT MRVG5HCNQA_HLW"IA M0^G6?R=4M3HL5]8,Q+&\$/9 @JWS-
Z/B%:+5FJK;1.T@S0T20VN\$67<#ZIQ&[M9CVI^Y%2&5L8P@\$]V0<@Gf@HYT8X&0U<)>
f@B9A'*:0\F0EV3]5;*. *AT@J MGOZ\$*A<"7PN3C[!W.^M_D)K""[<+(:@S)9" *57[\$R135P]4
MY.MDM2P">>'%R/&T^B*/G&]:2HCU73&MBI<,'ET-4&F7+ M8H;DXI\$#/7X*SF/C;52LJE_L_BSNJ[!50LPP:G-
MBZB[FQJ7>_*Y)YQ_::Z7(,40%^K EZLPFZ]?E=\$ _^5P>H^H?IQ5.@\$8-X MUZ5EAW?YD,NB?
%S4G"9B0IR515TIB[,=B1.41E3**VV8VJ3GS5A9D-\$XD? M]9.\$UU.!LZ*SREE->Q]H4!];M MQ"TP
M%"9Y#7F53EMRML70T#K3>HFW+Q;P>QHU?89]7^>N'1]*^E(B@9:4 MTV"E^[3+6_\$0
"/-9,7[<A]H8&UE3QZZ)\$SQ(-&DT\,?TH&ICUTCN@(- R M,^<;L8\Z\$&N.>@>78W6V/AE"P.?
\$4D8&.:1#=\3403Q5TH+^:B3(% ,D%PQM MTHR.VK!'R\$EC^PZ!!: M80+?HW>;8A?
MUVV>0P_96P"+MN\$/,+K+!0DE%G8]/H-\$B7J?K,^Z95006.T: \RS,2&%##V-UN%@RU= J4+' :4[[^! "%[?
YS!FU<<\$][0_2.21I@?QS M.MX4=2)[!%HP+S[!AXUT84LE^S##_W&C=J?)A?V9:0V?D!<8F0TAAKU,_Y0!

M'(&9>>@HT)?!RER9N)>7DRB%(XZQ@4;&(KWA)S8;U#W\@;JE=78G=7!|L-(?M)WZE=
<8M9&*%>_UJ<25IU0;@TJ;*;6S[Y=U2Y;#-?1\$!4!4@8W@BF&M3;+;X MQY(QSK(3UM'42K\$B06S9)R;8;JFC
M_K,||2+'&)#?F=(YB?V"CY0?WY.!J\$F'*5 5E,(DNT:6F&4XFY MY2_GF)S.#/'JVDBX3&:GDYJIR?
3E2]#AK"SJK9<[AVKJ;@M9J^--4K9R2=&A\J%*QLJEVYS*++<4/XY4'?X\$CARC[4>_/F'1===0*\$2'4@A>*\$6
M(8.3:JV0>=.V:=>J0Y^%(Z=\$.E\YJ!A*G/>'>U,>MX/F'SRKL>_&8[D'U
M&K!"G\$6.;0/L*L^V).40XW%GPL\$QII!Q/K\$4J1>*"<,.UHH5+N-,GRYZZM1 M74|VY:5^N0F W'Y:
|LXS:@QU%F/|&3,SD!4#1^%\Q(1X) I>_/|B^7 ,@M3 M8I'?
DI+"ENI!|V6^EVL59;TM+A:R0D3/P=P|T8T!X47A M: LDT\$0*G!'S^Y.GM91>AUY) _&B=:)X@-
PXT76'7U#V^,W8T7H,X7JN]-XJ M2D:D-V\5&/0E-5COR'@NX#&=T3@N^N6!"7UA".\9TW:8.0#0^K#N"N<6%4=
M#ILR4DS5N);WY0^X., Q.(E|9R#|C'I>&JXG+*B'6J-\$2.D?S*',"P01S"S
M3|0.N8X7#VK\$<-4CV3(/CG?'"'-YL0TX\$CZ+<1(#0X.&=)+LEL>_6 :2)4F MVSU=+*\$0BV;TZC3_Q?
A=|937F@3X2Z?C*+@C\4H L.^?CL:S,59CZAGL\$@W M!;70ME60?T LMRT<
8X&&:+ X0W @J\$7S6FT\FJUR]=[SA30 +X]1G-+TG M?3\$|L'7CFFIV ?\16'6F&Z\$!,IV/\(YE/E\$M7-B%
)0C \F#30]. "UW9Q RR%?K; M +F=>J3V0/E6JV/K\DR;L0A>0"D#>9:TQ UA0&KTS,CH50=T&&JN:|167^4
MH6=)<#2(XT \!@RYS&^,T3Y^?NI M.G|K,G' <,-SW>2S>) L:KQ#H.,|X\ZL3#,1W,:1DAWBCE 'FJ'P#?
H1U&| MDX&), *EY25T4B0T5;CK60-8 H;.C, MI?%22GNF-' :U95J2!?-0&2@?|:JV* &'70HX7)38MJ
M^7"0Z|I+"B \2LY^5C8|9\$=7K;F#H%0S!=NT|X3.=8@%#RFBW+E10 M)4@P2/D\$YX%YNHK?9|0|YDJP>"
|.6RC|:|KKNSI\$ZDK8\IG;HT K%D5<0"@U M@J7(N1GHA(0(XVM 'CG.R|*& IPJWPSOU+C6E"8J,K1E^
CNW>+1>>& B5|] M&,J6(S|WBKAC+\5P*X:K3\$?^JOM\$SK"ZIA.PI|'^HWET^WJ=:/U16|@);?X3
MA%#PQCVVLH01S:4TEC)2?BC4\$R3>4.5B %|,BS R'445(5G?L2-"00>3\$(H> M'5R51)ZW.TC>-,<<\A0N\$-
,^H|]V>- M^@ZX"4|+E,#2W49 (X!7S* 2*=23*,0\5:SV670#;H9D
MXTL3|!=IIV&&1AM6D;1:4^>74X790^K(DFG7PS) J!@LA>(5FX,CV^L?L23W M0TG>EB"GVCNU^I.A 4#U\$6R-
/(%M<*>*C,!U.Z:D|6C|IX)0.5W7C|72T|6| M|3D)0L\/-0)7R6:;+
|2TESYT(1U2!*\$S>P>JA=:0(&*Y\D"Z|9F:;0L6>.M'^;YD&S?VD3 |B|?JN6Y\$'N"|?1P,9? >B%L%=HB-
G=09KS>Q^DD|T|\$/0 MK5YAHE"J\?H/Y K1F9M*_FD]-SL=);MS/0 \)|F(>D^QJX'*>03%P#>N ML6570<#0
#1/'GT<)?0Z1J|/)50NH9(/,)?;MR6FM\CA^?BT\XXP1E*>UH\J M4I/,0(C3R9.7NR2|26@|*?
R\WF>T3,=7;JRI4<,SJ-Q\>30'\$(%FDTT55:50 MPR9(CAY2\$'Q"#1P,);@3.'E\;K%02*GU*OR@
5Y|,5"V:#TL_Q9%3Z9#8|+E MS|5|G9/TY7= Z?TW>7;@C5MT'E,=DM;XZD%(&5W;M0!
M_*PPM|V<,6XH8==Z06|'>Z7B.2&A/&PX>H/&(>-8XPF^XF,V=NCK|V|]#7(?
%VU|["W7]"865QXBRX>P^LP=2Y9GU& MV1?U3<2| ;7=)YWM8KBL|LV+63/&'<.'W8Z\$U>"M_.V7LV94'J?
^(>YN/^ M3.#3;\$+\$@- I5AEVZ=^XJ\$69<*>30S)GA'M,#&'C\@E|EN@:V" II"!YNN M10:=C=MTV;@=W0/3
DZHEQ)2<8*,D,K|AFI5S#'\>7*CY
MK"A\@,V(+1&F6|IF'Q:D/B>V/'XH)9.C4.#)VP9CA\KZR+/J1#E)DY*,E0* MD!; 5GS?TRH;@_A!@<4^,
<3#9#5+'CU9Q40AR;>='T;YW.0=@A., ' QBF*B M)80R;S0\1C?+5X(,JGX"|.W|>9>XRG5:?
EY=|"3S8'%N2@4B%M| M|GQ*\A+,4)M!GQSH?'D5SF2LI3*,TDWCW\7+\AJ'8&'BZ=8LSF@0 9/PL'L MW?3
CDGWF'ERWDT)4)HD|AR^35M96S9|.M*?'@;Y%|E-KQL|#ZZI1|QT0!8
M|.L0K(06|5LL^PFJU#;3 AKQ2TUM,%4@Z' (0X0F(HDWZ4:\$1AA5 M&D+H)4@ Z=*;!
\$.|D29"Z*\$&\$*0TB7T4*23@\$"4X07|WSKW?0F|,?,G*|G M|IR|]EK/VNM9SR+J/;?
1>S0)C<*>?00C<18L"3C: ^SE|N<- \$Z1B/OWC7T0 MKUQ<V\|.2JP.58YE)TN9XJ\$SZRL=AH]>SS/Z+.
<+5(%*.7M/|?E>;3#TI6W\ =TZ&=A,9 M9|8|@&
GBAW&=L<>|!"ICBDF/\WEQMX84#;IYY1S6 <&1T60(.10|%'C)MR> MJ:IOYD?+8(U.D% TT89K<;!M"
'+ZK1G&<0W03MGLY?VG+VQ(!5XFI-K.^% MCN,7?>2#>M| \@?4JL0&II1\2P%+PKW|03% ZCIHLP;84GVE "'B+!
I| 5L. M Y;00<3YSCF>,S>U-1IM/CYFR|H7H*JLZ4--L=\6X^2BAY7,=MDJ=A D1B-P MK<|
"+34\KLM6.9=C')40=60P' \$!;N,L%'-K+!@W|XHY)|WSCY\4M9N'W& M'Z#I??
HS@Z;Y=D%^(PH6" /;)AGAM;4ISS|SAU^K#-4EJJZJ,BX)(W^VH2= M,) 8^P6%0CY2\$Q(=J>|!
E*+TETO/JKMWQ'?@C2|EB, 'Y/ M,.->TN3N\$ UWGXLX1DWG3S.>I?;MA:\Y8M\$S"770WC<&=|F-8ZUVI(UB;'X
MI5F<"LQ/RKVTH6'"C|'#96FZYBI,/F503!Q/'?F8;CJ?8PE3-0/|P2;W;J MGN'(F:': DX;D6 K:2CTH0X
Y AN6DP8\7<97T01'69 8Z7\$D\$7 K.| 23G M8P27NZY8"1G1.7|RTZ.IN"!\$|)+Q2|AXM,0/4^Y6KBQ5:2U/9?
X0)F+G&NU- M%|,|EKI&),09G1;(QXY=3M'Z9"W-6Y)2UKX^R9MU0/D=X%21\G\$W^9?0)0
M|RM6SG/|B|JML*+Z0"+_QE2^C\$RRX#*MW. TYQ2&?T(T/A)USMMD./ @-D?.@ EEELUV_Q9\7G\$E
M7&42A5"P;A?G=\WTYG"|;|E9@45&|=GR3UL&SAMF0%)(|X\$JILR<#E?;#34&S)WW/-P|Y WGDELO MAAQ32-
C.*\%+!V1|3E|G^UK6IO/GYQFT@|]=LTT\V%L>*>?0 @E4|&R^EN)N MWDDNLRPU|.L331;#:4#?
1X**M5U|SCXU(;863J""8'6X@='!KQ"*9E'=@3;C M&?R,9/?0'>W2\|Z=|AHZ7KEE- 29;L3L)"E3J1@T*|_ ^1-
\$C36ZW=-" 77< M""17L=/7@LM8?ZN(.PN^4P=5#I"Y;/=<=MGNKMZHNL!#K)*!U+@G*S_1>4
M#PS>D3#WNEJFF;F!2_92L4MP9GQ) ;A0PPLMJ*W M.9CT8"-5NR% S0%-
E|V%2G;B:5.BB^TE(C.=&2.7L+*/.Z-^)20YF6G!,'Z MZU-
>#@NAL|.9)L65|K"\C:0DB75N<8DYS1%I2.DJUAH\$S|@',_@K78"M@|Y
M=B62!%5YX"*!FS5=> XWXS>IQ0<6E\|+US6; ,PW5HYQ2@2,KB\$!= :9?9Q2E MMU2E0\$1T@CA;N3H/R?
N^|&0NSSWY \\"^|D#-@?QDOP|.7A<,K662)DN1)?4, MR_%0^)!>50R C7=/YNCJ*;6Q1A|A'R=W6'.G%S!
|D|>0XP|9IKZ) (9=\CRR M^9GI)B<|;|'%55|M#|IN@*"R%@W?G*=>)<|HT>0-| ^BC5|NC"E6R&0D6Y068|
M_@/XET+VKL8Y.PJX\$ LZ^+S!;|1G@LU)8\$HXM8T:08U|H'(L'PWTVMM M=A% ;Y\^XMB;>^'"|W)^D2%
<-TIWUWDXV6=|!D.QE/G^FQ' '"V?|E9V|11 MW?D%Q(MU)7Z*C1+B:CEL"-
-ZZZI,&U.I\$^GKZ@|+>'!HVAD|4K|1>>&@;0B MRL.XBJV19C0F(H*2U%5VTM [=H_N@4?&2)TM60C:=
8>&13(7BZ@M7QXG|) MOPW9#!21)84/_G.=|B'| ;|+>9C:F,Y, 5BUK8T5A(Z?* M| CF>R|>8\+R\$"'@^10R-
HLK|1:|? :*>T>#H(D)0^7 MT@3@>E4&0SKCG| MSN=,\$9?|5VQJK|B& 7MLZC0ATKNVXK-
HB1)71@2=ZFE.A1Y|II|XKI_X4^%C M#T(IL;\$5ZI9ZE(#W5A1KLI4JF-JQ(|F0*&
MQQK)T574#HZF%L4Q:Q<)^AP=N5IYA(=0U_V-K;@)!Z0I#N4BR.E\A ?U.!6G

MRT>90*-6#VC/78\%/:>FCEBNV_)_0G,0?\$(\$PZ6\|3IT.+>FK%Y|<|V"VPCA@.RC<4|K|CRCQ<|^-
)H+%/0LVYI;#^2,;W='4TIRV M_07TRB%=CP\00J?"33,,Z/T;|, /A6L38S\2<3N0^4F.02P#KE!H; (>K=R0J
MAR^Z_MXCZN8_[C|#)V^X@M?+0K8?RXI\$^-04C0V>J0+=\%73_0*:VHQH^I\$ M-X=|
|V_B|0JB@;X\$S=U\UR!/I)?+6|=JP0(|5=D|)(RP+?65V/UU%DX%_NZ.
M\$|46EE9ECD<=>|Z|LKKZM_@|E%\WGWNCA7|X+5P^6DH0854*='9''_2GKFQ M|1M|'7NZ0\$^?KW
/R0'9IJ=1ZN!5HDP15Z8J2*B7YU|I.W'(Y_ZY2A>H"" -E;6_PT0J_B|6K0CQ-LL8DES;3+8?
M_P;S|375I8CW=\$;@BB%++&E@4":3\^7K8-SW3_-U_I%#!\AGO"&|WRL9GZE
MP=N4'!5Z%^U."8S\KV; ;3;WT&_ T03%\$ _F;XK0?<+P' M:/\UF
R8^II94@B/JZDR8PI6,/=S|'1AZ00*20.;P=|EU-8*^2Y=1|QJYI#T M/A=W0C3WRUKYY?
@E42(2W|I=L_UMZ_<3A7:*J|GIGJD|3V9EK#6|2\2\^37H MDWF2WW<9H\$E';Y60YXVDCG""^/74B"JW3JQ-
AM;40&3(. ,UA:&KYP&\ZZC? M+:0X|=9?V,3Z)L5U*+MI4AM^%F,KU(3.>3X0<6#5JE0AX)31=V"? ,L2Y(|T=
MX%FJ; 'KQ@/00|0S0FH*#\ -#Z7#YC9;6RX) *B(V&AN"2683K0"=9N,9:GMB/ M\J\$U_&'7Z\ .HR:| -
H907>GZ2R33%GV^N>ZK%F GR.U8&@7< TTUHT7)+\ (I' M>.>.) '9JW?=CR7R)8!
M7KSL8^&X5;J33W8A5*\$9DFGI5J(WW^2QWA+W&R>6T1S'\$'Z,,N! A&.G|)%
MP5A|X>/4TDFWJXKY|9JRAW(LHJ4>C C*B\$SJSDIHA^XXE)1IPZ#DJ M\UW|WECDDM8?
(7>JD<"7!VRDDQ+I.R|#; .1U&Y=!8U?S;HG5.NIC\$)740T3 M.K*.RVG?WUX_Z&0; H?:P51T?(/U/VW-Y'%,
|/|)/X79//|&%R(=="&>JBA+0/ IB8*4TPFX(0M^U6SUSXYUNY=F|I-7! MW3?19_ .P=5K6DPH|66B0#
| ^|)%*| /5NJM\$/XTXZ5|B72-!\$, "U6N""\$.K6"EZ0B!/*%3I^:"0%EZ0T6.
MCY/6@Q\^| \$<^JT0J!*:X*S&8N0:X^PH92#0S+%T8:02|0|J8LPT*GW\$>LY& MGSU^F81AN
7S5*NS2^3C!|FRV M1G+7H89K;1>CR"N: %M.^|M>SPP&_74ER^+H&Q^W?WM\$NTGL_5L-J#.@HNK* MFJ?>U4#*
;=VWM39'V/6)X|I%\$4FHN2"0GDXV<| \$|H59|8>6.;P M/L|0-;N,VL)0P_0|45^/N"MY
FHTYN,V(|*6:U92HJI*TH_K|E9CZB/_!B| M\+@%B%|6*M01|-?RV00|' WR#^D=| -
Z^/BZ&DL:62;BV7#R;4_4WGCJ\$(&(5 M&?^IJ,K;2,,MFHWT#R_SHT|V2+("/01)A?+.)KX0+MHS\$0#
<_OACSVB%2|V|K8' 'WX-/L/8%]|&CRI%QSL MY26+N9DL?C|U7;J-/ _6#7NYJ=8"CM@A?>UX
MI6|9#S:LVP/LQ3>8')&*P%R00+,2U&|?Z|+B0KN\$"/07+NY', '7KV?HV9>S2 M"XF.
<=>1F\$LLZF#;_XKZC>>N;MNV/HT|G27\$9>T&C\$?CXK68VB(7XGE:0>=>|Q M&7)C_|)G<6CA/2>M#*@XM2B33K?
1AV"LS\ (WM&(IS(FMJ7X^M\$Y@<6%V MDGK00"0C0G_YGM(00:
<2QYM*MMH>\$Y'@)8/#J,@TL|&=0|+1%T>R\$4QDHG>'2^Z)4+SG_N6V7\$ _6#0W5'| ^#:6!|MA^\$H^59(-
L5&0W%@^)' ^')V7_ |?>?JJ|B)#NEV20K(|:G9A MH
RCYI"TI9| ^.HMY:L1=E^(' @+42D!|!%W|I8E)M0>;+BWN^,C7?'| |9R_ |0> M!=8@-RQ>DCME);A6?
0'GH>PEYXMK(|SH.88#B5Y(6|SLF7'+0!|G>@_G2|"Z MR8JW^2? \$@1Z4K%TL:1JM3Z#%+.,3MS(SKUA:"+10#
|+&\$|Y)/^",>8)&A= MYI&|GK7BP6GE'.|BJQ*;KBPGQ*5W_ LRBLBU4J|Z8\$DPY4A0TWJ(W6=I08^*
MR\7,8D8X|V\$J7RR7<-P7T*C,-:;+^_A&3|Y#N@ZB" |M?,L&=-| -KM:B|N;|: M9\^2JJC/1U\ZD
Q(KY=DNL&+'M,GEJ|] = 1/RUW,4JMME)|3Z-T_3B>XGIQ_M0680T|I| U1BRM(TF1'>(A)|Z&E)?EKDB
M/UN.^/T8\)|R(8&BR*#R:(F>.910>>#-E ;M|6|U*.5\^U/%('*)0@8? "-J M99PG^6%K4|J.E>'A\)|A4M@-
MJWF*WI?M+GW/ZIEVMZ^,3* MY>)>6:%E'^5@^(Z^5N9>9<4X5>| 'Z/&|MK@4KV>XPVX;S: ^;_4Y.9F.@102=
M2"GY\CL02Q>B)S>CF1TP-!DZ8;)7"&;.5Y(BU<8\$)
MX|X3<40\#IWHSNS+01\J|4\$6P,73CN!>'F'I070A/N.P9UW*!N&^SR?J(0:U M6& MTG@9#"E8?
EM1W!"U00F50|KF'EU+QMM"|> GG?KLM8A,&A>DV^OB_*+).;@ MQM^EH|B| -&&T8-6YUG\^*IH|(R>
MRJVEG:6+^4A@4*A7@/>9(%G\$38U%GT"=?JM0)JKM3(SBL\$0RF4:=-DB*2-|)|V+/BI% 61KA3;N3L M-
MFJ)A05\$2&K(^KG4<^'5410(+L MB_X1G3V|605D, \4*3+J?2)">"I,<9\$ \$*F3|)- ^ (D=Y%H^KEP9#0&FNK2E5
M2N\$R^SB"NJZ_4|X?YIX("R:MV"|N, "G*HE-|Y(2/0.() M\$|)).,>A= SM0:48+'|E*A4Y|QT|SJ^ -
=X=PE'N6KQ2)#WPW)>^EML1D-5P_M_RM0Q|#@EL00QZA9>&\$P*U4I9V55C"8400?
|:/|DKD| \$Z/E\)%8.TK+. @V<:F+*?%/.,%D_9 M+P9\N+MBJ.+NNODMIG_S?>W1X|&: ^X'6U#>D>SPRD\|5=-,|
|6":S<'0)/ M?>H,CG.XS-(4RERH?GGVZ_CDUC>K\ -WW\$;A_/400B7)QJH-*HT=(MN7)7&_9':
<#B<9/"AV&Z1X0CZ\$ "90-2;*|H9&:F?Y|0?3L'V,@NN9TF2|@^? M.'DZ7?Z,,|
Z(|VKT9YY=^X\$B*>XYR:H0%E6B|IH_DG0V:5DC&-""@UI0IH_M)>X_!|S@RN03B.\U"D^+C10M20!53L(0T2'>:
(=QE:F>M*)I*5Y_FC@_6U^ M\ (D4JW0/>J>;R?Y8J(2\|)%#\$HE|UIC)UB_4P9@^H_PKQ^AT7N\$'OK>2T8NTK
M_H5""Z^!L2275*+=&ED"D*| %N8TNMQYC_CJZ'2YJ|'PH=L; M.NY_+/#NUT+
| |VJ.0FI&FVG*\$=8CLY\$G\$G^15FY%3>UT_1\ S;)KBUIJ^9#D0 M&>#\$-S5LFJE@KB.S2!++\V
X*M9NR;LS.\+&38C_-V=R5\$FM_*01U'.UZ*|E9L|_MD@Z|0/^H5Z_M<@% M%0G<_RXA@V\$;\CIAP0YF4EMS+?
N7>(*_-2-6BSQ^)|QLPGN!=4\$=G0-^"YL M7IM0S/X>ZX1S>Z-'_0"\$86CH|TGZV>>*;^3?(0\9G,3W
WM.N|C45PPK7ZV* M08/|2JQW\$#|R2SE-E@M86P.PJ|B_4P;?4J<|;^;K|KAA/,7+XE2=!,Y4,M|)
M40FV60,FH^FX#D=W@;&*7H2/VT>/K;0:CY_8L1Z0/X#:Z)C@T@LIFV?&F:"6 M*:_RYL-*R9^7|DBG/\$VQZ*
8L(.LF@|UT:I_I=*(Y|G9DMP4\,|: ?3|H1'^Z MIR/9|UQ?;=&M-&+08=KM*S6?@=3.U6'_%D_|@|KDF8A)A+A.
|,UV_EWVF|L MYZFF+&F69'+\; "P/#0"HVD9^V9ZMK_ZD<\$+)|-YZWCM1T<2G!)S5Q>N|G=@
M;_DZ"RR'V&N*)JT9&ANM(|"L!;NV+H_Q(R,15PS7E#A_|X4&X|J\$Y9YV>G0K_M?
00C@FF)5|]+;FKZ9SZMW>)\\$;7|:8?<=PW^,I6\$N|C;-S|H\$#<27(TI^04 MT''EYY2?JM|:01NH)"RJ-|_KY8|
(|W*93L^;->6?J1A^L?1:L<6E92?F89*E M%'+>0=7(B58&!.I>E)/?+EMK_.942?
1D=|L|A5IK65)GB&/3|91N|V%0\$@Z_M*S,UZNC)+N71^(|HRR?9,?, "%IMO%_D#F&B.0&+;PXK),MK0K!L?
J&C\$>GYR_MQ>??N="P7PV5N!" ^N&DJ\$ _X)G+CRQ_C&>DDMC&:I@3-". M)60BH\$4|ZD(%IZILHSH1+-
IG,B5W=)|#ZN"A-91??IALJ,ZP:#\P(R(E9(NE
M=\$\$AK*FYT'Y24HV": 'K\ -8\3GW":*5;DHJ9I'AS|.XBE(|U?.\$V\X9_MNM-M_M)6%|&DFV*A0\$5(>4:|)"GUW&?
K0,,=4521 MG0;2C|8CU%GGJ<=R,K9--5#?59MA(P|IGK6)>3S"MTENA\$U_&I.WH\^"YD*
MN7|#=/(0.8@2JE#&RSFCEL^0+U8K30^_ MS^&'B&!,MFJRSF0|-=%*0R:M7Z/,UA(\$9"+ET+-
H:S\UDY\=ZL\$KHY,V\$@0_MNB\$*L0+A.1,+(\$S*N9\$!_G4+!0)3U7VA7J?," -P'6F/HUHX2CT@6A)#LM"8
MLZ7.'!P"U"HDAIHF@YH|_@_B:|0R;5TXI(<*H=0J\I-M3H+LP)_MB@E^5325S:3I'#&Q:

6@SDN: +0E\$BG4Y"X" =Z"2KGD?N: Z1H+D 8)G.H\$ MVK
3"8Z]J,K,U=XD"Q2' QFH: H@+*/PUIT*KX'4@^MIA%50*KER-B^FI6 M2034GJ\MVS]5#8KY'2-+|-
'B'P#XH<2AX/2AT)13WFWRV 694GS00SIU!V(5 M%<@?\$CZ?YA8\$IH?!E NVRPNV@P/'S],!B8-T"->\1G?=5@Q
M2R7F=.)HZ;:E6V7[+9> TUJY8)06UMM!6 =:GLDW9:>FPJN%VCVIY#W9:4. MKN58]0W]S^
TU]IMTR7V9.V)DS:I!W&C\$'!WI0=W[;S@2;JKN+ '-#Q?--NV% M7NW-2@NUU0ALL8+%D7-U(0V/_8=05H0"IG.
[@Z(I]VPETPU.E:@HJIR79A9V M8LPF XN)7^EJ<'91[4R\$R,SD\NU7!WJMNA6.H6K//41%J&J@HE\+*R*K_3_1
MX;37FSC(<#]B8[6A]+NC&\K*0X!X!'6,/ ?1X-8\U?9),,,:!7B<4^;%R+
M952C2FZ<&NPC8]U95>VBX.R9,K6<\$LE\$*&Y(^\$2Y5.C^4ISK2[6& 1<<>^S M->I;B(
>,"4VJ#;^AX(-.8'X@*[7,7\$YW;+;9_2NM%X<\YC+ F_Q]3Q@H(_J MY_1^,)-KREY4F,G]7H;5@#\ 9F
[K05G^W)3/VEVE5?=XMCZX/S-ZH6J_) MG5['\$'K4G*3 95S:0BU-2U3#FG7/@1A587'QSY#9_0
2U^3)I6:W]' :A>5KG M10-E4=\ ,V9K09Y>,(#N[0V?R5ATM/T*@M&F+X=^AV&A] 2&:L#0RQNGQDN
MV@&DTC#/'6NK"SV^XG#^1'DP=. [KH:#,=)\$S&U93!>? --3CAD (AMISX=[!B
MQJK/'Y=0!VYS/LLQD.UWU0]BDN_0 C\$B16S4=SDN1)W %2=QP?/JB]UZ5L+J
M>8S1U(&XNQ#*P7A8T IJBL\$;, ,4^70?2Z0+0C&0 [HZF W6#F/4. C4TVC MQM=1'WSTJ?C?
6=R+ILSS7V=W_0#J73.NRJO2]1L=YGL0@AG1R_8 'D[61X/ M*TZE/X+M']CR4AFHMBBC%^3]D@CQ., '-
=8V;>\C.@ 0XQRS:97N?T 6TS@*X+ MWFM 7B+''* 'F@3I +15[12ZJE MY;+*?C1?FWV3K[98TA0\$U99@-5"
(H&F*EPJ N%.PY9[0/'M1=;)K]5G.1J?; MR]0%6\$30'^%Y0?E:Z:2:F0\$]V.MZ9^0]=V9 M!M.5V-
] 'C*FCY] &H?)6 D81HK70^,"&9C>=T\$\'Szt('U5E,1\B KJVMi) MN-!E=8MDV2=]@?
UW2!X0&A^HV",B"0!AW,\7,03)T\2%MjW!,XQ;3 M:/G *LL^H6AY/;9@=T"'^IZ;LV;7_HL?@_00_)BP
+6\$^X73G'.%]+XJWC. M#S5:H?Z @X]=%29W+)&+>T.>W] "PW6#!YBAU"DQ^D(@X(%\:"GY00\L*@D
MMT(3B" ,9]YK0R[,I&N)LI<75;?H)MS?,/74W8(, .T)D-X\VBf@ZL=%5.R,
MGYY5HC%D4;\$K,Z^A7*U#UT0./!+RU-LG45:7 M0@830B030"\$ (3J^5.LB@)0B1@=T#01N'W :2-S '&_E&?
Z@:!: \W(V1\Z_9 M9BWM#"6'***^1FUFR34^Q@^)AWHT6P65\5#PIN&N<<M3KYZN6'ZLB;PES;+
M6E5D2V@W[=TM;&500" 5*S10XWV,060>H)-L6ZL'T^W'26\H08LU,+H8,Q*
M_Y:>U\$L4.WU#Z(OWM?"H0\$MXE=08N:2[(AA0K8[H/4V:>/%VW H4Z,0(AEP= MY527\$E"ZJ; B/!:TQY1L/[L?
*] MTA7]0KHG3-YNM2H1E<_H\GDDH @W8.9WA)6K@[G-5MI<*8+YAK-ZKE!6VGNJ MG8H*=@5I&J8>#K7EWGRF"
[J5_==T :LJ;2I&4\Z3FV.IH7Z45A5&C]0XM4". MZ4-N9:*WR*RZ*R%S=-N0[X=[_S]0,3-F*0:0Z/M6_P_HX,
)WWS:,9S-T^?Q M(XT^I7/00L"B5&@AK)/ (2"15=HB*[:?5@AE!\$=A(2^P27^(GWRC]T,]_ (U"
<8U1TK**MLI\$]+MU@5-J N\]D\$'N! M@G&'EEBD6F?,XL/-C8D%W31^ER/=X;AD>ADHWY#8\$;1<,>
0F6B"X>&Y.WZ,, M41_(R:'AU[H^=2U%. (6M4SHW(YQ;U(\$[TE!G\-[&J1T7^B57I*3?{JX^=:81
M7GXVP3?"N9\$.0Y)=W[0C;,A\$J_FS;%5X_0R;]00, \#U00'9D*[*0K\$G'I3S
MBP0;1CNO'4 :H@9T62H9&\$!N? \U0-+8Y!J6;>*X6[X/PL4MQ?W0RK-D\--!R'%0J-//2\T
M: @FRNL]I%/:Z08+QY.5?A* M\ -3KJQA1E^L\$E+EB.7Z*]H[OH1NM1 23S!N12U3>:AHL5 \P\$0G[')55,7L'
M4K[[]RJH&W:PD;3]BN!, =YKS*6+30,X?'C([T(VXK;\@3E]4]L^H^0KU\ 'IW\ M4F,END+\$(/?
E4&DSR\;Y9DE""&TC/]G\$ \U#\,Z\$HXM2L>,75-<2;:17I,) ^MYM"";=:E0Z7T'4]H4SPT)7@AS]T MT
+4KBT]ZQ^F]DS#<=>=\74"DD^5(^RFDD^R'T\V^K!4]?<2]7SU\$JF>+!1 MIWP!KH#?
F,H\ E,OMKD+I!;NN #JB/DLACS2^/%!XR_M+^H^ON'Z0ZBWJJ- MGF:P(%1^8AS%XN<7%-2\FL2!X9
MH>Q1,T+GB)>"7:=(!Z @6'W-7&E MW=2*/0I7Y!*K0U7T:E50%S^ FCP568AJ0L*NT-S%T9"H?. 'U/"^JIHT
>!7" MAKF*LP_ETB)?&E/?&JSCU-3R5MN#M-[JX @D<880F*>]1: M%:NK\A+Z3!'1F VMS,8&MTWV?
%'6\$L!40^L1C2T,K0>\2KG[ZSX9\,75U+?! MY;KV5NJ+>SN37-7%W=)=)6^YZD)B#V-\SK), [HM?'1=<0M0
Q3+J>6ZP\$S05;9K,+DE/WY4T@^-VKL3IQTND!\E8;E5!= M_M_F9RQ_4QX%?2CJ65%3LZ+G\,\$W_U40K;"%
M"^^;SF)^4M^=L[;Z0G6-Z+;]*V91^W5L7G M"8R_) '#&EN_TK^9= M8R*NU&'9W;.<=Z;D08*DJ&
>1DG"1:TMXP<_DHZV%01NUHCC'C'R,Z]A)0TS
M945IW[/>=V[9#N8_QP*#6^GK!N7A_)2T %, ^EG=*+&9[_,2+9]G\$4H?8@Y- M\6C^L.&I?
>%, \='%=9D: %*%F^[]F1*E50-S]L@\$:YW\$XPBM5V;6U_1U_, MC8@/8(, ^9&A/NV(XR?
A!0F;+M'M]3T,RAC5;0L(3_5FR;:HB9'!GY/:P M*^FR+-0W,K*)\$'Z8A08A."F;-
>XTXM]E@K0TA@QM".Y.U>UY#)L.>WSQ2^ M^P=0?C.E:"]'\$^1;7?68 T3MCR[R96-D+0
MY>K>N\$&CU+^EK^^S\28Q2=, RU@*Y_) #B MC,NBPT,'?X^,;-FPL!Y;?
%]4_1CIEB>85;^YH2:RE230ULS)7_+@Z+[]DP?#? M1^>*Q#;+3E01UB ->^JL]U(B6&DBJ\$.?
H7'ZM\DTG3N50\$Z_UG^A>T.54W_MLB5";EVH))_F-8?;25:CHM6I-.&IB9P+H@Q!#1H_KM7%2I.-S(-:2)J@+0X
MD \/:;SS;YVW-RJ6P1!BG10GJ;:B\LL+P01([\$=N[P-L>LB;HEAJ>0:7W\R M8,\$MP>W)I9;?
+74V+\"V[4S0Y.X_MWK#V[J]A1D_-92;VN5_MZA>"KYB_&=56%LM6NK)[Z^1\4L\M_-ZKJ6\8#TOB*)\$!_?
K:5]H>II9!"K MSE@C-\>D:" >.:P I : MP/=A9,\$M&1'@B+W7&2-MBU-
Z(B=Z@4AU#056;K&W4IWC[' ,1BNMZS) MD?IKJTT];DTH19PD578_R+P2+F.#_%V[-*6CSW=(?;])I+R
HFE<3Y*-3 M<6WJF-\ '!46P\$A6#?4H;&=VN[M]/SB#B="#QQ+MKX&3_4Q)S0*+7TSMME8_?
M!7'.XI(IP2%RX(3\CEV#>!C.0]^~?N2Q\HM'\K(HDU4@TR%XMKIB?YIF']2?I-"
44J_Q1WD_&/BZ/LM2!']\$\")N!). M1IR[L/HE=#.7K \PJ#.N2402+^G;/GFFPQ[/#/QR-"434G7M
M2PBA@SWK2]>0K"L9X.NYAE)W0.=]TW= ^N0.N74SGIZ7V"S56Q_40B_MR;A#3P'I77-I-Q\W>M9_S-368,?
@5YEW'M-"<\$S0[Q+(=3+BHN5=N:\$'[\$H M#Q*(Y69C*='><%SBPCA;'I'I50J2E4ZVU--
J2L5"6[0"!PN4_,P6DU-N@>86 M])\$FR4'1S/NK2<*>YI\2'Q:Y \$P,I0\$W/I;.#JFSM"08+H-#%/!86W.(LF!9
M_23%;J1TFRE5HKP3++:R?% A[&DGT."&) 7\80LWW8/_@!2:' +^ &S' P"V M>\$L,04"UA0)"#G:?
XL1DNN*\$/_U/_UX:[]75Y1AWM&SPZJ_ZJ4S=MN;L(\@_M\$, 0/IY'8NX+B9LU?J(:S)*;00;8J*]ZQ-
30JXT.:X4&<13_ =DT9*-M#*BC MC&(VDQD1:P4H49A7H6";C6LVH;W9R6%HG2#)=/M5\$T+&3\$-#R*/R_/KYXCU!
M<"E8@:-7\$!HN_YW\USQ#V+ 51045]<%N_L?W@J\AX4+XAG9LSA)X(KC0J"W9_M*/N_.+6[U?_
Z@CAQUA\$0EH_ZMG1/55E46N)ZC6Z,MGH&+/>4/6 MD?6 &K+[]AJI+,R\
(JDWFPNHYB\$<0:0J\$UT1Q1<&+9=\$VN;^28SJYYTNY M]?
!F*,7F*K':\YC^A^T\$W70HII(ZXTNM!;@XNNMSB17J(2\V.*LIK9=9#M+^0/6*<:)@R7<48_0]LRL<4NX"(\)-

BN6 M U:;652Z^PD^L^G^TTQ9".-ZVEP\3% J.7\@05(<*\^AD\@FB^&3K V M2Z\$/N^AG=H!8?
S0+A2^*KV=(B@Z6W-0^4=**,J B_U.[7A_10+1J/-H^W\$XK# M6B#G!9"00(:?X2:
[*Z70E;I#NEQ'* 7.*"TPW103 0SW,3-Q@0.N@Z^+\$1 MP+%;U A;?FGCLO=:H&K0> (52)1^Y-
BZ@<61I\SL\$(W.AI\$,C(&D#(C!K/5J!H+7QE MTI 0\$6;+\$\$K(Z96!RT>8\$%1CHOP2U;M#;DW)]_LV_=Q&-
Q5%8^#RRX&WAO< M#3>FB^K8U&MU:/(:)J-Z;)]T@P;2X;L)<,^P33P9S=^VYCM8!]??'8'-R-2Y)OR M)-8]?
0/+9Y?U?F/O:\SL3BBW.TD#[,L)'0YMM-U,(-*);.J&V,M\SBR.!N3' MQ,<]&,55[:/T4.G3I>K|T6X%
[YX|8I|1U61;]L^XH>V6-L:3 -R^,%LQ9@: M ^\:9D0D+U8SS)6XHP'AY"/PD36#!&QR
M+|0B70R[G<8L#GTT|#ZZ3\0MMM M !|K2)&3?
%#XD'^3+R],|]G8H(Q8&8HHA#|0Q[|>), \$S13,R7|RC/M*6" (L M|SJ=(M .LK_E401EDP>^GCI^/N|Z
MGNO;W'L+6)8\$ @IY&:WR2^@&IU4%|+@:VQB.00I835|<^R^N!+19QW2:YHL MRGJO@Q3XM*"
[K|'XJN^H^\$&Y *0 WYHPC*;E\$=]:0L,*B4NGWOG^3=40\3F MY, X?L3T2GT&WN-
#3M'GA\JUV@RI3;^J]1|G;|3WC3 @D_V35X6BD!:=,-W4 MD3-GA J-2*99NL[|L0?^'3^H)=_T-
3&LXJT#%)*/=|+(2.J/*V9=GM1C;91 M-*|+-,C1AUH2|0D:4UZNA=\025K473L3?;|?
MWDA0:"TB|\$)5(95H/|)B/PW& MDF:2|&9XCI6%N:8%UBS' M ,HSM/ 34\$0V>%=|:U2\.?\$6:BUL#P^RN|>HJM
M-LI+.XN20W*I>ZG|FXGBJ8\ "Z9 ZMU0==',US=WW6E)H2P81R#J MU,3B\$[*IGVN>OZ/"P9E4C?
2|EHOL 7\$4U5B3|15^F|M), 9|\$)XS|M.07+65
M/G#RNV;|)B/S)PJRWO|>=Q U)\$ZU,W&.2%K'VK6F>]S:N^(EU:OR27(R|#86:
MH;0PM2,5#NU1""AJJ>!M05K@RQ3|!JI;|:IS L05<(PGGP\$FE\$D^UZ<|VR!J M!/6&<%
<9==+0%|=)3ZGB2Y.N770\$%1XD|B|\$"? 'TGS H:G\$.5E2 _L>%7:1(M^VVB\
<'2)EN; ,N0/H/Y|9ZF^Q,E)3 <8%3VP>E,GI?UGFK:79\$!TYV(&LYI< MZ 78>SRS6'^3\W91% C 5TXF8AC!'N-
_)8Q?2L>I!(7&0(:G|)2;| C6U.2& M.=*+=/9YF; -V%3|/QW@'/H71 C%GU+4VTLT0<2"LM[
P\$|C\006K;0: ^, M%(>?RG1_H"%|(|3;<3J/_>5NY- %|0|B=69T01T|FPI8RH.?&N0^FJK/;Z30
M=P007GL_59:KYL:~5*77!~H>S9|&? MV!,>%#0*S3^47+@|Y=VLHL \$LN&;!YK&S'M,M,\4RBVH'X4.8YQ\X?
^U\$%\$ M?S9W3Z1Q3N"=D03&5_3Z@XJ*|!&A/|:R0 RUZ9^84?(2-|Y,? 'P 7""IJ MDNZ^YW5KKI\$M:
TX.YIME0BS(VZF00?4GA9Z\$S;4MTFY0>H?.0*8,#9I|]"9W M7)8#L55JAS@ Z6E;-/&TJZB\G*!2S(H!K6"&/V%
(>LRAZX.S\$=%;U>7<=3| MYAY;UP\$?(&TL'-2GW9V-**,I(|;*LM'E/0'3EFF=Z02^SQ.>-6H*"?X. "\$W
MM1^F<*?)05-)GM5?)\5CM9&Y<2Q.2Q.0/AYQLMC M8-, \W&78R.P?~1'XQDHH"3\$(TU\$7^L9QHEY5\5F=TM0?
C'DKWN#,E2<*:39 M,;@49SR7%5NUY\|33!\$; _G7 +>4S1+1P20Q9&K,>)GMUZ8U7L|_% 0V(F2.Y M65|?
&VSV22[|A?0WL>22,\$G+LI|R\RY]|9?7PV7\,W0H6KX; &HG|VAS!#% T7 MMEE)|M."8POBY*EA\$KG^W;5-
2^7U#KP#;ZRGU<,[R"]N(&&0'C5!-1K\!2"4 M^#@=; %D-A3QV|_,|P7Q00TQ>?
1;BZ>D)K'LOE^RE|OL*';QDAG^0R7RB25I M>;9Y00'-|; ^@SUR,4X?(7,LH/J'USEG<(LG8]?IV|JT&M5M-
Q+~5?"K+RHP" M.RMBB|Z4RT"#X);::P1R7RY, J@. (^&.'NV4W@D3(9!8+MZSL +~0
MP3',>~*WM; '%UDV%'B+8|QB.#/F)AGD=L5W\5LL_#XC.A_A|_% -'RNY?'. M^K5I;.<35_:J4Q-|G&?
+W'&*WBDQH;F1K@4YFVYYD,UMI"159D|W8CG-\$|+%"H|M)/=;K^!7\K\$V^&\$NNUH
MMDXYF1NGLR4@VC%Z|4FC2L@~9M5W.4;/G4QUWJ?)F'JVD;06W&=S#,09A(7P
M5D^0Q'5*22\$E4N0/&U(3J(.05^0D@&L?E@H>%:J&C);@6V0E0?EC2K2=1; M#:61+ZBI;7Y4-
\7U#!4'?;CILE*6T],T#UB2^08\$3Z:NLE6RZ0D3UJ&M^R MK'BA&C5=U'6 .&0VW^Z,[HMT/1B?3Z;6PY-R0>
|'Z;CNZ M\$*9==1H/QZ;Z6:"LLU< ;GZ+=%S<=*AEN*P7@'|)WAK\$^Z1-ZW5^;+L\$K\$K?
M@&D7Z_9:AFC7Q50S|S 'FO/^OV/-:1%|RT8^,C4|LT0T\$RBI6|8PIYVYTGW M\1P#Q.)F2MW7?J-W
ZTAC],4W1>7|W|A_8 \$AH|5N.)LE9NFZH>:\S'C6W_7 MA.*BUG!#W,EYGR!C4Z1(S?-!S,>|]1.Y;)|FI7|"U?
6+AP2G1+SFHRE4%>/6 MT6YV\4*Y,|]6T^RD#%E*/03",#3BN^;!QG)=R-#&)AF\$UJU390EK_KP#V"E
M*N)\$PG7-I&G2G?4@Z'/5=|%"|Q3D<-##T53Q<*6-+F\$9T>@7TJ"|=?!&0 -^ M^ULN,|]E<
6CIP|#\ 'A5!A5AX1&|6+)|T18T8*?Q#Y@^:572\ ?%RK8,)90=L MIMX?T\DL#27=H4=V4)'1#NREEP+-
\$=|W,9=T'D1BK^89B!:"TS|3FN' 6 MJT)+7:P17??)-6U)PT,A0\CV44/5=:;.=F_H02SYS@'SJ?;:9J?|=
|@3,|0T\$QH^LH1H|9>" [-+ARL0ACWJI RY: ML2>G=1|0C1VS;QI0+\7W?7#/S'N5\$Y|W-CNXXKP?X?*
< C@U),0| NWZ,!G MXUL!9;A6?5640F87%I%+4W"G;Y/4"00CSD3K1?^,S32> .6WUWT|7"PV,\$5, M@YWSC-
REBEG>|T|UF!%R_0G#QF|J#|J8H0=95%6&|9I3Z5U6-R65CX\$Z,|, MJ'\$0@VRG-
Z<._T8MM=\.=2"!XR)K)+*SN9&9BFQ_C'%|U'.W;@1TT';\?9I M\$S;\$3 -U=C(6N^V^M@K-GK-
SWT<_W&0J03|J&V&K@Q?K>P9_3,P*PHGE&#G| M!;QRJ#I%&7V|Q3H^TPIF-5')7> M@X
(QF|T'F'|,M0'&@)TDR^HWZPAU4R+^|_|2-I",*8/_/7,5@C+SJ|QM3
M76^/JDU*+V7VZ'|?)1Y32!FT)F=ZR).4?ETFF20&7PWE;1P*-*195/FQE6?I MS&W>T6
%2>,=ZC9.MZQ99E%2ZW;72-R/2+:0RHZ/^~8G;Z. MSG(?H6L,TL6\K7!]|2T#CJ6E7(|_ _'/UQ;K^Z)2UDY+-
,7|,,06 M8\MD12XPG?G_,&H^5|'6\$GV<5J'FG,6FD<@2)WHX?^Q>+ 'R(Q)Z\1RHR9G% M/<6(T^M^N|3 IGO ?
00LEJ0#\$:/3PERJX?V%/N 'XF^X#3'^,XQ+K|V|!;]? MGR>,C|I\$07*3.T_!PK|AJ-
|[*ZJW4=4V*/QR)&=0E|K\$@S^90F(C^G1FS|YU MJ\|GA-#!5)Y-
1Q>0Y0(KAK98R:04UJHQ)63,/>H@?:|_ CJ\?:P= M9IEVZV\PNHS#_ 5SD:|]'*N3&EG67G<,R&-
-(1*DV)I%9"2>AL%&Z,?#M\$<7S^ MR?0* F(G2#0D"U"%"7) ZDBNWZ-;H^VC98-MR;4!'",6TAUW^(4JJ4
M:|J7JD+?^~*")LU&Y\ '7=/(KR)UCP-RBJPZ@^K1&/;&3ITK(C+SP^P16XT%/ MN-6#Z!
<~9LP>M"A@H|IK6^I%1!=J0V=SJ)Z:"X MD%I5-715-
GT/K8K!RJI8# '=^Z#Q0];=ISE [UM:GY#H4^ AI (_]LY6V'8A M5H^R(,;EI:_; (4^4HX9!JF7B*QIA^N^)-
_#)/>+8YD%2XGY%8+IE1>JB?4C MZH:0Y=0!68|MC<>V4Y=Q.P8*= _+3#!;W%\<&#UIF^?!5N,R\$DT0-KQXXNSTI
M0:CL| M/T;@F_L^_9HN8GX0&<+#+V?E0S_J,|GN8\|*U<5U:X050?PE9Y9@H<>7KH:S
M/DMT_K.T308J1J&TC74?9JK03_ ;9%WTPZJ|^\$|1U1T!-AI-P0|(^)50'C M6;KK6?J.K 'Y37)+ORKX#_?
=>2'@(NH8P\$P9U|+ '_0/4|ZJ0DUZMT M?ILI;0C,0T4.|B,1Q"J:^EUBA^5\M0^*(\$%X)R|@YT|N6A.+
(KQW:PQB9(0 MDX0S#9I<*G@AE/'A>R'C63F^P@^300\$6,@:'US=R*|_ *ASGS/I/B50F.TTW(
!*K4JQ=H/38J4C(4\2 M/8U65'RK\$X,;1T%UGH\|Z"DY)9D+U9QK|Z:~#9H-IN_5=>STV2>E|\$N M&1%*
|(|S7S+@;'A0*(?|IJJYU1_@#\$A#!.U;>)#N*6#3WVZGC^&V5?&=36UW=+ M6TJAN+L4 A27XE HI5AIL!9W)|</p></div>

07(H5*.Y0W(J7XA(2(\$!QA^)^NP3UXT%[^MS_/.G??,G30W?3Z"0Y+[
M6+[\$A]93^GJ00V=YEE)BG2:Z#+\%%I@]>^M[\N(.?YZPT[F//)/&=J>-#&*-
WK%5V)SX'V@/^NA9.+/\GZ=.*"DI:.;ZWJ M\$2#4[E?TH..0'XX8%=HC%
[YH7Q!Y5Z;^JSJ@C8LES_I\$18&!MT'2/#=Z7N? ML%0^'(9)3*LWS\$V,SQ;L*;/)QWBEY/";ZON\$RYR-
VVRIY,FZ9"V-.C,Y0/JD MD(A0!3\$?821"V!02;S)UA6?RUCWB.>0&@=*FR.,C9"[1M=FVJ?)>7!;8
MM=T460QY_%PLJWLMTY6#?RNS!JKK@QKHS:T!>2X,(B5G#UCE'9]T&U,JV,YP M'D:'.36N!E\A\M
6:.,2[&SS][3>7XT'/N+48N@1\H0V7F4KGKG2:6"*>;T MRKFMPHYAL6)MEQHIUB)%7#8JJ*/@SV3D4=L8DR/<
VF M;=L,7^."G^X.^@0'S%,7Z=(4[C94H&60\?'BP)6\E!'.>I M<^?,(*)
NYRU\$BR@%5>70YWK<;\W)RR)NG=S*A@/>>ZQ]44 M6XNKV?H:[U4352CV4)WC5QR-^D&/PUASU(-
;Q=\\#Y0VX@+>2\$T)&';@C3AQ MUQ [9Q5QR2K!9L0&M4>W)TQB,Q-9HE'XT5]85MW]([,Q #+\HW^61MV-7
MYRNR.*C\$&M)UJ4&BQZV!K4YK0;X75)//L,L@26-X?7C=0\3>7H/4"OH_13D64IAJ5>!
M40>1IK8[TX'YZ.%)8#C180#7]A6,MKZ1?BH'5=G012=\8[KLX(@'8I6L\$@H+ M =AHP"+T]2KA+DYYW2NZ(=R?
SPF0X*Q<\@)MLAKI34\QY%HHTBB2PY9D03K\$ MPJU=PZQPG D;?MX=Q)/88PQ\M=I2[E+F:=)QJ5[5^N=0R%Y
*I2,G\ X0T- M %"U/[=5 Y7ZJSE6^/'N=I2&B^.[+Z0%J%1S6+(90"<.(K3699L\;!S300/-5>'#-
ZMS"K%6(XJK\$D0Y'XZ MIS?@ 7-A\$:\$^."H4?YBNR.J"IXN9EDWL ,36782<1DN QR]/N;F%I
MI)DIFK>L71[/[G\$]>[^:VJ("XM<60UU+A\0LIY>/YU?0J7Z ES0&"6\$/\$>)G0 M?"7^KD87>>LL+^DP-[A=L0_&,
D>- \P1R'W*9^]=AN L/'UO!I:=)5>HK][M \$;\$?L^;2])<@FR2[Y"0&N04!
<3U.I\$^,R.SL+=\;BK4)UNC]_VA[ZN*'*C ME]-HFI02]CN\$V"\$S\$*:1HFS&"#\BIG1QI4U-
T\$L]-3R*EF+M)MVT10 E'GL'+ MCG+A0\PI/SW[N7)=?N\$ TE8-'@5K7)@(+)/1SIL:>ND-)J^"E+M:0*UT([7
M91EH3Y3SW)8N:BMM(%*\&843!&CH2(/;?])&I^J10P'BX1HK/ X&1I'WJ@8 MV:F@V#M/ED&HLM&EN;ML7-
HY65,@9DXXZ7 ML]4%J61]MDRF3AB"TA;#8 (?\$KNKWEER/,9A49@ETI)\PQ3#-20D0V5DZ E! MQG9)SG*[9'
S[HK; T]?ZR['2+=G2P&T&*BR"OPD &*=< ZIR\3\$15>C M.HU;ON_NXL.(N\;KA1*N45-
H#S'1X,Y[MB\0:84@-NW%:=>3.)/#BN. NU& MMX;'!\$G(@5;,1?G" >2.FR39.)ZC4I4A:/R%5\5SKZC?
W3Q'BDM/."@0=\R/ MMZ+J_F)0H40<"(D\5?UQ;"F<7V <@#].XMH7/?H! T40Y;/G\$G)@PY>I-%)>
M4'(WQ1S0BZZ*[F_9HT8ZIZZG,W)YN@J]Q.W!/S@3>%!BK^U;(E3>=&0>&DG MYQ/D(CZ?(+!M+
(CVS0<\!F.5"3]5;.;J%C4-52I]U8%#KE: ^ [7<4+%-;*2L
M"#U>ZS9FFLI#46"! '= 'RMI,A>W_8A#:T7QFPRES.'P2*;Y!DJP-[7X7# '@6 MV- E[-
F\$PUVG1>0U%\$>YRZ#G-/2VW>JY"TN\$>+P5% (,7SX>)51.F0 @VP=0+ M02I=\$D&EK?030H+;MXTPI!
[R+P;V;.;S^ MM-A4^D3IB,.;N@95B;J;OK;B>'=410@JS8CJ;080VZG7E//_8C)HTYBNN[9T MLTZL<*A)='1:;%?
WIE<]0XI Z#"VYRF5"7AF6/PXPDN4U/F<6A6&-2:9@0F]7
M3_D_7&5KI#0W^E07;8^\$'VR!) =5K(X8]H7U2K+|VB&)*5A19&PLGP@Z8;\LW M\U="F/(N+QX4)^ (01IL?
AFAZ,K1@?H^SNWBBIOM1BBQ|BF#T: W8PWBDFF9Z MN *%X=MG1+VX.R4?Y90RR*G1]C;]7.JB9 +H/0"?
P3] HUS5RRWLE3BQ&49 M' I3"^->XGKYPH5.X\J.U'^K+?K\QFI5LH6_UZ3"WOPRR 8"Q#&H+*7S4
M&1MY3P2?R/04,@Y&R!4-<.YBXN. "H8+\$K(N?B[D> #M"\3VR34Z(PU5)]PUNAMZ]M5K,8Z 5[#K"FZ&?
L!QH<"C\G* M967L \$@<\$A>7B[]#2@MF M1 +0KC-LE4A"NCUW)Q,[:FIJ5+;\$:&8T?S<^%:W.B;7C?"1?
MDE%&\$W(9%] M#@DSRKT:7'3W:YA>4 *FB6I==S-
]3H6/8Q70H)I&%BP\R)AB>@=L]+4FQK!)R>]XT79H:Q'8P1+2+HQ'*0 MP(_=7="MB(2PS\.;
(1J>D_5W&CEB\$Z_0M%>(#IH!3WCG ^98R!#SR)GSD:> M[]YS-Z&:B]*0)0@C9>U_VE]7@\$ZZZ
BD=HQM2!3:+=KSR)GP605]:M6<7.3/ M7K-KHOE6#@P^&."60RB #>V 82X%";[51@Y!0720PI]DA@ >\$T61:?(
H48Z M/(@6.]@R&B6;WTY_20.Y4MC+,,,.5&0N'@43]HM)BC|CE\;W/U;1/-Z"N64L
MV"V2S(BF[9H:3#FV34F76% 42?E)?! MJB];EX^ FF9(I"! .?B!#XF-0N@UK MH1Z5DN8VGY*2]64MT&G\KB;
<*L',U&RSG;4BS6]LU.UNPP66"F9;H.)G)R M7ZW?K8W<64M8R1IT-D)&ATNMUTUF2U.7VS&PH_-/
MV7_/,53SAM#Q"W@T32K[HR<3E#A@A@C\N*]E^, M + "G>06+I/@^NN<@>7;J;?
>FXMP1=0PXMD#B6L/U1"70G.2W^==&YF7N>U M*JW>:R3L:"7TM :2 \$75;EYM-YJ-[A-
FL5R)?.0V:4V+.3H7N!U*00IRXL(8 M+4VSS4B\$")YF0L CR&T'*?Y5&=(]LT@WVL5<-
IJ)50#P_2'2'3(4UZ7!Q\ MJ[\$"?J4F81-ZKC!V* \:6003,&\$V=L!PT86L[W16W"1]6Q(&!N(D\$0J <:6W,?
+*]V,L):5FUM2KV*A?S'&7D!X^ BI\H?+;*G6J/,3 M="!Z5TE0Q6I[1AP?0DJ]+UWG!TD= V6@R([80F?
AEU/!Y\^-UM5QK1J%]|@ M6URAPR(W_Z?\$!YR2"VT.+JX2]8,+5+VHXC V.Q/(=0)-+63Z-MME=<-0;
MG;NVC)9W:R7F1'L:]!'-T(IG>Q30'!>^B_99K|^%MK5UGI-?OBNT /K ,D8* MA'?
IGH[&:03J0+F,XK%\3@CD0L?*B0P6LF-J'8]TW7\QPYN/)]7+J 3:G]R1K M^%<%EFY_2ICL-
N>]W;%V552I3#KY#HX;OCUT#Z?U6,*T)%(>24&W7F0U MHVS"A>FCS9"5/./';I?BE>#G%#8%J)?
#L"_:4U)P4=XE^IL>J_?;/(;0^ MJ43J^KD@ M<'9XMM4;ZL'IYK&;) S]0
M5:"RM0<5!J0*8\N+\Q\$96LIM;83*WL4UW\!8;K77P4*8K!(!,Y<&Z(*P0>_)8 M [.V\
[@L3(ZSMTPCQGG%N8%U,C;]-?'!]#N%V+D:\$4A <:@RHV3'7E!09%/L MY%NNMF=??
\$+G9]B/505#IFIX*7@T3F15 M_ ;\$T2K]?*4019R0T;"*. N,T>GJ%E&/)]2 M)<8F6YEP-
@F&*9FZ0I75P^V=004 /K"R*Z51+K?:2F"GGWGI6DP\X\HVKR[MD*5^\$KCN3"DV+Y6^?3/09360"?-A#U-
9C-2.\E1NKW' U0 [XK4TX>0&W MDXU4GF;_%+PWKN K2D=, #S>1WGPPZP85" G(\H:C_Y^ANAZ9CB3Y#&-
LS@T,HZ>5B MMW> 8E@QAV^08.W?9U3HT= U-4I["@:R.@GRG#"S1"V)Y!+AJ!-]9?JLL3>8
M_#A!7,J; '%>%\$+YGH;T5I1<.RW\0GE.V99NJ \68'8!S] ZK.@&[-?2K@*+5 M#8SM:K@&Z
AZ9UJ<\J,UW2!L0@J60!>2;^& 9;\$@]N -+ 'ER1"[;W<+@H&G*+! !#2(G>&[1;G1R\$/F%X7\00\$'&U=N&, J1<
MRW0T6\BB?:2XG&R\$NX;+D7=3CG\Q[WB);PD3>.+"]&(B?TH>;=#,!! MX1EFS+?IT.V & P(4,4>\$=I>
[;X01R?1 %9%\R 4H4=G04#\$E(X'@VEMM@:' MI?W'AY<=XH?E6*?X8*'03-IC;%[;9I=?/&8?)C.UM0D,;F@'
T_(\;:>6LCA.5M'Z,R[_1[N[&[<= ZI"FY:] MJ0C/9J\$3N*H6PHVT!H]!F." :9K* Y)&S8^/F\0-[MK5"+
(\ '[#C!EF5D>UFCUBF[]8N!J(V8-1AM"!#@CW%+5I\RJER'I":\ \7/ MF[?<]+IBM>8/-"(WE1(YPS7I!S?
040?6VD.Y9,?W86W;Y)SXH@=ZM0R80F MI07%).4=R;W.6UY9="EL6!V;#S^UT;6N@-"[X\$ \]*> ^AAAZN-
WEY1X0K0F M7<%LM*"OD:[;-:R(,6I GT%L\$X%W;T@OE8KRI9\$.KV/=4\$?_1#"K?:*)22JB
MM5^]B!J>%NP=M" 'R&IS//+2Y\$0+\50]5S@-P@I1"/Z%4] M\$KOF^=9[. [SA

M)'4>9NLKL;ES/V89.%E9;\R,_LK L+=V6(PT>J(Q?4M-D>&65)!('UTP]\WY
M|M(#1A2>U%]%%4.;ZG>HY/S[;JS.R,?PF#>2,.P,:**/NH.%"RUJTIZSOMA M710 6!(F>04HLO
.,I!)XD=AZ2L]%;+^95DGW_8E3NQ*:S_[I]@ZJ\93=>^DP9 M,C0R\$U)=;*CK6SQP*E4I(@*\
<1;U<'>*SW0C*RV\4;Y)?.FN>X<C\$CL5WB&\$>(M5B[LP%H8X5\K-DU40(\$\?.P38*;J!0?
X{NWTE\$A7^UV5CYK86_X3@T M]+!@0E@%J/:QKM'>.QZSHU^56\9<<(!1=: 'B9YHAF MT(%(G]/3N:.*+R IX)4+
)";4<;Y%;C>!@KQ3*VFM/W(Y5.)=1DN/6UF?U&\+ M/- .Z;-V 9Q6LNNL,QQ&GKT7;YR
AMV[^'BNX7KP0*;Z'I1XD'Y'2[Y&RY;KW M?^87E,APP[_'"J?
&+B9\$B!Q985JXP3.A,>+JN\$P3YR)6HE1C.&:/G'8\;- M&JFY+0:BZ7%73*\$1\E8?&?
M[L;49/6E*_BEC<|>AL9C?22&2>+IGJZ^ .U6PT MX\$=:I^F5?V0Y%&SIW&]\$,!X-GQ-87WJ&6DI:]?8/N ?\T=
Q.5;7=606),&[M1CCOU\KV\73\$L%HE"SD.)2""?YL3;'V])" _8\,-N9":D*DE:)C_N(M08_7F_HJ65:S:L@H^
\$6<"+5/4;R;XQ4\JPGZDMSHORBUX9X:8'ZS^ A'-J; M2][V:3Q:@6^P2>0?
2%QA7B]DW=2QTP9S.NV6!^7#0(U)/!/:3< MW-W3RAE.L'%0QC3%",M]^ _=E0JS)Q5V:)<>RI9'=SE@P/AG-
_H0A]T7:[+5 M-ZS1W3]&>\C7ZT>!G&]B60!.W=15@NXKSNV%7[:6> M'JIU"=,J:58DP0W?
A[C>*RI&^;45F5(5;CTS<\$ MDSQCN.\ \9(D'XG/G^N4>1],0N>1\UQF0H'BW<\$+U((L"BH:0N)&EK10S\ P6-
MW2EN-JRWL,==>"YU.Q2C7>!\HR"BF0Q3?-@)3Z4U9,^+.6>:[*UJ,V@U9L9 MA\ \.2%1WBAXVL-1^& \$LF\$/?
7--'D4?UMK8%WGJBT='%'1SN EI[Y+U MET6R=)SU&1G@34&/OJQD !F6=J)T7;J!T#KA>AA0N4'_NXQ_1[
M2@PC*9/?0\$N@E7G5NS2?FG)R2=*9F !\U=:*C>19H3WUSM2TEA\$+:\$Y26B#BU_1#?<:[HEJ-
Q+UC.%*NAZ*&2\H[W-08\$4)H^8U MAC^77Z9[+D21^+M7.19'K9!7\JZ-W5!(R:R'^=JKEXM2["^T6A_IZG
&BY:K M#?'X>W.GQ!E3@M_ :6CWM?S'P%ST;\$. \ ;T5JNRNFE1\51^" &R0^[I%Y' '4/'
MU5H]'1-49^0ZI?/;7L/)/2ZNZ38LU0UX;7S\J6K5N -"M\$21[,&+6\+50*IA MV\$=R*#(UM;2L>+(*K: ^N#?+:
M%)@GS]Q\$3CJ;9"4DS\$K!% !.^J*,^ AQM\J &&"58LC\$ _3)#\=:5B7]/NP&T M1GIQWC-
\UBG*)=,F_6K@/IM'49R8,VS\UN?H1FM@KZ.WKBM?/O"!@^D5L63\N]-A]?(\$KY9 M@92DT!#W_"YQ1@@I='!
-3); T>]GAUETVB MN[ZA0#NH9B10,\2[X5S1(X.,?:Q]S]\X5@\$5 _>^#3V?
MP_!4ZE]., %>X?,7"*E9M+ZT3Z)BFA?IJ4"F(8_QWR\O MH^GVY: ?ZMV\JHZ5>E"PM&(V(5%SB"@T5S@S*
<:EL(/("28";;KJM8?<;XS" MMOKW(=/H>--;33 SC]#YG-F]EFJAR#MB4:Q<("72EZI00#C^(VU]?E\$8P0[
MU:;1D&6REGDDWS.01'9)^>ZE?9Z/7"#P4D!%HG?J(B6>0B9LTM^UQ;#1C"PN M-#WC?J]B6YGHR=,0=?
6R0/_X_2RR#H";B=%[I?Z*Q"WP>/#0V,NE;@3TJ_L_0@GH=%"MNE:Q>&5;@- B3W-,9_77GZB#QB1
M<^,^F3>@2%\)&;05Y25U,,!V&;==)KMU02\JM.NKYEA9Y"W8\=LE&B_9I_.L M PH++D8+J055
)J_ ^FL3Z^62>B53^49X7XW62]L>6-1-2^-XRG7J3RZ5>A40 M='GYD)E4Y)08Z;7Y!J3YF%;Z6Y=^9DLE?K
Z<7*V= 6J\E3,E"9F@D3?UNV MTDWN,0Q>S>G\7ZMR8*IO^_/1SC7CV@F\$>)XMS^0SPNCF MS;370YUL.-
GDV:"G@W: 4V>C9,E^,GE]"S*4NX4<3R6N&K%=JH,%KQ#*IW++X_ M=N:\$KE701-7&-D?!/VX^= S4)@M'*,&>]?
4S1W&ZZ=?-X7@A2*MTMS@#60U%X\^/@Z4S%7XS<"N%05&50
MX:2/HMMG\$]5J^RR#W2FV""H>AATCXK2(2KPWW\$KT(_J:'Z.A"Z!N(P+M@0M_ M%\$^4>AZ(DM1+H
M/S:UD<7B'[F.7\$Y69>E*J0H(L+:>-WP_V*X&S#W
M,H0*GY/>=5JKY@996#/EA:XU/I(HLZ[@W@CV7*: /B2J2Y2V;2F],&B@_Z4:17 MDZC01CV%+JVRT^XP-V8-
3[_NUOF91]]DY*YLE2-SN G M_!'S;%6?/23A?I/9FJ]>H>@7H\GO]<0[@TN ,0/] ">Y1T>@+G42U1AR"\$06)
M@5-.V&=M2-M1> I/I?T]356];MD9*/1I'!DY(79F+W==)*A*1P_U6JU4" M*/.*8N""3TOH[V52A)%_B2?
%G@F0!\$C;/57I9 \$NDN,T!%7PW\)\YRYGX6E/
M[7B\&V\6>%L@2K@<.1JYF#"S>TX8V\$(\ "4UU,UB41FX>T^"PXOL[5AGU86N0 MP?BY
[G"*Y%#K6GQXU\$. _E0'#=OKT#]"LG: M_DVQ \+78IL(E0SZ0)^>'U?<.H_\
[X*0HA.;";M0>+^C+Z*,95^P02:QX/)_@S%VI1Z* MF^*;J.'OC*(3C'S!QZ4JMLE\3LT-
P499.@[N.J.&>1ZS8]TAC^@B@BJ/\&- R M/>G#L?: T,OJ@?3&>YVD):([C,VT38W.S0BV[>%+QY7+),
[*VC5CM?0'T.G MCLKJHME.->JD)2?1WSED4.D\R:EW':K ;H+K9KS3GYSFZ.]^DZ0K""X1LAHTI(^*[<@B
M;,"04BGJ\>49ZB]S7M0-SQK.=>QMX,P&=R:(0=\$+4W?\$8;>;CD./(-G#7;V\$
M>0B[DADHCW\$^YNY2_\$IWS<-.WOIHx*ZHS.H0J(2B9Z65-B5HBV(H[F@EEE(I MVYZ;CH(,^)OMQ#"0-
\$!\Q">3>*>"Z]LLG30'%%;0-\$ \$"Z(-N4?P>.5N[0=2 MNJ\$0;^TPP3?PI=-A2#>TZ8BD#0]<\$+
>;@2<QJ;W.;K!ERM3AZK-NQL"(APIW,?WSC2CBP"\[/*UU,(ECY+UUNF*I M@2MW!) -E4 -Z/LVFG/Z@_WVCX5(
7'.P6F]><."5J:Nf2%3U,+]",472)8F3 MW07[N#39MH10<.GVGDB#5_'NGPSOG^CE@)]424[VUP>
MFJBEK%]HAS79[&6'1">[*34(A\$4N[/W^R[]0@K<(GP+BN1;_ \7L9SZ.N)]I-2X22AL, '"ND>IWR:;([M4&M-
)0G3;<) ML10+4B62=?P!IK@[\$L.)%JSE78A*;Q;9^ \JZ+] ;7ZEZ\$MVG"G[Y?*<\$Q"8/
ML\$)!VBF,J2>%&/<;>/>E;6]IR?X;]H:X/'N^Q[PI#G-OFH1D=NBKOFHYPO' M)D%GA'0@1=5CAM B=) :
2M%>F&!AP \$8[5>C(6%/=.C,LN/'"3!^ -S?&ORD MBP\$?;0LM]]'Z.61EQCJN6\ "VKE8"H\$16:F_"
L,XG\$7G,R9^A+YR?63C(L M%MW2H\$)23\R-F;0GHQ-^F@E0MZ?R33ZUSRYVHTXU=:+T-6+ M'-
 \.PGM2IZI:A00GR(_1A>- /BP9>+7KCN(X)X?UPM7=46\>J8ZNMCC" \K1 M':0@)1EC-?U:0_)KON5PJ0WR
TY#@TG"A;G\H_N_6-8 M3[276[.-PJ@;F/=D[F+@P7E5",].J+?P-98%?(A\NDX,6V);H00.19!JB>7 M)Y' -
ONJ'&VC[^9"@TL'] :HG&>\$'1W@5@X%/'#M/# _@(!I8S"]12/MN@.E\$Y"M=0 M[6@E1+/K'. ,712/+S:082^SR-
6.Z#@[]W>NMF/6,]?2>7.4/^61U/3%SBI@^ MUNE2"V-XU (F_2A-.PG-V-[G%;HI59&M/>
<,E)8&K8MDA.*>A^99!G'0QC2 MCP]G_M;(0QG[Z4N9/\&M#)V(&].V#Y4&?KSGT)S1-*&%_M_+S304 LP)H@8
MYM(M.Z=Z\$7(.Q?5GUV^)+B\T;>ODKGU""ID^(/OYM[-S\$;ST/\VB*?Y=20\ \ MYD):'855@.6S)I>_N9ZGDRN^
<2J3YB;D_]VP\Q]H>M W;9.(VZ=Z(';U:1[MM0AJY2_&-
R'PJX_C9:Z6]3439;II+I@N _>0'48F]%HRB:.)&JLYP%K]7P>K< MK1V\$>'U%=0K>H(:;"0?PX6'^Z<;=>A6
@]3&76\$2]LV4B)3';8ZTU4+B2 MSM/C?:12]=CY]KX;&:(9=0CEB!C7^XD^[9KVHQES+05+RDX(XP*U[2-'B&P]
MJK\$H\$N<5Z:KGE_&"]B.ZGFN^!!PJZ1C=G0UAZ)%4\K*<@B0E* KQ[AV0^V- M_C+.H?
#\#A^)>T07WJ<,&C@% Z2U>VNEL@ZB_&NV/?BC2"80QQ>A\$-X<(N
MZ%T7M!-8E7MWIEI#U*]DJAOR;!,+\4)*VH.&^ .BG (%\$M0I4]6/%XRD]^M8 @E0A?X\$ _X\
[M/3BE)C5'T*\$B0\$FRCW&YNS0MI1 MA
ZZGFR]:3/98!'#6Z'+^+>#>BPI>L^#-BE0;MKWT!],',3B[\95W@C^H+4 MBI\$]HJI->[#4X2&].A<^F'

\$C9/VZ^!^W[,QYA1>-#-^_*\9L/]/ TY1. M/

<+N9E_F.URH)SA/5B_R<'N?][X3N\T+W>.QT1>W,Q!B@\\$}QEN-**%SE(WM"JT_K39:KI :. "(_OC&VGY\

HC: 'QA, S0\$J^ M"M"=L*KQW.O[E0YI6\;6G=\$UX,WBS;6WL7(I_MV8==>%NN'I2=EZ]V'LGV.=

MIEB[CQSAF!\$GBXQM\$J)]!P*~S\$YV6@,\,U1\%^,6MQ8W!G?5AV@^8W2Z,%AD;5:G-T0V8<1C@C7>#S[.G[<\$].

(C:2E0\$WMF6M*?~1P!I(VBW--0?][FW9S1]/SG_M^4&KDZ*3]4B/?@4_94/3=9_9!_Z05\$ _1A@H5H-9

%^_#5V[}\$J\9F;>({B03S_M!)U[_(E_#%C>-GL)GZX;4TT(Y4318*7?DU@=+}RS-\$S:')=YB*P0;)>R)\$37

MRXE%*:#FKP29NQF?XI)C-2NN9GZ)D@B-D9(L;I3+{[.'_80-N\$J/6YV\W5 MS;/-HL+AM99YA0'7@:

(I5"2Y],D+?T\ (T?5) [=P^A-'&MKS63=Z&U[%#CX: M#!#9@BR9NT2=3I-CE: SXDNK#IZP1-

;:>4T+G8Y490VZGY=[M:6IP#TY?(-P_M&5%C+"F7U?*AXC:39[%N^-;XA_8-";=<+&)J?BN=[Y

K^R?;776)X8_M&)RA@3Y6E3XTHSY_F5@I8;HEON8Q!X2>BW^A'=N!,:%H.;1ZD"0P1 MN,%X0\TB']0;#?

R6(,@I0ENW+W4,U*%FM_\$8D#R_YZ/U\SD?4_M\;U\$V^XD/18A)A"LQWP=-&XC83YZ-B*PG\8]'G?YH)\0;9\$)

<^12"?)K,D0 MQ[ER!A],YRXT1]7U)Z#EEX?Y\3ZT*\<2+3WJ :J\$>S4^]7U]?:7P1?&042_M'HY&?

BA]GF+Z8[ZZ%P]4=]Z\$.96L6-*&:FV_.)Y12=-,W8" M^0WII),NCJY+4^B13]Y0E7?6G0Y]>"S99T\$=XJ&13,H

M4\=K(!6_!5Y6?D!H]_T8S8<6F;0L\ P.U3[!I!/_G,@?>>;GD74Q!I:17_K;V

M'G\$2@4^^Z;EG1J^L/3]J*~TD0>=M=2P3^@7&RSAVW%_W\$(1\$;M;.,K_N\$

MG7UD^44VR4*LZEG!/0_T+Z\"E)V0GC:Z)4\$E7:386_FW%.F/KGNZ/9TZ2E3'_M>I/W!H+9]JZ-

_4D+I!8E0^E9_*2.!]!T<'YZUND0UV-B@0%->>3,B^0#_MJVA0'TMM."4![3/W-STYZ%I-%&-

D" _X\&M9I0G#FJWJ]2@+2]PLO_UU<0LA1_M.?NE(%S!JKG00!]6*]'%]*\$ \2,BW={VM<>>G,OZJ.;6Z-

MGJXN"J-UK78IX_M6?K]LH2,96:/&+8W?G]R'RUDV^U_G"VX<+Y0037N>[3PWF6X0C:0A]:.471*_M>6RIP]4H#

(!(7-^WFIA81T*+;1U75*+50!/>E=@U(_MPJ].N#1#]VP]!H?:RFN,UA-F/L>;FOM'O;E_)D99UW16P._?

A5V\73'J\$;YH_'7QP/QM*J6C^6'\W9N=ZFGJS[YKZ1+%

MOR%/[>XIOGU>2V=Y.;05+_N#VBZ,]5^6_*&'UJ=+GAMZEHDN%\$0[/4[#+D-?

M\,FN"A<,2ZNWYF" _MJ2^ZN0>.=+^"0-OLK'Q@FK;#-;@.F0\$0=J*; ME

IG38WSH+LXTQABK67DW+>9VW9/UH\TEMWJWESD><>]J59;8*ML%.=P,MEB_MCLL9PH2AC/%HH

>ETS;*+01YT_@IQ&@?H+BB;_CY^2=;!OL_T*;78W-E;=-8

M=V7Q\$>\$%#96T\E0].J/I=D("8\ \3/JI^M\3*CI,>SKW+0<=%GU*[X#E])WWO_MN#-\$JM65V\KI/W9\<:_M=\$\$;

[1F>14,7E)H0JQ."FRSV<0PL?J5U0"PMUX[_MVJM&B.G'(V8&-_MYI@P[H" _Q*ERVB%WP=+_AM*HU

=';/S0\=U4Q,-?5J:D_F(0N [I=%P7198K

MNY7KVE\$.^0)T=%SH0X=)\E@HN7\6ZCRGA3S#X)B3;_.0PBNG=E))%C73X06QM

M;9ZH6Y;840\"C%;LQW@QBU+9G;>4#ET;\ZI<337)RVXJ'3]Q<"6\$EZ+ME>= M/!>;S)NHN_&

UC>.G0\L]QJORY?:"ZCZ]C_MWAT=#4;V;;J\$<[0F%\Z\16WJ/NEEL_&E18H[OGT5Z^X6EQP6J%N>06G3![:4

M@Y]6E%U(_(!3NHM*W.>^+@MQY^,*_V3EZW"K0+3P<'J9IO,U%(6:(I/\$'5X-

M)75)343GT/7U"-66*QB^1M0C[7X]"!:/7@WU8+5\$1#_M&>[2V'_J[@ _CB+'S7WY---W00>4^]+%YU9GMQ;H,D-

M/E>J.F+0:6^0->0X_MS=+)5[;E/)]#^VN/XM\$D;6;\4J@VE/A+>E3*VMTX;F6\3'6EV:6_M3F.WS*C,;)(:_U-

@.&%(X,@_]AMP\$Z(D4E6A2.,E[AS@HDQT#;@4N>R3C_&U

M_FY]6I]5J%>4XN30:%D+A#B!2XSDG/4M&OU%7+^K\'_ :J@T2!<_IWM^9)0 _MKT^;CG8CP[MTD;K7W76-

=X^TU'TJX>EIAS!Q]5%A=>)42Z%B/'[:(-A'KS5_MM0QLEX8A*7'_!>D_DJW!G#"3B*'1ROSL[2IPH>:+*]D&

-4!>]EGZ_69^VM(E_M??*46/0_[A&V^R!!_43%VEF:P0XB_MQ&]W#=%UA#LFY50L;U5FH"SD.

@C>OCU/'47)U_?)'#D626(=0_01!%0A[Z5_M=]!0?-5\2&%_502\$@G4PT-SW2+BGK?<5-

'FCB#IG^0G=)Y054099HC&(\KG:"SB-*&DC5D_MKUK:&'KZJS5.ET%+P)?_MP.)31_4.8[*//[H-

R+]*'L2;'"#_71]7J,K[TX1#_M,K79VVX900'>66I<_1U'(Y>3JDJ^0/1\$ _X:[_OL&<(STKSZO_M"=\$I]_EV9

MV6G!7XS82JA0Y>#P_E^,RJN++1/HCCF> \7%=WX6#MX\$0[?]H;A^HY9>=]CF@!8N>9F:FK*]/> _MQ*3@T

F*QXBMDTA0C[XE<8GZ^K8')=.DY0U]M#&_]N>C&0*JH"4-K1%>Y(91C"@0+;-RQSM,J^2JM!XH:3#_#-/L

M<]J2=^V]9+9@\$4@KL/U3V]<00RB5^>M!.G^>J(&#H_-9N;*\$I=&6*]<73(B_M3?

4RDSDX>!4';)TG8RBR1H*%WQ*JW0WC8\$'_@[RUV[H050I!#[CI]\$/_\$Q@V%_-;RFX7X&0?G^

M(.MFZ]2G3\YF4X\ZR.,_9^LII!KY<5H77)]_E&X?EKG1_M9AA\3]Z48^V>S8NW0&&AJS.KIWL\$PWAD-[ZJ%E*&4

-7]H!<(0>*UT+.=J*" _M^O.PI_U(S&P!?_Z5%W_WH\$K7)C&[,4*]<\$%@^-UZ,,\;_ =13BK=\L]"_MAY>33PI>Q

0HL5RG\;16)P^RID(]YURU(J5)_F8IWW^A\$W0&2X/J6*=_3UG_MOP!^6H_\$0JR>'

I.CA!T(=0%S@L*FTYP8G&+)S[_M>2"VU+2-/-V(=W!\U_#8\$JQ_MA-OLZJR)+<50?2_X0'+-\$V&JL)^A1%YC1

M=PZDL('5PG51?Z7*S@W53ZL_>EQBR!IE=05(@_MVU^GRSS[KC%X"=S%U04624,=@02S/;#&:LHFE#]-2WR]-

#JED'_9=SM2@7:_M6K:C6G%\$4<\X07Z!4.QM1/79X#H0;NGV2C+S]00-&2D@UP>S[XK,X7FG'_=B

MY0:LM6",_5]YNK%#7JT99"Y;=:7;1UWJ3;-AC@,EB3\$WCY>D7F'GU]_L,.X5_M+A?6YUXB\859JU=C

%B*4<2'XI^V<8?)T,DC('2Q\T+D#HH,ODPGT0=#-_M8]6YM"57\$'0!K?0.Y9Q!\MP_1,,0)NL"Q-

Z%PJ<_\$R0Y@&A[_Q5_M^=DR6XW;[%ZV9=,EJ8WV.),SP%\;;;/:[+Q[07D)/"UJ0J&+?/[6G&

FY=*,'R!W,'F08F7C(>3E*%6AY]_M0L,GX0\5IDF%\7SIWVKEX0<*9>G^>]^=Q

M;\380C400L;>D+02)1)UU+;,XZFCGZ@U=M8'/J(1?Q'I=MX9KP_X)A0))NW5_MG!'

B']>Y/CZZ2<4W^_EYSZB\K\$CK\8_70!FEX[BZ>B9H-=4_]>(\$&#XQ_MH%;D_;GXWI#'_PY3[+^*C!:(E?

VQ+][@N&F3,5+18^_MP6.PJPA"IT73XT50WUX^03IAY[R_&EM\C4\,YD.C_@-5BK\/[@I\$!/_("&!0Z+.5S2934Z?

E]([ZP@2\4,_XM!Y,.(:@U'\$JLW,S;KZ,V_MON/8DT"0N-0V2!\S-<&=042(9'X;F8YT@_M)E3+>

[>,9A*F3]UN-^?)5DR!M1]JPZU-4F]K7A%D.@J,;40PM(:Z9H!%QE0;

MP.73=0\D'+@0)_B!K*WC1U[K01;_MTXUKP25L/?F1LN++"C3+YWVTQ\

MM:"GW)S2'Y_GF;I"1,0!\$L7/DGG>50%E>>7H6[G/IQ;FR_]Q=C@NK+00([X_M!IZ\V-[?H(>)N*\. \$

ZX"7\]"MJ2FY5J1_9J\!]&N>T>,)C'A90J4A3X;Q_[@=>TP/0-AST5G_MW'P95X-

3[DG!!!1%+J=TA3UML4\708D[_M]M\$RC;2-2U,"6Q>--[S+ULP_MW&XQ\BSU4;IBM-;N7/GMGF)Z

M_J\WD(1:G9UH]>XKHW_T<,^%CNOQ0_]@R*R>%E7YM/8RQF&[E?_,B+6F_H<&

MKA[6S7M^&MA'#NP<6A\$/'_>]]\$B:+>>5?_0Y_E?[9W750/8%L9Q0_(J2A&I_MBG05_B+=4_2D&:E*(ET(00(#

(89J!*47Z4@5"\$&Z)\$AH\$B(=9\$0Z@02"26,_M+80X,ID19<*4==>Z3_<^W_NP_X+JG?WMWSEG[&@?&(L,8&OCUP

M5XQP+Q@_7Q*^\$X/PEYC/"2P*7;*![_%X?#AT1=%63C4LM7&\BVB_5K+&4:/# M67L\ .SII39X4X #5#,CHK??
PH+QL=/*BK=I2;@@X#_X:0M8^NFG\>I\NZ"P MAPET9+>0>WMGD4.^8SKMY0=[T]J7UX=.#G M/C>5QRLM=/
3!""%,4QZ825Y @\C@#,67WJ|0?0#TR<'3ZZ)J..Z!7XZPLG|. MCP\$-W5LG\6?9YH\ U&ET02|38^
M-.)\Q,M/K;'#Z+6>=K|!= \$JCCQ_03D0\LI"4LDS@NNRA.B3+M+ _P=D"/50E* MJ".K!5B>>*=@9K'YX<:JYH_ *
|.HS+VX70#M4?G=+J(TOPT1;%)HS(IIF) MX3@|'RYWS>0\0%4WC2QRGJ69|_6'UH\J22HJ_4*.6H6B<@3P*-
;F8*>7>L\ V M"/'=.049UE|MUV!FE'LUV*(U\$0*1\$?!704,GH?M>@ "W5GA(-[23HV2F|H"J' M&L13&J4?
%=:Y('&X@2K3G=9_K<<|7|5<7E|\$_E=#ET.WR9"ZY#!#(U.8,9F4 M-%'-IDZB&9XV3\$=-;-8-
_L+9PNN09J3|>C", 'FBTED*%\$:WXL|Z|4T2Z5AA,E M*-Z?PC3|6E*
<2=D.F,Q^\CSIU;+;9\$6R)5LY>6U25W>A'POPLD ?IYAPF+YS MN(;:QI)G^|_W**^">H6,|?=-
_E<7&Y;)_D.>MO|& M)CC35CPNG6\"C)T1V1I:1|D6>?/=E8H.?S*I5Z"FTJ3RU;_RM^M\$!CM>N2!X
MJ.+Z|0|;"U4I2OG=JKK4?9;-YK+L?PL-0#LED'B)?!+HA*0Q4R14R9EF|HV7D'1:P*_ \845I1#GNLW%Y8XQLV
M5JQ8X;A0Y!;20_4XD=[_8^17|GA63..^ *^ ES*EK?*<0N!)FDQG&C3A5K|: M %& =IT|)2@0E\9|D+\\|?1?
('|6+#[|NNJ0/VLA.;#>2YB|0M6|IE7F_ \3:Q M(-K4N:Z!'H08Y+H\M05(&LI'|2S56LJ|TWN.=.)#-8U|
|3J90|%=4!.M M-,&\/?LR_OMP? %M6-LU1LS_6,0_FUU15BP6C@E4UV#.L(-<:_ ,=7VLP&2H4
M)R!)\$%Y0#LLRZX(Y"-[-0(LW@+\$ SKE)1_VT:FYI+KKP00;73M%! \$5\|CQ= M-
;?:9M7Z14)C'I==K"/_>3:|N<#BL1*ST.LR3!E9\$SYU46TE)"(MBG@!>?+^Q63@/P3K.,0D.,?|BNY_ '
M2C.MU0B%9)\$&P;)=40|KD3)#6?=/S# 'E1<^*&L, (|O'DT&/(|:F9A >R-Y_5NA
M#PJ)|L48%PQ=N\$E8+P782LBG&0CDV!@V89KC>XZ19L+P!HA\BF5-&QZ!\JGW
MX.8'#JH='W)6QS/T7WTMVS+J6/,D\$YJ_W@!82=!(?@_ M1^"1J0\$!>D'.|-LX)F0Z3ZB?* @41.QVQ-9F?
LODE.W9C; ;XU?|Y7J4U1G* M*0MW3,EE-|EY M\K1-C9!<3MR1Z<7\$21#577,^DZA2Z-DA60;YH1/G56^ M&B_P-
G>TR8'W|A\$6=C#Z4S6+LQ"LT'E!\B-C6Z4&'7"X\%_M7(7|G<^>WXZC
M06YT.,.,.R66* (|TEPIH:@6C(R:_NF(>S-!*7U;2;|:/:|#'0+_ E2_5130N MYW-U<3T'.0YT\X6?9M
LOSQTUH<7|6|P|B24|=X%|TBK6#K_V.!4=D710?0 M9_XJ|,?H^U*48,7B5&IP-
YX75G6PW5W;AZG#KTX(<-0|IFSEL_B4H6>%+YG' M08\$4QJV @,?Z|'J.2TCDN5DB=A
;5:0&L/<0)TH1|4VE||J2".CV49-N?T MB08QPEJP,E9V\J|40%3\$SZ_C(:DYVS+@#U^3EY60.,-
|NFP5=70HI9KH M|'1QE!|'YJA6:B9\LI,#Z^0I0ULMH|_A(|\$:N @-7'B>8(5|2K02FRJ<_A4":S^0 MKZW%EV?
OP\$THA1/NA4 BD;J"!\$V-6^4AM10NOZP6^VW
M2:BJ*\D:I=|58T\$ '*HX%^(|TQ:_2H)6:4)E|LZ(RI'T9WN;B6:_CG@L5=G-|0 MVPZ4H2!&
(%;*0(5DMA/8\V)0|Z?#|X@>)0@85#W(??27|M.Y0%D3#@3F7N%D3 M"|+^10DU3JK_.6 /DI)HG3*%@
M#5:Z7K):>(H\NEZ)9+ M7)W56(#DZDQ|"(HB; ;'|7%7K?7HMH%5QTSTC.26A'3\&(55AM|_/\$C^CI75/6
M+WK20AEN?J&+ =?P\$|A@L0061^*D>,4!1R|F.K%PKJW> (GTxQ4:Z)(,I+A
M&%CTP?)EZ+0Y/#QC7(HJ<|'AATOXY\$,KA W(R'61%DNUYP.C-7KY!T<:@NJU ME|,^K45-B|Z_GIBRE+?--+
|''Y(>G0#"T3R7_4YF3C8WG<|<#_XW\R 'N+?P!0 M2P,\$% @)XEM63W\$2IAR\$ \$ <= ! !0 !Q;F-
X+3(P,C0P.3,P7V@N)@H#4" BH ME"!%>N|%(KWWW@E(;PDU0\$AN\<_Y9|SWCCWC7/?N^.-?Y.U(60-/>?YII|
MK07M\$, (H818X_T|931D@(\$!6HD_&\$"4_1(SYPY?1\$/_N*+ "PY.1D9.14E M)
<59&BH:&FHI:FI:_.L;SM'0,=-34YR^>9|C_Q,S,3\$//>DT<|2&. V0,Y(Q7Q14H+F@|
MI|SFR"3Q+N+;6:Y|A77,VGUH|ALOG'S/45UDN<3*QG.=EX|?X.8MR=MWI*05
M|RLIJZBJ|=|YHJNG;V!H9/|2PM+*VN:5LXNKF|N'IY??> ^ P |!P9%1GZ)C M8C|_ ^9J&1T;!PU-_|K
M87%I>645L|VSN|= @#T_.L5% I'2_ 'W|I|@8B+C.D)&1DE&>XB(YXWXJP\$!& M?
E6<@E!B_*YXX5K\$N_.,MV+^98=X|KAC:;853'15%|ILH'LPIM- (FO M?/?>?L78/^*:QR@(24A3AXI_P
&3G22@_F_U*+J_2QWF%!?':L6WS+H>0L M?="X18G56S=;_07H<_ '^M)|?F:5X>ZB>/-)WL^
@Q5#!|J'/#L|Z"4_*#CN_MLC\$!P+CDAD|H M:UF)*G|\5G'3.| \#; >VI>*@Y A&U\ASP'J/40@<^|0I>X?
5H|&N1_U;_3"T MPV_-1(\V5F#2QWT36B8:.\$"\$&BV*^|A10_H|D MB^)\$M@)AQ|!;OWLNB_ |V
M*)>Y"5:_B74GZEL*0/[11_2H&+5T0@|E)WI4^MLCV; \|LE5R-\$-7RW/">@|0
M2!S|[^<)>R/^YP|FEPMO+C|@BMT_ZS/|.6PGHMS_Y@3.(.*)@|XVBM\$|4P8ZHT'
M#=&|%:)'_-.93|5H;5W&M(WTF@3@1^C.PWK^&&XC#VD3_IM&B)W10 M\$-&_>#!.E|,?
U.DWH8VW.\$AP96Z#U4^BB0GZI4/ASS (72Y+3YR0<#|BV0+!
ML%FFPPBB.W|9&.XS0>"\$|TD1A_\$N(!RKXJE|8GQLZT'|=ZS!6_EBI@:GC \0 M=0>6I>\$ZMJ3;|3\10UHX&T4
;@3X_ |%HAC7"GR/>.,A|1)N?3EWZ;0(Z?GI> MS#ZS(2Q5,V_8EM)SKPA%;Z|E\=6AN9,**WP%
(\$&N@M5WH.\$GM&RW_U6^ M_7<'&_YTONGU|N("&4G-;D2B3649R0&!J%" 'XN_9@R'GAWW;8_LX|RM+T
MT^!*" \83@PM^@8|82^ XNM\@B1UA*(TC5A<\$CA9^_AM_U2/H,*@S/#AX"89Z MX:&/#WC,2P!(\$?
,+#@ (BY+96(^36.,/\&*<0|36'C.;YUV3H/AK(XH|< M-
N^'H27|Q(!@#4Q9P#0B*V985A"V_Z_B16|#0ZBBH/0,5@|#{8XNN2!Q-' '< M-0%X?UH8=\568*>R?
7|5K=/D"SL2I,1?V*(%'7Z^V8.C_DMVI%L5_P&@67Y M|Z*K@M3X"TA:Q""!|?E|C "<@PD\$+M|)|IK
IM7&;; ^'4%5F,1MZQPP5EU6 MB@_H;!#>|D!G_T,=0>|=4+I,H.CTL"D|7T%_5;+T5>N|((X%7:HK2,ZFQDL
M\$V)>|7<|D7A_)|TC", [-?Q-GU>!. -PI,KKE>1").IF+WCY=CK1I#8L#(3^ M8@W:91L@YB8/N!F>JTD
\$"";BOL?-U_W\$2.)_FQMLM:0)P08N:S@5%B07!< M\VO PJ6SL,+#{!^S+)DIX+C&2=F|.M/C2G\$GAF
0KEB^_C0S=%&^RDEQ?J)T:E?H'D/. M8>;W>S\$<L%?
2Y|>.>3A1%.9BFTD|5TU%,F!03;D1Y|XMM1T=;D|3585HFRI MY>\$,HP="\$\T9YI'>H,>NH\D@/R-
P+H=V [0|J3D:U!65+VTEG4_ ^L)QODRH68120(SN-"B
M_<1Q,/H3L3,R)3PU)Y4L8C#ZLB0/#>U&5V|7R\36)494'\$X<"R\6BB3^D%)IZ?BB+_#C\CON!0(3;G1Z/%/;G<
M+C5'_2J/J/|6Q,.H\MN1C|-\$=+/250(EV%7;AW_#=7Y|'|<>1;>\$G-?4.\$3E_M2R*&|QK\<2PHYJ_XZ-|A5-
'CRL(,?5CC_QKY=T@!>>E|)!T!:*5^1 #RB(MK MDGZPBND(:N:0Q :QUP; ;I3J1>0>>#B#>|
<2, \&6340:9L6)_|WL_6_TG1> M\$@'|F0>NDAI|=KLWSZU#A=:^ AA&YIJ^&MG8|^AH2USUQ*_8&|!\$3.QE?=(R
M9<#RJ\$FUG>:9| |FU?|1C6PZ66XAH&?+*GQF#BRM=S*|,2,RK>|1Y(H\NSZB MB:V<'>4-9L_@'1%B->C>^
\$3|V\$H=FDMHEMPUW:.,@!/#>'02Q|"/9XE;N|7 M0P.J%5@T89JED_<--
PWY^G40<)LU6'E^A;5<+&8&6+IY57|(\KY:"?LG?L22/3

M*3FR;W3//&'2J2D3+N\$7#AMMN;.\$Z,4KQT74K2NC=IN==Y0.4"D_"ZD,'^J6
M1&E!1WSX\|D;":J02(W\$H=VD76B;VM!(P3_2I0-NV8\L)4^)"PLR0{HZZI:
MLNK|B\?|JN\MW&D7W0%ZM)MGU2ZIQV6XH<2BQ80?I/4>.)@932I%&2A/7|&;\$
M@0RYT5%6|0G0TGA=7BZ|7@N!;.)GS2864-H#E;:CNLU05;(Q;:Y?<@
M34JJ3AH*\V)KU!\2.7P^FL4S(L4NM7\$428 ?N,<0@\$G|I?1THQ/&DR@,Q;<
M.\$."NY*MRWFA=T_FL'9D<6IZI4_CQHM579/6=@VJ)"BSA@8VX5C\$S,QHPM@& MSZP?XW!=5*,:!
(EL^YV!8^21>0+W*Y*2GQVZM0!Y5 M6\$&;2&^YT%RK:CK6FD_N0C8<|.)! =1P'\ ?\B0
UAICM^0=I^F&;J|X"%CT M6P34/U9^:&WRV,+Y|;I_VBWBXFN&+VES#;?F6);1VYUVR<^>X1AG/X>I_CQN
M9FS?0.B*FC>RJ1VVL5FYHB3,5E%463*7]=GCKSC7+[%76|W!NT;IR;)).DE0
M5W^G)##P\$%@WZD\$;SA|PGX;\$@FR6)+%R!0=?T#8?;LA(|12KH\$WG36H9P*DL
M/9JD*CXCF2G04G#EI=-66XU>'=K=>WT/2S8G_*H='|E/2L-SKUY5)9N-*J'7
M"9U?"R:UJP|&M;3|D\$.YP!6H9\2:|L*CF_+^GB(|)W MC57)X=\$G*>8T"\
|{|V<|.)*0)+=0Y^ZTHJ,|BAE#WZ%K:0(TJKD#\$,KVBDBH_,M\0MHMQUZ2R^J<9IY0+X+)= -0M2UHJM>.FK
^=/P\| H7\ +/#,'C\$H?/\ '8) M# ;@ISH/:\$!|"N48,SV"\$FL^>S0(U0Y4[W4]+N.>L&QUMIPTWW63J?NY0C-
FZ;&) '?7@E*=:M#|:F/7BW5J"76&\Z\$+F4+Y0XIDG07'^>L)N\ MBB75I:BW2&^YRA8PG\$F0PA+P??
+V|D;|"&H':DJ:S|7,|:#V0JP=9/66PD| MG9 | /M U30;F2WM=\$TC?1\$0WZA!N-
%0+A5, B;^E\$8CG*>T3J;BAAPZ3:7?&GZT/BJG0YWF.3|0E ?>N-VIT*U\$%+4U\$N57\A< MJ\$|Y|J_YJ%
|'|61A/I'|TYC@A(<@%0/"@AJ#<K?).6R8F02,&WM|WWG<)>VD MCXVU"8F1|:=,R0-
R.4DIEC5!4@KYN"03M6*CL(JP<|JH:F8.C?|HZ.@GT5?\$ M6KE=FV @6I;,C/!39I0N^11=J)X+'K:/
E5**X33IYHL:-XT6I*DO<|2\ 'WY MS(KU,N2M6 Y7*\$?/|07D>5E1U0PA4I5 |;)C|TP0I7NW>41Z5*&Z6+
UJI!^#-[*5 M?4FS,5()R+M%/?&II+2H1B+*SK|EG\;^42HC0>""^.<&2^-5T+R#RJT|SD6X1%X.U"0KQBZ)
MW6MC; M&""2RN232)@*6@65";!S6\2-P\$'0,\ESXL04FV;)OM=[RH5I|KX3+9XIRK^
M(X0Y\3ML0+&82AXMWX3'?9.X=W8URURM.P M*+NV97,KESJGRB\071X(.Z?V MM'BHP8+YU8"NP&"8S 8T?I-
U_SJZ_ M+XZE106\$P- 1,UB\$Q@|DP4_N &SR"[RXL|51=B7LSRQ#(|(MZ0>&4\RVGHB MEQ@|!#N8|Y0\$:YQ|,/
M^Q^6S2=,B4|_K#+AUS4<|2?_(*-*^HWL#%B"X?WVDH^0T&DC.L0+0^7)=[2"#\$ MFM?
S9ZXMM# 'J!0'0F)7JXB->BP"4*+* MN=>),SWY@);"0.X8|R;|1S|0FLQH\$8I^WZ@>9|(ZZ^V73NGF-482&
(WWSB'5.0I3LMQV!<=P,UBXJR(E,I6,G"
M*YIAGW\$K;F(M|9XR*AP;ZC9TYD!3\$WZ.HD^LG<_#)V%ND|*;%9%\=JKHC0>?"CCV
VP0W\$^,PIG!)BMNMY\$JKOR*0&_FA|?;HU;_9E\$'5E;-6#G'YG,X M2J/^5";.*)E"+#A+3_-
|0B/?|)\@L^10>2^Q|JW@,ELAC=,(B5'B"||>SI.N MM>*;K"P|J|>9-
!M%)C\$59VY;,G0403TL"64\2YF.9,6;|)|14CC4YWU7D>?S MDQN>1X++^&LK3V11R9F>>WEW?U-
+A:0_/*D\$P"XG2_.=45U|\$"X=600013*R M3'VL@3|\3R'I;VXE1<+MRD.D1G-[4HDBR]?
_(Z*X:/!R#|AS2#!C)1BW?%WC:Q.G,Q.SM1H_P?FN3)Y M#H_1Q_%6QN!T)/F2@T_B#|;.%H<|U'9\$=L?HDEE?
_C'P""5^R M|FW_RCD0VUT |-(7(P&!MU)U;&/LS(!*MF;0T6QL1\7-XCI< D&S2P02P MV;.5+BKP4
|B5.T0S4B\KP2SK;A3)J3;_)?"?7PZV|8!|24\!|MW0VR7=VQ\J: MU0ER5<5_&|^VY+"3-;SV^98?
G,_')=1NRX&KRF%I.KW50@!<;*DV\$3J2H? M0RG K02*9AP0(VQN+LX*(X:AJ!5.KE)5RB@I|M>|,Z?
=R>Q^<2&DM:D_RA^XT""|C|0RTJU22*2_VA.J0A'|LA_F'V(AHV+;VF)|?T>G49;FT
MW2WW0R,.S^#!"0M"GJ^107W^:H,:%#W_5(/ZOUKXZ)F12^;-|^_.GR1YCPR MRID1|R'DWY;E+Z-' B!2SS-
6TS9%K(J+??G|IR6^G2>'0Z\$S^%@7=9U"75%R M>FG6;!U?2W_R'7IU|>|B^>+(-
8K62B>7E3WX|Q>0==ZE_UM!'Z)F?=-.V' M
W/NC;8:P>#2Z/!0V9.CCU\$APDXC&GX|D5(YX\W\|:T|UWMS(NUC'E4^(XMS M+K\$>L>+/06#@0=/.-
+|.)G.7MDEV|WZ/|P\$H!00B*3TX'5A0QKXC6K5PVP|R M1E%GVY>1T6'F8GE|7S14J6N'J1S+4V16/\$
&)PBD=:Z1 YT15IJ67H|L6HDF MIG"E:*IH4V^,)Z?R8U;>(35DE(OTH:P+C.6|48X3X* 20UEX?_RD0KPAT0*D
MJ6Y|8N*|0U;PX85|. P\$?)X ^(|<5V9YF&FWPJEA_9@0@)PK0L\8\630V|*C
M0BV3(H8^Y%ZF\$@\$D|#7CG@JM^B_,\#*(X03F^W.0W+;R/-0RW\^R+63I#TB MV7'E10TQAKV=63):I^
P&R&DJE>|C(:'0|BSH#U.6,1C|,\$8A(4SSE/V*U^1 M_VT%UD^/09&Y"PD3W(??
M7Q+T=ZD&AM%1W>AF|E|ZM<^3^2*|CN*NN#J-T M!XN7K;UZUR;5W"/T*3ND=%3TF!4IX8V;J3F5GDBN);-
Q|CD"4)_P92EJ M MZML2L*?J\$#EG6YQF9.SP3E0)XT!YH7;GZL0!U+1&/QDK>;!0B35&\$P"UD;S<
M;YCP4F^K(H/*)=/?VT6J2RRE\$9T7EPP(WG(\!\$IV%8M0.T6F/R*\|K(S2ZN
M1V\$|@PXBVL/=@_3\CXHNV|^8J5=;|.T1A;V-,#|35GAIMB4.7\$7KNEM97NC
M\0G/|^6?/I_LYJ1W6HRV=_D?"EZ2Z0.JX|0.D<=U0<|UI5ZTVE8UP3X6C411 M;FB@NWT4ZX_(H"Q5Y3'&-
RL*"L.'Y^KG7XCM,%|C^03;NG6A5NTL35H6#;8Z3I!JMM%'XM*'(1>%" YTQ9,|/&=R^AJCTX=_#,MWN7|+/00?
9VZ7|Z: '%JK7I^-/4XT*V?>V5J0W,;/S3!30E|Y\$0 !AA\$5WA\7 M0??X>,RHGV;L((-;+!T)
%HS_U!86N/D+1J=C'K,+S(_#6D?,0&|)\$XS01*Z#)DY#T!F'VY5P|K^"G/T9K!
MKH"Y%EHY3LJ,5|Q;1Y9ZJXNH.D_MC?:*4867&_\$|^M2D;3\$W.TF|SS 76A3P?&G MF!S@IV()P'UC8KZ!"
(#ME/X<'NZ-2N!2|U-%ES9F=.W|D|_0H|UBC%_YZ| MODF?^U('._Q_V')24)
f&.NVH.D,=G0*A1>>;RG0H%>9R M2U"-S;\$!1!@;-T?+I=+/+WG@T_2VSS3W|U<%K1ECPTG9+2Z5G3*==D;R:TR
M9TFFKA5<0I;!UN=3/;Q4X"V)EXJ>2@L:/@_4&=AX?K^,2E4U/U|ZA M=>Y|IU5@|(|34X;%F5+
f>|B2SA:8J9^Y"LI!;|3,>#E2,I&1*NVS|704LNY MA4;\$K=;G"2@_ SKRNQW(2LC-87E2;-^X_T%
20|)4|I4R'UDX_A+2>>'E)|0 M7_I>|M11.B|6X+3)>-F!_,VP@|6;)DPIT%NZ-'2,CY9)0)W---5%Q?@|f|
<'^ M7(#204+|A<4.PQNM*H9P0C16X=DPB7;=3\^I"GT#&8T0G_FML>;E>F3)101Z M<_QAV_HMF1#WHMKM2\$-
H&|?'|0;42"XS,7&|+^(|^*3!1XB6K|?KP&.V#=#Z
MM:6S0T9>UD;4E'VM%US+G&*^7RP;=3Y#HBV;G&+I1; ;OZ#9HPKTQEO/\28HL M?YY1D5KFBI=%|BX_GP/?
H;YSA3)U*ZU0^BC;OAS|_E|KQ_8NC MU+,C:\$UE&+=!D\$2#ZX%YG=6YJWRX-UF&-@H*SM2T&K3*9=
<^L87&ERRJ=,^4 MZ.6B99HX6S.7' MPOA.+W!H#9@7#G\$;QF_E+UEZW|S!#X+@B0\Z@^S(>F0%(70JB)|F??
1;XB M &.B"EAG5-2\ V7:NI|;R#F.|@39>M7<^8A|YUY8GJ"NW40-00&KM?'UF=I(MK'F.-1MX/3_ME70,\-?
P%S(K?V\$>|- =YHE20A,Q5?=-RW I%>&@NA19>+7"MS\^0H?T&RZ\A%H|YQ=\LQU*|9M|&G\3VL4I-\$P

4.PPP'!E/S:6T3"0T#%Y MP0@N"25CD&[-J&[Q=N59G=#U)H \C>=HBHY91'#)1.YU-6/T8L%+6V.NC0'6
M.'='%Q)S&- "3L8&?S&V(\$ALH 6_%(@:F8'!&'++M;>"D3_0VU8TVLSGS@VPT7
MN0L/AX0W\4KIRUK\WY\7\K\I(S^ ;'5\$I?"U1&05#^2^^(#TA()PIJC?B6*#P0%J0R\$\${E69>UKELGS=
IU!WVI[\$I0,1%ZV-)! 'IK\[@7F02+(E'8QN" =<9R>4'E +VBSCD[+;M'K?A1A]=
MM^Y+44VEN5:/R^J+WLV'\$I?0 1%#0>*95/[41;:?:=]#9N&<7'U"J"88V0 MQNQF2=SH&34GI'B+
[3!\^,JW)NJ5?XLW>:NO/K1G\[\$0Y\27N,%->%R1(:U\$_%@) !KW2 M\?W#)00[CZR()]P\6S@LVNR6\3R=/?
A&L4N 49U0-'P3N 003-1%4(P-FMC:!'C<"K\$!FD#D/[@13S\ MX8^FE-W?*DR4HG-SF*_2R\U\$?CAZ,-
TC&6W\$V) +*PCS=:/!CR&V\>0%CGY0 M.N? IZ!GSB/_PNP-VTAH61^:*UQ^08,U53"]201WC
Q5">3,D<3FDC,,FN M(P0@8HCY9&9'!=.S\$HZSP\C/U9:/V0EJ\5TM'*SQ#?&6\9#P?,/16JRPRDF3
M\;:X7H4XB7/@MQ0?C>.4MX?A&MN M63E+Y\3=M)!\$Q6?;KT2_LGG3K4-'L67"#Z=L
\$FY:#_3K'7WSDE@NEW37 M?E##-35_5#%;-[N\].9M0EK7'!?'>*DZ1;PA?P MX^C"/,/#,M4KL>/B&S0
ML[?Y.1-N,TOM8Y/;DNN*7/^N[U18\5S>(HVJ9Y(#/U@9,A 6C0A+:5[:B1 M5266NJ;:U-
LSWDG8XR.1^N0&X>TN=M\$G\3+T4;R@N'^'"NO.?KNGCTN:H*G0 M'@2Y03R%M?3W\T<+M97I)E,AHY-CI34?
\$[]R4@ SJ% ,>*^[\& /.ZSY?AE: MJ)84B\FKCRC1,RH.>]7^>Z76_27--DW20\X-
&N#2PH9:KAN7%ZCY7^>^2(+ MXGCPTLF,'/FK& (F\G3V\$PA &L/(\^ Q:L^?PVA'X)/ :<4/D'8Q-GRW'Q3@\$
MGJ[' \C=9.EC8SP5*P'@-B/F:<\$0LR,-1\,^/%EHT2*RJ)!R*9=)RZ2E!92"
M+)@)N9GK,.0 /9\Y>..A8J*M\X33/,1B(="Y\>|C\<*F^;/<==K;LQIK#/,
M.:!;75RK*Q^N05I4\Z2DZKF=QU@4-: ?Q@5VAE,VY>Z,HV\4PD.: (K-C-\$P>- MBA\#/&H0?
6>TRR*2GE_I^1QRS<5*0\ -P06F1(-/0,"C 8G M!:/+VW>A5:=B7SHZ6P4^/R,M==&Z5!
[C.\29G\$E=D"2BNR3;+SBJ+M8X>V MN\1PN&);_*!7/\$2VM-#@P)\ D@Q72E\IC'00:0\$-?Y:
[KK:;9\46T8ST=IK=, MV2ZZ+);WX83^J:TJ 2CC&F)L-6T^4UAN01 QYSSTJ<0[\\$U+7SQ'/I8WF0 T M?
1YF!\^]APROR,UL/ILM.=)! \$H);YF%WJ) MMHF_S^X@2Y#%!
RG'W>2&8#\$7E6#6H!=7:;@!T4.;I0I07V*"NG40_V;0)P309%N3XU" <%T]E#
M##\$2 =UVJF.>5;ZKW^QSA>IDKZF4TUYE/P\/*),.= B-K*^AB%L32:;!'E
MSKRK\$7=\$P1D5TA\$W?*" -40>W!\&Z^YQ;I*W9@H+!D1S.=N7M+ T\%FM^AB\90 M""^!\&9C\EI85(%?*I9CZAV-
7I.?)#);B1N\!,C17\$B7< =SRB_\$^2.UM1 MWHJ3 (L;3X0%7XE8JRJL-U^>S526K4T\F+;'CAY-I0>
;68H7HVG4K'1-A\ M-U9SM1 2-V&]*+ \ W=E@1QL?2'M;WJAZV;A1" !\SY M5L1B;IX.,
<)R^,PFV*372IN(ICUM\$JR0&%/G9HAL^#QB\5\$6P'/ "JZ2&=&B
M\3+6&2\^J5.=*N<6HK\GS,D'/+,A1!&+R'SEU?2>+<8096QK> --:4+}QT\$-N MZ&LG?J%JLC3'WJ2NE]"1
R([G.M?EK_0?[-+5+W_FX'(MWZ\JV\?.]\$/=.VC M_WS\Q3T0NX\$JY54 'QZT>7TOM)T %,^\$W.IAN!NU6F
Z)=6J\SCH MAN526#>WLD5\2/PLG>TL^|K28%Y:9<57V^J@J430H*+-?I;IC9WYS)Q5Z.9%
MV5#76[X ^QN<1#R\,WV1FK#7/8>2"*:3U\C=(BI<;?X@_83X")XU00D" S1F M-7\$B004\$>BZ!E?!DQ?
#77C)9>KY M1E+)M+ \!X8.U=10,5%QDW!,P2I?0WKW&_107(02KJS*?A;6PC4-WQ?KI0=W M<.!Y(\AKZ9V=1-
>?7?3?KN.-?K^BQE7W9UFVPA/!-.\,23++E=-N\>0"[N M\9SQW/-CJ?*!'P\%CS.N?0+G/\]U0_[2KX6_00>+>
[#+-K62)S4E^:5E"<[? MK9TX)%GM\5]=8AJD ,_WT-VGA;IR%!\>LN0/R74_2Y'E04MC7\$&GY^QZ//!;
M86]>E\0LCT#59T2ALHM/*R<1[E(3&\;WQ Y6.?@\$^@#MQKF\6*&;DM9N96Q;8= I].U\|C,%]_ER2\V*S\T0 M?
0L^)\$NUU3E%GE'4\IH5A0510\["1A4^80Z_,IV YM-#1SUI9=U2\11W)>K\SWFNKS-^]5 ML_K>2/*
<;7RP!ZMHVZ(J:%G#%00>\$169_L\ MV2R _KJ(IRQ_UY4@N=DXGJC9G@T+%)@NIYXYL7=/0;)\DF:}RX0
M<!'Y\UKLSPYDZ/E1NJ'L8CYR': 7KMVAX\$V M\[\$V5H&:N+HN;MA I#,M/^G%V\1IT%]Q7N,1[X/Q6GNX\$M
!@4(K590M 7U5_ZC^U_D M_R@@"7&C\$H/8W5KG)\$C?H+&|N<.FMSPDL4C#M]"_LH3Y\5\]>FG-P\&7Y^
M" +9J)A%.=W17JA5P*Y@E*! "N,?#LH\I)X37%YX\$=\$\C:AIH! !-X/A=,(0 MET?
5+PL/, 7*KW9\U@V30>90T##>J1\BW\N;2"X\ ^'F5S)??E+\B7X,V72'8\T^KZY@)DHL M/7)0P6REKPE
[QFS\$S[?TJC0ZTE>|L&]*?|T_R?S-GDMGR!0\,/,;="@\$38: M!\^XRBjn>YJY.7#3/W_Z=SN^I/\$T,
[]@J1JB9KD402\)]*SR+ X! UW\ M/POZICX1L(: (6#U@(\MZ#:@9\R<=&V 7_?+\$+U \TG5&K ^@E5\X'\$U0^F?
X54 M5/_>AL^M#7CWT!+*JZ7\$C +Y=LP\5V+25/W0L0/?U\$B&<3RU90-00>RU\4V/_ M7#0A0>QSEHE69R.2._V=?
\$8#0*3&(\ T1<+E*(X+*HP4E\$FWQ52-69=A^?0A% M=-+ UES"\$-D%WR:M(%(A"!\FR TE&
[;XC_M6F8&=5HKT^01M&\F+(<:5*(\1%3D?S\BG7IE7J\$3\A/TW:%-U;/'+/N0DWA7FQI%_D0
M.]\N\+/+*B*W\01S_2A\$[]R/.^VGXGE(K5F)0\GEH7E7)\B&9LEY6X'#- MPX92NKZ<+*T>,
<89MT0TFS#FUV"56\$RX,9D0>,8A&94P52 M1^!]+6S+[;,>WUST0=-1(B*ECW>\$SHL M*29D-M;09I=&02GS4-
0#WZF4JA@"\/3+-[C6QZR4UJ)' ^DN%/J0G-LS36W; MD%;@RUAWA9-<>1Y;Z?#J\Z,V++!0,Z0:RIKP.}>G?-
A^VB[Y0\[@?K9-8?LK MBV]_YAQL(AKLOBGZYDAP?P^C'S80&F)\DL1F8;:!\V,2A9A5HC?3(5DQVT*/P
MZI7+YQTW!9>,\^)\L.A+=92%Z5^>RVI\$[H&18\$:P)1HZUG:4,0#EEW/25\T0& M?7M!.A/\$FEW
M>2/\^!;,\$LFTRL/&J?0YF!E&Z0II(H,I7XK=)25WHV350K%NBPKF2P-;B3\ S M'.A8\;96_+Q6*V)F=
IV\$>+H:26KKQ2_3+&<@|8+>S*-00KLQ6?D/"&0QU9>LIT
MKS0Q*I>FW\7<5!;1)+^+U<'HH]*;B>OSS,|IL6%AG.2PET\MK"0YT)%A&^G
M+*X*7^5GTLWL5C*&;@40K\3"&C3.0WMFBGL:;!UI*8VKAUQ\-'Q*QG&QICZE M\7:_BEJX,\LDV*
<|'"I8/RM/ANQ , M:6P;@?"KZ(4??+<^Y#('1=XS3*K40J'"^E"5107/;,'E1RY.<,M%2^Y9 M:<-
"JB^TLKIXS6\$>)\7_6/D\3J4#0=.L-\-T2&[[:Y)RGV/VK)1#U,2WTJJ MG/.2+>%1@0G.'G0EI
1K/ZT^UQ\BRS_8A\I+0989"B /K^>7!B =D'XV@T6 M@5\$AUK*(U)/-UK&%\Q4,S6HD\3BP';P(CWM5=*;+)
MX,4^U.\D *56&Q= S0E>PK>5/)/055_[+[\$IN]\6863J\@AG(IRLN41W.CP>G#A7VG<=
\$0Z:;B]=N\;V9E094IG0\$SA\ \$ MWQ*^CI_0&5B4K-4=BN\0T@Q>(+Z\/&- B5'71:L>*8YN\<7S'!UV/1A=2\|C
MV@';\P12H)P\47G-KV^)\;VX54+VHC%FUH\6\=W8R22&WWL\$W&3+-) M&,P,^'=00
4=*%&P=50ZEK)W^AB&FHGI^6\2<+=+8=R#|=1,[S\I62'0@:A@ (2S&V6 MKI*# 75F0GVYA(?UCA \%^9?
G>XCG70S?^BH5!/MN'S"CX2TT+ M2?0CI9"@BSSWK0=]J\0)\$I,?H?>#N0:6/0=;:@F 5DWDW0"E\J:;+!]/+
M29NSG-&Q2N;273\W,%+1CQX+N'!M.B7ZH5GF^+&&/&JE_N9L^+6[:!YR M,_S("7P=H!3Z=D)?
2+QY+ZCL)8/90^B\$4;F?/)<'N\90B<:EY8/QYL W&0L^
MB;D72C!=""JGKNCQ?/J6J"#PAWY%Y9\;DI5)Z(/=Y>5'WJG_,1=.#V\ZYV(<^ M=M\Q^FBEA4F,T;CQFAYCEVPW

Y?2% ^H;XK, "7?BY_P\F#T\2)X) Z] *M!Q M#R, "SYEJR6D25\$B?:9+).LM+'IS"2&% 9N9
MM)0L/:TFP,4I&\SHJC54 KQAB\5&KXKI8C+U<[HL\HV\$8T;,-'-'*0NR5^J MS/H'"BV3ZZ]=P&-1J.A?
G+P%2/21Z94?T'"\$B3;DU4CR@(0^5WH:F)RK{U*M M=%S%KSY:KT#=U2G&_HQH8_4)6D84]#03
&JL8,-1_G0<8YCMMS:YY4\$[\$9'% M";
(X%/6UETFJP9^);M!.6T^87>DS/+:JZ7;2{A(<:/)Y}3V}WZSD=H.H'^<% M})@-0!07W)\$0)@%X;B8?XFS'I-
F\$A?-W;\$II%2\$^5#8\$N-<>IZ MJ!!6B[>!(!>Z56]+0-R7NFYGNV4UCL]B;^GC%3DUNUJ1Y)!VT>NTS}[RW9
M9%10A65W .^\$=@'BH_?8MMX-5MSRDQYD73YN\L\$>\CB0QYG&[4!KNDF([55[M/FGG%BCV[...R_64VP%2\$QF-
@fGD70>XQJDL'IPWDK5;:!D+WG?==*TW3> MKMRMWC\$A-W20;C<_TCIEPKLF(+HXJ#NT
)_.^T!?)U>_.\RN;U:R"}5QZSV\}S8Q&!"5@'TZ!_54SR M,-
<+,:@=6HBX)"+"NQU3U'J%PT(#)\,0(C0JU7K0)+YX4L1XPY=,
MKDGEF:H;I]^EYI8&81&M+=L[MIY"MOJ<66Z;\$\$56_P' V5.H1!YK.%(3MF MFM 60#S6\$1TSKXUA"
<)<IEU7A0X'&DHL?LI==++#G\?0-M9,V].45?)^F):=827E,BT_0B.S@12
M31WTV:\B((@)B14;684,QD0&SHDVT3-@4[H^INW-?+'00U_8^E&\$R \R_Y4--MI;MW5W7A7@N"
@/[47>*B5MR<2?5W?PA#3:/-11E(XAVM!\77718J4W[>>X*BL[=?6C9%H\$?V30=<^409
M#^KM>14659BFK^PD""^,G'=ZTSI\LY%G-C6RT)'G8*QF0:652+ 0LEEHR3A) MF"TO_%F?
=0 CVR@03V.GK;:U78H>8L[.(<+)T7U9&N*B,V*:/^?%XN+5XJ#A M:.A[|HNY\6.-Z0#50FB&>C5V2TDJ18&
7Y0@6SY123A[K,7Q8XBT!CWD?DT) M>C&?M R_&&*6/G^9;]\$,]+ZU([186M7;B[@6<-:ZF2B*L2+0J+7%
[-5: MOCR<@RMN9(-)H5UFY';V>QWP\8>XZB@[==+M8\$Z,C69)\$H!/-0!-) [1#P3M MZM0%N^3IS: 1X[\$A-
5H.P_::W@ *0\$@P9SS:>^:80%+W^589 M1JSM/[.0TX20ESQ/0'?>(7NA68=;T&K977@ZF'@)8]&9F^;A-
6%4^/!) M;03@VR^E>#&Z@LJ=]7+F5'&G +MUEX\2QB04I6;?X<2?UMT\$7 M[\$9]VYW2A(^-
Z2>5'!VTG:J,>8N/SB,2F??*Z^G'\^N] AN,'0+!%THR>?KE M6X7 I71'] [7058>^>'+?T-RZ]_Z'58Z00#G-
L);D!'M/Y^+1>D0-QGDKH_1J M7I#+'NX69F+?&4-1:9,,NC@H+7/\R^?'U,42]C\ LD\$?.F4]?IG+8RR;19
M90/]C6(T?0.2;GW7@<7#J)U#H/YH^<^318U@J_.R6\>-%J&A G-2GS(\$;BR0 M:RL+9A1@ M<+T=;/,XVUEP?
H0N6.W8ZS=:!QSSN&WR.08SCS_I"Q-K8@*LD;W*GQ%"^RMQ'1D))?D,XJ]*<6/ M-?;7X\4BPP4TG6'T
0)5)SFU0AZBC3, 1.W["J=P[Y[]:=WK)WHC]_BW\6? M<5RW73(29-5;1,C!V=%E8
M'N\$4E5R1:%Y2Q\$A21\DY5^N: '+P8_R-UT_-SCLIP5G0UL8(2D\Z=?YX%_6][M%I131Z]1G3A=N@'E6+HW0._
#1ZEPF2KUJPP7K;R'\$=N@!16;2=V)QQMK6B MY^9*I&@'L*>_&G_N 600RT7>3_3'HFERL. ^U^C_Q?
>H_?];:\3JQ++-X!AX MJ+S_G=P7;((2DWZ@)?2"@*X4H@H_FQS,5\P[]@20?T!.W/)\1A9 M/_526^A
MR[^'P]"R9X[!0,E]PI%ZVQ 'NCI<1D&B4B?U"DQ
M:5ERMJ=0(R0XDH.%&0Y1^8_*^K%##U>240);_7T7Y,^5N*.SSX_0-5_E=2 M9N9F5J=;_JV09^*X/I?5T!<-
#1I_:LTL?Q=<<|T0SSH'B'GJ]JNW<|H|:UH; M\ M'7:2\7_;F&6)\&Q&QVG3H*H=VP]OK3J0,@X9)7<+=6[+-
19[S>0PZU1V&J MZZ>I_<7+ S5I=:3*_^E)Q=*Y"[FNU8B@(_B[/V403Z6&#L/.XE0>;Z_K%
M"\$0BI1S*T=P0_9N9/07>40L0?Y=KZ]R3@<,G<1J'S)S=/E]R^'L*98GE'L1\ MW59J
&\$)M@(\$\$.6BF5Y3>D6[VJJ%1XU#15NER6)]"90M[3%8)N^ "7 M98W-65""M7?BGUQNDKX2IW;3Y/
ML9SHK,'I'G)CZS[D;T,2I^0!:0BB:7 [BK22;_P]*X\$P_/J&OM[CL_6^P15 M\$A<8+0>SK>!HVO_!WG>-
+5MZP9%4>F] \$Z6*-)\$J(!&5+B*@]*+2: ^A%(I\$N M00DH'DB1(M)[C?3>\$:23A"
(1H08(R0M[GU0./00>>1Z1Y]UWW_0\OC63Q5R9_M_QH9XQ]CS\$G&6DOYMTX)PLG;U0<+[]>)\)LFJ'GP-
1X%QIN\$_I9Z^>) &OBP\$ M<9"FJIZ"N^NJ[,+DU &RNJ8=0[&!YP,V,WS_.YH2A]+NHR+.7/!
#YNJP&N@Q;UZZXZU'_EF M\6.F15+!0J2\?7F]QLO0BK('=2Z'FBZ2"0(.2HN1&=7ZK"S>+Q1EMYTCFFS
M*"="^8GINJ//QP!Z%/K"%"H03IB1_V9QAYF(U@&%9 M=Q=#=V+/H)0)F!(@A_U6@<67>+_\$^R7>+_%^B?
=5;Q\$W\$#ZK)W\ V4MZRNV\ MH=M96)<<#Z"P>T&GG9[,<=7ZRDW"2-WA_/1X0/7(DB@>XXYY*B;LI_M^6_
L=GR#Z&SH\$2.WUXU^MF&/_E*0_DI\$X"\$>8KR9&CUDHZ;LK@-QP"HY_!|
M\TC[5@GX;C#P[%]=\XF\OFK\ /00/X228[JPE#"2\ZNW\9JGIH-KCX7_NM&&+PVD#RXL/08;R ["9T]_U9IQ'
M^%;?H>7*I^ -9&V@P.-+YYDIV-Z4X]-W^W>D0-N20-NRC=P6CL\$!36\
MQ0/2W'_[0)I]TW)4TW*\$R!%/(&)D?#Q@80>S;_5'<=#<<)F+WN>C8B\6S\$
M8'EU)G2>#VOWNUZEN,=E.&W8Y/PP=#L!)1YT_Z7(Z0ZTXW>3)8%Z&,P(BC3_M"30LQ@-8-+E^0.=Y<_&
ICQ""+J(^BM)VZ5\TCIK!"-F6&*SS:PUCQ9M3F2@US>;#1\$^C\ M\$X(EKQ=9)0>(RA?3/7_Y71P]VAL_0#
[V8P7V,-P=J;_W"/LSOW0)!X_2M7'_M_FP7L:9<8A14PVF>@_ABF29W00_M-
+TEIYTI*_Y.\@Q;7NCO'3'E,0HXZ)4/="B50[,G%TS*
MV^FX20VI5S:\$['@(J@EYB_ON?JJ)%*86;>F)M8=#PCF4'L)1>9B;[0JVG/,FAS%/3TD MN7'M-1*)8_&XS&8-
7"W'PK"56H<#1^-'!&)+YJ67H ^J=NX+^/OK[|=;R MWQ!(6TX&'%?BP]/2&X;_W#8@0-T0/GSVN
MT%*T^LMX/XQ+6?+V)J+;=#0X_'8]NC#T:UM_]L4<8;)-+G>5^+#.0#IJ2_M>R+S!)/W0G&RR@=1G:>DAWC
X0ZA*WKHXG?ZB-,L%SS@WBD><(JM@Q.0%5"; M&=>@0#(H'0,1NR[L]<-3Z!?(+Y!?(+Y!?(+Y!?)H'^
0D%\@0D%\@0D%\@0T!^ M@?R?!I^R1=YFZG@Y#0KK[];;YU*W)\$?V7^_WT= M,W^ZD)G@?(?
PNLU@J]_@R=/'+"VX_\$[K;_15&G+^11!0<>D1?57.\&X\$'
MW/U\$G0*/_0\$Y:QUH96SX%.S4IQZD\4=K%*=I3X=60^D_P> MHJ5)Y?0+R#ZB.\$2FK8D*]=*H&Z\$8X[B_N<
I>Q6]I1&8U;U;<&CZQ/%5IY5. M^K7.\';M%IV#1,J0WV,\S0:RNZ8N<<)N6&'T 4=Z*I;<_%FY'CJI_G_2/08
M3>BT1/7I)):A47EA<+,9P2YF7#F*N]I]6IQIHM;AJ/5,I6CCW8Z4H#XERXXS
MK?.,RHO'UY9SH[,IF[IRRG7P/7L(G/GPUVM*\6[]02;f&
(^G=H3DV[FL)6]S\$851C*5;3V,/E21[V46=@],#U_M9U]\^06Z3A_-3CB1\$]6S8 _@P;UW"E%<3';NO(+];0J
M5)=JIRR8G'MW0UHB/8!\ \W\<[S0=-;9)Q@GQ_QCE9>2D+(W9QY72R:6MLJ_M
GV(*8>TZTHI5L7\9A9;;\Q*5G:/A_Y@N_%4A89095_QOU.JOG?^W=HBE_MPZ3!4H^D/_WZ;D>>*NEY^NBHT?
9M@5=NZ4U:];;M^M9V1#^>)M> M,%Q.%(G<')3>+^X]_4[?1UY,]W44G.,*/WW^X55[87]4GG\6;IT^BCGF)#IQ
M'[HQ>*(!; &PW0-1*5MG8ZH8>>FJ>9XUW/T<JQ?+AC^OH?#0_G=;/G0%F'[M??(CD_ 'VY?#\C
'S''SOMIX<85FJ-8/\$-\FVL\#C>X/'U:D[@.(ZM) M[&]Z0)??:K^PDZHRJA?7'-
&AW7P_+?])"XPW/99VVL\$KKPM@5W: ^Z>534*K M4K\$F)MX:\[HJ'5:E3://]=K=G0E\8#.]4V1UZ
*JS#TO\$;MR2W5['7=[2;_ M&T05=6W>JIP>WSQNL[X9&%^ANW"Y)XV3WD.9@5:ZU9Q0(W-31&PZ+_MS4=;_,

MOY_+4#!"E,^]6G_2RXS(^OR+EP#XM_9?_I\H<)&GVY_MQU/"#.2 \/*+X- MW;L"F/R3GX_.\6I--
GLZ'U#=:,3D1#PF XV+4R\$=LH.0L#2C<-(3...2\$W(
M#;KG&!IHN5FA1D*'M,21([K\FTSZQCRZU&F0^4Y:TD2A5Y8:??>2M|EB+T-#> MH*ZPX8|BP=S(/D-TN;1N?
NA;&ZQR)YK. JZFZAMNBC[0:/PJ6>7<#K9EHQ8Y M+K#@,P=\RR.PP/L1<[;3I&\$N<\ZM !;,.0.Z,U+N_LD#
[W65RM&] M[NSZ9Z6V*0ZWPDPN7>C[V0E:]8=!!_LDTQWZ@AWC4(&^FS\([I]3]\$/1RW3== M-JI-
NTU;ZU.E?"1&^<3#V^CL:0)84(:]L5.01X%ME=;DC'RZ(W7XW7?14A?5 M(^. [J-)=YQ(GH;VM31QI=< P-
\$'G!-/8.!/>T!,Z[,WRH8U"#R!%TV=?MN05 M>F;@NB 3-:ZIG2-[X2&3,L^#?EMH*R/DVCH><"FN\S2HZ&PAX#?
[+VZ[MC,JE[Z<-PP-"WT#N\$"@#).RB.*;Q@'A^*!P!I(3^)\$% L215>,!B^"84'H&C M(A
I&XHR|R)0V08/!"!W"9+FH8-&4H;.\ M&H0[/PW=403^X6]/&(K T400G|H@C&C|;VN55D;L-
3P@0P4/6.C8)BPY"#+6 MN*X ^VG# T2^ZW_2)U#Y)Q+AF&:PRM,KRGC 12DHUC/:L+\$U61IG\U\$/*W#
(W,ZTQKPCR*[?M]BJ^WP)Q5%"AN& N/""0 M%498S U:9+9*WU!A^RP=#'&.
[1U_I@ (DXX'\$&W"CCAC MA1;X9Y@0<\$@?;X M@5BF63P /07ZH\A+!3.WW6*6P|JAK6WR'(0CE(2@B:%TQ .ZZ?
ZVBWX*# @; MF_Z-P\$*F_-Z/4/%' CB.:ZA#W&L /CS@FR\8IY+UQXZBB3_8,N:/ M^V.Z3X MQ;[%
<,W?;70.^YIM" Z[;8NRWJ1&0Q2)2J<5ABA8+^D4>WH259M;=R=A2 \J MRT;W[(W,Z&VK)Z22#M
M(@Y6NTT E/5/#J8FP+R MYNX;FY@58DT&B@^H#2B2U\$83. A<,I0]0+95% ^#I=Q6\05EH<
MLM7\$/&D'I!* 7.1Q,IEVN+&K(G)^LDUU)\M2E2YRBM>:6% 2CTLD\$JJ!WN M'!>EMPW=;(RZV31-
'W50PTY=^2<>K4UPF?^4'YE9GD7T7]'H5S3Z'0>-?K'0 M% M^L>7^WZQ[Q?]?K'0% M^L>7^WZQ[Q?]?
K'0% M^L> % :E_1' \W^7 M@60/\. !X 0,<9 2TPI/@WW"0!PT'-TW40.5"DZ,' \SI9\$D;() \0EUZ ZSV^
MAS)FV;&KL6U)X]6Q@ETCJ04T)=P490.3>= /4C(='^2 B=9K M 8;5Y3;#:\$VG9E?
[JE05.+^['W\$)B"0=,C\$BB>.V'-#)Y\I07MU]0\EFXL"6 MI7K2V;=,W3;2-I(F;=LZ=1*
[ZA7CG_5'=\;:&-0J2=@VG%>5L047 060A00 MW47R#[#.=1];R\JJHMRKQVNY!1YTE9-
:F90@2\HVH.FWSHF%'XN8GN8VD%0G MF [FKI% 77.);+>HTE\$Z!&Y70 '2HR"G*%BK'AX ;)(Q-)I0
VX]5>+H;\P&<8_ \ M'IMWGGJ 9EGE8S"U)XP8-7!H78HW;^N+B3:T(EL*I,QL1G+<0.N)\H=K=]4*
M1.0K=Z'G3],+;F;]=].W40NQ>1G4'#GTL3)[Y4899TR3"CCU91P-,0@I2+2- MKM3CIFL4XS90])TR-9D)/S)U
EI^""R&"6R9LHZH0%L6K%8=5\;0,+@MWY3/
M>,T*G3.NKH0\AU_FP5">W+,M,YXA099CA08:^(2Z+&50'[M%*U29=L[[80F% MTJW*/:7Z\$TU0AD'UQG3-
_5;#;21S>+=#3M06;-Z6DPC\$@L(#&4TW\B+^8W(MZ!:PM JU,9;8UT7T;470:?
4S0_H,/[\$1=GP!X#\\$)\ \&'RY"/% ;3_)&:F MLK:E6,A4?=>SY6@AVIKB5??"U1F!L98S!K*ZC#KV7/<7_?
BR7)6XII4Y>EQ#0 M/+RFT68CWC=# !0;DF\B' TX]8?I3V;0I_L/CAK0+BC%WR!G?->^ M.QIM7 MLHBOR})
[;6H00?22^^JV&JY1&6G;PLKV!,5DI[V2J\ \$KDQ0NH#/\=Y<6\XLI M_5[KS,]0\XFL?E.8W'#CWS8QBG_V> M?
8' ()4M51<(V3P:0'&97I E0DZ_W10B&.0DB;(LDX:S:3&5(QH%F0%,>]Z MY(DP1CZG&8XYFE_720LL0@X-
)L7NN@8_M,0+^"Z+3I6#T[CWW??/;*20U\;TU(T&*+34@3\MSIMJW" X=HY;=Z[^S^L]KP M?
RH22Q"W>LT0KG;]/ZP1_ [0;7^/_ 4R':X*&K0'N3B%]/TQ5,?QZYSM/JAE&/ MY&FVE*3DJ] \$&7*:2-Y_U!IP+ \-
SZ]G2V@MIT'!8E(*)S0<-0C&6,' \5K2NE MW#8.0FG46]:5RX1&9]>5!H!0J13N%0M;F6UQ56QEX8ACS-2Q
A@1."SPY<-Q M4^;1<8:Z'X=>.NRC,W5%0P.XAJ10+0']E4I(T\!#7PMMCE0'Z=\$@2664D1\C MN?#+)R-
Q/'1:1ARQ?^4)JBEB_0L%^K]='/&[\B.'SOVS6ZD2E%\XH+!J=AMK
M=1J.Y4\$_.CY\6BH";_3; ,I/077^ZRYD:IC'G0+[S<=-\AZXWM;]F8A@6S#N0 M%LK4ZY9,' ?
PY/)3GJ3M\$TQP/()ZN,BH0R ->4R]@XMWE#I]7VUFVQ""D'ZV! M%E3V]V ML
<*T8JN]\2GGKGN7UAC)>'Z.R=WB^;9-0KW0YDUP6G6SA)_1;
MVDRA?)1(670)P0V^@Q5F,1[+ WQM3UM[0#/[WR,5_5]=%E"8\E?5CX\0]0_? MNCSE0!1%@\
[#KIK>ZX0^@ [EF2Z9FZ&GDG>10,1?P /#;ZF'*UFR8Y^P'Q-JA<85(7+;#D)>EH@A\$ \2_//VRM[MH\$21=[
Y=I>)>> !]I '77!_9#Q@/^#/FOVMO.ZKE-JV]GTP&I(Z"9BW6=LXAP@*EUAL6\WAE)@_?=_+7N3M\ -
%03T;LV^T%*7ZM") +A?M!/+ZP1<D^3X1-1\$M7)5^:4C M0#(>/M5A\ISK*:#V] \$0>VM/-
=%9F>N/9]3=\$&^,' (0>=3-;1I0X[P0\ (X+U M:EMHA-P#6F<[L>U(+0+\6D.X(+%69IM1)Q
N;SUL6./,1N2%0X%SA>2Q,' U':MJ;E>N+!R87_3>>R3_ \4AE-N-YIY=%07E'.!1G]&.9E-^("WS
M[^K=;LR9!VR_K\!8Y1Q]4+UPD0CLT^S55ITQ=\;0GF0Q(\4 ^N\$D;M30CD_5C!& M:49*3#^
Q5NGD/[WMP4Y202'9B -Y!+N)FK[32&X0D7,;VJ&' ^XAEB;#%LU(\0301>^ %N.RZ^ [0I>4!&X4;#IL\$4USI-
KWR'/ZC0_ IFFB\$AM&@,*&]+/*CT<7(Z5[N M;:E)1&I
)P0#,ZZ:U^ \4V1Y[V=ZR*AP\$JI%EBP8U8,#;:I8\A>\$N98*0GE M,! ,Q@]3([5(59=V2-
NG%ZN#RGMUN+&D=.N1S MH4\$[/,+W;:,CNG,\D*>TI+-Z^STI@&"N6,;:S\$M-M+@1,W*L5< 50EB
M^:0G+!H2Y0I""6&L5%*?C/K?1\G/?9 WT0N0,*YD1G^ [3 M?2P>P\$*(3F^@!' "G@R:FHF+ "&I[GKGH=Z-
G;NYF7J8JSD0HSA\$6DKK!(:ZB?HU]_ \$ M4S8",9'/0M_JA.]W%.175J;V9REXL;=-6D1K\K_0YEM2XV!-["J*@)-
L>J!; M!K !*,5 ")\$WQ]98GNHTM0(:6+;: J+B.Z,8<6.3U.%.X45GR"3]SF-SX4\3 MY7%L/X^]',5+=
&QEU>W' _5#XL G\$(A8"0:&)!?31=\9B,FTK3I@D"R08Q'J MZ0(G&:57LP=P"3ZS&A=;#FY]L*1'7\$X=\$0?
I'#\9@U)M03SVR'([CGE4N02D M!ME2AI=IOF)26]+.M8*P:[N*! X6*0NG\CID3%{#Y43L;
<1=UT0>>DI; _=2D7TXX<<5 < M 6G6N!1%+=, _V]L,(7B :2YWV"H+\IMQ1A503P ?L5>P5LB1K2*C@M@+EN]
MLKA3"H/V1LWH*K?&3!G!H\$]#GV7[L M\$!FU+
24QFA5Z>0QZL#)I7B0#QMHHY0ZR'M]Q%Y4M%=9%1*I40L^37"' +2L7 M;)FV0?3XW.^-! [3%3'V
Z[54#7>&04S,;4_+[0^F:>V*7PH+4B3J08(2J)N0 ME<>2%)>;BNH):WSJ!BDXB'C&>U!K? .)JI L\#G-
85(E"JYZTV<)'65=02/L;\N(2;0N=P-@&.F# [HP=U "'X;V\K?+JIK4>U/E M)A7(=0N)#[;,\$RVC12>SC@+-
G5F'U7,6Q)20FG# :YT?+7V3YA.0!1(F%>-- M/J?94#L@&40\$P^Z%B&)M SK5C@L5"6)0?[%!0VT,[^
ZG\@/]S\$142S*DK

5NT#0=V;I^#N#H^]N;2Q\W@>G84YX^YQ0%_9?' M<[R05;I]GN]\RE\8@J9%@@+DZ<0%\$-
04DQAW#6L7'X>)'7\$ _N^DCI: ?&KU9. M-_3?
0+9W'74"#8"7H; ;@D'16#_5^J693WJIQ#U)IW65UW7!U6V+%@.0HG@?" MX1TW]
<\1N1,'W!6SDCWCH@;\;&XL4&9)+/A\$!H\#\$[->#TB]!'N)8T=:10GN%

MGM(/1J:4[5WJ1F&0B^>=";L7239=05*0\^)\W3?P0 M"Y1R\VP2UB;/BTIOGU50-N48W;_NZ'26EJJ?CVA*TN/
_B-\$R48?2-WK(8)2 MFXE2?L'J80X7@/YUCHF'T7(*!\$4&6+WG++
(JFGZUB0\$!\$4%;A_] +GZS"6T8+.8*V0J")V_44\$3M"CQ_+?WL)95F%-;WM%">Q2:-\$1.Q_'\$
M;03#>VU0<8PS2@B+D2MHMN?*Y.DR\$Q@@[QCFW19;_L\$#A#20'L7M+>^0++_Q M>6R0/BJ6PI"\H%V2.J
I&V;_*B4GU&Q;F60D MC&WY+UZ/=%&@P((PEZT1]XGP#R&YK4LIL@J'7])MG#>D'&>#KW_309?BXMVY01T*+1]\
(R?&PQ1SL\ZH2%0 M._S*9NR\$"DQR0Z_0YB&/G&*JI&L%^7W%\$0/ 6RBYG1;%VZK!?'&C]=/IR;'X
M;/(<25(WI^3*!;7CF\$"#>4YK!K:S=OZ[0@X'J]G(CR0[ZM4F2)Y(IA/-MQ=
MB[S<8]RZL^(UX,VJP180\)\XCJ]%G\$+=HLZH\$-TZ*0FZ2MID*H8\$AXKV=Z0:H MGY6XD!4\4\$[!EH\$84(/)*#P
_1M#LD* MRB>-!CG#0](:200F4]G0\$B M_0E[;ZB!^E6>IC5"Z.5EJU\$A7*0S\&RVS>!UU0.?&S_S#-
Y6W;7I/EE/1BY MI(= @ @8N;>;3GU=H"&;L=H5;?J0\$JLLK6CM.)K/TV)HF(<(H0ZS56NAS?T&?
0S15B\$VLF"/%M)+* MI4XV&J*TX1JWKH6%X1J.(+T(K-II(8X6RX46GV-%FT5\&I7X\=P@MR)\9'D5
MK03XB>Q]VF!72?;"@/0\Y^/2[XW)V6<9VC_8CMH]'LPV[;6]\FV9A>1NI6K MDU.Y/?L&Z M#
[7>62'7FW>%.0QNQEQUZE\$W @S[R::X&01G#(CY+33>P>\$F\$V(5]N"&>IA MCMA\H=D75I--
\$DGBPE^:GY00G[0+QWU\L-W]97/>DC4-^'(
M2Q=4GMV[&I[7^B[;_96TB5X!\$>98>XM@ID4]:C07(C<(1XG1=81VL+2]Y\$U> M\$102([&*5R)V"*-
BM&I):@EP)G5G9BL.! =G%A#2)HY3#Y,P^83[:I3"&WG74 M@I?4V3K2%3TH=.+7 ACIG^>V)BR?WSS8-JQA.]
M\ P"H_?9%K\$-91&L88KI7DWW=JRZ M-Q1*'YY8\$;#A:=\$:*FOUG0S_23)XT7# M=M'\$
7BL8A9T\&I8PAH3ZH*,XF4JMD[08]G2L!E5JJ85:PB -W2-7V6_U7_X M6.I1X06=N#Y?
W@G5X+ W6\]0>JS,W(1-6P:Q]'G2=AF:>&VH!#89>WMH2P>H@"C8M;/_&1^X*%-
\$=:GPAZ"6[<3G*SXK(1ZSKA-%M[/[0LWJ3U0\$&PGPGIB/F/-9Z M6"EKH9AZRA[U0,\$B7(E6(;4KS5TCC-
9SXGFMTKV\$;0GY1K1YJRD0\$Y;A57&, M_Q6A7B_I%GX//F_-9)]2BAZYH5G>K7;!6\(!YQD_\1ND=9FP
MJ(=C]=!ZK1SD:'!P@27.>/I]33>.%!507VE!)V0?G#!S6_UWB0&9@F\,LJ< MNMP+;#XQ+4"6GR_*+
D:9(0F:2_89EPUY_0W(,JWFYJAN<^;P'DI<->7)5& MI',FL?
[D9RVV9['DKF4^<702'M*MY^/B!@VE1,YSW>XTW!\$)A7(T_2%^(IN; MA2>P1YR[+8HW69;YS>K(C)-
>,CK*:L, MEE6?310>%8MBE-\$GW[+9/CSAN#0.J@:5-<1YX<(D:D+[9IZ(?&!QP@-T7[[-4
MRQFW"OBS_S#_2^,!2\$;ZC_FK":R(3_D@0"(=(*\(\1+N];J8L76.!QTTV@!*<
M*_H:B5H]*!%)6:>*EPSW,='ZINT*N_HL15;*^&9EOL_J: !FG#,XS!F. M3.V-SOSKM###.D3Q3_C;
(0,GWR&.)2@](M7X_1>8,[ID !/XSG0)K8_X0#0)\N1WN MQV/3=+, \J,L)XM(TU=.S+M:5CROL4R]W07]8:[%?
L&BQRS5FF_G_Z@:S.D66 MW""P"/>T9PIKA)(X#_'+*3LB090SWB_%,-7=",>^! =>]9RL-'U_0I=^2^X<
M-.J5H@^T^30U"H=%R@G7%>6C25L,'Y2;SGW5/4SYR)!\\;L(7_18_TV-NQ"9 M""RJ1=)5(6&]'U[*35H&4-
1;F_D?Y\$50^Q]XP_NAXNGHSP=03VY63\(&=L6J M>W^0@=@=\$!UR40[%:6=[EJM7?Q>^8=AJ,"GOY,-
+JZM\$DJ]?/, \$V\(!IEDC)-, ^@.??2"G^N=I.C=:QIS4U\$>_9^=Y]C.J-=9F_?>92"2<2
M_D0#Z%Y/2UPQ8Y1[<6SV#<:(R6H]CM24J_X5\1"2TJEL0R\Y6B3QQT:U*.SD
M\$UM005K0\$B^_F+09A/;:R+4[;CW]T#%0[3R)GFC)*9:@R.90H5V! [=.(P0: MJCIV1P2S006]TE1T\
[N]2813AL(L\(''@W'9#0I"FB89I/,#![N:4S[3D]N3R_MS=GJEV?/UM1Z--
[\$Y:W9Z@>LF*BT0Z<,@WU*=%82MW*H),![811S^X=:6^Q-=IW*\$!E\K[5NG)"Y!ZM-
E,WM#WJ#0C<9*5S81+>XW",5 M6B(3HB\(%YY]#-&VE0(Y*46DR+RL0LKK,N,4'V0C_\$Z;DV?S;Q^ZEB*NRQ?>
MX_B?)UH=7N/@F=B#4?Q00>X07&G?M?G"]I+5)18E0.F53G;G[(,"F<&PBAB*
M5Z\$G1D_+1G#S[DF2Z0XU*G[#SD>39+Y0YKF>P954F[]]TA//^WK'K9.##=7&
M\$G0\^\$:\D9==_GIN0_SQ@;3NU&V3K+!%P=87]5E?DKZ]^'I11;R)#@T+E?/) M[8;""Z'J:/I(UW<
MCSA(%M&MXY*):.W%LW.0G0*>G_I*?^FNXS">1JRV+2V->=\$TWT)VA.09V-_0=P\$LUT9JW>%YT5W;I M=C&I
(^I^5^3N&YJW'BY%YI^F<#%-L0^S%YKR#\M\$B".L@*)RNREYD(TKX M.;9[\$?_63
MX@%=A=G0B8]FQQ<V60HB8(_I*Z/%N\M<4DA.[R !PPCJ*+Z\ZOKSY4<68+2<2)[R5XR7;M(D
MAS28Z[;^8D_ICK%_ \#GB6-Q^?-E+'NZ'L\$8VG0#8P:?:Q>Y8%0DOLF:7=# MG@_5?
I34J&0+.0016XAZH7Z]XL2&-_Z6\$U.&08[M>;=J MUKLXFM+V[UC'&028&8T?J?J,0\E?ZG\$'@0U>2@T!A5Z_XB
MM4V[([1IC62*^SHE04XKK'R^?3Z@.B4W1)X*4ZTPBF.=[RL\$@Q\$1ME0%5X>@3,+^AFNBZU""5
M!Y_MG)I2%>+2]P6E7C)EMR.;&3?Y^1:3_C>8_W05?4HQA8\@*\$>T>8E+^I. M!:(NL>>5QE6A58!Y.17V8)?
4DD@A,L-3I_8C,CE\$ M/)5W_FFY';C07.4GALH(D6>-;@,^0+0[3IV@7
ME++05H.JXPT2A;UPT)LYA0C&*6]50V[3*]+W""N0('VZW[^PPG"W>),HEG;2*>52">6K!J%Q1\$=;SY6LG[[+V=
M4PID">>;]I?6\$4V<6(/O(.MY_ZFDK%=>"Z_W+P\C"\70/%JMF+10-_ZT;]Y2
M%>]I\$46S\$0L>/[&I_01603_/(<3@Y_T?1?7\$P9#!;Q8Y]5\$0Q_T!],U;L3_M+K_4AN7EE""%&&0!;Q_%]
(V3Z(20X<9KXCC1+SU#(?4S315K<=W&!MCF#7_MTV^HQ_U(5:&Z;T_%WBT*N!N?:1[!L&%1*K_U69>E]FP%&IST=@
?8S@>GL99@_MTA';=!C-CM@UU;S5N10UID>)&X4&W[/>0Q8M8(Z-[3NC]3K!_M06GBHUN.ST<@7*>%IQED?
>MR,/M*E1<[3Q\7.#Y3!W/1]]NE_QJ4[PC#B+' MM)&/]'%<@_E,'9>G-69WZ0:09_1A>5\$^_(31IH*XT6&KR
M/6\$49KL)U:K#K"Z87<0D(\$RV6\Q"#J< "' M-
^E]=1,^U::02E6PP];R\V53%6Y+ZH8XE0_GE>A\7+=D6_.+RP20Z9,B[5/] MZ1U"8'AC:(PX.*SIX0
>TW9T/GR>PL@V2<;C9_8-IC6,X=Z.F0T1XM@7R6B0_M?]-D/NXAS[F*YYVH%TSB/_&Q'_\$^EC2:&*Q=!
ME2(M=\R1UM_2::Q%[M545'V7\$+-=ZLV3S29=,KD0YF2I[*1[2X;C^Q.<=-6#_M)MI6/SG("TRG!RJF0:IN_IL!1
)^TGM94.*.ZWP;0UW%.,M;\$)?4MR[R9Y[M?
4CA%\RR3AN[C8;G+G!^D#6(6#4;:_WA&XS480]3^,%P9(M8)BV+0D\$Z@-4W MH4\[-D-2G-
/NBWG4=:GCZ[0,0PV%VVT0U>'+SI09,T:L\!U'@X;VA4_M_D(IM,_HX0?IP>Z-
+N=NG4Y8F75QIU4\@.0#_!X&,@.134,0E*#+U._4PFN>_M6M5X13(:)-F,;Y4^<7*(RCC'7DPK-@BRAD4F[T
>H.>#Y%DP2%U,^R>18%XT_M1ZA41)*YS\7L*#9^&Z043%M.SQN=UZA=&S+(MH=P@Y(RD7.*,S<-0P<&81)
MSGN0?+P=V*#JX+!09T!6VQ>DZRH_FAVI>S3#N/%;C_U+I
M,YI4'^V4"/ZZ9DH\$)8\HE!P.MS5,&"B[+.2X"+Q3YD#C=VP5-U_UC_)6B]*_M&ZWS%&/'U6NDYY>'>6T'BT-
E;R>D8PJ:7P:GI1/Y"H_MVLZ1C%E5.CC'>["-C)EOMTL;\$XT!#>*U\$@+A#M:K;0>>!\:U(6&JA,XLW?F
M9IQ.]\HD1TH=SC%]_XG&I:2BN=I-1=#*6-IMA"NF7A-]H<#6L(V!Q7A.H,Q;_MPJA14G9:*D"]

(8_FH924,GWC50X]&E#Z4BE"\$.:(L.>+GP0JPN.1]RT>D_M1AY!
M2^RA9]*TCF;%2Y8CBJ/G+\\09YLY,M69C'JS-3U\$_'\$CH/:A_\$B+"_2*Y#AQ_MU8ZH,F&9@8K1QVCA
+1,=F3,S'4WKW::+/+T'[,SGQL[^0-,ACV[]%T9!7YJ
MF/=E1DDLRL\J.W#NF3[M<,H&\RY#PT'H^4,ODKZ4Q10?!"!0;WNA_N&S0499_M3*]JMOZGIRIE_A]S\$-\D-
RC/88K;Y^@Q&0L^.\$20,9*>7[,JZ+4<>0)X6\$D*I[]-[G!RHT=I^KFE[XIHGHC*.7F6D%=[#0;D
B;Z=>'/=3IA6Y16:-,.\TM%W%2Q=\E3J_NS?^SZ>H*6?)5M4!U'#U",&^GUVEL<>3JTARC_MK66M;"(N8!_Y8-
#/.!-^F6='J()T85J2&_/, [.MU*GBQL*MW)/,ZN5V3<&EJJI;B"&:1Y_&<\$2LJ_ID@62
M8,8VENE5P\\Y,.LOK+Z#91*X?IE;/.4EEX0I*[UY%W\5A8B#*8Y\DG>TSGHTE568Z'I:~080UQRW?0EKV)?
J'KU/NR9TU_M!CR_N@FP)0-P0,R;D&Z2,LR=Z[X63<1_3>)W=\$)OWHN8H6%L3MR;UK+(063)+@^MM
^&1FUPJ8P^[\KAU^+AL_M6AZU.@G7WIM#[RW1:1DOP_~KY80&U9\$0<-86-.0D\$4.]YORSSOB6(MEALH,N
M\$W:2@50X00%=/5D]Y_NIZ#4%K0R0A3I*\$0;E]65-:3UI#6&4[Y&;X+'N!TD_MZQ)07V""?
-8D=HMUNPNDPXVDDT+H4>?A'%EH/3A?F(@?T\$Y/;SP918@8^I:C
M\$JL\ -5&)&N70N1(9:&6S7;YDF\$0>0*GX.NGMX/]MV+\W6'LA)@N%D]N29<33@
F/0XX1E^7;+'>0'9HL8*/@L(J3T(*9^)BKJ&*M.Z4W\0"X/42E0JRF_?Q:U#FE
9#ZZ^;G<%;5XL58YIRJ>.G4D):J=#L5E1H0_M!TEIR],K(Q*D0NJ;%;!1L.V^/H/&@1IA_~
RG)PLKLC*_4X\#8U@!*T_T!_M#_@."I\$[CSH&\$MM,R40C=.G2: '-F5'FF5-GZ!F^4)KXKJXU_6."R2T6B-HKR
M"G3?/H]QZKP[[]+@E5-\$H*7KABXE0K^S79_&T?7&3/7FR3VB# 'Y_#?KKR00==
M3>=;%"C@V"1[0DI0DS6_UY'6CJ'4VX^IZ%56P] +NW*UX";<>28XCUMWE"J2_M?
@%8NAL&6TB#LK7FS7*NQP4K=3\3;@ *U(:4L+Y-[K?|62@94=@D@ABJF] MDQ^+E6--|P5"LF5FK*R_
"E*2RHI)_I^\$A>T?AD0G9A?G+WVQP1QJW0F['U_MF+H4U52^JJJQZ@++@SE:9=V&31JJ+6N5.XWF;=2^J-
P02(PS&Q^MI!)]M'(*02'D"G0HX;':ZRG>Z_+"21(:>IAF13];>%65!,HP'V+4-?4#&?+,>M00BA[T
TK%9.^"U\F5.<8DTJ/EJJ_W0-4VIU>@+L*[Y4U/K>/:>J5*K.2^S?=-)Z*"- (S.R2U"D.#Y8KK&
M<045U10'] :69GIF5VYU1TW+U#\$E10BJIM%DS6RGE]*->TY9J46YZH2C=&@\@_MCSE1GF,U@E89=L+77=PY^_**.
+Q>([DZ%! [ZF]^E_Y9@)^8.: [VIFD>\ M^>"#H=CS0/7" CF2'SUFM1W-
'^NF&,CU=KLL]X9:73&R@=]L<,];H;C_S1&B MD+D&1G^*2LE)4MJ/5C,&[011EWC)2\$/M)WNE*TD1I?5K"
(+6K6#U!T!K+) M2>1,XP'-HNZZ&C([7/:??DJA+FW&Z9*&652)J0.SN0C2?0.3=BUZ(9V@N]Y<
M!\H83=2V!IH^Q!].7%J-)H^LL\JHVUJS30K>K!RIRAV)#@"FIM:7Y*9&5'^= MD"?%W&+])WN&>950D^Z
^3WQ+7!G^-FBY3) M(._] "X'#E&#>XH]4@1+-KVWE]I,/%%:@\$/UV&"\$R<-;6IJN--0B!H5#Y
MCVQ"A2T:+J&2S3?S69(?D&73TT2>IF=@9?|K(0_M0?PH8T.+#%@=/63LC\$Y_M6SCK*U-
<#V]U59WJ205;KF>;0F105(S9Z\NKW3:G&ZL=0GAQ0:(^7!S!_ZSP
M@%&\$77Y9/1A!\MV&VS/0[P:]*6M:H=Y<5R\ 'EG8;H;%\$IL\ZA2_MYFG;>JD7;FRRZQ!Z]MCYYR*CL0":X/
M2@\$A\87;%U-ZJTVH?F@5>26W[JC,E3=^%6334/MG)"-24AR"%6G@0AU)\$Z0Q\ MR_36?Y^A\N5>-/+],P_=\$?^-.!
[QD/G/^*!W-&12L)U\86)2F9BHH?8+P^8<#M_MIIQHx=3<7L="["R_C\D?
@BKY>J=@T8_W(T@=3'R'AM8=G_K0P^.-8001+.XA,M*8L:X:UE>N*0!)P495M8..=%\Y(L;:*0,D**
<10'#J/:>Z7KB#:P-X\$3?H=0%TEIH_ZT) M.!05\$[R?+K59I3TS\U!8[F<20^LVE\JM-
XS;5\;K,\$_AJ6:P7F_2QT-9Z2WJ
MEA3)'!^XB]:\$D>X;B05%Q1]Y[P]_3U.7W*!I7BJR#YB4CUI0@ZDA+F&:)1"
MAK9N4T'N8Y#62'(S=9;XG\>"0Q>*DMT>2HFG3EMLF>:E=JN!C06*S^J@)6!_M009>W<>QG-
] \:9*Z^EV>RSY)+T>?1L'%X3/42WC+%#200L-60_V,22W_.4^&_M!UB"@T\$DE1W?
L4(+!4;L6B4T.,^4'6_)K0\$G[F\!3TG"&-18%\$ _Q<\FT@Q_M/AG>
/N"3_H:SR0:=4WL]KI=!)M>S31#)N4] '3]MF+U]1KEUW/:%XJ8\13Q?_M
NXR:XW:PY_JY=TA!,J"3Y';\^=+N1I?X0%9F\$%#B8?*C\8<*KDD"AQWK\$;@
M/\$*.PMN<9HG1/^<=/IAM574T2TL,8J_+@T\$-8J@*K,RHNV<9"E*5+.F8*[A3_M/N-U87^:0R%_\"TX1F>9+X#}
<\(N;\$3<&0NPM4KR_M9)XBBZ^7=>Q10C_E525329-\\$E000-*".T;PR=Z?GU(05=W0BHN5W75)8@D
ME9^FS1@]-PH4F9++8.5X\$G0VG8EM#.E*L'GQ!W
M!90ITI/[0DB^"Q3D3^T%.\$^G<'K;E(_@AJ!\$6[A;D.>8AU/1H1<;%TPDA9PH_MJ92=NP*X:RKT-
W0.-1]N=9SJ+W59969R(#P8V@7!@,D]:K2R%18&:'/>[TN
M;I5+*=8>@.NW5+;:19:/W/R7)>5WK6IK7PB;>6/6#T_H:#N0!2+=5(U:Z8S!_M/&A0L/QB#'N#!7G
28T*3M17>5W[001/+)/TSGN]6UC,OPMU;ZEJL\$5-MYI>_M/DW' _ZQ%+AFL3WFU:5(HHL4T@]9*VNF2)ESZW2
C_>W@HD\(_M?KJ-TN]I_MMJ5/DL*E.BCII<+DC.!\$^>N%-\$;17N0+[04#;ZX\$X!Z^*9HV8HV1?9W=M-
EW<*2%_ '09];>M@5_JK;6"34<<7"@FE2P]B\$54T)GZVM+R07E(Y>7'MGV_M9_++E1,)^4KA@?
6!\$AI]= "AA=\$RNU*&@Y3KI2X!XT'_:06SZ16\$':;P&RUK_M6V>.D9_0049J)?2F4=+TV>1A*Y@:'GJL-(,
[;HI%XP&MA><17D'@!C%\$!+/\$_M'8K#9VFS3CS![[[@B@=I!4[W=H]Z/W1.@N:@?)2!@:&WH.MJ'7=*C&)]JJ5
M).:X'U3?5%FS+H"3!3X"A=P.]:B935*NIP0;N0K"-GG0>UA^\$5>B%R3"1A'_M#;N3_:Y"!6>K_\$}
)3"^2D[P]YW[W/;^]_W//?^Y/@]KL=9Z9N:8[YACC06.M>::QD&/-,@A?-'":(P_M]/U6?3]"4I?LB_9D.M<
DGO-BUZ?[\;K=W\$*F=\7VJZ'C:7/9#1]+'"0I(;_M"!Gyr/Q1Z?4WZZC;WA7J'
&0%55\$6UCZ7',T+"0#W7E2UB;:D7;PD&_4(E#)_MG'-@G8_8D1]9Z%*2'"8") ;@H=5762]9MNSWA-
\$\$;]SEN0T\$*(.SYTD"NQ<>VF+_M^VY9[EGI.%S8_V*D;+:0"P3>!EZI0]I_P-"+[B\$^I'+L/:DZ[-\$'NF]90S*
MNGR&OPL?SNA2PI#G><7A*LB<)0\$8)"(9U^2R!-Q2""Y>+[I010_M]9F3ZY[BS_DR;R+Y"XLJG!?
XY6=.RT75WDK4.[M]I[R2_G@1V@QY)BN_QP:C_M@]88.MPX\$+W^49EZV&.;I^S+S+%ZQC+B)Z=H@I7U02,#!J0
B@HFFE)F&4Y. MK*29+Q26==-\$-EY"TL>>SW0,7\$VS;-[)H%2\U02_@B"H^#'/OCK@P5@&WXB2>
M75C@:++@X>XPZ4?-5>)R#5#<[\?G';D,/-?N/<)#0(VL"^&V"H>UGZ>_36D9_M42'5;M?
_&;_T_?/W8ZG*5#>_3D3WINV&[[[]>%YV+GC]X.UU5V,2:YA^)%\$3)_MCTHORU0H1M_7\.(4+P9;?0PSB-
(A,;C>BW>\$**%_QG0CWQ4J4]KNFS8!(SG_MD;"D#80MA&Z4N4*KMP\$>?-<%4%(N&)9X@_D7^P>2+4@
Z=1,>@ECUSL?=:V!_M=1*86?Z@"GY2_V(7S6?ZLL\A);+F390_3NFQJ9M2,6_7+@N!)V_9Z,#3DN'I_M_
MBU_92VN*B=LC8^,&W[H0QM/#&!>E-;GFLGMPE[0@+AZ657#L\$:[96!OKF
M^G8+0&UL*RM_J&091;56Y7F#B3E3&7QC+6_2H-;6]L5_JRC0#;ED@

M*.. \6RSHC=_E"U2\$RK6:"CAMUTHWY/67#0Q>ELV20'.L3LL4A\$Q+IZ#*9C: M.7AU"UJR99KZN\$X. !4\@K9L2
M# H@*,ORY/)N L%+<6/.@23N0#010'JW C+]+^#FI4WPJ]/&,)D'Q7L0R0I=5 MW+%GH_ 6F)-
NODL.Y\Z3Q_7"EZY?X\L]56>2;UAE*)-,&.*\$PZLNU/W9\ (MH&:OJQ:~9D2F=* M#ID/[QT\ :C
R'R&7.2N:7F"IHIG-)UV2531<*&1'S_ /92T!BA PL*(07, M>./4RMZ#)4-
XA2Y")*;F\$4'6H3=]XJ"Y!0E%G9,)ZB/[>01\$36ZW97XH45\$ M.X9S(L_=T29L3^!<"Y0{M\$
M/GON]&9<\$[M'0C\2X5:~?[*].53RH8;0#&&35/GU?1P\$ (\6J]*#SB^=3J=17US':,E'Q?D.HR*P9T[;UYPW;
(S<3%D!R[!=#<({Q\$=U M8:V5=1>BI9]1R(5_MA4@0<9^7=VN3-W0.K;!>^+P%4EP3E5]5F"S31^0T[TP
M'8T(4->J)7KPQSMLOX%F-:;\$?*-W3'"_S35].>G00S"JB8E@W8&A20A\T[[" MW<3L\RBDLMX[?N14# ?
CK,96ZNT/E0XA.K07J]84BP*RK<6IY_?T4R@ ^ZZ MP-7=(1P+ AD+PIK1P.E42\)VNL'@V'L(B)
[I1U9_>U9WOM#%6SJB\U(MC6H]QPK#KG[E//:@'CEZINGT>A;\$K1WM6JS MSA^7[MI]&ST)"(#-
@EM<:~&[<@]P>U&>QL^F+N9J#8A&=^*0AAZ;\T1_&1.3 MIMY_\@PDRJ(\$HH'9P<+@)TU<#"<:~!RRNJ^N^;?
9I:W:6A].PX4=5)!3!;[^ M538R46E=:/~<+?^.!BSVE'@#\$,)0\$'EG\$EI9D7=ZWGC@.9CVJ(NFV]2=5N
M\$++1IM?..^+:UB]QV3I27VY\$/5U6C!A*U; (MSNX-WX4?
\$D8.XJ7P*A49HBQ4'@=K+=*~/9V.0:G/:J'M)EM7.=BK\$LG_K5NY M->9;F4R*JXY5H*&(XF/1=SA8"XS6A^HSG@
\$]V5\$MKQBQA6GN&Z97^00YF0(MQSA)V=C&;97\$A5V_9AT S/8-CH/+!TX=#=*..HW ".7;\FP_">2T=NVV06]7I
MED801M=D#)[//V\$_9FRZWK5_HZZK6WYDFWR604\$L.7&_MR2BE0HL">-BS7DL!. ''?
73_Q&0=SOK)NL,YA\$<@A'/((45;E%,LPJ6(8N9"E M)9 XT+E
!;9[7:~X\&9#)0U]6.RI00H[0@QDK&0G'7IC,05LKTR\$EHR?U)9>
M,SR87C^YJ]@Y%14#"&AA,8^Y56+2'\CS78T+;Q3>H)WGL#7A9'&!%74/OBXC MW3TOF,+)W%7/@]XJ3A@U>
[~X+0A'Q,%~*N*FT\W9NUMJFKTY97N)H: "[VW- MQ"@I*N40[M5&*P5, .5(#~B(/M8-\$T[D\$F6F%! 4\$=Y[6*
.\$37C: ',F^U M'H1TI AMGW=;U&!XDT7UQ&0: '*0UA(G2L]6CY\$!!#?LD2,A,Y;A.D)E>]>0
M#&,I1+F45/X/TH.RV;%0J:\P&Y, '2VE\$D>40"0L+2^4I/X,0[! 4P"W1W>X
MHIUWT=00&80, .G^F_.N\$DV^6%Y*\$2^YPP1F@.%IC7GMW>K806C/#"8R MDV8?FW&8)6ZEK0FC
Q[31205Q5RP>.W+8"CC?L4.Z5LW@_D5NN(UMV#-?.X" M:G[GU[:LRF'59/Q1)/(8[\$?40^I_AIV"T@VZ/"7188?
Z'@_Q/RP.SS1]Q6]C M_JF(OWC]^1F1=^L&/6"QB;))RKS_BTJRT+?5*(/!N-/1Q:_Z\]&3J
M_[T[I^6V"=H<E8W^I8D2&";@0=578V.#6J03^~G M*Q?; ,SB3D_9PS,Y>^0; :>K7X0/TK0Q?&8- MH:-W39,
<>)W&NC [UU<:/H!T7Y!00]EYG*6DM(DYL%>-G;!>8+&R:XE&[T4^ M\$WII\$A01H
'=0T=/BK060H39']Q=R!TZ4VNMLR%\$Y^H'7A. (I1+H^ M1U-"A9DPN^Z"-
>UVR!GXL2TJ4YB\NT!]_N;ZHN;1S>'K*VIID1JT3-03.Z%; M6]WJ*#^%5LEP9-
EP1Z2G/XBIM]CG\0]'2*%I#K91:0E.9Y-;G'[J*X%D?3A(M2GS0(Y*G0;Q@!5@Y&MS\$2I#4Q+&1^..I@(:8CE=-
G?.H4@F_&XS=LM9Y\$C(R# MT1(G88J8XK*2MUV(U#^L?BDM]?/UPRK3H;M,#@>:-E'[_=I/DPMM
M]]6L%]H9NJH3X(X)60XY3GXJ'Z;0#~J:9R,: M\KRZ)TZ==9 OBR)NT%??*D^;X[/M6-
X"!G%J[R2I030'(*V(6[.7L; '[C-. M]U1(5T"6NY9J8=F^Y57N;%N@J'"U:=>1R&= \$1:-I@Y24A+@B&,PYL:
<4Y M=I>FJW0.7!B])DFS:Y?2D]ZD,@:'0ZU=VK&K=L?W-(FWG#KKA&3*L&0C ME< _;0;?33:H/])=6?
24"F:W%/:;0DWZ\@WNX;7D[&;I(,]@9V%BN+GFP0' MY!@8M8\$3&S0*D@S=?
G'+\FPR!>TV\$6C^..Q06<>]N3'R)Q16%XI^5,ZS7TU[6>>]?0E* R'Q"J]4+E+- [L+UWE/=?WK,#?UY-C+0; .H-
4;S>UQE12Z M;5&K;'X9"@Z^EG4(&%11WG'0HLM:8916R05!WRG#1%WW@V2I_1 M3U@P99G@733: [(?I0?
N7:R\$:_I88GF3L*!PC" (^)Z-MK0X9=2IEXEV-C3S^ M,!YX&21VDK8^D3216H&N*7DU75X=IL;G0_!I'WV
EPPB&0GDC97(P:A6:*\$S M2=>3LK;'VB>^V0J<.*'R?'+)"\$*^H<0 P_7D(%^0^(@61S?YW5P7%49L_ \
MUB!ZW@RPA:<@]:00X_6;3Z9 # <14;!B"AB9;:7>9QV3#0\56R2Y>TTPE1Y_V M?
OZQTWWA+.9.1%5"8*\!P0B:XI>7CL.T0T"W3AOW9C!7?75L=TE85#-[1*KW
M!85(GSRBBMY;G\$JR' *&D>VB[(M]1MHB>)0IX5)SU\%S@T?4)%\-.TDQI+WZF7&/8!C36/
MP]#V>30Z.PM8#*H4IU;E_0E4_3^HXTM8):.8& GAIL0/8>=XS(W:FVBPILE MPQ\W#). ^>(0J_&G#6-
[K;EZZ:I0K\$1:48>93>&>P6/#700-YWZH(\)Y&"HW\$)#2NY7APX;L&(.]KURBML MRL\$B3TA&7!KVS-
0.S4:P8/!8!1>Q;&!;:<:'?M"& \$9Z8 ;ZV""(ZC6 M^6:0S;4H'(5!BQP730(SK4B(-9PF.^)D])4V=*E;
[~DOHEQEN!SFLWK("J8 MG>49Z)DA%5-?K.C#H@VH;GY %=[NJ?KQTQ[Q(5]1A*TV%I&3H^MHK/3,CHV^.
[RSAR?: "MC>\JX0=#NSN3 J^X58G? M!TAB4="M;SI\Z_E00FT\$;A\T+&1=GC:#BP"3BL+C^(),4RZ.*0LL#2
4(Q7,NFQE#""> M,G ('QVK"=: QE7. '"\8[+U!788>;[HX_109&&NW.]S\$Z97*- \([*EJV<
M1,0;];1ZD,ZZ-R-4/I=LJ2,67D,)S^F*6ZWKN[[ZK&)+0LE^@=, '3]5\$^PM) MUYUL<#-3INCI=0[GvH?
00:Y'Z5![E'L#7GOM3Z,]5FS /OKX@IOMV[8~-ZMTQ?;6>L)L]6>GWHCIJ@?% M63XJ6N\=# -/T-
C,PAFTQ+.KJK,, 0ISOAC4H\^8Z]C%QRN=> XNAW(0;+ #3
M075J62Y8PJ:DG+C!\N8SP]GT2L=0 ,OC)H2M=%Z]?NG2U//D9 MOROU=C[4/R=P&,G5Q&W\<7R*0X4Z0E%Q3>?
G@S^' MIOH-8U("35,3@F/3XAY.8?<9+FQMSZIXC'!C8\$/H&>3Z#I73Z\$.!J// 'KY6' MT/<+?KMSNP?
U#9: ^Z!C>-25QMZ'8U_*I],TU/3 M%3=1EPI?SX]W+U\KSDEF=V:W40E862"=P\$TWPP&V!,L/I!L\$C?
<.WF[38V/? M,Q7[)4)S6-K+\9//);P[6#H7\$ANLDHVM16^J:UK=0-[HP'&AD+@\$Z.WA80)\$
M(/)S[JQ4!5K>&RD]M6\RKUV5B]T M2@P(\GTSJ[KF/FXQ0>S&_8?;6KQQLF7?
0'4/XLQXNSGCOK!LP,I[499G""8S
MFZCI<_9DUG[/ID=BRP\$,C5!6IGY76SOM0A0;I'&GMW8(^&GS803LCF:1A0? M\$=MP:~7CH_ :<=?
J%83')3EV'&0[,JRZM%G(#4>-8ZHU+]G_B\ D L?YB-793VAYRL_ \9*+NYD"9Q: MR-R40+AR*YE[\$*K^N'R_?
WS%R\W\..0>[<"G\$9^Y94AC/>PQN741+K(EG:=Y M7V'-
!50\5'.3LNQW3313G"V[R@8A(UP^>\YVEV2/:6HK87W%-TV'[NK\,]ES
MA8]9_VV1H;\M7J33GP8P^=L:1[~N_Z^] %N4\$0\0:900F_Q^(:C =>W1 (@S M)SZY\~^5E_X;#:A :TME?
N)QC78)G;X;0AN+\$3YII\2C"E/?-_0JF^411?D] M18<6?#19WKTS]ZVV+N-QM/0UKM3P\$P*)'BNJ3HNK06BB\$=
[V0;\+;N*S4>"E MZNM3H737\3623B0 HA+0 ;3B]I9BDT>& ME;3.D8=S2/'\$V#R/-?0>LI(W2*P-U)\ "R
32@S:G]@C]%" -Z-PT"4=PHP " M-Y'ML3L)PA0 ?!7/L&YB^56RYL!;K3V*R+D?268UZD#N8W%SY,-I6#3P=RW8
M()+L*8""T0!],0+<+W&_Q/T2]T0<+W&_Q/TE<2D'70./JMDAA.T6260)2 \$MAJ%CB7@!9%E98>003
#M' 'OF3\%*\$85MD4#C, MR8"L%= Q6+LK^Z_WV+ _A"4G";Y)]H(H4 -)]>D[_T+JS>0>G5AS_DE;^7"M_

MIQ7\$G]+*/XD ". \$ XV^:6YXDLNRU-J; '0^K%0Z5>(!^2?LE[9>T7])^2?
0_K33+U+B)*VRJ[5[41Q9, !'7^:9Z&V^D]0#R5 NCZC1%(1&ZH?=B^ROU">*&F MA(F@3=3R\9A-
SI95CG1"TOE4=UX.H#*.ZN CY?=8/SZ[PY7.@6Z[#GE3XG"> M3T@YE. "'8E,,4XA&-16S>; [!2T-
2A +380^Y\$ ^XQV08S5SKTS)A6/7XUBT M)J\H"0^M>9WW_\$I<6I&3Z204#W.*'CK "A; M_M0[3M?PW] ^W-
\\$007&=XHX\ *?;N61=..MDK_0X^" 9&_6]B?T?ZT^+@ M1 T-ZUWXL_8E!_H/%S3TFP0;"
(CFV)7;90M7Q_A'^8-_E9[=P0)_HZ.4T/G_M],4 &76FB;3]%/7#0I<&)3E\$;!0#:7,?';,;Z0@G!
[6I1STG]I_0^T?Y"M5; M7JKX"'PAYD,CFCW- M^(U'?[P=A/L!MT&CDJ-E3G8W!\N_%\W?F"P_+X?S?
MY\XJYNA0@1HWG"8 ECML?SMT?/0%\Y+SYZ-GCRP#]:I-I1#@E_J M1KGB/;X0.Y%W._\IWT^4)_1Q_BJT=+
<3B"T)/?J;\$6<68]W\9K-\X^7\$'0H] M\2_'''=FN,*6[+0)NK[0(?*X-C:]@(?ULL8RX6?ZUI0)%YG)?
8W.5]/<3TP_M2""OERHRE'7HS.F%/X-8DSDK.DPR=0J=2EX>B\$73I]A?EDD7HZ[0V%\$ M=H"QWHJF]-
BV+MRDK"Q,/T2\R_1DJ2"N#5[)N3(JAP.APZVC>'T)!\$H<"8#_M>%-*WY@W&A?5+V=HZ@1^GD:7?2H6)Q
MR\$[-_KX[B??!F"],Z+P\<9)#8B_M]".N]Q9Q'_3_W(UV9QS\YTG?K\/_68>=U_K7;H1+[@]00DN!+A=-
S2T49'>_M85_""OP&_#+:/@B50DVWN40X=*#!D85/Z'489@K^_C7.]3_MJO%&E5U8>!BH'/;=<'?>Q]
[_%G6QGG'5@AI9_M!7RQ9&Z^<\F\U,%W6+IRD_)XTTY:_F^Q?="I\J;05)M7_M';B#@6X%?EJ_-;]
[(3F\$VYNIT+N>[\V^RR4Q:VG(Y\$;0 ^BWL@0T3KTEB;;, M?&<,/PPF5""JU]34^Z]/9H=^.;Q'-
)=YQHD05I!)!0.Y&C5;"_MHDU&UU;SJS+R30DPBV&[5V0/P@V%=>&FZ?9;;<;E83KE21ZM\$>"31A"\"T>[3_M_D_6
ML]??"Q*:T?RI\$ _P3833.#[BV';+.2MZP/?\';)=>E)0E7!+M-:*XM" M=\XKT2PFA>\-2A1\$W.K,RA=&
[_^FI+^>JF4)LT6[U5#%7]6_78'S:/2-/29]<_M]:TLQ'\$5NXE] *G=QJM" \$0W3+MI
M]HQE25^@HWGX=BRJ"9GB(:&.KD4797*]WUD"]B2X[C=9;6UAI0S(X*T2\$9S+_M^IEW/@5M&""6W.?
A]=C4Y@%ZN#X)T@M-&_M"!KX%X-S%L\$2B_+)NWIN.;?^M2]"TQ1C#6N\$]HM)V.W3K/WZH0_6X8[3,7;
ML%G"0WFBX_#\$XIB7W3N/5;!:Y<|=8B%<;2<;0+;#0#K'_2H=7'-I(ZP2:/_M<'
Y+N/'E/-8FX=#P7ATB0SVS8DY^GWO\B/_+)J]#A[Y85U6WBIK.G4XJ^_M-
PE'")',L5U)%4._P0:*Q;_B.@K;:T9Y']&[*A=C\$>8;=Y=&&0;_Y2DH."(L_M""'-<2_"\3=)0*AJ5.22S?
E'H55[TDD!H%SKW1FC6"U)TAH1%BED,K2'<8_M]9U/N.%WHRC)\-R\FN#T?6\|9"?;T_Q""^8V_X_*
FLM(\$&/BAR]12AA*,_M)(%)GLKNUC_P&[ZJE*VF"Y^X?.7.NNJT&VU^2P,1NX02!WV6.L,R;3"RH5.M_MX-
\$""\$PTAU%PRW">HE5%ZLW6)9;=!UJ(5*\$0+4_M_ZY+I9V2[BC4/T_>G?A/#G./PZB?
DK*?,UAG)M8HG:B7[]_PG5MM)D7[]JZ?
MFIWR^(P\0S(M(MARKXXDAUL+A>J+>L:]>B(D\SS_V_AR"/\&RU9*"'_+S&.\$
MN.SE@YY8?.S]2L)'KR+^^(""SIJ8F?SD>6IJK<5]GM=?XEG<;7!(\0_]RS@4
M5TBF!,+B)EP\T0RQF:=_95YM>T/3EYT_0!._\?/03@,1"EV0^!\|QK4KM\$MZB_J-&I+*YJ#X;F[?V^92DL?
P(A2>,K#;JS:YM\FG!_M+;!*JC!2_+;1R;!?MM%0Z3YN)3B?_(&X?;RI+1W>)\)\$;+%;_H6?X=37N*/[;_M=^J-
N1>5Z)0%]G5;>Y?^0E^>\H/MK;+/SJU+[,#H" TJZV/(W/1MC):\$4@'5!
M%Y""+=#.A/9"_7]5HUH7+D?/E>^C]\$3A>#/\$ _\8Q1^?T#@T[B+-EDH8H!L^72E/'7&V0\!BI?MFAA[?
4RZ5,&H3+X!%Q5S[UU1]LVG62%MF\$@9@;_U31_MKH9ZQ_;/_ANH"QU=R59ZT2([Z96])N;&0:]WI<\NJ4
4U3IB<","RWX>HT'[_M=0M&5'.2D6C)()('50*LV81C6G'CK'KXQ4'KA]!P5+Y,#Z?.)XC81+?N=H>
MYEE0#*_\D!H021)/C\A='JT>'=E->#S;SOP:_I>55,94F25W8'MU)GN_M+
([]INTE3]&PE7L88LX*&1MI/X3KU;QR5M?BIB_6*3\=5;\1G3TIV-SF]Q16_MI?_B_00A^C.C'#A,PD6@ (KB-
+4T[6MH@I)ZE/RI*KP-_?12?5L^=;FR_T<]^MG[73?,D])L4;[([]&GCNDL?^0+,#CT&A1'RC_[S54)I'_C&-
EZNR0<9+]:_M8\$H!3_!GUG>*6LQ-)_9VG2M3VU'XG8XU^QD0/@9@(#MS&&M_%5;F75+CV_C=3M+>D3(6#EH"W<
MRZ7@>SX5N[DX<"B4*_;\$_NP2U0_MDF]OK)JBCQT6&442Q&;HEKC(Q3+J5?
7EP)-7G4ULHBT"MN>)]S]E[H^FD9=;_M#SK:Q1EN\$AJ/?
&Z8]/6/\A_H=-7_8LB=Q%\]W36^Z:'J04*WM\TZ^_\$0^=^MNITPBJ\$_/@=>J%#>^IVAG?
Q[2[[@#L[:+3\02'=6(A4>J<+Q5+'4T,DF)*&Y" MV4+X#&,4MA_K=%IF<;2[]I>LI046@U=
M]'=*BG&RU1>/0Q6_*M^IP!\U=Z.)A-8'6_VT^=,I:ZDB@0T^WD\0&0BHP.
M*46EA85F>'_SJ!=GU+=EK>XT4V6\$<'Z4W&]0S<68#^;-_2.1FV/V'Y)1")VS_BZDB_K#]2R(WEH]_R4X)&/]=
M9L*?<[FT=!\WN^M7%!">L?GY'U: ^SG37)YK>A!+#+0-H7GQV9^,PJ0I9*)?@%_MZ_I,!!#_W' L5)&.
[_QT]X2X3:^9G4!G1P_J84[4_-G2/-0_]JV?'-/55J?9/
M9Z0!3\$3D,Q7Q=1IF45&0%;G3W.).G[\$Y5ND]88DVMTD8>_G_M\ DKE.FX%93@HMN-T!K'L;6KYN4(3-
FL\$(XEE&^5_5/#+9I*M]!%137"\9M44!_M+!>3<\&J+F\$;0_K@K_)V^I!;C9T";-9_4@!
<661F%Q3RX!Q4B@)X\$0DC*YCW_MRGIH?'18PY+RZ(Z*@[_8F;-_%_*2!"JI@#FGLU/5^XUP^DEFR79IGU<6CA9
M8HKH"KUACHC!]5G89>&[2_HM'W0CB[K77E]1*LDN]1L)?)^7FV,M5]1ZQNUD_MYU?9_W3?
00LY2;K&KMXS4.ESDRJZP>)]PFU[P^7>_-37^<[]UPU-;UD.0F7H-_M9_G"X(MJV1X1@T?
#)K)%*P#_U3X*IX=>;_Y_0;_J:0'\$F3J]L?/_U3V,%)9V,
M,)_RKQ7KH:)C#?"\$3M'[_CV[30U*&N]3NY=RUAT8K.73NT? \93V-3<^Q0)JGPF>([88J(B(==
F^":\$A<+MDK5W4LS0<5_M51(W1=?EXQQ*#S.7NB#]F['L4!!(B650>_8LDX\0QCMG[7!.*6#"TF_QF4&_M%.J9#
[_.#G5Z&0+CK()@PYCWYP019I03PJ/A-6JXPZAV8BX)!XUG]N7;Z:"WB?+_M0\I%:T
@M(;,.)%L5API0.SE6,&6W;N2BSB[9HBA9&RF."%VME9VHE8P=HWS_MI)?
\$0*0VE'F;PR9*Q6#M@0.K+UV30/%NN0\R_BR*)1HAU@*]+.(!&R[>&RN*_M7[9A:+2V/@WI_B'N)-
->U+IQ3HQ7"/'_S@!40?+!6IE5L+_M0(23#" -9+!\!SDD_ SI;)/A5NU^IB%#Z0E3\F6<
M2W,)D_-5\$2WTA/, %Z>>DL3QQIV:@&S!;F_3>]6'U0&_M?.JA#.W-];/R,]G0Z[*\$R9P+/RQ#_L_BAA>:WN?
X@-7]=[ZC]+!P.S,YU40 !_MEX(/C)[Z?,I>QB"&2H3]DXGFF]5?S#J^6%:..!G@T^?DBR"XZ>M05C!<@Y=C
M6TVF\$G,,]],8XB>>^GYK,DZ>E#SX2E.7-,YH]2-VK7G.A<%G>Z8G6C),[_+&
MW."U04E/PN,G\$9AU9@ZOCGFS;;9KZ*TJV&&/Z593;:=S2BS2/= _8'MB\D
M.KG@:XUJRG90<]>4*Q[!])Y&'.YN:P3,P>H*&';FYW[.;KIA^%;XVI29T7G-I
MZ=FU^02\$P>%&#==I6'N0\$MNV@0[#NY;RJN'&\X4P!1WSD8ZZ><3M\L!WWL;_MH0_?-/SS!"#YDU1HP?UD-
J_1_'PD-V'"B2+V'=_^R392][+4?@!^%?W""=E_MW,>^/?\$],)5\['[XB)GML+=LS)3;*;[\$>1/-(#*5(1R\"
[I50]++_7PBW/?_MT8:4/;\$]\$8+YE! [+]88^^^P(/BRZTA+@XPXQ,D[Y4A;]H0!NJ8,=_GC,86W_M#%6\J

:/R#Q/)7"N00B2C%/\$ M:S/ W\UXDH>*HF*\$2[SLA@)E=,/3Q@,X*#|R006C8 G_Q&*!(K\$X|MF8T> M|JK-
J3:R4H+|&2YY\$PU<^<;*CV*F+|^50@6;4Q5H%<QYKG.,E&R*9^D'!PP MZ0'/L0HAD M?
BZ(BC"A@3*"X.> I"B1SL!1I\IY*/ _BOK&2?OM?[6-4)%RC5]>ENNS9S M2CW?G)/ZV\$@B|^3D-
(&Q[S>M\$S^S#G'5?W=@MV^PA\$&JG0LSG76L@W2?D),# MY<%.!E|)34!NK+1@KH6JJM%M/\$SGCS\>@H).I" T
OTC".ESH3DXA0X,XWFH MZF!>-2\$D'W.MJLXB.F_R10Z=-9^<< :A\MS38]?%+V,PMJ#K1D_==>Z4%\""
M: #LDVS< I_15C"2S2,(XN|[-QT.R0:<)'EI-0=77GUGGHA:WEK#WGSB\E)M
MVN1Q6G/7F:9+5L_,MET1+Q+5: !HPOYMMT^DC&!--XU:<7U22! Z,@IO="+0'^
M'^VE,\$YJ5T9F0Q<,L|I|\$ (CIB;,-: M7_L@N&ZG| (R*%28/8!:OR;U+2A:X+& \H\$(-
SN|CZ5C38TM0G^#,&B+=6/ZS' M30&9F|JT5>\F5=XKIU>|:6>(5N0)8.L;Z0.Q0(7 GVIOI(-_ZR@V%TQYEB|0
MZ/!,#":9N54B'3"T@MH8A7J0F%W=W^L%& \00+ #MM>U@0QY3F0Q:5=\ 'SB1M MX@62QF EX=34XGNU+"1D1-
M=7|EM()F=>I>>H_10'>M[%7]?./UEZ4R|6&J-'BZ=:J00-FIND=1P>KEC=* M*L>>U'A\$N6SS:#MW5\$--
%3F1*YI'2@0Y-)G<'>6|@+ \?#>X.|I"SU>": B: MH/&F)91)(3KV^=K.2*
(3&WWN!8&&ZAH/V2"62TH19G0":#XWDB!O(-&|!TB+ M,(%CNC/BF:&N.Y3;-0=@B#) 0-
D8A:HL.G98NF(Q|0<|7B0B(MG(0=S+ *^ \T'M%:@AL1W=8PB61NT6\$12?)?:EXV M2CJU;?
7RX<>JQKVYX!*2,###KVJ\$#JS MA5D1(A&7|UTV2\R203&,#X>(&ZV1UW8!6+5A M^JJ* C?
Q5\$F%M+M;1M&PV^(2S9|GY'T8ZE0BX|S<%.!<-TH!S+R59(53QR5C M9M>*YS|'\-0=2-
J3.G&,SZL#''JB=ND02(U3/K-;Y>V05 8RCG45R<-S'?)T M7^V9|?=>IG4F^' 7M?WXQ8?&"I&CEV|S-DLH
5A3JP'', 'FU3G/+XTP.(^!"8 MFMUN+*+^1JB\$1UI7!<\$;RP,R(T|6XJH2K M|X_4/"TXE"G07Z2.)GW/U8)'P
M|",1P:Q6=0NAQ\$|''F|18+V*00X-*C K#KR/VVQ'CK=TF61JR0G|R#C#DU-I
MS' 'Y,?;/K##TG,X+8,\Z1C,:D=^ M3#'I#.|X|OF.CB3WH|S<&BLN+Q ?
4#HJXL=24Q|15#; JF3:G04*X&MMR#? ,ZBM)66(!'#/33&0==3U.E.-BRGRLVU?+ M^U-
+1^9(,=*TZ7#J,1+9F;LAL,EFA_SP/G&4=>J(KEZG|\$B_?3EJ%(^*PK' MSCT-
:)X%A04RXT.&\$3U(:#33PYI0R8L2N&5|R;?"N.O:MV3MZSM3FM0|,+|QBH.'3;|3:=+1?6R=>_! ?I7A^WHQV(8
M"\$S6ILV0|&A). 'L9\$SV7|P73#N(=03L0P;:C5D-;60:2;KS@-PYZ(M/W;)A+.J>.-=
WH@|0Z1VG27Q.,J'J;2WMW0\$)-Y.:C:"D\$V7S/U>M [F G\$ MA09CN00K^RIU%6Z4QVNF0A|8CQ_G%
|@^1)Q|=,IDH;6W|U&|3^ \105_> WJ M@0.3|!M'H:(,)A'9<|W9L'H>20H@R!1/;|TD.<\$1&C8'"FX2:7(I|_\$
XZG9 M|OI)|9.IZ|: V)UXFT>)T"S"/>|)L|29:M /#AJ_N@ =Y'=!7.!3+IQ>^*M9,
M=T|Y|])W_?;%N#/'/H<:= W9R P9C5P=B;6:%97)V',A9A_ M?,6":F2^/N^|4BE\)|I80>2VVZ!^!
6PJ/AE/W;7%U=TL!#5(>ZJ5T>D9WB
MNU,S8KIFQ/GVZ_'LTQLSWSYH|@>Z6@0(U+Z04%LUW%NS"P"&JUV\$.N%9XI*7 M;@|OS!P\$;(:0:|[[SH\$IZ
=#IS'";A0J??A6,WC.)8(S+%(624^ (M0(67+SHLL'&2!=D|P3+7UMU\$3C%\$ABQ* @^E61-
&5YIP=J"IK04'9+LB EYH>I MD*=#8("8NSF?
30|3@|R&' \5KM#VLM?;*S6)|#P7ENL>|_3/#0:VN@25:>|8P?::17>093+?(0@3I^J<;^N/S|Q?
\$0T^+OKDW\NM5/JDZL06'D!'E/'!'D1FGGP?2ED00;XI'3"?S M.:OUK2N9^96\,<*5F\$Z\|0|;%|UTC(@3B:
|W/4%-=0VP;EB|B,R|5&L 10?G MK7W4A& %Y'R(L,7^;S- \+ *P1VHE^?
J&OPM|':2@5U4_3MZ|NCTC*HMXZ0,QX\$K87 MMG!/'S""9X4K&|-K<7
D020>G2P&\$0V\$S^U|& \MY;J=3LKNY7UT=IPLRN=,* M2FVX71_1SBYR|5,!+:D7+WAS*%
J<)>HNBW!6&Q1^EL:%)@FT40!1.L+Y7P-. M)KN* \9M<#7|9EH|B=|F@J?ON14YZ,DG+\$J|;1R<0-I1
&BV5@L90LHL!1#* M"QJ076?KP'""%.#^! \#H(5#0&370#.4L/T9^T(:A:/61|@3MA&M|.2R@_QU7D
MNVUTW^:K3Z61EG|W"1PV,-7\$8H\M"B9"3K|1J7_+#+0?H#LQ\ MTI3C69|0|YV#FGN2(\$L\,TA&-"\$. F-
Y,G\$8!8W>H;4 M>;Z=U^SB*J4'9|1Q1*|?OYXT=L6IFP)PH/-HY>6B %Z\$0Z6&&N2P^RI&12AL M"BOZTC3X2?
5;Q|0->8DLYN%K%, Z8T2|:) '2S9|> 03+7"\$70ST!/&Z,52< MT)|%<\$80F<5,\$|F,< EZ?;|QM;=&
|J>BK07C*ZU*0W@0W996>(.TW""CH=P7 M|+@R,OAV@!E0(PA.8;9Z_0SQ_@ \$V2|5Z2\$M2Q<?>
LJ(#@*C=NNRKP;WN\86U M4QPB|SK#|ZJ&Q.)N|>G*1\$@W0 QFNF(4K0@HX +.;#05+B=K1
MAE6!3U^J&IRKB1&6+9#>G/[U\TM044L)#%. \JVW&1SF-%WPV<;6H+@:|;|+ M+^'M%A>T|/D'W,
(2MV8|KM|\BE_.BVC?):\$0@I(1" |0BG2M(676;LW| ^D: MGK0Z:EZT)Y(%>\$8R?--
Y*6TC0'&BR^ \P49GJ|;K:JV1UU'T/^>!^BZ!H(25 M? \$K|WGUCB)>K<..D-MZ_8_5WOH9'H\--
_LZOR6C,!5%7^_1(W(8\$2L,1ZAM MXC:R8/D^=MH-(Y6|_7(<:|/QV_K;R1Y.PK&>
<1Q|8=1:QU**94P#_5R|B|\ \ M70KXH^2;?H3)TBN2@S=1D20\Z&FNNWEK',AKDV6VXUU)ETC<04R:8^&0KKV9J
M8= ^Z?#6Z;64LYU/#,UU0=CI-I>7!|YM+&4\$TE4|\NTZA Y|T0CS1V\7!6" MKF\$Y=_)I3="(1BIM5!Q?,%+-
>NG88ZG>LFW9W:A#H4EZI|X_\$G'FQGHVI|F MQ"+S)_ ^5;V=Y=>W5J_%^VC;JS+@AK12|<<^&V%,4_X**
"+0%L MYFC,I6\A+&|CIKL\|KZ<_X,ER; Z&:ZJGGS13P|4JXYIX2\$>3Q9A ^0:"V M|B\$^HG4HDL|+>
<"9UGD9H06C\$T|6*_<9/3Q&FG74M"@ZPE2*?)PH|PY3 N; M>I!-|B2D4 #JH! D+JV& I@_+;S#GX|
|'!9\BAZ_]|@=(/-0 MPYE|+ "F ,^EPLK&17,D8H?S(1|\$CJYYE\ -U%0"SNWR\?R\$6DP'9M|I31*P\H M@
Y|=YF"N^Z0\$5#JV0W*N_>|3@F("P#<@R|'-^1+ W 9Q| \703G5"8Z1\ M M.XMG
TI2N>:Q6\5D0EQ|P|/9"CQ90Z#!VV\$;BX93@G<.@6U^S.=F.WM;|Y2; M?8YX(GH2PMI'
8A>"06^0C4C(BFW\|3&5%G/U=5^LF#Z> /)|@1-3'39%9UM M/+N(W+1L4L|D008ZD!WT/0I\$9AX!8<%HM2NP?
G882;@0UM)4.H>.42U80@|K M%) #D WSY*ZP|8IY"J 2^H@""^""% B#<,Z8_0H#VA*,(Y*85!8#++3MB\ >H
M6\$?%W:S#>YW(I0DBBB@|!|.E-(/?C@GA* H JVM-9@|(FJ,Z9 P|ZI2T#I+H M*KUJ_APZ=D?
_Y|QEETV&M1J8LIH^\$=S.<,#'<"1 +I9P=S.7SA^X?B%XR>. ME(./2;#>ZKVP73-0!ESP\/=A/X
RFB\$V |N|P*XDON_%/00P" |84LW_9VUDI_) ^5=ZS0IHW\$K2G&J8HZ;2_'@5'+ \Y:>0Z|98QT\|N_U|U"2=
M3ZY*7'M.:DL^UROKYX 5I|_-#J-A K>\$P= \6B\)RP@WSBZ&9NT@NS\BN=.W-
MT#J| \G@RHX YGTD\$>I+TAIB0(&GIZ(T._%V/%-/FO;|.W.!0U-D5(IU74@'S M78+9J.^G;H7|ON-B_Z6'
JPZ\$-S^!0_H2#S,!K4_0@7|SW|R| \R?J'R>0\ M.9- (%TR#_/Y?UM1.>1/-G\8)/\&D0/_U!7?
+Q|WW|00_@4<|WZ/0\MR?'0V MMG75U&T.Q(SV 6F|!@N,) & 3X|7RJ+S3N+XC MZ3RELGR<=,)N#\8;)CT*TI-
&97P;% -A_W',Z\$/ \$RE91;/I.CNW=H(.S|V(2 M5 S!89=YSZJ%.0.I-
(.7(NHWM#4\$Q+TSFO\W_NSYXK*E\$03.8?PB7J'-E0!^ M)I;3\$<2@=D'W+ 'IRNLTY+20;MT:M;GK;*[G%-&K)?

NO\$TTEOH_ZAI+LI\$JVW M528R:7"07=-,P+@2T{)'?L,9=Q MC:7P#5^GI&+P_#0A:I\W0(:V-R7G,6B\7
C5TWE=X9V&>N M#f0B^R2NJEAO^/Z=LFS{3Q%9U*!(#UZ75F3%V\+P+A_D-H0A7S_#VGKKB/ZKZ MR2CD.E?V/-
OV'BE+@88\$W.HZ_+0';(EMR1SN\$7<7)PFKVA3 " 1QD\!NOXZ6@A(6KMIBN>GU55V/-0:V<=NMK\$B@W4,*
MP*?)I [:0{4I4SU0,DIX3{Q(V){S;JF!\LU91AJBA{N;\$*>+((4*(2,8XYNN
MVDP:"QJN^9\K4PU5U9YN=JX=U\$.X'!L+V|9FH4NSR/'+'/'-T_2S_U"P0FC@
M!0)G>Z_ ^H(J#M4,M60&Q\7R\$/P^HIOIM7S384"E!I;>((\$5Z5TJBT@0\$!_2D1D6I(B_B_4*"
MTGL3\$!2B%.D@2)\$:Z2)@Z!U"\$@&1EH#"0D+R^/;>Y^SS{7???.N^>\Z|Y|WA_M&)ECL-:8:\W?
0\WYFVNO_I,LMDJ2#4'?WTL(P564;?;F?^>;W=//&'83G^Q ML:E*!X'2W|*|QS|,FF\+5XW10??M)>?
[EZ]X_7^41#144TZ\N\ _V>;A7R-MS_MB=K|. ?M6"QU\$K9[-B8"8S@^&6*V)R#H+=G|)/[@+36HEFUN%MZ*
[W\+W9>_G MSP?*1K+MB=:@S{K?RG/BK|:Q0;IT_"3SI^0A%J>*9P"3/5DXPHJ8U=V!YP<6
M|XBJ|0{#>RI,C27'-'ZQY2+<5"NHTK&_>PV4R"8?=S|BL=W+|\<90#.IB0RJ3#_M?C/MWW|:KZ/ZHYR+R\$B-PS-
C5V&JM,R-E<:40>5E.TB'!*!-Q{IS_K,?X(DX3_M1K1_N=WS&0=0&WT_3DHT1I3Q1929#J@E9JL-?
@@8\$XM4G19E_M:075:HKG/'_M\<&.E<^:;:W%D93@YH|'*,N77U8U7L3'8KD?5X2J\20:ZYW?+D.+35:7"8X\
M;|PI5U#I9.,/5F!2@={05>@X0-@_#Z==1-ZJQ-QLH>A4M+.HF|9)'HLK6,:X_M--SZJB
P_&E!4_*9\$EI!85/!3(7|+;H?08:E=#474N|1W/PSNVH%E)AL\T6-_M)(WG"*;@S_G6*FM>347.C(H?8
95/[Z2|C-[9!S{8AVD_7U|'%.Z2#FFH,X_M|DZ,H+%KT4%QIO|XPJK>8R?7L|ZDLF#BP|J
=ZWHPEIV.1ER!L'_C<232F&_M_?EP1|IE,:YE,8;QK^K8+0U5&H\{K7B\TP5/_#90+E_/JQX-+WN!WP;^*PR8
/>00TK0{#|R#H3JUMQ+*85Q(*)[6VF0_M4=\U,Y|CJ6|M>@-159.'_4Z\E^FM; #'Y@(/G_T=P_%)['=-"@+?
#F@-:Q_MT4&DQ0AR{P'CM(**!Z_="V;MT4'MK"XCM.&7Y|'LPD/Q=(P7SZ\XJ6MB^
MK@,W94LH:#,4.+37"16I&UY%7F%.Y|T_VJ1@W^Y_ ^GB/UT_7R?6,\$_M_!+?&
M;:*#8!*,X3B!EMH'!^Y7_'J!_PUUPI^_FIO\$XMC34F_Z|-Q6\W+BW\ 'E@0" M1R8J"@ET4_H%08CPHRJ,
[UM41\$, 4S!-6>|/1P{X1;T/8+E|/WA^T4%/J45^_M,HK8!+NAW8A_;;\ZC_WT)_I<|W
MLX7^XP#|@>M*G0+#!X(|_ [Z\$+EBH2LTWI_4G/VSSH%]PK'10N_T=5%Q#.5_|
M^0>XP0_ ;F9*9VKU,E;U,*8CI008E1J2#^LCX?Z\ _>SWK#R+^WXVP_#;RV\A0_M(|^_#;R_PTC@|=Q4-
V85PTY|"#4"S=0P?I^!#1-' ;X?GFQ' :J_Y?S@U!RI_M'<*MX>I>)\$)S_*RP9|&9Z:[L&F9Z;M|{3\5?)Z3CMX<|?
M\$>/XH8<7E" M=Z* M#Z&4=!X8\8T3.T#/_ ?BEK3UT\XJC.TE:^6-ELEE2X0NBQ7/ZR/J)_*=M;T=7
MODG+WJP>7;W37-E8UU+U(>Y^.'%*)_F2;:VEI?FSX|_T;#Y1K\$)_X/E<5*=4_M*NX(T+|\>:;(#_8>_)NGC-
%L9\$|L3_?G'PVFXS"_8>5SDW'E_DVA2\|U2S:CJ_MNR!DI+SE2?;'#PPB*\$ZT_M<^F_I/FFH\KN1H)?B-
NT|;FNSW,J;>X0HS@0DG1XG)\$S0_PCV:E;G40=GEQ(MQY:FX19F5\MQWJ"6LQ\H3ZJK=%S9X_ACS2YF:#6^8?
K"+RG'_/):@/,:8ZG|_MG!{01\ "\$M/#M.60Y%D^KO"&R&\$|_ =9\$ZG&AV28Y@Z/\P5,'C/-
%N3:IF'@N1\$TDX,!SB!@_MR;WPGY8MXFB"-@P8A?SI*#_- [Z.+|]\$)^7|QK^SE_X_%,W2|#,0\$' {064&!0
M##GI#PY'J/EM>/9U.V"V*0_M5(?NLE)A#X90;KP+,F3Y"5|6Z/[WR""QVD)?_ECMU4"C;>[2*R_71W^BA?|.
M#R^;ADP9\$KJ**+>H*E64\|WXV*9=#SKH_>VZC.&^:-'DFUMM_K9)' '4LDT<-_M^4Z_S+?:EZDNFP_1?
=^1MI1?|{N/J#2FZY>HF,UVU0>S51IJ52^@K?N@HX_MQLOI|_6M%I>,0_==.E?V\$+Z1@!N*0_\$00B#B#U^
'K7Y5^)^\$ _WG8XMUD6(R_MG'_%U\J;;_>PB',_ ^YM_ZWOLE^D@+L|_ '8= _0)M%#7E0.Q'PICAV\6+^'FB2)
M%Y5GS4WT\Q0"N479B07\$XR:=[FWF\|U@,XV_ ^=6|Y^=MK<>7_FCR##0_8AG_MEYF!_)_1U
MF*)92T9WXE8TI;@43B\ \$SG07*!#|EQCF)>-1)|2QAURLD8:3+,Y4M8\$[A4_M)A9|^=PK+1G|_6&B+0=4
/_/@M47_S(9%+/_^*1_+D^00_KD8.(S@,I)EQR_M:;>S\(*,^ZXP5^" <8_8*7,8VQF=|+|9\$ _|^=03Z/QH?
#9^M0- <->-3#+/_ _MV1Q_58:H&AN?JRD@|\\$+-/_|Z|??KP?_-HM?_ =B.|(3ZY<*BR9""^="5
@P24B(RQ3HWWZJ)*=<_M^E:R47U>N._I_%6ERB)AQZ/JMA>%0!2N<"R?|Y-?H2TOPZ617F0%ZBG*8A:E_MH-
VTYVB3GSLXJKJ0S=| ^GJKPU>A),6S7AFK_00UK7JR+_ ;J_.,09,^I+J/V_MXB!-
<(EX<0.JP+7XUK2#C;V6KZL/;S\ S^9/@)=-@H=2((VQ7CGCW6_>[!]?*5_MQ.BPWW#| \YNF!V-
_*L<6K.+R|Y2|_I\5R3^|);)5_E,YMM(YP2?_7PK?_MP'@6U2RC>M;|X|3+*3C.M6#ED9'W_DM'35*Q@-JV7-
=TY+X_M%JEV\9M.S=09T_MD+-R9W-S=(K(^_|;TFZ)RXE^W/S)WIK/W|E;&A^A^FW2@P%Y(|^4U-,S|A
M#G=M5=6SBT)/_2=/EX|"\$084.W!H_M\.#0RTPZHB|{(&GVC^PET'_#TPKB#)Q-^_W\$@W@7^(>+N|M20@?
E/;+*D_:"_M0*JG^YWGG30<6;!#@2LK%:QN-VRGIG70I;D*CNEHZX#2{EX#L>HKFP)APB18_M*)JCA6L90S;&
WI4>+F+GX^_HIDY_ ;&_9PKM>E@3#X;-609;Z*"!&SUQ(2E\$31R2_MFZZ3T2K!?
DM8]=M3!4QH/+@VYZX#1_+#E/C:TVB<*@(5B'0H|Q23WU#H;\$)M
M."FHL;GC8/,%!QX?"2>|!1SIH..8<.4*MGS,=F*|0;|!|G+NI#9PIFFL=
M27WXLVS';S.)F\$ELV>9%|E90Z.Y*?J%QTZ;3;* &.D@-B-*VM<(-=!I@{W)
M2\$|;K|;S4.1&HL00J=;%F<."P\TY7=:5#0Z4EVT.6S06#NXXU1VS\$DNZU26W_M,%+N|_,@Z-
0\AI2C8FMQIX\$VF1|@.A*6^;/SY\SE0*;!MQ4GIPY)F>G|f6: MEG_LXM=>?
^/CVQY82|!32A|{(12H7,PR/6R."N<0>104+\$_MU9&\9/&RZD|K:{D3.VQS+>>>-YR|E_!
(6/63", \$>L\$T(=2>#24L=1NY=: \$9?_M<&PV!R6_=?1'R1K7U02K#|-..6WG)MOYWT#^U,
|;:;H"*;)&'I)MW2^EH=^VSX_MG@5J6_5?K;=:|C!=92Q-4(J,BRY|0-5RON|5QWE(|WT3DW0U*;''.8R;^4QU
M!*/7U,8/KB|9J4#BSD=-K7:H%&7*575D|QWLRGZRV*W|LB|QM' 'VX@8#G|, M;Q1&4A(4>7-
75V&^ZM(F?,JP36V\ _S?9GT^_6*44(UB_PSFU1"S5G.)_S|I9_MRK<&GC;28#N;_90Z(KE*B&FQ(FUSXR)^0|&-
A)2DY9*@(5GPMK_G_BX38@U_MEUI\#9%)U.C"9Y?7;:;*;Y;G6SI\$/ '*=3@0:FV-Z7EPF/K.*38V"013|[2C*
M7#YEH86->GZPF@'_-NF;>W/TI\D9.^_T60\$K^Y/A-YY&73<|EP>5@V@BB##I^*4=<' ^/'%H\;S?Q63AF8>_B
MHTUT=RB\2>@,UQ'G_81-(AV&GA)5%WS)F(3H.?)RALA/US+;/7;|9%Y=U\$ _M;R?9|)8=VN)|<3M1X1-
LH9AC"W3:D0_=@LK;|D)-85X_3|GCZ_1VQ5W_P|/<_M[DMT4+3*\$S)J%')\$|0(S|<;
(FDB1S(L@_T%IU6*EC""^C"HJL'|]-HE_JT3!.U_M/20\$AS;8G79H;J%TKX40^J%MW\$Y#&F<*3+S13WHN-
/FI>J^>8NR:>2Y_T2'0_MF%"50*EF_HR'K(,.,@&7\|&4WM0Q@^./_60Z\$ \$8=F*EU;VB^&JLXE'4E_0G\$A
MZRDE'B(+3WG>LU;,*G6TU(QBVA^\$7TYHA*NYJ*;/,>Z_T|_KP+G<(U69F\&Z<|YSBP)ZHQD0ZH9
MM>>|!I>|M?^'G9)T65!SSP(AUH\$|_<>7S+P(SS8NF#/EV!MW?B^)#W+^WZMR_M>SVQ8|?2KI\$GS!?
01)IU(*7)W<2\$U;TW")5Q0D%70DCS-_M&75_25B6TDK5MFI&SSEE5I5/D7SN'/_!>-
Q418Q^H2?.\$ZPAD2P_L0\$Y%!U%\$T=>!?KW;!"0ZX"CSQYL#G_W'RF?_MW|. *JIDV+%Q|,,M>_;

[CWE,4[C,]>B]NX;WN,[T][H\]>]U?U9Q9A+X#"GPH
M5NUU*%XRK@W"B+CRPS*4<<2WMUZH:BCGJ5QBS*T;*N!U;0^>VRH?{MTXC%\$# M#/>N 10\$ \#(*
(Z'\S5L7*" 03-#VJ\LF\0540US4CW0IHGE>I#@/\$AYG: \0-\$X\$U8]T_K0D<57
MH(F0%10E*3ZG[79LQ/+^\$W=8%;QUW_\$@FB:1IE^@>-P=0&0\$>60:E>*PT1"2 M\6#RIKTG8DI/4B3LM+5*I
/%"+@3X10)!\$EP MV+9J73+BI5G#LV\K=SQ6+77D=TL"\$:#6?%,<<,DD>CE!W209X*@NP-? V4L
M@ZNM7^QJN/E9:5QYZY9]:J2F=19@2&7T\;+TUS 9J=0]T\U0/\$14M=W3"/ M.<0.UFY: 'P>%ERA<89D,AEA
820[,^Y0TBQ':+*'LN]4RSY>7.Z;MI:]G8 JRGVZ*>+3KT!;B!30R%KR")3M2I@2)HZ0[G"UK6!Y;1'&
M'L+V([S3'5-I205S->Y0N]X7@9GC1/V4WW,>-0=U!2&-AJ_GP_MP6"2)4Z M8)4)0-
^P)RN4;.\$G@,B9]1G,Y-E2/[1G=0;#B;IQTK!'E/\D7J: M\2P@0:0\$7FP[>S^5>GN616 ,J>SCX>J-
=G4GKB@/K: *K W.7>(IV)\Q?6?V M]GY0_OE\$+JU&GCG!Y0*I?
9()T;D;S.F*KBX(AG(A%/4J&ST,1FL2V:R^IVTV M/6D(J+\OV'-F415Z_103FZN;E073W";WR\8[///8T
"KBD2V?HV "8@< =:-7 M/!FW.L04%MI|CCW=N2_63^).=2&S/=308)!FS@U# M>1\$0H\@K2S.#,
[&F>7S/E:'0_03J05QXBJ[RZ([W+8.UPDXHJ-? /&URY10MM@S*4H67<:(1D#W[Z7 M@OW595MU7*)X:FJ&D[-
02\YE8M'PMHV2R.ZK/ 1:1L9 /4HQB?'AHJLJ]=<'LTJW,D2EB73;^2+5F7H_UOI_?ITZ\$=?B'0#
^+77NF)^[A\Z#U' SS\Y5J<1:2< MU>M&OJRS73*9,N D1*GMU*
<(6P3>=N 4!4%"! 3VOA5A80Q1J9?;WRJOS' / M8>? \; **, #IH8IYG04+II)/20QW6E\$Y4'TV"S+@FL'=I.4
03#G(4(0\,RVT MH;PH;\+Y\1(3>K,W;U'[P,WN[R7C^M4B(+8G (V1-#JE#\ (F/L;\$!M#*" MA[0A0 4=5
0M*798WM)R]\;:/1WN37TNN7[CUNU7P=>(-<1S>^1[-^=G7&! M GX16%=(+!TDB"5(CT-
9\$8ZMW6V\+#+3067=D>7E-ALV&8>QZU>5'\$Q=XK"1 M,H>J7\BFHF5?4?S6",1F1VW0]T#9//SDU+2>>X5*2-
ER0W/3SJ VLZN(8J>& M66?-160EJ9Z=!:91Q@RM>?N=>-A+=#. (ZSGDE\VM:C\$U>C_E&:Z1=Z/GK.%
M:YN>0>+EZ_%85>_?46NYSCTXS\509 'K>H09<&T;CJ('2E-E(:LHM0HQ@?<
MA+=M"TO6U)Y 'ZKUF,W4UH0\I3>^DN/ 63)F"DN35 !|E@I\ !PR!G-!AS M 92DD5X[U]C8K_%<
(WV%7Z1&5*8V=0.ENS:9\$F DV37Q^(\+UD0+H#&H >FX\$ M^R#&)(SW:\$M*\$&%;<
+)GTJ%Z1D>HN.KH]>Y,NZ/@+33V#)VPD\$%^KQJN7RC5UST5_Y35W]!\&.N"2Y@[\^A0; .3NQVW_UI#BXPFFK1B<
M\$E;7#&PG0BKJL&6.R0VD^I[\$+T00U*\$9RQYAZ03:<>QNPUII((Z0 ,8#M3L? M46?<
C?}DS&E]U:GBZ&'Z]?.;=A>U!"2:~>?TF:F%7\$Y9D7\$_RG&(D83YZ.!H#<
MYJ0LX/V.P.!|M*YZYT\WNP20!*G&\NWA-P=#3EUK7+_VRL MT=5?<
M :4TM@%8T==0\$A^A+/\0'/B#Q9*YMS8WI?D,2:7G(9DZ3KH@];S?C=!
M4H]T4M@K(BPN:/IMF^SG*F/C>DE&A\MXV0,8XYKX"H-2+&HKT0JC=1FI5^-6 M'S&?<
+K+_HE#\>0'NAIS=@R)-1Z%G:.8Z0L=@HP'Q+=Z&G_FVGG/DS9!#>M# MOHTM\E)I"^\GR#3P^9^]R)##:<
<:Q"WF';,;RN-MV=F\$C!"^29N5,)W;P]S56# MRD?/?<
>>WL^L10I9_6%S:B\,Z6.J<1P7VMX^+N'45S0%3NR>4#E+G\5-C_P_I MM:KR9\1&>R6 :PU8?<
#:.0N]AT.:N^*AHD3LT*17_-/[WT27^<400V&S)@PG0 MBN.>1.C-HV.66NIOY36_^S!_F_&BKG"^\!(,*M2E<
M=&_I'6[2I(-+4&0_F\JE/.+=-C!1\$1WT2*_G7@ M>7SH\$MFJ#703G'J<
MN78)W5#V0=.F.AQZURS_]+ "JUIVOC0[:E'2%_SB^E\NX/0/P0&GAU5EF5T4 M/6KT%';?0Y<.>GWC6/\?<
E2_~5T7X49[9X&7(>2!\;&];G[)82201EVS\$A0XB M230./8X<*\$]ZS(\$J+S4U7/(X[PU^T-0PFQWXS?<
T,6#C,H66PEI"V#?#WZR\ M S%Y[/+UZQ:WNL_B/L\K)): M0\1_4XN]"6UM\$<
M!T\$GU ^Y"V[Z,/16_ZW_6 ^W_F]W_J_17_K];K?];[?^?I^WLP)X2,6KU*!P'%9=YD,2(L\$MKC283\$<
<[\LNE?-.2,>-N;W=F MH8'T)2[FZ(S6[7 J^;./8]U?;H8F,78WFAQWZR&8,'5HF%-DYJ6>J(GH/!-6<
M2YC[TKY@87%'R\$S+XS; *XB]>1[>NHSB^J;V/+L3RT]6KFW>Z0FR)C;3\$BD MZ02B3TW MVY_V.)T9AL-
/P'I)X \$ AU4,PT\$DG3KCJ4-^R?IE+N^EW:((!K?'>F@X*TZ.DTV(P-)LG:*J%5)V] ,S660;*'T4,'#C^<01A<
M!%/J?3HHYX]%K,P=!" GER@VV]?T* N\PI;SMXBV\$FQ_6B##?7*6!B4#F: MR/Y>9, M!YV0-
%=2+18Z\$H'X6H#8.T8AF7L22I3#L+1G M;C;6[C@QA3N)-?0.!(R'H=0R@%XZ2>/#B*?-RD'#M4" *R19<
2!!IWE4K)E20P=MQ^>EI^B2V\7],6S%.8GU^U(V.+_5 M?<
&^,&M7)/!=5^N (LD#^0\%R<'8I&#D=*M)=)#,/^T\= ^&9]S9T?6?02R:S6X%X'F+*R?G<7U<
99"5BDA#D?)^TBC M/4.D024%':G4N\1\$F'LJUT"F93Q0X)\$M1[BLSSY9>"Z9K>7!>VY#T/5A8QNV<
M"AXN5>'A"^\R^ X_K?S)(S?4#GAKV1 I9P6N%?MT\^1750^"1?*=I/;L^% M>9'++(T!(#;6:-<
":7K.PF&\$YJ('%#T.7G9^RK"VZNH5_?=Q(0.JR5"?\ MVHKEYZ^&?U0\1S_I<_.B",BEZ;C :Z/^6_Q_)<
M_18-1V2C(^%,W^=702K[T"*+M<5ELYD.4SA/U;[DW X\$C9-_X&BQY!G:J4#X<
M!AX]WW7@F^(/IN#QYHJ=#2S9T9L.ZA8_#"ZXR &.(S0[> !^0]T\$.DYNDW6 M?7]0@H]@Z9\!DWG5,<
(7#6T_1T:\T,8L AOTS10:@].NB8*H3Z%CE6ZD) MH+.&0@;102%\";1+>M1SVUA"QW4&M=-<
!_&_9FGX#>\$WA-\0?D/X#>\$WA-\0 M?D/X#>\$WA-\0?D/X#>\$WA/\R")7("UH(^#70U_WX,[L%<
[)]@_FZCVD!KZ/;:\$ M0-V,.BW432XD!DO_9R7E0^6W_);?1E\A>/F+N^DIU3[XX1]*C>^>29F[2R39<
MM:A<*@^0[TG>.@\$A+U/&H\0&'<>1"4==*_^A]B77R5QWEJ1"3NL\]T[(\N\I MQ3/1)G%\$!E77CF<
@]*HIY;UU3*FT&T.0"E5ANP^L6AT]0GS.) Z%_&@GM?@ M?&H';?_G<(7W6):#- \$!%=@N*+F?VV1+-<
NXU'G.D>\$8HC8ZLK^=,SA1U*;Y MM>=<[~*73?="/ --6,"YE_%LC8-'Y\6QV9,?/YPY%7V>U^K]7>9J<
MBC.,F#T\S',19Z#*>HD=5&UVSYEG,2GKY0T7#(D*)H^&)->>_CY3*C@YZ% S[ME2Q;G9CC-- 6\$ZN5P<
MXIQZ&;H#RBIG[4K4N[DEFFC0(-XXVJ18^-Q[D3]\$>6-J82/F28A-- \$@L^0[M2D#&=8>F_M5]Z!<
M7Q9H!@XM!G-&>[YHRFH_7*\$IOL6UUUZNMMD<,%M Y>WL2]#4>7"/VHKZ+D&T" M-ZX&?<
7>\'0.J(=;W9WGJN<*KX"MGY[?LN#HWX@3!P)GY7:0IJ2Q_%OPM^&3<
M%9]S&J6;GZZ=ZN1WNY<4;/F(0_1DZ2Q[(L/<;E1W7],K5M?1S8EJR2#0Q[6BB1MCE+8L,_%@ZKJ"XL]4 MD-<
+MM408KPUE(QI3]1D&9:8: '[S&Z=9KDKB!>>,[KRUFY[<310\5G[DYHOP MF2-<
Q&J=*+EQD[JC4Z1'\$+LH:];Y:6\\$/19_Y'5/;_AEC;TB@Y>^G%AL6=I]LU9A[0#G,8,V3X>.VM'AB!"7H<
MX;N'1>2WF<(. \$1NT]ZU-/X](065F?U(FM8C0 M0\>T98N._G D2Y*>0'0/ZS)A7W]7YY'7-(B4Y/@J(6[AR(-8<
M?W'LY+?@948!H8-Q3^*'#)F5/*T(WGAWJ)QA=255""*9 B+@("I^L1^7RG-0;\4&KD*U85-P"E7J_<)N" _S7\$-<
^~\^REE27N,#G>KAHJ1GD^QQW22\$W8""< M3]-5.WJR_7!(,"Z<
@HF#5.^\$0X\ ">P1,F,:5@A4NFX0.%KT]1<.7Q0&ULR)?0CSBRKS+V?JKX00S^4>L#T"&X!L[F0<.^'+ MT.<

S'DL'G779NN\$HDZMY;>4+K+""?[\ Z[KI3/N,.CQ,M27.PJQ&E!IG#305 MQ*LOWDWS3:"74!X4-2??
JX@ANA;A8\$;\^,>"7M&=>4102\H!M5 M557H097[!/]X@-%#1U20C\$>P&E1]T/;V@ 5=\$TT)/!GKL4L"@>-05.
[!MTVJ M%PW HR&Q&07A0[R7#(=9*YF6:22RRYY9,0 ?0?ST7M.] 0?8UZ('4&! /MU MY/IY"TSU0+\$A2/
K]:ME=)Q\ /'8+^SR)VU0:W8 =#E<JB0N MS,&*MGJ-0\$>:\EUS'.;\YM\3)X>M[?IY^!M7@15YK)
<6E=TWW(Y\$*3CM*G MDMBJ>.]0//M#APR>+VH[KQ6_3P?ZW_)/"0.E(@XJA+ EU%'9B=(FG7/G!ZG2
M;W0)3SURF\8JB. #M6&Y6(U8E!7WGS\$=:DM96)\\$,6U [J%"T&RJQY\$7J*(MM?'2*0T:5W^ATLNG9F:,:JQ?
WG,5/.H/HH!JX%N"S'00XSI>YC=N1 ME]KA)UQX%XH<.=^=5%Y9Z=M;=
R>8HC_&85&1T=K,%\$P'2^*4.WZM&DD5#T M\$02TRUZV<84)^0"R;308#:WVMH^,Z.J+IPGC[(&&0;4#P M1A!5D
YZWH7TT<026&H0 =+)/40-6'#@VI-W!P9BYN?R/0CPJ15]X#!A9= 0 M !15<_1LS8?Z :\$T9XFC\$3]G*,:?
SMWSEK+5W50+DMFZ#>+F-E-T0; ;I/L=HV MH>"ZWLP\$@4].+6="B#_?P
M/"9VHT4\$R4>6C5&.7".,4^*\GG#; .359(J40M=TC7&K0UU?,E*COL1\ P'N.> M?9(, #J: #YK-I%P=H?-
_EW%\$GWY&-ZSG"BSR0=3F//-.9MY0^&:A7S[D&-5H8 MW[SPM-J-]HD.XD6RP%9]R/@. :6+9N=[V7X)/'7.-
X0MM\$VU%\QILOZ,7.OE%B\$ L\T\$0%%J5_3(30YBY#DL:Y*KNX>[M5ZTLD [M0\$]OT\$UO/[%9W[VB;SX 5-
OP_ \$@W()74+!M!OH4XAIM DB?2.-R3 M^00.-C/19+)MF)1ZZX9Q&T]3[8W!;M&N?2(;3+4%W\$4'D9=,XJ-
JZNB@-N<' M*J17NPVR'+^&*>];U2(Z*D)0%\GE+P9:B]T;.- D3 <@^A)%ZCB'M,.0/GWI
MXFOF\$/[10>T&XQ=!GH,IK(\$:XBV0*\$>>)..? <"% 4+B[PS[TD&1^FCFAM7(MU10[V\Z'5VY9/"\7N?
Z5U<\S'KI!H(/6E(G@: P()09@],E&75\$4QM:4%1N- M[#/9)FM*09: ?P?+2),3)C'9%[0^7\ S#RYF*4-A)
M['TC&!\$?IP2+Y"V(D<[T>]G%6UM1K%74[^Q13^;\!VL4CNV.^)ZAXIN^T*0N M7>[#8[1# +9+\$:H\$30/
:2V2D"KX.CV/+:/ \$R2T%GJ4 VNSI0P19 MZ2L2Y]:%U[-1T=3D\ (MGH>#GC\$&HUM-H9X3SL3; !@#;T\ -
!2LV40\$1&N(MS6,B N8J2(UK4\$SKV)A9>;Y*?T',N60\ '/'5NXQUD&1SWL; M5:G5S"A@&#N?B7V?G5!D^YT-
J?!,W\ -9GQB_8C\$B<[?]TK(025\]KR251^]J M0>+ 'Z\$ [M4HQ]JS?Z*#WNAgy4U?
>+M?"N#24G=T=W=GB+^9<4>0F90B.+%0) M/G9, C(WC_K4C&E-P\, PH4\$4W"Z2
P'42P;]V+T0XFXS+B(RM,G^JI&V3 M.VK78L)U/&4DH)0%7P + :R(QG C@TH16JVJ\$(8F(5>2Y
:WCF"N>]F*SEIU MT(7.3\$;7]:X?B9]Z0?%*3.82J]Z9+["C#&DGH[90[; SH*]T4,=[.L@X+741
M=0;8)ZF0ZU:7R<*\$ERX-LK%(' ?**P:AGDP61);D[?X*)[669IU TP_*G<5]/
M);WS.!HBE\$H\$ _82\$HXL9. #,5,0@133590 IZUZ.R#5J&%6"L"\$T-^)?(LB0
M>NY:\$L\A0\;:=3\W;4@F5DYEI6\$K'[A=:99#W@ 42-@)[2 ,VG (68/5V+@42
MNL;3X_AWC+7=F;W:2D2N)W<^#B5J>W/.+S ?TEBHQG #[K231_>@W])5 5(!
MU6'LP4%7G=U26@GB[#7\,.BWK-Z-\$6A\C]JWYD\$.-.FD?C\$*P'>) [L_8GA; M9('0;M@)E*0]
DQ225>RS)RK)&39*Q]E33ATOC;]0W6&[4/G0'G*.IV71'M MKV;XE@[GJ\&%PAA^XB)A?#\\$U-03H?PS=8F
T_(&H?GV"K/9QPI>)2>BGEE2 MHYQV,DQ^- "24\A98V+, ? @+!.YXC126B00]WZU=%VY%W-40\AA"DAF.L_:=
MNVATKII)RCLU=>3UW<(:NLFH-90WL\$%,B,37.%//['3:0*WS?H-(N 6XD\9K
M/HQJR+,G>)1,VEC[GW;H8.>X:T-9Y]6YE7M*6.XXNW30B0):#^H(D\$5^#A3C
MMU\#W254C9\$?/>6BS2V4S_OA@0H%. ,6HLVY"##?BT1<'\$/ M#AP[E+P4\WAB_?
6P[YH*B\&8>KY.ZKEL^0L1QPV.G;S\W001[PUCIX.:[OU+\$S7J'RM?NZ\
M'UI&R3IDPP02"]K=V9X#EN=A4SYZ+?M95+!/W@H=Q":#U!
((';:=97%H/7T94Z.^U7X128'7_H*JKV+W)V%7=U@F/N'RD48'-,\$.?OP[[/W+;PWQ M607?
:=^EDQ[J+=N8QQMR\QLPOMKW\$.KI*U195.+G@5/' ;1EXG\$WT)JOJ,(MIL#P#9 [2]-04[0Y;2>\$KQ-
X6:Y])%K=:?'W\MX640'\$-; R%=#PRP A+. M>]I(Q'X631#09L6K8?,5*I2P-E98.M#>+?
R,]@ (W]9M(E*',E0NW&,VT6& 3 MD.UL" F<9-)^L2+*? [4_0@K-\(5]A+3]DYY;F>EING_Q(+ (M+YI:/B.XE+?TH
MNR=T4/5%&'D&6V4%^: "%!RV7JRW]L1/,9\$5'BT3=,%29*ET_6H92_2Y:1T- M-KMQA9.EY4-7%LX\,W7*:"MT0)
>E6Q&6041T?.0J+013*W#03H>W8=>?EAF MC7U?L19!3MD.HNAUSQ[N;I&F=806H"2!F!OAD-7IQM@K+>([Z]%;
X:BA*KPYG>WKXY*9Z#WS MLS/HQ!YC<8_8&NNM]3N4A X'V]N)&,JZ5X!@*>+7_&,5E1V@S,.GP&UUT+/D
M807[13E3REY*Y"9X2WJ:#@/0D*IOE_M?240C5,;Z4WDB%XF:FVHVKZ4]#X5F1<'R7C8N17",?.9AY\ -?P?
1V,GK !OI M60J\M*GG5)-)=3Z_0]\U[LU^2NB)%X?^(XY;\X>,V0-.4G?VDVE@ZGU@L_#H
M)>'#H,J0<%.J]9B,S,MK' L? ; -?2!NQ,CE:; &3ZRNAV9(7039WJAU!_6SLU8 MB/JXW3U?%X^21^&X,G/G,
(SN\$B4NQY8LM@J'9+:5DH1/^;0<;&/VD-35P*IM M&A_S@TW[[J92)X[S87G/\/(*C3B5&\R/N+
4=>Y40KC+1H. M*!RZFC.%\$M*6S?:NNHK\L'0,*D+.SI60; ;%ZE[*C[R[NRIBF_?3KD]AD1R: ^ M8(0
I>U,W,3S\$, \A;6\$ LX)=^EL M*RE>>K\$XW:3= !PW>+Z"=1<#- X*KNU)MLB03).YX[S'W<4-K7":6\$M=Z.0U
M[>3+? %I[NTV!@WN/; :@J'&)R\$!2PA9-UFV0X\,0% =\;<.W_ ?DRB2HT6 MLV 9Q! /GH
N\=7N/@T',T<'6E4!=-!V]E@+,ZT7^QX7IX1FFK2KBY'54,' MN_!R9F\L3,U,*E5=*,#-?
<9_0.UJ6.071N6M!.I\A<#6,&TQX*=L9-!|W])! M=XQ1&['4XR;0]0BV?B5\ "59MD44-PJLW50?
GEU0\$@.F/,-8-#88CA>-SD,&? MMM5C2A,%NT+Q[NDL1^*3FTZI=YX)%UFS,+.7/EB(U9P0'2E:VZ8- U3Y>3J(
MQQ4%'0CIC\;KK05PZMX0,(Z^N^B2LQM)! "Z>#H25_Y9X6\NHX2D6?G#)0%?'8 MR+&S0I,TJ*5TEV_QZM/GXS%W
MS@EBA2"1"IXUG7\$D*;>\$00_QK3CN,NR>61?Q>* 77_F:QYTP)V>5A=8;IL-'
M@EE+'5=%F3RIOALEX])_4P0<,\$S-YU @V"=>+DB>P*(=V\G9AETGM-7*:Q1 MT&/I:Q=/4G@8M5E>5JV1??
2@G\X"]?G(#KH&8HJ"43D"\7WVE&D7U6X]/50 M6X_UWC",U*IVL>M6^/1RF]#TKCW\$(9^X4)Z
60D%CO)]F3_?;40BS3;M;J7 HF..&V275+JC.'R4:Q;T!;06#',+Q
M\$1JL;OT:/%6\>X:XLZ9#8;39S^.;MVJ%LR+@%IOGJ04ZI2N9N)B'#\VZ36+X M0J\$W#R&"-
+!5<3^G14QM^8^0IR% F6Y0\([N M-2-71! [Z_LNW(EU()W-"0_Z.HW]B^_SHX/(@8HMD*^:3-
&>KAN2\]W@GEZR00\$7)UV5*85)\$0B=?B-^U:; /7.I3WA M*U&GG? CEG'
[E:\$!_BX;3,5,LT:&JF\$+VC@: :K-I=6]00QJ@>4H&4R;@Z. MBVL:8"R@]>%Y:C!Q+)>0;*Y:90ECJN1;-
T299YVWN/+C"V(RVH[^J^L/GNQ'> M]L6!TM[8_T+MFL".P&S_ .+(9IO=!B;,"]VBM8W1/*M;HJ@\\$)Q1-
V+6V* M!]FBSE[E+_Y-S#N3#EE6(PIX.Y%\]_N3(F(. .IIV^HWHBX^[:RZ;(I)JSL4;
M<:F17X9N\OM'88X,>CR@P="MEV%NFJJM:NMQI9W\$A'!57H>L4MNY_, [0Y%[7_M_ (^*4E?&W7H_R-\POB*@
PI,>\$8'N>"F^+9?- (XAKY!MV[(/#4)Y)AV,"I8; M\ GW1IA6%D134< ,/SFG?
BW&)\$5_>K+_ 'NF"G1X*_>UM)6L'SH2:GNB.4^ 1D MB=YCNW:\5,](=))/J(K*B6RAY6*R1I\Q^)]/6-UZ]T8

MUH4.FMHS']XHJ_@QC>?LIG'W=[_0PTS1''M=/J>6S&-][?;'Q"N?B,'0%_L)
M:!=9P#4A.)N7TK2]S1E0,YB)0UDY_% [R7JV8^&6!TSISHA(+)]"JM/UM".7 M^093:;% @93L1S@^\
<[4,\&N_]?/M,%(XB-^[\VZ]HNKU>M!&M?+7ZX;3&N^C\ MXVFJ,X/KGK&T2\BK%,BJ*\5Y^QF9,:S"\Z5<-6K-
*.7T049-<9'03YT4 WCV@G&51)Y3/94^5/5&.4X+=/: MP6HXJ_7[J!K)R5?%5_A\$'GF(*J=VF6-
DG>=\.2AU:T5\$\-0CDTG&S@J*0AUW>-H7?5%*T0Y(K&F_]?SPD8L MK"EP3PEY?;3"XP<=Q(2
=U&TBK*JFKXE]WO ,I-R!+[',H+%TESGYPDE1Q< M@4'00>UF|C
B60!*THY7_Y91|,)ZSFD@]KDQ,BG"@1'10<"!/#2C(VHDTU72EI>7M-NF,S[|LW9 ML'N6R'>?3)_%+.H+5E\$#
309KR0[Z#M@E)!PY/L48VS3%0 "2VD?PL^%#H^W M#D8?=-/99N.&I4)E^_ED.L.03K_(@231SB-
5;= '\J&Y!*,4D]J)=Q!S#%*30 M%<6/Z:0)-"WK500LCV1%Z0_2%CB9)^S-G/'H2C0QKM00'\4=((!,7S|FK0!
MD!(VD@Z"0"_)@)!N\K;W;!'Y75Y&' /U;\$;=RPIQ#7+.J6@_%=3."MBX+R'9N
M3,40660VKJE^K'C6PD]N*2&N21K'6(\K8SAG90+C,9RJ0Y&%J?;3.[771>*^ M'L9-
F3/,J@69=\\$XJC&3W<31@SP-?@*0^@X5)-/>#,,/71J&0+M,+PD>LY0 M/\GAHIQC6*Z?4V+>T0\$PID5D(''8C-
N.!EZM%_0?R#|=7NR+G=)2ANVM9QE M*ED>:
[+\$XW2 ([H0^K>X>%08STIGZRJV_VLF0!,'090H'')]:X_0;DLLXU927+'1:>[K9J'ZD83SV1J0&\ "X736" ME-
QCI%ZB)\$2@!! H&"?0>^ME&XV?7!=QUDCQFM%5]^D/1"?=|!W3,TSJ1Y&- M=7.Q\H^*_
UK0G07:;%\BVAV)D'9T!.V FX>^MZXTZ(UP.4SR|DZU/I- F8M MJ06YBBQM--6HVS^5[-EU%64>Y"QD
TJ@I=N-GP8Z.^&V,"<|CVJV(|;KY MA9=&' ,Y+3-(T9=NGKW?D^*UF^2S/L=*QH2CA)"69(&-
#OPTN!W.-7YY)/E@ MDLZ=&XWK!2;BE3XBD98YNF*E/6>)?DY;Q2DR4"^FDR);0|@K+3"HNS']50
MS4/P@CF^9RN&F,=OZ_S;%V1LW*Z);.7GDEZ0\I(:7K1>"/4(X)DN'ZII15[= M+T1IT#XW%(3]1,>W0
" _0JKZN*]XM?]/SR,S>#V9%,6J^LR;6=;Y)J+JZ90\$
MV#3YVPWMM78@U8I@X*')Y/DJ.31!N07GEWIN2!_*=P%MG&"D'MI[#0+M#/J MY@E[CUI>@P? \N@F+
(9@7'YLCR064HV+48\$S;VCHL13\$;50/ETRY*I;DI7,^ MG374\$X)+0^#.A1X2-
4IJ))V\ME\$(RHD6_RW_0>5P'!T49DY P<\$F7S@2;L8 MJ:*P20@YX2 F[? ?*>WI0&5M80':.ZA*]#>TR4?
SZXJ)-JM*?Q;=M!E++3 MD<"P?.,;C,>7#@+WYT\AHK]=Y4>,F5V|V@YA#M=K%Q3>? [NI>./^\$14>Z"@
M1G)\$N^SQ;S0!(&N/%['200>=>G#;? \B_I@]-E[]8KH1XPTK,-RIRSH M2*^WU^UGC06II%#;0,
[L+,.GXD)E9AMU@IAT0(@F=)5JVPL4-P)#&,6&0*XA MPZ-J1\$=|?7F'OB.\$ I,'58#M#_+%;Q%/\@)0/(&
(VFQ'B|&\&'SW(|JBH7, " MZ423.>S\$MH\/?Z+_ :1Z1JP(+))JY?-#7V/4*W9S@ M2Q_059-
X\$T@C,M0=0+;!,&XU\0>QZ5*/=JE0/62C5W4K,,T?.C*ASIASZ!C&Q?,%ZK6F9I;=&Q9)'S+/J*:? ,Q2\%Y?;)'=
F6182-HQ/?ZE!@5>%K|H>EH%HS5P1*-S^Q MTT%YU\@=T?=>J M\$^QU.*W%U&ZFB|
M8KKK/5M_1]:0GQ;R;ELWG/:J^: ',SH!#P-04K)X^=02'EJ[CP#|EH)E/K+9U-
M]4'8^Z=WH9;\$|I|)A35U@S5BRXN<8(7']JRX|E\ZM>E0;TTM3_F^.C\N,-%400239@J0<9T;C#W\$+"B"?
='0%\SIP[P\W7^7JGH^J M;/B_VCF\$?[:3/8ZGA|H)B:4A%4I;4|L4S73()):IRJ2:UJEM@F"LU)U+\$4U
M\$7NU2BUIAY;.:@:56D94-"&QUMJ6JE DMKYLB:'Z(Y:3\>P>;V> MJ^?
U>E|/_E\WY^;YQ0|/CU/@S.0C^7T=6,7I\$=QBBS?6>H"/D|=]D,R6N8
M'C+U5ZXY.E0:\$4\$VG? "R|M>>PNE=E+\$R/I'8/Z)&HY=6E26>IZLFG!'U9+9%
M\./+Y&W:D+\$/U\K79;KC!>0;"SEC])"FFZ:JM;K!H<_9T
M\$@L'U'1/GY"0TE!>+=="]10Q[B"&UY'@/LCP5U^>@5](*W73^_9|^Y47/0^"/ M_EA,1J8ZRH@GP1U&
(%QH9Z0%:2652]0/ELTVW\^F^]|@|X|P>PQR: ^/)LK;^S MF&^2FK_@6?"*R6%!ZT7XM^ULY4-
WYOK.X>,S\$0+?BX| \C/#A|B:@15/WD M\F45|^E6;2.I._342,7_4-!JX"+W=H.86CXJ+UB\$1CI='.U(-
"K|;=:*, ' MCVNBB9>6*(Y0H0Y025;BH%.:C=,0#,?6E|0X!;TC-W'&EKV=*MX30S?@X(7C
M98FHN=F9]A+I@V\$6M(2+!HVP7U@1|C)>%4|Y.=^XM)J1=N6=S>,'D(AB|L96_M0"03|(-^LZ?
[3BN:\GFGYA0\$ZTG:##V1|/*,ZP!@RQ>D[35/*A>KNI0;% M3&TZBxBK=|&3+^1FA7?
HPD3>:5G_7^)]V'<[B,LAUF,"*.009?^P?G@| \< \ M6@+==N1
"MN28_8>@0@/R3")5K)E#F'KR3'0VL"LF|@J_&SP\$ M>6\N41AX6M-G3")99JSM]"0>Q2M\$-
^.;!%340B>+/J]H&GG.32PELI8M\$^N MRGD1+E#VR?M??\$Z3_&3@3%K\9L(YK0/8K5+1TFL):+E;I[X]!
7M!"D_VA<* M([9#*. 7#T'NZY\$K^5=DMD.! B8.8 JR_)9>6\$"9,D:-L*" "(5L M@/W(<=(K*#0Z#@14.
M9"]_JK&EQ%B;0(V+4WVMX7_/**?Y(|0L^V'&&ULXGDM)16L #GP;H@I@SJ7Y MP_-Z>\F9^*D)?3.2L\$0A*M7-
N#VT*3CHF'D@B0\DPZD8R*CC.RHBCI,4BT M'H-)LN>Y%L]/3E|&[L^|K>FG650R3E0?05>M#BHKV-7.!
(GP=XGUB(Z2^SX6_M>5T^YT0FVLULP/[MNRGN#+=%AR"S-1/''^-UHI!J^6(4GM: (@IW&|8[W*6K*]JR1C(\$??
S6|V9K3\;" ^XA)Y1N91K4T^P7-!0; M-4D|BW2|LD2TRP:&A<^B\AP3P>1\&J3E/)ZI ^G@GE#7|.
[0FN"KM9C'7- MJ|@R,T@RXM9T5K !:PUPY726>49/57 "6>XK6<\$?R9_-8 ;:#9!=% #)7S\ M,-3BG#
(/7|H1J|/30XYK_2RF0#H.D\+V%5)UCX|L80|KUG: 0W371T0JTF(9'T;0""%;YLS^W MZ' = #+L.I:H_Y>
<8>&0(*\$V5#0A.N|@Y)KY;9G|9,Q>R|(/9G?%&\$"1PU:* MQJ?'@U.L!@TZ>)6/F|5:HS.;\$*W/7Z\$-
\$E;%2H+4M:4^J7YB(E=E2D7;7(P"DV(=)94ZT9V^R%(X5?WFP=&0&1PPG \$!6S90MQ8'S:61D'_ M\U>0G?
614L=C(7N1H=U=@GYD"+F7UR/) '07E2%X;RW@C.+FVS894 M23@Y2C*IN?
&=%3U100LQ]*8MY3K/E7VIZBG8LA'0X3\;1>NN:%=8TY@ "EHTKX5&0MN: M62UR=@F**2,\$!?
L_<"3V.P|<1[4SMW0|F*%=\SAQ+^! M4\$#%!0 (->);5EI_HV)<3\ ")'G_@_4<6YC>"TR,#(T,#DS,%]G
M,RYJ<&?L0'=44|NW+|X5%001Z4V)"D@'Z=*28Z&+B\$A0*@(" BH=0J(B042I M D)\$1#J1KE*B4I4F0=?0:T(-
I/TVGG.^]_Z^|TQ|GUCO+>V60--NPURV?. MN>.:/'CER ME)&>_AC#"
<83)Y@8F9B83]*=8C|>I*)Z137*59V#DY.SA,LW#Q<^#0L')P< M!TP.T8\$T1XX>/WKT. .,QZB([U\$*T!@_#
MH:.'?E_7|>APZ".Q^@9CC,R@1,J3@&'#]'1'3Y"=Z_U^#0(? X<83W*=D|V
M\C%VH|0TYQ]SR#U|E*7D&^>M+KR0_+TGSX\S06:II:VCJZ>|6T34S-S"TO|^PZ.3@<^73R|0'U_-?
P#@E^\$A(:%1T3& MQ2_/?_00808/^!:0@X07<(!X=*P_#*,;0(D6!/?\8_XW\V|(']'4=K
M";9G")B=7'S8MY#//6N8^WWDZZ_6#<[7.S_8/2?
JZ/F*#_/JG>G;\$^1'K2|@'W7KS"G=RX(L|76V1C9Y9S(/3=;:
MC!8X:9TH|N;MR^+109'DZ@5>QXT@!E%"*:&[B'09DXTH.D!#0AM(GZC_5>] ML\$2),AJ
4T3WW_%'+TNSE\%NR:_0=X&D6"D:,%52=Q'Y:TR&RKA" XCM\$/S@ M!_]LP3V9!ASU09(=02+(_Y0&5?

@5UF\MXHAX[520G06E 44(*QI0:P^_0P,R M0|B1.8=H "\$5|N|<+)XB"S _=:*/H=&*7M8)H@ "6YZK^
4\$#^..QMh&4 #+!ZE MI^R _L &B#DPQN+ UA@*08Z'J*53:0+;@@?Z|>Y27#36,*J |7Y@L7V393CX^A,X#57L
M&L0NB0;\NYG_G.J?USUCZ0^<=4_KOK'5'?^XZA|7>..J M?USUCZ0^<=5_RU7= T&UCNQ/_M,>(
[ROYN#^I_-8=B?M_N7M_A1V> '82VR M^HKP=)L _QL#..VA100-^>W%/67\$\'"?+2Z"UHCX\$CTP.XP8G.
>P43|K10? M#NB^'W ;4/ GY.27 1H08[3|TZ:>8G^@WLD'[0@|Y+|_ VT\$7VHH 9008@=&
MQ("8+|LV"E0L5R5+<+|YNE*DL7|Y^N 'AJ"MZXF?05L_H6Z84"A6&4>@M9129V (?#*5CP9,-
U-.VH,AU(\E.V8M|_Y- MD0XG'8;H.A\$)8E5!SJH>Z'5+FW0'-]. WX?A;5Q!WS@!'!22\$!LWQ('!WZ0&8 M|>V|-
%!U;X(=->PS M?&L1CJ|U;..!F(/J60| ;|>Q\A(..4M*[0ZV]|2U! RJAX0,@B3_76\$08)E*(!G05^U-(
MF*/,=C"H6.;\$LRR\XMXBJ-95@PUU!^&WF@^T(DB%93P-
N\#TX\E<|UVHQRHALY>>9WL)!LPQSM=G:XRV!_P.BT M)UT6(41G5_1L2PXTPU-3\$ P8Q\Q2! @UU.(ON.;
(D=NPQ+="->XR*.G'%F@S MS#-050LZ(>205E#..")*0CR0KA#4@|WG_XX'RU#8@1CH|F@0S%(98MA?>QR,
M7101!<:N\$)IXW TT5!Z8(+NPK-B%^_ \$T %C@D\$SXH>1%I0/FU|N;NF.;N.B|!#89EI M?F ">3!+*&)!W
40 " T*>2"HQWY\$+B&8WJH8|]W'&B _^CT1/2C-6CH_1D8 MR: '/B2"ZJW(@X0D|LON!-0|A(;
^+QBWP#TP+WA#1@9MVV!5%RDI.^,/V@^" Ma(G4/+&EAS>T@2U69S_Q)0!8,!(L)_D-5UJ?
<^>YC3QVNWWS: 'OF=:N"@ M3*;-9N06#Y)|+9;#5 #,I.Z:X12WD090 MN5'_24Y.3M/ZZ8P0?
Q%D'219>^H0B&, BY[7WENV\$T)^7R+D4(ZE_2UDB|B% MDQ^P|"
?.X#512V|JR;+|=VUTE4MIT%L|Q3A,K| =KN_T S?^"4E@0 PK\$, MV\XY.K|+OU-[LFT?"
|.4W\8DP*;>^'52@PW^L@R2+"W#B_OU%X0G^VU;YV ^ ME&\4S-4R:\$ \$|+R81#,M'?JW48'#I'LJD
8Q(LM0Z#PWX!>XNP@<_P_H+6="C MD.\$M-?FEAUVI>YY4K0EHV,)%))X/@>3|_ =A
I)R#+9A"\ 'GT@'KBW;CI!@8 MN);=>0; W;D(W@PZSJH13),@TQ\|D-\ST-SJM\;|+7|39U,K)P-AG_Z<;Y&E
MN*E-ED)S@-)OV9&/A9'%/8B6ML*@_QJP1&86XFUDT2|D/>@;)0|4_F5G?S3%
M=1Y"M(0*_6L&N#4P;3>@MWB2_T(#&SC|X@2;)0LTC|I0\V3_IIS|PJC!3#0 M>9V1D-BI0
8PV^_T@'L+!@ED.50^C)2|\$_N"6+YM&_T:=^L\$XT0J|E* RX_M^XLF%19A*ZCAT4S9A!|-[98_V)!+29'4WJRA#
J1#Y10!..2#FC;C*VX?@>|<.,\OBHH..V|I MC)VZ2PRC(K5G(<3;-*!XR'>C=0VRDRCOMBLUWA0SWE2CJ1XTS;4<
%M_#3H M7&_ 'Y|.1|UL(H|_Z5QZH\$TS20SD&VJX7|==5X,1P08^Q<^=A8(K_GI&AU-|I M<^WW7)EMG!35
C1HMG;91I1.;|:|^=TI",=2U?CYRHK/GUN#7|=96&.1# M|/_-W%=5./04/FA?=.PCRQZ16%L?|. [|X<@;B
L;)00JHQF/N&6+H1F\$(Z5 MN\$U1&F 26V"E?G0UUWYMN9S@IJ2|:BWL\$3\$'WXCC7QA,346>7|!YBGW>|=5
M+/V?-(BVQI20|Z9.';7|")R4B*LU=\$0E3)^ ?RS72-28N;0V,#X^?F +C(4| MQ@OCM409;"(GJ+0L*L|)_*S??-
D@B|0_ =3_N|*8H'OW5T@6;/_=[\# M'V7+M9|>-UX\$%5H&(B0?CN=LYK@)) +0LZ:68T;*VL@5+&#M?9JF0:NI6X'\
A/W@";L M"XG&(3B%Y=%Z04_&ME7!1*ENRA=1J")C7Q_M6-&2,V;N?DZRQENSZ1W#EQP_M/342!%-6?
6@0#\88^_M647B3'YR6IUP^H(0&:UWZ^Q^&_/?6"1DT?0!;0 M^)>|!-(?L?_5%8LZ8%Q9_-1<|]W+)_1%-
JWT@ZX_2IWZX/V+6TC'_JKDZ8P_M?
+S%"0+80VW1'V13L|*3GS#|>!ER+=.HSZ='L%W6CW"0\C1SE192B5(CV3 ML.>JD:*8+I9KHN\B@7|?
F^NQ73ED,5@X_ ;V9!;|G&6I!&3+7%1/W..V|9&9UIZ^&Y,M+VMRF/'BOVERW#ST_M?
VUP=L&A>).!!AG^A3J!"@N<=:GE7-P2PW429|CTX)&|1KP_5C=8|)C/\?:B MR|0+_9AV)
GK#;|C@WZAW>M:I5%&IGY302(98J;JB|5U|2E^UR;44)_<%XUYM\$ARD&
M2S4FFQN+7M6NOKI"#E6Q8W\$7,1EUGD.-FS/3IAI1,C|@55GP2/7J?2TK46/WNB!\74DWUC"9?
W/(|)\$50R@Y0DJ\$VU|PW0-H^YC<^)%#0^&R8-1!" M'SMWL"%@WR\$'5060EK|1(7_|0?W(A<#LWKNO_1VG2YNT-
X?'%W)7G22^DV MV?(-BX&/2:=AB,(\XT>\$:E)|=-N#Y>XN/90)R.TA|)%)-U5\$%>)E4VLOTAV
M\$1.UBL|K3.QN+3FIX'IA7K_3K(3&L6RZ.#,|F U&4)&66/#D?830'ZNS;8\ M^-
KQ\$>Z@=,R%4\$QN\$^OKV&=@MOBVZ_WS#0JUS!.E)(Z*'%|RK|A3%D7WU3I_M16**\$5?#"JYTZ339*_ST?
W62FQ^LD-.V#8>-I|5*IGY|6H(DLF6':CYH.=^
M*ZLF136|&|G&:9"X|>..!1@G/..@92|VW.'M;7"\X1Z+)IA.LF,("R+I+WD@F_M5-\$L6-<*=M&
D|0\$^!\$S_ =16V0DAH8KHHT&E%L+YRN+|^"=[&LM,0_M24(+53;.J=:/<"&_T/V\0(8"X30PBX9AB7@GDYAL-
E8KB2:U??=>|>C|KT M!>"ILI#|+&AX_UU\VB1+-\$).07UJ1*>N\<3SX|0ZT_955VZK;HWJGGNJQOHS
M+KNRX+F*339L#")K&2.I)3@T>7YH_K;9+P\$92AA5V,|0A|H5J2'3P,+0UC| \ MNUNA?D:H-.M=A
KD\67|5T|=4904,L0>AXT99^_ ;+K"#=N0G.69,/&\$EA8|K_MQIH/^9N*FCSCN=0#49NP|LI+N5(CH?5B\$M?A
5>AH,A(_D0;9?%N<%I30J_!1W MBTC|P|CDV:N2F(|;F;SP/B3+!,_#<%7.Q&^L6Q4I'J+D)'!Y=;X7UC-
*""^%@V++_LP9J?R/N8!K1LSR). M4-Y!SY\$URFN#KPW,5=AD3#9@)P'=&((!;H@FNZ&H|7TWEKG)2H+*NX|HQ
M\J\L5,HK0T+D#BH25F'6B#I)0DYP3,SQ2|];5MKG7N0FU?US6(M56|[[80-SF_M\$8!A)(1%5|@)^#TG-
?"MXEPL^.;E#6|TFI|P8J*NTC/?QM0^/_<9JGZ:/,2 MQ_%BG#M+P(NQM_VF#U_Y=4YL0IQI2<&M<,"HP(F=9
_E'KIF961H*|4FJ9_M47%|G063>|/|^5_- "T:UD4S?GXR^0=81J MA3<(-J3I,MC-:"PO0D:J00FD#GS=\R|-
KQH^,V/VJ"5?F57H.1=*PR=>0\$[5_M/<;PIMB71PDP+Z|:|*('(^ML-=^)|0A7ENID;NC*"&N)NQ^,
(5=0='A;%;'_=,_M^1>|1E@|I3.%/.7N^%\Y%Y=W6FL^IBBR"&1ZD MI-
:4NJ:Q*7(XL);Q^J4%&N!)CVDU|XFGHQ@M?,19Y|W&1Y0M<)C|P(;;XT3|_M7+_L|5HHR;BG"R.C4'W?.U;"1-
H&EWJE>NBFW!+!+0_9;Y'FL0J"L6%#2+ MXPU0>; M4_F3M4/-336V4W='DXA.F,#PJF :4 MKD?5*?
GY+%MU>91'N5H%-I<|V#XN'&DGRVEW2GWGW,J4_M/KUNWL;V>D#D+IJ.VHAF@S|^5_RA9'&?
46%#ZV'%;E+_C);L)D\ _MT;SK3!\ M/19F3Y(DZ_4BSMKX*4UH&@?>L4|:VG <4Y*LU5|&MY\^CZD1W3-
2.JE=SWF+- MNV&VBV)^5|0Y#50*\$JT>.,D\$XW|_%QJ1:|G.7FZZ86UPHKAEO,;A@V34GL" M7C=*
|@F4F0DWAF|4980"L&\$13N96*5-,4J,U!B2!(GUW|_L5DV6V|2H#^:; M+LF>0ZW"
|. "X_ELG>#W&C%8L4BK9??)\$. =BD_M"&7U_Y;|4VUD^YD66X8+HY#'"!KTJ0!W|CXY""
M2Y5I9=*B@YL@0U;*@&0|MS4@@1WZ?BJF,W_@TWH=V-,N,&FCRQ4&-%<)TLT
MFPS2;|A0RLKL="8G95<\$W&^L9=(S\R(PG%.F2QF7*1D0X7|2/6|^>PT|I|_M"JYC|\0-?
_90^GQ\ "278=;T7|W.W_M=\$|RH>N=D"93"6KVYJ|0|(!"9CM9L%*(TFZHI18M9:A?!\G8/&T|P+36;
M6ZX0\$E16N;Y,9|0LV.8XMQ*\$KG-2W^ROP*3|UAN0H?L3W|'LU@|\$SCT=7CJ5_M;)YR|-ZGF_C6=GXD6\F1\$YM-
+&UG3!UN+|KD>N>QN=^F2<|:FW8?)#WB-+;1_M(SQ5)J21'" |X"G:N_M3;2EA+C\$WCT'K;UPL8VGG90L,6C%(
A><\$<7W"/1,52^_6_.'L4STGW%,>VS_M(3B(H%+W>0^S:R+^+X/&B#3@OG&

(6'0Z9X25;:V.;L^N"HJ7DH5U@A"=L\$2M MAHSSJD-JY(VA4JXI=;1(3@<-"&R;[Z^OK.NA <|?
D40)4#I4\DU84;:3 SL M7F<\$E*6LW;^AWS-?>U=N97;N5G_3.?CQR4\0JY<^[27/HIRZ?:R?%;;T0-Z
MMG1_3, 7I7!ESZ1I>&G2Q-5 MZCU;BYYC7J T7![^>?+/@7!^N.!V\?93XV8_U45C3:[1 ^NBLX^]1%,%:-
M:\VZD'&>\$DP5>9!TP8KU_?(+@[*52K-LQPT:4)N2%>-) ^BRP.5NHH[E-?7? MRJLSG@_8-VQ&?J0!X61V?/U-
@OYR0-!.=DZ!K:VS3\OR::5\Z^IFA1!XTVW^ MG5*9*\ MDTG00X4)]*&S79-)G#75W;:,I,L7WDDS"M7
=/KT=4*>/_SYX>3E1R2C'\$1@ M>@I" (#K/S'M1Y4FSH8S0=,!,P&53"('JZ8-806\>DVE8)=-,W3:D\YK*R>
M\2PT][M[:!*XNWGBK=(J5K#D?X04!^80&EG8VL\0: MT.0C[W:V^\$HI^J;V;?OMYA4;\$G0)06>,*[)4E.
M=!.JX\>,VL[HG=+=W)#/..IIDTG_0D?&E: (TE*= *RJ=WK*F&S.PXI0DJ5&(M#YHN+5@1].W/-^NE ?
PP^W7>JP5^-*)/6S)V\7F[^B[:J; M;U?HL[@?#;0TJH^U?>(IP@Q'36'#ZKC@QLE7\
(TC_':EVD'>;NH%\E9M&ZWA M5P\E*N7Y@Y),OS_9-* R0P\$64 MA\$K5/5WT%UG"1(,A[RB1U,S77XT4*FG-
&_0A.],V9WS:H:GE:D8XZY600:=' MW22NA#;GV+\$8,B7UQ-N2?U*9\4&[L7";'+RNEF:<6\V5^6(,L?
U*KF/#!/5 M1IMJWDS=M6'-Z!(/%\$+ 3XD&-"C[6FJL6#XI^'\$2K=[]LVM&[*&Z'M1Z#?IU MP!4LLQ2C+
F(/)S\$:W=.KW!RFLKS2Q'S*7K)9AW=BVPAHEI*;3&[C/MEW\?5 M?R'D72#LZA#96.K [2]NTG-C7.9#13-
5MU *.V'>)+\B0[X48?BHW>M!X ?Y M[*29K<>73-20EF?CT0F)6Y 5\$ND"IAEU=,RU8-
JL2V!\Q^#22\2LG.45ZZ[[M^!0T1<|56RF<#/\V\$'W?C<%C8MJ?*MX:2L:LG[I^V_6/QYU&D2HB<\JU:U[5U
MH@BZ'>]J3K\&ENWZ-."=U++JQ9IM\9H<>KUBQ:FEACW(-QIP9*01>6:6Z\$;) M[1^1P7A-
%00E/[DWK!*E&CK,&^,6\$%?*= :04\$SMP)4B#MI5J58:5DIW3
M\9D]#;@0:=P)6C\$,A\3:.1,-2+0X1<(6NZVP6P@46X8>3"NYR2DB"[])0E7/\?J3^E\9Z0"I%?/!85C
M+ZBFSD%-7)HP'?D\$*S)CJ=&4"9>(K;7J\6^MGS0!^D(&>|#.59\$%\XY8<()#)TULG"9+ZLF\!%T
M0]B/M%W/TQ\$(\$00[Wm>H'W?JR9:Z4NONEA71 ./RTL^VDI(QZ'\6UD8R2!^6 M/&^X-
NT84T(#@\$;_B6AUP0*ROD#0ELRIR0ITP7 B>^/KF8VV-JRE_5&&*10@Q\KRN.V.MUJ7^2E3 LM34700QZ=\$K?
=/\$X'A- MBW4#@0/JZ<^;T1/LP988R0SC.(&ST.Y>ZM4C?-D10WZ.%^JJ K2Y;?2Y,-L9&L0M>JZ#,C[DVK
M':0K)[5@M0D0_V\^Z[F(KW9L#Q^"7S&I)RFA\=CT=79US?10SE3;\(9M.-&<'3\$A'GRX7=H-T8('GZ=\
M^*>25#GD@TK5/'\S+ #CU@'B5X'KK5] \$K9*G[E8E%Q/T7T_W75[7.13\$7EVKQ
MEM[H\$UDW91\DHB8G8@0=MPW\$<3<&MEQSB#;VF90VZ&G3R<7L1_:=C&6N+0 MR^JUWRFUZYC"/:9)^
MS!3+\$Z>BJ\B;@XP%\1-A-7"([2()B0B9BFJ..3E09>,^H=F3F5ZDSY Z;:=A MPD-.T=P@B-
@,X=8&0@;ZD26K88VA>\$19X&3@.0.%IU]>0**@&HY?' 'L\^W4< M86\5))MH0?>Z02.N-*MP^U+I%X42'I23K?
IX6'LE% _P0\TIH;%>30&*&JH M.L1.0?30CL[G<-A PRU7/IY?PLW">,F6Q(7 Z=\QH
+G'V&9"XR=J&?)9^|SAZ7K>Z[GSV\0*W;#238Y'Z M\ !A@3#0:#@Q^)#2K9>CYSE80V2RK/?D>T^_V=#^G>U
]-F*TY@;@BMXZT9 M6?'H48R!#D28Z<5IQ?&@)E^*;?X4G5F=5=WX+#9ED@ &I>?THXI'<3-%QSC7
ML&Q8^PD>LB1>.GLZQOYFETA)&6M<4C)[>OZ\]3CXS_IT'TERN(-H1TC,GTV3 M9"'!GW_)[8G1N;Z],7I&\H9
K1[ZGBIRIGGN*.<*C)X&.'1RPQ_B5_NKWDTL M_2R%'<2)CZ(AZU8\$42:|E5=)+C0;PL,A!Q;&YBE MBKY&>]GS?
9_ '/@';KSHPO.T[89RA:8E6CF!QWX(IQ%-5#P,I|N|T\$4\$|3DR>**DXG3/&_W4^UN^6.<,4Q M/95-
CQ[1D7A9F-/ +VL=#82>Q(SJ'4_IKU C0G;E.DK#;6E('DX_GI;0+H^M' ME<)_1MRX.A]>NQ"B F[EUA?
LS%BC=CC/#FSZ0\2)/=^#05UPQZY[I3XKR? M7=>IVJV">_A2_MTEM*EEZ:*0=6D/Q#-&);\$-''0AG_#E?
L@:3^(\,+?-YE= M\$BML&V)'6/_BOUT._%H[HTN1F?.M:QJ15\$|2M!.\XUW'82VCK7?"YY7;:MT^E;B2I?
YQONE/#H;/9|<#2R MW<3)&#&F55X\7!4*E8(U:'TM26A6=0N8I7*]?!E7XF=R2[BY;6TFT'0NDW2(
MK%M2]CE.;>P8#6A]^H.SMK;AG?U9ZBE+(5-Z2HZE1LC5')(\$/[8,ZE)<_9T&M.,*-<#*,2W7GN072(LJE^-
CV0\C/[&,5+ \IEE?G07H1&&0L.VYGTN28.,6L M;T[P29NRN*,OY;BT+Z7^S:>=J5\$RMH2Z=?*VQZ,;
[&]>]+^GL1!,2U_4!4-Z0 MM2>3JLN3&P+Z*G;39'V5EM4 [LFF-W)6,02?:7;W_%1K3\AM?6R0B,BAC& M!
[909K^I%;D#B88S';\$6E6:RS-=KWS"19P)0-[CS^Y^F8.E^ MVW=%50,S# (X/V|.Y-?
BBHF^>'0CA'/_PPTN\;XS7S&!7?^|;=I[N']S0";D3<^/;YGFT0(RL M^VCDGB"X7 -0D! \$?2_9H-
"3VC'%&H[6_8I/5MM[AK/[ZZP/-/JT3:V^?;HW [-A:NQ5V7& M[5(>72K\&1]I],9I9:D HNEGN,-+
#=!^:SE2LNJL.[.6V6A^PQK3NF.YK- M3)DS/'[)][SG&[8ML+NN"X(. /4931##J0VB
"R9R_\$07^9B\$/@'VZJZSVYFB M]-*AX9:0/ FBHTW2;P&)]6"U/N57'W&&ZJ') (I@&A)N-9N#_?RQ@U?A\\$,;:
M7\B' M\$G+L)MI&\$KW >G%5U8_07J* \M]?9E87=(QMY^)'J69Y.E#+E9 M]9FB\$NFX&
[08.J&,:&9<#U*.Z^<'1U\$W>V- K_(9F[D+GW MYVOU!V"00:CB(_YH)Z-]\$,^X7-\$9_A7!KP=[8;E=AJ_0I)
[,EBNJ]:T6=+07 MC.P-FZB(D_0JMI[Z&>\[N59]J&[DMCP909.4;%H9XR]9U=W*)CUP3;3:*\$+E M9=
2J1XWL+*>[[9W]]DR^!V_X4G']0]003*J'=1 MIG8&?>;3G_GWF.=U0L%7^MW=I#')5:4_4#UE^%#
M8TIK7L;5LJE3RZDWO;:<(E2-LZ%Z!>/0=+N#B\$FBHUZ@<@M,/[S]5CKX)N4I
M0FAP;/_3'F9U@Y.S7_ (B=W)]YPWA0PE^=S(L0.;RVXG*)(A^KHE[?Z3TQ4- M1NC\$;
[<8[JEL8V+@="1WN^XW7_-&[/TRC5_)]W/QE+Q_87+K%YR"EKG!(2& M=: [0@'/K-
MW96FQE3B.XBRJF7.]%35X4DS09"4[!WNN'E]F=\$6>[9[LP"?+^ MON%7X<7&_B(\T*0](LY=X?
K0>^9+72N#DVF;:A.PH>[-/573^Y(?+I0P0]; M5R2N:[ZXV\&LV;#KW-)1N"(>,\42@9!SC5\89&6CB*ANBA0JE
2\$>#M,DV9RE MRN2DFW8CB_T2GM)0"IT_GLTRA.J][#]?*4*J4^ "FC308B.'L].R^WE0EE!!Z
MN="C.\$H'03NGPKT1_48E_2=+N.'[?G_%|P8G%(P/7@C&M85XWF!^L'^V]<M4)5P.0-^4;?
6\VM;ZCIH0984UU[LU\$0RP3FJ3BJ[1]4"=I_&#&&J6;#%TC; MB3-
[@R.S]HA+32NF1MG0)H6/%4MZMRGHKW[>^IW97L@3=9)^"V"#WHJ_;S. MV;J:B4JK9N^P&6W/37'91=
[B')SR5P@KG)G:2->A&[J5Z0FI,\P2^M"/!++ MU*K>S5/NY,V@931"#)DLLU5,JCZS|T"EJ\$UR9!&B:R&QV)"
[N\$#Q;:##&TN+ M%[+^KR[JIF.Q^V;MY'VS1:75V"PJ+[:1#GC>;XT'1PE&""
[N^,H)KP7G/0QS,Z|SCB>]+=)28T\$YVF M4!%DFZD@JP95K?C'2B'97SL#D:+FN)@KLSO M\C0@^2D5_0^
N%:@3RU?&J\NK4V=<@Q24;\HESDR)5"BSW5M6T,BBI-;:L3 M(L6B7@*7^7*V68B1L\^WFA;PYY]G=Z&!RL3?
3^-4R MQ&^%[\$;B(H9]0[]XL[#I%@W:CB\N#?
BFWAUSTVZ>5SYU9[|BVMC4]S>E+HD)F2G1'\)V;RV>VS\K&>ENOMX9\7-)[*4E5Q2.T,K
M*T.3'L=D2]NC\$WE<#A7[:.W<)8=U9YI04G(V4>[LG;E(2X+ M:)]LR!BCT+T+!FWV>PCW)(VD% :<*\$\S/&-
Y9R;4EXD:7.%Q\+EED[514S6 MT8C0M0PR#3B^]R"6JWR?0["4QCB=IW?LJ2S[-D,I>M'\0%5\96*6V(DJR
M*5U^G1,==^3GQ-@]!EOR'?+/I4^/!X2F?F2I[QGG:2\$Z\DM6(&6&WT8\HC+D M?/J._,AT?G6N9L.*Z;&@_?

W[VP8SNC\WU\$NA6MZ*43A,Z Z?1Y-KY[\$'RNT: MN5\J>E:+I2^8G?<_/22;>]:4;0<:GK0
MQW(RK%1^ZSH[KNS@R71G0V4\!R8.E_J200-PW'^DW2_\$3<^Y/1EV0I_8I=:R M>
[SVAWK2PS<9.2**8[<2SFDEJ+;M1PX&>#T:](/;%!J1K-QH.#30@&134W.PM
MZKKGRU,7W5[X/&EIKTU\$J]RW2YY1-].4;MAK%L&JDU-K0TH M5U>GAY6\$R*)!6H?-ZGM2)^EG+?:!4]-DN^4/_
B/,F4A'IVBVOZ8!#C4X0LIXU2FMRW; + M:2V)2A1I_PD?G"A!Q9H\|=:@H]*_]H.+:;>(:{&F
2+0CH2ZM8\$)AOR-98?CF M;,:-M 'T#BU-WR_0W4:N]U1?TQ)
[-.:V,X[BX;9'X>#):+_@RX<\C6T\%"SAM540,4U]X M"WF?!@?@!3U* UZEME+F:<
0@=IX8D\$3F8D&""HFDSIIP%-0!&"V9HU"PTX M/T0#HFB_6\06D64R]EVDQ-
;5K0_5*=Y+++^8C6LU8+S?.7.5!NC.8%J^4+R(MRS1_2+^9!NPB1HS!JG
3!S6(QJM0ID%DT\='_S7^@RE&3J*1(*YR M\M4"0[E])NV*\ICR\$>XD#FK>\$J0?
#2.Z[B;Z#./T8.5N"\$0U]KS!P.\15P"#0BY E) M?G2X)M:#*)J2<|!@+VS@:J+VR3M)WGA!
&Y>KFNU83[DM^S(M600-F8_\$+"%N^<@!\$Q>.\$3^IBY'!2=B/!< EM6;82S1%=@*F)S9;J /N=J?
M!\>Y10/(I*/NQ+Z'^3=\$A/4\=GT2(TK)I/(VX]'33569P_7JE@%Z9>8U"S]X
MGEMS,C2B7K]:WVA%0RZ57;,:%T(CNVY8/F\[\$J!+]/F1V]],0.JBV5I:KR M1JSSA@4]F>/<%;)+MU*T?
3T!=P;,:+8)YK<8Z. =4X%A%+?!0Q)4_10Q8+ P MT("M=P%[B\$@:P!OJGKP38CR,M+=+VXG'QZXA7#0J^CV?
[9M5(+ I(00)&0LN M]-L5-(#5H+\$2P-^"!J+ 03@/?Q ^ 0P1D#< UPSS6B^E1DPR9U=CY.; @6
M4&6HUXA@DUL'^4RP"]^*8>..D?;67_ BW0]B?44H<=>P(^*> ##6\$'\$,KD)@
M1GT/1!Z'"W NKA\$[+ =MWD8] VSP2>NFI<+0C0'N]Q^H8E))RKN14P9N."^ M4T5[MEN/AAI7?,WB&K[I1C=T-
UWT?0.Y+;)R#MC;W,F- M]0B&5!R!BG8)AP[/3:L%V0@^5WI07[ZPA72?0Z%.= S8UW%7)Q65=CPZ!/:- M!G"
[-,GUH1.**Y,2@SM+;^J0"";=-D0EFL:/84?X12M*'!U@ [DV@PW7APV+7
MUS]D,%@&UEK.37V(TS_J([ZS+GC*9,9!TWCWQ(07&['Y>0K0KS1':S0M*Q:N M) DD)-?6I&PAGX*Y0B;.!K
5S76KFST8Y_GRY?RPE8T>K,+ "6C+;V#GAPJ\T M)6YV23^V73IOY6GME1P\;GH@I'@;=>A"[(+;0+Y
M;._9>8[(N3],7T(@B<|(#\$1206^:NMJ9JBB0*KK[A%;.PGH!VR-Y\D=Y1DD^ M9?./H;W?7>.,\
)E>.TI@2Q(K%155]M V=+)4IMS^@N&>5N0M9D6-4>-1R5 M2!*Y],E3?S0?9SNDMD'F/%.E0?DFJT3X@)I0-;
(P/>)4^J;:M,H 6*:926;ME.^RZYE M-*NU@S#K#^GMT:>X1ZL9B;N&9/9?R;D?N2*B@PU?J2?!SDM<\$R;
[W\$SU@G3 M #1^F%E; \6,U##QVFS9MPD3)@>_370N\+/QYNB.(U^07"QJ:U32/YT" MJ/H;VNYA?0!1#"A%BF
>/TGMK+00ZU6PG"Y'A96\$K07./X(MZL=)P\$(&/T&J,F^:A1T60E(T)L3%KNC(M\40G3JPA;=QFX8K;?
1XA;XW\L-4N 0; &YU]N9*9,E_ZJ)Z,=G87^D*A%/W M"IA.NVE0_G%IO/B#Y*FK9C^2)[C50?,M.UW]
<8;G0D;LM7ZUG]@07(03JC\1 MG8V_?PR?7#JS/Z:2\$K1U(Q&WG*QT^-] &\$YXFF^711VEV3ICSV&6(?
3L*FTFK, MFL>5[I""?0%8]F,(_@:Q#WIB^=!M4>I8PN0)9&MMK0\ -J/0@IWE\$(BJ1^Q9'
M']0A#67V!%6; *6'""- * [, &""; I01:+AW^BJ90G,<1LFN.TLTQ.U4^(T+U7WJ MWI)R#_3JCK.[, #S=)?
+2G_F4P?M54U3^V4J?TWB)<.,1B6F!*GSGU G?5.8? MI=A>S(!AX-0'DH_5GU277Z\I>,9-7ZP*!Q2<|(BF 3)-
'@*0ZJ6K-"A)VH:2F)!LL7^X4!ZK]JL<:..A4V).M\I@1EA9]-IK_=FJ]L@P?A M8DQ04^0-'NQC?D\T?
V5W;R_C['<4=+.)LL\<20A_H\BYL[;=: -QAM4F^PB M/0^#2.AY=M;GV#)G/)Z^7M4C_NL&\$ZC+8TX]',&
[-(F4R)BBF>L*Q%A;Y#?U.U-B%*%1P_1[ZSDS/+0 M@.3 @&F\$'&)T7
B/;9"RNX;/B/^@F)3\J% ^KLO#+"4]9DSH_G%QZ?ZS#['?W M9\T^T8#G_L@?0/T:L*H_HXF8@S.\$\ -8\$Q485+YT-
1+|7<#9,(I2+S05K^7 M>+N@G['/I!ZG_03HG)^W#&"C^UC5LL%;C=[B;4Y0?>ETB7K\I(0(==/_VRL
M<|E#>KNT?:235/ M??]/!I9"S]J?QC&X; <:1, HY*QL*05U;>G0(!6K&?>"'M M;20&RH\&K)KB5H85/B(?
2#2=3>K0BK590: !B(NMN7/V_384JV:6 ^Y++IC7U MSF)/0:V8'74, :@)"?0;72^706@_K+U*.' :5D@7_&?
U<)R+N4M;1&SS'(K4? M_8@] ?V=""FYC\$];8R6] D)\6B5 W.M^J'A S0DGE0:DI9W5^DC_A\2NV8D^R
MGEHD;CGU =XVJF:B.,[MC-LC79YE^=0T1:;H;BW)V03]
MN"+0;DU2M*05KPS[^R9Y998&N!BR^=\$WVD(K:XB^K08GXRG)IY_0_*?!BC=N MCTIU;LR(/BW1^L/0&E
S&\&6I** (CA/'3Y (K!UI-MSZW,R)]XB&.79&"!S% MK^[480P>.G]QJ!9L]Y(I> X" E-1DE6
MYZIMF+0! 'PT8YA0W0TDD^ P2UZ?65X\3V!LF(#7*08'313?XW0MRB,-E'A3 M)/0%
[NL,LYS[K*0CM_/U72#X.N:SV^"AFUT/!"2 M(|<.[AE-4H(X('X6XHH'.QI.H>@4FU.W,^+-YQ08-
*YI!!!M*G.3U'M31 M^\$;2:12M\$C=^V\$Q0:K)!UE;#Y06W?\$&NE)\$4#7S0.CL)Y'P8Q+SYU;1^INGM
M[#FY'W'%A)0495D5UMQFP*QMHA33U'F:6+43T255@>1Z97H1^@[P \:0. ;>[.IL9]WE0E6
9\$E+)Z)Z#X:EPL M4_/I*@400/G9]P)GFH_>^D)B[Y0]EJN\$A30DMD+VVHHW\$G_+;A0-8EB915Z5 M6#
<%FRVQ-9#>@J%!"!*(A=3TPH0;=-8Q"WRZW5*#BR\OK]9C1LTZ01I;(6* M1@5DWMEVFW3+S^XV(>-
SN_L\$M6<9A28G061B?>3\ M G.=V>&.;]1"+^-% KB]6AXB2IGVVM_.6\0TDCE!M);2H MHY_%=;D<=!6>D!
(: \)4&\ W#^WXD"%2\M5FP5\$KAP\$@L]6,>#K HW&J*XDNP M&9SH6,>/_4*,0CC2=(FUD[E>+7<_]<\$E8LSD](3-
YWPMU".,H [G[L:TT,_I M:L D^M>3LD^A3#T#TD"[H\ V-E5V#E85'Q.YY\$YAR1YZOV7=>2>:6&L7-7*,*
MG6K85&620'3,,XE0J;\$ (M6A&U\2>Y-# M073.TT%\$7,MC]U M?
X:3\$13/8E'L%#SWL6@T=:]UQX2203;.@]_I5D2=(IH9=7NYG;Q=Z]A7]*'"
M_ZUQPRH<_JLXH40!#C.,0]@%'%"91Q2J=04Y\$K2B0].%EBK/1E,9>2=')/0 M)82%;%<'&@H:]9_=%
(F4.IP5E/ZK,";V^-J,N_H4=W=+*5,T([HB.5*SY*4 M_(8K]CA+0X5)1TYF(A3*>M5-IL:.'7\?
MZM;\25C\=W-I8)+*!?(S0>F-NV; M1?Q/CG-NV:VF=*X,3&-)8)+H;A%#J02L>>+Z9,!\$,F)1C_RFUF4\6?
>1\PIJ M=8407\4"L"HKWEK\N#;KE*6\$GP60(>GF=:G%?Y.' (MTQ,C84)N,!'.+5\R>R=5IP/T^MW?F:U.C-
@/-FP\ -8C"S&22KQ&_#HX*%8)U ME.0.9QU#R?!.>FVTJ0579>XVK]:^LW"Q*^L00'KSU^QP^_CZC,C)BJ7C
J9T7V*:^8 4W,\$^SZ5J."0I_1B:.;&VK[|U3*' ?9 [SID+GIT|= M?72Q8\$B /D0D[SC0C ^R4]AN.]-U
MK078R3=R#&00%841\$1I(B4H* H57HG*M)%I'="4:J]!:(B00F("@"1\$1\$ MI\$E'6D2ZE-![[RV04&
(@[=WXW#YMWCF/9^:<^>:;>?])@)LE>>^UUK?I;%RM7 M=-
+;MF&CS!W;/YU'*V.J6J2*KA99X\$F8K&9_VKC:P#G9+NH'84KDT62K7#^H MRKA=ZAC3A-3X*'[?' UC>B
76GL0#U0^9L01)[Z,GD/U"(WNI3= BA4R"^T M.W0%?7\$<"[[WKC@@_%[QAW0PE]3SRZ4Y)Y0?\'IV5TT-
(#\>4TAWI*OH[I MS044>D\([!1UB./C,AW7..NGF3IYJ33U]8E0<)<LB5"1H&[\$:5=8 +91M; >H
MX(SI:G\Z6F<,QWW9)N2EVH4[LT:;B8^5M/B6\$MK;2S"2Z/QSTNII R0#A/.64A\D5&,
(EL9>2JZW7VN/J4LV6^0WJ JBQ0/@N:#_!'4JBTQ=K3TD+7QR /XV MV^UP;F: !+ C?@.130"LUU6CXS_?>A

'!53SB0*2-4&1S3IW/E! LT+T% = M!=2&8#+L/9SD;?2#/<(&R7MCG9>^].A-J-6+P;K7YDYAC+9%ML-
8,59KHFGL M?4@5B T+, MD)201R>F1\$YR2#@%?CQP0@4Y\ VY*TERQZ8#Y1>;+,B:) \$@NH"DVOIP,W*RCM
MJIS,E:/YHYQ;+9"XB7JV B2:G2 POCK\ DPM=F0RV)KZD:#W9X_5D+! \$2-.P-051K+!0F
M*/8(0)I_5NCL!L>|2>'RFB=\$+Z=>BQ(9KJ' 'D<|?D3*9W8P(6_&?L|D-53 ,^0+ J^D-!A?SD*:'2-
\$T&FQU6_KC4-,E![[W]1@2JETL '@B/>)(\40 MG+N.A?% 'X@6-I*V3QF#TJ&(L-RSK.(T98M?7R,A|?)')LJ'
M8?YB&2XVDJ"3WYYX;+MVN*)0X&)\$V&:|(.PCE4TPPR'I.!0;E,?*MHVHNEZ.
MCS;8YSF#|VN@2B#=G9QR)TTT^!A/*O(IL;1/W90_?|8RA:H ,|T(9EX''|03.DY4
M'/2LL|%/8RG@''#N+535_&R=IB5NV)4L*5L93;|]SF=A.#)H,(,6W_B1>*M^ M6.YRGF_|3NZ BT60F9|WS
MN8:~LY2S=@@MVD*J\$%Z3^#:-6Q!\I:08;6I;\$BL:9+"0^HEP<%HXC27<#N5
MRZBUV0T69VB,07%2IIPX|I@NU0_3".P8*60@|L")R&)P&Z=CPN12\$ADB\|; M+0S6'.G*:UXQW
6E"J(G*F*+ZX>)IU*T%5(Y;\,=W(=T9*M.E]Q0N_7PZ)TF M#HFS>_ 'Z|7FD- 5>HB.6*CHT>_'|Z%0BGEMD0B-
|5* P:WQB/G9PVDW6^9 M?Y:\$C9>6NVG3^K.%[VP?4\$#&C?W?#5|,CFF0P;2PQYH Q!TM9Y7KJ, K"1Y'
M20GBT9+R;-R^;9FA0&Z_3M0/Z-+X|<40-)K+?7/2+D/TV>1&Q&S
MB#/F+97,HA20K;V|YK\$:WMKK)2EF19VG*UI1E5L>D0|^2F_:0D82Q#E&[PRMM'R-TCQ]'="*ZD?* K@#0@M0)B
+ZLH \N#)5W\$BT MHS'1XHVD6F!;!CZ\^L,O UNC*: [FVNCR!=BB(YN#'GXF;K)!NK8UI>I=7V MRP\NUF|1-
&G0A=G'##P (D(S@D,C%>0Q<+!6W#*Y\0!%CJHI|">?N9?Y\$>^0 M>GQC0.5^TYAMQ?!(5|9PB(H*?Y-43<
T,6(-7,P374X|L<&N#8",JE^,->' \ MRW_5E3|T97UBER^ =+7E3J;E>Y;00YY01BCRDCPBE'S-
MU2|/RFSM&10,!|M MD\$5:I5.1C4YVG?06VF,X <=H<>0CA0JL;DT6=MZG@NX"[7310"(8;Q8\$89DG
M!&C/D?;C0W(9XW;TR3YJU|,+3-#/T\$J+,&8+HL;\W4IY.3;T)3!@V""+;R|
M#)^S_H@"RGZIDXFY%YU(0C&2P63560IHYNU*+@9J="93!>CX@81_'|>W\$|>" M&N.;XX=?
DE/!T3(XFMP54<@53RI(BBZ@J5*)|N*/_IQD MJPGV.MIZB#.)J4.'E+'GM/YIP6^74"-;XYQZ\55GL<>:A/J\$?
_1P,!!6\$)AF_M0@51LZY74-QT/>;2_-TT7|5%_:"N9<32BFJ|6/Y/DA.NV577:@*>?0A@"0F
M*M@D#YBYR,C+13T<>^/T MMZNX/?\$="-H/D|-\\$-9*R^(-;7U|0\$CL:EEYC<;Z06*3C9%UR,B7MHG",+[H
M|)3%,\3!W;B-V7DPWA1<^K8^V.ISJU71Z&K,>|35B\$<(K
+K;SOET<^!QP_9H=Q_@29R9PZ79G>;,&\$E0IAPDVA=Q,^0Q/K;80A
MW0S*L;J\ZM'?;3,Q'&7AZX,.*Q|JCN>>@@3,RSE5RZG6DU00\$|(V=SVWG%S M^U5D^?)T|C0?
3'67LA;Z9@GP76'Q *:U6;B|VZX%F2F.| PA*0|=I55G(D^ M?|_UL8+HFQ3NNB'WP;:F64==3|?
K/^VFH&6&L>+P4.A)F,;<-V@.)^J92Q5 MU8D>L<0/QJV?:(^>TPS6K+,MN,#\$M_>(EX89" Z#FZ_
M6V|<7H|]6E6)V@8GF2N3\NG6YIWN2Q=RG*Z|X*|*C6>TP\2QN [|0C13UM5\ M9W&6:R\$ _5'D,DAA?
Q1HZCF=>7!F1=UI!A"CP#+DBK?G0|LL&|55#P|I#U\S5 M35.7GS0^,T6BC0_\$|Y)ZWGI|>+<
M#0.UH!ARH*U(3DH)LJP?MC+">V"D|!I/LL:_#GY^A(7|ECANFGBA>_\$A
M7G|N5&/N>\$%GM|]E8,;T62K+|VZ|XEB5J"!&W|)0!JM^<^S4#WK1"=M.\$(4Y
MSK:~SS6\R3+;|QT3_&|L>/GIG)SW15UUT6I+(SXY=7= _94-AW<@M\0['I)> M0QY|-540J:P#((\|
(G|C3(9D\$K!%Y.%5M& M&Y%F45" _|ZCW>0B0JRS9E=>4K.,/ W^5'J%=H_6E0_X"~D^C|!VJ&#R51_M0
Y;HP8+|H;)/I?J<(@+J+/7M16FZ2)M*W@WY>JZ:VY|2TU^0Q31;#-_AX^&
MM9|Y*D?'&260P1WT8+=NPHY;KFFM0_4CNL\$3I2#1WLY_1;I GK(1U7#?2E MYS=B)QK7!20 :V JP>31# (%=
((>D_%ZBAZS%3\$T0F,R10\$1)/W?-<7+N0JR_M_3QCV4:5Z;TGCBDF|_4HJ;%) "7C('K/HIGFOEM.&F^E;9)
M\$*NLV+X^0H'Z0I?,-2\GR+EPL(ZS=N8(_KJZ/H34&J'%6>W\$M0A+BBSDLD MB.N^2#P%9 TFSZ_.!06.-
XY;0|X'66XJE!_0 BW)5HSA3/??6_/7IL/+>4\$A M\ 8Y^\$+,&@6\$8TNA@.Z:|C7";-
ED@,Y@M)'XD/153FT6'GZI)606GN>>DX#@_M8KY=H.V4KJP&:[5J&|V>?>ZMT?5N0Q|%4,(QHEQ0KP)3Q|RHLS-
"9R@GGJ0& M\F|]XP2_@%-RUQZI00Z9(:9V2^\$|YE6(R5"PS;MA+|;#_>+ =(IXKVRH7H MF'QG%T(-)AVK#
|*6:MT&QE'\$\)'0086B9UM MH"4&Y+TCE=8RNQ4&H8;260+%=H<|I066JJHJ8SH#LJ|0A|]RR;0|X4NEVG\$ M?
VM%9*|N3'6_M,:QY*W3ZDAP7ADRCU9)67_I11;|1LF;|ITI_K37KW+U9_M.80!:"K8@2H@^|M_K.3;->/_@
P\$2:.*A3:.N88+U%\SLV@_GF#:E4-S9U|P
M666_J7V)#|D>\$G9,:K%.TPM\H4@<|1Q.A9|0V=&|M3X%T+'9"|:.)UBYG8W
MT:6GXUZH.'+&QU:7BYZQM(0\HYX37S_G_+&HQZ=5NMWFK"!WFQ(T_M2829;I_MG0:?
UW\^B!,VE*TW\ S"Y(T@_L/OE-33/,%L|6TT=AL2M;H/1+(\$|F&E<,C8<_M4Y&3Z^OND!/I(%@V'J;&|6
=:TP7S0EJY^BLOZ7A(_54J14I#C|-0-)7N"Ma_M0E"J#;2^;C*0|=67V|]S0D+
(R^>&0#GL(E39L'2"K2AX3*/Y6V+T*!9QX|E, MU%J&&>-DVF'80Z8J/M1M_I7T6ELVB_2>P)8PN%UAZ.K1HG=-
<, MX%,#M!RS3#WVD/-:C7;X8LRT/J;\$\4;V54Q\$VNJ,Z.-1?0>'H'42RF*"\$S\$|
M!@0>!=0K!YGC"S2\$8D7QL3\F^VY;<63\$JW!'7'FC5K*RP>WG*KIC=3ZX M+T/E8)H@5-#5
;%TPE01!^%CQVM*4C.31+W.0)%YJ:SWTF|!M:B+,!V5(3-0
M("C@0G288\TS#1|CR4S7?|NG.F(5_ZK^S\$M53HR'18SA??H!\$K5DL^47?+@&
MG=H/LYP A:"6DA:2PKEB)\$0S),YGL<).M+U|H3+AH\$Q&9S^|6#NT"S?M70_YR M^ZQ30|>X)^DU_%\$|JUHQD(TW?
F5C00K" _KT'Y=^F0M|P*6R(D :HMY*|^<, MN\DEFX=-/CE)6P\$"AP2|\HW<_Y5M+6;L);W_GFUU(-)5-
UDD%D35Q0AZ%/>:Q_MDEGLZS|+;\$|(M(4\$HOPZCN:~1M;P6L^
MEY)J&H|_4>+9J0V;Y)T<+58C)HV\$S26_TD^PS@0RX!1#IZ%RAA|&1=U\$:/_ MFS6>+>:V!-|!<8Z/A"|V6-
WWJ-%|A+|W|6E\$1A5B380"7N.\$3N.?:WV'ER2G_M%|I|<+>8#;()W3PUXA)=ZWUYP-(F^E?00Q>EJ
_4ZK#+\ZV|X'IH(Y?G"0K M#@ (GWW1J9K1SJW;<.H\.^=90XQ9MF^2R9RK0PBGVNM0J\$;A&5YD>"\$PN+C|/
M&)KB2%|T8G|Z;#TQ\$E^#@^_IYPLTYK9""YN/AQD_Y86"5L^;B;#Z@56_0^2I
MTV=>|P(0|=1=;/OULP\$AP019Q?%MA%:% @2^\$4*(A^"UZ8#M\SA"XC"LW'4
MRKD>'@+|:R+ABQR/:NUCZ).C8>,7-2|30G&)NMAP-5"QH:\R#0(P0\$#V5I(X_M:0|JE-K'\6?
AG2DW7)Q_Q(E>Y' L6:RWH)*2+F&._!!BM6#XN:@@0XKM_MWAK3^*X4ZU>|CG:0+G(\$+|P#*|
0SQVC45\$@F@Y3\$ZX2V;#<=<@:I6%Q+>HU
M?|04|/W02TL'(V,VG170%Q5;5%*?|UF65^8HX@,|H0U8+"SRK|IL\$CT;%A2_M|V00<\$|BX')47-
TP>5(>@6NE@!)=L1#"\$/3_ _1,%J,|MQ47Q/%6105CEQZH_MD)\@B7,=>|K="?60TQ::3&&AVKJQW;(@551%_3V&
|TM00!=(CY&|A6>6(_ _MSPTWPDmk339#_ '\$F&_-"]5M\0HP\#52&.=ZYT%+X//,("K1;IB367THI+T

M>M=L;@X*2[_BN@^K7VTA@GKJ95N0&LK#1"N"??#-V0F.;YDG,V&AW,9<+|\\Q
M3=E;V7'^^B/ET9K\$_)#|N?.X[.VTSQVGLB2Q-NSSY\\B:ZZ08N0B0?L7)W;3)I M^&^BN^}D?
^,>XX\\KR#G2YA;S\$9%E)EV,3<\\;=<U2>5E<9R.B\\L5[4RP9A M=;W|!1^%\$W(SA&6Y
;#U,Q|\\OR3!8|WZRYQQQ5I)R^ M?7+U=(1XH/4HF_J7Z>D.&;ZGMRP+FXZ*6B\$\\UJ&N1)H^(>)M J-\$4D[CDJ-D
MFDN1D^N^^(M^'X 5+;+8P1+VJ3A YHR3F"9@PW0I90W;.T:>1T7-8VJL54#
MG^..ZG,6=)!N^|&321:N0=UM=,\$M2;UD|YWM56W-Y>"PH/&NZHQ/E@U3:5
MTA!|7&:.!W%+M4_,|C/O,P|KVH (+S1>?&H0\$091:(KP?- 090V)G),;Y> BL\\'DB\$\\OJ)>
MI'P8%5'.2GB=L_/H2X8R\$Z0"\$0>S4|\\^/G-<0>#9 M08^#EG7|A7JG0G|4/0S/;FT|\$EA:YY4F6/C4I9FD%W;
.)-K0|'"*0#29/X&+UW!=!Z08K;NU^H0 MN)+H&77V7&Q3 J'B,R=K080ZLFP>Z0UG7EU<3L0S'
6DU\\10V\$C:6I)!CIX4 MAY2B0F)[DQ(PL3+@X\$+!T31E8??H|< M\$#
|<.*\$;'H306FIQ!#67K0;5M2!|G'.F0@F=^C#K?UJ8@^1=<7D&T#&"%,9!4%(5V/+6\\6FM)&*):"MP8;-
>'\\6D5P%|?|J_Z&I)!Y M"JC/;WWN(@441D10)|@5|J&G0|/):@9)P+V^%-!NAC\\^4F:IDP**C1:= EF6 M>L!;
4ED95! F+ | "U=(A)CD;=00#0XJ1UH(6R@B/C!);A=3| <6%PF#|:4 M F+U@80|N0GZV@J8/0&ID+?
+C#,'7M'.;F6CR'\$)Q3 @40!T M706<->?53A:6#G[A;+| U6=/B>*<,|'NA,5'C;L9YC8U|Y-^M/K_R\\|+;9
M=6;<5(TM2'^|>\\IR89 *KSS\\KB%/NW<|]:8T*CD:TSRK;BI!PEX NMGA .^ M =R&-
&|=F@5D695T+F%+##|V0+1'| **APR/-J..C J;,%4F3+^%;&RG=/4 M FU5@IR0RCW, WW@9='Y;96 AJ%?
W2MI_6N@>9GM-%A^?L%:=.W)RT*FF%V5 M&I6M<#@< :KYZ& &/XRM Y+EW4B@&KN*CHK10;^/-G?^?
5(| M,!\\|P;M7 MW Y&9AQY />0GK??X=>:#6/S#6|1_6T260..3(),+/#W5_9\\E_)JZWISWJ&
M5F@MVHGZ\\T' /A/|4Y *^..00!=1, 54T'<"H,"K:2HP'EU="&+10G?BW/S:J M5NC^0L(!?3E7"8%|&';
<,\$J|KF!5C*N!T!- :^\$#K;I#2\\-M(?/S^, % M0!0.<&N!26DK,8#^E_Z.9&5"*;!|'ZP:5JZY.*L?BB?
\$'R:L|:^-7ML2>/5\$ M4>BX#^/Z|_6DDRLKT123U!HFKD\$CV'^ *H.%6^*!>JSV10GN2;X9%Q!VX@QF M6>DEZ,?
%A^#7=0\$|?5_.M75*BIR|(9=TX*^K#X2XDMS|*R&2|U|5TF3UUG&-
+QP#LX6K#,TR(3NB\\QZC7DNVCVDV=BDICZ14'T#T.?M
M(VSGA(FY%F/QZA|6|7!Y'GT*PC#W(;*4XR5Y7\$W6JH3/D'#9E?5|9?%7DRYF MGC%J6WBA8'6L_K3=509L-
H&B;'%?UH-ZI994A+\$?_^\$[L@\\V;/YD)1;1-'1I MZNO)MRD.HK_D/:V/3<4^Q0JVN M&Q"\\ZF,Q@L?'_2GC?
02B^91K4LV6*DFNU,+ZPVH%JZ3MPC2 MK17^-\$F:'#RS9F=-)V-CK)B/M(\$|H|S8\\U+>T_VY N8 M L&%05,(>M?
\\0G1FF'(?W)P:F2D|1\$T)YT|XL#PJ850HN& U|ZPRY|&>('S M0|44G;39J075UR-S=WQ;:WC+G!NX|2V)
M|GTMA. %T^_A#T+!/- " &KJ1W-'B?;?>3T62?Q1>?S"9JP. BOU@?>I9\\ " MXY2JDEF@F0TV=.,_5H)YV>M|)-
&*Y M 0?EIOIK UYYLV<-#Y*;ADNXX=Q6BRD!-R8SGB*Z2VY\\BKIX6>|Z.^1Z*T|N MCHZ(<_MD2
"BJ6B%|T=M6>R;UVVK M%BRWCZ2|L;.:QBTJ26K7 M=;>|CAQ)#U#;"AI0HU? "0ATL)G"WO:
|_Y?)3&>IH(X0IB(C)BNS:AW(RL> M1EU/7(^G18N*;@G?#?&-EVUQ:CUU=CR\\PPW5DP#1@8NJZEU(\$/% M
|%.XANYYT85U;X-0C*_|HY C&%Y)',>TYS2+MM4J\\)Y94MCB+V.X:-9S)5%;5Y:6 MU|S^X-
RMAFXXV\$0^2S0G0\$|3SXP"8EFE@\$X&0?")X:X92(7|E)@^T MXN8: MTW;%-
%_7^,^'|^LM"ZVUPM,FD4T:*':3^YXQWIK*&KM5I>[OY K-DXY*GY| M&2%RREIV6)BTA2M&P#R(K076>)<.
(&"7L)D9'/*@\\MUA|@0 KQ JNN(RMS MFM|>:=D^ER<\\|*V<08;Z>IJ?|!%;C\$-|@_B+0-7+K^LHB> MQ|?
+KS*R0 -OP3==9VCKA3!TS4?4HBV>50#F=D=="LVA.Q;.>.ZN?-\\#?|#'
MRV|SJ,89F\\2!GC6)_&Z3UY&#N9\\%@|:\$5JK9MR+\$Y2'W^C.-|ZC;WY>71:0R
MHY)B|QYP'|.TF_FR(EU43P\$Y(EF,B0PD1-G6L55:KDF+\$<\$8!^|N>AL303,? M-M&+^P'1
3;+5IVC9M;U3!A(G^A1Z,&N2?+XPZ\\XGEJI/A\$; M(1!>1*CD'6VD]"I?>F"\\SXV;9,"FIV%TLE00
|)|C3@0V'4W"JB=<>?(@_NJ M|8>.9-;SN>NQ_Y=.K*?#9\\U#2W%285KY!.\$+87503*!H^E'1.;XR)J%:_|D
M^;-4V%>FVQVJJ^W11>H*+.21#%&\\|DP +8V#|R5NG_D\\0;SH"5UGY|XG0PNZ@ZA(A8P9U<.=T&#) MS*)9<=?
E1H5K_5XU=&950A^7 MF?MW*\$6V\\#WSA6I%/@JW =?2N92L53VXCW,0)IP5\\5;J|2\\A)U-\$OE/<-
HY#C00;J|'6(01 |T5>&4L3^0:QY|24 M"NFM*^ F#JQ@VE|E=7%XA18M/2|@^
URE*A8M&+8E;.&@|0=U"R1/J?9J1ID M>\$+KK(I"\\3Z4-(WSB'N\\U^P/C4(Z"\$5PR/6XEK'|<-
7EK0Q,A|49 !@BK;B MW)\\YY (QAL,K+003.OA (I*0AR&?>X0.*+^*F"; RA@HJZ"UCW\\/"P3/;"
M3Y\\4^LE),15^3;E-\\X7X"/Z-UH2F!#6Y!;U;2"X7:!*R5DK,0.?3FH002+0M MS_F030?7VW;AP110F61TT-
DV^"RX+B: \\(/(A\\AHUU%\$F;^B?|\\^RZ>Z' :2 M://1;T5WL,SH7JQ6D\\\$UZLM9*|*)/N-B!;UMOR \$TH^+Q+?
L_KONWDL0?|DX M(-VB8)50'3=(1Z"S6"QS(W<0EIV'5M_2K1\\7),U-4 U=2 M\$7Z1W'Q-
\$5.B%LZ_2M\\4ST!YS6'I>|LY7/)!|>%AZ1-DE3\\">6N3='PA^LTR M=N^#GE\$+XYWHQ&|
!*A6TK,86F90+W|B5A\$[MIX)UY?SI|:-R-;I|>'A7&(71^_4 M4DG+G*,>?@XDD ,
|COK7F&..JY6^%CN0TL|?&=?Q%W|\\\$5B4R^#05;:UN+S MAVQJ-;CAB\\>^'%FJ*ZB^XD
K,I&!7:Z78P<22'L|X#5R=\\1#_6U=%A>"JBQ MLH1;PN*)|)OSLM/VCX7;2..I>B/?5?6?"HLV'N"\\X(!!
<0H|RB?W#X-)MI\\ M6I%(4\\B5C+,.TXDT5S^9X&2_D* E4E^NXUXQZQ0=%H?PC40,.E3T6
MHRB!@L6: "\\3MQ;Y8QJ.BWQ9.'^+.^ZV"<=UK\$310\$" |I#7>%9@KKGFLKEY MY^+)|4S|\\^?"&?6.|
|/.#596E\$G+9+R5Z|;#_@;RQ'R-C\\7/(-=LAI\\66F)U
M?;/,8\\>F\\..*JA&61Q17LDIAS(8W&MX6)S8*_L.%C\\E?US^3_QEDL/!42LYF M7V=(L=)Q\\D3PT)867F.5SI5E-
"TKQRS'M\$FUQ+5CTH;MA&N<8 M0<#EQI.QT>3)|7 =#%6D/\\9>S@1LSHFDG^V(NA;=.NDBF'Y\\..:K |Y;VN
M?X2*\\PSVA#;K|/6QOK.RYZ@#_QV>R,N0X/IEK5*M9UVGY.5BUQNA%\\619XEF MKN\$5#U;W/G>Y^?
ASIEYL6+I_|;A-YV1K*NE@-\$-|+N(5/F:\$_1.Y98(\\XIL MAXQ7;5Y-UW9EX"\\HX)|FIXT?H(^ZC>@MLG@IER\$D
+4GA4&:ZN-@AD8.ER_V> M?G5#C%L6W*02.=0@+B-0G/#+9=SMY:#XP|Z/DMM/-*X\$/Y|4B=Y#LV1U(-
G;DF+:01B^L7Q+F>S!X+A@Q;Z;R|0"X@+VTA M=L8#8\$CA?7^/_ C<4D()3?^T-@CI1_Z,9'@B:ZC'=P-
^07'UR6BE^\\(V^Y06N0=>?"^N@SFJ>9J&C*^2K-?B"PA=| MEP7<7-*:#R:ZZ#|U=+LQ>0'#20. &U90\$#\$VA6
49WY|S=|T5B_#)N.V>|Y?3IEB2 M^=3.2|R@S_KJS#R|S<5UK*_*+";Y(|H2|6
|\$\$\$S76RT5MK^0%+*2>5V90J98^W|'#Q=Y%:\$Q, M<&*>\\T\$;8VGG'KWR#YS*XDC\\T!;#V)P;M3_F|GU&F9#>
MPJ@|L/#YY\$0:8M>G9N<_4F7>Q.3G|H=*EAL)\$:*U'507V.P6;>7S!BD@5U0D M'3ZX)0WZ7&P\\-XW|VFBAT-
RY|REA+F M.E0?5TY=((-)C'R|\\0&3_X=|S6.4;7(P'H'D/^&NXY MR>'JE=& "3AL-AK@AV"1)CGJ;V_QD^\$?
8''E=\$I1>\$:5B&|8/J4-7)@T|8N_MZ0HK%RU_S>B3T9730'6VWSWAE?3)SS09)"KJ>WQ4WMS^@+DL18+T0

C3P&%>FG0 MT\$ _].V:X)B)CF(B7;*FN;\$1[H\POI/55_[H*]7L=K*4)H5>\54^U'X\F#+^2
M="6(^X0Z%76M)8<|?\$0/&T20:B2ET;:X\0'E/=L\$UNLW1CUC5%Z@:Q%05,0 M>G%JUAJCV={=9*OP+?
['T2\$2*3X MTB6HQD[%Y1:/6 W"H%XNGL;#EKXC MK"P#Z.-B+J>XW""05PZ#H>S)X)WPD:)/VOD?
K/%#MM]QS8IL-\$W*E MQUK[8RB@\$V?PD8W@405F]JKRPX.?(C%'+ '6\$C3>F/ 7(S[CEG5@^7TY1.
M.U4==W[YD=']5C>5%\$LA5"Q_H^&9M6+@1D;M,J(U3;Y<;850YZR^E^.@J87* M5^(14K&<'=:TVT_RI4%^,8T
=L5_[9W+'GH6LLYLMOCM;=TAD;&^=?>T@/E MA]N=Q=*NR7]+*7^>0\[\$IG\$Z&J/_QP_M!;/&-
Q80['RH96%#3FW/RDZ\JNOMOU(/UY2Y9JFLC%703Y'[IT2Q@09!.;8 M:]I(Q(MN,9F\$Y#N")_?
**.\U,8UNY4G;2@M,(]W/_/1;0E36.K8 MC(VL\%AMR;
M+6M""JPQSQ\$+^X/<+YTWfZ;G*K6BH26Q\76\]M[V/LG&*V:W*N2I'.H2%<: M.GM?9+LFOM+&>1M;
(S<I!8VI^]Z+[#*K'KG\$?2< 0].\N M)_@1U6I+;BJ>"X!50"D@P\4&Q^4\?@_I%Z'@C
M<\$26IFZV_NJ"\$SZ0^5)K MC'B7HN'PYOB# 1>[\";F9JKZB0\$0[H(P3T&@;XKB?:[&%:]U^5%4XM7TA,
MK,W(M@&:F#PO!#> (YY'ABL1&XYW*9(>;64D'E?@KW25.V7>-!SM,^8[4B MT315K>S">)M]77TV;\GL\
(09\$G&[+ L3573'/:T0 :F%/[I;\K G :FBJ5@ M20?\$M1P4)R7D] 0-\E-
8['EL,N1%)!.51KN;MQ"M%S)UB/9TIX+^ TPX3E- MPX8ISG[ONG/+&S+9;Y:<9-0,JLXQY&4=
(QZG/[5R^TH)'=-.Y^T\$X*T8[5T M+-3X)?9HWKR3K9&KU1@MCIY,G/STZCX[# M9A\$ASC"(LZM5GM%83?
B'P2MI#DS&=5BWD6]LR# 0*V(>H, MNX6\$T M=?M&.T-UBM^0%2E-X"-X6P\$&&K#^E}[8Z](@K?=
<'P*TUR.5HWC\;T[^]+ M7ZN]0%HS,]2E[J.&T/HK-'BCOV]/K6,!%(D03E>*0TW2]'%!3 6]=FXHB
M3'XVH^CACWUC%Z_6&36IL==5YWOWGM8(?#EEJZAV1W20@P\D'YS',NPIO MJ;?
R,K1M.GUU>W;LZH592ZZZDPK7@XW(PIF GX5G\$0<_>"HPCK2FR?3]00 M ^="4M^R6ZZAC<9-"\$=+&-YD6-
X"B+ZWC90LU/>#L=>YZZ<5R4708-S5Q^ M2+*T8E;[SLK9]Q[K^+4ID MQF'Q+ZL-
1U[(W*PE0%)P6\5JN()QB?UT&\$HHB#QE,3GQN-E0["&40;=M>/S9SJ!;U\$@D#G3DH5KL^" MT[W.HH^BGIZ-
00X^'CXK=.;#&S)CM2@X%450W] MV4*/V%M\!L:00R[0&X+%B@R(.24',4#"R1S-RVND8H5KN 3#?
J*8H@FCPI> M]*+8,U)8;SMY<;M^K5T2<;5<>6(MXLS7SE+H,R_9BCH/_Z1LZKE4N8_3Z MKN?"(X&E?
=/ZW;C^#0%TL[4A0;..AP <199T@B-ZYIT*PPKS)S\$TF'=\$*Q MP/0Q2C_#0#0A=X.UD-
L^K%*VQHD/HW@,X00S'QH*8^+F?T:23Y>3*IX.#4M(M.E6;LM^J^99H>73E>'A#.,BNA_:VA2-
2P@,UO*:UP[,CSD,LU6MMR^&M>X8# MHGJ"][:I^WT!&BJS+9_2
JF@:BIB=F02@3L*/DTN0=ID<"!H':M\IW7'9\N; MRI]X",4YAX1:A.
(R./\$+U498F@J\$HR=2ZNZ8NTR[ZVCM:WV5IMK]ULX2W!2 M+:+[M&UZXRKOM@V\DGy:.0/-L7Z-
E(_%7W:%\@G#H:\$R@R0.C022GI"M M2@<\$C)^]#_5J?XJ44KY8G>W0VX0+[G'0@C?
[)AL,CSB0%L%]200+5!62: 0 MVREI7N@>/3I_6 :;7XG,1,>P%7 MB4T!6B6H+URW=U5;]P"XBY+?
M)9F, YMK\$!071\"-1K7\F6@];&M];R=HT^ MV_8'[UNL_\$ QT2NJ5XW9SBOK:PW>WN [M3T>W@\$/0.K
4R&IN8KG&8]>@M:@ M=]]]?=:5:/Y64/[;L9\$Q0JH.\^ 0"1 M\$1(P(^T5X1FGX-\$*
[#&*0\7B%4]1F^>6\$[/:1519>,0#FF/1];S=7)]FN=F MDA]9(+Q9AB#N;V2U!-S\T3RPG,C<]&\".@1@1=06:
<-49SAYO>K!(7DKBH M>/^N)JA[#:Z0IS+D;:&YUT1+;8P%\$")0<)>FIB9F_#LK,F\NC-:U322TN(E= M?
KX0>VQP7ATTF/KK0 :?+ !9JH\Q[%:"84+)!6T0G7RH\$XQSU3_XB4?S@VV M=F0I6II_-9AF0[-
Q%UL*Y>@QKT\, #0HS.MI=2XG1\X]-S0\$ M7\$Y;YN_3A!KC:D)>E!-F2LTW-
C(=&^6W'RY6V0XB]&+ZF0\46BL>/_L*>^ M=N%W5U0FD48MZ[2:;?)V9]5(\UKS&@;UY6Y,/T9-D
GQ\$JFHRVQ6QZ%CR)& MTP&,L<7W8[NTIG.\QE5\H7? 5-DCUJ-&
=]\YTV6B4SZK#_A)J=>8WVU=:;H,^JK&G&I4R0:N;
MMA62WLJ40M]2K;X8,6M'R!S<16PXS;S>+.^R:4ZYZ509I00(?>T@//54[,W
MV]1(6TS\$6S>XCN/G%:"K@W!9&GF'(9C;P#SB:GW"Q[\6'VIU)YRY,&Q5*0 M/Q//U[Q&?
3TGC[:5ACFNT*)+"2K;V."6L#GFICI# :P.D.J_(A.^E?#7&.,G M,3"
[T>' /9K8=E2G6G\]CC/AT^N9K3HJ.E0J,16^&*E M("["*0JB, IH=7R9'4I&U*2!"(!B#WJ& E(Y10-.,
11%D8!]=ZB@'Y *"#7+#[]/7SEW= R6-!];3,I
M^#7\QG\B[#^HNPITP\$0@'W\HY!\0DHL>P\$>D0R=RFE\9CL' 3U1_Y(*)> [/R0V=D%?XDDB" MUK]
<^5=5']3=07XIY6C] \$Q?@^3,A<;\@G?P/ 3 ^FA:W]!'Z63D={X-W^ MRR
4RNN\$CDB' <=@!1N^ N \$RW\F^# ^X\$ +JS^TD% 87\&7K0)N0\;?LZ@< M\ E_FTDY@02\$%?
[1TR!^95.7/4ZD((L'[>) "@*%HIM_XG2K)(MW?RGS#GG+
M93K%]1B;]7]@#"SIEP! CZG> V"N3_] CR1\W[& J4B0S/]>8DZ-.T/T0
M(^0VGWK,.PKHBP<5[H +Y!\)"V2XLW^F@\$(%)'_,>.N'-0V_B\DX3]S5\$"5 M<"M;^;@_5630'V:SAD[PZ'^N
*^1?Q(D\\$/7Y&\M_H,4 NR/,LG !BX!%/E' MBU'XPS0+Q"/X?
S(=0_X[R/*G0SG'(L/"F[+]1*^0^IJ]'4!NZW;0']>WP7H_MZ4G5*0;03R;SMTT?ZC?^5U@4W*&
BCV8JQ7\$8B,)D%_7 0]/8(67 ^E[[]L ML0[Y/+3A0 J+W8:9Z>RL0A_!&[^RDL,HH+]
<#>^C".^A@'XG<2R"0"#/5:UBK[9Z<2 -9X"\$;SD#7P=A0>@T/^ MC?504HY>]D!@3>=^)I+ #F0]B#+CK%(^)-
HH">NYZ"#F\NIB48LQI7W+EPS!Z, 'Q)*%/PQ0@\$=^IU08SF:40:8^RW*4\WOMI1!0 M,@23[:#%;#
9V(9Y<70MA1%0*%K M7(-@# ".8\$R#"W^6Q7R&10%!Y'EF+-8R#%;G5QK]94U]=0>,MAP!]\]G\
M0U9PXLTW63GIB130"2"FXGI)B\$A G*JIUA]) &,(6;^]*XT#_D,X U@(\$X; MJ7] EMRUB(R
5,84D.U<]64*R'H^,S?CXNI&A.NJI!'Z>X5Y<)G0S\ "3VG_MVQIER1>]H0=LNG\]9
@Z^KJP!3&"1RTJF!]^/0=@/!NV!-"W0'YQ/ES0Y71R M& .@,N-#E2%+W,R#"6!68DZG..!;N\-\$8?[I72F V7/
\$5L!EVD"XJ]G!H'G M@Q"#2LGMS=Y@G()D\8ZX\BH[4(@".FLH2:(!G/MOBX;BK0&?67\$%G7"[M>J M\$R,!-
X^/V8!-H[(5ZH'/OX4 >V5^AQ"9 'D MPP519!# :#& 'KL2'1V^ M1R].M78+#R3M&A*%"
[ZMS@W\EA8PL,T^S =EX8VBS'!1X M8V\70A3AIH\V)5H!X1L X>T!YHKP U;
(=@8\$CWY\$BHH!6\$05MZ)J#W375R#X MA]Z (%_@,[5P[)]@/4407WC.\$Q(, 4J\$-,U<;K5^,R8>,F8DB0#2V3>-/
*X. M)!A..V1/!\$(^ D2J5PI.4/(+.%<#1BR \0%' 'CF/BM+9A\$# MU ?<2D4!C0! 7=L/-2A'"U"/3!@FB@2
8@ Y X,+054F@N938*L6;L>?0%\ M8X7\$S/!20G?\$0 M% +9J#6T:5R)K>LGLX0
5K"\$X\$]"-60V==0" _WL61!;-(%IWP^,!94FKDAF^ZBS%X"Y+U)]? R3Q(8H&-H ;)/P2Y1#\AUTX#RY\$]"
(/Y!ZX+)+\$"*79' _MBR*+S#*D=4"+(!X'-+(.V7,5)B0]3(/;S05P*.FH6'P%W&^AT2%W'X QWHB

M,2AW[^?K[U2#BK3X*CRGV&X()][BA4' L]> RX<)RQ>0G1.0?0V*?U *[W&#
M8T[[]HB_]! TBXR\$[]),)! ,Z[\$0KH&Q"]S8"+G[D"/S@'7T@:%*Y!,NZ""+(\1 MNB"EZQE0((%; +GJC(CK
8W0+16ED!F \$KU!["?S+[@/P/.D<(@'J'["<;E00Q M(;9.E,P0#5QF@1*/ 6J#D!G2X_8C*: %Y" 6AK18M^Z=
(<6)'08QX\$LA@@ Y M Y0(<-L >T U^;3[HK&A4D0Z2(E*[]*K1%1 0*3W\$A7I3:D! K'0 MI0@*2LS\$/5:F-3
VJP7)2%-&0EJ+^\$7@&S5&X \P-FTN1Z%Y M0.R2",@32./72/0;^%0X6_A/Q'4V-7.0C[G,%;IG7\>;3!\
[VJ4A+8:@\$^@ MX] =IK00."<;IW7V^>\).CDC&6H_N3[P=I1R->EW@?Z]SF,7XK!V5\$7KSZ,=K'G9KQD8GR=%
=E?#H3+OUIRE_E\$,\$(\$ U3!Q &D@; D""H M%IG(90![!1,*800L:~8;_BV0E_W^)H/C_MG[,OR?=030W_@;_R>
<;QRN^DGC_M']X!1K\$0[];0HB!IV9HI4#6!0]UXI\5,^NL1:PWN!0619.0?^V=1!D47A)@N3
M(*7!RNP^,3_6I8_\$1/JY0!LLJ^F=286SRR_W<[32MJU;K+V2YR489FPJL3(
M;6[PHZ_KOAGP1EI+,G;)S*_.^XB'^^']"/! E2-\) [=Z**Z>-SRJB=METO,J
M]P2UXB=9+.#+!59#^@9)CHLBA6]Y=\$7H;TSX%%CE!BUE23+7L.TU\$6M46UEY^\$]J%^^ V' *
ML> NX95PPDL.\$21:B[9%>*1%9X5KJ3213[8F%KL5Q?N"]\WQ?&-^ _ G*G%4 M>I,Q\$)2=F7C\<9GV
K[AD!J/SH>:X!(QR(ZL:QLC-3%B=7X2BE5LD9;>N8/M MVH2ZG,>/-FS01P][L!)E.8N=D=2/UT\~@&J,IA(_&?
75 ' C; Q'\%*1&QK MU%Z,HW,\#.CH?.=?:&YEKE9L*: 'I:0,HJJ1;U8"-BL+@FNJ%5+QM,Z@Z*Q;V
MHC)P\$1@70!NIK,\$CETO; ,E\$/?,[I,9&L'N4PN(T<\+T MII:#^LV;#IH;".IS:\KCGWJX3,35EYRWK@P_E]UM?
VW5\$V&@X7]!7?M^U" I2H\0906. 8%COZR)W M[UGE5; \3!OAY& \%\9/=4\$Y_9CJ7DA;%PK8AN\$ \ %W?
9\$89ASR^IWGCI>Y0 M!Q?F)'L6/GK8QW&=.27!FWJZ_S#0W8\$"#\Z"FDSK\$E87!Q_MJ0YQ\$N,"+N8\/[08Y]A;F-
UGM,JTP^XQ \[-^ +EWXV^YP0= Z^GF0Z_ Q]! MRT(+\$, ,J5PK%X'(. 'XV0I*&/JW%Q;8IN0BW^L0_=^DX!-
/P^(D0-T;G=C MTWA_=#3>J?A07N78?M'.X%M!] *MHTT\$P5M^#GAU\%2 ^4&)9J6^!&E@>]G"
M>J_VB*!+4K)AP_&7@)'(%W_FB'C[G4T3Q\$ETB)7EYX?E)5+JFZLS35;V#4,R3BQIMED%""QU<
M5RI=CJ>&)+#14;F?ZM_ ;PN4U@%V7Z"K;F*-0<#(^Q+VPB.TZ4)<9T!XC#(# M6D?
#J.+MF"HQ,H@EWN0Y[C^W11Z7;41&M90K/SST!ARJ9LL#0 MD9CY,5<)FLOIK;Y>\$)?6RB?QN1->08GF*C_)
(DZV'RYFA[G%Q[. *M[KO!& M9ID+GRY@K&%M9.>0(9\$,JS\%TW3IFW5,U_B99E6H/G
MY;8E3J8SRSLN^AFTG)\504-BXM]"X
P/FICP;T5X\67QJ,I;7J^V8; ";EV2+,VII/N\F3EJ*#M,1G5*KP\J2G6T/L5"ZDV/LLF M=B@;,\$Y%A=0?
\$(Z"ZEXZBFH4X?F(D; *98_ [V3_ ^[];I_ P<'I>M;JXZ'MJ?# M7+;&PFTD;W%K;_ 9U@@,%0?
UEM!JM3TR8FZA'UW;K]= [I>Y?(XWXS!K1PASH91GV3@#=#J MC'KG_L;?.,-
Y/2.NL:I/Y ;.,, ^P8FMH0[<82PU'RW9%D7P7X_A>JE#Y/=\$V MXIAX\WW78[MW3\$;NUG71^T6'6&. MD_Z!
[LGU&RI^A0I;KL-1<8=0DA?%0_>/06?,Q'TP!KZ6CC0<\>M505P=GVA&'R73^K1M_ZA8>U](CWSNOKX(MP@G?
PE4*.NVS# \QFCH(G I;X!_D;8+?@%2?10U90T&#Z_LT0?VY36D&49? M8!<27Q!
<60L7YENH_4JRV\$;;>X0%^&F.S':RX@X;\(USH05R&\!^!\$?<'EK09% D0'=LR,?) D4>5NW,.J ,Q3 MU(LT=
[\6ZN3U('78KRK9YA<^UZXW?C3*@G5)\[L9X0V;+BA)[4W*8Z2_54R MI1X=),8P<:6ANC'X@7;\$F-
96;D,/ST.*YXMA"FML/=^^.8B14',TU>7&GZ=. MBS_<.P6I*=SD]!.6Z+YK4WB'[^*#-
[6\$L4C5"#09F0)8G(\7*9(I_L+?=T+Z* MR4X"R;CIXS@D1-
2A'3S0&C[2)0T]W3NM7ZT#R]="0\$LJQ)13ER_L/26P*AG+ M8B\1WC95;LOF"[^D
U^#)*R6DE>4.4R360W3]]^#E/) "VDR_Y3RA7TF6\$ _! M%\$0%=Y\$!YP^RWATV<3>.^U@#C;LF#\$8L-?>=?
F50=0+T7(J'W\$)WRCDX#03= MZ6>9Q,(_P!8S@Z7KQY79E^H=7DFF5%J[7*R(YKW+2"C%F)QE_L4?+]
M(4=P^(Q*9T,1]/+42D4(MMR[Z@'HK:EMR?4W)?H;_X;AGWN: ^) _R%FN-;NB[MM*W,+H^E+KXW1-^#\$L1\V
L78V;86B00L&T>_U4?1VI)Q\$D/)9(!BU]314N[MPJ&'07VETU;_S(96';J4%:V\G'>URKK2[F*
[*86,8^#CLS'^ZIM<1?=>@CH6W*03\$[]))3I2)G_M08'=F>DNGAK3&S+PAR;_V! !DSA"JU"8@V!<_2-
70NVQ:\$A99&5+.I#0\$,!*?LV^A><&%>X M&3'>X_RG^LI8W8!04Q)=M>N)S28]E_,S>#*#
(.,,6JC*KLC=645CJ@^ZSKR@44MBMNB!K&W^16_*H]W7E==?12\NFM)6>D)Q*3C0[Y*E3)8TX*34U5%XRB]P
M.;@EPW+)(:1:Q](RLN3_+?@1;.NQ)N%N8V#T\X<@;<L69WFCZU='^^-IJ/! M[];F!Y_5(,PE.-0-@7LVB?
FJ/2<+L70CRN*J8E2>2/?%XS/TYZ-I/Y!T7L!- M>!ZC5^IZ05 ?UWU_0 *3\$F;.>>["[*B?!">C!+[C?^:N
BTH)THKHJD0IDL_M5#R>3@9(.M4@]. =5.88??^2FSHV0,48*V1S41;S&R0FZ1PGDF_V0,E6M4F"E MX_E8Y38"-
S+9YNF8/'\$XF?IX- [2_HC&Q;V0 ^",9L' LW MT!0S@[,UQ_.68+2.)[PK\$ \FRYG=-TVQ;CE;I*BTTH5RPD
WQ0M79!0^XF4!QVB?R MX4]"%723DPZ3.N+,G;1EL_9%7;@X3&(#."> .T*;SBGR3.YEGRJU+>L2[QT
M*GY&0V IW^@K]\("D\E9EL1^9],6P/9[0+KZ&9^DKB]U3G]I#97>NBG4(^
MQM>ABTYU')8C[XMGSDRY5MCRG-BS[ACNZ)04T2DHS9Z@CE@]L,&K=?V*-W&) MD/4.%X\$]QT#YZ+LB#06\$ \HFT?
9:M)J53;Y,@DTW=' MBLN\$^[AFJ3++Z+!L +F8N4!0"Y,B6+82=J\ M^;U*?_/:ZQ"FM8!/) ("A]W%" M,7G?
_0^<(<4ZZ;K5I?LK];5CC(LR+>H:CFC#F"P!GJPTWK<-%'FDD2S@P0_7 MVG3TP_VL_ QU;LV9.96I\;?
J= _>/WF]GK[%D]JYY+DU..ZS-UEE?WLNHX)]S_M#8HC@\$A#)[K-G,RDB=Y5M.\$8/_0I_#QXV#G?
#1]K0,C08:TFSXB;JN8"]-= MFV#YX.YY47P&6I3%;.+4/^C284H@4TF]VICZ<'R8'0/M!+-/1;MM(ED^L<.]
MY2_-0>HZBA^4+G,J>Q>V@N' 9UQF""?J;VA;<2_ \%,;?^#=#.L>U&.3T;MMQ MK>F2?MT/1'6L9L%GC?-
E;YYXJMC&M2AH!>SL7 M;/_A(&AF6DBT_ \9MJT'"3N1W59]LN:Y@'AY_&4,S;=RFNV)/87F3DZ9,!@*D2
ME\]C34J0D=W-(S)]LZYUC_-91*J@@"J('Z.+^B_TH(6K0+J(T<*28,D25Y]K<_4Z[KGQ>D8MM]2J!
(\N#T!K]0.;)%[M+@/]N=L(N'CSKFQHJ MU0^TQV^,2^/=2W_1MTCZ1RT>, 5N3ZZ4R0?%9U6JZZ?
[_SP1R\$YQZ()A]<0Y M(' \$M(Q!&1ZZS!R1>(DA^AVY;223W43>\$;R;=YVIG@+M*%;P%! 'VU#&+M07^%
MX]\935ZJG ('H4PKK/PM8P8Q#5-H)5/Y\$;H_\$ Y3QF2B7]0"D0]PS47CE,&% MZ-CZH^=^-%.?Z\ 'U=%AIM
M2)H-&QZ<6-ZUCU^<<&RK#2FUE-< ZPG]'48"*Y^_E6F?]\-'@_A>!\$87IRE M-
+8F8TD[[@ZSLQ5M\$*Y7V\3PHUU_1L%UF0-?Z,K-_:!E;:-^%0/X8<+MF5,H M/0%9&1[9V72S"6N
MDPK""..R6ULGV(79S0X^/ZU&1&LP/JK/J/_V[4WHN7N :P" Z>-;+?%]?%84 M0#J N=?JDPE?
AJF+K9D'!L!/JBR-6]T*0.\$U^+>9M7(P+M T2AXR#Z,"CR- M=Z;Y[0;6P8G^(E_4G;?2\%C-
J[0WT/Z!&'0PTLJS1+-\$&P\T,@9.!CC".8!0 MD->VQ=537'RH\&1 ^X3!E;_E%2+S=B&>K
L^12'7C:C/A[(+KUTYUGUSZ+2T M@QZE'N;* \JXCG@*^>^R*:KY]7
M/*!KUB@L:A>&8FB',2K++38H085RL8]"C9:M\U>\$7MY&K[H6\$E/*#
MNCN1];GT^H!3ITA.ESR*2/E2N.KDM\PJF!6\$S"+-Y\$W2>F'I7K",\I>/UN' M1_9WSTFQEY5\$C'=U

W6I&_8P8(BYV#V\$0\9:~??)Z4=59[6ZTA'R[B*7MM9 MG'^4;\$}Y14,R "US'\$-@PK<=AF&'VD1-:;\$-
-(W%]"#9=Z?"%>|K'\Z_76U5= M%Y)XT-'R:1?7@E4."[>A*'Z#K\CB9]/C;'K60_C3+\$3U:*[+I?T0_N=KH04
M(8*6F,+3,=6=0/NY[F!G3)'6Z*W?6R\$QK71QN\$!:_L6L5R_H4.#HU(?9W+C MG^7A04MYN_X) S(G
X66@@AQ5MB"X.RHJT'^-.?#-'//ALUX_%>""W[2!/^C M\$'H'?V01&Y<<6>7_RUJ+8-S0^4^FSNC>,IU-
4UJE]6>F[,MB?I'W A0I?W\ M,-#>JX-CLNTZ:6:|@42-'|4:ACD"PY-(7*,^8=&J01!H@V@%?:0ZK1<9#JC5
MFR9RYG22,U85@B?"AU_PY<50!CS+LBZ[X\0A(J L^="#CQTS<([>6NVJ@Y'= M<|DZ9:Z00(7
)M0#B(.=P6BBRU(G\7NPTJD)-H1+*'~!M;_:*\$XM-BF'&IBJ M2|A|&\$-=[']>ASJ67E?E3G<=&V4A96SIC?4V0@
8:H@=#,^'LF-C)B.#^3?N M !B?"(?>J0Y!QW'9:DLI: U>>1W3|D5ITK=SA@%D= MNMLIP'CR&1!\19*N MQ
^X8201L) 2*-LRI_[K41\EX3BAB>?=>3R4.[<5'!CX4SCZE8>\$1-,B90Y5
MG'FYK/NB/|4P1PD4B0AD1P'^356K[+--\$^4%0%W^;+7.)R#W0E9;/Q>GP9.
M<(GT)A3F'5YJU+J]EZ1&NCV3W8I5[W2;,HCKA8!)E\$S%ZR><&9GE2X4^&>H3 M3-
H9]YS0_Y054<=%W&NYRH&;+8\$@1/[09V?X6)+%8??94W7Y"-E0.LF\F U@;T
M*.\$%#!=%L%&6W&%;,;+V<.07JV@&|(>X0@DC7?~JZ+./)|;2WB3>87?
MF\$H*I0=\8[AZ614\$G)C00R24/[00D-@0#& P4WQ;\$0NH0 MI7Z92S I*(/*\$.BF%J#R^
XT&1".ZDCJ^XU)TN036; QWAQ: 4+C7G^";+>/ MYTMC0R#\$-A-0B'N03DQ|@5MKT^5<9SF12?
400QV2GW\$CK4/@MF^*W6?|6*- 'MZ=>B.??;!.!J0#-0VHE&= FHW>/ZS (^L*T^.,? :?*(LZ(1!2HP+0GFF=I
M.04>01Y3S ']=>+MG,JW% J+*C#LD\$)3H\OGM 8T[V@5R6B!AC@F|Y]-M| M/!^NW>-!LY4|ZDH%-
JAHT(8G/E9V>)T K4B\$C NJ0,F MS[6SA6.*C)5F<*A MP 3;\ M,V1>[%DPS:YJW+2;GDVR#;W \ 'U9>?-
0>B) >RE:P|^0Y3W"VU3C_Z\ (2CH M\J#V7^V-?^/_63@.4+0VOKUB2SU%>.>.TCJL27MT
|QF9A"2*7F",\,K&AZ M.NO\$39&?%*+FF;S V7CKZ:0MP;B (-!'S)Q7-SVD=YN"4906+;E,D#@LCSE\
M)*8L0.W%3'MW+QG%:A)UA.^@LR8:70R(>2+,W7T%CDT[62?7-E8\
MSOHRZ+I,&Z5@L\F1MWIB7CB@8_N#.%\$|,6X80/3C, MC|.?,(/UZ0J90ZU2F>9PW2BB18]'JS@DBHGEB-
[9YP7%'|A_/5-/6B\$5R+BL\@DQY4"0Q??K-/FN<:(7VDG>>|!#7 UPDLJM M0I|#!,N| [61
PU+"P>1IC/8.ZCE0T^X^D7)Y6<1VL+9^=X:\$-WIFE7B\$85M. MV9H*_U|!8SL8-0<^CH#I-?
6Q)M|*V3;EIMFQXYA_?BMNTSD_# MIK6FZG1E<,5SQ,6JM?AW_?
KU\$V?;.!US,7=D\X|@_65E,,Y%*#A\X"2\8YQ MHS(LV6HL)TEF=TKCUFNZ|?
+3AF "XATL4;CU(X0CU76F[SL_+0-14A-7NU=-NZ3Y6 MX9(0XA!5: '|PF>@8CX2? Z??ZSI*.JJF|?
1[\$\$DIO\$)T-A:~!SPD,TKN9@2 M?0+8=[@.A+UZ|!N*RV)G:LV!N/ J< WD93EHH4FK8+W-E?
MXX(YI[X/F@X@G8,P;K[R|0NZ0!0H2M,/=HR[8\$0DU)^%9N8RJ8FG3"(T_!7 MILMB159XNV
3:GF[WU[=9\$!7\$>,E!<"Z)>|L 7C(XV\$K+W^8"- =CK8.-] M,F#3"KG62R
#%H'\I+PV\$@Q4B|. =7NB@+5S ^-N4RWZ3B;[M=D\=%+'F '#K M5+@,|>+E3\
<,M07D>AJS2[5^1@7@^"QACQWZ:VZU=';I!B0#AY*V,TZW"]'B<6#9,#GCXMD MP.H7\$0(3(2
I(>D'P\X_YZ9H,V".M--|74B61CN'4H@+6AV)W1B9[U62&|F/ M5WK ?97'50C*MBU|A(\56EX?8PFKA+<
F4Y9_U0H)&'TR6H,=6ESRV:7!26<#;#7Q10\8M48!HTZ;?5WS+EE MQ'&N>4L1)|@7.R"K/.LV50L<1.\F
_74/L&'P,)<@?GII=&D8Z|>.*AZE3_94 MT5@2G.\A[5#<=US)
,UP!5&^5PW;UQ)Q<6W@4%"U7&M<=.8=?'P^5&IX;,:;1 M[7"H1LW_F\6/W&#HYLMYB})ER6+5^V>KE[0BG0Q>?--
D^T\EN^5 %C|D&?04ST2X#(-*7^~0(|J'.! MD|1KT7X?-
=E"!'K"YE_)&H|9'+T;1BZEL21XGA/J+EE>W9PDW^7VURI <*EY: MB+!AP?/GKF5FPJP|[N!0^EZE1E>I)T%
<*H%*C/L3'8VRJT|!#;M MR>|K5-3PEW\$Y763 .:CS+T2@([JN3B4(0,Z/I&ZD-?1";M>\QY@FZD M;=6,,,:-
YR*"HN=S?5("\$G0!MI'TLY:5|<2TK^DB'K2,H3W|[-^\$CRN?
&H#S,\$P1E*0WEA1U'T/60S47400QK^GI(#JOGQRF:@P/>XQ,Z-9,4Y2 M"NZO#R)F, "\$KD6DSJ].+/,F"&:+F0
Z-|39'0%3S Y<>>|!7YP'4'DO(WV'!4EI9?;BW;<|JZ[R^@BI> T2I\T.=X&CC\$1=U-
MXS&V"7GXP^:7+B/8(1S#+.E.Q2T(2Q(,7MU.'. 41P_U\$?(V>#3,|+@Z_# M6@1=77/P[,MIX]_#
[JKKTO=;N^-*!06N\$C#.A?|R23!X\$NZW0*G3E!;PPK\ MG;(:0?K4EIA!DG!N4L9?94Z#. |X8;Z/*N@)6-
HFD@|DT09ACM&>-U*=3U|33 M7%GZV"^^>H>2I)9JJ&90SCES,9DY"9%5X0+=Q875W+UVI2)H=NL%P,7_W2H|!
M\ "9CDMIL(\90|7(F/[KWC\X_*=B/696EILAI4YEK5EY1" =E#
MN\$C0(0!\$6".%)UEK,\$|3K8L^_961WLH|/::<(F7<5F,VH0^% ^HG4807>Y1M^
MYQ",8WG;2).#&@CB,=%W0@55/0 XW\ '4+~8DEQAC;/0^S0<* &>QFD!7DISD M4=[
UTG2H#,?,9/\$Q1>+!P\$KSUJFDP'9&A--[L2WT@UW@6@51J| Z?"#V?IA M)K>9*\$8TAZZ#VL4G^%M\$%,#XC)|3
P#P@J8K^."C5A@%E";,679UTFADGU-E M9&.LI|%-Q'>C"KKPXP1W52 M'>*HVP2U;2HS6[#E21Q)&+R
NJVH=--|4@"RPL2:~@2J93D^|=0:~6!3"K M]8^;D|QR?E1(= Y\$)QJ*Y%YHECPC&D,S3+MK&'<L<@<9P* B
;TT"97)J8&"U|+CA+FUOM7 M%\GGYF6_50EK :Z+G/[0I|JC"78)0|:J(RV8494NK# 'J%,H9F2KVXW%\U;NKB:8-
9M+7E0NV0'@~9'9 M3^Y\$AM3|=0Y=TEXB&FB_5| ?Z"C=?YI5.4@7#W:~J;BL?LGR;2YQHHTV0D9W
MZ@M'M'K9=PJ'+L#9A=YH@S;L!C:RX3BDU6Z M.NR|OXW"#"5:ZLKB"- /Z4X0_SHL "0|FBH>-1 +'UEF?1PQ
M\4M+ _D+ _VZ_0'\$7*YQJR&F\!&ZQ>WA& U^3 >7S"%LT%9CE5.UIV5=L^M|@ M;2=[3=(2G,JJE-?-
<|K<;UHKPY|*\$HS""7)^25\UGEF,/MG|J&:-/IMP[A] MS&05L:CSB SP:~?I45?
TS<&W%>CL>EZD;P9*I4(WUB)#.HM?T/"KFB_ |J15V=[C'\$==MMWAXZT-4_9[UP*CJ\$>N>[4P|)44%BH^!D +?
I|{+Q?>""/!2H MFZF[L'!K>G>3YU/PC5UKW338BRQFJ|&.& (9^A@QELV.&_C+X!Q:@-,P(V)N-8W? M>?<
,0FP^ MD!E)GUP-Q|S"\$K2([X%*(S+NJVC005F"W-6?~5+TSYV\>ZB.99!/SMCN0P9
M(V+-9[0+ZT)>QZP4\$<4'%#^LZ'] "\?F94?U? |7>=-0_0&XS;PP?%(^LGR M5R=FN;9'>5'L)XRL!
[~ZY*UXM1LSS*5W!N-VUN.2FX,5@ Y8CWJE^008,A|J\ 'P,Y1?8| MF0@0<:.\$#_AZQGL.(!)F??
T4&!)GF:0ATCN.=9/Z0!MSFVK00\$/TM*|\ 621= M,GL 3Z[613%TL"0%ZI=N02 =5!<[D %<"U8#1^WB3!MR?
\$X^A,5=6^>90=RY M*C?0;>@/E\F"-E;DL;| URK\$6+[M,G"QU7!78V(255V387|D:0K20#F'Z#TJ
M=-4EVG(.8NI432WT"7&\$Z5|_#CN4F8&Z\$B,#T00VY@D_5S2+@HW=\$3>RI0?SEXNU9NCQ3-
M6VZA*BM\R26WI@K9"*FLN,?TW%/1"^^D'VEXCIJ|)@%#NQ->)L_4|JC|\$|1=2 M_.L5^:-D@'WQZXDB? B|&V\.
(S_8SR|.\W6N8J#9,J0V_L+2796Y!,B.>'N& MRKB"GLH;V=&U|I<\$M:&3X\0|,|1">%+)(?8#2"7LH-?X05B
=.9LS[4*/M^ MA0Q '\,FOAL:X>2B_*;|3YK*W1<";BF/WCIY;68Z@!K\$Z=

B;V:0)C:BE=DLWGA\$2UGL5K4_GD:=FWXF/-3K>XYVN7Y@F)E@ZY#AU%N,#YE8])49VKFX6TR
M8+DX4!=/M40%T4_M73YTJ5*>?,)!NG?*E+B^/Y?CZS7@;^SEZN816WR*Y)[
M2{#;#Z:DVI,J4>;/=0*C>>60:X9Z0@8\$F+D-LS7E4J>.FB7(H+X!|L|GJ?E7 MI.>59_P|EUZB#1.DV9V\Z,9Z%
[*IK:VF^B5-X_\$K|>'T18>)?\3^QNZ,)\$69 MW./[J4@I^PZ5%/6L:~?GIM;&G ?\,Y)T{2T_ZAQ'&OR-
1:I,:EG8(17%[U3FD MJ]6DAF460KW?7GW.?S<%KD1ZKON.#\$A]=T(RQ&Q8:%GLZS;^J|/-/7"@)_0&G
MRX*H:K?>-8ET VG'EG="']HNY*PNKAV1U500(@PH0;3JE3NJ.Y|75USFF?_6XI7>;@T0|^~W3 MHQA=?
2.8JT<\$"MF&# MFP-(D5U,|2^T6B@('(*KX-3X*)3#1ZW:"?&1\$<+\$+TMH0*;~K84-U
M>^6#TE_K^/NU9\$VS=)6BB?S6N,-0/Z?QGG910?+; Z.S)2)Q@#B>B-(C!\H9 M,*7ZN(A-[8M07MWXTQ>00#J,"
[0QNS.\$'10^-).A4" "34A.2Z;(V '5PV0] M?RX=D&Z=J'!GFDY%:~R3UG>JA!ZQ|{&6"U| MM.\YJXP|
<&XSOM37!V0W30!WMOP(9B #VKK6YN*Q^V3 XJ\<|)V3>Z*44N6 MB|IMP3G-
7*R@H\N(,X44UA34=/1!.RX7>Q(MLB/W6\$Z5P\ G~!IDP&5N,B#: M-
~6S80!8L*)G6>W6,NZEH~:5^#*70^>UL;-B0*%A60MG^<60 @3(>[7KD\$ MG9NY9W_YEH;J'H>[SJP6:72A,@L6
COV<\$*>^M;YYYW^/NY-+?#*ZS%ENTBD
M=2&F@9PHB%_9VQ|0+CJ&/[I.5X.?/0|SD".&="HC)WX,^9K*+&55FK:3 >\$P M>MH(C==00GD669@#P9VH.-
_ @.S?)0/&RN>B039I<:6!~4HNW|+;B@|D|:6\ M;Z^I.,S19BK+C\$V:TE\9X3'N M*|=|S62:0
2@,YU|]/BHH=8FC0'J.8.CK0#[E(L(4|]:FMJ>|J^|2\$-NZVB8<=TGKCOL^8Y@<24CL MBAW%\L-(|&Q-R;
J^W'(MI' >:7NVX38)N=1F(?')*CF;*DW #^2BHH>
##P_7Z|NRIR\$DK&P034!5K0&@C3IS>/SXZ6VV+1.Q5QA14<6=G;~2KSM1YR&S|/C
M28<3Y/TXPB"0^&; (E0_\$D|:~/78.>-#<^(@1|HK9JW0AIDTPALR0.SP,, \$
MG'1BS#2X@:SJS+A!~G008DG(.H&DW"3%6,UG\$.0@8>;08J)-*XKZ>|W)W82 M7J#8FBN-(+M^!^7:~.
[!7T<89'[X|A|T^T:H|G<.,M" U~BBBUBVTL6N=P(G MBWJ<054.D67V=9:6+E3R\$<291|&#(\$Z"
<~.H8202/, *S:=?<)<S*/;';7(JBP_M?0X/'5=P6MUE+8YY2)_GXY,L MC&|@^4@1&UY(VF<+&3L|X)TJLH?
C+LM MF;6< AB1U17|(.R=HP/29|AS|!8X|)#J7T75A98)DG'I(6'!>\$ (3*-IGV2.9 ME>/6M6YY FL^,XPVUFX?
G~3I(CJ#AU|YIH%X[64.8)\BN|6&R@1C6"7=I^2\
MAP)2T[4C+)ZM= +AEI25D?/.00Y#|>"MGH##!GCU9|&U_9K07" >9|'N"G(MTLY45TW*I8:VJ:LXCB?J-|7JD
&E@>>_P=4N8'-1<@Y?X7PU_I]-R(#DZ\$,! M|+QI.%X@)VZDB0^0^~B\$[K>))P49D!4B!3R->)"<6#
[BZMU@AZBJ"INX-#CU M-?IV='KF94[G^7'TFZXGB0H= C+^X\4XSN3U5Z%WSARM<"IC!_Y/-
/_|L6*& ^L5W*0Q*Y#%4E R|QD@'6 MV"/BG,8Q:0B,\$J#.+G%40#FEXSG|_V&J:089(,'?0@8,J!)A@H<'HKRB
?SS M_SAAP\$#0,JCHK'.^/F" 607C;FXR=PW|"30A1Z^Z|LYWT-Z,D01|9&M=,06| MX*[P920|]*
(XU09"TO:~WJ|^?1)|0=)\WAG[X.4|]C>0Z3|;QZ6BS|@DDI,>71S5_7:2VV?1;P M?&8I)F*G\)(RK? M1UM-
AR07E02!.502RUJUXA,TV5I^MW%<=T'#IMPT3J7E,%JUK&1_2+&01&?P M="\$'\<^&<\$ _5Q"#5A8;#
[0I7|'6R1|[Z2P&IMK2:~QSZ1IE! YIEUTN[3 M%>1Y\6891B'ICQ(3|@/\^F \APRP/V
LLGFB6.XG)QH7#~4&AUSN=G"U2(N M^E0C'Q_0D;=KVSbv<|0ZK>8C'KYU-E5Y4R60=,&
[:ESTN,Y0|)RLM48;~%&M5CB_G#;U=FV79KLVN4=,:@D%0#6)"~/OF0-S9.\N*MN&0
MF|RR\$V9J5)S/K@~*C7&+ 00SjX14Z'\1I0IHDZ8Z8<4X!H5!KATM\$4@6\$(% M)E2NX.\$ZX|)P!G#^~|+?
\$S>&#D.8AQ|AFV>F^23E?~PV^\$28S8S#%AOHU%.3 MVA*?/~@0|(:6\GE-6W0+%%+=W>3A-#>H)C,\V?>K50>
[TP5|&|YX: 49T8F M_+D-8G:3S&L2>B?IKVP&C0^#0WJH@V' ;0%;4ETI<*6"#=#XQ^&Y&TJ4K
MGUM/.Z6K4UIW4 -"253?[_I9A)\R>"VZ'85-/HI3&ZN:>|C" 9|Q/2G)WX,
MI##/L3L00X!S;NRQS4JZ(D9!AV+^VK:~%ZRN_%'9.+X8MD0A=Q|7<+XQ(J;-0?S8V|W<0^.=%-)?
8~RIW&#MR4V28Y&T M7D4V,QL39?"5SE #8 ;T""*RN'+!|@Q|QXHC9DZ>|OR5_7A7)! M:\$)0 RR?0|I|+X%-
[RR6I>\$J#R.(. ?M#UQ?F-!= *^MP.JNPOTF=E0%'K1*V M,-*%#|,\$6N);!<^E=ZX1P8-CW#PN*7M[GE.\$N-
8L5F5V=,/:~^SD^WT@/;A\$ M].5A07HI37\DZTTI-W7^IR+0:|W%&CV%Z^"#<-3"H?7/,WJ-0+I.!C"3:-N*
M(9:6V ,,(HLS/V|5U>T"B_H'JK>#G9HV_BE>WW-4;#L/5|<~*|L>C+@J28E027|M;D?A4E94&U:2-USZS;W-
XVZ4A"G,4 M_DCS3-V1'>X+C@U-VGT-9BPW|04,^*/|G7Y*K60I**D:/>%>|(:|P*~9#EL0
M>%6GLH\$R'+!C@GY#|0KL8|]#P|.WX)'7KSWN0:R!37=76YA0Q_U^ZF'!4F7J MSQ(0D&
[@D21*4=P)NAE)Z5:E>P5RPLG0J5,RTP5SRMN0\$,0C+)A>^20EA\$BC M9+^T-?7?FZ3<(.
PK0LC9(H~&~K0&T;S%-MU%.HF|+1 >;ZG+DF,6NKT0\$ MI?3/AEP|@E=D?^ZC^T#RW04!_,^&WM\?
(')HX:~8W5CJP5=H7+HN[3MII\$~L M*)|J\$1_YLA;F(-[R0!J^4I^F!NL M)9CM!E^E3,KWP#B\$M16#N|G95W.
[5TD& ULWWS_M?N&:Y8:A4ZI#V*60XA6APA":IL9L|C7TTP4<=:SP#0?(CF#GZZ%G^\$>\$?B M@Q@NLZ"Z0AL<~
1J\$~\$W<,G75FGPH.U6"0J+~T6=GA%HZ,V|D6P0?) !3R M4&<4Y!!\$V89F;9F9B:-P5F%-
D/*Q/4S9EK0*2R<2+QU-!LBN^];KV"9(JL0? MUJUK8L>7G_ICC|IL^!.F2 (FI/NL'T|OS-
YT^FI.Z2X>S9FCT2V"BG%).\$ M42FB!+++ S7W<%(4A0_/T2B9,NQM,(|M:DU\ _E):ZD(R34\JU^:08DA%!W
MGXV|21"K-"E6_+ =|Y|S*CE"(GV"C|J= M)#|_>%N**,FK%^K8#6=ELA=3Z
MF'-6>C6C7*/.2W39/OE;7K66YQ@0XQC\|D|('4R-ZZX?5ZL%I(C|N#(A5U/0|\$J)UYM5:/_VE5-
P/_+~*1M.NYDD.Z*L|HPW*];[M8?VI>9|+IZ"|~K<_2'4TR7QT+;HCX*GY6.[BC4/D:PMP&Z6094ECX7HBIY0
M%HC+D &-;J06KC0?<2S09-RD""RCNA/>-0C+|PWLK(MR)IC5H/3N7HJC'6MWCXR?0AMXF84=.&-!L-_)\$/%\
MT"|PU?H0<(.XM&83HZ94 ;TD90V,'03^E2QUEHV@2Y*S>;&:~7^|VW" _E.< M0\;
(HS5'0B0\32\$LR.4_\$>05I!,4V-9NF\$ FJ NAVU5/\$3;2YE\RU>7'V0.F M "Q'P@/E?@FGC)%4(.J|DX-
1&\0'R#HWJC\3|3/6WEA(U\$+;~.0AW5/ZST)Q3 MBW*PU(@[RN0'GFD7;YF8H6!~\,YA0CJP|K
M\$=EJHU;0A0.\W|YZ#,/U'A1B22IEV)4#AU#+R-T-)9V^8:!.T/R|P<:NDMF+ MS, 01"C%"R=%<72Z:4|
P9EKS;305L*G;%YL=HL@%93%7N^06T^2,1&GPL/; MD^-[I4M<-L: WX^U.FQTY_@6CMQUQ1A.S*?
8/#X5>WWSPR)J)""797TL6 A MB*5V)>%Q/3&M8YTZV [THX|7?1SF\E(@U1L.0^N-"\" ^5MQIX%N_K)I6/9.
MOTDU/D14)^V.U9,0,@|=3._@I@JGCHF0VIP|MDP+C.*\ 'G"X<#('S|R@%M M7*;XV*-0(,IWR?!3.I@#CD(8?
S &:OVS M-\$C:&K+7P<7SXT.,I7Y#TN^;VH'^64^|JM_!J@\$"C67'58P,RP(R86L,58DN\$AG,Q
M'L9E,41\&0HL G/(8EHP+TD("NOU(@~\$W/EYPY> M=8' J>7?"V:YK\E33) M10? 0?P|&?
FZ=F):8. LZ'|V#1QEMH <\BT-CY429GV9#XJ)2LU<'"/+KRT=ZP/N-GC\$&CJG)59F-*?/?
M91|\%~!YK_0B6IY6T>5"[G T)#0%6/Q,33],#DRF2VP*D@ M02-/E&F@:>U+=D|^G_TS.8L5W350-2UK4-

75MDAT7 M 10#&YCT:S\ 6J/7F+;;;A'+F@@@2U>^"P2PP"[?A7SV^T%G?*FR .JC./I
M&Y;,>P]#WGU8\GVZC6+JQ2,Q/;?)@#:UX#Z7:N00YU[6GC,5?C3+Y!Y"%WWR
MLG3'I@+Y/:NYI03Q">I4I=)RLIY@*-!0QYR[0 M]YCCSR4"S>&*E 7"7T;=2& M.T=\W9" 5>N!YYO.
[4\$DX;GX@S-:UA]E.1G>2IU[Z"L1"8RNGC[J-22NA^ M40_Y#C'TB&E?<N:ORDAGY^!\;^\\$3QB5"R1)?
BF&8NRA MWIU0@.8+KX4CL>(M0Y=/%7!R4=4[M\$Z>3@'PR+*!PW(0:NTCQFL[L8)NZEOT M@&#
[,XTGM:R11JN>=IZG "U9E9UUB[100 9HX#(<=9@&]YYXTF>[:6DF.5B MY-:FM82MO^T;V*&#AU>?
SKZ(%;*0-R:--(%99-<5!LS L-\$ VQQ;SLZZ%+OXS)=.0[SSU]1 %'M6BGT&VM]/1" MBP@07*1.+0-
+@YF@SLA1,1E:*HOU\$<>1#H>Z% 1952+07H%%&+W^F-E7[Z0
MW8W^=RQY:6!K8(0.>:3G#9\$> 'A_H0(UXZ!|0-F=EWIJG M/ENBUUL.?XRM&[KKU*GWZM=GS^Y)0
)!#**.7HB2F6-IB2ETYE>/HHJ4N5J2 M&S7A./0A0!*T)?&=V#23MF330 M; \BKM-!@M]S:8A30&K'+/6EY@F/K-
L\$'B M_V"A'R%95[6P5,?^D?L+@N0\LE5K 4#1.N;4'@-[\$(F/(41/%NR9J[^%(MSJUH60\$6KU!*NT1.*-
^P3Q\$7'?L*8[IM#X M>S)JMT=TMLE^G=Z>%RV\IEW5:=JW!W2?ZXQU#&SIXUXA V8(A\G8HR@2Y\RI
M,);YJQM:QZ]#3H_G=(@'20 MWHETZ;W7A*XB"360D\$S\OK/O&>N.?^YR[SW=^/+|6UL@:ZWW7>N=<[S/G
MA&NUMYIJZ'6P4 \9)=SS[7*?@&+N=H:01PYLBG1KZ:&#Q509 MC%);98'0J'4S',^*L8;/BE-
3.-8%RG\A*7PTI^U:/>"/[0'4[!%09G&', M/'10VR\$44G8^ER6(> Q?+D?("#N+S7[1%1S5J[(B(&I
M=;^5?X+2C\$7?Z92&1L@^*U H+ Y/(Q+\$F5@MG8J[2T^?;,?W;SP"1 M!4*J1RR:LF-2PJ3XL15*
<\$"Q(XM#1(0'=?YI-H;*.#@GT]/VI1XV< M\ "6^GFLH4+|+6P(Z#(2+^)H50V);'%*2,,UD-89P1K50\XICV
ORM32T5R MA7:N?|6M)+5-?%KRH/ 1=-[X !4QJDKQ@.EI3 Y&\$2,\;|)DU9E\8.S0[|3? MF+1&XJD?8.>K^I>
[<,UOKR8=R|6Z&\$5A' NORA BL=T^F#IX/YPN1]'E[- M?DDQYB|T=X-8BQFSS/B-*S\$);#E)=&4T<[MU-
-0DBDV1J 8=\@Z]\CUJ%JJ -*W#+C0^:6+ \ (S5+=Q|GU5@F#P%:F//C+65 M4;EZHIQ|
CFRCT*DOX1TWA<7WN@1!JL:Z8!|G|], [PUMX;#|X3SNMA#,+S?9 M%V;'S7IR26+\ '?
[D]/O!HDK''\LG#D.!RL@M5*\^VNCC M,8AFY[.J50M;0[K+@'XZL ?='TB09P\R;''=P_ZYH0G.E#4.#I6|
[2(3T&-WN/)Z-1T(X4-/LHE>C\CNG-[X640!%HS%T+=C?/Y>= M\$HV[V1+G?&*D="80F!>*B4FPUK_U|8?R
M\$!/1UA>BXR1/ELSC7|7?3A*M2%>^S\$E'?VGE0L\$&TQ.U&E;43)6>&,I/30=S MS.(J,:IHLQ>7T)
G%LYM[.%'5JC,'@T1=Z&0"F <7A;K?Z0G?D%X(6.,?1&R-V0\$2@|H|D%R2_36.BI4P220,AJ
M4;EYZ(@,.,>>ULN0Q>#&3NVM5!6I?XN[?&-%8JY*|V93|"3?MAD:7R[,Y,F:ST6BYIDB\^G\ ^?
L_N:YEQ%MK]!T_UD1JQ|379KY^-4\X|DB#GD'%|0\$0 5EEI%
M(>/L=RI3+MD)*E9!AT<M.M.>0#%'H>*.@WFEJ6^+U9-,7MY<@284?1>N%89Q MZG\$EJ'&7270)^J9%&:W8*?
H6\$ANEX/7N-V&2%B;-7YP9B 0VNO!0+P4\F>3 ME>E2\$#E) &R;[:4US+1HK9'FU>#|VR;SH/'5
K\$"#0BYRY'Q5F?PX\CEFC5@ M&F(2L2|& /@5\%YP[|7I=9FZ?V+ '(C7'?TLN2>H)0 :C-VJ|L9:T\$^YA)2Z> M
R)W QZ.SUR>1NL;C01Z=, #H7,@HV\^*F2RASM=E@V6':B=G<-MW!G[/S9W M>X9) :+0!L?+E8=^0?
3\$G^'(:@*4S)00UVBA!<=>## \$9",@2JBQP#Z_L='4[MYKU|+=VSUA'%#0] ER0^;P.A2-XRV87|FF85-
VQI\PD9--|EAP"H%BQ> M#&BY:)FY079IKG-K9*^I24YLE?IC*1(6X/)X'W8TC?"E/B^?A[E]|L6\VCK#
MUS*6(5X:'FGC0/S9_\$6XU^B0XA&:*2':Y;5(B+DA&FP8>UR5#B@ ;3K4=B M/#U-
U:;3N!Z27|)7(DRR'>C6,>22:VPZV'+P<^!|H[6|M^6>E%D)*'?\$D\$5 MK;<)&9KW9-
;J&AFG.T]\FLV9@J+S() 7098KX|7W|.;LQ\8\$P,K3A?C+ M(P0#+*R\$LZZYK+J&4
!^N%=#M B/BXM&)5C\^ILGX7B< U\@L00 MOTV-Y;8MJY)8|M=L4P>9FYXQ:[5@-%89/VIY'R.)5E\=B?
#^%"Q_I(DNK|W, M@' =NX\K,\$)=&*Q|\$@"NFL@C\$FSML?Q:H#OGV_N3KP+U ()F?D.JE)'O USSF
MR1\$1L3@IA/#-;C@2I/S|9-S8IL\$)PA.,K)UVYU4+|R;0#4D+*.W|/9I+(+ M#JH-6'W;AP@W<-
UX|K0|=X&.KG&&TW=Q<', MJ#\)'@7+3LN/IV'5'NMML?,J-D=(FT&AJGN444MMKP@ W|:(I0--'9Y47V(.
MI=@/.JK./CDC=-Y&T=X\$1/=JV6Q)/@C%:HZ9Q*0[B;*H9&U!D MUNM-?C Q(;LB1^8:%!AF2XL|BZ:L3.8W
0;N>JKW)AK3@!;*QW%=?=94\ \$:F M4|@G=4=%1)1&973'7MY\$ZDTIFQ G.G ,RI50*-
!Y2CD+6V)0Y77ZS[31\3XD MVH3.3ZQ!8N3)"8 . D) W Z>S8XSI,099/YV|MVNM% MOQ96DT\$,!(##"(0%4I
!JGBKDS\$H\9%WHN|T\$|^/6 6?T53,6:HTU6P-YVW; M6"V\$[AQ/X?L&1NY4S)G>-!\$F) M"NKQY<*&PF7|40QH-
7P>X| =T?3?D\$ \PUM@:K|+-,X\|H2|ZYR&";;JJ0- MCBA? G?GY' / :D@P6H)]#:'E:DA,B:A(PE M+XNU-
J&HBES\X \$X6/5\Y^GCY|D|1TY:UE#FY|,1TBH/(CZGNJ GS,0[2\$@B3N1=V- M)R;LB#&-R|ZMA-
_G EAFFX(=^H+E MH)%|Y18%XSD.#@&VU75?3.G5)V.,X5A3K| \ D|L?Z8|H\$(J^|A/)|M<1C00 MY"U3*S((
#08/&.7%7M&-W A/23C=9/57'>S<4DL0D|B%3M7&2\H'3@S1@!T M3C?0@!|B2|0\$.
<)>CWJ|K5!_FY9=1J_RK)36>,A2"'+? 6>3T\$SJO2KE'E'X|34EM^0Z4&Z5M;C5]F_P.401>|;J/8M6# M?
HA4:|IPJ;H01^4KTNFSTKA|J%GTY A6RQV|&YAT7SLJ;57N3M=-D!A J@V/
MX)LUK|AK#HU^CM0.TV*_C[766F)\B40*&K<#E" (|F:R5G ^J/#LF5?,X60[MN<+K9K]_+W=H-
%.03@TZ0VMJHQ|*2&L,EA\$ 6J*<()Q!H'Y5BSTD (ML]-PT
M\$37:0'U";T'*044WF\3T'*9|F2 [C|.,%/\DXH8>%&XS(@!@:0:7 ,E-F-8U M0=U%!>ZR-[1:]
[N+ " TMG]+DITXQ5F6AM#G|HXPU#/'8'U .6EI&700>)/Y" M>8_R@1FP.B(U9'*GR\$60 M)"3+7H-
2A4T:|)J%Z;?#9_GJ<*&Y\$W_FA,NUV!W;YYA"GS+HTG5<9@OL(J MQ&+1W&(T^*U0KQ,YJ.[E-|!
(0;G.@8=6'D,^Z-C:=,\$,8YN1M=B#4J9">^>1=2 MUM#X5RIM8&TR[|\$_5B2ZB=60?D< 3+1XJ5_J-
@4+GWJ,E1E.FRT,E)SG F5= M*E_9_A%IN\$(MWI?9"A&[6Y?@,*3_%_I3#NI.W(C\),S1@|YR#JE47_D%.WU;
M!L7YM|YMBNB*IW?^\$IYB\3_JI\$NVD:15 N#C<6-,@N/G0AZR18\L" |W4ZS, MLXD:PH)"89I|>1EV_HH'??
5:I:JP7F8.HS,-Y ? 2-(6;H,\$?Q4 XUET@ MUS PD\D??J,5>6V?|W!^R?T&/AFLNEUP6(;D605&>Z1PDY0=V?
%\PTH '*ZT MT@L|&Q65A@QK0-6*JK0ZW,VT\=:#WVW %U150? ,^Z?=(|)@D
>)F\U0)E^26H47S6JN_Y3&5^+V\$WSM*V\M|)A#3FI\$?:HA\<#NW/H4GZ|EUWB
M>WQ'UB&RY\EQMW1+>E*!P;*NZQD0?<\$<'R#EMXCJ1N\$ZW|; .GN;W:NF;YR[- MOF/-,W? T7^F=^T?26-?W?
[9B_ ;?K@^7"V!U0\;+*U(NH H7:N3%6K(TB0D MJPR(TJ@X6;D-6YJ 94W|^T<"5HYHP4#
<)'#F\$.JA.ZX|\SUX|9|625P \-74 M)B9&WX3"J6.MJD.:BU*UB_EK1I:FYOF!RN|Z:L_ROS4:?
@L|DY44T,1S7A: M=)E_G,5AB&Z+0H5,J& @UX(B.= 4U)?%R7U?G80\$IS?L7|ZV>U5IS9@U_.ZW M+P'@KDB.?
1\$R< ("MIL9B*\$OB_-H#LY%6LCVB\2.#0T,\;+K8*5Q(6,@QX.(M1YAZA;@&?
49J^R!;T\$IM4ZQ!|M4H^BH^W.X?B"FOQ|H6HV'5\;U(R)IDMW!, M&|NTH/B>AF2|],JI+Y3KJV:5.A#JP_-|:-

Z'='6GL82AV:@N(4H,MAXR\$/' X M3\6DK}(N0C%'U<#?U/U?3ED5/>;Y3_,%KG%T2}V{(P!<8,RX=\\W.3TB7G?
M M45\K8&["GX",. &N(+8H1_AT3WSE0/J[, #2M7X)0XLV-2HL\VII7H"IL6"?Z3 MV(6UG>\HM, OKS" 21"?K*
[f3ZR:SR5+'+;-'N! A?TA<\P#)>VT"0(;MVX] M26AS7)#1U'D#<; P0P!_Q3."U5
\'5K7)+NU(@+96Z4'BBPMN>-]V- JAL80 MJV\G1B8 **N3;1;M2U+67AY8U?K(_A@3BU5PLF+!/W RS"90'CN&
[;=R=,P' M;[W6L13T?/5\K#117F7\p\W-\QG[&(>,7F@DE_BLO,')
M>6#0N18N&DPX"7Y*W:Y?/(5ASZ0JQRW11\8 _/PU0/;63@=0 " +0\#K+?%, \$
M\$1./ (Y0H/42TC9T6>NG\$N\$=0; 'Z-?WB9U09RA-7X=:."S7*4Y;Z31U2U5&;B M3NMUBJM[@']^YS,SF[PAJ].
<[J\H->I>0:E5;X; ,9#\0/A)!/ [%U0A";[T& M?08F!><;3\9SKL MIX)R66G/EJN[!=WU^IVYF@G%T'5WH7?
N\]Q?&[B-1/A*^\$%1^A51\$QKV;-V# M["QQQI:;DQD!\D, N)^USV^PS?!/6?2J7=B>QG7@1R!W*GM6R'=33PD
A>1: MPW@!5Z6J3=F(4W8T Q1N-?NI(QV?XWV; ;IEE7VRY-+S#<4[#M3\$8UTW'8%." MX\A^)%7Q9
SB:A4/9/.H%51>K>] 2A]U^'H%I[FW*/#2C@AMVLNT8#[?81^W MU<"2LF:&/UVL2(:AMGVYGD\$/-DC
_BI(&F@K&_K)#3M+36_A9JF)^P> MA-+I2+23MC?-D;B\^?0)*M3?.74162_F X]/-(X\$ _ODI?--!-0?4][+F,?
0N MV* 5HX56Z"A;78F<;G0UHD:597J_IXR_N\$APXSV-DM'RCM#=\$NJE\&V(4\4\ MQ_1CA1 D^B4/0*UG^V)R\$;
(:!:/JK!DJ;F< C[CN?3M0*5(6RI&HEN\$+H]Z\$ MUFU"70@_2EZLJ\$5W0>_E]V4.XZU&FGM?
^N).>U];L487)5N43)PELF^V\JS! MIN\$(#R:<):JB&Q:Q5%D\AO.#8X7WM _/2CRD.PY7!GU?
8'!*JANZ=5:26FW MF;#NR1MCJX0.S[Z)0"H0^1#1M.U8L7=6!'U[6GW)VH7?B,%3SQN2<[3MK\-- M3]SFK"
[N;1Q=-H@,-2\$[>\$7;>N9X2IJS@JGH6K[7B)5(^+;S MY[=[W=>CU+[*N21\$1F1F-@]G?H@'EI8+4]D&PUFK1-
_&P.'(SDZG#)4'@%+?#6 MGIB_R?R"L=G#_].IWM-/_.L#7VU^_VJ*R^PUY@V>;-M+TI3C30:XY;6 M=
W&F)S0UC[V"VW;#(U+H*BVX)19[^ <7\ -7CG\J=;4I\47!KXF;M@ZQF?< M%< ;9' ,Z[WYO/Y\49RI&-
KYNK=+1RY0H,#\$@"W?J2A30M/@Q;6?-YZ>U_*
MN?])>0#HFP59DULOM]ZZ8=L!KT@I5PU!55H]L.AZ0Q@J<^Y>' ^/@4&&^>00
M;H!U;5D.EJTRT4G7;]R06P[VU\$9B/-%42_SV7,(; ;>' ^.6P4:R#1[\$P_G0+R MG20-;EGN7E-
_V\$8(W(K6Z4P!F7Y=Y)R%RXN03S'7 EPHY>=,+G#)0RP^6EI@J;^GEZ!<<7\X*,GNW+Q8^LS/%TL3-B[J#-
>BU9T.6Y M^;N]\IJVTK;.)QOV, #P:@W[^.39X; ^ (H0;QC:8,"[\JQ/.OVQ'5V06^R&PR%0UDQ#CU
9W;VF1JD0Q^9/7ZH.1HB+%.W9?UD>&)F=;,% M0M-MY8:*ZY'#4]&72C_EE].+;%J5* M;!SA27L;RI-)!U^,#-
_+GU5";C0!L8/SH3Z?SJ-;_K"G^/DL0'3W;WVI->R M6A-VMA3@\$=D2C #2NL?
K3)9SUUN'U]H=YGH4QU\$&"S"&B"3A03X!4*X8Q" # M\$*,.'=T)>8(9],_M'I][NK_00GF8Z[K.[*4 @W(']P5-
\$2H,D,0Q]6V#H+31=8H3_906RK)^0]">(NPKZT406H MZE6))J\X4.= - VDD]5N!?'=&9%\X],/[/ D =M0\;SP!
!S U^ZQ S\$\\)L3 M'%\?3Q>Y>27TQWH*+5XGT<@(.860[9;*L_B;:52J.X)]@^4Y_T_-YMV&;,5
MW=S?";.#6:%D93_ (^4>\$!,ABR8#P0F =^!F]C*\$!YU'E=CN17=S\';HT-"UR&^KHK"^!?'S+G0Y8?
JH8A"9+LPTRE-@#7_P7 3? MI003_E#=#/;!GKSK,3!S4/;Q4380;SL/H>H<*I= 04W\C#@1R.] 0P0BQTO M
7!'SG1WHSDX^3[Cu8)0.5HL\$PH*DXMX:91F)C0(YR83Z!AX[. \D(_6\R(M:#80A-
N!I#NB9BJGRMK95P, &;/LT/RP]C?K 'J2!:=>3/#8*H8FW=PEA^ M1[.P^W3(L3BA
_JGKJI^)^9*]=G^PVJL"I@EK.'J[^K)&;UQ\ _0][)4DY/1_V4 MUU=H7"*&/9?-RDQ%D;-];J]U#3?S0_ ;5'*C?
^Y@S _MR]/%_NOA/JQ*M\#*V6C:QCGD"8/XD*\$%6)S@;6&/9]<.9I-B4\V7DIS2-Z.-3(*M0V"U9*Y31ZI_Z'/\)
MY> [_^DTSFZWJ>F^I,&%E9:;WQ\2H*NL#NS",J06T^)\$0\SOA^;MT_I#?XLLYE(K*)Q*Z87IP-; ,^1?
5MC[C::]&Z6L]5H_MFC@H\$SOP%?KNR%/\$&L7;30+;^?#09%>TOVMA-6<3).X:A@M7= _\$ \$ Q"<' MGG7#R,
ZTVVW9S\$K>DTP-U;E9/5&B=(J?E(>Y3J]3Q_?V)(S\S-K0=^%/_9
M!\$*\$\9W(' / \JX7CIB/@[NDU]JN(@&E(+SEC/^UVB&D)Z#R0[1*ND_TH^@!>I
M]5JN;K'W\$!A*SU_JV/E4P@G0NG' [C/3-8VZ@ +=
8'RZ"IE<4]5P;878!T>\$L"JHIA=; ,0:QKG_HI[2:J"NV6("A.;+DLE=Q:*109GK\;B?
S!340YKIE3W_VJFM.K1;*6K9V)0?FU8_M@>)N7.YX50J;5^.,[<8(AN>@G0!@Q-
_%C0&7;EF)CT!=30K4[%;J3B]WR]UU<_M0&^(0^PL=5MNRW5V+BYQP!&,]?+U#;NL@V^%;D/_M]F\R>B<0G@0A_-?
K%.VI;UKJBQ;S8!V>&+JK+=ZH@)T4^0["AU=H'6LV\!1^ M*G3"JF#[^',OKERO0^5--!J\$N]34!M(LS]VY+=/
_*!N(B&V2V)P_MJRXWR7TC07DKTY7Y\$D40Q4V+\$4Y=#@_ZBDY4I93([55!(3U" _CK&":N'[=- M;:-
!27EX%10'Z4:QCZ_-/)6(V2*2 M&F)5_G;R@]!&K+#"8&4TI%?=(^:*C_FYYDTCWW*GP%/3>=<[M,>_
M4UB//T0H;+[@\7U7?Y37@HX_M5^A^@EV_1\$M&0=<A)0;&HBJ0_3K7(!;QRD-4-4.LDUH_92M!! A\C0UVF
M_P%3" ^"7+\'FH/N"N[]*',-A,I?02.\$MB7;HSC\, _T.47T8=\$S@>57GW^E
M5"9,&:C]5)8YVH/6D>Q70+!/G\%7;00KF=>A9N*,>9:LB\3\$=19?6-C-'_6\$ M0W!,
].\P..AQ(,DST;160/>)I;?[@\$S4&";Z*6%4"U_VN5["]0?@3> MM; >+H&"/\+!P0"EZ_#NUM)E+B>!9?
BM64MXDCM7U+.M_V9^((@-]1>@&I@ (M)1PESXP3'J_180*OP_8LWX\ _GZ4G+<;@S:16UGN&P3TOAHE4!A>A#7D/
B.2 MVSX>YA_VK*I]4%:(UBT;JA*B\00JTND\$ _?Z3+6;-^@J7;0F0;:G@>=?L9\$ MH*'PD5B.&3!_?NW9>V0I
1!\$UE&ORIDG0Y7&Z#I&S"235 _XEZC^M:*(7FYD_M3<5&T^03B*7TY-!;5T\;Q^%:>17UA',@,T8!3R;X?
<":PS^W,^5T1N0!D7S\ _M_W-?%J2+;,&0%J\?7Q(Q)'[3C.H57;/&^#6#9N4?4DX\6%X@_!+Y%UH,4'Z_
M\.)%Q8N'?,&R*5)]I=6;TV43[/R?3]4(1>9 _(![Z/=Q23V03B8<&P&0HT_M*5<;Z5&Q6XW^@LBGD@L2-
_W_L\$VSUNRFGM+=MQS)K6V/VBS?, 'H',AC/UKCFR^)]RRL]K?0U&M&71"F0@I,KAJ6^0T?_32%(-D\I]>[#\$LZ
MMXE^)^KL_KV<5\$F\]I&TMZ8"0X*A7&UWMQ\ ""^;+ \^WK9LL*]L]YW[!Y=34C_M3002&U^&MK+J:4V7J,\$WM9-
2?:NP._M+^IC(-;PJ,"LLNQT8904<27VP3(QK\ _K1#"T3;NT^J\$G,Y=0_"/:1'#;6@+ M?
CQ]IN,@3#KE8PT;KVV3E-!&EH^)^T\^83<_P6BXA"U_MJ0=>G/>8[QT'H;1_3.9[[]1HHXAR=K,,-SX\$?
RIGTL#\$. _W-@:R?.'0X\9Z_M[.1K3ZFI^#>U9J&KPV6HZ@]I^I*RKNE_6"1G&+ZK"UJ]T-00PZEPI,Q[9+](
M*BL00(;M#I8HIM?PG8@7>"P_PQ^K8GV0&*>P_3="YOG_5\$I_[]OJYCB#?'A. MNF(' +
[SYW8D*KK,2!&*9S\$L14K8"<\T%RYMU6_M*FE,\$Y-]X)'_BOW(#7\TV*X5P^+Z%T9!! MH?+@^4LM^M4=]
<38+6'.8/XK*F+)BAH0EPQ,'_)N[JN08W?]Z&&QX*^%8>^#M2.J(KWPT-0U\$S3+2X(*V85@?+'+I\>943#T?
@X4[ZX88,NP]')D^(.^JY?>_M-G[?5_8ZQI;RB^K!V_AJ77FSZ=V:R>WHVWB+/7B,#,>. IYC;RC-9A>MGA1
MU'M1*_ "ZIU5QA73*_]"1'1DF>X9UEB1;U=2RB]/. "4N/F-.5L@VF?W#Z68)
MF9<_.68?:^;XJ.\$XE>%IE8'M1!\$ _U\Z-\$K2D>WKJZ[\VKCC4+P8EB=XES]V _M3Z6XY_Y.(P#(C'J_QR1?)"(K?
QV-"K4^M#V*/?L1_P!VEHRX!SGFNYCPJ,Q? MV'>9(@!;/2LTC0D_*[%N_D_-/)7-4/8RG=>)0>?@ \7*=A[]#AS].6

!W4&*Y"' M3{GB%<5-3IM6BH=;[P]Z39T7>G*>Q@)T:BASW^<4/=GW\IL,ZUU,LPL5E>' M.H5W\I(KT=T[CKPP53/MVF6]@0?_5.43\$WWKIJ0YE]/C_QV;)G37>J^ S&86 MJN+704IT+;;:"7W7-M]?RL--M- \$|X+9./Q1W==ZHN?D2W*_I^W_9K^AM(#BE0TK9I6*)A'J|I!;WI\)!# MH\$'7| 4TYK%WAF[*RX3\Y/%^B50L+C[M_GXR XW1Y:Y10Z>G\$V[BD%E8 MS{0\$P\ _9.=/.@G8/-S>FN">V9GL^HH 8NTG@#_&DASDP.^&(C7<\C"")T.Y GP&22=?YMW&;5UP [MKC PL9#Z!;(0)=3-E3S|X(5?_8K5&HM)3.2;; M#Y3_/,WC@7!LXZ)9Y0-NE#N3*N;T\X&RWJ23+0:C:,U>.5Z^@ M\;<4D\ _R/#4+-5NZWR_7TC|!' /Q- BWVIC\ \$FR.L=;A9J=PE|\$F0P\COXA_// MS^N)F,40G9YG^-=L782^0/W?<8,3D58%/TS?I5&.4".8S(-T: [-X)\|D'L M&GXL^1EM\$32(XF:6C7'<|!'M>E-2I#2?|V5>J86JE|+63HU86N1]-UAJKE5P8LB+S;97JB&=00- S9:6E@F"N @MS|;RT_P@_H'/%"8XBI&CG3\$9/Q'TOK*SMG_+4M:D2G\$I\3^TYY)KTU;@S M>Y8\$Z?3? _5LFRM>:0Z85_XFZ3U<3D0^P<3'%9\&SN(-.3";=0)N9?;|G).NO M/[PCZ!Q@0C?|M%+X#J|MZ|QC&,N? 0I_K)9#+|]|'2Y@TU-1H0M5UVLN\$!4 MNNV:+)P_\HKPA?M7ZTR_1>>U,^DZG|.;30V- #DNEH#FIB24W@2P;E)^'.TI M*"R71!BU ZFN8%8:BHR-FPD_YU.RH!@ E@!"0HP54?7\9?LB)U%)73D" (SZ!D.A?TTR3/-HP|6GG#.,BP MMV#T0&(5AJ24[*V(7!9'"9S2YZ|>|!7^HGZ2@9DSVK@^|G2@U5D8%* \$E\CH"APLQ*LF+JL'&0,Q+V-V\V=8?|. \$CZ3T M: ?L9"3B0D\$^_GM^5L^YN'!#L7- #66/&C9/0/Y#4P3F\$MY8/E!6: ^'2'#G#ZC M6U?I5EDA,-;\$ (?-322^V:|W%75HP2_1^N)0%JDI M>^&_0_R0|KFG>.3HJ15^8V0R6^FK\7,Y3E8\$=43V3^%2C1_.|Y.5E|\R,! M0 2\AS.M+8@HLSB<^|B2TV0%J\$!18>DL7P!^LOT6,WEG,*%WH" I>N_-B9F3^ M#,E8N*0RYG@|F=,|2\U^? 63'C&U4A\$/83K;JE^A>>+|+3:4*6J? M:_.\+**=3XRC_'|'.109!IS&3PIR.WL&R\ P4'@&R_0W\>X JV&MK7*' \$D:"5 MF0F&_%RHDN|<^AWT,9Q,R?P&4,0:/Z=GF9&#^VYCK|:8SY08K;YV\A3Y15U(MM\$D |)8TSZ|/07J%780%XT\$+Z)M._/\$BY1'<&8Z:M@U-\$HD+|NJ3&SJM\$A= M(&|;?%8K"0%ML*P=|]?=;U8HZZ6, (-C;V;C!64E@\$I0(R0|D-[H| VE,&BQ1L M2X?\$WX|KZ5D>8_S>R?(- ^(|>Z\GS3/C;3)3,08R>"155P,&'BUSM)B.!|N)KA8!JSZ M%|4/"%167C.0?X9LK0!&.,! =TJUWF.H@H> [""\$?'@7|YA8RIQWL) \$V&DTF\ MM#|H|C,4I04Y^R, (@@ |8/+) ^9&8VVUZ)E|,70U?"L48@|CWKZ8B<<)YSK_ M#&Z12\XI,VL7?7T!_R+2\BZFA.C<:+1)N-<*@F7.1F5M<[#_@<|FG*'NF< M\=R55*=|IRYPF|\$/^QOV)KV;M=%^G.*;(2:SGK4(2P;8@_!\+PF&XP_L>%' MTCM3B21NYWU.!D|EL>ZQ%A7M6 MBP+V"M\4|LRRM%FH12+90JMJ8A)\$5*|MD--Y'TT|/->&\KUI04C@T!\V#* M7+R%:H,@1%;MLG W6459WS|Q9U_SHN3!K?M50"+)R\SV_-&^#,7 M,;<\$P(5R@.42RJ,S\$!(+LH?<)<)3._|DP|N- !,FNZU#,A2AYI7QEK?I/DS1/. MP/&81BVG_ M""/LAXK'D|:ON:S_2)8>;0;Q+3WC505 M|B0P2PLTQAJ+"82EV2>"V9T|PD_1V)KEP%M%Q/(U\9%7HDIIN-SHRV;?06/L_8Z.60=R-64C9?0I+D-1H!W\ (N0> MB^*D1S3&NH2\7^=K\XG+R)D%"JXEVI3RIG8B+G MS\-.F!#U\G=P=BB/'@* :J0,PV|DX:=;U^!BU*0>|,I*RN!N.:?B%A7UF0GA MYEE<9&'6)9V."MA@Y\"";(%C&*L3"YC%;1W5SE|TH|JLK- #U^A&I MQ>0W+G6)C?GW<,NX<41\E0=KZ%Z19|. #9RE08(-1R:'K\X7|S]"5'304S.# MS9+WYSK&+!3=BJ5? GD5PV|+"8A>G*,M+J-G(|)B M_0L@M#XE0RC|Y|)%HMF3(?BC;:S0@80|B M;Q6;+9#1DU|0"8P2733#?._@1V\$%":GD\67#HYH/(|>%)U4'R|^-!' ^5W7_X MW#S"D/Q.6*>A0S'WG_V- 980X|RU0USZ!KF%L#6=J)10+06_!*[KHXQ|Z8(|5>Z+6)0+G7)1N_3TN.K%UKF\|FX\$S M'E7.IC(E);9R^1NEDLGU-#5B9H0W0!,EF.SM96\KWV"G!, ^@^4|I4\$:Q0D(> MWC(9%:16&HF5|2PC|I0B|(.5HAHW0K0+MZ.ER>;! ?4\$1%=\$7^|X45V+|(@? M8#T,R2HD1F/3/^ (EK95@: ? +H|B,995GG\|4D&6->J6N=-4GZU0#XL!9#KA0 MF,|I1L^4S03#YC47B&4\$TG1S1NQ52&U"/S?S3L_3- 4PTD@13?4%XES)+07 M^3CON\+D#8,D3P+@>FXG!*5YP*#"MMH0397TP^0\Y%5R|W!3RN#Q|_#M&I|8 M?,3J|I|NDEHM).##3.NQ?#3: ZF%*H%;1#NA=N02/YJ9|=R; \$M#M.W|9FVH%10.2CH=B|]'-.? M7_ZI [Z%65RUR*2ZD024]_9-(HFAU.JUIPR%08/KC^X?U>|^K7\$2_'Z\$S.=A M)0_RSY3_Z\7|!\|J1+M!;0Z!-1;|E+K4GFJE:A0@7V^PICC\,3=U+3;;-X=@2 M=+9?I|ZJ=5D#XL'+6="|F? *DFOPVUQ098_VS^&0S=S=0CSG'*J76P7NVS:S.#D M21|IXN0Z@=\2U? /Q.=/B>+X=QZBE0S8G9'/Y5T0^J,uke"+SFY="U5+B2| MK.ZV""XK'PL\YAS_=\$ *QT'D+6IC9- 1Y"LY>9U0Q(=T^W@LFS|KA^^*WL) MM7P5\$3"'E30.E%0.HL|RNR^7N5+0Y&%,?\$X6_K%V|FN>B3T^D/OJ|@=> <3E_M|U=2?)|Z2/&GNSN>?5Z7=I>E+7524I@(<=|/ISI'LG=TT#Q1.+="<4;)^01. MU1B3|CNBL:U78!GO,WX%EI7_#2P7_@7+DH-T,0VWY&TZ+ZM^M&5-'&<(D?|,S9]?|,LY9&X\$MYL MC;|H'EA|0|:D8(J3Z.L7D<[LKK|HN:=566/T>.D!ESHK:|_+RT\WU-Z%/"^G M"ER=N/"NR*B(Z4+8!TXTGJ2:P|@_QA;J_\$6V2HSS\$K'.*6M M0DOM8KV- 2IH)/"J!Q;RI?.,X/SGYB:C_VL|Q6\$S(4?A|DV\$&6K+CC\$&PS,1, MHV1;3&P!^IBLKR; *SD6/&E\$9K<26W+01I51:>I491() "4?6 M?XU T*"T,JG+95TIK4P8?'D%(((\$D\$))-0_'I|.Y\9= BXB.E3D/+.0|.,3" MK|WM+KY|:J/&A2%S9#_0'S.WC-QK.B\$2\EEYDS/?^U|X,K6-S?S*Z(M5C@UQ1BA(<8L|9|D.6R+G#|RJ\^:(+E3_@ST9#JVQ>-.\H/?= W\!UTP.9& MX!7M7%_|>3J2_U^< 7IF,0(:&NVXC#M/H|3|-NXP<4FZ_>ZQS*T-NK8WGN*X ME\$EQ@?BQ|ZM,A#9;7? F(E_3W8B/IN=|S83&H'6TQEI^1:Y0|4/6QC50I% ^VC MN\<34 RC.|_QXX? BPH.=FTH_Y;@>7VVEYASE1S(\));Z|'"Y_Z+E0*|7TC MMA?>2^R(H:.3I=NWYY\|CZ>;DBW*671E|/PE41LPB M=#XR4Y|].)8+\SD>CU|2!W9.Q|92^CM0%CK. S^T,2P[W?9WJH50;E^()SMT MUJ\$R^MP%\$.^*S00T55- +G&|SW*U|*E4A=ADK?V<1QX61XFV8_/VDCJ15!;NU M_1V2AJ,HNSP#?+U4'U(=0HC,^<27" \7208]? P7Q#M'/,|I8ZT6ES\$9=L0N1 M;K,)T.&BT|'6_I^E?KJZX|HDW3"4CAP|?D\%I53@QN""|YU0AR/E5^EVB2L)7 MP|_8_/M?MZ8,(-\$M;T|_8HI6K:)I,+Q@1AM#,S:IW&019\^KN;=P)>;0B=0E MOP" _B7"E|?> M^YBA4HR8*DH^AP @)0#FE".?\$M4E\G^SX,1Z;Q&=&^ :V^DP M2&;G=:WBBRP_NOG4_Z69-|/DT- GJ*|5=ZV(Q\Z;W+7/4UUQ1&N045T@Z M*/\$SH#?L*8?K#3ZCZ(0>U= [|]+3CP_>ARUC4A|P/WS+1:0:V!@&E1!;:14N?B MC^*TWVPY+A/4,@.6!E'&IDF;7WE(%=6S#6%=@? C1P)@)4S17VFB5;94"|"4"6 M8PGYS0%?G7->)2I-KXWJA)XG4M^9:5+6|7V5>CPQME|]5M?|H6;H7F0:6KAK M'AA6FU*+LLS_KZ7MAG>|]|^@"KZ@ERF*BI4|V,-"5&N0|/EY^,LARYH-3#V M&,F'UV_T;IHLI^W?Y? 45IYK^*9KL50;3+K,*|XM6/V*S*M;2B9U>8,ZP>.|+MK-)1|U.>&6-\$,&&4_N& MSOP3Q:=M0UCD? BFG+KB6VU0TW77A (Y"X17BE|EK"E@YG#;K\$@C.,\$6BN6*; M\$CW_M='.X2&-RY;VHL|LR-%>_)F?#6N(|(<#7@Q

MZ%(Y"=JM(C^ LW8R *T7PUAT^!A333VTC_K\=270"I@S]H+(' ?EK+%MQ66'I M*5983(@6+K %96F9^WA(-)
[8M[4:@H?(*')?GX'_8_WWLA4?1/F0'-62WAM# MX+>[JJD+S87Q "E/NOM% MV,B02+@3%Z?I2@"
(^T;\R=WT)Y[Z ULK2J.8SV[DMDLJ.SRD+,58,^G5 .3X M:U ' ^UB\$Q; ,6Y'.S8'8.' ?M\$":L@P!8FSH.A^:;
[\$B,+!4:S=3! M]\ 'K*='[(7,\NTMV/K?']F@SCU:J:\ /'E1\5*:SIGTG= SR2*I%I
MV+I0)JN'J4@KB^ZRL1\ R]9-OIGS?:RI&2\5 *<82 MV\ -R?CQC; ^<5:DXC #J!X94>!\$#W>-.C)%-/S'K*X
&\$Q:JG1=WBLD*>=EMR MAL%(7J0^X#YS\$0)>]B:HPSCA"TC!0+P5&PA^,G8@V_SD)-99C#KMM\$3F:<-)
M_,%!ML0([F;UZ>@?KP&1#H7 R LMW[%V[C;Y*_KYSG^M*X0JX]?;4_3-HIQ/
M86U'X1E!7+''TF@6WI,*OFTGGG;RH&NAG@!P,L___M < V^YXWCF#-^+Y.S9)NV2BQI M/T8'0N72-V=-&YS<^7
<9)X1H\NK0L@6(L ^)@!000%8RQ@- *#M8#0(3^4. MP30AMBO\$LBUE&1N2KKT>QB:*.N2P^U&;!RH8LT.-
UL.1BJTYH(M7TWB#KWW?/-K63MV;W0D6=60GZ/SV>N .EYK%9/EAE?RS;M5EQC0_W((3_I
M)!IROZ@LW*U3[^3N!Z]L4BF9RF,=11^@RG^9I;[.4Z!\$R RP=A!:-8)[\$. _M) ZU-
)7YL<82Y:' +\/@R^MWL@[EI/@63,0TZ#U:5DW B!X'7)(&5"/HU]2 M.@AM(:K9G5TKP
7,;+M^87H+V]"^XLN95*50?UU0^K!E>>,@MYC/T8,'X*?E M;UWFF>G4H%IF+D(J7KVLVDG0XJ?LBUA_8&?
@9000RI-?-70;'<@H40\00^)" /0]7@\$K7>:+K]"\$]+!+S8#)R M%,NBIC<4--*V: 1 M3>#VJH">A'BX\?3BY?
_"9[E.Y-M#)AY]?=LK>&50/Y6@2]L8M?M8G/3M<3W M8S ?[\$!Z#1=;7ST9+AB@\$FID? \:ZP@D-
1()HK2PL=\5^-WJ-#:(>W-RKU+T; MMLVBS' ' \NOJMU 4JIM]*8X]7&;>\$UT?
&B%8\$Q@EY@L(^AU0'28TDMW^VR5 M/(M>\$<3S5 & G0^V=P5Y)Z\CJ-,T=92LHC7W+'W&/>?+3R;H*0'J?
MB^\$66M=;\E MWM*XK#CUNH^K I6/VP< >D0J>X##B 8 @5Z'8+? ?*XMC4-G7F^X9'R*/AT[/?86?
&E^B9E. \L/[1763WUIWC!PE?@I?'*3*P,20KC)>D-48" M99'H<\$J0A]/ VIVE&SN>'V?4ESAS+:9^NOM*
M)S94*+LG6]&T?ZWIE! V^&2CLWF!SWE(SDJP(\$*F.:S(.0AJ8 E^B@W&#]X M\$A1^NZ-F7&9>
8,0_1'EHA3^ECG*OR']?;1_10]Y*(')]'NO>0<#2 M1ANO! \$*AS(G4XEC%>^D(-SBJ>VW':TUK[.F^OF_N0;R-
B]9]G0HF;'A=L,Z MKR=(=F/(:8;U\28KUL(3E]SU(SYTM0# MOH0X).@)(791.A3(HB'^9XUX?
\1UM^K0HY;0) Z^^TUWFILR'P^*L75=-;0: M%Y6>8JVX.I5?+VW*0.; %?/12Y8V:H/MN^%LS=3
1^T.ZNBZ>:^HCR3'\$G9\$X M'3NMMU9FH)NLI5P@]1(3\$:1MMUIZH=UFQ/U5XX@"GS+\$[:9V_'F)
[=;>N3530\,HQY?LU-I+!U?G(6Y0\$/B M>]4[@UU&GRH(_9)ZZL+CI; ,TI,U)% :?U9= LQ,X@:C^S0]9\$@%&
Q%4WY%W05@7?>?#JW5W;4:ZG M=7;>/)ILH?Q9%R%-BH FTM?+\$M^X'L(;',.25\2ANN@/?#[QD9S!FZ)I7369
MIF'QZ.W-1W'U)L0V7:+X'XGU8*\$%T1VAQ>F+560I9J]'%3%)<>.#'>6=;) T MV3@= * \^P?+K[!T'C#ZM=
[U\$562/??ZF\$I\LG7H4 .L"73SS\$YLE.#_E%UH# M6D?E!0:\$ _3R! ?F!&F0A/ %57P/ACI8\X-
NN8,H#U& "6(W4\F# U)<<-R&[MR5X'0^>@S^K)/9B;^74S,>J%HQ%YWH* 3IJO!TN7:XE\$40 Y0S
MU[Z^0P"3\$UU#=-9-QR8\K.T*Y\;NW?E5'X,R'04"0HW0HZR8;U^N3EX]P8/R^ MN;C5UH%CV(++C*7F]:NI]?
R7GF8Y@)T7\$C_5E'#1> =L61:^V"B\H;TI:8E3 M"3]DW?G=;U*]EWFV,@:3+K*]CLLYV(Q_%M"3P?
_(CGNGH#UXT) <"N/:S.3 MPAJ7W\$SG]&V7]+X&ZCN% \;CPF5[Y'Z:'UBMJBN^8AU)&YJ^JL>:1@ (2,0484MV-
2RW4XTZ9,68)B 9-? M^EQ_C?3G_D80]T=:Z,X]&]RQ2W0+-5@W\"), EIKBM.-) -V8RJS]=H\$*3Z'<,X\ "QV0]??
LC,=DEG7G941VC_WU70YS-6'8T^ZHNT@ \ M&2^I"E2L;VEZ-P#*R0IH-\0VF7M="DYV2Q'PM5
M\$;L,\ \$GFP[(TY>\.RZAV #S"!@=P5S31*\$S<3676+"Z!)3R'TGP^/=5KB!KYZ8T\X^ M^R0ES(K=[NGS%
M4I1M*\$S?: (0-N:N9V;T>^3C9\$<\$ _Q']6S7(R('-[3.^-= M<\ /L M E]8V@&VE[*H ">-\$Q\$U45ZF27_2DYG--
A9PA&2#\$'9"Z;RSI-TFMS=#WTX M0R8X40II+)C^SXZV),=;VI)X\=-?^WE]X_E] (,G;2?)GF@)1X4/5MP*"#6
M#UI> \ER][:XQBD2N6Z@,?JA",T_V!Q=M^C:8Q=BM-S2G0HR\$E72<>>Z;AR,N MMJ0]0?&2C0.^>U6Y]F?
2:;YG_7,XTYM*6=!NF9/-S3NE#T\$=G!RPY]JCB27 MML&=+&Q\$;30+A;&,"B",01&E,
(A@B35A2W#2A1HJ8"5J<*J]00=V+SWSIM F MXF %:WF1R1+2QY-7K]*,YXQ?F4,'\$&LB
MS=T/14]D"@QY\$]23&G(#(\N(^0-(0 :RS"X)4 \ (C?X768.LJM! 6*E!S(E
M#E0[@+4.G7#6X&2BQK\$>EM*>"JHLY3QHW(TXZ*"Q;0VTS A,+M*0@&:WNI4%
MN<' /WI^S4TB)^05K00V(FVA]0T/:S6Q4SSJ%]Z<*F@TP!D M/+*-4K-?ZN4\
<90/3=07M0B5%RCZ6RW\$0/1'18(6<@3%& ;1W]5\$ \C9:'L-SX<[/
MFP<6_S0^LH^AU3T#J("=29P5N\$+F68;H/QKN>S4;^/25R0WB\2?0<\$0^\$/RE M]/M3Z["DE/)M3(*;JW7]?
[,SDHZ3Y9H0!05REXV!1=L57K0K#@INC'.I7\$ M;XV?V4G7UYA:H<3Z3I"=U4G()D^G\$>)*_D54
(;1UY5V.)Q=6]R":2KFKBI M[^BVDZM\G6*1?1^*!=#3K_%U>N'!K"TW"8LZL2R10>9+XA A0]61TKU==X0?
M,9R.HU>J;Q5.7)HSSR'G7\?M+)D>0T)22=G./ +0I]9F?W.M.QEIXG MV 7R*^;%S0.X+PSJ[]\$IX GE-
&17I]XI,/ZONXVT3,IR>Y5)CV/[]3 _JTLDF M.8RUV4:/T\21 MKW8YT^Q?
\TLB96.^='>4 ^831D^Z+Y00(E5S?GXPJ[])/2@^APIH560B8\YH M<)X3PDC0&;-4Z3N_K(XS57FI&#M(=D
B59!=-CC'\7@2]..[.]9N*-!L.0L M/00/OANXTLULZL-;YL&0."50-
2QA>UUXK8F&*J!6%#W)*MD0SNF(GI+.BX3U M6>X^"RJ_.3N0/W&6KQ?",SA0!%T027_/K_255+V+?
E4'.0DQCX'R"\VD%:GS;G+(?;/1JY\]@_*4C M6:D27TZD&4JK.LV%53G/XP\$T^WEX#35T 9+.CTD(DB"(8-
='GC=,@!37!%>+WAE4JRI^ \Z+GSIN^< \L N5@B?N\)1GCP]WZ31*MM
MXEW5N'Y;:'1G@'F8Z_#!\]2;ZL76U?J6NH?9+]V?W0UQ:73\<7G2W6(*"2+
MI(88E,L"N[K+ICIA<=4TIFO.%B%E=I^*@RGVA" 9"]0=2K3I0Q9<7LZ /!"+^ M%-<=3G*
<.,^=&W\ 'K70,QF@I0);J<\02L;Z_"M1]>4\$0P/Q0KU:#Y7%,D&;^ MGVB9[_OP*DC6VQJ-
WU9[K"-05*)/Z55B>T#>60JWCFNC\B=YU761UGS;PX53
M6^_I/B3M3FNTM\DN5J%Y[HD;XL0MK057 _]Q1]+VY>I[NJ=JVF4#QL"< M]<855J0780Q=F!MA.J1]
(>M0>?"301I:^Q+G+Z^W)6E.WF=V\$ _Y=NF/'P:#^ M^RC("7#^X&]YHU?
\!1TF:QSZ\$[4<MTE=F04S,VK50(N:Z5/'ACJ1@71DS]3 M!"D#^DV9;"/K*LT\$!G0#E87*:?AG0:GG7RR:
<;#5LV;0[B? EM]&22P=QZ&= MF;F6+J#LL>N+W1%JFHL72>COX\$VY;(/KLEV#3>K;NA%.]#,4WM.P'^-N^Z">"
MR_+ \D:'1U:]7<=P^4*8\$0Q/(:B))M4B1*\$%\]9B;D8B&N) MVS_B_4I\
(^V[0E[!])UQ]V]3R;0E@J '*]6WH2U#%WK8' W0",)ET0LU\$8(>@^
MMKM4\$3]9T]/R:BLC7I0I)EC5.WW@R#^IY!8!CG<@=!.U@UX.D?QQ>\$FE>[_E M][9-
0>_]6FK4G7CIR:JDSQW^FGDMV2&Q576J>+7^R?'@(' [/TQ-H%G1VY/50 MR[D@E9\$]MU@f>^4J1XU,*W08@F1?
MY\U_HK%/\$0RS8^CN#QLA MBVM75=R.YI!JCXR^#, _H\G7TJ+Q@U)-#/CE2V

+6'+^#*4"7VV&9L2!3,|#"PB'5T/!J.TW U(>X\+!3,/)S+PBRR;R\ LH""49'D: MW-
_BTJ^G,69&^(F=^X@^E0.@=+-\=?7[Z>*/93[;I=H"!MXDV*HAEUIG;V% MQSP=*.WF8_R&DH33KJ\$,>(H
MQ3B0I0'4Y68I3.M1L\C#U7Q#X#;,,>00^!(!,^9:0MB2=,@I^CV#%_K:VN\9YGJ@
M1/2(EPM\$H+2196[5X=J#87'9M\U*E70WHA0A> CAKCV69?%RZ*+P@RF*6!#9 M<' /BK!2*_YQ<^!.M: ^??
Z]C/KG:\)4^E]'8IR243%90Z"ORNT'\$Q(D\$C=5C MEV5\$-/\!D 00/FQ,@[,)!PY/?TC07/AM.2?
16,QC6*S\^2Y\$)*B+>'0/TQ> M+[AS7"NN%5G:-BXZ4K&C>!Y" PP>A+C=X1I08,F@[*00N?4:--=RR&"B>VN.
M'L?]]\;Y1:"'I>9@V\,%;9SGD==6R[@SK(SHU_EWX=2 1ICR\#JY(XM^'LJ MH'(^1J\$QUM"%L=[UYLCAT.3K?
0>E!)VA-I/:G LZ\$)E\$U<270N=NB35^" MQQD11.3%D)68#S79WR#L@U\NH__X0H
EX@M*H:++;UMB!0470]NK"#M" T(MIP
M?/= @DE+N'+,'9Z:00'W>S9+7C^8XD:J,P7J]GPU;WY<+.7 *_JS0YWMH8GV M: ^? -'Y\KC*F_T 90@-
+*2\$IZH?0E*&,'0'G;:0/85,&Y5^7=^.;M8P.5#4
M49[I09\$'=X2(FA0]N<'%CT=M>>NI@, @WZ=IA@EC<_KW\^>.(-: /ZQCWS"GBK
M5A,PN!BJVR9X+4S00\$DW9RE1N5=VF=4/^D]1\HHW8TA\E_Y0\#@0#IR]YPHBH M0KP/&W=;/E@[,ZC*=2].*Z
M16: 2*IW0'LF./ORXC"D/1(P:+ 3EX_6U67])DK/628PGRH8_EA^:G&2(:4 M=0#
[R"MB[&%>K0L3A/.F10PVS(ORBPJXU*2\$<^B"R8=VXZR=>3NCNJP,6QJA
M:TYI%LP=%3LW='T^WDKXI)NBY>)&2TF0H>I(8:E2*082E/8 =?J]H?383^4NP4DP!1.EAU=
M*@"D<9,*:/L.W]?V'ZKRRP^Z(/@F2Z^KC+,?+3E8U<)+XL'"VYZ,LH1Y^PY3 M)MAW5-WST_T2,]
[Z0"\:9F5',?#&U4'GDT&\+A;1*Y; ^K3][Z 4>^ M5#9'IU4L]V TX*A@Z)]+43+B_Y42V0]-)RW0./;:;S?
L),4Z8I1J/TYV@.*6 M3'@1!%9EE#(&Y%A*:V0GF,[1]*4YI381N&3U]_D= Y]!%+3F%0F<\$APX-
U6:K#R72U1:X3F*2+&Y#CK88\$.9# MPXM3\8BJSC%CW1ZSI3I#V""]WJA#H\M\E7G\$-DMR?
J=&H=)KR95.0M()&C=B M8[<\$CJ.(C&5DUS0C#\$+99./&9&^V:=!^)^G0[]00SD\,FC;8WJPLU+1W>P^Y
M,2XS[";T=D^KOYC%;-8F^2N)"UL0,7I^0,.!P-FBK[9'\$-57;I8R,3^GNSBWWIJC;A.90
M!M+Z^Z,T"HIU[:Y=5&0T)NJ>#_H1<^TY<'<7E7-5@? \.6SNZH,3;8_QI=N/ M#ML[-063@&\$R0U1
0\$+AIC\Z0(6>\ /B?COS.:L9W&D=\$?YHN#F*AH?-R]9^:
M\8^65L(R)SZV>^YF77DP;* _8R\$YAGE+ K]5W _^QB@%0CYW8[R8 M1_-I>ZV YJ &:'U*\$)\$X-
/ /0SZQ0\$; '*XWND(91C(U*160R[:ZTJQ_LM');B2#W)+]R%X1@ZKE)Z^BD;X_*T09\$V\$5[A%_F6^4=VQ
MF: '!@BTP&Q70WEU !63[4P&)(51 ET0D%1 1'J1#!7PU#Z-]W]5E*N#3+8U* MH_IV->
(YEAK*\N'],WL/+='2/BS3JDL[G4V_9 H-E((7D\ M^TU0Y/?YEVS)V2 +R\4Q\]N-
=3_/"\S5K56J:2\+L+>>^C=CJ0M!.A6SJ^1B MDP9]Z#50GQ*21BI%WB,4XNYA:\$ZY @>)N:UA1S>BZ1?
(YK#G!DEA.OY1"F:F M]"(Y228I:0(T"-&QZEE#VMCW5?35\$#S:A^N!;2@ 'Z&W+\C"/^0C/U>X?# 'MMYPF?
95^N^Y"IS^A^62ENX?;Z5A.[N:#=;E8'T' _FS3D3B4VLV08Z1J.N2M+ MV..D?-IRPMJ_0H;".B6 MU)
<+0)L\Q+ _1C7\$&T]:+0\$N6;.50TUVZF&%X=OMM/[8Z(YV/#T*FR;.B# M"+R[V^/E#F&8%P&!3R,4+0F%N9-
-\ "CL^([K96)+IRN[=E='%JBEZSNSM],":V M0LC#6>D^/@^[@PN/JURT/X!([W2\$EJO)WL,/G=
(X.'@E3SH'Z&\$4;#5=/J M2D;0RZ/&!^BBA&?T^4>- ;]>&JHFF#=541;XU_.UL79/6MZ\$YCG-"4N
MS.!B*Yw@/3+@/3==7]MW3F2Z6+NNNKH%Y,+;<^.:0GTF;L_#%N M)GF\)\0S*6=U0F^%TXZ[:-(3HRLX*
(+M0^D:?:GWC@GZ,1 M)V0YI,TE4/DZ+)^P-/)RZ1J%V_FKG&FH=Y+T8F#B6)1SVE'PRN\FT=?C
M:3=C;7.FY\$YB+R!=/UYWI9LQ _"T?10,1CP<9?TZ02\V/1+WQ>[D\6:]N5V-
M0)/68A3X>J;EY2CQB>Z'EK=B79/:W_3_K:RXK/B[.9%;]0T98HOWX^B_X@MI M/C-E+%U\$4Z/NJTX1@_\$@(#YJ?
%ULZF^#EU?7=5U'T R=/_K(JD&&C;U"Y].. M&L3+]0+6SNRYQEF0&8HL4IC*E?F/4>
(XT9U8K\$/;\:0Q026ZQ(Y,& +IR]Y@_M'N#L@:VNP?SV]JS5XW9,*4FL]D^9_:W11=POH9D+3M/%2R
->*>MQD)"=4V4[MA77\2\$"K?Y]4:@EU79HD[P9KEVN!.Z80T,;*0QV."[S.%S0W<4+=LWJAHB>
MZD]>DJN=E2FGD9>>K021-BW50W,@*!B":2W1+Z]W<]M I%_F^YSN1L0>5P4<_M%4#BT%]:Q:13
6%)F3PC,4,VA-(\/?=KHf>'A5@S95HQ3G!9KH\]0KWQ29PX MKBBT"R1Z3HJHA\$ _N<'0)4A%QCBAU?
Z360W<30P!51F2 ?\DE/U/:_M/C2,:@]\$&S+4BI17C1D0A8 MUU@49>?((2&RWSI+HQ;
[0.,:]A@C\KE=EJ055\$2R//:S\PI7P<-?(HB/\YK M +M Z#/D@(@+>8T\L5\$@E56>>Y4S*.ZN']E[R0&>(U)%?
MH2''3S[V'C#!HN^LH<\LW?)V6C.STW5\YJQZ?0D^Y\$/_V%+8+3<[HT!(*\$ _C M4X0WD=%;T,)]7((-.%)*I4G?
24,E3R^Y3.B*\$F/P@HL?]>=(\;WSUDUL?GGU) ME>##6,8M=NE: ^ _+;SW*;>(>:,DI!D!-P!E03' M4@\$[R]-
J5?2J.EZ9&62GZ;^-=;>'7_S/0X#INE]S_08L^M>C3VQ1EF)GPH5=
M[3D.&@Q@EKY#?13_5MUGEBVVNW7Y+K^QB87'\$];-*!\.0&"J)S;:!B M^H).\^1^(1#Q4.\$XU2\KE((#>4
CUWDW[BX5T^&A _\+A7%/CLZ\3TDS,TORL M0Z_5\DMI0)YI_9-
>0H86;+D.U5^<#0%IP96EDU&YU@8"M7B'R:LK1E)!G7S" M;1F95K_JH]X*#5I7'P20DSA4)'7&_ZW0X3*SEH-
[;?EG(0^X.K:AWV]>9.M0!EXRA4MK^<590:2 MPD\$M-\HD6*,3;ZMK^^-/8S^L?.MPMP]D/#Q*_MV)Y%
[3+_5/XII.YRN*3(N)8*XVQ%: "PJ._2[]MNJ-(BT?Z'K9J_075K? MUL<
@,1#\$P_+C\$GWJV4>H9.\Q4/\$"Z#*]* (/ *_M)0"AMA^ M(0VJ0E=%![]JU!=\U0T9!+T^N5)^HK_,\
!5FW+B (!' :=)!;Q#Z UH"-BI MPY<[0(1.30_@.3[]M9Y\WL^@ZPFW.+^H0+J3> G0,D4 M+0H=/2I
R9.0[R_5QJ1!/_SZ\$-#]'XU#3#E2%-]'_6I@/M;5(-\$B)Q?5U](!
M!0QV!6&JVKR['QPB)D4[P9QJ.A0Q(+M;M5A8?2UE4"4\72"3W_57>CUJ,._^I
MT=)R=!]@8L(#,0C&1TVBNX@+Y:WK'+7G.(5!%4.C^7#I"II]&7-]3NI-/;?6U M/9[T&F0-#.!+>(0
[]]Q>\$]/ZTD121%)BXW_[E/F_ZG%[J7_C!<3+3]_N9T/_M#-9TYE=LE<^R:(0Y6.30A7B\$^4((Q7\>JMI_.7)
[;,>SU]0SF2Y)%"X3DVRCV MXHTR10=.1Z55MZEM3K0,FXE/%^ 44&[1ML6S; MU:%93TG.VN#+71#TI+1UD#AV6
7U?9* LH5@4I6&(YCP@I@9SF63.EL*&TB21 M4]DCI=(*/#D\N097NKI')
_@R]5KF2*\$025KBRD)EY^'\$]"W#N/V5R%5B_0 M#202NMJM#4.(\0T2].-'3V@*6JWD<3P5<\$X-0ISX1\6H=?
[BG0_&)Z?;V3(M M/B,\.GM[;J[Y>QYREH%R>=(RBHQ[9LDS50XF_,755?:I]:F@9>AH?].G'E=
M&E8G/\$TMZB+N(-SFH=%ERH!*X0J>3ZPAHX2KD/_5\@L)3D_9)Y:>\$G5SG^"K MY=E090QM\9^#T+>^!,?
@RVZ1M#\DI4"+:++?248B/+RN4"6S_\$GP6Q@,(X%B MG)!N*5YKLY1CI'7!"0T?B=]'L7;<9@SJ8:I\#
<,XL*HYJSFKE',%9_QI'M%F MTM:=]-GTY)Q.[+LG;)=U.1HUN86B+"58Y\$H>,8@[YI_S13RTM/S?V_Z13IYL
M(":4%I90MM5XF'_CQ/'YK7WER1YCY=U0[Q[B>E\WQ_KM;6E*X:N"@6,NCQ_M7\ ""?V2R^QV+^0

M61SU*!#SMS;>S@9V7K=I?WMY7.%;GX;#5,G.0?M\1'0+=!J\$Y5U3HWD*.BYL
ME5@}#R[#U^00JH1'[3H]'13Z[R0AXL? MBT2E]T3V/Z](%TLT:EE6'6[7]);#@KXL'!'V5NK]/QZF\$ _02@S+J---?
>>#13C M7%IA0,V?NLUPL.@\FR[0\CC1-%PC2&\$FULQH*C(5)E(G+] M:J<&?0CAB.) *CE\0KW[04\AV/,
[M"9J%W3)YGK=6Y5(]QU;CX+*W\$ \2X51 ML%/.%0N&06K3 9?THFVZ!@%#13BSA+5P[6M,+LK/B;,>;MX= *T6?
)" MQG#/(S[W<%A#9*(= /M0SI;;V4;2V[Z*=W+K* '@'UC+0@MG!U0@B7="C,4E7 M=W>DYK
(Y"A)"5,RW'FX;Q^JIX 3[20 0, _1J*EN6\ MS?8]=.: />4@4^?2#Y17@H/JI3@]H5;XXB*:%?V'?
1%.HJ0[>W'E<7 G Q=# M! ?0M2E,82J@ 0G]P>S;E% "2-0\!XA8\$=!&'>I014= FXYMZI2/*#+#FN
M?/)2Z[] 4\$ JL:SHH,G!0 Q7 MS/;>3]V]"RH>RBB,61@7@6L IT>;6,1A!P%
<5I64MN@9KUM8IL'>9THIF.TJ753@,T F?@R3C M77K[1S2009@ \I> +/J=FM9..)"?
R4]'[4']&@6F' 'YF"M(C02XC;VI%<8N%T MJM&P(&/P/B7)5B% 09VYIS.^TPV-S(R42R,%MQL5T-QSx&?03VZ,E
Q/CAOM M0?P^VTT[HBK5JKE/ KR7TE=UR:TC JH:C %75)8 +@U&:56@298%F020VGZ
M>+TI=;D8FJ[:6S)I9H\ XMY=7S;0 @;_0](E@BL7\$(LB2<=> \:M@1N=NN7000H M&6#45X6.<[LMQ
B_Z6>J[RV;5F]-BC+=VDO(HG#AB.33'NSDA.,S.,NC^ #<.I?^ **JXH MG:<2=?[FT(:V) >3078,
TUBR PMTNMPE^=YB,\<08U\Y1HD*J'ZI@G>B<.:HJ)X M]^>F'<<;I,-OU 5-
ZW\$69NZ/@V0\B524I979E=W7%?.H R8V^ F!6 LGU;& M^=?!3J2=9B"99\)"N-JPA896?
U16ZT>#WV5\^ L> 9/JJXYKY-+JY 9Z *%-0?Z!Y&'HAN46@ MAFAS\$H8IC55;]V7^,[P8U_L+(##=U*I(^0(B-
J445M0>IT3<'["AQ<@A6'5:%36F^?P\$8!8H3,"\$;^D00\38JH/%,KF) M"ECL.0U7*=%8ZROW(98-W<.:]E>?
%TX\U>/_7=1=C M.EMM2S+?30'1IVJ/*@_GJ<"SJ#& MPF*D-4,V'I@<)>ZWXX\;ZW\<?Z?PJG\$4?FZ\F
[>22.9;*1#JM4D/\#W,<9S](J9P<=19 A-: M+I7NW5?G7I 9I7!SPS@);09!9\D%%8TDR,%2'R@"
<);0W\ZY]ZW/5NNL],8 MSK-1=SH29+P[12=R3,J+Q!H%&T\#>DA^WS:L..ZJ=8%YM\$[B4S<+PH!{RJR
M#INZ\0Q<<.G#}WBN0QZ7WY.XC^A'\<%;99M,+M=0 =@/!.3#^J%7P0<:>GN9
M^T!-79C]3YKB71I00L _5T%*9=BER*KJZB][4=IV8UT30G[8D]<4
M"]+B/\3)'60LD\1PS)*%F(7V" T4*S1%L; ^/V0(W0W'8ND3%Q?7U] \^H #ZYJ\HGFLK&].=JSG'\CB2/
M[4UC2E75S'L-W7/6DTHS> 0DKCMF1UV0S8HM PX+E5 [\$KVPGMCK\ S/I _[MNY%';\$6=-.*KR9DD?=Q0DP+-
I>W,I3J0T_\$H\$&A'CL\?75GRH000XNF%YJW M-JYVB2M*70 LYSF('?!/1#&RLSB(OH+YU)+8YY?
XC*1FP>W,:_P ^WV\&I7/ MQ?Q#;\RR(8FB"9WV+NUFV._2<376<^ \7;\$:[0I(22.)UB<=9MDY\$MU)!06" _8#?
(4* M\ .9ZCBWFM T\ M)11H7+^T3%VC2%7V>9#"R MM^0^JEGP<3,G>T'BQ.(LW^K=A9/?
I>8B0=>>,X\$U /9:P%WH\;38NR% ^Z^ M\$ALJM P3QDA[=@UA.-N1(6!F-\$V<@&F6B?K30PX/L&+
(7ENKX[5])08;4[K ML;7=@S'SS!2:K:F"\9)+*IUJJST91=?K [1H.:J1\0\$},J#KA,/@3'*J_U)
M>%0M[(K+""8DW!@3K!8(\$Z3&=8@AP) W=JPUY'7PA\G2#T /.R(/[#5 M&7W=5LM"0+
(U=3D4)]%U:=G@G@0+]]P+=>&JG[F0A\$](7*^XAS 0^==&+<
MP<'..9; ,0;P2;CP1B\ '\$XW10*)N\YNJR;H^AVY^Z\$!Z]#N=.3" >)305G\ _M>06_N6=S@E-V+LM[-EXHMM^;-
E1Q[#9SA)C4[8+Q\$ \P)]7]?&UIYN^/KK ! MJ00.Z]7&<: ^ER< \P; ,J6,5>E'@V3G@=I\ \!Z&^VB-\$"@*?
3@39+7-E]4T9Q MC58F.: J7.W46=W0;-W=1#-\0]E8I\ (IR]2P5(69IBV)[EC*:=BV27_EY9- M^0<[4V0@Y+-
UB@&50;>TL..P^:)IS9MR*^RIB""Z/0@9&]LER-2]X2FMJX@ \ M W_Q.[?T/5;/V /%64/K/R/W7,NV-
==0%M5RM(0#047XP M0=I1C>L&*1E*#W &D6JV7I@? *S96DIY;E#P# (U/@7>:P?L\)\$ _B8QFM =0-
XF\R6QE9A-QEPA MNLBER@MWK/I^B%\ "]=SWB:I\$Y6> VP]:K:^1P4,2G'NP'\, @FK 8JAV.)V
M&YY(YJ1XYQ^MU7B%7P?6# 1*5WGTB@A00?4M,\]?X _LZ#?_1)HS[P "L=#ZI)92ET8Z\$G[
MY5K _R6Q]Y7E'W&F%[CIX;HW %J1F9\ Y30M^(N 3H[KYU-1\8+36M
M7\$NO/_KL,>HQM)K#\$>VWN[*]U6^E)2M)-W87@0+ \3]*3M\$/K>C[R>;+'=9TA/\[GKJ3]>*Q-_K,?)
MM@ZHFJ\ C2!R7]L>^\$SB MYVDZ44]KD87,7\$!C? R<[S30XE?AD:6H!S7R)M=.. R+0\ _-3
M()RQ^83II63\$T_5'(SYH'NB'?G>;8!6^K<9F7'9#56#'\1XCD=H7V# +0\$YGI0;??)DX^_G3%FD?14:+-8
M5T/H>TMEQBA![-LI%=">3KE\FZLX)T40;:S2NR,^(EBH X[-\V@G+2K RSGW
M[T2;RRV!'6+C]6*00\.\$K'+G]M;LC9=T]\<;? 3YH'JNRZTT3",C04C\%JTB2@X41KG.CW,])02F/P&_M?
0#)@3+A[X1H0]X4.OEXZ^ZJ49P34&X+6=0=T;C%U @L9^@P G+D5Z-HRL.U ML?;K!BRQ>PZ&F>=68+S[-
_VK(J]Y6,VNI[+JW7/6[SL>44.)MW.5-Z*(0>V@ M2I:V>0:%0B2;2R/V3G<3=GHP>;Z'D^N[78'+/,=ER^U4 !-
):%_UE[0\F/' / ME/K, ! [0 : , +7^, ?WR8I'W^W3 *>\$Y83^T!@B@M6TAZI^*^FA^_LUI"1TJ5 M;G0/#-
FAA\$!C:X9:@1@1,G:CHJ69+0*GC=0C2=5;Y!0^W# M'\$HXZELQA(TI&.]";. !M_.2;-V- M0CW|N*B
CWFH.76CT[F6HW&G> _COOM57_AEM >5,"=,\(UQUQLJ>\C" 'K/
M,IZPX*V+ #R%1(\$NX>>20(' ^KK0=\ 'T%.ES;:' IOFBE=11="!@783V.MW(X;!
MWYZ<1CC=@/1K^V8* _&V"1;"4X]BQ L70,[NSSSTHCEF5!F. MTG^SE=RY]7?G;V3BG^UPW9"XPZ&#Y
@JP!8<=BIA79/E4N*R(WM>,0066TN3_M_T*]-.U5F[95]3UIOF@>[MX_BPK=MH]?>A: !#PFLPU[6J*
MW'DF,1X]7^,4RY#;0 ! !A:W,#++S0\M&H8I_92.8]T?A% -N7;ZCXIV7G>HD M\CU=-^]ZK(50(MV;V+JE#.US?
*N%LXF/&U\$ "3KXA0U\F10\$?F7)DZ3% M@10.6B"XA'!61#RT% /D=0[KTK^VP _7?
@YGF8:TGR9FF*7\Y!! ,Y2_3N;N> MZ13TS[-9[3>9PH2\A3WZ.3[I*]!*
[:&R.>DJR;*L0BV(=/(7]ZF^R /X!G,\$ MH1=_3!!=!-?H9-YHP\$B5@E]4#6WG04Y]GR7'7U;
(*\$:YBAT8I7+ZL.7S]0#^;=A&FSN4F;LEPG1;G=VVITA=?%3 :W9!B>E&Y>@'4=,9D-LY01B(3!^E ,4
Y2]" +PCC# M^,7YZJ1]G8)0VI!U- [WT= Z6[1+SNIA(+G M#>K2*>]D>: ?J^R]B(7, Z(MM(
M1#N*KQV>U+@/!AP)M1U^@[>\7 9NK;Q1FS(#A6E7'@IUT5Q_ZSP#N4(>)S#> MZ.-
I,M'V,0)]XEC/FS\$IEDI;K<;TQ.N M/BGKY%("00@9C\=SI9;0/9GW?%2H;&"0]Y')#\$X;5T _&5E*%A#60?
%3D0 M/# <.:?Y>.1X[X8KG@9? 0>J>U.JR\#8I0LQF6HXLZ[*8/FG-)L:0N6]Y>&Y M=RUNCKD(0_ILU#Y?
LV]D25;\$SF^[82%MQXA NP4K00K5]UJQ3RVJST]0K4_) Z*FZTL!K!/20@939B+ M0*YZ@V8]] "ESE%3PY\$01LJ,
(I@H%X 4)SDB[0"F.:9"/[>VHVUN:7572G)Q_UW;?D=A\J[M]^CW8""\]^IHPFY:HK[Gf&^/,Z?F(H92?
4#L#LM]"%-FC)\;DH4 IEP*7IR& MT""]37LYV-
QLYM<*QWN[/:/BGZ060UXD<]10EZ: +P#;+/J7R >M'/Z:>+5H*N9UHVN;:01=W)BC;0 M26/9T<5%+
(0C+X<4.X6X[KC9ZC."V1SWV_#C0^+;MZ[H= @4K'E=)T_2G#0H M3T0KV.0+B'
8'U_ \] /OP/5JKYYDQ6\X68N@HE'\X:TZ/?SX^CJHW2ATGA7N_M!

(DVG2PR870AW#. %F[0563=TXI=J'@;\KS%Q05]Z"G? !G J M9M+ #8/:3XR+M6+?JK"8V!-2H?AT? N[7#-
>I"JZ@X M='DBLA/(.D,(:30-A7&/9KQVFEI97'S]SI.LKG\)P4]]X)/^,+4 Q\$2_.]>
M>P" T:,V)W0JG&)E0\5[PL=,&Y.(, / !V\0>8, :-7(\%|=3DN% '\ 'IU.P-!@) M9F*1FV!7[^U% *WRU5,
[_H+Q[^Z0/^Q\ .P/7-F";S'G>;J[^RY >L(60@]W M_ . 'HCT/XQ1?6(=7ZH15=/#S0?
8M854(: ,YH2;_0#H"+; >2@)C; -- '@K\;V1R M5^]Z.2)^0\+@EP^!81HLE5A*B ->52*
(7: AEPUU8>5:X1./@RYD_ :9KV>F MCP=<5N8GV)=>YRP-7M@2Y\$, G6:54<=5>]>J7B? \T9^; QG1VS(B0'XX64
MQ)9Z-<;PH4F#!0J<)>7>, FNB941-MQX# [DY' _Z 79\#8S?@&*N'H"XE1\ \DB MN(@8VY?\$WCV+ _5U PE=
[U%R>"4=JX[N5V/UAU>;_JHXZ"[MW' SEW(*K)J0<;7 M%+-F=ZAY ,QI<=<=0=0YR;JU&CM+@)3D1830KJ)A0U
=SK];5)%0&; '>J:Y) M^>4Z+>0EN:8\ L\$%L%:_@!=]U1N7GMFU'KW4]-=' \]74K%P 8EOZX1#]6-.N:K
M\$0.*4[S=I +K+ \4 M4J6?=>C87I'H" ^7"@BT]\= \H 575,>C/LC*2';R;G? ! M;@QS8<(!,+W4SP9(3C?
5\ "FUB\$ _U32FY@]:LK[A(!;PU T: +,Z'D^ [T2J7G M3F0)#\$PCCC[%8&&^ZP7-CCA '_3!ESVA*0W'Z]
(0G6>MCPJ8N_4 F'OS<*C_ M0U]\2J5(DGV=2I%L2<@Z24B2\$,HV(:\$)V/MFGEY+ _^+8 G_ %Z;J2;7FL4
M [ZT7=A\)3:EK[RHI_0] (4Z\0XEH"9])X:1X*1I.=Y; ;#!&?YHZ MS\Y^1A!D]FC#G+6FS>W3'Y[-NLR[C" ^
8TT4M@*6)Z>3%WT[L+RXB=NE-?6U^-[P?0/372GH M" ^D=&NA([\$6+0W;40@I4HIIAXCJ?@UL5^ -
[&MRQV., 'RIOX' / ^"K 9\? ^-B^ M.C2XJ[TA. \J3T%UY S\$R? [Z/S!\$*/1!] =FX#B&V_65/3W%]\$[K+1NC5+I+2
MKQ3?;C&@PT]\$ '% _!F]ZGC50G,M*A1ITNF;PWI\JG?I'19> ^AJ4)QX,0,UVYW
M;DJW2>G0GV=' \I5C!K7;WJJ4"@TZ\+J8R M]LM) LMT\BZ!]< ?B-'0B@A\$?
I"\$UEU7=)P=Y3%V[YJ]] "F!*00RDF(WXZ^02 M07IA6%.CRH%U6[#J\ /H:A^ [N\YN<'2\
L!J_8V4J]W7BVNUXVRC ")<;=ED M&NCYS;\$ /B#U3N?VV?U0P4[# W06W\! \7W+K5C\$(D;F]='6 MP=NK93U-
LOP MU*03NPYE9K*N:0%]SD3?/B KS8YNXN/G 71BR8+ 009^37=0YU(!\HMJQ*\$ / M->K@'#R' /HA%J/V+]
<&:)]Z%\$ \=7#SB'R. IS:RR*H5:87Y.6W8.EUUMSJ ?% M>53!1C_R;1JH2X8&FM]%T*DMM2SK\$='A+VJ; 6:=)
[J%0;G\$?ET,WB>;R7 M8HRZTU)&U',5^C+LPXM^HVN<=PF>
[H'2*2;0/DT.OH3XBK8I>926>S (SCE@TDDWEU;_%@ _EN[LW8)6X. '6=0^>5EA+GDZW+\, 9FW'WPY% M[S7-
R'6MT4 5^FT ^ZAD15_ , [LES(MN\WUI-' CQH5KR6K7:MK=*^N&74=-DK MD:1(OMZ_0WQY_2\
M;#_F>\$CIK9#0W*Z/0/9, .6J1JF(!5GED,NMZ=(^QL8,<@5+5L>;8KYDYCL2 M0!ME\4Y!Y++QSVCN?
L') _&3F: ?]@BWRPE5D0\&M5D=8@'M#. ^81C^Y]? %0 MASF=8,2!D#1C%XS DYL1 <73'F@2SK@8DW M*NAC6
ZT\ \5MG\#F!U 'UJRN4L0MHNH,CQJ>R4#6C:SCJ"!F/>:JLQ6\ /?3 M)5+V^0+>JW40\$-7YI#V?B+Y-)?
30%NJI.1PI>BU+Y,<*-Z)!0JYVT]MIS&3 M=7!5UU7)"#-DGFN@#_ :
M[:0Q6L]='4J5V29\$D<[ZBPYZD/QT8_ C6'L, 'K>0JAT2?6 ;P=SV[#6%:0P\$> MJYH+"UL? 'V<]0J]@H-
+H<)>^X9W"GD9/35#T*]DW5CD+7]:0QPY^@RR.A#!\ M+*) \!\!-: ?P4W UCD]G@: !7&LH?X7EH"G1#_ =?
A5*HP0!\ \,KGPSW*J\?LC\$= M0"N): ^90^SBJ# _*^!W;%T.#^2K0P..2Q<]M.[CCK" 'S.QU,I# + ^X9\$=7/+RV\$
M[G:<0&B"1/I7M\$#+,KI ?SI^F' _E<./SX=&G_T,1('K3_T[U1!U-8\=PRX4G M@F&3EP(U/CQ/L/CQI/-
SF\],E)H" 'G.&'V_0\$; ;C=3"W5Q_H,*4.QXDK;P-&, M'V=/7)?EY]Z_3BNKDYN?EJ,OHIC (5^WX>.[?
FB(D]8Z%\$2;?HI"! ?ZPG5T M<\$<00\$V=3I^19B/S&0+"68_3STX['*1NDU?< L1GH5Q D\%YDT9]9N*YQ<=> M;
(X^A3, ^#TJ/74K[>,>."?GFNUY-AR>2_S CF.[\B0:"C*U/+AU>;L^,\$8[7
MDRF_Z4_8EHDCR@1\$ / *E"8M\$2H3S&?R5C_ '72R4>7=%];K:QB&AAZ7C M1=ND3\+5<&/PX+9:D2B?2U
'Q),W\$U3T/;)_ (S\$1;S /E:<6 MXXX!<\ ++,VTJA,URV02GUEGKG.-7#<"L=:40: !CFS.1K0@1NS%KG/5E1)\
MYRBQA[6%VL]F#_ ;=5=R<]B:JQA0NXGH\$(*3IJS+4^E[1C.&0Y*N2"#\X@LK\$
MCOMN.0#&7WH&&+4F^#1"1W>*1*RE5-UOQL#IF@AD'9U +*,R18!(;D3S'ZG7 M6[Y'Z?98T4'0]?QMG?
1C6D>,KWEY]2B M T]/6X0&VECW B#BL87&8<0X)-Z6>2L710/(KF) "BX14]@82ILE>55./&3#)T"?H&WN?2FAG*-
W\T? M=]X'J2WV%)+E#N+GP&/4/6""T/J\$Q\X2!HZ9:LX7 -T\FGK0]+IEY6VS
M%F5ZCI(1^95\+V^*A2PG8G.DBHQ[X:\$58VL7A[G-G98_P"&2MG'\$ \$C8":05 M_V%?:<<@I2/PK%\$]>M?
[.K>/U=Z1G>I>M.4973FW,[IYX0<^)%3+*,-5T# M(28D\$B?WEI?-WB,? ?; /&!C\$2MP8>/CQ.*_+PY3
[\U\$;@32:90"6F#RY,359W6T[+(*WMNC"- (G]M M99?VL+Z1,N-
E29(\$! !*W*RX "YDWF6CJX; ^ (W*7.YFSGMN9P?TE"HR(PKW@M#"AC+>YCX6H/2PLN&/\$QU&>.7>*\$"/M7K\$)Y4
Z;1XDN MLX\$?LUCQQT/:%A8B'0^,0V.\ TR91^2,%[, =@9_6J:':67Z11(G);:/7N7\$; M'6V(L[NJ7H01?
A++F40/8E]-)&QI"=T9)15]UY 66+?E/Q*?M/35H*:= (XZ= M-QIIF"0_Q55@+";C1*
US10Y0Z\$S5\CE^C2.FZVXCOR>4(2661G8">,N!9R M(4.\(R4J%) "9R#8=KDM3['_G)@6.,F;QX0."/ :?X=
.\$VXRT;Z0JR_P: #"? M5W>ZP/ AGQU\$QYD_/TC!]M/79+8&55U[/(Q(!NN^/IZ^&Y[7AA=ZKGA*)/S\
MRE\$^(:L>#]503^1)FIS M8EGC*_ ^CN060K1J]@",XE]D013C[V+RBN1Y1DQBR<;ZVJY>T.?AY53W\=D>5
M6\$H,DW;W5\EMP6IEQ L[V#>@P8VS\$0"7M85E=9.GACE'M]9, ^MUGQ<6\3K#LA\$
M6IC#Z9>1Z/,'0X6C7]&1EP:RA[# /R;Z%1&K6K;&=)UR.Y6896\@72^5W"YU
M"CG&R.]6_0/2%KN[V /9% C+55K8];KP\ \&UU+E\GKZ>;!JH"VU';@>.>+F\; M^4>*R3KL9FOI;R?(SAD-
K>;Q+;P+@CG3108XC08PLD M9S15@'_W-]]5IYV9@6P6M? !UP^FB]DGEKNQ=>Y=%/??
IB\2(.;KV]CW.ON0&;M=LQYIB"++.,Q0>>=84.ER0ESHXK)!S= MXWU@#L:;YA&]'6YE)>\LUI3"QB?
V@.HJ]7/^#6Y+\$F/TZ63G^SQBMHB[Y6%B MWDJ\A0Q)']",; '#G:>RV "E]D*0A]F,E)*>7U!!- Y7)?
NNV, ' ;6' *-C"3)M M6RL"E]IZ0#Q=:]Q6FP:@H39'\$)9ATE433KYG@DGRV<58>U,Q8:E!SG!AH6#W
M5]IDD&D]EC'HNEK2(N/] .5*7^--?,9J_8# =I?IUQDQ*Q'# MKR?);KJ+GM!,*?U/R'MHU
QID\$;>0T=J)Z6_ '*E0_ '=':IOX\@C\$63I\$*1#A MZ>E89_5C0ZVFRZ\J[Y%&S7)KSZ,>
<#1\]0LPT#Y678^>#CA%' '#:0R;)L1*0 MI
9Q36^2E&^CBZ7F70\LF=0X[>JR_JU;0(JR563QB2X!WM\$7\1UL&*5=FTXM MOE'*E3\D] %Z[-IVM-
H9)32>0TT!A(?[T?WV\$A@(X0L.P: ?%X%*5<3=H":MG; M*\$ (" ^5IUV+\$D?XTQJ#VV??
\$Z* \E!3W0\$<4^ETU7JN#NK&VKPBUE6\$B%"5.A9U; (*40.MIB0+%I5Q)&B@X M4
._+ +4W60EMK2NR97(K"IP[2EH= 7>0A2VB?0' ;??16S(BK:ZIN+R=\$? \$?P6E0[, .I-+/(4\$
M*6\;06!Z'FBEP+2//+@+30=VH:\ @?BX)AT'0E4, !-L V-F)Q["TJ]-1^>+P* MVX;+>S"X45PD5]ACY: #=:6?
_I3<1,MC[F,]3A#A[Z(R]E2I(^ ^U00%L>7)K3(P8++1_D0[XR16(J<7GS29/66 >1EL MBA NP4;;[I68.0:-
:-^]M\TZRDC"Q_AK+TM_LD^5B., %0HALKT8=CJE\$PG@9R MC3^,@(\:0LUF6RDG&J1]VW\$YHYVY[

['\05NPM9B] .Y\UXTD.=Q\TP,00> M7\$ 6)R=7D1P,\W).TCV\NT7+PD_N@L: ?P;,'PDQ8-\$&6>
(>.!FJ3;+W[;['1 M,VY_,?BC+?;&:DH18%[83.5,6\JMPN*B8,"M@:UN*N]F8&!'D(5"E,K?A*# M"8G\$#
(SN4-9FA)*0*;_A#1)+?T7\$K D(.7B/RX5;GQQB.X M9N3' 4G\8>"^N?V7)RLIK\R>3&C 8,Y1'
J00SEWPR#\$V. '" 022K9JSM L. M(TC)Y^%+] [B=Y\W&WZD5RUGI2IU"A :^MM'JEQYKK11(@?S/^'?>/Q%W-7
M@A6Q"!.@ZB)!!@-.,!;S 4GUS. 0?J:3# 8QT=Y0#7()%,G?=[]7L!W?] MU<*;SW"0!&!)!R+=2H
2\$G@5!H61]%(RYBA0?;#CIEVDLKW* :-ZHS20BY/' M 7VL^MK1"OU2>4@BH#^8L9CPUV;,'R^MQZGT&8#\
[18Y>99UR'< RPF81@P* M"?[H\!C#;V4>>KF^?L'50-=OKL>: ?]A=H"<]DQ_XUNH-U/ &(0G#&Z#0B2G
M=E'LP*QF%0TDC\XJXJN4Y5%^,!? ^V" P9H59GUGFK/H S.' M3G6*4\''(PDZ-
P42Z\$0N\$;S'7>QKM^R@Q'&Q\K83@XKG9[J.//3P\?M 8J>/ M_A5\$'417H>T3@EU^HJ0?+E&>DIRO-;+&4CL-B
+TZ. W+TGU!KPR-!-ZR. MOI:)35IG06&^Z^J0I 0WURPMI?B.FS_)(6QZ
MD83)"J*1_KR5*69SW&N[@WZH9-J0[B\$?EZ7T\8W["879E&18?}EXWSSU)% M+509=>M-
EQ0B(;YC9>J!W_B|EZ_)B8(M5/F1!T MD[9(5*RA,()0A:GO: (/@'NK'J)V0U^T6-.MHQEUZ\$>-B;6
MQI6NQFDE4Y1VB*S21)OV,!U*L0S+_)56_X03NHJW> 7#IB189Q7;8:%XE_9- M\$/&,[@1P%MZG/;
I<6'&W5X^EZ?VEA**A=RR;GU4-FMCWQYZ@+J#EA8B8^ M_>:2Q6QHYUZ+VH^5^?
R2,XZN,MF1AJRIGI@ZC0' 'DV<9XSfZX6K<,MGYEG^
MLN'FRQTRH=X/M(XN+ZF3Z"YGF=1,@<[YHS]1BZR ,U+*N'D.7KC10"\.V;H\$ M"6B#X@R0; F8-
2D([T+B1[06F3%Y2? 884>:.\$!JF2%<=/.%[4:C9 /2W/7ZP M.>31EA?30KE%U* Y0-="U2MRWQB
IH3TV9^RM\A9']I(/3\$3(TGPQ';? !W\$+ M'&=I(#MS'6_Q#B/Z:T0EF]=\$;4-B,P2G!PU5.IW"S=?
=^NN !H,' \=5\J^2Z)LETV7I]/C,-XMS0,IS?.S+/R^UR5CDV^
ME&H6Y\^X];ZJN^@+S#YH&8.,:8)QVR\U52@BJT[!W<]&(4L@X,>.#79QD
M#*CWZ%4M1*N46T6*-0HW63=,BIP1[]D C[V//+0ZJ\&U"2+\$I0D39>G@XSUY MCFCW]R'M7]TY48G@]
[:2\$L[=U[\$,WFQVJ42HW'H@-UV46\ (K<71I?DHTYD8F
MN\$LF'"@M^HS:5B>U[F=I)\=,>)NNG(R69HA4^5[3S/K#E,59\E<>6?%J8/AR MK\$%H[\$K9'S 3T"07R.LP^
@29IH^\$ _&EJHK-0D-U0,GIU1V_5X7G3AD+M>H@ MP&M:[[G](Y(\=@X,DR%34+/][@[\$0\HT5A3KDL9G3(GS@TR?
+L4(M=TLJ2TM* MJTK+*B.>]DU/7XZ]F6,0H0GP6@&CZ,QQ\ \<,+!>IX;>H811.DZ\TRJXQG%D
MARPV9,@S(PG4J0H;SOYE<-8\]?>G JD_#]T)('29M&\>-&YZ3"\?; .W+V.X
MI,EB^US@DV0'WND\$'0070_I#!A3;&CQ2=W6_F]!.['?%="R)M9+UOH"ME%J@)D)7ZU3C@)FCUWTXI
MS%=/,1+.GD\X]XI/A]74!M2I@F-\0?{3'\A&=A[)"<:PA,16N'I\LDX %<)# M0= ;ZDQA#Z\$]
[TI/G_\0680Z[8L.5>-K^[*:(@L/:WNW&3E"\-=^ M^=0G:8?%M0_MB@^+A&^2MJ"17**;5@9<'QU'-
Q.>=DKVQ[J])C.GZH*K< M NN-DD1\$QUGUN5\$7M\$&][AC7J3D_^)[Z,7[ABYZ2?% CF\$B/MC9TD,7&#Q:%
M/PF8+D)#J\$)D<\HW?VVG A@W-YKOWN1)M\$7]N*3D6:=S-V3FV#IEG-1NT4!/ MA* .<@Q=^;"20X?<^*^\$I
M40&#? L15 \$^, NUX33NG#8=1'9ZM UC<0M'0!XEV#DASCNIRI(ZDN!1[5E* ME&@5'TP
^/[@2V""."UT<,Y*"+G)W=1;6LC,0\$K Q-HFXQ+BH_.C/:]Y:<-1,
M95Y4!20 "R\$AHK>+PXCCJTJN/0*>N7"BD^LVGZYKS?S544W-"U&,DR>?,WT MR'+: '4!HU4@I0&!XU.I\$*
J9YQ/_#2\++LJ3"V77>@,6Y9H(&!\PR1NHUF8 MS:OR[* 6DPE0&R\7H-U'Z B623TS=&/F##RG5; ;9]/Y07M!
(3QJ0D+YHC^E M8^10&4M7>4 MIZA. *U*6\$H\K%0DHXQXV[08Z8CMB-0F&'%1>4I>:,TR6>*
M'5^."%+9KV;\^N-G\NX07^U#KF=GT+((^R%2Y8:P 3S#0T343"0_NQ15 M?SH+:.C^@NWIT=-,
MYPALK/2E&\B/S/>X M5A5CZT7)K)Q+0NKYMHM'/9@>E9V\$6G.
DMTWS6CD58"KKQ"AS64FW>\&*J6, ''2J]&5FU3 M7U)!SK S&[R[-?
#:NR=]!7W>DC\>9U<^/,K5JR[SIF*,.0QR&7)"Q;C8FMKN ML=RYS6"EJ%Z'[@9?4UN +=N^,V@IG",1\A(B;3:
(*08SOPA[2@7>1.2M@: ? M1WV1=6U-[0F"S#(D'KJ&IJ\A.,C:F"*D?(F[X+>VW-#IT7"TBVLR[U,4UK3_M
2@+38.]&EQ-SVS;]J\+[#D;HB]();A3>\4'RJ''1KYPNCDA4/V:5@B_ ^*K M!W?M7=X030X' &(_@-K^I8
9,CMD =?:=1K(MZA3J]MH(?>EUZ0B@ENGSS=+ M)1T\DOSPJY0\YL.D#RU-G^\$ P;6L[']/(*+6?
6&1V6,+0;'6JBB)('B95A_9 MS;/];9H:CCGM&7!^GSM^?>XF[\$@8]:)[H+WJ]Z+H'=RD* ER+U3LE49GS+;:
MC_)GV^JE2;1Z^1F9-AX!G.+ Y'Z4P^,!18X,Y1ABDAR
M1T=Z<@II910HZMQBZ21\071L%Q2^NC1]IXM;Y:RBA=?Y06)["V+5+.KT=\$-L M\$8;"?
J\AVAWFE]"@=KK_BZG\$)%4,!C7<:G1WIXX@ (Z!S52\$-2-9+9E]R%#8 MJ0[6]^ '3US872@>
(99'#CZ@+V/T)UKF8H,)0)GEJMG*NWA10D"B:/*;)I>; M'8<;&+4YXQHU;1(=IUA6A9?)I'3+&;-1YE8
9^!R^LDX8AW*LCH>LYFY\$+Z9 MQ?^XD@;R\RT0H0>=?@;78>4>[(N\$J>+TZM(W@FF")D7W9W*1A#F[VC00'\$#
M!VUJ2P)EWTXKI.T]=7'53&L[?^06EM>\$>\$P0/I@Z%2,M.90QZ\R, MQY=]IJ.0"R83G:
[5B9N !\.;*0=3K_H\$TIT;+ NH0*2VUHGO;C)JY/\$,5%:'>[
S5I.!J*I!&5^7D,+P\$ V&RR.R.EZL\$3FT&TV(50AQM3X MT\$@Y'F"8KI-Q]>000
RF\6\$4'"P8MTEFS[.H+6,IAJ,>#"*KUJ\]'E?>8P4E MK>/E@5FY43A /34XMP:%D/S:#KID+((G ;0QW.
(FZLBV5&!A*1+!-JKZ)LDP ^/J[N>0->Y5/A?IUQ ;X-AP1JH\'-GLK\$BZ?SXU^B MS?/4J6+
(_L6&;0U*L!KWLK?AI)5:1?&^?>[8P\ S7?H>WH/=.\;/OBM1B^0G; M1)V/,QIT39G9.TOM*-2BSY/?
M>K]E_@DZD6\$E/#^VI>YB/BVF? 6\!+9/18 M--!L7N-M* EE?#,Y8R.[H&60\ -UAF+C.\$/)'3L.S??
U;@+""#006&J92W\0K MV^N27,GBQ>Z\9YM_Y^'Y-(UE0[\$8U1GC&CY2=M"@0\2Z?M]2?]XF8P=RT;E1
MD*R'+^^<5MQX/7#QS>D;ZXF/NES>V;"["4C=04^&,^*=^P X-AY.%+/, M4Y\$MHL* IS,1M<-
)M#B^\$_)&3;CT]-<;94PM-8348JHZ5+&&HV,TNXEJ0+ M#V[S=8I+ 3PIF;#+
([/:/77>R56"E1M(%SW\Q8Z"#2?QYDWC/'4""LE,ZV@ M)0<;-?0AP.87NSD^CT9?6LQ>0D
MS*SY_&+0UH9<.,4_?]YV'SVH9D8#N;K&H,)R;\ZE'CNJR@+]'C\$A@/B;CI=0
MXJALCZW,+,SA60(I807+0]"I"FRRK',>/0=*:;!2+?&J\-%_BL=9'\$:B'F' M@7J+0*D%CG0?/#H*
(+1R;C'JW)A_0?DV[-YS\#)S\$RB3)\$Y_#;!K\$=(Z4\$ MW6<*#CL<,><4C!E7Q78>JH;NP^J4M0)<[Y9<+,C7/.
(+4C):_GABW6A8'3N0_M0B?@]_XBTT?H?_<.U*;0;K< *+0_?CBOWF[,3 ME?
5Q;0BR)BWJKE,09%P00K4=L03^L\XX_MXG5Q4B),=G\$07G] *US@07+P!6[Z'R[(SFDYZ9)JA,F;/ R@0
00VM\$B%75EE?66<@ (N M@_9F:;!1R+QH1\$POT0T^#@=D/6_W+S_QW\$ 388J.N[6 M<:SP\$RWWZV?J?
@U+ /Z01ET9M#^DTW18X%7PH=NW= 6I6X_8UI'NG)J_CUKU MB#I5/#\05E4?3\=''.

[J'BL+ :2;5#9X('\$2VE%,?'WW/5=M;&[I!2E@9/%8 MS!YIR:6"F6>+M).LO : 'F:3/-GR+.-
..KDIMUV>W>,&OHBT48>?#;MX!RS%K M\$['-B>W0:EID5-DXYVRT!^N-]#(/\$1.01-
WSOJCL8HCWRI"XU/=Q[!;^+E(>L='U"(AZ1XW# .AB?V(JUI8\$X M)OG^Z72K]@CG?[_IRI'H(CB4>LH/.?
UXJ55-== "C0;N'!C+Z[+AMV5%5YA-W M20]!9"4SH;3\RW>\$&E2WR2N_/KUAC+
<*L!+_M>I [N\$.=,F]6%&-2[D0(09W MH9[JQ,7=&N+#[,OU:#R[SVRI;3!V-I7JNWC\X[SW00&V4-
#&D]4#6K%>J= MXX\2W9:4=I8P\1*Z?*+0((@0;'JXGMX_) 'PWT8I7 ?< #-V?NYZ'L_G]2F =%(K8<; M4JM?
5[41FX6XEQ*9<2%F;^B[SJXD%2:N#7UXZN\I!9BL4WSGPP3?!WIF2IJ.*QY;9(Z*I\F[!|2:#L
M2\RI;96&L2E^>\KC;ZLM60)Y\>G62U'-73&J0XQ(S W/7\20& +/MBZ\$)Q& M(#0& MXX&J@5.+TK/:[!55-
TVK#046S0#HF^6]>WT2?S M,\1G!_D9F)L&LZ*6%3\$NY). '[I2^D+DI&N@,X9TG6MU)\2=)L^K5\$1HH-7"6
MM:MF"60W&P>S+KM _V079V&'S%+J&)21^PWF%ROIA"6 +]@fWB*E/KN#C/#W M)(F33Q,=90"&@F?
ZA2X&\$&C#NZ9%VM:AWLC"6 Q>JZPZ/+D*>]9V#*\PN MM;GP+?M.5WU.K4ZY>:/ 'YUE\$46ZDZOK"ER<"VHOM-
B]EYZ]RD.>,&Y%XT79\$ MB*%#;,:10:E2]00Z8[HM.3T<"L=A.->VNW=:C\$0\@]2,^/?Y_9NBZ\|L2 %SH MS*-
<0*/+7A[9B"5*MBH(3V2: M' 746G9C9BX19>!' \$F/Y4]F?FV#Q+55^#?R!P:(|1ZQ.LKSQU*G)JV4!61S)
M;7#[(=31) 3RV37I5%?Z@>CS M;>GIOM' M #&9+ L\K\^XJ!6'\$9A:.*1!%P=>M>)H6/;7YSHF#05"Q=L75Y?
J-X)[!> M^;.'V9M\$^#9C+XN"/CRKV5T3CU*X'MM QZH8N(AO MWL-H-TL^7[#):.7[X';/Z;.G<89TK6-
V@025VI94G;.=54M2-A10Z.POK5^E MITY=BG[M>ZWC&-]EH8?1-5\$>!IHZUO^%NUX,2K,#SJNR&H(%
87;J9@EK"-> M7X.8B>F!Z.\$0*9EDVA5,/AX:EXR^#HK B0^UZ5?>\$I8<?<
EJ;*0RZ:R4!' +4 ;H\ "V!JG\PO.,%)9M8+;83F5BZ"*-)1\$?3 W=1^%, [0]0#50D MM \$'UJ38RR"&W*+"Z=0(?
#G=E439%R'QFN=FW;3A^I%:0 MRE!+-N3NX)#\?1Q*)X;*RR/N>\$D9\A!&K126Z*!4#J'=;)0(5UX^&C|HY5&
MTQF-RDJ_UY_TTSW/!;1\WVO^;E_]5N[507\?OH?N]\$ M%V<5-+|0Z\$0S\ ,/E5^=OH:7CAZ?
[MI\5#MTR7/+;0S2>/3T[DC^0,6U#W M;'COHZEY\G'3V6,?(I^?+1';K1FA)3R, LS="68G]/CP8(\0>^;
[VIT5E* MUHD4U/0@'6"" *#A\$?^&F;IX%SI)%\+*[5U8,+&VN%F01K,2A80&GV)RYNO M?,-
XGBDN!WH@05/M/QKH69CL1I^:A^0[3>!:6X\$K]= \$FDG;4ICG-MXIF?|-./,J;-;H=0 MU/%+EHKU=0XCW71(8?
@U[+PXU L9%MNR(1\ESQ I\+X(8#;'3+7^HP.5:9%2Z<(X?JZ@ ?UJ/&4KVY[RF'96!FG M
_+N'QMB!CM44\V8,M@8RGVAR7.)K%^] V%VM!*J="B?\$(?=NB05WUI@ \$1L2 M+I ^8F<5L\VJ,8"2)ZN3//V-
<=>#S<=> 9PZWNJNG'0DV.0*^--MX)D(\$:6--X M-H;ZR?X&.WS@456M=KB/B=
<[W2!YP6(VL^NY0V&,"E!5";\307W\;BS3\6D M];6D \0--5Z'40P5S0<^4/7AW!?)AL2"S&ZA7XL"FV-
UX8W%WA)4HB0EGJ' MSM6?1'?SRVF@-Y!S%9*WQSM56#&7\$WPJ6P=6I)F\$?>L3KK874DELCP-@Y3RH
MD5.Z1+B/[,f&WKS"&X^&VXOMV^U4<"ECIUAO M7^IZ8TUI+3ZWKI/Q
%T>A^E4\=,]=SU0J \$B#10J1VQ>@N!'" VQ(TT 7=*'U MOHC=AH"U\$C!.'XCPIXNNB19A--.7Z/
T40^)'IS5=NCVRB@#K:1J(?9GU;. T M@F7'KT^JQS/&^:"\]>*WWH7^JT!|#>M9H\$GK!C-00@,]A6L;#?
F0;U(':G30 MVVY@)Q:7(-B705"JP]C;:0NS^--Q,4\KZ^!0\$S2=/J==?*(<\CSM<5Q!D9>0
M/IF]N^G=DXD011A5[X>-M]3ZY;Z&CBC>70D?5X 0*8[^VM;:]LF-)IM%V3#Z
M_Q9S+6S]93H58VFX;IYT:F6A0';^+^V#@VXQ\$5X\$TR]^K5S5L[,K&Z^?/GY MN01@3\ (=B0A*'"NU!
<54K@KI;!S<9?'55\;:"7PY)9RD>QM:KE'?,64J'T4!V
M^B%6W/4**8&L)0GV;V^SD%0GK=5[L8FR+/-8S_P_K<"UQIR ^;9H .FI0U7C MH'UE#>ZI%29Q ?::B TOM[?
B07/S4;Y*<=>Y_YA^V^+],,XY/H[VCO,NG%"H MY=VGL;T!SG,+,E/R5][Q0HZ* [XIK\$G5G\$6=6ST)7K,
[\]JA;50 Q-?%]*:,K M-%=169H0+!P<.VFJ3X" 'X:0M=C;7=>WJ4^I+6U#5'DQE, :6\$@TTQ]C:8[;E
M5S=S'%ZYM8HQ4AF<=>20VKKK6R=S/V5!/6T!L45%V>&! ?Q5_*!&B6+XYRHS1W\$TN4R4\$YT5<.-?MY.HJEG07
M>(N-&' :E=E=XFDF3V1&FZ>W#N])\XROC44>6U.WS&H;\$8S,L/T>@Y#CW4L3J MM'.AP[-
>VF&X0Y)]^Z_ME>:1@^=3+JT'#;NCMBD#K5[?UZf; *1@C!%'0,YUU M71S7H@DK
YR^P39ECLGG!'97,62]V]D)?D@<^CZT>!?3T7003- YG0UJ\28[!/^ M)I>P<;T W%Y6)W!3N5/UV7#
[JH&GVK'J <-!S02J%^M4JT&0C@0XCGPH6??2 M8-;*ZH>^ZC|FF\W:E;F W--4BLS)299\EZ\$MP*07M?
(@.RCT 7"JXT-3GHG8 M*UM#&UW!AS'40P^/.C%\;!--^?CT"@/I-?L#CLY#(?L6B]GX&^:99B"\S#;
MV]*M+J.KB;#0]2&_ZJ#=[!|! ;"J]2300VM6YI%V%CDU^6'FRW""M."M.+S MNV5L7G&:)HS]6.L1*\$UY=
[E+9A*]IB>YB^3%0[!.* 9;\$>RC .8"*UV/*:A MF[2J.!^D'? !DHH.
(L':_8WI=/(&3@TAN+K,=Z*F>*KM6N1P'MNXN24R+::I MJCXJJ3MNZMG\Z4*K5--YX(B!9"ZJ";GWR6\$0D0-)S-
R5*MV+R\$11?,EHO *9 MD[F#FW0 MPKXXTIEH-4@UU<5M/2B[WZDS3PE,Z-AK96L1[(FV^\$#HKVJ\$&S(MV1
[ID#(\R\6K_53>&Y.-W /C.N -4P4 PX^?MW< M9EZ"JT&W&873!T=/7U30 VP_PY_F:%U0:EA51 @0B1,
Y3R2, :R*8M6-ZQV= M? 9@IQYXI[F\)CB=T6C(+,Y,Z=W%*4 #3AYHLZI/'0IJZYZ<[ZR[IW(08WX M\$;M,T!
[J4((Y#;0"G)BYTK(P_M_V\$IP(\$H9YZDW_);1-3:4RHB]JLIF1 XGYA6>"DMG)M9KN\$=21-KSPLL(\$\2>>>8
+5ZRHW&R0:M,DMERB>8+ V;&:WKTIE\KVY>=[&; MYL%4>_T.%/5W\!@!ROSUY^-\$Y1D?)4P0&
<[7!JJ*N <=U'N009%9+\$1NNN;R M(!%QSPPA()B;XP5#B510Y'17F M&'1\%33W,7Z:1KHG<27(BAFV/Y/1R@-
-(L >#W7RK@^93M."ZEI9Q)Z3(U# MLKL5?/VB;XZ8_4%Y"-TT9(_HWAZZ%&H;'XFBWT M6V V<^;DSHE:
[I'QJH@MTVZ^9#HI^^,Z?9QT+4JY;K,7-E;/C5.8HTMUJ^8 MAB9?H4P _^W-
M3L#QI.= KN:E50=5^3R_ :CD4GR32-TL0AY^JAYL37RX]6K;WX?B0S@>.U@+,C!VISZ5T[V0Z!Q.-
S,2[0Y, _K_0T^V_R0(MN0"\BP6F9#?N[\$KM&81K @00R@//Y,9CJ:E&\$@9W=!XJR J>,,
M2AV5AXCL&+%B1^\$V(ER_32QCUK"PYPSEM_7+UL?.[0\1M29%MKH/E"5-VKJ' M\89G<:->_1YVHT[8M-
+517D@!)>KNGE+-5L;:BW:V M\$ "D%>]99:*M^6."IH2*Z-);'\> UT>.Y22[<=)M(K*9.)UX?-Q.(Z*0P%=8
MMD7@"XH/^X3G\R+SU_I^C+KA"R805I_\$!5(Y]8:U;X/J*%7K9YUR!(8EC1< MD<0*+C0DG.NO=PPFY>\A>
[K5!J._2DP =^;:Y;5!WL7\L^9<1.E94>?'RTJ MZ%<:2#NVKM';EPF;=_R!0%J+=%-
_LV'#0KFGKZD[WRZIUP09US^D[4Z3Y]' MTM/G#;E8NC[00+6P;6<21K0=,JZ/.5/F.F0 M-I-1GR6Y?
EZQ=;_WOGUL.H^2!*#V-7(<217:# ^0%Q_91F/1R!=J/)1\$ZL5I M1[3:G=(Q5:1<(30B8(-WKNI90
M8;]=0\$T()0(T\$+/&;%R,RK41\+AW;6S:S8K*)\>LBW.@UR]URS8WZ9Q0 M9W:2*E
2WC3\091:9VKD3652F"L4M"<8H*6E);D6 _@VV@_Z7G[!(A;3Z04G MFJV>IUA\$/T-8ZLSUZZH
P24&F,NBEI^0N,XN6,+L^';FRGW"([460(T\$9. M*(A\\$X<(F6^ [?1]3C*2,0/3IZ\+CEG6ST^F)2P[A!M?
9T5IBU)H<)XZW_M*@.^H>' PV/Z>P #]!V4CP-H_D-\+=.\$]@0!I_XP;!VC/D=!S3>H)U#GJ3>

MSF=X&H@25@&F7\$FHED&TJ(\$C(6 TA^;SLR.W^GI?>G!1(?@S:9 I5+3CFUP6
MHN_@?;/I412[;:#GGU+55^Q\$P^UM)W]>Y\$047W.^ T>@Q5YK)>B\$-B[)OT
M6>&)K5E\3D8FM;3;DSV43]Y"F%19T5,"/UAK&05?{R ?NHQ"9H/MU9ALXRRM M:.*##=%[#:Z9-PMV[;:<
G/ZW3RV>,*8*SL?/02*TJ^KX6S"Z(I9%\-R TQ:FJVR4H, 35=!C|FN#4 !,,.^03A=,4T3}@A>#40.60"BM
M2(.MQZ,S[=;05)?N):UUGZ74-.M< 34]H_N:|Y ;=)U^^)OV-B(3@DL9IX'Z ME(L/|8\$/B)'',
(ZS;2&0C\V+ EI\|P:;#<&MZXC=@=J|!ZV@|B=@GR^1*0&& M5T@-IDK2Q6ZW/E4+;1,CQ1&*>P\4)@/) 40-
Z0IQ|6(P&(R2-R<9N&<0EI%6 M5\$&LXM)8S1|Y0/^E!,AQ?Q-*ND0AH^=(Y4H#<3)&U98! M'0MYAM
/MG1[V.=Z"W.F?H8J5' 0?WG^ MKZ143YK.0SNC&N*XBL#>AX9N/YD\$[(F(UI&|4N%OK*Z2Y?V,V%#H9IG-'UH0#
M8BLZ@9;"PU)A7Q#\$!\>L2.?0R0DI!<"| N%E70,4@4N\$ 719)6U.20Z6+T% MVM(\$(?V2P+Y(\$M"D'\@5;:N.?<
PK>78'10)UR33102V\$QL)R?1V5'4(:UR4JU M2|3(2&!.D0::,D:6SL7M|TMWD&,XRC1+M7,=
)PA,L2WLLS1WM,>H^?J]WG MYY?7<8DA[L#V1LR^N*DU72A@<9=V\87 ;.I#&FB><|:0/EV*,MU,,0EBSM6X
M)2@Y/9<&"C.=I('ZC:|D458:Z+*I"FY26;*PQO\URZ|5Z4@#J:&G :K("GD
M7N=J1T\X*@J3^&@1AKHO!%JKE'M.'U1<18>:E% /6%;-!(RF|IXK+SZ> RC&0* WT*:@:(W.XTT,\A&JB4Z\$<-
FMG= M\$EWS"2/0JRT=#KTF#M%JIOGE\$PS/VO+5R9WZ55J.HSR#>EQ@/2\$09@;@?B.8 M(A+W)FG M\0'/N5 XD*>
6<(@#125-TKV)OH40I^,.4ZKXMPV*%N)\|/2E-E/|<4<-F% M"7W4GXLH&B*/7(G5)1T&
MZW<)3(20F6I @BDL/#22"ND#70?|]#7;C,"ZCI'F%M^MZ4TLM\$VM) MVR55N@Z;4&|D*0-/4@
!2RB^>>F8IV\$!X!, \;I;&|9\$%*/T@?E9E'&8/H
M760KDFB &3&SH^=02:QKHW|74TE'+#+K#" :9W1H(PR01))MIC M^*?7Z?T#QN??^7&6|Z70&=G.OMOP^9N0-
&OK#?2?;E%5+X|;FT>^"1RF@4ZB M0P,0\$0VPFGH=!!-\$0KG/A'L5D')B =F\ZG6'5*8!W?0/,(CW-%#%*ATA0P-
| M?9+2>)0;U#R(:0(0+,J(0IRL?|380=<@-G2@V\$50WGL08,S9GT/AS=M4NEP MFFD9+
V>,NM5\$16C@5@Y&;>0/OEEW: 8T(&5GU|VF S@0|'1N &CVA6@7Q_0 M0F65@A!K(?
_A^R!%GZ|00>;V\$BD5K/L|?1.-CN)X;BH?,R:;PLG*3I S>?J8 M(V_19\H&
<8&^!/KIF&D<=0A^< 55K!2DI9!06TI06)0&DEK8 R.AF?P-;ULL M-) S(C:;|0)4\ (2^R8!\$&=FLC?
XBK29/5DAK'WF (S:2J7/0 :KMLV\;ZFG M-,GT07FLK.#LM 0E<#+@RF2 ^!8SE;|EWH7"VG%8WIR^*.,
(+JPQ,SL0,)ES M%,!'(G1G8@SAXD?U.3@@7M|0W(-TM#M M"ULC?0:#PG=;LU#5;(TTD/\ZH;B0*N2\$-
Z6^#J3WT |F%?7GFUVSXN? DWGT MEQGAW"/%#18'0,P4=RBP;3!5R/7P5*M_G9KS'QOH*IBQK/X"U!:=,;&??
1TP& M?G!?.?BKMB-|;:';<9&HG;.X."J(/D.V|, #_J6'UBSVY<%, =40*6;K\ 'S0-(MWI\Z+"EH)&<(&#(M"?
UA4AM:R\$, #Z:2C#?SN6M!);RA]*4<-Q)&5M6DS +W M2"H'E-)M\$1=:|HP&"B\$BMQ6H0\TTD,P!0_6!0?6!Z=
(>657GWT|LH>.!JR%P M(")./YF;!G)_1_5IB')^V33_61*7@C5=I/2,1#3\10| XS;I8|KM@V*: #L
M29K !F8+^S:0|ZH1;60)B25U\$G=48(&4I\U-F(\$7D"XS>)V06_00 AP))CP
MA7L_KJ%,T|~/BPU(IWZWY*F3Z7+= B|U/^?FT:@HXH("D/WQHT#*C?'Z/M >'3/L W ST*+W7/(&_I0)| B+?
#M**JI M"E:JS&/ WA:R| N%XX*.Y -*:F^S&^D0&WI I'>IQJ&,RCB4410 2X_,QUQ MZ5B T\NG3USHV&C?
_K8T^7C8WY=-.M)|3J0Q@'XMD0|(T.6 (+S. M7Y<^55@E 6)M|~/|>I#(I-3.5+Z=0/+4:5_NI?W^?:KG\$N)0B-
"QGJA!Q_H4 MU%_@_&|;|(?I0TF8|)Y2)+T(|5D&\$0:2_OH+*#EMC|=R\I.G6,E"YG10'B/
M_|P28(:;@M2\$5>22NS=5V;=09-E7N&6Q\$Y/G| 7E-LG"@6(#_IJ\$VXW>A.>?
M./L2JU^!NT5=YBT5WJ.F77J_)UW6&|?%28_?<K^;*/J|0^_3EPVA0.V<5|N0
M3+V&>X007\H(#>U9Q|JPK^3E257|I703GWZAWL?#-|,A?\$6GIVU"+;ZW^YQ/
M\$7S =/Y\$HP.E#/(B"CE&5R0)M5I!0Z?@W8|)#-6 WD\$+=)U.9EWY^2+%YG'1< M'BQUV|W,=G?N>X5KH|
CD?'#WE,@ M7WA+95Z.:#X?QT\,QIB@_AM|QW55-?MC4:EB(*(|J5#M*E2(N(@(' |\$X4 M1)J 2(= I\$!7\$!
0HB)2I(AT*4%"D2X@(\$&I+<\$, 32;GC><|Y|Q GN' >> M\9|IG&| _0\$;8^TU|MZ9>Y6YYF|FKKG\RW'%-
LT3_NONJM.)X|U|("O^NR^J MI1|R,.IMA#.100.IX*Z\$U 2Y6#?&C@VXV>HW'OE7NQ0:UO|@0
MV|913+U8J) +:IKMM%I8,.K;((IWR=4|@B&@#0T='^?/K2\$+FBL;8G|+W#J| MY|JG*;\TW=OZ_>-
UD=F|7KWY|(|0|NLQD(U; 2LC|-NA6|!|+'.%*00977-[R MD4TM>JJK!C\|4N3=\PB\$K,HH?
NFT8335G0A_N|7/&Q>[KS-M-\:9@)4 REQB MQ(EF=|H|JG2AY^-J|4|/; #%)G0'&K+9AIPV!
2=TO;W2UVQ%Y+;6CRZP'4- M7;0L87EX 47U:MJIJ ABMIC;=(/3#;SL!X(G\$+I#P(?D8M>>I*@7PRVSS@^
MEI+=8,(Q9|_%4R\RLKBUL8W|^N&?;#AYISHIQJ/BEE\"R|609FR/SER|;I@ T"XL3%|DT\$LGKS
MMWU&&SV75TGV4(ZV*3J0X_D4C,M?X8Y GA0+4DK+6U4%C&\4<%)QH=@AZ%. M14HMC;2HJLY+;=G4_\\?
Y"NHGDTc^9R-4'*BY.-!FB7E#.WS.!NA3-03*=2< M9;@=^3CPXQM7KI760)8.%80&0IS
KV@6IN>T^IQ|=C|(|0)H/\^DN0G%BI,D| M=0Q(VJ@#7H7A?J3CN'#!,F\$8+'/7#EI3\$|@;&,Y-D<36ESX0<-)82-
VL+0?>J-|3A),*0|:W./_U7)^P M9E\$YFVSRFTC>|3,G|/ EH;D^Y%S'&(F78(D;+-4JGUYS\$,
(\ M+25^W>8+\$_MHZ%R13KRT+Y5@FUK*U|1-9Y<#4?)\YT 4X|WWH8U|+ =BUPF"EBQV|6@3N8
M2U:3Y5H"G5W9:|10?)ECF11F&FXNE2#R5WQ1ST#CLKP@P:;<| ;=0&>7E)\ MWC9.?.OT'N?
2+W,66K=K3""D0JJ:(NS MCVK'- \$PPJ6=H10E5;K&2SE2 !>9 M_1\4K9-L=Z?2JPV'.F,R;@R I3E^UAVB-8;
|U+W;#CP1/"*K%<&04D0'/H:U M@6_|(|40|>H)@TC@/\$MTVVE=C; YYJ#M>=^@"6@|)*;ZJE\$@*3KW<70"N5|1L
M"7)!6482V"&"RZZ|]/<^BP@^+?,9NQQB|9? SH\$ \$ M+/B,0I=?L.A>K ;VG/@MB^C530R6!2900W"S-
I0|0900S\$2^ED>^RS\$)8XE M*C&QR\$">|!|6KS>S+&1RGAR4*M-L64GC%0"/\$,1_!-2>/_ \$@_G_)N'.X|0
MU=<";\$\\0C|N773;TDW@IL*0@XZ(' ^FAYJU3I@E'>=A97*GO BCVGNM\$H(SM M!M_58-G.7TDJQ*3;=[?HN\$_-
C/1LQNM+GEMV-%E.E;0A(|\46R3V^>=0,H_7 M
D2[='YS3NULX_LTCK1J2:VM%92\I)KQR?"5/SBGDY|16:MVN=X5@("CQ0XEL!>=T MHWS%\$CMM\E,'E?R|4T\$U,
<3,\74,0;)!DDB51Z H?"SFD_-IH?NC6G0JYC0* MLBDLA*7 =;TFUZ%EI/C"[G,@\$^!&H3|T@R?
E""M|),PT0_(&S+!5+X*M5,QD5VY@S\$XMA?,&A>P%RVJ/?_OS3#C=>|;@
MNJ^7|I'I0\$3\$C6FA6??"!-5(S_D|0|P!;8IBIS2F3GU\$S&AA3MWV7\$>BSEH MX0).#D?*!-XLG7WLO?
NH<(\$76| (RZ0PMWGOV46<#18^?0!%*AQ1;\$-Q,0N&J M%1W4=FBZ*
|BZNTRO*%AJKSYQFG;K#)P%K^H&AHAWKNE5\$J*L|61?4'>8/#
M: "&99=A0ZYBK^#QK.T'!.XZ!2.'X9VD) />=AUV9/_#W8!S#X\NX>A5;QR6W\
MW+4 '&RH"\$3<@3G'K&* -5|/E=62U!'6L)UB,M0 GD-;D6.=*;0^%/B-|7 4E M RG\$K\,
|.3=M0,H0I^5&I2Z_0L)'U*J^|L|GH2\$!3>|NY0*#@6W@*V0FE07+ MD8/N.-,2>*JU!>|_JOY3P71U^!J_.1DA-

[5J% ^6K6MHZW: .Z7;2IW=0S[M>G, ^W#]]FVMH0GNR&!8ZPL0!!/XUC:G\!FE'CWFF-Z.9U: ,!3F\$+TP->7
MYNN >91/6Y^D;38}@ACN26Z8,0:E&U? =5\$SK-3>(%BVR =<3YNU8CU+
M1Q"G*M_XP9R:NUIS"#7/KQ1]JAL#2YT/7!W-/ : \.0(E\2ZAITE1!2+ =JIX MX7^NJ"J%,HZFJ('TAG_V5'<1,
[(I)/.E#YP^G,IMGHYP @\$J6=*C.8 [C\$QR M%2?]X(K>Z.0,T>>0<:S-V#4@= M:8U0>BMF#4
0*7I0]=>)"T(6T94 F;?:02+% +3\)0?% [1]^I\+9^ZZ_NPK M)8C\A,^R; (B<:J/8EQ3-
&WP2RVE:4AR@4MW,CB <*W3\JWI#]*QW%GP6F,EG M\ V 7STXV4(+ \$5/\2X8?)0S ?K&/G>Y(1C; ;H/_*?
_54XUV\$*>77(7/TTY'4X MR[%HDLM+V"Q+L"YQ0.A=XN=@IY\G;VD9Q8P/PU%HW>WY#A". _R3M'<6B5B=
(4BQJ;Q20P(2D6-1? M=M<^'G=YKT)#V3\7\$S[NJ!)]!+0"8ZA@Z]'2'&/N'V7, _*/3NRA@4E4]B)0-&
MKJ.AI+.->4-QL""M+F&/#/KPU=0IQ9(P*M*R(FM=\$'?48[N*N?&MM>N9.DY=!!/(L@_FLEY0GA;))&^_LI;* 'K
3#3DR=< M%K1W#*;0%CFILE&2^2\$0.\$50_T57>* +2#R%8U+(&CTK6HH4[4,&1'GLDD#@_MFQ16]= "X@9AFA-
>G6&&@Y4/X/ONX*U1X(8B6(!W8/EL&IT<3/AY:XAW(@#/K M^&,0*BJUYY[':DEM\[@02-ES7;]M@+TXX&4HHIK\$
M#0V.6"0#"/1U)VXN\$.HG&7 >008_R714'I\3SXL(A4ZD40A\16!9(#7"GB? M! Y.Q88SD\(*E\@_7 "H8->8
P(F R(HM"=9_R_/' :@9A\$X+0JC#/4)>&G), M!GC#-[76H1,P+-;EKV^(\^<;?C&>0(...8@4/HPHAY.2+7;38
N9!P-P..E M"/QSBN-^4FD)^.74PZ'.+@5CL*-LJ->9[2U+:0^'Q43X;=+@5?9W!N64U+! M!S,3?M[; M'"=
<[?U:J^&J.W13TIT,6,;CLX\8\5)GV\ZB:0G*':NDA%PH2AEZ)-:H,HP3 MRNZ\$-CCPJG3.<3:.0&AE;7:_8@,"
(\$;ME20ZUL:0>]; M>5N0_8*D6UFFT=E3(&DR #4%8J5T AI&HIXYZ00@>@N6,' \@C3,B T[00(^X
MX\$8*C\$;CR5%C\Y6IOYNODX(H\K?(\,Y(-P5[! ?W/-^=10JP+5TH&:.R>I=QG M?N*5M5S'?ET-
0X4\$0X2/C\$P2"PY>0&H^E-8:M^V+XFN&>.A-^JUL^T^42DW MNCA@H6"YDPZOEM/D(GEE]D\$1=
(2G ^35W/R\ &XV:3\EA\63#U;D>4%FX\$'1 M(DG[:: T<.D19733"V/Z2=':9,#7NC@R
%A(XC!;RB;>33X9XHR4(5X5JG.H MLZP10M%YF1)6?J7L\.= 7XLS%\B0#G=-
EZ:/G<,00%9\&Y=8XC074>>R' M_RS!Q]^KA0=58(\$4=35,/%QCQJ*L9E\$!_YY\$J#L;0AYJJ+K2D/'/L/(X80
MR0\HRNI[?@-/,\$&- F0YTHXP^6#N*KW5;\$IH\^00_Y4RVNPL7%FP0!T-IB\JZG.T&Z MI\$SI'.U-
)=95,#,9W'0\3-<9K%';(,;@/G1!\"";/69'S ; M8J]=
_M>W/8@7L\$=RGV=%VB'SD]2+)#^0LST'&FU/3CX\76FR_VW.9SFD35E
M,>E.ASD>51*+SU0,6\$.D\$W8R87,/X0L\$N0*C\]) +C[P_9C]IF-,&M38QPE\$>3)HH,...>V7;8I=7ZF5KQ.
[YU(; \ CLV396[N>A3X;R4-% M<,. "J]G*#K.#3P/5':[/K/9^VP6Q;H?]/.P&U;)'>ZEJH5HU-3_7UK>%T0&/
M>PFG/,H\W9M^B8UCH(G@L>Y]LJM\$XH#;-E)^G@ \, _GD6>Z1L_QWP.ICV>P1I MG(H-
<)>EKRR7FDR[9\$)AQ1F\QAHP255>3^J%/\$S,;0\RGK^2XRFZ77S*@&,SZ MC(C\?8K'A=]QR6LNOU4]\$U?
YH//G1MW*I_WEU"GU2<;,>[^2RGKFU)^BH5N\ M:% \$>6>!.9YLAY9ZV+!^A>.QB00WH*QGNJ
H\V553QG4LZ^T\,8@2]1DC.I9_M22B*&SV1BD+Y730B9CY@;TZ4HT?/7\+7;M;MT[0:\$?*
MH%4E)\$STMGMCI0*#;5R@H%PX[^ET'_V?Z_Y_Z+3F/YW =.7_!8?;#?TJY:J_M0*]"Q
(Q7"VRQZBIH,]W_WKAT-E0&\H752/ABL'LK%AC+X]7F.'HZ\/('T3 M-
F:%E;LSL0A,%HG+%KIU.P@4ZNFK0+&X3%\W,E\.] /=DP\$F&E]LH1>-?.@0- W1Y4_(SJ=X_MP*;
[^~9K7(:;!V6L7,58UQ3EQ0_;\$LM471B[R8_4;+TZ1\J\F=;%M:Q+TWH" M*2M/]V2>V(E=EKWKR-
!,3[.])*:S7BN.KV7H[8+4X!5)/5!T*43#>0%\R0%1 M&A3+D:L2ZD'C76/39)+R-67L2E#0F;>2HT-
TOG4]X^YON\$9?.C,;&XDA)J,* M^"]6B\X [R">IFWK&X2SMF5^#QUV6B""271D@!,'YIL9(HK="NVOJ61BUW5
MO>/T/%VY>6;!2ZI;8W.X32\$*SXM3Z3R,+UZ'\OCQVAQ]L;6:_GHM;JW TJ>W0_M!;DYB5Y5F+3X,)Y)7QHU#HY
V \ '0(?M@5/!HMB+ZU_MNIK*H%?;6@FD"PII.M#9FL0K4/2].M2K&D,W,6UQT8L,N(57,A(>Z_8\$;*Z\$
M9^X\$KP(L!\ '5X.X*R\7LR-V#UI#0Q%87S2\$S*M[@W#E[DFZ \ \$H&4_UB,-)I MR"X#K%L?=%2?
L/VAL" LPYDI555[AJL&%) +U3R<*G)!Z08G_#F_!/\[2J_TQ_M_D?AFSTZT M\$YTV;=\$_""?
BJ\ /3)8^~2W_WCZ5S^F]*L/DE^Q2-Z[8ZXC* J?]BL@BQ04LR' MS2S=RYF>=>)W=0@M.1'43VZJ%H1M],01Y-
X'&>E'W1VYWJP&-(@*S'1YX/5" MD\^J&ID_X'PDL. 0<%(A)FX8+-\?1K< <\$@-S.#<2 @>-B35\$D\ \$33X4H?QJ
MTDGVJ!-YV0\5&U0 =\4#WAJP40@\$N-;R.>ET0TQWW(-B!\D/7NK?)S>03"V _M>L+L).F[
@+K'8/RVWXS:W/OBL\$J;K];KAY\7JQBVM#MPH8>2\IE0BU@\$A\S.@??FB*_H6CV29/,@MF&;16S-GS
M+QU']*=7*0>SG("SXQ@'P"+;R=0Q!! M!KR@I;R_ZZ\7;/C=[^/@8 _V\DY8K1CVQ9-
W\$':MH7/_3N:0&'K'+#7U[17T3/7T9L_#*BZC] MGJB--F4R(#+2+5M9?KDX"J)6QJMM592Z'1+5Q6SSK?
>Y\^W3YCI-9?5SF5+M M\ "0G[&>,0A4*^MSAPG?)!W%Z62NC.RHNEVP_WGF^P9G?
5T.;W*"JUN;D(9Q55R+,@=J5/ M% \2*]&MF]N9_RJ%22E\$@FLT"@1_0^J-F.PTY//+\$;ZN301.KUQ> >]7QY,
MI359^_Q^8Q01X%:@P,XE5JD\L0X=R,ZF-]I0_I5\$,I5.\F_6I#%V(8WXN_V MAO[!_QP8B*F)_GAY'I--8-
\$W&E]%KT:MULM""U2,=P;* "9[F?V+.=^9JP056 MX?L]A?>A0_ \$%9XE9X=1!A1W':J3L#U_OI,&YES]
=9)11@W+CY Y\%F%L0-@; M@SBM4*DP =I>QRAL=H13CQ)DJ)-KX0/#
=K_'I400GP9.])MD#6^46PN8]>,GQ+DEG"[N\$U&'M,_FJ0[*9K[. [U1L
M""\;1.E0;>#T[@A#&,N\$Z8P*2U.3KYVQKM=K2E'XLSGE?+IZU[=&#+)&\-%0? M4T, ?FL# '5^(H7(!FT^R/&U-#
M=;!\!)" :.NC*T,K0B\$FZ4\Z5Y&=>\$-];60M9B0DM,^'@2]!0^! *H;P;G[+RW- MZG221!6AC_!G=9-
7,S\IK0A>+W13R5909-V>1V.DXF[?7W,X<4UZ>%/TKCK? MH"?_H01(QY#ZB.,,T F,U<7\$=7E?
K)4=7Z35^JDF<:K;G"Y6^_VP@:FZI@#_M9U*K[DZ.K'+K"+7D+<1M,Z+F4X'3XJA-7I/.17"C
0D[A:F!>7"0V93Y_8') M"J<4C[;\ID#U7:IW)3I9D,WN1CRJ1?W=L^!\ST\$Z0<;#9/.<2^>9P_A
MPCE&* _U";^SN%F6B?G"2_5_W%?P*^8TQ-'K7]L=Q19'NYYTF)QN-0BU_H
MII]K@2/6'5G=&SMS*\ \$K40Q@F5=VSCF0GAH)" \ %UD%096<8&>Y,E@-2;U+Y] M&2^/QM2A3-F.[I:9(>8S4E/
A@:G?I\Z4,JRH<,\+(\$M+ ;Z0S1R(MJ<94 MJQ9. AE7K3RY4Z]35.1A0X)V0UEJQ0EW-
K2-.)]!!\ \$D0%EUJE7^E!XH0% MFP51R=KK^%Q3^7_ZE+?\$Y+53EV5^71_?#_I=Z*5!2V6.Q.=GNHZ55\C\07S0
MEEB6S]^G+8WB+7*]&EV8\D!;0%MKK'A2P""590Z(4]6LF0@X%)6DSAB ?D4& M?"U:/<7AJ/;+B5KM(@7*F1B
M!V%NY_V03]>4;YT9<"NK&]X?#>RD507M2F(4?9YW^18'F0&'_P_M/PJG[!%
<.,FM:_#&C^7^"1G3/XF00_ \7<850^F_BC7_P!W_P?S9RANNN1^G7_M-X*8(\$]PP2C>\$ \$^@->8PUL_3@K?-
_Z6H?/JK\J6R_E>S7[];T&)8WA5=]KR] MRP")P]N%([]#9*JS_V
7)%\$8QD[NZ\$:WW/'PLOMI/. *BC<\$*L.;7'3E37P89 MQ"QWB%BKYZ)3DZ\#>=T^; !Q31Z0_1>M=133!"?R_K*-
Q6,LQ+\HB'%[7.G! M._Q>A% */PU1Q1F@%1=)Q2C@V?5<:NQ;5.LCV\3FT*?.#]. GYNZ,OV+F"7TI

M'7/GIMG%NCH5;9N<_KF46!."!F4(?V)-(\A#.B;IAKDV)BDTVTN6"KT(*WZ>! M@0<;G+GYS>
[YBMXXK"JEM<\$UD.B.N,@ A"KN^3;GNFBC4X\I5E_#8UMPT[N MTUJ A<3TPUC+T97%V"IW-
Z%VE^\$(A%3\Z+9"G,74N)".WC!\\$4^G---DE_D SH-"8#SNLCP >7R(#>8#@N ;#I M6JE/8LN.A:\)D@'I^U ,"
[1C%#U)I(+0.7B3KCY310Z1XX\./W+D>./' ' _D^/' 'SG^R/%_B!S%+GY2%5<:(Y+BKP5;IK9M8I*2MJ;-S_.?
7S5ANQ%)+Y8R M&Q,:(U^HW6VNNUKR>],0^Y,1A#-%@["J2 JZE\$+^0)KQ ;CJ+9T8-VP3]M"
MF:CC7DW#;+S&ZIO39:21=N&M0XRJR#G:F+J; ,NO8&T%5NLCFB![UQJK,-N7P M;^&*N-XE7JAI-
6Y]D9\$>YVV5[+F,GBVW0#1=_H@J4NN<9+I:5=W/5"FJ)N\$; M\OJ.K=;'0[\L^K1Z\IE5C'%!H_\$ZV)/?
5.IS\LUUVXDMK#D74+G M#]F\N4CG?ZQE<;(J=\$3I)3_94Y^D_A3X%S6;A_3ZJ_ S.V;000"' .Z:US+
M=Q)M=I=13T;_0SY^ ^/_K\"4D,&4 -P74M2D7 :/W0?K\K\KKE=/<>0?PJ. MJ56D\765Y(SM9?WQNO-
"V,=157;4[KIXCP,CFK+^;(5+X\$S\$U=P[&/3F5/+N MF)@G6(W\D+97RU;RL86CS:/!;!78!<*;I2ZV+:6U\ -
[@P:>@DXT>14 & A.Z MIZ.-J^T\Q%QM+NK=E/5L/W5^C?9="TRW/<>,Z'VKTW3F2W4!7?I3#N=6!9J"
M#074NQM'(0P\ 'R'43(6J=:#[5>U''''!@+0%;L*9\$D7JA0>ZAX'IK&_C M)Y\V9R)<=I(PX
(.'LQX\08@7AMGV\5N4P>+)\$@M-'>3\$.@#9'*. -[)KQC1X M18,.T\$GTV#]<%-[''8_+WM'> MA&
4',EHCTF>BS0C,%R\T78 VF;+1R!'J#%7U-K,"]D7(B?):6X\Y0WW8-"" M.L)Q\EP!R:Q#I=BS/3]W?'E
C_%W:C/K/18\$BTO:Z^2T0J_6M)L('S\RE\H! M&CY*[6ZCP87B52%!F/G(_#S\$=)([FSJ<-D\>00U?>(3P3
U0ILUFBS/[I94 MHS)"KM\$G-I9]#%G5\N)' .#\N<0&\M12Z"(L_1%J4+AK0=)%&CS5>VL[?%9!! M/M/SLLP.^!
(T56W_\]E%8S&/1FU+M6),T2"\$;@>!: \UVKY2:--TV_7FVB4! MK=PGTF;7D9:QD*Z]-R]4\$P12.-
^9J]ASTKF]=[/[4WI/0 ;'C\E8E.J I7Z' MT.)@)?!D@1_7YG81X:))VI][J800G' 21-^5/G\Q"@_DE\? M-
9_HC\FA9HWH95C<8)IG:P\]=I(3;[7^N%\Z\69^?>HP@-^ MRS-V2ITBC7"E;J>AB%!\\$V^7&!IPE"]93
(3T*7H9X\JW\:/0>?@^]Y8@\$@_D M>PQ6?GPD2^(@_KNA4M"?U9[DP'0#0HF<#&+Q!
\$Z9P\&HZP^#)1Z(F:'KXP MK#;4QC'3Z*8;J:9Y 1U5_2K8>"\$--EMUJ.7A'6JT+--
,,>=2*057DL"?_064E@SU<,CU]/*%.0,[_OI+,\$EAWXLVSH^HMX,4TSG%E55]/%0*=E0*!F5 M&+
]JK8U;K"FI^F!%[U,NE\|V>ZOL51 ^SUT_TCY\$., ^ MN'I>.+00ML[-22_!E!;H?^)IXJJXB 2&.[%P*U,
M3%X'Z +I*BX+&N]P%@/9='GG,0H\|V S-RF'9G1N\8BS8070ISL*5I&Z\$P+ \ M9.6#;\;D[
I;@DCIM;\C>0C(A73N%":Q&TH=3K_V93[2_\. (?%[J18W\|^== M08S20\0),:2+E]Y(XL%;ZN#Y",\$_2
H0F9>X-,\$:S'S8+CK.0LVYMXL3Z_0@ ^CW48A:G\7\$!X_T,.6E187K3%G
M8CK\$SNVTY)\6R1C7)H&>RRX,RG'<2W03E#4J)\#/\J2&Z3D;1*?I??J-S(2C M*+6T:&<]HJ&U4;K+>H\
[S@5\2*R5'XX.VK500>BR@D.C@09NYF!+^GU/6N,7Z68-AS\$ M<8H+|H%631X5EA;?R\UNB0.*MDG/'=9S
P6'Y_-294A:8('Y=@9Q\I-1< M3*" \$0,J+7I;H(\%"L46UHGF\ 4\$/UUP4_K/@\$CH5_622J%MI0A75*0>\E580
M&9385!N[/:4A8-S!HYSI;@ M6PP)QD@] ^U),RMO;Z2;30IUJ_I6Q*H,Y^K#?+.W@+@)FE>\$N=MTCMF_DJYB
MI+8]\<(_W0-"#LB "Q#-Q;,_&'3N7%)!MK9BI\X\SE(TSWS [YV3R7S1&M/G
ME]WUM*GH9PV:%AL]&2[50*PZ4'98<-15>;RG@]6\0!78P.* ,SWB>IW;CH./ M.0/>=
1Z#Q\N)I\$!D5E!TYT.9W#;, \X\$# "XJAI4^/F;B)W:0%X)9]?!BC\$6 M">[39IFF24MBC.Y'4*P/\37\$W-^T:5;
[;P6KK\2I[V^R!W^62=ATB0)9^<< MW(7,>2CN%Q=^7UCR(:C5*]S)H9?203PC.Q Y/#]!9<1;/C\$Y8 =A,
[;U8;PR_M475REP_FQV7IU++S-#KKAD#&H->+7G') +7WK9G#+:.'^1=M@CJ"Q!<9M!DS*
MIAG&X2W&"QR;&_UBU0#M\$N=5:3,T(<_WMM38E+PD(83U3S=/[J'ZL,#\$[H%E MQ\$TNP?E M-
E7IX)'/_,<[M6)S!8\TP+Z9"&'?)2)(I]"T<0(8\RX@TZ*G>L>=&:2F=VM<
MCB@U[>"RW@U_NKJ<*3,1:)'X,#].#L6&*U,7,'I_?4Z6#?H@U;2EN<"7H>F, M.,0C%:4;#*0*G>-
>Z&KARM71&0%(_N(Z&?_8'A7"L)HLI0I&_8'KN7>?SH#7 M/R\$NWT]X+DDOEXU-
+^\$C&"\Q'CXT"0IJ;RQK\YP8N;C?F#/+DZ4+68A1]46\350:0.C0'JL MLO(@J@0L(&-K.PC,!R*0]N2M?\$K3.-
OW-LZ^>+DJB)A..D>9AE3AM.M<@A^* MW"KLP5+83.S'XD&!\LD:080SG0.&3DP"(N6-]/R,SZPF?C,OMXP602-
N:IK. MK+U+6%'^.V(R+| N!<;+2]\$1N#%#S84S>0.6NM^KJK9=F.)5F\XU!-RZAU\B M?{N4<62\$9216MCS
R'5F%\$#A,D0S!C5-ZSR-\$+D07:\5H.XIPJZ55TR;J1J= M!74*@3,SSBG#V>N\2(TSX<-@B7*ZA\--
@,>B0J&@R'".,6/08E8T[S\$JJ@" MI!0G1 UC/U&V\|FP+U"=,C?JF\X7^*I ,/.40WU;P/>N<8_ZU_?
7]58%=0V, M-+ 'B;1ZK5=/LV!>)V " 'W49,6&=?
(29\$X3\B0J\1V0!*,04YFJ100")/0U%RJ2H(UT'9)>\$VW%TBWX;S1B3I-KF\Q-#D\:=PY M3-
8/\$#N0;@^S!R]\7[YTG6GGJ(/3R^H6/SQ15@3\X%0TN^JH=WG^A@R ,03 M/\$JX3U+|09(*,J?{PB-
MH^.1]\$*FV?U=E?9HF:M6J;+!FM/XJ7@I)] IDI^ M8@I!9XGQ;#D'F+;XMAS(K<;5^M-I!^,F#;FE-
/UDM7YL=#YH+&\$JR1!0YV MF""L@Q-XLGV.&B>#UR*-M/&.\$'P6AY,5R0#&=+Q^+9X&AIX*3@:17_(6'.
MM5!7@,^N:#PG\55_/:L&KQ^H.KL+'',WE7%3J#Y*Y/IH\6GH})4^WX+\$8H;RG3GI7:I:W5*2.-S-U_0TX->*5?
-^*\M^L0*G ^T#/_297H,"Y?4'V1?_G9Z:1LT% MW<3B-
R7V\$.+T>M/\$5>1W_K6VB/+SU(Q?;MLV0ZN%VZ',Z]#;T\$(7U#GK(N9
MNCR&PG=4[HZZ{(3TFQWA+H,]@S4#>Q_08;!FW=(R!W=A5*KF;# V&#<'<9H
MVN>RC/2S[V^UM^%K_'9YW??"LZ^%\$;4><9;-XZ46<;\$;P*=F=G5-W;|LNW]&VZ]N3-J8QV@&4K&<:_I0T"*(/
MEX9X\$/,(3\$6N;4H9**_GU\=;/>PU=7+F3<>+9^JJ\$;0>[*(-P90YWS*#G_
M>UQJ_T;;*=STXF0[#/F&)+V_A+\\=='/1DMI M6?GF=*:]0FGM]9?
KHGH6/"X[M_%#Z0DHDCC\$8%2=*8C6&I/]_%&N&K=^_U-M3VY=
<3G9]ZX)Q2LN:40&^84K_);)2[DR*XJJB=AN8C\$WA:@X?8>(RX\$A!I,# M]19"/"N:FE^?RM[Y-I3-
<@#H44W;0PS_!^!V^X#0\$IQ_G?A2W2)DH1M!8_MXJV66^L:ZVHB&=0=SZL:GW\H/ZU/]<@EPR?UZ1:]%H0)
[=L^K#7JI"P\=A#7 M[^\$Z^KRD][+!>W#>I.53BE\W8-Z59G%TW4#V@)4?7SW]C(:B_M(H?H'WEO;M>,>-
<"5<43_Z8S\$NJB>J\0HRCHZWW'"B050:V= <<\Z**?A05>NH0:5YW XB_M0]V[8;CT^Y F,S0919CN[A]?
V>DW+\0IS N!%9;DL\$J8AXK-TT&K/,NAS'@ ME<0;MGZC6RXR\$DRYC(\$X.EY?<%W@ULI\
[22B%=0QN,B&'@(>1F2TV(+JI,1_M92EMG_M@R^!WU_2<7D\ILR:PIECH6NE*4P0?=-JS+=1!,)-C/8#_R :?
&J8AH3?10\$S_ML@E0A:%=*S+ DE/+/-8D52\98#VJ;@K\N,L[YE]:[Q>>%\(:)060]!#QB.:+
M8KU^>\$XWYE\APS[\='C)@;\KJPQ2STPVU]7W\$K&8M<:F7=#U\,"0U)OPL M[K\371*!6=JV-2\$-
M7UYH5!>SV7P8Y3FXG18HD<\$3\I(MY,%@AT9H4G^R[05
MB((QX,:PK.BLF"4.">'0\AK^+CX>D%OBS>X9SY>H"!V:5V\FW?%_TGSV"8,* M

08I+'^|=1WW=HD,8(:8P\$/U6]5'[6V6N]I>970S%4=R%D,;58N#-TD3DVU MGKG0WT\$&?+;,>T0,]9N/4N?
_L=NB\<&V;N S&\$F;&]H0/M.0W,?TT-DQ5=K? M6K53@JN;*B+2-"%.1L=TQ\$TB?4>)P-
<8'%\0ACV#FB"NACZM8U\$#*GP0D1I M7VY;)_L_9JB<36.R8R-ZK1J1@?}MH9Y:D;Q_\$\$-?ZD30&1!0.L^/>&9W?X
HH M:3-CE];@U066B=QC:VQJ\$/C5SG+C&G3U;)_I];==!0%,@[-19G\$^W\$/IX:+M->-
":KJX<({@.B="SUZD)SC6 90HBKF^Q(GK0Z F\$L& M.
_GIA=70\+,>:!Q(1^*9G@6:0}%MN,B@JW\V27CI\DKZ*@Y_Y[Y0 MG*VA*#)@JQ4-0H\$[^VUA].L*(=
)U_\$6;+4-7,L&G0?UT(MIG3?4406X)& M=D5N?
N.DH@_6FB0P%VPBU/G')=08"#8882:E,F41'>.^YCA!ZTL[:1K:8-T M,N_J6717%
(5]7R^VU*BTJUZW;_0^%QL.L86G#>TK^Z-PP*_D@2 MRAB=>\$H?.RTR(A,[P.S3G9Z/D7QYDEE?
0#U)=J=0QRU[,HMDP&I&03@WG#5 M=>)[%]*+7V3 :.IE8A,H\$'^+U/\<
<)>M80C^Y3HB5*6X>,.?:U#>_]D#R=\FH= MV0):@FTMD&U0,!H1?MM
MXWTOE_8>NS&H(W@*0J#801L9H!C2'>5=%3340;+(^UBH*I@9(8P45%A>TDT[M*Q-\7S;ESN7\MPQ#&M*?#V=-
<\$%0E%.BVP89?N-IQN)P8*P*2NYGDN>TY1U M=;4 RK5GQ WJGJP10_/6TR-<0!-A#-0L_]>;JL?
945>+^J;MZ88H7D^R4 MX!OK?7KK|GE|OE'9E1_#60X|<1Y%I&|P@#HP"- \Q:A,4@M#^Z+:PYUZWY/H|
M.GP]:R"']6>?|\$&0[6K0SP9=?"Y:C\|F00HJ5<&E\$G8|PBV+ XK0;Q,?5A8*& M1
1#AX.G0=6K&W3C13;\UR0%@9?=-S,?)\1E+U2V/4Z[0\$J]NODL0 ?S_MC#,4RU2LAY W' ??(X@_:_Y-
=&)%NA'V9RY\D\E MBFS0%(A&NZ]9'914-(49HN3)HJW[?}\$W&K;ET;M&Z)J@^!8YWH(BM@>;,/:
M= 6T0#R1]DKJGH%D_.\$G U9.].'\\$T2VSU4U.>0)MR>)_&A_ZJ&HYSNME% MOD&QB90SZ9S+"CR*
(6WS^OZ.0/|B.Y9 M?;8!:)31NLK09H!4S*Z_+LE-3UI4#,"=9SG=CL.*V=C8WNQ MT6._:W-G\ Q
M<30ES&0&*&.!#@ I"Z10X_1+I]Q]I\84,M8|AGN)0S0&T7-^=H/;UE+;E*Z*&KIUWPY5M_IVM+^D%3-
TDG" ^W/LW&#E M,0A<4'A "K7\$GM3/V9F8;G-6ZU3/TG6' K00T*06IF'K\$'ULP&P29VH/TOD\ M)L4JK=
[03_U%8\$1I@]?=:VL4*I0HZ<>;?3L,401#4/,T;8\$U6TK('0:1@0] M2EB7VF*5J.X*).U0VXG2,](*6/8?
0M&^X?I<=EF+3A;C&\GG.'ZK/[C|B|/ MFL\$G|(D"21\$/4X*LNLOP9KHK"G0SJTK@YPZ6:A^?
CEL^^1U.'OX.*RF(:8V M)\|PY>XR+'KSWW>+BY-KFX)I/OKB0[Q5]6D;KW[\$:[B.%\Y_"1[F' E9]!
M#@N,^,-2C/W\%@;/A0-> #_W5GT06NX0--]SJ\$'8#C5+ B3S-Z6[9JPZ9T[<
M56E),>1VT\K\NJYJ1!D4ST'NC<)>][TOR5= /YCRJQTA=7)ZG9&8'%P-ADD1 M(+ %,B
K++AL)>5K/_\ '8F&A&;&)\$)M?H;\$%&:I!#Q8E0A>)3#/DPQH47@H
MV_2XQ/R9>XWM50]PF2ASS"\$"RA;DH#_QR<#&\,L8W[Z706,!6U(C+6\$^U-6W_U-VRXUVUW8!0/#RE?
C,M&,';#S!U7,);EZF6[4_#K-Y94H]PP-EZMJ<0XJAZK050>S;H0BK M.!ULUNA]Y;:\VQC6)%FM!Q56V01EG+9,
W%\$ORLS,G??4BE,&LG\$7WU'DNG/ M>[LVSZ+*C9+B#5*Y-]826.Q&
(8)9G,)-8;KFC@WF.@PB:2D/'IK\TCN7N<'!
MY[\$"Q0D6%,I/;LV7(^1G#A7JP_F;\$F;LY#PC@36VZA>9G^7E3Y]0?^3S@V0P
MQ.3PQT5UI]M,06[CCA93.7#N\$V!U_P6K|Z8KG0<%%++>6G"U.07KX5LEI6/[W
M:@2!N1"B@I[(0+Q=B**^902';\$YX* _UM)1B1_ =5@,XIZ0B&^"L,)&@WBU8*B M"XP(H<\L./]FJJ2-
L\$@<[4P]%)7_70Z[|J#B=KI"IE=A8?3]2C7_F<^K|T7_M6\@_ [+V3]=(9%UB" LX;?#5:-V@:2^ DG,--
==ZI]D@%N0Y6)CC*KZ\,H|JU[YX33!SZK3*#?5=XX! M_3/FV^]E);]'[%;6;L-DNH_) "#R3=A]S>1[T09PH
MJK:4#,@(QC_2DPZ!QSHN5C"T/NRBFXT1_LZ!8]NPJ,;\$YU<.!H>^G>5'^+UX M5;\$@^6W)Y^J= @7C0P[
3T'=P_DI':R0]U0V:NXMZ@%'2)!U<#>Q=24D_K:
M6XR%9M_.I\Y:GL+D89E&PB|#_EJT0S10FW.H"%KS=DY5T*/T++/M;*&TNB= JS'-;F<2*KR7YJM-B'F
M1826:WJ6;3Z>_%B-W M&.017;[T-;)"3UF9_N7X3HE=T" Q"L7&5\T**/5&6GE,*U;/(/\$N2_F]FSL
M8^,7TQ[56&B;[M-8<'19H2T)S!,=1KQ6086+9#V\^H0=;^[\VG)][VBDCJNF3
MEPT%LK15)7XIW2WI4]>6/:8(X\$@0!0.--F&ZWRY[4X4VEH<5A^Y6F.U90G MD.JK?-5+NTEG=*X[]?%SI8F
Z;:Y,F_V%#<@VJ0528E*H_&:"92*!=!JL2 MI.^!%DJ;(U_J5B)=BQQ+@=L3%! ?
<_1HH:C"5*^F^YT[|;K0|@X>'YMO'BK_M.NZR"^?48/!J#,7FM\$?;FLM[B:=7U1H]/0U2-4/
VYI6,R((0ES@3G[+EL(M'&BYV\$T.SVU(VA^>W0_7@0:JF0BK \JFE[^JJ+5%?'H,9K%!WPK?*2& MAK(2"" ?
>8AN*[\$-4#?&6H=[VSWQV8Q:MX0;-L! ?6YN0\$XZ]WG]^T-#S0/7(MJENY0Y63VPB;MJ98B^VX095V\$LUVGX7"D"
(-"@B0J@S8@@"=2""^>5@5M M=LY=&Q7^/FDUGFN9,#3^+NUB175.9XR#&_:@>Y<0/1/>0
8PX'F+CP2[Q[1/?H\D'B_&E"^^>00@%-4#H0!E)G^G^T/B:R#* MH_ 0^APFF|P/.[]%5#GHP6'Q(
&RWWA=,A1N%-:E)#ZT8+EC47HU_]<'8= M.KMK?U&[WI/1(%0?@-)860NRLQ!*8^V1
3V]),8CE\G<&X6#&CK].YV'DCY@ M-C+@J]GU]1VX2SZ;7TWZ!C?XTK217&V#W+?XW- 204^?KH(1V
M2,4P([A@L;^)ZKPZ6C\>N\$IZ%CNRF3ER/WG0]_D3_=F05*?/7N8:N00+)G?] MM5WAVVOT_6%';C\$"QC;Q+>C
C]+C%0)DW^3,R|]|>6=J=9]4!%>5G*^D M;"7@&K#0&TXL:DWU\^NYU,78@J;W^5(&FL>[;P8MIU!EF7"F
M_Z5_IBN^%L!A#8%\EA,9&0]S26W60?\$.LM* MOMU\B:@RIF8"WT(/1L^\.5NCY9;72J3PZTTL\$?
@2,S+9Q^*_V#ED9_ \9K* M%LBE?A9M0'CX]=6RLKP60Z[0Y ME,EW3,EP>+ _8\TP2?9BHZQN;YR-F(N;GE,
[1GLYV78\X"9EJMJP<@16)W&L% ML-3>.Z/Z_BBV"^\&_5""9M5EK60*&YM7X*YE[=19]1B.X/K*=_Z5FJ#Q&J=UV
M4#<^,BUY|XR|SI#NGM% H9,+/0BC?<%,P+0 BN['C'W/ MRLJM1.AG#6]Q>4PT0_S%W]UBW?
M%\$96ZQ5\$GVI(1]C0\$SDEJE_%B&4_KAW^KX)QWB*7JEZ8['Q38;]'R\^DJH, ME4VV3W(N_FT[^3TY:
<_P1W0)C2\L/ RE? Y5\$:69W,R5!\$[KU%V)H>05&JX\ MZ;)_G7\$PZ6F?
0;PLM.,3.'K+U1"+3V2UZ;JH6?}M'.13FLL1LY>B[*_1;'0# M_:'J0_)=YJ9N:D6 M8KKV]Z<6^8,_,^(
LA1N.?,A^P]SS?>GA?*,*S5-'AP#(1=WZ):DX_%U?F M5J,2%0F8#'#.>%^T?E3_&Z29W!XMILZ5+E^F>:+#X=
[H_53_2FU+VBI\$6&IG9,0(\3)\$Z]WR_7ZMAYY.S*PDX7,V?>F2Y3(N M/0MAW&;%>T*,"_UFV)YS+W+Q0:'
M)]Z?N00J>;2CA5\$G_S#2C>7+1EE":=DR!UX;BI;_,BZF)!>?1ZM5\^8M2G&0J_M?"WIP%H=C[*-%
[8M:5GW^YJG1;'2E\LJ\$3Y"#28D?GN*CIYW;TMM5UVQ?2Y9_M(6#M6"!D+B[(@)5M>9'51AP%9L^SL(-3&P"\$?
5X&KTD47I_>G&&1E58T_7)? MJDX\]G9.K5/L#/^+PF0?;GCIATX\$1I&\$@TP7V9%P%!0&,'51S0V>'1GP<(-I
M]GE@NEE3\B0)96WQURX\QF[40PW^W!_Y328D#0+%=HZ/UZ])E*,\XG5+VUBS=Z/S<)U4IC._7<*4)@;\$6E24UVD|
0VWM.OPN1\7(IT_M'U52=;6SR0"-\$.^:Z_*#H'S)TA*-]VX-EH>3:5/6R,ZQ?M\G)#.?JZ77=GJ6_MVQW^J6?
XU/Y3SV#_N6>Z22,G+(=^Z-[VZ,69VMNH!\$A+U!(TZI= 15N?*= M(J:J_QV",L"C!RIT00

ZJMP8PA,M@0^D7S'T6X700LYBXSKB:904Z[HKA^5A
MUE':.#+X.G)B)B*5013AZH07#)A+BFZ?I9D*.0AI^ID1;\TJ,KT#.<366+"QIY4@
M\$!ZCV1/D/3RE;F,.8_V3I18>J:BH.=!5\CCYB'+)2/2\J<1?+=,SGK%LK#76_MN0+?
Y:YA(+AQ'/06JEH*+^UR_Z3P8Z_J14I]'ZZ_0,>3D
MA32TNLZH.C(D+GZ7,@D254*GJ9I7/O:Z800*Z_XK9=7'BN*GZ:@Y('VS9P\J_MI';[&0?PQ946UG2.^DL^1S>
[-4B()G)[N5<:Y9AJKD6?UN6_S)T;I\VMVAUG_]>H8L)T1RW-*MCK(/CXQR":CC7!L@YNV6GV
M&CQ03IOZ/6IGD84T#7'P??B0U\/%T)#P!CV#7,GWKC)BAUW(D.@fWU1XE'*0_M&+ '\YX>|(\$ZNX8K?
F6CYH>B]*=\RK[OSFMZWR;4>WY:9&J)A2FME?"DY* M-8G>7(VVB\LEH3:HS0.\: ?W\$]=*
<:,OCL!^!TD;5]=*Z%S^!9#_S^#U\,\$GS_M80#_8N\|HYK\OG71J_A*E2XU*E6J=-1,5*2+B
I(C4COT@,\$@B*@[!*"@5!60_M#@*AEP"A(R")EXOF)9!0_PGAXG^?L<9YI00Q[ACI'/N'N/^/CP9^?2N]:XY
MYS/G?,:=:YZ(9IX/S?K_. '3&^="B7I|29_H8>53**"BVD0_IEV+'?\P0+,,/ M-0>4#T]P&>\$08)?
8L\$SN40L,CX+QB>_TCIVONGSVFA>:&^#C:KX2#K%@2W_M_7F?M7^'@/K;T1E\S%E_+IWR^F9=N\$IN!:@W
IW'9ZL=GZ#%T?H'Q7W-L:<_MR(OTL(Z0>P:@P()SCGIXF47F(+8'VEUN/74T_:00%(\4@--^_.?CN,S7C
MUZJ\6SNA/AH_.|%TA!A4APEK6%>F9;?#T?#-_/3VI&WKF*\F/C>0^0>GID_M?Z@R|I'7M\,IKG[*VDI(PAR|
(S\$4:~1!(S0)&<+=^,.QC"8;|3EL_PVGSE8_MK5I|UJ(K2QH!%)H=4C',
(E1J(,2^7UWU&P|LTQ[[3+FW];H+8N:|PM0HC<_M|YK'N'OH[8\4WMBW%0,\$=)C8A7KY>90I/J>VL\W?
E1S\$CKJ\ _M!4I6P'W<^ M4\$:\$I!6?T(P'PK&^(:;@86D1G=6/Z0^>1S+P\>/OG&,QGN)Z\$S>>K=IHO7
M=9WN'6S01DJSG<'H'M =^.\Y23+U_MUAF_,|8X1Y0D5!@10G_ZJ-1#)&PZILC0,\$IEAB|J0=4F"I9_,?
CBVZY<ZWTIWP+,4,=?_)#J47007&S(!)F0H3#%&T-RJ<9_MQP:7;KR30K_1I0(0'43:
[NL3I\NM,4>L_U|*WN|Z0/I\0_/018"=:2Y_*H70:>G@0WN*EF?8(0)EW+(\D@/I#QZ8%D!:-
%2UWY9;2XU3=F@2;X6RG:+0\$ _MJ?JU|0*_0Y3I70(L'98BXAZ9X#P@^\G8^,"4MIN*^JN/0*>0(R?
[SIHH|Y5%04XVW&L(0896!R"Q(:P5;I4SZ0&|A0B/[L5ESZ#_M<@?._%G_0#
JDL^OC<[560>QPVH,NC|P>5=\$I6R<#*Q+<;BF7:&/%K>Q\$?K%[_M1;_4CWG&^@86?
3LHBX00%EU!X@:#N)75C3K8MNB5@.7SM*=^X=:,+EP"NM:4B|1=|F,.&^H5^|. \$8\$>XB9S1_\$;"17
M()ILQ6T'A@|H1);\$FC3SQ(E*TS\|3|GHZY;LUCN47(S=E|H<#2T25+9*EVQ_MM75U#SE>2J_"EN@V(:0/
)L3J|I[8_[0R_W?0#)!_Y6Y^4[N2:~6/|530D9GJ_M":G!_CV:))>L"ELIN@D\$CV*0_K^8XD/)U-.PW?EQ
(4VZ0F/.G]=*P#DUAL_M3|1_)?V|VHPEII+6";&>>!WRU:5"A_KQ-(Q#,S|);'3;:H10I(|XD<8AR)0M
M9AX\SU.RG!-IT1YV;VJ!>B06=X&7"\\3'H\$0I0MX4INP|WBT&-V\$2&)|Q-S^_MAU_CRJ)T0M|VP9;?
>70*Y##U@'7&H_59G>00:_.65_*F<##%_M|2;7"G=T3('5*._+DR'6:\H;2_N-U<731?00|_C|L#%SIO_(0JH|5
EXT|.I _MIOC*/U6LRS-W3GVC>|0J,E!(NZ&YN5Z'QDG1!|-05,>7MVT0"<5D_M(CQ^-C|!G#/=G>_Y_
RCY:7WD|B6M7I|D0??2M767.TRT\Q->YS_ \LR45,AIK>6R4'=RN_MCS)<:U?-%Q'KGZH?/IX40'|_
BZ/4F2!)PSZS@*2;ZD=@;HW&@ZZMBY/0^R_MJ6J^0/YNV*4N#P:"T?>#(QKZYS\$K2:FNY-#V,_S!_1Z)
(A8DQ%X\V)>6A3_M(+>|HA0\$N:.<9)Z_?J3G_?^(+MTR_)C<7ZSP4Z_M:./=(U4ZTV7>_M*A\$
/_5_S^#)1\ "&&-|GBB:(M|RXI4S?T)G_M^/)'@!208+2\#)MDK=+^|>DF<)-
Y.YR!),V^BIM/S'(2/GP!:@\$6VDRI6|Y05Z|RUDF'ISS?_MS48?
=6&I#CU/JX+N\$++;#U..D0=N6B6"I*L>IW5>_X\1W|=-T@SFF6
MV1&BB=Y@+ "/:Q12|UKH0#KHUX3UXI:5NGD5U-HL|W,ZTOX(RKE@:I)@1ML|_MD?%=)5/.N-
Z6+7C),HL;0BUWXAAW@32X!0GNXL:,I9155F<74:2PNH0KNY53_MT_FYNK^--
_B\M!":.0+AS!K#;F93\$2'PLOJ/'Z*A\$7U+LZ(-T,'XV;%?A|7(H_MR?|*.08-5]=GF^E?#4|YIR%8Z_K3:!
(K+6=HQT?|JNL)VQ.|T0=7R4NTWU#?_M+,F_14"R1W2V/J5@'+S*5L0&007">_>4P
50'|=7|B|?._#T#20_MSS+XU=6^>_6_M'C>H%Z87";H98H(7K.+3!55A!AF;L\2W"G|VE1N^/
K>Y0!9\84H_%H3C9\$Y_M9&^L(#@1=6#;!&.T)/L,H:M%]'5J?^B6_HW|I3BYVF,+0:F+;,MMRQ)F,| ^.
MY;'Y2%MS*%+.4'0!&HRS\KK_K_.V|JWE>DA^F;W"Y;CIOMWF(K-,Z=)1A,_M|V8Z1X8\$#TM_1EHVW:'\)|!
|^+^UK7I)\$A^9LQ'7VY9|WBC@'3!@D|P"0@V!2*B4#.VWHI;|27FN?^B_I00/*:R//LA>D=._?
S4S0AWMJ%2&=;|;_MH|Z1M5M;6RH2:P9?|Q'K;06&AQVG>N1'JW,5|W,>C;_M?AAUJ?RF-0('3)/PEFJKB
B'\$)8ZK\EF,N&K\$WG23:(+M1>L|B;1\$ _0C_M|W+1N#%?;@.9&K\$ZUI+E.K|K)<"_YQ|P@^W|
<,S?/30M0")X&@W/T@6"CDF\$ _MLGAFH#Q^*B=|,39N?'Y(=YK=S&D/K%P(_M:~0K(BRH_28|R(XLD!3S-
LWY*5(0;|8=4W+3X!+.2%>?>(W'S01+0|'4ITDI_MST|GH>EJ@^_L3C\@G<'AXYE7R4/G22H5AJ(0S\)!8?
J|A|H:5ZPPQVK?_.6?_MM>|.4A0<:3|NIGEFM*U0+\\J5K#AKKCNV8ISW"@=|WQIU0|=AN?=(#')
M1C1(K3%ZQ!GPQJ@6">D1ACPA)>>30K!JJMC(ZJ/9*&4EFT7IM+&^>&L;_MFFH?
T<|W_.X^TD|"UBW|PVD.M3Z2:0L?G&^)_M\D(-60\$/DR"?RS.))|W_
M7_)4TX&N0)9_KIYC^F*..^"+5:WA\D_U.4A_P&R.7V|B->\$\UZ:8(UAAP)3S_M)@0JK?.7TNC07+!'--?T->1S
3"W\$S3<5Y />|(>6|M>B#|9(_B=^PP7SR7V_M%BZG,B8S07PG3K7|5)7Z|!I>3XLMS=48|9L7NF/L?Y?
WP,4SZAQG"75\$>Y@4_MP6@Q;"C.^"M.GAJ+K|;9Z,ZE8+!/K/Q@W_M,0?LB*\$T_W0\$B@*U\/?@_USD?*48U-
X;C(??*K@T\Z%;SN'NQB08L300MTS0%PCP!CMMR7G;*=1JJNX)G_M@,-
#PH)0H*]*D\$0\$ZE>JEE5%|8C+8R<.8F':-|\KX/50DCMFDNV#TS(8H4ZZ_MBSQR<3011)(_Q!*,>)GWNPPYY_MRLX
C!;F>.+A7900>|F%>9?0YYJ_53C*.C>|ST/.7)3+JN:W437E|U2|Z3^Y_M041*|D*%|[ZCH2'"T9J*Z+LN\$WJ|(-
MJ\ZAEGR@Q05AQ!;>IL"!I>/,(,1Y_M#."^6^1*,RD0E54J:M61R3Q*HL\$[C|LIL).?_JM5|F*.(Q5.0
AM:3)X|]A_MM'E6-M0RHL%R9':8V\$3S'6A;'|J"HT)F@_TFC/@EHS%-L>:R7T9YU=;/5.D9_M|<*\$S6Q\$+!7KLX= '
8J7(Q+K=YLX\L*10L_?|I=,BD"A,!A>6AD;20|JX9=SZ_M?0?Q?G);B8R/RI+I8519)GN/K)\!;FHZB_M:
(KZKNH9X'\$WW/\40+ _B"ID<>S00\$J8B"A_A@A)%RM1B9)"^_A,S--LV0Q_M;>M0? (7"0;WGVFM-N@1|
9#.|X\$<1'T@(>7_K:0|3Y6@YT|A#RSY)G._+|' _M0",|B2Z/HG&0SGDZ^Q&*
(C/03!ZA)SY2W+8ZK2IVJ&F;^%T!39#\^4B500|_M_46@.|^0%.BPAF@IXDD^7>[E0898%BQ:,V-(-
+X|R3SSM>+%PSQ|VHM-_GA_MON--?(0_KJRP:+B/27@|Y.KZ4369K/4_"QTY"E>)8'+^8@8=\$_
HW(|.B<^V/JY1JV*4_MXG8/ENIF/'7#E%BALA#L;66\!,^6>1'RU)WFNF|J4*L\K=A=:3_M5DG\
<6'J:~^>|&N6VUV6M.-/;722L(!NN\$,0&JV32\$M)7JC1\$CN**S)2DM|,_M>EZ:E88W6C):M%MNV@;|Y0V-
C\$7I00?NS).@ (5C&|1%|_Y8"U?6":\$.4G+P_MF6K^?2_PX@9KF')9;JA^=B3U(+Z.|V.ZZU

61WM0<<5MD<8;:IT^N%ICHK& MXN [,)T; 'UZPQK/P@9]@I2TY, \$KY6SRCK_KU^M!/?S082_'9>(TX9*;9=//
MT; L=A E8; "M6E]7?&4ESKK5FN\$ M\$-(K'JOERY":H_8/+F"[-%V:MN\$S@--&D\$IM]8@L039@U]6U))W*-
I20IS;F M/M;X)N:=6;E:;%0X[J\$#0PHEF&Q/8EZ!>99R*FP/;(Z\$V/NZ>5.Y.8:W [=W9FC=Z]^IUQ='K
M)*\$U#>SG;#(0#^[\.4A*Y8SI0IM#,C05\$' LY3RFJQTZ;4XA!.,YF9\$-8Y\
M#Z=071U<1'',V[B0LN[8]W0ME6A'YE1%*YRR,E#9D5&'620/1!&'J]K7R=&ZK
MN]Q(;/SW=]:2:]:>G^(#H8>U4S0F1L#J-5NN!PN(=BKB;Q"1@J_L#K-B&?5,: M7QB*JG60)^IU_J=6
QD.V<=:V:"R)0>'63]>008Q_MB8>75X YT@)RW=6,: =M:T41/% (,ADS?GBG@-0.>Y84>^ZBH7S90GR%[9,D
52WJ5<0'G627>GZXECB*MP=-G_/3@1]:5>R7Y.HRX MM9&%60XQ"7'Z\YN-TVFRZDDX.T@C&KH-. \0#6:26(
MA>#40K'A[09'P"&G/&=)3\AE?/S'NI1=Y1*E?PF4_>:"BU"ZH=8'Z/\#2W= M@.\
(0UN0TRK^X48UXC,2'RZK/!=V3X<_JG:5M/Z8XV1Z5_)!!LA/8YYYI^M%:
M[&TA,5[OK:X0&#N1B\1"7CCW=N:P]I.P)-XD+U?G'9AX:=5<%<\$88)V@X5#3
M^M\$SPOCP,%PA]A0(TAE6"6Z"=PQ/3<48ABI5K>' M:/B0ESQ^_7MMC*"4F+-J9;\$C-[-.
[)W.SM>YY^50'#KH0MQVP,A7C>7%]7_N#4" J/R@BNMEE;Y*4[G,-P)V[G^] MM*B'=
<(5+1EF_S!S!+%7CRP/"T2,>'0+@NV-*3'-+SUYT_F*4ZUQ,[W2P6Q@M-
4=PU5IK(!@%F:D@J?]>1MSIN\$=MMS0[-']*)-(F2G;FF\$-/TA]^[:J<-
\$J>'C.*]36C"";@VZN=K%#ER&F8+)K&B/2;8KW6X70I+BN39I?SR MJ6XY5'?F5#U]5]F%&6@EZM
_MS1#9>\A^XN:77X'/I>&3Z5_M5AY2JG;^4NR;-S38KR[5SF(<_XW\$?Z>_,^TM.3N[W8]6BPV!"?")@J]3
M2DA3JZFN&W6F\$'N?EX)J-^*S%7HWW*L6N*.2.##-5&>L-Z_)1/5]PL\$T MR8U(7E<%U]W@]2KX33.#0!=B\$&
(RJ1):5E"65"F?M+:M[K3+/C07Y]S+C, ME:N[UY5GIL66P!(MU.QK7XR21J2SGS-
_3!*I7+.T^+)X!IA^CM\$+1G#143W MBZ5:Q-LU](868\WD5Z6\F9H?U]S!SRWL(-^1%7IM69<)B80L87+B1FU*0
7Y MW1,!VV6R?VP^8>N_L\$0T:K4%-_D#;0^._+10]T0_M/UUD<=0EE]K#6'/-D M VY_IJ\$LSUC41?
C(E7D5SA2],W2WIZ;%VS'4%E7L!&B16S>33C\$8E/0A!"WL& MV(_9;<[\29!^7!&;@= M*\0RP"
<'W,8X2)0[0&XM?@T:A-,J A5" M]X0Q\$Z?T(F#[R]N\$,Y, \$J&'I@%P+_UF9MM9EF-'KK%';^1KSX_PCN8"2)
M'-0@_9B!+T0Z=23N]QF@2AI['71]5ETYL0]^R\$>N><0@2_/D=3^^[V(PT\$H M\X[N\$KR-!I[,TW3%+(?
^3S<1E2(=D*N1PTXK\3#7N_3WS:-\$56C#;<&-]! M^8<27P[\[J\$#1SBD[ZHU-\$\!+B)/WQ_Z5NQ&T]0%QF
/*U1_9\0"FYCG,Q< M/Y0S6A7@0]G5NM';X&4@1^_%JWPBGB,#?_JB001B"LD"N:+*YPX?\$\8 -V#
M\K7/"X[/6-@CIL1LB;)0)A_1&J*,_9LFUC,SBU9J\AB_!/BJ9*X0/Y(G%BHA
M(:Y488U"Z#E5=\$95=Y3\MY+)PI)Y?AK./H^*_I04-HI^'S0GX+^"+QA(P&/: MU1Y-_BWRP'N:H 'DS@X*5]C:
<7F(04!CND3MS@#!=!GY=T6K.)50!BRPFZR0]1]:<1@@;-/*P?IK37CD
M8WTL@>^]00:229UX[UT6=0:@V_:'6!7(T*K4.[E>^,="U'&-U..A,@\$F5=>\$
MZRBT<7J,EM"V7%DDW#)4G_@H:#1'F(K,%*MW\$C_*;R=['R8<%93@.9\3]_9B
M9Z0T2"K*BY9=HJ>1B"...0F9B%.VP[+^,\", (WE!Y00)HH- YE!6=G;TTXC1H!.;?/7Z7R=%M,:
DT.0D4\%T,_\ZY+EA/43*6BY\;S(RI,X*_CQ@<207/?@>B=-"/QX&PRRF(1\9@=UH; [Q0' MDA+85V90/W]
[F2FU\G519B7MK0*#%T]\$%QG"0 M"QUIL[@RG(- (U*_7,L)&]+AS/Z;\I3ZLXT5\IEL\%-)RRI<> !40#RP+[50
M55BZG/6>=%\$CT=3S/]0:!*RUQARBMO<9]3H7FS5EYW<,+H%W[IM1QLW9D#H\$ ML\$M1==2WRKXULY*
[%FB#N\$F/AH)NDN[6CWEY*?FIE8]XA]6-R(GZ02#C?S5; M_ ;HS5(&-D[!\002;V06!?
]&C5^+DML)SY0>;93T\T;/5,3:860J\$G[_*0\Z
MOY(0PA@/6^>S/Q(K[!&>JEDM2X7=08C3M)YGN,@P\$AA']6SH%JX3:9^%BWLY MI<-
?;]'J*CMR_5V8[KKK\]Y=XV?R%U4LERD0&QK+8!^9V3*B&?0,@ (R@QT# MRL(A+"J00J@HNBQ4[%:=:)
[ZQ,4SP--461M;@X^/'/G7G[:V0.2?073/^E% MKA/Y30ELIEFA\T)(7&PLHL<3[WI9[A1@GJJ5-WKN3?
OU7F2/(A0V8 MS6=E MZUE,H!L/B"+DA0FR(0X]G=#[1I>+CNV;,>\$FLG? @B/[X M,JX0]ZGN^8@G27?
QE@8.. "<*.^MB[JF7]@I#D-E91N9:76YG]>6;NKNL MC[%]\$FI&C75^UTQ >-]#74)&&'V
MX8I0_#60%Q2S[3 T:H'.%15C?C0<..?U.);04A>^E,ND@=J0;PWG/ER*"M?..3_0!+9P#JS+Y6?
_HT=]:.'Q_S902N"MY]7:UFS0_00.\$>!U@;KK80\BZL MLA,Z^E(L=Z79YC+\D2!5[DTUUVS9#5'FG-
T=20+@_\$5") [9##?FDVGT[? M4TL>&M6=W;W:70DQMU?YT^/N;"Z-!S\$9]U197KEW:90XNKVY S- SP"00^\$&
MO[TU54Y%GU%YLN3H'A0#+D*\$\%E06WFF2'P:0PM1;9% M*\$S_Y;570@8GLO^"BJ>M:6!4^J MD(9&2(;
[OZCYX2]D[\IIC\$W5NBH&ZMV]+K^;J_Y+D%(JYA[;(!KR?0\,\+\$& M>:W\$"UK2;!KP2G:FY
G3^EH;S07Z[&5;WA=,J]=,K1WKIK\WN&3[0]\$94#ZEG+\$DRF#K\$F29/[0*]C2_'[5X7>*S%NR6L M?-T;
()I!@!#%2**\$!R5:102]-GDEGZ*,SVHJ9>9^?39\9NF7,2W>=Y/*@8,J M?;+LD^'&5S(OP@7R8',X2V;:38,/2
PF-#&L6A0H\$7FH_\$4@NS^DNIE#X<,6\ MNV?UT8+_75;S_I06"\$S%7^0U<0XC4,&I<US/I\$N\$
M@XE\XJVC"J^/ "290GWY="G3Y08GG\$SRE*NDX6/HL. NOX>' 'A200@9'*Y2 M-
BXN_28C&^0E76!T873[.2*^J\00LX[(3[J]-PKUBJ5W#*(>7AU!0!.X+CCS MSF.N3
2(^.&E>UL0L7P7VV7*/9/OECEDV[=>QR1-&G-3H?1"@JX2E+.CP:W-
M0%6_T2D7+;G%X"X*V_K%B"86!M1P"NU'N]0_MZ5Z&;='Y>?1UM74PM_CVOXW[>F:/EIT[#KT+K6 M;?_ (W=
[CWKP.RC\+P2_M.YC^:3*(E60Y0C2N8HJFX=\$SB/79_&.,%805?I71HLG6J;*B5F_.0B-ET5H5_M2%6F+5_V]6!=
^';U-:]Q0_*KBQ#P=]N*I!ND-D00WEUMI+0,H&./M=)\$S!" MVT)/[/-ST0:@"+ZE[GCC=>M+%(;
[0W*]G/IM">8Y+!="VD\$Y@-_.J_5^14[<_M_ZAUFIK@8^YHD/(T9MJ0L8!#9?@C]V-
M]0C;%)IK^B,OE.*D9P2%\X0JVH)7_MEZ\$SU=2QWEKAUDX/N^?,ZU?%V4?QTE) X'8@P<#]&V>_%2?] M\TST8-
^7&S^Z/%1?E0EHM[2+ ;>&9@)\8IX\ C6P+NCZ\+YRJF)WJ=(51X/.C M*QJ99E1)N/Z]INT*KKGYWMU6JJ&[>]VM;
(*K\$%]RG>'F6D),SBV0MT?Z!0A:X M>TF=96^XL,Q3@_?BT\MM'7A>)=P99EI.<:[6,]EJYB10X?
1:YUC6Y^EP!J7A M%"N^C?;]D^!UEP]7U#FHLZLL85*G*4L MI)0C0\$-TM['PB_ ;L-JN-KN;DG20]'&DR1F49;
MVQ)"VDX4(F73HD7-AL6\,R06"U*[GE9K+7XJ\$KUM<;@9V^..]9L70&-H3K.#"F_VB<2B;RC@N.MU@8C
M7D7BP"=5(UMBV"UG\=0_" +@4?-GT>X3J?WZ9Z=_ME/@ZX9!>G>T=\$ MFRX!?)!!IHSP&+F
MPAG@0VGV(QSY"[I\$7E09DB[*HI4L]J80P,&?&+.<^OM[I\$"Y M?MZ5AL[;L/>E5)BR5B05S!6WK\$05C?@Q+EODI
WZ,[T(+#RL@T5['%T,/ \- MS]^I.^0RT5,M@Z6WL>7?0M\$0^DD"&'5B&)*+6G8PL2F6-_SY,55/\HGD8M;
MOE+3@+7A6%:H3UH5H0\$/FDE>'@=: "J/*K#Z._A?,#K_A@.JX
MTK=XB;46^4%TUG7H]#QZVQM28T8W,2PV_ ^++;*X09/!SY^L2@ (HAQH4.0XZ

M;JKQ<6FLZ*4;:JPB6R#3E=JG,21F-QP2X|MV&H RZ4|JK|GH=/WFIXTG>|HF M*RB68Z,^S>PDZT^:?.B? 18;G#CB52*9^4 +50P5=QMFL1J(#I=>W01FX-WU4 M]/0CZKQGSQR'|L*[J*VDWZ9)0-'IY-CKG3="#[W.=\L :=GH23\867L5U| M!>\$5BI ()"4)B&| 0?G#JS \\\W*XI#04TWI8ASW\Q?J)|R\M#X@/70LFMZ"/ MN'3.;,/C5 _6YB _BZ0"00)XPR8T5D17T@ 0MS!3|:5Y0B7+*4NZ^J\$R JWZ| MPQ,^:B70EJZ0P\|^4\7 7IPF@=A)CA/9\$S '-=-+X ;2X,U.0Z#U61U04:Y57 M\$Z\$0U;L68Y9"4IY8I#J| CXV&8433@-YNE2\|JZ%JW%JQ25HTAW"6J+"^\\ MP5:XK#9)FK!&.'5U#8*+50&VU?V^H)WFSF:[?A)_8-"|P:&!B^E*@V/U@1V MPH|+R&WPB|#GA1:."G &,73RGUAI49JB2,47^3-) \$1R&F0EZH_I|W131PG= FT>4T_E .(=8)6?M)@1?Q MF=D3)>(@VR- +ZVH5)*9F:Q.WL/3NH8H;VDG7-L#YUCQ|POS*"REWANE;MX4^ M<1Q1S-6H+,EFT8#MP&\$+%)@0*JOHTWNW3%- FCP*6ZVI=#1J1YUY%|TL43T-Y M'+WHJ,^_E%IX6L'N\$J@V^L1#5_G(:'+D,A!C6C M)4&\T|JRBA=%B461W=9;"AWG<<@K=)A1Z/=J\|N#_.%>*CRM.^F3H7& M-:A|0LTRN6U??C=UEG94 M2AJ>F>FH>U?@Q ,NJER_S|.19U/|F-W3W1.C)8M!_?:^C0%|J\T""/P-P)* M"Z|QF'((JLS;I'K/*=OML|6Y^&\$&/KB8JD>WN;@,EZ2P?1_W)%5G.%D5HDCQWL6.OJ.U_MDV%VMK6VL3U>C MEICW*2EK6R7\$HS#-.Z>0(J1%KZ(9>TE!&"\$0F'FQ4|^ MMJ&80""3482#;G.159ZC5/^|]VE??0YRZ7D RP#Y1?J T7*8D!B4"%T@\$G6 M=<+@(|SG1J;-*+0LX@^+-? %G;G5.W/1/4?PIIW|/+FL'00N3\$U(D)!X*RXE M\$B')*I? P//J7=C18F/VPYVFB,N2>) MDI<2(Z?VU3 3ZN*Y4@Q%G6C?>,2N.T4'^I=-L&-A.'C\$0,[LH MMR0=ZW9GR\VU\$.]'-'!G.UN+E80945&@4|P4^|UD ? IJU1LF*UGA^Y\$9SY\W M5XT@-A5U.SI61C'"EM'JY0.J+4;||I8+I2H08)".NK!T;*BYFZH^0&LLC\I MRK \8|*|\MAVL:^+GSUZG7>^+^,N78YV\$2J6V00AU2QC/%N5U==UPQ7= NT\ M;YZJ1J|/M|;CIPP\L)P'*^GTQU I(Y59!)-K""\1*>5\|F/W< +IDA|^=JC MHM2QB(S._@EE45E7IFR7Y+3,, '5XVI+N|96^(F+-M)-3B6 &->PD3X=>#*\# M., "=;:K)78?2|_00?KG5?I97 HG5V+M4W\$;WT/ 8W@0XT/\$LEZ^\$'93)5NJG M01D' 'K|2A5J3HM"1PS?R? 30&KKDY6LP.V|MJ\$C0ZM+O/W^UL11NA@|+1.,W M%K#1=GI# WF!0%|L3K,|N<\$.18\$S-R(|&:2-)GTZD5*MF'KJ<^5EH""4.:! MA#J5\$'Q-1@Y.F=;\805'7),0^;|A&:42_0(?1'&_4IAVR55J5T\$0C|S9V? YAHRIIN;+=_K<)|#K;NK_F6SM+K|7_FUS_?B+R M/ F/1\$3S&0|CE\$|]|;=.HA@0(NP\X/;:J+7+A3 7^\$ M0|\$)Q"R|T%3J"E'!KH0>W7YGF%U>5V-+<78ZJ%*G(*H'G1NDA.6H5|\?IHWQDVFT|30|V=L:&L\,DD;+;IN%9%:5 M_4_,\|\\RP=+|TZ+I\$RKF.01;?0&)7_K<";^D|PZ.4+C'WV>W_Y?>?3MX M|PR1F+|- %A,B3Q5Y_%@|>EX?,SU/|X015W.KL,XGVG|W@ HVH?9W9/\$E M^/G(!, _C^NH IM,R|1%U9D3\^Z<,#_J@++H5K/\$\$01|"&?>FE M5B W" C3' /JX0)B&N|BHK6%.3=,Q=F-W^U"EV@+? _4PE|/4M2T0>|SQ*R4' M4PL7FYN:5_)S00_?|80^Z2\XFVIJ|1VWLN2DJ6G.HTQ'?>?C W7+^:&!(| MF/Y>X67N,=C.J59=| -BLJ'D07P+,|\\|BFXHXX27K^Q6& !74H= V\EW>5& M&SP7"DB'^.PMR0;- U<'U1U7FY0CZ|Y-\X0INTSYRW%4T7^8/YQBXEMA2E,F. M|_FRI\$L|:(K;+LF#AF04T=\\:111UU%6G6'URB0I- ^MF|N)@NC5WC^\$H?|J ' MM^ U(KW@E \8F2Q|J"H!WQ\2K^:0X|>=\\B9EM?-, :TJK_,7ZF;BSE _EU\$ M<"D4I85#^KH=+E;F_5E|WAS|N((\5!<#1,R!L'J=>?%1+>4K2"?% 'W>?Y- MXH8,)(%I,\$D B(N&NZR? 7!Q@>%:/:(05NJTIE3B<4'YT^=F30V&DX^;&MDJ=N^Q#+=VA M(3ZPY5MJBH(@& 03B>V5,6P9CZ"!F1<(N2*UYP'I*JV/LN1W8I30|"4^NIB MX&S-@_N\\?|R\6?_LZL1P?|'I|/_%ZORUZZ:94+ |E0)0.^'^.29V\$20_=|F- MH^?&#GUC)Z6QJN)81@&*B K-JP\W-C,0""/*2V*0PQ|BD*A I85G>+N/LH,T MDRI9MCHE=L|BQBD3.29Y;9_V0|>*J36\YWF?QYS%2-E021RH.XYHNM5G7%XY M5J6G|G*|QDBJR|U|N? 08|DG\"X6C^N|;ZF4| |M|4:0|&7R%G@*L^L>< &B0^ MR(P_G,0/M"2/D'N(C^'.1*&TE6.R(99LN),8-- =0.P#|2K?Q|W7\$0JT|K|V ML-WC^&SU+0#>?==|=|=1AL%MP=TE2G570\L0K?>R?@'6!&L7*&#G-(7G>Q&H MT)9Y3E,1:V-#U+4=)% ,0Q/VB76:|+CNUM7SVGJ?ZY7BGZJ(D2C M37?8' 'G9\$/@GL=Z8:!'?"N^|WC?Q.- 'LFW=VV|A@3L1V8A_):4.TZ%RIUQ!@ M-@<+,\$7,=(HUQ^01E"03\$^VA2(OM+2>F2B\$U- BI6E|=,7T0(JL7WPO*W/SR6H%TU,="HR+P< Y0MU?0V?E\$TF>M.>G2!V' 4S80'M,A""5S ;71E1\$<7M MZ4VX5(F6V!=KSK)9*RXPAS_D9NX\$0JT3LC+?D&*-) |@A-&;BCUD)%P"1Q:# MAB11;D""S- MX\>843Y9AD0FY@Y\$MW5\% (5'\>KW7S?TH*3I#IP.&|9)-XG/ M|. 'T0;+&4%\$C0A).KV4ZN>DI"" :UM"&S9@- \$MS<#."#6XE,OMZCN|T:LUF M2EWF^&R\%Y+3.; MT@XG@IL.#T^+Y|KSFSW\UH&|QU)Q=WQ23Y"+L5U9|"38,.QY@;V23XD5>SA) MU1--S#^(?.XD:G&? 3Z*'2W| ^:HDDYCK%9< >1& =L(.41,88B&^0X9B8:(% MT(;V>9%*)+EUV*0'IR\P|-)T85M|Z>3K*7? ^,G>^PL|D77EN;|EX&.ZB=\\UI MV" F3MI*@EZ^'WU&|+;|>#\\IYP85,.4)=Z0;5A?9J10;M|\\Q@?|S#WC>I\\AN) MN)A_6HNT7N*R3"\$SS=+572(+Q+_30)3Y1BEFLDR"H#0 70R9Q?U0X@Q R"X) MN3 P.&=_ZN%.N\$3*0S1T(|D|2'Q [|@#=-H:)|15"2 ^^KL_SX<9+LK6@*=-^5 M)|5R9N,'K|/LC,)T1V09S MPR6MA.L6NI03CT.K%\$GKGB0E6@8M|BZ;7 7=+K%NZ!YWHHD30W.T8TTZ0\H6T MW\8W#I8|/-(|C6 VN,'V^JZM1*(\$21M'^1%4M00.5PH*+RF)SOPF5S)W^F+ M\$'J0? L&C>\$|, _8AK;9H89CD2BU5@P/RYV"+KDR;\$.H:3 S77F^J)EZ7BNEP ME?3IAK@3G587P0,^S: <|53Y)TU(C&ZGA(7\;, 04?^8;=10Q2054?.|RNJ44Z M? 1EFZ=&Q7Z| |E.*AET0M^YF_,)ML(JOUAG@W1<81_/;\$L'\$|GK?*-B4L\;; M|<:|WJ?EAV,)FN- |KRDC|^)'182^H.3'A3V*5I%50M\$D+>)3*&0QJV7&20:' M:@>RAC@VWQSV+KB9NJ-9B=\\WKWC)ZILEKYFQ)/#- UDF?ZT.?>GFP| |2'D|2 M)ZH0S@'+X1T90B;OU00(:-I0D'3"PH#\GN/1L%|^NN|#.1L:E2+^~Y:0&|\R MP3|?|9TH"9IV6BQ .L9.02\$|X@6"J+LB./?(3&|\ZP0B!26?9#JLDK@R@\$. M8'U+5 WJ. /P-\$0"1,?V(4PP> W^9*;|)"8#?:Q"|V-*RR^ 6N9AN5EQ:\E< MS|3JQ80%Q?00XOR\"-_0>C,RF/ M&PR=K|;00;>W,,S +4/'MCNNG/;RX(H7 MX7\$Y@GXXU/Q/I3J_0&-UZ >**(I'A(.HH>&' +81@."M#2|6PEM+_XGI@XEW MEC6)JC6 +VK60!QW&;-U/EY2D4I"V;|AMYF|4.(VW=0HM0B>\$6T#R1&.?!|= M8,QN='H |(V8UQ/FU_UM2P>=JN,A.GYGS, M"| (EEH(\B&0N)8GBE9^,D1CR9KL.FYC;L?9'|:|EUS1A8\\0- L;_2NBYA7B< M+L(|?VI4>' .R%!)#H<\$8:M7A(!(@A:ZJGA"JJAJ3@_GX<2?KB2/\8N1BV.^T MH05|7HYI26\ |5UI| (3F:)<&M9=333I&+"^R\$Y=EY\91#MQ!\$=0|R'1\ M&(4:\6=NY=C(Z,3 PL^=\\.)50@=^\$T/UOI'=?:\$L-.AVXJ/8-K)MG&QMV;>: MRC@=3Q?7BTG05&|I5|! <:&|*URS:U^L9|FE4\$10Y6--S.@E-47M^PCBX0_Y2I016Q M W;L N/ZS@#7D_PD%|6RF^? RM@(|R0F^~^X#Y2!M|Z3,T6^LVM;H/9NJ%0| MW6B)U@5W\+=+5UR>E^XV8M\$|7IW/TEA)6/= _\$/7Q?

*R'\8XVJ^&Q*K7H13; MX: +<, <\X+, \$)IB,)58X<- /F-LXC%*\&53">G+[\^JN*UCO"VTQYA!CXGZUL(W
M*T#0.\$\DP>5V+1!F\$D@3CK8G _ _/EB@;6H_#X[\#3(6?83J-?P)[\L/195]K
M#DU9T0<&I^ZY3=,LRBY4(DE,FQCV\(\, YV0F2;8-H^K4P8>62'.0(WB1)' M@3C9J([JPB]>K7-ZE0RX5?
GS*T,QW(%A&J)ZF@X#.A1 9F:=@@3'?I '?ZN(MYU\$F')DT"1C<>JN.*>14FR6:
H)9,Q+D^TE41&NGIS#C(3(0S(;@YHZS@^!9 M D@*<@-U] 4VA9H5+@%P1/M;IB C9XWD64J#3-
9\$TY>P5[Ln^:3^G38N>WMKN3\ M1=0@Z2,D0_,9/B<9CX-X89SG,\2G07!; 20MN>HZ^A2;W.YA%QTXHC>4-XC+
M2S5I6MTXP2:V\$VE78G_8CI -T-<4 MS^0@#>L"4#?@W+I))1/HSR7 M^Z.Q%!M_BNI
JG.7)\$7H^&!7I)\$XD'1^?BC<+MS@5- MEN#-S]W48?W3,DW6+1V;'UIF^BSZ-S6*G,7#G4U<70:)6VC.\
MOM3V0^I!VXV&2B;'H=J(EP,^08VB^Q*XZKY>/BUI-"|T!%;4; ,VA%Z["5\$R1 M%PF'>ZAJWWD>SEG[2M5EU+T?
\$1)F?LAF\$:KI5CW)K6PA)NZ#S\$LO>H+180B!
M/U/@]+,7PWM>Y7\$)T@.7'V9 _ _>*FG+83KR>R0XDZ-/[\MHGVS]4%)0_40Z
MB,=S:)TF(RVA[|S/TZ;8MPJLEZCDG|1MGDP4!OV^"4>?^^[=V"!|3(0T7]== M'G-
_,^R(=1"TI]+@=\$@'=HGG.>H,0\$5FFR6|3D'MIC\$P.AJ>')0GZ^9^T6UC M E]>ZBGE"[YX\"&RLUA'?
M04/N/;RJG7TA2_4%= [U?Q:WF@<.K8AD:([T] M>:NNSHB'-
I3RU<'>Z0|5LX"LCBVM&4F6F)W0,\#%H&LP&.&+"U&?(*_)WDZ^
M,;JB@X9SFEIL/'L),=938JN0,HXSA.HPS<3MMD01+ ".:RMKU& C*JJ>)^['<M)%J" X8.V-
I\D9\DN;3NU> B|CVM7;X:K\YYT0|C+X>H\$M|#\Y'[50&7RL> M[Z_10'A "C!UPK>BH('JH'L\$|6*89-
@>QBU<3I1F,UI;7/WVV..TK|53G^+% M:P,? MN2J9\$%J4|'/0W#R!3"Y1"C=I.(.W1SQ?|D50-
M50PII=PP/7(TZJ/4/507E@-5Y*TT4J@K5'JC2KB*%*,=<
IU!\$T+VWV.S(8L388U2.*0>/C!R'K*II*I1EHLX:6HW>8'3NL3Q5" K MD6>V(N'1. T5K)?E+0;=":3#KM]\$
^N,PK\$;K8 ^[_;^Z@IKKOW5 \$!.G5 M4")%06DB30\$3%044\$5"4#BHB38A("Q (17H)J(" \$*1+?
9%0I\$5J0!'"D:Z@) M34HD00W!A.3&|W_0S/W\F|GW/W?F?CA?3L[9;^|UG07L]>S,K.4_JY!'A9]K MF*TMT[OG?
W-P/\0A?NR4|+,J00_'00_901*1J4_QYN1T6ZA:Y&T*E^I/@/DI MDBP3?
J0[7]_6Y0L4N5@Z2Y&75S!*"&*X/3*Q/#A@YC^NQV.E*(&:C@90LB) M0GAJ)A:RS1A9T\!;.
!I=996MU,7F!3_]@)Z6JDEL71@PG.52_0->R=5,1&I MD@R.[=T8#/H>"\XRBUI N G=47:0D_7*L!7 ':)17
RS5="Q6#W8|&??\$6CD M3Q,-NR +FSWLN\%@BYQ0.758K_0B|2X\$4JVKC\$G;MQM!.)>S'=/R:KF> ZC
M+Y=]%-1F_4WUAA'H\$S;:Z_Z)Z7 :17L2\=B.<<9;GPD T,7K4=HFV8N[X_Y M+6G*N6|#>7Z>G%MV6AG*|QX
7^*)-*MK810-;V<"H+BJJ^D;CV"QR*IN4Y9 M%|\?/
T+^0SP=W"EBJGV+RI1/;S(AB:'*" /K20C9IFA7UUDFH*FV)'NjNFJA MLZQ+?
Z%7P%44/W6[,):*+1EKN,N[9KW!%R=9)0,(DSP;--<)'[ES#?%,P/5Q MJ[]7]
[YTMLWKY,S6MBW."A0@[5]WY%MSN!> GQZ^L<|A\..07]XP_3W2A,Z0
M^SG6.Y:T#A:";C!)*CRH,63G;8GEBNIN/\$J@XSI^.!PA!IN\,0G\L;>H M\JLZ.!EWE!V3J;:VSJ?P+M-
!_DQ&0^L)T^4XZ+"RPYS,/="E2@TBU,?0@P3! MJEY
*.5S3D*3NIVSW=8|BP810.;R\|K+VCQ+/&OF\9/@YE4[\$XUS1CN3:[H
M\$TRG@7D|2X=YD6!JP'(|%I**XNXP=Z_11W88DZ|LVT_H\$, %88DJ01Z64 MBV\$:N<'&[H\$E^N:C,[>UZ;?
2J]A865TCH@_Y6!708+.?V.J#Z&*"?;C@V!(8K1_%
M\9L)X(4+SVB*J'0\PZ%#)/5F|AK5F^9QS_K7E9Y"^^+VNP0%DH_#+[^#.R4HI0;B(G>GK<4#X[, 2[I-
F7.0):F@)%=K3EM#7/I8H\$3(!\S>Z&"!L M_@Y0[I\$06!>LWEA*5'3F>@_14S_X%Y+@E#J9L'R<(?I2
GJ/KZP@=2+G0%Z_M4 C?/E_(* M102!=7%/FW7^K++"B6S^446+^A*Q3V^/31@TB&7MX.AN"_?00[S/):2-TB
M804"TK(7_(KM#A;5;-F'Y,2^H|9!0BWUVV)X [^-Y?3EY)7J.;RT+RV^"\,^
M4^TA7DSV1|'S;M+=N4_W'J(9JK_*"W(.T9|&A*68MM^R-? MADO[-D- NJ6EU-3MDJ3>6G16 M-
I|4(XY\NH))]*K+TQE&[460=*R!1=0BD\$ZJ(X,TR6JK9 M/5EM*W@;IPD0|4|)!^^_2CI4WK16=QR1F0_U98).
(@Y?0@N3?ECE-/??GQ MBQ'Z):NW^&F?(6(NG?)|FMZHQ!]|^I.^ZHI/J:PZ=YT?4L&XWQ-|A2U6.>
'E=2>|>0+0A7AS*A?L^K\53'K *F.68S\Y%90?5#T\9C91_R MCY@90CIC-KZ'D>GP)XSAW/"!2L(-
0C9F1\Z8PE@R_3QR#8>[V7_D_]#@=EHYM/,J3H%TB!
M2Q*,4Q;'M(H<6|0L&Y<68\D0_*#@A3>7QVQURLAL1+*G#4CF% MVD@ (A#2,\$7W)H@-
_,B0[7;+!) "8V\0\$MG|&9= *:S8LXJ6)NL;#-+|JX=SD MK'GPW8&=FU^(\T>
[%#L/2R\$^FL+P8!+C)3B7U#76,P%3-)EN4GB0XY(5Q&:X M>%G8N4?
_0MOPGIGKB@A6B"LGX_69V:C1*X+/L01H#!/@D>;C0#)!E7\JMIIJ MPR01=?KB'8-"VAT#W;TTWB;>XNQF"
[:7?/C^',I]|N(#/69!0G6[:])!JF|_I MOS&RCG&DEN<[%6F:0:K^650WYPG%G0)D>.J(AE/GC3X5BW),+"0%M-
H|B<# MNRA *EA#)@:Y)@83?GD62C9-E/,3N/*MWESR|1!NTWELZIDT>)]TD_T'3[TO_M07\54?
7.LR%>)@0)MFL\E2%*:466^3H); \U04U*13+HMX ;TG M1C#51>'N\$>X'?H9LA8:@\W^
MX6JW,0TQ,+=!PNXHTU1A&SLYP/2498L[W5V*,UV?R\$?=&I.G%1]6_7C[9ECG
MAN1%_|&X8Q\Y.JD5*^4S:%3LHCQUC,0^=Y7L">+<1#NS3W?/X^V)>0'GSIZW(Z0\2Y+PEI/S_
RM!#AB4IE2&)>\$04^#0IL&6_2P8B MC>8S=#;A|C:3_4K|91'WH|R.>XT>Z_M
M%63*9KV=@Z!^?;81_0>TBJ'V3Y3=ALS[#=:FNT]0_:'RHM@C;0H97Z?ZR;<1> M'/00F0>
1T]Y6%D_J388>_3G6+P0\$ _#@<\B5EGJREL>2UZBOXLTT(X%>IDZ= M,P_:DK[Y*:0>#DGJER75QN\HNI^~^D:X-
"G?A2*N]/=5D\L(R\1|N4LNPK5 MY("XX?I^;6(S+7QB,XPSA9M^(8X6TI4GB]_KU;AGPI,^'VE|0H\$_ICZUHT4
M@+=-Z8_B="SEHLN=7-4+^B?F3DXE5PS%?CY!]|K\$!0QZJK9\Q*T?[D%3CQQA_M D_:5-_:7,YOK S\5T:@.0|?
NQ>%A51=T'5)D.\F8_011[DXI_S/30_0< MAP58DRV?0VMK:P-?3;^W_P/3N&.&.:YU-\4671]?
NK(7*Q(IJ)IX_0_H_-NDNN:V]\X.L'BI1-&!HAI? MV9\$;GSZS)^E%*WH\Q"JACE!9Q-\+UB.;?
L1(4!U7E/0J4Z'_* _6F\D_93NDS MN=G>[/U=^:RN82\=Z]>E\$*WT\WPUUERVJEV:VHL(;TWV|YB6I?X4RS@Y4&>#
M@6N4_V&WWT4M?4'IPZ1F>4NVH3KX6|]II_20P\$2XEI0X,&|,\0B/A0(#*:J
MKNC0Q*Y@%\$KN4J]>XTQBB7FT^E:2|A:T0|Z#J@Y!W'NI;4B0G|!5N|4%K |& M|Y9ZKX(BJ-/DEP=-'/H3C|?>
D^!#R\$8\$R#JXL0\$E)]Z68Z;.WTTNZ0@F(7A_M!>=F\AHE238FJUA0,63'^|C\$:2;|4ERHF2Y:" QZ-/\$,
\$N,\$" ^APXAWV! MW4HAV2YWI\|VL)>AR?3QG60(!+0A*E7|\$-H3N&].#T*.KK^,/ ZWF.T2H,M/ MP?7^%&
3C30K;@30W| %R|*SVX2=G/#IR|/'99U)NQS\ _M@_SCD@*"8P(\QW"NENE,0/^?XK>DV9>(%:RVC^092H0(-

:55?,Y3R!DSX7%. M'X6:Z.EP)%7E5*Y701>"36?A"F(:K*>H>\$IT=((<J26,7)U^RE2NH3}N/WU M8[69Z?P
F"G1 H^)BE3JH+J5P]G PI;ISV 09BSY%F%KSLTWN/_04GZTL CNG'Y..\$H%KKYS6 <6CC0Q&):E[B-WV#LMB0!..
(M?L!WXVB\;FC='4EHU("EJL(YM]MS*6="-?NA[)M+#+Q]M=HKD"BT,\2\$ZE5U M
%3N4P?.W(%Z^'!'!/:80KX!Z 8GGKHQNX>^FU+RVX5=JU&0CUZ_T5Z1C0&K#
MN\ 'GJ,,KH/@E0=RP220I)H1_0^_::0*I]N<- 'Y(IBWSQ>>JC9,Y4GM4'4H"0 *WLR0&G
M\XCA^C=2*'(U02)0;N%.Z:}!\$!RBVU42<=J2F*K< M: ^4]Z0, ^3KT>SM6IA M7[RHXV86BV)B^9A 7X>9*EZ5>9
QAW#0^ 2AIYI0\ MT0Y'R+>*9=LD7R.^Z@7/2,4\$LPD=)H#? \]QA&Z-?>;+0\$2;_,SB_XH[(Y2\$3
MW[7&=I[A99:R[\])?TS:[Q5,!G\$'(>.[3I"-[CAYZM [4]05X!\$D(S2DB\W5
M>2!^ *K;JL4NK>]3T:/>YJ) 4P _N]I8]1')N Y]F-T]J]3WUHW"W-700Z_ M-7%'[V+\0-\,?>B?C!P
[H/']\]VX3PB\$KE12BCAG(4)<96\$0'9(I= @)L90= M1C:\2&@1CB?N?S3D%\0WQ6-
0A>=:1]V0U\$B5]Y,+4#+0DX MV>,4P>JY7CN/P?8?BBBLRSX,RVZU'F0KS.,X? MG*0^(Z?
<>V=MU3' Z5[U(*D\$/V)W T&/5G-HSG=4+!A\$5_.AQZ';> #P4G
MT1:7!HPN5\%K%)HYS0;>G8^")0=;_XFT _U\A8HX&\$S":A?<\ZM&]*XV[->- MX:7?FFQ"
<&SN:0W67R4;_.ES\D5]S502D:_.07BE Z;U9K:@R;Y*\ |8)\ ' &2 M,AY&+<(T%98M0[E;HHV.D)5-&L?
I('!)N=Y+]] T/=BC]G1QBVS /2>E:N6< MGS7S@)YK5H)72+0\$H1771.LMN9/4<)*B"QG;TZ[Z04%.+
<&VI;&]L^4Y89TP M:Y%US^NC ' //VES>G9-* BG?66+) 'Z=-)9: ^B42")>F-] =V6[9]2 M@R//U55.2=6N?
[CIW,50W*OF<2C-W\$ M'7Z)@PGPT02@JU+MB^"JY(3G='L0 M,J*[^2DL# KPS#/'0;^%JS]
(N:Y^H2PD07@9 JF6-P]U#)X)) M;K(I:9@=0>+J5];S;=<0W7I=)WU(GCAD@JZY]!R L0.7H/-
RAK7Z5BFW&W[6 MOGZ?UF]\FG JG?.GM ^2WU&I('1"[/Y>"L0%/T0BQ ;7 []=SMZF?M MT#,3B'?Z^K?
C+ONU1ZPH%P-=8;R&&=M M 3S60U+[]_.55+26W6%TFAW,C0\$32('U0GC%?'0P^26.E,WW:S^T<;EAVRK4]2PFY?
OX@HZ1:D ?S M*HID3?1A"\$/XX2(SH[F(VF84^<[5=@_ EVR%6S079"<3WR8*=]WKNNTW*QJ M2@%-
_K@0";#XPCBZY>"74 W+!E4F9+^L3M.\ (]/^]SKHI@]@G0\B<@0 MX0'BE."K%S;'0G U9]! '?
K92;JS[JJ<]*PFW=0M&*H4 ME=;P6>S6/;X, Q57+28@5\$A=Y2\2 =0R97T^ E8G\$M+\$8YJV@_6G'T\ =6!
M\$B7;M*FY!)S^&'BN^46P<7:VS?>7T0J;J/0^9!5F[2'FZ*!5; M1MW']RAB:Z ;X MXT&)^#M%>
LY_9U9\R/(@PH]3&88SN1Q^CRI)QH],&)LYX. MC_3*"2PE00(A\,XY)S'IR<^Y-
HZ'HBP#7,W1/*GG9]=LN@U?;@P %;2/Q MAW*[^"M> _\Q'0 @OF-2KVSNBRF0(T7Q:P+|E3>;G)9
KC\$:03&!) *L@]LFOR M[\1?OMSFB6/A\$4 MW9*-H016LA^K556VY^;&%GWP^0 LZ/.ZPQ=5MK;0A?C
MICA3:Y\7:GNN E*(R_42XL0/. [. .U\$ _ZK3_ MX[/_72P4]]].4>A^N7 (SM6 "XDI6QJ1"+?&[Q]Z'C-?/J>>&-
*W, X;% TG5 M/FK6>Y\!8!]2"C:2)=.P?,M,@*0W2CB2GUK2C2N,%=.WV@0J)1'TI]_F/#-I
MAGJ#03H&YXU&;4NRAX\M<;!7Y8I\ -D\&FZ'/7EBKJ:-P,PR0!Z88[1C6N^
MQU48Z\$X%E,:0"703N&]0U+P _@U=<&8/-0'2\$*>;-+0TG195(;IMA!U;H/R M.SB"\PF^EKT03Z\$B7]Q\V-
:.*CD2"AXL70WD6.G# M<*[4/-]=-%;-R)[P+-\$RBW23>2IISWRLSA;NXC\$+:=R^J;J3)6N M]F((-I-,RE:&-
PFQ/134L?L-^7<_3"TI]^QBQ FR,KT%585_0,RIJ>,UC ;-<
MP7HY7I[ZJJ80^C!W^C(3\#JKP6>'[HYH,W2!T19DAR6\$I)030U)KA0L@2<>4C;7>S&]
[Z/FXS33_),VD""4LUE;,<^<'4!^ NH980L/VL-\$B" M9!H?N)2@0R3)4 (CH0%UB] FRU^6JBI=E]F+:/.
<\$55K.??Z-706J&9!U24R? MHS)R3DYCJHN';C.-MHQ?^LH\$B'?)J*407+EAL;=5\N!S]GZTJJ?
Y@1=\A9)]6*T#%8&;D2X^9\E+740""&T'6?A"8C8G=\Y#\$. MMAC)00N&=.*#+&*>4(-
AU8F@ (RNO(G_K!6#8(F6V] '\$88L0R G"EOU!INDF0 M? ,>-\&B8;LK,64V T:[Q#K!=&XMYZ?;UY><@<;
P)HD_1YYEWX: MPX6CSN&SZJ,Z.(IA" I_6QP9RP"KHU0@ YWV+ONZRJ\#\$"1[Y&K<^E]IY_6DA
M#I#9T/ECTIX@MM\% B\C6WS%:5U505%IG0+50F M+QW9V3-M#-7J]/>UNXER00A0/D#S,@.OCPUVYZ:
[4_6>KM*!=X&W*0#GUZ= MU >%3Z5QWG: (*+3FBZAL>^54 "/#38N8%06F4G-H3BP @0%0/E@8#;L/\$D*G
M#!CW-#0X=)S;NJ/\=418 (61L:AQ\,\AH_RKIY_08F74PU]3((#-4/YIX(M@DC!;*B*??JG+)N^N^(RMB#N?
>G0;-0H> WB_29_1>JG%EUW;S95?C)P"6=._ M_2:8C-
=W7"CN+X7%2,N*VAJ+KZ.X*;K0^Z%GVK75,NNF[MN_%G_R\G-\$G1A; M%\$",4^?
) :U#1XC,0\$[''=6>82*PX(T!N=-3>\$EB>I0N1@(%<2(Z7JN@=7043%50:\$L6QW M6CG\$ZP7A9\$9'D9'5&WK68TLI
MOBS;/Q_UR\$1)V;M8S?I=#]=>RZM[P44"YI1]:R9 BOSQH.LC& MG_==!BSC;:#VFR3+^\$AN*M*Q-9Q?
U)S:\-9;LD7DZMC:99;*4HRSQ\K]4J? MF%@: ^D]X1Z&'%VC&B^CD!A)^@6:U6:8&\$;MVGZ_1%:-#;/,>^
M6;QI\$=0)'B _&GN#YP?LC708'6?Q6!>4S57F9C6;XM^@Q'5CD7]HT30X/-LU/\KF?G#;+G&3E-('0/5N63,%?
&Q&9TFZ M=+/'!;XUHR,003:ER=Z09NUX8\$9R4G002JC]R3R\!5>UA!W0J6>GIN#K=Q)H M,K"0/@>G-
HDF*!EJ]@%EV6;HD6@9'J'CHQ""]]+P;#G=>_JDG2H[FNUWP@Z4 MK.A*MNT=QG#9A#45@:@\$RH_B]JN5F]>
(\$D/6RK*31T3'Y%6\$0TD]&G[]]W< M\$7C2\I*XMZLT9/FM*U>DCBX%KDXP7Q+U=!N\$7K+?6,R @QA*9"W2! D4?
^_J1]K,GW%4:SL.2E[A'K@+HTM=NE9!VNE/XGD;H05D6?3E)=!#VT\8TB*6D3:[LLL0PC(!R-GINWM(^EE5
MQ'@'_,[BC0TFX,-WCL4N22JY2P4&,B=K?3&ZAE>\$N8\B63E7PY;0P; ,AR=T'
M0W/MC\EC9]9\NBE(:IC+/#^&5-Z8ZH\BCFS\K ^BNBVS0<8^ K&,1^!/D+E3 M'(9'YFI@A;1%;U%H9BF7?
7(=L9U29QN5#^EN.^0*!;!0!) "GA+(2F?J/F8 _L M4!&F[52K0"?ZH\$>%&X&?JSNB;_2D?R0F&[Q/3
U^L(]NPBFQ0%96PQ8<+K# MEM#Y_*+TY0F"]N*2DX0= 7F"0W4M-^5,E<;ZX_N5?/ZNY[=ZC_SNJ8,)41F??
RCS60W>M?0\K7\2!_[5F[H_* M:Y\F'Z+[\$L)]*7F1CZI;TRHC5Q<' \$K5U\L!AE6KX^:5Y.L4;@XIX&YPD^+0
M+@X*;!T@>_68@'_6V]\Z?C4G>?0_H]\P5I+\$\N4U+ELGUVXNM,B;)?3>M[MH)21_4A>_ 'U57W%4Q
(9NE+1ASI&_63!C:_HCO @F-0WB^45EB&JC(OLKDS\$ M/\$A>]'G5/[>L]?+38.KKJ6;"IS=0NA%'+X0TBB
U8/"2LRS-K\R8^]LBB2\$ \$ M: ?Q\R"*SHQ+S3('"WQYKQ8X4#P]IH]WYV0S&%Q!0:1;CC1&'ZU&1Y#M8\$ _\
MM+0\$*[AB.4SP9EN*-5GV\7#/L#*R-7)*GX%RRHGI+H"WG!PY_>5CS1V=N7H0^Z^R;S.G[!&!:,[: MX2Q*(G?-
@_UNY*S20I+)EI5R0: M61SKBLRM'0I52K",) \ (A00MCGBP1^X\B2\GYL?B^B^\$'F1&M[K*@@WI(&7
M'+:VR9">/_4-%=L.30=8 M#L45)##R\$]A@0(-=X^3L1KR;MH+;>Z\$?CV3J9L^IP&*T;_# \ M1\$1), \$-
+5@^5_ :A977!'@-\$XB_S;?;,%3?.0;=!\$Q;:FYS?;2=L7EUX);\$JA
MR8975] %Q^K;C(+FNL^8DS8^*]RD[&I"FL" _V[P"TZ00:%Q;]4M6"&C,E/B MLDBK6IGP:@;Y./>J:PI*
BS'8.4Y\$EU%\B17DU;R6!+ \XHJ0\NW9#EL?_ \$M MS04)]4+[5%0)' .&!;MF1%TJ7,H@<_ /T=
+;=)2#&QZN#FZQI274C;71/PAVI MN3KGO/5QXND5LJG NQG.B[]34\E#HEJ/<\$BTT(I:&=[^!Q\$>V).@ K0/;-

MXG 4XBV%6HDND%Z?%6GV\X"UL M65<':ZR3#3R\E*RX/\ 0'%;M4N-
HL@0P8%B0KWP9^0%=0+;:W\$T621;/2+TQUL)\!\',J63D,8^V]?XU;BRKJ#""*OG ME73%")-
87/17(7*.*Z]Z(4L@!43(N7.2SM .%15&5("ECH5M[;?A\1U!NI MV#@-UWJ IPUI!
([I;:T!'XWG>3DT^/B;J@G(=%NP) FUL[^, ME**;DP6[QY[GY?
34JEKENY!&45I3NL[7;Y^DR>AG8E4=7T\9;^V]?!5L.IC% M'A6111^<:P "I0\;=#%IPM3P?
J!'KV.;*EZMS6:NV7-4+1RFA5#R=DVR%\ '& 1+DSKK8QF: M]-.S.;VTMC-IRG=
(;P*\|VW;.K=,8DZK@=\4XKJFG&|H6(>8;:VF?%JJ9%'I MSJIM4%R72,MXH(5Q;|]5,(LW|OPT*E-
;PIXH2/7I_504Z5YQKIH;/GLF1/02 MJ))\$((T,V08\0
YA0YWT|OM+!T;\$HHO(W.10%^WOG^I8Z(OA/;@BM&@M9E M VA0&J>Z4ERS!KCWL!)\T9*TL?
QL6XZG%6E/UD|YU#0./ZY;^DY)WW: *,5+ MXIYM@0?;G|T95>>11^*WEB-Y- 6 + #F52W/QRFM"
[-1\$8)00C|J -[:GVA- M^ 5!./+DZ=VL|S;0!A5/\$\$)H>@QLH2X)-##L|(-&Y_I4"8M?MJX1 WUT203
M'5G'>3E>C.=C#+QWFT3W()F.1N+3X=WCIB^8T:\$|;KD_HCJZTRK'&
MKQUQVH;5N*0AHE%+E9H;651J=2RXG*0S|=5AE5ENYIJA7;NBD*-.:;>PENJJLY M-
.;*SDV.R.6F0S2@3K< |=83%VV0^\$ &61\$ XKF'OV>.:YU5\$N2VKJ# CN7K M2EW-!(A0QT72TD<7|JDN%?
C5Z5JE&6G3F-^!V^\$6%VZF4)+JE8R!\5G!9WZ= M|W97!PXM0|"/TI@ @8B)IZ\15&.C.V(;;C+Q-^M-
P^KQ;B^XFI"DAM4L0ID\X M4C06UPKW79;1XIJZ TJZLKK1%;NKIU7EVE5T2.W(9 ML% W 4R\$ZD ,_+&;
<0V(0!;UI]/%BPB;RR.[9D;N2J5*R?-P4|V|ZW=[WI8 M^31;|G@G5P<'09B\D=:E0-
>=UL5(S#M|MSG#0=@M09=3>;2M6Y7?K*|]03 M64E5'"R ! GB<3?+0| 4VWZ3=4^Z*?3 |")L^TIQW=.B1Z0+
M06#TE@I;N^13WQ+6,&5EK"<:@C/1|W|+%2G47^,@55A?X0 ;JNC90=V0,9|Q M5'LB.QD S>
[42_6X>/I&_*#BA>6)\40>|.TDKHP!.J&DT?E9W4QP\$)*B|2) M5JI;2YG&%ZE_/REE&68@\$\$+;C;_=[C+= 'H2
,49G>5\YN; &5|00?0Y A!;S? :89W^F5N-:! M\52W"N^@0|:B|%
(%WEC_SXG_.V7,@BPM|' <9|N)ISR+.0|7890>SDU78JH'5 M(F+L81DL&?T&-1J?9A|]YJCL45G(*/?;K; N?
#=J(Y,J9_#%[=YR5>.:7|M0 MF #EH77E-*|R6!B=?NLS#X3('HP65G\$5>--8V9U=.02-N,9PN"N50D 8.#/
MFK!NBVC""*79;ZCYI!06W?*\8F!N.Y<>' M0< 5;Y6/O&>Y 8%BQ;K\K2K\VF(,8Z|ORNPF900Q6T8";J@?
5TBK<=<#/[; MW'"|@70I/& \$CG/ZI)J40!779.[?C|PZ^=<'K04ERN^P!|_ \$ I9X+42CK;@S M&2,0CB5*
(%42CTA(J4,)\TLY^T|AQ6;&(04!;03^3@K09_#ACZ6XL-GL_"M\$
MYI+BE63GDL(CZ@#|AS_XT7Z_L3I/G+ _AM"?/,P'@V+^S.F;GYN1|38K-!+ L M\$/-
&3.,L@/07\$'|3G!E%,AL5D;EE [HZG66= 5S\%MONX* -;^IB;*,!,\$/>P M4W3T'0(FXD;P|\$*|Y|(V\N<6XE_?
<@J97)-/-. [^|071@&36C?S+6RHX?='H MEU,\$UM@+_)CGSCW90@/;C.4?^H0BP*E6" %?JHI/1?
#T|T95/+PQ^AX82|V MX/>_X(!F)YPHQK>19Y#JD=17\ 78-J|@&D!_V'C:YF=AX5>&S1.G#<^Q.LA8
MT7\AF\|SXV;_M*27M(F@-E26BW(M4*L\$A8Q^145V@000@|7XHD|RXH"D_Z5 M=-F B2A)SV-
V;*VIHBP(*\LW9N5PK4N_JU28|C+BJM=UC+*,<=Y8PRV\3><& %5#H,E"6?90?"1L3\$(P) M^/-W"
(N2=&Y9U4\=MB169C, .@|G6PE'B3LY?I<32J;\$NPK8?|1R=AT3G60J
M'TF3M|7#0|'"Y*ERB;\$9<|WV8M37U6NX5(%H\((Z#Q1W&)K73EU?E3/V_,/Y% M!3|0|0M64)'--G>4:P_??-
D0\&9#EISLG#+IB97M-+A3R0I^0>0K#<'1Z/N! M \;I_XHJ"A/ =F#=\$%!0/L/:I3U=>6M>CG9M=)?
H:T0\=CH6PE*;5K8C6LWB0?, M M?'0X02:6_I'^|I<50U70#W^KV_.J/A+GU/\W^/Y6YN!*G+|,=HF|'K00\$Y_F
M6!4|:)2^0;P7^X_BMLJJ7#^)F3_2Y#MP43I@#=-NZ1|80+%^+(+F^C759^A)I M\T<%4'I"WSJ|18UJJC|91-
F0+LL @3J'^^X:WC(Q0<\$" Y(ZHNUB6/C&P6PF M'4R56^1AB6Y'@LIL?%&7\$1!'"-
P<.RK^GB3=\$B6J^AG\4.\YM42IGGU7D|Q@ M V+YQ_/%)0Z%?U;WM&=/, '!.!Y.Y0J=0LW&G
0_+GK'*B50A4P>|.D)P:F:, M/R/"XM^ >2-;G?'L_/(Q)V#;6WMWDU>+JEMBZ>GK+B"-;XPB+66+%0GT60
M%:5?/\)04XQ %NJTEF3&S?|&E7-|<-J'42VLT\3R7ZKC|Y0^+5*4^25SDL|2 M#T N#%FCRE@F+A5I !NK+#!
[Z|U\/^0_W]=U,; \#4\$#!!0 (">) M;5FLRG6UD-\!,*. @ 4 <6YC>"TR,#(T,#DS,%|G-"YJ<&?
LNWD\E/0 M-WZU+Y*=(N84180*J3|S.B5)3"ADFZ2L,4FRC;E.=;(SH1)B3B25-,F6=4|6 MA";|;AC|.C.&,6-
FKKD0G7,^W^ G\ W|<= W/|_ '7BA98MVX=\ 7^!PC|@=/ A07KU|@QT;X:|/639LV;MRT?
C9NV;=JT35I41%3Z_@A_.0V+IA?NNS#>0V >LEUFV06">L!1 L&|3 MNA\X* 'N04PQLU;MF|;+@)?
4"0.K^W8L?T MCY\X>?J,\5F30V&F|N'IY? G8"[@4'!(0|^>Q@>\$1D5 MG9CT^,G3Y&0M&.*-
CXQ.34],SS\$76TC)|A<--7=-K';!AW=^/ T^|)&"]UF !@D !0BL,Z/5@'|;SPY0R5:L M?-UAV-
!JB:-.2J^M.M(U>W7M-#Z- *|?N_,U9>1;(#\3>/WLW?,T.F9""!S/ M6G0Z76_.S-B8!3ZWA-
=>?;^S\$PN^90:VA(-E?R0 S=7IGF\KL*RHI'PVN!< M6W@)H\^M0\!KW3^B_A'UCZA_1/U?
B3K@T6)26HEZHI#6SK52JHS2.>MEU#+- M?
STP1/SZ;TC.II,Y|4)K*L\$!%37U\|9_#V\$K=*R^_4*_&W6VGNPF)3,K+5|
M<6L'_,"SL*+KNZ(|)\|6@3|Q\$@+J^F+@UT?>/8G1A,#2K,#2G*0=^?NE0ZJ) MFEBF\$@*Y=0KD;^K8,8.C:W+^?
*E&?G0ET2VV(Q3^=A#R,^;?;T|2=+|SD\,=G)E\,-7J|7@F%'0NN" YBOM@38'AD=91ZX.)ZQ|;4F,6L
MQ5<;2|/T\$.<-2R|^4LV8;:J.)81Y@D@>_QFWICBJ82F+*5"3^|(F@6|R;D)# MJ:^^SJ1DZ|;\$&I>% MK87M(C\
FRN8;SQLA=\S7G00DY/D!/PF_K'/ZL4?ZGDN9WDNO_DD"5*/I&Q
MN;H&IM6B>G|F6MT>JXXMEN:T>+6U_R;B/7;-'"S50?Y|P^M7+!-=8.8@>3(/ M,9D'G(S&2EN^C&S='U_/ \$?
KR/.)|/."#=#I"TOK3.600@?ZS^0F++RZF&| MQABU7YG|^!, '=,IC!A4<)XN&%('9K/E-U1P3T7
ANJ0@@IN\J/|JRC=#RB)\P.;Z+ M2Y14|NG': '"(|%5.3)|(:|JUR(^T;=H\$Y1/"7*6)V.A=7(R+%'I6-@W(? 9
MH|0J|A|WL\$#|QY-83Z9#\$ -2)X"8'P9DZ-\$#@= PY_!<"L:U"0#2%0% MR,)|;N0(@=TDFJ
MV*&V_P&"\.\D!.5)AYY/K^&=EA,"J!LK!7WD_P"A^Y\>-=Y9/5=6D#\8XA M#/&/(?XQQ#^&^,
<0_QCB'T/\8XA_#&//(?XQQ#^&^,<0_QABS1_R1_,L_XE MPP>6\953MR9#"/R7D"?,&"A"
[E]"9..34PE8ZU+0>8W;:9A;"NXB_Q>W'E/OPHK0\$QI_&CP;-C@XDE|U!/PO>PL|SDU,+&+IN/Y?P--6I3Z
M>"80TPMA2&=8_YX+_#DHO/GB#X6'.C5B%M"#2CNW\ :US^
MS8CP800@=J&F_, "D(7D6_/!/X7L!YPA%3U;YZX)" A#^MC=0W-V*!\$*[SC M7XS=@!FKXN3--Z0
"S|C\$*P^T:Y% 7 M:/Z0DP|U(V3%^-^T8??I7_-?U)D U)4\?IT E/D1)1E?B\$4-=?|=9-" '@'
M|VLY1RS*J;L|2V,)|@5|M0-C#?;\$F6J3,Z@F|9TAR| \OH|BB^YIH!0',8""P MAP9\K)7J0!/3;0E?
KYU/*9HJ7F=>|NX3(|)'(L,^PNL@CN7AUF(|!D+%|3:\$_. M(J,3)0-.-^:

(X6W[\$8J/K&^4WJYW@A/;L)R(.C0*9X'7\$A,#X&ZX4:>5VE"GY0 M\$ *)QX0 WUB;K[M22U_=18& ?B'
E!F_K*T;YKV&"S&\$<*P%*8UADV^\$0(T% MWP)6! X(%3@\\,-')D+P[?#?LOX;9/+E5T';VGV?(KP*
P_[4RH75TF>15E3+;?>/? M(.%MMC248 ?Q+VE/.RJ^,Y !K&KOSNG.Q["8@LG7,,9S?)CY%TE_8TR"Y%K
MPMS %L;2\\EQ._0/Z4;LY:R&03* ;Z4/R&G|#^K\$-Y.N:U&6=PF!Q?-4(1!) MTHE_ ^2E(T)@[
E9"\$A8@S5G@GA0^._F -0TN MT5U-<3TB CF;T35FGY&XJ0"K#10Y81@*1\\E!V,QJJ!\\(11K(2T?UH76GU01*
M8Z%?KR[\\,* _NZH0JA">02<)D&,%J)9 9.\\6@?? QLH*5&G9CN=F\$ST]>,Q>< MB;I7,F
KB; QY|DLA\\'!'^E+JZHP1: P->.@S07Z6\$|/X:;#EJM 62RXD#IXY2 M.5NVP#08F3";ZHE+NV& 79-
_0DT0%6 \\G>U|PORE8)&[IQ",\\@HXB\$XEPSR< M@WE C00&M4,/X*C_11'(E*E1531AQ_1(>6Y\$>|@'&U;2ET
%0V|X2[|@(/_P M"3CWB13 HG:A5F9@L)|VS=0&\$|/*E*ZK7-W1?2WQ?_Y)#1XWX:15 #Q#<|2AH7SJ,++
(.1B8\$0DBL MQ51M1T6'\$/!T1:U5(^_EMT+@&\\2"L^7#&AIE=00LC9J_\$,B'DJ%-
VBR0/%LH<"4=Y&LB9,#0&"P\$Q5XM98P0),ZS!*< M[K\\<60/8V%'1!79|HG,%V0SMF(D?
\$)L#0\$8!#@Z24UC^@S595K 749AB@LUB M BYAC;SSV1-1;I_&8=*RA<_1,W|+-
(SLV2QJY\$90!/1@"\\3_(0M12Y)0*0L, M<_E#5-_.E!%A4CQ#X2|9QVBRY,(#
(R#>\$0^>4/VPH6&0D?;##. !J**\\#REHA\\ MX|N=VGI\$|GL47-"\$P|ID|I,? _ 636 _MZ&BH.WP6\$?
^0873!"SS40UU>T>PWU M-*P5=7 85EH' :X;\$:U #/X^160:%7C/V6@8P|W|CCP\$'M;-- M|J*BR=>&5Y>95W
YSK|F9N\\KI03H%Y_/6V4%'^FP- YC#DE;&@/ N:YKWK:2 M(@HU!FU600QZ|&KV-Z^?(MM|1FM^,\\/^;|'L?
T4C3ETRO?I6G4 MPX?2EHY;/L//V_Z?V7)=/\$U.:|0^,|,;&*XKDY,;N3+YXX# |'9VLZ6<(IXJIWN8^C
BLB@F76047*?|YWC;15:P EPC7Y; P PRK_5< MY=08!<*1WAV*(8^SG9|C-X623|=
[9%9%,4A5^J,4V2#7|V'].* 0AF;#|2? MVP?0\$Y%CL<<1,V%U:076'#U5L8=Y43Y6#^|.X>:-P^#LN7.9DP_|.
:_.5"J/_ML-88&W3#)6U3!1SPX_+<4V'RWW0JDGLX 0_)7F*%,#QYB&"NFD1|^@0I*;Z
M7CW8!QB|Q05^FB0&:)|WXV@I3?)@GR1K#\\K<2U'N2;LQJ#\\DOM7*SG-;/ITL2
M/5EIX/+92TDWSKQ0PWDUG.%V:NQ,>B."*4TSEKXTN,=@3MK6>|B,@/9RD0/ M:T%84_GBK+\$*
(->*&A6T=|FV,15'A,"9T8/96(Y.&D>2HGZ9%W-/+.KPC.IK@:)C;! M)%#0&3)P\$"| [8&^F|;Q<\\0?
CDQ**YG1K)FV, + M|T3.Z)8'PTREA[E30V0)/&>>5S>7<5-2|=08KP@7-\\X4]"J35|GZX45BF|WE
M|+5*/30#1\$Y41,U/G-@8 B=\\F6U\\T:B;UV\\K7/DVPCFEFBDIQ>HHI#"+"\$JF MPMQS1+"S?
3Y0"J3F|H'QIM>%P, /HN ^;KD/YRI(PYDP=\$P+J|J+G+;/#7WU
M&2|ZD,Y07<0&&Y88" _K\\RZ&R_4C3VRP|0^JN)W*1EBNR" T+ 6:S9N9(RGRR3@0;_10!
M'&KR@Q01II.K'B;:"^WBU&=ECW4F43\$|;R=@T|E&PW|092QK+U^I,'8_ZI|C
M; ,V(!NU2MH5H=@^W/GJ)' \$TL(!+P80E)M|TM7<|1\$ZI7#?01PPTH/"K#G'CR MP_20?
+9%W3WD=F'LV|9H;=CUX-')Z\$\\EIYH<*BL9-3,[H=YF6JUNU3;I=%/SIJ'KR;>MB65A;"%P M&/88+?;5
M00J@_[Z _M>6QM+E\$#@S70H)/@+;X|AJ6>YB+&UYQ\\BP.EKC%<=>P;/D M9(T::=38FX_G09.0PTZQB'N
M|:1>N\$!BUJ,^AI<'9P\\>>Z5R6#-V\\;Q)TCB=-T5FM570_V+=3_15|-BBWSL _M#W?
4H9JU%"%P: 'JQLBRU\\X75\$|3K?0I=C5;,,<=>+<8A0K?3K)N9SE!\\WD0L MF)\$;NIX%I>+'|U^._\\-9L09B?
D,M=: -V1M\\YIFA1A<3\$|'EB;@.HE&' M*8#;W=X9P7.>(K67;@'M.9=.EJI5RRRC/'30*"+"\$9.@6,+Z%^_G|22?
%I-VG MJ>U#.@>K%2N_E|=\\J;E9'L|4? M@!_IT7C|(-
\\5N^_8.^7G?|; &\\0=|G0L>GXM2F|Q;XS*\\G,H)+*DEK(H\$82_X M3<_3I-?H>?2+WAVDW5;+;
[WJ"R,\\4R.=XQ:X1AS6B(W6,G7GJ\$6X)XIVPX77 MA%U.,ZR>ADA@RB(W3:-
E|H2J00!S08,60PV>;/5<8FW7H/*5>>)|?>("B9,9;NI-/ '6X:2F,V'/B9|XNZZ.&|0@+@H>0WMOV@4.0'G-
@#CD<=,T MJ|;>B6AQ?9:*B\\0W%0|4<(&|D3.W,SMP:RB\\4|? :OK*L,E,'D\$1=B'TKEIF M-
-/#7JK|JJJBMF|&#NB(0%A^MG/G|^NR)S#?!0V|IL&)9FEBQ?I:X'\$VRT?AI MNW)FY-
1Z9\\E;YY+&W^\\G,H\\>"734: +@776HW0;PP070.Y-0PG=2PGR59Z%?^Z'/OKNC_PS=RP5K|TT
M5;2+SVVP47ZS+CBG_41.V|/? SRJU.S0I36AN@IB,%I8B6WW|INUS&NOKOSZ M)XB/>H@?*-N>_77!D9\\3?
U#S6A>A:/>6V1G|9?W)_NCN3)1K_12_ ^*6T_> M#U9@_R_OZEP!X0J|NJ'| (RB#'_\\# 'D8UB1PRNX>
(_A7:_.J.623YC)/X_?CDV_M6FW#K_ ^SL2-UH^/)BV0>93@HMINF*?.6|5=*S\\[* M=+L280N2K'-&)>=?
RC_0',+7,^?/ACC'8I;1FDS.M'1MH_P%,Q'0=W#|*|^_MAU/+B>U\$!9I2PG,0)Q|P|RRH4H&W+S
T\\;J^R=,E\$P+*,X#5>.\$|H/G=ZF;:(::(K\$IB_\$0 M<@:F_|00)K-!U|)P;,&
0!^QB\$X";K2=: #7!11A|TY00YQBHBI:LCI^:08 M5\$3NN?EYT>IPU,H(6Z:#B_1MYG.8XJ&12
M.,E#^@X^(VTFZ;=>&0>8PLG810YQ5+90" M@=%9I90\\(HY&|(^@AF.UAS W<5YJ?ZZM\\W:MD?A4#C8R)/
MG+R"P#R3Z80\\<[R/XC^CTVSNII|Q,DI9009J-,V/ MM'/M8S|+XR(U^C^2+Y)=4=QCQ.T''+CT,
<3./BFIX/HM|KX\\^\\7L@\\6/0U?! M%*8.OA>SR^XJYS,\\:E_|<3?<_BS@-;:>|MMM61VS>Q|NZ@0>S+
//IEUY"6=H_M3P\$757KE"10D2TV.M&3759%'G7|IZEJ!)_V6#%E9&=:%,QX66=XM
ZQ!;!N\$0WS=Z^!\$\\7|QK2^Y ^XL>0_5 M6500:=AJ;1GL|AHZF; M(0//*)C05:KGN=Z9=UZH MS&<3?
L|+; 'URHEYZP+Z_ ^0%;B9&1_CM?I*#3A|\$;7^10N"+UB/A9HSIR*^+6
M5A;!_F62\$X/=P&';^_9WL45)'M^'\$|4>R?*>7+\$TV|YXH@5%/@ODK*V!1
M62'H1NSKAJ2_P?/XUHG2K(%9I3TZE;5R%|&_K#&Y'@UZE@B2@=1GX9KP&94
MD7RPPX'S:M5|9I4BM:F/:QVJDS?,|=W;QILS)E_0/TE,&N<)|@?F+J8^#K\\X% M6!<;+;/8Y360%&\$,C_,D#:
(4+DCP4H\\8WU4F6B1(G!;WS'>C#?5Y;K25P^%9 M2PI2\$W=8B(FPY>."C\\C#Z0-*AV^"/4?7|L)V-
TAMWMHO,UYH|V8\$#)|K\\^_W\$A!:<1!Z^"R%3<3IK MR#-
P2(0G1@S;\\;3|F|!P*5!M#/_J*&H@8Z!Z@%K0STVRCJXH0JUYII_YG\$W>3)\\:ZQXA=CG&2.UTD9_|PK.J,+,Y8
12 M!MY|Y6&A;>#|I?; X3_@^BK\\W4V09:B2WLO130!AGB)LY|ZEWD8N;E)|/%
M/#40^D|=E(Z691*;EVPZ#!5XDGO%GEJICX/U)T^M0254WKP-ZQKVUM\$S'JA
MXL)K1%C:!' ^1J1\\5("8/M_Q=I7>TBA0:*|@+!:_:(85DK&0-4&?P@7NH|_B>G_M0FEGJ22;^P?!
M+R%|]]IC>B#ZI,*-[C=RB+37EK+:0^#N)U5-^RY_19%:) M\$Q_>QT"FY?04_6-
2N3@_M)2#27SY^4ZE8L9F)4\$B,|,06NNGN#W6Z%)|\\2N_M&\$1!7|TVN2PP>\$!_D)F9<0P?8Y,
(\\15R5=VW=\$8U&I3""T|M)6<>BY;"/)GMB3L0>&3HS2!_#B%!:1;_Y*&+ECD+W_\\|+PY_L@DMK""9I8\\F:
M<[C;34S'C-;://:NV;\$80%Y%FP5N_MQ""N|]]>Q0SHP7<0I>90GCZTW7Q,0*" _]\$#?_%H(2/*(7/=00?JQ'
\$36AGB_MS@ZBKJ/ZDFJ&I!@52AN85YR4AMHNZ@HN3GXE?DL*CL61\\UUS! M8Q_SGM5>ZS-Q-2-

/)4GJ#B_G6@C|Y7\<6Q4"G_-IXG#'^+M%TL\|JG>L&0<< M/1 8&Q"W K9KL^/PP;9#U)*5VJ8PU<\GW1|H0A<"
[.*'FTPS('C+>H_ ("44\$&+MB'=P\$GUHE3I5W4TI[S24*3<2G7,^0(M*W(/!W<% "X&|1IC)&/#L^; ;8YZ-
S09U/\+?KBQEN,B'UZH#7Q,+ODL4@>6<, MR^&@=^[T^R'G\J0Y^Y7(W&4=+FFH;/L0=\$?
WVEB#N" ('^00H|:U363Q\K T M\|6LX0:\A8W7'(+&\$4B+; &H+CL_#997G5_-80|R"C,V,'R2:_*V^&1W9=^
M\$MA.S+ #450RE:,VTB|C%L00@;54G\G%2I*VR#3?DN:C8?S1P+V#I-P^K(^: M^8UTX&L
L>>"S0F,.NLFM9M5VCI%!'!/&AGI0_F49X><"5Y<=5<;U.6%'HMN& M,-K@4S05Y*Q'4H_H^|0%*FD)
(JL.!*'/G0P-U80_2?RZ(,TTP_3&B\$@*/_ =3 MVQ<.L,=NV0-0-%0-57Q:"&R;KT P\$B?-
&;F^0".I[HDZHN\1S80I,FG?W)4G M4?K-\^5X^4^8>ZCMD[_]//WY#J\7A%3+,)W7|^_C|%R9T<- \#A1^P3R-
'E0 M.&N12/?)07,U/;XN\>)066?|DL)NA\$EP)W.F5TYFSV=G/R3V:[FES;'904*@ M\BG-'>Z)
I;DPD\$7|:B^A8P2N0<7&\$L3C@+BQ2K6?L12^|I!=7=H"UJ0=W.< M&W/EP9=?S_Z4-AF.7ITF-ST|T|!:0?
H;+B9I_>9C'YP_MLC80ZBQ_L,6B,=@@-TP+G0C'JYX1_EXER606WETPO'B"45I6.6:QYDFKHM4M>
M>M+J2=#)Q)B2\@+ #9-KD'XC=?)FG748A+0|_:/^/*KJ;'UCN81>J(3M4&&K8 M(ZVBI+|+.L^>E%E(=M|4-
/!4!=.B8A4EJ80C1PH!U0?N 5!:_MUZ'2G6W3F5?AX-%=UN\$+RKFCDM0-M!A!J4N)Z/7\$V(16JJ;[*])\01
MZ|NIRL>6/>4J2=0V\9_SJZCZS'ET|*Q\M\$00T2C5\H_6\;P(GT_TB3|XR-ZX_MQ
@+SZ.1I(/N7U6XV#92X\$/RR=VU=R|.LAUZ3Y=5D#B_348|"1?3BBZ@*YLJI"81A1+S@|C(|6 M"@@Z) 2*EGA?
|!1DV2C7-)|!15(>^C_%@:J29G\$|. |00\TK,MQ'+S\L>E4>
M_HLWC0_5=#'(5W9<3RZB0>="425@9S/F^NL/&C2>|0>00W|>.=!FS\;1,^3
M"EZ3I<9!|700A@9S13J4L|73UQ?W"\/80R_/H9EIZK>UGL,OW'..H\!<|GH_M0N&"4Q
DXRXSRV0TR|X|",WN.X4-W'|/CF4JG7DI7I_R)4X(&@9|D'0I9 MQDJX%LZ< 7WI4SRV6TM/\;CG6-
JW*Q@HFK@-44_EBKS_=V1*B\$0'G/'2/RR3":I7K@<'W>?D,DVB<@=|(1LJK3'.Z_M>?7&6"IN@BJP34V\27+A)/
0G.Z1B/MZ&&G0DZ|>DMW'^?_W0_|^8R>(|,5Y_M8=380R_A_-64\$2!"(ODT>'-\$".SJIR71;PB!
|\$>7ZA;)|W=&E|D_M(|<=?Z.'-Z^_NZJ?|+|= @7/=(^B\!13C:_B'58W*1|129#UH\$&:_ (L8=A8R6
MKXS%HS_M,AW/1'Y##X3%'KZ=654MB+N-0:3N&C.->X^&B\$F_M(R;AY,/""8\$Y"A+|>Q&%=!|Q|D@
T6CED_F03U^>S3INK|>8'4P*OB|C(QU8I7|8(2*7,98,J88S_\$UHA+0,G:E\04_C9"+5:V83FN#+0_M|:
7\G08MD2_M15Y|)(NCL8>WHKK./RJ3-!G8=V&4QWP!25Q"W7A:CNU%GF'\7B0\$?B-|Z<@?
M"W;&LL.YA@1|L(GLG@05<.Z".S50UTJY%EL20\<;|3RBLN<*,0B8H\R+3SM_MAG_@I0J(7,>S1S7?8:~S?
(T(SZ,?,-\$-8B\$@P_|DD\$V*._@W-1JAS8<@K%0|N_M8?/&D-ADE72)?BBXNYVJTCVLH"?4B26HB=@FQ|<71B,S6.
M6E-Q_5KM)|!"9'V\45,7WHUL:_DM'':<#1VK0>KIAY'R4A<%23:/C@>@+L
M8"D*S;V+WZ<_G\ZHKKMZU9UF&?|044W_7C4-4DD&A!\=-U/C2#F*80\Q#E
MY;|;CY._.9M/09'W@_*I8^|#: -Q=IR'6ZK|B-22&*WYE04E|9FQ,1Z'=[151.VY&N;4_M,/F|N|8,4T^0Q7<-
Z3+0|PQ-LSWNAGAVN79H;?J0@4+NLC()6J%C*Q%I<#E' M!'M-GA4->23E+B8\;3&MWP,8Z
4RDAC7V=,UFM80064/<;N.ZCU4Z>>)_U_M6Y_?>\$/^;A|A^0'J8-
G"H-.66/(U0E2&5('Q3Y|3GCWU\3@=""14VJ'|FX/B_M6I5^X3<|Hfy1,H\$?1#1J>1J|.E?
E<7ZQR+H(#!:_0)'PHHJ_-T30L.).WK)|+X|27/9S0U,2Q5=?N(;A_M3KA*HBB+T-Q>&8X>6?
ZS>)NPYT8\$XD|T0V3H-M:YZ"8V7P\;P_&G_MR*QFVS>XNXSX|&\$AT&[_^>CT#)08+Q_Y/4W&7&32:.)1F#
|_%NKB2@G/RJ_|M%_Q\&AR+\T2P%6.\$P|G'2|S|]._|K5_5:L2BTYUNR'D3|^*D'42<,7/8B|JC MG^KTIJW6+;
JXUP4JX*B0:_4DXV,N4^"|QK\$#+D\$6?'(?OW!7J=1??*PD?J_M7C\=_^L*B0J|Q7;>DZ5)0I1/0G:M|LH=^F2
HVV|&|<5>A/\#IX5_JUWGZ@_M#E9&3E@V,=H^NS_EG^EWX4KP99Q_F;+>CV:;#Z6X;(HC1ZIV5#2GJP=0/'P3
M(|XS3;_RZJT6_K@'#0*4.2GF:?\THK|HVO>V_-I_@N.\$X\$|9GD'0=1U1C^
ME=&XT)J0KGR_7\$|J;YN7^,"E9GAAR\?ZW;MB=6E8Z)" +G'0^652J_M6)RKVD5^:_^_8ACS>H:(_H
MHC5Z^\$TVRC9V;_R_MH:8/MOD<-/_LR,R<>N9LH/RUW\L9"RB"?IWN>.S7N#I:|f0=-DD9>&^%_M,
|_*3@MBP;\$^0KK?MQ|W&;I%953=0KC'=CX|50&FPT\$#PDS@HD:(_/5@:(DK7_MPM2WN
MI%_|_*D=U:_T)ZTI3F61?3,V*QB|N_|&>(.57:S9SAY-/0Z#TBFS5_%|P&MI|^66|ZJ)?
Z*W0L7D/;&|_QV(3T'&USX|C5W7K?=-I|+;_*^>|>0P7;PT#TWQ_MGQ_"48B/YQ?JPFA4S3@;_6'J|D;K\E
M5(^#VIPEA\$('RZ5JB1XBKB.4? ("99#;G56C|\|4MRWZ**;.H_X|GAX_"X82
MEXFSV|TY0W(|_0=5&0MBA<#86(4RM#P)): (0TAYG|>^P^CS"X+S;|R5_L+Q_M00CH|&&7V)FJQ_A\QVH|+Q
|_0G#:_B_2H_(\$;2;3+D&Y6AD,0BE0W_M|M4(/_8.+I\$YRT8-"H0_<<65SN\L2BZ\|1>Z-%7#0T08>RUHH,LF0U
ER;X4_M)|7J7X/\ST0_'A8KJ-/K8.X_WU%+ #<1*X2;C&!Q*^#P.BKW*?!63-#G
M769.BM*NW572\2SL&9>*-.PXTZ0*+^!EV_Z@Z+9-A;9BQSCOMK_M=LI8+X)*;A.+MOT_4<@?
Y|BRR;=YY9ZED(/Y078-?W;S4K%M9N5)34F00/N_M68^X|IM>J;_ER_C;LV&8.8M&3IUQ:DX=LF\
|DKQ8;G)0MH"X|VA^DF005C2_MW\$?| #CZY|I-2%D|TSZ8Z|6%Z|?&3NZLH?MY^0#<^\$VBN.\86_(RL"!DT>;|
MJJW6&|N7SU4-8MD00_I|BZ\$W|_%9?|T"%0)5Q|7| #48:&KUH-G&W?KTL6-_MV7Q=L7\$N194^>E1_E4)<(2_?
^NF=;82+AJ<\$6LUU/QM)3EB+X4BT@_MK7EF7@A8|0XL!/X(#6%H1U&+P#IP)^X"TT^)|#1H|W\YN9J7XNT-8=#-
QOVI0_M>W*\$ZN|T>+A?;_LOS!0+(\$\,|N!|LI6I_4-/5(I+9\|P\$@|:-28B^KM#>I8)Y':_M;
)BP|UE'_":|/|LW1+9\$0:CKR/'\$X8?;:AY-?2KF!)K#V^&E\+5*R>YB
M6Z^36X9;EZ:UAZNSC">1B8P_F|DN" T+ 2_ =D%4Q|E-.)99WDK.Y^P^D^/?W_MAZDD77I|S\SA:P;>'A9+";-
A0*&1+11H*; \;_='%;1@1JYTW@9|T%)V<#_)_M14RQ^H,7C;49Y-40\$)HW#_80|M|P-
|GZ52._)87F@I8*0USDQTE9SIE/8H|2_M\$-54!8^3V'##?;X3LEIRPG/D#C?MY9X9C!W&#PP9_MI?UQ,B,&|/8)?
N-\FAVDUR/6Z_8_3*DRCUH,3CML|3;X;*_!=EIL*|1)W5YU_M>'J#*?-T_|3DX"BEK<(|,2&R->IT4^(Q:UK/'!=
<2:X|J0|I/0+KX>DB;27BX_MLX@Q|*VKZ0JXQ/GI_G":TR^R7/XG*"QA|JVT.K'Z5LYMJ8K|Z2|3M>UUUQR9
M=NH#K5|L^47DULQHC5_YLQW_'SJGY|/_?^_5I79"\$Z@\$_-@645?7K;JN4_CL_MJ&-U35;-
Q(F69)B#0)0.B2U"U:U^|OR+&H+V5-,_B?6NC"GJZG02|E^DDC4_M_FD8U,6E21I-S?(*1&".R%EQR8FW-
|D7\HQD|G6U8>*6EYI(/501|V0,@1%_M3XUT,G?<|S*(>B|G+D+A@_M(|1ZNXWL0Q8^?
Q|2Q)JS)^VWP,^&>|0Z\$5H1_29_W'5+5&T7D_,\A-4J0*H|_MOW_3G<:_N7)WVV'+X|_|B4U%3VF'
M,V+2011|KQ:80)(/PRDL2N863@|I>U0\WZVIV=|!2WY'4?PE%|R0SN-93'V4?@H3P:I:T4(F*F2FKZN8,+)
MQ6)Q>#F.0GE&?5SVE+5G%|_|47JR@PF|_@D.&CYUZ/CH&|-BYS_K|_M?_"VB4_83BH0_L-
\$A\$2>YCR;_I.7G\$UQH+6%GBB2>0SIZ+:/?@)*@G+\$"@* M7,%2YD.|_|F61=*W5MH5JUH\^-B8T%_RSCST??

9M]>^+XK>,-]VK?,FU-.LA* M_/W, AJ4U/*5.T:N]?;D"#I]_ZS=9\GW9.S)Y ML)W
KYX3>^+)W_4';Q' 'I', 'V26#04Z&W[N'!MA^N]Z)9M0(J!0,D?)G,D0% MX=S!M@IS;.[^DDB]<_A600HHMZJ?
R#-,\,'& 31A38.;G3^R;-X_MM!Y! MS!&8^J:<|)\$X6Q0&"AN9[0+6 >,XB [ST5X8>70Q]S-V[8=N ML2)I"@<-
^T' _28.]?*MXK]!;#S.UQ(=7SEH^!A&S7Q0RA,#G,X97+E;PE6-?R#>C.9VNMZ_K*GK0)))+W
MRR(&&1H5#B@1)Q=L;KA8.;?9GF](>3;JI"TY:;]^40_J0YR8&\$HN"L:^\Q93
MT]_REX[TT'Y]4/F\$C&)MYV5!VT9I@TCT5DY,32A[1MP+T:>]?SU%JC[R@JM! M? -AXLMH\VE^*/2D^--
=6Q;Q("H&R?MTF6S9P^=5.#GQV/M&* HU^SS^F^V) MHP,.G[LO]_8L(:3Q+0@)782"4]#MIFK[C-R-
^AG&55FBCXENGR+B\$H.)TW(MRASH I]ZNZKUB!"HT82:-J"KF#)Y[XM<7@TX]#@=^0E-QP&6203QA_CZUH3R
M]\>=N%V^V,,MMQ!45>WKL^0_[-?]?PKEE#VIVX>9UEA9J.J?QJ+:-\80F!,21
MZD\$YM(>=V93H(NR\=XQ:K#A^XCCMUR7F?M>" '4P/OXD#08Q@ZVY^CA75N_M09=?L%+G!-
)4H_D:KFQSD5K[5TD^AJ_CST84VEGSUG5+TL"=UI@;!' /H_5U
MB>E;GN09'NOH@)E)EJR#F_MEW^462\>*M0\$B2JI=],#SC-;^#G+F5(G23UUY
M=W(5T\$4S^DDFV\$UPYLB@' /@'"?"Q.%T&,H+W\$U^N4\ _G]I*S\W4GKY*[']:[
M)?]F%N3/NCET5XNUDIU0Y20\$M*L06R\$M+\SFY;1*+[FV.Y4.UHM%#C8P]Y0* MV1T^,,.F 4.&\#QZ*Z>.=R:
(-K08\$(*>]J-+CSQP/R#V_XW+>:58Z'YZ>? M&YI6J/C';\|FS+\$_SKE):66=9';E]B(C-
)D;&N0C:DEP6MX/IV6%M;0L]D2N MD?=I%)X3?^1E_V.96-)!?YW/;ZPNNTWJ?]+MPS#,JZ=L0_NU.J:/AXQ0-
%!/U/+1(:;%Q(MFG(G:0@9M'^#I\$G!UNL+6IV\$B'"N0^<)+/=]T,GU[J_]*=5/#:I:Z:549_M-
A:Q2X\0YWR@N&NYR<#!X%F>\H<#U=0V1=8FFA[_!](Z.AI=&&_1)]16)FR^UH[>E1E>50N\48
M!)B26&A[4X#60:-F%]VJL/J4L&U/VV@8;?>G)E0T9\,KNJ;^;TL(LH@7RK_8_M,;?@L[?D^U)NU-E-
+7%P[B.7LM(?00=>)-L-AA8F7';Y7@[[CSKN4I)=&]Z_MQ-
P*@UHKPK,;F"9+MG21\S02SR3;Z,N_7'1\9473BZ>I@E7\$RD?0\;-W;=!)
MW\>V\$CJ'ETA\$'FL;C<''.E/,S<4\$+|TY=U\$=FD%[C"=.#?RXMZ&/3C8VQ=*
M?/N6F9N)HW3Q'L[7[KJ+0>&3D*2:&^140_L#K.M<)'J9
_16L@.5<(!@G%Y5=,6>WV\$5">ST4PS^UEXQ+V>5(V;:,]Z,N7
M(WGT3N(USBS0)M141N>K*)!']@N!WMX9Y9T.3!8""(RK@#[_14+XR2;GM9\< MP(Z8J)7BGYY_Q,*MXA5#N-
=S&80=V:31\89G4%;M%>">K-055_M0<@QRAMGT]<6FG!^W^9L0ISFJ-4RP*DPM0!*?;Z2L:'6GSHM
M\$KRJ]>=VA4WVMED;#AB,Z^?
R\$XC\:"0VH3,E#ZI#R2R5S\8<2>+2*W#\@%.,LQLF5YUV36L*VR!HW1'BB*@7M>R+Y)5R5,7!N_M>2'?\$?
9[+E*W_.K1[_HY&[VB\$(*PE%BZ5_EWN_6-X;I4L?)"MUN_:4]WQ=?87_MA)VYA5\$H\0+?
MB,/H,;2^3U(WT[!D^/?.\$CB>X^]:\$Y)8NH_+(0?P_90%^B_M'^M%(P^GEW564'=6&&>EI??
%0<]CI\!EJ7S/A[,)D-LVE#JGB;:E#B7-0UA6
M5,JTR1/D^=V0N""\VT+#GHE3'XS.74). \)UMJP,A52C59RGYV59':J[5WI=86_M+0][;N?
P"V%FY[HG\p9#*2F*=&1\$]UXKC14_&Y;[*[X59PM3Q)\$S3G0VCG_P_MK;/' +7%T%!2_?
\$CU^H;\$PP^RISA!L_7Y"TTNYZZYC>-4X!^QV3_M%(_<+02JI7+[IY/[KG_0=VAY37/Q/_OP-&S07%0)-
^C*X&*@;L>;EYTK>N\$N_M0]:82,C?Y@C7_CPIA3TYY_E4D,I7,Z*03?6-LR,H\$:A9"\$CHT17L.;=7X-+U
M9&,WT?U3QZN/27/%#856F?,]-A5V+DIA&1Z5->0H#=-I-U^?L8GTFZZ&T:&^
MWM.J00M:/R4ZD#),0!WZ'%>Q@7\$WC[@#&B"*50ADV4];BVI?/G8QQB\ 3N+=
MUL0KBFX7)ZD(.J[C_67F:1\02,I=X^F[[]])6Y&I0"L\$E*>\$0']Y03@G=!C7_MM<&SZ8R0+'Y8;2U;@]Q:D.
T+:\73W&2T&?I%T0T[3S/B;F8_M:K9M?B(<:_G_-7KD-D#R#P18%.75'I>WB45W6\$2:F%AX\$+7>1B0FENG(/E
M8M:#>>455)EU\$N(I405'%&14L1B(\%=5_H*F9I6TJ2'9A)EN+2TM05XH<H?_M%?Y)XI[/]>?DH]I.N0EZM_M1P
Z(N3,1[&G\$S7S<8>0HRTFISG9. 5FZ_@V%I+C_%XS:F;HY&R^OU8^F3A1_M!_(H0Z83())QI410>-04?
LJHZ0J@1ZW-%<^YE#<[(%)Q?>5/B7H?\$.=KT(_5_MV'@._0JXZ'H'[#X)X)A41/S/R\@0+F9L>-
UPL+1UN^/[T]T\@G^@&(5!*,%T60>Z04" MT];-#KSA_.Z"@8@(<=3.,]&E,L<^>=\$F0TFTY>,W0SNS(
MX,"Q]F^34W+S+QBY-ISR8:I(4KUWHHSJ;4K]9N-TA9;*8C\I_I^/X#@TK'4[MPX4P0Z]D_W\$F^!NUD\$I
[NR+TSY755+>LI_=F3*P?/F7V#>2"D*7^BNZ;JZ].B"[C/#-VY:1VKC%YB/Q]Z8YQ"S/6:L_M_2>-
ML0WS5Y3CD0\$S<[UFZVP\^S^AF?V72:[_[CCXWL(6FR&*P(1=>-1,LP+%HH2<_M)&BB(B
NKUS=Y;)9JL#BYC'LV=LD,YG,U_2AAN_@![_&]?BAJ08V?I8R= '\$HY8?T+L3<7#)\JT4"X\$/4)P0R)S72&X3
C>I465@_MG"_.V&C\;L;X6;@7./0C^Q._5HXT<<'D7=X;=10'TB]%DY%M;)FM)QY01&,
MY\$S7W>+4='9E=E@6S]!T')?X,[%^C;\$_*0FZ>&J^H_-+EXNKT=N4>PH_&4^_M^H,0_-7>/%NERT&[*JW1L-
@[P_Q0-"CS"*Q&Q#;*L\$837+.(#_#:#&*'\EW2_MV]ZH/BD'=#?-J?YW;_BV;)]LII"H?_LVL9PG,,\$-
Y//'"DMAEG#R:]@_H0UL_M>=>0=G:_MRSC0HDX-Y\BEF00"*=5[%7\$7IMIUG;N?AVQ>*66*C.5@_YM&J\D_M-2E0-
+U'2WZLYLI2['?'5*4IW,0/M7]_F'ABUDWF@YWA33^9[/UZK0J(PKK*_MR09"WU-JC=
>GB[LFR4U0B52Q"RJH3[6X]TJ_W^>*>5/_MRV=2"#QMEZ9BET_MHF"'?'9=?Q_::]C?43IS\Q.*]-
UD768(;)@=N:AE(KJ76J]3L5CK>CE_F\5EZG_DZG(>0_M^9K,5TDIGP-M772K
A:2(G@Q\$8PQ0&W"WTEFM;7ERC6-W63M,(B7P'!)"(<18_M&#QW;-J/JH!?"-I3!" /5YLF2^,E&H=;
/_H<9^QU#U3[G!P^:UQ/;/8K)?BV_M*[6YN+#_7&Z5_!?'S&7?8\HU@'-)
[WNG[\:]VK91U'5'@M1D<"C\$(_-9[T6, MNP+\$Q_ ;J-,VM0866>*UD&J5SH"M"X-WY[,0J\6&[*R_T6C??
B,ZA_W*>_M^I"0B5>':B#=-IQE\$[1\$ _N.\$S)S1>NGDON+QV]\C-E];HQ%3"(D..HL+*X<_M^UK\$H+!W,
_CD+VJL5KD\$7C7?>KGTV47@X;.:>8TF^_LJ[0CI'K5;22Y;LRS#I>1?]+(-&_M0<3*MA/8Z&RGK_K;+Y!]|0-
+WX8PY&D)@F^_C^H79LW6"HLXH%K[=6^NSVJ8]_M!\W0GQ#A4U6H#W\<>,7J;_72]VNK+WVCJ]JR:0-
0@<%9QN()8W0/C%V-F_MQP2A#?6BLWR+N.!6>PVF[\$_L-V&<=F@ZC*\$5VK!6-46S0+-_N_G--+ \PDU[7B_8/B_
MV'0S@":VYD&TK[LB._W^V;FFWGSWLR\|U|_E_ M)'VJ3E6=ZEI.G>Y&N:54["[BD^:NE("C@Q%(55Q@P;
[X1]SFXM2%+@ZI>59Z^)E@ (Y\$R.W/)L\$P!C)VJT_G4@/N-11+B\B_MU6/3Q[:NM,?@F=E;-LH]@<."J0S\0-
-';@YJ1.L8+MCNG<4@28=6A\8,7V3,[WXVMK%F;?F4#^&Y)M@W1(U, M='1S/EX>F67YU(';F/>IC-
0':Z(G@VE&#/5PA"S6B1X8C]KJNF[.)-Q9[4KK_MCX=[PLD@%S^E!:[CSZT\/[C/(H.68%'M6!R0B-
T3,YQ].XPQN;S;_H1\ _C_V_M[%5VWI?W+&TU,&Z?A-Y3#DR_-ZFE5;"/82,<:,^#("U;ZRB^_0P9?D7F]<
M:4@TBRYW5B:%_VZTQTEX*_MVT1_]E#J;J26MDV\;IN2, _9/_'^:K*(&:YPUGGCS]*VH70/T\B\556B+>|

M'N7*>UT[1I"Y&]FZ=J4_8W3M_D12(MS5R9M0H6\$.8:%4%P3L]+:N; 'Z)Q/? MVP-7N#2Z\ M>
JE5&*ZIYW8SUN1958Z6R; \-DE77D>R0%-W^)_ X>,R'UP^,9' M > G !;6\$ZY#^AS0, [<5AN\$CP!H5NE682\$W6-
4{CJFWJ3&(X',P?F/S*A\UN^[S,HR)3! Y,U^ : =^ M5TX./QJ\ - 6=T!GEX)M&=<3B_?&R%:A"EH9/\
["^DZ4WG4"+# F!YWIRK M?S@?2*Y!P*7*2 =N]4&YWD_KQ]I/Q/GYKPDWIF&\$;CN[\L/Z(I%6N\$ISENV
M+^@G5Q5_20^S%M\< G=\0/'Y7 \K30P*'A /070%<^V0Z%5Y}KC;:%Y/R% MZWERD#7U-
W..W>C.G_ \/#P)%XK+BLDX%08PM_13-9>QK;V3@[CE\$RYV*[YJY2D=? 03Y [Z*Y8;1-0U0L?
93RH2\S@K33)&.C:1 M/ X+I\]]Z7\$4B_ZI^7W%L5==2_S_TFP""!8']3MS=%'9-I,%VN#U
M]ENC52A9X/76V'!H+=FE@V?04FJ'H'6MJCYX^NIZV0(,CRSEAE/XE;V8ZZ#
M:0@:-3U:/2@WRKEKT"\$*CJ7Y+8I9>\$D7:F;:I#ESC:+=.&3>8\F@-Q[I]KUV MW?:!T:,[RULP7IB?)RJ<+
<>38X]&#!1;M*V8R07RA[U'>%I<+)-Z5>-)A%7 M-!ZALY8+< WJC.=X7TAI+M MOM^6" D &YC"S^:TW5H!D
U^QWJI'0;S^L?/\>6_KF7;DI ^0>00UKY5Q8G_+XCR4GD3_+Y2]2/N_W6.G2']YW;N!^07W]IBM/BK/ M?
W;PS[Y?@M5]Z6<%,4V\$E\%0"+W7Q M(K)'88&/.6FRIU"PPQ"INQ*0D9.=
\$B_"2S[R08'E4)9H)ZC\$6I>\0N_M;3ZB_M_X+%J9]!3PV-
+LHV^E_AVJ"67]V)6#F=T'DH;XZU]M&^%1FJ(=-9(9\$5"5W5_MKK0>^"E0>M05&S^CV-
N1JV(M/_008"!0Q_8*R'LPL6<\Y'0+7TGJQPR09^N M' VP0X5@I;P(Z@G[^d5'Z#_4P!_URGY,+RS7PW\H-
!\$#H M[48R5?^*+AB(0]J#[.5\$<^V7D;IR,:2\DU.99;A@L5_)2^NP*@Y12:M04/ M&;9_H7J?#%] ?!UMP
8CN<^"*_OKLBMXH?>@U<,"?P -"AP,>G=3UPPD0 M:V#\Z)OP/&YPRJ'YN!%!4!%X8@_2_XGLA500&?&,
8%7%+&\$'E?D0DN !;P]3"4&P^@K;\0\$0R+,_S\$P*09FHF7'FI3'U\$ MY!\3B(\$50:G_-
&+Y\8S9.-3X&P\$P\CM(7^*:AR,)QAP]IK9_"%\$.F.\$&#P" MS?
90XI0""GA@@"v@G5LL%FWL@0]Y.)XV2UK"+ZL5SR_!_6>C#3J MVPIB'01*X*7!;' \$W1<>V'X_0(;J+\$. /+7"/
BM_P2[*PRF/@V3/)]M""^A?P]> M@L]1>3IRG353;ST4""G52\$^E/L_ :0D_YB3(.V + -B_"RB?"ZK!KL> GAD!F
MX+4?X,_UY&R#=#J@20_WAZ= P)YDH2C_9"KT/B[\$\WK;%@.DM!2^_0.J_M5V+ MH'W#" "]YN40;/[\$> ACI/V%
<:G5'&K\)@#VHK09" YK63>P287LC(5"W>\$A M)&@ MLL0F00H].K/G^B++
<9<;2%8.5\$/ (+T1!/_LJ"U9T,4B[]% /42E5XLK0@ MCT(!4&C=\?R" ""\BGJ*RJ6A0V,) F#S67 <8\K;#JL"S;
[V8AD5M8*:->F_M%QY+03TE3+]"S" 4P0IQ0%^X]N>LYV F]H +40"=M18VF0*4Y_RNTGK>??ZS
M8)B);;#1M2X&TQV684^0(.IQ_4M=4@(.A.T\$I8_H.8(:EF">%N&(0_0I\$8[P
MG/DHFNU/=JOG!4!S+YZMNKSN'R/BJ&ZV^K*#,NW0!MCR: ^#;M[D'L4)*G7>0 M!]/-
^\$E771_QM\9\$5A@^#%;L@KV#WG5PA=@G(NW[Q]HHWC>Y<IACO^Q*@Y0_M_54!#.NE7,C/_X;^=R\$%;.#P'P
ME%./[=0R79):#_V&@'1@[,UOE/C"PO(P_D_&4**L<0J?NR?D-X8F>WH_8NQ0P!\V2T_MJEJ7G[HY&_6@V<0_
QC2^0"T=V^(BN"2S"MMG%\$5L^K@8L]2#.PZ:2EP%6 M'(''R\ '#:V!1[5GZZM/[B2L3U\$\$_RY;V@TQK,
(!"8.+WT/Q\$F)THF!T!4 M+ M6-7UN<4"(HP0&1.!<[P*KH80+^~/L\$(#)HCB* B_GN40=L3W02\$(7K0_F)X:
M4,X4_-;S9,Y".0M6ZHHA4_"TQCE8@_VP_"BH"0]KB\$I>_.OPH_)WN*/F(2
M@M<>@3L(WTU@3Q%Z1^DD\$QUN]+\$/VQ2^;1UQK(Y+YH2N3" M !YN M% !F#_ \AP28E*\$4(UA?
(3_3GBZ,F.V\$0A"3N!%"',+.0\$^\$IYPG_ \$[\\$ \ (1 MV*SL4#2191%L81\$(<#@AX7GQZ%\$%QLSHAL+B<%.XW4)^
.!J\4</8W"0_MP;/_9E7?N/P#9]Q:/[0, [+F= 6_\$P#%0+
M0=")0GP^3V);. \$\$/R!Q8:+J7\$F\08V7\7C\PJ2R_+"\"W+@0YX9\^J60F"9
MX<5_B"00;\$>PAI<1#0\$408[K.YB;_GEPNF-"#/:0EH?^1JE9E\$;-0TJ*I0F
M_VTU6F3G*X>PE"A.8.^D]\SP)=,90(H_*#BQU!MZ(/P^6.4#6VM^[Z9M^C[M; /17;ZG_!;_@?
SY<1E3BPY.VLU\$4--M0U_&][LR7.>45?\'_G^!E=XYMM;U.L^YOJ;X^W1U[R#ZXL+0L>XT)7K_M/E('?,^_
A1"22W<.-:ZN63)R29+I4,T/V'GP4?9P\$ _*/L23ZJ\$&A-S5\$#_0_M5)?3!I.;0:6VSA@YEP\ \$64GAZ0HE?IG0?
5EJ.T\ -AN0>GG=B^AHO+40>3_M_ '*<8N0"=SQU'.BG'22-H'_SS:JRE^9_0*K"@5*&/65\$B_T2L17SZ>;2#4*@
M[#_0ZD8' ?G^LCKS7LWJ&7)PN'\$=<;LB?BFWR7\$'PE>=PN!Y.'"5-V+5U-9-MDTNZ230^X^[W; M)IK?^_W(B
N6CIR&["_WJV\^P2V&SB\$I'Q&[QWTSW<^_5%[-0)92>\D.H<7[M@X;[BNG! ?_6.99%W_X+(QEFW
/KZE0F2KLBR_JSZ-F@.2Z;8\$UKR0!DKS) M\C=[]/L*NE6NJ?7#5E] \?;ND.TFCT0CMC0_7-]??
1.1]9/DQ=NP?;CPIBNKJ_MZ52A0M-P5JTKC>N0R;0?2P9[4?0*>V\$Z@F(.1KR.V^8K5_G[9&=L_"OR!'J\
M^@PQ<*/>X7)P)%5-?B_-ZBFQ+J;^6-2?Q;>PC5B/KUWTHP64ERGXXL7"F>\$_MW6ARE.RDV*M4_-
I+M5ZZU;YP7B[24^Z5XXC_/SDY&K"&-W\$A0X9SKE^3 ^" M8GT_A9[8%:&[C3J5;6\$;7C]=
<[(TM/[SAQ=7I9[=;2E)+;U1HMT;8%V*TI9> M3T=I?N\LM\$0G3UF(+I%\26TH9]S==]*L^B"IZ(@_"G-
'E[1]-G#6/6WZ_ME=CG84'3#IE/DFZ7.]#?VW]VGD=TT-Y+7'^S[4?-8-X""V<0>^_)@%]1D;U^8M++R'KP<_0]3
F[7LF_MSTC>+J=J>^D<7)L]2/'U;:"UV;#SOLKN_DCG/S]T_DSK^R/*YG\$[OP?7\$&UZ_M["!1*03%
["M"D_4HMS6Z,\$*_+D4A8\$?=%M;C7+K!=""W-H0H4%0_W142#FHFB
MV*,"8,/##MH+FE:P]0^.]LH:6_8_VFU0Q=0W8VI. M=RFREE>2P_<)=0???(+_CU@9*/7W+R>A,/_^!)
C\$@2_1BHYSR7?2S_[-)^ MXCQ=ZD?M[4/>B0-16+AXUZT;L>S)&C,DWL!'DG?D[]A-KVJ[-="+CHC'&P>0M
M8(7R=[/ <]=&SW(\$09#EL51!S/CQF(7;&D,X<^F\$;XAGG&6#K2A1U\5DG91LP_M_YE7%ATR<_B-]]V8T\$
V'YF;R""F"[7#FJ3C\$@L&W@BR6\LJW35E+""=AKN_M25+;"5?,LOWN04702K!CP;M"N*N*G_W^
MYC;_#X');_1]UDF#V%TX-IF%#6(XS,AA&NW(TV3:6\$W0,?9,)N\ "03/. * \54_M)&&XPGUC/F/\$EX?;?Y(^_
V\NC1V>[T,Z<;8>P+50&==\&S0SN;(25'53_'V_M\$ _43?MK<-?F/CXLEI?5R6UL\$Z6&I,==/^>DQF-"_ ;705%
MG,/ &^(!'YU;=AT#IKEH(R2]_X8;FJE!8H6!^CF.!M-4WN^/7\HON?OXV;=8TPE1COU7_CJ=(
M*^P.O^<=3K%Q_MV043^L/I>..BI[ZXE/+>[D+L.:#3^RE\$U;HXZ0,E0WR: >(2,9PM0Q1KQ
MW_*\$LGJULE,'V3C/5>#^FN0*KUN'9_Z.7DH_>Y.1-\$D%_]&.9[ND0U*.5B_MC^A:2-1JUL_@EPLE'C&4]?
X>1G_N#7+&CY(PW+')]!K_'YN1,4^NC3!0".&' M2_U'QZG724^0LM!@E]52?N]
MRRID_Z>3C0QI)673F#V)]+'ZG;VGYUH+%XY0;ZM84DB*R>@3@N/@CAFW'_;N
MFW:=0B=TB]1]PFDZN080TCS=G]M:NNQ5&+[5VJ)_R_ ^0MCYWW[!+] 7>PZ8_MG>W5XF[Z1A=Y_F]J?
MOMH=U7N0^X>LK2T@5==6C1G#_4Y#+9E.PM.2C[\?KM)8BM_ID<_M2]P\$]:\$V+YILKQZS[\$RH*^GR8?
GU2X7;+>J'C0+\PA(0.V8\$0'3^10GI,7D5_M3XZKWN49*>[<.,4\$Z-KW/;0T7MNSDFBC\P:R#R;57&8.D\$^"-)
&S9(">_M=CW" M8Z2!<_3*_7>P26\$JLT+K1=J7G>PA(2_0_)TG_:/.;IO_J-%J*YT^>,K
M,\4,X\$L=]'_+8KD6YD0] M#@+@=KC[]/_/?-]]:GX:.,[B<]/-[\$<-H(IX\XYTIHI<5WL^?D:04ED#?MDU\$

MG2H*5U9PCY3K\$0"!VS^B9\^I>#-MD!0X%13ZU.:E%207USIU:D.>E;I\$@_4;&G,G0:UM
8)1+9WEQEM/945R7/F MZK(5SYSJ\$*JM&&4MA\p >Z9?R4F&>>Q!JMB+Z*"J/X9 RB#YXHOG2&MQ2S
MZ5"ET4/I4VW6905M#"W4=7 GUH)^GV[&CL*\M7F/<() (W* 8)J+4B7%P7CWN MB?X"(27NWG \#=#&G(D5Y-
"TX?T)0;KT0(/.P3 R,L@ Y.T ME\$#B -IWA^/A\1,VQTD?ZSF.H8 -1^UJ603%#5I_NRN07_#_\$G<^Z?SJU>[?
M":\\$(L Z!FS8).=7LN(6.7GE[2.%#7F,Q=#J\$0T0XZA"EA?'[MF;[91/+ #-
MOCJB^PJI!84 U(79X)EFPFW-.*)' MHT5%[:
<41>OV 'EZC1[BR);Y&D;*7H[6V!CA]S;B%518E[=WFZG'&QON3 :M9 MVA(,S@L!L\$:?M@%L?VIF6(C-[XIS?
55]^>*\UL2=M;U LM%L(I\$H6,\$BUT MX** I4"#2LL>9DGVG:6EQ =/\IU@
M"OE!\$(IN)7CH#3 F?; Q=CS&ZS@Q0;RT7J[F.#'I8<\$Z4\$6=A?)BH/IS@IE6 M[\$*)ACU6ZFQ5M8[& "FC)7?
M&;4<9M5,N5^6K1G=';0G5^"5KA"ZBMV*-L M0ZZ#BTU!-B7;GJ)[PA\$C+2'0QF0^U*&1TD<*D=?MN-ZRY[-
FI'SN)/AE*TS; M612^&T00';VZ.2828ABD>+@H([HND&"?.1SI?@HAU3)45^2A*^+EC58SLF
MSPEM>9Y9#;\$([@*=LYM* 4XG-E\N">L-6^K=A/!#*(+&Q[;T? M0:SB^?00% ?U'C)D^SK8J9SPS')\|
<9F_KCD8E#& M1QOY*U*JI\$-1ZH6>[U^DUCD?N!-,3 E2KEY(+PR9\3ISNDVY\L.+VI"SF]_P
M7%.ZVYGV@X,C,Z!&PM2%,F('8:Z7.7\7#GYP['\$XS#6&1(^;"=-*K\;\$\=GU^W;*!A JJ#57-
1V(P>&JN6>16I9[K+[R!QM0I1?C1, B*VE)OK\F L.TIA B.0C0H^=^=S^ M)DP .!>&00X]+0&;;0U\$&-
OL(SRY*>LJ2,R;R# .S[II/V,X6);,RW5MM,YL
MZ(IYC^HM0\p>H^&./=XSCZN%,+JWBE(\F5U26"#U;:^QBC)G=BVS62EIK';
M" : \$3+W[M3;NV:UI3+2X4H=5Y0(1ZF3 M7,?EG^4&GI8,N!8F0 I3&X@W1Y7E&(E-NZ)N== L#.
[>J1:)\$E9T;#%)R\ MI0649].W :B9#LP9&. \] 00;\B)-TA1T36MBH9TV5MXXH4G^3'H9-,838FL@
M>+HJ%'*01&6< ""X@A#*BNGC#&0^5:-Z[BZ>&E(S&; 1@!\$U(\$?"- K6PA M(JY7.IQ>
[OKN9]8;JS0]=X8I]IL5[H7CN)<7B>3Y7,=F'-H7/@P]0G[1# MD<=!EXA-)(L)-
4ZC9PW8N[XP;F>B\$@RHP&*F3K2UUFVXY(^PC&V)4U/>=\$S M3)?[@IF^V;]X"/X7_#'\02<- *T+*./(9Y@2;2
MM;=KQD-'7[P\8[]HY5K0JG-WON3K9BS^CWW3@Y5&[I&S574VU\$7U<.2VMEN\ MB7RN2?
D'XU'8*+P\ED)GUE("Q!M+NR3Q^:4746QF[W3&_2HK2\$8+,L#;:GX] MSYXDD.:FX?3!028L6T_-LE3:K:?
4W9ECZ/J._02 FR42KT+2\$J@]TR9)MU\$, \$LU/!4W\$& M\$SB5?
<=MJX+V#C@PLXTM!0#^,8@T!.EU"W(5EIWY[ZI1&G7X'5?)M)MU!IU+ MA6&:C>(GRLKS\|
[;Z)%W'H5@M.3[F&*&W;ZA>KS-P[[6?DWB\$G"849! BZWR
MC\'';7GFA9\EC52"='Z^XF=;UB4;:=3V8L?;_)S! LB7@6)'5D&P/Q3/U\6I
MCUV8I/HEC!/3[[93=>0.>^V]6GRMA#@AA9 LWU,Q9'>RM\NX3, GTTW\$-^6M^ M: \$
NQ_J)/D+0C)"I#)#0^A*03SNP+9>-)J-\$!2A/UCK7B,NX=KX.A7*-1C M;,>"3CR4B:VBNE,*A?
K:17Y4C;FD!7P96Y++LQ+ S4'3+PB=8#;?:S1N;UG1# M. U1'&C&Z +=%#JAQJ4M9F?=JXYX5&""?
=>*YRZM/J;7;/:N=97SH(K\ -P" MV<2 TVLF -; Q:\$M??U\$!JA3@0J12IPJE04 G)* !T;U(\\$]3Y;0
S?.T= MPPUJ04KPVK6A\M4S2S"ISN3"0VI+ L^"07N=E5=3R6SEZGS=8Z8/-'&ZR]E:
M7]R;+Z,74R+D\$!09T]:WV"MLD()>S30)3W2@99>EV/2[6-4SN1<=#I'UI MT M%Z<,AT\$ T!NT.("0AKW9XE3-
6;MH&^ U2&;8.6DSDFU(-(AI^L)J)'7G\$?=- MX*KL\$(3H%"J77(W99--S-
5V)F5_VB8AY,&38(1>IXN='1>G4^0[S^]'E^A(M3'21J\?
>HPJY+=+7LJ4J=>_2,R1J73%2F"F/LN47Y[E:=F3*/4S/^+(+J'K+\0\$C/(%V M#6:/IFQN(??U?
KTS7W>;=EW]+@201[]/?\V/FEP*'A4Z)_2[8NF#YH M>%LM74*T/F,V+'5-39G9-UUS'GZ!-)K#8%
[M'I)EMS'0TP0#L=K(-.=W+B MFSCC\0Q(Y0:3/8'))_8TJK \$4A"L59S4?8666?0AYJYVK..0;2+XU;\L^V6'
M000HU'&SH(B]?/JJ]+[CT:/_GTU^TK,JL[>9Y1USI#E MPY@+ "N\$'&;0\6?;Y?W050\$)CV6@X].B-
8PDOP.E?,? M0848VFI[5I5GJ D3B:++1QWW/; S(4+ !IS69>,N (=!1J? 4(6+R,NKPI7? M ?L//Q ".*?
N9E\1*7I1B?HY8\$;&E4/2W1)Z: !F!U]&S!MJ' J\VIID>,ZK9S7[8 MMG02VG4#0XWC+.V!OV(+0DP;=^6'1M-?
VC+=IXUE!RS% MP,M4=(Y-<:(VTZ4SM42199E?\$ /RQCQ.-X\$>7J.HPG3\^ MOR71^ \$ #I!VH0 MT,/RK.
[A"SZ0T0C^0],0&X;UBCX*?A?4&I]:#SU,Z^U?7\$KS Q>_ \$8RSY.> MW='L2WA=\\$4 X'SW/#D-
SF63[*02>6MHB0_Q48?SjX9_D0,LP@_MON*YA;="*Y;\=@5.4!GR J"1 MCLBC=/0LP)=>=A8S&B8"0+;95(DN--
HTTR_R=.B6B_0'Y# : "[WZ=)&7058? M+X9YMSHX69FWM\ \@0;[D84 *FH1N\$X4@8/'5&L5V?3V\$'0.0f&
[-74^A% M5QVW_4LF* \$@6E(BH\YT:D_/\$P#G.F;\%P(W\$?5+NS\$8GL^+G@7,*#I'+;3K[6AUAJ,05L:!
MZ>2F-*/QY0@CXRF.,^1-;BW;'EU:\$I>D55ACR6<=>SFJ9J?W([DW1\7"?)[3V&G][
M*9<;>D\M;+>MK6U55H26LG\$6LJEAZI [SY7EVN*L8G0X(S0^T_3T\$ H.?)W MYR),XI8/(J,6#PJ_8;B.NI4"
[0R%TE&*+@^BYG3M,[GE[V\$2S0R5S#J!YAU M"]KXQ*C<#/[87*XRK94=C"TR1CZ3)GCEN_8^2G0QGSU,U6"
M6^+##\$GKYXAZ\$#73(,%0'SP\$F0Q,VEC9+ @60J?U0JIWU^077\$0"241[3FK MWR:'7Q\$S0V[>_#_4E3CC;]
[R!T(*_JG>_6M<_E.&B'TQY5;APUSU-2>2S2, MBLI^CT0%LT),6=3(=U
/XG>XYD1MQBK1(!!10()Y^<=Y+S>+)%@F*3L<&9^ M@H&:&R;IS&.+)<;DLIIA?8N\$EB/8CRC""^C670N\$+;
[1@U;'3#J5W@5&RT4_MH* F,F8YW(SIC?A8+S_3KW .+;%33-T>D>W+NBAG1&MOX8>09)(G+SW\='^& MEW-
06CI2A/0DIW*@I"AM9W%1C2U^9T3(7JI+;X:\$_ZL"UXQWNI&8#6P&4X=N M :#4
02YK9:0.CITMFVWX\$N+>HV^&0E; N_%BMQC!, [JQ"4F#)KN;Y-L?PR M/SUH%3MOR*E*?
5V5J!7MK/'CF3R#S04<+"R79S\$9\3PS@JP+'M#G3\$VJ[W=(M.@3DQ)NY-R]\+-6E=;BN>>_'[0[3
M'[R%ATX3,HF44[RC N"-2_6*K5@[I]?*L.?81AN#_D1M%@_XLEPTIUSIBU3 M) 1]?
U[S;D/%EEI07AAWVT5D+"\$ZA0?@+,M3[H9(7@GF<)7UK-.5\9D%]N('S;D/IA\J1YA^SU+0][7KZ]:R=,<:>:6;
(J-7>S5UPFBZDZUQB M)] 0%4D:7=FJ^ --K&?V4,FFUN&[1_H--^S2^>QTZPI_=G'Z, /'VT:&3%93
M6*UZ+KR>-0:H2[VX?F_?6?_?SLP_&M^~:Q(K%9Y>U]T68F
M_*J@_0#>I8=E!;!D0CMHW+Y[YE, P3N,:N1ZR^TAM;>W3P#X\$S4\%P#3,4V7L7?IKV(3!\$!^4!UJ
MK/WKSN4R0#6CHF@R?9Y*:\FNZK82Y6@K@]Y(S)NECAZY/V M4W;0@):BSD MV"0R9WK@29#70+2L/-
VJY%N3JK7Y9V>#I6#>Z+@;:H06'(U499/8^5WW^%V)
M3BI"10#H]=GE4B8]0=RC<*CL'&+Q78XOFZ0R4[[JSGLPI*2<9?^*EUH//H92%7./5"
M%FZ3#G(N*9@FWLC*U*QT'0CJ[05*J'T\M\$L W+M87CEXRT47>6H/W@6]>D(M;AM/[NC@_URM7=??DA;Z)@PH
MX.5U%0XF9\J4G[@956@09ZT-M[G\2<&7K%?0KGL/2EB5N0,!ME6N1,:4W6

M18QW>J'.9398+Z0M0GH16F%D#I7I36+UPZ##%VN:..1"7.0:\$<*MW(V) @VC\$ MAU-1*/["HY*\@U3\$C@7)V+
U2E"\G9_4U)2;JK<2).[.] =S6; %5'N;79/TZA
MTMS: LK/**78*Q.D9:H\JA5"V5ILN9Y6S%A2@,E%G\RUCFT,:K0=+;)C)^'9D M@P
0+X8KL"\&#^'4)4\ZKSML#**7\?2Z3VP,-^5RRB(P\$2\KH?
011>5^L07#I,82X*Q>JUL&1)10W=&'V5+;*!ZDAXB15N' '(/_ M*\$
Z#7)/.Z\$27N2\$&K=HSBBVZSLZNCFM9UW\|S1J7WL:X5":2SYR;R'CN+_0 MV>,(2IOQ,/4
669T!&3HXM5QH87YXK;KJYS/I.6'/KV>QZU-6C!8:,J/&4T \6I@3UQ>PW0SJ77012_88_A1KF(:)\$
M,OK.'HTR4^C>-MH04#)MB%T\]/MUIN('NE*D1^J;_]JRD\>F6V?+/Q<\$U[M. M\$5%GMUXV\$M(2BFK.
[2ZW4:\+7V\|RQ/6&HQG98<\$_,0)\<;.ZK&*WIJ9-W04 M%5B';ZPIR)'%+: '#^1N,Z=YSA:GR^"M%
<3RBVGY,#&(-,JQG5P)6\ MV!\$5Y\$0XSH\ -4CC!_?TB^S\$%7\6UQ6\|W_N\)#*1BLXC^61,JHY\E4K5WP9N
MV/T,ZHT!]\8YG*"GF+? @?P->GNI, 4?6F-92B.'*!3A\>GJ3\|W<]-. ^!/_- MP%>UW.*4"[Z0
&ADF0WH<"0.9\^RCAY+..S*7=IKJ.^G/;/Q-<^,OC\XUD50 M5G:P,6WLD?#\SIS%,*LSY?
4CM:..G41\|J"CS"C^F@JY>%+-YS!C&\4T.FU:9B MKGE8@.V5SH\|:G.=VCRYM,0!71+6S.\$"&W:L1TQ"-
RSG>PK\|B2FT7"R<00\ MIITJ #'!S\@^TS#/-T\$G%<;/P(Q:LD,OP!&(7B\$T(#NSOA* *04%K1CDH7? MP/.A"
!A\IVIK4();08;TA)F0*=@+)X^I4\|S0\? :0 A#;PMTNM:1A.)>,7/J+;&!\HT F3\ DRQ
MUD&T3@!,1F0Z@! "I!"W;CS0 M'XGFOF P%JVO(U^YTH:C\F+A3Z^9VM\A01E A0.SH'V3\|FOY+WEZ
M0 BU+IT59B\$J>S -6/4;>.T.=RV28\@-I360"OMM5ZN\|UF&2FK)YTT:97/- MK!(C\|FE2-3&_I@8?
RD1JTJ+9#I3!!*;&X8(\$3=3\$40F>)W\$'03: C2I\|K/Y\
M9S+'D1/7+M\H\H#H2GH\$Q5&)\$,\Y89X";,\$P%.LFK3B\$IFN\!JF6&3,"P'ID M:S3C*&EV8.=3S_ZL9FW&AZ><
@9R,;ENK6\["3X,4D ^)5Y#&&F MZ10R#M&#ZF/YI\6U\EI6.[<9(+9.DQ/'R8P&Z\ICK&_D'ES%TI\+GN1MI7\|P
M\|D)IIA/U43;\$;=+*M'0,B5?-2.U0:6M1"1T320V5'NS\0X3IFRX=@CN(P\? M GG;
[4%Z/\$LW!&W66:Y(\$YE^1K.E>B5,RDK2JX0?1554)@OU>>S?J8X\+ -OG M#V;I^/"G?
>:8)6\M5\<6_OFJ\ 'C_VELF0L545:?\T-G52FEWW.AME.|P(&- 1S\|HBL./;W\ (DG-D;T&- M+'<|:RI<3
MMKARNI=PD\$1A!7X)H007W\\$()(*2&8\N3MX#C6!H)VN(F -@E;&XE_@,I5%=R M?Q.1[G&V57CL^Z-3H#K5-[K!
M0]*MVM/

:7#^Q/' [=J' 'H@#<)&H&SG\$>9

SLA:31NB)YJ*'=TLDPCC;KU?@CDRPHOHY"N6CWK(:V (U5@.I'"A\$W9(P%(05+:5G3%>55R ;9N+/8A@Z<)6-Y)
<_%V^3:,@) MW++U_52+0=0WW40*R7'=??>16!WN->0\|AA|-74L-*?T*"51H0I:W4+%F14V
M>^U,#J^8>1DES[4YW&YZ\X*10&3C\|?ZH\$)0A^Y*-9C!>-%JJ@K*%=A7*<8B MPHTI\|L+G1@IZEI">IA=26?
@&NH*+QD0BS2E68\KN",D=%4\A@/@P\0\J(* MH=9.3=>18Z00H#P5X@&3B@-#HV-%D2P,'WU13:@I9)\L
0"&4E0#% B"P:|'">E?4=Y4@.,4;ZBKH' M2=-NE/DX!\Q51CMK2T@&Z.8B#E\$-[ZUMD=*Y0GJ62;B:F:WFK-U?
5!-ST48Y M.4 Y?V7_X7\|K2)UI?=D#S:@RMWG+)\=%G3'E7NA(JFA\NV3S\|S)P\R8_N#HP
M\W.WYXHD\^S/:K_/[K3\|HLIHG#Z/P63?JDP?,0-DN877HGK'"9.B,*"7!E;"G\ C)Y5TCA*A>6\$V7ATI0
M3)_IZ0_LF@5F!-/ V">C60)5^2ZV\$?5]<4GEBOKH7/_.,^:7N\$>\$:5A!<7W1; M'P6Y\|WT+)\@=>
[3DG0_D>8T8IEFY\2Y6MI@>6?UPG_KUI+Z"LV/M>@ QP:' MOD>C>4&?'2JB0\|E5-VQ@XENN,5;B9
+W0/8N0Y9'RE(0=7CC;(V _\;EC8\4M&IIT%KN@Z_Q=ZA/4RXG#R9304U4%26QG'G;I,[2\7(/TA/9MV\$!,#U MD?
3A^YKN<&6TV-(7U_C)N98V>J4E@+,C# 'PVO)\EDJ%)#;UCC!/[3=Z\4U MU "MM)S8>FR*U&MZ-GR@0"IE4F*K
+!YY1"IL?@L8-.7=@^@;&?DJMQC;-59 MB'Q&L7QH_,7Y6K20TD\|P"PS/'Z;R\|H2"@==:M9K^
YRFMMT\8W\$=I9-' +18 M2>;=Z\4Y1YW05?0C+5U1SN\T2J/.RQ27I-(N(6IO,Q%\$^RH JF9S;+A4I7 , MYD_&U-
(+ "N^R0BL,*Q2+=ID B^\$W90>RSDP;I6&^JR\|U1:&VY\|OUVJ^0C MST\|LQF\>?"T>KA#1L^SK?
\$ _^GA5GER7@",!\@FMPJ &JFR.FZ% MQ6D=[63R/7ETNF193G3I4MSH500 ;/_;_I^*,/03!
(#;L\4NAFY350_UX\FW M4\|LN\|0\^D.XW04,A==WHX*MDY-.40E5SUA0L;4G : 9*7ZK>P'OHV1XSTEY% M==5I?
T0..AY_45I5A&)AMF\UYV+-'=1N(^ND=?ML5)Y/CQA?VY+114\|Q7L T MI:>E1D=6?
QX\WP@.2TU?;0=&8YJ9UN9B?;SJ/_-UL@JY=;LNI+.K=BU-!>&GIT@-TWB JM72NT,--YKVL+D0;W<|I8\|C
M/_*)BJ05 MS2 M&3,*,[**^=4A0%'[9+Y*SCK6\^R2?JL;G#9;1#= TOY&N^H+(1) T?7>Y MNW
Z\|D"TT^D>..^\$P\|D9Q.FR\|ET2 MZUFG+|H-GF(@YQ!^AT.Y>EB=SB\|UK#@='>PI[,!:=>D^W?#\0#1T4:>%EZDE
M0Y\$1JX8\|@5&0-3>_*:@\7'T8\2<(S_3)^A;,DRJC10HV3M/' +N\|?9KR;JQM
MM8H^%*GM=SJR0AZ2"3_8VC_ZBI3PG(;JE0@A'6\$CZ!KL0\ -I6\#;Z\24\|H0!> MJ;7#^ZH,H<1U&\+?
S,/6>LWB*6B:"SJG';?%; M-IC \G+MK80K< M 0"V; G\,CHB6/?HNTE)RZ:(MRY6WBSM8XYU^&/?
K!\^5.WN+GW#05(76#F0 M6ENM5\=/ (=4\$P(/EU^V4_<: -"?!SC75VQ-?J,U\93"=+P <#*"!B<50_9"+
M^H(0#6H"A1;!S>SX,>.R=07#<5Z\|ELZV&HJ\;#XAB (-\^ 2SBV0>_5^*(5! M!\#6V4>I;K)3)GD?..?
R^"EOT\|H5.U0\6-&XU2N'5#:/B_RBF\F=[F%V=@ M.L+0#&UQ:RU'P+Q<_.FK!X?..RU0_AH<7'\-Q^G6\<
<#!1?7H\|#RIA_M MB00\|W?Q7J.%!2 (.UP38UTY(6S*(TX<%@)(HUQS^#ZYU" T?!\FK3<- \^D609
MUC @FG8P8?EF,OC8-J8UM'PSM6K/L^V1YU3JB#<\$P+TD>3:*KC>\$>)3_%.MK
M0J:ZE\2,?16/)>W_4#4V4(<=&'M?>F)>1Y. DN5%[\8N2:P-L8SA%\CRM4 MC>-
;IN:V<3I8N+8&ZFH)P@OY!;?!(/;/>F=;>|A\ONR;U0S*->T#4XDE
MW4\5I7BL00SM#ZDF=IFZ*UIU,60T1>S<^1Y'NW=N+4GLQ? >C#*QX:,9H"W1_/2C*J1-9-^)>'WNXJJ0D=C1ZV
MT: ^-EP\|J1\|*1?A\2_09<=>G^?;Z7N>FZ0\|.*8ZI)^!RV/ZGR\(:DP@>30C7A MYJ):I='?
(4R<'(*ETX57,L;:XK<|ONCBVU_-\$>)KDAKB:50^Q*/G\:@ZWSK MA8*S\$BW.E;\X:OL\W.B^Z?L#8\^@^?
%:/5!\$!SK3=A/_V >>K4=IB3G\HX M9-KG2@UYMH5PRVW\#;G\|D)9+%LXNA:L2/Z6&>8C/L826>T-?
(CN6#&7ES0\&M\LV)5^-OX24."3*=ZCGW=6?(-D<_2T'^&2+U'.P.6GTE4K%M M\$9,[J671;VL\|5\$(#
(15M/7UI/CNV^KV^N\JL@S0TKY+6E M;P_R\2KZ7+,G:"\ J98_3#,*5X;Q.UZRCM)4ZJ;Z^FB2H3-
ELM<C"ED+;= M=1)^/9\;[RJ=2R"#Y'/_/ 4-5&Y\&^7&J62\,HSI, M:S\CC@=:?KYMFN9MSC;-J>-
G=,SEZFK04AU+0&B0334S0;T19HR.DQ\X7"[3#G4TCB'6@G.WV
MZ+AU'K.#T\|^5RM')08LF"_;T\|V8JHJ=\$YJ\|V\W\^K_LM03U^L9D^ M25>\9_S99TP0A@-

WGJ9,H9716.^5PQ"8{)FBT<\$-#J)X{I1'IY#04)5--0-J MAY>>AR:9/K.F%43P-8P6KE9;DB\H33V4
M^93E003#.1G&[/74LA,>JHDYL3.: H:W>K(P:F2!.'AP{0)8D;>V\N@+.7{7 MIBX"['^!DEP#X)/)P_WFI@,?
99P6 JR "4G'S6,+ -J%X5_K)=4K^J_2*WK7\$ \$ MI%M&I0_M<2Y: M4R\$-/T\$7V[DR"]&W#="+^'20HCF ML
L9RZ]"D\Z^QWQ3W^YB%71+TJ0S4\$ETY?PG\$X@{(4.9ENJ!%ZQ"S"SZ(&MYC MW(90&=RF/7TM,^?.W#0WS-
SSQ_XCZUWON[+W?IYG?S{[:2Y_*[443M!B M\1&-S#+!QV6S^#7F86T1(&)D@+\$.QJNA?
FN8NF7^M0X.Y GP03S*VQ68.0 M%D)HI?H?V@T>,;LRMKF^8'Q'0A(:0Y"[6HJAZC^A?
+*>!.AX_5X"DW[^MU3W\PV6?RGX\$T6 MOW*IX^*OM0!0L(F1Q\VI"07IJ8\,+X4 X;-FCL?6MF9GY8T\+@AL=A
DVP)0 M!DJ-I4^N*AT1KD&8V1F)7V*_FQM)-?]'^S^1E^TQ!0![:@ZCRUI07\$K30&[:F):440HY'+S}%+IH)
MON.ED)=K<(DMZ^U2"_:93+:0W5Y37^9FNB(67KKBB(\$;:T10(4T%>WFJQ67
MUC+M\P7QVT?)3N4PU8=/THI_*RI=6IR?%RQP^*9^R9*(Y?FI^L9[(V<6+X5)Z:#+X6\$]>1;Z!C?&(@E!Q@_SA
MBI->]J"/%FMG39^)Z!\]5A0X/.S)<-A5@IPMZC)FB(WPY^]0R2)7K4#WVLN3^:D1.%_EN9\$0?'.G-I8S!FV#
M0*UAN0Z M!K08;Y_FVI[9-H.C CD3N^'0)%]WV\$?+NN2L<1U!.\$IMX??\!8)S-^YPMK0B
M#\E.W\$%7C&^5FGBK%!M>NJL()YH+P1-M+>B#K9/=538YBE|K:S\>5EP[:0
MP)PY]*#:4(9VZ^RLX86E1[:FWSX8?G=U{]ZZ,:H2+!)^0YB.\OUC]\$H.(UA,B@&<[I^B+1S5X
MC059@C&@%ER;B;:[EH-NI!8KYK;N45S6Z.'C?]U"/7:82M12I0AG?,H6-IX< MZ/2ZBZ(-TY^F#RY\MQ->
[RLUMT[\F_W5/Q0.,R(M7)?MG@:(7E,?6H.V[2 MU#50=5):%DF>5[BQ:;C#_6N>"MT0(+^TN+\$^M>5F?
KU.K;U+*@L/=ODT(M5WMMWLS:LG.9-05ZMBZ]B^S<#A[!J6-VY: ^]MM1UM@]^SFT^9Z^MX ST-FM4A
M]/%FG85[KB8Y=)XEGP+39(ZK-F68G>AU!0 MYLANH@N(MH@;!T8T]=589,YQMNK3^03TW#TG3?
5Z)\2MW*:0YS:^]-:00,J M.%^UHCN0AJF''(\$)/;:>6>:CDGYNO"*:-TWVA@N^0C/YR%N6:PL>X!.-CR&C
MC!_HP5BGWS+8(P:@/W&]+L4*>@T2[3("0H7&QJ#. %U2/[-Y\VB_03?G^X&J M L-
E;P6^_N/#F7Y1)@*4\$**FWIZI['6#\AF2-R09PW;7TWCG&A./]!E<]?#< M,G?L;9.:@#>'-
0PI!1\|D<,S)9ZRICAF!VU/R,DY!V_\$ICC<,S\D M)N2.V&S_ZM&[YD^T[PMRKX?
6LE_/8CLY]S:6S4*%\C):L/E0-0H_%1T59KXJ M H2 W?J\$JHBB>U5D2)C[E3_H^GX"/9ER@A?
AUK@'355]2#;IP>S1MVEHHWA M+^YVJAGUKJ:8^XI/PZ6^QMX<.%R@^,GK<.[IX[G_%.P!Z;>NP^""^W<\6^)4A
MT^_,W>:7]E+^"-MZF4A>7\$#D)GB\=2P:(@_&^LG" M?T)W#3W\J(JKK(60TPP;0D2
E@N#N>;V;K<&Y2RI7X6LH>R8Z;ZR#.07PJ0G M9*_P"/=N\YA2:.,&QT]>[!695A\$@D-
"Y/QC@^VN.@_FZ181&9]ZE/FZ6D-4? MHA"016G2BA4!CG_VN.%R\V9GDRG5^*_4[M)
[7S[60U90+TA00%]Z3WIDNZ;4 MG3/_ "X/5_^-
0:BD&=D08/7X7\$_.V1K_(A;WQH)CZ]\$F027G^P<AZJ3RJH_ARZAN9_.F">\$4ZX;3_(* M[#>QW8Y1FUN-%X-
140=Z4.N]>(*&^AU1=F.>.W!J4/_ '*@5)08\XI0+82= M./JV4>[?]"\$F3^K<#E-],.JY,B #(.J\$0?
71B]42]^B70 M,S7+@PZ#JU&!/ ^U[:=[RX&6)3KT%Y72)CRJLQ\FZ1XR-C^Y'\!>GM(:5 MV-DB0/&FN+B0[?
[!\|+U&QA31K0BR!)KU2FN0TB9@IV:))\$S2F.1,G-4V?*\$ MQ!=[/H#%['']^XLA;0[:/B !QX8(\]-
(S\$6"D]DI>W64SRD!; ,H4M,K,BGL IM0DTX+\$F],OW:#7L^Y*V0Y=EV8B:- :-L9BY,0JF#; M\$3]&+20?
QGF\GZ= GDG*>Y7_\$\$S;&TD)^6^9UE-"17RFN"D]3;] E,M"J5B M-Z^K5!Z(L"6Z4L.
[>5S9&Y68B0#0;,\SKM004C5>\$0'(ZZ!90ZB+ M[9?;,L,WS*G
@_,*4MWN.#0?;Z7=7K\|9L?)73?7=TR6;"/=@W2+_)EIXNPY M[A&JF?7([1<==MK#T8FH1-
I%45?,80Q0RBD&49)AS:V-020B01*,9U_33[MR1N,+/9=50G-7!&@J.)]X*(<")B\YA-\H
V9[H5%ZV0,N1FSC;E:70%/D88> M#'+#XJ,IX^=.9:4KA:]NH=M);BF^R\VSY\$I"V\$;VX "U%.5-
M6TC6"/35VMIRON)E=WNM\$E^I9^>NW%+]4\$; U3G6KPE0!FWXCS8=:@^Z5,S-:.\$D1P_5(
MDJ8W#KA]LWZ&5 TP,E>>99IK=GY09IZ=](D7JZ>6(@00(EZ_4D>*F\]Q0^9J MMHZ8\$7-
1LJ@!PF[A&40"%]-2\B>((V2V\Z,\ "'40&R;6 M9;!^/)!+!+C-PISS_09[3WZ4K);*./,=(K7=P*=(*5W-
M7+;.*?;]EY.G(N=>T MD]PL FBTkW/XL7JLU!ZV2W:E?S0-EG AP=#37E %WH^P?%#96X12>D@T4%+C
M@0>H^Z=3N.E23U^0J0X%^ZW<< H]'^'D;*&Y=LP-]0LS5+&1_0)5G-0^WLG MY,0G[^4Q(:91HX/Q2^5!I/
(_RS#^CTTD*IU^P76TXZC:L-N/FFP37\MJZ
M,6[MM^P]1820)>/#@(:;PEE6PCPI=AMW"LKWH\$S*" \]Z>]N>=TA]\80V#F MCJ^W&58.*TV7F2H&TM-
&HB[!XI>@Y_LK2RLWQ\$@\$"'HB!WL4:>@W(N:/^W2/-H-;V<[*T M0K?;W?K^6\$S^H^K")-@J/,G5>Z.F8-!
MG0F[0# 'ZRB"D^1&7[0R67EE ['B=W:C1NQ+(H#0*>[X),?<5P1(<)XWOZSE M4NC@)\,NL\$+
<@#RR!=F3I=P1.\$@U^P!R&_%PZ24N3"=@;+2W;L>&+\$6S^N M328P'=A!7&_->NB*.1#YRS;CLOE./
3SI,S2).I:]\$B+<6_<+S27=7SWK" M30[>"9L!/&,V: !6T;^&<\$=03,V0^A77;XXGU&X9I>FC/DW(JIR#?
(5N@K.; M9S-6#J5J?9EJZ#AI78\$+NH8/[2HN^XS^9PY/^;^V^K^Y&(_;[7]0LH^.!OE MG@Y+F^F8^71B\$-
A97!LFQLI-HQZE58+0?WEAN'-/62S0?1%,Z03U^+ MM5M41+;(V4!4B47@]R0LRV0W7P0U;3;74?>P?
A^GYKT+.?*PX(>XQ4A!P0Y MI*,D<^B\$8?0=ZN)1';"(*6^2[-PWN6'^<[=T
MG084E9;'+7\$@3KQ;CNH_.VZ.9[3+5UTZW5> P& TD<1_?M8W*V+9LP=*7YG
MG!QMKP@R3L#.ACND."76F.CN) _EEBT+A0/D ^#CW+/(LSG(2V65%00\SZSI
M9^]J;\#%\$*6M3G];KFM[L.23Q!UWSHV+YZ):T;*HD_8DK6C0!Z5EWU.VSL+Z M.0GIII,=*S^R(D
EWST%#^6^JU@IPHW M9YL=S\^W'^^%:'M#DLX3](M^+O(W M"?^VK80>>F1\I M^L"7X0&X4]5="G-,]9-\$F.G<[
UJ-QB)>+ M4)BTJ^3ER"CUA]LT-DU:NWYHX! !9_647->+3Y.W"!&X7DL!BC/&*^C+RSN=\ M?;=3=XW
V9_]0^XK=:#JX:FF&0@* 8,/> !:0D_]0%=N,'4**<6&/"/@.9, MY)UR7#KZI\$9XLG&L7\=.&83ERH_0*0&]@_
27\!]S=/G:S"!P863??Q+6=R7 MI,-9%<+>7@H&FD#>N9[8:58QLHGYP): \=EML;1Y=0TN).M_7[)!YRD*]SF@I
M7030_ ;V^V.IE10<)0LG^549&N7X#10Q MH@#XUW_ZM?; PJ&N;4+*<">\C.=S+M#C72L8TJ@?5I#@8?
B_+Z..%_0^D1[M;_]F0B9R"(@YV7D5S/Q/!F M5\=L]Q5,P000A,'T4M(%M7Y,-
AEXU\$S[XQY\V:")00Q!Y@T\$/W2)3A:N,ZUA!\$<7I3XBY^2DIJT5Z Q!GFV\$7,'L;->RIXS)?
E5/K[>*5(I=V<_G(VR >>!?V MH0:L,9A0X)"Z\; HF'\9\$H(T<14 F^1 M/'1!R>Y%6:6U5\CW?
^"JRV>.9\$S,A-]I@_R4WIPA7,OK_-A^D\I<@5AGUB.. M&^=
[0N0E3B^7'^^CG0TQ\$^VY(7^R^G[!4\;#53MI+\$_WV86BY^Y;. W<6]2: M06/T)6^E!\$\$\$!4]R:BI2AH
%ZY9K_[@Q]#N499^I/?=6Z0F#]<]Y,LSW+\$0 M>ALRZWJ5>DU.P3BTU*)YNQU82B#H>@7K^?E(?9/B-
P.,#%!/ ^8FBTSF*.%BT M&Y^<GEYKH""^+8>1]V5_F*)^][P]LBRGW\$5])SBBNUBMP^XN^0S#*R,G+J,D?

=%ZRMU:VV_A=)0?Z/9X%<2^NB0)T03XSD^W6G]!,0\; M1!XJ?
G1&*00;=CC;^%}\TU#;2('E'88B\"0(E#*G0GN'4592V46^KV<<[M0\$. \$31Y20E=TN_J3%?Y'-
@C/&\&/B0#'_ ,EED'''D\$;4(RD)%F(HG5#K7B^" M9&"&<+FYS>1Q<21-6KPC0E=@57\#A5Z?A5U&U\=-
U'/+EVV", AC\L'. /! MV*'L7+8A@50C\$#JES-#(A(YUSNPE_F(&TP-SK0:=X6)Y(#\$-,I&\$F.J8-X@
M;9AR33&C(}RX%0}\$=01(?/2)Y4=R4}\$3BEK+G%9/3Z*QN=S)X.E\80-DQ0.\$
MTQ)\$@7B^7RQ)WAW/[,48LR^K9I;F/4C=G'G=C2SRL[[3WYYGAMBLXU\J]_4F M
>G*TRSA]]7LDS6C)'>=VP.##JP]B-NW826&/\6-RE/^#MGE&]2/N VY&*-- M2V3G0NF4M!_%/EWA%9JC1&G'V"
[K?1;&\$20N?/,LL%)#&T+3W4?,500\$ M=7(3UK%WK?,J1R. (SDXXS:CB=-H,MW\$PH_1-' +ZGY'P+*9E/42,,
[,.KS&> MH(DU6K_S"\$RU7=BX+W,W;!ULS[G^!|8MAO-BU9R.KJU|91?7]B@-<9R:0>5[R\ /P^Y ^W\$#>96?
92\Q] M:9)}: N\$F)2->5: ^- 5&V.&G%[^M?XB]:R.[4CH2.;I.9Y<_P*B7IY\$88(})LFZ==6J2B(8&\^..>
(K.6 QUOK;UD3=ZY>>1F MP?88F\$U\$VA_47#+K|95AH['''F0%-
'=MFP06]HA@80@.QQ(64/2MJ[R)K5L\$Q+G\|87VG9U:1CKN)Z<'YL?#9V"D" MX*Y:2LL*J* ED/@"R3+\$*_
PV2!.#)3H324^/G[[T&@T8/%2I60P^U*I34-/J@1+:9J.0%5V=82+ 0M;4 M24?''-:] A<' +0;3S
G"/A*'>@/(;N6> **QDARH>073NZ0V/|@10A-5?GKNH MJUQ|0E>I%Y?G6-&GB6H"Q:%/B0"+4 %GPR5\$
41H)8.)1G;Z>XSSJD&;4,- MHG\$6&)IFEC-L)THBLN@PE"KW2TCVA@/C97Z9MKB%Q\#HS6K.8*/[D?1SU4ML
M^(@SWA8T^ ^./,36CY10??VTJD\15OZ UHHBU S-0&-0:*W' MN5UG5V%OP4>YIC\U09 ZE%J-
-ID=6.\^8;?;.!X_J6&)M>U;#GV45EF&<75]J
M6!FFT30HGI.PMVC&76B(@BK#L('T3&G;:T\L: +U+:&-G/PI8?R[1C\ 1&@
M0@30PR;./2EH+9R\$ZT\$A9#G,*[MG6<|0Y_D0=[03^&RX M04KZXFV-0.[5
#M0:&G0*N &G[X5L30=/D7^Z50QZ,#^%V=;IHT-#JT[N(:6 MN(}VL<^+
! 'X,YORGNW,T<,L36=V;H_0' *0%AM\$*W:W'3PG2M4I&C_E!*G1; M9<4\$ZP?
QW=|*' (Q0@Z6\6LB=TC>LVU7A\$ \DD1,U03E2S0#S0EK4^X#7=JG.Z M.=;VK242J2XH%AY%NC 01%&
(N\9=\$JOZIU/+.=(%V:/ [\]W(JL3AW|H\$K@ M[:IS;?
119N@ZC(W@=HH0:3#%FV#BJ!/#8U8(?)=A'7G|IAUC1.Q'?NG[EB// M6\[[-, 3[+H; \M&@.
[QSR9!_VR2]G_?)*_V:1*R"7^ OH00J;|WJ W)(F*
M|C1C%'NIB5W2R04??.^L\$ \@ '*AYA4P4G^ZAQ4:5/*LK=?,'!-] \$ %=-;79\$
MMQMX^U ^1P43GTEU=N"9]=0IVU|0W186D_4; ,IOX<07R*UP\$\$. @9KCP"=8\$
M,#1=AE%7S7/N|FIWZ4I;FD15QQN-*; GTN6#-9J_5NDZ4-6LGD\$|07U+HJ1 MU(/KK__OTN5-3(T
5SZ5^.;,K9!I\A1(U|UNIP'LC_,JUNQ<%[%-V%R<&B[V MB-,J4I/R&8NY3'AK850(6K,XGA?[\B+3ZFE\$J%
(<)B?TYP:\$1IF\$BN&ZDB;1 MVR0Z;X^?;.F<<4Y4FYHQ7(\0@3P6U\$MYODB!ELTW7(02G60QWV\$BG'!+!T-
+&5CS/6P MW"G'9-K"Q&2V/V:)0#DU240K_Q3_%BM;T:HL:3WGCY1'/E>:P^@MT ;_E" M;L\ _#4-
L0,UZEE93}%WUY8S*<&^.[|E_I5HI0@>P'>"URM>X0FPF:\$[%]Q5Z M=?]|\$ 5U#VIK" LVP%R0LMW'%RNS'L
MG(' @UR3;CJ:8XL'Y+NP1_63C0:I'(')*M+M]_9:E[UQ%Y(:\=6_R3G#79)/M M!8H +<)^%W3]F"
/:@.5\$@ \$HFB_10+\$'73\JR!,WA4H!>?&9(L"4-;7T4F\$<
M6#7[ED'V:00SZS99F&\0)\CK[\A=C(>]66E:WFE7[GE\L;NJ('7#WT@!Y2"+ MWD>WA">B2&P5L4]%J9_G0,-
(^V80-U,H;5'XV>5|(')8'X5TUX>U: ?R=T!!N0 M(-/Q@0J-6H91_E(DEU\|I-
2\Z5[0FZ?/+04G_8F3^M^T*^JL\LIH_ODY#93 M(V..)^F+BVQV3LR309G!.S97][C^>7JRSMU:Z'<\$*#)@,
M#?8Z>CT12RJ97!X"GD&3T9Z;)U61_@#:6?..!;R=EEFY23E,>Z96U58\$\-2 MN?2G ^EPPQ1WZ4'I_/S8'
+QC;_EJ*? +\$ 3/0&Z6C[6|\$&WQ==.\$H\$(+Z(\ MN\AM6 >[CIM^MAFRM3HW+ #MD!<6]Q>-
R6*/D\|LI8)8W^>=NI" P&7@!J M_-)T J+MZ)6\$F[15R'"V|RZ=M%M|UMX0#=_ 1XH\$*QJ\$;I0D%W:U|,#5;)NQ
MP.Y9>ZU40-Q+ 63B0+ X=@(=+&Z^GE2CMM|1@]-0B/W,\DFAD/=SE^E=(3VS M%NGNX'X/82.:U;V(^RT"-
FY\SA5N\$Y\?#-'L)2Y_*8+#6FWUQJ18#U"97Y M'JKJ\R\$W)7IF4:"WC&(D-T\0ED?01\$NV>D%?V1_I+:@?
CTRS= CN7I':|58/ MG3^";?'V5TW)&)IC/|:0T ^XB*[>=N7L^@/<(59_L7?
Q0C55R(7>Q5=68DW)GA[|JZ3ZLJ5;'!6BGW9CFH|LX:ZWD
MU%28|^>=&^#U&K^3329^Z7XBP&Y('79U.X0K"1\$!9(SY)T2_[2+ [TU]5G42 M:B+0[\4\$FE[8#=_ B
_L>NIZ&\$KF=K#F| #NK_B@I&WZT.G M%8_89D5KY/V\$5Y"60^_L2/S#J(!/'[0(.K6/C=GKN#&8\$3_WQ'F?
9EP5!C MNFA3MV0BP;+ \)UR)#(2K)4\ZD8K9'0AJB5M13*0=\&,[3_/G.K#*L8)Z@05& MW'A*I#FTEFX^ \D?&
[|ZY3D&\$UJAIM\$W43Z"A<*. 'B*(MI2@WOKQX0=XTZ MJ^E05LUBRM=^"Q""5;XY'\$41W#?'4UDQ5@28LQ(+4-
2]Q"KF9B;[RL6-*:Q M_\X_4M"4A7UYOY"TI! ?A30:W|IJ.-%*[R1(!HNR/U3*P=5AY5VN+7S_Z5L>V
M;@A)4[3W5]_[K.B]0=,7'XT7JA=?B)D[:QDB;('LKS%B0MD>C-QP/M3?V^XE M?
UR0L=@:K3BB119AH'CRT[H2##I02\B754ZUL7N;[87U6+TG&YQEM.\$N&^," M+WBK%_%WKJS_JU)SHS/_CK8I)\2
UH.EQ'W.'-F0_\$#7K/EN3YW^U3PI):Z? MST50%.)I**V2L7B?F1Y/J3WADEPSF\$C&WN_R@J3L@_? *E@KD6(H
"4%FJ]T@KUHA_X?@1"CM";0IU_2C)F?XH MX3 ;?4&NI>N\$XDH*JSA@-QBC]_@?L5C98'KT8UKA0_[8A/561=K
M%N)^Z8_M)F"UM-'C2S680#5HM/W>;I2J5>;9769:CKWLDP\$6&E|00N\$3%RPCP132D/E/LIYXPWC|!>+(DQ.9-
>_B3D!-/HBAQ[2_0*3BE\ \$0_M_E8\ -70F^'; X_)WE2D/AE: 5^19Y-|JA_/@WX92_V*>Y,HU*M47[:|&\$:5L
MVJQ\XC2*ET8(/('(.J.3;UKC=+9\%C**AGV/"R;MPZ"5(&[2M#K,X3T6!RRV M)?+J>'6*&E?F&\,,2M>_@^%T
<=>*-'!4S8V\$502NN09K; MSLPR\ +VH3Z_J|4Z?:F#QM3H.&%P?WD(\$W-7*N;J+ (=IB?
8&\ ^#^Y]1C\%!8./5+GF M0W=8VW9U^G!.Q*+;:0#VC\&T/C:THM^VBA7S^:63EU8F5,C/5*VG_UJP.[*
M3F0LOFX\;#SB_K> (J#\$]#^ZMHU00SN@B6HSPMDA\$6#0)H!1@8MQ\$8A"E7+F
MKI*K7[|>5FD<=>>%Y<7ZZ; ,LE+\NPSXN/?/?%T\9 Y.A/<_ =20-W(D(&FJ4B M#0!M%=\!Z\M\ ^+6N5@V)>6-
QZP<_J0D865X" I^U?L#Y1 +SSGWVK^Q\8E]) M1_Q=ET6-?
CUG8J3CL7BCA;R:C;+*&YDG+Y.Z^EJ50ATP;FV=TXADBC=C=L\9 MP|F8\$Y?888W\ATW/&N-DVC*S !&PG.&N!
[9"">^KKXU|96-E;_)F0(M|B.;_*_8&L-|U?R,F9C^T=2D8#EW.%*#0_)%K\$ A?70+V)9J,(C-V+VZ\$W'LM
B#R.^? \B-I= M)5H/%G '-JA)J]=[8-FMDT5+"\$03^9W_.6M M>7MB*8&J8G[M?RG;W8""K>:'L?PK:|2%-
)00EF JK5V_F9=5DB1FRYE"R/Z>)4P2'\(SY\$9:' ' /! /NUQ^S4'33JS M\78=S5R@GX<.DQLV?/;E*F| \JZB;:
(,VP(GKN(')*GY6J72YB)Y|/Y9*-RU< M,)>MOU|U8HGF\$9FC##.KF+WS?N?I+8UDSI,2#00&H@
9*7D@:>'FR^R<^ \. MAJI?<@ \ \I5Z?7'HHY)7Z7G_\$YNI?&1'JK_[38_ ^?6,+4YP0E2CP;2!S0\$&S

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~3IIQY\YD;7_R0?..?T/NQH^N=NW.PUU!R*+\0?\" f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

M;KE] \$WSYNK>W PM*ZY* CSC8!@PA; ,[:2< 50GI,5#[]\^N_20^9GFI2\$= %L MA.OXA+4; 5.@(=P-% %4
YGB\YORGB0A/Y)H53AC2X0IC2(A5#M0D[]F8?YG MEX'D@90+R,B173U63B2?0_60N3.K!00K!.&N355113-\$@/G
/Z]';. @/E,1. MQ]E%OJ0,P'HF,RVC:W0F#,^ [V*LQ]R520L /D3&^7=;7(\$I@CJE^"/KP(%/ MC-
!&^"X\$=TPKI,8D&_%^*.P6Q 7*#\80] W;) KVS6\$/LEG"]+YXEG",1&@ M5+>19T\$%/W%<[-YJ>E0\74=>I
09!JM7R\ _0L'22UI\$ZYN'5Z/5RK MK6)=P_EN+N@E]-Z)0E2\5* :M4@>X?K3_T4?'TJ5UVJH0I;X*=
(M;J, '0+J\ M-\8GM5= !< F-IH*:W-) +K*!HS+)WGTF!KIG3&>;SKN?BX[6F\5TX2\0TKI\ M=&0-)LMK#D
+E&H*/86[%IDI/-45^D1(%<=5L\;X(:.S7P08INCJ>=<;>7X M/:/Q.A,5\$ '^M0/1QXYME: 82P;?
KHUY"7JL#W7JFQF*R:"\ ">%L6&\Z_FLWU MA2; E.T6RHM)#3.;V/K&]'74U;5"3.;@="AM>!)^D(]@&D=G_*:?
94Q2'I8% MW8&5^GE \PNEK,N/+<YQ=KJH#RNH:+Z2>@B_M/HGIL"X:^QDU!H%Z!\AF
MU]G[S]GL,^;6@H2L=>?76XI>,B-@W_T]U-38A]A588W/)(RYD"F(F/HN/ M0\$J0(T0(?
5T!'J^PR>D:"\$YIY9#5WK*U:)]PA;(CJ+S-B:9FP+,+M6^AIV? M0(<5'),ZG'AB_7L&G,KZ^>A-)X#TI
+R52ZSA!B)JJ5_G+:S\,F)@CN7);JKGU%>!)\$; +T./3KA)\$ _]L=+3?06^&;978%IY MSZ!R5IS)E
] ^\$WJY"MM>X<)\$8_D0>%\$RVT@E>A!TAD5_/U8#?F,5;9IJ*> M-+:+G2SZU;G")_LF#[]-JF/3
MF0F&W.ASP.34P]"_R?9=-706) A-Y/@6\$6%0=-, -3 M%' +\$0IEA=L#Q1DVJN) M 'M:>9=\$@&Y[-
=17@3&&X\$8' =B27,&A[LT)*6!%@\$9+Y:=W#3&8AF\H:86V MY-SVS9ENV1.3BIKA. CV?
T)0WYK>% 9)*VI[1/I]'B:@B/C(P79#0PV"4 %' M 94XU8L H:!!T+"6UT@;\$6"7>HTTE2L".
(^, !6*=DJ:9NXL2JS0B%DFU[\] & M>B/F<[!] \^N[/#./W" 736C\4/H!YV3USZ[P;:(,P8D_0"+ M1M#KZ<-
PBF\=5-)V\$2 !^ -VMXURP+TVSN[8B]:=- ^[JB^,<#3P4M'?37H1 M9F760S=/QJS ? 3W/[A]=4SX/&NX7?
!\;DZS')1\A3HLFDU_YV0Y.9:Z66 M:N\ M/('] OC?J'0SJ*:V;UTP]@T*(@AV\$(^ B
BH@A"8DLC(F*TD5>B\$B(@%" M<@2EAP@(" A1Z42\$B!Z\$!5>FD@;^D!"WR8\$TI!DIS;G=]^K5S6J1MU1=>^
MK_Y8&1F!D:R]YUS? +ZYUYR+G0YP+R\$) ?8&55P<[U&+QXGGSHQ.8>C1HC\$#1
M*\$ 7X1X/4;=XJEIP3;XB_N5&)(4+H9T" 'SY"9[\$4PA82;X=AGC&I+%_US
M3Y+F]DC\Z*KB[?%, '5]G1[]7U-F[[]Y?Y'N,+C&-\$2NI6//NR=7)^9T%]DX: MFA*!6E\$>9Q(0+,-
]Q1"%!' =0KA14/BVOZGI 5+RK=] &@'3Z+9Q(0_OX#/1V M90V:#X,V0VY4120^M:F(C2VK0+6W-L<'<
QK#L5G6D"4^5GG\ /P_E-,P_ ^S2[TT].NW4?KU4B+ MCGF=U#TEWXM+B2'2_\;R\$/7JV\;WU1/DC" _H/!F]-
X=W_H>;ZP0(R:=0-H M.RU'M7^1DS=H'URTZZ?4VPQ%Z;(>]A+2=1^>JW/5X,+, 'P.Q,>?
\$0IR";0L&V,, ,1#A0F;[:;^ \T,%.Y? M6&D]Q\$HF[:+=?WZ*<(A_J/.K_*SD1A5/, \;,&DQI+?
02PSYM** #.<= MA0N3N;70+!SP7F.V%>[R!+6%(^1),0[,4ZT] MXD/KE7MFR962;ZG'[''']>?D"J=D-#?
WD6ES0\+E*IG\$TH6"L/+UGQE>PJ8N@ M?-,TZ7R+3(NILLN8:>S@?&^DK5.\
(&V%KW' ' ' *%R8@^Z@38X"3MMUTA1097 M(HIBW! ?3]\7^(@GH\8LND@A=N[R P%SIWBB&>Z0,;1N5_2:A7
MVT_0;N/NX1^EH7,])WXE+J1[0B>E/Y;?2V0'N 1]:9XXFC]Z0)"PA[K2E6QF M]K-
W>9%WC"0,;0@ESSF7KFTD^4T'U-&Z7<_A?0TC20U2&R,36*5 "W4_I;[D MA-?
Z[G\V/#'N[/*KE>AZ&CMGX7'9(,U7@2#4_0!0 M'+ 7I0"*KJNOLZI[4GU'#4_OF_? \BZV4HE<49?#L+\86?
%M15/G#IVXKQU&4 M!OC]GG1EU0/#-).2LL.(HA9M3LE)\$D6[<6G,0MM!4PS1 M&C^Z\E,(8@J(0^N ;3ETN-
1U.-WW3&&7;KH1AJH[3TB&TI[S=QE#FY;@'970 MLP61(XMS,C[,3LXK115RCX86Z:"KKZ\^+J18-]WT<4EEZH-
+Q[W5/_0&BQZ9 M5J?W#PED%4%UNFFK&!)_G0=R&<3CSM?5UF\=CM:=LK7!:>N@=S(IEWD_!5"> MTB_%
(^XA[;H6VUS5]/HF3C3NTY@?BS^I7,#M]<1:&+/+L#)7X4"C/VIPZBNA#_A? MR'^AH5.M];-
\$CZNGD6SP[F:3PA@?X "JB5Z_H9"+H:%D5ZG-]JC4FM/^:=FI MKOZK 30M]]+?_HZMGWSE]B]?2))-
U5_M]G'65G+*Q?^0TV_J_'3<60-6]Y
M0005(B)! "8+M^QYJ4K^E=G^SZ<[\H1^B[K*+J8,;@\$+6H5ZR;\%B92'I,FN+ M4
N[C8:RI]YEJ48<]ZPRUXK/LK\$H,)T8-%0'+(I%\20'F,NQZH=RKRA!1ET M0TL)X?
2PS0_ ^J";V3]#VBEHIB2\!)F50MTZ?&&+N+=2A] =?9%F%DW8)S_' ' M=Z;5Y414P316#J2::'
EH">5_,9/G'%JN64LOV4A)[FR&_7%Z]D'!Z9](LL^ MR^W+K;@;I@T)(B#GE7&FT/((>YF%4K?
C!7_A6=ET'69_EG\$V00<\ M;J'CFX^ \,]#>YB MB.1 /! !03_P9>0/^ASF4.5_.G_I\$
+;!\$E>9^HN1!+JBFR189U=Y7[2_JYF(M5UBB1[3]]'M6"K^&8\+\$UEEL+8VPJ(W,-YH_M^> \HI1!<4>CA. :
[*I[C\$ MK\0_KR7/?_IPD94^+ GI\$]+?R"%]KR7IEZ=ML^?T\^3;S<] _[B18_2=CH9
MFMTK*2E0D..S581*%N^ .S=>S9@E2C^ISW)[GC'I3' *V,;57^8II[Y\$KM;^>
MG#EH0X&L;7\$TW,CP#)+JX3=,8%76^7\^9E;7.-&2MK,4ED0SQB0L[T4'*]A8 M*=Z90+>IAR\)-= \4KZ+
(<\$.TZ)+=XK;YZPG5A>&^X^&6+N^,PH&E]BH+B^F M6+[#:I>%S0?
A!]TZFDP&TL2W%MAX(MI4JC(!BM[] .DDD(YY.N0)K00UIK#KUY#V?G5X?]AH+6UITS;UDRT['
MH8_JY/D]!;::QXMG_OZ.. \M 3UFL3@M!N1E#E!;TC41)8 MOB,,,]F(5PDHP0G@/_ ?
S4@D_30Y=9/Q\$66KS&)9J2"Z863940=)9'&"Y)R&K M.A,^%"*]5Y@KAKB-OS,&FHR3N=A.V6>VM ,/WQ\&8A=
H*9B+K] -TJ'SLU M&AL%#T[B](Q%J3KW/SJX0D\]!W2!SNZ<C+^ -@%TH1[JDJA1J2KJY]](Z\$BL
M\$AK0LH!G8-0^PS&&= \?#G"&,8D3(\ \$'F3+!#Y06'N_UH+GCN
M=V=J2R!EE6IUT*UZU_:4.) * _CZKE\+,GJ]/U2S00MJM=&=?
3HK/GJ3, _@#N0VT.16\ PQ@8>F>W\ *SGR;\#C!OM#?EC9W0?5ZBV MA9@_Z" \2I!U5N
V\G00L9)^!4J9\ '(S10VS2S42R)QZ0%Z"KX?.E'XCR;HA M;0KZ*+06;ZGH]7"@JF)
(='9>ZN5*F=\%- ,]6\F@J9C%'JMN%OMU=IZC0A<,R:WUW.L\"; : _J]Z>&)G?]0#]\YAES"IU([2G=-
MYK23NC917E=!GZ?0_S_ L*!3N4>XD^;VOCDS':8S9&DV-A3W/Q>7+>R:A M(C,_D
()DM415_L[ZE:L'8*T _J7AZ";8SH0%Z9IG3J_H!1U _C75%&Y'/. MS4/ID?
8#\;86R7T*8\]PGU)3KEZ1^I1:!\^I\, /U(1GY?_0(TD8S/F=KEBA< M494MW0'0[D6DIG_ ;V[2T
I> _;L:/6@^-3-' [B=T!\M09/!\^5HN0?+G@XRR FA%6 X)1_WF2-MXB&8WK6*,AW(98MM/.?;'4?"
MS:N;70M_MPYP8V9LF][X(OG<#943!:=;0EU*#7L >55^S>W)[NCTEPJR@E,R' M'I0"EF@%"< \%(C]/PS>
V&.)\$YF#; %VZB>J\6Z54,6%5>00+.,E+S]1?(5Z* M(3M+L8V1HU&KV,%
<9;>R5Y3DK^*L;5?.K1CN((4<#H67I"3,?Y_37,^Z MYC/TGK!A.#0SC6=TZ.? \! ?^VZ8"0-KB3P;.YZX[=U)?
VQV9H_MGU)1W*ZF@TYV;Q:* =1 M, ' ^0;NS:D_E?.P=LFF?.6KSSL=7UP]>0H6[80D0M00Z%M>^0S,VAF>X5F&[->
MEQVNC-6D:U41J163N@:W_=(PU=*D!A"W\$3^B0R&*3-7\$M*Z)\,(Q_/A\PO<

M0\$5T]-9P54IE0\$8]S+P2WD\XE78YRT^;'67H=J+6R&="]/4M/\FS"7H!\U,,MV:UE8#.B8%635.HK?W-
*V^B0>XQ)<10\J/Z@L.^4E+I[]=[.!]B0C@BS[N/ M2_6JCZ;GC,(WSBH>[HXS0\SS-5J)7[^]?/>0?
=IBELW'\Z50?^02]S0;3_94 MNC25V0H,"G257@7ED]^M%619W/ZOAM+ HYMK7WL(M+DL[RQ5^92R\V2FY?M8
M_I\c\^4:*M[]V.*X3NSYRWNEI8>7RADALZ%3Q1L,5.E/\$\X'A=UKU!MYPB MJ2%CGA@!"
<[;|= "2JGN\$>_662B?[\KVG;GK];]FF[T]_(7'/Z+JE;[?@?/MU MJ0/;+QUH,B\$9?8E%K=60??
W7Z=4[A<,GMXE&ACHG,62F K'9IG=V^\$Q5[9;: M70N2C9A.=A,'X6F\)\UG\$1?,0M6/LA]E?R"QQV=9CNI+HVI6
>C'9?M*50.0 M"D6EF\$7!=?33\$J46*)P8>YSC19<[6]"\$IZG MX#2%7Z0.V\$R,6YJ@72W=H
I87X507"MA6E90Y00P5]XZS'^WP\$[/P]62;],/-0/<^0,I:2[A@Z3M9NJW-W@6>BQ:"\$ MRY:\$?QYD8JR07-
W;AE9C*BZ7+/?HL\#9Y:Z.(1EX+%BR\$%"K@Y>BU<- V UA' F<9\J0^>/D>0QYJL/SB^B."=LGT]%^?3PK+U-
[227M^D?/ MC2/[B:] (B*J(;)4RS9FUH\$ AH*2HPXN0= @:JI [3QUBF9TA,/G>L@/U?_9'T,_CL*:^V@G)GM
M;[6%Y4P0#<5LX\%F;X\$C%0+-9\$EIR\W3.>F'WME8YP]L7<]OGS]-;KM=MRK
M/0/:"2:=D6^731:GW9<"ZFG,&X1(V.&>G6VA6.2HA@ZHI9&.R.?8'FSS_2-&
M; &4N[I\$8\KT8I0ILEV^M\ "0:BAGS .I*1^X8"B28I1YK M9\$SY<^TDZ:P,7(F0TY[IT]'0A B?=G3ZYKS-
)Y8I3@%=F0#? \$GZ7/'=&)DUJG*M?J80KPG-I.,<0%(8T* I4\$ '*QB&DP4EBK;/)\V,V<*3(F(5,E/X
MX#0/CE7S4PZ09AW)\MI5V%7\8,D&PZM/9+VE;:U30'3,CU5Y^OVWY4*204@ M_7W&PUY0)SMB)8=Z[P?
&35I559/)#\40C6QYJ2W)*TLCT=@170I([-C'\0=\$CGLG*B=CSGP^QI'G5P^;YA6T4L9
M'I\HYRAXT78)_3*\$NDS/0GJK1UTV/0^D[=7"*YENM9KT>>240G6#/BY-\1+ M{]G5_71*\$+"I9\4F-
B\WQIGM*BUL3 (-,T>HB)/]JL.+B=+P]L;Z_SFW]"?0:'K+
<>6G19J:^H'%0R0@Q)1P'Z]6DP0Z7]5]'?)DZ#MZL MG0.*U^HVK,2#,W'FL.U^6:4E%;R-+'[\7+SB
S'D:G#)&?.I F6\$+JA^Y = MH0.;M?HW"VXQL^FC?54J#)&D(;;?^WB(^M^0E=*H_J%AF:TAKP&?WV@*>WYU
M0PU,H=- 8S1?76)'0A55K&..7D@LV=AX*\$1GVWXT36_2TH6^I; "N7/^ \$0 M <, +01&F9 P-
*ZUBG6ATB7V+@VH1F03CJ6LMC+M^6CA[\ (C/8)*CV=Z-Q[MOVW;K9 D0ET>)PK%ZXB003 MX^V?
9:]*IW0G'\! \[0>&5BR5\$?E@Q4-@+F#1P#606Y>J7FK-;&)#9C\GF? M\$.K740C;Y+8?6T0AJ?G65K_@&H/J72-
MGOA2)0&PC7/P=?:STR*>D/9&1--3 ML H,G,^;XE1P\+XY,W)0[%VIE@8R Q;RR;+M9VHR/HX\$P=.D\$N--\P8-
9U+/- M':3\ (H?0EZ^76C<%G^B4COUR:N#%YX^&;4R;M30>B5HRCY<\2U8)T3Y'<9P7;VUR1
+VJU<&H'X#XPCZ\4X\X@H/6.\$ MME0HR?,[3>#;:7L%SZU>>FIM-F.N\OT"(9+47@/+/+ML\%D!J]C0[';:/)"
MIU9,LJ005U2ZX#RU %M,C)RL2!EH*XI0B3G5,"MH&%)C/QY27]1Y]B0-SF?C M0'1;14>5)Z)K]6N-
AN33D;L'7%_X0TX0TDR1-PTQ&5WJV*I,651HPP; ,]I,B MW^AD8)L^N,S9="W!0@7X\2S5MU^F%=7KY/,?<
M@;,\$H6Y#M?5^DUB6F*7&CE3NV>0)D-@ZS^]Q\$.@+M2I[W04/H6*8J8\$'S,K> M!GN=J.?R84A-G99HK0^FX:^S-
F+ (^A6+L IN4'\$UDGYX6LX_)L-5H6/:VBC9
MVXVS;@FX/8QNHQSIW/NP\0)'SZP@D&C;!C4,,PQH2U\009)PITLLV*NCYT3 M0:]U' (H7:)V/V*T@E?
ZFF1.)&V[D/S=_%8(@I50T(HI*Y[-&*3'IARJ8KX%8 M0Q%LF)R*<[%JGN>]3]SI3.80[<9P17N]RP]#?
_@8NW7<'GSXF*=@U96VX#4, M91TI8FISIGH,SM(]K&?0,"FULR83?X@:=^FFI%:=4P9XA]VP1H8Y5\ _DC7\$5
M[G2G8!'0F%I'9MZT;32 CM!":+L\c46JLQ'\7(VQ&#;?3L.01M+8Z"ZNQ06
M/:0\$MCO56P, \$=^N1'0]FY[]J7SM'T>CG_].#UW_Z@+6/GZRL1H\+K#\$4TF\$>
M\$Y#3WS21ZJ)3^\$QU_ZNE*WB]IM[-M4C^F/NT_M7D^XT3M0]'(S*GNGCW^;WP MD70Q1)HBK\$-
KPHH&L:R4+4(9&OVL&/*N]+48LBAJ\$\$/V\$518]F)UAY% M2 U(BU*_M'IY/JRL\$)NQ+0!-Z*0?J\I)Y556T#
[JEI, M9<^I)1ZE32QU/"X#1GL! !Y#!-W\$/,UQ6[W2^NN5>..M8[#*:.;]) M[H1^&B;I6?1YZF33AM,9C_>8-
_8PYCH" MEX\ "UB?YXTM0'51#1%5%P1ZPCVLNHDXTX:/@!NE%Y!>8Y^[-!Z@:Z*K"M^;-
=*Y(AT"H. 1YA48CG!Z%=(UKT1^7E^D>Q MA(>F]IXT:G)[N W9 DQ[RL]8= U8!^-
VFM^UXP1HYR2_0<2RE2P7G.?A+.U* M-#: 37?9&P0]C>#^6\74PNC2<8S2'0G-04L3A;:F20^?
>T\)\$N9T4.5Ww>? M=^3AQI-+W06;0/9SZW\$2+AK%;G"/U'V\^A^=QXY@GV,T\$'HXGDF5X\ M%N25 M&-)IIE
*?&6M.B>&T,T0^"*4]] D5Q89#\\$A+X[";-=\$6!=0^-A JN;^LG
MU\$0R891MV0YML\K3/I3^ZTL/C&*SK>M)GK!./ZWD,
%>X[08,N4S24^I0".:;>8)P+].)^^(1= RHE("HZ3XI.P;]]?ZT1+96J9I. MP.S_+M1&?:0@6G?
TXDDY_A4]0A.4B5TLLY?+E*@4R[0J<@NR&M8S) [V&8A M6!P UMD+ M;?KAY!EF9\4-V?E]58A0:ZFUW7
ZB]JJ2/H MT0J199'K=;6NNW)S/MM2P#>6CT'\$N 5?W:'X \.X"E\$S_70[S8";U:4[KV3H M*F[]JYBQE#-
UV%JM[-.;!D0+G7W+.9Z98QF5"J\$W.T^I;90,U^&7[%JU#GVZ M^)+7 P\SN)*%0IB6=ZU\$@Y&WS MA;.,
[T8=.!0BVPRIQS)70-'P"?SQ! HP7B !*JP+(" [<\$I_I @ Z8%0*91"Q!^/?HIR;-3!E&!Z3578^A
M1#HB;@H8,8#?\$P87!"YH%Y8@UDIC@Q6B7/NZ4KF("F#3:C3D*)SZQ9E9^FW\$UBX]7=]]_M
M.\WIT<:\^T[YAH17&B]]I\$*@NXA1LY6"MG.? Y>FG'-+"LK+_NSJ))"=08L M^:6J(U;NZ@SET3]"&U.;D&?
B>6IZ(G\H_3C"RQ_!;1J*A\$KS:BXP5^9B)]TN MRV40/G*&\HMZ]_Z,*(3:&'CB4%B UPEB6?;!(-M.
4X2".Z_HH@A\$T'"5\ MR%I7+L_1=PY%9^QM*PPXF(ZMPCJQ,9." /U./\D[%HSZG&DQ1/(W*>>XG9< M@ 0.-
(\XBZ2.8Q=DL&)(0?NK*0!K\$H1JG8L%]-)VH;40&E0B' 'DAI8,=,";D/B?SCB!JN@M+<+>86R(T-;N*V3E! M
;@,5PB_\$=<4F"R&!.(\$=WZ@4>#7_2CS\$9%;00F?=>*)5?HK->0J3/ 9[RE MN(>R-UHJJT T.1XWAL3V7-
/K!>;60<-7]=>0!UO[H,=\W[DZA07?&?#N1TJ MT7YESRJYLIF"?YW/]D#>KJ\$PL^]9396[P3
QQMH6F2)B4\M>; M<*0T+TTTE6MST21I;GZ@ (X*R;]X-%?6K>*JR?A7ZR?%/FH'.';L&<-)TQ=C_
MX,X\X,!X8W_:D;B_0'[U\$ "DJ(AB+(:&WT*H#>)Z)T%4,>5F"%4;:X\$0AS).V78B'(\4XNRD#=[W,ONU&?
1VYL! !X61R:3) M=4SJ"#D()N\$BA00-2S+'":\$;V7"R.SHYYZ>0XI,Y:]/3R8\ 'JML&1Y^J-V" T M4%LX^!
[8H1DJ0A)S&.5<,[PKM5E. T761B.7DPU0,R#>B%NWNPY MYLEU*E#+@\IC?^6+B&#
<)/"TQ)"UHKWQ0!_R/AB41ZF%?Q-#(I_#PS*#1#+ M)S'5^S-M)@6]+P199'0@,T-
Z+C+XH&5#&GX>+8;4K:C(=ANE!+YNQ"6NG8!! M.M1)Q/PPL MF10H&J605'LF6H'@KS;U.F)(BJERB\U?
J'K*D%'XV.)M-CR /;^6!XE (-.\$ M#XIX&:R:>@Z@R3J2:F#48-X>V> AB#\PT(AXC+EGNI\$P9A015:NMC?
3Q0'GW M!YBME..KFYL=IJ%!*3L77P\$2//G+W1Z0\$W->G!:_G2->YACS+#[+!&:_I9I,+K0H%\$/&KH' (f%Z
M3Q:4_?#]0^ZL4)&A0Y& L^:'!] M,42>R&L>+< S0&_R)P<+S7V\J;[T,Y/JV#S N3,D4 #-[-?
W1>#*FZ5>16 M=N#VN0N=<:_X#2JMDK<:_V"' .PUNC>:KV644],R:=1^GDxCD^K5D,M2!X0T
M/;5@20X_Z8@01@/MGW3\$.AZF7Z+5N*8TUEU00F)JJ7(RPD\I5FJU^LU]0_?" MEN_9W8)*(GB0^Y"

<5SQMM^&#/#C+VUQQNVE660F1M5&: P89#|LGAES!EYPU
M#VM[C%2#X]:2*+VK6GVK(ELL>S)=K">F#IQ?:PY6J/=@G(77R.4!N\JTEHLS\SGV!?!_S{PX.}Z];=
M="Q'Z4+5-@.XEKYE.&EHX2J^%~4J' [AVFN?\A'W_ \JA6AY:?? 4HA\JS!
M!_X|)E9PT4T1VC/"VC/Y"OWPT\ /G(N_K(=JJJUWQ7/(+XUZEMW6%G0Y7YUM1 M^ BR({8?
R[CRADFNQ4=6;&. ^9?.IT%XF90G)/MS)+"(YF- MG@RU?4>=JR2[ZFKE22?
#8LR'GFPXW'OP+M&1(M5F|++|_7=WTZLG\>;W+
M5\Y>2GI(VUZE,DK;@-9C|D2.GM580.LZ.NS|5E|B\GOPRC=IK^H3W_=I3^C@ MZS0D%A%RF"[K>YT@SGS
;RFHTDE*M%>N MKP-^Q.TYH%E|?/, R4GP=V8#,: MCIE5PTP>"5K*MY6N|7+CX'DG'Z&UF
/TA7_R83YE/8=\$T\/:1Y0'W'%:DY1& M7!\$/8%?|)\U1!= Z)LZ^BD6(KKKDQ2'"RQ?
69|B23YEQ|BPYF'I%F.Y+0_33 MXBRGY,>>.^L"YTT0#'/EU9,N18,.^W6M#,7WW\I0",5R)'7>8!Z+QJ'S'\$<"
M52"(4'C+NCDMN|J')|M;0-3#|AI_%,BDV54UH=09'D,-IF M,R|K-|;R\$DD?
+J6\$K\$K0L,%2U2MEPI*0)NNV/W\N\:#XI+2PF)J<4Y)W-9; M7)?# 4I^I\|PN=@\,01#-
@6"920EE1,!B8#;%|^7-0V'NH5+B";Y M8HA1=TF4)"K'8\.'AHZ_UWV).GC+KBU*097G?E^?)V5\SLIN
0))"1^G M\?8+@F^A5>| 3J>^?M*M;MC@:SVF;&+H.>'J.Q M3S5PZGAGD7JW,VFV8BW.ML0@Y@"
(_XT0ZBC+A;>#KTK.^ (7M7@9+P M)+.T?E&:|QVIX-F|80(PAMX_|#Y|.'&D*LZ/G195,&KQ5AMDC/E\
(V7A83I'|B#-:TI#A<<8&.0Y?%WT|&^,BKEIW MK?Q/W (6EVIB%. 4D|)=U'3T\$M
MW|X9JG>9IE>;=|Q;>0#?S\?9BSX:7/GB+#C:/WT"2F|(/K\$JS\>R^NF>6B"9
M.6C0Y)7KYKL%) "9.HC&\|QRC>>T1;<+R;92W-.G(58E%F'VIW\$-"T^0@7*WR MP,F.E-
_Z"PF7//; ,MS7MS2."VKM@A8\UL%J7C^GH<)K0T*#|S>#JR1?YP|=4 MD3P%|_UZ/Q|R;GJ7AS/W.Y8M ?
>SV=L:LH?ZU0J) WD.[6NX4EA;01S0 ;7^ M\$/TH*+W(0DR*88Q9\$'!R'AY|TU87>_G.(B6N+?R?'CB?BZ4VN
S+-W86YP4XU>_X:?.S. M^*,WV\I,F&L1YOH'7;9?.0PVSQZ5,W|R94Q('EU ;0X6Z R=5J'J/H5/#S<8
M8' 0""6?? 'H3PS.YB-=1*5/'E 05W^ /(V.(8<4K6*CB\U>M=|;&N%W/%
ML%2)V)\$3_AW9A*&96Z7\$H/J|QU08D1^MW|;SI%|<4>RRHP\$V,KAH;?CU/"7KB05_MA3X-C:?
6U'HM",KY=GG'"0(@F04-3+A;C-00=4I\NG@-F/DM&U2A|CB3GBE M*.V.*.\$M7BMGLXHAC4HM72>_>4\$0H-1>
(KJ7_9;K^B\|BV2P<:_S|N%JU/A MIG>:(71F*7DGP?4SR4_9)G79WC0>';"6-JQ(&PR 78T|0>-|0(|P?#*LRW
M=C\F|7B-WX<=4!"*YC=7KPVGGJ&B@I0K6>B>>S|?~ M>U>,#TVR2L' 07T^N^5Z_,4_#)/
5'=+;QX8'LLP>X>'Z; A"5E#?+!|< M|J@LVUMYC|?'8J?|P'5501VMG=+-T*1E|6J0^0L|>WP%..I@A)Z4M?
FE>Q*B_.|6@2TYB2\$ZSX-X1\$Y>F\$|X/<..6<@E>ZF M\$PMW10A:%'VV,&|]\$7T9S|NN8@)_|!+PJ0P>7
S94D(6/B.K"K4&D(\$Z\X(ML9#G3>@;K)'JWS(P(MAH#%_N\,@50YX (A\X\Q?|('GJ,IRGLS;U>@,|!'S
M&"-#A*X17*_B?%1:EK\$7%0,2**P5WJ*<-9XW=/ \$4|6%)645D|H+RZWT'@-4" M1"V>>8,0M*H0;.:8.V-
_N(|)DF-^SBSN|G H.WP->R/T@ K\$+&8<^0(|/)! M9BBPQ6YMC|GS|/T@0|"9+;T+|PVK0F9-^|)Y&.
M!+W+\$?0NI=08>BVSS"p>|@VH(* G*FK0+7AJW.B%>DL\WU^FY.18P\&W'93 ML%JITR0|T#CGUUI?
J=&10*/D>HT7#8W? B5JX0F| B.\XPIKK;:@)9=R@+,5 MI"XQ)&0G3PX^L=:HQ,M=# \$,
|;:.\$@.P3_@HF \W=#|IJ+02",P_|?%K69N_ MP< ^YH%0KQRHQ_(,JM9.'N!LN,33&X'N<\$0LSTX8P4E-
K;X>,G'(?/GCC|+ M|ZXKR*Q209=BP&GU'-\(#WZ)HX\$^~0^2_?%>@LL)S9ED|C:*'\HQ'*W\$(_\; MNB3UIE-
K.:|Y-|J0,3QM#>LGP@ZJ|((6NWLH^=M%)1&(0X'DYF|0&4:RRPQH M87@YXGN0XM0;),W:HTN=&9N6L|_-
GOHI)|P-P91UXKQ3C;0Y7FW|*:%|@D>\$+ M^EUT4U:>4|\$-3Y5/%\$ V8|RF_Y+/_ M1N@/TZKAV0CW|WAS8).L-
YE.D9B)_0;|E@' MB##DURF.T=69"\$D#S<,A1T<1\&M'?E0/GTQZ?GQ2E'VNDEN_X65,E_9<2J' M'6
QX|VHAS^VYE!@W/LTX?'HB<)^3|EG\$R" IU9'T8"((:P|:|W>>\$>D49) M5|68|5\$.;|0&
G/AQR@WNVZ_,#F;V9BS(.MUR|\$WZP,M)4JDIB>%Z(BN\$4:< M1=;7%Z(R\JTC?^|+^H7%:\$ 1:('N\LGU M:75?
_#G_N1D@30S4;G/E!).QR:KQI_0P26+(/;ZG?SNHN,A%6VI\$GAK>%RJ9
M_C,GQ)#/Y>6L|7:B|XNT">|):X#-.+SGR(\$8(I|Q|3JPM|>#>PE73G@J3\$CVP
MFN|L44P:3%HOX9RN9U\$K;73|S\.;4!;5?UP*GOW M7QTG%7ED8|+|NK.H\$GV86?8+CY|11,#
|V>=W,871<:R??|0TVD(3:\$1KXEAM\$8GM@S,3W<20?C'D\$1M&\$42B2*|6F0BLM>!/&M<0HM)U>&8BT%>VIA-
\$L1R: MUCRTK#1IP2\=00.Q/SV!(;@G'\18XJ8|'|?%6=L00;YA#F)@:6|HT*6A;JQY M9MGNZ;K= W>ZB" T7Y-
7#;3Y :M/QPG;\$N U%L MU6 "V\0|3;DIUQSP>6BH85/)NT7VM;_7WC\$0K1L/TALMJ0H0=^;YVM5"*,
M935LQAT+L1>|TWU|:MBFU4<,.5Y+&7L"6IX\W@2JN|EC^?4'&|G:Q|@UHXXW
MDVH#C9GD^G;A5>;FAK.OC!^!#%QIR&I=-S!?!I-@LU"W ME.5;:VZ!(!<1*XN80LMWT?
7>G!+0\48EZ!%+I7A13V\S4+_GV-6;-X(-;)U. M5U_M>0K.;X8;D%
|)E.+TX^B*Q&P>LJ|">MJZ>BY|F'|C\|U&)A0-0Q@C8(!R
MP(6LO>@MU%WY_NW,8=)V\$3E_N56JGK2CY_EKN73U%#7GL0+.R:4%L006F1|WRN:7^;K^9T1F2LX3|L\$#NJ*%:
M)--=0U0B,VW3A@0<3U-U@IG,-?BN@AFJ@^S2\$69D6==,/ #0S|)'\$6)C/BG.-, M#XY5-
24(4M&_W@0+F|8@22PZ'>H4K' ("P=@|+-+Z2'KUB!*KVOP_*\ \$CZ_0&QS&!;1|A*X5\$0X/&
M2%G74DSW*:E1JZ6AY(3A20)^|/\$8VCIC>A\$>*KSB2I=XN8,46/Q'%_'SY)*Q M?
%L36|'R")M^QC8+'J1:*Z0*3DY8A7BD7%+ M8D0H7=RCJ|9K|05?LE+M*"2K %NKJ-(N5/TTY)8RD>_Z:?
H;@U)-30LK9&># MDP3Y-PQIS4> -"+H@U"Q?<50_OAQ|"VZA,L6X2N=V:V03K\$ZN9WU8@BW8W06 M/K|1RV?
KSMD*#D>, ?0MYFE|5+;Q9!?!IB-#CP9LVM'\0X(KY.0#0PL9:L<| MOTP%C%;D&NVSV.C.D2-2ZV/-?
JT!4(+)6AG2+W=/#G\$6=?/=5HX7Y^V|UFE| M%74#3F&D+!4*7-#0\$;S<":52CMVD&+
(02\U(L_5|)|TF=H\3|15=G!.FS909R M< ^IX&JA=0TPZHL7.GUU(1-+?^%VS9&@67VUH9):^4Q
M_LURJEK|J|J47NBX\$U1X2'.5@5JKQF&M=U8!M|MB2\$ 4BR?U2^-|N|/D 3D3/ M(MDGR\9F6FG03|C'ZVOC?3
MW(Y%?&2S24_L598<>7XVE<9>!\$Q'(>E1^_/J'GA+<)N M(P+'S+NGOX&+X(DA:R>#S7868_OJ?
->SV|J(9I%UYT|ND-[ZUH&ZB\$EU;|>| MKN/YUH@AS@*\$AWN9>R5W|S+47%&8\$+D*@I0_2&&5'9,8K!;:&-
"XJ1?G|CB MFC,^+Y^;M0(P??'.R22CEP J;2#\QB00W?ZM+|=0\$?"M4U_S:Y?->0#_F N M%D\1T0+#!L-
|TX#SETW?CYDMH|E;4SZT+V**; ZSKU@:0|AV0?WCK3D'^|(X0XL|M<+ ^|DY-V|QI.9-" MM#AE\$087K|_-+
06X>2JIY>E'CX%2|R@XWY'&X\$B05+AJ=J.1GA\$VKOW;WT? M=|V5#S.XD(5R,"WOUDVSIIV?
OR9.,,9/10Q4%BN.2AIX3|N;.^-^0W;:L(\$ M|6|9. \$4EM;U|>9>6|F+L)EDX;|]?>P*4(|_
_*J@(%V\$Y8\$Z|/,"!A#HI& M'VKW?7:K(7)*7NV|\L6"=|?VT+:AH=*_1%5000^NV|=#LD-

@^-5\5;1%K.UNPG/.Y:* M;=<40WZ#J \9-1\VL-5M_@+!1JLU(I\T070Y?I\2\4+8V 4?R:9)9U95)M;4
M#,L7E[S'8;%3-M 'C\$?%T/\)E7?17)4!<0&5!*P78J59TN2Z9VU=@\JL'22 M\$[13\^PC^#*5.PR*+89
G62@DDR..0;+/TC0_R5*)<>NMAN-SB)BK,60^0Q6 M1JVUX=#KAI@"\$D40\/\^>:!Y6@PY *B[R_926,#W8:
(Y\$>R)[,JU: M"E=IB4N[C8+0<> *V\3&CCUF?T\$V\HDO20W-?Y9^G!<^:K&>^)FE&JY#D\$RM
M404U&Y&0061S1&* (5D"IR;"/^Y5!^LB\$TTL* WT (WCR];Y)M\Q5ZNI:ZT/] MCI?
*P&GQ+7UVCK@Y2U;E[2]B1? /ZJ-^EPR\Z#"G30WS,'[)H)'%\$.#8-J\ M-
UGPW042DH2[@*Y\C<\F(@TJUI7\6E&A?<% 'G1#60\&FIAGK3%,9) _1SYA5 MLJ>RRY\$\I-9+[/+*!C!CR%%1-
@#9B-\H*V,9@A=9N'D/T3J'8' ML\$2IK0+_RL'0S4F1N;>#C=\4RKX;^8=5FE:=!^S?R)LD2\$*F MI=5D<4*
MM.#FBB&/QVX#!C88/+/%X@ N020.<)<+;/S+M.JHJ&,,AZIVEPD\["Q?F L+DS4._?0:IL
M;0K771Y0N(N=^@QB08084I&7Q01#A#(2/THJ-(JMR1'""[ZY4BM<:U0I,9P\ MGYI9)K3[XG?F44051Q)(#-
JX.0'UE;WVAPKWG%IRM_D\U,\$]:/?*3]Y*WW: M/_K0.'!AN]]!N\EFCK+33HI.-%D"HH"*YZ6&\$\XAH*
6RC,K\$@5+H)?\$AY M=&UM8]R\&2?J .8+TB+\;T0!A9>8@V"F4Z=#ZNJA1M06I42NCTK\Z.:0 M\N6<: 5+W\I
!J]Y<,+3>0VY 1:K*RH/V6<7=7!!1*F!9D8TYZ.0(3ERWD-C M(L5BV290L -W28.PZ\$#[(/;'T' Y?@^F!T1W! ,
<2RZBV G/0\1-7E>->9, _M,-437+T*F#Q0D.CN/K 56+<|ZS0XC? M7ZZ!1. 6*LG 8]B>XR7IQ=\L
=*E^W9^B ;&#,\XQF(D309& 30-4V)-1E9- M.0J,4I&!?CZ"^"73B?H86J5H,NG.'-
P9&U&1,)Z5"9446G*2L\VPR] &:]*,D M3W+5\ \X*+L=N"HJ|B<+V7U&ZI?J>0,\$>[040)C4:S7;^C
ES[^>0A#>(Q& MYP]0@V].P8HAB@65%T'\ \ \$3? [RX.,M+39,P3G\8GS,CWZ9#M" [1-
+0(@AH[WX'0)>4CV"M\15#&GL[D'Y ML\$3 ?CCGD-S^<2U8_H40PP MA%02>E<2R:P^&22-[M.
<573D M>6T14D9E'? (Y+*@2^0B%#0! ' MHN*ZC@6G1.BA5\$[BZG%_00>Y NR 8'BE!UMC* 0![9/'J)10&A2-
K#U3598\ MJQV%J(@8]F=;JQB27.QR"^\$HS;^J?U3V'70X S-G ;9= M6]M6UKG]I;/PBGJA <9" @WMQ582?
JSX' H^X]V@+HTQ@#MZ;OR^W\$/5SY0V MVY'0]; '\1JC;9)60X ;Z&)/<1QI@Y!^9;5/>U,D.Y!J?7?
=6R6JUSUI<0S+ M@d:XHBEV681T(FI >Q26Y.SCA2P8^+6SZ^R
ML2#TC.B2Q1#HU^IJV*1LT;4=V/%ES'*@Y16TZ6?L3Z-1W(URP9:70) _3=PR= MSKB]E.4BLCXI\635\$YP/:---
>U@JE#[XMZJ_LEP0_39BB M%A0;]R34@:(%? M^GFU^3:I7#2X\$3L^4(A31':#(TY
_GZ^ZUIYH4[&SPI@PI*/V&;PD&4M!L M2ZS-
U396])UTHA2Q5P^0T(#S6K7R;YX9KWVG5>B|!+ I*V5MWCP#UQ>&DGCS MK-TB+8FX[R>!<3.?
3^B;0(\.SEA#?)2!53;& M:3-(V32T;(#7J+V)'NJ< ' 6)XDJOU0D7VLJE%6F].PTNU/<|:2 H.79,=RS M-
;J3HOTD10:&Z2,+ "\20)' .VR(8Q0H5P\$MD^?#S1VE]>#HA@M3-D=K@ MEH@Q;5C%KFZAS0*52- 5(06XZZ(HC-
;PFUP/&^4]]\WLM'EK?1YRW ;;;1\$+ MQJ#%5_F!Q2_0AJ8]FBS9CZ V"I#6HGR2K(L\NY="GU(N>^7-
V:M:8;],1J= MM%)@Q!5DN1*J\$6E)(GL2 : MTP0X0-0N"+BB-TYV3Q"+D^ZR\K-BP,6GM>0^
,%GVZH)!3H3E)-">\$0BIMWN MCS-VS\7^0%EFQB/=>8%V^642S0M58T8WMN2]A+[0]'WYE%-95N :.H.%3\$V M-
"I"5%14!\$H14('L4@L1*:00 :6+/9U (=*[+(!%(24HJ(B1\$1\$Z2)*(UTB M08H0^BA=2)"^2P*\$-
#L[;\4Z]7WGU/>|<>|;]]YQ[AC0_;\$'(X0=K&:N.7^ M.>=:R[09NFZU"&F,7YB[1AH<@L6I=/A,"K!UM\J!
GD#,66V^GMN+DR?3\ M:S93H?' \H9'"DB3L^P5V3TJJIVYC:JZ;4]564IU (";>3[#DB#VP,?Z1^E.1 M,HSB?
1.MVEF&<%MP -;2=TF635?4U5= 0LYC\$ =W%P|H---.@K5<%TC9)7 MQ=,W\$<955\$4N\$2JJRVWR3
08%JH'<1=*F:B:^KZAJ1+K668ZU8,U,QU*UF^ M2W03N\$^V;IE2ZD>_Q2)\S\7\$XS#K8 _0-
KQ30X"Z*3[8(%Q=?HTT!JDB&H M@%DS<;1CL'.HIFZ<7_-30MZ0/D1:;#9&'3:Y;*I:C8J%?5Z
M=367*5YPA1'<@0 M'P,#0X4M,*43[3-AVL%\@K\7JHS0 M.V+!D?3UM,=WWX+ [SV/^HXEK2]S?'
I&'6M\$YB0-1"UJ"[G3=@36T_AIW* M.-\$X"S]"GHOP%Z:#X8413(DS<2,<0UDR>>-6XG[S2MG
Q47KB3Q3Y=15%@\ M>>BIY-9MR M&2N+>HFX|(VG:6.'M'GF6FZ-03*[T;.M8\$072R0L6/6 :]'H\>,M0\XG"93\
MH54T=0]8U50 --7| <4K/VEPX>4MUWXB69Z%^Z\$(ER2G6M1[S]J\$ _@2]78B M01%5-\184?.[P\$+.^2WL&WM]
(:X74.? \,?"ZG +G>=\$R=-#S/;32U/WK" MXUBZ_3-3QJ]@*
+,15(0[S3U\$9@8:\$ J3NYA[+*A0HGNB6I7T+0/6@TJS)"6B(M"[111(S0^G8?.GLC[XJ! MI="]HI=-
=&19J.DI;1=\$D24UC\$5-:QB0^M^W Z|^\$R#80]]Y+WF25U*#4! M1:F0(?3K3R?74)1#1CN957>\
(+|W165+E!A)RYS[KNG>),HPL_"H(&L\5L@: MHN8\,'NAG_1TA/"(IB(,Y/D)7C-S#,TN\T>G#G0?-BHG+0LJ;
(ZHDYCB=N!) MC.E0J&ZN,\$(L-8J']QM/Z@T'[8NG/!Z;6'/(:CNQ\T MU@49I>S()#A2]#|-
#654X3JM:;N0P\59"76J>H7HV5>F8Q2E1^>JM>;B4TY\
M7"HZXV89%>PBR^=>EP>>UQ.L^Q=3KGJDI\ZM)S[8:5+|^C%DY +?|?98@Q4 MJ#?A! /8J?3D\ _!W GS33/Y-
*QEFJ3&;(5VLN4;&J9 ;S94G,PVUN!|XV_L, MUOUXA>T*9FD)\$0"^!;.TUJ2#0,#L=29.H[|^]-40V)
[|2]0W.F6@;F!\GAG% MH6# #;TTHJ0W(J_+NW/4'P\X\$=8] 7C3J7')WHFR"7J B0(4=R5S
M'MFK\TFHUKG>BC,I:DI+5P5[1"C;.@1' K5@=H%\DX@R"]^+(ZX3:B;(8P; M.W*)>NY#8*S'1NU=#/_UJG>/D
@ :DDS;79"K!BCT_C#U#Q3\$VY %7XMUZSH MQI4&U496U>N020M;U^&,M!2Q*<:L9+:HASUY?K+1FT/H.G2(5B
M0>>-7>Z\ MGN'6XVFTP65>L8%YIMH=J)R?7DUBE5.;*.Q%)3N,U_G .AIP4">9E2J28;@V
M%A2!LY1F2(YR4LGYP6,VXFVG0,)V^UD_W_BV|MX&X/!RR0[2Z^N%.RR>50T M?AAN6B<15X??
T#H+Z&EP59>S>JI_0/KP[I\$YB8WX%JD.WGM;>N[=K;%)F/,R M*R=N>VK; \>, =X^_3_@?KN<*(4P_JBM\ -G?
#W81^XK&HL=01&YU7W5\Z-Q.F;- \$NM ML(JL,+U8?X[21>;10'PUI[A0S5T5E\)"J5L_H-)S1]T:GU]L'R?
>WB3MTCTE M""J0V%0D1*3A][=,Y'2? \3[EO-4 M\H;0XJQ,TGU1'0GMK;)IUXW=D_UM0=S*Z0>7X?
TSZ:=#&Z^U""%Z&N>\$';#YE/\16;X6' M&LLZ[| Y6IJ9 #B&HPRS.6+|W@?*"2>2P6#-J5T6M_CB>IT0@X3*(-
-,K 6R M"?R9<^X^F/\I@F_PX):/B?,>YP\$<;'=\$U5MMN "8A#=#!##SIZ=";6682D _I
M;2BB>25L^*T^PC&X>Q]6ZI': 9&1^7/.0\TJ^VH^HR\Y5X412> \)F'NK6X9I M30^R>W]!Q;
[_H84,\P,\",T^3N3+7] _SU^LU\$BJ#=[G#PL.S^B* 0YH#NVRV MU&X72>AGF[AX9YN2(*#,-0!!&.M)+
[_4EJS/;2(%"74#)>]-E&#PLULN2 M82Z
;S&2F5)A[DMN|W+ "\0WZDS+,MUCR"FU!&KIO_C!/OL@B0=0,G+3HGV]/ MM!!"_3EAC8Q?6Q L)\[QV).+08-
U5N_N|HQ@S-Z\#X_6KH4_7R)-H5->#67" M"TT0P!-
PQ:71.>K1.21(1,EGS=%TT;|T/1FF,T#"4I5AS(X70^U4\;WHWL"= M/9 HB,&45G7\$5770-
QB36E/H:A#_E56I('E66"S#W#]"&T%G?PHO\4D(J! M+HA0A'629V8<;<,\$QV:IW+']9& ?AVKEQ?
Q]G(Z^UW*8KQ#\$Z;J!J8 ?^32 M:5M!C_W,2T273T'"DE\$9YH3W3_ZNND[BB_M_ZIW4S/?5+!""D57Z@6>"QNC?

M!L^\$ALHP_3[E**D/YNX\$:X\$7#Y9AC%7 Q3T>TA M6(8!J/7/I^G_>!^:P8&&90 "7-
<5T"I*T3\Z:*,4_43\1B@E+']\$*+I!O.N MP*# YI* @FCOEHH7,5;USA"?\\WH^N0DAWQ15_61@!L3-
24<\$B&D6>#5SA\ M3S=8^F1C++G" 0L Z,9L?G1GK,78K(IH/F@;B\= HP\$>098#(/IM>6M[>/5H M]-
N_2MIDF,PU4T/103*,:+7-1#9TD42W)?P!<7M8Z^G#X7\ESN@CQM%UD!B' M19?
FR|U2|FB& 'P77#B0+?.=8TJX6| |:<0S^@:874K;!S<)8*Y|AGQA\$ _2W MW^19N2,/.C-
'1W^&NT|Z,B8APDOJ!YS0=RJ>,&-&050 MT@PI?
M|U"Z_1MJX0|^>S3>&"553<' (3=CG3"FH(^E_HHY0^WH_!/G>)200SJH@V%\L M-
2;*XQ\FQ^R/NEQF0(T3I7XP'1A\.. <|@M;L)B9L6B_#0(DI\\$_\$U0?|U
M(95%I8C,IY:K2=|&3J+|LXMB\$)H,\$ _T8L0/2KG8="-T\,&IW/?Z:,D\X:VTB
M>%!4*M6*B&WK=/A2_[]^K2_%1 |:9,-():#C\B= K=9)BKXNOF)
)_Z|HL00*B(AA,DP/Z+,RCD\$^S_WS32I70,\U"EABJ(% M_#5Z'^EI,R&109TF0, S|
|@PBG'|,IG@#0<7LI7^&"KCE,LS\V45W_MZ?HR#^N0KDP?GM_1AY3*D\DF@#:3|CC0K=181X!,2DH+>:?:
FY|,*6#LT#=& MG8A1:GP1@P<,F=?KQ&6# C), (APCPQ@<&7SH&0@'0(<|J(PI8=@K,-4 5;/_ M0@= S+AX0=
S8!6%WOKSP88 KL!@8=V@9><@2A<^!0I|Q:'H3G\$#(#W|WYQ M, ""7P?3!GH!FK&|^"6"|65)GT&I&/VY:X?
\$9M2X\$)\ (|W9=F*)* N^S\Q^M8 M(A<99M()8H\^J_0S:(.15I0(2YZ##,HM="@C: 0"1#1_!G%/1?I\$/R0=R%F
ME03A1'@_ /AB(!H.TS:B:6\$=4B505D#D0[KPL0&|00|S#9_KGV0X0*,>LV:L
MZ'R@3;0SX:S0#52\$G\$/2'.NH_!|Z;R&M50&20B6\)|N N: 5;2|K!4EHKOD M@|!|9
+J(UUM)JB.P%P|010DP<50RV='I#BQVT>:"G0DY:9D58QP^M7\GCM(M_2MW4%X#4Z&[#'.0"13H^!
(D|,W|2Q.QJ3YVGT|TW5W\?8|SK+3151S4_N@XIH4\$S_MWI08H);46W1/,CF,,K&0MW_:5RP)
|L+Z0;^?^6|1NZX6_)^H|M;T"!A_\$0=/HTCM*Y;/?5"&LGE|VV=<% M:FKK/D1=C!6>2EMA5
FSSJ#MX470|;L,*B@:16>>'A)0L2%_0=-&&|N.X0+7_MXPQUGUM(!S\0SR07#7;-
%:)'|..@7XN;IWP,U15+LZP>7HSG|([VPCN<00.D M+BD7(CIT;G_MW?&|>M)*)#%WNI*8KM&LV3
BI#DE(&HK*YI>/K5><1M44M.M00&>L|1H-ZPH&X2A?46=(X X% H(4TQYL:P?Y^EU&MDQ<' +UOPMOGS"8(0V
MF*G%XNN6=\8(?U@(|H2#\!.!_J\$U_=-2\$(8|00:ZF?09P&F"/\6Z4T_2#NE(MW'L(Z+|;QW7 Q-!*. =6.S5-
E=/94M1WW)=B*F!P* LORSDD?8=#V-Y^EH!3| MB=,/M(#H:C^29X+<|8*7H?6P&F(?HGN)I.'=\$;SKH#;.
|_KX2J!&6RT+,Z10 M)8!@EJ^#ZVH/0N31FRCSE?ZU6)B9*^9Z0FDA-P<>3!/^!"0|'+ "KV%R|:DJJA
M<05E:;|T7E+WW/7SFZHA\NN=B-R3#+-@)|>..0#'/= M%5@_LB,PVDNTR!\^'\$/;?Q7(F7L M|T3*C=\3*:%?
_B61TN2|*'MV5?VGY&ES&20.DRB_XXG:/%TP\$"5WRM ME;";:K/;XJ|D1>M4N\$+WDH|AEF>@W\W\$X#
2%,&=;,*KZT@(+, #D/?3, BB3_MVZ|KED|AR3 ?|HU>3.CG|/K-PMPZ0FR1WH|G(' @NN6H0L T4:9&F-
/,PXJY_| M6|N&@Z8-&-0-UX.0NU|9E'|> A1CN4TYJ3U='9U#8>93B|3.F23Y|^EB#[U_MXCZT)|<*5?:W4Z18
*X6.L'R32J:*4KH)V@Q4?=TQP-H^0T*UCR-;,"|CV4^2&P15L?1SU+8^0BB|&=?XV7*!C\G%D
M9)F*%'X!C2.7YG*;*A+= Q&G_0%H=43E|. 'E Y&..5^_Z(P&1LQ)\NEG<' /2 MAH&|KY5&FII+N4#J\ "\$<\$!V?
T+P/CUG0#VNJ!.(T'+D^A>";|3-?"909E*|_*
M_5!;=DU|]-4""Y.0|!@Q1:*@54_@UGW)!%IASOMEDPOS&HIS*LSS\X:B^9;62X\%2/U>S_S|(7+!;)DQ341-
*VW3Q=;M)51_Y^>)DT#4 MY@,4+EI7:@VA2|R#=7.R\$V68%1,^>L2'B,399W5#;(;,\X"R|Y'IYR=@M+ "
M|QFCNV4C_H>|]47A00UV@|0+;^R;A,X @7*MJ\$K.!>|YV0&SUB MG.SJ-
<.58XMMVV6Q5)IF)4^Q'R.CP3US!|*)LV.MMT?K%|;\XK7G6#KDVR; M>A1:YMA|&;|&R&YA4TRC+D|Y0/-
!/>?%,1E=RRL5JESMEL|&;1-U_M0V_KDXN^V(H<=>X-9^V,V6&R^?=S+8D>SX>;!-&MY\JKY\|RQLYC#USC)/@
M8|-C?+&|I25?D/9XY|)C\$=N0A7J.7=-//P_R\VS8Z8J&V.ZRF;="M:9>\$Z)|
ML6A_||Z%YTZ6VVZX\$PVS|"_ES/2|A^\$N:6H>N0(@IQE|#;"#32U:%K|?ZF M>#XAE&7KMA:(6!HW&(WJ
+CZ>09,KHVKE(:N|2PJ+C0^5V<*_/N_Y@^(>V|+"(QGU#CP*AF\$P\$ B"Y=I=N M8H,HZW LI/.
(>0@_7&#>J'Q!02_BV*&0ZFUVL>NGR-,RC-VY,\IY%+\$'L1EH_MU?Y90+-UX2S4|)(3YJ|4K^'WR1|A=<)>>W^W
B,-|W7"-15XI_SC1+020+;S+X/VI5=_Ma?..V7PC05N(\$KY)"OSDS5I5MIWMG.J>(TPXVCQY_D:C|JSB,#NA?
KU:59%-M&)(#"-\$6GCIZ@Z_,|4#JGHS|ZV-|Y)WTNUD&G4NQ)R?Z_/23<)%C^0%RR> M*L=*9MTZX0_GIS^?
0-?0I%/0B!6S23N-;\$'<=2WZ@FB\$'!|S6F.#-,XJPN)N-Z>'Q2FH2/?Y
M*CBX_N=\$R+4=\$,+E/4EHS#JRY!H^P^V*?(N>,.%VW8UH\$V|Y:>#E3=6M%;IE
MNQZ9_)B=TF&H3W.F*N!*P>.W5K0_)#;PC7M@P6EL99<^!&;TYM<)/0=) M>9D6XKVV\MU>#|*T**(;
(004D0N"6.\$GZ0UYX,=3XE,H#_P,2?%S|7R+C,F? M3^&F)@W;ANE0;"KCYJ&*PZ9: ?ENJMEVD6R7VN5?ER3"
|U2+E*LE/?A"0W8L1H\?6|W.2 M|S|S|JQ8\$;5XH^N=RAC,4LS(B-^',RN?3I;:AC\$7^C41R+(._=|."|TS,*A
M|^&X\6|G_V;R<-RN97E(3^N_/!RG0GY/N9G(+^SP.@3GJF9@|4V&>>X90*(J M>I189WV'/#L#I/
FY0CXRZR5*E037B!WN00/1@BNK7+DD&8;%+Y.0L=(:0SCLK#(HB|\$
M7U"_2WMJ8F*&0L_!W'S>P(B1VT\$M^\$X;+9-HW/GP6A^U10\$(Na|)(32^|0'1,
M4QN@R08W>6J29;L1+1;QB=\)0?HY#AX^U\A&'HD7\$Q/WFU?#//5,|=TDA\ MG'&|IFN=02?8*5,9\QA\$Z
M\$CSG7FU+^U7++51ATYTT7,V'5QY/'9I34XZ+;0?TT_\$Q*2=V+^X_2;/7\H%
MJ4VV.F&SPW*SLJWY0J61COCR|6V;GCV0WGKS_|7.I-H^HI8S0VFC;|=A+S:N^PMZ3@-)BQ2|QAGSJA=7X\
M=%_ZDK.0|Z9A;SVTDK@3-W0^&^;P%P\$C<=\$5Z+&?F76T>3SC^H#R.G5J_3^_MJRCC/F\$F)HI#WQ6E>+QX--D?
|C^N=-P|'|:#^&C7EV\$+@3NE'TV?6\(|S1!?(M<8P?8L)D#TD7\$8'>0|H"YL4,>673=#0U0/;E;JQH7\$G,\()|L-
?'?D_9L5>& M>?W=_%|>XH/VY03K?0)7QW|C*0V=@MCZ_:G) ?|1Q4*T7<,^ED%)%R^NH9
MU@;&VB_>\$R|YK\^E7VD=|!|P57;M00=@*|-Y|Y'MLN|";EU;!4HM_:JJ="7M);Q|V75ST6*-T;ER&. ?GG06%-
^Z4Z'VF+T49T_M07|YH-W37J_@N%>B@T^M6^(/27(DN_+4T+!ULW>ZSY:<%MUGI%:5|#:8'IRC MG)FQ-
;=M^VOK#&*/Y|RI/@A@EJ+?=77S!87Y0"#R/I^M@Z.<(Q-!97>DS_8% M:7&;ZU+4@H2M@UVEP7?
A*D=2\$|J0^Y\$|6@46N9=K)4WYU7|VL2G=EI-F=W|S^_A%=A_KX)0-%Z8@F%=TE6C+ 0Q4_M55N-OM+4&KW-HD]?
*/S|B+&(K"[2#HW7N/.T>0NJ'93D.Z1B=\$>@RI/TSR?. M?=JB|JWSBWE\U_U|QA5
F_)^Q@\$8G\8Y1TIUCZ4/@F.#1_.FD3W\$3FD)5P#JI=| W"LI|(3^G+KCM/F7'.*U?|6""1&?2M.JD|_EMS5B0
ML9&:ID)3?|)%H@QS|JW5*2RR7#<7FN\RA.P*KI@2^R+SMT*D,)MQ_8|]_&U_M&K5XS6#.H@_\$5R5H\VSQ:
|>Z))ZSRTS;SSQ>|]5MMX4_MZ4|(-0)N\8!??2, :AUPF>+;WW|WYT.E)|ZMA2_G|<&(YJ%.M+E:TR#!GA-
2CI=\$?!P<%VH5_6(WEK3H&|06*YYM?V&FXG6C%P<# M&)0>UX_CDBG<*(<(MW(PJEPY(U#0Y?+|/L?D"

<.)B3[=^W9K\$4;^J1VHX\$S\$P M%!(F+J)&: FNN6(IX7B,6AYU"IV}WR)_A2D2V??
1G\B.D)2[OG'RCW@>0/]19&PL/OG+(@8 .TU:[ZG+R3%;4P'H "GSN)VX!'6?>ZBWMJ*N[U[B
M9P38ST@=WFKT!@S0X5TY.LRA+A?J]^0?P#;ED>PIC1%\L#N])02@FD!G"6Y M+V;DARTU(@/V)L""CUFO[-
W3Y\?TL[>\$LT&;QE\$KPE-L=UON"6\!&[Z&[M/%YC50!0S:\$*\$T6+Q "K)%Z>/T7((3G),%=
(.)]8P)6G\;#0'\$EE&.K#1&P' M87H5.B74'JA#C BU./%Z++IT7.X L@RU#IS.\$F+.B.VLCX5 MR[-,-@'@R,
(24A\S*PGSA3%BGT..W ?1F:R/U8F.)>=?>CV&>C9Q\F282IC MA?XRS\$%
<%,RUE@,D>\DZRC0004I^"/K1"K\#/,/(;B 60(8M(F*L)HV86B*DV M!Y+.,]4!1&X:&(U1,;:(#^_@*H<!=!
J&99N.+N@==*%^:B]_&/^HD-+\\!5
M:Y#U@,!:TKF>\N,F7X709S7*,%C^M=K\X.JJ73T!W8)C"A?'E4W.0/W_5Q*
M^3#/.RG"YA.Y87)IJ/Y;5.*5A&K^S)HYYBC#*,#2!K>";%(U8:FAE4E2>,32
ML:./^Y-!BW/MHXI^G]!NZ_WRC7ZQJ@_N[5+.%JT*K:[9WTZ>4G MY-..A_MHW^HE6=]*IM4,AWV=2#:F2=
[U;3&Q<37/>8# I_)9GC8D_IJIR@,EF%^(JR2 M8?KD8712ER]'-
_C9Y;MCG9:KZ..N3HB^0I1.LP,/02H(@6YZ7,EV@.*(I3>D6\$. MV"R#0^=BN;!N0F=QL>NL.37N:
<[>W'S<6+8?)V87@*2,Q^=@Y')I\XED># M5]'=9@P:S XE&ON)**;@_]=C8500T4EXB"NI[DQ0S,H4:E>5-
&;XH *8UJ&B MQYY!<6EZ8R.\$)A;*\.L@89M_) "UG8 Y?.*IC9?R'*N,+H(;WS,=@WK=\$]#K M
ZSZ(F9]Y%>>4]5*)]P%*8#8ESB)=9%WBTBW2H\ H3T68#<# \]"5*9SF7 M2V68X2!>"8(8X&@&\=-7
L@|=4.=8B;311-789Y-%9%T@3J M@EKJ]!%,1W[0ZN6#R6-/9?(T6+T?HD(1X6\$:@8MMT1>Z4R/AF6.F&X%B-2&@
MF\A"=]J %-!WP>P@Y#"0];\$G-!4'K4>>\\:=FK#D.5<9G6VIJC.6MR@9IYP
=]BF(\$8,"H9XJVH?.6D!I#E1; I81 H7" M4M; P Y^B KHM?H%9/F&JUZ76LS=L#T,C3_DW@/B36]#6
MQ&EZ=8_(C>T7I(HHH3"5:;?4T?)_DH=5?Z7\$B=Y,BD0\$3'5^3[5=648DAXD MG+4\$XK)0"0AA1Y2D2JPD%\
([WCY^IL=;%C3W)^@IH!';H(E)L D^K\$G1[DF6 M2 ? 48:)"A6"? W,DH=PM J =%_YCX_1QZB5B, ZCPD
#/:NR-OZ\Z&I2N=&]8D0L,.YLHPD@&0.<34@,V2_E &:OR[0.Y2 MRAICH"2HC#4F"IZN\$XLT2.42%?
G9<1\FG^?\\|E#T]+HSB<#KTDN+UR%(@4 ML=U&)>I^E3*SF8+(Z3A0-(@L\25JM^_,\?
4UE.3L\+Z:X/GRY+\$+T5]1T; M:'0D(D;1%2RONKQVCA3D8JF#9TS!@TT\$X6J=SH%D=VSY6IA;<^'ABTAH3Q?
MI[\-KEKXW0>Z&6BC#0EB8;*C-905&'([@,=+D/Z/82ZL1.=^D",OGP8/>N)=6['87[[IX_P.R^'
M*:.JF*SDZPWND6C6=JEFJ[.KUY_6&GYE]ZP&+KJL\>A?;#G2=9(AE&'UF2 M5(>-3*Q2)DIDF&5J7
/T1@ (83V?YPG4+Y\$?">X9XE0VJY"=WXT; VTRPM2KE MI4DL@*Z&)>XNKM##:0[E\$RALZ^3%L)-\3#7!ZB]NI=
A)8+5<#L!;JEHD!> M+TWJ4_HZ-S,.#S[2YB)Z (9YC/A1)4,PRB8TQIB"4\SKA)FM(I0I>|>8QRW
M@CZ//FP!"8WDS6R?680M6&^'MM;!#!'<9X-40SY)\$,W00A'EKUZFSM5!;P2 M:G]?;^]"N470>T)7F"U-
-4SP[L5=]0EL,8C5JKPT MW2P*H2M<\$P6%" \+QG MPG%9*PXG@D\$0R# /:6E1,'4NHR' MPN
/2J/"M<79X5#0KY-;H6J/OZ?GU\$ M2;X+@9=8AJ'8#%>84@4=0-RA@;G8T;WP-X3!\]3^(C^"9_@"+Q%=U
GS#7'< M<2@*GMDM! 9G0@D6D>KZ.^(- NS[+, \$, (C2N.OXFP9/K ^+GW7:C_8=9T M#-
P5F@AD8TJM[3=0.2+H\N55\GC7(;D;VZ@5S+Z7_ [4-[8+E^CEK-?/IA=/Z M\J\$0PZ='H2>(\$?_R\[_^0"??:
\$"5:4M^A/9=2A4;"Y_V1MX-;0FFTLY9JWW=LZ*>0*8M\T?F(=;0IEN! _\RJ92M=#KVR M=A>
<,;71E&V* >R^*T-Y"FI,\$M0<^ T4CXCH(IT^5)JH(Z;6[Y0+ H2&HL M:KM\$%12]'\$A4G3!=SUF[6(
@.:97YB[3-.N.<-;>K)XNK*C;9IWRGK '[I7 M\LFU2W7&&:0@BA\1;^K6MRIV#
(HTSETK<0A55FP2D0KU;*9R"A4CCK/?1% MNY*N@-AZ0C@SQ6=DD(^WGJ83_B,X3PI MN:\7MOMR1,ZY]^GW..
[X4Z?TCV-0 #:N5J4+0=]0@6RAK2]K)UKX+W!4DV&\ MVK[A+CYJ-
JT/03\IS@!UNXGG1MS([I7X;Z&)%4VM=S?;IZ@YYG^\$0HG0J< M6GCH2>,81< K[2V0\^"Z?
N>HVG7"G?;/0/8!|>/YCTE^"" , "HM5X;X(92\$& MS,IF&6;=/[6^J4">H=44]')8]?G'-..A3P&)U9-
^:PY"RXZ+EIUD20)5Y].V M_0:0?9 @U9Z"PC=JC_ =FG+>]:C=J=J-&6YFTY]R(^1];UXMM&W1 ?,W8&BNZ
MV^F<&C#,2M?7?K='#=>;JSG7K W[3%=7J?.4'K"JXX_6@M") M%6(''-M=RIPCB,'Z)0)%<==5XXKNV[3?
0_50=X)?5!55CRI(G!HV *;,[MLG@RC-9\$=@S090\Y;M4]09.#:' =?MZ[A\$C)PID>5B)^ *V;%KQ\L\#
MB:0/D*HWHWP2N#5-I3,H6=?BF9W9Z&CDZ)C*]?;P7'/8>E1HL1[Z:\$P4F*L30@20,G3<90%<:/ MY(P3%3,
[77;B0R4^07ED?-) YR-!EH_LNH"!<#VQ!|/.*Q)"J9,Y AW!XD M<0\$N>%<#M&:"ZU_XDSIZ>["I'-
PG42J;LR4+U^]Z@Q;P]) (E:L CI_MLC;=G\$'NT%>?@:2M@Q\$.K\$%@.50M\$H!4%0B&HR8L#@6TH5\$H!G@24C88%-0
MB7[4V=.PPR07?>=[-1IE172 MT0(0*^JVV6VKVZC63%"(#'- "I2D\$1IY5?[QP*Q%?;/H'[G@? S:8\$1
.' 'LYU=0D>A^XUS_*3YY(. U_M_#FCN60AKT[* ,#0J#KWJ!@S:\FEA,.N4W\$/7)??034#L6!(6C/M+P' 'E3*'M
ML19-2ABBYN^E9T@TCQ?6/U"IHJEJ\ZN+(?6T58\$N(PW.M!4V_)CTW\ MCR4"ZV^(U#(*-
&NITZIOLOA0#->L@'3H[B&@.39L*TP!D2\0AKJX=^#6('4IE MH;-8\$-K0-?%0:\N4NMT[7XS\
[4Z/N6^&^)L689(L]XPKT[*!Q22,CE%X>+0@ MJZ(#;-;7
[UU0=X9VZ.;AE#6VI2_SK1CYIHD,6T84]IN&Q.FWY9A6G<-K,7)0=*MM[%'G:B95<7Y(7Y+!%VPP701JC'\$PZ'7-
0&* MH,_AD+.E^L*@;M; ,K=J?&T'>]9Y.VSIE-P"\\7R&*?MF\$?7L6= _5/[;CWC]0[\6K7?
%>_D#1:.)PV5G,1=EJWL M0>^LD;0;+C\|=^@=5_-^?H3;"Z]AH1_RWV1P2[?,>58U-+!=8E=9KEAFAAW
MPV(. \$\$0'TH"YY>7:84Y-1XKF[U]NRB#MJJ1 U,8F<"AQ(/5P4 M/= [176CZAD_\VL7X%
(<(\$\$:7^<+YMIEAL+6T>W7N]96Q<_2R*U(9 MII%7*MHP?0&-
+!77"-5Y\]E3UPQU> <(2<1#^H\V#_VZ>@GQ9AE== 4X5?(*
M#XL\OL\$Y,LS9.05^I^WNI38TG&/OZ, JWW8L>XQ0&7\$;1^0&!DF;U%!0[>9=04Z M-,OG>'U03UT+M+2N\|=
MFW>LH]VS*74#TA\$>8>('7@*!IU])6=[MP?R5G*^>I\$AY\W\$Z+N7\F\2?XT/I M[R@SK5/(I-0/
3B\,Q\$EE=F"K_T"(==*)7TSOU5?>1JK(H7?C5WMIUY8 :0 M)'F16+PW_??-
%"U1DOHD23Y.+^@&M(;9<6UTJ:6^='4ZP/?-W[+@&\80^5DS*"OP.W"J]0/7T)T_GNDOI]I+@'@/1
M0U%7/6.25C#CNZAY^@I54?J8[KE(^A1B;^QA-[-EF' 'Z6XH0D1Q);IS>A2B2_M9^&<(\>U04\<,VR.4
*0"FR4<.>TMP6'WVUI.=Z>\L> >S>^ _^JW.[00F=9 M9\1(\$,4I0KE@+:[?8L F/<-?J7,;)]GRR%E_JY('=W]?
6U> ,\3'G/62'NX+ M:V:\@-<%ZFZ\W;G=B/H;M./NW=@_LUI=Z_AOF2@30-DF%NXF%EGG8: ^V+B#;W)3
M^9*XFWGPL#V8+LL[_ _EL[HAR*[00[8)] W<&6@ >L0+@S(==PA=4A>NE/PQ_MC_@#]17P=FG
M?:DE0HGUXR1JA-%8)5\Y\]USYJ>(D_CYRW.=R6WTL^!NU;#(AC*^AL2^S.Z\ M2]=H(6K/D.X1]>!0R5'IH>?
ILTZ';:)- (UP<&R2!7J]:BYP!W;:/S05TEW?; M_\#

W5FW2E1Z&FZ@BYB1U7#PN.INUY_AB>KVP@/\8RMRM^60>8:0^R21XI97?[BL)DPZ)-\L>4D_K9]'
M>WAJY#T4\$]0,986'>@_- [DDD (L<9*C)(V?/FN/?\$ZLRH&Q*S>3?H(K)X5Q_M@- 08V!N*&A=?
-4!LJ\$U/(ESM!>L!KN;8W:?'3.A050!DRBK_0.2<52._YW_M)W:\$}X\$6Y%!.&MZD&X+?JV;BY9,!1YI?
0=,44W.SW31_W1_?Y?CF0T]UP.N^(\,%I21:'!'DR58"3?)>#1,0B\$C!;C&.'WA:N#%@H
MC7'Y<'YV>B6G3CI]BL6=*(;_X^#Z9@E:L_1-^D3_GT6,(0^V.NL&6-C="D5_MDB>0=^(4Z,.^?
HB*&P"0@/E7\$[C'7"_W?I!A3@MIC?S^1DXGVFAULH0J/7,L_R3]UZE<;FV\$V75[5\?_M-(U-
F&#>\M:62A*]T;/Y,#N<".Q?ZEP5)-Q;)'>ILJ6'!/.%9&]0_YVKAX,3_MZK#BI' 1_@C%"(6Q2A^:#+],X=;2
+M6M3E^HT:C_M&D0W[GUUV;:/IOGY=38X'\7K@N7.ARL]6,A+Y6QPZ2L1.^[\$0\$W4*PYCC>>Z_MV_,-G%E>B?
Y6K?#*40&)"\$]89P]Y)=Z9@=U,*BSUZ0YXK^'-IW/F:A@:GBP5_MQ-
/S0G]R4&^G0D6^>GB(H24G9G%+L#I>AG%Q-#['8W_TD@?2V_#&3.OJW8_R_M_C)=K)>K0>3W"(Y
K%PKIXYI+0+0\$';ML:4K?}M/\$+K*M^;\#N%:Z')_JDI_:P2&[E6:18/?"[_V6N_MG^>>8CN\][],L0EZ?2H]
%BF2EL[?_+.#'2]S"LP.W9D>000X0^WY;S\$:B.)?C2RG8-;39E-.?SH>6]W>%G*"<]9_M?2%0TI7WA;>
#8)B(*ZEW&70F+;.;T07992DI;3%K?//,/_4XR=?*W2<2=L2_M8E59=);AS-N:~
RE;*N_WTN"Q;*4DWTT9)PIEDVJ9FR+-]\$/4E"5A^^[PI_MS]=*;Z/,53L_0>?1H2M37[\$<-
_W;)\'"C9L)/3LMP[3H^W_2];]HT6:@*:8Y_MF_7%G5-;+"
7G1Q)T>0GX4;F*FWRP]Q!B#UX3Z0CZ/(_L7GDWIK-J*_^KGC8GQ\$[29?NJ#:=?*_M_.0,,U@(>*!'H_ \G0D?
_%T!1F1%7% (SZ1\$2[5920/*L9]^#WC6?_MRS_8;"F\$6=;N1E/7;6F0\+W?*[^TG?S.^@:+^%KAM[_&T)
M07>;!K57,G30J^2U@">I89#PHHU+ 1-PHK0ER[=ASC0FZYZHXYZ^SI]WWD
MB4U7@@"1[:4UY4G)Z"K/QY\$%W_"K#J?T'MB?/5>TRJ(XP0;,-AF&^Z/W6P_K_M5W._P9\CV4
=_08.HYL2WV2BS=#71^G6/%7(R-1<\@01GD?X2F+U)Q]G?-P@_MPSR%GT:@E-\$@586[/\T[EVCW/9%+;>BVJ?
U_G\@EKGHQX0_-2SN69?3/U+M#_MJM;]/N_TE1EQ^JL/#IK[U;I>MYS?50ING6^C7@6VK030X!H7EZ>7W#]?2>W
M.(6@)=6R>A>U'H)WM9X_)06/0_\9D3;X_I\$6W[0Z8F4[NS?XC;.:JHCBC]\7
MJ"4Y&8]C>1;'WQ:6I00?:0'=0-;(R7P36HA6?30\2&@6J_G,S;5_X8/^"0M7
MGN_]1&5H0P2_5N\=!*LCWS>LH-(]=0B9+>.!==&_09[&T_@M\A,!G0QA#0L(M_"&.->--
_7BHMIR4.'&T6[XRZ^'6VL_T+ !QEJ;_0SP(BWS6=;HC\$3C_M]4>N,KKN.T(:RL\$)-
@EMT[|V.;MX.#IE= 3C0.BT)Y;R!# [^IE12564-W.5_M=\$5IQKB;0HMO&6>)<1\KHKG6E"/!Q[K1S?
WDV5SOV:G<5H)_Q5?B.JYF4KAG_M)\F^Y'F?!I?0FI4:"N_[?*_QJ?S/[|^_.55_%>>V_+;UQR&EFY:~L.\$#2?9
MRN;@W<+JT#TD9?'VR+)_JSNVE3DZ'M)"7B-?1H\X\$K*%K]N3G+{P6L^WYC_ ^
M({0^WQ_Y=7'\I6^2IA>0Q+CV'FD+D,25CT-?F&C%&"Y(W#PCPXPY4-R!_2[
MZCB&K!LH;@2_FUI<4&2V^,#)LY_U2@#5T;>V2#<+=_M0Q64^5=^" QC[0:RE&8^>RV32MIZ.=8Z#?
EC4G2XLUF8UU)@U0"5]I^R-3I_MK%-_S^;-:_.U0NYO@."UA?+Y99LUC" *9RH1>+X)[JT_<[(B@XB22G6'B)MW
M+P4=,2XC.=W)XR47B/W55>,LJ0SL[<9I>L_M+,TW4T:
[1ES=6\MSB7&_,0ZN@GZM*"XMHXJR7!A;C7>D2)/\7CC5:-#G2R\E_MJ=?K/;H@4B_DQXRV#XAQ\$[:
<5U//K)W[W*]Z9-R1=,4N]M\$[0SXXCBV/+6?2_M
1VY2C3A97'48@PI&G!UU\FBQ[H^>SM"DG>Y6STU+8=^W.#*)GSZA\$N8H^6_M?A(7<13&I[C4:KQJ*=F..YC
K0[=?8F,3989W)FH-\$@R-^GVM\$!%A2M=_M6]NK*1TM]DB\$]UJ%V-
1MYE>L26\$>5V08I4M\$K&:4X=2"DYX.3KZOUAUE.KD^_M">H->[4A-
_D^H\$C0Q^Y7^C.YDA2+,&\$1NH21XV+Y0LBT7#W_Q=?Z"P'+0B10_MZM??_OKRPTIFYX\$H
U=ERA[LB_H\K\$14G//)0%UEAXP7_RNS0/Y/NW;'1&09_M%U-E##]I+D4&*>8_%CWL-
=06WT(QUSUL/ATFP^S8S>I! [7650?0?=A+2E?.7_MD_9PV8FN,5'3^
3]^XM&707D!^WKNC7'4[:092VZ^S.;JH;*/JD_MPU?0AW!KRH@*4H4'G'3;73KAZ_SMB\KL7*1W22]@+L,L/&]Q-
7= M\$27#JG=8X0F%;DL,&YP2]S>)/K-T7ST\N.OY_XH6?S)&'D'%E+[0#_A:+-S7_M_4
*&DB^#99^Y@>1S:R[&L*3L\$0K237<5](GR,[J\X/@_M?BMM:L#)N@0SBAD+A086PF!VJ>0\G]Y*5),1]1?
H/@[=4BM2I#<./\$\$F;.:6_M!'+'*C]0<-H)^KFP^X5&K^L67=(^8+1X1G[^5;:&\EBIEG6X_M]XGIW?;56E[W0-
C\$87/F+0S,T7002LEQV/J.O)F>]:U5H=MF;S_TEDQ#B]0_M*WQW]=UG04@-\$N%7FZ%3;633Y-"A!%/A5Y\M)=1
MX_3+DG/2E&J+HUQ+#+,08JYC@<^18]7PB,/^\>I,DR\HZE76TR1_MENG2D,]U2@L/L+L?.Y1_@M5-
S_A+CA'A@B+N,^D+0015\AG_-Z90B?5X:WT]
MK8%_A!4P\$#NES:*VSE;6_C#A]@-72V#=#A%_,TL0192";\90Y1/+ \$DM25%IB1_MA^?JU\QM5:\$%#0?=<+Q
C6"_T]Y4D+8H*6\$T;*W;\ER-8X4;P]LUOAHJ_.&Y_MR.2X)9KSQL1AJ\$2_7R*LD>@+)>RI,\$-X-;+=^5[+5-
I=CI7/IJ%QI@-4RUW<_MS/Q,AB]0E2;Z?;IH\AVS='/=;X\F=8=6GU1_?A?2LSQB"M>?_MJ\$=&!HE=I
B*/[4.%ZTD/X\$A"M(XRY)A8JGX)YXVK'+RS:HS+_0/;=\10]2Y_M%N#:Y=Z" *_&ZPG0*0@V\98?
D)/T>XZ7K(57E(V'F:Z%=<5!T<%91/=U#H#+_M;:[?/TCK@V\$/MTVMAB^N:P8+
(KX%:UKZ%2='T\NOA\$=U37Z<=2UYW_M5)FF;&6^1=>VZ=^M70^=E[%R8[BAE>40UMK0&FKC6\$-[Q-
L4%>=T1,VFIS\]_M>[S9?;/2;<]^_L==1IV[P?L;\P&W\$%:=;IVX4'R6;BU;N\C*UV04.;4\$8+_MK6>.2-
:'M\$)#I5,=M(3G.[^"VCV^9?SQE0%FYU'ZDQ,N!;C=-157G)H["_ \P: M2&AE
3!\$/H5;!'D11+,\&W15LPS#UXTHY6ES'"*Y&95%89.E@0*K0:1?E5?0_MY+M_B]F,
[E.GU&L/J+!97"X]FC"SB&>,SI>[G^7?/_V%F7N(JXE;=NZ\Y]V_
MF9)D:DWZD=3F]46U=QM#*M]@E:] +BJZUVM:[:%04_\$@GEQ4\$Y\FIS.]RMQ^)_M]N+PE7[+IZ[C,
(.K8N2(\$THY&C^N51K@*;7DM>A+BA@"/=L'-_.U0/
M&ERN[/4(\F.JE9[5]^R)#>NBW4.I2':T7T26^K"3)6&'^DV*^6N'XB==OKQ=PY0AJ;/HX_MN8\5V_"*0
1Q0CLD:VYW4X06&:&^402D:.@7&2;+S,QL[)T,\$^WS\$9![%9A[M!)]! [6I!0MQ\7D[(";>
>+5BU);GI8K=\0GPB(7/'@XKIN/WW4B9D)5_9)7\%#_MS!KKY/@<=Y+_M3\ (922UL@-LT5;M)[_-
BRH[S4D:CK0RY[OP-R/'K;R?6A>-NS?+,5_W[:]/]?_M_Z=[G!KU8P-@U%-Q-=4BV']]?V,U*;PVY=BY*4E^ \9
0[K/O_M#L\$*G(5:'.IB#W%N8GK135WM*-H6Y_C(T[P-!Y)7\$BA_85(W^5_6-4*G]:_M.??
@00LCX.G7AIVX_XN]]XYJ.V%T1_4&(TA\$QBA2^D&Q%FH@(*B@M_M"BI-B\$@+\$(5I0H1\$%
0HA01\$5#I+9\$N(D1Z3R#T\$E*_D)!VPON^W_F^[YYQ_MQ[ACW/>,>?ZX^X_Y!XSP,/.LN>;\S;7F6G/!!S2[HKFY-
-RVMYA'6VNT=LZE_M_\$)>47YT_Y"00%!>0TTCR3]*@/:A,D5U^@RX_X=-J)_MA8V-W

G7N350A3F0C2+WGIKRY^GI>K&"[;=5(Y)2SAF;B%:@:G31:H@TI\ M*0SM5IK0:GRR7^?;'.KAF^P-]CV/@8
YNX=U185A.+9.!>L2-9=\$@#N_L<9 M7]^[^Y[7-HL0<1@^G&W3UZ 5LY[1N200CY/G]Q<;<@LW8HT/VN;E_"[
<9KLS M"FR1S;(RKN[3&;/0,>ZYTXX-1>L;[Y.-_R6%?H4DEFW>FUZZLU'NFG5ISQ)\$ M 6'/N8I[HTFA:;4!-
+M.-\$R^042AK<8FG\S3'Q].;0?'#T*5)&G&VN;HY MHWD%SM&)R("]/\$94_) T?94<4+YQ"SK/(=2YC +<(?
1D%H[8CJOB:4%"UR M1%.D25Y4\G1SP,[EEA\^0-@^G&.\^="=,!\^W3S/G>MY64\$P([]H\6Q6CE?!.8W2QTR8F)
[<3K.B)*&3.UN;[! M7;9AX)L]:6A^?6M;Y8V\$;"WCPT%(Q3C,>L_K\$33A*R19AP9? DW469%!K58Q
M0+F4AED+V@Q>IQ.;\$Y;U4\,Z3&)T-YB05+T7D8"=)3+,5TH4!XC7%Y6E[AX< M*< J[C^*ZWG0^I8X*]VD@JW
/ #T?R<2HB'!'%X\3Y3 =@/.WM?*UT0W6 M[P6 WS A1'U +0'T/-;=^VS^NJ0-W=@[CV=) %E"H-MM\$BD-G
3\$P#^M*4JRP#Y&U?)7%W8[CN6WUBFH24E6TD +S# MI0L 3X0C%>D07)'KTKUH&DJ4/H[D>J]?
A;C[U^%N/0_7X6X^]?A;C[U M^%N/0_7X6X^]?A;C] Z/'1]:6C6J)B6MK J[6A<\ HF"@22G=HD,J4HAMB
MF1 "D2YZDEEDLXH"4I .AV&45M\$=Y8%7WG"V8^4H&BMO0AEVAJ97W:(S_6 M]GJ%?R*:3UU.#
(X^*GK:D3HK7?Q>73U?VR+F_C^7;.R,J_L" K%D<^S NF3# MJ.!>0<-%)=#M;\$<0X[4]&IW_V*+1(
\$)Z;90;1A:=310G[L&^LY3S>7,R M+@CB8H-18+)F\Z ^K':*M=/EB6V/0@7G_1ORDHA?*=YMM>
]X:NZ!]JFH;"< MRXA/[5?^*8@P0FMZ%RPHQ1+46\;. G3FB/RL^0& 1:J]IZKN# G1M1KJM-.J MM&>58W9B=?
%FXB[-=[^M,=* [X@=>'BZ==J^ ':6NX67S06FH5M20_#1D#. + M H#8TLD34V5.(-L5[D?E8\$6TGI:306^3:
[+HZ=PPF9#^,; \$F:]!< HQE^P3 MG_X?
<##J;_D_4W980X0=!/04[RW]1QST,;^ .ZRU;TH@UUCOXJ@7RW [9/5#A M43GC@]?'^XfV>2P![].%?
SBKRC5&>U*L]02^RKVO'1VX>. @T1UC\>E W51 M^II=+NB2TX, NC;[JN90.H#^ -G/.'_00_R_R\
(=Y752B^95"SCN'L!= *! M"#!AL;^'C;[C=*AM%E2F[6,78_8[9BI7]1M0T-
3RB8<8!055<(QFRL+LOGNABU\7\%_A%',H16>\SC[,MK.SL:E:@,5RW02SU8_2 HYNF%=:?
<3[073"&.9(/7(^,>B=[M:F^1J8=)A9VUP\9K=7VYK]IP5AI(J.H; LM.#L1ZQN23[KL@B"12D46G)Y%W
M%+I#%\$;0)VC;WT(X/Z=1FA))I(,8/D0Y 9PJROW;HKW+%6<0NZ&[4FXDEWR
MFRBQ[D,HF/<;AXHBPLD52PF<\PC9>GE=>M]L\$SR2KUW+@6#S27P&E0*?_@) MR>KJ)>0@K
M>QPC]LKHR]=*8&WGZHVPV!H0]8[JK\0%G10;)-=%&OURG1[S#N\]1 ;FL\$ "4 M8_D_0F3*Y3[6DF6Q"/6P M7?
R#L@[P*(CJV*, #>J;?EB;>!!WKNB#[T@B!ICE##\?4P^%AB:~8F9TK1DJ M(Y5(W[
4T7&H2'&4/PBS41%5Z^#J,1LG>E6KPQ5,A%\$52;YGLE=F'^0?XXR< M*9%-
(N+0"@##HGP9BPD[KM+*0&6V9V!%HL?P\WP!P,8M3C'I5RRK'/RHY2&W M>(Q-K00-'W(RB-'V JE3# MT<:
[/*YOC^0-FQ]% 'KK3Q08JY44AQ>@%]1!Y^EVT=(##2'\F0R+'86\$X)^1Y M[UFCV:H\$.0\$@<*JUW);
[!.H(@"D0Q(GEX7 -IJ6+'^EE,3[&D4)2E@GW! M/3^)?>)M(ZN&J4#\$0.\RDHC]_F4>0U40[JH23%
[49,R#H=F>%LC[M/>P5C M;W? !TE%202A#9""KGAX[07C&#?"=H.Z9QYU((0L CI49S43LKII\$[8I2?]Z, M_-
EU-EH!G?V F.E*=6068?5Q=K,*&0FZ5:S8 J0-S7"ZE1FV5EX2#-+" W([MW:-@f4=]L^\$5G?I?Z,8*&-
<"X0LRAC02^H:0LKTA&/\$4)WH70%02\$=I7=3D3;[W.=&M_184-6S,>LY <##"(?Y0^V+ MGY6-D-3*4])\%?VM^@-'
\$KS2X'XN \0ZIXH?SWE3@FI,VTX&F8_YV/X'? M2*U8>4^T!/(&S8N<6UA'P'!UM01"*Q[L<[;D04>PU=)]!0"@V
_#B6FH?K8J M80T^]0&5HU/,E6T[]>^J2-FE).B!ZM;[] MLCK&)6FLEN^VS*5D&N,)T]5+-]N1V! !<.RMHL@-
(MGNZBI9TCS]9RG/N-\$A' MEJ+B:G/#K]+,UCSUS8;!J73 ^B\$,BDPZ@:XD%:Q>.U M0&^T+0-+K<\$ +][]9*?
(8/B9+*ZKD&.3^(#)\RZXACCS\$ 7L'R@U0+ _#+VW M)>X=[Q,Z"6)2RV-C^P?L0B0K;
()RHN\$S6(A2]0T&AXY\$;)J(3.*J&Y](R# M80"N^-T.A?F]XW15[,>Q"X-2>IC@#
[PLJS,N5#XY599I*M/;_2(D_C/6:#4M M!7>?5XIW+W08ASTMS8#6,UL\$@-9,M5K]P_3X-
/C;_IU0E,R IMPZE/M<;#_* M8\0P0G0>VP/H7>BP: !-1AC_6#W771)02_Y:TK'S?U_OZ,AV"WZ;&@f0.=RDN_M;
U^2+F M871P9K;#IR'F',+)P%WEQ: '>,+&*QB7^3#IC\ZB0YT*>'LD.7>X;@@;['<: #W- M#9W]
L#E\C,"@#0,3*' [F(/!A75)?/!XPM3K5H[0#Z0T\S\N^7(L M0:ZKNE70*/XIJ'A?'I'71.ZAY%WL.1D
*A%.1^04\$T-ZG3L(55V\$[4"ZLUSI M*TS+;G]\=(A=BS>,K)N<0S0!K?)<0I-C?
Z+'MYL';N4*E;S4RQJ<)ZAM4K, M0',L\$:%-0M-8&LGA MF-=/W\$DK ,;TB%'.W5E@7JFJU)?
RB)1Y=0ET:TUY8(LHD>H,Y=0%\$)J<)5ETSMF;[GS%WE460>MT02\$JY03\;HS& M'*[K-
KC*&MJ_S_PH6P"8S0T.6KK&.0V%22ZL)*P3DXOV7CCE-2_E MN8\$>W@9S?W/R!+BRMI6M2&19G>*-]M?
&Z%19IQHP[2 +^9I(5;H\$S80!VR5 M0<_8NSL\T\D?ZK*K)^8]NZ;HA;3B"-,*M"&'NR/L\$1
(+YJWG]>! =H_#! MLIUVVPNB40K8*\UI*>WB>F![J;>LN)Z4+(W=._?HZ,[V2A]90Z^R0;&89Q
MV08UVF&*P[BKK'6.&L;'FN+WP'9-Y^R3H0BBD+M^G34@\$LA8%&F[J<%N[N ME;0'?B.C0&W#"M906XJV-
N)W()4G@\$<0D2WZ5S_E3=4"@-[&VW6MT?930,;0 MX""B8Q@T,/V:6_0T26"34LKT)? "8U40N0 (=1100/QUW
MH9_4_JP>1]ZUD2/)"" ,;0+H@?N_*K8'E@4'H'KZ2.TP:0#;U=H(<]=7R=_ / M K/V:>TPESFGX)OYD?
YJ4J/UYZ\ '1JUA<12LWU.Q];'T3C?_4@1VKHUC(Z MG7AR,(6B^4 AQ6PRR0 \VC(;]*-3#_K3XKA>
(T3&IV@XP1AYKT?86"U.0FZ M09\$158!P7UT+*Q6YT0]L>;LA_-Z,["<.UV.M9Q*_9AC*88RR8C1>C_X57+I"
MBD0C49_Q][^F';J+C%/R\MSU!I@#JEY1]RR"Y8"BC+>GJ,W(0LX._H"S)NL]
MV0N_AVM>ZS5VS;J\$W_U;1_US5BGGNAE5KL6[FJ=Y)&.:T<._Y>CC.AVS\$<[\$ M",DPE/5> '#!%0@_.8\&IJD-
Q>'ZJ5'X>UZ\$&.>]NBG.NJPP76""^ W M(SV_U'FK0B85ZM/'/^%]A;H7H(=Z)I3[ME083R\$ZWS>]D7U2)
[8AQ/=Q1;RI2=VS\K>*]7YZCD(5EW"[N[2Z(-?)T#]CA
MW>@ (L.SB=DK.F>"6EB63#Q; !^_N4WAM>BENP'I@.4)TI?JZ?C*=\$6'0JY*>92WL?0>Y_P/,>R4EL14K=]4
M]#A6_)#FWJ*7C,\4%R\$(MOR!WHF!W""1\]ZXT5#,[@I0=[_EM+N^@M+LZ)&_NAB8J_&D4.4E: M,D#GL@JY?
I^03K1]/2TZ&\$K&f(^M(5'\H&3*.ANK-,<)>G9+;EEC TY9I*<[MT*A+G'^L\$:0A76X&PZ2\$M,R,V'P=
V9L'1J]\03F".\N/*KD2!1ZV!Y[]Y/Y M,JR4N.BZ%'.)93,I!-]LE.*M!:(&?6=>+\$.5HH_P%,A-6R(-+<.
<.:@J)+].I MRC_#1C-^CVY3^0LP1HF=*V<7\CX=CRG%2K(T6CEPL-6X0>7J2-0%PDS;(S_M M4&7%J6
QRH\5(R1[=F;?HE7L\$_2!-=F]540P_M)>2Y CZ,C3@X6TQW[VKR/F8MQ#ICXP3+XVKRW2.\<_F#F'MH1
4!&AT.2\ \$P[M4:%+/%7%,1U>.L:@@.D-H2)#=L-1,; &(*.HQU'N>ITT0;8\$)#@D/#0@]SN/*EA=XDM!.
(LI>* &+.?6_M3/HFI%\=[U#;ZKXU+TPY+X0!]U!)\4Y->J<Q2;\R&840[N90IWI>\$DN7=8_M0QP]M" L&XE_2;
(4+3@>;VKP;GI_-IFI!)1#"M-,F/<2NLFMTX_0&G^*BI* MUTP46'^%]P)WU()7&YQ,F]9=]=^&_20_M[-
B9+M>V#*CE+3]M#2C'='^9=]<-_NN&U?&^P;\$:C4P[CC.J._,8#5>][^'0G=FF2J5G;
<70'WT#,QECG_,.^[I8K1V)@%U@2C10X9[6&<+="" M5C6U1>=:['* P8A7J#.R5'Z2]0^%+/CV[V%>B^=*HL)U,

<,5'>;@5,'F& M5G.9+EE#GD/UH,EP*>=69D%4[:^>J119KND%&ZL\T :M%V;06/AEF9S
MW7,N&1147LJJ;5CR\2 JR L7RP[9PU\$62.=A@+ .JSXMYRK:=E *:<.>K7L MZ^4W7WV,!:Q1=_H\$ M=&C#@?
W[047\5GZ"W\$ HKP3L%26-6R%Y2Z)T Z>0-3UKHL.NS7;5 ;TV#@00 M/[C0";T#;/T[1?
T2LC (#1E1RVZD//ONIE:&# ")Y3R9JBYAC-FIQ\$57*F\!N52+S+!K!\$;)0WG5M9;DQ4+1U@KL
M7HCL0%W*58=Y>^U32!-\X,PY=FAT7 (9: M& 7L59\5WG<-TQL&E5E,'DD-.K%[4,G?F!/S\--
,!\$(P<=)]&.H"NAQ;5LMZ M#A(?[2418S/R84&:J/[TT WJ@-)*S/<+KS31LOXZ MC2Y5;6B'/T>78I?
8>;9TB6:(0:\;7; .LB8D[-6#,+3 -^ 9;*>H,6.=#%0G M%C,UE@AQL.W(G71&0T\C1+>DK
;'.GC/00A*'*K9"LFWR[/\$/QRN7-JU'4T M;ZKX>"70"?*PVV>\$JF-W0*\$-
P9&V'KTSJDS\$P6X0.N!SDN^1;E, U;9.%XR7 M:#
(D<+AS:6V4 00[C12)=Q==ZC#QAMD* \# ZI6\$POF@;]@0'8GSJ@EXMPV" M^E#/W<)I4T[0+G7]Z6'"
[3C=],!1.A034H%!NQ@" Z3?CZ-+.=,'GN7V*Y;C M:;07X)JJ/,WMC3 HI&?
B)KK&DH/,);0M./0;T>T<*^,)J\ .H0=B.-4QTFDY M HW3) \XS@=:P1T1+?E%\0*02!8B=)""N: 7S&.!
\$1'1M0!K39/SX\BL\$W] M%=B#J%,(+%GWC0NZ:[4F7.E/<7KJ#M-,N]T*IE^9#U!8:+LSG4YB^M'0%+F) M
B>)Y0(2): I%\$G]W.AX@YK[2G"QFNRP->E[:G9Y= 6MRL[3NTUL!J]>@T0! M (">NP!EZ?
9"6;P@/[! (+;39[\Y[W5%2RJ]ITVM3U8\K0^(3^1K17XXE6NF, MK? +W(1 DX+J6[D(I5W!2,+B',
[!OF>+!ZM((%C31C M>>#&^XJIL#>#<[B/+ "-> "-^*UC*;0*Z>Y"7?CE2T[!#0+<'0= M[&HEDG.9& M'
K\=#PJZ5N%30N+X SV ZOP)&S+*P;^(+K40P* *5<<;8(RSXRBY^4R M0J66"C6Z
D"C*M*PCE9%&4JN:Q<2[+AW/G&.28[&0\$%M0N576D?J ,M%? ? M?G#[]? W@N5Z;F95C%RX13>/XC5"&+[#LM
"0GRT ^*SM@;&.X[GIA\$C\DEN% M -!M),)?"(E!0@I5F1=*@PEZ,EZ!81!7L%@-+G!;>"H7>:4L6EU]EQ,^C6
MUB0T02[0\$]X-S?(@1)8[2VVVLGKF?V0!=P'Z0/("U4 Q;5,'[K 0)E\5^C= M#=\$4YW;0S3M>G^;>=%R
E<1CM"7M] *9*,7RJBH01 D3@2,\?#+% 'RM1ZW6.#E<['W'T6DN ,V^B3YU?MH1^9.DQ4\$F>PG?/XTN
M&@X 24\$!D?YTNW"NGK8 X.%T?-0\22[51CN0]DQ3(G!L 3SCF?-0EM:+[/;0
M;: ^RJZ90[0@) IIE2\$MME2DEB6K76(#\$;JJ?Q'X\0[UT_YL_BKM+/3\>;8 M=M(7?
6[V67)=>R%="6F\$H\PZPW3[5I5NYE7HUA1\$-X: '%<&VK9AMV1V0)#0Y
M: ^H.RZK[4SN"!'M/#E0IU0*&CW5L_YN1^U/XKRMFAYP2 !P2V&?P[E?;4/=- MKB,QR2RQ?*0SR^>,
<)Y8:&G57Y/FI/K)0XT4Z5RBUY=[04HV[WE; ;\$Q)NN MP*T9^B1\$#ZLA->Y-7A9X-QW*%Z+P,["L6CK4D\$XL@X(?
L+(1&]@ 89X>6XWIXP[=C(HY5=&M[:ZEEIPQ0 MHG EH0'#V6?10U[\%@ROIF>1=WZV:U=W)0=RN2VDDSH%0!0)
[WD+2H%F>L00) //+\$ MN2"P 7 /[C!@!\$0-U8G3Z+5LKHA8A4J8&R[G39DKZ0H ^!+4);?A(ZRTU7/
MX!56BTNTPUQZG' LH.B*0A;T=^LM*F7M?*Z^XI.D=-C4]<@#!74QBU6UZ!CFP M5/ \$5/(F+^]RNLCVAB-
6WJW[Q-] ^F60B-0X3Z\$! M.A0#LA3WX+5)J=A:04 =[/ZB7>P>\6W M;*,5VUP : "9P#E\$@\$7;- \ZS-
#0M48N34P4\$HTV):0[NT]GPSN+@ " MYK'1+ .9\="]^C9S?&S?B]-GT1&7-
)!V%2./X0B58)N:JIG8H\^AYA,18 !+] 2X7@)Z@1]J@D M&MR"%?0IJ6!>=V.;LWSEELM0]^>:3>)A
V/RJP13MM]Z3; Y\ ^5VNJ*T14@ M207/?2/TB) [CK [4F-SG]:"&:[9\6L@#^0P"HUU\&BY*]+! H\$
++/[!+ M!TJ1F @%:0U09)5,'U0H6U;\,HT'\$97<69CIP1\$GP^Q)]-(05=?;R/8]'C\$'FY,^!9J'S M0(1AZV\$/"
"#!:]AWAL8P(PGA=!!0W;;0 \$@PI45&CP1N.FX08+SV +#0@SR
M7L;1&X&ITU0T>WJ1^,VFU#\$T7:>0X//C\$!F_#^TA .Q VK/RR83(-/N%P\$P% M6FW%[H>I3#I;:Z]
(:X)2@KX!)M\$*%VK1S5M;UQBOCP#TT9U0; "(R'ZB)B! M9J9,W>Q3R-&KQ@!'7+!+HDJ;?
KBJ<89,91LWVS@G! ?CES W;ZJ/&4#ER : \9!X(8-ML\6-]4/019 *E8_L^8E
MY"K'TL"J]&G/E;+HHQ'#NVHKWT?0\$!/: "=@//=[R/M:E6RCLIR5Z'00;MS
ME7 !39!;9K"ED=QTDC!6<@ZMP7B*B3C\$Y08&NJV6%?FOW8WB?(@B" \P2 "9F M8\ "G30*;
NJT9BTYYK& &."YS#,JA%0E.\$^#@+ \&R+Q#R=-4*C/"5'H"46I MM+=IJ2,BJ4.G<6==&=PZJ@
K@OM[*PGEXPL@N"R+*)TCRJ)\H%7IQ/6&[M020)!E[^0P\$N5 MIK&SDB%/6A]YB4]5?
4G%!Q)*VJL@TV%L#A1YJ\NR97,Y MY' VL.RUWJB3I^4^7 ,P P;CTH\$P,1,'3U.99> DA5>E"S? \S)6]4
H0SEG% M0L>35?FG Y-37-'U()T.J#D+3;9N=29JIL8N!2QF7)B]4"E 8 0 ^^YF6!0 MP@ \ZVY07\$T<*.T/%?
JM8VNRGVT9CKC<('T-+V-M0Q=*"\$M&^])ITY/0280W/ M9:01G='T;*,8; Y1I)\$0)JCU\II]!&E\$MSF *R#???
SUK.:1:*6GVHC,<\! ? MLAE'-% KCU(2,HNNO'B(-R^W(R7;%1+G[>L! M-E".N-L]*VYZ/+!EET+=F7H\ST%E
MLW?13\$0^145B;UUX176E[225T>95\$ \6GGE8R(910'STDKL,%)W =<10G4^ M1H,*W6\X5
RBRGJ+B%H4F2P4.B#=[*#JDG0B>=,!\$=VXR!#01G6+UC>OJI*X MX3#,5\$8&@7MHZX0J+U8*N &Z5IP%3Z1K8>/
3(U%0 ;I!K!>1001V[S?)=> M5*TAN494W!FAV+P!2MV.R <6Q7)R@A#?>>G?R3^<%(RD>?P+5.YNSD@P@0P
M'*)#BW\ 6>?0C%.BY^9VU D T6L>]]G\$D?KCR3\N7)65I&OLD)%@ZB4FUW;
M2>\$QR[["20Y+J#,U'(V+S.02V) MR4,K? IS@!@P2Y+""4 \$36*?4I'JY'9@Z7S2G7>51M&4#X>'P%:81.-
S&XS" M*J=7LU<<\$ZL"% FRC@NE82X#SCV% R*\$!;5,62\$A*/PG(8P7R@ \#I='U-XH" M@/M!([>
[0.7#7. :*SNBBG^NKH\9=EKT]N50SU/WRR S0/ M/GHGH?TVY-K'K! ;QL09/1^SV@ "I(LW2
M0NTB5*B>>C9=EWMYRTJ)";P@VRQ]<&&S?DG]\=N-[LUA^G[0V0C47WVD]V_Y M6_Z60^40\$ 6""^ZX%
[_EP^<^SJG*?<1%'Q.WL;VKGUPX0-HU^%/^L5K=U\$EGVG1% M,K;,,PV1>\$(((=S#5FY9C""-"SE.FW9
6&NR[MT7A.CVS20. AGARH];Y] MK'^5 C*I[# * 9-J<#&?0K!CT0:15N (@/@?M.E=3IB,\V?H,IF'-
M,\SEV^W[!' M@(.C7=49WP,,>":T*-I.Q0Q!UE0[<-*Y]+N=>8R74&IL^S3X A# 4!W]]#& M@
'D.L,E<=8*%;9LVWH]3H^8[P!W1F:[01N*GS@&5C<&U M/>JB=7]\F'/I,H^YHE:]I?=& 8-
13\E^(%):\15,!VC\ "*)BIR _I^N38:) MS30+Z458E<39;AC H/?UV*%CCTSH/?V?
6;"6:M&XT0Y>L\$&A1PBOUN>.GG[8 M5)#8[IW7B6]F\$^S/FIMF=A*?K9AP*WKGU3TA=>ZSY1H&\1N.B3\$,S+
\$,YQ& M72*-MT,E\$&F\$:S4]1=1K5E0-(L[=\$Z])='9BS,#\$ZPL-&0. ZS>.%46D6W(N M>&ST)>/>/U %UC'NOS!
[:E4WU-J= R&YQ7 U&B(W)]U>8Y7ATQ90 *77 K0* M,Q_K)Z9;E/[>^K'X+1 '*R;NX;VM=?
68P(A[R/"8V<"WY- EF3 =[7I:.] \$T M:>;RZQE%YT?H\0+8)OPKS,9!:7L(
D!B@96;AJKWK'SCP!J@A[6S'LV.F<\$* MH]. =H3L785Z][TIC%B8MJIZ:%;T3?1M>^2#)E1LW;?#I")*D/SOH>
<01I60? M!#364TE\V=IE;GJPZ+&]>DU^ \&K6W/; 50K\ [0;+,5.5QW+&CX@J]-E(KHRF MG1-
] YOLPR53&1<8!NBSQ:06QAF,Y\] -%:,:. :JXH3I7'W'9F.EJU-)7V,+
M+77?)KI3/Q9MP1D@SU\$F"9NM9F8V;Z4KPA@-E!+\$ /9@;\PL!Q7MWV9D+?M86^?+515K\-

X)8=Y%-7!WU="UX0^7*91I\|8 MTU23N7BZ72UY,J%U WR+HLXES1I%6 :-H<6#-J?'T0>'6+.;!9JZZ;?L(6W
M'!8D&WPY)!7WIB@ESMC;,'6P+SD=NA6AT011Z<7|WD#%W0/|Z|BUDXI\|:IU M%K/,-%K++GP>=C+@H%T2GX
058W\$>XCN<&*E-^J&)'(<09"!5QEB;^IG0 M,OLL:)\SPIH*)4YWH7WP\$39"] '*G6_TYP
X%J2R/^Y0)Y0YES5 L(U19'[U!],_, S9Z>)]:54*|YY&.!|58K0K-K8|(|>,4;.
M"BV.V4^S6YJ>E+7:AT@R&Z"6R;:KK6W70WS XG!T3B(8JW6W|;3,2I(L-V> M985A2X\$|!
(#'MFANLD/HN5L&/0<73"B!D.Z<8EF6!N<*\$L)B%0/#UXK+/: : M&P?XYH|6*|E=U9@|NBRK-"@ * 9?
68@\$ZG56,4^X9%FD/NJIKMQ0?U65<|K7 MQ0J2T##3T_3^69H?|5=7H/\
|15W= =T.VY.YY\$*@:26CN,S!P0SKNH^J&6\$0 M9@1^B4TBX000!0:(IZK|M&0.@C2IE^|2\$A131+YF^=:(1):%G
0;R@0+ H5MIL\|V@_1|5EGT= MN/P\XFBSI^&MG2_UY9,&9\$T| D2VWJS^4E?&
M.4%;/3?)\$4Y%F%WDCX>'//E4L0Z?6/X1U@L|\?0^ZB#0B^FK CQ;:N=CI"\T M\$NF0\$TI(\)G014I|D*7B1^?
QLVR->2SKIKSL" B3_P:|P<,(#'%\29>?HTH MD7ZD_-]
|G#8Y^9I|0CE!!X=.UGLJMWV<#"BX(JGF"EABLT\$|<,5FX>:6Q#X M6|9LN'_2N@2_U\574
H#RC|>YI_A9=60B1R1K0G|@:|:EF7-CF'| \0^BXV03 ML+ 0\$W<7U%R2M UI JZI"!|B?KK^92
MU.ULPC|U|26.|8><:;KNC+IL8!50+:Y0VE5"/'_1=5@#HR:T+|\^;8('0:46#6
MWDD'Z%*:Z86ZC9V|7^HC.+4N350*0C)*RRCC^UO| |6>=(6\$S 1E:+-E'% M4,-8:0I* H&Y1%N/?
LXLFW7R.A"MR%:E0D#==3W5SD79T=#?'T@|H"\$|9CAK M(|,PK!PECU;F#E??
+A%KMNVO#QXDW8V>.@_DEK#0H@U<)|ST?|4WWPFIM^FS8 M^ SL/T<=.N/4JX-AJ<*: 'RS:NWQW0'\$K0GG+=6M;|
=L^64C8^4G*2XT:\$GQ ML|T| |&0QT|*|G|I00TB_YB6/HB(5!CE"&U|YDG%NDI2IWR\ Q.-DYK |A;Y& M
)|E&36:3&@|@1KL/QDQHU|\DPP-C59*0!"2&KSW"/(|M|].GTXX^P+^>6|'Y MW,H3JYR;98< 5>FM|=
(-='/:VHR#7GZ =<27\FE,'2>3@>ZR7X46M*?92 0 MF),EK69\(|:BB^BT.W.L|,>Q3+47/ZW\$6EY;MC1*Q^&
ZU@MY1#A\|LY5UEP MYE0:V|1RG&MPMF>URTBMHY;R\$=-YK ME=XU&\$0-
KJF|+JA|E_|'P?:4.;BG0\$, @^Q|0M0F^=E=0007A;4&|0?N9PTB(|'
#%!_0+QX_F|T03>A^W*,>WRK^LN8N;YV|(|C)AM)>>>B#FHJ?XXZSW/P*?Y;G&3Z0#
M:ZTTVLQ+:IMBIW.J|\$PHR3|1K?J2Z63"\ @SC@|YZA(%W>07DT+B,@/(3Y(M^5V| |0LZ"R0 7*:0K9@'|L!2
|+ZMU|DWZ:XFJVB. \|^175#R_+"H?=C9=T# M JK|D;:H@Q62^G+15MJ/C^R^AV;?DZB)V#&|\VYM?
+PP0E9D.#M+VQ!|T4"TF4P_D"YH0PC" I^|KK^3ALV(|L
M&KZ&WNV5@)2N|=\$)U2NK.JYS^NADM"00Q=,+ #^6@E=|U|%_|LDW;NXSZA: 4X+=
M=N70)F77NW*46;:NFIH4U5YE7%45X|C6SE1*4F0=#Z%05/+|8&7@:05 Q|V^ M;FGIVGKNH-
50#; .K"Z6/2+>E01=DC;*D6ICB/|+|YX\$-YZR6GMRU|UG/- #P4(|(H>Z^-WH,J0PN\$)E;^IL#I?
Y1V/EY0A(EVL=1W?^80|CWS*MM;6. M|&@:QGQELC"4Y)R*2*@78:BQ.5"OHG_X0UY^83CAR,1S0%+"HE| |V15E
MEZSI65ZC'),8M<|B#?_V%3EUM2T>N|_|B+>MG9U,?:R,4N.JT:V>?887:1=T
MV+28':NN2/_YJU+6QG285//HC|/UH\|ZF|H^&XSKG^L?.2+T;H@ #1>0&K. M" T.R:/TL?
|(|YFXE4|;:TBV7N@90ZCR?KJ-7N D
MMWR5W'GBVMMY,TXSAC_M=.@|0D\H2V_YR5_>|5;T"H;0ZW99\$+\$EM%41S'>L MFT)IVJ9%4++>4B/|S
0T(A5&ASXK^ESJ/FVF4AD1&IJT8Y(1G"4%!&KPSIF MX=S2XJX0;W9/H?&E|Q">40\09)#=#AQN\0?
1;|W:|+>BP8 M.E'GLR R4.WS/K>ZX3\$|Q086.WG>KWW_J-^7SYX50)+@0U?|0 =8 .09;C9 MEG>1(>2A;U+-
U".(^ZVP|EK%@."|!;:%@YL UXL@P+^L\$^0/IF@(|\QZ;P0G MQ^|'|'#FF|= - MBC.JA;2TZ'-%?
>D1I_LS" U+7LP%DP0|1A7UGLPH|50#(|\WX": -90W=C T"U MHD7|VCZX?0\P5\L>7-
|4&Q64=.=AYGU">M\$0,JZ(ERX 3!'Y4@+ 8^&N #!_ MY :M3/QZU37#N2K|5/=5;
WL""N=0^=0'KK!.V@""YRXK8\>D6!T6V78LAXL++G^1K24AER+H @-F(|(R;15,GRV7>"#.-XF,@_V0*0
M@F|DU9UDS10U)?C@TS/87\$0%5R*V0082R=&:D^F(2/|V^|P8)*6U(|44|0-. MKYJ(5JOPRC--V.TZIH1
MX/5A<=0F+B+|R^U3L|U=1 /KWQHJJI=DP*4EG#*J^S<70^L/%J&-7*>- 73' MG7BV^RUQ^"|C>4|M0NZ7%Q>
(-=U;|UK1;*XPD:YK## J,U^-;-P\$G(53;:IWC+FB=ZVBI7W MJ-B;M\C?
UYM5%6|C\$.V:LNM#@B*0GS"YTISS9@%G|,QVT.Z07;^T9& |I|>I"MU+.DM8?W0F*2S3M;&*',|GIW|\$/
M1*46H?+(+339>GNG0J(0;??J+P_85.J>,>P>;DAH5(I6.&I5:0)TEK" I< C M><3L\;<#L%UH;U", "
EUGDB+9|R7M1BJE8\$!0_U0,IP,JJIUU_0)-/ MN(|Q: ^C;ENR@7T\$V,IQ\M(OC_VF'3MC|16';E8QN?
U'%1/>^&J!-P;_G/EHRW4TAA?K%|+R_#/TRJ'DBKX*K>\YH@ M2,ZE=HW"QN;997I_>,6?0-(DM-
AGF6;87S|U"6?|<+U;YS%/ \(<+4<1>VCK M37) _N8:Z2014 /23|64HVJ#M\$26B8XN9M/#3BRC%;MS'
6!FF"M-00&5J3 MX+.NGYPT5|Z+04^J-3:MAOU(E\$ "%A(GK54/Q1P>,50J5@ &,*DE>AZ_1A&TCA M?
%56W(>;V-4XFU'S |MJGVHIFBD_C\$^@6G* Q6V,@7>H3@&@/'6S("1BL4%J MPWCV"?_HS=254L,
|52Z)\$!8Y:1=!02D8,286 =S2)U=0P\$0@ K,19YB/;/0T M)9.|77FYV;<|I1K&T -C'7#9MA-
OU\YMQ1U4*#ITT.X0:G!8/GT"*L2|1W0(MQL4?*^YE0QH2P,^_2|R>>BJ^F1"5JR|\$065E^*;0)7BJM^2+G
F0FV_.J:TX M,@6_80=FCC SS/II->H*YX GB"Y0;|2,GB&<737+RKC M\$X|Y16)BG=
(|%9BT|;:"Q%"2K.P);R(^%|!\$0@!Z7V*CG|XZ!)&%QM%-&8HK
M*@XN<6MP86("G)SA0:N5H!:=,K&4FD^,L&LNQ0^0R,KVJNM|&+W1?B7=YRWW,
M#DKD\6J0|]'A&.E?'JY#U;2%0KX>7V6KQ M5:PMZ-'WN!GM(%AEWHGFAE6^JC\$17GP@&M,QCQO/MX%EE+:|0>I
M>W W!73\HFR\$ M2D5EY(T4=;)0I/D!VB,HN.|CRV|=8C|5=2\$;:JM%'AH&#|'"1CU"*N_N^HPDG.7TBI M-
LSH&U0|5Y^F&>^\$1IFG%HDZ+6"%.@IG)P_)\LS@>;*:=YJ' "&8X0T|(|< MYZH.@\$'9EM|>Z- IZ+_V%U2+?6
ML^|(|WB!WX'3!-;'HMX0&S M\9BKJ R^X0<4\$F572=GX'5_OU#.\$SX\$P3 "(A(WG\$X\$SC^W45L;)*0RK6
M8T|JJWW7VY|: &YV?"Z1B&F|P?AW!NJYFM4Z" I=IC%A8 &7=I2K.= \$P9>7M MJC^1="G\$!/(G%FX5@:-
>-7XW7AWJ(M<2%60"#D|]KLM|M|DU*&1MOWHJ+6JW+:0 T+>AP|140:"P"N
MAJW\A*&|;:0G|!#XW"0U!BU=&@?'|@)_N="/_-2K?L>' :/.,AE&TE#YZ? M^V4#
|5Q&ASH' " %W.:A.X;P|8 +^45N:/(|U!IH;:8JI.+Q&+Y\$L<^N\ M)ZSVS|2VP09S|TV
)/XTQW4/#ZNC.EI8+?<1V%E,.\K5&3=2\)|SW!J(R00|9 M36@2?>8Q(8(FQT5\$?V|S|RUB|6DB\9D(20?
9:>^0I;BM^ G|PBLV^R Y>@/Y M"*MZ>0W6&.<&*W32>#VBS&H;PJIQ&,0,Q^J0I1,UKUU|TSSJ|\$/KN#=-
@6\@Q/LDNS;GL,S"2 MM\$\' 'BT0V05F0!LE\$=0L@^QD"9!AFQV2|1?K%_96QS8TA%/0|?;0H60WV#S
M|>/_Y"42|@30(QN0=/_+,Z\$.L%=\NS;WIIY+W-V?J4_BNJ/#'.X');0|YS:5V MBJ|R,EM?

LS0QI7:10H/9KE*596#0:;N4LH&+!%5;*65 "9V;TVYP_W1[1AF6XXGX!T80)D,+@,C?CLZ(L)U*?\\^-
+,%EFJG8IE+? M=A-;\\0NBR?JL4RS\$G?I3? G{T;UU1XB+ @'^W(#,N:AEC@:[F&VTR9+5I?A# M=8Z*(I
<8@\\YALPQPJG/+/ZP5.8YNDJX[\\=%W6&/TZ;H,Z8HI^G+% ,B M46H=48%10?QOW=/)0E_3[\\(P<;8
11M6;I).0[>DN3VIU9EH+XXB0FHA_L,[M\$D[?\\B8SUF_"0E_\\[R(1IM;)@_HTV2Q2_S>3G02WT9?TE68<@19/?
T,I^:DS-FVP#DI)G\\,@CRYMKW7VVP#:.<5613 M\$U@E15'DV
OYR_UK>:2=PS_.\$%CXNKZ^6K%;,OW1+M_G'"XPW#P_E2RZ2 ' M66PI=#-
//)WE<&7I9\$P15A)YCC:U8NI3/46S.G'A0F*T(N+8Y.UD0B65@T^6 MK13TXDM"HZ#C.< #
L#\$=GGIN0Y5IQVD)2 M/7JZ[.0S0HH>+ T'>+1NCA? MG,#;6(-&.6 GY4&4\$%
16DJ55'UL0QF[DE'"0.QKX00/IAC_5 RW=+>;'U MAEJ+I(W#FWQSDA,F?[,4#0:/80GE_RR%MP07[^*S\$E)=
M><>Q?Z.(Y1OU34@+.UA8^/VIX^0!+6EL6\\Z\$5'R9PV)Z?BEV-3WZUXJ+.S2V MF#[0KYV\\>(^= *#
<)0E@V3)FIW8;C5WKNL\\HT*F0;1J&IF5S/02 / T\$ /1F MN^GJ1CWU>*Z)NW\$-80]*C%N1B-KN(FZ<^6ZM8?
ML1VF@F_Z'*J?T#"I4 ^Y2.!0D:[?FNFAY[NRW^!ZJ=TOSS" LZSATR'2B-89K MP_E\$N@ZLH?(3YN,-G#?
X\$>V!U<>\\M*I5:>^1CB(\\1B/&.A7:01U&S+H/*\$Z=A>BS1 M<:MHL+;X*FG=, ^#0?<*:VI1VWVCJ*B
D2XU"B@JS4)1"(F-M)B*6J2@ (F8K20LA\$*4%"8J,+9B"B! 5\$!\$0Z2TD4B,"1GHG)*\$H\$)(AH%I M* /;>U1
['^R#15 7M:Y0'4;BW/UB% M&\$2S24P*IXROA(MP(V_0LW2BAB_43\\N% (07AHKHP4"\\I. MB "?=F75CQ[
MW11 >N09*ZU)'[0_0L,@; "7,IU+(XKJWHU\$W+ ^/*1" K)/.(?0A)A>&^H2+>3AD&8T1&"/>WU-8_KTA[#J
M1LAFX37 C>?!1061#L4GT+=71A+5 7CK0:@"!+>-D&E 1CIGK,/"[8Z&<<; M^(E=, 7*
(Q"105P:E3"J07)+,&^T:D^LI3"N_KPP:1^*F_K- &BXJ23;>KC^ M1" : ,3 ID12@/" T=7II^?["4-
/B[^NV^^^PSH+6#"0-45/NHK7P* @>S[AD-G\\ F?)R+ MP[!.\\DJ&JN8V7'00'DG6-R;L:6WOK>\$ M?
5S7=@E("ML^D,^\\?N\$;R6> M[-\\M6@4G#JID20..>RTIW9E^LQ=,2*1 39+9[MP3S/1CW\$6(\\(0P#0QLL2D
M(*74+T#.&:1R)=7 3T7X ZI> Y/BJ^H50=3/7M:B?+@? *F75CVW1!%Y,Z;H
M<_WL_\\T009BP4_&130+MY>F76B&/[#_K^DA :[!;'RF.N^\\2T :FZ)58\\6>. M/0_V^8.G0/(3!
[AT2H!@KDO.#ED:/++1?,WI(*&0)>Z M1_WU5WS;B=QS<'6[\$@A@!_7(1_)1
M++;5@&I(7Y9*J)GBTFE[\\WBX\$+^/L[37'_0/J4+^\\U?)!RKK@7BFCNG/309^VYJ^U60JSD'[\\/[FW>
<_@_/I1\$LR2.V_6_WH\$/D^YDK?)Z\$ M6S/\$VN)!HAI41AJ\$F01Y!"/&AY>1QC?-1+
[32C736R&1R"5T#1N_D(1D%Q!1 MEZ[V0\$^ML_12^/J3:"/4 +)+Q+U>ZKR/T2S.\$\\V:EN[#]?J?D%&W/!Z*K
1P-K.-[R97I# M61=1[RQ?(*3ER+IDM52BUD8D(+0];_ZH6NU):A:YTIPYFX4(41UY/Q"T0LW9
M00)"N6EV##<<>X5<1DDBH3 M(A_@== = ?S=N+=/^' /+?3/@03JB#FAZK\\<3;H:G7Z ?NA%;@U_";D(=FB M
JA#?*\\)7&-XH[YIM1VIU1IC@Z+{10<&QK?>V MJ+U^>9;6NN/=
T01S7I4U4T91%J3B(I1!,E(U58"QP*C_FJA)&@_ZLC_V: MOBWH=L3D ?U?
I_1Y\$210>G,:WU1^7[R78_/2^0J!.N?+[I#RE4:+X 86RJN) M\$>R.H\\8H#^Q(&0+C3)BK2QF.WQZD"2=>FEX
MX6.\$_T6/2+0;+X<[1P)&(XD; H@R8@0<*E_51WP5HN!;DD\$FTI KM^+^9VA MP;P/";Z6T&([>VB6_N?
\$";)L6F"0C3MTGDS5CP\\CQVV(B8\\1\$3-NZ M7'P.8TG3U-^M>RZEE0%;TA_K;31-R#AN^?*^R.'6(+)
%1J;Y8E\$N(>)\\% M[#X(+ 8MAJ;!A3_5E3I5&XG?'L%M1V1,?U5(Z2CK :^%Z05B1_ 7X^@A>AU"
M2*"KAD0290%X2T54P0ENVUJF-CF@\\^JUF,,I<@<5@D<3GB&YH<(1#C_VKUG MH'%U/*Z0Y0(L0>IJBKAC6&-
>+W)2@VM20,!IF^31Y9S00Z9D^;Y" 0'^#59) M'&/06WMI':B&-810JX\\\$=8LXCLZZ'K. MDU.R&&8X6(>2GG-
B;"6?47LVK01[(0^Z:N.A:>S"I?-V)D"&V",ZK6?61I MBU86\$9B&,?B>C#7Q'S6'-
' ;03*;Q:H%'7,A6NS+WAGHO'[3246DRG(?D94U+=Z'BB\$0Y+ YHV=?M7)!
MV,0:M(*/[Q/K#PLM^M29Z:7(#YAFU,JX171E\\IV8=ZE0[4,4HYK12@&UMA M3XKS[E_JN6X5?
L^QR\$C*4XZ0_S?LM;G1U.W1I27: 2B5G+=E^%LE &)+): M@&L_U.^C70>V2;'A#33%M_00HLPM*^&*QBI3S
MBN_8*X7[<7G7394U+@X49Z&[A(L24&PDUD\$">ET331.1I*FI';GH.L)A319P
M2QF6L0S4+61DDGTG[4B'=T/'K94.0ZWGKL+*)=FS0[8?+.0+,G02)_LWXY.%
M;:X60=^W0'595JA2T43>S10Z7+*QLP4'Z2?9%9YF(B/?5?4&YLQ?W^E30^5\$ MG-9#BZ4KZK:HW&W(7?
P[XCGA&,BXNI8H^\$4HJ7;6MP;J26 [/?K+&L.100 MM^6(A1WN<>6R3=XJN.^:J,D2KAE3-
NFO^T0T5JLA98'TL./U.&3R<[;INT MGAJ8;K(7.(NY50?S1-'[I:'GG] MG/WDP)EH;3/9F\\
(/L8L5WN^Q9D^X!)0U%9_/I1!E^97E%/AR??TZ^=3;K@f M!.,-4MN6<=Q-
!_'A#34E4;G7=/=QES*9I0H!HSN*_ \$PK&R11\\] JNG7N^N;V
MJ53#SI6[F=I7)P>#HT&W'T;6FB\$RV/N\\@:DF#Y6C==^E@19KGNG P8 MY.<<>+3'_@\\< ?#2_/F6EUEZP1
[Z%_M;X1]NDIL12_=\$N0 M@/S0VM>!Z119[42&"+;3^/#?P0:UCBGBX!7#M)7UBTOAB-3ZXV\\B&Y_VWZY7
MQC>'\\MQH7AQG/ 0%?P*FH+30N#_G0_+7%5M*73I0Z1F+5M)NE= MC#B"5%G+JA06)I"C+[#&75D8V^Q"
[*=N"X=-5\\L^,15"R10.I4\\; M;2X>)1^L_+1].@M\\/_R:.?0X,850:09\\0EG.\$Y7MKHO=TRXLOVW/C%]*J8
M?SRH4,^%Y0S6V(7%)1!.36Q('FSW<[OM7PY5R())^7WLY+ZII#*[R"J5;"=/_ MB_P\$?
0!0^R#WF5A9P);EAK>\$D55YI9]+53\$+-_HVCDE 0<;=XZVE,GC;C]K M^20M2YU^%UTL
75I9.6*TG%;L2Z[C/8&6C)%HR_%161 M3'C2LBDLD>0890(MVH>NSZ\\XJ0YE;5E__G/\\K-8 >\$HKC4QT
_6YDI<54I0 M/7_EJJ,+8VT>\$H ^J\$S(I5XGV@L4J;GGBP_5^0I,C3%1P1@+=/5\\KH:S1X M5&W1TQ"K<; M+
(;:Y8T&N^%9;%S*CI_/MQP*J1AV*\\=0BY5JA2_!7LQRO\$2T*-BT\$4" MJD6+LTV,8D7\$JDX):+B&I4-
E\\N=Z4UXU-59;MOK6@VS2A. MF.F[8G!\$5A[\\[; '8HTWE!.0:1LPDQ.+VX9M/2T!;1TM\$Q5AX\\3B_OP@fDQ*A
M_BSB%8H- M=3/#-'DGF8Y1K5K?=BJWW[^J2Q0XX/I@EMPXK\$-/ M-'R>ZR=#B:OP3(\\#111<_V
W+DK<)P%!H+X19P;Q,T)=N'L@1)7KE@3USKV^ MEQA7;*K?(1Y,X':@=;H2V(+HG"&E=23)XM.(<>'^PX\$N+1K'
*\$W9#_Z%B M2M8Q;R.H1X2K36H)5\$5MA%@4VSM!?'^J'NR3_/4[;VYYTAU2?J>W1H>0+PN M(M2\$8%\$IUN6#;(\\
[UT+7P20RT\$]-21ZJC-Y0R)-14HVWZ\\M!;1@92K(/80\\! M=KF_9_ RIS?:2D13'QMY11UFA:[P-@C8'Z?
57_)+4(32&W)H4+ H^NXUX4M: M%SU3AY;5F6?RN\$6D& YVKWGD<3-.\$#8C[4N"@9G^XKFZYMN\\M+;K0="\\
(UTC=#>6\\ M80>J">^*5VBV#BGX1\$6)LC@=!!JNO?YB[-0\\^ET:"YT L_U0RK0 M8_K.18;\\1
[G.0Y21^2^N5^H;#IG>J*YYEWE+&\\@HXEMAI":C(9)DS3\$:Q.K4H M"<0M^0H1\\>^Q;.
<;:TN#,HA.E&J]=G0_,-6QJ]_W;-.-.8D5_JMP6N_!\$0_M
<9*0+%/<=\\0W#0)Z\$]\\;*,LGR_\\TDV>R(T)TI870"LR1^RCM]"22DF[CX/"WY5LVF-;#GPC?;?
EF'/7HD,;)-10TYJOZU_}N06*N).%+5N<_%D2-M\$^:0&%7>7

M? !S71Y?'^ 3EUK0B%*UBX=5VU&'XJR!3E@FGB?3FB[6>7PI:W'0XW5J1-!V>;)>M,97,RUB M4-
0*3E_3UT)**,:E&5'MRX9PPU0ALJN-5P5B1IUG@8,64*(0W994J?;7F_> MB0V)M(BNE!@0;%ZM!8?Y%=0/F(V?
ESY@([CS Z(!)AFW&ZAB.!,4.AAE*\$;6 M+DZ5*]B3\$[&I[,3[DI6ZB/A9]7&%U0E013-GIB#V6-C
FX(3W!4'Q! !,PSF> M;; 'V#1.R=WU-5W+*G?8B!Y]IK/F_L?%(\$!ZHRG)=0K2#GY,UPDB76<2HM?J
MSY>|I]E6D>LBD'_R,U;^)^HBTQ^/UG;(WWE&D&RU_*5K;Y6;'RVV'67/AT2@+ M, AK''U>L*BQ5FD29''8(4C#J>4
TYP@[RJ=-Q&7].KV>*-4&K'^:P-YDE5DTP MU0&A78FG*,VQ9W&;TEBW[.6JM_9B5!V9&Y;6KNKZM2D*C
C.+F@NZ]GT8(R M0A K3JA#I=P?EUDB;S6%@^1'C@=CU<.R=K)&3X>]/P'0,I7^)+>CA HAY:*
M]'(>6+M&2UL2>I27^/FWVU.LU@<)' F@+ZW@NL/Y\$7M6A'6Z5NL&5_X*I^Z> MB6CZ@%'<4\$KWLM+I X-/!7R
MC8#SR&[*5+Y[VQH5!6BZZ.Z.[CJ34!@R2ASV]B7?JQ=1/BFNWOT0X[DEQ27 MZX-3K[W\NW0''NQ/<7V_T&I
&85@!//HSE'!1 PZ/(?I3835\F6 M:9L\$)2][PG2LP[KC/9G M<#;:-JU0#*.'!G\$FI29?MYE\6]WBT)7R-FX-
[-,OXVP;AA8']RM-I*B)C3'E MS400R8:1W@-5\$S;-+@4:J+Q)NX+N00T' *M0E;1)T*6[VR6@>0)EESEXA>03
M*A,C BW11'S%\$LP]Y^K!USQ'XB\MCGO OAE;[799@I/Q5(&J(&6<]ZUCH; \3 M0+\EH#\ VE2W%L,1R(ADRGG-
^-]VHKOR/&\%!'!Y5QP0.SJ<\0>/3?19N[73
ME'4#W'P!C7E/4=HX*GYD'6YL,LHB">F>,ZNE8!\$80'PARAEW7?)T:W3U7C& MDU_\$&
@_E\W'3M8,@@\$V%I.2X!&6B=W(L9 #6VL!@W'?\$!JP5#]E"EZ]"* */.*VG
MZ']P!Y+&^_SYS_RYCC&#D>ETE53XRU0)2,XPW=8%)5HAW7B.?/[ARS<3F[
MN7/2CZTJ-_.#.#Y9FN[Y%>7,_%BW]TG-6AP^0B> WMIIIMF^/;M]* *\$^7<;DU8 M:AAPNJ)\R-5-
]CY",8=%_UYIU -EK?,=YTCZ'5(9R ML<\1?X0'=RT9A''M!)D\MQ?/18;Z3SW^?/J'M*0T^";H:0-M4E%\$[3&\$
7R6T M*HR@^#0(H, 6Q3<(6L+4@[4VK&=W25-#*,0.7#0,HA^F@V\R'R2YY?
IJ@.^;X]!%+V'!:\$%I>JXX;IE>H/Q\$+6L;XL:+\$U8B47^IJ60@^P+B^ 93%,K#N''#!0GCI0;,%\^N]/^ MDT,Z?
=90S-0UE" 6I9^L!5"0VZ\$, S MR@?U2ZTVAR6X]70YV(1A3J]Y6(P-ODK,ONIS9#!7FSQ&ESL5TJCR>.&(949
MR630F/"07I@.L T'^1GF>J (/]P]NZ, ZEI)GA'^GI_#\$ILE&A^[A%HB7^;9 M7L9_=Z]IJ2.&>F@S5'=+
M3>9T09JN?;I@ND0Z/>6LL5?B0JGUB[4U#14U]>50? 8/RW??'H3^<;=K=,R
M+^BWR\@[=HPHUFNN40E@JEG"\$%W]0T[?
Q3UG1\$&8*IKJ0H.7:A1&52M\\\$U]!\$;0+/]=\$@T_AF>+]N"2=?".070JP-NWLL]S30(;&G; M,F\#+ D[,<7L
F>%!X;IU3QI'J#&#(*0_W@,(;|=;(LPL#?4T_DS6;^:IYN5 M'W#)7WG"(W8YJ1_F\44_96BM,%Z_-
;YNUZ'1@1]7EB'-M%'0'MP&P%]P\$EAH M@T.Z20D
MN+&6J94%AVU5@E=TU]N(D=UU(T,BQ/A8[%_@PH4XGJRTW14PE]MS5+E!145: M''5,!9LXS">?*8_*&[/?
6RMB[FL=CH7;F+V=)?\%0.%%G.Y^PA,<%PU'4R2 M\9W24> JW\NM+BRD&<90R98GDB,HT>[#?
P&G;A/!2K1HI5]0X4\F?9!Q,Y M3G4>)K;5WQJ7=ILXDVE[=E(K>:^B2VZ3P2V7 !BAH\UWV5&+E9I6SECC%+P9
MH7(#''&E^IH0H() V 4/K[T M''K-%#H,STLDPBQ7;WGG54RUGC>1487(2WU,@WEU?XTC3@9+T [EKE3/+&S
MH^J*^@Q()Z,%G8!3!9H8#7A%P+#5VC?> /IG'+*,V'7HRR6KY6E7B09# Y>> MCJH^;M/A]!>&WA93-D'^-
OX+?->BRSZA AH>C[U<2+VY)9N1;7J,0SI==,XV M1N\YZUQ#V1'RFCQ^\$#6Y]%(L&BIPQN)%1+>6G/VBUU#(U "
*@RL&:@RVQCU M\$4F1I^VCF3KWAX=@UM*T(C:3]EAJ)2N#?Q&U>6A-LJH(5.MD/<6\02Q46B3 M-
R\^V,/P=&B5+0W\$-[4\$^0Y6NBW7@VB([('].[&BP^A-<+P\$U^DE3C2]U*@- M9PI\$,R%/ AE1-B@&)6%TTZ4
"&]_PM7>JB3SSG*;,2=(\+9,?7L'5!-E=.76 M\$YF?!\XFV"!0%090JLW;"PZMT59+_S!42-
XHU@=*3UG8%"6)]CXXM!#0322_W M= \R&6;3Y(80PII:+Y:X3Y=1;>R\LG0!-/]:2).5CQ\$WC> L\#<8W"227;
< MFG9U+Y,\$[D]K0C/*RZ.LH!NI3M1#4(^E>9 /- 'Y 97G1'KKQ9]QRTOP+Z74JE:Y
TN)3KW'=93)JB^T_WV/A?^RN3 M=&E*3B:BL>P'@7:WE=-28IXQ=I(B7P2=^VV''0<>S8?[3\1LQ",80H)1!B]'5
MXYE6\=R<>DTDH/+ H"6V,0>>-33RV8Z).,V,=1^-RZR1PP1_LES&6(? MYX\$9#DD[GBDD9_DR(=MN7+ONI%
(SBB2EC#M9^CRW:K%Z#A:6^ZY/7/9?/V\$K M3E@_ A_EL^R&8%" VDH9H7#SR=J3#F\])GY6*SD5TN>;=CL7X7,"
<4L1T.== M^PES]I-! 6\$PNT(QW>LXU_8-KS01>I)K-HQKUHQ7PYBU3!X'\$G=Y)L%/ M5@0DET4?
4#R'B00Z0G@H+VJY,:IV]8.0 ^1SWT'&UE@0JH>'35\$1"0RY7AXG M_1W4[\$W:
(I[!+ "K/\:XG4&*!)1+NN01AH2G)W/D'SYFA[P&]V00[PDM_B0Z_M6[Y,?
QZ.CBSP.JW37351W'RM(+X=F\$X:XN3*#-66IJP21R^WTU7@4T04[S1C M+6XUFM=.->'UV]%=
[@T_J\ K^FN''HN#=1S\ [C64R3'U^>BLH%6=>YE\;E,Y> M;WX4]UU^\$<;W"7>\$^S=L6QE:[@=.L[&V:C#
(9]E\$ "7C\D3YF'V.PXL[(33] M:3=!\09^DBJ007@?D('XKDS#%@'\Z:0.=T>(103_UE/<2&% LU1;G@)[##"
#>(I;AJ69WKST67M3N M07[KV08(?0A;WQ'E3<10Q!!'P5]U\$=CW#VSO,>?:T5NPV+[4'7:[]Z];ZZ?
SJ=!6T=0]K/6+V'TA0H ?E%C(E\UJ[\$7]5MR"9.@_@) M*^@DHHYPF\ 6**UPG=:/&2PU9C+-EM-7WZ-
?/6MYP0#\M33ENGDI\)\$)*_21 MQRQJ(DX?
2= \IW,PS.M&WBH\C;VZLJ1E(CC7+RD>TW\$UU\K27XUML40CQY2\B]9=P<;I-K6C
M\2N6&"^%&5\$M@14:=CFND\$[84F6XX8W1;IXM.685 R5%"#BW(,RPP/(LG&.
MA+TLVI'3SJI@YW*=A<;W\$PW=R30I3ECW06D];#B:3@7"?5S28_,2M;_ [N]OK M6
N=\?;Y1H0Z \UI%>W/5L.)0;-I,YZ%C9]M?]'Q6/<&(+C&VY+E MS]'*5.G'UY!X>\NB>3,=BBZ3/A+0HIC#5'*
MM?+..!29L0]\^RMI2B/SWT7E/4'/?]+#^89.NV0WM*9H;"HDZV0)GIX=E&V* MBF0Y1,.[
(TM\V],1\J'X6&MTIWE64C.5<"!-4>%;+1]Y(%;0+P+5[R#36\+K>T'[-7'J&#]!'&1&8Z
M;%004N_53>/VB)GB-0Z\Z_V&70.J0'KL/PW'JV :MLK!'\.D#9?)@Q!'@N M13E3*
[PL!L2YVR0@Q^5+W=^!]TF\$#D;M<*-4^Z#%VUX1>V4RG^_ 2L0GN!U M5T?
[AA=/3D3#%)V(P;SU<"1^\$4UETI4B4KIP5XUJ?'E! *AN&_Z/?HL8!..(_U
M&;];J5\DA/'",IF1UX[5>F"IH>A,'?V5UU'E=I3.C*! ?GL/C%!/L'&_L%_2 M1!\S.P',3LKP9-M*M]_
!+DJ)*+EAZE1'S#W.9%?]B9LMD.;]'6Y'B)/!1E> M#44<- /Q%B(%7.GR61D\ RDZ8
6!V07<)>M5I+XJ@'I/_ ^ (WVMW0AC@)FN''BVP?4A=IE?A^T&(SZXT68MLN!^IY5N-JX MYQ@F\5K?
=] ^NY#,3*.70E1F-0_\$IXG+;DW_.A15G4) M;TR\K8(7,-4C04\$T97N^] ^Q2 M5 -]".Y'&-LA:(\$K?
R1K''^#8AT,0G54^(\(\$?;;M<+ MLE-/ZCL2Z^--!5V]QGH!^+<2_Y/+@)JF>R,F
M_(:I1\$ZUG^93M''&IKU%%KC1B?M]_AD^'/RK7@JOLG!0L'9@4MKDA/)G47L M7_B3PE[E]<- 02F4^9:S
<>EIF!@I+.,\$5T0(ZK8\@+6^)'9^N%[V!'17J ^RI M*%D6.) :DA9J'';.[:=H +P09JSGS<7#SL F%CSU;R*
(^JZ!594;I?'6]EN.1L2FWFS+V\2+XY6^C!%1\$.ZE#].YS _^\$4H2\$#5C%\$NPZAJI M\$/EV5/QS

EP=P1QL8@7VP: 'D*R8>(UYTV<)Z,D^U/WEL::5G_Q+=A;+ 'F.
MIM\X3XG>FK5(PH\ZX_DWR,YANA0CF]&MPJ#0@_MGFZ\RV+! 'P\JNWLIWR#FE6\\$_ML+[\IJ+UNU+T75,M?
VQ*K&NPD@-\$\J"+4M+U*N\3\^G+MR0@_M9?R2EM0MG<\NXT<[\&\!.X&\$#*(TQ):[\(:;)>E:#4_IBTE\77M+3?
#EAB8S_MU_.P>:[JWG-00JTAMD5R^/7)D9.P\$^+|\V\7D3S6\$UD=:[#(YC6F)_7W0\5_M'='WQ_+\$_
[U=7HG^H\6\$#V+5'VW1_+NW[R],Y=JA@CZ9.AR5\Q^0TASYA;4;X-J=?Z(AO.Q&NLU[C584VEC38D
MWHDR.*NI\V6%>T1F074&=?X9HY\5/QPP;=IX\Z%;_\$.#[NY8TN389I:_5XDI-97
+3G?,WNMBWLM;P:~*%U%&598/K,)>X:.Q8P6B\|E_D
M0*J:P*4Q"SX31ZC.7,^16)0960PE'!]F0@2.>X1W:5K>L1X83G
M/6M+HZL;UMHBELIX64UB'2"308\=36Y4*\$VJ_H),0T3*2D[\&W.9DCN'7@ELW_M#490CU
ZTWS8SUG\$,D[R.R\Z(=2#2Z'>;RSY6,>]CUXSQE&\$[\&R^X]\\$5XJI\$'YV\Y'CEK_MQU?
83G,^/(OCK\$7<=9GM_D0L07*=S2VE\X!\\$)]XFK%[\6:T+XF=)HY0P'\IJ7
MB04>P(H^FHG58F/P##\|EYJZ+\%&TH_ZT^X1\W4+_M_CE^WIP>H\N;TD0@0,#R.9^&H=X0&?[\L,7Y+V[-
=Z:7>DC@LJS8*&+L-\|T%.&T^,R&>FHKF[\\$U>@15!_M*?K)Q_H\$WY;M'\NX&<[\>0;PD'^V7@-
"EVH#N=V"H+6N2;R3_M\T>&)/\CC;PSBNVG12^9&.QG3D4_/F^05?2;\A;%;<'P0^46(1I8JV65@KW
M&WX,PBW%,WD24+_U&OZQ(JE,#,I, *_9>*[A4*:PS*PH6+.3@Z_;OLF\$52
M_H([\K@STLGUI\C<8AD17>G3MVWCM#F:~H_T])ZY*33>_DN5"5/HA_L7)2FW_MW?>-7R7&6)
(-8FAL:S5*P0TZ+9)V'"MW'*5MW*)[(WI.Z0\$YQ.96!E)JUX_A_M.IX,Q[_8E,=0Y^)\QS)8YQKN*\&
(Z_4:\$6PKP*&*U!!AL/^!\Q\TPUYN"7-\$\M2.#J+04\F[R]>?>2B<;T;%_Y#"NK\,M;WSXRT)I.=4#7)LAZ-
9/@_V\$P@M3_MFXB*P0NB3"QBBK;M!G0H(XP6NIF8I1T^3>"U,*/OJJ%_N&-KD*0&_M\>F\$E
S"/,P\IK_<0;^7\$M:13#I;F2?W!\|CUFSV\$*?3&XI7]>~^S&5&X=N^_MCSOD^0\$Z=0\$36EK5=\$Y@K&?
6)JD)_&0E5\$HR%"0X7MF/4GDE-A&J_P:#;L-0_M(UF@0V_MT)JK\Y-8\FEXW1+EPH_R*0*M+GWR[\5):C@?ME%ET-
YHA/I\$&0Z\$\$_M;)\@_Z0PL_-\$0_BN=0HU\G\JF,=)P^\$SU7<[\|Q\^&DWE_4G5GX0'^0(C24@_M_D2)K"X\/(#3
AR:(:,0):"88M+I(N2D:5VZ[\YM[Z2@0D6A9:HZTK_Y/F0K_MJ0ICC1/B\$^!W?J79@Y7N&K_MT\X\?MM\$GDM/05?
J_3?KUR<-&&(9<1\116:"",3L)4#[\A(&YQ"9G6TWF"*N_MUNHN4KD;A=K34?Y"')80\8C+14B^510^2G.P(")?
S**UT0KUJH@#"#7W0MX:#_M?A>>YEIV?N8V[\&@,*09#S0K\MB%4U;_B/V!\+VCB.151SLX1(Y\I,.-?-\$^ESVL
1,K2H>N()C2-;0\$/C^<<6^H_M'U\Y1\7)HCPB:6)U>E116U\$U4&Z"=Y0_VU0\$=:+X0=%DH)5S&L1Q-"VF"%
MK0/>0I4;%0#RL,8*Y9/VH=YK\T\U9JXU0FC2VF..?/C\+^#WBQ/GM1.IC2>_M<[\
(UJJ41AFFM8J51"EP7\3H=L&UN@&M9MAVX'G1<-N\$[\\$)#'\$LM_M?9#WX.&#+^R9=[@S\A*09=MLX3R^9B@9";#
(IFTG=@=UAU\>^T>U,2T%;,M\ZF+JIR4[\17;RMHC[\@Z&POX,'ZF"?\$U#&DY>/_L=_J,,T'B*W76D@S2Q,H8
M=-/+JXEW5'08-WB_9EIS+SVGCE<^ZAAA.=ZWH=7<AT5_M/<<9
G,7N1,UL4(\5ZS@ZSH84C>]\L@B0*C;I*IU129M[\&\$]\(6H=8HP,C/F\X_M9:0*A2=2_M&CF.Q*GX]>-
WQE#C6=ML_=@))[\J.*Z77B%.M%)R34CET,U,N\|\:LF=;H+JI!>9&Z6;
<=XH&>:M00QRPL_KLJH+)8(;_W'SA3D:7^/'-S*(MMJ8>_M8U62TKGUBR=>^&K?TQ@?%(S<%,PF@[\1"
(5\$@#G1.P1<]\N&B'\XMPQBT,@8%^_M&B*U_OI/=W-UW:#L'Z6R9/&DA"-^BKQW_M+5-
MW;*,%I'K)7U&!\J%8F2W>W>=34^,TJR8!P5.LK9UG3C%&A)7/3V-3X'25_M'[\]4R,9?I7*8&;
[8ZN'\$M#M*&=&0\JM*030T)JCWB>T"2U_/W(U60PBX00\M>^L:07.LHHLO_077\$EY&0\]#8,:D,8MHBD*;
9SN0\$<[\KH>]\N(OW\U*S\|=MSJ;JL,"H:10\QG4BN\QVM0%2_F@[\C941'9KMS6\5959U*D_N-?2:WV3BV3KG
MIT>=3!;A\$[9*9I;G_@F13Z4P3\[\JGY7"!0X"E+I*0(\^8&_S_B>U\U!8HRB&
M1R0RZBYRF_ZGVHS.W0*4&ZHC^H^U23+\$\$-\$.&.0M_Y@6%]\PB+=NU?S8;K09Y
M'LSH=I^4@!#2X&EJGGC=^(YRP,YNG_A-Z3\KCAB\>K)_AQ!;5S1Y3)2-=>)/
M\\$^)\B\$LDBSQ_/D*%K#WJ\|O=MTK?>7W7C#03'!-,6#MM/0FMU!
(UZ01&8"R]5\FJ()@_*CXEH[38.,\!\!,<10G+09FE_MVI&R#1,K[\?'^?>FJ# '@"0'*FX'/I\$YQ%3Y69\|@F_0:
6,\3N#6Y-->LLA#_MUU0+0&#=@I]*-]IGT0\LPTRDG7U1E/6B]>V1X?5:&US@5;,'.J5Q"V8H9@Z>82'
M>\$BZF(>LWP0S_,2[\3LYU09]=;TU-I@:?,!/[XSSJVWJ?PYKGE:J.&[1M6_'MPB:R'+S0
H'M@Z2Y\JR\$TZEKY((\^Q+/\0:C&8W;(P4_@GIM8A]?2SX6?0.(M8-^P[*6Q?>F(C\$*@4,"
69BJ:9,K.7H%L&+BM3'\?N^YEXND\UBD7VJ{#3A%
M0\$<%A*VC*=]"W"#IY4^5!CDXU^D7_"Z#D)PD*=9LFVTQ+%! [G90P]7:7%*
M/R2@X=^ZN<%;WJCO=VLZQ^]\SZW08#I^D[\]'_6,IN[\?_MT+=@FC#+_";>1_M&\$0>[\<=JM39IG_[GNES05-D.-
\$#A_Z#5[ZJ/\TOR':1I5WQ*_Q'F\|S&_MLT\|C*H_9/\H^0R)K2Q=-
=6_MIT[\:K<[\U6IXY>]\CP:\4\$U81HXBSE"&X+SRA_MWB?SSKW[_Z@.H\$C:~*<:0;20/5,PAN?VRZ\|=
(\VWC5>E:MUS@1PV*#XI;_M\=N\$Q^\LJX?P^JPFC[R#5PGH65_Z4@"AEAU(@0B\|0\|L_BC+
MHBY^H&^1@*9>B@V\RU.V^A=XN,IWWR(?W\Q?SZA0\EG3^=XJ0R\QI#MS.Y*
M.9/86!U42MK_&IR.#T3\$BFUBVR_*.',LM*=\$Z/E1>)\XL;:6^W?6H*?7M^6M_MC\$JU93-
AC>/W19>2\JCL[60Y4U4E]\ZXZXIHV8J0F4#9WH94N)\PPY7*?VFY=-M7<5B^W36\$BQTAJP>(;WAB3
M^KB4K([\IHY)W\8@)%,;!\Q;TK3\N=JMGX_">0792Y=V*:DG[V^*>F6_3.X/_M*28^(B0R?
E\$7,P37^9B(C0&3NCQTOBA'#='TNEL^S=EJU'Q5D1HX3_EY8!;'_M-GB*PF*KUKI5-G#I!#
(\$^"#@HT5/5X0P.P*&U'+)\@C5@XM&J=X'LEQCM*R<_MIFM=,I/TIX[_9>D[VW;?E6JV?
<&:RHX7'\$6F:\+RP_/\6EHEH%'K*K*5(_A_MB/K\!EZ!+T9TUV9)YSM&9/2S?K_,2I8[@)1=G.,5,#?
E0\$7\$+!;E"=:WQ_LH_M<.1900@ANA4?>)\CVBL"E[,,"%(*)D(PWYQ-V40/5A%J.%V@IIU8H5,0C\,5
MRE<#UXL\LW8^SN8\5%'A>4W6Q0:49F#J\].C(6P&4HUWL#LY\KR+VW\DVXMS?_M+S-%2*(K0_T%C@'\$C8A3
(2GU3()Z<\$9_E3_79W/1)D8SSSNL,5\1A/VG?&_MZWS4-G":88\W24"&DZ02<2@OW,"535@E_'0#"AER=
(7Y:IPQ3)EG4L/7:7N2_M0J_L<[\+M.\^0(GD\$/S:/?0(A\$D0SZM4ZB\$?>X5[\|C_KZZT/6[\&:5:+6VH^
MI3K>JEA#/W2M<&*XY(:(M.0KU-IX_P79+\1JNYH\$H3+0WA2\K03\|<)&G9/_M.!\9T10\?L"GQJ9TB_0=
[E7RL\F8/B-33##'AP_DE!_M8+_WYA!A6G7\DA_#*TAG:."18WPWS/168C.0>|R>HF-&J7I^-(N^CJ+WA'
MH190BC9)0>"Z*/.7_M@=>!\

K10QU7^ B+D00ZEE3?,S]@ M,D 1E;A!;(V)#"MFN\$J0,08&U^Q'T\WFRG8Y66KIF7#.3!W],:YA/= \[KZP M? 5+T]NPQI3\G M.P4RA90B /K=UL9(V?"^#0^=^; \$KFV092KHIR=:@<# [R1K MQ5UB? L/LU0&/S@*H*W@_0+8D6J"IO@?HK"ZC<="N!_B ;)#(_4\N=;"A! MJIFI1YL#.T5'W^(1J [%@G,7W&&YI6/7:JL?[%09I.AD:66\09MX3ZQZ7TK=83:;#S/#KF_&.Z0@)0R\$6=JDH\MW2761BU4 MS(VM;*Q:VZNR88ZH2=88P?H!EYFT30B3VJJARI^+FU0Y\$I" VG() \{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f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

(V0V^*_\$&KB,OB.*J< M=Y%N84;QZ#0YK#9G9FS 'SZW;F+!R(HQ!3/T>)\)\:2UDS@KF9A:0:Z5;OL(T
M1;X\U59]?:\$GA:Q__^',W:15>WC1RG9#)_Q)S935I1X1P8+2\$0AXADM,A^\" MH9(M(N_WR:'N:/-RQ{:(Y(KS?
FS0 -V:1TS;K08?YF}0!<KW>;LGUTSHG;I MJ8FEB[@C0&UZ\5?:ZE\"MQ >D9\$:/Z WXJN:4A-
PFF@=R[\$#K7B Z]F&K7M M=^OMC-4Z+,Q!Y\"J#TW2YSBJ1R:P#\"P8[VB?'UD_TLL=*P\$+?'D(57GZKI\"
MC^=4>I4?[\$E#(M/XKAB :--19\"406960Z4^A!B*3#800%9/5\"%8CFF3EZM&P; MH:1C1IQ\$,P-
6KM\$H\"8G4^L!|1S8*FG5\$ 6'4H0JCD8%*I,7 _[\@140\$!) 'KE M5!7N8AVP1\$^*T/:JU<;B!T(G,D[
+P:/F/SIJ0K(FP(*M/'^M9\610^8]OPK0<^;50@7%>? M',1I[+2L)Q:\LWRCY-
M;U=!A5C(7&R:%4V2U:OPBNLI02]1)T M\X+C\"ZT?C+.S:[\$&^0=\A0+X\"I'5JLF04 -\0^>'0Q^
MW'ZP1.3!;6J]?AIKX@X0#^LJ\$>&10:K7PFH=&D#M5=M#R#D40%FAF_9WWR2H MPIS'H4/SDF(\"
[B4<%EY2V3=X\6AUXY&Q43L#(>;AK>] ^I2Q>S2*M#];0(5 MVH3\YY<10T\"IJWA-2+F:?
PEXC,FX7B[(4\$V2VH;+4B,#C'. VUB=3\A\ EOD M&,EX],#C9F44D;SKB^D690@f= \"J2LM%\
MF.>UY8NEI\"*/'3<<,(X^^(6^A*3Y+!_G3%W2Q!#YR/^#?][C_I_Y3_]=%4 S_M%U!+ P04 \" GB6U95H48?BLD
P);P0 % '%N8W@M,C R-# Y,S! ? M9S4N:G!G[+P'5%1-ERAZ\$!!!\$%&03\$M. I(EMH)D
_4B065**BHJ4G)JFBN4-)\";H.\"HZ'/S X-#PR.C8^S> L+BT M0+*ZMK.[MW]P>(0\ /L')A0?
@X WC\W^4BP*4ZPP! 3X!\$4XN0#,>. 0* D)F MP; .7;FD1/7AZF47H^3E*N!RZHKE\"D'=V*#0S;)3V>/^PY?
81#H59>K2Z9MUFEU M0? I2\"+\$6G.;0#00PRJF\$0]1=RY\L/'NPI*2@YF*> JU\RM 8J M*?'6A7^A1-?
\\YYR(G024A\"X\F0S?\";PLW>JLCNK3^C5']B<9AE:).&=C'H%? M)HU\"#8PP+ #
(1\$ &=B+1F&!/\"9G&.P@9?;7C)^7(R2@]2=]3W[*4K. MP0+K2A ATZPORL MER*>+W^11;F!U,5YT30F_ ?
#17P\"A3A:4UF2)^{?7^-*G5=^/[M(\7JE/YW\T:=+ 'T2IC/9>R]Q9&!V 4 JV]BW&MG)^42)V,\"[Z15;./
MZX/6 3VA^V6\3-MK*>W!,198H XJ:0]JOF!9\$U2)]1%'RJ>]5,S)3]2#S,[J M0!&?Z+Z[QWU';JG=
(:AU):\$MAKXM=05YT'P'Z)5?J+_T5N) 10VJP[P[KEMS MFT\31.RHY.A3 .D2.-1HU/IQ7P_3/*@F]V QT,R:
(%&EGS/'/8]PUK!.05D; M5042[NY&5HJ0&W]'0[)*;A;T#F7(Y[N\2]4*] K\"S_]-E\$R%'+LI*T3PCH ME.-
,*XEX^L.#?48K\J>C^<\$DS26@-?6)3/TRWU>B#]+0/,)\" MH-8E-46A(&9-*F \$6>G_M#@-^HT;^0'_M5W M
:-='V6/\REW^B*U?@U* _QRL39-ZSL>G\,0U0%<&/6Z3&?T-Y_824D*@: !T@
M/LKA6\Q]W*^;6#%_M]0AB\"=0JH\!4*&,'C_K04C4 1GK>.;<\$+)=H\"WL:] M#RGBN>D97)2?;*8+40R
(! /2M@W3!(-S7_31=6ARAV,]5!\!\"N-\(;\ -7 MDJ\"= (4JN(V7B56NG=JC4R#FY(3\"K3-*MB'MA2&QB,
[\$U.30,?\$8Y94%BA> M/] ;;W&BT\#IVV9XJMBZ CK<;E_E[Z# &?9]X.*JE0\$76MNX2UJ]M4;&E0%F[
MM3!E^CV8*W5JBSKN\"?A<<0=L#C)E1(LLS7KY4\"E1+A4V'V-\ +?\"/]#\$+2= M3>5VMRASAJ-
B0(>EN[8Z=,RRN5>X\"7%-LRLV#17%-/ @NLY0=(B9K->GLD;EW M1V,?
8^N/6/)K8^X1*1B/8MA3/(IY*,SN@\\BFKI6/KMN0@#\\=#\"SE M8]Y42^@\"+RJ7;-
GD: \"R%.XDQ] %3D3\"6JF^V0!7).]FFJMW!Z1_H,VN F7]! M%>X=1 TU0.W7 .T/LCVXV%?
US[1=Z@&V8M35%G5]M;UC^%,5Q+>;LZ4V@+ [M!:HA >EF,0G0\"JI#Z.-S?<8:FT?
K=XM,/[@K20144UN)XL%X,?/-W64[B8- MB;A?X3KBVH[;!]C@??SX_#5.S+9F'>5BS_>+4/7L, 2N&\"> M@LN-
NQP&5J M:2R0 R(>;&MS>H?Y# 9-^1] &;W59:+MC@4 L(*3P9SS\"1LJQ2V)Y>@+\",ZE
M[V<%J*T:2D9[3^]1E\!A/>@V&1Y-U8C^M/VLPVA, <9B^>>@0;J,U U\"(:U MLZ6P0
_6^&\"K709\"EJ/LR[6*M6NWM[4V.7%K\"BMHV^6PF1VP>&2-U\"HGKG/K M)AUQ:SAM_H.65N>10>\\>Y0\$?
_5@N; %>X= !Q_8%[A1BS'/_@)DZPFTR4\+ '.F MWAVFF>UGECY>Y-V2]?
*P[!N(L+5WG10=HYS49\"XYP[%Z9,Z7;66EYI;0.)X M\4>\$00X.: /L=M7CS3H;=K3:_W*D] _0%I5MM\CAU
MZIK]55KN3N&XW&@^' 8Z'ON*KHT:JFQGX3\" YDAS/WSG\XL@R92JJUP0%; MOU+-
)4+QTC&A 4P!8UL<: !0*AKW)M_H1+:#J?)]1 (+<' [;UG:*< S22Y?89 M)I@27;:QP5MGH%80!^3S=
(Z#E S&6([RCV8?^V[>]%' \" L4&!+7K]4@]3+76 MR<_N,*+4ID,TDYIS9, NZ36)MINNYFUC-U&;H=,S?EPM&
[9Y[B\&3TQ69 MY1T6J(('R)LQ3(LD0\$F;=&-L=[/YMBBU%&2Z?--; K^0@;G_VWZ_E)WR%D0FJ
M[*CIP]40=8FGZ3]2J'749>FG BN20'Y')KL=ZW+5[LI5KLOZOI\$&E9U]IB.- MFL\Q-Y
6#YS A\$!2W[IT=INA'GVV2+J\$4 A9K MQ*^;\\'?;UUDZ*^;?\$+9\"1CP8+H UT*/ORT@S3\".%2K# _%!JNNR;=2-
_7C?U MTY:0/K/NZ<*>YG/'LN>%8\$4CAW<\$WY(;5M(KG6IC'<7H:QX=.5,,0?'\"
M+%.S\=,F=\\)+ZAS\$M\$.H3V'>FW_0':V,T%WE14*KAI!%0\$=4JMD\GI.W\NI)-*
MS9\"H)K\$7G5]BS8CPI%BR_93)T^9NS\NP(BFFF 7;- [EF6B0A>*)I%-4?\" U M(VW'/7(#LCS/W1
%2FV);=@KKNP-5Q3HE_3WN#BJ: ^)0A_-ZZ0BH5;[8U\"J)
M:I\$F0)HTM\"X&+])L2I3KID\ P/UL5%\"7&+;-8]00U%Z;VYU*0@G(MK6!W^; (3F91254\"
Z<(\"%6LGHX]9HBC0'JM_GSYFX\$9!'Q_G^;A)]P%'D_031C_1HII\$S@ M;,>,FV#8F08PJ90@PM;@G>=TG#
M9>\\,==G3I> M\"6+;6\$!_,]3)K&+=Y)&%K+64<)1KNJI)J=Y[+6,,+>)Q]7R7BFL!N0VUY' R
MQ^0MVX#VLX\T!5\$]9.AJWYS(I-*5D[B-N!T7]=*;.B\$)J: _5XA
MB+IX+71#N;5YX&.H_L=H[S0G4D;0SXB7=KV[=#Q;A9^F/:WN)MP9=!USK1Y5
M+7EKTMA[1SREXL=EP&#QT<)S^/=LW;\$\V@ZN]@0]^N'6>2\$ VBJG2C; ;\Y! MCE%<8^#QD
'M;X&I\N:W..AR_:JQ\$XQ]SX^18ZDF/IWPB[;^PJ=8))GC0E< M1SS+<;;J8\$ZTD9T; Y M776*M/3[;
(@X*W60-M5&&74I>%.6\"4VVD]GX_@=:_BKJ8'71F5RZ7]_X
M0,*XN!BGG@_BMT!VI?)G04A'2*EUTP;7#!&Z@&\$4 !M^+]@C>GP(8C[W#@ 0 M6X.#>)DW?YXC_+N-A_T+
(<[!6KI9:3=!YJ;!A'61+; !A[JV+; ;N._PJ<&0J;?D9J4\"Z;=K;Q@RF93#+ M.]&XK.84S
A: +7/ZDQ)70T\"P+E[Y>302EQ>EXG*6W*3%2P+>D5*#<=K@UR!\. M-S2!*0M)7']F\NTD7#
('9BWZ]Y6]27PEEM[_A.G0@@@QJN3>5:U3YDT2T]H')@K='!@Y\NOTGW; 3KX1:@SE#7)XH M#LB+6(\$-
F(+5<8\"A[8S_](_MV:+\$ I&E 0\"%_GE\M*4WRWZFC&Z9'UR3Q8MIZWE]-
J]5;ZCC[1=0D+%XL:U>=TMP0J0(6%_1(QV%&@K1.^8ITR7ZQ43? MZL>B_\"ZUSUKNY5H@?L1/?
[7MZ(' \$^W4_*!%]6- MA0&'GWV0*VR_*?-VVKR'DNQRFTU3@6B54<;]Y XJA\$F\$R0.*MW_.7#SWK9?T
H7RS)!!24I&9)T;C<7U_9UW,1-2 L28B3H9 M!.QUB0-)BW(086R<%5FHH?-\$X9+AFJ;&D\2 M\";8PJW?
>_@JI\L85<\\('9 'SY\$@CEK;:I3U(' \"#]=GX./3F,TH-^.,0\ [NP;[>A\"^\$K ML\$-(' !90R>?- %V5;-2\\N' '-
P?N#J?>S+BL[T]\$9NU\ :VGAW&0DVL8P>B: M>_2HE/'XI/'QB]E0G,\W=S <=2H09
M#]W#GU!0/R&^070R]H:\$Z D12A -08Q\ [WEQ.\"4[_*F\8IAS8,(HSM#2+K\"T

M3%"XF9E'/.MB)2GUTF,KV@B+@6_5AA M\$U-/<9/B\0*0SHHD:W\|V3"#:&;'P!=0GH41PE>!Q*PL16T0@0P906?
[-;*0H M\$A1<#0N\|"+#V2.)\,;:*2-0*F#VJ\$%3)ID^6;F.B2:TAIE@3B]5S-EC"?TIC M"R^G_OI#"\$(^@=R^/9
L%26T#8LVW7F=0Q'I)&CLC[>^SNJ91>KC].B7U'E M?
MGV3#0,38E.Y1E5_3A9G4,/VM'J.\K0_.SF2"@_J8W%;\$S\$S_%V16'E,@X MQ\UGKVTH0DC?
RBDDQ20/04]KT!;R'FCPCY7/TX43_.:G?453/_ "9%EG9J=T MZV&QY+ (%2P09:%2@C.:&VDZ'8037MAE&B[NE
Z52YS] BQN+*"BU5(\I@H@; M[K#'0'LU_J2MA\$%,1F#.8,-EACSHI*GY"V+;.NY(2*0\
(ETC,B3C876:F^S*9X@[<8 M/+DG8ZSFN65ML\$>T7>NCR4[VNRK3IU.23+>R,)+^|;L2%:'*_F.>0?;Y,50
MQ@)\K3E"8TR.WZ@1')??#W2:6ZVFFN.Y6U)QSM0Y??#^P(+UG)8W,ZV27^V
MMM!11%3SPSU2&7_0_'[E4]G3=Q@A.RA|>,:W5*UC965AU-6;7!&4A0+I>'<
MDVEAP9YM&;L666G,Z)08TGS'P@S1'9VQ(FPSS(''\$!?'9V1^%4&(FLO_TM,8] M0Q0#/((\$V#Q,(0>0!'
+;_.8LD4]PNV/ZF:Y#-HUAJP04(|JI_2)]^B-QRR0_M]S1JV+>R>--@GGH.%=J?'+"QC;N]6/^'I&G\5'\V*/-
R=^U"'S]-LFUE4 M?);*_IL9\$3MPLWT\$B+(^F3\G/0"LL7,(SCX6^(:A!V/1H^EG_%UM(F-OI"Y>6G5)7Y'
MP2K%Q[H0_@VNR#A>NFR+4IJ(1_MP)!'.1%T[D\$U6]LS_MM+/@.T\DRX_1'!I?5%KXY%N*+%(DS_MZQ+*/:/%:LRM
5B.LFB"\$;EFN]1?'[*DI<@0-#-L?E54#Y"*L%80?5*ZF\GS!_M!Y^Y_) \CR5!JON)(083_S23(>)\|NHWN;L?
JWQ@H^Z+Y?F\$Y?(!B_:4E_!1.V_M-Y3>=9;_1MU #FEXYIJDAD:]+#V0=1J6I4\$V-,3;Q\67!|AU,I=.5T8H?=-
MB2P\?M+S#*#/B:MH7N83JK@J=D#X!;AJ\=8PK')--E0>/_5^!@08VY&'3ETS
M)YE">J&ELDTS4,3ZJ_G)%8_DV4(BZ80>&\$!0_+L7+01B_5'_L>ESKEC@-?1B_M;0Z^G_"&&<,
(7UW_9UK9'JIVV4=ZP+)C:&6B(MZ'.>YVW)WJK_40_14>V|MT&P|ZT"&^U5|\3%3G>088]Q'P69VAJ8!'--/IQZZ
MB0_' "U+IOM%RFHJ11*0'F],@/120'EGR LUR;CB6H,#6M0BVC#!,1%Y.T|06+ M(0_8A3&]-
".UTVC1'RM*Y|CB" T_VR-54Z'#YCV4K&=J7)=^Y,.P#U];.CH#
M%SL L()Z'QZAY&;2\$W16!D'BJ>;"/"A"D<5X!_", \$A!I602>SVXQ^<+HPYBJ MSM&3E;72VS%/YR;A5+SE:_^9-
I+@TGW|'XMG&G?"B?P:PY-BADS1|F#M=>:;\$# M/W!00.R%@)#740]R.,V0E]"5%4^6NIG3^+J+2*M9S6_5,"8|;
(HV[U1L6+^ M#_NOJ>[!YFV;0/Q.\$[F&^8?/G0\]+K/9#@"0_2]0E(JQ/FI\Y*=8DW])00
MP+7%.6PL0E]S;9ZY|1V6'F,2<_QL4I\$>0K8U8H^P6=A?3=01X^_V2\$;4*6Y+ MV?M;Q2PYM3_9H/=;C%\$&AX1(!
[,\,4T_X06&1>]6T;*6EZF*T'[NBGM(4>)\F8L1@WW<1ZE.5IV_&.<VX[ON|[U"E;70>SW;,-!-F9H0&
MRJQE]RUD#5AIW(OM_SY08MN^G9\$ /X.V1]K,K6_XD7MZ3D1V@B09V>8F"?L#_MZ=:7R\$5^NVEU;*Y><10^R-?
8GB4/S|7GC#_Z5M7U\6Z.IDS'ZEXN1;,\$V\<+ M'S^N!T3-VQ,ZW4X0)'\$-RQV|T^04E6S^|'+K|VS^-A'MK1+-
@&S-CED>B@.) M4D/A_M+II?X#*/R')^K1A4W.(X4VF/-2!>90;+357NP!(IMG;:5=FB^K" _F6?%VJ(FS<|&"0-
X85\]#%>/) M; >GUNI"TD&":=9[W6I!X:\$>0>'G>J=003=<;NXF>?U#R97?A5L5,6X-%QKG-- M% ^3+IH'? (0
&'*I1F;6A?>>?);I<^F5"=K|8<9&\G_M9HZQWXPQ(!!KH@7XJ<|S;UP2_C+?*\$T&.0+YH,7SX?
A7#VSNE\$"7('\$@D\$!XZQ'S_M7*3\,R6R0!ZEKN#C@18L@-!,4':ML\$1H0N'/VY97J2*SLPP2FW\[,1^F^H0Q
M^,WTTQ0T0IU^DC73EJ>7:0]62N_A"SSSEBTBH\$ _;<0%LC^V%YJY+W;H\4L\WT1X|CB|/50>QX
TOXMPVB2:Y;/7+TQ0'^230F5%619M(?AP5FQ_90') MF+9N(*%&/^VTX0\$I7\7YMK5^Z|+L\$!_JUVXR.3
QQ+KXX^R9C00UN?LH-XR_MLDI+X7\$I:V8LPUC:E%\X&C^R^PT6.%K+!KD_1KWMD@*SV53!\$?];?SK.EB
MWU@:D9J/E|GH6+_AQ0+MIEHFBS7(:AWX'0L_.8"<^HC|F; ,KG_M>K!9K1C0.IG0W/=5SI-
[;@)IFG<\$^['KM]PP36EC3+(VDD0_M]+!/_E2WUKAUW0#^KE]&)A\$7Z(, _G)J5G=CM8U)2PU
Y*ME:T\CF">_! *NX5]_M5JA'V>*Q10\YV=F<_6CEP)0@K4"GE|]&+1,+V%J7,=\$5#^; ;/R/HY0L4/L.E_M?
=/Q(827,:^03006G"PY9DP,2B7+.8&4A9)T69#-PC?B_\>U.KR>%F="KXB_MU*K4CR8],Q/QWN'_\P?
QEG<\$6|*GHI|]0C4\$?L(?(E(6,U@GN4"D"GT|TD@2\$ MN.PWIZRB|/< >(W8AC|]9<-
\$=V%*48J7.74QC&0>CGCIX7RV;2.
M*E%U'P\+ZNJ8:/N_P0JG(K)LC94"&\LOW/4H\$V.'RMT49BWI2=6L"6:36%WF
M+W07[U+4:6S/P)KL(.LLYN8U*>S>YE<%0GJ-0_.B8|,[PBUGXS2|T4I\$ _B] MN##
[X0J=S|OU]^*0A;]:6/%1TRR-Z"#UBF+XMO>!*, '0:OKED70_\$90^5.V,
M.:6G|C|]K56#9\$;DY2\|C@+VEN60V@JGK2,QVD;X#+!B?0J0
MT2,_A>&7N\$00L"4;06CT2\$1T#6SC5>JG)/([VM5&".#^RE-LZBEU;* _C.CK@_M@1B.@7VN
Y\|L64MZ_1+.C"Q|&D5E@IZ-G|9NV(50'C%9V_(ZP/XY;6(LR\$9_M)LC@7:ZZ7@?|Y"@#BH*MHS.?
G948>SV+^(\;|IG8GJ],_)F3>6_P\9RRSB6_MVR0>FS;]5%J&Z\68W3B<[]Z04-1/4_D/\$?
45'#.0]E;+&:FGFQ%VS8NSLS] M\$]_CZMW;3|I88VPX72V82:5+VXLWWL1"N7[X-]V+7W9N^|(. 'Z8R]ZB->%5S
M;Z;^HJ>\$@X%);RDC%0=I6=DF+=<8;1V=(NAS@DN;AFC_MZI)>.7M"BE'7E1%NP30T1,5?;;(8N?9
M60(YI=>^HB@M7Y) TP\$^I JW%S?2:WD>AYQZ_6&'69*QVK38;,)ZH4VS]-LM4
M\$G:NRU0X14*#J8230<;_1L\$4GDA'_KH41CFI|I|J\$U=5.JA%.T5/_SA)>9X
M_RI)^N0S7/.H(00,Q8A+Y!2P|]#3,.\DYK\$E_KA#%;95';SCD,=;-XG@QD?;_M2,ZU7#CM@<5N1^)^9_4N?
LTC)FBI9GW_"\$V4Z/AD9@%ZNX_,\?^BRWDV;Y>PU_KVC>+D;9&_"Z%L^%#;P:2F6T3[D_MZ8B|!X&;
(|)\00ZE8=^YD(=FWLV|&HGZC#N|DTN)|U@%/#0]B\$SZYYKT_[3_M2RNO>IX.5\ _+I'"6NC'^3#^RDL4P
MRH!>*M2GYP:AX)GL?I,: '8N\F#Y#*[-7QU"><#YK6=IA7SW/PRK^:+<21:0_M" <+,_8&A\FW!N5BB'&_C-Q0?
YTMAC.ZN>I"295AK,/5RRBSK0Q,"TZD+8.A%Z2_M)'_G!F7T?;0S@_RP(|7(Q!9\);C|Y(E#
<=>1[K2LW=L490%I'/_#3A;E:2MM>U_M?3X?B2X/JJL%[0KX\5@2JEER_2)(N%*>8]|<_[0-
"V^9]P&>>P\!_E/V&4(MKZ:#[5.?0;*/MG;2X#02/[H, /S0^#<+.N;/_?/C(|%|_3^_WK2\J_I\J-]
M|M*Z=3\$7P36*?**]_.\Q-FE%G0'&8T:(A_MDR-
A;UT&^?_R.TA^H%9;YS+8SIB#\$J>"H0.*5RI'_W6870\$[/_!'!;1_L';G_
M\9N(N#&\%E#B]Z#HO/P!2LYZJQIF)4,@*(U,Y3!|M|)]P=N!E'7RG@/X,"P_MD[-_WU'\[Z]M[_PYNR_R>?
Y/) _*@#?Y:P*@P2L|!&T.)!?'_2.OP,;0UW_I_M'TOR8P%66W-
H6])K(F3K0L*J1D:JAM,'GY72&.PK7ZP0!_ ^ZVXJOEYEGM0_M^9U;WN1'!L_CW3^>[7/[JVAE\3?BK<6R0Y=
M\1G7.6:VMFT=_19HGW0JG&!'&'9P2.]^@M\$U_1K/1F_*(S1'%FT-._>EW+S_M!F|U?
J0\$]BW;2;,*]X>C>HZ"IC^_CNO>7VZ_M|H]U_.]8+^I9RCGGT"Y ;/>VQ0*:DP"D_D)*\P6JR9^Q;)!_0M1NA>|
CRT]_M: (;&PVG0"0,E2JVC6<:PHCI"&ESM_EM6CM9UAJ5APFZ55\$K\B+-%B277[U1_M|C|}
(=2SYV)6!&CR,8\TX04G4#%QT\@P6<>@+OVDX1#_@^(#_S2TTU_M,:=4348IY?#Q|?E86C>5.SY/!

[JA;P9MT7?/:63R(M=[V*""P,3HX1\Z4*VBB6PI+FU RK\E'(LBGW*-M1=^!JK^91[M3E38X28TU)
MU7^WQA/4%*?J'2103?Y1I8[5 RY^J8AC.82K<7B+5I\^-,2C.@)#\$6#!=K*
MD&JGZ_6GU^+K!:=S\UW7\8']10W&@8JE> M#M83@?774"?'!6X8+B&N=:(4HC.W9M^(@NE**
+J\$RW\$A\X8(=G.1TV3\PMH2\$J[-J=2;C\''0,0FM4XX\$%'G1,GW)YS_/F(B0\SB;06#7'72E*[\H]Z5KH
MG92_&L5-D<_6P\$T0_B,G.M+][Q1_7:DLW)P]]ON;' MBELE>'@@ A-*8]1 MW@H\$UT/6[\?/U=TYC3G(@S9@
8@T;Y9M^?)8R+Y>&>YN,LU00X'#00K68*# M(WVPF)D]:S&:Z=/G@E*(_GSP]JK,P-NYS(B+>YY#24L6
S(K!;ZFGU8W MM+WIE\$4;RCT-&BY;K^L+TP\%Y65_1MPX6"ZV41,?*,UF^3A.[N?>'#6V# M^:SVR(MN&
<7)?4@0+&=1"\$U0!Q\$B2P[YW%5\F^"U*+@6/(UJL'VR::S4X3_MVN:AD
MNYL20^0;T'IK!/%T*_"IOFAN=.5X.KG9_M.*)I#TL_6*KY.-B*0'0F)41)MK/PCCA3\G2V/) '1?.D_.
V10M^A_EYE]1K- MGMSBQI3 DN!@L(&Y[?T]S.+ \CK8H10/Z2MY)X-^D,!:XE-WGPT5YW*NS/ Y-I9S9WX_M+7!
(IA)RL8ZAS;[**=C1223<^:5C4M5CV-0_5([00-U[C'?8L^?.T@/2/[
MYA1>;00Q>ISSV2::;Y&=0YV:6E9U)0*A[R?C<];.DSG4^F)^#2EA@Q/S?>'W0T*9"Q,EA*STSKPW=!:/
MWH5+\Y/PR>735>T9R% W^U_% J\Z#BU&2I=#6B4S_SCJ+FY=8]V(UK%)D,5)
M7_U\GY%WM]8'"XP(HI0\%'':F)%X:'A:\$.+8'B/L'G*(KJ5SI-@Z/B))V^A MD=:#<3'C>1Z?
(6SV);%I;CA+K%?/X^#1,J2]X>-4^C'W\
M<,@28_OVKD=9'/16_4SB,18(@.;#3R+4L4#;X<\$>^>8[%Y2R9\INODIZX0: M@4,&9,(L])P0]Q#?
P?:E53JJR?B&R32Z\&12(2'1&I*0>OKF^92F"&Z'X%0_MZF0],{7Z"(.&"4?
6%M4E'OX%/2F]16#4&' /+6/=HZS\$LO!C[?;5_6U,J71& M=#[5^W6@!'!N4SZ!*9)?]=2.Y6*PN*AW'Q1*>;/-
JM"7B<^Z@MY_5L\$S=T2_M=V^R/EGIN!>\%[5D_Z'RZ5*P_N" ?&N'^J5&2+;)H2V=1,SPD7K]F7LN'/WG_MHCAN=
L)W:)I/PD^@H\M'V;M_(B(\!6>[;(RQ\$SWBY[VE\NK[B_F]HER.00
MKFA46+15Z'23B#]I,P73;TY4=P/I/'%KYYU^&;7.6;X'P]@Y_U/[2ANN5THY\$CF2?6MYZ&U=)@, M+*+J81?QZ?
-/ \$+2*TB;Y#K_M9\R7;GV9V8GV>C"R]*UD7J+X]#: MF?
S^2>K'TYH;!Y!/.NCSD5LCN:6&#G53_/5%6ZQ5GK=0\$L? !A>;R,%HD+E MQ=:AIHJ[XR49\UT#<1;#8(:?E
H]*XH%\$#>/P8_15<>#G(4C39BDB3\$E=AZ= M8J=HXXK15Y"9Z?9U\U&[.
(,"7'1%G5#Z,ED^W'HFR+3*]1GW4U\09Y3"#U_I0_M1LJ@S?R*8UXI-"3I>M*X9<4+!JM=.Y\LMDL*+*6-
[WF^(9SQ:/'G/XF&V?A0_MB4E0N,X>D.'"0]9W\$80'BUAJDL;1YLF%9T8_U%ACW]@M.+'"KPK_V].7+%Y,7
M\$M<7+;'_B_" +S0_M4KMAZ51H^Q0N2V\H5KAK28*/3B.E(H^X7M!>^-*LT&4F8BQ.?P<8>ER-L*DV
MBKU=7C[<=7:2SSU*E46WL\$B2IZFA*L',N&9D0I653NB@N^2I47UZ)U\F,AW
M\$@Y'82'P"Z(1YU5F%ON;CJ)#GF!G<0]0\$BGMHME_Q/VQJDWA^?&KW[.H-^>LHE0&3'<=K!\3)[K=\$@NK_M-
*:_7J=X>1\$@65*B:506MLV;D)Z4Y8P3-AM.B4U((MNIQJA!(\A/E9PB,'=4 MS-)1%&BE./ &?
>7U2[Y&L7'S(!:42)0Z3\0BY-7'Y0\J? !L+K;];GGEDH9G_MUK*SKGR:=,!U#@^;Q=AXEE6/=5?
>16W<2327>--'\$LR;J:HJ'D<\]]SY=)&*.5ZF0T+S_M/6/M071_@f63IN4WI;RU]^Y&=]?
6)ZE5!Y%L_K@6;MHMEF42V]W[B708^3KU
M@MER)7PX4S6P./WPQYA&1G^A0>#6_9(2(_JBO@;]U\36\$49&3V[?;?F8YFD_MMZ[H"@ROCL,&>@f#;N09;=C'-
IS\G(FK\S)E!fB2_G30^:_Q)Z=SAQ-,HIU)T\YQS_MIB!'0R;,[P.*SK]0BA^9/*>N^1W#"N48"
[V4^13:U,VX6FCH_EP\$?AZ'/(R_M%&LX;E:4..DL7TQ@IVS?'6,DR--]\$KCY?D94PVIUNR0&Y0[E&!>\ /5=09
M^8E:;AVW[[G3!%>9)]]*7A;"YCC1X(05.Q]'X4I_,S40L_MP#\$Q-X_9RL3\$RILGPB]7L:R!KB?
MD&TW7EP39:)RM?R5:I?;,*!IS@\$X2'[M^I;ZZ7\$57_11Y@LL8&T>@_7H9>GJ\$N=^6"B7Q*|-
_0^5Y#W6+&JJ6791M'Q0_MZ:%4:4131/9JTSXX2UV]7:;E>;-68P>%ZN'2."965N4T%+P(.V,.9W&1*J;
MC6\$!0F8L\$.+!'1VL/QROJB='ZR/Q\$="F84G-5Y]>.\CK5MY3"S/7U'E*B==I_MM.?\$;H'*Q^.);<10(^
EV1.8&&@08]PI1U^=;S@Y?5U.:NYH!"UV8H';72?_M34MF]G"PZ\$G>SU+AT0[K3*3S-"E+)]
(2FUZK;SWAABUTO(:N*&*!'1)DSN\$- M+!_=@G#J7\8"RLL^V5A@UM93"D,+10EC+B5"4 :8BUB@" M8@>+?
60:;0H\% M#,K=/0Q:P='X@>STQ%)5+5# K,#)1U.I;GEU_-I6HU@HO_>P>HQ?JVZBG\$: MW8J&6*X9YWFK@#
[EC_45P]S43!M8;)]7N>TJ]TS9C^_*Q-6<6X,-FXW+4,9P\+WS%80TTC.+ ,YYQ<*(\$SPP_M*T0=S(;)-0?
F]=X"ULC),=\$5.8ZC<*;X@5>^5^SI8X?3K?Z9"P6>(U7-M6%_ML>H#62-
9R96KEJ\$?/9H@Y43!)>8TOH8#6_OJJCWF):87N(S]Q):D_BZ=#YJV_MX5)N!1CRRW14N=GM4*C95K.OQU*!=ZW
MZI_).@TQI//AE_M? [VT052&J_F.Z(\$6ZVZGF*JKS4\$IE!9D&OF_04?FZ(Z'1>7QM]6D+ 4-VR^Q_MR9?;Z)AA
81!DRS33N;W'\+ZB*1P5PBY1E2(W=GR8'P*%3-Q>I:' +Y?D/&76_M0\L*>JK-D_?7&(F'X")1|-
AS\$71S? "\$+/:6BG%W_G4W(PX&@R_4Q_WSV=90_MX^J>E]_2HN]>-41.%I^FQCVE5
8,10LRUHZ>W&N7^XQNSU!\3%#1\$1TKP1;E_M80PMJRRVQ92X.;HA57R*IH;K:V(K0_MIG^DK(ZD[_B>?
^8K;^_FED"W3:A!4<+&T;%07N-E!WW!(LFR#3'=F2SIUZL? M[]=LB&?)RNA[0AWKHK!"92T!G,?
#&YP/8&P&!K&1UNZ*>N%>;>5A5([M*&.. []QL[@;&^UM:6.HEWX5>K!#< M;J>TS[]^EBB[E2UI :YZM#TA-
5>,ED/FB460=V0@f60?V7T,K&#S2V[6,01= M7]R+D=581"W5D&12<(' ;V8>3KE,6TH0K^PKB?
@K]19KPBYS")2E72C#P[]0@_M>SS56AMN@SR7Y_ ^H\$3L; \E!^/.K=8=HGB^A::/Q#C\P[](^_BL)^UH>] /? .G
M"LBH]JL; \Z:;LH_V&85,%W5C#Q'@=R58K#8#D\$KTS029UCS25\58/O/_JK^
MRK^C)\HK%=1T!U0#0P8[^XMC0^.,9X)*MYIP[XC_5%6MRH3(_YA61V>L5UM*Q22?;AIU6"A\ ;=\$C+UR[A!,9
LIN5-M^ M.^G/3Y]K&\N9_NAML,/BZ9_ZJKK6"SB1&T#9C5QYI*(*_A1#A=\$*[6=F>C_\$ M_0+EVM7UX?TVL?
8Y22GV,\$9*B\=; *#IN#F_M0:L_3\$Z>1[EGJ&/2Z]X=2^EP8_'M:55V1!%[\3Z4D0H3%G"#0?
RN2^".;*.!KZY@#=V5T0;-N6ADHK?9(M15S5]L648.Y04/YKJ(@/:?/YR3_'%7MM&L\$Q[R/V_
)12BT%=0_YVCK&,^ J MD(0@CCXH?=ZNNW5<+]K/+']CXN8.K)M6V+^\$.;F++:YL8MWI02^0BGVT.
<&-6B\$E3PG==P1F[X&EVB5?DEJ_BCZWY@T>GEERN6 M9*U@='A#TG+!-
>N41,4UJ43/2@, #S.6E%4@#J86(.&N._C1*QM5\]VR<&5=7@'22A9X8J_2XL-V-?1-C5,TPL_SLIHQD_ /!"P>\
ML3T'9B'XF.YLPK@M*#;G(\/= ?650X^GG5:U,3#W@*0N-C?=E^KEQU8\;2*1Y!,T*=79U?.^4[+8
M36)9E(Q2E\^D^;9&3V_%[->GM_ ^05IFHG5VZ>[13_N4[J^W0?E7D>[C[]Q? M!;K*Q%<2NT1M)GO/%'B[B?H,?
#92=0XK9LLT*_) ,?UXZ\ -@:(0+4P,#4=>5_MQG\\$1UVAU\$K.-=5: '@P=NEK.D-
Q^7=J>6APH7D[G0GR/\1E53#YR-L8>G7_M<56?(CY1WKHYN*,XPXZGY'\5M5)7I0Q3;\$T[0/;?ZF"-
LU!K,N:0.A'KMKA_M5/_VLBAL:YJ5-(&@-&\$270+785IR_#_5LB;-/_I6S0?T)\%AIV/W"S<>_UI

MRP)0J.>:1X%8X)[HZC29@{X,0\\[5+%X&V9%VC]M!&Y=91]?
EDY6\$>V+-4\7KGS^1I_LG?/M@GVDI;UP4/F55&3?@.[D8LZV1EEXP M30XD7,,F&I;18%.{W/;U/*E8U,W{?
04,00?ZS#D_6'=4?A^_2?)HZC1\$/M" M1#+;S",WWM)NF9KQ: Q- M9YX%031A ;+Z%1T8FLX,MK,&G0W!D,-
Z,[4J0&5U4)-8B\$K#4+',\?U>]" M!58*!LF1#\"UIO>YZS%D_C_K^0[W%60+KF(!?4%8#Z06"TO>PQ3\/\\$;J-
%, MX',P^,"!L/'" BU9X+.. %(&"@E@-EJ_QX6B- Z\"(Z*0S!>)YNHR,Z3G@/ M\/^>R6T(.S;]@GE-
!8X&P='>T?DM\$*!0LWW6K9A"]7H@SZF=W"Y(+,.)T%] ML #K+B;X].;_@0\L0&J.\,\$\$B(.99CKX),J4NK9+?
F!;!C=Y!31]#X08-UHC^ ME9- U8C!6U@.3?URQ!06:\$77I!3?_3>L_%N-G-2\/#4\$.9#V/\(H+9Y2G3S-
MMXS\JT:&%0XVS=^F^=LT?Y0F;]/\;9J_3?.W: ?XVS=^F^8^8IN!0#_@?[@'-
M14USHW[9_'^X!W37_8=IC/QG9)' \KZJQ_Y0T?^_=_]&;YK^-:9)GTWK_6=7I M9J46L'!7;T:G&J8-?
RE['7=>Z)\(&:V?P0)_8:E"+YMN7\ R?5%V*!
M{X}69ZW0;K5%6*#43CQNI:=R40X&XX9C\H8.KG)GWPE#250+/27IP@+/CV!H
M!QB8)33@_,#W#>@F9AW4;C^FY[/ @Y%,E@QWY,MEFDZ-*P508U[#[]_W;\5"Y! 5PR@2(@; MSF(-
ARI(74G/1W&8.6ISW!RAK!%R \UY\XAC2%)=#,]0>^CT^@Z:J4C:4FE M_00=G/' ; FBAN ;
('74\$A02G,I0.]0R&KB!A\$S'C.-> JPUGF,6_Z1,NSFSI* MYK""C4+\$-Y>('0:8:4ZX?VC=[A8&3<'(;&
MG\?\$AZ^:\,;^'P%09<"A>?\$38(@.F"D\IA'G;")@Q8LP)"*8BIW-3B\ P'H\ M_H8\$ GI3S=&]<\$>3;\VK9'"
M'E\$+1S(JC!>D0GK+,Z_N57_7I43\$*;7;G/ M)\S71I@D"MSRD+.XTY.1'V!@ZH20U;]L0!Y@
7408RDH%J#6@!0+)-1B@?=\$& U- M4"INV\$, #C*4YCL&X*= K/.:JJ! ,+70V^A100@+EX#[R=2)!!G!-
!?)WZ36H7E5(3< M^QFDP9#R<&0KXBWN/X\]0?CW^!-B@4_TL!E+'(LW_'LPA.;'X2PP,1/\$RF= ME
?10'^\1%VJWV=-T.G5F>T1/?B*Q)\O/R&X#BI]#%1ZE1:" &0]/K\$3^L+
M8N\]H)IJWKW1J"!*\$:G2HX#20:37J_@(" B(2(WT)DUZC8*]":@M"A%0)KT M3NB]]UZE\$T@H(9"0W/#^SW?
6^9]]SOKN_=;]UKGG6^]:S-KLS,R>9W!SS%-F M]GX&B@=\$Y%*L[^\$D@*N@X#^F8#0.;,\$21Z; ;#D1D_(L
]UT62H+1PL* FU1 M">(" \$JL8UR>L0.LHOP7&@:7:'SAR&6;/'\$LI MD[AK3& M()PNKC+C
5>M_H'[_ #1/UKRN6PI*;%15F\!T=KR M%,"S3P3.K;Z\]=:P&D^0W\#/KQ\B>)X&LVUO#^K0^#
[%TM88R\$L#YB\$(&YY M",S/[H3C_&H(LQ]H%V>G(18U@G;WT9U=:?P "D>BUXP#&I\$ _8&04N&YW*U
M0&\^]\+ #E6I* @)F!'4.6Z_Z+L8_DS*@_Z8U+_DH#;]]\$R*QJ056T(@ET3QTN8 MB:2>K=-!C4M
ICG";@]@+HD&Q9P002PF]V-2+[=)SR4N0X0+5L:VQEP0.)70 M5;/E5PLKX'-B(&&N\$@BAT\ 'EK0D@NY
\$SH!83.S'I&0:07+;\; \N^/'7=B8I M7U1?ULJ%M/Y P"ZN@0X)8@"I"]P)D?A+? !8ZNKIGD+E+C<42[[C
2M;:&/(M!@/D@/!PY"L8(M]/B(!H&QX (8QX,\$\$)C6.=CDJZL!&X0H(%MJN-/-N+C0@_
M+D3K\9CF!0Z"X_WBQX<8/1XSQ.\$!#!ZF4[00["1H>PCPD'*0KG%DN>\R:AY! MLJR\1KM6I2V=GA%XX!
<8K8MC(3"Q*V2)8#6LYD/R:Z90:V@">+ "RG24WK[^^ M&CRE0G2U8QIFN(!#I>TY
JU@2B%L+67G^XY0WY!Q00 (BT91B60GY>LL4V60 MUNIAT.;_U.!&NWP04=/# V"C\$*0N:\$=##
_HZ\;.! ACTV7NS@0X&9L0VP9U M=T(/Q_K6J3ZP^**6G>'K9^L'S"3Z\'I&/)M;=>=E;;*77:CE=<87N\K71P
ME.(0<)5C >=Z^:]W=LMW?@G/LP%FV*#MM.C;87KF>N0&U-*FZ!{30QLRBG\I MYD'!(\$HYGSXGPD3C%\$N>
(\11RJHVVA M]>]N/L38GH@ZR/_,[LYBCR#N1M^OVQ0>#*C\$*2D^K&5KE2&4TG85A8ETY;+
M^0\7AQXP\$1ZN"!A]AW%B>X8/'9:BIH00A7IKWP]S9[UM]UDW9;;ON8!-1"
M&GC2NBAW\$WZVQ!^G]>*TVB6L#W)LCW)06PUMM-!OH+PAPU_O/.A%<3DM,QK
M8\$ "D@"8%7='1>GP;=S6F^=7X2R+PAZP8%*05X5CG%ICCD:S,S]2\$?S]+Y",
MQ/NTQ)\)UJ@J:\$@U/OQJ.SAW17GM_%6%]E1=-ZP[W?*'6V#CTZ-J_/M]2#-T01\$[NC(]T+EF-:HBG/Q*MM#
[E7H6JJ+6:@ MW,,!(7E8CGRX.->0R;:R7_\'K
D7EG/O_P=0R0VW3%=N=M#.R%A818L\ILS,&AA*L4X3ZS_V;>WQE_9_R=\7?&_VIE*M:5T"%W;6M
MGT72_5000]W)*F2STT\$+_ \31X0/P6?%W#E#U;.%]H> F>(93(J_-ZF^7]*;\$ M0UH80FL[" NC3(Z)!K2[%L"
(N%36/L=2#0>*AX&6KC+= !!9_7U4TW5-9*^-*BCMWI/955D^/'8_:L[V@N^E@9AHS3P@-"X/CS@&1*\$ M<(.
<,3709]8DL9>XKF?X1S[2^8:B4#(\$SYD8ISP+010*0;8RN""W80_#BT\@)(C&1>V^EG>(I_H MYJ>0""Q3,
^J+ET:0@L=RH]N^9CT-XLL&--&CR_1!D/B^M8[>4^[S!9N6B, MQD%:(' %GD#QB1U<2R_G%*63@V9:\$+FG8\
MH&4\$#_ACARX+ER_5JX\$XF<.@"/_?_1Q_1RWPG_JBU_%ZR2\L0WCRXK% P()
MO\!!_TONWO\=S)A"W7W@W/3!)0;.&= 6#_@G>I7_N3<32\$M:?[,29]0B%P2T
M#.0&:/X!>D'_U)N2".ZL0['_&_N_L?;\;^!^Q_00[0['_&_N_L?;\;^!^Q_00[M0['_&_0_?
V,0\6_HU41[TRXTL0G]#WHJ+NGI^%=PW)806MNSXA'T7F\.)!1C M\$XD#6;\VY;*YD!PX^JFV=*\$.H#D]T-\$6-
M^*Z#B0H,(F_3>Z&+%ACD&[5Y0 M!'S'=1_Z!=\$<_Z/@_"F0@NDH_0/92.\$V\V%J8-MP6H9JXT\X]WG.KL-
F**3_M^IUH/\=25+S/UD@VNWJ@IRO+UZ>6T9WBDMM#%"X//:OCJ^_P\|)+L*61TE_M5&_XXR=R&;7
[+^Z&_G)ZH2RI)CL?,@S)V_(03J_\$N\$7J_4[^=X@ (X#U0* MP+8Z!8,6Z_&T9X"V\$VDR)ZD]
<6."31_7_ABUET<5*]1H@Q]*1"KI4@;\E]> M_OK_X^0,924(BPB0_URSWM*YQLD9)98'MU4R%?.?
_/:WSI_YOW\,(0=S_M0SL2)A".QR0TL;U\$U1C]^K[HT5\$?,\$[P07W]D,W9YU&I7.0Y[Y]&&=-Q8R2/
MC\$Z%0^F^N,\PX8,'0,T#,QM/40'H%D3YRD^P0:&?Z[('4CQ?_H=_QV^G!EG
MAKN^P]XF%L6%TQ:Q:VE6366(B=P6N.^*P%"]+R@TA=W&V<_8S_!5K#(,K(+?
MA7RY*H(IC[9_8SH<1:;%J'TF[* (AIGM>W+413'<2\$P.R\$?IPW04)^0\!_00_M
+1=,V8=,H0!D^8*L2NKES8A'ZRWE54I0[_NYBM_P+HT9_"]D6.T0H^2' 8_MW6*^~T4DV&;XG6Q.0-*~^L_0'Y-
PY"+27+3VLGR-M^KS!0WBVA7+5Z7YCEW7_MK_H0ALMF6]8F:(=@J]-JAH9#; MV<.;'_RX\(-;=;/^6?_@C/3BV-
#2^AEDY^0^7.7Y\4*7CJ*JUL_J\4@K/19. MSG5=\3HV"47:F8?-'\$[<\U_' +9I
GRA7N3"-9YM3B>#7(\LY1:%:8%L_3C3%_MLE,PY\$97!^ASE9;]!0GZ.#_&9E1!Y'KKT^?%=/+ZAF0;SA?
78'465JI(YE1_M3NCRK!VF@*R58(1*,/EO(W\$H76'A:RD5X<92YWZ8%)5*>K_.C?['Q26FEMXR
M(E0TFMQCD060M!(F!,'[;?6&05=PPGZ<")+0\$S5->C]0,KBV90QG;66M+Q_? M&?N'+C8.6T[A^%<%096
08WKS0+%E^X\;-: #)0S!Z2?0.S*.\MN_M?B=0WU\EQZ[^6BH()5I_U801(ANL
V2"&A&5STPL,CC0]E1^ISE=GP[UJ4R/(H_5.AI33*HE1_ ^KIP1!(NU:B?5VYR&IU+T:N_MU<-!^6UF4]9%
(D['3P9MC]CLE-:,6!W8_R\$[Y@_%R:KY5RWUS_IX_HI%6WYQ_M2+UVV01IK2^_#*WY&)V/7%(!=1+=B58.#02P?
U04Y60'YF4^3H)2T2W9JS0?Q:X)YL.DW#M:R'HJ%D8I058"5\$W-B8_M2]LA#:L?CI_M9H<#.@W,T\$.*
(^YCG+;:= [T18)"85Z+.Z6T(R5(!:=FZL[Q.9BI3<-23&/-E_MBT_?C[5J2+^KE.C.1GGED,!3;#+L-F

LK>HX)=&\7MIY'>NA7@-P+V]=- \$ M%R'X5F*BA; !?GJS^QV>?W).SVXF[
M2MER.=92?)M0NW98;>E@T0_V#S#K#GAIKC_3, MVPYF-V7U&-[M,.5=X?]9.PXCY<2WKZ(G3B%=%,K+4\U)PV93
2S;IX<[6D,HE]PMC->)SY\Z MOEZJ\NZ&*"<='40K9 W:0;##7S0_X(K^)^L^,?!TL%(S5+;29 M8J?
RS#7NL^3^&*;Y\ 'PDL/Z+L\$[U01B2\$I*[ZJI^9+UW]8>;:JP,"50!.U8 MCBC213?&"(\E37IN;]!J@14#.0\$
>NP=1)8!4A3''>.JZ\$ZF/^\$QLY*.-CC MB/WLVG.)I\$B\$.%0H_H;1K@;+X;KT;R_WSP5,KHX2HW"@]
(CQG78'^Z?(.S&5 M \IM/A*HZV\$N\AAUF?=0WD??CXV''YSOFWG(^@&<%WN4VW;.=LD]?S_029:R
M<&GHC&Z,.%KW]>\5T^K-@A :DI-/D+IE^ZT\$L2X@A]B[?& ^)ZU'W.8]Z=X
M@'IGD:5*9TJ'G/3T'642TCR5(NS-K)0,/6<.Z?_VO!T=R@% V40DB^
MKCJND\$]]:06G+BPQ["105H'B@Z_*0JZ*N58[+D@)\$'I;U_7X=P?0_HH]4-BY2%&35\$J\^9]ZG
A*!T1:U\&JK+JQ\KGG] M?>=8NMJ,0,.2^1%]> 9&07;G2R";YHS0KLZMH5?Y\F]FK7V'?-;T-) %5CB
MG7WT9@-HT"<([L@]IC;@?0D M]N-) %>8QK]PCN@6\$099E,R,A254MT2\S'B1[K02G&J7]WOK\VB%]=&U3-
M!N:J'3K].CI%AJ<^P"!341&7EUX^QH"/1MV,E_0L"2D&6F)[L^]G,A+ZE MD.E2]1Y,=<7
NZVG@H/*_D: HFZ^?U6<(*^5"5.60[&S+=U)NKA*5#/DW"%L M]/7U&L,+IA[/FYF?
6\ \L/S8K3#%T[QJ1A#?)!@SAZ*8J'6YMKAAI+VQ[0D^K M<;(!Q[!9G(Y:@?2QU(^XD\AX97M29)-2?;,*C;#?
V;^G2BKJ M0;]MIZ2#VU&3BP8=ZZV'=\(\!'5=F+F>VC/5>H,5-G)4.M4%':YBS1);;31 M61T^E'0[MD7J>
[P<7_>[JA3R];-<%/Z]1CVMSI+4D"7[!0]GC\$\$(LATBV5
MU;*KFG2[TF'4>L=X<9#?,I'G"W63H*TS,/0=H'TX2?MMFY&>\$J+;7R[;7 M;* 2.;UUBWC>N-X
\$/#\$/2U59(VWW2GMG.[+9,'\$7TA KR+\P:J^QV=G&Z M*W&/^?>ZU9S#-G@LKP^U+7!0N5,"0^CE67[BS@
M+,26QEX?62 M=K3AMSF5BHI'[1S.9H^4.D(G@^2&.D.A@?.S]WYTD9"OWEI?Y\$H,A.TN]FT
M_T+M6X\Y=.,310D0%L?7/)\X,07.9D0-"3_?Y0-*[1]Q5]'J30(I(39"'YF
MGRK(*07ZA9VZ.0<;ALMR8>9L0?QVZ]W=T0&QPP6]==\$\$"!U!BZ1 #T=7% M?E*CCN_V'9-Z%\$.B;
[Y(PM['\YWM025-T[KU0?T];/B%9C4930%DN"?CS[MH>A07NAGC-9'7NMX2IR0E4%525*(\OR?M'Q/4F*
MJE4\$.GIQ5/)\0.-Y[*TP9 .YE@00@ZL\$ M_007L2V@3]P]'#;@.SA <\WS<;6 J5AK07.C>,"V6*,?H)%D&,*
[^,I(VW](MCR:Y08[]77>]OYY,D=99MYQ/,7BYA(0+X#I7Y&IW*IMA2\$QW3H5YB&5'>\$9! MK#50#15Z:2HW-
#483G,U8%A MJ:HYVNO+FY=M'S26FR,M7,/1KJMZ'YT"'+R. M]!\$3V];Q66;Y'0Z_-8;*AXA907#!0Y6G-
8D:5,*JAHIVON^;QK*0.P>E0AS M)DC]XAN'6>,'G[3][(-#)UBLH[|=CDXR"30L"D68VWU_2[BTM?(M[?Z7E[;2;
M%P:(^HTV7AZBP%Y'/OB1Y:6I4#K.;0]\K;YJ]'04F/0>8[A_VG0-@ 5B76E!
M%]>FH#9+UW;3W##' 'F#&*VVAA: ?W;3T%51PUG0!Z'YS:VB?[QZUFGY;7'1*4 M=\$3X0)%\$TVPPK=XHJ+2Z!4B*
+U!\^GH5]ZHKC6F\$+%;/OT#^.'J174Y[[U V MIY/AEH;KG(&S.VN\].\;6],"7BITD_7
N)X]XDTYU@XA\GRD0*G6;*\T7N^! MU^%[WWA*&,04&!2AM7X%QQ9;_UZ,\J*J2)=14LI#QG9]+
(.MR!XS[.LI+Y@9 MSI>D%Q5S+Y>5L[U? L'Q,I-!?!X9P\$0^0C[G7RXETR-]/NI'=Y+N554NE-)=(>+;>VZFJ
MSW3&5QYRD=?U]B+}F(&>0E^H3LLG7*Q^LCTG KVQ4%6NT,& MN,/ *S.UG-;&?1YY^T,3(\$3S<>@-' F;
<@7RE,ZZMG2*1 MM9GGW]RT%UWQP^0AG- _\2T3\OT!&\=A "U%=[4-*WL24/&Y[:H=P#7T9] M7]\$+
<8#CLOL#EK]7F:N,1+*)>?N^\$9"/-+58;_"B:LMR,L"/[\0># ^6E0 M_ZT2"]=0#QWLK8&P\8YL>
(!TZ08/\$!E\$7;0\BNL!;H-LR9):#H2A+0E5#=#Y M+\^Z3X!%>)\>ZS.U5XY8!(8M,57PD=4[5=JB[I_P55P7QM1,
22=/3M'15W* MA#B?RUQ5CG\(*@ M_A\$PE!_]U++^Z=\$/X&5C\$E2]T/[7W.8MY0J062=:^E-2X^9@[:D@"-E:5;
M8;./ *D_J"U^?BG#>;^AC#/U&WEXE^NNDN9D1\V1(M7@)H15Z1]Z[LG67]39E
M<(/#U@RTMA3IVNG5X;/T,8#C#6X*2H(US.VS=/HOK[)A_.!N+.HSC%2],Z+ M3]Q\$PHLBT68K97R5AZ^THX: *
K*BHGP>%020EU5-@L0M%BW,-D"i&[HFJM%/ MB\$Y;B ((XA?Q&0_H0\$9@R&E*?3Q@I^H7\0"6-8]V-8&-
"0V(7\1U6E5GW+&T M\$HA+)PUY4K&(#Z>-KM*]517[[BSG\?W7S5:U&\ZM*I/\$Q ;G)>GG5M['4>,&>'A,Z0K6JD
M(H96L9[2+>\$4\$CIER>I]J%6/:#ZS#@LE/QX& >H?G!]]^-%L*_*R=&?/^=
M9=NPP_MS<"E>0A1I'<.,@J0,M8(HY:EV#"ZR'Q8L#.3J:SK8Q0"V!5#=&3V M@"(6:2MJ,B0S&Y
JZU9_9EVT4XZ?VHBLA'A\$0DB7>+X] TTGKH2'0G6K '^, M;AK<%WRTYN08#13ZCG7[??]=
&MV"J808S@!WEIXQ0IN@G\MJ5=1EX+1/OAB MM;809"%6C0=-/!01,\$P/8JMP"M8>6H/1V.K-
"NRV\$7=&*V8.#@XT0G+XJ\$#' MD\8AM<;IH&V?F>WF\AR%3-#.U4XN=ZJ,+S0+B\$,DKWV+H6#B_B0AC9)U(6J
MV-0?>+>?*(69\$W\NQMRFJ2Q50C_&3;Q"BS?:ERD83!Z0%1)P>/(!'(GM M%A3T>44HFQ?R/G!^1F+-?E4
M917[@GJYU)XET#;./,P"'(P30/.L0-Q17WM?)_B-0W3 MR=XU+[00:F<98ZY9H?GCEN3T.9CGD3-
]6=1&D>A[K4^EMCJ=PY-*D!H,LIU M^[2:0CK.Z(D_>8C,5T>]=W'=T@7DY)
(!'SU_4BZNHA4)PI0"@@>E2.H>*4% M05;8;,\$M6:VU)6I[^E(5)Z<\.T\]6R?G7V6=)1QEH:3/26Q-
1#IOP,'N?ARF M> Y90!!\$)GN@LX?;>3>6DV;4NC0F1)D;S [V"_6DN*82_G,JTJ6UZBY?
_1*8(\$AAH^\$@S&+^QV:L)^K-8 MU.9DK5,=U7?T/N%KYWQ@0]*Z\$FVLZBG@0"'J4+T&,H4&?,!QZ2PIFYBR.W6
M\F?!,Y9-&Y!GS_BT/N7%L0K>B0744,%GK*1TS\V?.A<7J21KJC*J]>X=?AB M_UT9L=; />"]L]1<\$]=8[QT0=
<6'Z"?ZU"=MQ](7)64C;[UG"M:ZF1_P*RX M6C;US;DG[N8:%&W,5'WQX2<,> !KA\$[/&8J4Y-SCNT(-
+&G>@\$(*,"_005Y M!4-H0LX\$F+HN/EC]H]SJF,-%(_S&[D5]%F2KWN#8VTF5QUU^_I6GK=T-G(L M_1=@MI
5TX:R=J3Y2FKI_PT[]FYI;4V150]EY/YI_5LXY#*V_%;I;I4G* MS+S; ;B !OX_AT50C.*X>JV3VE]_5+L6\8%
MF%4"Q!=A!DNEWR^00D-4FWU[%'037"Y(7S0YAKK8_EYTE7(A1\$#;B; ;" 7 M1<7E8)0+;
[(Y&9S0IZ&]A\UKC\$-;H_40-%>]",OC[\S3S'0.,]=T,F'&7#6> MF\7:U>0_#&
<4%+4U_:1R]_KKH[00PVN)PYZY-D0.94R(EW_8I'?=Y-[JU*Y M_#>V5/D6L5BY)A0BL!+G7&X[\%9,
5*QL3HGTU#"0>GT;^QOI!; &ZNN.M& M3W+&83_XC05^NNA<.-F#T'^!M)%L#VV4/:MC"[L73_;0934?
C3UT[]K3<5\$ M.UG89(Q&VRO'\ /G,G/DF<&9HM3JHB:7-W^D7&H"&=AP9=PF&\1F']X\$K4>J
MEB1]"NTZ8'\M4,_I%]@0W!]MKC(JJ#P5\$&MLY@Y4SMS!\J%"GP>7Z\R@1T0RY4;G5M>Y5E%M#KY>B74D_M5:"
[22T5?\$/H_?9Y^(YU#,D20>(RK;I?@TZ&=4>+74W5,-P05J&2Y*:\0U[
M9^23!2"G>;34_-4LMC>'33F6X^G<.KE:"RH>8P>R"J@'"(R7)BH%^?/35"#6
M]K7\$K(_F!S)^0=C<)V.078R2@S<']?LA[R!G4D(,%PZ@XW@F5,E,Y\$>,C9_6_M9J0=]-PYNL\$0U2-
UD=U@&JU\$R(]F:JV_N/9Z36_E62:!!X?NE.3"_CHROZ.\$
M(\$H88<>9BTVFEVN9&7MWUC2*\$F+0<>H\$345_\$L(&E2.2:@\F?7D_L%Y^(!!45>!=_X/(#K_AK;
M94D6,3@8H4%R_P^X7;Y-R(Y; M\$?J\$!:(NV)E]BP0WC?R?0#9,38[HR]#7R@1TESD9UY(^0?0BGB[8!_U!5*M=

MI#;1;>,>U""\N*:[HH"!D4QR6GU=QZ1F'W6\PJFE5*. \SGW6*!ZR E.G]: MH4?6?0 "&.K#YGG6;@LCJ\Z9\$?
91F2LK71CI6KW7>M M)J7GDT[5' #B=*(LG=+@4EJD. E0F1.SSA?K!U""L>95N4K5L0P&DS#.E\/:
ME+.A;=*3T+6ED+KD3T*%'CDY\$^/0.!43-I8<9)0B6415C<7A74G,7F:5R(-F M/(#.2V&%)++AB262N<5AU??
KS3'\$[Q8W!ZMHLS*ENV94(2Z8EH3\$-7;UKBU6 M2N6+ G=&PPRL]+K
M(NB\ \$7Y9120UJ^ .YI)6MZ06VC[IR97KU-L="P7@ ;65,E\$\$. 'A#28(@(/&I+49Y>/!BA6AG\|V%1A>?{N=["
MVE0@/HIR&9AW9-" ,?PQ!JE=W0AC|E"9 (E%0WY]>#FZ327R^40+0LJ)W5&YG MNQOH\04_X>ZQNH:.]DA"#57-
)E8E8%SNGL1G\C\$;NSZ0J4WLIFH08,WW)C!8 M60UV>WS=3D*T0X+7S2[G@ =5%3H.K8# :0,
\$J%9FI1X@%/Z6PTE) _F!]:^? MC,S{((T; ;F0,0I01RBCFDIT#F)I]?XZ+@700BNF02[R: *9PH-WS=JN^[- 1I
M6PCHT7*,EE; +!YP VN.M-(DAI+; ;!>*IU6'[- G,>ZR3G=T'>+A+RAM&7^D<- M|CH
[9%8RR5.0LEGP70UE1Y8:M"= ,!WJ&\;0%]9ZKOK)<@DKK^FOTI:9+0^ MZ47%QQH/0!
[+'ZH!>S"S+!F&\$ _UKJCD#B/A:\$SC):X;[& "T2\2+7/54J70\$ M9*).WR@)@C@C\(?MBY MXHW"B\
(04C'2/Z4+'[H43VP.6.:J:YI<-#80;J>P0;^CIYZ/%NX5.PK^K!P/
MKG&+WUXP<' /B9XUN+JS/!DG"UX(=-2,=@H/"\$S!VE-1^ !2X!=EY ;S1;^ M27^.=KM9W-
8R1(P#BM:\$Z/PLT,S6JT+!/N-,FI]/%5W%\$F[DRB0^26J0^/!+
M7!7[Q 2WE&Z"5S7#D#M7@]VF3H^(/P'CBW23;@= /['Q!@YO MRTH!1\2\QV6?VLAL.)(>CKPMOK52^[R'^.,?
FHB5)4K<1%U[LJWG*A %+4E|0_) \M97/, \A,0=PBC2\7'] [7^05.\$>.2/9" ?[Z?
##)],M>5=3\+%; -7E<7/!%0 M& GR+)HT/JTJ8+-0"Y!KZ?N&NU?, NG[(.WRB25*93!WKL;F\$:NFWA%
J0C5;72\$P[E M2RY^X"2!'P-N 9X"E:8;&M8? [X=>6PVK)(Z!]*6I#]+
[91]8M(49S\ 9AB0^P2A'HBUMMR3NUYK M_I8@B MZK7U[(&#P)CCD.0!F1%#HE|I#V7BL(=2I*Z')9\; %
J]RM#RU07&7H&'DATU MMOW>7.#.)44A/_0BYT<[]\$@^=2K?T YT*K,RQ7UA\$M.GN0ZP
M"/@EUU;JWM=TJN3,0 RIX2@VJ8WAQU*I+?X<+0X*(+-8P0F(S(M_9GZ?==CJIKJ;60J];I#+@WG<^?
>'P8.CO'# _MKON(H>7@W\$ZAV8A5J4DXVV; ;K\$9.P)293,BG'LYD:GXMI4V4]HY4 _XWD=ZDE M7+>;A"[*&H"
(Y(Y1+[XVW.TC48<'R[/SFF; ;@Y+I#TR=[P59C54&D9<..TV
M831;"QB4ER\=AMAIAN.8ZL(BSW\$K0>S>QE#00%WM#VZ?:536]FA/9C-9%'M
M@]=2!*2TI*W=XN0>F&\5K4P[T!^B\SA M?GAXY<1J\0NY(G*1I.L2J0DP8T%W6*5UB0.)'?
#F\5)8TXWR\I&WP0)6<> , M,/QWDA+HJ&ANZ%Y .;H8-29QUV2NU805; ;7W\$2/7LBIGKE(-[6#3F/M&
MJUOM,0^B-Z W7H1:RZ/8PX+JFDI%V@8,KI50"R6'6!;)M-RY\$^+ _5,V757S\$ M0/5;4 _|P0SRMX)L'[*0:AM>?
DH19HJQ& MV:S8<;RLJ]P?!YK/!BJ)M\N%DMD=3 ^&;@XA9K!S*
MY5Z[N+9DV/G+\$Y30WAW\$5'L3\;B? .625E?I *4;+W@8>L\$CDVLTNLK]9; ;E
MA(RZ>*)=JWT30;EFC4UR8H5, _V,7LMA@4"-^8_Y0Q/950=)HHJ4MBR6MEI%R MY\/,<.[+DY\$ _V^2CL4LAU4
+R)DAIYU=?WXV2Z1I2G- [3\ *)Y(XWP#KZ M&X=L3&>*AD9;I.%8B<+N 9KKM,W>?
L"P75ZL<2PV%9!\$+R+|K+F_K\F3D3GH M_SL@4-*393-R*! !6\7("9.^@9U"G\N[8B4&USDC+,D[WRZ=RZR?
U;NU*5""* M8S+BCP?|#YVH]' '=D/+HZ/*6B]) \ [,9@6>;VKK\$V=5M,!]S" _I\$Y/7,7G2 M4W"*>
Q2^Q#KA6+3!3<;A9^X>2N[=% M^FSEOK<3 _=BQH\&\$7^(&^6A44>2IJNK1 46M9B5Y[W70/\$3A?X<>10)N.ZW
MMER"3=*|B@=,0R=X0ZK43=T7V15Y. 'E(&"71&7,M^(B,PJ<;*.91%3#"V'+2(CG\$*0R0.L,@
MSB[;2).&56'&ZG;|@?K\N2>.5"8*=JMTCD4-S0548F*P=*Z@I".1Q<+"GB
M0\ 'J3J0FDC7ZQ: 'F;MDQ.%Y^E&#N!S"J\$3^EXF _J1-
=QHV%J5R^E'#4UW+=]*0#*=ZB.%PBJ^ .AT;BV555U=^>Z*RC]-G4VIA M#BR^8WZU\(\$4RU0,/A19M8_I2,+!=
>>H0\$ LAP]BV'X(?N-WOE ^JYW,0):4 M?DF6=:#5,0SC%S9[/((#T G &PQ+T'S^@973A07_YEXUQ\)&@U2RF?
_WDF7 M=3@,Y^*4N7WC-8>R\$:&3=G-.=.JYMBGKC?L1J!]>"00>LJ ?<2,\$./+GXV7,L-&,(#F&6Y5M/0
MJ&'8@0A1YW4SA1&L-1F+SF//TJSNSYK^R2?E=/@>S M|0*L'0@&ROY!X7E4S M^3@D-\$/:3NUR&'E\D14A\$
M8Y5S=^NBSGM0/,5+EZL>\$C[^K/*A=8GEI<-N/A]>U" T@K.52#M^N- MJ?W<+B).*\$-
_6!;9ARMORBIF*>U91[UKKBVOEFS/T2WEC5GE ?4J'CUK)#2@_MGB0(MDVP'9PDNA+TL>M;M+/D)D=
(R7#1BT4L_46\$00C6VEFI^D&%T@DL2B[W\$P;W8' _9'4U=,U4N]W YP'CC-)0(, (U]?-("ZC-Z
M^=&].AF: &W%9J1=VRU9<-9C)X!@);8H*!T\$^5PS!R+E0 \$ _E6+[5%:74HUY+TD
Q5)W8Q7S_+\$+J@2&X1B\4E\A,%CQTJJJY !UC-NL?X+^7\$ _M MEW:B9T*#UU??W.UV.XM^V_0TB4
F+&N&R=18W/Z].VOM: #)">6]EVM[C:\$W MA)R!A_Q:IP _TV6T8:7V%U> %\ .FMF|VCG*2 G@?>FIXQ61!3" ZQ
J]V08*X M"]OU_P\8]4W!GB? \2R;198]J(\$&\$5X#';)=P[-MGIE3R'+^MZR5JE]H_Q^M-\$-80;>KE.=1; _"
;56]Q:5*B4[U. \M5/Y80K'9;L]KK,&33>YS>V,3*B+[(MP194\$VLI=4RRCLJV;1_6_B:"_*E
D^';/\$#GVHG'IUC;B_0/MGD?.V#08D66 MC+;G6-
].@[R^0:&\$.FM)AXT; >%89I97<46IKKCY>6+&;BA%+HN*L&C-,NB.^ MTV4SB]/I0-E%)/7B^S4R%!?
B! !H.LX8RVD\$SS/+7*CN= _QYF:E%FQ3+U5?K M S>-ZCMAH*M%I ?BFI/\(#0 _JAP^"6\$YJJG1&07]?0@
8X#>\$ VZJ2RY/[/ MS:8LQE7;"50C-IU./V _ ,]L 483_9B0PBA>0C(#XZCXS! ?W^T,LK@D^-L!I;
M#,1(+>\Z/I)?'F5MS]"LM*]NNG81@J7(%L@-U3% *AX'/-5DF)'; ;Z&\-
M=@E_Y%=U^"4NOL;H.A\B)M"/(/=00"* .U2\$|F)>C^ _"#E#F/)3&S.,ZY]*+J
M^X""BC6Y@0V#V=R56Z68IUZ4K0:\$ (;*.T!5WD6NGCVR]TQ"X _ .SU, \]9JL27 MK-GDH8Y/
) *CGI:AF06U(T&B*+7/-)Q: '\YLB8R)\$D; ;ZD)64^!1H\ICY5 M9&9H^(U1JWA0)'V6)'#WK21_\5-
D(/[/Q+050,P5M,=;6P8WNBC;CI+ \-,4- MY1'?=TTX:E&\+FK&DWS-1T(.:.*AZ_XITVPQMEX&!S6H%WB-^CH\
<=%K25)3 MN:]\$']NRL:%B15&]0U@=\$)R!#40E2YW=3(TMST/-PP M\7/?^Z5'/%*SG)&LM; -
Q>."&3XP[>00SHC@7#.A.T1NG^HPP![\+L]XIIGK-\F#LK6+ M+PV^7' NSU5]A[U[B'Y^TP[8+'17RK
V;6TSKQ:B @CHR6IJ0@;EU080BM' M!-(*NU&; <>.B^9W\^H!\<-?G:F& (-?+U9 _."P:8.<8 M6-,G\$U=
#&B%:Y/QY"0%QH\$?.;QOCK\>?>H007KS\3[B-;IW*M0\$(N3LMX M%#@)-@>A,!8Q);(HSP[/%.4I MV9
G!CW0^=+1&79NUN)IR8(] D#7\$30@&2I0@Y8ILI*KG;*D.+JJ=\&T!-5T M?BB.4+J0.
_X5A34\328\2K#. :169ZL460#1-->/LZ4<94@=I T6.S=GRT#6EYNLKYBE:DY85
ME5K'L8D1Q=YY3P\PMW&H:17P20! ?ZCIG.0?%D5)<;D9H0+:(*7?C/3Z!)=)A_M,<=BFU-JLZ(Q,?UK3%Z]
<>%ER@L9Y,A\$/*#M8)I#%7GKZZ@ "OH^(:;3?.0Z
M;PD^(D0^PMK7+Y76^:5I7N(FV6C&FD3\F(=QW&A'D+00F70*TU\ _=>S:Z57(

M[3;=J(.MVL>.W+2#)*'#&&F4^@77/)[-"LM45"!35T_VY060608H'2*]D6/.\$ MWCAT/IS-1\] Y+,PI'-
+"T9#[I[B\$5D#LJ?DARI\WDDY?2*L'5\3DKAR9J-F*G&>*0-&&W1C,<)>RUU']2!
M@IFHY=G&\$"CDJ=7)]3JYVYGR)TS6W2CLO;BV).,DX>U'.@%&& MR(/ "X#K^0.CXBL6=0;]5VWZPP3W#GC1 U?
<.:10\$]4N=,L\IHA0D>PPC+.1 ME!Y.)/7RRE40\7U:\$HRCG0%CO:AM\$,ZRC;="WA"XBNM=5&&SY0B#.SY1LF)Q
MB)=R5N\$L("7?M!X9ZVK2X@R8! /H&Y8D&@V!R/%*Z\:+^X(+ !KG\DDW0WC M*&"Q6F){SOM-
%R1L11=4X%60@=2\$GZUPNYV1=RF70U_4I.L;B']S*,ZV?\$UT MV&3SFB2VY2/KT.6BXE,&B0 M@&DV
CO>]R,:WKPO0 B?G]Q+Q_93!|T&]9KF99R0E2:0*Y@?4_C2H MYVB"PKXYU3('0B>3,TBD"X16:,OUT!TZ6X"
[,Q7=Q++EL&+^ 2*YH\X!7< T M.=5+W^-M<0>'Y[?HF]LF1YB7?N8C\C? :!F#&D0F.MF\$'25SW;:AH^V=9,:T
MQ*I+^^!B\16L7WX7&[P""9271&LBS5<:IR)\$&=UV^4JHIEN3^SA%,\$ 97Y6\$ MZQWF
;N1R^=,*"\$T]W&&!912LZ^>*02>&[FZF)6B2BV[M5I*BW#?'3"P+3_Z M".
UW()5).5"\$5DCEW_EJ]0>RH= #7^'F<2P8(P_\$P5?470,./AFRN!Q3K< M.R)V505F\$7?0#7M_3I+I;:E"-<
9BWI!N=1)R;#D1X/N/ M]TQ2:9-YK;]E*(F@Z!P*#%+D69#T^2NL/D/Z(X[9I1/\2_TA&!\&MAO\WF>J MB;V)
[P(9_F\:\!J_".GDH^N;P?35\$8Y[J0!M9\$59P]J4P]4\$MPKD(?!I\$^# MC0" T ,#5)JX1-
U\HE=VDC^XGL.VX\$U]!H]IV& GR1=P<: MX;J*!T0M\$5PZMN\C"<%)_ =JR*\$V?
L7^Z\$('S2ZV>U.BANH2.I-.8A1L,VN' M;ICZ7%\;<0LE77!4FPL (?
^64LLD\$:/DQXQ,#I*U7073VM7=*QT14W]_L'>G MSY7L6XI^3H883T-<+*50P[]GR7>0Q<',<[2'/9C):^J%)CR-
/T7CFW2I>#/\W MG&Q+*\$T:B]!S'/'*X+A++I=X9/XZNE!)T.W<+=6A7BY*<]9PY;)K#X-8:U\4
M1A:UVMRV4R%N3]+A8Q0P^ZQ6T1/SM?YL7C%0N;_9DQM&B9XS@=!]S8&G+*I\
M5=SYMHMGZ9/[J<[B1<[>GDXS.^X!7&*&P\^K46\$(DBYPM,];,,)^>Y&A+ %W M?I9V'"X1K7RP<8%\GM_8??
M]4CH#3R;2&0Q9SM\XPUX\$*NCCFF8N=\$_JQLAIA6 MZ_G_:=ID]Q\$+N&>5T?C_70\$ @1C_T00?#+[S0!W@
IV\$7!'6UB0"8_M9TDW9\$7S5-'[:TDTUZ;?)M;@B2*M7EI,J&\PK=:+) _FD5>?W^]T9/M\$+8UM
M1!_,E98HUEW\;+IGXJ6,HWJ ?,)\$_.9V@:4A<\$<(Z_(0?|T50^&YL[@->@_I. MIZ,ZWC4NYI2GE;H\&"
[[_;L[2B_S.IL+9W2;6V/GD;MH"(4'A#) V*M\1=8G M%\M^GIUB.DX0+'*_L>#&3UW>_\
AD4LY8\$UVCXJ,U.@8\ 'Q%='KS+-\&1&] M=A-V&-*JTK00Y)'ZKR7-395' '2P/5A4J/6EC;\$QI;MF*U'K_B6+7%
[Y4+'T];:4.Y[%L8V MQ.\@M7G71\A1QG./%Q51;..SEJ5X!_6SB%Z21H8;90KCT\S(W)V-HCG9F M^;%P9)IE?
X6U.9*&(!4B<'SB4(+>)%UY\50TQ-0IXHTIE0C\B&1_Q#4];\$I. M\L#
(55J9T5.2U#7\$M++I]9F^)CGEC]5PWNPYORG1=+M\$ZR&)_VF.Q?93?>] M*)_AND<: # -V=+*^WT#6N*KB-
\$+[,UOVIQ_N]VRI(ZQI=V>^UNVH=AGNP,[SD M%:-5.VGYS#+*T?I4>)-\0S)YW6C/'++[[,6.B?T0/?M_>:)/)-
W0E'CU15H\92_M\Q)S@R=B1RRHK>G!N("N.CM%A'FS[=A@QYM#X7#H5U0H/P]/XW1Y3*D4R+2)!+Z=?E]9-
DQ35.M1],\;)F[=!XFIPV##]KSW0-&M^[']SUSX_M72D^+SP0)@W_7_W%\.[^2\LSAT\^""^3ZQW\?
4X7\$E4PYNISKNI?{04/FAC5P_MV:X(*!A+L+%51C-DEAN^&70GW)EW938<+(G)S0BVQH^DU572D!\$FL)EM)Z7S
MF82X.!]-369:(LE/S0_0&)E-IP[|T2XWC==Z\$/_?:^(:M2]9*5(D/,@T,; MBNR2/\H-
M]&4J],A#QY,DAI(,;T>?'>I*R;K#DDW[N]2P5>;-YD_T:)"-B'R:S]Q7N67??BYG5>?(Q(V0S8R@-
RNTG8:VBU/<49*5Y]42Z803K+ M-
6/ZB:/[4@X6.ZU?.WV7&,Z<"TWN@)X52A(%Y=Y">.4+M2)9[4X9L2TA)*0%<8#UH@\28R*\$-3]\2KRP3\$%B]@Y
M[\^>!=M=-5^0'[7?][6(Y=.FQT(']:SR.N!\$(G)[NU%+S/N>Y_>]-#RIMZU M=-.-?
<9,RJ\$3(@-37<[|,0YU53\$7IG:HK7:M0KLBZSMA9&Z^NYID7HF%=VN_M<:8_V7FHHM.X3D1?/PS=WPA8!QY
[R71P90< M(=IH)P_#|Y|":X":.2@NOMHY96'2#BG?1|E0(1K?N ML+^<05N@Q?P5./%J=-@6'U-
XAJU!_SU79^,1A/95E4!@;.]JP4+T [:2+ M^[_8>P^XJ+HE7[3-B@1!D1PD2;)F5:4+" Y@X@2):<&&EI%.7?
>^?W8U_ZKUEZ]5JVJ^J : M:W=W0Q+9MR[\\$_>[8>DT90R&-LOT"X>E3N\$?.,=16S8B_B*NJN@QU#\$0V6!2#
M=MI@=7-PD'.5_Y2W1S"(9>:NJ,+),\Y?&>^J_Q81/5*Z(>8>PE\
<7P4[:V<3!|KJ:X\ _HL1X1RWIX>6FQ]8<'5XG ML9F)J*2.[12Y0-IP;I89LW:BX7R#J>:)TXSTQ9@IG46+Z
/A[US&_KJ,[B70_MI[F^>U5VC[D>%0_2M),6Z'C!06YP\GD>-"I"/_VT9T@41^/CD9=E;877"]>
MB'W[\&A3(S+K;:,K\$=E\$;,<]#0VG,6UTV_M3P)'^_VJZ]T#S5L_@D+SA4>'Z
M:=5:!.#1H.Y/93S]2@98M4VJIZQFK-0\%/V_(0?"XAZ(_0/#VJ>2G_J_M;B-
[F#U0C_E,IXC+C,SPMZSZRF^*:H+D>\W19^ZA82,\8\$@EWS\J.ZI-<2!] M?
=7CS!.Q@^(17KG\Y0BD!4;HR%;N!R_ ^B5_*BP"=V)T"0+#{F]G%A@#@J&+8\$
M066^_85<;QCKK_895Z2V0EB10[L01F(#T6>--A_R88WVW710I]3'P="(MMUT+[H88[MSX;DI\$8_9#
H#\$' '7<5N*W_MZ%5PMVHQW= ^V>7QD6U*5C3EWDAA7=VEX(3IN[1U@L;:0AZ+0A9G9I1!8H;^7U0;TCX[D<
_5;]3H75A6Y_VVZ[IX_0V3&,^VG_M^K,7;YZ(DA@?
[6B/W+^Y.FMA6M765R50F5ZWY.STX"%2]U=1P@I;8DL>2Q7H_MZVB]G4=34!^=0=TNON15H=W^33/5?E
I7RFQVOU.%8I'K9!;,XXVS8@Y?G0) M^UN41@6NE)NG*(]8T75U=1=2#F+KAL,TQ2%5G^Z:T
M!/(SRGV&EXN"3*I_3/&>5^FQ=V2%,'V2=%@STE0L"D773BL0Q8J]0^?'I*lw92QIPE-Z%0+#E3)P>UUA9#
M#M8>_3**52F"V,\I_*K"L.]#BU6W>SZ\571;2R--=\$?,M^]0@;GBL&@3(WPG_MU4;6DMC/7K;7LRLQ-ZAZ.TW
FKQ=/V\Z7PPZ,3*,52\!P;3" M-XW'5L?X\$Y|XC?N^CY(N?-=[)PGS1<7I&0VG]0_FK_L*UDK"0S">RL@FQ9>X
M#+=+FEP,]B7)-;I5;P!KUW:#D=\S:51Y5\EP@03Q9*:LK/:CT;Y_*,0JGM
M27BV#^BDU6&,)#2G,I#)9JZD3+%;2^Z5.16#-^16*97AF#-8H=C"?BHRXQ4._MV^?
I,L^]JL]6._&&>_E43Y6K6SNN,D3GMG&Q+K?JNC<19U;_RMF_M_AA1ZF_M@X=^4#+
[,>.2]RW36M]JPA>G%CJ@Y4,*'USFZH&J^0H\];^:Q7(RK6K1(:C._M3N=7CY'L-
+BI&@\$W5VC[,I;CYV9TG&KY%G;T['C\$@,_,ZJXTGK%)DJQ):Z#N_M3L91;S;W>N9#UCR[20VX^(S50Y[1(CF?
1DWYW?E._H_)#6PN0ULICDW)\$DGD_M1'D<#2/S5%@24V8U?06{&4T7'.V8ZD?]|F2-0HUZ[!\Q*':
<#0GK6^TL3WZP M=-VA?[[P!;DS5Z#U."&CUZU-/SXB(166,@E61+ M@ZK+7G1[7Z1^_OPKFQ?4L_)7TL10.-
EiY[RXEGY/^8//45)I+Y7]C@^C4"]H MH]-50K;HZVM.+N>0%
(]R0:\._HG06Z9CHJGSM^Q)OF[Z1JW@9E)I_5]/>0?E_M0A?>B*TO>/1.RB8Z\=<4&?(12K-
52G?,*T.T+D%DSD6\27TKFYDD=TWQ->#J_MA_HQ#UX(F_=IK5&_MUU#3V9W2LN9L2J:ZDLM;+JB90
,:!"8@NUBS_1;3%2@2J!^]-\$1'_%"B8WKT3S1#C#8^;18R6"_UNI;G5)H_M-YS;<.K?YNNV?Q'&L;??
C)".N>N@6=AG&W6'\X5RDI#)VJLG1(&NESYF?LD:C:J"+H%5/<:DY:Z(6=56G>'\&/;#R-T!_M.X\$-G(19]J#

\$G!C(\$S\$>R3,U4#1E#8K;75S1^-5-.8Z&%X'USQ(;K6'*5[MJ+N9D5Z/2GB6"N-KUD}[0LZQW3@X]XL
8)#Q_HPF=/D._0Y(/+?F4 JZ*1? MR/R.IGNY5MW,535#+!AE?'8[U?QY6J9JACT*5L7Y')9-
NHW50^;L@'Y@8J&Y M+AYZ&)5?PQ.#5H(W"MSM\$S]\-W%9Y&[3@,%YM13T#:JLNI\Q-*>_B;FX]U;290F09!;.,^
M#6U0"Y]?D]BE[7ELF0@G M+0,D1X7XZ1'+L;NS(U/LJ M)Y:M7\$3GK4 07>S'YF?ZA0YSXM]PR;_7YP3 EE)C;-
M;ON3I3E(D3T5YLE; M>]@.CVKMM#CYZ"1;=JN;=K!5RJ=Y!;QS)NYJ1HM"+Z'<]YC^A
MZAGE#JL^X0+4+Q'9@K#NQV1+P%;# P/QRL1A3:05M; BK?;:>B6KW+,H!7H+
MJSUV[P_'Z6"N<&WR!>0>"P]%UU;M]4(AM8S67'<'> Q/BE"]#J:3F=3M^G)T M2DY6>>
(*5"&^7!R3^;!P_B,BI?C?[6B&!Z"[G03L]H:UDGT1_J;0H M:M%(S+A]>/LTTK<+5H#A,;0-
PM(=!1&MSW4M87W5>Q75*:9K>CHTW]UR&EU M#+]=_QL/_;WR,MR<#69"ETDS.ZU '\&_21G=/IE0PUU"P?
NQ>=E-RB!92T,X MS??3<+M!7N-D9;-ZS%5TJ^ZN>!A2=)YD V@UXM@+0=QR?9F[-
+IXX0GWT\0L4\5&2=9^B('1R.FJCI>LVL8-50.T04D54.=+IC#:HW< WSNYC&/V4U_5999&_19-+}]G\$
MY;UN,JL!0(!7V%>J9760;Z=2F^T0%+K*D@5R@0SMGE3F_4 "J,80NYG+7 M3"S:IF@W2#-]Q9/?
V'^L@&\$8N09"A*%<TEE!<9JN HVQMN9C+]M\4@M2*[[C MW[-'U-ERLLK^A\>F,]X[4QH#SY9X0L04 +A3946)0
P%@WVW(EA@[OKLA5GZA[L, M-3(&*E3(-,0[F:4./E@>:8HM41DBA#RV>4#6WZ'C:UZANH.[7DQ[@21&"6*
MMZF (>-1'D4WP,][2&]XXWLK)0 4H =+GV65H8*HD\$A1"! ,H[MA\W D_73C[M]63?
QX%1E:5#30=\$J30B)U%'5IA>&LS:T044*5]E5U %0L8.8PL_8]"INNS MU\9/:7&/&'HH#ER3(U'2J4RS>8;%
X,W^WBS I_%]!;7 [.W <-Y\$[('N< M) %000#'RMPG9'69VT1[*+^ \.^VHZ/*EG!.*%
7+)KJ>R9DA7G+0= RX<=< MXWT7SIFU4^;VC_- '/[7'RK^S3K[DG]K[?.[1 JJ00QS=0PIMH&]RVRI%L
MB]S' _&&*3/,BX%,3YJ0P+N*SB@' ?;:X-Q(046-[<^!J#-7)-076\>^UWG9 M2H"5FAZ0/HJ \$0!N/
MVN8/.#8) #17#0&PR'/@ 4FRU+FH=*T?GS8MY8IS6*W\$'L&\N0#X_3 N]08 M/\$L,6B] C #X
CSK0&;U,Z1);I'=-, -C'9BKf8N? WQX&SR,=VKE%AN>%T MD)^99W):R%LZ@U/9?RL-@U\[(NY*H^,N!(#!.@\$@>-
+^K]3#20 \$&2PYG]X^ M_+T\$?@:"HCR5[J,?//2< 990_9]@&3V%] :X0EJ*4##QR\$ +@BSH15"(C>50+Q-
_,FVR+Z0[]X :H"tiny2/:').]\0Y& /SS M"^C@G.UJ3%\$I_0?
V/\J]AP[C _UF)'MCLP;R7.0T9.T.]IJFG>F?1D![3T+]P_]>G^D?' \[/P,;_ M]:/]G\KK@P;U)A0N06]7(H#?
_F9FHM_DBYX^QM0;]_9EVb(\$/4\2K%30? \ MRG9-%:UBJ>>>*K]DMBH1=(_%[YTY;?/4!7<"X\$Y?YB !
<"!6\F0HR.WUL5!D M'35W0]V\&ETYJETNULZA\K0]JTQ+X59.--' _/'"V2HI0'2IS]*_!3=^'UBL(\V^,L?
EP;_UF:/G#.;MLX_ M/]_IL[\9WC'\$ _U=']:G,SCD _TG^JMZ?5QHY\ />F8?_,FU1D?M[]F, 7R^P
M7Q@+*6"R^,5Y8>;/.P+H_PVBEACH'WC>-%>CDM8_10*_UB8_/& ("]Y,7[+ M/YLMZE(9^&,WC M3*
6N+LC%ZAV8PIR5I/12B-#9P7_+//?2=2T' 'Z>]X,HF?J?(M'V^?#',XK8
M2S>>RR9KB_4^5PV!V2@/\03GDM" I-7E_KU^2'@G%RP42< 8D((@-) "JA\ MR_,(@,XS[1F_
3\PT?;_!CLM>\KMQWJ/R\$>5\$IV+\LTY26S_=2Y_QK?09W]V MC>CYI2B%/L9S51I:9<2 M_7GWF[+G,LJK^E,
W_Z5N?\$X#[]NU0GEV@^'YZV,=N3G*?MCQ\Z=]\$_%_0=G MLZ^8S^ \([\$/5=X'8""^(@'PUHV
MW7<>&M(>Z\ S[K_Z]G_T;2Q?Q_B-<,-0^ \,P?XKX"_.S&M0%9W_ MP+J';9HS<1I(04;ZC1>X6_'3-
>'[AI>,+F_Ssu+=AJS/Z)/F=M#EV%NJ:W+ M*17K)7738DJG_5-0F0==^+7#H@B?M^0SC]E;
<]Z>Q"RU>:]%CM5C]197#F* MV8VVH)]!0]K:CE]U)#J'L&>1>"[?Y5M!I9UZ005V+9!V" \$2--/#P>W**>D
MF->#Z79K_C)8>4(KL\ (2W%A,A72U_N(KC#I3 MDXXE6,WMWQ=*VB<>24#(_D89F5\$*=::_SK0[E:SYSP*6U6Z?
^T_?W**+F[@= _M@Z9"S!>B?3!/T9".#.:JGZ*Z+LC7>=60B_'M"R_M_\$ER=>E5AV4N
5J4W*YGG^:9['=)\5*>Q=0#,DVYA#U M+ '-IB510 NM"81>UA=QCW]SH8AZ/@B\$M_>BY"LE" I'*:Z(W@R])-
RD??ARAG MX'7DVS^8!3ZZM3HMF4+;1U'7VN??R&@['\ **?@S[]X'VWVK%)H3J]EF56!_M"Q-
RT5KR@L9K,">NV*.10WT0*[O()Z7FI\89U]:1M-9+_*.:S2:0GE.]N\$U8 M4+(%L9\$KZ4YI08_+BCK1@U8-
9,00+8;_*V""2@:;55?7?N0E+<- /156(KCUG
M(NHE2@.79#R\UNCX_.,.,U^;P652T2=LR"-9#'.SZ!\.LOAH9VPH]S%#H3/TV M:W#!AA,5M.%=>KB)6#:/W
1#;L*Y:U/F. MOS\$V?#08D%004\VR_(5762EL?)(FEZZW_\$"&#+XA;*&!%4'C/H/UQ_&_M*B/45:9+M-
K1#+JOCBN]7:94_8D//4> >\$CHYW^>5EL[CT!06!-7K MBJL_L%? \-#LA\$0'D%D%XYHJ*49\$2MU.D<3^)+#^K-
_4#5M>ID@HKQWA>X\$K2 M!6(%)>G&40:PK_E:BEY:>[(\LF=LX-?GU.+> 4+/M;^M#&;\%PYB%5^8F8ZP_.2+/L-
MH%VU+3.N(+9"5S'7JN')5: !Y[M@<'A?_M47_U\&]UPR_7!/&GBZ!>05,#G M^\$,^?[[F_F_X#8]"X@V23J=&H
6^/\N3'J:E(MGMY51\$]=H [3C2R)LL2A1" M:@2B_-
=?' #KU\W1PF&GX_Z(#1NCN8<0.DKT4%'R@X;AU&/54:+JSM0_XDQOP M]Z[U[U(JON2KP=26L8+C-55_:1I@+1
VTRTKCEGU<_.D*51[. ;+9-]9:N47 MV^>B\$DZU]9#&6T;+2T"AN>8!ZW4D,Z(Z)(\NR<=%1MD(AV"=
_Z:++T+G]X M<)-_I[[&NF'XJ/]ASS M/_FT<\$3ID[8]ADXKT7>T4#%M*W09#4B"YT#[+68DLV^'N-
X#+>^50F;0XPA7 M]ZOL*FQ[_L;%S9< \A9MLPCKQ-\$AM@MP@8Z6_F%8 [(&)8678*P5>(<_DB.,_-
MXK8K^OW#.:Z99&5U9WA""V.LDK]^R^>35[XW2/D%(APSQ-A?1AE*D\>1*>MD92_
M^X!0=^>JXTLKVI,]1KC[SUR0H\$?;
M&FFR=6E<55RN0FZK>S(Q81]EH[./_%!\8%D%ZZ>Y86(; '-7IKT++ZX+\!#N- M4=
W\TP'9\$'F9(U#57[]JJJL;#JMU?)"COWW>8]6*ZF\\$_WT_0,Z]NI^7E;&6
M&MJNN4GT*3W>0';^A0"@.FRT:IGC&SW,0&S/R(30*'?X6_+-B94;#UV.K4X.
MD]M)\$'XS#_ ;8:09!CBK'&HQDEI309I!".M<4A:B1>!\^C7X9LETM=7,-Q9 "7!Q8#ULM'V3'<)/0- M)"EA]2-
A0\$.&1&]D\$XC]\8/\V5:.)U\':+*T[55,/5%Z/NO#.H,GC(V[\T?1 M@P',#KL@WYVG(P?
^;MK3C@*0T>S\7E] \$TP*DH0A]=A-\$S0AXW=A*L-B=OHX
M^<#2@A'=:5J!3L3HVU* @W22(Q;R37IC42%*I77ZG%M(_>&Q%PJ2#+QJF/*)/
MP3Q)P9RLG>I\$IGK9?'E7(-50VG]T^X\HLS1[]#S">10RGX_V'0&=UZ+V#*[_ M\Q57R(SQ;)SCFE'F0\
(UVB0/*\Y/? *<1ZUO_FT+]S\G4?B2#B]4VL\$ _Z]I MD5\)>#XK8/P4&N;)ZI"-E6X8*=V%#&XYI:1%\$E=?
J>T(J#I(@&S>;J"R\3? MM[,@:K!T+W*X-:=F)Y;_.7H"AX)%@7W(=4\ "0-;KWJZ0^V_ ;11-DGV#]2U']Z
M&O@=2"NCM#APQ\A.'\$Y<-4 \-4.C.V^APEK,;F4CR2A/ZN6XB=4+0UTZ2DG^ MW@2LWXU*?K\ \[L37?
2>.;I3,04DD?0G1;7)8P/_X[XMYR_(S0\$DHM-(2E77C?>;T\$.7]YY30!LB>9"D(U\SES"ZC#A_,U MA/_
Y\K9\ '? CG_K?>CN+AP70.LPQ##.DR_V+^4F'B_W,4HZEBO^V7?#K061% MN3EW"=41AKK=60UI+M[]:-
KH8<2+9=4*3B;64HUQFB5ZRN8K89>1\ \;M_G:N M#C)V?%4M'ZVC-6M9'C!G\$P!ED\W0.+C-K(8S_/13:N?

=UN".QV9/:KHDN-\(MW/['00I)3CJA"K?NJF:(124 !0L?"-J182] \$ M>Y0SU9-F@!|T5AFJ"-
XS\$HX32]0<\$3/Q9I*RP[.-0ZP)@\$C?QHXYVSGF)+TD M\52M>,0&L&G? ;J+RUU]M/1(U_1N1?
VF9+0E:K[%@E)468054;HMBTNEJB;J M21'-Q#X;1=SC>Z\4)_?
*!9<+D32ZR]..%;34/W0+1XVF30P/KTZN2H8]-\$5R M?+GLJ<\TQZ!9;W
)E;^8A67>+2FM/%49>S)>9'<\$D;6T^\$1CP1Z>;(V8?"H M&'3<:BSWQ?U5 2A0;:ATB?
F'LY\2<.'ETX7FI_KW(,|AX!@*(,H_/BG]J;: MW63EAN%#3B=\$0&&40HD=K7(.KFUI)^K{X2%3C\$.!EML@G
M3:3LHJS^G*QB#T*_UL=!2/IF!-=RRDN@B.5C_X\>TQEYC3=;X;=%S=00\% 9 MM6*0QKY_=!B+7
2]DU(MBNJFC@-84Y@Y[KY^I*C/1D%^"[J;HD]@R.T0=;5+4+(\8/S M-X%]R'Q WK<(.PI(MLXIT
JVG<;MN%<0;)'=0=VN/[ZX MF[AGW\55>9UR M4KL'Y)N9V=T#HVN;#TI[\$' D0Q;VX3CR+
(+/L>5J^=Z;6SAW^YQ\$F,J/D-V MG AAG'N,8407*>WVR0^A1=V/:Q3MZP0^,BXIM" L8G\$K=+>Q N,V3+61:
_M31XH0)-4X4)P_UZ0F0 M_6=..SCT!(ACGX\3CAY ML/B- '!T)E]?
0_LIHXBKYO158%E]RQ8GS02A*D*HB99"2:9-LF0?M.-,CX4C MBSK)Z)5DQZVFL7Y+)72(^1"GPW1C)5CE6R-
P\$/?|I! ?YQUIW%U05=-P>7)"\ M3(NJQA4+6
6)/MI=TTUNC1#^AL!^,\$[ORMOM9CS/;Q ET5A9.') ,W"N\ \$FG=2F[VUS@2X+3SN9N?IB@IBJHI-SUNN
M(0T*^2K.=J\H#-.U9T[>IHBUI>Y;!=VH^AALS2*A*JN;S ^BR"JS4@0.7754 M>V 3"-:Z%B4CG+^9E 3STD^V?
2IHH5AP[^'6)8316YV8Q(HNP'%),05=]*Q0 M !QG96@L\$-X@ET%6-K;E>9-' :KR[:Z?:2^3P@7^2]MT#[D-
KEUVG^HXW2,R MP AR-JD+[M1\$,<9^?:J28@4;L4S,7 %Z7&6'Y]I^VAAXI??L761>Z>"2U_ M
1) @0< Q)/00;S?D^P8,#^\$?<&"4-:PTLD)4RSOV,&T7VW<#?[[PE05/P"J MZRN<)SZ67;|-
@I:|^'71 BP|YUN>#(4R59.\$9S*FJ0XZB M/"9?7SA\ 'B_0^"MX8\$,#\Q-N;=40T-?,|-
>P6:1"2HN_P]\S1ZL.M\$25S!J+ MN.9/[BC'01A4ND\ID\?JG +;840\AA^%,3(TAH(Z\$=NU""#\[04]32C-#W9N1
MA2'*QR21;4BY% ;>'CD>4V.[^:J6F3Z9NTDN&U/ZF*3XEX*QE&72,=AK!U!% M7(\$<)^BQ-MI)I
IH,-2@|-5<_5K2F'"GZY&"?1;0GUZBFGBB. ^Z)>];';% M]\3 INK2H6-9.NMMV>?3(A,4R0[MO R\$M0IPN*
MTL;3 OKKU,>B=BU: ?IK)[S8D];BESK0\$2;Z*T_U TDF7I+!OX1!I'M/GJ3 G M;C.LE5:H\$[E2?VXZBB?
^DR88K^_] AH.74CS8-:707@UG9XP2U #10J)3L^% MD.UI;R%2B76L&4 -KDV\$" ' !+
(>.!|F=130<5,>|'G|F3(J87]@)ZY-H)= MQSCQIC90=UCP#%5XNE11RXNLKY,WP|IKI&U^*Z68/BP!A
R4(B60PS10/C4 MC6\| !H:U00[+W,R6:|AV@K3"Y=9224UIFGew Q #+=WWS9?W)Q^/ WV1 W@ M;V6&,|+0)F-
9X7;X\$0<=W)>U\$S^9R4A9,3'W0P;I\8+G;QJ\ -L= 3Y80G3@L MO>HUF*_L; %5+-?
GJE)U@Y\Z^[\&1,I5G|X|T7%8#[VWY)4ZM<+P* MDG\$ I2T MW&H!%->L63^[:7 C\$5C/(/<8'W?
#3:|6@NT\|T0RT.CF[M=,J M&V.1,X-X-8ELE"+N_AKLW;)>-X1D7FJ=8.X5 ,8|'T.9 =TJ%"075F=\X3+
MI)QE*Z7H#/[G_.TJLIM8[D&L'D)=0YEUA!|! &A@Y!9W9;25593TEQ.B0@\$Z M ">N_6G8PC6E\?
4.H;H*I6_[2J]G_1+=X(Q*&F|17ZKWUU0?! M|6*;9E;5> M3KYE(GTG;*;A*9'@2ZN!GE7LM?LH]^/-+^+EM
MD^E-77!!80.M>"30;>3UZC#B2+ZE9PQY!0S!3V|8'!M2:[T=5;<@QMK6UN2 M/OPYHRJMD(0=BNM,
MH0E4:HKCR|[YWS-#803 '1E2T72;IQB&8; ,?EU_0Q+=J*[0\DU*7/Z&6Z6+
M/16_9*&&S0Z\;4'NR71M'=8'*9R8|B^T.6.,L9WVS6:%5(MCY|7F15<)>@,M8 MLR5(!-,-
T(BQG>.A8K(IJA&BK;*Q\ M\$ K'8H3 -=/R;RB/%RCHSDL%\EG.VI@^P576R)Z5KJNCW^>_Y_9UNZ01:"G&
M13=,9[IC'<&=;N_?"R686ECP;H_LBJT'V?T44:,6W> M4DP1(G:S2=N+-_\$#\$ M#5JZVS="727)B" T[B=R)TFD*
(,V'.E0?&\TA6W4B;3V& M^P\$6(-SH\6;X;E(?1A&T379%Z45=PMZ&H)I/X3Y#&>:1%8&\JM0LL00F3SA
MC'V\$#5YRWY66=;|Q_S#7=>B'TKVV^0+ M8,4D.7KDD \$<@V?CG(>G2/PCFT!-U!YN%9"F[6ZF?"JR77J>LK";
MPV R H!E-' ,0?B &?J+%(K^>0JE4#K=T#DL]: RH:I\ ;:3P]>\$2T8&?M, MO',+TD5[C*]1^6,Q
|,9=J6>5/B@)XD0\Y Y|,DEL#\2^EH=Q1'BQ>0%"Q@X|Z(MO'0S8V7J8S9A>S^4 [#6U^GZ+0WR0/304?08K^?
)*;-.VF\X.04CR,|(|Z< M?0] "M1V\$!Q^EKG0.?4E7'RON(Y>Y|L#^:UK-J)P!>PFG0WJWS)#M(
M42CY^JG T(9&AW3|U\|>C\$|-?P20_9)57I* 5"JU^0E\$)--R0&N@9AM;%8_B
MC6^];9EW79 =*/IJKTATI[124J|)A=##\$Z U,#AR2&2.[EENV"ONVT,UF"WR M-N?
T./K10,#H.%H3T1D,OL;+^0#G: ^2K*(W)I9/\A[XK [WS82*U%@+WWKMX
MSEX)F:07!F6W6E3D0Y%A0,RZF>14M;OZ1E>\GF;(E_5]KF:FC-Q N%#5U;T MYN+)//*FSRZLS?Q2_ =A!3SKM?
AM,(WBT>DD=*|AIK*&)^.. M(,TIC_EN:<@2B6SEK,G3".VJ#Q77&C"-+M[0]"&3M20(P-\$.WX1 !70UG0F
M|?"CX98D]|E|;?+;10DA0)?;L/3\$S+?|'Z2\D>IFM 8MHPG^"105^K6|X.N|
MW)MG7,B\B,64ER,>|8^6XWAhM\$JF.,&XKJMC5Q+#9=[&6(@LK4R;)>0<'7 7Q M.-9 XT&#P2^V2=UJ-R+QRBN-
U2Y=(-XE:0[5\PFR-|KD<|(IB7I1&*G%>< M-
0: ^R0+4=T,+HU"6.3: _C97"Q>/<*.EE6K;B\549711LW%51B#&T%[<_ F# MX71[R<;7<0,A'] =EWH65'F*/'80?
KVA2@#G\>UL',\4S2^%GAH1H@6+73V< M*9P|QC(JIW5.?)\$0TKL#8R#5@/79F>[G*R=8:9D&9ISC#+#.
+@D5HVOK_I MXJ"G@ZQB:VN V6%.DU:5K M TS5B@:+I0E/U:5)V(FR&95.GZY|/;KVA?) +
PCB949%.#;+FG@LG/WI+J5 MNFY=\$VI#9-)M\Y*-|?W;F("I 'ZT.(I|%.P>E1S%]|6T07!:[P25N I>4>
MVQ?(F/21Z"24FZYK| \&H|]|%R5/Rf4'JG.W|7/J;1\|I>C6?%)(9C6+D?ZW7L;X>25= " 0!3F60\ M?
G)C\@P90\)|[:@LIB6^_FX(;8VL>E5'D6Z0UX_W8;
M_@YW.\$\Y20/=H9\ZV5'YB("S_,RF+J#^HEL;X:I0V:EIW\KY6%PYID9\|!7 M3_*.XQ^TJ8UMCJ;VI/-A=#8+
<>6@M|G@21\%VEB\$G([E>GXUMY7SGYT)7K7& M>'X_6<8AE0J \P=WZH!;FPM\5/H5(Z|EQ?<
FC54K'@&GMMGVE06)X5S^_1_D MCG.MJ&0FNE /:NQ'V&834VOW!Y!){0'W#9/L;I5&0FM#6P2F^(54UBTT[#-I
M&F|D-(NV#T0<-%^IW|;EVV;YA#'"5*M5GNQ+6]"0('9|>#|;=%(\?QW\:"1K MQ!-
)ATP>;%\NPI4J\$P#>C;G;V00@'7:K*7Q?)FGOME6Z#,_=.-.-],750D5"0
M_6YII*QTX!,KMNGJA;*)3YXVVNF-. \)M37=M89GTG(40-)ISEBJ7^55F_.G4!I\$>AMJ=ZM]"-&0'
T1FKP<*&S]'4X,/J]6 M\RZ8:3=C-4;7/MP)>DLX)"@0^BC08&QG2*6HWX8@'V^D;P*B2/^T3_W!//;?-
R1'I1^QR+ '1BZ@R?ESA1>Q' M^FR#D0PA-! AP&0_.,(, @BLK*)V')OVGF*+Z#9;N_3Z]9V5G^Y_U^0QF@KA
M'!3 <.*.P!'=-(&G" F/[I,B.9R/\$E\SD@VYBRN|IM^TD[PCN&-#;:=B%M&# \$ M.?2YMU "T8R7?^(9\ ,! L.5?
I)\0/DUL-HDSK4X?;NIU30.39W4UQME'5)P M\3(.B\U2L\$13Y9B,4NZ\$693*0*R_-SUI|H\<
()0|@&EFU)F0"P<+Y*%|6H\ MR55=FZJL_US\$RVAU?X !U*T86.?P'G+F5UJ5E]' .5*>G_D5)5NVV.8 J:."<
M1/'>G*1.65,&3:>B834!UIS*91^V*)S,*,80F-,!&?2->@L,U\VVPE,KILS MJZ\6|!'!QS:B12|R/V8+NPE0.

[-]E"2*_U/=R/_A,>8\$Y:7\VM.S4HZ>U; MOEX[!/-!>#*T6HNNQ\$S1_W5A\TE\$4-#9U&##(EKHDG4U?
+M'YR9=K!@M@(@) MQM.K^,H \W!OH7<#A7WV5%99G/;0-J^MW \N00-&%G)&,A\U*(H0^@7P@1> MS
?)7#0#,8 IVS.=L&)=8W4D*J:#5 MR0L47G7^SDJ1R^];, &U-[-!#L97]-# &1-?5G-J^I?
AVQ&PD_Y0EX4^&/E MB\ ?&84W?-\-E]^@Y<-0G4&(6-_,.&'N2]K-V\DBK/DG.WTFWQ!3)> OM!W'. M=ZCKG"C-
>^N49<&BXGZ# ?8V5R?GK .')BX[&#>9+(SEMK)+C,AM^:)H M'YMGC?7C Y#J%'\HE+Q2FAY;UX)
(M^*\Q25)2B20X2P*(>I!0\$);U2:F+\$X M>-HAJTCDYD0RD6RWPJ<#3H50Y8@I]9)>%1<03FT*>5]>\$Z;
[-2N95SJ= (C M^N6?>2>8^&<#<,K8K":RPC#^329U6<\$LJE87.R3@.I:[*Q#%VW0/9-[310M: M:'IBSB?
#U("\L+N>S7;::^P5IF0V!C09+% P8Q^0P<@-2U(\1YR+@;I+B02 M^AD9/=KXWA Y':TY\$/V TE]I82?:8R
\$6"\$65+HQI\$E9?!^A%'M)V:Q09/HV MZPK=QRLGH?2^=00=M\WH^0ITYJ:3/QZ?2;3)!XXKXC]
(@-5G(CK*^3Z;*9>W M%DA .OF,K0<,)!V+S9)'Z\$TJS^Y;L?F]VHD242,CA8?S5W^R8:7XY"9@5.29 M
ET2G^Z]9M^RH;NDB&B:,M\$U-45?93NID7BEN.9EU@0X\.;5"8;D@9M.+ \MM'\ZLO/(E?;.023*7B,NHD.,4+
(->+2K: (@R; 6*B<%LF@%DE5";INF(+<\ M; \78/'<=%]5648,7.2S?
F]5Z0^V.Z@E^76" %N/&&IDSG.K+^0.D5&G1IFV6 M!Z\$10E12-B5KW(0A<5160+L>Q*Y:/0(J=LF/X
MYON\$GF;:VDQ90?2JE 0\C\VL4[R1>M1M^T<8K/.R[D]LDM_9)T7V.JY*=I!M M--U2.,&C51S//TC]9=8?
G6]#&.&?W%P02 M3^RW"MVW\$;Y'<4U]8:T0DE3-2 ;CY^*1F4.BYJ3^&U2!L%-K&:S
MF]2)&YBGA\G@+FSS]\$P?6:*=(@WP MY(W?7>B0XY=D/H#V-<%^E ,2,)[<\F4KET/N?LI[CJ]P-
=10B.@ZR[=RE\$9(MD9GRS>M;SMG6EA61]Y?JFIZA"SPIDY^V#^0(-B\OE/V4^4E>;+8RW-0YN^G! MYI3V5*
<5>!%>V^6: ?XL4&2JV-"0;T@)&!=]>2/S\$ZRDR &Y*]?9!%HD6MB?R!P4)[&R5K]2!;0;YU+,\TM0B[4P, MV
L([LFTS^WUX]1A1=6UF]W>@I:DK^&,%' (==;CFH5\(%Z]0P16\$.N;#>R MH@.+L8JCE=-
^MOP<-4EC^0LL1J6KU@8/.#&#E^U89[P]GXE JY:%;.+2FAC6 M85RN9,&+PHIN82+
[3Z,RDQ.]>+!FFS^W\$(&:57AVIBDJ]=07//MWR M8
MMYH:D9^0^:A8UGY(P0DQ/5Z[H@^DDZ/\$JHL;>V6]YN7ZBV^H^Q\$ " M//\$;S5TB9G(A^2-U?W--CF^!D4JS%E?
H^&578;'SBU\$70;J],2CISANV#>* & M#]N0(I5!+=N-1; F;V&OH"&+19TCGD!2XX;^ !^E;C9G-E]I^?
1.>6S/00; M1YVR9/\SUY#WS\$!R+:1\$WR&+;X161NX&/.VB1@5\$Y8W)IK.*(W47U!B6W^V MNB=TI6.
<.,+6"J6<\$ _KP:@/T*&NW/W,! LZ<:X]/W!;!X./\$TJ(F.+ &BYMX< M70606QJW.<8Y%/X\|QC>+7-, (V#9?
+L, <20]:E=V!.VGN]+0FYML=-W^M^ MK2R.3222R+3.;BNQ6LF9G!K^C#F,Y+J+V!.R7M1BGAJV;DL6
M]6"\$L!)&MV)(E@N(=3"*OYP [T!D QJ^0V?=5]8[CF4&[H;@0!<41D6\$P&# M
G/[#>OU^T:34S_H1W;1X0GL2NIZ,52X.*P-8IX,+ Z0^&M0RE_5BN0IM]> MSGK[TT?0BAT-'S(&HG #S)1%#?
QF]IF\$.T^CS?Y."?R39-8/?CC/<-\$:PFZ M!T/2]\$A&X\375UG^EW\$?
^;3"RL,@1_DD#INCJ\$%NZK@'3[.=+1#79,_,P(8 MPDBS2U^6=>E11562J+1-S&KZAM52]=^A9C2 +Z M,P"
[WB&>/YP^V=TS\$1#0C%J]^HIHG.+>Q/,L ZN@9:>64L#--4@EWUK+/#F(M=,=DF- #88!B5HI.?
SA06IKFI0J;'60,*FOWOM000BGH690-KQ*_ECJF2)&C M84]'(3]5,?E>Q0V=+T >(2:\$98WE-T^T.-
T9C(63>0BK\DQK\$AD->(20WZRU MSJ#^M:S>]](/N-; <'V^(JZVY#6?4>?D(QY1JX]H\@6]<0+ 9EJ=JEWHQ]=U
MX\ ?;/I^V2:5STXP^TB*; +< \;G\$V&37V5=-+T",)=XU",0J7:W(_F7Q6
MNHR;>Y^HU^>:RH9_Z]GIQES =/L4[5^%!ZM@:L4YI=15TRWI,(DEH);I:@& M"@LFV 8X>,T0Y/ 'S.MX57P-
^ (R-JW:GW[&3#@ M9R-E.JUV5)LS+?3 %J_0G[]ZJ>3I\]&M&&&2*\$BBQECY0G-[E!B)S5\$>K?^6
MNF5ZW)>Z=Y(G]WEX.L#K#A\F]\$P(QV;: %(-,M^&!/BCB^DM98]S^Y=[M]5+1:ZK5K06-V^H3J+8 S+ ;7;&
(6/0K894:D0&^"9S^4Q^2_0* ;"2/F^BT M,LN7,W\XE30-,T]6L0WA7TVP^RUR]Z7F-XY+5)Z^N=[D_?
@RT2320W;Z54! ? M#0PE./OCZ,[0D6SFZR\$;87B>9;KZUVL;-&WP]?B+\ZP;0(=]-SM^^J#GP\$+
(K@>NTO>#55[FJ\$^C.0+ 8&\$^XT\ 3%\$B,ZD#J S! MNKN-[>];J_57^R^2TT9:KNONIQ!X^3^2^F^N IM#YD
^ (S,R3_M3<.>>T M%G^HZ:!=F^0VT^GW,:UN#F-,U#)T.:#Q^9 V^H&!+Q;V.Q^>X^&FJ!
<#DR:U]9I\1=15=+;8"3& M'"N .0\JP KEUZE3MEV0:1 D*(6UK";:]K-N]!,Y2XWW.QIDQ0H2[2H813M0
M8Z;MM85TJ5/JQ8:*VF^PY!Y,[M#8^P@6+.L[\$-)^T^72M!; ;T;+A!TCZ9*,#H M?I)*-?),LN&1R#""@-
-[RPC34*:+# ,I//M=V82#EUJA83M^6AG;-TX#SN^" ML=0407\$ XN=M^UU6]6LKRT8+)>74+ZH>M?LBQ07ZD&Q\$
\$W2J9XXAZ3!W5[SE MU^82;CU+I33V^*.*?[,% UU^F0WW90&LIT1(W;![EOZ!^TW#7#:2]]G1?1J9<
M27K%_01*M%_30P(\Q^TB;H0+FA]DA+! M]!%F7^4GB@N1LU&@]K+\$ZN/NP/?YRVCIME@'^*
<7(TX^BUQ5JSE(6F@*)M8;D MY?- .RN[19)IF50MX(;3W;I&^OXG9;G*,8Z4)QB0_>60>5I-G(\$K2!/0N3+XB M:
+E/!VX4M#^NBG/RMFB4VDE29PM<5*=/G/+M0LJ/7)FK#2#3_L+V)\$[>@93,MR/]4?
EV8E)RB0R)08EYF=:%3UPGVI?;4CN9 MF+4"]W<5';&R@>A!'('7]!!_T4^
VXF#^_ZE^/A#%Y]CS]1>WTH1^CA\$WJRL0V^*^D;%]U25W%YW? '_ ;>,JK-KWT330LU* 5* ML2)I<7?
7TA8I% "CNI+B[0X#B#@6%*U(*%'?7% U.<0D6M^B"-4 (A]_TG7/6 M? [0S*PU,U_.6>?#L_:'Y,G^LY]
[W]=U[7V+R7<> 5Y21^9/(02;QJ<2GFXH MV@DAC*S'=963GJM3?8^\$/]MY.)VJJ34[F5AG!0YVFR-
MX;DWBGGKNI V)]^E08=8^/.W; ;N^H29V&8SH:;]A2*&QMZ\1GA\W.F7@3D-J MKSE+C@:K1@2N\!)SKH"?4
>CU^% 928T73^T?V=A]^BYK/&6(A_J3^RT_2,E;^<^<^<W]>[D!(- M0G+R^VJ;T&WS) 6)I>BVVFKFC;=E(
HP,5(Z[BS^P\CK=?S1!],XCF ?>KV' MHR.=1F[Q0B%3IX?M6:P(9I5L
M3=U;C006ZU3^MR;J*#\$4850RV&\$P.#KT9]2E4<(#1IBR\D;?&RS+98&OUYH#
M1+X\$0Q="UE[^ZS0/)^#C^NG4A^>4M4(A5];[6N0\$H?V ?>X6V0J@^1G= 0-%F M_"C3;\ACB//S."^FC/1YFV0A?
+!+7E1P P@#(391^P\$ \8EX9:^9X][90,;+D M):] KVG[0TSI! [+KSM]9%B[;&ED0@^U!-U!'^(
2[V]:7M.G.]0(@JT6M<- MDRZD ?^G" WOI@L9/[JR#]S@G0C<%R3\$1N7\4-]4/A=U\$>RHE-,2I_USJ_53
ML<.@XS<8X1N \$^A22]#787JZ/:ZL=GF,M#[_S7^23]8:/?S\$T73X^A&,,R1>
MTH8ILUE@5^Y]6J=@X!9Z3YS0UF/A^PLK^V\ H?&SPT0G@>(#R8-CEU#^D6,, ME!N;:=FR%
@38PYKDV8W0PM1L*7VM;8F+0K?/*0K7M@*85C*/SG**&A?;Z"+X^4@E5+]0AUC^36-"<2X2/R= :DF78Z6]7(
, M3^!WBLQ\WVA)5G"=6P@3^VE00%<:_J820Y.QWJAV42\Q52A>LI\$Q06]6Z9H
M!>@-.AL!>88.44.>9Q==M%1\ C7>B/V9(>\$1,-#!\$MYW4_@C?GP#J#NY@^3N M.>!0@U%
<"3U7B=7>H@Z(9^&M:8\MT0RU: ?G\ .^#5KS=.N03M!8;AM+I;+SL M*)8J(-@AYK336@I+(&0\$XC5
GK>_&23[R64+())T5^+;#?9MLFSF#B0SC]\ M P\G#Y=70A[7@1X =VI,2:#<+2\$YC3NS_BA^S6_4C6Z9_7=@,
(CT4]7)>? M\$Z(5#L C^U8G;1D29;>\$Z41BA70H]HEV?M@N?G\$HWADBEF,[MK/+21ZAGA)* MTVY,11G1&_?,V,?

Q+<+X+M19N\F>,"QH;IA4CTFE;\$.1XZ GY-IB/BAJA:MA
MRB3*MJ(Y3\$'L#VD.EC'.')&S[\J.MKM]K.^&Y'Q0#4PKL%[@:++^RT;]A]HK9 M:4%J:5M^T^S:*,Z#-^\
4R^UR&VNGJ%\$6^;09_AM-8N1?4+_E0IB,%94:-8 MKR%RC@;*.K T5B#
(D!UY^_HYBW]+W)*_/K7W;ZS[>+3D7(X/J;Q?K(?('^^:V M@?A:_AIX\^-^3WF_X8B!;Z*T^WJNY
8@5DU\FGF&#RW<"CTEJ;\7C&8W'[0K M/WN)!_#Z3\^B@H,8K1M DLDZX=7=E<
=B2_Y%UK#):KS64/5T[>?'J_L2_^1 ML+@!.(*N7(Q4\$S)N RP=S> JBGI2R;?K?,TP^VOU=#],6*TX1\:' :WJ!
MBC-Q=-T0HX5<2\;,@/K\!WSA0?Z<,\^V-5LRU%*0&VF/!M?IL9&Y(3"=:.CX MZ^!#DCHMYA*9:
[!7<[X,F=&E#!&.RH2E M#=#5KH<"A 08I@G328^@0,35V\|-Y6X-#X=+Z26&2;LHU02\$BSB>*@A;=//
M8UMTH[12\E.:?>*/.N/M^MU_+^QNR4;/D/*-3CCHS@ANI+K]<7Y5<?7E/!CM
MY%,JE)K#5AN]2A.T1/DRV6I05]'L>-X;43LF: 9;Y0@EH8R\$]947[)&U-\$(>B;C90&I16X3S+F74Y_ ^FEZSD>,:
<7_K^861*4!'3XWE[:8NM-?9 MF_K%V,OHG4A=4-(&]5J?@#@#1J2?27 BK0^6A>218'D[,>%(3:X0MG\$79,8
MJN!2(NC!QT_.8HD@.6_5/E_N! 'W:;'D#\U6IM^WI4T)]4?D5&T]'MK:&^"R
M.WV\$+FK/0\+3\$2B!DE[Q^5JK3-%*KNM"/?)54-1PC0&B 7#9?S&F*!KA0#=- M";2ZQE^K#'\$Z\U?
W5Z2:XP[HE\T0212+1/A#!1RE\$RI\$3D41@^":384AXMAL MMMU0,[12B-D !N 4M0 6NN^PR^3<@I09VG40-
J=-'NVDV+)\;%)UI[:?@P? M8\0%(-#IX@>N?)IS600J-;=)W1)-&T04H:AR89HHI">([SDM].XH
MU+3M4D2:++XZ/^\$ Q CK=8=/Q.6#YIU(G)\W#G=B\$I%G-6!& \B^K.(E[9I; M4/>3+7(;"ID*" [OS4Y;Y*
[A(7SC? 'IJHH0^>X\$+*1W[V;XD/2]_5WK"W0:] MA88^N6!?
M/]N=*5M#)*MGT\$#KGP>6?"1[9N[IT07W'. \$D'D)Q30^R_?6C-*) M08ALE8\$-U54BJ^#]?T@-
AW(_E*KX,OU5\$0<^ MO,04L0D,15=F_D^Y%J^WG3^66V&FS9+>HV-'T.NV1@NB1G/\$V*A]EN& \4)
MD.WG%HZW5D>.5\J=%)C:.*?*=E;:K5\$'\$E[5&%'=-@T26>J' _K'.2CI^_ M9JMBX^Z40-?:X\Q0?
X*13AZEXQIW^)^7VI5X?YU!('/_ "6^X)SQ[+ 8B)P)Y MM%^*+7\BA(IU^V/>@G7X*[OUZMM?7.J2J[?
+J_F5H;#0R^03\$E17(G;^; ,0^+11/N@Q%80J0LP1)R^-W.K3T^K0_#" M^F62D]#FI*8J7AUH^K ^DI/[_EX]>@
M)W6X.>KIL^MUYI(&K6V/+T9ZJ2)I#NM%Q>PK09[D/L:0W^!DI5H7KREA8J\3 M%OK*U600\$A#7B)>7\K=?
U!;E!D/*00S76=UT1. *EC M(.!+CQR^8&^UI!JZT_Q2SB>B!T<=-'74]9K2,I7[0%1JSF0I@?M 6^J0.B%Y
M]/@RZ,0>)E(I\$W.NEWK5+2RF\$RGA4FZ7VD>1IBB_V^#^A#C1@H@R?E/BQR\ - MVUK?37_R+NE^IR/X""\TLY9!
(/% .CN:0\$:I<&;:VZSM]HUC(Y KXQFQ<@@ \Y7\$7]\$'JC< "ZJA M>\V3IS> 2-
JL2,3AEF7: ^X9&ZP5S^FT==F&^CRQ<^RKN8@H""\$^!1&!\)#2J M@_8WEK)9KX+#+?
37*!L"Q#>ZJ;G#XR\$A%K2^N/&S!LX+4.=SK51U?83_I IS5N" MT9VGAES1RD^&2W^3PYXJA9&(1R^64U.K-
=%^X7>13)%]I@7Z## MB06Q:\2+[HU(DJH[8^G2^*! [0%@5^0HM38XE:NPE0#>=/I54W;>Q
M\RO+^K3E/I6(3_ *BQ\Z/\R-G8D^JL9^QLI)Z<9R\==/;COC&^82.E6\1\$ M#@FMV%X)I]P
'N:++!TQ/CAZ3#,S?,GV)D2QI.!PDNA/H<,LLC-J0@)!S\$%KI MP0(X&PZNK(4E" ,[MRZ, F,L170]N
J0Z&^#)Z\Z"/MM^Z>=ULRW^L"/"=< M)RAN -[S3&W^YLC7F(T#C[C#@T/H*U&4AL_3NUC^WFP7^Y
9S1L,*HNPR?Q MR82Z8W0Q&ZF(N%NT^H^E.JJNV;*4 RIVWPP0W@V@1AKQSM0.Z=9# K%]J077
M*_2^A^4^(\^R^;/:RP.CBVE#A#T>QJVV!7P-7+""; &#""\ (M+-W>@ER^Y\B6C:NS;N=+L:-R"/\$3_H2VMTM-
ZY0_M4S84VI\JA\$&S1JZN]V]E1^G520 MS[\-2_G0#1.5RZ0H2#?D0AP^=D5@'[URT5,!ITI@5-AWCT,=
JS,]CNLMQ^C M<4\$ _9J?A>3_I)]76/5!GH^9D><;W)'U>WYZ YH? +)+R2^V4J\$5K0[<6+/- M2^V3E-
Q^>+!.H0?=>,C;K2\$Z^R\$=&0*> M*QE3EN&\$G9&4E=XM!G^0 -:6*9#0:
>P=)&ME^QI8%A=R^ZM%)F\M\^V;039 MTJ+6&(7W^SFT3WYWD5U+VKE_:'+=71^7_)0%VSCE<\$A_3F-
+;?/,]2SZ?WS ME?[%K7C;^PG%"W:^DA5Y)M(+98YK>M\@0=_^@8I]1S(W#)=]P=:88IS75
MA20CMOVFAG9H=8-GV^F_1#\BX990=EP3*"0FC^Y0SPV;=77;
MY:KG;R;K0,..0C!;9=:7&P^QFG^28LWS"+G=>4N+ EM4AX52+W17:;3G(60+ MU>N\$C=ZJ0=
(V1FZ^LFH^B2)-3;(0*0NHL>="OU/-FT&&L<%Z0+ M*;02N^D/#?
^98RYT,8(18L_I&EIF,#=\$ _M2GMZKFEK!K%><*K.\$-&KGR.T
M^.@!'"A2AQ\$7FFPI(+ (D@M+^/G7KV>5L.E\$\$.B/;=TVVATUAC""V,#[=FY MR,0W05F%@\|_+!H9@6;Q!
M:T#([9+=JK;SYS!HE#V199\$Y3CV>U\KDA1XY +;C3Z>26;7S5[CY5^LG3^0% MA]'0-:MPS-
T7":'9E]6I]L1/+Y+Z-7#0^R?J^H@_D=+X-;5,@#H/6C_@Y18@_M4(1_B*1KR]%_3+I%_.
[1TIPS;M]_E,YY1@G_E0CB;^0\KCL-PR>.G0; 9UURLYZJL5C>+"54:\$MJ M^T,;
[LZ/97,EZ]Z)N@[S7H60P45D[V,W90.]6]>1H6V\$?;U[2X<10^D!3-1
MTDADC DL=7)XVJT7@.L^GSCI[67;/_Z0[UA0MWA [KE=SF?&1^9P#J.'7>!<,\$/ MJCF^5\Y^L!Y]?
D\$S^N@;0\+^N MS^T=G0\ UN]V,MB_28++F(/203ZH+,9G;)'?Y\]2S?&HXI+\-R7WM-CS20AC MUQ;_JE9
V:W6H6K1H+J4IL1>Y-B\&6[YQF6C_GHPHO)EPN/T)WX,W M>E@Q=#T"&.\$U8+5FY.END"&^>#(4/-T.-
A;&#,5(!D3.'4C&ZTUM3@0_N9.=OF.(;85M8?X M\$^;!07^MU\$MV/FL=N#G/F-ZG\$UQVT[K,)
<1T7)1*SS2M\$)'_ \W\V:W5E!F\7?L7F" (^3N?PDU MW]^0IV^/J0_SB8AM+^3R"(T?^)^NI%(:MQ-Z[A=%R
>_29A6_ ^7[7]3P*K1! MUPW9K<1. #G.E+JU;Z\$IV&V4PM?K_G?U#66X60*QVGAHR<*YY%ZF,MRUIX94
M04^FJR2^~58E=4^G\$V30">@.F!%\$?;J<^>Q>2Q1C:- 'N!D;4Z.^!S>"]%\$HU M.I))YU^YU2M^--
+RG^0,6916,>>,CU68?FB30(3#&T^B]2=0!IKDGJ -!|=8%+ (US%8;4\$7:W2MK0I-&R3VZUQ2>5=L&A-MR?
@=CRO^E\RCD+T&=MR# 1:.*500
MNK!%8<@=P:NL1XC6AL&;:ZOKWHZ*^@>!'B\>=*6;"3^2FWU@^CTHMG1]=J3K:;.4]'*0P6
MWA,BVF3,UARX5G3&M\DJ]=5ZUN8+A^6/4+*-.]NI\4?9-B#@A1'_5ZD)J4V2/[W.HS_0;Z42^6.74G>XWP_L?
XGQ1BZ=/[E008()JXT@#U M !-4&;@7^KG\$T4D*),0\G^&3V/^;C2R8-+?VK^()W9E(53@_1EU\@W_I^CP
M]/W9\$7@V^6#2&^>VXZ7W?9@R\CISV:B[N->-[+5\1945".!-QB2^?9(;PIM M[S.'5036^RH?DJXEQWR^1#<
."SV!1E0^!!]IK=B+ ,\CR1I\$9WEV^\$]5=< MAK\$,>5IU@#:ET<0#]I#DYXG[I^H]U!CB)606QU'.
(^H6>EQ\$4L[IZ<,"F=5)U1 .GCA.B4U/A&D9T,B,MU6 MM' # -L:*IS87T1Y.(Q_6M#4=PP3.HVXCM:8]Z?
7(\$\X@)V)(>?VP>2X<""<;M6,N#!:ICPHX<^X8\$A65?..T M?GJ (^!:PZIQ/BW9KR_1\$+@%OP.5E0^G#?
HD0)>&?ZR)2ABRK[:50_N]1E2 MU-KH2I4G-BS&37*]SZ,9#T%P7H_]!-
%Z^W6WA^KJE_ =VA'+^60XA\ -96F9I>A#F0>6GMC[] #\?(Z MQ">>=7 ^U6UW@HB\3WHZ@-.GDEP&.V8-
=GYSFTU!]'&D0UT/+5_IA8@EGA_) M72_7Q^:Q_W9A\$PE[H+W0-T 2T-!=!*>84[.%0D>J]HM9*5/@UB\$P!\>

IVYV@ MM"0M1.0%X?GF-F5R@U@!#%?-UR }C1%)P%"R.CD,!/I\J WLTA*T=KA45>0LZ,_0L*02C*\|2G\$G
I4R,-#-Z0#C@< [1M {PT@1-^KI_(^+\$^_3!)\:5K78M'5U4KW MTMEL=&*
(N"LI4JRD80;0S0&2ACSZJ,S;./#>LH'NB'6_0?DL=IZB.968A3\$# M,\T5YAK70K=?2-@>)4CE3J-
(\GVAJ+FB+%+JV<[E44*Q2W,6C]70A!^Y,/8 MGF?^MI3<#0UZ> WH?W^)J'5H\>5X0&,8 'K0H7WJ.4L
MD00?AE6KB9Z#6P;TPL2? [4[&1(N7S3>0/ /UL)!SW<0MX
PIWLY: .V&!BD/@<-1)L4Y006S ;20["WO/W1)W.? "5W/ _H_0)&L*D/CI*ALC"GMJA9^A)@GZMF6 M\$PX:LYSS,
(1[Q#64\KVD%P=NX4>0G0016E0@(\B*; M'\$7EMB4SRF?"1W2'\>0&4\$C[(8BHJ=N'[_Z5'0&UW5T!S:!,.Z')AZ
MM'"XDE^64VU+Y&)?**R/_SFSN-01>W*.>(<=>[?,0CTD8M]DU0&@GL#"%"1G M-"^S^89UHM/B_50G,L+(7=,%\$
MRW,#J.+>[TT>,-(1',.\FG3TJ+R+3E"M"QEK;9UTY,PUAD@DIL.DD=)J:FI7 M#: (H8M<"1IJQA!N
%3#"="R4A&83M0X7G(J1K_"\$C5X09V,36\$7BK>?7U4B'E
MV+*D^""8'ZVV:L1%0QZ\TD4M%Z!%0',*@Y7@D<2R<+5&2\VDW_P]DG]"5A. MN>("Z*XNZ,D/@A>B^_C>W-
*I)ZL)P^[\G]2-DL(I%K-?[:TT_#D07I6T6B/0 M0J(1?UM[Y3'E^]5-B>PL@== '@QT\W"G/T6Z7\>:/YR%XV-
EI5T79;P6I*G9" M"YHSEPCGZ[ES!6WY9IN..X%KE;5-AZJD4MSD TN\$Y_4P^,\1_D7!ZMGQ.71*:.*]C>([
M.\$.'\$FH(Z6<8]DD)^CQ0.BM4.LN/RV6@F/8C")\+70C#I[XR/OJ'N'QFRQE5(8\L#C/BF\PaG'KZNT0YIT
MM8SU);V?J^1D\21V\$GK\!O/N!N (0=0B<%VIAF"2:0RPW1J!O]/9 M6]\$H1)Q&GS3>V0&]?*W?0\5-C/\$:
0J#R\$7Y5=@DW- THESJ_E* C=RMQWSO MK76AJ^\$]:0Z[R0>+&M.JF3_Y^DR*N1'9??<;P/\\$<'Q
/0Y*FLC*_3/D["N/ MU)DA=:6LTDG,N0^##\$02XYJJ2P\YS.PAPW;QKRIEJ]4ZT[1_6R3'M!HK_&" M6(Y]
3]1S3J0\"(3;[U:E3"/5^"7NS]3/\$X#8VX]T^/HHP)\$N3J=>LN3J=M MW(? "PCS?0EZ%22Y(I0]C)/+0\B]
[=M>55NG];^V)0@<)'??0;UZC MN20FYZUW2,]2D_GC# ;C*0_T%?0D"(VEIVD0SE]5!0TD[<*P3IZMT&*EAE
MN6<=6RG-.000.<=I825\GD,Q=7G+BU9T_N%K;>:_/Q_MP(M.H0_Wt, !E!CZK&XL97LU+7-Z00- _P<&J6+38C
MV4K/Y0ZK46,BE%,8AA+Q&\./DD8DLU\P)NW/I0L^DDEV+2L8;/BU]4K/\/\$+ MY8IW?
=L'DA4\$3CW+!,,"7YI:D!N9I@6;X6GFWYF;GHP6F7V(??/QFJ='+XPR_A*W0BK!;85H#^R^Y*Q(C_VT8EC>G-
[FDD0SV*K30_ZBALZM[VZR M\$;PG8?XRD,1;HVLGSS91SSN0.W5\86'E7;K\$IBK'W:LI['A\U60P<^= ;;6:4_M0!
M;8X()X\=4B2'Q*#+V%GX-T5KV>%?V/7/G1\S@Y\ '!QT')U0"(9:\$K MJW;0@KCM _RR3I,?(W8%0[E*:XS44BF-
QDVD!08ZM.Y@49JR0""G/O[3>R6J_M-
&5J2R*9*#FF%+/C<7BS()")0Y35K5XJU94MU]NUF"J@%.8S_B]@T3+F8/]W_M!^+>_U:M-05QB<9;^
DN&4]D3F0T35CV7TS]B?58!=4Y17H8^?4M/T'[]?5\T M6@!"#.4#W233/P]1/!E,()*)
[%WPO20YT:5F>6/MUX*]!>DR_L#HD,.BH;7S\$ MF_" %T75 \ \$0QS_21M075@5['[]7F8I\
%#V>W(TESZ+4UU\$]*MMEXD2>*0_M-0:*JT;GW(M08[7UB+P3HM;8T\$VZ4"/]_#!D"-CZ>WYH,X#S^7+1XS6:J
M_"RPKAXC)#YJ0=5&M3;,&"(A66@KI9U2=/UY67Y#GLG8(-E&.3]5%A926W:7H;>TT)K(!WA!JA%
MR((Q75C@!)\$2M:7/@L:F'%YVQ*/PEUI835<9>,A76U'J9Z@0NW+Z>IR.OB ! M-Y"@=Z
:_@3UX#4MTV1E73G9S!K?N;XZ0*]20%QG*U25BJ8,GY1/ >?NR*= \ M2:];GH9EE45-(K"-=E8>-X"'?
R)G%NQ\NMZ^:N"C=\A\06&AF==(T\$3*L%FE MN^TP5[1N\X]+&LK~/]VV6K,R4W@
:_2<\U(;L#?;I\$BJ>#>32:2X@_M^D4P"QJ" ,4^A\;Z<[]' #S52/%XCK#,RJ'GV58&T1'2?VQU?
XVXD!Z734!#%J#D,SW^@1N_M0449*\$8Q*)P\NG^WID\$+US:J\$^=EE?/ #L\!W@GK3+EK=M82R@C=J4)(PN;
M(TXNP00':4P_LQS-)?K-'K_ ^R&KJ\$EM)7PQF0\$&[5FA!WB&(RF2AQ&+>)&6"
M@BL10#>K+%3/^BID7C_T6&G\K!]?Y4L+<63I0<'S:,Z""1CW^C4M,)4[Q5B
MA3PEVB&V!9H&TBW@05,*C@4/,SBN:/<0S-W#D!6S)Y_1IL5@Q61CST0';[]?+ID"Y<8_MAX5.?
&P8BK03I7GG[-5'MJFMQ.[]^7"M,-7JBB]@6([5JDN6'X,^Y^"6HD.0 MKTE'E5=-E0A6^&Z,4H)&8T^P?
>/9Z7I'I')7ZU[OK>5<2LC39!GV.TD#&R MB1LFQ?J]+EY"R4S0]P[N>Z+PE+.?4X&@#8YV? H!0
00WD6)>1D@R*FEBV_M9.18A6LU8259+U2H]-3@7BZ30/GK7IU9KR4VH-\KJWXX]V9GF&\$C*?7:W*._J
MVU>2(PSS]0)Z=DT8DWT_N0Z0J[QNK*P)5]S0"9I7V4ZVMGBP09WP46QV\ 9_MVG'K-6X
ZQ9',6W"WW!>MFE":9[('QZ.X_VF\8L-B"9B;)%7N:U\!0W\$"#VW_ME>I\[]#?
YUZJF\$]IBN0JKF:QB5MB<=8RLJXCJMXPGUIW?=
M/(8\$-6L;4XG9%A+^"HQ4!AJ]@5;2A/,8*]1V3)0J6E/>5+V6]Q)G_B04?]&_E*9&!?@!_ZSV["=AK5[
XG\CPW*%M>-W=]KMP%/\$Y[*&G_MYT]3K[RG>%M)(8K#F\Y?-4W7?=R,SV_0H(Q%4H^(H_72_Z-@'+XD%5QY0=
MUK1^['D'T<+[]^5M64\$T?GX8=4_YULWEG&K/L%B*%C]JDAVC46=3F=[!%7T?\$GQSR0A>"'_'.G1?
R)\X[CWW).P^8>QH"Z_AV6YR"SE0?_M_18+5KW7^R7U_@3V0\$%AF1%0 !6?[] M5EIQ;?
M,E/0EA[K1\$^_W<@4X1!IV051?S_#)A+7#0#6<(N]1(WK%<<[G_M1DS+%)0V84;Q!?'CK'.:C6XF-.,=FCRN(;=
(_Y*H+.,FBL0TCPJ+[]5T_ ^CY.FLJ56^ \\$/%_Y_#0GQ/'-;?8_M5.'GA0?RG-D%)SN-
PL+G/(Q3TGMT2]32?)CNPIF.^04#9YQ[7XH#LF163]"S
MP\N";/(&U):0SV)!>,C&Y;X!MJK#E]D'##4"LEYH105R(U7L"0QZ-&!G#HC+5_M0".[LN0:1T.PE+-]5V'-
Z,Y*^3K[GAN_=:>Q*^R:(=XM/GM02-KTG_ \81IH_M^VE!H&?JR/\$\$P2R=XYM3?ZY^_X#5BH;_B#([/2/\$*D5@(-
^+0', 'M/#:442_MY-31V0%P/]7I0Q_@[]4"MP_R\$WN28H0_ZG7=-RJ>=25SH99T7W_*Z\$;P_ \YF27X9VDN[Q&?
&T"H!R?AZJW%M\F;H/B[83TM_M0;QAS;J(MA=\$C%:LHGA#=-,007;VX\$)V+TP>!>-A;1=5U.[D2+FM4!RSSUHUK
MIW#CZ^]\$>6N27[W+?"CF[AL_D:YUZA_?_M_"0J_W=)[XST=1+QY;3?/\8)EJ'.+@NPM^#6"&X7[64X\H,.
[P1:@'+(I9%)MML0\+>,%DP+=CN_44N0QT*_W#\Q2_SIJ17S;"LQ2N+P\$=MT,K*PZU(Z"FK#_M32-?8C-
4HK=@N,07>?[]9",>_U#2N'4CJM!<960*@ZJ26,TDL9WQ\Y*D6,?)79?GS!'V8/8K2Z:, M'[]T\$Y?E\!Q\$0-
64^_@=@_N+[]?6D@>D02ZKM?2(^*E8_MU%KUK3P)W#ARDMX7++D!' /3Z1Q6!WA3LU"X0*I[]OXAM2VI?
KY*B[&SX7P+V\$ _H_ IHD.20;2>.,4B<_F.!-!/?+-3KE;)K8MSW;E>, C_M'9FV/FG[HP0A05[K8R0VP?A-
=4;W?V<5;_?+-QY*E<>3E_52?5\$YX\=]#H%_M2_N;5N@76'ZMW+=+TD^MI2-UVGQJVI\$.ED8=VR>LE0%
(Q+1GE;77C[L;%'') MW:WZ2#E77[\;S&4R[^_#H' _#L#,5\$R,)BTA5_[XJXVWU6=KP5>T&1=T<#V4_M-
I\$"VE@6Y!+*[]S@]8?WG.VJF3+N<*;)WXK40&[.^&>*<:F[]\0CJ(3^V*JGL_M-LR\Q;K@/Z\$-G#,Q>34&-
EZ0+5)GM&)9XI5<7(<2NPBVA.[YUH6FLNQ"TM+-X]LX_[\$!_]@_8B@.*T,M!=T_0P>]6,*1I7"F:Y\ \$0K2FTP
R\MGZ1W-?S"E;<%CQTK-L,H)U%RY:C6_MUZCP6J:\$@M]2=.,%4A80""V^YWA9F%#V&\$D:01V/Z:
7("Y<].S.:NK:=S1_M2W_)0_XEA#[C97#UXZY9+;MH+QD,) #2H>\$U-8@AI#LP9])0F'G_M1R%0@'
!56<'2PW*3R\#H_[R9- _>YPZ40"=*&7#_MNQH]@H^FM1N5GD072*6M&=V']2P\$U.?

0ZAMJ2EKVXSZ@S@KM'ZZH<;#\,!)\$ M_3%8Y-;MD/H_&'&^ 3S: !WM9Y?:#?
8IM+L,+F%/[4ZVSOM'J;PF[:VG#*/I6 M1;MYZ&E@M/*^D)2"?=H%5E? *N!0=/_H;8W_#=C_"0+1P;
(\%3Z%%.G@TAD M8(S4VRN7V0[QYWAJ[/IO #;0.W021!W N9T%1@B\ (F)J/5.WL>;HC?P TF6+VGE!A
M3F9(\^J)LC3-NT0&_A3^A,(6;PYY>&0)"%\$8YK[NU#'^T=,G XGS5@00)'L MQ+;/OKI0+"SRWATG7R
MSI'C'/;,'('5)Z-HNN-OHW%WNNKW,\$!|]Z\$>D>;>]P/R^#%N Q^8Q0=W76 M#0_5G7^JRK-
=7K*K3^=W,'+'\$AH6 "=C5CY%U_9K7K+U-19\$B/N5)6A,(<^ MH<]WH2/U3*7&:5Y5K4A^Y7((UE41,09A!B=U
5. M>Q:[2<%S0I-OJM=())/<2%=GA3C MH1"00IK^2,UJ4N\;CH,CCW9_&:Q61GG\$.-
V5L5LK0W0Q*,QI2V':?/1!>L%X MTB02+RG])G6?V]AL*%IM[? \3/ \V%Z?=T#XWYS'([%9R%I\$]K QT>2W7ZNS
M'KH.E3/SV00NQ/%RYAQ*/C9?M[VPUMCR0@V,P7\$.RB50L]A2*<\$[;+@K_?6 M9'#C^1
2;J+!M6RH[S/&U]]2S**NKR_@H#&=#'"Q: ?K\$B)G+^W=5E1J=7M_ M&.2'*'V4FV8 E,=K?0YYD-
B9TF@A8D2HBCZ[I: #=\MU'9/HJU69WG]5.]W;Q
M=Q(G;!)=3/3U/MM@<1= !3]Y<4'RXZB9(EJE0,6#W&JS.LK)KF)GI48UNN[M\$ZY>>T6SZ-S#59[Y@"C#H<"5]
000)**PCX (>L)NAM @I;06<'AV&[=<#< M-I6Z2^FX?.,\NZ\$6FKM;X8'8]J1E\5^&T?
(7*FQUF3(>^5V0M=K!!^Q(E.57= ML\$>32! 6+/_B-2S!]WNS4PHASB8SU[+/#V^==4@P^*X\$]_3G_?U
M/:9_5'4IZ] "UH<;UVE@H\!;<18A M3<(8[Z>MS#3NE-
N891/ KBU#&S1,2S="!"D2#F31G[Q." : "QSN%!+K>N3Z= MAU7N\1D-6\$#5HR0CK*-%E=)71!,STJM-G>
]\$\A02NX#[]J!^+0G0J4&MKZI MY^J./S0<^4AR0>3UV7!6 A\$-)L]WTX96K/ MY":>=>'6R*9+R"?FS;YQ>?
+Y5>;,1<%0(?)>L =K73ZDW80^P,-Q,J6 M2N<% G8P-F'^+H.VC;-6 R (RK!Q-X#
<>DT0L:H5\$N\$=&U8[LTD\EN^? C]U MV6D4E[^B7/YWR71GT']3>-**?[3W[^ZE'F? \7S"RB?
V+1=K_*CD)0]]^02^ M 463%BH@^49_*GZ(G(5 MMML]2-TQ!
[S%90SXCL:'"YIU*U"6S^7*V*;WIRA53GHIFS.W0_5F]7,G_3G
M\@,*N!EK(>W6S[-10@ZJJDFCRNS:M7(Y"G&P!>)5"NV%*PTI/FZJ^WRBDBTK M4J6SI^ MOEABEALC7?
K[Q%0)^-.C^]G^],(++)D>>5QH1I&+Q]H3]N,0+'[IF^W@WC,F MO_Y>CN\$NOWC3U1)6YSS/H^LUEL3@4#1,64
BT\@&8)L[E&6TB]9M\$BF6/:L^ M^#H^PI&A1TFX0MVH(FX6+^Y[URWY3[%HJ227C?0?)3=]/_L_EB'\7]>\$W!3
M[++^;W@<IQ_GMB1]W8\ 'F_S^SZ2;Y>JY&?#T@ \4JP\$>/5#-#EQ]<8723_/Z M0--P;+2HDCIND*?
\$,,%7DF^BV>T6WDFJ/IL-XWL M'(*,EO\$UK>+M*>6/_^:PR. 081TW\.*0[RL_X.XVNS%,T/;+.M>[0_58_75]
M&SY!;UL-;,\KBCIKD7-?EN<.7FB98H^K6_W4)8]HI<60-FD3A!'9F.+ \$OMED MV8'9\
<0R39]4\^ (C4U>WT7=2^:@\$>K32E;(N^#V*W]00PP3S)/>@PXSK.X_M MLEZY\T5/+IZ@ZH%=7Z\S\$+D=!!F#-
C.L9X6J] =174-4<0DY&:0](5A[E.0221)8_)XI3K!AHI1T9H9X-![->_RA\$ MYZYG<1/V(00XS9JBM3-
WN+''7FB][NP_3D-W<2\# ZHPRE+EQ"Y/^IV+T7 M_#>IN(^T#U,JXJ0M357Q\$3F6Q/&J@*_\Z%WR0T3TK-
SW_P:S08B'F7@C9N0S M8G,,6L&QL &]E\GXC2(OMND)%^1&9:B[0DQ^8?R^>#YJ097L6A? [X2+HDPN3
M[J&AB8^C^D[%?;>L_9&Q-VA+WF,=K?^0QT7!]]W9MI/B+T_NX MM#H>HV\$9-P")D[ZC'?3L<(Y(].S/&T
#;4B)T9(/:K>4[-9)Y##I;M1JW0_Z M\$E77=34742?
X"UE&#!UK0/BGOBHT1S<_)JGUDSD0U7J*GCDJYGUV9A(9S?J M!A!V!IP/64M)BP)+XD*0\40D;,(\LIZX@M6?
M[>ZTK2=%[]=,C/7H'[*':N M90_3,D^ \<-[*S5^*YZ=!L: Q4W6#G#4QNL1%@P,FL[Y2EXZ8G(=<4-
*RC*UO/,Y!./%[I)236\^Y>'^M:,E#-9J0KCU%M4C###I] MYJ=DHR##I9A57-UPM-]0_&Z%F-
K*K%RT7Q&8^J;!#_B:J\@JW_&>)EB^X2V2Z)1)>5: MZLAIIT/02*35\$0F63Y5^0.&Z5?2GQ/J!4''98F6
J^74#""=;3X_BVKZY? MT%H?Q??52W%C7D]CJ=&.*0KC&\$Z/TOY)' /=?30-.,XM^A%0 >U^H>0V)&
MAMZG4.T.)!J0>)=0(^9V8:-\9#ZWL:-H/XQ7[\$ M9C]J[\$,0B)!PQPA 1@<*>77*7_8)BZW6+.)J[
M#I\=#)/^A%HRZWJ=-X_3%< (=L4"PS_*%6-D_?5Z],&/: S_P42;-B/NY^DS>#&S[41\ P)<(^SM
M&B&ML^,K!_F^,W-ID>6C[>F<;J;M.OZ=[H0:P.BTT3?SY*#9*M8?!<.7A[14 MU\$MVA;W?Q
7_D04F6W]K=@WUT\2\BBF\V\W_ 'D0[;VKS >2BV%@3A_W.3+57KG#0_!6/C(SZ&Y\$,?>6#@3*,4'0:7#I!
<<.*!%=.GU]W5D1SU>-)\! \5GT6+&EU>@_93"0Z6B-3-\084?1%]7G M\WPU?,
_4<>0GC]JSU/<;>:C#^U;1F*_2H=;[^K^3*^0.60G;_N@'(UNLD7[M-Q_TW)P: J>94_E83(/N/09?^E)/_2T1<
MKE>&W(RFA?I5EN=XK>,!LF_&)U3IN2G0.64EF8!\$&:0]1/[+\$-QN0UUPS>D M3]*L9Z7&ZA-8!CS+R,WMI]
[*T(Y1S#&QVCVGA7(2!,00>E-I)>=) 2I\$15\$!_ \$@M*[]-Y[MERZAA]Y#"P&2[SQ-
[GIUG)WN0E;777FOM55!:_ M1E/_%FB5=Q4VQ6<4F[^K;#J?*_]VQM)S6->]T)2Z1+MHH:)IY_L-^J@*EW
M#^E)HS*Y;R\707Y3^SSM)=4BA-+A/'7>3=M@_.)(1ZW1';YDY\INF0,\2'@
MKDA92S1]A2]MY;:4B5PFH8*40,3''8].TS?/^I<*(]*#DP(5M<^B+@D(B\$K9
M/[./,\$J,,W"N2\$%U3+7I\0J(C.!^#5,ZGW'W_8_H;':\$_U5ZJQ'\$3>*=,%7U/_ M"B(ZA>9-.'Q)L\$A=>P*T&8-
KDM5^MUAY;DR!;* _7SN[T0Y9UT MS#9=220>X,'J,3GD-'++&58N47@_ .2]TFC MST]J@E7W7]/?VA)^AX'D%Q
?BNHA6%,4(37,Y M^0?)#Y[1/!0QY>.E)!H71)-
M#3!T3DHU*!5W3'"4JKHVBEA7[U6L9!0.2I8PMQ83YY7!#MHCTL*7E+1_@DL1LJRBKB#T]B)6LNJ0]2936?DP;
MW)FR,G9;:,GN>0QWYZ6Q-F/WR?GRD;:=VGJ.#TJ)%Q:&\ M0\$8)<+.^)-D.BP0
NV\^LWFF1U\K^]CE[UOC7TF2_M-KJ0^J6+4/_ M@AWJ5H_XW&FH?]XFH)MR)/3B%\$,B(5
77.T>BYC5\$W+JKHWVZXV 'Y;:*5AU0*,U^09!_)6F!Y>@%HMHDQ(OV.8-]ZGY1P_+W0
MKMJ;R0C=BQ!*X@7*L143/.QXTXNR4:N4#++B^T=6TF4ZEI4FL]=+_51
M+ #NV7Q>;;B^U\Y2L+\$JMT01A.6E83ES0Z+@2!]EMC-P54777B:T4&-#YHX=S&+P3_ ;YP2'@F=!2-T2BC>V0
MY6PD+?57FPQ.0=K8)&C(@^S!4WT\''0L09>%;.-[K%PK"J^M\!WYNJDA\!N]@4\$WJ_7@ \7W?E))C50MA8
M@^L"8&\$%U3]-7,(+T1;CQVX-SA'.!(G6@)X!M03DDZ898@.-+ B58-U'>T^0 M\$ \(\$P=<]T,:94^M0\$ZM-<
0#.*-#-\$CI;M#>@_ ;W'BA<>W4@/R0&],>RH[3@_ MV6%>:HM-UXUY=NV6.@L=KMZ+M
HHZ.UC8WG/\$7\MYW145)\HS0>(>GVR.!FP M]W4?&'I_G_@PZH69PA)4CM>V1U;8_ \T]E)ZK M\$'B; *LF3.;.]?<
=,?'=T'^&_Y0H0;?'2!^Y(5-)]@MLC6*&V M3ZM?CVALRLB@._/#D_CK.,BV,PIRC,T/*93).--J1-
Q\$;0(00_#0W08(&A; M6\$]\$F.VS105':;:0AY.WV!S,^,R)^;VTW?01*>IF:Z5[G@]5??"BW<,\MRS
MGY'<3[%E0+8S\EQP:9H.-D83#^9TR5?;:MX"]T!+0\$0N@NW*N9:.)PG%PF]+_MHX>VISE0KZ+59?I\$;Q^>60D"
[?A&[K(XXB?0"TBLY\5DY>N*B6#L!0[1R]P]6K5*B=61P;^H5B<[Z7B=P;:JT@SI8_M9%
1N71KPSN(_5,4T' '<(N;Z00;[Z\3G<,S,:%8H@B@4E2G6\$.]XV95FM#G M&FV!AU=;,GHZE9/I3FYF-

U[%3NE^K*+A"72FM:'F81WC6:F5ERBK=SCUT2WV M"0.#+##&:\$;415,I;9;F:\\$=:'^6'28CF4DHI">*FT>QN)!
21=8MQ8'[D_J< MP9QXM-7>#;4--=WH!QY%W=O>&N(''+^TDY>6?W09U!FY "RS6EP #!).QQ6:
MQJ**C\CME2[Y2@H4XVJTIL%X 5"7:0K^'?'F#RE(_W@[G(?AZ%=?ZE4M%P#2 MF>GI+@?F^-
+QN+-3)X42J2'D_CV.75PS;)\0KPZ:YKLN6!RZDB2!6W8L!77D>;V6+(J9L6R%61^K65
MT,L]_1I)%Y.NHHL!>_HN^[Q5=)!/WN8\@GTE95:F+=>^^'R>B.E\Z\$,]P8*D M3;LA[62]TI?
9PH:AP'[*D=R/[7!@'DQAQI%9AF3!E(3ZFY.03S0BN%.D\3Z: M8%\R8@?
>!0>4)#D0A3^)\JRTW,@2'M7P050\$1_(ZKZKP.!ECB\AXGBM#M)-;2#\J;W+.-N!)U (D[DM_8N>"?ZS4_K9P
M/ECD1QL[U00B7R\$7GN\ MYHF3E9N6;LJ,HBMHLNVS=N?B(:\$0(490)[2QJ:PJDES9_6X2HM7W.MT-Q@>!
M70"BBBX_TB,5V0-])>L^!R_0+DRM_V<%P.M8S>|B!3+";\$; ,I0_TD=GJ69, MJ0+K2!3<6TUP0 \7D/L0"G=6N
2H_/X7^_7@EKNND4UAN\ 3.7U9DNY;5W_L M\$/!:=5_8G;EAT)M(C;0/A!*Y- 5?*FT6VOL^Z?!1CQ5.\$-
CCN725SS9%W-"] M4@?_@,M]BI,&U+4'L'X[BTRT@7/HN7TSUU=NQ;=XZ2+^-?E#D) 7V[5(&?);
M8;_9[80*IV-Q=0T,BT:LPD0D\CW\$RX@^F)_M/V7MK3-PZ<|=,B8\IME.^HA_M)?
&VN[25U2;5(1B.^8Q#LQB9M8,+@\$B\$A_[:JSYJ0=2W%+JD*@[L0RK8?![Z MC.OBH9E*3R=T.2L[:7YHQ\53W>?
08T2(SLTIW_U5\$ _N;BB2",8/?X[\RV*_M[S4JVX0U@N]J0]'E:4ZD_K2T=J89?
[Q#)T>D]I2[MX?:V(%0(.13RSDU%?)N M9;X.\ 4"8-FTT(@0#E8=N=%[9A0=_(P*0,R\3N0\$K)J*
<M'W*!U.WZ0(M/P :.3E.%*D&.0J15)D7'E\$=;/^F2[9]='(BBPDG*D^=LFS>29[?P;*_^S
MM%>.;Q!7)%F,'%)RLVK'K\$@J"A%DXQSE:2V,G,B,P[J/@9*U6?=-6TFG(0TJ M"=SYCN1L\C?4-2@;N" +#{&
(N8T]*3J4NH<=2W7-9\6*>,W/>V4'''/'VR)YK MPK5)ZZ=%-HN%R3!
(6Q/!M*H]TF/G*%^!65,ED0JN+5\$^_.X5E);2@'.7R71;
MW4C8P>|Q5>0_*>5(-E;+M0\KYD6E&0Z6(=&>#0%CF75%JD-X86]S35[71CS=(\$T M[JX+\$+ \=A>3[.SAG*.^I:
[-@^T#^\^]\$*M9017&X,6%U;??F&B& "WEYUO^^ MD->(01
JJD'643<'YP[\0;+A<.04]P)&&>CQIK3KGY1^M.C+X;KU58;\0_R MPEXFAJ?R8-
*NIF"0(7;=&"A2V+5_AR'708,9<,>PU%,V;E+.^RF3[\L"LO\UG6A_M,\$;[N4\9L)XPT'Y!@>#%&5+L[E4=#+0(
M2P*(DQ15344[?I!H-DF\IHXTIZ+^-Q;Y_L3>A;<6+4_8PQH<+Z1(0AS.Q;0.MP%BA<-IXI-X[6F2[(\
[-2SX;N0L/3\&.H=38Z40]S2@>ZZ=F7_[]PVP)][:B.*4A:M]+2\$=D3FZ4@Z MZ3,?
XK[D8R^YRT3:R=0C/^7S\$=4#5R5T-VFIHJD*\$?C,]1;&2@3.?0:AZ0,;
ME3@2WME))PK6KZ?R:R:J01MM=B!80E8)9]PN_3DE%53DEMT"?G@Z15GB\,97_MZ8.06 <-
G"RXQU3,4YY/G94,V>)M+JSJFK[4G)OIS+5DHOC;H[]\Y;:&&\$V M0IV^7WD2S6QD0*Q ==
[:.^.&#S]'_AVK]H0G%]>6QJ!A%D.[I-+)][:*5Z6(-)C M\5P/5%&48Z3D1,+#22.";F+C\9ZW+D
7)E%:Q0)31K%R\33W9X1FILRG%GV M(1_-'1_>?#5F80AU*W0Y5_B'GV4N7#EEU^GJV3_0G(;A2Q= X7:H?C M
I!6-NJ1&06RC ")""ZP-;^S#(I"Y12#N@]R(:'9E,W,--F.+;C%[KP/BM M%QUV#R\
MN_0^:F8G'JIQONHE44N&E&6BM"SWI\$!BU?4KV3A68 M;^%T;^E!KH/UGF#R0>S-<@RZ;%S<>>Y7:6WN-_0[=45E
>_HN#BN>J7F(7 M *-EC[?.[]F/6YH).A86WA1HP)ST13['2=M>W2S
M7>!LSHPGF].+98DAIJ_[:^EU4PFU7I^P3[[]5S2'G07/N,!.B.J5\$LN3C%B1F_MCY-\TK),ZL=Q*>M:
0TV|07: '(>RK4(D=,!4,1/V\$G)VUQ|9SC!D%#T]H05; M?I>,WD*(00QW:8+Q/ZW>)Z02HJGDYEH[-[5!BXH8?
M8)8[,\Q]TS.9\YJ!> M#R9A[W1F>1:;>,BDX>0J4<5]JAU)N>[WPI@Q\$WTO?%+L9=\XUT)=7%Q%6)UIM
MM#2/9LRQE.)_S3H4:K?EH3ADRD<-X3P5^JV;(-)\$GU+M902%T67STQ5&^UTM M4%+WL@YA6.?G?
0YM!*9A2I/&H"JEE#XG-[IRP65Z_Y:#2^I&VW.SG+\$^HP9DD]Z62TT ML#Y#[[\$9XY/4Q?+G=G\DL&T%YG6?./=?
NZ6S<1T!'Z(+%T%#^W00Y:\X00A@J MOR4^Q0)-!WFX%2E02%;!-:\G[,DW5BQLYG6-H
PPQ,2A>505UHLCL=,FLA\$ MZLN<:M.?T\B#"EU."QYF,3N:FA>H\2CL_B&X0JJM&#D#R.OK'#"?)\$).
M%\$NDGG:\Z->5EX]G_V3JU>R![]PI!60#^+6+&091S,S@_M3^A]KL:7LNW6,U,G=[0]ZM%K_G+V"P"N^EVL(G+
(D8&CA>\RSW0,U)\M\HE M"0,H3N)'2NQ,2"Q(VDAA.[&Z7>TI)21^AI%5_JV*"B0.!EBV0#4GF3+B%A" M%OF
BTM0:7TM6.)K?_Q<+D*0<5X_B*+*MQX-Y-\$51RAN:C0%CI<-+%D9-WYP3!P:RL;BZ/7_M5,DRV_@D2!?
5P[=\$9JDJ2?MXNNIH=>]5\$*,>N5#WB4N6F&RLJ6KP=&IE!4<-MN2[,P(A)KB@FL)DS,4"9M%?RSGV@'6?
GJD990>E70VF*X13'F_M6[UT-BK],8(A-V-6UC-;GV5)1N+!AZ4[3MUH_.9[_KF_7/(=7PE00!27VXK\OK_?
=FB1WD<=6:L3_MHX=+U]GS@#I&:#=BI3B;?>KF],.^ MRCLL[+ /Z8[]]KX0V,00D
0(7S[8&\$8W'J]2,0"B+@"T004XB]/0:"6/%UW? MKC;Q@C92&B&J7579Z.<(N_PE;Q)Q+F![]52IE7="*'^>Y
_,Y!H-9U;F;#FB%(_M':R^=0GILA_.52+>Z0[XF+%ISVMG>??. "SZ:)DAKJGA!]+A8=Z, /JWXA@#1 M'?
03E)I3AGM#;%0M!1%?EV.\73\$)4+1;_I@T'\+U M"P#^\$82@+5M?I>+BC4SD+LY>&"A_3!;
(.)3[DQUVSVS9=BBJN9_W:Y.M%BQM? M7-231P#D52J;[_DFM6'P;_EDHZYFUV9U:]J@0Y?R/2,BW;
(6"2V@=6G@[\LV_MZ.)K)8H^06)F%I8DWWC?ME""'1E'IM]04[]#5NZ[V_11:AM8S]%.%#B?9Y6.
M[7*N1(XLN8Z'JF=P[-[446_V#E:>[_.603KV;J\$?8.>&0;3LYN@;SE5A#!L[
M*2E/='^2J/C">0B]IV]&_(US^U#1.(Q0:#B\$5'%E/;H3F-I3MQ(A8Z\$C\$BUX MM\$G31.P;-KK>[@-
A99TT>\$%'2GH/T*"L+2F6<7_2#+9Y,_,L+6S'PJ,;LF/'':7_IU_MOU=LP,QSET&;0+131KON:A+(4.A:L<>7
BK&(J)JHF_9[W_Z5[VXQ7>>FL= MT535XDVT**(&8@FCB*V]GUJ8?ECX!H+)?C;[. #;,\$@G'IX=53HY)C9GWJ\[-
MK/+!64/,--/?2=0>8I. M:?\$JRZY],VD7_-)\)*'_[@PJM+W.EQWR.LE%_.8'(_M0?L7_,YN/<_28\YFBB&X"JM
(6U&C/U!^[M*L>+G00!;[-T1)X,^DRWQ/\8E_M7?G+N_*_P+OR;Y;TYOU)_X7]DX:C'J*9_.UB^(' _G;6^_
S+RW&-FW"2R\E/0_MSY8[A0;G4BA0.X7137LTUQ*8Y>MHP"3%=[@0HRS_HXZ M%/W>*4[(N?758[MR>Y[0Y-
\$"U8(36*GJ5D.\$R5ZF/L_D_L< MEK_N*UP_Q#YW&!(/H^TS&A,*-X8W-8LV-_W
_@^N)N9&3=+X@^G*N\G&#J0YWXZ: KG\YY M1[?^I\AJ8ZL>Q5[NBK/RT?
@!^ \D(+5DK^EGN_@BRUK)6\''?!:Y-U..1>ZWQ_M;PQ\$V[^_Z*0%&S;:_5A<-
'04!Z|L33>E.\D+/_IJ6%!0A*YI38\G@.,CG97>KZG5L/11F8&!'E4I49_<@_5',YH:>Q_V<%YY0&V+R\F5
5GLL-2P-C\$/= M(L+ZSI_)3@1_Q7;_E[NDIGMGVB',@VD,M_?6/BUY*-RC08EE2Y&V1=>9A+E9
M([&6J]'04I1!Y?K%QCI5M0!'+0_8ZNZM&%YY.LRNR&GN;S4A*;K4?_S-P>P/_MQ@_.?^T56?60HIW,U?&4W
2Y.>J7]'G_M[68VY978GZAW0H(16F\$^--:I[-\KQ"53:PV5#+[8]@KVL*01S/>[)]>TGY_
M^BV99TZSV&XUTD94)C'75330>?AJEN,<'LIH<2BH]0)PCJ,4J^39*2VFY,3<-M0QD6_.*GKR]#
H+G:1'Z|4R#3;\$.J#3Y77=_5K\$KX2T[A]-\$#T7I0MMNE1@_M'-

-5+1A4S2MY)6@7#\$\$@7L8GW4]*F,\$\$SF7P|E#6S|<>T9N^;0,5V=C0^VDY M&:VH9.=|K0|-%V
6Q7F0MQ_%-6TIBGMT\ (M @1TG(^A+6*^% MIZ5@V[V#IYV?VG0.2]|%2-8EB6:RS6CDR!60@1#
LH5E*VC(04\^4'4N&7S MUSS/EM)^)J6P'BD55I35^?UX-.T/|04!?!V=FRV/X>P.<+R.6^%@@^5+I^9ET MWA+P+
|{V0_N69PT#-Y9ESEF=E'1)IBR3Z"D14.".C^4"BJA,2?BH&-RW-"|E MUD3Y3X//7ZCPMV"OH
7VA0.T.E.))X|V^%0559?;^M*=H7E>IA#0C,C40&F MJX|(^GR)PM0/,VUE&T| |;B;?%\$658CRN;GG
E,M|0S.\$3%OM9;1"PP-=(\$ M|0@;6UF6,'!JBVE@|C;|DT^|06_F01M?') (XZ28/#UCT&M-Q40F=/E/M MU\$
M/|RG07)\$D6R,6#^PEGY'@S3&-YG\$+|J36E\G>C9|YNFI|8R1\$E?R- T2(=<4 ME^D%
|N9(!2RDJA*H'\H+/A4KC1. 2FAFA|C|-TLQ|U?MT%0DS%0IU5- Z4S0 MY/=8%9E3QY=K17>JB?G-
MU6*5+D60S&?+0N^=>=JL1\>*Q7'P>%)|=)JQB5M MFM 2RQ/1J#06_&)LY2Y_/,7'^5_V5@ (X/2)
(&73=IHUK&.J5GY7\E)J>>?F> M@Q1L-X2'RD=,ME<:T=55+\$'P-VQ0,\MZR612&/;N== 'JGGW6N*_3C
M\ROFS|UEVH\$\$.)P>U(K|-U09V3-1 %3Q)?DF5Y? =G,Y^2F&A+YPK,MMXA\$ M>S80I_RIX_Z@|F(Z|70^|)?
I,5^4CD%N-0_Q!5;|7#=#Y;&VL0C>TU>B&CCL, M1*%C12NX8N|@L#9
T9|^|Y1R!2LU/0G3JSC=2BU;J&9B<,G\$H"1-[4,;-[8N M!,#@>93|\$RX-\$PV?+,I0--
Y0>3|9H"\$T^#9#,0!DX-^,.W'0ZYW "71_K5 M|!%Y7;*Y1;WV,>Z;8%\,D0_26;>|%=|!KI
M8;RA>/CT0=U,9M&ZJQ3G*YS7>NHM@%/G,,MK5MA*U#HJHN9N3FSJ1|?6NY" M40K" /7U.=S0QJ,"|
R2C%U."A-;-5&?W)GK^/E-KX27-,/P)KSES.UZVSL MA8(D'R;FY. MOP7|\$ 7YW+. W7Q"TZ87LC-
!36^&FZ*10!6>/:#=' Y)0.J* M|RRRA13, DN PMB'+(WD@H^;HY&E ?;.,8-N!ZEVV-ZJ7VY JM(R&!2_'C2_*A
M\U|A|E1|R|;" ?(8LA|T_8>2T|?Z*.10MR0-7HXH-|;VH6#-R\$2[,..2Y W): ME #PI)MPC-I,K9Z?
>U5\$7<:XI!R.!J<0!&-1"A/653@UW+X@-/M^B %YI60F;5\N7*"SDG*V@!"1%L;|/9RG?WM#>A4Z3QNI-;Y
MDQ@+.WA|B@U."M 4=16D&7D7%3+8S M\,Y#(\H+/8JLRQI*8?5PN= |'5G-U.V0,BRA +>CN:4,,LXA
DYJ;/J)BX0J M&18L&:Z//S1#"@^0.U*>UUQIBB9+ NEQ5DS!I1|!|+/ M2'>%Q9\$|YG9^?T+5>1|Z;|2+Z +,
X=;CH2RHMR=8BI_&|FIK28W6D|V9|DFJ_G#< % |(3M3,@CH6_F_8.GM,A_AKZKZ' M&0J0H?|;^K|VZ
@=Z+|V^=T_0#'^ZX%._QF#.+ZE\:@W-3;ZH-PMOL1I0\$4 MX<&=-
0^VP7;:Q+G1.Y&W0)@/.3'V,E'\$>&J&K/0#)=.0I>@0M3=IZON #^1< MS
BEI7X|^/X<,@_%#I8MQZP|Y@EZTMD+.!DDH#ER(>MLH+VA"X"% !\;G'5\$ M/\;W'>J'!UR-
\$569%X"TM\$0@09@4X!|;=*7;#)W%)A&7FG|I!2#0A0>#BXM-VT;*#TSR" M_2-?LA&6'817L)Z>6?
M<' /3Z.PFT?GAI2PW_ =6'W?+MC529,YRM8|G|W\$0|?>-2!U7(A.MDLY+ 6P* MTEJ;@/7S0Z(Q
\$CG/S0<^|YYTC1\$B>)%05AR<=:CLB)VL7@+T/S3B#?S_
MNY'6#5IE_Z=>4Z!U|K_K!7WI1*.*#M@!;>5=RC7? M#+9@4N#6>"^G>BR5)W^RB>|}%Q?XTL!/Y
(0+|6&::+6_PFI|_92S>6\$IQ>G MD4W\$D&F&)A2&|>^A4HTW"-RV=I;_ \$|-M^V 'T5^\$|9|.6.+ ('AQEPGU=M@/
M%W;Y:\J7XYIXB70MYW#^V@"5?F)H;-0!ZS_ D-1??\K_PY1<@X?ND/^G;IZL M&%SY?^|&0QDI^@""&-
N,@BT&L&"|/[-|]:8*_9Y'QW;MKVQ*TXE)A-0>[D MAWM^ I|-|G1|E*S<=V0B.\$TPMQ22#Y)1W647|5E;0^?
@|'M970"86'8E7UQJ MGKKMJY5>QE"4PIY/_B4T7"9.^H=@A?T|Q9JZ7U9V*X|\$K;%?-M.WOK\ LJ=: M/#N&
+JY MET""TQ< 4|U-%2<@629%(1005PD%+5), '&& ?J|(:#8T |+#:SDNI|0P2,? MH-4Z:(+21=)#(60.^:|
<|1|T&L_,0N6:F:XV8T9VQC;&+3>6_#*8 M?D,D7>U_,T+^S^ZD&9_ \$!8?(>HE '/\$-E3|*
)L2!S4(5'LHT)4G?004"E MAPK>EG.0)\.RP2-DU)+5.D"A(NG/0_Z?|)3_;/6C2047UR,|HD(>L0(75ZZ+
MJP+ E@=U/JPQ8=8C;|0,1|T8?^ ^04D^ (=0C.[-6E<|D04)35%.FCE?80| MWT\K/OHL?B61\$K3\Y2
WRO+MUQ0| LK?KE_>;+?:R: ? SZA8, -7V|^F?V2 M,K\|I'\2_+<&\$ /7;^CT'EA->VN_5C|>_V&/_06E|-|
QZ#CT#-PP-X&#UO MH@,!ZC|GMSQM\Z?7+F45@R:D;%6C7UPT|\$-*+8.LAUFH *FCW*%-ON%LN4)
M_"NGO@>W6H;S(UX4L+'*LXM' I|!|=>(DE7)+
MG)RLG70P#6#S035.;GJ4|NEG&I0JNY|AD:H_^|,5"1I|^Z*:N=;&NP=<(
M@.X#H5"V| |C_4T4RD\9/KY8X#R%PH=+/@FZUFA^IXC=\K5UE6>_2#((E/#63'6MR)BP!;5!D)\$SV&T?LI#G:LU
M%00\ '=#V AVW=EVM(&=DW80@AR3|=UX&|Z,M\$ISI_%L3XEZ;"OV40?1MA/E ME4?
G@D>L/CZ|5UB/BCDQ99T^!N^", (2FN"-D^L.-#.4I\;.!R\$460CN552
M5G&60FW#D90"28G|LYW^\$;G";RG)8-8/,SL+1T56+U=<2^:'2^1(YFXI8U(
MJ>C9NEL\$HF:WF"7R'VSX*PUXI9_ 0+V3X%B*HG\$W.U922KD)F|!I;|(J47F'S MDPT;5"
|CM#S_UO_L(8W9^60&*A99C@ &VYN6E2E^V';JM)^9WN!D>=|,7!|9 MH-K|I|?Z&>\$-P\$1TSDYN)IV+Z#
R|C02T\$KZ%6CY|'|;V\$ YX|;0T\|MH'*6RKC|
M6,|/H#I,ME.6@:YDX\$>'3FBUJBCS^Z0\>6P/.7*;F>M(.SWH5>61V0^>ZZT M
|2RAA+7|Z>A/JLB)K|DG.H6'C&NPD"?S\$F>@\RR+V##B^A#|VW7U^ MY?9|\AHF MIZ (L|&L)VL|T7L&6I2!%?
U>.*?|K1=;T?62P;|<:76!/0A+VG+JG0H1|7 MHVX6V3J(7|.;#_41='=KQ0*6(U8+N3JADCMEAI G(|IA9IG;?
ZZ_/^_ROX/@* M\XWGMYL8ZRCV&.B9R|5\$;@/./;HG@A^VEQ0^3S\$?55M3L-8U\BC,'A78= MES,LF"G,
|ND^=@=,\ISK>!DEJ);4(30_8)*SK?OWE5Q\7BLL5)>;0H|MZQQN
M39.'W'2,\8\AI,TEJZFC&NMGZ_R8E;+M_>|2>PKW&6JB\$0.16XEI!19P'JOE
M6>D^466%EG4|W'K3NFAZ2&|W+8808V=CD)V'V&=B#0|AA9!NIW"/@XQ2;!4,K/NI;
MPE>%#>#"SJ;@9N"BW8^MGN*/(,MS|\364F<@/.1+38V?;NDF#UF3TZ#?(_H7_MZ|&RT)RV2*\NYM\09#1WN_Y|\
M+MQE;23'TN?N"%K6VF+X6_EL"!-Z*-E10L5^"04*CWH\$K\|]'%NU;(B9;:XYR
M2+=K(T08IV1(9CR40_"M:.EU%-I-WZH8.ITSV9P%!Z&-"|V%U14YUVI\#60I
MLDPU=3Y0V#;/&L!=0)N!,2Q+U0D=%? !RM8#W10+W5%G MXS?:3\X"|MMI
13L!KX+0)DQ3=FN#B+|_RC_9\|WQ|5X!-DH5@?9W*CF2!2T M=|Z'8%\3.8TTVJ\$RE|U>8G+*);|S*+C<%II0,A
|JAGN+|G'-Y/_P8V#^Y2\ MF767PP/_ M6Q:81:X1JWX;,#&=B=5E-9FG0Z5.AN?
HBV_<0VTPW,|UX8FI>A|QIRU6, % MP*RD_'U6*H2G?XHFU_ST<;P\$SHG-
FA&L#HZ&@2/VWAU5"THR/3|DC/\$_D56P MXU(&UY@XNH'G2P@!YS&.GJH+%X!P&%%\$(^\$6
TEI^5C:F/,>0K)Y3(#"4BSE;DR'YD*4+49^L(F?|PK-TB5FFS"|,V\$6(')OMM_(1^K-LQL&D-Y4,3%^N-^6-
'\$/>H\$&^2_MBD|>V:EI^N0.M(L.'|=D|Q|;Z_VHC5?;\KRM34^7T,.
M'"N;&UI/7LWQ|8^U:KKZF<(I>U'1@^1XFX|MJCH+HMM>>6 MIY"|2'E:HTV<_C_M'X.?
X:ES+HG4C0*WFGB>0|5HM%G=FR)J3TBRE6)"7"\130!(K|,0_/D=>.4 M:RE6>|5Y#40"|IB \.)7J'?|)G(H-

^0/VQX9_5NVYE7!1V0:89R98GT*4/ MSB@T7#GI,%])^4Y/72%31?.)00,CV%7\CKKT
M=EW+_*HMU6R[*;I!+*K,ZQEJ)PW],/:9S9;-P 05<28^6L:MUB6LCC ARL? M>4%B):W1A\<20J*9-
7D=:M8;J5\$#G&;C;=PC;VU/PX2\ 5NH"5!X04\$6BJDM MX6PUQRM?W PW TI>ZYW3MU+\$K>'&DM,J\LY?
3>!1/5.50L<+,L;X22G"8 'M9\^%1['/CE+B/+B_S+;,\$)\ MEZ1I713EU=J\WKD%?6E.E=>\$J) @00#(!!=?
!@^PM QX11F!0NBK53=WRW MN,#2R'+<;I;&!EHYXS4<\ '*C01YQ!FQK&@3=P%*AW#J,Z"7,%G?DE0^=4\1W MS
=!4@J(??VN6UZYU M5ZC8/>K5^'. :?BBPFDY6,!M5X'P!H'%WTBRKJRV9
M/.JKLU')@J_.8469_%U=3P.UE\3UJ+\$;>:#+!1&5\$R\9\$?;JB!L'-Z.K;JX(M#@494J.
<\$%5=1HC(#>"4">&3&M(J*'.C?8(-8 &\23@)1M*FI\HN9[* :PKG05;:(-&KS95JV?N3&V:KHNC IP0;ZSX8>
M/V<'U\0G<&5%P26YL=NY4K(1,TYUA!< AT@00U.@P;A@!+,R*Y)!<'8Z-'Y
M&UTK'@MMC>N/1,U/WT9/U\$1=1],B\$GPK%.W+;W.<"VYVWRY30=9 ESFSJ/[E\$R9.><(P/L)[D6H<*Y7-R68Z-
*H"7>41/=22#WKU M:U,T;(: (E&"J:N!#J9 1EP&=>HH=ATQKI%C]TW/Z;0N=.#W 0=-! ?[&A0*D
MEVRFNX6J38.)>ME(("TA*#;M@T T12J(71G&'ZKW/-F* MN*\5K][EN>7?UVH?,Y-?
TLS\#6]W40[<@GLO*V:PUV3 EEJ#Z\$@_1910WE) MNA>K) IUU!C/S[?9\UV^'X-0NG-
\$AZ!E3T33YS*W%.0Z\$GP!:-PR>;0/\$0<' M2]H=>3\=TBCGE(>:B/4&G*QWD2] KC;BHI@Z@;
<\$(DQT\$603%7KIHC%+.Y,X M3#LDY^@A+@= M%)Y@J-)9Z!(<93]?%>(1Z>;:[D>(U^4):/A([YQEM
&F5I2&A%XD*&G!V%2 MK4N\>S.Y WFNZ1?POSYE08"5-@*Q*0Y3-/UV^;KC+QG#[S8UZH?B'0520
M@A"FT!OK=);JM63HPE7R:SOJ8 M09]=?/(#H;)T%&DK5@RERM-F]JRR.44=HLVV*L63V*^;C:T.ON06*I'BC'A
M?0A!K)AA"Q:\0[J\$0E,0*JTP7" CP)0YD 1&S\$SL)F6@=\W1'0./U 0"& 2F MBZ\|R=/ K I=Y5N.5\UD(@ZZ
M>!B;@ =8):^#0;&+ED4_QE#6]J%M\K<>YAB;C@0 ZPL B9+' L:D\$40J;6[W MU<#P\V%- \.D3U06#8?|S\J@-
+8B'?,WD3C;-MRS\)\ 'J;^JC'M-HP ^?-5X1 MU7 @E1<30K5MXNU\^'F=^>SQ6EH1NRY^=\,7']*4F>;!
[, :7HRX N=-1 M^-]*&*3N0=PFP+S/>8AG^4H(V7UR|X0SJM\ .HY=T4 ;ASQP0GJ)8HX[BAG
MX\$9^TA(0IX,G*!;<'SO>\$!,ZQ=HIOT4L:10KYHD5CVU\9K%)<^BU%T>#&V4 M<%G E[#_D,,)!P>B;
(\$>"I'; F7E *2B+{FANIF0CM.I -H'/3M,5"X&2H M*0(- (G;^L4>B8\RG7-IA/L2P=
(_24>XNTXD=S@VADDY";0VC4%"I3^P2]TC M%4HQT\;-D!21%>=F>1(TQV+E0N ^[I_Q3MF2)4:3E/JFR.\$+C\
"F03 M8N1\8:X.\7VCTN?^/M\T2^6[A<+KUVK'P#RX-3\$33\JCUMX9RQ|>@%'V:CX'
MNLMEDK.^]DC2LJAWGX:S!F(I4:X&-AU) T70LM)MSV6W/AX"">=T"77E[|]' M<6N &RG!\$J-
=<\$>)=M[FQA\T^C%63]TKB[E;WJ|<(*/?5*,DR,N&;X=DLV8! ? MW8#9K,W3N=OKH&P6C;:"|/.)\$EI%=YPQ
M|^=@\%TK4HGN+3);1N7KI\NM@5J0WT08|,13N(F(\PI5K3|, :#ZU\$YPW1'W"V9EM=\X>UT64U;*S5?
07H3UPI;8&[?'Q\$B^@M M>(I5 9;R M#RA VT+S;I-*AHL ?N"0IHG0)"VH9/KL!(UTP-+)BSHB^ZYS@C&A;
MVX.,4"I !CJ\$SRO^ .1QZ1R%399-D#@J\5Y P6;60'\$5F=RGYT ELZ6 6RE M(-;
A]/U; '82WW#;T +MN5|"8V0853Z#""64<\$@6HH="7+X^6UK2XWP>)0;
M!W%RLR.G? .OUK'MD'KYDS\$NBU\M\V+!C%P "J3N;6QFH \$XA39K8JT/&MYP,
MA0!;OUDQ^0E;:I^&E80@'AZLX3& X.<1=)?8E&D\$ZJ^T>T;;U=9/BN%;*8)8 M1;#ACS"%W=:2%6;B2E.-
URR5+;;W'Q;Z<+B#D/;[K)T85C@F<&G6/<&P=HS3 M+F.\$I=:_G<9\$[\GK;XK+1MRJ]X]|L0.H2
1QI2;>P<=82E0\$ZNSBJR*C"FC M*4-I%Q,/.L[AD\9;0;XD1_0S@ 8C\$?! \$(B',Y/4%E MPVT\|08J\
(W;4\$[RGY\GPL|,[Q+QMI]?>Y4>Q\$RA>)4#^P71U*PKW\$9T;1U+ M\W>N51LYC1+ ?
&I=6#E&A_0\RMNX,&!=S6?JM05@VG)J8UDBKZ&LM^&LJ6 M|F>N:]:+4KQ>KQ%1+4;\$,!L?
_HD\$Z5\$[NXE.CBP_Q2KE|EU2XG0>%A.?V?SZ MK
J.#"30X0M(BW3C54Y.^2A\$GBL8V5&Y5]YVJLV0S!VLY#Y/4"X0.%&Q', M5J9 -? * FM?J>3 >7GTZ7
+W+ '#\F=4>0:*IS;1\$0\B] M%S ;XT+=+2SRA:17S8#|B=.A7 FHA.ODF% :&IR\$B*N1Y18=\1?H7K)OR.*
M0YF^LZ#"LGK<#SKP8\B2] 0JA#[UU\$7RXP/%KLZ9CX0V7*,YMMFC6:5S7;&^RA7\$U-%ZY5?.YC01UGB1!>#"*<
M66)7G=< I)(\;IK+8JM)\&|C6V+CCU;3(RM[*]5"0L[DDAI|UGD! ?A&;H M8S|V&>H3@W:JXGB98K(E")8N
-<3QNK%\$8=R\$X(\%*AJJY\$6\I3Z^*)0>B60
M2L4Y/\$;PD<*\$*T[GLXW^""%+5<1\|TLI:PGZ_E73R%'V^VT0TB_650A*]*+Q
M#^&G\$8X\F631^W"">\$6FC_9)B\B&0Z<'W);#VC4B7?;=&4J\$% M318\&/_1Z<.(A@M -)TK0".I?
XSM:RC@SUSL#PX/%D,/I^G.G;#NN99I1%#! M0>F\$A:@ ">F\]21HA&Q69I;!@G+U8V\$5\$0_G629YQI5|;
HN=B^3AA\$.\.]&(M,'A"6/D> U8|9|S*.%H 9/; *K4]H=9\$BNZLJY M+N
^UTYMIM07+VX#A1M2H5HRZ/5;W:H2SJJ3(EQIC56HK@UXDX+Z.T1Z_WQ(Q M'F!62=[V*MJ(&PLS*I?
S|X#G8(EDX1|U#U_'MC@M26J+1"H<3>*XQ)5|,NAD M?GP:<2#740|WVN2POAB"249#%\$6=##@TH-;PZ0?
UHFG@;V"IN1NO/, '-0+-T M.:7TS;&KW\1 B#) LQ;EC 4*/T)EGJM[<:) !;([@3^;SMIO\&6>LWNC<-
&DD^A3>&&D!M2ZXV!|IP\W?>9J?|[H98S5S/I MW00V(^1S.KR<+/?M(+*(IOVRY11;2;>+&NA@EL#7\$GVQ)
M/"A-0I@+.EQ(VSM+5(H87KP69%EE|R"16P \0[IXT0 MV);T!18P.#GZ\$. 1Q/J#"9?NX=U2!6+&#F*)M1|0
BPQZ@5\<6^&-;D*.2:F M,EQ26UM5|4GW?<*]F =3%*(EX:M"JG'1U80UN_DQ*+T%>MI%B)] %(&[#U&9
ME9A&J6X+,#Y\$FULZVL^7H*:/WV35G&LLYBVL9|>*TIE,39;1|T^RUEL8MY?E
MPP)UA8_/5N=Z>RRM*\$EXFGDC^B9D;@ND/\(6!5?T/)?:&XQ0':
MS0C135CREKV%>5>8ULFVM.5*,#^I4?]:DF/=XZ4.?5*TT&' /D^92C(/+ * M<302,'*;\CU#8?
1U001(^Z>8 GPW.:U0N %4|8\$XZ7R;G(M4)JEVQGH_6|QSD(YHM%_L5S'OK
XB;=2N7(XF0DJ TJ0>OX!G+&PJ1><3FA: MWY|[@F^M*NY# MEP" TE?@P^\\
@'\!, -2WJG(SYT/<70ZZ!)C JC&4"?--@FAIX 62%-&1 MK0BV=M7?*M, %3EGDY"J%Q ZP](<|
|\$ZH2\Q0MS"\$> #B%W0]?P+0'E"Q R| MQH>89(00
N(88/N)%A*AZVXDC8!Q5DU,#E#IW=>S|(ZY0GW0|D#CU(%8=JN:*7#SDWU3(>7;51|6"&G1D8:A8-/:
M5UV3\$/;0=>U#ZNF_8 <,V?&G!(A"\$)HBK2"1P0J,3V_%V\$4|U M!+Q3Q+T:S=\?
62+7RMQLGZK,IN'*BC\^!RN06IQK= [& MWB1&X*UV1?&!&C!1.2;9RB&\\$!PC1=Z!U^Y-
[;IN_D>T.TY:-4))ABE@KMFQ MKT+>)7*!L]_2RL#/:!RJD6?& \%R]7&[,D C*X0R%R|JJECU"XJ_'3JM&TXQ
MX"; E3W[A.+>F"8\$LT#:I=31U7150 !WGM'1;\$U?;-#\$\$\$2BY#PH28F21<*(M"\$-0\$)2<)(/D/,# J\$A. @(''
I(E2\XY9\DY#3G/\$ >8@>^|[EWWKGO^Z-737=.[JZNK:N_J7?M7E/'<=MC,Z+)J*X@:UBH\$CZ21S=G) MOUT=-

AMD09}[BGT52.@8LIPWWB7F7LXSLRQ8*8&,&?U:XGJA&^40/3.H:H MOBZM>,((#D#BY?
&CPU4J!.)'3G^1LQE,L:SBR>,"NJ?,[XV%Y7:AF%X: M0%DFI5ET4\$(JR/W8'S9G,5T.N (.T3-;;N1<62-I'[[F
@ ;_)^6!|E;899U M!0SM"SR87+0(PENG8E12PHDJ!\VZ9^PIN'7J<4;M0<#SBQ+,.?0DL8)X4D>DM
M+@3XXEI)WQVG@>_FYDP7?RH2%JVL+JG35+2WG^0.I331 M?
GY()VM6V&/96AZ6X9_\03'U.S,/,BX2<=GVI#A(40%'5Z;5A20>^0:~L[8\
M/BT.;@F;G89&'SG@5A!>UP>H<3;JLHW>MRECB'TB]L>S*NHJTF2ZP6GL M[KQ9;6COK&/S1P)
<^0.J=K'B2VVH0TRK.T\$>&-'7[!50<'= 6 T3JC|N',VA M3/28?>53H"4M5[0IN T0T0.Y/' +.PRXW-
NJ9+%J-&3BPEG58<*>?/[7?V MG'XAU *S+>-' /QKI=^(I0)0PXR,MNU/MGWAT.>F#6V&WT083C71;/
M#H\$YE\|=GPVM#=- GK X-L0 TU0 =NSIE%=E=!![1;C=1H6FL,ZU?;_VD7R/ M5^4]*LW[?])FY5V9VV?7UWH@?
#3##PC^F|XVK:~C)/NVB"K"IW,PMK]1< MWCRM&W:-
IX/0>MZR^60J#?;|71\E0_00+Z0%/Y:MK%8VBKQX[=,DB/)!5!K=17G0-40/3K-\M/B\R[0: M=9=-L
#"IU\$MCGT5&N00?8RD\7?SX1RRL>80S*K2F9!;?S1<6F8W5 G=M"GB4/L1RK@D[5]&@H'4IM]_Y M51NBQV;
(\$;95/?*]82';FW?@VEY7 [W-.]E*0%TDL M33/L EI4.H9Q35@Y+A8!I/J2[2=2L!7KU1UYDZCF9CVR?
I(COK77XAI,!.: M,">8EH0/.I@4*8)B(0<#D80&2*WW]T>ZZZ!5_6"<
MRP90*"I=P%U+_)Y>M;+'H..IOYVU.YN4P5-6T.*]F>^Q,VAL4<-GXM C%H/ MD5SXTSG\3MI#KPGD- ""'
M@A9NH J0K+HC%1)#^-.ZHCE9!QJUH :|\$T8)9US XP!V 6U0\$BVHJ8"N;C&* -CH)9:&[!FC*
[VY"55#A:BV%9" I(- MCZDNTT0, M^MH40^,T@1LUU0/@.@SGV%-170^5V- D3'69R]<-S;*_! 3A3
M]#=-.'!/D'V.U[%D+VI85S /-D6TKX4Y+6HZ';H&1)0GP*8L@!@**~NK81B>
M6VKH(B)2.MS3QMYU&91ZVL.F^5G!Y#)}K=96R0V\$R=0-B\$&:!M8ZA7 :UCQ5 M50ZZ3C';>0J^++D2SZZ8-
:];H.P2Y^I6F!WMK9RPPQ0PJ09!W;H(4\$4A5\# M" (#-4@P*E^!IFE>(<,%PQV'/D)#3.F=YF6TP2Q@,HC7DRUR-
"KP4L :XL*]8 M5MT;NFU@T% :Y1 WD 3W7E@>28?S5HU9Y/J=IP2#/ADWXT-?-I2ES^CY/*Q=
MUWR\W)W0,DNDH3IV3U^AXXA2HB^2/H98TT; E/;IGM,"L5DC1+30 BJWNZ M\Q!?
S_#,LE[%.J0^3Y6[[=J5A&M\$24KHNM/07K&29"]U^4'W(H^BTX[BT10
M#?,5!RRKB\8\$WB^<\$ \$F|IBN0AL@^')("Z;:U4^V\$B>.>GD M^|F
=)B2,WV_D28,TK#E[>.%&\$QLAW8.@+Y>E+,%)\B*\$X@7MRV(\=FP0 #BK M%HZEN!6AG!GJ7_*7]?
7J2FYZGP)0%\$E^@#BN7>FQRZK=?@=X67W7% HG46W M-0W\$ G]=9(ILG(KH*8SV%,V-
R83RKH!CJ.E3.FNC80MY'X#3^R7EGN|#G8N| M0>('9V#K2VDTUK@T%2KTS7A%4IUW7U^HQL>!/4-Y _\S4"
(-#7!|DI:S207# MWN7@3XQT:'FDNU6JTY{f0>"33A,E#=-8T80^KUC17IP7=F;:*B1 4GV,(WX?L
MX+>+G(-VX|DPL3L=H4W;1R'RFLK/VH9XNH?SMWK#T!\S7L58X3=BX2"*C5\$,B\$[8IT;\0*6XY:*3
MAPZZV_0>'@L%[1\R7'LINF9P9KVJC+];"644 &J;T757U++W"-GUEI7=P9?
M!SU4+A[BGK0V\$SXZ%Y%1 "X\$60G\$-U]L95,H5Z=\$,SVX)S]P@\$3D'8-&!:: M5&EA.-4+
[2>_Q7P7'PKS5)T:Y%9>T6H]1E4MK62R[;:%*[]45T:KGC@K4\$W: MIG*+SA=A:"*J)1P|801H452,SLYA;
(.C#I]'C*\ S[94C['\$5D&]6.\$:"1;CN5\$,H*R|B. M%ZT2&LI5=F.\<-
VU: VZ(H<;J_9U#Y4&U26T^)CLTR#9B,N,)B>2U;>05*:
MJ0_K+DGP/5TU.@A[FQ*8XRP\IY#C|U0HKSGK,G'BHS(I.^+@Q0ML:79JN0EH ML*=.6I=X7V40"8LJ*6+9!F|D?
PV@*U\$P.W]4 M?!20,|D+XI: ^3BWD00J? WP5UT*-2!85PZ=[_2N,9TOR;0UM=!&?|#F6N(G
M[!Y\E^5Y6;#9H58=@Q\$N&F MUE7?4YL-(-I5)#P20LY=<.XU7.8@Q%. Y;?\$5.X|U Y*#K#ED2VK@' *) (A
MI\$U;G&+.D+5E004130#\S./+<#4#W-8R|XW388J)X701\$ [5-,0T?+\$+1&1>I009 >0'B.Z')Q M^
'V8#50F:5|]DIT#F=;!;A0 W0Z:.S0'#TV3J?TN7G1U2U?_E4%YV<^JL"|L M V>E(C(
P:J3H0S>W(ZVW0@7W5(GZ:<3TASSD*.EU(_0NZ:L!CM'1M*I/+f0 M6HM*:\$=PS>:[G0E,6YQ!GB1+)*.1)?
6\RWU ?)10V -1\$^V"W7MZD,NZ6f0\ MJX"ZKVN#^0]900%7T'FQ7@S.ZGD%4/46Z>DIM^MRQ1)\$LM8'4A9!
<*I.CV> MM\$[9QD1(V>P\57B5T| @:[J^X\9'IT&Z[I>QL>V;FMP>4\$ KUVV-NJA|EX# M.*60-
%=PHPNGD,;T;G5E:GV<_4, -(88,MEFY/=DR,17&?7?? F,SE*GT:Z[P2=XT\MCQ*XJK5'P6YX*N;.%10-
5TVH"JNNJN:KI0I4= M&G4IAJ890N(7K1?1J5!(4E5X;C0=S55" 'BQKWV^&>12P=CL1C)8G?ER("R#
MCJM)^/D+^7A7;')FWBN^7E@T,"K)5I/MPPVN_2^B M_707 !U|I "17V<;%:;
<1[G2@"U1B86X)!R(&7)V6>K2%A7\$> MV *5>.91D|GW39XZ+,1\$ 8JT#VR^!M"<\$).VWP2|DFK?
MW^>V);J8D,^IG+ MXZ V[5/5RZG@;"QE-Y8|6Z>:2Q 4&+/,&6 /;WRD6+86ZK*7F/RD9TV'.0Q
M_\$"7%7US/LN\|9KUT|I! #R5<4*U?|4; (UF?(^, I=55UE58
MS6@7FX0|(T51\PEL|IRTKR1XK^L&\|0QC07T7:RP>L:T'8EUE&K^4&J*40\$ M3\I&C8;'N+XT7(<.>*A#*R?
X2\$+S<|/K)A0FA8|'TU.(XEE0C)%?T|]9-D.OAH9?'Q?CL?00LMMBPGE[Y@DF*)C+>DA@:0?3Q:8+6)0KB)
M""HR=A]1W\$;K@?'R^?J6I_M/9K3>=K;{ }^Z\$ I.ULYH>EN1W3E,J%["!CY/ MV*D%(VRDA7P<_+59>0VP:1C?
GY)8- #R2/H)}|/)[^?=?2JAYB>4TMB\$B%\F M/O [>:G<(?UP[+4NTC<;3L#W0 @YTTZGGY[VID] HX1]:
<&474(?+C_4'LDZ7:<[fXFM)U>\$MZ)3.206WAU0^SCHR*E%_2/?-4 M+=\X?}CNK
|)+I(!OK=70VCUT4==+\$+CLB!;.:8+_M(!)=9;Z|\$[B8C4'K/_ M4-U
EC2[E:&>;0.1^D&Z.HU34)V=^NP'GE6N5?|N3"242S@U(,8F8KBAL\K9 MC*BL/+ WR/,MF9A&03A_*^!K D M7
-VJJZZ*\8FAJ?.K-&W'Z2'9#S]3\GEV VC7PX1.LJB@J|XV8!04\$S 9V <- V;62\A#,,>98"(BN4,F)2
M!@5"7((1D0&F4<(^@J(10L))J^Z6EE\$S2\3|N|M/ =B. "6DB9|YX88\J;I M@*0;J43
NRV>MRKKX [SC@P./G2T+ M\S#R];*#0Z\
Q/3J[B*MU>G%000H&WS!N5=M#+&YJ3'\GLU|I>L0#+5&XG<:THQ,0VP*%!DBB\GI*!53",E4ZQP.&CXMZM1_\,JY
M9D!>OU#X>J-I6,C?Y-L9N|0:D@XW,J,TVV00F\$|/-\$/?INA3_\I]D,\$> MRO@MCD@!VZ7%!""\
MHPYJK4D*U\$<8D?7,YW\$[26^G%32V3GT0*/\$LR:61=:,+(FB6S)2JNA7Y7> M?@JT\$0(?
RH055;Q2#1N_7^F)M8HB?*JR5&%3/U,#WGX=]8[8!D>L'!CW9N. M/Q<8%.B FB[[X+6M;S%(Y_-
PD)NFXR&*J*B4;3(5|W4B\('KG! M\%\$CBR:D=R%:KT0]1E@B%/J=12W0"USQB-?3|<1G"HBU<7A:2TJ(:EKT=
MWH,J2%L4?:DV>=-AK<;Y@ /+];31,DCN=F>PPW>(EV(LCB+;!W*=PS9;:Q0=JPLV
MUJ02)SHHTTL.">R4:A] =M#&T-!9%:+&S,+4N6[@X,:D2(P+0#=-]WMD/^SJ M6NNR,8%V3HEGNS3+1G>AZF-
7+*E,D\$MEI-S>V"3'Y80Q[_Y+6K1WY1?D3\+5 M/N9M<.\$)/M6=0(Y@;D>*F?[?I,(L!1-
#F@UN)VZ*B5:=3+>00).<&5K25M9 MV:S&^("DNS[3|GN5W-\:V MRCB0L<29J*C\ZK_+]+%RA-L/L;B;")6

\\K &F0N+?5I@SEW#)>9 0+^T< M31QGV8W8:.308*E[, :?7I5)!27_5.R\$YVPP%D+?CW|0@^IV):I?
[Y5]A*0[M%U7N+9AC4]T M>7WQ"I4J>/0LXK066X&6BB(CU.TAWRXKBS495\39TN2'XV0 !V#%0@GBH&52
MRYWY|K@DLZ0*5%RJ35 VUF: #GL,3ZJB\$, <[; -@J"KC+;EJ;P*!%8M?44&:: M)Z)U3.UF20&: 'G'.M/:V?!GB
=L\$3^9>A4D/5I@TZEM('PW7D0= MJK&38BI(CA87'QH,|T[S_ %%^7_CY)R6J9]_0%B-
6EXB6W_ "*"1B<'P6W8S/R0G,V0I)+!'|N^CG|/-Y#6/^[@ =0;>"(RX
M6+6K6,2B9I\$9X@ZC@5ADF%:4JRFC8B@4(M*"SEVJ6 2X MWKR7I="2EL +: _S>TQ\5!0\$ M0-
X?,IM*X\$NW";HM# =R\NGOS6CDBL^6'.RUBH!'|NX<2W|!JDI.# 5 @
M+.FVE\$P#Y 0 0\$0!>:69M)Z/W;>R+UAG5,ITQ,*E>CNKHZ-@;JY^FX5LC<-R
M;4AI20M: 'F6\$R(>?!:A4K!"SRDP>EY@S|A7W#| -F9=IM!"J7LV1J|T47Y6G,
MEG1X1J(IJG20TF67_)N"D*A^A-Z\ JRU5LBN|OH [70SN?V>2J,G(CCV8P&/ M* %BXJ"W,-
SL..\$WR/A((_A0S.F"/^F(#K7KV-#IQ|HPU_|CJ#W!>W%!.?F M4K^|+M|1M9(FK\$0,?
AJU\$LFED"IPZEKKU|H@*=!X8|I/1 4|HM;|A;|C.=K-2:EP)^^I&A6Q&0+/,/#"TA_*:_?F'L MK&?^&@!'(!G(-
!4/_0R)E^4AF@/WX0:/[4>?:2\$>8W.3 M?(-:R0:ZB0:\K>1F,6;>R7?B'H218/J-!-
G!N5M&V&@Y' B!7^/M21'NV/JF ML7)>Z4/XLBG!^D0V<@=68XVG?13-K "K9.8G+ -=^QHE -;:R<8")7-%(Q+
M*^6T"X??<'5^>(KUE!\$ P \$ \+A52KTWWU&JR=WS UNK\31LYCN>:K!)1-= MD6J
W(R37(6QCE3WD\$B0.J*IS4"HN9%>M1Q2!|U>KA|V|.BP65IJ'46|!%&")58FN<=@2\J5FDG6BSD.SGV&WJVEHFK
M"FI%G=K?WCK6E"H0!01DPN @W.VLI+|/&H MW<[KP]/01| M#3!5)4'9-=Z'^D0D5/Z,Z\$8N|+|:T!5?- 4
MIP!7J S:6(44.M5 ;+0|,()7N'TLVU-PD!*Z3-('Q#N.:<\$!^DK|^8>05ZW MXZHVF6&0 =ZW&T&)7 JCO);
<3DZS,F4\\R&1;P29E#0HQU MJQ0C.5\$8?>6AH M ,H80V@0EX@=L- /|SBX2-CTVD%M417X+;!(4C
^J"=GIIE1-^+83L2/A&) M:6TV420V 50)G^0^H^?N,|,*Q5.;CQW0\$Q\RPPH?+UVN*(I;('U#\ |S2NT
MH>#5_ #3018-0F0K8R_02B%9Q#;X|.6E)QK*!|V#"; =/E1; |HEW)N|DH2<@W ME+MW7'4
X;|7Y8(KA|SEJ^Y/GPG\$62C|Y8P*|IJ)+0_E0" <5ZA64F_!+!*) MH4SC(LG09E|/H#7@R496=4B:X'W_]?1?
0(2.,);,6K(2%|RBA2D@A_UKL-J|FY: ^,^8^D;Z?^!|FQ ME8X<+Y*A)KL6!|!\$+7|=.'8AV+A#0*@8A?0=*G0%
|F)|U-JE*%0(T=2B>G>[E0-#@;"/4>N,5&=60K:7!(/4 M,^XD&T|F.M|Q.ATF/T#7@SM-IOX;M@^L"W0+38-
D:#Y=(\$'2!|Q?#A'/!MUJ M3**G9:T?|\$^PYFFNRY) &.[0J_X&72"#?([Y4\$_'A&?C0KL;)1&Q@>4=ZF6
M02R-)C_5.N|J:I^"&9V\$+81M|X%?IFE)Q_+3S"\\J#A;A@|.E5&RC>M|\$_W M-3!9"H|3/0'.)P|GN;+R_AJM&
<\$0<\$27\$#;|,IA|/N2YH_IH,NI=|7|QI1SJ M4@UYTA18=,(? "0R0#AJHS|U&&KJJ!V08; , -
R%AOCU#QQHB)UFV4\$0Y6&<=M6K:|3'9%S|CF;1#02KHJ?>P-(=VI4(W|H?-|S\$|^M3,(?5G0<:
MTBKS=73IH(RX|SYR&4Z@*Q)UYWQAYY0#0;P1PE->-H.IZ;9GN%|F TQ;\$VS/QV(MW@X,F4!1Q
M_F*KFQ|"355B+\$?Y^N^LJ+X)>K'^^@7BAP2\D8BX|ES(X|).J|JJ66-3#UE0F*->*B9Y^>H,_%SRE"R|%4+(-
MJ?3EUX#@BY|Z"9%"KFF>XP'ILSY1|UL\$#S8_/MK='N#&BTVUCG?>FV7N5;<^ M(E|Q,Z4X%
<>DF&*2KRBZ<@;OUK\N\$/:X:!! YNOI?R?I;|YCG.#C MUFY Z&D,*@VN?
@HD|&74|2F#DX;R6F#0SM4KIFD0L<4?"4*1=YONFM(Y?5;F MZN*!W1.2#79JJ#X,FF,("_,|7Q%G=-
'G_|AX|P5K@9%);JSXZX5K=32RQ?J. MYR|Z0A1VY\$J7LZ-NE|..-9\$-
HS;Y7B>@T3)0..6!9;K>1(+&1!|"?;D7T!1(MXH8--'3X 0516?X-
'^:K1RN&E>+J|J|G3BXBI1R%\$UL]|%#PXQ+ MDCDC'12P\XJZ9H+?+9_T-
J3M%6(7C2M(CND|U:0',5CC;FG|BMK@|^H-#2\ M^4-3RZ|"D:90?
D| (WSP<'BIZ\$%022783"5|>.H|K0Q5(-;Z0S9&510"Z-+A#, MM'?T(OUXXP|18@AP^B!#_!J1(
M;S^<^WV&1UW1|L|B0/^FM<:N_L:0R%#; I-\$|?7W%ROM0G?C/_%T&G 2TXJL M1!L?C-@?
AYYVA*|:N*&#_ \T|J:"_ 5\$AN*7(W"+L1JXT|BA8=D^ MEZAH>N+E0=A"|#E'^R> RA9M%51JU)"Y\$%0-
>K/ZR@0%2#_V,3LG2" MC^M\2Z^LLJJ|[".#PMNJBN#GK^3L >&FK|"72 |'WX18353|=|T%+2J|;0L
ML8C|A| 4| K P.|/I4W XRLEGO,\GWRM|S:=ST&PI(=PA?|0L^LY8MR>A AC866EA P!40'H|X:|9"L-.\$RY
M5M|Q!QARK;*^\$Z0JJ5B/0<:J'|'/&5:?? JNTGI,|<?7S?' %R<9(')>R0_?2V MM>##,?6?Q-
U9W5GI\508=0U_L)+RGD6X_%| ^"|^E!L0%0L|+Z6:18|V"B5>
MCMH+W|M)0_W0I' Y\ET#HB+.MILNL">XW8L>55)'!9,?CN\$J#A=K|J_W8G
MV,N_E>?/T^_+/E|J^UW\$1J^WV:+Y?C;41'^M0>G_US\7|XWZAE\$5:@|=E- M6-3WU/)(N;_.\$TSR_L56"S-
|E^CR-3DJ.33_F:|< VW|^P/;@8IP^'LHD5 MY|XXW|PT|4@%FOLJ(D,-1X|*AS//BSLU9.5MTZ"0/-
^ON!0R-F8MD4TFQ2Z%?#J3?I^67M-;#I)CI#NOJDM%WY M%C4=|,/0!FHW'>6=G1+0W5/@T8G;-<#7|!H
W|R4"D1C#/YL->-&V^C=?_C M54#>G|> U/SBRR/@-8#FC6=&(HY*QT'9%&QH?!)S'GD-
",WX2X/;D38G\$W0@C:V=Z|077^ MI_ ^E/3?PC?X+|OK^A7GI_|C@CR.P,%YRZ.)?N ?_00;'F6|,;00?
<^67\$W4U?IR*M0@!_4\)\$5:|W17E":8 M?/T;HG%K@\$XJ|> %6&?00Z+5,BIT86>%KI<0847T:0QUX"PX;|
<38Q380U#_M_X?^#_T?^C_T?^C_T/^A_T/_A_|_7_KX0*C-%G2HLL4.3Z!L|ZB\9N?;&@U3
MP|N|_Q|F\^^/F=F5+^+>;|]"P|/|/0_N|?Z>|/V'I?EGR#F|V_5TQ5HC M\56@FP-VL7<-
*,5U\$REWEYJ:8=|YD|CU|]|F?EG^^|Q_YW|WDE6I|!#<(AZ1_M_S10<^)>?=R@365%-4!&SA(WHWKG_C7
9:;%Q&@6U)*5\$)X31&Y,7QT-22?*_M?P_;J;1=W"3Q"0<_T17ZF,T7+EZMI&FM?
Y9BM5|3A(M^CIALYQ;/1BRD5Y7, M/M+)L\$JAN\|C*-
+Y72#DUT/|^#G\$U8B+9F;BDW0J(0=S%U0;#G+T#&SVX,, MFU->JDR(!#4)KD;Z#P6D-WY !VU|_3(;H7%55
M94,LY6K'19)22ZPK5X0,8\$ZJ?1'2IM\PX^<1C|=4,-UV\I*%H'" +AJN\^K\$
MSIV+K|M|3JNB>!#>G8N"*9YT/>=Z48N%NNNA:0|S\DBLUA//;^^V0'A75UGU M3 ;_1L*D&>,FT_&
|'QGW"B/X.PBCU,?|2H_R*N|ATNMGY(M>IR18-AV^NLT M)-KW2\$N"V6J|?@.NU>5 A.8>%\;POPFY.#P\7-
R|BXE@^RR'=8 "T5*E()/ \$ M:8RY(@%&AE7B|)\^3|KJ,4.TPY%/R38PM |S%9<
M/' ;7|*16S5|0*Z5L@-' "MZ'8NI'NU\9X1=|BV51KW7K=5@GME|D/1\ZSC1I-
MB/..-2#&MWC2*00WI5GPA5Z|K..%|,P#0"91//CFRZ|J|UR8BVH"@U+F0;HM M%UBB>!'ITF*'*DJOD:YN
E1ZXWLDDR;+T&IZ?/H1M6.^M:G@.,\ YWAG-) MK/X% FH3CDI OE9_Z63/&+Q+6|?
IJ?|:N,2|3H:G@|"&YA|^G |]|< 6V6ZS MG>=|?*H,^|5;DY&X(8F#Q%&)2W7^7B_A7RB;:-G?^9+FJ0<4?
@0TD\$AK|1VYXS3|>PH-G*|[KQ^;?1 =>TW93!T&*FJ8'--[K|OK#3US\$@\
M5&7T'96F0WG#0Q=W^G:ETAUI,8IZX\$).0_N\$SZ>?W!U#PUHLX|P7KV_ MN_9@4%77@)63I!|Q&Y0EY:Q\BD(+</p></div>

ZTL-5*C+8:E^6#6UP!3G<49F.6YH<-L M1KB'9]+IWC0KS' 'C\39WPWK1V=1VSNL9<*+\$[_0#5?
63AM\I&+GK/T7CEF]> MBVC#''B]A&TWBRY0*#T:*=U5 BS(_[,X?{CMS<59#V T*AEKQP],%U-W=5JE]6
M_+S/@JL2YFU1\$M^IR[014@P53 QS*-,=:3;K+-]JA!/B+7\0#8U5%/00*\$S\$VM M1U@KFH&#/4T?SV-V :#/E-=&
[U?>D97A#**0YK'&W2F_[69GPM!CQU&C9W1, MJ>FH)!%1RG\FM3.0>MJ/T ^##@BUTY#0;/LU4*!;H3!?
[0>R0?"MSMR@RK!D MU]>@%US[5C#D<:,--*V&0L/UGNEM^9M:=[6#SI]W"-3YUPF>U'J!>S03I0-8"?5U-
6(4)CGE5'LVJ?SDI*R,P08!=[, @ M+QFK<6&]Y=*M:-B'36 ME%:'3<_0[LT(K74CT4U--WHV\B-
G+WFI(T9@JY'50U(,T:VS*_0, -J7'K8 M[5'*DT] [KB<A>PR&HJ8E2:ZAKP"?^*0*ED!S@-G %-
IVZS'IUY&CJ@SPI M*-MK #XF S:%5ET_U[D&J#%CZL2N 4->.)2).]7:WIFJ?DV#Y-IGX2IG;#L,
(J@QV_5V]I&S, ^ 7T'WHN+2#\#GT9.[UXB@]W%QV7CC'7 M@.-B0P0HK%#Z'L1BJ%WSOK&#]_HMO: ^GU8=KD/-
K0*/4RSL>%J\ZU/+18B[> M-P\+7!%KST)I+2F'6SV/%QLO=I\0+;6?%MY7P5E!4>%T^YH-Q8^8@C]D8^]*,
MM'/_#FKFCL-B&T &7W8;(^)&Q6!0E9'\$[;T*%H\$%QJT0]D7]TU\$/^*"R:EZ M]I&-^N:?
0(]ES0NM!..3;4@0659Y5;@H'3EZ7@_D +^1/'Y1I.1 'LK!\KNH(Q M_B=*ZG_4F[-/W/(-
B7&67T"DD3Y/;:0!'H^FG_R454Z<-G M2@'6A4F'AH:,A<6=[]W(+>&]J:7F,B504^&B\$[,@B?
U74&\$,T[0\98X;XL MJQF%+(71:7WX_3;T;=Y '.R9523K[=V[XA.F/38E M?QE&N64;
[K\$1\#X5R00\Z686YUU\M@R\U]_69_QZZ[Z4ECTLCS1/K\ 0 #*6 M^#\$.S\@]HE9-2?
KP05Z(I=%\=@BC4D63#%[6H]UZ9GFL8%]-\ZE02)<;Y1G M/%:[VD@(%23.V72R-2@4-ORS3UA-
CN70YF[=X6((VV-0(%'!.YA\$=MKT-/X M#B^0HY1_Z&R>=QNO(\T/R9V,UXV[IEJ.,WUH\$]-F'B\$782W?
C[M7%)#]T!. M..GNSK'6)[0_)]@]-A53N%/,E>3XAR;JBYWPH%#H!6>VOK8"X7;K80XDPK6%K]
M(ECTH4F:I0#J\C11&@L9D?8=UII[,X[VM5SSRX-XM+5N]]IU \^PD M'70;*AB+EI*'-
(;S51G,YX&=AK2(A:*\$8MPL\;Z=V%[-0<13@3",="5NQJ_MA#1=SBI>E-![IVJ021FD\FG5'PNZ;:1&0,M
I&4HOROMK<[210IAW74I=B)E MGI>.N]U!1?Y?&6.Q07C>\$(VN&KMZSU/U0,"=NN#(>OXL5&B;5YA79[@/S0S0
MOBDN'=F;RY&I#LN&2W.UP6L7U%-U.9A*64=1&=,05Z\$/N%K<*"\$SNE
M:18_19G^@M.=^NY7=HRU'&*VE]V;T>S<*_5W\YB_E@4P]JC M0%^:,4DY.+\$\$S=X-
\$U(7_1E]'13.C6*T7L\,+I2R^2WZ6>8L' ME_X<*:%\RUH08'L4#7Z,D5BI>F:9,TP'MSI2?S-R?
#'(E,Y\$ _R':@24BZ[<"G\#F_G M^F*[KNW/13U?]&Q:-&U;:5F)/H!@9NDBT9Y'/&I[3,L/+83)JQ=!,G21+N4>
MJ]Y%X7<_S2Y]4F)6B+D0I>\$71*7[5<]VS6;4/JA]?,KNNV.:@4I#EBFCC')1
M8N":D0JCNQ" _#JUPFZPM+;:/'*5?QX2CHW>C"I3H!)6)\\$@<\W;:10Z0T0PJM MJU*P&\?
9L")JI(2Z0,K4_WYFD\$C=&YK^'0)SKD<\$YQ&, ^6%J\8Q+(L0Q%!P M:@6^_Q43*MJ!L,4<3LJ
JJ4EWU]YAK#_,N._1HW_,V<"?N][L3A1V!*VZF\+B>A%"V?V@*!\$%!U%G&^59EG02-@53%0T+ MR:S*/-X<=
_K0YJ;X)0PVK<[SHC3G!*/VOFB]0'Z"E-4_Q#1I3]Q\$\$.!T7KP M/=FG0?HV,\$2\$5;@+M%T9! M]>
(_NO(W)Y\$^Z00; G[W&8M\;>W>.M_Y?+0S-JY)*C>)F=L7K00H_6HV>KZ_MZX37I05"I<1NN=RV_HVMX/
%A^W>V\$I^DOK?-I, _M-04W6@R5[S_A2Q)=5:P!R4%6-^,B*#^RZA/T8=Z<_APJM+WJ]\ST5N4=]CCA
M.!GZH4XN\CU[Y?F<5!?!93A;:2B*PA"8W* M2MPBXJF3&>Y!7VZT]K T,-EG,<3^0FJ2YW;[T:L@_RY?'DBR-
")BY]WNU5\$F5+0ER*JW_M56D\+3WNPEW+):^C#;U+X@ZCMAIO\$!S0T0CU/P(%^45[7P,0ZT\F_@*I.C
M5/_;=?\$R!S3KYW1U.):C_-8V4S](N:.#(E75&=66J_HD?(9RQC"MD8N5'B^M-
8W\I'9@\\SSQ[;]HYJEM#TM49?"0>)\$#GG+!5=1E7GUM@JHU47&E1R.N5 M#;]KP#('PF=W,M\$J:?
>PL)V4\0,+5C#DF]BM^'[_W:79DZ\8J@Q*BH=RH+R M*(2TM?.RC_A_A4Z;!0"+K/*TD(NH/YT;
[Y>HL%0V0^=^E;R+L?@3(R=XR+A M%OM ^P&>-BJ1E_3-,(\;:7I-:;#F)2A9I*Z5* :+;:186_11N[3,N1?
U(2%H_M-G]Y8*(P S[;KGE%/E&<];,\$.3X8P_:\$JJ,-Y[(\Y65A6T:;Q*,\$N1W#<;6
M3.R[1H6U")"R<,U@1&#SD\DPR9>L79G6)071GMSK/:QTN\$Z=[]^+^95B10-X M%FP;2R;?
5F3.J[H2B:*A%\JMT4;/2L-%]16&-F_)=X<;QHU)G_Y-?^9@_P_M\4%E/--)R?"-2@?WX_";(=.N=XH0HGDM?
\$-6!W?T+Y4FJ+-]>#\L*JJN'R_MC8<1>UP-\X*S:H6[Z\$;0[(SFA.=9(],HF%_6Z_M%\$1IP6G;!EC;=2L6?
IK5>Y[]VB,R+?NJH24)GW6A)%SVN6.L&TBC\+JH34L_M63ES;S#QEM&@8\$.05-
F*,=A/\D[K>07=Y^CH/[WNF7%0P>FM,-\ \$1M8^8WC_M5S00[7]JPV0_C5F0,*@,[16W!N<]0'S-
%=!#>AY5HEZG\JMP^\$L9H]_F1"/S_M+U]"%*=6XR_7H'M5/T0CAU?D^NS.95P'9;PUMVJ+&&7UUN["=!0
M2\;A^,_QAZ9A&\$_.V:S0)0=F="J;0UFUPTFT_G%==OX89Z]_M;DKH37BP0IV+?
+V4YW_PS%,'SI\Z3@LD:D_N([GV>#RZ>R=&)J";B60Y\$?6%Z!((L/&2L\ MFGZN!I@CDY*G^2VKI>=
[IU*YG.9<)>\80;]&'>H"[X+V.:!165MJ#\79A@>> MQ.33"S;N+P;7P0^"9XH#KWC1CW_6(P8#1
R4NE1IU'L+V;N(:RNB/0%R1Y+;:-CX"=B@6DCK!.N=77/ MD\R<).,%!X?
N=U";ZS_HX\)^;0[ST(X(4@3J!)9]N@A(RY%*.X30LH\5T'1I.@H:Z+Q03=\%@YD>+*>\$@_ M47B'7''FV*
[J=RR'11HR#FRAX8MZ]E(*;=H5(KX)3LJKR'8PG8G5>Y[]4UG#HH4#3(+4B_M'B7Y<1>XAG>%A_"G-
@7F].;YH*=0(@23FF#W9M?V[; \K/)+RU01C"Q\GC;Q99[Q,ZYY+WIN?PC79^&
[LS1D7/KNSB(!%.2QN;6Z^S071_0,K&I!I+4 M?["RE3^"=,;?-W@8=;1+F//J-.=EDI
+YTLYQU%EI5UAYD=U5I5?L!,:3N_M975E@.)WS0A(!KEX;66,4\ (8PCF2EFYE370%Y
"&"S6"K1SX>U\$WY=*F'&XJ ME2K24\V9QF;":/OR>^K".IADBY4#")5D[FTAC+.)^Y^XR;
MQ[]G;ZTN*A)..)F6%SPM5\$9%=3V4&Y0;*7IW4&0YB%4!(%)B7<3+H&\$=!\K
MGU)9ELOI/*%HT,YA>_[6S]_V&*3?WI;2F\9V-F@U9P8.ZJ0ZF%6(C8%@Q1* M.GGVL9_(4A@G>/D<+!_H#
[6XCUUQHI40\JE2'=VCD@ (V;,"UM7,A);WfD0\$' MU3.R70CY)S[#U>CFBXH?+CEIRN6*5DV*WWV,?
>5'G):'5GNW@;1 M,S6I0F>1-(G.1@:JR];0 K.%(3>DWFE-I0+U-C+H4% MX[7<#<>49P3,\$0*VKYF4_M
P\RSX]7\$SFU(A=]M=.QP-.H59_H7 FRB=9P=[<;-2#'=[F*4)12%*I>M]V M^@WEE@!M27[L?{701D]Z>+ \B?
#=A6&4X8V_A, JXY^&^*0(\$R2H*VG.YVB_M'[Q8=/KZXW"2LP_ \4BQ20"QE_V??&5RGC48MG,](
8038>'CP%W_MIC_)U[]@,\$X\4?>+0W\W0H=9B2M%WZ1K@/\$/V/&+DS'8P(VAS]T<5[IF]5?E
MJB274!E<#0SAHVA6^(&:(%*W?!>Z@FQ.K?W9\$W*X=)!@\$*_VH_P^]=T^F\#_M_VWM.Q<3&_J62#MSKQY9>\6?
1GRK]2W+%G;:.X=FYLVB&BK.Z:V^=9; J2GS_MWX"9DIYSZ\$9B_BQN^K5'6MR79-> ?
&0DI@:VYU5KG1WOHL^6<^>+>/)8D<^S_M9F%SDKU^8%Z\K9U--0)&0\$@Y:
[!<,<S00J_0I>654S4L[A7Z2196UWA[6@_M+!H?F?FYZF\$>.=
(8C!P*W:0'7S;0,FQ@6"JMLM36Q5'JNPL+3MK[CFP]Y0_MGK]^?

&8,*QI2.C:*N!DG%EV10S.DT0.&F(T6,\.J\N!9:SY&5+3'7W!.URW M-3-U+G(4M-E(#+:/#\$>3(B7DD\$,A:
G+C'00-5;(GR0VEM(QG Y9TSH5> MC%\$=*BG,60_V4U*%9#M2RVDZ5'':C M0?LLG<3'?
WXGA0:E*\NZF'+3ZF0!3 M\84-VHFH%+3 @8C!|VH4V==^A3."?EB,,GU9TC!\@HJ3B!N: #_J;>07B!IY M6Q?
F7=)R#=#TM*^@V4N!|K#UJ5P#?0:#+CB\YNL13Z#/, (FN=BQZ%1V+:-;3
MLFD>;Q0,UKW7M)IN+-3B88@M0'0ES\$T\BT"\026,RAK.ML8;Q859-N)%W[X&Q*2@0J!\30R8QQU&Z0P+
M5(>+S9'GX@=136?DUX#1, TW\E\$9^%:'1DZ0S|V50@.TQ%(3V?;P|9<#\$<,TF20G+J)#33-
96WW=^|:W|GGWK6->|*?|:.->V4 -JK>J:XY9-<:L4>,% M3T240/T9RDK1KPROB(^9>=HR- RD:/J5A!|"-
L/\SMD+^|!\$'?&;0P00*< MC/^ C0|M@I&0'YP'|:-?&2W,\$) 07BNE(.N0?,WG|!@?(BKPU>M/!)1_B*
M*52I|6,89K)?0+QICT%'MY@RNF|@F>662#|)T%6-N'- NR\$F+0!)N% :LZ%T09RCVTR0D(P=WQ7@A+(2(
M5*0GHK=F6G+3P*^9W!;.%W:9;-15^C+I982DE%JNW)>"5)-A%6-100_L+DZ)|
MAA=0'/*#FASD>XC\?/K0,U.6M185P:9S .%98(&JE8FD07:VDH\$XZG^'7JJ
MN\34[115M0)S*>J+@E>54[QB3B_362GR7HL M3.A)!B/Y8*RO-C021?6DBQ^U@'WENC1TV08\JMTNN*RX?
0B;32>TUY5?#*G8 M|:XY?|Y4KDRM>MF#HMJ|@Z)2JPS0&_8 IX;C.|.I=63?WEZKP) 4-YS4>V4 M94X|
|3024H F E&V?'TSSTU% MLW39I;UX|R+?|GGQX&|Y*Z"KPDT"2H\=@|<@/8(.W.K9K-ZQUDR>08D|U)|
M%8J@&35KTT1914)2E:5\$,1@-NI "T_1>7^5ASL0Z@Y5V:!'CM MT#E1:YG|&QHOGAS-
9P&7S|-6)'7;L#3;3/=V&OG!|!>R(PY0C#970<_S7M-C MKCKW0UQ?
+/'S(A43W/'N@5WC90AV/P*X>SUIV(WYWO#K&8+(70%JDK'I;W^D M(>0%U)I'54+86<92F@/NS.,=\$Y/?F?
9%J\=-:T>=KF0%\$30LS&|YYM;*5Y" MLIS7DD:~0&+;-'.6')1WX0=UU2=8<E,@*K?F#M'<'|]A5B32
MN12LSPE#Z_7<|'.~M*M(-H|.=.=N57X-Q>4"|;S(##8M2(/J%>!G0=K\$VW\$|
M);\.A:PSC9E>Z!U:BBI_X^9CA&XE2F&7HL!.1C*EC8GPR!VE M>EF|FJ>1_2_00-%6#V#X#A<\$I_RT66N";
(MP|()CQ\$;|)3U);7CHA;(F8 M)!BJFK_G0(|\H=F=I^&TUN("<|=(D,(IM*=@.L6@VTAUCZ+QH|TSWE6/*UJ
MW6QUM)=?&V62,,HX1C\$APT|Y^ND/7+;0(0VGy,LJ741*70P/AB7HEIN M(LF-A"*>&Q77HUQ>^JB%?
7H"~#@/K^T/'/K MW9_@v\;MP-^(K9AK'3.40)&3*V77I#KZ6EYLHJL:D?";/06+%BD8:"_U|= M3>S-
3J=I9M<8<%9*BD|W6L;>A /#X(4>N@(%>BT&FZ=#NUZF91F\$"'#DYNW:
MAQ7'_K*ZG)W1U);WX5!5HSY"\$B"%7B702%#,[_5R%A6'MCAP>;5|/#-R!9#W M0"NX19@25A=RNR-D@Y0/YYS\$
Y\$52QW=1)(Z|8;B-9^ VNU)?(Y0\$R.(M3(M:'P1^4"H|C6XQ|X@-?
;JP:V+8Y&J|/1U=#^N%2W'H01Y#EVSS|W/\$14H7 M*9>NAN:I>"MI=P*U,V^E5MA_,*JCT;7,
|1\$9DQGC)2J;^0G&5_ P3(:S!JG M0|USJM|0=GX\$|1_N)D(F_&8R&ME.|Q&;C#%301->4*LKBV>;P4-
TZ.P5XL" M,1|KG|#\$0U< (@44 >BIB!CHVS@KZW&'JRE-I>0G/|0\?YKM FWLZ84W=UJH M*T@#VXA+XJ|[-
JA_UXM^WEC;\$Y6!>AK*C.XW2X+X6+.^8&RBD;9LI%\$|D\$4 M CLI%ZE.1MJ?YRVO\+7"B;"&?
H6P:@3BAMY8(+8;.S+&'=^:YVJ<9E,?9,BB M7)U^|N2)1VS@3J0A87=|;"7WV7I\$DS5=V0-
#51B*JJ,Z_7S0\5C6Q/=YEV^: ML3=KQ7L\$;M7%>],G0J|0A9.08*_5" T<4=5B7HJU9(G??CYG>6SLF!HK41|0\
M^_X'F>^\$|F60)\$5> Q)P?NWJG&>60V"PS5P=)?\$Z(8H|LEPL9M=BK-480%; M65DV1|:S9X0KW)5^~,R" ;?
F_6" K@!Z\$P==NPT_%S% C/%2*M&V|PE#6^> MK43V/|. +?J|YE,3GHQ^1CQKG>6AYOR^;8#MS#FUyTV03_)
|1!G=^B#0N*FD.>V|DX3VTUW1L)>\KA0Z84& MN,^((M6M)0P065 '.V-!\$>^7#J3?
D.%1H0)"3/|.C2RU0'GN^884RR4+0Y M%Y:W0,\$2!C_4_:I6)+%0^CYQ;BBH=19C!^=QD8T-2)
L?!S#_WT+1GR*-U@_MEAD|R!E?F*YJ<07X-@GMVQ7CEMDPNC\$05*S?H96D\%U?
&@S+A\$QKI+G4B'1BFIV%U(=XQ2!/^25#|P=|5'>|>WM@ADDH(6GG4P@_M_,?^=WXZ|=?
YKP(G12=8:R|C(7K(G^B09D2V"^(=K7\$|S#D4QDW@T,GU|J?0 M7H_X\$^!|>Y;,*08F9<#G %MN\P4(IZ)Y@
P_) +|18L0 MECC%G22.7|Z|K> FJG!T5=SOX=%RJONZD#05GE_M6?8|SI(0#K, MWV&T87)!:,T/H7DPU6Y*W<@
=CP?5=REU)07B=XW8COD_9VQ\5\!?'1@785T MT!L8'61&NX.L0KP.74BF%1&850?, \$0|N.'U| M.!?G(C
6N*50_#|N<|IT!ZTRM.JDI\$=X T#F|7 CAUPNY@4JJ;,LT\0_?7"H M&C#8X1@2!|, %/\$TWP)TQPK@[R\$Y@?
WNZA|ID?9&SS?C5MF|&LG58B7Z5L=G+ MR4|YKH8S03A1+ZS,+YKKM9|ROD.EA\570G:M+|[-
EF/M6>+74PK9;YIGX0>;? M506\1&C&031TU3P?=ZV(6YSRZ7 SP\XZ,Y8241FM4*#(QH3|S(4:U>9Y,D4-
M)ZF4_W<+HRXZF47VNSEZCQ+H\$G_9:B%\&X?:"@KS<7!07N;0?G0:3=|/:*;V M9\$W;1\0YYP^AH:"&*I!0-
,75\$0.+ K\XIL)U"AR^@JKOU&\&":@>>8YI0 M%48/IXF|ZCI,|)^V:?[V00=+AE;N@)\$\^W+\$ JA8:8P.\-
N-U@C/+*9K/0! M<|CB+;G/WV(N!\6"5K\$|+ 4_S,\$T,/?GM: ?^/RWT64,&0'15Z?A00^'DYB5 MV!OW-
>0T00WGR+UKIDPRM"\@E:G@H|1K6|]G,BEORWG+"M%IRC-W/^K%XUI M=;<2DXR^+G;+V'7=#Z8;+1R-
Z|0OR^WS;G1*P^&MASX0?90;H+NBUR%_#F%'D*@VM!|(_ZS*0>?KJ500?VC@I8BQ42 M'>@?&T&FJ-
X.N0(@J9;VBB_DP-\$JZ'V4!\$|^?R,1TK5S>4;N4|7,>,0G.|GQ M-NXQ^=1%-DIL M99
M07U6\$TEK2DXA<_H_EQ\|ZEN%4;<[HPI/D MR2I0Q"3",?R'#2-MU?BN#/6F&-T58(R?
4CT_WTC(RUNLQOZW@_G,*>*&?8_2 M07'E'87\;6S_N6/T8IJKH8P@RB2>LXN\$QBA2I9WVP?
8=X9,V(MZJ;'5*0M@V M\$#;, LN#5Z/F,<2';P4CT,L\)*+KLU;/.|('U"#K(SX0V7#J.WB'X!E\$6N#\63M;0&D8%
(.S|1|QF"#^N=+W\BY!5!A@TZ3IF0QH8& M8!|27:P9*"@QTG17* <=07(%B/0E?
U=GW\@PZ>;W<+/0W2U,J3"KW3)A16_ \MX\@:JZ8|N|IAT'T=R//R3FB69'K(=)X)ZF7Q5*WEJ-
#!0)D0A>+@>H7CK7. MK014!I_2YS18540|1L(H4WT/M*.D#Y1Q>+XIG7"YKN8_|&B^JZ^;>DHC@_T)
MC<8^02"V,V"W6NK50K)4HS0/[9/\$YK6K_P94V0+@3D%4+D6JA\ (J@0)%SVY:
MB\$<(5KT'|6:A3#71ADB)0RSIA=U%!CDX|)R?V#8_K_F@/TD,I|R;U=T)J|FW MFL!V%BPC7LR68J?UI)YC9/T*
<--=T<^6'|'6X7?0>^+R?BN09\$6"*IB)C\$XE
M/%^J0;X^2CLA*R9!QP2'Z/|)SM.'E;MB|28\EY^/%T*KF9"%&/V5+R,&'71 M06)H.X)?
0.!@Z0*VP^Z2"#AZ\$=EN(F M>X&(ZSIIT-E|4,0'M5BS/L3-CWW6R0ID|D\$4.|0N#S|;IDA39!ZB+I3*A(2?
|0:E9'B\$K3,#6| MZ@_8BB7D;\$4WDFW(B(E>6|91D#>36!D4?C;3_5\$3|QR:\07&
MY<^W933\$WB0A)M3(A;8KP,08.R,=TK@A/33'""R7059[5+B64E)M|P;\1902 M|]BOR';BCX*4%SVOH?
L@Y,US|;SCUN9#2|1Y*I,PF@AY
MH7/Y':.4B_%\$IS'U/DMJ:20&SOK:E%V(|X(^@N/.A"7.TC=CQ\$|3PC/35W<;JWS\$;:Z:,H@LG>FA7'MM::%
M:|X*Z"XZ3%5YC022#|1R(DF:9%A1FH7-X57J1&DUZB+(-2J=3;*\$MCG73\$ MIUOE:<6G)|'6+)+|[-
^N0=7K3>W#6;,B#"8Q^X>ST50H]"4/CBJ(8%2(,84HL_MZSRD5FKQ^3=.DH:G6|P#P#>I@MLJE_\$0'/Q?

0@:0>KR<0MEN,J"4?)S9-&]@ MM[.R\##*BZ?W%S)%C8<\$46(-/K*="1P=I2L*I(I%'YG42T(X5CX8X0*1,"?
MQQ&:6^AA:\$XFRTAX;3(6S%7ZET1Y+R5=;B\7%.1GN#UC)G1YJN(C*0@XFZ M"S 7?TERP-W
2C0\$>FP&'5'6>PK#TJHB;X<4TCW]=ZS-;V2XBAH+G\A"^\^ M^-9K0>YZ@ECH-H\$]S@H>)=)K=S8[!/YII?
=0\$G@3+-ME6F[:Z4>-D1LKLD8G M49Q4759XYQ=X(?B*[TS;6=NZJ3R.%#6X/6(9J :UPI7;H6"DD.#UGL\5X%VF
M/A)@=7>@4XS>7*:A;"B02@J?IGF;CC@NFC:-J",W;[*!*PBVH0)SAM)2E5(MSK
*50BPAW**6 &XIG#&;TP\$2I#7U?R ^5G\ .8D4T.5R5]#AB-.E6H.< !Y+ M1A>_G,!?(EB-K[<1EW0!
AWAC\$U&H:!/U^\$ "1^Z8LE& M^\$*-P!#M#I\$HX6>QNWQNA6LDN\0\Y59,[\$?#TH-M:K3QAN\H+;"S
M&-0I0YW< 1=?;B)ZYX)0_3:[T"4],R/?1UKSMHD%5WUC* JAY@D!1VK3@W1(:77C8=AF104 MN2G?
K%&@U^T)P1FMQN\6ECEWCU")L.5*6YC4D)+&W"1 "U2!JC[CY2/YJSY MVI(39LF\$D1A#/GKNAX5,M(W
=TWD0AP=2-8ER@(>N)*+L93"<0K0L3(Y7 M4*Z4:2&C1B A]E[9'AG#\,5Z" !C(QV:=9&. R[89"*SM&K-
+C3%06,6C;-6 M5BHFZ6#B!,!YC:~M?LNM1/C[4'KE ADX[1W2H;C){0-2(G&CK66LS:@7H7F
M@UVF'5D3E98^]=BYE=5+UT0]9=6G,>HY?
PVEWJV%Y)KE="R]#3]E6[00IYRF:5S%9A0LHTC+.3) %S(E*B8EAV^E8&07='%<%T!
M;B,4LKNL\]'KIK71RLC)\$%=(FB?/9:5YI?0KE1S?T>L[09[1D'R65?[]5JJ MM0000>-&0D>G^GRL2^:QW16
"1PPB7,%(/^QI U35/ MUJFHQ:." R(O&#<* 0004XU7P%NS(&A';JJ-U- !VP"@\$/C?GG-V^9LH(12 M)PD
=9DV8=NRZ3T,Z^112G00D%+*55@ (HHCJ:F\B[&@7 ?225:Z<>1S6^WB+ M38'TS);E"50[MX#N4:6CI^V<"R
Z;X4J%,Y29.-'SHX,16**04"V?*&@ H/+ M;YA\EUA%7;*~H>>A[CK0T@Q,QCND\$BT)AL!S&4HY=&(L ML_!+
[TU[W-Q+A1[073*QWADP X!0KR#8# 7ZY\$NZ 5ZUJS4C7\$8\F0;+!EY8 M-
@VQ@'L6267F&.-! D; .D=B=C08VIC\$DE>Z0^S,*6[93I\$U.%6^0T)YU&W)H&
M]!2;+PMRH/TTTIL_B)>C*GTI]4SLCFW36Q5Z32^SF7YZ1PT;ZX558&53ZT)X MG1+;0.1:~^1LCW1?
N7PT]3(6PFG[3K@/=0A"UX\UXW%7R!G=;:P5R?V)F+3I M/=-*4#1&-A>]L@3J(*)J. 6]EMF/CU8T;:-"
M!\$] WE\$?>D"IN?Z6\AD'C=86]89;/D8&#;J'@EY/. 'M'&18U#2C>B2);>U7*
M4W?/%S*0WS[I+7'!F:Y)5X4L+-5@M"]4[00@G78.8G+CPB1\$!EL>&81N*9%7 M@,VD\(>00TMHJNT7V\$L)
[>@NMCXF+; #<K\,+)84FTZ0W4\$3EYB9]UIPCUJ M@5Y:X8[]@Z4-3;C2/]IEE=-&8;;?KD30Q !@1?
D/P6#1JE+*'S':MA2G&6 M^G48W4QZKKM.%8WA19YWG> /R[#9UA630!*Z3NU+N@FZ8FEE#2-B0+\$ M53J-
(#_Q6#.Q#500^+>DC0E>;^FDZ=/^~98\$C;<4 M !6?D!Z'+;0I
AFKVN\$")M9(L45@L) UPLV^)^2@!0<^WN#WCYX;1SU<@I^1* ML+6W8059[QXL:SQ--+;ECU&>887CU>\
(UVW_KEK@5#GB3PXBVSWMMWS\$%GH[>3E%,#6K M+.N"8ELG@]27!^*-#ER;XR,"MISO55F"\HP-2B-
!'-516E+!/*RL01Q1K@WR M!IX]/(QPV#)GE['021CZ\$I#42A-T>+.=U%]>R]' +]4P
M^_8(942]D\$2M>E2%8NGEQ.+0G0TL#C[18VF?<+TXUPTXW;4;"\BX9S'#6C M"EE[(EL96P69\$N=Z\$YJS)/, [
CLTC+::V3E1Y!EV)RCT[/]SNCF-[DSVU"]GBIVKGU5W:12^]\$(MBUU(DJ*/IMN]TQ@VX;AX8: !#7MWON=JY]
MY*G^HW[,8)DSD@.LW"S3"8KSWZAK#(%R&3"LQ->0^3;[./Z.6^3>RR69)^]E4L6\"XG
M<.5.+9I_ ,H*5PFB.PAV6Z^> K=]!8&2Q?% ^ MU%PH=P;K/MP32HAGM'1;*)6T/<^>0:?
S[\"2Y :^M;:B\$Y!:=FAH MEJ\$M;>74)\$H6B(@SI-*V-*/+DTQ(R@XI2&Y;!--[\";[5FDC+F"0\12F:V:XY
M6U=17AF!V=4V*7K_L!AKLQ87-K0Z^DU!79]'D(Y#^7J8Z5\$Q!MM63^A'9"!;1D\$H*K0(R50'* J2DS1 M 7=0?
7[.]Q?.]3: '=A?0[=/HPR34:<[;8M#C." "X/\$^4.5^CHU/KRP'U60_G4J _>&0TFM0/T[]UUY,
<&1@5<]GM>IZ&=VQ,N% >X:0J0 MH]5'R>: ?4%C(RT?=>5BX=E:P7Q_URT MD7DQF<>)*!'Z^V)_.:;
<4FU0,Q%H6EFL2DC@YR;#"G25 "S%;U+RFP;>^"A M&/*\$4-"YR^_EY*FPJTJLY\$^*J6Z>EZ2C5\:')NL%
HS,V'?'DSW^JB=5X;*6 M;C#/.L.: HML/P[Z8UR>)< M7_I_Z'+A@0E=-0)F5.J^*73RKN1'F0L\$U,GET
MI#ZU/3Z+4G2Z_NQ.51\J'+OPQJ:65EK\$K?[,RD3[MK76B:0GY/SLR--'=*WF MP.DBS.-
<[KQU<1U4DLE&A;KS\A&]7M6/E757YRU9LN%PN-#7P&I?7VQXB@G MBQ>LBKFM]'4GAF1 >-%,2PL?
S]-6)R.)!B966PMX8)KR S=L:Q42JJA*7KFH MS3%([D">HUV_8UXBSS]A0D\$)*.0Z4^'J!G)7N4N-#/#)
MF0,+1UZGT7D7K34RHF_)H\V7#^U(E!&3,4^L\$S=9]2WC/19']V0?6KV;Y=\\;
MUH,*N1[V3A/04;BNM^A>S)SY630?QWH.U-+EE3&HF+1L(CH2>=*W# II*A/A'E->
[%C5M\#V^Q3S#2MG8?)^S5)< >8CN65; M&4G+D4S!.\(,8DYE91R]V)/)2V2K/T^0W;Z.QH&[*]\% #\$.--
:;>;1Z0VM9N& M2)BV[Y,PL.H99MFSZVL4F=KG,]^P="EJ" \$AF MAURN -,2#
7R<16=HQ\CG3[):\$0.14W\DW\BW9 @J#Q*TV@\$/#4[<6KP"!\$F*!\$<" M=\$G00GKMA/NS)^XU!]C! 'W,?M([?<
E.7[]1I^XTV:QEWUZHR=08*.BQZ'&JU9L/6&VDQ B-8"ALA6PDC6)R!J0-)M1># M JAF00BUOK@\\-
'V658R[=07S2P:)>4N4A3WXD)0XT-ECBFW)&-ED0?2SR=. M!G&ZC%:]B00FSCW7X?@Z
FCN9D3V^T@XE<%D#GE6\WEJ/F=,2TA_6?:[HEFD M\B_S \$'7: ?J1 84*XY?S)"2<
WW%>^#3"*!E\$QZXSZAN,MQ47QH3K)]57.M% MU[UCG'';PT)R2/C]22B5H4920JV9_S;+LR09.K12+
[NR:6SQ,7N\$4'Z5AX#2 M05A_?'@KF_WN[D1Y0])1E,U:A21%Y'0\KF\ '4Z]02+A0L.W1?
Z;PFP!A&:0D3&X/13R2F;HC"B'W+9>4GXWBLH7;5I#0.?&WHRQ9M%G.!I!\$+8 7RN'#J,A996N1#JR4
M+>%,G+2+KNJ& M25IZ6#VC U HW'BP+LX@2.3,R'89#\ \$K>6?J\$,E?*1"A1/2Q[+8GF=*C.-8; MG%
(Q\$X_.2\$!6:U\$VJ (NK1J?08Q><3Y#BRR!'-"FFLC)^'M5L EFT;DI+A>V MFG11'3S:Q^RE2H0X&05!-
"+62R%M#)Q+)&N&BT=EJ4HE3Y#XE\K5IGH44+^S? M\$[] U;UU ^AM7\6.Z81-YZ0A/55K=,
Y52MPEW,4"EJC]0_WJ@'_E&,S" _B, M"!\\:G%,Z:>ETPCA?/\$8#N](YZB9[W]%*'UV\++ ,ECNT0#G,Q*I-G&:
(K?;I9 M+[4R>3U#&06D4Z8N=7?;.\0-=E) GQ_A0SLFVV/MA(^.J7LZ)G&,!7:RS;XD M8W"
<)>3I>DI=VA7W>8\$*Y\\7G.% MP;T\@Z]EP8>DI?&Q'YE-YFRKH1)Q2]M"P4D;>@*427]TU"--_W MS:.A=K4/,0?
0:;[]52JVB0.! 'T#V^N9QK[7JRAT)\ +OPT*:U6^KU_XAD?%Y MKIQ[V2N]*YKG0*)& %AV?*V'.]&CT>5]0>=
[26]100]NTAC M&X;M&I6:4;&SJ#2F\$S4D9<4<'7- GZX)OST(TZBEW;:]J.TZ4V.+Z M+>:8]U> X(7;4N+
(\@0]FA'V1L4JL:CG%;TEU7NYST-).W>S^NTIK3CCKY4B MV#7^B7-#!R\$[K>,FH^I*]'1("U8*)3)9J:L^LI^L
Q7C&4-L[W_J_9MA&S& M<@M>[LYA5\$7' H&4\$ K0>=7H<:&6X%-J@SD5EVU7DK04H5_V:1#P)\PKZUJ=
M\$0,V:TD5+RY?12:0SJ*@1-@>+-ZP.UM3_G]59>3\$2A16[^.CC9;/I9'WQ5<^
M*.FL_Z)>S[]6.=7:;B@:>SAJ*7;3CA0-P[;:"R19V#ZR)P1+!G52W<)Q<9UW M51
Q*I@DR1]> :4QC(*B+9IPFX)WCW*H1I36NB3M;F\Y.M+@[>*G\Q9\$U@3 MI)*4= 6/MH0(I[0*[M,%
[\F/0@ (XKB_9;*ZEXGNMZL.E38TF-@=G]9L.V3^Z M5V&[;[Y%K%P!QNT^H+60YG)H^;H4FU//)"! "GE<,3LR@?

9QVRJ[\$^]37H-*& MA.=^[/;5\$U^7]K-72=(/{?^"/X!\VF'X7;;;>TMW;=Q2RUAM C*FV7YQ+\$9;#3 MR*!IJ4("-
-)>6I,]'0AUU?P2XGVR,WT%D.*>NYZ'';GJ?W;J*0LE5=H9ZJ&^ M7@&L3>|. +*DXW+JP-
@E4AC7\$JT>1N].&LMN,/AB-9DU]4\$-!;.!FHP=U51*
MTOD((F[!JBI''F8/%9I]W_J!X3;Z#LTA<97ZM)_>&Y84\$2<>V0331P\$R(8<78 MRJ0%0#I>+38[>+G3F0[?
LHW[IL[S[([12 2Y9#%L9[23^\$F+M=DID?7H3(L'1 MBI%9P2@+N9I:.*[T)Q%L4?
2DI\])K\RG8]'0%D" _5>,K%,CA/^"RQ""D.- ?B M[YZY1WKY=W.OS^Q),6;48*NVYV\A'?
+;:%@BGT1[M_9,G)F8ZM3Z#D!Z35W[[M3<|,9T<&9\$Q:\S[F*!TJN+8VV44#9M%9S8^W\$WTA%38\!P-V.&.0.=,?
>.NJG)'F]&3'T(PU/ M@=Z]YWMGP[I9US-)+<5>VU;92=R/D\1(WUR_D"-IL=9S -R4G)RTH-2'9GK#
M#MKTN/W2A0E/\+|.1QL<%)N?J")?%2[;BKBX\$PBPA7-0)NZ%@R+B-I9B0[5: M)!6E3I|
+;_UH8,'6V;:\$V&!!JR]?C:1"AI(:*08&\$0@3XESOC)\$">280AD M]Y#YH[8.,750T%.\FTZOU]]
(J]7ZW6KZ&678,*#_+E<+@Q\$YE3^)"|=P=[91Y+T/9+"J: IK/C!1^(HUZFP M9*HT.N\$J\MWBH'
N76^AHJLM\$Y6+*%+01BDV3_+Q%> 1P-.&WM91&A5!J: T M(Z_RI9;9^JC;)9[-
&>6W60:##&SFJHY(<*="EX\$]C6,\ &!.#.,B@=(4 :CS0 M,# \ \$F/68D08,54WH0(5T=(;I=;.)2#PFY;Z4)MN&.#
RWJ0:\4FW Y=P5-0& M1)17M'>WBTX2%CAU*XKK,& 8(HQH>=-R,)FVBS-K!T3JZLGR_##[FM\U)9[
M\EI;7721\$(CI;-ZOZ1KM"0\ "M#&@^&^ @1E7@\$(R+'W=L6PY"2[)+M,NT2'
M7KY^0:.*&>0V'X!W#2]Y3N#&I206@@YJXI/1(7G&(5;IV)5['UN9]Q+|3 M/2UL15)^F" P-OE@/\R0(KH-
&M%'.@.YK]7A_W"Y)R9VU]LSM1V8K-(V<)^C6 MERY'YT%-L+W5?>-
_X6 KIK>05[S \$),;TQZ2=\$L\$4@3+R]N4%6 Y.';I0.2H58KG0DDLDM.#MMD;^R==}OHEQ ?_S>L_-K>-
MYD[;T0#449UIRWUI0(['@=66?3%C,R&A9J5SNLV:P*+(\IFV M'2V\$Y&]APCV:4VYKD6&,EH4U?K6N-1>N&. &/
])U/%DQGU%0%JG\ 0_RH)^\$BJ%;+J31>"M=)VH83HD[DU> W4DRX&U?>J-\.K'"LAU9>PS_I!UHJQ'4KB&-5>
T,%0-=*U5#3T4P4V MP)L8\J6,X!,L7CGR.&TH,)-'/08'GCG'TEGP\$]988_3Y6F+*
MY_0=HQ]GZVT9I;#F!1([12V=!9)=OCWFV700J#RIA@-ZM0/;I*#DR-W(7N=. M@2H[Q'Z1V43E12%-
=BWIG"R;.)IUW/G."A0^-[\$;*V;QP9K93BZW*;KDY62L M)%GCD2\$!;GX L'Q?
FPGM&.]1,5DG\$P=B\+XDA1+;7H]D.%E ?WN%D "GJU4- MB,ZW#TC0R J>YZ<)&[4D^V8M4W]DGE5B"ZNX'?
J(4^Y-0' 7^?#;YT>ES5# MG!P/OM=-.8U.@U)\ML3!WSE*&/29/F^WX M3C^XS9--B4Z_0L4*\$."-P: '[@*0\$-
/LJ-";4[@0DN;[&U(D%W28!VC#Y0@ MA\E]9,JF#/-8>\#D@?2K0>?I%YTF+C>[&56F/;3+7&HZ<,X?
KP!'J3'.2^ M[(24E]D*P0"/B1W".#N14DR,BJQNANTCU>,7_9J<;R@,+ '#EM1\$N -RI<"FJ
M+!/!*RR= !B6: !BK8J/0(,; 6: ?;1?1\$5(#!(AKW@^X&VBLRL0V\TQCW?2F M+SZ;==&D)5\ /S-
F&VD@ \/>0YY;.*],IYQ)!; &7GC&4^Q MWFFM= 7EK8U0=R)9[_40?,S?@5P[0F.Z0A0?4A,D89
MK'R[|2FK]0E##^KJ'N)]1N5]%,Y@!+^/ CR;(0-NX?&.&,L2]0^N68I54X5 MFG 2<[<<+R#G,Z;H65/>II.-
AT>R;P: (*"\$HK9F@\$=Q+][&V6QE)P8%0(P\&\$8\$(00MB2>N7"V+=AU(9 M0FB8^:7U0G-
3\0',XXYL:W''^W'9%A\$'0C/IXB)6B?%33G\YEL]U\$I R6YJ3 M[
RC+LQF)"ZYVQ55^@9&PHYD,L^NA\K*\$[S?;ZVR-*]T"+#!;00QN[2, W M^-9)]3?1E6HI[(+RN7)
<R,7\$0(^JF:\$A]QD M9G;.0' 'K*Z T^/7LQ:0A=JJ92FL SNYGC0&^E=5H\W" T-W*]S90 +FG[#6PJ
M5SI<^2,@L[PL\JVN&2W':9>@3+M1A64*(/68\$D%*&S#\$DQ(R>50TGH%:DY! M\>?
S0(5'!T3ZP^K04<5^K7X4\0B7U,6CX->4KAQ580%9]:?#IH@F7 PI: NS5
MF+V4PQ+ZN, [CH&W%;G*C1\$!P+VX|NXMDELXS7.T]&2%4?'- \T3#6\$:T8U>; M+UTI;-3-6)0]&-&YL-
<)>3SUF2V0KXXQ3\$6"+L OV/;8]YW]1!-\$ (@ :WOL= MJ^0Q?
R%6U] ^7 TVAS/Y. _02G >#!K#0DB?"]U^D#%36\$E6M%&=H]YQIJ1 MU?%L'E';W9X+|Z9+W.(FU!4 RU?ZV?
%42I^] YCKVA;WW+W6CX[N5E\!N0! MK#,'NGX/'T\$80RM >#8WWRJ?S5K)9=T"UE]G 7T%^(-99Z;X"K"!X7
%B/Z# M[N=F6J_1R(#QG &C8897@.%',U< IC]X=H@D/U\;V04GVW[G^(9^U]8YQIC) M\$7;=66T8%G@%Z!BF]?
S_ZL@WX3W-X- U^;]0ESMY[:SN9<6UH+]KVG[OU M8:06)5F\L.G/;8 \N52Y)PJZZOG[N.>M?>X7WZN\!^7M
_AZ00P?D[P'Y MWST@ T\$4*]8V0[/Y\PAFR#%UT\@R\%#"*SC87(DB?.SW<- ;#"?QP(>HV]IS"BE 'S=.&(?
KQI M/\4/*Z1P(GUZ>4N\$ V)MX0^6"5HZ-QW.? \D:N8SVN3;*!E2P9W \$T1;&@V4N9]=B!OF(),4T0<7ZSD
D^]A#W\$DPZ),C TR#0+ X\0? #BN@./A[]WZ,X#>SS5.] MW FX0[.'*? Y[;3T'00IPOB 66^^\?
S^1(WSY0<& M^5 W*D;]= 'DS^(YI# M** &/QCA*)R0_97@!.YDMQ:T)_3CLP1+LD-0>\$ /2P0_7?
V@0Y. _\2>+! ">X\$^0\OD MN-\$>;;)&G'C]^ (N 2U+=42R0Q%P_G%KM.9XXY^0M,6 B1V_X?WYDI,0-6+P
M6WA?VL[^EEY=BG/FWZV'7?ZS30;_,8D-/N*\$VXR08;/40S^/>M\%-&Z#_% M^HBRR>]W.?
Y9S]]W>V&_R/GG\WW40G TU\$H^/ T1M? Q/T@+8.D*#@0 =F1 MNH1AXN\II E.7*[,E&'*!M ^/8'+1<4G
]S0+^10-W^I;:%ZOP9C:X3_/=Z! M_%&(NRI@,I?;,^"L0\MZ?
3WLXI_(5L,6%DU/PE[D#_I&2Q^0K#Y0AEG>IYQS M?4 "36@VX_*R_400"?Y;4E3EV'HJ\$6;LX(G?
%T=GQ=P_[.F"('75\1V_'18 MZ[]*BSIX:T6M0P[];G0V/8HOB@4JC.V@WW?VB0LV*A" 3P<*H4*55\60)XY
MYUX![&8P/!.<8I?;\8I]Y28%1.J!=@,S0)V|V.'-!9D3WKYF@C=JHVS KPMV MBD(Z4AZK#1,W1:I>
'RR*:/V+L;??G@<+72FFHQ%RF@0_B@-KEROU16XE#0 M[69.90-
47;8,^*CU@\$Z[MEZ>0G+0E.10,!.U,\$EXZ9;0AIWSG3*+,!M^5KE8
M65QM ^>0,]L<6H9N>LZ#T#" +WB*!M0!)V^S*.5:/L=WS9@K,,;CW,+SVA1
MJ5R,C!RC48A++B[<]&581%M].\$R2?769-PFEH24!TH90';'/DC'+\$2@NQ[9 M+W86&Z?AKTW#J0?
ZG43*2*>2AF:R;UY#0FJS8M\$9\ &CF^S]_&E]W(MK]AR M=,@Q])-\$4N_/W%F_K2A3ZXM<]?T!
S?)MCPTFGPU>L(0%3&1F]D]+U)U\A MB.!\$L=NN,A%5IX1KD95GU0(=H<_I)P78;::%#D!T[MLNS@=&.F2;
MK?!Q?? MCK1)/H[*6.[&CH/VY]D%YORR.\0Q^G,#'3D\?I,&BASM;94C5I,Z)0L9!

]Q=*ZB5E]G4W: ?TKJ MN[@\5D,B%;NTAE;&0+B-;JBN]FA:-' 9UA9-I%+T8MC\$8#/V7=&;CW+.SNQ]
M"N*\$NI\$SSITR^K3Z [4E/8(1-MV\$82[&6>*SGVA75-CZ/S8/YFW;S7?H4B; MQM#K3,NZ_8CDZ#R[HX?
7"E%8U5# M^=-DBTA;GE/-'AZ-D"3'540?.3X9X1G;JFLRU':; 8@0'J=//ZVJRWCJJFHC_NAX0ZERQ<./C*
==0%FLY\$;5A5\0J\;M= * [W.0 M>A22H^0. T@_7FP4R^4F6=E/^: ^?SQ9?E9"Q):5RK2RTKOH'"FQ8H5E-6+;
M.OB]'D+;:"-)Y^3BGWG+Y*(JD"J+92P5[G1"1);];AETF!,C/0@]0)E!0/EJB
MKPTU.X,P*\$B)R:=W_(9WP\OLKHH_,!U4/#) @EX>FTDX#(6Q>9"\09E/#Y M>!/H8_K#W*-'9 &"(=>?

K47<*,;:~F)!S3S6(P@*<[T MD8B.^&;WC>,K@!00W\$2D #0"]!-(3=4L 0NIFU.PJ\$N:<<4VW\$HZL#>Z A1%
MUV*XQZ1H1)0\$@HOR4"\H\$\\W/IDL([ID%.D. \$/BBWLMW#75HW*0D0M+&[%S MM5"XT'**Z0,UX0-
L_^@,+ '\$220>5G,R/@)R%V?~@*\$=:>G@_M+)8:+T\$X5M8AD MCDRI1.=~V*0N:9=T=M+~):?
UVQDK1(H'PR ^27VHK+H4)@8+JLE,MC&>?*&8&FE=>V1T"\>LVD M0UX592ZX^L"R;:YI"_QL
858=!=>PT)0>#5FX% MPQDNPR(M\>>CRG=+U?B5F)5I-53/@[CYR\$SIO@4U\$,0:V)N#>+L(\$\$@;/D>
MQ\$Q02/B3L=3H1#VTGXX3H@:V'0(80>^?DNJ4+ (=C#3HS<4AHLWWJ;&VB)A2 M,=\$R1.?+>P3'%.56W3#1\$-
+\$XG= LX!IUA\$N\VM+M0]'G52,Z5> MFAU+G?^FCSH9DVZ85EP!VG=UEV&!4'<' \$SJ;DC=-<1,R_1\$%YK>C),KV
M6:'J:XWB:!*J#E[99@FX"4&2XAB/6:-W=>*F'I"K\Z_07U@/@9Z5'&/!MXE] M4304VZ853!T#H&6KZ\$**
[1ZZA4TK#C&[>Q'\RR0S0DP\C[C/RHSK_4%>M3,' M8=S7:AX?P2([~V2_!E]?
\$>M4]+VW>6[4~.TWHWLZA6[6/MN7\%1,](5#QM?0 MQG#K J%W1Y;\$HQ+0H\ \
(6G20'ZX=JN131,YZ\H'GS:WN'2V=N:*'KW2@JYV?#0(,;6J7@P[4 MG:S'"A2RW,]_ \$PA&1Q@0H,
MTHA_-79L9RGF(=A"U"LUK PC_2'(L8L6*FM%YF.D5;W5'EP!*KER>&68NL^%
MDL6A#]'YJ\$0BNL74=~/X1Q\F!JM=!/%(=^G2#,<%N;#>--PI%91DRAYU'#+^C M1:Y5 "VT7?
8VXX.&"YVR'TQ53~*LK^!5[\$:0\#X \#=:7YLU?+(D&['0FDM= MX,Z61?PC8UFW@Y=\R224XJ3*%5NG?
4^0N>!P]C%K@@[K]?K@]6Z"6I^G,AJ@
M"]TY6[2F;MUI6Z2I\G")OP.3+"&>KCZ>>@ (YVL;=)G#Y/3QZ49PBX(OLRSE\ MU%;F_4R,BI8=;FKV?['WW6%--
=V^0454NDB3\$!3>I2,\$HB)-! 2D-24CTEN M0 2D=0"0+DUZ[UUZ!^F= *\$(4A) "'!2R_0Y?
M\|Y|SR0/AH9A'"0G4J\|XBF\GMA)_I];D@=:33XJ7ELOPQL,SW_SJ*~\^Y86M40YSBT
M=*^T=R)UPLSR|N'"|VE~^03KY#U>1SLD8E+N'2HH'BDH'/4AV3 M'PJA!JBV;0Y@<2@UOLL;HVB*\$..-=
ZOC22~!2] M?!\P7]U0WIC@U< Y9=603A\$S& UL4%)?6['4RM2W/MAE.T&S=]HTPPX\&47<3%0+WVW6]_AJHT?
TK5^T MB'%4\..8@I4(%/8)!|,<*+7SWMR%\$!"6U1.\$#Z3HCUTZ87+D/HS[5[CI!LE.2
MWAN\XY\$5\$[>";I5A10M'@]'7:E0#SR-3\$[W4:7Y]?@U8=P60?6@_,F5*=5F4
MLLGZ[B.%KM*9J1ZD:PN0Z,ZM.48]FP[34=HN\$[>.=[CE0@QTJX%T: M^[?]'#BLT&8&M0[2Y56#8LQ7_0B=
(S^7LI&X->E3J,^6NM2PXV2SR=L7#U2M, MLH"W=XX_#~+1
4[J2_I3=3%XHVVZ0];*%*\I\$PUB&I1^XMFU.%1P>3VI-
M(FGP#R#EE7V3:TV5'%\S^4CJN\UDA&;OYT+GFH6\I\$62E@L)@YG%<+Z'N=9&
M&C|MHY37I+;)=39#Q#77R6XJF3Y^_ \$ [#Z7M"\$S^_J9R *J-N3G3&.,#*)7KD MBY2DEYR4+!QU-
WD8J6*J755P@%Y#|SW:M7S, V20KA6TKGZ22IE0F0/AINWA MSGRY+,>L2_=]K]?SK*TKXY:|
<,9D]WP&1R&'L_C=RC0B8_IU'7=5; M>9G,'@:.T2JY2;62%J19YS&2]H^00L3M9017&<"OM&B'E[E#I!1X-
(VA0+(M(N3">*~>5=3*B- JY?Z3>U(X#R%VE72;=8Z(!_5CT2~,AJ9^=2 [Q".D3R/E, M!H8;/9J-
.,;)]L_UJQZ\$VXR\$MK!JA:<+"IVW'8K]?EV=7,XX>U40L]"&=^17F M\$FE3
E:I;PRD;90JZZ=]+U;+5ZAN!JDSV,98!J3;4^Q+Q&\7Y- MKK5?,>03"1J))=YCCL#TK,X\2%4Z CC\$?
*&QZ,LK\9F(;E^S:>(EZ/1,#'-1 M%0XR6=,B^J3_3G2/G.I2Y>Y[SDTTIHD7-
OZ48&>Y,Q,CWI)5+W23Y##PWI6(XV_VTHHG#EY5 +/ <^01Q0WWM<. Q&3AF2F MZTH3]
<;D\$H^E.8GSZR;|V,]65@2Q?XX6(<9F6-4.BHP&N[X2H@S6 M7<_HL_RF@ZFJKIWFWR/@MRQV08'M'"#MWUHJ|=
#TKT?U))V#P8CE]T[LO\$ M_30'"[OZ--(^NT[B!,!|D0GB(EFC6Z5ZPI :[OP1>:66>:I&I;,BM8/3)=\^
M8):MDPV/SB?,:LIWLT PF4FA/7=G"VYMCWS0[C8[[^@&S"4= M!PC|B"E2V-EU?^0*,9E*U_+Q'PMS-
J\]|7Z0PIG^?[#6Y@PC YEG8D#(TNPV MX[00HG^#F_'Y)P)6DC#,+U-]*T :F9/*_CZ'TN4*_3'
MT*=/WEA.\2@Q-#;L03)<5=(H%'D0C<.,0]|HU+G-L\$;Z[,L.2(01ASH]@L9 M#, \8>%4,!?/#\!= [M(^;VR-
69TK-9]Q&633:%?7U;JM1^&W"2K"B|GX:J@Z M?]|Z+04LZ3W|B_ ;T4JH@#W,(FL0?SBW!^C-L-
]2A1KD[8KDEE[CLD0[-.@8V> M'7E1-Y[.]0T]2'\U34-
VN@1.:E@7MG<|=WYT]) GOHQ#5R=R1&+ 5P7N\R52\EH>7SF7YH#]'| M-P,* P?
EY@Y<4""Z'W7M8&VD#MFY9A&2HP0)FE\$Q=%>9@HIQUP0L! ?X*J:P2
MB#=#06!"4(P%~H#0RIKI,];G[#@NZC,/ >1F=T>*;E^R)@MPQV3B5D-W-M68=S
M^GF[?P7U7_A.9@T101F@3*/4MR!TP@'HYC'J:'?%)HJQK=1;+(.,XWT~+=,^ M#PMR.%5Q^~2ZU=7A-KM-
]B>Q[GM5X9@]3E2<,0K>6X_A M1YY5TY4102PXX-WS-1*SB(M0['BD2,WY%ZQ7V-??* LT3G_RSI_GW;4\R?
T9A\1T(NMTB8&DA9)CQUGZ^AZ,60 M1=R>5W],>\$6SUPCF5N6X(/. ='05HN[T|\Z9GFL]BGP(?]4GW+N_4\OU?=
(4 M\$"GI!TH(>[3L<3?J?7G0=10&9W2I' [P3@+Q[FYV!Z4Q\$,W#%H M_XNG/Q.-J4I]***\8|(M\KW3>I#6*?
YF&>X%Z\;7E0VN),&@_LHJ_0.0';39_MCV&IW+"5C(HRC"#_!|5/_ 4M3VG7HXY!BS5'YW"7IQ*&I-
NZUG4%,PDW=, M^UI0\$#R\M]=\J\KH5KM.5Z2TY7RNV[XXZ;=&"D2U4S4R@_S%/CS! MF+"5#VTO/^'JK3=OU?
3;J9J0C:0L-1,UA_&-S<%A">?0;+~ M?>,|U<|>U=U1U2Z%WD'6[]JF\$UG+^_2L!=2(/;PH-;(7?U
MPSSBAI?'&]\R691#;EX_)HJ:W)=3&D~D(B3H*10>\$X@.6EV-KFE'\509LV
MBGQ\SP^3\)MR(N[?9!/1"CVD~."PE/31_*U60!!!#~:"[X+N0@T1W QT\E73
M)T96GD8)+!Y0*M|HB=;'IP:YWR"C) /@<=\$F4:RG\$-K2R8Q5XP!!IWHG!057 M8UG?
S\RSZ01G.2.,+XK,AE++\$A3.V1\.\T<%#H?6'_R4_I0%)KK
M'4_(K%NJ#F*J7T\$<%Q0Q0_J+>PIX=#7.Z=*HKT'(@X[&J!"H?%\$G]H_&]\12 MP^MSTGKAIN\^*%6(0_I
9<%U[^X3*0IM3A3UZFF@~.N/F^)/: MR/GEA^6Z66_Z=DBA:3G_^/@Y,J[='*W6+"K'"6[?<
SA%B)OC[00;:PXWMI] MPB%,Z\K+K]Y<%TM7HA;+XL6.W6^@>?9\$6?YQ!H:;QJU*,T~?3GF0X(FU4\$%
MMC!W9V'_',3;FAZQ0GG=&B.'#(+*[A^P?>E ;UV\B-[OX;+^PL*)?7^0V, MCZZ^=#LYJ;W@<92YL~-%+C|
[/_ZGB?@IJ30,74H5"P'4B>3H3CC4B1E\ S+C MIC[OLR4^ICB;(;,^('SDRLF?
85Q*F<^Y),| \R8_V@!8[.=.PDF(<V-C8_"G^AL7Q!N01EQFI7Y~.H7RTF1X"1'K! MN1-VP0DA^*:=0)Y,\$
&2=+0MT]T9M*N,\$'IU(;~829~@SV4NPU-AZLR^Z)#! M-7'ZGA&5N0(/~
Z8\$/4"E="X#T!59\$+=5C(:ULVA0,5KJ*]6:DLZ\XFJ]4A!_ M6J_H2>%C<^.,4+;L3+!0F#8H(!Z
^!@:"B5F_ET\$UUJ4+UN@BWN;4A\F5J_02_M9H:,Y<3/;~
[ZR3+A\UQ38(#:K*5F4+0RH/WET76H%QFW0.!]JT@_M);0J1[0EC38JN*7:?DJAWH_~5JE
~&0.8S>;&AGZ5A.Y=A M-7>T^8BE"+@VXB0NY>6RW>0SRZ(*"B[0MY\$PH#YQ?P6?~\A2(MZKXI9U",],
M>,ZEP/5TQ>\I#5.TLYZF;^~WCJ50FW|EBJ#4.TL65^(\$Y+/S.! T2&=@6Z=)V.F75)V.?T=EK]&X9UE&R58&*

MLL4^G^U'2^_>GT>*S\000&7[70PBTYIBKI4\$?6T!TZ(85_C?:G_>0H0XE>M0)>;QR'EAB_+6\;#%_L=A*_
IY&9S&T*[_>F6GN5M"?CKM4RPT3UGKL.TJ.F M*\$IF.[T%\\%/>M 4Z*%R8)J);D%QRZ%ED3B_-LH]F*5>F?
MEL.+>#>3DC:X8T M=?'0I&N6YFJQU.F0?D;''W;XPQ6\$B+4U5@7['(.%7'_BHX\D(|Z&4*C:/'// MFJ+8V>
[QT:L^S<@I(#|7WL/F0{JL-:RVV):I(5>":G:+C;#F:/((NFF"8LN) MK)":D^6EKRW_F\$2V15S0-U0FK#2!
[:VS*RT:1.- A08ICR+IGGV393&?)] MJT6;2VU2137E65VPM"#4 !VRQ6^_%^G5N4S9,-
[:P(LMR1%V95#YLA5_8[*5 M[>W0G0EH/.N.;BZI&&32>L(0Y/VG&&\%;+=1B]PT)K42TE-T=#T)>>FW-"X7
MJC#V82@I_D[I/;&TMH<5\^*[_BNCW0=!/DRHDM[V43*("EP!97N<7*#2L1;F M%1"GU
*)9VNH2P+!'PVL]&F9"63*WBEFJ%5\$FV4#LNVQ@%(|V0V-#308&3M M/BK<+3/'@IY7%JX#E0IF
>8+.M'=VG YVCS2LV=PTV^K\$[VI9V/Q(S1?)]<:M&&:-;%NO,A)T\J0N/)CV:GZ0==<./P!VQTR&"U*=
M<'L0*)@070>0.\8XA0;HI_2:Z'%DY;S]#X0?_ZM\$((:ZWJ,'[!PE??"-BF(K M((G*LBX7/M6.HPB>-WZYIQ@?
N?+ MS=U0CU;\PU#P8&B;9]9FICJSU/S&S\$J%IA@)|D'('\$\P13^"M/LW7J4&<\$\
M;QM#L73Z75J\$PB|I&63<1P>>GND:QE06#T#%";>5]L0[,!5_B'J)U:?.^C/ MZW55=!--Q%P9\$4,H0_8CP?
P!H#03D>M1;1K-3W),^F;|N[QF#70FQ6^_Z%X) M%(HRC@1;E:&U,@@?C0\$=>] ^?UP5IK(4->0!GCN]'?
7Y8)Y!3?FTAFA D_)L4E M_-'7VS9>)T/HSF(H-5K" 'B-@+;(55E,B1TPHI\;^GW068"%G*:?XC;=GF\$I M;
<=-.76;=@S_5^QW8&5&)WA0D/\V1-0H^WU5M_)(^7^ZQ^FZ?L1V6FE[(W[@ M&[P?|90;5J#06HGI;\$1AC5ZG2
M&-,"0ZF6'\$7B)B7>R=*M'[R6R\?'#=#6W>LW(.+WQP%HI9D,,;K36)JK&5,X MC/^>W09@Z?
9|6>"&6WE3^7*%J);.%8%\$(G85">R?R6M&@0/&\$QDD*TK@S*A0' M('+-=[&R25LX@#/FV=XS&(I-F59:X;CNYX|
(9,LS'X1V0WH?7I& &X_28NAS?&20_Y560[)]I)2[+;9.CGK9");E+5J>#(.\$(F54EV)"AK^L@0Q[120P_-
E2;K)Y7LF\5TN3D\ M%/05)Y?>8DT0[(404R>RM^A?;A\$7FW=|XR^Q0^'AR716+),#YH6R10:;R9 MYA
=I38NPJO[I1Y=X0\$U?|QU6\$_+5#C#90EEN'D\$8ME|138A)H91[80X?6UD MB\$"*SFU_W50Z\$7|U>5HVLE1PJ#1##
(|7U)MWW0^K+X M8 YY[C7|/0+'\$CB4;|S\$;|_*P/[*5MRF5;B^822/Z76<*162&45>"/I,2<7
M>4V"K&JA7;M%;'0W*EC>IH'#@'ZF*' +AT/_*U&=32EG&BI(V,=CJ_E-G3W> M!#JKZ_+V_>|==
&*/\$LW+X1Z507J^FS3B7874"-ZJ/K;:-;4*;I;Z7" CZJ] MRQ2-H:-
:.\$|PQ|YR\$SW/YR&OW=-8=1.@Z<5)ER^0NJ<[|1|>S/CRJYU[C=4JA6(0 M?*:OR&40_8G+6?W M](:;9BL8!?
|&#(4A\Q%H#P0LV(@|YM=(7.RTT|I4.[ZI|.DM.@9:)>R@7,4G MK\L7QA4<&B8)IF4_.U*!H;SY;<&VP+5FZJ)/
ODT*EH MT[!:X=LK_RW04@>;|N"12|V#@\$F M=/G6B5?S^1-8.;==G|XKDHD9DU'UA9HC|V6G7>\$D##*:#=:#??
Q\)|#@ 0)^F MCT@<\$>-'ZGER)8;\$0V4!.M]J86D;C%MA9&+6% MQ_V^V;5\0^0(L>?I_ "9&1)5<&R6':DW\
M4B6'^*]=M0FR*#>50CXE\A,N0/*'Y@ZL6 M? .RH!_W>KJ:8U_\$80| B8\UQ-A>|DWX=3.*3L?
I0)C4L6_3>2K)NP?H=';4 MW!38>C2H4C@3T9,F6.TGH@VT=;HI14?/N'YG"P>P(KUCG6R_1S0CS50?7(<.
MKHSI.Q6UI'A>\$&:CQ4,"|.QM W9&HLMR:U0 ^MR;JMF3U,Q0ACOGY%CGV2:M M*,0"EQ|&
(SZQX^NGW06:A@>#N+/1@|JVDKH30_=[9A;2=K>'7CH4]SE&PP57
MJWH1JC&2>9.-2;80,,,+7AF/WL%N86|NU[D],D#/HS:;7&>G9\J':243G09, M@X0-*F@6Y>1\$D=SRB
F[R_Q68/R="B'KR\$P/ K\$A=SL@9]"|SLG8!+H;31L ME4'I0E4%.5RV\
K/;KPY;DW6_,Y.Z6|6RR^7*P"D0/H"XT.T\6H9!:1PL.M^ MO_-2S_L.QE6&0),Q_AM"+&>N0JV#R69W
99YFHS(?QB_QKN3I\SWKYP\ (83 MX +!|COI=DGHZ,8;L-'U'"M&\$!*QF+H\LM2CUMA)C'*,[W\L'"_-
KNF005U&C)-8\A|NAS_O&V7:6F;I\$JM;07*UH5\P0\$2 M[;+]|_0@#I7T=U81A"Y(4,#YG9L5CV:CFT#
|[@.Q#_1;KR8|>S6>50J737()M M7*E\$6|=I+4^6#6U0I9A279\HA5DCU6A&_A*6|-
M|6.6\RKZBMP+!8@);TV%-.JZ\$CX0WF2Y>"Q5H
M^];+&YV!+QWU|>D8L[,YWUZ>J57J8)STD_@+Y"#\$E\$#S2%0(7/6(4?Y3?EF_MEF\$6':E%):=[7AP_3Z.RL%/GRO#
9LT5.-V^?K<_*|N'X0BPY#LN.\$@ST_B_M148|B-1-F\5F4F10)YA\$_1AMHX(=5MK42J/R8'DVV\$1#M!?
5| (DWTV9+2@F1 MET>UQIX;U>7)%^@U%14*59(-/%V-CP\"'#.+|WJV:XS/@.K-A|_FJAA3N+|
MNSCA12^*)JUED"13ERP..|0FC(>'K.PEQA%61)%;U=LM>%C3C M;83<2900.9,^
M;U)Y^+=;123H"H5R|X*630ZFR|0=.BLW1SH';N|Q028BR9_MBI1P*VYQ7HT*A&I>R9@NB-3DS5<:;Q();GP\
|/|.57_F0!RKW68PG_MYSM[XI9/04TG(U<=6HKG7QUZ>+GV20F>Z!-
=I,NNY=5T6IA#GF|D1|9ZLVF<0NF&&)&X_"S|U+M30! M^""*52_E9S,00F?7U\$T|L.(3
H50BFIR9IRF06WGP%&QM+|0F3TXS4(M#19 MA>NT0#C_R2,<(-8\^P>8M;"_I,!W:JL@/6^CN1IZB=B9LB_-
="N&A*LG<2*)_M02|13!7IIBZFL1ZLUJPW,"*&>=UE^B)3=C,^5=U'.3|1Z6=-EE>W, M:07D4*+/-TUX
@ML+4,E^KJH|M\W\W1KL3SYZ?I)B=[8*H&^_(9KA#_C;41> MB965)TG:JC?
7A.+8+K8S=Z[G85T8GD,^#]' ^9WUKAF MU-ZLH_YN%D/^?.T_1+8\0V@H5|E;\$_BY\$'I=4Q\B>@7.>X-
+6;_1L,50?GU M)| (G2PRGIFCG;IDS(0<&.C|XDJ>;MCAK9^!|20NM)-B"1*-8&HVB8UE355U%
MF119B!R@B[7Z]|LN\X;8T[4/B4MK.*1>B.;^W=-P_EK3%=/C,X0""+ZL/+H@Z M<8_LR|+*T0X;1-GM0MBPD9_37
M#0"LVLB%ZXM%|H|[:M;LZ0^/6%XJ;L0#)"Q9|"-5Z#1/1S_!+=>0?&+MS\$D9'6\;J!|_I
M41\$P>4\,7LN|:.#@PNG|Q"\$VM7E./ H*=- M&VI3_8 >?*|S(H)S^"/+!
|'F;+HSNQT'5FF;R")Y66\N\$".V3.%/MJR#)CU(#C0\$>VNG-AQ,D^?/)FH M=&6F01GX?*AI('30)1-KTB-:&?+
(|J=("6:M!,K7:T\$)K.NG? (69^79D03(G& CKJ0_.UT^AK%:\$RL@1)KIWS=YF+F40#;NJ!0 M"P?
I;&KN_!2!948|@XD-*S"Z90(U&ND|&/%)\$4|I;|X|TBCOG(ZCSW,&+GL MX>0;KEM=K)\#1|X_-
>WD\; '%\$*9TBLX/I4M.\CX/H\^8.S)<|/Y*Y41ALY#;
M)%'9I^/0|!K0%;_|:WBC)3W;FD6,&W\IQW@=FK*/+SF+1!(<[MJ-|,TNJX_M3
(|'"1&VUZ67*F\$;'E>Z#>+G>6@:*C#N_LQZ8DU,CZ.GY!_MG\@Q:4?&&2N6"_.CDJ60"+02:%(/1/Q?
U%RM3C83V1=6C3TAN^3(4^?804[UGF_M1-;%E#VL:AM2I)RL?/A\E#39B3;IB?9=
[CPF>OR^1;QSHGXVNL578HTA/OB*A/L#FH%!= MRJ)&JI(RW!WO\$|OG@^R169T9)#S?)!%;
[88|00G)LP%G>|Z-[N7XVV>\$ M\<&23DMB3DYM/>N#>(:E^C-"B0)'==WV%-8^;)BE|PP=,B7ZE8#Z;1A0V-
F1|0)(XJ4'Y->,9S%M%3= MW8AT#JU:.PAH08<.1BJN\$;|U5P_K)U4H;WJT1I9VPH20[BE_Q|0#3"60N*
M'\5_8MNX=Y8VFNi#;/A.&A^|G8WF5T"-H?@#FQM2^F07Q@CFEMU>^2:|.0-U M(HOVW&*-)VEX?|8B\$,1|E_-
SU0>(|1_180G1AJ0&076LS9)?%N9'E,33#'.2 M\ '[6]"75G0,IT",*2I.>|5S.1A>8N_>?
CXM>40(J|+,>00MVV3ZUB"\|02\ MC0#VA|)95D|WZ7@^PXVP#\#2HS]->D#-
/7H\0<8WJE,>QA.HU+S(&;_ABYJ|VSY&G2ALT=- M5U>NH_ ^UIC_P?5.53V1T7J)U-?2|5QD=ORHY&&:C

%++,@3%LHWRJ15%-R4 M/"QJE-91!Z%:(JIS,Z08F@*#>IDT@QW|P<-2:U+M(>8 CD2/7T\$0^N|!
M"C'IZZK)}R| *KCN4.(CI9.?@;,_VN-K\$^<=VCW/)Y\AKG)LU\$3&Y,D112X M@_A/8B=%2\$/ 5,+&-
[9CZE+>\$,F,;)DJ3@UQAVC4N6):?***#)82'1#'+QM<5?%JVT*D7: M?
81.'E6(@,J"*@U\$*\$K,L2/=..6^*N[5Y5)=^1GK>^=EYYG3[0^QD7'WK.%** MH:0=!=_@YUE\YRS"XH:>19FW#-
YIY1+*KM9921%=&#N\$Z)ZAK|M. !H]5FLBZ M!KY9B?MV3>0ZP*^4]*D!
<#=<QC1C8";OK;U>CK*0Z7JRM'/_R5*C8\2;%\Y99 MRUQ037MD8H>HSR-I[JKQYC2H07GST6:0A5I,X.2;YB I*>
[T*XEHBK;08V1< M#G4 3Y1*W52%[SMK]'Y-&)(8[YY7K*M5J;7N[IG "'..1LG M1?:J,U8-K-
QORTWFO"XYN%T+*XKH0>AH2L0;+?8UM9H&+RLR M#4074C;^6DF7..I],:/3TUNC(A3/5LAM;?H-9DHWR(P3=;+;
(':@UF4WCY19K7\$,>H%!"8M9.>R3|P|R K#*MV6HU1I.J.9=7 M|@AI+X;>=KZ?|SCX:\$S\|P<(P 'N0]5LK?-
.,V[7+^92VV6XEF0P36 M 0" ;.3LD0.JZ!?!L[94]DB\$?8,VPP\$(VBP0I+C8 0>5]34C;=51QNOQ'YV\$
MM78*,YJ#;4?%S _ILLST(LVH|J:|J8F5/L(#ANI*>@<.,=@Y8|ZNMS+B21_|MW,[&62S)H|UH,E>K LZ#NN[?
3%LK84.\G&*W>| [B:(K2AX(CU146K3#0X(FL\Y6WE;1@PK!WCH(JW++R!%!..D]_9*6KVGv--
^|QWDDE0'YK,D=YN)RHC9=';HQN=>XY2ZP9=U M|(?[I\$BE%,MO/T.!H->NP3 SS/@+|MC<-8.,&E0C?
IH3#MH(LG?R?|,8H M#F#8|C U|'7+^(>GK !=,5|;|B3 8"^(LZW'W84;*G)T8A)J84RV?|_/&M
MSR.D7VN9)IC37Y|NY;X:79UH>1R .!KD -6LZP0B??E"[2>4FTT28?.,L+AR MV68@/T' |72;@|
[C',1XJ:##"B)KM/C3M0@/"A@-|W-71^Q ^'=1EK2 M +00JCF3YQ*ZKA)8)22JS.,0RKV[\$Q+(R"6C<
M3:UR|H.^0+.0P>BM&870:6M|JGK(F:XRIFFM/?./8G=%<8#;V^-4HM/(+ F+ MY|
(&0^0,^P!;>4&A2S59/A0BGJTK3332YZ'.3WCE2,J%A(Z51\$14C|@%21CX M(_NR_=U9 :|PC.!ZGY
KM4>42XZ/0-LU#UP!,)/Y1WR9G[U6 _M,&BG.0R6'!|7GTSXJT=UM!0-
5ZCF%1";05^VX;%@B4/^T(P:X)4BXHM|&"# MR@N9>3Z95Q-YS@TK-QB|"(K)0DM0[_T7:FV#5.W*\?
LV/C\$=0[LLB', RCOW>"2:%4J|)*M\$H=TEH)>7H;VMG"; '\$VLHN(J.2 MEBK'X,%>+IB>-
H;+AM FS9WIK=1V2X |8!K1 D966=G)&)S0(M+Z?1D*IH+|+N*B CV&8=(W=?\^> M'T.1BP9!WJ!#0=SJ
KTZ/>ND7SZ3U7Z@AE0 K%^3HZ5M;5P9T|P3GDU7MG>B MW\$Z|&G;" >Z"8*M7\KWU;C,*'&K?5GDL
M24%3WW)H9,P/#;F/R2_NY=L1)RAQ%58?/[V^PH]^K_H1AIR[WD00_0 J@ /< MN00CZYGP0@^G^V7FUAGK#?
WVPW+(J>;K9'H @MEM.DJL)T.%B)(UV*0.07P
MPX^3A(KXN%>QD/#R/&;R@I=-0G@UKY&JMY:7Y+A5S&='XX\M-T=W\$1=*4/Z,
MK0/\$[K]P:;%0Q)I;IG#"N7G6=MU\$^Y?MBT>UR*QG?9\$RCRT6A|0"7U0-D"Y(MXZ%75\I"?
4BF0)JKPV[+1YWS^H,,FWDNL?,"+V.02,Z(\QGE QT/J*(-@+& MSP+;2BKJZEXW3&8T-
L"^1@R3/F#H,^/(5AY_0?'WMLV#QMM=WL@I=CXCX&S'W\$9>3:PDC.(#R|^H+I3#7:/%
(J|UL16JNH3RBO&@%Z4M5+X7JJ&E+U|WUJC,E MT8H0!W>;GT#DHF5&KK(LD[3V96';._M
(UJD:E=9D&=&B!Z\^|!*.%\XKFUN MAK?5)DS0A-&DRY3N8P5FH5QH6/F"&^.\$MD'9K*H&8.EFWT7_|&Q-
6>76<;6E MVNDP#Y:A)W|J|3A6@+ZHx22^GXCN*Y|(+V+*,L&-C0KZQAWH& Y U8PZ008%FM\$N4 ET*?
Z;TL9WE/;4|AF0@UP_HP842YLG T M05DU^",6/_803(>NWT|1G|!|VN2HI[W6 M50]'A<|UKL|]\$?
YKT:TT5[WIMHL&--D6<:\)^ T(D^;'NW(&17YQ'08^D00;UJ9* M?,9*=6(Y!* >^%J#DEP?H
Z(R)4X|I|G\XE,YR?7:67@X"KXWA0S9"R?ZQ40XS50"%13>/_ZK@=XLVFVA\|5MWE< M|f&Q-+LJGT(V2"
(0*9[XL'%]9N[S24Y[WDB)#45_R3[T"!FD6G?Y"6;6@!D M+Z3'U3=;_+;+RCA'|fQ41-9;EM^,7&X>0
K0";TFB"#+3,54?%BHU#>5&2 MW8WI-:ME(4:@+=JP5N6,75H597HBMJZ /()P0>'FY:20(?K|Q|'9.QXZADL
M0=@ BV&<47=[C2X37.!SXYU/)]|'+3-NNAB'EB:F)K7^VT^_MHL^(GL3#U' M&?RY|&>(_Z=\$HY+VKH1'3(\@
N|S\VOWW)S.9UOF XP'?Q08E7GK|9:"(*4 M7 "[&5#>JM@>P0IY,^".E_HD_FU M;0MP3:7NHG[A;5!W. 6/3?
1+U0%+?%DSRU|L_YU%GVD8=@B10NQS|fUE-/X%J3N2N"-0Q5%/B4JY:K:W8I|f3K\$+/KVX8SE-1%>NC>/
MM=Y.^G1.G\ZTXJ-Z0^U(J+X?*7L@Q?WX MK9)+\$L;_5I)5.M:#?|. =Z+P0|?P=0^I M">4 +U^<-0XN6Y|CS|f
(WEGZ3622_0GVS^*6J:" D2S4?Z37*6#.|[C|TVY MCHW|/^NJO;|R5K'H I0 W<-94,WE)|f^9Q\$ L \$W6?
^8B0= T6\7APBYK(0 MN93H(G^SNXR7.YW^5 FL?'IG =L Z0&>L?*8&_VNT#14_A0!I5W'K+Y?|XG MR|>2-
?E3SX8CM|U>0/f3X# Y|D_R6GE_S1H0E0RCOV#L^B_NVULM/Y|5MIJ M-
ZEYV+4KRR7_^|)*& TW\NR4R^0E)5BS X0+R"UVLG;_C_A//%\$C*(E5/Z MD["H>0:\$.&#DP;+|;FN6)|f
[X9^L/X" L^J|f)\1SB*MZ7X0!E ,NGF*_8^+ M 7?
J<8!2'.#BX8R&OKSIOAZ2*2N4*^*0QLSY._WGTXWC_*&8S&7CNKI6?Z M4I0&*7L%J?
E9_[WWL')KJ(X40|CHKPN<=9

M C&&MF-/ 0>E TQ@;_1@,(VK|W,1A>6+VB54/=B!H8&..\$#W|-*5@?W|M 8 M?V/_C?TW|M 8?V/_C?
TW|M 8_078.R=VFFQ[*+@L5&=6J+"U"\$U|TKG0: M5K|7: _Y'L.FL+"|G'|>?-CQ@(+X0"W&0ZF8,?
XQ78VE0|^;680')+^KQ5/_MD8K?|.D3@-14YG|G_V69 ^|(!|:01;|]=J5B+;-
K9.*!\WCXLL\0@108_W.ZT()|98|;_+C(&%G(T.D/*(EJH>SC'<?TS\$1CF? MY^6RLQ+MTJE!8?D;S3I.
(\|\$=E=/0WCNBRJF5UW0\$P\X#U2\$-B4X9P)T.'0S
MF|>&6Q:E9L06@YJFBG6%E+^;ML3+1X'f|'UE@^=&8!FE^YVB;_N.DQ'UOK MIUWY-%J*@;D>@4V*-
F8"QAKU5&WU/"WA|N_LI73_8?J9*,A\$5|0=|ZW"/^|; M17QM.0U@"V5/5|1UE^7:=ZWWR)E-
824/Q(-.^)&M;%F?L&D:9M*;T8Q@2V;^ M.08!HR0;=H&'E!(&V;^Z>6|;PU ^R92_K\$S;)#8=1 B
>MH(VRMR>\\R|HO MJ:DI4Y5PZ]= V!@=AB|\F=I,%B1HZ<,"<["V|f7^RT|9ZTT|+L M1?
NB_L;QI92SA0:V07;MLXE2015W8%;_0_3?XS%= M\LW@;C/;,'?F^H5X-
N*MZKH9;?,)G8E0P#)B)*;_GV105GP,SKX5#IVC>9Y2 M,2(F/LJTMQ2Z#K9L"T^\$41>+C.|122HI/^NP.N(--
S<14.JXW+(0#G-U|+WS)&PGFV37%|U@'<^=WALD M;U6;9^%M|Z)2(17EWJ_?X.J;
K7L)5D'+QJ0DZ4S)I<\$C*08TNG5;9MZ:&^ M_E.,ALH95PKJ| -EJYV#N_/(0%\$QI' 'S;*4T3=R;QFJ))E8=U'\$B
MI: *@B:E'=/D8V)ZJ/0%*|I|I%Q^|SJ4J|8LWML\$70^K="MW/L,B^U^5T#R^&_M0+1C,5#TF =RQ)9;Z?0T@B.*%
|. G|9U5ZGR\$>!,.XM&+>XD?%(:@#7=10F37^;_+ M/S;%0\$*\$+|^K&U4/7|f#C_GP#R0.[M6\$!|P^\$(Z;PPT-
0QZ MW*^I?0S|1FNHYH>19-J-W5F-|Q'DT#?#SM1?[*PS-)#7VR34L;@URHIM>_ZC;
MG&!|;/_0;)A0A:|_ZCE)ZLI1-8R2^X3.VB/RJB_VM5*@_=?DRE#\W0F,K.6Q
M4B1BG^;_E&PV@J/2%V|C'R&CTBVGV8L%+8-@7,^IT0./C|V M1\$|f0#WW;_HJMU|TJ?QCMSU#

(#0V|Y\$\$\$8.^7'?D'S40Z<.\G&S6S_U\IKIR_MR36H-RD[\$%)\D*,I%V2Z?K@]AFD]?FSU/,<2]1U<6P8VH:
(BL(!J+\"TP^97_M6@AU\$;,R0[>Y^;V9>[=61US.V,;\"P:W7P<+==]!VJA&6Z,.N\"8R,H@Q=88L
MK*G>4\$]A==G/\(M!J@70D0R[WGD;&WJR(35J0-^!.,TW53JXWS_MC*-?PJG3A0K'\$\VQK;_/'8P-
J8HF_G%FP\"86G89B5T5KK[I/U]#X3.IIUM;6_M;&^IS'\$UM?D'V*?4M3W;#XE7Z'_M_45!\$08E0J'>.>+GU%L*
(?*[+G_[#;?_M5\Z6F0\,<\\WEM/XU17\;*L_U'2BE6R;JLI_7VH_SW.(9T^MN7P5L/SR\YEC_M_Z1]Q-,QY@?
77\"2(Q4IT?<^_S,F)%(1@CH\T9K_CZ_Q!@5+_M@>]=U!@W>,.09I_S;0*\$S=A44]3MJWXZX\$-PF20-
<\$!.=.)40KLP4&WN\$[K7_MVNPNO.R-+JIO&2@X2_-1\\,\$5F_)SX3Q_C_/?E5PZ\"L4#EZ[J-;^G%:L,^_M+X
>0B<;<&K'NIJ(_Z),S0>H&+J+W)UDUJX@HYQ4ZR#ON^()EADQ]5987?I_MZ9;3IP,7\BRQFMKBF<^B]S9A[?
K\$%,7E44:1]F3-&L0&H?F4Z\$/\$G+//]/3
MRCZ1\0#&T'==YV)D\$JNC2T=0^D\$VR./KWJLEI#CJO,3^08WZWXQT5[;-'\C/NU_M2_*N-
'0K5+&N_A\S\"P[OI:Q^((/V70.6ZX%5PN>M\$RGT1ZN&YA[V#^+5QJN=%
M2TPVS+*\$S0ZLS70ZAQ3##J>#IGT>0\"C4)C%/O=E*W*D*IW?&>NG?5\2'A,R'_M^XJ+6K\"0_5.NQFH#11
#U;3^/4GM\"9!==0CA0?B?([\"\$A0?R8\9?J@W-HS2_M:SY6UU1W\Y\"//9(7.<0!./SPL_QD!JP#B_//V*)7\"J
H]*1\$NKP(3P]E_MV2!U=FUOWA^\\HD?8=;\\(3@_NOAWFN2S,1#8U?T&0[, \$]A#406?-4HU@*8[9
MNG'\0_(\RA>CC/*[Z]IVA.1U2\$@%?GCIM[D_<RKA2XC?>RX#(XM\"*]) [4AX_M>V=T,;PN\V?JV+
3C!KDB@/<@7_3*ZUR=(E=[_GD5G([\"Y^Q;S_E2C(<*&5B_M%'^E^NX(YHL#5%,5H
B[W9,]0EP60.B2F\"+W^WF_6\"6;S34-/MGUL2\"*3/\$L_ML_!#-%QY,R= YERNFJ*7FUYY5RUDWZ-
.X210GL4HP/'N;V%F1]5X]BY8*K_MAD(6,AH-H#E.Q)_9/ZP([\"TZ(*_<+KN\$^\\D;-!9TUWJ1=RK0BU:7
3S'/5_M-*]K_S4%RO/_EA;_C;WNCFNJZ=;&HZA(\$^F=*\$60WCM!0;H447J)2\"?26X_M_M([\"_@B/ON-
72D1KITZ;VW!;!0\"A/!RWWJ?\\W0>\\WWG>Y[GG.^_X^5[.SL_MF;UFSYJ9;];LN=9<><6/UJN/WF/-CB*0^LR
0*4\$^'=]H.V_MBL[89A!D=,;VJ\QZ0<4++8F\"Z#0@%Z);F*_9^]8888H5Z8P8AYI.00?*4[\\&
MG6F23]H6;EJJC=>;0\\L=SN71\"[)5U2C>;D8_BGNM?
AX85UF9/3Y75<]Y,8>^TH(.6'4)2\$^3;\$\"P/;OPCP4;6K);>59K1-
F_40CG*=GC\$%ZMA[AVP\\\"C6&>+)1[!/13/C60X!;_MCQU_;;_YW]0G\\;>HE'I'=N.9-G(>?
@\";.\$)7%SNM6DNQ7T?G?I\\G#PQA04S_!\"(%*?/&;Y/,0[,04W6W_1IK_M30[Z58&[]SR,)YK4D\$/(++)1)K61-
-]/>CSPQI50BV:_0?='G@L]\\@S:49M0TZ_MTEP2IZB<_%YF^%L]0KI(_W%'P*CP0Z9V-0_2G:D\"ZKZ6LL+]=T_M\"
[->^H0(G/X0#JN1AS2L,X?/2Z_C4J_E:\$;F_!Z-C#,S0\\BB']FF-1J\"';738_M_NBL4Y+N#@*!39RM)
[GD60JV\\WBHR:[, (#&;H?@5A*W/C#-YCQ'56-:;Y85_M/II=56_X_IZR!3R5)98CQSJ>H8V%RT*6.H:?.9?
QE;W\\[9LZ_]W/%+*J(@5_M1\"CH0@9RI00,XXTK&&^'RN!F8LU\\;+++MD=L!_##)*FDT0V(@2]16V16S%E7_MN+
(T-!9YIV,TQEK-YWA7B,/M6BM,14KL[5RK18\$MJDFU>*308DD0Y/\$-\\6VH1;P8\$R:2)=6Q_MUL*C1]
#E\$KTHC9L33\\5FQA[J,K5HB);;KC(\$*8=EW->)-2;6FQ-8@UZ'XX_MMWMG[Y?
B1_B[&7SEY]6X:U\$]7^7CC<6[XOI]!.5UJN+_[EV]+WV/W/<0^2;Y_M;\\0/4J0TD_[E8&,GWM3QV7\$9K?
DN/WHP.VL%0LR89Q=96#;H28-ZU8H-SHDJ%ND89@99*7X-&NF=>L6TC'RV_R5C9.V:QK_Q>[?-U65,[B
M<:;1*H^BLG0DS5F_]6J.]QZ8NA0#]:[:V0+Q)ZT\$E\\)X_M5%=940#B:8_S1!NSEB)I;WB6JNG3-S1\\4KT[,I9??
9G_:'IHS+).K7U-,TRO_M0\"Y+,1]A=2<,I]\"U%M],/(-\"#AHR?'BWN\"\$)UE4<*[+I'6.R8\\;UG^%?XA
MNE&^XWYT^]@;,. \$0G9%JFB;E908MK#10<70Y\\B0C\\808;GWMQ.}\$(\$;/]Z?&3;^7\"#M3^^'-F]U
MO=\\>LY\"YQL*4#%8;_A@:5WZF!#W.?!-W%R*&(_MX#%&FY\$+4.*=30KR^8/WR13MCP\\WYW*%_0IO!' +ITJZ]
K^\\>HZF6Z_F-2:_MD,\"?Y^FX2PA_2PG;AA55X[/!_'I,GU+^>SZ]I=MI04&.10Z)<2SR0?C*F8HX
MJ0:E5G!'N6)!T^C1G0_?&'N?B'70:_FY<\$0WN_7B.7R:R=:XB68T]LZSN.]8V_ ;I^8XT;:_ZLA_8P
M%+-2UJ/Y1W3\\F1\\F/N2X,(XI6\$]S+F52P-316XL. 6=LB&:'KFG*[*P!BN\"L_M0I@4?
0T\\#H);F*D%#_<3#&\$IE(<^T%,_MI*_D5A#A+GIF5T\"5,;MLX*IZF+C53T=/S%_.P+H =>XG!\$?\"_[:)_D_8NO:
M@R_90]=;Y:F@N[%3%K&'-->\"2+\"P)\"*;;[!W]&V\\YNN#\"#)3C3BG901ZS5]9_M)0YKUE(Y<?7KW1%?
\$;XZM^\"\$=S!PL60ZU:Q(8E_VG8>=D8RBBL%5K6^:A,M@_M]-\\5@0@Y[\"\"\"/;ZIZJ)%8^MS;?
SH7<117\"7AV_ ;1@UL,;SR%PAZ/N>SVPYA[+PI.W\";=\\'_MZ,)R-V[5Y:<&VH=]+.X3!D]=%*TK_\$HF-\"
(D]]G.7@%W)6GE4_MB1WIJ;-/F.^WL!I5\$C&9\"\".ST9\$*&.[RGNA2_A[RE4]DE]-0\$P1#QNC*:QS
MXU2EQ[0\"GL_N_45#;[/FIY;KSMJ+\\F/->^]9I(*Q]Q%ZZX@.L!WU);;'Y
M26S#5\\2QZ7Y,05YU\";#6P.M:DHFB\$.!\$40:YE:(EM:%+S=6U5I\$(@2>OK\"?D_M7SUYPI1?V+W4FB<@Y-
\$27)GH1E-DP,HD&1/J-?EE@=I:0![]%#I-#_EQ]WU03_M0[%\"\"J@\$_IL1<5+T\"KYS[/!4?N1NH65@'9T-0
1&D1;_!G<^'SN#; ;9LN5Q3G=9[LY>?U0L00_NUZ\$&\$W^!'Z2>UL\"?WI=VPBQ^S)S%/!IND#*= MG<] ^9_S.\"D)):
(3*7)4P5\$JRX!+0[N92]M@K7J)TMZK;IB96*;ZCV5^K4J&S_M^*63(LL#L/\"#\$\$\$[5:UF?
JC,TQVF!)6&EF\"*X;S\$>0+/_D#LR_M@6L4S#>H_M/.XM02&^J,=!%X\"?D6L,3XWUQ]R0W9/*
(UH/)AY\$:Z_KG1R^WE?(@[PW4^/_M)Y<_[]I-;&'ST\\XVL\"JODHA2S)!-;W!O@0@D2:4-K;Y50;=N5I>\\!Y3&X
0_MI^@:SS;-RCOA9T:^=U\$W=1'5D>YFW?+FAAIH2&Y[PT#CW*8\$H>\"V9HDSGMV*4D#/_M8>)L;XE(^ILX!#;S\"
=>N;*(\"&MB]BC8%\$T-]E]V=Q_6&0.?>Q\"7HY7;=H0_M*6\$,A_07J_9Z_*\"Y*5KMMZ8J9'F7_+*=@U0?MU-
UW[Z^A[\"J3\"RG9KJCE<4AB_MB19G(77X0M\"&DX=YZN(<(WP4LU>\\1\",_\$_;CL2LAD03K*L^I)849JFL%J=):M_M<;:
[V7?PTRZ,_MDZ\$S4TW90BP\"L6RY;*U;G&LGMX;+<'IV8Q(X7!D&F; &B-_MY=NKX>(/JN_0-\$WV0!FTQ5G0Q.-
>0/1\$7?4:W3DMT#_M*,YV\\!U7'QX\"A;:)/-7NT;W5YUQD>WKQFTT!10>I>M&/AY+X7[0_-XN1X.,,
M1GKXN5IM6H%!)\"2'T006.#8D+W)4!\$F55'^I8P2LUP902>GTRL1Z&JW6=&\$:9^
M^;/<'YMBG>EAQZM1N7QE;\$380Z17M_>-/30N7^<%ML;!BVL-0PRAZCJ8[M:_M6Q5IR\$U*ETI&50L*Y%0\\&NZP-
H03VW_]GNY;0-)B^#96\"%JL/^IG'7/MNTU#_MZ<^69^\\)H\$VM:@HIGL>\\1.,
%2IXVC_\$,;_\$MQM\$FX%H/]MOY%0**S1\"W-\"4_M8M2[3MXG\$-NE/;&C-6J/H1.-R]%H_!H@6JLX+7A_[9'Y)4_'-]
/>]_N\$ _MRQR,MSI>**&G=IPR3->NIW\\%AFT0T8[,N\\R%6LJ![]Y\\K1\$:.B-;>IK50P63C@8^;2UW(+
(XTJCP8Q[)@I_MHTJPE*-9S>[1TW/&EAF+LD'P/N_0[60KR7MUIX+5%,]-\$L?8&0GFRSRT(\$:
M\$^71>;D0.=:;L4CC*0N!-8\\D<4VS15^E'II[[]2^72512,3SPWY_!;C8%-0_M\\]6VU+5+P\"0@3U_ ^2P\"
<]Z+\\B0,E\$S<;?C6].^3Y-G<)P0;KLYDU_'3P]W.G_MT[WR=ZY3?DN>ON.D)FV.]D)\$
+Q26JHP_4^U;K>9\$72,2_V:[B#^UW>]SLN[_M,QF_(7YWA*->/3Q77;OWD7Y0(_(*15_#WH)&=/D2
M.MS5AQ[H(F^4HWM1KF@!2Z4>_-6B*(9+HQ/_@1^_I7;QD<8J]76>E/\$7'_;!QE@BI_L+5;+[]&%HM!R(\"0.(87

MQ=L^(/<\$9;P0=B#US.4X-ENSQ;C\OE;(&SM/\\"'ER"D"1/*! ;A&-_PC"0[6 MEV[G<\Z;9;-B\0#
(QVU2M&\$9E%"G\G9NB_=G-0+9@,NZ1+"["#W"50D#"3"3 M;R 6#.NH*YAL"\$5ZI->2NL\074(J%FIL-CA=
(4AA'3P)%+*^_K;W);8QL_I6 MZ;+A)2#8EQ U&%=L;V#NHM?NQIQ0=/5#F;1)G>G&S4A),99:7\<[RE\VP&O
M+P&G#PP\+H)-+P'#@I.0C^A70+08P+ K3?HKU0.BF7:6>-8X9C/\&\[4 HG. MT?E5]Z2+U74+QZDU*G*5-
Q,'59<1W2%^;_C0V8_'E2T3 0\)FSPG+5;G\5Q MQ /\$?GIXG\0 OM/ER-
YD8[\$[HA'UK)D?;EPQ)MD#^("#:Y+#+YA7Y*! M& 36P-NEK;K4M%ILC7Q9_0S]RT\;TA./W7@IGL2CF=ZU% K?
CH9(&J6BE3< M2_%YA91;X>;=.R;I+N\U?3]-T]UEV=>M=VM^1C#@C?VB2^ ND!(\$FL*P3E1#
MC.64F^HKFX/V5?NMW\4FRZF\$2-5B=3U&'Q[BWK0R43T7 6FA 1W]C& (= '3\$
M=95!/ZG."H^YDSW\FK!TG!H^94&=G%.\$5):U[?1#+V1Q5*U2=WR[U MSLA%':U\10LME@IJ?
0,;*8,]00,F0&C&M3FL%>,1F@,.X[C,[S^].^CH= 1= MAY="6]M!-('==S\$F52TH*1&[<?GT1&ZI^
M@N:]ZS67W,9[4ZG50KD1N9;MT])KER#EU!MN,7=/[''9_15^=N@8J,;9KSRM')Z5:BOWN;@@;_%\$ ML)
<*I]I<=/\$*60>1AA\$:9PE,;D/E,6W\< YCQ+V*]\$4!@2X7NG03SJ@4LD*G MS-C/ZS4@Z(A-
P.LR8/G.]2Z,36S'005:;!<[Z% M_!+0PXNTNO
ON03\4)FH'FV4*)1UXSPS!&;9APW&A,;F>/75!RI%239HN=P4R;>K2_?'@Z MJ*XXS\LC7@9^,9F%GC07@-
KZ\$3RFKY4PF&!!SP4J>977D 10TT\$'-RY^ Q# M["W?US=00Z&[+4#L9#SD;* Z;BNS 6@;+XN4).R32<.
[IYZ =>Y.0SA+R M59)H8J^TXPQT8<&F+MP\$XU5460PC /.@/U+@Z%CNC=;)60USF"G*)U; 8 M?^D>
<\$U\R9<)0:*!#CM @@8:?!N\7-P7IB,@WB/#4;R14-I;[8 7PX(W*;X1 MU\UG.-DB!DU;BM\VB
N\N;WB78U T%);;^Y3ZY3('CGX5N0&-BP[>"8>9\2H MXRHJ\$5[MK20JMW0&KI<==+.3
M)80PFKI/>L1I5+*'\$29/'0\XCS@W]J-%KRQVY06:GB08(/]8]W #S\$Z;96&2L
M6=NN'(G.LL>0%&YW %:U0!E6 ?Z.8==B\U4* 4I;*55SD9S'9!V,7PN3=]B M-
#9CM[4.JSEW\ "M&>ERT7\$S_C_+/8E?Y8TE;W4*(0,@\P-S8F85MS!5H\$L=;Z4EY] M2\K-R&=!!!=]ASW-
Z>2G+RM.06^5G2Q3=8))L\$.M>*YV'-A#-4B7;MXVR @^ M#^A; !&VCZ8G806YXY9/PR'2Z./0BQL28^ M%-
%6ZCMDLZ170B]\$4" LKTFJLS+ \JX6 ^2.]-?WB04(>%%(4+= 'FTDKY3R/ MB[9:0
T"#GDNE1/;#AL90[T7EJVV0=: [Y%/VH+ @?51"XG*044BC<0SE[2& MO>]1R\A\$*
(%)AK*H924LR[804V72[F/NO!P+#+G/KN=[W'0T"=Z/JEE3BZEZ^ M>>)7\R!1I&*IF1FA,
[VV0.DU.M5\$R]!9*>7> TT0P6'&<>T)ONS^S;G!P]LX M_ =A[4(UURN")F5737H'KE17\$G^WM*89H-KZW
MB'Y01NPV+NIS9YLYV->2S1IU,*Z&TED:+[@BC>- E;32*S0NZNE*?>,;K;OG MR T3Y%Y&7-DIZ3J^281/Y[/^
L.1\ (WDOV%:W " M320X^,=ON^E:;W PSZ;G:5#[Z7[SK>C/W)>\ H+*GX/[@\$=90Z(
M'*VR8ZYIYWEA=N04KC#NC\@KZ)25&))M&2+#[@,+R0B3&, \2A7+IG7?0'^JM
M6RK3XP&T!SMJ906_/!0%T*!@\$5+, *]=M,-RLY:Q\T-&G8KZAG<[S%]#6:/! MHDX644LZ=A\2S=HCXZTQMZ]ZW
HJ\$N D\%CXK<)8"MW87%J?B^#H^C^R7 M(G+Q>.0#N?<(;**!/)V]*VM,Z
0URR"PJBCUY:46U4DM*EZAC"FP\$*T3B0 MTL;[/(/[K^ZVAV ;1?J=[TV (1P#0FJHJ@G(. '1/'B\FJ1N5))Q
M/T493=.B!Q^GD#2RS39,G+^T\PO&_ B=X"D]7X\$<&T1RR:*EX19>2-JM&2 M\$UX"FI:H^F?J " WV
N: '5,M!#/PAB;T&DWX8'5#"K2KWK%RUZ.^8T\N=.H MXNHAUHWUX(A,ZCZ('2MS5Q/7^3#S8?
R@XJNU1'XT]CY,!W4)"'1MI9S;TCD\$ MSQK5[!X;J;(V-WD0TW*00?:H:,SFCGAD+ 9%;C,[@'30QC:;M8-?
^\$8TI[R M*;6-)QN:Z7DOGN\$EBXP/>VS'-^MDGKU^G,2\ \@D*4%QTS>M'&S<)\6; ,2%8@K\$6TJWIGP=A4DZ>R0#M
M:,FH21-30^A'PKUJH:A) /VU\$]P:3XV\4BNIGL7"?<.,9MIO\00GN6]J6
MTX]8F&.)V6P0WN4A7'Q.;]B1?NUC[J&[U6:Q>?,0JL MD:8Q\N#S-Z\$S:%93DXWV=P-
%H6A#0\3=Y_6S6(@<'3R&.T-YM9R?//LJU5B@K02B-Z%A M[L.;SN+;>3V\(&=YP753VOA\1C03@7*,^"S&'3V^?
/5;P) =A<2AV1(^<"- MQ01?W9"2'SN-!+X*G7)APJQ'W'A6[!;AKT/R<3!J&4+MW8FH2,^FH@X[*5J M-
T!7]/>?807Y.SPW>N(6M/0+(!26U22@'[!B2[4[LSV<*;B,JHWZ*V1DUQ M;L.:XY3IS&/OJKQ??
D10SXIG>/C/.*R*8),2;!*#578VAA!X!62EF^XX>U. M 7 46AZ(F;L\$(,Y726J2'^>MK& 5-ILM>
[R^>2S0V7)R4W7IM) A1SG"[\$NY MS8V5:0&>DLZX!^-(TH" TIN;:)] !',W!TQY+=9\$UP1;=+\$^%;,Q
MZIQ4*WX1F0;H4:F[J6VGP?4A0FLTQ,A2%&K^5 =<\$H8T2D4+,-4XS/Q/K+PZ07"2Y? MW:\]D+-S>L?
9+5MT%_.3'^A&C(^.[G0>@*':@-L5:KAQ47K8#UUD+'8.T3^I
M.%4+;UIXEBM&130DV9K/U/L'KI1 M; >34U.*4VK(LZ-2 0(-=LZW5XE= C@ MU4T5G&@;>0?R%Q>U7!MIV+L]??
S0?EH;0JH>') #8WI(9I1M0G:~M!HEMVFP0 M#EIQ@8F>?"WP8J L]RCU[9\G&A>6UNT2-1%I&F,+ '0QB>
[.3,J;22'SNH:32 MXJZ)"00*01A^8[,N@^0@GB: (-RI^8@< (3++=6,:?&S.+WI921/L'Z%@UWI
MM7A54'(M[L V/\LC),X<] /&3P!8;"3Z0"% --?J[? ;F7JA'70Q!5\$W9+MB]R MGX0/\$, \Y(\$5<#,' '\$8?[D6Z.?
(=, #%/\$XMF00E+(V1=H%&]3?%;OYBA0-KI0 M*VV]WHUE_YU5;DF.R0 EP'HGPN\$-<^?
TVS# /96_0\MUNPX)^]TG=>U;> %(2 MS6R^F^30>V-X.2#!-4B-3@T2S(,)F(0W2K/*N -7V0,)] =S6G0CQ.
Q"\D,0 M88!L:;%SE&].77^D%C%\$;P3^(2;\$#M#Z+#[@0M0< ;C5T\$005]STT@Z<5-+0J M<2'QI17:U
EU=^VWP\$",3"\$,/[G#!>%S"<"3V[)Z A_ =N0^0V_@>L:;P^?7C M3;9.8"<_0W"ZSJU0L[VR'+N]/R486RW%
(Q[3)=C\$B[CQ\$ST]8KAFVL8[@X M0&N,--\$="U]9-#Y"V^AZ<4E_,90:HMP=/,;Z+S(J)YE+,BI;
(5^ \Z]T2;TOK M/E];.&T>0E-A5W:VQ; !G/IQK0_X6* [=X,1?U08,ZUY!G3S(A-C5H1FZZ;2
MG98)+I=ZYL&3SMTZ5>+A\$ "K8_ ;1)84YD\3Y?7H:E@ "E,M# 9V1X40E6UD+'5 M',BI>N^/^+;0EQ,_YAN:?
K*N28SE8E(%>U8H#/9EEC;^+YG.6HR\>"0)5F0 MQM3U/-RI7=3@+/,1^F*1F
0L;V:Q["#A'K9V^C&5(DB':7,V?("/D9\U#YI?)^7R28[A:16C9-)MDPV MB?2!.;?<,)#)PAFY%)]X7%Z:;5 S[
<[S8_0(IS%<_6E"CWTA^2>Y-X4-MR+M MZ0-;[T,'@1V7 .*=S&K<+CN SHF&#UBZNDCN3HG\$LA&[D^!H:NW83C
_5Z]S M8'I3Z@Z(QW<0RUZ+5" VD>EDD.OBVXJ->#=:<^W>TZSISL9>] \3(> 'QP?F< M%WWS'HK2\E**
(JP*>]+\$SR]R>9C'0=F>[A^G>IY@383R! M700"2ZW76CAWL'A(GfWHN\$5NU2Z=J@6A]NV^_AD2*//SVS-
D/[H].2=;[0S] M&%57@%/X-H,^?KZ\$80;J@[JS@B\^M G->'9UM,& /\$NJY3;:JKG K"7R)"'.
M!0#89GJ_XIBSL.8ASR!I,L6Z21 A.F]ZWN'!DUHJ[@-ZGBJ9+9*R0AA;8U@BLDK3X\1#[]!(!"(\$
MAV967H2\$[/-,,]B_77UZ/9&4^T<4Y2(BQ0ZI7;%VQNR^?/76JLM-H&*AIAAR;C'/7\$ =*
M&#>]GM2RF4R^JUZ8/0\RU<*QC])VA?= _9^:#M4!SPQ -4:N'@f1'
@/0A0\$&R\L6L'3+ \; \8'#0Z1T6+S;R,#F2'8_N,13009(C4 MY/XYK]J^JL EI"^(C_??
9048&V130NC%00S>DOEA_7S>GQU7 *]Y=:YS[M^7DAJ &(85ZH">FDTZCV*?=Y-^GK<.&>,'?:EYVG G-W7?

3(/,= MN020)RRNZ=J J@S575E" SDY>U1TM,0:U: QD3>D29/)-^0_BSA!N^ Z3\55W%_I\,-;|#=G<-
P>|0U'6J<^F/0E(/;I M)>#GE4&9&VQ#K'>|J{ \$WR))_0FAZ;^P0JUG5C?0R%B5A07A|4'!+S1Q8=,|
MHPLT74XR%8R9GZ:Q0:W\$SV4;4L\U|*37G%SY*|?RX08_X;P\)?5(=%XY, , MG<14H3LZ:AEYD?
NY'|<_5Y^9%\$*\$=\$=LF. |#<^7H"BSN^W,@XD;+'G? !TI#E MG8S"%W\$8)A]-&2I-4S*
&LKV<70%33PBS03R9ZC5)X'%3_NG/UB/PA|#2Y& MK[@.JIB0RM-8J9_8.C,N#<&0:V&A+\,Y(X:"587'XMI)\F-
M(ZCC0IXCS*V; MD04U/[9=900. X-T,;+DI> T Q>] H*5Q&.W C'F-T0F3# IX'-L:G+R|](M?/_&
(KG7/P6_\$,QESDD9+9-7JJV@|V#DT5! ?S//)5I8Q56|:)J| (: #A+Z\$P MV104@K|*+L=-
B*0WR[<^Y"]SJTPJC.SS'I0Q57ZN"=NH;\J0C|H7I& \U7/Z
M"!#0#?!R*X_W)4<4^8Z":P#HSD)0.V1'NTZ"3099_-+ \PMX)5|#XON_@Z:E& M&I_5|0<7XPVQ_=&%&^
;XD|B4#_R%EY|*.AH"=YYNX5PTZNR-I\Q8JD0(@7V_M>%6E,
[WWZPTN30X|7XH10Y1:%M|+P&+FM//T\KDLLCL3J;@<\$K(|K>I-9U.& M8>?
F>AV;*&9*\$10Z*4H)%Y#X|\$2=R+9YW(4-I:=!>X5:6-*,4"*YR)7EI\$+D
M|\$R75DUW38|AEJ|13,I3/)JD&9NP/4N|D@,^Y|TN<:T(,\$A?|I/-2L=DJG%^ M*&|+!9I8M_8;B&&3?
Z%K#<K:N;|L3_)JM2DJ3KZ1*9_WG*) MN;+0*2GYE=/89@N0|S=1K"3JN&I1@P;-L;-T"8BJWI\$?)U--
_2E\|Y\$6?LH_MNT| ^MC|KRVB0Q8TW#-'(C#G;7N>LDS\|= &?1Z?6W6HS0HFQA+=R^HP9#79"%
M&SN^>,B! &"R|@E'Z*>%W>FH @5;U>Q|;P*>W5+98#7\$E|. ?# 0)VCH/HW@X M8WVVT6HP;)BJ^,KVRK8^_I/A
0\|B05/AAKXL&I-B\|X,.-^H6C|:Z|&Q+ M7?M%"G2F.VPL;JS\$;7T|&'JM"2?|?LJ+Q4NPRT:
<"Z:XIA7RU#RLZ:L7MK:D M-C3\S/R8%)8=4U7:Z.:7JG#;&N1%' ' &G9Z_EWLN84LR\PO^>1<:C?%V%IJD
MM%)Q2\ARN^UI/,E6T|DDZ|5\$3!; %NZM= FV4@R, ?U*\$! --VYYS5ALD\$|A'M_M_?
PP4G|KQ)I1:S>"G./&ZF|BCZ5G>-Y0. %U=,R*Z-XU-H0,-=H2C&MS3"E@ M|40^|2=Y\$K?R\@+ /3F/.?
 %&)E0|P*W,I<1F^*-9D3P<7UJ**G| KH#<D&U^L MSVH027AZ)\I: \L1'.D>L|KSC43W^8D
 MIWM%11\GS.0ZN\$^71+8# NB?) +TY067^TU?XXCU&\$52_+*V| --1Y\7RI_5HQ M|>.G#A_-
 +H1GF.%W'4|K|Y.A^P&M/A>4EN8\1/+|;_3'F02-E^P\22\TV(.S5
 M:C)8DIUFCM%.JBL,B5L\8PV\|X.|?)D\$V0&|910=C+*|&6A_Z+X_?8L5+J,! M_UY|+, =XK@Q8?_3PWKQ_M)
 (,2^(+ \$7XW9|[P8=A1X(YF7" ^,8.. '3*+0A> \& \HPZ7|6*H*Z:|F-U|. \$E M0- SA53RIKC?
 K9G. !/8|/60UN9YB|L|BKZ87. 'RN.)964UN'. *X+30'.2SD1Z:2_/A^ V3U'5
 MOCY68^.#KE>V|02?)B8K!E>QL+Y| \X(L20Q6-E/C\$@"VK9C5';H\$U+)U\$S-@
 MN)%JB? ".S|L|&1PHT.>1+HKCQ-P>GSM)H>35E44X1|6+%<6PQLJ!>LWLN/'0
 M*: \=P;7\$,34QH3.@ZS|AJ!N886<|?H>X>250:117H'GLZUI(?Z_BY^*DJ"FE M!WH=7C\$1K5;&HKI(80\?
 W&2&XU+295!* =K*.E@>UX32\W-.2+M?# 'D=RQ8G-
 M;.,@V4C|Z2)J=/P2LDNDL:+D.DX:HR2U.=C6;=4N\RSOH9+SG5;%2M^ M4;Z@*F-
 IS',K|XIX*+BC0I5XFDU5WOEN%5E-QX,-HHIXH|, &&2(9&V|!Q:\$_. M,!\$H!#EJ\$+A(5#ICTMZBAE)?
 D2\,;+87>%M\/.5,H(A,@V0L=Q9\@0E:97|W\$8Y0Z+Q|XWC7"< MCM1?I?.X1E(\:U1R/C_@_0
 I^ \S%L#_ZSL*%5X7VZUKL"017\K,C|'N.V(\S_MK_527?&&|_|L+/_A%6GYJU=\ M)EI1+F/6VUMK&|?
 W#>B+0\$':?9E1 PM|6)&.)2(R,\$KX|)2I.J2#|B2>S*DB MY0U1Q0S\EG1Q;#M%+ 7/,R^_J9-
 EME#0/7WTPE)YYQSMH , -6LQP:WJT04+- MM,1P5G8=+_ \$Z:0U)R1#)
 (|Z^|GWK;\$3518F4<8|10,T\/_HFBA1A%/_ R'TMR_M_9*V| ^LU5P1N*;V25<=J>|Q\$\"B|;,BL(NZ0_5IG/\$
 GHG"7@0G9D_R19CC_MILBAH0.91#)%>21(M !VAB:9:TF-J2&C706LHY^E|T>09/EY#SE^5K7*7!:IU35Y'JZ
 08A%,#D5T_M@\$GVFXQ=%@<=\$*WT&.-<4(\$4JT>)7)XAU*|#|D)PLR|I\$;,-0>AA(Z5&DFP? MW8%- ,V|GYIV?
 Q-.2*^ \^HUL|\$@PP;\$CRR :81%@J^ \Y303CUOR\/_%K-?Z(
 M0@G@CC|R\$, \$2FA| %9721@96"%B\39;X50@0P0^41.B).MI09-)6&+ #WPIFAMDY9U1>
 |'0*I&SRT*ELGGFU@WI>.I;J7 MY|K>UO'F1%=LR#K?>M2;*(9K0Y=(+1'C5G| |(@K#0.Q #&7KFEX(_Q&\$Q.:N
 M_G|T'S7&+\$^|G<>3 (5JHE:E40Y>PA\W?N&SN4M\$UJSW_MWC\;_R'-
 VTG9YU'T12G1I'(^S/M1|/'PAF|IX2'>SI; &B* LW\$X: _//(|N+G_M'G\1^9M-
 !/@6XV|ZY952%CHM|4D<:0:YRQ<, MV1',=N-:F'WSOI/H>S;!(#L!,>QS\K|C0|98'RGD?&TJ1%VF5'6_?
 ES^ENF_M&547H_+2*J1)G'/6NH5^1_B2+T?78V9&_ [3G)#S9Q#V|:6,ZKQ%9%E-DZWZ6_M?AR4#
 |9UWUKK\A\$N<9|Z>|*0#9?TM>??,C : 'N|YQL%G^*10LHDS&YKRT<=* ML68LJ,H2S^%>U#R3TXFHS^RBZP_&
 <:_ #P>FS057)8B>GU|L%\$RZ(!LIG'ZY+ M>
 B+ "KFHL83T4'AS|P_@MC>P!4LM|*KA:@Q+83P7II+B.EIIN0=:06FD05B39I
 MT&S(G)E&#CEQ"PXS^N*',W%74T|J,M,U6%"54Y3CED6<12G..T2)Q5'D'2G%#2
 M9T6ZIQTRT'(C\Q507JEMJEI201EK=*X599:9R(+ (Q+)P/%0'+> />A8>GB5|C M+=;K\$4R>3,GX_TPR?W:
 |PK|*,^/V:MUC;(|)NJ07_LAZM+63,CQ:/77TE#|P1MQ<<99NH<|.%;)| M:U&LX|ZRM,?
 6<5QNEV.CN>4^:N_)M?=2+RYMG|^" \6NSS|8T<7L#;|! \A_6T
 M?,9|'D/7\$8,V>CM|PH0E9J>\$R+/4\3|HJXLCA_F-=!,;X3\;"40" \6.XIG1
 MK8UZ6^C@;>/'GJ8Y\A=K:X1+WSP7A-V-LNR0* 1S\$C0%\$RE?V_M)6ED,@!.*WS^8N1U31\ -EQNG6
 T|3>UI+9RD) Y\$+;"0\+1)NL_M=P\..MRQ&3| |V3\1FZ8':|2TY)K7W*Q_0>%@G"U|T^%(49B^858K+|>|M'/_
 MI6-:(Y1;:T9W)&N<.VL:-37WJ/(3?%:KR">|P?L%(Q-DB_AM>0G_DC0+\PK3_M0=Q#GM:">
 <1:MN1QU\ '<." _A_8+^6X9_D'7CY-/UE!4A(GP'P/AN8!Q\$R0|H_MP4@9\$TI^;ZHS.:&DLN3Q8X'K-
 "WN'HZSF76)|7H0_M'2=%/5P_NZPH>8(M_",8F5+90!V|M2:A_F(I&(|31TB\QAIXK^TL|HT(B6>
 MMW7RB()4WP"!<^ @39&,P=15K:|IN#+VBC;7W&X0Y^?JPF/Y.E0!5DX1<@G_MOP1T_&>
 TZW(T,U+P+3GT' 'R|U+L*;1S|)!Z_5H|6_V'RP:6G07?9N7+G@| MW9>)K%1" JB=,*)5_0: %DV03/C@9B>
 |S@|S"6M,3S_PE'\$Q09YW\%+K0_M|9C6#2T=67@V>F_ \|018C"?+0HI8<# \8_P6FPP/X7/CDE_M)#9MJW2W@
 ,2R(IM3:PAZ|N_M|_- &E;C*%U4R3\DCXGN|S:"Z3|Y_ =CF>NI7=>(3_MXU9BM>M=T=@S-
 ^H^/KBP'V.;K(\$IB|KC2SHC'+_5-6;5:I8,"SI!>X7W^#P_M_-:U;87I>5_530\X*&&X9V.4E0YA3""7<=
 %>R9>92GV_MNT=B*?S^V%*G(I^4V,8I3V.P\$>0*)B-PGW"-D'YJ*+)IWA @3DLI=I|;8'6%_M?BB*BK3?<7Q-
 TWPPCG.| ^0V#S,6+JS0-NMU1FC_ ^WB>PKG4VNNL|[-84NB2_M6'XN1UNO)|.0W\$8H91-
 C*2X|P3*U,C5^2R3#EX#JH\ P|W@K#BWQ0_8Z!1>, M:;G-B8A\$::3'L6!>CVFC0X6"46"0:- \8/GR_?

G3MB4*4V(-X@Q2"084\I^, M; "6T@6D1910C\$P93BM4\#!%!.@Q?#%['UGBI/?AF8Z62I@fW!GR2J?+\$0Q>G
MNx; S/=9I&^5:IX0KG82*1]06M-9#-Q0Q=5\ (3; <#6#C*(H9)CR:"ESD"6. MC)_#?
+>ZJ&0/S^S^5\5<2DK_8<,9,8+3=@>S;*C08%- 'Q..H;.J >\|4.<\H*@!, TM0MFUCB1R,
M=YMRZ_Y605FC#W2%+UA\$Y7,] N[X(A?0U.3^4CN.5.M M2X#;^X_/CABRQ7]0>/|12L;|!|(/_N5;?
QKMVL[\5EVP>2Z0%#686ZQMNb[CD M39G5!P[I:CT^#<3DQW)
(L\F.2LG83YSIQ)GE/!EJ'NF^&:3 &9>CR1&PM:--;
MGYVJ+LHYU7X2/R>;,;|;2+CVKC#2N22_3/ZJ;Q++*W>^!'05\5<#;T+].N#+
M)XK(_4PK|ZZ8Z;V/T>*>Y|/EX.Z<"00G#CI:+.WY\)Y;Z)+EU:RQNM0L,ZE| M|Y:6WU07TJL^*0]=W_X0Y\$=0-
N8 MKBV#\$;E:[00]|:(T7)9.Z. :%>DDR#;/8>PY|7Z4: ?0]:C0HN*K,-0LRRSFT MKN*XL*2/^KGL:'F-
I.OACV\$7+ #F -GOV|7\|)'TUB#|V\FTC@3LR_P
M:G(L'+FH)J0B5D6EJCIG1'S<:B#DML0> /*:5>MVM>\$[(J#CP1H*M5^QZE; , M TQ:H!<*8T:*^N^9\;)6FF>-
S)%%^=N_1<@0%SC8I\N*E4S5!R|=-37W!< MS-PNXJEKB0]QFR\0.33/|TC|DC5#=-J='E7\#!=-BXS/NL| -
+P,E)*40BDS ; M34#P(>ZUF/?Y9N13*.HR4E*=I0!RF9/.PI|ZCR ^2_&^MJ|,|0A%8V6.
M8)|6'G|0948|54W-;L4^2K4HJL('0D28?.L8=[4@;]*.D"CY|KSKF|9K+ MR?CCA2@S\$5;"MFTJA@MIR&Z)#
| ?90YI7.NROAH13%V|=#\$\$.7\$Q/*-A|R1 MI<1 (#W8P:X=4&,\$=M'B\ -V.;!)KVQEGU0P'DC!53C>S8_?
Z31"& RY| %C M"2VI4 Z(S@ 605UC?_%9LFYCY_D?< (16K|7JCHFA/G-W"P&&A)\$-X_N4QHG M-
AY6YY/8), ERF&L,U\YYRBL|S-
8F_#0=:=#@5J#3;FM8JQ,Z\$B\$V|+0#5\!SI^=1Z:4G9@)7!4'8\$ \|C^LVV#?'0Y M:>V/Z+.;*=J?%?%G7=G*
<[6:0J6I(.TF4I8D08TIE^F4F4U#L-4"3Z|1M00&)ZKB1?E+(87^1JY_/T3D+F? MWI!=??Q;.,2",)'|F.C
S \|XZE ^+09_6% ZQIM>409N MY)K| [+G_PA;@WT+2H.6^GBX/N(>P-;B:9DH76G^*02TY,ORG(^-?
V521\$,0WQ"0Q:-5^Q+PC;*B0LR3 M6^..P_P0*IV1)T: ; %, '7_QGQ'\CCKY^_3UI3\0^T;U*Z;+F|I?5"HW?
P6K M^ Y0DSUI8 M_K/NL|_E?RY_M*P8KHU08^E=BKQGK4.GFKCIT,*G#9EGL.7%Z|123@F:W
M6Q+C+N+|+@&@29F3=97Z?V2=:]>JDK(Q3\$ENK?A)?'K<< EH%7AV\$5/@-U0S M>7\$:7W UN)4| \T0L?
#\+P9P;^RVDL&,18S(;TSM83,^+JW| \^F;S?UX=L^LC MA_4I:SWH3U3|PZ+^309WLK^3_9WL|V17R1I<(RX|I?<
U?_2P6B(Q!4+VGR8V M6/R&*^>%, '^"@CWF+LXN069WNG%D\QD2T9_0,"044T1X_AE*Z,F3THW2TD9 M.SG;
<| "PA/NS"/Q_A|,8_R.9LM=H;7:M\$N / \|E(.I/KN+ [C: 5W[MS|*N\$)VAVB7@R_M+ M0'<,6D5(YHS IA5-
+D3_25? \MQY_Z &W'G_K|;<?^00MQY_Z &W'G_K|;<? M_PMZV|ZG%>EMFUA|+|LKJS7SFUK3G?FP(B;E*I-
H_N)2U97L'8)T#V|!' D M_.U#B/X/_ #@UD8C&C46'\N3:|/ ^:PR6?_0_1/!F M_R,LN/) 'EX;.[P\$\$.
|F1CZQ|?WD0S(I/0Q3W\YY,ET^)V?S?T.3L|0\ M M?=/+>B?P3W/XM!GM9GG^JZFIOB_UPOU|@?
0!WXRG^TOEST5:X_B|J|S^6F& MQ"G&BK|<^+J|M^C08T _|D:8#-'Y9ZX^IM5_J56Q,3|7ZLLZW@|?Y?2P#9
M* <3??FDF'JCY:PEA_4|J7_K13TY|_T2**3|U_<?*HM0S<|K;-E2/_.*,T0 ME^7"FI1RJ(|8| |RS3_]|0A+=
|W MNH51QZ|\$19NZ' LH _K@P"?V5V=4'^8,6;Y=3KZ940;:WWYQG|_ |W)G^Z|" MF?
C_906G_761MJNDR,CC7^=<-03^R0KGYE^/Z;?BQ>\$'!;^)^LD&RWM _NJ MYC\27!W\$A0==+,460A21/WE_G"
< \|RUM@9\$!0M|\$ (UQ9\C^Z-3BW8_3\ MQ _M1T6R\E=8A.A71HE7A;#RF<-IJ;G7KL82?=538J M1*)>AK(?
%/UXGC+ME\$%'>G?JKR|M_1W^*|H\$Y2|5_ ']|>5&400-H/W-BGMX
ML_4?'\$5K_]=*3K6| |+3?|:N1H>#;0|\$V^M_*0UP5VC35C\2?4JNW_ZD5P_\B
MSPW>C7@!JI\ _RLV|/JRL^F\TU:CI2)2J)F6X|6CAFV?*|@#N?S4'5F8M39Q" MF^*)9'0A'V6XBL&_5Q(MQK'@-
PSR_N\$ _'+0/_?@=)/3^N1-TJ7FH-\?9 MCRN:MSXQ>Q|I\ZG7/0BUUA-7YQ=:1K!TTGX)8,
HH#WLE@F(PT'W@I>QXF|)%
M/*BT6A|H0M|5A0V25|)S:;Y\$K^H:GUM4EG<0"7KSX>A%U|E2C;:" N.PO'WNCFY4P*:'8GEA(5>'HV_X'10,%:L|
M|XYJ1)B" |U|CH_BJ|1D&Z\$.DM\$ 3I)0(" D*2Y<2.J\$7 M07H/G5"D)X_0")#+/GM_Y| |0= _X0GC?>
|XSQAUW_| '&>L8:R9K/7,|<: WF M*K|)U;5,^IU(UGFJS&KBS'9IC|S" 'V:"09&2.4=
|0,VJ<23S)9.+* '13R6(< MS5YYB9E*P.UR>0VEWN7S\^0Z""E!%B\DY|MC:Y+Z&Y4?B;V=|RKJWLJB94JA
MYAAH"XS,;%.*C7N2IQ|?|39>R!6G?B')@>0L/-CD>0_#;6>*7|4|66|,>8- M#8;:05|6B6&
|5S|N42*0C\$DL:4PZJA%6N"<0P9ERX_!37/I&4|!|XJMW+07? MH6\;PA7L%^\$TW0*@& \MTL'M_9M*;/N?
JOEER8EYSB^5W0C2;L.'8<#8IK; MYWEP)VCA6YN^AC.'_G("PT|L*5Q^CP?
BOLU&,^R*MFL'&^HRB/:20FKSK|L M"+E9>2C8<3MR|(HHC8+0AIL5X(52>24LK-0-
0|9,,F;J8_5|8Z|YY/67&Z M;LMVC>YZ&58?>;K.F\^2.=IAD?N|. @H/[FBB=AF/16.0\$D!0AN>]=([K)AF
MS='>%>37Q"TAAK0&Q]=BP(R&7.4V)RX3Y#>>M&U_+V^J_%\$7V@*-/@|WIKBI| #;I01MZ795>Z2G;K?
H5'+)40=P|WN_MZ9|=9D;&!0HCI=F?BZ0\= \F.?:4M:I42+= \$=3| |(QE2%>D2#PPAY25A&P3L1
MDH&1|G=\$LH=GCD0"--X+K2C*" EV*HC4"\$)0\ '!<3!-<(&*=_BFP#BSZ@T(Z M)W_1D\$U4H)2&5|_
_C17L7|PWZN;,,^1:0^VYAJ2-58HV+6)5/YEZ\$CL6?H9NMRN77|]:#=%BJ<;I^XPYK M9P-XAJS5E|LL;!NB3AL-
FAD%/*7;%-BS#;*L19J"'3|%. '%EJELJ+17G0C, M@&.X@,RXB*T5T| |, U_>
(_V5^70KEJJQ'(1Z0=51X9|>QT|V5";ND|_|33:9 M'Q"KKQ,3"0Y+)93/TW3&SE|D/0%CR>(3?%,?
PGUP\QHDYL#|7N/H\$KAM1Z"= MG6R|476I7|2*_*#?9&/6,_V=WNPC\$9=|7;3WV5U&SWUOUM/)@68*#W; 3P|S
MX+)-7"&,6M/|9*)Q,JJ;YV;"0#1-2M+S@'U9&\|WP4F;=E&G.QJBD:D3W?;/
M9I*|8S5#416ANNW"#_5@EKZ&02"Z10/2,|'SS.UHY/VQDC-Q'\F2K6E\$1X+*
M|X;MNAL\6PVIH,##*!WR.Q3J7Z6H^0;J..^|SD'EI\ _|1HJ|VCC|*QU M^L7.F0K-.R7EY\W^_IC.)| M*6+
'1?VJM6E2V ^@88D0J/"*W+=#3)G<L4"GR<>0^+ '%|D/F9*[0?J04 MR6MIMU'I|D4K<,>,*T6AW(&D5F3KB9BF"
+4YS1DMIU_B_7'_ \$|-@TNN&3RM\$ MJ| |/\NWNOD73>DH?7EIEZD-'9EI=(W:0T\V% MX_J,
<|L0ATC,U_<'K#G4;N/>,TL'T+8+3"R",F9;_0=@9-JR_CDV5V9S95KC
MJ0B3VHKLXQ%Y470>'PJ&9'C^F9J.05&+|8LQ?-(JL),T|FR(KN+9XZU0F0V M8/0ZV)4A<@I_43-KM!->&Z*8J
)P_JY', 'K":U@;(K9:614WYG9E=#+\$RG1M M!3B'+Q0@=J#0^=0I\$IHSS'
J1)0QT0BYJHG6;%MQB8>WIE!7=P&N*8)#19" MY=CDEA)M89S:X MG**[HWRC0"S<&?PUR"\70@_K2PPU?'?
K(MC(W7LLE,2_!0XV\5;Z^\$/W&NW M\$3&J;4)">SG0EJ4F,S|?5R' '3UI^4=A+|0X/K8,>
M*Y5DM9Q4K9';'LX_ ^K1%.;CR6)NQ|A>ER?\$K|'WR:H90QVA(S(\XRA\$=V:@_MDE-(;2EY=9-
2XT3UR!DGL"0<84\$VX2'H.K_L|Z,TISR\$PU/W;6'<=^C^V;)

MG0B50W23TT5' LJ\$@&"U@T)#A)Y.+B./TFF/JN?#ZWZ13RMM->RPI)@!*(Y M175Z-!17_&1CN7
XCC>YQAGYZZ:0/^A.G.AWX=3N\$BE1IAF&0(FVN7.;Y(*T(0A%[< MPQ '3HH&B-L:3/4VBKW.;2/?8\1W"AV\M
8VS M? LK\RZJO/2TBU+?L.UL+/1QM4MY/=QZ @M_5%NPZ1-G<\]"<[0&/N<;0V- M#3\J06"WF.\L
[6&EZKJFD:*WG@7.;>5Q6Y[!&S[K: \$Z-YJ \ EN> M:I% MW"&5079>K' NH!JF--+X2/SII,%Q^6PVH&M>-
M"ASU;I00ZZ0;C?&81P3X-GZBKB!I1F6?9H6:KC"2Q=VT#ALT\,(OM MXQ.ENJ20YJ12YWE&:?
3\$SC\ 3!Y.28+6?>^L/9L:@)+ "S;#-86= J R04LL8J M=U8+@:ZLSV!(3)!ETU?Z-
:=8M\$:)TEF\$A2"9T'12N *J M4NM8) B*QUZS*/+ [N#>QP#Y)Z)=JL]<[3L/Q\$MC.2;AE3#'200ET\Q\1H^5
MCH)H^1=M+- @X+=,YVY.V2?-0U/S[(CX:+!"X7GJ64:)\$4I\$@YDA+[#L'YJ7 MK+V#90\I; "C,+@+P'
_YI21\+J0-%QNQ/?AC3%41\$ 0(I8^HMET*E+9)ZF M[D#7"YB"4/H*/B.,.!#R!#.XM!"[ZT')NAEP0S9-
[?.,A=F/>^IV+V6#?:QS MP\$W[ZPSXH\$;=Q8 H-"P:/I.+Y,&%;5_T>[<(>KB(0D5S=]:Z:Y@5\$S*FUC>% M(Q?
VGYU9\$0"03!?.>.,1:N=IA !PII3M);4^>0<"<>;C>9:M\$G/(B-5=4\$Z
M141L\$ 'M9?:^\$@UQD<&Y%NE<<'ZE))P5)KM#B61R06E"P:L ES7BZ*F#ESQ.
M6>TP'HH(\ 'FS\$>T":UJH\$<;0K3'%&@7T\BTY&RJ)R0U(Y@TL#)0;%7&0IE MG'JWUSA:@ +JH\V9\$/'110.
<7S0SN&;JJ@D\$5ZUMZ(% C+X)=;B(2\$2/%2_8 MY*20LWX>AA4X*GPZ45IFE0/74A"Z06CI5!(MH%|L&)# ^B15C
MR;5+6W90I5210'L?*.6[X<6|T2:@. [BB%N3=L5V\$0Z96XEK0YK(/MU#/UIW. MJ&I/:OWD51;1K1G04?
DD@IW\3'JTU^W+!*U:QU0!J[*OK!)LT[A]KI21U9B] M/!E1-7CS##K<:/ 5D:Z^0PINZY?
B)+Q<+ #|I@U99>*-6R6A7-?B5J)1IK? MKA\$ 4: #L-+NDE 7%|XF@Q;TS T4;LQ3+N9IS
:HL+F*G)29:\R\V71? (FAQ M[X|?A=T91%'64AUV/39"8\W2MK[V/D ?^*|8;&!&6RMKPF2("E&P*CG MO;-
V'9-JI:4090 &VS?KXNJM%) 'OB?X)*\2C0)?K BZGD?OE/EEJ.*-'5/SWF/VM&M?00MW+,9YU3U8T316>_G
M*E2(L?V>)J;OI@I5,X.C,I+HVQ8*MV&*!"= =/P M_6?NT=IU(WIK5;|;0HPRY0WW-700G\9CCB.0< H?
LGOP/+ MFM+S2D>CZNZZL<26GWA'*RGI@T6CV,3N%,@;0\?HW'8 DA\$ 2U=A.L/NYXZ M-
"K8WM02%)>+6;VLASNU6+%#9LICH\NH9X<,7QZ5260.M#GB89;W!ZE^0N[MW3 M6:/??E-0?;WZ;;N6C9@
)H\$YGGCVTU6A[Z/-BK66F@;P2I4_4B2WVWM M4VCY&+S/WR &
("V9106W@T=TB8>]:KWM'QN'4\0)SN>B)Y_5>MG7LGA3:B5 M-?]*9,&-M81^0 4DY(@DDT9,R8U3=\$*<>OB'-
K:2;*>MP55].D\GVV4M;^FRF M]6 SP1 =6Z3V.#U[E9/KXSN- "?D*CRY1MH225 J&[8=<+;M]LL\$P-26|JC5
M>\$F5AP|H;8+7R\$F=*6K5QK(D9)T3 &GUV?;773*K#B& ;,% "8#(M\ (E#Y;| MTD9XV|/|YK-E7WY./24
|+ZR&4@N6MEA?X:>AQEW)P\2.SC)7HS+ MB;@+/M MX5X?3H5\H5:9IP!6]=R%[QX,#NFIZ/P6"
[%]/*JQ\ #T!@'0/7|GQ(#*?|E) M^E/MO&R(|'| \L
*7/^+ML]@++1<>D2Z#/"TOUQ64=UVMGVC^L\C=*MFIY :K \9/ M2"CY>WU?3;];]\$(,KNJ#3V!Q&SC"/.L]|Z=
<,E]HNU*H\$GL0+[2TY#<.28WK.#UXP??G9 M1_E9DTK_\$?D< N!^6R9 # R2%8ZHT)
['"X8=%YC9.*H_L\U>A^I4?HH9MS+@CBQJ MC(K7?,-20CBI@T6WG@I' *C'A0H|U1P-
FW/(V:I(|DU^*%W7>#4&B>3D?T'!F MM01['V_G7[KN&3R882SM6DJSP:ADPI%
W4H23TQ6+,G'#\16EH_7\$YU3T"QC M.2=U6D4#%9TJHC-CI[K&V!OI2[4C:(.QG<,&8Q:5" I#9
PW0'G_8@Q0H*C3; M8:IJN,0"53MW5V*!B4-2>5UTGZW>'3JF7ZI ;'CM?QMJD\=?VB M?YQIA
X17BGA.:J^(F\$ZE>3VD?NER\ \$V YI' W% G;Y)F6#67(U2C6410RRTDU=]ZZL=NM=YL <+7R-L\$BQK(|]X4+
[3E=[UB :**3L6;BJC^]*@ M@ \$RX024PZM+J2B6AE>?9EX -E=J.;H37K:[Y(\ 'GX<@*93BZ7MV1>10)EZUC
MP7D[7L[K^6>T&90\/)Q=*ESXV0[(L7#9-)3I|Q]=1^:DYG&K<^AM1?.9C# MF/,@KZR4\$,6XF?
8,]MI]23BU08DB^M:%1:8_B_8CRRM3_3NQ=SGSY%>./I+ M0/0\$R|QW(+7^?
&YMW20Q:&4KUE^Q\LMDJ1U<7I05NM]S_2T5\A M=Y+<6%0E<|)&=&?
LCRX0^67>D^T7K&.WDLJ7!94&=B)A%:.#+*X'Q|].S2\$^
M0FDEWK9+X.V3XBT@11G(\$!\$1V>DB1BFZNO+'0:W.UAKZT/*>8J"(4?>5E\$%0 M#,TB?
2C\$8U\$>2HW+8"Z[/;^Y_ZRUM'0UNLM_5=5R\$W>)+\$7C8M^14&'FWAGH MADXX:+S(0^XCZ6=V:FWJQG>+<?)Q(
|)ZP M\ P04)OSZH4=V<-NDY-U].29,2C\$ES+H3-;KFS],SP>UYA>%\$ N_G6EG_!3* MS[J87F0^K;?
E)*;|M@M:0;#GZ=[F7ML\$LM M|^QCJ\N%/R7_,SY1|9T;.SCIF;%BZ5KZ(>Z66+8:(.0BQ1BS5Z3&>.700P)
M1-6K+*!723|R%RRQ<207\$E)5&/WK'IYGQ;PS|FI5FIZG\B-47?/TY.)>F!(/ MCOU%/9:0<:PT.\-
!V\0/XDE^)9!-F8?_M8/XJUB*!)QS5[BB5KV>L&>5_DQ5Z)LHG|6/>3VK!HITPXY&90P32FJ('98V
MMJC\$'B7\H<11I091Y[-\$9:;.TB.=DQ.]I[5- Z6(*#AF_\$= CYQU6:2\$.L0 MN1FMPE\0%;M@EB-
@F,|JBH#0NP#S(WWIPCB/0:Z! UKU,(>=%DPCQV6U?PZ M=3?,0@'U(Y"TCF?U#%(SXI!^G_LC>2C% =,/A?
^II4=-6UP|@V#03@=E|EA M&718#>\9Y8H;.HR\$"&+;WNN!(Q?2S* WT?*@OI))>1P2'QNP<4S63&6/P04I
MWC/=,0*PG^S74G0>MU6@;7J>V/N*;>YT.B3\^P >ON)V^=);2." M0@QW%];>QCCGZ)]\$T2EUK*U0?
M3U+\4S\NQ|R|Y> G0:S#_?801U!];&7 [A4S#>?>SMSL1\ V76>6F)4V3T^L6ZW PX LOTL+F?C/N
M@+@#1D\$4[L / 7" ?E+'@G:\4LV\L\$- "MW|U|P@^EI/MT#IY, %N_J03,N MYAP8DQ_2*,:7.W0&^)]?'|Z
LHR[I2KX/UW)0\0TTVP(NG7(Z83M0%PW' \] MLI.'BILWUR|GE%YX7NP?5^<G/R7\%?
G(QXG/T9[S8"E5+\$_X_ME,32R%J^<I M8" @?<+(F"7?>5{(&C6IR"/"J>^Y7Z5DXQ6UU"NFV>[N?]
MV_85SP.%.IMUV[5@'5U/D\8%11H2.'TCQ40@>)Q*&).Y9;\,ZQ*HN)VQ>>L MJMA-
^D\]5WA70)\QMUZ=&>\$0UIC)=NF:Y|[/3#5>>,5"0136(KY)V7E MK@BCVV3DD3#L5_F.!K\7P:??
CCB!.B+RC0=IYRJKZ0?BQ7XI@=,?V@HTQ4JS M6/'R]3=1.'RN3[P_'AW_77I.4;D([BA'EX75:^42
!&'&PH@'|81,F^3F[LJ MK&V)L&M\$E>0,?&B;I5A'FB-3S"N,34+90Z3 <./3BGZ;!W*L2W6A -IF[^/*
M.BZJV#@A==FK=-0-F.YV."80!^YZHM8=4?FNZV!'EP<0KQ;64VRXFUA?*0S MR=QVZ?JG%ZNRH]*T1A?
K1,#3ZSXOM%W6W" H3B3PII/6Z3')G^PV^F--+UBME M3T)TLW%.EN8@P_*1:R>B3; 'W@DX=;TS#M-
JSR\Q' 7P, =%R?@'Y@0/E0&S*L;S1"IXCC@>(46/+ \&[EI'4*Q96S0'/S"] M,>NDZ-;13/XV|Z>#-
W1@HQ[MK4[Q-!'|&\$%0^5EI*/>*C9+ERK<'VH\1(-G1 MWYLQ*OG"#8*P7.;NTVL\)\U+G*-D1DZFN=
(0UB8#/\$^*BZ5L':V\S/. '1GY9 M\ V?J564QAS-;2Z3,|)U;|DR\G>7CDZ.(/5P'HOF LOT.U1H>J
M<'9< \MQ//8YINU^&N7?H':M1(^94:F5DF\ '6<\V@+\$/530!4,7K7M)0_G0J-?N_X3E<')]'#'=^
MY^79W019PDNA^K\$TRY112Z'ZF9;L/1V]>V*QWW\$0;ECMTDH690T(F1.+2# MN?R_G;8VN=HL'B?&.L|
[%Q"@=4507BWy.I">;@.SD_NXT6.6[%V9+#,V]8; MC[I|QZI\$003T:~/Y=W_V;|K/K+;<|)=^@AL|3\!
<;>]"Y.*[9/^D#F M"@!+\$WN.A1=)\$0G<[T.3ZJM&R_83=;[ET5),@ODX_R74D"JPXW =SL/4.E] M-SZE7/UN-

U>TZMW :HH@V\$WE2"ED"/14CY/5;W=,3C(%Q2I8#"('J3;DEYQ
MX/1/#HM7";V9N4JG^B^N0(KD,=9LY11+6<,(@DE@7 I44@=\$*KY",DPJB_HMSGK^050MXU'74 M"LUH_QH-
NLW:\2K)NF5*0"]@R,0IZ\P2IU[8?L=RY:GZ:,DUURPT[ZW@^:~"]LWUUQKA: MH+STST087F6B^KD?T>_XQ7:
[KV0+1!X@BFM80('XMEF_F QU2KG8VU!W@@.L M>%BS/V%DG<#!8Y23EJC_(J 0,?#F6GFU?
K6X2^9C2V0R*_3WZ'E M!,!UA@FGM^0&SNYEH106?DR[YQW=ST= & ?9_,C:B_. 572*2?RS'NCZEF5
M[^A]^M>VX4T1ADU7J@6DKBA@/_H0L:5WG]P(5!@2L!UL["<0 >W1&9T"KR# M3E_GVIE8([+-
FHZR^:7C*#JM>Y/,^P\H\$]48+;_B*+>:!6=[Y[7 &)9EV=+JV MDVGG_J.EK1V3S54]!3<>CHI>^=A*Q.JP?
R0;J'I C(JA[M3_RH\$%?I1@"0HKN"*&G-< %3/07L@[E0\$7:-,]C&SYS\D\$[9M]\L'\K2#F7W
MT<7Z2+0^AK65\$5^,6-S#C7Z#6#8TX0U#(8^\\J>-^HMU[.G>Y^90A8/CZ=Z5 M1XR(BJO?M('.:E-!
MG#}BQU*,==HCAMQ0):%LJA>V8<65A P!"=2NKF5:I"/;HX(8!GQM'>1F#1I
M\7%Z8WT,,LLPL.A9"Y=+5S%KJ-[=0ML'D")5BLSK<(Q"//M4S&0UDUYAG MQ;DX>F6?IS?
R+:7IR.8UW2ZG4N?X4!Q^ATU,]*2A:=3CR2EERMZ\$3L,7S6\$M M"U?]}Z<1PK2;.2#0,+/:3X-
*F=XS*5.]+>)W/3]^XPC BS+/!7G^A@QC0^T@ MJC-V()8)3A---"8X+:EPC.X10546:-!]
(3^(4U@K6[E\$2]L@;0@9BLRAYNOM9D?%!]+U> .DO)XT%T7AU7# =&\$+[9? MSPK[]/T?TH4D]QF[4M"F
>!/6M^E5BT2@MN\Y5B0-BCI!KR&HA(-9\0=&]9C M@4\$2>
[=ULG^N;4=>]'1RD'=M1,J096ECKE2U74!?"*J\$1V5"60L4 G&1WB/=7VM*>*UQ+LT\$9YP:4/60 W0%6FUCJ?
H@W_,Y=X4F M.P=OVT^RUTA0GV2V0\07K:R?U[J1L(>G)K, "F4J:?(CY]H8/== M]L=J1/DR_*QB/V?
T,JR<*0"1 -[E(V=F\$90WC U3],A];8F#*=P>R:RHL]8*^5 ^T[C1R00E%ANZ*P/"V2TW6E&L5>P>_*P<5I"V
MZ=Z1* F!HI, B)(R?+672F_H(A+G+V>N,Z;B[P V ,Q.7 \$/&& <&,NZEP*
M<#PZMX2:'7/,%IB3AGCP%<L5'63I[Y,6>[V\$U.)9*E]5+AF?6&@.YS+PC%, ML"
[9LN0&S\$"SQVMK*ZE*01PYBJ1J[(GT<-0 (IVCM<&X?>0>7##4A1+YPK?// M 5>W HB;L;8=
(/9!MFPL9^<^R9Z5F8*)&9&X)>7HK: -S?:/V/0*<8M4N%
M[5!B!9C:W(W+>1QR4LE#U1S6T9FMQX@*5=07VV0HW(VS4'8X!DUG_] '9"("K@E60I\E1DB[KD!R30MSV^6/"
MS ^VW[QB^,KE^07]\73X_*[I:@SQRP6)03J<83>334J^084X]K!D:2 TJ,87 M.#W3AF1\$'*0Z#I-
1W8F7X'YC5!-=7%0>K8TUK('08Y,[P,1G0A,!U&-53[%]*]0I02X0N);[^,C'RRS+---N2,
MC,\+8Z1#)'VJ%L+>6Z.6S4%;#6/7JN0-3/7N/-L>D<*I5\]PWN#D M&\$^[JUKCN,0;NG3^3>F^,C:
[P^"V&4Y5Q7.T\8KM40I7J'ZL/9W32S72\$&/S MR9MJUZZ]-'1W48,,=EJ0X2PS."<#:, [DRTMQS*ESNVM-GU<
M<@Y:=7 7T3K1+M6D)Y[FEXU0NPU8 31Q^UZ0KVKWM0D)/_8KR0?&NDMF0F]%
M'X^S^NY7(XS*LFYQ?,PZVJ=,?)P,3C@.>=%\$@2++F57ZLF*,VV7\7->L"GYS" MNQDX-
&73S7=JQ#\Z5PK>P.E'KLD]0AR" A7>]>M^_6FZ/B\20N:]^R')6'FC
M.MPY_H4RYJUW_(\$&QN+]U^J2945036.G0+=UCBE5A>9NR1E3"L.M/ %5IQ]!K9D]4:3QZ]SJ, +K8*919@U7?
NB(;/KL%+5)9 H ="J MH0#(.C.@-^!>=5.MIFF_Y>E 5Z\ " #!"N?=97\062JL M\$5N/* M6\H "0F5!-
QH8ITR*Z/8: &?H_CS_ZK#R4?&@GY#X?L% 'P52X#],\G J:Q MH= ESJ;3LHM
1\$R_Z^"R;10P(H,7;VSGF]>,V=,I&3F,VK'0'^?TTF1@LM'? MSV4I/)N-E,,UU,
(K;LB^AF&"VX_D\$K],2'^/"DDB^0\$;X! UIWH[\$LUT<2< M*EM\GCXW*+ 9-U- 82
"1BH[&'Z(87AB^"S]9[X^W[UI_I.]A M2:_%Z;*Y0)#YIYA&>XOV]+S9BEYG'^", "Y3\$L][S\8#)4=-NW8A=?
<=, 'G MU#8?/C'@%.B-EQVY%/=JI%MZ;9#VM,-,?-YI#9DX;EX]#?)6Y'X3C_XAD< M5#>I]?ZV=:UU8\$ _XPEL?
+F/K+;\$;S U\$-C:"W)\$2\$#&L=@QZ"00^?S-2T="H
M)C]J0F@0X6\$1)> "+@G >1S;RG[V05'G##H6JP]7I!I5Z\")_%[0"&#-@_R
M!I>Y[.2F@QA",D!MIMK0XC4=*27\+"G2(#50M(HSPWMB#9S?&]TOUHE&TDQX ML*-H6DS2,R+\H7D/)0[C3R?
F;:M#>B96@V\3]P]RU\FLCYUS]+., '0E?6?3) M[),%F]!UU80(JE]]@LG^A%="RG++J[7,K@U2-
WIM"FVMVUXGW?)FVFQV\$ MKV[.2^/-S =4/4="HJH0^340S'&[7]ST6KZ0L)B12W
MWY3K1I\TQT+TT=]P\$Q8D\Z02Y0^?90Y11)0>W>="V[?*;UL^*P00^3:2]5+ MQ]H!00'FV 37#-
!]>KF8XG9W?CR]C,:3,SQ^P#Z7[Y"61GZAP(/*KN; R;C M#3]&[P+G=[HS7 \80J409:(IP^8YACM3^V;-
IM6/0,41J=;MG<&7SB"MS-Y" M]*1./\M\$H9S1]A')RR-JY6%:="24DT^;L+?SW0XUSUD-&0&(-GSX'&_1!U1
M[ZU)DK4W^,B#U-U+H (-0R5'*])#G@NSI#%-#\ -G=QR]AZU=R*<+>TN>I+R/
MY&B1,0B0AWFMQ3H"WY18QVNI20F0ZN\$Y\ZDY M5> A;K@HVBH+G%.[>\$'DY)W;[\Y7WCH= \QR32 I<*?<
EJ@;I!^F/=X?T(VDG6@49X],,QH1EABL M*DE[PCU&K5)Y_P"YX5S;,Z"H[, >SS)6Z&E 0"(B\$AP";S-.,?<
@ARJ"0#R MWP);--IC"%;=EYW1ZGG&Y[E]S6)A9BR<*A5"BR3D/V+S&H\7!]>[0_80FLHW M,]H-
NI28TX@&J;]Y0Y/[Z]MFK)+K(QN#Y\^1]>F(0T,)-\M26EQ(6^UL>+" M'_.]\$TH6N&,\],I2G"0P8I9G6\?
69VNWFTV,0T(C\0R2T9BGU'1#R4J.G M&^RD4YV&@2QZKEZ'"SYCQMT=J.[7U')'1S M#V3BIBK)-
NB>L<[]K)K:&<7KI\$A)?U[B6*6U([<,J)/N5>#0J?0^E-/0^Z,\$LV6S^*U4V[YL^'3#8("\$B\$S)]5,N MLT
ZN^'JET*+8P.E)^?P #;5,LB;^"['\$[[\]99/Y19-0R1^0SQP]9VUI / M+KU^[)RQ@+(J\$ 4W?5JK)S\]T_K\<
 \7';*=K##,@##@5^\$UWY@9.] J8\>WE M91ST>?7(BA\F^:"5RW,W8 +N7@-JGT#">+D>/7H5N M:P?2JFR>
(R_9L0#J&D/X+<@+1]K;QH8T]?K]903,KU'6TC*-IN(:/DS"47V0Z0+\$ \]@2]C;1;RQUM>(GL5N*]4:20
MG\V3JB]0]A:;U+ T2',7YUAF+SUD[KC%0@[\$ \^44\]M%?\$43.Z#&ERC9EBR MM\$*4=[-
CB(<^<*L8;%;&%WNM/X/VUM?0;VZ5,FEY!\$NSBK+'BM1E7]N494Z* M-
H7LUI(KD#5WOEN,0,9S^ZW60=\$+E6PAE. !0F>,V8I(A,/3MINK\5YUL.Q[M G4GK1R)^NJN:<3SI:9=)N!
(B#%>&N>GD=#.= 'AZD5Z0^RDIP;Z\$)4\R@E[M,M/[3T:IDK.&W(D'(\C*RT;R\$Y@#N?&GN-0,Q":K]C63(?<
F]VY?*@MUWKD'X ML9(K!@ (B>-4X+F%.M3V>.,0J6%S1<4Z)\$=>GCT6^E]PM7RH:))M_XCJQ-G'L M>?
(XBTI8M,P,W3QW:52R1=&R6I@IXR\$#M_H COUC+HJ6=<)_40C;92#DYP]"1!4&,< ^ZA%5AXW_SA3 MN9P
R\$C0]]> \ [-;U ;]W;760K9K./#;P+%^"TIQ1%EP,@<@.FRONT>,I.ZK[M75R<:X1RE-1RW?M)"A
MR!E6>SNO_#%0XRNIB,SP(BUF+MCGQG>8/6\$N(3&P^E>S.@Y_8(W,T4DWDE7W M=6F!S7'8%Z30&?>@\$C5&IU5W
V.N5?*>R8Q'BT??>WW_&4G35:>>3Q(NB0? M 5B(N4C]AN5L:;+^6U%! "%!8X0?
G^".Q[HCYBT;2,&V4T(N#;+%\>0W. MPU9!A73G-"05-F=C;GZUL/!+NV M>2Y@/;N,D@4# 8"4.U^&M0&6\$<
#M3 3 :ZC5'-09.B3QR")=04*PXV+""^>)D5L.+()+%>2;"9.*XI/%0?@DAG?W4NT)2N39.E6WWA^<
M^2K*_GF5P>.PL+F2-7T0,(!V:]+BW0?D]C7FC=*TG8D*X<2KG3>%*YMG68D5 M;ZX8UKOI_8X1FC\$; 40,+')7-

D1\35KXR\$.>ZUE)}+%00;:'\4Z=SUL\Y6:\$ M3*^P7C'\$&)/_ "+M;D#V_F11 --
QH;>L0#IR!*#0>J00#LK^GK,8LN'#RRE"4 M\$LL7+2B1G+T;;_ 1?W0%JM^ <+7FK\"@0E%_ B0K
E|M&=N.^S"0[F3V /V1D=2 M]FGPBR%G80Y, U\ -AZX^SG8[.\?+\$4] (%'1N/S#6>U?X+CO!(@R30SB?
M@&GV&*.:=3C]/;GG/!&U?DN^1KXW\$, N^G%;J,N+=I66RIN_?6[WQ0]BB]5 MU='F=' J'#MH^*U-
./>M0-.EK7K';7AQM?AC/(\K:](F\$.069EZB MR;!]<6&9H CNTWCV*J/1TC,!ZEM*[4(+>QUCQ0_#0B(>1
M\^_0' H/XQ:C>' ^7F4IW6>DN'@H'*)#@=/I C(@I>WG928E!!9([4[?%APY M*BK_9---]G/'6Y57@
) -5DJ5HI6_0XT5_ ^4N08]%G_M,J^9%?S<@Q;7;:,X\$ _ M-
H:/3J0S4,]'7*%6"QGCA^1E+=PJ90H,3#5!0+.A\$>#GR:>.:!Z00=.JN.KNW M=RHD/EZ]2;' 'S1;UD0K5M6
%Y9P>QR20FM+SK2V]NT\$]D6)*#=-C-@*U@[\$Z M5/[RJI;S& 5)YH]/-703T;C'WX^)W+&1]WIU
 \CCTOKMS!K+V77:'YN?Z9VP M6)4ZL6'\U0Z=Y! [L^]K4G7]FQ1PW&Z\:->KMJU0^0)=-\$M#],RPHH+_],P86_M
KT&W@D@VLJ@0)I16@D5N_CVQ(K9XD51&7JP58R1V^4]UMJ7)*W\LCI7< W+ MJBWG4L>MDP0_}5A!R\F>CT[7*&?
^F1H!(/6TCX;\$TE: ^58;?%-T@?)I5*IL MH?M9FRR\$[UNMQHC&I +]LG0[D.!,!0?ZM40Q!I-%,CJ*.'Y9@5%
(.EO@/@]G_M\FM&>4[YJ5KR0I)H:OHT+'\$'.-+B'L9_(:CT@AU\$ #C//73_@2CC3IU0%65_M?ZI\AY:#
['2R*>09ZS_QJ]=&IS7AKKE0&IY&U6IH-L*),WDN!EMU_/D099 MP<^ (VOC.7B_:+APD1>1?
EB*S"HL_1&W*RM?0_!4@,,08,HS8'/U&\$!54,\$ MPLM[1^BK7?JG3M("?7-.<4BE&QV:D" W>3CITUCUA?
IEB!N!IB \$<+>+8HLZ+>U&MTAE" ME>-TF\M\$>2=9],9KU\$7.:BL=1<%C7FC@?:#!P26"ZOX)V\9]>\QW)K3>0\"@
M(%WF"*^B#_2(TJ'8I+' 'YL\$%9S231U'AK7J6U:VXB?@\$ABX^2EFLIP>833UN#0_00 HXS2]A1,T0SS6BR
M6Z0\$@/)WIB![U]DG'E;4R MY83!&>4G)5X'\$-6%.\$2^FA)SX<\TJAD0D#+R2,! _AEI5\;SZ_/W\N9S:#
M!#I?-] *[5_#)C"L#X300/ZKZ;VP>;6F,7I,+:*EZZL4L8=-;L4JS10.YFH6<
M4ICKR0]PA50!>S3L[,#N@WQY=@:F,+F,S&L^V@EY/9%R:GW0\QF1U35< ^ M90W@>F0\$MN6J>]-
RQ^~HX8XWNPD6M#UC0=20) VS<&+7,-HI"WZ(J7K\$DDT' M;+\"_8VU!0".A'/R\G,[I 66UT,\$PA#92&?
TQZE,3W'B^ (WI9,ZK@GXN#/1I[4"QIZFCW M KR<*HS(YEJ%*]T\$*'D1=3UW]_QC,-Z>--=8F@5I6C%*AD,K
M8XL*]>V7-/>8<9X[*%,KRW@^0_ZX)!X)UY0H2Z>/T"KQ(&U8*SSL@A>KT]DW M&*'\$-VH]'! =090MV54WC%/-
AUKA2RZ^\"Z_0]4I:;%KU!<0G4*@_NR?K60PS8 MG/;T'0!=-,^LV6BNLH5)D07?.T4-6\$&J#^9,?
H;W@FD3K+Z3TH-U2F[C; V MU8!)^L=CEB-0Y+.0^ 1.K9N0(MAIS/E MI9F=>[8I#_;<&5">]7.<7Y-HDPE
\$5KQ0M+ MB;[JG8^~44/Y_K!)0>TBEFV\=S0HC'4Z'6B%>>* 2F= _07\$H)4D_I*6F,\F MYYG(VU!["\$?
Y"\$0X/ZLTM&W1_0/CIL'B_I2:991,0(%;K<#25-67I+?JNP]R MGGFN]Y'>\1"
(^/*8X7>\ /A%K?]]Y5SHX7S>E3Y5SK5];#;/;7^VP;>XSD&KFG)N(>6I.*+?=A[\$^CN9H1MB'MXJ;7I
M4,G\$YHFE2I* <=R\6RL^I*4:;%KVB5L<5#;M&4XS>?:07-UWG&XLF -C(" () M?'L0QK9UCK=5200+C(QWC)K3-
\$M221C]Y;A807*;K4,_Z)5'\$-?H. MV*^ALLD)7W%AVK,@WMM(9ZF]J%H^N*]>ST=-.?+H@8LL!;?C(?
\$*EWN]A+C6K6V7*MYF\$R, [J80_%LU%SV(L8GA MJ6/[LYOWLR*S'_XOUN6N-J&=8)ZK%@NB+9MR\
(,)I,7PQ8TS0Q59T1S0XEXX M1/;:M] 1-J]ZJ-\$].0%J23>]WZH@)MX3?6%U&S<3LE*I\$/-;BUN^JEB'WWD]
MYF(2N0<0#WEZ-L\$Y44R4"[9EF<^4@PR#-DX.'. :>0^, Q* M]AM&"G'_U:%-9XH8W6%TK +;
(IT"*10X[L:/]/19N*.0/=JJU2T.6FV)CQ@VY MNW;7P\XLTf8&A\$]>4:Q<&J:*V4W@7>J-@DSS[FS0A7:F>
(=3GDS^~J?][KER(=/3Y^G3^ M8X.GCTD =,1B^9._>K(.YF=H!<76A=8IR\$6\$P%>D!<3\$@*#=&;V5@^_EV,;
M07G2[?+.@VS)]V-64_4%0P=&&RCT\$SE/;\S(?EP*%(3#R\;<10<+"NS_")<: M^JJL9R9T=W77+ZB(F'W E>
[]\A\$["D.CIN8';% M3*=25#]CX(!+U^2Q=&1Q=XQJ.Q3W] **J/Z ^M@ \&- \%%!XX@4XPM/("6L8
M98P00""LDP%BWI-M3!X7^6! [S*!ZG;FF\^R\$MNZ86=@G*8;]M[HPW\$)@=HJ,+.WU4LMT-/F1/-[/K+4)@,;
M^,%*[0_%X1^H_0\8K'4\$,>#%0=AMI- 6\ [R A83[7KDKD3YTKE2>Q0F9ZI' M1D8%RI?Q7NDD>
[UJ9GGM;5D#/=B05+X#>2.S^ME+)#+_KL6Y9VYR:S) U>!^ M5L[W?R6<)S."<3DI\$K#/CJ]
(CIXI>QU=.A&-00L_ M9^_V5,Z7YD6_N"M\$;@9PF>*RMEKD5IN#>ZMJL\$]0:04>\$T4\ /7<30X/] MK4"[>(^>P?
2#%@.J (7FDK2[?Y*%S%GMA#+ *52\Q0D7;%K/.2_GQZJRGX)S7.#KQM"34\$J7
MGD\$+N467]ZCB8>5'_ UKXW#^V\&4PU/9)X(WM M5W'[!8DVIS;C43XI+1SE]T=CS]Y?L.BGFG"=A+W*BN0C_Z]
(*;27LY//>0>MG_MA?_Q\ (TB/QG7#L3\$S9\;\$@_/3;K6JB'_1%)05HE+61Y< FM^,;W]YQDFD;]8
MU/\;LL2(&KT_A8AN <5_YD6HDYJ\ \^S5X7V]JRK?Y&M?/U3M:\$K M_X>RL2K!0[ALM,C_5\$ K^M2?T_0?
R:6^IL/Z?>3Z;:0?VQ84CJ\$0G_/1@Z_M/'W.JB/Z3WN4[A?WAR_&2\U_K)NV)X&0FSEG150&H"GVPO-'
@"*+N9FU:%S_M,!M\ (ITJ6P+JJ1(& N3%P1 M^H9)P'PUX]RRQ6*?Z[%_NI<4!\$ IQ \$ =", M'28_A(
YTHF!, "[A>%@8V;JF3^/Y41 !^@W!!Z-Z9.[& ^*5IC?Y#";0- M2_#H)#4?7\@1):9\&>ZW)P#^ [R+@\$CL!D-
 \^PA, K%=Z?P[8K541_/10QHZ! M\$0"CJV7G!\$!LX*J-K82;"?0?BF#_H,=#UTKQ_T*UK[+&*?TL\$ _!*,K^!RV'
M6/Y6_&_%U;\;_17_ZKX?WCT]JQ\$[/M_UI'C=\$W"N?DM8@4ZZ^VN?*UV,W;T MG!\$!+,0F3'G40I8U[WR+=
H]94,*P0A<^;XH0&)P^RG,=&+SIAN H#*5-5J M.C^'"J"L"06CH&ZZ!\$ +&>SB'FP'K[/K_5=<2\$_.029TMP->
(_\X\E@6> M6@)@^?[%0M7%VN77"*1G/[L\$V<-&\)DC^_P8_8"YBB8 PK/Q_:/X5/@%P_R*
M07.EYK^J_/F-.=J(\V;[\WX= @_@!,1% FMV@'4%!;#B]3]>\'"SW[+_E0VW
M[+]E_RW[;]E_R_Y;]M^R_Y;]0TEV\$]8SS_J#*6]ZI5]:LY M?U4UYUHUJTQNG5N&X@#!K[,3PGXHE-
'.'3J8SJI-\$ %?VH>@=<_Y-X#D,M23_MVQ5;!E4Y7[X5C2IS*0CB.U;HD.^I<5\$;?>X.OYUF_K9?@6DBX6
296_.H5"1 M?<.D>]>06?>]04?>0LC.QK\$;&V\Y+!6)03TF;[BK70Q_C'9F4H+X4W^46G>9(
M'Z08M<@S\$FPJ2+G%!=!^]N\A[ZAYGBT08B;72%VZ^77,<.4PE@K">,>,E_B7I2K(R5U<=D^JW\ [W=2^.)\
M92F@%];+>#9(#*#1S_H^JMB<_T_J2VIV->> (J!T7]INKAW64C_MTDIQ5Q\$9L[RYU%4:(P8LI<_&RW:%9R\,V5MQ
)I&BN4^Q1T#JN_V_M;M*!\A(HBD^M#1P[,0W7#E)4)Y)Z!<0S,WW>8(4P)@0JL>>F\]W'<*\$H)C1%0\$02N;]
[>#7G>D71< MKPT-\YB;DWS:X)"KS50!.T;[L(L<&7%YA_/3">R,I(P1\$C&M_M]W3*?[\B1&E;39B-LY+?
2K;6B0,\$!'_B=B>6@I5:4XM8S]YTF2SUMBSV-E1_M0HJ>@)W)1%>0>E"P).DKPES=>N]%=)U9E)*!(B+5N*I4-
P^*QD64.L @[\$]'0*) G%/\$@-3+5E7_,B%7+5 MKDS7&#
<032.\#H(/V1^;T^+/R0!29*\$W59R2*;!M\ZH.J"&KU:BM<^?Z8\$B
MYARQ/4+CT[V#^K*K/[Z96@RMU\.:)P]+^TSVD4>\VE&U#LN(-7*ZC)3_M#B#3YAVA;>
;1W<,DT+6+VWA)X'OHFENO)V3#<&T-CIJX'EG\$^_S:G19XG*]
M#'_VJTX=689HVA3M\$UY03FE[Y6=AT20EM+,5_BR_[6(:43F"Z4,N;_&8Z3TN8_MB&=AZ@FORWOKL1W<-
E>"ZE9@1U[1[PB\R),A>' [W_(&:0_F080/J5@J]EU2_MQ,*M]OJ/Q^,/YN%K8N;SZFSND_MY(QT9S>X=6"P

G.A6/X8'4/WF"=%#,H' '*=V ;(:+9@QF0E#-NNCB0>GYA5E M^P?
4UEPSLIL5:T2UIP2Y" '553Y)T>F.C'V4&;3GZTZH%=/#&N'Z_01N4".;.*
MFLX;C8\^SZ,]'H^9EZ',C#KQ\UXY')=6RH\KS4;G+PC)066+^FFTHI:%T10T M<48JZ@UQ'W4=%=J0U'2Q^4:N?
66//+:UA77Y'P>4= \T]*8G"&- "M8K^&XJ9WY3;L\$, [V* MS=0AVDJ+ LS8'H/&A\8U0;
(K:KSL441M)F2<#NQ!M+RW\$W< Z\$D9Y0\$PS)/ MQ3C+&&3F6D33XT_DQ7N20A1S4C!P
VW.)\^+ M41K,Y#D!K;+1I 'TOC,>4 MZIG=;S+<%Z 2:09B/7%Z/S4A>W -0 MY62KEUH7J^\$?
>Z[B+XES#@R@D/UOXZ-QC2DB.?3C3>_1CA0K6N."8LME68
M"MA.!K,"K@2V!;0&MP(J!+ZM1!0LEM#89D@,FHW^5%X==1 PUY^?!VF]"AHZ MCH_:9<>WI'FKM;
(FI,VRP'T\$CJWH8YB(RT?6R*;V\7NF(*"-.\$?=0A7S/C70
MJ8RCE%0M8#"RN@<.&F_R0CLAK9^@DN!0202+8V TSR)NOVXABI)IF@X)V*\$E M_4^9I.I[JS,P4/.I>WAE,!
<[P;FMZZ*PL0\$2%-M"QR8\$EL.&=T54%.N8\$< M:['5J+C'0 '\$-SFJZ+^)U7'+](LV/:-*36&*G6H\$TVW-
IT^232P/.0!(Y<>R+0)Q2YUS6-8>JN!76 MMK;&'E.XGRBM0,SKR6ID*NIH%\?7?9"@!\+N@#1
MGREDQYJ\4J/#;.,7+I:>C3M8E8R')UFH.X01V&!/L)A_Z\ (P0W>[NNJBB_ \$S;
M2NDWP* I#Z/W) C@-427%)1DSEN2&Y+@9VP^>))AL]:DA18]%T [+8G"+CC;
MJ6M2%NN_4S\NBH3G7U7E4F2N9Z\I\MZ' 4.\3-N*KCJP*Z8<&(H7&VQ?B(^E MD8>%9ME?
'BQREC8!K=KMW>H076=IGM<2N/FN16XBW\80"--,B@W/J(=.16*5 MP"\$XP.XV#0_L)Q-J>*=,MWC#,'M
8RW&CK.@P)M>W_I[[J>]4F@RVZ'\$5\6: MM=F.3]?48PP)&+PF"*S/'V,D&R>N)SLM?
9>A'YPA5PE@>_M,,T^_FR2L?E1 MU\Q MJ[\$\YCPB=P7W6J:@YZ9*07Y=M/NT=E=GIX>]KGZ<)'&B?
[2IP2SLPQ\ M)MY0E8M9Y2\^ -S&BXPV"548P"DXEUNRV_*I,RNNA;GC,H0AQI'8N<4\20+*N MXKS-
E\7EI^0467Z9[/+-,Y'/G835]-77NL6P\5PS[EUX>]KL-7HR_LMN=79U M!D[M+JJNK5:78^BB3ABWW9W!;);
[U,/F6Z'_*] MAL>)\OUB&VKJ(TTN"?&QB>QDS]X;J^Q WCE1;C@#@HL8[<: \$E.G-MB*EP-9L M^0J/X=
<6@N>S*.\$Z4%[2W41:[1]7IX"7)%!A08"F\$S)!B_=0C.2^"P['*!L M+
[JI*L_8IM['B579D%\%986YN0;26H_*>3DU4\&.7[!\XLF4A-S70M; H('U MEK-TB-
3^ORP^Z^0H\K8TPV732C,4_9?EU,'KV>.Q^;A6(?/_.';BQW7EDYS@T<%CNZ:)<[R5R]Y+^W_%G3H M\D" %*?
01;KWTB?N0;\$V(?=:91<*9IXI6JW@US5[<2+KL^/8U.4%(ON:V*G- M#++;ADK4\$N3#6Y0!5)_0-L\Z-
QYW+B@(:9.V: '^\< M:P3"=.LJTRMG0",[IRM;10%0CMQUKAL)5 W\J<<@*<6EN'I'MD#YDL+%;;L MX6{ }
MF/..WWJKCT\8S=!/8)S?750S5'IEG9%8,X\IK8!,N2>A(0?24\0S1>&@-T"6
MU0+JJ>:%ABX_B'1:4IN.,^;8J:W^WEQ6\1Y_\$/J!P*RB@,T71!;:Y145\$7Q M?
ZH)#HS3;2@['K@<*3MP.5,Z9GM0#[,2T7F2A,LB@>YC1_-[-X>G^)-I:[M&/9[75G3W0G8Q;/B_%1'\$!K?
AC:_1^?/ME,T.,*SPCLZVA[=Z'NX?E)6DY@] MP\$6X8D'>I]48MV>M1G.193L&X>7?,QKJUR[T; M_MA##!
<;^[2:<):WJ2-%N;Q\JS/%QV.>;3[0Y9@5*LTKS-K! [QX*Z.6JW? M0=3B\I? \]09)8Q07_U?6RRFP6+ #2B-
U=U&RJFQ<>+[(B4:PD IK"?M,,[>F M2"[(KAX5F^&UN*RH@ Y'-).A%98[Z-
QSC_OHID5K,T#0@W8V:>Y/Q3:] /MC; MNK*XE K\W\WK].+81?=(@L>>TPBE\$XF
5A27%40M0FT=2C0=I)PK>_E/Y-S@ M"LY;G&LS],*Q)K+\.1W/HK<-?Z%C7,YZQ"A;Q)U&ULUDDSJ/C
MUKNV2T7T<"\ "ZKT![LE/Y-'U/74/FKK\$E^5-'M^6]2QBX.36D.B90 @WXI, M:UV# Y,[(5GS.L":Z\0[T
1+;3Y;S0*9>C0.@#R>,*#3PG)6U#7:NM=64"@# MK,2U!:_ QKUB@8B/VI[Z^D52[W^YRC>.N+Z(B0>'%'I"%4Z]+
<#37(*U2H^&1 M?09+.3(CWK5P2S?6]EC\$0DDE+VNZ;_6-[JQZC"G[(YA2)6LKT0">RMB?ZDGU
MQ4P02_=E5YW%]-5JF:C"W,\$"4D0)P46AL.&%P7F;W_61*DEUGB*_ @BF:"[M1.\$W\$D* /-V>U!=C>4KM\
M3F0_EL[703+!8B[*;1(*U:3M\$K>M*/L)OJ2@N_KH1=Q@9E'>APU%,P<' /3 M2\N#[Z])EDVD09-HX,&: \;?
FYMBPEUJJ'-\X/,C;Q '>7.3)W'M^8H60H=N@ MYAE0\AJ*I'^)
<:=F2\3'+'\=I'I[HSIGHK1C*=+:GQS,01]\K2_*W- +6A MK#&WF8T=KF5+6.F\ L&-*P27I-Z#E-A-
:K,,S41><47 YKRO^/OY^AY"C%) M+^AMD@%1/T=1M\X9=-VKKJX86G)XTI=9PU'&1B9#2:EU3?.V)=
[74/07#Z^2 M3D\$[HI=*@NF\E+ 0"24S/X_3C=:2Z QBXM^D WHXX0B.2- G]!#23FWG<)\S
M.C+Y\WU+94SGU_2_30S[[0]YD2K!A:\$0Z8'00[YKN>XR0Q3Y#^ \KBPW_8?&(
MH:+Y7"Z2Y6L\$1_35_[-MM^J=05J_U !*U>Z^'- :L2H?>_C3A^T"!I?PBU>^7^@ M1=82ZN&EG)H?
BZ.! '*+=VY1@\$9V\?\$^\$)\7IEGVM9^%9)=,=WBLG@KV.-\$]
MCDE\K1H;5,JC@&QV>3CVB)M'Q20+U_/K5J+7./3:<;HKY6IPK\T4M<@>TZ/8 MD,4-
6""\W84/Y%S2<,L4[!]"@S#Y4%7'G&-0\$XS\$=YC0Q1R0_[C&'-'-]'
MB.!9RZ[.,=FA+'Z/1_M,N;!S)@)) /]#FR'[Z'TT5R!))IV-?A(\YT03-!VX8X
MR; !&6QP7[M86UKP*Q>2\6^=R0?QCUP*,A9R,8;(!T5+)6B^PD;[SR;H;,% M>(6:T<6X3?
WKQL_01N9=4:,AG)RN=3C7*U\7-^]7\$]-@D/J.C MZ4>2*09_ ;^.[/U-<:/[W<<;M!_YQ#F<-
QF4ZM;)]&6^<NTOFZW\B\B^PA_*:;>.FN3"ME_ID" I3?XXT",& MA.>N?
-3)'@ \^2E3H)_YWS04K7]=+ \Q.#Z'9TG,A6""VG@9W-%^UF^? \$=[; M] <#KKZV'+7L\$JM(M;
+J9%00N0&%\&1=DS)K5\$S>1GULTH6IAKQ"U>[W3G[X[_G",\PU" MJ%L,0\$-(<8JB75Z](?V!B^CZPK+\;;E]
%,4\2S?UH\$D&B0WBW9DZ M-[->9IT".I7= 8= !P.K>YX4V5MU#SLC'NA.P4%90JU7\@S=G\4(")^/*5]=?-
PP4[47][JS>.A MRL/963&E+ +TD0U,)J_0#^=:+N* >I"[Q]&6@*Q"(E#T3Y/P)=F8!68AY M7E/C1XI4"\$N9
?DM*B123W])H3JTU%ZS."A>HC<*J)7XR+' 'JJS4Q(GLSJ: M?4GQ/9;%MQ1DVD' '&];Q.6K@ (08;S'.5@.MV7?
1D] PS+=R=X9WPZ\$0'#E"E MZ/[N8;IM :D]Z-%FY"2+H#\SFX9>Z@-:=#?
\Kf@T(')8(0^BP/<\$L8!H@8Q7&552*<0H?!WF<>0TBV*1E0VLU;!9<\V'*!P;H0_
MB\BK9E=T4=IZB1IVSBCYM.+<;=0KS57ETB+F][3D].EM5>3Z;@]>U TY,B7 M<
[-^]+4;V)'XR&SC>6^^)5T;Z^,I5ENT'0=@Y/@&L?K^X9TJ[S! !0P>K5!_ M=^C--V[IANT&P1G9]X\:#&8?*>
M\$&AHEQK+00*Q0&CW?DEF[>;\@>C;_/#2[#M8<20Y*F6?:82.;#T; M3[+F5K\$@7\#J6N_"&>4J8M(2W@6H
8[;ULM[W/[:17\; \-!T]XF\!P '/')@FA- M651BM.^J\6;\$^-
[XR6W'N348FPL!H\YASV.7^R+>X\RMX^LVT\F\UY9W@2^' MWCC]
[-' YI02M:N=J5H3" _R\N+=VK*C\$0F+Y"8J\$ 3AE[VT<;3-\$N)>\$T(? M:5^9*-ZNX+L>U, L\$/M=Z_
CN'9<7>1^2#-Y\$QW&".4CA?[#Y<.\1>J&OZG,\F:4?I-R+.M&UQZG_MZ,I6<5N@>\$87*#
(2ISAH>^G%\09LS]\+@L^3CE\$ \1_% J?HJGMVU?JJA'I4J MY/*JN"&)6;=#V-BRPI[&J MT.87Y#3Z0<- /2*M

Z\EP:-R?Y(0::S>Y-T)U, ""/= \$A0['%U%B'7*Z;NN[+, MZETMLD>(IQC4P!7R&5V' [&PWX4"C%A?(-
B5>)\F7&8K4?IJ38SXK2&9[PZI4 M>'U, #8\$#\$ [SNX\V%XQI08TUI?;/FY\$0 A"VC?=%\$K)DLXK:/3AV<[X]?
96A MJ1C,0'\$. [F&8&@;U/4\M[0Y=@&QJXUB6RF; "G*&'C]1, (-[A+URK+G/'", L M.U?SX44QMY>@Y15#?RY4?
R\PIH0V1TMENY(-&XWW+78; ,AU%!SW&X02'Y&& M+Y#(=&G3YM,SW+0J/._9)^. B27^)
(VDIQOH*+>H%;N8HS0\$^*K(FFJ26:@=HM0&?+KGU M\2X/A%<:0J_9&SR([+3U?%@-U:J+NVI\$6WY_IC;?
@6%/K['E#EFU;' ^1^'US MNE'#8-\$; #26LTTTT"QMTN0'0(DL(9U*- ;!5P[:A78Z7";ZS:4V++K-[B_L^
M:XV9QW!D_%;3C6&,[%6E\$SKN\?&9:RVE0=JTY3(.K>,,YJ, MZ3E\$.R!*VA0
MY+; "X/UDG@<5^GA=I&>E)KKQ9DC!&K^YA8ZH11T(0\$?(QW+QN_U3I:+[14U5 M]Z<-%0^0*
MQ7V1*UVUU9BM\J96'%R_5;W+W^Z[C01V3?IH]@) T_#9%&JP[W'!FWR];:B
MBOA,%D!+I EU6[\$AYX0D&)7XMBY M[I1>=>QB4!/D))7,F75RA9T5Z0:
[U3D(#:T"*ZA2,J3094L0NDB]??,:30YR M?E90E!AZ33# MJ501WW)FE?/F7LV8Y>C7X'WX\$.?
3N\ D_V'YVR1I6^Y\$-OMN?:E07K!AZLR,L M';EIM0;:-: ?XH9KT21:\U\$5VP6^
U12P[0Q@/!F\$H.>YQ_E0AG,W9K\.:0;Y M>7XQU>W5)**9F#\ [AJ+TXB[GDFHGC)D,I-
EN0E,ODC@BYR'H\N*E7,F00=4Y MT+|E"+BJUQG#G_8A'#[P*H,Q?R0N9*-BXRWSBB; ,J5.[@FF
MG2AZ4\3: ^3]<6@K(Q%WMV7I: [+GI*N9J,P/W: .@S-1VTL\$8WM<0/>^LQ_ ; M(Q\T(\$]:Z-
)#PRKSN/:A6BG.U0=[704Z5N'?/ #(%HLK?# =BU7B3Y4:/C\$85- MCTQ0VS: \$H5: 'J0.Q* @)00XD2K@;=?
W%9[?]ZC.T1)"-PTJS; , [?>NJC<J?%YZ;:A-#: *#G8"3.], (09U+; &*(VZ60X] M[\$'6VVEA1R?,T7UW-
CCMMDH)09P, !+V;B8Y0!Q/O_W2ZM:EA5Y X>1, G'X MYGU0 -EUK>OI,H_1Q5&9P@;??I6T)]A ,GC5UN!
WK18\$#V,Q3\;!#2>I MKV^IA0";Y#IKLZ^[3@WJXQ5&=QN'RDP: 'S48=0'] M6HL\SN4[3%Y-7.BA9E
]#GI(I*4\$-[NN^YUBT#WW&E)S(=F*"NX02:F-+ \ MI\@RGA/KJLGW5J: \$4>P@<\58A%J_EK"[:6-5
M\$Z"AS&)C8205>3X0\$F;N\3S-3?@+2@ [1A)E&1*4>5&,\$GZ8R\9F\ -ZL*)Y
M6'<+6S915SS0*D%OBP,020& ;ATK' _X^8V;1^B4N5?!F61"]U7',P8^L8+H M5==R,:0\9]PV2SX=RY#
()";Q"Z@/:R; \),EKK\+|W?GDx0L?PX77"*-J>4;*
MXJ;*/X=.; \=&G,6W^)&MC3='0XIZ2DU5A9L%J>620[LL2L_C_?47P!BADK)) M(),9EZ."3]5&A"?
VP+;GP]U.:@5K]')G%' [P#M/>;#0_CD5WP]K/B' ' 4:B MM(_N0+>ZX'JWG_WL!E,#DYQ-2)'QB-#P1D[4"-
S0[NB[??9GHTWC7"N'R_&\ MW+VNBFT-YOYSCS'>VBI=& ;1P)! ,9+--
_((2%A4_L12PG%WA(H\@9V<=VX2UKP@S;E#&D9G=-;I[R.;.P6I MFC?>C)^!,:N6;;-#&B] H\
(VL,85H!+\$,RJE=QM74^,DDZ.1B MD.>Z# X@SI205M*;NN&ZO-FU9%LG?
W#*_ -1'\$*F3N]A,.0"Z"!1WV.'A04W, MGX\$1,=-YV0[F>?3)L[P9N(=UFFZ05VB[+T&'>4\$AHWI89,*F-
2F9+6EU3(A MY[:E5YL,%0WDG-Z9&&K\0!#@; #:#QDPGK%;,3ES00EI!'=A2WL3JI?;_H_63\K?@98?
DJQ\$6X0D/?; ,; ,R?;|P<-S%^RI-0K-A@]H' (?) MQ5H!/'\IX>Y=1%-7!%R(R8V&E+HK0.\$CN?
*2)6L;:Z:1IN12,@0TE4!&M,+R M[0([53 C%'JK2X_OIG#XH>E#V'M) *UP;@>R3,BRHI>SMQKX9JP!I?Q,^6
MEIB^50;CP[Z#/:/2%YEB""EY9,T22?.YE(T)91WRT-""D5A;K>0 C6W#6NL M^;3!Z\U8N[%
[QX=J([V(^615IW,/ &A7; .V0*S; MH^V?U#3%.: \$3##0GN%' .]QOIZ0#2,](+N?
PU&J'*PWI.0061XL=BI:"]W)P M 'T>5K7T)0.);5,IT#49<0P060Q\$S %;4^BGIPKAM+R.7ZPX^0>#JI&\/)V?
M2^S0UGF@&JU! :RB<3CLC\EMJXNVI*:7"2)+V5L1"P6GZMAY3S#5XFEF*S[CB M)^Q_>2AH?
LVNX**J]Q*U_YMW^Z131:NS\$FFZY+Q0AN>L9-UIGN_Q#I72M_V1 M\$AA7M">'& @|EL\$?YN4JQ
S1UM8'I_9X>)C-. 8>V4J80:JM-31SH]V,C(0, MG&8T39HKAGR\$LPWG/G&YW;2V_ ^9Q3?
^8)K#@K3)SHU/2!V4"6D+=_D9E4] \$-5\$LVU* M)T,]-8.NGIYXBDHH@3K3/V:-\$|.81VQ
0&]T> \H'EJU2EOHT,AG,-=L82C^0
MODI/+ .!JSS%3\$IX;1YM[H]R9U=%IGL0YGO338_Q\$U[CL6]V;:: "4%VY&N7W= MN_ ;WYJ'6", \F?+2^'_ =T=G!?
0@J#SDELE[7'0:W_C6&! \E>=*MMM_I,:RM<; M#9>9VYE#3421%U%^Y,BT%)
(BXNF:M.K\$8Y3J39WS>94/G>" /+MH0QAC[2:R\$ M#SVJ\$]+(BK".65<9JYKC>"0S0\9_D[S+[Y
)T3!TIFR/EVYW_K&^9K6B?)?P MQ1T&@_@1,)P9;U_*&ZG8YN7E4(-Z\$&E^6P0@LT17SW(N>_A8H(65-
-7Z+>MZ@HCV:Q27[??AM6YHOK[0P_MZY*YNF"!+?6\1]V4+' /++IG@+L@' ."K\$SKC]P5P_M,<\Y#TU-
^Y(T/=07G_M41>KIKO_U)]];K>0/>TN?EV[BXCL/12KR&JY89C^2_HR'OS/N_UM4]=2&=YM_M4&,IP>%
1#P.@#"#'=N(\$4E87Q\T#K!\^V'09NYJMS^J+3)IT>+<.0D^#K\6X
MMH")&IG!Y]P+|KI>C&DI07IVU.P08X%^:UL7_AP -C!DV;3MDJ@Y9S,MAZ: M>FE7H00(+;+38L7@I_BQE(6?
P_3\$SCUX^=1AQN6&,E4EXGMG3"Y45\$DY7%1R<@Y_7Z+)4.8=*0,0']7%9LI*NN_] MB2.57N_Y\]|?K.@9TFB?
JM&<*LII,M*&\$,Z/B3>5'\$HS+V'CK?,N'405%40& MQ:#GC1F/2N[I/]PG+J/\$TXFQM_M7IS'+-
KL03^#SP(K8PM)*.6^']=@,X(-"2_*#)=*;" /&-DU,109>Q_KV+849J(F"H7W361=> \V<" MC-
PDN'FOVOW&+0(*8I"PQ.C33\$"-UD8=A?A!@395.D06&=M=A60\1;0FQ_M]2V9ML*5;+VTE40NUWX"W6\^]U
#;=0\520\H!; ^U(MT^F,!'WI@Z0V3&#J4N/C3.%#*RTAP?_9'_CV;EX)< MSJ=1??[MB8H\$^X3\U\I@.VNSKS*+<
#-C4W@A&K#_@DV_05M=SJ56 &>\$]N: MGCN96IIUHM_B90WS3;M17P0)1YHH')RF,32G9HNU;0'F18P;
[ZC/\$)^TNSM_M:JP-[\WK%Q=-BQ.ISR3.BEX%CI\$<920-L=8(01^3L.-WR'7WU:VB[]5 <"Y1_M.EE>,Z9
]>Q81/_#3!.^US)#PJ"K3CFMVC@9&_M.3BH?<0RH\$.UQAN-"T"9FDBWS@YBP]59D;J:\$_4V_@0J]E;
FY=*9+N,]+<@_M3]' [.UQ:;7M,6XITD*0"FQB26F]C\$IU=5IQ-4E;_]EKL->WQ\;9Z1%74[:;\$_M2=\WR;!5E@MP
#(?87MNQ1=-UN6QLV^ \G<8!HF3P,%*CQ8BJP<*CG0--T=YIHY0>5W\ \BU^I+*FZ3G/I_MQ_>WKEHU6,N-ZDAQ7
/W#'^< >)GJ=&MN6MGS6JP6423#%G=R=9S6C=77 :US_M_ \^2\$#5ME\< ,X&/=AXQ^Y-!8>VFFQ1;22.LL@=
G[,YL/G+EM:9=,W-+0] MCL_\$,K?1-2U@6BG500N(^N#TL<)-ICP'-N>JV3A5A0>58L3T#D2\$NS3P*Z^N_M%
(D;^K2^2'CV*<+U([GNC0/E\,]_4=I<1J]P,B,OZ6&+,GS*K4SGD5R5>?X^ M=-K%\S1_#&6GV.RAY\$PUZ
M7Q\$]#;W=>#GQM[I840\$(D>AH.>M-U2/#Q[L?RPF+(63N'X@_C,UT:&WEQ(A
MB\D4LJ'G=0./^K]05JU8T5@X70)=.M_TDQH_9LTV2MH234RW@M\$GD^HW- GA/OYJ0Z4794XP""Y&QR'KTT>:N&
M>R/1HX40%5+E3K)' +E.2?HH#8\$8<8&6]B1\$ \X#H0!"8:/!YCG[]&; ,Q-*(V
MG@B:IM51XBDL_ X4P"*FEE!^8TLDML4QGQ,.M+<7]Q'-!_%V&0@FWA^Q.C"Q
M6G6F9S0NUO+I9'L.PNYZE;23DH/BUEN0QJ!;:KY6VYK55):CHBT?#_U+2==V_M\$H*<6!
@%LJ>MPT&2>U#Z6*'SVH\$&HQE%/VW3:X,KJ(T,)SH=RBID]MA5?MW_MC!OK\$WSJB

)%I@,HM<*4'Y4FD=U]*TN@ (HM>7VHF1009,=U\NA7XB TZLI1? M75/C.;R00;);CK?64)\6?=->W&WSY0\NL]-
+V+=0"0G M T)D%>HX'U0B2QI\Z;JG4R2"L\ LZG=*WV,)MN=F827E0U()E= ZH5,*<^9
MWC\8#0_&80_JURP)(Q2^~^IT7F2\ZM3.*=(^0'>^= MP%(2&JF.G87B55@-?E"2Z:YQ3;4+-
*N!,J_72C3C>+UL3SG0E_% =25\$ISK ^0.;)D;XE02\$F>Q;.,RR MQSG[-M.M,>&&A2 <@-
RIBG6V9CHC0BC5P;!!EN\E6W7\$&T_B!C9_0U8S M0!Z#7?V#E-4W?
0LI&P.#PA"TS\$GCQJPF'MXI*9RAL'J\FJ&00@_DG:"^G/F;K MSL+,.,T[_.Y)_05PH,@S=,
<422V/)D6DSDA*IA;YFHZNGU05 M+!DK\R;E5'5U"4A2L3WL(DQN6TFK\$)3TRGY>-?FM@%NA2"*"X\G?>!)~W;@
ML>M9;.,]?\$0\$%:.4+?E&A0YMD6C^4FV+ #N"3G>VS00VV\$#^;.=9M\ZY/9VN%K
M,=.*L4*K(2#1)M<;D3617\WCZ>]NQFAQ5,P\0\ (IQ",[N27J&01!B270E1W/ M\#V59+UA5&
[X+H9@LUM3V= '/YM!=88L8F\9%J +]IO_2;IDMHJB-)A(2_K<\Q63 M[, P]W6HMM"\$"/+HT+;!ZGA";M&G_4/-
.,D+2&+> M&NB:ER ECYW*T;IY\AGL8T=U4@XH@G9RP:T,[0J:VST"#/@A-! \3_N\K0\B3
M%@NG5*=X88DRZK3N\I;/'ABY*]6(J&,*E#J0-DTI>SD35)D(\$!<7NP ^UQJ+ M+?V00IK^)^G*)?
M\+|E'=0&EV\LFBN]"KS1(MQ)%TA&^9B04A=P;7.D MRE;'97;HS27UE-K^Y0H6PI009%DY16LK@
+;@P,40=0M0S\"%U,-X&7.YU(# MB OK%|BN6F1G&.\|=<HBS=GBHW_.8S0#FM%0=KVZ8TP?*@'C4/15F+0T\$?
\$ \$NB<-4'I@H09F:7F M\SH\$H6Q4"9.S#M;4H\WJ'AJ*HBA#+;K.W0DD\$'9<[5%#+<\$47[AU\0X#+!7\$
M\>@P/4 -SFYSR-U-!C=X60*M2\$ (Q1Z-94\$ '*L1KH1S&2D/T,\5N\$?'G<>* UA;3<%&DT7ZJ9E\S5\EW23])
ML%HG33;GK6-0\ (F-UTC> (SOB2\GD_)UH3GSJ%Y0"FKTMW*5N8NL\VVFZ76"B M*=@=N4NK_CW&?-
"RTMZ\W0B)32YH94/M>C;U47Z0E^*&IDB/[1\$=0#)U/C-< M=J\|YB)1_DV'=B^?
P&)\$3;T^T54*HYF9X(-68;V9CX)0?1JS9^_NVN\3Y) MMRW2ATJ[-+9HY:K?!:FHQ-X?/<0!T
=BU:P_ :)G1%34\$NG[X54JC\$QMPW\6 M3JF^M 'F=M'M'2'R5UQ4ZHE\IA5];\$I\E:SVU\$KKY;3W##?
24B_ ^OPN0J?, MM601T;F@F;42B\4ZK\#&QFSP;NTP08NJD16>CIP#5G?E^!9Y4HR_RFSLDKP
MTZF*\@HED3JX+K"D\A,JZ=4_0>@X\J2I[P?_% L0WAS5LL%!\RC X)R0\J V M>67TX+ + ^<1ZN,#49?
3^TW&_3'PSVN%CO;.)8 HI? \$FN^YFK5TW7;K;7*|TE+4ZY^;+F;|LN MOBG- @;.,+WHJ,QR\9-&^V;Z/!0*' #
[Z855;'?BN*8;3DU"PB0E9#0R(3=<[MH@_0WUCH;*RJPL<+Z;QF'W-9.1NAQ3AU(+1WS\D\JQNO#UP\$
EC[NF>1[C=*;SZWV\#_G<\QCR;0\|^] ^G5/@+ MV\&75XG8;^XYAH#B=N;M=]|_7' MPC%(GXMRSI^UJ(;ZFOM?
@?6Z\$! ?Q)+>37[Q52Y&&)7N8@G[U(5?%6E>>] ?U? M?2C&YH3\$0;LM7V"? (^/D2?+Q- MILTWS.6/S# ^Q?
N=Y7>6WUE^9_F=Y?'6>(20 "DNY NOYAKR\6R8>C;4987 M=NV3'"Q0A_3-IJU;|[I8^YA*Y0XD7@F03-
H\&25Z1'57'=-]Z89L\?9W8? - M\9C\$>\XND1'>4 @WRA4^\:P<2@<*GC0UG:YJ05\|D8X)"CC5!"/L0#/'84&(P
M#G\]@AEC[-=6R+^"B81F2W;I\?&N&0\$27RP06\+&V&3/4Z8(!M@=N&T757)#0X0\8XF(@N0XB]\$#S//)4?
27WA/H@ MQQ +3(M'SOB;1\ S_RD\Q3CHK&DWI "X1GKD^%L 0P7P6P" !?;!; +\% %L 0P7P6P" M!?!; /_#
F#UT4)50_8C^% \$P"/*7P!8_P. ?W5&K'\H..%D\?H@?;PF";3
MLK>7)7=N7K:F7N8N#C"XOP3!;,Z"46YGF\$'VR_9G'5!@/4M6U;8.#96J/NC\$ MQ+8#&[W3Z]=MCISB?
F"!/OPLAUS0\K\ PD# Y1\$9^ (!!Y_N%5-ISA'X#),%+70T3KHGM DU_5 M'[_[@Z#>-R])>702>DS"B@UD_I.<
9?D'\$*18D/!=\ "+>W^0(?..?<36;-0T" M4/\$G/2?53G& DD9@J3/SS\08?33["ND_ZX'Y/ZCVXA<
W_0_:=8&'KCP15P\$ MA>\$ GT/ H!@+^)_UL/\$?<)5,[/\ "%L_Q018\8^Z0Z#X@7^GP3!^U\A2/,0
M!,R_5%,*/<0!3\$ '@WP3Y39#?!/E-D-\ \$^4V0WP3Y39#?!/E-D-\ \$^4V0WP3Y M39#?!/E-D-
-\ \$^4V0WP3Y39#?!/D_0)#-?U+\$!!2IA@/0@R =PZ"-[>FU0,*B_M;V7\8%M39=?507.%W8;)W?ZQ?
HE%+|U)DS^_9\ S,3\NDY M(1!50.K:3/!Q
M##86K3SNH0+Y0ZE/[!'VEH'!MLR'AU\C'0]W=CG^G7ZGW^EW^M^6=+N;D5KL M>CC
Z_VPWAG_M3#A^Q8, >,3\L0@ \7F5\!IB/%H"2_VNH\MO^UP\$S (S+JF M\J(CKU_%*11-
R)M>&QD^2N6\09!*U:6=?;]\$2##[4\<+6J/I;#HUP%.\@*SS M\$:_|W,) ^P9\FC0-PZ0YG*)TPA?!)+/;&??
&A2[P%*NF'X06J7S;+4+P;(77 M*]_0\BD/B!\-F/<7W2A);V+TFS.]*L,%RF_0TF% MR\$>;AQ>S1K-
];,B93.*93= 0C#'%\$I*=JQAB !?0HT@550-^
^AT"'E%/G5G\$XH\8?;^W6=>GY0&^Y0(^)>>TV'\$9?/3,HBD!"*B& M>M_\$A@[*0>0T;QL'"D\06L4H+8>
(SZTGLI279CP6K_N?:V"/\J-?(GPGBFPFJ*2(B1*X0)N>2,/)B;8KM..WUE7TCW_M%0)P*?<|EA9
MM\@<9D*)CL\6RP/)M: ?H1KS\824RX)VY(.!|^_R.>%3CF>0BM_'U%I^)^DF)
M.&R.7KCJ0W\$NBS8;@JQ)UG;F6KCYDZL-3U-;|3-LI?-IP_M;N77";Z\08,17:1(22.<:N_EK9,*A'(U4%K_-
C&XU.+N^0FU\T-W'Q)IA M6JMH^0H0<^&H;0"K4N>.@!#YN66A8Z_OU;">*KK&7;1_W'"4SM6H=B>R
M6G_JA?JLR_?ME;RFZVC.X\#>;808X-<@/QDWIVCFH'II'S4*?0KIX;7WCV M^/Q+K&%PXHLK^X^9V4H+W.
[80=,"\$ /PI=4F1\$'FV?|";[\$1]\$3QVM? M\H;89.F\$5S>N&JYI(4(X%Z1>+T4#6YHHQC#R!?-%.0E9>GW?
3(W+*T\YY.F5_MV0+N"#)PE+4%@A8I6@;\$WTK@X*G<=I-|:" J%3&0R_4\|V2^LPU(4S7G\7R" M^GG%+&A0J4
M(C"!1\|GLQ\4?9>1WL=";-ES*5"Q\$YD/\$)F\$83W\|I:Y>6@,MC.9=0R>H\GI
MRG9;S90;9\$|TEQZ."R06A6Y>@7N'>=Z=C\Z\$Z_N_QHTTU;0%./#70!R,@C;
M\1(ILQ;!>MN059J\\$_BB3.%U&_90SR=7;0#Z+N5I\KF\70L83X;8K\|M)%!4: M)\$5Q\$;LD+329:M^Z\T=G;I?
M.1'[24"3VLH##K9XG;U6_K* &JN*'B9^JF\$ABYBP89/!\.E-8\,XJYW5>'BW*W5\$4_1W^M93/78X\XL00
MR1#QHZ6\T\6?%!BB1R(J(0R@-0'#)'PBISM:>UYU/7LG-GL0LJ=J.X9B^CJ_M:D8\QN\CH=?])0PXU\ZK8
EOGDM0,HFH\$2NC-!433X00UN@fW\$N00VVAS:&Z_M8C.(?PI?/Q3)F169*[3/OLC#
6R(68\=T)%*Z!+UAD"8YKG4> H;M7N%ZK7Q_M\&//\KJ#T\ \$*"-<5#@0:KW?;?!F-DK>@Q?3<8!JM?
=2#D@HX@160@XZ.&EG_MIM\K0V=,;(8J'ETF">0L<9_MFR_)Q)KSA@K??)?^_W!W7E%-?6&4#P*B("'
@02D@J#0I@E(2!&E2;50A*B!- M""!(D\$@\$I#"3TJ':1+26A2_@DE7\$P(D_,FH=YG'F?I.F=W\$2'(>ZF?6!
[X/4:F6G8\N;_D.0R"E(%_Z0_M.HUB@F)9*_^2,6])@OVPJKX0:&0U-_GSL\|0+X>D_|:U6A;@_[1W6UN%@U!
MUZIV+\YRF?R&!8G">=K)_ \$S0M6_2T80MP700_MX7WI/JI" T&\4+NS^N1+-4P1MW?ON>1,T/"9VA"QY\B%9W):
M#WT>"R-#3T\$B5%'*6P(ELZ+[%_3C2A50^!|\LV%>N+=1\F^(E<2%\)Q69
ME4_OTZ?!61G0/&7H_..*SHK9<:PJ_OPWZ,8B.P(*JW"SN"G;VUMMYYYJS^8ZD:A.9_&?_S7YX3=94P7E&X#+-
_X@AW5>.3\ M';[JN]H;:6M[BV=/PICXOF;N)\.^>M?W8P4ITXCMB"(L_8W600N1NX\TT^>_M@AI\
VW\QM=0VZ_G_0R9H\0E9_+T(!)5G\K#P:/C##E/H!* (S0-W_.F_7':_M.[-(G,W;99K#?J9RKT-
J%BE<:!"*B.DPBQ"Y.@D6E=VI*%@)NBV)H&%K\Q9_M,06)M15U4LQ-+X,NT6F)^H_.;,DY)ZM+_00?

>"\Y>B+@8M+-:;<@B(0.L^V"&L1PI;VCF.'VZLN;>1Y.!JCDJG77MFK
M4;]'LE3U8/[.46@*JNG#6@4W7KD2F2C(YR5K?5& M68\$0 3V5PX+E*[Z?'/E^7 [0.Z=,UZ"+P!-Y29L
!P'5^PC^NH?F?+73?D;0 M?0J[.WN\+CXGP:GL(50&\$XH2^CIZ=& ;ZDZ.)8L&DZQS@7&N\}DKD?M1=?
@LRN+Q7UE-A)>C#A8.\$5DK^=;EI;_8&696^7.RK<8+' .D+Q@J07G M<{P^
!U,V>.!#TUHE[&6JG(Y9%1,J73;1N<7/;+N06QV;HMA;7\#48 M\2W6%EK%KAI\;Y<[*0NZ"&?
JR9\$F'\$5K(//A2&M"C[G9-]>T>*0'\$=M%TK8 M,]:?"DO; '100Q"Y5A\#A/UE&(P1.RL!
<02.9*=1LFH23_I\$*',[\>6H38QMC MW>-4?QR=K%/8A+EZ5=X6 MQ5N:VOXHJ*MY !.[-\S'HMGZT4RI]49%,J?
07RV(3G&.B!.'.^\$UC*%5[3J M+&G'R/[Z=:T>8%?,\$8P1!N\$ 2WU_7FUN;(S'YUB+7'\<5S]. M4V6-
I(^/'#GB8@M614L@YZA77=!\0<)_110)VVO0!*VKHW?.C.6U!J:M190\$
M=Q@).@G[W&^N0&L)Q_E0Y8!@K!F36Z8("B?*X:JF\K7DUXAK:F;8@9=1H-R# M^]JQ2S^Z!\S?A,8MW_X0K\$
<)T4#?F3U#37/KT2F7A6J4,S#).90-S4@')^ MR]G^2?PBE@W_0[JF0!/JYRJI< MUH--
0Q9^/U^V5V5*C[7W\$-.R.>[\G[0KPFT]FFYN>[0G\$6\) M^G'@* "T#K6@ZN^E>5;*;&&"'^066<\U Y%7[LJN:
[W[U_?]?^'ATXAJN9? M*^<9APUNV%XB@Z1Q8;:/0J3?V06[^VL.>(>'0?GLD'B'*-8T#33G2TMD31=
MKU,0) @Z8(9E^K!.Y(T)G&-GVU_0?[%E_E%_7;<'L>])TD[<@50?=-LU[2 MP^T7J3,0IB -(-
I#L(.J.7YH\T#0D6GF]>WR\$3ZNL&L>54/.3:P?HGS MDH,74^NH05,%X@V Q(I&NB_9!?:\XS!/?^IC#7T
MQD0Q-TN)+:A/G#?;7-1)"'/0;5>1;0,:PLLL)J:8;I4-<?7 :];>6(0\$ZA]= MAA(YMSN,=:+*(*,
<[Z8_T<*G 'K,461VHL:\=+0NZ0C%YI,1K/EN6,A'7 MSN#T,Z!<_%Y"<\$)VN-D0Q1[+:HH>4(!-"*5R-
A'9XV^=J'?//KX2,0MS>F0] ME:;V0!C UK=:;3^VZHN5+68"#XC
M"UZ[7EKNR9=/F-F.N%Z:F\X<;>;!/YZ60^L:;9!< N01!< %MRGE0([U^)\R MR7[!@L+-U?4/%D?
5"/K9+CQ9UCZ3MTF\VCB^*]N&#%9[U>H+;SD-\G\D^H M?2N:8(R<0?DZ!0G6ZA=:]@AD=
(JLK8LSB:9_82]UJ1 @5/2RA103\$ZE0!&F3 MWZ>*HV\!2Z\$; 'F=M0!5AM0'>M\;\$;{25}\$VSW0,%-?
35S"61&E<6CB8 M%1 X!76)*[/NR\#B;^6I^H_#M[6WI.YCVA,0:VY70(ZM (Z&K137,X?!=VN M&R0T
^PA+V[\@X7N;'M4?)FZ9,(>H:% %#3)>MPXFYK:D#JE!L 1\$>NKZIGBZ\$NZ;S?^RBC-_XW_M_@ZF467+#{0>
<+0D_T&M(KRV0@A>8D(H6[!D[!S/,G\9/T/YH)?EURV?(J+Q_M@ "T'- M&C%?&TFZPZG2\$193K@6.S6TWH\$%[>-
8"4WSQ X[!SU^8I]1>XG"4S-5; B7(M#I-IEG"!7U%?QFJ0(%HZY.\J9HB.KOZC\TDLVMV,CN)&, NA7"D"^I"
<%.UQ MA*RS7[FMM8NYI8T"V*<9SR-1'"_PM]T0#)\UW2R"E^*7/_MU/;)?
H0V4+*\$"C=R/@6=3XNI%66YNO=#ED:\$==D!CI5=J^OJ>VPM"DUN%YH MSWVOSBRMU-U<\$-^4/^=FXS'?
_05Y@,"?NP'N8C\OC:('RF!/!>Y\)[KHM\USH M?ENN4A;/4#C(=Y&=5F_5^&0,+-_4@30LPLPFAZU@\$[Y^*7VH?
1.V&BC-33V MJ*(801N2_7^20^'"'"80V9\$*Z#>\?KLB5)TF3!"OR@GIFDBR/KI2Q['\!\$+W[H0 MF#.-
'UBNH?'/_0?6G\TTC?1\$(E-0N3YHZ/G5_M'\6AIMKP\HCU\$?5\^0%F-KY3
0XE%*4B\$D=6T7PEKM3M^C\BWX\EK-\U\EX M?Y4_,\$\MY\$,X2/3I_R@M1LMA/"7CZ78\$9AP^~^J:
X\$(Z<)6W%UZ^[\WC>UO_M]0%/X^T8)M<'7EKZ=-F-1A@*- ,J+NHL2QE\$\$_UTN"C,056;&V^W!=#<>A^FR_M:;[/1
BLSNDZ^>A.ZR_Z\$*,<4QP>MNA^K^S@3_.=L,>VOP"09#;X_):KXE\ M'^3"+4UDIX6;1IMM\]7-
UT\W,G_LE5NH9#LY)P\;2NE;R0S*!5_D>2EZ?S:U_M/^3=3861-TP+[V4>V)N0K3U/0>\$_.0.-C3P@APAURG?
_4E,90ZKWX\$:(&M)#8_M3SZ_SR)>G:0@N);9^>"7W:CB0^&S" M/RNI[=0U\HG80F:Y\Q65;><.S0:&8AH-
JD/.\K_EB_T]-F?;_.JA-#>N-\M/_M_1.@_*\$1!"\ _P/"4Y1[]?YJ\#;+MI.R&,%&Q&G?/_M],-
+_R_L8]!2*Q0I71DC;HS5;SV%(P0.F;D!=38(@I2\$CDK/L?#6=B3">4_M'?
\$\$.W8!GMS#TVS1@/OI'*K;T,YP[4\BPR)[5FUN06,L:)L_8\+2&=>\VST_M'GS9E[6X'8*7IYV2KG(Z._:
M:GXJD)/E?;:@R%X[CIC4SX53_!_.0**1EJKP;4\?/L?/F?'U\E) VN
MKJK207LGHCZCG^U.VR[Y]\%FG#NH"D3_X&1KHNI7TJC_F\FZ [!S6J_W)R+1
MM%A\X#)6_^D(TX8=]_ \$H<;DCZ-9_60*#^8@GP-T2*)0B./;&UAUUX3#;W075_M=EZFD\ZMC)25F;4?
FS/\B5=]ENC#1W,6EME<;R_L_C/2)[Q\$X0*:%D1@?Y MW\$^L^7BDGR])\AK6VJ>T;) USTY]"UIT960XR3Y
"4B^EX.0_ZU> MK"7,E4Y6F&=!V"A^>11C0GPV_M#LENXNWW=?-C66_VX&#^9*'+T)MFC&+)AV?TTAYTG\(?
=@9_84N-!A*HS+K\$ MK!XP(Y&ID_W,OH)<(X\$]0-6C(EU#!V>B^M=ZT7JF6S.S*0[09ZWTQI?^&\$J-
MN6G77[+;\$85+&LM@X0U%W/8(0\$)B\<8)SW%0=G_#V_Z5D5)#.=_30^BP\!! M9?[]98.069=%GX_VZ-
%6B^B^=*P?HN1X)+J;5DA(3/K^2)?U-R_4N-1E_M)L;T2.M(A5^W\SZSPJ*@EUH5"+".*>I-8FJA\C"
[;QE_2W0\I&L7;^*+1ZL] MI:<@)8.\] KBG\V9_'0#]6,A+HL1HNSMES:0G @=7. [IV1K; M;.%9VD7E+H?
K^~0)5YE7FF[/,>]I04\|E5"*%3XUL]:^;/ **@W!CW)]TA6]RU002ADG+-
\$B*_0+=#DV^S2*02_E@UC32"E&0HAQ.VL0L_M_1&Y9*)Z3]JIN*QM<#W+0SFIW^5BXFT'_X0)OZ"I\$D\ _K[:?)-
BPGBQ=6D) MY8=D6>DNWDF+?Q\)\$)B049CJN-\$X_ \W>M/W:.*38P%W[P?^~8+VUKT\10V"C]!
M\$,=AHK\2UL/!XJXU;FF"#\;<[!;MAC1\$="0(P'>&.P6D>F(\$=R_VV>QP*F#;SX.W[X]P]W?N]+T
M(E^;CC]_@U..Q^Z_S\N^XFHEWRS9\HY\$@:4^5!A7%BD%_0:D+0:*X?2A4"0';^F\$RLSU!'?2%;^;4VKD-
J>S,2(!?ZZ;\5_MF93G_[,41H7V<7Z=X275'6*-^0%#/7Z3_MP+[D4IJ(V87G%W[VPIW?
T0=!G^J\$^ML^D(",RQ,:TI=N4L%<@NI+T3VILQ2C-/FM2_MJ-J;9NUP?M[GY;V<<_6D%4P/5\5Q+X;<0D\$A?
9#;T MJ3R^]KBZ9,+=_ \$KWQP=5-#PFF_C;]/>(UEKB [Z]-KSYEXH*Q#66RU:425GG_MYDBU30 +\|-0/
XY)W'Q+D.L.-=?X4M3?Z7W2DBV)^GM@D&CB[4TPG8)N@)W_M@8?500G[2>P'%\$T+ M'_\$U"15=;]?C?>V<^]
[80"Q8RKI6<;@EN)(B\$7+^B8B*5G_444"5G!C;W%4 M^"\$ 5/EJ+T) 4W+?/[Y([,BGB\$%
[(S)AKUJ1G0\$V@]P^75>^K%W%7/Z^G_M.9B_] \HXHEEBD[0>,C'1W+^S+L3YG6U? K8&\$?U6QG)+8Q)_Z_G?&\.?
7%3LW,N0E\$^<\$?GT,W7G6(EU*/@&Z7E_M=QFY]=A!E>M_WR[Y* TB3@IIA]8Z!3FW.?2-
P=T@T6\U+/(LU)M=L&P0#>]) MIXKM&?0P@G7J*(,5+2PM/BOT!;,=,S;FJT6
M8&)\!^3K\$LA/G&^~IW8PD#;E=^3#%FG21TSN5+&_2?#8F\$1H?@LHG"3,&<'6_MMA-S0>N?6/*Y_-
K[FA]^5[=37J@71@!)\CWPCA4]T+W)/A125PM:-M&WS% MM'/DS(!CBHJGWX,KL@R4/BM\$ZR'_*0AFT_SR;!
#D*0IVM>N,>Z;95T=1R? MFTE:FP_16QZ*7U!U:9"(J?W9X*5QMOL9_<*U"A\$4*1>PY>UL28CF_+KZ=CM5
MJ340A!LH)[MT.V4!D<'U\I6K1ZY8T_\$/Y*]J7,G*70?EW[E0S!5RBP<=+ M!V9S4UAD5+L2]1?U@%\$6>M!=
L0\Y-&;'_BJRY2ONCAW_Q2D45I\,[\$%,:#4_M\$)MY1)_ \$GM;\$?N=9T9IXK,/G_TPY'8;&6NL1<1
W=0:@W^CSIZ"7'DC3MGHS_M3F0\$4T*K_>51'%1J6S5+3I4[+C0]KKAXK;'5COWYA?B\HI/R_!H_3?8/&D8S
M^I'=PPD%M;SV-UJ#G2WK?TM8[=B<6Z]W0/8C0',BYJRL\)_0*HX[R=?D,^\$ M]?

=)702F/E2\$M^W"QI2]]#BL]4%>4;+GJUA+#HV&RI.1GV)? Y@4 ^*'- (90
M;A\ES/:3 (AF08.VV/4X!#U.VH0>)]5]8KA[T.AWYZJ)RL[U6+\$UEF3FXUQ5
MJS>KB0S&B94G:T'''+4>S>8K&H6L3N@I,7&;-E".DURWJTD7. YH9]TSWN?@ M;# 'WL4P0WWTIZ0FC/R?
8'>@E*I)QZQ2.>ABGFZ0/K30*\W* -MW[4YLR<;9V M+Q9&UY,LGLCLW6I*K\$EB698]2LA%&#>G&0,)Z
=6A9#@@0FSF;* M'M@*JQNW3)AE)#N.M+YXHY7'30*S=+)7367VN03^+H'I:0H%YB)X9
MW*VS.:&\$]JE'=?';"F\$%0;Q3S@9KT0[G5WBXU2D&T1DD\]"<[A34"B5L;L" MT"?YGH(^ (-RS<]#-
X/4FHF]!04++6KS]\. *XM^-)<@<%U^J' / &?MC(*CP M),F3JN3;SD]8_Z#A3\"8\$;0B\$%+8?CM9N?
BVLU\#0M0U"BGH2SR8H^XL7#58 M=Z60X7P9>>6*?>LR-
J(;%8^N4LDJ@4MUM#/'+'!=UD^/NV^+&+::B:1\X (=R(W(M1 M=<,Q:BH16%D50EG-M(!8,E3NHC/9.INJ+XC/
-:<@5'BZLK=&JH&VI];,T1>5*T0=*' *P#04YDU
M3T^2^F^2^4]#TVN(_VP++Q<,]=GP9014#X0:K!PV*B!,*/\S6)]!(@#-;Q[;) MM0\$*64)RU\R++.'GJE@YV\$4?
1Q-UT+^MAN43Z?VSRUU@52**PAVZ;) ?V/N@R MLJMQTH\$P_6E0\$SU=N9GC>V;J/BM3BA*CW<"#UJ&\?
LS;DULPNDJ.WU* MTTG3FZ^!J06C>#. *Q*2-^2GHP?-V MXU\#W>YSMSL3/H\PC4+/!EVB0_FJ47+R&DAB)<5P-
+|VZ=I!&"\$L->ERH[,% MUW%EE7.'M:4S4E6J '-'P[]70)T]=C%4@*G;.9.%"0@N_OYGLR'Q!VDRU2*Y
M4[GUJY&';%)B_9U9WU->DFKS4#]YM9HEGDH ME0NOMF2C[]?2\Y%X*06&5*KAWM>J]KD\[]\^7,&#
[-1JU2<&]LT*6@&JW[P92D >6'J0\$ [Z"B@LR7J6ET*0S# M=/(5XBQZ'HYYF'F^;E]P>D0D\6B+
[,J%T9\240+%X8;/91:L'M0Y;ZG*^9%M MI=(;\$UYFX+.^#;JV3E_) =YMI\ /RK;V*;10!AD'7'&'8H-X/,
[]0?!,^4D1_M12/\U"UKZZ,G<0]\$UQ2B_N>!3/WE+[]C9^Y6J#ZGCT%LI1!8VFJ/'Q12;-- M?XD];H.P?"^A)
[GCCR\$A);5D_8]L00D_929=,;GPULQ(@/4N-!] *30%?3C@+ M0"0-8ZA@",=A!DP_7N>0VUEP;'Y)JY[Z6.9)?
>6;Q<4!C!0@3U(@T"!2@2Q&_M49QH%8\$X0P%C%\SIS^](EU-0EW>AM09-
M%6*=M *^D')3HB^;KI?[]42Q3(_084_3E!M5^CB\$UF&21*3K8^+[]+0=-=L MRF&=W%BW,RZ[
I.MJMGH\335MDF_"&V+=Z?;QBY0VMQ[0M] "GJI&+7W@M9E_MIZ =_E-0D=']0_D9);J)^+1252S*06CSE,4?
HLPW',*XH;5#0K3GK 'J45/VE*T_\$BBM>NNTD&Z'T#9!>@G0GL&U9G(<())I43_M+FRD\M.WOT_G*UM\X!D!
NS7?D9+Q]A9V6P99*VMFK@2AB(,F.4%B@/#G[MIJG"WK5!;89H^QMXEW8MQ/_H]/_0H+S'!-
#;*SE=^I0>V9"VG8"61(XZEED MI@ACT4SPZ&&#B'NAUN.EB)B_2SEK+,Y06F)+\3=*9()CDISN.;3&/CX%U3=T
M+ I1'@-XLC(\H2N3RVT6\$DJY[\?JN>JY%+'],;M-LWL[<2+_5[]?J.3:5 =. M&Y!(\$LU\$+D\$SP'H/TCR+G2?
M10*\)TL_W8#HV\$B\$J*@D#9I^'7(7%-P)&F'J M0M98M!\$=-E
UL/!662QLAM=HLE6^Y. _ ((*=R;*RNW#4U"=5J%1QE+*^1/'"
M\ _1%KWMGKH0Q,^51,6!6()BPVTD[0_K(F(5S8XC\$A*&MQRV30N^D'J#K6JLK MQW?B>M)27XDGYAI9?+=?
XXYCSU)8EV!&7!#7"\$S_AW_8-VVR' U9-\)ERYG M;S[P?;BW20!9.V'M[@=\$,!-H97+ZP&%+Y)*DZTX'9#H?
QHE]T900SU_M(H#Z!H?>)59\$00S9-;H9_1#G5*C#.6LFG#_X4^9ER'/QDOM,V4W6*4] 3\$D4_MBY/'=I9-2+5_3)
P0@J X7;Y*"(;LLW*0_JP["&3J/*@5]9?H20N8?\$50>L M":9]*JF4DY
;,0&%@.JDYRVIIYTY!)2;%]L/%3XN"4:@3]Q>XH<',4!NK))H_M.W[]:NF^|=,;P;15+A\?
6(7I9PN.'/#*HY!3&@3T')/(#KX>]3T,&Z0[TH_M[2,R(2>J-&B*MEKE=@5:%E![]+C=XMZ^!N[^A]\$S3QEC%T=N?
C_M0&=C^/79RZ[C!T:-THUG%K>=:7:~>#Y((VAL]A04C7S6\$F1C;';0RWV4AL+PW67_-?
_NRNJ\$@H5U<0*LT!YRU# MKM9/MF;!CS;I&"F1CB\4K6U^_8;Q>=109LSMY8QCAVE= D?2#)IHBRO,^Y*N
M<;X,[LFJTFU)?BR[-B0^KB/U24)17F5?>" XR-Y,&<4)/@M?[A\$E/-@-@W_K
M[[]+73;T_&,+=H)N+KX^UB@)3WCX!'K]_T_?WKW;SBL#YFR@A"#9';*4Z , M9TT5HS'S48<+}090T:MV0(
"E"?J.5-W@QX0@V9?A?F !"&L]HWM5/V/J;N_M.4COB)Y#*!!_(E_]U7@-
Z92*8""! =7@!#_5>GOKFPY0_EFEN4[P*FYQ7:PK)
M:8EC8KM""^* _!\$S=EN0#V@^M!,J100BQ8C0K54'U"TA1=U0&HIJ?")_5JYW11G?KYB6%;/DE)50B:9.[?
OU'GAVRX=;# M=E)U"G*\$7MPPG]WX-T%"^?/0^]Z")IH?JZ9Z1AI\CK_2'B^ [07[B_]R<>
M+\$AA)Y;3L(Y1#/A*-(?1530N;<+AAJ/_R8&>"X@NC25+^WI9/"N-63X/*;0_M:??>Q)_T
@LNH;)00+;.@." /M#UL]0G(J*P'D^46.^>,"_0ME5X+3^-+3T\$2_MBI1B-H7A!UHB ;3C\ _"??(^D&>),
MLRR\$P13X(D*;H)G=\$'4+&?X/MUF!#TZE6\$742NGVYY_Z3 MSPW#75&&NMU(\$4E"VUH!D:NKWO[]Q-
56IYH10!_W[ZL-=8]U637^,L"D?T@F_M'SVC\$^PI6F/5\$I&E_9){ZLCGIZ!
(S&UZL0+G]W=/05'9A6>EAY#.N\'(6G_9_M011;M0-
%IB7%+LU\>^"U2>;XD0C#^#I9@M65/UIT3KIR%M<+F\$;]_+S]W"D(M!@0/D0!ZR3> X;&"D.
M;SY#T234T]J3H;:;KIJP%L/:M3-/0GC5#WJ1Z#S<] 'OTIYS#H.BU;9-WVJ M*.
[WX!%U9);]]00TZT!2H)5H."R(1S44\$5AL/S,W#2"IG(+JN[6V07ZN"HUD MK1E.9\X\$F7JD'V:A?)?
*712%QH:>@K!V[T*I-TY!@_5R&CJ#=\$D0];_D"(&) MZ#>+ARC)D[G_4MTWB[D9Q*K5_Q'(_ :G'OK6_/\$5MZJ?
2TB9M2'DTH;QT:G8+8MI1<,N^AK), MZ[PAV<-21[]>];
[2=#\$2N))7KJY0+0FLA,U.4B/J=J!EH9PXK,3[]=%\7I"04D
MFZ2A+F']%\T4114E'>]86F"C!)LZ*ZZ=A**=\$GCA["0C((J_P14F>&/)"9?<_M,J.-N,L.6_<%;>/_LW]^)/6-
Z?&EI_E6WP5]U_5Y(VM,VXC.'>@:LW"\$ A;Z_M/]U9J010Y?S\4Y/EN#L0IN(&6-;^#%
[X970TZY>Q#P]SU@L^9M#A\+1J)X2;_M*CI',1[]3""R"4UBQ1@D7CVSR2Q>@Z
M:&49!3B[D@VI_>U,XT\$".Y=;+W09_MC'B).W#V/8\S5\$BM"#C)R<)-#(?
*'XK&BD[S4"7:6WDM,B'A_8+05,:W1Q@;_M7K[]:272RSDC7B#;BE%NZ%3-UH@F&"3-
%V(8>LS#J=>)N%\$6^")Y62YU*TPW1_M=)M4+S&R>GA.\D*BVJ=]PZP+*SQTX(5V,@9&F/1NZ)E,CA6KE-
0TU3%76_10>[@V?I\A/4C6#_MIE%"8"G\$-2_7S.VNIKD'J#*. ;I?-[E3GGD.9[BN,03\$P^/SK%Y5DZN_7KA#
M^BEHXCT+JL8L%,%/U@V:\$5\$#YK#H\,E9_ ^YB&?\$ (T\E;@[(AIGH.-L^Y]7_M8UYV@H?
%%"PMM1],PU)U39FPJ)Z*2*K,20-8_QC7!938>W]KB3.YW5:*#FX9'0>VMEB%FM5MZ?(Y@@)_BH:\$0@C
M%G6A+TIE=L0AL.1WN0[UUU8-_7E0.%AWRP1:W)U#W_6N\$M6Q_MJGC^"HH78,T !D?T_'NE0E,V;FK12;IG?MB5\
(7_Z\SIBI\$?<(B41VIY/.D, MH/TY0"@IC)B&-Z,5L'#:]E\$1135\;,](GGM3&N@!_'8?YMD1KCP@MQC,-4
MZQVV+(>2=]5G]ST9WGJN['T(?R)8MB;J&+QWQ" 6H9XNF^T'I,=J#_KXQ] MK1L_+,\$ '[1HVMX?,JF0&WG&N"?
[JL\19J-[RGF]UPHYE1JN^+_M/P.;_0&NHTT"\$XROPK]M>=RU\V%8>?Z3?^037_>H0X7<
M,H39>2A+FQC"50^7<6W^9UQ7D?/0SQA>A-Q\;<[] (=D.P\$! ?QUXGL2T7-PS&>Y3MEV.#1^]]U^*W!.\$^L!4#?

H_/?"K?0]#&, >Z'B1I'Z2CWX) M^/[18_13"IN&^; 208[_8^6;A6E7]>%U TLLF1@\$%LE>EH!
[-,TV&ZL/H0\LTl<34 MI*^61P@^@B.0BE?<@<@MOY_?0[0'0B\$-(E!\$Z:7=A^8ILA<"#*)Y.Z1S6:5 MBL*&
<(3K!46;6>4WN?>D V22L0<5P^_J!&H2GR7N[KP'L;&0;%500A#8*P@ MIKF5E_XA089\$Y1J]W-
C(>W%&2P3'GQ_SENM2_*MIZ087%G\0-EQ00#/EDM+ MJ@A2]-Q'0=]X:TR0>* _7_%Q"M\0%"==Z@-*, \$?E]"7#
^4%X0 MP044\$%A(>5/M"@>0D%\$7.N=9>G'M431D"RK!"/ MK,ZI!_MNL'>JU<4[Z1J
M'ZG>,9>0^ZS:NQN*JH5A\$N+1(*H8\$-%9_U8R_K0(V>VG&0;JT,@VRE?:96=[
MUB@K)FF#E">238'Z;2EzC'/C2L):R*OY<&K8G_Q-JEC|S3%L#^KV2D#- M077[L\$M)V]'YJ,QT2PF,VB@80;3+
M_181\$NG0>Q[#-&JYW[IS5-]F4C&VJ10(]5][9V1Y%A\@L*:\/)%Z2S&1_
MKN_R|RUG0QE9Q;Z1_& %/:6\$2TG/ZR\$*\$9&/R*:'_WZD_09R6>Z(Z\1E7:1?1T7G_M:!!1,9"EPK?
MV044V0@<\$?#|8C0\%0AZY^0J/6,D9F/Z+UDPW"7"?!#PD[H_MAX97GN|0P2A0:TX*P#);X+-
\$U0CTRw>J7>#;A/8;&)*=1A&*XYX[4G514I;C_MA;X*]SU67.<&8@W#!:??
X7_S'5RZBP2+JL'A[7@!/]J*=-.DGO!HN..8WZ0\YMI_M":ZNI1M-F5"Q.Q^?.R]>F94\>WE-
]06#U=M9RQ[VV2R<5!Q"M4B^RXX)*Q]> MMON\:_0DG+S@^_%'|ART^RDH3(T) M8P;
<8*)%Z;/PP0/ERL)&7=J!)8&V*)D_I;+?G\HX\$5,L7.J3\E6ZWGQZQ?V/ MG?
31]/\$5Q9JL!*QW09@H2E\!59L)F\DU6UE!D|KQY4GP\,U\$CP)OD7/BDAJ7_MNL-8+^M|I+%S)H>X5^!
[-2G5X[!T#@7->0^K*N6/J\$9 ('/'/?BZ[J]04!-PJ_MP? \$1|SG2^H)*H;)SZ=B_R.
IB3;60I=LW"t&^,F.V\$F4&6\$A1P/W%LW4>DJ3;!!)EM0?9L;NU_MLWQ?#5^]G'XXU0|@.F4WTG0QH>183'K6\$P\$
M?G6D55VR,?.I"J?;K.F_M-V,KZXZ?V|0U0K)MM_U@|I;@%Y"Q;(S?D+J_RU-M)&(|&CK1(-
>W:;2UDE(=G+J=-3\F&24;-G#RPRON@4QZX_P=;L!?C\2\.<M@H+!&LG+SF%=@8I>T,[T3GBX*?
RNT==;\N6K6>VWGI>S?H5; ;7'"5-\R#L_MST/DRLZ5,;##081I\<(5\$F.S&XPPP9Z"90),",@XBGSIW&
(W#@D8^ZU1)7E_M6J<;,3KA3^"B9M2'5\8WUO_]|B@=?"&+W8>LTY?23DZHW_*VJ(H'(C>V\$!>
M1+N91=HK\$0:R3T',15J_/C9=FLCK6*<>^K_14Y,5#;'Y3?4\F0%SN.X)!UC_M0UN?X_P83AXY?
U:0LWw#YPRC_\P&&2X2,F=;GZ)PZ00@N(IZ_.]5=/\$;NG4X[JJH9E2IRC5H>7=D^R^)]9_Z_S\B|!9%E*Z
MA05T1C7ESF@IE#5.-;:[X";_9<^CD;9D:]-PUTGMM@*0#C67=WU\$!+Q-FWF_M,,LOA*^H=5SN?L_?*C,]>
<1@S,L/|K'Y^#/%X0_3I<'*BX&&_M-(@(\$(<^S-XALGW\N&EC[']|S_F>1F<2SZ0RY"
["KK4W7)2<%9J'0"D=J;>@2[Z")G)0CJ*0U=|]*\$2^**;>7CK
MAQX+QCI.N945Y;^|J=IYEJ1/" :38DZ|@<\$, \9+>|+?"ZU|+_XH)+CAQ4<./1_MHDOUU0\$N=10P;Y<,RON"E-
_+#,60V=N")J\$U%=%!2;S+?"!8R2+JDD,/G<_A-A,>8W7\$TV!C/>D@?+&G>).J1Z8@_'7S_W_M<.4K10'=(B\
(U/3DR#1,7JXQN|HA)NBWKS&XIAB6I#ODCPD9^"(B3C07H-'=M=DDXF20|2A5WY:ET4|0)E6W5S90|]9-
S6*/YH=U<7M_VKZR<>Q?*>QRNQ--;_M-B_[C36DI74\$*M;5CKR|7C0REG23"A)MEWJC#/+Z(.ILK\ (CYQ|[[JXYZ'
M/[SKCT\AJ&*@W\$&W@P:H\$H3RR-GV!"P|)]ERU+;GT%LB-Z_J-\$C_M<8Z\?^ MKK-]"X";2[:IE""-
MM=3: !ER0&ZT29IE+GYEZ0^)]506*)!DV_X-%<-H@[,2I;A.E#K_PH2+"P|=X
M|~K4\]|R=48_DOARX.BS57WEWY#0?,3GWRK4TBAXK0(_M)0CA6|\$^3_*
(#=\$:KF0[Q+VL7J1;;;+9[_00&=E\PTLZ15V]'CG75J3<#-)1
MJUTUID/H(/07Z\>UR!020#TF"X,0;+X>63^+A0?F/+&%^QI=A>J|@_%KF/8PY_-F)[%6#_G8'@*_.G\4
M<0L0,*=?!R\$D6|0JG.B&'RM)*[%60%H^"WYMWX]%0H062I;A/_Z2;4\RV(+S_M|.R|/0)+Y1.4R7E.]+?905=*
Y_R"+^*;"PSB(B,%32C\(@0/?H>W-+9(.4%_M"3P2P-S>.0X7:/F7"3@%W0=H#0^8\$=|,D=8_?
V))!_3""0BK.491Q|8_0U5\$ _M6LW)6C,|!7EJ905Z+-Z8%]|Y=|?0=F?YL_501GX"!)NUC"@C@VT@W9JVVY&X
M>N++EF5U\$],I\$Z\F3K|+4=ES_-[E6P_!DJC-[4TAK\$"X;1U|T'X'NNH4JY,_MM0BK\$5DB\;2#RB8MX?
LLZ\$D>@(*SXJ+D1?<\$*C/((SB3-*2/'"@ZN=|,F1,M\$X1J]|0TDL5*;AA(Q\$7\LJJ,XVF&3J^3GH22G
E!)=XEF_M_\$4X^>M5.IU=@_M.WXGS?|):R1N_B>STZ?C>(V?UBM0^K3UAX\N^Y-05_&*/9%Q)PUKPK*LWQWW
MH";?E4F87?_U^X?@FMI_7'0(_Z)=/H>#2ZBT?+BMBN1C%WL
M9H_.N58+)!/V^]Z&;0R3;W\7'R03R_ZYM!0!5E%.^0:G\$#C\$L\$;?20?N_&
M>W9C44(4V65W0&HGNF:4.!019LU:WXQP=GKFV7"/9MY_Q|]ZSF|_531%M,;S
M67X&H\$00'N2LSG)1!/@J080P!|PP0CF|)?!P>KTK3?P3ILD0T1|2VL\$W2=#
M(2<'09|G3|\\0=:^2W:G(*KN,*UMWA|29,=JB8@2|W1\$V@'5.31VYTD#4C)_M'SC+P|1=(|+VPKOP-^,%BG?
7Q<)>"Z8EP+*5*!SWGOZV%_&YC*+9F!.28;.=M[227*1BAZ07+!-@D6WBZ,FLEHU?;U|H+4HK'@,3QB467-
^A0T(4Q^<|P21!SZ<|0+>I=,0'=3_M00E%(:XG4GTBTC1C7X36*<;TP5T37?NVY/#\9_V){0YQ2>
[8/N=P^,,FI;_MG(+^HT7I_/8)GRDWP<*TK\0C:^5CJ(NDF@'2K\$BC+0>:'^+0?6.]^^(+4_MT&,6M: A, I\$=\$
(I\BH0N)ZA"4DVM*_+FV_|@?3*^|7W2_^H_2@#,W|GCQV0_ME.^H\$*8.H^DH.MC=2!MY\$D^#'\
[U\!R>_L,Z"=B,C2E(_G93J5'_\$/P+^X3N
MO_L#>/^B!>I0<2C>UD=%0#_.;05SZAL!SS1/08ROVF,*'+_M_60(|RQ\7E4I_MG'_.*M:&ZQPJ?
DWF|)1ZP^M:&\7IX=XGX+?- M4S.7L330F>/W^|<8S|Z<('@;|F.7='B)S01F_\>%)G+/?BB*2'?'3R!5\$W:C_M-
&@+P6@*Z;.3HAF;\$_I\$KW?&R_H-;S?Z78\$EX%\FGX@Y&|0*|_05%TOKA@3_M+#=G1^10'!T=T-P\$-%Z64(&;1^
G".1E".V7A&-P;'_'8!#;5|*L--!GY+)\$|_M>*0:CP7WMNL-|IU&Z\E|I.
7MK%0,X#6Z83&L_).J>@+G_LM,9DRTA\$R*M2_MQJ&_UH^_B_J.<^((2Z="V&M\$>|
[4\$X\$9;Z,%_L8\$7_9*=>7'P5GE6V=91IM/0_MR?*J?B&?/ZY5Z0FQ173,&(80.0K+>+&V?JH
/2GM.)WZLR#K*Z8G6S4X^!1D_M?_H2M8>7HN?4EZ#Q[=<1?B>9K3I8.\8Z.]"'.!4FU\#H?N?^]B_DJ<2+^'+;
M!R: ^HTMT&U/0JL4N1N!U&;!J!_1B\3R8QV.".CE;1N,>DR=?U_T4!_X(HS^H6BVM1: V8W_MN%Y4_+U4-
_L4[FLMW@C@R?G\<8;VZZQ+LDN;)9?|AFSY;I1_M8;[*|=,S=@0_GX!Z_AC1FF002."-
>KA.Y3+C@)09\$Z4B7|9G!L@5M#57943, _M:BSQ0|2ZQ_'C)AC^YW.2=0L*N+I(24=WFY&C3D\$;8SMM,-
(^0E_!,BP8R4E1_MSYT|J;"9:%4M=B6I;/_(M2ZH\XW7W-\$.&=H\$0P_-P?0,?D)KV(K(QD%#\$:_\$ _M-&\$#_3)
0\LWH;:"E_D<=>0WVM0'9)LW&Y),_6[F!_7KS7=*T5D)H;FXDLI;*;2VJBQWW"4WHBR='^(G:_.1\UCL\$,?0N
)*_ML*#G#Y>5%(-U\19BQ#;&""_-_*'8..=E!(\((_H_VQ+#+8|H42S=Z5!?.7,
M'D[9:NA0E0QCNEIG|T;/GL'AP3">@V"! (84#JCA8A.5L2E\R6YV06|JH70F(
MX:50RJ8.SR/N2MRW5FQ)N\^OPPI"+.90+?(J0\,M4&RXD\A:VP3ZN7L?=[8_M_50W<|;=?
DB8;\F\DGBW9H'1'SM"CKSEAAGUI.'87Z6B+^K_HVBK+V-M6_M6K.12N)MJ*K0F+6R*GC?@E'. \$KDC/*99F0-

0Y[S@_9);K%(X)KP#8;A#)>@B M,N0MI =YT>7?*PL08\$B>OR MD'?
[R!EKIVHTUJI#M.WQL= _XEQ"M7&9LY0H6;LAT516F4K\ZKF%M**! ?9=VM M/;0ZHY5.CT.&ORV*;;\)3^Z"5C-
%'SZAR2=+%U5A0IF<.,\;?/(N4C%:U&,WQY6"+V 3:)-8-U34V)(! "C=24V># ,MPY=5V=63DQW*TW MOCY4?
J*N74RG]?0:" 3B)@fWF@%2.]&HZIRHI0HZ04QH#Y118M'UIKZ[M _[02?
*V6FMJL7+)./G)0^ER&,.00[6]070H+T2P>84W8-6D%XI86@;NM=KS _M;I&RA?
%M\55JQ2<'[)>J7T@=>[7/_5XU7>+1! TZ*4(Z+9X)^KW 6C>"<'?R M\$0@%J[7:G'67\9\TOK +T63QR^"21%
<+UK#;.%R+[''9@>4;J@,23!%,6H&MMZ MBVC# 'K7(6EN,?[7KB^3H%F>1N(K >B)X]=W'OF'F!#'?
J]\$A61>3240XCE,0 M*TLND-?VT8DEG3 >-0KJ&7%[VBD.D MX2 ?J!#JM)<50H58U-V/#\$&R[\$C9HCC!45
M'>A,3<26+E0.ON>-Z_EU=,A18P#VY ML,(+ \H//D6RN2P+MT%"8W5(>%"&M!][8 M Y>%^0)?
>D>E%T[GYJR,ZV?VXL>A^IOV3(2\$""J;'5SI,5DSHINLR7@0&+E3 M(7PEU#B> _7I/=F2F!.*1(LLS5,(N)R!JBI
M)-P:,20*,*MZQ#;QN47#NR97=R7%G#%6/T5AB7X,XBD?CN22 TLBK@+=2S 6
M#%\$%#0<<&LQM+RUHGFS7,YCZKES>@#T^H7M:GVWT2Z#9'\S@A2I#' BYN%L M7/!%A*T <0A6=5M?
QKB6"1Y'/HU/(E?Z63MC.6 ?#00PG[C 7GR3]#+YN%X M>UG@:_.D4).!R1%NE5D;L8F0[TTT9U7^R?86SGM6>S
/&4@"53%*4B(W\EJ! Z>=@X>\$0:Z0'9\@X%U M9Y^TM^KC()>"9J%G@ B172SL0;+,PT9I/=>7F@f0/ND52LC+' ;
MY/?2,8[P^='QCRF>>I^B!;B2W>%IRT4T,SW3280:\$^/#,XW_F9\$&! /Y'^^;^ M#?6ZQ_&)+C8QH6BV7,
(6,6B[3")36XF*(7=B(D(N0R\$RYIOD3NC"+ANY),I(MQI
_XS)N36WL<=EFB#\$E6X89,K[,09F]SD_G'SA[K;/.#^ \X%G/6N /Z_6L
MSV.Z%5C+TYX:LEXY=M!;0CKG2]4NUZ.\$#7038HG%59P;+^8\[-M'9)CZRK 0 M=Z[=%T2\$LH97YA[K*
_.;:DD2R98GEX<*\$W9)%3\$MV(QSU%)%0-QA?9(7SGBN!5B4(/EQP%1\AQH,75NRP'
MIXNCF(N0(Z9C8^LG ;2YN[,&'GIG9T;:)L=B&@B0>M^ ^NT*XNV.SN):'W(=U M\$N))T3M00U-Q4B'
7LPRM4]DP#V2#5 /, *-1DFE36.'3!))RR@,+;I9P9PGZ MY/#7R1TGP?<'EXP]TAJC.W8=T J_B'_G/??
^XM*42I_#^Z8;JK&\)0,4I6LQ ^LY8\$5W0*H*8 6WB=1FG>RFG>AH3?903JA\7E&FZ6 M[)EY?'P*]
<+&E\>P>XPSUJL/(00 _1'31 <=([B^Z40C?EBGW9-).W '#GHY
M^3L7%^YDLW3NG%3AW>+;UK+RD@\$H[@+^)1.TLONP'M0]%^XA;;90\$JLC!TQ5E4NL!R M%BXC4E"]-D')1U-#C
X3]27HTUK'\$TJ4TQX"#VQ"0/)KI\$*C'4A*FX[35U)&3?TXS1#KN+[1F8"MYG[W]35"VV80(
M9FSG.00T]M&.T6C4+H0!H0X]('3F!\\$%814R *FPX SN!(\$Y0]+X)(? ,^XB? MR-<<4;KX]LX#6?0*A^CH
M6*;P_)K-B'M#GTX)X\Z4! ?R5Z0]GK!RE60-5@K:6\$11;X1F8"WY MF0%\IDDU1!7Z?]
[.UM6R0U\$)0;Z*49;!0^*'[D3>@P_#J* Y[HM)\$RK^6W':UGMXV;P0M=TXP_Q 6" MR@)%A'W#,!#RFK[F^
?;0X%6)W"1);8)VGJEN<:F9UUS=TC?0<"43UV?PS/ ML56G0YZ%]B19,NW!8.;:GU1,5RK_V; \VW-
!.V\PRT/Q7U#\$"ZH\$R_I1S\ \$L M,[M1MD?2-@0\L@U96N,>F4VG;\$/RMEY0=)6^BA0B C[-]Z/=6U#LW!9E]D^#
M=V&'3I,<5#8#93LB9YC'('S36]*"&F&1#M; -*I.+ MMR%2,'V61;&;FGG8
MR&]^U_WLTI>FR>+/+ ,V+VYGXBNR[OM][?>D'T661NM_Z*G+)Y>]=96F1)>X/
MD1;7[Q[=,8%\5D&7RLNA\$.PZ4DNF8HY#DGI0C>643!J MN.\$?E7M7\DKUA\T<;'IVG^&
(L<7**'(U9/S!03&21]IR#<FKZ@_CXZ_XZ[IZ M3G0%@.I,]?MDC@N0*U MF27+""RXE"-
>&&FIF/60BL)/T\,]AWQ^,HBLB+JLB@]3[<+^T@, #N?+R3>'[[X6,)C^6>(MBR/ 2 MVX65U0)=%2\$=6F\Y+[*;
(BZI J? '#@<DRW[7U\BP>U]]QK<1,:3^(9?8>>6Y MRD>!"PM-
)>KP<9)DAA.]BE.)""IJ0E3G,99ED8,J\$(-2J3Z0#M-]Y)W=DL9 MJ9@&K=W5E60!8&@f6J2J(GS8N
WAVX@4,!.I)!\$@:J_AJ"WLR;]*2L]M*1>0 MA1X6#/X[H0/'J-MH+}8*='B.1330X%\XQ+0GPD?AD5P3V?
+F%#>0;/5 64PL7_OXDUS#K6BNNH.?+8I]7H4* XU,0 M9G7!\+V]W_;>30[4+KW5*=(0ULUQ<\$4.TA6ZY7=F_)
)@.80I7[-"MPHH!>CQWW_L:6%]JI*7' MJ+@EQ**T>0R35N:+\$E?JK5@*KA09.)1M)<,(0@%].=><&CE3
]EKJ0^HJ?5 MU-904\$D_Z.<2#;WRK+5(;8I8]35!I./4MI=.Z7VQT1(Y0:0G?F!]
MY6D\$JM?:8A1#]+WI.@H+; 'U;:EF+'S5E2#9"]IZ"@] ?92R-0<2UP40)BAY M8@M6M\$9>+}0' 'E^(+_.\ .T?
ULVW.^;8CF!QJ:)41A-\$"R0:7>C&:[]L":^0* M4DOW&M\)0"#M>8@PJJX_RY638S+J
MAK36"QX80YNL\$,R3T.ZPVOK,JE_QMJ3R%Y5G)GEONGB0:J4WBQ26U*WP39%Q MG[EJC[G* OE@D M_="6N)J?
H*R,/CJD,\0(TAD67=5J/%&-L,- E+6%KC!C=MYW27(SJ>(#(%6
MXMP,VQS,CJWKWXN<9!]H^!4(KD7L9E:DY@<^]JJ"P156KD#;:U[RRHT_);V MV=0^:"X1V.* /94%T*_Z??
R*08ZH:6Z9W^!A6SL/Z4>AJ*.;\9EE_60-PQ\J? M]6WET,*) FQKY7B"/MM-Q1V>K8\$V M-KA?
W'S(8]A=GRCG[\$S.,#RPAV8]PW0/>2:1I?M?B_3&13<;)3IIF7KE]M?5 MW:1@9ME2+Q.5AE2R2N)J?MJ&>
(Z3W%AZA,180,,!JC>E_@,8NZ\$C+896QR?D*GAN)\$7B10@CJ['^+G]G1+0@'T2^PUT%,':CN M,1;KJWQAO,
(G\56[\$C-B^:)?@ E%,^B*TJEJQ"6YS[=4%R>ZD6ETHVYHNIHZ M!Y..IS/L1I980-1 Z9\>PN &;0=R9WOR7U!+
M P04 " GB6U9^5&[;VG^ "Q_PD %0 '%N8W@M,C R-# Y,S!?:&%B M+GAM;-R]>7/D,)
(G^0])\ "KR>M=UN,Z&+!T@003.SIKQJ/[AU+>Q:& MBQ*G0T\$U&:%,S:= _(^X@P\$@0\$JU?U26%
K2W7\@G.X./[E?_R\GX-'6=5% MN?C7/X1_#0X Y(*7HEC<_NL?0GU][!, _([]^Z= ^I? _!+ _\^KS!_"FY*M!
MN5B"UY6D2RG CV)Y!Y9W\$ORMK/Y>/%+P:4Z7>5G=0_A0S660RX>GJKB]6X(H MB%#_M?
ZOU5]%'\$:\$0RIE!*B5,;0Y!F&(DS"0&:)0%R=?N7/ SC)\$T\$)"QG M\$&4AAA33"#)\$>9[C+\$IY>]-YL?
C[7_0_C-82*/\$6=?/K0_[A;KE\^,L00_SX M\>///UDU_W-9W?X2!4'\2 _M/W1? WGP_1]Q\^V0\$+)>+]]?
U5^0BV! ?5;<-? M_L]0'[[P.WE/8;&HEW3!-8&Z^0=?/BAY'39H'Z6+W#R&_HWV'\-ZH]@&,\$X
M_///60SAW_X)@!:.JIS+SS(' ^0_?/K\ _29+\HK_QRT+>ZK7]) *NB% ^6M%I^ MH\$S.%??-W99/#_)?_U
7]P]SV7]V5\G\^&WG5;5S5\TET5R&J>;RGT!1^4" M]CWQNSSDU0-SC;@???\$XA.E';^0^51I"CL_P%IF+66X?
J+<+, =6SNR9U,>0C M<^SKL2B7=#[!8[\$AL\7R7'_P0?W4D=\$W&E" F#9U.=6^0*G\NY4+(5E0NW!H4
MXE_H'Z:K6IX2^G#[\$-!63\$0ED_ORNJ;TN;5DA:+K_3GI[(NM":07Z^J2KT; M9V%:,99C#',N
XAHE\$2TQ2RC,4X(XS).)HMU\ _Z3"[@MR\]6PUM-\)L\$!B M>6)'5[(N5Q50WX6*&6T'M/S]VYHT6-*?
X*\$C#N8]= _RRT8_CVC.GPVCN14\ M:PZ ,G_F@?UNT+L03*J[B50#,GZ"G2\G
2LY#M\$Y[I4**M]Z40N+/UF2]9* M_\$;TG-;LD;^I\ (ABG^1\V7=?P+U)\V^M";[R\ 'S<%WU,M**GUF,[AN_\%+1
M>%C"G77)J +^,C"6Y66/4KM(BLD_@+(2LE)V]!&!#S: M@W%:BYO\F0.JY52 MRAW=0M9?
90+KTHW05" 7TF:)@KM9% A'-E(PM*(2\$)@QCC.)0\9,H2ME\$H MYJ1'5BD]
(Z#,0<<*>/0S02YJ60.Z\$.!&N1950U _%IMVRL8":S-U,PZ"=@KG M&'A;;(#0#2- _*1*QQZ0?;7C<

<[Q?./!/?Y^ZQ= M\90\6RVOZUHNZYL'62D=' '[02H7LKY>B-U/MIB8"4'B3-E*4&2Q4D,Y429-M1!
D\$94TC@)*(Sf;MC!/:J-+63':5&>-ZH&JU?F-]9*N=^T8>*E#Tf8-YP MV&BH00_7YI"QCKIX688UUB10.^F0-
<:.*+=#R!=9L@ \;B/<^M'\-7/[D=V&0 M)F+S(J#>X>B2Q\KZJ?fSY6\17T"UfQ1]-_VB0_&)^@9EH-
D+,U@BD4:PG.HXC8F*\G*8ULK?9& MEMRV4,0&0N6=A6JM<^C)T,%@X)%(039?Q'&62"IC
D0H@TR&,AXJER'2*9 M'+T3D9\!])HH#J#/@J&94>\%&;MWX!&f?83PP%G!/!GGI^E,:HN?%7??]#Y=
M@9U*K*0E[+-:90F;0&>RFD4\\$DD@8YA2'1'DZB<6B0#B3%#<' ,%J8D"W+00 MV,ZY-BfJ9<'5M0U-
02M6E6R_ KZ_*>]IL3CM30YB,;P5+Y#0TGEV^K^U=E594_E,GRFCZH0RR?9D@(1G":0"DR]5*D+:YV5!1#0@5"
(LL)5ZZH M58C=G/C(VZXC"UA/U (M:(6C:7!]'1L ^R+)M;5@%Z1JY C]B:%] SXS/" M;@^!MRB[!>F)
(^WVH!Q&VQWNX:9A/LM:JH0NE!/T1Cf*>?F@57X7;YYAQ'"6 M!QB&\$=9!fEPHE9)\$D#)*>!
B3!FV42F#U\$;6(3WMQKH6&^IVFF08+S/5X0T% MR]C2-@!;A/03!7^*P4A_3YIF-:D6f]
(f/V];G:1V^9^0^"5#FB\>W WR_6 M@0ZE/@KE>UZS>EE1KCQJCG@B8@1QAE\$&&-(6'K"(f
(B%)1D\$0EL=KHYZ9&W M_>Lf;8W5^L!Y\$#KPGQZ(\RW0\^+QV,U>P \:18+PI.J&7M]G6.PQW<="K5:U,
MF;I^7=ZS8M'\$Y3f]+7MXNB0^4XKU0BJf("WV.UP9FK_6^4U:/TH5;<0?UM]6f]
M%*]IK97D6_651SI7E]8SF1'!TIS +(Y"B#)\$(<.,X@8@%(LX#%K*4V2BM<=D= M6f]\$I@G:Z:N35,=-
0+P=S.YW8\PVV&+\&f];!-N]45f/??/FVYH)76.OE#L:6NWX>^ZJK2f]
MIFW@5T^;KWRB3_JCZQ^T\$LHV+JKFRV2\2Q_ IFGRBU-HS03MFL6P R%&80S MAB*1*^,UR:U2P7Q0-
GHPNN1_5U9M8Z>"6\>KCYfR(#PT+ECEAWM;\$3/D M']*607%-'[f2#(!M)L\$6EX
f@>W0=9R"AM4KL&\$6?;I>%/N<,f\ ^DI)\;7 MM!EKON\$2&CS3L
AW^U353X6NKKM75E="f'XN73^6=Z0%K*C0001/,HWZH7Q M*!J?'"& M?;f4 _E_@D (T(5UJE=T)8Y'B-
MMK#*0f'%K*&=NM\LGv(9;'@&VTP#S35H M=?W- G2,@XYS\7\$Guz4>KHJJ\0\$]J\$WVDf[)-_)B%h4@RDB/(
M:!!!I\$\\(F/H(TJ!YC"+&\$)DfRHJ55BZ69S9MM,DVL^:);9HTT+0M\WU&790\$ M^;XX3
/(LY!f)-4R92R.H>"4\92'48JL@J#f030N2:@0CZ.HR0P2MX6BX4^:GY% MYfIM#fACLOfUf\T>=;UWIX CfF-"
<fA1A&&\$@ (M;Y30>Uf_XWU?*"S^V^8fOZ>E]_3N?Xf%G#X\W@#MJ3I2MR;,%@GD'I R07S MT
HUH>'A>QVFLD:ff?VR3f3?RVfMMWAGP,V8>2/9fDUI\WFI:S4V_1K2C% D ME",HHB34_KJ\$) Y"F*H#.R5_>A7-
Q"==Tf]T/3M-/TI9,ST ML@=Yf;2H)^@v%, 'W41I4G!' +DU(Z1652?7)&U/T-?^fKKNFW>J]K/="V.OHH MEf]?
W9;4L_K/1)S>Y)EFNE.Y03DXE[X05_8QB*9A(8ICD>0_1"G5R6Yf A =) MRA*>2f+-^DEEP+RL8\$WG\$A1K\$2SK
M?EQ6P\$Q%C(6J8WYNST\$75\$N92')Yf!79AfGEJ\$LPZKGPfZCI#XBUCUYZ#B5-W MG2\$ZS.%U0Y6C.KM_H\$6E*=
fDfQ?*<;LMUJEC;W_R^4Hf;f;^6I?A1S.>SB&& M\$J7(A.Z.@P(J(.&I#H20+,*"1#P05@4%-M1'MDPVf]-M*
E"LF0-<&8:F!fQN MR"8L25(L0DA"t%X1,I60QFD*:40\$C\,XH!80B*\8W0)R^f]E& :fONQ'CY+
M/f;f]fFGSK>P2R_ ^XYH7T#-S.D)BKf]=0/"EV:UH3Z0376 YT.9.-W\$,@2_5
MGfQ)-1FD=^5<75RWONNZ.BD+>731K0IKV54+f]4&L0ZU*NMZ)I'\$B"EM\$>6H3GS?&MB: ?AL+<>1.DfUH^&J3-
fEVBNX7V= %K0V0FJ@1Z)9<_I^R\$4=(E,"L>3U<9D% YC0\$-89K\$RHW\$4019A F4 MDB5IAE-
_N!RU),B*W9\$5_B6U0:R5 RA!UH4(60\9YF0W:,P_+IX>0ML:1U? M4&GRZLC:7Af]?
VfEJB.S6=N1BHM'6>/JJ(KfK/7Z!D1/TWBN-f+AXV25'3HA> M7'0D1M7-37R;YY(0;_*W/WG3?>LS7X@H?
_:B'Q6=;+JN#+=7N)W0^V MN\D\$82)2F88PST6L:XNQB>QXfFJQ M)>!=AS.E.+AU#Z_QELK,+WSF!;f!
fNV^Pf]D%FE^N>:AZfNSQ8IN!=1SV7U% M6VMf\^Y>T<895_KXKN0'52X\!M1&f-R3fS@&AY-ZD"-0.f]CDG*?
Wf(NV)1 M+.6f>)1B%B1f2-(%_7*RG>K"IEYK:MK)I3KXU1TGRKJ;fY+)=.X)D)M. "HX) M#f F(8K3'%'*41S
3(LAH&BG+(9L=3\$P?#D2YL^_0_GEJ60QP0_>5ZB;3G^T M*;ZOUFQ81_0@-X@;#LRDHYI3fJREB60@Z*B
Vf4Y+X=I,(fYP>VGBTQ>CL%.R- '#f9Q*HJA0H3?+=^GNOY MB5F<,Q(ED\$2@I1+A
DNE0E26C,44MGI/*T/4f]f71_GA%U?X.>^fKS#KTOVIK9_MZX58ISfS/fHf)(%*61+&"F7"B5Z##'-
_YB&>9*F<4PHR2QWZ2E;X^_4GG)S_M0L*W:5MOVI_&6f]<'Sf8;fX=!%X;(>"R?
<_)Yf\+GZ0Tf38^)*1K7SV\$K?M M?')">9_Q_68EUW5&A\$H6)@3f7f>'HC1&,(N%A)%@LDXSL/0+:N" _&1-
_QF MYE3#Rf4Z=0ATU?<5NE+>IW2NY+(fVDP0C_6?G;+XH*L_%&f!#"Y+P&23N*1/ M:&Hf]/C?)+W
fW2IG+Z12KfMK2VfHRNZ=JR+W-!f MAL9W)Y?'3/,f]^B6f>+&fFM6f5ML?
VfFM6=P_2Yf]*=Y.WT7SN'+S>FLR= M)>2FPM>MZ?;'N6TfSFN^+fZ5!;f7 A:&F4P("Zf4IJ:R-),
\$I^AF),-<-C(0M2#(4(M>1;%2)N,4YfK*YZV3B2G= MB;N96,}QV-
'\$f@;fXf[^M=%M>CSJSP>IE=074G^TU>#f^0:V:C*!WB^4_E04_Mf6^,SF=2f*G\$(8=9E"DW-Q
fI'DN811E)\$I9%.#*\$E3W;),Y YWUH.,=,N. M0QVUTA\#VK1.^*(>S.8_!
<3f!%=#9&f/ZRNf/PC0^f20K_ 'R^fU\W#fC;K0=\$ M?
ZR^M3U08"TF6,09)BJf]'_fXK5Z(3ZfINQR_*]_XN7R'2.XG"&'-%f]=2_H@_MZ6+3H?857?
Sf]0TD771I\$QG*1I4&F3.V:f*\$6JZfE\AMf#WJ6VM)\fRF"KZ;2F#330fWDC#Gf8Y,?ZA,4M
M" _9">.SR7\$W%'79R4PU0LA.E=75ZP9;9I7f;fF%\$#fYYD+QJ)U^f]LR^fN>4?BH6\
MR5f74A3+=Y0W20KZL_>*6CW+(QSBf(B@VH(A1"B5D,2Y@f(2fGf@P4f>D-JfS
M(+61f]Z*fHYW7ECKHR8/QS1\:#BSS6f:Q,W,U02fBMV?X9KS:M6<#DAUH>Y2f\$8^RGG9Y,-JYV51RfJQ<
BSA.A"5Z(#1=-I\$NS86%56P%J MX"',f9,=9NBX_&ND=,>L+49_SfG9ZI(+\$/P2<9"SLT_Z1&LSCUK5X"W//W9
MDf/B@L.@XV)UP^F<&f!H0E1D6fHU9QXB-K)fFW?0:L*T*&\$3(S(KR);>=JM0JKS#Z8\$3";V-^fH@_M-?f\$LK-
"'PfM,KCF@B-,=CY4S_Y&K7,NYSI16_H=&RX6MUV*9Q3P2(@PAZEN_MT802fBDSBU.8X#=#\$+;f;WRS&,1J'(RN-
+;+-^6)S;+18CZDN'X;fLTVT2A:' MAL^>_>2f@=LKf]=^Y4;f)PQT#4I]G=EfYf_XL;@QXCYZQC4+(39'W\$SL4-
ZQ8_M-,P<fHFGZV9<@YWB/^G0>+5f^J1VF!X\$N2XQG3f\$A4TQH!'&2Y4JYRQ"22":0_MfT&>Y7%(4F15
CH)UR,K_)YNFUW2fU4Z?Z_CU3,NH9GF?W\$+8_DG43UJ6MCGKVf/5_M80B4G1f]_3BF(f;G25fFDRf#_@MF
M6N*N)RUK2EUD85WCRG&4.&^G*"<)37R\$A+3#fL3B<,)!P\ C!BZ?KJSfP,I=HX:3+f0.">VZ0K(-B4<
MGVAU4S59(fW'P\$^R:GSJ&>,f!0S)!,,#_fN6-'M'550);%0(f;PFIFC?@RTf+;f7#ZTN*D_M6%_f&6B9:'f/Q=001-
M3G<;*LE=R^YLN:\$9UVRJP5\$>S9NVNfJ%_VCH9EN4Y_MX@Q#*1%72B/'D.G1L7F(9)Y\$1.AT4S!
fI3:XC_\$0PY",*-HK@'87_5f,U_M@*Z6=V6E0<4K\,>P^f#M_Z(f(Gf<?H^R*KY_MfAO)M_4-
G^*KW2V@:X_*f[E_.ET/H'Q_ ^BWD8N83K095W+Xf9EfEBZ:XQ:
MGV,4GE\$K#;:' #f'WULNAf\$X6IFfEJf]99DS)fE61H0#f,48(B00)#E\$8\$B3f.6_M8(P8M>IV,41L9
VTCJMNT;X@VW00-KM_]f5@.,:7K7%PC@4/f">@YA'N4U+-\$

M7H>\$ /A4P';QFXD+OMOK\(:)>5HT+6\|L[V3U]8XNNE*[-8>+0GB]DY7W3W* MBM[*7]6MEV_4.UE/>&_I9?
S^;NRTG>=!3B-XP9)\$(H4R:*|IL6B,>\[R (8)#M2K.\$-ZUAR#69!1\$A.:Q;'56,J3
ME\$9^*6[H@H8PT)3!|Y:VIE_&BW#UY(/#"Q?&&[BVR0FZ
VSE[&!#L>A= +;M\$="T1J0XLN2P>=1+%C"DG/.8X@2D+"42A()")@,&\$ MIW;[E];!%VNU\$Z.U&^2ZHH*<:/S
MJU:5GE*F0J"LC*K_5=DH1=UTF9R1B&=!E;J_1Y'*\$F]"6D0"#T#)I:U ML5-MFV6YV@*=[H-^#FYK)>
<=&D_:T!]?DZI-[W#NZU?_!"XRPY13MIYRLU0_ MU85H9D[HB&TW5>1=L: +KEEIN_SJ>4J<"\K3G\$*!A!
[NH,PSAK,\$!C@/OR&H MC!/L;J.Y,36-=?'HLI\,ZMJJ7<,.EDU#DNA)7%-R*NEYB#("KS=BK)=CA
M;'NZS9HYL.'.N[EX&4A^;4E'7I[#T+P,MA-6Z(4W==.;VFUT ET?0+,FV*N
M<^QF"4:Q"!F#D0^4=SWD,\$,TA\$+\$/S\$*KA=Q=4).B.;CQ_E\$LS+NMVYL\$(M1\$0ZXNRV4]"9:2D/@-
CIGY[&)D?M"61\$_:F5,U)Y4ABGJ\$RJ"LZ(NK_)SWW= M;?0^6I;B1S&?*\/I_6*IEKM85^;L_ZIG!?
:190SJ,PHS!@,H8(9Q&D2:+^ MR>(TCF5!;-JX6W-PHU,78.(K\$.7"PK0QIPM
_.@077*ORPRN[:0G\$M)01@A!AF,15HXR MF#%!(.18XB_2GC*969_%.:(RLB]8FP7=-
\$W1\$+>/DQZ"Q,XXFRD8A6"2<I+9;A>.*:Y%J?#E8KM5"6_ \$ M?^C\$%PUE3_7!PV(-E@:?
N'2ZJN!AWG<*@L\|/:5.5]M+(-.0&X\I/5<'E+ T# M0\$F&,(J"\$'+*(LBB\$%,NPA@KAK.\$V(UW?
%901E:.)G/6+@WS/O/S8&9!_7Y6 MV>XU\3RSU@XRZ'MI02/N"\B7][ILSYT>[T>8WT\$FWX FQ%7%R;+05\| M*
((=?!7QN!NJ%1!,! HS]="E\$B)",:0)H5"*G_0B"V.9\$*?TMT-:([Q&E(@ M=LQ
_P*-8;C.C\ "64;FM++&6[A7HY/J]W[-EQ3N.\$!QBF
M,E/061['D,4X@SA&21IBG&.4SY0C593BRY)6RVEMZK8XW3D- MDL%YEA?1[53:CM0=3?
#)G]06QUI>I'<[V1I8>U^S^XQ21D AF MU'?[X,XC*YJ.%FB]F>VR0^F'UT M9H?Z86-M'-YIDLUR4H!^?
YS^@L-;^8UDRTT#&+7%N-9^M\II?],U;N0;3[6 M06 J7>R1IQB'*-OR@A!Q#>E89&,P20201#@.!"Q>>*)
P,C;[-#]IY\$GW7 MT'5S<[|S8?&& (3&>81PC"+4091\$F%(HUS F!).*\$HNOWL '@DOD M-WL!.4ME]XK0
K5TP!|UI3^!Z^6R*MAJV43ZEJ6>W"%|3B4]*I@G=;M[TD5 MXE&Q]E76\2_YFIHYDYE
&.;YEZ<3=4Y^\\+4UDT9 M;KV>Q9I\$(B1\$0 M'C:S_>D+#+N=ZHZ#>];K@("TUZ/D7J>0-41<\$%;2[,
M.1E;,>SW9]ABI4G%VN;THAX7%N ;:I I(+54+T?1[)C:P-FQ-4GSGHM1&J?_ MA04?S]D\$PQZN,YTP'&
[HI0K>+X3,BT6QE!^*1WG04.@W^A]E]7I.Z_HCO>^' M,:0DP#1%!.; *K8=(Q!RR,,10AHQEF.
(\B*S<>0<=I9W&XY@P]*QEEN-6Z#A M"VC&'&=>N"R F>(&58[E3<.HM9J[&),/'DX%PXF56T70+20U"ZYE6.
(1*H[MRYN')MEJTKD]5R;I^8#?Y-;\KY&-SVM,5Y>\$HE\$*!21!4QE#!60D(5#FE-), M/>LH-
1J3:T!K[&2M#7&=K;5%WB*IZ Q:PUO<,P9V^WM;_)L=< \< 7-5K8)%'
MY0\ /MY2I0<=";CCPE9!M)N%>^M.96TR7Z60FRTY2D^\$E%Y_ ;*\$^NF1Q^5\ [5 M]74[L7 =\$,UXP.*0)3
3@N@XLC).\$A3"(,QD)M(@385EL;49X;'-E/?7K]Y-
M>/_U=L0X/KC&_#EZ\WK_ =WGQX\ ;SE_ZSUD4X0\ .W0f0;^^_K0SD<\P MKM8'0=
[0:G08+;/)'A"R#QA;B.PK-FQ"2_9CDRRGRV)SW%D7;3>GV[)]N>X739 M0"P'C#.:2:G;X6/,E7+.-]
_HG/ATHR32"+193I[E!4KGQ?E;1:,<7Y]IY,P M=Y0=7SYVS _E P=W-.0L]?;6;S-
H_EN8+S8:!*I9>,.C@>=:KOR@_MJDm2_0 MU!Z_+U?M0+0<>N,#L6JF7NK[^^UX=L)LT-VVN^-TWK>3I#0.N-
L='&N+3GN- M-\$TREJ7?*LXR!E&2ZE*@(-"A%&4QYRE@57'PF?S0[<)]_ZV;!CXBV7)SJ4N
M]G,XU2V=JQ,YSJ,XUY.YTR_@;9WF4=SDJ]?;3'7:Z040A1MNZ
MYUR]859S/40UUZJLZV^+2M)Y\9]2Z.SL5U*]' .17^G.&1I0\$+G2:GYX6E2_><50GU5Z??F M%YA)[^MZ)
<6;QD1NZ^?:KGO-'[OZKNKZ\$3L00'!'6)+N\Q"1#()F=-:205 M8<(S+@305:B%_67%A(.JM-.2?
5&T["E>T'0'F(+H\L_.,>,[!G=ZL^V;,) MYP2:3]/.CH'I33XG@ (Z:@FYW<@B*7C\|5.4CG: \S]1].D""
(D1\$!_.:OMK= M"R"3B,(LH3F3<<8E,W+W!JF,[>D]2%[DA2]/[Q@_&PXL0D+B)UC0^=X-/9+SL:
M4/Q.BM5J0CJNECK\R"5?0PZU\;MIILB(XQH,07M6VKW_FMH6!I M:#DNA:&U-3[EB;7%K8]2Q0HKHX
_+UA;9PJHP0A\65<.7(QK85U&50'9M:%
MMYMXP\$'SCQY=M#8(PYER&RD/@@R+00@|2Q7+F6>P)C0.,RHC",TS6"](\Q- M\$<,'K'&
(J*;>3LS3AU4V79E'619#Q?A,8\$ NH#;_ QW# AW3\$6!\[C[VQUA[
M69VM'\$#UUKU^B(9+B]RBY0J\$7(KN/7"*WVDH^U!&!#;QND2_1%)I6YC\$<\$H MCI3>38,8)Q:-
<\$^1&5E1;N@^V1(&5%,&RX&XN0U*!BZP%]DM#QDV8GL"@V7WV'/2#?>(/7GUA)U@STFPV^U[+?>+,-
/5<-02*2T\$XH)X48] M[@: 7A\$@B0JAK.F*>EIR-L9<08(FIEF?G&Q4UR[D&CJ&HX-2Z' MV9\!92ZL)
[/(@."DQHX Y/LFC,65CLD;_!^KHI)B(#-ZKV7GMUKFJ_F'(I>S M* P3@G0G/\$PCB\$(Y/L7FWS_5HN
M5<,'F"M&+,V+L'73-=,A:KE\$4+'%IBNI#C2_[CE#GP8PMH^+<,#2+ZR,2YA M9=HD#
^@>1>^+CGI2<&9YIH[(6IE95\$PU@2M90Z;97&")(X3B'-;!02&F1A M9-6,T)&/^*4\,:%4]-
+:^_07[;+,9UR,#N[6P/3(8#6'W(X/S;7LF.B]PPL;[M>8\$=%\|T7N \$U>GS K?;370>T"81;P:3U#?
+.^6FWM%ESWRL>QF07XNY_-W M9:40F@5)3#%.&(SB6"G+0"+(A,BA#)7%*#F-16;507%:]D?6L9N1NVTNSD1'
M#&XK.?(AQ.CK,_D01==<8\$LDT,@\$EDJH39;=6JY^+N_F>0#?M:R@]\$:GTG^6 M57KN4Q WYG?>
YR07+8RWYD3+N'!\H16WBR(O.%4\|":0JH]Q= ?/8K006APF M:9Q1#%.><(AXA"#E60XY(3%*&9&AV=!@.
[)C&^FK^WM:-2V+M0@!&X9 SY'E MJ\4,4\ -7@G>D+%7Y,#(CM;:SD]J7:C0C.JU*LP+B0!797?U,\^_6F?)&P[
((MHD&TDRI(I%"E :Z16: (,\$<)PFBB4B-CH&?A_V15=KQ@H]GG8-GM]J>[.1G M6S/_=K+Q-
+PC!2>_IX%X3D0R4F;BV3'_LHSB41;&^V0\ -RXNG*;S?0&P6M8? MY*._! P[#=,YI#7RNZ(A!4+'
MB3E'H#'"3W9X\$ME.TFTXV5Z"E>P4Z^<_7XKB/S#DMHN^).4[/M\$ MC!%X1=607&<.,: \C>3-8P'B\ KH/>
(3!+P)"1*;4L9!1 E>0!)\$FUT]-FGWEH/[/_L M2>FN;SNIAMT79E^='OS=,>]1/9[+IT]S'318-
\$')!VV;:0)7'(>93B':9(C MB!"ED/!4P@2'E*,D2EA@-83^/,D)3^M[9M8=CAM.KG19GW7ZXSD@S7:>7WCL
M]F1/^PHTU'!=&?5DW5QJ?WF0YPA.G0=I", "1/\$C3*UW;K=!EX[2U)Q;:HRL7 MVH>[_EG4,Z4/9,8C
I,LC2#"N8 T4AY2AH(PS'.9!Z'5#)M!:B-KANX4IB(>L:\/*%>8NN0VK'#J@4/VZC7(90'-[P(V%<?)?
CW+I&0":@[8^G]JM MNICXQ\=MY(TGG"X??>.*E_,H' /)34?B#-WJ64;C&,AV:D2.R:5NAD\S"= F
M_Q05<>0E3?
59AZ!W(L_K/];=7^MPEB\$4,^4QP3CF\$B)"4IAA%,%0I*C\;HH8I%DN(4EHE#*2I+&TZI\W0&MDM;=-69LDHJ5M;=)
D! MP-)6VY.] (SM"9H&!>+Y,K@%*TQI6YT4^,)\, +IFX_JLM3KG)V]*4[9[IOVHK M;A9\$69B\$0L(HRW6"?
2PA13F&08"#(,11(IE5+Y&Q&!U9B_Q&?Q;WJWM ;V^K MIN\$Y6*RK>MJVY;K^9PGNZ1-@A1-

6V:P6HBF,\$B"!W6WB>K SJVH873 !:R3 MG;+S4-MU4*FU9K\9?}4(\ +*M0PA?N["K'-
LOJQLTP0!}E9L94K/<.:VK&LI M/TA%J8VL>54T2:S-404,:;-N\$@,LG=TAS,R4J2'*"@;[L=CG! ?0U"7N TK3#
MK\^+?#0VN 2QVU=+FZ_RNI>S[CYCZ2Z{&3>?Y4.K6&K=<:I03N2#}B+_7=+J MZXJREG"\$,-9#9K">W(
0AVK/"QBf>2K4GRA)K3J>N# QLB)0CTJN=E=D#34 M B/C8ZD>#=#0LP,T/U>@X^CI"FC20-'VJ!XND-
R7WG!A85J%<@%(!YKFDGM- M[(%V=32=-; ,NHFEFKVH U9G1.BZ=IT S>";EA[C@.(63)L M)K!NZ&L?
L@.G9P%&@DI*.ZTH9%# [NU@J%^G+/9W/^SS=&8E%A"77W=:E,E)ID,,,*IL5AHG:2 Y
MB8Q22D[0AET_Y' {4SU4UVH"00-^I))T T M!2D9B4B4RQ!RFF<0I3*-
"4Q3\$4L%2IG8 CV"6B#"D89I(:32^ [MC-0SZ(TN1 0Z\ [
M7#9_M1[(HETMM% C8\&LWJBG)'!ZG1[<:+)WZ2DQME^D) [CX*P[QPZ:
MH\$;\$,9@E02:E\$!*F:43UF\$@:218%,.4) (SGC+';FD[Q] <#3RYFP'#C:15:MA MD/X0-P@!3(VC0[@4&
(9+P9P:1LD/3?M<23X+8,(4R^#6PRBA:F==LJWEX/N M+D>]];WN2*B=CKJS&WS-0?>)W6
B/H^<90E#%&\$&YRD\$,E40I(J\T \$,4HBDC(96!W17E)CH,@G=!TL/P M?9W:52@RA?@L:W4C?
J>GPNNV@673WN;M3ZV\$9?UZ557Z<"5B(B8*-V6\!'B M3'"8B3R&041XF,48IUQ:-*TPISRR\$NM8
57'2}.526RX ;)CQZI#@P6P!0;T M6'#9Z:X>J9X-H/@ 6XR GA/0L3(68E:+=
<9!SK6 A>&S=@5XRY,0<18%AS/= M+BQN.&7/"WLY|SI?.-S@PL:
(0TE:KZK&R/U;L;S[MBA9+:M'G6+;=G/]++7L MQ;QH'C?UFZ)?
+&Z5*5S4'XJN4<<7N5S.V^[/ ,T09"23)H,@9ATC|"XE2TI P MR6(I:1:%V6S1U
2)KP[ME;US;+3W2+0W#0@VWW TJ5PU,P/Y)FB0)\?K3U0/ M40F=JWU \$T#Y7:%6 JY8ETVPM&86\#.0U,5MI;?
8!C\4WV";\;[I--AE7900 M'?.@X?X*K/F EL2C-":>C24?7>V]L H\ S3&'@WPDWVUQZ-XX=OCU=,6:^\J
M^8^57/"GYNR4A7F.(I;#5&0!1%\$&-GL%CI'MM:W] <*: MKM/)LPE^EKK6#RIV2M,)\$'=%UY\$WQIK@.+SJ)
[S\$]S4(0:7NBF#FX?F,'M0 MV]1IK;7-1R5:YS,%,LI53;*68JC'U(0 M;N%2!]+*GA,P;THGYOTQOI/FSH-
HI@^\0F.G#=:D^P+*+0MH0]^?7C 6U9-6 M.\$|04IU@+/Z^1C" T\$T?*/=U615<>4E?+=+0 ;XM"V2=?
005|S1YE07#KYNGR4"[I8_E8L= NQ5\I5+2HI7M/ZKAN< M-
6,LH%)\$0MF.NKZ!I\HN8I3#E.=A\$J8TI,PHP]F)^MAAI18PX(HB8"U)YW)! M RP-
SH# '1,A.H1T4#?; ,7(\$>MYX?H!D"K\8'T+GTTB^0GJHP+P7TDII,0,K,C?2!PH4(U\$]
[:UCLGF2VS<\+N6UYGO^]@4WW]47Z]*U2&+!>&1-[9Z.B*PH=M,/K0P!&P0 M-#"B1L+%;Klk@J#GHLD
+:G0WIFTHA_I=6>FZDAF7B&)"E4%@T3WR%:65:I^HCR*0L&U=K9J M-3DZQR.K\NW\K"TI^ERM)G?N(
7K,& K(&UK2QCP78L#.GE<,SI&>R+,#,@7 MM:-.AI.R7G#6%F
MVPR*Y_5,YCBE9SAP&13Y^&G*\ "6.I<+0M[DKY6**9;0 M*&^R=
[J]!' \$JD%3>N_H/0Y0S#+, \#90?'X0X!2EL1/L%U=*%2 M!CUIQVD\$)^\$RV\U>0+#;RZ[RVY?
EGI/-5[WM23K3%M*>\$ _>@00;L!6Y;^-N7 M7\M'62W: ^WU4+;MH/2,N^M;J8P"67_1QD-G4#3QDIAF<8)9
ID(>):F K*0 M9S"+J,AHS!*4AG:Y8 Y3JIX+(-I72I?L0P\$;(P>B T8VF" 0;R+43[>ZT+'3+JUUS;[^
MW]M_K(I'.M?5D_M/*DFB),8)AY&DRC+339@H)DS]J0X0)BQ,N-'QJ175D16@ M)G|590QL=
 \W> \7C[>#I*+NOU-0K5U9G\$8X"1((AAE M6FN(. (,D"4)(XI2D,I=Y1%#?)\-,;PQ0,|H)NSTN[/2%AG#Y!
(HU23W&YT-0 M>]<*V_B2KIK/DY04G(Y0QEC*8!B*!*-!AGBBG,(FCE.5Y&\$B\$K4:X
M>6=Q9,NC9UA0FIO5LEZJUVO;LK)4*U;0^?P)0.G\$ #>5^ANMGOKYT|TT0#\X
M.T>_ZF[-5>I0NL1(/P^ZBVY[H>5H./^K;J;/GGY\TJ=?'0<4RJ\;#U-
1K./X/33H8;#>#"P7#C47(NB3 =T:V+/9. (X00 M#'.J D%*W<,L%Q3&61 (&499P*WTO@'-L6-H9SH-
6I=]G\703(MZ1L8RH+8- MRI\$&EN-4@90*ZZ\6 "S"J20"32\$X4A=N?*F;=E#FB'9"/U7E8Z&TTJNG;[4>
MP=9:J4H=77.E0AK%=8:2+(0Y"130&,"":848D1D'\$4T9\RJ M\L; >A0G"3R"?
ES]:TZ#H&0%TSY\G%1EFE*GGA:F2EMN,&U1LW2.ZX07S7 M:96] &_2@W*!V#HGS3',_2V>F%B=?\$#M-ZW%\$-
Z_3P]:1*GN>\$RH!D:0(HB A.,L(A8PD42Q51!)N52^T< >0 MU6(S2,EYC.2>KKW=TE;#6-PDH0TP@,\$6-
PXR"&D0AMXL4RH) *% ;5Y7^S>?F2MW02/ MN*"SAX69JK774([!6DAG+7B.BZ#) 6R=-)E? @ "UGI
[6G3KG3,.8DP!0*K)M/"88@PSF'@41)*FD2Q31P:G5B0GWD MS;KI:0'6A)N3WX 7? [U\JM=I3,U>F*,A9;?'AT
:X17K)/6(L[! .TW[V\59G M83&96'7^)HZYU7*A;C?756_B0E@4^G!+!V3WTFKRD,4T"B!'@8")Q1FF,3J
M)YQ&4J:9)%9FM!'5L6,F+0]M@>P.%VZI-69(FND4[C8Z9)M:'89&# '!QDIF
M7_G81C2G5\$@1]0J8D7ZMRKJ>)3G'"2\$8 MIHE00H%R\$R!+6 !C0J)81CQFH54&WC"YL3WPCGBS\$V1/V=
(+' \;+T"OWAH*E ME][106J:6;= !-;T=>Q14??HMOM)Z>8MCH9>[GI.? \$*W/@+8\$NP+K9Z23#;R% U02
2V>Y[.BYUD: MG\=&\$TLP_0G2\RSIT<.D9V+%L?A\$4[G]0!7RNJ]E\H;I5@DZ1?3M3WZGN7Y7
M5B=F0L[B6,0)}BF4-\$00H6:(L[*+LU_A+',2&:55G0!+R._GAK,8)G#E7(1 MJ6:N!F7'GCZAEAV#("\KL)
_(U^061]S%X^\$Z%N|0)9 Z[8 @U?X&8+[[?; M>.^-EMU,F058)'Y1KZ*9R[@9-
JBFLLA.RBV\7!+IZ=!#WV\^*>JBKH]]_J8 M+N6Z%"3*.2,8"\C#B\$-\$4:04(6+_K4_6T?1- M:D%H?,\$,EOA\$0*
(TZ%T@4IU\5W"60\1'D4(1YP:M>XQ8D/ MHPUQ24L7S=5?0*\$3V9MWES! MAB00LN6]@.0B6'SU^W7B8=I>P)?
=- G^**;N2F05ZM;V49UK?Q05BS:&0+* M2=SC8>#6TSM38QAG9*KF<.;'W!3;\@IT&=W3?%I/M
MI!9 *L\C9)X4H ^.)E6' 'B'<5XX^;WW9(,2/BH^EE(NW]P_S\DG*QKC\I! [U
M.Z60MT;34<0PQT)"G\$EEX>62PDQD 4PE#1"1/ BX47&R(V156_4A_2\ ?+I MD]M@/U,0A[7= !-#8:;:=R8@]-
Z!G!S3\@)XA'P,237%TFY,X IX>Q84N>EQE MCV0=X/K0XSK2U\$1+- \$R')YK>]EEF*%K*?&J4HNUM' =BU/(F?
ULOBN0E1]8S M+,-(\#R!\$4-* >-00"+3#)0)CAG:9(SJU2Z+-DVWX^/2^9H3M=-,=*<4&5!0\ '@C%B,5;W
!' ^0'\$S:7YMQ0J.0!F\$#3;S(L MP!00H%B8,G[!<3=-AI\ [??&1CHR4' M-#W0\$C20 SS
85AI72J=G8:R\$,RJY.^4!\$ZU?@V/;GWNZAF[LKS+96=#AJOA_F+;%P^PN!/S\S]3AN6#XT8'8F*FXH_
M<8+Y>E554C?MS',1X1C#+ F:L\$P*:88Q%# D,I3B4.9689EAE&?
YC8Z;JAM(6.N#^=92:D)QUTAMBD.L5,\ 'T=87B5:U6D M?*"Z HM^XB-L&\$'!?)6UGB,QL35C-
B'A8Q#Gwy4A^KZ376 M9\$'7S9M],RN(Y0')HC" 24(E1%\$40Z)K-%@J!4;Z;#I@;H[329I3>4-ZY%/3
M*+!EPM65.8V=K7_B!1%WIV,;C(FF'YV5V+MG<)KB,YG[9R\$X;<.:?0]10\$&UC
M^2M+0\R7/Y2Q_WZQ5,],H2@TQ+I4@3!':4PX@USB4-GG0D JLQARQH50:H&* M2%@-HC6A.K)NZ'D /1.6,V>-
@#-3"] [AL%,,!TCHH9H]!UT)E?_F)E9" ^OHU M:T1SVE&S-C S4C^ \J2]]0Q@<6#0CJ3XM4CJ! !@3K?DC*,H@B M
DF0!5&\$>8@SHXQ?.[(CZX@-' [ITL/(R= \P2UV\$-,AY:=-BID%ZASL\A& ,%\ 'PM8 #)X+F]]MNN-

A:PEW3HGMK[ZPH64?>BEDW:4HBQM% MF20?KUCY.%L@DWZC.5GFT}/W0-.&@XUS54 M&I
[-;0@*PRSWXKOD'C0"6IV&C++29Z-2C. @AS40(HPR).",I2Y%=FW\W/D:/Q+=3?;L^D4:|V>T
ERTQ#^Z\$#:.!0FW,=14& .S9ZH9<" 96AY< Y*\7HA,74S=)0 2J(1T3+J=:\;DESLYG^M8!ET\|S<(L#'*>9S#"
M40H1I40I+B*@"#.>9EC9L,*H1N(X[:?))FFPH@HZD;=[D#AK#.N5R6>U4A95X M#MF3QZ2X('1RYW839U
>\$^4PA +HMT;H.=(UC*0?K.2 *V VJP)5SC(>T33(M\$L@84XXB#15/<4PACN(X3(7@J;0:D&#-P#R!
15MU#1F|T6>>0:_Z/ M55\$730-+ :.ZI>&L>I!|TA8!FX;>C"
MA0!!^D!|!110CX%7(R%1A5""B4T;##42 ""L:7:5VP['*'<\Z8+F7KL/U7E M00W(VP-
;->U^^^F54Z|Z#E!RJUG"8T@2F4(6:H^HZ X8\KG5_]+;6P 6P9& MSQG@33_Z-4M@ER?=
519U>H;HG08VK8+LT; ;3&N,B:&='E&FQ,'3Q?GTB\ (HN_OZAI(NO%5WP. FF2]=3 MRD=097I
&00((H:5.4)8!\$68IU\$HXB2R2&(R13IV2/+]*Z")@JN.+ 'ACD7|C M#-VPGAD-\$,0X9<6;IBWV\ ' ;01&
(EYMZ#^J|VYU0YKKOGK7|V6U+/ZS-7B# M3.0H3SADZH4\$48+4>RI1=D(:I\$H?QA&54MI-N;1GPFBK7M(;
<(LNV";L+2!\ M"MV+@27(#9*X-@:2I_1Y#-HC!|A/L7 2XDZGP'(A)|DX39,7*&<9C07!
M20Q9\$*80(1+!+.8AC!A/2!;G:9I:N2V6|,?/B\$E'S(A1^)GIGQ%1L5,^;MDP M/\IGRH790/\$-;1@|?-
!.,|W+XH M9=%\$-\$<^(3.[&7E 0R|EU)3; ;&A> 6VFFJ *6H^+W5!DK|7T!D!/:UJ3E&9 M1)5R1M315\>YK|N|
(C9Q^ <+7M|KK@W-!,29#!"A2M!M6EU/@03,!-Q#H.\$ M!(0PG/ TLGE'G"
(T\DNB)P.*AJK=7CT)CMEF|2&RW6|= .A!K23;=4X9'6EIO MT7-B>=JC)\E,NDG/";N_2\|W|DUTGVY; ;2-
'UOZ =U09)BEG&6Q6F6PCA) M\$50IR6& [5+*98\H"00R"J'^02=L<^L&JKMF*0K4#>\$0=%0!G\L%MTG?|)N
MBG04,L/H^5 6.;56PR^M|BT--7N;:AZ;70T); UD9'J4S=S&A(U"/MBP; M|G-^Z688H#XDKW-955*\$LR0@-
",TAD&<)Q E:C-30B(H)8Y03'B&4'SYH-+C MQ\$?>X5M31I0-W>0S [-"UANF/\$QM/0\$Q &*)\$ZR"
JB*SWBB\$&:0(YC5 : MR2!-TM@FQWLTB.TSOE*0&;Z=2S@|)3NR4F06ZA]-4#-TS#78?%'G=IZ@00+ M&,\Z#
(K9'-8S|W!L8ZM?\$Z|H+84NFI6+NB%P72D*MTWRZ*NGS5>ZV-[U#UH) M?>2Y?-KXP;U.\$-!
(<@5:6; ;"3G77(GBI0 &=/%>@6WJU\I^&,WCL^P1/0 J^F@U/ MQ?:T'8LG7HR#ML=3TW>H*5!WT'4^|%;>Y'\M|
<'2Y^+V;EG/ J\$/C&,162B4 M1Q'K@QX94Y@PC#*, 4DR8E0#<(K*R*Y#2PI4#2V|W1_6?%ADQ)^\$;%@Q>Q/<
M3HMN*&I;0D.@)>I#9HNL?Q^RNV7Y|V+PN/T4^&H|>DZXP4S^DQ= /E|E_C0^=
M3/V57W:T@N6CU)G^G59+^M0&:L\YI0',, <|@RCC6'08##(:\C04F?K';N+= M|OW'CD3J+-6Z)PD>NA-Y2Z-
R#Q)#V\]=4\$L3;2U>0\FCW71< E_FS=[-I|5" MCHMV8'R<^)I|,
|*NH|G3VY\3EL:'^F|G)\$X%&FF|I9Z=8B4ARV@.L0BC M."<1P=*H)/
4@9\$W5T\2|]#2!)FK>DNPH)L.;RX>DMK0+2DBKQF1#DCBU)CMZ MP\F:DPV)L|V>;/!
[-#N;RFZ)F* 7T:M7>N>9"1399H;&A?'C_D3?6-D&K>I93G=N0{X^V;+;>Y 7R9G&ZF M|Y'U|&7RGA9GT-
@|L\$N9E\$),P83B\$7*88H"26D MG,?=-L=8,PTE*NX=DJI66U-II'68PW'\$>Y|}%6ALWWK; MZHLCOAV45AS|CN.+?
U/^U03M=>2_DG=R41>/LLWK^U#6NE_93?Z5_IRE61P0 M2=2&2QF*B*E=I|0-@P@%(E?&
/\#J|0=2_HCZZ7MHL>R.8CCV_PX9=;:(FQH M6XR'FZ7%L059>W:YPTJ7G 0^J+GY4|./4.LZ09)' : \0-
'U\VBB7U:2T7-V@. M|!G'VUR0;<+.GT.R_7/(YA|)UKB.^&|. F:1B#!!(H)\$2&4NZ=[K+I"*-(H
MQ7&8ARC<=9L=(X7C\&GS8|=9M;N|0%T/#4:+=UVH(R'N510B|B,4)KU>G\KB MH'3G^+3KU7'>'6Q?
@4_G|Y5;+L|8V/I,W/'X_19.F/! M?#0E9S1B;J_GM_67 ? (8*E299"@2+U\F*IA"1())\$12%_D4N:) MI?
WA!1XW&Z(|J'SH)NBVY4NZ"U:Y6M9+VA03^+|-|,7B!00WE-:Z6|VYE7W M (TPP_VLL)ZT|6DZDVK^7'=N
MF6N6P'S#D\5YI2FFPSI@+*2L R&:@?V>-COC=#LF1D#(XIAW!*3 M) @507Y8*W+:CJY"/B!7"|% ,W%|2GX W+
MDB+BM M@8\$""A|9.WW<\Z-CS5U70Z|9_LU)E/ZPY0KLL 4Z0L:'U"8Q9W1H'9-W>HCU MHTA;B.<:XN99WCR?
@.J G+?>R|.467W>K"6(*L M'@LNCU@>?2R;3B.R#6K45<'Y|JMU|0+^EFJEU+/-R@?9:5^UR/LM\$&G
U#W^R<*UCW()WY*+,, M+V|M/8MWL,7|'"&/22'W'4R9A0GGB=!, MNC GPS|3FK MP=/2EGEPDW=MP;JN8.#:
|A(\^*6T,)|>Q%+Z>;A/?N2VKF"HR,|Z"V.1WTZ MAW)T! '=|S0&IV;VT;UZJ,W:50>5G;CA0PY1 MJE?
^X+&F2^ 6<|+|Z|]ZDM+4/5S/B7RDC^092UY86'86DR#(HXC &&B(|'Q M|IDB(\$-!A\$689VEDU6M]-\$Y?
4K#UA41+GSLP^KN(@5|?Z^'JOX.8Y^E0/E M221S\J"EXRM
=R%YT\4*0JI+9Q'CF409",HY)0):I#\$:R6/77.<:X4U^=G1M-UD_G&0; M?72._MTA4-\-1/IR)^52;
[ARH7ND?2@6\OU2WM; .B#[YH#T+!PV0VVA\X@|NX1\$+L--S46
M%L%DCYBXA81|; .H&&WX<U^Y/8;2#H9ES|UCNN"JH30|(5+3:|P= 3FSZP|3 .THR)
MG%*9&^6P#5(9>6.V=\$%'\:K_310D)N%A;U^&J?SOKL7Z>VVJ;/@5L;16<&< M+/W3=YW,
[-#|KV+8/@G^U\$QAF3|AT#73\$/?VK',\V|MA/B M/U;M&\$'+0Y;+U\^L73XING;J9,,; ;@#&^; NA5@!W|/(-
CB\$&@6NQ,>GU,S M/0'F; ;SFI?Q,/(?3\$WR' SM|W=BQUYA2R**8KY;*M?HN)"U;G'\IM0)XS,N
MLUB(D, .0*)6()\$TAC7*LC!P4L_13EL96Z?GG"(ZL|K;)|@PW|*XM>X,;0F:DR MGX#8;+I|+,#WEKS'\$GE327TU
3M';MJN7X;""[3Y,KW.)>5Y=7|/JZ>;0"LT M7<|/^*H|I: RY_*5\$N^0LP3E>4JC\$%*; \$QU119
A@B"GC*6,DC#J7D"LOG1 MD?7 %WXG06K>#?'I:YXWDRETA>=GV3;0> M3'^E8E=";XFH0;AT!+3LET3%P M'*?
0#1= LP\$:/FP"L*8HV63U^D?++2"KZ*WFM)BW658 T@| -<37GR*9"WE M'LZ8-;57A/F0=M+M9K-
;7N08'7'%:0F/E7I,WCF|J\$ZXF*AD'8\ (T3&UI)KDJ"AV6UXPUT^B(Z9<72IS+:ZSE)< M^WYP
+X:N=VC,2TW=@&A#QHIC;T7;?-N.GL?I-0)V1T+ 1F-M)!|GN|>=^0
M@&DZWP#2PB@I=R, _86(S);SNL)K';XI=B;J8- M)D324G\$,YZHI/6)@(5DK\$T|P>-(|EW(SJ8KR!-V^-0-U6S?
%IVY:U(VEH], = MB\7MIW)>*?VW\U>B|6|1T(, *9\$Y1\$RIMBPA'!*,XQ2'*0^H47Z,'=G1,V44
M\$|K&_J3;|]'3FNIT.,X3/3?7Y!\5.(ZWQV'!P!5KJX'OW_U&4DIW@GG2/(=) M58P=\$/N:Q/)J-X6Q5D#E-?
-'JJCD|2,MYMH\$>U=67^A\^*#4###! :1J%'\$4P M2B-E&1&IS\@0AQ2G0F0D";'R:!:R5NLZ,|UAR8'1?B'M?
MGFPWC;?%*?W^E^ M=VKG%\$U^K\,AF"VL9AIE#*C7G.E%0|9X'S1R+D(KE?UA)]==
=N93R/ZX%:OUDLMURCC9U5Y,RJ\$*XPHP M_L2%J|R@H^,8KL-)I)0^N)K.7?
J;VUI7=>.JVQ_3U03)G"/.":B*TNY)D!2 M2\6MB2WM_S1E\$. ,@_PXG:\$=\99JUB%K580E'AJ<
HF3 _|X(N<.= MZWZI4GG3)ZB,ZS|WBWK@+Y^Y/&ZI;J?%=IIN_ZJY" "I3_/?G!&M'JC=M9_
MGR_\$2B_K)/\W\X?^NNQS+NU=M4)J3KV0\$%R2BMN57;AFIY #)NU_B M8=
(YKC'KJ5?, PD=2=J<;9(U/YEWIU/EGV4-\$@G=FI1 R-*N52-SP)56 #/| M(ZY,5:B@H=@1/(R8PEJ/ 7#;<-
/JQOW3N|X:E,!5'X&_ITX8%M5 C=\$!M!>] M54CB:[A6B<J^W3A954@BUS/ORYJ0Z^#MYFQA8F"NA,\$5R TN7?
<+"(3AE37 M"V5HK@JDO\$8XGJ\$S\+II^W=NR?HV\$@&?MM:BY(ZH<>V5*EGEZG\$J M(|>C|HIZ6&7:?.EUSNW?

+99&3]>/KE0X0)GG,6&*(TP5 3G),4#(FNV420CR MBNFB&'!6!F68C0
EX.G(;/6D,^DJ568S:X+^NY0@X_BP/_\TG6>KNLGZZ0+Q MT5[8. ?ML2_AZB?I'<8S^|H^|T :&OV\D+
<3=S0'K|I]=%* MV\$Q|{OSNT_K>NM.\$T<)/Z/Q'07#. L(& 6TL)<#=&DY=*,8'#3*9Q&!>BG)4
MLOEB#EH.NE/,XY)1!GZ5?L;4"WH|EZ7*= 2XZ31LS[HR;"*N&RGJW@S=X^A6 MD+H? .8]=WY0;3\$G3?HT8
862!DN5"R#H:"3:B *+#+3[M8>8?QTZ.1\$28V^G-^H<.%|8 W2;Y9#M.TD;"@X1/&"CWHSMZ'#T(CF-A)K '
M1+2%K|;)N?/^V\|CNCX2T 836T^\$1DI5906*4FBG*4K BDH *+C4
ME:F,J91W,ZA>4D/'XAMJV;0E5Z\0X|;#|WH|!#?!| "07V6DA21,1|05?#NZ MV0:=#>5D\$ 2TWLV|3|A0\$Y-
7I+L|6?R MNR.9 [U3D+M,E8IJDQ.L0,&T!\$@+=QS/-"@4:*@1!=54\$ZV'|F!E=LQ'^MB
ME<8>M\$NZX687.YR=@R>@1JTA\$D|G*MWC.BU7;4>(#QA,LX M+^J*"VD-)8R#LH,OYFA@%?/9?
J|ZZ4(R=0^IFVSU*/ZNY=KU!=C930&GE9> M\$4\';4R< QTWQYH+|+
<\$|1>=U22W(|SM|W8L9@V/[FS2<7EP5T*+A5FJ?R] MB_D9UP|,!=^!|?YCLP1%*X,6FQ-LI-
5|BH&*PPH@3"7@L#0 4U2A@C,F)9D\ MU.>47|9\N?9P&)3"%E|SRGY6P_ZZW0^=^G5!QU< |RB WB4D:00
H%"H!(@ MMU?07!D \$:Y01:P1:D0+S|OYF.:.1.!LZ'A#|18NG\$Z+BX>3?(FD82KXH.GQ M16 |1,(X=|=?
TC#W|I0D01|MP4WC.;&G^-WS6T|>-,C|FK< Y.S1+;1? M%@OUYW0VFP@N8<6M|K|6I=4=C&C &|(
"P9)23"!I0)7K;%LC*-|V^&0+;\$ MWFA9IQEG97Z3.3L@Z8":0Z I(HP0-Q(-5=#-
0|!6/68Y@#FBE8("Y@7W5=+C MP1RLQ =! F+72(LRK%& Z/L9ZD/B508KG!^R\$ _VTY:=;./>/-|3D(QS0B>
M0 (0:5K/27 "A .N0X(G|*XF(YPS2")9>U50[-|*|L
M=KU>3L7CNLYB62^RSWPY5.5#KZR)E0QQ&J.NZUXQGR> HM'KGAPA|7KI|U! M1Y/=
<??/YVWJ|L=%W6U4JV<|J'YQ00D;0M;:,|Y):9J@)0Y8@H1*GU-T+-W)<@ MV BF\X4?5!M!^5 U-?
GMT"^!U>\$,@151(V).=! 'I*LW!A&BM& MYMA4K>,RI4V >D;C&BE5Q\4\D29UXN)+&E?=>1^|W-
3MB072N3:BS(&L"2=!(03T-Q*\$ MR)960>(E;6MUG-(56EQUBGR\057 +3'YC+4|E|ZIMJI5Q.95|3DPG5I+ N7
MXET!P;AKM5"*JBK*G!?'^M6 'CQ|XZ;9Y"?>6H&LFE:WZAK+YH.'A#PD8|BB M;7|KXUX03/G?,0+2=;
|1,S(;;+TC;S-50=I)-*XZ(|(|5@A=WY0,[#V.3LB.]*\$ MN/ =^>D9XR\$;?|84">IP4|=
|L1A|Z/AQ9E|FS/%>X*)'C0<-;P|W-OY>KI^ MLD;7IMF)K.DV\8^|0H;RDA"@L;8>C|8&
<*PQL/I-.757;>+5V?HLI8'55D.[M-07WJ;<6/X=Y/KQZM=#25\$(4S'1
0UF?,2+JKC7/^31VL_YR5@MQ>=WPUQ M=LLF7|5:07KZ==X6P9\$&1"W_2
R_LEH'V#%,^9>L="&M/R*0|;,\AL\$K3 5L>*B|V=:@ M;=C(.GQDCI\$V|S6=M1\$N?R++(H#PJ\$9\$."#/+8:
()UR0^.!LDJ6^MV;|)+0> M)>1:0;:UP37"D#(J "<:2(;12 EB|HR\$4'#&:!V=#G*<|3HI\$EXW,&FJK
MP!1X7Q#|U,D T(3ID@:5/0|VT^90:E-C",5,?/R "'XFBRIL#M M<>JCR>#Z5: 0%^I|G:M5;\@3I?("(6& 484
B.<(<)-K8 QS;:BQ0=RK#?49 M.D,|DUNYW1'T/6' ^!2T>X7CVZXNG7:0G&I']?
6|)NM;MPR.1W@'T+03U@*N58K90 | \ M|T^,? Y68N5.TP0A< 0N%?.";@BAXE|6\$6&U|{X':H00%2FH-4)|X_7:
(W3Y M|FV1L'=AA#IYNWQZHV?M#>DB5|@4V@&"C ((J@)0PMU,.(L7PZHTS#^#L_OD MH;?)Y5-
F:04LG3VQ/31#K#"'!>W4CQ_GA>6<\$"M !L8+%K?V&6JH3U6.\|R|R M010&6|S'^-Q;U\$A?UU'RQ:VIB/%\EX)
M1\7H,|GM#1USV_YM9VK0/VN4!7*4 *N 8A8'UP);D M-DQ.R;TLHF#W)".:X390UN+00\$B\$L". "D4 MH 71%;:
(Z:8FF00U/R"Y\F0B"U0J*EF/VWH ^Q.%|K# MM|9J^|8?H9A:|6^1T04MG"-P3A):F|S8|~)IZ<;4AG M?S3\$
|. +>P#S4P1I8 A;_K\$(A ^X."MHX@8P6N8@)Q#!BLND(KD6\$ \$"L080)15@)58 \$@@K23F;M!Z6);<4)#'VHU.>
(= MVJ|C&#;,"<,K/X5FQ*"L"4;*WU\$@GR.:!>DQY|X\,CI\?WB'6;'G|D^;E_| ML.#SE?7\$7=0>8U-??
0^5>9X"MMFSZ'FM|TFQ")L#=>\$LY;RX%-Q/<5,M ^?HS;J?NPI M^0-|V?>VB)!
|UT|W.:V+NT08&^T_Y3000>\$NV= _C?E6P>|F|:~+K|.I ^CU:;,D&'6VQ: MEMW.U0?
|S|-9/3K.LY^0:J.3'ZT4.S^QHVPMA\$T!:"8\$H XP8|C)D!1%I41 MQN0Z#VI\$-CC' R0;)N
^7|S!):U2AW|0GJ',E_0V G7\D?F -|F.^ZS+ F:" MST: >C|\1X2LE>&F/5#9B9'\3&4TR(<:/IR8WV0/+1X&?
H^10P,1CNQ\H\5Z M-T|T|CN?SFK30&FK<^=^GE ,BQPR!"#F=C-0&)J_6.OX|SD3&-K37MEK@70
M'%B=.PZZXW:W/#@CL6XXE?U1\0':P|8#33\5G1BC,"7|(#)Z;'3|+); "Y_P M=C3^\$J?J.>-!
<=S&,0X0''2/";@U-09M==BW0;SNM5DWHEEU!J9,K|K(!5=6 M*QBF
&)N!JY!"N!2<%P5!1%I\Y^Y,.)@S<;*:B-TQD'2Y"X^&| /I&Q5/! M\$A4;CT8D(D;N(^@%D?>+QX\
<+<1|3|J|G77(&-LNQ\$04:&BSC31W*6;"-?^ M
7,)6(D*N_89P:@.;XGK2WI@)?!^#AZ6"~F<#7N5MAC>UPZ\$TM_U;/'@HB^! M+2
"4/6S\$H;!*DPS>\$Q0|8R_I9Z=>C+P-/34U-%C5?& !\$Y*31?#BIX' |&'; M'CXWKJ0&(F UC0:H)#E@J,)
E(7A"\$M89#FN9RE@35233T|,XGL53N)+#LR MB>R";OP)WI>?3AOW+83INHMM P0TT&B =9M>>0?;A.D,'T@&8;:
|9X9,CTPLW MIZR0GK8 _M=4+YT|_3|V3)U&AV#I#(-?>4V"135%2 FPH"4W"B*-(P-UZU M26%DQTB*;
(|_M|1K&^|C|7|_9A_ZH>BGXM)C\$Z;&^F!)GZ,8)&RJE\$4_HN-F M, 8!
<9#0&'9W1/Y\$M*9JYS#>SM7'13N4\6!HX|L?>BFG*[UZ|PHLIPLU88KS MRFH7D+LY#
(A2#1CF"'!8%*Y|\$#%>="=CC,0|T(|G:058'|,0C&L|Z (NJWJN MD/U|M|RXW|7_V\$A0KU_7|UY_M|4^C7XN^!\
<>85&>,^DW^F4FCEB4GSK0WXX4_0W8R.&M6*Z\$|'-H@ZN10X& MQ)J7^RW\$9>ETW|7L?A-_YM8=;
|;EN06WT17)\SMCPT^\"T MWU"8I;*AG6V(9S|U@6GI)^P8|R|L(J?1@^"H#J,_,^=Q8 |8SI;35=R\3BW
M#ZN|T+0%9W<^E_7?_MDGI\93'*I)<-0 0)=:@'"\$K|<: "-PICIRF#D56@3 M0WSH1**6FVQILOWI'Q4(H8='-
" P88IBQT@;8|I;9"TO|3|)\,H>'A ."%|*< M:S@0(YMW|6B^7#8EE_5:[OHW|MR"~?7B^4GA_B\$248
8VMTD48(U\$I<|_S1Z|H|A#V6&&SSVUQ/FRC039-A3;C8W*%!)&&6Y?+, (,) (7C A MJ-
2T*'AN@BIWCE(9>*&_WJNQ"4RR.@Z+GW|UL;|A" |D1(Y M3L=IC.HK|8KYW#WJ0_BR47RW\X.DJ! TPI;UADX=?
C|P=&ZRWB^ MAI/LC ;/._ UCG;VRG_4 \$BJ 8\$ 2S|T|3 \X3@U=<__ 9'M2USGP-U\
MZZH40A#.W70L!!"5!%#|!#"|J2F5)E=8DJ AK_\$#JX:&6/1H^&=0^"F"> '# M5KN ;.'M18Z*D*J;R/|#QVT>+
|U/+ M|"2G6FK""D"KDKISGMPM+ *JBH0".LK"0*_HY#E"XSC'+>V.^|>A'^H2GX#+
MUQ>^' (0H)SA" _@C7MU^X"WS>\$P\>V=GM^ _ORSUS?<01P|V?BSLW/=%;4.Y<
M>#K7:ZVWQ*N/_ TN_YL/X|V^E"98Z(K@8%D0@ (D9_Y\$J1 H"R28+\$E)B7|G_M_4#B_R_L_N8L<|0"
(N2A\ 'D<+PP(2MA"MXQD&TZR6Y?TU/*R2WEJN:E1BQEL M%0I?P '#@##&'3 X.-<;..M\H0V+(0^<|R3A4AI
M|TX68I\1YWU\U.07?'5?ZW*EU:NGWU>N&NS3@W:QS/G76|>LL:DUWT8>C:B8 M*G. I8\$ E=(=-
I05@!I*!4D))5:3|WHI%KX^2C@3(>NERXI_-+RDY69XL|5 MYMYQMMCPD0\$M,V'.3032?

@{0L.B%*>V/KMV8@V/#C53PFB;RN" 9&]53^:._Y@HK@I=*@88EM;CEX4&PB5JDYP(B3'42K,0
M)9V*L:&5]#>7/^ ZDL@97ZVFB; /*[=LN=>9-0QW-K0(\$P=?SI]?N;S*,YVDWV"Y_.LY\{F}
[E30WK2UKTYG;LB'E'1Z(>BG\Z[3S.U8%>];M&W<@1,I&VNW] M.M1.CG6F' 9FY;E[L^4'W_[8%/ETZ1.
(4SH025E\$D.*!(*(X%X Q6H!(48FX* M;M=]D!W50VS@E;XC5AL[65WXN@DLS1P[@?9/'VZ>-DTB-+ME*W4-
=F;K(/, MASXS,-SP\) OE3'11VI< \#Z(--W^>>B(/2MX]+^XWS^?NYZ_U0E]GR^3<=
ME)6[]9_+> VJ/; ,B4N=:4+0.*TX!@KD"E-("Y%R5&E*,#?4*:@51'3KGH9UP M=).U9+-7 :=\WM!YG(X.
4C8FM]PD.U8R!P/SP&*.0_U1BK@('0(Q.).0'V1 M2W3R&2IX[Y&G]\/&.^L,E6-0D#/XYNL/4-DUY._\{L-
B_05.+[\^Y8,&\$,TDU MYAH8: TK1#D& BH&1\$4KK0PK65F%<6/RK_7"KRD0MX1N>D.5[G>5]7S+]/
M[GMY+^@E350IS%GI_/XF\W\8+',1RG0>[_% 6/]RP!+PT#F',%F8_+|"D:>0T9N<|*87PN8H>6+-7L\$TL\=%*
(\!\!;[@@V'SA8X1?0IYP#R">^<@]3X@T25RBU"=3Z[(WBV)\ M.I](70CHAATH)9A5* 6Q%HCFCUG_#%*9(U-
Y]1X_36)H@,1=%E?-7E#\ /FP"0_XZ,[_W KH]OX M_?=:]JML/'G1AKMU/^Z @(*5WT)\$5&]2T9_W6Q>W%YD8[
9>^U04?U, M_C5&2'D!G6RLE!^U^&'BNZ;M]4 DG4.\$<)4#5\$4\$4,XDX+S(K0I'G\$%LE.15_MZ.SP?
1(#Z]LZW7M'\=OX)%<_)3C9=*\$*,9_0:/F>Q^7)>\$X[V<\$1I_>?5S_M8\ .Z3UP9D0+V^MZM^??S[5@HUX-
VME@]+04\$"TX+^2_!.< "8Z!=6\,T*1T M[]VT*(W0S0KJ(32TNU-3=B-*C!M=5@=7
_*7^A#J7X@IY0YT@!J1W\^SSK2V M'>.\$T@!E8'E+L)5WY7)\B\WQS M*/XT@8001K0"FHK*>G(2
5Y25\97P9P55<[_%14GG6SH#;Z5/^GEV6Q#]Y(T M\QU(LBI*K*D"
KH!>045KHFO<7/6!5:D)*42(5'0%""%A[COW"W94KNPPF!0 M^5E3"0 (T^\$'?>?@?SHI]80;^@5"#)-_0J%PQ[_Y
U/Z4^\/+XU3:K_9A5C&Z M+>S]_.0?6:1L]*UZ#2D!R5&1<"*(+RE2%0[3:;5(#*[8-
MX:RFG#G2YX.PH8#Y+=LT,(2MW@.\$@I?0>>\$2K> >0J,NX0,"/U_'G=\$'@PM
MM9JNWW%9ZX7;+4=8527F)=#&*!>N(\$#DG_ "6EX+EI#!0!\$W!/B0QM*=4\$\PV M%*"/%4=P\3P@NDC:0/\H3-
#P\Z&3LJ0Z'SHD,.[YT\$D!#Z'3E\9\$;ZXE7+Y MJ-47_5V[D@Y7_YR9M6\$0Y)(P*7A1>VV/%Y\$XAS->^&
(L0=' 'DK+>ZT>9_J3^960VZ8: MGTPTW,_.I?F[&0SU"(8)M\$A*S"D0;F(A*J0"0,P9@B0,N?8".X5.XUE8&!5
MM6'' '26>[0,Z>R;==&_/7[+'JSNDM,'Z]>W8Z5#Y1#H?8S+X8\$, \$SG=;' ;M\>+^ME_"E/U1L
5>,EZXUAZ0X)/[7>?8H,;_9CE[@N(\."Z:(5*TL\$7_P4.> M)!\$?AYRGN_1>?
*XPST.13J8[' 'DDL@3AN57/I_ ^3VV005[,5X095#6I\$'/5_MCMYL.QJ^F\ZM-3'ELSJ50=[5=N<0?
TKXAMX&M#A]";,X[7.X>MR6QME&WZS'<.= M\$V!K6PQA50R%9ZJ#B-3LC7N",1"X!T: %12_MXH856T5,C-
9Y7F%J0(85!U\$=6)UN.A1MN\B\3MEVYW7"!D41>(2I/\V.Z)' M:5#T>H_&11&
(#>J@Z/2GE;A!T>N4#8I>0[P&1:\0:5#T_,;K5%#\=UT-8+7] MVQ\ /6MH?{Q;NG}
[^T\$LY73F/[6]Z^07>7>.B;.%]U^00]>3F5>L)(3BK"%:B* M' &\$3_\$\$S_6@1LMN*,W@:4%. 'H7?<7\$SX?
>7W[QF/^N\U<#H_M7L(2CT;&VK[?2)FM%_4_WV0=26^RC:09*^SFMSJKQ7TY%2%I7ML+J1RY4)B_
M5(5)FA>7NA(E\$5=Q^Q_ -[7&3X2-@4K22D_04I: #X0I0_FW^HB2!#): "K]0A%
M<80H_5PN78KE&]W\^7[^>:D?^%2]T4:[DUNWLN!;3'C&/'Z=" I;]DR80W\$FGI3L=N.:&G;(/*: MD[
U&PD[*0N]"XQ!@:FKR(*,)X;4)%*&2P4)1)N8+_SUW6C87\7KAM_T^I1_MUA:<-_RZK2
M'"I4EC1H<*,0Y8%MNPX?[7K:XR1K6,G^09TX%3ATT1M>/UTU"&AAZNGVT^OW
MV>UZ09R*QW4=C[\$N]V=>Z_:ST>7P,8BA_J>:<^A-=]Q!AJ%P'\$PJ# 'Y_9/H_
M7]V[_[L1VM_YS!U]6;WUY7Z07+0\W-0[]JQ_18NEVVZ8RBPE, ?8S_M,@QR_M8>JE_:WN1??
V.6@U)TT"X'L/T,++\$H+E3U6NX\$]XW#*&8\$_.RAO"GO!Q#]ZR_MS_CK@R;C;#S_X= \$*]CCU/_E0;>7-
(;B];\$9%)N/8R/5BWW] :D,+_8SB,N'V'X. ML0LY+'>?P[3].33!G(QW/X?.\G:;_SZ'(VO_QDU5WM,5J3J-
7.65]&9JC,01 M>.D>5T^Z+V?D.AQMWBV63;'0>\N/J\Z:(%-H M[]8\$6W0#FAK8FAH4%3F06G"&E*+8!
UB#^9@: !>IT]L_6[9,9&:QS*8M_TDF M'"NB[>DE#8EAH+.TU_N_Y:9M4YK]UH6S+4+;L#3() (P--+/!?"D?ZTI
6'P_M],P,"'00G*[:]J0J=(AXM]3_?-1S^=0>92-2N*8-%=:YJ0#2C_%.H_%05E6E
M"VOR\$93)YD%\$8'W4;4VRI10Y[. ^#H) _&28Q+F(Z)A"18D00(F4AU^% <55D\$ M0!/K"X!(I7_!B\$]10?
E>.>"0L(N5R:/&5I@+A_0"\ M8_"YGUBN[. [.92Z)8K(B0>-[CI,9>\$'5_4&ZY;P;NA'-Y8]@Y+?(+I< \;+E%
M"!W5:/ZT3_F;S1\A,GK#^=".'FLZWW-UY.[FJN&6ZR>WYM4D_JZ_U0BFQ+C@V"DB8*UQ1P14,:H0J07/@I5LW^?
DP=8&K._00_MT^VI4^"FZ_&YUZ9%I*P-7T2C0\$\\ !!4^VU'A3'W8+](3C8F0-NC=,';[\]
MS!9/6G_1R^]3J8_7IMWQ'Z_T7)NI=?\7W[J_:0\Q)K@0VL<_R@,?
=K,YZ[^Q^NM_UG*93F>EA2>16D0\$U*B;+RV0SY5CXJ?'Z<[FNM\G\YM^ M6"SKU.40^FN3'RD+0I&A&!2FTBZ&*0
SBH,B%VZ(%G9CMD)TXFE2 ^NYW03#_MY99TMFIH!\XY/HV6G^9*@T&8-MJ)OZ.;;
<@FG%A_5K14\$XI/\$QIW(0%9@0\F M\$)^ (](*XDLWZV2UF92^=\$/=BJ_MSUT?V73G4:SJX\CUV^]UCM5G
MR(S;C^2,L_>=0LY=?W'*8IU>,*F48,9U2BY00>TN*SE@A\$A@["HF58YSA0/(MC,2:P.#+M)MP>)/17_#?
(,RS!]Y./;S)<@A08//_-NLPXX_K^\72A0EN,E3> M%*2ZJ6!5ISJCXH81^T\YK0,5VP3H16?R-*];EW^Q+
[P^[_S7?>DK^)\E0,G< MX6Y]]1LMN[_*ZU^5+N5ZY5JV3+_KV= /I\V>_E^;G."YY%6\$*8S]0\;|;Z-_7_M"
Z2F;@G30K\$P^;QU\HKW!.N)VUP_[HX=?"+]<^??'8[5[?#*31PIH'[1#"TI^C/5[CO;1%9?W;U;\$\Q-LE^
M2C.HN_94\$0A0F1= (\$D_+6@A"9Y+PV0_MYI(KC(?8QJ*4]1N4- KPBBB_D&M2AHL2J*HD)89*PS+
(H4C"USC/XRPK3F6.]AW\$51_X4ST_#TUQD)<2Y0F0;A<2KX;LF5=0F@FT1[MGA<\$5J@\$W
@.\$'1]]V,78Y4+D4)566"9NP^)"S"P8JS)U2G#@;UP#H#PTT^7_MB!>F:CJ2#=-FZY0-
_7<6GA'N^(\$]>%)T+S]5^?UXNC%ZM[\$+FLW=: MK]HB\0G!_I&J, *9NT6(3F@I?6)&<02B-
R&C;+JI_8';V1=C[Z9/1\$ _U3-UTP_M=XQE>YQMNR8]W61;YK(==PESOE. E"H;_)>QLT33P';009YDH=&Q'GO[
04_M_T?SY>U\ /OUN]0-?/K5F-(1'5;*D_!>_ \$A6!>"R1*#_UI,06E0:^\^-.TUG_M:+?"\$/S_M@05&CGMN'R^"?
%Z&04BR0^6126)-BFB3,VK5V^?%; "J?F0_N9M>6\$ \$L*2P&8_ME*[06PE_2:4_*PPNJ2Z%+(,;!GM1'3I]
[%R.\@5X^9E+R5\$(TU-,?--@N!X2#U+.CFR&!,W;U0\$U#_#,NRS_40_ENK
M!&H%!\0<\$,\$5PB9'7.#)>K'F,_82_?I02M]2_,_W*W7#0-91\+S^!K(2!_ML92:S!"!DV\IXJ3[#U[W+
(,;\$.HB!' +XJM*6^'B=0I8:T99TS%8:D@)\$BY_MJ46\$ KN_568YX4)I)8Q_7D9^'Y"!_Y@MR2:I,+16-
@HGD&&"T4-C!WL2SG_M04*?/,F*0H^0&+G*^[20AV7=/==&ME:LCP/U!S?DY_-R.I?3!SYKG?_5A%="=
MEZ6A(*>*_51R"AAD\$.0<8VHH%IKE89/;>NEY?:P7#6AK";GS<]-PDLT<*X&[M7C]J?J0UB9ZW73Y_M&M^&
[7[EZ>E_?/.E4/N_#/%JE+BG(\YQ5_&B'_N\$"@R@VLE#56*Q5TE!!
M>VB05MYK]3C3=>Y,TX'XU^E\^NWQ6[,6M@L@WUNL6W_\?;K4NL(;S@\$W!] MD1#)B[1'YVA@0,L1>

R@:\Y10IKF\82D3P_Y/N(" M+ K]MP<^7;KU]?J>+[_JE:0:P#G&\$&#I3 Y##6"F+ 4-(<44R%0&93*<)3,
MP+IF1R^3#<\$ (K_H0FP#W^B*) (_SLK"/RZS,BQSG<)R5*Z7D?\$AG? !3\IZ%%? M_/35<
=LUR2I6!@)05!HA1##B"!@A#I<*T\$!:#+D#4;PU-RVG]S "J29+3YM^E#^ MU(Z\^_DFFX=VMCT#FI^&2
=%F&)H4.@2W@Q8_ZFE?7K*5W@5E9>0JGIY*VU2]9/[Z8S07S-U_KK80DT*9\$L2DYR0!2Q;YL:
M#1AE!FC%D!NN2R7Q*I\X\?R!%W-#,:M)9AN: ?LOX%"#]ZS:!F&\$+-4Q"[Z5Y M1HXC:W&EY;]]77S =WMGLPSM#
{05=^IYHRRW,\)LUM>YRR(R=M\^NF[3?+Z; MG_V*S_08<'G=TL^E ?ZMCW%9CD30"HED%&2:Y'G"#!8N0-
])NPZ@U_P^%, MOE2'7GS07V6.Z\$W6DLUN_])90:'K7Y"#_1*X3%L.LAT+F>/A.4 QB;_>2_6D_M
0^!6%Q2L"]RB=*\$0P7031KV?MAX*<2A\NTE% ??'!G!V)1?UX^NZUEK2_0&.DPB= M#WJDD#M,PT2)'!0
_2=35!3DY\$-'X6<\$ZL;#SE[;62[:KZZ=_JWC>Z\^YG+ M(;R=JU_Y\A^ZG4\$A75;55*]VJ8
HEY4J!06,E(4U1+@_0!-<*&HHJG+*I0HZ
MKXS@8>A%;+FY:8[A.DS5'CE=*.L9+M=^FX07D.6\'. .9T' 74Z=-]-- MLE=\5B=5-_WY_Q\^?
W3=\$9KF^R@P[7R05U=R*+5B# B45VZ&N0%<% ((CA4K M)7.AJ ;5V:WS+ 7B-0P&G\$6IPW>VG:F0;
<8I0(375C%=">U&SY?\$M87B!E!N M\$,AS;2K"J-0L:'KVU5]9A+GA>&[F:63?
=ER'%G, \GK\+)"K@QYFH]1XMT,T M.AQG?UJ6LR[/6<-TML_U3;9E.ZOY[@1-
FLSW';'6[G>,S*;\$IH;1:VIB"6+M(" %+H!66A.&645)4)\ \ /F! MU>VN*+R=:60PMRC[:3IO_5T=E4,CG[J-
!TZ87KQ6;7\33-1<)7M: [5-W]* MQD\$JZ^(7;&6_I3@_57U)^^*/.8].EVX,Y3ZU=/NDK8"!?
9/0JQ'MK0F>J0U_MLDXH6-49<?7W?/[IH=980]A'K'?0YY]K. 90>0KU?JW5[7>]Y%IU_4L7P]HJ
MQ(DPA2B,RUT5.0=(XA((0C60"M)*",PQ"CKC>C&2#;S2:H*MWOK]RYO,^@V- M_@I47R&+1\#]I?"
[X!G^YUY\5TANT/C, _&4'9TK[T2]R1IALXZT69-60+;R M9JW -UDC"S30-'2@W#6@!2%0(@:*UV073EVN- @@E\$
MD_69[CVTAL[@VC3'>,V7RZ>ZP?.W0:/51PN3;7@)W.YZH7(3ZLCWY\$R&=]'ZU_MJW0I1T3W<=./W191P=
(M,&T/=K[<:[VN+8]CE<\YHR0G>0\$(+OU_F!2_24\$ MJHAAN48\$0R^E\$5]8!6QJ0T-
K1Z/0[?)?PR.3Z!QT*TDWYP UKRT3E]@37D" M_+*78;\$,:[L90]/T>*YJ0%NXR7S\0%]ZG2ZM73[]9'?
&_10[86N#-^IW+;EKK6^[*@_+E!T)26"N1" MEY30JI &AG3?|B<=I(;#6W-;1K*ZC>CBSI9DV07I,
[/S]ZY%#8_4VT8L,)T MLL.I3HG;<.\$"=C]WH#V<[;E99")1>\$)# +H @B/:MN%_+05J_4M2Y]D0"+HL"8 GS
M4B!10!-^U#((JT;/D@W]3.\82)0Q->#;'S@>N?H[&?V\8WNB>'?S85K)1CD MU&)0E%,>0PS#Z/CG"H,"?
02@8%B*\$2&!--UJL=V<0V\.\$-X_Z;0%NL=33K_.F M;\$0^N;+PU:QQP!"ME- 2_5-I#I"VABFG4 "%,"6D(
77U*]A_@5<="F02]KH M6_JNW[-I.&CG0\BG;+WC(<#GC83:(W(P('Q1^M?QTSDJ[ISS9BVD+5?9AJWL M;DQ(
X())PT,;%U*H(9]N(#:[_ %]U_JM-%62X#)W>4\$/DH\<+.%PF^U[8X<)' M7=B8X_6,KU:?
3!UN00TQ74T(L5J=Y!1PP:QR%ZY-6,\$8@!52T%K\!4\$LJD? ' MYP2 M]V2;CY,WC-;Q8S.FCN:\D)@*D-<
2P!\$)S!#0JD="D,K :NE]YS'R_B+2. M^!5R?>5F^V&S <@!;DR!7-#F(GLP\$(NJGPP;\$<+?W-&[R;:<>L%
_SZ6IEJ4VJJD2TR W LH!V260H^CT4)** MYR4R!^F@)=U+;>A@Q^+;M\6\27>MJ]#0]>R"
(M1^X/P6>S(X(N,@+6'[P60U_MZ9ML0SQACR ?&5-U ^JE-6[?'Q^0#SK\>-
T4<8CUBA>3*0T(W(&'.Q<)F_E_.I&XM\U?0IC <3Z0V\RD+IB0U%>!&8X_PUD! :QDP:8U[SF')
M6%!7PM.DAC;0C9E*G9D- <V0*<1\M0XT\@=IE.V-.LV@1NJY_5*>#N=L*E_MZHE\$FM"XC6W."GS0G>;\ '1&
[_(G@XT;U"UCA0N6@0LCU?D *T,*N8F/->.NU_M8TZ,_X;?2VIP0_Z2 PP/I#R,@63R!UKN)XX:8JR#,U^+0Z&0#
(LXF^\$4)JE2_M.+S\$Z[4B^I\PGD'A);>%W1YR9L9_3\7YN-8%>K7_C:UT?%0/VKY0^S%\ MU9."E%
(@('P"C3G59,\.JKL*=7Q1E:2BF6.@0L\.?),"JS.K^NCRA82!;>0V6298%16:H*4(5#B18FVS*1;;@ (K\ -PM-
/JZ1&*4R?) H/AG,0^+4>6%])^*3 M(N8!PLEL,9]([YRE^E1E6TSV0?/5UH='DF0\$\@KPBDN_M"H!)80"
(@VC7%2_M%5ZG'F?HC'&'V2E[;\$@'. @]'EX2&GD#E0HQ0T6.<8YZ9_PC-)@\$.<6-5CL_M:H5G-?
543M%YR7H]HI;QW.'SLNPYPMY7)XL?7U)/XZ=UU^WR0[YJ=FZI(\ M;E\$;\C.A7@SN82KY6,ILMF,\ MZW*>-
@RP??D][,UHJ<+T64LFQJ;<%RG_C(P6+[?;9Y!>)>33/10P^!7)S#ZK5FK-4:N9J\$!+V\$-
'W0;==EZSDG5X&23Z\$@?# M<'MR' %K;[(>P'CLFCY/B0WK+N0_[A\>J:0D],5KB0E<20*[(=(\$R) 46" M@)
(BEI0"M?JJ0GI]'9((VA;#>WK=N5N;5-26[+ ^"RUR\I^9KLF'!FH/\$\$*Z MH)I@!#A&KB%U@8_H%
:55EA;GX\4(@?L7<93@D&Y+6M_2^&)\ \ KCJG2_\$N> M_X3*RLU9M?|A6D!L[';\$3.@I%]YFEK\$D[+E"PZ?
T!@Y%C*0\$/(\^GK[RT<_Z[Z7RZUA^FWUTGM[5] MS].M:U5W5I_P4ZJ<6;UE_1H(\$%<8)KF=IU2P;G_2E
3UTC'.FA#^DZ]>0; M5D#-2[9C9A/^;)K,AQ[6^6/LN<@_02[PX"X=:!>TX>5/WEW_K.\$K]2LWQ>0
MT[W[09\0IW_VHP'>?W0@TZ7S@#L5JN)K*K"&Z"4A0JNC%"JUR@ <+^FS4\$ M!-(,3[[KI5CXJI?CA\$(61)><[
[K8S]J.8;NEF\IX0>S)A0G_J[?78HA6@!I7_MFI(*)]Q;G4RM-8D,)@@'M; >Y'*4(A?M^\$&@8L=\)YQ2PTC"
1&D_(8494!P) M;0W'W&Y0F[9N=Z,@M-^>[>ZE_.6WR5S^981M*!MZ-UE';D(\$ MD5'W@WY!G^0^,U?'Z?
G?],IZ!7+=CH+8%*E47# &-<@1MLX=,JJ4W#(184()P) F_N_3(&!<).-#2P)@B5U
M(Y6\3ZZ>/WWH15B3"ZTN/8"@?%\%+=%C@0M0)%'.&=2!&@"SD;*UKTR30]V+/\^7NVK[-73WH5[S=HOC2A=M^A9#
TXC0IOX>)1/"_U5;P_] (6-6B2!, 'M*ZE*\K1;P2P7DZ():*0+H&][\M M9K-WBZ4C,=,X*JT1IPRA%@UK_T0E3I
Z9*A2B\$C_D-K%P/RLLZW=? M<&QD+1\AAI\$'BAYV8%ILPI3;M6"Y0-=\)#P7]]4_#M.P/>./2!G3'[[[F*OW
M@C\BDT_?]V.W1?8ZV3RRS>_B/Z_CWR^GKJ% ^%W0CD8K7_1'5['>= ^INZ+>W]A.\7Q_M]V%?W,.C-
7E=EM^6N6S'W:#\$TT=%-7[FE%X'K<3SIBOX:"ISJC\$(>;TP?? M0_*_+Y9U!\ "/)M^L_C&I_.)+*1 "B,@,(\$
_84!%8@#52A2"0:)W?6#>HXP_M^@/0 ?TY'3=9S5+6M^MT3&5_-&P%1C)"0?=4XL-!&+B.DZ,8KG[CL\$BE2_.I
MCZL2XZ_Y4&Z1C[F@T[>+1"SU09Z0+-7W<[GXIMV9];%Y2VX0<9T#WIF^=*0^ M_MCTX0^HUY, '?\QH655D+! "
%'NYA"4&_@(#2!5CJ_0>56407;P,&P.K?1Z MQHYE?,M-H'DFU!0+&46ERW*!?'YF_90QA
PN,Q+AIDF6H2E3%W_G46E7'F^ MM1?QTOSVK^N_B+!MKFEHL,=PUG"< >1X_0GFQ_#\$A0':+^FPGNUX0\G<['#K
MAUK^\$W>Y'PS?E-WQTS,Y?E?]P8 ^VHU_.&H7G[BZ/(Y73[4YT)R^04)447(\$ MN*A5N":
DHH!@JA5WZ@J<:DBSU"?TQH09-1D"8FGUJZ]](3S_+7@,\M+L+C@_M%#(,ADM.%\$)F/Z,\(#2M4[]3HG<>N?
U%MBCJ_G"C75IYJ!;AQ_M5:LE,X_OU[H(NY9LPAV3!,VI&Y[EP8^JVSXW:_XCFVV&"+Z(YD5[]TU@0Y_Q
M(!>XW[/Z%0;G]XHK_E>.,;R-Y(>\CX=36M#VH_M.E>\^\$94IT!_V=VHN@Q?
NU0&0"]@I+Y4QRA'I(Q]7NH'/E70YZ0'I>L[L!EQ M"(DI(48<4%ZW5<_5H%0S0"5\$K"@P(=(_3^P\$D8%WW)9J-
MV0#4AV.@5+0XI-M)6R84MS(N:5X=LRC0[P!&5T)Y(Y+XSIXSVUD=YVJ4.",9+VI6Z?N'2]?ZPSW_M>TE:YZZ-
Y)[MW>.&V8W^H#G9_@EAB1, M29U\$(_0#\$4X84 @0,Y&MY\$-05&,G (+GUDK(K;'#8AZ66DZWK<:^+9;KZ?^T
M&PPJH=+6YV1"N&Y@.0.<60M#"48,456!35#/F!Y: @ [0].\JUX\\$[M\$, 'PYP&

MS&_E)X(A;5WB3H7ZV&F=ZT#.QS<9!\7\X?E0CW*7FPB!L"
M\7)6Y,.9+N=OB=VV6V^ECJ37)2^K)\U,Y3P0#;:**6I\!"!^C#1W4M?
TW[0#JK]GS&S^2N@<[W\T^!2+!CD@+QI<&C(9L M]C[Q'.KSLB7;V\$2&GD_/R?
PX39^]H[K'OUT8Y>0ZE+EL@1426DU BT-Q@! M*E51586LJ"ZVW7C\X\$.Q&Y\$Q/DNMK7HK!.QY TGUXL\7S?
<=>.,;XL/) M(Y;|OR* /'+4^/)0\8:KSI-V)1K;#*B)T@PZ10T@HA @S4H@L&2 5JK0D!.2
M4Z]I6W[DAD[N=:51W^02J-BDT#-P^2G0=" \$1FQV=/<*B&_/@Q&LQ_QD3*2. MSA ;5:OX"?
Y<.7C>=6\$=;5,\$^\$%_U|-BTR*("25YR0 KG)56: -XC@W0>2YD MR7-5Z:;#X3
^MH:;SCE161!>:'H'&;S\$G\$CAL)>\6[TU;V6G-D4;^ 9JS>8B8
MNNKR"*7KU\$J>%OEDA6//+6^K5^GIY*VK07YZ^TT00T[G7W]9+OYX;P.NVH9QM2&<-[:PE[K><
MSR'50Y03RA^VC"-%]U| GH(=6;PK+? MZ^+[0]LG-.06 K!;KN>>.I2]11N MLT0]X9!\9_3+|]?
OM<3XEXMW %"- \6\SI.\YH_3*W+WX1K?M,KO?RNW270 M'M>/2^WB-^Y0=J(-JJ>C (SS\$B!)K)DMK9G-
"*LJEE=56?D/M;V8G8\$7?,M? MUDS5R,QBF8FL\$Z"!N8]W'YR^E7'N-#'J9C-F@W0+DJ
MK*SAKBU:/;G;1'8W'-87-CQF[Z^!>L@ (MC'1CQS;=N;E^U;\CVDXU^2X5: M_|BxBZF,..&(N%2+
[8^F2/37.^WM>D?Y1K] ^D+-'-YMHT A[4D(*85X0H E2 M !\$A@-#((-
U17A1!>IF0(T8&WF4ZSA9BQPEZP^;F(J<\$ (VP".-)UP%;4 M;5G(-
CR1NGX<(8I)I\FO=06R<=Z]I%UKR,3Z;NF7Z^UQ!@I8[_.N),U1? M2YC!FA; 7JLU\$;GQ3-
>TV.S9KXD? '60\$RJV!-[HYL W\|-!B-V^M1.66(JJ MLKL1T@ APP&3%0<5-)!06 CF%QJ-I#^X;=MPD?VTX>?
G;-HZ]'U+ W?6,175 M'3@6=5]S># L0RWY#!&&,I18"2SF<.HCVP^1T\$S:\$G'/2;\K.9-N]^^FZXD
MGVT(\$JKU/67BH#*YT-W:PAO LH M6M+^IS2G,3I 1I-\$\C 5\$25TT/G,6:&B3F=;/W6TLYFS@G5/9LY?
G+JEZ^K M;1YG'Z9&3PA1IJ"0 "V+"B"9Y]988!IP6BEB(*,H+'?=A^C B[4AE,TLI53M M6#N
^>WSJ6\$(6[F]C5=0LA:@#WT)>RT>BCOX.U5.R1?2\$ 500#\&ZD>N3 M"-9!KN:ESTL5 KF5I6KVS,+B@|F-
S1/+)0.7+N:6_L@YH\$]-^,0Z ND>'*J0L M"H4!+%S),T\$4,%(8JUD+@|0H4)4'Z=,!>1U:U78(9S0*83IUR%?
EIVY?R L(MT_0GL\$>A&4\$N/CVN5VN[<"VK?]/3 MK =KK6Z_6]Z_ZK<_]).5_KS1?UGRY|M-B(W\$?LJJ?
R^"]P#<,9"T'V8:%K,;AOB[MK].YVZ RP6=U M'TG70N?W+V|<'GZ3:0_8Q6>TEU^H0FM7VDXK2#4Q8R2NQW
,>ZK.)CG,3+YR)&1>\;1VR8B/E&T,\$PI!8K<.D>(M; &MA8,@_0TQ6]I>P-
\$%Y#T>I#.P&>:4PC;\$ _/|,M7E:W -YH(8_#I"?/KY8 M[##M>>#.M!03#L?K\$RC5;+NC-,8=3=PF8?MC=?
N&@|Y;MMGR"6E|GDB@-B5 Z0TJ]J \$-@M%*Z M+.W>*H-J#0XH#>Q4N^T PI;G(19^*_B"
<,6Y5Z0@_2MD4Y*DFC1'3Y_U/5V M4KSG2^WTA=#\$)J36:N5.')H1KG?|QV _:/,[5:H)RGC,"#1"L*!B"KM)-
@60 M2N[T5V_G8\$A9I;\$6?G2#9\$X36KLZ1%GA3XR-N+\/>\$U,J^GZZ?;I>:0%TI/
MJ++K5I8&2*8W3DQ!4*4"C###,8YJS050F4QW0-5KERC/UNLV|KM5RKZ=U>?:LUG M_]_TH?XX!"&RX%
##"L,D\$\$\$"\$0Q@H;R.RJR5D>UMG0&)F!ETG;W:ZE?),U MM#-+/'#=#] !U?
A6E\$3]L3<5*"M'8KT^P" KZ'7WLR&W]^D0[[.K7>W6<\$?H\ MN^5. UB_LCS^8\)I07*:0U 410D09 S8+8L
4G%C7<&1HA/VLSB=R!;[,EN1,Y^\.1S6JZ"5W#L[(E,C-/TQ65 MQCPK[G,#\ P-
T742UEC|LN;K.NSVP;VHZ6+^90&-3^>3JB);Y&4)8,ER@"I) M 2NT!@6MJKS4!6?"JV&1
[6!5V_K)VV)9Q0JV1_-?|V#SW(^:WH9'B\$K>H+ MH(BI,S@08KHB@AY:8U<(G!)?[2/J_QTT7MK70E
0\J0GJ<:G5)S=;XW&YM KF M%5]-5[-/%*U5W3S->K^W&[TQES:NVI^=0N6*I3FE>:"P H@4&U.D'8UB9
M&VT]40046QJ'R:&/;N2]5H\|S[7J<=10-=XMZ-B)D=H5MA_IL M7Y+('0TIW|.?-
KOVVPM3@L.\+&L>U;|;Q\$@:\$N#4,PE2LGB=808#@'OR"L(0 MM"YMR=-D +MF,X25U!2ZLFZ;)@#E
@ (AA20@TB0WC"*X;B&/%L: VOIYYUI MVNSU"YK0[- Y'U5)(' .8;HL0]X(V/ <")6C" LW0FE5KP'
AUN@'/X:5A2V^U M7\$^Z* Na; HQ=VG@1GRHBB'B56VL5'J0*<20BJ7'-&*\$3"S\;J MI3+P_NL2]MP_9CT+
[EDDH8MNBZMA(Z4ES1]N|=]0&?GMG ;K;0^9X^R\KS\$ MVZP|OX03E6W3^;U8KY>Y,@4R@'| (Y7
E3J\$G!3V&W1" HA%0R6 M7B=P B0'7IHF#M!4&%0>&?<,-S W(2T:860W9/6;8\ "Y=AL6AJUV
M.R|N@/5MSPA>0;+M. ^-6PG[@S?B7^=SMT\$BC9\$RS"C\])NMT4]J5WFRN| # MR-
J_I6*858(;XI5>>0#D@5=V2\M_L|T7^ P&&RU,V,)LR21,1C0) 5[Z/[S M1MLWCXK1W2N/7Q"W/SXKN-
CTJV[&L70*,V|%JM'Z6.:(0>+R.0D\$=L8_ *@[<"PXS_?CZ.= \$I[0:K7_1Y%KE MKV_GRG6E?
G#VZT>]GB">4R'+\$JB*4X @8<"ZS-1J'5E4&E,H2168[GJ2V, : M9D.Z;ERA-
W10LKD.G,/= "UA>%41I2(&4I'#9&26@N578W!AI%"0%K? !D05CS MV(&*2@|]F"XY^#2IL9.#
MSPI])#GX_#V117'MZ6.K; _*=^H:@[9X]E:NI]^GZZ?Z@&IWMH<*KBS>!9#< M:DVD9_&XS_0
,,E+S(1'W"NXGXZE\$4]LFTJ7EIMLPY@V=WE[|!|I8R+;)CB M.50.U !UL\5XT(/2=\$BE*@>\G%02P>3
7A09ICNR:F'"0Q>/?W*_ [Y80I[0 M5=,)4>202\,,, \$P+@ (35DI33"N#*5#D&\$ (19\$P&T|Y8"?8V_%^Y?
B(U.UG- MS[GVB]?C[?*_ !D(03-\$E!2[AS(23\$ P^N&0\@N9H' 2\$0]!"JD\$*4N>MV(%T)==-45_
<,% ,R61%:Z3)HRD):]H8.<;=3PQFWQ:.U-JPU MU\|^EEU&LX?&&@E37HG?DY]^NQ[Z82IPPV?68?0FV[&:
[?':-0-7-UG-KGM9 M&X90-DEXCNETFG(8,! ,IT\3,C:IOAP'VN4H>B\$JDE[W)R/YD70/5 ;09XL_5 M-
CAQI!\$E0J[ZD%L;458:L IQ8/^U*\$QAA&)%D/ <0VQHSWA;\$_.!0%WSE9JZ M3V
^'#= /GS<1&H'>;#P0X;ZJAX2IO- ^4N/ZEQY"WB./O=\$#'_=?>^TQ00Y M&VWT]7&T-!&M@6&UAF
MLKM%UF%G..0"JJ\ /AV#IRL>Q/0(Q\1 M.;&F=M*W-@5\$#!IN06"M7:5YB:UN9GD!2D\$UDHPCZR\ '#9G9>_S UM?
MER]0 M[[X\$CH'9E] /IHJ7*DS_M2&Q(8RFXR*D&HFR_!QIY@<%>Q@,CQJ^+6T" ^+ MA?
IS.IO=S@^B7V^F*SE;N'*D[259U\$ MP?)K]|I:CE,SY50ZM25AC0S+6G=\$WFIEC4SU;-'\$ M!>% "Y08X(*UQ
#G@%&.KR)B I3*\$E>3"8'DB5H(F2^8S0K\KU1F10.:XW:]1I;YF^R 2VLX5\$>+I>BM%KQ]43 ^X18T]- M,;
(4;_?X;87\;J>9%KF\$B(.6&4*@ I% 4?V/P26B!>\$TAC8%-J0[%0#/J&[!|!
M*W=XPZ5K=@QA900(DWY=7F=C[Q&Q9P6FJJY4QT[7K6CDQK*24EPJ@BN8 D=+Z M/P83D#.,L3',_D000?
7NT0,OLDW?S> :CHWD?NLJ3IZPY>1\$;:00_>0H_5P? ME\T>ZP%\GQ?
+)F%F05Y.Q>.]Z[076BWH2BJMK7LQF[C+K@VM+(FTEQ5/)T]5M M;|X\=I7&,X&.U&0\0^+Z 8MC>P)"6!"6,T
JINVJE1H(NUT"7< *PMPH#(.: MYP[,[WC];<8;)JX80HC?PU_06W@1@8RAS8R1\ 'Z!(8VKFS\C03]D<".]66;M
M)?#9>A[FU.EU:NGWU'EA57/&\$V;&1^RT>8@^ UD]7#P-8N-U8 MYR^^[F#UDV,DF\Y_SK:\9+?G40M6GN\$)-
*# 81'56GA@#S73A%/N+MMUHOFF1YL"1;9I]WXN?KAH2[3"-U6VOW,+:TUEYG+;)@:"D
M;HGL2_XZ[8X#P3G9RCCT.9=T:ZP[0[W1*FFW00DS#KTL5\C:>I7:%1XUG1CW=I/'|;G +XM+[7 M2]+99?

^\$Q <2JH<= 4WQ7:[:>%0]}F ML=16.;G*7NL*-J,V=K]?61/MD[GC/R8<4JXHA\$!+XBPBI0\$GA ') "I\$7I((5
M"FH",!KG RNEW^+=S6=UT. M,Z&Z*\$M8@IP; !E#%""*#6K],\<)ZV5@ABB??]5(L M(ONBM!RE>=65ZS^E5/
MY]]UR^!+?==^F]N+?']AV^2GU^ =YBC6V8Y!;X OK4 ' DWV2_U>VS,I47.> M[5B]R;BQ*L+5+Z7;4D?'-
]F/![:?HV[SH[^.YP;#^ S\$F1Z_Z;5+=%IM90*U M/9,90+HH= \$@9\)-21&
%D8!*C%"I<1821IB)QPG,W1NL)2/WQYKGK#452U. MY32P<\8)^N"?Y.I;Z=S=J9>IN:AK<='K1,
[MK*&K 1GY\$GA2GPBGH:WJYQ_)X7U MU&EW6B*7]J1]^UAMGC2UEA;?
K=,'&_XN&/MD]F=T^N)]&\7JS6G3,0@6@N MM\X?IN@FRW+Z2?:0>N0,!
MFKQU;FH^K]11=R"X3S?:'8K@Y84@8Z7\$*/ @[QGP+SM!^&B I,^R0:H-CE*[FJE)WW"]]6A]-YW_9SY
MUX_+I;VAN;*.(\$ZTU\$8R H\$J46[]=FT *S0'6"K!%)8DKX)2F(9E=V!;L::1 MR8:LRYG7H<<)/54KS,=/G3:+=
:/DCS/YE MD^5/ S]DKGP/U<@6;\].?MQI9N?TYLKFOL?7=NH=8;91 LN#:\$Y@\$I1@ JI M\$7#!-
*"JI(8CA:G/0^S'4 8&MB>W!#-' ,!:=7"B6?LIY2(3"U*W74;,*@()PZ([.B(LC"/\$IE%,PQB \CHF?
JKA8TC!]]T BYL9)V%! ,GL9P2*&7" MR0&- \9-#3HEY-) 'CY,50"W\$S3009+S^9# M/9IC K7. ?[-S0;^9'Y?=-
[#1"!E6%%I@%6A -+ \ Z NRWH;R;%TW^=7\ .FB M&C!G8B&#P;G ,ZE&L;-2GLRLWK0J >]JU,]2LFC D-SI^?
67C\$4*[23%"&L& MF"ZG+<4YYV/P/\ "L"E*<%I!*7A)N#M0D]OH+?I;:T&=H100,ZM*,I:4.%QJN
MS3^"CM;ST#'%,"HDA:3,"VA^OK!460*5]6I)SDM&F6>*WL,[<9FB6BFN,@8RUPY2VME+8;K1 M7E?
NYM5J64]]J,.[X6*E&B>P3)#!"*>\$,@43V"J)"X0XM08.#X:\0B-\$1,2
M/BWFC ",60YH\LZWC'1%GIZ%:L<0<]075^+@MYLC0>"]L<\(&6D['Z,PZB8^ M(^+^UCWWTJ M)(0ER*H
@2#" .H.4V(,^OPE*F<*97]7]*P/;ES55&Z:6#GD=1Z-Z"Y]7HU'6U0&Z]=96S%/]7?"M(IL@,JADZ)\$&P>Y__R1
M9T">\$.]P\..I#P9&E(6P)XNYX#TL9E.QTY&:%X+GA,"2E,8.XV:[]T327,"^\$ M5"036&.
6(G20V\Y;:\$04&C1&S<]F0<%/PV9R _D'?B[+%"N^>)C1N M(/>BP 78\JVK0AJ.^!VX*#0BM\$S0:' M66GS
V6I(14XAZI FJ99P?- \$N&SRZ]@8T26S[<55=0.-;YIV@CU>;^ILLZ ? M%\M5X[OH<;YMW<56_99HH5W0KES
 \UIG0&4)]!#>MS.E]U< W-:3T[]H>Y1
MQ(378U#L*#"S8SM;P!10_%ULU&U \;WVI7\$FAA[-2IGA]>&WV\..)7([S M40;ZIX49BG=SJ?1T/EVI3]-
G=3#\]MW+;^P?B^5[VV[BTZ906H94P@724#-M M3,@,(Z4DA# Q\ -FR90G6/!T9]QC>F"X(=#
<[=&@H]E^I'78UNZNUH?U M\:=BFFEJMKY4P-8>\\$,Y\;4JZ:B-0\F6.1EDA"KV[B&2\$@)2X[JB9H93K!D
M1'G-IAB#Z7&"%D"UK'A&)\$99-D='VAM;C/\XQ\$[Q>T\ VT/]!:-RB'Z"H;)EV
M*XFQ%4\$CBQW;TPK27(4B>OU&Q#V6(W\$,EL?U38ZX" ?NSC%I7]-]>3=/IBL% M>FE9JKZH'VQJ3K[E0?
YU6@DV^[MBRPDI:48(R6#)%(6H3#3DN4ZAQH13G=N^ MFU[F<3@K Y\\$]N(&?
EEVE.TU=/5=@I=#V3.+]PJTW53].!CZ?* "NP?-!EMR& ML9NV)=4#FTI;4MD#NF\$06
YC=X"^\J6HS:&#&'F%OM'7 ':\I?153PSU!#PL M%\)0_Z(J\ S3Q_78N/ZAG-5L\69IMA)*;R[YD*8-EJB5\$C&)
([0 -56I-%\$V3 M-/6*'CE1'?JN _#E [?3_W@^\MW@4PUVM[9!A\[^F@I0\Z\FK'88^% 8*
M7D)'NY6[T]SY&NX!P^&]V^?+89KA_.*.;)G';121I;9\5A^KU?0'6ZDZZ/4R MT1E6J4H4Y+I0\$"6"G4B!M1UV7
IH>7 D/K!^V;)A[EK\$09;V;?; ,] MG%%TTQA#8..G-'JP;%@
+0^@8^*F"4V_@#:_P[2Z,L7C\$C*Q)GLJ/K\$XQ] ME>+]?3^M(M5T\M%06+W<2KFT+1G,C_?+;XM_SB_\$08P
(L:3=]<0Z? \ZHADM1^6B!(8.<- M[B#2D;U<*?&0CX0G?S/?;K:Q^6&
f> \]]3P2&T+E"LM5:*C%2C\X0009C(*=+XR7)"',SYVX_]\$/ M7!\$/XY>=J0R\$4_5034+X7&
[Z]B_LK^[7JVIE+H/&)/@090L\$S6>>C07]J!HO MA/F]M1ALKMN:S6Q:53JAJ\$@2Q(U**1B"B"44,ID1R!46A?
7JMP;DR0VP+WQ &.Y-0.H3K'L3#/\Y0GI _MV[Y'"WNOD/VU^=16ZA00R0U:P<%&T75*"("4FTNTIH2GB1%JK'P
MFB]PCMC0\$GX]-]FF<=Y\':[G<;*V=46!0%0]]J6ZFANM(N"QG.=G28UMKOL MHM!'7&270Q-HQ: ^?GF:U-
F*S=\R\;\$;:\$4ZG5AVDE9@M;H=";*U&B5">:5P]R\$^^-Z0R8.:?FT,+>;*]>ZF%YJ.=NA &'E: MBCTNP"Y6/4;
'\ ,U0B (-)9UY4-Z7/LG)0#"R7D&=>.,#HR6*EZ]]+[US8@ ML!/^Z@TMDBA+,=/&Y-
%1#JED&+&H"AIF6I6X+SP4T/Q>!M82QT00>L2H9JY M&-V4JMW@(?
AFS,Y*J^72.X\$VXLHYJKS760]/C=A;BF/SYBI[<=Z9/W^X]JDA628*DE M3,0\$3J)C%/*4Y9 (3E7.\$YX6F-
K\A;'C_3^> /% 00\$P)\FR] 8(20>Q%\$ T78-DXS*)][M\$9K6M8#U7X2="6;=B]#-%9KU7X35SHL0+;HY G*
<#YJ.R,^(,=G04=X-^;X" M?>4K0 M'JR0*=&R;?%2+&L-\];_LW> M-3^L([,W[-\$=*2/VD"%Z/GN3?
ZL^C; /=HH.?\$]*N++2JMW:MD%V M8^9\7LR;?S3=)WN]00_J?B=IA@M1=S9+EZ&Q\ M_096EW?
&3*Q#0[9#U.+ #[\ZU;3MJU9U[!JW]99M]9N]"-M7,9@'9/YKG MKY;3.H&H^=QZ/G4-
Q+W:B^'_@_GCCRVIT.NI2MPM=;S]W\$[J6!NZN.^] T:P MK05KVPBVW? 2,^(-Y.^'1]>]001F" N-[;
[W299[002-7]W%/[CK#Z'7EN MPEN]=VINOM[\NOWN;MZ&[3NB^N (4RUFM YTK[="YW0700)?(W:]>SW4=_OE
M02(?UTV\$WPD55;M[W3EXFCJ?^0[(1/?G;J(2)"4E#.(RRR R/YJKGA8=U (W2YS(P 9& G9B7+WZ->#
M*\$YCC&#Q#/1"!R,/1?;EXE:GG@5"=&F<>^K0%B%B;?N1?%#-?^ F;= KJG4X
M3Q);I!+;NG!]429N8ZQ,LT3A@II;F/4>E4P.M,<6"UU'K0CV^'4(NX>6F
M;:BX*=3.M+@EX[X7ZPIM\^EX0(N 4U!'&6-UA#D\$KV1FX\$XBG_8",3UBZ\$U M!]9[4,^I]J
VKZG;]^KY8VIC5A)D=GTHE(4MX"A%,_*1**9@2@1/*#%*P:_D MX"2M@??[^YZ/Y*:Y!QF39\$.]GE;<=
:SP=DY^-R40"10_+9_B\?7!H^&+M@2 MCEEZ<%Z:)4'IRF-7'AP4>3#NH/+7PEPW/ZVF^*^S^K+#Y0-
>AW&IO/'055^ MP-: #@C*A**S F[[EHW9<=(R Q;-: MUDF\RTTQ9.<2??+U=;GCZ^"U' 0U/ZW0 =;GH6M/;
%JV?!"W"KH#Y>'*&P2P M, ?0 3#(B4B(Y+Y+E([41Y#2D5)11YJ055F<)>E MZC70; H
PZM;;7)0+BY6:5#H.%W&-50U-?>&[5A">K%\$EJF(HY"\00WUF T M5[+CCDGS!.-@;)K0]\?,2>CNTW?
SSV0;9N5>M09WC^DNNGY;/2P7-MG+/+K[MW+WN&>L3SG"IRT)#F2<)>1+:674D0A3D0I6 T(0(YM01_0S(-
G;G0.9[,C7M> MQ_?3W[POLE_ (=0'36QXM1?3^4W<>P+
M;7+>=;D.1]KD@,W;=3<'C:AV9%WGW]B\749Q^VLNYZ;Y,_W M1HV1%0%J;]9K94I,A]-?KYY!,Q2!K\$R?
U8AC60HS"\$VT6 M[N9F._YH*W)FK.[P5_]@V!\?2J52)9,,EF6*C#G'!&1EAJ'D'"-6JJS(2G=S M[DIN1LRX/]-
UI,8;AGW.0&070L4^&A%03\0&#^!0"!1&PF/W\$(OU MT%?NXK [*B+;3]XKW^0VJ].\$.&BU\$1
CHH<(BX1I'I',%8BX3*+,W=RR/& MXW0@VT[<*0>N6!IR<.%ANNJ*PR_7/E6
TZ]IHZ'!'0AP007@7=0+?',)Y>-3!\%8R7HL;7/3Q,C=KDBSKW MHM7G.WK\ -Z.WUT;
[W]LS8+U<&E7>%)HMMW_6?8U+24J=Z.EL6Q,^#W+06,8W%N_5\MC_ :D^TZ#I M%?
^'Y104C'MV_(B]I&Z:^M46RD]C;]?HIEND_>059I\$6_45B5RR2M^X>!,Q(M.CPN;Z/J\D@W=?IPO_)

<,T=5M%L6+07{Q;+Y>*?AEXU02B1)2T9Q(7*C,HF M E**FPUFLH?9{K0%-^S\$ M?F/_6"S?SUA5W?
Z<5A,M=)K0HH ;*7-[-6D&&]H2 M9Z%RTQRQ /!3\$Y_LU;(V)RS\F\;3'T\EN @5;?^?)37J9G<1>G]G.WTG,. H
M [-NK9-0"QL3G80I3'VVB59B\4-],@0^;?&5= \?EH0GJ53RWDWK2SYY?=FS?[2RUC:LF_,IU: B";4
MD/C&"H8.P>*XL=\$!03X(E0Y)*^P\;)WYEJ>[^-Z]"LNL59+_W=P"ER=F'\$XD1XAA M4\$B.WL4-'G
MQ2/VXPZK0X1L\$+#\MK %:)G ;0'UK =, \!R RP[3=MJ MPP"XW?[X;00C>P_]X0FS@[(=#CP_C1N V^5@W=4
>FCAX8 ,4\407T0_A1R& MQ%FM[/G(\51SF*P[^CGP\$:\$Y#8\$-#QZ4>E69TT2:,Z3N7_ ; M^SG]L?
XQR0CA5,D<4L92B\$II.Z9S\\\\"I3(A.BFH5\?T(9D=^!C808!KYW81?
RLKXG>VU"S"."SV6NGE2\B/I1NPNYX]"9I&2:"5(6;:R/!(M1TL&9#5D5-7A@?],/EE!)J!I2&G(^2;?
+L/TTK,%M9/,RG2\$J=\$:H@XXQ"E MRJI_R2"C*LT4Q:@43@VUP@/G3S3+V=;E- F\$>9=2"N;JIY.+3\E.V09W-
E M;0J9QEMV(I9.!, \$0JS;"C BX00]!P!Q4-X0]3#@0EXM?BSX=*.Z?%+,RKQ(MJ(:\L)\$5&V/A2&&8&?
VB<:JSE'M9F <4!M8B[]G2,T1] (%C?/D:P3R#PUM2 M
Z3/GA0D5A3VX/GCAE!/B7<0 SSYP>M&^,4H\V\^>A0I3G"N%20IPQ 15\$!6 M2_Q9ENA<89(G-
BG>/9,M/HNCY+_M]>T(&,7<5G<%,;K@NVG<09J1W.A8T[P M2,'XD\$:>-AB1P5<91!@?
X%,S">@%!!L^2]E.ZF8)SVKI;G^;09\V+B.S6M9
ML]E0;-5V\$;C7IW033TB2R407YK:6"PH1RQ5DQJ""*"FPY\$)GBFOG.\$PTM@8V MPCH^ 6L8[0VM\$5M6P8_-
K];EPW8Z>U2&W][H#X\ 1+RU%Y9760R/0-&K+\$I8#"G^3HD5](\XMGPA5QJ MXT6FHB.T\$[2*_20WM?*4C=0U
_IMP?R!\$LF2IM4D!-M;B)(4DAM I=6YD1+ M-*\$\$.76A.4MEX%-J0[:9%MYK\$^C3#?
D40@Z'1PRY/>,T&Y%KDCV+/H;(/HV= M(X@>V+#9'P+/CLP71#0?:?G4ET?LH'R!_]W.R)
<^/'(0 :.Y%JQ>MN5)U?WJ MNUI^^[F]T_V\$951CUI-;?U00K 5FKC9IT03%!JZP5527.(;,,M
M1E0&*6L'.Z"R&4[B,0;Y;< U=.#^ MU=;6\^BX/L3?2 IZHH):5K RPH)6VA00D <&'<-
Q>;IF!%;H7Z'H#60&#+.-K MYP_\$>K/D6DPR\$)&RTD8AKN J\&7Q0N;K5Z^F.?]0IK.I0]K[B9U[G-3+G;[
M]+1<./%]HG*1)@D2L!0Y@:@L\$*1V!(YB6I88YPHCIXX?/D0'/N%:+L#2*J%U MS8>7 >T*G<,58@!_(Z%#@0+
=BPT-9SM(6K'1<#0.10Y1@_JK ;R)'7QT+6 ME'),&\A8RTTL;XZG\&?0*[/&N_*XBG=S@W&]
[N!%YHUK]3_K,V[\0'9 ,^F M.K,4#.%RN6D7B"RKA6VWE1#_RH"Q\ /VZP/RX502E: &0;J9,_6
MM/KX4RW%M++N3\ '*K"@Y3+\$N(4)9#KG&"HHL%PF7-, ".]M>I#CP!N[H [LB MVQ&C^XGUZR?SHVIYJD>.-
0GV#;-^_.TRR&Y[/BIT?KM_%[4F3;VE#C;DXZD! M9TDC*83+,\$95#<[B(RL)]R^&C&?KC8.S5[6%W%[*-
KUJB\$[-04;*ED-;0?#BLBQ38%FBC"F+FSE%!FB36&6 %IHBG,,LQDE3JG,:J2KG(MS= 5LI[8M MVCCU+[F8E-
0'E?P.Z MX7",6'/LU8X457[%-8P?/ZXN!)" /A8AMI])&KB/!XD XV4 LW8I1XH&49*QX< MF_VW%?
D=;'&\8[Q#1'J]51/;"H_K2LJMNKY"/+S6';G+*K22D13[AM(Z64 MADAI KE.-)02HTR5>;9+Y.?
W0\$AS<,[G50%0#00-L+I%G972V/BKH)T%S") M5JFB1\$,A2P,FXPFDHE2PL!,>I#U)7EW%4H'R=Q@TZ M+?
4:G"8+JKORM"\$S= !P[RQ0-=7R9XLC.8V<(#MW'[E^]KE*X+FJKIE;W=VD^ M1J.I:E7=5=5:R?NE_-:]
\0^M@7*][H^/MJ_3G0F4R)2"8NRS" 26\$N"@6-
MPE94<)HDB\$S,N<\$7KNHY#F,^>ZG/G0.6^L_UU'H>0YEE84]J09J*:C=N92\'
M]:7@C)]@R)5Q4TOCH^WI^>Z*@GL,]I(Z&QY!PX5Y_T'Y0UH^+0!PX;3^!7
M<3"+7/5[)5.04ND;!\A3U;V1G0Y&BPJLDZHQTR>"89EAB:\$@2D)\$DAPRHX(A
M314V6KK(D=23N7JTH\7/B<>^D0FBC00HR.&N2W1*!(,T\YF)&"I0L<.=!)^:;F&&N(P%\$ISD*V/W*B.,
C0*ZV/_^\$=" M:NSM%;4Q<#^LE]/Y8Z-!&L/WB[&-EU-A-\$0]L5H;?5&K:3.T98(0DBG+."QY MIB%*T@0RF>
<0BR*A::XQ+5AG9GYSK<8/YR? M8;ZH;D[P07XP
M (CI\$Y0=S3^KGZMO_U2S9_7;8K[Z7DT\$RDHLDQSRE&80E9I#QDH"2\ \$0SUA6 M4.R5?7(5-P,' MX&?
5N'06V=MRG(=>X;IM\J2D2\$6),+*OK (BQ!/(<6;K0T4F2*D3 MQ+Q&?6X?/;"2J0F!)TLI3G::=]
[8&!E=@V16#9;S]K92)?SA&)D\ 3[MUHO M5F &Q=WF=(2LD)G4*)'9GF92HWWBIJ:&:\$&#E7\$A'_TP,0F]-
!C_P9L!'@SG81<07[M MB,-%/0<\057N*-%YP)AIT"0?2D24)9@FF>0B00@2AA&60EHC#+4YTKGHM<
M)CXIAKUGCY)*V&0-AF0+IE^P4XJ!LOFIL7ZF7S05X^D8Z)IU(CGI^H"P?[/I?Z3?;<"S;V-[8
MPN;9YJ=J:IYU4" U_K0]\6Y^V.0GJ_N]8F0;'A-)YH3KJ7*C.VKC0&L,(%4
M2VX,8,Q)@9*\&=,*!M&]W:B]T?.IXLS]NF0.S[9R= MJR=N#;+6;MKP#;Z@GT(]/IMKRQ#8X6BG0-
9\;+/RC21V04]]]6:KI0<=V34D_M_/-\1J\$Z]>[C7D4CA,_!J40/_5\\$.;X-%\$#_.I6V>/,\$\$\$RJUA)BKTMP-
M\$PTI-69KB3%.2,:U+C+7N^1"@,K_XYFEW5BJ-;MU-V0A\=QN7P_0%I:3\03 M5U"0*^!)988+NB,>?,-HE\;Q
_50B^0\&#B(6YIGKFEDI,ZVUL?IZI M6@7,I=GOR]7T?^0?/RP73VJY>GDP"[XR?[,)VD]UFIA"F*1IAJ'9I-
;MF5-(M"6-0ESA-\H0@AI1?X4TLU@*2(TV]B>C3/\=L"V[@/7XJ@N-94\ SS')L1; (MS4H;%?2PHH^E=9,-
MQ*'.D?&+0LZ%E0C MCI",#.;!Y.G8SP_U@K]7=K;<[&XNU<_IUXF"1(HPTK!C%,\$42D0+,V-&8HD
M)SBA9;8*I]D-)RF,XP=0B8*;*C!D?3WA^BXNL*0D#;(%^XN:(W_(0P5[C#
M]Y\XLC_\A\$"'#0%3'PQ,T]WZ43:#6#Y,*S%;5.NEVG8.%ECF#'-[P[#=X-(" MEI)R#.\$L*)IRH13",J/[,
;LL?&0WLFX+JAYF9=Q,?";[0VZ-_TIEB!+0\N MW83]LVN]Q(Z51NM&=-
Q\62\@#A)C_ ;X=>"&:U>NIY/\$TD[8;S03K3)12%/9<
M+B\$B*89,))GY)Z:9P@41\$0GU?'\$C[+,W@NI&Z_H(R.L\+M&/'+7A-+!4C>V]
M6G3S!\\"CC5FZ3F+R!)IKF91(")CFQ.KD5\$)FFW.FI<;8(L8)3GW4<7R8]1Q MDV13G8!Z\$!P=KW_1T?
%3T\$>S"+=>R)NN>U?\$"YN7Q+&N8VY\$Q[UL>0%Q<)7R M^W;T=NE_7=J.W"Q1G#!-(4&);.;&D'LKG<-
WA/=H#K[[]0;!=WLQ_^!9^
MMDKCG9HK/347LUS17&4(\$L(H1#0/(5,*04Q8EE.EJ133NK"N>^%CIL2C""SG^YKQ344-TU*?
VF)1ARS<\$&L2)KN%)51%=P%4??U MVJ6/7Y>(:9[;Z\$CSPWOS[^GJ/5LN7_1B:6L3NK\$*DS(M"=4TA;)
(F3%AS!73 M6# *ID27""6%HKX72S\&AK]@?E\L5W!EZYKOS"UHRN;F2EDI@^OW-E3VK&+
MVJ]N_J#7L\>>!^WE(+F7?<1<-N=@7+Y M[45'D;PWWA'F(VVS_I-'W51'1-K?
0L<^\$G@X;GJO_#J=L[DP3[7.N6I2I%0P
ME1&H+JF_JY>F=X->)\SUA:2H1@IDD&44:0N6Q+9LX^GL@"4]TROPFJYZ@-
MO(5[Z0R_*69)UWAZQ@_.PN48/(@@F?DX%@Z1P7^L*1!330B>>HD8ZR@P5E: MXT8,7,0^"!W?3*NZ?
Z0J3^>-7]5B_JA.*,.&:8\@15G9KVQD0C,." MDB)/E"BD]"I_/\$EIX&V]'>&RZ"B#JB'MM[5/0^6VK:,
X+>EM()0B(*.:KR] M?%&P2/OX-)U1]_!%]:0;7IT]@A[=&L^BDS8D#[]I]\(]P;4,:0/ZR[MM>1^[:

(0"76V%_3)+X_7Z/D2_SM=G"]^+.!# MH_BNY'JF[07M,Y0.;\$3IU\7R*YNIKTJT'58_3>?J;J5^5!.DI,H20B
I2PP1 MU1*RE_F8)EQD.DDD3[VFK7I1'U@W=;R>PTVW-C(\$+#+@''U#X_+\$JAY\G2N_M^:'M9GX,AJ&?MK--
>7L@W6PQA'JQA#6&3L#YMS4, 2!6JT(OVN.V'PR!Y:"E M8-!#HG5@^:+\$XG\$^_5\E[Z0Y>:9ZRC895?7D0J62?
UTLY#^GLJGM7/;RX,UG MS&\$E/Z05A.>2*Z(T)%F:0,09@A3Q#&HBJ\$H*DG#D-=5X(#ZIU)M_^\)?=WJJ MU
_8:Z=B&VQ5363EZG8J41;._3?^]@>7PTY3'VZ5L>09]IMOD!=""Q?0,ZQIM* MW1[OH&7^!ACV!^V/\$A/?X?
JA1.'RM?N?Q(3:H=)5'(!M]^Y>)Y6AE&S"ES M*V4]EY7-0J@?ZWFKIA[85-
99]/> &V68(P\$6DARL3)W34,>X,G=+3\ F.# ;;A M&"Q[+(-Z^GM3;.;.P.6@91W40--8D0\$M]QZ7V/@+ZW#G?|7E
M\HRS;5;*WCBVS((^M\R"YHBH/LY:#D&OS^!;T=7ZN%MK)2'G^)55RS,P7'- M'MMNI7^-Y!,9#,"SSI3X5,?
SP@R&V([9C@J@3W9.Y_U)V5H_I>:/GY?7Gf_M; '[fJ
Q; ;#K0_FA'fJ0356;*LX)"D1!LFU=*6.8LAXQ0@A*=>*L=S-)2!@4_* MC@' &@fL[FU8_#/+
ZCSLFT6Y(MB2)\D2&^TW:X^OV+HZ>0>A*J:C=@V?+ M#-BPTWP"6(8B]IL/1")64WI?N-VK@\\$YZ"]?>AS
BX"33?%!_9BfQ^/RWF MM^+[U*A%>S[?ZZ]/2IB[B9]&-ZIJM9BK":&9HI2DL\$AY"1\$0%*1:\$.@I+A,I M.L
>0]T/'LTU!Y M= \S/X(?X-VZ[;.)C?YVQOQE G"5%GD&NU_QM]TFC-5T[*D"_V=KQ
M#P18,YM]U=MV7YIV0=\60['E?R0;-M&&U:H)8YJE:99"@(\$ (EH(6*;\$^B]Q M+I,T-7!>>\$-M.-
DY*GH]DW[4W-1!C0%3(M'%*2<,A0JE,DTB+ATJWU0#RF?'904#N"SXLY%*SZ#AY;=NNM,MUV'JJ'((+I
MAB,@OK.E5Z@ASNHX:/31\$??3]1U[M3+?[^T\$MAS8+F\MDV#/X];[U.@+X'%\$ MC+X088?'2 OB=[!\$Q>
[LD1.'TGB'451D=HZIN\$_.?;NUVTIL6RVT+4!+707,+LD2&PN]D M.\$!AIR/S(15\ '0)&:XEUF>+([;&
<(3ALE>7^U3!U\)\LQFE\:" G7]506;3&(M\$3,C5!;&9E,,HE1RR#.9F'*4A1I3C*6&B_XV2&=A)8HMMW-
S':X\MSU)[!Q MV^C72^QYPZ^%;: Q-<7+U4'>N_F\4)\$V\ DBH^[9\X+N;],+G[ZN%:\W19LJ
MV258JNJSLI/AS&VJ2Z*<) 9%SIFY26+KYL/(]DFW Z(0%TF*)2?8:9))"/&! M=
[\$E%=86PPDYMT\%]Y^>WS3/F.UZ%*XP9;1.E.['GAI[]D=- '[:0A@\$+G7
MAA/I5^F_X0/*J9X<7L\8(('%+6A%K52;&C9]J>"82_VY%#E\$,J&0ES9^ M@*A*;5Y0Y-=XQY>!L1.U9,L",%PJ\
NKNJS*F#E:QX!VTT-#PN>GBR[G:'7L_M,O/)GUXI"RM,UB,D:5UC/S;R=(Z
XY7EM:YYP2.A:F0.>TJ,LPN:F3J,+[Z8^NC>YX MXZ&0B07\$'C[B*?
S!SQ/F+87N^;:7[*Q/U0.L/"YQY.= \$4)ZQ0!2R) MS?1)&
(4TPQRF'&NBD4ZI\DH0/T9DZ(M+TQRZHPG^:*AZ%0D?1<=M=U\KL]^& M]A;7>P.?DR?
2GCU*8M1M>Df[(_9UY]K/1RN:KA\5L*EXFV%CI6F@\$M404HE07 MD",I8(EY(3@K>8:\? RG20V\,8^53'NZ!L
Y+8WXPCOMT./R@T:JN"/\K^# M1 \$N2SM)_7+N*&N0LODA0W(/<5?R#4]WYB]?D#K=-.QXDV5V;<< I9EIA3'6%C
M[5XGM&\C60/UTL6 MDG0;(.&UF;7M&D;/G-T3Q2T]M002*^3 [0%[/-%U_T-AMD\MU/N^F,F['T+
M19,WVX6Y";,ZPX1"67 %\$4U3R C#T-S+2RJ(3IC?#?P,K8'5Q(:R32_M2'N. M9S\#E-0!'TE\ /S6RE;Q/=8#\$
?I8LU;/T-IW""KET4^F*SN\]6PC;SGF.]Z M"7^8SM;=L.#J?KVJ5FQN>PI)P#&LB2V/_\X0(+Y/?
MD_[84;UFUI2-C80%CO_&Y*TG4H'%EB, @6R8#1].Y;L(:HIC0&C]E,E!&; M-[SA_038N \$M@_%T3" OD?
2.+_51=5\$@-/OZ*?0QHW;H/-HH;C]1\GfU72V_ M?6?S+N5Z0G#!))'&<[TS
M=,"%#/:00HWEN=YEZ]S=\W1+SR,3WVNAP,I(M>D)^NI=/Z];C=?M!1K(^VM[MJ8=?EDA]0Z]D(G3(-%]M6U70-
f'^HMC,,0U7-IU_6E35),T(22014)<8VZQ< M#4NN,E@PFF="9F5>>C6X]R, _*'1D0./AIZQK9=@MK
IB[8CH8&]+H.V0_W! M5I;A%VLGLITN[04GJHT\0@.G09;"[=08#F_M>_0_MZ> NT"6'[+Y:CB//K MPZ"(-
G/:B_C(,Z=#@#F<.1WTE#"U]<6:]??Z]ZI1B_=\99YKM>7'G\ (HQT=+
MMAD'J&H71:=87R:9\$)J@%,R325\$6<\$A97D*I(XZ[@"YCQ:BSJ6QBK S#^K
M]:0.06\^&,AS1DFZK/-3\N%KYR;PAMV(8)TWP9_PU1;(MVQ!8R>ZQBK^_.V MK+4UTA0FXFG!J_&)I!##^1A5-
UX-U[Z:0/Z!5]9)?/SYI.;&JMDDUI94"JI4 M'DLA.416&98XHY!@FI0T,\J294\$%\$?N4!C;?MOGfJB7LF8-
_&B(WU1-%<#_5_MLI6YHSE(H0%R6)7(!S0>9U2@U/BGJPI./F%2!63#TL[S'/U\F#> ML_Z*/Y
M[5,=\$L*@54B&\$R1U':.@X9<"0ISG\$HM*"&BIL1?RC#"G+J7N) >V%7H#1.K)\$\8,%PT/GF5+E[%S_M4R!Q\$?
%3'#TP'EHP60(WH&\$ U!Q\$+%QREC96Y)=E@N.6+CD#<%"[Y/[-J.J@_M30UB28K+\$G'(:&K,C,2H
U84!):2\)\RG1E%HKY*)L]3&4P)[[WT4]>"53!4- MAZNV/MQ", \$!E9.,PV[XUTBKX?
_KX@6*Q(12DRXP:5+PA[\$/^]]/EK.@E,>*X4RG & MRU0AB) QPVFJ.#16>):0/%&ZR'W&13:/]=J2_M-
U0]7S=\$-2<5JI'4]1;UD\ MC\OS @06\,<^IJ'OD(I_LG#;/>0_C,SWB^>U7+CC2VX3!63)2QTRFT'PRY_M5
Q*I8T9FI64IDX-,PZ> //"Y5--R\<|>D/_\7KA**K MX'R0U]R,H\ P'S#BU60L FS'%?2E!3TS
7T#_Z)'GC0Y]I8SDI'UA@0;U=!fOW*?,#;? M((>!) N:5^I_UK:#_G,="-HT9LA]M)@!S/FAAB>ZK^?
8D':E)_4;18:0 DG7&UTB50#Y3\$ MQ2\$!D_ ^L:Y67=SVN_WN(+Z8E,9JNE*?
57+YZFPW2>G"]G6#=@/U*WJ)I)* MRE&2PR(M;1;.%L!OF?,X_Z^: M:PSH]:R%IU_LX>[]S7%
[=70NVB(ML:SS6FVfZ_M%M0[%F/&F<;!,5JH:F!V
M1XYVC0/^8A09@.LETVCA"V7&)I+,:0"LFP)DFFE%>:C001@15TKQFNN>!N:/0I9R?PW'1L;\$C\].06C9LM
M%@\$-VGVDc*3%G\$B.JHE\0-C7)E]?#;S>&36CJML' []:+I6L39GV70TT1 I9+N7:6*,0DRD!< \SG#C-.':@-
;2!5E,&MV:#^T(NF3=6CG>]. AX MW09,"#_ CG>0+] :5[PRE<2]]ET4^N/8Y?"6@!>&G0?S1>GQL">1037&P(?-
% MM?W?JG0]8-2&F#ZQV=\56WXS*Z%NY_+;=V7,86UVU803FF&EJ3GY&8<(ZP12 ME6N8%)FN9*"<=>A5>S,
f!.,*\4J3W6JPU%CV: UX-]7F.,#Z&?4K&LU5YZ M4-=4;[D#6_9LZ&C#(+
<@IK%&050KX.Z1\ _&4=\$/:)_8K\+*KH*TJ !CNPK+ MG55XVJS"BUV'U685MN]^K/:0T5 [VT_R>BKC-
: ",ALA.Q\IX3PTX:K8W6SM# MZ]UB0JZ^AN'F(MN8_U[5!.L"I(G0I@%+.QY(B0L\$]L7C_\$\I2G"2#BER'C0
M'/C0Z&4JU0/7N64#5!T?W5 KYC5@W1%-AP,C/D:>'K@M//6P0)H#L&\$!/_ P(MCX=FCP]3F/J.)>?
&K63[8>7KYU<#2=W06]EHK?38RF8N\ MK>YD)4M103GDRJ824II EB ,29EQ+4B&6.DW#/_ DJ:%3B.IF9S-S-
,'.*IEM M>? L@C\--EMM-.PX\$?MJOD;Y'] 9LR48L@f\H6JPZ^-. \$QBV\$ORCP027\Y6]< MD>?X[G]:Q[0]M
Y;)KMZN9M7J^6ZL<^Z%FH["1]W\ \;00Y?<\5?S_-4'ME(; MC^"\$I5@7-NU>\$Y%_)+GMEU'F4%'-2R%DGB9>
(=@W[]G_*JI-5;/-B'_ ^L\$: M;\$U38L^>Q&\&+I^,QK? [YM.:&R\$!3UI^ T[]], =S204"'TDK;\$6'%C)>Y,8
M(V?I)'F/_A2';DH1] ^8!Q. /'\ M?E!\K:KNYQ^FU=.B8K,)28H4(5[5!_ %D9;,-7-H%AfE2N-
2%X(DH/8)E_6/**_M6A0:K'-!!=]"G)YM+19?P_4\$U
M_S7_GJUES6+3[/:+N6%\UJ)U807BJ6:9U!J1NU>SB%5@D\$A;><9R4MI.TNY M[^5QV1]847Q6*S#MLN?
K9G75]SJ-H/Y!;1GWG_\$\A*[J:6WNW!^_.L]R=M.\$ M%WL,VL3?CG?0?,2NX\X0=[_1"+4MG_BED^L0=4U%

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

V+ 'GABI#UJS=A)Q!>T(<>L/!/? .H1\@IQQ9NJ<%\$>MA-&!
M_GF"0TH549@Q@"'1N; !2@>: @XFE"#12I=0ZP>7(1^GFQ>0G154C470 JK=7
MZZZW]'^'LPN0I8, &., !. 2LJEM81XB-DC%T;W\$; "#PM.
MCF)W!XBYU;AK0[^5Q3F>-44\$+E2C+&@G5D!FY. "ADL&)UC4F|VD8. P|F\$*P<
MQ>@./ (LYW4J4#A[&Z846;X(GZ?D8]W:UB3705:T)1"F>G:54)X|YT#@6\ <74 M 0K?X2I, 9YA?A<6,
(HOEK>V^Q#)-T|7\$N)R95AYRENL.J'7ZBG0@%!J6931D M|QL#| M4C7NG.1#6&@NC W@|9-
3\$!=""C(N(#,DX|J+EE 3.P8FS.GB00GFH3 MUR;6& ?B0A?|3E1)0>3;.S6I""I=\$| T7YP#+M%&5K7?0|
MFD8:TSK6;>;QLIV=HH\ M*A6"@5C0.06C(#+H^M22)8\Z6:|5ZT?54|2SNU[C0\V^GB0Z*Y|)1+NL P=J M_|
<8:FJB=<\$JFY6)K1-L|E(P|IU58R0-) 'L|L+7^J2^A=G8;E\4|9J^-G7 MZ7*2(-
)LMI,VFA0WEB(18%)\$GNBD\$8:T?|Z? LQG4#H E0 \M1|.X -[?I M?
SD_IPAC002|4)PF+S,37XK6\$'GF4%QA/%A6GAXA=-"5YP,J.D'^*>*)?^=Y M'^*\|0,M|7%00|^Y%_V^X'L.;=,'
8X(@A*0Y60*<2Q2+:D.DE.B+;|Y4=CLY MX^+G6\$G?US:-V-
X#@JY.%CFE^)J^7+|4AZB1B#=&@E*,|E(*G2LALF2*":M: MIPT\I&+L1Y;VENDP|G<
D;LPIQCCS6*|J;Q^*J+B 5('8HJH|:U;T?;1660 M) N!VTC U\ES|EF,K;W^W2CK0'0=*/\GWW2;";,|B&U&-
#V|6'V;+Z; A7F" MUGJ;>8 I\$.PT|J;.8WRF47B^7%|03 MJ53,@AG
6"L05*HM8R@XY3P[A9ZVU|Q\>#LU8S \#@ZA YC>*7QN#XM33&JA M@H1<0JHMJ@IY =Y"=BX7G4,R|JF9?
*TPM.^ (0@?<@<'TJ'L|P|-MS(>MIIJ MH|/ADHZ%B%G6.S()T:< !I%|);G/JG5%\ YDC?UDVQ15K<70%
|(>6.Q\$,6:* M.MV)51 ;19FN\"('UBF53Y S|NOM4\$@ZBNT|)(NC28'MT@M?,+,+=+
M0<"P&IQP&H)0D2\$7PIZ,F0R632 J3YV>/%@2=#X^=0Q0|0D^>NF;BOK74(MK;F7V MU9R^|F/I#EE|N!?
_HSG1* -@DT5Y3M0J4V>&MI>US4?+ZPUMHV@M\$NZX)U-G3K>ZBMQ|Q|
MJ|D"!5M;9Q5%|PYLY#N2!1%0YUB|Q"|X-E^/8+C5!#J T|]Q1CPZH|T\R^?3V;3R9T6Z M_FH|Y#K(7%B
\$@VY%MEZ")PVEFS(H=@8"FM|K?D=DL;|'A\&4BVET .H+GON
MOS| '*;+M9M*KL/\$&>^<8Q;\$L:R6Y2APKC8G0I^5MK9HWAQ+CU(R|07X0! Z MGN<'(^<+N^U4"-;_K?
E/MS'1X9ZL BETEIO+T>;28I-J&@KB*V3/!HM.M M\U#V(G#<^ -AD#;ZU\,M\L:6!U40886VV
M\$DIR@I1R8IN=1<02E.7!W2_Y?|@;|K_LN'G;1\$U,-,|L(0/^#7QJI"2'PR M-6%9I3IEPG -
+C.08D&NF| (/!'BW%0S8;32<9SNH.+I>@,WI;03I5 %FQD\$ M@Y60|@5X)*
|P(@CJ,BK>W+P|0L;X'O>@MP\$'G|S#N#RA, ^TG-7DW3'. :#M* M*#I+3D.T3(QP2>.48?
|UTE|6;>|V_D.YDZWQ,<0S-T?WZ#EIE^K'>S;;SJ MV1?<;&7#0+;D.2TFJ12D!\$W0'C"ND)K@;".8
T7R0700 -1E|MH&==7'D+- M-.%Z#UY;?7P^WPVOZLVKVXGC!\$RQ,! \D0LXN2=!>D#**L<<2UF69I@WZ2
MHG%|Y\$,5CL)=("G&ZM+7VWBQ;?SQ5H^J|5B&B|6-3/^P|QVV*0X@8_6V_Y M\03H4B(FST"14&<-]|+/B?
@4C.5-0N&M7:ACZ-X7'|f&,UV,@EVX)I?|Q*^ M/& /<89ENIID*;/(@M6!00E4%+5% VW#Q10|%R(SU|I?
V!92QLUF&0YAQ_&\ M"']?K=US=BC(*8|&|%(C>&F6(0I13Y &(W# "0\RZ|0C&.P2,F|8R!% .YV\'
MFN6I1E*\$_6L&&15+C-E6WM3.BIHV:&,&'WP)P:./K'6WDQU)&|='ZF""5F.9
M=.!T/;4MBF|Q^G&V&6V40GU8A-F2MEB%.,OKOYUM1'H=\$5|W.7,^9N6< HN2 M3'E@=4"@TJ!+\$#X)3PP?I
M|YV,G*HP!.CV /:)\$-#Y.7CV)4S/JN=*|@? MS0 |IH0%IMG1|;Z?8R>0<-4R|ZG99KN\>6F
+!'@NNYSS5XC9>>+U|ME , M9&SL(8^;2,AY,.#M C/+G>"AE6YR2+=<8>UB1D'5&\$3,XZ MRT@|D8H-D-
_C9R1&|(-X9RT8GX'0N|5;\NK*JGG83E-D""YUF0SP:HU*2J3 M-2D."@H>94Q6\9*\U""=L/.#Y4#>SS#. |
^|S?Q98>UET5'54H,D&)=3Y=SC5)7'P&\$+DEN7V/;;V) '\$W!|Y03|9#"NF'
M+8Y|V.9WV(*XI|8|31'OJ=|PI\$;\$\UD|MNN>G38;28HF4Q|<:Z&+))MMV1L.B94!+7|9P90+ :2."N1%:'4S>/
M(1|CI!/, "'H^V'DT5S0 #JW>B5<=F7-PH=,&A>TL*:6?%IP,=9.=D*\$J#4J MV_H)|
\$1XT*F@6"W=Z0X@,L=P&3+F+++S4A>0,4ZETSKVK0>48A24(!6TGGC M1'*B=; '_DP2-_YS3'C|MN-
_#E+X>.0R8|J1Y'5BD)WAM8 F@D\N I=<;>\$X MQ^;M W*\$)EY"1JR0+0*<
ZH+ Q;GYV|LM\|6=8Y(F..K(8*+9(M=8I"-05:E14HP44I(R^,MZ|-VH0\$3@*U Q'0,.-
Z,/%T@+Z'=->N6*Z=5V2- M1:QY-[5CGG6DN;V30|_<6J MD9U|,/*PI((^>UU|C|0(@J(*"7D;
OY!#ZB:S|TZZ#ADT,F'9P.2,=)8'0D MK8N,K0)P<-
UBD8*&2U\$MPNSC6J<_W;S(V #M 4#9V7=F\ KWHS/90GW^6SS MEPT37L^6J\7%0WJU5=JM8 M3#K<<|ZW5(.?
EN|1*L'!W708|B|)< !K%E7\!_&'^F8SCI00(%DEY0W\$+R0 MD"*S)F3RL H?|K <30SH1?
2=GY@3P6+T8U/90FD" 0)B4:MS-\9K|8.10|KE M-*TN|V&L^?
(.5|/%FG.3Z"/Y7M49\ZE>5Y5,9C5'T,HHADB|Q?V6C|0@?S@1 MHU?PGPC&)Q+3L86P'P9%Y?I,?
F>W/B0L)=)IPZ1|F9ID*C+9+(>2F28HSX& ME#00,'H5_ZB8;"VD\2%Y\U9T79+S8;|EX6A|(N-
J>.,B>W+Z0K?X^++..&& M4^|PS3 .UI^R9MI\$Y22XL(7"\$46&(\0,KK8\2,+6#|!+F6X|N6#H/8W>;^!D
MT697Z.C@&FV@E+E+K4"CC! 4AZ\$%QX2\$D@"-Y,HR'3G^A00="U2M390MKCA(?D| 7%0_ :1Z.+7 M+H|2W5XNT:
(2@6NH|]V@4J2 6SH%TFG2"H)GDUNG8^|?V?0\N&38?)PQG?@
MDCQ|66),%5G;_B@R&F1#5("000=G@|FLE<)>UZ_ZZ U_V_J)/>_L(X,@'F5>S M-
GVZ'GE64IYG\$90'JRFH54\$B)CK U.VG+NLL+001#GH86_0 MKTMCBT43I*I|/?Q1<*5|
UX,5E;=.%NS&\EVI/*3K*JCD70(S|6D.+JPH&G
MS97I90(0|P*M|!) "48^S/=EI4L^*@P,1';D>PI;7R%"@3HH._ML54BM\$|6' MV,>X"5TGA0#H0.C@,#R>TS
1(0I87W?)X24/6)-K'7Q)Y% S+-9K.0'-G99' M*1E7IXZ/D,>"WN/\$U0'H7B*MG*;A\FK^V7GMXOY?
FZTD)IFF_P.A'#D|4E(0 MSQ*"21AT8|3/-;_?>(*<+QJ"Y!IBEBJ@=0'=07|K6|*-[G|NN-
F9W:#G6(YWH+/^'J;SS0|J M,UT=A^HUZFDYR2IG;D.E73E0&\$5|/K'D#6MM4'/Z;NMKXR?(&3>5LA0,M19< M%
|-%GE\LIS-<+LD#C=/96JA;|J?>2HU>00A40WP|(Y_A8GW-|?B0_#H-<7HV M77WC\$VE4G6S'0"9BAZIE|-Z;#"
(Z&VWT2C6?&G>BK8V;U-G=Z>@14&.|!@]? MP*XG1+XIS^>+Q?S/6K8_<4'8J(H"KG@KSLKTB-
FG7=A2^32L0ME@M\AAT7 M'#<'L00H#B:CL7%W-4*=HKM|8|90_.SK>>0;'/&)3T\$E)T(=F\$W|5%#_]|:A
M<.^52|F60%LQ4Q-RQLV.| NSIY=0%T|)\$|X>B\$0M07U|47K0+5.T(\>7M L^G M%>3)*PTP7E
=.282:P3,G(\$EWBR#)G1H?7XJP/('#>%L1MPGTK0HVK@ZQ-\ MY?>\0%S|0_AZY>,0\$U|>X(?Y|0I
JC7;|V1TQB|P>70(NLB(GSH""VS\;)8Y9J'9|BP)! ,!F24?W.@,D2<# MTG%IK&@'5BN'=RD/=P9&0-
R;_+5\$;T< \$M68ITY0_0 MEI.D@S \';!2RMH.5\$,0D?XH0N:79I^:IY<<1FE0'7|:X.:|&PNQ/'-;LZ

M&N)-H8.^(?^N3U[;="S]SBW#,E',,!,3 00>07EGP#D90&;.??#&:}SM0>\$(M(GIK\$=04B2>54*^F?
EU9M*ZY6UV>,"U%B%XSH"#1@PHR@L]2U.K2(#77EJ?A M>^@]I*NWQCXG4HI'"JA3V#U+ZS\N^39\6W>Y]-
+KR"AJ\YQK4%Q+B#4),3BK MA.,&512#8^X>4;WUQ3D1X(X139>^(6UH<4%TW"CN*Y?B1K/?4NK>%2Z+MA!\
M{ (01:@':G"G;7WVB9.2!Q):!Z-WM^QL7G\NL#MC1!> M8EQ-0B'+\$RA\$\$(('\$M84AV@I=B,G)K,4E(C&-
T;CGB1V68'4##'W*Y &%%\7 M00\Q,B'FY2_\$Z;H?DU^"ZNZI6]0R0;-DOEQ*ID4P7)#VV-HP(54W[-D(H2A
ME/H._FB\N[R8G;B)-<^,P,Q M5;U?1R8[RR*88B)9!NF=;UU;}'VJQKTD&ED' 'BFD'M4=;8ABM=6WMV=AG652
M>XI\7F=-20PSD8Q#KM)7)(<83W?H\0MVX2?(G!N1 0NOWUN>7
M2ZS,TA9&!A:SC@E\$J/=;VK(Z8H735TFB5C+EYJ/8]Z=R7)?QU<^K<35C\F M..M[%2./;)I.7T)G:'>Z*
-JU-,G"]9JTV \$9]]Q@6SX801W>2/4#5V/F_43 MB+;?L&>\$S\$UQGEKQ=3&E3GVNC\
(U_,Y%>B9BL!BPN@!*^ECQE,DSDT5B&*C+5_MVL(_25"7%SY#P;&=:+IP+._\$;K5IXN5\$FZNA-
7E2!\$9AD@3Z' _G*B]JB0@\$) MN72UCZM0?T'^/.*Z0-H93 \$V%5\$'QGIW DTR!)951.*U;0W\$/L(UQ M
3Y8.#2VP#M0P4=M=C-^YF'BU66!Z6VV;E@]T<;86)P':60-%HQ5&53A)4;? M4#X7TSK .NT.Q[UH'>RD=
R3#@S'<1JC6"\$TMP'0Q0H@%Q(\$;1-PIGB6GF05 M?);7\,9@L*0;/B&^EQ!' 'Q?=9LLB2?
(AC;DM]\$MU(C,\$JQ\$86;C@F07] M\+@=K+E)I[C=1XB]3-6X^/SY;.,W*<'%;RM>S,E^<;X1YQ=3H7!2:3(=!YD!E
M2<%PX AD5UP.%'V\$W#H394?2OFU9,A@2AQ!,!R[R00K -W\$5IK,;\EXY+K_,M%X_7
'Z;1,\OR6#!UZIL51)"E*!8UXY3"X4WUI' 'D'NR%,2AH#/?!Q9_B"P
M07V'?;-1;M!+8!@<1*4(90@0'8@1596!(M2M>Z/>S"Q(Z?G=P+9X^78^LFK M\;RC-XN/87;5M?L.R;L-
.,KS^TVF\$VVGJ-'8H=L+W\$Q VK3F?GN+[#?E\NHU MG-T,1[H15LH\=R3TG(N0'22@U!2EU"P<-%Z;'
#R3,Y_2Y_YA@M\$+F("\$BR*"XPSI3V1)?C71&DUUH @#1>@ CF0?3X E! M9 \$Q,=',(VBL6=]?
G)^'Q;=Y>3]..N/?IVM+DN\R05Z2S0*]87K)V[XR:A EF[\$7!RB;[W]HFUFY^)%^"B6D"@HC
M"6(AF)J+YB0\$5]L\$!2%8Y"98U_KZ?4@E] B'UR6^BW @JM95WI3TWIP*AJA# M*!R\8A2L1%Y'9SH-;
(RR6G,TN06M06^X+*1LW)V9>FCNKS='QJU_/:#3B;0";Y M==2Y#WWCJ)068'CJ[;.'IA'I5,YOVIX>HEX-)1;LA-
"H(5I7; M;HP\>\$=G0;JL,-FB0_/JCJN7&ES6%,U098N\$15*"XVZ&-8%1Q)6E/!+1. M?
7Z:HJ.=DD<_%;W\$!6CTDXR,G"B%K63T;_<2A9FY(#S^U;J^U,W,@Y+^TP M\ C&40\76N@A /E#]5"6R;5-
]%.WZ&RD3:Z\$70=GGBSV#L\J_D;+^;+U7(] M;SY6C6.4#^47STU/I=5W]^ M>_5;5P=.1#+6&7@)ZS&
=&A9DL"\$\<7(Q)AKW9;02)+ 'U7PGQ.>#. ?PC+7&^[BMZ2!W^ ?;A');*6JE\$>F#;T1_C:3,F13;_.2@N*))F8>2)
M^PPE"A*F*(5AZ^N2QRDY6H/='<=0;N'+G\$EL7I(2"%&!(6UL1J#J*Q,I4R-3' MU@UWMI RLL8Y70X/-
\$D#E0>J(39CR3Z\$KX?=<MS^]2;Z82L]C=3#]><_@A\$= MDF%66\$C^U(?3XL\$'M'"'- \$-X+IN7]44LM9CYL(Z?!"
(S['WT#7>_.5R";1WIBG MD(-\?PH^D@9C2Q"TT?1=YZWNNI^@9?=19\$TP\,JNBC01Z51Z_XZH.--'R+B[4C
M=8@"N?>1393(DW0U4B20PF)6)X-?+7*-&*81A7)D6JHX50Z%_\$91Q^4XJXVK MC01;7X-
LH^7H5AGW/0>6Z4LRF,3H6*24R9Q&8L:Q?(OR[@6\$VL"EQ! M2"E 1..T"LM;]WC9"\ "CP^IMJUP*PF?
86T!J2E@4 H4#Q;(8'L@N\V,\$\F\$ MV/JB:0>RQE5-PZ'H8?T:A&ZRG*6CW"
MWUOD&CN2*D"43QJ0#WB3G2B6)CAXF.37@0'] ;HY=:BB'KP@=HS)T MK
I11[ZTU5Z"]*D^8\9JVV(\$RR26K(S2V+H^?[@*T3LUU>L/_W9S0J3W4?E
M)R39=>%VC2I"!A.,SEYY(;#U^_A3]'1;#;H/(AZ4/+020 ?M:YZ'Y73YIMSC MU+?
[NQ*L>_V,AEQT[7'B,G@1+863.?(L>'&F=7 _W2@;MS'-0 ;0"@C0FU=
M\$!NNOQ'+0SZ@^S&HK;665V9@UL;2CR5[(6D#2\$'07B\$D#F"U-9DEXTW:+YG M_'9>;=R>]HV1,PR/.]!/?
RSQ37FU7\$W/PZI.ZY;)%^42:%;/F=&#B;Q!%A* MQ>JBE7*M1W'ABZ/SD1%P9V,&@0660,35_0?
()V8@JUQ_ ;WXMNI&;=)]% !N M>00F=P"C)]X+]0_]H008..*%]
ZQHB!@=^A*QI29Y:W31W8NVE\>=WF]QU);/\$KZ*DRWTA,UFRPL\$91Z&2+L2]2%ZI"D%K*SS3 MN?
6]V*ZT[7;URGXPRTBF1X0MYD@<7^DS W+91F-%Q!80UW*96!L&YDF(0L MS#DK9.N'OYT(VPUK/]P]?W.9=
"TW_'/6^Q:S&?T9=IT4'P\ LK6!9EC LRU MR"83&UU.%!)]JW5,5C5?I#X?C3N!K?/[15@4\$GU^CK^:&0/#
[616+LFI)-+//\$5#THU+><; M'F@6;2^0]P7YSK,D9 M?IH9] .SV>+.[RIOW)A?1I-OWG!6[LXZTG:8N^YL;
=[4AH-<*G,T9)+?, MLY14*JV;H)QD8^-F&)Q*UW< BEZ=V>^VBS[X&1?YL*7R?7;?)7BF>0A%\A2 MUZ/B%-ON
[<@HS,ZZ+\] !T' D=>[7[0.1.-M5IY-&!D: _=56ZZ=# [\$J9G M=3^_S! ?0:; /W]N:Y-M(G#Q\$YL9,CAZ@*
V&=\$CH(1E:D\8G;A[Z.?= %#@#BX MB'JUG(^WD# [<7#]Y>0-V6A_.,
[28I0":91UAFJ=+\$T:J(X7YK&F&W#K,K/6 M\+R311BFW_H] ?IV@9 #-+ _Z6E0\$8=6M;U:?'<+)'EMMO,Qf&-
<8F>;/DGE[&2M MYG",%JR]!644M\$?*45NHDN^]?ON#F2-8^6& MY0\N@ 8F\7\^X6'U[>U;+ MX6:Y>I"?
J\MXZR+41J^LJ^WKZEBZ7.N#M!-@/6-U;+\$3S:= ?Y^J<6XNA@98 M8VET@*^;(_ ,LI<4%WKZ)N7]RI"DJ,
(1@K*E]U!"\Y@42PX"666UQ.\$WV/>K&
MJ:HXG4)K*IV02[DN2WV0= _4>0^"B\0#>GM#J2,%0!BEK@SWI:D02R2=PZ)/4 MQBH?=0/1=EMPG_J)8=VQ
5C=;\AW.;#CX!#OSN\WG'HSX-WF0>DG,E5)H01C MJW,C)07N5G- KS4/V9#KT^?LFTNL/CZ:Z?6LS! ?GMSM_?
YC?XNRMY@X*R=:2 M#HQ,<3HE)9#M51&,#DBAA0X^[7B->20E78W\$V0<4]W3'">71@2^T&2:/ZZU<
MYX;^E;UTNS;0:TY\$UR-2&E#2/K2!4-?10N2*ZV\M\$SXYB^,NY,W]B5F _P- M+9)>3=CC-]!:=
<\$504^MI@2"7(N6B&261D MK5-FQIV7?Z0A% MZ43M6\$N(:SZH\FBJ?^BI*?N@='00>!*!=V"X?
Y^07U(QOZ,_%) -\$ZTWN=[_MMCWF@,45)T&8.F,]KON+\$8NM]3DR:XP6K?L<'4+GN*9\1!@/+M0.@'MS5%^1 M-
9]_0WR/BR_3ZF< _=G*?G:T_DKYZ4VI^X,?9]+^(Z[B8SC>BN'4=Q*74,7L(
M0(Z*2RR"LSQ3!/]RHJ.L4_.\EL\$V,VX67!>:?\$QX].HKWYY#=<2ES\-/;3XE M:TA0^/%922X\$7H1F\$-\$
_H)BPX\$3)P!@+VF4,(@P[2JJ]]WH9]4UQ^:94YGZX MS=Q;N20(-<5Z\$;+I>:N*
(A1*0#HT0H156K^&K80C5U.U]H',=OUU !"ZE7] MW)M0<[@&>OR#AIBB,Z
>VCI#A0N)12L+RNH(R@0\$)Y4' 'C%A,4\$7%QN?QZ%F
MZ=PRQ _=6J!GIZ=DLOYR>7=3KT'01E%+,%9/!)/(#%*.0RAE6'V^TCC)K9TWS
M9L^'D=KI')Y],/2\$#S68T+J*))[-5M-KSWBQ MNG04M\IBMD(&86"\$#F"DIZ4=.
1BE\$L'2VE=P.^]S?;Q;CA\\"('D740=KC M1WIG'9'MN_7#AAI/-;!MWG.LD R">ZX1V!H,BC1?
0%RWHYPY.H=\$I-_.4?- (A M53<'Z&K=6XLLGW^[]>;9C&U9?
>4M,6]Y9CB;_AQIWM0\NM^0,TXJ*_]_@YD[H=:;M3+\@6-\$<2!Z:1@SS(H;UR]8L4ZA8=SG1-CMG6/M,9;&--
2H:.J4B@=*KF03B@ ^H%F02#H04U MQX&D_DASY/9!VW;E-YPDNS+00^R^11M4ECK4F]=<6Y\C1"

<%H'0B62%T<,,Y MK3N3.:Z9'@.HPTBP*Y!>L?5F*\ 'GS(+
(D*V03_9%@I.U*00768Z%RQ"&\R6\6'P/YNY0!QK@*T[. #?+S'/J:.)@_==^AIY=[?7N3-U
MC"#VJA;U: ^439FD;SM[3= !N\$D/RI%RX0 C0UMG':TU,"A@S4TR C0*R("B>%;%B4RJ/4
MZ7Y)R_ 'JFA]0,7(Y200QWF_-? !RONT/+R_EYF,XFW#EF7:X#1UQ,C\$Y2E>3!Y#I\$/>8(
M@6);X,)1Z!MXEJ%UIM1*#GH"RB&2?<(4'<#F#H!2L[5>S\@J7U0#03X[QE!\$ M62S1S6P=J T)J-
F*)@+ \$V@Y(HF6M= 0&0BI%+V@:004?RNCNT ![. \>H014\N M76)@ V>@+"9P: T=HI +Q:M!X1!=WAZC9?QTRV-
D_"1D#F3XV/T?7EW4/BIA M=M, \7F8 >/>9A=ZDP4'H5,&5(QI(>#ROU MA(U#A3D?BK,=Z)?
W%W&)_ [R@?;SZ4MOLT*^MCQ"6K" T612*0K1! I" T"V%* (M\$ 6Q+LC4>EC<%E+&03 \9/\$C3N//IA#%@["70 IW?
U>6B&^2I]^UE%<^<Z2^+3EUBF:;J:\(S" MR%*?@WVN<[L"N* @9,"4X!B&PI-97.=^GJK];XP,A,!]4'0LCS&\0-
L./=%0LEU80#H^H FD*L4PRT4"Y%>8NRK7N,[4Y= M? [= \$;3
WD'PZT&ZWJT0G+EER' "C:Y3R3URD4L:AHVH5DWM.N3/*M>W+<7K^_ M6*X->@[F\=@717 G() *: -
TT: +%L%0; ^GU7[L^+. @XZP[. +VR]046J\$OM(? 'QY205%[42S(%,[X4XE(:4!;X*C0,1H"&3,P6N' *0A01-
0'P&NG0<=I3GM2A+47 M0E\@N[^GR_U.O!,RZ411;:P=\$A-S\$+6) ("G^X8+,N+B?5+\3K+8LMQ.0S \- MI!;,[L
WNHFH=)TZ-?NX[N,SR5(&KS.#I' (= JD(;5 !F:0BM#%)VS](KN- MEIW09'\<-#7E?;_9L9==P>?E_?
3C;\$HQ:QUG& &^1%YL LMT*81Z>=%[:I1K M^ \04=R^BC=;4J2.Y7@A("L\|M\!S*M:
[D'CS]ZKMU!S=:0&BWLK6HL+/%' 6 MR[KW^' \$3?"HK98RJ6N124]*MA,"2A>25,MI9J90/S!Y.S;@74(W0*
M8A0F M=V#>KG;RY0.Z0'KV\7HC64E5UDWR5+U#LRE#B-&"#2X&[9+,IG5R]59B0KU1 M&AA\$0[&^
P0=%: ^\ /0\Z,T\$'H:,'WLN.QF G7^70>;F]-?YHLMK1\F7CGFL>74\TW12\YKWL\A+-;DS2.
M<+;W7Z2)PWWDWDXQW3N60+\$:YZ 9KF,UTD: ^M H(: ^ONDMS1V*(Z=X/BS:-
MV\5F\X9N(0(NFUD1;"/_0:G]H> (Z0U M; \&Z/I7)S<,
50L,BN(J?;X"12EDDFWP)U.7NAXOUWW" TR4[X]XQC6VJ M#A-+!0"[?"+: 'L)>3ZS;Y&?13UR.K: %H>I*
<\$P5C@9RU 66\ V^E >MKA18L MVF'K7*>C".Y.RQV(F\??^4X@Q! JCN)**?[0^ \0^+;ISLX1! ?FX-
&02L\LDUE1# +C. M.DFI9&K>' '\$WRL:056X*B/N3?MM+IR?,W;8M# =W&: @5(YWC.8#(-;6H3C#V
MVDLHZ++2QI2@!U/JN0#8B:YKB)!M(&PNKIZP^'KV^6*U7'. ,7P;W*C+KCOW@ MZWZ4] &
<30J"]%IRGGQTS<>9;R>G\$YRU!\\$VN!TID4[!]2ZW4HKW0;,#&Y*L M'9 ."ZQ")= HN>;D5%Y0)G#0@Q0M2]X*!
M-IX#ZIXYC"DTCHJ>(*<A=0[9%E)& '@\$^M./?@/\=P.C#(LR6M/*Z+G<]I7DZ^WBKY^W-
M[I;U5\;R\7^Z/)I62Q>8IJ.I-8)*OH#/4M?7.V%4CB';UC%H2_I']M]; &K>
MB70[0/90\QE^ ^RTL_H&K7RYF>7G5U)]\$IDF;@RV1@5+)0LS90Y\$ \)03H2VYM M>! ^G9%RTC8>,>7,Q=0"V%
[A8K8MW5I55+ 'S?'G=215YUEDRXHFK?1-+G1]= MJF,AC&2.RY\$;ZWX!#GC6N5N8-=*8!U@[X_W?
Y]_P<5L4^R^ ^#S?/ !6%C [MB+.: WWC"%UN42I!NW0)F*0-KNAH@4]9
TKR3KGCEPBPSS4J984K*\$%X*"I*-6C/FD^&N,W[T(M'!>Y0\<^P\FJ
W6Z>2] Y(7R^H%2>9Y+8@%82(%\$ ^3@0Z" _MH," \AL5HW! M]UVB>DD; ;@Z(^9#2Z0%N6QEV]01/1\$PYV2PAI2A
R1+IP/H\$,K+@; "(/Q;8> MD;\$K;2-7++>Q'W #2&?+BSN5KY-0K&L,*V!VT!;B8X<8;)63%I^2\U-CZ
MY6,K,2,7,@^+K282.%R)S5?AK%'KV.04LB=Y); *UL09&U9P4/W(D7KD"43K-
M2/M+@X@IPY,Z".CR; ^7%#N1.; /: #&TFT#GPF5B M\$V=6!C2TL]8- I^F: .R^M(/CJJ%
FCEQIZVR>/\$ID*HF'7XY,G7]H -RJ]SE M':Y;C#]+:7&Q:3X^OU@MZ3>_H^: '*]\$8GN93U">4UA&'H+4@R7<#5
<SVICR'!3P!ARR,*S!-)D!LHK 5%7?9(RKZ/9N,FMR5]; [Z&3 M%-ECT;R8X^YD2IQ6I[:6-J0*(KAB-
(@HD^0E9RD'ZV03<8W* MN.@YK*!E'U'V!-"=4DRM^TS68B07=&W5G< %'H ;D9U/(B0?^G7QKU?0LA="'
MCBIHV4=H.=@G+;R3@I:] M0+! /60@>\$ND)7,?;DILKYYB-L3\$'VXW/S^*8ZL0FCX7:X@]0
1#V=JEM6^S^GJT\/-K^ \N OE75Y=WT9M M;NICX9Q[\$DQFMDZ'DQFBB@8*VES01,7R*4K,C][(7^;TM
#K#D[:9%S\ /'Y MC(OI/+]?A<5JU\$.TA1/0<;4ZV C/DU#(,T#)0<=:6,\$"@UB?)Y*S(:%7D=OF M]8&#
[>80X] %U=)P:8^C8.; \$?QNBOPNX*S0,+KXM\$S&\$,'Y:L? H<# 6\$Q(8Z^,"CA"+)Z0\$LM):MTP'& M\ \$AK)_H
NAMCD M9 !60(7@G+I? \$!96A^E(]K(C-H 0P-J)>72SFGS',-EWY M*W.>A]D ?
IV'J\UPJ[1+3H!.B=4:+T/&A!C%3 W%+%;FYU];V5_D*-8 [& M55-IC BMY6(U>5?SP=>J/B>,25@B-
6H'*F4.=!S(*OFI\$ "^21K=3GC!]ZBW; M27^[L9MW%NR_T=\A'MKA/.T!)"?XC?6MRWB"+J= 1P6;(9;:0:
[8G]12(>PV M>6P7*(QIKHX0UGUQ'\ "YD07^VW0V;\X0R3PDB9_5F(Y&Z4XJ!1^*D MY]F@:B+XVXN.H_J; "?
Y@_G40)H20=;!2Y=:70' ! MC*!\@7>2I\A]4-#!43B@G<4M=JW9,Y'9&U90+CG MWD_0,EZ\$ML5\$!I[Q".0M)W
^,0#62RD3+R'_2*7UN_AK(EH;G)8074W\C;Y M%-) R4\$(B]YR.T1_G1_W97P?
C!SR,KZ/0#JPY3N6N4;/0W"!E+FOQ2.A,*!P M5("++ILM./E_Y^IV 0AY6I[R.=GC"W4\EK\@I-*>0]Z)Q
_1\$@,D,[]#F3 MSYR\$#\US-/YR9>I[(>2H,05]Q-43%A\IBB9B+[94@&0*SH9#W8Y>I[P6"/COH
>HRI'4Y68R=C; ,D+>3L]7 (8HLL&'-.L=H4R4.?T E=*T;=U ML/%>N=R6=
(SOK_4CW13N)>7Y<"S00)5M:RY:1]A'0SR1PKG:6%(0=UBDZ"H9 M:YC51K566L?T=VT.K\$'\$06-
CUWUX/WK1[R;#;=W. \?7LL3ZBW-ML9%)DVWFF MPY:P'C8'PEL==+(NW&^;MBW/T;/OP
MON?:S! =A^:G^ [Q7]TQ=R,BEF#K-\DX? [V'M*[5W\Z*^]_S1?K#[@X0S6[U\5
MZ88;YMW0;7# \$2U1/Y# =YT^II0R= '1.A>"3E#^0L.2B9/1U4C9!RY"G9E" FJ
M^8>>QV[:):SG" SVC<_QD\3K]P._SV>*.+;7!L240#JF&@6J#DA !; 'F/%D3 M' 'G1-=0;K&'0L<1W5+@=Q-
FW[0-0W;3^LL!_7E1/:S,K7: "- M=2I,\N0)02* SJJ S1RL)H5]* 9L,+V-K\$Z0>%K ;'^0:R*]G@#YV(8NK_M#
MS\$%)QT![K]4(P4+ 4B G%X0J3& ZQ1/=/: (Z 60K*.SP*G>,7#J%VDWBY.43
MD!\$Q&64E6"\4]4EK\+1'\$+D8E+P\$U(-U&WV"KD[U@H,NSP!'R.9'M"VI82\ M!!--=D@RBK'6V"A&"50C"H+
<)>LP->XT*0;.>A,\$ESHF;(S00W[GB+T -63GB'VDVP&RZ]W(I0'0PNB\$
MHB946@ \$J)TX&P#JP23GCE(E%FL:X0%G]+]1 8B\ \$S)N(HP,@_3: ?X;??PN(? MN/KE8I:75RD_W,3@DJ7=IUI&X
SX%"0DX9P(+ 9N6B97)R;A)"KREMLB%F02H): _^ M5(?Q"0*B&;>AI*: #Z8[@,QQ2TR[@>G0
NZBI>X+7*RF94H_5CGY\$C_/E]/5 MY68\CTS8+*!XI>E %@YT/HEY6&1)B;D26E\2/D'.N.UMNT%*X%UH\$&?
AS/B M\$+[_A+CZM?YTE65UI'F*1L8Z9-H6#K4!B4%,S!4BNE2C)6MQ\IMHZ635N.C M!M!-Y-0IWBY/I-
1&LA1)6 -LZXGTX()FP#(F%HOUD;6.. [93,VX6?ZF 9=&&^1RAUL2 \DC.K+ (, . 5+V3#FL#F,GJ*G/R = M(0-
'PM,F N@ 3(G?VP\2>M0&.F ['8 E10')QPQ2ZF8.3?D([1VOK93,V[@ M.A"0&C&_QBUN32V:WY2T-
6+SRYX&GJ#7;?\TDF2[EB M%=>DWT5,H' (0X"A& R^=U) TG!HNMZYAA<"ZPNM3L3Y6#3UA@PA0TP) B5)6MA.!X

!NE1J;11"N^A\6V M)'7B71X+H30EAN/(JP-/N&G%N\PG\$W "/?B1N_SI?+>?69]+W9%\$0-UF6 M3G)+ID
@U\4:KUM/-MZ/PDZ\RE;@/(8.8#AFJ4G7+R8G]/ZGW"V7,])"N& M=2;C]K-H-K?'#E%
MN!.4(/!1A.X)=Z30@H.8BH! 'J+5F@G10.';V.V"0:G<(F UM\$QM*:. "V(9 M/(9B=;3<^18UX#]VN^!],')
(N^!];!-!*4=U6/1'(7H@4 K" "A0I+0@J:0#. ML\C(;;#C; "C]J(-T]Q+YCN50^ "= 0@U3LA0 ;0
#E=,W%+7>9SI\$ MK1@*V1A[? URJ+T -60YU#[2]0#96\HC%.<%@4Q>@>.;), "'740;/=>M[
M[*J6\$;MNWY,1--\$ ITBZ?*LL8A<*Q.!"T5>A2/= [VKO>F%4J\$V;^:MVR/] MTE[] J4?5C? 8B>+(\ (RGD?
K(&B:C=Z5D>S9CI06D4F G+DS=M^_)#U M*70?)_ZE'T\$T &8GBB1X#&BX8Z!19M)4?NH9,<=>!)>J&)3CLU'C?
QX]2G' M *D1\WN T5XC,S+C%'F10'JD4(;\2J\I#D&0"H\R6K M#H!X?TOWF'E.!ZZFX+R8+U?KI-P)
(T9FMSZPWH*#,D)0MD!2,3'0I1.\=8' (MOC3^2--P]H++=U+LF\JN6<;S8-
A,Z>+XJR.+/C]8KY<-C%;W,H7>UZ?Q+%F MV)3LR0E6 I!, :C;\3X2RT\$6(^0))V04.E!H00B/-
!9]0!0/(/.7^U>[63=?\ MLIM-ZXC2L1#!9U]0FP2"]J JJ#&6MG-7&N/LPGAX_H+_4/[<"D?._SEPPBU
M?!!I90B] >RGJHZB%X*,@HR376;V,7/B!07Q4+=]@V83CX;2)K'I-.+P=F]8,
MW0GL;D[=VP5^#M/\ZNMGG"VOIMYMDGW78YE6FW*R((-6R[?)-UP, 'X3FQ(ABLY8%Z04L*(P4IY:D(?)?
+"Z\]QVVM ^ MJXXXY+&A?.\4/@W&] Y\QY>7RY)0L#E]] ,4+^OMT]2(L%M *9H38\G*Q[(, #120"U 8\+;
BE4\?Z#W T]@G:12U"JD 0*M1\$ER2K MG25-2S(7E,0\J8 8 X0U?ZVE=\< ;L72#HZN'Z[6\6NUZ\2*>!Z_BU-
3UH, M@LRC)!Z!4MF",YD!8XK;8H4.J76'H\$>VTAU^#I\$S 3S&!DS0%#0UR07B+K%*
M%, \$D6HH5K2(FI9@A^+\&9\$LL'56 [-;FCB=L87H!\#I<#E, "R-T0V^ M_+)<7^+R>EJ&*A0*Q
@A)0>*K#*\$P@T0NZ23A4?T9M 1=?=S^T/!\$1);MF%?
M%T5"K^H59"UKV:B%8, XEKKCD3#M7NEX<9!L@:*M]+MS&W#01Y08&NKL' /O[P M.9S! '1PY?WPD00T0UC6#[%,-
[G:R6(7%A^VPVA^>?0N=M^'KILZY40R-[5\$^ M2YS]/7RZUK6<0U;.%F!"5UW+ 6(4L?8FCA:M+4FT?
HT8@XYI3=H1L/HNHWB M&7=A! ^X7*; ?0.YDGZ=3LY8E%X2)Y/CH(SP\$ ',F4^X3+U\$4ZYH7]'ZWB8G3
M6"='QGVH'B6DJ3VM=TB!\#0=8M[0L>_1M0'YW'-&KBAJR8@.+UX,AMFYIEF47,- 6L4)'G- M@HD%?)1*IJA-
NE^~]J@5&KAD=[=-!XIX.3J _X@&WJZ6"3&0?R%&;GN=0@] _MO<-2&[W,T\$F3???3
!8/;H_OI[M(\CA@-1=!!W"B M _^0#0N?:JEZK@ZG1G Y>\$@6 MD7-N,I>MN\3?
VT)W>4QM4'4,HSNP91ND;X(*.0J05I0Y"D3'3&E0F"!&.)<%
M.: "64) IVRB91V\=12RM7V0>V4IWR4QM<-. "5, [Z'>Q_P]3\ L.BUH#-BC9: M%LL@NF+H0#<6G&
6HDZ&A:1,46Z0/ _8"MWE(S5POYMP2B\$F43Q1GYL0(JID032AF&0=UYP M&8'3'9Q'FYNT^,1MV^ZR+3YXV?
80LJ=D2= _5R4'KVTR@P,(%9X%KE4!IJ\!G M7T"+6C&CF&#VM>L]"B&#<.S.!L?]"V/IYR#V9
27I#F4P208\;05]0FBUE M0#\$T2%02]D8X6IZ!)1&Y*LE'WOINHSD1@S#0_X,PWT+8'5CZ5Q>;W\ '\ /+
M]56C4\$DJI%,KIQ!K!V9BKPZMF%6C+E8N&S>LV?0SH;= +.S ^8(?QSU)TD,YX+HRBL25K*VE*03E
N\$JS2IDAEC#'#0/,U MR8S_KASVU^7B0VWE]W19+++LE,D2@D@*5"ZU,L5R,(E)GE.23 ^+<0Y;0[L7 MJH-D?B?
D.8\$@.C@8M[.G<]f0^0X3SK]LWX2SSBH2!9P;.M]+L.("<)09J([DV MZ%7SP?&;*6[-ZJCH-62[QW I[:I0?
SZ&UY^7-X>0#;+DN6B60">L@9E8Z&S MFHYN'8I 4^HL@-;30A[92G?02TW@TX+0D] >;:SJ _&+0.NF-
"0%N,SK]9'4 M&UZ%Q;?];RT_X^KR:UCD:AX M[\8'C]J]"
[,D53]1U;#C5)PBQ\$JNYA(&#YY:!"I*!,SZ"D2IY1.F,6#5\$>BH7
M4F?'<@H(T5:%0TV*\$K@&+ZU+TF0K0+#'0+,L/MY'>H.+C =A:0?'TK5"U23J MRU>WM.J'KS>5))IQ@SE&
<"SVFE4@,LR0Y3H)4\B1-.Z FS MKK#U0'R_SZ3 MKZDP>L97)6B7L<^M-
";0^1V"Z>%"ZD%>IG"10*":RB0YU: /UR%8Z MA=2A(K\ SZKF=#:9D<*.!*HGMS8M 5=IX)8.]E,?2U\$GW!?
7ZS*)14CP>0\$:01:MQ\R M:,EY=CE[Y @@I S]SYZVP_Y8Z&C\R X,SZ\U< [C\B* _01YM?R"M^=819NL
MD;P.2W9(7J4M1\$K1]!52L&*R16,;FYLGM-C-M _RQC4PK.70 J5^N5H0YY=6J M%E[\,0^K?G5-22J8C-
(92J001070(59=(1/B52D1#60M%3V^FVFN)\$\%J\$92 MF/JH>BXS)G@3HS8*BE26-\$)%8I\$PP+U@60DZ801T=
<6G;PAS2.#?G*\=V)Q' MM6DSS69F2Q1)1 F9.;*F1&'3+\$01&;,(5'6?#\$0TS0J[A]I0,D/#?#W%T,'
MH+HU%.DGI\$VD^:[IZ.<+W(AJD7>#]38 ?Y3X&2-6:L\$<)<L5*,5"S=SC0\$; (M11U\$Y*+Y;*Q&>^_
[K4]ZB2B/;::=%Q+^3M>SGC*/#*KB!IKR.&@,R5(R8"C M(\4M!GWS5D-/[:>
[Q)*1K>2^((C79V320M45/C;Z==YB/+.WI@**.4&G-X4D:*/R)5GTS![A;Q [^'RM8M>9I;X:4POL@;RJ!?
%\0U*2"T63M(?GHB!KNP'&>*)";C"JQ%/KVK^G M=12=];\$3C640B<6ZLWG6ETX7WS8W#'? \B&N:8J22X-U%
(*,0(YB#^!";*0L MV@HB,7,<-LUBX((=9PH?:9>:LKH#D]3-;]W2]@ UOD70D[/@0V9\$4D;P+!&[
M9(S9QJ*);%W!\02.,LXR/L(D-91"!YAZG!"NZ;?K5":0')W7Q=?G#@JL:T]\ M84HN>- \.M3KA#D32)
_R&AQN1 _+^S*)=;KJJC'^[\-U2I[0\$>)K.\$]P5V"2% ML-R \$:H6R^12FR(G""H':WU
M&J07W'R1/5WRXN+7]95I[,8HRLB(@BK?&WM M7,#+3\$RMY.'H:Q9H5[LF?8Q+ROA;+
M'*6^8#B28CH),MZV.0S_4 N#@H'B^P!+_DP ATL?/+)Y\0\QV587;;'P.M% MJB=HGME,Y!>70?89&:
RP7N7M4[#+D8?6Z&[VYQ1('\$0/WNS"V # MG%C"G4DR; D8K*9(D.P,1" 'A!,\2U9D.0@0]=.
[NWL9!0Q[\W'2%];'35SP MD=9'"TXV-T+- M9_0.^-0F(<=>^NS\RNKB3%?0-#15H8A+*
'>)&06K>E%>7L@S>J)B0/ =QS]UJ MDY#<[%GR5UR0\$7 ==BU?I]5\,T)HF\IGL@TE*
8LF3J8NI"V.)M(@Z2V3I6, M,C8G[M'M3%LU=(3IR1N[KY28I !^X + *GS_.4[C8%N0I M,J;
<.. "I4&Q6W[NB\@:\X2Q5%7/ 086,M,HMS-!WW_#RY :F1DHC\2Y;\WIJ
MP, "'^R3LLLJQ^0A/(=D:_MIHY""+JLA;+E3HXQ.ZB*[#G /+;!:0#34+#+ MUER>.GfY@62P0IX<6T1A&)R
S\$2=9"<[>)'H#Z9%1N&== -0[6Y]ZH0R;R.A M90MV32WGS"3CQYV.\=8DDW2 /GI"
(IG!2X2(<85+@L+SL=A_0S0?.PTU00C M2?IPAG7PT/;8R'&>&;?&6= ;,B0/M8=5(=-
'C%&T\$7/_60YH1_.1K4Q;-]S: M=6C)]T[AGN#^!^Y 2Z :G] M(> (:2U;L*X#8S*DLPS35A;!/01E&"@L&ARW
H@KTI:0#)ZN(\^>'9]&ZUXP MUAG56AX]0^Q6077F'A/J"*@W62[90HB)0L)09_)*(KEU_Y47T?
1I+R@%]8'3^(\LH!44=1;!.^Y0"B))&L0V'YL,Z&CZ_1*58. ME>6R/6,[,\$60KBZ7GY9Q?G%#
"JEE>.%CFM&Q55W\$F*(I\$K9%<.)\$S(T3]Z _MOXG^NS0= ITV/.\-
^?];>5)R2M^>9\$!%R)&=/9J#E8T#HXM726@N<^0: MW&>V-&U'GK%[AW^3A5;1 M
)HZE"SE!)&A!RR2TU_)H&3K J/G=]7CC4 ;8#662 <8NT0+]:R[\$*QVSBA(MKK[95;L;G-\$U"YFA
MJ8M*NCK*) / 0!6,X)TED.N @3F+)K6.BMKFF6Y'\$MW0\$[@MP@D\$GYP"%9RN M^0*A\$E7?)1JM9YLW=W,'58=
[!TO[ME.IRQW7E#]V/0*\$6IY\$-)BFRY#12# MBF@!I2I)JFBS:3X@K-^[@&,D05?

HOP;.\#0K=KQ&^8H1505.H.4LI)0)#@7 M),AL98@ZV0:S5![8QM0! ?S,C?:\L(3\ M:U#D_0:.(#ZEB!#
[L@.H3[_6+I]^6V5)0(\DFKH#9CZXD6%84" M'TH ZSVIH"U<=\;S;.,FM@:G091!\J@7U#-
DN=.%S;J(N9>%SGE&<=>U'\$+F M6IA8A ^V3HX|Y0YZ0&0TP:H+WXWZSMSX)708S'K)G'A5N#Z;=:CR(F[I,%Y
M5U|U-#D!J0:*5DD%}(+^=\|O>N2.:~^5I[ZB/MH5&I ?W=F@?V,-##" JI7/ M' =UI2(V[?P?%:
<,L2L!'(S.019;?WD/!@6,J+!0)NG .R[QPD;EXP+ER?M M66/9]8[-G^;KM+Q:7+X+E @65ZF> ^11IB)3
)EJ0XYD*\$!&&X E+*(SI-M MW4QYWSU.V\$&E'VP>*[ONL'G+4WD;OFY>\$7ZZPF^MJTJ*JD0!*=?A6;5U: <
M"4W&B* M,*QF027K,[-0@B?5,015X*Z ="ZZQ'PPJ06EZN&[G?JML=T-VFD\$=B[0]-7| M'?
^Z?/\G7GS!WY:~RX_K&3?)HBX68N 4>\$5I*9CS#+0(*G.TZ&7KC.1#|SI-
M+]:I8'FLL,X(E%7AW0^YG,58A"@U4TUX"8()W+.6H3="AN*BSNMC@(- M@08%0? 0T9P;|@A*.(M?:Y@"/B0
H30DJ!A9.D&#ZYR4'H8;J|U+H14YP9"4"R\|K9XQDS7N>[[0'0>CS+PQ] M>P0GC, WX|YIIA%)E;@
)>I|N\@6;\$1,NG97M5.!,MC| (7M!:-M+&A,^@0RB MZY^+0+M?JD/L4FV\$|*E^-U.F4!05&<@Z\%4082 *=
(!\$>"9*L_3C=#?<:;://2QZ,MF:M@SH L7QVGEPR!(PYWG2R02A>BI\$XN>0F-2" MU|T.#_GC?GM+I>9
M8#\$R12YY2J BTQ"=C"" ,4|QSEMJ7D#Z|HV,MRG62^INR6>>'KS|>A/5Z6UBL
MA,DL*P4AIU@+BR4\$)CR4DK21F46E6A|C3VQGVJRUAKBX;VA:B: #I[SV. @] M?-KV43%1\U)3HX3P==Z%SQ
2"&DEU/L-9@|E<\$?H MV#7 T"DJM,H"| \0!);'.0W4);\$X|"BL2LV/AHXM61 =+|A%(' ,#6J>L.-^4! MZTK
KHV)Y"7X+0D4A*RHX\$V;PP'P9VV@;9/0!B41'; D_N0|2\$B6K;B5P<6 MX*8G|<8;[FSC1@DD=
(586NKHYJK3"L'MG,M-G,8YT< M;7C? 8AN[^ZEU*(W&@FP6!M!A%J 2V3'&J(Q^C_9\$BMWS6^W\74#FH3\ZZ;
M\KH#M/R|JYK6 ?9Z^0TIU|:SA%*DHKV3\NSJW(J*8*.,Q**L.&\-FR>V,RU^ MCI7T?603B.T|
(.A:L|9QWZV)D56[@LR6,8^@DZRIKMY#(\$!SXS^1I? 7>LN MFT|N:-IL^-\$/KZ-ET &@|M&PTS9N43*=JE-
8IZ5S'2%*8T'D[(U7J+Q0[0\$] MN)%.CK'C!;ULS?4.H./@/45M4B|]0+2UJ%K| -YFA,"5MDHABZ5U-GI_YU<#
M\7|7R=(7G> E|NG^J\WC6SLIL4>^8\$N*#K8-9WN\$H|A?G=0>AM6;U;:4S[*UQ';!LQZ=_A]4J+ "[?
MK#97I=>-U | =+7;%.C&"XN,/ P|>>0/M|]WIE3*I<0\$'PI@7P%4< S)+6R
M*9"WH^F4K2.YHS<|];;37'INGE6*OL/WY+URE^1K?KN8); YR0?0;-9\%GR-R MPT"&7,=\$YYJKR10X%9CGNGC9/
WAH(U.Z^=")Y-I=5K>|>MBQ56F&N(A80U M5HH/S2^K'? MBZYJY ?04Z*2)=XES|5K?
=C?;_%D;\GTP^T2.ZPG% MWT%\=R?+W.%QFJ*.HJ1V\>#:*T%SDQFB-[3'0\3,F)/"8&G\F?WD4='6-J|
M;0FKBM#2 5JF0=E4=X|)\$A&2I/"*Y^8C9'0-G|U+DD_GS^| #UJGS9|_N7S_ M<7FU#H0\;I%_GR_P\$G'Q@%^T>
[UTQKI-8^|8ITTHI2Q|50=:U,&F(ELL8EA< ML^?"?2#E\$ \$03\3M#LS+P?'6M|NU3)Z!RUE">T@E!C!%66-
_581RU0| M9D?ONIMTWPF/Q1/+ IS1?0,:L7F,??6%0LS*_E^6JW_4>| ^9,#P;XRP4\$8@/ M@9@1
0>03423?/+&MTZN&(N6B1W&\$V.RE4JT!,C4#L;|3*#S<%7KIE\0'F?' MZ_7ZJC8'?;6N\Y*7J_K1U|^WB5
_+1>;VY\9DTIAD :XM'4DMF40!)VIV>>H MK?7(V<#>TEW0, &),XU>=<3_0?|TSF?5KN=M^\$#NQ9NKR_4EN:
[SQ8=M0F/X M: [IZM-,DH=:4@R !D65902?A 8K:W\$(\ZA%\R*(\$>F9./_|3,^LUD#I0&EN MZ?N/X?/\,EQL+
<\$[0L3J"V8R&+|<75ZM\ -ILS")%:*3X :RNR<*Y>(A>20A. M<*9RIRW|J*R|R8G3IF=%M|CB00%/ ?YM_LF;S?
C28\9J-EIYJF? 9[G0QUN@ M"XG^BDRAZ |E9'V@S@**33)F64)@K1-??\I;8+!1F<04*;6PH&1MK:YDK*U;
MF2A<\ "B;5XW_1:X)V; '>P0<1 P=>"1W7BQXCXZPM'03L(40KI@!3;YX;>20R,4AK\HF;TNP
M.@3;>0)"MV^!>TGRZ;? ?=@Z|57=0J|3/EC%=";W&VLGUA))7<|>5=. [T:2DA58L2. 8: ^JDMA_SG?+&
M,52(WIG|UZX/607ZU%L6A;[[9DWN+/A27N(.90.YWP/<-FA/"N)TL8,SJA,
MVQ9A&|Q;)5CBH39W'G2#, @P4UJ3(X1U7|P'<&YB@?V7|3|P-W&=>(\^Q)J_M5B
"'0V93)R7M0.9\$E)Z9_@\$.P9D=|9=&*A'R*R900^32WX|47P;N-\$H3'! M)! VA'IT)HA"2T
GB|3)ZA@'01L\)_C;BTYS0#03_,' \ZR#@^!>N:S/LC<'# M0(0;Q\ '60DL5K0)0G0&,4DKGC13-.W?
>6KZ;#D<3AJZ'2J,?(.T<\\$ "P&L# M%532D2Y%52^2ZIL %J0)_ ^->|?!CDT3I9!>F|;5RWWQ2!I)S"90M#
((4)\$=DT6N5_M2C&MW_-/5#HTV@SY/MR#\$M^ZF#E8'(WQ1|0<35?YADI=/:*DM\$PE0B-R8'+ M5M?N*-
&30VZD0;VVF(WG10EQ0!I4HUPJ"0|,=7Q>9KC?9K?7JW2QW#3YNQ6
M+NXN>7SFZ5"R)I1Z9>7)BD@&/EL.&"C0C\$5\$;5KG3X|'S=G7Z|RB%9V!9&I; M?|LJXE_+>D^S;>DWT\
(AEI2A&![J76T!I|,'%+0'2PKS2_0#IBD,13/-#'"&')0)%H*)'HPV,>MDN->M<N;:;?|L_MRU4FL:)'0:
7|!' "|\T?NR00>E\%GDF_PH12G+UG3Q1%,Q,":U9MSRA*F; MGA(/[' B\$+\$\$\$9@""+THP2':?YOVW<# 'FS-
QYG@=ON4M.%|J09LF|TEZ!JSX M&|VY5%(T'S|: _+1>7'R^&OEZL+\/%Q>:&ZAW6^U0B M|([:SX*51@F;
(&=)0;7R"0)JXCC+%"T8Y3#F0:[VX'4'0=,^,&B.*)4.;/&K MB\W08'Z8N^10T9_A=>0L.T+"8_ ^|ND-
&NT'^F0'1*!-+^Q! 4|Y|<(*W!'&1*V-9\^%V M)R%LV#,-^T_6F)-BYR4KU-;+^V6YVOVH_AZ?(8_%!"M
DL=ZU08DY+X3_5>VE/H6> IO-JS7.=E|\$LK|+E_,0\|FM9KD9MR3-X01%;
M\10&=1\ M>)+52@+R^|["4"DZ&009L=A"EBCT|!4UN?:0V8EKP%"MBS172GN7; M=5B"DU% \3D7)4J2I?GKU-
M>;/\$|(@M>/80?P<>TYU&(1Z#U*E8D,%K4#\$; M\|6#W-' /BPA>A>9STU|B"YY|(/!4"YY|Y-\$1EJYK=|B-
83(' "A:DI=UG06P0 MB8B)0CH=699C-73J(9W_<\$D^W8)G'[9_ :JQ;U.8G)/.RG-(M7>;JJW4G!"
M4E#!9&&YP/*<0WCV+7CV\$0 Q+7CVX?;42/I|^86.?US>VGX1203E2(FP5LBH
MZ&0|70<^:ZYS8BJ*86#Y_K.GS75LA83:UR. _" ^?V?Q+F0|+7BWR5-L?P M+;IT\$, %A4A!3?
7Z3/(&W,8+!D@P2DKD95AR|QZ+3IB2.8S3;<;D#?'^1N01W' MDJ7(!@2W!/V:+>;<4^!50NUXR\$*VKE' '= 'BZ1#N
T2K6<=%RP_M3"J5C/>@T"CB9G:0K'=2*N&Q^7/E2Z^#\B2),%)+BF*4
MJ@XC>@3G/= %H8WG(1AN6J># _"=5SNZ%D^&5LWL(K0/T-7CS,4RFF!6K>7|U MS&"*\$.3CY,2RI)!S/T(3| -
-4SIY#\$Z\CW(,3R_ZRV(3+SDX'PT\>3=:08EXP5HR\$RQU.6_V!RL)Y\
MWJ2" '\$95I==:,NFD']>E=G|X_5*:SSS"B62HBI,B(2(WP"%#J'P*SW_M0G7/L1'(-
/Z|7XUYEBH|'"VU&BISD;#_-/5ZJ:~8T/V^G;JSL]_X2K-B0\ S
MKA/F:#A\$M^G+%7SM2DI'NW&&N6"DNU|^<[PR|+W+,ZV6'Q'KXPIZ?RC|+907
M^*&FMG1A^HG/!>=U6N"-4L^"XR\$*5*" -JU,ZB@)' _2I4R|HF0RYFUKCQ\DX_MTZ+|?DW_L5!Y\$?
KRO<K*\?!Y,C_XN=%=[KR;ZOUVIA??<%5^ (#7!^ZF05*56=G)K_A,V3@\$ (TRM_MHR5Q!4_VI&0>9#8VNM+Q'=9
L\T.GN?FL,4/40GYR&0|.2D>3(!&@596W4 MAQ_L'>#6I6*DT\$+TTVMT|/)>S#W9* B?
1B'W@MOYW*P| ^C#VX'W)TPOR6HFB M)!AB%-1+%8BH+6@N!1="FB)/'G:U(^),#|U.=7(BV)W#Z?@<:ZZI'\: =
(\$G_MZ^M@;T.NCI8DQ3I+UV.VRD96!&|=1W|:'E_,K>%9Z.5XX'L)JOG_#=.3_\$G)
M6(S&4X3/*:9.*,\$+EP"3I5!;6E-*= \JY)XTOYA;S+-1S3 ">@X(VIX#A>E7:CC!'![(5>KKW+>-!)%]|_J

MY[\5060#<=#,V0DAA2MR&40"(FAE"&14Q];EW2/2M"9^JA\7)BV@TH0)UA\ MGAEQ;Y-
RT^+SQ^5BPYJK5Y_\$&,F*6%7\$6F.,0@1{(@,B\Q%\Y1C5*M ME'*-N?;\: ^+ \$?+&>IW^%BRL*@" ,C]
[H\$"+I.@ZY] M7EP=)#)[Q8I%F:T-I.^]KR7[U;11L00"= MV\FA6FRZ8X!F)E00% CC2\$ITI->V)
*,CRBRC6A4;Z\A=T2<|VUBOUIT'%I>
M@+H\;T:>0%#EQ3NIBP>&A@YTY@QXP>E;H;CCWB:TIC/= .H[B,YW#U+TBGA"' M+U=K;UFS){G%I%-
%3JY7\$CB5B%N14U>>0A:&NZB&N>>2:\>|Y^!"= >J)D1!3=!!BY#DBJW/ .GMI:\$?IF4[W MZOX!8B)\OES-?
MP./L\$Y\$[/@M4GG)EPWVD#D*D/BG,# '*;8VQMB.^K/= ,C9 MN6KVV/CL1;- 'C4M>??BPVIO=W\OK3I8%
[TH\$D9"!JF/G7-2.OI+ A\$>K+GAYAX6Z9LKN,X#-AHRP:B73T9+%XK>Y.DH-TR*62 M,JJ!{4CH4V_AE;[[AM4I"
[Z486A["7MY+.=[@,0-J!TE; .V[CJ'J&0,: M8E("K/)L3BU:"4GR& F;(E_A'"NB_N S@WL_ ;FW,ET@&<#F?
<\$|-DG(TQ"\V@%,- 82)N MRD+?)NEDT4K9 \W=(8>B\7G)0+GS^N9A?KM_]M\<=&<"-
M3[H", \$D5X<590@:)"<1;HB%&E=:7RDQ0J0 IR=+PLQ0)>!TAL M4,?ME\$)IZXSYQ%CM]V')YXFUK"QXSM
P5'\ /F>K153BQ[, \9\9L_ZG/D3<- \ M/C,N6W+))1F-1+0SD2'2CT'7\ 'D,Y+#G;A+' 'JA_YU:,]?
9:0?}8('2@!* \N M-K^#^6\$FU.?WQ1IGJA3K/(6>1L=:*"P31*D%<(PNL92ES:UGW0S;V9G6C+;HMO;?U^??'Y?
70X77K[/M/RP MF/\OYIF.)0! :V911\I1W7;GN\$@3A\$A%,<=:5\2-1LR9UG.W 7X?#\$FQG(=K M-W-
9:@9!6.1W?[QJGP3QY"HC9D4,IZZ/- GC@02&0D\$72YW&77NSZ63!!10^ M!4E8:5W(\%+2)!AJ*\$S\$)2"P(4,
(-)\\$BL*]X:YCR9D QWFL08:1+[8':\-(E] MQ-^!-W/WKM0FCIQG!SQ)0X>>)5=,% 106!UBD>1?63< M
/6#9#4FC;-VLX@)^<8] /\$LC\GM/ \ M/U?SRZ^0%Z3W5QNI0+G\B*0W'\-
B5[QT<\5W>ZHI.D\G"*\=@1UQQ05;6XE'
ML%IBE,2>Y+IY@CZ[PLZ]C<;X;:4^XX/I/T/5K00%>D+F@+9U>G0227PB@[T
M\$K\$K*00B9\3\ +=NCZV! "G8"A)]>&0^ V_G,OCR8/7>G%\Z,"<@*6K A6U""^ M3BAD":'4MG
>39*QFYX+>]+6>03TGZ"+1X#M11^)VR85-WPI9(M*M@QXX;7F MPW\$(V5!0D(7Q(C(IL2F[U(EH.]-D@Y>DA\$>
;7E]LE7&P:K\$P\ S^M9SN0& M\$MYBCK" \Q-K+.!;:0!42GM=1@&8V*(W!JW3RJ9?MR#03S0(021F/@]P+U\?]
MKKM19)1N6:RFS[THT2* ?6G?TFZ> SBD3^2+ (P1E=E\$V6R3.\GGV6 M[A=XG1H! /9" \7_S[-
/DF9'4/<@0%:CH)'A>6Z/R;"2+/H0VF=*] M\$'^F)_A_E"48\$ \ \OVA&X>QGX/., \ZB#0XBLG:3?
IYKC!=M!6<@T=2<|K)HY@E)DK+@].U M; \396(%)*' Q-^80P_2,AN07K?][Q%*H=4#0B%U>U'IK42
*K4!S+%JDFD\$S M/L% XQN!<[ZA?P&Z/Q**F][NGZ1&7S#NK[F5:]GY%]Q43RR_+(D)R^;5^@/7 M&
[N_Q"*^ZC@1R,P28>002]U0GB &+4\$+DQ*=0B2N8/E^0CD#B K5-7&%][.I6\$73%K%C%C2A*D
M1U]K'33XC:XHS'J:A;)M\$H(DZ1PPGKD>\$Y^W"NJDQJ1',27-4DQMJ*
M7\$))T7KKL.#6\B^E&_XQ,>:ATN@'2#L?6Y.^9\$G><"8R0!DI(?!B0= (/I6?: M>VS=)N;.:!J8-. X6X\ -P.
("G4X>7;Q;X7QA6KQ;+^1?ZQ+#ZNC./WEA=RR\$ M5:A3>YP_)F!)"(S@FQG-L.Z5SVV0A>2/T1BR];LFQH#
[TE^CY"A@D3A>(\$< M/&F&):5P%'E#9-Q:S)F;X >AX/\$UI@TZ&&@&\$0L[.! [NS>Y*Y 5I*2!I0:X6
M+0BAIE7R[%@V,A0/6B<[-^/=KS,G"Y\C<,ET@&<1FD1F'PB']^1714^D/^> M
 \14ZARCZ#G&Y,GHGC15YX%JU/TH]U'QAW@_&;B1,UBV*:M\ .R_U2RB
M=!\$,KQ<,0(YZ%4R!3M\$@QA!X\UZTCVZF_ *GT7'RV)B0HX0VM?OV5-_3X%1! M;QCH(-(A%&!V\$PC3XS+7V0#"?
_AY!VP943671@45K4&1L'08EN ,7L8 *MG;= MC1ET(262C\$
FNZD3_W60'K3C)81VX7*>6/8=H/W'B[!>ORG_#I7&RS>K=S71 M].><)>7F:WQ+*HTW?[G> >V:SRPF.A'(3=
(BZCJ_W4#TCH,LD4<7 ^>Z=7AT MT\$8[/<;HVEY:M%V@-^#>;SMBK(S-^M77\+ \HIJ/7Y:K37;U++#D+4,'12D+
MBAGRA.HM:8JJ'F8,.5.]V/!G:.G<41E7"[H R-2N\L%,V)!ZW=^211M]D% < M_&\$\$.")
(2E\$%RR)045A!0G4+79SIM6KQV%Z&EGV8N7C\ S3'^S2_05JEC^'F MN*_ 6FYV(0H0(A:5S'+42<.)D)F:5,[;R
HQT!I9TW(NJC2^DUY/&K.M"*S MH:6?'B13V_K=GL,'(N5?R_K(LW7M9K4CL=+2@8GUJM,&XBW3#F3-^\$C&!172
M(/O]V IG6E+8P"8WX?DYV]F?_ H\7VU>?? >\$04)>\$@U2\$P2J8(D14DC5&V MIC&A9:/4U+?8_" &XVDA
OV#^'[YH => J6=#Z+600\$R;7"\$B*9C0 M1\$9A D=FN#
 \J6X:RSRP T\$:8%R!DP!A!Z4X!#M0TW][NS[=B;F/(\963@ M7"UHB3I"0!V \$0\|]"K%/\$K?|=:\$%#
(+|Y+58E)H3.U9 [9<7'Z\ V#1L"!<7 MFZ> (=UC?S8BP.VH_XZKDY%,@/T\8.OI(V.=YJ7J]H8Z/5Z?
146"6=2.& J MTVH.M2TH\$H'T/0):\K6*S[*\$UN^.>V]RV),>V%(/8U,.P#MJX0-[V!^F-\$4 M)-
"7.'.9(@\$A.;B0,ZB:8Q"D%,1#^I.,55RGUK,HA^UL&#Q?ZI/A"-+K),W MZ4ZD80.\$#]-VTVMIF[OR?DFZ>?
00:PN1WY>7_X67[S M/RSF [0+=GU:IH) MDP76MH02U2 WF@Q!^4#1KT6G-?
&'M[Y(/@EAPS3BI3X?|H>=EZQ06T>-#L'= MC^K0\9DUWD6E.'BG*(;6&,\$9]" ""#2J[\$+,Y&\UZD,)A*0;27C//
\$U31YR- MDA>J,XGYGY] K\$QDC9D5PP>FXANP9!^68 ,=3JJ&11"PN_3/252"!6N0F.3Y;-4)K8D9IBD0[>&U
M+XPT4Y83]5,5X04B7Z6-?&H1P @M5!];8M2NJ8/HZJ-1:K12*IL8L"Q9!;V'
M&,D@JR!T2"\$)HUN_\$;Z41JD^Y!)L00ICIM2)BP&\1@Z8+?>9.\?;#[+|NU'J
MGI@=KU'J/N+OP(NYT\Y1FFRTH%,N%3I/E&"9P@_#("230Z_XW_G6[9%?8J/4 M02#P5*/4?
>31\$9;N&S>80+%L\L_4UJ&N\$!#D0A)=(M>F M;[4G1WU;U%YOU,XG9]" +|9@#ZG")= "G40K3LV"Q9,
[!"\$M^I_\$" M8G8&1&1>V>*BQ=3:X7_AG4_V@M4I,I_L(^,.\$F&^&I,WYU/3H23P9U/JA%:;!AK<.D:N+;
<2DXDZD#^RG#G .)0?U(JV0?0AZ\7@M]W6>W:OUV]7R M\W)5/_KZ]^Z4
LXL<8EG"AV4U0H44Q[(4B!HQ;GE&16/;%#LU <[G1\,C2'< MY'5U.CR=K0K>KCF/,BFI.0,LA4Y8(>GLY#.T0K
M.@-)!^JR?Y6"*L9+E)YBLD(G&F<.G-,>;*2(+))&[!U/0\XE2<|YY,= ^YQ
M1=H!9@>6+0@01;1:0LDNDM=%ZNAR=F"#*IS"?!YLZUSBAH4G/>=P'8/.\$837 M_21/4SM D8,)UB406=1!3KEF-
M=:VD*^+ >[P;IY@0.>Z(V8=' \.!/E*1E<60:K=WKR29? \L%>%/FU:CL164Y
M&-7:AW@IJ\$P,*+87VP9%B!QNXJ*.400/^D7^G(N^)^V?%2D?<1 M?P[7^@ \J034A0" ZS,J
E*4FA!@)T2H&Q.Z(TJZ7N(+ASM9)0RY3 MA"LL\$E\$N@T^ TNU!64Q)K#6P!JTL2X!=@@0EF-
+I0.HU3MRVL!'HNHG_((7 MR\^5:W=)4HXSKHT&E'&36\$Z1GE<6DH]" ""^83\M9E/0.V->TK]W@P:RV1#D#6
MX#J\$A:*B)(YZ)@3Y&UC !^ \ \$6U@BF>T)T^2;I/0=P;Y_L?X>2>6?0=H' C@ MDY.00H0,!C.OJ;X<:-D-
UD"\$ (G5ED4K8^0ENVB>0XZG000!SV6K> \, [KRO-. M^0E-]L<8712>76G\$:\W]J.SC(C-
[ERSW"EBH@ \RYJFG57M;F3HE+4Z+!UK=Q M+^4B,Z" I'44=*0]J*SI_*
X\$I(C1>7%6GX_/?/0B\R38W:\B\Q]0-^! W&G M\MN&P)**%J23Q\$%# GX(N4".7.KZWR.X#@&KK
6R&5BK[&L^K[XV0M%Q0<1["'2J0_]W\)? M\T]7GV[R]_ :G5FJKK&021,:CTBV(2A3ZR:\'9Z^+>S9>Z

V6SG/\L9#8J! M%*?&,">US Y|<3)\$,%A0DX/\$6LLL(7LZ+PWR:/,PT;)|T'/V99 ':T?_+
M3QVX.@=S[?;IU22+)\$RH'0-@?E M75"I=6;|F/2,EZ}RWA1/A(07B{|.0F=PT>0/@1.UQ96WA:\$HJ MI?7MP<,
[.=;@UD^M Q|75U5\$MM&YC;[.=\00-(N@0-4U,UP#S\YS941*L?7[
MU0/;F/@EZGBYWS=9Q[*Z@^/Y+@F;>VT608XZ"RC,\$ 4%R8Bf8" IDV6P%+26 MYKWW0|0%|@Y2K!/
F50+G>'DUMWVM&Q(I(-D+7&FMLE(\$32'Z6%*Y8\$>Z/ M\VV,EE|>AHZ5\9.0.9#A4X?@/U|1,(-
A\7I3*KIQXL+BOW|=WKQ2)(;26%Z M>"-!&:4ANHRD8UYC1I.TL,_Y+H-
6Z@D;APIS.19G>X')-0G0R>=/ '5|K|_ M|/|XXZT\$E@4WB;@C%?2>(08B4@IL\J&%:6MV
LTP|:=|D(C2/LA'(W ^EY0 M|3W3KHFLW>IW=%ZWI^>"2(BDBE)94#QY"+QP"-DJ%4),0V^I#UB\ WR-@8)A
M5JN-2/J'W'65CRI)4IP!!DWM*:(8>%Y'10NM1";U13MLV,30%3L UVA"WP|A M!TB@UA=LRV%;
(ID#HRS0#0/) #C&#V;(D85! [LPSMTQ6G>TCJ\$U2\$2Z!Y6 MU :>-(+"F\$)4J)J\%%TM%\L%'+->BF%N%_]?
BBL|G&UQH75Y\$?A(Y*)7"C?,D>A?40|X72L;)^\$R@&, M|@_L|97Z3=E2PQ(P(970+85"):G/0"-
/=*1X|H1.LNAM_OHB>@'"'+9 M95,V3PB4|>IR|JXF&VS0|GWUZY VS6FKY'8%""X+DB@6IY1+>EC# /K46|B@
M|YAXLZ"t^95M3I;#N=A#X* OANP.N98"FB5R1\K\$B\$J,I?6!M36E)#*H.%/ M0T0_I0TX0ECWQ7T
YR86^& S10 / OM*0Q+S@D| MK++|<.'?7G2;,*9X_F7P=.X|17<8W BN!WYJ0;8N90W" \D A
M>"'COYF\$*!Q3/NHKU^E [F;K^UL=5"WYW"IOZY0IO-\$L' MF9-U\$')U I1&|\$G\$++HH+*3N?EDOF\&Y|:G|
(.\$):RQ: LZ\ "8W+6Q M0|14>B7M1\$ I(4A19^!E 2[83"IB\$H0:ZL!R8Q/RR%:FG88U;JW 8?SN #:W
MWP&NGQ=V5P<+>KY9_S08N;Z6>" M(WN+C'23G/THBS=R6*[E]Y=4T+ <T"?C^0)=N-RV6K|5
M*SP+P3&ML@7M0DT |8+X01A\$;HHG_ZU%|\&PW?7TVM@&XLSDF0ZP\$RM9GZ_MJV;>1?0^U8XH!FL^8.8<8K-
SJI#N7NU"?1ZT^? MKPC7UTA_L|@Y6-2"1XZD)Q;IZ6:F MP=G4BIU3P^(N8WYS#^&|<C'4C/D# O M YW
BD(+GRRZHB2S?)C|LN?*/855+9R;1G?%ZIN=T3Y;,>;\7YL8YM79\$F MS;1,I"Y9_R,U(?
XETAHE"M#YHF))ANLT+*0 @,6G';\|,K;:L|\0>-VG:4?0 M# /W1A>\$%|3;FF%0D@+Z\$9J;):#3L%-MT'##
(.3.%\$(M6-R!;WS=S]-^65. MUC;56X7;\7\FBI<.)8>@!#' '50>_MHN-&CDK0A7CF<1?V00@W#DSP%'3;D^
MM+=TBG^17^ \ /|)1?Z MM_G%19W1HN;J^0(DJ\$PE44B?0DXS#SU^QKP^X7V3E@ ML /9G2-R?
|#+/Q\$7WQCP:I&#9H|P0^? @P\|E H4|^@ZJHI"PI_*"SF10(D MACV^C;|58<@^BZOS#F5|CDC_QPH#+?
^8U@|S@3C62|&,)*)S457SE) KSED M%-P:1/*=|6@ ' |+#8;@^GY0 +B0Y-9Q_6H4_%|?VGGAVB@D-
D;RCVC*(>DH) M(=,^6>(AL#*L2/G>:P| #SUG<|A_-MZEE?A?B7^0K>|EB|BAI70&0*CC?4BF M\$
7P(-4KE@7G1|V| ;H\$|_P; &MJ|: ?WM\$P_M1)W%|?| (N@ 4.2IX?S#XLYYLWMCZ)WW' |W
8UT148PJ>8R&|3@ (F;) '*WC#.6\^% M':?? >T\$D=\ "<7ECX- AYYM; \!MVDX; :YL325;T97Z=P|5\85C-
\$;B)C%HIA M9/:B.IP29!;992)C0|R:NFK)SR)ZG3T@|\$E%/9?F,+L0.#N\|Z'V|^)TL MP?L_ \>(+D:GQL?
U3#.>@|:<^%L;AG')*<"6'E@2CDDAR6MIGBY|S(:G3Y.= M#JY'BN_JT&) N))^,+";R*2&ZV^?T>;93
M(0,084U|8;<^@10R""Q8&\^%Q!6&7,V)\%X!%T;8:C MM*^H+64%UC"/@85@F|_|1/K6?
Z;.!&QNZ9LP_ '\$C+RW#1.K?N7IKSS\$<1E(\1 M4)H *H0Z:[5ZN*@88X)9-C'IYU>7C'HK-Z*WM!=SFQF-
QI=MKQ?T);X/?^\$Q=V@/ M?\$J3J|'G=M?HQNMFF0?0(H6*Z!EAQ"4&2K!;)X-";!9U%E:R(EM/C'UB.\<:
MAYN/_OF0.C\$5? \ %EOGE+&:E,Y>% '*DZICNJ "Y'!";2<|5SA6|>_F1K4Q| M4|4*"?M1@N^|WI?
_SM>_KIS;C=;U?8=2S0U?;SE^6'L)ZGL,@_S2_J MZ7K0'QUA>UHNW\1HC<:/1M;NY|!:U"JXZ|5N
(XR:RF\$A6"+JTYP;51"03|6 MMH)&1=4ZQ5|Q_9RK)TC=FY5KC+UFP9K'Z5P\$DJR'%2.'CPK'"P015N%SJ?6
M3Q@/;F1:&|=\$_0<-W/\$,|!\U0D/\$+&*(HD|\8=;5VF&9(%JK0:E2K/;:&6^M M#GX1VB9J<-;Q&8\$5C;
M>%I7|X!\$ADB402K&\^2R-;GU;> C6YGV*?@DR#F\$Z6=W27;+M+Y=7M)2\W!Q M\75#^OP+;LW0SW^EBZ0:-
YCD\&.X2%<7NTNDTUVFC;C-<2=3L7?L2_GDC9! MT!D/@I0:VAXE>"X8Q\$S0=[3&9]:Z ?
=8EW/7PGE37I\$X\K4H,.TR0*|%\4L5 MQ|<|TS?E_H:V07/)*MBDA_19.RXIP00Y/|(- VJ2S\3*H;Z61K88B-
*6@T^0 M?1#WW3"%Z43<@?>P),T ?'WX_S;MY:5!ZQ51|B/+M=P?(9C,@540G_%7GGK
M\$90CDC/Q()\$)4;KL\$S+=:L_0X=-U5_TDC_N"2B)YYIM44>(U3Z.W BF;?;: MG\$8%0NUI6AQW
YY!H#Y0DAT@V=RH9=?\$?^X7*;_?0.YJ@Q.Q^Q,0!Y,ZS+)1S?3(Q8/E?G|)"&) Y&TA=BHF&HGB!YQM2-
#&&MU0(LDE>BN"9?^A6#1)\$:8Q(N;1^"7IP(|/>=YX2_M1P;RG=R=8V. STB%;QUM?L+?;^|2V M|N7\$)(>!X?
R58%=2(GAMMI#KT\$A' %B1P#<\$F.D@2ILOE>LY:#WIMLO\$>W<>Q M,=<6^<H-
=GB^L1=T10G^"V*+CI|0=Z49;K3YL?'0'DL.\239X+CJ*KT57_M0WM8Y%?K-5|>GBAX?1UKA=2R^
Q&UHZV5EL*;J2%H)+V)0N9L'6(N=\.VST+ M/#!8!S|!8]->361*6Z5!JEP;>%H"t=D,(CN==1*Q?
<|\,8.53W"5/H; \ M!TY=WD<8G6+J|008)35&)Q*84DN.G,0@/\$=(RHF8G!;E>0KZF4Y=WDOT>T|= MWD<.4_>
[N#,ZF"=K?58!K"B^9MD7",594(PGX5)@_7|6P_N8NKR7M!Z=NKP/_MZZ;6^6_S"UQ?
+A>XZP^W50D0I7&60|8YU>\$="IPB-D0F;.,(7"ELD.P?^01> M+DE&/&W;
<+8W;.,QT1)!A9%H;R*Z&QY)P|D52P%A).EAK;|PVR^OASY_&1#22
MV%/R/X|]4R/@U>?/J^67<%'#RGIGX1C/F;M2JXVQYFHR!HY|["T4D'K2-VK)A M,042['X>N\$%\$F0+F?
OPN+#5ETB_M9N:8CR!9B;,"JT,MZ|)(MJV ^D7<+9\|87")C"<8QXDJ90,\$2Z:4<6,%E\F39WT:Q/42 MX#8&P3"
(^2B1J0/>1ZBYCLM\$"(0\$8%0AM5)19:Y*! Y%B2Y'86X'ENCU(F,AK^T2?
YU_V32F)F|@3@9|D^E#AORW\/^6JQ\OPGI; MLF6*8=\$X!|S4UFJRCK81,D(T0FCA/4=L71^WYQ:G;1]^TG-
Q3.'UC\U0Q-VJ_ML@B)%T\$>)G!1.PAY#. "3)ZUF8BSY(6&|LV&|]|FU(V(1X3-?A_16H9=P/3M
M;IE(T|^1&&DG^U\M_D_X|2^6GV|=AF;>548>Z""P=7HB.@BU"YL3MLX6D3FE MUNEE6@S;6-12/A\=W<&PMJPX
^,L>NERLU4JR#)DY \IR \'|#%@23|D3_TSK
MN&*/[4T|T^&D9_=80NL;CP\J='*;3<.H#E^U7(6+=_G5XCDV)9A0(B)6HCZ_MC19+G51MH>3-M-
7@ (2C20^MY(8*#4|9U:N:@C74)L\$. L!Q;*AU |>%@^BY) M.6L6E.<44PM/>FD%A)0T""%49%FGHD-CH
W8UK2E)N/!K+5\$.@#9'U=QC?|S M5VCFYFX^KJ\$J)^'SP%\|P| M.\N*HH3@>(2LG*L)U88LJY4@E
C%HO/>CFR2>G"BB&@GY;>@

#7|?^ M" Q'X"+0|@4, "G*] M|: ^+>?_7"1<7=+91"2|7>Z,RX|7JRJRF2R1RSJ5RH920!FAP6>LMD4K*:2(
M-K: ^WAVZMVGCU|' .HIH.H#< TIX-SUQ%1;K|<|XS+.\$,B.'7_H'I2)"*!2N_MDT'/>;92<48 M+G(=RZ#)J-9L
A,-1)48,]*8'%H|>(|L9=IJE|\$@TX+Q/>"G)@J|*? \. *|*. MEV|6|^K8SW\NYEMBE |11V)+-
J0'2@D%>5%LEGGFBL?\$BV\=T#ZYH6DSQ,?# M4C,A=("HAX_AA^HN7E5R/VP>4-;:4L8W=2Y??

5A9_RM<7. '(3;53!UM[X M0,C:24<[B%Q(T)EK.T);#A!@!LC*)@V,+&WM9)Q#QUC=:VD?;\\+4&W?\\
M7#L-WC30>%/^^/S_V[NR7K>2&T^OV(P[YS40@#"1S;W3#@V(;;QCP*K,U]M)[+DD72==G[!L'17WU5'JJ-
3]W: P)U\$;HE%?BR2Q2U'\\LASNAP*-6-8X[OR3TR9)QP'3./R> M&D4WQ]S-5\$%M,4?0+%)0DW(M_TP,-/?)!
(Y.Q=TNH)0?/'&*8100',2^;F1_M[5K\\F.>XR>G3\\F^X^G0>0%BDWY#^UBPC:4?
E>E3@^G:F+!7)^M8#>]'E1=;A)_O[*PHKC,]79&7>WK M"ER#"X:#EU9%68036NR\$H]U^;S<(/9VW\\
[8_2"PV:4;[W0HP'9NX^TN;RRCR?1#D!\\[@;\\LKS/.;P\\Z90%
M=]3^AL0XN;D^UEN%9&)7^BJ#\\JNSC;QY#SP" QYX,EH0GWK!H"#"-X-N\$ _0 MC?}X4NP
L@_TA_V")ZOMNTLU,-EU_\$D]1Q\\>MR MF?YQ,I_/D'!C?#;,\$#2\\H>'>:[0#_07AKD[0\\.=ZY^Q1#
[@;UI]@J\$3E\$Q] MLWY<_L#YYD<-#S]OZ*#_I+M@^W9YUI6T74I!0>/,B12Y#P%\$M_R4BKH.\\PS_M;(>?L"S_9!
<_MZ00HJ0Y.D=>7_'F=R^G\\[4G),^455S(D8-I[4)E.'50].CHLR5H>+6]LJP^A_M=[<:WJ>3_3BZ##0
ZQU,'''ZBK_C^JP@\\,5?M[<^\$KU'[GZC-!R@F"H%!(UW_T0CRTEL#N.D!=D/TT[G.3'_E/B'^
MU,409WK^FGSIS8]M?33&BX_7,QTESU@HCM0U/V68^@Q!8DA2A5\\,TK_MC?6A4*Y3\\L-SB_T^;Z:_U=Y@R?S!
<_'7I]_M_39_M/1A+#+^%.GV[#=-GR\$8\$F'X"4D\$6HU%".>%2'_2IV8CC'2
M03F^6[!#SV);QIB2,*0\\=MM\$/%4:GF/IY3;0+^7E=E>NS9*21F@{D,8(B@^PD_M)Z];M9[\\2A1?
50I!XE^!SCM+X>IWS-?KWZ\\R0/S@2*&\\Z-,L4"7-Z_#MP(1_MSB((58LXN<_0=MM???U;^T/
=);MF!=GY?)5=B5B1TAV0@F2=(.16?!"E"EG_M%\\;I:"CZ8JU+&@Z>Q3);@#JUJ=I/+!U_+[QH:/UI>:YP%X?
+ZW>9X0"7N/[!_M(A:~H29%,>1'_B\$ITD\\V_0K%0<=LDLW*\\-+Z060(?=W=87NBXNZZK08BZ@!^_M
T8:0*83UM(U^0&\\WI0W(U/H4_+5J6)P<6&[;_M12:'.PZHT\$+FSJJ_D_L0B_M'"40^Y+?;B40_E8
[P/8#>00K:KE>SZ173/I40"+6);3DW6!,'H2SJ+@,MDM06<>9C-'4\\,66D*W2X*/;8U0>\\LL6X9XJ=:X/MN
MN]2>AXP,H^_M"#NB/#JXT@9-('+912)?@.%UB#-CM:(\\9@J:8K?M+8W&WC[&Q(U3<'UD0SN_M,!^M#
[^:E!DK'K[3:7B_NO_9WIW6N/[!]^6F"C6_NIR3JW\$VE03E/2A>5@^RB_M\$;J\$HHZ1]MV#\\HZGP[2
[!'%VM"&3Y(57B_+SU7!>/"AR#LX\$SP\$,UY-?>S\$!%8X.(@4/Q=6B34AR"4PJ<
MY3R+X'+\$(U0[/L%,\\#"Y[Y@)'B*,3C^U!,1;*WS41(30WS,
MT7MRF>!!TKHW\$SR\$=7U>)E>Q^&.8N4A10!4J@8I6@&>JMN[7\\#ZG0@'80S+!
M1S)5^XFE(XBU:\$<[_RN718A&%^Z\$AV+J/MU0,J_H_40I(I3"L[&MMQ2,=YKN_M[L<[!\$3=B-(!XG]FBK#-
S2^VJJK\$ _SF4M0240\\K\$JX40[41RG[,U:HPR#TS/3I?%_1M;DA,\\,\$,\$%7;[C4];LY@5>%
M(BXN"75)J1C9M8FZ=: (^REJ>L48="*)GIE(?5LM0>;7Y\\6&.B\\VYY=YNN9Y)_M+ZR/RD-
_3(!BVH"S*8)_M"9SI6SI>2WA00?KHZKG&2M8&TA-_7K9DB/00VTK_M6A9?WF9-^(SK8VW:12XG"PH3]ZP3\\@_3?
&G6XX,9F8_.6"7!;R&).5X#*A5!>\$WNM4A\$IBW"\$>LT#3]''
MPK/.0#XQ6#IJLVC!@>0_SX5TN"6ASI\$N'BZ/3Q:"*#5B(!61J%4T6/508UT_MI#XR-EW7!!P*A.?
T='7^6G[M@T\\K3/E\\Y>=ZQCD74D<.1G!%?EM62X@>)1)_MINA843=*WX_P=04(T<^G"N!@I([U@M42-
L/5R9^ITR)_J50_>E>H%S&N3G.J_M0VX7:^(^0Y]M<+X63,BS#9=,*\$<148PDSBC,U:JR"57J]ME]V)4_F5(=
IU)_MU6H,N5V]Y5W[[.UR\\>537GU]E<-FIGT23&,Q\\G#5L8@8&(9R*TMCM%B0D8\\U
MS^XH!WP^M0.M=+!_G/TYU/"LSB(^9U01Y-&+.A6G#C%#0P7D;+5F-K+8?"C7_M<4[V?&H*GISB#4?
6L].X:S6"USZ<.6G0.Q:(\$^1>JU@!'06F0%M1D)C"=.ZY_M@.?N4SV?PH.>-:T!HIZ=EEUGA-
'6D55/8+VG\\#66",Y8#R@U#UD*>6MK9E>J_M-52?
GD290<_ZM"\\V#E6B3U,_M%>DX>ZVYWD\$S:\$A#)!\\5LQ\\0S!%P-2_M+;JXV1<\\E28]=I0^@J]>'M:;'KY9HJGQ
*2;Y007TWU>XFKUHZX#WBZI6I8W_M"PK][MW@=L#PH]8D-!E-"I?&@T]N@;0F^1>+?F^-!1,%E\$L^"L0#(D.=?
_M905..40CE6?-Y[-(K#>R.');(^:T17DGN3B1TZ%_M*)0?>)_1=6+1%FSH
MHS\$[AE\$X;8IG/&S=/_VHN=PZ*(9YY\$Q_?W_-EZN4[5V20(R=))XE_\$M6.?CDVL5R-T"Y"D%)+MG3>NQV@-)
[&4V4GNT+((GN0Z1>76X=_CU8AH,9J%S_MYAZTW':9*0_.*T;<=5'5!ZR26^\\+VX/,;1\$Z*FR&0?
1@&78!TP^K9230_2.)_MD2BI0?F0\\0<\\7VX;LBX&#.E8_A+KE\$YU3!%C@-8[!\$"GY;(*C/UJ_9NQ\$6=-0
M/!P>M^#86E9='!G?;X*5Z0:HG(' @:R.([(^C@B)4-#:PGV2H?GKVCYT]C(_MJB=;OI^0^P?
JQ^5_LMR]0]]>BAUZ'T&GV,@7UUHE8)RQ38/?880.*TI/08P1Q-9%[G>1[A('PG_M7Q9G-
9300W:WR'PKXE_)3UDN1LB#E<<35-0+0S'VHY'F.I,JE;B@3\\:"R\\;#T,Y[(-).W]J2;R")_MTR)R-
CL#LF#Y=8!++=]Q)7\\]7E&S#%N=-+\$Z!>ME#S+40K#JT(R4X>Y"P/.F0B:0.22HN/"_MN*.!
[HJN;J^V/=&P,]SV%\$W7<%0_NJJ/H5CHYDSFM:Y\\77Y6IS\\L^M&&>2&Y=*B>1U_M<%*BNLD]B)C!HG>"?
L%'GH_NGNHG#;:,B4,6XBMS3@_V>L;4>9F:B]#X_Z_M4&0E1000D8.QM?0(??
2Q=2;Z88JF38M,";FAXNA@W.!#*?2SD\\K26,SM2\$DK;^=4RZ(VG3]L^/#K/_QN] *GO!(!;"[.970
_0!80,8VM3_3SSN4,P=4_>XB_K#<000: ME\$]IYE+K@#;+=RERB\$-
M\\LF%/M!.1&R]S")MK"V1N\\]8GPKL>N=WY9\$85/_M*D/BR\$'9I'^D(@&%"=K*E"QKG2BY@XRG].@W!"7W76_[2J
C_SES)1E404)A_MB@>N*8-G.@"3T2KEBPVZ=75+^P[6P4*\\;V_G\$(YV,07A'HM-0:_1-B;PGF\\+
M8@L@>D6AK^7.>M*?YCF&'AVFL;!R_+3[_M!6D+F,BY)AUQRK0>0+0[==.6T(T^L<92ZN+G[\\SU[I37D
MYA,2&7#)ZPX!ER!H0G;T1AMN/+K0NFG@+CHFSCZWD/ZMXH=#V=V!-7E)/WFR_M^05C7?3P8Y0;9!(Y5Z\$N-
F&\\LB0#!A.!UU4?FR',2UH!30)#'7@)XQ3-([:V0A6NG6[\\UW47'M&_Y5+8/0F4/1G<
ME0J,_KZ1B_C':9^SUJ\$RLJS5C)@>-G.Z\$TLD8(A>J=?_&;2IZ_LH^DETV_M97,'0*E;5]\\LR!;!UE>
K>Y8SGDMY(<<3*I9Y0_A.,,%!YE2%*GUF'-;2HF_MSL&W-C\\'LKD[H%PK?
='%15.4!9.C!,5%!">*!;&C,Z:@]K+UT_]IM\$Q[NQPJ_MXPU(/%1=_?[0\$Q?EUJ1@3S'-+UZT0
MH)2NZV>#A8FJ07#^\\3-N6H)M#YCXG4L_M:-UL;2@:")A)_7@@?M%_;!@?.3U8IB:B?
AP^>_] /P"=WYY&,KHHI8-<>_95_M,11_UI&+2DK0#%-10)'!TX/9;B3DAZ&S!\\?
[@\\W;R[\\JUX'343\$E@+!!GO(N5_M10PXQ86VB)QY\\VT2]]\$R;99H;(NU'\\NG\\HA_]@_Y%6L,0F2WY>+U?%0%013
MY-.17))KM]KD-"LJ^'\\3D[R'C_>U06TI\\B7_M1^1_7_BZ>;;S\\XDS]D8D8
S7Z++X\\G*YWM2Y"9+KK.0FU;4\\C_M.1+^?K_'! [I9D)*0SLL,! :)93):I#08!5:
[!]^GDM*MIB^YVK^U.R/WZ>VQW_MWDC8R6AV=S+H1AJ@V^5RE>0Q4V6[\\SU*;9^=G*7%Q_K>S0S>;[(.*JYP*RV)-
MW))@E9'_M%D'EDS68M=:G*J98/J66==J?'?E'Z48YY:+?29G0^TW-V%)[/
MCOP@9R,EIN=60HZ9%.WI#CI=2B.XK?4[_3B2)\$S\$X0A=_UAT^4E0=-([_D^T_MAZX0#WV,G6;T?B^713,E-
_Z@UR_MZ40*FPZB=OL?>U[N_'01A<5@&IW#GT''_MNB:N'Z#,JG(0=:#)TI-M\\DP^%/OWUY0-

1./5:;T8+_M_YVZEF;7%_7--?0QY|N|GR^N|JG|;#;L; M70IWW7:'W7QDJS\,V=W%[?<7U\.
[YLV0_QS^FUUM0IN&*Y;R,3%-8TD3D)--I6\$ _55P#=[F4W5*I MM&6J8!^5SEG4;0!\$5
(!6<2\$2)'F)556QJ;!KHJXQ1*EH8/8;T\$%(TRZ8'=4 M6LI'I-
L1V ;I|UVP|,3%E56%T1/\$"J\ED+T>8LQY.6/&,)C_*,Y6#2ZT*'= @#(,;,?,K#&\$X@EAHI#F+ EH\$E
0B9I#).F:G< MCT7 "6FJE3@'\$J8I 3?'Z";8:+H\#1Z#KP"" MW6\ '@L0262#(#B^+H#:/XBC62^URP*, G1)Z
'G9)6C\$P!G*8(-@ \$XZLBH1 M=P=9!^4L6V"RAH-Y-C1@+Z13W' 2508! %\$!+7XXX^V)N4E9DJF)F:%4TX,T
M5G,,Q-W+8#>L;"R!S"MMW-XNU\)SI0|XT|T|M34B*K+"4<1*DDD M'GW8KAC7Y &"@,M11CZ!\$5
YRJ1)G;@3RT&/CB+=LY FSI2IT,\1IU990\$JI M54P"KPT| # \$ 6DA^L.G..7% [\$+<-
)ME4\$BZ0)FU#^@0|\UZHOP%!ZE*S6+ M@%"GGSGB6@)N)S9>N!DI6!.\$@PT2|3+<(:\$JP: ^I-PZ?
M0:)90>\,.,=@6F0 M=1*YB?A !CL*1,0GM4 #J>\$2;LPKLWT7E_E&!&C4(X5|B!% MA=?
CJNP%82Z3KJ:.,>ZS5R72!ET9-R*Y1@C0ABU&9%'Z3:ZJ1D4)R+9T#,J1\ MGP8*IZDR+@W|I6E\ S08DJ05!
(&00?:<2%:2,JXP|;H=:WHA%.D>/4!PLUS3X M:T1.\$/2+ B2^@&YW#UL#&8AA+X?#*C2JXHW9N
M@'577#H0+49Y"GVJ&RTB5@ M;701\$L=*"V^ +U,?J\$ "MD0'=: '\$|).%4((!'&-YR1(D_HHP'.\2A@,=#\<|
MJS0GNO!3DJ!4E&.\$QFPH^>95018<'!XW5X\$>LN@ (C2AUARIRKYLP399@L^E MR172R: ?W/FPT*|'|*J0P\$|
G:,POP.M G=@EU-7,&0*Z#@RW":^K.-^R\$7V? MP9R9=&XZ|\$ GS M W>T4%1SNPZ#52DW\Y+&
<: #'/0F?' /Q\U,0|99E\I*P^3'@FW CB*?I"K. 4 MIJS 2C9E DQ2S)9(8\%3CC:78;J@+>TSRA
UJK9N6D<:U5VLQSO6\!E7DN MK27ZG:0P4J@J7+N0L,\K.0"8P<'&<30^N\IZM@+IMTK"?+ :JB+V9PZ'?N_U
M.EAW|!>=QDJ-52.\$F!S.UZW=XXE 1UU0IY0@2;\$'UT"#I6;3&^Y02'G|,C MHL "7+U;"><-&ZB-"W0T-
&>V% %95ZKH I"AH&R\$*L"@!#15#HA@EKPS=4;9 M>)BV->N-E+4J'W3AEQJ<#6?
@)\YU.5W'F+I '-+BV@GJB07CVB00/B7KK5#G?3 M5N. F(U<-
[=\TY\$5ZVV|X|9)^7F=BMZL>T/4G0D30YF8V9,R80W>]V|68<: M.8.-^<2BU3MH!Z:UR5'EWDIHGB.0_WQ-
AG= _;J,>IB"#\|Y,%Z\!NH6-X)1 M-|P(/ONXH)[+SYNF<%6>:.*^AL|0|GM8=0|GXH|
|[NB?|8F0XZF+Y8IKFSVJ M&<(GDA)FNF-#YNP|_8;B^0|8?DLKL>^HTDE)6SX1'E#EC8S=*F(|3|BX2S M=-
;BOG&5X>#;Q,BYH=&WM6FU0VS@2_GZ @I?@ MN@E@.Y9?TL1)
Z1IB@UP2'83+ ;NTX&21A812=22E!WOK|^'I/P6.U<7|;9N M< 6:1.)P.,-Y^,R0U'EJ\NSB/"4>7_SM._-
)0L@HRJGPK!(\$3<4LTJ+8L1^ MCTD_LF:SEKJ2Y52)46I8I|WIL=^E>A1C|MN-,!E=S/2<' GG\R,WR'DHX^G%
M>2S&3,30|L3|<=C0=3I)IQ _&03#H\21H\^-NV#0I=\$|#MZ? "?:0%>*^CS;3 MC-[MY:)HIF3'' 3ZI3F;B-
BD@Z#=_L>>D|LX3V1A,)A"9 ^GU|&NB:L1E!E9 M#H(-.!EZ,DV>B5\$Q54S\4AF4@WVV^|?
F6UI)CP7V73PTU#DI-DM3=B| MS'G04T/S0C|C9Z>=-@|Q45,2_8 MS|PH>-
I@ \$2DCDBDS*3=0|0LG9VSKV)4\CK'.FADE9M#0S:(IBAB1'#2|Q|_-- MSZ
U<^+;C|XZ+9V35M|.PPU+^9B8HK&@"1C*I\$*S7RNN /ELRNZIE,HP6;"/
M4N4L: #=_93*!@"@B8L.4%"^I,B+2#7931"V62 4=0/[P*AB""JT/5!K*0U)0
M|H/C|EFWW7!0HJX=G8NKN^YQKPC;0F4/19RDE\$ \HH8/K_)!C25,*"2R M\$T;@HF"\F+*J,*HB>
(!|Y5(7HLU9CB,82'N&58C('H1KIY=8\$"HI(:ZZF M5B3GC^0@,=>I\2Z&,1@R0M5#.
ML@4F: SCH9T,#|K&PBAM6HLH@ "!'H,4-IYT|\$>=CN'M^%*<-|LGW2"MV>Z1E1=3EB*D\$DB\,C"=L.X
M(@<0!%R&\$;D\$1D!EF F=6G\$KEH,>+47:YUCH*).Z0C|+G\$IF'BFEDA'>*W9 M 8 1\$Y#FHW_|%*6!&|!?"
=50DD@BY0!0T#.G1=@W|LG_RCL/5FX1%J|3-+ M7\$0 |4"RMFP|4+(R4(*!9HEZ&M74+I 3_<&9CV6J>!G8@/
MI+&M0,1<50LTG!HVX4:\TMMWL9D0)\$"C'LG64EDI* !!C85VM 6V40 M"" .9=!5EW&&M3J8+0#1J0K:-
N0)6|3,1.QVNKH*M8@5\ (Z('S*=VF@L)HJ M;=.P6YK:Y6Q'DE(3#,(>UW4J44&*J,JXY7:XY8Q8I'/T\,7!P,
<&7JB K4&AG0C1:|0XJ="\$IPCV L+U&"Q%\1AJ=-PK"GX^LQSRK'63; ME"0H%
<48H=\$;2KYY5;\$%! 0'S56@@RPZ@C^UKS5#69F7+=@F2 "Y--E".OGT MWH>%LQ+=K4+R,P%|_,8<
[P.U,6|A+J: .7U UX%A-^%U>=:-J+0, C2)G89 M196RX5 *HANTYE(;0+?GG="E(RB: '>,AMRKE>EYR6 YTN*?
8)0R3>^>(J^\$.L|M2GK0Y)- MF3N3C&=+I+ '@*4N;RS!=4)8%VF<4(&05|-PTCHK62*7G,=^|@,H%\80_8^D
M\$ \$I4%;8|K#/*3D F,'!VG(\?MNZ>K8"Z8|*P'RWVJHBW M7I<9*C54C@)@LSM>NW>.! \$==;Z>;X\$FQ!|M
0:5FT0!KN9TAY^S(Z+/PER| M6_'G#1NHCHW2)7|HL G#8"!' 4"3NX\$N\9=PZ=&48QE-B:;'PL^
MJ@_B59G!):)ZGT5,E74 T4?I7BH;4-# D(&|?!JEM#@)4\$U.=\5+3 M8/;'&1B|S/AT(- HW8:|3V2K.|
WTV*8U!/U :M#E&|>7\$ZWV0Z"VBC\CV.9.|V9@97?+BW5YW;|:A1LZ@4SZQ M8/4BVH)I:7)DN;<2FN?(ZS)?
D [=\MU^500|3| \$X|\>+MT#>XD8PZ/H;P6=? M&-1S^7G3Y. K-T 4|_#YS7X/R\|]?';+/??
VK\+%)W'7!G3%MU33ALDD) M,^W9(; /VG?U P?U 0+>=7W|;V|6'>
[;:VY200E|;S_6LD4;KR22LW!'?'7KBSET5|P|^,4?-" +S?YS7 +70A00XV,'ZR.7N M#5XM?TE62NWN5P?
^#F%,| |^6+:C)?_VH@L/P0>56>_RB<_IZI ^R|@C|T7> M?P%02P,\$% @)XEM61100T^R!0 .1H !@ !Q;F-
X+3(P,C0P.3,P M>&5X>#;R,2YH=&WM66U0VS80_KY?P3E8ZP"6(\EVFMAN@-1UL0!;TL8NNGT: M:/ (4\$9%
(C:22>+)|1TI^2YHN'1JG+6H\$@!HP6>X5_T>[GDAPYGB\Z,A%U=\$\)<-\$8?1 >MU.H>S*.I"+Z3|+(D|#: (W
M>MCK_A4U<"E.K|88._ @92,7,DC|R>|W>X4=7 MNTWX4AK\T +RC8:*D16\$: M%U=?QYW.5%|@Z+8
M&3&^2<5,6-*)V|&F!0_3G:'G03^1|J/Q^?3DS'IR=DK>0C^?0#\^G9+I M&9F,1W|L,-PG9V_N-
>QK,63ZZYA,CL]??9^.)\ '9'|^-R3'HREJCJ@/8|*, M#LC|J|J0|:B\ -BSJJA 7MTJ|H?
M>I\$J;D!&:%DN1+V)38%,B|DFIT=38G MYU H;8E*
<\$Q(!F2:@J8%E%8PTR(GDK5)TRUYMG,0Q^@I/*"RKG_%0UV"7)| MHW1.HC!X10*E/?
L'E56<@.284R906,AGH)_M1/OAH!.VJCQ"#4E\$AA.66DV ME5I8@>93R_Z9>XV^YT62-
P^RSV5%)FN,\$8;IC,86,)*7S2HFQA4Y%7-[!V6-W""+Z|+%)|(KLEM3|JS M "ZMVVMWH|Z|Y+ =W40[%-0]=AC?
0_+ 4=4SD!_&PS@RT:G ML0P)99<76I62!S7,\$_|9H+?%SCD45A07;|Q9W3^1<1J!|D\1 M^*U|_--
X_3+VMK=26^%P!|/8?"SG>Z+ M@?'_R6NA+ '&.(<-|>|?#9|&"P|0CQ3UCUF;"\XSV^YQ| (6LK8\C?UH5J+_*
M!="" .\6\, 3|00S7\$;|G:QT+\MX7K42H@P6(#:UDKKH"<)5A\$@ ;WU(KV.W"G M|(+R _|K/V._|_|JP76:
4",XfV+V+|3U?-GVU; ;^I:X6QC5889K+5==NV4 3%D02#*_VKJ(U1"I+.\$".Y>_G-^K<,>,T#^<|
<7NL=|M:I.Y';K3EFMZKNL=-I#N+=X B3IF: ^8YZS.45E(4 MN-
%!, "4ZN3+R_K)^ :FC4,9W" H^+"CUSN/'JMKWA7NX6D)G>, M40^OGF[V_)/10U!+ P04 " GB6U922BND'\%
!?!&@ &'%N8W@M M,C R-# Y,S!X97AX,S(R+FAT;>U9;6_-;A#^0E !.5CJ)8CR6^)|09(7 <-

M,,1M[*+;IX\$B*8N(1*HDE<3[/]3M2\E02="G0.&U1(PAL'7EWS[V1=QHF)DM/
MA@G#].2WX>^>A]Y(4F1,&\$04PX915&@NYN@C9?H:>5ZU:B3SA>+SQ*#0#]0H MHU37_ :7=,--RDZ6?
(:'Y>_AH1,RC''1=G PIOT&WY PJS\?KN3F\ \$MIR;I![[M1\VM.QG&4A@0IF!S^;7D\9 35G-@9F3>#T+@9-
B=\7#*YZ>0\ -5*5LOE1*92 M]?=\]0E8BA?CC*>+ JL9SYA&E^P67ICL!RS/U0LJ/QE>SB_.+T>GL8G*)
MWGVXFGXX09RAV01-QR/W[-COHLGYH\"^R"SMV,T/;TZ.[T<3[W]7W^_.T:G
MHQEH#E'0AZ@>'*\$ /S6ESU%P!"UH= ^"I#GMV5.W/HKH0B\$@A&#%<"G3+38), MPM#| BLP=;I 5RR7RB
9PS,N"\$.SA"F@/1C++ ML5BX7\ '@ '7>Q1+Y=CGH*RDB D*-67*4PJG@ MI2R&W%G5'@YXA.E[K>Z+!7<16*7?
[L50VR5L-UMM:PA(GV5.044*"48@85(; M&ZLP5^Q3P16S!Z:VCIE6V1FTZAB"2J&@4Z>KZ-J.DL[QP\$;
(S^"\ \ /MT'A=0 MQ;*R?#\$I-!BV4GCJG+'T+. :V=N:*>0\$AB7C-\$6P#;3!*;A8Y^!5W7"[8BZP M(/8Y,*3Q M?
NB:J^]V.#BS S.R-3##A+B^TPXL;!>ZGNVMQFS<0...0@-@^UZ-A#2(,I9! MD_SUXSS[0.(!_"/;?
1.IH,=V;R.B!4B*&1RVQ%)@.33\$5HHM/U^<6\$*,<75? MB?5,KK4YDVN@:FJY-;RKWR8,'BKHZ2D#S6*IF%V(8U-
Q=C/(JEE?F>D ;**J M[I ?.+K5>) M;5F.D62:'=0" /:X&P 1 " 0 !Q;F-X+3(P,C0P.3,P M+fat;5!+ 0(4
00 (">);5FXV(CDX10 * P 1 " M 4S4 @!Q;F-X+3(P,C0P.3,P+GAS9!+ 0(4 00 (">);5ECTU/@6", M
 .%J 0 5 " 5SI @!Q;F-X+3(P,C0P.3,P7V-A;"YX;600 M2P\$"% ,4 " GB6U93P 4601V "4C@4 %0 @ 'G# ,
M<6YC>"TR,#(T,#DS,%]D968N>&UL4\$L! A0#% @)XEM6=D9D=N/X0(MA4 # !0 (!'H,# '%N8W@M,C R-#
Y,S! ?9S\$N;G!G4\$L! M A0#% @)XEM63W\$2IAR\$ \$ <= ! !0 (!WV0& '%N M8W@M,C R-# Y,S! ?
9S(N;G!G4\$L! A0#% @)XEM66G^C8EQ/P(D><" M !0 (!@W4' '%N8W@M,C R-# Y,S! ?9S,N;G!G4\$L!
A0# M% @)XEM6:S*=;60WP\$ PHX" !0 (!)K4) '%N8W@M M,C R-# Y,S! ?9S0N;G!G4\$L! A0#% @
)XEM65:%&'XK) , "6\ \$!0 M (!Z)0+ '%N8W@M,C R-# Y,S! ?9S4N;G!G4\$L! A0#% M @)XEM6?
E1NV]I @ L? \) !4 (!1;D. '%N8W@M,C R M-# Y,S! ?;&B+GAM;%!+ 0(4 00 (">);5EZY!E!K; , *!A"
5 M " >&W#P!Q;F-X+3(P,C0P.3,P7W!R92YX;6002P\$"% ,4 M" GB6U9L40!X!@' "M)@ & @ '!:Q
<6YC>"TR,#(T M,#DS,'AE>'@S,3\$N;'1M4\$L! A0#% @)XEM6;,&1E;X!P F"< !@ M (!SW,0 '%N8W@M,C
R-# Y,S!X97AX,S\$R+fat;5!+ 0(4 M 00 (">);5D4<;]!<@4 #D: 8 " ?U[\$!Q;F-X
M+3(P,C0P.3,P>&5X># ,R,2YH=&U02P\$"% ,4 " GB6U922BND'\ % !? M&@ & @ &E@1 <6YC>"TR,#
(T,#DS,'AE>'@S,C(N:'1M 64\$L!@ / \ / , %J'\$ \$! end XML 98 qncx-20240930_htm.xml IDEA:
XBRL DOCUMENT 0001662774 2024-01-012024-09-30 0001662774 2024-11-05 0001662774 2024-09-
30 0001662774 2023-12-31 0001662774 us-gaap:SeriesAPreferredStockMember 2023-12-31
0001662774 us-gaap:SeriesAPreferredStockMember 2024-09-30 0001662774 2024-07-012024-09-
30 0001662774 2023-07-012023-09-30 0001662774 2023-01-012023-09-30 0001662774 us-
gaap:CommonStockMember 2024-06-30 0001662774 us-gaap:AdditionalPaidInCapitalMember 2024-
06-30 0001662774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001662774
us-gaap:RetainedEarningsMember 2024-06-30 0001662774 2024-06-30 0001662774 us-
gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001662774 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001662774 us-
gaap:RetainedEarningsMember 2024-07-012024-09-30 0001662774 us-gaap:CommonStockMember
2024-09-30 0001662774 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001662774 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001662774 us-
gaap:RetainedEarningsMember 2024-09-30 0001662774 us-gaap:CommonStockMember 2023-06-30
0001662774 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001662774 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001662774 us-
gaap:RetainedEarningsMember 2023-06-30 0001662774 2023-06-30 0001662774 us-
gaap:CommonStockMember 2023-07-012023-09-30 0001662774 us-
gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001662774 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001662774 us-
gaap:RetainedEarningsMember 2023-07-012023-09-30 0001662774 us-gaap:CommonStockMember
2023-09-30 0001662774 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001662774 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001662774 us-
gaap:RetainedEarningsMember 2023-09-30 0001662774 2023-09-30 0001662774 us-
gaap:CommonStockMember 2023-12-31 0001662774 us-gaap:AdditionalPaidInCapitalMember 2023-
12-31 0001662774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001662774
us-gaap:RetainedEarningsMember 2023-12-31 0001662774 us-gaap:CommonStockMember 2024-01-
012024-09-30 0001662774 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30
0001662774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30
0001662774 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0001662774 us-
gaap:CommonStockMember 2022-12-31 0001662774 us-gaap:AdditionalPaidInCapitalMember 2022-
12-31 0001662774 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001662774
us-gaap:RetainedEarningsMember 2022-12-31 0001662774 2022-12-31 0001662774 us-
gaap:CommonStockMember 2023-01-012023-09-30 0001662774 us-
gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0001662774 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0001662774 us-
gaap:RetainedEarningsMember 2023-01-012023-09-30 0001662774 us-
gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMember 2024-09-30 0001662774 us-
gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMemberus-
gaap:SubsequentEventMember 2024-11-13 0001662774 us-
gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMemberus-
gaap:SubsequentEventMember 2024-11-012024-11-13 0001662774 us-
gaap:MoneyMarketFundsMember 2024-09-30 0001662774 us-gaap:FairValueInputsLevel1Memberus-

~~gaap:MoneyMarketFundsMember 2024-09-30 0001662774 us-gaap:FairValueInputsLevel2Memberus-~~
~~gaap:MoneyMarketFundsMember 2024-09-30 0001662774 us-gaap:FairValueInputsLevel3Memberus-~~
~~gaap:MoneyMarketFundsMember 2024-09-30 0001662774 us-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001662774 us-~~
~~gaap:FairValueInputsLevel1Memberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001662774 us-~~
~~gaap:FairValueInputsLevel2Memberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001662774 us-~~
~~gaap:FairValueInputsLevel3Memberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001662774 us-~~
~~gaap:FairValueInputsLevel1Member 2024-09-30 0001662774 us-~~
~~gaap:FairValueInputsLevel2Member 2024-09-30 0001662774 us-~~
~~gaap:FairValueInputsLevel3Member 2024-09-30 0001662774 us-gaap:MoneyMarketFundsMember~~
~~2023-12-31 0001662774 us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember~~
~~2023-12-31 0001662774 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember~~
~~2023-12-31 0001662774 us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember~~
~~2023-12-31 0001662774 us-gaap:CertificatesOfDepositMember 2023-12-31 0001662774 us-~~
~~gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMember 2023-12-31~~
~~0001662774 us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember 2023-~~
~~12-31 0001662774 us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMember~~
~~2023-12-31 0001662774 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-~~
~~12-31 0001662774 us-gaap:FairValueInputsLevel1Memberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001662774 us-~~
~~gaap:FairValueInputsLevel2Memberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001662774 us-~~
~~gaap:FairValueInputsLevel3Memberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001662774 us-~~
~~gaap:FairValueInputsLevel1Member 2023-12-31 0001662774 us-~~
~~gaap:FairValueInputsLevel2Member 2023-12-31 0001662774 us-~~
~~gaap:FairValueInputsLevel3Member 2023-12-31 0001662774 qncx:EryDelMember 2024-07-012024-~~
~~09-30 0001662774 qncx:ContingentConsiderationMember 2024-09-30 0001662774~~
~~srt:MinimumMemberqncx:ContingentConsiderationMember 2024-09-30 0001662774~~
~~srt:MaximumMemberqncx:ContingentConsiderationMember 2024-09-30 0001662774 us-~~
~~gaap:FairValueInputsLevel3Member 2024-01-012024-09-30 0001662774~~
~~qncx:EuropeanInvestmentBankLoanMember 2024-09-30 0001662774 us-~~
~~gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:CashMember 2024-09-30 0001662774 us-gaap:CashAndCashEquivalentsMemberus-~~
~~gaap:FairValueMeasurementsRecurringMemberus-gaap:CashMember 2023-12-31 0001662774 us-~~
~~gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:MoneyMarketFundsMember 2024-09-30 0001662774 us-~~
~~gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:MoneyMarketFundsMember 2023-12-31 0001662774 us-~~
~~gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001662774 us-~~
~~gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001662774 us-~~
~~gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30~~
~~0001662774 us-gaap:CashAndCashEquivalentsMemberus-~~
~~gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001662774 us-~~
~~gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:CertificatesOfDepositMember 2024-09-30 0001662774 us-~~
~~gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:CertificatesOfDepositMember 2023-12-31 0001662774 us-~~
~~gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001662774 us-~~
~~gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-~~
~~gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001662774 us-~~
~~gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30~~
~~0001662774 us-gaap:ShortTermInvestmentsMemberus-~~
~~gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001662774 us-~~
~~gaap:CashAndCashEquivalentsMember 2024-09-30 0001662774 us-~~
~~gaap:ShortTermInvestmentsMember 2024-09-30 0001662774 us-~~
~~gaap:CashAndCashEquivalentsMember 2023-12-31 0001662774 us-~~
~~gaap:ShortTermInvestmentsMember 2023-12-31 0001662774 qncx:NovosteoMember 2024-01-~~
~~012024-09-30 0001662774 qncx:NovosteoMember 2024-07-012024-09-30 0001662774~~
~~qncx:NovosteoMember 2023-01-012023-03-31 0001662774 us-gaap:ComputerEquipmentMember~~
~~2024-09-30 0001662774 us-gaap:ComputerEquipmentMember 2023-12-31 0001662774 us-~~

~~gaap:ComputerSoftwareIntangibleAssetMember 2024-09-30 0001662774 us-~~
~~gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0001662774 gncx:LabEquipmentMember~~
~~2024-09-30 0001662774 gncx:LabEquipmentMember 2023-12-31 0001662774 us-~~
~~gaap:LeaseholdImprovementsMember 2024-09-30 0001662774 us-~~
~~gaap:LeaseholdImprovementsMember 2023-12-31 0001662774 us-~~
~~gaap:FurnitureAndFixturesMember 2024-09-30 0001662774 us-gaap:FurnitureAndFixturesMember~~
~~2023-12-31 0001662774 2023-01-312023-04-30 0001662774 2023-08-042023-08-04 0001662774~~
~~us-gaap:StockOptionMember 2023-01-012023-12-31 0001662774~~
~~gncx:RestrictedStockAwardsMember 2023-01-012023-12-31 0001662774 2023-01-012023-12-31~~
~~0001662774 gncx:BressoMembergncx:EryDelMember 2023-10-31 0001662774~~
~~gncx:MedollaMembergncx:EryDelMember 2023-10-31 0001662774~~
~~gncx:EryDelMembergncx:OtherOperatingLeasesMember 2023-10-31 0001662774 us-~~
~~gaap:AutomobilesMember 2023-10-312023-10-31 0001662774 gncx:MedollaMember 2024-09-30~~
~~0001662774 gncx:RightsPlanMemberus-gaap:SeriesAPPreferredStockMember 2023-04-052023-04-05~~
~~0001662774 gncx:RightsPlanMemberus-gaap:SeriesAPPreferredStockMember 2023-04-05~~
~~0001662774 gncx:RightsPlanMemberus-gaap:PreferredStockMember 2023-04-05 0001662774~~
~~gncx:TwoThousandAndNineteenEquityIncentivePlanMember 2024-09-30 0001662774~~
~~gncx:TwoThousandAndNineteenEquityIncentivePlanMember 2024-01-012024-09-30 0001662774~~
~~srt:MaximumMembergncx:TwoThousandAndNineteenEquityIncentivePlanMember 2024-01-012024-09-~~
~~30 0001662774 srt:MinimumMembergncx:TwoThousandAndNineteenEquityIncentivePlanMember~~
~~2024-01-012024-09-30 0001662774~~
~~gncx:TwoThousandAndNineteenEquityIncentivePlanMembergncx:OneYearAnniversaryMember 2024-~~
~~01-012024-09-30 0001662774~~
~~gncx:TwoThousandAndNineteenEquityIncentivePlanMembergncx:ThreeYearAnniversaryMember~~
~~2024-01-012024-09-30 0001662774 gncx:TwoThousandAndNineteenEquityIncentivePlanMember~~
~~2023-12-31 0001662774 gncx:TwoThousandAndNineteenEquityIncentivePlanMember 2023-01-~~
~~012023-12-31 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:TwoThousandAndNineteenEquityIncentivePlanMember 2024-~~
~~07-012024-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:TwoThousandAndNineteenEquityIncentivePlanMember 2024-~~
~~01-012024-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:TwoThousandAndNineteenEquityIncentivePlanMember 2023-~~
~~07-012023-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:TwoThousandAndNineteenEquityIncentivePlanMember 2023-~~
~~01-012023-09-30 0001662774 srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-~~
~~01-012024-09-30 0001662774 srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-~~
~~01-012024-09-30 0001662774 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001662774~~
~~us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001662774 us-~~
~~gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2024-07-012024-09-30 0001662774~~
~~us-gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2024-01-012024-09-30 0001662774~~
~~us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0001662774 us-~~
~~gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2022-05-19 0001662774~~
~~gncx:NovosteoPlanMember 2022-05-19 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2022-05-192022-05-19 0001662774~~
~~srt:MaximumMemberus-gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2022-05-~~
~~192022-05-19 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMembergncx:OneYearAnniversaryMember 2022-~~
~~05-192022-05-19 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMembergncx:ThreeYearAnniversaryMember~~
~~2022-05-192022-05-19 0001662774 srt:MinimumMemberus-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2022-05-192022-05-19 0001662774~~
~~gncx:NovosteoPlanMember 2024-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2023-12-31 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2023-01-012023-12-31 0001662774~~
~~us-gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2024-09-30 0001662774 us-~~
~~gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2023-07-012023-09-30 0001662774~~
~~us-gaap:EmployeeStockOptionMembergncx:NovosteoPlanMember 2023-01-012023-09-30 0001662774~~
~~gncx:RestrictedStockAwardsMembergncx:NovosteoPlanMember 2022-05-19 0001662774~~
~~gncx:RestrictedStockAwardsMember 2023-12-31 0001662774 gncx:RestrictedStockAwardsMember~~
~~2024-01-012024-09-30 0001662774 gncx:RestrictedStockAwardsMember 2024-09-30 0001662774~~
~~gncx:RestrictedStockAwardsMembergncx:NovosteoPlanMember 2024-07-012024-09-30 0001662774~~
~~gncx:RestrictedStockAwardsMembergncx:NovosteoPlanMember 2024-01-012024-09-30 0001662774~~
~~gncx:RestrictedStockAwardsMembergncx:NovosteoPlanMember 2023-07-012023-09-30 0001662774~~
~~gncx:RestrictedStockAwardsMembergncx:NovosteoPlanMember 2023-01-012023-09-30 0001662774~~

~~qncx:RestrictedStockAwardsMemberqncx:NovosteoPlanMember 2024-09-30 0001662774~~
~~qncx:TwoThousandAndTwentyTwoInducementPlanMember 2022-05-09 0001662774~~
~~qncx:TwoThousandAndTwentyTwoInducementPlanMember 2022-05-092022-05-09 0001662774~~
~~qncx:TwoThousandAndTwentyTwoInducementPlanMember 2024-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMemberqncx:TwoThousandAndTwentyTwoInducementPlanMember 2023-12-31 0001662774 us-~~
~~gaap:EmployeeStockOptionMemberqncx:TwoThousandAndTwentyTwoInducementPlanMember 2023-01-012023-12-31 0001662774 us-~~
~~gaap:EmployeeStockOptionMemberqncx:TwoThousandAndTwentyTwoInducementPlanMember 2024-01-012024-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMemberqncx:TwoThousandAndTwentyTwoInducementPlanMember 2024-09-30 0001662774 qncx:TwoThousandAndTwentyTwoInducementPlanMember 2024-07-012024-09-30 0001662774 qncx:TwoThousandAndTwentyTwoInducementPlanMember 2024-01-012024-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMemberqncx:TwoThousandAndTwentyTwoInducementPlanMember 2023-07-012023-09-30 0001662774 us-~~
~~gaap:EmployeeStockOptionMemberqncx:TwoThousandAndTwentyTwoInducementPlanMember 2023-01-012023-09-30 0001662774 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001662774 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001662774 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001662774 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001662774 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001662774 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001662774 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001662774 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001662774~~
~~qncx:TwoThousandNineteenEmployeeStockPurchasePlanMember 2019-04-24 0001662774~~
~~qncx:TwoThousandNineteenEmployeeStockPurchasePlanMember 2019-04-242019-04-24 0001662774 us-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMember 2023-10-20 0001662774 us-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanTrancheAMember 2023-10-20 0001662774 us-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanTrancheBMember 2023-10-20 0001662774 us-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanTrancheCMember 2023-10-20 0001662774 us-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanTrancheDMember 2023-10-20 0001662774 srt:MinimumMemberus-gaap:LineOfCreditMember 2023-10-202023-10-20 0001662774 srt:MaximumMemberus-gaap:LineOfCreditMember 2023-10-202023-10-20 0001662774 srt:MinimumMemberus-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMember 2023-10-20 0001662774 srt:MaximumMemberus-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMember 2023-10-20 0001662774 qncx:EryDelMemberus-gaap:LineOfCreditMember 2023-10-202023-10-20 0001662774 qncx:EryDelMemberus-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanTrancheAMember 2023-10-202023-10-20 0001662774 qncx:EryDelMemberus-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanTrancheAAndTrancheBMember 2023-10-202023-10-20 0001662774 qncx:EryDelMemberus-gaap:LineOfCreditMemberqncx:EuropeanBankLoanTrancheATrancheBTrancheCMember 2023-10-202023-10-20 0001662774 qncx:EryDelMemberus-gaap:LineOfCreditMemberqncx:EuropeanInvestmentBankLoanMember 2023-10-202023-10-20 0001662774 qncx:EuropeanInvestmentBankLoanMember 2024-09-30 0001662774 qncx:EuropeanInvestmentBankLoanMember 2024-01-012024-09-30 0001662774 qncx:EryDelMember 2024-09-30 0001662774 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001662774 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001662774 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0001662774 us-gaap:RestrictedStockUnitsRSUMember 2023-01-012023-09-30 0001662774 us-gaap:RestrictedStockMember 2024-01-012024-09-30 0001662774 us-gaap:RestrictedStockMember 2023-01-012023-09-30 0001662774 qncx:EryDelMember 2023-10-20 0001662774 qncx:EryDelMember 2023-10-202023-10-20 0001662774 2023-10-20 0001662774 2023-10-202023-10-20 0001662774 qncx:ApprovalMilestonesMember 2023-10-202023-10-20 0001662774 srt:MinimumMemberqncx:EryDelMemberqncx:ContingentConsiderationMemberqncx:ProbabilityOfAct 2023-10-20 0001662774 srt:MaximumMemberqncx:EryDelMemberqncx:ContingentConsiderationMemberqncx:ProbabilityOfAct 2023-10-20 0001662774 qncx:EryDelMemberus-gaap:InProcessResearchAndDevelopmentMember 2023-10-20 0001662774 qncx:EryDelMemberus-gaap:TradeNamesMember 2023-10-20 0001662774 qncx:EryDelMemberus-gaap:GeneralAndAdministrativeExpenseMember 2023-10-20 0001662774 qncx:EryDelMemberus-gaap:ResearchAndDevelopmentExpenseMember 2023-10-20 0001662774 us-gaap:InProcessResearchAndDevelopmentMember 2023-12-31 0001662774 us-gaap:InProcessResearchAndDevelopmentMember 2024-01-012024-09-30 0001662774 us-gaap:InProcessResearchAndDevelopmentMember 2024-09-30 0001662774 us-gaap:TradeNamesMember 2024-09-30 0001662774 us-gaap:TradeNamesMember 2023-12-31~~

0001662774 us-gaap:InProcessResearchAndDevelopmentMember 2023-01-012023-09-30 shares
iso4217:USD iso4217:USD shares iso4217:EUR pure qncx:segment qncx:lease
qncx:plan0001662774202403false--12-310.001600010-Qtrue2024-09-30false001-388900Quince
Therapeutics, Inc.DE90-1024039611 Gateway Boulevard, Suite 273South San
FranciscoCA94080415910-5717Common Stock, par value \$0.001 per shareQNCXNASDAQYesYesNon-
accelerated
Filertruefalsefalse440016432675000207520004517200054307000387100023810005171800077440000;
0.0010.001100000000100000001000001000000000000.0010.0011000000001000000004327660643276606;
364014000-
3196440004493200085084000126519000167900000491600014310001276500060130003630000466300013;
2683000020820000586300060940004527300024699000-5863000-6094000-45273000-
2469900044900001252000068300095900023930002464000150000-216000-158000-504000-5479000-
5351000-44290000-2273900013000080000-248000-5492000-5351000-44370000-
224910002158000158000203000309000174000101000169000496000-3160000-5092000-43998000-
21686000-0.13-0.13-0.15-0.15-1.03-1.03-0.63-
0.634316413643164136360730403607304043090632430906323594123435941234432766064300040436000;
358522000469680001124000112400021580002158000174000174000-5492000-
549200043276606430004054840003419000-364014000449320003632799536000391990000257000-
3053990008688400070394280002800054757180001800013310001331000158000158000101000101000-
5351000-53510003634363236000393331000516000-
3107500008313300042973215430004016380003047000-
3196440008508400030339122500022500036210003621000203000203000169000169000-44370000-
4437000043276606430004054840003419000-364014000449320003613648036000389105000-289000-
28825900010059300027044511000011000063293180001800041340004134000309000309000496000496000;
22491000-224910003634363236000393331000516000-31075000083133000-44370000-
22491000362100041340001700001800006600007100007800020820000125200001713000059000001858000;
2272000170000-1920002920000-424000-161000532000-576000-24352000-
12214000895620009511600010072700084514000050000009000012400013600011041000-
11148000500000000600022500092000-4775000860009000329000-18077000-
22947000207520004457900026750002163200023200000700000organization<div style="margin-
top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of
Business</div><div style="margin-top:12pt"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated
to unlocking the power of a patient's own biology for the treatment of rare diseases.
</div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's
proprietary AIDE technology platform is an innovative drug/device combination platform
that uses an automated process to encapsulate a drug into a patient's own red blood
cells. Red blood cells have several characteristics that make them a potentially ideal
vehicle for drug delivery and our AIDE technology is designed to harness many of these
benefits to allow for new and improved therapeutic options for patients living with high
unmet medical needs. The AIDE technology platform is believed to confer several benefits
over conventional therapies which could be applied to a broad range of small or large
molecule drugs and biologics. Our Phase 3 lead asset, EryDex, leverages the AIDE
technology to encapsulate DSP into a patient's own red blood cells, and is targeted to
treat a rare pediatric neurodegenerative disease, A-T. </div><div style="margin-
top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">By pioneering the encapsulation of drugs in
a patient's own red blood cells, we seek to advance proprietary therapeutics that hold
the potential to redefine the standard of care and meaningfully improve the quality of
life for patients with rare disease. </div><div style="margin-top:12pt"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources
</div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has
incurred losses and negative cash flows from operations since inception and expects to
continue to generate operating losses for the foreseeable future. As of September 30,
2024, the Company had an accumulated deficit of \$364.0 million. Since inception through
September 30, 2024, the Company has funded operations primarily with the net proceeds
from the issuance of convertible promissory notes, from the issuance of redeemable
convertible preferred stock, from the net proceeds from the Company's initial public
offering (the "IPO") and from the net proceeds of the private investment in public
equity transaction ("PIPE Financing"). As of September 30, 2024, the Company had cash,
cash equivalents, and short-term investments of \$47.8 million, which it believes will be
sufficient to fund its planned operations into the first quarter of 2026, a period that

is at least 12 months from the date of the issuance of the accompanying unaudited consolidated financial statements.

In connection with the acquisition of EryDel on October 20, 2023 (the "EryDel Acquisition"), the Company assumed an unsecured line of credit between EryDel and the European Investment Bank (the "EIB Loan"). As of September 30, 2024, the principal of 10.0 million euros (\$11.2 million) was outstanding on the EIB Loan. The Debt Agreement requires the Company to maintain a minimum cash balance of 14.65 million euros (\$16.4 million) until the outstanding obligations under the Debt Agreement, together with accrued interest and all other amounts accrued or outstanding under the agreement, is repaid in full (the "Minimum Cash Covenant").

Furthermore, the Company may at any time voluntarily prepay, in whole or in part, together with certain fees as set forth in the Debt Agreement, the outstanding obligations under the Debt Agreement. In the event of a default or a change in control, as specified in the Debt Agreement, EIB may, subject to certain grace periods, accelerate the outstanding obligations under the EIB Loan.

In November 2024, the Company entered into an amendment (the "Amendment") of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment.

Management expects to incur additional losses in the future to fund the Company's operations and conduct product research and development and may need to raise additional capital to fully implement its business plan. The Company may raise additional capital through the issuance of equity securities, debt financings or other sources including out-licensing or partnerships, in order to further implement its business plan. However, if such financing is not available when needed and

at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of product candidates.

364000000.0478000001000000001120000014650000164000000.020.0920000Summary of Significant Accounting Policies

Basis of Consolidation

The accompanying condensed consolidated financial statements include the accounts of Quince Therapeutics, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the instructions of the SEC on

Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the management's opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.

The condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the

condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 included in the Company's Form 10-K filed with the SEC on April 1, 2024. The results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period.

Risks and Uncertainties

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company's potential drug candidates, uncertainty of market acceptance of the Company's drug candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. The Company's drug candidates will require approvals from the FDA and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any drug candidate will receive the necessary approvals.

Use of Estimates

The preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company's consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances, determination of the fair value of identifiable assets and liabilities in connection with business combinations including associated intangible assets and goodwill, contingent consideration, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets, eligibility of expenses for the Australia research and development refundable tax credits, impairment of intangible assets, including goodwill, and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company's estimates.

Foreign Currency Translation and Transactions

The functional currency of the Company's wholly-owned subsidiaries are the Euro and Australian Dollar. The Company's financial results and financial position are translated into U.S. dollars using exchange rates at balance sheet dates for assets and liabilities and using average exchange rates for income and expenses. The resulting translation differences are presented as a separate component of accumulated other comprehensive loss, as a separate component of equity.

Foreign currency transactions are translated into the functional currencies using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses, resulting from the settlement of such transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies using exchange rates at balance sheet date and non-monetary assets and liabilities using historical exchange rates, are recognized in the condensed consolidated statements of operations and comprehensive loss.

Significant

Accounting Policies

There have been no significant changes to the accounting policies during the nine months ended September 30, 2024, as compared to the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2023.

Segments

The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing therapeutics. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating and evaluating financial performance. All long-lived assets are maintained in Italy.

Business Combinations

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business.

The Company accounts for business combinations using the acquisition method pursuant to the FASB ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company's financial results beginning on the respective acquisition dates, and that identifiable assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using one of three valuation approaches, the income approach, the market approach or the cost approach. The Company reviewed the three valuation approaches and determined the income approach was the most appropriate model to approximate fair value for the EryDel Acquisition. The income approach model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the "Purchase Price") over the fair values of the net assets acquired is recognized as goodwill. The fair value of identifiable assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible Assets

Definite lived Intangible Assets

Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. The Company regularly reviews whether current conditions or events suggest that the carrying values of its acquired definite lived intangible assets might not be recoverable. When such conditions are identified, an estimate of the undiscounted future cash flows from these assets, or relevant asset groupings, is compared to their carrying value to determine if an impairment exists. If an impairment is identified, the loss is calculated as the difference between the carrying value of the intangible asset and its fair value, which is based on the net present value of the estimated future cash flows.

Indefinite lived Intangible Assets

Intangible assets with an indefinite useful life are not amortized. Intangible assets acquired in a business combination or an acquisition that are used in research and development activities (regardless of whether they have an alternative future use) shall be considered indefinite lived until the completion or abandonment of the associated research and development efforts. Intangible assets acquired in a business combination are initially recorded at fair value. During the period that those assets are considered indefinite lived, they shall not be amortized but shall be tested for impairment. Once the research and development efforts are completed or abandoned, the entity shall determine the useful life of the assets. An indefinite lived intangible asset shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the intangible asset. Qualitative factors to be considered include but are not limited to:

Cost factors such as increases in raw materials, labor, or other costs that have a negative effect on future expected earnings and cash flows

Legal/regulatory factors or progress and results of clinical trials

Other relevant entity-specific events such as changes in management, key personnel, strategy, or customers; contemplation of bankruptcy; or litigation that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset

Industry and market considerations such as a deterioration in the environment in which an entity operates, an increased competitive environment

Macroeconomic conditions such as deterioration in general economic conditions, limitations on accessing capital, fluctuations in foreign exchange rates, or other developments in equity and credit markets that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset

Goodwill

Goodwill represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.

During the nine months ended September 30,

2024, the Company recognized a non-cash goodwill impairment charge of \$17.1 million as the quantitative analysis resulted in the Company's fair value being significantly below its carrying value during the three months ended June 30, 2024.

Contingent Consideration

The Company determines the acquisition date fair value of contingent consideration using a discounted cash flow method, with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC Topic 820, Fair Value Measurement. The significant inputs in the Level 3 measurement not supported by market activity included our probability assessments of expected future cash flows related to the Company's acquisition of EryDel in October 2023, during the contingent consideration period, appropriately discounted considering the uncertainties associated with the earnout obligation, and calculated in accordance with the terms of the definitive agreement. The liabilities for the contingent consideration are established at the time of the acquisition and will be evaluated on a quarterly basis based on additional information as it becomes available. Any change in the fair value adjustment is recorded in the earnings of that period. During the three months ended September 30, 2024, the Company recorded a \$2.7 million adjustment to decrease the fair value of its contingent consideration related to the acquisition of EryDel. During the nine months ended September 30, 2024, the Company recorded a net \$2.1 million adjustment to increase the fair value of its contingent consideration related to the acquisition of EryDel. The adjustment is reflected within operating loss on the consolidated statement of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations may result from changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Significant increases or decreases in the inputs noted above in isolation would result in a significantly lower or higher fair value measurement.

Cash, Cash Equivalents and Investments

The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash equivalents include marketable securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as short-term investments. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term investments. Collectively, cash equivalents, short-term investments and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded as a component of other comprehensive loss in the consolidated statements of operations and included as a separate component of consolidated statements of stockholders' equity (deficit). Realized gains and losses are included in interest income in the consolidated statements of operations and comprehensive loss.

Premiums (discounts) are amortized (accreted) over the life of the related investment as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. These amounts are recorded in "interest income" in the consolidated statements of operations and comprehensive loss.

Recent Accounting Pronouncements Not Yet Adopted

The following are new accounting pronouncements that the Company is evaluating for future impacts on its financial statements:

Improvements to Income Tax Disclosures (ASC 740): In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." This ASU establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Under this ASU, entities must consistently categorize and provide greater disaggregation of information

in the rate reconciliation. They must also further disaggregate income taxes paid. The ASU is effective beginning after December 2024 under a prospective approach. Early adoption is permitted. The Company is evaluating the disclosure requirements related to the new standard.

Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"): In November 2023, the FASB issued ASU 2023-07, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.

All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.

Basis of Consolidation

The accompanying condensed consolidated financial statements include the accounts of Quince Therapeutics, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the instructions of the SEC on Form 10-Q and Article 8 of Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the management's opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of the results of operations and cash flows for the periods presented have been included.

The condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of stockholders' equity for the three and nine months ended September 30, 2024 and 2023, the condensed consolidated statements of cash flows for the nine months ended September 30, 2024 and 2023, and the financial data and other financial information disclosed in the notes to the condensed consolidated financial statements are unaudited. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2023 included in the Company's Form 10-K filed with the SEC on April 1, 2024. The results of operations for the nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other future annual or interim period.

Risks and Uncertainties

The Company's future results of operations involve a number of risks and uncertainties. Factors that could affect the Company's future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company's potential drug candidates, uncertainty of market acceptance of the Company's drug candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. The Company's drug candidates will require approvals from the FDA and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any drug candidate will receive the necessary approvals.

Use of Estimates

The preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses, as well as related disclosure of contingent assets and liabilities. The most significant estimates used in the Company's consolidated financial statements relate to the determination of the fair value of stock-based awards and other issuances, determination of the fair value of identifiable assets and liabilities in connection with business combinations including associated intangible assets and goodwill, contingent consideration, accruals for research and development costs, useful lives of long-lived assets, stock-based compensation and related assumptions, the incremental borrowing rate for leases and income tax uncertainties, including a valuation allowance for deferred tax assets, eligibility of expenses for the Australia research and development refundable tax credits, impairment of intangible assets, including goodwill; and contingencies. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from the Company's estimates.

Foreign Currency Translation and Transactions

The functional currency of the Company's wholly-owned subsidiaries are the Euro and Australian Dollar. The Company's financial results and financial position are translated into U.S. dollars using exchange rates at balance sheet dates for assets and liabilities and using average exchange rates for income and expenses. The resulting translation differences are presented as a separate component of accumulated other comprehensive loss, as a separate component of equity.

Foreign currency transactions are translated into the functional currencies using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses, resulting from the settlement of such transactions and from the re-measurement of monetary assets and liabilities denominated in foreign currencies using exchange rates at balance sheet date and non-monetary assets and liabilities using historical exchange rates, are recognized in the condensed consolidated statements of operations and comprehensive loss.

Segments

The Company operates and manages its business as one reportable and operating segment, which is the business of developing and commercializing therapeutics. The Company's chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating and evaluating financial performance. All long-lived assets are maintained in Italy.

Business Combinations

The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the requirements of a business.

The Company accounts for business combinations using the acquisition method pursuant to the FASB ASC Topic 805. This method requires, among other things, that results of operations of acquired companies are included in the Company's financial results beginning on the respective acquisition

dates, and that identifiable assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired in a business combination are recorded at fair value using one of three valuation approaches, the income approach, the market approach or the cost approach. The Company reviewed the three valuation approaches and determined the income approach was the most appropriate model to approximate fair value for the EryDel Acquisition. The income approach model requires assumptions about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant. Any excess of the fair value of consideration transferred (the "Purchase Price") over the fair values of the net assets acquired is recognized as goodwill. The fair value of identifiable assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other acquisition-related costs are expensed when incurred.

Intangible Assets

Definite lived Intangible Assets

Intangible assets with a definite useful life are amortized on a straight-line basis over the estimated useful life of the related assets. The Company regularly reviews whether current conditions or events suggest that the carrying values of its acquired definite lived intangible assets might not be recoverable. When such conditions are identified, an estimate of the undiscounted future cash flows from these assets, or relevant asset groupings, is compared to their carrying value to determine if an impairment exists. If an impairment is identified, the loss is calculated as the difference between the

carrying value of the intangible asset and its fair value, which is based on the net present value of the estimated future cash flows.

Indefinite lived Intangible Assets

Intangible assets with an indefinite useful life are not amortized. Intangible assets acquired in a business combination or an acquisition that are used in research and development activities (regardless of whether they have an alternative future use) shall be considered indefinite lived until the completion or abandonment of the associated research and development efforts. Intangible assets acquired in a business combination are initially recorded at fair value. During the period that those assets are considered indefinite lived, they shall not be amortized but shall be tested for impairment. Once the research and development efforts are completed or abandoned, the entity shall determine the useful life of the assets. An indefinite lived intangible asset shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the intangible asset is less than its carrying amount. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the intangible asset. Qualitative factors to be considered include but are not limited to:

- Cost factors such as increases in raw materials, labor, or other costs that have a negative effect on future expected earnings and cash flows

- Legal/regulatory factors or progress and results of clinical trials
-

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 120%; padding-left: 23.5pt">Other relevant entity-specific events such as changes in management, key personnel, strategy, or customers; contemplation of bankruptcy; or litigation that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset</div><div style="margin-top: 6pt; padding-left: 54pt; text-indent: -27pt">•Industry and market considerations such as a deterioration in the environment in which an entity operates, an increased competitive environment</div><div style="margin-top: 6pt; padding-left: 54pt; text-indent: -27pt">•Macroeconomic conditions such as deterioration in general economic conditions, limitations on accessing capital, fluctuations in foreign exchange rates, or other developments in equity and credit markets that could affect significant inputs used to determine the fair value of the indefinite-lived intangible asset</div><div style="margin-top: 12pt">Goodwill</div><div style="margin-top: 12pt">Goodwill represents the excess of the purchase price over the fair value of the net assets acquired as of the acquisition date. Goodwill has an indefinite useful life and is not amortized. The Company reviews its goodwill for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the Company may exceed its fair value. The Company first assesses qualitative factors to determine whether it is more likely than not that the fair value of the Company is less than its carrying amount, including goodwill. If that is the case, the Company performs a quantitative impairment test, and, if the carrying amount of the Company exceeds its fair value, then the Company will recognize an impairment charge for the amount by which its carrying amount exceeds its fair value, not to exceed the carrying amount of the goodwill.</div><div style="margin-top: 12pt">During the nine months ended September 30, 2024, the Company recognized a non-cash goodwill impairment charge of \$17.1 million as the quantitative analysis resulted in the Company's fair value being significantly below its carrying value during the three months ended June 30, 2024.</div>17100000<div style="margin-top: 12pt">Contingent Consideration</div><div style="margin-top: 12pt">The Company determines the acquisition date fair value of contingent consideration using a discounted cash flow method, with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC Topic 820, Fair Value Measurement. The significant inputs in the Level 3 measurement not supported by market activity included our probability assessments of expected future cash flows related to the Company's acquisition of EryDel in October 2023, during the contingent consideration period, appropriately discounted considering the uncertainties associated with the earnout obligation, and calculated in accordance with the terms of the definitive agreement. The liabilities for the contingent consideration are established at the time of the acquisition and will be evaluated on a quarterly basis based on additional information as it becomes available. Any change in the fair value adjustment is recorded in the earnings of that period. During the three months ended September 30, 2024, the Company recorded a \$2.7 million adjustment to decrease the fair value of its contingent consideration related to the acquisition of EryDel. During the nine</div>months ended September 30, 2024, the Company recorded a net \$2.1 million adjustment to increase the fair value of its contingent consideration related to the acquisition of EryDel. The adjustment is reflected within operating loss on the consolidated statement of operations and comprehensive loss. Changes in the fair value of the contingent consideration obligations may result from changes in probability assumptions with respect to the likelihood of achieving the various contingent payment obligations. Significant increases or decreases in the inputs noted above in isolation would result in a significantly lower or higher fair value measurement.-27000002100000<div style="margin-top: 12pt">Cash, Cash Equivalents and Investments</div><div>

The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash equivalents include marketable securities. Management determines the appropriate classification of its investments in debt securities at the time of purchase and at the end of each reporting period. Investments with original maturities beyond three months at the date of purchase and which mature at, or less than twelve months from the balance sheet date are classified as short-term investments. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term investments. Collectively, cash equivalents, short-term investments and long-term investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses are recorded as a component of other comprehensive loss in the consolidated statements of operations and included as a separate component of consolidated statements of stockholders' equity (deficit). Realized gains and losses are included in interest income in the consolidated statements of operations and comprehensive loss.

Premiums (discounts) are amortized (accreted) over the life of the related investment as an adjustment to yield using the straight-line interest method. Dividend and interest income are recognized when earned. These amounts are recorded in "interest income" in the consolidated statements of operations and comprehensive loss.

Recent Accounting Pronouncements Not Yet Adopted

The following are new accounting pronouncements that the Company is evaluating for future impacts on its financial statements:

Improvements to Income Tax Disclosures (ASC 740): In December 2023, the FASB issued ASU No. 2023-09, "Improvements to Income Tax Disclosures." This ASU establishes new income tax disclosure requirements in addition to modifying and eliminating certain existing requirements. Under this ASU, entities must consistently categorize and provide greater disaggregation of information in the rate reconciliation. They must also further disaggregate income taxes paid. The ASU is effective beginning after December 2024 under a prospective approach. Early adoption is permitted. The Company is evaluating the disclosure requirements related to the new standard.

Accounting Standard Update 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"): In November 2023, the FASB issued ASU 2023-07, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses, including for single reportable segment entities. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company is evaluating the disclosure requirements related to the new standard.

All other newly issued accounting pronouncements not yet effective have been deemed either immaterial or not applicable.

Fair Value Measurements

The fair value of the Company's financial instruments reflects the amounts that the Company estimates that it would receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company discloses and recognizes the fair value of the assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows:

Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities

[illegible]

[illegible]

[illegible]

[illegible]

<table border="1" style="background-color:#cceeef;border-bottom:3pt double #ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"><tr><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">69,687 </td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value Measurements as of December 31, 2023 </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="1" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets:</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">4,285 </td><td colspan="3" style="background-

[illegible]

[illegible]

[illegible]

71,135

The Company classifies certificates of deposit and government and agency notes as Level 2 investments as the Company uses quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trades of or quotes on the same or similar securities. The Company does not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services.

Level 3 Assets and Liabilities

Contingent Consideration

The following table reflects the changes in present value of acquisition related accrued earnouts of contingent consideration liability using significant unobservable inputs (Level 3) for the nine months ended September 30, 2024:

(in thousands)			
Beginning Balance as of January 1, 2024	\$	57,706	
Payout of contingent earnout based on milestone achievement		(5,000)	
Change in fair value of contingent consideration		2,082	
Ending Balance as of September 30, 2024			

54,788

During the three months ended June 30, 2024, the Company enrolled the first patient in the Phase 3 NEAT clinical trial. In accordance with the purchase agreement entered into in connection with EryDel Acquisition, the Company notified the former EryDel shareholders of this achievement within 45 days of achieving this milestone. During the three months ended September 30, 2024, the Company paid the cash milestone payment of \$5 million to the former EryDel shareholders.

The change in the fair value of the contingent consideration is primarily driven by the cash milestone payment of \$5 million to the former EryDel shareholders, and the passage of time. The Company owes no further payments to EryDel shareholders for development-related milestones. The remaining potential contingent payments in connection with the EryDel Acquisition pertain to regulatory on market and sales milestones.

The following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition related accrued earnout as of September 30, 2024 (in thousands except for percentages):

	Contingent consideration	Unobservable Input	Range (Input Used)
	\$	\$	\$
	54,788	54,788	54,788

Expected present value		
Probability of achieving earnout objectives per the purchase agreement		
0% – 100%		

Long-term Debt

The following table presents the changes in the fair value of the Level 3 EIB Loan for the nine months ended September 30, 2024:

(in thousands)		
Beginning Balance as of January 1, 2024	\$	13,429
Change in fair value		
Due to foreign currency translation		218
Ending Balance as of September 30, 2024	\$	14,899

The following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition related long term debt as of September 30, 2024 (in thousands except for percentages):

	Weighted Average	Unobservable Input	Range (Input Used)	EIB loan	Expected present value	Credit quality of company and credit spreads for comparable debt
	31.172%	0.1%	0.1%	0.1%	0.1%	12.081%
	0.406%	0.1%	0.1%	0.1%	0.1%	0.406%
	23.748%	0.1%	0.1%	0.1%	0.1%	0.406%
	13.600%	0.1%	0.1%	0.1%	0.1%	0.406%
	14,899	13%				

Financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements by major security type as of September 30, 2024 and December 31, 2023 are presented in the following tables (in thousands):

	Weighted Average	Unobservable Input	Range (Input Used)	EIB loan	Expected present value	Credit quality of company and credit spreads for comparable debt
	31.172%	0.1%	0.1%	0.1%	0.1%	12.081%
	0.406%	0.1%	0.1%	0.1%	0.1%	0.406%
	23.748%	0.1%	0.1%	0.1%	0.1%	0.406%
	13.600%	0.1%	0.1%	0.1%	0.1%	0.406%
	14,899	13%				

[illegible]

[illegible]

align:bottom"></td><td colspan="3" style="background-color:#ccee		
solid #ffffff;padding:0 1pt"></td><td style="background-color:#ccee		
solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span		
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font		
weight:400;line-height:114%">\$/</td><td style="background-color:#ccee		
top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span		
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font		
weight:400;line-height:114%">— </td><td style="background-color:#ccee		
top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>		
</tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-		
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New		
Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities:		
</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double		
#000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt		
double #ffffff;padding:0 1pt"></td><td colspan="3" style="background-		
color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3"		
style="background-color:#ffffff;border-top:3pt double #ffffff;padding:0 1pt"></td><td		
colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt">		
</td><td colspan="3" style="background-color:#ffffff;border-top:3pt double		
#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-		
top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-		
color:#ccee		
padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span		
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font		
weight:400;line-height:114%">Contingent consideration</td><td colspan="2"		
style="background-color:#ccee		
padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-		
size:10pt;font-weight:400;line-height:114%">54,788 </td><td style="background-		
color:#ccee		
padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td		
colspan="3" style="background-color:#ccee		
padding:0 1pt"></td><td colspan="2"		
style="background-color:#ccee		
padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-		
size:10pt;font-weight:400;line-height:114%">— </td><td style="background-		
color:#ccee		
padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td		
colspan="3" style="background-color:#ccee		
padding:0 1pt"></td><td colspan="2"		
style="background-color:#ccee		
padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-		
size:10pt;font-weight:400;line-height:114%">54,788 </td><td style="background-		
color:#ccee		
padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>		
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.37pt;text-		
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New		
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long-term debt		
</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-		
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New		
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,899 </td>		
<td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-		
align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td>		
<td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-		
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New		
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">— </td><td		
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-		
align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td>		
<td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-		
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New		
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14,899 </td>		
<td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-		
align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ccee		
padding:2px 1pt 2px 8.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-		

[illegible]

[illegible]

[illegible]

weight:400;line-height:114%">\$	
background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">Liabilities	
Total	
57,706	
13,429	
Long-term debt	
13,429	
Contingent consideration	
57,706	

71,135

(in thousands)					
Beginning Balance as of January 1, 2024					
		\$			
				57,706	

The following table reflects the changes in present value of acquisition related accrued earnouts of contingent consideration liability using significant unobservable inputs (Level 3) for the nine months ended September 30, 2024:

Payout of contingent earnout based on milestone achievement		
		(5,000)
Change in fair value of contingent consideration		
	2,082	
Ending Balance as of September 30, 2024		
	54,788	

The following table presents the changes in the fair value of the Level 3 EIB Loan for the nine months ended September 30, 2024:

(in thousands)		
Beginning Balance as of January 1, 2024		
Change in fair value		
Due to foreign currency translation		

Ending Balance as of September 30, 2024

September 30, 2024									Valuation Technique						Unobservable Input								
									Range (Input Used)														
Contingent consideration			\$						54,788						Expected present value								
									Probability of achieving earnout objectives per purchase agreement														

style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center">0% – 100%</div></td></tr></table></div><div style="margin-top:12pt">The following table summarizes the quantitative information including the unobservable inputs related to the Company's acquisition related long term debt as of September 30, 2024 (in thousands except for percentages):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000"><tr><td style="width:1.0%"></td><td style="width:31.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.748%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"> </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle">September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle">Valuation Technique</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle">Unobservable Input</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Range (Input Used)</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle">EIB loan</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">14,899 </td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">Expected present value</td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">Credit quality of company
 and credit spreads for comparable debt</td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">13%</td></tr></table></div>5478800001134290001252000-21800014899000148990000.13Cash, Cash Equivalents and Investments<div style="margin-top:12pt">The following tables categorize the fair values of cash, cash equivalents and investments measured at fair value on a recurring basis on our balance sheets (in thousands):</div><div

~~style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents:</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,678 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,521 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Money market funds</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">997 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,285 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Government and agency notes</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,946 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>~~

Total cash and cash equivalents			2,675	20,752
Short-term investments				
Certificates of deposit				
			729	
Government and agency notes			45,172	53,578
Total short-term				

\$	45,172					\$	54,307

The Company's investments are classified as available-for-sale securities. As of September 30, 2024, the weighted average remaining contractual maturities of available-for-sale securities was approximately 6 months. The unrealized gain (loss) activity related to the Company's available-for-sale securities is included in the Company's accumulated other comprehensive income. There were no significant realized gains or losses recognized on the sale or maturity of available-for-sale securities for the three and nine months ended September 30, 2024 and 2023, and as a result, the Company did not reclassify any amounts out of accumulated other comprehensive income. Based on the Company's review of its available-for-sale securities, the Company has no available-for-sale securities in loss positions as of September 30, 2024. No other-than-temporary impairments on these securities were recognized for the three and nine months ended September 30, 2024 and 2023.

The Company periodically assess its investment in available-for-sale securities for impairment losses and credit losses. The amount of credit losses are determined by comparing the difference between the present value of future cash flows expected to be collected on these securities and the amortized cost. Factors considered in assessing credit losses include the position in the capital structure, vintage and amount of collateral, delinquency rates, current credit support, and geographic concentration. There have been no impairment and credit losses related to available-for-sale securities for the three and nine months ended September 30, 2024 and 2023.

For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security's amortized cost basis is written down to fair value and recognized in interest and other income, net in the statement of operations and comprehensive loss. If neither criteria is met, the Company evaluates whether the decline in fair value is related to credit-related factors or other factors. In making this assessment, management considers the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors. Credit-related impairment losses, limited by the amount that the fair value is less than the amortized cost basis, are recorded through an allowance for credit losses in interest and other income, net.

Any unrealized losses from declines in fair value below the amortized cost basis as a result of non-credit factors are recognized in accumulated other comprehensive income, net of tax as a separate component of stockholders' equity, along with unrealized gains. Realized gains and losses and declines in fair value, if any, on available-for-sale securities are included in interest and other income, net in the condensed statement of operations and comprehensive loss.

For purposes of identifying and

measuring credit-related impairments, the Company's policy is to exclude applicable accrued interest from both the fair value and amortized cost basis of the related security. The Company has elected to write-off uncollectible accrued interest receivable balances in a timely manner, which is defined by the Company as when interest due becomes 90 days delinquent. The accrued interest write-off will be recorded by reversing interest income. Accrued interest receivable is recorded in other current assets on the condensed balance sheets.

The following table summarizes the available-for-sale securities (in thousands):

Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
\$—	\$—	\$—	\$—
Money market funds			
\$	997	\$	\$
997			

[illegible]

\$			
\$	46,169		
\$			
Classified as:			
Cash equivalents (original maturities within 90 days)			
\$			
997			
Short-term investments (maturities within one year)			
45,172			
Total cash			

[illegible]

[illegible]

[illegible]

[illegible]

December 31, 2023		
Cash and cash equivalents	1,678	
Cash	1,521	
	997	
	4,285	
Government and agency notes	—	
	14,946	
Total cash and cash equivalents	2,675	

20,752	Short-term investments:									Certificates of deposit			\$			729			45,172			53,578			Total short-term investments			\$			45,172			\$		
Government and agency notes			45,172		53,578		Total short-term investments			\$			45,172			\$																				

54,307

1678000152100099700042850000149460002675000207520000729000451720005357800045172000

The following table summarizes the available-for-sale securities (in thousands):

			Fair Value Measurements as of September 30, 2024																				
			Amortized Cost																				
			Unrealized Gains																				
			Unrealized Losses																				
			Fair Value																				
			Money market funds																				
			\$																				
			997																				
			\$																				
			\$																				
			\$																				
			\$																				

[illegible]

\$			
46,169			
Classified as:			
Cash equivalents (original maturities within 90 days)			
997			
Short-term investments (maturities within one year)			
45,172			
Total cash			

[illegible]

[illegible]

[illegible]

[illegible]

Sheet Components<div style="margin-top:12pt">Prepaid Expenses and Other Current Assets</div><div style="margin-top:12pt">Prepaid expenses and other current assets consist of the following (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:68.154%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.968%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"></td></tr></table></div>

family: 'Times New Roman', sans-serif; font-size: 10pt; font-style: italic; font-

weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</div><div>

style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-

Prepaid expenses and other

current assets consist of the following (in thousands):

~~top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-~~

bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td

[illegible]

[illegible]

The colour of the "ffffff" setting has 3x1st test string center aligned	

`style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom";var style "color:#000000;font-family:'Times New Roman',serif;font`

align:bottom"> </td><td colspan="3">

```
size:opt;font-weight:400;line-height:114%></span></td><td colspan= 3  
style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical
```

style= background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle;float:right;clear:right;min-height:1.2em;">

September 30, 2024					
December 31, 2023					
Prepaid research and development expenses		\$1,415			
Short-term Italian research and development refundable tax credit		995			
Insurance		841			
Prepaid expenses		809			
Other current		365			

assets		55	81
Total prepaid expenses and other current assets			\$3,871
\$			2,381

The Company is eligible to obtain an R&D tax credit as companies in Italy that invest in eligible research and development activities, regardless of the legal form and economic sector in which they operate, can benefit from a R&D tax credit. Such tax credits can only be used to offset payments of certain taxes and contributions (e.g., social contributions, VAT payables, registration fees, income and withholding taxes and other tax-related items that companies usually pay monthly). The Company recognized reductions to R&D expense of \$0.4 million and \$1.2 million for the three and nine months ended September 30, 2024 respectively, and \$0 reductions for the three and nine months ended September 30, 2023.

Novosteo Pty, Ltd, a wholly-owned subsidiary of Novosteo, LLC, is eligible to obtain a cash refund from the Australian Taxation Office for eligible R&D expenditures under the Australian Tax Incentive. During the three and nine months ended September 30, 2024, the Company received \$0 refundable tax credit. During the first quarter of 2023, the Company received a refundable tax credit of \$0.5 million, which reduced prepaid expenses and other current assets by \$0.5 million as of March 31, 2023.

Other Assets

Other assets consisted of the following (in thousands):

Other assets consisted of the following (in thousands):

September 30, 2024					
December 31, 2023					
Long-term Italian research and development refundable tax credit					
\$					
4,074					
\$					
4,993					
VAT receivable					
5,354					
3,463					
Equity investments in Lighthouse Pharmaceuticals, Inc.					
78					
78					
Assets held for sale					
—					
10					
Total other					

```
assets</span></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,506 </span></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;border-bottom:3pt double #ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,544 </span></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:114%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer equipment</span></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38 </span></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">36 </span></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Computer Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30 </span></td><td style="background-
```

[illegible]

[illegible]

Professional fees	140	211	101	64
Current portion of operating lease liabilities	101	64		
Other	198			
	257			
Total accrued expenses and other current liabilities	3,803	3,436		

For the nine months ended September 30, 2024 and 2023, the severance accrual activity were as follows (in thousands):

[illegible]

461

On January 30, 2023, in response to the reprioritization of the Company's pipeline following the decision to discontinue internal development of NOV004 and to pursue out-licensing opportunities, the Company's Board of Directors approved a cost reduction program to reorganize operations and allow continued support for the needs of the business. Under the cost reduction program, the Company lowered headcount through a reduction in workforce. The Company recognized the severance of \$0.3 million and related expenses of \$0.1 million over the requisite employment obligation period. The reduction in force was completed in April 2023.

On August 4, 2023, the Company entered into a transition and separation agreement with Karen Smith, M.D., Ph.D., (the "Separation Agreement") in connection with Dr. Smith's transition and departure from the Company as the Company's Chief Medical Officer, effective as of September 1, 2023. Pursuant to the Separation Agreement, the Company is required to pay cash severance, equal to her annual salary, in the aggregate amount of \$0.5 million, of which \$0.3 million was paid during the nine months ended September 30, 2024. The severance is to be paid on regular payroll schedule through the third quarter of 2024. Additionally, pursuant to the Separation Agreement, the Company paid an additional cash bonus severance payment equal to 100% of Dr. Smith's target annual bonus opportunity for 2023 on a prorated basis, an additional cash severance payment equal to 12 months' of the monthly premiums for health care continuation benefits, and provided for 50% accelerated vesting with respect to Dr. Smith's equity award. The acceleration of 612,141 options and 54,757 RSAs resulted in a stock-based compensation expense of approximately \$0.1 million that was recorded in 2023.

Prepaid expenses and other current assets consist of the following (in thousands):

September 30, 2024					
December 31, 2023					
Prepaid research and development expenses					

133	995	993	993
Short-term Italian research and development refundable tax credit	995	993	993
Prepaid insurance	841	809	809
Prepaid expenses	565	365	365
Other current assets	55	81	81
Total prepaid expenses and other current assets			

Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">\$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">3,871</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; border-bottom: 3pt double #ffffff; border-top: 0.5pt solid #ffffff; padding: 0 1pt"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">2,381</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr></table></div>14150001330009950009930008410008090005650003650005500081000387100023810004000001204500000<div style="margin-top: 12pt">Other assets consisted of the following (in thousands):</div><div style="margin-top: 12pt"><table style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: top; width: 98.787%"><tr><td style="width: 1.0%"></td><td style="width: 68.838%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 13.623%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.13%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 13.626%"></td><td style="width: 0.1%"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: center; vertical-align: bottom">September 30, 2024</td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: center; vertical-align: middle">December 31, 2023</td></tr><tr><td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: left; vertical-align: top">Long-term Italian research and development refundable tax credit</td><td style="background-color: #cceeef; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #cceeef; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">4,074</td><td style="background-color: #cceeef; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #cceeef; border-top: 0.5pt solid #ffffff; padding: 0 1pt"></td><td style="background-color: #cceeef; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #cceeef; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">4,993</td><td style="background-color: #cceeef; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: top">VAT receivable</td><td colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">5,354</td><td style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom"><span

```
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:114%">3,463 </span></td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-
align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Equity investments in
Lighthouse Pharmaceuticals, Inc. </span></td><td colspan="2" style="background-
color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:114%">78 </span></td><td style="background-
color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2"
style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:114%">78 </span></td><td style="background-
color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Assets held for
sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px
1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">
— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:114%">10 </span></td><td style="background-
color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr>
<tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 8.37pt;text-
align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Total other
assets</span></td><td style="background-color:#cceeef;border-bottom:3pt double
#000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:114%">$ </span></td><td style="background-
color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9,506 </span>
</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt
solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#cceeef;border-bottom:3pt double #ffffff;border-
top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeef;border-
bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$ </span></td><td
style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid
#000;padding:2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:114%">8,544 </span></td><td style="background-
color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
</div>4074000499300053540003463000780007800001000095060008544000<div style="margin-
top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the
following (in thousands):</span></div><div style="margin-top:12pt"><table style="border-
collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-
bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td>
<td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td>
<td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td>
<td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td>
<td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-
weight:400;line-height:114%"> </span></td><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
```

September 30, 2024		
December 31, 2023		
Computer equipment		
	38	
		36
Computer Software		
	30	
		30
Lab equipment		
	534	
		486
Leasehold improvement		
	36	
		36
Office furniture		

			237			
			153			
			Less: accumulated amortization and depreciation			
			(667)			
			(507)			
			Property and equipment, net			
			\$			
			208			
			\$			
			234			

380003600030000300005340004860003600036000237000153000667000507000208000234000

Accrued expenses and other current liabilities consist of the following (in thousands):

			1.0%			
			67.033%			
			0.1%			
			1.0%			
			14.529%			
			0.1%			
			0.406%			
			0.1%			
			1.0%			
			14.532%			
			0.1%			

September 30, 2024

December 31, 2023

			Personnel expenses			

[illegible]

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%;>Total accrued expenses and other current liabilities</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">3,803</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; border-bottom: 3pt double #ffffff; border-top: 0.5pt solid #ffffff; padding: 0 1pt"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">3,436</td><td style="background-color: #ffffff; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr></table>

</div>2301000234000010630005640001400002110001010006400019800025700038030003436000<div style="margin-top: 12pt">For the nine months ended September 30, 2024 and 2023, the severance accrual activity were as follows (in thousands):</div>

||
||
||

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">41 </td><td style="background-color: #cceeef; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #cceeef; padding: 0 1pt"></td><td colspan="2" style="background-color: #cceeef; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">770 </td><td style="background-color: #cceeef; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: top">Severance paid during the period</td><td colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">(382)</td><td style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">(309)</td><td style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr><tr><td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: left; vertical-align: bottom">Ending accrued severance</td><td style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">— </td><td style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #cceeef; padding: 0 1pt"></td><td style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">461 </td><td style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr></table></div>341000041000770000382000309000046100030000010000050000030000010.506121415475710000<div style="margin-top: 12pt">In October 2023, as part of the EryDel Acquisition the Company acquired operating leases in which the Company recorded an operating lease right of use asset and liability in total of \$0.4 million. This includes a lease agreement renting office space in Bresso, in the Province of Milan, Italy. The Lease Agreement commenced on September 1, 2016 and will end on August 31, 2028. At acquisition date, the Company recorded an operating lease right of use asset and liability of \$0.1 million. This also includes a lease agreement renting office space in Medolla, in the Province of Modena, Italy. The Lease Agreement commenced on June 18, 2018, with a duration of 12 years, until January 31, 2030. At acquisition date, the Company recorded an operating lease right of use asset and liability of \$0.2 million. The acquired lease agreements also included other operating leases two of which are car leases and the other a printing press.</div><div style="margin-top: 12pt">In January 2024, the above-mentioned Lease Agreement for the office space in Medolla was renegotiated. The new Lease Agreement includes an additional space and commenced on February 1, 2024, and will end on January 31, 2036, substituting the Lease Agreement commenced in June 2018. The Company recorded an additional \$0.2 million of operating lease right of use asset and liability during the nine months ended September 30, 2024.</div><div style="margin-top: 12pt">The Company recognizes lease expense on a straight-line basis over the term of its operating lease. During the nine months ended September 30,

[illegible]

[illegible]

agreements as of September 30, 2024, were as follows (in thousands):

	2024	2025	2026	2027	2028 and thereafter	Total lease payments	Less: imputed interest	(104)	Total remaining lease liability
	\$35	\$140	\$136	\$130	\$214	\$655	\$655	\$655	\$655

The table above represents the data extracted from the provided image. The content is formatted as a table with 10 columns and 2 rows. The first row contains the headers for the years and the total lease payments, less imputed interest, and the total remaining lease liability. The second row contains the corresponding values for each year and the totals.


```
#000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">551</span></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div>400000400000100000100000P12Y2000002000002200000200000100000100000<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases as follows (in thousands except lease terms and discount rates):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right of use asset, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
```

Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">64		
style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom;">		
td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: left; vertical-align: bottom;">		
New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">Long-term operating lease liability		
color: #cceeef; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">		
style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">450		
color: #cceeef; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom">		
colspan="3" style="background-color: #cceeef; padding: 0 1pt">		
style="background-color: #cceeef; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">321		
color: #cceeef; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom">		
td colspan="3" style="background-color: #ffffff; padding: 2px 1pt 2px 10pt; text-align: left; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">Total lease liabilities		
td style="background-color: #ffffff; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">\$		
td style="background-color: #ffffff; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">551		
td style="background-color: #ffffff; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom">		
td colspan="3" style="background-color: #ffffff; padding: 0 1pt">		
style="background-color: #ffffff; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">\$		
td style="background-color: #ffffff; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">385		
td style="background-color: #ffffff; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom">		
td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: left; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">		
td colspan="3" style="background-color: #cceeef; border-top: 3pt double #000; padding: 0 1pt">		
td colspan="3" style="background-color: #cceeef; padding: 0 1pt">		
td colspan="3" style="background-color: #cceeef; border-top: 3pt double #000; padding: 0 1pt">		
td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">Other information:		
td colspan="3" style="background-color: #ffffff; padding: 0 1pt">		
td colspan="3" style="background-color: #ffffff; padding: 0 1pt">		
td colspan="3" style="background-color: #ffffff; padding: 0 1pt">		
td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: left; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">Weighted average remaining lease term		
td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: right; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">4.9 years		
td colspan="3" style="background-color: #cceeef; padding: 0 1pt">		
td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: right; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">5.4 years		
td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">Weighted average discount rate		
td colspan="3" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">9.11		
td style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: left; vertical-align: bottom">		
span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%">%		
td colspan="3" style="background-color: #ffffff; padding: 0 1pt">		
td colspan="3" style="background-color: #ffffff; padding: 0 1pt">		
td colspan="3" style="background-color: #ffffff; padding: 0 1pt">		

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.95 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom">%</td></tr></table>

</div>55900038500010100064000450000321000551000385000P4Y10M24DP5Y4M24D0.09110.0795<div style="margin-top:12pt">Future minimum lease payments under lease agreements as of September 30, 2024, were as follows (in thousands):

</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle">Fiscal Year</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">2024 (remainder of the year)</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">35 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle">2025</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">140 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">136 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle">2027</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">130 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">2028 and thereafter</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">214 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease payments</td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">655 </td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">Total lease payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"></td></tr></table>

Less: imputed interest

	(104)	
Total remaining lease liability		551

35000140000136000130000214000655000104000551000Stockholders' Equity

On April 5, 2023, the Company's Board of Directors declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of the common stock of the Company. The dividend was effective as of April 17, 2023 (the "Record Date") with respect to stockholders of record on that date. The Rights also attached to shares of common stock issued after the Record Date. Each Right entitled the registered holder to purchase from the Company one one-thousandth of a share of Series A Junior Participating Preferred Stock, par value \$0.001 per share, (the "Preferred Shares"), of the Company at a price of \$6.00 per one one-thousandth of a Preferred Share, subject to adjustment.

On April 5, 2024, the Rights Plan and the Rights issued thereunder expired.

10.001Stock-Based Compensation

The Company operates three stock plans as of September 30, 2024:

• 2019 Equity Incentive Plan (Quince)

• 2019 Equity Incentive Plan (Novosteo)

• 2022 Inducement Plan (Quince)

2019 Equity Incentive Plan (Quince)

On December 4, 2014, the Company's stockholders approved the 2014 Stock Plan ("2014 Plan"), and on April 25, 2019 amended, restated and re-named the 2014 Plan as the 2019 Equity Incentive Plan (the "Quince 2019 Plan"), which became effective as of May 7, 2019, the day prior to the effectiveness of the registration statement filed in connection with the IPO. The remaining shares available for issuance under the 2014 Plan were added to the shares reserved for issuance under the Quince 2019 Plan.

The Quince 2019 Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to the Company's employees, directors, and consultants. As of September 30, 2024, the maximum aggregate number of shares that may be issued under the 2019 Plan is 11,755,418 shares of the Company's common stock. In addition, the number of shares available for issuance under the Quince 2019 Plan will be annually increased on the

first day of each fiscal years beginning with fiscal 2020, by an amount equal to the least of (i) 2,146,354 shares of common stock; (ii) 4% of the outstanding shares of its common stock as of the last day of its immediately preceding fiscal year; and (iii) such other amount as the Board may determine.

The Quince 2019 Plan may be amended, suspended or terminated by the Board at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the Quince 2019 Plan as required by applicable law or listing requirements. Unless sooner terminated by the Company's Board of Directors, the 2019 Plan will automatically terminate on April 23, 2029.

As of September 30, 2024, the Company had 2,288,074 shares available for future issuance under the Quince 2019 Plan.

Stock Options

Stock options under the 2019 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the fair market value of the shares on the date of grant. If, at the time of grant, the optionee directly owns stocks representing more than 10% of the voting power of all our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees and non-employees generally have a maximum term of ten years and vest over four years from the vesting commencement date, of which 25% vest on the one-year anniversary of the vesting commencement date, and 75% vest in equal monthly installments over the remaining three years or monthly vesting over 3 to 4 years. We may grant options with different vesting terms from time to time. Unless an employee's or non-employee's termination is due to cause, disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of the three months from the termination date or expiration of the option, whichever is earlier.

Activity for service-based stock options under the Quince 2019 Plan is as follows:

	Number of Options	Unvested Shares	Weighted Average

weight:700;line-height:115%">Exercise Price</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Weighted</div><div style="text-align:center">average</div><div style="text-align:center">remaining</div><div style="text-align:center">contractual</div><div style="text-align:center">life (years)</div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Aggregate</div><div style="text-align:center">intrinsic</div><div style="text-align:center">value</div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">(In thousands)</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle">Balance as of December 31, 2023</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle">4,267,178</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td colspan="3" style="background-color:#cceeef;padding:2px 0;text-align:right;vertical-align:middle">5.00</td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:right;vertical-align:bottom">8.85</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td colspan="3" style="background-color:#cceeef;padding:2px 0;text-align:right;vertical-align:middle">197</td><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom">Options granted</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

			3,602,500	
			1.26	
Options exercised			(155,311)	0.93
			65	
Options cancelled / forfeited			(165,861)	13.06
Balance as of September 30, 2024			7,548,506	

\$	3.12	
\$	8.72	
\$	5	
Options vested and expected to vest as of September 30, 2024	7,548,506	
	3.12	
Options exercisable as of September 30, 2024	2,062,912	
\$	7.86	
\$	7.76	
\$		

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation

expense of \$0.7 million and \$2.2 million, respectively, related to options granted to employees and non-employees. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$0.6 million and \$2.0 million, respectively, related to options granted to employees and non-employees.

The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the condensed consolidated statement of operations and comprehensive loss for stock-based compensation arrangements. As of September 30, 2024, total unamortized employee stock-based compensation was \$5.5 million, which is expected to be recognized over the remaining estimated vesting period of 2.74 years.

Restricted Stock Units ("RSUs")

RSUs are share awards that entitle the holder to receive freely tradable shares of the Company's common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company's common stock on the grant date. RSUs granted to employees generally vest over a 2 – 4 year period.

The following table summarizes activity under the Company's RSUs from the Quince 2019 Plan and related information:

Restricted Stock Units Outstanding									
Number of Shares									
Unvested - December 31, 2023									
1,488									
\$									
4.30									

RSUs granted		
RSUs vested	(1,488)	4.30
RSUs cancelled		
Unvested - September 30, 2024		

The fair value of the RSUs is determined on the grant date based on the fair value of the Company's common stock. The fair value of the RSUs is recognized as expense ratably over the vesting period of two years.

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation expense of \$0 and \$4.4 thousand, respectively, related to these RSUs. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$6.4 thousand and \$37.5 thousand respectively, related to these RSUs. As of September 30, 2024, total unamortized stock-based compensation related to RSUs was \$0.

2019 Equity Incentive Plan (Novosteo)

On May 19, 2022, in accordance with the term of the Merger Agreement, the Company assumed the 2019 Novosteo, Inc. Equity Incentive Plan (the "2019 Novosteo Plan"). The 2019 Novosteo Plan provides for the grant of stock options (including incentive stock options and non-qualified stock options), stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to the Novosteo legacy employees. On the closing date, each outstanding Novosteo stock option

granted under Novosteo's equity compensation plans was converted into a corresponding stock option with the number of shares underlying such option and the applicable exercise price adjusted based on the exchange ratio of 0.0911. Each such converted stock option continues to be subject to substantially the same terms and conditions as applied to the corresponding Novosteo stock option prior to the Acquisition. The maximum aggregate number of shares that may be issued under the 2019 Novosteo Plan is 544,985 shares of the Company's common stock.

The 2019 Novosteo Plan may be amended, suspended or terminated by the Board at any time, provided such action does not impair the existing rights of any participant, subject to stockholder approval of any amendment to the 2019 Novosteo Plan as required by applicable law or listing requirements. Unless sooner terminated by the Board, the 2019 Novosteo Plan will automatically terminate on May 20, 2029.

Stock options under the 2019 Novosteo Plan may be granted for periods of up to 10 years and at prices no less than 100% of the fair market value of the shares on the date of grant. If, at the time of grant, the optionee directly owns stocks representing more than 10% of the voting power of all our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees and non-employees generally have a maximum term of ten years and vest over four years from the vesting commencement date, of which 25% vest on the one-year anniversary of the vesting commencement date, and 75% vest in equal monthly installments over the remaining three years or monthly vesting over 3 to 4 years. We may grant options with different vesting terms from time to time. Unless an employee's or non-employee's termination is due to cause, disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of the three months from the termination date or expiration of the option, whichever is earlier.

As of September 30, 2024, the Company had 246,797 shares available for future issuance under the 2019 Novosteo Plan.

Activity for service-based stock options under the 2019 Novosteo Plan is as follows:

	Number of	Options	Unvested	Shares
	at the end of the period	exercised	at the end of the period	at the end of the period
2024	12,081	12,081	12,081	12,081
2023	12,081	12,081	12,081	12,081
2022	12,081	12,081	12,081	12,081
2021	12,081	12,081	12,081	12,081
2020	12,081	12,081	12,081	12,081
2019	12,081	12,081	12,081	12,081
2018	12,081	12,081	12,081	12,081
2017	12,081	12,081	12,081	12,081
2016	12,081	12,081	12,081	12,081
2015	12,081	12,081	12,081	12,081
2014	12,081	12,081	12,081	12,081
2013	12,081	12,081	12,081	12,081
2012	12,081	12,081	12,081	12,081
2011	12,081	12,081	12,081	12,081
2010	12,081	12,081	12,081	12,081
2009	12,081	12,081	12,081	12,081
2008	12,081	12,081	12,081	12,081
2007	12,081	12,081	12,081	12,081
2006	12,081	12,081	12,081	12,081
2005	12,081	12,081	12,081	12,081
2004	12,081	12,081	12,081	12,081
2003	12,081	12,081	12,081	12,081
2002	12,081	12,081	12,081	12,081
2001	12,081	12,081	12,081	12,081
2000	12,081	12,081	12,081	12,081
1999	12,081	12,081	12,081	12,081
1998	12,081	12,081	12,081	12,081
1997	12,081	12,081	12,081	12,081
1996	12,081	12,081	12,081	12,081
1995	12,081	12,081	12,081	12,081
1994	12,081	12,081	12,081	12,081
1993	12,081	12,081	12,081	12,081
1992	12,081	12,081	12,081	12,081
1991	12,081	12,081	12,081	12,081
1990	12,081	12,081	12,081	12,081
1989	12,081	12,081	12,081	12,081
1988	12,081	12,081	12,081	12,081
1987	12,081	12,081	12,081	12,081
1986	12,081	12,081	12,081	12,081
1985	12,081	12,081	12,081	12,081
1984	12,081	12,081	12,081	12,081
1983	12,081	12,081	12,081	12,081
1982	12,081	12,081	12,081	12,081
1981	12,081	12,081	12,081	12,081
1980	12,081	12,081	12,081	12,081
1979	12,081	12,081	12,081	12,081
1978	12,081	12,081	12,081	12,081
1977	12,081	12,081	12,081	12,081
1976	12,081	12,081	12,081	12,081
1975	12,081	12,081	12,081	12,081
1974	12,081	12,081	12,081	12,081
1973	12,081	12,081	12,081	12,081
1972	12,081			

[illegible]

Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">Options granted		
Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">Options exercised		
Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">Options cancelled / forfeited		
Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">Balance as of September 30, 2024		
Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">Balance as of September 30, 2024		

[illegible]

[illegible]

RSAs granted							
RSAs vested			(73,010)	3.30			
RSAs cancelled							
Unvested - September 30, 2024			102,753				
			3.30				

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation expense of \$0.1 million and \$0.2 million, respectively, related to restricted stock awards. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$0.2 million and \$0.4 million, respectively, related to restricted stock awards. The compensation expense is allocated on a departmental basis, based on the classification of the award holder. No income tax benefits have been recognized in the condensed consolidated statement of operations and comprehensive loss for stock-based compensation arrangements. As of September 30, 2024, total unamortized employee stock-based compensation was \$0.3 million, which is expected to be recognized over the remaining estimated vesting period of 0.99 years.

2022 Inducement Plan

On May 9, 2022, the Company's Board of Directors approved 4,000,000 shares of common stock that may be

offered or issued under the Quince Therapeutics, Inc. 2022 Inducement Plan (the "2022 Inducement Plan"). The 2022 Inducement Plan was adopted by the independent members of the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules ("Nasdaq Rule 5635(c)(4)"). In accordance with Nasdaq Rule 5635(c)(4), awards under those plans may only be made to an employee who has not previously been an employee or member of the Board of Directors or of any board of directors of any parent or subsidiary of the Company, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. The terms and conditions of the 2022 Inducement Plan are substantially similar to those of the Quince 2019 Plan.

Options under the 2022 Inducement Plan may be granted for periods of up to 10 years at prices no less than 100% of the fair market value of the shares on the date of grant. Options granted to employees may have different performance goals or other vesting provisions (including continued employment) in accordance with the applicable award agreement. Unless an employee's termination service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of the three months from the date of termination or expiration of the option, whichever is earlier.

As of September 30, 2024, the Company had 1,666,694 shares available for future issuance under the 2022 Inducement Plan.

Activity for service-based stock options under the 2022 Inducement Plan is as follows:

	Weighted	Average	Exercise	Price	Remaining	Contractual	Life
Number of							
Options and							
Unvested							
Shares							
Weighted							
Average							
Exercise Price							
Weighted							
average							
remaining							
contractual							
life							
(years)							

[illegible]

Options exercised		
Options cancelled / forfeited		
Balance as of September 30, 2024		
2,333,306		
\$		
2.98		
7.65		

Options vested and expected to vest as of September 30, 2024		
	2,333,306	2.98
Options exercisable as of September 30, 2024	1,361,094	\$2.98
		7.65

For the three and nine months ended September 30, 2024, the Company recognized stock-based compensation expense of \$0.3 million and \$1.0 million, respectively, related to options granted to employees for the 2022 Inducement Plan. For the three and nine months ended September 30, 2023, the Company recognized stock-based compensation expense of \$0.4 million and \$1.5 million, respectively, related to options granted to employees for the 2022 Inducement Plan. The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the condensed consolidated statement of operations and comprehensive for stock-based compensation arrangements. As of September 30, 2024, total unamortized employee stock-based compensation was \$2.2 million, which is expected to be recognized over the remaining estimated vesting period of 1.64 years.

Stock-Based Compensation Expense

The following table summarizes employee and non-employee stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 and the allocation within the condensed consolidated statements of operations

Three Months Ended September 30,			Nine Months Ended September 30,									2023			2024			2023			2024			2023		
General and administrative expense			\$									786			945			3,096			3,096					

[illegible]

bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">4,134 </td></tr></table></div><div style="margin-top:12pt">Employee Stock Purchase Plan</div><div style="margin-top:12pt">On April 24, 2019, the Company's Board of Directors adopted its 2019 Employee Stock Purchase Plan ("2019 ESPP"), which was subsequently approved by the Company's stockholders and became effective on May 7, 2019, the day immediately prior to the effectiveness of the registration statement filed in connection with the IPO. The 2019 ESPP is intended to qualify as an "employee stock purchase plan" within the meaning of Section 423 of the Internal Revenue Code (the "Code") for U.S. employees. In addition, the 2019 ESPP authorizes grants of purchase rights that do not comply with Section 423 of the Code under a separate non-423 component for non-U.S. employees and certain non-U.S. service providers. The Company has reserved 1,924,262 shares of common stock for issuance under the 2019 ESPP. In addition, the number of shares reserved for issuance under the 2019 ESPP will be increased automatically on the first day of each fiscal year for a period of up to ten years, starting with the 2020 fiscal year, by a number equal to the lesser of: (i) 536,589 shares; (ii) 1% of the shares of common stock outstanding on the last day of the prior fiscal year; or (iii) such lesser number of shares determined by the Company's Board of Directors. The 2019 ESPP is expected to be implemented through a series of offerings under which participants are granted purchase rights to purchase shares of the Company's common stock on specified dates during such offerings. The Company has not yet approved an offering under the 2019 ESPP.</div>31175541821463540.042288074P10Y10.101.10P10YP4Y0.25P1Y0.75P3YP3YP4YP3M<div style="margin-top:12pt">Activity for service-based stock options under the Quince 2019 Plan is as follows:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td><td colspan="3"></td></tr></table><div style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Number of</div><div style="text-align:center">Options and</div><div style="text-align:center">Unvested</div><div style="text-align:center">Shares </div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Weighted</div><div style="text-align:center">Average</div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-

[illegible]

			3,602,500		
			1.26		
Options exercised			(155,311)		
			0.93		
			65		
Options cancelled / forfeited			(165,861)		
			13.06		
Balance as of September 30, 2024			7,548,506		

Options exercisable as of September 30, 2024

Options exercisable as of September 30, 2024	Options vested and expected to vest as of September 30, 2024
3,12	8.72
5	7,548,506
3,12	7.86
7.76	—

Activity for

[illegible]

(In thousands)		
Balance as of December 31, 2023		
310,431		
\$		
0.55		
8.23		
\$		
155		
Options granted		
Options exercised		
(146,592)		
0.55		

Options cancelled / forfeited		
Options vested and expected to vest as of September 30, 2024		
Balance as of September 30, 2024		
163,839		
\$		
0.55		
7.48		
\$		
37		
Options vested and expected to vest as of September 30, 2024		
163,839		
0.55		

[illegible]

[illegible]

			—	
Options exercised			—	
—				
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	
—			—	

</td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: center; vertical-align: middle;">Restricted Stock Units Outstanding</td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: middle;"></td><td colspan="3" style="background-color: #ffffff; border-top: 1pt solid #000; padding: 2px 1pt; text-align: left; vertical-align: bottom;"> Number of Shares</div></td><td colspan="3" style="background-color: #ffffff; border-top: 1pt solid #000; padding: 0 1pt"></td><td colspan="3" style="background-color: #ffffff; border-top: 1pt solid #000; padding: 2px 1pt; text-align: center; vertical-align: bottom;">Weighted Average Grant Date Fair Value</td></tr><tr><td colspan="3" style="background-color: #e6e6ff; padding: 2px 1pt; text-align: left; vertical-align: middle;">Unvested - December 31, 2023</td><td colspan="3" style="background-color: #e6e6ff; border-top: 1pt solid #000; padding: 2px 1pt; text-align: right; vertical-align: middle;">1,488</td><td colspan="3" style="background-color: #e6e6ff; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: middle;">\$</td><td colspan="3" style="background-color: #e6e6ff; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: middle;">4.30</td><td colspan="3" style="background-color: #e6e6ff; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: middle"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: middle;">RSUs granted</td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom;"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom;"></td></tr><tr><td colspan="3" style="background-color: #e6e6ff; padding: 2px 1pt; text-align: left; vertical-align: middle;">RSUs vested</td><td colspan="3" style="background-color: #e6e6ff; padding: 2px 1pt; text-align: right; vertical-align: middle;">(1,488)</td><td colspan="3" style="background-color: #e6e6ff; padding: 0 1pt"></td><td colspan="3" style="background-color: #e6e6ff; padding: 2px 1pt; text-align: right; vertical-align: bottom;">4.30</td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: middle;">RSUs cancelled</td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom;"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom;"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: middle"></td></tr></table> 		

```
color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:700;line-height:114%">Unvested - September 30, 2024 </span></td><td colspan="3"
style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid
#000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:114%"> </span></td><td colspan="3" style="background-
color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt
double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-weight:700;line-height:114%">$</span></td><td style="background-
color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px
0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"> </span><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:114%"> </span></td><td style="background-color:#cceeef;border-
bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
style:italic;font-weight:400;line-height:120%">Restricted Stock Awards</span></div><div
style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-
table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td
style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td
style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td
style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td
style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr>
<tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td
colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-
align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:8pt;font-weight:700;line-height:114%">Restricted Stock Awards Outstanding</span>
</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></td><td
colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px
1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span
style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-
serif;font-size:8pt;font-weight:700;line-height:115%">Number of Shares</span><span
style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-
serif;font-size:8pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3"
style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px
1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-
height:114%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3"
style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:700;line-height:114%">Unvested - December 31, 2023 </span></td><td colspan="3"
style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-
align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">175,763</span></td>
<td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td
style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-
align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">$</span></td><td
style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-
align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">3.30</span><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:114%"> </span></td><td style="background-color:#cceeef;border-
top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td>
</tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">RSAs granted</span>
</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-
align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New
```

Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom"></td><td colspan="2" style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr><tr><td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: left; vertical-align: middle">RSAs vested</td><td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: right; vertical-align: middle">(73, 010)</td><td colspan="3" style="background-color: #cceeef; padding: 0 1pt"></td><td colspan="2" style="background-color: #cceeef; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom">3.30</td><td colspan="2" style="background-color: #cceeef; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: middle">RSAs cancelled</td><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-align: right; vertical-align: bottom"></td><td colspan="2" style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr><tr><td colspan="3" style="background-color: #cceeef; padding: 2px 1pt; text-align: left; vertical-align: middle">Unvested – September 30, 2024</td><td colspan="3" style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt; text-align: right; vertical-align: middle">102,753</td><td colspan="3" style="background-color: #cceeef; padding: 0 1pt"></td><td colspan="2" style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: middle">\$</td><td colspan="2" style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 0; text-align: right; vertical-align: middle">3.30</td><td colspan="2" style="background-color: #cceeef; border-bottom: 3pt double #000; border-top: 1pt solid #000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: middle"></td></tr></table></div>14884.300014884.300000P2Y0440064003750000.0911544985P10Y10.101.10P10YP4Y0.250.75P3) style="margin-top: 12pt">The following table summarizes employee and non-employee stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 and the allocation within the condensed consolidated statements of operations and comprehensive loss (in thousands):</div><div style="margin-top: 12pt"><table style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: text-bottom; width: 95.606%"><tr><td style="width: 1.0%"></td><td style="width: 41.847%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.687%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.433%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.687%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.687%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 12.693%"></td><td style="width: 0.1%"></td></tr><tr><td colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom"></td><td colspan="9" style="background-color: #ffffff; padding: 2px 1pt; text-align: center; vertical-align: middle"><span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-

Three Months Ended September 30,			Nine Months Ended September 30,								

338	386	525	1,120
Total stock-based compensation			\$
1,124			1,331
3,621			4,134

In connection with the acquisition of EryDel on October 20, 2023, the Company assumed an unsecured line of credit between EryDel and the European Investment Bank (the "EIB Loan"). The EIB Loan was amended and restated as of the acquisition date. The EIB Loan provides for maximum borrowings of 30.0 million euro through four tranches; tranche A, 3.0 million euro;

tranche B, 7.0 million euro; tranche C, 10.0 million euro; and tranche D, 10.0 million euro. Each tranche is subject to conditions precedent related to the Company's business and capitalization. As of September 30, 2024, only tranches A and B have been drawn. All amounts due under tranche A and B are payable on their maturity date of August 2026. Tranche C and D are payable in equal installments of principal together with all amounts outstanding under the tranches on the repayment dates specified in the relevant Disbursement Offer. The first Repayment Date of tranche C shall fall not earlier than twelve months from the Disbursement Date of such tranche. The last Repayment Date of tranche C and tranche D shall fall not later than 5 years from the Disbursement Date of tranche C and tranche D, respectively. The EIB Loan bears interest at fixed rates for each tranche and is payable on the maturity date for each Tranche. The fixed rates range from 7.0% to 9.0% per annum. As of September 30, 2024, principal of 10.0 million euros (\$11.2 million) was outstanding on the EIB Loan and it is recorded as Long-term debt on the condensed consolidated balance sheet at fair value with imputed interest of 9.0% included.

The Debt Agreement requires the Company to maintain a minimum cash balance of 14.65 million euros (\$16.4 million) until the outstanding obligations under the Debt Agreement, together with accrued interest and all other amounts accrued or outstanding under the agreement, is repaid in full (the "Minimum Cash Covenant"). Furthermore, the Company may at any time voluntarily prepay, in whole or in part, together with certain fees as set forth in the Debt Agreement, the outstanding obligations under the Debt Agreement. In the event of a default or a change in control, as specified in the Debt Agreement, EIB may, subject to certain grace periods, accelerate the outstanding obligations under the EIB Loan.

In November 2024, the Company entered into an amendment (the "Amendment") of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances and additional limitations on certain permitted acquisitions. Additionally, during the waiver period, the Company agreed to convert 2% of the total 9% deferred interest on Tranches A and B to be payable quarterly, with the first payment due on March 31, 2025, and a one-time fee of 20,000 euros in connection with the Amendment.

The Debt Agreement includes a provision for additional remuneration to be paid in addition to interest. The amount of additional remuneration to be paid is equal to 2.5% of revenue up to 125.0 million euros, plus 1.85% of revenue between 125.0 and 250.0 million euros, plus 1.0% of revenue in excess of 250.0 million euros, multiplied by a varying percentage based on how many tranches have been drawn. The varying percentage is equal to 30.0% in the event tranche A has been drawn, 50.0% in the event tranche A and B have been drawn, 80.0% in the event tranche A, B and C have been drawn, and 100.0% in the event all four tranches have been drawn. The additional remuneration is payable for seven years, during the period January 1, 2026, through December 31, 2032. In the event of an occurrence of an event of default or prepayment, the Company may be required to pay an additional remuneration buyout fee.

The Company elected to account for the EIB Loan at fair value, which requires the EIB Loan to be recorded at fair value at issuance and at the end of each reporting period. Gains or losses upon remeasurement are to be recorded in other expense, net in the condensed consolidated statements of operations and comprehensive income. The Company presents separately in other comprehensive income the portion of the total change in the fair value of the EIB Loan that results from a change in instrument-specific credit risk. The EIB Loan's fair value at the date it was assumed adjusted its carrying value based on using a discounted cash flow analysis with a discount rate based on a yield curve that was adjusted for credit rating. The change in fair value as of September 30, 2024 was determined using a discounted cash flow analysis discounted at the market yield. The significant inputs used to measure the market yield as of September 30, 2024 relative to the date the EIB Loan was assumed was the change in credit quality of the Company, the change in credit spreads for comparable debt instruments, and the change in the risk-free rate. As of September 30, 2024, the fair value of the EIB Loan is \$14.9 million, which includes a fair value adjustment of \$1.3 million and foreign currency translation of \$0.2 million during the nine months ended September 30, 2024.

serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum principal payments, as of September 30, 2024 are as follows (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Quarter ended September 30, 2024 </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Amount</td></tr><tr><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">-</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">-</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,190</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027 and thereafter</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">-</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Total future payments</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11,190</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Imputed interest and fair value adjustments</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,709</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

Total Debt as of September 30, 2024			14,899		
Future minimum principal payments, as of September 30, 2024 are as follows (in thousands):					
Quarter ended September 30, 2024			Amount		
2024					
2025					
2026					
2027 and thereafter					

[illegible]

2024			2023			2024			2024			2023		
Numerator:														
Net loss														
(5,492)														
(5,351)														
(44,370)														

[illegible]

per share for the periods presented because including them would have been antidilutive.

	2024	2023	2022	2021	2020
Stock options issued and outstanding	7,469,163	10,045,651	10,148,404	200,099	2,975
Restricted stock units	102,753	102,753	102,753	102,753	102,753
Restricted stock awards	10,148,404	10,148,404	10,148,404	10,148,404	10,148,404
Total	17,619,316	20,296,808	20,296,808	200,852	3,953

weight:400;line-height:114%">7,672,237</td></tr></table> Basic and diluted net loss per common share is determined by dividing the net loss by the weighted-average common shares outstanding during the period, as follows (net loss in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle">Three Months Ended September 30,</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">2023</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:middle">Numerator:</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Net loss</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td colspan="3" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">(5,492)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span

[illegible]

style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">(0.15)</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">(1.03)</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">(0.63)</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div>-5492000-5351000-44370000-224910004316413643164136360730403607304043090632430906323594123435941234-0.13-0.13-0.15-0.15-1.03-1.03-0.63-0.63<div style="margin-top:12pt">The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented because including them would have been antidilutive:</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:top">Stock options issued and outstanding</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">10,045,651</td><td colspan="3" style="background-color:#cceeef;border-top:0.5pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">7,469,163</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New

Restricted stock units		
2,975		
Restricted stock awards		
102,753		
200,099		
Total		
10,148,404		
7,672,237		

Business Combination

EryDel Business Combination

On October 20, 2023, the Company completed its acquisition of EryDel, a privately held, late-stage biotechnology company with a lead Phase 3 lead asset, EryDex, that targets the potential treatment of a rare neurodegenerative disease, A-T. The acquisition will drive Quince's next stage of growth, as EryDel's proprietary drug-device combination technology platform and promising late-stage clinical asset represents an opportunity for the Company to expand into several debilitating rare diseases where chronic corticosteroid treatment is – or has the potential to become – a standard of care if there were not corticosteroid-related safety concerns. The Company accounted for this acquisition in accordance with ASC 805, Business Combinations, which requires the assets acquired and the liabilities assumed to be measured at fair value at the date of the acquisition. As part of the acquisition of EryDel, the Company recorded deferred tax liability of \$5.1 million and uncertain tax position liability of \$0.5 million against Goodwill.

The acquisition date fair value of the consideration transferred for EryDel was approximately \$66.9 million, which consisted of the following (in thousands):

Fair Value of Consideration

2,615		
Quince Therapeutics common stock (7,250,352 shares)		
7,164		
Contingent consideration		
56,128		
Settlement of preexisting notes receivable		
1,000		
Fair value of total consideration transferred		
\$66,907		

The fair value of the Company's common stock was determined based on the closing market price of the Company's common stock of \$0.989 per share on the acquisition date. The aggregate stock consideration consists of 6,525,315 shares of Company's common stock issued at closing and 725,037 shares of common stock (the "Indemnity Holdback Shares") were withheld by the Company until October 2024 for general representations and warranties. The Company has included the total fair value of the stock consideration within additional-paid-in capital and common stock.

In October 2024, upon the first anniversary of the closing of the EryDel Acquisition (the "Holdback Release Date"), and in accordance with the purchase agreement entered into in connection with EryDel Acquisition, the Indemnity Holdback Shares were released to the EryDel shareholders. As of the Holdback Release Date, no indemnification claims were made by the Company. No further stock consideration is available for issuance and no additional shares will be issued in connection with the EryDel Acquisition.

The contingent consideration arrangement requires the Company to pay \$485.0 million of additional consideration in cash, comprised of up to \$5.0 million upon the enrollment of the first patient in the Phase 3 NEAT clinical trial, which was paid in the third quarter of 2024, \$25.0 million at NDA acceptance, up to \$60.0 million upon the achievement of specified approval milestones, and up to \$395.0 million upon the achievement of specified on market and sales milestones. The Company estimated the fair value of the contingent consideration using a probability-weighted discounted cash flow model. This fair value measurement is based on significant inputs

not observable in the market and thus represents a Level 3 measurement as defined in ASC 820. The key assumptions in applying the income approach are as follows: 15% discount rate, probability of achievement, 0% to 100%, each of the milestones and future revenues from commercialization over the contingent consideration period. No contingent consideration is payable unless and until the milestones are achieved. The fair value of each milestone after the acquisition is reassessed, with the subsequent change in fair value recorded in the Company's consolidated statements of operations and comprehensive loss.

During the three months ended June 30, 2024, the Company enrolled the first patient in the Phase 3 NEAT clinical trial. During the three months ended September 30, 2024, the Company paid the cash milestone payment of \$5 million to the former EryDel shareholders in accordance with the purchase agreement entered into in connection with EryDel Acquisition.

The following table summarizes the allocation of the consideration paid for EryDel to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date, with the excess recorded to goodwill (in thousands):

Preliminary Purchase Price Allocation	Assets acquired:		
	Cash	\$	560
	Tax assets		
	10,187		
	Other current assets		
	644		
	Property and equipment, net		
	238		

Operating lease right-of-use assets,	383	
Other non-current assets	14	
Intangible assets	61,096	
Goodwill	16,929	
Total assets acquired	90,051	
Liabilities assumed:		
Trade payables	(1,685)	
Accrued expenses and other current liabilities	(2,943)	
Debt, non-current	(12,564)	

Other non-current liabilities	(854)	
Deferred tax liability		
(5,098)		(23,144)
Total liabilities assumed		
(23,144)		66,907
Fair value of total consideration transferred		

The purchase price allocation is preliminary and may change as a result of additional information obtained regarding assets acquired and liabilities assumed and revisions of estimates of fair values of intangible assets and related deferred tax assets and liabilities. The Company will finalize its valuation and the allocation of the purchase price, along with required retrospective adjustments, if any, within a year following the acquisition date.

The fair value of identifiable Acquired IPR&D intangible assets was \$60.6 million. IPR&D was determined using the MPEEM under the income approach. MPEEM calculates the economic benefits by determining the income attributable to an intangible asset after the returns are subtracted for contributory assets such as working capital, assembled workforce, and fixed assets. The resulting after-tax net earnings were discounted at 16.6%, a rate commensurate with the risk inherent in the economic benefit projections of the assets. The probability-weighted, projected cash flows were calculated based on projections of revenues and expenses related to the asset and were assumed to extend through a multi-year projection period. The IPR&D has an indefinite useful life, and as such, is not amortized but rather tested for impairment at least annually.

The fair value of trade name intangible assets was \$0.5 million. The trade name intangible assets were derived using the relief from royalties method under the income approach, utilizing royalty rate of 0.3%. This approach is used to estimate the cost savings that accrue for the owner of an intangible asset who would otherwise have to pay royalties or licensing fees on revenues earned through the use of the asset if they had not owned the rights to use the assets. The probability-weighted, net after-tax royalty savings are calculated for each year in the remaining economic life of the intangible asset and discounted to present value using a discount rate of 16.6%. The trademark has a useful life of 21 years. The trademark is amortized on a straight-line basis over the useful life.

The excess of the

fair value of purchase consideration over the fair value of net tangible and identifiable intangible assets acquired was recorded as goodwill, which is primarily attributed to the assembled workforce and expanded global market opportunities. None of the goodwill is expected to be deductible for income tax purposes. Goodwill is not amortized but is tested for impairment at least annually, refer to Note 13 for this assessment.

The transaction costs associated with the acquisition were approximately \$2.5 million, of which \$2.3 million were recorded in general and administrative expenses and \$0.2 million were recorded in research and development expenses in the consolidated statement of operations and comprehensive loss.

The Company has included the financial results of EryDel in the consolidated financial statements from the date of acquisition.

5100000500000

The acquisition date fair value of the consideration transferred for EryDel was approximately \$66.9 million, which consisted of the following (in thousands):

Cash	2,615		
Quince Therapeutics common stock (7,250,352 shares)	7,164		
Contingent consideration	56,128		
Settlement of preexisting notes receivable	1,000		
Fair value of total consideration			

\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">66,907 </td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table>

</div>66900000261500072503527164000561280001000000669070000.9896525315725037485000000.054

The following table summarizes the allocation of the consideration paid for EryDel to the estimated fair value of the assets acquired and liabilities assumed at the acquisition date, with the excess recorded to goodwill (in thousands):</td><td colspan="3" style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Preliminary Purchase Price Allocation</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Assets acquired:</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"> </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Cash</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle">560 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Tax assets</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">10,187 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Other current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Property and equipment, net</td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">238 </td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">

Operating lease right-of-use assets,		
383		
Other non-current assets		
14		
Intangible assets		
61,096		
Goodwill		
16,929		
Total assets acquired		
90,051		
Liabilities assumed:		
Trade payables		
(1,685)		
Accrued expenses and other current liabilities		
(2,943)		
Debt, non-current		
(12,564)		
Other non-current liabilities		

style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(854)</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Deferred tax liability</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(5,098)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Total liabilities assumed</td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">(23,144)</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.37pt;text-align:left;vertical-align:middle">Fair value of total consideration transferred</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">\$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">66,907 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div>56000010187000644000238000383000140006109600016929000900510001685000294300012564000
 Assets<div style="margin-top:12pt">EryDel Intangible Assets</div><div style="margin-top:12pt">The following table provides details of the carrying amount of the Company's indefinite-lived intangible asset (in thousands):</div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:84.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:top">In-process research and development:</td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top">Balance as of December 31, 2023 </td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">63,197 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New

```
Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">Impairment
charge</span></td><td colspan="2" style="background-color: #cceeef; padding: 2px 0 2px
1pt; text-align: right; vertical-align: bottom"><span style="color: #000000; font-
family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">
—</span></td><td style="background-color: #cceeef; padding: 2px 1pt 2px 0; text-
align: right; vertical-align: bottom"></td></tr><tr><td colspan="3" style="background-
color: #ffffff; padding: 2px 1pt 2px 28pt; text-align: left; vertical-align: top"><span
style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-
weight: 400; line-height: 114%">Foreign currency translation adjustments</span></td><td
colspan="2" style="background-color: #ffffff; padding: 2px 0 2px 1pt; text-
align: right; vertical-align: bottom"><span style="color: #000000; font-family: 'Times New
Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 114%">867 </span></td><td
style="background-color: #ffffff; padding: 2px 1pt 2px 0; text-align: right; vertical-
align: bottom"></td></tr><tr><td colspan="3" style="background-color: #cceeef; padding: 2px
1pt 2px 28pt; text-align: left; vertical-align: top"><span style="color: #000000; font-
family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-
height: 114%">Balance as of September 30, 2024 </span></td><td style="background-
color: #cceeef; border-bottom: 3pt double #000000; border-top: 3pt double #000000; padding: 2px
0 2px 1pt; text-align: left; vertical-align: bottom"><span style="color: #000000; font-
family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-
height: 114%">$</span></td><td style="background-color: #cceeef; border-bottom: 3pt double
#000000; border-top: 3pt double #000000; padding: 2px 0; text-align: right; vertical-
align: bottom"><span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-
size: 10pt; font-weight: 400; line-height: 114%">64,064 </span></td><td style="background-
color: #cceeef; border-bottom: 3pt double #000000; border-top: 3pt double #000000; padding: 2px
1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr></table></div><div
style="margin-top: 12pt"><span style="color: #000000; font-family: 'Times New Roman', sans-
serif; font-size: 10pt; font-weight: 400; line-height: 120%">The following table provides
details of the carrying amount of the Company's finite-lived intangible asset (in
thousands, except useful life):</span></div><div style="margin-top: 12pt"><table
style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-
align: text-bottom; width: 100.000%"><tr><td style="width: 1.0%"></td><td
style="width: 23.142%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td
style="width: 9.203%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td
style="width: 0.1%"></td><td style="width: 0.406%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td
style="width: 9.203%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td
style="width: 0.406%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td
style="width: 9.203%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td
style="width: 0.406%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td
style="width: 9.203%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td
style="width: 0.406%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td
style="width: 9.203%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td
style="width: 0.406%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td
style="width: 9.204%"></td><td style="width: 0.1%"></td></tr><tr><td colspan="3"
style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom">
<span style="color: #000000; font-family: 'Calibri', sans-serif; font-size: 11pt; font-
weight: 400; line-height: 114%"></span></td><td colspan="3" style="background-
color: #ffffff; padding: 2px 1pt; text-align: left; vertical-align: bottom"><span
style="color: #000000; font-family: 'Calibri', sans-serif; font-size: 11pt; font-
weight: 400; line-height: 114%"></span></td><td colspan="3" style="background-
color: #ffffff; padding: 0 1pt"></td><td colspan="15" style="background-
color: #ffffff; padding: 2px 1pt; text-align: center; vertical-align: bottom"><span
style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 8pt; font-
weight: 700; line-height: 114%">As of September 30, 2024 </span></td><td colspan="3"
style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="15" style="background-
color: #ffffff; padding: 2px 1pt; text-align: center; vertical-align: bottom"><span
style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 8pt; font-
weight: 700; line-height: 114%">As of December 31, 2023 </span></td></tr><tr><td
colspan="3" style="background-color: #ffffff; padding: 2px 1pt; text-align: left; vertical-
align: bottom"><span style="color: #000000; font-family: 'Calibri', sans-serif; font-
size: 11pt; font-weight: 400; line-height: 114%"></span></td><td colspan="3"
style="background-color: #ffffff; padding: 2px 1pt; text-align: center; vertical-
align: bottom"><span style="color: #000000; font-family: 'Times New Roman', sans-serif; font-
size: 8pt; font-weight: 700; line-height: 114%">Useful life</span></td><td colspan="3"
style="background-color: #ffffff; padding: 0 1pt"></td><td colspan="3" style="background-
```

[illegible]

[illegible]

		26	
19			
Total			
\$		464	
			
\$		475	

The Company performs annual impairment reviews of its intangible assets during the fourth fiscal quarter or more frequently if appropriate. As of September 30, 2024, the Company did not incur any impairment losses related to its EryDel intangible assets.

Novosteo Intangible Assets

In January 2023, the Company decided to abandon internal development of NOV004 and pursue out-licensing opportunities. As a result, several of the assumptions used in determining the initial fair value have changed including discount rate and expected cash flows and thus triggered the need for an interim impairment assessment as required under ASC 350. And so, the Company performed a fair value assessment of the Intellectual Property as of March 31, 2023, and based upon this assessment, the fair value was determined to be significantly below its carrying value and resulted in an asset impairment charge of \$5.9 million during the nine months ended September 30, 2023.

Goodwill

As part of the EryDel Acquisition, the Company recorded goodwill, the excess of the fair value of purchase

consideration over the fair value of net tangible and identifiable intangible assets acquired.

The Company evaluates goodwill at least annually, as well as whenever events or changes in circumstances suggest that the carrying amount may not be recoverable. As of June 30, 2024, the Company performed an impairment evaluation of goodwill after assessing qualitative factors that indicated a possible impairment of goodwill.

Under the qualitative assessment, management considers relevant events and circumstances including but not limited to macroeconomic conditions, industry and market considerations, overall Company performance and events directly affecting the Company. It was noted during the assessment that the Company's market capitalization was significantly below its carrying value and a further quantitative analysis was conducted to determine to the extent, if any, the Company's carrying value exceeded its fair value as of June 30, 2024. The quantitative analysis used fair value based on market capitalization adjusted for control premium based on market comparable transactions. This quantitative analysis resulted in the Company's fair value being significantly below its carrying value, resulting in a non-cash goodwill impairment charge of \$17.1 million being recorded during the nine months ended September 30, 2024.

The following table summarizes the changes in the carrying amount of goodwill (in thousands):

Balance as of December 31, 2023	17,625		
Impairment charge	(17,130)		
Foreign currency translation adjustments	(495)		
Balance as of September 30, 2024			

[illegible]

[illegible]

[illegible]

[illegible]

\$

Balance as of December 31, 2023			\$	17,625	
Impairment charge			(17,130)		
Foreign currency translation adjustments			(495)		
Balance as of September 30, 2024			\$	—	

1762500017130000-4950000

Subsequent Events

On the Holdback Release Date, and in accordance with the purchase agreement entered into, the Indemnity Holdback Shares were released to the EryDel shareholders. As of the Holdback Release Date, no indemnification claims were made by the Company. No further stock consideration is available for issuance and no additional shares will be issued in connection with the EryDel Acquisition.

In November 2024, the Company entered into an amendment (the “Amendment”) of the Debt Agreement with EIB which waives the Minimum Cash Covenant from January 1, 2025 and up to the earlier of December 31, 2025, or the date the Minimum Cash Covenant is restored. Under the terms of the Amendment, the Company agreed to amendments requiring monthly reporting of cash balances

~~-8?20\$3;8T.P6BP^0"X99K>]9!:G~~

[illegible]

<7IVLGX" 8^%S7 MDZZ/H B2_NH/\$&JVMLQ23;+&SV\LKLBF4 (P!;>H#OS/P>_P"4QGOS/; A M#;8Y^D6C
_RY5X7^S%K%PVNM)^ /AZ_U+4Q\^=4@M;BYT"&6 M9RD%O?7<4I((F1Q+%M&\NV1+O_ 'V\+ VLO&7Q5_9A
<_&H> + #PK;Z9H^ MHZEX?MJC6O\1^W\;0S%D)D2&)DC\R(Q;H\7X0!7?W3X)^,H\XD?!OP+XLU MB.WAU/Q\H-
AJHQ9JRQ)+/;)(ZQ^S,RJ"Y RQ/UZUXMKG@KP#X#_ ">_CC0 M_AOJ,&M^"K#P3K5AJEM+>+B@6.CZKJ%Y<+:PZ?
>0Q0PRSO0(Q\AS;:NQOU&7Y M64D\& P#10+XA^)_V" B_+;K1_ "7B?PWK\,D6EK;6MPMB+26"DR(F^
MAG%W)\U\U^ZGH<_0WPMV_+13P6^@&S^IV"2\T\F;^E\0W_B\3_9+ MD9584\$|^"&RV4_")L;IXA_ -IX/QO\
_=/CHFUM_PF=L_N_<^;HO%?K3_M_/\;H?SKX_<_"/NF_#JFJNZ%J&EV\EXS) DMQ;21(9"@9MH9U)*AL!>_E_!
MSAX9_;"^/"\2&JZOKGP^_<^"_<^GS?8=-U_P"(27\,NNR(1)<6\5N05A5 ME*XD3.0.=V^/_N_A_P#M->/(B\A?B?
XGTGP3<_>)0?D^M^/X3GD_M_ 'U6 MR@IQ+>_X^IG#;T2X0*22.5,@Y^4?V"OY;1+^*GP/MH1/CC\7\WBOP|>7.G
MZ_XA^A B5M,AT;:\3*8T-H;Z;2+EIW0R&4?>5U7Z9_9Z^\$/PJ_94T_XM^_M_#^(&J>+9IWF\8;MJ^J0ZG-
9W%O+>B6X67I/\$&\$H^T\LSH/_A^X6\1_<_"/L?A#Q=?6?FAHA8_Z_0\$ _@D4*_E.6>(O_\$#P_P#%;P;I?
BCPOJ=OK/A_4H^N;2\M02DB MJB/NGE^5U961AE64A@""IX\ P5\$^;JAGXF
MZOXIQM/L_!UM92KJ4VJ0B.WD@<%3&R; &TQJFAQD+!=K;RBOR=<#JWK6@
MGI\B^X%^(<7L\7US3;XZV&HZ+I=A(+JYFM(HY \=M#O^1VN8I@("E,N\ _RT M#^IXT\ _@FK^SGH^I6^H0?
#^"26UG2>*.ZU74+>)F5E;_D4DI^N5&4="IY# MBLC\MC2+3PIH_P"S1HFEVD&FZ;8_%SPU9VMC:Q"..*)!L<: 8"(J#:
!@8Q_M0!@_&H\HKI^X^&Y/BIXD^&_P/_P#A7\$/!_Q\!O"Q"IXROO&\$4>HVNMTZ7MM^TJ MQ9H;:>|&|)#
(RW"E(4>D+>*P4^44?DO^"HGS?L_ \$P#D_P#\$L_ \3L5YGX3_M^AWC-O"W\GP(^&;+HOC'Q%_M^U6^>5>(-DL>EV
LOFZUMS(INKH&_Y!&1 ML&T%&R&5X@#U^X9_M_?SWPS|>_'^\$OQHT^PO.ZYXHTVZU30?*\$@H\XZ;*/'<
MR6)6XB)\Y(TEE;3S_H0P+MRZY>_>_D^+>GD^7COX>_CP_X).F^ YQ9ZSX_M\;7EXT<HY\$;POPPJLD3)+%=
(3B1^\$6X;F4SSEM)8^&O^""@7H/NB>_>_CC MI_Q>UFS_ _\$@S3K21;+2\G1=^DIOY=NI^<5D9?_>197.37K?Q_9Q\"?
M&KXN^("PE^*UUX#^,VES16FMZQX9U=-04.CP(EMJ5@9<%0MFR""*(S1L9!_M) LVT>B77QNUX0_?<
7/B#;!\T\PY<^'_RWD/AFZ>_A06#K#%+ KOHT9N)' M4I&L;\$22/S'5@X3QIOCE^U7X<^'E_P#%KQ)_?<
=MX^L.K.XURY\%2:E>VOB2_M^R4.R^9-(K0++&5E=2@8JA01H)^I7YQ^_BCXC?M6?>_?%6J;W<_%XCUCX
M;^/7M;C5/#\$4CVVKY5I9>1)>O!058EKQIAI%6*1(S_("%UI"_:?^R7X\$^>)WP
ME/BJW_:@<^>K_#S4\,FN)KV^>)8K^6\\WL\HUL;S\JEM_!J,DDP^EFJ2WC95#+G&'W_M*2M7_P!G?
X8^&_@_&_ "7A3P9J\QKOA>T@>?3=4N+R.X;[BG>2=7,D;JCHPF_M)4HN_JKUZUQ/QW_>TT7\GGX0?#^PCXLTK^S_<
WXO^U1OXPOK^*UL)8H^H5&_M3;IMN^XE=^WAN^%F#IW^?RP#Y\>_>^G@/HS1HIG?
P/V= A1?E<:_%KD/B8/I=;HK_#+%9031.48_>_DB41N_M02I8\U) #3_8'_>1:MJ7P_<^=W?
\$KQU^T9XOU6WML;4/\$&HZ?J\Q%:*RPI_>_M+J4D@B#;S!6V"0G_ 'N<^H>K^CZT>R_M_!3X\>!?V@_ "MSX@\
:_O_>FBVMXVGS7^6+S\S=;FRMQ\$8BDC1^9;L7S@Q7< MRAD<\$_JA>+O%&F>!?^NL^>)M;N18Z+I5G)?<
W\QM=Q%!\\$A=G_527(56_ "3A1Z_M^OSW_9+^&#_QE^<_&G^_OCWX4^1^&4?Q_UBXNFTAM!@02);07\$%\M%)>+?<
C%<^SQ>_H\Z?VLIJY@&YU7SIWTN\IC21 M(Q%Y_%3^"&TK1CR_>)!G<_VW7YE?&C0?B+^QW^T=^(\OCC\2?
B7#=:U"WTF+0TLK.02-&DD-L\C7""*7GN0HC/S6B#(9D*_IH6^YR0_+=&BC0?%O_>BY+E-%T5)86D@MQ,KO/_M-
E""F<#/#X&_&XRU\X\7G\I\06D_&#PIX0L+2R\&ZLUCXD)\ZC;_>5I^"3
M\TEK&D^ED2Y^;DE_+&X\>N*_9^LX_@K^W%<TQX^57U08^(/&FHP^)?#L
M#^9&FJ632WUQ(T,CHH9HQ<*KJN>8YMN\1.P^@/VG_B\X7U+X%?/PG;>)->(N MO%-
CX&UBYN\#A0XGOK>\$V4A\$DD>_>JD2QD.0!^>7^>/_D\X7^_>_>8%\$>_! M+13?(_X?6+9^"7_>-(E/B;Q_YIT_F>)<)<
(CYL.1NV^8&#&#PR*>U>R^A_H\6 MO@S^RI^SSXTT?PO97+>+SPH=H\H&A:>|>7.W-DTLD&G6Z_""
C^OH6(S@#HOB?XVA_#N\ 02HUIX?T?5;M-8TV?Y(8YKEPT\$CI^\$30%\$X8DI552
M72W^U)^T%IMC\4V4;K0_#^@_P_9;7X^UJ.2OUKQ)HTEQ>6%O_-I E7-BS%#_M;2%)U8Y&I'=\$UCQ;HT4=
IXIU_QQ\0>--1A2^>8^_MR--4LFEOKB1H9^10S1BX575<Q\$;=XB9A\7>_>CIX^\$V/C_9M?L\1UKPAH
MTVN:MX=T^MY-4AM885F9S;EP5\1TP2_#O3GD4>"W^Q<_>NUBSUCQUHWPR\<
M;_%X#MB;ZR\)^<(YKP^*=2L4B23;HM3)^#E(8\+7\$MG*HIS.WY6=;+4\$N(0\1H7_ MI>&?%WQP^_WPOM_C/>_>KP?
>?5\))>+3K+1\#5K>VM6N#%)=W\JS%6Y9B_ML3(">!504CDWQCY%<^'_ "AQ^!@I_P#"8W)_#SM9H_>JOD3XO?
M1?;\$6OVD_M&^>1P5>_>|5\7:5IT6LZYK/BVYN4L=/_BQNS/E1^*KNW\VR821O(IY^TI@_Z? M7=?+Q\^<
/PS_>^>)SKI_P0+CP=^>O#NG&*RU+PKX@^"ZOIUKY20PB/S\=\$B9HP^"SNL;_0D>PO\^?>P/^(%W?^>)>^&90^/_>^<
_P#>R^4" M\ X2^_CYNQZ_9_>CZ\J7_M5ZA^QYA7/_BIXC?&+X>_>?2\$V@>_>WX*_%M%>@>^>^TMG_J
M\@NH^IU+33;&Y3S?M?VRN?L^>S_?>^S_+I9C=Y?SXVAT>G_LS?&6?C0WQ_M4.M6FG6_""^>=6\+V?V&*1?M;
<1&_Y-SMNE/F^<5VJ>BUQOP_>_&F/%?B? MJO3XC?2\L=^*3PQX;VQ;M;W=O%(M\)^T=@S^5R^PC-W)IU%<^I^Z^?<
L\$ _M+PY_>V\>VD\>RZG;JXHM_BAKVLR;8P/GM;/(D^SIGJN^E8C.TE0<>8F?>_>M;M;X_?%>VH\<
>Z\H\VLQ>*JAC<>7IVL6\ZEQ822RVFEP#;L0=JRI@Q4\$Y!_M^44>X^" P\HSIH;HBIUGQA%0^G@+1/AG97DVGZ;K?
CV34^>OE)I5^TVPB_M1&2+;(\H\Z?>Y9_I E7?>C7\^FL>/KWQM^V=K^AS0;^2_B<=;C08?>#^JR+?6\<
M\+C4W>S;J21(^6W0^02^N?WGW1MKV3_@EQ^40^DWI%FEV0U_3HKSPE\O.NI_MXA&FOO=W-PDDQ?
\$1B8L)/N_+(N=T; <_>P35UBPUK\H_P#;^U/3\ZVOI-O? M%L=S;WEK^LD_3W6K.DB.I(964A@P)!R.*
/ICICW\H\+AICX">>&O&H086_M>K71FM\4L=-N1)%9W<3E6&T_<
&4).L;Y95F3)8\$%KV_U+5_BU86GB3PBEI<7;IQ#?WEZUM=10Q0QJ5N7VY>.56R_M\9VJDRN<#1^O@>\&|>^>?P?
>+>-(?6VA62P27@5T-W.6:2::;SL5R5Y9_>MF\JGF;5;10!S_P^U!^T)!^SC\8O\$;Z\X\UC4_<
1MM&T7PY9LXFU*IF=17QM^VIX@>_>LT?>S5XKVT_W^+M>%>_>4;IG;*>Z)+>_>3^>D;
(=ZHMC;2.I+1@>V>_>K_P""GWC_>7?H#_>(J@_M@>2;1_>XDAT^XT2..^B9M4C74+.5GM@&_?*(R^)^3("G/3F@>^>U_>O?
@C^RC_M^_>\$(^>9O&^Q_>8>)>1+L?^_>A(WES21Z?;M+<3RC;\$@A616?+>#(48^+YDD> MLOQI^<
_P1\>|>#XU>>^>L.K;XRI06WAFRUSX?7EQ&VF7DVX\H<0W8W3+(00
MS1LNQ89^VYBB^Y^>)7PW6W\O%/C/5/A\XHU3X>_>7XV3^2_Y_//VE;1W3H4\8_>M%;2?V6=MXIT_M;U6W?4/M%G?
2.)D1O*22(1)\$T<+>Y;1R^6<@M0\J^?VLM1^*_L^_#GQCX=<^<
M^7A^>Q;XRUB;POX<+>+>('>S2\$U^>JNXFX9&E_>=1\$PL\7R\MIZ_>732\1?RYAN&?I9&^?>Q\K+M1_M/+?S^>ZUATW&J;_<
I_P#P2J^>YU2ZN_>#>QXW6^P56^TWG^&Y\J6H_>=1CCA96_MF>_>*.50@9#O?>AGXA?%;P^>_>\$WJL/PU^7UT#4DO\<
PIJ3T7V33_M-(275BZK;RN+6Y8W+JVI8N_P9^NUG20_I4_>+>_>8?2?XA?2?3PWF@_>#Q7J_MGC_#4X\O1=;<
=IYGO8+6(P1P7+>4L<^"S3YEGEA&V%&?>NTK7!>?>+J^X\>LJZ MIX7U?
XZ^'_AWJ/P\UW4HM^GU;P34_>V%IF^_#+_A09Y_X3.U_/_>W^<^MH_0#S%_O+^>X4ZN!OOC)X.TSXLV7PSO/\$<_<
IXWOM_>KVFD\$J27%>H^>=2T7GS?GW\=;_>=BNRHHH\>73?L\ MZ/9>)O^WQ\^Z5#H/QEU_P/S;7>:>(KJZFDMTE\$;V\>^<
L\2JC6UL25B.0AR_M&R0WR3X_N_""PR\>(Z/X=^>)W\I&GCKQA_>6Q@5M=10VG@VT4J)^>I^EN_>I2
M;1FG>1G,A&YA&S&_>9\$8K\J^*_D\I@_JGOQ5\&_%<^>(N>)>J^*/@VY8>J9\7M_M?UG?
Q7%CH=IO;RTC^>B)9B&VDH2K116ZX0J57K/#^I^/P\&_>BQ\M?03+<
<7\@>F.YE>_>V.AA383\>@8V\$+MV\17T+10XO^>R_>^87AAX_MG^>5OX_@M?>?B;4FU75=>M+J>""%<
IDM\$V^>X;J;_>^>D>U\^L^R\;HHHHH_>%M^<+I\$>P7^>7C^>Q3XT^>V^>J>(9HH\>4(IVZM^G1_54R?9Y4#MM;N.3M5%S
MA%_>I30?@>X^>+>V\^>FB>%>+>1_""%>92V%>IU@>GV5X_E,Q_M?>2;J\>H\H_Y^P#^>V?#_>_>?!\^>D^>/"FCQZ-H.EQ""RL;
<_>L<4>23NSRS;69_MF=MS,S%G);FHOBA^?>#^>QB\^>IX\7Z5_>7AS4A%>JLC<30F;RY\$ECS)&RN_M.BGANU=G10
5Q7COX4^>?B;_>_>(X?>VCC40^>\$=U>VU_20;B6(V\H;N\J4^6R_M\@N\OD;?>W@SQ7X+@U7P_P""H4M\>C;
IN4FLHTB6_M%42=)>1*4*(NY3(0QCC9LL_1\110\X_X9_9_>^>W@?5/16J>^>O!>=CHMWX/_R-(

[illegible]

'UF?ZRX3LSI2,^_P"MS&???:+?_AL:XP?I#=#+_,"N MS_C_V\8/^ANE_%=G_P#&:/K,
UEPG9GZD9I PI:,^_ZU^6_#8W MQ@_Z&Z7_._%=G_&:/^&OOC!_T-TO\X*I/_P",T?68!_K+A.S/U(SI_K1G
MW_6ORW_X;&^_0W2_@KL_C_#8WQ@_Z&Z7_._%=G_&:/K,_UEPG9 MGZD9I_UHSI_K7Y;_/#8WQ@_Z&Z7_P
%=G_9H_X;&^_0W2_@KL_C_MUF?ZRX3LSI2,^_ZT9I_UKIM_P#AL:XP?I#=#+_X*I/^_T?A-C?&#_H:I?_M5V?
QFCZS/I9<V9^I&???:^_P"MEQO_._C?&#_*&Z7_P5V?^_9H_X;&^_0W2_^^NS_C_UF?
ZRX3LSI2,^_ZT9I PI:,+?_C&^_,'_\$-TO_@KL_XS1_PV\8^H:I?_!79_P#QFCZS^A67"=F?J1GW_6C/O^M?EO_M_P
_C?&#_H:I?_!79_QFC_(_&^_,'_\$-TO_@KL_XS1I9@'^LN\$I_4C/M/O^K1GW_6ORW_X;&^_0W2_P#@KL_(S1_P
_C?&#_H:I?_!79_QFCZ MS_/I9<)V9^I&???:_6C/O^M?EO_PV\8/^ANE_P#!79_!FC_AL:XP?I#=#+_M_."NS_C_UF?
ZRX3LSI2,^_ZT9I_UKIM^&OOC!_T-TO_(*I/_XS1_PV_M\8/^ANE_P#!79_!FCZS_/I9<)V9^I&???:^_ZU^6_P#PV
_8/^ANE_M!79_&:/^&OOC!_T-TO_(*I/_XS1I9@'^LN\$I_4C/O^M&???:_+?_X;&^_M_0W2_^^NS_C_
_#8WQ@_Z&Z7_P_%=G_9H^LP#_67"=F?J1GW_6C/O^M?EO_P#8WQ@_P"ANE_%=G_&:/^&OOC!_T-
TO_@KL_P#XS1I9@'^LN\$I_M_4C/O^M&???:_6ORW_P"QOC!_PI#=#+_X*I/_T?A-C?&#_*&Z7_P5V?^_9H^LP#_M9H^LP#_
_#EPC9GZD9I_UHSI_K7Y;_#8WQ@_Z&Z7_P5V?_9H_P"QOC!_PI#=#+_X*I/_T?68!_K+A.S/U(SI_
_T9I_UKIM^&OOC!_T-TO\X*I/_M_P",T?A_#8WQ@_Z&Z7_P5V?_9H^LP#_67"=F?J1GW_%HSI_K7Y;_C?&#_M#_H:I?
_P5V?_P_9H_X;&^_0W2_P#@KL_(S1I9@'^LN\$I_4C/O^M&???:_M!_+?_AL:XP?I#=#+_P"NS_^T?A-C?&#_H:I?
_P5V?_P_9H^LP#_67"=F?J1GW_6C/O^M?EO\^C?&#_H:I?_5V?_QFC_AL:XP?I#=#+_P"NS_^T?6
M8!_K+A.S/U(SI_K1GW_6ORW_&OOC!_T-TO_@KL_P#XS1_PV\8/^ANE_M!79_&:/K,_UEPG9GZD9I_UHSI_
_U^6_PV\8^H:I?_!79_P#QFC_AL:XP?I#=#+_X*I/^_T?68!_K+A.S/U(SI_K1GW_%KM_AL:XP?A_0W2_
M^"NS_P#C_#8WQ@_P"ANE_%=G_&:/K,_PI9<)V9^I&???:^_ZU^6_M_V\8/^ANE_%=G_P#&:/A_AL:XP?A
0W2_^^NS_P#C_UF?ZRX3LSI2,^_M_P"MS&???:+?_AL:XP?I#=#+_,"NS_C_V\8/^ANE_%=G_P#&:/K,_M
_UEPG9GZD9I PI:,^_ZU^6_#8WQ@_Z&Z7_._%=G_&:/^&OOC!_T-TO\X*I/_P",T?
68!_K+A.S/U(SI_K1GW_6ORW_X;&^_0W2_@KL_C_#8W MQ@_Z&Z7_._%=G_&:/K,_UEPG9GZD9I_UHSI_K7Y;_
_/#8WQ@_Z&Z7_P_M=G_9H_X;&^_0W2_@KL_C_UF?ZRX3LSI2,^_ZT9I_UKIM_P#AL:XP_M?I#=#+_X*I/^_T?A-C?
C?&#_H:I?_5V?_QFCZS_/I9<V9^I&???:^_P"MM?EO_._C?&#_*&Z7_P5V?^_9H_X;&^_0W2_^^NS_C_UF?
ZRX3LSI_M2,^_ZT9I PI:,+?_C&^_,'_\$-TO_@KL_XS1_PV\8^H:I?_!79_P#Q MFCZS^A67"=F?J1GW_6C/O^M?EO_P
_C?&#_H:I?_!79_QFC_(_&^_,'_M_\$-TO_@KL_XS1I9@'^LN\$I_4C/O^K1GW_6ORW_X;&^_0W2_P#@KL_M(S1_P
_C?&#_H:I?_!79_QFCZS_/I9<)V9^I&???:_6C/O^M?EO_PV\8/^ANE_P#!79_!FC_AL:XP?I#=#+_,"NS_C_UF?
ZRX3LSI2,^_ZT9I_UKIM^&OOC!_T-TO_(*I/_XS1_PV\8/^ANE_P#!79_!FCZS_/I9<)V9^I&???:^_ZU^6_P#PV
8/^ANE!79_&:/^&OOC!_T-TO_(*I/_XS1I9@'^LN\$I_4C/O^M&???:_+?_X;&^_0W2_^^NS_C_
_#8WQ@_Z&Z7_P_M=G_9H^LP#_67"=F?J1GW_6C/O^K7Y;_P#8WQ@_P"ANE_%=G_&:/^&OOC!_T-
TO_@KL_P#XS1I9@'^LN\$I_4C/O^M&???:_6ORW_P"QOC!_PI#=#+_X_M*I/_T?A-C?&#_*&Z7_P5V?^_9H^LP#_
_#EPC9GZD9I_UHSI_K7Y;_M#8WQ@_Z&Z7_P5V?_9H_P"QOC!_PI#=#+_X*I/_T?68!_K+A.S/U(SI_M
_T9I_UKIM^&OOC!_T-TO\X*I/_P",T?A_#8WQ@_Z&Z7_P5V?_9H^LP#_M_67"=F?J1GW_%HSI_K7Y;_C?&#_H:I?
_P5V?_P_9H_X;&^_0W2_P#@KL_(S1I9@'^LN\$I_4C/O^M&???:_+?_AL:XP?I#=#+_P"NS_^T?A-C?&#_M#_H:I?
_P5V?_P_9H^LP#_67"=F?J1GW_6C/O^M?EO\^C?&#_H:I?_5V_M?_QFC_AL:XP?I#=#+_P"NS_^T?
68!_K+A.S/U(SI_K1GW_6ORW_&OOC!_MT-TO_@KL_P#XS1_PV\8/^ANE_!79_&:/K,_UEPG9GZD9I_UHSI_*U^
M6_PV\8^H:I?_!79_P#QFC_AL:XP?I#=#+_X*I/^_T?68!_K+A.S/U(SI_K1GW_%KM_AL:XP?A_0W2_^^NS_P#C_
_#8WQ@_P"ANE_%=G_&:/K,_M/K,_PI9<)V9^I&???:^_ZU^6_V\8/^ANE_%=G_P#&:/A_AL:XP?A_M0W2_^^NS_P#C_
_UF?ZRX3LSI2,^_P"MS&???:+?_AL:XP?I#=#+_,"NS_MC_V\8/^ANE_%=G_P#&:/K,
_UEPG9GZD9I PI:,^_ZU^6_#8WQ@_Z M&Z7_._%=G_&:/^&OOC!_T-TO\X*I/_P",T?68!_K+A.S/U(SI_K1GW_6O
MRW_X;&^_0W2_@KL_C_#8WQ@_Z&Z7_._%=G_&:/K,_UEPG9GZD9I_UHSI_K7Y;_/#8WQ@_Z&Z7_P
%=G_9H_X;&^_0W2_@KL_C_UF?ZRX3LSI2,^_ZT9I_UKIM_P#AL:XP?I#=#+_X*I/^_T?A-C?&#_H:I?_5V_M?
QFCZS/I9<V9^I&???:^_P"MEQO_._C?&#_*&Z7_P5V?^_9H_X;&^_0W2_^^NS_C_UF?
ZRX3LSI2,^_ZT9I PI:,+?_C&^_,'_\$-TO_@KL_XS1_PV\8^H:I?_!79_P#QFCZS^A67"=F?J1GW_6C/O^M?EO_P_
_MC?&#_H:I?_!79_QFC_(_&^_,'_\$-TO_@KL_XS1I9@'^LN\$I_4C/O^M?EO_PV\8/^ANE_P#!79_!FC_AL:XP?I#=#+_,"N MS_C_UF?
ZRX3LSI2,^_ZT9I_UKIM^&OOC!_T-TO_(*I/_XS1_PV\8/^M^ANE_P#!79_!FCZS_/I9<)V9^I&???:^_ZU^6_P#PV
8/^ANE!79_M_&:/^&OOC!_T-TO_(*I/_XS1I9@'^LN\$I_4C/O^M&???:_+?_X;&^_0 MW2_^^NS_C_
_#8WQ@_Z&Z7_P_%=G_9H^LP#_67"=F?J1GW_6C/O^K7Y;_M_P#8WQ@_P"ANE_%=G_&:/^&OOC!_T-
TO_@KL_P#XS1I9@'^LN\$I_4C/MO^M&???:_6ORW_P"QOC!_PI#=#+_X*I/_T?A-C?&#_*&Z7_P5V?^_9H^LP#_
_#EPC9GZD9I_UHSI_K7Y;_#8WQ@_Z&Z7_P5V?_9H_P"QOC!_PI#_M=#+_X*I/_T?68!_K+A.S/U(SI_
_T9I_UKIM^&OOC!_T-TO\X*I/_P",MT?A_#8WQ@_Z&Z7_P5V?_9H^LP#_67"=F?J1GW_%HSI_K7Y;_C?&#_H: MI?
_P5V?_P_9H_X;&^_0W2_P#@KL_(S1I9@'^LN\$I_4C/O^M&???:_+M?_AL:XP?I#=#+_P"NS_^T?A-C?&#_H:I?
_P5V?_P_9H^LP#_67"=F?J1GW_M_6C/O^M?EO\^C?&#_H:I?_5V?_QFC_AL:XP?I#=#+_P"NS_^T?68!_K
M+A.S/U(SI_K1GW_6ORW_&OOC!_T-TO_@KL_P#XS1_PV\8/^ANE_!79_M_&:/K,_UEPG9GZD9I_UHSI_*U^6_
PV\8^H:I?_!79_P#QFC_AL:XP_M?I#=#+_X*I/^_T?68!_K+A.S/U(SI_K1GW_%KM_AL:XP?A_0W2_^^NS_M_P#C_
_#8WQ@_P"ANE_%=G_&:/K,_PI9<)V9^I&???:^_ZU^6_V_M\8/^ANE_%=G_P#&:/A_AL:XP?A_0W2_^^NS_P#C_
_UF?ZRX3LSI2,^_P"MS&???:+?_AL:XP?I#=#+_,"NS_C_V\8/^ANE_%=G_P#&:/K,_UE
MPG9GZD9I PI:,^_ZU^6_#8WQ@_Z&Z7_._%=G_&:/^&OOC!_T-TO\X*I/_M_P",TOK,_UEPG9GZD9I_UHSI_*U^6_
C_&#_*&Z7_P5V?^_9H_X;&^_0W2_^^NS_C_3I:JP_UEPG9GZD9I_UHSI_K7Y;_#8WQ@_Z&Z7_P5V?^_9H_X;&^_0W2_^^NS_
/AL:XO_/0W2_@KL_C5+ZY2+_PI9,)V9^HEZC?EFGI8WQ?;KXNE_M_P#!79_!JG_P#9Q=P"AN"@NM?_(U1H&
IWK?P?^&O/BY_T_X_%UK_/&E_X_P#BQ_T.8_!:=_&CZ12I_MA_K'A.S/TYW>I&IWK^RO^&O?BOA
I#E_Y3K7_P"-4D?I7WQ7/7QD/I=:_MQUEI>I=P_PI8)V9^FV[IWHW>I?F;_P-=??_HI=P_UCPG9GZ9;O>C=[U^9O)
PUU^5_HS#_6I"=F?I3^%&?_OS=3J[XLKXH_P#)M^U^4/VK/BNW_SC_P"M?_(U1_-LP_UCPG9GZ/I&C&OB?
_DK7_XU2_M2CV9I_K'A.S/T;_T?@:_M.9/VJ/BNW7Q/_P"2=K_A:I?ZM3?%8I?P_P#YVO_..J?I4H=F^I&\$I_1;
M#1^!KI/^&J_BA_T(S/OO)!^!^!_P#AI+XD?I#=#+_X!_MVW_OJG_A(2\$?_H9)A_P#M?_C5+^V/V8?VIA>S/O7S/NS/
/H95_&+_.U!O87LP_MS#IF?;>_U3_!_O'W_ORK_X!1^MQNG^>_O^H86_
8O_C=+_6#"=F/^VL/V9IK;CZ4;CZ5^8^"/?_08_M?_P#B_C=_.X7WXI_Z"I^@_
%_H_U@PG9B_MS#_RL^SWCO_H+M_X#1^QNH_UCPG9C_MJAV9IE;CZ4;CZ5<_M_P#"10^7_07;_P_HO\XW3_
/A>GCK_**S?^T7_QNE_K'A.S+MFA_*SI_M#R2C)!^A_A>/CG_H+M_X"Q?_!NGR;O^ZZLW_@_%_VJ/I9<)V8_I9
MP_9GU/^YT?YZUAD^+J:2IHO_&B_P#C=I3XT>_SUUIO_+P"-T?ZS_M83LQ?VOO!^ML_6C/UKY_3XS>_#UUIO_
&B_P#C=I3XR>_VZZRW_@-O_P#&_MZS_UIP7GIP?VOO!^K_6C/UKY0_X7)XS_Z#3^@-%_!_XO&7_08;_P
M&B_&TOI:<%Y<^IKT.S/O_&^5_P#A<C+H_G_P#IH?_"G_!>>8_P#0_M9_!:_H_UJP/GIP?
VOO!^ILT9KY<_X6YXP_Z#!_H?^?_+^7_1M!C_R7A_PJA_6S!WON_/I4H=F?3^?K1GZUOQ_!^"UO%_P#T&A
R6A_PIZ?_M%SQ2W759?_!_"E_K;@>S^X/I4H=F?36;_UT?A+9^4_P#04E_!H?^F_X
M6EXE_P"@Q+_X#0_X5^MV!_O?<^I4.S/I#/_UHSI:^(SUOQ_WS'_A67^NF7?RR^XK^U^9GOWX&C/U_MKP3_
I6/XD_Y_P?HO_X4_(6_XB_Y_A^4?^%_&NF7?RR^X?_!5^LSWC=M!&C=I&O_P#A8GB+_G^_2,?^%_X6^XA_Y_1^4?
^%3_*I9=+_+I^VE1I_MIRW>QHW>QKQ%/"WB%NMZ/^&8_P#"G_!>>C?^T?F'_I(4ZI9=+_+I@_M*

[illegible]

MI\$X53Q#M*7PGY25H!_L^_LFK\>!=UKJ^>7T1H>|DXTXVXL_M^1\$?=-NWIR?M,'/M7BWC+P??>I?
%VH>|35X=3TV4VMSOW!PW\$J@HOI\MA\R-U*!_!^!O^">?MS?IK6?N_P!N2\HBWK.C"\3R\IP=*KC7AZL3Y"!_
3:Q7=Y?AM_!C6_MVR^O=,&K?9=R8MHYB\KS,Y8Q\G?6Q^T=^SC_P_!GPV\1'6SJWGEI7V<)>MY/DI/G?
IWF<^M=P'XUJ_XNR\$!_U_6Q17U*ZBMK>&:[N]W5(+>'+NTA?8B_M)CJ.YCY5.GK_>)V3_&7QBA(R^(-
&N=/_L=,!KXV_P!K2RQ\!L49D0K\WR9?M.NZ|HNVKA_BE!+M8^>C-O#NLF%IHU1_A=VAFc958-\$S(I;^>Z-7Z(:IK6
MA_LH?|OPQ83W,4_K.WMGH7.T3D3F6?==2A%+,'V?>0N<9P!N.%/C7_4\$M^4ES9:%XYM+9'^R_P"@WAS+
(66)FW6Y*?>VJH3C)VG=,@|C'9.A'D/M,,D| M&E@G.F_WD>7F/B:BBO/OUPOC.>Q\IA+5Q4N2\$'+T/#:*H\1?
L0_%G1+I5LM+TW6@8?,^TV= MVBPB3^|B9HVQ_P_Q7C?C#PCJ_PHUZIT+Q!!_9^KVI43Q9CD\LR(CQHI5F1F
M(D\5:RC.&Z+K8+!\$8?_BTv9%%?0'@_!A_XE>+M)_M^5_+!V/O,,PVVK32K*=<MQ@AF1\$81\GIC,,^(!%
<^6/@#XP^#RJ=BZF7XJE2|M5IOE/!Z*W_!/@+6_B-K#Z-X:L9=4U\$Q/<"W_MCIW;8\MSOM"#D8_Q90?><\$>
|ZA^P%!\2;&SN9(IW0_!RX#)%!V!Q*)C(/XCY!MB16!_P!IHUC2G,*!Q6(A|2E3/?V?A\H^Q5^+!%GH/B*XDBM-
DLXLH@ZO>?M1GR#(OWM!8L.0%VCY!MB_!<^H^\$Q:U+0K9%_LFY"W^E^9(3BUDSM1B&+
M#;ZR1AFR3M4GIU83V/B/X-^K&IU32K3M?T.ZBNX<-21EB8QSA_IYM&SC_M75PK
9#"OL+|O3P_!^*OA/X:V7#RZG;V%R2)K.F.W:VN(!_FEESU:*!5?>M_M->?I2XWA#W)GK4,"M@*JY/?
AIQ^UH^SY^RIJ/QXT.YUM=;M|!TZ&=K4L(-MFN)?/548_)E%!\O\$G7=GC|M>%U|9_L>V^Q8;P?K-[X^OO#2:
NH21_8_\$?#3=>M<=>7_WGYC7=DQE5SYF,AODK*CK/4XLKHTL1B/9UX\WH?GCIP/J?PU6:AX=U
M9HTU/3IECN&0;T>JA1E^J2!C^NRN?KTX^_!Q:_.EIX6O=2M;KQA<7IY!=MZI<2NEN9K?S5K%_M5S(+!+9H?
EE^6;!\$#-AL=)!TISV/J5>M*BO=?B5^QG_X\MAKX9O-?O9=,UC3|7B5=*DD:2&(-?
F<\$%RBCD|>4ZAKDIX564HSAN<^>PM7"2_MY*F&%>Z_\$KICWQC\+!NI>*8U#1)
I&S%9?6EQ.TIWS@X^C^_5X57Z?_ME_M8!_?BOG()LL#_M@KJHTXU(3/7RW\TL3AZI2HB.G_DQ^8%%>P_!_9<I7
M?&SP|=;WHM_I%M.VIX|BT>H22Q2^8BJ<^>"RXPX_*MCP/^Q:2?&^CJ^Q:2_MH*M_)&,+Q
TMK<^,=&.;PN>_RJ=CSZ>78NI&-2E3?O'@U.WA?POJ_M?C+Q!9:+H,\$N!E/JQ6L4.G>P;)9OX53EO3^+>
=>)\6_@SXE^"NM0Z5XAB@_M6&X0S6VHVQ:2"X_QG8S;2"N0K*?4\$=48_1/!\$W!VIG6O#OO/Q;FS_LE;>Z6
MS@MV(O>B^%_?R,UPF7U<1B_85(-?S>1J^>-/NM>_M/\$5|HFOVL6GZL|/M(OXYRF)\$<L9KY\A#^
=,^<(VL/HOAJOFU34FB>X%O&FVQ_MXW;G?;\$'(Q>R@^X\O)TIPF&-R^IA^OZ?(>E|I@45|+!>C^P%!\2;"SN9\$O=!
MO_+@_D5O;W\$HF_@_A!:)0%8'_&G6OGSQ_X7U+P9K=|HFK67/F_MQ%1G)/0AQR&7|_R_N!Q2E3G
Y1@L1A(|6F9E>^>^OV*_B5X1L|22&+3_\$M1NKJ*!T6WTAY7FA:0D)*Q>%52)9)M+|NID81CE-
WWEI5QE:5X9U+6!%VF^>0%98\$LM9NKZ+3S!_M=|T+Q2R.L2|T#E1O<Q\$X3(1!_1/X5!1^>6X_9S!1^"6N|27Q^K5M?
>,7/5A*#HGDUZ%;#SY*J|MXZ|X=-"Q1\5|V|M?"NDSZHUE_KW#+MC15.W8/D=4WGYOXL_(U^,?A7X'_MU/Q-
K&H:)/96/E|E|B=I3OF1!@_"H_C%;2H3Y+H|S\$Y/5HX:%;D?^>F\CP_MJBNS^%GPA\2_&37)|\VAD^RO\$|S-
<#;.%Q%BFYV/!(+6/_%C8WSK*_W^CC7\WK_.*\$V&?7C#PSH^NV6K>"TL|2LX;Z".YGG698Y4#A6_AOD_UI_P##
MO7XDI|/7+YI/MEQG_TGKSS0_P!JKXK>'=&TW2M+!3^186EM^V=LMG;R;(8_ME"C68V\$K0EIL==3Y*?
@GK\244L=8+!>!EQ_\CU\Q5|0?VQO_MC_PP?%TN/^P79_\QFH/@_\LN^+OC9X>NM:T6^TBVM;>!\>Q:/4))8I?;55;
M_A88^9X|17N?>3|C3XE>-M/H_P!FP>&X_MDYBC\02/!Q_KA_EFJ!>W^>^JYX^_7D^ACPMJ?C+6|!-
|)M\KW4;R006UO_M%GS92PSP>@#"DLW5^=LCBHY9|CSJF#Q?E|K3?O?"9E%?2VGL_L_F\$|L:2_M2|T'3|
DEM|BXE,PD\)*Q_J@?I+M7A^C;P%K?PYUA-&|2V,NEZB(DN#;R_MIMLF=NUTW!QP<_W<_/O(225;
<#2M@<5AX>TJTS_HKU^X8_LU^.?BYIZ:E|&F_MPVVb32-!|JE|=+%"BX)R_SRAF^0.B-|W^4,1UWB_P#8A^>)7A/2?
|OCCTS7W_MA&9K;2H6E&(R2RHZ*Y^W%:18Y&_/95.PHY=BIPH-V/_*Z|7/A3XG.^#
M=+!7;ML|HH.I3*MO=2|Cv9BKG_4A|>UDC+;,>^>N?|WX.ZQ;O%U%UH.C/6
MEU:VC7DLM|+!\$B|71"B|48DYD^WJ^>V\CU^SOJGCSX->%/!|A>|M8OI_N+4K/
M|JCJ7@AM9(1S&A)D^93|W^6MH4>>|Z&_R|BJ.ZG;X?_6BNX^+WP=UKX*^M)(-
"UFYM+JEL5O|>GLAD(C9W3;N=%;1_9KAZYI0=/1GB3I3IY*J|X^G5_X_M)Z_\$E@/^>)OX7^M|HNA_Y^J#4/V?
B38V=S)?#?>7_9(K>WN)1,9!_""T2_M*V?|HUKZ|_<!:QV?@AXB\0:#?MIVKV?V?R)MDB=&EU;-:0F01%T.C1&
(1XDVDA"_P_A|UW2I482_MLV?;XS_Y5A:D*%6\$KOS/\$_%G@W7O_NL3:7X@TN7|KY0S>7>(0WRN4WKCB2(D
M^YTPIV^PW5B5^C/I=G@FSUKX^S:T45+|0|V^|AD51N822>2T>>NTF57QTW1_M(>H%?
#7PK^\$/B7XR;Y/IWAFI,GV5XGNH@;8K>(L4W.QZ@D%N/F8|H|L<:ME+EER(>S#*ZF^Q?L(>|S;_%T5|&Z|>P;|3-
)|N|ZMI^!U>2/_4V-A>N^|_M_1QK^;UX+XF+;EX_UR|T35K2:RU&TDB>WESYL9_RNTI&#&#G=_\$OS+@<5S5
M:4X;G%B,%B,)_%|H|1TO/I7M\$G|C_C|_!5O9>+L;_JMI>64%;Z=8K4(ADJDB%N>-K8KIM#_
&^_B=JEG:75G|HVCER?ZZQOKHM(G_?F.1?R_M>CZO4!^5+;:/_EV?D=%;_C?P!K_P-=8?
1O\$6F7&CZG&J|MGPR3|LH;D9KJ?C^>?7P_-L7_(2&|TNIJ>=Y_TN2|HOE;|MZ+G_6^I
MY|O/85/"UJE.56WN1/3|BW^QC+!)_AKK|BN3Q>NJS6_@V6<6EF&7F1,\$F=M0I_Z5W^E?I9^V.H_X9O4#
(+67^_Y!7Y|>^A;XK^*5D:~%)5)88U_MGGE2;..V=OS2,O)PVU?XL/TV-MZ\51M)0I(QO-
L#3HXJ%#&#0WB%|6|OZ|H-Q-H6EP,|?RA8XXU^Y?87=3(P0.V8|WWD|4QS\$=?HWA,?@J7_M@/X>(!WVNU?Q#K\$-
Z|RIY;V6:6+RHP;HK;0JQ9^3KN!</_B|>S+XG^"A_M>VUG6K|3|H6>X2Q"6L?>S\!M;2L6^<?|?
P|U#Q))K=A>WNGJUW>_9"C|K8%RIQSL5PA!G;R+T-VU=WSS7_MV)\<|XXZ#A|J2^B;7-"N-
*AD1;R|TMY5OJ^*218EC<>2D87,B|M@>3^I@Y#.M#K>^O!L_\$368-
^V,NH7S1/<^WB|SMCQNW|>U4'(Q>^RH^X(RQ\$(QDH4_MX.C,+3C7A0P)Q|TQ*(Z^B+K|A?XBV|K=-
|NT&GCAIR^&VN)0S2?W3NB52_M#[NM>)>^O!L_#069M*!06_NGWZQ):6'
MJ4|SAK8*OAX\|6F8=21UZOX1_9A|8>_OAW^XRTR73YK7|/-|D663|5,87=
M"B1B)DW_8_E^>G(S71^>_P!BSXAZ|HH|)FTK2Q=0AA9:E)(MS"OHP6)ANZ>_M_A"?
EHCA:T^ANLNQ4E^V=^_CJ2.MSQSX#UGX;>)+G0M?M_LM_#A8V09BG_MC)(\$RM_=8@A>_&#|RNJX<=;G;5!FA
M:9\$A0Q);"W\$C8V|D|4WD2-V5S^V#ZR-ZG/RI+;J>_P#C%X0N;B:2XN9MTFNEM
MA'9RR,V|E9Y9%>7Y#Q71>&_V0?&B;0|!#6+/4M\$6SU&U@N+>.XN)U=\$=^&MQ#|H|KVO|N3,?
POTHK|O_V\$C&1_U|SUW+>^TC\|H\$TZO_L+Q(IK_V=LMO%!
M|96K_Q08Z^5Z^E7HX2C5|FXLT|KT,^A,1^E6B^4|W_AB^QWT_M?P|G_KXF_\MC-2>^1^_U_YBGA_P")O\
XS7TK_PE>J_!*\$X_22|4|6_X10^T?M^D+GS_M_LWE;IG3&
IG;7QXOI47Q,)/BB4_|N=K_P#&JTKT<%0Y;IG7BL+EF"4>:\$0>
M|RWX!_9C\6_\$+PCL_B'2K|2(K\WX2|ED65=CLAX\$3#JE=1_PQ7XZ5=W|H>'_M_H)YL_\HFO/'?QU\<^"!|@T?
2M5^QZ=;|MMLEI(\$57)).DC)Y))_\$U|L?_M7Q3J?C/X2Z/K&K737>IW/GE|B2)5+8F=1\B8_P
|Q6>\$HX^%+D463E^>R|&+ME2?RGS8W|&CE5R=3T#_O\!S?_QFK?P3^>B>.9O&^FZ0?/K.ES3:4%17
M|J'3|V7(Q|+?&7@?>V?O)CC&=^>)#C\|2N1_UY6O_..K6_9Q\74?QLC_MO=0,?
2GTSGB|H|>S4^F<^E/K(427GTH,Y|^69H2^E/CIG/MI3XZS_L4T41UB;\$D=6(ZKQU8CJ0%Y|^?3,?
2GTFIB@2^E/G|J3ZY2RQ4O/MI452^E|H|J2_HZDCK"8\$E2^E15+SZ5F^I>?2HJEY|R-1|2^E15+SZ4I
M@J2_HZDCK,4"2I>?2HJEY|^@T^OU8J^5BL@".K%5XZL5B:A'4D=1QU)'4_M=#X%_P"1FLO|Y\T|ZID_BKOOP+_P
C-9?|S_\H#U|)_%7|EP/_P_BV?^MB_!_8GT^_@CJ***_1#T0HHHH **** "BBB@_HHHH ****_.^O)_\$O'_M&=0_>
2>2OR+K|=/CK_P_D2|?_/8!U#_TGDK|BZ|!%?&C\ZXI_BT0HHHK_MC/APHHHH **** "BBB@_HHHH **** "BBB@
HHHH **** "BBB@_HHHH **** M*"BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH M ****
"OKG_@GW+_P^T_\$K>.;Z^T>UM(VTVQ>6%&D>9|KRLIW90JF%)C<M)B_.*V?D:OTT^6CQ?

LU LUB;5!J2;8RW^H*QCMFN+MR&6\$RIF5GSLMU<;MB=J|<<+71AX>_P
YI+P_0C6QJU3X8^RK^VM\1IM<^.;H6I^D^A810)/:WX M^176197=,E MPD3%H=J%=QYEAP1G0.WPZ.X^(\A;
(X_\@5|1^SO^TMI MWQZ?4I0Z5_86KZ;JR/8R7"3F6-N-ZGY2=C(WR8&^+&
<^YDJS6+SHR1B"7!4(Q8^8D>_RRY^8LC^K7J_3W;;\;=5_1M \$G_405P4XOE^BO\&89NE_:%4H_8U^;H/P
MCNY^A^Z^UG.1^E>U2%)2/;A?HJ_6U_P37BOI&?A RU M_P#127_7?#W_
'=1_G:UI3_@2/PW_(CJ_XO_D3X_P##OA^YA5^(I(T2%XTN_M=40H=/ADNEQ"))7V
L5^8C/:OTI^ (7PY0V/PGM_"7PEN=*2(RP>==/*H@_M@PY79;F)_A1\;?AWXR\SO/XQL?\$GAN;
I2Q,%)C,32QC\WG\H4)SDA /GS\JB.;X,?M00^*-\$EAMKFXCMJ72." H1D M,ZS(^V0;Q+Y)W@; WFMG,3G-\)^%/VC=
!=K^Z;?%2^_M,BD^2I(U2_NK2&WS M)_06_W\O;_9;F:+\^?7Q ^/1\(>_1^<^FG@A;>I U:YN&FDDL%=BKVIR,0
M5>1E15/W#(28\HJ2DN3D47A"EAZ4E\VF?1_@A;2^_P2K>;2_M/=%HWABZNB+;6UU*/I597^R,4VF4)M^;-
A<3+@2|P-U-^)|!*?PX^+7A:[U MCP\$FEZ5JUTQDM=2T>;S;+1ES\$R_&3&J\$J03&0R;FR=ZGY_-(I"/C|PW>;
M/I=MXMFTMP-D/7@2I,P48W/MV\^=HSMKZ=91\ZS\$?A?J,CB2W MT6,SVLUN/F^2H^PKN^M??
W_1/7#?!G6F(ROUR4DGO_M^;U+?2\$#Q%;>*/OB;6K821V>J;O=;C1%<9241R2I\UW(#C<.V>E?=/!0 M?
\67UG_L_2_>DJO6&'_B'^9^&G"OV>OQ^Q1\;^!<_7C_(I_XGNHGI_TWDKC MF=F#_L2&^ID|><_CS79?&;
)+'X^_[#NH_<CY*XRN:INSYI%?IQ^<85^MW MOJ^',GQ4^&FK>%UU%_*2_\$);Z:W,Q39+^)D_.G=/7OFOR1KJ3?VM-
8O_1^MS\XFU^2KZYTR_C^QB.ZLYFBE3-U"IPRD\$9I(^A(KMPUN25SZO60AA5-I6_M^2I/G\H
B>&&MMJGB#Q_.B.RMW206\$>GI%)(DBG\$FIY=Z\$)M9!@D=3VJ_MA^W1\;I.N=!M_NA:M:WKJ8L\$\$_7R9?2
M%\$SQUJEK/:WGC3Q#=#VUQ&T.T_<JSNDD;##(RE!%2^00>#FN3Z|B>2R|#[K@#!_M|L
#*B551AR15CBK9MAXT9X?I0Y5/I?JO_#KQ%;>\$?V;O^"OW:RO9Z7X3M M;V:&\$;I&BCM
Y^J>;X^X_E7Q\6/VQO%/Q<\+ZSX;N=-TG3M#OW>+&^9H4_M697B&R;=Q"C/R2-
VQ7V.Q5OV*0!CCP% C_RGU^83.S^RLQ^LQ<@G@L>I/N:U MQ\$|WK?
M_EZ>Q4_Y'\$A_\>/_VEOB#X3^/VM7C>)+ZXT00M;GMTT?)MKB T2>0>0T0_M3:3M5H_-(+9V'/
KZD_.*^(>M_#/X0QWF@W)LK_4K|=/>Z:Q+'\$3^=<A6^69XF^Q55T,8VWIMY>A5_85^>)WB3Q|HOB+2O\$6H3Z
MK^H^T+VEW<3/-/(LOG;A(\$SD@>6=HJ3GMLQ?>_5N/A\|=O\$|UX7CYAQ7T|_P3;55N/B^0_04TX\$@=;K;%9/P\;Z
M;XF_3\>OJEE^>?V9=ZE?6GG^VV_=;X^LFW_.KYC8W^D;,%00:U(0,Y4YXS_M X57U4TDB&<_8P?F=POF_M\$^R@?<
4/Q-T2US|EK7+?Q;%|KUF PW|LOEC^H/MT4 E)7RR:D3Q|N/ER/2O_M//VA/B^;K+Q_>+&OA_X9O(-(|+?6H+\$W;7+<
D\XCLIBAC|_7\$>5ODW\K M8KTIQU_/_#|^O#Q^Y;7QX2N\I29C^D7V-O.Y0;AQW1C^UA%QYM3W^*0%
M,57A)RDU^5RV?H>)/"O^U? M1"/>DZ8UEI=PUC_<LVAIF_6-W21D^2HNUB|L?KE5IC_<QY?AD9UCT_MR7_M-)<
I>OBGXTV?&Q|CHNNZB|I?Z0I93GR48L^K%8JOALKH.A+E/I_@G_/_\$<
MYGAU+P!=27\$Z6L1U.P=E9Q^E\$F0ECA6O(=W5X|)(O\$WPR^<(GAO
MQ1&LL\$>FW?:88D\$LSVV^L^U3QDQ,V/H CZU^I4FFZ#+KUMX_P#M5N/LVC2P_M?V@KQB"6SD;7>TF.54Q;E.I:|
(Y_BS12_>0%EW+FF#ITZN|^5_<W3Y5_P""M@7Q*FAATIX?26K3PPW4/HWS^C0(B9(XHP5.&
_*1W#)CB)@WRU\75V^Q<|_M3?SXB>)/%\$BRSQZC=O|FAE013);8^P;E^&1\$JYS_\$H|BN/KFJ3YYGR^9XM8
MK%2JK9^Z%?A_!;9^""L3?%#JF^Q4;I:ZYI7AUM82|EC_MOC<>&FDD:XWX?/P9U@?A_4O_/BA^R=44?&
M^Q9:KIWA=-NPOJN;VWF_>H&C>5W5BIDJL.HS7-W)0AI-7/LU6KTMH>P M@I?(Y?A_:D2>?<
%7CZVO/AW;V..D_V7^+_&?8M9QM<+)(3N0H@+&%0\$|<_M_#M7V|^OFH_X9M\)^<
RAO=O^3_2YQO7P;XP_9L^)'@7P|?;|KWAL;IENR/_M="^M92C.Z("60Y<<^U?>)/I&A_R;X6^O>#_RARY-&O\VA4J
M5X\KE';8^_A|<T)1/\$WQ^<WU|XJU.&VU/6I2*3389F2S6^61(V@IAR4P\$ M)&<A^G=G?
S7O/;I0I05OAMX;U;R7=KJAM5GS_RSF@D.ORI V/EIX/UJ37QI M%<
(UC^_@)T4(S:HY+*,SYGCS7VQ_P4+X^#_BL_&7782#W|^SW%^+JWUEJ_VSI5HW<>_".0/*-L9.(<A(MV_87Y>E?
3/C^SN/VBOV6BNF7=K+J>N:5;W<(LJK1=-1&_8PC+|03)&8_F?Y;_M-9>*:;%@_W|)"7SN7|L=7_P4E_UGP|/MJA
I20H3|HCQUJ_PQ^<#_M/B3Q%HKHEIVL_<#7(WH&DG2+=CID^*1|XW<5|_%)>)/AZ/4?YVE>|?M2_M>|4:??<
Q+IN@VLE_JLT,3PPP|^7V3Q.X&>K%4_*2^=CMYIQQ_=/XN6/_M_*2?
+GD/OZ^=_;M.M:=Z%HVF120^*K6KVS7#S12OHL:E%W8W|O\W0_M?MP?%)M)^+W@J^3(8;C5?^N-
5S*)5CF=UD\B5\$^92%AC<@^YDE&_8!;%=4K_MU3QZ?M/I)DL;OS^L/I2^BY/V<_@-IR>"I6/11)?<
P6%|H|KL<6W#3/(<D5P|,(<MG#%N2SLY_|)/SG^RI^T5XKL_BUHVD^(<_%>H:QI6M.ME.NI74EX8I2"(#^R=K
MM(ZHQ^R+&\$@A_R217I1OA>;|HKX^V_YX\$O(-)OH;ZS\$11%NU&Z;XRAC^J/_M-<AC(9^"NW)KYR_95_9I4ZE8-
(UCQ#X5U^2=&T.5+UFU_VFM7ED1^\$(CR%+M\$2JLA^X4(W)"M^C_M4=8BN(I_+0^C?
9W0K(V.KD3D;CSA%)^<COVS(U_X9K6G;L+;_CKF@!_2O
MG7<@H7XTLI05>=|@FDDO=M;J>Z>J0JLXCVH?|L+&S\$=0K1MR^17T7^V9_MS^S7XK_IWK_MYQ^<G|1^Q^C^<
'B/I|XHU+28M^U2;RM;*OE;&W^03/Y99"=LVX_VXOBGXUHK_1B?JRAE_MW41M(X_X^)#_L.C;
MHP:/+QE;=/+;X.WH??|VB66I?L|K?W4;O/87=G=VVS(Q^9EBY|1LE;CU_M&^V_P""=_B;6-O6;CG-)+K^7SW"/C5\42
&N,8XKR6O7OC|!%>@^/O^WB.T+4(=%_MF68:DT7^C;_M9YG:%MPXV|GX^5CM?190/(<^I%Y\|F^M(UY^WBS|
OV?6;P3^Q/J&N;*IM_M=8^P;MJ#3^Q>XA_L2;R.X@B&SIP;_/WHNW^T|5H_L|+;^+/@/XH\;ZI
M="^B^WW..VF^*R;VTL>4V9W1J|SF9@%P;LQ^)-2;GL.GPEO?^OQPTC1KZT^*M6^G3F^U2V08D(6.%D\$D30N%8|L-
L14KYI+(<5T5(^TY\$20XZG+\$T<(J7VHV_M/MKX<_*OI-OI-TDFHV-NM|MC_J-
(C2);JZ<,(P+@ONDSL@G.G0%QV6OE/I_MBOXC3^V^V9?AWRW4_M_P|L^H_C_RI75)PYK7;Q53^T^I&FZUO9>1SWI?
WPUAT;Q?I7C.VBF=-93R+N0_MQR>7"/_JMNSMW0\$Q4(I@K1_2;I9_XY^D_P^|JA_UK/_ES_MVZ3_.\$O\$O\O^A
R)\65I%_LA_PWE\92%^/7;Q>;PT%3<2;XT?;HJX@CP_M6/(R^H<A&^J.YKYTKI^V_-*?#X^_MZRUK.W.M?
>36>:9\$7RK4*/^R_M56QM\I?7.WR_.88X-8X>/_\+(-18QEW\?\$>/&O^"WC==0\3Z%X2AD+06_M-K)>7T<-T71D)H
FB4.B("K-D@3\8_CJR^*V_1W|+=OHU_6^V^Y_MF;|5+#+>6YVI<388%W8QQ3%&.2&4\$D'=7DTW_18S.&X4#
M((^9=V|CIN|JN/G;|K;X6?X_>2>2ZFTCP_P"))4OY|JH&DBMGDD9;IA^V_M9-I^G_JXP0^P;^S|A4^*^?_@?<
0=#^&UWH_P#9ZB"?A+VNIB6WY62;)N_M&#X^E|=I5@%V^I0&QA&W-
XLW66K=*UY\@O)"1^JCY0L;1R^%_@^IMQM&T_7PL_#^*?AZXL|10O_M^<E1^6^T+P|+^9VWYWN9D&XC?NV-
(J^NU;X_XUYU^Q^XX@^!_Q0USPUX@D_MBT=M66.UCCO(V\$AO(9&5ODG^OAYP0>2^T AN&
<C@F;5;G^V8>G.+IG^K^J_M>I2^X4^&SXB>_O\+^+;PYX;A@^6UK;ZG=6DLK%09#^T49R=XP/1_8)<^MK?#?
PQI7ZQ\#14\$_\$5=+UC59H9K2#4;=&N2\$VJ8H/-5?-EC<|MPX240YW_MY->*?M6>#_C#IOQ_OM<A(C:MXON?
#M|';M^9Z#<3.EO.\$VM&L\$3EE!\$0D+A-N_M9^OWCD^3|K5|N.JN@&D1PMN3O^4_-M<(S
M@_*6S5\RC/X6;5,0J5>JHT.C\I_<=_;SYI2TF)O&MEN\O5H;X6.6Y4^_M9_OF+M6;_<C.\$?&MJK>C2RR2V|C8W
MG_<O\$(<^_I^3^'(RKJ|_Q8IO^EYVUAU?|WX2_\$/QL;I7_B743Z9(\$%_-7+6_M4CNX";(I24ID
D+&^C8;I9%50JO|FCXJ_<KQ|XR&@^/?""%VD20RW\$N|ZAH_M;+PP\$0X58YAR(_Z_P|9PI/"5H3AVE^J?\$_Q_0:
M_P"/&K&C|XJ-Q_|I2-#<K<0^"2_Q^NLM&^PGR^;U_BRW^<Q@8_#_NG_MG/S^V%HA^I_ZRUKYO_?32(C_Q?
OH!+QK^!M3W|(Q3H4=1G=GE8&MLE/@_Y_MZL_<^?V19)OAO^R)X9I^7<_W%S/_&9H;R^I9I?3.IKV+JN_MKXH>)/
<C^&I^A_ZC<4FKS3/=7EO^Q\$S11AVB-U(|@W8|NV/CWP?_Y/_MXN?^P_K/_HN|KM/^"DRAIOAZ2_3LU\$=_Q-IFMM?
8S:/7A4='+0XNWO?_(GJ_M|^\$GC+7_!Q)M0?Q+J\$V13V>K3VMK=W\$K32-"AD&|F))8^X&>RCTKX^*_M&CV?
AOXF>+^TY6AL|+5+JSM+;|Z1%'.XR6;^+QH7W'_P3R15^""M84#=_MKLQ;I_U_T>WKXK^<#^_A/^VE95OX,6|6OK
MJ;JY|N|IMMF1B4S+&%SZC9^W^J_UX/_,\$_2\$V17OQ-Q=\$N_5OKC1K71)IX_M_-EN^_WBD-
Q%FTE)VJQWOR;GYV|37T^V62O|_OBMAPW^A(FMR%7WXD/T%;5/XT+;C).*-TKQ?KVF;?";3R|2SU.*)-UK"QPBL

[illegible]

M3-A6?4+R:*UM(F9%\^5CM10)-@9^"PZ#FOOO\;K96_P4_9^TIP/I#R/=M7M@NC6DDSKYCG6D,*L{MY?
EIC'MCYV,V5QBOA;P/X\UKX;Z1%K.@306>I+ M8(+R:&&41(1@NHD!PY!
(Y(XZ5>^(GQ9)5_%BMK6Q3JK;JJE"7_9=I#&C8 MW.L<8 #G R1SP*UIU/9P/5PE.IX/"UHTW\CD555W8-&
HV\U^M+1161X!F M\^?VI!O^PV5,WNBZ!8Z)+8RW\O^HPS,\Q1(5XD30&:\O\X>?%\$3K_&1X M6!Z?
>MQ_P#)??,14\$Y(RH1)-H^AVICJ7E,VLHDEF7RYD+2.G)C^1*/AG^V)XS^%>@>P\;-78- M)9:?
YNUKR&9IG\R5I3RLB)PT@'2O"R S;B.MQS!"2/U)_T!6W 8;GGZD\$ M J!^0I^VF3_:6+Y_:^T?Z&OX5URY\,^M-
UNQ\$,M_IES#>Q!%/,C+Q2IU7" MXZ@#JJ)^,I4'BWXT>&;+1=>LM%BL8K@7A?3XIE?>(I4"\R\WD%>_.LBR##*
M&&0>1GD=#2A0#D#;ISG?6CVC2LCFIXBM3INBI^ZSU#X/_M\$>+@F-1AT"6WN MK640-
INHMA(^3DY2,"1&#^IR>IPWJU.W?&'187Q"8;G15W<26ME8V%U!> M16&GV116ES-!)0T!3>V<^69-N
&^*3Z!0.BG^*QXZ?D/RI=QSG)S2\K M.VIYABJ<%2IJ^5^TWOH_;"2_@Z&?&AIUL=-\X1_V=;RKN\WRMWWI'Z>77
MZ_M>.,M5__OQ^K^A7S:~JIGIG,&VVR.OY-S\$A^5P5/#\$<^M?E?=-VCWFWS(5LK5_NUA(GCBXV@_A6U.MR\ISU
M\FOLH5IUW>><^QZ+KG!>GQ)OK\IMH8=&TAV_U=[8V4AE7Z>);(GZ5H7UJ3W=Y<2W=U<2---
/Y=Y&)+.S'DL2223R234" (VY?E;^\#164JCJ;GC8 MC&8G&+EK3NO(I^# P"T-XQ^#W_A_X1^IC.RNI#+<;5=J9!5\;-
P5?F0@%,> M5C?M7=G KT+Q%^W1\4_\$5B8+(;H.9-WVS3I3?)Y?I^>2/I^*=R\,NTL2O!
MW/%,DC60Y=0YQCYAGBCVU1%0S+\$TH>RIU7REJ^U*[U.G0+RZFNIN=S)-/(M7DD.?
H21^I/YFCVC;,>)KT?;0IS^,I@^#W\4'BWX+^&W1= MLM%EL9;@W@?4(IE?>8HD^2)WC->;>*M0X\#5\$6.QX?
@.3I\$D?J3^9I- MB@2*)/O?>Z?7J?S-'M>YK+&XFI45;<?1IQX\;2^(7CIPY)HIC1\,L MKN)HKR2Q@823Q-\$4:\$^<:
I^6"9!ROS\<\$5X10>2">2.GMT_P"Y"BESWW,<1B* MV)?I^?220I"GQ2MO!"Q*O\ P!>R)#9>(HHK>*>0J)%W&&.)
Y=5V\I&38 Q M+M\$%(I- P_5/6L_LG?_QCJ.@VFCZL-XEBCU**74H&DFMHHY);/C#1&:- M?<
YB/FI54!4S7RS8WMQIMH!>V<MK>6IK+#+<0.4DC<\$\$.K#D\$\$.@CT%:'BCQ M-
J_C+7M1UG7;HWVI74WG75W,Y0;RH540#H@55_'3 I5MI.T.3J>G3S.5/##*
MAHJG+W9=#H/BO\5_\$/Q@5)XAU.VM\XVT-HB6 "P^2CLWR\ANSIG;&3PS\$=-M*XC;/2A5"JRI%;D@#@8_E2UC?
J>34JU*M3VK/,_AC^UMXW^\$OA^V-Z9I^ MEWFG6TSQF^MY7<1NQ;,"MD3(W\$GGN32?#?JIK7Q3^J/UBRT'1_#-
GJ6JS: MA-.R6\VRWFF"@0+I'(J*%4!R *051&SLHYM(.PX+?7UI<#TIZ/3.V&9
M8N%OWCTCNO#7Q@UOPS17&^(ME#HJZK-<7=Z)D8P>9.)01CS-W'F?WZU?C1 M^T#XE^_WIA?
)#I^G6QTWSO+.G6\JO-K=JZ1^GEFO+RH9E)4Y!QT/K2_ MW?_9SCVSUQ3JH6,OKF(=-
T>W6%>J>)/VR/&^O>HWPBFV>=(T6^LVL!% MIMM(KPVNS:47,C1C"9!&\$.1S7@M-6-5;<%;@Y
YX-1^M"J-.QE2Q.(PMU2 MEN+M'I70!?!
&FH_#+Q9I_B+2MGIHZ=AD8E.160KLCI(IV5S7MG\5^@_P",7BSQ1HD_PZOIV/1(I)DGM=-U5;&1
M;@RC+2@NA==A4J_3_JW^YN^?AJMI?+Q^7ISTYS_#YKTIPI^TK\2_I&C1Z7 MI?B;I2Q##R+>\C2X>/ \$2M*AQ&
+1P.U=4*RE_\$T/I<-FW-2G2Q>O-U6_W MGV=^S+HGO2"\Z/XEN_BMKH32(2UQ;IK%^MS-\$JC+SFX\$C\I(=O)+9P02
@IW_ M W\./BWXXHUG1K(6=A>W#&+;.&46I79M\IE\$P9=K2D^G).>32^./CIX MI^)\$&98K21
VX.T,>%+@@\$C(P/2N^R2I4=)))*JCG.? MYG\S652IS^XC",RI8BC##T4U&/5GOWA\JN+XE^\$I&-
A<3Z7KL<2A8+K5(WD MF1!=\$>Z.1#+R;=S?O#DY)K%^)W\5GQ#^)^EE^HWJ>DZ3(C17%EHLVJ'GSS/%3AI+V
MKY3Q?ACI;O&P=(P-S>+M9FBB9S+)HPN^UN274E7CSM#%(L.XP).#&:13UOI MO3XDXWMG>6\,6C:0IC\$=
I8V,AE7_OI(Z?I7S?L4"0!0!)I_CIW7KZ\3^9I5^1 MMR *WIX<&A59K85\,51HJG2JLI: 9UA"W/O?
^_6DPW\S:C%;7OIMZOL:JFIF:.^O;QKVIN#^Z0SN=WRJO\>?K6OM/W?)U.B&8 M,UX MI2%03DC)SG?<
6LTVMCSL/B*F&J>TH>Z=WX:.^&M^&?BXWQ%LH=.DU6;XN\T0 M3(QM_G\$H(QYFICS/I:OOH_:\2_';^P^<
A(=ITZV.F^=Y9TZWE7=YOE;O MO2/TILUY>5#;I(1*G(.A\7^I_LYOI9ZXHHI6_KF(=T>:W6>P?;IJJ#Q M;\%#-
IHN@V6BRV.MP:P/J\$4S/O,42%>)\$IQFO-O%6N7/B;O/J6MWPABO\3N M9KV5(ALC#RRIV7#9Z
G\ZQRH)R1DYS^/K2*BQC"J%&2>!CD\31\1M69G4Q%: MI35%SIU#JIT^7I87C/XJ^I;_P
,ZI8Z+I8ZAY6YK;&99D\N595Y:1TY;C\ M7A=1_9MQ&3QSI"2/U)_TE4ML*EB*U\3I4I^>P?;IJJ#Q;\%#-IHN@V6BR
MV.MP:P/J\$4S/O,42%>)\$IQFO-O%6N7/B;O/J6MWPABO\3N9KV5(ALC#RRIV7 M#9Z
G\ZQRH)R1DYS^/K2*BQC"J%&2>!CD\33\HVK;=3\$5JE-47/W4>I?S\$H M3QG\5O-I_P"&=4L-\$M\4/*W-
9PS+,GERK*O+2.G)C(Z5Y/X\;ZM\VM=L)=
M\WKZ7JHMDI,RQNSDH8B=D@.(R02,^I8;#T;U9H/8G\$555G/5^T;KW\>/Q(U"QN\6.'1)9AB;L;*OR+_W\I
MD=/TKP_P-X\UKX;ZU^K7AG49=&U14;,2_1L9U.T\$&X(W(A\YJ#U K\7Y&W M+\K?WAP:5790H#\$!2
NX/3G/X\T>T>IRIX\%5Y*L=K'TXW_4^*(K#^ID^ M%QVXM;C_.2^*!>?%Q\A3KPWOBC7+S7+A0PBB:10EKN
1MD*85R>O>?QYHJM4GH%?,575JU5M>1HG3\VO\&Q6#W_AK5
M+1+>OU#RMS6<RS)Y1WGOB^_M_C&8;WKL&G0A#BQ*Z M;?@O8WVG:\$UC-I\$SIQ9:A:L5\$S\$O\<
I*E).X1AC.SGI7E 4*_.#&.G;TH*^K M@M@\$>F*?M>X+&8E5\;*?OCJGO>;*V7_!CM;RULV-OI<,EV9=I8E?IN>*.
QSG)S_I;\J?M:US>& M,Q;?L>?W#M?AA\7\%P;UR?4O#.HM#-LZU^WG\2;RRN\;"11'=O\ 5WMC8R&1?IVLCI^E?-<
^Q0)% \$GW^/O= M>OKU/YFE7Y&W+\K?WAP:%6FMAT?B:-4Z55Z>1K^*O%&L>-Y\ #8/C M+_A6?_"?8-
%_L;^QO)_RIOA\LWD^3OW>9LW;2FW?=[J;HP-N,<=,2AC M^5-5"8WI8BMA;^RGN%>P_IWJ+Q;\%?#-
IHN@V.B2V,UP;P2:A#.SIS%\$A7 MB1\9KQZD*^G)&3G/X^M".6Q.'Q%3#5/4/=CQ5KESXE\3;CK5\8K_%^*X
MF09\$C^2,/+>093NST\IYTWPOXDU7P=X@TS6\#N?LJ6@ICIZ\+N\SVLN;GOJ?2^G_M\ \$BWL MI6%M,T#4-
D.QINX\$E&GF+IYGNO(2?^>3?S\XV>,OC%>% \$NM3RV^X.NF M6XV6EOB0D^6_K\;(OD\DOQFN"RG0?D*^I;
M5#MK9EB<13IG4JL\X^?I8_Q ^&2A6U\VOU8:M8YKN(I-4BFFD6^!IL2KE M5_P>@Z57LOVQ?
BE>.,3XG&L07J^3+;_D3\$BP"M^>7\TF/F!^57W^9CAR1 M7AZJ(V=E&UI\AV";Z^M!12_MV9X(UB"+\$/*=/,*-R?
GY.2\)\8EEVGE>.#TX!_0G\SO."2.">OOU_Q/ MYFG\1DPQF)I3=6G/WGN=;20B5KWQ<\2?
VQXCN4EO5C\$21VINJOVT0E+B%W M^SGF3+=Y*DV*1&"H(C^YQIWI\I.@_(4M*H6<=2JZCYF\3W3XF?MB>,_BM
MX'O_SJEAHDP%CI^E;FLX9EF3RY5E7E\3EHR.E>%T^S9\XY\I21^I/YFB MASON;XC\$5L2_:5YAP5VOPQ^+7BCX.ZY-
J\AG4F@GN-OVBWFC#0WBK(66.5>G M"B0!DQ(-S<\FN^I-B@2*)/O!>Z?7J?S---QV;..5%\T79GTEKW\>WQ+
MU"QN\6*/1)=O17>V-E(95^GFR2)^E>--^*O%&L>--NVU#4;F<375W/ M(54.1A\$0^I
I?R*%>1MR_*WJX<^&DVCT'8=3I652HZAUCX&G\$JY(GS(M4;0I80O#G\I>F;MI#8\IUF^&BS+8\I@2#U&I\FODQ?
V?B0NE28A#HP MO/L_E_.OL4GVK=LV^9MSR\^MY>W=OLO7G: MC\$=_/I_";XG8^OL\IG? M8396N?LOE>3Y?
^J\S;MYWYS7FO;&..IOQ\WK8GF6A\F-SJ5106&DX^IV-7Q M)XBU?QEK^H;UKMT;_5+F=9\FAFVN+6\&^?3=0+M
L^#(C@B-N(0 GN%(A6O,XU7T'8=/3I2JE'93E?8\= M/R'Y5Q\TKWN>#3Q%;C5\K3>HEXF_;\$^(OB35M*OC?
Q:9;V\$T<^=GI<;06MU_M)&^YO.8R;V#H<&(R;2O)&YWX\$?SQ\(\;3I4Z6)A\$=.1E+>;Y6\IT MC\I/+<
>7\I\ZDQGI/7I>M/VU2UC;IG\357*ZKMZ^NOQ&_;\9?%7P1?>'=4T_M1(-O_)W&SAF69-
D8R=6D=-L9%;K\V<_7ZD_S)_U)_RS5.?(IRJ@?2;CVU3<)X\I\$SJ*M
MI5\ZCV7QC^V\A20%VH6.GJ+H"6LR75OHN8HY&0DC\$=I\I\WK\A/EG R#6 M+8OCYX@^_2Z6/\$_MIJ=+X1-
IR;I.S?W?>D?IY9KS<=<C)DI&(I+V_..8S M^0_5-M'H_ZI;S\K;UBJF.Q56.XRGI(I0^G\IOWC^X-6E_8Z&UE\I5P_F&S
MU"U9@9"(E.Q*E).X1AC.SGI3?BK^T%*XO^_5JEEK7V&WTN%IYM=-.M64>;ME3S
MLL7DSMD"XSLQVKS%E#+@C(I#1\$H56_ W4#01H6>Q/US\$^S5%SIU^N/Q\$_-W M\9?%+P)?>I3T_1(-O_<
"2TEG#.KILD63H2.O6.CI7F^@WQOK^PYUF/6?# M=)_H^J+&87D_C8SH2"59"!&54_50>PK"/+;B,M_>H2?
YD_F.E#\$!0"0%<I MI?2B=-I-W">,Q>JLJYV/H>I_J^ (EU9W &G>I\EDAV\7%O!_YF_U3?(4; M\17B7BIQYK?
Q&UJ76_\$FI3:QJKO"!93Y;M#&.Dj(C_LQQ_M'U-884IV<I MV.2V.33E8D;"20WWO?

```
ZUE4K5*BL:8C&8G$QY\^9'MGPY:P#8_#+P+9:I= MAHLNGV/G;9:N&9G??(TGWUD1>L@'20+O#&N/X9\2?K-  
FF^TZYBO4CE/IMG MC;>%QIX'Y5CPDPJ8<->'7J#_-#IA4JL6&&.1D'GU P#^7%9^VF|7Z]J8G$5-M%3I  
[X#UKXJ_M>( C#X;CT;7K32X;WN!>>;A@KP_QKH;=  
5^_5Q:6EPIA^@ZG|/9OM:=JND7|HGWIJK<=>=.W.+EUVA2KI/U/8@D M'V)J&:JN-  
0NIHJZGEN;FX9FFFFWF1 [XKS..H@H= MF9AN+'))YR%G^Z'5I) L.^"8IK7-8\67.&VWM%-E?: K2"4 M@%R<\HR+A-  
8VU[#]:7,+2$1.W1;7<,<,% MLPLIZ%B>YJ-55&MSR.C\XB.&KQJ2IU'Q@:\XA?'O5=5MY6^QEE@M3.Q*B!"  
M45UW;<*^Z^:Y+\$1237&\E18&U5QJDE5I#. MUJNHQI2^\E15+SZ5R&CZEY#BJ7GTHF66.22GTSGTH?  
2GTSGTH0!+SZ4^F<^E/K(427GTH.YI M*269H2^\E/CIG/I3XZS L41T41UB;$D=6(ZKQU8CJ0%YI*?3.?2GTIB@2^\E  
M/IG/I3ZY2RQ4O/I452^\E/L/J2.HZDCK"8$E2^\E15+SZ5F ^I>?2HJEY)*R M-1I2^\E15+SZ4I@/J2.HZDCK,4"2I>?  
2HJEY)*@T'OU8JO'5BL@".K%5XZL5 MB:A'4D=1QU)'4@='X"A+^)^K(C EF7W> _R?\ US^=>P^M<#\_.=$;  
<#RV/M/M>1258*)12'T445IH=P4444 %%%%\1111 M0 4444 %)2T4 >??8X^"?CX?I0'4A  
TGDK\ C .8WQUX73QCX+UI0)9VM1J MMA/8&<_.P2IE-V/7YJ^1/^<)W8_X6!_ Y1_ +?7%B*Q\645H \ #M\ I% _\H_  
OH_P'';Y_Z'!_Y1_\MI'?2^K$%_8.8;I\645H_P##M\ I% _\H_\IOH_X=OG_HH'_E'_/MJ/ZO4 M' 8.8/I)\645H \ WS_-/  
_P#*/\ ;Z/\^:_Y_Z'!_ Y1_ +?2^K$%_8.8 M?RGQ917VG PI?A T4#_ H_P IOH X=OG_HH'_E' \ MI/ZO4'_&#F\A  
M645H \ #M\ I% _\H_ -OH_P'';Y_Z'!_ Y1_ |?2^K$%_8.8?RGQ917VG M_P_WS_T4#_ RC \ V^C_  
(=OG_HH'_E' P#M|/ZO4' 8.8;H5_868|CXLHKI3_P'';Y_Z'!_ Y1_ |?1_PI?/_10/_*/_/:Z7U>9I/@9 MA_*?  
%B_NINWY=O(QOBAOWFI=\VIDYYS7VG PI?/_ $4#_P_H_P#IOH_X=OG_M**!_P'4?_?3^KU_L'/Y3XLHKI3_X=OG_  
**!_P'4?_?1_PI?A T4#_ M_H_P IOH^KU!_V#F'\A645H \ WS_-%_P#*/\ ;Z/\^:_Y_Z'!_ Y1_ M+?  
117)"_L'/Y3XLHKI3_X=OG_HH'_E' \ MI'_ ?/_10/_*/_P#;Z/JI MOK^PLOI'Q917VG PI?/_ $4#_P_H_P#IOH_X=OG_  
**!_P'4?_?2^K$%)_L'_M_Y3XLHKI3_X=OG_**!_P'4?_?1_PI?A T4#_ H_P IOI_5Z@_['S'L2 M%E#?2,6)Y+?  
>SWXQS^%?2:_PI?/_10/_*/_/:Z/\^:_Y_Z'!_ Y1_P#I?2^K MS%_8.8?RGQ917VG _WS_T4#_RC_P#V^C_AV^?^B@?^4?\  
^WT?5YA_8.8?RGQ917VG_P_WS_T4#_RC \ V^C_(=OG_HH'_E' P#M|/ZO4' 8.8?RGQ91 M7VG_  
_WS_T4#_RC_P#V^C_AV^?^B@?^4?^ WTOJO?V#F'\A645H_P## MM\ I% _\H_\IOH_X=OG_HH'_E'_/MI'U>8?  
V#F'\A645H \ #M\ I% _MH_ -OH_P'';Y_Z'!_ Y1_ |?117F'|@YA_*?%E%??:? #M\ P#10A_RC_ M &^C_AV^?^B@?^4?  
_P'WT?5YA_8.8?RGQ92;1Z#L.GITKI4_X=OG_HH'_E' M/MI'_#M\ \10/_ "C_/V^CZO;PI@YA_W*?%E%??:?  
/?/_10/_*/_P#;MZA_AV^?^B@?^4?_ WT_JI0/I'S'L2%E%??:? #M\ \10/_ "C_/V^C_AV M^?^HH'  
J1_MJ'U>H^PLOI'Q917VG_P_WS_T4#_RC \ V^C_(=OG_HH'_E' P#M|/ZO,G^PH/PLOI'Q917VG_P  
_WS_T4#_RC \ V^C_M=(OG_HH'_E' P#M|U>H'IAGCV/BRBOMA_X=OG_HH'_E' /MI'_#M\ M10/_ "C_  
/V^EI7F+^PH M/^PLOI'Q917VG PI?A T4#_ H_P IOH_X=OG_HH'_E' \ MI'U>H'I@YA_M*?%E%??:? #M\ P#10A  
RC_&^C_AV^?^B@?^4?_P'WTOJO?V#F'\A645 MH \ WS_-%_P#*/\ ;Z/\^:_Y_Z'!_ Y1_ +?3^KU!_PI@YA_*?%E%??:?  
M_I?/_10/_*/_P#;ZA_AV^?^B@?^4?_ WT?5Z@OI$S#^4+^***T \ AV^? M^B@?^4?_ WT?  
\ WS_T4#_RC_P#V^CZO4' 8.8?RGQ917VG _WS_T4#_RC M_P#V^C_AV^?^B@?^4?^ \ WT?5Z@?  
V#F'\A645H_P##M\ I% _\H_\IOH MX=OG_HH'_E' /MI+ZO;7I@YA_*?%E%??:? PI?/_10/_*/_/:Z/\^:_Y_Z*_MI_Y1_P#I?  
3^KU_ L'/Y3XLHKI3_-Y_Z'!_ Y1_P#I?1_PI?/_ $4#_P_H_M_P#IOI?5YA_8.8?RGQ917VG _WS_T4#_RC_P#V^C_AV^?  
^B@?^4?^ \ WT_ MJH0/I$S#^4+^***T_P#AV^?^B@?^4?^ \ WT_A WS_P I% _\A_ ZQ^JU  
M_L/Y3XPC^IN BI> 3^J7GTKI_P''<+CIRO/_ "C_/V^EX=R-T4#_R MD?A_V^CZKA+_ +%S%IH^-(Z*S^S^!  
I'QA4O/I7V5_PID; H?-/RC_P#V^E_X=T-TA_P'4 M?_?115K!_8>_I'QO'4O/I7V' PH HH'_E' \ MI2?A_I6_P'A_P#_"D?  
M_-Z/JM8/I#QV\CXSJO7V)_PIKA T/P_$_-OIW_#N^3_H?1_X)O\ I?2^ MIU^POI'QO8^:(Z^Q?^AW?+_P'#ZA_P3?  
&^E_P'''>Q)>T1UIA \ #O>3_H?2%_P#!_ \ ;Z/\^>G_O^+_P'';_|?2^IU MS19%C5T/D'.I(Z^O/^?<@_YGQ?_3?_;Z?_P  
^Y/\AI7_.$_P!OK/ZCM7#^P;V/DB.I(Z^M_P#AWZ_$_X_P#I4?^X_3_/A@%QT;#_P5'_X_2^HM U^P?  
V^C>QAD'H:0#P1R.OZU+7UE_PP%(/^9U_U1^/TI_(8%D_Z'7'^<M*A^?K/ZA7I#_L3&LD^MI4?_(1_9^*I_8N-  
IRI4D=74_#"LW_OY)_X*C^_Z?_,+RC_FQILT_ N-HQN+8JSU/UKZE_X8.F_P'AR3_P5'_X_M_3O^&^9?^AQ3_P%1\  
GI9?V9BNQI_8^,E/EVI>?2OI^X8?F_P"AOC^M%1^/TI_(8AF_Z'9%A_P5G_/TODQ78/I'QOAPU+SZ5I^2.S2I#A'  
M_P'''H \ Q^GA,3S_P#OX)_X*S_?K/^R<5V'_8^-I'S_4O/I7TO_P_5S?I M#=#_'_L_P#Q^E_X8LG_.AOC \ !6?_(1_9.*  
I&GID8WL?- /I3Z^C \ MAB^X_P"APC_%A^/T_ (8SG_Z&ZA_%A^/UC_9&,I_9&-I'SC'4E?17_M_#&MP.GBUA_P5G_  
/T_P#X8_F_Z&Y/_!6/_CM1_8^-I#_LG%=CYWXI?*?7T M/_PR/A I#:'_P'''P?_QVC_(9#?_H;/_*/_ CM9?V+C>P?  
V3B^Q\^E/K MZ#_X9';_*P?^?"?_:= PR4W_OUK_X#_XI2_L7&IC3^R<5V/G_GTH?07_M_#)#?1#(W_@%_P#;::?)  
\D_I3(- @/_9UE_8N-I_9.'I'S_SZ4^O?^MADP-I#))_P'_V=-_X9^ATC?^?-G6?IAXWL/^R<5V/^?2GUIW_PR  
MB?AH9'///P"Sj3_AE3_8F \ \LC^P;V+_LO%=CP7GTR=>[_P#M^Q_Z&O_$_SI?^&6_P#I#&W_@)_\  
9UE_8.8?RC_LO%=CP^B.O=@/^&87_M.A@/_ @&/_BZ/^&87_Z& \ @&/_(NE_8.8?RA_9F^I'A=6(ZIJ_X9CD_Z M&^  
0_^+J7_(9G?_H8#_XIC_XNH_U>S^1?>|F8KL>(\^E/KVS_AF=O\ MH83_.8_P#BZ? \ UM_P!!_P#DQ_?76?  
^KN8_R+IS3^S,5V/%>?2GUI/_M_,VO_T,'_DF/_BZ=_PS> \ T,'_)C_P'+I?ZNYC_SI7WC_LS%=COZI>?2  
MO8/^&J \ ^2_P#0>^X"#_+J7_AOLW_0<7_P''_Q=9?ZLYI SI7WA_9^)'E M%2^AE>I \ *F_P"@VA_P''_71_P*  
(G_Z#G_DE \ 9TOI6@?^9D_Z"H \ ?^ASJ3_A3G_04'_@/_P#9U^JV: \ M^_OIH0KICSN.K%=[_PH \ HDI_WX;_  
+J2_X3JG749#18U_QJ?I5%_IHWKS>)?&;2R(R<8<_A7<::X"TK3EW-$+DX;4.OTKJ_M5147_%?  
593P9?#_9A.Z_E6WWG=ORIK6J-MI6*WB2_-41IM557_I4N*6 MBOU>_5%*%VIH@444501110 4444 %%%%\1110  
4444 -VC.<#-+44M%;":M1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":M1Z4;1Z4M%;"  
":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":M1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;"  
":1Z4;1Z4M%;":1Z4;1Z4M%;":M1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;"  
":1Z4;1Z4M%;":1Z4;1Z4M%;":M1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;"  
":1Z4;1Z4M%;":1Z4;1Z4M%;":1Z4;1Z4M%;
```


[illegible]

BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "MBBB@ HHHH **** "BBB@!;!:#!;KM(D,O):3/*!?!?
321P2"39Y9%8AE.8P=O&\BOHH@8ZTQ8UC550:548 M P /2E).*Al>Q9_ \$3ICGQ9XA^%_P
/?!"CJ">F377AV""6IENH M8U8SNCA8PJ-E5P5 ;:A0/I7G"- \ /SXB-(\$&L^&\ \ 7V\ /(I>U?MV_%C M6?A X7V:/HEY=:7-
K\$TTH9W/D3".8? *1EPP9FD1\ @ =B=2XJ/T J\ @'X MD7UG:R/? :#8>9)):>XN)3.)# "2L3JH_P!UVKAER\N5GOV+Pl..
(=A3E/MEY;VEL61_P \$! _B_6Q_- /AL?IOD_P CU^AL?HL2237YY?\AOB3_T?" _M (%W'_R/7Z?'RQ@,=S'MZ:45))
f&3TG34^>F^(\^)\W)&(V\UN?) #1B_3/BY MXZG/36?BB?2KVY7 _j&XMTN8E1LH&E7CI MQ6LHVAl.
(PI+ \$OY*j,!#N AS^R+!1 B2VJ*VE1^&OLOD_IC%W5IYVIS,> M5B/XMN&SGU3VKLV_X)!?\$F-
_M;POOR#N%W<9R!\ /V?TK?^)7I7WO"?->- ML:#X0VEXNDV<3I6MJ.6ZN-04X#7!1D=HXU.-GR@DGYLE@J<-! ?
f2GQ_US1HC M5I/U;5IOT.'=YVH6FA6T\$&P;I-T@MP.%YZ5YW+AUJEGYJRY70?
LHJJ!8>YKY^U#H34VA9+/08(9OX99)YE4?-BL.YC4OCMXTO+KI W=16.?IM:P?*?
_OMI>KIX=QU7>"CZLA&MQ9EE'.3EZ(I)^/OC9M%T&+2!1XIV\; ^I7Y:TXRY&?LT9IG^G0^BBBF6"?
_l0+QQXC\>2>!IH#B#5-#%P MM_YWIFWLEOYN TVVW=L89QN;&>FX^M'!/WQOXC^8R>.AK_B#5-<%NMAY/H7
MLEQY6XW.f;08XSM7..NT>E8G_!27_??#W=_U'^=K1_P3:_UWO?_W=-_G=5P<MS^L6N?
#^TG_-W)S.W;I)H04M)2UWG W 4444 %%%%\1110:R_C+OUPI\ -MZEXD\2ZE#L.@:?\$9YKN9N H_.F2S.54*.68JHY+
5!2LT MR6WI27Q6UWP MMHWA2YT2QL;"XU"*4+B^fIW\$4=Q#\$ T'H^Q67=\KL/3=UK>^-^(MO)?/B5_M8;
fXO:\^(+IP5:10LG@NWE6WL0M.;GH07DJR%U;CS?WC;9@H1!V_L0Z:::
M/^WY\;+"PM8;*QM8I9A@M;>;1Q1(NIVZJH!A0% X %=.(1<) =SGE.7I% M'Z0TE+17.=!3FN#!G?E4)!&<#JOSP
*>/@I^V.-/XS.KX3T?PM?V?AJ_M#2)M7TWQ>+3IJJD"\$=\$OYJ6X0\$1F0RX;?N'E8958E5YOX[^-K_\.^<'X&_
M#NX0HEK=00X_P#\$UE((H;&R+-YEA'(8WW7\$A!4#_*%&ROG"/E/@?9IX>-X
M**>/O#=JTPT/P(X)M+=TRU.Y>5+*UC33F6.%R3RSL<>I)/4FNB.\$XR;.)2IZ_MQIQ4AHKR?H3Q\4/#?
@NSN/AIX;TWO5XDDOHX)/5)Q#&EL8Y"FY::(-PRQ MCIV?F/RUSIU-SQ'QE_P4"N6<:SH?PM^&M?
%W3I)98fIO5M&DF\$RG=C9Y5O_M-NC8)5E5SM&-R RI7?ZJ,ZGJ6I^&DJO-5TZ/JMQ;1R7>F_%.N/LHCW/%Y
MBC.)L.*IEP#C-?F^Q7XP_-&_# +58/A/X\$T'Q3X\$5AYSMM<8?9MW(?FKMJ4K3Y(+&?N\YI.T?BH.GB/X
M8:7X/^&E&GF2S37ZS.A*; MT1Jf<I46_AI3=8;.0:MX?+LMLA+"1B%D6G?: MYB!6-UD1.MMU'LY>
fYCfHCUI.Z_60AQOVP?CO\5O'\$B_X1_f";PO#"I7-JK-MV+F2\D2-#*MK-DT.CA))/C#(LAD*I
J.KIKIP_MZ7WQ3.ZJGP\AW7B7XG_MZC"JU=:?\$"UTN./F+.SQ^Z.6 C<.@.I=VQML3/V4B/(\T.6OC?X2?MC^M-
+/XS6WPL^-A*Q\&> (=48#3=3LKCRK68LBF) KO(CEG\$R>9'.P.SRHMFEXDU MJCYJ)1Y=RXR4MA.***DL****
"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** \$Q1M&.E+24 ?&O_4*O-&C\.\$X+RPNIM?
DFN)=/NHID2% MO\$HBVY9%_B+;HL+P1L9MV%*/RGA?_@H5J^GZ'9V>I> &H=9U&UA5+G4IJ0M#<
M/CIBQ\$#!"1SQUZKA>*^KOBPQ@.S\OK-(AT;2KI2=,_-J.GBI-MYK'C15"
M.068Q@f>H.3TKY3T/H7X3^+OB)HN@Z1\%M\$.QU+4+.RBUM*LK9)1YKJK.T* MPMT)/A=<51SC/XSX5'1J8?
&.K3K1@Y_9MJ:W_#QZ7<#_.*[X]/I9'_QBOM> M/#+O&>.^90%FK_I\$PC\.-&^Mf\=
=)%QJ<.:E=2'A^%;>.:1P(\$Y7.BN7K\$1E4C7J*7H34CJ"IXYQO2T.<3f5j>N_M?#7f\$=C?#CXQ>/-
(?:Q9;+Z.V6228LZ1]+67RU9\$= S)(MR'5R<%53'WAC MGQA3'8M&-9IDA>?
#3OWI%_JVFG59(H2FC1J.Q2@B=IEEF"F.5\$B<#HP=W.H MKT7ID_OU/XO?
\$:Q#;W_AIPH^HWE@ED)JE0&VGN&A.;)'9FD 24I') M^4*<;@1CW3XC? OPA5;SNSO\$OA^/4+JW39#-
YL+A22=K&,@DD Y).9 MKDC'FA^/D DGRRE._5-CY_P'''=5UJLF@^-.2>*X71\$NI=K=L# MRS<&-UG ?
IQ8(E61-RXZFOLU#PN.5R7@/X=>?ACH*).X9TV2=-63S6A7< MYD<@9=G3R \/.XPG_H.ZN5O_M.PIH/Q
UP'M='LX8\BO*W_'ARJUZI+(K/"J3992_Y>.7HKGT F MFH?-"R8.JHOIO3^M?)=U7O&6K6XADU:X"2?ZOK>-
(BGT9!N%9'f^)-%4/V MIH1UEA_RTJ68_F"U>C'AJH#^/5C#YGE2XNHRTPI"4_D?5FH>/-H:3)<M:HZW.0^-%;E"^\
WQNS7_ZGI?O"5G.^;%=7%WJRVA;/_CVVO%-)^"OBG4C M;Q/9?9HJA=SS7\$RIM_WD
W\$_5.ZS3OV9I2D7=J&J6<#=#O(CDF_JE7_9V48?^M/B'+T_!6SW\$P"IX9+UU_R-
2^_.8B6^O3I"N+B+&/N+KRV [X5&%*9I-B'L+(D8/Z&W8N/^W*5W5C^S7HHM1%?.O>7%UCF2!8XE/_AC^M=
MHOPe*.3<>=?Iso_1?4>(A7_%K^GZ'S?J' MQ(AZK&EUS4HY8U\MA'(8_1K^NZHK+P1XH07BO^H MN92<^A
Q5)=Z;H>FZ3_8; &PMK*\$MO.=O\$L.ECWPIUJWL10H5%^7I@=.3X@A_M3TP^C\$J'"TYOFQ JE(^6=)^?<
BF^4EH+6QI/<7_?T6#75Z1^S?%LNHQYO4 MMTFWIGGPQP.L=SJ\$?A_SSN)@%) MI37T'T/
HK1J^%*@@5R4LUQ'MX5JTG/EZ-LIZ^389X_M:=&A%02G_/2FIY^k^ M?E7T_P#K7+_GROO_.?) ZEP_Y_/ICQ3IG?
Q0^HZ9/H5QYFZQ42PR+)N7RW MYV<;<9&_W7=O XHLJ342PQQ*BK4V3CWKXK%UX8FO*M"' +S'WN7X6>\$PT*
M%2?_XCZ***Y3T3X@_P""DO\ KOA\ NZC_UH_P"";7^N^ (7^HWAJJC_(*2_M_P"N^O^HA6C_ OM?ZIXA?ING?SNJI=-
)B3XA_YJ#^OY3f>I:2EKT3_MIP***** "BBB@ #YU_: 9R!>_%IOE9ZUX:^&O_#JTM!*S?2D)\$f0R,)&&K
M".YC&XAU7_.X4>U;?I.OP1\5_!@/(A A*/BCKOO^&H_9_) MAI?I\AL29V> M9<2_?WKG&fIG->UI0RMP.'KQUH*KOD
\<5?M)6BC(50< <#L M.G\S7YV?L9_I#/CC_W&-P^Tz6I?4Wf1BGXV>?3X='P=*:+XH_P'T#5OI_M:D'_9=HC,&S_-
f2_2TF<ON#I7OC?A3A^*(C)XP^&F?#IYI>A?://
MMD5YJEJH'YZW#>6JWB.F&CQSFMZ2CRRU.ZGQC_3IM7CWI3'BWX@>#?@MX MAU;X;8VM>+(UCMI.W6!
fB2/((FFBA5&YUSNV,< LV0I1^=\2A;?^?I* M6L1"VM?I_P 9,JTEC-
KITP2*\$BX^[#+YDH5Y+; &UQ)\KOG>A7*;7I*OAWXA> M%_@GLF?SRZDO_%4.\&_M'^.='
&Q_"CNU^#/B#4_\$J.I':WG@^+I0+I3XEC_MM-LKI8&8J?
LZ&3S"^=.W)*+9D)?/5O^"B%I.WGDObUYK&YNK>6REMS/&A.\$IO((-MR5)^ZQ261=RV?7?
G'YXGXJH_P""8&E<#_D6/#?_IK8G^=<;XB_9I_:(_U2M#:2;.=\>"M'F2272M&E247'\$I>:%!)<;IR-L0:9U6-
'W(C;9\$;Z_:_R.M^&NJ^_ V7_?7@KP-HJK-?21646G.?-#;P+_%5C55CBX&O!@=JT4H
MOY8W.O>ES:-7 LYJDOV_ AD7&MX7TO<6YS_*) UKYN_8(TNST?XI?M-Z=I MH!8Z?;>(U@MI2VC\$<4;W5^JHB*
%4!0_,"OHX(^fWPG&? VB:C;F MUU32]T^TNK4R:S#+';1HZ;@6W8*GU_6O&/V5/A'XP^&?QB^/N^)=;3MA
M4:_JKTBY_4OVB+[I?2;BL;_4^66+I^WfUIS?\$(+))Q7L^G6EO^TS^S%?Q6 ML5I<>(HI>Z2."66*.JLC^S8R54RRD
\R/CIQSI5N?M6?"7Q?A \$SXQ_M? 77?#6CMJ.F>%M>^UZO<=">+{/%HIL9-
P61E+ _+|S=JVOJ0=-.FNY+!?" G@OOI^ SC%X6MI_K&XU&CJ=HD9EU)\$EL_+

HHHH **** "BBB@ HHHH **** "B MBB@ HHHH *2EHH B'T/YTISZXJ%I%?C?#2+NOIW_)KEJ0^*A73K8W,GB"S>!
M1RQ!W_ 'RF6_4Z=2JH0BWACGG7I4?CDH^K.O4^!V!W_6O_4^/WA;3ES M\$UY?- TPM63_--
&%:XO4/VF)HTI6>BQK\$1_ HTEW=I2Q160)Q_P!J5Z5'*,5 M^&DUZ_ \!/"KYIEV'^_JGZ:GOZDTK-
SUKY>U3IH3Q1>6>U&MI&3^!;6K9_ \ M'MJ!4XPPED,R?HJ;3_P!FJX#6J7FO@QJ!HCHM
MI7+^0*Y;_X_W?Z_2_@#X3T^W9)XIR_ G63I.5 ^@3;3YAP^T7/^OD^Q)B MMY*X?YGCNH?'CQG=Z@#_<5DO\
S!PVB^7_./Y?!.P4U3Q_XI WV7GZOK%N MWVHA/_A^H!85!1Z^A.O"NFV"PI>|^*5(QIV;)9G/U9AD_B:ZE8XU^ZH^X4/
M.)1_P!VPJ7J_/#F-Q#YL5BY/T/D73OA3XNU>_7*Z1H&UEOKNVLX6&9%+M)*GL OR_DU?22KCU^C#=:YJG\$F-
E_#M^Y^92X M3P\$/XMZGJSQ2Q_9GTR^?)GJU=-V M\$(O\ XJM!3_@+X0MX49K*XO9LGTW_V<UY57-
L;6^J_R_(INEDF7T?@H+^S.L!/">B:7<=<6>D M6-I_P!Z6&W1&ZD#)K36)(UVJH I^?17FRG*6LG<IB_.\$/ABD-
M<\$;1@!M>_M+2T5!H)M^3!%&T9S@9!;6B@!-H!^*H^*6BE9_)M Z^C:#VI:*8;[B8 [4 M8^I2T4_)12T4_VCTI:6B@
HHHH ^(/!^DO^N^O^!JAI6C_@FU_KOB%_NZ M=_ZH_X^2_Z!X>_[NH_SM:/^"/;7^N^ (7^!WV!JO_ _YB3X/_
J)#^OY3!>I_ M2EKT3!P^***** "BBB@!***6B@!_H/49!&JXPH&.1Q3JY00?&V@>*_6U?3!%A0
M:=JUI,WV;4+6RO\$GDLY_L-DR*Q;-MRN_-M^X22@#HO+7^Z/RI%AI@^~M
^4:MJ^GZ+X@TI5KW29OLVH6ME>)//9R98;)D5BT;E<8;_!P^E'_M1TFT>@IU%_#?
+4KMVC&,8QOBCRU^7Y1\O(XZ<8IU%_#?+7(.T9!R.. K0L;+ MM"JH"C P.@!*=10 QHT?(9%(88.1U^I3J6B@ HHHH
**** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "D+24 ?'G_!00QAJ.F^&?'OA
MZVF;UT_5L:FZN6B2V)Y7)X/S>2Z8<_17?_MB?#OPM0/"6CQZMXFT MKPSXBMIGDTJXUB_2TBD#-\$MP^K-I
(5/RCAIG(!->7?;G!D7QZWC_2=:=\?J MT-GXN&2J<CX_&1Q<55ITOM
M\MO!O>YY#:=>%?/!(^BCP9XLU/4+)=>01Y-/T^Y+2O&FTW%M.VSRSPX7*A\
M_&9>54U^G:DLJYICK7RY^TUA!_%_QH^*G^M8GB/(@FUA*7DBRI%+;NTJM,PW
MDET6(1E0^~B8^8&+5!1*K^QY!A6!&/_+*2/1RW#SPI6K#507+RW_\$=))Y:EN3 M7Q/_./YIV1V3_..#D?
_&*^V6^:CJ^X5O@3!^H^>&#_WH!?.(K22E)_M:'7C:.*KAT75/_C:J1C\$D!OI>AV?E'-9J;I:Z-7-!2V!H8V4374UU<2"-
(D5_M:C\2^ (K/PKXF;9!+7=R%)\$\$.;Y&(&I_ I_6OSC!7?M>^"OVI MO&@T+X@:!A
#_X2;?);C1X8!FX00\$CK(_E13O;PD0!10&9%?AONLI\$/#K3 MIN9G*HH;GJB^\$!G!NSXY;-
XWN+;;P^"G@^9HJ!74!;R>!(E90;B1(GCW+!L MT4\$;^83N5"@_!@B^XZ^M-
_V_9TTG3K73!^QE#96%K&D;K;Z#?QOQOH_\$ M1\$%OA54 <5!%*:51RT3"GR CZ***S- HHHH **** "BBB@ HHHH
**** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HH MHH **** "BBB@ HHHH **** "BBB@!_U_+>QJ.R+!%#N,A1%ZLY_F36?J6O6.
MEP^9=ZA%9K_>G=5^ZXD2E_,F4ZD*?QR435J_LYZ_^=<9!^Q?A_ "6F77DR; MS"Q"DH5_!QTK4)Y?X8YW1?
JZLU>G1RI&5OAI,ARMFV M!H?62!-3V@\$_P^31GTS7SQJ!2FK7"XTS2!V/K<2F7^6RN2UCXW>,=2NI(MSJ;:?
%_I0V!O;I#R-OR\$ _O_V0UZM+AO^3^)*J\$Q*W%F74?A;EZ(^K! L?
M+&1>#&#M9FH>*M^TF79?G969_Z;W")_BOD9_!1>*G-J9=5UF+NGFS3K M^0+5K6/PF8ZI"LZ;!
<_& CED6.3!4=U8?G79_J_0H [SB4OZAS@?%&)K [K MA6_O_P CW2)_\ (6,)\NIN;^X'_"
IV!DYA_[Z517.ZK^TOIT:_P"@:1>2 MG_IXF2#^C5S>G?LW>(99?^O!7L+;#'\$EL&D;_O@HJUT>F_LVZ3#;+;I5;R>Y
M_P">D^!S/R(:A4IR6H_M&>)KF.Y6UMK"SB(M_=M(C,X_?'LKFM3^+/BW4!3R;G5!H1^RTUJ?L!^8JHT_X(^\$K%K<-
HN)(M57#2S2.KX!LF=AS!BNQTOPUI6BQF/3!M+;%#U6WA6_!^12_M;+/_P!_7^ME^!B9QB/X^+;J#Y;P5>)
(%NY+?5=9)'RW+6^DRGZ-MO^E;^G_ P_87EUM MDTZ/3!/?&?M%Q\$ M/+>:LIGSH!L,EZ!KNOM9@MY_2VA:0?
^!%:Z6P_9Q^V!6TUS>:A<=&FC5_ME5&^N\$W_*U!JJO10/PI-HW9Z&O)K9YF%;_>)_BCPWE>^"BCC!*\$\$_A3
M3%81Z%9R!O\ GX0S'_R(3BNHL)=L+=MEM!2TAM8\$SMBAC**G)X^'6K>U>.! MQTXZ4<5Y_
2O5J_%)L!NEA(%XO?)H4= _!2XH:~S!3J\$YV@\$<4;1Z4M%_# M=J!!^GK2!1Z4M%_ "8%&T>E+10 F!1M!2T4_%%%%
!1110 4444_%%%% !11 M10 4444_%%%% !1110 4444 ?\$'_ 4E_P!=V?JW4?YVM'_ 3_ P!!=\00! MW3OYW5'_
4E_P!=V?JW4?YVM'_ 3_ P!!=\00!W3OYW5>=_P_Q)'_ _U! M_7!HO4M)2UZ)IX%%%% !1124<_J7BK2M-
U!1^NM5M;34!4S!#83W<<<1 MWL4/((HR=TAC7:S8Z<1^P=<^G@+POJMSI>M^/O#.CZC_R6=YH\$-P@QN!
M>-F!7CU%?)7_4CJ!%3.6V!D^!>SBXQF^'K!G!?)CO_3O(K6^24@D)ND903A7.W.<3U%_M^A+QOH7CW39=1\,>(!-
!0V^R^3)>:9>174\$- \$GO)^7B>YU^QE^Q6.MZBNGV.C6Y"*D2O&T>-LCR!2Q4\$3897 MD)D?
YPOM^'W!O!6WPHUCX(^*!-U32Q\$U^FBZCHUAK/H06T4CPP-09)C(X
M=6WJ)BP66%6&X+L11H6P5Y.0_2HR^V)E" EON!OX_PXR,C^~N-T/XV>_O%&
MK6VEZ)X^,ZQJ.XS^9V>KP37?#C&XE(T8EN/05! MN/XF^, _QP^?P!T+6/^
M\$;TK6! =M4U6!D)UN5#2MY9C"_.8TM9G"HK_*I8+L#UW6H?A\$W/(@;?>&UTB/ M1=2TW43!%_:=OJLIO_X
#/M8O#O< (0?W6T;CL [3RQ4?78N>4MCZP-<#KWQ ML!>%)!6N=+UOQJX9T?48!F2SO-7@AN\$&-
P+QNP^>HKPGJLCQSJ_L_!+!%MI M7A75!;O=6OKBWA/P;HJ&JR7.IHTBRR/_TL@+!["TW_H5WY0J8T6OG+P^X;_M_&
(/#GAF^VU_Q)>^,M2)#W_!7MOJUJZOY<,%4BMXT"1?^Q_!AN.7?K50I+E MYV\$IGZ:K(WEH1*^*>V_QI!@X&3_
!5!4!L8;I;Z^=AVK!N_>&TT^T30=S MW5S((HXT6ZOV9B3@!4'S_8'D\$YKG?V!^B7#IGQH^7_"CPKXLEA?;"NSLGU;
M0!_4:22^ZC82!XU#^F%G^A-K-%YBA-!^!P!GOX^Z^;VB/VC!^0W!U) MX.@32-J7AN^FMDU>=KF^~SM-
*A\$ABC<(!9S&Y^?SMO6^FN9!_RV/N/ MPR8!OCN^>P^>+!^!2ZPMG_
!;^#^!K>%M;V7MMY=IJ7F06T#%T:0^X+.QDE>*)ES ML*,^8;V/K!6GI2&O>?'V/I\$^9^'(KC2=5\;064\$4EI=-O_
-2ZMFN9^C<+E MG6..1%9=A!D#@@J^*2C+EY&:W+N^0&N?&SP%X7U_YTO6_ 'WAG1!1@&9+^U M> "&X08W O&I
KQZBNFTW5!^5M^M+^QNTOI^A6X@NK2198IXF52LD;C^LI5@_ M0!@_VKY+^\$O_3=^&/ASP99VOCW2?A
A+_%;MIHNIY+R!M8%RI^F%!(GC^EI MT#/EGSD!051.(^?AW6OV1/VP.?X06FNS.YX^76\$NHV\$-Q/I^9(I&61EV8
M^X^V>-C^M5U9^(^39")%_+GE^<0/^&OB_@HM^KCP+^*;1/"^CZ^1/&
M3:S;QW!H>HQ+J4=HGE#_JMYL%*UMR649^L%Z2&OL_&OST_X^>?H!PGH/
M@NV^ (MH+6WB_6=>M;_&_U^KR=FN(9R84Q!O^0@VT/1?^69!L/F_!X MN!<.%X^TV+4?\$_B/3?
#UBTODQWFIWDB5K!)^02\$W2.H)PKG;G.%ZBN!"^%GI^* M_P_/!@KXAFU_P7X9&B:S-
9FP>X^W75P3;EE8H5EEC4^Y45!>_L!^!V+!N MIQYXJ^_?Q.N+BI_6^I3:9IGA@74J^4JJ&2-I4\$96&*.<#>#
(Y=VQ)PD(PC M^F#GD?>W@_XF>%/B%IK^A;Q3H_B(VI3!3_9.H1W8AWY%\$S&S!=RHQ7.XXKK ME&.IK!/_-
J_JDW3/V=!"L/C%!_VX!&CX8DC_U8_.9!C<))1\$LD32_P V MZ7;Z/F.2,D8X(D^YOA OXL?QYV/?
#7B>2V;REUC3+7439!P@:;%9"FXW;_ M_*)PBHT^XR?PLZVBBBL30^***** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *0!^6B@#XS_X^&:-;7/AGPGJ6..MYGE!IHVS M_JQ^M>"ZU^R5!"O"IXVG:I2+S2+N^D6=YK5A%
(!OU"O\$".UO2OD71?V?A5K! MC:W^G>*_U_SFXCNI2_M9892^P(5E@P<%#G_%?72KM7^T05O3Q@98RI%
MRQ:CY+KCOFIQJ_ "D M_W!9W%I^DD\$&(_ FSDJ!)^5<(K;YGS IEQ?LR_ OP9!4O_ C;2!\$5A)9^<_
M=+OI8%FE:Y!1/5XBD#^!%OC63.*DP^*)3#<\$&O;_@%I?POUCXY^_&7@OQ3_ M_C2ZK_7DT98!+=HP^B/_B;#2AI
K!EPJ^3:<[EKDOCS^Q#J7C^QC<:WX^U M.SLHM3D>ZOI+5)9#&)W;+21.J,2KG)93!TI/E8!//C32A!BN?
#PR^2H!J4X^ MIR^U_P^;?H!^C^P^!>#-6TS^Q!33!9TMK=;B!L;&. W5NWF?9S(R@;W 63. M>0K(?!OLOKZR_%>#?
LM_L_2_ OPOJ<6J3VM!XAU.=9H!R-&(TW>2B!MO(S
M(Q8HO.FW!J+7O!QCZ5UTHRC%)GTV6TZE+"PC45!E%)2UJ>F% %%% !1110!4 MU32K+6!-N!U&SM!_3!R%

I>YM+J9(IHG!5T=&!#*P)!!&"#S7"?_W_E_MZ)=X+Z8_Y%^TZ<\?ZOW/YUZ-13NUL*R9YU_PSA))?^B7>#/_
G!3_XW7HM% M%%P"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH ^-+^-)TJ"28)G!WS>F3BDE*1\$I
M*.Y+N!Z7)KE!3>Z!H;2PWFLV,=W&F!U\W_O@?-^0KF=3^/GA&RM?.BNKB M^,^Y;0MG_P>VUUT'B*W\.#?
R.*IF&%H_Q:15\STC<<1/UIXKPS4/VGK)+K MRM/T>2=/^>D\ZQC_,=W5RVK?M!^)M0FNH;!+.S##\$;(KR2+!@GY?
_*!;CP M_CZN\7U9X5;B?+J.TW+T1!-?=I U4NKR.UADCGN\$MX4&9&DZ+^.<5\EZ!3_M-!7J@C%UKMXNW.SL.WV?
&!0\KK^~580"-BOQ)>1RC2M50'N1UW=0R9+BV%3_=J\$I(^G-1^*GA;2I/I3+K!F7I#*)F_-)U M<J/I0?A>PN!^!%-
=Z@,?>MXAC_Q!;7DVF_,QG?712:WBL8/IUQ.AA XZ'K MIK+JFB^:U#7^NVUN_P#%#;VA=!_P-
G5JT^HY/0_B8AR!"/I2S!%?P\,H^O\ MP2760VG&>.\32I)\O\ U4UQ*6+?JLT_+^KE!0^/GB_4E @NK.R\O!YL8@V?
M^~H>I6/I/'AJRO#.TNI7B@<0SW"A1_P)4#_/CU=#I?PG\):6L@70;7S.O MVE#;? (A-'UW))+V0C5M1
MNY;H(\$MI>9I@QTQ&F%^;OZU)I_PQ!3.O.8%T*\#==TL;11?DY45!?PV=0%&J_M1P1HB-!550_,=-!I5-P00?
E2_P!8_9JV'H1C_7R"A3VCY\3B)3/F"Q_9Y\5 MWUFLDGV&RG/_ "QN)R6'XJK"NGL?V:H#=&6^U^26UOD10VZOL/
@99A^E>I M>6I39M39_=P.4NWXV%>?5SL*FTI>AZI'AG*Z6I-L!PTIX!^\$+>UAN;";4#_? MN9WW?
FI6NOTHP!XCVL:XY3:IN5LYW XX.>I= H/HM/9 ZE2JD' MJ".#7C5<9BJWA6HWV>W1R-"4/X5)+Y#5@C7HBC*?
M'I2T5S;IGH**CLA-H M]*,=J6B@9'Y\$8QB-1MSCCIGK3Z6B@!*-HJ*6BD F/:C:*6BF E%+10 4444 M%%%%!1110
4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 4 M444 %%%'Q!_P%)? \ 7?#W_=U'^=K1_P \$VO\ 7?
\$+_ =TI^=U1_P %) ? \ M7?#W_=U'^=K1_P \$VO\ 7? \$+_ =TI^=U7G? \ ,2? !_P#.0?U_*?;U+24M>B?> M:1110
4E+10\+? \! ?\$5AX1^-/I-NN:IZ^(?VQOA%X>\%S^)_ ^\$T;4;06@N!23;&^B?4+G?G9&EL6VT2\$
M@Y#A=F#NVA7*^+_MR2+_,-%?LMKM;_D:LH8R1C_\$C3OFZ\$\$8SZ<*WO7K*_ML)_N/Q.^MK\K-
;UIK!4RB!N1:D!P^PV_F>3LW +Y6S9M&8XKJ;AR1N<IY M<ICR;_@FH6M>(+^)^7Q5U>V%G<^M)8X
MX8T&U\$10.*H P_.*XGP+ \ / \ PY!3>*M>\ / :7)I>J^)KLWVL3_Y\Y/M<^Z5 MLA'8JHS-*<1A1TZX&(E4YG)E<"4+*-
KPRQD8",S2&9S3?C5XD^% ^M?M*? *W^% M>C:9:6-
GXJCMMOUC0J'BL!*^N/MEH&ACF55%P8U4LQ3>R\>S/(H!)&&D9I&+.V6);K74:M\!A MIJ\AB.;PGIL\$7A?
41JFC)IT!M%L)O,\$L:(0A>'D57=/NLP!8\$@&KJK!2YD1 MI.7)RGRI^V1K,_P'_U^%7QJOI,N-O\+6NG2;-+%9JED\$I^T+
(-Q7RPYCO/_ MCC9P9#;RC*%CJ%:A^UWA%= _ VY)\1=">S\F.06T%R9KP^8?E7I)&&FSG MYD\O>O.X#FO5?\$'A?
10%>CW&E.WI5CK.FW)4SV.H6R3P2E65E+(X*MAE4C(X M* @J!2T'I!A7X%^%I6MM2M?A!;S30?
L=_=7%Y"^1L^>:5HVXY7KR.:S